PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chua, SMH; Wizrah, MSI; Luo, ZY; Lim, BYJ; Kappler, U; Kobe, B; Fraser, JA				Chua, Sheena M. H.; Wizrah, Maha S., I; Luo, Zhenyao; Lim, Bryan Y. J.; Kappler, Ulrike; Kobe, Bostjan; Fraser, James A.			Structural features of Cryptococcus neoformans bifunctional GAR/AIR synthetase may present novel antifungal drug targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE SYNTHETASE; GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; RAY CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PURINE; PROTEINS; CRYSTALLOGRAPHY; PURIFICATION; MENINGITIS; VIRULENCE	Cryptococcus neoformans is a fungus that causes life-threatening systemic mycoses. During infection of the human host, this pathogen experiences a major change in the availability of purines; the fungus can scavenge the abundant purines in its environmental niche of pigeon excrement, but must employ de novo biosynthesis in the purine-poor human CNS. Eleven sequential enzymatic steps are required to form the first purine base, IMP, an intermediate in the formation of ATP and GTP. Over the course of evolution, several gene fusion events led to the formation of multifunctional purine biosynthetic enzymes in most organisms, particularly the higher eukaryotes. In C. neoformans, phosphoribosyl-glycinamide synthetase (GARs) and phosphoribosyl-aminoimidazole synthetase (AIRs) are fused into a bifunctional enzyme, while the human ortholog is a trifunctional enzyme that also includes GAR transformylase. Here we functionally, biochemically, and structurally characterized C. neoformans GARs and AIRs to identify drug targetable features. GARs/AIRs are essential for de novo purine production and virulence in a murine inhalation infection model. Characterization of GARs enzymatic functional parameters showed that C. neoformans GARs/ AIRs have lower affinity for substrates glycine and PRA compared with the trifunctional metazoan enzyme. The crystal structure of C. neoformans GARs revealed differences in the glycine- and ATP-binding sites compared with the Homo sapiens enzyme, while the crystal structure of AIRs shows high structural similarity compared with its H. sapiens ortholog as a monomer but differences as a dimer. The alterations in functional and structural characteristics between fungal and human enzymes could potentially be exploited for antifungal development.	[Chua, Sheena M. H.; Wizrah, Maha S., I; Lim, Bryan Y. J.; Kappler, Ulrike; Kobe, Bostjan; Fraser, James A.] Univ Queensland, Australian Infect Dis Res Ctr, St Lucia, Qld, Australia; [Chua, Sheena M. H.; Wizrah, Maha S., I; Luo, Zhenyao; Lim, Bryan Y. J.; Kappler, Ulrike; Kobe, Bostjan; Fraser, James A.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia; [Luo, Zhenyao; Lim, Bryan Y. J.; Kobe, Bostjan] Univ Queensland, Inst Mol Biosci, St Lucia, Qld, Australia	University of Queensland; University of Queensland; University of Queensland	Fraser, JA (corresponding author), Univ Queensland, Australian Infect Dis Res Ctr, St Lucia, Qld, Australia.; Fraser, JA (corresponding author), Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia.	j.fraser1@uq.edu.au		Lim, Bryan Ying Jie/0000-0002-0554-909X; Chua, Sheena/0000-0003-1501-7254; Kappler, Ulrike/0000-0002-2642-1319	National Health and Medical Research Council [APP1130192]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This research was supported by the National Health and Medical Research Council, http://www.nhmrc.gov.au/, APP1130192 to J. A. F.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; Anand R, 2004, BIOCHEMISTRY-US, V43, P10328, DOI 10.1021/bi0491301; Antle VD, 1996, J BIOL CHEM, V271, P8192, DOI 10.1074/jbc.271.14.8192; Arras SDM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18106-2; Arras SDM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163049; Arras SDM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122916; Bera AK, 2000, J BACTERIOL, V182, P3734, DOI 10.1128/JB.182.13.3734-3739.2000; Blundell RD, 2016, ACS INFECT DIS, V2, P651, DOI 10.1021/acsinfecdis.6b00121; Bruggemann RJM, 2009, CLIN INFECT DIS, V48, P1441, DOI 10.1086/598327; Burdett TC, 2013, BIOMED CHROMATOGR, V27, P122, DOI 10.1002/bmc.2760; CHASKES S, 1975, J CLIN MICROBIOL, V1, P509, DOI 10.1128/JCM.1.6.509-514.1975; Chitty JL, 2019, MYCOPATHOLOGIA, V184, P273, DOI 10.1007/s11046-018-0315-0; Chitty JL, 2017, J BIOL CHEM, V292, P11829, DOI [10.1074/jbc.M117.787994, 10.1074/jbc.m117.787994]; CHRISTENSEN WB, 1946, J BACTERIOL, V52, P461, DOI 10.1128/JB.52.4.461-466.1946; Chua SMH, 2020, IMMUNOL CELL BIOL, V98, P819, DOI 10.1111/imcb.12389; DAUBNER SC, 1986, BIOCHEMISTRY-US, V25, P2951, DOI 10.1021/bi00358a033; EELLS JT, 1983, NEUROCHEM RES, V8, P1451; ELION GB, 1966, BIOCHEM PHARMACOL, V15, P863, DOI 10.1016/0006-2952(66)90163-8; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fanos V, 2000, J CHEMOTHERAPY, V12, P463, DOI 10.1179/joc.2000.12.6.463; Fawaz MV, 2011, BIOORG CHEM, V39, P185, DOI 10.1016/j.bioorg.2011.08.004; Fraser JA, 2003, EUKARYOT CELL, V2, P1036, DOI 10.1128/EC.2.5.1036-1045.2003; Friese G, 2001, AIDS, V15, P2344, DOI 10.1097/00002030-200111230-00026; Goins CL, 2006, FUNGAL GENET BIOL, V43, P531, DOI 10.1016/j.fgb.2006.02.007; HAMILTON L, 1954, Ann N Y Acad Sci, V60, P304; Holm L, 2020, PROTEIN SCI, V29, P128, DOI 10.1002/pro.3749; Janbon G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004261; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kanagawa M, 2016, J BIOCHEM, V159, P313, DOI 10.1093/jb/mvv107; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Li CL, 1999, STRUCTURE, V7, P1155, DOI 10.1016/S0969-2126(99)80182-8; Loyse A, 2013, LANCET INFECT DIS, V13, P629, DOI 10.1016/S1473-3099(13)70078-1; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McPhillips TM, 2002, J SYNCHROTRON RADIAT, V9, P401, DOI 10.1107/S0909049502015170; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; Morrow CA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002957; Nierlich D P, 1978, Methods Enzymol, V51, P179; Perfect JR, 2010, CLIN INFECT DIS, V50, P291, DOI 10.1086/649858; Pitkin JW, 1996, MICROBIOL-UK, V142, P1557, DOI 10.1099/13500872-142-6-1557; PRICE MF, 1982, SABOURAUDIA, V20, P7; Rajasingham R, 2017, LANCET INFECT DIS, V17, P873, DOI [10.1016/s1473-3099(17)30243-8, 10.1016/S1473-3099(17)30243-8]; Roemer T, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a019703; Sampei G, 2010, J BIOCHEM, V148, P429, DOI 10.1093/jb/mvq088; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; Schlee S, 2019, PROTEINS, V87, P815, DOI 10.1002/prot.25744; SCHRIMSHER JL, 1986, BIOCHEMISTRY-US, V25, P4366, DOI 10.1021/bi00363a028; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; Sonn-Segev A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15642-w; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P8791, DOI 10.1021/bi000926j; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P15480, DOI 10.1021/bi991618s; Wang WR, 1998, BIOCHEMISTRY-US, V37, P15647, DOI 10.1021/bi981405n; Welin M, 2010, NUCLEIC ACIDS RES, V38, P7308, DOI 10.1093/nar/gkq595; Winn MD, 2003, J SYNCHROTRON RADIAT, V10, P23, DOI 10.1107/S0909049502017235; Zhang Y, 2008, BIOCHEMISTRY-US, V47, P205, DOI 10.1021/bi701406g	58	0	1	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT	2021	297	4							101091	10.1016/j.jbc.2021.101091	http://dx.doi.org/10.1016/j.jbc.2021.101091			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ2PR	34416230	Green Published, gold			2023-01-03	WOS:000755323700005
J	Luo, HY; Lu, J; Bai, YX; Mao, T; Wang, J; Fan, QX; Zhang, YP; Zhao, KL; Chen, ZD; Gao, SG; Li, JC; Fu, ZC; Gu, KS; Liu, ZH; Wu, L; Zhang, XD; Feng, JF; Niu, ZX; Ba, Y; Zhang, HL; Liu, Y; Zhang, L; Min, XH; Huang, J; Cheng, Y; Wang, D; Shen, Y; Yang, Q; Zou, JJ; Xu, RH				Luo, Huiyan; Lu, Jin; Bai, Yuxian; Mao, Teng; Wang, Jun; Fan, Qingxia; Zhang, Yiping; Zhao, Kuaile; Chen, Zhendong; Gao, Shegan; Li, Jiancheng; Fu, Zhichao; Gu, Kangsheng; Liu, Zhihua; Wu, Lin; Zhang, Xiaodong; Feng, Jifeng; Niu, Zuoxing; Ba, Yi; Zhang, Helong; Liu, Ying; Zhang, Li; Min, Xuhong; Huang, Jing; Cheng, Ying; Wang, Dong; Shen, Yu; Yang, Qing; Zou, Jianjun; Xu, Rui-Hua		ESCORT-1st Investigators	Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OPEN-LABEL; CANCER; MULTICENTER; PACLITAXEL; CISPLATIN; PEMBROLIZUMAB; RECURRENT; THERAPY	Key PointsQuestionDoes the addition of camrelizumab to chemotherapy improve outcomes when used as first-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma? FindingsIn this randomized clinical trial that included 596 patients with advanced or metastatic esophageal squamous cell carcinoma, camrelizumab combined with chemotherapy, compared with placebo and chemotherapy, significantly improved overall survival (15.3 vs 12.0 months, respectively; hazard ratio for death, 0.70) and progression-free survival (6.9 vs 5.6 months, respectively; hazard ratio for disease progression or death, 0.56). MeaningAmong patients with advanced or metastatic esophageal squamous cell carcinoma, an initial treatment strategy of camrelizumab combined with chemotherapy, compared with placebo and chemotherapy, resulted in improved overall survival and progression-free survival. ImportanceStandard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti-programmed death receptor 1 [PD-1] antibody) showed antitumor activity in previously treated advanced or metastatic esophageal squamous cell carcinoma. ObjectiveTo evaluate the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as a first-line treatment in advanced or metastatic esophageal squamous cell carcinoma. Design, Setting, and ParticipantsThis randomized, double-blind, placebo-controlled, multicenter, phase 3 trial (ESCORT-1st study) enrolled patients from 60 hospitals in China between December 3, 2018, and May 12, 2020 (final follow-up, October 30, 2020). A total of 751 patients were screened and 596 eligible patients with untreated advanced or metastatic esophageal squamous cell carcinoma were randomized. InterventionsPatients were randomized 1:1 to receive either camrelizumab 200 mg (n=298) or placebo (n=298), combined with up to 6 cycles of paclitaxel (175 mg/m(2)) and cisplatin (75 mg/m(2)). All treatments were given intravenously every 3 weeks. Main Outcomes and MeasuresCoprimary end points were overall survival (significance threshold, 1-sided P<.02) and progression-free survival (significance threshold, 1-sided P<.005). ResultsOf the 596 patients randomized (median age, 62 years [interquartile range, 56-67 years]; 523 men [87.8%]), 1 patient in the placebo-chemotherapy group did not receive planned treatment. A total of 490 patients (82.2%) had discontinued the study treatment. The median follow-up was 10.8 months. The overall survival for the camrelizumab-chemotherapy group was a median of 15.3 months (95% CI, 12.8-17.3; 135 deaths) vs a median of 12.0 months (95% CI, 11.0-13.3; 174 deaths) for the placebo-chemotherapy group (hazard ratio [HR] for death, 0.70 [95% CI, 0.56-0.88]; 1-sided P=.001). Progression-free survival for camrelizumab plus chemotherapy was a median of 6.9 months (95% CI, 5.8-7.4; 199 progression or deaths) vs 5.6 months (95% CI, 5.5-5.7; 229 progression or deaths) for the placebo-chemotherapy group (HR for progression or death, 0.56 [95% CI, 0.46-0.68]; 1-sided P<.001). Treatment-related adverse events of grade 3 or higher occurred in 189 patients (63.4%) in the camrelizumab-chemotherapy group and 201 (67.7%) in the placebo-chemotherapy group, including treatment-related deaths among 9 patients (3.0%) and 11 patients (3.7%), respectively. Conclusions and RelevanceAmong patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of camrelizumab to chemotherapy, compared with placebo and chemotherapy, significantly improved overall survival and progression-free survival. Trial RegistrationClinicalTrials.gov Identifier: NCT03691090 This clinical trial compares overall and progression-free survival of patients with advanced or metastatic esophageal squamous cell carcinoma randomized to camrelizumab plus chemotherapy or to placebo plus chemotherapy.	[Luo, Huiyan; Xu, Rui-Hua] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China; [Luo, Huiyan; Xu, Rui-Hua] Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou, Peoples R China; [Lu, Jin] Sichuan Canc Hosp, Chengdu, Peoples R China; [Bai, Yuxian] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China; [Mao, Teng] Shanghai Chest Hosp, Shanghai, Peoples R China; [Wang, Jun] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China; [Fan, Qingxia] Zhengzhou Univ, Affiliated Hosp, Zhengzhou, Peoples R China; [Zhang, Yiping] Zhejiang Canc Hosp, Hangzhou, Peoples R China; [Zhao, Kuaile] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Chen, Zhendong] Anhui Med Univ, Affiliated Hosp 2, Hefei, Peoples R China; [Gao, Shegan] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China; [Li, Jiancheng] Fujian Prov Canc Hosp, Fuzhou, Peoples R China; [Fu, Zhichao] Hosp Joint Logist Support Force, Fuzhou, Peoples R China; [Gu, Kangsheng] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China; [Liu, Zhihua] Jiangxi Prov Canc Hosp, Nanchang, Jiangxi, Peoples R China; [Wu, Lin] Hunan Canc Hosp, Changsha, Peoples R China; [Zhang, Xiaodong] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China; [Feng, Jifeng] Jiangsu Canc Hosp, Nanjing, Peoples R China; [Niu, Zuoxing] Shandong Univ, Shandong Canc Hosp, Jinan, Peoples R China; [Ba, Yi] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China; [Zhang, Helong] Air Force Med Univ, Affiliated Hosp 2, Xian, Peoples R China; [Liu, Ying] Henan Canc Hosp, Zhengzhou, Peoples R China; [Zhang, Li] Chongqing Three Gorges Cent Hosp, Chongqing, Peoples R China; [Min, Xuhong] Anhui Chest Hosp, Hefei, Peoples R China; [Huang, Jing] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China; [Cheng, Ying] Jilin Canc Hosp, Changchun, Peoples R China; [Wang, Dong] Army Med Ctr PLA, Chongqing, Peoples R China; [Shen, Yu; Yang, Qing; Zou, Jianjun] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Harbin Medical University; Shanghai Jiao Tong University; Hebei Medical University; Zhengzhou University; Zhejiang Cancer Hospital; Fudan University; Anhui Medical University; Henan University of Science & Technology; Anhui Medical University; Peking University; Nanjing Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Tianjin Medical University; Air Force Military Medical University; Zhengzhou University; Chongqing Three Gorges University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS	Xu, RH (corresponding author), Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Med Oncol,Collaborat Innovat Ctr Canc Med, 651 Dongfeng Rd E, Guangzhou 510060, Peoples R China.	xurh@sysucc.org.cn	骆, 卉妍/GWR-3383-2022; Xu, Rui-Hua/AAW-4766-2021	骆, 卉妍/0000-0001-6312-9299; Xu, Rui-Hua/0000-0001-9771-8534; Gu, Kangsheng/0000-0002-5800-5256				Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burtness B, 2019, LANCET, V394, P1915, DOI 10.1016/S0140-6736(19)32591-7; Cocks K, 2008, EUR J CANCER, V44, P1793, DOI 10.1016/j.ejca.2008.05.008; European Organization for Research and Treatment of Cancer, QUALITY LIFE; Fang WF, 2018, LANCET ONCOL, V19, P1338, DOI 10.1016/S1470-2045(18)30495-9; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Huang J, 2020, LANCET ONCOL, V21, P832, DOI 10.1016/S1470-2045(20)30110-8; JENNISON C, 1984, CONTROL CLIN TRIALS, V5, P33, DOI 10.1016/0197-2456(84)90148-X; Kato K, 2020, ANN ONCOL, V31, pS1192, DOI 10.1016/j.annonc.2020.08.2298; Kato K, 2019, LANCET ONCOL, V20, P1506, DOI 10.1016/S1470-2045(19)30626-6; Kojima T, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01888; Kulangara K, 2019, ARCH PATHOL LAB MED, V143, P330, DOI 10.5858/arpa.2018-0043-OA; Liu Y, 2016, AM J CANCER RES, V6, P2345; National Comprehensive Cancer Network, 2021, ESOPH ESOPH JUNCT CA; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Petrasch S, 1998, BRIT J CANCER, V78, P511, DOI 10.1038/bjc.1998.524; Qin SK, 2020, LANCET ONCOL, V21, P571, DOI 10.1016/S1470-2045(20)30011-5; Song YQ, 2019, CLIN CANCER RES, V25, P7363, DOI 10.1158/1078-0432.CCR-19-1680; Sun S, 2019, ONCOL RES TREAT, V42, P115, DOI 10.1159/000495700; Wang F, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00886-2; Wileyto EP, 2013, BIOSTATISTICS, V14, P340, DOI 10.1093/biostatistics/kxs043; Yamamoto S, 2020, FUTURE ONCOL, V16, P2673, DOI 10.2217/fon-2020-0545; Zhang HZ, 2012, CHIN J CANCER, V31, P281, DOI 10.5732/cjc.011.10390; Zhang XD, 2008, AM J CLIN ONCOL-CANC, V31, P29, DOI 10.1097/COC.0b013e3181131ca9; Zhou CC, 2021, LANCET RESP MED, V9, P305, DOI 10.1016/S2213-2600(20)30365-9	26	91	93	36	96	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	2021	326	10					916	925		10.1001/jama.2021.12836	http://dx.doi.org/10.1001/jama.2021.12836			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW4LI	34519801	Bronze, Green Published			2023-01-03	WOS:000700129100011
J	Kadri, SS; Sun, JF; Lawandi, A; Strich, JR; Busch, LM; Keller, M; Babiker, A; Yek, C; Malik, S; Krack, J; Dekker, JP; Spaulding, AB; Ricotta, E; Powers, JH; Rhee, C; Klompas, M; Athale, J; Boehmer, TK; Gundlapalli, AV; Bentley, W; Datta, SD; Danner, RL; Demirkale, CY; Warner, S				Kadri, Sameer S.; Sun, Junfeng; Lawandi, Alexander; Strich, Jeffrey R.; Busch, Lindsay M.; Keller, Michael; Babiker, Ahmed; Yek, Christina; Malik, Seidu; Krack, Janell; Dekker, John P.; Spaulding, Alicen B.; Ricotta, Emily; Powers, John H.; Rhee, Chanu; Klompas, Michael; Athale, Janhavi; Boehmer, Tegan K.; Gundlapalli, Adi, V; Bentley, William; Datta, S. Deblina; Danner, Robert L.; Demirkale, Cumhur Y.; Warner, Sarah			Association Between Caseload Surge and COVID-19 Survival in 558 US Hospitals, March to August 2020	ANNALS OF INTERNAL MEDICINE			English	Article							CARE; COMORBIDITIES; DEATH	Background: Several U.S. hospitals had surges in COVID-19 caseload, but their effect on COVID-19 survival rates remains unclear, especially independent of temporal changes in survival. Objective: To determine the association between hospitals' severity-weighted COVID-19 caseload and COVID-19 mortality risk and identify effect modifiers of this relationship. Design: Retrospective cohort study. (ClinicalTrials.gov: NCT04688372) Setting: 558 U.S. hospitals in the Premier Healthcare Database. Participants: Adult COVID-19-coded inpatients admitted from March to August 2020 with discharge dispositions by October 2020. Measurements: Each hospital-month was stratified by percentile rank on a surge index (a severity-weighted measure of COVID-19 caseload relative to pre-COVID-19 bed capacity). The effect of surge index on risk-adjusted odds ratio (aOR) of in-hospital mortality or discharge to hospice was calculated using hierarchical modeling; interaction by surge attributes was assessed. Results: Of 144116 inpatients with COVID-19 at 558 U.S. hospitals, 78144 (54.2%) were admitted to hospitals in the top surge index decile. Overall, 25344 (17.6%) died; crude COVID-19 mortality decreased over time across all surge index strata. However, compared with nonsurging (<50th surge index percentile) hospital-months, aORs in the 50th to 75th, 75th to 90th, 90th to 95th, 95th to 99th, and greater than 99th percentiles were 1.11 (95% CI, 1.01 to 1.23), 1.24 (CI, 1.12 to 1.38), 1.42 (CI, 1.27 to 1.60), 1.59 (CI, 1.41 to 1.80), and 2.00 (CI, 1.69 to 2.38), respectively. The surge index was associated with mortality across ward, intensive care unit, and intubated patients. The surge-mortality relationship was stronger in June to August than in March to May (slope difference, 0.10 [CI, 0.033 to 0.16]) despite greater corticosteroid use and more judicious intubation during later and higher-surging months. Nearly 1 in 4 COVID-19 deaths (5868 [CI, 3584 to 8171]; 23.2%) was potentially attributable to hospitals strained by surging caseload. Limitation: Residual confounding. Conclusion: Despite improvements in COVID-19 survival between March and August 2020, surges in hospital COVID-19 caseload remained detrimental to survival and potentially eroded benefits gained from emerging treatments. Bolstering preventive measures and supporting surging hospitals will save many lives.	[Kadri, Sameer S.; Sun, Junfeng; Lawandi, Alexander; Strich, Jeffrey R.; Busch, Lindsay M.; Keller, Michael; Yek, Christina; Malik, Seidu; Krack, Janell; Athale, Janhavi; Danner, Robert L.; Demirkale, Cumhur Y.; Warner, Sarah] NIH, Clin Ctr, 10 Ctr Dr,Bldg 10,Room 2C-145, Bethesda, MD 20892 USA; [Strich, Jeffrey R.; Boehmer, Tegan K.] US PHS, Rockville, MD USA; [Busch, Lindsay M.; Babiker, Ahmed] Emory Univ, Sch Med, Atlanta, GA USA; [Dekker, John P.; Ricotta, Emily] Natl Inst Allergy & Infect Dis, Bethesda, MD USA; [Spaulding, Alicen B.] Childrens Minnesota Res Inst, Minneapolis, MN USA; [Powers, John H.] Frederick Natl Lab Canc Res, Frederick, MD USA; [Rhee, Chanu; Klompas, Michael] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA; [Rhee, Chanu; Klompas, Michael] Harvard Pilgrim Hlth Care Inst, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA; [Athale, Janhavi] Mayo Clin Arizona, Phoenix, AZ USA; [Boehmer, Tegan K.; Gundlapalli, Adi, V; Bentley, William; Datta, S. Deblina] Ctr Dis Control & Prevent, Atlanta, GA USA; [Bentley, William] Gen Dynam Informat Technol, Falls Church, VA USA; [Busch, Lindsay M.; Babiker, Ahmed] Emory Univ Hosp, Midtown Campus,550 Peachtree St Northeast, Atlanta, GA 30308 USA; [Krack, Janell] NIH, Clin Ctr, 10 Ctr Dr,Bldg 10,1C240J, Bethesda, MD 20892 USA; [Dekker, John P.] NIAID, NIH, 9000 Rockville Pike,Bldg 29,Room 5NN08, Bethesda, MD 20892 USA; [Spaulding, Alicen B.] NIAID, NIH, 40 Convent Dr,Bldg 40,Room 1100, Bethesda, MD 20892 USA; [Ricotta, Emily] NIAID, NIH, 5601 Fishers Lane,Bldg 5601FL,Room 7D18, Rockville, MD 20892 USA; [Powers, John H.] NIAID, NIH, 5601 Fishers Lane,Bldg 5601FL,Room 4D50, Rockville, MD 20892 USA; [Athale, Janhavi] Mayo Clin Arizona, Crit Care Dept, 5881 East Mayo Blvd, Phoenix, AZ 85054 USA; [Boehmer, Tegan K.; Gundlapalli, Adi, V] CDC Covid Task Force, 2400 Century Ctr,Room 6209,MS V24-6, Atlanta, GA 30345 USA; [Bentley, William] CDC Covid Task Force, Roybal Bldg 24,MS H24-8, Atlanta, GA 30333 USA; [Datta, S. Deblina] CDC Covid Task Force, Roybal Bldg 24,Room 2107,MS H24-2, Atlanta, GA 30333 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); United States Public Health Service; Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Children's Hospitals & Clinics of Minnesota; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard Pilgrim Health Care; Mayo Clinic; Mayo Clinic Phoenix; Centers for Disease Control & Prevention - USA; Emory University; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Mayo Clinic; Mayo Clinic Phoenix	Kadri, SS (corresponding author), NIH, Clin Ctr, Clin Epidemiol Sect, Crit Care Med Dept, 10 Ctr Dr,Bldg 10,Room 2C-145, Bethesda, MD 20892 USA.	Sameer.kadri@nih.gov	Ricotta, Emily/AGX-9953-2022; Lawandi, Alexander/AAA-8505-2022	Ricotta, Emily/0000-0001-9928-8275; Lawandi, Alexander/0000-0001-7948-3161; Powers III, John H/0000-0002-5150-5119; Babiker, Ahmed/0000-0003-0578-4871; Kadri-Rodriguez, Sameer/0000-0002-4420-9004; Busch, Lindsay/0000-0002-5332-5883	Intramural Research Program of the National Institutes of Health Clinical Center; National Institute of Allergy and Infectious Diseases; National Cancer Institute [HHSN261200800001E]	Intramural Research Program of the National Institutes of Health Clinical Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded in part by the Intramural Research Program of the National Institutes of Health Clinical Center, the National Institute of Allergy and Infectious Diseases, and the National Cancer Institute (contract no. HHSN261200800001E).	Abir M, 2020, INSTRUCTIONS USING R; Acosta AM, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa528; [Anonymous], 2021, LANCET, V397, P1683, DOI 10.1016/S0140-6736(21)01052-7; Asch DA, 2021, JAMA INTERN MED, V181, P471, DOI 10.1001/jamainternmed.2020.8193; Auld SC, 2020, CRIT CARE MED, V48, pE1382, DOI 10.1097/CCM.0000000000004687; Auld SC, 2020, CRIT CARE MED, V48, pE799, DOI 10.1097/CCM.0000000000004457; Begg MD, 2003, STAT MED, V22, P2591, DOI 10.1002/sim.1524; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bieler GS, 2010, AM J EPIDEMIOL, V171, P618, DOI 10.1093/aje/kwp440; Bravata DM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.34266; Centers for Disease Control and Prevention, COV DAT TRACK; Centers for Medicare & Medicaid Services, COVID 19 EM DECL BLA; Centers for Medicare & Medicaid Services, 2020, CTR MED MED MED SERV; Chao TN, 2020, ANN SURG, V272, pE181, DOI 10.1097/SLA.0000000000004166; Choi HK, 2012, AM J EMERG MED, V30, P1433, DOI 10.1016/j.ajem.2011.10.027; Manchanda ECC, 2021, J RACIAL ETHN HEALTH, V8, P824, DOI 10.1007/s40615-020-00840-5; Courtright KR, 2017, CRIT CARE MED, V45, P1863, DOI 10.1097/CCM.0000000000002651; Crutchfield P, 2020, AM J BIOETHICS, V20, P84, DOI 10.1080/15265161.2020.1779395; Demoule A, 2020, AM J RESP CRIT CARE, V202, P1039, DOI 10.1164/rccm.202005-2007LE; Doidge JC, 2021, AM J RESP CRIT CARE, V203, P565, DOI 10.1164/rccm.202008-3212OC; Fiolet T, 2021, CLIN MICROBIOL INFEC, V27, P19, DOI 10.1016/j.cmi.2020.08.022; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Griffith GJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19478-2; Gupta S, 2020, JAMA INTERN MED, V180, P1436, DOI 10.1001/jamainternmed.2020.3596; Harris Gavin H, 2020, Crit Care Explor, V2, pe0136, DOI 10.1097/CCE.0000000000000136; Hart R., 2021, FORBES; Hatfield KM, 2018, CRIT CARE MED, V46, P1753, DOI [10.1097/CCM.0000000000003324, 10.1097/ccm.0000000000003324]; Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horwitz LI, 2021, J HOSP MED, V16, P90, DOI 10.12788/jhm.3552; Kadri Sameer S, 2021, Open Forum Infect Dis, V8, pofaa616, DOI 10.1093/ofid/ofaa616; Kadri SS, 2020, JAMA-J AM MED ASSOC, V324, P2553, DOI 10.1001/jama.2020.20323; Landon BE, 2006, ARCH INTERN MED, V166, P2511, DOI 10.1001/archinte.166.22.2511; Lasater KB, 2021, BMJ QUAL SAF, V30, P639, DOI 10.1136/bmjqs-2020-011512; Ledford H, 2020, NATURE, V587, P190, DOI 10.1038/d41586-020-03132-4; National Institutes of Health, COVID 19 TREATM GUID; NRCC Healthcare Resilience Task Force, 2020, MED OP COORD CELLS T, VFirst; Perez S, 2020, MMWR-MORBID MORTAL W, V69, P1827, DOI 10.15585/mmwr.mm6948e1; Premier Applied Sciences, 2020, 1 HEALTHC DAT WHIT P; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Raschke RA, 2021, JAMA-J AM MED ASSOC, V325, P1469, DOI 10.1001/jama.2021.1545; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rosenthal N, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.29058; Rubinson L, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.35041; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Tarnow-Mordi WO, 2000, LANCET, V356, P185, DOI 10.1016/S0140-6736(00)02478-8; Thompson AE, 2020, JAMA INTERN MED, V180, P1537, DOI 10.1001/jamainternmed.2020.3030; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Washington Nicole L, 2021, medRxiv, DOI 10.1101/2021.02.06.21251159; Woolf SH, 2021, JAMA-J AM MED ASSOC, V325, P123, DOI 10.1001/jama.2020.24865	50	68	65	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP	2021	174	9					1240	+		10.7326/M21-1213	http://dx.doi.org/10.7326/M21-1213			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA5GQ	34224257	Green Published			2023-01-03	WOS:000720675500022
J	Gelissen, H; de Grooth, HJ; Smulders, Y; Wils, EJ; de Ruijter, W; Vink, R; Smit, B; Rottgering, J; Atmowihardjo, L; Girbes, A; Elbers, P; Tuinman, PR; Oudemans-van Straaten, H; de Man, A				Gelissen, Harry; de Grooth, Harm-Jan; Smulders, Yvo; Wils, Evert-Jan; de Ruijter, Wouter; Vink, Roel; Smit, Bob; Rottgering, Jantine; Atmowihardjo, Leila; Girbes, Armand; Elbers, Paul; Tuinman, Pieter-Roel; Oudemans-van Straaten, Heleen; de Man, Angelique			Effect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill Patients A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY; THERAPY; RATIO; VENTILATION; MULTICENTER	IMPORTANCE Hyperoxemia may increase organ dysfunction in critically ill patients, but optimal oxygenation targets are unknown. OBJECTIVE To determine whether a low-normal Pao(2) target compared with a high-normal target reduces organ dysfunction in critically ill patients with systemic inflammatory response syndrome (SIRS). DESIGN, SETTING, AND PARTICIPANTS Multicenter randomized clinical trial in 4 intensive care units in the Netherlands. Enrollment was from February 2015 to October 2018, with end of follow-up to January 2019, and included adult patients admitted with 2 or more SIRS criteria and expected stay of longer than 48 hours. A total of 9925 patients were screened for eligibility, of whom 574 fulfilled the enrollment criteria and were randomized. INTERVENTIONS Target Pao(2) ranges were 8 to 12 kPa (low-normal, n = 205) and 14 to 18 kPa (high-normal, n = 195). An inspired oxygen fraction greater than 0.60 was applied only when clinically indicated. MAIN OUTCOMES AND MEASURES Primary end point was SOFA(RANK), a ranked outcome of nonrespiratory organ failure quantified by the nonrespiratory components of the Sequential Organ Failure Assessment (SOFA) score, summed over the first 14 study days. Participants were ranked from fastest organ failure improvement (lowest scores) to worsening organ failure or death (highest scores). Secondary end points were duration of mechanical ventilation, in-hospital mortality, and hypoxemic measurements. RESULTS Among the 574 patients who were randomized, 400 (70%) were enrolled within 24 hours (median age, 68 years; 140 women [35%]), all of whom completed the trial. The median Pao(2) difference between the groups was -1.93 kPa (95% CI, -2.12 to -1.74; P < .001). The median SOFA(RANK) score was -35 points in the low-normal Pao(2) group vs -40 in the high-normal Pao(2) group (median difference, 10 [95% CI, 0 to 21]; P = .06). There was no significant difference in median duration of mechanical ventilation (3.4 vs 3.1 days; median difference, -0.15 [95% CI, -0.88 to 0.47]; P = .59) and in-hospital mortality (32% vs 31%; odds ratio, 1.04 [95% CI, 0.67 to 1.63]; P = .91). Mild hypoxemic measurements occurred more often in the low-normal group (1.9% vs 1.2%; median difference, 0.73 [95% CI, 0.30 to 1.20]; P < .001). Acute kidney failure developed in 20 patients (10%) in the low-normal Pao(2) group and 21 patients (11%) in the high-normal Pao(2) group, and acute myocardial infarction in 6 patients (2.9%) in the low-normal Pao(2) group and 7 patients (3.6%) in the high-normal Pao(2) group. CONCLUSIONS AND RELEVANCE Among critically ill patients with 2 or more SIRS criteria, treatment with a low-normal Pao(2) target compared with a high-normal Pao(2) target did not result in a statistically significant reduction in organ dysfunction. However, the study may have had limited power to detect a smaller treatment effect than was hypothesized.	[Gelissen, Harry; de Grooth, Harm-Jan; Smit, Bob; Rottgering, Jantine; Atmowihardjo, Leila; Girbes, Armand; Elbers, Paul; Tuinman, Pieter-Roel; Oudemans-van Straaten, Heleen; de Man, Angelique] Locat VUmc, Amsterdam Cardiovasc Sci, Amsterdam UMC,Amsterdam Med Data Sci,Res VUmc Int, Amsterdam Infect & Immun Inst,Dept Intens Care Me, De Boelelaan 1117, NL-1007 MB Amsterdam, Netherlands; [de Grooth, Harm-Jan] Locat VUmc, Amsterdam UMC, Dept Anesthesiol, Amsterdam, Netherlands; [Smulders, Yvo] Locat VUmc, Amsterdam UMC, Dept Internal Med, Amsterdam, Netherlands; [Wils, Evert-Jan] Franciscus Gasthuis & Vlietland, Dept Intens Care, Rotterdam, Netherlands; [de Ruijter, Wouter] Noordwest Ziekenhuisgrp, Dept Intens Care, Alkmaar, Netherlands; [Vink, Roel] Tergooiziekenhuizen, Dept Intens Care, Hilversum, Netherlands; [Smit, Bob] HAGA Ziekenhuis, Dept Clin Chem, The Hague, Netherlands	University of Amsterdam; University of Amsterdam; Franciscus Gasthuis; Medical Center Of Alkmaar; Haga Hospital	de Man, A (corresponding author), Locat VUmc, Amsterdam Cardiovasc Sci, Amsterdam UMC,Amsterdam Med Data Sci,Res VUmc Int, Amsterdam Infect & Immun Inst,Dept Intens Care Me, De Boelelaan 1117, NL-1007 MB Amsterdam, Netherlands.	ame.deman@amsterdamumc.nl	Elbers, Paul/AHA-0344-2022; Wils, Evert-jan/ABB-3992-2021	Elbers, Paul/0000-0003-0447-6893; Rottgering, Jantine/0000-0002-9392-3239; de Grooth, Harm-Jan/0000-0002-7499-076X; de Man, Angelique/0000-0001-8738-8295	Netherlands Organization for Health Research and Development	Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development)	This trial was funded by the Netherlands Organization for Health Research and Development.	Asfar P, 2017, LANCET RESP MED, V5, P180, DOI 10.1016/S2213-2600(17)30046-2; Barrot L, 2020, NEW ENGL J MED, V382, P999, DOI 10.1056/NEJMoa1916431; Barth E, 2008, CRIT CARE MED, V36, P495, DOI 10.1097/01.CCM.0B013E318161FC45; Belda FJ, 2005, JAMA-J AM MED ASSOC, V294, P2035, DOI 10.1001/jama.294.16.2035; Bitterman H, 1996, AM J PHYSIOL-HEART C, V271, pH203, DOI 10.1152/ajpheart.1996.271.1.H203; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; Cornet AD, 2013, CRIT CARE, V17, DOI 10.1186/cc12554; de Grooth HJ, 2020, JAMA-J AM MED ASSOC, V323, P792, DOI 10.1001/jama.2019.21981; de Grooth HJ, 2018, INTENS CARE MED, V44, P464, DOI 10.1007/s00134-017-4859-0; de Grooth HJ, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1609-1; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Gershengorn HB, 2014, JAMA INTERN MED, V174, P1746, DOI 10.1001/jamainternmed.2014.3297; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; Hauser B, 2009, CRIT CARE MED, V37, P2465, DOI 10.1097/CCM.0b013e3181aee8ad; Kahan BC, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5840; Kallet RH, 2013, RESP CARE, V58, P123, DOI 10.4187/respcare.01963; Karbing DS, 2007, CRIT CARE, V11, DOI 10.1186/cc6174; Kernan WN, 1999, J CLIN EPIDEMIOL, V52, P19, DOI 10.1016/S0895-4356(98)00138-3; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lehmann EL., 1961, P 4 BERK S MATH STAT; Mackle D, 2020, NEW ENGL J MED, V382, P989, DOI 10.1056/NEJMoa1903297; Ortiz-Prado E, 2019, AM J BLOOD RES, V9, P1; Panwar R, 2016, AM J RESP CRIT CARE, V193, P43, DOI 10.1164/rccm.201505-1019OC; Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617; Schjorring OL, 2021, NEW ENGL J MED, V384, P1301, DOI 10.1056/NEJMoa2032510; Smit B, 2018, MICROCIRCULATION, V25, DOI 10.1111/micc.12433; Therneau T.M., 2015, PACKAGE SURVIVAL ANA; VanderWeele TJ, 2013, BIOMETRICS, V69, P561, DOI 10.1111/biom.12071; Whiteley JP, 2002, BRIT J ANAESTH, V88, P771, DOI 10.1093/bja/88.6.771; ZANDER R, 1990, SCAND J CLIN LAB INV, V50, P187, DOI 10.3109/00365519009087509	31	20	22	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	2021	326	10					940	948		10.1001/jama.2021.13011	http://dx.doi.org/10.1001/jama.2021.13011		AUG 2021	9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW4LI	34463696	Green Published, Bronze			2023-01-03	WOS:000692210000001
J	Ansaldo, E; Belkaidi, Y				Ansaldo, Eduard; Belkaidi, Yasmine			How microbiota improve immunotherapy	SCIENCE			English	Editorial Material							IMMUNITY; THERAPY		[Ansaldo, Eduard; Belkaidi, Yasmine] NIAID, NIH, Met Immun Sect, Lab Host Immun & Microbiome, Bethesda, MD 20892 USA; [Belkaidi, Yasmine] NIAID, NIAID Microbiome Program, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ansaldo, E (corresponding author), NIAID, NIH, Met Immun Sect, Lab Host Immun & Microbiome, Bethesda, MD 20892 USA.	eduard.ansaldogine@nih.gov; ybelkaid@niaid.nih.gov			Division of Intramural Research of the National Institute of Allergy and Infectious Diseases (MAID)	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases (MAID)	The authors are supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases (MAID).	Ansaldo E, 2021, ANNU REV IMMUNOL, V39, P449, DOI 10.1146/annurev-immunol-093019-112348; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Caruso R, 2014, IMMUNITY, V41, P898, DOI 10.1016/j.immuni.2014.12.010; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; Fluckiger Y, 1998, INT J MANPOWER, V19, P369, DOI 10.1108/01437729810233190; Grit M. E., 2021, SCIENCE, V373, P1040; Kim D, 2016, NAT MED, V22, P524, DOI 10.1038/nm.4075; lwamura C., 2017, BLOOD, V129, P171; Malson V., 2018, SCIENCE, V359, P104; Mayer L. F., 2020, SCIENCE, V369, P1481; Priem B, 2020, CELL, V183, P786, DOI 10.1016/j.cell.2020.09.059; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sepich-Poore GD, 2021, SCIENCE, V371, P1331, DOI 10.1126/science.abc4552; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329	15	13	13	5	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2021	373	6558					966	967		10.1126/science.ab13655	http://dx.doi.org/10.1126/science.ab13655			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UH8WC	34446595				2023-01-03	WOS:000690202600019
J	Natnael, T; Adane, M; Alemnew, Y; Andualem, A; Hailu, F				Natnael, Tarikuwa; Adane, Metadel; Alemnew, Yeshiwork; Andualem, Atsedemariam; Hailu, Faris			COVID-19 knowledge, attitude and frequent hand hygiene practices among taxi drivers and associated factors in urban areas of Ethiopia	PLOS ONE			English	Article							INFLUENZA TRANSMISSION; UNITED-STATES; ADULTS; PREVENTION; RESIDENTS; BEHAVIORS; FACEMASKS; CHINESE; HEALTH; WUHAN	Background Although several studies have been conducted on COVID-19 knowledge, attitude and prevention practices among healthcare workers and the general population, there has not been any study among taxi drivers in Ethiopia, including Dessie City and Kombolcha Town, the lack of which hinders providing evidence-based interventions to this target group. Thus, this study was designed to contribute to proper planning of COVID-19 intervention measures among taxi drivers in Dessie City and Kombolcha Town, Ethiopia. Methods A cross-sectional study was conducted among 417 taxi drivers in Dessie City and Kombolcha Town during July to August, 2020. The data was collected using a structured questionnaire and an observational checklist. The collected data was checked, coded and entered to EpiData version 4.6 and exported to Statistical Package for the Social Sciences (SPSS) version 25.0 for data cleaning and analysis. The outcome variables of this study were good or poor knowledge, positive or negative attitude and good or poor frequent hand hygiene practices towards COVID-19. Bivariate (Crude Odds Ratio [COR]) and multivariable (Adjusted Odds Ratio [AOR]) logistic regression analysis were employed to identify factors significantly associated with good knowledge, positive attitude and good frequent hand hygiene practices among taxi drivers. Significance level of variables was declared at a p < 0.05 from the adjusted analysis. Main findings Out of the total 417 taxi drivers, 69.8% [95% CI: 65.2-73.9], 67.6% [95%CI: 63.1-72.2] and 66.4% [95% CI: 62.1-71.0] of the drivers had good knowledge, positive attitude and good frequent hand hygiene practices, respectively. Educational level (AOR = 7.55, 95% CI = 4.55-12.54), place of residence (AOR = 5.41, 95% CI = 1.4-20.08) and attitude towards COVID-19 prevention (AOR = 1.67, 95% CI = 1.02-2.74) were factors associated with good knowledge about COVID-19. Further, age of taxi drivers greater than 30 years (AOR = 3.01, 95% CI = 1.76-5.13), educational level of secondary or above (AOR = 3.16, 95% CI = 1.88-5.31), income (AOR = 3.36, 95% CI = 1.48-7.61), and knowledge about COVID-19 (AOR = 2.1, 95% CI = 1.21-3.54) were factors associated with positive attitude towards COVID-19 prevention. In addition, attitude towards COVID-19 (AOR = 5.5, 95% CI = 3.40-8.88) and educational level (AOR = 1.84, 95% CI = 1.15-2.95) were the factors associated with good frequent hand hygiene practices. Conclusion We concluded that the rates of good knowledge, positive attitude and good frequent hand hygiene practices were relatively low among taxi drivers in Dessie City and Kombolcha Town. We strongly recommended providing training about COVID-19 prevention measures for taxi drivers that considers age, education status and attitude areas essential to improve their knowledge, attitude and frequent hand hygiene practices to prevent the spread of COVID-19.	[Natnael, Tarikuwa; Adane, Metadel] Wollo Univ, Coll Med & Hlth Sci, Dept Environm Hlth, Dessie, Ethiopia; [Alemnew, Yeshiwork; Hailu, Faris] Wollo Univ, Coll Nat Sci, Dept Biol, Dessie, Ethiopia; [Andualem, Atsedemariam] Wollo Univ, Coll Med & Hlth Sci, Sch Nursing & Midwifery, Dept Nursing, Dessie, Ethiopia	University of Gondar; University of Gondar	Adane, M (corresponding author), Wollo Univ, Coll Med & Hlth Sci, Dept Environm Hlth, Dessie, Ethiopia.	metadel.adane2@gmail.com	Adane, Metadel/AFQ-9478-2022	Adane, Metadel/0000-0002-7039-4768	Wollo University	Wollo University	Wollo University funded this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelhafiz AS, 2020, J COMMUN HEALTH, V45, P881, DOI 10.1007/s10900-020-00827-7; Afzal MS, 2021, J COMMUN HEALTH, V46, P476, DOI 10.1007/s10900-020-00875-z; Aiello AE, 2008, AM J PUBLIC HEALTH, V98, P1372, DOI 10.2105/AJPH.2007.124610; Aiello AE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029744; Akalu Y, 2020, INFECT DRUG RESIST, V13, P1949, DOI 10.2147/IDR.S258736; Al-Ahdab S., 2020, BMC PUBLIC HEALTH, V21, P296; Asemahagn MA, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-020-00254-3; Assefa D., 2020, COVID 19 PANDEMIC IT; Aweke Z, 2020, CURR MED RES OPIN, V36, P1955, DOI 10.1080/03007995.2020.1835854; Ayinde O., 2020, CROSS SECTIONAL STUD; Azlan AA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233668; Banik R., 2020, INVESTIGATING KNOWLE; Benor S., 2020, ASSESSMENT KNOWLEDGE; Bhuiyan MMR, 2020, RES SQUARE; Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826; Centers for Disease Control and Prevent ion, COR DIS 2019 COVID 1; Centers for Disease Control and Prevnetion, 2020, WHAT YOU SHOULD KNOW; Chen Xuyu, 2020, Int J Environ Res Public Health, V17, DOI 10.3390/ijerph17082893; Clements John M, 2020, JMIR Public Health Surveill, V6, pe19161, DOI 10.2196/19161; Control CfD Prevention, 2020, WHAT YOU SHOULD KNOW; Cowling BJ, 2009, ANN INTERN MED, V151, P437, DOI 10.7326/0003-4819-151-7-200910060-00142; CSA, 2013, POPULATION PROJECTIO; Czeisler ME, 2020, MMWR-MORBID MORTAL W, V69, P1485, DOI 10.15585/mmwr.mm6941a3; Devkota HR., 2020, HOW DOES PUBLIC KNOW; Edet CK., 2020, KNOWLEDGE ATTITUDE P; El-Gilany A-H., KNOWLEDGE ATTITUDE P; Ferdous MZ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239254; Fung ICH, 2006, TROP MED INT HEALTH, V11, P1749, DOI 10.1111/j.1365-3156.2006.01734.x; Gholamnia R., 2020, PUBLIC KNOWLEDGE ATT; Glabska D, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12124930; Gondwe G., 2020, UN C TRADE DEV; Haftom M, 2020, INFECT DRUG RESIST, V13, P3727, DOI 10.2147/IDR.S275744; Haston JC, 2020, MMWR-MORBID MORTAL W, V69, P1443, DOI [10.15585/mmwr.mm6940a2, 10.1101/2020.04.01.20050039, 10.15585/mmwr.mm6940a2externalicon]; Hirose R, 2021, CLIN INFECT DIS, V73, pE4329, DOI 10.1093/cid/ciaa1517; Hosmer DW, 2013, WILEY SER PROBAB ST, P1, DOI 10.1002/9781118548387; Hossain MA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239646; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Islam MS, 2021, J PUBLIC HEALTH-UK, V43, P13, DOI 10.1093/pubmed/fdaa182; Jawed F., 2020, MED J ISLAMIC REPUBL, V34, P908; Jefferson T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3675; Jemal B, 2020, KNOWLEDGE ATTITUDE P; Kassa AM, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-044202; Kebede Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233744; Kelsey JL, 1996, METHODS OBSERVATIONA; Kombolcha City Administration, 2020, ANN REP KOMB CITY 20; LARSON E, 1988, INFECT CONT HOSP EP, V9, P28, DOI 10.1086/645729; Lee M., 2020, ASS KNOWLEDGE ATTITU; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Luby SP, 2005, LANCET, V366, P225, DOI 10.1016/S0140-6736(05)66912-7; Ma QX, 2020, J MED VIROL, V92, P1567, DOI 10.1002/jmv.25805; Machida M, 2020, INT J INFECT DIS, V94, P139, DOI 10.1016/j.ijid.2020.04.014; Mechessa DF, 2020, INT J GEN MED, V13, P507, DOI 10.2147/IJGM.S263665; MOH EPHI, 2020, PREV METH COVID 19; Mold A., 2020, IMPACT COVID 19 CRIS; Muluve E., 2020, SSRN ELECT J; Natnael T, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247954; Ngwewondo A, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008700; Nigussie TF., 2020, GSJ, V8; Olum R, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00181; Organization WH, 2020, COVID 19 WEEKLY EPID; Otter JA, 2016, J HOSP INFECT, V92, P235, DOI 10.1016/j.jhin.2015.08.027; Park JH, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-222; Paudel S, 2020, KNOWLEDGE ATTITUDE P, DOI DOI 10.21203/RS.3.RS-31044/V1; Peng YL, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09392-z; Reuben RC, 2021, J COMMUN HEALTH, V46, P457, DOI 10.1007/s10900-020-00881-1; Salman M, 2020, DRUGS THER PERSPECT, V36, P319, DOI 10.1007/s40267-020-00737-7; Saqlain M, 2020, J HOSP INFECT, V105, P419, DOI 10.1016/j.jhin.2020.05.007; Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; Storr Julie, 2013, Nurs Times, V109, P12; Tadesse AW, 2020, J PUBLIC HEALTH RES, DOI [DOI 10.21203/RS.3.RS-38099/V1, 10.21203/rs.3.rs-38099/v1]; Tang CSK, 2004, PREV MED, V39, P1187, DOI 10.1016/j.ypmed.2004.04.032; Taye GM, 2020, INFECT DRUG RESIST, V13, P4203, DOI 10.2147/IDR.S283999; Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018; White S, 2020, INT J HYG ENVIR HEAL, V227, DOI 10.1016/j.ijheh.2020.113512; WHO, 2020, RISK COMM COMM ENG R, DOI [10.3390/ijerph17238838, DOI 10.3390/IJERPH17238838]; Yue ST, 2021, J COMMUN HEALTH, V46, P286, DOI 10.1007/s10900-020-00877-x; Zhang M, 2020, J HOSP INFECT, V105, P183, DOI 10.1016/j.jhin.2020.04.012; Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	80	1	1	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2021	16	8							e0253452	10.1371/journal.pone.0253452	http://dx.doi.org/10.1371/journal.pone.0253452			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UA6JM	34359068	gold, Green Published			2023-01-03	WOS:000685266400030
J	Rahman, MA; Shanjana, Y; Tushar, MI; Mahmud, T; Rahman, GMS; Milan, ZH; Sultana, T; Chowdhury, AMLH; Bhuiyan, MA; Islam, MR; Reza, HM				Rahman, Md. Ashrafur; Shanjana, Yeasna; Tushar, Md. Ismail; Mahmud, Tarif; Rahman, Ghazi Muhammad Sayedur; Milan, Zahid Hossain; Sultana, Tamanna; Chowdhury, Ali Mohammed Lutful Hoq; Bhuiyan, Mohiuddin Ahmed; Islam, Md. Rabiul; Reza, Hasan Mahmud			Hematological abnormalities and comorbidities are associated with COVID-19 severity among hospitalized patients: Experience from Bangladesh	PLOS ONE			English	Article							C-REACTIVE PROTEIN; TYPE-2 DIABETES-MELLITUS; CORONAVIRUS DISEASE 2019; CHRONIC KIDNEY-DISEASE; D-DIMER; CLINICAL CHARACTERISTICS; RISK; PROCALCITONIN; MARKERS; WUHAN	Background The hematological abnormalities are assumed to be involved in the disease progression of COVID-19. However, the actual associations between specific blood parameters and COVID-19 are not well understood. Here we aimed to assess the correlations between hematological parameters and the severity of COVID-19. Methods We included COVID-19 patients who were admitted to Evercare Hospital Ltd, Dhaka, Bangladesh, between November 10, 2020, to April 12, 2021, with a confirmed case of RT-PCR test. We recorded demographic information, clinical data, and routine hematological examination results of all COVID-19 patients. We performed statistical analyses and interpretation of data to compare severe COVID-19 patients (SCP) and non-severe COVID-19 patients (NSCP). Results The age and BMI of the admitted COVID-19 patients were 48.79 +/- 8.53 years and 25.82 +/- 3.75 kg/m(2). This study included a total of 306 hospitalized COVID-19 patients. Among them, NSCP and SCP were 198 and 108, respectively. And we recorded 12 deaths from SCP. We observed the alterations of several hematological parameters between SCP and NSCP. Among them, we noticed the increased levels of C-reactive protein (CRP), d-dimer, and ferritin showed good indicative value to evaluate the severity of COVID-19. Also, there were positive correlations among these parameters. Moreover, we found correlations between the outcomes of COVID-19 patients with patient's demographics and comorbid diseases. Conclusion Based on our results, CRP, d-dimer, and ferritin levels at admission to hospitals represent simple assessment factors for COVID-19 severity and the treatment decisions at the hospital setup. These blood parameters could serve as indicators for the prognosis and severity of COVID-19. Therefore, our study findings might help to develop a treatment protocol for COVID-19 patients at the hospital setup.	[Rahman, Md. Ashrafur; Tushar, Md. Ismail; Mahmud, Tarif; Rahman, Ghazi Muhammad Sayedur; Milan, Zahid Hossain; Sultana, Tamanna; Reza, Hasan Mahmud] North South Univ, Dept Pharmaceut Sci, Dhaka, Bangladesh; [Shanjana, Yeasna] North South Univ, Dept Environm Sci, Dhaka, Bangladesh; [Chowdhury, Ali Mohammed Lutful Hoq] Evercare Hosp, Crit Care Dept, Dhaka, Bangladesh; [Bhuiyan, Mohiuddin Ahmed; Islam, Md. Rabiul] Univ Asia Pacific, Dept Pharm, Dhaka, Bangladesh	North South University (NSU); North South University (NSU); University of Asia Pacific (UAP)	Reza, HM (corresponding author), North South Univ, Dept Pharmaceut Sci, Dhaka, Bangladesh.; Islam, MR (corresponding author), Univ Asia Pacific, Dept Pharm, Dhaka, Bangladesh.	robi.ayaan@gmail.com; hasan.reza@northsouth.edu	Reza, Hasan Mahmud/AFL-0151-2022; Bhuiyan, Mohiuddin Ahmed/ABB-3632-2021; Islam, Rabiul/Q-3277-2019	Reza, Hasan Mahmud/0000-0003-3287-942X; Islam, Rabiul/0000-0003-2820-3144; rahman, Md ashrafur/0000-0003-0146-5312				Abu-Farha M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.576818; Akpinar EE, 2013, J THORAC DIS, V5, P430, DOI 10.3978/j.issn.2072-1439.2013.07.34; Ali N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00458; Anjum S, 2020, THER ADV PSYCHOPHARM, V10, DOI 10.1177/2045125320916655; [Anonymous], 2020, NEW ENGL J MED; [Anonymous], 2020, IEEE SENS J, DOI [10.1016/j.ijid.2020.03.017, DOI 10.1109/JSEN.2020.2965086]; Bajgain KT, 2021, AM J INFECT CONTROL, V49, P238, DOI 10.1016/j.ajic.2020.06.213; Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Clark CE, 2021, J HUM HYPERTENS, V35, P304, DOI 10.1038/s41371-020-00451-x; Coban E, 2005, EXP CLIN ENDOCR DIAB, V113, P35, DOI 10.1055/s-2004-830524; Corrao S, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.609470; Daria S, 2021, ASIA-PAC J PUBLIC HE, V33, P665, DOI 10.1177/10105395211021686; Daria S, 2021, INT J HEALTH PLAN M, V36, P1950, DOI 10.1002/hpm.3257; Daria S, 2021, INT J HEALTH PLAN M, V36, P1947, DOI 10.1002/hpm.3245; Das R, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-045727; Das R, 2021, PSYCHIAT RES, V295, DOI 10.1016/j.psychres.2020.113568; Deng YT, 2020, CAMB CHINA LIBR, P1; Emon MPZ, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-020-04952-3; Foldi M, 2020, OBES REV, V21, DOI 10.1111/obr.13095; Gaffney P J, 1980, J Clin Pathol Suppl (R Coll Pathol), V14, P10; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Hahn WH, 2018, J MATERN-FETAL NEO M, V31, P822, DOI 10.1080/14767058.2017.1297410; Haridas N., 2017, INT J ADV RES IJAR, V5, P2139, DOI DOI 10.21474/IJAR01/3387; Hasan MM, 2021, VIRUS RES, V297, DOI 10.1016/j.virusres.2021.198390; Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369; Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003; Islam JY, 2018, J HUM HYPERTENS, V32, P668, DOI 10.1038/s41371-018-0087-5; Islam MR, 2021, ASIA-PAC J PUBLIC HE, V33, P469, DOI 10.1177/10105395211004371; Islam MR, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1685-z; Islam MT, 2020, J PUBLIC HEALTH RES, V9, P389, DOI 10.4081/jphr.2020.1794; Kang HT, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13111058; Kermali M, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117788; Khalil, 2016, AM J MED MED SCI, V6, P120; Khanam MA, 2011, J HEALTH POPUL NUTR, V29, P406, DOI 10.3329/jhpn.v29i4.8458; Kim JW, 2015, NEUROSCI LETT, V589, P126, DOI 10.1016/j.neulet.2014.12.064; Krakoff J, 2003, DIABETES CARE, V26, P1745, DOI 10.2337/diacare.26.6.1745; Lakoski SG, 2005, J AM COLL CARDIOL, V46, P1869, DOI 10.1016/j.jacc.2005.07.050; Lee CC, 2009, DIABETOLOGIA, V52, P1040, DOI 10.1007/s00125-009-1338-3; Lee DH, 2018, ANN OCCUP ENVIRON ME, V30, DOI 10.1186/s40557-018-0251-y; Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0; Li HQ, 2020, DIABETES OBES METAB, V22, P1897, DOI 10.1111/dom.14099; Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327; Liao DY, 2020, LANCET HAEMATOL, V7, pE671, DOI 10.1016/S2352-3026(20)30217-9; Lippi G, 2020, HEMATOL TRANSF CELL, V42, P116, DOI 10.1016/j.htct.2020.03.001; Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650; Lippi G, 2020, CLIN CHIM ACTA, V505, P190, DOI 10.1016/j.cca.2020.03.004; Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8; Magleby R, 2021, CLIN INFECT DIS, V73, pE4197, DOI 10.1093/cid/ciaa851; Mahmudpour M, 2020, CYTOKINE, V133, DOI 10.1016/j.cyto.2020.155151; Mejia F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244171; Mohiuddin, 2019, INT J DIABETES RES, V2, P14, DOI DOI 10.17554/IJDR.V2I1.2457; Nishuty NL, 2019, CUREUS, V11, DOI 10.7759/cureus.3868; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI 10.1001/jama.2020.7681; Rifai N, 1999, CLIN CHEM, V45, P2136; Roberts WL, 2000, CLIN CHEM, V46, P461; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Safdar AM, 2018, BANGLADESH CRITICAL, V6, P3; Salehi-Abari I, 2020, ADV INFECT DIS, V10, P67, DOI [10.4236/aid.2020.103008, DOI 10.4236/AID.2020.103008]; Sattar N, 2020, CIRCULATION, V142, P4, DOI 10.1161/CIRCULATIONAHA.120.047659; Shaheer AK, 2017, J CLIN DIAGN RES, V11, pBC1, DOI 10.7860/JCDR/2017/30272.10528; Shankar A, 2011, KIDNEY INT, V80, P1231, DOI 10.1038/ki.2011.283; Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950; Shitrit D, 2002, CHEST, V122, P1674, DOI 10.1378/chest.122.5.1674; Sutradhar I, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.3970; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Tang ZY, 2021, PHYS MED BIOL, V66, DOI 10.1088/1361-6560/abbf9e; Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829; Vargas-Vargas M, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.72; Velavan TP, 2020, INT J INFECT DIS, V95, P304, DOI 10.1016/j.ijid.2020.04.061; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wang L, 2020, MED MALADIES INFECT, V50, P332, DOI 10.1016/j.medmal.2020.03.007; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Xiong Y, 2020, INVEST RADIOL, V55, P332, DOI 10.1097/RLI.0000000000000674; Yang L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00243-2; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Yeap BB, 2015, CLIN ENDOCRINOL, V82, P525, DOI 10.1111/cen.12529; Zavascki AP, 2020, NEW ENGL J MED, V382, P1859, DOI 10.1056/NEJMc2005203; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou Y, 2021, DIABETES-METAB RES, V37, DOI 10.1002/dmrr.3377	82	20	20	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2021	16	7							e0255379	10.1371/journal.pone.0255379	http://dx.doi.org/10.1371/journal.pone.0255379			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA5TU	34314447	gold, Green Published			2023-01-03	WOS:000685225200018
J	Tielker, JM; Weber, JP; Simon, ST; Bausewein, C; Stiel, S; Schneider, N				Tielker, Jannik M.; Weber, Jan P.; Simon, Steffen T.; Bausewein, Claudia; Stiel, Stephanie; Schneider, Nils			Experiences, challenges and perspectives for ensuring end-of-life patient care: A national online survey with general practitioners in Germany	PLOS ONE			English	Article							COVID-19; HEALTH	Background The SARS-CoV-2 (COVID-19) pandemic is posing major challenges for health care systems. In Germany, one such challenge has been that adequate palliative care for the severely ill and dying (with and without COVID-19), as well as their loved ones, has not been available at all times and in all settings., the pandemic has underlined the significance of the contribution of general practitioners (GPs) to the care of severely ill and dying patients. Objectives To describe GPs' experiences, challenges and perspectives with respect to end-of-life care during the first peak of the pandemic (spring 2020) in Germany. Materials and methods In November and December 2020, a link to an Unipark online survey was sent to GPs registered on nationwide distribution lists. Results In total, 410 GPs responded; 61.5% indicated that the quality of their patients' end-of-life care was maintained throughout the pandemic, 36.8% reported a decrease in quality compared to pre-pandemic times. Of the GPs who made home visits to severely ill and dying patients, 61.4% reported a stable number of visits, 28.5% reported fewer visits. 62.7% of the GPs reported increased telephone contact and reduced personal contact with patients; 36.1% offered video consultations in lieu of face-to-face contact. The GPs reported that relatives were restricted (48.5%) or prohibited from visiting (33.4%) patients in nursing homes. They observed a fear of loneliness among patients in nursing homes (91.9%), private homes (87.3%) and hospitals (86.1%). Conclusions The present work provides insights into the pandemic management of GPs and supports the development of a national strategy for palliative care during a pandemic. To effectively address end-of-life care, GPs and palliative care specialists should be involved in COVID-19 task forces on micro, meso and macro levels of health care.	[Tielker, Jannik M.; Weber, Jan P.; Stiel, Stephanie; Schneider, Nils] Hannover Med Sch, Inst Gen Practice, Hannover, Germany; [Simon, Steffen T.] Univ Cologne, Univ Hosp Cologne, Dept Palliat Med, Fac Med, Cologne, Germany; [Bausewein, Claudia] Ludwig Maximilians Univ Munchen, Dept Palliat Med, Univ Hosp Munich, Munich, Germany	Hannover Medical School; University of Cologne; University of Munich	Stiel, S (corresponding author), Hannover Med Sch, Inst Gen Practice, Hannover, Germany.	stiel.stephanie@mh-hannover.de		Stiel, Stephanie/0000-0002-5963-2526	German Ministry for Education [01KX2021]	German Ministry for Education	The project PallPan is funded by the German Ministry for Education and ResearchGrant Number: 01KX2021). https://www.netzwerk-universitaetsmedizin.de/projekte/pallpan The co-author NS received funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	aerzteblatt.de, E HLTH POL TREIBT DI; AerzteZeitung.de [Internet], 2021, SARS COV 2 VERST BES; Alsnes IV, 2020, FAM MED COMMUNITY HE, V8, DOI 10.1136/fmch-2020-000512; [Anonymous], 2009, EUR J PALLIAT CARE; [Anonymous], COVID 19 GOVT RESPON; Arendt F, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113532; Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X; Bundesministerium fur Gesundheit, 2021, BES STAT PFLEG SICH; Cheung G, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09900-1; Dahlhaus A, 2013, SUPPORT CARE CANCER, V21, P3293, DOI 10.1007/s00520-013-1904-6; DEGAM, LEITL DEGAM, pC2021; Deutsche Gesellschaft fur Palliativmedizin, 2018, ERW S3 LEITL PALL SE; Deutsche Gesellschaft fur Palliativmedizin, 2018, DGP BEGR INF KBV ALL; Deutsche Gesellschaft fur Palliativmedizin [Internet], 2018, DEF HOSP PALL; Deutsches Arzteblatt, PSYCH BEL COVID 19 P; Deutschlandfunk, 2009, BES PFLEG WEG COR DE; Girum T, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-020-00285-w; Global Family Doctor-WONCA, D LI COR 1 LAST OUT; Hawley CE, 2020, J AM GERIATR SOC, V68, P2431, DOI 10.1111/jgs.16845; Johnsen TM, 2021, J MED INTERNET RES, V23, DOI 10.2196/26433; Kassenarztliche Bundesvereinigung [Internet], 2021, VID DVPMG ENTW PASS; Kippen R, 2020, AUST J GEN PRACT, V49, P745, DOI 10.31128/AJGP-06-20-5465; Kuntz JG, 2020, J PAIN SYMPTOM MANAG, V60, pE28, DOI 10.1016/j.jpainsymman.2020.06.001; Lieneck C, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040517; MAXQDA VERBI Software, VERS 18 SOFTW; Munch U, 2020, SCHMERZ, V34, P303, DOI 10.1007/s00482-020-00483-9; Nds, REIM VERH AUFN ALT P; Nussbaumer-Streit B, 2020, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD013574.pub2, 10.1002/14651858.CD013574]; Oluyase AO., 2021, J PAIN SYMPTOM MANAG; Randhawa RS, 2018, PRIM HEALTH CARE RES, V20, DOI 10.1017/S1463423618000361; Rawaf S, 2020, EUR J GEN PRACT, V26, P129, DOI 10.1080/13814788.2020.1820479; Robert Koch-Institut, 2020, COR SARS COV 2 APR 2; Saint-Lary O, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-042119; Schweppe C, 2020, HAUSLICHE ALTENPFLEG; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Verhoeven V, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039674	36	6	6	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2021	16	7							e0254056	10.1371/journal.pone.0254056	http://dx.doi.org/10.1371/journal.pone.0254056			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA5TU	34314417	Green Published, gold			2023-01-03	WOS:000685225200026
J	Aref, HM; Shokri, H; Roushdy, TM; Fathalla, F; El Nahas, NM				Aref, Hany M.; Shokri, Hossam; Roushdy, Tamer M.; Fathalla, Fatma; El Nahas, Nevine M.			Pre-hospital causes for delayed arrival in acute ischemic stroke before and during the COVID-19 pandemic: A study at two stroke centers in Egypt	PLOS ONE			English	Article								Background In the current study we investigated the causes of pre-hospital delay as this can compromise the patient's chance to receive thrombolytic therapy and thus impact stroke outcome. Methods We surveyed 254 patients regarding reasons for delayed and early arrival to hospital after acute ischemic stroke. The survey was performed over five months, spanning a period pre- and during COVID-19 (between December 7, 2019 and May 10, 2020). Results A total of 71.2% of patients arrived beyond four hours of onset of ischemic stroke. The commonest cause for delay pre-Covid-19 was receiving treatment in a non-stroke hospital, while that during COVID-19 was fear of infection and lock down issues. Not realizing the urgency of the condition and stroke during sleep were common in both periods. Early arrival because of the patient's previous experience with stroke accounted for approximately 25% of cases in both periods. The effect of media was more evident during COVID-19, accounting for 47.7% of cases. Conclusion Pre-hospital delay secondary to misperception of the urgency of stroke and management in a non-stroke hospital reflect the lack of awareness among the public and medical staff. This concept is emphasized by early arrival secondary to previous experience with stroke and the pronounced effect of media in the time of COVID-19.	[Aref, Hany M.; Shokri, Hossam; Roushdy, Tamer M.; Fathalla, Fatma; El Nahas, Nevine M.] Ain Shams Univ, Fac Med, Neurol Dept, Cairo, Egypt	Egyptian Knowledge Bank (EKB); Ain Shams University	Shokri, H (corresponding author), Ain Shams Univ, Fac Med, Neurol Dept, Cairo, Egypt.	hossam.shokri@med.asu.edu.eg	Kenawy, Fatma Fathalla/AAX-9282-2021; Roushdy, Tamer Mahmoud/ABG-9151-2020; Aref, Hany/AAW-3366-2020; Kenawy, Fatma Fathalla/B-7929-2019; nahas, nevine el/W-1672-2019	Kenawy, Fatma Fathalla/0000-0003-1444-4254; Roushdy, Tamer Mahmoud/0000-0002-3123-9204; Aref, Hany/0000-0003-1497-7915; Kenawy, Fatma Fathalla/0000-0003-1444-4254; nahas, nevine el/0000-0003-0430-6528; Shokri, Hossam/0000-0001-6154-6806				Abu-Hegazy M, 2016, EGYPT J NEUROL PSYCH; Arulprakash N., 2018, J FAM MED PRIM CARE, DOI [10.4103/jfmpc.jfmpc%5F122%5F18, DOI 10.4103/JFMPC.JFMPC%5F122%5F18]; Bahnasy Wafik Said, 2019, eNeurologicalSci, V14, P68, DOI 10.1016/j.ensci.2019.01.003; Baracchini C, 2020, NEUROL SCI, V41, P1003, DOI 10.1007/s10072-020-04375-9; Bersano A, 2020, NEUROLOGY, V94, P905, DOI 10.1212/WNL.0000000000009508; Caso V., 2018, IMPROVING STROKE CAR, V2018; Ekundayo OJ, 2013, CIRC-CARDIOVASC QUAL, V6, P262, DOI 10.1161/CIRCOUTCOMES.113.000089; Fladt J, 2019, REASONS PREHOSPITAL; Gomez C R, 1993, J Stroke Cerebrovasc Dis, V3, P1, DOI 10.1016/S1052-3057(10)80125-9; Jorgensen HS, 1996, NEUROLOGY, V47, P383, DOI 10.1212/WNL.47.2.383; Khan M, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116727; Koksal EK, 2014, NEUROL SCI, V35, P1567, DOI 10.1007/s10072-014-1796-3; Li SD, 2019, STROKE, V50, P455, DOI 10.1161/STROKEAHA.118.023317; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Mellor RM, 2015, ANN EMERG MED, V65, P279, DOI 10.1016/j.annemergmed.2014.10.018; Nevine M., INT C ESC COUNC STRO; Panicio MI, 2014, ARQ NEURO-PSIQUIAT, V72, P938, DOI 10.1590/0004-282X20140167; Pulvers JN, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00617; Roushdy TM, 2020, J STROKE, V22, P275, DOI 10.5853/jos.2020.01550; Siegler JE, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104953; Song D, 2015, J STROKE, V17, P159, DOI 10.5853/jos.2015.17.2.159; Teuschl Y, 2010, INT J STROKE, V5, P187, DOI 10.1111/j.1747-4949.2010.00428.x; Zakaria MF, 2018, INT J STROKE, V13, P525, DOI 10.1177/1747493017711949	23	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2021	16	7							e0254228	10.1371/journal.pone.0254228	http://dx.doi.org/10.1371/journal.pone.0254228			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2MK	34260632	Green Published, gold			2023-01-03	WOS:000678119300050
J	Schol, PBB; de Lange, NM; Woiski, MD; Langenveld, J; Smits, LJM; Wassen, MM; Henskens, YM; Scheepers, HCJ				Schol, Pim B. B.; de Lange, Natascha M.; Woiski, Mallory D.; Langenveld, Josje; Smits, Luc J. M.; Wassen, Martine M.; Henskens, Yvonne M.; Scheepers, Hubertina C. J.			Restrictive versus liberal fluid resuscitation strategy, influence on blood loss and hemostatic parameters in mild obstetric hemorrhage: An open-label randomized controlled trial. (REFILL study)	PLOS ONE			English	Article							POSTPARTUM HEMORRHAGE; HYDROXYETHYL STARCH; MANAGEMENT; SURGERY	Background Evidence for optimal hemostatic resuscitation in postpartum hemorrhage (PPH) is lacking. Liberal fluid administration may result in acidosis, hypothermia and coagulopathy. Objective We hypothesize that in early PPH a restrictive fluid administration results in less progression to moderate PPH. Study design In four Dutch hospitals we recruited women of 18 years and over, and more than 24 weeks pregnant. Exclusion criteria were: anticoagulant therapy, known coagulation disorders, pre-eclampsia, antenatal diagnosis of abnormally adhesive placenta, and a contraindication for liberal fluid therapy. We blindly randomized participants at 500 mL and ongoing blood loss in the third stage of labor between restrictive fluid administration (clear fluids 0.75-1.0 times the volume of blood lost) and liberal fluid administration (clear fluids 1.5-2.0 times the volume of blood lost). The primary outcome was progression to more than 1000 mL blood loss. Analyses were according to the intention-to-treat principle. Results From August 2014 till September 2019, 5190 women were informed of whom 1622 agreed to participate. A total of 252 women were randomized of which 130 were assigned to the restrictive group and 122 to the liberal group. In the restrictive management group 51 of the 130 patients (39.2%) progressed to more than 1000 mL blood loss versus 61 of the 119 patients (51.3%) in the liberal management group (difference, -12.0% [95%-CI -24.3% to 0.3%], p = 0.057). There was no difference in the need for blood transfusion, coagulation parameters, or in adverse events between the groups. Conclusions Although a restrictive fluid resuscitation in women with mild PPH could not been proven to be superior, it does not increase the need for blood transfusion, alter coagulation parameters, or cause a rise in adverse events. It can be considered as an alternative treatment option to liberal fluid resuscitation.	[Schol, Pim B. B.; de Lange, Natascha M.; Scheepers, Hubertina C. J.] Maastricht Univ, Dept Obstet & Gynecol, Med Ctr, Maastricht, Netherlands; [Schol, Pim B. B.; de Lange, Natascha M.; Langenveld, Josje; Wassen, Martine M.] Zuyderland, Dept Obstet & Gynecol, Sittard Geleen, Netherlands; [Woiski, Mallory D.] Radboud Univ Nijmegen, Dept Obstet & Gynecol, Med Ctr, Nijmegen, Netherlands; [Smits, Luc J. M.] Caphri Sch Publ Hlth & Primary Care, Dept Epidemiol, Maastricht, Netherlands; [Henskens, Yvonne M.] Maastricht Univ, Cent Diagnost Lab, Med Ctr, Maastricht, Netherlands; [Scheepers, Hubertina C. J.] Maastricht Univ, GROW Sch Oncol & Dev Biol, Med Ctr, Maastricht, Netherlands; [de Lange, Natascha M.] Isala, Dept Obstet & Gynecol, Zwolle, Netherlands	Maastricht University; Radboud University Nijmegen; Maastricht University; Maastricht University; Maastricht University	Schol, PBB (corresponding author), Maastricht Univ, Dept Obstet & Gynecol, Med Ctr, Maastricht, Netherlands.; Schol, PBB (corresponding author), Zuyderland, Dept Obstet & Gynecol, Sittard Geleen, Netherlands.	pbbschol@hotmail.com	Woiski, Mallory D/L-4763-2015	Woiski, Mallory D/0000-0002-7553-5929; Schol, Pim/0000-0002-6486-4508; Smits, Luc/0000-0003-0785-1345				Amer Soc Anesthesiologists, 2015, ANESTHESIOLOGY, V122, P241, DOI 10.1097/ALN.0000000000000463; [Anonymous], 2017, BJOG, V124, pe106, DOI 10.1111/1471-0528.14178; Bagshaw SM, 2013, CAN J ANESTH, V60, P709, DOI 10.1007/s12630-013-9936-4; Bateman BT, 2010, ANESTH ANALG, V110, P1368, DOI 10.1213/ANE.0b013e3181d74898; Brandstrup B, 2006, BEST PRACT RES-CLIN, V20, P265, DOI 10.1016/j.bpa.2005.10.007; Brenner B, 2004, THROMB RES, V114, P409, DOI 10.1016/j.thromres.2004.08.004; Briley A, 2014, BJOG-INT J OBSTET GY, V121, P876, DOI 10.1111/1471-0528.12588; Calvert C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041114; Chappell D, 2008, ANESTHESIOLOGY, V109, P723, DOI 10.1097/ALN.0b013e3181863117; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; de Lange N, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2512-z; Duke MD, 2012, J TRAUMA ACUTE CARE, V73, P674, DOI 10.1097/TA.0b013e318265ce1f; Ekelund K, 2015, ACTA OBSTET GYN SCAN, V94, P680, DOI 10.1111/aogs.12607; Flood M, 2019, AUST NZ J OBSTET GYN, V59, P228, DOI 10.1111/ajo.12826; Ford JB, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0788-5; Franchini M, 2006, THROMB HAEMOSTASIS, V95, P401, DOI 10.1160/TH05-11-0753; Gillissen A, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2021-9; Grady K., 2009, HCACC MOET COURSE MA, VSecond ed; Henriquez DDCA, 2019, EUR J OBSTET GYN R B, V235, P49, DOI 10.1016/j.ejogrb.2019.01.027; Hopf HW, 2019, ANESTHESIOLOGY, V130, P677, DOI 10.1097/ALN.0000000000002663; Knight M, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-55; Kozek-Langenecker SA, 2005, ANESTHESIOLOGY, V103, P654, DOI 10.1097/00000542-200509000-00031; Kozek-Langenecker SA, 2017, EUR J ANAESTH, V34, P332, DOI 10.1097/EJA.0000000000000630; Kwan I, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002245.pub2; Lewis SR, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub7; Malbrain MLNG, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00679-3; Mittermayr M, 2008, BRIT J ANAESTH, V100, P307, DOI 10.1093/bja/aem363; Mittermayr M, 2007, ANESTH ANALG, V105, P905, DOI 10.1213/01.ane.0000280481.18570.27; Morrison CA, 2011, J TRAUMA, V70, P652, DOI 10.1097/TA.0b013e31820e77ea; Munoz M, 2019, BLOOD TRANSFUS-ITALY, V17, P112, DOI 10.2450/2019.0245-18; Myles PS, 2018, NEW ENGL J MED, V378, P2263, DOI 10.1056/NEJMoa1801601; NVOG, NVOG RICHTLIJN HEM P; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Rossaint R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1265-x; Schol PBB, 2016, J CLIN ANESTH, V35, P26, DOI 10.1016/j.jclinane.2016.07.010; Sentilhes L, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-019-2718-4; Sheehan SR, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4661; Szecsi PB, 2010, THROMB HAEMOSTASIS, V103, P718, DOI 10.1160/TH09-10-0704; Thornburg KL, 2000, SEMIN PERINATOL, V24, P11, DOI 10.1016/S0146-0005(00)80047-6; van Stralen G, 2016, ACTA OBSTET GYN SCAN, V95, P1104, DOI 10.1111/aogs.12950; Westphal M, 2009, ANESTHESIOLOGY, V111, P187, DOI 10.1097/ALN.0b013e3181a7ec82	41	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2021	16	6							e0253765	10.1371/journal.pone.0253765	http://dx.doi.org/10.1371/journal.pone.0253765			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9CN	34170943	gold, Green Published			2023-01-03	WOS:000671694400067
J	Yan, XX; Imano, N; Tamaki, K; Sano, M; Shinmura, K				Yan, Xiaoxiang; Imano, Natsumi; Tamaki, Kayoko; Sano, Motoaki; Shinmura, Ken			The effect of caloric restriction on the increase in senescence-associated T cells and metabolic disorders in aged mice	PLOS ONE			English	Article							INSULIN-RESISTANCE; IMPACT; INHIBITION; ONSET; RATS	Aging is associated with functional decline in the immune system and increases the risk of chronic diseases owing to smoldering inflammation. In the present study, we demonstrated an age-related increase in the accumulation of Programmed Death-1 (PD-1)(+) memory-phenotype T cells that are considered "senescence-associated T cells" in both the visceral adipose tissue and spleen. As caloric restriction is an established intervention scientifically proven to exert anti-aging effects and greatly affects physiological and pathophysiological alterations with advanced age, we evaluated the effect of caloric restriction on the increase in this T-cell subpopulation and glucose tolerance in aged mice. Long-term caloric restriction significantly decreased the number of PD-1(+) memory-phenotype cluster of differentiation (CD) 4(+) and CD8(+) T cells in the spleen and visceral adipose tissue, decreased M1-type macrophage accumulation in visceral adipose tissue, and improved insulin resistance in aged mice. Furthermore, the immunological depletion of PD-1(+) T cells reduced adipose inflammation and improved insulin resistance in aged mice. Taken together with our previous report, these results indicate that senescence-related T-cell subpopulations are involved in the development of chronic inflammation and insulin resistance in the context of chronological aging and obesity. Thus, long-term caloric restriction and specific deletion of senescence-related T cells are promising interventions to regulate age-related chronic diseases.	[Yan, Xiaoxiang] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Inst Cardiovasc Dis, Shanghai, Peoples R China; [Yan, Xiaoxiang] Shanghai Jiao Tong Univ, Sch Med, Dept Cardiol, Shanghai, Peoples R China; [Yan, Xiaoxiang; Tamaki, Kayoko; Sano, Motoaki; Shinmura, Ken] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan; [Imano, Natsumi; Tamaki, Kayoko; Shinmura, Ken] Hyogo Coll Med, Dept Gen Internal Med, Nishinomiya, Hyogo, Japan; [Imano, Natsumi] Kwansei Gakuin Univ, Sch Sci & Technol, Dept Biosci, Sanda, Japan	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Keio University; Hyogo College of Medicine; Kwansei Gakuin University	Shinmura, K (corresponding author), Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan.; Shinmura, K (corresponding author), Hyogo Coll Med, Dept Gen Internal Med, Nishinomiya, Hyogo, Japan.	ke-shimmura@hyo-med.ac.jp			Japan Society for the Promotion of Science (JSPS KAKENHI) [22590814]; Takeda Medical Research Foundation; Research Grants in the Natural Sciences from the Mitsubishi Foundation	Japan Society for the Promotion of Science (JSPS KAKENHI)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Medical Research Foundation; Research Grants in the Natural Sciences from the Mitsubishi Foundation	This study was funded by the Japan Society for the Promotion of Science (JSPS KAKENHI Grant Number 22590814) to KS, a research grant from Takeda Medical Research Foundation to KS, and Research Grants in the Natural Sciences from the Mitsubishi Foundation to KS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbar AN, 2011, NAT REV IMMUNOL, V11, P289, DOI 10.1038/nri2959; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Barzilai N, 1998, J CLIN INVEST, V101, P1353, DOI 10.1172/JCI485; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; FINK RI, 1983, J CLIN INVEST, V71, P1523, DOI 10.1172/JCI110908; Goldberg EL, 2015, AGING CELL, V14, P130, DOI 10.1111/acel.12280; Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361; Kanneganti TD, 2012, NAT IMMUNOL, V13, P707, DOI 10.1038/ni.2343; Kasagi S, 2010, J IMMUNOL, V184, P2337, DOI 10.4049/jimmunol.0901652; Khan S, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00267; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Lumeng CN, 2011, J IMMUNOL, V187, P6208, DOI 10.4049/jimmunol.1102188; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Messaoudi I, 2006, P NATL ACAD SCI USA, V103, P19448, DOI 10.1073/pnas.0606661103; Messaoudi I, 2008, AGING CELL, V7, P908, DOI 10.1111/j.1474-9726.2008.00440.x; Minato N, 2020, INT IMMUNOL, V32, P223, DOI 10.1093/intimm/dxaa006; Montecino-Rodriguez E, 2013, J CLIN INVEST, V123, P958, DOI 10.1172/JCI64096; Palmer AK, 2019, AGING CELL, V18, DOI 10.1111/acel.12950; Pawelec G, 2007, EMBO REP, V8, P220, DOI 10.1038/sj.embor.7400922; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Salminen A, 2012, AGING-US, V4, P166, DOI 10.18632/aging.100444; Shimatani K, 2009, P NATL ACAD SCI USA, V106, P15807, DOI 10.1073/pnas.0908805106; Shinmura K, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/528935; Shinmura K, 2015, AM J PHYSIOL-HEART C, V308, pH894, DOI 10.1152/ajpheart.00333.2014; Shinmura K, 2011, J MOL CELL CARDIOL, V50, P117, DOI 10.1016/j.yjmcc.2010.10.018; Shirakawa K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186303; Shirakawa K, 2016, J CLIN INVEST, V126, P4626, DOI 10.1172/JCI88606; Rojas JXS, 2016, J GERONTOL A-BIOL, V71, P310, DOI 10.1093/gerona/glv117; Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001; Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098; Trott DW, 2018, EXP GERONTOL, V109, P99, DOI 10.1016/j.exger.2016.12.016; Wang HY, 2016, AM J PHYSIOL-REG I, V310, pR449, DOI 10.1152/ajpregu.00449.2015; White Matthew J, 2016, Front Immunol, V7, P667, DOI 10.3389/fimmu.2016.00667; Yang HW, 2009, J IMMUNOL, V183, P3040, DOI 10.4049/jimmunol.0900562; Yoshida S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16347-w	35	2	2	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2021	16	6							e0252547	10.1371/journal.pone.0252547	http://dx.doi.org/10.1371/journal.pone.0252547			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BC	34143796	Green Published, gold			2023-01-03	WOS:000671690700014
J	van Manen, ELM; Hollander, M; Feijen-de Jong, E; De Jonge, A; Verhoeven, C; Gitsels, J				van Manen, Eline L. M.; Hollander, Martine; Feijen-de Jong, Esther; de Jonge, Ank; Verhoeven, Corine; Gitsels, Janneke			Experiences of Dutch maternity care professionals during the first wave of COVID-19 in a community based maternity care system	PLOS ONE			English	Article								Background and objective During the COVID-19 pandemic the organization of maternity care changed drastically; this study into the experiences of maternity care professionals with these changes provides suggestions for the organization of care during and after pandemics. Design An online survey among Dutch midwives, obstetricians and obstetric residents. Multinomial logistic regression analyses were used to investigate associations between the respondents' characteristics and answers. Results Reported advantages of the changes were fewer prenatal and postpartum consultations (50.1%). The necessity and safety of medical interventions and ultrasounds were considered more critically (75.9%); 14.8% of community midwives stated they referred fewer women to the hospital for decreased fetal movements, whereas 64.2% of the respondents working in hospital-based care experienced fewer consultations for this indication. Respondents felt that women had more confidence in giving birth at home (57.5%). Homebirths seemed to have increased according to 38.5% of the community midwives and 65.3% of the respondents working in hospital-based care. Respondents appreciated the shift to more digital consultations rather than face-to-face consultations. Mentioned disadvantages were that women had appointments alone, (71.1%) and that the community midwife was not allowed to join a woman to obstetric-led care during labour and subsequently stay with her (56.8%). Fewer postpartum visits by family and friends led to more tranquility (59.8%). Overall, however, 48.0% of the respondents felt that the safety of maternity care was compromised due to policy changes. Conclusions Maternity care professionals were positive about the decrease in routine care and the increased confidence of women in home birth, but also felt that safety in maternity care was sometimes compromised. According to the respondents in a future crisis situation it should be possible for community midwives to continue to deliver a personal handover after the referral of women to the hospital, and to stay with them.	[van Manen, Eline L. M.; Hollander, Martine] Radboud Univ Nijmegen, Amalia Childrens Hosp, Dept Obstet, Med Ctr, Nijmegen, Netherlands; [Feijen-de Jong, Esther; de Jonge, Ank; Verhoeven, Corine; Gitsels, Janneke] Vrije Univ Amsterdam, Amsterdam Univ, AVAG Acad Midwifery Amsterdam & Groningen, Amsterdam Publ Hlth Res Inst,Med Ctr,Midwifery Sc, Amsterdam, Netherlands; [Feijen-de Jong, Esther] Univ Groningen, Univ Med Ctr Groningen, AVAG Acad Midwifery Amsterdam & Groningen, Dept Gen Practice & Elderly Med, Groningen, Netherlands; [Verhoeven, Corine] Maxima Med Ctr, Dept Obstet & Gynecol, Veldhoven, Netherlands; [Verhoeven, Corine] Univ Nottingham, Sch Hlth Sci, Div Midwifery, Nottingham, England	Radboud University Nijmegen; University of Amsterdam; Vrije Universiteit Amsterdam; University of Groningen; Maxima Medical Center; University of Nottingham	van Manen, ELM (corresponding author), Radboud Univ Nijmegen, Amalia Childrens Hosp, Dept Obstet, Med Ctr, Nijmegen, Netherlands.	eline.vanmanen@radboudumc.nl	de Jonge, Ank/F-6475-2013	Gitsels - van der Wal, Janneke/0000-0002-5742-7246				Allotey J, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3320; Aviram A, 2016, BIRTH-ISS PERINAT C, V43, P42, DOI 10.1111/birt.12205; Bohren MA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003766.pub6; Bolten N, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1130-6; CBS. NUTS, REG IND VOOR EUR STA REG IND VOOR EUR STA; Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3; Cito G, 2005, ACTA OBSTET GYN SCAN, V84, P335, DOI 10.1111/j.0001-6349.2005.00644.x; Coxon K, 2020, MIDWIFERY, V88, DOI 10.1016/j.midw.2020.102779; de Jonge A, 2015, BJOG-INT J OBSTET GY, V122, P720, DOI 10.1111/1471-0528.13084; de Jonge A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180846; de Jonge A, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-103; Downe S, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012392.pub2; Dowswell T, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000934.pub3; Feijen-de Jong EI., 2015, CHAPTER 7 GEN DISCUS; Hedermann G., 2020, MEDRXIV2020052220109; Hollander M, 2018, WOMEN BIRTH, V31, P505, DOI 10.1016/j.wombi.2018.01.010; KNOV, 2018, TIM TASK MATR CONS P TIM TASK MATR CONS P; KNOV, 2008, KNOV STAND PREN VERL KNOV STAND PREN VERL; KNOV, 2020, COVID 19 PAND DRAAIB; Kozhimannil KB, 2014, AM J MANAG CARE, V20, pE340; Linde A, 2017, WOMEN BIRTH, V30, P376, DOI 10.1016/j.wombi.2017.02.007; Matar R, 2021, CLIN INFECT DIS, V72, P521, DOI 10.1093/cid/ciaa828; Merz WM, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-02962-4; Mullins E, 2020, ULTRASOUND OBST GYN, V55, P586, DOI 10.1002/uog.22014; NICE, 2020, ANT CAR UNC PREGN SC ANT CAR UNC PREGN SC; Nivel, 2018, VERL AANT WERKZ STAA VERL AANT WERKZ STAA; NVOG, 2020, AFSCH PREN ZORG PREN; NZa, AANV MAATR NOODZ ZOR AANV MAATR NOODZ ZOR; Patane L, 2020, AM J OBST GYNEC MFM, V2, DOI 10.1016/j.ajogmf.2020.100145; Perdok H, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0975-z; Perined, 2010, PER ZORG NED ANN 202; Pflugeisen BM, 2016, MCN-AM J MATERN-CHIL, V41, P24, DOI 10.1097/NMC.0000000000000199; Pflugeisen BM, 2017, MATERN CHILD HLTH J, V21, P1544, DOI 10.1007/s10995-017-2284-1; Philip RK., 2020, MEDRXIV2020060320121; RIVM, ACT INF OV HET NIEUW ACT INF OV HET NIEUW; RIVM, 2020, WEK UPD EP SIT COVID; Sandall J, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004667.pub5, 10.1002/14651858.CD004667.pub3]; Sanden Evd., 2020, BEVALLEN ALS ER GEVA; van den Heuvel JFM, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9262; Visser GHA, 2012, J OBSTET GYNAECOL CA, V34, P971, DOI 10.1016/S1701-2163(16)35410-X; WHO, 2022, WHO RECOMMENDATIONS	41	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2021	16	6							e0252735	10.1371/journal.pone.0252735	http://dx.doi.org/10.1371/journal.pone.0252735			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9AX	34138877	Green Published, gold			2023-01-03	WOS:000671690200051
J	Jin, JY; Chen, B; Zhan, XY; Zhou, ZY; Liu, H; Dong, Y				Jin, Jingyun; Chen, Bin; Zhan, Xiangyang; Zhou, Zhiyi; Liu, Hui; Dong, Yun			Network pharmacology and molecular docking study on the mechanism of colorectal cancer treatment using Xiao-Chai-Hu-Tang	PLOS ONE			English	Article							ANTIINFLAMMATORY DRUG-USE; 5-FLUOROURACIL; ASPIRIN; POPULATION; FORMULAS; INVASION; CELLS	Background and objective We aimed to predict the targets and signal pathways of Xiao-Chai-Hu-Tang (XCHT) in the treatment of colorectal cancer (CRC) based on network pharmacology, just as well as to further analyze its anti-CRC material basis and mechanism of action. Methods We adopted Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and Traditional Chinese Medicine Integrated Database (TCMID) databases to screen the active ingredients and potential targets of XCHT. CRC-related targets were retrieved by analyzing published microarray data (accession number GSE110224) from the Gene Expression Omnibus (GEO) database. The common targets were used to construct the "herb-active ingredient-target" network using the Cytoscape 3.8.0 software. Next, we constructed and analyzed protein-to-protein interaction (PPI) using BisoGenet and CytoNCA plug-in in Cytoscape. We then performed Gene Ontology (GO) functional and the Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analyses of target genes using the R package of clusterProfiler. Furthermore, we used the AutoDock Tools software to conduct molecular docking studies on the active ingredients and key targets to verify the network pharmacological analysis results. Results We identified a total of 71 active XCHT ingredients and 20 potential anti-CRC targets. The network analysis revealed quercetin, stigmasterol, kaempferol, baicalein, and acacetin as potential key compounds, and PTGS2, NR3C2, CA2, and MMP1 as potential key targets. The active ingredients of XCHT interacted with most CRC disease targets. We showed that XCHT's therapeutic effect was attributed to its synergistic action (multi-compound, multi-target, and multi-pathway). Our GO enrichment analysis showed 46 GO entries, including 20 biological processes, 6 cellular components, and 20 molecular functions. We identified 11 KEGG signaling pathways, including the IL-17, TNF, Toll-like receptor, and NF-kappa B signaling pathways. Our results showed that XCHT could play a role in CRC treatment by regulating different signaling pathways. The molecular docking experiment confirmed the correlation between five core compounds (quercetin, stigmasterol, kaempferol, baicalein, and acacetin) just as well as PTGS2, NR3C2, CA2, and MMP1. Conclusion In this study, we described the potential active ingredients, possible targets, and key biological pathways responsible for the efficacy of XCHT in CRC treatment, providing a theoretical basis for further research.	[Jin, Jingyun; Zhan, Xiangyang; Liu, Hui] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Oncol, Shanghai, Peoples R China; [Jin, Jingyun; Zhan, Xiangyang; Dong, Yun] Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China; [Chen, Bin] Shanghai Univ Tradit Chinese Med, Putuo Hosp, Dept Oncol, Shanghai, Peoples R China; [Zhou, Zhiyi] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Oncol, Shanghai, Peoples R China; [Dong, Yun] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Integrated Tradit Chinese Med & Western Med, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai Jiao Tong University	Liu, H (corresponding author), Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Oncol, Shanghai, Peoples R China.; Dong, Y (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China.; Dong, Y (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Integrated Tradit Chinese Med & Western Med, Shanghai, Peoples R China.	liuhui79@shutcm.edu.cn; dongyun0429@126.com		Dong, Yun/0000-0003-4286-2701	National Natural Science Foundation of China [81703887]; Scientific Research Foundation of Shanghai Science and Technology Commission [18401903000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Foundation of Shanghai Science and Technology Commission	This work was financially supported by the National Natural Science Foundation of China [NO.81703887]; Scientific Research Foundation of Shanghai Science and Technology Commission [No.18401903000]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdellateif MS, 2020, J INFLAMM RES, V13, P1245, DOI 10.2147/JIR.S283069; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Banday MZ, 2016, META GENE, V9, P128, DOI 10.1016/j.mgene.2016.06.001; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao W., 2020, J LIAONING U TRADITI, V22, P173; Chen J, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0757-z; Darband SG, 2018, J CELL PHYSIOL, V233, P6544, DOI 10.1002/jcp.26595; Du J., 2018, WORLD CHINESE MED, V13, P1452; Friis S, 2015, ANN INTERN MED, V163, P347, DOI 10.7326/M15-0039; Gong FX., 2019, J NINGXIA MED U, V41, P584; Guler OO, 2008, METHOD FIND EXP CLIN, V30, P335, DOI 10.1358/mf.2008.30.5.1143022; Han G., 2010, ZHEJIANG J TRADITION, V45, P687; Hua XW, 2017, J CLIN ONCOL, V35, P2806, DOI 10.1200/JCO.2017.72.3569; Huang KF, 2019, EXP DERMATOL, V28, P568, DOI 10.1111/exd.13912; Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.1016/S1875-5364(13)60037-0, 10.3724/SP.J.1009.2013.00110]; Li XJ, 2012, CHINESE J CANCER RES, V24, P196, DOI 10.1007/s11670-012-0196-6; Li Z., CHINESE ARCH TRADITI, V2020, P1; Liao HF, 2010, AM J CHINESE MED, V38, P173, DOI 10.1142/S0192415X10007749; Liu XD, 2016, INT J MOL MED, V38, P1250, DOI 10.3892/ijmm.2016.2700; Liu XQ, 2020, ONCOL LETT, V19, P1881, DOI 10.3892/ol.2020.11278; Lu LL, 2018, PHARMACOL RES, V129, P318, DOI 10.1016/j.phrs.2017.11.032; Mao D, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/3502460; Menezes-Garcia Z, 2020, GUT MICROBES, V11, P1531, DOI 10.1080/19490976.2020.1765946; Moradi-Marjaneh R, 2018, J CELL PHYSIOL, V233, P5613, DOI 10.1002/jcp.26273; Negi Ram Rattan, 2019, Asian Pac J Cancer Prev, V20, P1675, DOI 10.31557/APJCP.2019.20.6.1675; Ng K, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju345; Patel M, 2018, TRANSL RES, V197, P43, DOI 10.1016/j.trsl.2018.02.002; Prasad N, 2020, MOL BIOL REP, V47, P987, DOI 10.1007/s11033-019-05191-x; Riahi-Chebbi I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36808-z; Rui XJ, 2016, ONCOL LETT, V11, P685, DOI 10.3892/ol.2015.3935; Sezer ED, 2019, J MED FOOD, V22, P1118, DOI 10.1089/jmf.2019.0098; SHAO S., 2020, SHANGHAI J TRADIT CH, V54, P132; Song L, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109120; Tang YC, 2018, INT J ONCOL, V52, P127, DOI 10.3892/ijo.2017.4183; Tiberio L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059410; Wang CZ, 2012, AM J CHINESE MED, V40, P657, DOI 10.1142/S0192415X12500498; Wang K, 2020, ONCOL REP, V43, P1103, DOI 10.3892/or.2020.7490; Wang Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01233; Xiang YN, 2019, CANCER MED-US, V8, P1958, DOI 10.1002/cam4.2108; Zhang Q, 2017, J CANCER, V8, P3945, DOI 10.7150/jca.22162; Zhao Jinyan, 2017, Afr J Tradit Complement Altern Med, V14, P231, DOI 10.21010/ajtcam.v14i3.25; [赵怡 Zhao Yi], 2020, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V26, P208; Zhou R, 2013, INT J ONCOL, V43, P611, DOI 10.3892/ijo.2013.1972	44	12	12	16	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2021	16	6							e0252508	10.1371/journal.pone.0252508	http://dx.doi.org/10.1371/journal.pone.0252508			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6SI	34125845	gold, Green Published			2023-01-03	WOS:000664643500007
J	Sen, P; Majumdar, U; Zein, J; Hatipoglu, U; Attaway, AH				Sen, Payal; Majumdar, Uddalak; Zein, Joe; Hatipoglu, Umur; Attaway, Amy H.			Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; NEW-YORK-CITY; PREVALENCE; ASTHMA; RISK; INFECTION; EPIDEMIOLOGY; POPULATION; MORTALITY; STRENGTH	Inhaled Corticosteroids (ICS) are commonly prescribed to patients with severe COPD and recurrent exacerbations. It is not known what impact ICS cause in terms of COVID-19 positivity or disease severity in COPD. This study examined 27,810 patients with COPD from the Cleveland Clinic COVID-19 registry between March 8th and September 16th, 2020. Electronic health records were used to determine diagnosis of COPD, ICS use, and clinical outcomes. Multivariate logistic regression was used to adjust for demographics, month of COVID-19 testing, and comorbidities known to be associated with increased risk for severe COVID-19 disease. Amongst the COPD patients who were tested for COVID-19, 44.1% of those taking an ICS-containing inhaler tested positive for COVID-19 versus 47.2% who tested negative for COVID-19 (p = 0.033). Of those who tested positive for COVID-19 (n = 1288), 371 (28.8%) required hospitalization. In-hospital outcomes were not significantly different when comparing ICS versus no ICS in terms of ICU admission (36.8% [74/201] vs 31.2% [53/170], p = 0.30), endotracheal intubation (21.9% [44/201] vs 16.5% [28/170], p = 0.24), or mortality (18.4% [37/201] vs 20.0% [34/170], p = 0.80). Multivariate logistic regression demonstrated no significant differences in hospitalization (adj OR 1.12, CI: 0.90-1.38), ICU admission (adj OR: 1.31, CI: 0.82-2.10), need for mechanical ventilation (adj OR 1.65, CI: 0.69-4.02), or mortality (OR: 0.80, CI: 0.43-1.49). In conclusion, ICS therapy did not increase COVID-19 related healthcare utilization or mortality outcome in patients with COPD followed at the Cleveland Clinic health system. These findings should encourage clinicians to continue ICS therapy for COPD patients during the COVID-19 pandemic.	[Sen, Payal; Majumdar, Uddalak; Zein, Joe; Hatipoglu, Umur; Attaway, Amy H.] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA; [Zein, Joe] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Attaway, AH (corresponding author), Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA.	attawaa@ccf.org		Attaway, Amy/0000-0003-1959-9773	National Institutes of Health -National Heart, Lung and Blood Institute [K08 HL133381]	National Institutes of Health -National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by the National Institutes of Health -National Heart, Lung and Blood Institute Grant: K08 HL133381 (JZ).	[Anonymous], 2017, PNEUMOLOGIE, V71, P9; Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Attaway AA, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100515; Aveyard P, 2021, LANCET RESP MED, V9, P909, DOI 10.1016/S2213-2600(21)00095-3; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Bhatt SP, 2013, TRANSL RES, V162, P237, DOI 10.1016/j.trsl.2013.05.001; Bloom CI, 2021, LANCET RESP MED, V9, P699, DOI 10.1016/S2213-2600(21)00013-8; Boose E, HOME MONITORING COVI; Cameron MJ, 2007, J VIROL, V81, P8692, DOI 10.1128/JVI.00527-07; Cantoli M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00451-2017; Chatterjee Kshitij, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc059; Cheng VCC, 2020, INFECT CONT HOSP EP, V41, P493, DOI 10.1017/ice.2020.58; Cobb NL, 2021, ANN AM THORAC SOC, V18, P632, DOI 10.1513/AnnalsATS.202007-805OC; Cukic Vesna, 2012, Mater Sociomed, V24, P100, DOI 10.5455/msm.2012.24.100-105; Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2; Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003; FDA, 2020, EM US AUTH SUMM CLEV; Finney Lydia J, 2021, J Allergy Clin Immunol, V147, P510, DOI 10.1016/j.jaci.2020.09.034; Gerayeli FV, 2021, ECLINICALMEDICINE, V33, DOI 10.1016/j.eclinm.2021.100789; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Halpin DMG, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01009-2020; Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3; Han MK, 2007, AM J RESP CRIT CARE, V176, P1179, DOI 10.1164/rccm.200704-553CC; Heron Melonie, 2016, Natl Vital Stat Rep, V65, P1; Homma T, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56030098; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horwitz LI, 2021, J HOSP MED, V16, P90, DOI 10.12788/jhm.3552; Hosseini M, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1198-4; Nannini LJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006826.pub2; Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20; Johnston Sebastian L, 2005, Proc Am Thorac Soc, V2, P150, DOI 10.1513/pats.200502-018AW; Jones SE, 2015, THORAX, V70, P213, DOI 10.1136/thoraxjnl-2014-206440; Kiljander T, 2015, NPJ PRIM CARE RESP M, V25, DOI 10.1038/npjpcrm.2015.47; Kowalewski M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02925-3; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Lee JY, 2020, INT J INFECT DIS, V98, P462, DOI 10.1016/j.ijid.2020.07.017; Leung JM, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02108-2020; Li PF, 2021, INT J INFECT DIS, V102, P375, DOI 10.1016/j.ijid.2020.11.127; Liao SY, 2021, RESP MED, V176, DOI 10.1016/j.rmed.2020.106275; Marin BG, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2146; Matsuyama S, 2021, J VIROL, V95, DOI 10.1128/JVI.01648-20; Mehta N., 2020, JAMA CARDIOL, V5, P1020, DOI [DOI 10.1001/jamacardio.2020.1855, 10.1001/jamacardio.2020.1855]; Milinovich A, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.13; Oliver BGG, 2014, EUR RESPIR J, V44, P1666, DOI 10.1183/09031936.00047714; Organization WH, 2018, GLOB HLTH EST 2016 C; Park YJ, 2020, EMERG INFECT DIS, V26, P2465, DOI 10.3201/eid2610.201315; Peters MC, 2020, AM J RESP CRIT CARE, V202, P83, DOI 10.1164/rccm.202003-0821OC; Prescott E, 1997, EUR RESPIR J, V10, P822; Remels AHV, 2013, J APPL PHYSIOL, V114, P1253, DOI 10.1152/japplphysiol.00790.2012; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Roig M, 2011, J CARDIOPULM REHABIL, V31, P120, DOI 10.1097/HCR.0b013e3181f68ae4; Rycroft CE, 2012, INT J CHRONIC OBSTR, V7, P457, DOI 10.2147/COPD.S32330; Schols AMWJ, 2005, AM J CLIN NUTR, V82, P53, DOI 10.1093/ajcn/82.1.53; Schultze A, 2020, LANCET RESP MED, V8, P1106, DOI 10.1016/S2213-2600(20)30415-X; Shaipanich, 2020, INHALED CORTICOSTERO; Shekar K, 2020, ASAIO J, V66, P707, DOI 10.1097/MAT.0000000000001193; Singanayagam A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04574-1; Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343; Swallow EB, 2007, THORAX, V62, P115, DOI 10.1136/thx.2006.062026; Titmarsh S, 2019, INT J CHRONIC OBSTR, V14, P2799, DOI 10.2147/COPD.S222139; von Haehling S, 2014, J CACHEXIA SARCOPENI, V5, P261, DOI 10.1007/s13539-014-0164-8; Wu F, 2020, J THORAC DIS, V12, P1811, DOI 10.21037/jtd-20-1914; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yamaya M, 2020, RESPIR INVESTIG, V58, P155, DOI 10.1016/j.resinv.2019.12.005; Yang, 2020, INHALED CORTICOSTERO; Yang MJ, 2019, INFECTION, V47, P377, DOI 10.1007/s15010-018-1229-y; Yang MJ, 2017, INHAL TOXICOL, V29, P219, DOI 10.1080/08958378.2017.1346006	67	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2021	16	6							e0252576	10.1371/journal.pone.0252576	http://dx.doi.org/10.1371/journal.pone.0252576			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6QS	34081722	Green Published, gold			2023-01-03	WOS:000664639200028
J	Liu, ZQ; Lai, JC; Jiang, H; Ma, CY; Huang, HY				Liu, Ziqiang; Lai, Jiacheng; Jiang, Heng; Ma, Chengyuan; Huang, Haiyan			Collagen XI alpha 1 chain, a potential therapeutic target for cancer	FASEB JOURNAL			English	Review						cancer; collagen; extracellular matrix; invasion	GENE-EXPRESSION; EXTRACELLULAR-MATRIX; BREAST-CANCER; PROMOTES CHEMORESISTANCE; ANTIBODY FRAGMENT; 11A1 EXPRESSION; STROMAL CELLS; KEY GENES; COL11A1; CARCINOMA	Extracellular matrix (ECM) plays an important role in the progression of cancer. Collagen is the most abundant component in ECM, and it is involved in the biological formation of cancer. Although type XI collagen is a minor fibrillar collagen, collagen XI alpha 1 chain (COL11A1) has been found to be upregulated in a variety of cancers including ovarian cancer, breast cancer, thyroid cancer, pancreatic cancer, non-small-cell lung cancer, and transitional cell carcinoma of the bladder. High levels of COL11A1 usually predict poor prognosis, while COL11A1 is related to angiogenesis, invasion, and drug resistance of cancer. However, little is known about the specific mechanism by which COL11A1 regulates tumor progression. Here, we have organized and summarized the recent developments regarding elucidation of the relationship between COL11A1 and various cancers, as well as the interaction between COL11A1 and intracellular signaling pathways. In addition, we have selected therapeutic agents targeting COL11A1. All these indicate the possibility of using COL11A1 as a target for cancer treatment.	[Liu, Ziqiang; Lai, Jiacheng; Jiang, Heng; Ma, Chengyuan; Huang, Haiyan] First Hosp Jilin Univ, Dept Neurosurg, 71 Xinmin St, Changchun 130021, Peoples R China	Jilin University	Ma, CY; Huang, HY (corresponding author), First Hosp Jilin Univ, Dept Neurosurg, 71 Xinmin St, Changchun 130021, Peoples R China.	chengyuan@jlu.edu.cn; huanghy@jlu.edu.cn		Liu, Ziqiang/0000-0002-0150-6826	Natural Science Foundation of Jilin Province [20180101158JC]	Natural Science Foundation of Jilin Province	This work was supported by Natural Science Foundation of Jilin Province (20180101158JC).	Andriani F, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4772-0; Aquino PF, 2012, J PROTEOME RES, V11, P5836, DOI 10.1021/pr300612x; Arolt C, 2020, CANCERS, V12, DOI 10.3390/cancers12092466; Biteau B, 2011, CELL STEM CELL, V9, P402, DOI 10.1016/j.stem.2011.10.004; Boguslawska J, 2018, CANCER LETT, V412, P155, DOI 10.1016/j.canlet.2017.10.019; Boguslawska J, 2016, J UROLOGY, V195, P1892, DOI 10.1016/j.juro.2015.11.050; Brandes AA, 2016, NEURO-ONCOLOGY, V18, P1146, DOI 10.1093/neuonc/now009; Buckanovich RJ, 2007, J CLIN ONCOL, V25, P852, DOI 10.1200/JCO.2006.08.8583; Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544; Bynigeri RR, 2017, WORLD J GASTROENTERO, V23, P382, DOI 10.3748/wjg.v23.i3.382; Castellana B, 2012, J CANCER, V3, P175, DOI 10.7150/jca.4120; Chattopadhyay I, 2010, MUTAT RES-GEN TOX EN, V696, P130, DOI 10.1016/j.mrgentox.2010.01.001; Chen SR, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1204082; Cheon DJ, 2014, CLIN CANCER RES, V20, P711, DOI 10.1158/1078-0432.CCR-13-1256; Chong IW, 2006, ONCOL REP, V16, P981; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Cun XL, 2016, ACTA BIOMATER, V31, P186, DOI 10.1016/j.actbio.2015.12.002; Dabiri Asma, 2017, Gastroenterol Hepatol Bed Bench, V10, pS62; Di Y, 2019, HEREDITAS, V156, DOI 10.1186/s41065-019-0083-y; Dong X, 2019, NANO LETT, V19, P997, DOI 10.1021/acs.nanolett.8b04236; Ediriweera MK, 2019, SEMIN CANCER BIOL, V59, P147, DOI 10.1016/j.semcancer.2019.05.012; Ellsworth RE, 2009, CLIN EXP METASTAS, V26, P205, DOI 10.1007/s10585-008-9232-9; Erkan M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-88; Ewald JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055414; Feldmann G, 2008, GUT, V57, P1420, DOI 10.1136/gut.2007.148189; Fischer H, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-17; Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820; Freire J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/812027; Galvan JA, 2020, VIRCHOWS ARCH, V476, P725, DOI 10.1007/s00428-019-02714-6; Galvan JA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-867; Gao XY, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.152831; Garcia-Pravia C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078327; Ge C, 2017, ONCOL LETT, V13, P2777, DOI 10.3892/ol.2017.5750; Giussani M, 2018, J CELL PHYSIOL, V233, P6280, DOI 10.1002/jcp.26513; Gu SQ, 2020, MATH BIOSCI ENG, V17, P1428, DOI 10.3934/mbe.2020073; Hao SH, 2019, MED SCI MONITOR, V25, P2488, DOI 10.12659/MSM.915382; He Y, 2017, DIS ESOPHAGUS, V30, DOI 10.1093/dote/dow018; Ho XD, 2017, EXP BIOL MED, V242, P1802, DOI 10.1177/1535370217736512; Januchowski R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/365867; Jiang H, 2018, INT J MOL MED, V41, P2021, DOI 10.3892/ijmm.2018.3401; Jin YL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18060860; Kadler KE, 2008, CURR OPIN CELL BIOL, V20, P495, DOI 10.1016/j.ceb.2008.06.008; Kleinert R, 2015, ANTICANCER RES, V35, P6153; Lai K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188272; Lee J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695534; Li AQ, 2017, ONCOL REP, V37, P333, DOI 10.3892/or.2016.5276; Li JL, 2019, PEERJ, V7, DOI 10.7717/peerj.7705; Li L, 2005, WORLD J GASTROENTERO, V11, P4478, DOI 10.3748/wjg.v11.i29.4478; Li S, 2017, ONCOL LETT, V14, P3967, DOI 10.3892/ol.2017.6707; Liang H, 2016, SCI REP-UK, V6, DOI 10.1038/srep18205; Liang H, 2015, J CONTROL RELEASE, V209, P101, DOI 10.1016/j.jconrel.2015.04.029; Liu JX, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317714899; Mohan V, 2020, SEMIN CANCER BIOL, V62, P192, DOI 10.1016/j.semcancer.2019.09.004; Nabavi S, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2942-5; Nallanthighal S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2442-z; Nielsen CF, 2017, ONCOTARGET, V8, P44605, DOI 10.18632/oncotarget.17883; Nissen NI, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1110-6; Nizri E, 2019, PANCREAS, V48, P367, DOI 10.1097/MPA.0000000000001261; Pan AN, 2018, DRUG DELIV, V25, P1495, DOI 10.1080/10717544.2018.1474971; Park HJ, 2011, EXP THER MED, V2, P1111, DOI 10.3892/etm.2011.318; Persikov AV, 2005, BIOCHEMISTRY-US, V44, P1414, DOI 10.1021/bi048216r; Rada M, 2018, ONCOGENE, V37, P4809, DOI 10.1038/s41388-018-0297-x; Raglow Z, 2015, CANCER LETT, V357, P448, DOI 10.1016/j.canlet.2014.12.011; Ricard-Blum S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004978; Rice AJ, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.54; Ryan RE, 2015, CYTOKINE, V72, P71, DOI 10.1016/j.cyto.2014.11.007; Schultz S, 2018, BMC MED GENOMICS, V11, DOI 10.1186/s12920-018-0403-5; Shen LH, 2016, ONCOL REP, V36, P877, DOI 10.3892/or.2016.4869; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Skuja E., 2019, Experimental Oncology, V41, P323, DOI 10.32471/exp-oncology.2312-8852.vol-41-no-4.13841; Su C, 2019, MOL MED REP, V20, P4202, DOI 10.3892/mmr.2019.10667; Sun DF, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0669-x; Sun H, 2016, ONCOL LETT, V11, P525, DOI 10.3892/ol.2015.3929; Sun QQ, 2018, THERANOSTICS, V8, P5072, DOI 10.7150/thno.26546; Sun Y, 2010, CELL BIOCHEM BIOPHYS, V56, P59, DOI 10.1007/s12013-009-9071-6; Tan GF, 2021, CANCER SCI, V112, P397, DOI 10.1111/cas.14726; Tang L, 2020, J DIGEST DIS, V21, P639, DOI 10.1111/1751-2980.12936; Teng PN, 2014, BRIT J CANCER, V110, P123, DOI 10.1038/bjc.2013.687; Todhunter RJ, 2019, J ORTHOP RES, V37, P313, DOI 10.1002/jor.24178; Toss MS, 2019, MODERN PATHOL, V32, P1460, DOI 10.1038/s41379-019-0286-9; Tu HB, 2021, J INVEST SURG, V34, P664, DOI 10.1080/08941939.2019.1672839; Turkowski K, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081755; Vargas AC, 2012, BREAST CANCER RES TR, V135, P153, DOI 10.1007/s10549-012-2123-4; Vazquez-Villa F, 2015, TUMOR BIOL, V36, P2213, DOI 10.1007/s13277-015-3295-4; Wang HB, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-019-1066-9; Wang H, 2021, J CANCER, V12, P1406, DOI 10.7150/jca.47032; Wang JX, 2015, INT J CLIN EXP PATHO, V8, P517; Weng TY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161007; Wu YH, 2014, ONCOGENE, V33, P3432, DOI 10.1038/onc.2013.307; Wu YH, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00206; Wu YH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1555-8; Wu YH, 2017, INT J CANCER, V141, P2305, DOI 10.1002/ijc.30932; Wu YH, 2015, ONCOTARGET, V6, P23748, DOI 10.18632/oncotarget.4250; Wu YH, 2015, J CANCER, V6, P1011, DOI 10.7150/jca.12738; Xia FD, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013802; Xu CJ, 2020, MOL MED REP, V22, P3677, DOI 10.3892/mmr.2020.11490; Xu SS, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2058-1; Yang CJ, 2020, CANCER BIOMARK, V27, P445, DOI 10.3233/CBM-191200; Yang HJ, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.588; Zhang BH, 2018, CANCER BIOL THER, V19, P364, DOI 10.1080/15384047.2018.1423915; Zhang Q, 2018, CANCERS, V10, DOI 10.3390/cancers10080260; Zhao Y, 2009, ANAT REC, V292, P692, DOI 10.1002/ar.20874; Zheng XY, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.106982	103	13	13	6	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2021	35	6							e21603	10.1096/fj.202100054RR	http://dx.doi.org/10.1096/fj.202100054RR			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	SJ7FH	33999448	hybrid			2023-01-03	WOS:000655695900009
J	Brinkmann, U; Kontermann, RE				Brinkmann, Ulrich; Kontermann, Roland E.			Bispecific antibodies	SCIENCE			English	Editorial Material									[Brinkmann, Ulrich] Roche Innovat Ctr Munich, Large Mol Res, Roche Pharma Res & Early Dev, Nonnenwald 2, D-82377 Penzberg, Germany; [Kontermann, Roland E.] Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany	University of Stuttgart	Brinkmann, U (corresponding author), Roche Innovat Ctr Munich, Large Mol Res, Roche Pharma Res & Early Dev, Nonnenwald 2, D-82377 Penzberg, Germany.	ulrich.brinkmann@roche.com; roland.kontermann@izi.uni-stuttgart.de			Baliopharm; BioNTech; Oncomatryx	Baliopharm; BioNTech; Oncomatryx	U.B.is employed by and owns stocks in Roche and is a coinventor on patent applications covering bsAbs. R.E.K. is a coinventor on patent applications covering bsAbs and reports licensing agreements and research support from Baliopharm, BioNTech, and Oncomatryx and consultancy fees from Oncomatryx,Roche, and Immatics.	Autio KA, 2020, CLIN CANCER RES, V26, P984, DOI 10.1158/1078-0432.CCR-19-1457; Banaszek A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13196-0; Brinkmann U, 2017, MABS-AUSTIN, V9, P182, DOI 10.1080/19420862.2016.1268307; de Weerdt I, 2021, CANCER IMMUNOL RES, V9, P50, DOI 10.1158/2326-6066.CIR-20-0138; Kitazawa T, 2012, NAT MED, V18, P1570, DOI 10.1038/nm.2942; Labrijn AF, 2019, NAT REV DRUG DISCOV, V18, P585, DOI 10.1038/s41573-019-0028-1; Lin WW, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00652-z; Middleton MR, 2020, CLIN CANCER RES, V26, P5869, DOI 10.1158/1078-0432.CCR-20-1247; Nie Siwei, 2020, Antib Ther, V3, P18, DOI 10.1093/abt/tbaa003; Slaga D, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat5775; Staflin K, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133757; Trinklein ND, 2019, MABS-AUSTIN, V11, P639, DOI 10.1080/19420862.2019.1574521; Waite J. C., 2020, SCI TRANSL MED, V12, P549; Weber F, 2018, CELL REP, V22, P149, DOI 10.1016/j.celrep.2017.12.019; Zhao Q, 2020, BIODRUGS, V34, P111, DOI 10.1007/s40259-019-00400-2	15	15	16	6	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	2021	372	6545					916	917		10.1126/science.abg1209	http://dx.doi.org/10.1126/science.abg1209			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SK7YO	34045345				2023-01-03	WOS:000656432400029
J	Kocakavuk, E; Anderson, KJ; Varn, FS; Johnson, KC; Amin, SB; Sulman, EP; Lolkema, MP; Barthel, FP; Verhaak, RGW				Kocakavuk, Emre; Anderson, Kevin J.; Varn, Frederick S.; Johnson, Kevin C.; Amin, Samirkumar B.; Sulman, Erik P.; Lolkema, Martijn P.; Barthel, Floris P.; Verhaak, Roel G. W.			Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer	NATURE GENETICS			English	Article							PHASE-I; DNA; RADIATION; PATHWAYS; HYPERMUTATION; TEMOZOLOMIDE; MUTATIONS; DISCOVERY; KINASE; BREAST	Ionizing radiation causes DNA damage and is a mainstay for cancer treatment, but understanding of its genomic impact is limited. We analyzed mutational spectra following radiotherapy in 190 paired primary and recurrent gliomas from the Glioma Longitudinal Analysis Consortium and 3,693 post-treatment metastatic tumors from the Hartwig Medical Foundation. We identified radiotherapy-associated significant increases in the burden of small deletions (5-15 bp) and large deletions (20+ bp to chromosome-arm length). Small deletions were characterized by a larger span size, lacking breakpoint microhomology and were genomically more dispersed when compared to pre-existing deletions and deletions in non-irradiated tumors. Mutational signature analysis implicated classical non-homologous end-joining-mediated DNA damage repair and APOBEC mutagenesis following radiotherapy. A high radiation-associated deletion burden was associated with worse clinical outcomes, suggesting that effective repair of radiation-induced DNA damage is detrimental to patient survival. These results may be leveraged to predict sensitivity to radiation therapy in recurrent cancer. Radiotherapy induces small and large deletions as well as inversions across the genome in multiple cancer types. The genomic changes associated with radiotherapy correlate with poorer clinical outcomes.	[Kocakavuk, Emre; Anderson, Kevin J.; Varn, Frederick S.; Johnson, Kevin C.; Amin, Samirkumar B.; Barthel, Floris P.; Verhaak, Roel G. W.] Jackson Lab Genom Med, Farmington, CT 06032 USA; [Kocakavuk, Emre] Univ Hosp Essen, DKFZ Div Translat Neurooncol, West German Canc Ctr, German Canc Consortium Partner Site, Essen, Germany; [Kocakavuk, Emre] Univ Hosp Essen, Dept Neurosurg, Essen, Germany; [Sulman, Erik P.] NYU Langone Hlth, New York, NY USA; [Lolkema, Martijn P.] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands; [Barthel, Floris P.] Vrije Univ Amsterdam, Brain Tumor Ctr Amsterdam, Dept Pathol, Amsterdam UMC, Amsterdam, Netherlands; [Barthel, Floris P.] Translat Genom Res Inst, Canc & Cell Biol Div, Phoenix, AZ 85004 USA	Jackson Laboratory; University of Duisburg Essen; University of Duisburg Essen; NYU Langone Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of Amsterdam; Vrije Universiteit Amsterdam; Translational Genomics Research Institute	Barthel, FP; Verhaak, RGW (corresponding author), Jackson Lab Genom Med, Farmington, CT 06032 USA.; Barthel, FP (corresponding author), Vrije Univ Amsterdam, Brain Tumor Ctr Amsterdam, Dept Pathol, Amsterdam UMC, Amsterdam, Netherlands.; Barthel, FP (corresponding author), Translat Genom Res Inst, Canc & Cell Biol Div, Phoenix, AZ 85004 USA.	fbarthel@tgen.org; roel.verhaak@jax.org	Barthel, Floris P/I-4653-2014; Barthel, Floris P/AHC-3558-2022	Barthel, Floris P/0000-0002-7425-4180; Barthel, Floris P/0000-0002-7425-4180; Lolkema, Martijn/0000-0003-0466-2928; Anderson, Kevin/0000-0002-2362-273X; Johnson, Kevin/0000-0003-0016-5158; Varn, Frederick/0000-0001-6307-016X; Kocakavuk, Emre/0000-0003-1920-0494; Sulman, Erik/0000-0003-4933-9120	NIH [R01 CA190121, R01 CA237208, R21 NS114873]; Cancer Center Support Grant [P30 CA034196]; Musella Foundation; B*CURED Foundation; Brain Tumour Charity; Department of Defense [W81XWH1910246]; National Cancer Institute [K99 CA226387]; Jane Coffin Childs Memorial Fund for Medical Research; American Cancer Society Fellowship [130984-PF-17-141-01-DMC]; Boehringer Ingelheim Fonds; German National Academic Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant; Musella Foundation; B*CURED Foundation; Brain Tumour Charity; Department of Defense(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Jane Coffin Childs Memorial Fund for Medical Research; American Cancer Society Fellowship(American Cancer Society); Boehringer Ingelheim Fonds(Boehringer Ingelheim); German National Academic Foundation	This publication and the underlying study have been made possible partly on the basis of the data that HMF and the Center of Personalised Cancer Treatment (CPCT) have made available to the study. This work was supported by the NIH grants R01 CA190121, R01 CA237208, R21 NS114873 and Cancer Center Support Grant P30 CA034196, grants from the Musella Foundation, the B*CURED Foundation and the Brain Tumour Charity, and the Department of Defense W81XWH1910246 (R.G.W.V). F.P.B. is supported by the JAX Scholar program and the National Cancer Institute (K99 CA226387). F.S.V. is supported by a postdoctoral fellowship from The Jane Coffin Childs Memorial Fund for Medical Research. K.C.J. is the recipient of an American Cancer Society Fellowship (130984-PF-17-141-01-DMC). E.K. is the recipient of an MD fellowship by the Boehringer Ingelheim Fonds and is supported by the German National Academic Foundation.	Abyzov A, 2011, GENOME RES, V21, P974, DOI 10.1101/gr.114876.110; Adewoye AB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7684; Aldape K, 2018, NEURO-ONCOLOGY, V20, P873, DOI 10.1093/neuonc/noy020; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Bakhoum SF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6990; Barthel FP, 2019, NATURE, V576, P112, DOI 10.1038/s41586-019-1775-1; Barton MB, 2014, RADIOTHER ONCOL, V112, P140, DOI 10.1016/j.radonc.2014.03.024; Behjati S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12605; Bergstrom EN, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-6041-2; Bins S, 2017, ONCOLOGIST, V22, P33, DOI 10.1634/theoncologist.2016-0085; Blokzijl F, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0539-0; Campbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Cer RZ, 2013, NUCLEIC ACIDS RES, V41, pD94, DOI 10.1093/nar/gks955; Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48; Chiang C, 2015, NAT METHODS, V12, P966, DOI [10.1038/NMETH.3505, 10.1038/nmeth.3505]; Davidson PR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07888-0; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Georgakopoulos-Soares I, 2018, GENOME RES, V28, P1264, DOI 10.1101/gr.231688.117; Goldberg FW, 2020, J MED CHEM, V63, P3461, DOI 10.1021/acs.jmedchem.9b01684; Hu Z, 2019, NAT GENET, V51, P1113, DOI 10.1038/s41588-019-0423-x; Kucab JE, 2019, CELL, V177, P821, DOI 10.1016/j.cell.2019.03.001; Layer RM, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-6-r84; Lei LQ, 2018, NAT STRUCT MOL BIOL, V25, P45, DOI 10.1038/s41594-017-0004-6; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li M, 2012, ACS CHEM BIOL, V7, P506, DOI 10.1021/cb200440y; Li YR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14261-4; Lopez GY, 2019, ACTA NEUROPATHOL, V137, P139, DOI 10.1007/s00401-018-1906-z; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lutz ST, 2014, J CLIN ONCOL, V32, P2913, DOI 10.1200/JCO.2014.55.1143; Martincorena I, 2017, CELL, V171, P1029, DOI 10.1016/j.cell.2017.09.042; Munster P, 2019, CANCER MANAG RES, V11, P10463, DOI 10.2147/CMAR.S208720; Nguyen L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19406-4; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Nowarski R, 2013, CANCER RES, V73, P3494, DOI 10.1158/0008-5472.CAN-13-0728; Nowarski R, 2012, BLOOD, V120, P366, DOI 10.1182/blood-2012-01-402123; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Phi JH, 2018, ACTA NEUROPATHOL, V135, P939, DOI 10.1007/s00401-018-1845-8; Pich O, 2019, NAT GENET, V51, P1732, DOI 10.1038/s41588-019-0525-5; Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y; Reiter JG, 2020, NAT GENET, V52, P692, DOI 10.1038/s41588-020-0633-2; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Su JM, 2014, NEURO-ONCOLOGY, V16, P1661, DOI 10.1093/neuonc/nou103; Thijssen R, 2016, BLOOD, V128, P574, DOI 10.1182/blood-2016-02-700328; Timme CR, 2018, MOL CANCER THER, V17, P1207, DOI 10.1158/1535-7163.MCT-17-1267; Touat M, 2020, NATURE, V580, P517, DOI 10.1038/s41586-020-2209-9; Touil N, 2000, MUTAGENESIS, V15, P1, DOI 10.1093/mutage/15.1.1; Tyldesley S, 2011, INT J RADIAT ONCOL, V79, P1507, DOI 10.1016/j.ijrobp.2009.12.070; Stormo Gary D, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1110s43, 10.1002/0471250953.bi1201s43]; Volkova NV, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15912-7; Wiggans AJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007929.pub3	52	36	36	1	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2021	53	7					1088	+		10.1038/s41588-021-00874-3	http://dx.doi.org/10.1038/s41588-021-00874-3		MAY 2021	20	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	TH4XS	34045764	Green Accepted			2023-01-03	WOS:000655569100001
J	Tillmann, BW; Fu, LD; Hill, AD; Scales, DC; Fowler, RA; Cuthbertson, BH; Wunsch, H				Tillmann, Bourke W.; Fu, Longdi; Hill, Andrea D.; Scales, Damon C.; Fowler, Robert A.; Cuthbertson, Brian H.; Wunsch, Hannah			Acute healthcare resource utilization by age: A cohort study	PLOS ONE			English	Article							UNITED-STATES; ADMINISTRATIVE DATA; BED NUMBERS; EMERGENCY; MORTALITY; MEDICINE; TRENDS	Background Granular data related to the likelihood of individuals of different ages accessing acute and critical care services over time is lacking. Methods We used population-based, administrative data from Ontario to identify residents of specific ages (20, 30, 40, etc. to 100) on January 1(st) every year from 1995-2019. We assessed rates of emergency department (ED) visits (2003-19), hospitalizations, intensive care unit (ICU) admissions (2003-19), and mechanical ventilation. Findings Overall the 25-year study period, ED were the most common acute healthcare encounter with 100-year-olds having the lowest rate (138.7/1,000) and 90-year-olds the highest (378.5/1,000). Rates of hospitalization ranged from 24.2/1,000 for those age 20 up to 224.9/1,000 for those age 90. Rates of ICU admission and mechanical ventilation were lowest for those age 20 (1.0 and 0.4/1,000), more than tripled by age 50 (3.3 and 1.7/1,000) and peaked at age 80 (20.3 and 10.1/1,000). Over time rates of ED visits increased (164.3 /1,000 in 2003 vs 199.1 /1,000 in 2019) as did rates of invasive mechanical ventilation (2.0/1,000 in 1995 vs 2.9/1,000 in 2019), whereas rates of ICU admission remained stable (4.8/1,000 in 2003 vs 4.9/1,000 in 2019) and hospitalization declined (66.8/1,000 in 1995 vs 51.5/1,000 in 2019). Age stratified analysis demonstrated that rates of ED presentation increased for those age 70 and younger while hospitalization decreased for all age groups; ICU admission and mechanical ventilation rates changed variably by age, with increasing rates demonstrated primarily among people under the age of 50. Interpretation Rates of hospitalizations have decreased over time across all age groups, whereas rates of ED presentation, ICU admissions, and mechanical ventilation have increased, primarily driven by younger adults. These findings suggest that although the delivery of healthcare may be moving away from inpatient medicine, there is a growing population of young adults requiring significant healthcare resources.	[Tillmann, Bourke W.; Scales, Damon C.; Fowler, Robert A.; Cuthbertson, Brian H.; Wunsch, Hannah] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Tillmann, Bourke W.; Hill, Andrea D.; Scales, Damon C.; Fowler, Robert A.; Cuthbertson, Brian H.; Wunsch, Hannah] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada; [Fu, Longdi; Scales, Damon C.; Fowler, Robert A.; Wunsch, Hannah] Univ Toronto, ICES, Toronto, ON, Canada; [Hill, Andrea D.; Scales, Damon C.; Fowler, Robert A.; Cuthbertson, Brian H.; Wunsch, Hannah] Sunnybrook Res Inst, Toronto, ON, Canada; [Scales, Damon C.; Fowler, Robert A.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Scales, Damon C.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Cuthbertson, Brian H.; Wunsch, Hannah] Univ Toronto, Dept Anesthesiol & Pain Med, Toronto, ON, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Tillmann, BW (corresponding author), Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.; Tillmann, BW (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada.	Bourke.tillmann@sunnybrook.ca	Tillmann, Bourke/ABC-6001-2021	Tillmann, Bourke/0000-0002-7815-5972	ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC)	ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario)	The authors received no specific funding for this work. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and/or information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed in the material are those of the authors, and not necessarily those of CIHI.	[Anonymous], 2019, BBC; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; Canadian Institute for Health Information, 2020, NAT AMB CAR REP SYST; Canadian Institute for Health Information, 2018, IS MOST MON BEING SP; Case A, 2017, BROOKINGS PAP ECO AC, P397; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; Coster JE, 2017, ACAD EMERG MED, V24, P1137, DOI 10.1111/acem.13220; De Plessis V., 2001, RURAL SMALL TOWN CAN; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Dolan Doug, 2012, Healthc Q, V15, P19; Gelman A, 2016, P NATL ACAD SCI USA, V113, pE816, DOI 10.1073/pnas.1523465113; Gomez D, 2013, ANN SURG, V257, P160, DOI 10.1097/SLA.0b013e31827b9649; Halpern NA, 2004, CRIT CARE MED, V32, P1254, DOI 10.1097/01.CCM.0000128577.31689.4C; Halpern NA, 2016, CRIT CARE MED, V44, P1490, DOI 10.1097/CCM.0000000000001722; Halpern NA, 2010, CRIT CARE MED, V38, P65, DOI 10.1097/CCM.0b013e3181b090d0; Ibbitson J., 2000, GLOBE MAIL GLOBE MAI; Jaakkimainen RL, 2016, J ALZHEIMERS DIS, V54, P337, DOI 10.3233/JAD-160105; Juurlink D, 2006, CANADIAN I HLTH INFO; Kangovi S, 2013, HEALTH AFFAIR, V32, P1196, DOI 10.1377/hlthaff.2012.0825; Kellermann AL, 2006, NEW ENGL J MED, V355, P1300, DOI 10.1056/NEJMp068194; National Health Service England, 2020, MONTHL HOSP ACT DAT; Ontario Health Coalition, 2015, HOSP BED CUTS; Ragin DF, 2005, ACAD EMERG MED, V12, P1158, DOI 10.1197/j.aem.2005.06.030; Rice S., 2011, DONT WAITING ER CABL; Richardson LD, 2002, ANN EMERG MED, V40, P388, DOI 10.1067/mem.2002.128012; Rotermann M., 2017, HIGH USE ACUTE CARE; Sayer C., 2017, NEJM CATAL; Scales DC, 2006, J CLIN EPIDEMIOL, V59, P802, DOI 10.1016/j.jclinepi.2005.11.015; Siddiqui NF, 2012, CAN MED ASSOC J, V184, P1237, DOI 10.1503/cmaj.110895; Sprivulis PC, 2006, MED J AUSTRALIA, V184, P208, DOI 10.5694/j.1326-5377.2006.tb00203.x; Tanuseputro P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121759; Wallace DJ, 2015, AM J RESP CRIT CARE, V191, P410, DOI 10.1164/rccm.201409-1746OC; Wilson K, 2004, HEALTH POLICY, V67, P137, DOI 10.1016/S0168-8510(03)00101-5; Wodchis WP, 2016, CAN MED ASSOC J, V188, P182, DOI 10.1503/cmaj.150064	34	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2021	16	5							e0251877	10.1371/journal.pone.0251877	http://dx.doi.org/10.1371/journal.pone.0251877			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6NP	34010313	Green Published, gold			2023-01-03	WOS:000664630900074
J	Lu, ZZ; Liu, WY; Gao, HZ; Chen, WJ; Ge, WS; Li, F; Deng, YY				Lu, Zhenzhen; Liu, Wangyi; Gao, Hongzhi; Chen, Wanjia; Ge, Wenshu; Li, Fang; Deng, Yueyi			Traditional Chinese Medicine as an adjunct therapy in the treatment of idiopathic membranous nephropathy: A systematic review and meta-analysis	PLOS ONE			English	Review							EFFICACY	Background Idiopathic membranous nephropathy (IMN) is one of the most common causes of nephrotic syndrome in adults involving multiple targets and factors. The effect of conservative nonimmunosuppressive or immunosuppressive therapies is unsatisfactory and with many side effects. Traditional Chinese medicine (TCM) can regulate immune function and improve kidney function. Purpose To evaluate the total effective rate, curative rate, recurrence rate and adverse events of TCM alone or TCM as an adjunctive therapy for IMN. Methods Randomized controlled trials (RCT) comparing either TCM alone or the combination of TCM to western medicine (WM) therapies for patients with IMN were retrieved by searching English and Chinese database. Risk of bias summary was used to assess the methodological quality of eligible studies. Dichotomous data were presented using odds ratios (OR). The primary outcome measure was the total effective rate. Secondary outcomes included curative rate, recurrence rate and adverse events. Results 29 RCTs involving 1883 participants met the inclusion criteria. There was no statistically significant difference between the therapy of TCM alone and WM on the total effective rates (OR: 2.00; 95% CI: 0.80-4.98; P = 0.14) and curative rate (OR: 1.66; 95%CI: 0.66-4.22; p = 0.28). However, compared to basic treatment or immunosuppressive therapies alone, results showed that TCM as an adjunctive therapy had beneficial effects on the total effective rate (OR: 2.59; 95% CI: 1.38-4.86; P = 0.003 and OR: 3.01; 95% CI: 2.25-4.04; P < 0.00001) and curative rate (OR: 3.01; 95%CI: 1.24-7.28; p = 0.01 and OR: 1.73; 95%CI: 1.10-2.71; p = 0.02). In addition, the combination of TCM treatment could reduce the recurrence rate (OR: 0.28; 95% CI: 0.12-0.68; P = 0.004) and adverse reactions (OR: 0.38; 95% CI: 0.27-0.54; p < 0.00001). Conclusion The results indicate that TCM is well-tolerated for the treatment of IMN. However, there remains a need for large-scale and high-quality trials.	[Lu, Zhenzhen; Liu, Wangyi; Gao, Hongzhi; Chen, Wanjia; Ge, Wenshu; Li, Fang; Deng, Yueyi] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Nephrol, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine	Lu, ZZ; Deng, YY (corresponding author), Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Nephrol, Shanghai, Peoples R China.	826703071@qq.com; sh_dengyueyi@163.com		Lu, Zhenzhen/0000-0002-6233-7376	Shanghai Municipal Key Clinical Specialty [shslczdzk04201]; Second Batch of Scientific Research Projects of Construction of National TCM Clinical Research Base [JDZX2015097]; Scholar of Longhua Hospital, Shanghai University of Traditional Chinese Medicine [LYTD-85]	Shanghai Municipal Key Clinical Specialty; Second Batch of Scientific Research Projects of Construction of National TCM Clinical Research Base; Scholar of Longhua Hospital, Shanghai University of Traditional Chinese Medicine	This work was funded by Shanghai Municipal Key Clinical Specialty (No. shslczdzk04201); the Second Batch of Scientific Research Projects of Construction of National TCM Clinical Research Base (No. JDZX2015097) and the Scholar of Longhua Hospital, Shanghai University of Traditional Chinese Medicine (No. LYTD-85). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, OBSERVATION IDIOPATH; [Anonymous], 2014, NORDIC COCHRANE CTR; Chen YP, 2013, AM J KIDNEY DIS, V62, P1068, DOI 10.1053/j.ajkd.2013.05.005; Dai M., 2018, CONT MED S, V016, P186; Diao X.M, 2017, MODERN J INTEGRATED, P90; Dong L., 2014, SHANDONG TRADITIONAL; Dong L.P., 2018, CLIN OBSERVATION TRE; Feng M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006335.pub3; Fervenza FC, 2019, NEW ENGL J MED, V381, P36, DOI 10.1056/NEJMoa1814427; Floege J, 2019, KIDNEY INT, V95, P268, DOI 10.1016/j.kint.2018.10.018; Gao F., 2013, INT J TRANSPLANTATIO, V011, P30; Gao J.J., 2013, HEBEI J TRADITIONAL, V35, P1168; Glassock RJ, 2003, SEMIN NEPHROL, V23, P324, DOI 10.1016/S0270-9295(03)00049-4; Guo S.L., 2018, CLIN J CHINESE MED, V10, P125; Huo S., 2016, CHINESE J INTEGRATED, V17, P714; Jiao Z.S., 2018, EFFECT OBSERVATION S; Li Q.F., 2016, ACAD EXPERIENCE CHEN; Li X, 2014, J NEW CHINESE MED, V46, P73; Li Y.J, 2017, SHENZHEN J INTEGRATE, V27, P25; Liu C.Y., 2019, INT J TRADITIONAL CH, V41, P229; Liu X.Y., 2018, NEI MONGOL J TRADITI, V37, P28; Lu ZZ, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/2697672; Ma C.W., 2012, TRADITIONAL CHINESE, V25, P38; Perna A, 2004, AM J KIDNEY DIS, V44, P385, DOI 10.1053/j.ajkd.2004.05.020; Ponticelli C, 2018, AUTOIMMUN REV, V17, P1022, DOI 10.1016/j.autrev.2018.04.007; Shen X.N., 2018, CLIN OBSERVATION TRE; Sonia Boyer-Suavet., 2019, Front Immunol, V10, P3069, DOI 10.3389/fimmu.2019.03069; Sun Y.H., 2010, YIQI YANGYIN QINGLI; Sun ZF, 2014, INT UROL NEPHROL, V46, P1977, DOI 10.1007/s11255-014-0801-3; Van de Logt AE, 2019, KIDNEY INT, V96, P1292, DOI 10.1016/j.kint.2019.07.014; Wang HX, 2012, IFIP ADV INF COMM TE, V369, P115; Wang L.L, 2015, CLIN STUDY SALVIANOL; Wang Y.H., 2018, ACTA CHINESE MED, V33, P882; Wu Q.F., 2017, CLIN OBSERVATION THE; Xiang Z.L., 2017, ASIA PACIFIC TRADITI, V13, P151; Xie X., 2018, CHINESE J CONTROL EN, V33, P63; Xu X, 2016, J AM SOC NEPHROL, V27, P3739, DOI 10.1681/ASN.2016010093; Yang F.W., 2009, CLIN OBSERVATION TRE; Yu L.Q., 2014, J EMERGENCY TRADITIO, V23, P1324; Zhang Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00387; 韩东彦, 2013, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V19, P1311	41	2	2	16	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2021	16	5							e0251131	10.1371/journal.pone.0251131	http://dx.doi.org/10.1371/journal.pone.0251131			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0XR	33989325	gold, Green Published			2023-01-03	WOS:000662175000021
J	Poorman, E				Poorman, Elisabeth			The Number Needed to Prescribe - What Would It Take to Expand Access to Buprenorphine?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								The Number Needed to Prescribe Policies have been proposed to remove obstacles to prescribing buprenorphine to people with opioid use disorder. But a larger barrier to treatment expansion is cultural: physicians and institutions fail to treat substance use disorders as the chronic diseases they are.	[Poorman, Elisabeth] Univ Washington, Med Ctr, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Poorman, E (corresponding author), Univ Washington, Med Ctr, Dept Med, Seattle, WA 98195 USA.							CDC Health Alert Network, 2020, HAN00438 CDC; Department of Health and Human Services, 2021, HHS REL NEW BUPR PRA; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; McBain RK, 2020, ANN INTERN MED, V172, P504, DOI 10.7326/M19-2403	4	3	3	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2021	384	19					1783	1784		10.1056/NEJMp2101298	http://dx.doi.org/10.1056/NEJMp2101298		MAY 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	SD6UF	33983689				2023-01-03	WOS:000649041600001
J	Al-Shamali, Y; Ali, YM; Al-Shamali, RA; Al-Melahi, M; Al-Shammari, FR; Alsaber, A; Al-Adsani, W				Al-Shamali, Yousef; Ali, Yaser M.; Al-Shamali, Rawan A.; Al-Melahi, Maryam; Al-Shammari, Farah R.; Alsaber, Ahmad; Al-Adsani, Wasl			Don't close the book on tocilizumab for the treatment of severe COVID-19 pneumonia-the jury is still out: The Kuwait experience	PLOS ONE			English	Article							CARE	Purpose This cross-sectional observational study aims to report preliminary data from the first experience using tocilizumab for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in three of Kuwait's largest public hospitals City. Patients and methods This chart review study examined the benefits of tocilizumab treatment among 127 patients diagnosed with severe coronavirus disease of 2019 (COVID-19) pneumonia. Results 90 of 127 patients (71%) survived. Mortality was highest in the elderly with multiple medical conditions. Conclusion Despite the small sample size and retrospective nature of the work, our findings are consistent with recent studies suggesting tocilizumab administration in patients presenting with severe COVID pneumonia with associated hyperinflammatory features conferred mortality benefit.	[Al-Shamali, Yousef] Vancouver Gen Hosp, Dept Gastroenterol, Vancouver, BC, Canada; [Al-Shamali, Yousef] Jaber Al Sabah Hosp, Dept Gastroenterol, Kuwait, Kuwait; [Ali, Yaser M.] Mubarak Al Kabeer Hosp, Dept Rheumatol, Jabriya, Kuwait; [Al-Shamali, Rawan A.] Al Bahar Hosp, Kuwait Inst Med Specializat, Dept Ophthalmol, Kuwait, Kuwait; [Al-Melahi, Maryam] Amiri Hosp, Dept Internal Med, Kuwait, Kuwait; [Al-Shammari, Farah R.] Jahra Hosp, Dept Internal Med, Kuwait, Kuwait; [Alsaber, Ahmad] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland; [Al-Adsani, Wasl] Mubarak Al Kabeer Hosp, Dept Internal Med, Dept Infect Dis, Kuwait, Kuwait	University of British Columbia; Mubarak Al-Kabeer Hospital; Amiri Hospital; Jahra Hosptial; University of Strathclyde; Mubarak Al-Kabeer Hospital	Al-Shamali, RA (corresponding author), Al Bahar Hosp, Kuwait Inst Med Specializat, Dept Ophthalmol, Kuwait, Kuwait.	Rawan.alshamali@hotmail.com		Alsaber, Ahmad/0000-0001-9478-0404				Almazeedi S, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100448; Alshukry A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242768; Berenguer J, 2020, CLIN MICROBIOL INFEC, V26, P1525, DOI 10.1016/j.cmi.2020.07.024; Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695; COVID-19 Treatment Guidelines Panel, COR DIS 2019 COVID 1; De Rossi N, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100459; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI [10.1056/NEJMoa2100433, 10.1056/NEJMc2108482]; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Gupta S, 2021, JAMA INTERN MED, V181, P41, DOI 10.1001/jamainternmed.2020.6252; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Holman N, 2020, LANCET DIABETES ENDO, V8, P823, DOI 10.1016/S2213-8587(20)30271-0; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Jordan SC, 2020, CLIN INFECT DIS, V71, P3168, DOI 10.1093/cid/ciaa812; Kompaniyets L, 2021, MMWR-MORBID MORTAL W, V70, P355, DOI 10.15585/mmwr.mm7010e4; Martinez-Sanz J, 2021, CLIN MICROBIOL INFEC, V27, P238, DOI 10.1016/j.cmi.2020.09.021; Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633; O'Hearn M, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.019259; Parr JB, 2021, JAMA INTERN MED, V181, P12, DOI 10.1001/jamainternmed.2020.6557; Pawar A, 2019, ANN RHEUM DIS, V78, P456, DOI 10.1136/annrheumdis-2018-214367; Popkin BM, 2020, OBES REV, V21, DOI 10.1111/obr.13128; Potere N, 2020, INT J INFECT DIS, V100, P421, DOI 10.1016/j.ijid.2020.07.078; Price CC, 2020, CHEST, V158, P1397, DOI 10.1016/j.chest.2020.06.006; Ramiro S, 2020, ANN RHEUM DIS, V79, P1143, DOI 10.1136/annrheumdis-2020-218479; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Somers EC, 2021, CLIN INFECT DIS, V73, pE445, DOI [10.1093/cid/ciaa954, 10.1101/2020.05.29.20117358]; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Tadic M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104906; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	36	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0254379	10.1371/journal.pone.0254379	http://dx.doi.org/10.1371/journal.pone.0254379			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE5RC	34428204	Green Published, gold, Green Accepted			2023-01-03	WOS:000687944100048
J	Wang, P; Wang, X; Deng, HD; Li, LJ; Chong, W; Hai, Y; Zhang, Y				Wang, Peng; Wang, Xing; Deng, Haidong; Li, Linjie; Chong, Weelic; Hai, Yang; Zhang, Yu			Restrictive versus liberal transfusion thresholds in very low birth weight infants: A systematic review with meta-analysis	PLOS ONE			English	Review							BLOOD-CELL TRANSFUSION; PRETERM INFANTS; NECROTIZING ENTEROCOLITIS; PREMATURE-INFANTS; RANDOMIZED-TRIAL; GUIDELINES; IRON; RETINOPATHY; EFFICACY; SAFETY	Background To assess the efficacy and safety of restrictive versus liberal red blood cell transfusion thresholds in very low birth weight infants. Methods We searched MEDLINE, EMBASE, and Cochrane database without any language restrictions. The last search was conducted in August 15, 2020. All randomized controlled trials comparing the use of restrictive versus liberal red blood cell transfusion thresholds in very low birth weight (VLBW) infants were selected. Pooled risk ratio (RR) for dichotomous variable with 95% confidence intervals were assessed by a random-effects model. The primary outcome was all-cause mortality. Results Overall, this meta-analysis included 6 randomized controlled trials comprising 3,483 participants. Restrictive transfusion does not increase the risk of all-cause mortality (RR, 0.99; 95% CI, 0.84 to 1.17; I-2 = 0%; high-quality evidence), and does not increase the composite outcome of death or neurodevelopmental impairment (RR, 1.01, 95% CI, 0.93-1.09; I-2 = 7%; high-quality evidence) or other serious adverse events. Results were similar in subgroup analyses of all-cause mortality by weight of infants, gestational age, male infants, and transfusion volume. Conclusions In very low birth weight infants, a restrictive threshold for red blood cell transfusion was not associated with increased risk of all-cause mortality, in either short term or long term.	[Wang, Peng; Wang, Xing; Li, Linjie; Zhang, Yu] Chengdu Univ, Affiliated Hosp, Chengdu, Sichuan, Peoples R China; [Wang, Peng; Wang, Xing; Li, Linjie; Zhang, Yu] Chengdu Univ, Clin Med Coll, Chengdu, Sichuan, Peoples R China; [Deng, Haidong; Zhang, Yu] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China; [Chong, Weelic] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA; [Hai, Yang] Zucker Sch Med Hofstra Northwell, New York, NY USA	Chengdu University; Chengdu University; Sichuan University; Jefferson University	Zhang, Y (corresponding author), Chengdu Univ, Affiliated Hosp, Chengdu, Sichuan, Peoples R China.; Zhang, Y (corresponding author), Chengdu Univ, Clin Med Coll, Chengdu, Sichuan, Peoples R China.; Zhang, Y (corresponding author), Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China.	tnt1057@outlook.com		Zhang, Yu/0000-0002-4714-2167				Abu Jawdeh EG, 2014, J PERINATOL, V34, P921, DOI 10.1038/jp.2014.115; Bell EF, 2005, PEDIATRICS, V115, P1685, DOI 10.1542/peds.2004-1884; BLANK JP, 1984, AM J DIS CHILD, V138, P831, DOI 10.1001/archpedi.1984.02140470031010; Brooks SE, 1999, PEDIATRICS, V104, P514, DOI 10.1542/peds.104.3.514; Busch MP, 2003, JAMA-J AM MED ASSOC, V289, P959, DOI 10.1001/jama.289.8.959; Chen HL, 2009, PEDIATR NEONATOL, V50, P110, DOI 10.1016/S1875-9572(09)60045-0; Chirico G, 2011, J MATERN-FETAL NEO M, V24, P20, DOI 10.3109/14767058.2011.607566; Christensen RD, 2010, TRANSFUSION, V50, P1106, DOI 10.1111/j.1537-2995.2009.02542.x; Collard KJ, 2006, MED HYPOTHESES, V66, P355, DOI 10.1016/j.mehy.2005.04.046; Dani C, 2001, EARLY HUM DEV, V62, P57, DOI 10.1016/S0378-3782(01)00115-3; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fabres J, 2006, TRANSFUSION, V46, P1915, DOI 10.1111/j.1537-2995.2006.00997.x; Franz AR, 2020, JAMA-J AM MED ASSOC, V324, P560, DOI 10.1001/jama.2020.10690; Gibson BES, 2004, BRIT J HAEMATOL, V124, P433, DOI 10.1111/j.1365-2141.2004.04815.x; Girelli G, 2015, BLOOD TRANSFUS-ITALY, V13, P484, DOI 10.2450/2015.0113-15; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hesse L, 1997, EUR J PEDIATR, V156, P465, DOI 10.1007/s004310050641; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hirano K, 2001, ARCH DIS CHILD-FETAL, V84, pF188, DOI 10.1136/fn.84.3.F188; Ibrahim M, 2014, J PAEDIATR CHILD H, V50, P122, DOI 10.1111/jpc.12409; Jakobsen JC, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-120; Juul SE, 2020, NEW ENGL J MED, V382, P233, DOI 10.1056/NEJMoa1907423; Kirpalani H, 2006, J PEDIATR-US, V149, P301, DOI 10.1016/j.jpeds.2006.05.011; Kirpalani H, 2020, NEW ENGL J MED, V383, P2639, DOI 10.1056/NEJMoa2020248; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lozoff B, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e51; Luban NLC, 2005, ANN NY ACAD SCI, V1054, P325, DOI 10.1196/annals.1345.040; Maier RF, 2000, J PEDIATR-US, V136, P220, DOI 10.1016/S0022-3476(00)70105-3; Mally P, 2006, AM J PERINAT, V23, P451, DOI 10.1055/s-2006-951300; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Mascha EJ, 2015, ANESTH ANALG, V121, P1430, DOI 10.1213/ANE.0000000000000993; Mccoy TE, 2011, CHILD NEUROPSYCHOL, V17, P347, DOI 10.1080/09297049.2010.544647; New HV, 2016, BRIT J HAEMATOL, V175, P784, DOI 10.1111/bjh.14233; Nopoulos PC, 2011, ARCH PEDIAT ADOL MED, V165, P443, DOI 10.1001/archpediatrics.2010.269; Shinichi A., 2014, ONLINE KENSAKU, V35, P154; Siddappa AM, 2007, NEONATOLOGY, V92, P73, DOI 10.1159/000100805; STOCKMAN JA, 1984, AM J DIS CHILD, V138, P828, DOI 10.1001/archpedi.1984.02140470028009; Venkatesh V, 2012, BRIT J HAEMATOL, V158, P370, DOI 10.1111/j.1365-2141.2012.09180.x; Wetterslev J, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0315-7; Whyte RK, 2009, PEDIATRICS, V123, P207, DOI 10.1542/peds.2008-0338; Zagol K, 2012, J PEDIATR-US, V161, P417, DOI 10.1016/j.jpeds.2012.02.044; Zhu Z, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234266	42	3	3	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256810	10.1371/journal.pone.0256810	http://dx.doi.org/10.1371/journal.pone.0256810			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9QF	34460843	Green Published, gold			2023-01-03	WOS:000729151200036
J	Amebelu, A; Ban, R; Bhagwan, J; Brown, J; Chandler, C; Chilengi, R; Colford, JM; Cumming, O; Curtis, V; Evans, BE; Freeman, MC; Guiteras, R; Howard, G; Humphrey, J; Kang, G; Kulabako, R; Lanata, CF; Montgomery, MA; Null, C; Pickering, AJ; Wolf, J				Amebelu, Argaw; Ban, Radu; Bhagwan, Jay; Brown, Joe; Chandler, Clare; Chilengi, Roma; Colford, John M.; Cumming, Oliver; Curtis, Valerie; Evans, Barbara E.; Freeman, Matthew C.; Guiteras, Raymond; Howard, Guy; Humphrey, Jean; Kang, Gagandeep; Kulabako, Robinah; Lanata, Claudio F.; Montgomery, Maggie A.; Null, Clair; Pickering, Amy J.; Wolf, Jennyfer		Commissioners Lancet Commission	The Lancet Commission on water, sanitation and hygiene, and health	LANCET			English	Editorial Material							NUTRITIONAL INTERVENTIONS; CHILD GROWTH; QUALITY; DIARRHEA		[Amebelu, Argaw] Jimma Univ, Jimma, Ethiopia; [Ban, Radu] Bill & Melinda Gates Fdn, Seattle, WA USA; [Bhagwan, Jay] Water Res Commiss, Pretoria, South Africa; [Brown, Joe] Univ N Carolina, Chapel Hill, NC 27515 USA; [Chilengi, Roma] Ctr Infect Dis Res Zambia, Lusaka, Zambia; [Chandler, Clare; Cumming, Oliver] London Sch Hyg & Trop Med London, London WC1E 7HT, England; [Colford, John M.; Pickering, Amy J.] Univ Calif Berkeley, Berkeley, CA 94720 USA; [Evans, Barbara E.] Univ Leeds, Leeds, W Yorkshire, England; [Freeman, Matthew C.] Emory Univ, Atlanta, GA 30322 USA; [Guiteras, Raymond] North Carolina State Univ, Raleigh, NC USA; [Howard, Guy] Univ Bristol, Bristol, Avon, England; [Humphrey, Jean] Johns Hopkins Univ, Baltimore, MD USA; [Kang, Gagandeep] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India; [Kulabako, Robinah] Makerere Univ, Kampala, Uganda; [Lanata, Claudio F.] Nutr Res Inst, Lima, Peru; [Montgomery, Maggie A.; Wolf, Jennyfer] WHO, Geneva, Switzerland; [Null, Clair] Mathematica, Washington, DC USA	Jimma University; Bill & Melinda Gates Foundation; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Berkeley; University of Leeds; Emory University; University of North Carolina; North Carolina State University; University of Bristol; Johns Hopkins University; Christian Medical College & Hospital (CMCH) Vellore; Makerere University; World Health Organization; Mathematica	Cumming, O (corresponding author), London Sch Hyg & Trop Med London, London WC1E 7HT, England.	oliver.cumming@lshtm.ac.uk	Ambelu, Argaw/GQA-6114-2022; Ambelu, Argaw/V-8317-2018	Ambelu, Argaw/0000-0003-1898-4100; Ambelu, Argaw/0000-0003-1898-4100; Cumming, Oliver/0000-0002-5074-8709; Guiteras, Raymond/0000-0002-4333-6829; Evans, Barbara/0000-0001-9815-3141	Bill & Melinda Gates Foundation; UK Foreign, Commonwealth and Development Office related to the Commission; UK Foreign, Commonwealth and Development Office	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); UK Foreign, Commonwealth and Development Office related to the Commission; UK Foreign, Commonwealth and Development Office	RB is employed by the Water, Sanitation, and Hygiene programme at the Bill & Melinda Gates Foundation and is contributing to this Lancet Commission in his independent capacity as an economist and WASH expert. JBr reports a grant from the Bill & Melinda Gates Foundation unrelated to the Commission. OC reports grants from the Bill & Melinda Gates Foundation and UK Foreign, Commonwealth and Development Office related to the Commission. MCF reports grants from the Bill & Melinda Gates Foundation both related to, and unrelated to, the Commission. AJP reports a grant from the Bill & Melinda Gates Foundation related to the Commission. All the other authors declare no competing interests.; The Commissioners of the Lancet Commission on Water, Sanitation and Hygiene, and Health are: Argaw Amebelu, Radu Ban, Jay Bhagwan, Joe Brown, Clare Chandler, Roma Chilengi, John M Colford, Jr, *Oliver Cumming, +Valerie Curtis, Barbara E Evans, Matthew C Freeman, Raymond Guiteras, Guy Howard, Jean Humphrey, Gagandeep Kang, Robinah Kulabako, Claudio F Lanata, Maggie A Montgomery, Clair Null, Amy J Pickering, Jennyfer Wolf, supported by Jocalyn Clark and Ana Mateus from The Lancet. dagger Valerie Curtis died on Oct 19, 2020.	Abimbola S, 2020, LANCET, V396, P1627, DOI 10.1016/S0140-6736(20)32417-X; Allaire M, 2018, P NATL ACAD SCI USA, V115, P2078, DOI 10.1073/pnas.1719805115; Bellinger DC, 2016, NEW ENGL J MED, V374, P1101, DOI 10.1056/NEJMp1601013; Brewer TF, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001734; Caruso BA, 2015, LANCET, V386, P650, DOI 10.1016/S0140-6736(15)61497-0; Ekumah B, 2020, ENVIRON RES, V189, DOI 10.1016/j.envres.2020.109936; Humphrey JH, 2019, LANCET GLOB HEALTH, V7, pE132, DOI 10.1016/S2214-109X(18)30374-7; Knee J, 2021, ELIFE, V10, DOI 10.7554/eLife.62278; Landrigan PJ, 2018, LANCET, V391, P462, DOI 10.1016/S0140-6736(17)32345-0; Luby SP, 2018, LANCET GLOB HEALTH, V6, pE302, DOI 10.1016/S2214-109X(17)30490-4; Null C, 2018, LANCET GLOB HEALTH, V6, pE316, DOI 10.1016/S2214-109X(18)30005-6; Pickering AJ, 2019, LANCET GLOB HEALTH, V7, pE1139, DOI 10.1016/S2214-109X(19)30268-2; Platts-Mills JA, 2018, LANCET GLOB HEALTH, V6, pE1309, DOI [10.1016/S2214-109X(18)30349-8, 10.1016/s2214-109x(18)30349-8]; Pruss-Ustun A, 2019, INT J HYG ENVIR HEAL, V222, P765, DOI 10.1016/j.ijheh.2019.05.004; Ray I, 2021, LANCET GLOB HEALTH, V9, P361, DOI 10.1016/S2214-109X(20)30476-9; Rogawski ET, 2018, LANCET GLOB HEALTH, V6, pE1319, DOI [10.1016/s2214-109x(18)30351-6, 10.1016/S2214-109X(18)30351-6]; WHO UNICEF, 2021, PROGR HOUS DRINK WAT	17	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	2021	398	10310					1469	1470		10.1016/S0140-6736(21)02005-5	http://dx.doi.org/10.1016/S0140-6736(21)02005-5		OCT 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WL9OA	34487681	Bronze			2023-01-03	WOS:000710725800006
J	Chleilat, F; Schick, A; Deleemans, JM; Ma, K; Alukic, E; Wong, J; Tuplin, EWN; Nettleton, JE; Reimer, RA				Chleilat, Faye; Schick, Alana; Deleemans, Julie M.; Ma, Kyle; Alukic, Erna; Wong, Jolene; Tuplin, Erin W. Noye; Nettleton, Jodi E.; Reimer, Raylene A.			Paternal high protein diet modulates body composition, insulin sensitivity, epigenetics, and gut microbiota intergenerationally in rats	FASEB JOURNAL			English	Article						16S rRNA sequencing; body composition; DNA methyltransferase; epigenetics; gut microbiota; high protein diet; insulin sensitivity; paternal nutrition	HIGH-FAT DIET; DNA METHYLATION; AMINO-ACIDS; SMALL RNAS; GLUCOSE; OBESITY; INHERITANCE; METABOLISM; MICRORNAS; HUMANS	Mounting evidence demonstrates that paternal diet programs offspring metabolism. However, the contribution of a pre-conception paternal high protein (HP) diet to offspring metabolism, gut microbiota, and epigenetic changes remains unclear. Here we show that paternal HP intake in Sprague Dawley rats programs protective metabolic outcomes in offspring. Compared to paternal high fat/sucrose (HF/S), HP diet improved body composition and insulin sensitivity and improved circulating satiety hormones and cecal short-chain fatty acids compared to HF/S and control diet (P < .05). Further, using 16S rRNA gene sequencing to assess gut microbial composition, we observed increased alpha diversity, distinct bacterial clustering, and increased abundance of Bifidobacterium, Akkermansia, Bacteroides, and Marvinbryantia in HP fathers and/or male and female adult offspring. At the epigenetic level, DNMT1and 3b expression was altered intergenerationally. Our study identifies paternal HP diet as a modulator of gut microbial composition, epigenetic markers, and metabolic function intergenerationally.	[Chleilat, Faye; Ma, Kyle; Alukic, Erna; Wong, Jolene; Tuplin, Erin W. Noye; Nettleton, Jodi E.; Reimer, Raylene A.] Univ Calgary, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada; [Schick, Alana] Univ Calgary, Int Microbiome Ctr, Cumming Sch Med, Calgary, AB, Canada; [Deleemans, Julie M.] Univ Calgary, Cumming Sch Med, Div Med Sci & Psychosocial Oncol, Calgary, AB, Canada; [Reimer, Raylene A.] Univ Calgary, Cumming Sch Med, Dept Biochem & Mol Biol, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary	Reimer, RA (corresponding author), Univ Calgary, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	reimer@ucalgary.ca		Reimer, Raylene/0000-0001-5088-7947	Natural Sciences and Engineering Research Council [NSERC RGPIN/03773--2016]; Faculty of Kinesiology Dean's Doctoral Scholarship; Alberta Children's Hospital Research Institute scholarship; Natural Sciences and Engineering Research Council (NSERC) Summer Studentship; NSERC Undergraduate Student Research Program Studentship; Alberta Children's Hospital Research Institute scholarships	Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Faculty of Kinesiology Dean's Doctoral Scholarship; Alberta Children's Hospital Research Institute scholarship; Natural Sciences and Engineering Research Council (NSERC) Summer Studentship(Natural Sciences and Engineering Research Council of Canada (NSERC)); NSERC Undergraduate Student Research Program Studentship; Alberta Children's Hospital Research Institute scholarships	This work was supported by a research grant from the Natural Sciences and Engineering Research Council (NSERC RGPIN/03773--2016) and funding from Dr DA Hart. F Chleilat was supported by a Faculty of Kinesiology Dean's Doctoral Scholarship and Alberta Children's Hospital Research Institute scholarship. K Ma was supported by a Natural Sciences and Engineering Research Council (NSERC) Summer Studentship. E Alukic was supported by an NSERC Undergraduate Student Research Program Studentship. JE Nettleton was supported by Alberta Children's Hospital Research Institute scholarships. We thank Kristine Lee, Faculty of Kinesiology, and Dawn Martin, University of Calgary, for their technical assistance. Shelly Wegener and Dr Richard Pon, Centre for Health Genomics and Informatics facility at the University of Calgary for their technical assistance and support with the 16S rRNA sequencing and analysis.	An HM, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-116; Anderson LM, 2006, NUTRITION, V22, P327, DOI 10.1016/j.nut.2005.09.006; Antunes LC, 2016, ARCH ENDOCRIN METAB, V60, P138, DOI 10.1590/2359-3997000000169; Ayala JE, 2010, DIS MODEL MECH, V3, P525, DOI 10.1242/dmm.006239; Benito-Vicente A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228675; Binder NK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052304; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Carlin G, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010096; Chen Q, 2016, SCIENCE, V351, P397, DOI 10.1126/science.aad7977; Chleilat F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020689; Cho NA, 2018, OBESITY, V26, P1692, DOI 10.1002/oby.22325; Clarke SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065790; Fromentin G, 2012, NUTR RES REV, V25, P29, DOI 10.1017/S0954422411000175; Gaudichon C, 2002, GASTROENTEROLOGY, V123, P50, DOI 10.1053/gast.2002.34233; Gujar H, 2019, GENES-BASEL, V10, DOI 10.3390/genes10020172; Gurung M, 2020, EBIOMEDICINE, V51, DOI 10.1016/j.ebiom.2019.11.051; Hall E, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0522-z; Hallam MC, 2013, BRIT J NUTR, V110, P1732, DOI 10.1017/S0007114513000998; Iacomino G, 2017, GENES NUTR, V12, DOI 10.1186/s12263-017-0577-z; Isokpehi RD, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14040345; Jimenez-Chillaron JC, 2009, DIABETES, V58, P460, DOI 10.2337/db08-0490; Johnstone AM, 2012, P NUTR SOC, V71, P339, DOI 10.1017/S0029665112000122; Kashani A, 2019, ANIM MICROBIOME, V1, DOI 10.1186/s42523-019-0007-1; Kieffer TJ, 2000, AM J PHYSIOL-ENDOC M, V278, pE1, DOI 10.1152/ajpendo.2000.278.1.E1; Kim SH, 2014, J APPL MICROBIOL, V117, P834, DOI 10.1111/jam.12573; Klenk J, 2009, EUR J EPIDEMIOL, V24, P83, DOI 10.1007/s10654-009-9312-4; Lambrot R, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3889; Lavery CA, 2016, OBESITY, V24, P1741, DOI 10.1002/oby.21561; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Leppert S, 2014, CURR PHARM DESIGN, V20, P1812, DOI 10.2174/13816128113199990534; Ling C, 2019, CELL METAB, V29, P1028, DOI 10.1016/j.cmet.2019.03.009; Liu XX, 2014, AM J PHYSIOL-GASTR L, V307, pG459, DOI 10.1152/ajpgi.00400.2013; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma X, 2019, DIABETES, V68, P871, DOI 10.2337/dbi18-0057; Mandar R, 2015, RES MICROBIOL, V166, P440, DOI 10.1016/j.resmic.2015.03.009; Martin AM, 2019, P NATL ACAD SCI USA, V116, P19802, DOI 10.1073/pnas.1909311116; Mashoodh R, 2012, P NATL ACAD SCI USA, V109, P17232, DOI 10.1073/pnas.1121083109; Maurer AD, 2011, BRIT J NUTR, V105, P329, DOI 10.1017/S0007114510003533; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Miao J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7498; Miner-Williams W, 2012, AM J CLIN NUTR, V96, P508, DOI 10.3945/ajcn.111.033472; Miro-Blanch J, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00638; Mulligan CM, 2017, J ENDOCRINOL, V235, pR1, DOI [10.1530/JOE-17-0303, 10.1530/joe-17-0303]; Nettleton JE, 2020, GUT, V69, P1807, DOI 10.1136/gutjnl-2018-317505; Nettleton JE, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061248; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Nicolucci AC, 2017, GASTROENTEROLOGY, V153, P711, DOI 10.1053/j.gastro.2017.05.055; Paul HA, 2019, FASEB J, V33, P5153, DOI 10.1096/fj.201801551R; Paul HA, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700820; Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538; Pesta DH, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-53; Rando OJ, 2015, CELL, V161, P93, DOI 10.1016/j.cell.2015.02.021; Rando OJ, 2012, CELL, V151, P702, DOI 10.1016/j.cell.2012.10.020; Rietman A, 2014, EUR J CLIN NUTR, V68, P973, DOI 10.1038/ejcn.2014.123; Romano KA, 2018, LAB ANIMAL, V47, P240, DOI 10.1038/s41684-018-0129-1; Samblas M, 2019, EPIGENETICS-US, V14, P421, DOI 10.1080/15592294.2019.1595297; Schwarz J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047303; Sears B, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0123-1; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Sharma U, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00215; Tang MQ, 2009, CURR GENOMICS, V10, P336, DOI 10.2174/138920209788920994; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Veenendaal MVE, 2013, BJOG-INT J OBSTET GY, V120, P548, DOI 10.1111/1471-0528.12136; Velazquez MA, 2019, J ENDOCRINOL, V242, pT33, DOI 10.1530/JOE-18-0676; Watkins AJ, 2014, AM J PHYSIOL-HEART C, V306, DOI 10.1152/ajpheart.00981.2013; Wei YC, 2014, P NATL ACAD SCI USA, V111, P1873, DOI 10.1073/pnas.1321195111; Yan H, 2019, DIABETES, V68, P291, DOI 10.2337/db18-0638; Yoo SR, 2013, OBESITY, V21, P2571, DOI 10.1002/oby.20428; Yu AM, 2012, ACTA PHARM SIN B, V2, P93, DOI 10.1016/j.apsb.2012.02.011	70	4	4	5	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2021	35	9							e21847	10.1096/fj.202100198RR	http://dx.doi.org/10.1096/fj.202100198RR			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ2LG	34405464				2023-01-03	WOS:000691122900010
J	Drayman, N; DeMarco, JK; Jones, KA; Azizi, SA; Froggatt, HM; Tan, K; Maltseva, NI; Chen, S; Nicolaescu, V; Dvorkin, S; Furlong, K; Kathayat, RS; Firpo, MR; Mastrodomenico, V; Bruce, EA; Schmidt, MM; Jedrzejczak, R; Munoz-Alia, MA; Schuster, B; Nair, V; Han, KY; O'Brien, A; Tomatsidou, A; Meyer, B; Vignuzzi, M; Missiakas, D; Botten, JW; Brooke, CB; Lee, H; Baker, SC; Mounce, BC; Heaton, NS; Severson, WE; Palmer, KE; Dickinson, BC; Joachimiak, A; Randall, G; Tay, S				Drayman, Nir; DeMarco, Jennifer K.; Jones, Krysten A.; Azizi, Saara-Anne; Froggatt, Heather M.; Tan, Kemin; Maltseva, Natalia Ivanovna; Chen, Siquan; Nicolaescu, Vlad; Dvorkin, Steve; Furlong, Kevin; Kathayat, Rahul S.; Firpo, Mason R.; Mastrodomenico, Vincent; Bruce, Emily A.; Schmidt, Madaline M.; Jedrzejczak, Robert; Munoz-Alia, Miguel A.; Schuster, Brooke; Nair, Vishnu; Han, Kyu-yeon; O'Brien, Amornrat; Tomatsidou, Anastasia; Meyer, Bjoern; Vignuzzi, Marco; Missiakas, Dominique; Botten, Jason W.; Brooke, Christopher B.; Lee, Hyun; Baker, Susan C.; Mounce, Bryan C.; Heaton, Nicholas S.; Severson, William E.; Palmer, Kenneth E.; Dickinson, Bryan C.; Joachimiak, Andrzej; Randall, Glenn; Tay, Savas			Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2	SCIENCE			English	Article							TYROSINE KINASE INHIBITOR; MODEL; IDENTIFICATION; DESIGN; VIRUS	There is an urgent need for antiviral agents that treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We screened a library of 1900 clinically safe drugs against OC43, a human beta coronavirus that causes the common cold, and evaluated the top hits against SARS-CoV-2. Twenty drugs significantly inhibited replication of both viruses in cultured human cells. Eight of these drugs inhibited the activity of the SARS-CoV-2 main protease, 3CLpro, with the most potent being masitinib, an orally bioavailable tyrosine kinase inhibitor. X-ray crystallography and biochemistry show that masitinib acts as a competitive inhibitor of 3CLpro. Mice infected with SARS-CoV-2 and then treated with masitinib showed >200-fold reduction in viral titers in the lungs and nose, as well as reduced lung inflammation. Masitinib was also effective in vitro against all tested variants of concern (B.1.1.7, B.1.351, and P.1).	[Drayman, Nir; Schuster, Brooke; Nair, Vishnu; Tay, Savas] Univ Chicago, Pritzker Sch Mol Engn, Chicago, IL 60637 USA; [DeMarco, Jennifer K.; Severson, William E.; Palmer, Kenneth E.] Univ Louisville, Ctr Predict Med Biodefense & Emerging Infect Dis, Louisville, KY 40292 USA; [Jones, Krysten A.; Azizi, Saara-Anne; Kathayat, Rahul S.; Dickinson, Bryan C.] Univ Chicago, Dept Chem, 5735 S Ellis Ave, Chicago, IL 60637 USA; [Froggatt, Heather M.; Heaton, Nicholas S.] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA; [Tan, Kemin; Maltseva, Natalia Ivanovna; Jedrzejczak, Robert; Joachimiak, Andrzej] Univ Chicago, Ctr Struct Genom Infect Dis Consortium Adv Sci &, Chicago, IL 60637 USA; [Tan, Kemin; Maltseva, Natalia Ivanovna; Jedrzejczak, Robert; Joachimiak, Andrzej] Argonne Natl Lab, Struct Biol Ctr, Xray Sci Div, 9700 S Cass Ave, Argonne, IL 60439 USA; [Chen, Siquan] Univ Chicago, Cellular Screening Ctr, Chicago, IL 60637 USA; [Nicolaescu, Vlad; Dvorkin, Steve; Furlong, Kevin; Tomatsidou, Anastasia; Missiakas, Dominique; Randall, Glenn] Univ Chicago, Dept Microbiol, Ricketts Lab, Chicago, IL 60637 USA; [Firpo, Mason R.; Mastrodomenico, Vincent; O'Brien, Amornrat; Baker, Susan C.; Mounce, Bryan C.] Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL USA; [Bruce, Emily A.; Schmidt, Madaline M.; Botten, Jason W.] Univ Vermont, Larner Coll Med, Dept Med, Div Immunobiol, Burlington, VT USA; [Bruce, Emily A.; Schmidt, Madaline M.; Botten, Jason W.] Univ Vermont, Larner Coll Med, Dept Microbiol & Mol Genet, Burlington, VT USA; [Munoz-Alia, Miguel A.] Mayo Clin, Dept Mol Med, Rochester, MN USA; [Han, Kyu-yeon] Univ Illinois, Coll Med, Illinois Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Chicago, IL USA; [Meyer, Bjoern; Vignuzzi, Marco] CNRS, Inst Pasteur, Viral Populat & Pathogenesis Unit, UMR 3569, Paris, France; [Botten, Jason W.] Univ Vermont, Larner Coll Med, Vaccine Testing Ctr, Burlington, VT USA; [Brooke, Christopher B.] Univ Illinois, Dept Microbiol, 131 Burrill Hall, Urbana, IL 61801 USA; [Brooke, Christopher B.] Univ Illinois, Carl R Woese Inst Genom Biol, Urbana, IL 61801 USA; [Lee, Hyun] Univ Illinois, Coll Pharm, Dept Pharmaceut Sci, Biophys Core,Res Resources Ctr, Chicago, IL USA; [Joachimiak, Andrzej] Univ Chicago, Dept Biochem & Mol Biol, 920 E 58Th St, Chicago, IL 60637 USA	University of Chicago; University of Louisville; University of Chicago; Duke University; University of Chicago; United States Department of Energy (DOE); Argonne National Laboratory; University of Chicago; University of Chicago; Loyola University Chicago; University of Vermont; University of Vermont; Mayo Clinic; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Vermont; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Drayman, N; Tay, S (corresponding author), Univ Chicago, Pritzker Sch Mol Engn, Chicago, IL 60637 USA.	nirdra@uchicago.edu; tays@uchicago.edu		Meyer, Bjorn/0000-0002-7903-5710; Lee, Hyun/0000-0003-2570-8120; Jones, Krysten/0000-0003-0711-5516; Nicolaescu, Vlad/0000-0002-6347-0232; Schuster, Brooke/0000-0002-7070-6143; Maltseva, Natalia/0000-0002-2871-465X; Tan, Kemin/0000-0002-4003-7903; Schmidt, Madaline/0000-0003-3893-3466; Azizi, Saara-Anne/0000-0002-9226-9917; Palmer, Kenneth Edward/0000-0002-2811-1111; Drayman, Nir/0000-0003-4460-9558; Firpo, Mason/0000-0001-7122-5109; Joachimiak, Andrzej/0000-0003-2535-6209	Human Frontier Science Program (HFSP) postdoctoral fellowship; federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Department of Health and Human Services [HHSN272201700060C]; US Department of Energy (DOE) Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on response to COVID-19; Coronavirus CARES Act; NIH [P20GM125498, P30GM11822804, R41AI132047, R21AI154198, U01AI1141997, P20 GM125504, R01 AI085089]; Office of the Vice President for Research at the University of Vermont; National Institute of General Medical Sciences (NIGMS) [R35GM138199]; DOE Office of Science [DE-AC02-06CH11357]; Pritzker School of Molecular Engineering at The University of Chicago; NIGMS [R35 GM119840]	Human Frontier Science Program (HFSP) postdoctoral fellowship(Human Frontier Science Program); federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Department of Health and Human Services; US Department of Energy (DOE) Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on response to COVID-19(United States Department of Energy (DOE)); Coronavirus CARES Act; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of the Vice President for Research at the University of Vermont; National Institute of General Medical Sciences (NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); DOE Office of Science(United States Department of Energy (DOE)); Pritzker School of Molecular Engineering at The University of Chicago; NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	N.D. is a recipient of the Human Frontier Science Program (HFSP) postdoctoral fellowship. Funding for this project was provided in part by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Department of Health and Human Services, under contract HHSN272201700060C (to A.J.) and by the US Department of Energy (DOE) Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act (to A.J.). E.A.B. acknowledges funding by NIH P20GM125498 (UVM Translational Global Infectious Disease Research Center) and NIH P30GM11822804 (UVM Center for Immunology and Infectious Disease). J.W.B. acknowledges funding from the Office of the Vice President for Research at the University of Vermont and NIH grants R41AI132047, R21AI154198, and U01AI1141997. B.M. acknowledges National Institute of General Medical Sciences (NIGMS) grant R35GM138199. The use of SBC beamlines at the Advanced Photon Source is supported by the DOE Office of Science and operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357. B.C.D. acknowledges funding from the NIGMS (R35 GM119840). K.E.P. acknowledges funding from NIH grant P20 GM125504. S.C.B. acknowledges funding from NIH grant R01 AI085089. S.T. acknowledges funding support from the Pritzker School of Molecular Engineering at The University of Chicago.	Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; Baggen J, 2021, NAT GENET, V53, P435, DOI 10.1038/s41588-021-00805-2; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681; Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489; del Valle JR, 2007, J VIROL, V81, P10597, DOI 10.1128/JVI.00923-07; Dial CN, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11050403; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Dubreuil P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007258; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Flatz L, 2006, P NATL ACAD SCI USA, V103, P4663, DOI 10.1073/pnas.0600652103; Folch J, 2015, EXPERT REV NEUROTHER, V15, P587, DOI 10.1586/14737175.2015.1045419; Froggatt HM, 2020, J VIROL, V94, DOI 10.1128/JVI.01265-20; Ghosh AK, 2008, BIOORG MED CHEM LETT, V18, P5684, DOI 10.1016/j.bmcl.2008.08.082; Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386; Graham Nancy R, 2020, medRxiv, DOI 10.1101/2020.07.15.20154443; Hahn KA, 2008, J VET INTERN MED, V22, P1301, DOI 10.1111/j.1939-1676.2008.0190.x; Humbert M, 2009, ALLERGY, V64, P1194, DOI 10.1111/j.1398-9995.2009.02122.x; Jin Z, 2020, NATURE, V582, P289, DOI [10.1038/s41586-020-2223-y, DOI 10.1038/S41586-020-2223-Y, DOI 10.1007/s10529-011-0845-8]; Kim Y, 2011, METHODS, V55, P12, DOI 10.1016/j.ymeth.2011.07.010; Kneller DW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16954-7; Lee CC, 2009, J BIOL CHEM, V284, P7646, DOI 10.1074/jbc.M807947200; Lee H, 2014, BIOORGAN MED CHEM, V22, P167, DOI 10.1016/j.bmc.2013.11.041; Lee-Fowler TM, 2012, INT ARCH ALLERGY IMM, V158, P369, DOI 10.1159/000335122; Liu YZ, 2020, EUR J MED CHEM, V206, DOI 10.1016/j.ejmech.2020.112711; Makela MJ, 1998, J CLIN MICROBIOL, V36, P539; Marech I, 2014, CRIT REV ONCOL HEMAT, V91, P98, DOI 10.1016/j.critrevonc.2013.12.011; McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Munoz-Alia MA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11080688; O'Brien A, 2021, VIROLOGY, V556, P73, DOI 10.1016/j.virol.2021.01.010; Osipiuk J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21060-3; Ottaiano A, 2017, ACTA ONCOL, V56, P377, DOI 10.1080/0284186X.2017.1288922; Pardo Joe, 2020, Drugs Context, V9, DOI 10.7573/dic.2020-4-14; Resnick S. J., 2020, BIORXIV 2020 08 29 2, DOI [10.1101/2020.08.29.272864, DOI 10.1101/2020.08.29.272864]; Schneider WM, 2021, CELL, V184, P120, DOI 10.1016/j.cell.2020.12.006; Soria JC, 2009, EUR J CANCER, V45, P2333, DOI 10.1016/j.ejca.2009.05.010; Terwilliger TC, 2012, ACTA CRYSTALLOGR D, V68, P861, DOI 10.1107/S0907444912015636; U.S. Department of Health and Human Services, 2005, FED REG, V70, P42346; Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589; Vermersch P, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-36; Vuong W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18096-2; Worldometer, COR UPD LIV 22559115; Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073; Yang X, 2020, LANCET RESP MED, V8, P475; Zhu W, 2020, ACS PHARMACOL TRANSL, V3, P1008, DOI 10.1021/acsptsci.0c00108; Zhu YK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21213-4; Ziegler CM, 2016, J GEN VIROL, V97, P2084, DOI 10.1099/jgv.0.000550; Ziegler CM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005501	51	75	77	26	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2021	373	6557					931	+		10.1126/science.abg5827	http://dx.doi.org/10.1126/science.abg5827			45	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC5JU	34285133	Green Published, Green Accepted			2023-01-03	WOS:000686562400040
J	Wang, MN; Herbst, RS; Boshoff, C				Wang, Meina; Herbst, Roy S.; Boshoff, Chris			Toward personalized treatment approaches for non-small-cell lung cancer	NATURE MEDICINE			English	Article							IMMUNE CHECKPOINT BLOCKADE; OPEN-LABEL; PD-1 BLOCKADE; MESENCHYMAL TRANSITION; ACQUIRED-RESISTANCE; 1ST-LINE NIVOLUMAB; ANTITUMOR-ACTIVITY; LIVER METASTASIS; SINGLE-ARM; PHASE-III	Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have improved outcomes markedly over the past two decades. However, the vast majority of advanced NSCLCs become resistant to current treatments and eventually progress. In this Perspective, we discuss some of the recent breakthrough therapies developed for NSCLC, focusing on immunotherapies and targeted therapies. We highlight our current understanding of mechanisms of resistance and the importance of incorporating genomic analyses into clinical studies to decipher these further. We underscore the future role of neoadjuvant and maintenance combination therapy approaches to potentially cure early disease. A major challenge to successful development of rational combination therapies will be the application of robust predictive biomarkers for clear-cut patient stratification, and we provide our views on clinical research areas that could influence how NSCLC will be managed over the coming decade. This Perspective discusses recent developments in NSCLC immunotherapy and targeted therapy, and highlights the key challenges and future directions for NSCLC management.	[Wang, Meina; Herbst, Roy S.; Boshoff, Chris] Yale Sch Med, Yale Comprehens Canc Ctr, New Haven, CT 06510 USA; [Boshoff, Chris] Pfizer Inc, New York, NY 10017 USA	Yale University; Pfizer	Herbst, RS; Boshoff, C (corresponding author), Yale Sch Med, Yale Comprehens Canc Ctr, New Haven, CT 06510 USA.; Boshoff, C (corresponding author), Pfizer Inc, New York, NY 10017 USA.	roy.herbst@yale.edu; christoffer.boshoff@pfizer.com						Abbas AK, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat1482; Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Ahn M., 2020, ANN ONCOL, V31, pS754; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; [Anonymous], 2020, STEP 1 CTDNA MON TRE; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Awad MM, 2021, J THORAC ONCOL, V16, P162, DOI 10.1016/j.jtho.2020.09.015; Bar-Sagi D, 2020, NAT CANCER, V1, P25, DOI 10.1038/s43018-019-0016-8; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Blackburn EH, 2011, CANCER PREV RES, V4, P787, DOI 10.1158/1940-6207.CAPR-11-0195; Boumahdi S, 2020, NAT REV DRUG DISCOV, V19, P39, DOI 10.1038/s41573-019-0044-1; Boyer M, 2021, J CLIN ONCOL, V39, P2327, DOI 10.1200/JCO.20.03579; Bristol Myers Squibb, 2021, NEOADJ OP NIV PLUS C; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Camidge DR, 2020, J CLIN ONCOL, V38, P3592, DOI 10.1200/JCO.20.00505; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Cascone T, 2021, NAT MED, V27, P504, DOI 10.1038/s41591-020-01224-2; Chaudhuri AA, 2017, CANCER DISCOV, V7, P1394, DOI 10.1158/2159-8290.CD-17-0716; Chauvin JM, 2015, J CLIN INVEST, V125, P2046, DOI 10.1172/JCI80445; Chen X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1047-2; Chin EN, 2020, SCIENCE, V369, P993, DOI 10.1126/science.abb4255; Corcoran RB, 2018, NEW ENGL J MED, V379, P1754, DOI 10.1056/NEJMra1706174; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Crispe IN, 2014, HEPATOLOGY, V60, P2109, DOI 10.1002/hep.27254; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Detterbeck FC, 2017, CHEST, V151, P193, DOI 10.1016/j.chest.2016.10.010; Dhatchinamoorthy K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.636568; Dongre A, 2017, CANCER RES, V77, P3982, DOI 10.1158/0008-5472.CAN-16-3292; Drilon A, 2020, NEW ENGL J MED, V383, P813, DOI 10.1056/NEJMoa2005653; Drilon A, 2020, LANCET ONCOL, V21, P261, DOI 10.1016/S1470-2045(19)30690-4; Drilon A, 2020, NAT MED, V26, P47, DOI 10.1038/s41591-019-0716-8; Drilon A, 2017, J THORAC ONCOL, V12, P15, DOI 10.1016/j.jtho.2016.10.014; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Fukurnura D, 2018, NAT REV CLIN ONCOL, V15, P325, DOI 10.1038/nrclinonc.2018.29; Gadgeel S, 2020, J CLIN ONCOL, V38, P1505, DOI 10.1200/JCO.19.03136; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Garon EB, 2019, J CLIN ONCOL, V37, P2518, DOI 10.1200/JCO.19.00934; George S, 2017, IMMUNITY, V46, P197, DOI 10.1016/j.immuni.2017.02.001; Gettinger S, 2018, J CLIN ONCOL, V36, P1675, DOI 10.1200/JCO.2017.77.0412; Gettinger S, 2017, CANCER DISCOV, V7, P1420, DOI 10.1158/2159-8290.CD-17-0593; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Goldberg SB, 2020, LANCET ONCOL, V21, P655, DOI 10.1016/S1470-2045(20)30111-X; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gridelli C, 2011, LUNG CANCER, V71, P249, DOI 10.1016/j.lungcan.2010.12.008; Hegde PS, 2018, SEMIN CANCER BIOL, V52, P117, DOI 10.1016/j.semcancer.2017.12.002; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Hellmann Matthew D, 2018, N Engl J Med, V378, P2093, DOI 10.1056/NEJMoa1801946; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Herbst RS, 2015, CLIN CANCER RES, V21, P1514, DOI 10.1158/1078-0432.CCR-13-3473; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840; Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038; HUTCHISON DJ, 1963, ADV CANCER RES, V7, P235, DOI 10.1016/S0065-230X(08)60984-7; Janssen Pharmaceutical Companies, 2021, NEW AM DAT CHRY SALI; Jiao XD, 2019, J THORAC DIS, V11, P4507, DOI 10.21037/jtd.2019.11.04; Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018; Jones GD, 2021, CLIN CANCER RES, V27, P2604, DOI 10.1158/1078-0432.CCR-20-4772; Joshi K, 2019, NAT MED, V25, P1549, DOI 10.1038/s41591-019-0592-2; Kim ES, 2011, CANCER DISCOV, V1, P44, DOI 10.1158/2159-8274.CD-10-0010; Kim JM, 2016, ANN ONCOL, V27, P1492, DOI 10.1093/annonc/mdw217; Koyama S, 2016, CANCER RES, V76, P999, DOI 10.1158/0008-5472.CAN-15-1439; Langer CJ, 2019, J THORAC ONCOL, V14, P1839, DOI 10.1016/j.jtho.2019.05.029; Le Pechoux C, 2020, ANN ONCOL, V31, pS1178, DOI 10.1016/j.annonc.2020.08.2280; Lee JC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba0759; Li TH, 2013, J CLIN ONCOL, V31, P1039, DOI 10.1200/JCO.2012.45.3753; Lipson EJ, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.9503; Manieri NA, 2017, TRENDS IMMUNOL, V38, P20, DOI 10.1016/j.it.2016.10.002; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; McGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Middleton G, 2020, NATURE, V583, P807, DOI 10.1038/s41586-020-2481-8; Mok T, 2020, ANN ONCOL, V31, P1056, DOI 10.1016/j.annonc.2020.04.478; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2020, NAT MED, V26, P1733, DOI 10.1038/s41591-020-1044-8; Neal JW, 2020, J CLIN ONCOL, V38; Oyama T, 1998, J IMMUNOL, V160, P1224; Paik PK, 2020, NEW ENGL J MED, V383, P931, DOI 10.1056/NEJMoa2004407; Palmer AC, 2017, CELL, V171, P1678, DOI 10.1016/j.cell.2017.11.009; Pao W, 2018, CANCER DISCOV, V8, P395, DOI 10.1158/2159-8290.CD-17-1320; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Paz-Ares L, 2021, LANCET ONCOL, V22, P198, DOI 10.1016/S1470-2045(20)30641-0; Paz-Ares L, 2020, J THORAC ONCOL, V15, P1657, DOI 10.1016/j.jtho.2020.06.015; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Planchard D, 2017, LANCET ONCOL, V18, P1307, DOI 10.1016/S1470-2045(17)30679-4; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Reck M, 2019, LANCET RESP MED, V7, P387, DOI 10.1016/S2213-2600(19)30084-0; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Redman MW, 2020, LANCET ONCOL, V21, P1589, DOI 10.1016/S1470-2045(20)30475-7; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roche, 2021, PIVOT PHAS 3 STUD SH; Rodriguez-Abreu D, 2020, J CLIN ONCOL, V38; Rosenberg SA, 1998, ANN SURG, V228, P307, DOI 10.1097/00000658-199809000-00004; Rosenberg SA, 2014, J IMMUNOL, V192, P5451, DOI 10.4049/jimmunol.1490019; Rosenthal R, 2019, NATURE, V567, P479, DOI 10.1038/s41586-019-1032-7; Rotow J, 2017, NAT REV CANCER, V17, P637, DOI 10.1038/nrc.2017.84; Rousseau B, 2021, NEW ENGL J MED, V384, P1168, DOI 10.1056/NEJMc2031965; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sabari JK, 2021, J THORAC ONCOL, V16, pS108, DOI 10.1016/j.jtho.2021.01.284; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Salmon H, 2016, IMMUNITY, V44, P924, DOI 10.1016/j.immuni.2016.03.012; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Schaaf MB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0061-0; Schoenfeld AJ, 2020, J THORAC ONCOL, V15, P18, DOI 10.1016/j.jtho.2019.11.005; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Settleman J, 2021, CANCER DISCOV, V11, P1016, DOI 10.1158/2159-8290.CD-20-1187; Sezer A, 2021, LANCET, V397, P592, DOI 10.1016/S0140-6736(21)00228-2; Shah KN, 2019, NAT MED, V25, P111, DOI 10.1038/s41591-018-0264-7; Sharma P, 2021, CANCER DISCOV, V11, P838, DOI 10.1158/2159-8290.CD-20-1680; Shaw AT, 2019, ANN ONCOL, V30, P1121, DOI 10.1093/annonc/mdz131; Shaw AT, 2020, NEW ENGL J MED, V383, P2018, DOI 10.1056/NEJMoa2027187; Shaw AT, 2019, LANCET ONCOL, V20, P1691, DOI 10.1016/S1470-2045(19)30655-2; Shen SY, 2018, NATURE, V563, P579, DOI 10.1038/s41586-018-0703-0; Shen Y, 2020, CANCER CELL, V37, P800, DOI 10.1016/j.ccell.2020.05.005; Shu CA, 2020, LANCET ONCOL, V21, P786, DOI 10.1016/S1470-2045(20)30140-6; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sistigu A, 2017, CYTOKINE GROWTH F R, V36, P67, DOI 10.1016/j.cytogfr.2017.05.008; Skoulidis F, 2021, NEW ENGL J MED, V384, P2371, DOI 10.1056/NEJMoa2103695; Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Spigel DR, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.8511; Spigel DR, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9017; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Spreafico A, 2021, CANCER DISCOV, V11, P822, DOI 10.1158/2159-8290.CD-20-1301; Tanaka N, 2021, CANCER DISCOV, V11, P1913, DOI 10.1158/2159-8290.CD-21-0365; Taylor MH, 2020, J CLIN ONCOL, V38, P1154, DOI 10.1200/JCO.19.01598; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Tumeh PC, 2017, CANCER IMMUNOL RES, V5, P417, DOI 10.1158/2326-6066.CIR-16-0325; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586-019-1730-1; Vidotto T, 2020, BRIT J CANCER, V122, P1732, DOI 10.1038/s41416-020-0834-6; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wang TT, 2017, GUT, V66, P1900, DOI 10.1136/gutjnl-2016-313075; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wolf J, 2020, NEW ENGL J MED, V383, P944, DOI 10.1056/NEJMoa2002787; World Health Organization, 2018, CANC FACT SHEET; Wu YL, 2020, NEW ENGL J MED, V383, P1711, DOI 10.1056/NEJMoa2027071; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhong WZ, 2018, LANCET ONCOL, V19, P139, DOI 10.1016/S1470-2045(17)30729-5	157	88	89	16	43	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2021	27	8					1345	1356		10.1038/s41591-021-01450-2	http://dx.doi.org/10.1038/s41591-021-01450-2		AUG 2021	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UC6JU	34385702				2023-01-03	WOS:000684533600005
J	Taghioff, SM; Slavin, BR; Holton, T; Singh, D				Taghioff, Susan M.; Slavin, Benjamin R.; Holton, Tripp; Singh, Devinder			Examining the potential benefits of the influenza vaccine against SARS-CoV-2: A retrospective cohort analysis of 74,754 patients	PLOS ONE			English	Article							COVID-19	Introduction Recently, several single center studies have suggested a protective effect of the influenza vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This study utilizes a continuously updated Electronic Medical Record (EMR) network to assess the possible benefits of influenza vaccination mitigating critical adverse outcomes in SARS-CoV-2 positive patients from 56 healthcare organizations (HCOs). Methods The de-identified records of 73,346,583 patients were retrospectively screened. Two cohorts of 37,377 patients, having either received or not received influenza vaccination six months-two weeks prior to SARS-CoV-2 positive diagnosis, were created using Common Procedural Terminology (CPT) and logical observation identifiers names and codes (LOINC) codes. Adverse outcomes within 30, 60, 90, and 120 days of positive SARS-CoV-2 diagnosis were compared between cohorts. Outcomes were assessed with stringent propensity score matching including age, race, ethnicity, gender, hypertension, diabetes, hyperlipidemia, chronic obstructive pulmonary disease (COPD), obesity, heart disease, and lifestyle habits such as smoking. Results SARS-CoV-2-positive patients who received the influenza vaccine experienced decreased sepsis (p<0.01, Risk Ratio: 1.361-1.450, 95% CI:1.123-1.699, NNT:286) and stroke (p<0.02, RR: 1.451-1.580, 95% CI:1.075-2.034, NNT:625) across all time points. ICU admissions were lower in SARS-CoV-2-positive patients receiving the influenza vaccine at 30, 90, and 120 days (p<0.03, RR: 1.174-1.200, 95% CI:1.003-1.385, NNT:435), while approaching significance at 60 days (p = 0.0509, RR: 1.156, 95% CI:0.999-1.338). Patients who received the influenza vaccine experienced fewer DVTs 60-120 days after positive SARS-CoV-2 diagnosis (p<0.02, RR:1.41-1.530, 95% CI:1.082-2.076, NNT:1000) and experienced fewer emergency department (ED) visits 90-120 days post SARS-CoV-2-positive diagnosis (p<0.01, RR:1.204-1.580, 95% CI: 1.050-1.476, NNT:176). Conclusion Our analysis outlines the potential protective effect of influenza vaccination in SARS-CoV-2-positive patients against adverse outcomes within 30, 60, 90, and 120 days of a positive diagnosis. Significant findings favoring influenza vaccination mitigating the risks of sepsis, stroke, deep vein thrombosis (DVT), emergency department (ED) & Intensive Care Unit (ICU) admissions suggest a potential protective effect that could benefit populations without readily available access to SARS-CoV-2 vaccination. Thus further investigation with future prospective studies is warranted.	[Taghioff, Susan M.; Slavin, Benjamin R.; Singh, Devinder] Univ Miami, Miller Sch Med, Div Plast & Reconstruct Surg, Miami, FL 33136 USA; [Holton, Tripp] Anne Arundel Med Ctr, Annapolis, MD USA	University of Miami	Singh, D (corresponding author), Univ Miami, Miller Sch Med, Div Plast & Reconstruct Surg, Miami, FL 33136 USA.	DSingh.MD@med.miami.edu		Taghioff, Susan/0000-0002-7595-0591				[Anonymous], JHU EDU JHU EDU; [Anonymous], FLU SHOT MAY SHIELD; [Anonymous], HEALIO; Behrouzi B, 2020, J AM COLL CARDIOL, V76, P1777, DOI 10.1016/j.jacc.2020.08.028; Bermudez-Fajardo A, 2011, ATHEROSCLEROSIS, V217, P97, DOI 10.1016/j.atherosclerosis.2011.03.019; Cdc.gov, 2021, FLU SEASON; Conlon A, 2021, AM J INFECT CONTROL, V49, P694, DOI 10.1016/j.ajic.2021.02.012; Erismis B, 2021, CENT EUR J PUBL HEAL, V29, P14, DOI 10.21101/cejph.a6573; Ferdinand KC, 2020, J NATL MED ASSOC, V112, P681, DOI 10.1016/j.jnma.2020.11.001; Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1; Gupta T, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106717; Halpin SJ, 2021, J MED VIROL, V93, P1013, DOI 10.1002/jmv.26368; Hashim A, 2015, VACCINE, V33, P753, DOI 10.1016/j.vaccine.2014.12.033; Jewett A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01692; Jiang SB, 2020, TRENDS IMMUNOL, V41, P853, DOI 10.1016/j.it.2020.08.003; Jorge A, 2020, LANCET RHEUMATOL, V3, pe131, DOI 10.1016/S2665-9913(20)30422-7; Jost S, 2013, ANNU REV IMMUNOL, V31, P163, DOI 10.1146/annurev-immunol-032712-100001; Massoudi N, 2021, J CLIN IMMUNOL, V41, P324, DOI 10.1007/s10875-020-00925-0; Pawlowski C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83641-y; Pedote PD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040358; Perisetti A, 2020, SSRN, DOI [10.2139/ssrn.3697160, DOI 10.2139/SSRN.3697160]; Ragni P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040675; Shouman K, 2021, CLIN AUTON RES, V31, P385, DOI 10.1007/s10286-021-00803-8; Singh S, 2020, GASTROENTEROLOGY, V159, DOI 10.1053/j.gastro.2020.08.028; Taquet M, 2021, LANCET PSYCHIAT, V8, P130, DOI 10.1016/S2215-0366(20)30462-4; Tenny S., 2021, STATPEARLS; Topaloglu U, 2018, JCO CLIN CANCER INFO, V2, DOI 10.1200/CCI.17.00067; Tramer MR, 2005, WORLD J SURG, V29, P576, DOI 10.1007/s00268-005-7916-8; Umasabor-Bubu OQ, 2021, AM J INFECT CONTROL; Vandenberg O, 2021, NAT REV MICROBIOL, V19, P171, DOI 10.1038/s41579-020-00461-z; Veljkovic V, 2014, VACCINE, V32, P6569, DOI 10.1016/j.vaccine.2014.07.007; Wehenkel C, 2020, PEERJ, V8, DOI 10.7717/peerj.10112; Yang MJ, 2021, J AM BOARD FAM MED, V34, pS179, DOI 10.3122/jabfm.2021.S1.200528; Zanettini Claudio, 2020, medRxiv, DOI 10.1101/2020.06.24.20129817	34	16	18	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2021	16	8							e0255541	10.1371/journal.pone.0255541	http://dx.doi.org/10.1371/journal.pone.0255541			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6IR	34343191	gold, Green Published			2023-01-03	WOS:000685264200043
J	Kristiansen, M; Thomsen, MJ; Norgaard, J; Aaes, J; Knudsen, D; Voigt, M				Kristiansen, Mathias; Thomsen, Mikkel Jacobi; Norgaard, Jens; Aaes, Jon; Knudsen, Dennis; Voigt, Michael			Anodal transcranial direct current stimulation increases corticospinal excitability, while performance is unchanged	PLOS ONE			English	Article							EXERCISE PERFORMANCE; PERCEIVED EXERTION; MUSCLE FATIGUE; TASK FAILURE; TIME; CONTRACTION; PERCEPTION; EXHAUSTION; ENDURANCE; INTERVAL	Anodal transcranial direct current stimulation (a-tDCS) has been shown to improve bicycle time to fatigue (TTF) tasks at 70-80% of VO2max and downregulate rate of perceived exertion (RPE). This study aimed to investigate the effect of a-tDCS on a RPE-clamp test, a 250-kJ time trial (TT) and motor evoked potentials (MEP). Twenty participants volunteered for three trials; control, sham stimulation and a-tDCS. Transcranial magnetic stimulation was used to determine the corticospinal excitability for 12 participants pre and post sham stimulation and a-tDCS. The a-tDCS protocol consisted of 13 minutes of stimulation (2 mA) with the anode placed above the Cz. The RPE-clamp test consisted of 5 minutes ergometer bicycling at an RPE of 13 on the Borg scale, and the TT consisted of a 250 kJ (similar to 10 km) long bicycle ergometer test. During each test, power output, heart rate and oxygen consumption was measured, while RPE was evaluated. MEPs increased significantly by 36% (+/- 36%) post a-tDCS, with 8.8% (+/- 31%) post sham stimulation (p = 0.037). No significant changes were found for any parameter at the RPE-clamp or TT. The lack of improvement may be due to RPE being more controlled by afferent feedback during TT tests than during TTF tests. Based on the results of the present study, it is concluded that a-tDCS applied over Cz, does not enhance self-paced cycling performance.	[Kristiansen, Mathias; Thomsen, Mikkel Jacobi; Norgaard, Jens; Aaes, Jon; Knudsen, Dennis; Voigt, Michael] Aalborg Univ, Dept Hlth Sci & Technol, Sport Sci Performance & Technol, Aalborg, Denmark	Aalborg University	Kristiansen, M (corresponding author), Aalborg Univ, Dept Hlth Sci & Technol, Sport Sci Performance & Technol, Aalborg, Denmark.	mvk@hst.aau.dk		Thomsen, Mikkel Jacobi/0000-0003-3880-9932; Kristiansen, Mathias/0000-0003-2372-2543				Abbiss CR, 2008, SPORTS MED, V38, P239, DOI 10.2165/00007256-200838030-00004; Abbiss CR, 2015, SPORTS MED, V45, P1235, DOI 10.1007/s40279-015-0344-5; Abdelmoula A, 2016, NEUROSCIENCE, V322, P94, DOI 10.1016/j.neuroscience.2016.02.025; Amann M, 2008, MED SCI SPORT EXER, V40, P574, DOI [10.1249/mss.0b013e31815e728f, 10.1249/MSS.0b013e31815e728f]; Amann M, 2006, J PHYSIOL-LONDON, V575, P937, DOI 10.1113/jphysiol.2006.113936; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Angius L, 2018, BRAIN STIMUL, V11, P108, DOI 10.1016/j.brs.2017.09.017; Angius L, 2016, NEUROSCIENCE, V339, P363, DOI 10.1016/j.neuroscience.2016.10.028; Angius L., 2016, PHYSIOLOGY, V35, P29; Angius L, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00090; Barwood MJ, 2016, BRAIN STIMUL, V9, P842, DOI 10.1016/j.brs.2016.07.006; Bastani A, 2014, CLIN NEUROPHYSIOL, V125, P1809, DOI 10.1016/j.clinph.2014.01.010; Black MI, 2015, APPL PHYSIOL NUTR ME, V40, P662, DOI 10.1139/apnm-2014-0442; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Burgomaster KA, 2006, J APPL PHYSIOL, V100, P2041, DOI 10.1152/japplphysiol.01220.2005; Christie JM, 2011, NAT NEUROSCI, V14, P62, DOI 10.1038/nn.2718; Cogiamanian F, 2007, EUR J NEUROSCI, V26, P242, DOI 10.1111/j.1460-9568.2007.05633.x; Craig AD, 2003, CURR OPIN NEUROBIOL, V13, P500, DOI 10.1016/S0959-4388(03)00090-4; Das S, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00550; de Morree HM, 2012, PSYCHOPHYSIOLOGY, V49, P1242, DOI 10.1111/j.1469-8986.2012.01399.x; Fonteneau C, 2019, BRAIN STIMUL, V12, P668, DOI 10.1016/j.brs.2018.12.977; Kuo MF, 2006, NEUROREPORT, V17, P1703, DOI 10.1097/01.wnr.0000239955.68319.c2; MacIntosh BR, 2011, APPL PHYSIOL NUTR ME, V36, P1, DOI 10.1139/H10-073; Mauger AR, 2010, J APPL PHYSIOL, V108, P98, DOI 10.1152/japplphysiol.00761.2009; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Noakes TD, 2011, APPL PHYSIOL NUTR ME, V36, P23, DOI 10.1139/H10-082; Okano AH, 2015, BRIT J SPORT MED, V49, P1213, DOI 10.1136/bjsports-2012-091658; Oki K, 2016, J GERONTOL A-BIOL, V71, P1109, DOI 10.1093/gerona/glw011; Passfield L., 2014, J SCI CYCL, V3, P39, DOI [10.13140/2.1.2787.7763, DOI 10.13140/2.1.2787.7763]; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Sidhu SK, 2018, J PHYSIOL-LONDON, V596, P4789, DOI 10.1113/JP276460; Vitor-Costa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144916; Ward S, 2016, J ELECTROMYOGR KINES, V28, P46, DOI 10.1016/j.jelekin.2016.03.003; Williams PS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081418; WITHERS PC, 1977, J APPL PHYSIOL, V42, P120, DOI 10.1152/jappl.1977.42.1.120	36	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2021	16	7							e0254888	10.1371/journal.pone.0254888	http://dx.doi.org/10.1371/journal.pone.0254888			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2NF	34270614	Green Published, gold			2023-01-03	WOS:000678121400011
J	Williamson, EJ; McDonald, HI; Bhaskaran, K; Walker, AJ; Bacon, S; Davy, S; Schultze, A; Tomlinson, L; Bates, C; Ramsay, M; Curtis, HJ; Forbes, H; Wing, K; Minassian, C; Tazare, J; Morton, CE; Nightingale, E; Mehrkar, A; Evans, D; Inglesby, P; MacKenna, B; Cockburn, J; Rentsch, CT; Mathur, R; Wong, AYS; Eggo, RM; Hulme, W; Croker, R; Parry, J; Hester, F; Harper, S; Douglas, IJ; Evans, SJW; Smeeth, L; Goldacre, B; Kuper, H				Williamson, Elizabeth J.; McDonald, Helen, I; Bhaskaran, Krishnan; Walker, Alex J.; Bacon, Sebastian; Davy, Simon; Schultze, Anna; Tomlinson, Laurie; Bates, Chris; Ramsay, Mary; Curtis, Helen J.; Forbes, Harriet; Wing, Kevin; Minassian, Caroline; Tazare, John; Morton, Caroline E.; Nightingale, Emily; Mehrkar, Amir; Evans, Dave; Inglesby, Peter; MacKenna, Brian; Cockburn, Jonathan; Rentsch, Christopher; Mathur, Rohini; Wong, Angel Y. S.; Eggo, Rosalind M.; Hulme, William; Croker, Richard; Parry, John; Hester, Frank; Harper, Sam; Douglas, Ian J.; Evans, Stephen J. W.; Smeeth, Liam; Goldacre, Ben; Kuper, Hannah			Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To assess the association between learning disability and risk of hospital admission and death from covid-19 in England among adults and children. Population based cohort study on behalf of NHS England using the OpenSAFELY platform. SETTING Patient level data were obtained for more than 17 million people registered with a general practice in England that uses TPP software. Electronic health records were linked with death data from the Office for National Statistics and hospital admission data from NHS Secondary Uses Service. PARTICIPANTS Adults (aged 16-105 years) and children (<16 years) from two cohorts: wave 1 (registered with a TPP practice as of 1 March 2020 and followed until 31 August 2020); and wave 2 (registered 1 September 2020 and followed until 8 February 2021). The main exposure group consisted of people on a general practice learning disability register; a subgroup was defined as those having profound or severe learning disability. People with Down's syndrome and cerebral palsy were identified (whether or not they were on the learning disability register). MAIN OUTCOME MEASURE Covid-19 related hospital admission and covid-19 related death. Non-covid-19 deaths were also explored. RESULTS For wave 1, 14 312 023 adults aged >= 16 years were included, and 90 307 (0.63%) were on the learning disability register. Among adults on the register, 538 (0.6%) had a covid-19 related hospital admission; there were 222 (0.25%) covid-19 related deaths and 602 (0.7%) non-covid deaths. Among adults not on the register, 29 781 (0.2%) had a covid-19 related hospital admission; there were 13 737 (0.1%) covid-19 related deaths and 69 837 (0.5%) noncovid deaths. Wave 1 hazard ratios for adults on the learning disability register (adjusted for age, sex, ethnicity, and geographical location) were 5.3 (95% confidence interval 4.9 to 5.8) for covid-19 related hospital admission and 8.2 (7.2 to 9.4) for covid-19 related death. Wave 2 produced similar estimates. Associations were stronger among those classified as having severe to profound learning disability, and among those in residential care. For both waves, Down's syndrome and cerebral palsy were associated with increased hazards for both events; Down's syndrome to a greater extent. Hazard ratios for noncovid deaths followed similar patterns with weaker associations. Similar patterns of increased relative risk were seen for children, but covid-19 related deaths and hospital admissions were rare, reflecting low event rates among children. CONCLUSIONS People with learning disability have markedly increased risks of hospital admission and death from covid-19, over and above the risks observed for non-covid causes of death. Prompt access to covid-19 testing and healthcare is warranted for this vulnerable group, and prioritisation for covid-19 vaccination and other targeted preventive measures should be considered.	[Williamson, Elizabeth J.; McDonald, Helen, I; Bhaskaran, Krishnan; Schultze, Anna; Tomlinson, Laurie; Wing, Kevin; Minassian, Caroline; Tazare, John; Nightingale, Emily; Rentsch, Christopher; Mathur, Rohini; Wong, Angel Y. S.; Eggo, Rosalind M.; Douglas, Ian J.; Evans, Stephen J. W.; Smeeth, Liam; Kuper, Hannah] London Sch Hyg & Trop Med, London, England; [McDonald, Helen, I; Ramsay, Mary; Goldacre, Ben] Natl Inst Hlth Res NIHR, Hlth Protect Res Unit Vaccines & Immunisat, London, England; [Walker, Alex J.; Bacon, Sebastian; Davy, Simon; Curtis, Helen J.; Minassian, Caroline; Morton, Caroline E.; Mehrkar, Amir; Evans, Dave; Inglesby, Peter; MacKenna, Brian; Hulme, William; Croker, Richard] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, DataLab, Oxford, England; [Bates, Chris; Cockburn, Jonathan; Parry, John; Hester, Frank; Harper, Sam] TPP, TPP House, Leeds, W Yorkshire, England; [Ramsay, Mary] Publ Hlth England, London, England; [Forbes, Harriet] Univ Bristol, Bristol, Avon, England	University of London; London School of Hygiene & Tropical Medicine; University of Oxford; Public Health England; University of Bristol	Goldacre, B (corresponding author), Natl Inst Hlth Res NIHR, Hlth Protect Res Unit Vaccines & Immunisat, London, England.	ben.goldacre@phc.ox.ac.uk	Nightingale, Emily/ABA-6907-2021; Wing, Kevin/I-7807-2015; Smeeth, Liam/X-5862-2018	Nightingale, Emily/0000-0002-9265-1841; Evans, Stephen/0000-0002-1474-2596; Hulme, William/0000-0002-9162-4999; Tazare, John/0000-0002-7194-2615; Wing, Kevin/0000-0003-2335-9641; McDonald, Helen/0000-0003-0576-2015; Smeeth, Liam/0000-0002-9168-6022; Bhaskaran, Krishnan/0000-0001-5364-8757; Eggo, Rosalind M/0000-0002-0362-6717; Tomlinson, Laurie/0000-0001-8848-9493; Forbes, Harriet/0000-0001-6888-2212	Medical Research Council (MRC) [MR/V015737/1]; MRC [MR/S01442X/1]; National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation; PENDA grant from the Foreign, Commonwealth and Development Office; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; NIHR Applied Research Collaboration Oxford and Thames Valley; Mohn-Westlake Foundation; NHS England; Health Foundation	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation; PENDA grant from the Foreign, Commonwealth and Development Office; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR Applied Research Collaboration Oxford and Thames Valley; Mohn-Westlake Foundation; NHS England; Health Foundation	This work was supported by the Medical Research Council (MRC) grant MR/V015737/1. TPP provided technical expertise and infrastructure within their data centre pro bono in the context of a national emergency. EJW was supported by MRC project grant MR/ S01442X/1. HIM and MR are funded by the National Institute for Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, a partnership between Public Health England and the London School of Hygiene and Tropical Medicine. HK was supported by funding from the PENDA grant from the Foreign, Commonwealth and Development Office. BG's work on better use of data in healthcare more broadly is currently funded in part by National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, the Mohn-Westlake Foundation, NHS England, and the Health Foundation; all DataLab staff are supported by BG's grants on this work. The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, Public Health England or the Department of Health and Social Care. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.	[Anonymous], 2020, PRIOR GROUPS COR COV; [Anonymous], 2021, NOTIFICATION LEDER L; [Anonymous], 2021, IMMUNISATION INFECT; Bhaskaran K, 2018, LANCET DIABETES ENDO, V6, P944, DOI [10.1016/S2213-8587(18)30288-2, 10.1016/s2213-8587(18)30288-2]; Clift AK, 2021, ANN INTERN MED, V174, P572, DOI 10.7326/M20-4986; Coronavirus GOVUK, 2021, COVID 19 UK; Courtenay K, 2020, IRISH J PSYCHOL MED, V37, P231, DOI 10.1017/ipm.2020.45; Dard R, 2020, EUR J HUM GENET, V28, P1477, DOI 10.1038/s41431-020-0696-7; Dooling K, 2020, MMWR-MORBID MORTAL W, V69, P1857, DOI [10.15585/mmwr.mm6949e1, 10.15585/mmwr.mm695152e2]; Duarte-Salles Talita, 2020, medRxiv, DOI 10.1101/2020.10.29.20222083; Eales, 2020, HIGH PREVALENCE SARS, DOI [10.1101/2020.10.30.20223123, DOI 10.1101/2020.10.30.20223123]; Emerson E, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0296-x; Evans S., FACTORS ASS DEATHS D, DOI [10.1101/2021.01.15.21249756, DOI 10.1101/2021.01.15.21249756]; Gensous N, 2020, SEMIN IMMUNOPATHOL, V42, P635, DOI 10.1007/s00281-020-00804-1; Gotzinger F, 2020, LANCET CHILD ADOLESC, V4, P653, DOI 10.1016/S2352-4642(20)30177-2; Henderson A., 2021, COVID 19 INFECT OUTC, DOI [10.1101/2021.02.08.21250525, DOI 10.1101/2021.02.08.21250525]; Herrett EL, 2011, BRIT J GEN PRACT, V61, P438, DOI 10.3399/bjgp11X583092; Heslop P, 2014, LANCET, V383, P889, DOI 10.1016/S0140-6736(13)62026-7; Hughes RA, 2019, INT J EPIDEMIOL, V48, P1294, DOI 10.1093/ije/dyz032; Joy M, 2020, BRIT J GEN PRACT, V70, pE890, DOI 10.3399/bjgp20X713393; Kinnear D, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018292; Kontopantelis E, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020738; Landes SD, 2020, DISABIL HEALTH J, V13, DOI 10.1016/j.dhjo.2020.100969; Lorenz-Dant K, 2020, BRIEF OVERVIEW CURRE; McDonald HI, 2016, KIDNEY INT, V90, P943, DOI 10.1016/j.kint.2016.04.010; Mencap, HOUS PEOPL LEARN DIS; NHS Digital, 2020, SEC US SERV SUS; NHS Digital, 2018, DAT SEC PROT TOOLK N; NHS Digital, BETA DAT SEC STAND N; NHS Digital, 2019, ISB1523 NHS DIG; ONS, 2020, UPD EST COR COVID 19; Perera Bhathika, 2020, BJPsych Open, V6, pe123, DOI 10.1192/bjo.2020.102; Public Health England, 2016, PEOPLE LEARNING DISA; Public Health England, 2020, COVID 19 DEATHS PEOP; Public Health England, 2021, JCVI ADV INV PEOPL L; Schultze Anna, 2021, Wellcome Open Res, V6, P90, DOI 10.12688/wellcomeopenres.16737.1; Secretary of State for Health and Social Care-UK Government, 2020, COR COVID 19 NOT ORG; Swann OV, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3249; Tapper J, 2021, FURY DO NOT RESUSCIT; Turk MA, 2020, DISABIL HEALTH J, V13, DOI 10.1016/j.dhjo.2020.100942; Walker JL, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10427-2; Watkins A., 2020, COVID 19 RELATED DEA; Whyte MB, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002942; Williams N, 2021, EUR J PEDIATR, V180, P689, DOI 10.1007/s00431-020-03801-6; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4	45	33	33	2	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 15	2021	374								n1592	10.1136/bmj.n1592	http://dx.doi.org/10.1136/bmj.n1592			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM9QZ	34261639	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000675882500005
J	Justino, AB; Florentino, RM; Franca, A; Filho, ACML; Franco, RR; Saraiva, AL; Fonseca, MC; Leite, MF; Espindola, FS				Justino, Allisson B.; Florentino, Rodrigo M.; Franca, Andressa; Filho, Antonio C. M. L.; Franco, Rodrigo R.; Saraiva, Andre L.; Fonseca, Matheus C.; Leite, Maria F.; Salmen Espindola, Foued			Alkaloid and acetogenin-rich fraction from Annona crassiflora fruit peel inhibits proliferation and migration of human liver cancer HepG2 cells	PLOS ONE			English	Article							IN-VITRO; APORPHINE ALKALOIDS; NUCLEOPLASMIC CALCIUM; GROWTH; EPIDEMIOLOGY; STEPHALAGINE; ANTIOXIDANT; INDUCTION; APOPTOSIS; VINCULIN	Plant species from Annonaceae are commonly used in traditional medicine to treat various cancer types. This study aimed to investigate the antiproliferative potential of an alkaloid and acetogenin-rich fraction from the fruit peel of Annona crassiflora in HepG2 cells. A liquid-liquid fractionation was carried out on the ethanol extract of A. crassiflora fruit peel in order to obtain an alkaloid and acetogenin-rich fraction (AF-Ac). Cytotoxicity, proliferation and migration were evaluated in the HepG2 cells, as well as the proliferating cell nuclear antigen (PCNA), vinculin and epidermal growth factor receptor (EGFR) expression. In addition, intracellular Ca2+ was determined using Fluo4-AM and fluorescence microscopy. First, 9 aporphine alkaloids and 4 acetogenins that had not yet been identified in the fruit peel of A. crassiflora were found in AF-Ac. The treatment with 50 mu g/mL AF-Ac reduced HepG2 cell viability, proliferation and migration (p < 0.001), which is in accordance with the reduced expression of PCNA and EGFR levels (p < 0.05). Furthermore, AF-Ac increased intracellular Ca2+ in the HepG2 cells, mobilizing intracellular calcium stores, which might be involved in the anti-migration and anti-proliferation capacities of AF-Ac. Our results support the growth-inhibitory potential of AF-Ac on HepG2 cells and suggest that this effect is triggered, at least in part, by PCNA and EGFR modulation and mobilization of intracellular Ca2+. This study showed biological activities not yet described for A. crassiflora fruit peel, which provide new possibilities for further in vivo studies to assess the antitumoral potential of A. crassiflora, especially its fruit peel.	[Justino, Allisson B.; Franco, Rodrigo R.; Saraiva, Andre L.; Salmen Espindola, Foued] Univ Fed Uberlandia, Inst Biotechnol, Uberlandia, MG, Brazil; [Florentino, Rodrigo M.; Franca, Andressa; Filho, Antonio C. M. L.; Leite, Maria F.] Univ Fed Minas Gerais, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil; [Franca, Andressa] Univ Fed Minas Gerais, Dept Mol Med, Belo Horizonte, MG, Brazil; [Fonseca, Matheus C.] Brazilian Biosci Natl Lab LNBio, Brazilian Ctr Res Energy & Mat CNPEM, Campinas, Brazil	Universidade Federal de Uberlandia; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais	Espindola, FS (corresponding author), Univ Fed Uberlandia, Inst Biotechnol, Uberlandia, MG, Brazil.	foued@ufu.br	Fonseca, Matheus/GYU-2786-2022; Fonseca, Matheus C./O-9213-2019; Rodrigues Franco, Rodrigo/AHA-5182-2022; Justino, Allisson B/A-7042-2017	Fonseca, Matheus C./0000-0001-9048-9775; Rodrigues Franco, Rodrigo/0000-0002-9138-311X; Justino, Allisson B/0000-0003-3616-6611; Espindola, Foued/0000-0001-7565-1164	Coordination for the Improvement of Higher Education Personnel (CAPES); CAPES; National Council for Scientific and Technological Development (CNPq); CNPq/FAPEMIG	Coordination for the Improvement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CNPq/FAPEMIG(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG))	A.B.J., R.M.F., A.F., A.C.M.L.F. and R.R.F. received graduate fellowships from Coordination for the Improvement of Higher Education Personnel (CAPES, https://www.gov.br/capes/ptbr), A.L.S. received post-doctoral fellowships from CAPES and M.F.L. is a grant recipient of National Council for Scientific and Technological Development (CNPq, https://www.gov.br/cnpq/ptbr). FSE received financial support of CNPq/FAPEMIG from resources of the INCT-TeraNano - UFU (FAPEMIG, https://fapemig.br/pt/).	Amaya MJ, 2014, HEPATOLOGY, V59, P274, DOI 10.1002/hep.26609; Andrade V, 2011, J HEPATOL, V55, P626, DOI 10.1016/j.jhep.2010.12.022; Avula B, 2018, J PHARMACEUT BIOMED, V159, P548, DOI 10.1016/j.jpba.2018.07.030; Azziz S.S.S.A., 2018, J GLOB PHARM TECHNOL; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burczynski ME, 2006, PHARMACOGENOMICS, V7, P187, DOI 10.2217/14622416.7.2.187; Chen Y, 2013, FOOD CHEM TOXICOL, V58, P394, DOI 10.1016/j.fct.2013.05.028; Costa EV, 2015, QUIM NOVA, V38, P769, DOI 10.5935/0100-4042.20150069; da Silva JJ, 2014, REV INST MED TROP SP, V56, P333, DOI 10.1590/S0036-46652014000400011; de Alvarenga EC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165371; Campos ACD, 2011, BIOCHEM BIOPH RES CO, V412, P341, DOI 10.1016/j.bbrc.2011.07.100; de Lima BR, 2020, J BRAZIL CHEM SOC, V31, P79, DOI 10.21577/0103-5053.20190125; de Mesquita ML, 2009, J ETHNOPHARMACOL, V123, P439, DOI 10.1016/j.jep.2009.03.018; de Pedro N, 2013, J BIOENERG BIOMEMBR, V45, P153, DOI 10.1007/s10863-012-9489-1; El-Garawani IM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70945-8; Fonseca MD, 2018, AM J PHYSIOL-GASTR L, V315, pG80, DOI 10.1152/ajpgi.00008.2018; Formagio ASN, 2015, BRAZ J MED BIOL RES, V48, P308, DOI 10.1590/1414-431X20144127; Galarce-Bustos O, 2019, PHYTOCHEM ANALYSIS, V30, P679, DOI 10.1002/pca.2843; Gomaa AI, 2008, WORLD J GASTROENTERO, V14, P4300, DOI 10.3748/wjg.14.4300; Graham JG, 2000, J ETHNOPHARMACOL, V73, P347, DOI 10.1016/S0378-8741(00)00341-X; Guerra MT, 2019, GUT, V68, P1676, DOI 10.1136/gutjnl-2018-317811; Guimaraes E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175041; Hsieh TJ, 2005, FOOD CHEM TOXICOL, V43, P1117, DOI 10.1016/j.fct.2005.03.002; Ivanova D, 2016, CHINESE J CANCER RES, V28, P383, DOI 10.21147/j.issn.1000-9604.2016.04.01; IVORRA MD, 1993, J PHARM PHARMACOL, V45, P439, DOI 10.1111/j.2042-7158.1993.tb05572.x; Jacobo-Herrera N, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00783; Jantova Sona, 2016, Interdiscip Toxicol, V9, P106, DOI 10.1515/intox-2016-0014; Juang SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep39251; Justino AB, 2020, BIOORG CHEM, V96, DOI 10.1016/j.bioorg.2019.103562; Justino AB, 2018, BIOMED PHARMACOTHER, V100, P83, DOI 10.1016/j.biopha.2018.01.172; KONDO Y, 1990, J PHARMACOBIO-DYNAM, V13, P426, DOI 10.1248/bpb1978.13.426; Konkimalla VB, 2010, BIOCHEM PHARMACOL, V79, P1092, DOI 10.1016/j.bcp.2009.11.025; Li HT, 2013, MOLECULES, V18, P8257, DOI 10.3390/molecules18078257; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liaw CC, 2011, ANGEW CHEM INT EDIT, V50, P7885, DOI 10.1002/anie.201100717; Liew CC, 2006, J LAB CLIN MED, V147, P126, DOI 10.1016/j.lab.2005.10.005; Liu CM, 2014, MOLECULES, V19, P17829, DOI 10.3390/molecules191117829; Liu JJ, 2017, MOL MED REP, V16, P2595, DOI 10.3892/mmr.2017.6879; Liu L, 2019, BIOL RES, V52, DOI 10.1186/s40659-019-0243-6; Liu YJ, 2013, CURR TOP MED CHEM, V13, P2116; Long L, 2005, YAKUGAKU ZASSHI, V125, P665, DOI 10.1248/yakushi.125.665; Lu P, 2012, MOL MED, V18, P1136, DOI 10.2119/molmed.2012.00055; Lu ZY, 2017, MOL MED REP, V15, P2415, DOI 10.3892/mmr.2017.6331; Menezes LRA, 2016, MOLECULES, V21, DOI 10.3390/molecules21070890; Moghadamtousi SZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122288; Mondal A, 2019, EUR J PHARMACOL, V858, DOI 10.1016/j.ejphar.2019.172472; Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055; Pereira MN, 2017, IND CROP PROD, V97, P324, DOI 10.1016/j.indcrop.2016.12.038; Pereira MN., 2017, IND CROP PROD, DOI [10.1016/j.indcrop.2017.12.017, DOI 10.1016/J.INDCROP.2017.12.017]; Petrick JL, 2019, CURR EPIDEMIOL REP, V6, P104, DOI 10.1007/s40471-019-00188-3; Qazi AK, 2018, CARCINOGENESIS, V39, P522, DOI 10.1093/carcin/bgy024; Resende RR, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-14; Rodrigues MA, 2007, J BIOL CHEM, V282, P17061, DOI 10.1074/jbc.M700490200; Rodriguez-Arce E, 2020, MOLECULES, V25, DOI 10.3390/molecules25010108; Santos MDC, 2018, QUIM NOVA, V41, P884, DOI 10.21577/0100-4042.20170258; Pimenta LPS, 2014, NAT PROD RES, V28, P1254, DOI 10.1080/14786419.2014.900496; Senousy HH, 2020, ENVIRON SCI POLLUT R, V27, P18463, DOI 10.1007/s11356-020-08332-z; Sigismund S, 2018, MOL ONCOL, V12, P3, DOI 10.1002/1878-0261.12155; Silva F., 2012, QUIM NOVA QUIM NOVA, V35, pS1; Silva VAO, 2019, INVEST NEW DRUG, V37, P602, DOI 10.1007/s10637-018-0657-y; Small JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/nrm971; Sotnikova R, 1997, METHOD FIND EXP CLIN, V19, P589; Strzalka W, 2011, ANN BOT-LONDON, V107, P1127, DOI 10.1093/aob/mcq243; Thievessen I, 2015, FASEB J, V29, P4555, DOI 10.1096/fj.14-268235; Vilar JB, 2008, BRAZ J BIOL, V68, P141, DOI 10.1590/S1519-69842008000100020; Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI 10.1016/j.phymed.2008.12.018; Wang XJ, 2019, BMC PHARMACOL TOXICO, V20, DOI 10.1186/s40360-018-0284-4; Xu WM, 1998, J CELL SCI, V111, P1535; Yan Qian, 2017, Zhongguo Zhong Yao Za Zhi, V42, P3152, DOI 10.19540/j.cnki.cjcmm.20170512.008; Yiallouris A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0772-x	71	3	3	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2021	16	7							e0250394	10.1371/journal.pone.0250394	http://dx.doi.org/10.1371/journal.pone.0250394			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK6VW	34237060	Green Submitted, Green Published, gold			2023-01-03	WOS:000674294700027
J	Kastritis, E; Palladini, G; Minnema, MC; Wechalekar, AD; Jaccard, A; Lee, HC; Sanchorawala, V; Gibbs, S; Mollee, P; Venner, CP; Lu, J; Schonland, S; Gatt, ME; Suzuki, K; Kim, K; Cibeira, MT; Beksac, M; Libby, E; Valent, J; Hungria, V; Wong, SW; Rosenzweig, M; Bumma, N; Huart, A; Dimopoulos, MA; Bhutani, D; Waxman, AJ; Goodman, SA; Zonder, JA; Lam, S; Song, K; Hansen, T; Manier, S; Roeloffzen, W; Jamroziak, K; Kwok, F; Shimazaki, C; Kim, JS; Crusoe, E; Ahmadi, T; Tran, NP; Qin, X; Vasey, SY; Tromp, B; Schecter, JM; Weiss, BM; Zhuang, SH; Vermeulen, J; Merlini, G; Comenzo, RL				Kastritis, E.; Palladini, G.; Minnema, M. C.; Wechalekar, A. D.; Jaccard, A.; Lee, H. C.; Sanchorawala, V; Gibbs, S.; Mollee, P.; Venner, C. P.; Lu, J.; Schonland, S.; Gatt, M. E.; Suzuki, K.; Kim, K.; Cibeira, M. T.; Beksac, M.; Libby, E.; Valent, J.; Hungria, V; Wong, S. W.; Rosenzweig, M.; Bumma, N.; Huart, A.; Dimopoulos, M. A.; Bhutani, D.; Waxman, A. J.; Goodman, S. A.; Zonder, J. A.; Lam, S.; Song, K.; Hansen, T.; Manier, S.; Roeloffzen, W.; Jamroziak, K.; Kwok, F.; Shimazaki, C.; Kim, J-S; Crusoe, E.; Ahmadi, T.; Tran, N. P.; Qin, X.; Vasey, S. Y.; Tromp, B.; Schecter, J. M.; Weiss, B. M.; Zhuang, S. H.; Vermeulen, J.; Merlini, G.; Comenzo, R. L.		ANDROMEDA Trial Investigators	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIBODY DARATUMUMAB; AL AMYLOIDOSIS; DIAGNOSIS; CRITERIA	Background Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease. Methods We randomly assigned patients with newly diagnosed AL amyloidosis to receive six cycles of bortezomib, cyclophosphamide, and dexamethasone either alone (control group) or with subcutaneous daratumumab followed by single-agent daratumumab every 4 weeks for up to 24 cycles (daratumumab group). The primary end point was a hematologic complete response. Results A total of 388 patients underwent randomization. The median follow-up was 11.4 months. The percentage of patients who had a hematologic complete response was significantly higher in the daratumumab group than in the control group (53.3% vs. 18.1%) (relative risk ratio, 2.9; 95% confidence interval [CI], 2.1 to 4.1; P<0.001). Survival free from major organ deterioration or hematologic progression favored the daratumumab group (hazard ratio for major organ deterioration, hematologic progression, or death, 0.58; 95% CI, 0.36 to 0.93; P=0.02). At 6 months, more cardiac and renal responses occurred in the daratumumab group than in the control group (41.5% vs. 22.2% and 53.0% vs. 23.9%, respectively). The four most common grade 3 or 4 adverse events were lymphopenia (13.0% in the daratumumab group and 10.1% in the control group), pneumonia (7.8% and 4.3%, respectively), cardiac failure (6.2% and 4.8%), and diarrhea (5.7% and 3.7%). Systemic administration-related reactions to daratumumab occurred in 7.3% of the patients. A total of 56 patients died (27 in the daratumumab group and 29 in the control group), most due to amyloidosis-related cardiomyopathy. Conclusions Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression. (Funded by Janssen Research and Development; ANDROMEDA ClinicalTrials.gov number, .) Daratumumab in Light-Chain Amyloidosis In a randomized trial of bortezomib, cyclophosphamide, and dexamethasone as compared with the same therapy plus daratumumab, patients with light-chain amyloidosis who received daratumumab had a higher frequency of hematologic complete response than those who did not (53.3% vs. 18.1%). Deaths were most commonly due to cardiac failure.	[Kastritis, E.; Dimopoulos, M. A.] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece; [Palladini, G.; Merlini, G.] Fdn IRCCS Policlin San Mateo, Amyloidosis Res & Treatment Ctr, Pavia, Italy; [Palladini, G.; Merlini, G.] Univ Pavia, Dept Mol Med, Viale Golgi 19, I-27100 Pavia, Italy; [Minnema, M. C.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands; [Roeloffzen, W.] Univ Groningen, Univ Med Ctr Groningen, Amyloidosis Ctr Expertise, Groningen, Netherlands; [Tromp, B.; Vermeulen, J.] Janssen Res & Dev, Leiden, Netherlands; [Wechalekar, A. D.] UCL, London, England; [Jaccard, A.] Ctr Hosp Univ CHU, Limoges, France; [Jaccard, A.] Reference Ctr AL Amyloidosis, Limoges, France; [Huart, A.] CHU Toulouse, Ctr Reference Malad Renales Rares, Dept Nephrol & Transplantat Organes, Toulouse, France; [Manier, S.] Univ Lille, Dept Hematol, CHU Lille, Lille, France; [Lee, H. C.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Div Canc Med, Houston, TX 77030 USA; [Sanchorawala, V] Boston Univ, Sch Med, Amyloidosis Ctr, Boston, MA 02118 USA; [Sanchorawala, V] Boston Med Ctr, Boston, MA USA; [Comenzo, R. L.] Tufts Med Ctr, John C Davis Myeloma & Amyloid Program, Div Hematol Oncol, Boston, MA 02111 USA; [Gibbs, S.] Monash Univ, Dept Haematol, Victorian & Tasmanian Amyloidosis Serv, Eastern Hlth Clin Sch, Melbourne, Vic, Australia; [Mollee, P.] Princess Alexandra Hosp, Dept Haematol, Brisbane, Qld, Australia; [Mollee, P.] Univ Queensland, Med Sch, Brisbane, Qld, Australia; [Kwok, F.] Westmead Hosp, Dept Clin Haematol, Westmead, NSW, Australia; [Venner, C. P.] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada; [Lam, S.] Western Univ, London Hlth Sci Ctr, Div Hematol, London Reg Canc Program, London, ON, Canada; [Song, K.] Univ British Columbia, Vancouver Gen Hosp, Div Hematol, BC Canc, Vancouver, BC, Canada; [Lu, J.] Peking Univ, Peking Univ Peoples Hosp, Inst Hematol, Natl Clin Res Ctr Hematol Dis,Collaborat Innovat, Beijing, Peoples R China; [Schonland, S.] Heidelberg Univ Hosp, Amyloidosis Ctr, Dept Hematol Oncol Rheumatol 5, Heidelberg, Germany; [Hansen, T.] Hamatol Onkol Praxis Hamburg Altona, Hamburg, Germany; [Gatt, M. E.] Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Dept Hematol, Jerusalem, Israel; [Suzuki, K.] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan; [Shimazaki, C.] Japan Community Hlth Care Org Kyoto Kuramaguchi M, Dept Hematol, Kyoto, Japan; [Kim, K.] Stmgkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea; [Kim, J-S] Yonsei Univ, Severance Hosp, Dept Internal Med, Coll Med, Seoul, South Korea; [Cibeira, M. T.] Hosp Clin Barcelona, August Pi i Sunyer Biomed Res Inst, Amyloidosis & Myeloma Unit, Barcelona, Spain; [Beksac, M.] Ankara Univ, Dept Hematol, Ankara, Turkey; [Libby, E.] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA; [Valent, J.] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Ctr, Cleveland, OH 44106 USA; [Bumma, N.] Ohio State Univ, Div Hematol, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Hungria, V] Clin Sao Germano, Sao Paulo, Brazil; [Crusoe, E.] Rede DOr Oncol, Clin CEHON, Salvador, BA, Brazil; [Wong, S. W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Rosenzweig, M.] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Duarte, CA USA; [Tran, N. P.] Janssen Res & Dev, Los Angeles, CA USA; [Bhutani, D.] Columbia Univ, Dept Internal Med, Div Hematol Oncol, Med Ctr, New York, NY USA; [Waxman, A. J.] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Penn Amyloidosis Program, Philadelphia, PA 19104 USA; [Qin, X.; Vasey, S. Y.; Weiss, B. M.] Janssen Res & Dev, Spring House, PA USA; [Goodman, S. A.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Goodman, S. A.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA; [Zonder, J. A.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA; [Jamroziak, K.] Inst Hematol & Transfus Med, Dept Hematol, Warsaw, Poland; [Ahmadi, T.] Genmab US, Princeton, NJ USA; [Schecter, J. M.; Zhuang, S. H.] Janssen Res & Dev, Raritan, NJ USA	Athens Medical School; National & Kapodistrian University of Athens; IRCCS Fondazione San Matteo; University of Pavia; Utrecht University; Utrecht University Medical Center; University of Groningen; Johnson & Johnson; Janssen Pharmaceuticals; University of London; University College London; CHU de Toulouse; Universite de Lille - ISITE; CHU Lille; Universite de Lille; University of Texas System; UTMD Anderson Cancer Center; Boston University; Boston Medical Center; Tufts Medical Center; Monash University; University of Queensland; University of Sydney; University of Alberta; London Health Sciences Centre; Western University (University of Western Ontario); University of British Columbia; Peking University; Ruprecht Karls University Heidelberg; Hebrew University of Jerusalem; Hadassah University Medical Center; Japanese Red Cross Medical Center; University of Tokyo; Sungkyunkwan University (SKKU); Samsung Medical Center; Yonsei University; Yonsei University Health System; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Ankara University; University of Washington; University of Washington Seattle; Cleveland Clinic Foundation; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of California System; University of California San Francisco; City of Hope; Johnson & Johnson; Janssen Pharmaceuticals; Columbia University; University of Pennsylvania; Pennsylvania Medicine; Johnson & Johnson; Janssen Pharmaceuticals; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Barbara Ann Karmanos Cancer Institute; Wayne State University; Johnson & Johnson; Janssen Pharmaceuticals	Merlini, G (corresponding author), Univ Pavia, Dept Mol Med, Viale Golgi 19, I-27100 Pavia, Italy.; Merlini, G (corresponding author), Fdn IRCCS Policlin San Matteo, Viale Golgi 19, I-27100 Pavia, Italy.	gmerlini@unipv.it	Hernandez-Rivas, Jose-Angel/ADF-6441-2022; Palladini, Giovanni/G-1763-2010; Lam, Selay/GNM-6409-2022; Merlini, Giampaolo/A-3817-2008; martinez, joaquin/AAN-6939-2020	Hernandez-Rivas, Jose-Angel/0000-0003-4550-757X; Palladini, Giovanni/0000-0001-5994-5138; Merlini, Giampaolo/0000-0001-7680-3254; martinez, joaquin/0000-0001-7908-0063; CAVO, MICHELE/0000-0003-4514-3227; KIM, JIN SEOK/0000-0001-8986-8436; MOULIN, Bruno/0000-0001-6772-7165; Gonzalez, Marta Sonia/0000-0001-5494-9009; nahi, hareth/0000-0003-4711-5094; Mohty, Mohamad/0000-0002-7264-808X; Salomo, Morten/0000-0002-1660-1607; moreau, philippe/0000-0003-1780-8746				Abeykoon JP, 2019, LEUKEMIA, V33, P531, DOI 10.1038/s41375-018-0262-2; Adams HC, 2019, CYTOM PART A, V95A, P279, DOI 10.1002/cyto.a.23693; [Anonymous], 2020, DARZALEX DARATUMUMAB; Casneuf T, 2021, LEUKEMIA, V35, P573, DOI 10.1038/s41375-020-0855-4; de Weers M, 2011, J IMMUNOL, V186, P1840, DOI 10.4049/jimmunol.1003032; Kastritis E, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01285; Kaufman GP, 2017, BLOOD, V130, P900, DOI 10.1182/blood-2017-01-763599; Kaufman GP, 2015, AM J HEMATOL, V90, P181, DOI 10.1002/ajh.23898; Khouri J, 2019, BRIT J HAEMATOL, V185, P342, DOI 10.1111/bjh.15455; Kimmich CR, 2020, BLOOD, V135, P1517, DOI 10.1182/blood.2019003633; Krejcik J, 2016, BLOOD, V128, P384, DOI 10.1182/blood-2015-12-687749; Manwani R, 2019, BLOOD, V134, P2271, DOI 10.1182/blood.2019000834; Mateos MV, 2020, LANCET HAEMATOL, V7, pE370, DOI 10.1016/S2352-3026(20)30070-3; Merlini G, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0034-3; Milani P, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-00355-6; Milani P, 2020, AM J HEMATOL, V95, P900, DOI 10.1002/ajh.25828; Muchtar E, 2020, AM J HEMATOL, V95, P1280, DOI 10.1002/ajh.25940; Muchtar E, 2019, LEUKEMIA, V33, P527, DOI 10.1038/s41375-018-0258-y; Muchtar E, 2018, LEUKEMIA, V32, P2240, DOI 10.1038/s41375-018-0060-x; Muchtar E, 2017, BLOOD, V129, P2111, DOI 10.1182/blood-2016-11-751628; Overdijk MB, 2016, J IMMUNOL, V197, P807, DOI 10.4049/jimmunol.1501351; Overdijk MB, 2015, MABS-AUSTIN, V7, P311, DOI 10.1080/19420862.2015.1007813; Palladini G, 2021, AMYLOID, V28, P1, DOI 10.1080/13506129.2020.1868810; Palladini G, 2020, BLOOD, V136, P71, DOI 10.1182/blood.2019004460; Palladini G, 2016, BLOOD, V128, P159, DOI 10.1182/blood-2016-01-629790; Palladini G, 2015, BLOOD, V126, P612, DOI 10.1182/blood-2015-01-620302; Palladini G, 2014, BLOOD, V124, P2325, DOI 10.1182/blood-2014-04-570010; Palladini G, 2012, J CLIN ONCOL, V30, P4541, DOI 10.1200/JCO.2011.37.7614; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Roussel M, 2020, BLOOD, V135, P1531, DOI 10.1182/blood.2019004369; Sanchorawala V, 2020, BLOOD, V135, P1541, DOI 10.1182/blood.2019004436; Sarosiek S, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-00354-7; Sidana S, 2020, LEUKEMIA, V34, P1472, DOI 10.1038/s41375-019-0664-9; Tang DI, 1999, BIOMETRICS, V55, P1188, DOI 10.1111/j.0006-341X.1999.01188.x; van Bueren JL, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.3474.3474; Weiss BM, 2014, J CLIN ONCOL, V32, P2699, DOI 10.1200/JCO.2013.50.0892	36	85	85	10	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2021	385	1					46	58		10.1056/NEJMoa2028631	http://dx.doi.org/10.1056/NEJMoa2028631			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU5EV	34192431	Bronze, Green Published			2023-01-03	WOS:000716568900012
J	Attanasio, LB; Ranchoff, BL; Geissler, KH				Attanasio, Laura B.; Ranchoff, Brittany L.; Geissler, Kimberley H.			Perceived discrimination during the childbirth hospitalization and postpartum visit attendance and content: Evidence from the Listening to Mothers in California survey	PLOS ONE			English	Article							PRENATAL-CARE; HEALTH-CARE; ADHERENCE	Objective Postpartum visits are an important opportunity to address ongoing maternal health. Experiences of discrimination in healthcare can impact healthcare use, including postpartum visits. However, it is unknown whether discrimination is associated with postpartum visit content. This study aimed to examine the relationship between perceived discrimination during the childbirth hospitalization and postpartum visit attendance and content. Research design Data were from Listening to Mothers in California, a population-based survey of people with a singleton hospital birth in California in 2016. Adjusted logistic regression models estimated the association between perceived discrimination during the childbirth hospitalization and 1) postpartum visit attendance, and 2) topics addressed at the postpartum visit (birth control, depression and breastfeeding) for those who attended. Results 90.6% of women attended a postpartum visit, and 8.6% reported discrimination during the childbirth hospitalization. In adjusted models, any discrimination and insurance-based discrimination were associated with 7 and 10 percentage point (pp) lower predicted probabilities of attending a postpartum visit, respectively. There was a 7pp lower predicted probability of discussing birth control for women who had experienced discrimination (81% vs. 88%), a 15pp lower predicted probability of being asked about depression (64% vs. 79%), and a 9 pp lower predicted probability of being asked about breastfeeding (57% vs. 66%). Conclusions Amid heightened attention to the importance of postpartum care, there is a need to better understand determinants of postpartum care quality. Our findings highlight the potential consequences of healthcare discrimination in the perinatal period, including lower quality of postpartum care.	[Attanasio, Laura B.; Ranchoff, Brittany L.; Geissler, Kimberley H.] Univ Massachusetts, Amherst Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Attanasio, LB (corresponding author), Univ Massachusetts, Amherst Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA.	lattanasio@mass.edu			National Heart Lung and Blood Institute [R56 HL151636-01]	National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by grant R56 HL151636-01 from the National Heart Lung and Blood Institute (https://www.nhlbi.nih.gov/), awarded to LBA and KHG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander GR, 2001, PUBLIC HEALTH REP, V116, P306; [Anonymous], 2016, Obstet Gynecol, V127, pe187, DOI 10.1097/AOG.0000000000001487; [Anonymous], 2018, OBSTET GYNECOL, V131, DOI [10.1097/AOG.0000000000002633 29683911, DOI 10.1097/AOG.000000000000263329683911]; [Anonymous], 2018, LISTENING MOTHERS CA; [Anonymous], 2020, PUBLIC USE DATA FILE; Atrash H, 2008, AM J OBSTET GYNECOL, V199, pS259, DOI 10.1016/j.ajog.2008.08.059; Attanasio L, 2017, MED CARE, V55, P830, DOI 10.1097/MLR.0000000000000773; Ben J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189900; Benjamins MR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215976; Bleich SN, 2019, HEALTH SERV RES, V54, P1399, DOI 10.1111/1475-6773.13220; Bryant AS, 2006, MATERN CHILD HLTH J, V10, P511, DOI 10.1007/s10995-006-0128-5; Burgess DJ, 2008, J HEALTH CARE POOR U, V19, P894, DOI 10.1353/hpu.0.0063; Casagrande SS, 2007, J GEN INTERN MED, V22, P389, DOI 10.1007/s11606-006-0057-4; Coley SL, 2018, WOMEN HEALTH ISS, V28, P158, DOI 10.1016/j.whi.2017.10.014; Danilack VA, 2019, MATERN CHILD HLTH J, V23, P903, DOI 10.1007/s10995-018-02716-x; de Bocanegra HT, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.02.040; De PK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239482; Declercq ER., 2013, LISTENING MOTHERS; Declercq E, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03137-x; Declercq E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235262; Declercq ER, 2014, J PERINAT EDUC, V23, P17, DOI 10.1891/1058-1243.23.1.17; Declercq ER, 2020, J MIDWIFERY WOM HEAL, V65, P45, DOI 10.1111/jmwh.13027; DiBari JN, 2014, J PREGNANCY, V2014, DOI 10.1155/2014/530769; Dyer J, 2018, MATERN CHILD HLTH J, V22, P679, DOI 10.1007/s10995-018-2436-y; Findling MG, 2019, HEALTH SERV RES, V54, P1409, DOI 10.1111/1475-6773.13216; Geissler K, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25095; Han XX, 2015, AM J PUBLIC HEALTH, V105, pS517, DOI 10.2105/AJPH.2015.302668; Hausmann LRM, 2011, MED CARE, V49, P626, DOI 10.1097/MLR.0b013e318215d93c; Haywood C, 2014, J GEN INTERN MED, V29, P1657, DOI 10.1007/s11606-014-2986-7; Henderson V, 2016, MATERN CHILD HLTH J, V20, pS132, DOI 10.1007/s10995-016-2044-7; Krishnamurti T, 2020, BMC HEALTH SERV RES, V2, P1; MacDonald S., 2018, MED CARE, V55, P1, DOI [10.1097/MLR.0000000000000746.Associations, DOI 10.1097/MLR.0000000000000746.ASSOCIATIONS]; Martin Joyce A, 2018, Natl Vital Stat Rep, V67, P1; Masho SW, 2018, J WOMENS HEALTH, V27, P836, DOI 10.1089/jwh.2016.6137; Mays VM, 2016, MED CARE, V00, P1; McMurtry CL, 2019, HEALTH SERV RES, V54, P1419, DOI 10.1111/1475-6773.13225; Morgan I, 2018, MATERN CHILD HLTH J, V22, P589, DOI 10.1007/s10995-018-2428-y; Noonan K, 2013, MATERN CHILD HLTH J, V17, P189, DOI 10.1007/s10995-012-0966-2; Sakala C, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03095-4; Shulman HB, 2018, AM J PUBLIC HEALTH, V108, P1305, DOI 10.2105/AJPH.2018.304563; Siddique J, 2012, MATERN CHILD HLTH J, V16, P51, DOI 10.1007/s10995-010-0723-3; Smedley BD, 2003, UNEQUAL TREATMENT CO, DOI [10.17226/12875, DOI 10.17226/12875]; Sword W, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-29; Wilcox A, 2016, MATERN CHILD HLTH J, V20, pS22, DOI 10.1007/s10995-016-2184-9	44	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2021	16	6							e0253055	10.1371/journal.pone.0253055	http://dx.doi.org/10.1371/journal.pone.0253055			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BO	34161359	Green Published, gold			2023-01-03	WOS:000671691900037
J	Chong, KM; Chen, JW; Lien, WC; Yang, MF; Wang, HC; Liu, SSH; Chen, YP; Chi, CY; Wu, MCH; Wu, CY; Liao, ECW; Huang, EPC; He, HC; Yang, HW; Huang, CH; Ko, PCI				Chong, Kah-Meng; Chen, Jiun-Wei; Lien, Wan-Ching; Yang, Mei-Fen; Wang, Hui-Chih; Liu, Sot Shih-Hung; Chen, Yen-Pin; Chi, Chien-Yu; Wu, Marvin Chih-Hsien; Wu, Cheng-Yi; Liao, Edward Che-Wei; Huang, Edward Pei-Chuan; He, Hsien-Chin; Yang, Hsiang-Wen; Huang, Chien-Hua; Ko, Patrick Chow-In			Attitude and behavior toward bystander cardiopulmonary resuscitation during COVID-19 outbreak	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; WILLINGNESS; CPR; KNOWLEDGE; OUTCOMES; RISK	Background Outbreaks of emerging infectious diseases, such as COVID-19, have negative impacts on bystander cardiopulmonary resuscitation (BCPR) for fear of transmission while breaking social distancing rules. The latest guidelines recommend hands-only cardiopulmonary resuscitation (CPR) and facemask use. However, public willingness in this setup remains unknown. Methods A cross-sectional, unrestricted volunteer Internet survey was conducted to assess individuals' attitudes and behaviors toward performing BCPR, pre-existing CPR training, occupational identity, age group, and gender. The raking method for weights and a regression analysis for the predictors of willingness were performed. Results Among 1,347 eligible respondents, 822 (61%) had negative attitudes toward performing BCPR. Healthcare providers (HCPs) and those with pre-existing CPR training had fewer negative attitudes (p < 0.001); HCPs and those with pre-existing CPR training and unchanged attitude showed more positive behaviors toward BCPR (p < 0.001). Further, 9.7% of the respondents would absolutely refuse to perform BCPR. In contrast, 16.9% would perform BCPR directly despite the outbreak. Approximately 9.9% would perform it if they were instructed, 23.5%, if they wore facemasks, and 40.1%, if they were to perform hands-only CPR. Interestingly, among the 822 respondents with negative attitudes, over 85% still tended to perform BCPR in the abovementioned situations. The weighted analysis showed similar results. The adjusted predictors for lower negative attitudes toward BCPR were younger age, being a man, and being an HCP; those for more positive behaviors were younger age and being an HCP. Conclusions Outbreaks of emerging infectious diseases, such as COVID-19, have negative impacts on attitudes and behaviors toward BCPR. Younger individuals, men, HCPs, and those with pre-existing CPR training tended to show fewer negative attitudes and behaviors. Meanwhile, most individuals with negative attitudes still expressed positive behaviors under safer measures such as facemask protection, hands-only CPR, and available dispatch instructions.	[Chong, Kah-Meng; Lien, Wan-Ching; Yang, Mei-Fen; Wang, Hui-Chih; Liu, Sot Shih-Hung; Chen, Yen-Pin; Wu, Cheng-Yi; Liao, Edward Che-Wei; Huang, Edward Pei-Chuan; Huang, Chien-Hua; Ko, Patrick Chow-In] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Emergency Med, Coll Med, Taipei, Taiwan; [Chen, Jiun-Wei; Liu, Sot Shih-Hung; Wu, Marvin Chih-Hsien; Wu, Cheng-Yi; Huang, Edward Pei-Chuan] Natl Taiwan Univ Hosp, Dept Emergency Med, Hsin Chu Branch, Hsinchu, Taiwan; [Chi, Chien-Yu] Natl Taiwan Univ Hosp, Dept Emergency Med, Yunlin Branch, Huwei Township, Yunlin, Taiwan; [He, Hsien-Chin] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Family Med, Coll Med, Taipei, Taiwan; [Yang, Hsiang-Wen] Natl Taiwan Univ, Civil Engn, Grad Comp Aided Engn Grp, Taipei, Taiwan; [Ko, Patrick Chow-In] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University	Ko, PCI (corresponding author), Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Emergency Med, Coll Med, Taipei, Taiwan.; Ko, PCI (corresponding author), Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Taipei, Taiwan.	patrick.patko@gmail.com		Liu, Shih-Hung/0000-0003-4178-1694; Chong, Kah Meng/0000-0001-8129-9021; Pei-Chuan Huang, Edward/0000-0002-4800-2561; Wang, Hui-Chih/0000-0001-9279-5688; LIEN, WAN-CHING/0000-0001-9448-5093; HUANG, CHIEN-HUA/0000-0003-2981-4537; Chen, Yen-Pin/0000-0002-2473-0847	National Taiwan University Hospital Top-Down Project [107-109 T07]; National Science Council Project [104-2314-B-002-034, 105-2314-B-002171, 108-2320-B002-053-MY2]	National Taiwan University Hospital Top-Down Project; National Science Council Project	This study was supported by grants from the National Taiwan University Hospital Top-Down Project 107-109 T07; and National Science Council Project (104-2314-B-002-034, 105-2314-B-002171, and 108-2320-B002-053-MY2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Baldi E, 2020, NEW ENGL J MED, V383, P496, DOI 10.1056/NEJMc2010418; Baldi E, 2014, RESUSCITATION, V85, pE195, DOI 10.1016/j.resuscitation.2014.10.001; Birkun A, 2020, RESUSCITATION, V152, P105, DOI 10.1016/j.resuscitation.2020.05.023; Bottiger BW, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017230; Caves ND, 2006, RESUSCITATION, V68, P93, DOI 10.1016/j.resuscitation.2005.05.014; Cheng HY, 2020, J FORMOS MED ASSOC, V119, P771, DOI 10.1016/j.jfma.2020.03.007; Coons SJ, 2009, RESUSCITATION, V80, P334, DOI 10.1016/j.resuscitation.2008.11.024; Couper K, 2020, RESUSCITATION, V151, P59, DOI 10.1016/j.resuscitation.2020.04.022; Couper MP, 2000, PUBLIC OPIN QUART, V64, P464, DOI 10.1086/318641; Dobbie F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193391; Edelson DP, 2020, CIRCULATION, V141, pE933, DOI 10.1161/CIRCULATIONAHA.120.047463; Fabrigar LR, 2006, J PERS SOC PSYCHOL, V90, P556, DOI 10.1037/0022-3514.90.4.556; Geldsetzer P, 2020, J MED INTERNET RES, V22, DOI 10.2196/18790; Govindarajan P, 2012, RESUSCITATION, V83, P76, DOI 10.1016/j.resuscitation.2011.06.026; Hsu YC, 2017, HEALTH SECUR, V15, P165, DOI 10.1089/hs.2016.0111; Huang EPC, 2019, J FORMOS MED ASSOC, V118, P572, DOI 10.1016/j.jfma.2018.07.018; Huang IYF, 2020, PUBLIC ADMIN REV, V80, P665, DOI 10.1111/puar.13239; Islam MS, 2020, INFECT CONT HOSP EP, V41, P1196, DOI 10.1017/ice.2020.237; Kiguchi T, 2020, RESUSCITATION, V152, P39, DOI 10.1016/j.resuscitation.2020.02.044; Kragholm K, 2017, NEW ENGL J MED, V376, P1737, DOI 10.1056/NEJMoa1601891; Kuramoto N, 2008, RESUSCITATION, V79, P475, DOI 10.1016/j.resuscitation.2008.07.005; Lam KK, 2007, PREHOSPITAL DISASTER, V22, P325, DOI 10.1017/S1049023X00004957; Lee MJ, 2013, RESUSCITATION, V84, P889, DOI 10.1016/j.resuscitation.2013.01.009; Marijon E, 2020, LANCET PUBLIC HEALTH, V5, pE437, DOI 10.1016/S2468-2667(20)30117-1; Moon S, 2020, AM J EMERG MED, V38, P1760, DOI 10.1016/j.ajem.2020.05.108; Nolan JP, 2020, RESUSCITATION, V153, P45, DOI 10.1016/j.resuscitation.2020.06.001; ORNATO JP, 1990, ANN EMERG MED, V19, P151, DOI 10.1016/S0196-0644(05)81800-1; Perkins GD, 2020, LANCET PUBLIC HEALTH, V5, pE415, DOI 10.1016/S2468-2667(20)30134-1; Perman SM, 2020, CIRCULATION, V142, P1233, DOI 10.1161/CIRCULATIONAHA.120.048909; Pranata R, 2020, INTERN EMERG MED, V15, P875, DOI 10.1007/s11739-020-02428-7; Riggs M, 2019, RESUSCITATION, V138, P259, DOI 10.1016/j.resuscitation.2019.03.019; Savastano S, 2011, RESUSCITATION, V82, P568, DOI 10.1016/j.resuscitation.2010.12.010; Scquizzato T, 2020, RESUSCITATION, V150, P92, DOI 10.1016/j.resuscitation.2020.03.019; Shekhar AC, 2020, RESUSCITATION, V154, P50, DOI 10.1016/j.resuscitation.2020.06.032; Wang CJ, 2020, JAMA-J AM MED ASSOC, V323, P1341, DOI 10.1001/jama.2020.3151; Wang PW, 2020, J MED INTERNET RES, V22, DOI 10.2196/20021; White IM, 2008, OPT EXPRESS, V16, P1020, DOI 10.1364/OE.16.001020	41	6	6	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2021	16	6							e0252841	10.1371/journal.pone.0252841	http://dx.doi.org/10.1371/journal.pone.0252841			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TG9BO	34161378	gold, Green Published			2023-01-03	WOS:000671691900044
J	Zhang, YM; Wang, SY; Zu, SL; Zhang, CJ				Zhang, Yumeng; Wang, Shaoyong; Zu, Shulu; Zhang, Chanjuan			Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study	PLOS ONE			English	Article							INHIBITION; THERAPY; COMBINATION; MANAGEMENT; SYMPTOMS; WOMEN	Objective We evaluated a combination of transcutaneous electrical nerve stimulation (TENS) and solifenacin succinate versus solifenacin alone in the treatment of overactive bladder (OAB). Methods Ninety-seven female outpatients with OAB were screened for this double-blind randomized controlled study. Eighty-six patients who met our inclusion criteria were divided randomly into two groups. In group A (43 patients), patients received oral solifenacin and "fake" TENS on the foot; in group B (43 patients), patients received oral solifenacin and effective TENS on the foot. Improvements in OAB symptoms were assessed by Overactive Bladder Symptom Score (OABSS), Overactive Bladder Questionnaire (OAB-q), voiding diaries and urodynamic tests. 70 of 86 patients (36 in group A, 34 in group B) completed the 2 months of treatment and 3 months of follow-up. Results Statistically, the maximum bladder volume and OAB symptoms of both groups improved significantly after treatment. The improvement in group B was significantly better than that in group A, as indicated by the maximum bladder volume, OAB-q score and voiding diary. Some mild adverse effects were observed, including dry mouth, stomach upset, constipation, muscle pain and local paresthesia. Conclusion The combination of TENS and solifenacin was more effective in improving OAB symptoms than solifenacin alone.	[Zhang, Yumeng; Wang, Shaoyong; Zu, Shulu; Zhang, Chanjuan] Shandong Univ, Dept Urol, Hosp 2, Jinan, Peoples R China	Shandong University	Zhang, CJ (corresponding author), Shandong Univ, Dept Urol, Hosp 2, Jinan, Peoples R China.	zcj810616@sina.com						Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4; Chancellor MB, 1999, J UROLOGY, V162, P3, DOI 10.1097/00005392-199907000-00002; Drake MJ, 2016, EUR UROL, V70, P136, DOI 10.1016/j.eururo.2016.02.030; Elder CW, 2018, MED ENG PHYS, V53, P32, DOI 10.1016/j.medengphy.2018.01.004; Finazzi Agro E PF., 2005, URODINAMICA, V15, P171; Goldman HB, 2008, NEUROUROL URODYNAM, V27, P499, DOI 10.1002/nau.20544; Gratzke C, 2018, EUR UROL, V74, P501, DOI 10.1016/j.eururo.2018.05.005; Groen J, 2016, EUR UROL, V69, P324, DOI 10.1016/j.eururo.2015.07.071; Irwin DE, 2006, EUR UROL, V50, P1306, DOI 10.1016/j.eururo.2006.09.019; Lee KS, 2017, BMC UROL, V17, DOI 10.1186/s12894-017-0294-3; Levin PJ, 2012, INT UROGYNECOL J, V23, P1591, DOI 10.1007/s00192-012-1712-4; Matsuta Y, 2013, AM J PHYSIOL-REG I, V305, pR126, DOI 10.1152/ajpregu.00572.2012; Nambiar A, 2014, NEUROUROL URODYNAM, V33, pS21, DOI 10.1002/nau.22631; Peters KM, 2009, J UROLOGY, V182, P1055, DOI 10.1016/j.juro.2009.05.045; Sherif H, 2017, CAN J UROL, V24, P8838; Tai CF, 2011, AM J PHYSIOL-RENAL, V300, pF385, DOI 10.1152/ajprenal.00526.2010; Tugtepe H, 2015, UROLOGY, V85, P900, DOI 10.1016/j.urology.2014.12.031; van Balken MR, 2006, EUR UROL, V49, P360, DOI 10.1016/j.eururo.2005.10.019; van der Pal F, 2006, NEUROMODULATION, V9, P163, DOI 10.1111/j.1525-1403.2006.00056.x; Vecchioli-Scaldazza C, 2018, INT BRAZ J UROL, V44, P102, DOI [10.1590/S1677-5538.IBJU.2016.0611, 10.1590/s1677-5538.ibju.2016.0611]; Visco AG, 2016, NEUROUROL URODYNAM, V35, P288, DOI 10.1002/nau.22795; Voorham JC, 2017, NEUROUROL URODYNAM, V36, P1796, DOI 10.1002/nau.23180; Wang AC, 2004, UROLOGY, V63, P61, DOI 10.1016/j.urology.2003.08.047; Zhang CJ, 2017, BMC UROL, V17, DOI 10.1186/s12894-017-0248-9; Zhang ZC, 2015, J PHARMACOL EXP THER, V355, P228, DOI 10.1124/jpet.115.226845	25	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2021	16	6							e0253040	10.1371/journal.pone.0253040	http://dx.doi.org/10.1371/journal.pone.0253040			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BO	34161360	gold, Green Published			2023-01-03	WOS:000671691900055
J	Fujita, M; Todani, M; Kaneda, K; Suzuki, S; Wakai, S; Kikuta, S; Sasaki, S; Hattori, N; Yagishita, K; Kuwata, K; Tsuruta, R				Fujita, Motoki; Todani, Masaki; Kaneda, Kotaro; Suzuki, Shinya; Wakai, Shinjiro; Kikuta, Shota; Sasaki, Satomi; Hattori, Noriyuki; Yagishita, Kazuyoshi; Kuwata, Koji; Tsuruta, Ryosuke		COP-J Study Investigators	Use of hyperbaric oxygen therapy for preventing delayed neurological sequelae in patients with carbon monoxide poisoning: A multicenter, prospective, observational study in Japan	PLOS ONE			English	Article							LONG-TERM MORTALITY; BRAIN; INHIBITION; INJURY	Background The purpose of this study was to clarify the practical clinical treatment for acute carbon monoxide (CO) poisoning in Japan and to investigate the efficacy of hyperbaric oxygen (HBO2) therapy in preventing delayed neurological sequelae (DNS) in the acute phase of CO poisoning. Methods We conducted a multicenter, prospective, observational study of acute CO poisoning in Japan. Patients with acute CO poisoning were enrolled and their treatment details were recorded. The primary endpoint was the onset of DNS within 2 months of CO exposure. Factors associated with DNS were assessed with logistic regression analysis. Results A total of 311 patients from 57 institutions were registered and 255 were analyzed: 171 received HBO2 therapy (HBO2 group) and 84 did not (normobaric oxygen [NBO2] group). HBO2 therapy was performed zero, once, twice, or three times within the first 24 h in 1.8%, 55.9%, 30.9%, and 11.3% of the HBO2 group, respectively. The treatment pressure in the first HBO2 session was 2.8 ATA (47.9% of the HBO2 group), 2.0 ATA (41.8%), 2.5 ATA (7.9%), or another pressure (2.4%). The incidence of DNS was 13/171 (7.6%) in the HBO2 group and 3/84 (3.6%) in the NBO2 group (P = 0.212). The number of HBO2 sessions in the first 24 h was one of the factors associated with the incidence of DNS (odds ratio, 2.082; 95% confidence interval, 1.101-3.937; P = 0.024). Conclusions The practical clinical treatment for acute CO poisoning, including HBO2 therapy, varied among the institutions participating in Japan. HBO2 therapy with inconsistent protocols showed no advantage over NBO2 therapy in preventing DNS. Multiple HBO2 sessions was associated with the incidence of DNS.	[Fujita, Motoki; Tsuruta, Ryosuke] Yamaguchi Univ, Acute & Gen Med, Grad Sch Med, Ube, Yamaguchi, Japan; [Todani, Masaki; Kaneda, Kotaro; Tsuruta, Ryosuke] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, Ube, Yamaguchi, Japan; [Suzuki, Shinya] Kameda Med Ctr, Dept Emergency Med, Kamogawa, Japan; [Wakai, Shinjiro] Tokai Univ, Dept Emergency & Crit Care Med, Sch Med, Isehara, Kanagawa, Japan; [Kikuta, Shota] Hyogo Emergency Med Ctr, Dept Emergency & Crit Care Med, Kobe, Hyogo, Japan; [Sasaki, Satomi] Japanese Red Cross Maebashi Hosp, Adv Med Emergency Dept, Maebashi, Gumma, Japan; [Sasaki, Satomi] Japanese Red Cross Maebashi Hosp, Crit Care Ctr, Maebashi, Gumma, Japan; [Hattori, Noriyuki] Chiba Univ, Dept Emergency & Crit Care Med, Grad Sch Med, Chiba, Japan; [Yagishita, Kazuyoshi] Tokyo Med & Dent Univ, Hyperbar Med Ctr, Tokyo, Japan; [Kuwata, Koji] Japan Self Def Forces Hosp Yokosuka, Div Med, Yokosuka, Kanagawa, Japan	Yamaguchi University; Yamaguchi University; Tokai University; Maebashi Red Cross Hospital; Maebashi Red Cross Hospital; Chiba University; Tokyo Medical & Dental University (TMDU)	Fujita, M (corresponding author), Yamaguchi Univ, Acute & Gen Med, Grad Sch Med, Ube, Yamaguchi, Japan.	motoki-ygc@umin.ac.jp		Fujita, Motoki/0000-0002-0981-847X				Annane D, 2001, INTENS CARE MED, V27, P1776, DOI 10.1007/s00134-001-1127-z; Annane D, 2011, INTENS CARE MED, V37, P486, DOI 10.1007/s00134-010-2093-0; Bader N, 2007, BRIT J NUTR, V98, P826, DOI 10.1017/S0007114507744380; Birmingham CM, 2011, INTENS CARE MED, V37, P1218, DOI 10.1007/s00134-011-2195-3; Brown S D, 1989, Adv Exp Med Biol, V248, P747; BROWN SD, 1992, J CLIN INVEST, V89, P666, DOI 10.1172/JCI115633; Buckley NA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002041.pub3; Byrne BT, 2012, UNDERSEA HYPERBAR M, V39, P627; Du XQ, 2019, EXP THER MED, V17, P2682, DOI 10.3892/etm.2019.7233; Fujita M, 2018, EMERG MED INT, V2018, DOI 10.1155/2018/2159147; Han ST, 2007, TOXICOL LETT, V170, P111, DOI 10.1016/j.toxlet.2007.02.006; Henry CR, 2006, JAMA-J AM MED ASSOC, V295, P398, DOI 10.1001/jama.295.4.398; Huang CC, 2017, CHEST, V152, P943, DOI 10.1016/j.chest.2017.03.049; Jeon SB, 2018, JAMA NEUROL, V75, P436, DOI 10.1001/jamaneurol.2017.4618; Jung JW, 2019, AM J EMERG MED, V37, P823, DOI 10.1016/j.ajem.2018.07.046; Kaita Y, 2018, AM J EMERG MED, V36, P851, DOI 10.1016/j.ajem.2018.01.054; Kim H, 2018, CLIN EXP EMERG MED, V5, P185, DOI 10.15441/ceem.17.217; Korkmaz A, 2008, NEUROCHEM RES, V33, P160, DOI 10.1007/s11064-007-9428-4; Korpinar S, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55050205; Ku HL, 2010, GEN HOSP PSYCHIAT, V32, P310, DOI 10.1016/j.genhosppsych.2009.11.005; Mathieu D, 1996, UNDERSEA HYPERBARIC, V23, P7; Mutluoglu M, 2016, UNDERSEA HYPERBAR M, V43, P49; Nakajima M, 2020, AM J EMERG MED, V38, P225, DOI 10.1016/j.ajem.2019.02.009; Oter S, 2005, CLIN BIOCHEM, V38, P706, DOI 10.1016/j.clinbiochem.2005.04.005; Pepe G, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-16; Piantadosi CA, 1997, EXP NEUROL, V147, P103, DOI 10.1006/exnr.1997.6584; RAPHAEL JC, 1989, LANCET, V2, P414; Rose JJ, 2018, CRIT CARE MED, V46, pE649, DOI 10.1097/CCM.0000000000003135; Scheinkestel CD, 1999, MED J AUSTRALIA, V170, P203, DOI 10.5694/j.1326-5377.1999.tb140318.x; THOM SR, 1993, TOXICOL APPL PHARM, V123, P248, DOI 10.1006/taap.1993.1243; Thom SR, 2004, P NATL ACAD SCI USA, V101, P13660, DOI 10.1073/pnas.0405642101; Thom SR, 1997, AM J PHYSIOL-CELL PH, V272, pC770, DOI 10.1152/ajpcell.1997.272.3.C770; Thom SR, 2006, AM J RESP CRIT CARE, V174, P1239, DOI 10.1164/rccm.200604-557OC; THORN SR, 1995, ANN EMERG MED, V25, P474, DOI 10.1016/S0196-0644(95)70261-X; Uemura K, 2003, TOXICOL LETT, V145, P101, DOI 10.1016/S0378-4274(03)00202-9; Wang WQ, 2019, MED SCI MONITOR, V25, P7684, DOI 10.12659/MSM.917065; Weaver LK, 2007, AM J RESP CRIT CARE, V176, P491, DOI 10.1164/rccm.200701-026OC; Weaver LK, 2009, NEW ENGL J MED, V360, P1217, DOI 10.1056/NEJMcp0808891; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Yukimichi I., 1994, J HONG KONG COLL PSY, V4, P20	40	4	4	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2021	16	6							e0253602	10.1371/journal.pone.0253602	http://dx.doi.org/10.1371/journal.pone.0253602			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BC	34143855	gold, Green Published			2023-01-03	WOS:000671690700065
J	Joshi, T; Pandey, SC; Maiti, P; Tripathi, M; Paliwal, A; Nand, M; Sharma, P; Samant, M; Pande, V; Chandra, S				Joshi, Tushar; Pandey, Satish Chandra; Maiti, Priyanka; Tripathi, Manish; Paliwal, Ashutosh; Nand, Mahesha; Sharma, Priyanka; Samant, Mukesh; Pande, Veena; Chandra, Subhash			Antimicrobial activity of methanolic extracts of Vernonia cinerea against Xanthomonas oryzae and identification of their compounds using in silico techniques	PLOS ONE			English	Article							ANTIBACTERIAL ACTIVITY; D-ALANINE; NETWORKS; ANTIOXIDANT; ENZYME	Bacterial Leaf Blight (BLB) disease is an extremely ruinous disease in rice, caused by Xanthomonas oryzae pv. oryzae (Xoo). Although various chemicals are available to manage BLB, they are toxic to the environment as well as humans. Hence there is a need to develop new pesticides as alternatives to hazardous chemicals. Therefore, a study was carried out to discover new potent natural pesticides against Xoo from different solvent extracts of Vernonia cinerea. Among all the fractions, the methanolic extract showed the highest inhibition zone. Further, to gain mechanistic insight of inhibitory action, 40 molecules of methanolic extracts were subjected for in silico study against two enzymes D-alanine-D-alanine ligase (Ddl) and Peptide deformylase (PDF). In silico study showed Rutin and Methanone, [1,4-dimethyl-7-(1- methylethyl)-2- azulenyl]phenyl have a good binding affinity with Ddl while Phenol, 2,4-bis(1-phenylethyl)- and 1,2-Benzenedicarboxylic acid, diisooctyl ester showed an excellent binding affinity to PDF. Finally, the system biology approach was applied to understand the agrochemical's effect in the cell system of bacteria against both the enzymes. Conclusively, these four-hit compounds may have strong potential against Xoo and can be used as biopesticides in the future.	[Joshi, Tushar; Pandey, Satish Chandra; Paliwal, Ashutosh; Pande, Veena] Kumaun Univ, Dept Biotechnol, Bhimtal Campus, Bhimtal, Uttarakhand, India; [Pandey, Satish Chandra; Samant, Mukesh] Soban Singh Jeena Univ, Dept Zool, Cell Mol Biol Lab, Almora, Uttarakhand, India; [Maiti, Priyanka] GB Pant Natl Inst Himalayan Environm, Ctr Environm Assessment & Climate Change, Almora, Uttarakhand, India; [Tripathi, Manish; Chandra, Subhash] Soban Singh Jeena Univ, Dept Bot, Computat Biol & Biotechnol Lab, Almora, Uttarakhand, India; [Nand, Mahesha] GB Pant Natl Inst Himalayan Environm, Environm Informat Syst Himalayan Ecol, Almora, Uttarakhand, India; [Sharma, Priyanka] Kumaun Univ, Dept Bot, DSB Campus, Naini Tal, Uttarakhand, India	Kumaun University; G.B. Pant National Institute of Himalayan Environment & Sustainable Development (GBPNIHESD); G.B. Pant National Institute of Himalayan Environment & Sustainable Development (GBPNIHESD); Kumaun University	Chandra, S (corresponding author), Soban Singh Jeena Univ, Dept Bot, Computat Biol & Biotechnol Lab, Almora, Uttarakhand, India.	scjnu@yahoo.co.in	Nand, Mahesha/ACE-1505-2022; Tripathi, Manish/O-2865-2019; Chandra, Subhash/AAN-6789-2020	Nand, Mahesha/0000-0003-3122-8318; Chandra, Subhash/0000-0002-8978-5427				Abirami P., 2012, EUROP J EXP BIOL, V2, P9; Adamczak A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010109; Arima H, 2002, BIOSCI BIOTECH BIOCH, V66, P1009, DOI 10.1271/bbb.66.1009; Aubart K, 2006, PROGR MED CHEM, V44, P109, DOI 10.1016/S0079-6468(05)44403-3; Autiero I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006226; Barabasi AL, 2009, SCIENCE, V325, P412, DOI 10.1126/science.1173299; Barreteau H, 2008, FEMS MICROBIOL REV, V32, P168, DOI 10.1111/j.1574-6976.2008.00104.x; Bhatt P, 2019, PESTIC BIOCHEM PHYS, V158, P88, DOI 10.1016/j.pestbp.2019.04.015; Chien CC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36575-x; Chithrashree, 2011, BIOL CONTROL, V59, P114, DOI 10.1016/j.biocontrol.2011.06.010; Govindappa M., 2011, International Journal of Plant Physiology and Biochemistry, V3, P6; Groche D, 1998, BIOCHEM BIOPH RES CO, V246, P342, DOI 10.1006/bbrc.1998.8616; Gupta M, 2003, FITOTERAPIA, V74, P148, DOI 10.1016/S0367-326X(02)00291-5; Jabeen R, 2011, PAK J BOT, V43, P1335; Kanugala S, 2019, MICROBIOL RES, V228, DOI 10.1016/j.micres.2019.126301; Kavitha H. U., 2011, International Journal of Agricultural Technology, V7, P449; Kim SI, 2016, SCI REP-UK, V6, DOI 10.1038/srep21209; Kirkpatrick WR, 1998, J CLIN MICROBIOL, V36, P1330, DOI 10.1128/JCM.36.5.1330-1332.1998; Kitamura Y, 2009, ACTA CRYSTALLOGR D, V65, P1098, DOI 10.1107/S0907444909029710; Kitano Hiroaki, 2003, Biosilico, V1, P169, DOI 10.1016/S1478-5382(03)02380-1; Latha LY, 2010, ULTRASTRUCT PATHOL, V34, P219, DOI 10.3109/01913121003651513; Lemkul J., 2019, LIVING J COMPUTATION, V1, P1, DOI [10.33011/livecoms.1.1.5068, DOI 10.33011/LIVECOMS.1.1.5068]; Lu X, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100138; Maiti P, 2021, J BIOMOL STRUCT DYN, V39, P5048, DOI 10.1080/07391102.2020.1784791; Meena R.K., 2020, RESOURCES USE EFFICI, P85, DOI DOI 10.1007/978-981-15-6953-1_3; Mishra D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081996; NEUHAUS FC, 1964, BIOCHEMISTRY-US, V3, P471, DOI 10.1021/bi00892a001; Neumann A, 2002, ARCH MICROBIOL, V177, P420, DOI 10.1007/s00203-002-0409-3; Pathak RK., 2017, SCI REP-UK, V7, P1, DOI [10.1038/s41598-016-0028-x, DOI 10.1038/S41598-016-0028-X]; Rajamurugan R, 2011, PHARM BIOL, V49, P1311, DOI 10.3109/13880209.2011.604334; Sahayaraj K, 2015, RES CHEM INTERMEDIAT, V41, P5495, DOI 10.1007/s11164-014-1676-8; Somasundaram A., 2010, PHARMACOLOGYONLINE, V960, P957; Sonibare MA, 2016, AFR HEALTH SCI, V16, P629, DOI 10.4314/ahs.v16i2.34; Syed-Ab-Rahman SF, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2019.e03151; Verma SK, 2011, PHARMACOPHORE, V2, P114; Vollmer W, 2008, FEMS MICROBIOL REV, V32, P149, DOI 10.1111/j.1574-6976.2007.00094.x; Yang MT, 2020, FOOD CHEM, V333, DOI 10.1016/j.foodchem.2020.127458; Yoon J, 2006, BIOINFORMATICS, V22, P3106, DOI 10.1093/bioinformatics/btl533	38	4	4	4	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2021	16	6							e0252759	10.1371/journal.pone.0252759	http://dx.doi.org/10.1371/journal.pone.0252759			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6SI	34125862	gold, Green Published			2023-01-03	WOS:000664643500014
J	Yalew, M; Adane, B; Damtie, Y; Kefale, B; Dewau, R; Mektu, K; Arefaynie, M; Andargie, A				Yalew, Melaku; Adane, Bezawit; Damtie, Yitayish; Kefale, Bereket; Dewau, Reta; Mektu, Kefale; Arefaynie, Mastewal; Andargie, Assefa			Determinants of change in timely first antenatal booking among pregnant women in Ethiopia: A decomposition analysis	PLOS ONE			English	Article							PUBLIC-HEALTH INSTITUTIONS; CARE VISIT; INITIATION; SERVICES; TIGRAY; PREDICTORS; MORTALITY; DISTRICT; MOTHERS; TRENDS	Background Even though maternal health was highly targeted in different global strategies, maternal mortality could not be decreased as was expected. Besides this, prior decomposition analysis to the possible cause of changes to timely first antenatal booking has not been conducted. Therefore, this study aimed to assess determinants of change in timely first antenatal booking among pregnant women in Ethiopia. Methods The study utilized three consecutive Ethiopia Demographic and Health Survey (EDHS) datasets which were collected through cross-sectional study design. The number of pregnant women who gave birth in 2005, 2011 and 2016 survey included in the analysis was 7,307, 7,908 and 7,590 respectively. The data were analyzed by using Stata/SE version 14.0. Logit-based decomposition analysis was done to identify contributing factors for change in timely first antenatal booking and statistical significance was determined by using P-value. Results The trend of timely first antenatal booking was increased from 6% to 20% in the last ten years. The analysis revealed that 14% of the overall change was because of the change in women's composition. Changes in the composition of women according to region, education and occupation status were the major sources of this change. The remaining, 86% of the change was due to differences in the coefficient. Mostly, the change in behaviors of the Oromia population, those who have lived in the rural areas and male household head were some of the contributing factors for the increase in timely first antenatal booking. Conclusions There was a significant increase in timely first antenatal booking among pregnant women in Ethiopia from 2005 to 2016 EDHS. The change in the women composition according to residency, education and occupation status of women and the difference in behaviors like: behavior of rural residents and male household head contributed to the majority of the change. Interventions targeting the male household head, rural residents and those women who lived in the Oromia region should be emphasized to increase further timely booking. In addition, promoting women in terms of education and creating job opportunities could be the other recalled intervention areas of the country.	[Yalew, Melaku; Damtie, Yitayish; Kefale, Bereket; Arefaynie, Mastewal] Wollo Univ, Sch Publ Hlth, Dept Reprod & Family Hlth, Coll Med & Hlth Sci, Dessie, Ethiopia; [Adane, Bezawit; Dewau, Reta; Andargie, Assefa] Wollo Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Dessie, Ethiopia; [Mektu, Kefale] Wollo Univ, Sch Med, Dept Physiol, Coll Med & Hlth Sci, Dessie, Ethiopia	University of Gondar; University of Gondar; University of Gondar	Yalew, M (corresponding author), Wollo Univ, Sch Publ Hlth, Dept Reprod & Family Hlth, Coll Med & Hlth Sci, Dessie, Ethiopia.	meleya7@gmail.com	Arefaynie, Mastewal/AAZ-8374-2021; Dewau, Reta/AAA-4202-2022	Arefaynie, Mastewal/0000-0001-9525-0552; Dewau, Reta/0000-0001-6531-2468; Andargie, Assefa/0000-0002-8409-7545; Kefale Abitew, Bereket/0000-0003-1795-9886				Abame Desta Erkalo, 2019, J Reprod Infertil, V20, P42; Abosse Z, 2010, ETHIOP J HEALTH SCI, V20, P75; AbouZahr C., 2003, PROMISES ACHIEVEMENT; Abuka T., 2016, J PREG CHILD HLTH, V3, P2; Adekanle DA, 2008, ONLINE J HLTH ALLIED, V7, P1; Alderliesten ML, 2007, BJOG-INT J OBSTET GY, V114, P1232, DOI 10.1111/j.1471-0528.2007.01438.x; Alemu Y, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0646-9; Ali S., 2018, J PREG NEONATAL MED, V2; Amo-Adjei J, 2016, TROP MED INT HEALTH, V21, P1552, DOI 10.1111/tmi.12788; Babalola S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-43; Banda I, 2012, MED J ZAMBIA, V39, P29; Barasa K.S., 2015, AM J THEOR APPL STAT, V4, P322; Bayou YT, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0930-z; Belayneh T, 2014, J PREGNANCY, V2014, DOI 10.1155/2014/132494; Csa I., 2016, ETH DEM HLTH SURV; Dairo M. D., 2010, Benin Journal of Postgraduate Medicine, V12, P3; Damme TG., 2015, J GYNECOL OBSTET, V26, P103, DOI 10.11648/j.jgo.20150305.12; Dibaba Y, 2009, ETHIOP J HEALTH SCI, V19; Dibaba Y, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-50; Ewunetie AA, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1748-7; Fagbamigbe AF, 2019, ADV INTEGR MED, V6, P110, DOI 10.1016/j.aimed.2018.12.002; Feyera B, 2017, E AFRICAN J HLTH BIO, V1, P21; Gebrekidan K, 2017, PRAGMAT OBS RES, V8, P223, DOI 10.2147/POR.S140733; Gebremeskel F, 2015, J ENVIRON PUBLIC HEA, V2015, DOI 10.1155/2015/971506; Gebresilassie B, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2490-5; Gedle M., 2017, INT ACAD J HLTH MED, V1, P66; Gidey G., 2018, ASIAN J PHARM CLIN R, V11, P409; Gudayu TW, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-287; Gudu W., 2018, ETHIOPIAN J REPROD H, V10, P25; Habtewold TD, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023956; Haftu Abera, 2018, BMC Res Notes, V11, P872, DOI 10.1186/s13104-018-3987-0; Hussen S., 2016, J WOMENS HLTH CARE, V5, P2167; Jiee S. F., 2018, International Journal of Public Health Research (Malaysia), V8, P956; Kotoh AM, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7400-2; Manzi A, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-290; Mathai M., 2011, ALTERNATIVE VERSUS S; Mkhari MM., 2016, THESIS; Moller AB, 2017, LANCET GLOB HEALTH, V5, pE977, DOI 10.1016/S2214-109X(17)30325-X; Njiku F., 2017, TANZANIA J HLTH RES, V19; Orsido TT, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2227-5; Oyerinde, 2013, J COMMUNITY MED HLTH, V3, P2, DOI [10.4172/2161-0711.1000e116, DOI 10.4172/2161-0711.1000E116]; Paudel YR, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00242; Powers DA, 2011, STATA J, V11, P556, DOI 10.1177/1536867X1101100404; Saxena V., 2011, INDIAN J PREV SOC ME, V42, P14; Singh S., 2009, BARRIERS SAFE MOTHER, P1; Sinyange Nyambe, 2016, Pan Afr Med J, V25, P109, DOI 10.11604/pamj.2016.25.109.6873; Tafere TE, 2018, ITAL J PEDIATR, V44, DOI 10.1186/s13052-018-0544-3; Tekelab T., 2014, SCI TECHNOL ARTS RES, V3, P108, DOI [10.4314/star.v3i1.17, DOI 10.4314/STAR.V3I1.17]; Tesfaye G, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0412-4; Tessema GA, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4071-8; Tsegay Y, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-30; Tufa G, 2020, INT J WOMENS HEALTH, V12, P657, DOI 10.2147/IJWH.S255009; United Nations Population F, 2014, TRENDS MAT MORT 1990; WHO, 2018, WHO REC ANT CAR CONT; Wolde HF, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0745-2; Wondwossen Lerebo, 2015, Clinics in Mother and Child Health, V12, P171; World Health Organization, 2011, GLOBAL PREVALENCE AN, Vfourth, P1; World Health Organization, 2013, GUIDELINES MANAGEMEN; Young M, 2012, AM J TROP MED HYG, V87, P6, DOI 10.4269/ajtmh.2012.12-0221; Zegeye AM., 2013, AFR J REPROD HEALTH, V17	60	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2021	16	6							e0251847	10.1371/journal.pone.0251847	http://dx.doi.org/10.1371/journal.pone.0251847			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RB	34086688	gold, Green Published			2023-01-03	WOS:000664640100023
J	Tano, PF; Apiribu, F; Tano, EK; Mensah, ABB; Dzomeku, VM; Boateng, I				Tano, Priscilla Felicia; Apiribu, Felix; Tano, Emile Kouakou; Mensah, Adwoa Bemah Boamah; Dzomeku, Veronica Millicent; Boateng, Isaac			Predicting factors that determine patients' satisfaction with post-operative pain management following abdominal surgeries at Komfo Anokye Teaching Hospital, Kumasi, Ghana	PLOS ONE			English	Article							INTERNATIONAL PAIN	Introduction Poorly controlled postoperative pain has been known to be characterized by longer post-operative care, longer hospital stays with increased readmission rates, and decreased patient satisfaction. Post-operative pain has been continuously addressed in the past three (3) to four (4) decades and has been shown that 20 to 80% of post-operative patients suffer ineffective pain management. Objective The study was aimed at assessing the factors that may predict the satisfaction of patients with early postoperative pain management following abdominal surgeries at the Komfo Anokye Teaching Hospital, Kumasi. Methodology A descriptive cross-sectional study was conducted among patients who had undergone abdominal surgeries between October 2019 and December 2019 at the Komfo Anokye Teaching Hospital. Structured questionnaires based on the IPO-Q were used to obtain responses from the patients. Descriptive and Inferential statistical analysis were employed in analyzing the data obtained from the respondents of the study. Results 138 patients were involved in this study. The mean age of patients in the study was 45.81 (16.81) years. A higher percentage, 58.7% of the patients were males. 39.1% had completed their tertiary level of education. The majority (50.7%) of the patients had had persistent pain for more than three (3) months. The satisfaction of the patients with the post-operative pain management received was generally high among a significant majority of the patients. Meanwhile, among the factors that influence the satisfaction of the patients with the post-operative pain management received, type of analgesia and pain relief methods (Pearson Coefficient = 0.523, p-value <0.05), patient's ability to request more pain relief, (Pearson Coefficient = 0.29, p-value <0.05), patient's access to information about their pain treatment options from the Nurses (Pearson coefficient = -0.22, p<0.05), were the only predictors of satisfaction in patients. Conclusion This study found out that patients were generally satisfied with the post-operative pain management offered by their healthcare providers although the degree of satisfaction depended largely on the type of analgesia and pain relief methods, the ability to request for more pain relief, and access to information on pain treatment.	[Tano, Priscilla Felicia; Apiribu, Felix; Mensah, Adwoa Bemah Boamah; Dzomeku, Veronica Millicent] Kwame Nkrumah Univ Sci & Technol, Fac Allied Hlth Sci, Dept Nursing, Coll Hlth Sci, Kumasi, Ghana; [Tano, Priscilla Felicia; Tano, Emile Kouakou] Komfo Anokye Teaching Hosp, Dept Surg, Kumasi, Ghana; [Boateng, Isaac] Univ Cape Coast, Dept Physiol, Cape Coast, Ghana	Kwame Nkrumah University Science & Technology; Kwame Nkrumah University Science & Technology; University of Cape Coast	Tano, PF (corresponding author), Kwame Nkrumah Univ Sci & Technol, Fac Allied Hlth Sci, Dept Nursing, Coll Hlth Sci, Kumasi, Ghana.; Tano, PF (corresponding author), Komfo Anokye Teaching Hosp, Dept Surg, Kumasi, Ghana.	pftano@gmail.com	Apiribu, Dr. Felix/AAV-5632-2021	Tano, Priscilla Felicia/0000-0001-9511-6310; Boateng, Isaac/0000-0002-3769-366X; Boamah Mensah, ADWOA Bemah/0000-0002-1114-702X; Apiribu, Felix/0000-0003-4534-2568				Ahmed Aliya, 2013, J Anaesthesiol Clin Pharmacol, V29, P472, DOI 10.4103/0970-9185.119137; Aubrun F, 2019, ANAESTH CRIT CARE PA, V38, P223, DOI 10.1016/j.accpm.2018.08.004; Batista J, 2017, OPTIMIZING POSTOPERA, V67; Behrens JA, 2019, EUR J OBSTET GYN R B, V232, P22, DOI 10.1016/j.ejogrb.2018.10.038; Drewett S, 2008, CLIN NUTR, V21, P116; Dureja GP, 2017, J PAIN RES, V10, P709, DOI 10.2147/JPR.S128655; Farooq F, 2016, INDIAN J ANAESTH, V60, P248, DOI 10.4103/0019-5049.179450; Gebremedhn Endale Gebreegziabher, 2015, BMC Res Notes, V8, P377, DOI 10.1186/s13104-015-1332-4; Geeraerts T., 2018, ANAESTH CRIT CARE PA, V37; Gerbershagen HJ, 2011, BRIT J ANAESTH, V107, P619, DOI 10.1093/bja/aer195; Hallway A, 2019, J AM COLL SURGEONS, V229, P316, DOI 10.1016/j.jamcollsurg.2019.04.020; Itisha C, 2016, WORLD ACAD SCI ENG T, V10, P285; Kesingland AC, 2000, PAIN, V86, P113, DOI 10.1016/S0304-3959(00)00233-5; Khansa I, 2017, PRS-GLOB OPEN, V5, DOI 10.1097/GOX.0000000000001400; Lemay CA, 2019, PAIN MANAG NURS, V20, P345, DOI 10.1016/j.pmn.2018.12.009; McDonall J, 2016, BMC MUSCULOSKEL DIS, V17, P1, DOI [10.1186/s12891-016-1133-5, DOI 10.1186/s12891-016-1133-5]; Meissner W, 2015, CURR MED RES OPIN, V31, P2131, DOI 10.1185/03007995.2015.1092122; Murthy S, 2013, SOUTH AFR J ANAESTH, V19, P102, DOI 10.1080/22201173.2013.10872904; Ramia E, 2017, PAIN RES MANAG, V2017, DOI 10.1155/2017/7459360; Rothaug J, 2013, J PAIN, V14, P1361, DOI 10.1016/j.jpain.2013.05.016; Schwenkglenks M, 2014, PAIN, V155, P1401, DOI 10.1016/j.pain.2014.04.021; Shigematsu-Locatelli M, 2017, JA CLIN REP, V3, DOI 10.1186/s40981-016-0075-0; Singh PK, 2016, INDIAN J ANAESTH, V60, P737, DOI 10.4103/0019-5049.191686; Stanimir M, 2016, ROM J MORPHOL EMBRYO, V57, P849; Strike E, 2019, J CARDIOTHOR VASC AN, V33, P1668, DOI 10.1053/j.jvca.2018.11.010; Ulm MA, 2018, GYNECOL ONCOL, V151, P124, DOI 10.1016/j.ygyno.2018.08.015; Umuhoza O., 2019, INT J AFR NURS SCI, V10, P145, DOI [10.1016/j.ijans.2019.04.006, DOI 10.1016/J.IJANS.2019.04.006]; Xu NF, 2019, J PEDIATR NURS, V46, pE10, DOI 10.1016/j.pedn.2019.01.014	28	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2021	16	5							e0251979	10.1371/journal.pone.0251979	http://dx.doi.org/10.1371/journal.pone.0251979			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6OL	34033660	Green Published, gold			2023-01-03	WOS:000664633100018
J	Karlsson, P; Nakitanda, AO; Lofling, L; Cesta, CE				Karlsson, Par; Nakitanda, Aya Olivia; Lofling, Lukas; Cesta, Carolyn E.			Patterns of prescription dispensation and over-the-counter medication sales in Sweden during the COVID-19 pandemic	PLOS ONE			English	Article								Introduction On February 26(th) 2020, a high alert was issued in Sweden in response to the diagnosis of the first few coronavirus disease 2019 (COVID-19) cases in the country. Subsequently, a decreased supply of essential goods, including medical products, was anticipated. We aimed to explore the weekly patterns of prescription dispensing and over-the-counter (OTC) medication sales in Sweden in 2020 compared with previous years, to assess the influence of the government restrictions on medication sales, and to assess whether there is evidence of medication stockpiling in the population. Methods Aggregated data on the weekly volume of defined daily doses (DDDs) of prescription medication dispensed and OTC sales from 2015 to 2020 were examined. From 2015-2019 data, the predicted weekly volume of DDDs for 2020 was estimated and compared to the observed volume for each ATC anatomical main group and therapeutic subgroup. Results From mid-February to mid-March 2020, there were increases in the weekly volumes of dispensed medication, peaking in the second week of March with a 46% increase in the observed versus predicted number of DDDs dispensed (16,440 vs 11,260 DDDs per 1000 inhabitants). A similar pattern was found in all age groups, in both sexes, and across metropolitan and non-metropolitan regions. In the same week in March, there was a 96% increase in the volume of OTC sold (2,504 vs 1,277 DDDs per 1000 inhabitants), specifically in ATC therapeutic subgroups including vitamins, antipyretics, painkillers, and nasal, throat, cough and cold preparations. Conclusion Beginning in mid-February 2020, there were significant changes in the volume of prescription medication dispensed and OTC drugs sold. The weekly volume of DDDs quickly decreased following recommendations from public authorities. Overall, our findings suggest stockpiling behavior over a surge in new users of medication.	[Karlsson, Par; Nakitanda, Aya Olivia; Lofling, Lukas; Cesta, Carolyn E.] Karolinska Inst, Ctr Pharmacoepidemiol, Stockholm, Sweden; [Lofling, Lukas] Canc Registry Norway, Etiol Res Unit, Dept Res, Oslo, Norway	Karolinska Institutet; University of Oslo	Cesta, CE (corresponding author), Karolinska Inst, Ctr Pharmacoepidemiol, Stockholm, Sweden.	carolyn.cesta@ki.se	Löfling, Lukas/L-6480-2019; Cesta, Carolyn E/AAM-2039-2021	Löfling, Lukas/0000-0002-2731-8532; Cesta, Carolyn E/0000-0001-5759-9366; Nakitanda, Aya Olivia/0000-0001-7392-208X	Karolinska Institutet	Karolinska Institutet(Karolinska Institutet)	The author's research group at the Centre for Pharmacoepidemiology, Karolinska Institutet, provided financial support for this project.	[Anonymous], COVID 19 CHLOR HYDR; Burry LD, 2020, CHEST, V158, P2414, DOI 10.1016/j.chest.2020.08.015; Centers for Disease Control and Prevention, PEOPL MOD SEV ASTHM; Cox S, 2021, DEV WORLD BIOETH, V21, P193, DOI 10.1111/dewb.12284; Elbeddini A, 2020, J PHARM POLICY PRACT, V13, DOI 10.1186/s40545-020-00224-4; Karlen M, 2020, GOTEBORG POSTEN; Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P2459, DOI 10.1111/apa.15582; Norweigan Institute of Public Health (FHI), SALG SMERT BET OKT P; Saag MS, 2020, JAMA-J AM MED ASSOC, V324, P2161, DOI 10.1001/jama.2020.22389; Social Insurance Institution of Finland (KELA), PURCH PRESCR MED FIN; Statistics Sweden, FOLKM MAN EFT REG AL; Swedish Medical Products Agency, AP DET UPPM MOTV HAM; Swedish Medical Products Agency, BEGR UTL LAK REC 202; Swedish Medical Products Agency, PLAN INF EV NYA UTB; Swedish Medical Products Agency, KLOR HYDR BOR END AN; Swedish Medical Products Agency, ALV 500 MG TILLF RES; Swedish National Board of Health and Welfare, EFF COVID 19 LAK 202; Swedish National Board of Health and Welfare, MINSK ANT COV 19 PAN; Swedish National Board of Health and Welfare, AN FORST COV 19 VAG; WHO, TIM WHOS COVID 19 RE; WHO Collaborating Centre for Drug Statistics Methodology, 2018, ATC CLASS IND DDDS 2	21	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0253944	10.1371/journal.pone.0253944	http://dx.doi.org/10.1371/journal.pone.0253944			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ8RN	34388166	Green Published, gold			2023-01-03	WOS:000684737400032
J	Sharma, K; Singh, R; Sharma, SK; Anand, A				Sharma, Kaushal; Singh, Ramandeep; Sharma, Suresh Kumar; Anand, Akshay			Sleeping pattern and activities of daily living modulate protein expression in AMD	PLOS ONE			English	Article							RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; ALZHEIMERS-DISEASE; STEM-CELLS; AGE; ACCUMULATION; EPIGENETICS; MECHANISMS; RECEPTOR-3; DURATION	Degeneration of macular photoreceptors is a prominent characteristic of age-related macular degeneration (AMD) which leads to devastating and irreversible vision loss in the elderly population. In this exploratory study, the contribution of environmental factors on the progression of AMD pathology by probing the expression of candidate proteins was analyzed. Four hundred and sixty four participants were recruited in the study comprising of AMD (n = 277) and controls (n = 187). Genetics related data was analyzed to demonstrate the activities of daily living (ADL) by using regression analysis and statistical modeling, including contrast estimate, multinomial regression analysis in AMD progression. Regression analysis revealed contribution of smoking, alcohol, and sleeping hours on AMD by altered expression of IER-3, HTRA1, B3GALTL, LIPC and TIMP3 as compared to normal levels. Contrast estimate supports the gender polarization phenomenon in AMD by significant decreased expression of SLC16A8 and LIPC in control population which was found to be unaltered in AMD patients. The smoking, food habits and duration of night sleeping hours also contributed in AMD progression as evident from multinomial regression analysis. Predicted model (prediction estimate = 86.7%) also indicated the crucial role of night sleeping hours along with the decreased expression of TIMP-3, IER3 and SLC16A8. Results revealed an unambiguous role of environmental factors in AMD progression mediated by various regulatory proteins which might result in intermittent AMD phenotypes and possibly influence the outcome of anti-VEGF treatment.	[Sharma, Kaushal; Anand, Akshay] Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India; [Sharma, Kaushal] Post Grad Inst Med Educ & Res, Adv Pediat Ctr, Dept Pediat, Chandigarh, India; [Singh, Ramandeep] Post Grad Inst Med Educ & Res, Dept Ophthalmol, Chandigarh, India; [Sharma, Suresh Kumar] Panjab Univ, Dept Stat, Chandigarh, India	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Panjab University	Anand, A (corresponding author), Post Grad Inst Med Educ & Res, Dept Neurol, Neurosci Res Lab, Chandigarh, India.	akshay1anand@rediffmail.com		Anand, Akshay/0000-0001-9003-3532	Department of Biotechnology, New Delhi, India [BT/PR17550/MED/30/1755/2016]; CSIR-UGC, New Delhi; Indian Council of Medical Research (ICMR), New Delhi, India; Department of Science and Technology (DST), New Delhi, India	Department of Biotechnology, New Delhi, India(Department of Biotechnology (DBT) India); CSIR-UGC, New Delhi(Council of Scientific & Industrial Research (CSIR) - IndiaUniversity Grants Commission, India); Indian Council of Medical Research (ICMR), New Delhi, India(Indian Council of Medical Research (ICMR)); Department of Science and Technology (DST), New Delhi, India(Department of Science & Technology (India))	This study was funded by the Department of Biotechnology, New Delhi, India to AA (No. BT/PR17550/MED/30/1755/2016). We also acknowledge CSIR-UGC, New Delhi for providing fellowship during PhD to KS, Department of Science and Technology (DST), New Delhi, India and Indian Council of Medical Research (ICMR), New Delhi, India to provide the travel funds to KS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anand A, 2012, EUR J NEUROL, V19, P788, DOI 10.1111/j.1468-1331.2011.03548.x; Anand A, 2007, BEHAV BRAIN RES, V182, P12, DOI 10.1016/j.bbr.2007.04.022; Anand A, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00115; Anand A, 2014, CURR GENOMICS, V15, P266, DOI 10.2174/1389202915666140516204512; Anand A, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/635831; Anand A, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/365046; Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905; Anand A, 2012, CURR ALZHEIMER RES, V9, P1010, DOI 10.2174/156720512803569055; Anand A, 2010, NEUROCHEM RES, V35, P1172, DOI 10.1007/s11064-010-0171-x; Baird PN, 2013, EPIGENOMICS-UK, V5, P239, DOI [10.2217/EPI.13.19, 10.2217/epi.13.19]; Banik A, 2015, J ALZHEIMERS DIS, V47, P815, DOI 10.3233/JAD-150136; Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004; Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241; Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10; English D, 2013, J CELL BIOCHEM, V114, P764, DOI 10.1002/jcb.24436; Fernandez-Robredo P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01862; Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578; Gemenetzi M, 2020, CELL MOL LIFE SCI, V77, P807, DOI 10.1007/s00018-019-03421-w; Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225; Gupta PK, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-114; Khurana RN, 2016, RETINA-J RET VIT DIS, V36, P255, DOI 10.1097/IAE.0000000000000706; Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674; Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13; Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115; Mathur D, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00044; Maugeri A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020159; Maugeri A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7532507; Perez-Canales JL, 2016, OPHTHAL EPIDEMIOL, V23, P20, DOI 10.3109/09286586.2015.1119288; Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2; Sharma K, 2017, J CELL BIOCHEM, V118, P2087, DOI 10.1002/jcb.25837; Sharma K, 2015, ANN NEUROSCI, V22, P232, DOI 10.5214/ans.0972.7531.220408; Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151; Sharma NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193423; Sharma NK, 2014, MOL CELL BIOCHEM, V393, P1, DOI 10.1007/s11010-014-2040-4; Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193; Sharma NK, 2013, DNA CELL BIOL, V32, P549, DOI 10.1089/dna.2013.2072; Sharma NK, 2013, GENE, V523, P106, DOI 10.1016/j.gene.2013.03.052; Sharma NK, 2012, CURR NEUROVASC RES, V9, P256; Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786; Singh T, 2012, STEM CELLS DEV, V21, P448, DOI 10.1089/scd.2011.0002; Takeuchi A, 2009, INVEST OPHTH VIS SCI, V50, P3410, DOI 10.1167/iovs.08-2299; Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147; Venza I, 2012, AGING CLIN EXP RES, V24, P530, DOI 10.3275/8477; Wang Yupeng, 2010, BMC Res Notes, V3, P117, DOI 10.1186/1756-0500-3-117; Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013; Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005; Winkler TW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194321; Zhou JN, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15512-5	48	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	6							e0248523	10.1371/journal.pone.0248523	http://dx.doi.org/10.1371/journal.pone.0248523			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SL3JC	34061866	Green Published, gold			2023-01-03	WOS:000656813600020
J	Soar, J; Becker, LB; Berg, KM; Einav, S; Ma, QB; Olasveengen, TM; Paal, P; Parr, MJA				Soar, Jasmeet; Becker, Lance B.; Berg, Katherine M.; Einav, Sharon; Ma, Qingbian; Olasveengen, Theresa M.; Paal, Peter; Parr, Michael J. A.			Cardiopulmonary resuscitation in special circumstances	LANCET			English	Review							HOSPITAL CARDIAC-ARREST; EXTRACORPOREAL LIFE-SUPPORT; PULMONARY-EMBOLISM; VENTRICULAR-FIBRILLATION; ACCIDENTAL HYPOTHERMIA; CHEST COMPRESSIONS; GUIDELINES; SURVIVAL; MANAGEMENT; OUTCOMES	Cardiopulmonary resuscitation prioritises treatment for cardiac arrests from a primary cardiac cause, which make up the majority of treated cardiac arrests. Early chest compressions and, when indicated, a defibrillation shock from a bystander give the best chance of survival with a good neurological status. Cardiac arrest can also be caused by special circumstances, such as asphyxia, trauma, pulmonary embolism, accidental hypothermia, anaphylaxis, or COVID-19, and during pregnancy or perioperatively. Cardiac arrests in these circumstances represent an increasing proportion of all treated cardiac arrests, often have a preventable cause, and require additional interventions to correct a reversible cause during resuscitation. The evidence for treating these conditions is mostly of low or very low certainty and further studies are needed. Irrespective of the cause, treatments for cardiac arrest are time sensitive and most effective when given early-every minute counts.	[Soar, Jasmeet] North Bristol NHS Trust, Southmead Hosp, Anaesthesia & Intens Care Med, Bristol, Avon, England; [Becker, Lance B.] Northwell Hlth, Zucker Sch Med Hofstra Northwell, Emergency Med, New Hyde Pk, NY USA; [Berg, Katherine M.] Ctr Resuscitat Sci, Boston, MA USA; [Einav, Sharon] Shaare Zedek Med Ctr, Surg Intens Care, Jerusalem, Israel; [Ma, Qingbian] Peking Univ Third Hosp, Emergency Med, Beijing, Peoples R China; [Olasveengen, Theresa M.] Univ Oslo, Div Emergencies & Crit Care, Oslo, Norway; [Paal, Peter] St John God Hosp, Anaesthesiol & Intens Care, Salzburg, Austria; [Parr, Michael J. A.] Univ New South Wales, Liverpool Univ Hosp, Intens Care, Sydney, NSW, Australia; [Parr, Michael J. A.] Macquarie Univ, Macquarie Univ Hosp, Sydney, NSW, Australia	North Bristol NHS Trust; Southmead Hospital; Northwell Health; Hebrew University of Jerusalem; Shaare Zedek Medical Center; University of Oslo; University of New South Wales Sydney; Macquarie University	Soar, J (corresponding author), North Bristol NHS Trust, Southmead Hosp, Bristol BS10 5NB, Avon, England.	jasmeet.soar@nbt.nhs.uk	Soar, Jasmeet/HGA-2279-2022	Soar, Jasmeet/0000-0001-5970-6073; Parr, Michael/0000-0003-3507-474X; Paal, Peter/0000-0002-2939-4782				Aagaard R, 2018, RESUSCITATION, V133, P137, DOI 10.1016/j.resuscitation.2018.10.008; Aagaard R, 2017, CRIT CARE MED, V45, pE695, DOI 10.1097/CCM.0000000000002334; Alqahtani F, 2019, TEX HEART I J, V46, P172, DOI 10.14503/THIJ-18-6751; Alqahtani S, 2020, RESUSCITATION, V155, P125, DOI 10.1016/j.resuscitation.2020.07.016; Andersen LW, 2018, RESUSCITATION, V125, P79, DOI 10.1016/j.resuscitation.2018.02.006; Balki M, 2017, ANESTH ANALG, V124, P890, DOI 10.1213/ANE.0000000000001877; Beckett VA, 2017, BJOG-INT J OBSTET GY, V124, P1374, DOI 10.1111/1471-0528.14521; Bottiger BW, 2008, NEW ENGL J MED, V359, P2651, DOI 10.1056/NEJMoa070570; Bougouin W, 2016, CIRCULATION, V134, P2125, DOI 10.1161/CIRCULATIONAHA.116.024746; Brown DJA, 2012, NEW ENGL J MED, V367, P1930, DOI 10.1056/NEJMra1114208; Cardona V, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100472; Carlson JN, 2020, CUREUS, V12, DOI 10.7759/cureus.11401; Chen N, 2018, RESUSCITATION, V130, P33, DOI 10.1016/j.resuscitation.2018.06.024; Choi J, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012809; Constant AL, 2017, INTENS CARE MED, V43, P485, DOI 10.1007/s00134-017-4709-0; Darocha T, 2020, J CARDIOTHOR VASC AN, V34, P365, DOI 10.1053/j.jvca.2019.07.152; de Charentenay L, 2020, CHEST, V158, P2404, DOI 10.1016/j.chest.2020.07.064; Delgado C, 2020, INT J OBSTET ANESTH, V43, P31, DOI 10.1016/j.ijoa.2020.05.003; Dennis AT, 2018, ANAESTHESIA, V73, P1345, DOI 10.1111/anae.14418; Dennis M, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016521; Dodd A, 2021, RESUSCITATION, V163, P86, DOI 10.1016/j.resuscitation.2021.04.010; Edelson DP, 2020, CIRCULATION, V141, pE933, DOI 10.1161/CIRCULATIONAHA.120.047463; Einav S, 2012, RESUSCITATION, V83, P1191, DOI 10.1016/j.resuscitation.2012.05.005; Endo A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03259-w; Fielding-Singh V, 2020, ANESTH ANALG, V130, P627, DOI 10.1213/ANE.0000000000004477; Frei C, 2019, RESUSCITATION, V137, P41, DOI 10.1016/j.resuscitation.2019.02.001; Fujimoto Y, 2020, THER HYPOTHERMIA TEM, V10, P159, DOI 10.1089/ther.2019.0017; Gabrielli S, 2019, J ALLER CL IMM-PRACT, V7, P2232, DOI 10.1016/j.jaip.2019.04.018; Gaspari R, 2016, RESUSCITATION, V109, P33, DOI 10.1016/j.resuscitation.2016.09.018; Gordon L, 2015, RESUSCITATION, V90, P46, DOI 10.1016/j.resuscitation.2015.02.017; Harper NJN, 2018, BRIT J ANAESTH, V121, P159, DOI 10.1016/j.bja.2018.04.014; Harper NJN, 2020, BRIT J ANAESTH, V124, P234, DOI 10.1016/j.bja.2019.11.005; Hayek SS, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3513; HOFFMAN CE, 1946, AM J PHYSIOL, V145, P685, DOI 10.1152/ajplegacy.1946.145.5.685; Javaudin F, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2672-6; Javaudin F, 2019, CHEST, V156, P1167, DOI 10.1016/j.chest.2019.07.015; KHALIFA A, AM J EMERG MED, V43, P83; Khan AJ, 2020, AM J CARDIOL, V130, P78, DOI 10.1016/j.amjcard.2020.06.019; Koga FA, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001465; Konstantinides SV, 2019, EUR HEART J, V40, P3453, DOI 10.1093/eurheartj/ehz726; Lascarrou JB, 2019, NEW ENGL J MED, V381, P2327, DOI 10.1056/NEJMoa1906661; Lee SY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194921; Lim ZJ, 2020, RESUSCITATION, V157, P248, DOI 10.1016/j.resuscitation.2020.10.025; Lipowicz AA, 2018, RESUSCITATION, V132, P127, DOI 10.1016/j.resuscitation.2018.09.003; Lott C, 2021, RESUSCITATION, V161, P152, DOI 10.1016/j.resuscitation.2021.02.011; Maurin O, 2019, RESUSCITATION, V135, P205, DOI 10.1016/j.resuscitation.2018.11.001; MBRRACE-UK, 2020, SAVING LIVES IMPROVI; McDonald R, 2016, ADDICTION, V111, P1177, DOI 10.1111/add.13326; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Moitra VK, 2018, ANESTH ANALG, V126, P876, DOI 10.1213/ANE.0000000000002596; Naoum EE, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.016072; Nolan JP, 2020, RESUSCITATION, V153, P45, DOI 10.1016/j.resuscitation.2020.06.001; Nolan JP, 2021, EMERG MED J, V38, P798, DOI 10.1136/emermed-2020-209627; Nolan JP, 2021, INTENS CARE MED, V47, P369, DOI 10.1007/s00134-021-06368-4; Nowadly CD, 2020, JACEP OPEN, V1, P737, DOI 10.1002/emp2.12241; O'Malley TJ, 2020, RESUSCITATION, V146, P132, DOI 10.1016/j.resuscitation.2019.11.018; Paal P, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0303-7; Panchal AR, 2020, CIRCULATION, V142, pS366, DOI 10.1161/CIR.0000000000000916; Pasquier M, 2018, RESUSCITATION, V126, P58, DOI 10.1016/j.resuscitation.2018.02.026; Pasquier M, 2014, HIGH ALT MED BIOL, V15, P58, DOI 10.1089/ham.2013.1085; Perkins GD, 2015, CIRCULATION, V132, P1286, DOI 10.1161/CIR.0000000000000144; Podsiadlo P, 2021, ARTIF ORGANS, V45, P222, DOI 10.1111/aor.13818; Ramachandran SK, 2013, ANESTHESIOLOGY, V119, P1322, DOI 10.1097/ALN.0b013e318289bafe; Rousseau H, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e06574; Ruttmann E, 2007, J THORAC CARDIOV SUR, V134, P594, DOI 10.1016/j.jtcvs.2007.03.049; Saczkowski RS, 2018, RESUSCITATION, V127, P51, DOI 10.1016/j.resuscitation.2018.03.028; Sandroni C, 2018, RESUSCITATION, V132, P73, DOI 10.1016/j.resuscitation.2018.08.018; Shah P, 2021, CRIT CARE MED, V49, P201, DOI 10.1097/CCM.0000000000004736; Shinozaki K, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007721; Soar J, 2021, RESUSCITATION, V161, P115, DOI 10.1016/j.resuscitation.2021.02.010; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Uray T, 2018, CRIT CARE MED, V46, pE508, DOI 10.1097/CCM.0000000000003070; Wanscher M, 2012, RESUSCITATION, V83, P1078, DOI 10.1016/j.resuscitation.2012.05.009; Watts S, 2019, RESUSCITATION, V140, P37, DOI 10.1016/j.resuscitation.2019.04.048; Wilson MH, 2016, RESUSCITATION, V105, P52, DOI 10.1016/j.resuscitation.2016.05.007; Wilson N, 2020, MMWR-MORBID MORTAL W, V69, P290, DOI 10.15585/mmwr.mm6911a4; Wu CJ, 2013, AM J EMERG MED, V31, P1690, DOI 10.1016/j.ajem.2013.08.017; Yannopoulos D, 2020, LANCET, V396, P1807, DOI 10.1016/S0140-6736(20)32338-2; Zelop CM, 2018, RESUSCITATION, V132, P17, DOI 10.1016/j.resuscitation.2018.08.029; Zhang Y, 2015, CHINESE MED J-PEKING, V128, P1643, DOI 10.4103/0366-6999.158340	80	2	4	4	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	2021	398	10307					1257	1268		10.1016/S0140-6736(21)01257-5	http://dx.doi.org/10.1016/S0140-6736(21)01257-5		SEP 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC6VF	34454688				2023-01-03	WOS:000704393000024
J	Pisetsky, DS				Pisetsky, David S.			Some disease-modifying osteoarthritis drugs make small improvements in knee and hip osteoarthritis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Pisetsky, David S.] Duke Univ, Med Ctr, Durham, NC 27708 USA	Duke University	Pisetsky, DS (corresponding author), Duke Univ, Med Ctr, Durham, NC 27708 USA.							Hochberg MC, 2016, ARTHRITIS RHEUMATOL, V68, P382, DOI 10.1002/art.39492; Karsdal MA, 2016, OSTEOARTHR CARTILAGE, V24, P2013, DOI 10.1016/j.joca.2016.07.017; Kraus VB, 2011, OSTEOARTHR CARTILAGE, V19, P515, DOI 10.1016/j.joca.2010.08.019; Robinson WH, 2016, NAT REV RHEUMATOL, V12, P580, DOI 10.1038/nrrheum.2016.136	4	1	1	2	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP	2021	174	9					JC104	JC104		10.7326/ACPJ202109210-104	http://dx.doi.org/10.7326/ACPJ202109210-104			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA5GQ	34487443				2023-01-03	WOS:000720675500011
J	[Anonymous]				[Anonymous]			Summary for Patients: Treating Pain in Adults With Sickle Cell Disease in an Infusion Center Versus the Emergency Department	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP	2021	174	9					I14	I14		10.7326/P21-0005	http://dx.doi.org/10.7326/P21-0005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA5GQ	34224269				2023-01-03	WOS:000720675500016
J	Seyoum, T; Alemayehu, M; Christensson, K; Lindgren, H				Seyoum, Tewodros; Alemayehu, Mekuriaw; Christensson, Kyllike; Lindgren, Helena			Provider-perceived benefits and constraints of complete adherence to antenatal care guideline among public health facilities, Ethiopia: A qualitative study	PLOS ONE			English	Article							CLINICAL-PRACTICE GUIDELINES; IMPLEMENTATION; FACILITATORS; PERFORMANCE; IMPROVEMENT; KNOWLEDGE; BARRIERS; PROGRAM	Background In Ethiopia, health care providers' level of adherence to the national Antenatal Care (ANC) guideline is relatively low. The reasons why they do not follow the guidelines are not well known. Therefore, this study aimed to explore the provider-perceived benefits and constraints associated with using the guideline for ANC in public health facilities in Gondar town. Methods A qualitative study was conducted using a semi-structured interview guide. The interview was conducted among a purposive sample of nine health care providers working in four public health facilities in Gondar town. After the interviews were transcribed and coded, a content analysis was done using Atlas ti version 7.5 software packages. Result Decreasing provider's workload and maximizing performance, improving safe motherhood, and improving the process of service delivery were reported as the perceived benefits of following ANC guideline. Organizational problems, care providers' existing knowledge, attitude, and skills and availability of training and mentorship were the three main identified groups of factors that hinder complete providers' adherence to ANC guideline. Conclusion Although providers acknowledged the benefits of following ANC guideline, the guideline is not fully implemented. Refresher training should be given at the start of the updated eight-contact ANC guideline and continuing education and supervision throughout the implementation process. Health care providers call for profound and urgent revisions of the supply chain system for supplies and equipment.	[Seyoum, Tewodros] Univ Gondar, Sch Midwifery, Coll Med Hlth Sci, Gondar, Ethiopia; [Alemayehu, Mekuriaw] Univ Gondar, Inst Publ Hlth, Dept Environm Hlth, Gondar, Ethiopia; [Christensson, Kyllike; Lindgren, Helena] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden	University of Gondar; University of Gondar; Karolinska Institutet	Seyoum, T (corresponding author), Univ Gondar, Sch Midwifery, Coll Med Hlth Sci, Gondar, Ethiopia.	tedysha@gmail.com		Seyoum, Tewodros/0000-0002-9915-6368				Abrahamson KA, 2012, AM J NURS, V112, P26, DOI 10.1097/01.NAJ.0000415957.46932.bf; Alam A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1697-2; Alemayehu T., 2010, ETHIOP J HEALTH DEV, V24; Ameh CA, 2019, HEALTH POLICY PLANN, V34, P257, DOI 10.1093/heapol/czz028; Amoakoh-Coleman M, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1167-6; Amoakoh-Coleman M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157542; Aniebue UU, 2011, HEALTH POLICY PLANN, V26, P423, DOI 10.1093/heapol/czq073; Bergen N, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4596-x; Biza A, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0625-x; Bommer WH, 2005, J ORGAN BEHAV, V26, P733, DOI 10.1002/job.342; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Carroli G, 2001, PAEDIATR PERINAT EP, V15, P1; Davis D, 2003, BMJ-BRIT MED J, V327, P33, DOI 10.1136/bmj.327.7405.33; Desalegn Daniel Melese, 2016, BMC Res Notes, V9, P403, DOI 10.1186/s13104-016-2207-z; Dowswell T, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000934.pub3; Ebben RHA, 2015, EUR J EMERG MED, V22, P199, DOI 10.1097/MEJ.0000000000000133; Ejigu TT., 2018, PLOS ONE, V13, DOI [10.1371/journal.pone, DOI 10.1371/JOURNAL.PONE]; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Ethiopian Federal Ministry of Health, 2010, MAN PROT SEL OBST TO; Ethiopian Public Health Institute, 2019, MIN DEM HLTH SURV 20; Federal Ministry of Health, 2013, ETH BAS EM OBST NEWB; Feyissa GT, 2019, J MULTIDISCIP HEALTH, V12, P989, DOI 10.2147/JMDH.S228951; FMOH, 2010, HLTH SECT DEV PROGR; Green J., 2009, QUALITATIVE METHODS, P304; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Institute of Medicine, 2011, PRACT GUID WE CAN TR; Janssen MAP, 2012, J CLIN NURS, V21, P437, DOI 10.1111/j.1365-2702.2011.03921.x; Jones SA, 2016, NURS EDUC TODAY, V41, P24, DOI 10.1016/j.nedt.2016.03.018; Jordan Z., 2016, J BRIGGS I, P1; Jun J, 2016, INT J NURS STUD, V60, P54, DOI 10.1016/j.ijnurstu.2016.03.006; Lugtenberg M, 2009, QUAL SAF HEALTH CARE, V18, P385, DOI 10.1136/qshc.2008.028043; Madon T, 2007, SCIENCE, V318, P1728, DOI 10.1126/science.1150009; Ministry of Health, 2013, NAT REPR HLTH STRAT; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Seyoum T, 2020, ETHIOP J HEALTH SCI, V30, P903, DOI 10.4314/ejhs.v30i6.8; Sinuff T, 2007, CRIT CARE MED, V35, P2083, DOI 10.1097/01.ccm.0000281446.15342.74; Tang JH, 2016, INT J GYNECOL OBSTET, V132, P240, DOI 10.1016/j.ijgo.2015.06.062; Tegegne TK, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2550-x; Thomas DR, 2006, AM J EVAL, V27, P237, DOI 10.1177/1098214005283748; Tuncalp O, 2017, BJOG-INT J OBSTET GY, V124, P860, DOI 10.1111/1471-0528.14599; United Nations Population Fund, 2014, INV MIDW STOR ETH; Vasan A, 2017, HEALTH POLICY PLANN, V32, P437, DOI 10.1093/heapol/czw144; Villadsen SF, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1708-3; Villadsen SF, 2014, J ENVIRON PUBLIC HEA, V2014, DOI 10.1155/2014/945164; WHO, 2016, STANDARDS IMPROVING; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; World Health Organization, 2002, ANT CAR RAND TRIAL M	47	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2021	16	8							e0255297	10.1371/journal.pone.0255297	http://dx.doi.org/10.1371/journal.pone.0255297			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UA6JQ	34370765	Green Submitted, Green Published, gold			2023-01-03	WOS:000685266800005
J	Goligher, EC; Bradbury, CA; McVerry, BJ; Lawler, PR; Berger, JS; Gong, MN; Carrier, M; Reynolds, HR; Kumar, A; Turgeon, AF; Kornblith, LZ; Kahn, SR; Marshall, JC; Kim, KS; Houston, BL; Derde, LPG; Cushman, M; Tritschler, T; Angus, DC; Godoy, LC; McQuilten, Z; Kirwan, BA; Farkouh, ME; Brooks, MM; Lewis, RJ; Berry, LR; Lorenzi, E; Gordon, AC; Berry, SM; McArthur, CJ; Neal, MD; Hochman, JS; Webb, SA; Zarychanski, R; Ahuja, T; Al-Beidh, F; Annane, D; Arabi, YM; Aryal, D; Kreuziger, LB; Beane, A; Bhimani, Z; Bihari, S; Billett, HH; Bond, L; Bonten, M; Brunkhorst, F; Buxton, M; Buzgau, A; Castellucci, LA; Chekuri, S; Chen, JT; Cheng, AC; Chkhikvadze, T; Coiffard, B; Contreras, A; Costantini, TW; de Brouwer, S; Detry, MA; Duggal, A; Dzavik, V; Effron, MB; Eng, HF; Escobedo, J; Estcourt, LJ; Everett, BM; Fergusson, DA; Fitzgerald, M; Fowler, RA; Froess, JD; Fu, ZX; Galanaud, JP; Galen, BT; Gandotra, S; Girard, TD; Goodman, AL; Goossens, H; Green, C; Greenstein, YY; Gross, PL; Haniffa, R; Hegde, SM; Hendrickson, CM; Higgins, AM; Hindenburg, AA; Hope, AA; Horowitz, JM; Horvat, CM; Huang, DT; Hudock, K; Hunt, BJ; Husain, M; Hyzy, RC; Jacobson, JR; Jayakumar, D; Keller, NM; Khan, A; Kim, Y; Kindzelski, A; King, AJ; Kornblith, AE; Kutcher, ME; Laffan, MA; Lamontagne, F; Le Gal, G; Leeper, CM; Leifer, ES; Lim, G; Lima, FG; Linstrum, K; Litton, E; Lopez-Sendon, J; Lother, SA; Marten, N; Marinez, AS; Martinez, M; Garcia, EM; Mavromichalis, S; McAuley, DF; McDonald, EG; McGlothlin, A; McGuinness, SP; Middeldorp, S; Montgomery, SK; Mouncey, PR; Murthy, S; Nair, GB; Nair, R; Nichol, AD; Nicolau, JC; Nunez-Garcia, B; Park, JJ; Park, PK; Parke, RL; Parker, JC; Parnia, S; Paul, JD; Pompilio, M; Quigley, JG; Rosenson, RS; Rost, NS; Rowan, K; Santos, FO; Santos, M; Santos, MO; Satterwhite, L; Saunders, CT; Schreiber, J; Schutgens, REG; Seymour, CW; Siegal, DM; Silva, DG; Singhal, AB; Slutsky, AS; Solvason, D; Turner, AM; Van Bentum-Puijk, W; van de Veerdonk, FL; van Diepen, S; Vazquez-Grande, G; Wahid, L; Wareham, V; Widmer, RJ; Wilson, JG; Yuriditsky, E; Zhong, YQ				Goligher, Ewan C.; Bradbury, Charlotte A.; McVerry, Bryan J.; Lawler, Patrick R.; Berger, Jeffrey S.; Gong, Michelle N.; Carrier, Marc; Reynolds, Harmony R.; Kumar, Anand; Turgeon, Alexis F.; Kornblith, Lucy Z.; Kahn, Susan R.; Marshall, John C.; Kim, Keri S.; Houston, Brett L.; Derde, Lennie P. G.; Cushman, Mary; Tritschler, Tobias; Angus, Derek C.; Godoy, Lucas C.; McQuilten, Zoe; Kirwan, Bridget-Anne; Farkouh, Michael E.; Brooks, Maria M.; Lewis, Roger J.; Berry, Lindsay R.; Lorenzi, Elizabeth; Gordon, Anthony C.; Berry, Scott M.; McArthur, Colin J.; Neal, Matthew D.; Hochman, Judith S.; Webb, Steven A.; Zarychanski, Ryan; Ahuja, Tania; Al-Beidh, Farah; Annane, Djillali; Arabi, Yaseen M.; Aryal, Diptesh; Kreuziger, Lisa Baumann; Beane, Abi; Bhimani, Zahra; Bihari, Shailesh; Billett, Henny H.; Bond, Lindsay; Bonten, Marc; Brunkhorst, Frank; Buxton, Meredith; Buzgau, Adrian; Castellucci, Lana A.; Chekuri, Sweta; Chen, Jen-Ting; Cheng, Allen C.; Chkhikvadze, Tamta; Coiffard, Benjamin; Contreras, Aira; Costantini, Todd W.; de Brouwer, Sophie; Detry, Michelle A.; Duggal, Abhijit; Dzavik, Vladimir; Effron, Mark B.; Eng, Heather F.; Escobedo, Jorge; Estcourt, Lise J.; Everett, Brendan M.; Fergusson, Dean A.; Fitzgerald, Mark; Fowler, Robert A.; Froess, Joshua D.; Fu, Zhuxuan; Galanaud, Jean P.; Galen, Benjamin T.; Gandotra, Sheetal; Girard, Timothy D.; Goodman, Andrew L.; Goossens, Herman; Green, Cameron; Greenstein, Yonatan Y.; Gross, Peter L.; Haniffa, Rashan; Hegde, Sheila M.; Hendrickson, Carolyn M.; Higgins, Alisa M.; Hindenburg, Alexander A.; Hope, Aluko A.; Horowitz, James M.; Horvat, Christopher M.; Huang, David T.; Hudock, Kristin; Hunt, Beverley J.; Husain, Mansoor; Hyzy, Robert C.; Jacobson, Jeffrey R.; Jayakumar, Devachandran; Keller, Norma M.; Khan, Akram; Kim, Yuri; Kindzelski, Andrei; King, Andrew J.; Kornblith, Aaron E.; Kutcher, Matthew E.; Laffan, Michael A.; Lamontagne, Francois; Le Gal, Gregoire; Leeper, Christine M.; Leifer, Eric S.; Lim, George; Lima, Felipe Gallego; Linstrum, Kelsey; Litton, Edward; Lopez-Sendon, Jose; Lother, Sylvain A.; Marten, Nicole; Marinez, Andrea Saud; Martinez, Mary; Garcia, Eduardo Mateos; Mavromichalis, Stavroula; McAuley, Daniel F.; McDonald, Emily G.; McGlothlin, Anna; McGuinness, Shay P.; Middeldorp, Saskia; Montgomery, Stephanie K.; Mouncey, Paul R.; Murthy, Srinivas; Nair, Girish B.; Nair, Rahul; Nichol, Alistair D.; Nicolau, Jose C.; Nunez-Garcia, Brenda; Park, John J.; Park, Pauline K.; Parke, Rachael L.; Parker, Jane C.; Parnia, Sam; Paul, Jonathan D.; Pompilio, Mauricio; Quigley, John G.; Rosenson, Robert S.; Rost, Natalia S.; Rowan, Kathryn; Santos, Fernanda O.; Santos, Marlene; Santos, Mayler O.; Satterwhite, Lewis; Saunders, Christina T.; Schreiber, Jake; Schutgens, Roger E. G.; Seymour, Christopher W.; Siegal, Deborah M.; Silva, Delcio G.; Singhal, Aneesh B.; Slutsky, Arthur S.; Solvason, Dayna; Turner, Anne M.; Van Bentum-Puijk, Wilma; van de Veerdonk, Frank L.; van Diepen, Sean; Vazquez-Grande, Gloria; Wahid, Lana; Wareham, Vanessa; Widmer, R. Jay; Wilson, Jennifer G.; Yuriditsky, Eugene; Zhong, Yongqi		REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19. METHODS In an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. RESULTS The trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support-free days was 1 (interquartile range, -1 to 16) among the patients assigned to therapeuticdose anticoagulation and was 4 (interquartile range, -1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio <1.2], 99.9%). The percentage of patients who survived to hospital discharge was similar in the two groups (62.7% and 64.5%, respectively; adjusted odds ratio, 0.84; 95% credible interval, 0.64 to 1.11). Major bleeding occurred in 3.8% of the patients assigned to therapeutic-dose anticoagulation and in 2.3% of those assigned to usual-care pharmacologic thromboprophylaxis. CONCLUSIONS In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis.	[Goligher, Ewan C.; Lawler, Patrick R.; Godoy, Lucas C.; Farkouh, Michael E.; Dzavik, Vladimir; Fowler, Robert A.; Galanaud, Jean P.; Husain, Mansoor; Slutsky, Arthur S.] Univ Toronto, Toronto, ON, Canada; [Goligher, Ewan C.; Husain, Mansoor] Univ Hlth Network, Toronto, ON, Canada; [Lawler, Patrick R.; Godoy, Lucas C.; Farkouh, Michael E.; Dzavik, Vladimir] Univ Hlth Network, Peter Munk Cardiac Ctr, Toronto, ON, Canada; [Bond, Lindsay; Wareham, Vanessa] Ozmosis Res, Toronto, ON, Canada; [Galanaud, Jean P.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Carrier, Marc; Castellucci, Lana A.; Fergusson, Dean A.; Le Gal, Gregoire] Ottawa Hosp Res Inst, Ottawa, ON 105, Canada; [Carrier, Marc; Le Gal, Gregoire] Inst Savoir Montfort, Ottawa, ON, Canada; [Castellucci, Lana A.; Fergusson, Dean A.; Siegal, Deborah M.] Univ Ottawa, Ottawa, ON, Canada; [Kumar, Anand; Houston, Brett L.; Zarychanski, Ryan; Lother, Sylvain A.; Solvason, Dayna; Vazquez-Grande, Gloria] Univ Manitoba, Winnipeg, MB, Canada; [Houston, Brett L.; Zarychanski, Ryan] CancerCare Manitoba, Winnipeg, MB, Canada; [Turgeon, Alexis F.] Univ Laval, Quebec City, PQ, Canada; [Turgeon, Alexis F.] Univ Laval Res Ctr, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada; [Kahn, Susan R.; McDonald, Emily G.] McGill Univ, Montreal, PQ, Canada; [Marshall, John C.; Bhimani, Zahra; Santos, Marlene; Slutsky, Arthur S.] St Michaels Hosp Unity Hlth, Toronto, ON, Canada; [Gross, Peter L.] McMaster Univ, Hamilton, ON, Canada; [Gross, Peter L.] Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada; [Lamontagne, Francois] Univ Sherbrooke, Sherbrooke, PQ, Canada; [Marten, Nicole] St Boniface Gen Hosp, Winnipeg, MB, Canada; [Murthy, Srinivas] Univ British Columbia, Vancouver, BC, Canada; [van Diepen, Sean] Univ Alberta, Edmonton, AB, Canada; [Bradbury, Charlotte A.] Univ Bristol, Bristol, Avon, England; [Bradbury, Charlotte A.] Univ Hosp Bristol, Bristol, Avon, England; [Bradbury, Charlotte A.] Weston NHS Fdn Trust, Bristol, Avon, England; [Kirwan, Bridget-Anne] London Sch Hyg & Trop Med, London, England; [Gordon, Anthony C.; Al-Beidh, Farah; Laffan, Michael A.] Imperial Coll London, London, England; [Gordon, Anthony C.] Imperial Coll Healthcare NHS Trust, St Marys Hosp, London, England; [Haniffa, Rashan] Univ Coll London Hosp, London, England; [Hunt, Beverley J.] Kings Healthcare Partners, London, England; [Mouncey, Paul R.; Rowan, Kathryn] Intens Care Natl Audit & Res Ctr ICNARC, London, England; [McAuley, Daniel F.] Queens Univ Belfast, Belfast, Antrim, North Ireland; [McAuley, Daniel F.] Royal Victoria Hosp, Belfast, Antrim, North Ireland; [Beane, Abi; Estcourt, Lise J.] Univ Oxford, Oxford, England; [Estcourt, Lise J.; Mavromichalis, Stavroula] NHS Blood & Transplant, Oxford, England; [McVerry, Bryan J.; Angus, Derek C.; Brooks, Maria M.; Neal, Matthew D.; Eng, Heather F.; Froess, Joshua D.; Fu, Zhuxuan; Huang, David T.; King, Andrew J.; Leeper, Christine M.; Linstrum, Kelsey; Martinez, Mary; Montgomery, Stephanie K.; Seymour, Christopher W.; Zhong, Yongqi] Univ Pittsburgh, Pittsburgh, PA USA; [McVerry, Bryan J.; Angus, Derek C.; Neal, Matthew D.; Linstrum, Kelsey] Univ Pittsburgh Med Ctr, Pittsburgh, PA USA; [Girard, Timothy D.] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA USA; [Horvat, Christopher M.] Univ Pittsburgh Med Ctr, Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Berger, Jeffrey S.; Reynolds, Harmony R.; Hochman, Judith S.; Chkhikvadze, Tamta; Contreras, Aira; Keller, Norma M.; Mavromichalis, Stavroula; Parnia, Sam] NYU, NYU Grossman Sch Med, New York, NY USA; [Ahuja, Tania; Chkhikvadze, Tamta; Contreras, Aira; Horowitz, James M.; Yuriditsky, Eugene] NYU Langone Hlth, NYU Langone Hosp, New York, NY USA; [Keller, Norma M.] Bellevue Hosp, New York, NY USA; [Rosenson, Robert S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Rosenson, Robert S.] Mt Sinai Heart, New York, NY USA; [Gong, Michelle N.; Billett, Henny H.; Chekuri, Sweta; Chen, Jen-Ting; Chkhikvadze, Tamta; Hope, Aluko A.; Nair, Rahul] Montefiore Med Ctr Bronx, Bronx, NY USA; [Gong, Michelle N.; Billett, Henny H.; Galen, Benjamin T.; Hope, Aluko A.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Hindenburg, Alexander A.] NYU Langone Long Isl, Mineola, NY USA; [Kornblith, Lucy Z.; Hendrickson, Carolyn M.; Kornblith, Aaron E.; Nunez-Garcia, Brenda; Park, John J.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, San Francisco, CA 94143 USA; [Lewis, Roger J.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA; [Buxton, Meredith] Global Coalit Adapt Res, Los Angeles, CA USA; [Lim, George] Univ Calif Los Angeles, Los Angeles, CA USA; [Costantini, Todd W.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; [Wilson, Jennifer G.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Kim, Keri S.; Jacobson, Jeffrey R.; Quigley, John G.] Univ Illinois, Chicago, IL USA; [Paul, Jonathan D.] Univ Chicago, Chicago, IL 60637 USA; [Schreiber, Jake] Chartis Grp, Chicago, IL USA; [Derde, Lennie P. G.; Bonten, Marc; Schutgens, Roger E. G.; Van Bentum-Puijk, Wilma] Univ Utrecht, Univ Med Ctr Utrecht, Utrecht, Netherlands; [Schutgens, Roger E. G.] Univ Utrecht, Utrecht, Netherlands; [Middeldorp, Saskia; van de Veerdonk, Frank L.] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands; [Cushman, Mary] Univ Vermont, Larner Coll Med, Burlington, VT USA; [Tritschler, Tobias] Univ Bern, Bern Univ Hosp, Inselspital, Bern, Switzerland; [Kirwan, Bridget-Anne; de Brouwer, Sophie] SOCAR Res, Nyon, Switzerland; [Godoy, Lucas C.; Lima, Felipe Gallego; Nicolau, Jose C.] Univ Sao Paulo, Hosp Clin, Fac Med, Inst Coracao, Sao Paulo, Brazil; [Marinez, Andrea Saud] Avanti Pesquisa Clin, Sao Paulo, Brazil; [Santos, Fernanda O.] Hosp 9 Julho, Sao Paulo, Brazil; [Pompilio, Mauricio] Hosp Coracao Mato Grosso, Campo Grande, MS, Brazil; [Pompilio, Mauricio] Univ Fed Mato Grosso, Campo Grande, MS, Brazil; [Silva, Delcio G.] Hosp Univ Maria Aparecida Pedrossia, Campo Grande, MS, Brazil; [Silva, Delcio G.] Hosp Unimed Campo Grande, Campo Grande, MS, Brazil; [Santos, Mayler O.] Clin Res Ctr, Inst Goiano Oncol & Hematol, Goiania, Go, Brazil; [McQuilten, Zoe; McArthur, Colin J.; Webb, Steven A.; Buzgau, Adrian; Green, Cameron; Higgins, Alisa M.; McGuinness, Shay P.; Nichol, Alistair D.; Parker, Jane C.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Cheng, Allen C.] Monash Univ, Melbourne, Vic, Australia; [Cheng, Allen C.; Nichol, Alistair D.] Alfred Hlth, Melbourne, Vic, Australia; [Webb, Steven A.; Litton, Edward] St Johns God Subiaco Hosp, Subiaco, WA, Australia; [Bihari, Shailesh] Flinders Univ S Australia, Bedford Pk, SA, Australia; [Litton, Edward] Fiona Stanley Hosp, Perth, WA, Australia; [Lewis, Roger J.; Berry, Lindsay R.; Lorenzi, Elizabeth; Berry, Scott M.; Detry, Michelle A.; Fitzgerald, Mark; McGlothlin, Anna; Saunders, Christina T.] Berry Consultants, Austin, TX USA; [Widmer, R. Jay] Baylor Scott & White Hlth, Temple, TX USA; [McArthur, Colin J.; McGuinness, Shay P.; Parke, Rachael L.] Auckland City Hosp, Auckland, New Zealand; [Parke, Rachael L.] Univ Auckland, Auckland, New Zealand; [McArthur, Colin J.; Turner, Anne M.] Med Res Inst New Zealand, Wellington, New Zealand; [Annane, Djillali] Univ Versailles St QuentinEn Yvelines, Federat Hosp Univ Saclay, Garches, France; [Annane, Djillali] Univ Versailles St Quentin En Yvelines, Raymond Poincare Hosp, Paris Seine Nord Endeavour Personalize Intervent, Garches, France; [Coiffard, Benjamin] Aix Marseille Univ, Marseille, France; [Arabi, Yaseen M.] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia; [Arabi, Yaseen M.] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [Aryal, Diptesh] Nepal Mediciti Hosp, Lalitpur, Nepal; [Aryal, Diptesh] Nepal Intens Care Res Fdn, Kathmandu, Nepal; [Kreuziger, Lisa Baumann] Versiti Blood Res Inst, Milwaukee, WI USA; [Beane, Abi] Natl Intens Care Surveillance NICS Mahidol Oxford, Colombo, Sri Lanka; [Brunkhorst, Frank] Jena Univ Hosp, Jena, Germany; [Duggal, Abhijit] Cleveland Clin, Cleveland, OH 44106 USA; [Hudock, Kristin] Univ Cincinnati, Cincinnati, OH USA; [Effron, Mark B.] Univ Queensland, Ochsner Med Ctr, Ochsner Clin Sch, New Orleans, LA USA; [Escobedo, Jorge; Garcia, Eduardo Mateos] Inst Mexicano Seguro Social, Mexico City, DF, Mexico; [Everett, Brendan M.; Hegde, Sheila M.; Kim, Yuri] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Rost, Natalia S.; Singhal, Aneesh B.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Everett, Brendan M.; Kim, Yuri; Rost, Natalia S.; Singhal, Aneesh B.] Harvard Med Sch, Boston, MA 02115 USA; [Gandotra, Sheetal] Univ Alabama Birmingham, Birmingham, AL USA; [Goodman, Andrew L.] TriStar Centennial Med Ctr, Nashville, TN USA; [Goossens, Herman] Univ Antwerp, Antwerp, Belgium; [Greenstein, Yonatan Y.] Rutgers New Jersey Med Sch, Newark, NJ USA; [Haniffa, Rashan] Univ Oxford, Bangkok, Thailand; [Hyzy, Robert C.; Park, Pauline K.] Univ Michigan, Ann Arbor, MI 48109 USA; [Nair, Girish B.] Beaumont Hlth, Royal Oak, MI USA; [Nair, Girish B.] Oakland Univ, William Beaumont Sch Med, Auburn Hills, MI USA; [Jayakumar, Devachandran] Apollo Special Hosp OMR, Chennai, Tamil Nadu, India; [Khan, Akram] Oregon Hlth & Sci Univ, Portland, OR USA; [Kindzelski, Andrei; Leifer, Eric S.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA; [Kutcher, Matthew E.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Lopez-Sendon, Jose] Univ Autonoma, IdiPaz Res Inst, Madrid, Spain; [Nichol, Alistair D.] Univ Coll Dublin, Dublin, Ireland; [Satterwhite, Lewis] Univ Kansas, Sch Med, Kansas City, KS USA; [Wahid, Lana] Duke Univ Hosp, Durham, NC USA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Peter Munk Cardiac Centre; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Manitoba; CancerCare Manitoba Foundation; Laval University; Laval University; McGill University; McMaster University; McMaster University; University of Sherbrooke; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of British Columbia; University of Alberta; University of Bristol; University of Bristol; University of London; London School of Hygiene & Tropical Medicine; Imperial College London; Imperial College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Intensive Care National Audit & Research Centre; Queens University Belfast; University of Oxford; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; New York University; NYU Langone Medical Center; Bellevue Hospital Center; Icahn School of Medicine at Mount Sinai; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California System; University of California San Diego; Stanford University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; Utrecht University; Utrecht University Medical Center; Utrecht University; Radboud University Nijmegen; University of Vermont; University of Bern; University Hospital of Bern; Universidade de Sao Paulo; Universidade Federal de Mato Grosso; Monash University; Monash University; Flinders University South Australia; Baylor Health Care System; Auckland City Hospital; University of Auckland; Medical Research Institute Of New Zealand; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Aix-Marseille Universite; King Saud Bin Abdulaziz University for Health Sciences; King Saud Bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center (KAIMRC); Friedrich Schiller University of Jena; Cleveland Clinic Foundation; University System of Ohio; University of Cincinnati; Ochsner Health System; University of Queensland; Instituto Mexicano del Seguro Social; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; University of Antwerp; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Oxford; University of Michigan System; University of Michigan; Beaumont Health; Oakland University; Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Mississippi; University of Mississippi Medical Center; Autonomous University of Madrid; University College Dublin; University of Kansas; University of Kansas Medical Center; Duke University	Zarychanski, R (corresponding author), Univ Manitoba, Sect Hematol Oncol, Winnipeg, MB R3E 0V9, Canada.; Zarychanski, R (corresponding author), Univ Manitoba, Sect Crit Care, Winnipeg, MB R3E 0V9, Canada.	rzarychanski@cancercare.mb.ca	King, Andrew Joseph/AAW-5399-2021; Parke, Rachael/AAX-4004-2021; Lim, George/HJG-7477-2022; Veenith, Tonny/A-9948-2010; Bégin, Philippe/AAU-9126-2021; Thiruchelvam, Nirosshan/ABD-2646-2020; Vazquez-Grande, Gloria/GZK-8271-2022; Veenith, Tonny/AAI-3067-2020; Derde, Lennie/AAF-2725-2021; Raithatha, Ajay Hasmukh/AAZ-4697-2021; Neal, Matthew/GMW-5601-2022; Leaf, David/AAO-8977-2021; Tritschler, Tobias/ABH-1772-2021; Khan, Akram/AAB-6446-2022; Tong, Steven/N-2353-2013; Effron, Mark B./P-9300-2015; Gordon, Anthony/A-3472-2012; Dushianthan, Ahilanandan/T-8390-2019; Zhong, Yongqi/J-1670-2017; Zarychanski, Ryan/AAB-6369-2022; Russell, Derek W./X-7040-2019; van de Veerdonk, Frank L/C-7256-2008; fu, zhuxuan/ABB-2107-2021; Middeldorp, Saskia/ABI-8197-2020; Puskarich, Michael/N-7849-2014; Ostermann, Marlies/B-8777-2015; Fysh, Edward/E-2855-2018; Presneill, Jeffrey/B-4894-2012; Summers, Charlotte/A-6973-2012	King, Andrew Joseph/0000-0002-9809-0563; Parke, Rachael/0000-0003-4209-0334; Veenith, Tonny/0000-0002-4125-8804; Thiruchelvam, Nirosshan/0000-0001-5974-3317; Vazquez-Grande, Gloria/0000-0001-5866-1045; Veenith, Tonny/0000-0002-4125-8804; Derde, Lennie/0000-0002-3577-5629; Raithatha, Ajay Hasmukh/0000-0002-9819-2244; Neal, Matthew/0000-0001-8931-6236; Leaf, David/0000-0001-7875-090X; Tritschler, Tobias/0000-0002-8775-0511; Khan, Akram/0000-0003-3091-632X; Tong, Steven/0000-0002-1368-8356; Effron, Mark B./0000-0003-4050-5030; Gordon, Anthony/0000-0002-0419-547X; Dushianthan, Ahilanandan/0000-0002-0165-3359; Zhong, Yongqi/0000-0002-4042-7450; Russell, Derek W./0000-0002-2716-1344; van de Veerdonk, Frank L/0000-0002-1121-4894; fu, zhuxuan/0000-0002-9190-195X; Middeldorp, Saskia/0000-0002-1006-6420; Hunt, Beverley Jane/0000-0002-4709-0774; Lamontagne, Francois/0000-0002-0360-3427; Dark, Paul/0000-0003-3309-0164; Puskarich, Michael/0000-0001-6358-4670; Ostermann, Marlies/0000-0001-9500-9080; Rogers, Angela/0000-0001-6969-6200; Lurie, Fedor/0000-0003-0644-0560; Young, Paul/0000-0002-3428-3083; Chkhikvadze, Tamta/0000-0002-1476-2415; Duffy, Eamon/0000-0002-4515-5116; Puxty, Kathryn/0000-0002-5742-6171; Turner, Anne/0000-0002-4092-1424; Bannard-Smith, Jonathan/0000-0001-7120-480X; Shekar, Kiran/0000-0002-1239-7514; Beane, Abigail/0000-0001-7046-1580; McGlothlin, Anna/0000-0002-9079-6166; Gandotra, Sheetal/0000-0002-5475-9704; Jhanji, Shaman/0000-0002-1116-628X; Douglas, Ivor/0000-0002-4541-1431; Coiffard, Benjamin/0000-0002-8896-5346; Husain, Mansoor/0000-0002-3740-6739; Nichol, Alistair/0000-0002-4689-1238; Fysh, Edward/0000-0003-1126-3773; McGuinness, Shay/0000-0003-0620-4787; Jia, Shijing/0000-0002-3467-8149; Houston, Brett/0000-0002-8776-4083; Laffan, Michael/0000-0002-8268-3268; Presneill, Jeffrey/0000-0001-7177-7667; Waite, Alicia/0000-0001-8734-994X; Marin-Corral, Judith/0000-0003-1320-4427; Wahid, Lana/0000-0002-2160-3287; Escobedo, Jorge/0000-0003-1942-7402; Yee, Kimberly/0000-0002-3703-1367; Hormis, Anil/0000-0001-5510-7639; Jayakumar, Devachandran/0000-0001-7134-3746; parnia, sam/0000-0002-6158-4404; Murthy, Srinivas/0000-0002-9476-839X; Rowan, Kathryn/0000-0001-8217-5602; Malley, Brian/0000-0002-1731-1046; Summers, Charlotte/0000-0002-7269-2873; Tolppa, Timo/0000-0002-4119-7335; Welters, Ingeborg/0000-0002-3408-8798; Mouncey, Paul/0000-0002-8510-8517; Vodovar, Dominique/0000-0002-8196-5511; Haniffa, Rashan/0000-0002-8288-449X; Estcourt, Lise/0000-0003-4309-9162; Binnie, Alexandra/0000-0003-2969-8177	European Union through FP7-HEALTH-2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium [602525]; Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium [101003589]; Australian National Health and Medical Research Council [APP1101719, APP1116530]; Health Research Council of New Zealand [16/631]; Canadian Institutes of Health Research (Strategy for Patient-Oriented Research Innovative Clinical Trials Program) [158584]; COVID-19 Rapid Research Operating Grant [447335]; U.K. National Institute for Health Research (NIHR); NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland [CTN 2014-012]; Translational Breast Cancer Research Consortium; French Ministry of Health [PHRC-20-0147]; Minderoo Foundation; Amgen; Global Coalition for Adaptive Research; Wellcome Trust [215522]; Canadian Institutes of Health Research [AR7162822]; CancerCare Manitoba Foundation, Victoria General Hospital Foundation; Ontario Ministry of Health; Peter Munk Cardiac Centre; National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) [OTA-20-011]; NIH [1OT2HL156812-01]; NIHR Research Professorship [RP-2015-06-18]; Canada Research Chair-Tier 2; Lyonel G. Israels Research Chair in Hematology (University of Manitoba)	European Union through FP7-HEALTH-2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium; Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Health Research Council of New Zealand(Health Research Council of New Zealand); Canadian Institutes of Health Research (Strategy for Patient-Oriented Research Innovative Clinical Trials Program)(Canadian Institutes of Health Research (CIHR)); COVID-19 Rapid Research Operating Grant; U.K. National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland; Translational Breast Cancer Research Consortium; French Ministry of Health; Minderoo Foundation; Amgen(Amgen); Global Coalition for Adaptive Research; Wellcome Trust(Wellcome Trust); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); CancerCare Manitoba Foundation, Victoria General Hospital Foundation; Ontario Ministry of Health(Ministry of Health and Long-Term Care, Ontario); Peter Munk Cardiac Centre(University of Toronto); National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIHR Research Professorship; Canada Research Chair-Tier 2(Canada Research Chairs); Lyonel G. Israels Research Chair in Hematology (University of Manitoba)	REMAP-CAP was supported by the European Union through FP7-HEALTH-2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium (grant 602525) and the Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium (grant 101003589) and by grants from the Australian National Health and Medical Research Council (APP1101719 and APP1116530), the Health Research Council of New Zealand (16/631), the Canadian Institutes of Health Research (Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant 158584 and COVID-19 Rapid Research Operating Grant 447335), the U.K. National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the UPMC Learning While Doing Program, the Translational Breast Cancer Research Consortium, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation, Amgen, Eisai, the Global Coalition for Adaptive Research, and the Wellcome Trust Innovations Project (215522). The ATTACC platform was supported by grants from the Canadian Institutes of Health Research, LifeArc, Thistledown Foundation, Research Manitoba, CancerCare Manitoba Foundation, Victoria General Hospital Foundation, Ontario Ministry of Health, and the Peter Munk Cardiac Centre. The ACTIV-4a platform was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) and administered through OTA-20-011 and was supported in part by NIH agreement 1OT2HL156812-01. Dr. Goligher is the recipient of an Early Career Investigator award from the Canadian Institutes of Health Research (grant AR7162822). Dr. Gordon is funded by an NIHR Research Professorship (RP-2015-06-18). Dr. Turgeon is funded by a Canada Research Chair-Tier 2. Dr. Zarychanski is the recipient of the Lyonel G. Israels Research Chair in Hematology (University of Manitoba).	Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520; Angus DC, 2020, ANN AM THORAC SOC, V17, P879, DOI 10.1513/AnnalsATS.202003-192SD; Bilaloglu S, 2020, JAMA-J AM MED ASSOC, V324, P799, DOI 10.1001/jama.2020.13372; Godoy LC, 2020, CAN MED ASSOC J, V192, pE1156, DOI 10.1503/cmaj.201240; Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x; Hippensteel JA, 2020, AM J PHYSIOL-LUNG C, V319, pL211, DOI 10.1152/ajplung.00199.2020; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Houston BL, 2020, CLIN TRIALS, V17, P491, DOI 10.1177/1740774520943846; Ionescu F, 2021, EUR J HAEMATOL, V106, P165, DOI 10.1111/ejh.13533; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Lawler PR, 2021, NEW ENGL J MED, V385, P790, DOI 10.1056/NEJMoa2105911; McGlothlin AE, 2018, JAMA-J AM MED ASSOC, V320, P2365, DOI 10.1001/jama.2018.17977; Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888; Nadkarni GN, 2020, J AM COLL CARDIOL, V76, P1815, DOI 10.1016/j.jacc.2020.08.041; National Institute for Health and Care Excellence, 2020, NICE GUIDELINE 1120; Nopp S, 2020, RES PRACT THROMB HAE, V4, P1178, DOI 10.1002/rth2.12439; Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430; Poterucha TJ, 2017, THROMB HAEMOSTASIS, V117, P437, DOI 10.1160/TH16-08-0620; Sadeghipour P, 2021, JAMA-J AM MED ASSOC, V325, P1620, DOI 10.1001/jama.2021.4152; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Smilowitz Nathaniel R, 2021, Eur Heart J, V42, P2270, DOI 10.1093/eurheartj/ehaa1103; Tritschler T, 2020, J THROMB HAEMOST, V18, P2958, DOI 10.1111/jth.15094; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Wijaya I, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620960797; Williamson J, 2021, LANCET HEALTH LONGEV, V2, pE69; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	27	716	720	3	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2021	385	9					777	789		10.1056/NEJMoa2103417	http://dx.doi.org/10.1056/NEJMoa2103417		AUG 2021	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ5BP	34351722	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000683387200001
J	Kingston, T; Tiller, NB; Partington, E; Ahmed, M; Jones, G; Johnson, MI; Callender, NA				Kingston, Thomas; Tiller, Nicholas B.; Partington, Elle; Ahmed, Mukhtar; Jones, Gareth; Johnson, Mark I.; Callender, Nigel A.			Sports safety matting diminishes cardiopulmonary resuscitation quality and increases rescuer perceived exertion	PLOS ONE			English	Article							CHEST COMPRESSION DEPTH; CARDIAC-ARREST; SURVIVAL; MATTRESSES; SURFACES; SUPPORT; IMPACT	Objectives Compliant surfaces beneath a casualty diminish the quality of cardiopulmonary resuscitation (CPR) in clinical environments. To examine this issue in a sporting environment, we assessed chest compression quality and rescuer exertion upon compliant sports safety matting. Methods Twenty-seven advanced life support providers volunteered (13 male/14 female; mass = 79.0 +/- 12.5 kg; stature = 1.77 +/- 0.09 m). Participants performed 5 x 2 min, randomized bouts of continuous chest compressions on a mannequin, upon five surfaces: solid floor; low-compliance matting; low-compliance matting with a backboard; high-compliance matting; high-compliance matting with a backboard. Measures included chest compression depth and rate, percentage of adequate compressions, and rescuer heart rate and perceived exertion. Results Chest compression depth and rate were significantly lower upon high-compliance matting relative to other surfaces (p<0.05). The percentage of adequate compressions (depth >= 50 mm) was lowest upon high-compliance matting (40 +/- 39%) versus low-compliance matting (60 +/- 36%) and low-compliance matting with a backboard (59 +/- 39%). Perceived exertion was significantly greater upon high-compliance matting versus floor, low-compliance matting, and low-compliance matting with a backboard (p<0.05). Conclusion Providers of CPR should be alerted to the detrimental effects of compliant safety matting in a sporting environment and prepare to alter the targeted compression depth and rescuer rotation intervals accordingly.	[Kingston, Thomas] Barnsley Dist Gen Hosp, Dept Anaesthesia & Crit Care, Barnsley, S Yorkshire, England; [Tiller, Nicholas B.] Harbor UCLA Med Ctr, Inst Resp Med & Exercise Physiol, Lundquist Inst Biomed Innovat, Torrance, CA 90509 USA; [Partington, Elle] Newcastle Univ, Newcastle Med Sch, Newcastle Upon Tyne, Tyne & Wear, England; [Ahmed, Mukhtar] Leeds Teaching Hosp, Emergency Med Dept, Leeds, W Yorkshire, England; [Jones, Gareth; Johnson, Mark I.; Callender, Nigel A.] Leeds Beckett Univ, Sch Clin & Appl Sci, Leeds, W Yorkshire, England; [Callender, Nigel A.] Northumbria Specialist Emergency Care Hosp, Dept Anaesthesia, Cramlington, England	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Newcastle University - UK; University of Leeds; Leeds Beckett University	Callender, NA (corresponding author), Leeds Beckett Univ, Sch Clin & Appl Sci, Leeds, W Yorkshire, England.; Callender, NA (corresponding author), Northumbria Specialist Emergency Care Hosp, Dept Anaesthesia, Cramlington, England.	n.callender@leedsbeckett.ac.uk		Tiller, Nicholas/0000-0001-8429-658X	Laerdal Medical UK	Laerdal Medical UK	No financial support was received in relation to this study. Temporary loan of equipment was received from Laerdal Medical UK.	Bircher NG, 2019, ANESTHESIOLOGY, V130, P414, DOI 10.1097/ALN.0000000000002563; Borg G., 2001, PSYCHOLOGICA, V28, P15; de Leva P, 1996, J BIOMECH, V29, P1223, DOI 10.1016/0021-9290(95)00178-6; Drezner JA, 2011, PHYSICIAN SPORTSMED, V39, P114, DOI 10.3810/psm.2011.05.1901; Fabre N, 2013, INT J SPORT PHYSIOL, V8, P263, DOI 10.1123/ijspp.8.3.263; Field RA, 2012, RESUSCITATION, V83, P360, DOI 10.1016/j.resuscitation.2011.07.012; Kiguchi T, 2020, RESUSCITATION, V152, P39, DOI 10.1016/j.resuscitation.2020.02.044; Kiyohara K, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005786; Kramer-Johansen J, 2006, RESUSCITATION, V71, P283, DOI 10.1016/j.resuscitation.2006.05.011; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Marijon E, 2015, AM HEART J, V170, P339, DOI 10.1016/j.ahj.2015.03.022; Marijon E, 2011, CIRCULATION, V124, P672, DOI 10.1161/CIRCULATIONAHA.110.008979; Monsieurs KG, 2012, RESUSCITATION, V83, P1319, DOI 10.1016/j.resuscitation.2012.07.015; Nishisaki A, 2012, RESUSCITATION, V83, P1013, DOI 10.1016/j.resuscitation.2012.01.016; Nishisaki A, 2009, RESUSCITATION, V80, P540, DOI 10.1016/j.resuscitation.2009.02.006; Noordergraaf GJ, 2009, RESUSCITATION, V80, P546, DOI 10.1016/j.resuscitation.2009.03.023; Oh JH, 2016, AM J EMERG MED, V34, P2411, DOI 10.1016/j.ajem.2016.09.006; Perkins GD, 2003, INTENS CARE MED, V29, P2330, DOI 10.1007/s00134-003-2014-6; Smereka J, 2019, CARDIOL J, V26, P769, DOI 10.5603/CJ.a2018.0121; Soppi E, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00074; Torell MF, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211723; Tweed M, 2001, RESUSCITATION, V51, P179, DOI 10.1016/S0300-9572(01)00404-X; Vadeboncoeur T, 2014, RESUSCITATION, V85, P182, DOI 10.1016/j.resuscitation.2013.10.002	25	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2021	16	7							e0254800	10.1371/journal.pone.0254800	http://dx.doi.org/10.1371/journal.pone.0254800			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2OO	34293018	Green Published, gold, Green Accepted			2023-01-03	WOS:000678124900084
J	Dalmau-Bueno, A; Garcia-Altes, A; Amblas, J; Contel, JC; Santaeugenia, S				Dalmau-Bueno, Albert; Garcia-Altes, Anna; Amblas, Jordi; Carles Contel, Joan; Santaeugenia, Sebastia			Determinants of the number of days people in the general population spent at home during end-of-life: Results from a population-based cohort analysis	PLOS ONE			English	Article							PALLIATIVE CARE; PREFERENCES; CANCER	Background The number of days spent at home in the last six months of life has been proposed as a comprehensive indicator of high-value patient-centered care; however, information regarding the determinants of this outcome is scarce, particularly among the general population. We investigated the determinants of spending time at home within the six months preceding death. Methods Population-based, retrospective analysis of administrative databases of the Catalan government. The analysis included adult (>= 18 years) individuals who died in Catalonia (North-east Spain) in 2017 and met the McNamara criteria for palliative care. The primary outcome was the number of days spent at home within the last 180 days of life. Other variables included the cause of death, demographic characteristics, and socioeconomic status, stratified as very low, low, mid, and high level. Results The analysis included 40,137 individuals (19,510 women; 20,627 men), who spent a median of 140 days (IQR 16-171) at home within the six months preceding death (women 140 [16-171]; men 150 [100-171]). Female gender was an independent factor of staying fewer days at home (OR 0.80 [95% CI 0.77-0.82]; p<0.001). Higher socioeconomic levels were significantly associated with an increasing number of days at home in both genders: among women, ORs of the low, middle, and high levels were 1.09 (0.97-1.22), 1.54 (1.36-1.75), and 2.52 (1.69-3.75) (p<0.001), respectively; the corresponding ORs among men were 1.27 (1.12-1.43), 1.56 (1.38-1.77), 2.82 (2.04-3.88) (p<0.001). The presence of dementia was a strong predictor of spending less time at home in women (0.41 (0.38-0.43); p<0.001) and men (0.45 (0.41-0.48); p<0.001). Conclusions Our results suggest that end-of-life care is associated with gender and socioeconomic inequalities; women and individuals with lower socioeconomic status spend less time at home within the last 180 days of life.	[Dalmau-Bueno, Albert; Garcia-Altes, Anna] Catalan Agcy Hlth Qual & Evaluat AQuAS, Barcelona, Spain; [Garcia-Altes, Anna] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain; [Garcia-Altes, Anna] Inst Invest Biomed IIB St Pau, Barcelona, Spain; [Amblas, Jordi; Carles Contel, Joan; Santaeugenia, Sebastia] Univ Vic Cent Univ Catalonia UVIC UCC, Cent Catalonia Chronic Res Grp C3RG, Ctr Hlth & Social Care Res CESS, Vic, Spain; [Amblas, Jordi; Carles Contel, Joan; Santaeugenia, Sebastia] Dept Hlth, Chron Care Program, Barcelona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC)	Amblas, J (corresponding author), Univ Vic Cent Univ Catalonia UVIC UCC, Cent Catalonia Chronic Res Grp C3RG, Ctr Hlth & Social Care Res CESS, Vic, Spain.; Amblas, J (corresponding author), Dept Hlth, Chron Care Program, Barcelona, Spain.	jamblas@chv.cat	Dalmau Bueno, Albert/AFL-6865-2022; Amblàs-Novellas, Jordi/AAB-4651-2019; Dalmau Bueno, Albert/AAG-6970-2022	Amblàs-Novellas, Jordi/0000-0002-2338-3054; Santaeugenia Gonzalez, Sebastia J/0000-0002-2725-4065				Aldridge MD, 2015, AM J PUBLIC HEALTH, V105, P2411, DOI 10.2105/AJPH.2015.302889; Andersen SK, 2019, J ONCOL PRACT, V15, P199, DOI 10.1200/JOP.18.00338; Auriemma CL, 2014, JAMA INTERN MED, V174, P1085, DOI 10.1001/jamainternmed.2014.1183; Barnato AE, 2007, MED CARE, V45, P386, DOI 10.1097/01.mlr.0000255248.79308.41; Bjornelv GMW, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-019-4794-6; Cainzos-Achirica M, 2019, INT J CARDIOL, V277, P250, DOI 10.1016/j.ijcard.2018.10.099; Catalan Health Service, 2020, CENTR POP REG CATSAL; Catalan Health Service, 2017, MIN BAS DAT SET CMBD; Cheung MC, 2020, LEUKEMIA LYMPHOMA, V61, P146, DOI 10.1080/10428194.2019.1654095; Costa V, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0077-8; Farre N, 2016, EUR J HEART FAIL, V18, P1132, DOI 10.1002/ejhf.549; Fernandez E, 1999, J EPIDEMIOL COMMUN H, V53, P218, DOI 10.1136/jech.53.4.218; Garcia-Altes A, 2018, J EPIDEMIOL COMMUN H, V72, P871, DOI 10.1136/jech-2018-210817; Gill TM, 2019, AM J MED, V132, P234, DOI 10.1016/j.amjmed.2018.10.029; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Groff AC, 2016, NEW ENGL J MED, V375, P1610, DOI 10.1056/NEJMp1607206; Higginson I J, 2000, J Palliat Med, V3, P287, DOI 10.1089/jpm.2000.3.287; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; McNamara B, 2006, J PAIN SYMPTOM MANAG, V32, P5, DOI 10.1016/j.jpainsymman.2005.12.018; Murtagh FEM, 2014, PALLIATIVE MED, V28, P49, DOI 10.1177/0269216313489367; Oliver-Parra A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240681; Penders YWH., 2018, TXB PALLIATIVE CARE, DOI [10.1007/978-3-319-31738-0%5F104%26%23x2013%3B1, DOI 10.1007/978-3-319-31738-0%5F104%26%23X2013%3B1]; Scholten N, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0099-2; Searight HR, 2005, AM FAM PHYSICIAN, V71, P515; Sherman FT., 2006, GERIATRICS, P10; WHO, SUSTAINABLE DEV GOAL; World Health Organization. Regional Office for Europe, REG HLTH NETW; World Health Organization (WHO), 2004, PALLIATIVE CARE OLDE; World Health Organization (WHO), 2020, 30 YEAR RETR CAT HLT; Wright AA, 2016, JAMA-J AM MED ASSOC, V315, P284, DOI 10.1001/jama.2015.18604	31	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2021	16	7							e0253483	10.1371/journal.pone.0253483	http://dx.doi.org/10.1371/journal.pone.0253483			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2MX	34264956	Green Published, gold			2023-01-03	WOS:000678120600064
J	King, CR; Abraham, J; Fritz, BA; Cui, ZC; Galanter, W; Chen, YX; Kannampallil, T				King, Christopher Ryan; Abraham, Joanna; Fritz, Bradley A.; Cui, Zhicheng; Galanter, William; Chen, Yixin; Kannampallil, Thomas			Predicting self-intercepted medication ordering errors using machine learning	PLOS ONE			English	Article							PRESCRIPTION ERRORS; ENTRY; EXPLANATIONS; PREVENTION; CARE	Current approaches to understanding medication ordering errors rely on relatively small manually captured error samples. These approaches are resource-intensive, do not scale for computerized provider order entry (CPOE) systems, and are likely to miss important risk factors associated with medication ordering errors. Previously, we described a dataset of CPOE-based medication voiding accompanied by univariable and multivariable regression analyses. However, these traditional techniques require expert guidance and may perform poorly compared to newer approaches. In this paper, we update that analysis using machine learning (ML) models to predict erroneous medication orders and identify its contributing factors. We retrieved patient demographics (race/ethnicity, sex, age), clinician characteristics, type of medication order (inpatient, prescription, home medication by history), and order content. We compared logistic regression, random forest, boosted decision trees, and artificial neural network models. Model performance was evaluated using area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). The dataset included 5,804,192 medication orders, of which 28,695 (0.5%) were voided. ML correctly classified voids at reasonable accuracy; with a positive predictive value of 10%, similar to 20% of errors were included. Gradient boosted decision trees achieved the highest AUROC (0.7968) and AUPRC (0.0647) among all models. Logistic regression had the poorest performance. Models identified predictive factors with high face validity (e.g., student orders), and a decision tree revealed interacting contexts with high rates of errors not identified by previous regression models. Prediction models using order-entry information offers promise for error surveillance, patient safety improvements, and targeted clinical review. The improved performance of models with complex interactions points to the importance of contextual medication ordering information for understanding contributors to medication errors.	[King, Christopher Ryan; Abraham, Joanna; Fritz, Bradley A.; Kannampallil, Thomas] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Abraham, Joanna; Kannampallil, Thomas] Washington Univ, Sch Med, Inst Informat, St Louis, MO 63110 USA; [Cui, Zhicheng; Chen, Yixin] Washington Univ, Dept Comp Sci, McKelvey Sch Engn, St Louis, MO 63130 USA; [Galanter, William] Univ Illinois, Coll Med, Dept Med, Chicago, IL USA; [Galanter, William] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kannampallil, T (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA.; Kannampallil, T (corresponding author), Washington Univ, Sch Med, Inst Informat, St Louis, MO 63110 USA.	thomas.k@wustl.edu		King, Christopher/0000-0002-4574-8616	Agency for Healthcare Research and Quality [R21HS025443]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This project was supported in part by grant (R21HS025443) from the Agency for Healthcare Research and Quality to JA. The content is solely the responsibility of the authors and does not represent the official views of the Agency for Healthcare Research and Quality [https://www.ahrq.gov/].The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham J, 2021, J AM MED INFORM ASSN, V28, P86, DOI 10.1093/jamia/ocaa264; Abraham J, 2018, BMJ QUAL SAF, V27, P299, DOI 10.1136/bmjqs-2017-006606; Ammenwerth E, 2008, J AM MED INFORM ASSN, V15, P585, DOI 10.1197/jamia.M2667; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bates DW, 2000, BRIT MED J, V320, P788, DOI 10.1136/bmj.320.7237.788; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953; Cordero Leandro, 2004, J Perinatol, V24, P88, DOI 10.1038/sj.jp.7211000; Davis J, 2006, P 23 INT C MACH NEW, P233, DOI 10.1145/1143844.1143874; Ghaleb MA, 2006, ANN PHARMACOTHER, V40, P1766, DOI 10.1345/aph.1G717; Hickman TTT, 2018, BMJ QUAL SAF, V27, P293, DOI 10.1136/bmjqs-2017-006597; Hinton G., 2015, NIPS DEEP LEARN REPR; Kannampallil TG, 2017, J AM MED INFORM ASSN, V24, P762, DOI 10.1093/jamia/ocw187; Kingma D. P., 2015, ADAM METHOD STOCHAST, P1520; Korb-Savoldelli V, 2018, INT J MED INFORM, V111, P112, DOI 10.1016/j.ijmedinf.2017.12.022; Kuperman GJ, 2003, ANN INTERN MED, V139, P31, DOI 10.7326/0003-4819-139-1-200307010-00010; Liao XY, 2019, J STAT SOFTW, V89, P1, DOI 10.18637/jss.v089.i05; Liu Y., 2019, CORR; Lundberg S.M., 2018, ARXIV PREPRINT ARXIV; Lundberg SM, 2020, NAT MACH INTELL, V2, P56, DOI 10.1038/s42256-019-0138-9; Lundberg SM, 2018, NAT BIOMED ENG, V2, P749, DOI 10.1038/s41551-018-0304-0; Lundberg Scott M., 2017, ADV NEURAL INFORM PR; Nuckols TK, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-56; Potts AL, 2004, PEDIATRICS, V113, P59, DOI 10.1542/peds.113.1.59; Prgomet M, 2017, J AM MED INFORM ASSN, V24, P413, DOI 10.1093/jamia/ocw145; Qin GS, 2008, STAT METHODS MED RES, V17, P207, DOI 10.1177/0962280207087173; Reckmann MH, 2009, J AM MED INFORM ASSN, V16, P613, DOI 10.1197/jamia.M3050; Schiff GD, 2015, BMJ QUAL SAF, V24, P264, DOI 10.1136/bmjqs-2014-003555; Shawahna R, 2011, J CLIN NURS, V20, P3233, DOI 10.1111/j.1365-2702.2011.03714.x; Springenberg J.T., ARXIV PREPRINT ARXIV; van Doormaal JE, 2009, J AM MED INFORM ASSN, V16, P816, DOI 10.1197/jamia.M3099; van Rosse F, 2009, PEDIATRICS, V123, P1184, DOI 10.1542/peds.2008-1494; Vrbnjak D, 2016, INT J NURS STUD, V63, P162, DOI 10.1016/j.ijnurstu.2016.08.019; Westbrook JI, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001164; Wetterneck TB, 2011, J AM MED INFORM ASSN, V18, P774, DOI 10.1136/amiajnl-2011-000255	35	1	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2021	16	7							e0254358	10.1371/journal.pone.0254358	http://dx.doi.org/10.1371/journal.pone.0254358			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2MK	34260662	gold, Green Published			2023-01-03	WOS:000678119300032
J	Jarrett, BA; Peitzmeier, SM; Restar, A; Adamson, T; Howell, S; Baral, S; Beckham, SW				Jarrett, Brooke A.; Peitzmeier, Sarah M.; Restar, Arjee; Adamson, Tyler; Howell, Sean; Baral, Stefan; Beckham, S. Wilson			Gender-affirming care, mental health, and economic stability in the time of COVID-19: A multi-national, cross-sectional study of transgender and nonbinary people	PLOS ONE			English	Article							UNITED-STATES; GAY; SEX; CONSEQUENCE; EXPERIENCES; DEPRESSION; ANXIETY; RISK	Background Transgender and nonbinary people are disproportionately affected by structural barriers to quality healthcare, mental health challenges, and economic hardship. This study examined the impact of the novel coronavirus disease (COVID-19) crisis and subsequent control measures on gender-affirming care, mental health, and economic stability among transgender and nonbinary people in multiple countries. Methods We collected multi-national, cross-sectional data from 964 transgender and nonbinary adult users of the Hornet and Her apps from April to August 2020 to characterize changes in gender-affirming care, mental health, and economic stability as a result of COVID-19. We conducted Poisson regression models to assess if access to gender-affirming care and ability to live according to one's gender were related to depressive symptoms, anxiety, and changes in suicidal ideation. Results Individuals resided in 76 countries, including Turkey (27.4%, n = 264) and Thailand (20.6%, n = 205). A majority were nonbinary (66.8%, n = 644) or transfeminine (29.4%, n = 283). Due to COVID-19, 55.0% (n = 320/582) reported reduced access to gender-affirming resources, and 38.0% (n = 327/860) reported reduced time lived according to their gender. About half screened positive for depression (50.4%,442/877) and anxiety (45.8%, n = 392/856). One in six (17.0%, n = 112/659) expected losses of health insurance, and 77.0% (n = 724/940) expected income reductions. The prevalence of depressive symptoms, anxiety, and increased suicidal ideation were 1.63 (95% CI: 1.36-1.97), 1.61 (95% CI: 1.31-1.97), and 1.74 (95% CI: 1.07-2.82) times higher for individuals whose access to gender-affirming resources was reduced versus not. Discussion The COVID-19 crisis is associated with reduced access to gender-affirming resources and the ability of transgender and nonbinary people to live according to their gender worldwide. These reductions may drive the increased depressive symptoms, anxiety, and suicidal ideation reported in this sample. To improve health of transgender and nonbinary communities, increased access to gender-affirming resources should be prioritized through policies (e.g., digital prescriptions), flexible interventions (e.g., telehealth), and support for existing transgender health initiatives.	[Jarrett, Brooke A.; Restar, Arjee; Baral, Stefan] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Peitzmeier, Sarah M.] Univ Michigan, Sch Nursing, Dept Hlth Behav & Biol Sci, Ann Arbor, MI 48109 USA; [Adamson, Tyler] Johns Hopkins Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Howell, Sean] Hornet, San Francisco, CA USA; [Beckham, S. Wilson] Johns Hopkins Sch Publ Hlth, Dept Int Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Jarrett, BA (corresponding author), Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.	brooke@jhmi.edu	Baral, Stefan/AAG-4818-2020; Adamson, Tyler/AAR-2314-2020	Baral, Stefan/0000-0002-5482-2419; Adamson, Tyler/0000-0002-9884-5110; Cole, Sam Wilson/0000-0002-9694-3091; Peitzmeier, Sarah/0000-0003-4552-1099	National Institute of Mental Health [F31MH121128, K01MH114715, R01MH110358]; Viiv Healthcare; National Institute of Allergy and Infectious Diseases [T32AI102623]	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Viiv Healthcare; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	BAJ, SWB, and SDB were supported by the National Institute of Mental Health (F31MH121128, K01MH114715, R01MH110358 respectively). SWB also receives funding from Viiv Healthcare. AJR was supported by the National Institute of Allergy and Infectious Diseases (grant T32AI102623). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed SAKS, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003042; Aldridge Robert W, 2020, Wellcome Open Res, V5, P88, DOI [10.12688/wellcomeopenres.15922.1, 10.12688/wellcomeopenres.15922.2]; Andaya LY., 2018, GENDER FOCUS, P64, DOI [10.2307/j.ctvddzn5f, DOI 10.2307/J.CTVDDZN5F]; [Anonymous], 2020, N Engl J Med, V383, P1698, DOI 10.1056/NEJMx200018; [Anonymous], 2020, LANCET GLOB HEALTH, V8, pE737, DOI 10.1016/S2214-109X(20)30228-X; Banthin J, 2020, MAKING SENSE COMPETI; Bouman WP, 2016, SEX RELATSH THER, V31, P359, DOI 10.1080/14681994.2016.1184754; Branstrom R, 2020, AM J PSYCHIAT, V177, P727, DOI 10.1176/appi.ajp.2019.19010080; Bui DP, 2020, MMWR-MORBID MORTAL W, V69, P1133, DOI 10.15585/mmwr.mm6933e3; Casey LS, 2019, HEALTH SERV RES, V54, P1454, DOI 10.1111/1475-6773.13229; Cicero EC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228765; Cook SH, 2013, ARCH SEX BEHAV, V42, P327, DOI 10.1007/s10508-013-0087-z; Costa R, 2016, NEUROPSYCH DIS TREAT, V12, P1953, DOI 10.2147/NDT.S95310; Czeisler ME, 2020, MMWR-MORBID MORTAL W, V69, P1049, DOI [10.1101/2020.04.22.20076141v1, 10.15585/mmwr.mm6932a1]; Defreyne J, 2019, CLIN CHEM, V65, P119, DOI 10.1373/clinchem.2018.288241; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Ettman CK, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.19686; Fish JN, 2020, J ADOLESCENT HEALTH, V67, P450, DOI 10.1016/j.jadohealth.2020.06.002; Gonzales G, 2020, J ADOLESCENT HEALTH, V67, P645, DOI 10.1016/j.jadohealth.2020.08.006; Hale T, 2021, NAT HUM BEHAV, V5, P529, DOI 10.1038/s41562-021-01079-8; Herman JL, 2020, VULNERABILITIES COVI; Hughto JMW, 2015, SOC SCI MED, V147, P222, DOI 10.1016/j.socscimed.2015.11.010; Jarrett B., 2021, ZENODO DIGITAL REPOS, DOI [10.5281/zenodo.4899912, DOI 10.5281/ZENODO.4899912]; Jarrett Brooke A, 2018, Transgend Health, V3, P170, DOI 10.1089/trgh.2018.0017; Josephson A, 2021, NAT HUM BEHAV, V5, P557, DOI 10.1038/s41562-021-01096-7; Khamis M, 2021, EARLY LABOR MARKET I; Kidd JD, 2021, J HOMOSEXUAL, V68, P592, DOI 10.1080/00918369.2020.1868185; Kroenke K, 2009, PSYCHOSOMATICS, V50, P613, DOI 10.1176/appi.psy.50.6.613; Linnemayr S, 2020, JAIDS-J ACQ IMM DEF, V85, pE90, DOI 10.1097/QAI.0000000000002507; Martin-Storey A, 2016, J SEX RES, V53, P85, DOI 10.1080/00224499.2014.980497; Miller M., 2020, JAIDS-J ACQ IMM DEF, DOI [10.1097/QAI.0000000000002490, DOI 10.1097/QAI.0000000000002490]; Millett GA, 2020, ANN EPIDEMIOL, V47, P37, DOI 10.1016/j.annepidem.2020.05.003; Moreno C, 2020, LANCET PSYCHIAT, V7, P813, DOI 10.1016/S2215-0366(20)30307-2; Morning Consult, 2020, COVID 19 IS IMP LGBT; Motmans J., 2020, COVID 19 PANDEMIC AF, DOI [10.1101/2020.12.23.20248794v1.full.pdf, DOI 10.1101/2020.12.23.20248794V1.FULL.PDF]; Motmans J, 2019, INT J TRANSGENDERISM, V20, P119, DOI 10.1080/15532739.2019.1640514; Murad MH, 2010, CLIN ENDOCRINOL, V72, P214, DOI 10.1111/j.1365-2265.2009.03625.x; Newcomb ME, 2020, ARCH SEX BEHAV, V49, P645, DOI 10.1007/s10508-019-01533-9; Nguyen HB, 2018, CURR PSYCHIAT REP, V20, DOI 10.1007/s11920-018-0973-0; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Niles MT, 2020, NUTRIENTS, V12, DOI 10.3390/nu12072096; Peitzmeier S, 2017, CULT HEALTH SEX, V19, P64, DOI 10.1080/13691058.2016.1191675; Peitzmeier SM, 2017, QUAL HEALTH RES, V27, P2138, DOI 10.1177/1049732317725513; Perez-Brumer A, 2020, AIDS BEHAV, V24, P2477, DOI 10.1007/s10461-020-02889-z; Rao A, 2021, JAIDS-J ACQ IMM DEF, V87, P644, DOI 10.1097/QAI.0000000000002620; Reisner SL, 2016, LANCET, V388, P412, DOI 10.1016/S0140-6736(16)00684-X; Restar A., 2020, TRANSGENDER HLTH TRANSGENDER HLTH; Robinson M, 2020, J HOMOSEXUAL, V67, P1675, DOI 10.1080/00918369.2019.1613853; Salari N, 2020, EUR NEUROPSYCHOPHARM, V16, P1, DOI [10.1186/s12992-020-00589, DOI 10.1186/S12992-020-00589-W, DOI 10.1016/j.euroneuro.2021.03.019, 10.1186/s12992-020-00589-w]; Santos GM, 2021, AIDS BEHAV, V25, P311, DOI 10.1007/s10461-020-02969-0; Sevelius JM, 2020, AIDS BEHAV, V24, P2009, DOI 10.1007/s10461-020-02920-3; Sevelius JM, 2013, SEX ROLES, V68, P675, DOI 10.1007/s11199-012-0216-5; Snow A, 2019, HEALTH SOC WORK, V44, P149, DOI 10.1093/hsw/hlz016; StataCorp, 2015, STAT STAT SOFTW REL; U.S. Centers for Disease Control and Prevention, 2020, RED ACC CAR HOUS PUL; United Nations, 2020, UN POL BRIEF COVID 1 UN POL BRIEF COVID 1; Valentine SE, 2018, CLIN PSYCHOL REV, V66, P24, DOI 10.1016/j.cpr.2018.03.003; van der Miesen AIR, 2020, ARCH SEX BEHAV, V49, P1395, DOI 10.1007/s10508-020-01754-3; Vasey PL, 2007, PERSPECT BIOL MED, V50, P481, DOI 10.1353/pbm.2007.0056; Wang YY, 2020, LANCET DIABETES ENDO, V8, P564, DOI 10.1016/S2213-8587(20)30182-0; Wernick JA, 2019, UROL CLIN N AM, V46, P475, DOI 10.1016/j.ucl.2019.07.002; Whittington C., 2020, LIVES LIVELIHOODS MA; Williams DR, 2020, JAMA-J AM MED ASSOC, V323, P2478, DOI 10.1001/jama.2020.8051	63	21	21	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2021	16	7							e0254215	10.1371/journal.pone.0254215	http://dx.doi.org/10.1371/journal.pone.0254215			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TK6YI	34242317	gold, Green Published			2023-01-03	WOS:000674301400163
J	Hasler, RM; Rauer, T; Pape, HC; Zwahlen, M				Hasler, Rebecca M.; Rauer, Thomas; Pape, Hans-Christoph; Zwahlen, Marcel			Inter-hospital transfer of polytrauma and severe traumatic brain injury patients: Retrospective nationwide cohort study using data from the Swiss Trauma Register	PLOS ONE			English	Article							SYSTOLIC BLOOD-PRESSURE; PREHOSPITAL TRIAGE; CENTER CARE; INCREASED MORTALITY; FIELD TRIAGE; 110 MMHG; OVERTRIAGE; AGE; PROTOCOLS; SYSTEMS	Introduction Polytrauma and traumatic brain injury (TBI) patients are among the most vulnerable patients in trauma care and exhibit increased morbidity and mortality. Timely care is essential for their outcome. Severe TBI with initially high scores on the Glasgow Coma (GCS) scores is difficult to recognise on scene and referral to a Major Trauma Center (MTC) might be delayed. Therefore, we examined current referral practice, injury patterns and mortality in these patients. Materials and methods Retrospective, nationwide cohort study with Swiss Trauma Register (STR) data between 01/012015 and 31/12/2018. STR includes patients >= 16 years with an Injury Severity Score (ISS) >15 and/or an Abbreviated Injury Scale (AIS) for head >2. We performed Cox proportional hazard models with injury type as the primary outcome and mortality as the dependent variable. Secondary outcomes were inter-hospital transfer and age. Results 9,595 patients were included. Mortality was 12%. 2,800 patients suffered from isolated TBI. 69% were men. Median age was 61 years and median ISS 21. Two thirds of TBI patients had a GCS of 13-15 on admission to the Emergency Department (ED). 26% of patients were secondarily transferred to an MTC. Patients with isolated TBI and those aged >= 65 years were transferred more often. Crude analysis showed a significantly elevated hazard for death of 1.48 (95%CI 1.28-1.70) for polytrauma patients with severe TBI and a hazard ratio (HR) of 1.82 (95%CI 1.58-2.09) for isolated severe TBI, compared to polytrauma patients without TBI. Patients directly admitted to the MTC had a significantly elevated HR for death of 1.63 (95%CI 1.40-1.89), compared to those with secondary transfer. Conclusions A high initial GCS does not exclude the presence of severe TBI and triage to an MTC should be seriously considered for elderly TBI patients.	[Hasler, Rebecca M.; Rauer, Thomas; Pape, Hans-Christoph] Univ Hosp Zurich, Dept Traumatol, Zurich, Switzerland; [Hasler, Rebecca M.; Zwahlen, Marcel] Bern Univ, Inst Social & Prevent Med ISPM, Bern, Switzerland	University of Zurich; University Zurich Hospital; University of Bern	Hasler, RM (corresponding author), Univ Hosp Zurich, Dept Traumatol, Zurich, Switzerland.; Hasler, RM (corresponding author), Bern Univ, Inst Social & Prevent Med ISPM, Bern, Switzerland.	rebecca.hasler@usz.ch	Zwahlen, Marcel/AFF-8559-2022	Zwahlen, Marcel/0000-0002-6772-6346; Pape, Hans-Christoph/0000-0002-2059-4980; Hasler, Rebecca Maria/0000-0002-0616-2313	Furstlicher Kommerzienrat Guido Feger Foundation	Furstlicher Kommerzienrat Guido Feger Foundation	RMH has received funding from the Furstlicher Kommerzienrat Guido Feger Foundation.	AAAM AAAM, 2008, C ISA ADV AUT MED AB C ISA ADV AUT MED AB; [Anonymous], 2011, GUIDELINES FIELD TRI; [Anonymous], 2014, REGIONAL TRAUMA SYST; Brown J, 2017, SURG CLIN N AM, V97, P961, DOI 10.1016/j.suc.2017.06.007; Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Chang DC, 2008, ARCH SURG-CHICAGO, V143, P776, DOI 10.1001/archsurg.143.8.776; Claridge JA, 2013, SURGERY, V154, P875, DOI 10.1016/j.surg.2013.07.013; Faul M, 2012, PREHOSP EMERG CARE, V16, P222, DOI 10.3109/10903127.2011.615013; Follin A, 2016, INJURY, V47, P1555, DOI 10.1016/j.injury.2016.04.024; Gomez D, 2012, J TRAUMA ACUTE CARE, V73, P1288, DOI 10.1097/TA.0b013e318265cec2; Gupta R, 2010, J TRAUMA, V69, P253, DOI 10.1097/TA.0b013e3181e4d579; Haas B, 2010, J AM COLL SURGEONS, V211, P804, DOI 10.1016/j.jamcollsurg.2010.08.014; Hasler R., 2012, EUR SPINE J, V21, P2384; Hasler RM, 2014, J TRAUMA ACUTE CARE, V77, P757, DOI 10.1097/TA.0000000000000452; Hasler RM, 2012, RESUSCITATION, V83, P476, DOI 10.1016/j.resuscitation.2011.10.018; Hasler RM, 2011, RESUSCITATION, V82, P1202, DOI 10.1016/j.resuscitation.2011.04.021; Jensen KO., 2020, EUR J TRAUMA EMERG S; Kondo Y, 2011, CRIT CARE, V15, DOI 10.1186/cc10348; Lefering R, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0476-2; Lefering R, 2009, EUR J TRAUMA EMERG S, V35, P437, DOI 10.1007/s00068-009-9122-0; Lehmann R, 2009, ARCH SURG-CHICAGO, V144, P853, DOI 10.1001/archsurg.2009.153; Lehmann R, 2009, AM J SURG, V197, P571, DOI 10.1016/j.amjsurg.2008.12.037; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Nakamura Y, 2012, ANN EMERG MED, V60, P335, DOI 10.1016/j.annemergmed.2012.04.006; Nathens AB, 2000, J TRAUMA, V48, P25, DOI 10.1097/00005373-200001000-00005; Nathens AB, 2003, J TRAUMA, V55, P444, DOI 10.1097/01.TA.0000047809.64699.59; Newgard CD, 2013, HEALTH AFFAIR, V32, P1591, DOI 10.1377/hlthaff.2012.1142; Rogers A, 2012, AM SURGEON, V78, P711; Rogers FB, 1999, J TRAUMA, V46, P328, DOI 10.1097/00005373-199902000-00022; Ruge T, 2020, UPSALA J MED SCI, V125, P58, DOI 10.1080/03009734.2019.1706674; Sartorius D, 2010, CRIT CARE MED, V38, P831, DOI 10.1097/CCM.0b013e3181cc4a67; Sorensen MJ, 2013, JAMA SURG, V148, P763, DOI 10.1001/jamasurg.2013.2132; Staudenmayer K, 2016, J TRAUMA ACUTE CARE, V80, P412, DOI 10.1097/TA.0000000000000956; TEASDALE G, 1974, LANCET, V2, P81; van Olden GDJ, 2004, AM J EMERG MED, V22, P522, DOI 10.1016/j.ajem.2004.08.013; van Rein EAJ, 2017, J TRAUMA ACUTE CARE, V83, P328, DOI 10.1097/TA.0000000000001516	36	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2021	16	6							e0253504	10.1371/journal.pone.0253504	http://dx.doi.org/10.1371/journal.pone.0253504			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BC	34143842	Green Published, Green Accepted, gold			2023-01-03	WOS:000671690700030
J	Peisl, S; Mellenthin, C; Vignot, L; Gonelle-Gispert, C; Buhler, L; Egger, B				Peisl, Sarah; Mellenthin, Claudia; Vignot, Lucie; Gonelle-Gispert, Carmen; Buehler, Leo; Egger, Bernhard			Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature	PLOS ONE			English	Review							CANCER CELLS; PHASE-II; INHIBITOR R115777; SIGNALING PATHWAY; BREAST-CANCER; DOUBLE-BLIND; GEMCITABINE; ACTIVATION; APOPTOSIS; PLACEBO	Background/Objectives Pancreatic ductal adenocarcinoma is a highly lethal disease with increasing incidence. Due to high resistance, chemo/radiotherapy has limited success in pancreatic cancer and only marginally prolongs patient survival. Therefore, novel biomarkers and therapeutic targets are needed. In the present review, we performed a comprehensive summary of therapeutic approaches targeting the GP130/JAK/STAT3 pathway. Methods We systematically reviewed the PubMed and Embase databases for preclinical and clinical studies, from inception to October 4, 2020, on drugs targeting the GP130/JAK/STAT3 pathway. Bias assessments and qualitative analyses were performed. Results Twenty-five preclinical and nine clinical trials were included in the review. All preclinical studies reported a favorable outcome in terms of pancreatic ductal adenocarcinoma progression. Futhermore, drugs targeting the GP130/JAK/STAT3 pathway were shown to be efficient chemosensitizers. However, high publication bias was assumed. In the clinical setting, bazedoxifene and itacitinib improved patient outcomes. Conclusion Preclinical studies strongly suggest significant efficacy of drugs targeting GP130/JAK/STAT3 in the treatment of pancreatic ductal adenocarcinoma and that these molecules are effective chemosensitizers. Though only a few trials have shown the efficacy in a clinical setting, the STAT3 pathway remains a promising drug target for future treatment of pancreatic ductal adenocarcinoma and may help overcome chemotherapy resistance.	[Peisl, Sarah; Mellenthin, Claudia; Buehler, Leo; Egger, Bernhard] HFR Fribourg, Dept Surg, Fribourg, Switzerland; [Vignot, Lucie] HFR Fribourg, Dept Oncol, Fribourg, Switzerland; [Gonelle-Gispert, Carmen] Univ Fribourg, Fac Sci & Med, Surg Res Unit, Fribourg, Switzerland; [Egger, Bernhard] Univ Fribourg, Fac Sci & Med, Fribourg, Switzerland	University of Fribourg; University of Fribourg	Egger, B (corresponding author), HFR Fribourg, Dept Surg, Fribourg, Switzerland.; Egger, B (corresponding author), Univ Fribourg, Fac Sci & Med, Fribourg, Switzerland.	bernhard.egger@bluewin.ch		Mellenthin, Claudia/0000-0002-1159-6829; Egger, Bernhard/0000-0002-2099-3367; Peisl, Sarah/0000-0002-1215-6964				Angelini J, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10071002; Bauer TM, 2018, ONCOTARGETS THER, V11, P2399, DOI 10.2147/OTT.S157331; Baugh KA, 2019, SURGERY, V165, P307, DOI 10.1016/j.surg.2018.08.003; Beatty GL, 2019, ONCOLOGIST, V24, P14, DOI 10.1634/theoncologist.2017-0665; Burkhardt Claudia, 2019, Oncotarget, V10, P3198; Chang Q, 2013, NEOPLASIA, V15, P848, DOI 10.1593/neo.13706; Chen JF, 2016, ONCOTARGETS THER, V9, P4225, DOI 10.2147/OTT.S103581; Chen X, 2019, CURR CANCER DRUG TAR, V19, P417, DOI 10.2174/1568009618666180430123939; Cohen SJ, 2003, J CLIN ONCOL, V21, P1301, DOI 10.1200/JCO.2003.08.040; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; Denley SM, 2013, J GASTROINTEST SURG, V17, P887, DOI 10.1007/s11605-013-2168-7; Eckhardt SG, 2009, J PAIN SYMPTOM MANAG, V37, P135, DOI 10.1016/j.jpainsymman.2008.02.007; Edderkaoui M, 2013, NUTR CANCER, V65, P1232, DOI 10.1080/01635581.2013.832779; Fu SL, 2018, ANTICANCER RES, V38, P6271, DOI 10.21873/anticanres.12983; Garg M, 2021, MED RES REV, V41, P1291, DOI 10.1002/med.21761; Ge YQ, 2015, MOL MED REP, V12, P7782, DOI 10.3892/mmr.2015.4379; Goumas FA, 2015, INT J CANCER, V137, P1035, DOI 10.1002/ijc.29445; Gruber R, 2016, GASTROENTEROLOGY, V151, P526, DOI 10.1053/j.gastro.2016.05.006; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43; Huang HL, 2016, SCI REP-UK, V6, DOI 10.1038/srep27794; Hurwitz H, 2018, INVEST NEW DRUG, V36, P683, DOI 10.1007/s10637-018-0580-2; Hurwitz HI, 2015, J CLIN ONCOL, V33, P4039, DOI 10.1200/JCO.2015.61.4578; Jin GH, 2020, J CANCER, V11, P1505, DOI 10.7150/jca.38616; Jonker DJ, 2018, LANCET GASTROENTEROL, V3, P263, DOI 10.1016/S2468-1253(18)30009-8; Kim C, 2016, PANCREAS, V45, P409, DOI 10.1097/MPA.0000000000000496; Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y; Lee JH, 2020, J ADV RES, V26, P83, DOI [10.1016/j.jare.2020.07.004, 10.7851/Ksrp.2020.26.2.083]; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Lin L, 2010, CANCER RES, V70, P2445, DOI 10.1158/0008-5472.CAN-09-2468; Liu A., 2011, ANTICANCER RES; Liu Y, 2019, N-S ARCH PHARMACOL, V392, P615, DOI 10.1007/s00210-019-01617-2; Long KB, 2017, MOL CANCER THER, V16, P1898, DOI 10.1158/1535-7163.MCT-16-0899; Lu CW, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1291106; Lu DC, 2019, ADV CLIN EXP MED, V28, P1285, DOI 10.17219/acem/104543; Luo D., 2019, PHOSPHO VALPROIC ACI, V40, P1; Macdonald JS, 2005, INVEST NEW DRUG, V23, P485, DOI 10.1007/s10637-005-2908-y; McGuigan A, 2018, WORLD J GASTROENTERO, V24, P4846, DOI 10.3748/wjg.v24.i43.4846; Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299; Nagaraju GP, 2019, INT J CANCER, V145, P1529, DOI 10.1002/ijc.32227; Nagaraju GP, 2016, EUR J CANCER, V52, P109, DOI 10.1016/j.ejca.2015.10.057; Ng K, 2019, INVEST NEW DRUG, V37, P159, DOI 10.1007/s10637-018-0650-5; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Palagani V, 2014, CARCINOGENESIS, V35, P859, DOI 10.1093/carcin/bgt394; Sahu N, 2017, MOL CANCER THER, V16, P1729, DOI 10.1158/1535-7163.MCT-17-0009; Schizas D, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102016; Singh RR, 2020, DRUGS, V80, P647, DOI 10.1007/s40265-020-01304-0; Song YL, 2019, J CELL PHYSIOL, V234, P777, DOI 10.1002/jcp.26892; Srinivas N, 2020, J CLIN PHARMACOL, V60, P1022, DOI 10.1002/jcph.1601; Sun CY, 2010, J CANCER RES CLIN, V136, P603, DOI 10.1007/s00432-009-0698-x; Tan FH, 2014, CURR DRUG TARGETS, V15, P1341, DOI 10.2174/1389450115666141120104146; Thoennissen NH, 2009, CANCER RES, V69, P5876, DOI 10.1158/0008-5472.CAN-09-0536; Trovato R, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0734-6; van Duijneveldt G, 2020, CLIN SCI, V134, P2091, DOI 10.1042/CS20191211; Venkatasubbarao K, 2005, CANCER RES, V65, P2861, DOI 10.1158/0008-5472.CAN-04-2396; von Ahrens D, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0448-5; Weber R, 2021, CELL IMMUNOL, V359, DOI 10.1016/j.cellimm.2020.104254; Wolf J, 2014, CYTOKINE, V70, P11, DOI 10.1016/j.cyto.2014.05.024; Wu XJ, 2016, MOL CANCER THER, V15, P2609, DOI 10.1158/1535-7163.MCT-15-0921; Xing HB, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3195025; Xu SL, 2013, EXPERT OPIN THER TAR, V17, P1303, DOI 10.1517/14728222.2013.830105; Yavropoulou MP, 2019, EXPERT OPIN PHARMACO, V20, P1201, DOI 10.1080/14656566.2019.1615882; Yeo TP, 2015, SEMIN ONCOL, V42, P8, DOI 10.1053/j.seminoncol.2014.12.002; You HX, 2020, CLIN REV ALLERG IMMU, V59, P334, DOI 10.1007/s12016-020-08786-6; Zhang X, 2018, ONCOL REP, V39, P1892, DOI 10.3892/or.2018.6241	65	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2021	16	6							e0252397	10.1371/journal.pone.0252397	http://dx.doi.org/10.1371/journal.pone.0252397			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9AX	34138876	gold, Green Published			2023-01-03	WOS:000671690200122
J	Nyberg, T; Twohig, KA; Harris, RJ; Seaman, SR; Flannagan, J; Allen, H; Charlett, A; De Angelis, D; Dabrera, G; Presanis, AM				Nyberg, Tommy; Twohig, Katherine A.; Harris, Ross J.; Seaman, Shaun R.; Flannagan, Joe; Allen, Hester; Charlett, Andre; De Angelis, Daniela; Dabrera, Gavin; Presanis, Anne M.			Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To evaluate the relation between diagnosis of covid-19 with SARS-CoV-2 variant B.1.1.7 (also known as variant of concern 202012/01) and the risk of hospital admission compared with diagnosis with wild-type SARS-CoV-2 variants. DESIGN Retrospective cohort analysis. SETTING Community based SARS-CoV-2 testing in England, individually linked with hospital admission data. PARTICIPANTS 839 278 patients with laboratory confirmed covid-19, of whom 36 233 had been admitted to hospital within 14 days, tested between 23 November 2020 and 31 January 2021 and analysed at a laboratory with an available TagPath assay that enables assessment of S-gene target failure (SGTF), a proxy test for the B.1.1.7 variant. Patient data were stratified by age, sex, ethnicity, deprivation, region of residence, and date of positive test. MAIN OUTCOME MEASURES Hospital admission between one and 14 days after the first positive SARS-CoV-2 test. RESULTS 27 710 (4.7%) of 592 409 patients with SGTF variants and 8523 (3.5%) of 246 869 patients without SGTF variants had been admitted to hospital within one to 14 days. The stratum adjusted hazard ratio of hospital admission was 1.52 (95% confidence interval 1.47 to 1.57) for patients with covid-19 infected with SGTF variants, compared with those infected with non-SGTF variants. The effect was modified by age (P(0.001),& nbsp;with hazard ratios of 0.93-1.21 in patients younger than 20 years with versus without SGTF variants, 1.29 in those aged 20-29, and 1.45-1.65 in those aged a30 years. The adjusted absolute risk of hospital admission within 14 days was 4.7% (95% confidence interval 4.6% to 4.7%) for patients with SGTF variants and 3.5% (3.4% to 3.5%) for those with non-SGTF variants. CONCLUSIONS The results suggest that the risk of hospital admission is higher for people infected with the B.1.1.7 variant compared with wild-type SARS-CoV-2, likely reflecting a more severe disease. The higher severity may be specific to adults older than 30 years.	[Nyberg, Tommy; Seaman, Shaun R.; De Angelis, Daniela; Presanis, Anne M.] Univ Cambridge, MRC Biostat Unit, Cambridge, England; [Twohig, Katherine A.; Flannagan, Joe; Allen, Hester; Dabrera, Gavin] Publ Hlth England, COVID 19 Natl Epidemiol Cell, London, England; [Harris, Ross J.; Charlett, Andre; De Angelis, Daniela] Publ Hlth England, Natl Infect Serv, London, England	MRC Biostatistics Unit; University of Cambridge; Public Health England; Public Health England	Nyberg, T (corresponding author), Univ Cambridge, MRC Biostat Unit, Cambridge, England.	tommy.nyberg@mrc-bsu.cam.ac.uk	Nyberg, Tommy/AGG-2330-2022; Twohig, Katherine/AGK-7931-2022	Nyberg, Tommy/0000-0002-9436-0626; Twohig, Katherine/0000-0001-9514-0097; De Angelis, Daniela/0000-0001-6619-6112	Medical Research Council [MC_UU_00002/11, MC_UU_00002/10]; MRC UKRI/DHSC NIHR COVID-19 rapid response call [MC_PC_19074]; NIHR Cambridge Biomedical Research Centre	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC UKRI/DHSC NIHR COVID-19 rapid response call; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR))	This research was funded by the Medical Research Council (TN, DDA, AMP; Unit programme number MC_UU_00002/11, SRS Unit programme number MC_UU_00002/10); and via a grant from the MRC UKRI/DHSC NIHR COVID-19 rapid response call (TN, AC, DDA, AMP; grant ref MC_PC_19074). This research was also supported by the NIHR Cambridge Biomedical Research Centre. The funders had no role in considering the study design or in the collection, analysis, or interpretation of data, the writing of the report, or the decision to submit the article for publication.	Abate BB, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-040129; Abbott S, 2021, POPULATION LEVEL ASS; Bhattacharya A, 2021, MEDRXIV, DOI [10.1101/2021.02.16.21251625, DOI 10.1101/2021.02.16.21251625]; Brookman S, 2021, LANCET CHILD ADOLESC, V5, pE9, DOI 10.1016/S2352-4642(21)00030-4; Brown AE, 2021, EMERG INFECT DIS, V27, P1468, DOI 10.3201/eid2705.203524; Challen R, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n579; Clare T, 2021, PUBLIC HEALTH, V194, P163, DOI 10.1016/j.puhe.2021.03.012; Davies NG, 2021, NATURE, V593, P270, DOI [10.1038/s41586-021-03426-1, 10.1101/2021.02.01.21250959]; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Funk T, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.16.2100348; Gov.uk, 2021, COR COVID 19 UK; Grint DJ, 2021, EUROSURVEILLANCE, V26, P10, DOI 10.2807/1560-7917.ES.2021.26.11.2100256; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Khawaja AP, 2020, ASS COVID 19 HOSP 40, DOI [10.1101/2020.05.06.20092957, DOI 10.1101/2020.05.06.20092957]; Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073; NHS Digital, 2021, 2 US SERV SUS; NHS Digital, 2021, EM CAR DAT SET ECDS; PANGO lineages, GRINCH GLOB REP INV; Patone M, 2021, ANAL SEVERE OUTCOMES; Public Health England, 2021, INV VAR CONC TECHN B; RIFM (Research Institute for Fragrance Materials Inc), 2021, EXP SURV 30; Tuite AR, 2021, COVID 10 HOSP ICU AD; UK Government Department of Health and Social Care, 2021, NHS TEST TRAC STAT E; UK Government Prime Minister's Office, 2021, PRIM MIN ANN NAT LOC; Volz E, 2021, NATURE, V593, P266, DOI 10.1038/s41586-021-03470-x	25	56	56	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 15	2021	373								n1412	10.1136/bmj.n1412	http://dx.doi.org/10.1136/bmj.n1412			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SY3PH	34130987	hybrid, Green Published, Green Submitted			2023-01-03	WOS:000665802800008
J	Eccleston, C; Aldington, D; Moore, A; Williams, ACD				Eccleston, Christopher; Aldington, Dominic; Moore, Andrew; Williams, Amanda C. de C.			Pragmatic but flawed: the NICE guideline on chronic pain	LANCET			English	Editorial Material									[Eccleston, Christopher] Univ Bath, Ctr Pain Res, Bath BA2 7AY, Avon, England; [Aldington, Dominic] Royal Hampshire Cty Hosp, Dept Anaesthesia, Winchester, Hants, England; [Moore, Andrew] Newton Ferrers, Plymouth, Devon, England; [Williams, Amanda C. de C.] UCL, Res Dept Clin Educ & Hlth Psychol, London, England	University of Bath; University of London; University College London	Eccleston, C (corresponding author), Univ Bath, Ctr Pain Res, Bath BA2 7AY, Avon, England.	c.eccleston@bath.ac.uk		Eccleston, Christopher/0000-0003-0698-1543; Williams, Amanda/0000-0003-3761-8704				Briley M, 2010, CURR OPIN INVEST DR, V11, P16; British Pain Society, 2021, BPS STAT NEW NIC CHR; Derry CJ, 2006, CLIN MED, V6, P381, DOI 10.7861/clinmedicine.6-4-381; Derry S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012332.pub2; Derry S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011790.pub2; Faculty of Pain Medicine, 2021, FPM REG NEW NICE CHR; Geneen LJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011279.pub3; Grahame-Smith D, 1998, J ROY SOC MED, V91, P7, DOI 10.1177/014107689809135S03; Greenhalgh T, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3725; Moore A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2690; Moore RA, 2010, PAIN, V151, P592, DOI 10.1016/j.pain.2010.07.013; National Institute for Health and Care Excellence, 2021, EV REV PAIN MAN PROG; Seers T, 2018, PAIN, V159, P811, DOI 10.1097/j.pain.0000000000001165; Toye F, 2013, BRIT J GEN PRACT, V63, pE829, DOI 10.3399/bjgp13X675412; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Williams ACD, 2021, PAIN, V162, P2149, DOI 10.1097/j.pain.0000000000002273; Williams ACD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007407.pub3; World Health Organization, INT CLASS DIS 11 REV	18	3	3	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2021	397	10289					2029	2031						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	SK5LX	34062133	Green Submitted			2023-01-03	WOS:000656257800005
J	Rodrigues, JC; Avila, MA; Driusso, P				Rodrigues, Jessica Cordeiro; Avila, Mariana Arias; Driusso, Patricia			Transcutaneous electrical nerve stimulation for women with primary dysmenorrhea: Study protocol for a randomized controlled clinical trial with economic evaluation	PLOS ONE			English	Article							QUALITY-OF-LIFE; STANFORD PRESENTEEISM SCALE; MENSTRUAL PAIN; PREVALENCE; HEALTH; BURDEN; TENS; VALIDATION; PRESSURE; DEVICE	Primary dysmenorrhea (PD) is a common gynecological disorder characterized by cramping pain in the lower abdomen during menstruation, in the absence of identifiable pathology. While Transcutaneous Electrical Nerve Stimulation (TENS) is used to promote PD pain relief, there is still a need to understand the parameters and cost-effectiveness of this intervention. As such, this study aims to disclose a study that will evaluate the effectiveness and cost-effectiveness of TENS on pain intensity in women with PD. This is a protocol for an assessor-blinded randomized controlled trial that includes 174 women with PD, >18 years old, with menstrual pain greater than or equal to four points in the Numerical Rating Scale. Participants will be randomized into three groups (active TENS, placebo TENS, and educational booklet). Participants allocated to the active TENS group will receive electrical stimulation (F = 100 Hz, pulse duration = 200 mu s, for 30 min). In contrast, the placebo TENS group will receive placebo stimulation (same parameters, but for only 30 s, and then the current will be ramped off over a 15-s time frame) for three consecutive months during menstruation. Participants allocated to the educational booklet group will receive instructions about health promotion and education actions related to PD. A blinded assessor will evaluate the pain intensity (Numerical Rating Scale), presenteeism (Stanford Presenteeism Scale), Health-Related Quality of Life (Short-Form 6 dimensions and SF-36), and health costs of menstrual pain. This is the first study to propose a health economic evaluation while assessing the benefits of using TENS to treat PD symptoms. It is hypothesized that active TENS will be more effective than placebo TENS or the educational booklet in improving clinical outcomes in the short-, medium- and long-term. The study will also provide information about the cost-effectiveness of TENS, which can be used by policy makers to improve PD care in public and private health systems.	[Rodrigues, Jessica Cordeiro; Driusso, Patricia] Univ Fed Sao Carlos, Phys Therapy Dept, Womens Hlth Res Lab LAMU, Sao Carlos, SP, Brazil; [Avila, Mariana Arias] Univ Fed Sao Carlos, Phys Therapy Dept, Lab Res Electrophys Agents LAREF, Sao Carlos, SP, Brazil	Universidade Federal de Sao Carlos; Universidade Federal de Sao Carlos	Driusso, P (corresponding author), Univ Fed Sao Carlos, Phys Therapy Dept, Womens Hlth Res Lab LAMU, Sao Carlos, SP, Brazil.	pdriusso@ufscar.br	Driusso, Patricia/D-8592-2012; Avila, Mariana Arias/C-7182-2017	Driusso, Patricia/0000-0001-8067-9786; Avila, Mariana Arias/0000-0002-5081-5326	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [001]; Sao Paulo Research Foundation [2019/14672-7]	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	JCR, MAA, PD -Finance Code 001 Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -www.capes.gov.br PD, JCR - process 2019/14672-7 -Sao Paulo Research Foundation -www.fapesp.br.	Akin MD, 2001, OBSTET GYNECOL, V97, P343, DOI 10.1016/S0029-7844(00)01163-7; Akiyama S, 2017, CLINICOECONOMIC OUTC, V9, P295, DOI 10.2147/CEOR.S127760; [Anonymous], 2018, Obstet Gynecol, V132, P1517, DOI 10.1097/AOG.0000000000002981; [Anonymous], 2020, COFF AT VAL COEF VAL; Arik MI, 2022, EXPLORE-NY, V18, P108, DOI 10.1016/j.explore.2020.08.005; Armour M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004142.pub4; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Brazier J, 1998, J CLIN EPIDEMIOL, V51, P1115, DOI 10.1016/S0895-4356(98)00103-6; Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103; Budgell BS, 2014, SPINAL CORD, V52, P744, DOI 10.1038/sc.2014.120; Burnett M, 2017, J OBSTET GYNAECOL CA, V39, P585, DOI 10.1016/j.jogc.2016.12.023; Campolina AG, 2011, CIENC SAUDE COLETIVA, V16, P3103, DOI 10.1590/S1413-81232011000800010; Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586; Chen CX, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0538-8; Chen CX, 2016, RES NURS HEALTH, V39, P263, DOI 10.1002/nur.21726; Ciconelli RM, 1999, REV BRAS REUMATOL, V39, P143, DOI DOI 10.1590/S0482-50042010000300005; Dailey DL, 2013, PAIN, V154, P2554, DOI 10.1016/j.pain.2013.07.043; DAWOOD MY, 1984, AM J MED, V77, P87; Ding D, 2017, BRIT J SPORT MED, V51, P1392, DOI 10.1136/bjsports-2016-097385; Doig GS, 2005, J CRIT CARE, V20, P187, DOI 10.1016/j.jcrc.2005.04.005; Elboim-Gabyzon M, 2020, INT J WOMENS HEALTH, V12, P1, DOI 10.2147/IJWH.S220523; Evans SF, 2018, J PAIN RES, V11, P3181, DOI 10.2147/JPR.S179409; Ferreira-Valente MA, 2011, PAIN, V152, P2399, DOI 10.1016/j.pain.2011.07.005; Hewitt G, 2020, CLIN OBSTET GYNECOL, V63, P536, DOI 10.1097/GRF.0000000000000540; Igwea SE, 2016, COMPLEMENT THER CLIN, V24, P86, DOI 10.1016/j.ctcp.2016.05.001; Johnson MI, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006142.pub3; Ju H, 2014, EPIDEMIOL REV, V36, P104, DOI 10.1093/epirev/mxt009; Kannan P, 2014, J PHYSIOTHER, V60, P13, DOI 10.1016/j.jphys.2013.12.003; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Koopman C, 2002, J OCCUP ENVIRON MED, V44, P14, DOI 10.1097/00043764-200201000-00004; Lauretti GR, 2015, NEUROMODULATION, V18, P522, DOI 10.1111/ner.12269; Lee B, 2015, EUR J OBSTET GYN R B, V194, P58, DOI 10.1016/j.ejogrb.2015.08.020; Manca A, 2005, HEALTH ECON, V14, P487, DOI 10.1002/hec.944; Marjoribanks J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001751.pub3; MILSOM I, 1994, AM J OBSTET GYNECOL, V170, P123; Ministe&PRIME;rio da Sau&PRIME;de Brasil, 2014, DIR MET DIR AV EC; Ortiz MI, 2010, EUR J OBSTET GYN R B, V152, P73, DOI 10.1016/j.ejogrb.2010.04.015; Paschoalin HC, 2013, REV LAT-AM ENFERM, V21, P388, DOI 10.1590/S0104-11692013000100014; Barbosa AMP, 2018, INT UROGYNECOL J, V29, P1747, DOI 10.1007/s00192-018-3743-y; Machado AFP, 2019, COMPLEMENT THER MED, V47, DOI 10.1016/j.ctim.2019.08.022; Machado AFP, 2017, PAIN MANAG, V7, P359, DOI 10.2217/pmt-2017-0021; Polat A, 2009, ARCH GYNECOL OBSTET, V279, P527, DOI 10.1007/s00404-008-0750-0; Proctor ML., 2002, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002123; Rencz F, 2017, PAIN, V158, P2259, DOI 10.1097/j.pain.0000000000001028; Saint-Mont U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132102; Slater H, 2015, PAIN, V156, P2468, DOI 10.1097/j.pain.0000000000000317; Sluka KA, 2013, PHYS THER, V93, P1397, DOI 10.2522/ptj.20120281; Unsal A, 2010, UPSALA J MED SCI, V115, P138, DOI 10.3109/03009730903457218; Vance CGT, 2014, PAIN MANAG, V4, P197, DOI [10.2217/PMT.14.13, 10.2217/pmt.14.13]; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Zannoni L, 2014, J PEDIATR ADOL GYNEC, V27, P258, DOI 10.1016/j.jpag.2013.11.008; Zhang FR, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/8791538	52	2	3	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2021	16	5							e0250111	10.1371/journal.pone.0250111	http://dx.doi.org/10.1371/journal.pone.0250111			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6NW	34014922	gold, Green Published			2023-01-03	WOS:000664631600010
J	Costeira, R; Lee, KRA; Murray, B; Christiansen, C; Castillo-Fernandez, J; Lochlainn, MN; Pujol, JC; Macfarlane, H; Kenny, LC; Buchan, I; Wolf, J; Rymer, J; Ourselin, S; Steves, CJ; Spector, TD; Newson, LR; Bell, JT				Costeira, Ricardo; Lee, Karla A.; Murray, Benjamin; Christiansen, Colette; Castillo-Fernandez, Juan; Ni Lochlainn, Mary; Capdevila Pujol, Joan; Macfarlane, Heather; Kenny, Louise C.; Buchan, Iain; Wolf, Jonathan; Rymer, Janice; Ourselin, Sebastien; Steves, Claire J.; Spector, Timothy D.; Newson, Louise R.; Bell, Jordana T.			Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study	PLOS ONE			English	Article							ACUTE RESPIRATORY SYNDROME; HUMAN-PAPILLOMAVIRUS; SEX-DIFFERENCES; PREVALENCE; INFECTION; HORMONES	It has been widely observed that adult men of all ages are at higher risk of developing serious complications from COVID-19 when compared with women. This study aimed to investigate the association of COVID-19 positivity and severity with estrogen exposure in women, in a population based matched cohort study of female users of the COVID Symptom Study application in the UK. Analyses included 152,637 women for menopausal status, 295,689 women for exogenous estrogen intake in the form of the combined oral contraceptive pill (COCP), and 151,193 menopausal women for hormone replacement therapy (HRT). Data were collected using the COVID Symptom Study in May-June 2020. Analyses investigated associations between predicted or tested COVID-19 status and menopausal status, COCP use, and HRT use, adjusting for age, smoking and BMI, with follow-up age sensitivity analysis, and validation in a subset of participants from the TwinsUK cohort. Menopausal women had higher rates of predicted COVID-19 (P = 0.003). COCP-users had lower rates of predicted COVID-19 (P = 8.03E-05), with reduction in hospital attendance (P = 0.023). Menopausal women using HRT or hormonal therapies did not exhibit consistent associations, including increased rates of predicted COVID-19 (P = 2.22E-05) for HRT users alone. The findings support a protective effect of estrogen exposure on COVID-19, based on positive association between predicted COVID-19 with menopausal status, and negative association with COCP use. HRT use was positively associated with COVID-19, but the results should be considered with caution due to lack of data on HRT type, route of administration, duration of treatment, and potential unaccounted for confounders and comorbidities.	[Costeira, Ricardo; Lee, Karla A.; Christiansen, Colette; Castillo-Fernandez, Juan; Ni Lochlainn, Mary; Steves, Claire J.; Spector, Timothy D.; Bell, Jordana T.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England; [Murray, Benjamin; Ourselin, Sebastien] Kings Coll London, Sch Biomed Engn Imaging Sci, London, England; [Capdevila Pujol, Joan; Wolf, Jonathan] Zoe Global Ltd, London, England; [Macfarlane, Heather] Univ Liverpool, Dept Womens & Childrens Hlth, Liverpool, Merseyside, England; [Kenny, Louise C.] Univ Liverpool, Dept Publ Hlth Policy & Syst, Liverpool, Merseyside, England; [Buchan, Iain] Kings Coll London, Dept Womens Hlth, London, England; [Rymer, Janice] Newson Hlth Menopause Wellbeing Ctr, Stratford Upon Avon, England	University of London; King's College London; University of London; King's College London; University of Liverpool; University of Liverpool; University of London; King's College London	Bell, JT (corresponding author), Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.	jordana.bell@kcl.ac.uk	Kenny, Louise/G-1112-2011; Buchan, Iain/H-5767-2013; Ourselin, Sebastien/K-6960-2015	Kenny, Louise/0000-0002-9011-759X; Buchan, Iain/0000-0003-3392-1650; Lee, Karla/0000-0001-5904-5586; Ourselin, Sebastien/0000-0002-5694-5340; Ni Lochlainn, Mary/0000-0001-5702-1759	Wellcome Trust; MRC/BHF; Alzheimer's Society; EU; NIHR; CDRF; ESRC; European Community's Seventh Framework Programme (FP7/2007-2013); National Institute for Health Research (NIHR); UK Economic and Social Research Council [ES/N000404/1]; NIHR Doctoral Fellowship [NIHR300159]	Wellcome Trust(Wellcome TrustEuropean Commission); MRC/BHF(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimer's Society; EU(European Commission); NIHR(National Institute for Health Research (NIHR)); CDRF; ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); European Community's Seventh Framework Programme (FP7/2007-2013)(European Commission); National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); UK Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); NIHR Doctoral Fellowship	Zoe Global provided in kind support for all aspects of building, running, and supporting the app and service to all users worldwide. Investigators received support from the Wellcome Trust, the MRC/BHF, Alzheimer's Society, EU, NIHR, CDRF, ESRC. The TwinsUK study was funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013); National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. Epigenetic ageing estimates were generated from the UK Economic and Social Research Council (ES/N000404/1 to JTB). MNL is supported by an NIHR Doctoral Fellowship (grant code NIHR300159). Zoe Global provided support in the form of salaries for authors JCP and JW and contributed to data collection which was carried via the Zoe app. The roles of these authors are articulated in the `Author Contributions' section. The funders did not have any additional role in the study design, data analysis, decision to publish, or preparation of the manuscript.	Abbassi-Ghanavati M, 2009, OBSTET GYNECOL, V114, P1326, DOI 10.1097/AOG.0b013e3181c2bde8; Allotey J, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3320; Amer Soc Reprod Med, 2017, FERTIL STERIL, V107, P43, DOI 10.1016/j.fertnstert.2016.09.027; [Anonymous], 1992, BMJ, V304, P809; Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049; Bereshchenko O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01332; Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896; Chen BH, 2016, AGING-US, V8, P1844, DOI 10.18632/aging.101020; Chen YH, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.08.023; Cristina Menni, 2020, LOSS SMELL TASTE COM, DOI [10.1038/s41591-020-0916-2, DOI 10.1038/S41591-020-0916-2, 10.1101/2020.04.05.20048421]; Davey DA, 2018, CLIMACTERIC, V21, P454, DOI 10.1080/13697137.2018.1439915; Ding T., 2021, CLIN INFECT DIS, V72, pe240, DOI [10.1093/cid/ciaa1022, DOI 10.1093/CID/CIAA1022]; Dominguez-Lopez I, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082456; Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587; Franceschi S, 2006, INT J CANCER, V119, P2677, DOI 10.1002/ijc.22241; Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697; Gonzalez P, 2010, CANCER EPIDEM BIOMAR, V19, P3044, DOI 10.1158/1055-9965.EPI-10-0645; Hannah MF, 2008, BRAIN BEHAV IMMUN, V22, P503, DOI 10.1016/j.bbi.2007.10.005; Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016; Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115; Jiang J., 2020, 20043943 MEDRXIV; Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Kurushima Y, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0614-4; L'Hermite M, 2017, CLIMACTERIC, V20, P331, DOI 10.1080/13697137.2017.1291607; Leong HN, 2006, ANN ACAD MED SINGAP, V35, P326; Levine ME, 2018, AGING-US, V10, P573, DOI 10.18632/aging.101414; Levine ME, 2016, P NATL ACAD SCI USA, V113, P9327, DOI 10.1073/pnas.1604558113; Lu AT, 2019, AGING-US, V11, P303, DOI 10.18632/aging.101684; Lusignan Sd., 2021, 21251853 MEDRXIV; Meditz AL, 2012, JAIDS-J ACQ IMM DEF, V59, P221, DOI 10.1097/QAI.0b013e31823fd215; Menni C, 2020, NAT MED, V26, P1037, DOI 10.1038/s41591-020-0916-2; Molteni E, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86452-3; Moulton VR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02279; Olsen NJ, 1996, ENDOCR REV, V17, P369, DOI 10.1210/er.17.4.369; Robinson DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002149; Scully EP, 2020, NAT REV IMMUNOL, V20, P442, DOI 10.1038/s41577-020-0348-8; Seeland U, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01851-z; Shah NM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00198; Smith JS, 2008, J ADOLESCENT HEALTH, V43, pS5, DOI 10.1016/j.jadohealth.2008.07.009; Sudre CH, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01292-y; TALAL N, 1981, ARTHRITIS RHEUM, V24, P1054, DOI 10.1002/art.1780240811; Trenti A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030859; Vermillion MS, 2018, BIOL SEX DIFFER, V9, DOI 10.1186/s13293-018-0184-8; vom Steeg LG, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005374; Xu ZL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv907	46	22	22	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257051	10.1371/journal.pone.0257051	http://dx.doi.org/10.1371/journal.pone.0257051			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9EM	34506535	Green Submitted, gold, Green Accepted, Green Published			2023-01-03	WOS:000729120700097
J	Nehme, M; Braillard, O; Chappuis, F; Courvoisier, DS; Guessous, I				Nehme, Mayssam; Braillard, Olivia; Chappuis, Francois; Courvoisier, Delphine S.; Guessous, Idris		CoviCare Study Team	Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting	ANNALS OF INTERNAL MEDICINE			English	Article								Background: With millions of SARS-CoV-2 infections worldwide, increasing numbers of patients are coming forward with long-term clinical effects of the disease lasting several weeks to months. Objective: To characterize symptoms 7 to 9 months after diagnosis of COVID-19. Design: Self-reported surveys and semistructured telephone interviews at enrollment and 30 to 45 days and 7 to 9 months from diagnosis. Setting: From 18 March to 15 May 2020, symptomatic persons who tested positive for SARS-CoV-2 at the Geneva University Hospitals were followed by CoviCare, a virtual, clinical, outpatient follow-up program. Persons were contacted again at 30 to 45 days and 7 to 9 months from diagnosis. Participants: Persons who were a part of the CoviCare program from 18 March to 15 May 2020. Measurements: A standardized interview of symptoms consistent with COVID-19, with grading of intensity. Results: Of the 629 participants in the study who completed the baseline interviews, 410 completed follow-up at 7 to 9 months after COVID-19 diagnosis; 39.0% reported residual symptoms. Fatigue (20.7%) was the most common symptom reported, followed by loss of taste or smell (16.8%), dyspnea (11.7%), and headache (10.0%). Limitation: Limitations include generalizability and missing data for 34.8% of participants. Conclusion: Residual symptoms after SARS-CoV-2 infection are common among otherwise young and healthy persons followed in an outpatient setting. These findings contribute to the recognition of long-term effects in a disease mostly counted by its death toll to date by promoting communication on postacute sequelae of SARS-CoV-2 and encouraging physicians to continue long-term monitoring of their patients.	[Nehme, Mayssam; Braillard, Olivia; Chappuis, Francois; Courvoisier, Delphine S.; Guessous, Idris] Geneva Univ Hosp, Geneva, Switzerland; [Chappuis, Francois; Guessous, Idris] Univ Geneva, Geneva, Switzerland; [Courvoisier, Delphine S.] Cantonal Hlth Serv, Geneva, Switzerland; [Nehme, Mayssam; Braillard, Olivia; Chappuis, Francois; Guessous, Idris] Geneva Univ Hosp, Div Primary Care Med, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland; [Courvoisier, Delphine S.] Geneva Univ Hosp, Div Care Qual, Chemin Thury 3, CH-1206 Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva	Nehme, M (corresponding author), Geneva Univ Hosp, Div Primary Care Med, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland.	Mayssam.nehme@hcuge.ch	; Courvoisier, Delphine/H-6054-2011; Baggio, Stephanie/J-6009-2017	Chappuis, Francois/0000-0003-0442-7610; Courvoisier, Delphine/0000-0002-1956-2607; Baggio, Stephanie/0000-0002-5347-5937; Alcoba, Gabriel/0000-0002-9423-1533				[Anonymous], 2020, NATURE, V586, P170, DOI 10.1038/d41586-020-02796-2; Briggs A, 2021, NATURE, V593, P502, DOI 10.1038/d41586-021-01392-2; Buccheri G, 1996, EUR J CANCER, V32A, P1135, DOI 10.1016/0959-8049(95)00664-8; Callard F, 2021, SOC SCI MED, V268, DOI 10.1016/j.socscimed.2020.113426; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Carvalho-Schneider C, 2021, CLIN MICROBIOL INFEC, V27, P258, DOI 10.1016/j.cmi.2020.09.052; Cirulli ET, 2020, MEDRXIV, V2020, DOI [10.1101/2020.10.07.20208702, DOI 10.1101/2020.10.07.20208702]; Davis HE, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101019; Directorate General of Health in Geneva, COVID19 GEN CANT DAT; Federal Office of Public Health, COR IS QUAR; Garner P., 2020, BMJ OPINION; Greenhalgh T, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3026; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Huang YY, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01429-6; Laine C, 2021, ANN INTERN MED, V174, P1159, DOI 10.7326/M21-2342; Lee K, 2009, GLOB INST, P1; Lerner AM, 2021, ANN INTERN MED, V174, P999, DOI 10.7326/M21-1043; Logue JK, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0830; Lopez-Leon S, 2021, SCI REP-UK, V11, DOI [10.1038/s41598-021-95565-8, 10.1101/2021.01.27.21250617]; Lund LC, 2021, LANCET INFECT DIS, V21, P1373, DOI 10.1016/S1473-3099(21)00211-5; Mahase E, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2815; MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580; Nabavi N, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3489; Nasserie T, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.11417; Nath A, 2020, NEUROLOGY, V95, P559, DOI 10.1212/WNL.0000000000010640; Nehme M, 2021, ANN INTERN MED, V174, P723, DOI 10.7326/M20-5926; Rubin R, 2020, JAMA-J AM MED ASSOC, V324, P1381, DOI 10.1001/jama.2020.17709; Sivan M, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4938; Sudre CH, 2020, ATTRIBUTES PREDICTOR, DOI [10.19.20214494, 10.1101/2020.10.19.20214494, DOI 10.1101/2020.10.19.20214494]; Tenforde MW, 2020, MMWR-MORBID MORTAL W, V69, P841, DOI 10.15585/mmwr.mm6926e3	30	54	55	2	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP	2021	174	9					1252	+		10.7326/M21-0878	http://dx.doi.org/10.7326/M21-0878			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA5GQ	34224254	Green Published			2023-01-03	WOS:000720675500023
J	Meyer, NJ; Gattinoni, L; Calfee, CS				Meyer, Nuala J.; Gattinoni, Luciano; Calfee, Carolyn S.			Acute respiratory distress syndrome	LANCET			English	Review							ACUTE LUNG INJURY; POSITIVE-PRESSURE VENTILATION; END-EXPIRATORY PRESSURE; CONSERVATIVE OXYGEN-THERAPY; HIGH-FREQUENCY OSCILLATION; MECHANICAL VENTILATION; PULMONARY-EDEMA; CLINICAL-TRIAL; TIDAL VOLUME; SYNDROME INSIGHTS	Acute respiratory distress syndrome (ARDS) is an acute respiratory illness characterised by bilateral chest radiographical opacities with severe hypoxaemia due to non-cardiogenic pulmonary oedema. The COVID-19 pandemic has caused an increase in ARDS and highlighted challenges associated with this syndrome, including its unacceptably high mortality and the lack of effective pharmacotherapy. In this Seminar, we summarise current knowledge regarding ARDS epidemiology and risk factors, differential diagnosis, and evidence-based clinical management of both mechanical ventilation and supportive care, and discuss areas of controversy and ongoing research. Although the Seminar focuses on ARDS due to any cause, we also consider commonalities and distinctions of COVID-19-associated ARDS compared with ARDS from other causes.	[Meyer, Nuala J.] Univ Penn, Sch Med, Pulm Allergy & Crit Care Div, Philadelphia, PA USA; [Gattinoni, Luciano] Univ Med Ctr Gottingen, Dept Anesthesiol Intens Care & Emergency Med, Gottingen, Germany; [Calfee, Carolyn S.] Univ Calif San Francisco, Div Pulm Crit Care Allergy & Sleep Med, Dept Med, San Francisco, CA 94143 USA; [Calfee, Carolyn S.] Univ Calif San Francisco, Div Pulm Crit Care Allergy & Sleep Med, Dept Anesthesia, San Francisco, CA 94143 USA	University of Pennsylvania; University of Gottingen; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Meyer, NJ (corresponding author), Univ Penn, Perelman Sch Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19096 USA.	nuala.meyer@pennmedicine.upenn.edu						Abadie Y, 2005, EUR RESPIR J, V25, P139, DOI 10.1183/09031936.04.00065504; Abrams D, 2019, CRIT CARE MED, V47, P1346, DOI 10.1097/CCM.0000000000003910; Aggarwal NR, 2014, AM J PHYSIOL-LUNG C, V306, pL709, DOI 10.1152/ajplung.00341.2013; Albertine KH, 2002, AM J PATHOL, V161, P1783, DOI 10.1016/S0002-9440(10)64455-0; Alhurani RE, 2016, ANN AM THORAC SOC, V13, P1105, DOI 10.1513/AnnalsATS.201508-560OC; Alqahtani JS, 2020, J MULTIDISCIP HEALTH, V13, P1635, DOI 10.2147/JMDH.S279031; Alviar CL, 2018, J AM COLL CARDIOL, V72, P1532, DOI 10.1016/j.jacc.2018.06.074; Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639; Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; ASHBAUGH DG, 1967, LANCET, V2, P319; Auriemma CL, 2020, INTENS CARE MED, V46, P1222, DOI 10.1007/s00134-020-06010-9; BACHOFEN M, 1982, CLIN CHEST MED, V3, P35; Barrot L, 2020, NEW ENGL J MED, V382, P999, DOI 10.1056/NEJMoa1916431; Bastarache JA, 2007, THORAX, V62, P608, DOI 10.1136/thx.2006.063305; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Beitler JR, 2019, JAMA-J AM MED ASSOC, V321, P846, DOI 10.1001/jama.2019.0555; Bellani G, 2017, AM J RESP CRIT CARE, V195, P67, DOI 10.1164/rccm.201606-1306OC; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Bernard GR, 1997, NEW ENGL J MED, V336, P912, DOI 10.1056/NEJM199703273361303; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BIGATELLO LM, 1994, INTENS CARE MED, V20, P328, DOI 10.1007/BF01720904; Blount BC, 2020, NEW ENGL J MED, V382, P697, DOI 10.1056/NEJMoa1916433; Bos LD, 2017, THORAX, V72, P876, DOI 10.1136/thoraxjnl-2016-209719; Bos LDJ, 2019, AM J RESP CRIT CARE, V200, P42, DOI 10.1164/rccm.201809-1808OC; Bouhemad B, 2011, AM J RESP CRIT CARE, V183, P341, DOI 10.1164/rccm.201003-0369OC; Boyle AJ, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2158-y; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brun-Buisson C, 2011, AM J RESP CRIT CARE, V183, P1200, DOI 10.1164/rccm.201101-0135OC; Bulpa PA, 2003, EUR RESPIR J, V21, P489, DOI 10.1183/09031936.03.00298303; Calfee CS, 2007, CHEST, V131, P913, DOI 10.1378/chest.06-1743; Calfee CS, 2018, LANCET RESP MED, V6, P691, DOI 10.1016/S2213-2600(18)30177-2; Calfee CS, 2015, CRIT CARE MED, V43, P1790, DOI 10.1097/CCM.0000000000001089; Calfee CS, 2015, CHEST, V147, P1539, DOI 10.1378/chest.14-2454; Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9; Cauchemez S, 2014, LANCET INFECT DIS, V14, P50, DOI 10.1016/S1473-3099(13)70304-9; Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303; Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171; Cheung AM, 2006, AM J RESP CRIT CARE, V174, P538, DOI 10.1164/rccm.200505-693OC; Chowell G, 2009, NEW ENGL J MED, V361, P674, DOI 10.1056/NEJMoa0904023; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; COHEN DS, 1992, AM REV RESPIR DIS, V146, P794, DOI 10.1164/ajrccm/146.3.794; Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385; Combes A, 2020, INTENS CARE MED, V46, P2464, DOI 10.1007/s00134-020-06290-1; Constantin JM, 2019, LANCET RESP MED, V7, P870, DOI 10.1016/S2213-2600(19)30138-9; Cressoni M, 2014, AM J RESP CRIT CARE, V189, P149, DOI 10.1164/rccm.201308-1567OC; D'Alessio FR, 2009, J CLIN INVEST, V119, P2898, DOI 10.1172/JCI36498; Davenport EE, 2016, LANCET RESP MED, V4, P259, DOI 10.1016/S2213-2600(16)00046-1; Devlin JW, 2018, CRIT CARE MED, V46, P1532, DOI [10.1097/CCM.0000000000003299, 10.1097/CCM.0000000000003259]; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; dos Santos CC, 2000, INTENS CARE MED, V26, P638, DOI 10.1007/s001340051217; dos Santos CC, 2008, CRIT CARE MED, V36, P855, DOI 10.1097/CCM.0B013E3181659333; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; DREYFUSS D, 1993, AM REV RESPIR DIS, V148, P1194, DOI 10.1164/ajrccm/148.5.1194; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Elharrar X, 2020, JAMA-J AM MED ASSOC, V323, P2336, DOI 10.1001/jama.2020.8255; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; ERDMANN AJ, 1975, CIRC RES, V37, P271, DOI 10.1161/01.RES.37.3.271; Erickson SE, 2009, CRIT CARE MED, V37, P1, DOI 10.1097/CCM.0b013e31819292ea; Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC; Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST; FDA, 2019, ENR STRAT CLIN TRIAL; Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554; Fielding-Singh V, 2018, CRIT CARE MED, V46, P1820, DOI 10.1097/CCM.0000000000003406; Fisher BJ, 2011, CRIT CARE MED, V39, P1454, DOI 10.1097/CCM.0b013e3182120cb8; Fowler AA, 2019, JAMA-J AM MED ASSOC, V322, P1261, DOI 10.1001/jama.2019.11825; Fowler AA, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-32; Frank JA, 2006, AM J PHYSIOL-LUNG C, V291, pL1191, DOI 10.1152/ajplung.00055.2006; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Fujita M, 1998, INT ARCH ALLERGY IMM, V117, P202, DOI 10.1159/000024011; Fuller BM, 2015, CHEST, V147, P1510, DOI 10.1378/chest.14-3161; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GATTINONI L, 1980, LANCET, V2, P292; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Gattinoni L, 2016, INTENS CARE MED, V42, P1567, DOI 10.1007/s00134-016-4505-2; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031; Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE; Gattinoni L, 2013, AM J RESP CRIT CARE, V188, P1286, DOI 10.1164/rccm.201308-1532CI; Gebistorf F, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002787.pub3; Gershengorn HB, 2021, ANN AM THORAC SOC, V18, P623, DOI 10.1513/AnnalsATS.202007-803OC; Gill SE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0266-7; Ginde AA, 2019, NEW ENGL J MED, V381, P2529, DOI 10.1056/NEJMoa1911124; Girard TD, 2017, AM J RESP CRIT CARE, V195, P120, DOI 10.1164/rccm.201610-2075ST; Guerin C, 2004, JAMA-J AM MED ASSOC, V292, P2379, DOI 10.1001/jama.292.19.2379; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Guillen-Guio B, 2020, LANCET RESP MED, V8, P258, DOI 10.1016/S2213-2600(19)30368-6; Han SH, 2011, CRIT CARE, V15, DOI 10.1186/cc10524; Hastings RH, 2004, AM J PHYSIOL-LUNG C, V286, pL679, DOI 10.1152/ajplung.00205.2003; Hendrickson CM, 2019, LANCET RESP MED, V7, P830, DOI 10.1016/S2213-2600(19)30175-4; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; Hook JL, 2018, J CLIN INVEST, V128, P1074, DOI 10.1172/JCI95823; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Iwata K, 2010, INTERNAL MED, V49, P2423, DOI 10.2169/internalmedicine.49.4010; Juss JK, 2016, AM J RESP CRIT CARE, V194, P961, DOI 10.1164/rccm.201509-1818OC; Juss JatinderK, 2015, Lancet, V385 Suppl 1, pS55, DOI 10.1016/S0140-6736(15)60370-1; Kangelaris KN, 2016, CRIT CARE MED, V44, P120, DOI 10.1097/CCM.0000000000001359; Katzenstein A L, 1976, Am J Pathol, V85, P209; Kerchberger VE, 2020, CRIT CARE MED, V48, P22, DOI 10.1097/CCM.0000000000004034; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Kor DJ, 2016, JAMA-J AM MED ASSOC, V315, P2406, DOI 10.1001/jama.2016.6330; Kress JP, 1996, AM J RESP CRIT CARE, V153, P1012, DOI 10.1164/ajrccm.153.3.8630539; Krishnasamy VP, 2020, MMWR-MORBID MORTAL W, V69, P90, DOI 10.15585/mmwr.mm6903e2; LACHMANN B, 1992, INTENS CARE MED, V18, P319, DOI 10.1007/BF01694358; Laffey JG, 2017, LANCET RESP MED, V5, P627, DOI [10.1016/S2213-2600(17)30213-8, 10.1016/s2213-2600(17)30213-8]; Layden JE, 2020, NEW ENGL J MED, V382, P903, DOI 10.1056/NEJMoa1911614; Lefrancais E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98178; Lemos LB, 2013, CHEST, V143, P901, DOI 10.1378/chest.12-1118; Lewis SR, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004477.pub3; Libby LJ, 2014, ANN THORAC SURG, V98, P1254, DOI 10.1016/j.athoracsur.2014.05.029; Liu KD, 2008, AM J RESP CRIT CARE, V178, P618, DOI 10.1164/rccm.200803-419OC; London NR, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000678; Luo L, 2017, CHEST, V151, P755, DOI 10.1016/j.chest.2016.09.004; Madotto F, 2018, INTENS CARE MED, V44, P564, DOI 10.1007/s00134-018-5152-6; Mangalmurti NS, 2020, AM J RESP CRIT CARE, V202, P750, DOI 10.1164/rccm.202006-2598LE; MANTHOUS CA, 1995, AM J RESP CRIT CARE, V151, P10, DOI 10.1164/ajrccm.151.1.7812538; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0; Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1; Matthay MA, 2017, LANCET RESP MED, V5, P524, DOI 10.1016/S2213-2600(17)30188-1; Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331; Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC; Mauri T, 2017, AM J RESP CRIT CARE, V195, P1207, DOI 10.1164/rccm.201605-0916OC; McAuley DF, 2017, LANCET RESP MED, V5, P484, DOI 10.1016/S2213-2600(17)30171-6; McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285; McNicholas BA, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00609-2019; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Meduri GU, 1998, AM J RESP CRIT CARE, V158, P870, DOI 10.1164/ajrccm.158.3.9706112; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC; Millar FR, 2016, THORAX, V71, P462, DOI 10.1136/thoraxjnl-2015-207461; Mohammed BM, 2013, NUTRIENTS, V5, P3131, DOI 10.3390/nu5083131; Moss M, 2003, CRIT CARE MED, V31, pS207, DOI 10.1097/01.CCM.0000057845.77458.25; Moss M, 2000, CRIT CARE MED, V28, P2187, DOI 10.1097/00003246-200007000-00001; Moss M, 2019, NEW ENGL J MED, V380, P1997, DOI 10.1056/NEJMoa1901686; Palakshappa JA, 2015, CHEST, V148, P1073, DOI 10.1378/chest.15-0076; Papazian L, 2016, INTENS CARE MED, V42, P674, DOI 10.1007/s00134-016-4324-5; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Parsons PE, 2005, CRIT CARE MED, V33, P1, DOI 10.1097/01.CCM.0000149854.61192.DC; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498; PELOSI P, 1994, AM J RESP CRIT CARE, V149, P8, DOI 10.1164/ajrccm.149.1.8111603; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003; PONTOPPIDAN H, 1972, NEW ENGL J MED, V287, P690, DOI 10.1056/NEJM197210052871404; Putensen C, 1999, AM J RESP CRIT CARE, V159, P1241, DOI 10.1164/ajrccm.159.4.9806077; Putman RK, 2017, AM J RESP CRIT CARE, V195, P138, DOI 10.1164/rccm.201604-0818LE; Ranieri VM, 2020, JAMA-J AM MED ASSOC, V323, P725, DOI 10.1001/jama.2019.22525; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Reilly JP, 2019, SEMIN RESP CRIT CARE, V40, P19, DOI 10.1055/s-0039-1684049; Reilly JP, 2019, AM J RESP CRIT CARE, V199, P62, DOI 10.1164/rccm.201803-0435OC; Reilly JP, 2017, AM J RESP CRIT CARE, V196, P1113, DOI 10.1164/rccm.201702-0405CP; Rello J, 2012, J CRIT CARE, V27, P434, DOI 10.1016/j.jcrc.2012.04.006; Ricard JD, 2003, AM J RESP CRIT CARE, V167, P1297, DOI 10.1164/rccm.2303003; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574, DOI 10.1001/jama.2011.1435; Riviello ED, 2016, AM J RESP CRIT CARE, V193, P52, DOI 10.1164/rccm.201503-0584OC; Ruan SY, 2014, CRIT CARE, V18, DOI 10.1186/cc13819; Schwarz MI, 2004, CHEST, V125, P1530, DOI 10.1378/chest.125.4.1530; Sekiguchi H, 2015, CHEST, V148, P912, DOI 10.1378/chest.15-0341; Shankar-Hari M, 2020, JAMA-J AM MED ASSOC, V323, P713, DOI 10.1001/jama.2019.22524; Shaver CM, 2014, CLIN CHEST MED, V35, P639, DOI 10.1016/j.ccm.2014.08.004; Shehabi Y, 2018, CRIT CARE MED, V46, P850, DOI 10.1097/CCM.0000000000003071; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012; Siegel DA, 2019, MMWR-MORBID MORTAL W, V68, P919, DOI 10.15585/mmwr.mm6841e3; Siegel JD, 2007, AM J INFECT CONTROL, V35, pS65, DOI 10.1016/j.ajic.2007.10.007; Sinha P, 2018, INTENS CARE MED, V44, P1859, DOI 10.1007/s00134-018-5378-3; Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1; Spragg RG, 2004, NEW ENGL J MED, V351, P884, DOI 10.1056/NEJMoa033181; Stapleton RD, 2005, CHEST, V128, P525, DOI 10.1378/chest.128.2.525; STAUB NC, 1974, PHYSIOL REV, V54, P678, DOI 10.1152/physrev.1974.54.3.678; STAUB NC, 1978, CHEST, V74, P559, DOI 10.1378/chest.74.5.559; Steinberg KP, 2006, NEW ENGL J MED, V354, P1671; Sud S, 2014, CAN MED ASSOC J, V186, pE381, DOI 10.1503/cmaj.140081; Sun SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059989; Suzuki S, 2004, CRIT CARE MED, V32, P144, DOI 10.1097/01.CCM.0000098857.14923.44; Taccone P, 2009, JAMA-J AM MED ASSOC, V302, P1977, DOI 10.1001/jama.2009.1614; Talmor D, 2008, NEW ENGL J MED, V359, P2095, DOI 10.1056/NEJMoa0708638; Thompson AE, 2020, JAMA INTERN MED, V180, P1537, DOI 10.1001/jamainternmed.2020.3030; Trillo-Alvarez C, 2011, EUR RESPIR J, V37, P604, DOI 10.1183/09031936.00036810; Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520; Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5; Villar J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1273-x; Vincent JL, 2001, INTENS CARE MED, V27, P1578, DOI 10.1007/s001340101077; Volpicelli G, 2012, INTENS CARE MED, V38, P577, DOI 10.1007/s00134-012-2513-4; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Wiedemann HP, 2000, JAMA-J AM MED ASSOC, V283, P1995; Wiedemann HP, 2002, CRIT CARE MED, V30, P1; WIENERKRONISH JP, 1991, J CLIN INVEST, V88, P864, DOI 10.1172/JCI115388; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yoshida T, 2017, AM J RESP CRIT CARE, V195, P985, DOI 10.1164/rccm.201604-0748CP; Yoshida T, 2016, CRIT CARE MED, V44, pE678, DOI 10.1097/CCM.0000000000001649; Yoshida T, 2013, AM J RESP CRIT CARE, V188, P1420, DOI 10.1164/rccm.201303-0539OC; Young D, 2013, NEW ENGL J MED, V368, P806, DOI 10.1056/NEJMoa1215716; Zeiher BG, 2004, CRIT CARE MED, V32, P1695, DOI 10.1097/01.CCM.0000133332.48386.85; Ziehr DR, 2020, AM J RESP CRIT CARE, V201, P1560, DOI 10.1164/rccm.202004-1163LE; Zimmerman GA, 1999, CHEST, V116, p18S, DOI 10.1378/chest.116.suppl_1.18S; ZIMMERMAN GA, 1983, AM REV RESPIR DIS, V127, P290	210	107	115	22	48	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 14	2021	398	10300					622	637		10.1016/S0140-6736(21)00439-6	http://dx.doi.org/10.1016/S0140-6736(21)00439-6		AUG 2021	16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ6OG	34217425	Green Published, Bronze			2023-01-03	WOS:000684589500021
J	Anand, S; Montez-Rath, ME; Han, JL; Garcia, P; Cadden, L; Hunsader, P; Kerschmann, R; Beyer, P; Boyd, SD; Chertow, GM; Parsonnet, J				Anand, Shuchi; Montez-Rath, Maria E.; Han, Jialin; Garcia, Pablo; Cadden, LinaCel; Hunsader, Patti; Kerschmann, Russell; Beyer, Paul; Boyd, Scott D.; Chertow, Glenn M.; Parsonnet, Julie			Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATITIS-B VACCINE; CORONAVIRUS; INFECTION	Background: Assessing the evolution of SARS-CoV-2 immune response among patients receiving dialysis can define its durability in a highly clinically relevant context because patients receiving dialysis share the characteristics of persons most susceptible to SARS-CoV-2 infection. Objective: To evaluate the persistence of SARS-CoV-2 receptor-binding domain (RBD) IgG in seroprevalent patients receiving dialysis. Design: Prospective. Setting: Nationwide sample from dialysis facilities. Patients: 2215 patients receiving dialysis who had evidence of SARS-CoV-2 infection as of July 2020. Measurements: Remainder plasma from routine monthly laboratories was used to measure semiquantitative RBD IgG index value over 6 months. Results: A total of 2063 (93%) seroprevalent patients reached an assay detectable response (IgG index value >= 1). Most (n = 1323, 60%) had responses in July with index values classified as high (IgG >= 10); 1003 (76%) remained within this stratum. Adjusted median index values declined slowly but continuously (July vs. December values were 21 vs. 13; P < 0.001). The trajectory of the response did not vary by age group, sex, race/ethnicity, or diabetes status. Patients without an assay detectable response (n = 137) were more likely to be White and in the younger (18 to 44 years) or older (>= 80 years) age groups and less likely to have diabetes and hypoalbuminemia. Limitation: Lack of data on symptoms or reverse transcriptase polymerase chain reaction diagnosis, cohort of persons who survived infection, and use of a semiquantitative assay. Conclusion: Despite impaired immunity, most seropositive patients receiving dialysis maintained RBD antibody levels over 6 months. A slow and continual decline in median antibody levels over time was seen, but no indication that subgroups with impaired immunity had a shorter-lived humoral response was found.	[Anand, Shuchi; Parsonnet, Julie] Stanford Univ, Stanford, CA 94305 USA; [Montez-Rath, Maria E.; Garcia, Pablo; Boyd, Scott D.; Chertow, Glenn M.; Parsonnet, Julie] Stanford Univ, 777 Welch Rd, Palo Alto, CA 94304 USA; [Han, Jialin] Stanford Univ, Sunnyvale, CA USA; [Cadden, LinaCel; Hunsader, Patti; Kerschmann, Russell; Beyer, Paul] Ascend Clin Lab, Redwood City, CA USA	Stanford University; Stanford University; Stanford University	Anand, S (corresponding author), Stanford Univ, 777 Welch Rd, Palo Alto, CA 94304 USA.	sanand2@stanford.edu; mmrath@stanford.edu	Han, Jialin/AFQ-6523-2022	Chertow, Glenn/0000-0002-7599-0534; Garcia, Pablo/0000-0002-8482-8192; han, Jialin/0000-0001-5731-8974; Parsonnet, Julie/0000-0001-7342-5366; Montez-Rath, Maria/0000-0001-5154-2182	National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [R01DK127138, K24DK085446]; Ascend Clinical Laboratories	National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Ascend Clinical Laboratories	By grants R01DK127138 (Dr. Anand) and K24DK085446 (Dr. Chertow) from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Ascend Clinical Laboratories supported the remainder plasma testing for SARS-CoV-2 antibodies.	Addetia A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02107-20; Anand S, 2020, LANCET, V396, P1335, DOI 10.1016/S0140-6736(20)32009-2; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Baumgarth N, 2020, J IMMUNOL, V205, P2342, DOI 10.4049/jimmunol.2000839; Broeders NE, 2011, CLIN J AM SOC NEPHRO, V6, P2573, DOI 10.2215/CJN.04670511; BUTI M, 1992, AM J NEPHROL, V12, P144, DOI 10.1159/000168436; CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019; Centers for Medicare & Medicaid Services, NAT COV DET NCD GLYC; Chen XY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00301-9; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Fang HC, 2002, NEPHRON, V91, P682, DOI 10.1159/000065031; Flythe JE, 2021, AM J KIDNEY DIS, V77, P190, DOI 10.1053/j.ajkd.2020.09.003; Grigoryan L, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101422; Grzelak L., 2020, SEX DIFFERENCES DECL, DOI [10.1101/2020.11.12.20230466, DOI 10.1101/2020.11.12.20230466]; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Hao L, 2007, QUANTILE REGRESSION; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Irsara C, 2021, CLIN CHEM LAB MED, V59, P1143, DOI 10.1515/cclm-2020-1758; Iyer AS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0367; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793; Lee WT, 2021, J INFECT DIS, V223, P47, DOI 10.1093/infdis/jiaa673; Legros V, 2021, CELL MOL IMMUNOL, V18, P318, DOI 10.1038/s41423-020-00588-2; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Ma H, 2021, SCI CHINA LIFE SCI, V64, P482, DOI 10.1007/s11427-020-1805-0; Marino MF, 2015, METRON, V73, P229, DOI 10.1007/s40300-015-0072-5; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Ng JH, 2020, KIDNEY INT, V98, P1530, DOI 10.1016/j.kint.2020.07.030; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Peces R, 1997, AM J KIDNEY DIS, V29, P239, DOI 10.1016/S0272-6386(97)90036-6; Phillips N, 2021, NATURE, V590, P382, DOI 10.1038/d41586-021-00396-2; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Ripperger TJ, 2020, IMMUNITY, V53, P925, DOI 10.1016/j.immuni.2020.10.004; Rodda LB, 2021, CELL, V184, P169, DOI [10.21203/rs.3.rs-57112/v1, 10.1016/j.cell.2020.11.029, 10.1101/2020.08.11.20171843]; Roltgen K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0240; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; U.S. Census Bureau American Community Survey, 2018, AM COMMUNITY SURVEY; U.S. Food and Drug Administration, EUA AUTH SER TEST PE; Vogtlander NPJ, 2004, VACCINE, V22, P2199, DOI 10.1016/j.vaccine.2003.11.046; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4	44	11	11	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG	2021	174	8					1073	+		10.7326/M21-0256	http://dx.doi.org/10.7326/M21-0256			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP3IW	34000201	Green Published			2023-01-03	WOS:000695277800017
J	Watts, G				Watts, Geoff			Drissa Diallo Obituary	LANCET			English	Biographical-Item																			0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2021	398	10295					114	114						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG0BQ	34246338				2023-01-03	WOS:000671078800012
J	Ferreira, GF; Sevilla, D; Oliveira, CN; Nogueira, LC; Arliani, GG; Oliveira, VO; Pereira, MV				Ferreira, Gabriel Ferraz; Sevilla, Davy; Oliveira, Carolinne Nascimento; Nogueira Junior, Luiz Carlos; Arliani, Gustavo Goncalves; Oliveira, Victor Otavio; Pereira Filho, Miguel Viana			Comparison of the effect of hyaluronic acid injection versus extracorporeal shockwave therapy on chronic plantar fasciitis: Protocol for a randomized controlled trial	PLOS ONE			English	Article							MODEL	Background Plantar fasciitis is the most common cause of pain in the plantar region of the heel, and extracorporeal shockwave therapy (ESWT) is an option used in cases where conservative treatment fails. Hyaluronic acid (HA), initially used for osteoarthrosis, is a treatment option because it has been applied to extra-articular regions, such as tendons, ligaments, and fascia. The aim of the present study will be to evaluate the outcomes of pain, function, and personal satisfaction after a single injection of HA and to compare the results with those of ESWT in patients with chronic plantar fasciitis. Methods The study will include 80 patients who will be randomized to receive three sessions of ESWT (n = 40) or a single ultrasound-guided HA injection in the plantar fascia (n = 40). The outcomes will include the visual analog pain scale score, American Orthopaedic Foot and Ankle Society (AOFAS) score, and Foot and Ankle Outcome Score (FAOS). All of the assessments will be performed at baseline and 3, 6, and 12 months after treatment. Statistical analysis will be performed using the repeated measures ANOVA (analysis of variance test) for primary and secondary outcomes and also Fisher's Least Significant Difference, a Post-Hoc test. We will use R software for statistical analysis, randomization, and sample size calculation. Results Recruitment and data collection will begin in November 2020, with completion scheduled for November 2022 and final publication available in March 2023. Conclusion This trial will evaluate the effects of a single ultrasound-guided HA injection for the treatment of chronic plantar fasciitis.	[Ferreira, Gabriel Ferraz; Pereira Filho, Miguel Viana] Prevent Senior, Orthopaed & Traumatol Unit, Foot & Ankle Surg Grp, Sao Paulo, Brazil; [Sevilla, Davy; Oliveira, Carolinne Nascimento; Nogueira Junior, Luiz Carlos] Prevent Senior, Dept Orthopaed & Traumatol, Sao Paulo, Brazil; [Arliani, Gustavo Goncalves; Oliveira, Victor Otavio] Prevent Senior, Orthopaed & Traumatol Unit, Sao Paulo, Brazil		Ferreira, GF (corresponding author), Prevent Senior, Orthopaed & Traumatol Unit, Foot & Ankle Surg Grp, Sao Paulo, Brazil.	gabriel.ferraz38@yahoo.com.br		Ferreira, Gabriel/0000-0001-8032-3077				Acevedo JI, 1998, FOOT ANKLE INT, V19, P91, DOI 10.1177/107110079801900207; Altman R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145776; Buchbinder R, 2004, NEW ENGL J MED, V350, P2159, DOI 10.1056/NEJMcp032745; Chew KTL, 2013, PM&R, V5, P1035, DOI 10.1016/j.pmrj.2013.08.590; Chinnery J., 2012, EXTRACORPOREAL SHOCK; Gallorini M, 2017, MLTJ-MUSCLE LIGAMENT, V7, P208, DOI 10.11138/mltj/2017.7.2.208; Genc H, 2005, JOINT BONE SPINE, V72, P61, DOI 10.1016/j.jbspin.2004.03.006; Gerdesmeyer L, 2008, AM J SPORT MED, V36, P2100, DOI 10.1177/0363546508324176; Gomis A, 2007, PAIN, V130, P126, DOI 10.1016/j.pain.2006.11.012; Greenberg DD, 2006, OSTEOARTHR CARTILAGE, V14, P814, DOI 10.1016/j.joca.2006.02.006; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Honda H, 2017, AM J SPORT MED, V45, P3322, DOI 10.1177/0363546517720199; Imoto AM, 2009, ACTA ORTOP BRAS, V17, P232, DOI 10.1590/S1413-78522009000400008; Kaux JF, 2015, MLTJ-MUSCLE LIGAMENT, V5, P264, DOI [10.11138/mltj/2015.5.3.264, 10.11138/mltj/2015.5.4.264]; KIBLER WB, 1991, AM J SPORT MED, V19, P66, DOI 10.1177/036354659101900111; KITAOKA HB, 1994, FOOT ANKLE INT, V15, P349, DOI 10.1177/107110079401500701; Kiter E, 2006, J AM PODIAT MED ASSN, V96, P293, DOI 10.7547/0960293; Kumai T, 2018, KNEE SURG SPORT TR A, V26, P903, DOI 10.1007/s00167-017-4467-0; Mrosek E, 2003, CELLS TISSUES ORGANS, V173, P93, DOI 10.1159/000068944; Ogden JA, 2004, J BONE JOINT SURG AM, V86A, P2216, DOI 10.2106/00004623-200410000-00013; Petrella RJ, 2007, CLIN J SPORT MED, V17, P251, DOI 10.1097/JSM.0b013e3180f6169f; Placzek R, 2006, CLIN J PAIN, V22, P190, DOI 10.1097/01.ajp.0000169674.34191.0e; Puttaswamaiah R., 2007, FOOT, V17, P3, DOI DOI 10.1016/J.FOOT.2006.07.005; ROLES N C, 1972, Journal of Bone and Joint Surgery British Volume, V54B, P499; Rompe JD, 2009, SPORTS MED ARTHROSC, V17, P100, DOI 10.1097/JSA.0b013e3181a3d60e; Saude Md., BRAZILIAN CLIN TRIAL; SELLMAN JR, 1994, FOOT ANKLE INT, V15, P376, DOI 10.1177/107110079401500706; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; Speed CA, 2007, BEST PRACT RES CL RH, V21, P333, DOI 10.1016/j.berh.2006.11.001; Team RC, 2014, R LANG ENV STAT COMP; Thomson CE, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-19; Yagishita K, 2005, ARTHROSCOPY, V21, P1330, DOI 10.1016/j.arthro.2005.08.020	33	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2021	16	6							e0250768	10.1371/journal.pone.0250768	http://dx.doi.org/10.1371/journal.pone.0250768			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BX	34166373	gold, Green Published			2023-01-03	WOS:000671692800085
J	Szilvay, A; Somogyi, O; Dobszay, A; Mesko, A; Zelko, R; Hanko, B				Szilvay, Andras; Somogyi, Orsolya; Dobszay, Annamaria; Mesko, Attilane; Zelko, Romana; Hanko, Balazs			Analysis of interaction risks of patients with polypharmacy and the pharmacist interventions performed to solve them-A multicenter descriptive study according to medication reviews in Hungarian community pharmacies	PLOS ONE			English	Article							DRUG-DRUG INTERACTIONS; PRESCRIBED DRUGS; PREVALENCE; ADULTS	Objective The study examined the Drug-Related Problems (DRPs) of patients with polypharmacy in 78 Hungarian community pharmacies, especially the interaction risks in terms of their clinical severity. Also, the objective was to analyze pharmacists' interventions to solve the identified interaction risks. Methodology The research was carried out in the framework of the training of specialist pharmacists at Semmelweis University, with the participation of 78 graduated pharmacists with the collaboration of 98 GPs. A total of 755 patients participated in pharmaceutical counseling which meant a medication review process. DRPs were uniformly categorized and the interventions were recorded by pharmacists, while a detailed analysis of interaction risks was performed by authors. Results A total of 984 DRPs were registered. The most common category of DRPs was the "non-quantitative safety problems" (62.6%). Interaction risk was the most common cause of DRPs (54.0%). The highest proportion of interaction risks were between two prescription drugs (66.7%). In 30.7% of interaction risks' cases, there was not known negative outcome. In contrast, it was recommended to modify the therapy in 14.9% of interaction risks. Acetylsalicylic acid (22.8%), acenocoumarol (17.7%), and diclofenac (13.9%) were the most common active substances which caused serious interaction risks. A total of 599 pharmacist interventions were used to solve the 531 interaction risks. Pharmacists notified the GPs about the problem in 28.4% of cases and they intervened without the GP in 63.1% of cases, most often with patient education (27.4%). Conclusion Medication review by community pharmacists is required for the safe medicine using of patients with polypharmacy, as a significant number of DRPs have been recorded. The incidence of interaction risks stood out. It is essential to develop a pharmaceutical guideline to properly classify the clinical relevance of interaction risks (e.g. according to high-risk active substances) and to increase the collaboration with GPs.	[Szilvay, Andras; Somogyi, Orsolya; Dobszay, Annamaria; Mesko, Attilane; Zelko, Romana; Hanko, Balazs] Semmelweis Univ, Univ Pharm Dept Pharm Adm, Budapest, Hungary	Semmelweis University	Szilvay, A (corresponding author), Semmelweis Univ, Univ Pharm Dept Pharm Adm, Budapest, Hungary.	szilvay.andras@pharma.semmelweis-univ.hu	Szilvay, Andras/Q-9374-2017	Szilvay, Andras/0000-0003-4624-5911				Administration USFD, DRUG DEV DRUG INT TA; Al-Qerem W., 2018, BIOMED RES, P2561, DOI 10.4066/biomedicalresearch.29-18-618; Aljadani Rawabi, 2018, BMC Res Notes, V11, P234, DOI 10.1186/s13104-018-3342-5; [Anonymous], 2007, ARS PHARM, V48, P5; Asher GN, 2017, AM FAM PHYSICIAN, V96, P101; Association PCNE, 2019, PCNE CLASS DRUG REL; Capacities MoH, 2013, PROF DIR MED REV FRA; Dechanont S, 2014, PHARMACOEPIDEM DR S, V23, P489, DOI 10.1002/pds.3592; Eljaaly K, 2019, CLIN MICROBIOL INFEC, V25, P620, DOI 10.1016/j.cmi.2018.08.002; Ersoy S, 2018, CLIN INTERV AGING, V13, P2003, DOI 10.2147/CIA.S176329; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Halli-Tierney AD, 2019, AM FAM PHYSICIAN, V100, P32; Holm J, 2014, EUR J CLIN PHARMACOL, V70, P1375, DOI 10.1007/s00228-014-1745-3; Hungarian National Committee of pharmaceutical care, 2009, MET SYNDR PHARM CAR; Ismail M, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3579-7; Jazbar J, 2018, RES SOC ADMIN PHARM, V14, P572, DOI 10.1016/j.sapharm.2017.07.004; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Letinier L, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00265; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; Manzoor BS, 2017, ANN PHARMACOTHER, V51, P1122, DOI 10.1177/1060028017721241; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; Mekonnen AB, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010003; Menditto E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210701; Mistry M, 2017, J YOUNG PHARM, V9, P371, DOI 10.5530/jyp.2017.9.74; Mousavi S, 2017, CASP J INTERN MED, V8, P282, DOI 10.22088/cjim.8.4.282; Nabovati E, 2016, RES PHARM SCI, V11, P233; Nikolic B, 2014, CENT EUR J MED, V9, P348, DOI 10.2478/s11536-013-0272-4; Nusair MB, 2020, SAUDI PHARM J, V28, P155, DOI 10.1016/j.jsps.2019.11.009; Olsen RM, 2018, SAFETY HLTH, V4, P1; Park HY, 2016, INT J CLIN PHARM TH, V54, P369, DOI 10.5414/CP202484; Patel Pankti S, 2014, J Basic Clin Pharm, V5, P44, DOI 10.4103/0976-0105.134983; Samardzic I, 2017, PHARMAZIE, V72, P187, DOI 10.1691/ph.2017.6855; Sancar M, 2019, TURK J PHARM SCI, V16, P14, DOI 10.4274/tjps.30932; Schorr SG, 2014, PHARMAZIE, V69, P316, DOI 10.1691/ph.2014.3848; Sell R, 2020, INT J CLIN PHARM-NET, V42, P588, DOI 10.1007/s11096-020-00976-8; Shenoy Premnath, 2015, Perspect Clin Res, V6, P184, DOI 10.4103/2229-3485.167099; Silva C, 2015, INT J CLIN PHARM-NET, V37, P327, DOI 10.1007/s11096-014-0063-2; Somogyi-Vegh A., 2019, BMC PHARMACOL TOXICO, V20, P1, DOI [10.1186/s40360-018-0281-7, DOI 10.1186/S40360-018-0281-7]; Szilvay A, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4114-1; Tannenbaum C, 2014, EXPERT REV CLIN PHAR, V7, P533, DOI 10.1586/17512433.2014.910111	40	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2021	16	6							e0253645	10.1371/journal.pone.0253645	http://dx.doi.org/10.1371/journal.pone.0253645			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BH	34157039	Green Published, gold			2023-01-03	WOS:000671691200031
J	Hessheimer, AJ; Trapero-Bertran, M; Borin, A; Butori, E; Curell, A; Espinoza, AS; Jensen, J; Turrado, V; Morales, X; de Lacy, AM; Fondevila, C				Hessheimer, Amelia J.; Trapero-Bertran, Marta; Borin, Alex; Butori, Eugenia; Curell, Anna; Sofia Espinoza, Arlena; Jensen, Joaquin; Turrado, Victor; Morales, Xavier; Maria de Lacy, Antonio; Fondevila, Constantino			Resource utilization and outcomes in emergency general surgery during the COVID19 pandemic: An observational cost analysis	PLOS ONE			English	Article							IMPACTS	Background Over the course of the COVID19 pandemic, global healthcare delivery has declined. Surgery is one of the most resource-intensive area of medicine; loss of surgical care has had untold health and economic consequences. Herein, we evaluate resource utilization, outcomes, and healthcare costs associated with unplanned surgery admissions during the height of the pandemic in 2020 versus the same period in 2019. Methods Retrospective analysis on patients >= 18 years admitted from the emergency department to General & Digestive and Gastrointestinal Surgery Services between February and May 2019 and 2020 at our center; clinical outcomes and unadjusted and adjusted per-person healthcare costs were analyzed. Results Consults and admissions to surgery declined between February and May 2020 by 37% and 19%, respectively, relative to the same period in 2019, with even greater relative decline during late March and early April. Time between onset of symptoms to diagnosis increased from 2 +/- 3 days 2019 to 5 +/- 22 days 2020 (P = 0.01). Overall hospital stay was two days less in 2020 (P = 0.19). Complications (Comprehensive Complication Index 10.3 +/- 23.7 2019 vs. 13.9 +/- 25.5 2020, P = 0.10) and mortality rates (3% vs. 4%, respectively, P = 0.58) did not vary. Mean unadjusted per-person costs for patients in the 2019 and 2020 cohorts were 5,886.72euro +/- 12,576.33euro and 5,287.62 +/- 7,220.16euro, respectively (P = 0.43). Following multivariate analysis, costs remained similar (4,656.89euro +/- 390.53euro 2019 vs. 4,938.54 +/- 406.55euro 2020, P = 0.28). Conclusions Healthcare delivery and spending for unplanned general surgery admissions declined considerably due to COVID19. These results provide a small yet relevant illustration of clinical and economic ramifications of this healthcare crisis.	[Hessheimer, Amelia J.; Fondevila, Constantino] Univ Barcelona, Hosp Clin Barcelona, Inst Malaties Digest & Metab ICMDM, CIBERehd,Gen & Digest Surg,IDIBAPS, Barcelona, Spain; [Trapero-Bertran, Marta] Univ Int Catalunya Barcelona, Univ Inst Patient Care, Basic Sci Dept, Barcelona, Spain; [Borin, Alex; Butori, Eugenia; Sofia Espinoza, Arlena; Jensen, Joaquin] Hosp Clin Barcelona, ICMDM, Gen & Digest Surg, Barcelona, Spain; [Butori, Eugenia; Curell, Anna; Sofia Espinoza, Arlena; Turrado, Victor; Morales, Xavier; Maria de Lacy, Antonio] Hosp Clin Barcelona, ICMDM, Gastrointestinal Surg, Barcelona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universitat Internacional de Catalunya (UIC); University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	Hessheimer, AJ (corresponding author), Univ Barcelona, Hosp Clin Barcelona, Inst Malaties Digest & Metab ICMDM, CIBERehd,Gen & Digest Surg,IDIBAPS, Barcelona, Spain.	HESSHEIMER@gmail.com	Hessheimer, Amelia/N-1855-2019; Trapero-Bertran, Marta/D-7437-2014; Fondevila, Constantino/B-8769-2016	Hessheimer, Amelia/0000-0002-7247-5051; Trapero-Bertran, Marta/0000-0002-9233-1776; Fondevila, Constantino/0000-0002-6161-6824				Baugh JJ., 2020, AM J EMERG MED; Bemanian M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18010130; Boyle L, 2020, NEW ZEAL MED J, V133, P96; Bugaev N, 2020, AM SURGEON, V86, P1629, DOI 10.1177/0003134820972084; Chatterji P, 2021, MED CARE, V59, P58, DOI 10.1097/MLR.0000000000001448; Curell A, 2020, J VISC SURG, P19; Doyle DJ., 2020, STATPEARLS; Glick H, 2007, EC EVALUATION CLIN T; Gondi S, 2020, JAMA-J AM MED ASSOC, V324, P1596, DOI 10.1001/jama.2020.18343; Hashmi P, 2020, ANN MED SURG, V60, P5, DOI 10.1016/j.amsu.2020.09.049; Hessheimer AJ, 2020, BRIT J SURG, V107, pE545, DOI 10.1002/bjs.11882; Li S, 2020, J NEUROSURG ANESTHES; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Garcia JMM, 2020, ATEN PRIM, V52, P676, DOI 10.1016/j.aprim.2020.10.003; Morales X, 2020, EMERGENCIAS, V32, P435; Nash DB, 2020, POPUL HEALTH MANAG, V23, P378, DOI 10.1089/pop.2020.0161; Naughton F, 2021, HLTH BEHAV CHANGE UK; O'Connell RM, 2021, SURG-J R COLL SURG E, V19, pE207, DOI 10.1016/j.surge.2020.09.013; Plott CF, 2020, JAMA-J AM MED ASSOC, V324, P1713, DOI 10.1001/jama.2020.19925; Riquelme F, 2020, UPDATES SURG, V72, P1041, DOI 10.1007/s13304-020-00854-y; Robinson E, 2020, OBES SCI PRACT, V6, P735, DOI 10.1002/osp4.442; Slankamenac K, 2013, ANN SURG, V258, P1, DOI 10.1097/SLA.0b013e318296c732; Staiger RD, 2018, ANN SURG, V268, P784, DOI 10.1097/SLA.0000000000002902; Thiel CL, 2015, ENVIRON SCI TECHNOL, V49, P1779, DOI 10.1021/es504719g; Zhang YN, 2020, BMJ GLOB HEAL, V5, P1	25	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2021	16	6							e0252919	10.1371/journal.pone.0252919	http://dx.doi.org/10.1371/journal.pone.0252919			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BC	34143802	gold, Green Published			2023-01-03	WOS:000671690700045
J	Dankiewicz, J; Cronberg, T; Lilja, G; Jakobsen, JC; Levin, H; Ullen, S; Rylander, C; Wise, MP; Oddo, M; Cariou, A; Belohlavek, J; Hovdenes, J; Saxena, M; Kirkegaard, H; Young, PJ; Pelosi, P; Storm, C; Taccone, FS; Joannidis, M; Callaway, C; Eastwood, GM; Morgan, MPG; Nordberg, P; Erlinge, D; Nichol, AD; Chew, MS; Hollenberg, J; Thomas, M; Bewley, J; Sweet, K; Grejs, AM; Christensen, S; Haenggi, M; Levis, A; Lundin, A; During, J; Schmidbauer, S; Keeble, TR; Karamasis, GV; Schrag, C; Faessler, E; Smid, O; Otahal, M; Maggiorini, M; Garcia, PWD; Jaubert, P; Cole, JM; Solar, M; Borgquist, O; Leithner, C; Abed-Maillard, S; Navarra, L; Annborn, M; Unden, J; Brunetti, I; Awad, A; McGuigan, P; Olsen, RB; Cassina, T; Vignon, P; Langeland, H; Lange, T; Friberg, H; Nielsen, N				Dankiewicz, Josef; Cronberg, Tobias; Lilja, Gisela; Jakobsen, Janus C.; Levin, Helena; Ullen, Susann; Rylander, Christian; Wise, Matt P.; Oddo, Mauro; Cariou, Alain; Belohlavek, Jan; Hovdenes, Jan; Saxena, Manoj; Kirkegaard, Hans; Young, Paul J.; Pelosi, Paolo; Storm, Christian; Taccone, Fabio S.; Joannidis, Michael; Callaway, Clifton; Eastwood, Glenn M.; Morgan, Matt P. G.; Nordberg, Per; Erlinge, David; Nichol, Alistair D.; Chew, Michelle S.; Hollenberg, Jacob; Thomas, Matthew; Bewley, Jeremy; Sweet, Katie; Grejs, Anders M.; Christensen, Steffen; Haenggi, Matthias; Levis, Anja; Lundin, Andreas; During, Joachim; Schmidbauer, Simon; Keeble, Thomas R.; Karamasis, Grigoris V.; Schrag, Claudia; Faessler, Edith; Smid, Ondrej; Otahal, Michal; Maggiorini, Marco; Wendel Garcia, Pedro D.; Jaubert, Paul; Cole, Jade M.; Solar, Miroslav; Borgquist, Ola; Leithner, Christoph; Abed-Maillard, Samia; Navarra, Leanlove; Annborn, Martin; Unden, Johan; Brunetti, Iole; Awad, Akil; McGuigan, Peter; Bjorkholt Olsen, Roy; Cassina, Tiziano; Vignon, Philippe; Langeland, Halvor; Lange, Theis; Friberg, Hans; Nielsen, Niklas		TTM2 Trial Invest	Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TARGETED TEMPERATURE MANAGEMENT; EUROPEAN RESUSCITATION COUNCIL; AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY-RESUSCITATION; GUIDELINES	Hypothermia or Normothermia after Cardiac Arrest This trial randomly assigned patients with coma after out-of-hospital cardiac arrest to undergo targeted hypothermia at 33 degrees C or normothermia with treatment of fever. At 6 months, there were no significant between-group differences regarding death or functional outcomes. Background Targeted temperature management is recommended for patients after cardiac arrest, but the supporting evidence is of low certainty. Methods In an open-label trial with blinded assessment of outcomes, we randomly assigned 1900 adults with coma who had had an out-of-hospital cardiac arrest of presumed cardiac or unknown cause to undergo targeted hypothermia at 33 degrees C, followed by controlled rewarming, or targeted normothermia with early treatment of fever (body temperature, >= 37.8 degrees C). The primary outcome was death from any cause at 6 months. Secondary outcomes included functional outcome at 6 months as assessed with the modified Rankin scale. Prespecified subgroups were defined according to sex, age, initial cardiac rhythm, time to return of spontaneous circulation, and presence or absence of shock on admission. Prespecified adverse events were pneumonia, sepsis, bleeding, arrhythmia resulting in hemodynamic compromise, and skin complications related to the temperature management device. Results A total of 1850 patients were evaluated for the primary outcome. At 6 months, 465 of 925 patients (50%) in the hypothermia group had died, as compared with 446 of 925 (48%) in the normothermia group (relative risk with hypothermia, 1.04; 95% confidence interval [CI], 0.94 to 1.14; P=0.37). Of the 1747 patients in whom the functional outcome was assessed, 488 of 881 (55%) in the hypothermia group had moderately severe disability or worse (modified Rankin scale score >= 4), as compared with 479 of 866 (55%) in the normothermia group (relative risk with hypothermia, 1.00; 95% CI, 0.92 to 1.09). Outcomes were consistent in the prespecified subgroups. Arrhythmia resulting in hemodynamic compromise was more common in the hypothermia group than in the normothermia group (24% vs. 17%, P<0.001). The incidence of other adverse events did not differ significantly between the two groups. Conclusions In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not lead to a lower incidence of death by 6 months than targeted normothermia. (Funded by the Swedish Research Council and others; TTM2 ClinicalTrials.gov number, .)	[Dankiewicz, Josef; Erlinge, David] Lund Univ, Skane Univ Hosp Lund, Dept Clin Sci Lund, Sect Cardiol, Lund, Sweden; [Cronberg, Tobias; Lilja, Gisela] Lund Univ, Skane Univ Hosp Lund, Sect Neurol, Lund, Sweden; [Levin, Helena; Borgquist, Ola] Lund Univ, Skane Univ Hosp Lund, Sect Anesthesiol & Intens Care, Lund, Sweden; [Ullen, Susann] Skane Univ Hosp, Clin Studies Sweden Forum South, Lund, Sweden; [During, Joachim; Schmidbauer, Simon; Friberg, Hans] Skane Univ Hosp Malmo, Sect Anesthesia & Intens Care, Dept Clin Sci Lund, Malmo, Sweden; [Annborn, Martin; Nielsen, Niklas] Helsingborg Hosp, Dept Clin Sci Lund, Sect Anesthesiol & Intens Care, Helsingborg, Sweden; [Nielsen, Niklas] Helsingborg Hosp, Sect Clin Sci Helsingborg, Helsingborg, Sweden; [Unden, Johan] Hallands Hosp, Sect Anesthesiol & Intens Care Lund, Dept Clin Sci Lund, Halmstad, Sweden; [Rylander, Christian; Lundin, Andreas] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Anesthesiol & Intens Care Med, Gothenburg, Sweden; [Nordberg, Per; Hollenberg, Jacob; Awad, Akil] Karolinska Inst, Dept Clin Sci & Educ, Ctr Resuscitat Sci, Sodersjukhuset, Stockholm, Sweden; [Chew, Michelle S.] Linkoping Univ, Dept Anesthesiol Intens Care & Acute Med, Linkoping, Sweden; [Jakobsen, Janus C.] Univ Copenhagen, Copenhagen Trial Unit, Ctr Clin Intervent Res, Copenhagen Univ Hosp, Copenhagen, Denmark; [Lange, Theis] Univ Copenhagen, Sect Biostat, Fac Hlth & Med Sci, Copenhagen, Denmark; [Jakobsen, Janus C.] Univ Southern Denmark, Dept Reg Hlth Res, Fac Hlth Sci, Odense, Denmark; [Kirkegaard, Hans] Aarhus Univ Hosp, Res Ctr Emergency Med, Dept Clin Med, Aarhus, Denmark; [Grejs, Anders M.; Christensen, Steffen] Aarhus Univ Hosp, Dept Intens Care, Aarhus, Denmark; [Wise, Matt P.; Morgan, Matt P. G.; Cole, Jade M.] Univ Hosp Wales, Adult Crit Care, Cardiff, Wales; [Thomas, Matthew; Bewley, Jeremy; Sweet, Katie] Bristol Royal Infirm & Gen Hosp, Dept Intens Care, Bristol, Avon, England; [Keeble, Thomas R.; Karamasis, Grigoris V.] Essex Cardiothorac Ctr, Basildon, England; [Keeble, Thomas R.; Karamasis, Grigoris V.] Anglia Ruskin Univ, Sch Med, Chelmsford, Essex, England; [McGuigan, Peter] Royal Victoria Hosp, Dept Anesthesiol & Intens Care, Belfast, Antrim, North Ireland; [Oddo, Mauro; Abed-Maillard, Samia] Lausanne Univ Hosp, Ctr Hosp Univ Vaudois, Neurosci Crit Care Res Grp, Lausanne, Switzerland; [Oddo, Mauro; Abed-Maillard, Samia] Lausanne Univ Hosp, Ctr Hosp Univ Vaudois, Adult Intens Care Med Serv, Lausanne, Switzerland; [Oddo, Mauro; Abed-Maillard, Samia] Univ Lausanne, Lausanne, Switzerland; [Haenggi, Matthias] Univ Bern, Bern Univ Hosp, Dept Intens Care Med, Bern, Switzerland; [Levis, Anja] Univ Bern, Bern Univ Hosp, Dept Anesthesiol & Pain Med, Inselspital, Bern, Switzerland; [Schrag, Claudia; Faessler, Edith] Kantonsspital St Gallen, Intens Care Dept, St Gallen, Switzerland; [Maggiorini, Marco; Wendel Garcia, Pedro D.] Univ Hosp Zurich, Inst Intens Care Med, Zurich, Switzerland; [Cassina, Tiziano] Inst Cardioctr Ticino, Cardiac Anesthesia & Intens Care Dept, Lugano, Switzerland; [Cariou, Alain; Jaubert, Paul] Descartes Univ Paris, Paris, France; [Cariou, Alain; Jaubert, Paul] Cochin Univ Hosp, Paris, France; [Vignon, Philippe] Dupuytren Teaching Hosp, Med Surg Intens Care Unit, Limoges, France; [Belohlavek, Jan; Smid, Ondrej] Charles Univ Prague, Gen Univ Hosp, Dept Med 2, Prague, Czech Republic; [Otahal, Michal] Charles Univ Prague, Gen Univ Hosp, Dept Anesthesiol & Intens Care Med, Prague, Czech Republic; [Otahal, Michal] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Solar, Miroslav] Charles Univ Prague, Dept Internal Med Cardioangiol 1, Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; [Solar, Miroslav] Charles Univ Prague, Fac Med, Hradec Kralove, Czech Republic; [Hovdenes, Jan] Oslo Univ Hosp, Div Emergencies & Crit Care, Dept Anesthesiol, Rikshospitalet, Oslo, Norway; [Bjorkholt Olsen, Roy] Sorlandet Hosp, Dept Anesthesiol, Arendal, Norway; [Langeland, Halvor] Norwegian Univ Sci & Technol, Dept Anesthesiol & Intens Care Med, St Olavs Univ Hosp, Trondheim, Norway; [Langeland, Halvor] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Fac Med & Hlth Sci, Trondheim, Norway; [Saxena, Manoj] South Western Sydney Local Hlth Dist, Div Crit Care & Trauma, George Inst Global Hlth, Sydney, NSW, Australia; [Saxena, Manoj] South Western Sydney Local Hlth Dist, Bankstown Lidcombe Hosp, Sydney, NSW, Australia; [Eastwood, Glenn M.; Nichol, Alistair D.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Nichol, Alistair D.] Monash Univ, Alfred Hlth, Dept Intens Care, Melbourne, Vic, Australia; [Young, Paul J.; Navarra, Leanlove] Wellington Hosp, Med Res Inst New Zealand, Intens Care Unit, Wellington, New Zealand; [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, Genoa, Italy; [Pelosi, Paolo; Brunetti, Iole] Univ Genoa, Dept Anesthesiol & Intens Care, San Martino Policlin Hosp, IRCCS Oncol & Neurosci, Genoa, Italy; [Storm, Christian] Charite, Dept Nephrol & Med Intens Care, Berlin, Germany; [Leithner, Christoph] Charite, Klin & Hochschulambulanz Neurol, Berlin, Germany; [Taccone, Fabio S.] Univ Libre Bruxelles, Dept Intens Care, Erasme Univ Hosp, Brussels, Belgium; [Joannidis, Michael] Med Univ Innsbruck, Div Intens Care & Emergency Med, Dept Internal Med, Innsbruck, Austria; [Callaway, Clifton] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA; [Nichol, Alistair D.] Univ Coll Dublin, Clin Res Ctr, St Vincents Univ Hosp, Dublin, Ireland	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Helsingborgs Hospital; Helsingborgs Hospital; University of Gothenburg; Karolinska Institutet; Sodersjukhuset Hospital; Linkoping University; University of Copenhagen; University of Copenhagen; University of Southern Denmark; Aarhus University; Aarhus University; Cardiff University; Bristol Royal Infirmary; Anglia Ruskin University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; Kantonsspital St. Gallen; University of Zurich; University Zurich Hospital; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Limoges; Charles University Prague; General University Hospital Prague; Charles University Prague; General University Hospital Prague; Charles University Prague; Charles University Prague; University Hospital Hradec Kralove; Charles University Prague; University Hospital Hradec Kralove; University of Oslo; National Hospital Norway; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); George Institute for Global Health; University of Sydney; Monash University; Monash University; Medical Research Institute Of New Zealand; University of Genoa; University of Genoa; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Universite Libre de Bruxelles; Medical University of Innsbruck; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University College Dublin; Saint Vincent's University Hospital	Nielsen, N (corresponding author), Helsingborg Hosp, Dept Anesthesiol & Intens Care, Intens Care Unit, S Vallgatan 5, S-25187 Helsingborg, Sweden.	niklas.nielsen@med.lu.se	bonatti, giulia/AAD-4989-2022; Jakobsen, Janus Christian/N-2419-2013; Battaglini, Denise/X-6446-2019; Malik, Jan/K-8681-2019; Solar, Miroslav/Q-1707-2017; Ben-Hamouda, Nawfel/AAM-2416-2020; Cassina, Tiziano/AAG-4891-2019; Rylander, Christian/AAV-3713-2020; Borgquist, Ola/AAO-6451-2020; Wendel Garcia, Pedro David/AAU-4579-2021; Evrard, Bruno/AGJ-3970-2022; Shankar-Hari, Manu/I-6948-2012; During, Joachim/GZM-7829-2022	Jakobsen, Janus Christian/0000-0002-3642-2120; Battaglini, Denise/0000-0002-6895-6442; Malik, Jan/0000-0002-2386-3293; Solar, Miroslav/0000-0002-5542-552X; Ben-Hamouda, Nawfel/0000-0003-4428-5223; Cassina, Tiziano/0000-0001-9700-1584; Rylander, Christian/0000-0002-4534-7150; Wendel Garcia, Pedro David/0000-0001-7775-3279; Evrard, Bruno/0000-0003-1829-4927; Shankar-Hari, Manu/0000-0002-5338-2538; During, Joachim/0000-0003-1538-9824; Lange, Theis/0000-0001-6807-8347; , giulia/0000-0003-2290-7749; Lilja, Gisela/0000-0003-1860-1456; Morgan, Matt/0000-0002-2357-7190; Leithner, Christoph/0000-0002-8277-846X; Melegari, Gabriele/0000-0003-4512-4835; Young, Paul/0000-0002-3428-3083; Bannard-Smith, Jonathan/0000-0001-7120-480X; Myburgh, John/0000-0003-4088-7016; Karamasis, Grigoris/0000-0002-4560-7629; Mion, Marco/0000-0002-3656-5965; Schmidbauer, Simon/0000-0002-5243-7170; Saxena, Manoj/0000-0002-0385-6731; Nichol, Alistair/0000-0002-4689-1238; Juhl-Olsen, Peter/0000-0003-1951-9091				Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Cronberg T, 2020, LANCET NEUROL, V19, P611, DOI 10.1016/S1474-4422(20)30117-4; Dankiewicz J, 2019, AM HEART J, V217, P23, DOI 10.1016/j.ahj.2019.06.012; Gotzsche PC, 1996, CONTROL CLIN TRIALS, V17, P285, DOI 10.1016/0197-2456(95)00263-4; Haywood K, 2018, CIRCULATION, V137, pE783, DOI 10.1161/CIR.0000000000000562; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Jakobsen JC, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04654-y; Jakobsen JC, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0442-1; Kelly FE, 2010, ANAESTHESIA, V65, P505, DOI 10.1111/j.1365-2044.2009.06237.x; Kirkegaard H, 2017, JAMA-J AM MED ASSOC, V318, P341, DOI 10.1001/jama.2017.8978; Lascarrou JB, 2019, NEW ENGL J MED, V381, P2327, DOI 10.1056/NEJMoa1906661; Lilja Gisela, 2020, Resuscitation, V150, P104, DOI 10.1016/j.resuscitation.2020.03.004; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nielsen N, 2011, INT J CARDIOL, V151, P333, DOI 10.1016/j.ijcard.2010.06.008; Nolan JP, 2015, RESUSCITATION, V95, P202, DOI 10.1016/j.resuscitation.2015.07.018; Olai H, 2020, INTENS CARE MED EXP, V8, DOI 10.1186/s40635-019-0291-9; Panchal AR, 2020, CIRCULATION, V142, pS366, DOI 10.1161/CIR.0000000000000916; Patterson T, 2018, CIRC-CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.117.005346; Pereira TV, 2012, JAMA-J AM MED ASSOC, V308, P1676, DOI 10.1001/jama.2012.13444; R Core Team Rf.., 2013, R LANG ENV STAT COMP; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	26	225	229	9	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2021	384	24					2283	2294		10.1056/NEJMoa2100591	http://dx.doi.org/10.1056/NEJMoa2100591			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SV2KH	34133859	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000663653100012
J	Majimbi, M; Brook, E; Galettis, P; Eden, E; Al-Salami, H; Mooranian, A; Al-Sallami, H; Lam, V; Mamo, JCL; Takechi, R				Majimbi, Maimuna; Brook, Emily; Galettis, Peter; Eden, Edward; Al-Salami, Hani; Mooranian, Armin; Al-Sallami, Hesham; Lam, Virginie; Mamo, John C. L.; Takechi, Ryusuke			Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid	PLOS ONE			English	Article								Background Cannabidiol (CBD) confers therapeutic effects in some neurological disorders via modulation of inflammatory, oxidative and cell-signalling pathways. However, CBD is lipophilic and highly photooxidative with low oral bioavailability in plasma and brain. In this study, we aimed to design and test a CBD microencapsulation method as a drug delivery strategy to improve the absorption of CBD. Additionally, we evaluated the brain uptake of CBD capsules when administered alongside capsules containing a permeation-modifying bile acid, deoxycholic acid (DCA). Methods Microcapsules containing either CBD or DCA were formed using the ionic gelation method with 1.5% sodium alginate formulations and 100 mM calcium chloride. C57BL/6J wild type mice randomly assigned to three treatment groups (3-4 mice per group) were administered CBD in the following preparations: 1) CBD capsules, 2) CBD capsules + DCA capsules and 3) naked CBD oil (control). To assess the short-term bioavailability of CBD, plasma and brain samples were collected at 0.3, 1 and 3 hours post administration and CBD levels were analysed with liquid chromatography mass spectrometer. Results We produced spherical capsules at 400 +/- 50 mu m in size. The CBD capsules were calculated to have a drug loading of 2% and an encapsulation efficiency of 23%. Mice that received CBD capsules + DCA capsules showed a 40% and 47% increase in CBD plasma concentration compared to mice on CBD capsules and naked CBD oil, respectively. Furthermore, the CBD capsules + DCA capsules group showed a 48% and 25% increase in CBD brain concentration compared to mice on CBD capsules and naked CBD oil, respectively. In mice treated with CBD capsules + DCA capsules, the brain CBD concentration peaked at 0.3 hours with a 300% increased availability compared to CBD capsules and naked CBD oil groups, which peaked at 1 hour after administration. Conclusions The microencapsulation method combined with a permeation enhancer, DCA increased the short-term bioavailability of CBD in plasma and brain.	[Majimbi, Maimuna; Brook, Emily; Al-Salami, Hani; Mooranian, Armin; Lam, Virginie; Mamo, John C. L.; Takechi, Ryusuke] Curtin Univ, Curtin Hlth Innovat Res Inst, Perth, WA, Australia; [Majimbi, Maimuna; Lam, Virginie; Mamo, John C. L.; Takechi, Ryusuke] Curtin Univ, Fac Hlth Sci, Sch Populat Hlth, Perth, WA, Australia; [Brook, Emily; Al-Salami, Hani; Mooranian, Armin] Curtin Univ, Fac Hlth Sci, Curtin Med Sch, Perth, WA, Australia; [Galettis, Peter; Eden, Edward] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia; [Galettis, Peter; Eden, Edward] Australian Ctr Cannabinoid Clin & Res Excellence, Newcastle, NSW, Australia; [Al-Sallami, Hesham] Univ Otago, Sch Pharm, Otago, New Zealand	Curtin University; Curtin University; Curtin University; University of Newcastle; University of Otago	Takechi, R (corresponding author), Curtin Univ, Curtin Hlth Innovat Res Inst, Perth, WA, Australia.; Takechi, R (corresponding author), Curtin Univ, Fac Hlth Sci, Sch Populat Hlth, Perth, WA, Australia.	R.Takechi@curtin.edu.au	Takechi, Ryu/T-9970-2019; Takechi, Ryusuke/D-3692-2012	Takechi, Ryu/0000-0001-6359-3382; Takechi, Ryusuke/0000-0001-6359-3382; Mooranian, Armin/0000-0001-7103-2067; Al-Sallami, Hesham/0000-0002-0685-327X; Mamo, John/0000-0002-5741-7849; Lam, Virginie/0000-0001-8463-645X	Zelira Therapeutics Ltd	Zelira Therapeutics Ltd	Zelira Therapeutics Ltd provided financial support for the study to cover all experimental cost. The authors do not have any ownership of stocks or shares; paid employment or consultancy; or board membership; nor received any research grants; travel grants or honoraria for speaking or participation at meetings; research materials; or gifts from the company. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson LL, 2019, J NAT PROD, V82, P3047, DOI 10.1021/acs.jnatprod.9b00600; [Anonymous], 2016, ASIA-PAC J CLIN ONCO; Bartner LR., 2018, CAN J VET RES; Bih CI, 2015, NEUROTHERAPEUTICS, V12, P699, DOI 10.1007/s13311-015-0377-3; Bruni N, 2018, MOLECULES, V23, DOI 10.3390/molecules23102478; Cabral GA, 2014, INT REV NEUROBIOL, V118, P199, DOI 10.1016/B978-0-12-801284-0.00008-7; Chan LW., 2000, J MICROENCAPSUL, DOI [10.1080/02652040050161747, DOI 10.1080/02652040050161747]; Chiang JYL, 2013, COMPR PHYSIOL, V3, P1191, DOI 10.1002/cphy.c120023; Deiana S., 2012, PSYCHOPHARMACOLOGY; Horvth B., 2012, AM J PATHOL; Iffland K, 2017, CANNABIS CANNABINOID, V2, P139, DOI 10.1089/can.2016.0034; Kaur R, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0763-3; Long LE, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0051782, 10.1371/journal.pone.0034129]; Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897; Mamo JCL, 2018, THER DELIV, V9, P703, DOI 10.4155/tde-2018-0033; Martin-Moreno AM, 2011, MOL PHARMACOL, V79, P964, DOI 10.1124/mol.111.071290; Millar SA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01365; Mooranian A., 2019, THER DELIV; Mooranian A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-53999-1; Mooranian A, 2014, DRUG DES DEV THER, V8, P1003, DOI 10.2147/DDDT.S65396; Pavlovic N, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01283; Rajesh M, 2007, AM J PHYSIOL-HEART C, V293, pH610, DOI 10.1152/ajpheart.00236.2007; Ruiz-Valdepenas L, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-5; Wagle SR, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12080708; Wagle SR, 2020, EXPERT OPIN DRUG DEL, V17, P1361, DOI 10.1080/17425247.2020.1789587; Wagle SR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64355-z; Xu C, 2019, ENVIRON TOXICOL PHAR, V70, DOI 10.1016/j.etap.2019.103202; Zhang Y, 2010, COMPUT METH PROG BIO, V99, P306, DOI 10.1016/j.cmpb.2010.01.007	29	3	4	3	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2021	16	6							e0243858	10.1371/journal.pone.0243858	http://dx.doi.org/10.1371/journal.pone.0243858			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9AX	34138862	Green Published, gold			2023-01-03	WOS:000671690200060
J	Kang, Z; Chen, SJ; Shi, LW; He, YP; Gao, X				Kang, Zheng; Chen, Sijia; Shi, Liwan; He, Yipeng; Gao, Xiang			Predictors of heart and lung dose in left-sided breast cancer treated with VMAT relative to 3D-CRT: A retrospective study	PLOS ONE			English	Article							INTENSITY-MODULATED RADIOTHERAPY; RADIATION; THERAPY; POSTMASTECTOMY; METAANALYSIS; RECURRENCE; SURGERY; WOMEN; RISK	Background Before generating radiotherapy plans for breast cancer patients, the choice of plan techniques (three-dimensional conformal radiation therapy (3D-CRT) and volumetric modulated arc therapy (VMAT)) should be made. This study investigated the performance of two geometric indices in aiding the choice of 3D-CRT and VMAT plans in women undergoing left-sided whole breast radiotherapy. Materials and methods 119 patients, previously treated with left-sided breast radiotherapy (61 3D-CRT treatments and 58 VMAT treatments) from a single institution, were retrospectively studied. Two geometric indices, which were cardiac junction (CJ) index and pulmonary junction (PJ) index, were defined and the relationship between these indices and dose of organs at risk (OARs) were evaluated. Two-tailed Student's t-test was performed to compare patient characteristics between 3D-CRT and VMAT. Linear regressions were calculated to investigate the association between geometric indices and absorbed dose of heart and left lung, including mean dose of heart (MHD), V-5, V-30 of heart, and mean dose of left lung (MLLD), V-5, V-10, V-20, V-30, V-40 of left lung. Results The CJ index was strongly correlated with the MHD in 3D-CRT group and VMAT group. The linear regression formulas were MHD = 4826.59 xCJ Index+310.48 (R = 0.857, F = 163.77, P = 0.000) in 3D-CRT plans and MHD = 1789.29xCJ Index+437.50 (R = 0.45, F = 14.23, P = 0.000) in VMAT plans. The intersection of the two formulas was CJ index = 4.2% and MHD = 512.33 cGy. The PJ index demonstrated a strongly positive correlation with MLLD in 3D-CRT group and VMAT group as well. The linear regression formulas were MLLD = 2879.54xPJ Index+999.79 (R = 0.697, F = 55.86, P = 0.000) in 3D-CRT plans and MLLD = 1411.79xPJ Index+1091.88 (R = 0.676, F = 47.11, P = 0.000) in VMAT plans, the intersection of the two formulas was PJ index = 6.3% and MLLD = 1180.46 cGy. Conclusions CJ index and PJ index could be used as a practical tool to select 3D-CRT or VMAT before generating plans. We recommend that VMAT plan is preferable when CJ index is greater than 4.2% and/or PJ index is greater than 14.6%, while 3D-CRT plan is the first choice in the opposite.	[Kang, Zheng; Chen, Sijia; Shi, Liwan; He, Yipeng; Gao, Xiang] Xiamen Univ, Affiliated Hosp 1, Dept Radiat Oncol, Xiamen, Fujian, Peoples R China	Xiamen University	Gao, X (corresponding author), Xiamen Univ, Affiliated Hosp 1, Dept Radiat Oncol, Xiamen, Fujian, Peoples R China.	grandamoy@163.com		Gao, Xiang/0000-0003-4025-2141; Gao, Xiang/0000-0002-3287-4760	Department of radiotherapy at the First Affiliated Hospital of Xiamen University	Department of radiotherapy at the First Affiliated Hospital of Xiamen University	The authors would like to thank the support of Department of radiotherapy at the First Affiliated Hospital of Xiamen University.; This research did not receive any special grant from funding agencies in the public, commercial, or not-for-profit sectors.	Abe O, 2005, LANCET, V366, P2087; Ashby O., 2020, RADIOGRAPHY LOND, DOI [10.1016/j.radi.2020.08.003 32819824, DOI 10.1016/J.RADI.2020.08.00332819824]; Bogue J, 2019, J APPL CLIN MED PHYS, V20, P24, DOI 10.1002/acm2.12527; Cao N, 2019, PHYS MEDICA, V67, P27, DOI 10.1016/j.ejmp.2019.09.240; Coon AB, 2010, INT J RADIAT ONCOL, V78, P104, DOI 10.1016/j.ijrobp.2009.07.1705; Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825; Demirci S, 2009, INT J RADIAT ONCOL, V73, P980, DOI 10.1016/j.ijrobp.2008.11.016; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Grantzau T, 2016, RADIOTHER ONCOL, V121, P402, DOI 10.1016/j.radonc.2016.08.017; Hiatt JR, 2006, INT J RADIAT ONCOL, V65, P1368, DOI 10.1016/j.ijrobp.2006.03.060; Jeba J, 2015, J CLIN DIAGN RES, V9, DOI 10.7860/JCDR/2015/13969.6211; Lazzari G, 2017, CLIN TRANSL RAD ONCO, V7, P43, DOI 10.1016/j.ctro.2017.09.009; Liu HY, 2016, COMPUT MED IMAG GRAP, V54, P1, DOI 10.1016/j.compmedimag.2016.10.001; McGale P, 2014, LANCET, V383, P2127, DOI 10.1016/S0140-6736(14)60488-8; Mendez LC, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1069-z; Mo JC, 2017, TECHNOL HEALTH CARE, V25, P851, DOI 10.3233/THC-160746; Rusthoven CG, 2016, ANN ONCOL, V27, P818, DOI 10.1093/annonc/mdw046; Stecklein SR, 2016, CLIN BREAST CANCER, V16, P319, DOI 10.1016/j.clbc.2016.02.001; Taylor CW, 2009, INT J RADIAT ONCOL, V73, P1061, DOI 10.1016/j.ijrobp.2008.05.066; van den Bogaard VAB, 2017, J CLIN ONCOL, V35, P1171, DOI 10.1200/JCO.2016.69.8480; Wang HY, 2016, ONCOTARGET, V7, P75492, DOI 10.18632/oncotarget.12260; Wen G, 2017, J CANCER, V8, P3795, DOI 10.7150/jca.21158	22	0	0	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2021	16	6							e0252552	10.1371/journal.pone.0252552	http://dx.doi.org/10.1371/journal.pone.0252552			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RW	34106971	gold, Green Published, Green Submitted			2023-01-03	WOS:000664642200051
J	Mancek-Keber, M; Hafner-Bratkovic, I; Lainscek, D; Bencina, M; Govednik, T; Orehek, S; Plaper, T; Jazbec, V; Bergant, V; Grass, V; Pichlmair, A; Jerala, R				Mancek-Keber, Mateja; Hafner-Bratkovic, Iva; Lainscek, Dusko; Bencina, Mojca; Govednik, Tea; Orehek, Sara; Plaper, Tjasa; Jazbec, Vid; Bergant, Valter; Grass, Vincent; Pichlmair, Andreas; Jerala, Roman			Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs	FASEB JOURNAL			English	Article						ACE2; disulfides; SARS-CoV-2; spike; thiol-reacting compounds	CELL ENTRY; GLYCOPROTEIN; INFECTION; HIV	The SARS-CoV-2 pandemic imposed a large burden on health and society. Therapeutics targeting different components and processes of the viral infection replication cycle are being investigated, particularly to repurpose already approved drugs. Spike protein is an important target for both vaccines and therapeutics. Insights into the mechanisms of spike-ACE2 binding and cell fusion could support the identification of compounds with inhibitory effects. Here, we demonstrate that the integrity of disulfide bonds within the receptor-binding domain (RBD) plays an important role in the membrane fusion process although their disruption does not prevent binding of spike protein to ACE2. Several reducing agents and thiol-reactive compounds are able to inhibit viral entry. N-acetyl cysteine amide, L-ascorbic acid, JTT-705, and auranofin prevented syncytia formation, viral entry into cells, and infection in a mouse model, supporting disulfides of the RBD as a therapeutically relevant target.	[Mancek-Keber, Mateja; Hafner-Bratkovic, Iva; Lainscek, Dusko; Bencina, Mojca; Govednik, Tea; Orehek, Sara; Plaper, Tjasa; Jazbec, Vid; Jerala, Roman] Natl Inst Chem, Dept Synthet Biol & Immunol, Hajdrihova 19, Ljubljana 1000, Slovenia; [Mancek-Keber, Mateja; Hafner-Bratkovic, Iva; Lainscek, Dusko; Bencina, Mojca; Jerala, Roman] Ctr Excellence EN FIST, Ljubljana, Slovenia; [Govednik, Tea; Orehek, Sara; Plaper, Tjasa; Jazbec, Vid] Univ Ljubljana, Grad Sch Biomed, Ljubljana, Slovenia; [Bergant, Valter; Grass, Vincent; Pichlmair, Andreas] Tech Univ Munich, Inst Virol, Immunopathol Virus Infect Lab, Munich, Germany	National Institute of Chemistry - Slovenia; University of Ljubljana; Technical University of Munich	Jerala, R (corresponding author), Natl Inst Chem, Dept Synthet Biol & Immunol, Hajdrihova 19, Ljubljana 1000, Slovenia.	roman.jerala@ki.si		Orehek, Sara/0000-0003-3002-6175; Hafner Bratkovic, Iva/0000-0001-5635-931X	Slovenian Research Agency [V4-2038, P4-0176, J3-9257]	Slovenian Research Agency(Slovenian Research Agency - Slovenia)	Slovenian Research Agency, Grant/Award Number: V4-2038, P4-0176 and J3-9257	Andreou A, 2020, IN VIVO, V34, P1567, DOI 10.21873/invivo.11946; Arslan B., 2020, SSRN, DOI DOI 10.2139/SSRN.3682517; Ates B, 2008, FREE RADICAL RES, V42, P372, DOI 10.1080/10715760801998638; Bagheri M, 2022, J BIOMOL STRUCT DYN, V40, P1597, DOI 10.1080/07391102.2020.1830854; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cecchini R, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.110102; Biancatelli RMLC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01451; Fenouillet E, 2007, ANTIOXID REDOX SIGN, V9, P1009, DOI 10.1089/ars.2007.1639; Gallagher TM, 1996, J VIROL, V70, P4683, DOI 10.1128/JVI.70.7.4683-4690.1996; Garcia-Murria MJ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030229; Gur M, 2020, J CHEM PHYS, V153, DOI 10.1063/5.0011141; Hati S, 2020, ACS OMEGA, V5, P16292, DOI 10.1021/acsomega.0c02125; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Ibrahim H, 2020, CLIN IMMUNOL, V219, DOI 10.1016/j.clim.2020.108544; Joshi S, 2021, INT J INFECT DIS, V102, P501, DOI 10.1016/j.ijid.2020.10.069; Kamiyama D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11046; Kaur U, 2021, CURR DRUG TARGETS, V22, P192, DOI 10.2174/1389450121666200924113243; Lainscek D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050431; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Lavillette D, 2006, J BIOL CHEM, V281, P9200, DOI 10.1074/jbc.M512529200; Mancek-Keber M, 2009, J BIOL CHEM, V284, P19493, DOI 10.1074/jbc.M109.003756; Markovic I, 2004, BLOOD, V103, P1586, DOI 10.1182/blood-2003-05-1390; Meirson T, 2021, BIOINFORMATICS, V37, P929, DOI 10.1093/bioinformatics/btaa744; Mesko M, 2020, ACS SYNTH BIOL, V9, P2055, DOI 10.1021/acssynbio.0c00133; Mohammadpour AH, 2013, CLIN PHARMACOKINET, V52, P615, DOI 10.1007/s40262-013-0071-8; Papa G, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009246; Plaper T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88315-3; Rentsch MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025858; Roder C, 2015, DRUGS R&D, V15, P13, DOI 10.1007/s40268-015-0083-y; Rothan HA, 2020, VIROLOGY, V547, P7, DOI 10.1016/j.virol.2020.05.002; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; Seif F, 2020, INT ARCH ALLERGY IMM, V181, P467, DOI 10.1159/000508247; Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101; Stukalov A, 2021, NATURE, V594, P246, DOI 10.1038/s41586-021-03493-4; Suhail S, 2020, PROTEIN J, V39, P644, DOI 10.1007/s10930-020-09935-8; Thomas S, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0369; Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114; Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200; Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2; Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054	40	20	20	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2021	35	6							e21651	10.1096/fj.202100560R	http://dx.doi.org/10.1096/fj.202100560R			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	SJ7FH	34004056	Green Published			2023-01-03	WOS:000655695900001
J	Williams, S; King, T; Papamihali, K; Buxton, JA				Williams, Sierra; King, Tanis; Papamihali, Kristi; Buxton, Jane A.			The implementation and role of a staff naloxone program for non-profit community-based sites in British Columbia: A descriptive study	PLOS ONE			English	Article								Introduction The BC Centre for Disease Control implemented the Facility Overdose Response Box (FORB) program December 1(st), 2016 to train and support non-healthcare service providers who may respond to an overdose in the workplace. The program aims to support staff at non-profit community-based organizations by ensuring policy development, training, practice overdose response exercises, and post-overdose debriefing opportunities are established and implemented. Materials and methods Three data sources were used in this descriptive cross-sectional study: FORB site registration data; naloxone administration forms; and a survey that was distributed to FORB sites in February 2019. FORB program site and naloxone administration data from December 1(st), 2016 to December 31(st), 2019 were analyzed using descriptive statistics. A Cochran-Armitage test was used to assess trends over time in naloxone administration event characteristics. Site coordinator survey results are reported to supplement findings from administrative data. Results As of December 31(st), 2019, FORB was implemented at 613 sites across BC and 1,758 naloxone administration events were reported. The majority (86.3%, n = 1,517) were indicated as overdose reversals. At registration, 43.6% of sites provided housing services, 26.3% offered harm reduction supplies, and 18.6% provided Take Home Naloxone. Refusal to be transported to hospital following overdose events when emergency services were called showed an increasing trend over time. Most respondents (81.3%) reported feeling confident in their ability to respond to the overdose and 59.6% were offered staff debrief. Based on the 89 site survey responses, supports most commonly made available following an overdose were debrief with a fellow staff member (91.0%), debrief with a supervisor (89.9%), and/or counselling services (84.3%). Conclusions The uptake of the FORB program has contributed to hundreds of overdose reversals in community settings in BC. Findings suggest that the FORB program supports developing staff preparedness and confidence in overdose response in community-based settings.	[Williams, Sierra; Papamihali, Kristi; Buxton, Jane A.] British Columbia Ctr Dis Control, Vancouver, BC, Canada; [King, Tanis; Buxton, Jane A.] Univ British Columbia, Vancouver, BC, Canada	University of British Columbia	Buxton, JA (corresponding author), British Columbia Ctr Dis Control, Vancouver, BC, Canada.; Buxton, JA (corresponding author), Univ British Columbia, Vancouver, BC, Canada.	jane.buxton@bccdc.ca		Williams, Sierra/0000-0002-1094-7324	BC Ministry of Health; British Columbia Ministry of Health	BC Ministry of Health; British Columbia Ministry of Health	The Facility Overdose Response Box Program is managed by the BC Centre for Disease Control and funded by the BC Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The BC FORB program is made possible with funding from the British Columbia Ministry of Health.	Aguilar-Amaya M., 2019, J SOC WORK PRACT ADD, DOI [10.1080/1533256X.2019.1640019, DOI 10.1080/1533256X.2019.1640019]; [Anonymous], 2019, ENV SCAN NAL ACC DIS, DOI [10.14288/1.0379400, DOI 10.14288/1.0379400]; [Anonymous], 2020, BESAFE APPL; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Banjo Oluwajenyo, 2014, CMAJ Open, V2, pE153, DOI 10.9778/cmajo.20140008; Bardwell G, 2019, J URBAN HEALTH, V96, P12, DOI 10.1007/s11524-018-0294-y; Bardwell G, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0203-9; BC Centre for Disease Control, 2020, OV RESP IND DASHB; BC Coroners Service, ILL DRUG TOX DEATHS; BCCDC Harm Reduction Services, TRAIN RES; BCCDC Harm Reduction Services, 2019, OBS CONS SERV; BCCDC Harm Reduction Services, FAC OV RESP BOX PROG; BCCDC Harm Reduction Services, TAK HOM NAL PROGR IN; Buxton J, 2020, B C MED J, V62, P207; Coffin PO, 2013, ANN INTERN MED, V158, P1, DOI 10.7326/0003-4819-158-1-201301010-00003; Deonarine A, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0106-1; Government of BC, 2020, MIN ORD SUPP URG OV; Government of BC, 2020, NEW LIF APP LAUNCH H; Irvine MA., 2018, LANCET, DOI [10.1016/S2468-2667(18)30044-6, DOI 10.1016/S2468-2667(18)30044-6]; Irvine MA, 2019, ADDICTION, V114, P1602, DOI 10.1111/add.14664; Karamouzian M, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0252-8; Kennedy MC, 2019, SOC SCI MED, V225, P60, DOI 10.1016/j.socscimed.2019.02.014; Moustaqim-Barrette A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238618; Moustaqim-Barrette A, 2019, DRUG ALCOHOL DEPEN, V205, DOI 10.1016/j.drugalcdep.2019.107609; Pacific Aids Network, 2017, RESP OV CRIS BRIT CO; Pearce L, 2016, BC THN PROGRAM EVALU; Rac T., 2016, EVALUATION DELEGATED; Shearer D, 2019, INT J DRUG POLICY, V74, P255, DOI 10.1016/j.drugpo.2018.11.008; Slaunwhite A., 2019, DECLINING TRANSPORT; Wagner KD, 2014, INT J DRUG POLICY, V25, P157, DOI 10.1016/j.drugpo.2013.07.003; Wallace B, 2019, INT J DRUG POLICY, V66, P64, DOI 10.1016/j.drugpo.2019.01.017; Williams S, 2019, EVALUATION BRIT COLU; Ye XB, 2018, HEALTH PROMOT CHRON, V38, P248, DOI 10.24095/hpcdp.38.6.05; Young S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030046	34	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2021	16	5							e0251112	10.1371/journal.pone.0251112	http://dx.doi.org/10.1371/journal.pone.0251112			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6MO	33983996	Green Published, gold			2023-01-03	WOS:000664628200044
J	Martinez, FJ; Yow, E; Flaherty, KR; Snyder, LD; Durheim, MT; Wisniewski, SR; Sciurba, FC; Raghu, G; Brooks, MM; Kim, DY; Dilling, DF; Criner, GJ; Kim, H; Belloli, EA; Nambiar, AM; Scholand, MB; Anstrom, KJ; Noth, I				Martinez, Fernando J.; Yow, Eric; Flaherty, Kevin R.; Snyder, Laurie D.; Durheim, Michael T.; Wisniewski, Stephen R.; Sciurba, Frank C.; Raghu, Ganesh; Brooks, Maria M.; Kim, Dong-Yun; Dilling, Daniel F.; Criner, Gerard J.; Kim, Hyun; Belloli, Elizabeth A.; Nambiar, Anoop M.; Scholand, Mary Beth; Anstrom, Kevin J.; Noth, Imre		CleanUP-IPF Investigators Pulm	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM; AZITHROMYCIN; DOXYCYCLINE; PROGRESSION; BRONCHIECTASIS; EXACERBATIONS; COTRIMOXAZOLE; PLACEBO	Key PointsQuestionDoes antimicrobial therapy in addition to usual care improve clinical outcomes in patients with idiopathic pulmonary fibrosis? FindingsIn this pragmatic randomized clinical trial that included 513 adults with idiopathic pulmonary fibrosis the addition of co-trimoxazole (trimethoprim-sulfamethoxazole) or doxycycline to usual care compared with usual care alone resulted in a rate of first nonelective respiratory hospitalization or death of 20.4 vs 18.4 events per 100 person-years, a difference that was not statistically significant. MeaningAmong adults with idiopathic pulmonary fibrosis, addition of co-trimoxazole or doxycycline compared with usual care did not significantly improve the time to nonrespiratory hospitalization or death. ImportanceAlteration in lung microbes is associated with disease progression in idiopathic pulmonary fibrosis. ObjectiveTo assess the effect of antimicrobial therapy on clinical outcomes. Design, Setting, and ParticipantsPragmatic, randomized, unblinded clinical trial conducted across 35 US sites. A total of 513 patients older than 40 years were randomized from August 2017 to June 2019 (final follow-up was January 2020). InterventionsPatients were randomized in a 1:1 allocation ratio to receive antimicrobials (n=254) or usual care alone (n=259). Antimicrobials included co-trimoxazole (trimethoprim 160 mg/sulfamethoxazole 800 mg twice daily plus folic acid 5 mg daily, n=128) or doxycycline (100 mg once daily if body weight <50 kg or 100 mg twice daily if <greater than or equal to>50 kg, n=126). No placebo was administered in the usual care alone group. Main Outcomes and MeasuresThe primary end point was time to first nonelective respiratory hospitalization or all-cause mortality. ResultsAmong the 513 patients who were randomized (mean age, 71 years; 23.6% women), all (100%) were included in the analysis. The study was terminated for futility on December 18, 2019. After a mean follow-up time of 13.1 months (median, 12.7 months), a total of 108 primary end point events occurred: 52 events (20.4 events per 100 patient-years [95% CI, 14.8-25.9]) in the usual care plus antimicrobial therapy group and 56 events (18.4 events per 100 patient-years [95% CI, 13.2-23.6]) in the usual care group, with no significant difference between groups (adjusted HR, 1.04 [95% CI, 0.71-1.53; P=.83]. There was no statistically significant interaction between the effect of the prespecified antimicrobial agent (co-trimoxazole vs doxycycline) on the primary end point (adjusted HR, 1.15 [95% CI 0.68-1.95] in the co-trimoxazole group vs 0.82 [95% CI, 0.46-1.47] in the doxycycline group; P=.66). Serious adverse events occurring at 5% or greater among those treated with usual care plus antimicrobials vs usual care alone included respiratory events (16.5% vs 10.0%) and infections (2.8% vs 6.6%); adverse events of special interest included diarrhea (10.2% vs 3.1%) and rash (6.7% vs 0%). Conclusions and RelevanceAmong adults with idiopathic pulmonary fibrosis, the addition of co-trimoxazole or doxycycline to usual care, compared with usual care alone, did not significantly improve time to nonelective respiratory hospitalization or death. These findings do not support treatment with these antibiotics for the underlying disease. Trial RegistrationClinicalTrials.gov Identifier: NCT02759120 This clinical trial investigates whether the addition of antimicrobial treatments co-trimoxazole or doxycycline to usual care improves outcomes among patients with idiopathic pulmonary fibrosis better than usual care alone.	[Martinez, Fernando J.] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA; [Yow, Eric; Snyder, Laurie D.; Durheim, Michael T.; Anstrom, Kevin J.] Duke Univ, Duke Clin Res Inst, Durham, NC USA; [Flaherty, Kevin R.; Belloli, Elizabeth A.] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; [Durheim, Michael T.] Oslo Univ Hosp, Rikshosp, Dept Resp Med, Oslo, Norway; [Wisniewski, Stephen R.; Sciurba, Frank C.; Brooks, Maria M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA; [Raghu, Ganesh] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA; [Kim, Dong-Yun] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA; [Dilling, Daniel F.] Loyola Univ, Med Ctr, Div Pulm & Crit Care Med, 2160 S 1st Ave, Maywood, IL 60153 USA; [Criner, Gerard J.] Temple Univ, Lewis Katz Sch Med, Dept Thorac Med & Surg, Philadelphia, PA 19122 USA; [Kim, Hyun] Univ Minnesota, Div Pulm & Crit Care Med, Minneapolis, MN USA; [Nambiar, Anoop M.] Univ Texas Hlth San Antonino, Div Pulm & Crit Care Med, San Antonio, TX USA; [Scholand, Mary Beth] Univ Utah, Div Pulm & Crit Care Med, Salt Lake City, UT USA; [Noth, Imre] Univ Virginia, Div Pulm & Crit Care Med, Charlottesville, VA USA	Cornell University; NewYork-Presbyterian Hospital; Duke University; University of Michigan System; University of Michigan; University of Oslo; National Hospital Norway; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Loyola University Chicago; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Minnesota System; University of Minnesota Twin Cities; Utah System of Higher Education; University of Utah; University of Virginia	Martinez, FJ (corresponding author), 1305 York Ave,POB 96,Room Y-1059, New York, NY 10021 USA.	fjm2003@med.cornell.edu	Nambiar, Anoop M./P-5319-2017; Sciurba, Frank/AAZ-9339-2021; Dilling, Daniel/E-2967-2019	Nambiar, Anoop M./0000-0003-2778-0433; sciurba, frank/0000-0001-7468-2225; Dilling, Daniel/0000-0002-9723-510X; Snyder, Laurie/0000-0002-5962-2184; Mooney, Joshua/0000-0002-4687-194X; DiSanto-Rose, Maria/0000-0003-2250-291X				Altenburg J, 2013, JAMA-J AM MED ASSOC, V309, P1251, DOI 10.1001/jama.2013.1937; [Anonymous], 2016, QUALITYMETRIC HLTH O; Anstrom KJ, 2020, RESP RES, V21, DOI 10.1186/s12931-020-1326-1; Bhattacharyya P, 2009, LUNG INDIA, V26, P81, DOI 10.4103/0970-2113.53231; Birring SS, 2003, THORAX, V58, P339, DOI 10.1136/thorax.58.4.339; Collard HR, 2015, EUR RESPIR J, V46, P243, DOI 10.1183/09031936.00200614; Collard HR, 2014, CHEST, V146, P1256, DOI 10.1378/chest.14-0492; de Andrade J, 2015, CHEST, V148, P1034, DOI 10.1378/chest.14-2889; Dickson RP, 2019, AM J RESP CRIT CARE, V200, P1544, DOI 10.1164/rccm.201903-0680LE; Eakin EG, 1998, CHEST, V113, P619, DOI 10.1378/chest.113.3.619; Gibson KF, 2018, JAMA-J AM MED ASSOC, V319, P2275, DOI 10.1001/jama.2018.6225; Gosens R, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02320-2019; Grewal I, 2006, SOC SCI MED, V62, P1891, DOI 10.1016/j.socscimed.2005.08.023; Han MK, 2014, LANCET RESP MED, V2, P548, DOI 10.1016/S2213-2600(14)70069-4; Ho JMW, 2011, CAN MED ASSOC J, V183, P1851, DOI 10.1503/cmaj.111152; Huang Y, 2017, AM J RESP CRIT CARE, V196, P208, DOI 10.1164/rccm.201607-1525OC; Knippenberg S, 2015, THORAX, V70, P636, DOI 10.1136/thoraxjnl-2014-206420; Krempaska K, 2020, RESP RES, V21, DOI 10.1186/s12931-020-1275-8; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Ley B, 2012, ANN INTERN MED, V156, P684, DOI 10.7326/0003-4819-156-10-201205150-00004; Loudon K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2147; Macaluso C, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00628-2018; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Mishra A, 2011, LUNG INDIA, V28, P174, DOI 10.4103/0970-2113.83972; Molyneaux PL, 2017, AM J RESP CRIT CARE, V195, P1640, DOI 10.1164/rccm.201607-1408OC; Molyneaux PL, 2014, AM J RESP CRIT CARE, V190, P906, DOI 10.1164/rccm.201403-0541OC; O'Dwyer DN, 2019, AM J RESP CRIT CARE, V199, P1127, DOI 10.1164/rccm.201809-1650OC; Paterniti MO, 2017, ANN AM THORAC SOC, V14, P1395, DOI 10.1513/AnnalsATS.201606-458OC; Ramsheh MY, 2020, THORAX, V75, P8, DOI 10.1136/thoraxjnl-2019-213485; Segal LN, 2017, THORAX, V72, P13, DOI 10.1136/thoraxjnl-2016-208599; Serisier DJ, 2013, JAMA-J AM MED ASSOC, V309, P1260, DOI 10.1001/jama.2013.2290; Shulgina L, 2013, THORAX, V68, P155, DOI 10.1136/thoraxjnl-2012-202403; Smith K, 2005, CLIN THER, V27, P1329, DOI 10.1016/j.clinthera.2005.09.005; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wilson AM, 2020, JAMA-J AM MED ASSOC, V324, P2282, DOI 10.1001/jama.2020.22960	35	15	16	4	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	2021	325	18					1841	1851		10.1001/jama.2021.4956	http://dx.doi.org/10.1001/jama.2021.4956			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SB7YR	33974018	Green Published, Bronze			2023-01-03	WOS:000650205000013
J	Ayeh, SK; Abbey, EJ; Khalifa, BAA; Nudotor, RD; Osei, AD; Chidambaram, V; Osuji, N; Khan, S; Salia, EL; Oduwole, MO; Yusuf, HE; Lasisi, O; Nosakhare, E; Karakousis, PC				Ayeh, Samuel K.; Abbey, Enoch J.; Khalifa, Banda A. A.; Nudotor, Richard D.; Osei, Albert Danso; Chidambaram, Vignesh; Osuji, Ngozi; Khan, Samiha; Salia, Emmanuella L.; Oduwole, Modupe O.; Yusuf, Hasiya E.; Lasisi, Oluwatobi; Nosakhare, Esosa; Karakousis, Petros C.			Statins use and COVID-19 outcomes in hospitalized patients	PLOS ONE			English	Article							SIGNIFICANTLY CORRELATE; RADIOLOGICAL EXTENT; IN-VIVO; HDL-C; DISEASE; THERAPY; ACE2	Background There is an urgent need for novel therapeutic strategies for reversing COVID-19-related lung inflammation. Recent evidence has demonstrated that the cholesterol-lowering agents, statins, are associated with reduced mortality in patients with various respiratory infections. We sought to investigate the relationship between statin use and COVID-19 disease severity in hospitalized patients. Methods A retrospective analysis of COVID-19 patients admitted to the Johns Hopkins Medical Institutions between March 1, 2020 and June 30, 2020 was performed. The outcomes of interest were mortality and severe COVID-19 infection, as defined by prolonged hospital stay (>= 7 days) and/ or invasive mechanical ventilation. Logistic regression, Cox proportional hazards regression and propensity score matching were used to obtain both univariable and multivariable associations between covariates and outcomes in addition to the average treatment effect of statin use. Results Of the 4,447 patients who met our inclusion criteria, 594 (13.4%) patients were exposed to statins on admission, of which 340 (57.2%) were male. The mean age was higher in statin users compared to non-users [64.9 +/- 13.4 vs. 45.5 +/- 16.6 years, p <0.001]. The average treatment effect of statin use on COVID-19-related mortality was RR = 1.00 (95% CI: 0.99-1.01, p = 0.928), while its effect on severe COVID-19 infection was RR = 1.18 (95% CI: 1.11-1.27, p <0.001). Conclusion Statin use was not associated with altered mortality, but with an 18% increased risk of severe COVID-19 infection.	[Ayeh, Samuel K.; Abbey, Enoch J.; Chidambaram, Vignesh; Osuji, Ngozi; Khan, Samiha; Oduwole, Modupe O.; Karakousis, Petros C.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD 21205 USA; [Khalifa, Banda A. A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Nudotor, Richard D.] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA; [Osei, Albert Danso] Medstar Union Mem Hosp, Dept Internal Med, Baltimore, MD USA; [Salia, Emmanuella L.] Univ Tennessee, Ctr Hlth Sci, Dept Genet Genom & Informat, Memphis, TN 38163 USA; [Yusuf, Hasiya E.] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA; [Lasisi, Oluwatobi] Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA; [Nosakhare, Esosa] Johns Hopkins Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD USA; [Karakousis, Petros C.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Union Memorial Hospital; University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University; Johns Hopkins Medicine; Wayne State University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Karakousis, PC (corresponding author), Johns Hopkins Sch Med, Dept Med, Baltimore, MD 21205 USA.; Karakousis, PC (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	petros@jhmi.edu	CHIDAMBARAM, VIGNESH/AAH-9488-2021; Khalifa, Banda/GRF-1928-2022	Nudotor, Richard/0000-0002-2281-4924; Khalifa, Banda Abdallah Abubakar/0000-0002-2525-5531; Chidambaram, Vignesh/0000-0002-4240-1027; Abbey, Enoch/0000-0002-3286-0529	National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) [UH3AI122309, K24AI143447]	National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This retrospective cohort study was supported by the National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) grants UH3AI122309 and K24AI143447 to P.C.K. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blanc M, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000598; Bruiners N, 2020, J LIPID RES, V61, P1617, DOI 10.1194/jlr.RA120000895; Cariou B, 2021, DIABETES METAB, V47, DOI 10.1016/j.diabet.2020.10.001; Chidambaram V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241541; Cuervo NZ, 2020, ELIFE, V9, DOI 10.7554/eLife.61390; Damiani I, 2020, EXPERT OPIN DRUG MET, V16, P1133, DOI 10.1080/17425255.2020.1822324; Daniels LB, 2020, AM J CARDIOL, V136, P149, DOI 10.1016/j.amjcard.2020.09.012; Dashti-Khavidaki S, 2020, PHARMACOTHERAPY, V40, P484, DOI 10.1002/phar.2397; De Spiegeleer A, 2020, J AM MED DIR ASSOC, V21, P909, DOI 10.1016/j.jamda.2020.06.018; Deniz O, 2006, CLIN BIOCHEM, V39, P287, DOI 10.1016/j.clinbiochem.2006.01.015; Deniz O, 2007, CLIN BIOCHEM, V40, P162, DOI 10.1016/j.clinbiochem.2006.10.015; Dutta NK, 2020, J INFECT DIS, V221, P1079, DOI 10.1093/infdis/jiz517; Dutta NK, 2016, J ANTIMICROB CHEMOTH, V71, P1570, DOI 10.1093/jac/dkw014; Elahi S, 2016, AIDS, V30, P171, DOI 10.1097/QAD.0000000000000917; Gower TL, 2001, ANTIMICROB AGENTS CH, V45, P1231, DOI 10.1128/AAC.45.4.1231-1237.2001; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hariyanto TI, 2020, DIABETES METAB SYND, V14, P1613, DOI 10.1016/j.dsx.2020.08.023; Henry Christopher, 2018, Proc (Bayl Univ Med Cent), V31, P419, DOI 10.1080/08998280.2018.1499293; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Jain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901; Karakousis PC., 2021, ADV HOST DIRECTED TH, DOI [10.1007/978-3-030-56905-1, DOI 10.1007/978-3-030-56905-1]; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Li J, 2020, J CLIN TRANSL HEPATO, V8, P13, DOI 10.14218/JCTH.2020.00019; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Ludwig S, 2020, ANESTH ANALG, V131, P93, DOI 10.1213/ANE.0000000000004845; Moore BJ, 2017, MED CARE, V55, P698, DOI 10.1097/MLR.0000000000000735; Parihar SP, 2019, NAT REV IMMUNOL, V19, P104, DOI 10.1038/s41577-018-0094-3; Peymani Payam, 2021, Transl Med Commun, V6, P3, DOI 10.1186/s41231-021-00082-5; Potena L, 2004, CIRCULATION, V109, P532, DOI 10.1161/01.CIR.0000109485.79183.81; Rodriguez-Nava G, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03154-4; Rossi R, 2020, INTERN EMERG MED, V15, P1573, DOI 10.1007/s11739-020-02504-y; Sapey E, 2019, AM J RESP CRIT CARE, V200, P1282, DOI 10.1164/rccm.201812-2328OC; Shin YH, 2017, HEART VESSELS, V32, P618, DOI 10.1007/s00380-016-0936-5; Skerry C, 2014, J ANTIMICROB CHEMOTH, V69, P2453, DOI 10.1093/jac/dku166; Stamatogiannis N, 2009, RECENT PATENTS INFLA, V3, P167, DOI 10.2174/187221309789257469; Tikoo K, 2015, BIOCHEM PHARMACOL, V93, P343, DOI 10.1016/j.bcp.2014.11.013; Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15; Volpato S, 2000, GERONTOLOGY, V46, P22, DOI 10.1159/000022129; Wei XQ, 2020, J CLIN LIPIDOL, V14, P297, DOI 10.1016/j.jacl.2020.04.008; Xia Y, 2018, CELL, V175, P1059, DOI 10.1016/j.cell.2018.08.070	41	15	15	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0256899	10.1371/journal.pone.0256899	http://dx.doi.org/10.1371/journal.pone.0256899			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9EM	34506533	gold, Green Published			2023-01-03	WOS:000729120700089
J	Harris, ML; Egan, N; Forder, PM; Coombe, J; Loxton, D				Harris, Melissa L.; Egan, Nicholas; Forder, Peta M.; Coombe, Jacqueline; Loxton, Deborah			Contraceptive use among women through their later reproductive years: Findings from an Australian prospective cohort study	PLOS ONE			English	Article							UNITED-STATES; UNINTENDED PREGNANCIES; OBESE WOMEN; PATTERNS; NONUSE; DEPRESSION; STRATEGIES; PROTECTION; BARRIERS; HEALTH	Objective Examine patterns of contraceptive use and contraceptive transitions over time among an Australian cohort of women through their later reproductive years. Study design Latent Transition Analysis was performed using data on 8,197 women from the Australian Longitudinal Study on Women's Health's 1973-78 cohort to identify distinct patterns of contraceptive use across 2006, 2012 and 2018. Women were excluded from the analysis at time points where they were not at risk of an unintended pregnancy. Latent status membership probabilities, item-response probabilities, transitions probabilities and the effect of predictors on latent status membership were estimated and reported. Results Patterns of contraceptive use were relatively consistent over time, particularly for high efficacy contraceptive methods with 71% of women using long-acting reversible contraceptives in 2012 also using long-acting reversible contraceptives in 2018. Multiple contraceptive use was highest in 2006 when women were aged 28-33 years (19.3%) but declined over time to 14.3% in 2018 when women were aged 40-45 years. Overall, contraceptive patterns stabilised as the women moved into their late 30s and early 40s. Conclusions Although fertility declines with age, the stability of contraceptive choice and continued use of short-acting contraception among some women suggests that a contraceptive review may be helpful for women during perimenopause so that they are provided with contraceptive options most appropriate to their specific circumstances.	[Harris, Melissa L.; Egan, Nicholas; Forder, Peta M.; Loxton, Deborah] Univ Newcastle, Ctr Womens Hlth Res, Newcastle, NSW, Australia; [Harris, Melissa L.; Egan, Nicholas; Forder, Peta M.; Loxton, Deborah] Hunter Med Res Inst, Newcastle, NSW, Australia; [Coombe, Jacqueline] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Parkville, Vic, Australia	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Melbourne	Harris, ML (corresponding author), Univ Newcastle, Ctr Womens Hlth Res, Newcastle, NSW, Australia.; Harris, ML (corresponding author), Hunter Med Res Inst, Newcastle, NSW, Australia.	Melissa.Harris@newcastle.edu.au		Egan, Nicholas/0000-0002-0854-7444; Harris, Melissa/0000-0002-5733-9684	Australian Government Department of Health [G1700929]; Australian Research Council Discovery Early Career Researcher Award [DE190101134]	Australian Government Department of Health(Australian GovernmentDepartment of Health & Ageing); Australian Research Council Discovery Early Career Researcher Award(Australian Research Council)	The research on which this paper is based was conducted as part of the Australian Longitudinal Study on Women's Health (ALSWH) by the University of Newcastle and The University of Queensland and is funded by the Australian Government Department of Health (G1700929). Dr Melissa Harris is funded through an Australian Research Council Discovery Early Career Researcher Award (DE190101134).	Aitken RJ, 2014, REPRODUCTION, V147, pS1, DOI 10.1530/REP-13-0399; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Australian Bureau of Statistics, 2019, BIRTHS; Australian Government Department of Health, 2020, NAT WOM HLTH STRAT 2 NAT WOM HLTH STRAT 2; Australian Institute of Health and Welfare, 2020, AUSTR MOTH BAB 2018; Bateson D, 2017, AUST FAM PHYSICIAN, V46, P372; Bateson D, 2016, AUST NZ J OBSTET GYN, V56, P655, DOI 10.1111/ajo.12534; Bauleni EM, 2018, AUST J PRIM HEALTH, V24, P422, DOI [10.1071/py17183, 10.1071/PY17183]; Black K, 2012, EUR J CONTRACEP REPR, V17, P340, DOI 10.3109/13625187.2012.700744; Botfield JR, 2021, COLLEGIAN, V28, P114, DOI 10.1016/j.colegn.2020.04.005; Collins L.M., 2010, LATENT CLASS LATENT, DOI DOI 10.1002/9780470567333; Coombe J, 2019, SEX REPROD HEALTHC, V19, P71, DOI 10.1016/j.srhc.2018.12.004; Coombe J, 2019, CULT HEALTH SEX, V21, P822, DOI 10.1080/13691058.2018.1519119; Coombe J, 2016, AUST FAM PHYSICIAN, V45, P842; Coombe J, 2016, SEX HEALTH, V13, P404, DOI 10.1071/SH15189; Darney P, 2009, FERTIL STERIL, V91, P1646, DOI 10.1016/j.fertnstert.2008.02.140; Dobson AJ, 2015, INT J EPIDEMIOL, V44, DOI 10.1093/ije/dyv110; Dragoman MV, 2017, CONTRACEPTION, V95, P117, DOI 10.1016/j.contraception.2016.10.010; Edelman AB, 2013, CONTRACEPTION, V87, P220, DOI 10.1016/j.contraception.2012.10.008; Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit, 2017, CONTR WOM AG 40 YEAR CONTR WOM AG 40 YEAR; Fantasia HC, 2012, CONTRACEPTION, V86, P530, DOI 10.1016/j.contraception.2012.03.005; Finer LB, 2014, AM J PUBLIC HEALTH, V104, pS43, DOI 10.2105/AJPH.2013.301416; Finer LB, 2011, CONTRACEPTION, V84, P478, DOI 10.1016/j.contraception.2011.07.013; Frederiksen LE, 2018, OBSTET GYNECOL, V131, P457, DOI 10.1097/AOG.0000000000002504; Frost JJ, 2008, PERSPECT SEX REPRO H, V40, P94, DOI 10.1363/4009408; Frost JJ, 2007, PERSPECT SEX REPRO H, V39, P90, DOI 10.1363/3909007; Frost JJ, 2007, PERSPECT SEX REPRO H, V39, P48, DOI 10.1363/3904807; Goldhammer DL, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0616-2; Grace KT, 2018, TRAUMA VIOLENCE ABUS, V19, P371, DOI 10.1177/1524838016663935; Grzeskowiak LE, 2021, AUST NZ J OBSTET GYN, V61, P128, DOI 10.1111/ajo.13257; Hall KS, 2013, CONTRACEPTION, V88, P641, DOI 10.1016/j.contraception.2013.06.003; Hall KS, 2013, J ADOLESCENT HEALTH, V53, P241, DOI 10.1016/j.jadohealth.2013.02.009; Harris ML, 2020, PERSPECT SEX REPRO H, V52, P181, DOI 10.1363/psrh.12158; Hegarty K, 1999, J FAM VIOLENCE, V14, P399, DOI 10.1023/A:1022834215681; Hoeymans Nancy, 2004, Health Qual Life Outcomes, V2, P23; Jones RK, 2015, PERSPECT SEX REPRO H, V47, P129, DOI 10.1363/47e4615; Jones RK, 2014, CONTRACEPTION, V90, P416, DOI 10.1016/j.contraception.2014.04.016; Kallner HK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125990; Lincoln E., 2020, OBSTET GYNAECOL REPR, V30, P219; Linne Y, 2004, Obes Rev, V5, P137, DOI 10.1111/j.1467-789X.2004.00147.x; Lopez LM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008452.pub4; Loxton D., 2013, J WOMENS HLTH ISSUES, V2, P2, DOI [10.4172/2325-9795.1000115, DOI 10.4172/2325-9795.1000115]; Loxton D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178138; Lucke JC, 2014, AUST NZ J PUBL HEAL, V38, P112, DOI 10.1111/1753-6405.12208; Lucke JC, 2009, CONTRACEPTION, V80, P533, DOI 10.1016/j.contraception.2009.05.122; Marshall C, 2016, PERSPECT SEX REPRO H, V48, P119, DOI 10.1363/48e10116; Mazza D, 2017, AUST NZ J OBSTET GYN, V57, P206, DOI 10.1111/ajo.12587; Monester J, 2019, EUR J CONTRACEP REPR, V24, P274, DOI 10.1080/13625187.2019.1625326; O'Neill A, 2020, EUR J PAIN, V24, P457, DOI 10.1002/ejp.1502; Parr N, 2007, AUST NZ J PUBL HEAL, V31, P567, DOI 10.1111/j.1753-6405.2007.00145.x; POLS R, 1992, IS THERE SAFE LEVEL; Richters J, 2016, CONTRACEPTION, V94, P548, DOI 10.1016/j.contraception.2016.06.016; Rowlands IJ, 2021, BMJ SEX REPROD HEAL, V47, P129, DOI 10.1136/bmjsrh-2019-200479; Spinelli A, 2000, AM J PUBLIC HEALTH, V90, P1403, DOI 10.2105/AJPH.90.9.1403; Taft AJ, 2018, MED J AUSTRALIA, V209, P407, DOI 10.5694/mja17.01094; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Westhoff CL, 2010, OBSTET GYNECOL, V116, P275, DOI 10.1097/AOG.0b013e3181e79440; Wu J, 2008, CONTRACEPTION, V78, P284, DOI 10.1016/j.contraception.2008.04.124; Xu HN, 2012, OBSTET GYNECOL, V120, P21, DOI 10.1097/AOG.0b013e318259565a	59	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255913	10.1371/journal.pone.0255913	http://dx.doi.org/10.1371/journal.pone.0255913			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY8KW	34379661	Green Published, gold			2023-01-03	WOS:000684029800052
J	Ontiri, S; Kabue, M; Biesma, R; Stekelenburg, J; Gichangi, P				Ontiri, Susan; Kabue, Mark; Biesma, Regien; Stekelenburg, Jelle; Gichangi, Peter			Assessing quality of family planning counseling and its determinants in Kenya: Analysis of health facility exit interviews	PLOS ONE			English	Article							CONTRACEPTIVE USE; PROGRAMS; SERVICE	Background Available evidence suggests that provision of quality of care in family planning services is crucial to increasing uptake and continuation of use of contraception. Kenya achieved a modern contraceptive prevalence rate of 60% in 2018, surpassing its 2020 target of 58%. With the high prevalence, focus is geared towards improved quality of family planning services. The objective of this study is to examine the quality of family planning counseling and its associated factors in health facilities in Kenya. Methods We conducted a secondary analysis of the 2019 Kenya Performance Monitoring and Action, client exit data of women who had received family planning services. Quality of counseling was assessed using the Method Information Index Plus. We conducted a multivariable ordinal logistic regression analysis of data from 3,731 women to establish determinants of receiving quality family planning services. Results The Method Information Index Plus score for higher-quality counseling was 56.7%, lower-quality counseling 32.4%, and no counseling 10.9%. Women aged 15-24 years (aOR = 0.69, 95% CI = 0.56-0.86, p = 0.001) had lower odds of receiving better counseling compared to women aged 35 years and above. Those with no education (aOR = 0.52, 95% CI = 0.33-0.82, p = 0.005), primary (aOR = 0.56, 95% CI = 0.44-0.71, p<0.001) and secondary (aOR = 0.79, 95% CI = 0.65-0.98, p = 0.028) were less likely to receive better counseling compared to those with tertiary education. Women who received long acting and reversible contraception methods (aOR = 1.75, 95% CI = 1.42-2.17, p<0.001), and those who were method switchers (aOR = 1.24, 95% CI = 1.03-1.50, p = 0.027), had a higher likelihood of receiving better quality of counseling as compared to those on short-term methods and those who were continuers, respectively. Conclusion The quality of family planning counseling in Kenya is still sub-optimal considering that some women receive no form of counseling at service delivery point. There is need to review the existing FP guidelines and training packages to increase focus on the quality of counseling services offered by health providers. Social accountability strategies that empower women to demand quality services should be included in community-level family planning interventions.	[Ontiri, Susan; Biesma, Regien; Stekelenburg, Jelle] Univ Med Ctr Groningen, Dept Hlth Sci, Global Hlth Unit, Groningen, Netherlands; [Kabue, Mark] Johns Hopkins Univ, Dept Monitoring Evaluat & Res, Nairobi, Kenya; [Stekelenburg, Jelle] Leeuwarden Med Ctr, Dept Obstet & Gynecol, Leeuwarden, Netherlands; [Gichangi, Peter] Tech Univ Mombasa, Dept Res, Mombasa, Kenya; [Gichangi, Peter] Univ Ghent, Dept Publ Hlth & Primary Care, Fac Med & Hlth Sci, Ghent, Belgium; [Gichangi, Peter] Int Ctr Reprod Hlth Kenya ICRH K, Mombasa, Kenya	University of Groningen; Medical Center Leeuwarden; Technical University of Mombasa; Ghent University; Ghent University Hospital	Ontiri, S (corresponding author), Univ Med Ctr Groningen, Dept Hlth Sci, Global Hlth Unit, Groningen, Netherlands.	s.k.ontiri@umcg.nl	Stekelenburg, Jelle/B-3129-2017	Stekelenburg, Jelle/0000-0002-2732-6620				Ali MM., 2012, WHO CAUSES CONSEQUEN; Amir D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226550; Barden-O'Fallon J, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0529-9; Blanc AK, 2002, STUD FAMILY PLANN, V33, P127, DOI 10.1111/j.1728-4465.2002.00127.x; Blanc AK, 2009, INT PERSPECT SEX R H, V35, P63, DOI 10.1363/ipsrh.35.063.09; Castle S., 2015, POPULATION COUNCIL F; Chakraborty NM, 2019, GLOB HEALTH-SCI PRAC, V7, P87, DOI 10.9745/GHSP-D-18-00407; Chang KT, 2019, STUD FAMILY PLANN, V50, P25, DOI 10.1111/sifp.12081; Confederation Suisse, 2016, SWISS POS FRAM SUST; Dadi Hailemichael B., 2020, INT J REPROD MED, DOI [10.1155/2020/2649340, DOI 10.1155/2020/2649340]; Feeser K., 2019, GATES OPEN RES, V3, DOI [10.12688/gatesopenres.12974.2, DOI 10.12688/GATESOPENRES.12974.2]; Hrusa G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228714; International Centre for Reproductive Health Kenya (ICRHK) and The Bill & Melinda Gates Institute for Population and Reproductive Health at The Johns Hopkins Bloomberg School of Public Health, 2018, PERF MON ACC 2020 PM, DOI [10.34976/p9dy-5h35, DOI 10.34976/P9DY-5H35]; International Centre for Reproductive Health Kenya (ICRHK) and The Bill & Melinda Gates Institute for Population and Reproductive Health at The Johns Hopkins Bloomberg School of Public Health, 2019, PERF MON ACT PMA KEN; International Centre for Reproductive Health Kenya (ICRHK); The Bill & Melinda Gates Institute for Population and Reproductive Health at The Johns Hopkins Bloomberg School of Public Health; and Jhpiego, BILL MEL GAT I POP R, DOI [10.34976/5w8--8512, DOI 10.34976/5W8--8512]; Jacobstein R, 2018, GLOB HEALTH-SCI PRAC, V6, P17, DOI 10.9745/GHSP-D-17-00396; Jain AK., 2018, PROPOSED METRICS MEA; Jain AK, 2016, INT PERSPECT SEX R H, V42, P131, DOI 10.1363/42e1616; Jain Anrudh K, 2013, Int Perspect Sex Reprod Health, V39, P133, DOI 10.1363/3913313; Jain A, 2019, GLOB HEALTH-SCI PRAC, V7, P289, DOI 10.9745/GHSP-D-19-00028; Kenya National Bureau of Statistics, 2015, REP KEN KEN DEM HLTH; Lee JK, 2011, J GEN INTERN MED, V26, P731, DOI 10.1007/s11606-011-1647-3; Leisher SH., 2015, QUALITY MEASUREMENT; RamaRao S, 2003, STUD FAMILY PLANN, V34, P227, DOI 10.1111/j.1728-4465.2003.00227.x; RamaRao S, 2015, STUD FAMILY PLANN, V46, P97, DOI 10.1111/j.1728-4465.2015.00017.x; Sprockett A, 2017, HEALTH POLICY PLANN, V32, P292, DOI 10.1093/heapol/czw123; Tefera A.S., 2015, SCI J PUBLIC HLTH, V3, P143, DOI [10.11648/j.sjph.20150301.33, DOI 10.11648/J.SJPH.20150301.33]; Tessema GA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165627; Track, 2020, S CURVE PUTTING MCPR; Tumlinson K, 2015, INT PERSPECT SEX R H, V41, P69, DOI 10.1363/4106915; Tumlinson K, 2015, CONTRACEPTION, V92, P143, DOI 10.1016/j.contraception.2015.04.002; Zimmerman L, 2017, STUD FAMILY PLANN, V48, P293, DOI 10.1111/sifp.12031	32	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0256295	10.1371/journal.pone.0256295	http://dx.doi.org/10.1371/journal.pone.0256295			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XM9EM	34506509	Green Published, gold			2023-01-03	WOS:000729120700026
J	Koikawa, K; Kibe, S; Suizu, F; Sekino, N; Kim, N; Manz, TD; Pinch, BJ; Akshinthala, D; Verma, A; Gaglia, G; Nezu, Y; Ke, SZ; Qiu, CX; Ohuchida, K; Oda, Y; Lee, TH; Wegiel, B; Clohessy, JG; London, N; Santagata, S; Wulf, GM; Hidalgo, M; Muthuswamy, SK; Nakamura, M; Gray, NS; Zhou, XZ; Lu, KP				Koikawa, Kazuhiro; Kibe, Shin; Suizu, Futoshi; Sekino, Nobufumi; Kim, Nami; Manz, Theresa D.; Pinch, Benika J.; Akshinthala, Dipikaa; Verma, Ana; Gaglia, Giorgio; Nezu, Yutaka; Ke, Shizhong; Qiu, Chenxi; Ohuchida, Kenoki; Oda, Yoshinao; Lee, Tae Ho; Wegiel, Babara; Clohessy, John G.; London, Nir; Santagata, Sandro; Wulf, Gerburg M.; Hidalgo, Manuel; Muthuswamy, Senthil K.; Nakamura, Masafumi; Gray, Nathanael S.; Zhou, Xiao Zhen; Lu, Kun Ping			Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy	CELL			English	Article							PROLYL ISOMERASE PIN1; ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; DUCTAL ADENOCARCINOMA; PD-L1 EXPRESSION; STELLATE CELLS; ANTI-PD-L1 ANTIBODY; BREAST-CANCER; IN-VIVO; GEMCITABINE	Pancreatic ductal adenocarcinoma (PDAC) is characterized by notorious resistance to current therapies attributed to inherent tumor heterogeneity and highly desmoplastic and immunosuppressive tumor microenvironment (TME). Unique proline isomerase Pin1 regulates multiple cancer pathways, but its role in the TME and cancer immunotherapy is unknown. Here, we find that Pin1 is overexpressed both in cancer cells and cancer-associated fibroblasts (CAFs) and correlates with poor survival in PDAC patients. Targeting Pin1 using clinically available drugs induces complete elimination or sustained remissions of aggressive PDAC by synergizing with anti-PD-1 and gemcitabine in diverse model systems. Mechanistically, Pin1 drives the desmoplastic and immunosuppressive TME by acting on CAFs and induces lysosomal degradation of the PD-1 ligand PD-L1 and the gemcitabine transporter ENT1 in cancer cells, besides activating multiple cancer pathways. Thus, Pin1 inhibition simultaneously blocks multiple cancer pathways, disrupts the desmoplastic and immunosuppressive TME, and upregulates PD-L1 and ENT1, rendering PDAC eradicable by immunochemotherapy.	[Koikawa, Kazuhiro; Kibe, Shin; Suizu, Futoshi; Sekino, Nobufumi; Kim, Nami; Nezu, Yutaka; Ke, Shizhong; Qiu, Chenxi; Zhou, Xiao Zhen; Lu, Kun Ping] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Translat Therapeut, Boston, MA 02215 USA; [Koikawa, Kazuhiro; Kibe, Shin; Suizu, Futoshi; Sekino, Nobufumi; Kim, Nami; Akshinthala, Dipikaa; Nezu, Yutaka; Ke, Shizhong; Qiu, Chenxi; Lee, Tae Ho; Wulf, Gerburg M.; Hidalgo, Manuel; Muthuswamy, Senthil K.; Zhou, Xiao Zhen; Lu, Kun Ping] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Koikawa, Kazuhiro; Kibe, Shin; Suizu, Futoshi; Sekino, Nobufumi; Kim, Nami; Akshinthala, Dipikaa; Nezu, Yutaka; Ke, Shizhong; Qiu, Chenxi; Wegiel, Babara; Clohessy, John G.; Wulf, Gerburg M.; Hidalgo, Manuel; Muthuswamy, Senthil K.; Zhou, Xiao Zhen; Lu, Kun Ping] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Canc Res Inst, Boston, MA 02215 USA; [Koikawa, Kazuhiro; Kibe, Shin; Suizu, Futoshi; Sekino, Nobufumi; Nezu, Yutaka; Ke, Shizhong; Qiu, Chenxi; Zhou, Xiao Zhen; Lu, Kun Ping] Harvard Med Sch, Program Neurosci, Boston, MA 02115 USA; [Koikawa, Kazuhiro; Kibe, Shin; Ohuchida, Kenoki; Nakamura, Masafumi] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 8128582, Japan; [Kibe, Shin; Sekino, Nobufumi; Ke, Shizhong; Qiu, Chenxi; Zhou, Xiao Zhen; Lu, Kun Ping] Broad Inst MIT & Harvard, Chem Biol & Therapeut Sci Program, Cambridge, MA 02142 USA; [Suizu, Futoshi] Hokkaido Univ, Inst Genet Med, Div Canc Biol, Sapporo, Hokkaido 0600815, Japan; [Manz, Theresa D.; Pinch, Benika J.] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA; [Manz, Theresa D.; Pinch, Benika J.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Verma, Ana; Gaglia, Giorgio; Santagata, Sandro] Harvard Med Sch, Ludwig Ctr Harvard, Boston, MA 02115 USA; [Verma, Ana; Gaglia, Giorgio; Santagata, Sandro] Harvard Med Sch, Lab Syst Pharmacol, Boston, MA 02115 USA; [Verma, Ana; Gaglia, Giorgio; Santagata, Sandro] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka 8128582, Japan; [Wegiel, Babara] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Surg Oncol, Boston, MA 02215 USA; [Wegiel, Babara] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; [Clohessy, John G.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Preclin Murine Pharmacogenet Facil, Boston, MA 02215 USA; [Gray, Nathanael S.] Stanford Univ, Chem H, Dept Chem & Syst Biol, Stanford, CA 94305 USA; [Gray, Nathanael S.] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA; [London, Nir] Weizmann Inst Sci, Dept Chem & Struct Biol, IL-7610001 Rehovot, Israel	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Kyushu University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Hokkaido University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Kyushu University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Stanford University; Stanford Cancer Institute; Stanford University; Weizmann Institute of Science	Zhou, XZ; Lu, KP (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Translat Therapeut, Boston, MA 02215 USA.; Zhou, XZ; Lu, KP (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.; Zhou, XZ; Lu, KP (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Canc Res Inst, Boston, MA 02215 USA.; Zhou, XZ; Lu, KP (corresponding author), Harvard Med Sch, Program Neurosci, Boston, MA 02115 USA.; Zhou, XZ; Lu, KP (corresponding author), Broad Inst MIT & Harvard, Chem Biol & Therapeut Sci Program, Cambridge, MA 02142 USA.	xzhouenator@gmail.com; klu@broadinstitute.org	Muthuswamy, Senthil K/AGY-2834-2022; Akshinthala, Dipikaa/AGY-8204-2022	Muthuswamy, Senthil K/0000-0001-6564-9634; Gray, Nathanael/0000-0001-5354-7403; Koikawa, Kazuhiro/0000-0002-3208-9447; Clohessy, John/0000-0001-5186-9775; Verma, Ana/0000-0001-9057-171X	JSPS KAKENHI in Japan [JP18KK0445]; AMED in Japan [JP20gm5910024]; NIH [R21 CA256720, CA224193, R01CA205153, R01AG055559, U01NS096835, U54-CA225088, T32-HL007627]; Ludwig Center at Harvard; Breast Cancer Research Foundation (BCRF); NIH SPORE grants [1P50CA168504, 5R01CA226776]	JSPS KAKENHI in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); AMED in Japan; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ludwig Center at Harvard; Breast Cancer Research Foundation (BCRF); NIH SPORE grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful to Stephanie K. Dougan for her expert advice, Terri Woo for her assistance with t-CyCIF, and animal facility staffs at Beth Israel Deaconess Medical Center (BIDMC) for mouse experiments. The graphical abstract and schemas were created with BioRender.com. F.S. was supported by JSPS KAKENHI JP18KK0445 and AMED grant JP20gm5910024 in Japan. C.Q. is Alzheimer's Association Research Fellow in the United States. B.W. was funded by NIH R21 CA256720. S.K.M. was supported by NIH CA224193. The work is supported by the funding from the Ludwig Center at Harvard and NIH grants U54-CA225088 to S.S.; T32-HL007627 to G.G.; the Breast Cancer Research Foundation (BCRF) and NIH SPORE grants 1P50CA168504 and 5R01CA226776 to G.M.W.; NIH R01CA205153 to K.P.L., N.S.G., and X.Z.Z.; NIH R01AG055559 to K.P.L., E.H.L., and X.Z.Z.; and NIH U01NS096835 to K.P.L.; as well as gift donations from the Owens Family Foundation to X.Z.Z.	Amrutkar M, 2017, CANCERS, V9, DOI 10.3390/cancers9110157; Ayala G, 2003, CANCER RES, V63, P6244; Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036; Balachandran VP, 2019, GASTROENTEROLOGY, V156, P2056, DOI 10.1053/j.gastro.2018.12.038; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Berg S, 2019, NAT METHODS, V16, P1226, DOI 10.1038/s41592-019-0582-9; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bleijs M, 2019, EMBO J, V38, DOI 10.15252/embj.2019101654; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Cha JH, 2019, MOL CELL, V76, P359, DOI 10.1016/j.molcel.2019.09.030; Chen LY, 2019, CANCER SCI, V110, P2442, DOI 10.1111/cas.14085; Dantes Z., 2020, JCI INSIGHT, V5; Day CP, 2015, CELL, V163, P39, DOI 10.1016/j.cell.2015.08.068; de The H, 2010, NAT REV CANCER, V10, P775, DOI 10.1038/nrc2943; Dijkstra KK, 2018, CELL, V174, P1586, DOI 10.1016/j.cell.2018.07.009; Dorand RD, 2016, SCIENCE, V353, P399, DOI 10.1126/science.aae0477; Du ZM, 2019, NAT PROTOC, V14, P2900, DOI 10.1038/s41596-019-0206-y; Dubiella C, 2021, NAT CHEM BIOL, V17, P954, DOI 10.1038/s41589-021-00786-7; Endo S, 2017, GASTROENTEROLOGY, V152, P1492, DOI 10.1053/j.gastro.2017.01.010; Ene-Obong A, 2013, GASTROENTEROLOGY, V145, P1121, DOI 10.1053/j.gastro.2013.07.025; Erkan M, 2012, GUT, V61, P172, DOI 10.1136/gutjnl-2011-301220; Farrell JJ, 2009, GASTROENTEROLOGY, V136, P187, DOI 10.1053/j.gastro.2008.09.067; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Garg B, 2018, GASTROENTEROLOGY, V155, P880, DOI 10.1053/j.gastro.2018.05.051; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gilles ME, 2018, CLIN CANCER RES, V24, P1734, DOI 10.1158/1078-0432.CCR-17-2733; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Gottfried I, 2010, BIOCHEM SOC T, V38, P187, DOI 10.1042/BST0380187; Gotwals P, 2017, NAT REV CANCER, V17, P286, DOI 10.1038/nrc.2017.17; Guan J, 2014, CANCER LETT, V345, P132, DOI 10.1016/j.canlet.2013.12.006; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Herter-Sprie GS, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87415; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Ho WJ, 2020, NAT REV CLIN ONCOL, V17, P527, DOI 10.1038/s41571-020-0363-5; Hosein AN, 2020, NAT REV GASTRO HEPAT, V17, P487, DOI 10.1038/s41575-020-0300-1; Hu QS, 2017, ONCOL REP, V38, P2069, DOI 10.3892/or.2017.5856; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; Jain Preetesh, 2014, Clin Lymphoma Myeloma Leuk, V14, pe47, DOI 10.1016/j.clml.2013.08.004; Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123; Jiao SP, 2017, CLIN CANCER RES, V23, P3711, DOI 10.1158/1078-0432.CCR-16-3215; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Kocher HM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18636-w; Koikawa K, 2018, CANCER LETT, V425, P65, DOI 10.1016/j.canlet.2018.03.031; Koikawa K, 2018, CANCER LETT, V412, P143, DOI 10.1016/j.canlet.2017.10.010; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kozono S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05402-2; Laklai H, 2016, NAT MED, V22, P497, DOI 10.1038/nm.4082; LEFEBVRE P, 1991, LEUKEMIA, V5, P1054; Li J, 2019, COMPUT STRUCT BIOTEC, V17, P498, DOI 10.1016/j.csbj.2019.03.016; Li Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068148; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Liu PH, 2019, NAT CELL BIOL, V21, P203, DOI 10.1038/s41556-018-0260-7; Lu ZM, 2014, CELL RES, V24, P1033, DOI 10.1038/cr.2014.109; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Luo ML, 2020, CANCER RES, V80, P3033, DOI 10.1158/0008-5472.CAN-19-2739; Mace TA, 2018, GUT, V67, P320, DOI 10.1136/gutjnl-2016-311585; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; Marechal R, 2012, GASTROENTEROLOGY, V143, P664, DOI 10.1053/j.gastro.2012.06.006; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; McGranahan N, 2017, CELL, V171, P1259, DOI 10.1016/j.cell.2017.10.001; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Messa M, 2014, ELIFE, V3, DOI 10.7554/eLife.03311; Mezzadra R, 2017, NATURE, V549, P106, DOI 10.1038/nature23669; Mugoni V, 2019, CELL RES, V29, P446, DOI 10.1038/s41422-019-0162-7; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Oh SA, 2020, NAT CANCER, V1, P681, DOI 10.1038/s43018-020-0075-x; Okumura T, 2019, INT J CANCER, V144, P1401, DOI 10.1002/ijc.31775; Pantelidou C, 2019, CANCER DISCOV, V9, P722, DOI 10.1158/2159-8290.CD-18-1218; Peng TY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14836; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rashid R, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0332-y; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; Ruscetti M, 2020, CELL, V181, P424, DOI 10.1016/j.cell.2020.03.008; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Samuel N, 2012, NAT REV GASTRO HEPAT, V9, P77, DOI 10.1038/nrgastro.2011.215; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shi Y, 2019, NATURE, V569, P131, DOI 10.1038/s41586-019-1130-6; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Suizu F, 2016, EMBO J, V35, P1346, DOI 10.15252/embj.201593003; Tessier-Cloutier B, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3634-5; Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203; Waggoner SN, 2012, NATURE, V481, P394, DOI 10.1038/nature10624; Wang HB, 2019, NAT CHEM BIOL, V15, P42, DOI 10.1038/s41589-018-0161-x; Wang XP, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01200-x; Waters AM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031435; Wei S, 2015, NAT MED, V21, P457, DOI 10.1038/nm.3839; Whittle MC, 2019, GASTROENTEROLOGY, V156, P2085, DOI 10.1053/j.gastro.2018.12.044; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yamaki S, 2017, INT J CLIN ONCOL, V22, P726, DOI 10.1007/s10147-017-1112-3; Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015; Zhou XZ, 2016, NAT REV CANCER, V16, P463, DOI 10.1038/nrc.2016.49; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	104	31	31	17	105	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 2	2021	184	18					4753	+	e27	10.1016/j.cell.2021.07.020	http://dx.doi.org/10.1016/j.cell.2021.07.020		SEP 2021	46	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UL1TF	34388391	Bronze, Green Accepted			2023-01-03	WOS:000692441200011
J	Munsif, M; McDonald, CF				Munsif, Maitri; McDonald, Christine F.			ACP provided 2 conditional recommendations on use of high-flow nasal oxygen in acute respiratory failure	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Munsif, Maitri; McDonald, Christine F.] Austin Hosp, Melbourne, Vic, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Munsif, M (corresponding author), Austin Hosp, Melbourne, Vic, Australia.			Munsif, Maitri/0000-0003-2755-4137				Baldomero AK, 2021, ANN INTERN MED, V174, P952, DOI 10.7326/M20-4675	1	0	0	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP	2021	174	9					JC98	JC98		10.7326/ACPJ202109210-098	http://dx.doi.org/10.7326/ACPJ202109210-098			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA5GQ	34487451				2023-01-03	WOS:000720675500005
J	Marafino, BJ; Escobar, GJ; Baiocchi, MT; Liu, VX; Plimier, CC; Schuler, A				Marafino, Ben J.; Escobar, Gabriel J.; Baiocchi, Michael T.; Liu, Vincent X.; Plimier, Colleen C.; Schuler, Alejandro			Evaluation of an intervention targeted with predictive analytics to prevent readmissions in an integrated health system: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HIGH-RISK PATIENTS; HOSPITAL READMISSIONS; INPATIENT DETERIORATION; REDUCTION PROGRAM; CARE; MORTALITY; RATES; RECORD; EPIDEMIOLOGY; ASSOCIATION	OBJECTIVES To determine the associations between a care coordination intervention (the Transitions Program) targeted to patients after hospital discharge and 30 day readmission and mortality in a large, integrated healthcare system. DESIGN Observational study. SETTING 21 hospitals operated by Kaiser Permanente Northern California. PARTICIPANTS 1 539 285 eligible index hospital admissions corresponding to 739 040 unique patients from June 2010 to December 2018. 411 507 patients were discharged post-implementation of the Transitions Program; 80 424 (19.5%) of these patients were at medium or high predicted risk and were assigned to receive the intervention after discharge. INTERVENTION Patients admitted to hospital were automatically assigned to be followed by the Transitions Program in the 30 days post-discharge if their predicted risk of 30 day readmission or mortality was greater than 25% on the basis of electronic health record data. MAIN OUTCOME MEASURES Non-elective hospital readmissions and all cause mortality in the 30 days after hospital discharge. RESULTS Difference-in-differences estimates indicated that the intervention was associated with significantly reduced odds of 30 day non-elective readmission (adjusted odds ratio 0.91, 95% confidence interval 0.89 to 0.93; absolute risk reduction 95% confidence interval & minus;2.5%, & minus;3.1% to & minus;2.0%) but not with the odds of 30 day post-discharge mortality (1.00, 0.95 to 1.04). Based on the regression discontinuity estimate, the association with readmission was of similar magnitude (absolute risk reduction & minus;2.7%, & minus; 3.2% to & minus;2.2%) among patients at medium risk near the risk threshold used for enrollment. However, the regression discontinuity estimate of the association with post-discharge mortality (& minus;0.7% & minus;1.4% to & minus; 0.0%) was significant and suggested benefit in this subgroup of patients. CONCLUSIONS In an integrated health system, the implementation of a comprehensive readmissions prevention intervention was associated with a reduction in 30 day readmission rates. Moreover, there was no association with 30 day post-discharge mortality, except among medium risk patients, where some evidence for benefit was found. Altogether, the study provides evidence to suggest the effectiveness of readmission prevention interventions in community settings, but further research might be required to confirm the findings beyond this setting.	[Marafino, Ben J.] Stanford Univ, Sch Med, Biomed Informat Training Program, Dept Biomed Data Sci, Stanford, CA 94305 USA; [Escobar, Gabriel J.; Liu, Vincent X.; Plimier, Colleen C.; Schuler, Alejandro] Kaiser Permanente Northern Calif, Div Res, Syst Res Initiat, Oakland, CA USA; [Baiocchi, Michael T.] Stanford Univ, Dept Med, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA; [Liu, Vincent X.] Kaiser Permanente Med Ctr, Crit Care Med, Santa Clara, CA USA; [Schuler, Alejandro] Stanford Univ, Sch Med, Dept Biomed Data Sci, Stanford, CA 94305 USA	Stanford University; Kaiser Permanente; Stanford University; Kaiser Permanente; Stanford University	Marafino, BJ (corresponding author), Stanford Univ, Sch Med, Biomed Informat Training Program, Dept Biomed Data Sci, Stanford, CA 94305 USA.	marafino@stanford.edu		Marafino, Ben/0000-0003-2385-7376	National Library of Medicine of the National Institutes of Health (NIH) [T15LM007033]; Stanford University School of Medicine dean's fellowship; Agency for Healthcare Research and Quality [KHS022192A]; NIH [R35GM128672]; Permanente Medical Group; Kaiser Foundation Hospitals	National Library of Medicine of the National Institutes of Health (NIH); Stanford University School of Medicine dean's fellowship; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Permanente Medical Group; Kaiser Foundation Hospitals	This work was funded by The Permanente Medical Group and Kaiser Foundation Hospitals. BJM was supported by a predoctoral training fellowship (T15LM007033) from the National Library of Medicine of the National Institutes of Health (NIH) as well as by a Stanford University School of Medicine dean's fellowship. MTB was supported by grant KHS022192A from the Agency for Healthcare Research and Quality. VXL was supported by NIH grant R35GM128672. The funders played no role in the study design, data collection, analysis, reporting of the data, writing of the report, or the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Agency for Healthcare Research and Quality U.S. Department of Health and Human Services., 2014, AHRQ NAT SCOR HOSP A; Bambhroliya AB, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.1190; Berkowitz SA, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.4273; Billings J, 2006, CASE FINDING ALGORIT; Billings J, 2006, BRIT MED J, V333, P327, DOI 10.1136/bmj.38870.657917.AE; Centers for Medicare and Medicaid Services, 2019, HOSP READM RED PROGR; CMS.gov, 2019, HLTH INS EXCH QUAL R; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Dhalla IA, 2014, JAMA-J AM MED ASSOC, V312, P1305, DOI 10.1001/jama.2014.11492; Dharmarajan K, 2016, HEALTH AFFAIR, V35, P1294, DOI 10.1377/hlthaff.2015.1614; Dimick JB, 2014, JAMA-J AM MED ASSOC, V312, P2401, DOI 10.1001/jama.2014.16153; Escobar GJ, 2008, MED CARE, V46, P232, DOI 10.1097/MLR.0b013e3181589bb6; Escobar GJ, 2020, NEW ENGL J MED, V383, P1951, DOI 10.1056/NEJMsa2001090; Escobar GJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.16769; Escobar GJ, 2016, J HOSP MED, V11, pS18, DOI 10.1002/jhm.2652; Escobar GJ, 2016, J HOSP MED, V11, pS5, DOI 10.1002/jhm.2653; Escobar GJ, 2015, MED CARE, V53, P916, DOI 10.1097/MLR.0000000000000435; Escobar GJ, 2013, MED CARE, V51, P446, DOI 10.1097/MLR.0b013e3182881c8e; Escobar GJ, 2011, J HOSP MED, V6, P74, DOI 10.1002/jhm.817; Ferro EG, 2019, HEALTH AFFAIR, V38, P585, DOI 10.1377/hlthaff.2018.05412; Finkelstein A, 2020, NEW ENGL J MED, V382, P152, DOI 10.1056/NEJMsa1906848; Gai YW, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4645-5; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hemming K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h391; Hernan MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254; Hesselink G, 2012, ANN INTERN MED, V157, P417, DOI 10.7326/0003-4819-157-6-201209180-00006; Huckfeldt P, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0634; Hutchings HA, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-301; Ibrahim AM, 2018, JAMA INTERN MED, V178, P290, DOI 10.1001/jamainternmed.2017.6148; Imbens G, 2012, REV ECON STUD, V79, P933, DOI 10.1093/restud/rdr043; Julius Shiskin J.C.M., 1967, X 11 VARIANT CENSUS; Kansagara D, 2016, J HOSP MED, V11, P221, DOI 10.1002/jhm.2502; Khera R, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6831; Kipnis P, 2016, J BIOMED INFORM, V64, P10, DOI 10.1016/j.jbi.2016.09.013; Kripalani S, 2014, ANNU REV MED, V65, P471, DOI 10.1146/annurev-med-022613-090415; Lagu T, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.115.002912; Leppin AL, 2014, JAMA INTERN MED, V174, P1095, DOI 10.1001/jamainternmed.2014.1608; Lewis GH, 2010, MILBANK Q, V88, P240, DOI 10.1111/j.1468-0009.2010.00597.x; Lind KD, 2019, MED CARE RES REV, V76, P229, DOI 10.1177/1077558717718026; Lindquist LA, 2011, J HOSP MED, V6, P51, DOI 10.1002/jhm.901; Liu V, 2012, J HOSP MED, V7, P224, DOI 10.1002/jhm.964; Low LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168757; Marafino BJ, 2020, HEALTH SERV RES, V55, P993, DOI 10.1111/1475-6773.13586; McWilliams A, 2019, J GEN INTERN MED, V34, P58, DOI 10.1007/s11606-018-4617-1; Mehtsun WT, 2018, ANN SURG, V267, P599, DOI 10.1097/SLA.0000000000002350; Moscoe E, 2015, J CLIN EPIDEMIOL, V68, P132, DOI 10.1016/j.jclinepi.2014.06.021; National Committee for Quality Assurance, 2014, HEDIS 2019, V2; NHS England, 2014, ENH SERV SPEC AV UNP; Ody C, 2019, HEALTH AFFAIR, V38, P36, DOI 10.1377/hlthaff.2018.05178; Panagiotou OA, 2019, ANN INTERN MED, V171, P99, DOI 10.7326/M18-1795; Rawal S, 2019, JAMA INTERN MED, V179, P38, DOI 10.1001/jamainternmed.2018.5100; Rennke S, 2013, ANN INTERN MED, V158, P433, DOI 10.7326/0003-4819-158-5-201303051-00011; Snooks H, 2019, BMJ QUAL SAF, V28, P697, DOI 10.1136/bmjqs-2018-007976; Steventon A, 2017, BMJ QUAL SAF, V26, P782, DOI 10.1136/bmjqs-2017-006629; Van Calster B, 2019, J AM MED INFORM ASSN, V26, P1651, DOI 10.1093/jamia/ocz130; van Walraven C, 2010, J CLIN EPIDEMIOL, V63, P798, DOI 10.1016/j.jclinepi.2009.08.020; van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Wadhera RK, 2018, JAMA-J AM MED ASSOC, V320, P2542, DOI 10.1001/jama.2018.19232; Walkey AJ, 2020, BMJ QUAL SAF, V29, P161, DOI 10.1136/bmjqs-2019-009734; Walkey AJ, 2018, ANN AM THORAC SOC, V15, P523, DOI 10.1513/AnnalsATS.201712-942IP; Wennberg D, 2006, COMBINED PREDICTIVE; Wright B, 2015, HEALTH AFFAIR, V34, P1730, DOI 10.1377/hlthaff.2014.1474	63	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 11	2021	374								n1747	10.1136/bmj.n1747	http://dx.doi.org/10.1136/bmj.n1747			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UA6HZ	34380667	Green Published, hybrid			2023-01-03	WOS:000685262400002
J	Lee, K; Lee, D; Hong, S; Shin, D; Jeong, S; Shin, H; Choi, W; An, S; Lee, G				Lee, Kyeongbong; Lee, DongGeon; Hong, SoungKyun; Shin, DooChul; Jeong, SeYeon; Shin, HyeonHui; Choi, Wonjae; An, SeungHeon; Lee, GyuChang			The relationship between sitting balance, trunk control and mobility with predictive for current mobility level in survivors of sub-acute stroke	PLOS ONE			English	Article							IMPAIRMENT SCALE; MOTOR IMPAIRMENT; OLDER-ADULTS; PERFORMANCE; VALIDITY; RELIABILITY; GO; REHABILITATION; DISABILITY; RECOVERY	Objective To investigate the relationship between sitting balance, trunk control, and mobility, as well as whether the sitting balance and trunk control can predict mobility level in sub-acute stroke survivors. Methods This is a observational and cross-sectional study. Fifty-five hemiplegic stroke survivors were participated in this study. The Timed Up and Go Test (TUG) was used to estimate mobility, and the Sitting Balance Scale (SBS) was used to examining sitting balance. The Trunk Impairment Scale (TIS), Trunk Control Test (TCT), and Postural Assessment Scale for Stroke-trunk control (PASS-TC) were used for examining the trunk control. Spearman's correlation was used to analyze the relationship between TUG, SBS, TIS, TCT, and PASS-TC. Results The TUG is significantly correlated with SBS (r = -0.78), TIS (r = -0.76), TCT (r = -0.65), and PASS-TC (r = -0.67). In addition, the receiver operation characteristic (ROC) curve showed as cut-off value of SBS as >28.5, TIS > 16.5, TCT >82, and PASS-TC >10.5. The area under the ROC curve in each of the four tests is moderately accurate for predicting the mobility of sub-acute stroke survivors (0.84 similar to 0.90) (0.7 < AUC <= 9 (moderate informative)).	[Lee, Kyeongbong] Kangwon Natl Univ, Dept Phys Therapy, Samcheok, South Korea; [Lee, DongGeon] Sinsegye Nursing Care Facil, Dept Phys Therapy, Chang Won, South Korea; [Hong, SoungKyun] Woosuk Univ, Dept Phys Therapy, Wonju, South Korea; [Shin, DooChul; Lee, GyuChang] Kyungnam Univ, Dept Phys Therapy, Chang Won, South Korea; [Jeong, SeYeon] Kyungnam Univ, Grad Sch, Dept Phys Therapy, Chang Won, South Korea; [Shin, HyeonHui] Dongseo Univ, Dept Occupat Therapy, Busan, South Korea; [Choi, Wonjae] Joongbu Univ, Dept Phys Therapy, Geumsan, South Korea; [An, SeungHeon] Natl Rehabil Ctr, Dept Phys Therapy, Seoul, South Korea	Kangwon National University; Woosuk University; Kyungnam University; Kyungnam University; Dongseo University; Joongbu University	Lee, G (corresponding author), Kyungnam Univ, Dept Phys Therapy, Chang Won, South Korea.	leegc76@kyungnam.ac.kr		Choi, Wonjae/0000-0002-2232-6744				BERG K, 1989, Physiotherapy Canada, V41, P304; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; BOHANNON RW, 1995, INT J REHABIL RES, V18, P162, DOI 10.1097/00004356-199506000-00010; Cabanas-Valdes R, 2016, CLIN REHABIL, V30, P1024, DOI 10.1177/0269215515609414; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P576, DOI 10.1136/jnnp.53.7.576; Dickstein R, 1999, J NEUROL NEUROSUR PS, V66, P218, DOI 10.1136/jnnp.66.2.218; Fan Zi-Yan, 2020, Sichuan Da Xue Xue Bao Yi Xue Ban, V51, P847, DOI 10.12182/20201160201; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; Franchignoni FP, 1997, STROKE, V28, P1382, DOI 10.1161/01.STR.28.7.1382; Gjelsvik B, 2012, DISABIL REHABIL, V34, P1385, DOI 10.3109/09638288.2011.645113; Hsieh CL, 2002, STROKE, V33, P2626, DOI 10.1161/01.STR.0000033930.05931.93; Kwakkel G, 1996, AGE AGEING, V25, P479, DOI 10.1093/ageing/25.6.479; LOEWEN SC, 1990, STROKE, V21, P78, DOI 10.1161/01.STR.21.1.78; Mao HF, 2002, STROKE, V33, P1022, DOI 10.1161/01.STR.0000012516.63191.C5; Medley Ann, 2011, Physiotherapy Theory and Practice, V27, P471, DOI 10.3109/09593985.2010.531077; Ng SS, 2005, ARCH PHYS MED REHAB, V86, P1641, DOI 10.1016/j.apmr.2005.01.011; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Shumway-Cook A, 2000, PHYS THER, V80, P896, DOI 10.1093/ptj/80.9.896; Thompson M, 2013, CLIN REHABIL, V27, P166, DOI 10.1177/0269215512452879; Tsang YL, 2004, ARCH PHYS MED REHAB, V85, P94, DOI 10.1016/S0003-9993(03)00377-0; Tsuji T, 2003, J REHABIL MED, V35, P184, DOI 10.1080/16501970306126; Tyson S, 2002, PHYS THERAPY REV, V7, P173, DOI DOI 10.1179/108331902235001589; Tyson SF, 2007, NEUROREHAB NEURAL RE, V21, P341, DOI 10.1177/1545968306296966; Verheyden G, 2006, CLIN REHABIL, V20, P451, DOI 10.1191/0269215505cr955oa; Verheyden G, 2004, CLIN REHABIL, V18, P326, DOI 10.1191/0269215504cr733oa; Verheyden G, 2007, CLIN REHABIL, V21, P387, DOI 10.1177/0269215507074055; Verheyden G, 2007, J NEUROL NEUROSUR PS, V78, P694, DOI 10.1136/jnnp.2006.101642; Verheyden G, 2010, DISABIL REHABIL, V32, P2127, DOI 10.3109/09638288.2010.483038; Wang CH, 2005, PHYS THER, V85, P887, DOI 10.1093/ptj/85.9.887; Young MA, 1991, JAMA-J AM MED ASSOC, V265, P793; Zimmerman MC, 2004, CIRC RES, V95, P210, DOI 10.1161/01.RES.0000135483.12297.e4	31	6	7	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2021	16	8							e0251977	10.1371/journal.pone.0251977	http://dx.doi.org/10.1371/journal.pone.0251977			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UA6JF	34351943	gold, Green Published			2023-01-03	WOS:000685265700119
J	Dupuis, C; de Montmollin, E; Buetti, N; Goldgran-Toledano, D; Reignier, J; Schwebel, C; Domitile, J; Neuville, M; Ursino, M; Siami, S; Ruckly, S; Alberti, C; Mourvillier, B; Bailly, S; Laurent, V; Gainnier, M; Souweine, B; Timsit, JF				Dupuis, Claire; de Montmollin, Etienne; Buetti, Niccolo; Goldgran-Toledano, Dany; Reignier, Jean; Schwebel, Carole; Domitile, Julien; Neuville, Mathilde; Ursino, Moreno; Siami, Shidasp; Ruckly, Stephane; Alberti, Corinne; Mourvillier, Bruno; Bailly, Sebastien; Laurent, Virginie; Gainnier, Marc; Souweine, Bertrand; Timsit, Jean-Francois		OutcomeRea Res Network	Impact of early corticosteroids on 60-day mortality in critically ill patients with COVID-19: A multicenter cohort study of the OUTCOMEREA network	PLOS ONE			English	Article							INFECTION; THERAPY; SEPSIS; SCORE; MODELS	Objectives In severe COVID-19 pneumonia, the appropriate timing and dosing of corticosteroids (CS) is not known. Patient subgroups for which CS could be more beneficial also need appraisal. The aim of this study was to assess the effect of early CS in COVID-19 pneumonia patients admitted to the ICU on the occurrence of 60-day mortality, ICU-acquired-bloodstream infections(ICU-BSI), and hospital-acquired pneumonia and ventilator-associated pneumonia(HAP-VAP). Methods We included patients with COVID-19 pneumonia admitted to 11 ICUs belonging to the French OutcomeRea(TM) network from January to May 2020. We used survival models with ponderation with inverse probability of treatment weighting (IPTW). Results The study population comprised 303 patients having a median age of 61.6 (53-70) years of whom 78.8% were male and 58.6% had at least one comorbidity. The median SAPS II was 33 (25-44). Invasive mechanical ventilation was required in 34.8% of the patients. Sixty-six (21.8%) patients were in the Early-C subgroup. Overall, 60-day mortality was 29.4%. The risks of 60-day mortality (IPTWHR = 0.86;95% CI 0.54 to 1.35, p = 0.51), ICU-BSI and HAP-VAP were similar in the two groups. Importantly, early CS treatment was associated with a lower mortality rate in patients aged 60 years or more (IPTWHR, 0.53;95% CI, 0.3-0.93; p = 0.03). In contrast, CS was associated with an increased risk of death in patients younger than 60 years without inflammation on admission (IPTWHR = 5.01;95% CI, 1.05, 23.88; p = 0.04). Conclusion For patients with COVID-19 pneumonia, early CS treatment was not associated with patient survival. Interestingly, inflammation and age can significantly influence the effect of CS.	[Dupuis, Claire; Domitile, Julien; Souweine, Bertrand] Gabriel Montpied Univ Hosp, Med Intens Care Unit, Clermont Ferrand, France; [Dupuis, Claire; de Montmollin, Etienne; Timsit, Jean-Francois] Univ Paris, IAME, UMR 1137, Paris, France; [de Montmollin, Etienne; Buetti, Niccolo; Timsit, Jean-Francois] Bichat Claude Bernard Hosp, AP HP, Med & Infect Dis Intens Care Unit, Paris, France; [Goldgran-Toledano, Dany] Grp Hosp Intercommunal Raincy Montfermeil, Polyvalent ICU, Montfermeil, France; [Reignier, Jean] Nantes Univ Hosp, Med Intens Care Unit, Nantes, France; [Schwebel, Carole] Grenoble Univ Hosp, Med Intens Care Unit, La Tronche, France; [Neuville, Mathilde] Hop Foch, Polyvalent ICU, Suresnes, France; [Ursino, Moreno] Univ Paris, AP HP, F CRIN PARTNERS Platform, Paris, France; [Ursino, Moreno] Univ Paris, Sorbonne Univ, USPC, Ctr Rech Cordeliers,INSERM, Paris, France; [Siami, Shidasp] Ctr Hosp Sud Essonne Dourdan Etampes, Polyvalent ICU, Dourdan, France; [Ruckly, Stephane] ICUREsearch, Dept Biostat, Paris, France; [Alberti, Corinne] Hop Robert Debre, AP HP, Epidemiol, Paris, France; [Mourvillier, Bruno] Robert Debre Univ Hosp, Med Intens Care Unit, Reims, France; [Bailly, Sebastien] Univ Grenoble Alpes, CHU Grenoble Alpes, INSERM, HP2, Grenoble, France; [Laurent, Virginie] Andre Mignot Hosp, Med Surg Intens Care Unit, Le Chesnay, France; [Gainnier, Marc] La Timone Univ Hosp, AP HM, Intens Care Unit, Marseilles, France	CHU Clermont Ferrand; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Nantes Universite; CHU de Nantes; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Hospital Foch; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Reims; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre Hospitalier de Versailles; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Dupuis, C (corresponding author), Gabriel Montpied Univ Hosp, Med Intens Care Unit, Clermont Ferrand, France.; Dupuis, C (corresponding author), Univ Paris, IAME, UMR 1137, Paris, France.	cdupuis1@chu-clermontferrand.fr	Ursino, Moreno/Y-1629-2019; souweine, bertrand/HHR-8972-2022	Ursino, Moreno/0000-0002-5709-4322; MOURVILLIER, BRUNO/0000-0001-5227-1468				Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Alexander PE, 2021, MED HYPOTHESES, V153, DOI 10.1016/j.mehy.2021.110622; Anglemyer A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000034.pub2; Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; Annane D, 2018, NEW ENGL J MED, V378, P809, DOI 10.1056/NEJMoa1705716; Arabi YM, 2020, INTENS CARE MED, V46, P2067, DOI 10.1007/s00134-020-06223-y; Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Bartoletti M, 2021, CLIN MICROBIOL INFEC, V27, P105, DOI 10.1016/j.cmi.2020.09.014; Batlle D, 2020, J AM SOC NEPHROL, V31, P1380, DOI 10.1681/ASN.2020040419; Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575; Buetti N, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03323-5; Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83; De Backer D, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03360-0; Dequin PF, 2020, JAMA-J AM MED ASSOC, V324, P1298, DOI 10.1001/jama.2020.16761; Fadel R, 2020, CLIN INFECT DIS, V71, P2114, DOI 10.1093/cid/ciaa601; Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2; Gupta S, 2021, JAMA INTERN MED, V181, P41, DOI 10.1001/jamainternmed.2020.6252; Hernan MA., 2016, CAUSAL INFERENCE; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hotchkiss RS, 2013, LANCET INFECT DIS, V13, P260, DOI 10.1016/S1473-3099(13)70001-X; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8; Jeannet R, 2020, INTENS CARE MED, V46, P1769, DOI 10.1007/s00134-020-06127-x; Keller MJ, 2020, J HOSP MED, V15, P489, DOI 10.12788/jhm.3497; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kox M, 2020, JAMA-J AM MED ASSOC, V324, P1565, DOI 10.1001/jama.2020.17052; Lau B, 2009, AM J EPIDEMIOL, V170, P244, DOI 10.1093/aje/kwp107; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Li TZ, 2021, J MED VIROL, V93, P506, DOI 10.1002/jmv.26280; Li Y, 2020, BRIT J HAEMATOL, V190, pE24, DOI 10.1111/bjh.16811; Liu J, 2020, J CLIN INVEST, V130, P6417, DOI 10.1172/JCI140617; Meduri GU, 2020, INTENS CARE MED, V46, P2284, DOI 10.1007/s00134-020-06289-8; Monreal E, 2021, EUR J CLIN MICROBIOL, V40, P761, DOI 10.1007/s10096-020-04078-1; Moore KL, 2012, STAT MED, V31, P1380, DOI 10.1002/sim.4469; Narain S, 2021, CHEST, V159, P933, DOI 10.1016/j.chest.2020.09.275; Nelson BC., 2020, CLIN INFECT DIS PUBL, DOI [10.1093/cid/ciaa1163, DOI 10.1093/CID/CIAA1163]; Pasin L, 2021, J CARDIOTHOR VASC AN, V35, P578, DOI 10.1053/j.jvca.2020.11.057; Piazza G, 2020, JAMA-J AM MED ASSOC, V324, P2548, DOI 10.1001/jama.2020.23422; Jeronimo CMP, 2021, CLIN INFECT DIS, V72, pE373, DOI 10.1093/cid/ciaa1177; Prescott HC, 2020, JAMA-J AM MED ASSOC, V324, P1292, DOI 10.1001/jama.2020.16747; Procter BC, 2020, REV CARDIOVASC MED, V21, P611, DOI 10.31083/j.rcm.2020.04.260; Ross JS, 2014, JAMA INTERN MED, V174, P1557, DOI 10.1001/jamainternmed.2014.3366; Rubio-Rivas M, 2020, INT J INFECT DIS, V101, P290, DOI 10.1016/j.ijid.2020.09.1486; Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Susen S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03000-7; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Tleyjeh IM, 2021, CLIN MICROBIOL INFEC, V27, P215, DOI 10.1016/j.cmi.2020.10.036; Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021; Tran VT, 2021, CLIN MICROBIOL INFEC, V27, P603, DOI 10.1016/j.cmi.2020.11.035; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835; Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang JW, 2020, CLIN MICROBIOL INFEC, V26, P1171, DOI 10.1016/j.cmi.2020.06.020; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zahar JR, 2011, CRIT CARE MED, V39, P1886, DOI 10.1097/CCM.0b013e31821b827c; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	61	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2021	16	8							e0255644	10.1371/journal.pone.0255644	http://dx.doi.org/10.1371/journal.pone.0255644			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6IY	34347836	Green Submitted, Green Published, gold			2023-01-03	WOS:000685264900040
J	Rose, M				Rose, Mat			In hospitalized patients with substance use disorders, the NavSTAR service model reduced readmission at 1 y	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Rose, Mat] Univ Alberta, Boyle McCauley Hlth Ctr, Edmonton, AB, Canada	University of Alberta	Rose, M (corresponding author), Univ Alberta, Boyle McCauley Hlth Ctr, Edmonton, AB, Canada.							Damery S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011952; Rieke K, 2015, SOC WORK PUBLIC HLTH, V30, P496, DOI 10.1080/19371918.2015.1063100	2	0	0	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG	2021	174	8					JC92	JC92		10.7326/ACPJ202108170-092	http://dx.doi.org/10.7326/ACPJ202108170-092			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP3IW	34339225				2023-01-03	WOS:000695277800009
J	Hopewell, S; Keene, DJ; Marian, IR; Dritsaki, M; Heine, P; Cureton, L; Dutton, SJ; Dakin, H; Carr, A; Hamilton, W; Hansen, Z; Jaggi, A; Littlewood, C; Barker, KL; Gray, A; Lamb, SE				Hopewell, Sally; Keene, David J.; Marian, Ioana R.; Dritsaki, Melina; Heine, Peter; Cureton, Lucy; Dutton, Susan J.; Dakin, Helen; Carr, Andrew; Hamilton, Willie; Hansen, Zara; Jaggi, Anju; Littlewood, Chris; Barker, Karen L.; Gray, Alastair; Lamb, Sarah E.		GRASP Trial Grp	Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 x 2 factorial, randomised controlled trial	LANCET			English	Article							SHOULDER PAIN; SUBACROMIAL IMPINGEMENT; REHABILITATION PROGRAM; TENDINOPATHY; QUESTIONNAIRE; MANAGEMENT; DIAGNOSIS; EFFICACY; INDEX	Background Corticosteroid injections and physiotherapy exercise programmes are commonly used to treat rotator cuff disorders but the treatments' effectiveness is uncertain. We aimed to compare the clinical effectiveness and cost-effectiveness of a progressive exercise programme with a single session of best practice physiotherapy advice, with or without corticosteroid injection, in adults with a rotator cuff disorder. Methods In this pragmatic, multicentre, superiority, randomised controlled trial (2 x 2 factorial), we recruited patients from 20 UK National Health Service trusts. We included patients aged 18 years or older with a rotator cuff disorder (new episode within the past 6 months). Patients were excluded if they had a history of significant shoulder trauma (eg, dislocation, fracture, or full-thickness tear requiring surgery), neurological disease affecting the shoulder, other shoulder conditions (eg, inflammatory arthritis, frozen shoulder, or glenohumeral joint instability), received corticosteroid injection or physiotherapy for shoulder pain in the past 6 months, or were being considered for surgery. Patients were randomly assigned (centralised computer-generated system, 1:1:1:1) to progressive exercise (<= 6 sessions), best practice advice (one session), corticosteroid injection then progressive exercise, or corticosteroid injection then best practice advice. The primary outcome was the Shoulder Pain and Disability Index (SPADI) score over 12 months, analysed on an intention-to-treat basis (statistical significance set at 1%). The trial was registered with the International Standard Randomised Controlled Trial Register, ISRCTN16539266, and EuDRACT, 2016-002991-28. Findings Between March 10, 2017, and May 2, 2019, we screened 2287 patients. 708 patients were randomly assigned to progressive exercise (n=174), best practice advice (n=174), corticosteroid injection then progressive exercise (n=182), or corticosteroid injection then best practice advice (n=178). Over 12 months, SPADI data were available for 166 (95%) patients in the progressive exercise group, 164 (94%) in the best practice advice group, 177 (97%) in the corticosteroid injection then progressive exercise group, and 175 (98%) in the corticosteroid injection then best practice advice group. We found no evidence of a difference in SPADI score between progressive exercise and best practice advice when analysed over 12 months (adjusted mean difference -0.66 [99% CI -4.52 to 3.20]). We also found no evidence of a difference between corticosteroid injection compared with no injection when analysed over 12 months (-1.11 [-4.47 to 2.26]). No serious adverse events were reported. Interpretation Progressive exercise was not superior to a best practice advice session with a physiotherapist in improving shoulder pain and function. Subacromial corticosteroid injection provided no long-term benefit in patients with rotator cuff disorders. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.	[Hopewell, Sally; Keene, David J.; Marian, Ioana R.; Dritsaki, Melina; Heine, Peter; Cureton, Lucy; Dutton, Susan J.; Carr, Andrew; Hansen, Zara; Barker, Karen L.; Lamb, Sarah E.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England; [Dakin, Helen; Gray, Alastair] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England; [Hamilton, Willie; Lamb, Sarah E.] Univ Exeter, Coll Med & Hlth, Exeter, Devon, England; [Jaggi, Anju] Royal Natl Orthopaed Hosp NHS Trust, Stanmore, Middx, England; [Littlewood, Chris] Manchester Metropolitan Univ, Dept Hlth Profess, Manchester, Lancs, England	University of Oxford; University of Oxford; University of Exeter; University of London; University College London; Royal National Orthopaedic Hospital NHS Trust; Manchester Metropolitan University	Hopewell, S (corresponding author), Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England.	sally.hopewell@csm.ox.ac.uk	Cureton, Lucy/GWV-3396-2022	Cureton, Lucy/0000-0003-0082-8468; Dakin, Helen/0000-0003-3255-748X; Dutton, Susan/0000-0003-4573-5257; Lamb, Sarah/0000-0003-4349-7195; Hopewell, Sally/0000-0002-6881-6984; Keene, David/0000-0001-7249-6496	NIHR HTA Programme [15/26/06]	NIHR HTA Programme	This research was funded by the NIHR HTA Programme (grant 15/26/06). Foremost, we thank the patients participating in this trial, without whom this trial would have not been possible. We would like to thank those who made a substantial contribution to the study but are not named as authors: Debbie Brown (research physiotherapist) for her assistance with development of the GRASP exercise interventions; Hessam Soutakbar (research physiotherapist) for his assistance with GRASP exercise intervention site training and monitoring; Jacqueline Thompson (research physiotherapist) for her assistance with GRASP participant telephone follow-up; Emma Searle (MSc student, Universite Paris Descartes, Paris, France) for her help with updating the literature search. The GRASP trial was done as part of the portfolio of trials in the registered UK Registered Clinical Trials Units Oxford Clinical Trials Research Unit at the University of Oxford, Oxford, UK. The trial has followed their standard operating procedures ensuring compliance with the principles of Good Clinical Practice and the Declaration of Helsinki and any applicable regulatory requirements.	Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beard DJ, 2018, LANCET, V391, P329, DOI 10.1016/S0140-6736(17)32457-1; Breckenridge JD, 2011, J PHYSIOTHER, V57, P197, DOI 10.1016/S1836-9553(11)70045-5; British Elbow and Shoulder Society British Orthopaedic Association Royal College of Surgeons, 2014, COMM GUID SUB SHOULD COMM GUID SUB SHOULD; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Buchbinder R, 2003, COCHRANE DB SYST REV, V2003; Contreras J, 2018, REV MED CHILE, V146, P959, DOI 10.4067/s0034-98872018000900959; Coombes BK, 2010, LANCET, V376, P1751, DOI 10.1016/S0140-6736(10)61160-9; Asensio-Garcia MD, 2018, AM J PHYS MED REHAB, V97, P110, DOI 10.1097/PHM.0000000000000817; Dritsaki M, CLIN COST EFFECTIVEN; Gialanella B, 2011, PAIN MED, V12, P1559, DOI 10.1111/j.1526-4637.2011.01238.x; Granviken F, 2015, J PHYSIOTHER, V61, P135, DOI 10.1016/j.jphys.2015.05.014; Hanratty CE, 2012, SEMIN ARTHRITIS RHEU, V42, P297, DOI 10.1016/j.semarthrit.2012.03.015; Hopewell S, HEALTH TECHNOL ASSES; Hopewell S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018004; Kamper SJ, 2009, J MAN MANIP THER, V17, P163, DOI 10.1179/jmt.2009.17.3.163; Karjalainen TV, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005619.pub3; Keene DJ, 2020, PHYSIOTHERAPY, V107, P252, DOI 10.1016/j.physio.2019.07.002; Krischak G, 2013, J SHOULDER ELB SURG, V22, P1173, DOI 10.1016/j.jse.2013.01.008; Linsell L, 2006, RHEUMATOLOGY, V45, P215, DOI 10.1093/rheumatology/kei139; Littlewood C, 2016, CLIN REHABIL, V30, P686, DOI 10.1177/0269215515593784; Littlewood C, 2015, INT J REHABIL RES, V38, P95, DOI 10.1097/MRR.0000000000000113; Littlewood C, 2012, PHYSIOTHERAPY, V98, P101, DOI 10.1016/j.physio.2011.08.002; Marian IR, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04704-5; Mintken PE, 2010, ARCH PHYS MED REHAB, V91, P1128, DOI 10.1016/j.apmr.2010.04.009; Mitchell C, 2005, BMJ-BRIT MED J, V331, P1124, DOI 10.1136/bmj.331.7525.1124; National Institute for Health and Care Excellence, 2013, GUID METH TECHN APPR; Nicholas MK, 2015, J PAIN, V16, P153, DOI 10.1016/j.jpain.2014.11.002; Office for National Statistics, ETHNICITY; Page MJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012224; Roach K E, 1991, Arthritis Care Res, V4, P143, DOI 10.1002/art.1790040403; Roddy E, BR J SPORT MED, V55, P262; Turkmen E, 2020, J HAND THER, V33, P288, DOI 10.1016/j.jht.2019.08.004; WILLIAMS JW, 1995, J RHEUMATOL, V22, P727	34	10	10	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 31	2021	398	10298					416	428		10.1016/S0140-6736(21)00846-1	http://dx.doi.org/10.1016/S0140-6736(21)00846-1		JUL 2021	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TS1BS	34265255	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000679392600024
J	Lopez-Rios, L; Barber, MA; Wiebe, J; Machin, RP; Vega-Morales, T; Chirino, R				Lopez-Rios, Laura; Barber, Miguel A.; Wiebe, Julia; Machin, Ruben P.; Vega-Morales, Tanausu; Chirino, Ricardo			Influence of a new botanical combination on quality of life in menopausal Spanish women: Results of a randomized, placebo-controlled pilot study	PLOS ONE			English	Article							RHODIOLA-ROSEA; HOT FLASHES; SYMPTOMS; EEG; RADIOELECTROENCEPHALOGRAPHY; PHYTOESTROGENS; METAANALYSIS; ISOFLAVONES; FLUPIRTINE; THERAPY	Background This study was designed to evaluate the beneficial effects of a botanical extract combination containing soy isoflavone extract (100mg), Aframomum melegueta seed dry extract (50 mg), and Punica granatum skin dry extract (100mg) on health-related Quality of Life in healthy Spanish menopausal women with hot flashes, anxiety, and depressive symptoms using the validated Cervantes Scale. Methods and results Fifty-seven outpatient women (45-65 years) with menstrual problems associated with climacteric syndrome were enrolled from April 2018 to April 2019 in the context of a prospective, placebo-controlled, double-blind study. Women were randomized to receive treatment with either the botanical combination (250 mg daily divided into two doses) or placebo for eight weeks. At the beginning and end of the study, health-related Quality of Life was assessed using the Cervantes Scale. Subjects treated with the botanical extract, compared to subjects in the placebo group, showed a significant improvement in the Global health-related Quality of Life score (38% [11.3-50.0]% vs. 18.8% [0-37.7]%; P = 0.04) on the Cervantes Scale and, specifically, in the menopause and health domain (13.6% [0-45.4]% vs. 40.7% [20.6-61.0]%; P = 0.05). By contrast, there were no significant changes in the psychic, sexuality, and couple relationship related domains of the Cervantes Scale. Patients who concluded the study did not report substantial side effects. Conclusion Short-term intake of the botanical combination improved the Global Quality of Life of climateric women, according to the Cervantes Scale. Since this is a pilot trial, results should be analysed with caution.	[Lopez-Rios, Laura; Wiebe, Julia; Machin, Ruben P.; Vega-Morales, Tanausu] Nektium Pharma SL, Dept Res Dev & Innovat, Aguimes, Las Palmas, Spain; [Barber, Miguel A.] Baren Clin, Gynecol Div, Las Palmas Gran Canaria, Las Palmas, Spain; [Chirino, Ricardo] Univ Las Palmas Gran Canaria, Dept Biochem Mol Biol Physiol Genet & Immunol, Las Palmas Gran Canaria, Las Palmas, Spain	Universidad de Las Palmas de Gran Canaria	Lopez-Rios, L (corresponding author), Nektium Pharma SL, Dept Res Dev & Innovat, Aguimes, Las Palmas, Spain.	llopez@nektium.com	Chirino, Ricardo/ABB-1873-2021	Chirino, Ricardo/0000-0002-5681-8931	Nektium Pharma SL (NK); Spanish government; Canary Islands government	Nektium Pharma SL (NK); Spanish government(Spanish GovernmentEuropean Commission); Canary Islands government	This study was funded by Nektium Pharma SL (NK), a private profitorganization supported by own resources and grants from Spanish and Canary Islands governments. The Funder provided support in the form of salaries for authors LLR, TVM, RPM and JW, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the "author contributions" section.	Ajaiyeoba EO, 1999, FLAVOUR FRAG J, V14, P109, DOI 10.1002/(SICI)1099-1026(199903/04)14:2&lt;109::AID-FFJ775&gt;3.0.CO;2-M; Amsterdam JD, 2016, PHYTOMEDICINE, V23, P770, DOI 10.1016/j.phymed.2016.02.009; [Anonymous], 2009, MED PLANTS E AFRICA; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Bialonska D, 2010, INT J FOOD MICROBIOL, V140, P175, DOI 10.1016/j.ijfoodmicro.2010.03.038; Blumel JEM, 2004, MATURITAS, V49, P205, DOI 10.1016/j.maturitas.2004.01.011; Cano A., 2017, MENOPAUSE COMPREHENS; Chen LR, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112649; Chen MN, 2015, CLIMACTERIC, V18, P260, DOI 10.3109/13697137.2014.966241; Cheng GJ, 2007, MENOPAUSE, V14, P468, DOI 10.1097/GME.0b013e31802cc7d0; De Franciscis P, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55090544; Dietz BM, 2016, PHARMACOL REV, V68, P1026, DOI 10.1124/pr.115.010843; DIMPFEL W, 1988, NEUROPSYCHOBIOLOGY, V20, P164, DOI 10.1159/000118492; DIMPFEL W, 1986, NEUROPSYCHOBIOLOGY, V16, P163, DOI 10.1159/000118319; Dimpfel W, 2003, EUR J MED RES, V8, P199; Dimpfel W., 2015, DRUG DISCOVERY TRANS; Dimpfel W, 2013, J ETHNOPHARMACOL, V149, P583, DOI 10.1016/j.jep.2013.07.029; Dog TL, 2005, AM J MED, V118, P1408, DOI 10.1016/j.amjmed.2005.10.019; Fait Tomas, 2019, Drugs Context, V8, P212551, DOI 10.7573/dic.212551; Gerbarg PL, 2016, PHYTOMEDICINE, V23, P763, DOI 10.1016/j.phymed.2015.11.013; Harlow SD, 2012, MENOPAUSE, V19, P387, DOI 10.1097/gme.0b013e31824d8f40; Heinemann Klaas, 2004, Health Qual Life Outcomes, V2, P45, DOI 10.1186/1477-7525-2-45; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Iwu MM, 2016, FOOD MED FUNCTIONAL, V1st, DOI [10.1201/9781315371627, DOI 10.1201/9781315371627]; Julia Molla MD., 2008, PROGRESOS OBSTET GIN, V51, P146, DOI [10.1016/S0304-5013(08)71069-0, DOI 10.1016/S0304-5013(08)71069-0]; Kamte SLN, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14070737; KUPPERMAN HS, 1953, J CLIN ENDOCR METAB, V13, P688, DOI 10.1210/jcem-13-6-688; Lethaby A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001395.pub4; Levis S, 2010, CONTEMP CLIN TRIALS, V31, P293, DOI 10.1016/j.cct.2010.03.007; Lewis JE, 2005, MATURITAS, V50, P209, DOI 10.1016/j.maturitas.2004.06.015; Lima JEM, 2012, SCI WORLD J, P1, DOI 10.1100/2012/620519; Lin CC, 1999, AM J CHINESE MED, V27, P371, DOI 10.1142/S0192415X99000422; Moilanen J, 2010, MATURITAS, V67, P368, DOI 10.1016/j.maturitas.2010.08.007; Mori-Okamoto J, 2004, J ETHNOPHARMACOL, V92, P93, DOI 10.1016/j.jep.2004.02.006; Nelson HD, 2008, LANCET, V371, P760, DOI 10.1016/S0140-6736(08)60346-3; Newton KM, 2014, MENOPAUSE, V21, P45, DOI [10.1097/gme.0b013e31829337a4, 10.1097/GME.0b013e31829337a4]; Ojo ET, 2018, J FOOD BIOCHEM, V42, DOI 10.1111/jfbc.12528; Del Rio JP, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00141; Palacios S, 2004, MED CLIN-BARCELONA, V122, P205, DOI 10.1157/13058170; Palacios S, 2010, CLIMACTERIC, V13, P419, DOI 10.3109/13697137.2010.507886; Rattanatantikul T, 2022, J DIET SUPPL, V19, P168, DOI 10.1080/19390211.2020.1853648; Roozbeh Nasibeh, 2018, J Menopausal Med, V24, P113, DOI 10.6118/jmm.2018.24.2.113; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Saeed M, 2018, RECENT PATENTS INFLA, V12, P24, DOI 10.2174/1872213X12666180221154713; Shams T, 2014, J GEN INTERN MED, V29, P204, DOI 10.1007/s11606-013-2535-9; Singh M, 2014, J FOOD SCI TECH MYS, V51, P2070, DOI 10.1007/s13197-014-1267-0; Swaha Satpathy, 2013, Asian Pacific Journal of Reproduction, V2, P19, DOI 10.1016/S2305-0500(13)60109-8; Thomas AJ, 2014, MATURITAS, V78, P263, DOI 10.1016/j.maturitas.2014.05.007; Utian Wulf H, 2005, Health Qual Life Outcomes, V3, P47, DOI 10.1186/1477-7525-3-47; Villa P, 2017, ARCH GYNECOL OBSTET, V296, P791, DOI 10.1007/s00404-017-4491-9; Xiao YQ, 2018, PHYTOTHER RES, V32, P384, DOI 10.1002/ptr.5966; Zarfeshany Aida, 2014, Adv Biomed Res, V3, P100, DOI 10.4103/2277-9175.129371	52	2	2	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2021	16	7							e0255015	10.1371/journal.pone.0255015	http://dx.doi.org/10.1371/journal.pone.0255015			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2OI	34288973	Green Published, gold			2023-01-03	WOS:000678124300020
J	Geraghty, AWA; Maund, E; Newell, D; Santer, M; Everitt, H; Price, C; Pincus, T; Moore, M; Little, P; West, R; Stuart, B				Geraghty, Adam W. A.; Maund, Emma; Newell, David; Santer, Miriam; Everitt, Hazel; Price, Cathy; Pincus, Tamar; Moore, Michael; Little, Paul; West, Rachel; Stuart, Beth			Self-management for chronic widespread pain including fibromyalgia: A systematic review and meta-analysis	PLOS ONE			English	Review							COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; RETAIN OWNERSHIP; CLINICAL-TRIAL; POOL EXERCISE; EDUCATION; WOMEN; CARE; INTERVENTIONS	Background Chronic widespread pain (CWP) including fibromyalgia has a prevalence of up to 15% and is associated with substantial morbidity. Supporting psychosocial and behavioural self-management is increasingly important for CWP, as pharmacological interventions show limited benefit. We systematically reviewed the effectiveness of interventions applying self-management principles for CWP including fibromyalgia. Methods MEDLINE, Embase, PsycINFO, The Cochrane Central Register of Controlled Trials and the WHO International Clinical Trials Registry were searched for studies reporting randomised controlled trials of interventions adhering to self-management principles for CWP including fibromyalgia. Primary outcomes included physical function and pain intensity. Where data were sufficient, meta-analysis was conducted using a random effects model. Studies were narratively reviewed where meta-analysis could not be conducted Evidence quality was rated using GRADE (Grading of Recommendations, Assessment, Development and Evaluations) (PROSPERO-CRD42018099212). Results Thirty-nine completed studies were included. Despite some variability in studies narratively reviewed, in studies meta-analysed self-management interventions improved physical function in the short-term, post-treatment to 3 months (SMD 0.42, 95% CI 0.20, 0.64) and long-term, post 6 months (SMD 0.36, 95% CI 0.20, 0.53), compared to no treatment/usual care controls. Studies reporting on pain narratively had greater variability, however, those studies meta-analysed showed self-management interventions reduced pain in the short-term (SMD -0.49, 95% CI -0.70, -0.27) and long-term (SMD -0.38, 95% CI -0.58, -0.19) compared to no treatment/usual care. There were few differences in physical function and pain when self-management interventions were compared to active interventions. The quality of the evidence was rated as low. Conclusion Reviewed studies suggest self-management interventions can be effective in improving physical function and reducing pain in the short and long-term for CWP including fibromyalgia. However, the quality of evidence was low. Future research should address quality issues whilst making greater use of theory and patient involvement to understand reported variability.	[Geraghty, Adam W. A.; Maund, Emma; Newell, David; Santer, Miriam; Everitt, Hazel; Moore, Michael; Little, Paul; West, Rachel; Stuart, Beth] Univ Southampton, Fac Med, Sch Primary Care Populat Sci & Med Educ PPM, Primary Care Res Ctr, Southampton, Hants, England; [Newell, David] AECC Univ Coll, Bournemouth, Dorset, England; [Price, Cathy] Solent NHS Trust, Southampton, Hants, England; [Pincus, Tamar] Royal Holloway Univ London, Dept Psychol, London, England	University of Southampton; University of London; Royal Holloway University London	Geraghty, AWA (corresponding author), Univ Southampton, Fac Med, Sch Primary Care Populat Sci & Med Educ PPM, Primary Care Res Ctr, Southampton, Hants, England.	A.W.Geraghty@soton.ac.uk	Price, Cathy/W-5271-2019; Newell, Dave/E-7792-2016; Moore, Michael/C-3447-2011	Price, Cathy/0000-0003-0111-9364; Newell, Dave/0000-0003-1462-3586; Geraghty, Adam/0000-0001-7984-8351; Stuart, Beth/0000-0001-5432-7437; Moore, Michael/0000-0002-5127-4509; Everitt, Hazel/0000-0001-7362-8403; Santer, Miriam/0000-0001-7264-5260	National Institute for Health Research (NIHR) Research Capacity Funding Award from Solent NHS Trust	National Institute for Health Research (NIHR) Research Capacity Funding Award from Solent NHS Trust	This research was part funded by a National Institute for Health Research (NIHR) Research Capacity Funding Award from Solent NHS Trust to Dr Emma Maund. The NIHR and Solent NHS Trust had no involvement in the design of the review protocol, and had no input in data collection, analyses, interpretation, writing up or publication of the review.	Amris K, 2014, PAIN, V155, P1356, DOI 10.1016/j.pain.2014.04.012; Andrews P, 2018, EUR J PAIN, V22, P5, DOI 10.1002/ejp.1090; Araya-Quintanilla F, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018833; Arnold LM, 2016, INT J CLIN PRACT, V70, P99, DOI 10.1111/ijcp.12757; Arnold LM, 2012, MAYO CLIN PROC, V87, P488, DOI 10.1016/j.mayocp.2012.02.010; Artus M, 2010, RHEUMATOLOGY, V49, P2346, DOI 10.1093/rheumatology/keq245; Astin JA, 2003, J RHEUMATOL, V30, P2257; Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Bartley EJ, 2018, J PAIN, V19, P372, DOI 10.1016/j.jpain.2017.11.014; Bernardy K, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009796.pub2; Bidonde J, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013340; Bosch Romero E, 2002, Aten Primaria, V30, P16; Bourgault P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126324; Buckelew SP, 1998, ARTHRIT CARE RES, V11, P196, DOI 10.1002/art.1790110307; BURCKHARDT CS, 1989, RES NURS HEALTH, V12, P347, DOI 10.1002/nur.4770120604; BURCKHARDT CS, 1994, J RHEUMATOL, V21, P714; Burns JW, 2016, PAIN, V157, P2393, DOI 10.1097/j.pain.0000000000000696; Angelats RC, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017289; Castel A, 2013, ARTHRIT CARE RES, V65, P421, DOI 10.1002/acr.21818; Cedraschi C, 2004, ANN RHEUM DIS, V63, P290, DOI 10.1136/ard.2002.004945; Clauw DJ, 2020, PAIN, V161, P1694, DOI 10.1097/j.pain.0000000000001950; Detry MA, 2014, JAMA-J AM MED ASSOC, V312, P85, DOI 10.1001/jama.2014.7523; Doebl S, 2020, PAIN, V161, P1716, DOI 10.1097/j.pain.0000000000001870; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Eccleston Christopher, 2017, F1000Res, V6, P461, DOI 10.12688/f1000research.10612.1; Eccleston C, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007407.pub2; George SZ, 2010, J ORTHOP SPORT PHYS, V40, P694, DOI 10.2519/jospt.2010.3396; Geraghty AWA, 2020, PAIN MED, V21, P1806, DOI 10.1093/pm/pnz312; Ghazan-Shahi S, 2012, CLIN RHEUMATOL, V31, P1177, DOI 10.1007/s10067-012-1989-1; Giannotti E, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/474029; Gowans SE, 1999, ARTHRIT CARE RES, V12, P120, DOI 10.1002/1529-0131(199904)12:2<120::AID-ART7>3.0.CO;2-4; Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026; Hauser W, 2019, BEST PRACT RES CL RH, V33, DOI 10.1016/j.berh.2019.05.001; Hauser W, 2009, ARTHRIT RHEUM-ARTHR, V61, P216, DOI 10.1002/art.24276; Hammond A, 2006, CLIN REHABIL, V20, P835, DOI 10.1177/0269215506072173; Hamnes B, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-189; Haugmark T, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021004; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Hsu MC, 2010, J GEN INTERN MED, V25, P1064, DOI 10.1007/s11606-010-1418-6; John PA, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j408; Kemp HI, 2020, BRIT J ANAESTH, V125, P436, DOI 10.1016/j.bja.2020.05.021; Kendall SA, 2000, ARTHRIT CARE RES, V13, P304; King SJ, 2002, J RHEUMATOL, V29, P2620; Kingstone Tom, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101143; Kristjansdottir OB, 2013, J MED INTERNET RES, V15, P152, DOI 10.2196/jmir.2442; Kubra Asik Celik H., 2013, TURK FIZ REHAB DERG TURK FIZ REHAB DERG, V59, P237; Lauche R, 2013, J PSYCHOSOM RES, V75, P500, DOI 10.1016/j.jpsychores.2013.10.010; Lee J, 2014, BRIT J ANAESTH, V112, P16, DOI 10.1093/bja/aet351; Lemstra M, 2005, CLIN J PAIN, V21, P166, DOI 10.1097/00002508-200503000-00008; Lera S, 2009, J PSYCHOSOM RES, V67, P433, DOI 10.1016/j.jpsychores.2009.01.012; Lorig KR, 2008, ARTHRIT RHEUM-ARTHR, V59, P1009, DOI 10.1002/art.23817; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Luciano JV, 2011, CLIN J PAIN, V27, P383, DOI 10.1097/AJP.0b013e31820b131c; Macfarlane GJ, 2017, ANN RHEUM DIS, V76, P318, DOI 10.1136/annrheumdis-2016-209724; Mannerkorpi K, 2000, J RHEUMATOL, V27, P2473; Mannerkorpi K, 2009, J REHABIL MED, V41, P751, DOI 10.2340/16501977-0409; Mansfield KE, 2016, PAIN, V157, P55, DOI 10.1097/j.pain.0000000000000314; Martin J, 2014, PAIN MED, V15, P682, DOI 10.1111/pme.12375; McBeth J, 2012, ARCH INTERN MED, V172, P48, DOI 10.1001/archinternmed.2011.555; McCracken LM, 2020, EUR J PAIN, V24, P1001, DOI 10.1002/ejp.1568; McVeigh JG., 2006, PHYS THER REV, V11, P217; Mease P, 2009, J RHEUMATOL, V36, P2318, DOI 10.3899/jrheum.090367; Miles CL, 2011, EUR J PAIN, V15, DOI 10.1016/j.ejpain.2011.01.016; Morley S, 2013, PAIN, V154, P1929, DOI 10.1016/j.pain.2013.05.049; Murad M Hassan, 2017, Evid Based Med, V22, P85, DOI 10.1136/ebmed-2017-110668; Musekamp G, 2019, HEALTH EDUC RES, V34, P209, DOI 10.1093/her/cyy055; Newman S, 2004, LANCET, V364, P1523, DOI 10.1016/S0140-6736(04)17277-2; Nuesch E, 2013, ANN RHEUM DIS, V72, P955, DOI 10.1136/annrheumdis-2011-201249; O'Keeffe M, 2016, J PAIN, V17, P755, DOI 10.1016/j.jpain.2016.01.473; Perez-Aranda A, 2019, PAIN, V160, P2508, DOI 10.1097/j.pain.0000000000001655; Pernambuco AP, 2018, ADV RHEUMATOL, V58, DOI 10.1186/s42358-018-0022-z; Queiroz LP, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0356-5; Rogers P. J., 2008, EVALUATION-US, V14, P29, DOI DOI 10.1177/1356389007084674; Rooks DS, 2007, ARCH INTERN MED, V167, P2192, DOI 10.1001/archinte.167.20.2192; Salaffi F, 2015, CLIN EXP RHEUMATOL, V33, pS93; Sanada K, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0789-9; Saral I, 2016, RHEUMATOL INT, V36, P1379, DOI 10.1007/s00296-016-3473-8; Serrat M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17020634; Shir Y, 2009, J RHEUMATOL, V36, P667, DOI 10.3899/jrheum.081073; Souza Juliana Barcellos de, 2008, Rev. Bras. Reumatol., V48, P218, DOI 10.1590/S0482-50042008000400005; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; Stewart C, 2014, PAIN MED, V15, P214, DOI 10.1111/pme.12251; Stuifbergen AK, 2010, CLIN REHABIL, V24, P305, DOI 10.1177/0269215509343247; Tousignant-Laflamme Y, 2014, J PAIN, V15, pS116, DOI 10.1016/j.jpain.2014.01.472; Traistaru RM, 2015, ANN RHEUM DIS, V74, P312, DOI 10.1136/annrheumdis-2015-eular.4198; van Koulil S, 2010, ARTHRIT CARE RES, V62, P1377, DOI 10.1002/acr.20268; Veehof MM, 2011, PAIN, V152, P533, DOI 10.1016/j.pain.2010.11.002; Vlaeyen JWS, 1996, J RHEUMATOL, V23, P1237; Wetherell JL, 2011, PAIN, V152, P2098, DOI 10.1016/j.pain.2011.05.016; Whibley Daniel, 2016, Curr Treatm Opt Rheumatol, V2, P312, DOI 10.1007/s40674-016-0056-5; Whiteside N, 2018, CLIN RHEUMATOL, V37, P1375, DOI 10.1007/s10067-017-3948-3; Williams DA, 2010, PAIN, V151, P694, DOI 10.1016/j.pain.2010.08.034; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Yardley Lucy, 2015, Pilot Feasibility Stud, V1, P37; Yardley L, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4055; YUNUS M, 1982, AM FAM PHYSICIAN, V25, P115	97	6	6	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2021	16	7							e0254642	10.1371/journal.pone.0254642	http://dx.doi.org/10.1371/journal.pone.0254642			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2NF	34270606	Green Accepted, gold, Green Published			2023-01-03	WOS:000678121400021
J	Ceney, A; Tolond, S; Glowinski, A; Marks, B; Swift, S; Palser, T				Ceney, Adam; Tolond, Stephanie; Glowinski, Andrzej; Marks, Ben; Swift, Simon; Palser, Tom			Accuracy of online symptom checkers and the potential impact on service utilisation	PLOS ONE			English	Article							URGENT CARE; EMERGENCY	Objectives The aims of our study are firstly to investigate the diagnostic and triage performance of symptom checkers, secondly to assess their potential impact on healthcare utilisation and thirdly to investigate for variation in performance between systems. Setting Publicly available symptom checkers for patient use. Participants Publicly available symptom-checkers were identified. A standardised set of 50 clinical vignettes were developed and systematically run through each system by a non-clinical researcher. Primary and secondary outcome measures System accuracy was assessed by measuring the percentage of times the correct diagnosis was a) listed first, b) within the top five diagnoses listed and c) listed at all. The safety of the disposition advice was assessed by comparing it with national guidelines for each vignette. Results Twelve tools were identified and included. Mean diagnostic accuracy of the systems was poor, with the correct diagnosis being present in the top five diagnoses on 51.0% (Range 22.2 to 84.0%). Safety of disposition advice decreased with condition urgency (being 71.8% for emergency cases vs 87.3% for non-urgent cases). 51.0% of systems suggested additional resource utilisation above that recommended by national guidelines (range 18.0% to 61.2%). Both diagnostic accuracy and appropriate resource recommendation varied substantially between systems. Conclusions There is wide variation in performance between available symptom checkers and overall performance is significantly below what would be accepted in any other medical field, though some do achieve a good level of accuracy and safety of disposition. External validation and regulation are urgently required to ensure these public facing tools are safe.	[Ceney, Adam; Tolond, Stephanie; Glowinski, Andrzej; Marks, Ben; Swift, Simon; Palser, Tom] Methods Analyt Ltd, Sheffield, S Yorkshire, England; [Swift, Simon] Univ Exeter, Business Sch INDEX, Exeter, Devon, England; [Palser, Tom] Univ Hosp Leicester NHS Trust, Dept Surg, Leicester, Leics, England; [Palser, Tom] Univ Leicester, Dept Hlth Sci, SAPPHIRE, Leicester, Leics, England	University of Exeter; University Hospitals of Leicester NHS Trust; University of Leicester; University of Leicester	Ceney, A (corresponding author), Methods Analyt Ltd, Sheffield, S Yorkshire, England.	adam.ceney@methods.co.uk		swift, simon/0000-0002-2812-4262	Doctorlink Ltd.	Doctorlink Ltd.	This study was fully funded as an external review of the sector by Doctorlink Ltd. The funder provided support in the form of salaries for authors [SS, AC, AG, BM and TP], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Aboueid S, 2019, JMIR MED INF, V7, P4, DOI 10.2196/13445; Aggarwal M, 2013, PRIMARY CARE STRATEG; Amante DJ, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4126; Backman AS, 2012, EMERG MED J, V29, P1004, DOI 10.1136/emermed-2011-200464; Baker A, 2020, FRONT ARTIF INTELL, V3, DOI 10.3389/frai.2020.543405; Battineni G, 2020, J PERS MED, V10, DOI 10.3390/jpm10020021; Beech J., 2019, CLOSING GAP KEY AREA; Berry AC, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819000268; Chambers D, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027743; Coster JE, 2017, ACAD EMERG MED, V24, P1137, DOI 10.1111/acem.13220; Dall TM., 2015, COMPLEXITIES PHYS SU, DOI [10.13140/RG.2.2.13111.57764, DOI 10.13140/RG.2.2.13111.57764]; Davies BM, 2019, J MED INTERNET RES, V21, DOI 10.2196/10868; Fraser H, 2018, LANCET, V392, P2263, DOI 10.1016/S0140-6736(18)32819-8; Gilbert S, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-040269; Global Health Workforce Alliance World Health Organization, 2013, UN TRUTH NO HLTH WOR; Lee J., 2013, NO 1 POSITION GOOGLE; Meyer AND, 2020, J MED INTERNET RES, V22, DOI 10.2196/14679; O'Cathain A, 2020, HEALTH EXPECT, V23, P19, DOI 10.1111/hex.12995; Powley L, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1189-2; Semigran HL, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3480; Shafaf N, 2019, ARCH ACAD EMERG MED, V7; Shen C, 2019, JAMA OPHTHALMOL, V137, P690, DOI 10.1001/jamaophthalmol.2019.0571; Swaminathan S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188532	23	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2021	16	7							e0254088	10.1371/journal.pone.0254088	http://dx.doi.org/10.1371/journal.pone.0254088			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2MX	34265845	Green Submitted, gold, Green Published			2023-01-03	WOS:000678120600003
J	Dougan, M; Nirula, A; Azizad, M; Mocherla, B; Gottlieb, RL; Chen, P; Hebert, C; Perry, R; Boscia, J; Heller, B; Morris, J; Crystal, C; Igbinadolor, A; Huhn, G; Cardona, J; Shawa, I; Kumar, P; Adams, AC; Van Naarden, J; Custer, KL; Durante, M; Oakley, G; Schade, AE; Holzer, TR; Ebert, PJ; Higgs, RE; Kallewaard, NL; Sabo, J; Patel, DR; Dabora, MC; Klekotka, P; Shen, L; Skovronsky, DM				Dougan, M.; Nirula, A.; Azizad, M.; Mocherla, B.; Gottlieb, R. L.; Chen, P.; Hebert, C.; Perry, R.; Boscia, J.; Heller, B.; Morris, J.; Crystal, C.; Igbinadolor, A.; Huhn, G.; Cardona, J.; Shawa, I; Kumar, P.; Adams, A. C.; Van Naarden, J.; Custer, K. L.; Durante, M.; Oakley, G.; Schade, A. E.; Holzer, T. R.; Ebert, P. J.; Higgs, R. E.; Kallewaard, N. L.; Sabo, J.; Patel, D. R.; Dabora, M. C.; Klekotka, P.; Shen, L.; Skovronsky, D. M.		BLAZE-1 Investigators	Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STATES	BACKGROUND Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and may limit disease progression and complications. METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, a cohort of ambulatory patients with mild or moderate Covid-19 who were at high risk for progression to severe disease to receive a single intravenous infusion of either a neutralizing monoclonal-antibody combination agent (2800 mg of bamlanivimab and 2800 mg of etesevimab, administered together) or placebo within 3 days after a laboratory diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The primary outcome was the overall clinical status of the patients, defined as Covid-19-related hospitalization or death from any cause by day 29. RESULTS A total of 1035 patients underwent randomization and received an infusion of bamlanivimab-etesevimab or placebo. The mean (+/- SD) age of the patients was 53.8 +/- 16.8 years, and 52.0% were adolescent girls or women. By day 29, a total of 11 of 518 patients (2.1%) in the bamlanivimab-etesevimab group had a Covid-19-related hospitalization or death from any cause, as compared with 36 of 517 patients (7.0%) in the placebo group (absolute risk difference, -4.8 percentage points; 95% confidence interval [CI], -7.4 to -2.3; relative risk difference, 70%; P<0.001). No deaths occurred in the bamlanivimab-etesevimab group; in the placebo group, 10 deaths occurred, 9 of which were designated by the trial investigators as Covid-19-related. At day 7, a greater reduction from baseline in the log viral load was observed among patients who received bamlanivimab plus etesevimab than among those who received placebo (difference from placebo in the change from baseline, -1.20; 95% CI, -1.46 to -0.94; P<0.001). CONCLUSIONS Among high-risk ambulatory patients, bamlanivimab plus etesevimab led to a lower incidence of Covid-19-related hospitalization and death than did placebo and accelerated the decline in the SARS-CoV-2 viral load.	[Nirula, A.; Cardona, J.; Adams, A. C.; Van Naarden, J.; Custer, K. L.; Durante, M.; Oakley, G.; Schade, A. E.; Holzer, T. R.; Ebert, P. J.; Higgs, R. E.; Kallewaard, N. L.; Sabo, J.; Patel, D. R.; Dabora, M. C.; Klekotka, P.; Shen, L.; Skovronsky, D. M.] Eli Lilly, 893 Delaware St, Indianapolis, IN 46225 USA; [Dougan, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Dougan, M.] Harvard Med Sch, Boston, MA 02115 USA; [Shawa, I] Franciscan Hlth, Indianapolis, IN USA; [Azizad, M.] Valley Clin Trials Northridge, Northridge, CA USA; [Chen, P.] Cedars Sinai Med Ctr, Womens Guild Lung Inst, Dept Med, Los Angeles, CA 90048 USA; [Heller, B.] Long Beach Clin Trials, Long Beach, CA USA; [Mocherla, B.] Las Vegas Med Res Ctr, Las Vegas, NV USA; [Gottlieb, R. L.] Baylor Univ, Med Ctr, Dallas, TX USA; [Gottlieb, R. L.] Baylor Scott & White Res Inst, Dallas, TX USA; [Perry, R.] Gadolin Res, Beaumont, TX USA; [Hebert, C.] NOLA Res Works, New Orleans, LA USA; [Morris, J.] Clin Trials Southwest Louisiana, Lake Charles, LA USA; [Boscia, J.] Vitalink Res, Union, SC USA; [Crystal, C.] Eastside Res Associates, Redmond, WA USA; [Igbinadolor, A.] Monroe Biomed Res, Monroe, LA USA; [Huhn, G.] Indago Res & Hlth Ctr, Hialeah, FL USA; [Kumar, P.] Georgetown Univ, Washington, DC USA	Eli Lilly; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Cedars Sinai Medical Center; Baylor University; Baylor University Medical Center; Baylor Health Care System; Baylor University Medical Center; Georgetown University	Skovronsky, DM (corresponding author), Eli Lilly, 893 Delaware St, Indianapolis, IN 46225 USA.	skovronsky_daniel@lilly.com	Gottlieb, Robert/AAM-8310-2020	Gottlieb, Robert/0000-0001-8376-8709; Chen, Peter/0000-0002-5330-1718	Eli Lilly	Eli Lilly(Eli Lilly)	Supported by Eli Lilly.	[Anonymous], 2020, FDA TAK KEY ACT FIGH; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Benton DJ, 2020, NATURE, V588, DOI 10.1038/s41586-020-2772-0; Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Cates J, 2020, MMWR-MORBID MORTAL W, V69, P1528, DOI 10.15585/mmwr.mm6942e3; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Centers for Disease Control and Prevention, CLIN GROWTH CHARTS; Centers for Disease Control and Prevention , 2021, PRIORITY NEED VULNER; Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010; Chidambaram V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241541; del Rio C, 2020, JAMA-J AM MED ASSOC, V324, P1723, DOI 10.1001/jama.2020.19719; Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702; Ejaz H, 2020, J INFECT PUBLIC HEAL, V13, P1833, DOI 10.1016/j.jiph.2020.07.014; Food and Drug Administration, 2021, FACT SHEET HLTH CAR; Food and Drug Administration, 2020, COVID 19 DEV DRUGS B; Food and Drug Administration, 2021, COR COVID 19 UPD FDA; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Gosain R, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00934-7; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Halpin SJ, 2021, J MED VIROL, V93, P1013, DOI 10.1002/jmv.26368; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Jones Bryan E, 2020, bioRxiv, DOI 10.1101/2020.09.30.318972; Joyner Michael J, 2020, medRxiv, DOI 10.1101/2020.08.12.20169359; Kim L, 2020, MMWR-MORBID MORTAL W, V69, P1081, DOI 10.15585/mmwr.mm6932e3; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Marston HD, 2018, NEW ENGL J MED, V378, P1469, DOI 10.1056/NEJMp1802256; Piroth L, 2021, LANCET RESP MED, V9, P251, DOI 10.1016/S2213-2600(20)30527-0; Roche, 2020, ROCH PROV PHAR 3 COV; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	36	257	259	5	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	2021	385	15					1382	1392		10.1056/NEJMoa2102685	http://dx.doi.org/10.1056/NEJMoa2102685		JUL 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP7AB	34260849	Bronze, Green Published			2023-01-03	WOS:000674415700001
J	Rentinck, MN; Kruger, R; Hoppe, PA; Humme, D; Niebank, M; Pokrywka, A; Stegemann, M; Kola, A; Hanitsch, LG; Leistner, R				Rentinck, Marc-Nicolas; Krueger, Renate; Hoppe, Pia-Alice; Humme, Daniel; Niebank, Michaela; Pokrywka, Anna; Stegemann, Miriam; Kola, Axel; Hanitsch, Leif Gunnar; Leistner, Rasmus			Skin infections due to Panton-Valentine leukocidin (PVL)-producing S. aureus-Cost effectiveness of outpatient treatment	PLOS ONE			English	Article							STAPHYLOCOCCUS-AUREUS; METHICILLIN-RESISTANT; MANAGEMENT; CARRIAGE; OUTBREAK; STRAINS	Introduction Skin and soft tissue infections (SSTI) caused by Panton-Valentine leukocidin (PVL)-producing strains of Staphylococcus aureus (PVL-SA) are associated with recurrent skin abscesses. Secondary prevention, in conjunction with primary treatment of the infection, focuses on topical decolonization. Topical decolonization is a standard procedure in cases of recurrent PVL-SA skin infections and is recommended in international guidelines. However, this outpatient treatment is often not fully reimbursed by health insurance providers, which may interfere with successful PVL-SA decolonization. Aim Our goal was to estimate the cost effectiveness of outpatient decolonization of patients with recurrent PVL-SA skin infections. We calculated the average cost of treatment for PVL-SA per outpatient decolonization procedure as well as per in-hospital stay. Methods The study was conducted between 2014 and 2018 at a German tertiary care university hospital. The cohort analyzed was obtained from the hospital's microbiology laboratory database. Data on medical costs, DRG-based diagnoses, and ICD-10 patient data was obtained from the hospital's financial controlling department. We calculated the average cost of treatment for patients admitted for treatment of PVL-SA induced skin infections. The cost of outpatient treatment is based on the German regulations of drug prices for prescription drugs. Results We analyzed a total of n = 466 swabs from n = 411 patients with recurrent skin infections suspected of carrying PVL-SA. PVL-SA was detected in 61.3% of all patients included in the study. Of those isolates, 80.6% were methicillin-susceptible, 19.4% methicillin-resistant. 89.8% of all patients were treated as outpatients. In 73.0% of inpatients colonized with PVL-SA the main diagnosis was SSTI. The median length of stay was 5.5 days for inpatients colonized with PVL-SA whose main diagnosis SSTI; the average cost was euro2,283. The estimated costs per decolonization procedure in outpatients ranged from euro50-euro110, depending on the products used. Conclusion Our data shows that outpatient decolonization offers a highly cost-effective secondary prevention strategy, which may prevent costly inpatient treatments. Therefore, health insurance companies should consider providing coverage of outpatient treatment of recurrent PVL-SA skin and soft tissue infections.	[Rentinck, Marc-Nicolas; Kola, Axel; Leistner, Rasmus] Charite Univ Med Berlin, Inst Hyg & Environm Med, Berlin, Germany; [Rentinck, Marc-Nicolas; Krueger, Renate; Hoppe, Pia-Alice; Humme, Daniel; Niebank, Michaela; Pokrywka, Anna; Stegemann, Miriam; Kola, Axel; Hanitsch, Leif Gunnar; Leistner, Rasmus] Free Univ Berlin, Berlin, Germany; [Rentinck, Marc-Nicolas; Krueger, Renate; Hoppe, Pia-Alice; Humme, Daniel; Niebank, Michaela; Pokrywka, Anna; Stegemann, Miriam; Kola, Axel; Hanitsch, Leif Gunnar; Leistner, Rasmus] Humboldt Univ, Berlin, Germany; [Rentinck, Marc-Nicolas; Krueger, Renate; Hoppe, Pia-Alice; Humme, Daniel; Niebank, Michaela; Pokrywka, Anna; Stegemann, Miriam; Kola, Axel; Hanitsch, Leif Gunnar; Leistner, Rasmus] Berlin Inst Hlth, Berlin, Germany; [Rentinck, Marc-Nicolas; Krueger, Renate; Hoppe, Pia-Alice; Humme, Daniel; Niebank, Michaela; Pokrywka, Anna; Stegemann, Miriam; Leistner, Rasmus] Charite Univ Med Berlin, Interdisciplinary Workgrp PVL Posit S Aureus, Berlin, Germany; [Krueger, Renate; Hoppe, Pia-Alice] Charite Univ Med Berlin, Div Pulmonol Immunol & Crit Care Med, Dept Pediat, Berlin, Germany; [Humme, Daniel; Pokrywka, Anna] Charite Univ Med Berlin, Dept Dermatol Venerol & Allergol, Berlin, Germany; [Niebank, Michaela; Stegemann, Miriam] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany; [Hanitsch, Leif Gunnar] Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany; [Leistner, Rasmus] Charite Univ Med Berlin, Div Gastroenterol Infect Dis & Rheumatol Includin, Med Dept, Campus Benjamin Franklin, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Rentinck, MN (corresponding author), Charite Univ Med Berlin, Inst Hyg & Environm Med, Berlin, Germany.; Rentinck, MN (corresponding author), Free Univ Berlin, Berlin, Germany.; Rentinck, MN (corresponding author), Humboldt Univ, Berlin, Germany.; Rentinck, MN (corresponding author), Berlin Inst Hlth, Berlin, Germany.; Rentinck, MN (corresponding author), Charite Univ Med Berlin, Interdisciplinary Workgrp PVL Posit S Aureus, Berlin, Germany.	m.rent@fu-berlin.de		Hanitsch, Leif G./0000-0002-8181-0093; Leistner, Rasmus/0000-0002-1225-9023; Rentinck, Marc-Nicolas/0000-0002-3009-4760; Stegemann, Miriam Songa/0000-0002-7968-0429				Brown ML, 2012, J CLIN MICROBIOL, V50, P86, DOI 10.1128/JCM.05564-11; Bundesministerium fur Gesundheit, 2021, ARZN; Demir T, 2012, J ANTIMICROB CHEMOTH, V67, P837, DOI 10.1093/jac/dkr568; Gillet Y, 2011, INT J ANTIMICROB AG, V38, P457, DOI 10.1016/j.ijantimicag.2011.05.003; Hanitsch LG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231772; Ismail H, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05352-5; Kapadia S, 2018, J HOSP INFECT, V100, P359, DOI 10.1016/j.jhin.2018.03.021; Kazakova SV, 2005, NEW ENGL J MED, V352, P468, DOI 10.1056/NEJMoa042859; Klein S, 2019, INT J ANTIMICROB AG, V53, P261, DOI 10.1016/j.ijantimicag.2018.10.026; Kramer A, 2010, GMS HYG INFECT CONTR, V5, DOI 10.3205/dgkh000144; Landen MG, 2000, WESTERN J MED, V172, P235, DOI 10.1136/ewjm.172.4.235; Layer F, 2019, EPID B, V42, P43742, DOI [10.25646/6320.2, DOI 10.25646/6320.2]; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; Mongkolrattanothai K, 2011, J MED MICROBIOL, V60, P317, DOI 10.1099/jmm.0.025841-0; Raupach-Rosin H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1503-5; Saeed K, 2018, INT J ANTIMICROB AG, V51, P16, DOI 10.1016/j.ijantimicag.2017.11.002; Septimus EJ, 2016, CLIN MICROBIOL REV, V29, P201, DOI 10.1128/CMR.00049-15; Shallcross LJ, 2013, LANCET INFECT DIS, V13, P43, DOI 10.1016/S1473-3099(12)70238-4; Stevens DL, 2005, CLIN INFECT DIS, V41, P1373, DOI 10.1086/497143; Stoesser N, 2015, J CLIN MICROBIOL, V53, P2122, DOI 10.1128/JCM.00378-15; Sunderkotter C, 2019, J DTSCH DERMATOL GES, V17, P345, DOI 10.1111/ddg.13790; Wertheim HFL, 2005, LANCET INFECT DIS, V5, P751, DOI 10.1016/S1473-3099(05)70295-4; Wiese-Posselt M, 2007, CLIN INFECT DIS, V44, pE88, DOI 10.1086/517503	23	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2021	16	6							e0253633	10.1371/journal.pone.0253633	http://dx.doi.org/10.1371/journal.pone.0253633			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9CN	34170945	gold, Green Published			2023-01-03	WOS:000671694400015
J	Williamson, AE; McQueenie, R; Ellis, DA; McConnachie, A; Wilson, P				Williamson, Andrea E.; McQueenie, Ross; Ellis, David A.; McConnachie, Alex; Wilson, Philip			'Missingness' in health care: Associations between hospital utilization and missed appointments in general practice. A retrospective cohort study	PLOS ONE			English	Article							NON-ATTENDANCE; BURDEN	Objectives Are multiple missed appointments in general practice associated with increased use of hospital services and missingness from hospital care? This novel study explores this in a population representative sample for the first time. Design, setting, participants A large, retrospective cohort (n = 824,374) of patient records from a nationally representative sample of GP practices, Scotland, 2013-2016. Requested data were extracted by a Trusted Third Party for the NHS, anonymised and linked to a unique patient ID, in the NHS Safehaven for analysis using established NHS Scotland linkage. We calculated the per-patient number of GP missed appointments from individual appointments and investigated the likelihood of hospital appointment or admission outcomes using a negative binomial model offset by number of GP appointments made. These models also controlled for age, sex, Scottish Index of Multiple Deprivation (SIMD) and number of long- term conditions (LTCs). Main outcome measures Hospital attendance: Outpatient clinic attendances; hospital admissions; Emergency Department (ED) attendances. Hospital missingness: 'Did not attend' (DNAs) outpatient clinic appointments, 'irregular discharges' from admissions, and 'left before care completed' ED care episodes. Results Attendance: Patients in the high missed GP appointment (HMA) category were higher users of outpatient services (rate ratio (RR) 1.90, 95% confidence intervals (CI) 1.88-1.93) compared to those who missed none (NMA) with a much higher attendance risk at mental health services (RR 4.56, 95% CI 4.31-4.83). HMA patients were more likely to be admitted to hospital; general admissions (RR 1.67, 95% CI 1.65-1.68), maternity (RR 1.24, 95% CI 1.20-1.28) and mental health (RR 1.23, 95% CI 1.15-1.31), compared to NMA patients. Missing GP appointments was not associated with ED attendance; (RR 1.00, CI 0.99-1.01). Missingness: HMA patients were at greater risk of missing outpatient appointments (RR 1.62, 95% CI 1.60-1.64) than NMA patients; with a much higher risk of non-attendance at mental health services (RR 7.83, 95% CI 7.35-8.35). Patients were more likely to leave hospital before their care plan was completed-taking 'irregular discharges' (RR 4.56, 95% CI 4.31-4.81). HMA patients were no more at risk of leaving emergency departments 'without care being completed' (RR1.02, 95 CI 0.95-1.09). Conclusions Patients who miss high numbers of GP appointments are higher users of outpatient and inpatient hospital care but not of emergency departments, signalling high treatment burden. The pattern of 'missingness' is consistent from primary care to hospital care: patients who have patterns of missing GP appointments have patterns of missing many outpatient appointments and are more likely to experience 'irregular discharge' from in-patient care. Missingness from outpatient mental health services is very high. Policymakers, health service planners and clinicians should consider the role and contribution of 'missingness' in health care to improving patient safety and care.	[Williamson, Andrea E.] Univ Glasgow, Sch Med Dent & Nursing, Gen Practice & Primary Care, MVLS, Glasgow, Lanark, Scotland; [McQueenie, Ross] Publ Hlth Scotland, NHS Scotland, Glasgow, Lanark, Scotland; [Ellis, David A.] Univ Bath, Sch Management, Bath, Avon, England; [McConnachie, Alex] Univ Glasgow, Robertson Ctr Biostat, Inst Hlth & Wellbeing, MVLS, Glasgow, Lanark, Scotland; [Wilson, Philip] Univ Aberdeen, Ctr Rural Hlth, Inst Appl Hlth Sci, Aberdeen, Scotland	University of Glasgow; NHS National Services Scotland; University of Bath; University of Glasgow; University of Aberdeen	Williamson, AE (corresponding author), Univ Glasgow, Sch Med Dent & Nursing, Gen Practice & Primary Care, MVLS, Glasgow, Lanark, Scotland.	andrea.williamson@glasgow.ac.uk	; Ellis, David/A-8322-2011	Williamson, Andrea/0000-0002-8981-9068; Ellis, David/0000-0001-6172-3323; Wilson, Philip/0000-0002-4123-8248; McConnachie, Alex/0000-0002-7262-7000	Scottish Government Chief Scientist Office research grant [CZH/4/41118]; DSLS at Scottish Government	Scottish Government Chief Scientist Office research grant; DSLS at Scottish Government	AEW DAE AMcC and PW received funding for this research from a Scottish Government Chief Scientist Office research grant (CZH/4/41118) https://www.cso.scot.nhs.uk/with Safe Haven and data linkage costs supported in lieu by the DSLS at Scottish Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambasta A, 2020, BMJ QUAL SAF, V29, P348, DOI 10.1136/bmjqs-2019-010332; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Chaudhri S, 2019, J GEN INTERN MED, V34, P1048, DOI 10.1007/s11606-018-4783-1; Data and Intelligence (previously ISD Scotland), 2020, DEF FIL STAND PUBL H; Dockery F, 2001, POSTGRAD MED J, V77, P37, DOI 10.1136/pmj.77.903.37; Ellis DA, 2017, LANCET PUBLIC HEALTH, V2, pE551, DOI 10.1016/S2468-2667(17)30217-7; Eton DT, 2012, PATIENT-RELAT OUTCOM, V3, P39, DOI 10.2147/PROM.S34681; Fleming M, 2012, J CLIN NURS, V21, P2711, DOI 10.1111/j.1365-2702.2011.04021.x; Gallacher K, 2011, ANN FAM MED, V9, P235, DOI 10.1370/afm.1249; Hull SA, 2018, BRIT J GEN PRACT, V68, pE157, DOI 10.3399/bjgp18X694397; Karter AJ, 2004, MED CARE, V42, P110, DOI 10.1097/01.mlr.0000109023.64650.73; McQueenie R, 2019, BMC MED, V17, DOI 10.1186/s12916-018-1234-0; Murdoch D., 2017, DOWNLOAD R3 4 0 WIND; Scantlebury R, 2015, BRIT J GEN PRACT, V65, pE649, DOI 10.3399/bjgp15X686893; Schectman JM, 2008, J GEN INTERN MED, V23, P1685, DOI 10.1007/s11606-008-0747-1; Soendergaard HM, 2016, J CLIN PSYCHIAT, V77, P232, DOI 10.4088/JCP.14m09270; Tan KM, 2012, EUR GERIATR MED, V3, P78, DOI 10.1016/j.eurger.2011.12.004; Williamson Andrea E, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101011; Williamson AE, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014120	19	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2021	16	6							e0253163	10.1371/journal.pone.0253163	http://dx.doi.org/10.1371/journal.pone.0253163			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BX	34166424	Green Published, Green Accepted, gold			2023-01-03	WOS:000671692800031
J	Giraudo, C; Librizzi, G; Fichera, G; Motta, R; Balestro, E; Calabrese, F; Carretta, G; Cattelan, AM; Navalesi, P; Pelloso, M; Plebani, M; Rea, F; Vettor, R; Vianello, A; Stramare, R				Giraudo, Chiara; Librizzi, Giovanni; Fichera, Giulia; Motta, Raffaella; Balestro, Elisabetta; Calabrese, Fiorella; Carretta, Giovanni; Cattelan, Anna Maria; Navalesi, Paolo; Pelloso, Michela; Plebani, Mario; Rea, Federico; Vettor, Roberto; Vianello, Andrea; Stramare, Roberto			Reduced muscle mass as predictor of intensive care unit hospitalization in COVID-19 patients	PLOS ONE			English	Article							CROSS-SECTIONAL AREA; PARASPINAL MUSCLES; SARCOPENIA; PHYSIOTHERAPY; DENSITY	Purpose To evaluate if reduced muscle mass, assessed with Computed Tomography (CT), is a predictor of intensive care unit (ICU) hospitalization in COVID-19 patients. Methods In this Institution Review Board approved study, we retrospectively evaluated COVID-19 patients treated in our tertiary center from March to November 2020 who underwent an unenhanced chest CT scan within three weeks from hospitalization.We recorded the mean Hounsfield Unit (Hu) value of the right paravertebral muscle at the level of the 12(th) thoracic vertebra, the hospitalization unit (ICU and COVID-19 wards), clinical symptoms, Barthel Index, and laboratory findings.Logistic regression analysis was applied to assess if muscle loss (Hu<30) is a predictor of ICU admission and outcome.Fisher's exact and Student's tests were applied to evaluate if differences between patients with and without muscle loss occurred (p<0.05). Results One-hundred-fifty patients matched the inclusion criteria (46 females; mean age +/- SD 61.3 +/- 15 years-old), 36 treated in ICU. Patients in ICU showed significantly lower Hu values (29 +/- 24 vs 39.4 +/- 12, p = 0.001). Muscle loss was a predictor of ICU admission (p = 0.004).Patients with muscle loss were significantly older (73.4 +/- 10 vs 56.4 +/- 14 years), had lower Barthel Index scores (54.4 +/- 33 vs 85.1 +/- 26), red blood-cell count (3.9 +/- 1 vs 4.6 +/- 1x10(12)L(-1)), and Hb levels (11.5 +/- 2 vs 13.2 +/- 2g/l) as well as higher white blood-cell count (9.4 +/- 7 vs 7.2 +/- 4x10(9)L(-1)), C-reactive protein (71.5 +/- 71 vs 44 +/- 48U/L), and lactate dehydrogenase levels (335 +/- 163 vs 265.8 +/- 116U/L) (p<0.05, each). Conclusions Muscle loss seems to be a predictor of ICU hospitalization in COVID-19 patients and radiologists reporting chest CT at admission should note this finding in their reports.	[Giraudo, Chiara; Librizzi, Giovanni; Fichera, Giulia; Motta, Raffaella; Stramare, Roberto] Univ Padua, Dept Med DIMED, Padua, Italy; [Balestro, Elisabetta] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Resp Dis Unit, Padua, Italy; [Calabrese, Fiorella] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Pathol Anat Sect, Padua, Italy; [Carretta, Giovanni] Unita Locale Socio Sanitaria ULSS 3 Serenissima, Venice, Veneto Region, Italy; [Cattelan, Anna Maria] Padova Univ Hosp, Div Infect & Trop Dis, Padua, Italy; [Navalesi, Paolo] Univ Padua, Dept Med DIMED, Anesthesiol & Intens Care Unit, Padua, Italy; [Pelloso, Michela; Plebani, Mario] Univ Hosp Padova, Dept Lab Med, Padua, Italy; [Rea, Federico] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Thorac Surg, Padua, Italy; [Vettor, Roberto] Univ Padua, Dept Med DIMED, Internal Med, Padua, Italy; [Vianello, Andrea] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Resp Pathophysiol Div, Padua, Italy	University of Padua; University of Padua; University of Padua; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Padua; University of Padua; University of Padua	Giraudo, C (corresponding author), Univ Padua, Dept Med DIMED, Padua, Italy.	chiara.giraudo@unipd.it	VETTOR, ROBERTO/K-7121-2016; Vianello, Andrea/AHD-3398-2022; pelloso, michela/K-5615-2018; Navalesi, Paolo/F-9559-2010	Vianello, Andrea/0000-0002-8790-6029; Navalesi, Paolo/0000-0002-3733-3453; MOTTA, RAFFAELLA/0000-0002-1886-9826; Pelloso, Michela/0000-0002-2853-4499; Balestro, Elisabetta/0000-0003-1373-8197; Giraudo, Chiara/0000-0003-0924-5883; Librizzi, Giovanni/0000-0002-2409-457X				Aubrey J, 2014, ACTA PHYSIOL, V210, P489, DOI 10.1111/apha.12224; Barazzoni R, 2018, OBESITY FACTS, V11, P294, DOI 10.1159/000490361; Cacciatore F, 2015, BIOMARK MED, V9, P669, DOI [10.2217/BMM.15.28, 10.2217/bmm.15.28]; Cester G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9093042; Chargi N, 2019, EUR ARCH OTO-RHINO-L, V276, P1475, DOI 10.1007/s00405-019-05361-4; Cicchetti D.V., 1994, PSYCHOL ASSESSMENT, V6, P284, DOI 10.1037/1040-3590.6.4.284; Cruz-Jentoft AJ, 2019, AGE AGEING, V48, P16, DOI 10.1093/ageing/afy169; Deng CY, 2018, AM J ROENTGENOL, V210, P526, DOI 10.2214/AJR.17.18020; Donini LM, 2020, CLIN NUTR, V39, P2368, DOI 10.1016/j.clnu.2019.11.024; Ekin EE, 2019, TURK J MED SCI, V49, P538, DOI 10.3906/sag-1809-48; Fintelmann FJ, 2018, ANN THORAC SURG, V105, P1507, DOI 10.1016/j.athoracsur.2018.01.013; Giraudo C, 2020, QUANT IMAG MED SURG, V10, P1602, DOI 10.21037/qims.2019.12.15; Goodpaster BH, 2000, ANN NY ACAD SCI, V904, P18; Hida T, 2018, NAGOYA J MED SCI, V80, P519, DOI 10.18999/nagjms.80.4.519; Ismail C, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00302; Kalichman L, 2010, EUR SPINE J, V19, P1136, DOI 10.1007/s00586-009-1257-5; Keller A, 2003, SPINE, V28, P1455, DOI 10.1097/00007632-200307010-00017; Khosla SG, 2020, J INVEST MED HIGH IM, V8, DOI 10.1177/2324709620984603; Kirwan R, 2020, GEROSCIENCE, V42, P1547, DOI 10.1007/s11357-020-00272-3; Lee S, 2005, J APPL PHYSIOL, V99, P1220, DOI 10.1152/japplphysiol.00053.2005; Lieffers JR, 2012, BRIT J CANCER, V107, P931, DOI 10.1038/bjc.2012.350; Looijaard WGPM, 2018, CURR OPIN CRIT CARE, V24, P241, DOI 10.1097/MCC.0000000000000511; MAHONEY F I, 1965, Md State Med J, V14, P61; Martone AM, 2017, J CACHEXIA SARCOPENI, V8, P907, DOI 10.1002/jcsm.12224; Mitobe Yuta, 2019, J Clin Med Res, V11, P834, DOI 10.14740/jocmr4027; Moon SW, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1001-6; Morley JE, 2020, J CACHEXIA SARCOPENI, V11, P863, DOI 10.1002/jcsm.12589; Nemec U, 2017, ACAD RADIOL, V24, P1154, DOI 10.1016/j.acra.2017.02.008; Singh B, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.10686; Sommers J, 2015, CLIN REHABIL, V29, P1051, DOI 10.1177/0269215514567156; Stiller K, 2000, CHEST, V118, P1801, DOI 10.1378/chest.118.6.1801; Storheim K, 2003, J SPINAL DISORD TECH, V16, P271, DOI 10.1097/00024720-200306000-00008; Stramare R, 2020, RADIOL MED, V125, P691, DOI 10.1007/s11547-020-01231-w; Vellas B, 2018, J FRALITY AGING, V7, P2, DOI 10.14283/jfa.2017.30; Welch C, 2020, AGING DIS, V11, P1345, DOI 10.14336/AD.2020.1014; Welch C, 2018, AGING DIS, V9, P151, DOI 10.14336/AD.2017.0315; Williams GR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.4783	37	14	14	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2021	16	6							e0253433	10.1371/journal.pone.0253433	http://dx.doi.org/10.1371/journal.pone.0253433			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9AX	34138945	gold, Green Published			2023-01-03	WOS:000671690200064
J	Perez-Lopez, A; Irwin, A; Rodrigo, C; Prat-Aymerich, C				Perez-Lopez, Andres; Irwin, Adam; Rodrigo, Carlos; Prat-Aymerich, Cristina			Role of C reactive protein and procalcitonin in the diagnosis of lower respiratory tract infection in children in the outpatient setting	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							COMMUNITY-ACQUIRED PNEUMONIA; SERUM PROCALCITONIN; BACTERIAL; EFFICACY; TESTS		[Perez-Lopez, Andres] Sidra Med, Div Microbiol, Doha, Qatar; [Perez-Lopez, Andres] Weill Cornell Med Coll Qatar, Doha, Qatar; [Irwin, Adam] Univ Queensland, UQ Ctr Clin Res, Herston, Qld, Australia; [Irwin, Adam] Childrens Hlth Queensland Hosp & Hlth Serv, South Brisbane, Qld, Australia; [Rodrigo, Carlos] Hosp Badalona Germans Trias & Pujol, Dept Pediat, Badalona, Spain; [Rodrigo, Carlos] Autonomous Univ Barcelona, Badalona, Spain; [Prat-Aymerich, Cristina] Hosp Badalona Germans Trias & Pujol, Dept Microbiol, Badalona, Spain; [Prat-Aymerich, Cristina] Univ Utrecht, Univ Med Ctr Utrecht, CIBER Enfermedades Resp, Utrecht, Netherlands; [Prat-Aymerich, Cristina] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Sidra Medical & Research Center; Qatar Foundation (QF); Weill Cornell Medical College Qatar; University of Queensland; Hospital Germans Trias i Pujol; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Perez-Lopez, A (corresponding author), Sidra Med, Div Microbiol, Doha, Qatar.; Perez-Lopez, A (corresponding author), Weill Cornell Med Coll Qatar, Doha, Qatar.	aperezlopez@sidra.org	Irwin, Adam/D-7551-2017; PRAT AYMERICH, CRISTINA/R-3484-2016	Irwin, Adam/0000-0001-8974-6789; PRAT AYMERICH, CRISTINA/0000-0001-6974-9165				Aabenhus R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010130.pub2; [Anonymous], 2011, HUISARTS WET, V54, P86; Don M, 2007, SCAND J INFECT DIS, V39, P129, DOI 10.1080/00365540600951283; Downes KJ, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01851-19; Esposito S, 2011, RESP MED, V105, P1939, DOI 10.1016/j.rmed.2011.09.003; Galetto-Lacour A, 2013, PEDIATR INFECT DIS J, V32, P1175, DOI 10.1097/INF.0b013e31829ba62a; Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598; Heiskanen-Kosma T, 2000, SCAND J INFECT DIS, V32, P399, DOI 10.1080/003655400750044971; Keitel K, 2019, CLIN INFECT DIS, V69, P1926, DOI 10.1093/cid/ciz080; Korppi M, 2003, PEDIATR PULM, V35, P56, DOI 10.1002/ppul.10201; National Institute for Health and Care Excellence, 2019, PNEUM AD DIAGN MAN C; Prat C, 2003, PEDIATR INFECT DIS J, V22, P963, DOI 10.1097/01.inf.0000095197.72976.4f; Rebnord IK, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012992; Rebnord IK, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011231; Schot MJC, 2018, NPJ PRIM CARE RESP M, V28, DOI 10.1038/s41533-018-0104-8; Schot MJ, 2018, BJGP OPEN, V2; Schuetz P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007498.pub3; Stockmann C, 2018, J PEDIAT INF DIS SOC, V7, P46, DOI 10.1093/jpids/piw091; Stol K, 2019, PEDIATR INFECT DIS J, V38, pS7, DOI [10.1097/inf.0000000000002318, 10.1097/INF.0000000000002318]; Tsou PY, 2020, INFECT DIS-NOR, V52, P683, DOI 10.1080/23744235.2020.1788719; Van den Bruel A, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3082; Verbakel JY, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025036; Virkki R, 2002, THORAX, V57, P438, DOI 10.1136/thorax.57.5.438; Zar HJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j2739	24	3	3	2	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 11	2021	373								n1409	10.1136/bmj.n1409	http://dx.doi.org/10.1136/bmj.n1409			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SV3EN	34117023				2023-01-03	WOS:000663705800002
J	Tutt, ANJ; Garber, JE; Kaufman, B; Viale, G; Fumagalli, D; Rastogi, P; Gelber, RD; de Azambuja, E; Fielding, A; Balmana, J; Domchek, SM; Gelmon, KA; Hollingsworth, SJ; Korde, LA; Linderholm, B; Bandos, H; Senkus, E; Suga, JM; Shao, Z; Pippas, AW; Nowecki, Z; Huzarski, T; Ganz, PA; Lucas, PC; Baker, N; Loibl, S; McConnell, R; Piccart, M; Schmutzler, R; Steger, GG; Costantino, JP; Arahmani, A; Wolmark, N; McFadden, E; Karantza, V; Lakhani, SR; Yothers, G; Campbell, C; Geyer, CE				Tutt, Andrew N. J.; Garber, Judy E.; Kaufman, Bella; Viale, Giuseppe; Fumagalli, Debora; Rastogi, Priya; Gelber, Richard D.; de Azambuja, Evandro; Fielding, Anitra; Balmana, Judith; Domchek, Susan M.; Gelmon, Karen A.; Hollingsworth, Simon J.; Korde, Larissa A.; Linderholm, Barbro; Bandos, Hanna; Senkus, E.; Suga, Jennifer M.; Shao, Z.; Pippas, Andrew W.; Nowecki, Zbigniew; Huzarski, Tomasz; Ganz, Patricia A.; Lucas, Peter C.; Baker, Nigel; Loibl, Sibylle; McConnell, Robin; Piccart, Martine; Schmutzler, Rita; Steger, Guenther G.; Costantino, Joseph P.; Arahmani, Amal; Wolmark, Norman; McFadden, Eleanor; Karantza, Vassiliki; Lakhani, Sunil R.; Yothers, Greg; Campbell, Christine; Geyer, Charles E.		OlympiA Clinical Trial Steering	Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DNA-REPAIR DEFECT; MUTANT-CELLS; MUTATION; SURVIVAL; PATHOLOGY; OVARIAN; TUMORS	BACKGROUND Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer. METHODS We conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors who had received local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomly assigned (in a 1:1 ratio) to 1 year of oral olaparib or placebo. The primary end point was invasive disease-free survival. RESULTS A total of 1836 patients underwent randomization. At a prespecified event-driven interim analysis with a median follow-up of 2.5 years, the 3-year invasive disease-free survival was 85.9% in the olaparib group and 77.1% in the placebo group (difference, 8.8 percentage points; 95% confidence interval [CI], 4.5 to 13.0; hazard ratio for invasive disease or death, 0.58; 99.5% CI, 0.41 to 0.82; P<0.001). The 3-year distant disease-free survival was 87.5% in the olaparib group and 80.4% in the placebo group (difference, 7.1 percentage points; 95% CI, 3.0 to 11.1; hazard ratio for distant disease or death, 0.57; 99.5% CI, 0.39 to 0.83; P<0.001). Olaparib was associated with fewer deaths than placebo (59 and 86, respectively) (hazard ratio, 0.68; 99% CI, 0.44 to 1.05; P=0.02); however, the between-group difference was not significant at an interim-analysis boundary of a P value of less than 0.01. Safety data were consistent with known side effects of olaparib, with no excess serious adverse events or adverse events of special interest. CONCLUSIONS Among patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than was placebo. Olaparib had limited effects on global patient-reported quality of life.	[Tutt, Andrew N. J.] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, 237 Fulham Rd, London SW3 6JB, England; [Tutt, Andrew N. J.] Kings Coll London, Guys Hosp Canc Ctr, Breast Canc Now Unit, London, England; [Hollingsworth, Simon J.; Baker, Nigel] AstraZeneca, Cambridge, England; [McConnell, Robin; McFadden, Eleanor; Campbell, Christine] Frontier Sci Scotland, Kincraig, Scotland; [Garber, Judy E.; Gelber, Richard D.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Gelber, Richard D.] Frontier Sci Fdn, Boston, MA USA; [Gelber, Richard D.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Kaufman, Bella] Tel Aviv Univ, Breast Oncol Inst, Chaim Sheba Med Ctr, Tel Aviv, Israel; [Viale, Giuseppe] Univ Milan, European Inst Oncol IRCCS, Milan, Italy; [Fumagalli, Debora; Arahmani, Amal] Breast Int Grp, Brussels, Belgium; [de Azambuja, Evandro; Piccart, Martine] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium; [Rastogi, Priya; Bandos, Hanna; Lucas, Peter C.; Wolmark, Norman; Yothers, Greg; Geyer, Charles E.] NRG Oncol, Philadelphia, PA USA; [Domchek, Susan M.] Univ Penn, Abramson Canc Ctr, Basser Ctr BRCA, Philadelphia, PA 19104 USA; [Rastogi, Priya; Lucas, Peter C.; Wolmark, Norman] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA; [Bandos, Hanna; Costantino, Joseph P.; Yothers, Greg] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA; [Wolmark, Norman] NSABP Fdn, Pittsburgh, PA USA; [Fielding, Anitra] AstraZeneca, Gaithersburg, MD USA; [Korde, Larissa A.] NCI, Rockville, MD USA; [Balmana, Judith] Vall dHebron Inst Oncol, Barcelona, Spain; [Balmana, Judith] Vall dHebron Univ Hosp, Barcelona, Spain; [Gelmon, Karen A.] BC Canc, Vancouver, BC, Canada; [Linderholm, Barbro] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Linderholm, Barbro] Gothenburg Univ, Inst Clin Sci, Dept Oncol, Sahlgrenska Acad, Gothenburg, Sweden; [Senkus, E.] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland; [Nowecki, Zbigniew] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland; [Huzarski, Tomasz] Pomeranian Med Univ, Int Hereditary Canc Ctr, Szczecin, Poland; [Huzarski, Tomasz] Read Gene, Grzepnica, Poland; [Suga, Jennifer M.] Kaiser Permanente Vallejo Med Ctr, Vallejo, CA USA; [Ganz, Patricia A.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA; [Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; [Shao, Z.] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Pippas, Andrew W.] Northside Hosp Canc Inst, Georgia NCORP, Atlanta, GA USA; [Pippas, Andrew W.] Piedmont Healthcare, Atlanta, GA USA; [Loibl, Sibylle] German Breast Grp, Neu Isenburg, Germany; [Loibl, Sibylle] Ctr Hematol & Oncol Bethanien, Frankfurt, Germany; [Loibl, Sibylle] Goethe Univ, Frankfurt, Germany; [Schmutzler, Rita] Univ Hosp Cologne, Fac Med, Ctr Familial Breast & Ovarian Canc, Cologne, Germany; [Schmutzler, Rita] Univ Hosp Cologne, Fac Med, Ctr Integrated Oncol, Cologne, Germany; [Steger, Guenther G.] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria; [Steger, Guenther G.] Med Univ Vienna, Gaston H Glock Res Ctr, Vienna, Austria; [Karantza, Vassiliki] Merck, Kenilworth, NJ USA; [Lakhani, Sunil R.] Univ Queensland, Ctr Clin Res & Pathol Queensland, Brisbane, Qld, Australia; [Geyer, Charles E.] Houston Methodist Canc Ctr, Houston, TX USA; [Geyer, Charles E.] Weill Cornell Med Coll, Houston, TX USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Frontier Science Foundation; Harvard University; Harvard T.H. Chan School of Public Health; Chaim Sheba Medical Center; Tel Aviv University; IRCCS European Institute of Oncology (IEO); University of Milan; Breast International Group; Institut Jules Bordet; Universite Libre de Bruxelles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; AstraZeneca; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vall d'Hebron Institut d'Oncologia (VHIO); Hospital Universitari Vall d'Hebron; Sahlgrenska University Hospital; University of Gothenburg; Fahrenheit Universities; Medical University Gdansk; Pomeranian Medical University; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Fudan University; German Breast Group; Goethe University Frankfurt; University of Cologne; University of Cologne; Medical University of Vienna; Medical University of Vienna; Merck & Company; University of Queensland; The Methodist Hospital System; The Methodist Hospital - Houston; Cornell University	Tutt, ANJ (corresponding author), Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	andrew.tutt@icr.ac.uk	Watanabe, Junichiro/AAI-8481-2021; Geyer, Charles/AGY-0119-2022; , Marta/ABE-6618-2020; Lord, Christopher/B-3295-2012	Watanabe, Junichiro/0000-0001-9226-895X; Geyer, Charles/0000-0002-2379-5702; Braybrooke, Jeremy/0000-0003-1943-7360; Biganzoli, Laura/0000-0001-7989-8658; Ortega Granados, Ana Laura/0000-0002-5727-3371; Rossi, Giovanna/0000-0002-4995-5161; Lucas, Peter/0000-0003-4880-7172; , Marta/0000-0003-0625-686X; ARNEDOS, MONICA/0000-0001-5269-1251; Hickish, Tamas/0000-0001-6770-7279; Goodwin, Annabel/0000-0002-8859-9980; Bianchini, Giampaolo/0000-0002-6790-6267; Armstrong, Anne/0000-0002-0774-7006; Lord, Christopher/0000-0002-3226-0515; Tutt, Andrew/0000-0001-8715-2901; Ganz, Patricia/0000-0002-1841-4143; de Azambuja, Evandro/0000-0001-9501-4509; Yothers, Greg/0000-0002-7965-7333; Jonkers, Jos/0000-0002-9264-9792	National Cancer Institute [U10CA180868, UG1CA189867, U10CA180822]; AstraZeneca	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AstraZeneca(AstraZeneca)	Supported by grants (U10CA180868, UG1CA189867, and U10CA180822) from the National Cancer Institute and funding and provision of olaparib and placebo by AstraZeneca as part of an alliance between AstraZeneca and Merck.	[Anonymous], 2021, NAT COMPR CANC NETW, V2021; Atchley DP, 2008, J CLIN ONCOL, V26, P4282, DOI 10.1200/JCO.2008.16.6231; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Burstein HJ, 2019, ANN ONCOL, V30, P1541, DOI 10.1093/annonc/mdz235; Cuzick J, 2005, LANCET, V365, P1308, DOI 10.1016/S0140-6736(05)61026-4; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Dorling L, 2021, NEW ENGL J MED, V384, P428, DOI 10.1056/NEJMoa1913948; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fasching PA, 2021, ANN ONCOL, V32, P49, DOI 10.1016/j.annonc.2020.10.471; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Hu CL, 2021, NEW ENGL J MED, V384, P440, DOI 10.1056/NEJMoa2005936; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728; Kuchenbaecker KB, 2017, JAMA-J AM MED ASSOC, V317, P2402, DOI 10.1001/jama.2017.7112; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Litton JK, 2018, NEW ENGL J MED, V379, P753, DOI 10.1056/NEJMoa1802905; Masuda N, 2017, NEW ENGL J MED, V376, P2147, DOI 10.1056/NEJMoa1612645; Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775; Mittendorf EA, 2011, J CLIN ONCOL, V29, P1956, DOI 10.1200/JCO.2010.31.8469; Morice PM, 2021, LANCET HAEMATOL, V8, pe122, DOI 10.1016/S2352-3026(20)30360-4; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Pohl-Rescigno E, 2020, JAMA ONCOL, V6, P744, DOI 10.1001/jamaoncol.2020.0007; Robson ME, 2019, ANN ONCOL, V30, P558, DOI 10.1093/annonc/mdz012; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Shah PD, 2016, CANCER-AM CANCER SOC, V122, P1178, DOI 10.1002/cncr.29903; Staaf J, 2019, NAT MED, V25, P1526, DOI 10.1038/s41591-019-0582-4; Stone A, 2010, PHARM STAT, V9, P151, DOI 10.1002/pst.386; Tryggvadottir L, 2013, BREAST CANCER RES TR, V140, P375, DOI 10.1007/s10549-013-2637-4; Tutt A, 2002, TRENDS MOL MED, V8, P571, DOI 10.1016/S1471-4914(02)02434-6; Tutt ANJ, 2005, COLD SH Q B, V70, P139, DOI 10.1101/sqb.2005.70.012; Tutt A, 2018, NAT MED, V24, P628, DOI 10.1038/s41591-018-0009-7; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Tutt A, 2008, EUR J CANCER, V44, P2774, DOI 10.1016/j.ejca.2008.10.009; Zhang J, 2018, ANN ONCOL, V29, P1741, DOI 10.1093/annonc/mdy209	35	289	295	22	97	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2021	384	25					2394	2405		10.1056/NEJMoa2105215	http://dx.doi.org/10.1056/NEJMoa2105215		JUN 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA7NI	34081848	Green Accepted			2023-01-03	WOS:000660320300001
J	Ogata, H; Fukagawa, M; Hirakata, H; Kagimura, T; Fukushima, M; Akizawa, T				Ogata, Hiroaki; Fukagawa, Masafumi; Hirakata, Hideki; Kagimura, Tatsuo; Fukushima, Masanori; Akizawa, Tadao		LANDMARK Invest	Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY CALCIFICATION; PHOSPHATE BINDERS; DIALYSIS OUTCOMES; PRACTICE PATTERNS; VASCULAR CALCIFICATION; MORTALITY RISK; SEVELAMER; ASSOCIATION; PROGRESSION; JAPAN	Key PointsQuestionDoes lanthanum carbonate-based treatment without calcium-based phosphate binders reduce cardiovascular events compared with calcium carbonate-based treatment in patients with hyperphosphatemia undergoing hemodialysis? FindingsIn this open-label randomized clinical trial that included 2135 patients undergoing hemodialysis with at least 1 risk factor for vascular calcification, there was no significant difference in composite cardiovascular events between lanthanum carbonate-based treatment with and without calcium-based phosphate binders after a median follow-up of 3.16 years (4.80 vs 4.30 per 100 person-years). MeaningLanthanum carbonate-based treatment without calcium-based phosphate binders did not significantly reduce the composite outcome of cardiovascular events in patients with hyperphosphatemia undergoing hemodialysis. ImportanceAmong patients with hyperphosphatemia undergoing dialysis, it is unclear whether non-calcium-based phosphate binders are more effective than calcium-based binders for reducing cardiovascular events. ObjectiveTo determine whether lanthanum carbonate reduces cardiovascular events compared with calcium carbonate in patients with hyperphosphatemia at risk of vascular calcification undergoing hemodialysis. Design, Setting, and ParticipantsOpen-label, randomized, parallel-group clinical trial with blinded end point adjudication performed in 2374 patients with chronic kidney disease from 273 hemodialysis facilities in Japan. Eligible patients had hyperphosphatemia and 1 or more risk factors for vascular calcification (ie, >= 65 years, postmenopausal, diabetes). Enrollment occurred from November 2011 to July 2014; follow-up ended June 2018. InterventionsPatients were randomized to receive either lanthanum carbonate (n=1154) or calcium carbonate (n=1155) and titrated to achieve serum phosphate levels of between 3.5 mg/dL and 6.0 mg/dL. Main Outcomes and MeasuresThe primary outcome was a composite cardiovascular event (cardiovascular death, nonfatal myocardial infarction or stroke, unstable angina, transient ischemic attack, or hospitalization for heart failure or ventricular arrhythmia). Secondary outcomes included overall survival, secondary hyperparathyroidism-free survival, hip fracture-free survival, and adverse events. ResultsAmong 2309 randomized patients (median age, 69 years; 40.5% women), 1851 (80.2%) completed the trial. After a median follow-up of 3.16 years, cardiovascular events occurred in 147 of 1063 patients in the lanthanum calcium group and 134 of 1072 patients in the calcium carbonate group (incidence rate, 4.80 vs 4.30 per 100 person-years; difference 0.50 per 100 person-years [95% CI, -0.57 to 1.56]; hazard ratio [HR], 1.11 [95%, CI, 0.88 to 1.41], P=.37). There were no significant differences in all-cause death (difference, 0.43 per 100 person-years [95% CI, -0.63 to 1.49]; HR, 1.10 [95% CI, 0.88 to 1.37]; P=.42) or hip fracture (difference, 0.10 per 100 person-years [95% CI, -0.26 to 0.47]; HR, 1.21 [95% CI, 0.62 to 2.35]; P=.58). The lanthanum carbonate group had an increased risk of cardiovascular death (difference, 0.61 per 100 person-years [95% CI, 0.02 to 1.21]; HR, 1.51 [95% CI, 1.01 to 2.27]; P=.045) and secondary hyperparathyroidism (difference, 1.34 [95% CI, 0.49 to 2.19]; HR, 1.62 [95% CI, 1.19 to 2.20]; P=.002). Adverse events occurred in 282 (25.7%) in the lanthanum carbonate group and 259 (23.4%) in the calcium carbonate groups. Conclusions and RelevanceAmong patients undergoing hemodialysis with hyperphosphatemia and at least 1 vascular calcification risk factor, treatment of hyperphosphatemia with lanthanum carbonate compared with calcium carbonate did not result in a significant difference in composite cardiovascular events. However, the event rate was low, and the findings may not apply to patients at higher risk. Trial RegistrationClinicalTrials.gov Identifier: NCT01578200; UMIN Clinical Trial Registry Identifier: UMIN000006815 This clinical trial compared cardiovascular events among patients receiving hemodialysis with at least at 1 risk factor for vascular calcification and treated with a calcium-free phosphate binder, lanthanum carbonate, or calcium carbonate	[Ogata, Hiroaki] Showa Univ, Northern Yokohama Hosp, Dept Internal Med, Div Nephrol,Tsuzuki Ku, Chigasaki Chuo 35-1, Yokohama, Kanagawa 2248503, Japan; [Fukagawa, Masafumi] Tokai Univ, Sch Med, Dept Internal Med, Div Nephrol Endocrinol & Metab, Isehara, Kanagawa, Japan; [Hirakata, Hideki] Fukuoka Renal Clin, Chuo Ku, Fukuoka, Japan; [Kagimura, Tatsuo; Fukushima, Masanori] Fdn Biomed Res & Innovat Kobe, Translat Res Ctr Med Innovat, Chuo Ku, Kobe, Hyogo, Japan; [Akizawa, Tadao] Showa Univ, Sch Med, Dept Med, Div Nephrol,Shinagawa Ku, Tokyo, Japan	Showa University; Tokai University; Showa University	Ogata, H (corresponding author), Showa Univ, Northern Yokohama Hosp, Dept Internal Med, Div Nephrol,Tsuzuki Ku, Chigasaki Chuo 35-1, Yokohama, Kanagawa 2248503, Japan.	ogatah@med.showa-u.ac.jp	Ogata, Hiroaki/A-7946-2011	Ogata, Hiroaki/0000-0002-0046-5575	Bayer Yakuhin Ltd.	Bayer Yakuhin Ltd.	This trial was funded by Bayer Yakuhin Ltd.	Block GA, 2007, KIDNEY INT, V71, P438, DOI 10.1038/sj.ki.5002059; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523-1755.2005.00600.x; Block GA, 2012, J AM SOC NEPHROL, V23, P1407, DOI 10.1681/ASN.2012030223; Chertow GM, 2004, NEPHROL DIAL TRANSPL, V19, P1489, DOI 10.1093/ndt/gfh125; Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523-1755.2002.00434.x; Cozzolino M, 2018, NEPHROL DIAL TRANSPL, V33, P28, DOI 10.1093/ndt/gfy174; Di Iorio B, 2013, AM J KIDNEY DIS, V62, P771, DOI 10.1053/j.ajkd.2013.03.023; Di Iorio B, 2012, CLIN J AM SOC NEPHRO, V7, P487, DOI 10.2215/CJN.03820411; Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Hruska KA, 2008, KIDNEY INT, V74, P148, DOI 10.1038/ki.2008.130; Jovanovich A, 2020, AM J KIDNEY DIS, V75, P453, DOI 10.1053/j.ajkd.2019.08.008; Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001; Kumssa DB, 2015, SCI REP-UK, V5, DOI 10.1038/srep10974; Masakane I., 2018, RENAL REPLACE THER, V4, DOI [10.1186/s41100-018-0149-8, DOI 10.1186/S41100-018-0149-8]; McGovern AP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074996; Nakai S, 2012, THER APHER DIAL, V16, P483, DOI 10.1111/j.1744-9987.2012.01143.x; Ogata H., 2017, J AM SOC NEPHROL, V28, pB7; Ogata H, 2017, CLIN EXP NEPHROL, V21, P531, DOI 10.1007/s10157-016-1310-8; Ohtake T, 2013, J CARDIOVASC PHARM T, V18, P439, DOI 10.1177/1074248413486355; Peter WLS, 2008, AM J KIDNEY DIS, V51, P445, DOI 10.1053/j.ajkd.2007.12.002; Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725; Robinson BM, 2016, LANCET, V388, P294, DOI 10.1016/S0140-6736(16)30448-2; Ruospo M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006023.pub3; Spoendlin J, 2019, JAMA INTERN MED, V179, P741, DOI 10.1001/jamainternmed.2019.0045; Stirnadel-Farrant HA, 2019, KIDNEY INT REP, V4, P864, DOI 10.1016/j.ekir.2019.03.016; Suki WN, 2007, KIDNEY INT, V72, P1130, DOI 10.1038/sj.ki.5002466; Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020; Zhang CH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008664	33	16	17	3	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2021	325	19					1946	1954		10.1001/jama.2021.4807	http://dx.doi.org/10.1001/jama.2021.4807			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SF3QY	34003226	Green Published, Bronze			2023-01-03	WOS:000652675100009
J	van der Laak, J; Litjens, G; Ciompi, F				van der Laak, Jeroen; Litjens, Geert; Ciompi, Francesco			Deep learning in histopathology: the path to the clinic	NATURE MEDICINE			English	Review							TUMOR-INFILTRATING LYMPHOCYTES; ARTIFICIAL-INTELLIGENCE; COMPUTATIONAL PATHOLOGY; MITOSIS DETECTION; PROSTATE-CANCER; BREAST-CANCER; SEGMENTATION; PREDICTION; VALIDATION; CHALLENGES	Recent advances in machine learning techniques have created opportunities to improve medical diagnostics, but implementing these advances in the clinic will not be without challenge. Machine learning techniques have great potential to improve medical diagnostics, offering ways to improve accuracy, reproducibility and speed, and to ease workloads for clinicians. In the field of histopathology, deep learning algorithms have been developed that perform similarly to trained pathologists for tasks such as tumor detection and grading. However, despite these promising results, very few algorithms have reached clinical implementation, challenging the balance between hope and hype for these new techniques. This Review provides an overview of the current state of the field, as well as describing the challenges that still need to be addressed before artificial intelligence in histopathology can achieve clinical value.	[van der Laak, Jeroen; Litjens, Geert; Ciompi, Francesco] Radboud Univ Nijmegen Med Ctr, Dept Pathol, Nijmegen, Netherlands; [van der Laak, Jeroen] Linkoping Univ, Ctr Med Image Sci & Visualizat, Linkoping, Sweden	Radboud University Nijmegen; Linkoping University	van der Laak, J (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Pathol, Nijmegen, Netherlands.; van der Laak, J (corresponding author), Linkoping Univ, Ctr Med Image Sci & Visualizat, Linkoping, Sweden.	jeroen.vanderlaak@radboudumc.nl	van der Laak, Jeroen AWM/D-3057-2015; Ciompi, Francesco/P-5598-2015; Litjens, Geert JS/A-2319-2016	van der Laak, Jeroen AWM/0000-0001-7982-0754; Ciompi, Francesco/0000-0001-8327-9606; Litjens, Geert JS/0000-0003-1554-1291				AbdulJabbar K, 2020, NAT MED, V26, P1054, DOI 10.1038/s41591-020-0900-x; Abels E, 2019, J PATHOL, V249, P286, DOI 10.1002/path.5331; Agarwalla A., 2017, REPRESENTATION AGGRE; Akbar S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50568-4; Alawad M, 2020, J AM MED INFORM ASSN, V27, P89, DOI 10.1093/jamia/ocz153; Albarqouni S, 2016, IEEE T MED IMAGING, V35, P1313, DOI 10.1109/TMI.2016.2528120; Allen TC, 2019, ARCH PATHOL LAB MED, V143, P1175, DOI 10.5858/arpa.2019-0229-ED; Amgad M, 2019, BIOINFORMATICS, V35, P3461, DOI 10.1093/bioinformatics/btz083; Awan R, 2018, LECT NOTES COMPUT SC, V10882, P788, DOI 10.1007/978-3-319-93000-8_89; Balkenhol MCA, 2019, LAB INVEST, V99, P1596, DOI 10.1038/s41374-019-0275-0; Beck AH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002564; Beede E, 2020, PROCEEDINGS OF THE 2020 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI'20), DOI 10.1145/3313831.3376718; Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585; Bera K, 2019, NAT REV CLIN ONCOL, V16, P703, DOI 10.1038/s41571-019-0252-y; Bokhorst J-M., 2019, P 2 INT C MED IM DEE, V102, P84; Brieu N., 2019, DOMAIN ADAPTATION BA; Bueno G, 2020, COMPUT METH PROG BIO, V184, DOI 10.1016/j.cmpb.2019.105273; Bulten W, 2020, LANCET ONCOL, V21, P233, DOI 10.1016/S1470-2045(19)30739-9; Bulten W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37257-4; Bychkov D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21758-3; Campanella G, 2019, NAT MED, V25, P1301, DOI 10.1038/s41591-019-0508-1; Chen H, 2017, MED IMAGE ANAL, V36, P135, DOI 10.1016/j.media.2016.11.004; Chen H, 2016, I S BIOMED IMAGING, P1204, DOI 10.1109/ISBI.2016.7493482; Chen PHC, 2019, NAT MED, V25, P1453, DOI 10.1038/s41591-019-0539-7; Cho H., 2017, NEURAL STAIN STYLE T; Cires D. C., 2011, PROC 22 INT JOINT C, V22, P1237; Ciresan DC, 2013, LECT NOTES COMPUT SC, V8150, P411, DOI 10.1007/978-3-642-40763-5_51; Collins GS, 2019, LANCET, V393, P1577, DOI 10.1016/S0140-6736(19)30037-6; Coudray N, 2018, NAT MED, V24, P1559, DOI 10.1038/s41591-018-0177-5; Courtiol P, 2019, NAT MED, V25, P1519, DOI 10.1038/s41591-019-0583-3; Couture HD, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523-018-0079-1; Cruz-Roa A, 2014, PROC SPIE, V9041, DOI 10.1117/12.2043872; Cui DN, 2020, J COMPUT BIOL, V27, P1264, DOI 10.1089/cmb.2019.0410; de Bel T, 2019, P 2 INT C MED IM DEE, P151; de Bel T, 2018, PROC SPIE, V10581, DOI 10.1117/12.2293717; Dong JS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01629; Dudgeon S. N., 2020, PATHOLOGIST ANNOTATE; Duran JM, 2021, J MED ETHICS, V47, P329, DOI 10.1136/medethics-2020-106820; Ertosun M. G, 2015, P AM MED INF ASS ANN; European Commission, 2019, ETH GUID TRUSTW AI; Feng YQ, 2020, IEEE ACM T COMPUT BI, V17, P91, DOI 10.1109/TCBB.2018.2858763; Fu Y, 2020, NAT CANCER, V1, P800, DOI 10.1038/s43018-020-0085-8; Fuchs TJ, 2011, COMPUT MED IMAG GRAP, V35, P515, DOI 10.1016/j.compmedimag.2011.02.006; Gadermayr M, 2019, P MACH LEARN RES, V102, P175; Gao S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232840; Geessink OGF, 2019, CELL ONCOL, V42, P331, DOI 10.1007/s13402-019-00429-z; Gertych A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37638-9; Graham S, 2019, MED IMAGE ANAL, V58, DOI 10.1016/j.media.2019.101563; Graham S, 2019, MED IMAGE ANAL, V52, P199, DOI 10.1016/j.media.2018.12.001; Guidotti R, 2019, ACM COMPUT SURV, V51, DOI 10.1145/3236009; Hamet P, 2017, METABOLISM, V69, pS36, DOI 10.1016/j.metabol.2017.01.011; Hermsen M, 2019, J AM SOC NEPHROL, V30, P1968, DOI 10.1681/ASN.2019020144; Hou L, 2019, PATTERN RECOGN, V86, P188, DOI 10.1016/j.patcog.2018.09.007; Hou L, 2016, PROC CVPR IEEE, P2424, DOI 10.1109/CVPR.2016.266; Iizuka O, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58467-9; Ilse M, 2018, PR MACH LEARN RES, V80; Janowczyk A, 2017, COMPUT MED IMAG GRAP, V57, P50, DOI 10.1016/j.compmedimag.2016.05.003; Jansen I, 2020, AM J PATHOL, V190, P1483, DOI 10.1016/j.ajpath.2020.03.013; Jia ZP, 2017, IEEE T MED IMAGING, V36, P2376, DOI 10.1109/TMI.2017.2724070; Kapil A., 2019, DASGAN JOINT DOMAIN, DOI 10.4103/ijmr.IJMR_1782_18; Karimi D, 2020, IEEE J BIOMED HEALTH, V24, P1413, DOI 10.1109/JBHI.2019.2944643; Kather JN, 2020, NAT CANCER, V1, P789, DOI 10.1038/s43018-020-0087-6; Kather JN, 2019, NAT MED, V25, P1054, DOI 10.1038/s41591-019-0462-y; Kather JN, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002730; Kather JN, 2016, SCI REP-UK, V6, DOI 10.1038/srep27988; Kelly CJ, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1426-2; Kiani A, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0232-8; Kleppe A, 2021, NAT REV CANCER, V21, P199, DOI 10.1038/s41568-020-00327-9; Kohl S, 2018, ADV NEURAL INF PROCE; Koohbanani NA, 2020, MED IMAGE ANAL, V65, DOI 10.1016/j.media.2020.101771; Korde LA, 2021, J CLIN ONCOL, V39, P1485, DOI 10.1200/JCO.20.03399; Kroll JA, 2018, PHILOS T R SOC A, V376, DOI 10.1098/rsta.2018.0084; Kulkarni PM, 2020, CLIN CANCER RES, V26, P1126, DOI 10.1158/1078-0432.CCR-19-1495; Kwok S, 2018, LECT NOTES COMPUT SC, V10882, P931, DOI 10.1007/978-3-319-93000-8_106; Lai MC, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-019-02204-y; Le H, 2020, AM J PATHOL, V190, P1491, DOI 10.1016/j.ajpath.2020.03.012; Lee B, 2018, LECT NOTES COMPUT SC, V11071, P841, DOI 10.1007/978-3-030-00934-2_93; Li C, 2019, MED IMAGE ANAL, V53, P165, DOI 10.1016/j.media.2019.01.013; Liang QK, 2019, IEEE J BIOMED HEALTH, V23, P1205, DOI 10.1109/JBHI.2018.2850040; Linmans J., 2020, P C MED IM DEEP LEAR, P465; Litjens G, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy065; Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005; Litjens G, 2016, SCI REP-UK, V6, DOI 10.1038/srep26286; Liu S, 2020, SCI REP-UK, V10; Liu Y., 2017, DETECTING CANCER MET; Liu Y, 2019, ARCH PATHOL LAB MED, V143, P859, DOI 10.5858/arpa.2018-0147-OA; Long FX, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-019-3332-1; Louis DN, 2014, ARCH PATHOL LAB MED, V138, P1133, DOI 10.5858/arpa.2014-0034-ED; Lu MY, 2021, NAT BIOMED ENG, V5, P555, DOI 10.1038/s41551-020-00682-w; Madabhushi A, 2016, MED IMAGE ANAL, V33, P170, DOI 10.1016/j.media.2016.06.037; Mahmood T, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030749; McKinney SM, 2020, NATURE, V577, P89, DOI 10.1038/s41586-019-1799-6; MENDELSOHN ML, 1965, POSTGRAD MED, V38, P567, DOI 10.1080/00325481.1965.11695692; Mobadersany P, 2018, P NATL ACAD SCI USA, V115, pE2970, DOI 10.1073/pnas.1717139115; Nagendran M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m689; Nagpal K, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0112-2; Naylor P, 2019, IEEE T MED IMAGING, V38, P448, DOI 10.1109/TMI.2018.2865709; Panch T, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020318; Pawlowski N., 2019, NEEDLES HAYSTACKS CL; Pinckaers H., 2019, NEURAL ORDINARY DIFF; Pinckaers H, 2022, IEEE T PATTERN ANAL, V44, P1581, DOI 10.1109/TPAMI.2020.3019563; Price WN, 2019, NAT MED, V25, P37, DOI 10.1038/s41591-018-0272-7; Qaiser Talha, 2019, Digital Pathology. 15th European Congress, ECDP 2019. Proceedings: Lecture Notes in Computer Science (LNCS 11435), P163, DOI 10.1007/978-3-030-23937-4_19; Rawat RR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64156-4; Rieke N, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00323-1; Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28; Saillard C, 2020, HEPATOLOGY, V72, P2000, DOI 10.1002/hep.31207; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Salle FG, 2020, J THORAC ONCOL, V15, P1037, DOI 10.1016/j.jtho.2020.01.025; Saltz J, 2018, CELL REP, V23, P181, DOI 10.1016/j.celrep.2018.03.086; Sari CT, 2019, IEEE T MED IMAGING, V38, P1139, DOI 10.1109/TMI.2018.2879369; Schmauch B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17678-4; Sha Lingdao, 2019, J Pathol Inform, V10, P24, DOI 10.4103/jpi.jpi_24_19; Shaban MT, 2019, I S BIOMED IMAGING, P953, DOI 10.1109/ISBI.2019.8759152; Sheller MJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69250-1; Sirinukunwattana K, 2021, GUT, V70, P544, DOI 10.1136/gutjnl-2019-319866; Sirinukunwattana K, 2017, MED IMAGE ANAL, V35, P489, DOI 10.1016/j.media.2016.08.008; Sirinukunwattana K, 2016, IEEE T MED IMAGING, V35, P1196, DOI 10.1109/TMI.2016.2525803; Skrede OJ, 2020, LANCET, V395, P350, DOI 10.1016/S0140-6736(19)32998-8; Song Z, 2020, NAT COMMUN, V11; Srinidhi CL, 2021, MED IMAGE ANAL, V67, DOI 10.1016/j.media.2020.101813; Staartjes VE, 2020, SPINE J, V20, P1159, DOI 10.1016/j.spinee.2020.02.016; Strom P, 2020, LANCET ONCOL, V21, P222, DOI 10.1016/S1470-2045(19)30738-7; Swiderska-Chadaj Z, 2019, MED IMAGE ANAL, V58, DOI 10.1016/j.media.2019.101547; Syrykh C, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0272-0; Tabibu S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46718-3; Tellez D, 2019, MED IMAGE ANAL, V58, DOI 10.1016/j.media.2019.101544; Tellez D, 2021, IEEE T PATTERN ANAL, V43, P567, DOI 10.1109/TPAMI.2019.2936841; Tellez D, 2018, IEEE T MED IMAGING, V37, P2126, DOI 10.1109/TMI.2018.2820199; US Food & Drug Administration (FDA), PROP REG FRAM MOD AR; Valkonen M, 2020, IEEE T MED IMAGING, V39, P534, DOI 10.1109/TMI.2019.2933656; Wang D., 2016, DEEP LEARNING IDENTI; Wang X, 2020, IEEE T CYBERNETICS, V50, P3950, DOI 10.1109/TCYB.2019.2935141; Wei JW, 2019, SCI REP-UK, V9; Wong GLH, 2021, J GASTROEN HEPATOL, V36, P543, DOI 10.1111/jgh.15385; Wulczyn E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233678; Xu G, 2019, IEEE I CONF COMP VIS, P10681, DOI 10.1109/ICCV.2019.01078; Yang H, 2020, IEEE T MED IMAGING, V39, P1306, DOI 10.1109/TMI.2019.2948026; Yu KH, 2018, NAT BIOMED ENG, V2, P719, DOI 10.1038/s41551-018-0305-z; Zhang ZZ, 2019, NAT MACH INTELL, V1, P236, DOI 10.1038/s42256-019-0052-1; Zheng YS, 2021, IEEE J BIOMED HEALTH, V25, P337, DOI 10.1109/JBHI.2020.2983206; Zhou C, 2021, COMPUT MED IMAG GRAP, V88; Zwanenburg A, 2020, RADIOLOGY, V295, P328, DOI 10.1148/radiol.2020191145	144	98	98	24	73	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					775	784		10.1038/s41591-021-01343-4	http://dx.doi.org/10.1038/s41591-021-01343-4			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33990804				2023-01-03	WOS:000650698900017
J	Nordin, FJ; Pearanpan, L; Chan, KM; Kumolosasi, E; Yong, YK; Shaari, K; Rajab, NF				Nordin, Fariza Juliana; Pearanpan, Lishantini; Chan, Kok Meng; Kumolosasi, Endang; Yong, Yoke Keong; Shaari, Khozirah; Rajab, Nor Fadilah			Immunomodulatory potential of Clinacanthus nutans extracts in the co-culture of triple-negative breast cancer cells, MDA-MB-231, and THP-1 macrophages	PLOS ONE			English	Article							TUMOR MICROENVIRONMENT; PROGRESSION; MEDIATORS	Triple-negative breast cancer is the main type of breast carcinoma that causes mortality among women because of the limited treatment options and high recurrence. Chronic inflammation has been linked with the tumor microenvironment (TME) in breast cancer progression. Clinacanthus nutans (CN) has gained much attention because of its anticancer properties, but its mechanism remains unclear. We aimed to study the qualitative phytochemical content and elucidate the cytotoxicity effects of CN on human triple-negative breast cancer (TNBC), MDA-MB-231 and human macrophage-like cells such as THP-1 by using sulforhodamine B (SRB) assay. As highly metastatic cells, MDA-MB-231 cells can migrate to the distal position, the effect of CN on migration were also elucidated using the scratch assay. The CN effects on ameliorating chronic inflammation in TME were studied following the co-culture of MDA-MB-231/THP-1 macrophages. The cytokine expression levels of IL-6, IL-1 beta and tumor necrosis factor-alpha (TNF-alpha) were determined using ELISA assays. The results showed that both ethanolic and aqueous CN extracts contained alkaloid, phenol and tannin, flavonoid, terpenoid, glycoside and steroid. However, saponin was only found in the aqueous extract of CN. CN was not cytotoxic to both MDA-MB-231 and THP-1 cells. The ability of MDA-MB-231 to migrate was also not halted by CN treatment. However, CN ethanol extract decreased IL-6 at 25 mu g/mL (p = 0.02) and 100 mu g/mL (p = 0.03) but CN aqueous extract increased IL-6 expression at 50 mu g/mL (p = 0.08) and 100 mu g/mL (p = 0.02). IL-1 beta showed decreased expression after treated with CN ethanol and CN aqueous both at 25 mu g/mL (p = 0.03). TNF-alpha were significantly decreased after CN ethanol treatment at concentration 25- (p = 0.001), 50- (p = 0.000) and 100 mu g/mL (p = 0.000). CN aqueous extract slightly inhibited TNF-alpha at all 25-50- and 100 mu g/mL (p = 0.001, p = 0.000, p = 0.000, respectively). Overall, CN acts by ameliorating the pro-inflammatory condition in the TME and may be a potential strategy for its anticancer mechanism on highly metastatic breast cancer condition. The major pathways that link both cancer and inflammation were NF-kappa B and STATs thus further study on the upstream and downstream pathways is needed to fully understand the mechanism of CN extracts in cooling the inflamed TME in breast cancer.	[Nordin, Fariza Juliana; Pearanpan, Lishantini; Rajab, Nor Fadilah] Univ Kebangsaan Malaysia, Fac Hlth Sci, Ctr Hlth Aging & Wellness, Biomed Sci Program, Kuala Lumpur, Malaysia; [Chan, Kok Meng] Univ Kebangsaan Malaysia, Fac Hlth Sci, Ctr Toxicol & Hlth Risk Studies, Kuala Lumpur, Malaysia; [Kumolosasi, Endang] Univ Kebangsaan Malaysia, Fac Pharm, Drug & Herbal Res Ctr, Kuala Lumpur, Malaysia; [Yong, Yoke Keong] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Human Anat, Seri Kembangan, Selangor, Malaysia; [Shaari, Khozirah] Univ Putra Malaysia, Fac Sci, Serdang, Seri Kembangan, Malaysia	Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia	Rajab, NF (corresponding author), Univ Kebangsaan Malaysia, Fac Hlth Sci, Ctr Hlth Aging & Wellness, Biomed Sci Program, Kuala Lumpur, Malaysia.	nfadilah@ukm.edu.my	Chan, Kok Meng/AAG-2296-2019; Nordin, Fariza Juliana/AAL-9786-2021	Nordin, Fariza Juliana/0000-0002-0178-1182; Yong, Yoke Keong/0000-0002-9442-7456	NKRA Research Grant Scheme (NRGS) from Ministry of Agriculture [NH1014D071]	NKRA Research Grant Scheme (NRGS) from Ministry of Agriculture	This research was financially supported by NKRA Research Grant Scheme (NRGS) from Ministry of Agriculture (Grant number NH1014D071) URL: https://www.mafi.gov.my/.The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abd Samat NMA, 2020, MOLECULES, V25, DOI 10.3390/molecules25122833; Altan-Bonnet G, 2019, NAT REV IMMUNOL, V19, P205, DOI 10.1038/s41577-019-0131-x; Amaral R., 2019, CLIN ONCOL-US, V4, P1562; Arullappan S, 2014, TROP J PHARM RES, V13, P1455, DOI 10.4314/tjpr.v13i9.11; Aslam MS, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/4685246; Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009; Chen K, 2020, DATA BRIEF, V28, DOI 10.1016/j.dib.2019.104798; Chen YX, 2019, EXP CELL RES, V378, P41, DOI 10.1016/j.yexcr.2019.03.005; Ng CT, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2270-1; Cortes J, 2019, FUTURE ONCOL, V15, P1951, DOI 10.2217/fon-2019-0059; Cruceriu D, 2020, CELL ONCOL, V43, P1, DOI 10.1007/s13402-019-00489-1; Cui GL, 2018, PATHOL RES PRACT, V214, P986, DOI 10.1016/j.prp.2018.05.011; Cyprian FS, 2019, BOSNIAN J BASIC MED, V19, P227, DOI 10.17305/bjbms.2019.4204; Dean SJR, 2014, MALAYS J PATHOL, V36, P155; Deshmukh SK, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.09.68; Mercogliano MF, 2021, CANCERS, V13, DOI 10.3390/cancers13030564; Fong SY, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1348-x; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Ghasemzadeh A, 2014, MOLECULES, V19, P17632, DOI 10.3390/molecules191117632; Gun SY, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2019.101174; Ham Boram, 2016, Trends Cancer Res, V11, P1; Ham IH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0972-8; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Haron Nor Hasyimah, 2019, Asian Pac J Cancer Prev, V20, P601, DOI 10.31557/APJCP.2019.20.2.601; Hii LW, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2663-9; Holbeck SL, 2010, MOL CANCER THER, V9, P1451, DOI 10.1158/1535-7163.MCT-10-0106; Huang YL, 2016, CURR CANCER DRUG TAR, V16, P765, DOI 10.2174/1568009616666160216130755; Hubalek M, 2017, BREAST CARE, V12, P8, DOI 10.1159/000455820; Intan Soraya C. S., 2015, African Journal of Pharmacy and Pharmacology, V9, P861; Jin K, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0981-3; Khoo LW, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/9276260; Khoo LW, 2015, PHYTOCHEM LETT, V14, P123, DOI 10.1016/j.phytol.2015.09.015; Kong HS., 2019, ASM SC J, V2019, P12, DOI [10.32802/asmscj.2019.87, DOI 10.32802/ASMSCJ.2019.87]; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Korneev KV, 2017, CYTOKINE, V89, P127, DOI 10.1016/j.cyto.2016.01.021; Lage OM, 2018, MAR DRUGS, V16, DOI 10.3390/md16080279; Landskron G, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/149185; Leong LM, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/2091085; Liu Q, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317712445; Liu SH, 2019, PHYS CHEM CHEM PHYS, V21, P23501, DOI 10.1039/c9cp03803e; Mai CW, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00007; Maimela NR, 2019, COMPUT STRUCT BIOTEC, V17, P1, DOI 10.1016/j.csbj.2018.11.004; Mantovani A, 2018, IMMUNOL REV, V281, P57, DOI 10.1111/imr.12614; Masjedi A, 2018, BIOMED PHARMACOTHER, V108, P1415, DOI 10.1016/j.biopha.2018.09.177; Mittal S, 2018, EXPERT REV MOL DIAGN, V18, P227, DOI 10.1080/14737159.2018.1439382; Monga M, 2002, LEUKEMIA, V16, P520, DOI 10.1038/sj.leu.2402464; Montfort A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01818; Mutazah R, 2020, FOOD CHEM TOXICOL, V135, DOI 10.1016/j.fct.2019.110869; Orellana Esteban A, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1984; Osipov A, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0667-0; Pan SY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/627375; Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912; Quah Suk Yen, 2017, Drug Metabolism and Personalized Therapy, V32, P59, DOI 10.1515/dmpt-2016-0034; Rosli NHM., 2018, J SAINS KESIHAT MALA, V16, P95, DOI [10.17576/JSKM-2018-14, DOI 10.17576/JSKM-2018-14]; Shen ZT, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0048-x; Siew YY, 2014, J ETHNOPHARMACOL, V155, P1450, DOI 10.1016/j.jep.2014.07.024; Smith Michael P, 2015, Bio Protoc, V5; Soave DF, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8910520; Son B, 2017, ONCOTARGET, V8, P3933, DOI 10.18632/oncotarget.13907; Speciale A, 2011, CURR MOL MED, V11, P770, DOI 10.2174/156652411798062395; Thornburg CC, 2018, ACS CHEM BIOL, V13, P2484, DOI 10.1021/acschembio.8b00389; Vajrabhaya La-Ongthong, 2016, Eur J Dent, V10, P134, DOI 10.4103/1305-7456.175701; Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456-017-9562-9; Voronov E, 2017, CURR PHARM DESIGN, V23, P4893, DOI 10.2174/1381612823666170613080919; Waks AG, 2019, JAMA-J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323; Wang J, 2019, CANCER MED-US, V8, P4709, DOI 10.1002/cam4.2327; Wang M, 2019, ONCOTARGETS THER, V12, P5741, DOI 10.2147/OTT.S199605; Wu C, 2020, J NAT PROD, V83, P552, DOI 10.1021/acs.jnatprod.9b00949; Yen HK, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-295; Yian ShimSiang, 2013, International Journal of Integrative Biology, V14, P7; Yin SY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/302426; Yong YK, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/462751; Yuan HD, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559; Zou MZ, 2019, ADV MATER, V31, DOI 10.1002/adma.201904495; Zulkipli IN, 2017, PHARM BIOL, V55, P1093, DOI 10.1080/13880209.2017.1288749	75	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256012	10.1371/journal.pone.0256012	http://dx.doi.org/10.1371/journal.pone.0256012			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY8KW	34379689	Green Published, gold, Green Accepted			2023-01-03	WOS:000684029800031
J	Rennert-May, E; Leal, J; Thanh, NX; Lang, E; Dowling, S; Manns, B; Wasylak, T; Ronksley, PE				Rennert-May, Elissa; Leal, Jenine; Thanh, Nguyen Xuan; Lang, Eddy; Dowling, Shawn; Manns, Braden; Wasylak, Tracy; Ronksley, Paul E.			The impact of COVID-19 on hospital admissions and emergency department visits: A population-based study	PLOS ONE			English	Article							CARE	Background As a result of the novel coronavirus disease 2019 (COVID-19), there have been widespread changes in healthcare access. We conducted a retrospective population-based study in Alberta, Canada (population 4.4 million), where there have been approximately 1550 hospital admissions for COVID-19, to determine the impact of COVID-19 on hospital admissions and emergency department (ED visits), following initiation of a public health emergency act on March 15, 2020. Methods We used multivariable negative binomial regression models to compare daily numbers of medical/surgical hospital admissions via the ED between March 16-September 23, 2019 (pre COVID-19) and March 16-September 23, 2020 (post COVID-19 public health measures). We compared the most frequent diagnoses for hospital admissions pre/post COVID-19 public health measures. A similar analysis was completed for numbers of daily ED visits for any reason with a particular focus on ambulatory care sensitive conditions (ACSC). Findings There was a significant reduction in both daily medical (incident rate ratio (IRR) 0.86, p<0.001) and surgical (IRR 0.82, p<0.001) admissions through the ED in Alberta post COVID-19 public health measures. There was a significant decline in daily ED visits (IRR 0.65, p<0.001) including ACSC (IRR 0.75, p<0.001). The most common medical/surgical diagnoses for hospital admissions did not vary substantially pre and post COVID-19 public health measures, though there was a significant reduction in admissions for chronic obstructive pulmonary disease and a significant increase in admissions for mental and behavioral disorders due to use of alcohol. Conclusions Despite a relatively low volume of COVID-19 hospital admissions in Alberta, there was an extensive impact on our healthcare system with fewer admissions to hospital and ED visits. This work generates hypotheses around causes for reduced hospital admissions and ED visits which warrant further investigation. As most publicly funded health systems struggle with health-system capacity routinely, understanding how these reductions can be safely sustained will be critical.	[Rennert-May, Elissa; Leal, Jenine; Manns, Braden; Ronksley, Paul E.] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada; [Rennert-May, Elissa; Leal, Jenine] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada; [Rennert-May, Elissa; Manns, Braden] Univ Calgary, Dept Med, Calgary, AB, Canada; [Rennert-May, Elissa; Leal, Jenine; Manns, Braden; Ronksley, Paul E.] Univ Calgary, OBrien Inst Publ Hlth, Calgary, AB, Canada; [Rennert-May, Elissa] Univ Calgary, Snyder Inst Chron Dis, Calgary, AB, Canada; [Leal, Jenine] Alberta Hlth Serv, Infect Prevent & Control, Calgary, AB, Canada; [Thanh, Nguyen Xuan; Wasylak, Tracy] Alberta Hlth Serv, Strateg Clin Networks, Calgary, AB, Canada; [Lang, Eddy; Dowling, Shawn] Univ Calgary, Dept Emergency Med, Calgary, AB, Canada; [Manns, Braden] Univ Calgary, Libin Cardiovasc Inst, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary; Alberta Health Services (AHS); University of Calgary; Alberta Health Services (AHS); University of Calgary; University of Calgary; Libin Cardiovascular Institute Of Alberta; University of Calgary	Ronksley, PE (corresponding author), Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada.; Ronksley, PE (corresponding author), Univ Calgary, OBrien Inst Publ Hlth, Calgary, AB, Canada.	peronksl@ucalgary.ca		Rennert-May, Elissa/0000-0001-9884-6423				Alberta Health Services, IND DEF; Brusselaers N, 2017, METHOD INFORM MED, V56, P401, DOI 10.3414/ME17-01-0051; Canadian Institute for Health Information, DAT QUAL DOC DISCH A; De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166; Foulds JA, 2015, J AFFECT DISORDERS, V185, P47, DOI 10.1016/j.jad.2015.06.024; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Kadoglou NPE, 2017, HEART FAIL REV, V22, P329, DOI 10.1007/s10741-017-9614-7; Ko FW, 2016, RESPIROLOGY, V21, P1152, DOI 10.1111/resp.12780; Kontopantelis E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2750; MacIntyre CR, 2020, LANCET, V395, P1950, DOI 10.1016/S0140-6736(20)31183-1; Mitchell RD, 2020, EMERG MED AUSTRALAS, V32, P1027, DOI 10.1111/1742-6723.13606; Pollard MS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.22942; Sporinova B, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.9910; Lima CKT, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112915; University of Manitoba, RES INT WEIGHTS RIW; Webster P, 2020, LANCET, V395, P1180, DOI 10.1016/S0140-6736(20)30818-7; Wong LE, 2020, NEJM CATALYST INNOV, V14, DOI [DOI 10.1056/CAT.20.0193, 10.1056/CAT.20.0193]; Wongtanasarasin W, 2021, EMERG MED AUSTRALAS, V33, P316, DOI 10.1111/1742-6723.13666; worldometers, COVID 19 COR PAND 20	20	33	33	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	6							e0252441	10.1371/journal.pone.0252441	http://dx.doi.org/10.1371/journal.pone.0252441			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SL3JC	34061888	gold, Green Published			2023-01-03	WOS:000656813600036
J	Yalew, M; Adane, B; Arefaynie, M; Kefale, B; Damtie, Y; Mitiku, K; Agmas, A; Biset, G; Alene, TD; Adane, M; Addisu, E; Dewau, R				Yalew, Melaku; Adane, Bezawit; Arefaynie, Mastewal; Kefale, Bereket; Damtie, Yitayish; Mitiku, Kefale; Agmas, Amare; Biset, Gebeyaw; Alene, Tilahun Dessie; Adane, Metadel; Addisu, Elsabeth; Dewau, Reta			Menstrual hygiene practice among female adolescents and its association with knowledge in Ethiopia: A systematic review and meta-analysis	PLOS ONE			English	Review							REPRODUCTIVE HEALTH	Background Previous studies on menstrual hygiene practice were largely inconsistent and single national evidence is required. Thus, this study aimed to assess the pooled prevalence of menstrual hygiene and its association with knowledge about menstrual hygiene among female adolescents in Ethiopia. Methods The study was designed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-2015 Guidelines). This systematic review included studies conducted on female adolescents in Ethiopia irrespective of their publication and study period until the end of July 1, 2020. The data extracted in the Microsoft Excel sheet format was exported into the STATA/SE14 version statistical software for further analysis. I-2 test was used to test heterogeneity and publication bias was assessed by using Egger's weighted regression test. Results Thirteen full-text articles including 6907 participants were included in this systematic review and meta-analysis. Using the random effect model, the pooled prevalence of poor menstrual hygiene practice was 48.98% [95% CI: (36.42, 61.53)]. Those female adolescents who had poor knowledge were 2.6 times more likely to have poor menstrual hygiene practice as compared to counterparts [AOR = 2.61, 95% CI: (1.45, 4.72)]. Conclusions The prevalence of poor menstrual hygiene practice was high and knowledge regarding menstrual hygiene was significantly associated with poor menstrual hygiene practice. Information education communication and behavioral change communication at all levels of education should be the primary focus area of the government.	[Yalew, Melaku; Arefaynie, Mastewal; Kefale, Bereket; Dewau, Reta] Wollo Univ, Sch Publ Hlth, Dept Reprod & Family Hlth, Coll Med & Hlth Sci, Dessie, Ethiopia; [Adane, Bezawit; Dewau, Reta] Wollo Univ, Sch Publ Hlth, Dept Epidemiol & Biostatist, Coll Med & Hlth Sci, Dessie, Ethiopia; [Kefale, Bereket] Wollo Univ, Sch Med, Dept Physiol, Coll Med & Hlth Sci, Dessie, Ethiopia; [Agmas, Amare] Wollo Univ, Sch Med, Dept Anesthesia, Coll Med & Hlth Sci, Dessie, Ethiopia; [Biset, Gebeyaw] Wollo Univ, Sch Nursing & Midwifery, Dept Pediat Nurse, Coll Med & Hlth Sci, Dessie, Ethiopia; [Alene, Tilahun Dessie] Wollo Univ, Sch Med, Dept Pediat, Coll Med & Hlth Sci, Dessie, Ethiopia; [Adane, Metadel] Wollo Univ, Dept Environm Hlth, Coll Med & Hlth Sci, Dessie, Ethiopia	University of Gondar; University of Gondar; University of Gondar; University of Gondar; University of Gondar; University of Gondar; University of Gondar	Adane, B (corresponding author), Wollo Univ, Sch Publ Hlth, Dept Epidemiol & Biostatist, Coll Med & Hlth Sci, Dessie, Ethiopia.	adanebeza1987@gmail.com	Biset, Gebeyaw/ABQ-3538-2022; Adane, Metadel/AFQ-9478-2022; Arefaynie, Mastewal/AAZ-8374-2021	Biset, Gebeyaw/0000-0002-8953-5022; Adane, Metadel/0000-0002-7039-4768; Arefaynie, Mastewal/0000-0001-9525-0552; Kefale Abitew, Bereket/0000-0003-1795-9886				Abay Fisseha M., 2017, COMPUT BIOL BIOINFOR, V5, P6; Adinma Echendu Dolly, 2008, Afr J Reprod Health, V12, P74; Anchebi H., 2017, J WOMENS HLTH CARE, V6, P1, DOI [DOI 10.4172/2167-0420.1000370, 10.4172/2167-0420.1000370]; Aniebue UU, 2009, PAN AFR MED J, V2; Asha AC., 2019, ASIAN J MED BIOL RES, V5, P126, DOI [10.3329/ajmbr.v5i2.42494, DOI 10.3329/AJMBR.V5I2.42494]; Azage M., 2018, NW ETHIOPIA ETHIOPIA, V10; Balat MS, 2019, EDUCATION, V16, P2; Bano R, 2015, INT J WOMEN HEAL REP, V3, P31, DOI 10.15296/ijwhr.2015.06; Bathija G., 2013, INT J BIOMED RES, V4, P95; Bekele F., 2018, J HLTH MEDICAL SCI, V1, P71; Belayneh Z, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7973-9; Beweleyir J., 2018, EUR SCI J, V14, P467, DOI 10.19044/esj.2018.v14n36p467; Bhusal Chet Kant, 2020, Adv Prev Med, V2020, P1292070, DOI 10.1155/2020/1292070; Biruk E., 2018, ASSESSMENT MENSTRUAL, DOI [10.1101/450007, DOI 10.1101/450007]; Das P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130777; Dasgupta A, 2008, Indian J Community Med, V33, P77, DOI 10.4103/0970-0218.40872; DerSimonian R, 2015, CONTEMP CLIN TRIALS, V45, P139, DOI 10.1016/j.cct.2015.09.002; Deshmukh V., 2019, INT J REPROD CONTRAC, V8, P980; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; El-Mowafy RI., 2014, IOSR J NURSING HLTH, V3, P48, DOI DOI 10.9790/1959-03614855; Fehintola FO., 2017, INT J REPROD CONTRAC, V6, P1726, DOI DOI 10.18203/2320-1770.ijrcog20171932; Felleke AA., 2020, ASSESSMENT MENSTRUAL, DOI [10.1101/2020.03.16.20036913, DOI 10.1101/2020.03.16.20036913]; Gedefaw G., REV 2019 SEP; Gultie T.K., 2014, SCI J PUBLIC HLTH, V2, P189, DOI DOI 10.11648/J.SJPH.20140203.18; Gupta M., AGE YEARS, V10, P54, DOI [10.18231/j.pjms.2019.012, DOI 10.18231/J.PJMS.2019.012]; Hennegan J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012596; Hennegan J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146985; Jothy K, 2012, ELIXIR SOCIAL SCI, V44, P7223; Katkuri S., 2014, J PHARM BIOMEDICAL S, V4, P298; Kaur R, 2018, J ENVIRON PUBLIC HEA, V2018, DOI 10.1155/2018/1730964; Kitesa B., 2016, INT J IMMUNOL, V4, P52, DOI [DOI 10.11648/J.IJI.20160406.12, 10.11648/j.iji.20160406.12]; Kumar Gunjan, 2017, J Family Med Prim Care, V6, P730, DOI 10.4103/jfmpc.jfmpc_24_17; McMahon SA, 2011, BMC INT HEALTH HUM R, V11, DOI 10.1186/1472-698X-11-7; Mekie M, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4644-y; Mohammed Shamsudeen, 2020, Int J Reprod Med, V2020, P6872491, DOI 10.1155/2020/6872491; Moola S., 2017, CHECKL SYST REV RES, V5, DOI DOI 10.17221/96/2009-CJGPB; Munn Z, 2015, INT J EVID-BASED HEA, V13, P147, DOI 10.1097/XEB.0000000000000054; Nahar N.S., 2019, INT J REPROD CONTRAC, V8, P5, DOI [10.18203/2320-1770.ijrcog20191930, DOI 10.18203/2320-1770.IJRCOG20191930]; Nakirya PO, 2019, KNOWLEDGE ATTITUDE P; Nazir S., 2019, J SOC OBSTET GYNAECO, V9, P164; Neelkanth N., 2017, INT J COMMUNITY MED, V4, P4520, DOI [10.18203/2394-6040.ijcmph20175323, DOI 10.18203/2394-6040.IJCMPH20175323]; Neginhal VS, 2010, KNOWLEDGE ATTITUDE P; Neupane MS., 2020, J CHITWAN MED COLL, V10, P69, DOI 10.3126/jcmc.v10i1.28075; Oli MK., HOSPITAL, V178, P59; Ranabhat D.R., 2019, NEPAL MED COLL J, V21, P258, DOI [10.3126/nmcj.v21i4.27614, DOI 10.3126/NMCJ.V21I4.27614]; Rorir E, 2018, PAN AFR MED J, V31, DOI 10.11604/pamj.2018.31.222.13521; Sahu I, 2019, IMANAGERS J NURS, V9, P24, DOI 10.26634/jnur.9.4.16646; Shallo SA., 2019, MENSTRUAL HYGIENE MA, DOI [10.1101/806422, DOI 10.1101/806422]; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647; Sommer M, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001962; Sommer M, 2013, AM J PUBLIC HEALTH, V103, P1556, DOI 10.2105/AJPH.2013.301374; Tegegne TK, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1118; Upashe SP, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0245-7; van Eijk AM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010290; Vashisht A, 2018, J FAM COMMUNITY MED, V25, P163, DOI 10.4103/jfcm.JFCM_161_17; World Health Organization, 2018, ENGAGING YOUNG PEOPL; Yadav Ram Naresh, 2018, J Nepal Health Res Counc, V15, P212	57	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2021	16	8							e0254092	10.1371/journal.pone.0254092	http://dx.doi.org/10.1371/journal.pone.0254092			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6IY	34347782	Green Published, gold			2023-01-03	WOS:000685264900060
J	Jones, JE; Damery, SL; Allen, K; Johnson, DW; Lambie, M; Holvoet, E; Davies, SJ				Jones, Janet E.; Damery, Sarah L.; Allen, Kerry; Johnson, David W.; Lambie, Mark; Holvoet, Els; Davies, Simon J.			Renal staffs' understanding of patients' experiences of transition from peritoneal dialysis to in-centre haemodialysis and their views on service improvement: A multi-site qualitative study in England and Australia	PLOS ONE			English	Article							TECHNIQUE SURVIVAL; DISEASE; TIME; CARE	Introduction Many studies have explored patients' experiences of dialysis and other treatments for kidney failure. This is the first qualitative multi-site international study of how staff perceive the process of a patient's transition from peritoneal dialysis to in-centre haemodialysis. Current literature suggests that transitions are poorly coordinated and may result in increased patient morbidity and mortality. This study aimed to understand staff perspectives of transition and to identify areas where clinical practice could be improved. Methods Sixty-one participants (24 UK and 37 Australia), representing a cross-section of kidney care staff, took part in seven focus groups and sixteen interviews. Data were analysed inductively and findings were synthesised across the two countries. Results For staff, good clinical practice included: effective communication with patients, well planned care pathways and continuity of care. However, staff felt that how they communicated with patients about the treatment journey could be improved. Staff worried they inadvertently made patients fear haemodialysis when trying to explain to them why going onto peritoneal dialysis first is a good option. Despite staff efforts to make transitions smooth, good continuity of care between modalities was only reported in some of the Australian hospitals where, unlike the UK, patients kept the same consultant. Timely access to an appropriate service, such as a psychologist or social worker, was not always available when staff felt it would be beneficial for the patient. Staff were aware of a disparity in access to kidney care and other healthcare professional services between some patient groups, especially those living in remote areas. This was often put down to the lack of funding and capacity within each hospital. Conclusions This research found that continuity of care between modalities was valued by staff but did not always happen. It also highlighted a number of areas for consideration when developing ways to improve care and provide appropriate support to patients as they transition from peritoneal dialysis to in-centre haemodialysis.	[Jones, Janet E.; Damery, Sarah L.] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Allen, Kerry] Univ Birmingham, Hlth Serv Management Ctr, Birmingham, W Midlands, England; [Johnson, David W.] Princess Alexandra Hosp, Dept Nephrol, Brisbane, Qld, Australia; [Lambie, Mark; Davies, Simon J.] Keele Univ, Fac Med & Hlth Sci, Staffordshire, England; [Holvoet, Els] Ghent Univ Hosp, Renal Div, Ghent, Belgium; [Johnson, David W.] Univ Queensland, Australasian Kidney Trials Network, Brisbane, Qld, Australia; [Johnson, David W.] Translat Res Inst, Brisbane, Qld, Australia	University of Birmingham; University of Birmingham; Keele University; Ghent University; Ghent University Hospital; University of Queensland	Jones, JE (corresponding author), Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.	j.e.jones@bham.ac.uk	Damery, Sarah/ABA-8641-2021; Johnson, David/F-2897-2011	Damery, Sarah/0000-0003-3681-8608; Lambie, Mark/0000-0002-6285-5368; Jones, Janet/0000-0002-9057-6956; Johnson, David/0000-0001-5491-3460	Baxter Global Grant Program; National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM); Australian National Health and Medical Research Council Leadership Investigator Grant; University of Birmingham	Baxter Global Grant Program; National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM); Australian National Health and Medical Research Council Leadership Investigator Grant(National Health and Medical Research Council (NHMRC) of Australia); University of Birmingham	This work was undertaken as part of the INTEGRATED consortium, funded by the Baxter Global Grant Program awarded to DWJ, ML and SJD (no associated grant number). SLD and JEJ were supported by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM), now recommissioned as NIHR Applied Research Collaboration West Midlands (NIHR ARC WM) (https://nihr.ac.uk/).The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. DWJ is supported by an Australian National Health and Medical Research Council Leadership Investigator Grant (https://www.nhmrc.gov.au/funding/find-funding/investigator-grants).The study was sponsored by University of Birmingham. The funders and sponsors had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen K, 2022, PERITON DIALYSIS INT, V42, P297, DOI 10.1177/0896860820975596; [Anonymous], 2004, NATL SERVICE FRAMEWO; Boissinot L, 2013, PERITON DIALYSIS INT, V33, P391, DOI 10.3747/pdi.2011.00134; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Chan C, 2019, PERITON DIALYSIS INT, V39, P4, DOI 10.3747/pdi.2017.00242; Chaudhary K, 2011, CLIN J AM SOC NEPHRO, V6, P447, DOI 10.2215/CJN.07920910; Chuengsaman P, 2017, SEMIN NEPHROL, V37, P287, DOI 10.1016/j.semnephrol.2017.02.008; Combes G, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0344-8; Ghaffari A, 2013, SEMIN DIALYSIS, V26, P706, DOI 10.1111/sdi.12125; Guo A, 2003, KIDNEY INT, V64, pS3, DOI 10.1046/j.1523-1755.2003.08801.x; Guthrie B, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a867; Heaf JG, 2002, NEPHROL DIAL TRANSPL, V17, P112, DOI 10.1093/ndt/17.1.112; Holvoet E, 2020, PERITON DIALYSIS INT, V40, P548, DOI 10.1177/0896860819896219; Hughes JT, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225722; Hutchinson TA, 2005, PALLIATIVE MED, V19, P270, DOI 10.1191/0269216305pm1028oa; Kolesnyk I, 2010, PERITON DIALYSIS INT, V30, P170, DOI 10.3747/pdi.2008.00277; Kralik D, 2006, J ADV NURS, V55, P320, DOI 10.1111/j.1365-2648.2006.03899.x; Meleis AI, 2000, ADV NURS SCI, V23, P12, DOI 10.1097/00012272-200009000-00006; NICE, 2020, RENAL REPLACEMENT TH; Nicholls M.C., 2014, QUALITATIVE RES PRAC, P177, DOI DOI 10.1186/1745-6215-14-166; Nicoll R, 2018, NEPHROLOGY, V23, P389, DOI 10.1111/nep.13198; O'Hare AM, 2018, AM J KIDNEY DIS, V71, P732, DOI 10.1053/j.ajkd.2017.11.022; Pancras G, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-1140-x; Perl J, 2012, CLIN J AM SOC NEPHRO, V7, P1145, DOI 10.2215/CJN.01480212; QSR International Pty Ltd, 2018, NVIVO 12 PLUS; Seekles M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-036931; Thomas DR, 2006, AM J EVAL, V27, P237, DOI 10.1177/1098214005283748; Thompson S, 2012, KIDNEY INT, V82, P352, DOI 10.1038/ki.2012.167; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Van Biesen W, 2000, J AM SOC NEPHROL, V11, P116, DOI 10.1681/ASN.V111116; Walker RC, 2016, NEPHROL DIAL TRANSPL, V31, P133, DOI 10.1093/ndt/gfv330	31	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2021	16	7							e0254931	10.1371/journal.pone.0254931	http://dx.doi.org/10.1371/journal.pone.0254931			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2NL	34280249	Green Published, gold, Green Accepted			2023-01-03	WOS:000678122000037
J	Kim, WY; Kweon, OJ; Cha, MJ; Baek, MS; Choi, SH				Kim, Won-Young; Kweon, Oh Joo; Cha, Min Jae; Baek, Moon Seong; Choi, Seong-Ho			Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study	PLOS ONE			English	Article							GLYCATION END-PRODUCTS; CLINICAL-OUTCOMES; SEPTIC SHOCK; RECEPTOR; IMMUNE; RAGE; ARDS	Dexamethasone provides benefits in patients with coronavirus disease 2019 (COVID-19), although data regarding immunological profiles and viral clearance are limited. This study aimed to evaluate for differences in biomarkers among patients with severe COVID-19 who did and did not receive dexamethasone. We measured plasma biomarkers of lung epithelial/endothelial injury and inflammation in 31 patients with severe COVID-19 and in 13 controls. Changes in biomarkers and clinical parameters were compared during the 7-day period among COVID-19 patients, and also according to dexamethasone use. Thirty-two patients with severe COVID-19 who received mechanical ventilation (n = 6), high-flow nasal cannula (n = 11), and supplemental oxygen (n = 15) were analyzed. Relative to controls, patients with severe COVID-19 had significantly higher concentrations of biomarkers related to glycocalyx shedding (endocan and syndecan-1), endothelial injury (von Willebrand factor), and inflammation (soluble receptor for advanced glycation end-products [sRAGE] and interleukin-6). The 7-day decreases in biomarkers of endothelial injury (angiopoietin-2 [Ang-2] and intercellular adhesion molecule-1 [ICAM-1]) and sRAGE, but not in the biomarker of lung epithelial injury (surfactant protein D), were correlated with decreases in C-reactive protein and radiologic score at day 7. Twenty patients (63%) received dexamethasone, and the dexamethasone and non-dexamethasone groups differed in terms of disease severity. However, dexamethasone was associated marginally with increased SpO(2)/FiO(2) and significantly with decreases in C-reactive protein and radiologic score after adjusting for baseline imbalances. Furthermore, the dexamethasone group exhibited a significant decrease in the concentrations of Ang-2, ICAM-1, soluble form of the Tie2 receptor (a biomarker of glycocalyx shedding), and sRAGE. Both groups exhibited a clinically insignificant increase in the cycle threshold value. Severe COVID-19 may be characterized by more severe endothelial injury and inflammation, and less severe lung epithelial injury. There is a possibility that dexamethasone improved severe COVID-19 and related endothelial injury without delaying viral clearance.	[Kim, Won-Young; Baek, Moon Seong] Chung Ang Univ, Chung Ang Univ Hosp, Coll Med, Dept Internal Med,Div Crit Care Med, Seoul, South Korea; [Kweon, Oh Joo] Chung Ang Univ, Chung Ang Univ Hosp, Coll Med, Dept Lab Med, Seoul, South Korea; [Cha, Min Jae] Chung Ang Univ, Chung Ang Univ Hosp, Coll Med, Dept Radiol, Seoul, South Korea; [Choi, Seong-Ho] Chung Ang Univ, Chung Ang Univ Hosp, Coll Med, Dept Internal Med,Div Infect Dis, Seoul, South Korea	Chung Ang University; Chung Ang University Hospital; Chung Ang University; Chung Ang University Hospital; Chung Ang University; Chung Ang University Hospital; Chung Ang University; Chung Ang University Hospital	Choi, SH (corresponding author), Chung Ang Univ, Chung Ang Univ Hosp, Coll Med, Dept Internal Med,Div Infect Dis, Seoul, South Korea.	tobeservant@cau.ac.kr	Kim, Won-Young/AHE-5670-2022	Kim, Won-Young/0000-0002-6038-9818; Kweon, Oh Joo/0000-0003-4751-7384; Choi, Seong-Ho/0000-0001-8108-2412	National Research Foundation of Korea - Korea government (Ministry of Science, ICT and Future Planning) [2019R1C1C1006417]	National Research Foundation of Korea - Korea government (Ministry of Science, ICT and Future Planning)(National Research Foundation of Korea)	Seong-Ho Choi was supported by the National Research Foundation of Korea grant funded by the Korea government (Ministry of Science, ICT and Future Planning) (2019R1C1C1006417). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alhazzani Waleed, 2020, Crit Care Med, V48, pe440, DOI [10.1007/s00134-020-06022-5, 10.1097/CCM.0000000000004363]; Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478; Cain DW, 2017, NAT REV IMMUNOL, V17, P233, DOI 10.1038/nri.2017.1; Calfee CS, 2008, THORAX, V63, P1083, DOI 10.1136/thx.2008.095588; Calfee CS, 2015, CHEST, V147, P1539, DOI 10.1378/chest.14-2454; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chiappalupi S, 2021, LIFE SCI, V272, DOI 10.1016/j.lfs.2021.119251; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Dequin PF, 2020, JAMA-J AM MED ASSOC, V324, P1298, DOI 10.1001/jama.2020.16761; Dozio E, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113785; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; He X, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0869-5; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang R, 2020, EUR J PHARMACOL, V889, DOI 10.1016/j.ejphar.2020.173556; Kierdorf K, 2013, J LEUKOCYTE BIOL, V94, P55, DOI 10.1189/jlb.1012519; Leisman DE, 2020, INTENS CARE MED, V46, P1105, DOI 10.1007/s00134-020-06059-6; Li Q., 2020, NEW ENGL J MED, V382, P1199, DOI [10.1056/NEJMoa2001316, DOI 10.1056/NEJMOA2001316]; Lim A, 2021, ANN INTENSIVE CARE, V11, DOI 10.1186/s13613-021-00836-2; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Matsuyama T, 2020, CELL DEATH DIFFER, V27, P3209, DOI 10.1038/s41418-020-00633-7; Meduri GU, 2009, CHEST, V136, P1631, DOI 10.1378/chest.08-2408; Morelli A, 2013, JAMA-J AM MED ASSOC, V310, P1683, DOI 10.1001/jama.2013.278477; Park JH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02145; Perkins NJ, 2006, AM J EPIDEMIOL, V163, P670, DOI 10.1093/aje/kwj063; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617; Sarma Aartik, 2021, Res Sq, DOI 10.21203/rs.3.rs-141578/v1; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sinha P, 2020, JAMA INTERN MED, V180, P1152, DOI 10.1001/jamainternmed.2020.3313; Spadaro S, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03499-4; Stahl K, 2020, AM J RESP CRIT CARE, V202, P1178, DOI 10.1164/rccm.202007-2676LE; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021; Uchida T, 2006, AM J RESP CRIT CARE, V173, P1008, DOI 10.1164/rccm.200509-1477OC; Wang B, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.101300; Ware LB, 2013, CRIT CARE, V17, DOI 10.1186/cc13080; Warren MA, 2018, THORAX, V73, P840, DOI 10.1136/thoraxjnl-2017-211280; World Health Organization, COR DIS COVID 19 PAN; Xia HJ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108234; Kehribar DY, 2021, BIOMARKERS, V26, P114, DOI 10.1080/1354750X.2020.1861099; Ye ZK, 2020, CAN MED ASSOC J, V192, pE756, DOI 10.1503/cmaj.200645	44	20	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2021	16	7							e0254167	10.1371/journal.pone.0254167	http://dx.doi.org/10.1371/journal.pone.0254167			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9LR	34214123	Green Published, gold			2023-01-03	WOS:000671718200005
J	O'Brien, CJO; Domingos, AI				O'Brien, Conan J. O.; Domingos, Ana I.			An anti-obesity immunotherapy? Adipose tissue-resident macrophages promote lipid storage in mice but can be stopped with antibody treatment	SCIENCE			English	Editorial Material							CHEMOKINE RECEPTOR 2; BONE-MARROW; CCR2; RECRUITMENT; OBESITY; CELLS		[O'Brien, Conan J. O.; Domingos, Ana I.] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England	University of Oxford	Domingos, AI (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Oxford, England.	ana.domingos@dpag.ox.ac.uk		Domingos, Ana/0000-0002-7938-4814; O'Brien, Conan James Oliver/0000-0002-7419-4448				Camell CD, 2017, NATURE, V550, P119, DOI 10.1038/nature24022; Cox N, 2021, SCIENCE, V373; Han XP, 2020, NATURE, V581, P303, DOI 10.1038/s41586-020-2157-4; Ito A, 2008, J BIOL CHEM, V283, P35715, DOI 10.1074/jbc.M804220200; Kim J, 2016, MOL THER-NUCL ACIDS, V5, P1, DOI 10.1038/mtna.2015.51; Obstfeld AE, 2010, DIABETES, V59, P916, DOI 10.2337/db09-1403; Patsalos O, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00481; Perdiguero EG, 2016, NAT IMMUNOL, V17, P2, DOI 10.1038/ni.3341; Pirzgalska RM, 2017, NAT MED, V23, P1309, DOI 10.1038/nm.4422; Poggioli R, 2013, OBESITY, V21, pE415, DOI 10.1002/oby.20338; Pridans C, 2018, J IMMUNOL, V201, P2683, DOI 10.4049/jimmunol.1701783; Satoh T, 2013, NATURE, V495, P524, DOI 10.1038/nature11930; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Wei S, 2005, IMMUNOBIOLOGY, V210, P109, DOI 10.1016/j.imbio.2005.05.005; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335	15	1	1	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2021	373	6550			SI		24	25		10.1126/science.abj5072	http://dx.doi.org/10.1126/science.abj5072			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TP8KN	34210864				2023-01-03	WOS:000677843100010
J	Knight, A; Satchell, L				Knight, Andrew; Satchell, Liam			Vegan versus meat-based pet foods: Owner-reported palatability behaviours and implications for canine and feline welfare	PLOS ONE			English	Article							FEEDING-BEHAVIOR; VEGETARIAN DIETS; DOGS; CATS; OBESITY; PROTEIN; SIZE; DIGESTIBILITY; PREFERENCES; TEMPERATURE	Consumer suspicion of conventional pet foods, along with perceived health benefits of alternative diets, are fuelling development of the latter. These include raw meat diets, in vitro meat products, and diets based on novel protein sources such as terrestrial and marine plants, insects, yeast and fungi. However, some claim vegan diets may be less palatable, or may compromise animal welfare. We surveyed 4,060 dog or cat guardians to determine the importance to them of pet food palatability, and the degree to which their animals displayed specific behavioural indicators of palatability at meal times. Guardians were asked to choose one dog or cat that had been within their household for at least one year, and not on a prescription or therapeutic diet. Of 3,976 respondents who played some role in pet diet decision-making, palatability was the third most important among 12 factors cited as important when choosing pet diets. For 1,585 respondents feeding conventional or raw meat diets, who stated they would realistically consider alternative diets, palatability was the fourth most important among 14 desired attributes. For the 2,308 dogs included, reported observations of 10 behavioural indicators of palatability at meal times reliably indicated significant effects of increased reports of appetitive behaviour by dogs on a raw meat diet, as opposed to a conventional diet. There was no consistent evidence of a difference between vegan diets and either the conventional or raw meat diets. For the 1,135 cats included, reported observations of 15 behavioural indicators indicated that diet made little difference to food-oriented behaviour. Based on these owner-reported behaviours, our results indicate that vegan pet foods are generally at least as palatable to dogs and cats as conventional meat or raw meat diets, and do not compromise their welfare, when other welfare determinants, such as nutritional requirements, are adequately provided.	[Knight, Andrew; Satchell, Liam] Univ Winchester, Ctr Anim Welf, Winchester, Hants, England; [Knight, Andrew] Griffith Univ, Sch Environm & Sci, Nathan Campus, Nathan, Qld, Australia	University of Winchester; Griffith University	Knight, A (corresponding author), Univ Winchester, Ctr Anim Welf, Winchester, Hants, England.; Knight, A (corresponding author), Griffith Univ, Sch Environm & Sci, Nathan Campus, Nathan, Qld, Australia.	AndrewKnightVet@gmail.com	Knight, Andrew/AAA-3707-2020	Knight, Andrew/0000-0002-9753-6199	food awareness organisation ProVeg International;  [Oct2019-0000000286]	food awareness organisation ProVeg International; 	This research and its publication open access was funded by food awareness organisation ProVeg International (https://proveg.com).AK received this award ID: Oct20190000000286. However, this funder played no role in study conceptualisation, design, data collection and analysis, preparation of the resultant manuscript nor decisions relating to publication. We are grateful for their financial support.	Alegria-Moran RA, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9060372; Alegria-Moran RA, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9050219; Alexander P, 2020, GLOBAL ENVIRON CHANG, V65, DOI 10.1016/j.gloenvcha.2020.102153; American Pet Products Association (APPA), 2020, PET IND MARK SIZ OWN PET IND MARK SIZ OWN; Zafalon RVA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227046; [Anonymous], 2003, PETFOOD TECHNOLOGY; Association for Pet Obesity Prevention, 2019, 2018 PET OB RES 2018 PET OB RES; Becques A, 2014, APPL ANIM BEHAV SCI, V159, P55, DOI 10.1016/j.applanim.2014.07.003; Bedford E., 2020, NUMBER DOGS CATS KEP; Berridge KC, 1996, NEUROSCI BIOBEHAV R, V20, P1, DOI 10.1016/0149-7634(95)00033-B; Bradshaw JWS, 2006, J NUTR, V136, p1927S, DOI 10.1093/jn/136.7.1927S; Brambell Committee, 1965, REPORT TECHNICAL COM; Brown W. Y., 2009, RECENT ADV ANIM NUTR, V17, P137; Brown WY, 2009, BRIT J NUTR, V102, P1318, DOI 10.1017/S0007114509389254; Buff PR, 2014, J ANIM SCI, V92, P3781, DOI 10.2527/jas.2014-7789; Buffington CAT, 2002, J AM VET MED ASSOC, V220, P994, DOI 10.2460/javma.2002.220.994; CABANAC M, 1971, SCIENCE, V173, P1103, DOI 10.1126/science.173.4002.1103; Callon MC, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00154; Case LP., 2011, CANINE FELINE NUTR, V3rd ed, P191; Case LP, 2010, CANINE FELINE NUTR E; Davies RH, 2019, J SMALL ANIM PRACT, V60, P329, DOI 10.1111/jsap.13000; Deng P, 2015, J ANIM SCI, V93, P823, DOI 10.2527/jas.2014-8520; Di Donfrancesco B, 2018, J CEREAL SCI, V83, P42, DOI 10.1016/j.jcs.2018.07.011; Dodd S, 2020, VET REC, V186, DOI 10.1136/vr.105828; Dodd SAS, 2021, BMC VET RES, V17, DOI 10.1186/s12917-021-02754-8; Dodd SAS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210806; Dodd SAS, 2018, JAVMA-J AM VET MED A, V253, P1425, DOI 10.2460/javma.253.11.1425; Dunn TJ, 2014, BRIT J PSYCHOL, V105, P399, DOI 10.1111/bjop.12046; DURRER JL, 1962, AM J PHYSIOL, V202, P375, DOI 10.1152/ajplegacy.1962.202.2.375; Dust JM, 2005, J ANIM SCI, V83, P2414; Euromonitor International, 2015, MARK SIZ; FAWC, 2009, FARM ANIMAL WELFARE; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Ferket P.R., 2006, INT J POULT SCI, V5, P905, DOI 10.3923/IJPS.2006.905.911; Frantz LAF, 2020, NAT REV GENET, V21, P449, DOI 10.1038/s41576-020-0225-0; Freeman LM, 2013, JAVMA-J AM VET MED A, V243, P1549, DOI 10.2460/javma.243.11.1549; Fureix C, 2015, APPL ANIM BEHAV SCI, V162, P26, DOI 10.1016/j.applanim.2014.11.007; Galibert F, 2011, CR BIOL, V334, P190, DOI 10.1016/j.crvi.2010.12.011; German AJ, 2006, J NUTR, V136, p1940S, DOI 10.1093/jn/136.7.1940S; GITTLEMAN JL, 1991, J ZOOL, V225, P253, DOI 10.1111/j.1469-7998.1991.tb03815.x; Hall JA, 2018, J EXP BIOL, V221, DOI 10.1242/jeb.173450; Hall NJ, 2015, J COMP PSYCHOL, V129, P237, DOI 10.1037/a0039271; Hanson M, 2016, APPL ANIM BEHAV SCI, V181, P129, DOI 10.1016/j.applanim.2016.05.031; Heath S, 2014, VET CLIN N AM-SMALL, V44, P427, DOI 10.1016/j.cvsm.2014.01.003; HOUPT KA, 1978, CHEM SENS FLAV, V3, P281, DOI 10.1093/chemse/3.3.281; HOUPT KA, 1981, CAN VET J, V22, P77; Johnson ML, 1998, J ANIM SCI, V76, P1112; Kanakubo K, 2015, JAVMA-J AM VET MED A, V247, P385, DOI 10.2460/javma.247.4.385; Keller U, 2011, INT J VITAM NUTR RES, V81, P125, DOI 10.1024/0300-9831/a000059; Knight A., 2021, REDVET, V22, P1; Knight A, 2016, ANIMALS, V6, DOI 10.3390/ani6090057; Loeb J, 2020, VET REC, V186, P197, DOI 10.1136/vr.m663; Loeb J, 2019, VET REC, V185, P385, DOI 10.1136/vr.l5836; Lowe J. A., 1989, Biotechnology in the feed industry. Proceedings of Alltech's Fifth Annual Symposium., P209; de Brito CBM, 2010, ANIM FEED SCI TECH, V159, P150, DOI 10.1016/j.anifeedsci.2010.06.001; Martens P, 2019, BIOSCIENCE, V69, P467, DOI 10.1093/biosci/biz044; Mellor DJ, 2016, ANIMALS, V6, DOI 10.3390/ani6100059; Mellor DJ, 2016, ANIMALS, V6, DOI 10.3390/ani6030021; Mellor DJ, 1994, IMPROVING WELL BEING, P3; Mintel Group, 2019, PET FOOD UK SEPT 201 PET FOOD UK SEPT 201; Murphy M, 2016, VET CLIN N AM-SMALL, V46, P883, DOI 10.1016/j.cvsm.2016.04.009; O'Neill DG, 2021, BMC VET RES, V17, DOI 10.1186/s12917-021-02775-3; Okin GS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181301; OSBORNE SR, 1977, ANIM LEARN BEHAV, V5, P221, DOI 10.3758/BF03209232; Pet Food Manufacturers' Association, 2015, UNDERSTANDING ENERGY; Pires KA, 2020, RES VET SCI, V130, P247, DOI 10.1016/j.rvsc.2020.03.023; Quiniou N, 2000, LIVEST PROD SCI, V63, P245, DOI 10.1016/S0301-6226(99)00135-9; Sadek T, 2018, J FELINE MED SURG, V20, P1049, DOI 10.1177/1098612X18791877; Sagols E, 2019, RES VET SCI, V124, P375, DOI 10.1016/j.rvsc.2019.04.023; Salaun F, 2017, J ANIM PHYSIOL AN N, V101, P320, DOI 10.1111/jpn.12542; Savolainen S, 2016, VET J, V216, P53, DOI 10.1016/j.tvjl.2016.06.012; Scallan S., 2019, RKE ETHICS POLICY PR; Schipper LL, 2008, APPL ANIM BEHAV SCI, V114, P182, DOI 10.1016/j.applanim.2008.01.001; Schleicher M, 2019, CAN VET J, V60, P644; Schlesinger DP, 2011, CAN VET J, V52, P50; Serisier S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096071; The jamovi project, 2020, JAMOVI VERSION 1 2 C; Thompson H, 2016, APPL ANIM BEHAV SCI, V178, P111, DOI 10.1016/j.applanim.2016.02.008; Tobie C, 2015, ANIMALS, V5, P126, DOI 10.3390/ani5010126; Van den Bos R, 2000, APPL ANIM BEHAV SCI, V69, P149, DOI 10.1016/S0168-1591(00)00124-6; Wakefield LA, 2006, JAVMA-J AM VET MED A, V229, P70, DOI 10.2460/javma.229.1.70; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Yamka RM, 2003, ANIM FEED SCI TECH, V109, P121, DOI 10.1016/S0377-8401(03)00203-7; Yigit S, 2018, REVSTAT-STAT J, V16, P295; Zicker SC, 2008, TOP COMPANION ANIM M, V23, P121, DOI 10.1053/j.tcam.2008.04.003; Zoran DL, 2011, JAVMA-J AM VET MED A, V239, P596, DOI 10.2460/javma.239.5.596	86	4	4	9	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2021	16	6							e0253292	10.1371/journal.pone.0253292	http://dx.doi.org/10.1371/journal.pone.0253292			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG8YE	34133456	Green Published, gold			2023-01-03	WOS:000671682700032
J	Lopes, RD; Silva, PGMDE; Furtado, RHM; Macedo, AVS; Bronhara, B; Damiani, LP; Barbosa, LM; Morata, JD; Ramacciotti, E; Martins, PD; de Oliveira, AL; Nunes, VS; Ritt, LEF; Rocha, AT; Tramujas, L; Santos, SV; Diaz, DRA; Viana, LS; Melro, LMG; Chaud, MSD; Figueiredo, EL; Neuenschwander, FC; Dracoulakis, MDA; Lima, RGSD; Dantas, VCD; Fernandes, ACS; Gebara, OCE; Hernandes, ME; Queiroz, DAR; Veiga, VC; Canesin, MF; de Faria, LM; Feitosa, GS; Gazzana, MB; Liporace, IL; Twardowsky, AD; Maia, LN; Machado, FR; Soeiro, AD; Conceicao-Souza, GE; Armaganijan, L; Guimaraes, PO; Rosa, RG; Azevedo, LCP; Alexander, JH; Avezum, A; Cavalcanti, AB; Berwanger, O				Lopes, Renato D.; de Barros E Silva, Pedro Gabriel Melo; Furtado, Remo H. M.; Scarlatelli Macedo, Ariane Vieira; Bronhara, Bruna; Damiani, Lucas Petri; Barbosa, Lilian Mazza; Morata, Julia de Aveiro; Ramacciotti, Eduardo; Martins, Priscilla de Aquino; de Oliveira, Aryadne Lyrio; Nunes, Vinicius Santana; Fonteles Ritt, Luiz Eduardo; Rocha, Ana Thereza; Tramujas, Lucas; Santos, Sueli, V; Abregu Diaz, Dario Rafael; Viana, Lorena Souza; Garcia Melro, Livia Maria; de Alcantara Chaud, Mariana Silveira; Figueiredo, Estevao Lanna; Neuenschwander, Fernando Carvalho; Andrade Dracoulakis, Marianna Deway; Souza Dourado Lima, Rodolfo Godinho; de Souza Dantas, Vicente Ces; Silva Fernandes, Anne Cristine; Eluf Gebara, Otavio Celso; Hernandes, Mauro Esteves; Rios Queiroz, Diego Aparecido; Veiga, Viviane C.; Canesin, Manoel Fernandes; de Faria, Leonardo Meira; Feitosa-Filho, Gilson Soares; Gazzana, Marcelo Basso; Liporace, Idelzuita Leandro; Twardowsky, Aline de Oliveira; Maia, Lilia Nigro; Machado, Flavia Ribeiro; Soeiro, Alexandre de Matos; Conceicao-Souza, Germano Emilio; Armaganijan, Luciana; Guimaraes, Patricia O.; Rosa, Regis G.; Azevedo, Luciano C. P.; Alexander, John H.; Avezum, Alvaro; Cavalcanti, Alexandre B.; Berwanger, Otavio			Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial	LANCET			English	Article							ATRIAL-FIBRILLATION; CLINICAL-TRIALS; RIVAROXABAN	Background COVID-19 is associated with a prothrombotic state leading to adverse clinical outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised with COVID-19 is unknown. We aimed to compare the efficacy and safety of therapeutic versus prophylactic anticoagulation in this population. Methods We did a pragmatic, open-label (with blinded adjudication), multicentre, randomised, controlled trial, at 31 sites in Brazil. Patients (aged >= 18 years) hospitalised with COVID-19 and elevated D-dimer concentration, and who had COVID-19 symptoms for up to 14 days before randomisation, were randomly assigned (1:1) to receive either therapeutic or prophylactic anticoagulation. Therapeutic anticoagulation was in-hospital oral rivaroxaban (20 mg or 15 mg daily) for stable patients, or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0.3-0.7 IU/mL anti-Xa concentration) for clinically unstable patients, followed by rivaroxaban to day 30. Prophylactic anticoagulation was standard in-hospital enoxaparin or unfractionated heparin. The primary efficacy outcome was a hierarchical analysis of time to death, duration of hospitalisation, or duration of supplemental oxygen to day 30, analysed with the win ratio method (a ratio >1 reflects a better outcome in the therapeutic anticoagulation group) in the intention-to-treat population. The primary safety outcome was major or clinically relevant non-major bleeding through 30 days. This study is registered with ClinicalTrials.gov (NCT04394377) and is completed. Findings From June 24, 2020, to Feb 26, 2021, 3331 patients were screened and 615 were randomly allocated (311 [50%] to the therapeutic anticoagulation group and 304 [50%] to the prophylactic anticoagulation group). 576 (94%) were clinically stable and 39 (6%) clinically unstable. One patient, in the therapeutic group, was lost to follow-up because of withdrawal of consent and was not included in the primary analysis. The primary efficacy outcome was not different between patients assigned therapeutic or prophylactic anticoagulation, with 28 899 (34.8%) wins in the therapeutic group and 34 288 (41.3%) in the prophylactic group (win ratio 0.86 [95% CI 0.59-1.22], p=0 .40). Consistent results were seen in clinically stable and clinically unstable patients. The primary safety outcome of major or clinically relevant non-major bleeding occurred in 26 (8%) patients assigned therapeutic anticoagulation and seven (2%) assigned prophylactic anticoagulation (relative risk 3.64 [95% CI 1. 61-8. 27], p=0.0010). Allergic reaction to the study medication occurred in two (1%) patients in the therapeutic anticoagulation group and three (1%) in the prophylactic anticoagulation group. Interpretation In patients hospitalised with COVID-19 and elevated D-dimer concentration, in-hospital therapeutic anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30 did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation. Therefore, use of therapeutic-dose rivaroxaban, and other direct oral anticoagulants, should be avoided in these patients in the absence of an evidence-based indication for oral anticoagulation. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Lopes, Renato D.; Alexander, John H.] Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC 27701 USA; [Lopes, Renato D.; de Barros E Silva, Pedro Gabriel Melo; Scarlatelli Macedo, Ariane Vieira; Bronhara, Bruna; Damiani, Lucas Petri; Barbosa, Lilian Mazza; Morata, Julia de Aveiro; Ramacciotti, Eduardo; Armaganijan, Luciana; Guimaraes, Patricia O.] Clin Res Inst, Sao Paulo, Brazil; [de Barros E Silva, Pedro Gabriel Melo; Damiani, Lucas Petri; Tramujas, Lucas; Santos, Sueli, V; Cavalcanti, Alexandre B.] HCor Res Inst, Sao Paulo, Brazil; [de Barros E Silva, Pedro Gabriel Melo; Garcia Melro, Livia Maria; de Alcantara Chaud, Mariana Silveira] Hosp Samaritano Paulista, Sao Paulo, Brazil; [Furtado, Remo H. M.; Abregu Diaz, Dario Rafael; Viana, Lorena Souza; Berwanger, Otavio] Hosp Israelita Albert Einstein, Acad Res Org, Sao Paulo, Brazil; [Furtado, Remo H. M.; Soeiro, Alexandre de Matos] Univ Sao Paulo, Hosp Clin, Fac Med, Inst Coracao, Sao Paulo, Brazil; [Viana, Lorena Souza] Univ Sao Paulo, Hosp Clin, Fac Med, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil; [Ramacciotti, Eduardo] Sci Valley Res Inst, Sao Paulo, Brazil; [Ramacciotti, Eduardo] Loyola Univ Med Ctr, Hemostasis & Thrombosis Res Labs, Maywood, IL 60153 USA; [Martins, Priscilla de Aquino; de Oliveira, Aryadne Lyrio; Nunes, Vinicius Santana] Hosp Estadual Dr Jayme Santos Neves, Serra, Brazil; [Fonteles Ritt, Luiz Eduardo; Rocha, Ana Thereza] Hosp Cardio Pulm, Salvador, BA, Brazil; [Fonteles Ritt, Luiz Eduardo; Rocha, Ana Thereza; Feitosa-Filho, Gilson Soares] Escola Bahiana Med, Salvador, BA, Brazil; [Rocha, Ana Thereza] Univ Fed Bahia, Salvador, BA, Brazil; [Figueiredo, Estevao Lanna; Neuenschwander, Fernando Carvalho] Hosp Vera Cruz, Belo Horizonte, MG, Brazil; [Andrade Dracoulakis, Marianna Deway; Souza Dourado Lima, Rodolfo Godinho] Hosp Bahia, Salvador, BA, Brazil; [de Souza Dantas, Vicente Ces; Silva Fernandes, Anne Cristine] Hosp Naval Marcilio Dias, Rio De Janeiro, Brazil; [Eluf Gebara, Otavio Celso] Hosp Santa Paula, Sao Paulo, Brazil; [Hernandes, Mauro Esteves] Santa Casa Misericordia Votuporanga, Votuporanga, Brazil; [Rios Queiroz, Diego Aparecido] Hosp Clin Fac Med Botucatu, Botucatu, SP, Brazil; [Veiga, Viviane C.; Machado, Flavia Ribeiro; Rosa, Regis G.; Azevedo, Luciano C. P.; Cavalcanti, Alexandre B.] Brazilian Res Intens Care Network, Sao Paulo, Brazil; [Veiga, Viviane C.] BP, Sao Paulo, Brazil; [Canesin, Manoel Fernandes] Univ Estadual Londrina, Hosp Univ, Londrina, Parana, Brazil; [de Faria, Leonardo Meira] Hosp Felicio Rocho, Belo Horizonte, MG, Brazil; [Feitosa-Filho, Gilson Soares] Santa Casa Misericordia Bahia Hosp Santa Izahel, Salvador, BA, Brazil; [Feitosa-Filho, Gilson Soares] Ctr Univ Fac Tecnol & Ciencias, Salvador, BA, Brazil; [Gazzana, Marcelo Basso; Rosa, Regis G.] Hosp Moinhos de Vento, Porto Alegre, RS, Brazil; [Liporace, Idelzuita Leandro] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil; [Twardowsky, Aline de Oliveira] Hosp Amor Barretos Pio XII, Barretos, Brazil; [Maia, Lilia Nigro] Hosp Base Sao Jose do Rio Preto, Sao Jose Do Rio Preto, Brazil; [Machado, Flavia Ribeiro] Univ Fed Sao Paulo, Anesthesiol Pain & Intens Care Dept, Sao Paulo, Brazil; [Conceicao-Souza, Germano Emilio] Inst Socrates Guanaes, Sao Paulo, Brazil; [Azevedo, Luciano C. P.] Hosp Sirio Libanes Res & Educ Inst, Sao Paulo, Brazil; [Avezum, Alvaro] Hosp Alemao Oswaldo Cruz, Int Res Ctr, Sao Paulo, Brazil	Duke University; Hospital do Coracao - HCor; Hospital Israelita Albert Einstein; Universidade de Sao Paulo; Universidade de Sao Paulo; Loyola University Chicago; Escola Bahiana de Medicina e Saude Publica; Universidade Federal da Bahia; Universidade Estadual de Londrina; Instituto Dante Pazzanese de Cardiologia; Universidade Federal de Sao Paulo (UNIFESP)	Lopes, RD (corresponding author), Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC 27701 USA.	renato.lopes@duke.edu	Veiga, Viviane/AAQ-9783-2021; Azevedo, Luciano CP/H-2652-2012; Gebara, Otavio C. E./D-1542-2013; Maia, Lilia Nigro/AAV-6938-2021; Rosa, Regis Goulart/P-6422-2019; Alexander, John/GVS-7271-2022	Veiga, Viviane/0000-0002-0287-3601; Azevedo, Luciano CP/0000-0001-6759-3910; Gebara, Otavio C. E./0000-0003-4089-3520; Alexander, John/0000-0002-1444-2462; Tramujas, Lucas/0000-0002-6003-1314	Coalition COVID-19 Brazil; Bayer SA	Coalition COVID-19 Brazil; Bayer SA	Coalition COVID-19 Brazil, Bayer SA.	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520; Buijsers B, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102969; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Cuker A, 2021, BLOOD ADV, V5, P872, DOI 10.1182/bloodadvances.2020003763; Dong GH, 2018, J BIOPHARM STAT, V28, P778, DOI 10.1080/10543406.2017.1397007; Eikelboom JW, 2017, NEW ENGL J MED, V377, P1319, DOI 10.1056/NEJMoa1709118; Fanaroff AC, 2020, J AM COLL CARDIOL, V76, P580, DOI 10.1016/j.jacc.2020.05.069; Frydman Galit H, 2020, TH Open, V4, pe288, DOI 10.1055/s-0040-1718415; Guimaraes HP, 2020, NEW ENGL J MED, V383, P2117, DOI 10.1056/NEJMoa2029603; Gungor B, 2021, AM J EMERG MED, V39, P173, DOI 10.1016/j.ajem.2020.09.018; Iba T, 2020, CRIT CARE MED, V48, P1358, DOI 10.1097/CCM.0000000000004458; Jimenez D, 2021, CHEST, V159, P1182, DOI 10.1016/j.chest.2020.11.005; Kaatz S, 2015, J THROMB HAEMOST, V13, P2119, DOI 10.1111/jth.13140; Lopes RD, 2021, AM HEART J, V238, P1, DOI 10.1016/j.ahj.2021.04.005; Lopes RD, 2020, J AM COLL CARDIOL, V76, P1827, DOI 10.1016/j.jacc.2020.09.008; Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449; Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559; Nadkarni GN, 2020, J AM COLL CARDIOL, V76, P1815, DOI 10.1016/j.jacc.2020.08.041; National Heart Lung and Blood Institute, 2021, FULL DOS BLOOD THINN; National Institutes of Health, 2020, NIH ACTIV TRIAL BLOO; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Pocock SJ, 2012, EUR HEART J, V33, P176, DOI 10.1093/eurheartj/ehr352; Roberts LN, 2020, BLOOD, V136, P1347, DOI 10.1182/blood.2020008086; Sadeghipour P, 2021, JAMA-J AM MED ASSOC, V325, P1620, DOI 10.1001/jama.2021.4152; Spyropoulos AC, 2020, J AM COLL CARDIOL, V75, P3140, DOI 10.1016/j.jacc.2020.04.071; Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929; Spyropoulos AC, 2018, NEW ENGL J MED, V379, P1118, DOI 10.1056/NEJMoa1805090; US Centers for Disease Control and Prevention, 2021, INT CLIN GUID MAN PA; WHO, 2020, COVID 19 THER TRIAL	30	224	227	6	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2021	397	10291					2253	2263		10.1016/S0140-6736(21)01203-4	http://dx.doi.org/10.1016/S0140-6736(21)01203-4		JUN 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SQ0SX	34097856	Green Published, Bronze			2023-01-03	WOS:000660072500028
J	Dalal, HM; Doherty, P; McDonagh, STJ; Paul, K; Taylor, RS				Dalal, Hasnain M.; Doherty, Patrick; McDonagh, Sinead T. J.; Paul, Kevin; Taylor, Rod S.			Virtual and in-person cardiac rehabilitation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PARTICIPATION; EXERCISE; FOUNDATION; PREVENTION; CARDIOLOGY; COMMITTEE; SETTINGS; CAPACITY; RATES; ERA		[Dalal, Hasnain M.] Univ Exeter, Med Sch, Royal Cornwall Hosp, Truro, England; [Dalal, Hasnain M.; McDonagh, Sinead T. J.] Univ Exeter, Med Sch, Primary Care Res Grp, St Lukes Campus, Exeter, Devon, England; [Doherty, Patrick] Univ York, Dept Hlth Sci, York, N Yorkshire, England; [Paul, Kevin] Royal Cornwall Hosp NHS Trust, Res & Dev, REACH HF Patient & Publ Involvement Grp, Truro, England; [Taylor, Rod S.] Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland; [Taylor, Rod S.] Univ Glasgow, Robertson Ctr Biostat, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland	Royal Cornwall Hospital; University of Exeter; University of Exeter; University of York - UK; Royal Cornwall Hospital; MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; University of Glasgow	Dalal, HM (corresponding author), Univ Exeter, Med Sch, Royal Cornwall Hosp, Truro, England.; Dalal, HM (corresponding author), Univ Exeter, Med Sch, Primary Care Res Grp, St Lukes Campus, Exeter, Devon, England.	h.dalal@nhs.net		Doherty, Patrick Joseph/0000-0002-1887-0237				Ades PA, 2017, MAYO CLIN PROC, V92, P234, DOI 10.1016/j.mayocp.2016.10.014; Al Quait A, 2017, EUR J PREV CARDIOL, V24, P1351, DOI 10.1177/2047487317717064; American Association of Cardiovascular and Pulmonary Rehabilitation, 2020, COR RES; [Anonymous], 2019, TOPOL REV PREPARING; [Anonymous], 2019, NHS LONG TERM PLAN; [Anonymous], 2021, EUR J PREV CARDIOL, DOI [DOI 10.1177/2047487320913379, 10.1177/2047487320913379]; [Anonymous], 2017, BACPR STAND COR COMP; Arena R, 2007, CIRCULATION, V116, P329, DOI 10.1161/CIRCULATIONAHA.106.184461; Arena R, 2012, CIRCULATION, V125, P1321, DOI 10.1161/CIR.0b013e318246b1e5; Beatty AL, 2018, CIRCULATION, V137, P1899, DOI 10.1161/CIRCULATIONAHA.117.029471; Beatty AL, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.003364; Bjarnason-Wehrens B, 2010, EUR J CARDIOV PREV R, V17, P410, DOI 10.1097/HJR.0b013e328334f42d; British Heart Foundation, 2021, HEART STAT; British Heart Foundation, 2020, NAT AUD CARD REH NAC; Buckingham SA, 2016, OPEN HEART, V3, DOI 10.1136/openhrt-2016-000463; Chew DP, 2016, MED J AUSTRALIA, V205, P128, DOI 10.5694/mja16.00368; Clark RA, 2015, EUR J PREV CARDIOL, V22, P35, DOI 10.1177/2047487313501093; Clinicaltrials. gov, 2020, IMPR ATTENDANCE CARD; Dalal H, 2021, EUR J PREV CARDIOL, V28, pE23, DOI 10.1177/2047487320923053; Dalal HM, 2016, HEART, V102, P1155, DOI 10.1136/heartjnl-2016-309429; Dalal HM, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5000; Dalal HM., 2021, PROGRAMME GRANTS APP, V9, P1, DOI [10.3310/pgfar09010, DOI 10.3310/PGFAR09010]; Dawkes S, 2020, BR J CARDIOL, V27, P79; Dodson JA, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.118.005320; Doherty P, 2020, BACPR ANN ONL C; Eberly LA, 2020, CIRCULATION, V142, P510, DOI 10.1161/CIRCULATIONAHA.120.048185; Frederix I, 2019, EUR J PREV CARDIOL, V26, P1166, DOI 10.1177/2047487319832394; Gravely-Witte S, 2010, NAT REV CARDIOL, V7, P87, DOI 10.1038/nrcardio.2009.223; HERMES, 2020, HEART FAIL GWAS SUMM; Hinde S, 2019, EUR J PREV CARDIOL, V26, P1816, DOI 10.1177/2047487319848533; Imran HM, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012779; Jin K, 2019, EUR J CARDIOVASC NUR, V18, P260, DOI 10.1177/1474515119826510; Krug E, 2017, B WORLD HEALTH ORGAN, V95, P167, DOI 10.2471/BLT.17.191809; Long L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003331.pub5; Maddison R, 2019, HEART, V105, P122, DOI 10.1136/heartjnl-2018-313189; Mafham MM, 2020, LANCET, V396, P381, DOI 10.1016/S0140-6736(20)31356-8; Moulson N, 2020, CAN J CARDIOL, V36, P1317, DOI 10.1016/j.cjca.2020.06.006; National Institute for Health and Care Excellence, 2018, NICE GUID NG106; National Institute for Health and Care Excellence, 2020, COVID 19 READ REH HE; National Institute for Health and Care Excellence, 2021, DEL REH ENABLEMENT C; National Institute for Health Research, 2021, RANDOMISED CONTROLLE; Norekval TM, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-031995; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; ODoherty AF, 2021, BMJ OPEN; Pesah E, 2019, HEART, V105, P1806, DOI 10.1136/heartjnl-2018-314486; Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106; Ponikowski P, 2016, EUR J HEART FAIL, V18, P891, DOI 10.1002/ejhf.592; Rawstorn JC, 2016, HEART, V102, P1183, DOI 10.1136/heartjnl-2015-308966; Ritchey MD, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.119.005902; Salzwedel A, 2020, EUR J PREV CARDIOL, V27, P1756, DOI 10.1177/2047487320905719; Scherrenberg M, 2021, EUR J PREV CARDIOL, V28, P524, DOI 10.1177/2047487320939671; Schopfer DW, 2018, JAMA INTERN MED, V178, P715, DOI 10.1001/jamainternmed.2017.8039; Shields GE, 2018, HEART, V104, P1403, DOI 10.1136/heartjnl-2017-312809; Smith SC, 2011, CIRCULATION, V124, P2458, DOI 10.1161/CIR.0b013e318235eb4d; Taylor R, 2021, EUR J PREV CARDIOL, V28, pE19, DOI 10.1177/2047487320926058; Taylor RS, 2019, J AM COLL CARDIOL, V73, P1430, DOI 10.1016/j.jacc.2018.12.072; Taylor RS, 2019, EUR J PREV CARDIOL, V26, P1252, DOI 10.1177/2047487319833507; The British Heart Foundation., 2019, NAT AUD CARD REH QUA; Thomas Emma, 2020, Eur J Prev Cardiol, p2047487320922926, DOI 10.1177/2047487320922926; Thomas RJ, 2019, J AM COLL CARDIOL, V74, P133, DOI 10.1016/j.jacc.2019.03.008; Thomas RJ, 2010, CIRCULATION, V122, P1342, DOI 10.1161/CIR.0b013e3181f5185b; Vishwanath Vivek, 2020, JAMA Health Forum, V1, pe201346, DOI 10.1001/jamahealthforum.2020.1346; Wingham Jenny, 2006, Eur J Cardiovasc Nurs, V5, P289, DOI 10.1016/j.ejcnurse.2006.02.002; Yancy CW, 2013, CIRCULATION, V128, P1810, DOI 10.1161/CIR.0b013e31829e8807	64	16	16	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 3	2021	373								n1270	10.1136/bmj.n1270	http://dx.doi.org/10.1136/bmj.n1270			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SQ3ZV	34083376	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000660298500004
J	Solomon, MD; Nguyen-Huynh, M; Leong, TK; Alexander, J; Rana, JS; Klingman, J; Go, AS				Solomon, Matthew D.; Nguyen-Huynh, Mai; Leong, Thomas K.; Alexander, Janet; Rana, Jamal S.; Klingman, Jeffrey; Go, Alan S.			Changes in Patterns of Hospital Visits for Acute Myocardial Infarction or Ischemic Stroke During COVID-19 Surges	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Solomon, Matthew D.; Rana, Jamal S.] Kaiser Permanente Northern Calif, Dept Cardiol, Oakland, CA USA; [Nguyen-Huynh, Mai; Klingman, Jeffrey] Kaiser Permanente Northern Calif, Dept Neurol, Walnut Creek, CA USA; [Leong, Thomas K.; Alexander, Janet; Go, Alan S.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA	Kaiser Permanente; Kaiser Permanente; Kaiser Permanente	Solomon, MD (corresponding author), Kaiser Permanente Northern Calif, Oakland Med Ctr, Dept Cardiol, 3600 Broadway, Oakland, CA 94611 USA.	matthew.d.solomon@kp.org			Kaiser Permanente Garfield Memorial Fund; Permanente Medical Group Delivery Sciences and Applied Research Program	Kaiser Permanente Garfield Memorial Fund; Permanente Medical Group Delivery Sciences and Applied Research Program	This study was sponsored by grants from the Kaiser Permanente Garfield Memorial Fund and The Permanente Medical Group Delivery Sciences and Applied Research Program.	Gordon Nancy, 2016, Perm J, V20, P15, DOI 10.7812/TPP/15-225; Nguyen-Huynh MN, 2020, STROKE, V51, P2918, DOI 10.1161/STROKEAHA.120.031099; Nguyen-Huynh MN, 2018, STROKE, V49, P133, DOI 10.1161/STROKEAHA.117.018413; Solomon MD, 2020, NEW ENGL J MED, V383, P691, DOI 10.1056/NEJMc2015630; Wadhera RK, 2021, J AM COLL CARDIOL, V77, P159, DOI 10.1016/j.jacc.2020.10.055; Wu JH, 2021, J AM COLL CARDIOL, V77, P1141, DOI 10.1016/j.jacc.2020.12.039	6	18	18	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2021	326	1					82	84		10.1001/jama.2021.8414	http://dx.doi.org/10.1001/jama.2021.8414		JUN 2021	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG4UV	34076670	Bronze, Green Published			2023-01-03	WOS:000657797800001
J	Kim, J; Kim, JH; Lee, HS; Suh, SH; Lee, KY				Kim, Jinkwon; Kim, Jang Hoon; Lee, Hye Sun; Suh, Sang Hyun; Lee, Kyung-Yul			Association between longitudinal blood pressure and prognosis after treatment of cerebral aneurysm: A nationwide population-based cohort study	PLOS ONE			English	Article							UNRUPTURED INTRACRANIAL ANEURYSMS; SUBARACHNOID HEMORRHAGE; ARTERIAL-HYPERTENSION; RISK-FACTORS; J-CURVE; RUPTURE; STROKE; GUIDELINES; MANAGEMENT	Background High blood pressure is a major risk factor for the development and rupture of cerebral aneurysm. Endovascular coil embolization and surgical clipping are established procedures to treat cerebral aneurysm. However, longitudinal data of blood pressure after the treatment of cerebral aneurysm and its impact on long-term prognosis are not well known. Methods This retrospective cohort study included 1275 patients who underwent endovascular coil embolization (n = 558) or surgical clipping (n = 717) of cerebral aneurysm in 2002-2015 using the nationwide health screening database of Korea. Systolic and diastolic blood pressure of patients were repeatedly obtained from the nationwide health screening program. We performed a multivariate time-dependent Cox regression analysis of the primary composite outcome of stroke, myocardial infarction, and all-cause death. Results During the mean follow-up period of 6.13 3.41 years, 89 patients suffered the primary outcome. Among the total 3546 times of blood pressure measurement, uncontrolled high blood pressure (systolic >= 140 mmHg or diastolic >= 90 mmHg) was 22.9%. There was a significantly increased risk of primary outcome with high systolic (adjusted HR [95% CI] per 10 mmHg, 1.16 [1.01-1.35]) and diastolic (adjusted HR [95% CI] per 10 mmHg, 1.32 [1.06-1.64]) blood pressure. Conclusions High blood pressure is prevalent even in patients who received treatment for cerebral aneurysm, which is significantly associated with poor outcome. Strict control of high blood pressure may further improve the prognosis of patients with cerebral aneurysm.	[Kim, Jinkwon; Lee, Kyung-Yul] Yonsei Univ, Coll Med, Dept Neurol, Seoul, South Korea; [Kim, Jinkwon] CHA Bundang Med Ctr, Dept Neurol, Seoul, South Korea; [Kim, Jang Hoon] Yonsei Univ, Coll Med, Dept Neurosurgery, Seoul, South Korea; [Lee, Hye Sun] Yonsei Univ, Coll Med, Biostatist Collaborat Unit, Seoul, South Korea; [Suh, Sang Hyun] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Radiol, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Lee, KY (corresponding author), Yonsei Univ, Coll Med, Dept Neurol, Seoul, South Korea.; Suh, SH (corresponding author), Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Radiol, Seoul, South Korea.	suhsh11@yuhs.ac; kylee@yuhs.ac	Kim, Jinkwon/AAR-6729-2021; Suh, Sang Hyun/M-5515-2015; Lee, Hye Sun/J-2154-2015	Kim, Jinkwon/0000-0003-0156-9736; Suh, Sang Hyun/0000-0002-7098-4901; Lee, Kyung-Yul/0000-0001-5585-7739; Lee, Hye Sun/0000-0001-6328-6948	Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education [NRF-2017R1D1A1B03033382, NRF2020R1I1A1A01060447]	Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education	This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (http://www.nrf.re.kr/eng/index) funded by the Ministry of Education (NRF-2017R1D1A1B03033382 to JK, NRF2020R1I1A1A01060447 to JK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study used the dataset of NHIS-HEALS (NHIS-2018-2-236) created by the National Health Insurance Sharing Service.	[Anonymous], EUR HEART J, DOI DOI 10.1093/EURHEARTJ/EHY339; Biffi A, 2015, JAMA-J AM MED ASSOC, V314, P904, DOI 10.1001/jama.2015.10082; Bohm M, 2017, LANCET, V389, P2226, DOI 10.1016/S0140-6736(17)30754-7; Chalouhi N, 2013, STROKE, V44, P3613, DOI 10.1161/STROKEAHA.113.002390; De Marchis GM, 2014, J NEUROL NEUROSUR PS, V85, P56, DOI 10.1136/jnnp-2013-305051; Etminan N, 2016, NAT REV NEUROL, V12, P699, DOI 10.1038/nrneurol.2016.150; Feigin VL, 2005, STROKE, V36, P2773, DOI 10.1161/01.STR.0000190838.02954.e8; Fryar Cheryl D, 2017, NCHS Data Brief, P1; Fukuda S, 2000, CIRCULATION, V101, P2532, DOI 10.1161/01.CIR.101.21.2532; Ha KH, 2018, DIABETES METAB J, V42, P402, DOI 10.4093/dmj.2018.0014; Hasan DM, 2015, HYPERTENSION, V66, P324, DOI 10.1161/HYPERTENSIONAHA.115.05500; Inci S, 2000, SURG NEUROL, V53, P530, DOI 10.1016/S0090-3019(00)00244-5; Jeong Hae Woong, 2014, Neurointervention, V9, P63, DOI 10.5469/neuroint.2014.9.2.63; Jin DS, 2007, SURG NEUROL, V68, P11, DOI 10.1016/j.sumeu.2007.02.060; Juvela S, 2013, STROKE, V44, P2414, DOI 10.1161/STROKEAHA.113.001838; Kalkman DN, 2017, CIRCULATION, V136, P2220, DOI 10.1161/CIRCULATIONAHA.117.030342; Kim J, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0799-4; Kim J, 2018, HYPERTENSION, V72, P391, DOI 10.1161/HYPERTENSIONAHA.118.11139; Kim J, 2017, STROKE, V48, P2723, DOI 10.1161/STROKEAHA.117.018140; Kimm H, 2018, KOREAN CIRC J, V48, P36, DOI 10.4070/kcj.2017.0036; Kimm H, 2012, KOREAN CIRC J, V42, P10, DOI 10.4070/kcj.2012.42.1.10; Koyanagi M, 2018, J NEUROSURG, V129, P1492, DOI 10.3171/2017.6.JNS17174; Lee CJ, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007102; Lee Seung Won, 2017, Clin Hypertens, V23, P23, DOI 10.1186/s40885-017-0075-z; Lip S, 2019, HYPERTENSION, V74, P767, DOI 10.1161/HYPERTENSIONAHA.119.12787; Mayer TE, 2016, NEUROLOGY, V86, P792, DOI 10.1212/01.wnl.0000481228.68055.71; Mitsui K, 2020, HYPERTENSION, V75, P468, DOI 10.1161/HYPERTENSIONAHA.118.12595; Onal IK, 2009, EUR J INTERN MED, V20, P369, DOI 10.1016/j.ejim.2008.10.003; OSTERGAARD JR, 1985, J NEUROSURG, V63, P49, DOI 10.3171/jns.1985.63.1.0049; Park JK, 2000, KOREAN J PREV MED, V33, P76, DOI DOI 10.1161/01.STR.0000078562.82918.F6; Park TH, 2016, J CLIN NEUROL, V12, P42, DOI 10.3988/jcn.2016.12.1.42; Sandvei MS, 2009, STROKE, V40, P1958, DOI 10.1161/STROKEAHA.108.539544; Seong SC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016640; Song TJ, 2020, J NEUROSURG, V133, P182, DOI 10.3171/2019.3.JNS183500; Spence JD, 2018, STROKE VASC NEUROL, V3, P69, DOI 10.1136/svn-2017-000138; Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087; Tada Y, 2014, STROKE, V45, P579, DOI 10.1161/STROKEAHA.113.003072; TAYLOR CL, 1995, J NEUROSURG, V83, P812, DOI 10.3171/jns.1995.83.5.0812; Thompson BG, 2015, STROKE, V46, P2368, DOI 10.1161/STR.0000000000000070; Walraven I, 2015, J HYPERTENS, V33, P2091, DOI 10.1097/HJH.0000000000000680; Wang YB, 2013, AFR HEALTH SCI, V13, P579, DOI 10.4314/ahs.v13i3.8; Wermer MJH, 2005, BRAIN, V128, P2421, DOI 10.1093/brain/awh587; Whelton PK, 2018, CIRCULATION, V138, pE484, DOI 10.1161/CIR.0000000000000596; Yi SW, 2016, CIRCULATION, V133, P2381, DOI 10.1161/CIRCULATIONAHA.115.020752; Yoon SS, 2015, HYPERTENSION, V65, P54, DOI 10.1161/HYPERTENSIONAHA.114.04012	45	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2021	16	5							e0252042	10.1371/journal.pone.0252042	http://dx.doi.org/10.1371/journal.pone.0252042			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6PJ	34043701	Green Published, gold			2023-01-03	WOS:000664635700047
J	Monzon-Kenneke, M; Chiang, P; Yao, N; Greg, M				Monzon-Kenneke, Michele; Chiang, Paul; Yao, Nengliang (Aaron); Greg, Mark			Pharmacist medication review: An integrated team approach to serve home-based primary care patients	PLOS ONE			English	Review							POLYPHARMACY; MANAGEMENT; HEALTH	Background Comprehensive medication review is a patient-centered approach to optimize medication use and improve patient outcomes. This study outlines a pilot model of care in which a remote corporate-based clinical pharmacist implemented comprehensive medication reviews for a cohort of medically complex home-based primary care (HBPC) patients. Method Ninety-six medically complex patients were assessed for medication-related problems. Data collected on these patients were: number of chronic conditions, number of medications, appropriate indication for each medication, dose appropriateness, drug interactions, recommendations for medication optimization and deprescribing. The number of accepted recommendations by the HBPC practice was analyzed. Results On average, the patients were 82 years old and had 13 chronic conditions. They were taking a median of 17 medications. Over a four-month pilot period, 175 medication recommendations were made, and 53 (30.3%) of them were accepted, with most common being medication discontinuation, deprescribing, and dose adjustments. Sixty-four (66.7%) patients were on a medication listed as potentially inappropriate for use in older adults. The most common potentially inappropriate medication was a proton-pump inhibitor (38.5%), followed by aspirin (24%), tramadol (15.6%), a benzodiazepine (13.5%) or an opioid (8.3%). Eighty-one medications were recommended for deprescribing and 27 medications were discontinued (33.3%). There were 24 recommended dose adjustments and 11 medications were dose adjusted (45.8%). Thirty-four medications were suggested as an addition to the current patient regimen, 2 medications were added (5.9%). Conclusion Pharmacist comprehensive medication review is a necessary component of the HBPC healthcare continuum. Additional research is needed to examine whether aligning pharmacists to deliver support to HBPC improves clinical outcomes, reduces healthcare expenditures and improves the patient's experience.	[Monzon-Kenneke, Michele; Chiang, Paul; Greg, Mark] Northwestern Med, Evanston, IL USA; [Chiang, Paul; Yao, Nengliang (Aaron)] Home Centered Care Inst, Schaumburg, IL 60173 USA; [Yao, Nengliang (Aaron)] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Ctr Hlth Management & Policy, Jinan, Shandong, Peoples R China; [Yao, Nengliang (Aaron)] Univ Virginia, Sect Geriatr, Charlottesville, VA 22904 USA	Northwestern University; Feinberg School of Medicine; Shandong University; University of Virginia	Yao, N (corresponding author), Home Centered Care Inst, Schaumburg, IL 60173 USA.; Yao, N (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Ctr Hlth Management & Policy, Jinan, Shandong, Peoples R China.	ayao@virginia.edu	yao, na/HDL-8772-2022	Yao, Nengliang (Aaron)/0000-0001-9000-0378				Brown JD, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070989; Castelli G, 2018, FAM MED, V50, P605, DOI 10.22454/FamMed.2018.391124; Chan M, 2001, INTERN MED J, V31, P199, DOI 10.1046/j.1445-5994.2001.00044.x; CMM in Primary Care Research Team, 2018, PAT CAR PROC DEL COM, V16; Davis Ryan G, 2007, Am J Geriatr Pharmacother, V5, P40, DOI 10.1016/j.amjopharm.2007.03.003; De Jonge KE, 2014, J AM GERIATR SOC, V62, P1825, DOI 10.1111/jgs.12974; Giberson S, 2011, IMPROVING PATIENT HL, P44; Grosse SD, 2016, THROMB RES, V137, P3, DOI 10.1016/j.thromres.2015.11.033; Gyllensten H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092061; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; Kovacevic SV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095536; Leff B, 2015, HEALTH AFFAIR, V34, P21, DOI 10.1377/hlthaff.2014.1008; Luoma Lori A, 2018, Fed Pract, V35, P22; Lurie N, 2007, JAMA-J AM MED ASSOC, V297, P1118, DOI 10.1001/jama.297.10.1118; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; Meyer-Massetti C, 2018, INT J CLIN PHARM-NET, V40, P325, DOI 10.1007/s11096-017-0581-9; Ornstein KA, 2015, JAMA INTERN MED, V175, P1180, DOI 10.1001/jamainternmed.2015.1849; Pereira F, 2019, PATIENT PREFER ADHER, V13, P2137, DOI 10.2147/PPA.S232575; Piazza G, 2011, AM J MED, V124, P1136, DOI 10.1016/j.amjmed.2011.06.009; Provost SM, 2015, HEALTH CARE MANAGE R, V40, P2, DOI 10.1097/HMR.0000000000000009; Saint-Exupery Ade., 1995, THE LITTLE PRINCE; Shepherd G, 2012, ANN PHARMACOTHER, V46, P169, DOI 10.1345/aph.1P592; Smith M, 2013, HEALTH AFFAIR, V32, P1963, DOI 10.1377/hlthaff.2013.0542; Stall N, 2014, J AM GERIATR SOC, V62, P2243, DOI 10.1111/jgs.13088; Stewart AE, 2020, J AM PHARM ASSOC, V60, P750, DOI 10.1016/j.japh.2020.03.008; Truven Health Analytics, 2019, DRUGDEX SYST MICR 2; Vink Jessica, 2011, Consult Pharm, V26, P477, DOI 10.4140/TCP.n.2011.477; Watanabe JH, 2018, ANN PHARMACOTHER, V52, P829, DOI 10.1177/1060028018765159; Yao N, 2018, J AM GERIATR SOC, V66, P1716, DOI 10.1111/jgs.15444	30	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2021	16	5							e0252151	10.1371/journal.pone.0252151	http://dx.doi.org/10.1371/journal.pone.0252151			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6OL	34033661	Green Published, gold			2023-01-03	WOS:000664633100033
J	Li, GP; Kryczek, I; Nam, J; Li, X; Li, SS; Li, J; Wei, S; Grove, S; Vatan, L; Zhou, JJ; Du, W; Lin, H; Wang, T; Subramanian, C; Moon, JJ; Cieslik, M; Cohen, M; Zou, WP				Li, Gaopeng; Kryczek, Ilona; Nam, Jutaek; Li, Xiong; Li, Shasha; Li, Jing; Wei, Shuang; Grove, Sara; Vatan, Linda; Zhou, Jiajia; Du, Wan; Lin, Heng; Wang, Ton; Subramanian, Chitra; Moon, James J.; Cieslik, Marcin; Cohen, Mark; Zou, Weiping			LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy	NATURE CELL BIOLOGY			English	Article							LONG NONCODING RNAS; MHC CLASS-I; GUANYLATE-BINDING PROTEINS; ACQUIRED-RESISTANCE; PD-1 BLOCKADE; HOST-DEFENSE; ACTIVATION; HSP90; SURVEILLANCE; MECHANISM	Li et al. identify LIMIT as a lncRNA that modulates MHC-I expression through HSP90 and HSF1, thereby regulating antitumour immune response and the efficacy of immunotherapy. Major histocompatibility complex-I (MHC-I) presents tumour antigens to CD8(+) T cells and triggers anti-tumour immunity. Humans may have 30,000-60,000 long noncoding RNAs (lncRNAs). However, it remains poorly understood whether lncRNAs affect tumour immunity. Here, we identify a lncRNA, lncRNA inducing MHC-I and immunogenicity of tumour (LIMIT), in humans and mice. We found that IFN gamma stimulated LIMIT, LIMIT cis-activated the guanylate-binding protein (GBP) gene cluster and GBPs disrupted the association between HSP90 and heat shock factor-1 (HSF1), thereby resulting in HSF1 activation and transcription of MHC-I machinery, but not PD-L1. RNA-guided CRISPR activation of LIMIT boosted GBPs and MHC-I, and potentiated tumour immunogenicity and checkpoint therapy. Silencing LIMIT, GBPs and/or HSF1 diminished MHC-I, impaired antitumour immunity and blunted immunotherapy efficacy. Clinically, LIMIT, GBP- and HSF1-signalling transcripts and proteins correlated with MHC-I, tumour-infiltrating T cells and checkpoint blockade response in patients with cancer. Together, we demonstrate that LIMIT is a cancer immunogenic lncRNA and the LIMIT-GBP-HSF1 axis may be targetable for cancer immunotherapy.	[Li, Gaopeng; Kryczek, Ilona; Li, Xiong; Li, Shasha; Li, Jing; Wei, Shuang; Grove, Sara; Vatan, Linda; Zhou, Jiajia; Du, Wan; Lin, Heng; Wang, Ton; Subramanian, Chitra; Cohen, Mark; Zou, Weiping] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Li, Gaopeng; Kryczek, Ilona; Li, Xiong; Li, Shasha; Li, Jing; Wei, Shuang; Grove, Sara; Vatan, Linda; Du, Wan; Lin, Heng; Zou, Weiping] Univ Michigan, Rogel Canc Ctr, Ctr Excellence Canc Immunol & Immunotherapy, Ann Arbor, MI 48109 USA; [Nam, Jutaek; Moon, James J.] Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA; [Moon, James J.; Cohen, Mark] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; [Cieslik, Marcin] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Cieslik, Marcin; Zou, Weiping] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Cohen, Mark] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; [Zou, Weiping] Univ Michigan, Grad Programs Immunol, Ann Arbor, MI 48109 USA; [Zou, Weiping] Univ Michigan, Tumor Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Zou, WP (corresponding author), Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.; Zou, WP (corresponding author), Univ Michigan, Rogel Canc Ctr, Ctr Excellence Canc Immunol & Immunotherapy, Ann Arbor, MI 48109 USA.; Zou, WP (corresponding author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.; Zou, WP (corresponding author), Univ Michigan, Grad Programs Immunol, Ann Arbor, MI 48109 USA.; Zou, WP (corresponding author), Univ Michigan, Tumor Biol, Ann Arbor, MI 48109 USA.	wzou@med.umich.edu	li, xiong/ABG-2578-2020; Moon, James J/ABE-4429-2021	li, xiong/0000-0003-0203-2973; Moon, James J/0000-0003-2238-2372	US NIH/NCI R01 [CA217648, CA123088, CA099985, CA193136, CA152470, CA216919, CA213566, CA120458]; NIH through the University of Michigan Rogel Cancer Center Grant [CA46592]	US NIH/NCI R01; NIH through the University of Michigan Rogel Cancer Center Grant	We thank members of the Zou laboratory for intellectual input. This work was supported in part by the research grants from the US NIH/NCI R01 grants (CA217648, CA123088, CA099985, CA193136, CA152470, to W.Z.; and CA216919, CA213566, CA120458; to M. Cohen), and the NIH through the University of Michigan Rogel Cancer Center Grant (CA46592).	Arun G, 2018, TRENDS MOL MED, V24, P257, DOI 10.1016/j.molmed.2018.01.001; Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022; Charo J, 2005, CANCER RES, V65, P2001, DOI 10.1158/0008-5472.CAN-04-2006; CHENG YSE, 1983, J BIOL CHEM, V258, P7746; Dai C, 2016, TRENDS CELL BIOL, V26, P17, DOI 10.1016/j.tcb.2015.10.011; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; FESTENSTEIN H, 1986, NATURE, V322, P502, DOI 10.1038/322502a0; Flores-Concha M, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00718; Flynn RA, 2014, CELL STEM CELL, V14, P752, DOI 10.1016/j.stem.2014.05.014; Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955; Fruh K, 1999, CURR OPIN IMMUNOL, V11, P76, DOI 10.1016/S0952-7915(99)80014-4; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; Garcia-Lora A, 2003, J CELL PHYSIOL, V195, P346, DOI 10.1002/jcp.10290; Garrido F, 2016, CURR OPIN IMMUNOL, V39, P44, DOI 10.1016/j.coi.2015.12.007; Gil N, 2020, NAT REV GENET, V21, P102, DOI 10.1038/s41576-019-0184-5; Harel M, 2019, CELL, V179, P236, DOI 10.1016/j.cell.2019.08.012; Heward JA, 2014, TRENDS IMMUNOL, V35, P408, DOI 10.1016/j.it.2014.07.005; Hon CC, 2017, NATURE, V543, P199, DOI 10.1038/nature21374; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Hugo W, 2017, CELL, V168, P542, DOI 10.1016/j.cell.2017.01.010; Jones AN, 2019, J MOL CELL BIOL, V11, P845, DOI 10.1093/jmcb/mjz086; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kim BH, 2016, NAT IMMUNOL, V17, P481, DOI 10.1038/ni.3440; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Li J, 2020, J CLIN INVEST, V130, P2712, DOI 10.1172/JCI134402; Lin H, 2018, J CLIN INVEST, V128, P805, DOI 10.1172/JCI96113; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Mbofung RM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00449-z; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Naidu SD, 2017, FEBS J, V284, P1606, DOI 10.1111/febs.13999; Nathanson T, 2017, CANCER IMMUNOL RES, V5, P84, DOI 10.1158/2326-6066.CIR-16-0019; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Perez-Pinera P, 2013, NAT METHODS, V10, P973, DOI [10.1038/nmeth.2600, 10.1038/NMETH.2600]; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Proia DA, 2015, CANCER IMMUNOL RES, V3, P583, DOI 10.1158/2326-6066.CIR-15-0057; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shenoy AR, 2012, SCIENCE, V336, P481, DOI 10.1126/science.1217141; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Sucker A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15440; Sui J, 2018, CANCER MED-US, V7, P3240, DOI 10.1002/cam4.1541; Sun QY, 2018, TRENDS GENET, V34, P142, DOI 10.1016/j.tig.2017.11.005; Sun TT, 2016, CANCER DISCOV, V6, P784, DOI 10.1158/2159-8290.CD-15-0921; Tretina K, 2019, J EXP MED, V216, P482, DOI 10.1084/jem.20182031; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Wang WM, 2019, NATURE, V569, P270, DOI 10.1038/s41586-019-1170-y; West JD, 2012, CHEM RES TOXICOL, V25, P2036, DOI 10.1021/tx300264x; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Yamamoto M, 2012, IMMUNITY, V37, P302, DOI 10.1016/j.immuni.2012.06.009; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Yuno A, 2018, METHODS MOL BIOL, V1709, P423, DOI 10.1007/978-1-4939-7477-1_29; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	60	43	44	5	26	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2021	23	5					526	+		10.1038/s41556-021-00672-3	http://dx.doi.org/10.1038/s41556-021-00672-3		MAY 2021	25	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	SB9NQ	33958760	Green Accepted			2023-01-03	WOS:000647937600002
J	Smith-Berdan, S; Bercasio, A; Kramer, L; Petkus, B; Hinck, L; Forsberg, EC				Smith-Berdan, Stephanie; Bercasio, Alyssa; Kramer, Leah; Petkus, Bryan; Hinck, Lindsay; Forsberg, E. Camilla			Acute and endothelial-specific Robo4 deletion affect hematopoietic stem cell trafficking independent of VCAM1	PLOS ONE			English	Article							BONE-MARROW; PROGENITOR CELLS; VASCULAR NICHE; EXPRESSION; ADHESION; ANGIOGENESIS; MIGRATION; MURINE; DIFFERENTIATION; RECEPTOR	Hematopoietic stem cell (HSC) trafficking is regulated by a number of complex mechanisms. Among them are the transmembrane protein Robo4 and the vascular cell adhesion molecule, VCAM1. Endothelial VCAM1 is a well-known regulator of hematopoietic cell trafficking, and our previous studies revealed that germline deletion of Robo4 led to impaired HSC trafficking, with an increase in vascular endothelial cell (VEC) numbers and downregulation of VCAM1 protein on sinusoidal VECs. Here, we utilized two Robo4 conditional deletion models in parallel with Robo4 germline knockout mice (R4(KO)) to evaluate the effects of acute and endothelial cell-specific Robo4 deletion on HSC trafficking. Strikingly similar to the R4(KO), the acute deletion of Robo4 resulted in altered HSC distribution between the bone marrow and blood compartments, despite normal numbers of VECs and wild-type levels of VCAM1 cell surface protein on sinusoidal VECs. Additionally, consistent with the R4(KO) mice, acute loss of Robo4 in the host perturbed long-term engraftment of donor wild-type HSCs and improved HSC mobilization to the peripheral blood. These data demonstrate the significant role that endothelial Robo4 plays in directional HSC trafficking, independent of alterations in VEC numbers and VCAM1 expression.	[Smith-Berdan, Stephanie; Bercasio, Alyssa; Kramer, Leah; Petkus, Bryan; Hinck, Lindsay; Forsberg, E. Camilla] Univ Calif Santa Cruz, Inst Biol Stem Cells, Santa Cruz, CA 95064 USA; [Smith-Berdan, Stephanie; Forsberg, E. Camilla] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA; [Hinck, Lindsay] Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Forsberg, EC (corresponding author), Univ Calif Santa Cruz, Inst Biol Stem Cells, Santa Cruz, CA 95064 USA.; Forsberg, EC (corresponding author), Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA.	cforsber@ucsc.edu		Bercasio, Alyssa/0000-0001-6957-0640	UCSC; CIRM Facilities awards [CL1-00506, FA1-00617-1, RRID:SCR_021149]	UCSC; CIRM Facilities awards	This work was supported by UCSC and by CIRM Facilities awards CL1-00506 and FA1-00617-1, RRID:SCR_021149, to UCSC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arcangeli ML, 2020, EXP HEMATOL, V86, P15, DOI 10.1016/j.exphem.2020.05.006; Beaudin AE, 2016, CELL STEM CELL, V19, P768, DOI 10.1016/j.stem.2016.08.013; Boyer SW, 2011, CELL STEM CELL, V9, P64, DOI 10.1016/j.stem.2011.04.021; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Cool T, 2020, EXP HEMATOL, V90, P39, DOI 10.1016/j.exphem.2020.09.001; Forsberg EC, 2006, CELL, V126, P415, DOI 10.1016/j.cell.2006.06.037; Forsberg EC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008785; Forsberg EC, 2005, PLOS GENET, V1, P281, DOI 10.1371/journal.pgen.0010028; Frenette PS, 1998, P NATL ACAD SCI USA, V95, P14423, DOI 10.1073/pnas.95.24.14423; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Helmestam M, 2012, AM J PATHOL, V180, P2527, DOI 10.1016/j.ajpath.2012.02.026; Jacobsen K, 1996, BLOOD, V87, P73; Jones CA, 2008, NAT MED, V14, P448, DOI 10.1038/nm1742; Jones CA, 2009, NAT CELL BIOL, V11, P1325, DOI 10.1038/ncb1976; KNOSPE WH, 1966, BLOOD-J HEMATOL, V28, P398; KNOSPE WH, 1968, BLOOD, V31, P400, DOI 10.1182/blood.V31.3.400.400; Kopp HG, 2005, PHYSIOLOGY, V20, P349, DOI 10.1152/physiol.00025.2005; Leung GA, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.176180; Li XM, 2008, EXP HEMATOL, V36, P1143, DOI 10.1016/j.exphem.2008.06.009; Marlow R, 2010, P NATL ACAD SCI USA, V107, P10520, DOI 10.1073/pnas.1001896107; Martin EW, 2021, EPIGENET CHROMATIN, V14, DOI 10.1186/s13072-020-00377-1; Mazo IB, 1998, J EXP MED, V188, P465, DOI 10.1084/jem.188.3.465; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Poscablo DM, 2021, STEM CELL REP, V16, P1598, DOI 10.1016/j.stemcr.2021.04.016; Rajendiran S, 2020, STEM CELLS, V38, P1159, DOI 10.1002/stem.3205; Raoufi-Rad N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185393; Sanchez-Aguilera A, 2014, CELL STEM CELL, V15, P791, DOI 10.1016/j.stem.2014.11.002; Sarelius IH, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.985954; Smith-Berdan S, 2019, STEM CELL REP, V13, P787, DOI 10.1016/j.stemcr.2019.09.004; Smith-Berdan S, 2015, STEM CELL REP, V4, P255, DOI 10.1016/j.stemcr.2014.12.013; Smith-Berdan S, 2012, CELL CYCLE, V11, P675, DOI 10.4161/cc.11.4.19146; Smith-Berdan S, 2011, CELL STEM CELL, V8, P72, DOI 10.1016/j.stem.2010.11.030; Sorensen I, 2009, BLOOD, V113, P5680, DOI 10.1182/blood-2008-08-174508; Suchting S, 2004, FASEB J, V18, P121, DOI 10.1096/fj.04-1991fje; TAVASSOLI M, 1990, BLOOD, V76, P1059; Ugarte F, 2015, STEM CELL REP, V5, P728, DOI 10.1016/j.stemcr.2015.09.009; Ulyanova T, 2005, BLOOD, V106, P86, DOI 10.1182/blood-2004-09-3417; Vazquez SE, 2015, EXP HEMATOL, V43, P578, DOI 10.1016/j.exphem.2015.04.001; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Winkler IG, 2010, BLOOD, V116, P375, DOI 10.1182/blood-2009-07-233437; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898; Zheng W, 2012, CEREB CORTEX, V22, P2587, DOI 10.1093/cercor/bhr330; Zhou BO, 2015, ELIFE, V4, DOI 10.7554/eLife.05521	45	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255606	10.1371/journal.pone.0255606	http://dx.doi.org/10.1371/journal.pone.0255606			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ8RN	34388149	Green Published, gold			2023-01-03	WOS:000684737400002
J	Velentzis, LS; Egger, S; Banks, E; Canfell, K				Velentzis, Louiza S.; Egger, Sam; Banks, Emily; Canfell, Karen			Menopausal hormone therapy: Characterising users in an Australian national cross-sectional study	PLOS ONE			English	Article							REPLACEMENT THERAPY; WOMEN; CANCER; LIFE; RISK; DETERMINANTS; PREVALENCE; TRENDS	Menopausal hormone therapy (MHT) is effective for menopausal symptoms, however, its use is also associated with risks of serious health conditions including breast, ovarian and endometrial cancer, stroke and venous thromboembolism. MHT-related health risks increase with longer durations of use. In Australia, while overall MHT use fell when risk-related findings were published in 2002, a significant number of women continue using MHT long-term. We aimed to examine socio-demographic, health-related and lifestyle characteristics in relation to post-2002 MHT use, and to compare use for <5 and >= 5 years. Data from 1,561 participants from an Australian, national, cross-sectional survey of women aged 50-69 in 2013 were analysed. Odds ratios (ORs) were calculated using logistic regression for characteristics related to overall MHT use post-2002 and multinomial logistic regression for associations between MHT duration of use [never/<5 years/>= 5 years] and personal characteristics, adjusting for sociodemographic, reproductive, health and lifestyle factors. Post-2002 MHT use was associated with increasing age (p-trend<0.001), hysterectomy versus no hysterectomy (OR:2.55, 95%CI = 1.85-3.51), bilateral oophorectomy vs no oophorectomy (OR:1.66, 95%CI = 1.09-2.53), and ever- versus never-use of therapies other than MHT for menopausal symptoms (OR:1.93, 95%CI = 1.48-2.57). Women with prior breast cancer (OR:0.35, 95%CI = 0.17-0.74) and with more children (p-trend = 0.034) were less likely than other women to use MHT. Prior hysterectomy was more strongly associated with MHT use for >= 5 years than for <5 years (p = 0.004). Ever-use of non-MHT menopausal therapies was associated with MHT use for <5 years but not with longer-term use (p = 0.004). This study reinforces the need for MHT users and their clinicians to re-evaluate continued MHT use on an ongoing basis.	[Velentzis, Louiza S.; Egger, Sam; Canfell, Karen] Univ Sydney, Daffodil Ctr, Sydney, NSW, Australia; [Velentzis, Louiza S.] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia; [Banks, Emily] Australian Natl Univ, Res Sch Populat Hlth, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia; [Canfell, Karen] Univ New South Wales, Fac Med, Prince Wales Clin Sch, Sydney, NSW, Australia	University of Sydney; University of Melbourne; Australian National University; University of New South Wales Sydney	Velentzis, LS (corresponding author), Univ Sydney, Daffodil Ctr, Sydney, NSW, Australia.; Velentzis, LS (corresponding author), Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.	louizav@nswcc.org.au		Egger, Sam/0000-0003-1808-6909; Banks, Emily/0000-0002-4617-1302	Cancer Council NSW	Cancer Council NSW(Cancer Council New South Wales)	The study was funded by Cancer Council NSW https://www.cancercouncil.com.au/.The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Australian Bureau of Statistics, 2011, SOCIO EC INDEXES ARE; Australian Bureau of Statistics, 2018, AUSTR STAT GEOGR STA; Banks E, 2001, J Epidemiol Biostat, V6, P357; Blumel JE, 2011, MENOPAUSE, V18, P778, DOI 10.1097/gme.0b013e318207851d; Canfell K, 2009, BREAST CANCER RES TR, V117, P671, DOI 10.1007/s10549-009-0331-3; Collaborative Grp Hormonal Factors, 2019, LANCET, V394, P1159, DOI 10.1016/S0140-6736(19)31709-X; Costanian C, 2018, MENOPAUSE, V25, P46, DOI 10.1097/GME.0000000000000954; Costas L, 2015, MENOPAUSE, V22, P1138, DOI 10.1097/GME.0000000000000487; Fahlen M, 2013, EUR J CANCER, V49, P52, DOI 10.1016/j.ejca.2012.07.003; FDA: US Food & Drug Administration, MEN HORM COMM QUEST MEN HORM COMM QUEST; Grossman DC, 2017, JAMA-J AM MED ASSOC, V318, P2224, DOI 10.1001/jama.2017.18261; Hickey M, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5101; Holmberg L, 2008, JNCI-J NATL CANCER I, V100, P475, DOI 10.1093/jnci/djn058; Izzo AA, 2001, DRUGS, V61, P2163, DOI 10.2165/00003495-200161150-00002; Kenemans P, 2009, LANCET ONCOL, V10, P135, DOI 10.1016/S1470-2045(08)70341-3; Leveille SG, 1997, J AM GERIATR SOC, V45, P1496, DOI 10.1111/j.1532-5415.1997.tb03201.x; Lucas R, 2007, MATURITAS, V57, P226, DOI 10.1016/j.maturitas.2006.12.005; Maclennan A H, 2004, Cochrane Database Syst Rev, pCD002978, DOI 10.1002/14651858.CD002978.pub2; Manzoli L, 2004, MATURITAS, V49, P241, DOI 10.1016/j.maturitas.2004.02.003; Marjoribanks J, 2018, HEART, V104, P93, DOI 10.1136/heartjnl-2017-311583; Medicines and Healthcare products Regulatory Agency UK, 2014, HORM REPL THER UPD A HORM REPL THER UPD A; Mishra GD, 2017, HUM REPROD, V32, P679, DOI 10.1093/humrep/dew350; Nagel G, 2007, MATURITAS, V56, P436, DOI 10.1016/j.maturitas.2006.11.008; North Amer Menopause Soc, 2018, MENOPAUSE, V25, P1362, DOI 10.1097/GME.0000000000001241; Nunez C, 2017, CANCER EPIDEMIOL, V47, P56, DOI 10.1016/j.canep.2017.01.002; Pansini F, 2000, Climacteric, V3, P241, DOI 10.1080/13697130008500142; Parazzini F, 2008, MENOPAUSE, V15, P164, DOI 10.1097/gme.0b013e318057782b; Peng WB, 2014, MATURITAS, V79, P340, DOI 10.1016/j.maturitas.2014.08.002; Tao MF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024661; Utian WH, 2018, MENOPAUSE, V25, P1172, DOI 10.1097/GME.0000000000001213; Velentzis LS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146494	31	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0253725	10.1371/journal.pone.0253725	http://dx.doi.org/10.1371/journal.pone.0253725			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY8KW	34379634	gold, Green Published			2023-01-03	WOS:000684029800046
J	Clift, AK; Saatci, D; Coupland, CAC; Dambha-Miller, H; Hippisley-Cox, J				Clift, Ashley Kieran; Saatci, Defne; Coupland, Carol A. C.; Dambha-Miller, Hajira; Hippisley-Cox, Julia			Sickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Letter									[Clift, Ashley Kieran; Saatci, Defne; Hippisley-Cox, Julia] Univ Oxford, Oxford, England; [Coupland, Carol A. C.] Univ Nottingham, Nottingham, England; [Dambha-Miller, Hajira] Univ Southampton, Southampton, Hants, England	University of Oxford; University of Nottingham; University of Southampton	Clift, AK (corresponding author), Radcliffe Observ Quarter, Nuffield Dept Primary Care Hlth Sci, Woodstock Rd, Oxford OX2 4GG, England.	ashley.clift@phc.ox.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Dambha-Miller, Hajira/0000-0003-0175-443X; Saatci, Defne/0000-0002-2414-2906; Coupland, Carol/0000-0002-2327-3306	UK Medical Research Council [MR/V027778/1]; Clinical Research Training Fellowship from Cancer Research UK [DCS-CRUK-CRTF20-AC, C2195/A31310]	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Clinical Research Training Fellowship from Cancer Research UK	By grant MR/V027778/1 from the UK Medical Research Council. Dr. Clift is supported by a Clinical Research Training Fellowship from Cancer Research UK (DCS-CRUK-CRTF20-AC, C2195/A31310).	Kato GJ, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.10; Kato GJ, 2017, J CLIN INVEST, V127, P750, DOI 10.1172/JCI89741; McCloskey KA, 2020, BRIT J HAEMATOL, V190, pE57, DOI 10.1111/bjh.16779; Panepinto JA, 2020, EMERG INFECT DIS, V26, P2473, DOI [10.3201/eid2610.201792, 10.3201/eid2610.202792]	4	8	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT	2021	174	10					1483	+		10.7326/M21-1375	http://dx.doi.org/10.7326/M21-1375			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA9CB	34338553	Green Published			2023-01-03	WOS:000720935700040
J	Pafundi, PC; Galiero, R; Simeon, V; Rinaldi, L; Perrella, A; Vetrano, E; Caturano, A; Alfano, M; Beccia, D; Nevola, R; Marfella, R; Sardu, C; Coppola, C; Scarano, F; Maggi, P; Sposito, PD; Vocciante, L; Rescigno, C; Sbreglia, C; Fraganza, F; Parrella, R; Romano, A; Calabria, G; Polverino, B; Pagano, A; Bologna, C; Amitrano, M; Esposito, V; Coppola, N; Maturo, N; Adinolfi, LE; Chiodini, P; Sasso, FC				Pafundi, Pia Clara; Galiero, Raffaele; Simeon, Vittorio; Rinaldi, Luca; Perrella, Alessandro; Vetrano, Erica; Caturano, Alfredo; Alfano, Maria; Beccia, Domenico; Nevola, Riccardo; Marfella, Raffaele; Sardu, Celestino; Coppola, Carmine; Scarano, Ferdinando; Maggi, Paolo; Sposito, Pellegrino De Lucia; Vocciante, Laura; Rescigno, Carolina; Sbreglia, Costanza; Fraganza, Fiorentino; Parrella, Roberto; Romano, Annamaria; Calabria, Giosuele; Polverino, Benedetto; Pagano, Antonio; Bologna, Carolina; Amitrano, Maria; Esposito, Vincenzo; Coppola, Nicola; Maturo, Nicola; Adinolfi, Luigi Elio; Chiodini, Paolo; Sasso, Ferdinando Carlo		COVOCA Study Grp	Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study	PLOS ONE			English	Article								Introduction During COVID-19 pandemic, the use of several drugs has represented the worldwide clinical practice. However, though the current increase of knowledge about the disease, there is still no effective treatment for the usage of drugs. Thus, we retrospectively assessed use and effects of therapeutic regimens in hospitalized patients on in-hospital mortality. Methods COVOCA is a retrospective observational cohort study on 18 COVID centres throughout Campania Region Hospitals. We included adult patients with confirmed SARS-CoV-2 infection, discharged/dead between March/June 2020. Results 618 patients were included, with an overall in-hospital cumulative mortality incidence of 23.1%. Most prescribed early treatments were antivirals (72%), antibiotics (65%) and hydroxychloroquine/anticoagulants (approximate to 50%). Tocilizumab, indeed, was largely prescribed late during hospitalization. Multivariable models, with a cut-off at day 2 for early COVID-19 therapy administration, did not disclose any significant association of a single drug administration on the clinical outcome. Discussion COVOCA represents the first multicenter database in Campania region. None drug class used during the pandemic significantly modified the outcome, regardless of therapy beginning, both overall and net of those already in non-invasive ventilation (NIV)/ orotracheal intubation (OTI) at hospitalization. Our cumulative incidence of mortality seems lower than other described during the same period, particularly in Northern Italy.	[Pafundi, Pia Clara; Galiero, Raffaele; Rinaldi, Luca; Vetrano, Erica; Caturano, Alfredo; Alfano, Maria; Beccia, Domenico; Nevola, Riccardo; Marfella, Raffaele; Sardu, Celestino; Adinolfi, Luigi Elio; Sasso, Ferdinando Carlo] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Naples, Italy; [Simeon, Vittorio; Chiodini, Paolo] Univ Campania Luigi Vanvitelli, Dept Phys & Mental Hlth & Prevent Med, Med Stat Unit, Naples, Italy; [Perrella, Alessandro] Task Force Covid 19 Regione Campania, Campania, Italy; [Nevola, Riccardo] ASL Avellino, St Ottone Frangipane Hosp, Internal Med, Ariano Irpino, AV, Italy; [Coppola, Carmine; Scarano, Ferdinando] COVID Ctr S Anna & SS Madonna Neve Hosp, Boscotrecase, Italy; [Maggi, Paolo] S Anna & S Sebastiano Hosp, UOC Infect & Trop Dis, Caserta, Italy; [Sposito, Pellegrino De Lucia] Maddaloni Hosp, Covid Ctr, Maddaloni, Italy; [Vocciante, Laura] Loreto Mare Hosp, Gen Med Unit, Naples, Italy; [Rescigno, Carolina] Cotugno Hosp, UOC Infect Dis & Neurol, Naples, Italy; [Sbreglia, Costanza] Cotugno Hosp, UOC Infect Dis Elderly, Naples, Italy; [Fraganza, Fiorentino] Cotugno Hosp, UOC Anestesia & Intens Care Unit, Naples, Italy; [Parrella, Roberto] Cotugno Hosp, UOC Resp Infect Dis, Naples, Italy; [Romano, Annamaria] Moscati Hosp, UOC Pneumol, Avellino, Italy; [Calabria, Giosuele] Cotugno Hosp, Div Infect Dis & Intervent Ultrasound 9, Naples, Italy; [Polverino, Benedetto] Giovanni da Procida Hosp, Salerno, Italy; [Pagano, Antonio] Santa Maria Grazie Hosp, Emergency & Acceptance Unit, Pozzuoli, Italy; [Bologna, Carolina] Osped Mare, Internal Med Unit, Naples, Italy; [Amitrano, Maria] UOC Internal Med Moscati Hosp, Avellino, Italy; [Esposito, Vincenzo] Cotugno Hosp, Div Immunodeficiency & Gender Infect Dis 4, Naples, Italy; [Coppola, Nicola] Ctr COVID AOU Vanvitelli, Dept Mental Hlth & Publ Med, Naples, Italy; [Maturo, Nicola] Cotugno Hosp, UOSD Infect Dis Emergency & Acceptance, Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; San Giuseppe Moscati Hospital	Sasso, FC (corresponding author), Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Naples, Italy.; Chiodini, P (corresponding author), Univ Campania Luigi Vanvitelli, Dept Phys & Mental Hlth & Prevent Med, Med Stat Unit, Naples, Italy.	Paolo.Chiodini@unicampania.it; Ferdinando.Sasso@unicampania.it	Sasso, Ferdinando Carlo/AAE-5665-2019; Caturano, Alfredo/ACM-4169-2022; Pafundi, Pia Clara/AAC-3991-2021; Simeon, Vittorio/K-6373-2016; Caturano, Alfredo/AAA-4014-2022	Sasso, Ferdinando Carlo/0000-0002-9142-7848; Caturano, Alfredo/0000-0001-7761-7533; Pafundi, Pia Clara/0000-0002-0310-3529; Simeon, Vittorio/0000-0003-2387-4125; Caturano, Alfredo/0000-0001-7761-7533; Codella, Alessio Vinicio/0000-0003-1657-6613; marfella, raffaele/0000-0003-3960-9270; Cirillo, Paolo/0000-0003-1732-6819	Programma VALERE, University of Campania "Luigi Vanvitelli"	Programma VALERE, University of Campania "Luigi Vanvitelli"	Dr. Raffaele Galiero, Dr. Pia Clara Pafundi and Dr. Vittorio Simeon were supported by the Programma VALERE, University of Campania "Luigi Vanvitelli".; The Authors thank all the colleagues, nurses and workers who are facing COVID 19 disease.	[Anonymous], 2021, IMP EP COVID 19 MORT; [Anonymous], 2018, CATALOGUE BIASES; Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857; Carta MG, 2020, EUR REV MED PHARMACO, V24, P8226, DOI 10.26355/eurrev_202008_22512; Cattaneo D, 2020, DRUG AGING, V37, P925, DOI 10.1007/s40266-020-00812-8; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; De Rosa S, 2020, EUR HEART J, V41, P2083, DOI 10.1093/eurheartj/ehaa409; Ferroni E, 2020, CLIN EPIDEMIOL, V12, P1337, DOI 10.2147/CLEP.S271763; Galiero R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243700; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Iavarone M, 2020, J HEPATOL, V73, P1063, DOI 10.1016/j.jhep.2020.06.001; Jiang B, 2020, EUR REV MED PHARMACO, V24, P10239, DOI 10.26355/eurrev_202010_23248; Keske S, 2020, INT J INFECT DIS, V99, P338, DOI 10.1016/j.ijid.2020.07.036; Omrani AS, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100645; Patel TK, 2020, J NEUROIMMUNE PHARM, V15, P350, DOI 10.1007/s11481-020-09930-x; Ramiro S, 2020, ANN RHEUM DIS, V79, P1143, DOI 10.1136/annrheumdis-2020-218479; Rossotti R, 2020, J INFECTION, V81, pE11, DOI 10.1016/j.jinf.2020.07.008; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849; Tortajada C, 2021, J MED VIROL, V93, P1817, DOI 10.1002/jmv.26635; Valdenassi L, 2020, EUR REV MED PHARMACO, V24, P4059, DOI 10.26355/eurrev_202004_20976; Valentini M, 2020, J POPUL THER CLIN PH, V27, pE14, DOI 10.15586/jptcp.v27iSP1.689; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; World Health Organization (WHO), WHO2019NCOVCLINICAL2; Ye ZK, 2020, CAN MED ASSOC J, V192, pE756, DOI 10.1503/cmaj.200645; Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577	27	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2021	16	9							e0256903	10.1371/journal.pone.0256903	http://dx.doi.org/10.1371/journal.pone.0256903			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5RP	34520465	Green Published, gold			2023-01-03	WOS:000707052100009
J	Maddox, KEJ; Orav, EJ; Zheng, J; Epstein, AM				Joynt Maddox, Karen E.; Orav, E. John; Zheng, Jie; Epstein, Arnold M.			Year 1 of the Bundled Payments for Care Improvement-Advanced Model	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY	Year 1 of Bundled Payments for Care Improvement-Advanced In October 2018, Medicare introduced Bundled Payments for Care Improvement-Advanced, a payment model in which hospitals elect to assume accountability for total costs of care during the 90 days after hospitalization for selected conditions. In its first year, the program was associated with small reductions in Medicare payments among participating hospitals as compared with controls. Background The Center for Medicare and Medicaid Innovation launched the Medicare Bundled Payments for Care Improvement-Advanced (BPCI-A) program for hospitals in October 2018. Information is needed about the effects of the program on health care utilization and Medicare payments. Methods We conducted a modified segmented regression analysis using Medicare claims and including patients with discharge dates from January 2017 through September 2019 to assess differences between BPCI-A participants and two control groups: hospitals that never joined the BPCI-A program (nonjoining hospitals) and hospitals that joined the BPCI-A program in January 2020, after the conclusion of the intervention period (late-joining hospitals). The primary outcomes were the differences in changes in quarterly trends in 90-day per-episode Medicare payments and the percentage of patients with readmission within 90 days after discharge. Secondary outcomes were mortality, volume, and case mix. Results A total of 826 BPCI-A participant hospitals were compared with 2016 nonjoining hospitals and 334 late-joining hospitals. Among BPCI-A hospitals, the mean baseline 90-day per-episode Medicare payment was $27,315; the change in the quarterly trends in the intervention period as compared with baseline was -$78 per quarter. Among nonjoining hospitals, the mean baseline 90-day per-episode Medicare payment was $25,994; the change in quarterly trends as compared with baseline was -$26 per quarter (difference between nonjoining hospitals and BPCI-A hospitals, $52 [95% confidence interval {CI}, 34 to 70] per quarter; P<0.001; 0.2% of the baseline payment). Among late-joining hospitals, the mean baseline 90-day per-episode Medicare payment was $26,807; the change in the quarterly trends as compared with baseline was $4 per quarter (difference between late-joining hospitals and BPCI-A hospitals, $82 [95% CI, 41 to 122] per quarter; P<0.001; 0.3% of the baseline payment). There were no meaningful differences in the changes with regard to readmission, mortality, volume, or case mix. Conclusions The BPCI-A program was associated with small reductions in Medicare payments among participating hospitals as compared with control hospitals. (Funded by the National Heart, Lung, and Blood Institute.)	[Joynt Maddox, Karen E.] Washington Univ, Sch Med, Dept Med, Cardiovasc Div, St Louis, MO 63110 USA; [Joynt Maddox, Karen E.] Washington Univ, Sch Med, Ctr Hlth Econ & Policy, Inst Publ Hlth, St Louis, MO USA; [Orav, E. John; Epstein, Arnold M.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA; [Orav, E. John] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Zheng, Jie; Epstein, Arnold M.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Maddox, KEJ (corresponding author), Washington Univ, Sch Med, 660 S Euclid Ave, St Louis, MO 63130 USA.	kjoyntmaddox@wustl.edu						[Anonymous], 2018, BPCI ADV; [Anonymous], 2015, HERF HIRSCHM IND HERF HIRSCHM IND; [Anonymous], 2020, EXPL DOWNL MED PROV EXPL DOWNL MED PROV; Burke LG, 2020, HEALTHCARE-J DEL SCI, V8, DOI 10.1016/j.hjdsi.2019.100378; Dummit L., 2020, CMS BUNDLED PAYMENTS; Dummit LA, 2016, JAMA-J AM MED ASSOC, V316, P1267, DOI 10.1001/jama.2016.12717; Dundon JM, 2016, J BONE JOINT SURG AM, V98, P1949, DOI 10.2106/JBJS.16.00523; Maddox KEJ, 2020, MED CARE, V58, P895, DOI 10.1097/MLR.0000000000001395; Maddox KEJ, 2019, J AM GERIATR SOC, V67, P2245, DOI 10.1111/jgs.16147; Maddox KEJ, 2019, JAMA-J AM MED ASSOC, V322, P362, DOI 10.1001/jama.2019.7992; Maddox KEJ, 2019, J AM GERIATR SOC, V67, P1027, DOI 10.1111/jgs.15803; Maddox KEJ, 2018, NEW ENGL J MED, V379, P260, DOI [10.1056/NEJMsa1801369, 10.1056/NEJMsa1801569]; Maughan BC, 2019, HEALTH AFFAIR, V38, P561, DOI 10.1377/hlthaff.2018.05146; Navathe AS, 2020, HEALTH AFFAIR, V39, P58, DOI 10.1377/hlthaff.2019.00466; Navathe AS., 2018, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20181204.525769/full/, DOI 10.1377/HBLOG20181204.525769/FULL]; Rolnick JA, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1780; Smith B, 2021, NEW ENGL J MED, V384, P759, DOI 10.1056/NEJMsb2031138	17	1	1	2	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2021	385	7					618	627		10.1056/NEJMsa2033678	http://dx.doi.org/10.1056/NEJMsa2033678			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UA7BM	34379923	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000685313600011
J	Madarame, A; Fukuzawa, M; Yamauchi, Y; Kono, S; Sugimoto, A; Yamaguchi, H; Morise, T; Koyama, Y; Uchida, K; Suguro, M; Matsumoto, T; Yasuyuki, K; Kawai, T; Itoi, T				Madarame, Akira; Fukuzawa, Masakatsu; Yamauchi, Yoshiya; Kono, Shin; Sugimoto, Akihiko; Yamaguchi, Hayato; Morise, Takashi; Koyama, Yohei; Uchida, Kumiko; Suguro, Maya; Matsumoto, Taisuke; Yasuyuki, Kagawa; Kawai, Takashi; Itoi, Takao			Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; RELEASE MESALAZINE; MAINTENANCE; ADHERENCE; BALSALAZIDE; INFLIXIMAB; CONSENSUS; OUTCOMES; THERAPY; RISK	Objectives Useful indices to determine whether to reduce the dose of 5-aminosalicylic acid (5-ASA) in patients with ulcerative colitis (UC) during remission remain unclear. We aimed to analyze the rate and risk factors of relapse after reducing the dose of oral 5-ASA used for maintenance therapy of UC. Methods UC patients whose 5-ASA dose was reduced in clinical remission (partial Mayo score of <= 1) at our institution from 2012 to 2017 were analyzed. Various clinical variables of patients who relapsed after reducing the dose of oral 5-ASA were compared with those of patients who maintained remission. Risk factors for relapse were assessed by univariate and multivariate logistic regression analyses. Cumulative relapse-free survival rates were calculated using the Kaplan-Meier method. Results A total of 70 UC patients were included; 52 (74.3%) patients maintained remission and 18 (25.7%) patients relapsed during the follow-up period. Multivariate analysis indicated that a history of acute severe UC (ASUC) was an independent predictive factor for clinical relapse (p = 0.024, odds ratio: 21, 95% confidence interval: 1.50-293.2). Based on Kaplan-Meier survival analysis, the cumulative relapse-free survival rate within 52 weeks was 22.2% for patients with a history of ASUC, compared with 82.0% for those without. the log-rank test showed a significant difference in a history of ASUC (p < 0.001). Conclusions Dose reduction of 5-ASA should be performed carefully in patients who have a history of ASUC.	[Madarame, Akira; Fukuzawa, Masakatsu; Yamauchi, Yoshiya; Kono, Shin; Sugimoto, Akihiko; Yamaguchi, Hayato; Morise, Takashi; Koyama, Yohei; Uchida, Kumiko; Suguro, Maya; Matsumoto, Taisuke; Yasuyuki, Kagawa; Itoi, Takao] Tokyo Med Univ Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan; [Kawai, Takashi] Tokyo Med Univ Hosp, Dept Gastroenterol Endoscopy, Tokyo, Japan	Tokyo Medical University; Tokyo Medical University	Madarame, A (corresponding author), Tokyo Med Univ Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan.	madarame@tokyo-med.ac.jp						ARDIZZONE S, 1995, J CLIN GASTROENTEROL, V21, P287, DOI 10.1097/00004836-199512000-00007; Bitton A, 2012, AM J GASTROENTEROL, V107, P179, DOI 10.1038/ajg.2011.386; Colombel JF, 2011, GASTROENTEROLOGY, V141, P1194, DOI 10.1053/j.gastro.2011.06.054; Corte C, 2015, J CROHNS COLITIS, V9, P376, DOI 10.1093/ecco-jcc/jjv047; Dinesen LC, 2010, J CROHNS COLITIS, V4, P431, DOI 10.1016/j.crohns.2010.02.001; EDWARDS FC, 1963, GUT, V4, P299, DOI 10.1136/gut.4.4.299; Fockens P, 1995, EUR J GASTROEN HEPAT, V7, P1025, DOI 10.1097/00042737-199511000-00003; Fukuda T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187737; Fumery M, 2018, CLIN GASTROENTEROL H, V16, P343, DOI 10.1016/j.cgh.2017.06.016; Ghosh N, 2015, FRONTLINE GASTROENTE, V6, P169, DOI 10.1136/flgastro-2014-100514; GIAFFER MH, 1992, ALIMENT PHARM THERAP, V6, P479; GREEN JRB, 1992, ALIMENT PHARM THERAP, V6, P647; Harbord M, 2017, J CROHNS COLITIS, V11, P769, DOI 10.1093/ecco-jcc/jjx009; Kane S, 2008, DIGEST DIS SCI, V53, P1020, DOI 10.1007/s10620-007-9968-0; Kane Sunanda V, 2007, Gastroenterol Hepatol (N Y), V3, P795; Khan N, 2012, ALIMENT PHARM THER, V36, P755, DOI 10.1111/apt.12013; Khan N, 2013, INFLAMM BOWEL DIS, V19, P1123, DOI 10.1097/MIB.0b013e318280b1b8; Kruis W, 2011, ALIMENT PHARM THER, V33, P313, DOI 10.1111/j.1365-2036.2010.04537.x; Magro F, 2017, J CROHNS COLITIS, V11, P649, DOI 10.1093/ecco-jcc/jjx008; Matsuoka K, 2018, J GASTROENTEROL, V53, P305, DOI 10.1007/s00535-018-1439-1; Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0; Panaccione R, 2014, GASTROENTEROLOGY, V146, P392, DOI 10.1053/j.gastro.2013.10.052; Pica R., 2012, ITAL J MED, V1, P108; RILEY SA, 1990, GUT, V31, P179, DOI 10.1136/gut.31.2.179; Robinson A, 2013, ALIMENT PHARM THER, V38, P531, DOI 10.1111/apt.12396; Salameh R, 2020, ALIMENT PHARM THER, V51, P1096, DOI 10.1111/apt.15751; Sandborn WJ, 2009, GASTROENTEROLOGY, V137, P1934, DOI 10.1053/j.gastro.2009.08.069; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; Shah SC, 2016, CLIN GASTROENTEROL H, V14, P1245, DOI 10.1016/j.cgh.2016.01.015; Timmer A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000478.pub4; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; Ungaro R, 2017, LANCET, V389, P1756, DOI 10.1016/S0140-6736(16)32126-2; Wang YJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000544.pub4	33	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2021	16	8							e0255620	10.1371/journal.pone.0255620	http://dx.doi.org/10.1371/journal.pone.0255620			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6IY	34347848	Green Published, gold			2023-01-03	WOS:000685264900072
J	Kahraman, T; Kaya, DO; Isik, T; Gultekin, SC; Seebacher, B				Kahraman, Turhan; Kaya, Derya Ozer; Isik, Tayfun; Gultekin, Sukriye Cansu; Seebacher, Barbara			Feasibility of motor imagery and effects of activating and relaxing practice on autonomic functions in healthy young adults: A randomised, controlled, assessor-blinded, pilot trial	PLOS ONE			English	Article							DATA SATURATION; RELIABILITY; BRAIN; PERSPECTIVES; PROPORTION; HANDEDNESS; MOVEMENTS; VALIDITY; FATIGUE; WALKING	Introduction Motor imagery (MI) is the mental rehearsal of a motor task. Between real and imagined movements, a functional equivalence has been described regarding timing and brain activation. The primary study aim was to investigate the feasibility of MI training focusing on the autonomic function in healthy young people. Further aims were to evaluate participants' MI abilities and compare preliminary effects of activating and relaxing MI on autonomic function and against controls. Methods A single-blinded randomised controlled pilot trial was performed. Participants were randomised to the activating MI (1), relaxing MI (2), or control (3) group. Following a MI familiarisation, they practiced home-based kinaesthetic MI for 17 minutes, 5 times/week for 2 weeks. Participants were called once for support. The primary outcome was the feasibility of a full-scale randomised controlled trial using predefined criteria. Secondary outcomes were participants' MI ability using the Movement Imagery Questionnaire-Revised, mental chronometry tests, hand laterality judgement and semi-structured interviews, autonomic function. Results A total of 35 participants completed the study. The feasibility of a larger study was confirmed, despite 35% attrition related to the COVID-19 pandemic. Excellent MI capabilities were seen in participants, and significant correlations between MI ability measures. Interview results showed that participants accepted or liked both interventions. Seven major themes and insider recommendations for MI interventions emerged. No significant differences and negligible to medium effects were observed in MI ability or autonomic function between baseline and post-intervention measures or between groups. Conclusions Results showed that neither activating nor relaxing MI seems to change autonomic function in healthy individuals. Further adequately powered studies are required to answer open questions remaining from this study. Future studies should investigate effects of different MI types over a longer period, to rule out habituation and assess autonomic function at several time points and simultaneously with MI.	[Kahraman, Turhan; Kaya, Derya Ozer; Isik, Tayfun; Gultekin, Sukriye Cansu] Izmir Katip Celebi Univ, Fac Hlth Sci, Dept Physiotherapy & Rehabil, Izmir, Turkey; [Seebacher, Barbara] Med Univ Innsbruck, Clin Dept Neurol, Innsbruck, Austria; [Seebacher, Barbara] Rehab Ctr Muenster, Dept Rehabil Res, Muenster, Austria	Izmir Katip Celebi University; Medical University of Innsbruck	Seebacher, B (corresponding author), Med Univ Innsbruck, Clin Dept Neurol, Innsbruck, Austria.; Seebacher, B (corresponding author), Rehab Ctr Muenster, Dept Rehabil Res, Muenster, Austria.	barbara.seebacher@i-med.ac.at	Kahraman, Turhan/O-5499-2015	Kahraman, Turhan/0000-0002-8776-0664	Department of Scientific Research Projects, Izmir Katip Celebi University [2017-2ONP-SABF-0008]	Department of Scientific Research Projects, Izmir Katip Celebi University(Izmir Katip Celebi University)	The assessment devices and physiotherapy laboratories used in this study was funded by the Department of Scientific Research Projects, Izmir Katip Celebi University (Project ID: 2017-2ONP-SABF-0008, Title: Establishment of Physiotherapy and Rehabilitation Vocational Skills, Education, Research, and Innovation Laboratory Infrastructure); https://www.ikcu.edu.tr/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akkarpat I., 2014, THESIS HACETTEPE U A; Altman DG, 1999, BRIT MED J, V318, P1209; [Anonymous], 2000, PRINCIPLES NEURAL SC, V4, DOI [10.1126/science.287.5451.273, DOI 10.1126/SCIENCE.287.5451.273]; Berger R, 2015, QUAL RES, V15, P219, DOI 10.1177/1468794112468475; Boonstra AM, 2012, INT J REHABIL RES, V35, P278, DOI 10.1097/MRR.0b013e328355dd1e; Bradley MM, 2009, PSYCHOPHYSIOLOGY, V46, P1, DOI 10.1111/j.1469-8986.2008.00702.x; Breckenridge JD, 2019, J PAIN, V20, P119, DOI 10.1016/j.jpain.2018.07.004; Brown LD, 2001, STAT SCI, V16, P101, DOI 10.1214/ss/1009213286; Bryman Alan, 2006, QUAL RES, V6, P97, DOI [DOI 10.1177/1468794106058877, 10.1177/1468794106058877]; Busch D, 2010, LATERALITY, V15, P610, DOI 10.1080/13576500903081806; Butler AJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/497289; Caligiore D, 2017, NEUROSCI BIOBEHAV R, V72, P210, DOI 10.1016/j.neubiorev.2016.11.005; Cohen J., 2013, STAT POWER ANAL BEHA; Collet C, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00415; Collet C, 2011, EXERC SPORT SCI REV, V39, P85, DOI 10.1097/JES.0b013e31820ac5e0; Cuenca-Martinez F, 2018, PEERJ, V6, DOI 10.7717/peerj.5142; Cypress BS, 2017, DIMENS CRIT CARE NUR, V36, P253, DOI 10.1097/DCC.0000000000000253; de Abreu RM, 2019, BRAZ J PHYS THER, V23, P279, DOI 10.1016/j.bjpt.2018.09.010; de Vries S, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00790; DECETY J, 1989, BEHAV BRAIN RES, V34, P35, DOI 10.1016/S0166-4328(89)80088-9; Decety J, 1996, BEHAV BRAIN RES, V72, P127; Demougeot L, 2011, J NEUROSCI, V31, P10712, DOI 10.1523/JNEUROSCI.6032-10.2011; Di Rienzo F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047207; Lopez ND, 2019, TOP STROKE REHABIL, V26, P576, DOI 10.1080/10749357.2019.1640000; Filgueiras A, 2018, BRAIN IMAGING BEHAV, V12, P1513, DOI 10.1007/s11682-017-9813-9; Fusch PI, 2015, QUAL REP, V20, P1408; Gerardin E, 2000, CEREB CORTEX, V10, P1093, DOI 10.1093/cercor/10.11.1093; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Guillot A., 2010, NEUROPHYSIOLOGICAL F; Helfferich C., 2014, HDB METHODEN EMPIRIS; Holmes PS, 2001, J APPL SPORT PSYCHOL, V13, P60, DOI 10.1080/10413200109339004; JEANNEROD M, 1994, BEHAV BRAIN SCI, V17, P187, DOI 10.1017/S0140525X00034026; Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185; Kahraman T, 2020, J TELEMED TELECARE, V26, P251, DOI 10.1177/1357633X18822355; Kleim JA, 2011, J COMMUN DISORD, V44, P521, DOI 10.1016/j.jcomdis.2011.04.006; Kraeutner S, 2014, BRAIN RES, V1588, P81, DOI 10.1016/j.brainres.2014.09.001; Lamnek S., 2016, QUALITATIVE SOZIALFO; Lebon F, 2010, J STRENGTH COND RES, V24, P1680, DOI 10.1519/JSC.0b013e3181d8e936; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Li C, 2013, STATA J, V13, P795, DOI 10.1177/1536867X1301300407; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Machado TC, 2019, TOP STROKE REHABIL, V26, P548, DOI 10.1080/10749357.2019.1627716; Malouin F, 2008, NEUROREHAB NEURAL RE, V22, P330, DOI 10.1177/1545968307313499; Mulder T, 2004, EXP BRAIN RES, V154, P211, DOI 10.1007/s00221-003-1647-6; Mulder T, 2007, J NEURAL TRANSM, V114, P1265, DOI 10.1007/s00702-007-0763-z; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Nicholson V, 2019, J PHYSIOTHER, V65, P200, DOI 10.1016/j.jphys.2019.08.007; Noble Helen, 2015, Evid Based Nurs, V18, P34, DOI 10.1136/eb-2015-102054; Oishi K, 2004, J CLIN NEUROPHYSIOL, V21, P170, DOI 10.1097/00004691-200405000-00005; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Olsson CJ, 2010, SCAND J MED SCI SPOR, V20, P711, DOI 10.1111/j.1600-0838.2010.01101.x; Olsson C-J, 2008, Open Neuroimag J, V2, P5, DOI 10.2174/1874440000802010005; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Papaxanthis C, 2002, BEHAV BRAIN RES, V134, P209, DOI 10.1016/S0166-4328(02)00030-X; Paravlic AH, 2018, SPORTS MED, V48, P1165, DOI 10.1007/s40279-018-0874-8; Paris-Alemany A, 2019, SCAND J MED SCI SPOR, V29, P897, DOI 10.1111/sms.13399; Personnier P, 2010, NEUROSCI LETT, V476, P146, DOI 10.1016/j.neulet.2010.04.017; RAVUSSIN E, 1982, AM J CLIN NUTR, V35, P566, DOI 10.1093/ajcn/35.3.566; Reimers AK, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120503; Schieber MH, 2013, CURR BIOL, V23, pR151, DOI 10.1016/j.cub.2013.01.004; Schreier M, 2012, QUALITATIVE CONTENT; Schuster C, 2012, STROKE RES TREAT, V2012, DOI 10.1155/2012/503190; Schuster C, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-75; Seebacher BA, 2019, MULT SCLER J, V25, P1593, DOI 10.1177/1352458518795332; Seebacher Barbara, 2018, Arch Physiother, V8, P6, DOI 10.1186/s40945-018-0045-0; Seebacher B, 2017, MULT SCLER J, V23, P286, DOI 10.1177/1352458516644058; Seebacher Barbara, 2015, Pilot Feasibility Stud, V1, P25; Sharma N, 2006, STROKE, V37, P1941, DOI 10.1161/01.STR.0000226902.43357.fc; Thaut M.H., 2005, RHYTHM MUSIC BRAIN S, P113; Tomczak M., 2014, TRENDS SPORT SCI, V1, P19; Treece E. W., 1982, ELEMENTS RES NURSING; Uysal SA., 2019, J EXERCISE THERAPY R, V6, P112; Vandarakis D, 2013, RES SPORTS MED, V21, P187, DOI 10.1080/15438627.2012.757226; Vasold KL, 2019, INT J SPORT NUTR EXE, V29, P406, DOI 10.1123/ijsnem.2018-0283; Verney J, 2015, J HUM KINET, V47, P73, DOI 10.1515/hukin-2015-0063; WANG YD, 1992, BEHAV BRAIN RES, V52, P167, DOI 10.1016/S0166-4328(05)80227-X; Williams LJ, 2019, MUSCULOSKEL SCI PRAC, V40, P45, DOI 10.1016/j.msksp.2019.01.010; WITZ K, 1990, J EDUC STAT, V15, P84; Wondrusch C, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00477; Zaccaro A, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00353; Zimney KJ, 2018, MUSCULOSKEL SCI PRAC, V33, P105, DOI 10.1016/j.msksp.2017.09.002	81	0	0	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2021	16	7							e0254666	10.1371/journal.pone.0254666	http://dx.doi.org/10.1371/journal.pone.0254666			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2ME	34255812	gold, Green Published			2023-01-03	WOS:000678118700020
J	Shimizu, Y; Sasaki, T; Takeshita, J; Watanabe, M; Shizu, R; Hosaka, T; Yoshinari, K				Shimizu, Yuki; Sasaki, Takamitsu; Takeshita, Jun-ichi; Watanabe, Michiko; Shizu, Ryota; Hosaka, Takuomi; Yoshinari, Kouichi			Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs	PLOS ONE			English	Article							INDUCED HEPATOTOXICITY; ORAL MEDICATIONS; RISK; CELLS	Drug-induced liver injury (DILI) is one of major causes of discontinuing drug development and withdrawing drugs from the market. In this study, we investigated chemical properties associated with DILI using in silico methods, to identify a physicochemical property useful for DILI screening at the early stages of drug development. Total of 652 drugs, including 432 DILI-positive drugs (DILI drugs) and 220 DILI-negative drugs (no-DILI drugs) were selected from Liver Toxicity Knowledge Base of US Food and Drug Administration. Decision tree models were constructed using 2,473 descriptors as explanatory variables. In the final model, the descriptor AMW, representing average molecular weight, was found to be at the first node and showed the highest importance value. With AMW alone, 276 DILI drugs (64%) and 156 no-DILI drugs (71%) were correctly classified. Discrimination with AMW was then performed using therapeutic category information. The performance of discrimination depended on the category and significantly high performance (>0.8 balanced accuracy) was obtained in some categories. Taken together, the present results suggest AMW as a novel descriptor useful for detecting drugs with DILI risk. The information presented may be valuable for the safety assessment of drug candidates at the early stage of drug development.	[Shimizu, Yuki; Sasaki, Takamitsu; Takeshita, Jun-ichi; Watanabe, Michiko; Shizu, Ryota; Hosaka, Takuomi; Yoshinari, Kouichi] Univ Shizuoka, Sch Pharmaceut Sci, Lab Mol Toxicol, Shizuoka, Japan; [Takeshita, Jun-ichi] Natl Inst Adv Ind Sci & Technol, Res Inst Sci Safety & Sustainabil, Tsukuba, Ibaraki, Japan	University of Shizuoka; National Institute of Advanced Industrial Science & Technology (AIST)	Yoshinari, K (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Lab Mol Toxicol, Shizuoka, Japan.	yoshinari@u-shizuoka-ken.ac.jp	Yoshinari, Kouichi/X-8070-2019; Shizu, Ryota/ACP-9957-2022; Takeshita, Jun-ichi/L-7806-2016	Yoshinari, Kouichi/0000-0002-2027-2017; Takeshita, Jun-ichi/0000-0002-3471-1594; Shizu, Ryota/0000-0002-0465-5077	Ministry of Education, Culture, Sports, Sciences and Technology of Japan [17K08419]; Mochida Memorial Foundation for Medical and Pharmaceutical Research	Ministry of Education, Culture, Sports, Sciences and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Mochida Memorial Foundation for Medical and Pharmaceutical Research	This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Sciences and Technology of Japan (grant numbers 17K08419) (TS, KY) and a grant from The Mochida Memorial Foundation for Medical and Pharmaceutical Research (FY 2020) (TS, KY). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ancuceanu R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062114; Chalasani N, 2010, GASTROENTEROLOGY, V138, P2246, DOI 10.1053/j.gastro.2010.04.001; Chen MJ, 2016, DRUG DISCOV TODAY, V21, P648, DOI 10.1016/j.drudis.2016.02.015; Chen MJ, 2015, J HEPATOL, V63, P503, DOI 10.1016/j.jhep.2015.04.016; Chen MJ, 2014, ARCH TOXICOL, V88, P1439, DOI 10.1007/s00204-014-1276-9; Chen MJ, 2013, TOXICOL SCI, V136, P242, DOI 10.1093/toxsci/kft189; Chen MJ, 2013, HEPATOLOGY, V58, P388, DOI 10.1002/hep.26208; Chen MJ, 2011, DRUG DISCOV TODAY, V16, P697, DOI 10.1016/j.drudis.2011.05.007; Cook D, 2014, NAT REV DRUG DISCOV, V13, P419, DOI 10.1038/nrd4309; Endo S, 2012, DRUG METAB PHARMACOK, V27, P621, DOI 10.2133/dmpk.DMPK-12-RG-019; Garcia-Cortes M, 2020, ARCH TOXICOL, V94, P3381, DOI 10.1007/s00204-020-02885-1; Garside H, 2014, TOXICOL IN VITRO, V28, P171, DOI 10.1016/j.tiv.2013.10.015; Hirata K, 2008, PHARMACOGENOMICS J, V8, P29, DOI 10.1038/sj.tpj.6500442; Hong HX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17701-7; Hosoya R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172057; Kaplowitz N, 2005, NAT REV DRUG DISCOV, V4, P489, DOI 10.1038/nrd1750; Kato R, 2017, CHEM RES TOXICOL, V30, P1327, DOI 10.1021/acs.chemrestox.7b00065; Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951; Lammert C, 2008, HEPATOLOGY, V47, P2003, DOI 10.1002/hep.22272; Lammert C, 2010, HEPATOLOGY, V51, P615, DOI 10.1002/hep.23317; Li X, 2019, BIOMED RES INT, V2019, DOI [10.1155/2019/8764093, 10.1155/2019/2728952]; Liu J, 2015, CHEM RES TOXICOL, V28, P738, DOI 10.1021/tx500501h; Low Y, 2011, CHEM RES TOXICOL, V24, P1251, DOI 10.1021/tx200148a; McEuen K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071335; MORIGUCHI I, 1994, CHEM PHARM BULL, V42, P976; MORIGUCHI I, 1992, CHEM PHARM BULL, V40, P127; O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33; Park BK, 2011, NAT REV DRUG DISCOV, V10, P292, DOI 10.1038/nrd3408; R Core Team Rf.., 2013, R LANG ENV STAT COMP; Stepan AF, 2011, CHEM RES TOXICOL, V24, P1345, DOI 10.1021/tx200168d; Therneau TM., 2019, MAYO CLIN SECT BIOST, V61, P33; US Food and Drug Administration. Guidance for Industry, 2009, DRUG IND LIV INJ PRE DRUG IND LIV INJ PRE; Wang YY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174106; Wilke RA, 2007, NAT REV DRUG DISCOV, V6, P904, DOI 10.1038/nrd2423	34	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2021	16	6							e0253855	10.1371/journal.pone.0253855	http://dx.doi.org/10.1371/journal.pone.0253855			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9CN	34170966	gold, Green Published			2023-01-03	WOS:000671694400041
J	Yoshizuka, H; Sato, T; Murakami, J; Mitsutake, T; Hiromatsu, M				Yoshizuka, Hisayoshi; Sato, Takanori; Murakami, Junya; Mitsutake, Tsubasa; Hiromatsu, Masao			Short-term changes in radiographic joint space width after jiggling exercise as conservative treatment for hip osteoarthritis: A retrospective case series of nine patients	PLOS ONE			English	Article							ASSOCIATION; PROGRESSION	Jiggling exercise is a conservative treatment for hip osteoarthritis, which involves continuous shaking of the foot and leg in small oscillations while seated. Previous studies have shown beneficial effects of jiggling exercises for outpatients with advanced- and terminal-stage hip osteoarthritis when performed for longer than 1 year, including increases in joint space width and remission of symptoms. We aimed to use the data from our own treatment to evaluate the short-term impact of intensive jiggling exercises on inpatients with hip osteoarthritis to further examine the clinical utility of this exercise. This retrospective case series study included nine patients (57 +/- 12 years) with nine hip joints with advanced- or terminal-stage hip osteoarthritis who performed continuous daily jiggling exercises, beginning from day of hospitalization to 6 months post-discharge. Jiggling exercise was performed seated, using the KENKO YUSURI(R) automated heel vibrating machine at 3.3-5.0 Hz. The patients were also instructed against weight-bearing during hospitalization. The values of radiographic joint space width and Japanese Orthopaedic Association hip score for pain at hospital admission, discharge, and at the 6-month post-discharge checkup were evaluated. Although the hospitalization period and daily time spent performing the jiggling exercise varied in each case (27-98 days and 2-6 hours, respectively), the joint space width increased in all patients and there was an improvement in the hip pain scores in eight patients. The mean values of the minimum joint space width and hip pain scores at discharge were the highest compared to those at hospital admission and 6 months post-discharge. Our results suggest that intensive jiggling exercise for inpatients with advanced- and terminal-stage hip osteoarthritis leads to earlier improvement in joint space width and pain. Daily jiggling exercise for an adequate duration or in combination with non-weight-bearing practices may be a feasible conservative treatment for hip osteoarthritis.	[Yoshizuka, Hisayoshi; Mitsutake, Tsubasa] Fukuoka Int Univ Hlth & Welf, Dept Phys Therapy, Fukuoka, Fukuoka, Japan; [Sato, Takanori; Murakami, Junya] Yanagawa Rehabil Hosp, Dept Rehabil Med, Yanagawa City, Fukuoka, Japan; [Hiromatsu, Masao] Yatsushiro Keijin Hosp, Dept Orthoped Surg, Yatsushiro City, Kumamoto, Japan	International University of Health & Welfare	Yoshizuka, H (corresponding author), Fukuoka Int Univ Hlth & Welf, Dept Phys Therapy, Fukuoka, Fukuoka, Japan.	yoshizukan@gmail.com		Yoshizuka, Hisayoshi/0000-0002-4979-7327; Mitsutake, Tsubasa/0000-0001-7515-6729	Japan Society for the Promotion of Science (JSPS) KAKENHI [20K23307]	Japan Society for the Promotion of Science (JSPS) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 20K23307. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Birrell F, 2005, RHEUMATOLOGY, V44, P337, DOI 10.1093/rheumatology/keh458; Block JA, 2014, NAT REV RHEUMATOL, V10, P324, DOI 10.1038/nrrheum.2014.61; CROFT P, 1990, AM J EPIDEMIOL, V132, P514, DOI 10.1093/oxfordjournals.aje.a115687; DELP SL, 1990, CLIN ORTHOP RELAT R, P189; Hiromatsu M, 2013, BONE JOINT NERVE, V3, P475; Hiromatsu M, 2014, HIP JOINT, V40, P70; Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140-6736(19)30417-9; Ishibashi Y., 2019, HIP JOINT, V45, P649; Jacobsen S, 2005, RHEUMATOLOGY, V44, P211, DOI 10.1093/rheumtology/keh436; Jacobsen S, 2004, ACTA ORTHOP SCAND, V75, P713, DOI 10.1080/00016470410004085; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Jingushi S, 2011, J ORTHOP SCI, V16, P156, DOI 10.1007/s00776-011-0025-7; Kamaruzaman H, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1540-2; Kloppenburg M, 2020, OSTEOARTHR CARTILAGE, V28, P242, DOI 10.1016/j.joca.2020.01.002; Kuribayashi M, 2010, J ORTHOP SCI, V15, P452, DOI 10.1007/s00776-010-1490-0; Lane NE, 2004, ARTHRITIS RHEUM-US, V50, P1477, DOI 10.1002/art.20213; Maniwa S., 2017, HIP JOINT, V43, P998; Nelson AE, 2014, SEMIN ARTHRITIS RHEU, V43, P701, DOI 10.1016/j.semarthrit.2013.11.012; Rice D, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111769; SALTER RB, 1980, J BONE JOINT SURG AM, V62, P1232, DOI 10.2106/00004623-198062080-00002; Tateuchi H, 2017, OSTEOARTHR CARTILAGE, V25, P1291, DOI 10.1016/j.joca.2017.02.796; Teramoto Yohei, 2020, Case Rep Orthop, V2020, P2804193, DOI 10.1155/2020/2804193	22	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2021	16	6							e0253643	10.1371/journal.pone.0253643	http://dx.doi.org/10.1371/journal.pone.0253643			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BH	34157042	Green Published, gold			2023-01-03	WOS:000671691200032
J	Tatonetti, NP; Elhadad, N				Tatonetti, Nicholas P.; Elhadad, Noemie			Fine-scale genetic ancestry as a potential new tool for precision medicine	NATURE MEDICINE			English	Editorial Material									[Tatonetti, Nicholas P.; Elhadad, Noemie] Columbia Univ, Dept Biomed Informat, New York, NY 10027 USA	Columbia University	Tatonetti, NP; Elhadad, N (corresponding author), Columbia Univ, Dept Biomed Informat, New York, NY 10027 USA.	nick.tatonetti@columbia.edu; noemie.elhadad@columbia.edu		Tatonetti, Nicholas/0000-0002-2700-2597				Belbin GM, 2021, CELL, V184, P2068, DOI 10.1016/j.cell.2021.03.034; Denny JC, 2021, CELL, V184, P1415, DOI 10.1016/j.cell.2021.01.015; Hripcsak G, 2013, J AM MED INFORM ASSN, V20, P117, DOI 10.1136/amiajnl-2012-001145; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x	4	2	2	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1152	1153		10.1038/s41591-021-01405-7	http://dx.doi.org/10.1038/s41591-021-01405-7		JUN 2021	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34140703				2023-01-03	WOS:000662941700002
J	Kestler, AMR; Kuhlwein, SD; Kraus, JM; Schwab, JD; Szekely, R; Thiam, P; Huhne, R; Jahn, N; Furstberger, A; Ikonomi, N; Balig, J; Schuler, R; Kuhn, P; Steger, F; Seufferlein, T; Kestler, HA				Kestler, Angelika M. R.; Kuehlwein, Silke D.; Kraus, Johann M.; Schwab, Julian D.; Szekely, Robin; Thiam, Patrick; Huehne, Rolf; Jahn, Niels; Fuerstberger, Axel; Ikonomi, Nensi; Balig, Julien; Schuler, Rainer; Kuhn, Peter; Steger, Florian; Seufferlein, Thomas; Kestler, Hans A.			Digitalization of adverse event management in oncology to improve treatment outcome-A prospective study protocol	PLOS ONE			English	Article							PATIENT-REPORTED OUTCOMES; COMMON TERMINOLOGY CRITERIA; VERSION; CHEMORADIOTHERAPY; FEASIBILITY; TOXICITY	The occurrence of adverse events frequently accompanies tumor treatments. Side effects should be detected and treated as soon as possible to maintain the best possible treatment outcome. Besides the standard reporting system Common Terminology Criteria for Adverse Events (CTCAE), physicians have recognized the potential of patient-reporting systems. These are based on a more subjective description of current patient reporting symptoms. Patient-reported symptoms are essential to define the impact of a given treatment on the quality of life and the patient's wellbeing. They also act against an underreporting of side effects which are paramount to define the actual value of a treatment for the individual patient. Here, we present a study protocol for a clinical trial that assesses the potential of a smartphone application for CTCAE conform symptom reporting and tracking that is adjusted to the standard clinical reporting system rather than symptom oriented descriptive trial tools. The presented study will be implemented in two parts, both lasting over six months. The first part will assess the feasibility of the application with 30 patients non-randomly divided into three equally-sized age groups (<55years, 55-75years, >75years). In the second part 36 other patients will be randomly assigned to two groups, one reporting using the smartphone and one not. This prospective second part will compare the impact of smartphone reported adverse events regarding applied therapy doses and quality of life to those of patients receiving standard care. We aim for early detection and treatment of adverse events in oncological treatment to improve patients' safety and outcomes. For this purpose, we will capture frequent adverse events of chemotherapies, immunotherapies, or other targeted therapies with our smartphone application. The presented trial is registered at the U.S. National Library of Medicine ClinicalTrials.gov (NCT04493450) on July 30, 2020.	[Kestler, Angelika M. R.; Seufferlein, Thomas] Univ Hosp Ulm, Dept Internal Med 1, Ulm, Germany; [Kuehlwein, Silke D.; Kraus, Johann M.; Schwab, Julian D.; Szekely, Robin; Thiam, Patrick; Huehne, Rolf; Jahn, Niels; Fuerstberger, Axel; Ikonomi, Nensi; Balig, Julien; Schuler, Rainer; Kestler, Hans A.] Ulm Univ, Inst Med Syst Biol, Ulm, Germany; [Kuhn, Peter] Univ Hosp Ulm, Ctr Comprehens Canc, Ulm, Germany; [Steger, Florian] Ulm Univ, Inst Hist Philosophy & Eth Med, Ulm, Germany	Ulm University; Ulm University; Ulm University; Ulm University	Kestler, HA (corresponding author), Ulm Univ, Inst Med Syst Biol, Ulm, Germany.	hans.kestler@uni-ulm.de		Ikonomi, Nensi/0000-0003-0780-5832; Thiam, Patrick/0000-0002-6769-8410; Schwab, Julian D./0000-0002-3050-0618	Ministry of Science and Art Baden-Wurttemberg (Zentrum fur Innovative Versorgung, ZIV); German Federal Ministry of Education and Research (BMBF), DIFUTURE project (Medical Informatics Initiative) [01ZZ1804I]; Ministry of Social Affairs and Integration Baden-Wurttemberg, project feelBack (networked, digital, patient-related feedback psycho-oncology)	Ministry of Science and Art Baden-Wurttemberg (Zentrum fur Innovative Versorgung, ZIV); German Federal Ministry of Education and Research (BMBF), DIFUTURE project (Medical Informatics Initiative)(Federal Ministry of Education & Research (BMBF)); Ministry of Social Affairs and Integration Baden-Wurttemberg, project feelBack (networked, digital, patient-related feedback psycho-oncology)	The funding to establish the smartphone and desktop application was provided by the Ministry of Science and Art Baden-Wurttemberg (Zentrum fur Innovative Versorgung, ZIV), the German Federal Ministry of Education and Research (BMBF) as part of the DIFUTURE project (Medical Informatics Initiative, grant number 01ZZ1804I), and the Ministry of Social Affairs and Integration Baden-Wurttemberg as part of the project feelBack (networked, digital, patient-related feedback psycho-oncology). However, the conduction of the here described study receives no funding.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Andikyan V, 2012, GYNECOL ONCOL, V127, P273, DOI 10.1016/j.ygyno.2012.07.124; Baeksted C, 2017, J PATIENT-REP OUTCOM, V1, DOI 10.1186/s41687-017-0005-6; Basch E, 2007, J CLIN ONCOL, V25, P5374, DOI 10.1200/JCO.2007.11.2243; Basch E, 2017, INT J RADIAT ONCOL, V98, P409, DOI 10.1016/j.ijrobp.2017.02.002; Basch E, 2016, CLIN TRIALS, V13, P331, DOI 10.1177/1740774515615540; Basch E, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju244; Basch E, 2009, JNCI-J NATL CANCER I, V101, P1624, DOI 10.1093/jnci/djp386; Bennett AV, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0426-6; Benze G, 2019, ANN PALLIAT MED, V8, P104, DOI 10.21037/apm.2017.07.05; Bischoff-Ferrari HA, 2005, ANN RHEUM DIS, V64, P80, DOI 10.1136/ard.2003.019307; Di Maio M, 2016, NAT REV CLIN ONCOL, V13, P319, DOI 10.1038/nrclinonc.2015.222; Dueck AC, 2015, JAMA ONCOL, V1, P1051, DOI 10.1001/jamaoncol.2015.2639; Falchook AD, 2016, JAMA OTOLARYNGOL, V142, P517, DOI 10.1001/jamaoto.2016.0656; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fayers P, 2001, EORTC QLQ C30 SCORIN, V3th; Hlobaz A, 2014, COMM COM INF SC, V431, P277; Holzinger A, 2007, LECT NOTES COMPUT SC, V4554, P923; Howlader N., 2013, SEER CANC STAT REV 1; Jin ZX, 2007, PROCEEDINGS OF THE 2007 INTERNATIONAL CONFERENCE ON MANAGEMENT SCIENCE AND ENGINEERING - MANAGEMENT AND ORGANIZATION STUDIES SECTION, P933; JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.2307/2333011; Kim H, 2007, LECT NOTES COMPUT SC, V4554, P950; Kluetz Paul G, 2016, Am Soc Clin Oncol Educ Book, V35, P67, DOI 10.14694/EDBK_159514; Martins F, 2019, NAT REV CLIN ONCOL, V16, P563, DOI 10.1038/s41571-019-0218-0; Olwal A, 2011, 29TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, P3393; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21590, 10.3322/caac.21601]; Xiao CH, 2013, CANCER NURS, V36, pE1, DOI 10.1097/NCC.0b013e318269040f	27	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2021	16	6							e0252493	10.1371/journal.pone.0252493	http://dx.doi.org/10.1371/journal.pone.0252493			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RB	34086740	Green Published, gold			2023-01-03	WOS:000664640100075
J	McQuaid, C; Halsey, A; Dubois, M; Romero, I; Male, D				McQuaid, Conor; Halsey, Andrea; Dubois, Maeva; Romero, Ignacio; Male, David			Comparison of polypeptides that bind the transferrin receptor for targeting gold nanocarriers	PLOS ONE			English	Article							BLOOD-BRAIN-BARRIER; CELLULAR UPTAKE; DELIVERY; PEPTIDES; TRANSPORT	The ability to target therapeutic agents to specific tissues is an important element in the development of new disease treatments. The transferrin receptor (TfR) is one potential target for drug delivery, as it expressed on many dividing cells and on brain endothelium, the key cellular component of the blood-brain barrier. The aim of this study was to compare a set of new and previously-described polypeptides for their ability to bind to brain endothelium, and investigate their potential for targeting therapeutic agents to the CNS. Six polypeptides were ranked for their rate of endocytosis by the human brain endothelial cell line hCMEC/D3 and the murine line bEnd.3. One linear polypeptide and two cyclic polypeptides showed high rates of uptake. These peptides were investigated to determine whether serum components, including transferrin itself affected uptake by the endothelium. One of the cyclic peptides was strongly inhibited by transferrin and the other cyclic peptide weakly inhibited. As proof of principle the linear peptide was attached to 2nm glucose coated gold-nanoparticles, and the rate of uptake of the nanoparticles measured in a hydrogel model of the blood-brain barrier. Attachment of the TfR-targeting polypeptide significantly increased the rates of endocytosis by brain endothelium and increased movement of nanoparticles across the cells.	[McQuaid, Conor; Halsey, Andrea; Dubois, Maeva; Romero, Ignacio; Male, David] Open Univ, Dept Life Hlth & Chem Sci, Milton Keynes, Bucks, England; [McQuaid, Conor] Univ Rochester, Dept Neurosci, Rochester, NY USA; [Halsey, Andrea] Univ Birmingham, Coll Med & Dent Sci, Inst Inflammat & Ageing, Dept Neurosci & Ophthalmol, Birmingham, W Midlands, England	Open University - UK; University of Rochester; University of Birmingham	Male, D (corresponding author), Open Univ, Dept Life Hlth & Chem Sci, Milton Keynes, Bucks, England.	David.Male@Open.ac.uk		Male, David/0000-0002-1242-3137; McQuaid, Conor/0000-0002-5163-8915; Romero, Ignacio/0000-0002-0322-9180	Midatech pharma plc.	Midatech pharma plc.	DM, PhD studentship to support CM. `Delivery of therapeutic cytokines to the CNS, using nanoparticle carriers.' Midatech pharma plc. https://www.midatechpharma.com The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Alkilany AM, 2010, J NANOPART RES, V12, P2313, DOI 10.1007/s11051-010-9911-8; Bourassa P, 2019, MOL PHARMACEUT, V16, P583, DOI 10.1021/acs.molpharmaceut.8b00870; BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801; Crawford L, 2016, J CONTROL RELEASE, V240, P251, DOI 10.1016/j.jconrel.2015.12.041; Cummings Jeffrey, 2018, Alzheimers Dement (N Y), V4, P195, DOI 10.1016/j.trci.2018.03.009; Daas M, 2018, THESIS OPEN U; Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010; Daniels TR, 2012, BBA-GEN SUBJECTS, V1820, P291, DOI 10.1016/j.bbagen.2011.07.016; Demeule M, 2008, J PHARMACOL EXP THER, V324, P1064, DOI 10.1124/jpet.107.131318; Eckenroth BE, 2011, P NATL ACAD SCI USA, V108, P13089, DOI 10.1073/pnas.1105786108; Fatima N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236611; Gang D, 2018, GENES-BASEL, V9, DOI 10.3390/genes9110557; Georgieva Julia V, 2014, Pharmaceutics, V6, P557, DOI 10.3390/pharmaceutics6040557; Gromnicova R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081043; Haqqani AS, 2018, J NEUROCHEM, V146, P735, DOI 10.1111/jnc.14482; Jiang Y, 2015, ACS NANO, V9, P9986, DOI 10.1021/acsnano.5b03521; Johnsen KB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11220-1; Lajoie JM, 2015, ANNU REV PHARMACOL, V55, P613, DOI 10.1146/annurev-pharmtox-010814-124852; Lee JH, 2001, EUR J BIOCHEM, V268, P2004, DOI 10.1046/j.1432-1327.2001.02073.x; Majerova P, 2020, MOLECULES, V25, DOI 10.3390/molecules25040874; Moura RP, 2019, EXPERT OPIN DRUG DEL, V16, P271, DOI 10.1080/17425247.2019.1583205; Nga BL, 2014, J EXP MED, V211, P233, DOI 10.1084/jem.20131660; Niewoehner J, 2014, NEURON, V81, P49, DOI 10.1016/j.neuron.2013.10.061; Oller-Salvia B, 2016, CHEM SOC REV, V45, P4690, DOI 10.1039/c6cs00076b; Pardridge WM, 2008, BIOCONJUGATE CHEM, V19, P1327, DOI 10.1021/bc800148t; Pardridge William M, 2005, NeuroRx, V2, P3; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Paterson Judy, 2016, Drug Discov Today Technol, V20, P49, DOI 10.1016/j.ddtec.2016.07.009; Pulgar VM, 2019, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.01019; Sharma G, 2019, INT J PHARMACEUT, V559, P360, DOI 10.1016/j.ijpharm.2019.01.056; Sreekanthreddy Peddagangannagari, 2015, F1000Res, V4, P1279, DOI 10.12688/f1000research.7142.2; Tsumoto K, 2019, IMMUNOTHERAPY-UK, V11, P119, DOI 10.2217/imt-2018-0130; Weksler BB, 2005, FASEB J, V19, P1872, DOI 10.1096/fj.04-3458fje; Yu YJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002230; Zorzi A, 2019, MEDCHEMCOMM, V10, P1068, DOI 10.1039/c9md00018f	36	1	1	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2021	16	6							e0252341	10.1371/journal.pone.0252341	http://dx.doi.org/10.1371/journal.pone.0252341			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RB	34086733	gold, Green Published, Green Accepted			2023-01-03	WOS:000664640100049
J	Mihaylov, IB; Totiger, TM; Giret, TM; Wang, DZ; Spieler, B; Welford, S				Mihaylov, Ivaylo B.; Totiger, Tulasigeri M.; Giret, Teresa M.; Wang, Dazhi; Spieler, Benjamin; Welford, Scott			Toward prediction of abscopal effect in radioimmunotherapy: Pre-clinical investigation	PLOS ONE			English	Article							RADIATION-THERAPY; IMMUNOTHERAPY; FEATURES; IMAGES	Purpose Immunotherapy (IT) and radiotherapy (RT) can act synergistically, enhancing antitumor response beyond what either treatment can achieve separately. Anecdotal reports suggest that these results are in part due to the induction of an abscopal effect on non-irradiated lesions. Systematic data on incidence of the abscopal effect are scarce, while the existence and the identification of predictive signatures or this phenomenon are lacking. The purpose of this pre-clinical investigational work is to shed more light on the subject by identifying several imaging features and blood counts, which can be utilized to build a predictive binary logistic model. Materials and methods This proof-of-principle study was performed on Lewis Lung Carcinoma in a syngeneic, subcutaneous murine model. Nineteen mice were used: four as control and the rest were subjected to combined RT plus IT regimen. Tumors were implanted on both flanks and after reaching volume of similar to 200 mm(3) the animals were CT and MRI imaged and blood was collected. Quantitative imaging features (radiomics) were extracted for both flanks. Subsequently, the treated animals received radiation (only to the right flank) in three 8 Gy fractions followed by PD-1 inhibitor administrations. Tumor volumes were followed and animals exhibiting identical of better tumor growth delay on the non-irradiated (left) flank as compared to the irradiated flank were identified as experiencing an abscopal effect. Binary logistic regression analysis was performed to create models for CT and MRI radiomics and blood counts, which are predictive of the abscopal effect. Results Four of the treated animals experienced an abscopal effect. Three CT and two MRI radiomics features together with the pre-treatment neutrophil-to-lymphocyte (NLR) ratio correlated with the abscopal effect. Predictive models were created by combining the radiomics with NLR. ROC analyses indicated that the CT model had AUC of 0.846, while the MRI model had AUC of 0.946. Conclusions The combination of CT and MRI radiomics with blood counts resulted in models with AUCs of 1 on the modeling dataset. Application of the models to the validation dataset exhibited AUCs above 0.84, indicating very good predictive power of the combination between quantitative imaging and blood counts.	[Mihaylov, Ivaylo B.; Totiger, Tulasigeri M.; Giret, Teresa M.; Wang, Dazhi; Spieler, Benjamin; Welford, Scott] Univ Miami, Miler Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA	University of Miami	Mihaylov, IB (corresponding author), Univ Miami, Miler Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA.	i.mihaylov@med.miami.edu		Mihaylov, Ivaylo/0000-0003-4518-5902; Giret, Teresa/0000-0001-7725-0727	NCI NIH HHS [R01 CA187053] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aerts HJWL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5006; Ahmad A, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10186493; Bauckhage C, 2015, NUMPY SCIPY RECIPES, DOI [10.1371/journal.pone.0116902, DOI 10.1371/JOURNAL.PONE.0116902]; Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Cupp MA, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01817-1; Demaria S, 2015, JAMA ONCOL, V1, P1325, DOI 10.1001/jamaoncol.2015.2756; Do QN, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211060; Ethier JL, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-016-0794-1; Gillies RJ, 2016, RADIOLOGY, V278, P563, DOI 10.1148/radiol.2015151169; GIRALDI T, 1989, EUR J CANCER CLIN ON, V25, P1583, DOI 10.1016/0277-5379(89)90301-5; Gustafson MP, 2017, ADV RADIAT ONCOL, V2, P540, DOI 10.1016/j.adro.2017.08.003; HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314; Lambin P, 2012, EUR J CANCER, V48, P441, DOI 10.1016/j.ejca.2011.11.036; Leijenaar RTH, 2013, ACTA ONCOL, V52, P1391, DOI 10.3109/0284186X.2013.812798; Loizou C.P., 2012, J BIOMED GRAPH COMPU, V3, P929, DOI [10.5430/jbgc.v3n1p20, DOI 10.5430/JBGC.V3N1P20]; Marciscano AE, 2021, INT J RADIAT ONCOL, V110, P35, DOI 10.1016/j.ijrobp.2019.02.046; Reynders K, 2015, CANCER TREAT REV, V41, P503, DOI 10.1016/j.ctrv.2015.03.011; Spieler B, 2019, INT J RADIAT ONCOL, V105, pE531, DOI 10.1016/j.ijrobp.2019.06.2438; Spieler BO, 2019, J CLIN ONCOL, V37; Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618	21	4	4	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255923	10.1371/journal.pone.0255923	http://dx.doi.org/10.1371/journal.pone.0255923			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE5RC	34428218	gold, Green Published			2023-01-03	WOS:000687944100021
J	Russo, V; Continella, A; Drago, C; Gentile, A; La Malfa, S; Leotta, CG; Pulvirenti, L; Ruberto, G; Pitari, GM; Siracusa, L				Russo, Venera; Continella, Alberto; Drago, Carmelo; Gentile, Alessandra; La Malfa, Stefano; Leotta, Claudia Giovanna; Pulvirenti, Luana; Ruberto, Giuseppe; Pitari, Giovanni Mario; Siracusa, Laura			Secondary metabolic profiles and anticancer actions from fruit extracts of immature pomegranates	PLOS ONE			English	Article							PUNICA-GRANATUM; ELLAGIC ACID; IN-VITRO; CANCER; ANTIOXIDANT; QUALITY; POLYPHENOLS; APOPTOSIS; JUICE; POLYSACCHARIDE	Immature fruits from Punica granatum L. thinning are a neglected side product of pomegranate production with cumbersome disposal costs for farmers. To explore value potential of immature fruits from pomegranate 'Wonderful' cultivars, the compositional landscapes and antitumorigenic activities of pomegranate extracts from two different stages of maturation were assessed. Cancer cell proliferation and cytotoxicity was quantified in human lung H1299 and colon HCT116 adenocarcinomas by crystal violet staining, MTS assay and caspase-3 activity. High performance liquid chromatography-diode array detector (HPLC/DAD) and high performance liquid chromatography-electrospray ionization-mass spectrometry (HPLC/ESI-MS) analyses indicate that immature fruits are rich sources of gallotannins and ellagitannins, with the highest amounts contained in immature fruit peels. Biological investigations reveal a robust anticancer activity by those immature P. granatum fruit extracts, which reflected induction of tumor cytotoxicity and cell death mechanisms. Together, present observations suggest P. granatum byproducts from the thinning process may provide unexplored values for virtuous circular economy.	[Russo, Venera; Leotta, Claudia Giovanna; Pitari, Giovanni Mario] Vera Salus Ric Srl, Siracusa, Italy; [Continella, Alberto; Gentile, Alessandra; La Malfa, Stefano] Univ Catania, Dipartimento Agr Alimentaz Ambiente Di3A, Catania, Italy; [Drago, Carmelo; Pulvirenti, Luana; Ruberto, Giuseppe; Siracusa, Laura] Ist Chim Biomol CNR ICB CNR, Catania, Italy	University of Catania	Siracusa, L (corresponding author), Ist Chim Biomol CNR ICB CNR, Catania, Italy.	laura.siracusa@icb.cnr.it			FSE PO 2014-2020 (Regione Sicilia) [11/2017]; Vera Salus Ricerca S.r.l.	FSE PO 2014-2020 (Regione Sicilia); Vera Salus Ricerca S.r.l.	The authors are grateful to Dr. Maurizio Abbate (Consorzio Kore Frutti di Sicilia, Marsala, TP, Italy) for providing the fruit materials investigated in this study. Thanks also to Dr. Sandro Dattilo (IPCB-CNR, Catania, Italy) for providing access to HPLC/ESI-MS apparatus and to Mr. Antonio Greco (ICB-CNR, Catania, Italy) for his skilful assistance in graphic preparation. LP was supported by training grant from FSE PO 2014-2020 (avviso 11/2017 Regione Sicilia). Biological studies were supported by Vera Salus Ricerca S.r.l. The authors dedicate this work to the memory of Dr. Giovanni Nicolosi, beloved mentor, colleague and friend.	Albrecht M, 2004, J MED FOOD, V7, P274, DOI 10.1089/1096620041938704; Andrade MA, 2019, TRENDS FOOD SCI TECH, V86, P68, DOI 10.1016/j.tifs.2019.02.010; Bassiri-Jahromi S, 2018, ONCOL REV, V12, P1, DOI 10.4081/oncol.2018.345; Berkoz M, 2020, GEN PHYSIOL BIOPHYS, V39, P557, DOI 10.4149/gpb_2020024; Brighenti V, 2017, J CHROMATOGR A, V1480, P20, DOI 10.1016/j.chroma.2016.12.017; Dahlawi H, 2013, FOOD SCI NUTR, V1, P196, DOI 10.1002/fsn3.26; Davis K, 2004, HORTTECHNOLOGY, V14, P282, DOI 10.21273/HORTTECH.14.2.0282; Hora Justin J., 2003, Journal of Medicinal Food, V6, P157; Jaganathan SK, 2014, WORLD J GASTROENTERO, V20, P4618, DOI 10.3748/wjg.v20.i16.4618; Jin Z, 2016, AM J TRANSL RES, V8, P3970; Joseph MM, 2013, CARBOHYD POLYM, V98, P1466, DOI 10.1016/j.carbpol.2013.07.023; Joseph MM, 2012, MOL MED REP, V5, P489, DOI 10.3892/mmr.2011.638; Kharchoufi S, 2018, IND CROP PROD, V111, P345, DOI 10.1016/j.indcrop.2017.10.037; Kim ND, 2002, BREAST CANCER RES TR, V71, P203, DOI 10.1023/A:1014405730585; Kulkarni AP, 2005, FOOD CHEM, V93, P319, DOI 10.1016/j.foodchem.2004.09.029; Larrosa M, 2006, J NUTR BIOCHEM, V17, P611, DOI 10.1016/j.jnutbio.2005.09.004; Li YL, 2016, BIOMED PHARMACOTHER, V80, P227, DOI 10.1016/j.biopha.2016.03.023; Musacchi S, 2018, SCI HORTIC-AMSTERDAM, V234, P409, DOI 10.1016/j.scienta.2017.12.057; Naiki-Ito A, 2015, PROSTATE, V75, P151, DOI 10.1002/pros.22900; Nuncio-Jauregui N, 2015, J FOOD COMPOS ANAL, V37, P11, DOI 10.1016/j.jfca.2014.06.015; OKUDA T, 1980, TETRAHEDRON LETT, V21, P4361, DOI 10.1016/S0040-4039(00)77858-0; Pathak PD, 2017, WASTE BIOMASS VALORI, V8, P1127, DOI 10.1007/s12649-016-9668-0; Putnik P, 2019, FOOD CHEM, V279, P150, DOI 10.1016/j.foodchem.2018.11.131; Russo M, 2018, ANAL BIOANAL CHEM, V410, P3507, DOI 10.1007/s00216-018-0854-8; Seeram NP, 2005, J NUTR BIOCHEM, V16, P360, DOI 10.1016/j.jnutbio.2005.01.006; SHULMAN Y, 1984, J HORTIC SCI, V59, P265, DOI 10.1080/00221589.1984.11515196; Singh B, 2018, FOOD CHEM, V261, P75, DOI 10.1016/j.foodchem.2018.04.039; Sun GJ, 2016, ONCOL LETT, V11, P150, DOI 10.3892/ol.2015.3845; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tortora K, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700401; Wang YZ, 2019, J CANCER, V10, P3303, DOI 10.7150/jca.29738	36	5	5	4	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255831	10.1371/journal.pone.0255831	http://dx.doi.org/10.1371/journal.pone.0255831			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY1UP	34375350	gold, Green Published			2023-01-03	WOS:000683572000015
J	Schwartz, H; Emanuel, A; Samukas, IIR; Halperin, I				Schwartz, Hadar; Emanuel, Aviv; Rozen Samukas, Isaac Isur; Halperin, Israel			Exploring the acute affective responses to resistance training: A comparison of the predetermined and the estimated repetitions to failure approaches	PLOS ONE			English	Article							PERCEIVED EXERTION; EXERCISE; INTENSITY; STRENGTH; MAXIMUM; NUMBER	Background In resistance-training (RT), the number of repetitions is traditionally prescribed using a predetermined approach (e.g., three sets of 10 repetitions). An emerging alternative is the estimated repetitions to failure (ERF) approach (e.g., terminating sets two repetitions from failure). Despite the importance of affective responses experienced during RT, a comparison between the two approaches on such outcomes is lacking. Methods Twenty women (age range: 23-45 years) without RT experience completed estimated one repetition maximum (RM) tests in four exercises. In the next two counterbalanced sessions, participants performed the exercises using 70%1RM. Participants completed ten repetitions in all three sets (predetermined condition) or terminated the sets when perceived to be two repetitions away from task-failure (ERF condition). Primary outcomes were affective-valence, enjoyment, and approach-preference and secondary outcomes were repetition-numbers completed in each exercise. Results We observed trivial differences in the subjective measures and an approximately even approach-preference split. Under the ERF condition, we observed greater variability in repetition-numbers between participants and across exercises. Specifically, the mean number of repetitions was slightly lower in the chest-press, knee-extension, and lat-pulldown (similar to 1 repetition) but considerably higher in the leg-press (17 vs. 10, p<0.01). Conclusions Both approaches led to comparable affective responses and to an approximately even approach preference. Hence, prior to prescribing either approach, coaches should consider trainee's preferences. Moreover, under the ERF condition participants completed a dissimilar number of repetitions across exercises while presumably reaching a similar proximity to task-failure. This finding suggests that ERF allows for better effort regulation between exercises.	[Schwartz, Hadar; Emanuel, Aviv; Rozen Samukas, Isaac Isur; Halperin, Israel] Tel Aviv Univ, Sch Publ Hlth, Sackler Fac Med, Tel Aviv, Israel; [Schwartz, Hadar; Emanuel, Aviv; Rozen Samukas, Isaac Isur; Halperin, Israel] Tel Aviv Univ, Sylvan Adams Sports Inst, Tel Aviv, Israel; [Emanuel, Aviv] Tel Aviv Univ, Sch Psychol Sci, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv University	Halperin, I (corresponding author), Tel Aviv Univ, Sch Publ Hlth, Sackler Fac Med, Tel Aviv, Israel.; Halperin, I (corresponding author), Tel Aviv Univ, Sylvan Adams Sports Inst, Tel Aviv, Israel.	ihalperin@tauex.tau.ac.il		Schwartz, Hadar/0000-0002-6446-191X; Emanuel, Aviv/0000-0003-3760-3289; Halperin, Israel/0000-0003-2254-2698	Israeli Science Foundation [1249/20]; Marguerite Stolz Research Fund, Sackler Faculty of Medicine, Tel Aviv University	Israeli Science Foundation(Israel Science Foundation); Marguerite Stolz Research Fund, Sackler Faculty of Medicine, Tel Aviv University	This study was supported by grants from the Israeli Science Foundation (1249/20) and the Marguerite Stolz Research Fund, Sackler Faculty of Medicine, Tel Aviv University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American College of Sports Medicine, 2013, ACSMS GUIDELINES EXE; Arede Jorge, 2020, J Sports Med Phys Fitness, V60, P1231, DOI 10.23736/S0022-4707.20.10907-1; Arent SM, 2005, J SPORT EXERCISE PSY, V27, P92, DOI 10.1123/jsep.27.1.92; Arikawa AY, 2011, J PHYS ACT HEALTH, V8, P111, DOI 10.1123/jpah.8.1.111; Bennie JA, 2018, AM J PREV MED, V55, P864, DOI 10.1016/j.amepre.2018.07.022; Brzycki M., 1993, J PHYS EDUC RECREAT, V64, P88, DOI [DOI 10.1080/07303084.1993.10606684, 10.1080/07303084.1993.10606684]; Buskard ANL, 2019, MED SCI SPORT EXER, V51, P2224, DOI 10.1249/MSS.0000000000002038; Carpinelli RN, 2011, MED SPORTIVA KRAKOW, V15, P91; Cavalcanti DD, 2020, J NEUROSURG, V132, P1653, DOI 10.3171/2019.1.JNS182036; Cavarretta DJ, 2019, INT REV SPORT EXER P, V12, P295, DOI 10.1080/1750984X.2018.1474941; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Costello JT, 2014, EUR J SPORT SCI, V14, P847, DOI 10.1080/17461391.2014.911354; Cumming G, 2013, UNDERSTANDING NEW ST; Cummings B, 1998, J STRENGTH COND RES, V12, P262; Davies T, 2016, SPORTS MED, V46, P487, DOI 10.1007/s40279-015-0451-3; Deci EL, 2000, PSYCHOL INQ, V11, P227, DOI 10.1207/S15327965PLI1104_01; Ekkekakis P, 2011, SPORTS MED, V41, P641, DOI 10.2165/11590680-000000000-00000; Emanuel A, 2021, INT J SPORT PHYSIOL, V16, P176, DOI 10.1123/ijspp.2020-0065; Emanuel A, 2021, INT J SPORT PHYSIOL, V16, P135, DOI 10.1123/ijspp.2019-0733; Focht BC, 2007, J STRENGTH COND RES, V21, P183, DOI 10.1519/00124278-200702000-00033; Focht BC, 2015, J STRENGTH COND RES, V29, P3067, DOI 10.1519/JSC.0000000000000985; Gorostiaga EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040621; Graham T, 2021, J STRENGTH COND RES, V35, P2451, DOI 10.1519/JSC.0000000000003164; Hackett DA, 2022, J STRENGTH COND RES, V36, P2701, DOI 10.1519/JSC.0000000000003978; Hackett DA, 2017, J STRENGTH COND RES, V31, P2162, DOI 10.1519/JSC.0000000000001683; Hackett DA, 2012, J SPORT SCI, V30, P1405, DOI 10.1080/02640414.2012.710757; Halperin I, 2022, SPORTS MED, V52, P377, DOI 10.1007/s40279-021-01559-x; Halperin I, 2018, STRENGTH COND J, V40, P18, DOI 10.1519/SSC.0000000000000383; Halperin I, 2016, PSYCHOL SPORT EXERC, V25, P44, DOI 10.1016/j.psychsport.2016.04.003; Hanson NJ, 2015, J STRENGTH COND RES, V29, P934, DOI 10.1519/JSC.0000000000000737; HARDY CJ, 1989, J SPORT EXERCISE PSY, V11, P304, DOI 10.1123/jsep.11.3.304; Helms ER, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00247; Hughes Liam J, 2020, J Strength Cond Res, DOI 10.1519/JSC.0000000000003865; Lagally KM, 2002, MED SCI SPORT EXER, V34, P552, DOI 10.1097/00005768-200203000-00025; Lakens D, 2022, PSYARXIV, DOI [10.31234/osf.io/9d3yf, DOI 10.31234/OSF.IO/9D3YF]; Ratamess NA, 2008, J STRENGTH COND RES, V22, P103, DOI 10.1519/JSC.0b013e31815f29cc; Reynolds JM, 2006, J STRENGTH COND RES, V20, P584, DOI 10.1519/00124278-200608000-00020; Rhemtulla M, 2012, PSYCHOL METHODS, V17, P354, DOI 10.1037/a0029315; Rhodes RE, 2015, ANN BEHAV MED, V49, P715, DOI 10.1007/s12160-015-9704-5; Richens B, 2014, BIOL SPORT, V31, P157, DOI 10.5604/20831862.1099047; Rodriguez-Rosell D, 2020, J STRENGTH COND RES, V34, P2537, DOI 10.1519/JSC.0000000000002881; Sands W, 2012, BASICS STRENGTH COND; Shimano T, 2006, J STRENGTH COND RES, V20, P819; Stanley DM, 2009, J SPORT EXERCISE PSY, V31, pS138; Steele J, 2017, PEERJ, V5, DOI 10.7717/peerj.4105; Steele J, 2017, MUSCLE NERVE, V56, P368, DOI 10.1002/mus.25557; Steele J, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4209-8; Strain T, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3774-6; Teixeira PJ, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-78; Uchida MC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208834; van Hooft EAJ, 2018, MOTIV EMOTION, V42, P931, DOI 10.1007/s11031-018-9710-6; West S. G., 1995, STRUCTURAL EQUATION, P56; Williams DM, 2008, PSYCHOL SPORT EXERC, V9, P231, DOI 10.1016/j.psychsport.2007.04.002; Zourdos MC, 2021, J STRENGTH COND RES, V35, pS158, DOI 10.1519/JSC.0000000000002995; Zourdos MC, 2016, J STRENGTH COND RES, V30, P267, DOI 10.1519/JSC.0000000000001049	55	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256231	10.1371/journal.pone.0256231	http://dx.doi.org/10.1371/journal.pone.0256231			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UB7PL	34407124	Green Submitted, Green Published, gold			2023-01-03	WOS:000686033500062
J	Lee, S; Yu, Y; Trimpert, J; Benthani, F; Mairhofer, M; Richter-Pechanska, P; Wyler, E; Belenki, D; Kaltenbrunner, S; Pammer, M; Kausche, L; Firsching, TC; Dietert, K; Schotsaert, M; Martinez-Romero, C; Singh, G; Kunz, S; Niemeyer, D; Ghanem, R; Salzer, HJF; Paar, C; Mulleder, M; Uccellini, M; Michaelis, EG; Khan, A; Lau, A; Schonlein, M; Habringer, A; Tomasits, J; Adler, JM; Kimeswenger, S; Gruber, AD; Hoetzenecker, W; Steinkellner, H; Purfurst, B; Motz, R; Di Pierro, F; Lamprecht, B; Osterrieder, N; Landthaler, M; Drosten, C; Garcia-Sastre, A; Langer, R; Ralser, M; Eils, R; Reimann, M; Fan, DNY; Schmitt, CA				Lee, Soyoung; Yu, Yong; Trimpert, Jakob; Benthani, Fahad; Mairhofer, Mario; Richter-Pechanska, Paulina; Wyler, Emanuel; Belenki, Dimitri; Kaltenbrunner, Sabine; Pammer, Maria; Kausche, Lea; Firsching, Theresa C.; Dietert, Kristina; Schotsaert, Michael; Martinez-Romero, Carles; Singh, Gagandeep; Kunz, Severine; Niemeyer, Daniela; Ghanem, Riad; Salzer, Helmut J. F.; Paar, Christian; Mulleder, Michael; Uccellini, Melissa; Michaelis, Edward G.; Khan, Amjad; Lau, Andrea; Schonlein, Martin; Habringer, Anna; Tomasits, Josef; Adler, Julia M.; Kimeswenger, Susanne; Gruber, Achim D.; Hoetzenecker, Wolfram; Steinkellner, Herta; Purfurst, Bettina; Motz, Reinhard; Di Pierro, Francesco; Lamprecht, Bernd; Osterrieder, Nikolaus; Landthaler, Markus; Drosten, Christian; Garcia-Sastre, Adolfo; Langer, Rupert; Ralser, Markus; Eils, Roland; Reimann, Maurice; Fan, Dorothy N. Y.; Schmitt, Clemens A.			Virus-induced senescence is a driver and therapeutic target in COVID-19	NATURE			English	Article							NF-KAPPA-B; CELLULAR SENESCENCE; EARLY-STAGE; CELLS; SARS-COV-2; CHEMORESISTANCE; LYMPHOMAGENESIS; QUERCETIN; RELEASE; BETA	Derailed cytokine and immune cell networks account for the organ damage and the clinical severity of COVID-19 (refs. (1-4)). Here we show that SARS-CoV-2, like other viruses, evokes cellular senescence as a primary stress response in infected cells. Virus-induced senescence (VIS) is indistinguishable from other forms of cellular senescence and is accompanied by a senescence-associated secretory phenotype (SASP), which comprises pro-inflammatory cytokines, extracellular-matrix-active factors and pro-coagulatory mediators(5-7). Patients with COVID-19 displayed markers of senescence in their airway mucosa in situ and increased serum levels of SASP factors. In vitro assays demonstrated macrophage activation with SASP-reminiscent secretion, complement lysis and SASP-amplifying secondary senescence of endothelial cells, which mirrored hallmark features of COVID-19 such as macrophage and neutrophil infiltration, endothelial damage and widespread thrombosis in affected lung tissue(1,8,9). Moreover, supernatant from VIS cells, including SARS-CoV-2-induced senescence, induced neutrophil extracellular trap formation and activation of platelets and the clotting cascade. Senolytics such as navitoclax and a combination of dasatinib plus quercetin selectively eliminated VIS cells, mitigated COVID-19-reminiscent lung disease and reduced inflammation in SARS-CoV-2-infected hamsters and mice. Our findings mark VIS as a pathogenic trigger of COVID-19-related cytokine escalation and organ damage, and suggest that senolytic targeting of virus-infected cells is a treatment option against SARS-CoV-2 and perhaps other viral infections. Virus-induced senescence is a central pathogenic feature in COVID-19, and senolytics, which promote apoptosis of senescent cells, can reduce disease severity in hamsters,mice, as well as humans infected with SARS-CoV-2.	[Lee, Soyoung; Richter-Pechanska, Paulina; Belenki, Dimitri; Kausche, Lea; Lau, Andrea; Schonlein, Martin; Reimann, Maurice; Fan, Dorothy N. Y.; Schmitt, Clemens A.] Charite, Mol Krebsforschungszentrum MKFZ, Med Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; [Lee, Soyoung; Wyler, Emanuel; Belenki, Dimitri; Kunz, Severine; Purfurst, Bettina; Landthaler, Markus; Schmitt, Clemens A.] Max Delbruck Ctr Mol Med, Helmholtz Assoc, Berlin, Germany; [Lee, Soyoung; Fan, Dorothy N. Y.; Schmitt, Clemens A.] Deutsch Konsortium Translat Krebsforsch German Ca, Berlin, Germany; [Yu, Yong; Benthani, Fahad; Mairhofer, Mario; Kaltenbrunner, Sabine; Pammer, Maria; Kimeswenger, Susanne; Hoetzenecker, Wolfram; Lamprecht, Bernd; Langer, Rupert; Schmitt, Clemens A.] Johannes Kepler Univ Linz, Med Fac, Linz, Austria; [Trimpert, Jakob; Adler, Julia M.; Osterrieder, Nikolaus] Free Univ Berlin, Inst Virol, Berlin, Germany; [Kausche, Lea; Ghanem, Riad; Schmitt, Clemens A.] Kepler Univ Hosp, Dept Hematol & Oncol, Linz, Austria; [Firsching, Theresa C.; Dietert, Kristina; Gruber, Achim D.] Free Univ Berlin, Inst Vet Pathol, Berlin, Germany; [Dietert, Kristina] Free Univ Berlin, Vet Ctr Resistance Res, Berlin, Germany; [Schotsaert, Michael; Martinez-Romero, Carles; Singh, Gagandeep; Uccellini, Melissa; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Schotsaert, Michael; Martinez-Romero, Carles; Singh, Gagandeep; Uccellini, Melissa; Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA; [Niemeyer, Daniela; Drosten, Christian] Charite, German Ctr Infect Res DZIF, Inst Virol, Berlin, Germany; [Salzer, Helmut J. F.; Lamprecht, Bernd] Kepler Univ Hosp, Dept Pulmonol, Linz, Austria; [Paar, Christian; Habringer, Anna; Tomasits, Josef] Kepler Univ Hosp, Lab Med, Linz, Austria; [Mulleder, Michael; Ralser, Markus] Charite, Core Facil High Throughput Mass Spectrometry, Berlin, Germany; [Mulleder, Michael; Ralser, Markus] Charite, Dept Biochem, Berlin, Germany; [Michaelis, Edward G.] Charite, Inst Pathol, Berlin, Germany; [Khan, Amjad] Univ Oxford, Dept Chem, Oxford, England; [Schonlein, Martin] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany; [Hoetzenecker, Wolfram] Kepler Univ Hosp, Dept Dermatol, Linz, Austria; [Steinkellner, Herta] Univ Nat Resources & Life Sci, Dept Appl Genet & Cell Biol, Vienna, Austria; [Motz, Reinhard; Langer, Rupert] Kepler Univ Hosp, Inst Pathol, Linz, Austria; [Di Pierro, Francesco] Velleja Res, Sci & Res Dept, Milan, Italy; [Di Pierro, Francesco] Fdn Poliambulanza, Digest Endoscopy, Brescia, Italy; [Osterrieder, Nikolaus] City Univ Hong Kong, Dept Infect Dis & Publ Hlth, Kowloon Tong, Hong Kong, Peoples R China; [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY 10029 USA; [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Ralser, Markus] Francis Crick Inst, Mol Biol Metab Lab, London, England; [Eils, Roland] Charite, Ctr Digital Hlth, Berlin, Germany; [Eils, Roland] Berlin Inst Hlth BIH, Berlin, Germany; [Uccellini, Melissa] Regeneron Pharmaceut, New York, NY USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Johannes Kepler University Linz; Free University of Berlin; Kepler University Hospital; Free University of Berlin; Free University of Berlin; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Center for Infection Research; Kepler University Hospital; Kepler University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Oxford; University of Hamburg; University Medical Center Hamburg-Eppendorf; Kepler University Hospital; University of Natural Resources & Life Sciences, Vienna; Kepler University Hospital; City University of Hong Kong; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Francis Crick Institute; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Regeneron	Schmitt, CA (corresponding author), Charite, Mol Krebsforschungszentrum MKFZ, Med Dept Hematol Oncol & Tumor Immunol, Berlin, Germany.; Schmitt, CA (corresponding author), Max Delbruck Ctr Mol Med, Helmholtz Assoc, Berlin, Germany.; Schmitt, CA (corresponding author), Deutsch Konsortium Translat Krebsforsch German Ca, Berlin, Germany.; Schmitt, CA (corresponding author), Johannes Kepler Univ Linz, Med Fac, Linz, Austria.; Schmitt, CA (corresponding author), Kepler Univ Hosp, Dept Hematol & Oncol, Linz, Austria.	clemens.schmitt@charite.de	Eils, Roland/B-6121-2009; Fan, Dorothy Ngo-yin/AAQ-2998-2020; Langer, Rupert/AAU-1174-2021; Lee, Soyoung/AHC-5032-2022; Landthaler, Markus/A-1427-2010; Singh, Gagandeep/L-8590-2019; Schmitt, Clemens A/S-9479-2017	Eils, Roland/0000-0002-0034-4036; Langer, Rupert/0000-0001-9491-3609; Lee, Soyoung/0000-0002-4614-2931; Landthaler, Markus/0000-0002-1075-8734; Singh, Gagandeep/0000-0003-3260-2631; Schmitt, Clemens A/0000-0002-4731-2226; Salzer, Helmut J.F./0000-0003-0146-8310; Ralser, Markus/0000-0001-9535-7413; Benthani, Fahad/0000-0002-3283-307X; Kimeswenger, Susanne/0000-0002-0443-8558; Osterrieder, Nikolaus/0000-0002-5313-2176; Kaltenbrunner, Sabine/0000-0002-2794-025X; Wyler, Emanuel/0000-0002-9884-1806; Adler, Julia Maria/0000-0001-8147-0351; Belenki, Dimitri/0000-0002-9004-9849; Trimpert, Jakob/0000-0003-1616-0810; Mulleder, Michael/0000-0001-9792-3861; Firsching, Theresa/0000-0003-1378-4951; Schonlein, Martin/0000-0002-1010-0975	Medical Faculty of the Johannes Kepler University, Linz, Austria; Deutsche Krebshilfe [7011377629]; Deutsche Forschungsgemeinschaft DFG [GO 2688/1-1 | SCHM 1633/11-1, SCHM 1633/9-1]; Forderverein Hamatologie und internistische Onkologie (Tyle Private Foundation, Linz, Austria); German BMBF e:Med programme project SeneSys [031L0189A]; German Research Council [SFB-TR84 Z01b]; Berlin School of Integrative Oncology (BSIO) graduate programme within the German Excellence Initiative; German Cancer Consortium (GCC); CRIP (Center for Research on Influenza Pathogenesis), a NIAID [HHSN272201400008C]; CRIPT (Center for Research on Influenza Pathogenesis and Transmission), a NIAID [75N93021C00014]; DARPA [HR0011-19-2-0020]; NIAID [U19AI142733, U19AI135972]; DoD [W81XWH-20-1-0270]; Fast Grant of the Mercatus Center; JPB Foundation; Open Philanthropy Project [2020-215611 (5384)]; Francis Crick Institute from Cancer Research UK [FC001134]; UK Medical Research Council [FC001134]; Wellcome Trust [FC001134]	Medical Faculty of the Johannes Kepler University, Linz, Austria; Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft DFG(German Research Foundation (DFG)); Forderverein Hamatologie und internistische Onkologie (Tyle Private Foundation, Linz, Austria); German BMBF e:Med programme project SeneSys(Federal Ministry of Education & Research (BMBF)); German Research Council(German Research Foundation (DFG)); Berlin School of Integrative Oncology (BSIO) graduate programme within the German Excellence Initiative; German Cancer Consortium (GCC); CRIP (Center for Research on Influenza Pathogenesis), a NIAID; CRIPT (Center for Research on Influenza Pathogenesis and Transmission), a NIAID; DARPA(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DoD(United States Department of Defense); Fast Grant of the Mercatus Center; JPB Foundation; Open Philanthropy Project; Francis Crick Institute from Cancer Research UK; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)	We thank S. Fukushi and M. Saijo, C. Ratswohl and K. de la Rosa, V. G. Gorgoulis, K. Hoffman and W. Brune, E. Schiebel for materials; F. Walper for their support in the BSL-3 facility; F. Kurth, P. Tauber-Lau, V. Demichev and L. E. Sander on behalf of the Charite PA-COVID-19 study group as well as members of the Charite Core Facility High-throughput Proteomics for data and measurements; S. Jangra, R. Rathnasinghe and R. Albrecht for support in the BSL-3 facility and procedures, and R. Cadagan for technical assistance; M. Almeder for handling patient samples; M. Recchia for the statistical analysis of the data from clinical trials; and members of the collaborating laboratories for discussions and editorial advice. This work was supported by grants to C.A.S. from the Medical Faculty of the Johannes Kepler University, Linz, Austria, the Deutsche Krebshilfe (no. 7011377629), the Deutsche Forschungsgemeinschaft DFG (GO 2688/1-1 | SCHM 1633/11-1, SCHM 1633/9-1), and the Forderverein Hamatologie und internistische Onkologie (Tyle Private Foundation, Linz, Austria), and to S.L. and C.A.S. by the German BMBF e:Med programme project SeneSys (no. 031L0189A). J. Trimpert and A.D.G. were funded by the German Research Council (grant SFB-TR84 Z01b). This interdisciplinary work was further made possible by the Berlin School of Integrative Oncology (BSIO) graduate programme funded within the German Excellence Initiative (with D.B. as a member of this programme) and the German Cancer Consortium (GCC). This research was also partly funded by CRIP (Center for Research on Influenza Pathogenesis), a NIAID funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract no. HHSN272201400008C) and CRIPT (Center for Research on Influenza Pathogenesis and Transmission), a NIAID-funded Center of Excellence for Influenza Research and Response (CEIRR, contract no. 75N93021C00014), by DARPA grant HR0011-19-2-0020, by supplements to NIAID grant U19AI142733, U19AI135972 and DoD grant W81XWH-20-1-0270, by a Fast Grant of the Mercatus Center and by the support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384)) and anonymous donors to A.G.-S. M. Rasler is partly funded by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001134), the UK Medical Research Council (FC001134) and the Wellcome Trust (FC001134).	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Baz-Martinez M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37007; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bent EH, 2016, GENE DEV, V30, P1811, DOI 10.1101/gad.284851.116; Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Camell CD, 2021, SCIENCE, V373, DOI 10.1126/science.abe4832; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4; Chuprin A, 2013, GENE DEV, V27, P2356, DOI 10.1101/gad.227512.113; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Demichev V, 2021, CELL SYST, V12, P780, DOI 10.1016/j.cels.2021.05.005; Di Pierro F, 2021, INT J GEN MED, V14, P2807, DOI 10.2147/IJGM.S318949; Di Pierro F, 2021, INT J GEN MED, V14, P2359, DOI 10.2147/IJGM.S318720; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437; Dou ZX, 2017, NATURE, V550, P402, DOI 10.1038/nature24050; Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69; Fridman AL, 2008, ONCOGENE, V27, P5975, DOI 10.1038/onc.2008.213; Gruber AD, 2020, AM J RESP CELL MOL, V63, P856, DOI 10.1165/rcmb.2020-0280LE; Hari P, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw0254; Haveri A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.11.2000266; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hsieh TH, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00375; Jing H, 2011, GENE DEV, V25, P2137, DOI 10.1101/gad.17620611; Jung SH, 2019, CELL DEATH DIFFER, V26, P245, DOI 10.1038/s41418-018-0114-7; Kang SJ, 2020, P NATL ACAD SCI USA, V117, P22351, DOI 10.1073/pnas.2010229117; Kirkland JL, 2020, J INTERN MED, V288, P518, DOI 10.1111/joim.13141; Kreye J, 2020, CELL, V183, P1058, DOI 10.1016/j.cell.2020.09.049; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Lee S, 2019, NAT CELL BIOL, V21, P94, DOI 10.1038/s41556-018-0249-2; Li X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00072; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Martinez I, 2016, VIRULENCE, V7, P427, DOI 10.1080/21505594.2016.1144001; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4; Messner CB, 2020, CELL SYST, V11, P11, DOI 10.1016/j.cels.2020.05.012; Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008; Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nouailles G., 2020, LONGITUDINAL OMICS S, DOI 10.1101/2020.12.18.423524(2020; Osterrieder N, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070779; Rathnasinghe Raveen, 2020, bioRxiv, DOI 10.1101/2020.07.06.190066; Reimann M, 2010, CANCER CELL, V17, P262, DOI 10.1016/j.ccr.2009.12.043; Roussel M, 2017, J LEUKOCYTE BIOL, V102, P437, DOI 10.1189/jlb.5MA1116-457R; Schleich K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17467-z; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Trimpert J, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108488; Veras FP, 2020, J EXP MED, V217, DOI 10.1084/jem.20201129; Wang PG, 2004, BIOCHEM BIOPH RES CO, V315, P439, DOI 10.1016/j.bbrc.2004.01.076; White KM, 2021, SCIENCE, V371, P926, DOI 10.1126/science.abf4058; Wiley CD, 2019, CELL REP, V28, P3329, DOI 10.1016/j.celrep.2019.08.049; Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2; Wolfel R, 2020, NATURE, V588, pE35, DOI 10.1038/s41586-020-2984-3; Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Yu Y, 2018, CANCER CELL, V33, P322, DOI 10.1016/j.ccell.2018.01.002; Zhang XN, 2020, NATURE, V583, P437, DOI [10.1038/s41586-020-2355-0, 10.1007/s00521-020-05117-w]; Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344	68	66	66	14	69	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 11	2021	599	7884					283	+		10.1038/s41586-021-03995-1	http://dx.doi.org/10.1038/s41586-021-03995-1		SEP 2021	31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC6YT	34517409	Bronze			2023-01-03	WOS:000709352000002
J	Gunster, C; Busse, R; Spoden, M; Rombey, T; Schillinger, G; Hoffmann, W; Weber-Carstens, S; Schuppert, A; Karagiannidis, C				Gunster, Christian; Busse, Reinhard; Spoden, Melissa; Rombey, Tanja; Schillinger, Gerhard; Hoffmann, Wolfgang; Weber-Carstens, Steffen; Schuppert, Andreas; Karagiannidis, Christian			6-month mortality and readmissions of hospitalized COVID-19 patients: A nationwide cohort study of 8,679 patients in Germany	PLOS ONE			English	Article								Background COVID-19 frequently necessitates in-patient treatment and in-patient mortality is high. Less is known about the long-term outcomes in terms of mortality and readmissions following in-patient treatment. Aim The aim of this paper is to provide a detailed account of hospitalized COVID-19 patients up to 180 days after their initial hospital admission. Methods An observational study with claims data from the German Local Health Care Funds of adult patients hospitalized in Germany between February 1 and April 30, 2020, with PCR-confirmed COVID-19 and a related principal diagnosis, for whom 6-month all-cause mortality and readmission rates for 180 days after admission or until death were available. A multivariable logistic regression model identified independent risk factors for 180-day all-cause mortality in this cohort. Results Of the 8,679 patients with a median age of 72 years, 2,161 (24.9%) died during the index hospitalization. The 30-day all-cause mortality rate was 23.9% (2,073/8,679), the 90-day rate was 27.9% (2,425/8,679), and the 180-day rate, 29.6% (2,566/8,679). The latter was 52.3% (1,472/2,817) for patients aged >= 80 years 23.6% (1,621/6,865) if not ventilated during index hospitalization, but 53.0% in case of those ventilated invasively (853/1,608). Risk factors for the 180-day all-cause mortality included coagulopathy, BMI >= 40, and age, while the female sex was a protective factor beyond a fewer prevalence of comorbidities. Of the 6,235 patients discharged alive, 1,668 were readmitted a total of 2,551 times within 180 days, resulting in an overall readmission rate of 26.8%. Conclusions The 180-day follow-up data of hospitalized COVID-19 patients in a nationwide cohort representing almost one-third of the German population show significant long-term, all-cause mortality and readmission rates, especially among patients with coagulopathy, whereas women have a profoundly better and long-lasting clinical outcome compared to men.	[Gunster, Christian; Spoden, Melissa; Schillinger, Gerhard] Fed Assoc Local Hlth Care Funds, Res Inst Local Hlth Care Funds, Berlin, Germany; [Busse, Reinhard; Rombey, Tanja] Tech Univ Berlin, Dept Hlth Care Management, Berlin, Germany; [Hoffmann, Wolfgang] Univ Med Greifswald, Inst Community Med, Sect Epidemiol Hlth Care & Community Hlth, Greifswald, Germany; [Weber-Carstens, Steffen] Charite Univ Med Berlin, Dept Anesthesiol & Operat Intens Care Med, Berlin, Germany; [Schuppert, Andreas] Rhein Westfal TH Aachen, Univ Hosp, Inst Computat Biomed 2, Aachen, Germany; [Karagiannidis, Christian] Witten Herdecke Univ Hosp, Kliniken Stadt Koln, Cologne Merheim Hosp, Dept Pneumol & Crit Care Med, Cologne, Germany	Technical University of Berlin; Greifswald Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; RWTH Aachen University; RWTH Aachen University Hospital	Karagiannidis, C (corresponding author), Witten Herdecke Univ Hosp, Kliniken Stadt Koln, Cologne Merheim Hosp, Dept Pneumol & Crit Care Med, Cologne, Germany.	Christian.Karagiannidis@uni-wh.de		Gunster, Christian/0000-0003-3085-6259; Schillinger, Gerhard/0000-0002-2940-2965	Federal Association of the Local Health Care Funds; Berlin University Alliance [112_PreEP_Corona]	Federal Association of the Local Health Care Funds; Berlin University Alliance	Institutional support and physical resources were provided by the University Witten/Herdecke and Kliniken der Stadt Koln, the Federal Association of the Local Health Care Funds and the Technical University of Berlin. The latter also received a grant from the Berlin University Alliance (112_PreEP_Corona). Article processing fees were funded by the authors. No funding source had a role in the design or conduct of the study; data collection, management, analysis, or interpretation; or the preparation, review, or approval of the manuscript.	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Biancari F, 2021, J CARDIOTHOR VASC AN, V35, P1999, DOI 10.1053/j.jvca.2021.01.027; Bonnet G, 2021, ARCH CARDIOVASC DIS, V114, P352, DOI 10.1016/j.acvd.2021.01.003; Brieghel C, 2021, DAN MED J, V68; Bundesministerium fur Gesundheit, 2021, STAT VERS GEGL NACH STAT VERS GEGL NACH; Busse R, 2017, LANCET, V390, P882, DOI 10.1016/S0140-6736(17)31280-1; Darvall JN, 2020, LANCET PUBLIC HEALTH, V5, pE580, DOI 10.1016/S2468-2667(20)30228-0; Department Health Care Management, 2021, DAT COVID 19 HOSP IC DAT COVID 19 HOSP IC; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0; Fernando SM, 2019, INTENS CARE MED, V45, P1742, DOI 10.1007/s00134-019-05795-8; Frohlich GM, 2021, CLIN RES CARDIOL, V110, P1041, DOI 10.1007/s00392-020-01783-x; Garcia-Vidal C, 2021, LANCET REG HEALTH-EU, V3, DOI 10.1016/j.lanepe.2021.100041; Hernandez-Fernandez F, 2020, BRAIN, V143, P3089, DOI 10.1093/brain/awaa239; Hewitt J, 2020, LANCET PUBLIC HEALTH, V5, pE444, DOI 10.1016/S2468-2667(20)30146-8; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Iba T, 2020, J THROMB HAEMOST, V18, P2103, DOI 10.1111/jth.14975; Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7; Kim L, 2021, CLIN INFECT DIS, V72, P206, DOI DOI 10.1093/cid/ciaa1012; Kuehn BM, 2020, JAMA-J AM MED ASSOC, V324, P2477, DOI 10.1001/jama.2020.23910; Pivonello R, 2021, NEUROENDOCRINOLOGY, V111, P1066, DOI 10.1159/000513346; Qian J, 2020, CLIN INFECT DIS, V71, P2488, DOI 10.1093/cid/ciaa683; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rogers JP, 2020, LANCET PSYCHIAT, V7, P611, DOI 10.1016/S2215-0366(20)30203-0; Schmidt M, 2021, INTENS CARE MED, V47, P60, DOI 10.1007/s00134-020-06294-x; Statistisches Bundesamt, 2021, FORTSCHR BEV 12411 0; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; Taquet M, 2021, LANCET PSYCHIAT, V8, P416, DOI 10.1016/S2215-0366(21)00084-5; Varatharaj A, 2020, LANCET PSYCHIAT, V7, P875, DOI 10.1016/S2215-0366(20)30287-X; Yang P, 2020, CLIN INFECT DIS, V71, P2495, DOI 10.1093/cid/ciaa776; Zettersten E, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03511-x; Zhu Y, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248671	33	23	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2021	16	8							e0255427	10.1371/journal.pone.0255427	http://dx.doi.org/10.1371/journal.pone.0255427			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6JF	34351975	gold, Green Published			2023-01-03	WOS:000685265700126
J	Inkol, JM; Hocker, SE; Mutsaers, AJ				Inkol, Jordon M.; Hocker, Samuel E.; Mutsaers, Anthony J.			Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells	PLOS ONE			English	Article							URINARY-BLADDER; CYCLOOXYGENASE INHIBITOR; RADIATION-THERAPY; INDUCED APOPTOSIS; TUMOR RESPONSE; MODEL; PIROXICAM; CANCER; DOGS; PHARMACOKINETICS	Background Canine urothelial carcinoma is the most common form of canine bladder cancer. Treatment with chemotherapy has variable response rates leading to most dogs succumbing to their disease within a year. Cannabidiol is an emerging treatment within the field of oncology. In reported in vivo studies, cannabidiol has induced apoptosis, reduced cell migration, and acted as a chemotherapy sensitizer in various human tumor types. The aim of this study was to characterize the effects of cannabidiol on canine urothelial carcinoma cell viability and apoptosis as both a single agent and in combination with chemotherapy in vitro. Results Cannabidiol reduced cell viability and induced apoptosis in canine urothelial cells as determined by crystal violet viability assay and annexin V/propidium iodide flow cytometry. Furthermore, combinations of cannabidiol with mitoxantrone and vinblastine chemotherapy yielded significantly reduced cell viability and increased apoptosis compared to single agent treatment alone. The drug interactions were deemed synergistic based on combination index calculations. Conversely, the combination of cannabidiol and carboplatin did not result in decreased cell viability and increased apoptosis compared to single agent treatment. Combination index calculations suggested an antagonistic interaction between these drugs. Finally, the combination of the non-steroidal anti-inflammatory drug piroxicam with cannabidiol did not significantly affect cell viability, although, some cell lines demonstrated decreased cell viability when mitoxantrone was combined with piroxicam. Conclusions Cannabidiol showed promising results as a single agent or in combination with mitoxantrone and vinblastine for treatment of canine urothelial carcinoma cells. Further studies are justified to investigate whether these results are translatable in vivo.	[Inkol, Jordon M.; Hocker, Samuel E.; Mutsaers, Anthony J.] Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON, Canada; [Hocker, Samuel E.] Kansas State Univ, Coll Vet Med, Dept Clin Sci, Manhattan, KS 66506 USA; [Mutsaers, Anthony J.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON, Canada	University of Guelph; Kansas State University; University of Guelph	Hocker, SE (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON, Canada.; Hocker, SE (corresponding author), Kansas State Univ, Coll Vet Med, Dept Clin Sci, Manhattan, KS 66506 USA.	shocker@vet.k-state.edu		Inkol, Jordon/0000-0002-7920-0990; Hocker, Samuel/0000-0002-7108-1050	GreyWolf Animal Health [054268]; Ontario Veterinary College Pet Trust [054331]	GreyWolf Animal Health; Ontario Veterinary College Pet Trust	Funding was provided by GreyWolf Animal Health (https://greywolfah.com/) Grant #054268(SEH) and the Ontario Veterinary College Pet Trust (https://ovc.uoguelph.ca/pettrust/) Grant#054331 (SEH, JMI, AJM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors are not employed by or shareholders of GreyWolf Animal Health.	Allstadt SD, 2015, J VET INTERN MED, V29, P261, DOI 10.1111/jvim.12533; Arnold EJ, 2011, J VET INTERN MED, V25, P1385, DOI 10.1111/j.1939-1676.2011.00796.x; Bartner LR, 2018, CAN J VET RES, V82, P178; Blessing EM, 2015, NEUROTHERAPEUTICS, V12, P825, DOI 10.1007/s13311-015-0387-1; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Choy K, 2016, VET RADIOL ULTRASOUN, V57, P341, DOI 10.1111/vru.12339; Dhawan D, 2009, UROL ONCOL-SEMIN ORI, V27, P284, DOI 10.1016/j.urolonc.2008.02.015; Elbaz Mohamad, 2018, Oncotarget, V9, P33459, DOI 10.18632/oncotarget.9663; Ferro R, 2018, ONCOGENE, V37, P6368, DOI 10.1038/s41388-018-0390-1; Fraguas-Sanchez AI, 2020, INT J PHARMACEUT, V574, DOI 10.1016/j.ijpharm.2019.118916; Fulkerson C.M., 2020, SMALL ANIMAL CLIN ON, V6th edn., P645; Fulkerson CM, 2015, VET J, V205, P217, DOI 10.1016/j.tvjl.2015.01.017; GALBRAITH EA, 1991, VET REC, V128, P561, DOI 10.1136/vr.128.24.561; Gurpinar E, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00181; Henry CJ, 2003, CLIN CANCER RES, V9, P906; Holland ML, 2006, BIOCHEM PHARMACOL, V71, P1146, DOI 10.1016/j.bcp.2005.12.033; Jeong S, 2019, CANCER LETT, V447, P12, DOI 10.1016/j.canlet.2019.01.011; Knapp DW, 2016, BLADDER CANCER, V2, P241, DOI 10.3233/BLC-150044; Knapp DW, 2014, ILAR J, V55, P100, DOI 10.1093/ilar/ilu018; KNAPP DW, 1995, AM J VET RES, V56, P801; Martin-Moreno AM, 2011, MOL PHARMACOL, V79, P964, DOI 10.1124/mol.111.071290; Mohammed SI, 2002, CANCER RES, V62, P356; Mokoena DR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194771; Morelli MB, 2014, INT J CANCER, V134, P2534, DOI 10.1002/ijc.28591; Mutsaers AJ, 2003, J VET INTERN MED, V17, P136, DOI 10.1892/0891-6640(2003)017&lt;0136:CTCC&gt;2.3.CO;2; Nanayakkara AK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19325-x; Nolan MW, 2012, J VET INTERN MED, V26, P987, DOI 10.1111/j.1939-1676.2012.00946.x; Pagotto A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.327; Pisanti S, 2017, PHARMACOL THERAPEUT, V175, P133, DOI 10.1016/j.pharmthera.2017.02.041; Ramer R, 2013, MOL CANCER THER, V12, P69, DOI 10.1158/1535-7163.MCT-12-0335; Rippy SB, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0882-6; Shapiro SG, 2015, CHROMOSOME RES, V23, P311, DOI 10.1007/s10577-015-9471-y; Sharafi G, 2019, J PANCREATIC CANCER, V5, DOI 10.1089/pancan.2018.0019; Shrivastava A, 2011, MOL CANCER THER, V10, P1161, DOI 10.1158/1535-7163.MCT-10-1100; Sultan AS, 2018, BREAST, V41, P34, DOI 10.1016/j.breast.2018.06.009; Vaccani A, 2005, BRIT J PHARMACOL, V144, P1032, DOI 10.1038/sj.bjp.0706134	37	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2021	16	8							e0255591	10.1371/journal.pone.0255591	http://dx.doi.org/10.1371/journal.pone.0255591			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6JF	34352013	gold, Green Published			2023-01-03	WOS:000685265700047
J	Ahtela, E; Oksi, J; Vahlberg, T; Sipila, J; Rautava, P; Kyto, V				Ahtela, Elina; Oksi, Jarmo; Vahlberg, Tero; Sipila, Jussi; Rautava, Paivi; Kyto, Ville			Short- and long-term outcomes of infective endocarditis admission in adults: A population-based registry study in Finland	PLOS ONE			English	Article							6-MONTH MORTALITY; VALVE SURGERY; TRENDS; EPIDEMIOLOGY; IMPACT; QUALITY; RISK; CARE; AGE	Infective endocarditis (IE) is associated with high mortality. However, data on factors associated with length of stay (LOS) in hospital due to IE are scarce. In addition, long-term mortality of more than 1 year is inadequately known. In this large population-based study we investigated age and sex differences, temporal trends, and factors affecting the LOS in patients with IE and in-hospital, 1-year, 5-year and 10-year mortality of IE. Data on patients (>= 18 years of age) admitted to hospital due to IE in Finland during 2005-2014 were collected retrospectively from nationwide obligatory registries. We included 2166 patients in our study. Of the patients 67.8% were men. Women were older than men (mean age 63.3 vs. 59.5, p<0.001). The median LOS was 20.0 days in men and 18.0 in women, p = 0.015. In the youngest patients (18-39 years) the median LOS was significantly longer than in the oldest patients (>= 80 years) (24.0 vs. 16.0 days, p = 0.014). In-hospital mortality was 10% with no difference between men and women. Mortality was 22.7% at 1 year whereas 5- and 10-year mortality was 37.5% and 48.5%, respectively. The 5-year and 10-year mortality was higher in women (HR 1.18, p = 0.034; HR 1.18, p = 0.021). Both in-hospital and long-term mortality increased significantly with aging and comorbidity burden. Both mortality and LOS remained stable over the study period. In conclusion, men had longer hospital stays due to IE compared to women. The 5- and 10-year mortality was higher in women. The mortality of IE or LOS did not change over time.	[Ahtela, Elina; Kyto, Ville] Turku Univ Hosp, Heart Ctr, Turku, Finland; [Ahtela, Elina; Oksi, Jarmo; Vahlberg, Tero; Kyto, Ville] Univ Turku, Turku, Finland; [Ahtela, Elina; Oksi, Jarmo] Turku Univ Hosp, Dept Infect Dis, Turku, Finland; [Vahlberg, Tero] Univ Turku, Dept Clin Med, Biostat, Turku, Finland; [Sipila, Jussi] North Karelia Cent Hosp, Dept Neurol, Siun Sote, Joensuu, Finland; [Sipila, Jussi] Univ Turku, Clin Neurosci, Turku, Finland; [Rautava, Paivi] Univ Turku, Dept Publ Hlth, Turku, Finland; [Rautava, Paivi] Turku Univ Hosp, Turku Clin Res Ctr, Turku, Finland; [Kyto, Ville] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland; [Kyto, Ville] Turku Univ Hosp, Ctr Populat Hlth Res, Turku, Finland; [Kyto, Ville] Hosp Dist Southwest Finland, Adm Ctr, Turku, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku	Ahtela, E (corresponding author), Turku Univ Hosp, Heart Ctr, Turku, Finland.; Ahtela, E (corresponding author), Univ Turku, Turku, Finland.; Ahtela, E (corresponding author), Turku Univ Hosp, Dept Infect Dis, Turku, Finland.	elina.ahtela@utu.fi	Sipilä, Jussi/C-8585-2015; Kyto, Ville/D-7971-2014	Sipilä, Jussi/0000-0003-0183-9054; Kyto, Ville/0000-0002-4521-1093	Aarne Koskelo Foundation; Finnish Cardiac Society; Finnish Cultural Foundation; Finnish Foundation for Cardiovascular Research; Tyks Foundation; Governmental VTR-Funding	Aarne Koskelo Foundation; Finnish Cardiac Society; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Finnish Foundation for Cardiovascular Research; Tyks Foundation; Governmental VTR-Funding	This work was supported by grants from Aarne Koskelo Foundation (EA); Finnish Cardiac Society (EA); Finnish Cultural Foundation (EA); Finnish Foundation for Cardiovascular Research (EA); Governmental VTR-Funding (EA); and Tyks Foundation (EA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahtela E, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4620-0; Ahtela E, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026811; Bannay A, 2011, EUR HEART J, V32, P2003, DOI 10.1093/eurheartj/ehp008; Bhatia N, 2017, CLIN CARDIOL, V40, P423, DOI 10.1002/clc.22688; Bor DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060033; Cabell CH, 2005, AM HEART J, V150, P1092, DOI 10.1016/j.ahj.2005.03.057; Cresti A, 2017, CARDIOVASC DIAGN THE, V7, P27, DOI 10.21037/cdt.2016.08.09; Danai PA, 2007, CRIT CARE MED, V35, P410, DOI 10.1097/01.CCM.0000253405.17038.43; Delahaye F, 2007, SCAND J INFECT DIS, V39, P849, DOI 10.1080/00365540701393088; Fedeli U, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-48; Gray ME, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3408-y; Habib G, 2015, EUR HEART J, V36, P3075, DOI [10.5603/KP.2015.0227, 10.1093/eurheartj/ehv319]; Heiro M, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-78; Heiro M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-49; Hill EE, 2007, EUR HEART J, V28, P196, DOI 10.1093/eurheartj/ehl427; Iversen K, 2019, NEW ENGL J MED, V380, P415, DOI 10.1056/NEJMoa1808312; Jones DA, 2013, NEPHRON CLIN PRACT, V123, P151, DOI 10.1159/000353732; Kankaanpaa A, 2016, SCI TOTAL ENVIRON, V568, P864, DOI 10.1016/j.scitotenv.2016.06.060; Keller K, 2017, AM J CARDIOL, V119, P317, DOI 10.1016/j.amjcard.2016.09.035; Leahey PA, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz089; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; Liau SK, 2021, INT J GEN MED, V14, P425, DOI 10.2147/IJGM.S298380; Maille B, 2019, HEART VESSELS, V34, P824, DOI 10.1007/s00380-018-1292-4; Morita Y, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011598; Munoz P, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001816; Murdoch DR, 2009, ARCH INTERN MED, V169, P463, DOI 10.1001/archinternmed.2008.603; Netzer ROM, 2002, HEART, V88, P61, DOI 10.1136/heart.88.1.61; Olmos C, 2017, J AM COLL CARDIOL, V70, P2795, DOI 10.1016/j.jacc.2017.10.005; Peled N, 2006, EUR J CLIN MICROBIOL, V25, P473, DOI 10.1007/s10096-006-0160-9; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rizzi M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-230; Schranz AJ, 2019, ANN INTERN MED, V170, P31, DOI 10.7326/M18-2124; Selton-Suty C, 2012, CLIN INFECT DIS, V54, P1230, DOI 10.1093/cid/cis199; Sipila J, 2014, J EVAL CLIN PRACT, V20, P327, DOI 10.1111/jep.12130; Slater MS, 2007, ANN THORAC SURG, V83, P2074, DOI 10.1016/j.athoracsur.2007.01.051; Sund R, 2012, SCAND J PUBLIC HEALT, V40, P505, DOI 10.1177/1403494812456637; Sunder S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223857; Sy RW, 2010, EUR HEART J, V31, P1890, DOI 10.1093/eurheartj/ehq110; Tan C, 2016, INT J CARDIOL, V224, P162, DOI 10.1016/j.ijcard.2016.09.030; Ternhag A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067519; Thakarar K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225460; Thornhill MH, 2018, EUR HEART J, V39, P586, DOI 10.1093/eurheartj/ehx655; Thuny F, 2005, CIRCULATION, V112, P69, DOI 10.1161/CIRCULATIONAHA.104.493155; Tleyjeh IM, 2007, CIRCULATION, V115, P1721, DOI 10.1161/CIRCULATIONAHA.106.658831; Tornos P, 2005, HEART, V91, P571, DOI 10.1136/hrt.2003.032128; Toyoda N, 2017, JAMA-J AM MED ASSOC, V317, P1652, DOI 10.1001/jama.2017.4287; van den Brink FS, 2017, EUR HEART J-QUAL CAR, V3, P141, DOI 10.1093/ehjqcco/qcw039; Varjonen V, 2015, DRUG USE FINLAND 201	48	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2021	16	7							e0254553	10.1371/journal.pone.0254553	http://dx.doi.org/10.1371/journal.pone.0254553			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2MX	34265019	Green Published, gold			2023-01-03	WOS:000678120600036
J	Samarasekera, U				Samarasekera, Udani			Etheldreda Nakimuli-Mpungu: innovator in mental health	LANCET			English	Biographical-Item																		MPUNGU EN, PUBLICATION LIST	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2021	398	10295					109	109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG0BQ	34246336				2023-01-03	WOS:000671078800009
J	Marufa, SA; Hsieh, TH; Liou, JC; Chen, HY; Peng, CW				Marufa, Siti Ainun; Hsieh, Tsung-Hsun; Liou, Jian-Chiun; Chen, Hsin-Yung; Peng, Chih-Wei			Neuromodulatory effects of repetitive transcranial magnetic stimulation on neural plasticity and motor functions in rats with an incomplete spinal cord injury: A preliminary study	PLOS ONE			English	Article							THETA-BURST STIMULATION; GROWTH-ASSOCIATED PROTEIN-43; ELECTRICAL-STIMULATION; CEREBROSPINAL-FLUID; CORTEX STIMULATION; EVOKED POTENTIALS; CENTRAL PAIN; RECOVERY; GAP-43; INTERLEUKIN-6	We investigated the effects of intermittent theta-burst stimulation (iTBS) on locomotor function, motor plasticity, and axonal regeneration in an animal model of incomplete spinal cord injury (SCI). Aneurysm clips with different compression forces were applied extradurally around the spinal cord at T10. Motor plasticity was evaluated by examining the motor evoked potentials (MEPs). Long-term iTBS treatment was given at the post-SCI 5th week and continued for 2 weeks (5 consecutive days/week). Time-course changes in locomotor function and the axonal regeneration level were measured by the Basso Beattie Bresnahan (BBB) scale, and growth-associated protein (GAP)-43 expression was detected in brain and spinal cord tissues. iTBS-induced potentiation was reduced at post-1-week SCI lesion and had recovered by 4 weeks post-SCI lesion, except in the severe group. Multiple sessions of iTBS treatment enhanced the motor plasticity in all SCI rats. The locomotor function revealed no significant changes between pre- and post-iTBS treatment in SCI rats. The GAP-43 expression level in the spinal cord increased following 2 weeks of iTBS treatment compared to the sham-treatment group. This preclinical model may provide a translational platform to further investigate therapeutic mechanisms of transcranial magnetic stimulation and enhance the possibility of the potential use of TMS with the iTBS scheme for treating SCIs.	[Marufa, Siti Ainun; Peng, Chih-Wei] Taipei Med Univ, Grad Inst Biomed Mat & Tissue Engn, Coll Biomed Engn, Taipei, Taiwan; [Marufa, Siti Ainun] Univ Muhammadiyah Malang, Phys Therapy Dept, Fac Hlth Sci, Malang, Indonesia; [Hsieh, Tsung-Hsun] Chang Gung Univ, Sch Phys Therapy, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Univ, Grad Inst Rehabil Sci, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Mem Hosp, Neurosci Res Ctr, Taoyuan, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Univ, Hlth Aging Res Ctr, Taoyuan, Taiwan; [Liou, Jian-Chiun; Peng, Chih-Wei] Taipei Med Univ, Sch Biomed Engn, Coll Biomed Engn, Taipei, Taiwan; [Chen, Hsin-Yung] Chang Gung Univ, Dept Occupat Therapy, Coll Med, Taoyuan, Taiwan; [Chen, Hsin-Yung] Chang Gung Univ, Grad Inst Behav Sci, Coll Med, Taoyuan, Taiwan; [Peng, Chih-Wei] Taipei Med Univ, Int PhD Program Biomed Engn, Coll Biomed Engn, Taipei, Taiwan; [Peng, Chih-Wei] Taipei Med Univ, Sch Gerontol Hlth Management, Coll Nursing, Taipei, Taiwan	Taipei Medical University; Universitas Muhammadiyah Malang; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Taipei Medical University; Chang Gung University; Chang Gung University; Taipei Medical University; Taipei Medical University	Peng, CW (corresponding author), Taipei Med Univ, Grad Inst Biomed Mat & Tissue Engn, Coll Biomed Engn, Taipei, Taiwan.; Peng, CW (corresponding author), Taipei Med Univ, Sch Biomed Engn, Coll Biomed Engn, Taipei, Taiwan.; Peng, CW (corresponding author), Taipei Med Univ, Int PhD Program Biomed Engn, Coll Biomed Engn, Taipei, Taiwan.; Peng, CW (corresponding author), Taipei Med Univ, Sch Gerontol Hlth Management, Coll Nursing, Taipei, Taiwan.	cwpeng@tmu.edu.tw	Marufa, Siti Ainun/AIE-1774-2022	marufa, siti ainun/0000-0002-7001-346X; Peng, Chih-Wei/0000-0001-9744-4094; Chen, Hsin-Yung/0000-0002-5165-3840	Ministry of Science and Technology [106-2221-E-038-010-MY3, 108-2314-B-038-017, 109-2314-B-038-132, 109-2221-E-038-005-MY3]; Higher Education Sprout Project by the Ministry of Education in Taiwan [DP2-108-21121-01-N-08-02, DP2-110-21121-01-N-02-01]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Higher Education Sprout Project by the Ministry of Education in Taiwan	The present study was generously funded by the Ministry of Science and Technology (106-2221-E-038-010-MY3, 108-2314-B-038-017, 109-2314-B-038-132, and 109-2221-E-038-005-MY3) and the Higher Education Sprout Project by the Ministry of Education (DP2-108-21121-01-N-08-02 and DP2-110-21121-01-N-02-01) in Taiwan to C.W. Peng.	AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Andre-Obadia N, 2006, CLIN NEUROPHYSIOL, V117, P1536, DOI 10.1016/j.clinph.2006.03.025; Awad BI, 2015, WORLD NEUROSURG, V83, P232, DOI 10.1016/j.wneu.2013.01.043; Aydin-Abidin S, 2008, EXP BRAIN RES, V188, P249, DOI 10.1007/s00221-008-1356-2; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Benito J, 2012, Top Spinal Cord Inj Rehabil, V18, P106, DOI 10.1310/sci1802-106; BENOWITZ LI, 1989, J NEUROSCI, V9, P990; Calancie B, 1999, J NEUROTRAUM, V16, P49, DOI 10.1089/neu.1999.16.49; Cantone M, 2019, BRAIN SCI, V9, DOI 10.3390/brainsci9080200; Chen YY, 2016, ARCH PHYS MED REHAB, V97, P1610, DOI 10.1016/j.apmr.2016.03.017; Chidlow G, 2012, NEUROBIOL DIS, V48, P568, DOI 10.1016/j.nbd.2012.07.026; Curt A, 1998, ARCH PHYS MED REHAB, V79, P81, DOI 10.1016/S0003-9993(98)90213-1; Defrin R, 2007, ARCH PHYS MED REHAB, V88, P1574, DOI 10.1016/j.apmr.2007.07.025; DELAMONTE SM, 1995, AM J PATHOL, V147, P934; Di Lazzaro V, 1999, CLIN NEUROPHYSIOL, V110, P1297, DOI 10.1016/S1388-2457(99)00060-7; Fakhoury M, 2015, REV NEUROSCIENCE, V26, P397, DOI 10.1515/revneuro-2015-0001; Fassett HJ, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00380; Fonoff ET, 2009, BEHAV BRAIN RES, V196, P63, DOI 10.1016/j.bbr.2008.07.027; Freund P, 2013, NEUROSCIENTIST, V19, P116, DOI 10.1177/1073858412449192; Froc DJ, 2000, J NEUROSCI, V20, P438, DOI 10.1523/JNEUROSCI.20-01-00438.2000; Gharooni AA, 2018, SPINAL CORD, V56, P762, DOI 10.1038/s41393-018-0152-5; Gnanapavan S, 2014, J NEUROIMMUNOL, V276, P18, DOI 10.1016/j.jneuroim.2014.07.008; Grasselli G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020791; Hakkoum D, 2007, J NEUROCHEM, V100, P747, DOI 10.1111/j.1471-4159.2006.04257.x; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; Hamada M, 2013, CEREB CORTEX, V23, P1593, DOI 10.1093/cercor/bhs147; Hsieh TH, 2015, CEREB CORTEX, V25, P1806, DOI 10.1093/cercor/bht421; Hsieh TH, 2015, J MED BIOL ENG, V35, P62, DOI 10.1007/s40846-015-0006-y; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; JACOBSON RD, 1986, J NEUROSCI, V6, P1843; Jette F, 2013, NEUROREHAB NEURAL RE, V27, P636, DOI 10.1177/1545968313484810; Kang BS, 2009, ARCH PHYS MED REHAB, V90, P1766, DOI 10.1016/j.apmr.2009.04.008; Kerschensteiner M, 2004, J EXP MED, V200, P1027, DOI 10.1084/jem.20040452; Kjell J, 2016, DIS MODEL MECH, V9, P1125, DOI 10.1242/dmm.025833; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Krassioukov A, 2009, RESP PHYSIOL NEUROBI, V169, P157, DOI 10.1016/j.resp.2009.08.003; Kumru H, 2010, NEUROREHAB NEURAL RE, V24, P435, DOI 10.1177/1545968309356095; Lanza GS, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10110806; Lanza G, 2019, BRAIN STIMUL, V12, P1579, DOI 10.1016/j.brs.2019.07.008; LEWKO JP, 1995, RESTOR NEUROL NEUROS, V7, P225, DOI 10.3233/RNN-1994-7405; Maeda F, 2000, EXP BRAIN RES, V133, P425, DOI 10.1007/s002210000432; McAllister SM, 2009, CLIN NEUROPHYSIOL, V120, P820, DOI 10.1016/j.clinph.2009.02.003; Moreno-Duarte I, 2014, NEUROIMAGE, V85, P1003, DOI 10.1016/j.neuroimage.2013.05.097; Morgante F, 2006, BRAIN, V129, P1059, DOI 10.1093/brain/awl031; Mori F, 2009, PROG BRAIN RES, V175, P429, DOI 10.1016/S0079-6123(09)17528-3; Nardone R, 2015, BRAIN RES, V1619, P139, DOI 10.1016/j.brainres.2014.09.036; OESTREICHER AB, 1986, J NEUROCHEM, V46, P1366, DOI 10.1111/j.1471-4159.1986.tb01748.x; OESTREICHER AB, 1981, BRAIN RES BULL, V6, P145, DOI 10.1016/S0361-9230(81)80040-8; Onifer SM, 2007, ILAR J, V48, P385, DOI 10.1093/ilar.48.4.385; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Petersen JA, 2012, NEUROREHAB NEURAL RE, V26, P939, DOI 10.1177/1545968312438437; Petrosyan HA, 2017, NEUROSCI LETT, V642, P37, DOI 10.1016/j.neulet.2017.01.065; Poon PC, 2007, SPINE, V32, P2853, DOI 10.1097/BRS.0b013e31815b7e6b; Ridding MC, 2007, NAT REV NEUROSCI, V8, P559, DOI 10.1038/nrn2169; Rong H, 2018, SPINE, V43, pE126, DOI 10.1097/BRS.0000000000002279; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Rossini PM, 2007, NEUROLOGY, V68, P484, DOI 10.1212/01.wnl.0000250268.13789.b2; Rotenberg A, 2010, CLIN NEUROPHYSIOL, V121, P104, DOI 10.1016/j.clinph.2009.09.008; Sangari S, 2019, J NEUROSCI, V39, P7872, DOI 10.1523/JNEUROSCI.1106-19.2019; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Sjogren M, 2001, DEMENT GERIATR COGN, V12, P257, DOI 10.1159/000051268; SKENE JHP, 1981, J CELL BIOL, V89, P86, DOI 10.1083/jcb.89.1.86; Song WG, 2016, EXP NEUROL, V277, P46, DOI 10.1016/j.expneurol.2015.12.008; Suppa A, 2011, EXP NEUROL, V227, P296, DOI 10.1016/j.expneurol.2010.11.020; Suppa A, 2014, MOVEMENT DISORD, V29, P97, DOI 10.1002/mds.25668; Tazoe T, 2015, ARCH PHYS MED REHAB, V96, pS145, DOI 10.1016/j.apmr.2014.07.418; Teunissen CE, 2006, NEUROPATH APPL NEURO, V32, P318, DOI 10.1111/j.1365-2990.2006.00730.x; Trepel C, 1998, CEREB CORTEX, V8, P719, DOI 10.1093/cercor/8.8.719; Tsai S Y, 1992, Electromyogr Clin Neurophysiol, V32, P615; Wassermann EM, 2001, CLIN NEUROPHYSIOL, V112, P1367, DOI 10.1016/S1388-2457(01)00585-5; Wen JX, 2015, J NEUROTRAUM, V32, P875, DOI 10.1089/neu.2013.3321; Wischnewski M, 2015, BRAIN STIMUL, V8, P685, DOI 10.1016/j.brs.2015.03.004; Wu SW, 2012, BRAIN STIMUL, V5, P315, DOI 10.1016/j.brs.2011.04.001; Yang G, 2017, INT J MOL MED, V39, P437, DOI 10.3892/ijmm.2017.2848; Yang Q, 2019, EXP NEUROL, V320, DOI 10.1016/j.expneurol.2019.112962; Yoon EJ, 2013, BRAIN RES, V1540, P64, DOI 10.1016/j.brainres.2013.10.007; Zareen N, 2017, EXP NEUROL, V297, P179, DOI 10.1016/j.expneurol.2017.08.004	80	5	5	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2021	16	6							e0252965	10.1371/journal.pone.0252965	http://dx.doi.org/10.1371/journal.pone.0252965			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RB	34086836	Green Accepted, Green Published, gold			2023-01-03	WOS:000664640100157
J	Knotkova, H; Hamani, C; Sivanesan, E; Le Beuffe, MFE; Moon, JY; Cohen, SP; Huntoon, MA				Knotkova, Helena; Hamani, Clement; Sivanesan, Eellan; Elgueta Le Beuffe, Maria Francisca; Moon, Jee Youn; Cohen, Steven P.; Huntoon, Marc A.			Neuromodulation for chronic pain	LANCET			English	Review							SPINAL-CORD-STIMULATION; DEEP BRAIN-STIMULATION; MOTOR CORTEX STIMULATION; PERIPHERAL-NERVE STIMULATION; RANDOMIZED CONTROLLED-TRIAL; ROOT GANGLION STIMULATION; CHRONIC NEUROPATHIC PAIN; 10-KHZ HIGH-FREQUENCY; DOUBLE-BLIND; CHRONIC BACK	Neuromodulation is an expanding area of pain medicine that incorporates an array of non-invasive, minimally invasive, and surgical electrical therapies. In this Series paper, we focus on spinal cord stimulation (SCS) therapies discussed within the framework of other invasive, minimally invasive, and non-invasive neuromodulation therapies. These therapies include deep brain and motor cortex stimulation, peripheral nerve stimulation, and the non-invasive treatments of repetitive transcranial magnetic stimulation, transcranial direct current stimulation, and transcutaneous electrical nerve stimulation. SCS methods with electrical variables that differ from traditional SCS have been approved. Although methods devoid of paraesthesias (eg, high frequency) should theoretically allow for placebo-controlled trials, few have been done. There is low-to-moderate quality evidence that SCS is superior to reoperation or conventional medical management for failed back surgery syndrome, and conflicting evidence as to the superiority of traditional SCS over sham stimulation or between different SCS modalities. Peripheral nerve stimulation technologies have also undergone rapid development and become less invasive, including many that are placed percutaneously. There is low-to-moderate quality evidence that peripheral nerve stimulation is effective for neuropathic pain in an extremity, low quality evidence that it is effective for back pain with or without leg pain, and conflicting evidence that it can prevent migraines. In the USA and many areas in Europe, deep brain and motor cortex stimulation are not approved for chronic pain, but are used off-label for refractory cases. Overall, there is mixed evidence supporting brain stimulation, with most sham-controlled trials yielding negative findings. Regarding non-invasive modalities, there is moderate quality evidence that repetitive transcranial magnetic stimulation does not provide meaningful benefit for chronic pain in general, but conflicting evidence regarding pain relief for neuropathic pain and headaches. For transcranial direct current stimulation, there is low-quality evidence supporting its benefit for chronic pain, but conflicting evidence regarding a small treatment effect for neuropathic pain and headaches. For transcutaneous electrical nerve stimulation, there is low-quality evidence that it is superior to sham or no treatment for neuropathic pain, but conflicting evidence for non-neuropathic pain. Future research should focus on better evaluating the short-term and long-term effectiveness of all neuromodulation modalities and whether they decrease health-care use, and on refining selection criteria and treatment variables.	[Knotkova, Helena] MJHS Inst Innovat Palliat Care, New York, NY USA; [Knotkova, Helena] Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY 10467 USA; [Hamani, Clement] Univ Toronto, Harquail Ctr Neuromodulat, Sunnybrook Res Inst, Div Neurosurg,Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Sivanesan, Eellan] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Cohen, Steven P.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA; [Cohen, Steven P.] Johns Hopkins Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Cohen, Steven P.] Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA; [Elgueta Le Beuffe, Maria Francisca] Pontificia Univ Catolica Chile, Dept Anesthesiol, Santiago, Chile; [Moon, Jee Youn] Seoul Natl Univ, Dept Anesthesiol, Seoul, South Korea; [Cohen, Steven P.] Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, Bethesda, MD 20814 USA; [Cohen, Steven P.] Uniformed Serv Univ Hlth Sci, Dept Phys Med & Rehabil, Bethesda, MD 20814 USA; [Huntoon, Marc A.] Virginia Commonwealth Univ, Dept Anesthesiol, Richmond, VA USA	Yeshiva University; Albert Einstein College of Medicine; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Pontificia Universidad Catolica de Chile; Seoul National University (SNU); Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA; Virginia Commonwealth University	Cohen, SP (corresponding author), Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.	scohen40@jhmi.edu	Sivanesan, Eellan/I-6399-2019	Sivanesan, Eellan/0000-0003-3419-9209	Musculoskeletal Injury Rehabilitation Research for Operational Readiness; Department of Physical Medicine AMP; Rehabilitation, Uniformed Services University; US Department of Defense [HU00011920011]	Musculoskeletal Injury Rehabilitation Research for Operational Readiness; Department of Physical Medicine AMP; Rehabilitation, Uniformed Services University; US Department of Defense(United States Department of Defense)	This work was partly supported (partial effort for SPC paid to Johns Hopkins) by the Musculoskeletal Injury Rehabilitation Research for Operational Readiness, Department of Physical Medicine & Rehabilitation, Uniformed Services University, US Department of Defense (HU00011920011). This organisation played no role in the preparation of this manuscript.	Akram H, 2016, NEUROLOGY, V86, P1676, DOI 10.1212/WNL.0000000000002632; Al-Kaisy A, 2018, NEUROMODULATION, V21, P457, DOI 10.1111/ner.12771; Alwardat M, 2020, J NEURAL TRANSM, V127, P1257, DOI 10.1007/s00702-020-02223-w; Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Bikson M, 2018, BRAIN STIMUL, V11, P134, DOI 10.1016/j.brs.2017.10.012; Boccard SGJ, 2013, NEUROSURGERY, V72, P221, DOI 10.1227/NEU.0b013e31827b97d6; Caruso AP., 2015, TXB NEUROMODULATION, P87; Chae J, 2005, AM J PHYS MED REHAB, V84, P832, DOI 10.1097/01.phm.0000184154.01880.72; Chakravarthy K, 2018, NEUROMODULATION, V21, P431, DOI 10.1111/ner.12756; Chao DM, 2020, PAIN, V161, P2872, DOI 10.1097/j.pain.0000000000001982; Cision, 2019, GLOB SPIN CORD STIM; Coffey RJ, 2001, PAIN MED, V2, P183, DOI 10.1046/j.1526-4637.2001.01029.x; Colloca L, 2005, NAT REV NEUROSCI, V6, P545, DOI 10.1038/nrn1705; Cruccu G, 2016, EUR J NEUROL, V23, P1489, DOI 10.1111/ene.13103; Cui JG, 1997, PAIN, V73, P87, DOI 10.1016/S0304-3959(97)00077-8; Data Intelligence, SPIN CORD STIM MARK; De Andres J, 2017, PAIN MED, V18, P2401, DOI 10.1093/pm/pnx241; De Groote S, 2018, J PAIN RES, V11, P2517, DOI 10.2147/JPR.S160890; De Ridder D, 2013, WORLD NEUROSURG, V80, P642, DOI 10.1016/j.wneu.2013.01.040; de Vos CC, 2014, PAIN, V155, P2426, DOI 10.1016/j.pain.2014.08.031; Deer T, 2018, NEUROMODULATION, V21, P56, DOI 10.1111/ner.12698; Deer T, 2016, NEUROMODULATION, V19, P91, DOI 10.1111/ner.12381; Deer TR, 2020, PAIN MED, V21, P1590, DOI 10.1093/pm/pnaa030; Deer TR, 2017, PAIN, V158, P669, DOI 10.1097/j.pain.0000000000000814; Deer TR, 2014, NEUROMODULATION, V17, P515, DOI 10.1111/ner.12208; Duarte RV, 2020, PAIN, V161, P24, DOI 10.1097/j.pain.0000000000001689; Duarte RV, 2020, NEUROMODULATION, V23, P10, DOI 10.1111/ner.13018; Fontaine D, 2010, BRAIN, V133, P1214, DOI 10.1093/brain/awq041; Fontaine D, 2010, J HEADACHE PAIN, V11, P23, DOI 10.1007/s10194-009-0169-4; Fontaine D, 2009, J NEUROSURG, V110, P251, DOI 10.3171/2008.6.17602; Frizon LA, 2020, NEUROSURGERY, V86, P191, DOI 10.1093/neuros/nyy552; Galafassi GZ, 2021, WORLD NEUROSURG, V146, P246, DOI 10.1016/j.wneu.2020.11.048; Gibson W, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011890.pub3; Gibson W, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011976.pub2; Gilmore C, 2019, REGION ANESTH PAIN M, V44, P637, DOI 10.1136/rapm-2018-100109; Gilmore CA, 2020, REGION ANESTH PAIN M, V45, P44, DOI 10.1136/rapm-2019-100937; Gilmore CA, 2020, PAIN PRACT, V20, P310, DOI 10.1111/papr.12856; Green AL, 2006, CEPHALALGIA, V26, P561, DOI 10.1111/j.1468-2982.2005.01068.x; Hamani C., 2009, TXB STEREOTACTIC FUN, P2227; Hamani C, 2006, PAIN, V125, P188, DOI 10.1016/j.pain.2006.05.019; Hamani C, 2006, STEREOT FUNCT NEUROS, V84, P248, DOI 10.1159/000096499; Hamani C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003722; International Neuromodulation Society, 2019, SPIN CORD STIM ROL M; International Neuromodulation Society, 2018, NEUR NEUR EFF; Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55; Kapural L, 2016, NEUROSURGERY, V79, P667, DOI 10.1227/NEU.0000000000001418; Kapural L, 2015, ANESTHESIOLOGY, V123, P851, DOI 10.1097/ALN.0000000000000774; Kemler MA, 2000, NEW ENGL J MED, V343, P618, DOI 10.1056/NEJM200008313430904; Kemler MA, 2006, NEW ENGL J MED, V354, P2394, DOI 10.1056/NEJMc055504; Knotkova H, 2015, PRACT PAIN MANAG, V2, P58; Knotkova H, 2019, PRACTICAL GUIDE TRAN, P541; Kriek N, 2017, EUR J PAIN, V21, P507, DOI 10.1002/ejp.944; Kumar K, 2007, PAIN, V132, P179, DOI 10.1016/j.pain.2007.07.028; Lad SP, 2010, NEUROMODULATION, V13, P265, DOI 10.1111/j.1525-1403.2010.00292.x; Lamer TJ, 2019, MAYO CLIN PROC, V94, P1475, DOI 10.1016/j.mayocp.2018.12.037; Lee DJ, 2019, J NEUROSURG, V131, P333, DOI 10.3171/2019.4.JNS181761; Lefaucheur JP, 2020, CLIN NEUROPHYSIOL, V131, P474, DOI 10.1016/j.clinph.2019.11.002; Lefaucheur JP, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e318207f896; Lefaucheur JP, 2009, BRAIN, V132, P1463, DOI 10.1093/brain/awp035; Lempka SF, 2017, ANN NEUROL, V81, P653, DOI 10.1002/ana.24927; Leone M, 2016, CEPHALALGIA, V36, P1143, DOI 10.1177/0333102415607176; Leung A, 2020, NEUROMODULATION, V23, P267, DOI 10.1111/ner.13094; LEVY RM, 1987, NEUROSURGERY, V21, P885, DOI 10.1227/00006123-198712000-00017; Lin CP, 2020, PAIN MED, V21, pS56, DOI 10.1093/pm/pnz318; Maedai Y, 2007, BRAIN RES, V1136, P43, DOI 10.1016/j.brainres.2006.11.061; Maher C, 2020, LANCET NEUROL, V19, P380, DOI 10.1016/S1474-4422(20)30110-1; Meier K, 2015, CLIN J PAIN, V31, P384, DOI 10.1097/AJP.0000000000000131; Mekhail N, 2020, LANCET NEUROL, V19, P123, DOI 10.1016/S1474-4422(19)30414-4; Mekhail N, 2011, PROF CASE MANAG, V16, P27, DOI 10.1097/NCM.0b013e3181e9263c; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Meuwissen KPV, 2020, PAIN PRACT, V20, P75, DOI 10.1111/papr.12831; Mo JJ, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1273-y; Moisset X, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-01204-4; National Institute for Health and Care Excellence, 2019, SYSTEM DELIVERING HF; Nguyen JP, 2008, BRAIN STIMUL, V1, P89, DOI 10.1016/j.brs.2008.03.007; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; North RB, 2005, NEUROSURGERY, V56, P98, DOI 10.1227/01NEU.0000144839.65524.E0; Nowacki A, 2020, ANN NEUROL, V88, P956, DOI 10.1002/ana.25887; O'Connell NE, 2018, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008208.pub4, 10.1002/14651858.CD008208.pub5]; Parravano DC, 2019, NEUROSURGERY, V84, P451, DOI 10.1093/neuros/nyy060; Pivonka D, 2021, U. S. Patent, Patent No. [10,898,719, 10898719]; Pluijms WA, 2011, EUR J PAIN, V15, P783, DOI 10.1016/j.ejpain.2011.01.010; Radic JAE, 2015, CAN J NEUROL SCI, V42, P401, DOI 10.1017/cjn.2015.292; Rasche Dirk, 2006, Neurosurg Focus, V21, pE8; Reznikov R, 2016, NEUROPSYCHOPHARMACOL, V41, P2810, DOI 10.1038/npp.2016.34; Russo M, 2018, NEUROMODULATION, V21, P38, DOI 10.1111/ner.12684; Sachs AJ, 2014, NEUROMODULATION, V17, P303, DOI 10.1111/ner.12181; Saper JR, 2011, CEPHALALGIA, V31, P271, DOI 10.1177/0333102410381142; Schu S, 2014, NEUROMODULATION, V17, P443, DOI 10.1111/ner.12197; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; SHEALY CN, 1967, ANESTH ANAL CURR RES, V46, P489; Silberstein SD, 2012, CEPHALALGIA, V32, P1165, DOI 10.1177/0333102412462642; Sivanesan E, 2019, ANESTHESIOLOGY, V130, P651, DOI 10.1097/ALN.0000000000002353; Sivanesan E, 2019, PAIN REP, V4, DOI 10.1097/PR9.0000000000000785; Sivanesan E, 2019, REGION ANESTH PAIN M, V44, P100, DOI 10.1136/rapm-2018-000007; Slangen R, 2014, DIABETES CARE, V37, P3016, DOI 10.2337/dc14-0684; Sluka KA, 1999, J PHARMACOL EXP THER, V289, P840; Stilling JM, 2019, HEADACHE, V59, P339, DOI 10.1111/head.13479; Stock VM, 2015, TXB NEUROMODULATION, P3; Talbot K, 2019, BRIT J ANAESTH, V123, pE263, DOI 10.1016/j.bja.2019.03.033; THOMAS M, 1991, AM J CHINESE MED, V19, P95, DOI 10.1142/S0192415X91000156; Tjepkema-Cloostermans MC, 2016, NEUROMODULATION, V19, P492, DOI 10.1111/ner.12429; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; Turner JA, 2010, PAIN, V148, P14, DOI 10.1016/j.pain.2009.08.014; Vance CGT, 2014, PAIN MANAG, V4, P197, DOI [10.2217/PMT.14.13, 10.2217/pmt.14.13]; Velasco F, 2008, J NEUROSURG, V108, P698, DOI 10.3171/JNS/2008/108/4/0698; Woods AJ, 2016, CLIN NEUROPHYSIOL, V127, P1031, DOI 10.1016/j.clinph.2015.11.012; Wu LC, 2018, REGION ANESTH PAIN M, V43, P425, DOI 10.1097/AAP.0000000000000740; Yang SY, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00114; Yu GL, 2020, ANESTHESIOLOGY, V133, P408, DOI 10.1097/ALN.0000000000003348	110	43	47	17	38	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2021	397	10289					2111	2124						14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SK5LX	34062145				2023-01-03	WOS:000656257800029
J	Ramnath, U; Rauch, L; Lambert, EV; Kolbe-Alexander, T				Ramnath, Udhir; Rauch, Laurie; Lambert, Estelle Victoria; Kolbe-Alexander, Tracy			Efficacy of interactive video gaming in older adults with memory complaints: A cluster-randomized exercise intervention	PLOS ONE			English	Article							MILD COGNITIVE IMPAIRMENT; PHYSICAL-ACTIVITY; PERFORMANCE; REGRESSION; EDUCATION; MOBILITY; PROGRAM; VOLUME	Purpose The effects of aging on physical and mental health may be ameliorated by regular participation in physical activity (PA). There is also evidence for the benefits of various training modalities on cognition and functional ability in older adults. The aim of this study was to compare effects of a 12-week active video gaming intervention (X Box Kinect Sports) to conventional multimodal supervised exercise on fitness, functional ability and cognitive performance in older adults with memory complaints. Methods Participants (n = 45, 725 yrs.) were recruited from 6 retirement homes and cluster-randomized into the Interactive Video Gaming (IVG) group (N = 23) or Conventional Multimodal (CM) group (N = 22), meeting 2 x 1 hour sessions, weekly for 12 weeks. Pre-post measures included: 6 min walk, timed up and go, dynamic balance, functional reach, Mini-Mental State Examination, N-back Task and the Modified Stroop task. Results The IVG group demonstrated significant improvement in the total number correct responses on the Stroop task (P = 0.028) and for average reaction time of correct colour-words (P = 0.024), compared to the CM group. Functional ability improved significantly in the IVG group, including the 6-min walk (P = 0.017), dynamic balance (P = 0.03), timed up and go (P<0.001) and functional reach (P<0.0010). Conclusion An active interactive video gaming intervention was more effective than conventional multimodal exercise in improving executive and global cognitive performance and functional capacity in older adults with subjective memory complaints. Trial registration Pan African Clinical Trial Registry-PACTR202008547335106.	[Ramnath, Udhir; Rauch, Laurie; Lambert, Estelle Victoria; Kolbe-Alexander, Tracy] Univ Cape Town, Fac Hlth Sci, Dept Human Biol, Div Exercise Sci & Sports Med, Cape Town, South Africa; [Kolbe-Alexander, Tracy] Univ Southern Queensland, Sch Hlth & Well Being, Ipswich, Australia; [Kolbe-Alexander, Tracy] Univ Queensland, Sch Human Movement & Nutr Sci, Brisbane, Qld, Australia	University of Cape Town; University of Southern Queensland; University of Queensland	Ramnath, U (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Human Biol, Div Exercise Sci & Sports Med, Cape Town, South Africa.	rmnudh001@myuct.ac.za	Rauch, Henri GL/HCI-8272-2022	Rauch, Henri GL/0000-0002-7709-3407; Ramnath, Udhir/0000-0002-9705-0789; Lambert, Michael/0000-0001-8979-1504				Anderson-Hanley C, 2012, AM J PREV MED, V42, P109, DOI 10.1016/j.amepre.2011.10.016; Anguera JA, 2013, NATURE, V501, P97, DOI 10.1038/nature12486; Baker LD, 2010, ARCH NEUROL-CHICAGO, V67, P71, DOI 10.1001/archneurol.2009.307; Balachandran A, 2016, EXP GERONTOL, V82, P131, DOI 10.1016/j.exger.2016.06.012; Bherer L., 2013, J AGING RES, V2013, DOI [10.1155/2013/657508., 10.1155/2013/657508]; Bieryla KA, 2013, CLIN INTERV AGING, V8, P775, DOI 10.2147/CIA.S46164; Bischoff HA, 2003, AGE AGEING, V32, P315, DOI 10.1093/ageing/32.3.315; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111; Cardoso-Leite P, 2014, CURR OPIN NEUROL, V27, P185, DOI 10.1097/WCO.0000000000000077; Chien-Hung L., 2013, GAIT POSTURE, V37, P511; Christofoletti G, 2008, CLIN REHABIL, V22, P618, DOI 10.1177/0269215507086239; Colcombe SJ, 2006, J GERONTOL A-BIOL, V61, P1166, DOI 10.1093/gerona/61.11.1166; DIPIETRO L, 1993, MED SCI SPORT EXER, V25, P628; DURNIN JVG, 1969, J PHYSIOL-LONDON, V200, pP105; Etnier JL, 2006, BRAIN RES REV, V52, P119, DOI 10.1016/j.brainresrev.2006.01.002; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Graves LEF, 2010, J PHYS ACT HEALTH, V7, P393, DOI 10.1123/jpah.7.3.393; Green CS, 2006, J EXP PSYCHOL HUMAN, V32, P1465, DOI 10.1037/0096-1523.32.6.1465; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Hughes TF, 2014, INT J GERIATR PSYCH, V29, P890, DOI 10.1002/gps.4075; Ito K, 2013, PLOS ONE, V8, P1; Kwak YS, 2008, INT J SPORTS MED, V29, P471, DOI 10.1055/s-2007-964853; Langoni CD, 2019, J GERIATR PHYS THER, V42, pE15, DOI 10.1519/JPT.0000000000000191; Liu-Ambrose T, 2012, NEUROBIOL AGING, V33, P1690, DOI 10.1016/j.neurobiolaging.2011.05.010; Lund HH, 2014, GAMES HEALTH J, V3, P277, DOI 10.1089/g4h.2014.0028; Maillot P, 2012, PSYCHOL AGING, V27, P589, DOI 10.1037/a0026268; Mandolesi L, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00509; Mayson DJ, 2008, AM J PHYS MED REHAB, V87, P969, DOI 10.1097/PHM.0b013e31818dfee5; Nishiguchi S, 2015, J AM GERIATR SOC, V63, P1355, DOI 10.1111/jgs.13481; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Palac D, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16183495; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Rakesh G, 2017, THER ADV CHRONIC DIS, V8, P121, DOI 10.1177/2040622317712442; Richardson JTE, 2011, EDUC RES REV-NETH, V6, P135, DOI 10.1016/j.edurev.2010.12.001; Shah T, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.122; Shatil E, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00008; Spreen O., 1998, COMPENDIUM NEUROPSYC, Vsecond; Staiano AE, 2011, CHILD DEV PERSPECT, V5, P93, DOI 10.1111/j.1750-8606.2011.00162.x; Steinberg SI, 2013, AM J ALZHEIMERS DIS, V28, P776, DOI 10.1177/1533317513504817; Strawbridge WJ, 1998, J GERONTOL B-PSYCHOL, V53, pS9, DOI 10.1093/geronb/53B.1.S9; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SUURMEIJER TPBM, 1994, AM J PUBLIC HEALTH, V84, P1270, DOI 10.2105/AJPH.84.8.1270; Taylor LM, 2012, ARCH PHYS MED REHAB, V93, P2281, DOI 10.1016/j.apmr.2012.03.034; ten Brinke LF, 2015, BRIT J SPORT MED, V49, P248, DOI 10.1136/bjsports-2013-093184; Thompson RW., 2009, ACSM's Guidelines for Exercise Testing and Prescription, V8th; WEINER DK, 1992, J AM GERIATR SOC, V40, P203, DOI 10.1111/j.1532-5415.1992.tb02068.x; WINOGRAD CH, 1994, J AM GERIATR SOC, V42, P743, DOI 10.1111/j.1532-5415.1994.tb06535.x	49	2	2	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2021	16	5							e0252016	10.1371/journal.pone.0252016	http://dx.doi.org/10.1371/journal.pone.0252016			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6OL	34032799	Green Accepted, Green Published, gold			2023-01-03	WOS:000664633100020
J	Bussabong, P; Rairat, T; Chuchird, N; Keetanon, A; Phansawat, P; Cherdkeattipol, K; Pichitkul, P; Kraitavin, W				Bussabong, Pavarist; Rairat, Tirawat; Chuchird, Niti; Keetanon, Arunothai; Phansawat, Putsucha; Cherdkeattipol, Kanokwan; Pichitkul, Phongchate; Kraitavin, Waraporn			Effects of isoquinoline alkaloids from Macleaya cordata on growth performance, survival, immune response, and resistance to Vibrio parahaemolyticus infection of Pacific white shrimp (Litopenaeus vannamei)	PLOS ONE			English	Article							SANGUINARINE-LIKE ALKALOIDS; DIETARY SANGUINARINE; MEDICINAL-PLANTS; MICROCARPA; CHELERYTHRINE; PROMOTERS; SANGROVIT; EXTRACTS; EFFICACY; SAFETY	Isoquinoline alkaloids (IQs) from Macleaya cordata are promising natural products for enhancing the growth performance and overall health condition of farmed animals. The present study aimed to investigate the effects of two formulas of IQ extract, provided in either a powdered formula (IQ-E) or a water-soluble, granulated formula (IQ-WS) and containing the main active component sanguinarine at a concentration of 0.5% and 1%, respectively, on the growth, survival, immune response, and resistance to Vibrio parahaemolyticus infection of Pacific white shrimp (Litopenaeus vannamei). In Experiment 1, the postlarvae were divided into five groups (four replicates/group and 100 shrimp/tank) and fed four times/day for 30 days with a control feed, IQ-E at 200 or 300 mg/kg of feed, or IQ-WS at 100 or 150 mg/kg of feed. In Experiment 2, the surviving shrimp from Experiment 1 were redistributed into six groups (four treatment groups as in Experiment 1 plus the positive and negative controls with four replicates/group and 30 shrimp/tank) and challenged with V. parahaemolyticus by immersion at a concentration of 10(3) colony-forming units (CFU)/mL and were fed with the same diets for another 14 days. The results revealed that all IQ-fed shrimp in Experiment 1 had significantly enhanced survival rates and immune parameters (total hemocyte count and phagocytic, phenoloxidase, and superoxide dismutase activities) compared to the control group, even though the growth performances were similar across all groups. In Experiment 2, all IQ-fed groups showed better growth performance and survival rates compared to the positive control. Other than in the positive control group, no histopathological lesions in the hepatopancreas and the intestine were found. In summary, the current study demonstrated the benefits of using IQs from M. cordata as feed additives for improving the growth performance, survival rate, immune responses, and resistance to vibriosis of Pacific white shrimp.	[Bussabong, Pavarist; Rairat, Tirawat; Chuchird, Niti; Keetanon, Arunothai; Phansawat, Putsucha; Cherdkeattipol, Kanokwan] Kasetsart Univ, Dept Fishery Biol, Fac Fisheries, Bangkok, Thailand; [Pichitkul, Phongchate] Kasetsart Univ, Dept Aquaculture, Fac Fisheries, Bangkok, Thailand; [Kraitavin, Waraporn] Phytobiot Thailand Co Ltd, Bangkok, Thailand	Kasetsart University; Kasetsart University	Chuchird, N (corresponding author), Kasetsart Univ, Dept Fishery Biol, Fac Fisheries, Bangkok, Thailand.	ffisntc@ku.ac.th	Rairat, Tirawat/AAX-8198-2021	Rairat, Tirawat/0000-0001-7966-3592; Chuchird, Niti/0000-0002-3272-0366	Aquaculture Business Research Center, Kasetsart University, Thailand [ABRC11082018]; Phytobiotics (Thailand) Co., Ltd.	Aquaculture Business Research Center, Kasetsart University, Thailand; Phytobiotics (Thailand) Co., Ltd.	This paper was funded by grants from the Aquaculture Business Research Center (ABRC11082018), Kasetsart University, Thailand, to support graduate student PB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Phytobiotics (Thailand) Co., Ltd. provided support in the form of salary to WK. The specific roles of this author are articulated in the 'author contributions' section. Phytobiotics also provided material support in the form of the isoquinoline extracts for the study, but had no other role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelnaby E., 2013, GLOBAL ANIMAL SCI J, V1, P19; Aguirre-Guzman G, 2010, J WORLD AQUACULT SOC, V41, P464, DOI 10.1111/j.1749-7345.2010.00388.x; APHA (American Public Health Association), 2017, AM PUBL HLTH ASS STA, V23rd; Bell T.A., 1988, HDB NORMAL PENAEID S, VFirst; Beuria TK, 2005, BIOCHEMISTRY-US, V44, P16584, DOI 10.1021/bi050767+; Broom LJ, 2017, POULTRY SCI, V96, P3104, DOI 10.3382/ps/pex114; Chen JS, 2019, J APPL ANIM RES, V47, P349, DOI 10.1080/09712119.2019.1636800; COATES ME, 1963, BRIT J NUTR, V17, P141, DOI 10.1079/BJN19630015; Dibner JJ, 2005, POULTRY SCI, V84, P634, DOI 10.1093/ps/84.4.634; Encarnacao P, 2016, AQUAFEED FORMULATION, P217, DOI 10.1016/B978-0-12-800873-7.00005-1; Franz C., 2007, EFSA SUPP PUBL, V4; Harikrishnan R, 2011, AQUACULTURE, V317, P1, DOI 10.1016/j.aquaculture.2011.03.039; Hashemi SR, 2011, VET RES COMMUN, V35, P169, DOI 10.1007/s11259-010-9458-2; Hosek J, 2017, ACTA VET BRNO, V86, P223, DOI 10.2754/avb201786030223; Huang KC, 1999, PHARM CHINESE HERBS; Imanpoor MR, 2016, AQUAC RES, V47, P2874, DOI 10.1111/are.12737; Itami T, 1994, THIRD ASIAN FISHERIES FORUM, P375; Kang YJ, 2013, AQUAC RES, V44, P1221, DOI 10.1111/j.1365-2109.2012.03123.x; Karimi M., 2014, Biosciences, Biotechnology Research Asia, V11, P855, DOI 10.13005/bbra/1348; Kosina P, 2004, FOOD CHEM TOXICOL, V42, P85, DOI 10.1016/j.fct.2003.08.007; Kosina P, 2010, FITOTERAPIA, V81, P1006, DOI 10.1016/j.fitote.2010.06.020; Lee KW, 2015, J POULT SCI, V52, P15, DOI 10.2141/jpsa.0140073; Lin L, 2018, PHYTOTHER RES, V32, P19, DOI 10.1002/ptr.5952; Ling F, 2016, J FISH DIS, V39, P993, DOI 10.1111/jfd.12433; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahady GB, 2003, PHYTOTHER RES, V17, P217, DOI 10.1002/ptr.1108; Modi C. M., 2011, Journal of Applied Pharmaceutical Science, V1, P33; NANDI R, 1983, EXPERIENTIA, V39, P524, DOI 10.1007/BF01965187; Newton SM, 2002, J ETHNOPHARMACOL, V79, P57, DOI 10.1016/S0378-8741(01)00350-6; Niewold TA, 2007, POULTRY SCI, V86, P605, DOI 10.1093/ps/86.4.605; Obiang-Obounou BW, 2011, J TOXICOL SCI, V36, P277; Pencikova K, 2012, PHYTOMEDICINE, V19, P890, DOI 10.1016/j.phymed.2012.04.001; Psotova J, 2006, VET MED-CZECH, V51, P145, DOI 10.17221/5534-VETMED; Rairat Tirawat, 2013, Kasetsart University Fisheries Research Bulletin, V37, P19; Rawling MD, 2009, AQUACULTURE, V294, P118, DOI 10.1016/j.aquaculture.2009.05.005; Reverter M, 2014, AQUACULTURE, V433, P50, DOI 10.1016/j.aquaculture.2014.05.048; Supamattaya K., 2000, SONGKLANAKARIN J SCI, V22, P677; Valenzuela-Grijalva NV, 2017, J ANIM SCI TECHNOL, V59, DOI [10.1186/s40781-017-0133-9, 10.1186/s40781-017-0133-9b]; Vieira SL, 2008, J APPL POULTRY RES, V17, P128, DOI 10.3382/japr.2007-00054; Vieira SL, 2008, BRAZ J POULT SCI, V10, P67, DOI 10.1590/S1516-635X2008000100010; Wang GX, 2010, VET PARASITOL, V171, P305, DOI 10.1016/j.vetpar.2010.03.032; Wang W, 2017, AQUAC RES, V48, P1, DOI 10.1111/are.13161; Yang X., 2003, ENCY REFERENCE TRADI; Yao JY, 2011, VET PARASITOL, V183, P8, DOI 10.1016/j.vetpar.2011.07.021; Yao JY, 2010, PARASITOL RES, V107, P1035, DOI 10.1007/s00436-010-1966-z; Zhang R, 2019, AQUACULTURE, V502, P72, DOI 10.1016/j.aquaculture.2018.12.010; Zhou J., 2011, ENCY TRADITIONAL CHI; Zhou S, 2017, AQUACULTURE, V466, P72, DOI 10.1016/j.aquaculture.2016.09.048	48	10	10	8	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2021	16	5							e0251343	10.1371/journal.pone.0251343	http://dx.doi.org/10.1371/journal.pone.0251343			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6GE	33956913	Green Published, gold			2023-01-03	WOS:000664611400097
J	Kyriazopoulou, E; Poulakou, G; Milionis, H; Metallidis, S; Adamis, G; Tsiakos, K; Fragkou, A; Rapti, A; Damoulari, C; Fantoni, M; Kalomenidis, I; Chrysos, G; Angheben, A; Kainis, I; Alexiou, Z; Castelli, F; Serino, FS; Tsilika, M; Bakakos, P; Nicastri, E; Tzavara, V; Kostis, E; Dagna, L; Koufargyris, P; Dimakou, K; Savvanis, S; Tzatzagou, G; Chini, M; Cavalli, G; Bassetti, M; Katrini, K; Kotsis, V; Tsoukalas, G; Selmi, C; Bliziotis, I; Samarkos, M; Doumas, M; Ktena, S; Masgala, A; Papanikolaou, I; Kosmidou, M; Myrodia, DM; Argyraki, A; Cardellino, CS; Koliakou, K; Katsigianni, EI; Rapti, V; Giannitsioti, E; Cingolani, A; Micha, S; Akinosoglou, K; Liatsis-Douvitsas, O; Symbardi, S; Gatselis, N; Mouktaroudi, M; Ippolito, G; Florou, E; Kotsaki, A; Netea, MG; Eugen-Olsen, J; Kyprianou, M; Panagopoulos, P; Dalekos, GN; Giamarellos-Bourboulis, EJ				Kyriazopoulou, Evdoxia; Poulakou, Garyfallia; Milionis, Haralampos; Metallidis, Simeon; Adamis, Georgios; Tsiakos, Konstantinos; Fragkou, Archontoula; Rapti, Aggeliki; Damoulari, Christina; Fantoni, Massimo; Kalomenidis, Ioannis; Chrysos, Georgios; Angheben, Andrea; Kainis, Ilias; Alexiou, Zoi; Castelli, Francesco; Serino, Francesco Saverio; Tsilika, Maria; Bakakos, Petros; Nicastri, Emanuele; Tzavara, Vassiliki; Kostis, Evangelos; Dagna, Lorenzo; Koufargyris, Panagiotis; Dimakou, Katerina; Savvanis, Spyridon; Tzatzagou, Glykeria; Chini, Maria; Cavalli, Giulio; Bassetti, Matteo; Katrini, Konstantina; Kotsis, Vasileios; Tsoukalas, George; Selmi, Carlo; Bliziotis, Ioannis; Samarkos, Michael; Doumas, Michael; Ktena, Sofia; Masgala, Aikaterini; Papanikolaou, Ilias; Kosmidou, Maria; Myrodia, Dimitra-Melia; Argyraki, Aikaterini; Cardellino, Chiara Simona; Koliakou, Katerina; Katsigianni, Eleni-Ioanna; Rapti, Vassiliki; Giannitsioti, Efthymia; Cingolani, Antonella; Micha, Styliani; Akinosoglou, Karolina; Liatsis-Douvitsas, Orestis; Symbardi, Styliani; Gatselis, Nikolaos; Mouktaroudi, Maria; Ippolito, Giuseppe; Florou, Eleni; Kotsaki, Antigone; Netea, Mihai G.; Eugen-Olsen, Jesper; Kyprianou, Miltiades; Panagopoulos, Periklis; Dalekos, George N.; Giamarellos-Bourboulis, Evangelos J.			Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial	NATURE MEDICINE			English	Article							PNEUMONIA; HYPERINFLAMMATION; BLOCKADE	Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety of anakinra, an IL-1 alpha/beta inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure as identified by plasma suPAR >= 6 ng ml(-1), 85.9% (n = 510) of whom were receiving dexamethasone. At day 28, the adjusted proportional odds of having a worse clinical status (assessed by the 11-point World Health Organization Clinical Progression Scale (WHO-CPS)) with anakinra, as compared to placebo, was 0.36 (95% confidence interval 0.26-0.50). The median WHO-CPS decrease on day 28 from baseline in the placebo and anakinra groups was 3 and 4 points, respectively (odds ratio (OR) = 0.40, P < 0.0001); the respective median decrease of Sequential Organ Failure Assessment (SOFA) score on day 7 from baseline was 0 and 1 points (OR = 0.63, P = 0.004). Twenty-eight-day mortality decreased (hazard ratio = 0.45, P = 0.045), and hospital stay was shorter. The SAVE-MORE phase 3 study demonstrates the efficacy of anakinra, an IL-1 alpha/beta inhibitor, in patients with COVID-19 and high serum levels of soluble plasminogen activator receptor.	[Kyriazopoulou, Evdoxia; Damoulari, Christina; Tsilika, Maria; Koufargyris, Panagiotis; Katrini, Konstantina; Ktena, Sofia; Mouktaroudi, Maria; Kotsaki, Antigone; Giamarellos-Bourboulis, Evangelos J.] Natl & Kapodistrian Univ Athens, Dept Internal Med 4, Sch Med, Athens, Greece; [Poulakou, Garyfallia; Myrodia, Dimitra-Melia; Rapti, Vassiliki] Natl & Kapodistrian Univ Athens, Dept Internal Med 3, Sch Med, Athens, Greece; [Milionis, Haralampos; Kosmidou, Maria] Univ Ioannina, Dept Internal Med 1, Sch Med, Ioannina, Greece; [Metallidis, Simeon] Aristotle Univ Thessaloniki, Dept Internal Med 1, Sch Med, Thessaloniki, Greece; [Adamis, Georgios] G Gennimatas Gen Hosp Athens, Dept Internal Med 1, Athens, Greece; [Tsiakos, Konstantinos; Rapti, Aggeliki] Sotiria Gen Hosp Chest Dis, Dept Pulm Med 2, Athens, Greece; [Fragkou, Archontoula; Savvanis, Spyridon] Elpis Gen Hosp, Dept Internal Med, Athens, Greece; [Fantoni, Massimo; Cingolani, Antonella] Fdn Policlin Gemelli IRCCS, Dipartimento Sci Lab & Infettivol, Rome, Italy; [Kalomenidis, Ioannis] Natl & Kapodistrian Univ Athens, Evangelismos Gen Hosp, Dept Crit Care & Pulm Med 1, Sch Med, Athens, Greece; [Chrysos, Georgios; Giannitsioti, Efthymia] Tzaneio Gen Hosp Piraeus, Dept Internal Med 2, Athens, Greece; [Angheben, Andrea; Cardellino, Chiara Simona] IRCSS Sacro Cuore Hosp, Dept Infect Trop Dis & Microbiol, Verona, Italy; [Kainis, Ilias] Sotiria Gen Hosp Chest Dis Athens, Dept Pulm Med 10, Athens, Greece; [Alexiou, Zoi] Thriasio Gen Hosp Eleusis, Dept Internal Med 2, Athens, Greece; [Castelli, Francesco] Univ Brescia, Brescia ASST Spedali Civili Hosp, Spedali Civili, Brescia, Italy; [Serino, Francesco Saverio] Hosp Jesolo, Dept Internal Med, Jesolo, Italy; [Bakakos, Petros] Natl & Kapodistrian Univ Athens, Dept Chest Med 1, Sch Med, Athens, Greece; [Nicastri, Emanuele; Ippolito, Giuseppe] Spallanzani Inst Rome, Dept Internal Med, Rome, Italy; [Tzavara, Vassiliki] Korgialene Benake Gen Hosp, Dept Internal Med, Athens, Greece; [Kostis, Evangelos] Natl & Kapodistrian Univ Athens, Dept Therapeut, Sch Med, Athens, Greece; [Dagna, Lorenzo; Cavalli, Giulio] IRCCS Osped San Raffaele, Unit Immunol Rheumatol Allergy & Rare Dis UnIRAR, Milan, Italy; [Dagna, Lorenzo; Cavalli, Giulio] Univ Vita Salute San Raffaele, Milan, Italy; [Dimakou, Katerina] Sotiria Gen Hosp Chest Dis, Dept Pulm Med 5, Athens, Greece; [Tzatzagou, Glykeria] Papageorgiou Gen Hosp Thessaloniki, Dept Internal Med 1, Thessaloniki, Greece; [Chini, Maria] Korgialene Benake Gen Hosp, Dept Internal Med 3, Athens, Greece; [Chini, Maria] Korgialene Benake Gen Hosp, Infect Dis Unit, Athens, Greece; [Bassetti, Matteo] Univ Genoa, Osped Policlin San Martino IRCCS, Infect Dis Clin, Genoa, Italy; [Bassetti, Matteo] Univ Genoa, Dept Hlth Sci, Genoa, Italy; [Kotsis, Vasileios] Aristotle Univ Thessaloniki, Dept Internal Med 3, Sch Med, Thessaloniki, Greece; [Tsoukalas, George] Sotiria Gen Hosp Chest Dis, Dept Pulm Med 4, Athens, Greece; [Selmi, Carlo] Humanitas Res Hosp, Milan, Italy; [Bliziotis, Ioannis] Asklepieio Gen Hosp Voula, Dept Internal Med 1, Athens, Greece; [Samarkos, Michael] Natl & Kapodistrian Univ Athens, Dept Internal Med 1, Sch Med, Athens, Greece; [Doumas, Michael] Aristotle Univ Thessaloniki, Dept Propedeut Med 2, Sch Med, Thessaloniki, Greece; [Masgala, Aikaterini] Konstantopouleio Gen Hosp, Dept Internal Med 2, Athens, Greece; [Papanikolaou, Ilias] Gen Hosp Kerkyra, Dept Pulm Med, Corfu, Greece; [Argyraki, Aikaterini] Sotiria Gen Hosp Chest Dis, Dept Internal Med, Athens, Greece; [Koliakou, Katerina; Katsigianni, Eleni-Ioanna; Micha, Styliani; Liatsis-Douvitsas, Orestis; Mouktaroudi, Maria; Florou, Eleni; Kyprianou, Miltiades; Giamarellos-Bourboulis, Evangelos J.] Hellen Inst Study Sepsis, Athens, Greece; [Akinosoglou, Karolina] Univ Patras, Dept Internal Med, Rion, Greece; [Symbardi, Styliani] Thriasio Gen Hosp Eleusis, Dept Internal Med 1, Athens, Greece; [Gatselis, Nikolaos; Dalekos, George N.] Gen Univ Hosp Larissa, Dept Med, Larisa, Greece; [Gatselis, Nikolaos; Dalekos, George N.] Gen Univ Hosp Larissa, Res Lab Internal Med, Natl Expertise Ctr Greece Autoimmune Liver Dis, Larisa, Greece; [Netea, Mihai G.] Radboud Univ Nijmegen, Dept Internal Med, Nijmegen, Netherlands; [Netea, Mihai G.] Radboud Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands; [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst, Dept Immunol & Metab, Bonn, Germany; [Eugen-Olsen, Jesper] Copenhagen Univ Hosp, Dept Clin Res, Amager, Denmark; [Eugen-Olsen, Jesper] Copenhagen Univ Hosp, Dept Clin Res, Hvidovre, Denmark; [Panagopoulos, Periklis] Democritus Univ Thrace, Dept Internal Med 2, Sch Med, Alexandroupolis, Greece	Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; University of Ioannina; Aristotle University of Thessaloniki; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Athens Medical School; Evangelismos Hospital; National & Kapodistrian University of Athens; University of Brescia; Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Papageorgiou Hospital; University of Genoa; University of Genoa; Aristotle University of Thessaloniki; Athens Medical School; National & Kapodistrian University of Athens; Aristotle University of Thessaloniki; University of Patras; General University Hospital of Larissa; General University Hospital of Larissa; Radboud University Nijmegen; Radboud University Nijmegen; University of Bonn; University of Copenhagen; University of Copenhagen; Democritus University of Thrace	Giamarellos-Bourboulis, EJ (corresponding author), Natl & Kapodistrian Univ Athens, Dept Internal Med 4, Sch Med, Athens, Greece.	egiamarel@med.uoa.gr	Samarkos, Michael/Q-5104-2019; Fantoni, Massimo/AAB-7371-2022; Rapti, Vasiliki/AGY-3601-2022; Angheben, Andrea/C-9167-2013; Giannitsioti, Efthymia/AAQ-5897-2020; Selmi, Carlo/ABG-4899-2021	Samarkos, Michael/0000-0001-9630-9712; Rapti, Vasiliki/0000-0002-8322-635X; Angheben, Andrea/0000-0003-4545-8034; Selmi, Carlo/0000-0002-0323-0376; GIANNITSIOTI, EFTHYMIA/0000-0003-2715-7457; Kyriazopoulou, Evdoxia/0000-0002-9585-517X; KOTSIS, VASILIOS/0000-0002-3755-8097; Tsiakos, Konstantinos/0000-0002-9167-905X	Hellenic Institute for the Study of Sepsis (HISS); HISS; Swedish Orphan Biovitrum (Sobi)	Hellenic Institute for the Study of Sepsis (HISS); HISS; Swedish Orphan Biovitrum (Sobi)	The authors wish to express their gratitude to the members of the Data Monitoring and Safety Committee and to M. Niederman, J. W. M. van der Meer and K. Reinhart for their valuable contributions and for their critical review of the submitted manuscript. This trial was sponsored by the Hellenic Institute for the Study of Sepsis (HISS) and funded, in part, by HISS and, in part, by Swedish Orphan Biovitrum (Sobi). HISS was responsible for the conceptualization and design of the study, data collection, analysis, decision to publish and preparation of the manuscript. Sobi had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Azam TU, 2020, J AM SOC NEPHROL, V31, P2725, DOI 10.1681/ASN.2020060829; Balkhair A, 2021, INT J INFECT DIS, V103, P288, DOI 10.1016/j.ijid.2020.11.149; Bozzi G, 2021, J ALLERGY CLIN IMMUN, V147, P561, DOI 10.1016/j.jaci.2020.11.006; Caricchio R, 2021, JAMA-J AM MED ASSOC, V326, P230, DOI 10.1001/jama.2021.9508; Caricchio R, 2021, ANN RHEUM DIS, V80, P88, DOI 10.1136/annrheumdis-2020-218323; Cauchois R, 2020, P NATL ACAD SCI USA, V117, P18951, DOI 10.1073/pnas.2009017117; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI [10.1056/NEJMoa2100433, 10.1056/NEJMc2108482]; Guimaraes PO, 2021, NEW ENGL J MED, V385, P406, DOI 10.1056/NEJMoa2101643; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8; Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567; Kooistra EJ, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03364-w; Kyriazopoulou E, 2021, ELIFE, V10, DOI 10.7554/eLife.66125; Manson JJ, 2020, LANCET RHEUMATOL, V2, pE594, DOI 10.1016/S2665-9913(20)30275-7; Mariette X, 2021, LANCET RESP MED, V9, P295, DOI 10.1016/S2213-2600(20)30556-7; Pontali E, 2021, J ALLERGY CLIN IMMUN, V147, P1217, DOI 10.1016/j.jaci.2021.01.024; Potere N, 2021, ANN RHEUM DIS, V80, P271, DOI 10.1136/annrheumdis-2020-218243; Renieris G., IL 1 MEDIATES TISSUE, DOI 10.1101/2021.04.09.21255190(2021; Rodrigues TS, 2021, J EXP MED, V218, DOI 10.1084/jem.20201707; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Rovina N, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02897-4; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Webb BJ, 2020, LANCET RHEUMATOL, V2, pE754, DOI 10.1016/S2665-9913(20)30343-X	26	147	148	2	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2021	27	10					1752	+		10.1038/s41591-021-01499-z	http://dx.doi.org/10.1038/s41591-021-01499-z		SEP 2021	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	WG9ZA	34480127	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000692308000001
J	Lee, HN; Bae, W; Park, JW; Jung, JY; Hwang, S; Kim, DK; Kwak, YH				Lee, Ha Ni; Bae, Woori; Park, Joong Wan; Jung, Jae Yun; Hwang, Soyun; Kim, Do Kyun; Kwak, Young Ho			Virtual reality environment using a dome screen for procedural pain in young children during intravenous placement: A pilot randomized controlled trial	PLOS ONE			English	Article								We assessed the feasibility and potential efficacy of a virtual reality (VR) environment using a dome screen as a distraction method in young children during intravenous (IV) placement in the pediatric emergency department. This randomized controlled pilot study enrolled children aged 2 to 6 years who underwent IV placement into either the intervention group or the control group. Children in the intervention group experienced VR using a dome screen during IV placement. The child's pain intensity was measured using the Face, Legs, Activity, Cry, and Consolability (FLACC) scale at four time points of IV placement: immediately after arrival to the blood collection room (base); immediately after the child laid down on the bed (preparation); when the tourniquet was applied (tourniquet); and the moment at which the needle penetrated the skin (venipuncture). The guardian's satisfaction and rating of the child's distress were assessed using a 5-point Likert-type questionnaire. We recruited 19 children (9 in the intervention group and 10 in the control group). Five children in the control group were excluded from the analysis because of missing video recordings (n = 3), failed first attempt at IV placement (n = 1), and the child's refusal to lie on the bed during the procedure (n = 1). No side effects of VR were reported during the study period. Although the average FLACC scale score at each time point (preparation, tourniquet, venipuncture) was lower in the intervention group than the control group, the difference was not statistically significant (2.3, interquartile range [IQR]: 2.0-3.0; vs. 3.3, IQR: 2.7-6.7, P = 0.255). There were no statistically significant differences between the groups in the guardian's satisfaction and anxiety or his/her rating of the child's pain and anxiety. The guardians and emergency medical technicians reported satisfaction with the use of VR with a dome screen and considered it a useful distraction during the procedure. VR using a dome screen is a feasible distraction method for young children during IV placement. A larger clinical trial with further development of the VR environment and study process is required to adequately evaluate the efficacy of VR using a dome screen.	[Lee, Ha Ni; Park, Joong Wan; Jung, Jae Yun; Hwang, Soyun; Kim, Do Kyun; Kwak, Young Ho] Seoul Natl Univ Hosp, Dept Emergency Med, Seoul, South Korea; [Bae, Woori] Catholic Univ Korea, Seoul St Mary Hosp, Dept Emergency Med, Coll Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Catholic University of Korea; Seoul St. Mary's Hospital	Park, JW (corresponding author), Seoul Natl Univ Hosp, Dept Emergency Med, Seoul, South Korea.	zzibii@naver.com	; Kim, Do Kyun/Q-3070-2018	Hwang, Soyun/0000-0002-4290-0213; Lee, Ha Ni/0000-0003-0450-8170; Kim, Do Kyun/0000-0002-6144-302X; Bae, Woo Ri/0000-0002-7434-4426				Aguinis H, 2001, INT J SELECT ASSESS, V9, P70, DOI 10.1111/1468-2389.00164; Atzori B, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02508; Aydin AI, 2019, J PERIANESTH NURS, V34, P1215, DOI 10.1016/j.jopan.2019.05.134; Bailey B, 2016, PEDIATR DRUGS, V18, P287, DOI 10.1007/s40272-016-0181-5; Chan E, 2019, J PEDIATR-US, V209, P160, DOI 10.1016/j.jpeds.2019.02.034; Crowley MA, 2011, J EMERG NURS, V37, P246, DOI 10.1016/j.jen.2011.02.013; Dumoulin S, 2019, GAMES HEALTH J, V8, P285, DOI 10.1089/g4h.2018.0111; Eldridge C, 2010, CLIN PEDIATR EMERG M, V11, P244, DOI 10.1016/j.cpem.2010.09.001; Friedrichsdorf Stefan J, 2015, Hosp Pediatr, V5, P18, DOI 10.1542/hpeds.2014-0084; Hoffman HG, 2014, CYBERPSYCH BEH SOC N, V17, P397, DOI 10.1089/cyber.2014.0058; Kamsvag T, 2021, ACTA PAEDIATR, V110, P704, DOI 10.1111/apa.15449; Khadra C, 2018, J PAIN RES, V11, P343, DOI 10.2147/JPR.S151084; Kipping B, 2012, BURNS, V38, P650, DOI 10.1016/j.burns.2011.11.010; Malloy KM, 2010, CLIN PSYCHOL REV, V30, P1011, DOI 10.1016/j.cpr.2010.07.001; Marsh N, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011070.pub2; Merkel S I, 1997, Pediatr Nurs, V23, P293; Piskorz J, 2018, J SPEC PEDIATR NURS, V23, DOI 10.1111/jspn.12201; Seo DH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197929; Shomaker Kyrie, 2015, Hosp Pediatr, V5, P363, DOI 10.1542/hpeds.2014-0195; Thabane L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-1; Walther-Larsen S, 2017, ACTA ANAESTH SCAND, V61, P328, DOI 10.1111/aas.12846; Wint SS., 2002, ONCOL NURS FORUM; Yoo H., 2014, CONT ENG SCI, V7, P1181	23	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2021	16	8							e0256489	10.1371/journal.pone.0256489	http://dx.doi.org/10.1371/journal.pone.0256489			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZI5YE	34464411	gold, Green Published			2023-01-03	WOS:000761695800017
J	Mmari, EE; Pallangyo, ES; Ali, A; Kaale, DA; Mawalla, IH; Abeid, MS				Mmari, Elizabeth E.; Pallangyo, Eunice S.; Ali, Athar; Kaale, Dereck A.; Mawalla, Isaac H.; Abeid, Muzdalifat S.			Perceptions of surgeons on surgical antibiotic prophylaxis use at an urban tertiary hospital in Tanzania	PLOS ONE			English	Article							ANTIMICROBIAL PROPHYLAXIS; SITE INFECTIONS; GUIDELINES; PREVENTION; ADHERENCE; AUDIT	Background Surgical Site Infections are a major cause of morbidity and mortality among operated patients. In spite of the accessibility of universal and national guidelines for surgical prophylaxis, recent studies surveying the present routine of prophylaxis have demonstrated overutilization of a wide range antibacterial medication for a single patient. Few studies have shown qualitatively factors influencing this and perceptions of surgeons on surgical antibiotic prophylaxis use. Unfortunately, none of these studies have been done in Tanzania. Objective To describe the perceptions of surgeons on surgical antibiotic prophylaxis use at an urban tertiary hospital. Methods A qualitative study involving in-depth interviews with surgeons was conducted in English by the primary investigator. The interviews were audio-recorded and transcribed verbatim. Systematic text condensation by Malterud was used for data analysis. Findings Fourteen surgeons and obstetrics and gynaecologists participated. Their perceptions were summarized into three main categories: Inadequate data to support practice; one who sees the patient decides the antibiotic prophylaxis; prolonged antibiotic use for fear of unknown. The participants perceived that choice of antibiotic should be based on local hospital data for bacterial resistance pattern, however the hospital guidelines and data for surgical site infection rates are unknown. Fear of getting infection and anticipating complications led to prolonged antibiotics use. Conclusion The study provides an understanding of surgical antibiotic prophylaxis use and its implementation challenges. This was partly expressed by unavailability of local data and guidelines to enhance practice. To improve this, there is a need of guidelines that incorporates local resistance surveillance data and enhanced antibiotic stewardship programmes. A strong consideration should be placed into ways to combat the fears of surgeons for complications, as these significantly affect the current practise with use of surgical antibiotic prophylaxis.	[Mmari, Elizabeth E.; Ali, Athar; Mawalla, Isaac H.] Aga Khan Univ, Dept Gen Surg, Dar Es Salaam, Tanzania; [Pallangyo, Eunice S.] Aga Khan Univ, Dept Nursing & Midwifery, Dar Es Salaam, Tanzania; [Kaale, Dereck A.] Saifee Hosp, Dept Emergency Med, Dar Es Salaam, Tanzania; [Abeid, Muzdalifat S.] Aga Khan Univ, Dept Obstet & Gynaecol, Dar Es Salaam, Tanzania	Aga Khan University; Aga Khan University; Aga Khan University	Mmari, EE (corresponding author), Aga Khan Univ, Dept Gen Surg, Dar Es Salaam, Tanzania.	elizabeth.e.mmari@gmail.com		Mmari, Elizabeth/0000-0003-1980-110X; Pallangyo, Eunice/0000-0002-1001-361X	Aga Khan University	Aga Khan University	EM received funding from The Aga Khan University as part of research requirement. It was a research allowance, not a grant. https://www.aku.edu/iedea/Pages/home.aspx The funders had no role in study design, data collection and analysis, decision to publish, or preparation of manuscript.	Akoko L. O., 2012, East and Central African Journal of Surgery, V17, P12; Alok Ranjan, 2016, International Journal of Medical Science and Public Health, V5, P1083; [Anonymous], 2016, SPECIALIST SURG WORK; [Anonymous], 2019, SURG SITE INFECT SSI; [Anonymous], 2007, QUALITATIVE METHODOL; Bartella AK, 2018, INFECTION, V46, P225, DOI 10.1007/s15010-017-1110-4; Bratzler DW, 2004, CLIN INFECT DIS, V38, P1706, DOI 10.1086/421095; Broom J, 2018, INFECTION, V46, P541, DOI 10.1007/s15010-018-1156-y; Charani E, 2017, CLIN MICROBIOL INFEC, V23, P752, DOI 10.1016/j.cmi.2017.03.013; de Jonge SW, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006903; Eriksen HM, 2003, J HOSP INFECT, V55, P14, DOI 10.1016/S0195-6701(03)00225-1; Fehr J, 2006, CLIN MICROBIOL INFEC, V12, P1224, DOI 10.1111/j.1469-0691.2006.01551.x; Friedman ND, 2013, AM J INFECT CONTROL, V41, P71, DOI 10.1016/j.ajic.2012.02.012; Hatam N, 2011, IRAN RED CRESCENT ME, V13, P234; Ierano C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225011; Jetta R., 2004, NATL INFECT PREVENTI, P111; LaBove G., 2016, PRS-GLOB OPEN, V4, pe710, DOI [10.1097/GOX.0000000000000704, DOI 10.1097/GOX.0000000000000704]; Lubega A, 2017, SURG RES PRACT, V2017; Malterud K, 2012, SCAND J PUBLIC HEALT, V40, P795, DOI 10.1177/1403494812465030; Mangram AJ, 1999, AM J INFECT CONTROL, V27, P97, DOI 10.1016/S0196-6553(99)70088-X; Meakins J., 1994, SURG INFECT DIAGNOSI, P139; Mousavi S, 2017, J RES PHARM PRACT, V6, P126, DOI 10.4103/jrpp.JRPP_16_164; Mpoki U., 2017, NATL ACTION PLAN ANT; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079532; Ng RS, 2012, AUSTRALAS MED J, V5, P534, DOI 10.4066/AMJ.2012.1312; Pons-Busom M, 2004, INFECT CONT HOSP EP, V25, P308, DOI 10.1086/502397; Schmitt C, 2017, AM J INFECT CONTROL, V45, P1111, DOI 10.1016/j.ajic.2017.05.004; Sommerstein R, 2019, EUR J CARDIO-THORAC, V56, P800, DOI 10.1093/ejcts/ezz039; van Kasteren MEE, 2003, J ANTIMICROB CHEMOTH, V51, P1389, DOI 10.1093/jac/dkg264	29	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2021	16	8							e0256134	10.1371/journal.pone.0256134	http://dx.doi.org/10.1371/journal.pone.0256134			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	US1HA	34437587	gold, Green Published			2023-01-03	WOS:000697186000032
J	Sopka, S; Hahn, F; Vogt, L; Pears, KH; Rossaint, R; Rudolph, J; Klasen, M				Sopka, Sasa; Hahn, Fabian; Vogt, Lina; Pears, Kim Hannah; Rossaint, Rolf; Rudolph, Jenny; Klasen, Martin			Peer video feedback builds basic life support skills: A randomized controlled non-inferiority trial	PLOS ONE			English	Article							ENTRUSTABLE PROFESSIONAL ACTIVITIES; KIDS SAVE LIVES; CARDIOPULMONARY-RESUSCITATION; EUROPEAN-RESUSCITATION; COUNCIL GUIDELINES; EDUCATION; NONINFERIORITY; EQUIVALENCE; KNOWLEDGE; STUDENTS	Introduction Training Basic Life Support saves lives. However, current BLS training approaches are time-consuming and costly. Alternative cost-efficient and effective training methods are highly needed. The present study evaluated whether a video-feedback supported peer-guided Basic Life Support training approach achieves similar practical performance as a standard instructor-guided training in laypersons. Methods In a randomized controlled non-inferiority trial, 288 first-year medical students were randomized to two study arms with different Basic Life Support training methods: 1) Standard Instructor Feedback (SIF) or 2) a Peer Video Feedback (PVF). Outcome parameters were objective data for Basic Life Support performance (compression depth and rate) from a resuscitation manikin with recording software as well as overall Basic Life Support performance and subjective confidence. Non-inferiority margins (Delta) for these outcome parameters and sample size calculation were based on previous studies with Standard Instructor Feedback. Two-sided 95% confidence intervals were employed to determine significance of non-inferiority. Results Results confirmed non-inferiority of Peer Video Feedback to Standard Instructor Feedback for compression depth (proportion difference PVF-SIF = 2.9%; 95% CI: -8.2% to 14.1%; Delta = -19%), overall Basic Life Support performance (proportion difference PVF-SIF = 6.7%; 95% CI: 0.0% to 14.3%; Delta = -27%) and subjective confidence for CPR performance (proportion difference PVF-SIF = -0.01; 95% CI: -0.18-0.17; Delta = -0.5) and emergency situations (proportion difference PVF-SIF = -0.02; 95% CI: -0.21-0.18; Delta = -0.5). Results for compression rate were inconclusive. Discussion Peer Video Feedback achieves comparable results as standard instructor-based training methods. It is an easy-to-apply and cost-efficient alternative to standard Basic Life Support training methods. To improve performance with respect to compression rate, additional implementation of a metronome is recommended.	[Sopka, Sasa; Hahn, Fabian; Vogt, Lina; Pears, Kim Hannah; Klasen, Martin] Rhein Westfal TH Aachen, AIXTRA Competency Ctr Training & Patient Safety, Med Fac, Aachen, Germany; [Sopka, Sasa; Vogt, Lina; Rossaint, Rolf] Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Anaesthesiol, Med Fac, Aachen, Germany; [Rudolph, Jenny] Ctr Med Simulat, Boston, MA USA	RWTH Aachen University; RWTH Aachen University; RWTH Aachen University Hospital	Sopka, S (corresponding author), Rhein Westfal TH Aachen, AIXTRA Competency Ctr Training & Patient Safety, Med Fac, Aachen, Germany.; Sopka, S (corresponding author), Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Anaesthesiol, Med Fac, Aachen, Germany.	ssopka@ukaachen.de	Sopka, Sasa/M-4990-2017	Sopka, Sasa/0000-0003-2165-5578; Vogt, Lina/0000-0002-1913-9083; Pears, Kim Hannah/0000-0002-8360-5747				[Anonymous], 2003, STAT MED, V22, P3111, DOI [10.1002/sim.1564, DOI 10.1002/SIM.1564]; Baldi E, 2020, EUR J ANAESTH, V37, P839, DOI 10.1097/EJA.0000000000001272; Baldi E, 2019, INT J CARDIOL, V296, P76, DOI 10.1016/j.ijcard.2019.07.016; Baldi E, 2017, CAN J EMERG MED, V19, P480, DOI 10.1017/cem.2016.410; Bandura A., 1971, SOCIAL LEARNING THEO; Beck S, 2015, RESUSCITATION, V94, P85, DOI 10.1016/j.resuscitation.2015.06.026; Berberat PO, 2019, GMS J MED EDU, V36, DOI 10.3205/zma001278; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Bottiger BW, 2017, EUR J ANAESTH, V34, P792, DOI 10.1097/EJA.0000000000000713; Bohn A, 2015, CURR OPIN CRIT CARE, V21, P220, DOI 10.1097/MCC.0000000000000204; Cho GC, 2010, RESUSCITATION, V81, P691, DOI 10.1016/j.resuscitation.2010.02.021; de Graaf C., 2018, RESUSCITATION, V130, pE31, DOI 10.1016/j.resuscitation.2018.07.052; Dwyer T, 2008, PREHOSP EMERG CARE, V12, P157, DOI 10.1080/10903120801907216; Fletcher JD, 2013, MIL MED, V178, P37, DOI 10.7205/MILMED-D-13-00258; Fujiwara T, 2011, ADV MED EDUC PRACT, V2, P187, DOI 10.2147/AMEP.S22948; General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14; Greif R, 2021, RESUSCITATION, V161, P388, DOI 10.1016/j.resuscitation.2021.02.016; Greif R, 2020, CIRCULATION, V142, pS222, DOI 10.1161/CIR.0000000000000896; Hasselager A, 2019, RESUSCITATION, V138, P28, DOI 10.1016/j.resuscitation.2019.02.032; Hauenstein NMA., 1998, PERFORMANCE APPRAISA, P404, DOI 10.1007/s003300050383; Holzhausen Y, 2019, GMS J MED EDU, V36, DOI 10.3205/zma001213; KAYE W, 1991, RESUSCITATION, V21, P67, DOI 10.1016/0300-9572(91)90080-I; Klasen M, 2021, MED EDUC, V55, P455, DOI 10.1111/medu.14420; Lomis K, 2017, ACAD MED, V92, P765, DOI 10.1097/ACM.0000000000001543; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Peyton R., 1998, TEACHING LEARNING ME; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Raemer D, 2011, SIMUL HEALTHC, V6, pS52, DOI 10.1097/SIH.0b013e31822724d0; Rees EL, 2016, MED TEACH, V38, P829, DOI 10.3109/0142159X.2015.1112888; Roshana S, 2012, WORLD J EMERG MED, V3, P141, DOI [10.5847/wjem.j.issn.1920-8642.2012.02.011, 10.5847/wjem.j.1920-8642.2012.02.011]; Rucker G, 2019, NOTF RETT MED, DOI [10.1007/s10049-019-0609-x, DOI 10.1007/S10049-019-0609-X]; Sealed Envelope Ltd, 2012, POW CALC CONT OUTC N; Soar J, 2010, RESUSCITATION, V81, P1434, DOI 10.1016/j.resuscitation.2010.08.014; Sopka S, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-30; Sopka S, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-37; Swor R, 2006, ACAD EMERG MED, V13, P596, DOI 10.1197/j.aem.2005.12.021; ten Cate O, 2015, MED TEACH, V37, P983, DOI 10.3109/0142159X.2015.1060308; Touchie C, 2016, MED EDUC, V50, P93, DOI 10.1111/medu.12839; van Dawen J, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-018-0564-4; Wellek S, 2012, DTSCH ARZTEBL INT, V109, P674, DOI 10.3238/arztebl.2012.0674; WHO, 2020, 59 HLTH ASS; Willmore RD, 2019, WORLD J EMERG MED, V10, P75, DOI 10.5847/wjem.j.1920-8642.2019.02.002	45	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2021	16	7							e0254923	10.1371/journal.pone.0254923	http://dx.doi.org/10.1371/journal.pone.0254923			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2OO	34293034	Green Published, gold			2023-01-03	WOS:000678124900082
J	Kostic, A; Buxbaum, JD				Kostic, Ana; Buxbaum, Joseph D.			The promise of precision medicine in autism	NEURON			English	Editorial Material							SPECTRUM DISORDER	Autism spectrum disorder (ASD) is a clinically and etiologically diverse developmental condition characterized by diminished social interactions, impaired communication, and repetitive and/or restrictive behaviors. Recent advances in ASD genetics pave the way for implementation of precision medicine in clinical management of autism.	[Kostic, Ana; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Seaver Autism Ctr, Dept Psychiat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Buxbaum, JD (corresponding author), Icahn Sch Med Mt Sinai, Seaver Autism Ctr, Dept Psychiat, New York, NY 10029 USA.	joseph.buxbaum@mssm.edu						Anagnostou E, 2018, CURR OPIN NEUROL, V31, P119, DOI 10.1097/WCO.0000000000000542; Artoni P, 2020, P NATL ACAD SCI USA, V117, P23298, DOI 10.1073/pnas.1820847116; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Frohlich H, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1122-7; Gaugler T, 2014, NAT GENET, V46, P881, DOI 10.1038/ng.3039; Jeste SS, 2015, J CHILD NEUROL, V30, P1963, DOI 10.1177/0883073815601501; Luo Y, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1007-0; Satterstrom FK, 2020, CELL, V180, P568, DOI 10.1016/j.cell.2019.12.036; Soliman MA, 2017, MOL PSYCHIATR, V22, P1241, DOI 10.1038/mp.2017.40	9	2	2	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	JUL 21	2021	109	14					2212	2215		10.1016/j.neuron.2021.06.025	http://dx.doi.org/10.1016/j.neuron.2021.06.025		JUL 2021	4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	TS1QH	34293291	Bronze			2023-01-03	WOS:000679432100005
J	Song, J; Dong, HM; Xu, FL; Wang, Y; Li, WD; Jue, ZZ; Wei, LL; Yue, YY; Zhu, CL				Song, Juan; Dong, Huimin; Xu, Falin; Wang, Yong; Li, Wendong; Jue, Zhenzhen; Wei, Lele; Yue, Yuyang; Zhu, Changlian			The association of severe anemia, red blood cell transfusion and necrotizing enterocolitis in neonates	PLOS ONE			English	Article							BIRTH-WEIGHT INFANTS; PREMATURE-INFANTS; RISK-FACTORS; CARE	Background The relationship between severe anemia, red blood cell transfusion and Neonatal necrotizing enterocolitis (NEC) remains controversial. The purpose of this study was to determine the association of severe anemia and RBC transfusion with NEC in neonates. Methods The clinical characteristics of NEC were observed in 467 infants with different birth weights from January 2012 to July 2020. A 1:1 ratio case-control study was performed in very low birth weight (VLBW) infants. Severe anemia, RBC transfusion, and confounding factors, including maternal and perinatal complications, feeding, and antibiotics administration were collected in both groups. Univariate and multivariate analyses were used to investigate effects on the risk of NEC. Results The day of NEC onset and mortality were inversely associated with birth weight. In VLBW infants, adjusting for other factors, severe anemia within 72 h [OR = 2.404, P = 0.016], RBC transfusion within 24 h [OR = 4.905, P = 0.016], within 48 h [OR = 5.587, P = 0.008], and within 72 h [OR = 2.858, P = 0.011] increased the risk of NEC. Conclusion Both severe anemia and RBC transfusion appears to increase the risk of NEC in VLBW infants. The early prevention and treatment of anemia, strict evaluation of the indications for transfusion and enhanced monitoring after transfusion is encouraged in the NICU.	[Song, Juan; Dong, Huimin; Xu, Falin; Wang, Yong; Li, Wendong; Jue, Zhenzhen; Wei, Lele; Yue, Yuyang; Zhu, Changlian] Zhengzhou Univ, Henan Key Lab Child Brain Injury, Dept Neonatol, Zhengzhou, Peoples R China; [Song, Juan; Dong, Huimin; Xu, Falin; Wang, Yong; Li, Wendong; Jue, Zhenzhen; Wei, Lele; Yue, Yuyang; Zhu, Changlian] Zhengzhou Univ, Henan Pediat Clin Res Ctr, Affiliated Hosp 3, Zhengzhou, Peoples R China; [Song, Juan; Dong, Huimin; Xu, Falin; Wang, Yong; Li, Wendong; Jue, Zhenzhen; Wei, Lele; Yue, Yuyang; Zhu, Changlian] Zhengzhou Univ, Inst Neurosci, Zhengzhou, Peoples R China; [Zhu, Changlian] Univ Gothenburg, Sahlgrenska Acad, Ctr Brain Repair & Rehabil, Inst Neurosci & Physiol, Gothenburg, Sweden; [Zhu, Changlian] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden	Zhengzhou University; Zhengzhou University; Zhengzhou University; University of Gothenburg; Karolinska Institutet	Song, J; Zhu, CL (corresponding author), Zhengzhou Univ, Henan Key Lab Child Brain Injury, Dept Neonatol, Zhengzhou, Peoples R China.; Song, J; Zhu, CL (corresponding author), Zhengzhou Univ, Henan Pediat Clin Res Ctr, Affiliated Hosp 3, Zhengzhou, Peoples R China.; Song, J; Zhu, CL (corresponding author), Zhengzhou Univ, Inst Neurosci, Zhengzhou, Peoples R China.; Zhu, CL (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Ctr Brain Repair & Rehabil, Inst Neurosci & Physiol, Gothenburg, Sweden.; Zhu, CL (corresponding author), Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.	songjuan@zzu.edu.cn; changlian.zhu@neuro.gu.se		Song, Juan/0000-0001-7132-502X; Zhu, Changlian/0000-0002-5029-6730	National Key Research and Development Program of China [2018YFC1004604]; Department of Science and Technology [171100310200]; Department of Health of Henan Province, China [SB201901055]	National Key Research and Development Program of China; Department of Science and Technology(Department of Science & Technology (India)); Department of Health of Henan Province, China	This work was supported by National Key Research and Development Program of China (2018YFC1004604), the Department of Science and Technology (171100310200), Department of Health (SB201901055) of Henan Province, China. We declare that we have no competing financial interests related to the article.	Arthur CM, 2019, TRANSFUSION, V59, P1233, DOI 10.1111/trf.15254; Bell EF, 2005, PEDIATRICS, V115, P1685, DOI 10.1542/peds.2004-1884; Blau J, 2011, J PEDIATR-US, V158, P403, DOI 10.1016/j.jpeds.2010.09.015; Coursey CA, 2009, AM J ROENTGENOL, V193, P1408, DOI 10.2214/AJR.08.2306; Cunningham KE, 2017, J SURG RES, V213, P158, DOI 10.1016/j.jss.2017.02.029; DeRienzo C, 2014, EARLY HUM DEV, V90, P237, DOI 10.1016/j.earlhumdev.2014.02.003; Faraday C, 2020, J MATERN-FETAL NEO M, V33, P398, DOI 10.1080/14767058.2018.1494147; Garg P, 2018, J PERINAT MED, V46, P677, DOI 10.1515/jpm-2017-0162; Han SM, 2020, J PEDIATR SURG, V55, P998, DOI 10.1016/j.jpedsurg.2020.02.046; Hay S, 2017, SEMIN PERINATOL, V41, P80, DOI 10.1053/j.semperi.2016.09.021; Jain A, 2015, JAMA PEDIATR, V169, P863, DOI 10.1001/jamapediatrics.2015.0987; Janjindamai W, 2019, INDIAN J PEDIATR, V86, P347, DOI 10.1007/s12098-019-02887-7; Jasani B, 2017, ADV NUTR, V8, P764, DOI 10.3945/an.117.015818; Kastenberg ZJ, 2015, JAMA PEDIATR, V169, P26, DOI 10.1001/jamapediatrics.2014.2085; Kim-Shapiro DB, 2011, TRANSFUSION, V51, P844, DOI 10.1111/j.1537-2995.2011.03100.x; Lambert DK, 2012, J PERINATOL, V32, P194, DOI 10.1038/jp.2011.61; Lee JY, 2017, PEDIATR NEONATOL, V58, P57, DOI 10.1016/j.pedneo.2016.01.005; Luig M, 2005, J PAEDIATR CHILD H, V41, P174, DOI 10.1111/j.1440-1754.2005.00583.x; Marin T, 2013, TRANSFUSION, V53, P2650, DOI 10.1111/trf.12158; Mohamed A, 2012, PEDIATRICS, V129, P529, DOI 10.1542/peds.2011-2872; MohanKumar K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11199-5; Nino DF, 2016, NAT REV GASTRO HEPAT, V13, P590, DOI 10.1038/nrgastro.2016.119; Ozcan B, 2020, AM J PERINAT, V37, P603, DOI 10.1055/s-0039-1683982; Patel RM, 2016, JAMA-J AM MED ASSOC, V315, P889, DOI 10.1001/jama.2016.1204; Patel RM, 2015, NEW ENGL J MED, V372, P331, DOI 10.1056/NEJMoa1403489; Shao X., 2010, ANEMIA PREMATURITY, P595; Sharma R, 2014, J PERINATOL, V34, P858, DOI 10.1038/jp.2014.59; Sharma R, 2013, CLIN PERINATOL, V40, P27, DOI 10.1016/j.clp.2012.12.012; Singh R, 2011, J PERINATOL, V31, P176, DOI 10.1038/jp.2010.145; Sood BG, 2016, J MATERN-FETAL NEO M, V29, P737, DOI 10.3109/14767058.2015.1016422; Stritzke AI, 2013, ARCH DIS CHILD-FETAL, V98, pF10, DOI 10.1136/fetalneonatal-2011-301282; Subspecialty Group of Neonatology the Society of Pediatric Chinese Medical Association, 2019, Zhonghua Er Ke Za Zhi, V57, P252, DOI 10.3760/cma.j.issn.0578-1310.2019.04.005; Sulemanji M, 2017, NEONATOLOGY, V111, P337, DOI 10.1159/000451022; Teiserskas J, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55010016; Wallenstein MB, 2014, J PEDIATR-US, V165, P678, DOI 10.1016/j.jpeds.2014.06.012; WALSH MC, 1986, PEDIATR CLIN N AM, V33, P179, DOI 10.1016/s0031-3955(16)34975-6; Wan-Huen P, 2013, J PERINATOL, V33, P786, DOI 10.1038/jp.2013.60; Wang Y, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02459-w; Whyte RK, 2014, PAED CHILD HEALT-CAN, V19, P213, DOI 10.1093/pch/19.4.213; Wiedmeier SE, 2009, J PERINATOL, V29, P130, DOI 10.1038/jp.2008.141; Zonnenberg IA, 2016, NEONATOLOGY, V109, P282, DOI 10.1159/000443320	41	2	3	3	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2021	16	7							e0254810	10.1371/journal.pone.0254810	http://dx.doi.org/10.1371/journal.pone.0254810			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2NX	34283868	Green Published, gold			2023-01-03	WOS:000678123200047
J	Schumann, NP; Bongers, K; Scholle, HC; Guntinas-Lichius, O				Schumann, Nikolaus P.; Bongers, Kevin; Scholle, Hans C.; Guntinas-Lichius, Orlando			Atlas of voluntary facial muscle activation: Visualization of surface electromyographic activities of facial muscles during mimic exercises	PLOS ONE			English	Article							PATTERNS; HEALTHY	Complex facial muscle movements are essential for many motoric and emotional functions. Facial muscles are unique in the musculoskeletal system as they are interwoven, so that the contraction of one muscle influences the contractility characteristic of other mimic muscles. The facial muscles act more as a whole than as single facial muscle movements. The standard for clinical and psychosocial experiments to detect these complex interactions is surface electromyography (sEMG). What is missing, is an atlas showing which facial muscles are activated during specific tasks. Based on high-resolution sEMG data of 10 facial muscles of both sides of the face simultaneously recorded during 29 different facial muscle tasks, an atlas visualizing voluntary facial muscle activation was developed. For each task, the mean normalized EMG amplitudes of the examined facial muscles were visualized by colors. The colors were spread between the lowest and highest EMG activity. Gray shades represent no to very low EMG activities, light and dark brown shades represent low to medium EMG activities and red shades represent high to very high EMG activities relatively with respect to each task. The present atlas should become a helpful tool to design sEMG experiments not only for clinical trials and psychological experiments, but also for speech therapy and orofacial rehabilitation studies.	[Schumann, Nikolaus P.; Bongers, Kevin; Scholle, Hans C.] Friedrich Schiller Univ Jena, Jena Univ Hosp, Div Motor Res Pathophysiol & Biomech, Dept Trauma Hand & Reconstruct Surg, Jena, Germany; [Guntinas-Lichius, Orlando] Friedrich Schiller Univ Jena, Jena Univ Hosp, Dept Otolaryngol, Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Guntinas-Lichius, O (corresponding author), Friedrich Schiller Univ Jena, Jena Univ Hosp, Dept Otolaryngol, Jena, Germany.	Orlando.guntinas@med.uni-jena.de	Guntinas-Lichius, Orlando/L-1871-2016	Guntinas-Lichius, Orlando/0000-0001-9671-0784	Deutsche Forschungsgemeinschaft (DFG) [GU-463/12-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	Orlando Guntinas-Lichius acknowledges support by a Deutsche Forschungsgemeinschaft (DFG) grant GU-463/12-1.	Cattaneo L, 2014, NEUROSCI BIOBEHAV R, V38, P135, DOI 10.1016/j.neubiorev.2013.11.002; Cui H, 2021, FRONT HUM NEUROSCI, V14, DOI 10.3389/fnhum.2020.618985; Dimitrova NA, 2002, J ELECTROMYOGR KINES, V12, P235, DOI 10.1016/S1050-6411(02)00008-1; Ekman P., 1978, FACIAL ACTION CODING; Ekman P., 1978, ELECT VISIBLE SIGNS; Fattah AY, 2015, PLAST RECONSTR SURG, V135, P569, DOI 10.1097/PRS.0000000000000905; FRIDLUND AJ, 1986, PSYCHOPHYSIOLOGY, V23, P567, DOI 10.1111/j.1469-8986.1986.tb00676.x; Guntinas-Lichius O, 2020, EUR ARCH OTO-RHINO-L, V277, P1855, DOI 10.1007/s00405-020-05949-1; Guntinas-Lichius O, 2016, ADV OTO-RHINO-LARYNG, V78, P120, DOI 10.1159/000442132; Han J., 2015, SCI CHINA INFORM SCI, V58, P1; Hofling TTA, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01388; Homem Márcio Alexandre, 2014, Dental Press J. Orthod., V19, P94, DOI 10.1590/2176-9451.19.4.094-099.oar; HUBERT W, 1990, BIOL PSYCHOL, V31, P73, DOI 10.1016/0301-0511(90)90079-C; Husseman J, 2008, FACIAL PLAST SURG, V24, P242, DOI 10.1055/s-2008-1075840; Kent RD, 2015, AM J SPEECH-LANG PAT, V24, P763, DOI 10.1044/2015_AJSLP-14-0179; Kuramoto Eriko, 2019, Neuropsychopharmacology Reports, V39, P183, DOI 10.1002/npr2.12059; Lapatki BG, 2010, PSYCHOPHYSIOLOGY, V47, P299, DOI 10.1111/j.1469-8986.2009.00935.x; Mothes O, 2019, EUR ARCH OTO-RHINO-L, V276, P3335, DOI 10.1007/s00405-019-05647-7; Osthues M, 2022, EUR ARCH OTO-RHINO-L, V279, P481, DOI 10.1007/s00405-021-06895-2; Pampouchidou A, 2017, IEEE ENG MED BIO, P1433, DOI 10.1109/EMBC.2017.8037103; Scholle HC, 2001, EXP BRAIN RES, V138, P26, DOI 10.1007/s002210100685; Schumann NP, 2010, J NEUROSCI METH, V187, P120, DOI 10.1016/j.jneumeth.2009.12.019; Schunke M., 2021, HALS NEUROANATOMIE; Standing S., 2020, ANATOMICAL BASIS CLI, V42nd; Stotland MA, 2007, PLAST RECONSTR SURG, V120, P1386, DOI 10.1097/01.prs.0000279377.86280.8d; Terminology FCoA, 1998, TERM AN TERM AN; Thielker J, 2018, CURR OTORHINOL REP, V6, P161; Urban E, 2020, CLIN OTOLARYNGOL, V45, P754, DOI 10.1111/coa.13571; Williamson SJ., 1990, AUDITORY EVOKED MAGN; Wolf K, 2015, DIALOGUES CLIN NEURO, V17, P457	30	2	2	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2021	16	7							e0254932	10.1371/journal.pone.0254932	http://dx.doi.org/10.1371/journal.pone.0254932			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2NL	34280246	Green Published, gold			2023-01-03	WOS:000678122000035
J	Han, XY; Liu, XX; Zhong, FX; Wang, YG; Zhang, QM				Han, Xueyan; Liu, Xinxin; Zhong, Fengxing; Wang, Yiguo; Zhang, Qiming			Comparison of efficacy and safety of complementary and alternative therapies for essential hypertension with anxiety or depression disorder	PLOS ONE			English	Article							BLOOD-PRESSURE; METAANALYSIS; ASSOCIATION; INCREASES; STRESS; RISK; AWARENESS; QUALITY; HEALTH; MEN	Background Essential hypertension (EH) with anxiety or depression belongs to the category of psycho-cardiology. Hypertension is closely related to anxiety and depression. The adverse reactions of Western medicine are apparent and the compliance is poor. Supplementary and replacement therapies have accumulated rich experience in clinical practices, which can reduce side effects and improve clinical efficacy. This study intends to use the Bayesian network meta-analysis (NMA) analysis method for the first time to gather randomized controlled trials (RCTs) related to complementary and alternative therapies in the treatment of hypertension with anxiety or depression disorder and rank efficacy and safety, to provide a reference basis for the treatment of hypertension with anxiety or depression disorder. Methods All randomized controlled trials (RCTs) and registered and ongoing trials of Chinese and English databases, related to supplementation and replacement therapies of EH with anxiety or depression disorder, published from initial state to February 2021, will be collected in the form of computer retrieval. Two researchers will independently screen the literature, extracting data, assessing bias risk and assessing heterogeneity. We will use software WinBUGS 1.4.3 and Stata 16.0 for pairwise meta-analysis and NMA to comprehensively evaluate various interventions. The quality of evidence will be evaluated through the Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results This NMA will comprehensively compare and rank the efficacy and safety of a series of complementary and alternative therapies in treating EH with anxiety or depression disorder. Conclusion Supplementary and replacement therapies have accumulated rich experience of clinical practices in improving EH with anxiety or depression disorder. We expect that this NMA will guide practice and research by providing reliable evidence of evidence-based medicine for the treatment of EH with anxiety or depression disorder. Protocol registration number .	[Han, Xueyan; Liu, Xinxin; Zhang, Qiming] Shandong Univ Tradit Chinese Med, Dept Coll Clin Med 1, Jinan, Shandong, Peoples R China; [Zhong, Fengxing; Wang, Yiguo; Zhang, Qiming] China Acad Chinese Med Sci, Dept Expt Res Ctr, Beijing, Peoples R China	Shandong University of Traditional Chinese Medicine; China Academy of Chinese Medical Sciences	Zhang, QM (corresponding author), Shandong Univ Tradit Chinese Med, Dept Coll Clin Med 1, Jinan, Shandong, Peoples R China.; Zhang, QM (corresponding author), China Acad Chinese Med Sci, Dept Expt Res Ctr, Beijing, Peoples R China.	zhang_917@126.com			Key R&D Program of the People's Republic of China [2019YFC1711700]	Key R&D Program of the People's Republic of China	This study is supported by Key R&D Program of the People's Republic of China (2019YFC1711700).QZ received the award. URL=http://www.cncbd.org.cn/.The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almas A, 2014, J MENT HEALTH, V23, P292, DOI 10.3109/09638237.2014.924047; Barquera S, 2010, SALUD PUBLICA MEXICO, V52, pS63; Carek PJ, 2011, INT J PSYCHIAT MED, V41, P15, DOI 10.2190/PM.41.1.c; Chen Y, 2013, NURS EDUC TODAY, V33, P1166, DOI 10.1016/j.nedt.2012.11.014; Cohen BE, 2015, AM J HYPERTENS, V28, P1295, DOI 10.1093/ajh/hpv047; Egan BM, 2010, JAMA-J AM MED ASSOC, V303, P2043, DOI 10.1001/jama.2010.650; Rubio-Guerra AF, 2013, EXP CLIN CARDIOL, V18, P10; Gardner DM, 2005, CAN MED ASSOC J, V172, P1703, DOI 10.1503/cmaj.1041064; Ginty AT, 2013, J HUM HYPERTENS, V27, P187, DOI 10.1038/jhh.2012.18; Hamer M, 2012, J CLIN ENDOCR METAB, V97, pE29, DOI 10.1210/jc.2011-2132; Hamer M, 2010, HYPERTENSION, V56, P547, DOI 10.1161/HYPERTENSIONAHA.110.153775; Ho AK, 2015, J HYPERTENS, V33, P2215, DOI 10.1097/HJH.0000000000000693; Ismail Z, 2015, J MENT HEALTH, V24, P29, DOI 10.3109/09638237.2014.971148; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JEFFERSON JW, 1985, PSYCHOSOMATICS, V26, P841, DOI 10.1016/S0033-3182(85)72774-0; Kayano H, 2012, CIRC J, V76, P1670, DOI 10.1253/circj.CJ-11-1085; Lang UE, 2013, CELL PHYSIOL BIOCHEM, V31, P761, DOI 10.1159/000350094; Licht CMM, 2009, HYPERTENSION, V53, P631, DOI 10.1161/HYPERTENSIONAHA.108.126698; Liu MY, 2017, NEUROL RES, V39, P573, DOI 10.1080/01616412.2017.1317904; Meng L, 2012, J HYPERTENS, V30, P842, DOI 10.1097/HJH.0b013e32835080b7; Pan Y, 2015, NEUROPSYCH DIS TREAT, V11, P1121, DOI 10.2147/NDT.S77710; Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630; Rimar Liat, 2004, Harefuah, V143, P73; Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016; Saxena T, 2018, EXPERT REV CARDIOVAS, V16, P879, DOI 10.1080/14779072.2018.1540301; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647; Shinohara Y, 2010, CEREBROVASC DIS, V29, P361, DOI 10.1159/000281834; Sim J, 2005, PHYS THER, V85, P257; Stein DJ, 2014, GEN HOSP PSYCHIAT, V36, P142, DOI 10.1016/j.genhosppsych.2013.11.002; Wang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062469; Zhang Xiang-Dong, 2017, Zhongguo Zhong Yao Za Zhi, V42, P2181, DOI 10.19540/j.cnki.cjcmm.2017.0099; Zou LY, 2018, J CLIN MED, V7, DOI 10.3390/jcm7080195	32	0	0	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2021	16	7							e0254699	10.1371/journal.pone.0254699	http://dx.doi.org/10.1371/journal.pone.0254699			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2NF	34270618	gold, Green Published			2023-01-03	WOS:000678121400073
J	Donohue, JM; Jarlenski, MP; Kim, JY; Tang, L; Ahrens, K; Allen, L; Austin, A; Barnes, AJ; Burns, M; Chang, CCH; Clark, S; Cole, E; Crane, D; Cunningham, P; Idala, D; Junker, S; Lanier, P; Mauk, R; McDuffie, MJ; Mohamoud, S; Pauly, N; Sheets, L; Talbert, J; Zivin, K; Gordon, AJ; Kennedy, S				Donohue, Julie M.; Jarlenski, Marian P.; Kim, Joo Yeon; Tang, Lu; Ahrens, Katherine; Allen, Lindsay; Austin, Anna; Barnes, Andrew J.; Burns, Marguerite; Chang, Chung-Chou H.; Clark, Sarah; Cole, Evan; Crane, Dushka; Cunningham, Peter; Idala, David; Junker, Stefanie; Lanier, Paul; Mauk, Rachel; McDuffie, Mary Joan; Mohamoud, Shamis; Pauly, Nathan; Sheets, Logan; Talbert, Jeffery; Zivin, Kara; Gordon, Adam J.; Kennedy, Susan		MODRN	Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BUPRENORPHINE	IMPORTANCE There is limited information about trends in the treatment of opioid use disorder (OUD) among Medicaid enrollees. OBJECTIVE To examine the use of medications for OUD and potential indicators of quality of care in multiple states. DESIGN, SETTING, AND PARTICIPANTS Exploratory serial cross-sectional study of 1 024 301 Medicaid enrollees in 11 states aged 12 through 64 years (not eligible for Medicare) with International Classification of Diseases, Ninth Revision (ICD-9 or ICD-10) codes for OUD from 2014 through 2018. Each state used generalized estimating equations to estimate associations between enrollee characteristics and outcome measure prevalence, subsequently pooled to generate global estimates using random effects meta-analyses. EXPOSURES Calendar year, demographic characteristics, eligibility groups, and comorbidities. MAIN OUTCOMES AND MEASURES Use of medications for OUD (buprenorphine, methadone, or naltrexone); potential indicators of good quality (OUD medication continuity for 180 days, behavioral health counseling, urine drug tests); potential indicators of poor quality (prescribing of opioid analgesics and benzodiazepines). RESULTS In 2018, 41.7% of Medicaid enrollees with OUD were aged 21 through 34 years, 51.2% were female, 76.1% were non-Hispanic White, 50.7% were eligible through Medicaid expansion, and 50.6% had other substance use disorders. Prevalence of OUD increased in these 11 states from 3.3%(290 628 of 8 737 082) in 2014 to 5.0%(527 983 of 10 585 790) in 2018. The pooled prevalence of enrollees with OUD receiving medication treatment increased from 47.8% in 2014 (range across states, 35.3% to 74.5%) to 57.1% in 2018 (range, 45.7% to 71.7%). The overall prevalence of enrollees receiving 180 days of continuous medications for OUD did not significantly change from the 2014-2015 to 2017-2018 periods (-0.01 prevalence difference, 95% CI, -0.03 to 0.02) with state variability in trend (90% prediction interval, -0.08 to 0.06). Non-Hispanic Black enrollees had lower OUD medication use than White enrollees (prevalence ratio [PR], 0.72; 95% CI, 0.64 to 0.81; P <.001; 90% prediction interval, 0.52 to 1.00). Pregnant women had higher use of OUD medications (PR, 1.18; 95% CI, 1.11-1.25; P <.001; 90% prediction interval, 1.01-1.38) and medication continuity (PR, 1.14; 95% CI, 1.10-1.17, P <.001; 90% prediction interval, 1.06-1.22) than did other eligibility groups. CONCLUSIONS AND RELEVANCE Among US Medicaid enrollees in 11 states, the prevalence of medication use for treatment of opioid use disorder increased from 2014 through 2018. The pattern in other states requires further research.	[Donohue, Julie M.; Jarlenski, Marian P.; Kim, Joo Yeon; Cole, Evan; Junker, Stefanie] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA; [Tang, Lu] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Ahrens, Katherine] Univ Southern Maine, Muskie Sch Publ Serv, Publ Hlth Program, Portland, ME USA; [Allen, Lindsay] West Virginia Univ, Sch Publ Hlth, Hlth Policy Management & Leadership Dept, Morgantown, WV 26506 USA; [Austin, Anna] Univ N Carolina, Dept Maternal & Child Hlth, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA; [Barnes, Andrew J.; Cunningham, Peter] Virginia Commonwealth Univ, Sch Med, Dept Hlth Behav & Policy, Richmond, VA USA; [Burns, Marguerite] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA; [Chang, Chung-Chou H.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Clark, Sarah] Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI USA; [Crane, Dushka; Mauk, Rachel] Ohio State Univ, Ohio Coll Med Govt Resource Ctr, Columbus, OH 43210 USA; [Idala, David; Mohamoud, Shamis] Univ Maryland Baltimore Cty, Hilltop Inst, Baltimore, MD 21228 USA; [Lanier, Paul] Univ N Carolina, Sch Social Work, Chapel Hill, NC 27515 USA; [McDuffie, Mary Joan] Univ Delaware, Ctr Community Res & Serv, Biden Sch Publ Policy & Adm, Newark, DE USA; [Pauly, Nathan] West Virginia Univ, Sch Publ Hlth, Hlth Sci Ctr, Hlth Affairs Dept, Morgantown, WV 26506 USA; [Sheets, Logan; Kennedy, Susan] AcademyHlth, Washington, DC USA; [Talbert, Jeffery] Univ Kentucky, Coll Med, Div Biomed Informat, Lexington, KY USA; [Zivin, Kara] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA; [Gordon, Adam J.] Univ Utah, Sch Med, Dept Med, Salt Lake City, UT USA; [Gordon, Adam J.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA; [Gordon, Adam J.] VA Salt Lake City Hlth Care Syst, Decis Enhancement, Informat, Salt Lake City, UT USA; [Gordon, Adam J.] VA Salt Lake City Hlth Care Syst, Analyt Sci IDEAS Ctr, Salt Lake City, UT USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Maine System; University of Southern Maine; West Virginia University; University of North Carolina; University of North Carolina Chapel Hill; Virginia Commonwealth University; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; University System of Ohio; Ohio State University; University System of Maryland; University of Maryland Baltimore County; University of North Carolina; University of North Carolina Chapel Hill; University of Delaware; West Virginia University; University of Kentucky; University of Michigan System; University of Michigan; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; US Department of Veterans Affairs	Donohue, JM (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Hlth Policy & Management, 130 DeSoto St,A635, Pittsburgh, PA 15261 USA.			Tang, Lu/0000-0001-6143-9314; Jarlenski, Marian/0000-0001-6907-5447; Talbert, Jeffery/0000-0002-4304-5167; Mauk, Rachel/0000-0003-1818-0305; Zivin, Kara/0000-0001-8246-6864	National Institute on Drug Abuse [R01DA048029]	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was supported by grant R01DA048029 from the National Institute on Drug Abuse (Drs Donohue, Allen, Cole, Crane, Cunningham, Mauk, Talbert, and Zivin and Ms Maohamoud and Mr Sheets).	Academy Health, MED OUTC DISTR RES N MED OUTC DISTR RES N; Andrilla CHA, 2019, J RURAL HEALTH, V35, P108, DOI 10.1111/jrh.12307; [Anonymous], 2020, J ADDICT MED, V14, P1, DOI 10.1097/ADM.0000000000000633; [Anonymous], 2019, REP C UT MAN MED ASS REP C UT MAN MED ASS; Azar A II, 2017, REPORT C T MSIS SUBS; Barnes AJ, 2020, HEALTH AFFAIR, V39, P238, DOI 10.1377/hlthaff.2019.00525; Bipartisan Policy Center, 2019, GOVERNOR CUOMO INTRO; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Carrell DS, 2020, J DRUG ASSESS, V9, P97, DOI 10.1080/21556660.2020.1750419; Cher BAY, 2019, MED CARE, V57, P208, DOI 10.1097/MLR.0000000000001054; Cole ES, 2019, J GEN INTERN MED, V34, P936, DOI 10.1007/s11606-019-04943-6; Cunningham P, 2020, EXPANDING ACCESS ADD; Deeks J, 2019, COCHRANE HDB SYSTEMA, pCH10; Department of Veteran Affairs Department of Defense, 2015, VA DOD CLIN PRACT GU; Drug Overdose Death Rates, 2018 DRUG OV DEATH R; Economic Research Service US Department of Agriculture, 2019, RUR URB COMM AR COD RUR URB COMM AR COD; Epstein M., 2019, STATE VARIATION MEDI; Gordon AJ, 2015, J ADDICT MED, V9, P470, DOI 10.1097/ADM.0000000000000164; Hansen H, 2016, DRUG ALCOHOL DEPEN, V164, P14, DOI 10.1016/j.drugalcdep.2016.03.028; Howell BA, 2021, J GEN INTERN MED, V36, P1264, DOI 10.1007/s11606-020-06339-3; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Kaiser Family Foundation, 2018, MED ROL ADDR OP EP; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Martin SA, 2018, ANN INTERN MED, V169, P628, DOI 10.7326/M18-1652; McCarty D, 2019, ADDICT SCI CLIN PRAC, V14, DOI 10.1186/s13722-019-0160-6; National Quality Forum, 2020, OP OP US DIS QUAL ME OP OP US DIS QUAL ME; National Quality Forum, 2019, CONT PHARM OP US DIS CONT PHARM OP US DIS; Neighbors CJ, 2019, SUBST ABUSE TREAT PR, V14, DOI 10.1186/s13011-019-0215-4; Park TW, 2020, ADDICTION, V115, P924, DOI 10.1111/add.14886; Roberts AW, 2018, PSYCHIAT SERV, V69, P832, DOI 10.1176/appi.ps.201700315; Samples H, 2018, J SUBST ABUSE TREAT, V95, P9, DOI 10.1016/j.jsat.2018.09.001; Shen K, 2020, HEALTH AFFAIR, V39, P993, DOI 10.1377/hlthaff.2019.01041; Stein BD, 2015, MILBANK Q, V93, P561, DOI 10.1111/1468-0009.12137; Substance Abuse and Mental Health Services Administration, 2020, MED OP US DIS TREATM MED OP US DIS TREATM; Toh S, 2011, CLIN PHARMACOL THER, V90, P883, DOI 10.1038/clpt.2011.236; Toh S, 2014, MED CARE, V52, P664, DOI 10.1097/MLR.0000000000000147; Toh S, 2013, MED CARE, V51, pS4, DOI 10.1097/MLR.0b013e31829b1bb1; Watkins KE, 2017, DRUG ALCOHOL DEPEN, V177, P307, DOI 10.1016/j.drugalcdep.2017.03.033; Wen HF, 2017, MED CARE, V55, P336, DOI 10.1097/MLR.0000000000000703	40	21	21	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	2021	326	2					154	164		10.1001/jama.2021.7374	http://dx.doi.org/10.1001/jama.2021.7374			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TI7EC	34255008	Green Published, Bronze			2023-01-03	WOS:000672962200015
J	Kim, SI; Szeto, AH; Morgan, KP; Brower, B; Dunn, MW; Khandani, AH; Godley, PA; Rose, TL; Basch, EM; Milowsky, MI; Whang, YE; Crona, DJ				Kim, Stephanie, I; Szeto, Andy H.; Morgan, Katherine P.; Brower, Blaine; Dunn, Mary W.; Khandani, Amir H.; Godley, Paul A.; Rose, Tracy L.; Basch, Ethan M.; Milowsky, Matthew, I; Whang, Young E.; Crona, Daniel J.			A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer	PLOS ONE			English	Article							INCREASED SURVIVAL; THERAPIES; ACCESS	Introduction Radium-223, abiraterone, and enzalutamide have each been shown to significantly improve survival as monotherapy in patients with metastatic castration-resistant prostate cancer. However, effects of combination radium-223 plus abiraterone or enzalutamide on survival and safety remain unclear. Patients and methods This single-center retrospective cohort study used electronic health record data of patients with metastatic castration-resistant prostate cancer and bone metastases who were treated with radium-223 between April 1, 2014 and February 19, 2019. Patients who received radium-223 monotherapy were compared to patients who received a combination of radium-223 plus either abiraterone or enzalutamide. The primary endpoint was overall survival. Secondary endpoints included progression-free survival, time to symptomatic skeletal event, symptomatic skeletal event-free survival, and incidence of drug-related adverse events. Time-to-event analyses were estimated by log rank tests using Kaplan-Meier curves. Hazard ratios and 95% confidence intervals were derived from Cox proportional hazards models. Chi-square tests evaluated difference in serious adverse events between the two arms. Results A total of 60 patients met inclusion criteria (n = 41 in the monotherapy arm, n = 19 in the combination arm). Differences in median overall survival were not observed (12.7 vs. 12.8 months; HR 1.15, 95% CI 0.59-2.23; P = 0.68), but median progression-free survival was significantly longer in the combination arm (7.6 vs. 4.9 months; HR 1.94, 95% CI 1.11-3.40; P = 0.02). Significant differences were not observed in time to first SSE (P = 0.97), SSE-free survival (P = 0.16), or in the overall incidence of serious adverse events (P = 0.45). Conclusion Combination radium-223 plus abiraterone or enzalutamide did not improve overall survival, but prolonged progression-free survival without increasing the incidence of serious adverse events in metastatic castration-resistant prostate cancer patients with bone metastases. However, these results are limited by small numbers and patient selection inherent in retrospective analysis.	[Kim, Stephanie, I; Szeto, Andy H.; Crona, Daniel J.] Univ N Carolina, Div Pharmacotherapy & Expt Therapeut, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA; [Morgan, Katherine P.] Univ N Carolina, Div Practice Adv & Experiential Educ, UNC Eshelman Sch Pharm, Chapel Hill, NC USA; [Morgan, Katherine P.; Crona, Daniel J.] Univ N Carolina, Dept Pharm, UNC Hosp & Clin, Chapel Hill, NC 27599 USA; [Brower, Blaine; Dunn, Mary W.; Godley, Paul A.; Rose, Tracy L.; Basch, Ethan M.; Milowsky, Matthew, I; Whang, Young E.] Univ N Carolina, Div Oncol, Dept Med, UNC Sch Med, Chapel Hill, NC USA; [Khandani, Amir H.] Univ N Carolina, Div Mol Imaging & Therapeut, Dept Radiol, UNC Sch Med, Chapel Hill, NC USA; [Khandani, Amir H.; Godley, Paul A.; Rose, Tracy L.; Basch, Ethan M.; Milowsky, Matthew, I; Whang, Young E.; Crona, Daniel J.] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University North Carolina Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Crona, DJ (corresponding author), Univ N Carolina, Div Pharmacotherapy & Expt Therapeut, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.; Crona, DJ (corresponding author), Univ N Carolina, Dept Pharm, UNC Hosp & Clin, Chapel Hill, NC 27599 USA.; Whang, YE; Crona, DJ (corresponding author), Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	ywhang@med.unc.edu; daniel.crona@unc.edu		Kim, Stephanie/0000-0003-2156-4238; Szeto, Andy/0000-0002-9195-6520				[Anonymous], SURVIVAL RATES PROST; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Costa RP, 2019, PROSTATE INT, V7, P25, DOI 10.1016/j.prnil.2018.08.001; Cursano MC, 2020, CRIT REV ONCOL HEMAT, V146, DOI 10.1016/j.critrevonc.2020.102864; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dizdarevic S, 2019, EUR J NUCL MED MOL I, V46, P1102, DOI 10.1007/s00259-019-4261-y; Frieling JS, 2015, CANCER CONTROL, V22, P109, DOI 10.1177/107327481502200114; Gallicchio R, 2019, TUMORI J, V105, P367, DOI 10.1177/0300891619851376; Jacene H, 2018, CLIN GENITOURIN CANC, V16, pE919, DOI 10.1016/j.clgc.2018.03.007; Marques IA, 2018, CANCER TREAT REV, V68, P47, DOI 10.1016/j.ctrv.2018.05.011; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Rathbun JT, 2019, CURR PROB CANCER, V43, P205, DOI 10.1016/j.currproblcancer.2018.05.007; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Saad F, 2016, LANCET ONCOL, V17, P1306, DOI 10.1016/S1470-2045(16)30173-5; Sartor O, 2018, ONCOLOGIST, V23, P193, DOI 10.1634/theoncologist.2017-0413; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shore N, 2020, PROSTATE CANCER P D, V23, P680, DOI 10.1038/s41391-020-0236-0; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith M, 2019, LANCET ONCOL, V20, P408, DOI 10.1016/S1470-2045(18)30860-X; Song YP, 2017, INT J RADIAT ONCOL, V98, P955, DOI 10.1016/j.ijrobp.2017.01.208; Tombal BF, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.5007	21	2	2	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2021	16	6							e0253021	10.1371/journal.pone.0253021	http://dx.doi.org/10.1371/journal.pone.0253021			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BF	34153052	Green Published, Green Submitted, gold			2023-01-03	WOS:000671691000034
J	Powles, T; Assaf, ZJ; Davarpanah, N; Banchereau, R; Szabados, BE; Yuen, KC; Grivas, P; Hussain, M; Oudard, S; Gschwend, JE; Albers, P; Castellano, D; Nishiyama, H; Daneshmand, S; Sharma, S; Zimmermann, BG; Sethi, H; Aleshin, A; Perdicchio, M; Zhang, JB; Shames, DS; Degaonkar, V; Shen, XD; Carter, C; Bais, C; Bellmunt, J; Mariathasan, S				Powles, Thomas; Assaf, Zoe June; Davarpanah, Nicole; Banchereau, Romain; Szabados, Bernadett E.; Yuen, Kobe C.; Grivas, Petros; Hussain, Maha; Oudard, Stephane; Gschwend, Jurgen E.; Albers, Peter; Castellano, Daniel; Nishiyama, Hiroyuki; Daneshmand, Siamak; Sharma, Shruti; Zimmermann, Bernhard G.; Sethi, Himanshu; Aleshin, Alexey; Perdicchio, Maurizio; Zhang, Jingbin; Shames, David S.; Degaonkar, Viraj; Shen, Xiaodong; Carter, Corey; Bais, Carlos; Bellmunt, Joaquim; Mariathasan, Sanjeev			ctDNA guiding adjuvant immunotherapy in urothelial carcinoma	NATURE			English	Article							OPEN-LABEL; MULTICENTER; ATEZOLIZUMAB; CANCER; TRIAL	Minimally invasive approaches to detect residual disease after surgery are needed to identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) holds promise as a biomarker for molecular residual disease and relapse(1). We evaluated outcomes in 581 patients who had undergone surgery and were evaluable for ctDNA from a randomized phase III trial of adjuvant atezolizumab versus observation in operable urothelial cancer. This trial did not reach its efficacy end point in the intention-to-treat population. Here we show that ctDNA testing at the start of therapy (cycle 1 day 1) identified 214 (37%) patients who were positive for ctDNA and who had poor prognosis (observation arm hazard ratio = 6.3 (95% confidence interval: 4.45-8.92); P < 0.0001). Notably, patients who were positive for ctDNA had improved disease-free survival and overall survival in the atezolizumab arm versus the observation arm (disease-free survival hazard ratio = 0.58 (95% confidence interval: 0.43-0.79); P = 0.0024, overall survival hazard ratio = 0.59 (95% confidence interval: 0.41-0.86)). No difference in disease-free survival or overall survival between treatment arms was noted for patients who were negative for ctDNA. The rate of ctDNA clearance at week 6 was higher in the atezolizumab arm (18%) than in the observation arm (4%) (P = 0.0204). Transcriptomic analysis of tumours from patients who were positive for ctDNA revealed higher expression levels of cell-cycle and keratin genes. For patients who were positive for ctDNA and who were treated with atezolizumab, non-relapse was associated with immune response signatures and basal-squamous gene features, whereas relapse was associated with angiogenesis and fibroblast TGF beta signatures. These data suggest that adjuvant atezolizumab may be associated with improved outcomes compared with observation in patients who are positive for ctDNA and who are at a high risk of relapse. These findings, if validated in other settings, would shift approaches to postoperative cancer care.	[Powles, Thomas] Queen Mary Univ London ECMC, Barts Canc Inst, Barts Hlth, London, England; [Assaf, Zoe June; Davarpanah, Nicole; Banchereau, Romain; Yuen, Kobe C.; Shames, David S.; Degaonkar, Viraj; Shen, Xiaodong; Carter, Corey; Bais, Carlos; Mariathasan, Sanjeev] Roche Genentech, San Francisco, CA 94080 USA; [Szabados, Bernadett E.] Queen Mary Univ London, Barts Canc Inst, London, England; [Grivas, Petros] Univ Washington, Seattle, WA 98195 USA; [Grivas, Petros] Seattle Canc Care Alliance, Seattle, WA USA; [Grivas, Petros] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Hussain, Maha] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Oudard, Stephane] Univ Paris, Georges Pompidou European Hosp, Paris, France; [Gschwend, Jurgen E.] Tech Univ Munich, Dept Urol, Rechts Isar Med Ctr, Munich, Germany; [Albers, Peter] Heinrich Heine Univ Dusseldorf, Univ Hosp Dusseldorf, Med Fac, Dept Urol, Dusseldorf, Germany; [Castellano, Daniel] Univ Hosp 12 Octubre, Med Oncol Dept CIBER ONC, Madrid, Spain; [Nishiyama, Hiroyuki] Univ Tsukuba, Fac Med, Dept Urol, Ibaraki, Japan; [Daneshmand, Siamak] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA; [Sharma, Shruti; Zimmermann, Bernhard G.; Sethi, Himanshu; Aleshin, Alexey] Natera Inc, San Carlos, CA USA; [Perdicchio, Maurizio] F Hoffmann La Roche Ltd, Basel, Switzerland; [Zhang, Jingbin] Hoffmann La Roche Ltd, Mississauga, ON, Canada; [Bellmunt, Joaquim] Harvard Med Sch, Beth Israel Deaconess Med Ctr, PSMAR IMIM Lab, Boston, MA 02115 USA	Barts Health NHS Trust; University of London; Queen Mary University London; Roche Holding; Genentech; University of London; Queen Mary University London; University of Washington; University of Washington Seattle; Seattle Cancer Care Alliance; Fred Hutchinson Cancer Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Technical University of Munich; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Hospital Universitario 12 de Octubre; University of Tsukuba; University of Southern California; Roche Holding; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Powles, T (corresponding author), Queen Mary Univ London ECMC, Barts Canc Inst, Barts Hlth, London, England.; Mariathasan, S (corresponding author), Roche Genentech, San Francisco, CA 94080 USA.	thomas.powles1@nhs.net; mariathasan.sanjeev@gene.com	Perdicchio, Maurizio/HGB-2966-2022; Bellmunt, Joaquim/B-8151-2019	Bellmunt, Joaquim/0000-0003-2328-3421; Sethi, Himanshu/0000-0002-5787-8901; Szabados, Bernadett/0000-0002-8786-0032; OUDARD, Stephane/0000-0003-0893-285X	F. Hoffmann-La Roche Ltd/Genentech, Inc.; F. Hoffmann-La Roche Ltd.	F. Hoffmann-La Roche Ltd/Genentech, Inc.(Hoffmann-La RocheRoche HoldingGenentech); F. Hoffmann-La Roche Ltd.(Hoffmann-La Roche)	The study was sponsored by F. Hoffmann-La Roche Ltd/Genentech, Inc. We thank the patients who participated in the trial and the clinical site investigators, the Barts Health Experimental Cancer Medicine Centre (CRUK), A. Yiu and M. Ravasz from Fios Genomics for additional help with transcriptomic analysis, S. Flynn, K. Zvonar and D. Rishipathak of the Genentech Biomarker Operations Team for providing support in the generation and analysis of the data, and E. E. Kadel III from the Genentech Biomarker Development team for data integration. Medical writing assistance for this manuscript was provided by H. Grewal and Z. Augur of Anshin Biosolutions, M. Malhotra of Natera and A. J. Pratt of Health Interactions, Inc., and was funded by F. Hoffmann-La Roche Ltd. M. Jacobson and J. Ball contributed to research funding for the ABACUS cohort.	Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; BAJORIN D, 2021, J CLIN ONCOL, V39, P391, DOI [10.1200/JCO.2021.39.6_suppl.391, DOI 10.1200/JCO.2021.39.6_SUPPL.391]; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Bellmunt J, 2021, LANCET ONCOL, V22, P525, DOI 10.1016/S1470-2045(21)00004-8; Bratman SV, 2020, NAT CANCER, V1, P873, DOI 10.1038/s43018-020-0096-5; Chan ATC, 2018, J CLIN ONCOL, V36, P3091, DOI 10.1200/JCO.2018.77.7847; Chin RI, 2019, MOL DIAGN THER, V23, P311, DOI 10.1007/s40291-019-00390-5; Christensen E, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.18.02052; Coombes RC, 2019, CLIN CANCER RES, V25, P4255, DOI 10.1158/1078-0432.CCR-18-3663; Corcoran RB, 2018, NEW ENGL J MED, V379, P1754, DOI 10.1056/NEJMra1706174; Garcia-Murillas I, 2019, JAMA ONCOL, V5, P1473, DOI 10.1001/jamaoncol.2019.1838; Hellmann Matthew D, 2018, N Engl J Med, V378, P2093, DOI 10.1056/NEJMoa1801946; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Nabet BY, 2020, CELL, V183, P363, DOI 10.1016/j.cell.2020.09.001; Nuzzo PV, 2020, NAT MED, V26, P1041, DOI 10.1038/s41591-020-0933-1; Powles T, 2019, NAT MED, V25, P1706, DOI 10.1038/s41591-019-0628-7; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Reinert T, 2019, JAMA ONCOL, V5, P1124, DOI 10.1001/jamaoncol.2019.0528; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Snyder A, 2019, CLIN CANCER RES, V25, P6909, DOI 10.1158/1078-0432.CCR-18-2688; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taieb J, 2019, ANN ONCOL, V30, P867; Tan L, 2019, ANN ONCOL, V30, P804, DOI 10.1093/annonc/mdz048; THOMSEN M, 2017, SCI REP-UK, V7; Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219; Turner NC, 2020, LANCET ONCOL, V21, P1296, DOI [10.1016/S1470-2045(20)30444-7, 10.11016/S1470-2045(20)30444-7]; Wu D, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks461; Wu TD, 2016, METHODS MOL BIOL, V1418, P283, DOI 10.1007/978-1-4939-3578-9_15; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057; Zhang Q, 2020, CANCER DISCOV, V10, P1842, DOI 10.1158/2159-8290.CD-20-0047	33	97	99	12	41	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 15	2021	595	7867					432	+		10.1038/s41586-021-03642-9	http://dx.doi.org/10.1038/s41586-021-03642-9		JUN 2021	21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ5FI	34135506	Green Accepted			2023-01-03	WOS:000662148600001
J	Dada, S; Ashworth, H; Sobitschka, A; Raguveer, V; Sharma, R; Hamilton, RL; Burke, T				Dada, Sara; Ashworth, Henry; Sobitschka, Alina; Raguveer, Vanitha; Sharma, Rupam; Hamilton, Rebecca L.; Burke, Thomas			Experiences with implementation of continuous positive airway pressure for neonates and infants in low-resource settings: A scoping review	PLOS ONE			English	Review							RESPIRATORY-DISTRESS-SYNDROME; BUBBLE-CPAP; PRETERM INFANTS; NASAL INJURY; CARE; MORTALITY; SUPPORT; DEVICE; NEWBORNS; MALAWI	Background Continuous positive airway pressure (CPAP) is the gold standard of care in providing non-invasive positive pressure support to neonates in respiratory distress in high-resource settings. While safety has been demonstrated in low-resource settings, there is a lack of knowledge on the barriers and facilitators to proper implementation. Objective To identify and describe the barriers, facilitators, and priorities for future implementation of CPAP for neonates and infants in low-resource settings. Methods A systematic search (database inception to March 6, 2020) was performed on MEDLINE, Embase, Web of Science, CINAHL, Global Health, and the WHO Global Index Medicus using PRISMA-ScR guidelines. Original research articles pertaining to implementation of CPAP devices in low-resource settings, provider or parent perspectives and experiences with CPAP, cost-benefit analyses, and cost-effectiveness studies were included. Inductive content analysis was conducted. Findings 1385 article were screened and 54 studies across 19 countries met inclusion criteria. Six major themes emerged: device attributes, patient experiences, parent experiences, provider experiences, barriers, and facilitators. Nasal trauma was the most commonly reported complication. Barriers included unreliable electricity and lack of bioengineering support. Facilitators included training, mentorship and empowerment of healthcare providers. Device design, supply chain infrastructure, and training models were imperative to the adoption and sustainability of CPAP. Conclusion Sustainable implementation of CPAP in low resource settings requires easy-to-use devices, ready access to consumables, and holistic, user-driven training. Further research is necessary on standardizing metrics, interventions that support optimal provider performance, and conditions needed for successful long-term health system integration.	[Dada, Sara] Vayu Global Hlth Fdn Boston, Boston, MA 02155 USA; Harvard Med Sch, Boston, MA 02115 USA; Univ Gottingen, Gottingen, Germany; Univ Illinois, Coll Med, Chicago, IL USA; Univ Calif Los Angeles, Kern Med Ctr, Bakersfield, CA USA; Massachusetts Gen Hosp, Dept Anesthesiol, Boston, MA USA; Karolinska Inst, Dept Cell & Mol Biol, Solna, Sweden; Massachusetts Gen Hosp, Dept Emergency Med, Global Hlth Innovat Lab, Boston, MA 02114 USA; Harvard TH Chan Sch Publ Hlth, Boston, MA USA	Harvard University; Harvard Medical School; University of Gottingen; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California Los Angeles; Harvard University; Massachusetts General Hospital; Karolinska Institutet; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Dada, S (corresponding author), Vayu Global Hlth Fdn Boston, Boston, MA 02155 USA.	sara.dada@ucdconnect.ie		Sharma, MD, Rupam/0000-0003-3457-4371; Ashworth, Henry/0000-0002-8989-8560; Hamilton, Rebecca/0000-0002-0350-4517; Dada, Sara/0000-0003-3910-1856				Abdulkadir I, 2015, Niger Postgrad Med J, V22, P21; Abdullahi F., 2013, CASE REP NIGER J PAE, V40, P303; Ainsworth SB., 2005, TREAT RESP MED, V4, P423, DOI [10.2165/00151829-200504060-00006, DOI 10.2165/00151829-200504060-00006]; Al-lawama M, 2019, INT J GEN MED, V12, P25, DOI 10.2147/IJGM.S185264; Amadi HO, 2019, PAEDIATR INT CHILD H, V39, P184, DOI 10.1080/20469047.2019.1598125; [Anonymous], 2019, NEWB RED MORT; Araujo MC., 2010, REV ENFERM UFPE LINE, V4, P137; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Asadollahi M., 2013, QOM U MED SCI J, V6, P57; Asibon A, 2020, ACTA PAEDIATR, V109, P705, DOI 10.1111/apa.15025; Atreya MR, 2018, ADV NEONAT CARE, V18, P500, DOI 10.1097/ANC.0000000000000510; Bahman-Bijari B, 2011, IRAN J PEDIATR, V21, P151; Abelenda VLB, 2018, J CHILD HEALTH CARE, V22, P216, DOI 10.1177/1367493517752500; Bashir T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211476; BASSIOUNY MR, 1994, J TROP PEDIATRICS, V40, P341, DOI 10.1093/tropej/40.6.341; Boo NY, 2016, NEONATOLOGY, V110, P116, DOI 10.1159/000444316; Brunherotti Marisa Afonso Andrade, 2015, Rev. paul. pediatr., V33, P280, DOI 10.1016/j.rpped.2015.01.005; Chaves EMC, 2010, REV RENE, V11, P195; Chen A, 2014, BMC PEDIATR, V14, DOI 10.1186/s12887-014-0288-1; Chen CY, 2017, PEDIATR NEONATOL, V58, P229, DOI 10.1016/j.pedneo.2016.04.005; Chenghua, 2013, MODERN CLIN NURS, P16; Chirla D, 2017, COMP EFFICACY COMPLI; Crehan C, 2018, ARCH DIS CHILD, V103, P732, DOI 10.1136/archdischild-2017-313867; Cunha MLCd., 2012, REV HCPA, V32, P480; da Silva, 2014, J NURSING UFPE, V8, P797; Daga S, 2014, J TROP PEDIATRICS, V60, P343, DOI 10.1093/tropej/fmu023; Dai T, 2020, J WOUND OSTOMY CONT, V47, P26, DOI 10.1097/WON.0000000000000604; DasGupta S, 2006, J MED HUMANIT, V27, P245, DOI 10.1007/s10912-006-9021-x; Dewez JE, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-031128; Dewez JE, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1311-8; Dewez JE, 2017, TROP DOCT, V47, P19, DOI 10.1177/0049475516630210; do Nascimento RM, 2009, REV LAT-AM ENFERM, V17, P489, DOI 10.1590/S0104-11692009000400009; Duffy VG., 2013, SUSTAINABLE HUMAN CT; Duke T, 2014, PAEDIATR INT CHILD H, V34, P3, DOI 10.1179/2046905513Y.0000000102; Earns J, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0668; Ekhaguere OA, 2019, PAEDIATR RESPIR REV, V29, P31, DOI 10.1016/j.prrv.2018.04.004; Goel S, 2015, INDIAN PEDIATR, V52, P1035, DOI 10.1007/s13312-015-0769-9; Gondwe MJ, 2017, MALAWI MED J, V29, P5, DOI 10.4314/mmj.v29i1.2; GuEmez Martuinez, 2018, INVESTIGACION ENFERM, V20; Hendriks H, 2014, J TROP PEDIATRICS, V60, P348, DOI 10.1093/tropej/fmu025; Hug L, 2019, LANCET GLOB HEALTH, V7, pE710, DOI 10.1016/S2214-109X(19)30163-9; Hundalani SG, 2015, ARCH DIS CHILD-FETAL, V100, pF332, DOI 10.1136/archdischild-2014-308082; Jabraeili M, 2018, INT J PEDIATR-MASSHA, V6, P6861, DOI 10.22038/ijp.2017.26364.2258; Jardine C, 2015, S AFR J CHILD HEALTH, V9, P45, DOI 10.7196/SAJCH.859; Kamath BD, 2011, PEDIATRICS, V127, P1139, DOI 10.1542/peds.2010-3212; Khan J, 2017, EUR J PEDIATR, V176, P1629, DOI 10.1007/s00431-017-3016-7; Kinshella MLW, 2020, PUBLIC HEALTH REV, V41, DOI 10.1186/s40985-020-00124-7; Koyamaibole L, 2006, J TROP PEDIATRICS, V52, P249, DOI 10.1093/tropej/fmi109; Kyngas H, 2020, APPLICATION OF CONTENT ANALYSIS IN NURSING SCIENCE RESEARCH, P13, DOI 10.1007/978-3-030-30199-6_2; Martin S, 2014, ARCH DIS CHILD-FETAL, V99, pF495, DOI 10.1136/archdischild-2013-305519; Mascarenhas MLVdC ., 2019, ESC ANNA NERY, V23; McAdams RM, 2015, RESP CARE, V60, P437, DOI 10.4187/respcare.03438; Meka, 2018, NAM PERSPECTIVES; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Mukhtar M., 2015, NIGER J PAEDIAT, V42, P12; Myhre L., 2017, MIDIRS MIDWIFERY DIG, V27, P263; Nahimana E, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0449-x; Ntigurirwa P, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-017-0252-6; Nyondo-Mipando AL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228915; Okonkwo IR., 2016, NIGER J PAEDIAT, V43, P286, DOI DOI 10.4314/njp.v43i4.10; Olayo B, 2019, PAEDIATR INT CHILD H, V39, P193, DOI 10.1080/20469047.2019.1624007; Organization, 2017, HUM RES MED DEV ROL; Organization WH, 2015, WHO REC INT IMPR PRE; Osman M, 2015, J PERINATOL, V35, P263, DOI 10.1038/jp.2014.206; Antunes JCP, 2013, REV BRAS ENFERM, V66, P663, DOI 10.1590/S0034-71672013000500004; Perry L, 2011, MED BIOL ENG COMPUT, V49, P719, DOI 10.1007/s11517-011-0786-3; Peters DH, 2013, INPLEMENTATION RESEARCH IN HEALTH: A PRACTICAL GUIDE, pCOVER1; Peters M. D. J., 2020, JBI MANUAL EVIDENCE, DOI [DOI 10.46658/JBIMES-20-01, 10.46658/JBIMES-20-12]; Poulsen A., 2019, J TROP PEDIATRICS, V10, P10; Bonfim SDSF, 2014, REV LAT-AM ENFERM, V22, P826, DOI 10.1590/0104-1169.3451.2486; Secretary-General, 2019, SECR GEN U PUBL; Sessions KL, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4364-y; Tagare A, 2013, J TROP PEDIATRICS, V59, P113, DOI 10.1093/tropej/fms061; Thomas DR, 2006, AM J EVAL, V27, P237, DOI 10.1177/1098214005283748; Thukral A, 2016, J PERINATOL, V36, pS21, DOI 10.1038/jp.2016.29; Tiryaki Öznur, 2016, Aquichan, V16, P159, DOI 10.5294/aqui.2016.16.2.4; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Urs PS, 2009, INDIAN PEDIATR, V46, P409; Van den Heuvel M, 2011, ANN TROP PAEDIATR, V31, P59, DOI 10.1179/1465328110Y.0000000001; Wilson PT, 2014, J TROP PEDIATRICS, V60, P33, DOI 10.1093/tropej/fmt074; Won A, 2019, PAEDIATR INT CHILD H, V39, P168, DOI 10.1080/20469047.2018.1534389; XIE L, 2014, WORLD J EMERG MED, V5, P203, DOI DOI 10.5847/WJEM.J.ISSN.1920-8642.2014.03.008; Yong SC, 2005, ARCH DIS CHILD-FETAL, V90, pF480, DOI 10.1136/adc.2004.069351	83	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2021	16	6							e0252718	10.1371/journal.pone.0252718	http://dx.doi.org/10.1371/journal.pone.0252718			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6SD	34115776	Green Published, gold			2023-01-03	WOS:000664643000029
J	Vervoort, SJ; Welsh, SA; Devlin, JR; Barbieri, E; Knight, DA; Offley, S; Bjelosevic, S; Costacurta, M; Todorovski, I; Kearney, CJ; Sandow, JJ; Fan, Z; Blyth, B; McLeod, V; Vissers, JHA; Pavic, K; Martin, B; Gregory, G; Demosthenous, E; Zethoven, M; Kong, IY; Hawkins, ED; Hogg, SJ; Kelly, MJ; Newbold, A; Simpson, KJ; Kauko, O; Harvey, KF; Ohlmeyer, M; Westermarck, J; Gray, N; Gardini, A; Johnstone, RW				Vervoort, Stephin J.; Welsh, Sarah A.; Devlin, Jennifer R.; Barbieri, Elisa; Knight, Deborah A.; Offley, Sarah; Bjelosevic, Stefan; Costacurta, Matteo; Todorovski, Izabela; Kearney, Conor J.; Sandow, Jarrod J.; Fan, Zheng; Blyth, Benjamin; McLeod, Victoria; Vissers, Joseph H. A.; Pavic, Karolina; Martin, Ben P.; Gregory, Gareth; Demosthenous, Elena; Zethoven, Magnus; Kong, Isabella Y.; Hawkins, Edwin D.; Hogg, Simon J.; Kelly, Madison J.; Newbold, Andrea; Simpson, Kaylene J.; Kauko, Otto; Harvey, Kieran F.; Ohlmeyer, Michael; Westermarck, Jukka; Gray, Nathanael; Gardini, Alessandro; Johnstone, Ricky W.			The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer	CELL			English	Article							PROTEIN PHOSPHATASE 2A; P-TEFB; INTEGRATOR COMPLEX; ELONGATION COMPLEX; GENE-EXPRESSION; PAUSE RELEASE; SEQ DATA; RNA; ACTIVATION; PROMOTER	Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing checkpoint following transcription initiation is primarily controlled by CDK9. We discovered that CDK9-mediated, RNAPII-driven transcription is functionally opposed by a protein phosphatase 2A (PP2A) complex that is recruited to transcription sites by the Integrator complex subunit INTS6. PP2A dynamically antagonizes phosphorylation of key CDK9 substrates including DSIF and RNAPII-CTD. Loss of INTS6 results in resistance to tumor cell death mediated by CDK9 inhibition, decreased turnover of CDK9 phospho-substrates, and amplification of acute oncogenic transcriptional responses. Pharmacological PP2A activation synergizes with CDK9 inhibition to kill both leukemic and solid tumor cells, providing therapeutic benefit in vivo. These data demonstrate that fine control of gene expression relies on the balance between kinase and phosphatase activity throughout the transcription cycle, a process dysregulated in cancer that can be exploited therapeutically.	[Vervoort, Stephin J.; Devlin, Jennifer R.; Knight, Deborah A.; Bjelosevic, Stefan; Costacurta, Matteo; Todorovski, Izabela; Kearney, Conor J.; Fan, Zheng; Blyth, Benjamin; McLeod, Victoria; Vissers, Joseph H. A.; Martin, Ben P.; Gregory, Gareth; Demosthenous, Elena; Zethoven, Magnus; Hogg, Simon J.; Kelly, Madison J.; Newbold, Andrea; Simpson, Kaylene J.; Harvey, Kieran F.; Johnstone, Ricky W.] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia; [Vervoort, Stephin J.; Devlin, Jennifer R.; Knight, Deborah A.; Bjelosevic, Stefan; Costacurta, Matteo; Todorovski, Izabela; Kearney, Conor J.; Fan, Zheng; Vissers, Joseph H. A.; Martin, Ben P.; Gregory, Gareth; Hogg, Simon J.; Kelly, Madison J.; Newbold, Andrea; Harvey, Kieran F.; Johnstone, Ricky W.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3010, Australia; [Welsh, Sarah A.; Barbieri, Elisa; Offley, Sarah; Gardini, Alessandro] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Welsh, Sarah A.] Univ Penn, Perelman Sch Med, Biochem & Mol Biophys Grad Grp, Philadelphia, PA 19104 USA; [Offley, Sarah] Univ Penn, Perelman Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; [Sandow, Jarrod J.; Kong, Isabella Y.; Hawkins, Edwin D.] Walter & Eliza Hall Inst Med Res, Parkville, Vic 3010, Australia; [Vissers, Joseph H. A.] Univ Melbourne, Ctr Canc Res, Parkville, Vic 3010, Australia; [Vissers, Joseph H. A.] Univ Melbourne, Dept Clin Pathol, Parkville, Vic 3010, Australia; [Pavic, Karolina; Kauko, Otto; Westermarck, Jukka] Univ Turku, Turku Biosci Ctr, FI-20014 Turku, Finland; [Pavic, Karolina; Kauko, Otto; Westermarck, Jukka] Abo Akad Univ, FI-20014 Turku, Finland; [Pavic, Karolina; Kauko, Otto; Westermarck, Jukka] Univ Turku, Inst Biomed, FI-20014 Turku, Finland; [Gregory, Gareth] Monash Univ, Sch Clin Sci Monash Hlth, Clayton, Vic 3168, Australia; [Harvey, Kieran F.] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic 3168, Australia; [Harvey, Kieran F.] Monash Univ, Biomed Discovery Inst, Clayton, Vic 3168, Australia; [Ohlmeyer, Michael] Mt Sinai Sch Med, New York, NY 10029 USA; [Ohlmeyer, Michael] Atux Iskay LLC, Plainsboro, NJ 08536 USA; [Gray, Nathanael] Dana Farber Canc Inst, Boston, MA 02215 USA; [Sandow, Jarrod J.; Kong, Isabella Y.; Hawkins, Edwin D.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; The Wistar Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Walter & Eliza Hall Institute; University of Melbourne; University of Melbourne; University of Turku; Abo Akademi University; University of Turku; Monash University; Monash University; Monash University; Icahn School of Medicine at Mount Sinai; Harvard University; Dana-Farber Cancer Institute; University of Melbourne	Vervoort, SJ; Johnstone, RW (corresponding author), Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia.; Vervoort, SJ; Johnstone, RW (corresponding author), Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3010, Australia.; Gardini, A (corresponding author), Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.	stephin-vervoort@petermac.org; agardini@wistar.org; ricky.johnstone@petermac.org	Westermarck, Jukka/AAL-6464-2020; Costacurta, Matteo/GYA-2599-2022; Hogg, Simon/AFL-2783-2022; Harvey, Kieran/AAD-5268-2022; Vervoort, Stephin/AAP-7854-2020; Costacurta, Matteo/AAB-8004-2022; Johnstone, Ricky/H-3748-2014	Westermarck, Jukka/0000-0001-7478-3018; Johnstone, Ricky/0000-0001-7053-9237; WELSH, SARAH A./0000-0003-2251-1111; Kong, Isabella/0000-0002-7480-4525; Devlin, Jennifer/0000-0002-2933-6240; Offley, Sarah/0000-0002-4902-333X; Bjelosevic, Stefan/0000-0002-3012-9273; Costacurta, Matteo/0000-0003-4605-7427; Vervoort, Stephin/0000-0001-7459-126X; Blyth, Benjamin/0000-0003-4754-6249	Cancer Council Victoria; National Health and Medical Research Council of Australia (NHMRC); The Kids' Cancer Project; American Cancer Society [RSG18-157-01-DMC]; G. Harold & Leila Y. Mathers Foundation; NIH [R01 HL141326, T32-GM071339]; Emerson Collective Cancer Research Fund; Ovarian Cancer Research Alliance; Rubicon fellowship (NWO) [019.161LW.017]; NHMRC EL1 fellowship [GNT1178339]; Kids' Cancer Project; Early Career Seed Grant from the Victorian Cancer Agency (VCA); Cancer Council of Victoria (CCV); NHMRC [APP1078220]; Academy of Finland [294850]; Finnish Cancer Foundation; Finnish Cultural Foundation; Australian Cancer Research Foundation (ACRF); University of Melbourne Collaborative Research Infrastructure Program; PMCC Foundation	Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); The Kids' Cancer Project; American Cancer Society(American Cancer Society); G. Harold & Leila Y. Mathers Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emerson Collective Cancer Research Fund; Ovarian Cancer Research Alliance; Rubicon fellowship (NWO); NHMRC EL1 fellowship(National Health and Medical Research Council (NHMRC) of Australia); Kids' Cancer Project; Early Career Seed Grant from the Victorian Cancer Agency (VCA); Cancer Council of Victoria (CCV)(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Academy of Finland(Academy of Finland); Finnish Cancer Foundation; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Australian Cancer Research Foundation (ACRF); University of Melbourne Collaborative Research Infrastructure Program; PMCC Foundation	We thank members of the Johnstone and Gardini laboratories, the Translational Research Laboratory, the Victorian Centre for Functional Genomics (VCFG), Molecular Genomics Core and the Flow Cytometry Core Facilities at the Peter MacCallum Cancer Center (PMCC), the Proteomics Facility at the Walter and Eliza Hall Institute, and the Genomics Core and the Proteomics Core at The Wistar Institute (P30-CA010815) for their technical expertise and for providing reagents. We thank Prof. Robert Fisher for providing phosphoSpt5 antibodies. Illustrations were made with BioRender.com. R.W.J. was supported by the Cancer Council Victoria, National Health and Medical Research Council of Australia (NHMRC) and The Kids' Cancer Project. The Gardini laboratory (A.G.) was supported the American Cancer Society (RSG18-157-01-DMC), the G. Harold & Leila Y. Mathers Foundation (A.G.), the NIH (R01 HL141326), the Emerson Collective Cancer Research Fund, and the Ovarian Cancer Research Alliance. S.J.V. was supported by a Rubicon fellowship (NWO, 019.161LW.017), NHMRC EL1 fellowship (GNT1178339), and The Kids' Cancer Project. S.A.W. was supported by a training grant from NIH (T32-GM071339). J.R.D. was supported by an Early Career Seed Grant from the Victorian Cancer Agency (VCA). S.J.H. was supported by a Postdoctoral Fellowship from the Cancer Council of Victoria (CCV). K.F.H. was supported by a NHMRC Senior Research Fellowship (APP1078220). J.W. and K.P. were supported by Academy of Finland (294850) and Finnish Cancer Foundation. K.P. was supported by Finnish Cultural Foundation. The VCFG ACRF Translational Reverse Phase Protein Array platform (K.J.S.) is funded by the Australian Cancer Research Foundation (ACRF), University of Melbourne Collaborative Research Infrastructure Program, and the PMCC Foundation. The PMCC Foundation and ACRF provide generous support for equipment and core facilities.	Adelman K, 2012, NAT REV GENET, V13, P720, DOI 10.1038/nrg3293; Akama-Garren EH, 2016, SCI REP-UK, V6, DOI 10.1038/srep16836; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Baillat D, 2005, CELL, V123, P265, DOI 10.1016/j.cell.2005.08.019; Baker A, 2016, CANCER RES, V76, P1158, DOI 10.1158/0008-5472.CAN-15-1070; Barbieri E, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108373; Barbieri E, 2018, MOL CELL, V71, P103, DOI 10.1016/j.molcel.2018.05.031; Bassett AR, 2014, BIOL OPEN, V3, P42, DOI 10.1242/bio.20137120; Beckedorff F, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107917; Bots M, 2014, BLOOD, V123, P1341, DOI 10.1182/blood-2013-03-488114; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Chen FX, 2018, NAT REV MOL CELL BIO, V19, P464, DOI 10.1038/s41580-018-0010-5; Chen FX, 2015, CELL, V162, P1003, DOI 10.1016/j.cell.2015.07.042; Chou J, 2020, CANCER DISCOV, V10, P351, DOI 10.1158/2159-8290.CD-19-0528; Cidado J, 2020, CLIN CANCER RES, V26, P922, DOI 10.1158/1078-0432.CCR-19-1853; Clark AR, 2019, PHARMACOL THERAPEUT, V201, P181, DOI 10.1016/j.pharmthera.2019.05.016; Core L, 2019, GENE DEV, V33, P960, DOI 10.1101/gad.325142.119; Cortazar MA, 2019, MOL CELL, V76, P896, DOI 10.1016/j.molcel.2019.09.031; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Eaton JD, 2020, GENE DEV, V34, P132, DOI 10.1101/gad.332833.119; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Egan B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166438; Elrod ND, 2019, MOL CELL, V76, P738, DOI 10.1016/j.molcel.2019.10.034; Filleur S, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-28; Fowle H, 2019, ADV CANCER RES, V144, P55, DOI 10.1016/bs.acr.2019.03.009; Fujinaga K, 2020, MOLECULES, V25, DOI 10.3390/molecules25040838; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gardini A, 2014, MOL CELL, V56, P128, DOI 10.1016/j.molcel.2014.08.004; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Grallert A, 2015, NATURE, V517, P94, DOI 10.1038/nature14019; Gregersen LH, 2019, CELL, V177, P1797, DOI 10.1016/j.cell.2019.04.038; Gregory GP, 2015, LEUKEMIA, V29, P1437, DOI 10.1038/leu.2015.10; Gressel S, 2017, ELIFE, V6, DOI 10.7554/eLife.29736; Haesen D, 2016, CANCER RES, V76, P5719, DOI 10.1158/0008-5472.CAN-15-3342; Hargreaves DC, 2009, CELL, V138, P129, DOI 10.1016/j.cell.2009.05.047; Hashiguchi T, 2019, MOL CANCER THER, V18, P1520, DOI 10.1158/1535-7163.MCT-18-1023; He LY, 2018, METHODS MOL BIOL, V1711, P351, DOI 10.1007/978-1-4939-7493-1_17; Huang KL, 2020, MOL CELL, V80, P345, DOI 10.1016/j.molcel.2020.08.016; Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jeronimo C, 2016, J MOL BIOL, V428, P2607, DOI 10.1016/j.jmb.2016.02.006; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Kastrinsky DB, 2015, BIOORGAN MED CHEM, V23, P6528, DOI 10.1016/j.bmc.2015.07.007; Kauko O, 2020, J BIOL CHEM, V295, P4194, DOI 10.1074/jbc.RA119.011265; Kauko O, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1093; Kearney CJ, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar3451; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lai F, 2015, NATURE, V525, P399, DOI 10.1038/nature14906; Laitem C, 2015, NAT STRUCT MOL BIOL, V22, P396, DOI 10.1038/nsmb.3000; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Leonard D, 2020, CELL, V181, P688, DOI 10.1016/j.cell.2020.03.038; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li H., 2013, ALIGNING SEQUENCE RE; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li J, 2015, HEMATOLOGY, V20, P377, DOI 10.1179/1607845414Y.0000000214; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Luo ZJ, 2012, NAT REV MOL CELL BIO, V13, P543, DOI 10.1038/nrm3417; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Martin RD, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093354; Mayer A, 2017, CURR OPIN CELL BIOL, V46, P72, DOI 10.1016/j.ceb.2017.03.002; Mayfield JE, 2016, BBA-PROTEINS PROTEOM, V1864, P372, DOI 10.1016/j.bbapap.2016.01.007; Merisaari J., 2020, MONOTHERAPY EFFICACY; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Morita K, 2020, CELL, V181, P702, DOI 10.1016/j.cell.2020.03.051; Orlando DA, 2014, CELL REP, V9, P1163, DOI 10.1016/j.celrep.2014.10.018; Parua PK, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18173-6; Parua PK, 2018, NATURE, V558, P460, DOI 10.1038/s41586-018-0214-z; Perrotti D, 2013, LANCET ONCOL, V14, pE229, DOI 10.1016/S1470-2045(12)70558-2; Phipson B, 2016, ANN APPL STAT, V10, P946, DOI 10.1214/16-AOAS920; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ramirez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Riemondy Kent A, 2017, F1000Res, V6, P1025, DOI 10.12688/f1000research.11997.1; Rienzo M, 2016, BBA-GENE REGUL MECH, V1859, P1269, DOI 10.1016/j.bbagrm.2016.07.008; Roeder RG, 2019, NAT STRUCT MOL BIOL, V26, P783, DOI 10.1038/s41594-019-0287-x; Ropke A, 2005, ONCOGENE, V24, P6667, DOI 10.1038/sj.onc.1208824; Rubtsova MP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38297-6; Sangodkar J, 2017, J CLIN INVEST, V127, P2081, DOI 10.1172/JCI89548; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sanso M, 2016, GENE DEV, V30, P117, DOI 10.1101/gad.269589.115; Sen I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13931-7; Shih IM, 2011, AM J PATHOL, V178, P1442, DOI 10.1016/j.ajpath.2011.01.009; Skaar JR, 2009, J CELL BIOL, V187, P25, DOI 10.1083/jcb.200907026; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tatomer DC, 2019, GENE DEV, V33, P1525, DOI 10.1101/gad.330167.119; Therneau T.M., 2018, PACKAGE SURVIVAL ANA; Vos SM, 2018, NATURE, V560, P607, DOI 10.1038/s41586-018-0440-4; Vos SM, 2018, NATURE, V560, P601, DOI 10.1038/s41586-018-0442-2; Westermarck J, 2020, CELL, V181, P514, DOI 10.1016/j.cell.2020.04.005; Wu TZ, 2020, J MED CHEM, V63, P13228, DOI 10.1021/acs.jmedchem.0c00744; Xu YW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15741; Yang L, 2017, METHODS MOL BIOL, V1487, P113, DOI 10.1007/978-1-4939-6424-6_8; Ye T, 2014, METHODS MOL BIOL, V1150, P141, DOI 10.1007/978-1-4939-0512-6_8; Ye T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1287; Yu M, 2015, SCIENCE, V350, P1383, DOI 10.1126/science.aad2338; Yue JY, 2020, GENE DEV, V34, P637, DOI 10.1101/gad.333864.119; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zheng H, 2020, SCIENCE, V370, P1059, DOI 10.1126/science.abb5872; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	107	27	27	9	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 10	2021	184	12					3143	+	e32	10.1016/j.cell.2021.04.022	http://dx.doi.org/10.1016/j.cell.2021.04.022		JUN 2021	52	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	SP9WV	34004147	Green Accepted, Bronze			2023-01-03	WOS:000660014300008
J	Zhu, Y; Sazer, D; Miller, JS; Warmflash, A				Zhu, Ye; Sazer, Daniel; Miller, Jordan S.; Warmflash, Aryeh			Rapid fabrication of hydrogel micropatterns by projection stereolithography for studying self-organized developmental patterning	PLOS ONE			English	Article							TOOL	Self-organized patterning of mammalian embryonic stem cells on micropatterned surfaces has previously been established as an in vitro platform for early mammalian developmental studies, complimentary to in vivo studies. Traditional micropatterning methods, such as micro-contact printing (mu CP), involve relatively complicated fabrication procedures, which restricts widespread adoption by biologists. Here, we demonstrate a rapid method of micropatterning by printing hydrogel micro-features onto a glass-bottomed culture vessel. The micro-features are printed using a projection stereolithography bioprinter yielding hydrogel structures that geometrically restrict the attachment of cells or proteins. Compared to traditional and physical photomasks, a digitally tunable virtual photomask is used in the projector to generate blue light patterns that enable rapid iteration with minimal cost and effort. We show that a protocol that makes use of this method together with LN521 coating, an extracellular matrix coating, creates a surface suitable for human embryonic stem cell (hESC) attachment and growth with minimal non-specific adhesion. We further demonstrate that self-patterning of hESCs following previously published gastrulation and ectodermal induction protocols achieves results comparable with those obtained with commercially available plates.	[Zhu, Ye; Sazer, Daniel; Miller, Jordan S.; Warmflash, Aryeh] Rice Univ, Dept Bioengn, Houston, TX 77005 USA; [Warmflash, Aryeh] Rice Univ, Dept Biosci, Houston, TX 77005 USA	Rice University; Rice University	Miller, JS; Warmflash, A (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77005 USA.; Warmflash, A (corresponding author), Rice Univ, Dept Biosci, Houston, TX 77005 USA.	jmil@rice.edu; aryeh.warmflash@rice.edu	Warmflash, Aryeh/Y-6763-2019	Warmflash, Aryeh/0000-0002-5679-2268; Sazer, Daniel/0000-0002-1057-4353	Rice University; Welch Foundation [C-2021]; NSF [MCB-1553228]; NIH [R01GM126122]; Simons Foundation [511079]; Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation; Gulf Coast Consortia on the NSF IGERT: Neuroengineering from Cells to Systems [1250104]	Rice University; Welch Foundation(The Welch Foundation); NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Simons Foundation; Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation; Gulf Coast Consortia on the NSF IGERT: Neuroengineering from Cells to Systems	This work was funded by Rice University and grants to AW from the Welch Foundation (C-2021), NSF (MCB-1553228), NIH (R01GM126122), and Simons Foundation (511079), and to DS and JM from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation, and a training fellowship to DS from the Gulf Coast Consortia on the NSF IGERT: Neuroengineering from Cells to Systems (#1250104). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Belisle JM, 2009, LAB CHIP, V9, P3580, DOI 10.1039/b911967a; Britton G, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.179093; Chhabra S, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000498; Deglincerti A, 2016, NAT PROTOC, V11, P2223, DOI 10.1038/nprot.2016.131; Etoc F, 2016, DEV CELL, V39, P302, DOI 10.1016/j.devcel.2016.09.016; Fairbanks BD, 2009, BIOMATERIALS, V30, P6702, DOI 10.1016/j.biomaterials.2009.08.055; Fink J, 2007, LAB CHIP, V7, P672, DOI 10.1039/b618545b; Grigoryan B., 2021, SCI REP-UK, V11, P1, DOI DOI 10.1038/S41598-021-82102-W; Grigoryan B, 2019, SCIENCE, V364, P458, DOI 10.1126/science.aav9750; Heemskerk I, 2019, ELIFE, V8, DOI 10.7554/eLife.40526; Itoga K, 2006, BIOMATERIALS, V27, P3005, DOI 10.1016/j.biomaterials.2005.12.023; Klaffky E, 2001, DEV BIOL, V239, P161, DOI 10.1006/dbio.2001.0404; Manfrin A, 2019, NAT METHODS, V16, P640, DOI 10.1038/s41592-019-0455-2; Martyn I, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.172791; Miller JS, 2010, BIOMATERIALS, V31, P3736, DOI 10.1016/j.biomaterials.2010.01.058; Morgani SM, 2018, ELIFE, V7, DOI 10.7554/eLife.32839; Nemashkalo A, 2017, DEVELOPMENT, V144, P3042, DOI 10.1242/dev.153239; Peerani R, 2007, EMBO J, V26, P4744, DOI 10.1038/sj.emboj.7601896; Revzin A, 2001, LANGMUIR, V17, P5440, DOI 10.1021/la010075w; Rodin S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4195; Ruiz SA, 2007, SOFT MATTER, V3, P168, DOI 10.1039/b613349e; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Sommer C, 2011, I S BIOMED IMAGING, P230, DOI 10.1109/ISBI.2011.5872394; Tewary M, 2017, DEVELOPMENT, V144, P4298, DOI 10.1242/dev.149658; Thery M, 2010, J CELL SCI, V123, P4201, DOI 10.1242/jcs.075150; Warmflash A, 2014, NAT METHODS, V11, P847, DOI [10.1038/NMETH.3016, 10.1038/nmeth.3016]; Yang WG, 2015, MICROMACHINES-BASEL, V6, P1903, DOI 10.3390/mi6121464	27	0	0	6	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2021	16	6							e0245634	10.1371/journal.pone.0245634	http://dx.doi.org/10.1371/journal.pone.0245634			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6QL	34077425	Green Published, Green Submitted, gold			2023-01-03	WOS:000664638500001
J	Romero-Brufau, S; Chopra, A; Ryu, AJ; Gel, E; Raskar, R; Kremers, W; Anderson, KS; Subramanian, J; Krishnamurthy, B; Singh, A; Pasupathy, K; Dong, Y; O'Horo, JC; Wilson, WR; Mitchell, O; Kingsley, TC				Romero-Brufau, Santiago; Chopra, Ayush; Ryu, Alex J.; Gel, Esma; Raskar, Ramesh; Kremers, Walter; Anderson, Karen S.; Subramanian, Jayakumar; Krishnamurthy, Balaji; Singh, Abhishek; Pasupathy, Kalyan; Dong, Yue; O'Horo, John C.; Wilson, Walter R.; Mitchell, Oscar; Kingsley, Thomas C.			Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To estimate population health outcomes with delayed second dose versus standard schedule of SARS-CoV-2 mRNA vaccination. DEsIGN Simulation agent based modeling study. SETTING Simulated population based on real world US county. PARTICIPANTs The simulation included 100 000 agents, with a representative distribution of demographics and occupations. Networks of contacts were established to simulate potentially infectious interactions though occupation, household, and random interactions. INTERVENTIONs Simulation of standard covid-19 vaccination versus delayed second dose vaccination prioritizing the first dose. The simulation runs were replicated 10 times. Sensitivity analyses included first dose vaccine efficacy of 50%, 60%, 70%, 80%, and 90% after day 12 post-vaccination; vaccination rate of 0.1%, 0.3%, and 1% of population per day; assuming the vaccine prevents only symptoms but not asymptomatic spread (that is, non-sterilizing vaccine); and an alternative vaccination strategy that implements delayed second dose for people under 65 years of age, but not until all those above this age have been vaccinated. MAIN OUTCOME MEAsUREs Cumulative covid-19 mortality, cumulative SARS-CoV-2 infections, and cumulative hospital admissions due to covid-19 over 180 days. REsULTs Over all simulation replications, the median cumulative mortality per 100 000 for standard dosing versus delayed second dose was 226 v 179, 233 v 207, and 235 v 236 for 90%, 80%, and 70% first dose efficacy, respectively. The delayed second dose strategy was optimal for vaccine efficacies at or above 80% and vaccination rates at or below 0.3% of the population per day, under both sterilizing and non sterilizing vaccine assumptions, resulting in absolute cumulative mortality reductions between 26 and 47 per 100 000. The delayed second dose strategy for people under 65 performed consistently well under all vaccination rates tested. CONCLUsIONs A delayed second dose vaccination strategy, at least for people aged under 65, could result in reduced cumulative mortality under certain conditions.	[Romero-Brufau, Santiago; Ryu, Alex J.; O'Horo, John C.; Wilson, Walter R.; Kingsley, Thomas C.] Mayo Clin, Dept Med, Rochester, MN 55902 USA; [Romero-Brufau, Santiago] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Chopra, Ayush; Raskar, Ramesh; Singh, Abhishek] MIT, Media Lab, Cambridge, MA 02139 USA; [Gel, Esma; Anderson, Karen S.] Arizona State Univ, Sch Life Sci, Phoenix, AZ USA; [Kremers, Walter; Pasupathy, Kalyan] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; [Subramanian, Jayakumar; Krishnamurthy, Balaji] Adobe Inc Noidia, Media & Data Sci Res Lab, Noida, UP, India; [Dong, Yue] Mayo Clin, Dept Anesthesiol & Perioperat Med, Rochester, MN USA; [Mitchell, Oscar] Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Mayo Clinic; Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts Institute of Technology (MIT); Arizona State University; Arizona State University-Downtown Phoenix; Mayo Clinic; Mayo Clinic; University of Pennsylvania	Kingsley, TC (corresponding author), Mayo Clin, Dept Med, Rochester, MN 55902 USA.	Kingsley.Thomas@mayo.edu	O'Horo, John C/N-8681-2013; Romero-Brufau, Santiago/I-4758-2015	O'Horo, John C/0000-0002-0880-4498; Romero-Brufau, Santiago/0000-0002-9922-0083; Chopra, Ayush/0000-0002-4070-4139; Krishnamurthy, Balaji/0000-0002-0366-2427; Gel, Esma/0000-0003-0472-4762; Subramanian, Jayakumar/0000-0003-4621-2677				Abueg M, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00422-7; Aguerre IM, 2019, DISABIL REHABIL, V41, P2538, DOI 10.1080/09638288.2018.1471741; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMclde2101987; [Anonymous], 2021, NATURE, V589, P169, DOI 10.1038/d41586-021-00045-8; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baric RS, 2020, NEW ENGL J MED, V383, P2684, DOI 10.1056/NEJMcibr2032888; Bonanad C, 2020, J AM MED DIR ASSOC, V21, P915, DOI 10.1016/j.jamda.2020.05.045; Centers for Disease Control and Prevention, 2021, COVID 19 VACCINATION; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936; Holder J., 2021, TRACKING CORONAVIRUS; Iacobucci Gareth, 2021, BMJ, V372, pn18, DOI 10.1136/bmj.n18; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Koh HK, 2021, JAMA-J AM MED ASSOC, V325, P133, DOI 10.1001/jama.2020.25381; Lee K, 2009, GLOB INST, P1; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n158; Moghadas SM, 2021, MEDRXIV, V2021; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Our World in Data, 2021, DAIL COVID 19 VACC D; Paltiel AD, 2021, HEALTH AFFAIR, V40, P42, DOI 10.1377/hlthaff.2020.02054; Pfizer, 2021, PFIZER BIONTECH CONF; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Post N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244126; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; So AD, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4750; Stokel-Walker C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n99; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Tuite AR, 2021, ANN INTERN MED, V174, P570, DOI 10.7326/M20-8137; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1	33	29	29	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 12	2021	373								n1087	10.1136/bmj.n1087	http://dx.doi.org/10.1136/bmj.n1087			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SF9GP	33980718	Green Published, hybrid			2023-01-03	WOS:000653055200001
J	Skripchenko, A; Gelderman, MP; Vostal, JG				Skripchenko, Andrey; Gelderman, Monique P.; Vostal, Jaroslav G.			P38 mitogen activated protein kinase inhibitor improves platelet in vitro parameters and in vivo survival in a SCID mouse model of transfusion for platelets stored at cold or temperature cycled conditions for 14 days	PLOS ONE			English	Article							4 DEGREES-C; RHEUMATOID-ARTHRITIS; STORAGE; CLEARANCE; VIABILITY; RECOVERY; 4-DEGREES-C; MECHANISMS; APOPTOSIS; BINDING	Platelets for transfusion are stored at room temperature (20-24 degrees C) up to 7 days but decline in biochemical and morphological parameters during storage and can support bacterial proliferation. This decline is reduced with p38MAPK inhibitor, VX-702. Storage of platelets in the cold (4-6 degrees C) can reduce bacterial proliferation but platelets get activated and have reduced circulation when transfused. Thermocycling (cold storage with brief periodic warm ups) reduces some of the effects of cold storage. We evaluated in vitro properties and in vivo circulation in SCID mouse model of human platelet transfusion of platelets stored in cold or thermocycled for 14 days with and without VX-702. Apheresis platelet units (N = 15) were each aliquoted into five storage bags and stored under different conditions: room temperature; cold temperature; thermocycled temperature; cold temperature with VX-702; thermocycled temperature with VX-702. Platelet in vitro parameters were evaluated at 1, 7 and 14 days. On day 14, platelets were infused into SCID mice to assess their retention in circulation by flow cytometry. VX-702 reduced negative platelet parameters associated with cold and thermocycled storage such as an increase in expression of activation markers CD62, CD63 and of phosphatidylserine (marker of apoptosis measured by Annexin binding) and lowered the rise in lactate (marker of increase in anaerobic metabolism). However, VX-702 did not inhibit agonist-induced platelet aggregation indicating that it does not interfere with platelet hemostatic function. In vivo, VX-702 improved initial recovery and area under the curve in circulation of human platelets infused into a mouse model that has been previously validated against a human platelet infusion clinical trial. In conclusion, inhibition of p38MAPK during 14-days platelet storage in cold or thermocycling conditions improved in vitro platelet parameters and platelet circulation in the mouse model indicating that VX-702 may improve cell physiology and clinical performance of human platelets stored in cold conditions.	[Skripchenko, Andrey; Gelderman, Monique P.; Vostal, Jaroslav G.] US FDA, Div Blood Components & Devices, Lab Cellular Hematol, Off Blood Res & Review,Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA	US Food & Drug Administration (FDA)	Vostal, JG (corresponding author), US FDA, Div Blood Components & Devices, Lab Cellular Hematol, Off Blood Res & Review,Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA.	Jaroslav.Vostal@fda.hhs.gov			U.S. Food and Drug Administration, CBER	U.S. Food and Drug Administration, CBER	U.S. Food and Drug Administration, CBER Internal funding.	[Anonymous], 2019, BLOOD PROD ADV COMM; Baker JM, 2001, PLATELETS, V12, P333; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Bynum JA, 2016, TRANSFUSION, V56, pS76, DOI 10.1111/trf.13337; Cap AP, 2012, J TRAUMA ACUTE CARE, V73, pS89, DOI 10.1097/TA.0b013e318260625a; Chen WC, 2017, ARTERIOSCL THROM VAS, V37, P2271, DOI 10.1161/ATVBAHA.117.310062; Colkesen Y, 2012, CLIN CHEM LAB MED, V50, P631, DOI 10.1515/CCLM.2011.806; Connor J, 1996, TRANSFUSION, V36, P691, DOI 10.1046/j.1537-2995.1996.36896374372.x; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; D'Alessandro A, 2020, TRANSFUSION, V60, pS96, DOI 10.1111/trf.15651; Damarla M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004600; Damjanov N, 2009, ARTHRITIS RHEUM-US, V60, P1232, DOI 10.1002/art.24485; Deng W, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12863; Ding CH, 2006, CURR OPIN INVEST DR, V7, P1020; Gelderman MP, 2020, TRANSFUSION, V60, P2379, DOI 10.1111/trf.15953; Getz TM, 2019, TRANSFUS APHER SCI, V58, P12, DOI 10.1016/j.transci.2018.12.011; GHIGO D, 1988, BIOMED BIOCHIM ACTA, V47, pS299; Goldstein DM, 2010, J MED CHEM, V53, P2345, DOI [10.1021/jm9012906, 10.1021/acs.jmedchem.8b00124]; Gordi T, 2004, CLIN THER, V26, P780, DOI 10.1016/S0149-2918(04)90078-1; Handigund M, 2016, TRANSFUS APHER SCI, V54, P127, DOI 10.1016/j.transci.2016.01.006; Hoffmeister KM, 2003, CELL, V112, P87, DOI 10.1016/S0092-8674(02)01253-9; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; HOLME S, 1978, BLOOD, V52, P425; Jackson SP, 2010, BLOOD, V116, P2011, DOI 10.1182/blood-2010-01-261669; Ketter PM, 2019, TRANSFUSION, V59, P1479, DOI 10.1111/trf.15255; Kuliopulos A, 2004, THROMB HAEMOSTASIS, V92, P1387, DOI 10.1160/TH04-03-0187; KUNICKI TJ, 1975, TRANSFUSION, V15, P414, DOI 10.1046/j.1537-2995.1975.15576082215.x; Lafrenie RM, 1996, J CELL BIOCHEM, V61, P543, DOI 10.1002/(SICI)1097-4644(19960616)61:4<543::AID-JCB7>3.0.CO;2-O; Lee MR, 2005, CURR MED CHEM, V12, P2979, DOI 10.2174/092986705774462914; LEVIN RH, 1964, TRANSFUSION, V4, P251, DOI 10.1111/j.1537-2995.1964.tb02867.x; MURPHY S, 1969, NEW ENGL J MED, V280, P1094, DOI 10.1056/NEJM196905152802004; Ng MSY, 2018, TRANSFUS MED REV, V32, P144, DOI 10.1016/j.tmrv.2018.04.001; Okada T, 2005, AM J PHYSIOL-HEART C, V289, pH2310, DOI 10.1152/ajpheart.00462.2005; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Petzold T, 2013, BLOOD, V122, P2723, DOI 10.1182/blood-2013-06-508721; Pidcoke HF, 2014, SHOCK, V41, P51, DOI 10.1097/SHK.0000000000000078; Piper JT, 2007, TRANSFUSION, V47, P1540, DOI 10.1111/j.1537-2995.2007.01295.x; Quach ME, 2018, BLOOD, V131, P1512, DOI 10.1182/blood-2017-08-743229; Ravi S, 2015, BBA-MOL BASIS DIS, V1852, P2525, DOI 10.1016/j.bbadis.2015.08.026; Reddoch KM, 2016, SHOCK, V45, P220, DOI 10.1097/SHK.0000000000000493; Reddoch KM, 2014, SHOCK, V41, P54, DOI 10.1097/SHK.0000000000000082; Reddoch-Cardenas KM, 2019, TRANSFUS APHER SCI, V58, P16, DOI 10.1016/j.transci.2018.12.012; Reddoch-Cardenas KM, 2019, TRANSFUSION, V59, P1789, DOI 10.1111/trf.15150; Reddoch-Cardenas KM, 2018, TRANSFUSION, V58, P1682, DOI 10.1111/trf.14603; Rumjantseva V, 2009, NAT MED, V15, P1273, DOI 10.1038/nm.2030; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cb.11.110195.003001; Skripchenko A, 2014, VOX SANG, V107, P360, DOI 10.1111/vox.12174; Skripchenko A, 2016, TRANSFUSION, V56, P24, DOI 10.1111/trf.13273; Skripchenko A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070732; Sorensen AL, 2009, BLOOD, V114, P1645, DOI 10.1182/blood-2009-01-199414; Stolla M, 2018, TRANSFUSION, V58, P2407, DOI 10.1111/trf.14833; van der Wal DE, 2010, J THROMB HAEMOST, V8, P2554, DOI 10.1111/j.1538-7836.2010.04043.x; Vostal JG, 2018, TRANSFUSION, V58, P25, DOI 10.1111/trf.14392; Wagner SJ, 2015, VOX SANG, V108, P226, DOI 10.1111/vox.12221; Wood B, 2016, TRANSFUSION, V56, P2548, DOI 10.1111/trf.13723; Wrobleski ST, 2005, CURR TOP MED CHEM, V5, P1005, DOI 10.2174/1568026054985894	56	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2021	16	5							e0250120	10.1371/journal.pone.0250120	http://dx.doi.org/10.1371/journal.pone.0250120			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6LY	33974660	gold, Green Published			2023-01-03	WOS:000664626600009
J	Pischel, L; Walelo, M; Benson, J; Osborn, R; Schrier, R; Tuan, J; Barakat, L; Ogbuagu, O				Pischel, Lauren; Walelo, Makeda; Benson, Jemma; Osborn, Rebecca; Schrier, Rachel; Tuan, Jessica; Barakat, Lydia; Ogbuagu, Onyema			Race and ethnicity do not impact eligibility for remdesivir: A single-center experience	PLOS ONE			English	Article							INEQUALITIES	As the Coronavirus-2019 (COVID-19) pandemic continues, multiple therapies are rapidly being evaluated for efficacy in clinical trials. Clinical trials should be racially and ethnically representative of the population that will eventually benefit from these medications. There are multiple potential barriers to racial and ethnic minority enrollment in clinical trials, one of which could be that inclusion and exclusion criteria select for certain racial or ethnic groups disproportionately. In this observational cohort study at a single health care system, we examined if there were differences in eligibility for treatment with remdesivir based on clinical trial criteria for racial and ethnic minorities compared to non-Hispanic Whites. 201 electronic medical record charts were reviewed manually. Self-identified Whites were older than other racial or ethnic groups. At the time of presentation, Black, Latinx, and White participants met inclusion criteria for remdesivir at similar rates (72%, 80%, and 73% respectively), and exclusion criteria at similar rates (43%, 38% and 49% for Black, Latinx and White participants respectively). In this study, there was no difference in eligibility for remdesivir based on race or ethnicity alone.	[Pischel, Lauren; Tuan, Jessica; Barakat, Lydia; Ogbuagu, Onyema] Yale Sch Med, Sect Infect Dis, Dept Med, New Haven, CT 06510 USA; [Pischel, Lauren] Yale Sch Publ Hlth, New Haven, CT 06510 USA; [Pischel, Lauren] Yale Inst Global Hlth, New Haven, CT 06520 USA; [Walelo, Makeda] Independence Blue Cross, Philadelphia, PA USA; [Benson, Jemma; Osborn, Rebecca; Schrier, Rachel] Yale Sch Med, Dept Med, New Haven, CT USA	Yale University; Yale University; Yale University	Pischel, L (corresponding author), Yale Sch Med, Sect Infect Dis, Dept Med, New Haven, CT 06510 USA.; Pischel, L (corresponding author), Yale Sch Publ Hlth, New Haven, CT 06510 USA.; Pischel, L (corresponding author), Yale Inst Global Hlth, New Haven, CT 06520 USA.	Lauren.pischel@yale.edu		Pischel, Lauren/0000-0002-7697-0084; Osborn, Rebecca/0000-0002-4524-3968				[Anonymous], 2020, REV BSH 100 LARGEST; Arcaya MC, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.27106; Bambra C, 2020, J EPIDEMIOL COMMUN H, V74, P964, DOI 10.1136/jech-2020-214401; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bertolini A, 2020, HEPATOLOGY, V72, P1864, DOI 10.1002/hep.31480; Bureau USC, QUICKFACTS NEW HAV C; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Chastain DB, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2021971; Egede LE, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2023616; El-Serag H, 2010, J FAM PRACTICE, V59, pS37; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Luke DR, 2010, J PHARM SCI-US, V99, P3291, DOI 10.1002/jps.22109; OJR A., 2020, NEW YORK TIMES; Pharmaceuticals G., 2020, PHARMACEUTICALS G RE; Prevention CfDCa, 2020, NAT DIAB STAT REP 20; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Rachel Garfield MR., 2020, DOUBLE JEOPARDY LOW; Rogers TN, 2020, WORLD MED HEALTH POL, V12, P311, DOI 10.1002/wmh3.358; Ruth Petersen LP, 2019, RACIAL ETHNIC DISPAR, P16; Sapey E, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000644; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X; Washington H. A., 2006, DOUBLEDAY; Yancey AK, 2006, ANNU REV PUBL HEALTH, V27, P1, DOI 10.1146/annurev.publhealth.27.021405.102113; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017	25	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2021	16	5							e0250735	10.1371/journal.pone.0250735	http://dx.doi.org/10.1371/journal.pone.0250735			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6GE	33956849	Green Submitted, Green Published, gold			2023-01-03	WOS:000664611400038
J	Addila, AE; Azale, T; Gete, YK; Yitayal, M				Addila, Alemu Earsido; Azale, Telake; Gete, Yigzaw Kebede; Yitayal, Mezgebu			Determinants of hazardous alcohol use among pregnant women attending antenatal care at public health facilities in Gondar town, Northwest Ethiopia: A nested case-control study	PLOS ONE			English	Article							SOUTHERN ETHIOPIA; SOCIAL SUPPORT; BINGE DRINKING; CONSUMPTION; OUTCOMES; RISK; CONCEPTION; DISORDERS; KNOWLEDGE; ATTITUDES	Background Alcohol use during pregnancy has a potential negative impact on the health of women and children. Binge or hazardous drinking may do greater alcohol-related damage to the developing fetus than drinking a comparable amount spread over several days or weeks. This study aimed to identify determinants of hazardous alcohol use among pregnant women attending antenatal care at Gondar town public health facilities, Northwest Ethiopia. Methods An unmatched facility-based nested case-control study was carried out to identify the determinants of hazardous alcohol use among pregnant women within a prospective cohort study from 29 October 2019 to 7 May 2020. A two-stage random sampling technique was used to select 455 (113 cases and 342 controls) pregnant women. Data collection was performed using the AUDIT-C standardized and pretested questionnaire. Bivariable and multivariable logistic regression analyses were computed to identify the predictors of alcohol consumption using the odds ratio, 95% CI, and p-value < 0.05. Results Multivariable logistic regression model revealed that no formal education of the husbands [AOR = 2.79; 95%CI: 1.24, 6.29], being housewife[AOR = 2.43; 95%CI: 1.12, 5.26], poor household wealth index[AOR = 2.65; 95%CI: 1.07, 6.54], unplanned pregnancy [AOR = 4.36;95%CI: 2.44, 7.79], poor social support [AOR = 4.9;95%CI: 2.4, 10.04], depression[AOR = 3.84;95%CI: 2.16, 6.82], and not ever heard the risk of alcohol drinking during pregnancy [AOR = 1.97; 95%CI: 1.08, 3.58] were significantly associated with hazardous alcohol use. Conclusions Routine alcohol screening during ANC visits creates an appropriate referral system for clinical management and provides an opportunity for healthcare workers to offer information on the potential risks associated with alcohol use in pregnancy. Antenatal care providers have a special role to play in assuring that women receive adequate advice about alcohol use and care to manage the problems especially for pregnant women with depression, poor social support, unplanned pregnancy, low socioeconomic status, and for housewives during the antenatal visits. The warning marks on alcoholic beverages including an ongoing message about the risks of alcohol use during pregnancy could be public health good strategies to minimize preventable harms attributed to alcohol consumption during pregnancy.	[Addila, Alemu Earsido] Wachemo Univ, Dept Publ Hlth, Coll Med & Hlth Sci, Hossana, Ethiopia; [Addila, Alemu Earsido; Gete, Yigzaw Kebede] Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Gondar, Ethiopia; [Azale, Telake] Univ Gondar, Inst Publ Hlth, Dept Hlth Educ & Behav Sci, Coll Med & Hlth Sci, Gondar, Ethiopia; [Yitayal, Mezgebu] Univ Gondar, Inst Publ Hlth, Dept Hlth Syst & Policy, Coll Med & Hlth Sci, Gondar, Ethiopia	University of Gondar; University of Gondar; University of Gondar	Addila, AE (corresponding author), Wachemo Univ, Dept Publ Hlth, Coll Med & Hlth Sci, Hossana, Ethiopia.; Addila, AE (corresponding author), Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Gondar, Ethiopia.	alexisersid@gmail.com		Yitayal, Mezgebu/0000-0002-9206-9528	University of Gondar; Wachemo University	University of Gondar; Wachemo University	This study is supported by the University of Gondar and Wachemo University. The Universities are following whether findings are presented and published. The universities have no role in the design, data collection, analysis, and interpretation of the data and in writing the manuscript. All the statements and findings are the responsibility of the investigators.	Addila AE, INDIVIDUAL COMMUNITY; Addila AE, EFFECTS MATERNAL ALC; Addila AE, 2020, SUBST ABUSE TREAT PR, V15, DOI 10.1186/s13011-020-00269-3; AddisBiz, 2020, ALC SUPPL CO BUS ETH; Alemayehu M, 2017, INT J WOMENS HEALTH, V9, P213, DOI 10.2147/IJWH.S131139; [Anonymous], 2018, TOT POP GOND TOWN, DOI [10.1186/s12199-018-0745-9, DOI 10.1186/S12199-018-0745-9]; [Anonymous], 2000, INT GUID MON ALC CON; Anteab K, 2014, ASSESSMENT PREVALENC, V2014; Ayele TA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155125; Babor TF, 2011, ALCOHOL USE DISORDER; Backhausen MG, 2014, EUR J CONTRACEP REPR, V19, P57, DOI 10.3109/13625187.2013.851183; Bailey BN, 2004, AM J OBSTET GYNECOL, V191, P1037, DOI 10.1016/j.ajog.2004.05.048; Banke-Thomas OE, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1246-3; Barthelemy T-U, 2011, OPEN J OBSTET GYNECO, V1, P208, DOI DOI 10.4236/ojog.2011.14040; Lopez MB, 2017, REV BRAS GINECOL OBS, V39, P322, DOI 10.1055/s-0037-1603744; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Centers for Disease Control and Prevention, 2016, WHAT IS SPIN BIF; Chaibva CN, 2011, MIDWIFERY, V27, pE201, DOI 10.1016/j.midw.2010.07.009; Chang G, 2006, J STUD ALCOHOL, V67, P245, DOI 10.15288/jsa.2006.67.245; Connery HS, 2014, OBSTET GYN CLIN N AM, V41, P191, DOI 10.1016/j.ogc.2014.02.011; Craney T. A., 2002, Quality Engineering, V14, P391, DOI 10.1081/QEN-120001878; Dalgard OS, 2006, SOC PSYCH PSYCH EPID, V41, P444, DOI 10.1007/s00127-006-0051-5; Davies S., 2016, SUMMARY PROPOSED NEW; Dibaba Y, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-135; Duko B, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0685-x; Elek E, 2013, AM J HEALTH EDUC, V44, P177, DOI 10.1080/19325037.2013.768906; Fekadu A., 2007, AFR J DRUG ALCOHOL S, V6, P40; Flak AL, 2014, ALCOHOL CLIN EXP RES, V38, P214, DOI 10.1111/acer.12214; Fletcher OV, 2018, SOC SCI MED, V215, P98, DOI 10.1016/j.socscimed.2018.09.008; Getachew Tafere, 2015, Journal of Natural Sciences Research, V5, P94; Getinet Wondale, 2018, Depress Res Treat, V2018, P3649269, DOI 10.1155/2018/3649269; Gray R, 2009, ADDICTION, V104, P1270, DOI 10.1111/j.1360-0443.2008.02441.x; Health AGDo: Australian Government Department of Health, AUSTR GUID RED HLTH; Health UDo Services H, 2004, NIAAA NEWSL; Henderson J, 2007, BJOG-INT J OBSTET GY, V114, P243, DOI 10.1111/j.1471-0528.2006.01163.x; Henriksen TB, 2004, AM J EPIDEMIOL, V160, P661, DOI 10.1093/aje/kwh259; Iversen ML, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0757-z; Kesmodel U, 2002, ALCOHOL CLIN EXP RES, V26, P1553, DOI 10.1097/01.ALC.0000034702.14322.25; Kesmodel U, 2001, AM J EPIDEMIOL, V154, P777, DOI 10.1093/aje/154.8.777; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Lee Mooha, 2015, Journal of Ethnic Foods, V2, P110; Leis JA, 2012, MATERN CHILD HLTH J, V16, P1304, DOI 10.1007/s10995-011-0892-8; Mboane R, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0010-2; Medhin G, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-27; Mekuriaw B, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4703-4; Muggli E, 2017, JAMA PEDIATR, V171, P771, DOI 10.1001/jamapediatrics.2017.0778; Myers B, 2018, ALCOHOL CLIN EXP RES, V42, P369, DOI 10.1111/acer.13566; Namagembe I, 2010, MATERN CHILD HLTH J, V14, P492, DOI 10.1007/s10995-009-0500-3; O'Leary CM, 2012, DRUG ALCOHOL REV, V31, P170, DOI 10.1111/j.1465-3362.2011.00331.x; Organization WH, 2019, IGI GLOBAL; Organization WH, 2000, INT GUID MON ALC CON; Patra J, 2011, BJOG-INT J OBSTET GY, V118, P1411, DOI 10.1111/j.1471-0528.2011.03050.x; Patra J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-258; Peadon E, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-510; Phaswana-Mafuya N, 2009, J PSYCHOL AFR, V19, P379, DOI 10.1080/14330237.2009.10820305; Raymond N, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-175; Smith L, 2014, MIDWIFERY, V30, P1173, DOI 10.1016/j.midw.2014.04.002; Strandberg-Larsen K, 2008, EUR J EPIDEMIOL, V23, P565, DOI 10.1007/s10654-008-9265-z; Teferra S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2911-6; Tekelab T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214848; Teshome D. A., 2017, African Journal of Food Science, V11, P234; Webster J, 2000, BIRTH-ISS PERINAT C, V27, P97, DOI 10.1046/j.1523-536x.2000.00097.x; Wilsnack SC, 2013, ALCOHOL RES-CURR REV, V35, P219; World Health Organization, GLOB STAT REP ALC HL; Wubetu AD, 2019, BMC PSYCHIATRY, V19, DOI 10.1186/s12888-019-2225-1	65	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	7							e0253162	10.1371/journal.pone.0253162	http://dx.doi.org/10.1371/journal.pone.0253162			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TC7AG	34197507	Green Published, gold			2023-01-03	WOS:000668791400049
J	Anbesaw, T; Negash, A; Mamaru, A; Abebe, H; Belete, A; Ayano, G				Anbesaw, Tamrat; Negash, Alemayehu; Mamaru, Almaz; Abebe, Habtamu; Belete, Asmare; Ayano, Getinet			Suicidal ideation and associated factors among pregnant women attending antenatal care in Jimma medical center, Ethiopia	PLOS ONE			English	Article							DEPRESSION SCALE EPDS; POSTNATAL-DEPRESSION; SLEEP QUALITY; PREVALENCE; QUESTIONNAIRE; HEALTH; VALIDATION; THOUGHTS; VALIDITY; BEHAVIOR	Background Suicidal ideation (SI) among pregnant women is a major public health concern worldwide and is associated with a higher risk of completed suicide. However, there are limited studies that determined the prevalence and the potential determinants of suicidal ideation in Sub-Saharan Africa, including Ethiopia. Therefore, this study aimed to explore the prevalence of suicidal ideation and associated factors among pregnant women attending antenatal care in Jimma, Ethiopia. Methods An institutional-based cross-sectional study was conducted among 423 pregnant women attending Jimma medical center in Southwest, Ethiopia. A systematic random sampling technique was used to select the study participants. Suicidal ideation assessed using the Suicidality Module of the World Mental Health survey initiative version of the World Health Organization Composite International Diagnostic Interview (CIDI). Other tools used are EPDS, Abuse Assessment Scale (AAS), DASS -21, PSS, Maternity Social Support Scale (MSSS), and Pittsburgh Sleep Quality Index (PSQI). A multivariable logistic regression analysis was used to explore the potential determinants of suicidal ideation among the participants. Result The prevalence of SI among women who are on antenatal care was found to be 13.3% (95% CI (10.1,16.4). In multivariable analysis, marital status with lack of cohabiting partners (AOR = 2.80,95%CI:1.23,6.37), history of abortion (AOR = 2.45,95% CI:1.03,5.93), having depression (AOR = 4.28,95% CI:1.75,10.44),anxiety(AOR = 2.99,95% CI:1.24,7.20), poor sleep quality (AOR = 2.85,95% CI:1.19,6.79), stress (AOR = 2.50, 95% CI:1.01,5.67), and intimate partner violence (AOR = 2.43, 95% CI:1.07,5.47) were found to be significant predictors of suicidal ideation. Conclusion The prevalence of SI among pregnant women was found to be huge. Lack of cohabiting partners, previous history of abortion, depression, anxiety, intimate partner violence, poor sleep quality, and stress were variables that are independent predictors of suicidal ideation. Screening and interventions of antenatal SI are needed.	[Anbesaw, Tamrat; Belete, Asmare] Wollo Univ, Coll Med & Hlth Sci, Dept Psychiat, Dessie, Ethiopia; [Negash, Alemayehu; Mamaru, Almaz] Jimma Univ, Fac Med Sci, Inst Hlth Sci, Dept Psychiat, Jimma, Ethiopia; [Abebe, Habtamu] Jimma Univ, Fac Med Sci, Inst Hlth Sci, Dept Epidemiol & Biostat, Jimma, Ethiopia; [Ayano, Getinet] Amanuel Mental Specialized Hosp, Res & Training Dept, Addis Ababa, Ethiopia; [Ayano, Getinet] Curtin Univ, Sch Publ Hlth, Bentley, WA, Australia	Jimma University; Jimma University; Curtin University	Anbesaw, T (corresponding author), Wollo Univ, Coll Med & Hlth Sci, Dept Psychiat, Dessie, Ethiopia.	tamratanbesaw@gmail.com		Anbesaw, Tamrat/0000-0001-8149-2534; Abebe, Habtamu/0000-0002-3861-0782; Yigzawu, Asmare Belete/0000-0001-7464-8158; Ayano, Getinet/0000-0002-9137-4141	Jimma University	Jimma University	This study was funded by Jimma University. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	ADELEKAN ML, 1989, DRUG ALCOHOL DEPEN, V24, P245, DOI 10.1016/0376-8716(89)90062-8; Aissat H, 2006, IEEE T MICROW THEORY, V54, P2856, DOI 10.1109/TMTT.2006.875454; Alhusen JL, 2015, ARCH WOMEN MENT HLTH, V18, P573, DOI 10.1007/s00737-015-0515-2; [Anonymous], 2007, APA PRACTICE GUIDELI, DOI [10.1176/appi.books.9780890423363.56008, DOI 10.1176/APPI.BOOKS.9780890423363.56008]; Arruda Marco A., 2014, Psychol. Neurosci., V7, P33, DOI 10.3922/j.psns.2014.1.06; Asad N, 2010, ACTA OBSTET GYN SCAN, V89, P1545, DOI 10.3109/00016349.2010.526185; Belete A, 2019, INT J MENT HEALTH SY, V13, DOI 10.1186/s13033-019-0262-2; Bitew H, 2016, DEPRESS RES TREAT, V2016, DOI [https://doi.org/10.1155/2016/8913160, DOI 10.1155/2016/8913160]; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Couto TCE, 2016, ARCH WOMEN MENT HLTH, V19, P343, DOI 10.1007/s00737-015-0552-x; Cohen S., 1983, J HEAL SOC BEHAV, V24, P2; Courtet P, 2001, MOL PSYCHIATR, V6, P338, DOI 10.1038/sj.mp.4000856; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Coelho FMD, 2014, SOC PSYCH PSYCH EPID, V49, P1241, DOI 10.1007/s00127-014-0832-1; da Silva RA, 2012, COMMUNITY MENT HLT J, V48, P392, DOI 10.1007/s10597-012-9495-0; Engidaw NA, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4383-0; Gandhi SG, 2006, OBSTET GYNECOL, V107, P984, DOI 10.1097/01.AOG.0000216000.50202.f6; Gavin AR, 2011, ARCH WOMEN MENT HLTH, V14, P239, DOI 10.1007/s00737-011-0207-5; Gebremariam Etsay Hailu, 2017, Psychiatry J, V2017, P2301524, DOI 10.1155/2017/2301524; Gelaye B, 2017, J AFFECT DISORDERS, V209, P195, DOI 10.1016/j.jad.2016.11.020; Gelaye B, 2016, ARCH WOMEN MENT HLTH, V19, P741, DOI 10.1007/s00737-016-0646-0; Gelaye B, 2015, GEN HOSP PSYCHIAT, V37, P441, DOI 10.1016/j.genhosppsych.2015.04.014; Gelaye B, 2013, INT J PSYCHIAT MED, V46, P387, DOI 10.2190/PM.46.4.e; Golbasi Z, 2010, MATERN CHILD HLTH J, V14, P485, DOI 10.1007/s10995-009-0459-0; Gold KJ, 2012, GEN HOSP PSYCHIAT, V34, P139, DOI 10.1016/j.genhosppsych.2011.09.017; Guardino CM, 2014, HEALTH PSYCHOL REV, V8, P70, DOI 10.1080/17437199.2012.752659; Haile K, 2018, ANN GEN PSYCHIATR, V17, DOI 10.1186/s12991-018-0174-6; Hanlon C, 2008, J AFFECT DISORDERS, V108, P251, DOI 10.1016/j.jad.2007.10.023; Huang H, 2012, ARCH WOMEN MENT HLTH, V15, P135, DOI 10.1007/s00737-012-0263-5; Kabito GG, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-020-4901-0; Kessler RC., 1981, INT J METHODS PSYCHI, V13; Kim JJ, 2015, OBSTET GYNECOL, V125, P885, DOI 10.1097/AOG.0000000000000718; Lakshmi Vijayakumar, 2015, Indian Journal of Psychiatry, V57, P233; Lau Y, 2010, INT J NURS STUD, V47, P1139, DOI 10.1016/j.ijnurstu.2010.02.005; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; Mendez-Bustos P, 2013, SCI WORLD J, DOI 10.1155/2013/485851; Molla Alemayehu, 2019, Psychiatry J, V2019, P4149806, DOI 10.1155/2019/4149806; Moustafa MA., 2019, ZAGAZIG U MED J, V25, P216, DOI [10.21608/zumj.2019.26922, DOI 10.21608/ZUMJ.2019.26922]; Murray D., 1990, J REPROD INFANT PSYC, V8, P99, DOI [DOI 10.1080/02646839008403615, 10.1080/02646839008403615]; Newport DJ, 2007, ARCH WOMEN MENT HLTH, V10, P181, DOI 10.1007/s00737-007-0192-x; Nisa L, 2012, CAN MED ASSOC J, V184, pE241, DOI 10.1503/cmaj.111255; Oates M, 2003, BRIT J PSYCHIAT, V183, P279, DOI 10.1192/bjp.183.4.279; Onah MN, 2017, ARCH WOMEN MENT HLTH, V20, P321, DOI 10.1007/s00737-016-0706-5; Pinheiro AP., 2013, EUR PSYCHIAT, V28, P1, DOI [10.1016/j.eurpsy.2011.07.002, DOI 10.1016/J.EURPSY.2011.07.002]; Reid WH, 2010, J PSYCHIATR PRACT, V16, P120, DOI 10.1097/01.pra.0000369973.10650.13; Rofman ES, 2009, J CLIN PSYCHIAT, V70, P940, DOI 10.4088/JCP.09bk05044; Rubertsson C, 2011, NORD J PSYCHIAT, V65, P414, DOI 10.3109/08039488.2011.590606; Supraja TA, 2016, ARCH WOMEN MENT HLTH, V19, P1101, DOI 10.1007/s00737-016-0660-2; Tabb KM, 2019, J AFFECT DISORDERS, V256, P278, DOI 10.1016/j.jad.2019.06.012; Tabb KM, 2013, WOMEN HEALTH, V53, P519, DOI 10.1080/03630242.2013.804024; Tesfaye M, 2016, HEAL CARE CURR REV, V4, P1, DOI [DOI 10.4172/2375-4273.1000166, 10.4172/2375-4273.1000166]; Trettim J.P., 2020, REV ELETRONICA ACERV, V12, pe2083; Webster J, 2000, BIRTH-ISS PERINAT C, V27, P97, DOI 10.1046/j.1523-536x.2000.00097.x; Zhong QY, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.04.052; Zhong QY, 2015, ARCH WOMEN MENT HLTH, V18, P783, DOI 10.1007/s00737-014-0481-0	57	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255746	10.1371/journal.pone.0255746	http://dx.doi.org/10.1371/journal.pone.0255746			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9YC	34432799	Green Published, gold			2023-01-03	WOS:000729171700054
J	Chowdhury, S; Leenen, LPH				Chowdhury, Sharfuddin; Leenen, Luke P. H.			Does access to acute intensive trauma rehabilitation (AITR) programs affect the disposition of brain injury patients?	PLOS ONE			English	Article							SPINAL-CORD-INJURY; HEALTH CONDITIONS; INDIVIDUALS; ADULTS; IMPACT	Early incorporation of rehabilitation services for severe traumatic brain injury (TBI) patients is expected to improve outcomes and quality of life. This study aimed to compare the outcomes regarding the discharge destination and length of hospital stay of selected TBI patients before and after launching an acute intensive trauma rehabilitation (AITR) program at King Saud Medical City. It was a retrospective observational before-and-after study of TBI patients who were selected and received AITR between December 2018 and December 2019. Participants' demographics, mechanisms of injury, baseline characteristics, and outcomes were compared with TBI patients who were selected for rehabilitation care in the pre-AITR period between August 2017 and November 2018. A total of 108 and 111 patients were managed before and after the introduction of the AITR program, respectively. In the pre-AITR period, 63 (58.3%) patients were discharged home, compared to 87 (78.4%) patients after AITR (p = 0.001, chi-squared 10.2). The pre-AITR group's time to discharge from hospital was 52.4 (SD 30.4) days, which improved to 38.7 (SD 23.2) days in the AITR (p < 0.001; 95% CI 6.6-20.9) group. The early integration of AITR significantly reduced the percentage of patients referred to another rehabilitation or long-term facility. We also emphasize the importance of physical medicine and rehabilitation (PM&R) specialists as the coordinators of structured, comprehensive, and holistic rehabilitation programs delivered by the multi-professional team working in an interdisciplinary way. The leadership and coordination of the PM&R physicians are likely to be effective, especially for those with severe disabilities after brain injury.	[Chowdhury, Sharfuddin] King Saud Med City, Ctr Trauma, Riyadh, Saudi Arabia; [Leenen, Luke P. H.] Univ Med Ctr Utrecht, Dept Trauma, Utrecht, Netherlands	King Saud Medical City; Utrecht University; Utrecht University Medical Center	Chowdhury, S (corresponding author), King Saud Med City, Ctr Trauma, Riyadh, Saudi Arabia.	dr_smahmud@yahoo.com	Chowdhury, Sharfuddin/B-7324-2018	Chowdhury, Sharfuddin/0000-0002-3794-4158				Al-Naami MY, 2010, ANN SAUDI MED, V30, P50, DOI [10.5144/0256-4947.59374, 10.4103/0256-4947.59374]; Carroll Christopher P, 2010, Ann Adv Automot Med, V54, P233; Cheng CL, 2017, J NEUROTRAUM, V34, P2867, DOI 10.1089/neu.2016.4930; Chowdhury S, 2019, SAUDI MED J, V40, P266, DOI 10.15537/smj.2019.3.24005; Couris CM, 2010, SPINAL CORD, V48, P39, DOI 10.1038/sc.2009.77; Craven C, 2012, J SPINAL CORD MED, V35, P361, DOI 10.1179/2045772312Y.0000000046; Grabljevec K, 2018, EUR J PHYS REHAB MED, V54, P971, DOI 10.23736/S1973-9087.18.05502-8; James MK, 2018, INJURY, V49, P975, DOI 10.1016/j.injury.2018.02.014; Javali RH, 2019, INDIAN J CRIT CARE M, V23, P73, DOI 10.5005/jp-journals-10071-23120; Li J, 2011, SPINAL CORD, V49, P777, DOI 10.1038/sc.2011.8; MOORE EE, 1995, SURG CLIN N AM, V75, P293, DOI 10.1016/S0039-6109(16)46589-8; New PW, 2011, SPINAL CORD, V49, P909, DOI 10.1038/sc.2011.29; Putzke JD, 2001, AM J PHYS MED REHAB, V80, P404, DOI 10.1097/00002060-200106000-00002; Saunders LL, 2015, ARCH PHYS MED REHAB, V96, P673, DOI 10.1016/j.apmr.2014.11.019; Shah AA, 2019, J PEDIATR SURG, V54, P2369, DOI 10.1016/j.jpedsurg.2019.06.001; Silver J, 2012, DISABIL HEALTH J, V5, P190, DOI 10.1016/j.dhjo.2012.03.005; Sirois MJ, 2004, ARCH PHYS MED REHAB, V85, P184, DOI 10.1016/j.apmr.2003.06.009; Stocchetti N, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1318-1; Wahab Romina, 2016, J Intensive Care Soc, V17, P2, DOI 10.1177/1751143715605118; WHO, 2013, INTERNATIONAL PERSPECTIVES ON SPINAL CORD INJURY, P1; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	21	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256314	10.1371/journal.pone.0256314	http://dx.doi.org/10.1371/journal.pone.0256314			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC2NW	34398906	gold, Green Published			2023-01-03	WOS:000686370000044
J	Enbiale, M; Getie, A; Haile, F; Tekabe, B; Misekir, D				Enbiale, Mulusew; Getie, Asmare; Haile, Frehiwot; Tekabe, Beemnet; Misekir, Direslgn			Magnitude of syphilis sero-status and associated factors among pregnant women attending antenatal care in Jinka town public health facilities, Southern Ethiopia, 2020	PLOS ONE			English	Article							OUTCOMES; SEROPREVALENCE; CLINICS; RISK; HIV	Introduction Syphilis is one of the leading causes of perinatal morbidity and mortality and is one of the most important public health problems. There was no study showing syphilis serostatus and its related factors among pregnant women in the current study area. This study was aimed to assess the magnitude of syphilis serostatus and associated factors among pregnant women attending antenatal care in Jinka town public health facilities. Method Institution based cross-sectional study design was conducted in Jinka town public health facilities, southern Ethiopia from the 1(st) July to the 1(st) September, 2020. A systematic sampling technique was used to select 629 study subjects. Data were collected using a structured questionnaire through face-to-face interviews and records were reviewed to check syphilis test results. Data were coded and entered by using Epi-data version 4.432 and analyzed using SPSS version 25. The binary logistic regression model was used to investigate factors associated with syphilis. A p-value of < 0.05 at multivariable analysis was considered statistically significant. Result In this study, syphilis sero-prevalence among pregnant women attending antenatal care clinics was 4.8% (95% CI: 3.12, 6.48). Rural residence [AOR: 2.873; 95%CI (1.171, 7.050)], alcohol use [AOR: 3.340; 95% CI (1.354, 8.241)] and having multiple sexual partner [AOR: 5.012; 95% CI (1.929, 13.020)] were statistically significantly associated with syphilis. Conclusion Sero-prevalence of syphilis was high. Being a rural residence, having multiple sexual partners, alcohol use were factors associated with syphilis. Therefore, substantial efforts have to be made to provide regular health education for pregnant women at the antenatal clinic on the avoidance of risky behaviors and the risk of syphilis on their pregnancy.	[Enbiale, Mulusew; Haile, Frehiwot; Tekabe, Beemnet; Misekir, Direslgn] Arba Minch Univ, Sch Publ Hlth, Arba Minch, Ethiopia; [Getie, Asmare] Arba Minch Univ, Sch Nursing, Arba Minch, Ethiopia	Arba Minch University; Arba Minch University	Getie, A (corresponding author), Arba Minch Univ, Sch Nursing, Arba Minch, Ethiopia.	asmaregetie2017@gmail.com		Getie, Asmare/0000-0002-4078-0078				Amsalu A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2998-8; Baldeh AK, 2019, AFR J REPROD HEALTH, V23, P49, DOI 10.29063/ajrh2019/v23i3.5; Balla E, 2018, EUR J OBSTET GYN R B, V228, P274, DOI 10.1016/j.ejogrb.2018.07.022; Blencowe H, 2011, BMC PUBLIC HEALTH, V11, DOI [10.1186/1471-2458-11-S3-S9, 10.1186/1471-2458-11-S3-S11]; Cooper JM, 2018, SEMIN PERINATOL, V42, P176, DOI 10.1053/j.semperi.2018.02.005; Emmanuel SKea, 2010, PREVALENCE ASS FACTO; Endris M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0848-5; Ethiopian Public Health Institute (EPHI), 2015, REP 2014 ROUND ANT C; Gomez GB, 2013, B WORLD HEALTH ORGAN, V91, P217, DOI 10.2471/BLT.12.107623; GSIA, 2018, GLOB REP INF PREV CO; Hussen S, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4562385; Korenromp EL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211720; Lawi JDT, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0434-2; Manyahi J, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1848-5; Melku M, 2015, HIV AIDS-RES PALLIAT, V7, P175, DOI 10.2147/HIV.S81481; Nessa A, 2011, J OBSTET GYNAECOL RE, V37, P1625, DOI 10.1111/j.1447-0756.2011.01587.x; Opone CA., 2019, TROP J OBSTET GYNAEC, V36, P224; Sakala Jacob, 2016, Pan Afr Med J, V24, P75; Benedetti KCSV, 2019, AM J TROP MED HYG, V101, P761, DOI 10.4269/ajtmh.18-0912; Tareke K, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4106-6; Taylor MM, 2014, INT J STD AIDS, V25, P716, DOI 10.1177/0956462413518194; Trivedi S, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010504; WHO, 2017, GUID SYPH SCREEN TRE; Wijesooriya NS, 2016, LANCET GLOB HEALTH, V4, pE525, DOI 10.1016/S2214-109X(16)30135-8; World Health Organization, 2008, GLOB EL CONG SYPH RA; Yitbarek GY, 2019, J PREGNANCY, V2019, DOI 10.1155/2019/1584527; Zhang XH, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2569-z; Zhou H, 2007, SEX TRANSM INFECT, V83, P476, DOI 10.1136/sti.2007.026187	28	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257290	10.1371/journal.pone.0257290	http://dx.doi.org/10.1371/journal.pone.0257290			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9EM	34506600	gold, Green Published			2023-01-03	WOS:000729120700096
J	Laowahutanon, T; Nakamura, H; Tachimori, H; Nomura, S; Liabsuetrakul, T; Lim, A; Rawdaree, P; Suchonwanich, N; Yamamoto, H; Ishizuka, A; Shibuya, K; Miyata, H; Chongsuvivatwong, V				Laowahutanon, Tanapat; Nakamura, Haruyo; Tachimori, Hisateru; Nomura, Shuhei; Liabsuetrakul, Tippawan; Lim, Apiradee; Rawdaree, Petch; Suchonwanich, Netnapis; Yamamoto, Hiroyuki; Ishizuka, Aya; Shibuya, Kenji; Miyata, Hiroaki; Chongsuvivatwong, Virasakdi			Hospital admission for type 2 diabetes mellitus under the Universal Coverage Scheme in Thailand: A time- and geographical-trend analysis, 2009-2016	PLOS ONE			English	Article							COMPLICATIONS; MANAGEMENT	Background Descriptive analyses of 2009-2016 were performed using the data of the Universal Coverage Scheme (UCS) which covers nearly 70 percent of the Thai population. The analyses described the time and geographical trends of nationwide admission rates of type 2 diabetes mellitus (T2DM) and its complications, including chronic kidney disease (CKD), myocardial infarction, cerebrovascular diseases, retinopathy, cataract, and diabetic foot amputation. Methods and findings The database of T2DM patients aged 15-100 years who were admitted between 2009 and 2016 under the UCS and that of the UCS population were retrieved for the analyses. The admitted cases of T2DM were extracted from the database using disease codes of principal and secondary diagnoses defined by the International Classification of Diseases 9th and 10th Revisions. The T2DM admission rates in 2009-2016 were the number of admissions divided by the number of the UCS population. The standardized admission rates (SARs)were further estimated in contrast to the expected number of admissions considering age and sex composition of the UCS population in each region. A linearly increased trend was found in T2DM admission rates from 2009 to 2016. Female admission rates were persistently higher than that of males. In 2016, an increase in the T2DM admission rates was observed among the older ages relative to that in 2009. Although the SARs of T2DM were generally higher in Bangkok and central regions in 2009, except that with CKD and foot amputation which had higher trends in northeastern regions, the geographical inequalities were fairly reduced by 2016. Conclusion Admission rates of T2DM and its major complications increased in Thailand from 2009 to 2016. Although the overall geographical inequalities in the SARs of T2DM were reduced in the country, further efforts are required to improve the health system and policies focusing on risk factors and regions to manage the increasing T2DM.	[Laowahutanon, Tanapat] Natl Hlth Secur Off, Bangkok, Thailand; [Nakamura, Haruyo] Int Dev Ctr Japan Inc, Tokyo, Japan; [Tachimori, Hisateru; Ishizuka, Aya] Natl Ctr Global Hlth & Med, Bur Int Hlth Cooperat, Inst Global Hlth Policy Res iGHP, Shinjuku City, Japan; [Tachimori, Hisateru] Keio Univ, Sch Med, Endowed Course Hlth Syst Innovat, Minato City, Japan; [Tachimori, Hisateru] Natl Ctr Neurol & Psychiat, Translat Med Ctr, Dept Clin Epidemiol, Kodaira, Tokyo, Japan; [Nomura, Shuhei; Yamamoto, Hiroyuki; Ishizuka, Aya; Miyata, Hiroaki] Keio Univ, Sch Med, Dept Hlth Policy & Management, Minato City, Japan; [Nomura, Shuhei] Univ Tokyo, Grad Sch Med, Dept Global Hlth Policy, Tokyo, Japan; [Liabsuetrakul, Tippawan; Chongsuvivatwong, Virasakdi] Prince Songkla Univ, Fac Med, Epidemiol Unit, Hat Yai, Songkhla, Thailand; [Lim, Apiradee] Prince Songkla Univ, Fac Sci & Technol, Dept Math & Comp Sci, Pattani Campus, Pattani, Thailand; [Rawdaree, Petch] Navamindradhiraj Univ, Vajira Hosp, Fac Med, Dept Internal Med, Bangkok, Thailand; [Suchonwanich, Netnapis] Hlth Intervent & Technol Assessment Program HITAP, Nonthaburi, Thailand; [Yamamoto, Hiroyuki] Univ Tokyo, Grad Sch Med, Dept Healthcare Qual Assessment, Bunkyo City, Japan; [Shibuya, Kenji] Soma COVID Vaccinat Med Ctr, Fukushima, Japan	National Center for Global Health & Medicine - Japan; Keio University; National Center for Neurology & Psychiatry - Japan; Keio University; University of Tokyo; Prince of Songkla University; Prince of Songkla University; University of Tokyo	Tachimori, H (corresponding author), Natl Ctr Global Hlth & Med, Bur Int Hlth Cooperat, Inst Global Hlth Policy Res iGHP, Shinjuku City, Japan.; Tachimori, H (corresponding author), Keio Univ, Sch Med, Endowed Course Hlth Syst Innovat, Minato City, Japan.; Tachimori, H (corresponding author), Natl Ctr Neurol & Psychiat, Translat Med Ctr, Dept Clin Epidemiol, Kodaira, Tokyo, Japan.	htachimori@it.ncgm.go.jp	Nomura, Shuhei/HCH-5356-2022	Yamamoto, Hiroyuki/0000-0003-3337-7595; Nomura, Shuhei/0000-0002-2963-7297	Institute for Global Health Policy Research (iGHP), Japan; Japan International Cooperation Agency (JICA), Japan; National Health Security Office, Thailand	Institute for Global Health Policy Research (iGHP), Japan; Japan International Cooperation Agency (JICA), Japan; National Health Security Office, Thailand	This study was partially funded by Institute for Global Health Policy Research (iGHP), Japan; the Japan International Cooperation Agency (JICA), Japan; and the National Health Security Office, Thailand. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aekplakorn W, 2003, DIABETES CARE, V26, P2758, DOI 10.2337/diacare.26.10.2758; Aekplakorn W, 2016, NATL HLTH EXAMINATIO; Aekplakorn W, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/1654530; Alagiakrishnan K, 2010, POSTGRAD MED, V122, P129, DOI 10.3810/pgm.2010.05.2150; [Anonymous], 2017, LANCET DIABETES ENDO, V5, P839, DOI [10.1016/S2213-8587(17)30336-4, 10.1016/S01406736(17)32400-5]; [Anonymous], 2010, B WORLD HEALTH ORGAN, V88, P84, DOI 10.2471/BLT.10.010210; [Anonymous], 2017, PRIM HLTH CAR SYST P; Aungkulanon S, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0479-5; Chatterjee S, 2011, HEALTH SOC CARE COMM, V19, P289, DOI 10.1111/j.1365-2524.2010.00981.x; Chittinan A., 2015, CLIN PRACTICE RECOMM, V1st; Cho NH, 2018, DIABETES RES CLIN PR, V138, P271, DOI 10.1016/j.diabres.2018.02.023; Deerochanawong C, 2013, GLOBALIZATION HEALTH, V9, DOI 10.1186/1744-8603-9-11; Gregg EW, 2014, NEW ENGL J MED, V370, P1514, DOI 10.1056/NEJMoa1310799; Komwong D, 2018, RISK MANAG HEALTHC P, V11, P199, DOI 10.2147/RMHP.S177125; Liabsuetrakul T, 2019, AJP REP, V9, pE328, DOI 10.1055/s-0039-1697656; Lindelow M., 2012, GOVT SPENDING CENTRA; Ministry of Public Health, 2016, INT CLASSIFICATION D; Ministry of Public Health, THAIL HLTH LIF STRAT; National Health Security Office, 2019, NHSO UC INF; National Health Security Office, 2018, NHSO ANN REP FIS YEA; National Health Security Office, NHSO ANN REP YEAR 20; National Statistical Office Kingdom of Thailand, 2012, 2010 POP HOUS CENS; Ong-Ajyooth L, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-35; Pebesma E., 2019, SIMPLE FEATURES R, DOI [10.1109/EMBC.2019.8856507, DOI 10.1109/EMBC.2019.8856507]; Pratipanawatr Thongchai, 2006, J Med Assoc Thai, V89 Suppl 1, pS60; R Core Team Rf.., 2013, R LANG ENV STAT COMP; Raumviboonsuk P, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0099-8; Rawdaree Petch, 2006, J Med Assoc Thai, V89 Suppl 1, pS1; Reutrakul S, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0725-7; Sonthon P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180977; Stanford Kristin I., 2015, DIABETES, V64, P2361, DOI [10.2337/db15-0227, DOI 10.2337/DB15-0227, 10.2337/db15-0956, DOI 10.2337/DB15-0956]; Tangcharoensathien V, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001726; Thai CaseMix Center, 2015, ICD 9 CM 2015 CLASS; Umpierrez GE, 2017, DIABETES CARE, V40, P509, DOI 10.2337/dc16-0989; United Nations Department of Economic and Social Affairs Population Division., 2017, WORLD POP AG 2017 HI; Wickham H., 2019, CREATE ELEGANT DATA; Witthayapipopsakul W, 2019, RISK MANAG HEALTHC P, V12, P13, DOI 10.2147/RMHP.S181174; World Health Organization, DIAB PROGR COUNTR RE; World Health Organization, THAIL DIAB COUNTR PR	39	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	7							e0253434	10.1371/journal.pone.0253434	http://dx.doi.org/10.1371/journal.pone.0253434			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC7AG	34197492	gold, Green Published			2023-01-03	WOS:000668791400061
J	Hutchings, M; Mous, R; Clausen, MR; Johnson, P; Linton, KM; Chamuleau, MED; Lewis, DJ; Balari, AS; Cunningham, D; Oliveri, RS; Elliott, B; DeMarco, D; Azaryan, A; Chiu, C; Li, T; Chen, KM; Ahmadi, T; Lugtenburg, PJ				Hutchings, Martin; Mous, Rogier; Clausen, Michael Roost; Johnson, Peter; Linton, Kim M.; Chamuleau, Martine E. D.; Lewis, David John; Balari, Anna Sureda; Cunningham, David; Oliveri, Roberto S.; Elliott, Brian; DeMarco, Dena; Azaryan, Ada; Chiu, Christopher; Li, Tommy; Chen, Kuo-mei; Ahmadi, Tahamtan; Lugtenburg, Pieternella J.			Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study	LANCET			English	Article							FOLLICULAR LYMPHOMA; RITUXIMAB; TRANSPLANTATION; BLINATUMOMAB; OUTCOMES; THERAPY; RISK	Background Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. We aimed to establish the safety and recommended phase 2 dose of epcoritamab, a novel bispecific antibody that targets CD3 and CD20 and induces T-cell-mediated cytotoxic activity against CD20+ malignant B cells. Methods For the dose-escalation part of this phase 1/2 study, we enrolled adults (aged =18 years) with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma at ten sites across four countries (Denmark, the Netherlands, the UK, and Spain). Eligible patients received priming and intermediate doses followed by full doses of subcutaneous epcoritamab administered in 28-day cycles; each subsequent cohort involved escalation of the priming, intermediate, or full dose (0.0128-60 mg). The primary objectives were to determine the maximum tolerated dose and the recommended phase 2 dose. Safety, antitumour activity, pharmacokinetics, and immune biomarkers were also assessed. This study is registered with ClinicalTrials.gov, NCT03625037, with the dose-expansion part ongoing. Findings Between June 26, 2018, and July 14, 2020, we enrolled 73 patients with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin lymphoma. 68 patients received escalating full doses (0.0128-60 mg) of subcutaneous epcoritamab. No dose-limiting toxic effects were observed, and the maximum tolerated dose was not reached; the full dose of 48 mg was identified as the recommended phase 2 dose. All 68 patients received at least one dose of epcoritamab and were included in safety analyses: common adverse events were pyrexia (47 patients [69%]), primarily associated with cytokine release syndrome (CRS; 40 [59%], all grade 1-2), and injection site reactions (32 [47%]; 31 grade 1). There were no grade 3 or higher CRS events. No discontinuations occurred due to treatmentrelated adverse events or treatment-related deaths. Overall response rate in patients with relapsed or refractory diffuse large B-cell lymphoma was 68% (95% CI 45-86), with 45% achieving a complete response at full doses of 12-60 mg. At 48 mg, the overall response rate was 88% (47-100), with 38% achieving a complete response. Patients with relapsed or refractory follicular lymphoma had an overall response rate of 90% (55-100), with 50% achieving a complete response at full doses of 0.76-48 mg. Epcoritamab induced robust and sustained B-cell depletion, and CD4+ and CD8+ T-cell activation and expansion, with modest increases in cytokine levels. Interpretation Single-agent subcutaneous epcoritamab for treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma merits investigation in ongoing phase 2 and phase 3 studies. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Hutchings, Martin] Rigshosp, Dept Haematol, Copenhagen, Denmark; [Mous, Rogier] Univ Med Ctr Utrecht, Lunenburg Lymphoma Phase I II Consortium, HOVON LLPC, Utrecht, Netherlands; [Clausen, Michael Roost] Vejle Hosp, Vejle, Denmark; [Johnson, Peter] Univ Southampton, Canc Res UK, Canc Serv, Southampton, Hants, England; [Linton, Kim M.] Univ Manchester, Christie NHS Fdn Trust, Manchester Canc Res Ctr, Manchester, Lancs, England; [Chamuleau, Martine E. D.] Vrije Univ Amsterdam Med Ctr, Lunenburg Lymphoma Phase I II Consortium, HOVON LLPC, Amsterdam, Netherlands; [Lewis, David John] Plymouth Univ, Sch Med, Plymouth, Devon, England; [Balari, Anna Sureda] Univ Barcelona, Hosp Duran & Reynals, Inst Catala Oncol, IDIBELL, Barcelona, Spain; [Cunningham, David] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England; [Oliveri, Roberto S.] Genmab, Copenhagen, Denmark; [Elliott, Brian; DeMarco, Dena; Azaryan, Ada; Chiu, Christopher; Li, Tommy; Chen, Kuo-mei; Ahmadi, Tahamtan] Genmab, Princeton, NJ USA; [Lugtenburg, Pieternella J.] Erasmus MC, Inst Canc, Dept Hematol, Lunenburg Lymphoma Phase I II Consortium,HOVON LL, Rotterdam, Netherlands	Rigshospitalet; University of Copenhagen; Utrecht University; Utrecht University Medical Center; University of Southern Denmark; Lillebaelt Hospital; Cancer Research UK; University of Southampton; Christie NHS Foundation Trust; University of Manchester; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Plymouth; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Barcelona; Royal Marsden NHS Foundation Trust; Genmab; Genmab; Erasmus University Rotterdam; Erasmus MC	Hutchings, M (corresponding author), Rigshosp, Dept Haematol, Phase 1 Unit, DK-2100 Copenhagen, Denmark.	martin.hutchings@regionh.dk	Hutchings, Martin/B-6959-2012; Johnson, Peter/L-2403-2018	Hutchings, Martin/0000-0003-3873-1741; Clausen, Michael Roost/0000-0003-3218-3633; Chiu, Christopher W./0000-0001-9744-991X; Cunningham, David/0000-0001-5158-1069; Johnson, Peter/0000-0003-2306-4974	Genmab; AbbVie	Genmab(Genmab); AbbVie(AbbVie)	Genmab and AbbVie.	Assouline SE, 2020, BLOOD, V136, DOI 10.1182/blood-2020-135839; Ayala E, 2012, CANCER CONTROL, V19, P175, DOI 10.1177/107327481201900302; Bannerji R, 2020, BLOOD, V136, DOI 10.1182/blood-2020-136659; Buhmann R, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-160; Casulo C, 2015, J CLIN ONCOL, V33, P2516, DOI 10.1200/JCO.2014.59.7534; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Coiffier B, 2008, J CLIN ONCOL, V26, P2767, DOI 10.1200/JCO.2007.15.0177; Crump M, 2017, BLOOD, V130, P1800, DOI 10.1182/blood-2017-03-769620; Engelberts PJ, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2019.102625; Fischer T, 2018, ANN HEMATOL, V97, P17, DOI 10.1007/s00277-017-3151-2; Gisselbrecht C, 2010, J CLIN ONCOL, V28, P4184, DOI 10.1200/JCO.2010.28.1618; Hutchings M, J CLIN ONCOL, V39, P1959; Jain T, 2019, BIOL BLOOD MARROW TR, V25, P2305, DOI 10.1016/j.bbmt.2019.08.015; Jurinovic V, 2016, BLOOD, V128, P1112, DOI 10.1182/blood-2016-05-717355; Kewalramani T, 2004, BLOOD, V103, P3684, DOI 10.1182/blood-2003-11-3911; Klener P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184417; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Martin A, 2008, HAEMATOL-HEMATOL J, V93, P1829, DOI 10.3324/haematol.13440; Matasar MJ, 2020, BLOOD, V136, DOI 10.1182/blood-2020-135818; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Patel K, 2019, BLOOD, V134, DOI 10.1182/blood-2019-128564; Penalver FJ, 2019, CANCER MED-US, V8, P6955, DOI 10.1002/cam4.2555; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Topp MS, 2014, J CLIN ONCOL, V32, P4134, DOI 10.1200/JCO.2014.56.3247; van der Horst HJ, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00430-6; Van Heertum RL, 2017, DRUG DES DEV THER, V11, P1719, DOI 10.2147/DDDT.S136988; van Imhoff GW, 2017, J CLIN ONCOL, V35, P544, DOI 10.1200/JCO.2016.69.0198; Viardot A, 2016, BLOOD, V127, P1410, DOI [10.1182/blood-2015-06651380, 10.1182/blood-2015-06-651380]; Wildes TM, 2008, BIOL BLOOD MARROW TR, V14, P840, DOI 10.1016/j.bbmt.2008.05.002; Yuan Y, 2016, CLIN CANCER RES, V22, P4291, DOI 10.1158/1078-0432.CCR-16-0592	30	48	49	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	2021	398	10306					1157	1169		10.1016/S0140-6736(21)00889-8	http://dx.doi.org/10.1016/S0140-6736(21)00889-8		SEP 2021	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX3WV	34508654	Green Accepted, Green Submitted			2023-01-03	WOS:000700774500025
J	Sandhu, S; Moore, CM; Chiong, E; Beltran, H; Bristow, RG; Williams, SG				Sandhu, Shahneen; Moore, Caroline M.; Chiong, Edmund; Beltran, Himisha; Bristow, Robert G.; Williams, Scott G.			Prostate cancer	LANCET			English	Review							PHASE-III TRIAL; MITOXANTRONE PLUS PREDNISONE; ANDROGEN DEPRIVATION THERAPY; LONG-TERM SURVIVAL; DOUBLE-BLIND; RADICAL PROSTATECTOMY; ADJUVANT RADIOTHERAPY; ABIRATERONE ACETATE; OPEN-LABEL; ACTIVE SURVEILLANCE	The management of prostate cancer continues to evolve rapidly, with substantial advances being made in understanding the genomic landscape and biology underpinning both primary and metastatic prostate cancer. Similarly, the emergence of more sensitive imaging methods has improved diagnostic and staging accuracy and refined surveillance strategies. These advances have introduced personalised therapeutics to clinical practice, with treatments targeting genomic alterations in DNA repair pathways now clinically validated. An important shift in the therapeutic framework for metastatic disease has taken place, with metastatic-directed therapies being evaluated for oligometastatic disease, aggressive management of the primary lesion shown to benefit patients with low-volume metastatic disease, and with several novel androgen pathway inhibitors significantly improving survival when used as a first-line therapy for metastatic disease. Research into the molecular characterisation of localised, recurrent, and progressive disease will undoubtedly have an impact on clinical management. Similarly, emerging research into novel therapeutics, such as targeted radioisotopes and immunotherapy, holds much promise for improving the lives of patients with prostate cancer.	[Williams, Scott G.] Peter MacCallum Canc Ctr, Div Radiat Oncol, Melbourne, Vic 3000, Australia; [Sandhu, Shahneen] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia; [Sandhu, Shahneen; Williams, Scott G.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Bristow, Robert G.] Manchester Canc Res Ctr, Manchester, Lancs, England; [Bristow, Robert G.] Univ Manchester, Manchester, Lancs, England; [Moore, Caroline M.] UCL, London, England; [Beltran, Himisha] Dana Farber Canc Inst, Boston, MA 02115 USA; [Chiong, Edmund] Natl Univ Singapore, Dept Urol, Singapore, Singapore; [Chiong, Edmund] Natl Univ Singapore, Dept Surg, Singapore, Singapore	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of Manchester; University of Manchester; University of London; University College London; Harvard University; Dana-Farber Cancer Institute; National University of Singapore; National University of Singapore	Williams, SG (corresponding author), Peter MacCallum Canc Ctr, Div Radiat Oncol, Melbourne, Vic 3000, Australia.	scott.williams@petermac.org	Moore, Caroline/T-2391-2017	Moore, Caroline/0000-0003-0202-7912; Bristow, Robert/0000-0002-8553-9544	Prostate Cancer Foundation; Prostate Cancer Foundation Australia; Peter MacCallum Cancer Foundation; Cancer Council Victoria; Victoria Cancer Agency; Medical Research Future Fund; Cancer Research UK Manchester Institute; RadNet funding programmes; Manchester NIHR Biomedical Research Centre; Prostate Cancer UK; National Cancer Institute and National Institutes of Health [R37CA241486, P50 CA211024]; US Department of Defense [PC160264]	Prostate Cancer Foundation; Prostate Cancer Foundation Australia; Peter MacCallum Cancer Foundation; Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Victoria Cancer Agency; Medical Research Future Fund(Medical Research Future Fund (MRFF)); Cancer Research UK Manchester Institute; RadNet funding programmes; Manchester NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Prostate Cancer UK; National Cancer Institute and National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US Department of Defense(United States Department of Defense)	SGW is supported by the Prostate Cancer Foundation, Prostate Cancer Foundation Australia, Peter MacCallum Cancer Foundation, Cancer Council Victoria, and Victoria Cancer Agency. SS has received support from the Prostate Cancer Foundation, Victoria Cancer Agency, Medical Research Future Fund, and Peter MacCallum Cancer Foundation. RGB is supported by the Cancer Research UK Manchester Institute and RadNet funding programmes, the Manchester NIHR Biomedical Research Centre, and Prostate Cancer UK. HB has received support from the National Cancer Institute and National Institutes of Health (R37CA241486, P50 CA211024), US Department of Defense (PC160264), and the Prostate Cancer Foundation.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Abida W., 2017, JCO PRECIS ONCOL, P2017, DOI [10.1200/po.17.00029, DOI 10.1200/PO.17.00029, 10.1200/PO.17.00029]; Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Abida W, 2019, JAMA ONCOL, V5, P471, DOI 10.1001/jamaoncol.2018.5801; Agrawal V, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.14674; Ahmed HU, 2017, LANCET, V389, P815, DOI 10.1016/S0140-6736(16)32401-1; Amin A, 2020, J UROLOGY, V203, P910, DOI 10.1097/JU.0000000000000693; Antonarakis ES, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01638; Aparicio AM, 2016, CLIN CANCER RES, V22, P1520, DOI 10.1158/1078-0432.CCR-15-1259; Appayya MB, 2018, BJU INT, V122, P13, DOI 10.1111/bju.14361; Armenia J, 2018, NAT GENET, V50, P645, DOI 10.1038/s41588-018-0078-z; Ashton J, 2020, BRIT J RADIOL, V93, DOI 10.1259/bjr.20200087; Attard G, 2018, J CLIN ONCOL, V36, P2639, DOI 10.1200/JCO.2018.77.9827; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Auvinen A, 2016, CLIN CANCER RES, V22, P243, DOI 10.1158/1078-0432.CCR-15-0941; Barentsz JO, 2012, EUR RADIOL, V22, P746, DOI 10.1007/s00330-011-2377-y; Battaglia A, 2019, EUR UROL ONCOL, V2, P174, DOI 10.1016/j.euo.2018.09.005; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Beer TM, 2017, J CLIN ONCOL, V35, P40, DOI 10.1200/JCO.2016.69.1584; Beer TM, 2017, EUR UROL, V71, P151, DOI 10.1016/j.eururo.2016.07.032; Beltran H, 2020, J CLIN INVEST, V130, P1653, DOI 10.1172/JCI131041; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Bhandari V, 2019, NAT GENET, V51, P308, DOI 10.1038/s41588-018-0318-2; Bill-Axelson A, 2018, NEW ENGL J MED, V379, P2319, DOI 10.1056/NEJMoa1807801; Blee AM, 2018, CLIN CANCER RES, V24, P4551, DOI 10.1158/1078-0432.CCR-18-0653; Boeve LMS, 2019, EUR UROL, V75, P410, DOI 10.1016/j.eururo.2018.09.008; Bolla M, 2012, LANCET, V380, P2018, DOI 10.1016/S0140-6736(12)61253-7; Bolla M, 2009, NEW ENGL J MED, V360, P2516, DOI 10.1056/NEJMoa0810095; Bria E, 2009, CANCER, V115, P3446, DOI 10.1002/cncr.24392; Calais J, 2019, LANCET ONCOL, V20, P1286, DOI 10.1016/S1470-2045(19)30415-2; Cardet RED, 2021, EUR UROL, V79, P413, DOI 10.1016/j.eururo.2020.11.043; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Castro E, 2013, J CLIN ONCOL, V31, P1748, DOI 10.1200/JCO.2012.43.1882; Cato L, 2019, CANCER CELL, V35, P401, DOI 10.1016/j.ccell.2019.01.008; Chi KN, 2019, NEW ENGL J MED, V381, P13, DOI 10.1056/NEJMoa1903307; Clarke NW, 2019, ANN ONCOL, V30, P1992, DOI 10.1093/annonc/mdz396; Cooperberg MR, 2015, JAMA-J AM MED ASSOC, V314, P80, DOI 10.1001/jama.2015.6036; D'Amico AV, 2011, J CLIN ONCOL, V29, P4682, DOI 10.1200/JCO.2011.37.0726; Davis ID, 2019, NEW ENGL J MED, V381, P121, DOI 10.1056/NEJMoa1903835; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; de Wit R, 2019, NEW ENGL J MED, V381, P2506, DOI 10.1056/NEJMoa1911206; Dieffenbacher S, 2021, EUR UROL FOCUS, V7, P102, DOI 10.1016/j.euf.2019.03.001; Donovan JL, 2016, NEW ENGL J MED, V375, P1425, DOI 10.1056/NEJMoa1606221; Drost FJH, 2020, EUR UROL, V77, P78, DOI 10.1016/j.eururo.2019.06.023; Eeles R, 2014, NAT REV UROL, V11, P18, DOI 10.1038/nrurol.2013.266; Eggener SE, 2020, J CLIN ONCOL, V38, P1474, DOI 10.1200/JCO.19.02768; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; Falagario UG, 2019, J UROLOGY, V202, P102, DOI 10.1097/JU.0000000000000134; Faria R, 2018, EUR UROL, V73, P23, DOI 10.1016/j.eururo.2017.08.018; Fendler WP, 2019, CLIN CANCER RES, V25, P7448, DOI 10.1158/1078-0432.CCR-19-1050; Fizazi K, 2020, EUR UROL, V78, P822, DOI 10.1016/j.eururo.2020.07.032; Fizazi K, 2020, NEW ENGL J MED, V383, P1040, DOI 10.1056/NEJMoa2001342; Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6; Foreman KJ, 2018, LANCET, V392, P2052, DOI [10.1016/S0140-6736(18)31694-5, 10.1016/s0140-6736(18)31694-5]; Francini E, 2018, PROSTATE, V78, P889, DOI 10.1002/pros.23645; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gandaglia G, 2019, EUR UROL, V76, P142, DOI 10.1016/j.eururo.2019.04.033; Gillessen S, 2020, LANCET ONCOL, V21, P17, DOI 10.1016/S1470-2045(19)30780-6; Giri VN, 2018, J CLIN ONCOL, V36, P414, DOI 10.1200/JCO.2017.74.1173; Graff JN, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000642; Gravis G, 2018, EUR UROL, V73, P847, DOI 10.1016/j.eururo.2018.02.001; Guckenberger M, 2020, LANCET ONCOL, V21, pE18, DOI 10.1016/S1470-2045(19)30718-1; Gulley JL, 2019, J CLIN ONCOL, V37, P1051, DOI 10.1200/JCO.18.02031; Hamdy FC, 2016, NEW ENGL J MED, V375, P1415, DOI 10.1056/NEJMoa1606220; Hansen AR, 2018, ANN ONCOL, V29, P1807, DOI 10.1093/annonc/mdy232; Herlemann A, 2020, PROSTATE CANCER P D, V23, P136, DOI 10.1038/s41391-019-0167-9; Hickey BE, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011462.pub2; Hieronymus H, 2014, P NATL ACAD SCI USA, V111, P11139, DOI 10.1073/pnas.1411446111; Hofman MS, 2021, LANCET, V397, P797, DOI 10.1016/S0140-6736(21)00237-3; Hofman MS, 2018, LANCET ONCOL, V19, P825, DOI 10.1016/S1470-2045(18)30198-0; HOFMAN MS, 2020, LANCET; Hugosson J, 2019, EUR UROL, V76, P43, DOI 10.1016/j.eururo.2019.02.009; Hussain M, 2021, J CLIN ONCOL, V39, P13, DOI 10.1200/JCO.20.02268; Jackson WC, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.03217; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Joseph D, 2020, INT J RADIAT ONCOL, V106, P693, DOI 10.1016/j.ijrobp.2019.11.415; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kasivisvanathan V, 2018, NEW ENGL J MED, V378, P1767, DOI 10.1056/NEJMoa1801993; Khalaf DJ, 2019, LANCET ONCOL, V20, P1730, DOI 10.1016/S1470-2045(19)30688-6; Kneebone A, 2020, LANCET ONCOL, V21, P1331, DOI 10.1016/S1470-2045(20)30456-3; Kovac E, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.19284; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Lalonde E, 2014, LANCET ONCOL, V15, P1521, DOI 10.1016/S1470-2045(14)71021-6; Leapman MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185535; Lee SH, 2015, CURR OPIN CELL BIOL, V37, P35, DOI 10.1016/j.ceb.2015.10.002; Li J, 2020, NATURE, V580, P93, DOI 10.1038/s41586-020-2135-x; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mateo J, 2020, J CLIN INVEST, V130, P1743, DOI [10.1172/JCl132031, 10.1172/JCI132031]; Mateo J, 2020, LANCET ONCOL, V21, P162, DOI 10.1016/S1470-2045(19)30684-9; Moore CM, 2017, EUR UROL, V71, P648, DOI 10.1016/j.eururo.2016.06.011; Morris WJ, 2017, INT J RADIAT ONCOL, V98, P275, DOI 10.1016/j.ijrobp.2016.11.026; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Niederst MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7377; Ost P, 2018, J CLIN ONCOL, V36, P446, DOI 10.1200/JCO.2017.75.4853; Oudard S, 2017, J CLIN ONCOL, V35, P3189, DOI 10.1200/JCO.2016.72.1068; Palma DA, 2020, J CLIN ONCOL, V38, P2830, DOI 10.1200/JCO.20.00818; Palma DA, 2019, LANCET, V393, P2051, DOI 10.1016/S0140-6736(18)32487-5; Park JW, 2016, P NATL ACAD SCI USA, V113, P4482, DOI 10.1073/pnas.1603645113; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Parker CC, 2020, LANCET, V396, P1413, DOI 10.1016/S0140-6736(20)31553-1; Parker CC, 2018, LANCET, V392, P2353, DOI 10.1016/S0140-6736(18)32486-3; Patasius A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031856; Perera M, 2020, EUR UROL, V77, P403, DOI 10.1016/j.eururo.2019.01.049; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Phillips R, 2020, JAMA ONCOL, V6, P650, DOI 10.1001/jamaoncol.2020.0147; Pinsk PF, 2019, CANCER-AM CANCER SOC, V125, P2965, DOI 10.1002/cncr.32176; Pritchard CC, 2016, NEW ENGL J MED, V375, P443, DOI 10.1056/NEJMoa1603144; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Rebello RJ, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00243-0; Rebello RJ, 2019, CLIN CANCER RES, V25, P1699, DOI 10.1158/1078-0432.CCR-18-3401; Roach M, 2000, INT J RADIAT ONCOL, V47, P617, DOI 10.1016/S0360-3016(00)00577-0; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rodrigues DN, 2018, J CLIN INVEST, V128, P4441, DOI [10.1172/JCI121924, 10.1172/JCI125184]; Rouviere O, 2019, LANCET ONCOL, V20, P100, DOI 10.1016/S1470-2045(18)30569-2; Rubin MA, 2018, MODERN PATHOL, V31, pS1, DOI 10.1038/modpathol.2017.166; Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Saad F, 2002, JNCI-J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458; Saad F, 2018, LANCET ONCOL, V19, P1404, DOI 10.1016/S1470-2045(18)30456-X; Saad F, 2015, EUR UROL, V68, P570, DOI 10.1016/j.eururo.2015.04.032; Sargos P, 2020, LANCET ONCOL, V21, P1341, DOI 10.1016/S1470-2045(20)30454-X; Sartor O, 2021, NEW ENGL J MED, V385, P1091, DOI 10.1056/NEJMoa2107322; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Sfanos KS, 2018, NAT REV UROL, V15, P11, DOI 10.1038/nrurol.2017.167; Shelley MD, 2009, CANCER TREAT REV, V35, P540, DOI 10.1016/j.ctrv.2009.05.001; Smith M, 2019, LANCET ONCOL, V20, P408, DOI 10.1016/S1470-2045(18)30860-X; Smith MR, 2021, EUR UROL, V79, P150, DOI 10.1016/j.eururo.2020.08.011; Smith MR, 2013, J CLIN ONCOL, V31, P3800, DOI 10.1200/JCO.2012.44.6716; Sternberg CN, 2020, NEW ENGL J MED, V382, P2197, DOI 10.1056/NEJMoa2003892; Sternberg CN, 2009, J CLIN ONCOL, V27, P5431, DOI 10.1200/JCO.2008.20.1228; Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747; Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Taylor RA, 2019, NAT REV UROL, V16, P281, DOI 10.1038/s41585-019-0164-8; Taylor RA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13671; Thompson IM, 2009, J UROLOGY, V181, P956, DOI 10.1016/j.juro.2008.11.032; Tombal B, 2019, LANCET ONCOL, V20, P556, DOI 10.1016/S1470-2045(18)30898-2; Tosoian JJ, 2020, EUR UROL, V77, P675, DOI 10.1016/j.eururo.2019.12.017; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Turkbey B, 2019, EUR UROL, V76, P340, DOI 10.1016/j.eururo.2019.02.033; US Preventive Services Task Force, 2018, JAMA, V319, P1901, DOI 10.1001/jama.2018.3710; Vale CL, 2020, LANCET, V396, P1422, DOI 10.1016/S0140-6736(20)31952-8; van der Leest M, 2019, EUR UROL, V75, P570, DOI 10.1016/j.eururo.2018.11.023; Vapiwala N, 2019, J CLIN ONCOL, V37, P765, DOI 10.1200/JCO.18.01927; Warde P, 2011, LANCET, V378, P2104, DOI 10.1016/S0140-6736(11)61095-7; Weinreb JC, 2016, EUR UROL, V69, P16, DOI 10.1016/j.eururo.2015.08.052; Widmark A, 2009, LANCET, V373, P301, DOI 10.1016/S0140-6736(08)61815-2; Wiegel T, 2014, EUR UROL, V66, P243, DOI 10.1016/j.eururo.2014.03.011; Williams S, 2020, CANCER J, V26, P43, DOI 10.1097/PPO.0000000000000427; Williams S, 2013, LANCET ONCOL, V14, pE524, DOI 10.1016/S1470-2045(13)70451-0; Wilt TJ, 2017, NEW ENGL J MED, V377, P132, DOI 10.1056/NEJMoa1615869; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034; Yaxley JW, 2016, LANCET, V388, P1057, DOI 10.1016/S0140-6736(16)30592-X	159	73	73	26	51	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	2021	398	10305					1075	1090		10.1016/S0140-6736(21)00950-8	http://dx.doi.org/10.1016/S0140-6736(21)00950-8		SEP 2021	16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	US3YI	34370973				2023-01-03	WOS:000697368600020
J	Busse, JW; Vankrunkelsven, P; Zeng, LN; Heen, AF; Merglen, A; Campbell, F; Granan, LP; Aertgeerts, B; Buchbinder, R; Coen, M; Juurlink, D; Samer, C; Siemieniuk, RAC; Kumar, N; Cooper, L; Brown, J; Lytvyn, L; Zeraatkar, D; Wang, L; Guyatt, GH; Vandvik, P; Agoritsas, T				Busse, Jason W.; Vankrunkelsven, Patrick; Zeng, Linan; Heen, Anja Fog; Merglen, Arnaud; Campbell, Fiona; Granan, Lars-Petter; Aertgeerts, Bert; Buchbinder, Rachelle; Coen, Matteo; Juurlink, David; Samer, Caroline; Siemieniuk, Reed A. C.; Kumar, Nimisha; Cooper, Lynn; Brown, John; Lytvyn, Lyubov; Zeraatkar, Dena; Wang, Li; Guyatt, Gordon H.; Vandvik, Per; Agoritsas, Thomas			Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material								CLINICAL QUESTION What is the role of medical cannabis or cannabinoids for people living with chronic pain due to cancer or non-cancer causes? CURRENT PRACTICE Chronic pain is common and distressing and associated with considerable socioeconomic burden globally. Medical cannabis is increasingly used to manage chronic pain, particularly in jurisdictions that have enacted policies to reduce use of opioids; however, existing guideline recommendations are inconsistent, and cannabis remains illegal for therapeutic use in many countries. RECOMMENDATION The guideline expert panel issued a weak recommendation to offer a trial of non-inhaled medical cannabis or cannabinoids, in addition to standard care and management (if not sufficient), for people living with chronic cancer or non-cancer pain. HOW THIS GUIDELINE WAS CREATED An international guideline development panel including patients, clinicians with content expertise, and methodologists produced this recommendation in adherence with standards for trustworthy guidelines using the GRADE approach. The MAGIC Evidence Ecosystem Foundation (MAGIC) provided methodological support. The panel applied an individual patient perspective. THE EVIDENCE This recommendation is informed by a linked series of four systematic reviews summarising the current body of evidence for benefits and harms, as well as patient values and preferences, regarding medical cannabis or cannabinoids for chronic pain. UNDERSTANDING THE RECOMMENDATION The recommendation is weak because of the close balance between benefits and harms of medical cannabis for chronic pain. It reflects a high value placed on small to very small improvements in self reported pain intensity, physical functioning, and sleep quality, and willingness to accept a small to modest risk of mostly self limited and transient harms. Shared decision making is required to ensure patients make choices that reflect their values and personal context. Further research is warranted and may alter this recommendation. [GRAPHICS]	[Busse, Jason W.] McMaster Univ, Michael G DeGroote Ctr Med Cannabis Res, Hamilton, ON, Canada; [Busse, Jason W.; Zeng, Linan; Siemieniuk, Reed A. C.; Lytvyn, Lyubov; Zeraatkar, Dena; Wang, Li; Guyatt, Gordon H.; Agoritsas, Thomas] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Busse, Jason W.; Wang, Li] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada; [Busse, Jason W.; Brown, John] Chron Pain Ctr Excellence Canadian Vet, Hamilton, ON, Canada; [Vankrunkelsven, Patrick] Belgian Ctr Evidence Based Med CEBAM, Leuven, Belgium; [Vankrunkelsven, Patrick] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Leuven, Belgium; [Zeng, Linan] Sichuan Univ, West China Second Univ Hosp, Evidence Based Pharm Ctr, Pharm Dept, Chengdu, Sichuan, Peoples R China; [Heen, Anja Fog; Vandvik, Per] Innlandet Hosp Trust, Dept Med, Gjovik, Norway; [Merglen, Arnaud] Univ Geneva, Univ Hosp Geneva, Div Gen Pediat, Geneva, Switzerland; [Merglen, Arnaud] Univ Geneva, Fac Med, Geneva, Switzerland; [Campbell, Fiona] Univ Toronto, Dept Anesthesiol & Pain Med, Toronto, ON, Canada; [Granan, Lars-Petter] Oslo Univ Hosp, Div Emergencies & Crit Care, Dept Pain Management & Res, Oslo, Norway; [Aertgeerts, Bert] Katholieke Univ Leuven, Acad Ctr Gen Practice, Dept Publ Hlth & Primary Care, Leuven, Belgium; [Aertgeerts, Bert] Belgian Ctr Evidence Based Med, CEBAM, Cochrane, Belgium; [Buchbinder, Rachelle] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Buchbinder, Rachelle] Cabrini Inst, Monash Dept Clin Epidemiol, Melbourne, Vic, Australia; [Coen, Matteo] Geneva Univ Hosp, Div Gen Internal Med, Dept Med, Geneva, Switzerland; [Coen, Matteo] Univ Geneva, Unit Dev & Res Med Educ, Fac Med, Geneva, Switzerland; [Juurlink, David] Sunnybrook Hlth Sci Ctr, Div Clin Pharmacol & Toxicol, Toronto, ON, Canada; [Juurlink, David] Univ Toronto, Dept Med, Toronto, ON, Canada; [Juurlink, David] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Samer, Caroline] Geneva Univ Hosp, Div Clin Pharmacol & Toxicol, Geneva, Switzerland; [Samer, Caroline] Univ Geneva, Fac Med, Geneva, Switzerland; [Kumar, Nimisha] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Cooper, Lynn] Canadian Injured Workers Alliance, Thunder Bay, ON, Canada; [Zeraatkar, Dena] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA; [Agoritsas, Thomas] Univ Hosp Geneva, Div Gen Internal Med, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland; [Agoritsas, Thomas] Univ Hosp Geneva, Div Clin Epidemiol, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland	McMaster University; McMaster University; McMaster University; KU Leuven; Sichuan University; Innlandet Hospital Trust; University of Geneva; University of Geneva; University of Toronto; University of Oslo; KU Leuven; Monash University; Cabrini Health; Monash University; University of Geneva; University of Geneva; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Hospital for Sick Children (SickKids); Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Geneva; University of Geneva; Indiana University System; Indiana University Bloomington; Harvard University; Harvard Medical School; University of Geneva; University of Geneva	Busse, JW (corresponding author), McMaster Univ, Michael G DeGroote Ctr Med Cannabis Res, Hamilton, ON, Canada.; Busse, JW (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.; Busse, JW (corresponding author), McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada.; Busse, JW (corresponding author), Chron Pain Ctr Excellence Canadian Vet, Hamilton, ON, Canada.	bussejw@mcmaster.ca	Cooper, Lynn Kerene/GMW-4135-2022; Samer, Caroline/ABB-2447-2021; Zeraatkar, Dena/GNM-9600-2022; Busse, Jason/CAH-3696-2022; Coen, Matteo/AAO-3994-2020	Samer, Caroline/0000-0001-8178-0616; Busse, Jason/0000-0002-0178-8712; Coen, Matteo/0000-0002-6156-1691; Aertgeerts, Bert/0000-0003-1142-5402	Michael G DeGroote Centre for Medicinal Cannabis Research	Michael G DeGroote Centre for Medicinal Cannabis Research	The Michael G DeGroote Centre for Medicinal Cannabis Research funded the MAGIC Evidence Ecosystem Foundation to support the creation of this Rapid Recommendation. The central operating funding for the Michael G DeGroote Centre for Medicinal Cannabis Research is from a philanthropic gift to the Michael G DeGroote Initiative for Innovation in Healthcare. The centre receives no funding from industry.		0	26	27	6	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2021	374								n2040	10.1136/bmj.n2040	http://dx.doi.org/10.1136/bmj.n2040			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ3VV	34497062	Green Accepted			2023-01-03	WOS:000702137100016
J	Berhanu, D; Allen, E; Beaumont, E; Tomlin, K; Taddesse, N; Dinsa, G; Mekonnen, Y; Hailu, H; Balliet, M; Lensink, N; Schellenberg, J; Avan, BI				Berhanu, Della; Allen, Elizabeth; Beaumont, Emma; Tomlin, Keith; Taddesse, Nolawi; Dinsa, Girmaye; Mekonnen, Yirgalem; Hailu, Hanna; Balliet, Manuela; Lensink, Neil; Schellenberg, Joanna; Avan, Bilal Iqbal			Coverage of antenatal, intrapartum, and newborn care in 104 districts of Ethiopia: A before and after study four years after the launch of the national Community-Based Newborn Care programme	PLOS ONE			English	Article							HEALTH EXTENSION WORKERS; CASE-MANAGEMENT	Background Access to health services across the continuum of care improves maternal and newborn health outcomes. Ethiopia launched the Community-Based Newborn Care programme in 2013 to increase the coverage of antenatal care, institutional delivery, postnatal care and newborn care. The programme also introduced gentamicin and amoxicillin treatment by health extension workers for young infants with possible serious bacterial infection when referral was not possible. This study aimed to assess the extent to which the coverage of health services for mothers and their young infants increased after the initiation of the programme. Methods A baseline survey was conducted in October-December 2013 and a follow-up survey four years later in November-December 2017. At baseline, 10,224 households and 1,016 women who had a live birth in the 3-15 months prior to the survey were included. In the follow-up survey, 10,270 households and 1,057 women with a recent live birth were included. Women were asked about their experience of care during pregnancy, delivery and postpartum periods, as well as the treatment provided for their child's illness in the first 59 days of life. Results Between baseline and follow-up surveys the proportion of women reporting at least one antenatal care visit increased by 15 percentage points (95% CI: 10,19), four or more antenatal care visits increased by 17 percentage points (95%CI: 13,22), and institutional delivery increased by 40 percentage points (95% CI: 35,44). In contrast, the proportion of newborns with a postnatal care visit within 48 hours of birth decreased by 6 percentage points (95% CI: -10, -3) for home deliveries and by 14 percentage points (95% CI: -21, -7) for facility deliveries. The proportion of mothers reporting that their young infant with possible serious bacterial infection received amoxicillin for seven days increased by 50 percentage points (95% CI: 37,62) and gentamicin for seven days increased by 15 percentage points (95% CI: 5,25). Concurrent use of both antibiotics increased by 12 percentage points (95% CI: 4,19). Conclusion The Community-Based Newborn Care programme was an ambitious initiative to enhance the access to services for pregnant women and newborns. Major improvements were seen for the number of antenatal care visits and institutional delivery, while postnatal care remained alarmingly low. Antibiotic treatment for young infants with possible serious bacterial infection increased, although most treatment did not follow national guidelines. Improving postnatal care coverage and using a simplified antibiotic regimen following recent World Health Organization guidelines could address gaps in the care provided for sick young infants.	[Berhanu, Della; Schellenberg, Joanna] London Sch Hyg & Trop Med, Dept Dis Control, London, England; [Berhanu, Della] Ethiopian Publ Hlth Inst, Hlth Syst & Reprod Hlth Res Directorate, Addis Ababa, Ethiopia; [Allen, Elizabeth; Beaumont, Emma] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Med Stat, London, England; [Tomlin, Keith] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Populat Hlth, London, England; [Taddesse, Nolawi; Mekonnen, Yirgalem; Hailu, Hanna] JaRco Consulting, Addis Ababa, Ethiopia; [Dinsa, Girmaye] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Dinsa, Girmaye] Haramaya Univ, Dept Publ Hlth & Hlth Policy, Coll Hlth & Med Sci, Dire Dawa, Ethiopia; [Balliet, Manuela] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London, England; [Lensink, Neil] Global Affairs Canada, Ottawa, ON, Canada; [Avan, Bilal Iqbal] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; Harvard University; Harvard T.H. Chan School of Public Health; Haramaya University; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Berhanu, D (corresponding author), London Sch Hyg & Trop Med, Dept Dis Control, London, England.; Berhanu, D (corresponding author), Ethiopian Publ Hlth Inst, Hlth Syst & Reprod Hlth Res Directorate, Addis Ababa, Ethiopia.	della.berhanu@lshtm.ac.uk		Iqbal Avan, Bilal/0000-0003-4531-4508; Beaumont, Emma/0000-0001-5763-0933; Schellenberg, Joanna/0000-0002-0708-3676	Bill & Melinda Gates Foundation [OPP1017031]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	This project was funded by Bill & Melinda Gates Foundation (https://www.gatesfoundation.org/) [OPP1017031]. JS received the award. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199937; Amare Y, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1196-6; Amare Y, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5922-7; Arsenault C, 2018, LANCET GLOB HEALTH, V6, pE1186, DOI 10.1016/S2214-109X(18)30389-9; Assefa Nega, 2016, Matern Health Neonatol Perinatol, V2, P7, DOI 10.1186/s40748-016-0035-8; Assefa Y, 2019, GLOBALIZATION HEALTH, V15, DOI 10.1186/s12992-019-0470-1; Avan B., IN PRESS; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P137, DOI 10.4314/ejhs.v24i0.12S; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P149, DOI 10.4314/ejhs.v24i0.13S; Berhanu D., 2014, COMMUNITY BASED NEWB; Berhanu D., 2015, POSTNATAL HOME VISIT; Berhanu D., 2019, COMMUNITY BASED NEWB; Berhe A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221161; Bhattacharya AA, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020411; Bogale TN, 2018, AM J TROP MED HYG, V98, P1653, DOI 10.4269/ajtmh.17-0824; Campbell H, 2013, PLOS MED, V10, DOI [10.1371/journal.pmed.1001421, 10.1371/journal.pmed.1001422]; Central Statistical Agencey (CSA] and ICF, 2015, ETH MIN HLTH SURV 20; Central Statistical Agency (CSA) [Ethiopia] and ICF, 2017, 2016 ETH DEM HLTH SU; Central Statistics Agency (CSA) [Ethiopia] and ORC Macro, 2006, ETH DEM HLTH SURV 20; CSA ICF, 2012, ETH DEM HLTH SURV 20; Daka DW, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239361; Damtew ZA, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1975-y; Degefie T, 2014, BMC INT HEALTH HUM R, V14, DOI 10.1186/1472-698X-14-17; Demographic Health Survey (DHS), MOD QUEST; Desalew A, 2020, BMC PEDIATR, V20, DOI 10.1186/s12887-020-02051-7; Fink G, 2015, INT J EPIDEMIOL, V44, P1879, DOI 10.1093/ije/dyv115; Gebremedhin T, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2616-9; Getachew T, 2019, ACTA PAEDIATR, V108, P2100, DOI 10.1111/apa.14888; Hailegebriel TD, 2017, GLOB HEALTH-SCI PRAC, V5, P202, DOI 10.9745/GHSP-D-16-00312; Hailemariam S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4242-7; Khanal S, 2011, J HEALTH POPUL NUTR, V29, P255, DOI 10.3329/jhpn.v29i3.7873; King R, 2015, MIDWIFERY, V31, P540, DOI 10.1016/j.midw.2015.02.004; Luel A., 2019, ETHIOP MED J, V2019; Marchant T, 2019, CAN MED ASSOC J, V191, pE1179, DOI 10.1503/cmaj.190219; Mathewos B., 2019, ETHIOP MED J; Merq Consultancy PLC, 2019, NAT ASS ETH HLTH EXT; Miller NP, 2014, AM J TROP MED HYG, V91, P424, DOI 10.4269/ajtmh.13-0751; Nigatu Solomon Gedlu, 2015, BMC Res Notes, V8, P309, DOI 10.1186/s13104-015-1278-6; Ruducha J, 2017, LANCET GLOB HEALTH, V5, pE1142, DOI 10.1016/S2214-109X(17)30331-5; Semu Y., 2019, ETHIOP MED J; Shaw B, 2016, HEALTH POLICY PLANN, V31, P656, DOI 10.1093/heapol/czv115; Shaw B, 2015, AM J TROP MED HYG, V93, P636, DOI 10.4269/ajtmh.14-0660; Tesfaye S, 2014, J MIDWIFERY WOM HEAL, V59, pS55, DOI 10.1111/jmwh.12168; The UN Inter-agency Group for Child Mortality Estimation, 2014, LEVELS TRENDS CHILD; Tilahun H, 2017, HEALTH POLICY PLANN, V32, P320, DOI 10.1093/heapol/czw129; United Nations Children's Fund (UNICEF) World Health Organization (WHO) World Bank Group and United Nations (UN), 2019, LEVELS TRENDS CHILD; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; Weldearegay HG, 2020, REPROD HEALTH, V17, DOI 10.1186/s12978-020-00923-w; WHO, 2017, WHO REC NEWB HLTH; World Health Organizaiton (WHO), 2015, GUIDL MAN POSS SER B; Yakob B, 2019, INT J QUAL HEALTH C, V31, P725, DOI 10.1093/intqhc/mzy251	51	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2021	16	8							e0251706	10.1371/journal.pone.0251706	http://dx.doi.org/10.1371/journal.pone.0251706			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UA6JF	34351944	gold, Green Published, Green Accepted			2023-01-03	WOS:000685265700034
J	Dixon, BE; Grannis, SJ; Lembcke, LR; Valvi, N; Roberts, AR; Embi, PJ				Dixon, Brian E.; Grannis, Shaun J.; Lembcke, Lauren R.; Valvi, Nimish; Roberts, Anna R.; Embi, Peter J.			The synchronicity of COVID-19 disparities: Statewide epidemiologic trends in SARS-CoV-2 morbidity, hospitalization, and mortality among racial minorities and in rural America	PLOS ONE			English	Article							OUTCOMES	Background Early studies on COVID-19 identified unequal patterns in hospitalization and mortality in urban environments for racial and ethnic minorities. These studies were primarily single center observational studies conducted within the first few weeks or months of the pandemic. We sought to examine trends in COVID-19 morbidity, hospitalization, and mortality over time for minority and rural populations, especially during the U.S. fall surge. Methods Data were extracted from a statewide cohort of all adult residents in Indiana tested for SARS-CoV-2 infection between March 1 and December 31, 2020, linked to electronic health records. Primary measures were per capita rates of infection, hospitalization, and death. Age adjusted rates were calculated for multiple time periods corresponding to public health mitigation efforts. Comparisons across time within groups were compared using ANOVA. Results Morbidity and mortality increased over time with notable differences among sub-populations. Initially, hospitalization rates among racial minorities were 3-4 times higher than whites, and mortality rates among urban residents were twice those of rural residents. By fall 2020, hospitalization and mortality rates in rural areas surpassed those of urban areas, and gaps between black/brown and white populations narrowed. Changes across time among demographic groups was significant for morbidity and hospitalization. Cumulative morbidity and mortality were highest among minority groups and in rural communities. Conclusions The synchronicity of disparities in COVID-19 by race and geography suggests that health officials should explicitly measure disparities and adjust mitigation as well as vaccination strategies to protect those sub-populations with greater disease burden.	[Dixon, Brian E.] Indiana Univ, Fairbanks Sch Publ Hlth, Dept Epidemiol, Bloomington, IN 47405 USA; [Dixon, Brian E.; Grannis, Shaun J.; Valvi, Nimish; Embi, Peter J.] Regenstrief Inst Hlth Care, Ctr Biomed Informat, Indianapolis, IN 46202 USA; [Grannis, Shaun J.] Indiana Univ, Sch Med, Dept Family Med, Indianapolis, IN USA; [Lembcke, Lauren R.; Roberts, Anna R.] Regenstrief Inst Hlth Care, Res Data Serv, Indianapolis, IN USA; [Embi, Peter J.] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis	Dixon, BE (corresponding author), Indiana Univ, Fairbanks Sch Publ Hlth, Dept Epidemiol, Bloomington, IN 47405 USA.; Dixon, BE (corresponding author), Regenstrief Inst Hlth Care, Ctr Biomed Informat, Indianapolis, IN 46202 USA.	bedixon@regenstrief.org	Dixon, Brian E/A-9494-2013	Dixon, Brian E/0000-0002-1121-0607	U.S. Agency for Healthcare Research and Quality [R21HS025502]; State of Indiana; Marion County Public Health Department	U.S. Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); State of Indiana; Marion County Public Health Department	BED receives funding from the U.S. Agency for Healthcare Research and Quality (R21HS025502) to study health information exchange. The Regenstrief Institute as well as the IU Fairbanks School of Public Health received funds from the State of Indiana and Marion County Public Health Department to support COVID-19 response and mitigation, including disease surveillance and outcomes measurement. The funders did not have influence over the findings or this publication.	Alcendor DJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082442; [Anonymous], 2020, MMWR Morb Mortal Wkly Rep, V69, P1753, DOI 10.15585/mmwr.mm6946a6; Barrett C, 2020, WILL COVID 19 TRIGGE; Bergdall A., 2012, CLIN MED RES, V10, P172, DOI [10.3121/cmr.2012.1100.cb3-01, DOI 10.3121/CMR.2012.1100.CB3-01]; Blonde L, 2018, ADV THER, V35, P1763, DOI 10.1007/s12325-018-0805-y; Buckner FS, 2020, CLIN INFECT DIS, V71, P2167, DOI 10.1093/cid/ciaa632; Comer KF, 2011, PUBLIC HEALTH REP, V126, P54, DOI 10.1177/00333549111260S310; Davoodi NM, 2020, GERONTOL GERIATR MED, V6, DOI 10.1177/2333721420936168; DeSalvo KB, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.170017; DeSalvo KB, 2016, AM J PUBLIC HEALTH, V106, P621, DOI 10.2105/AJPH.2016.303063; DiMaggio C, 2020, ANN EPIDEMIOL, V51, P7, DOI 10.1016/j.annepidem.2020.08.012; Dixon B, 2016, GIS AND GEOCOMPUTATION FOR WATER RESOURCE SCIENCE AND ENGINEERING, P3; Dixon BE, 2021, INDIANA COVID 19 TES; Dixon BE, 2021, J AM MED INFORM ASSN, V28, P1363, DOI 10.1093/jamia/ocab004; Doidge JC, 2021, AM J RESP CRIT CARE, V203, P565, DOI 10.1164/rccm.202008-3212OC; Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041; Gold JAW, 2020, MMWR-MORBID MORTAL W, V69, P545, DOI 10.15585/mmwr.mm6918e1; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Hasnain-Wynia R, 2010, J NATL MED ASSOC, V102, P769, DOI 10.1016/S0027-9684(15)30673-8; Holcomb E, 2020, BACK TRACK INDIANA G; Karim SA, 2021, J RURAL HEALTH, V37, P124, DOI 10.1111/jrh.12533; Kaufman BG, 2020, J RURAL HEALTH, V36, P584, DOI 10.1111/jrh.12481; Millett GA, 2020, ANN EPIDEMIOL, V47, P37, DOI 10.1016/j.annepidem.2020.05.003; National Center for Immunization and Respiratory Diseases Division of Viral Diseases, 2020, HLTH EQ CONS RAC ETH; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Overhage JM, 2016, HLTH INFORM EXCHANGE, P267; Peters DJ, 2020, J RURAL HEALTH, V36, P446, DOI 10.1111/jrh.12477; Purdue Extension, 2019, GEOGR CLASS W LAF; Regenstrief Institute, 2020, REG COVID 19 DASHB I; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Romano SD, 2021, MMWR-MORBID MORTAL W, V70, P560, DOI [10.15585/mmwr.mm7015e2, 10.15585/mmwr.mm7015e2externalicon]; Shah P, 2020, ANN MED, V52, P354, DOI 10.1080/07853890.2020.1791356; Tan TQ, 2020, J INFECT DIS, V222, P1951, DOI 10.1093/infdis/jiaa583; The Center for Systems Science and Engineering at Johns Hopkins University, 2020, COVID 19 DASHB; van Halem K, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05605-3; Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5	38	4	4	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2021	16	7							e0255063	10.1371/journal.pone.0255063	http://dx.doi.org/10.1371/journal.pone.0255063			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2PW	34297747	Green Published, gold			2023-01-03	WOS:000678128300056
J	Mocanu, V; Zhang, ZX; Deehan, EC; Kao, DH; Hotte, N; Karmali, S; Birch, DW; Samarasinghe, KK; Walter, J; Madsen, KL				Mocanu, Valentin; Zhang, Zhengxiao; Deehan, Edward C.; Kao, Dina H.; Hotte, Naomi; Karmali, Shahzeer; Birch, Daniel W.; Samarasinghe, Kalutota K.; Walter, Jens; Madsen, Karen L.			Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial	NATURE MEDICINE			English	Article							GUT MICROBIOTA; INSULIN SENSITIVITY; INTESTINAL MICROBIOTA; INDIVIDUALS; MODULATION; MANAGEMENT; COST	Fecal microbial transplantation (FMT) from lean donors to patients with obesity has been associated with metabolic benefits, yet results so far have been inconsistent. In this study, we tested the application of daily fiber supplementation as an adjunct to FMT therapy to modulate cardiometabolic outcomes. We performed a double-blind randomized trial in patients with severe obesity and metabolic syndrome receiving oral FMT, to test high-fermentable (HF) and low-fermentable (LF) fiber supplements (NCT03477916). Seventy participants were randomized to the FMT-HF (n = 17), FMT-LF (n = 17), HF (n = 17) and LF (n = 19) groups. The primary outcome was the assessment of change in insulin sensitivity from baseline to 6 weeks using the homeostatic model assessment (HOMA2-IR/IS). After 6 weeks, only patients in the FMT-LF group had significant improvements in HOMA2-IR (3.16 +/- 3.01 at 6 weeks versus 3.77 +/- 3.57 at baseline; P = 0.02). No difference in HOMA2-IR was observed over this period for those in the FMT-HF group (3.25 +/- 1.70 at 6 weeks versus 3.17 +/- 1.72 at baseline; P = 0.8), the HF group (3.49 +/- 1.43 at 6 weeks versus 3.26 +/- 1.33 at baseline; P = 0.8) or the LF group (3.76 +/- 2.01 at 6 weeks versus 3.56 +/- 1.81 at baseline; P = 0.8). Interventions were safe and well-tolerated with no treatment-attributed serious adverse events. We provide proof of concept for the use of a single-dose oral FMT combined with daily low-fermentable fiber supplementation to improve insulin sensitivity in patients with severe obesity and metabolic syndrome. Results from a phase 2 randomized controlled trial demonstrate improved insulin sensitivity in patients with severe obesity and metabolic syndrome following single-dose fecal microbial transplantation and daily supplementation with low-fermentable fiber for 6 weeks.	[Mocanu, Valentin; Karmali, Shahzeer; Birch, Daniel W.] Univ Alberta, Dept Surg, Edmonton, AB, Canada; [Zhang, Zhengxiao; Deehan, Edward C.; Hotte, Naomi] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Zhang, Zhengxiao] Jimei Univ, Coll Food & Biol Engn, Xiamen, Peoples R China; [Kao, Dina H.; Madsen, Karen L.] Univ Alberta, Dept Med, Div Gastroenterol, Edmonton, AB, Canada; [Samarasinghe, Kalutota K.] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada; [Walter, Jens] Univ Coll Cork, APC Microbiome Ireland, Sch Microbiol, Cork, Ireland; [Walter, Jens] Univ Coll Cork, Dept Med, Cork, Ireland	University of Alberta; University of Alberta; Jimei University; University of Alberta; University of Alberta; University College Cork; University College Cork	Madsen, KL (corresponding author), Univ Alberta, Dept Med, Div Gastroenterol, Edmonton, AB, Canada.	kmadsen@ualberta.ca	Walter, Jens/AAA-7636-2020; Madsen, Karen L/H-5898-2011; Zhang, Zhengxiao/AAM-7779-2020; Deehan, Edward C./ABF-6669-2020	Walter, Jens/0000-0003-1754-172X; Zhang, Zhengxiao/0000-0002-6977-4309; Deehan, Edward C./0000-0001-7697-1418; Birch, Daniel/0000-0001-8737-4184; Madsen, Karen/0000-0002-8636-0714; Samarasinghe, Kalutota Kuruwe Arachchige Sajana Indula/0000-0002-4173-4161	Canadian Institutes of Health Research (CIHR); Alberta Innovates; Clinical Investigator Program; W. Garfield Weston Foundation [RES0048879]; Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Innovates; Clinical Investigator Program; W. Garfield Weston Foundation; Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR)	We thank the Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR) for the infrastructure and support provided throughout the project. We also thank M. Emberg for his support with FMT preparation, R. Odsen for his help with trial coordination, and T. Dang for his help with fecal 16s rRNA extraction. We acknowledge S. Jamieson and D. Turner-Crerar as members of the University of Alberta Quality Management in Clinical Research Department (QMCR) for providing safety oversight. V.M. is the recipient of scholarships from the Canadian Institutes of Health Research (CIHR), Alberta Innovates, and the Clinical Investigator Program. Last, we thank the W. Garfield Weston Foundation (RES0048879) for the funding that made this project possible. The funders had no role in the study design, data collection and analysis, decision to publish or the preparation of the paper.	Abenavoli L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112690; Allegretti J, 2017, INFLAMM BOWEL DIS, V23, P1710, DOI 10.1097/MIB.0000000000001247; [Anonymous], 11 HLTH CAN; Aron-Wisnewsky J, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1180-z; Atzeni A, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9020346; Babiker R, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-111; Bakker G. J., 2017, MICROBIOL SPECTR, V5, DOI [DOI 10.1128/MICROBIOLSPEC.BAD-0008-2017, DOI 10.1128/microbiolspec.BAD-0008-2017]; Bindels LB, 2015, CURR OPIN CLIN NUTR, V18, P559, DOI 10.1097/MCO.0000000000000223; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Chassard C, 2010, FEMS MICROBIOL ECOL, V74, P205, DOI 10.1111/j.1574-6941.2010.00941.x; Chis R, 2018, PHYSIOL HEALTH DIS, P279, DOI 10.1007/978-1-4939-7534-1_11; Dahiya DK, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00563; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; de Groot PF, 2017, GUT MICROBES, V8, P253, DOI 10.1080/19490976.2017.1293224; de Groot P, 2020, GUT, V69, P502, DOI 10.1136/gutjnl-2019-318320; Dovrolis N, 2019, ANN GASTROENTEROL, V32, P233, DOI 10.20524/aog.2019.0373; Ellulu MS, 2017, ARCH MED SCI, V13, P851, DOI 10.5114/aoms.2016.58928; Finkelstein EA, 2012, AM J PREV MED, V42, P563, DOI 10.1016/j.amepre.2011.10.026; Gill SK, 2021, NAT REV GASTRO HEPAT, V18, P101, DOI 10.1038/s41575-020-00375-4; Gribble FM, 2019, NAT REV ENDOCRINOL, V15, P226, DOI 10.1038/s41574-019-0168-8; Hiippala K, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.575455; Holscher HD, 2015, AM J CLIN NUTR, V101, P55, DOI 10.3945/ajcn.114.092064; Hruby A, 2015, PHARMACOECONOMICS, V33, P673, DOI 10.1007/s40273-014-0243-x; Ianiro G, 2014, CURR DRUG TARGETS, V15, P762, DOI 10.2174/1389450115666140606111402; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Kao D, 2017, JAMA-J AM MED ASSOC, V318, P1985, DOI 10.1001/jama.2017.17077; Klebanoff MJ, 2017, JAMA SURG, V152, P136, DOI 10.1001/jamasurg.2016.3640; Kootte RS, 2017, CELL METAB, V26, P611, DOI 10.1016/j.cmet.2017.09.008; Kuk J. L, 2020, CANADIAN ADULT OBESI; Laffin M, 2018, INFLAMM BOWEL DIS, V24, P101, DOI 10.1093/ibd/izx033; le Roux CW, 2017, LANCET, V389, P1399, DOI 10.1016/S0140-6736(17)30069-7; Lee P, 2019, DIABETES OBES METAB, V21, P479, DOI 10.1111/dom.13561; Leshem A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01341; Louis P, 2014, NAT REV MICROBIOL, V12, P661, DOI 10.1038/nrmicro3344; Makki K, 2018, CELL HOST MICROBE, V23, P705, DOI 10.1016/j.chom.2018.05.012; Marotz Clarisse A., 2016, Yale Journal of Biology and Medicine, V89, P383; Mehta A, 2017, OBES SCI PRACT, V3, P3, DOI 10.1002/osp4.84; Meijnikman AS, 2018, ENDOCR REV, V39, P133, DOI 10.1210/er.2017-00192; Naderpoor N, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040452; National Health and Nutriton Examination Survey. (NHANES), 2011, ANTHR PROC MAN; National institutes of Health National Heart Lung ABI, 2000, PRACT GUID ID EV TRE; Oksanen J, **DATA OBJECT**; Paradis, 2012, ANAL PHYOGENETICS EV; Parekh PJ, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2015.16; Porras D, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01813; Pradhan B, 2017, BIOMED REV, V27, P1, DOI DOI 10.14748/BMR.V27.2108; Sbahi H, 2016, BMJ OPEN GASTROENTER, V3, DOI 10.1136/bmjgast-2016-000087; Schaub M, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0015046, 10.1371/journal.pone.0013115]; Stripling J, 2018, AM J MED SCI, V356, P424, DOI 10.1016/j.amjms.2018.08.010; Tan WSK, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040961; Twells Laurie K, 2014, CMAJ Open, V2, pE18, DOI 10.9778/cmajo.20130016; Upadhyaya B, 2016, SCI REP-UK, V6, DOI 10.1038/srep28797; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Walter J, 2018, CURR OPIN BIOTECH, V49, P129, DOI 10.1016/j.copbio.2017.08.008; Wang TY, 2020, APPL MICROBIOL BIOT, V104, P7143, DOI 10.1007/s00253-020-10689-7; Wolf AM, 1998, OBES RES, V6, P97, DOI 10.1002/j.1550-8528.1998.tb00322.x; Zhang ZX, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102291; Zou J, 2018, CELL HOST MICROBE, V23, P41, DOI 10.1016/j.chom.2017.11.003	59	49	49	8	38	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2021	27	7					1272	+		10.1038/s41591-021-01399-2	http://dx.doi.org/10.1038/s41591-021-01399-2		JUL 2021	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TK8OZ	34226737				2023-01-03	WOS:000669779100001
J	Clarke, R				Clarke, Rachel			The art of medicine Sparks through the stubble: dying in a pandemic	LANCET			English	Editorial Material																			0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2021	398	10294					18	19		10.1177/02692163211017023	http://dx.doi.org/10.1177/02692163211017023			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC9PM	34217387	Green Published, Green Accepted			2023-01-03	WOS:000668969500015
J	Krueger, J; Santinon, F; Kazanova, A; Issa, ME; Larrivee, B; Kremer, R; Milhalcioiu, C; Rudd, CE				Krueger, Janna; Santinon, Francois; Kazanova, Alexandra; Issa, Mark E.; Larrivee, Bruno; Kremer, Richard; Milhalcioiu, Catalin; Rudd, Christopher E.			Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy	PLOS ONE			English	Article							REACTIVE T-CELLS; DOWN-REGULATION; ALPHA-BETA; CD8; CHLOROQUINE; AUTOPHAGY; AZITHROMYCIN; CANCER; TUMORIGENESIS; RECEPTORS	Immunotherapy using checkpoint blockade (ICB) with antibodies such as anti-PD-1 has revolutionised the treatment of many cancers. Despite its use to treat COVID-19 patients and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, the effect of hydroxychloroquine (HCQ) on cancer immunotherapy has not been examined. In this study, remarkably, we find that HCQ alone, or in combination with azithromycin (AZ), at doses used to treat patients, decreased the therapeutic benefit of anti-PD-1 in cancer immunotherapy. No deleterious effect was seen on untreated tumors. Mechanistically, HCQ and HCQ/AZ inhibited PD-L1 expression on tumor cells, while specifically targeting the anti-PD-1 induced increase in progenitor CD8(+)CD44(+)PD-1(+)TCF1(+) tumor infiltrating T cells (TILs) and the generation of CD8(+)CD44(+)PD-1(+) effectors. Surprisingly, it also impaired the appearance of a subset of terminally exhausted CD8(+) TILs. No effect was seen on the presence of CD4(+) T cells, FoxP3(+) regulatory T cells (Tregs), thymic subsets, B cells, antibody production, myeloid cells, or the vasculature of mice. This study indicates for the first time that HCQ and HCQ/AZ negatively impact the ability of anti-PD-1 checkpoint blockade to promote tumor rejection.	[Krueger, Janna; Santinon, Francois; Kazanova, Alexandra; Issa, Mark E.; Rudd, Christopher E.] Rosemont Hosp CR HMR Montreal, Div Immunooncol, Res Ctr Maisonneuve, Montreal, PQ, Canada; [Krueger, Janna; Santinon, Francois; Kazanova, Alexandra; Issa, Mark E.; Rudd, Christopher E.] Univ Montreal, Dept Microbiol Infect & Immunol, Montreal, PQ, Canada; [Larrivee, Bruno] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada; [Kremer, Richard; Rudd, Christopher E.] McGill Univ, Dept Med, Div Expt Med, Hlth Ctr, Montreal, PQ, Canada; [Milhalcioiu, Catalin] McGill Univ, Dept Med, Div Med Oncol, Hlth Ctr, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; McGill University; McGill University	Rudd, CE (corresponding author), Rosemont Hosp CR HMR Montreal, Div Immunooncol, Res Ctr Maisonneuve, Montreal, PQ, Canada.; Rudd, CE (corresponding author), Univ Montreal, Dept Microbiol Infect & Immunol, Montreal, PQ, Canada.; Rudd, CE (corresponding author), McGill Univ, Dept Med, Div Expt Med, Hlth Ctr, Montreal, PQ, Canada.	christopher.e.rudd@umontreal.ca	Rudd, Christopher E/ABF-7259-2021; Rudd, Christopher E/GOH-2021-2022	Rudd, Christopher E/0000-0001-5295-9019; Kazanova, Alexandra/0000-0003-4850-9845; Larrivee, Bruno/0000-0003-1388-3108; Issa, Mark/0000-0002-0854-4147	Canadian Institutes of Health Foundation [159912]	Canadian Institutes of Health Foundation(Canadian Institutes of Health Research (CIHR))	The project was funded by Canadian Institutes of Health Foundation grant (159912).	Accapezzato D, 2005, J EXP MED, V202, P817, DOI 10.1084/jem.20051106; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228; [Anonymous], FDA APPR VEN CLL SLL; Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099; Baaten BJG, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00023; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; Bonam SR, 2020, AUTOPHAGY, V16, P2260, DOI 10.1080/15548627.2020.1779467; Catteau L, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106144; Chen DG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03225-9; Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03; Chen Z, 2020, EFFICACY HYDROXYCHLO, P114, DOI [10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]; Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072; Cicchini M, 2014, AUTOPHAGY, V10, P2036, DOI 10.4161/auto.34398; COVID-19 RISK and Treatments (CORIST) Collaboration, 2020, Eur J Intern Med, V82, P38, DOI 10.1016/j.ejim.2020.08.019; Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938; Fernandez AD, 2004, J INFECT DIS, V190, P1762, DOI 10.1086/425038; Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; Gesbert F, 2005, INT IMMUNOL, V17, P1093, DOI 10.1093/intimm/dxh289; Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024; Grisotto MG, 2001, IMMUNOLOGY, V102, P209, DOI 10.1046/j.1365-2567.2001.01170.x; HAUGHN L, 1992, NATURE, V358, P328, DOI 10.1038/358328a0; Horby P, 2020, NEW ENGL J MED, V383, P2030, DOI 10.1056/NEJMoa2022926; Jin HT, 2010, P NATL ACAD SCI USA, V107, P14733, DOI 10.1073/pnas.1009731107; Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363; Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412; Lenzer J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1335; Li Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0938-5; Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0; Magagnoli J, 2020, MED-CAMBRIDGE, V1, P114, DOI [10.1016/j.medj.2020.06.001, 10.1101/2020.04.16.20065920]; Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1844, 10.1136/bmj.m2328]; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006; Nina PB, 2020, INDIAN J PUBLIC HLTH, V64, P125, DOI 10.4103/ijph.IJPH_496_20; Page DB, 2014, ANNU REV MED, V65, P185, DOI 10.1146/annurev-med-092012-112807; Patel S, 2016, ONCOTARGET, V7, P59087, DOI 10.18632/oncotarget.10824; Poschet Jens F, 2020, bioRxiv, DOI 10.1101/2020.03.29.008631; Raghu D, 2019, TRENDS IMMUNOL, V40, P1149, DOI 10.1016/j.it.2019.10.006; Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMc1207269; Roldan EQ, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104904; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; Rudd CE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01638; Rudd CE, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz8128; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; Sharma G, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133225; Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153; Siddiqui I, 2019, IMMUNITY, V50, P195, DOI 10.1016/j.immuni.2018.12.021; Smith GA, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan4931; Strauss L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay1863; Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849; Thome R, 2014, IMMUNOL CELL BIOL, V92, P124, DOI 10.1038/icb.2013.73; Thome R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065913; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69; WALKER PR, 1995, J IMMUNOL, V155, P3443; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; Weber BN, 2011, NATURE, V476, P63, DOI 10.1038/nature10279; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wilkinson B, 2004, IMMUNOLOGY, V111, P368, DOI 10.1111/j.0019-2805.2004.01832.x; Wong YK, 2020, LANCET RHEUMATOL, V2, pE255, DOI 10.1016/S2665-9913(20)30093-X; Wozniacka A, 2008, BRIT J DERMATOL, V159, P1124, DOI 10.1111/j.1365-2133.2008.08804.x; Wu SF, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1393-y; Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362; Yu B, 2020, SCI CHINA LIFE SCI, V63, P1515, DOI 10.1007/s11427-020-1732-2; ZHANG L, 1995, J IMMUNOL, V155, P3464; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	76	4	4	3	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2021	16	6							e0251731	10.1371/journal.pone.0251731	http://dx.doi.org/10.1371/journal.pone.0251731			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9DB	34181666	Green Published, gold			2023-01-03	WOS:000671695800014
J	Olm, M; Donnachie, E; Tauscher, M; Gerlach, R; Linde, K; Maier, W; Schwettmann, L; Schneider, A				Olm, Michaela; Donnachie, Ewan; Tauscher, Martin; Gerlach, Roman; Linde, Klaus; Maier, Werner; Schwettmann, Lars; Schneider, Antonius			Ambulatory specialist costs and morbidity of coordinated and uncoordinated patients before and after abolition of copayment: A cohort analysis	PLOS ONE			English	Article							PRIMARY-CARE SYSTEMS; HEALTH-CARE; CO-PAYMENTS; MULTIMORBIDITY; DEPRIVATION; DEMAND; EUROPE; IMPACT	To strengthen the coordinating function of general practitioners (GPs) in the German healthcare system, a copayment of euro10 was introduced in 2004. Due to a perceived lack of efficacy and a high administrative burden, it was abolished in 2012. The present cohort study investigates characteristics and differences of GP-coordinated and uncoordinated patients in Bavaria, Germany, concerning morbidity and ambulatory specialist costs and whether these differences have changed after the abolition of the copayment. We performed a retrospective routine data analysis, using claims data of the Bavarian Association of the Statutory Health Insurance Physicians during the period 2011-2012 (with copayment) and 2013-2016 (without copayment), covering 24 quarters. Coordinated care was defined as specialist contact only with referral. Multinomial regression modelling, including inverse probability of treatment weighting, was used for the cohort analysis of 500 000 randomly selected patients. Longitudinal regression models were calculated for cost estimation. Coordination of care decreased substantially after the abolition of the copayment, accompanied by increasing proportions of patients with chronic and mental diseases in the uncoordinated group, and a corresponding decrease in the coordinated group. In the presence of the copayment, uncoordinated patients had euro21.78 higher specialist costs than coordinated patients, increasing to euro24.94 after its abolition. The results indicate that patients incur higher healthcare costs for specialist ambulatory care when their care is uncoordinated. This effect slightly increased after abolition of the copayment. Beyond that, the abolition of the copayment led to a substantial reduction in primary care coordination, particularly affecting vulnerable patients. Therefore, coordination of care in the ambulatory setting should be strengthened.	[Olm, Michaela; Linde, Klaus; Schneider, Antonius] Tech Univ Munich, TUM Sch Med, Inst Gen Practice & Hlth Serv Res, Munich, Bavaria, Germany; [Donnachie, Ewan; Tauscher, Martin; Gerlach, Roman] Bavarian Assoc Statutory Hlth Insurance Phys, Munich, Bavaria, Germany; [Maier, Werner; Schwettmann, Lars] German Res Ctr Environm Hlth GmbH, Inst Hlth Econ & Hlth Care Management, Helmholtz Zentrum Munchen, Neuherberg, Bavaria, Germany; [Schwettmann, Lars] Martin Luther Univ Halle Wittenberg, Dept Econ, Halle, Saxony Anhalt, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Martin Luther University Halle Wittenberg	Olm, M (corresponding author), Tech Univ Munich, TUM Sch Med, Inst Gen Practice & Hlth Serv Res, Munich, Bavaria, Germany.	michaela.olm@mri.tum.de	Donnachie, Ewan/E-3912-2019	Donnachie, Ewan/0000-0002-0668-0049; Linde, Klaus/0000-0002-2902-970X	Central Research Institute for Ambulatory Health Care in Germany	Central Research Institute for Ambulatory Health Care in Germany	The study was funded by the Central Research Institute for Ambulatory Health Care in Germany (Zentralinstitut fur die Kassenarztliche Versorgung in Deutschland, https://www.zi.de/).MO's position was financed from the funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], LISTE ICD SCHLUSSELN; Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Basu S, 2019, JAMA INTERN MED, V179, P506, DOI 10.1001/jamainternmed.2018.7624; BBSR, RAUM REF RAUM REF; Biernikiewicz Malgorzata, 2019, J Mark Access Health Policy, V7, P1595953, DOI 10.1080/20016689.2019.1595953; Brenner G., 2005, Z ALLG MED, V81, P377; Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164; Delnoij D, 2000, J Health Serv Res Policy, V5, P22; Farbmacher H, 2013, HEALTH ECON, V22, P1111, DOI 10.1002/hec.2955; Fitzmaurice G, 2009, CH CRC HANDB MOD STA, P1; Forrest CB, 1998, AM J PUBLIC HEALTH, V88, P1330, DOI 10.2105/AJPH.88.9.1330; Garrido MV, 2011, SCAND J PRIM HEALTH, V29, P28, DOI 10.3109/02813432.2010.537015; Grabka MM, 2006, MED KLIN, V101, P476, DOI 10.1007/s00063-006-1067-z; Gray DJP, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021161; Grobe TG, 2018, SCHRIFTENREIHE GESUN; Hansen J, 2015, HEALTH AFFAIR, V34, P1531, DOI 10.1377/hlthaff.2015.0582; Hernn MA, 2020, CAUSAL INFERENCE WHA; Heuer J., 2016, PLACEBO ODER WUNDERP; Hoffmann F, 2012, GESUNDHEITSWESEN, V74, P291, DOI 10.1055/s-0031-1275711; Institut des Bewertungsausschusses, KLASS KM87A 2015 KLASS KM87A 2015; Kilham R, 2015, CLIN EXP OPTOM, V98, P105, DOI 10.1111/cxo.12245; Kringos D, 2013, BRIT J GEN PRACT, V63, pE742, DOI 10.3399/bjgp13X674422; Kringos DS, 2013, HEALTH AFFAIR, V32, P686, DOI 10.1377/hlthaff.2012.1242; Lehnert T, 2012, BUNDESGESUNDHEITSBLA, V55, P685, DOI 10.1007/s00103-012-1475-6; Macinko J, 2003, HEALTH SERV RES, V38, P831, DOI 10.1111/1475-6773.00149; Maier W, 2012, GESUNDHEITSWESEN, V74, P416, DOI 10.1055/s-0031-1280846; Mehring M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016218; Noble M, 2006, ENVIRON PLANN A, V38, P169, DOI 10.1068/a37168; Ohlmeier C, 2014, BUNDESGESUNDHEITSBLA, V57, P464, DOI 10.1007/s00103-013-1912-1; Olm M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035575; Schneider A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011621; Schneider A, 2013, DTSCH ARZTEBL INT, V110, P653, DOI 10.3238/arztebl.2013.0653; Schreyogg J, 2010, EUR J HEALTH ECON, V11, P331, DOI 10.1007/s10198-009-0179-9; Shi LY, 2003, AM J PUBLIC HEALTH, V93, P138, DOI 10.2105/AJPH.93.1.138; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; Starfield B, 1998, PRIMARY CARE BALANCI; Statistische Amter des Bundes und der Lander, 2014, BEV FLACH BEV NACH L BEV FLACH BEV NACH L; Swart E, 2015, GESUNDHEITSWESEN, V77, DOI [10.1055/s-0034-1396815, 10.1055/s-0035-1562981]; Williams JS, 2016, AM J MED SCI, V351, P33, DOI 10.1016/j.amjms.2015.10.012; Winkelmann R, 2004, HEALTH ECON, V13, P1081, DOI 10.1002/hec.868	43	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2021	16	6							e0253919	10.1371/journal.pone.0253919	http://dx.doi.org/10.1371/journal.pone.0253919			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9DB	34181693	gold, Green Published			2023-01-03	WOS:000671695800025
J	Odwe, G; Wado, YD; Obare, F; Machiyama, K; Cleland, J				Odwe, George; Wado, Yohannes Dibaba; Obare, Francis; Machiyama, Kazuyo; Cleland, John			Method-specific beliefs and subsequent contraceptive method choice: Results from a longitudinal study in urban and rural Kenya	PLOS ONE			English	Article							SOCIAL NETWORKS	Introduction Evidence from sub-Saharan Africa, including Kenya, shows that negative beliefs about contraceptive methods are associated with non-use. However, little is known about the relationship between contraceptive beliefs and subsequent method choice. Methodology We used data from a two-year longitudinal survey of married women aged 15-39 years at enrollment from one urban site (Nairobi) and one rural site (Homa Bay) in Kenya. Analysis entails descriptive statistics and estimation of a conditional logit analysis to examine associations between method-specific beliefs and choice of injectables, implants or pills among women who were not using any method or were pregnant at baseline (round 1) but adopted these methods at 12-month follow-up (Nairobi, n = 221; Homa Bay n = 197). Results Beliefs about pills, injectables and implants among non-users were generally negative. With the partial exception of the pill in Nairobi, the majority thought that each method was likely to cause serious health problems, unpleasant side effects, menstrual disruption, and would be unsafe for long-term use. In both sites, satisfied past use of a method and the perception that a method is easy to use had a major influence on method choice. Concerns about menstrual disruption and safety for long-term use were unimportant in both sites. There were some marked differences between the two sites. Beliefs about long-term fertility impairment and perceived husband approval had strong influences on choice of injectables, implants or pills in the urban site but not in the rural site. Conclusion The relative importance of beliefs, some erroneous, in predisposing women to choose one method over another appears to be conditioned by the social context. There is need for family planning counseling programmes to pay attention to erroneous beliefs and misconceptions about contraceptives.	[Odwe, George; Obare, Francis] Populat Council, Nairobi, Kenya; [Wado, Yohannes Dibaba] African Populat & Hlth Res Ctr, Nairobi, Kenya; [Machiyama, Kazuyo; Cleland, John] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England	African Population & Health Research Centre; University of London; London School of Hygiene & Tropical Medicine	Odwe, G (corresponding author), Populat Council, Nairobi, Kenya.	godwe@popcouncil.org		Wado, Yohannes Dibaba/0000-0002-7200-6116	United Kingdom's Department for International Development	United Kingdom's Department for International Development	The study that provided data for this paper was funded by the United Kingdom's Department for International Development through the Strengthening Evidence for Programming on Unintended Pregnancy (STEP UP) Research Programme Consortium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agyei-Baffour P, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0022-y; Beguy D, 2017, POPUL DEV REV, V43, P216, DOI 10.1111/padr.12038; Behrman JR, 2002, DEMOGRAPHY, V39, P713, DOI 10.2307/3180828; Blackstone SR, 2017, INT Q COMMUNITY HEAL, V37, P79, DOI 10.1177/0272684X16685254; Delavande A, 2019, J POLIT ECON, V127, P2343, DOI 10.1086/701808; Grady WR, 1999, FAM PLANN PERSPECT, V31, P168, DOI 10.2307/2991589; Gueye A, 2015, INT PERSPECT SEX R H, V41, P191, DOI 10.1363/4119115; Imbuki K., 2010, AFR J REPROD HEALTH, V14; Jain Anrudh K, 2013, Int Perspect Sex Reprod Health, V39, P133, DOI 10.1363/3913313; Kamau RK, 1996, E AFR MED J, V73, P651; Kim YM, 1999, HEALTH COMMUN, V11, P1, DOI 10.1207/s15327027hc1101_1; KNBS (Kenya National Bureau of Statistics) Ministry of Health (MOH) National AIDS Control Council (NACC) Kenya Medical Research Institute (KEMRI) and National Council for Population and Development (NCPD), 2015, KENYA DEMOGRAPHIC HL; Kohler HP, 1997, DEMOGRAPHY, V34, P369, DOI 10.2307/3038290; Kungu W., 2020, F1000RESEARCH, V9, P197, DOI [10.12688/f1000research.22481.1, DOI 10.12688/F1000RESEARCH.22481.1]; Lessard LN, 2012, PERSPECT SEX REPRO H, V44, P194, DOI 10.1363/4419412; Lowe SMP, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-85; Machiyama K, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0514-7; Machiyama K, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-016-0268-z; Madden T, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.01.051; Magadi MA, 2003, STUD FAMILY PLANN, V34, P149, DOI 10.1111/j.1728-4465.2003.00149.x; McFadden D., 1974, CONDITIONAL LOGIT AN; National AIDS and STI Control Programme (NASCOP), 2020, PREL KENY POP BAS HI; Obare F., 2020, J BIOSOC SCI; Ochako R, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0314-6; Odwe G., 2020, CONTRACEPTION X, V2, P100030, DOI [10.1016/j.conx.2020.100030, DOI 10.1016/J.CONX.2020.100030]; Odwe G, 2019, J BIOSOC SCI, V51, P491, DOI 10.1017/S0021932018000299; Polis CB, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0561-0; Rademacher KH, 2018, GLOB HEALTH-SCI PRAC, V6, P603, DOI 10.9745/GHSP-D-18-00093; Rutenberg N, 1997, STUD FAMILY PLANN, V28, P290, DOI 10.2307/2137860; Seiber EE, 2007, INT FAM PLAN PERSPEC, V33, P117, DOI 10.1363/3311707; Snow R., 1997, ACCEPTABILITY USERS, P231; Tumlinson Katherine, 2013, Afr J Reprod Health, V17, P79; United Nations DoEaSA Population Division, 2019, STESASERA435 UN DOEA; Williamson Lisa M, 2009, Reprod Health, V6, P3, DOI 10.1186/1742-4755-6-3; Wyatt KD, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-28	35	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2021	16	6							e0252977	10.1371/journal.pone.0252977	http://dx.doi.org/10.1371/journal.pone.0252977			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BC	34143804	Green Published, gold			2023-01-03	WOS:000671690700002
J	Horton, LC; Feuerstein, JD				Horton, Laura C.; Feuerstein, Joseph D.			In recurrent C difficile infection, oral FMT capsules have a pooled cure rate of 82% (low-quality evidence)	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Horton, Laura C.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Feuerstein, Joseph D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center	Horton, LC (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.			Horton, Laura/0000-0002-7098-3650				Kao D, 2017, JAMA-J AM MED ASSOC, V318, P1985, DOI 10.1001/jama.2017.17077; Ramai D, 2021, DIGEST DIS SCI, V66, P369, DOI 10.1007/s10620-020-06185-7; Youngster I, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0680-9	3	0	0	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN	2021	174	6					JC65	JC65		10.7326/ACPJ202106150-065	http://dx.doi.org/10.7326/ACPJ202106150-065			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SS5IR	34058102				2023-01-03	WOS:000661788700006
J	Koulgi, S; Jani, V; Uppuladinne, VNM; Sonavane, U; Joshi, R				Koulgi, Shruti; Jani, Vinod; Uppuladinne, Mallikarjunachari V. N.; Sonavane, Uddhavesh; Joshi, Rajendra			Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2	PLOS ONE			English	Article							MOLECULAR-DYNAMICS; DOCKING; SIMULATIONS; SARS-COV-2; MECHANISM; PROTEINS; BINDING	Drug repurposing studies targeting inhibition of RNA dependent RNA polymerase (RdRP) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have exhibited the potential effect of small molecules. In the present work a detailed interaction study between the phytochemicals from Indian medicinal plants and the RdRP of SARS-CoV-2 has been performed. The top four phytochemicals obtained through molecular docking were, swertiapuniside, cordifolide A, sitoindoside IX, and amarogentin belonging to Swertia chirayita, Tinospora cordifolia and Withania somnifera. These ligands bound to the RdRP were further studied using molecular dynamics simulations. The principal component analysis of these systems showed significant conformational changes in the finger and thumb subdomain of the RdRP. Hydrogen bonding, salt-bridge and water mediated interactions supported by MM-GBSA free energy of binding revealed strong binding of cordifolide A and sitoindoside IX to RdRP. The ligand-interacting residues belonged to either of the seven conserved motifs of the RdRP. These residues were polar and charged amino acids, namely, ARG 553, ARG 555, ASP 618, ASP 760, ASP 761, GLU 811, and SER 814. The glycosidic moieties of the phytochemicals were observed to form favourable interactions with these residues. Hence, these phytochemicals may hold the potential to act as RdRP inhibitors owing to their stability in binding to the druggable site.	[Koulgi, Shruti; Jani, Vinod; Uppuladinne, Mallikarjunachari V. N.; Sonavane, Uddhavesh; Joshi, Rajendra] Ctr Dev Adv Comp C DAC, High Performance Comp Med & Bioinformat Applicat, Pune, Maharashtra, India	Centre for Development of Advanced Computing (C-DAC)	Joshi, R (corresponding author), Ctr Dev Adv Comp C DAC, High Performance Comp Med & Bioinformat Applicat, Pune, Maharashtra, India.	rajendra@cdac.in		Sonavane, Uddhavesh/0000-0002-2482-9126	Ministry of Electronics and Information Technology, Government of India	Ministry of Electronics and Information Technology, Government of India	This work was funded by the Ministry of Electronics and Information Technology, Government of India, under the project, National Supercomputing Mission (NSM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aftab SO, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02439-0; Ahmad J, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04502; Allen WJ, 2015, J COMPUT CHEM, V36, P1132, DOI 10.1002/jcc.23905; Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210; Bakan A, 2011, BIOINFORMATICS, V27, P1575, DOI 10.1093/bioinformatics/btr168; Bauer DC, 2020, TRANSBOUND EMERG DIS, V67, P1453, DOI 10.1111/tbed.13588; Caffeine, SCIFINDER CAS; Case D. A., 2016, REFERENCE MANUAL COV; Cherian SS, 2020, INDIAN J MED RES, V151, P160, DOI 10.4103/ijmr.IJMR_585_20; Chien MC, 2020, J PROTEOME RES, V19, P4690, DOI [10.1021/acs.jproteome.0c00392, 10.1101/2020.03.18.997585]; Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717; Dar PA, 2016, CURR PHARM DESIGN, V22, P535, DOI 10.2174/1381612822666151125001751; Delang L, 2018, ANTIVIR RES, V153, P85, DOI 10.1016/j.antiviral.2018.03.003; Elfiky AA, 2021, J BIOMOL STRUCT DYN, V39, P3204, DOI 10.1080/07391102.2020.1761882; Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117; Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011; Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033; Koulgi S, 2022, J BIOMOL STRUCT DYN, V40, P7230, DOI 10.1080/07391102.2021.1894985; Koulgi S, 2020, RSC ADV, V10, P26792, DOI 10.1039/d0ra04743k; Kumar V, 2016, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00308; Li C, 2020, INFECT GENET EVOL, V82, DOI 10.1016/j.meegid.2020.104285; Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Mani JS, 2020, VIRUS RES, V284, DOI 10.1016/j.virusres.2020.197989; Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h; Moustafa IM, 2011, J MOL BIOL, V410, P159, DOI 10.1016/j.jmb.2011.04.078; O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33; Pan L, 2012, ORG LETT, V14, P2118, DOI 10.1021/ol300657h; Parasuraman Subramani, 2014, Pharmacogn Rev, V8, P73, DOI 10.4103/0973-7847.134229; Parida PK, 2020, PHYTOTHER RES, V34, P3420, DOI 10.1002/ptr.6868; Pawar AY, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105984; Peters MB, 2010, J CHEM THEORY COMPUT, V6, P2935, DOI 10.1021/ct1002626; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Prajapat M, 2020, INDIAN J PHARMACOL, V52, P142, DOI 10.4103/ijp.IJP_338_20; Rakib A, 2020, MOLECULES, V25, DOI 10.3390/molecules25173936; Roe DR, 2018, J COMPUT CHEM, V39, P2110, DOI 10.1002/jcc.25382; Salehi B, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9100551; Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315; Serafin MB, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105969; Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Shree P, 2022, J BIOMOL STRUCT DYN, V40, P190, DOI 10.1080/07391102.2020.1810778; Shukla S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090637; Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360; Stefanelli P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.13.2000305; Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326; Thompson AA, 2007, J MOL BIOL, V366, P1459, DOI 10.1016/j.jmb.2006.11.070; ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009; Vardhan S, 2020, COMPUT BIOL MED, V124, DOI 10.1016/j.compbiomed.2020.103936; Vijayakumar BG, 2020, EUR J PHARMACOL, V886, DOI 10.1016/j.ejphar.2020.173448; Vimalanathan S, 2009, PHARM BIOL, V47, P422, DOI 10.1080/13880200902800196; Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762; Wang HH, 2020, EUR J CLIN MICROBIOL, V39, P1629, DOI 10.1007/s10096-020-03899-4; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005; Wang YY, 2021, J MED VIROL, V93, P300, DOI 10.1002/jmv.26264; Wu CR, 2020, ACTA PHARM SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008; Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3; Wu X, 2016, ONCOTARGETS THER, V9, P2935, DOI 10.2147/OTT.S105586; Yadav PD, 2020, INDIAN J MED RES, V151, P200, DOI 10.4103/ijmr.IJMR_663_20; Yang HB, 2019, BIOINFORMATICS, V35, P1067, DOI 10.1093/bioinformatics/bty707; Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560; Zhang LL, 2020, J PHYS CHEM B, V124, P6955, DOI 10.1021/acs.jpcb.0c04198; Zhao Z, 2020, J PROTEOME RES, V19, P4698, DOI 10.1021/acs.jproteome.0c00623	67	14	14	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2021	16	5							e0251801	10.1371/journal.pone.0251801	http://dx.doi.org/10.1371/journal.pone.0251801			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6MO	33984041	gold, Green Published			2023-01-03	WOS:000664628200119
J	Wu, Y; Levis, B; Sun, Y; He, C; Krishnan, A; Neupane, D; Bhandari, PM; Negeri, Z; Benedetti, A; Thombs, BD				Wu, Yin; Levis, Brooke; Sun, Ying; He, Chen; Krishnan, Ankur; Neupane, Dipika; Bhandari, Parash Mani; Negeri, Zelalem; Benedetti, Andrea; Thombs, Brett D.		DEPRESsion Screenin	Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTERNATIONAL DIAGNOSTIC INTERVIEW; PATIENT-DATA; RECOMMENDATIONS; RELIABILITY; PREVALENCE; VALIDITY; OUTCOMES; QUALITY; ADULTS; MINI	To evaluate the accuracy of the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) to screen for major depression among people with physical health problems. DESIGN Systematic review and individual participant data meta-analysis. DATA SOURCES Medline, Medline In-Process and Other Non-Indexed Citations, PsycInfo, and Web of Science (from inception to 25 October 2018). REVIEW METHODS Eligible datasets included HADS-D scores and major depression status based on a validated diagnostic interview. Primary study data and study level data extracted from primary reports were combined. For HADS-D cut-off thresholds of 5-15, a bivariate random effects meta-analysis was used to estimate pooled sensitivity and specificity, separately, in studies that used semi-structured diagnostic interviews (eg, Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders), fully structured interviews (eg, Composite International Diagnostic Interview), and the Mini International Neuropsychiatric Interview. One stage meta regression was used to examine whether accuracy was associated with reference standard categories and the characteristics of participants. Sensitivity analyses were done to assess whether including published results from studies that did not provide raw data influenced the results. RESULTS Individual participant data were obtained from 101 of 168 eligible studies (60%; 25 574 participants (72% of eligible participants), 2549 with major depression). Combined sensitivity and specificity was maximised at a cut-off value of seven or higher for semi-structured interviews, fully structured interviews, and the Mini International Neuropsychiatric Interview. Among studies with a semi-structured interview (57 studies, 10 664 participants, 1048 with major depression), sensitivity and specificity were 0.82 (95% confidence interval 0.76 to 0.87) and 0.78 (0.74 to 0.81) for a cut-off value of seven or higher, 0.74 (0.68 to 0.79) and 0.84 (0.81 to 0.87) fora cut-off value of eight or higher, and 0.44 (0.38 to 0.51) and 0.95 (0.93 to 0.96) for a cut-off value of 11 or higher. Accuracy was similar across reference standards and subgroups and when published results from studies that did not contribute data were included. CONCLUSIONS When screening for major depression, a HADS-D cut-off value of seven or higher maximised combined sensitivity and specificity. A cut-off value of eight or higher generated similar combined sensitivity and specificity but was less sensitive and more specific. To identify medically ill patients with depression with the HADS-D, lower cut-off values could be used to avoid false negatives and higher cut-off values to reduce false positives and identify people with higher symptom levels. TRIAL REGISTRATION PROSPERO CRD42015016761.	[Wu, Yin; Sun, Ying; He, Chen; Krishnan, Ankur; Neupane, Dipika; Bhandari, Parash Mani; Negeri, Zelalem; Thombs, Brett D.] Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ, Canada; [Wu, Yin; Thombs, Brett D.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada; [Levis, Brooke] Keele Univ, Ctr Prognosis Res, Sch Primary Community & Social Care Med, Keele, Staffs, England; [Benedetti, Andrea; Thombs, Brett D.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Benedetti, Andrea] McGill Univ, Resp Epidemiol & Clin Res Unit, Ctr Hlth, Montreal, PQ, Canada; [Benedetti, Andrea; Thombs, Brett D.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Thombs, Brett D.] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Thombs, Brett D.] McGill Univ, Dept Educ & Counselling Psychol, Montreal, PQ, Canada; [Thombs, Brett D.] McGill Univ, Biomed Eth Unit, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; Keele University; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University	Thombs, BD (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ, Canada.; Thombs, BD (corresponding author), McGill Univ, Dept Psychiat, Montreal, PQ, Canada.; Thombs, BD (corresponding author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.; Thombs, BD (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Thombs, BD (corresponding author), McGill Univ, Dept Psychol, Montreal, PQ, Canada.; Thombs, BD (corresponding author), McGill Univ, Dept Educ & Counselling Psychol, Montreal, PQ, Canada.; Thombs, BD (corresponding author), McGill Univ, Biomed Eth Unit, Montreal, PQ, Canada.	brett.thombs@mcgill.ca	Julião, Miguel/G-3868-2014; Gilbody, Simon/AAY-3720-2021; Patten, Scott/B-4434-2011; Wu, Yin/AFR-0274-2022; Strobel, Natalie/O-9174-2014	Julião, Miguel/0000-0001-9283-5045; Gilbody, Simon/0000-0002-8236-6983; Patten, Scott/0000-0001-9871-4041; Jenewein, Josef/0000-0003-4271-918X; Strobel, Natalie/0000-0002-2962-5704; Rieckmann, Nina/0000-0002-6870-451X; Thombs, Brett D./0000-0002-5644-8432; , Gemma/0000-0001-8931-4513	Canadian Institutes of Health Research (CIHR) [KRS-140045, PCG155468]; Fonds de recherche du QuebecSante (FRQ-S); Faculty of Medicine, McGill University; Research Institute of the McGill University Health Centre; FRQ-S researcher salary award; Tier 1 Canada Research Chair; Vanier Canada Graduate Scholarship; University of Calgary Cumming School of Medicine; Hotchkiss Brain Institute; Alberta Innovates; CIHR [THC135234]; Crohn's and Colitis Canada; Research Manitoba Chair; Bingham Chair in Gastroenterology; Waugh Family Chair in Multiple Sclerosis; Research Council of Lithuania [LIG03/2011]; National Science Council, Taiwan [NSC 962314B182A090MY2]; Waikato Clinical School, University of Auckland; Waikato Medical Research Foundation; Waikato Respiratory Research Fund; Catalan Agency for Health Technology Assessment and Research [102/19/2004]; Promoting Psychological Research and Training on HealthDisparities Issues at Ethnic MinorityServing Institutions Grants (ProDIGs) from the American Psychological Association; Research Grant "Ramon CarrilloArturo Ofiativa for Multicentric Studies" (2015) from the commission "Salud Investiga" of the Ministry of Health and Social Action of Argentina [1853]; Birmingham and Solihull Mental Health Foundation Trust; German Federal Ministry of Education and Research [01GY1155A, 01GY1150]; Maastricht University; Multiple Sclerosis Society of Canada; Drummond Foundation; Department of Psychiatry, University Health Network; Japanese Ministry of Health, Labour, and Welfare [11-2, 9-31]; Japanese Ministry of Education, Culture, Sports, Science, and Technology; European Commission DG Health and Consumer Protection (University of Ferrara) [SI2.307317 2000CVGG2026]; University of Ferrara; Fondazione Cassa di Risparmio di Ferrara; Federal Ministry of Education and Research; Federation of German Pension Insurance Institutes; Medical Faculty of the University of Heidelberg [175/2000]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science, and Technology [20090087344]; Korea Health 21 R&D, Ministry of Health and Welfare, Republic of Korea [A102065]; Kathleen Cuningham Foundation (National Breast Cancer Foundation); Cancer Council of Victoria; National Health and Medical Research Council; Bethlehem Griffiths Research Foundation; medical faculty of the University of Heidelberg, Germany [121/2000]; Instituto de Salud Carlos III [EO PI08/90869, FISE08/00268]; Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) [PFB12/2007]; Fondo Nacional de Desarrolo Cientifico y Tecnologico (FONDECYT) [1110849]; Japanese Ministry of Health, Labour, and Welfare through Research on Psychiatric and Neurological Disease and Mental Health [16190501, 19230701, 20300701]; German Cancer Aid within the psychosocial oncology funding priority program [107465]; French Society of Dermatology; University Hospital of Saint Etienne; Australian Government National Health and Medical Research Council program grant; NHMRC Program [1073041]; Scottish Home and Health Department; Ministry of Health of Spain [PI040418]; Transport Accident Commission Grant; Instituto de Investigacion Hospital 12 de Octubre (i+12); British Geriatric Society, Scotland; Research Council of Norway; NHS Lothian NeuroOncology Endowment Fund; PRONEX Program (NENASC Project); PPSUS Program of Fundacao de Amparo a esquisa e Inovacao do Estado de Santa Catarina (FAPESC); National Science and Technology Institute for Translational Medicine (INCTTM); Universiti Sains Malaysia; University of Sydney Cancer Research Fund; IDEA grants from the Canadian Prostate Cancer Research Initiative; Canadian Breast Cancer Research Alliance; German Federal Ministry for Education and Research [01ZZ0106, 7DZAIQTX]; University of Leipzig [formel. 1-57]; Federal Ministry of Education and Research (BMBF); Western and Central Melbourne Integrated Cancer Service; University of Melbourne; Medical Research Council, UK; Chest Heart and Stroke, Scotland; Government of Western Australia, Department of Health [G1000794]; CNPq, Brazil; Fapemig, Brazil; FAPEMIG [APq-03539-13]; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (Fapemig) [APq-03539-13]; Hungarian Research Council [ETT 395]; Melbourne Health; Kaohsiung Chang Gung Memorial Hospital, Taiwan [CMRPG8A0581, CMRPG891321]; Victorian Health Promotion Foundation [91-0095]; National Health and Medical Research Council [628582, 299831, 251638, 509103, 1026265, 009367, 1104438]; Alberta Health Services; Health Solutions; Health Foundation Limburg; Adriana van RinsumPonsen Stichting; Irish Cancer Society [CRP08GAL]; Freiburg/Bad Saeckingen Rehabilitation Research Network [01 GD 9802/4]; Stroke Association; Medical Research Council; Catalonia Government [DURSI 2009SGR1119]; Federal Ministry of Education and Research [BMBF 01GY1154]; Hunter Medical Research Institute	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de recherche du QuebecSante (FRQ-S); Faculty of Medicine, McGill University; Research Institute of the McGill University Health Centre; FRQ-S researcher salary award; Tier 1 Canada Research Chair(Canada Research Chairs); Vanier Canada Graduate Scholarship; University of Calgary Cumming School of Medicine; Hotchkiss Brain Institute; Alberta Innovates; CIHR(Canadian Institutes of Health Research (CIHR)); Crohn's and Colitis Canada; Research Manitoba Chair; Bingham Chair in Gastroenterology; Waugh Family Chair in Multiple Sclerosis; Research Council of Lithuania(Research Council of Lithuania (LMTLT)); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Waikato Clinical School, University of Auckland; Waikato Medical Research Foundation; Waikato Respiratory Research Fund; Catalan Agency for Health Technology Assessment and Research; Promoting Psychological Research and Training on HealthDisparities Issues at Ethnic MinorityServing Institutions Grants (ProDIGs) from the American Psychological Association; Research Grant "Ramon CarrilloArturo Ofiativa for Multicentric Studies" (2015) from the commission "Salud Investiga" of the Ministry of Health and Social Action of Argentina; Birmingham and Solihull Mental Health Foundation Trust; German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Maastricht University; Multiple Sclerosis Society of Canada; Drummond Foundation; Department of Psychiatry, University Health Network; Japanese Ministry of Health, Labour, and Welfare(Ministry of Health, Labour and Welfare, Japan); Japanese Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); European Commission DG Health and Consumer Protection (University of Ferrara); University of Ferrara; Fondazione Cassa di Risparmio di Ferrara(Fondazione Carife); Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Federation of German Pension Insurance Institutes; Medical Faculty of the University of Heidelberg; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science, and Technology(National Research Foundation of Korea); Korea Health 21 R&D, Ministry of Health and Welfare, Republic of Korea; Kathleen Cuningham Foundation (National Breast Cancer Foundation); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Bethlehem Griffiths Research Foundation; medical faculty of the University of Heidelberg, Germany; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)); Fondo Nacional de Desarrolo Cientifico y Tecnologico (FONDECYT)(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Japanese Ministry of Health, Labour, and Welfare through Research on Psychiatric and Neurological Disease and Mental Health; German Cancer Aid within the psychosocial oncology funding priority program; French Society of Dermatology; University Hospital of Saint Etienne; Australian Government National Health and Medical Research Council program grant(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Program(National Health and Medical Research Council (NHMRC) of Australia); Scottish Home and Health Department; Ministry of Health of Spain(Spanish Government); Transport Accident Commission Grant; Instituto de Investigacion Hospital 12 de Octubre (i+12); British Geriatric Society, Scotland; Research Council of Norway(Research Council of Norway); NHS Lothian NeuroOncology Endowment Fund; PRONEX Program (NENASC Project); PPSUS Program of Fundacao de Amparo a esquisa e Inovacao do Estado de Santa Catarina (FAPESC); National Science and Technology Institute for Translational Medicine (INCTTM); Universiti Sains Malaysia(Universiti Sains Malaysia); University of Sydney Cancer Research Fund(University of Sydney); IDEA grants from the Canadian Prostate Cancer Research Initiative; Canadian Breast Cancer Research Alliance; German Federal Ministry for Education and Research(Federal Ministry of Education & Research (BMBF)); University of Leipzig; Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Western and Central Melbourne Integrated Cancer Service; University of Melbourne(University of Melbourne); Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Chest Heart and Stroke, Scotland; Government of Western Australia, Department of Health; CNPq, Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fapemig, Brazil(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); FAPEMIG(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (Fapemig)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Hungarian Research Council; Melbourne Health; Kaohsiung Chang Gung Memorial Hospital, Taiwan; Victorian Health Promotion Foundation; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Alberta Health Services; Health Solutions; Health Foundation Limburg; Adriana van RinsumPonsen Stichting; Irish Cancer Society; Freiburg/Bad Saeckingen Rehabilitation Research Network; Stroke Association; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Catalonia Government; Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Hunter Medical Research Institute	Funding: The study was funded by the Canadian Institutes of Health Research (CIHR, KRS-140045 and PCG155468) .YW and BL were supported by Fonds de recherche du QuebecSante (FRQ-S) Postdoctoral Training Fellowships. DN was supported by GR Caverhill Fellowship from the Faculty of Medicine, McGill University. PMB was supported by a studentship from the Research Institute of the McGill University Health Centre. AB was supported by a FRQ-S researcher salary award. BDT was supported by a Tier 1 Canada Research Chair. DBR was supported by a Vanier Canada Graduate Scholarship. The primary studies by Scott et al, Amoozegar et al, and Prisnie et al were supported by the University of Calgary Cumming School of Medicine, Alberta Health Services, and the Hotchkiss Brain Institute. SBP was supported by a Senior Health Scholar Award from Alberta Innovates, Health Solutions. The primary study by Marrie et al was supported by the CIHR (THC135234) , Crohn's and Colitis Canada, a Research Manitoba Chair, and the Waugh Family Chair in Multiple Sclerosis (to RAM) . The primary study by Bernstein et al was supported by the CIHR (THC-135234) and Crohn's and Colitis Canada. CNB was supported in part by the Bingham Chair in Gastroenterology. RAM was supported by the Waugh Family Chair in Multiple Sclerosis and the Research Manitoba Chair. The primary study by Butnoriene et al was supported by a grant from the Research Council of Lithuania (LIG03/2011) . Jurate Butnoriene, PhD, who did the data collection and analysis as part of her PhD thesis for the primary study by Butnoriene et al, passed away and could not participate in this project. Dr Robertas Bunevicius, MD, PhD (1958-2016) was the principal investigator of the primary studies by Butnoriene et al and Bunevicius et al, but passed away and could not participate in this project. The primary study by Chen et al was supported by the National Science Council, Taiwan (NSC 962314B182A090MY2) . The primary study by Cheung et al was supported by the Waikato Clinical School, University of Auckland, the Waikato Medical Research Foundation and the Waikato Respiratory Research Fund. The primary study by CostaRequena et al was supported by the Catalan Agency for Health Technology Assessment and Research (No 102/19/2004) . The primary study by Cukor et al was supported in part by a Promoting Psychological Research and Training on HealthDisparities Issues at Ethnic MinorityServing Institutions Grants (ProDIGs) awarded to DC from the American Psychological Association. The primary study by De la Torre et al was supported by a Research Grant "Ramon CarrilloArturo Ofiativa for Multicentric Studies" (2015) from the commission "Salud Investiga" of the Ministry of Health and Social Action of Argentina (grant No 1853) . The primary study by De Souza et al was supported by Birmingham and Solihull Mental Health Foundation Trust. The primary study by Dorow et al was supported by the German Federal Ministry of Education and Research (grant/award No 01GY1155A) . The primary study by Douven et al was supported by Maastricht University, Health Foundation Limburg and the Adriana van RinsumPonsen Stichting. The primary study by Honarmand et al was supported by a grant from the Multiple Sclerosis Society of Canada. The primary study by Fischer et al was supported as part of the RECODEHF study by the German Federal Ministry of Education and Research (01GY1150) . The primary study by Gagnon et al was supported by the Drummond Foundation and the Department of Psychiatry, University Health Network.; The primary study by Akechi et al was supported in part by a GrantinAid for Cancer Research (11-2) from the Japanese Ministry of Health, Labour, and Welfare and a GrantinAid for Young Scientists (B) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology. The primary study by Kugaya et al was supported in part by a GrantinAid for Cancer Research (9-31) and the SecondTerm Comprehensive 10year Strategy for Cancer Control from the Japanese Ministry of Health, Labour, and Welfare. The primary study Ryan et al was supported by the Irish Cancer Society (grant CRP08GAL) . The primary study by Grassi et al was supported by the European Commission DG Health and Consumer Protection (agreement with the University of FerraraSI2.307317 2000CVGG2026) , the University of Ferrara, and the Fondazione Cassa di Risparmio di Ferrara. The primary study by Harter et al was supported by the Federal Ministry of Education and Research, the Federation of German Pension Insurance Institutes, and the Freiburg/Bad Saeckingen Rehabilitation Research Network (grant 01 GD 9802/4) . The primary study by Keller et al was supported by the Medical Faculty of the University of Heidelberg (grant No 175/2000) . The primary study by Kang et al was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (20090087344) , and was supported by a grant of the Korea Health 21 R&D, Ministry of Health and Welfare, Republic of Korea (A102065) . The primary study by Jang et al was supported by a grant from the Korea Health 21 R&D, Ministry of Health and Welfare, Republic of Korea. The primary study by Love et al (2004) was supported by the Kathleen Cuningham Foundation (National Breast Cancer Foundation) , the Cancer Council of Victoria and the National Health and Medical Research Council. The primary study by Love et al (2002) was supported by a grant from the Bethlehem Griffiths Research Foundation. The primary study by Lowe et al was supported by the medical faculty of the University of Heidelberg, Germany (project 121/2000) . The primary study by Navines et al was supported in part by grants from the Instituto de Salud Carlos III (EO PI08/90869) and (PSIGEN-VHC Study: FISE08/00268) . The primary study by Massardo et al was supported by Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) grant No PFB12/2007 and Fondo Nacional de Desarrolo Cientifico y Tecnologico (FONDECYT; grant No 1110849) . The primary study by Matsuoka et al was supported by the Japanese Ministry of Health, Labour, and Welfare through Research on Psychiatric and Neurological Disease and Mental Health (16190501, 19230701, and 20300701) . The primary study by Hartung et al was supported by the German Cancer Aid within the psychosocial oncology funding priority program (grant No 107465) . The primary study by Consoli et al was supported by grants from the French Society of Dermatology and the University Hospital of Saint Etienne. The primary study by McFarlane et al was supported by an Australian Government National Health and Medical Research Council program grant. MLO was supported by grants from NHMRC Program (1073041) during the conduct of the study. The primary study by O'Rourke et al was supported by the Scottish Home and Health Department, Stroke Association, and Medical Research Council. The primary study by SanchezGistau et al was supported by a grant from the Ministry of Health of Spain (PI040418) and in part by the Catalonia Government, DURSI 2009SGR1119.; The primary study by Gould et al was supported by the Transport Accident Commission Grant. The primary study by BayonPerez et al was supported by a grant from the Instituto de Investigacion Hospital 12 de Octubre (i+12) . FP was an investigator from the Intensification of Research Activity Program of the Instituto de Investigacion Hospital 12 de Octubre (i+12) during the conduct of the study. The primary study by Lees et al was supported by a "startup" research grant from the British Geriatric Society, Scotland. The primary study by Reme et al was supported by the Research Council of Norway. The primary study by Rooney et al was supported by the NHS Lothian NeuroOncology Endowment Fund. The primary study by Schwarzbold et al was supported by PRONEX Program (NENASC Project) and PPSUS Program of Fundacao de Amparo a esquisa e Inovacao do Estado de Santa Catarina (FAPESC) and the National Science and Technology Institute for Translational Medicine (INCTTM) . The primary study by Azah et al was supported by Universiti Sains Malaysia. The primary studies bysupported by Malaysia. primary by Patel et al (2010 and 2011) were supported by the University of Sydney Cancer Research Fund. The primary study by Simard et al was supported by IDEA grants from the Canadian Prostate Cancer Research Initiative and the Canadian Breast Cancer Research Alliance, as well as a studentship from the CIHR. The primary study by Singer et al (2009) was supported by a grant from the German Federal Ministry for Education and Research (No 01ZZ0106) . The primary study by Singer et al (2008) was supported by grants from the German Federal Ministry for Education and Research (No 7DZAIQTX) and of the University of Leipzig (No formel. 1-57). The primary study by Meyer et al was supported by the Federal Ministry of Education and Research (BMBF). The primary study by Stafford et al (2014) was supported in part by seed funding from the Western and Central Melbourne Integrated Cancer Service. The primary study by Stafford et al (2007) was supported by the University of Melbourne. The primary study by Stone et al was supported by the Medical Research Council, UK and Chest Heart and Stroke, Scotland. The primary study by Phan et al was supported by the Government of Western Australia, Department of Health (grant No G1000794). The primary study by de Oliveira et al was supported by CNPq and Fapemig, Brazil. The primary study by Pedroso et al (2018) was supported by FAPEMIG (APq-03539-13). The primary study by Pedroso et al (2016) was supported by Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (Fapemig) (APq-03539-13). The primary study by Tiringer et al was supported by the Hungarian Research Council (ETT 395). The primary study by Tschorn et al is part of the study "CDCare-Supply of patients with coronary artery disease and comorbid depression: a patient oriented needs analysis." CDCare was funded by the Federal Ministry of Education and Research (BMBF; 01GY1154). The primary study by Turner et al was supported by a bequest from Jennie Thomas through Hunter Medical Research Institute. The primary study by Walterfang et al was supported by Melbourne Health. The primary study by Lee et al (2017) was supported by a grant from the Kaohsiung Chang Gung Memorial Hospital, Taiwan (CMRPG8A0581). The primary study by Lee et al (2016) was supported by a grant from Kaohsiung Chang Gung Memorial Hospital, Taiwan (CMRPG891321).; The primary study by Sia et al (PIs: Pasco and Williams) was supported by the Victorian Health Promotion Foundation (ID 91-0095) and the National Health and Medical Research Council (ID 628582; 299831; 251638; 509103; 1026265; 009367; 1104438). No other authors reported funding for primary studies or for their work on this study. No funder had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Ali S, 2006, DIABETIC MED, V23, P1165, DOI 10.1111/j.1464-5491.2006.01943.x; [Anonymous], 2013, DIAGNOSTIC STAT MANU, Vfifth; [Anonymous], 2000, DIAGNOSTIC STAT MANU, V4th; [Anonymous], 1987, DIAGNOSTIC STAT MANU; [Anonymous], 1994, DIAGNOSTIC STAT MANU, VFourth; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Brennan C, 2010, J PSYCHOSOM RES, V69, P371, DOI 10.1016/j.jpsychores.2010.04.006; Brugha TS, 1999, PSYCHOL MED, V29, P1013, DOI 10.1017/S0033291799008880; Brugha TS, 2001, PSYCHOL MED, V31, P1001, DOI 10.1017/S0033291701004184; Clarke DM, 1998, PSYCHOSOMATICS, V39, P318, DOI 10.1016/S0033-3182(98)71320-9; Dickens C, 2001, RHEUMATOLOGY, V40, P1327, DOI 10.1093/rheumatology/40.12.1327; Duhoux A, 2013, J AFFECT DISORDERS, V151, P265, DOI 10.1016/j.jad.2013.05.097; Duhoux A, 2009, SOC PSYCH PSYCH EPID, V44, P385, DOI 10.1007/s00127-008-0444-8; Endicott J, 1987, Acta Psychiatr Belg, V87, P361; Evans DL, 2005, BIOL PSYCHIAT, V58, P175, DOI 10.1016/j.biopsych.2005.05.001; Fann JR, 2008, GEN HOSP PSYCHIAT, V30, P112, DOI 10.1016/j.genhosppsych.2007.10.008; First M, 2016, STRUCTURED CLIN INTE; Gilbody S, 2006, BMJ-BRIT MED J, V332, P1027, DOI 10.1136/bmj.332.7548.1027; Harter M, 2010, DTSCH ARZTEBL INT, V107, P700, DOI 10.3238/arztebl.2010.0700; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Joffres M, 2013, CAN MED ASSOC J, V185, P775, DOI 10.1503/cmaj.130403; Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8; Levis B, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4022; Levis B, 2019, INT J METH PSYCH RES, V28, DOI 10.1002/mpr.1803; Levis B, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1476; Levis B, 2018, BRIT J PSYCHIAT, V212, P377, DOI 10.1192/bjp.2018.54; Levis B, 2017, AM J EPIDEMIOL, V185, P954, DOI 10.1093/aje/kww191; Macaskill P, 2010, COCHRANE HDB SYSTEMA, V1st; Meader N, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X613151; Mitchell AJ, 2010, J AFFECT DISORDERS, V126, P335, DOI 10.1016/j.jad.2010.01.067; Mitchell AJ, 2009, LANCET, V374, P609, DOI 10.1016/S0140-6736(09)60879-5; Mojtabai R, 2013, PSYCHOTHER PSYCHOSOM, V82, P161, DOI 10.1159/000345968; Mojtabai R, 2011, HEALTH AFFAIR, V30, P1434, DOI 10.1377/hlthaff.2010.1024; National Institute for Clinical Excellence, 2004, IMPROVING SUPPORTIVE; National Institute for Clinical Excellence, 2010, DEPRESSION ADULTS CH; National Institute for Health and Care Excellence, 2011, DEPRESSION ADULTS QU; Nosen E, 2008, HDB RES METHODS ABNO, P109; Palmer SC, 2003, J PSYCHOSOM RES, V54, P279, DOI 10.1016/S0022-3999(02)00640-2; PRESS-Peer Review of Electronic Search Strategies, 2016, 2015 GUIDELINE EXPLA; R Core Team, 2020, R LANG ENV STAT COMP; Rice DB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150067; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; Riley RD, 2008, STAT MED, V27, P6111, DOI 10.1002/sim.3441; ROBINS LN, 1988, ARCH GEN PSYCHIAT, V45, P1069; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rstudio, 2020, RSTUDIO INTEGRATED D; Rudisch B, 2003, BIOL PSYCHIAT, V54, P227, DOI 10.1016/S0006-3223(03)00587-0; Salameh JP, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2632; Sheehan DV, 1997, EUR PSYCHIAT, V12, P232, DOI 10.1016/S0924-9338(97)83297-X; Siu AL, 2016, JAMA-J AM MED ASSOC, V315, P380, DOI 10.1001/jama.2015.18392; Stewart LA, 2015, JAMA-J AM MED ASSOC, V313, P1657, DOI 10.1001/jama.2015.3656; Thombs BD, 2006, J GEN INTERN MED, V21, P30, DOI 10.1111/j.1525-1497.2005.00269.x; Thombs BD, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011913; Thombs BD, 2016, INT J METH PSYCH RES, V25, P145, DOI 10.1002/mpr.1504; Thombs BD, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1253; Thombs BD, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-13; Thombs BD, 2012, CAN MED ASSOC J, V184, P413, DOI 10.1503/cmaj.111035; Thombs BD, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4825; Vodermaier A, 2011, SUPPORT CARE CANCER, V19, P1899, DOI 10.1007/s00520-011-1251-4; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; World Health Organization, 1992, ICD 10 CLASS MENT BE; World Health Organization, 1994, SCHEDULES CLIN ASSES; Wu Y, 2020, PSYCHOTHER PSYCHOSOM, V90, P28, DOI 10.1159/000509283; Wu Y, 2020, J PSYCHOSOM RES, V129, DOI 10.1016/j.jpsychores.2019.109892; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	65	32	32	3	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	2021	373								n972	10.1136/bmj.n972	http://dx.doi.org/10.1136/bmj.n972			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	SB0RA	33972268	Green Published, hybrid			2023-01-03	WOS:000649709400002
J	Kwok, ABC; Haering, R; Travers, SK; Stathis, P				Kwok, Alan B. C.; Haering, Ron; Travers, Samantha K.; Stathis, Peter			Trends in wildlife rehabilitation rescues and animal fate across a six-year period in New South Wales, Australia	PLOS ONE			English	Article							CENTERS; ADMISSION; OUTCOMES; MORBIDITY; MORTALITY; BIRDS; SURVEILLANCE; SALMONELLA; FREQUENCY; FACILITY	Globally, millions of animals are rescued and rehabilitated by wildlife carers each year. Information gathered in this process is useful for uncovering threats to native wildlife, particularly those from anthropogenic causes. However, few studies using rehabilitation data include a diverse range of fauna, cover large geographical areas, and consider long-term trends. Furthermore, few studies have statistically modelled causes of why animals come into care, and what are their chances of survival. This study draws on 469,553 rescues reported over six years by wildlife rehabilitators for 688 species of bird, reptile, and mammal from New South Wales, Australia. For birds and mammals, 'abandoned/orphaned' and 'collisions with vehicles' were the dominant causes for rescue, however for reptiles this was 'unsuitable environment'. Overall rescue numbers were lowest in winter, and highest in spring, with six-times more 'abandoned/orphaned' individuals in spring than winter. Of the 364,461 rescues for which the fate of an animal was known, 92% fell within two categories: 'dead', 'died or euthanased' (54.8% of rescues with known fate) and animals that recovered and were subsequently released (37.1% of rescues with known fate). Modelling of the fate of animals indicated that the likelihood of animal survival (i.e. chance of: being released, left and observed, or permanent care), was related to the cause for rescue. In general, causes for rescue involving physical trauma (collisions, attacks, etc.) had a much lower likelihood of animals surviving than other causes such as 'unsuitable environment', 'abandoned/orphaned', and this also showed some dependence upon whether the animal was a bird, reptile, or mammal. This suggests rehabilitation efforts could be focused on particular threats or taxa to maximise success, depending on the desired outcomes. The results illustrate the sheer volume of work undertaken by rehabilitation volunteers and professionals toward both animal welfare and to the improvement of wildlife rehabilitation in the future.	[Haering, Ron; Stathis, Peter] New South Wales Natl Pk & Wildlife Serv Ind & Env, New South Wales Dept Planning, Parramatta, Australia; [Travers, Samantha K.] New South Wales Dept Planning Ind & Environm, Parramatta, Australia; [Travers, Samantha K.] Univ New South Wales, Sch Biol Earth & Environm Sci, Ctr Ecosyst Sci, Sydney, NSW, Australia	University of New South Wales Sydney	Haering, R (corresponding author), New South Wales Natl Pk & Wildlife Serv Ind & Env, New South Wales Dept Planning, Parramatta, Australia.	ron.haering@environment.nsw.gov.au		Kwok, Alan/0000-0003-3212-2654				AAMI Insurance, 2019, AAMI AN CAR ACC DAT; Molina-Lopez RA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181331; Aslan L, 2018, INDIAN J ANIM RES, V52, P623, DOI 10.18805/ijar.B-877; Brown JD, 2002, J WILDLIFE DIS, V38, P699, DOI 10.7589/0090-3558-38.4.699; Burton E, 2016, ANIMALS, V6, DOI 10.3390/ani6090056; Camacho M, 2016, PREV VET MED, V130, P106, DOI 10.1016/j.prevetmed.2016.06.012; Clarke K.R., 2006, PRIMER VERSION 6 USE; Martinez JC, 2014, HYSTRIX, V25, P107, DOI 10.4404/hystrix-25.2-10248; DPIE, 2020, NSW VOL WILDL REH SE; Englefield B, 2018, WILDLIFE RES, V45, P103, DOI 10.1071/WR17099; Garces A, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10081305; Garces A, 2019, BIRD STUDY, V66, P484, DOI 10.1080/00063657.2020.1726874; Garcia ME, 2007, VET MED-CZECH, V52, P464, DOI 10.17221/2049-VETMED; Goldsworthy SD, 2000, WILDLIFE RES, V27, P573, DOI 10.1071/WR99076; Green-Barber JM, 2019, BMC ZOOL, V4, DOI 10.1186/s40850-019-0047-8; Griffith JE, 2012, AUST VET J, V90, P457, DOI 10.1111/j.1751-0813.2012.00963.x; Griffith JE, 2013, J WILDLIFE DIS, V49, P18, DOI 10.7589/2012-05-135; Guy AJ, 2012, AUST MAMMAL, V34, P108, DOI 10.1071/AM10046; Haering Ron, 2021, Australian Zoologist, V41, P254, DOI 10.7882/AZ.2020.045; Haering Ron, 2020, Australian Zoologist, V40, P605, DOI 10.7882/AZ.2019.018; Hameau O, 2019, J ORNITHOL, V160, P581, DOI 10.1007/s10336-019-01633-2; Hanger J., 2005, NAT WILDL REH C GOLD; Harden J, 2002, J WILDLIFE REHABIL, V25, P4; Heathcote G, 2019, WILDLIFE RES, V46, P415, DOI 10.1071/WR18127; Janssen K, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10091500; Jijon S, 2007, J ZOO WILDLIFE MED, V38, P409, DOI 10.1638/1042-7260(2007)38[409:SEIFWA]2.0.CO;2; Kelly A, 2006, J RAPTOR RES, V40, P231, DOI 10.3356/0892-1016(2006)40[231:ADAOFE]2.0.CO;2; Kelly G, 2020, J NAT CONSERV, V57, DOI 10.1016/j.jnc.2020.125897; Klocker U, 2006, WILDLIFE RES, V33, P5, DOI 10.1071/WR04066; Lloyd Hannah B., 2015, Australian Zoologist, V37, P492, DOI 10.7882/AZ.2015.015; Long RB, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238805; Lopez G, 2011, VECTOR-BORNE ZOONOT, V11, P285, DOI 10.1089/vbz.2009.0232; Mariacher A, 2016, AVIAN BIOL RES, V9, P282, DOI 10.3184/175815516X14739467542487; McAlpine C, 2017, LANDSCAPE ECOL, V32, P663, DOI 10.1007/s10980-016-0479-2; Mo M, 2021, PAC CONSERV BIOL, V27, P61, DOI 10.1071/PC20031; Molina-Lopez RA, 2011, ANIM BIODIV CONSERV, V34, P401; Molina-Lopez RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060242; Molina-Lopez RA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024603; Molony SE, 2007, ANIM WELFARE, V16, P361; Montesdeoca N, 2017, BIRD STUDY, V64, P523, DOI 10.1080/00063657.2017.1411464; Mullineaux E, 2014, J SMALL ANIM PRACT, V55, P293, DOI 10.1111/jsap.12213; NSW Department of Planning Industry and Environment, 2020, ANN REP 2017 18; NSW Office of Environment and Heritage, 2019, REV NSW VOL WILDL RE; NSW Office of Environment and Heritage, 2011, COD PRACT INJ SICK O; Oros J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149398; Orr B, 2018, AUST VET J, V96, P475, DOI 10.1111/avj.12765; Pyke GH, 2018, CONSERV BIOL, V32, P50, DOI 10.1111/cobi.12937; R Core Team, 2021, R LANG ENV STAT COMP; Randall NJ, 2012, J WILDLIFE DIS, V48, P646, DOI 10.7589/0090-3558-48.3.646; Rodriguez B, 2010, J RAPTOR RES, V44, P30, DOI 10.3356/JRR-09-40.1; Scheelings TF, 2015, J WILDLIFE DIS, V51, P712, DOI 10.7589/2014-09-230; Schenk A., 2017, J VET SCI ANIM HUSBA, V5, P1; Schenk AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093517; Schmidt-French B, 2006, J WILDLIFE REHABIL, V28, P6; Shine R, 2001, BIOL CONSERV, V102, P271, DOI 10.1016/S0006-3207(01)00102-1; Skaug H., 2018, GLMMADMB GEN LINEAR; Smith WA, 2002, J ZOO WILDLIFE MED, V33, P228, DOI 10.1638/1042-7260(2002)033[0228:SICWSP]2.0.CO;2; Taylor-Brown A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0206958; Tribe Andrew, 2000, Human Dimensions of Wildlife, V5, P69; Turnbull D., 2007, NATL WILDLIFE REHABI; Vidal-Valles D, 2018, ANIM BIODIV CONSERV, V41, P379, DOI 10.32800/abc.2018.41.0379; Wimberger K, 2010, ANIM WELFARE, V19, P481	62	7	8	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257209	10.1371/journal.pone.0257209	http://dx.doi.org/10.1371/journal.pone.0257209			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9EM	34506558	gold, Green Published			2023-01-03	WOS:000729120700121
J	Lanzkron, S; Little, J; Wang, H; Field, JJ; Shows, JR; Haywood, C; Saheed, M; Proudford, M; Robertson, D; Kincaid, A; Burgess, L; Green, C; Seufert, R; Brooks, J; Piehet, A; Griffin, B; Arnold, N; Frymark, S; Wallace, M; Hamayel, NA; Huang, CY; Segal, JB; Varadhan, R				Lanzkron, Sophie; Little, Jane; Wang, Hang; Field, Joshua J.; Shows, J. Ryan; Haywood, Carlton; Saheed, Mustapha; Proudford, Marc; Robertson, Derek; Kincaid, Adrienne; Burgess, Lorri; Green, Charles; Seufert, Rebecca; Brooks, Jasmine; Piehet, Allie; Griffin, Brandi; Arnold, Nicole; Frymark, Steven; Wallace, Marcus; Hamayel, Nebras Abu Al; Huang, Chiung-Yu; Segal, Jodi B.; Varadhan, Ravi			Treatment of Acute Pain in Adults With Sickle Cell Disease in an Infusion Center Versus the Emergency Department A Multicenter Prospective Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							UNCOMPLICATED VASOOCCLUSIVE CRISES; INPATIENT MANAGEMENT; PROPENSITY SCORE; CARE; CHILDREN	Background: Patients with sickle cell disease (SCD) have vaso-occlusive crises (VOCs). Infusion centers (ICs) are alternatives to emergency department (ED) care and may improve patient outcomes. Objective: To assess whether care in ICs or EDs leads to better outcomes for the treatment of uncomplicated VOCs. Design: Prospective cohort. (ClinicalTrials.gov: NCT02411396) Setting: 4 U.S. sites, with recruitment between April 2015 and December 2016. Participants: Adults with SCD living within 60 miles of a study site. Measurements: Participants were followed for 18 months after enrollment. Outcomes of interest were time to first dose of parenteral pain medication, whether pain reassessment was completed within 30 minutes after the first dose, and patient disposition on discharge from the acute care visit. Treatment effects for ICs versus EDs were estimated using a time-varying propensity score adjustment. Results: Researchers enrolled 483 participants; the 269 who had acute care visits on weekdays are included in this report. With inverse probability of treatment-weighted adjustment, the mean time to first dose was 62 minutes in ICs and 132 minutes in EDs; the difference was 70 minutes (95% CI, 54 to 98 minutes; E-value, 2.8). The probability of pain reassessment within 30 minutes of the first dose of parenteral pain medication was 3.8 times greater (CI, 2.63 to 5.64 times greater; E-value, 4.7) in the IC than the ED. The probability that a participant's visit would end in admission to the hospital was smaller by a factor of 4 (0.25 [CI, 0.18 to 0.33]) with treatment in an IC versus an ED. Limitation: The study was restricted to participants with uncomplicated VOCs. Conclusion: In adults with SCD having a VOC, treatment in an IC is associated with substantially better outcomes than treatment in an ED.	[Lanzkron, Sophie; Wang, Hang; Saheed, Mustapha; Seufert, Rebecca; Brooks, Jasmine; Segal, Jodi B.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; [Little, Jane; Griffin, Brandi; Arnold, Nicole] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Little, Jane; Griffin, Brandi; Arnold, Nicole] Univ Hosp, Cleveland, OH USA; [Field, Joshua J.; Frymark, Steven] Med Coll Wisconsin, Blood Ctr Wisconsin, Milwaukee, WI 53226 USA; [Shows, J. Ryan; Piehet, Allie] Our Lady Lake Hosp, Baton Rouge, LA USA; [Haywood, Carlton] Johns Hopkins Univ, Johns Hopkins Berman Inst Bioeth, Baltimore, MD USA; [Proudford, Marc] William E Proudford Fdn, Baltimore, MD USA; [Robertson, Derek] Maryland Sickle Cell Dis Assoc, Columbia, MD USA; [Kincaid, Adrienne] Kincaids Kindred Spirits, Euclid, OH USA; [Burgess, Lorri] Baton Rouge Sickle Cell Dis Assoc, Baton Rouge, LA USA; [Green, Charles] Community Partner, Milwaukee, WI USA; [Wallace, Marcus] Louisiana Hlth Care Connect, Baton Rouge, LA USA; [Hamayel, Nebras Abu Al] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Huang, Chiung-Yu] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Varadhan, Ravi] Johns Hopkins Univ, Oncol Biostat & Bioinformat, Baltimore, MD USA	Johns Hopkins University; Case Western Reserve University; University Hospitals of Cleveland; Medical College of Wisconsin; Versiti Blood Center of Wisconsin; Our Lady Lake Regional Medical Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California San Francisco; Johns Hopkins University	Lanzkron, S (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.		Lanzkron, Sophie/AAD-7584-2022; Lanzkron, Sophie/AFU-9516-2022	Lanzkron, Sophie/0000-0002-2878-0251; Lanzkron, Sophie/0000-0002-2878-0251	PatientCentered Outcomes Research Institute [IHS-1403-11888]	PatientCentered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI)	By award IHS-1403-11888 from the PatientCentered Outcomes Research Institute.	Adewoye AH, 2007, HAEMATOLOGICA, V92, P854, DOI 10.3324/haematol.10757; [Anonymous], 2004, J STAT SOFTW, DOI DOI 10.18637/JSS.V009.I05; Ballas SK, 2012, BLOOD, V120, P3647, DOI 10.1182/blood-2012-04-383430; Benjamin LJ, 2000, BLOOD, V95, P1130, DOI 10.1182/blood.V95.4.1130.003k03a_1130_1136; Bhakta HC, 2014, J EMERG MED, V46, P456, DOI 10.1016/j.jemermed.2013.04.018; Brennan-Cook J, 2019, ADV EMERG NURS J, V41, P261, DOI 10.1097/TME.0000000000000256; Brousseau DC, 2010, JAMA-J AM MED ASSOC, V303, P1288, DOI 10.1001/jama.2010.378; Buchanan GR., 2014, EVIDENCE BASED MANAG; Evensen CT, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004528; Han J, 2018, AM J HEMATOL, V93, pE20, DOI 10.1002/ajh.24938; Hassell KL, 2010, AM J PREV MED, V38, pS512, DOI 10.1016/j.amepre.2009.12.022; Haywood C, 2009, J NATL MED ASSOC, V101, P1022, DOI 10.1016/S0027-9684(15)31069-5; Hoffman EB, 2001, BIOMETRIKA, V88, P1121, DOI 10.1093/biomet/88.4.1121; Imbach P, 2008, PEDIATR BLOOD CANCER, V51, P317, DOI 10.1002/pbc.21560; Lanzkron S, 2015, AM J HEMATOL, V90, P376, DOI 10.1002/ajh.23961; Li F, 2013, STAT MED, V32, P3373, DOI 10.1002/sim.5786; Lunceford JK, 2004, STAT MED, V23, P2937, DOI 10.1002/SIM.1903; Mathur MB, 2018, EPIDEMIOLOGY, V29, pE45, DOI 10.1097/EDE.0000000000000864; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; Power-Hays A, 2020, NEW ENGL J MED, V383, P1902, DOI 10.1056/NEJMp2022125; Raphael JL, 2008, PEDIATR BLOOD CANCER, V51, P398, DOI 10.1002/pbc.21537; Rizk S, 2020, AM J MED QUAL, V35, P236, DOI 10.1177/1062860619873402; Smith LA, 2006, PEDIATRICS, V117, P1763, DOI 10.1542/peds.2005-1611; Tanabe P, 2018, AM J HEMATOL, V93, P159, DOI 10.1002/ajh.24948; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Wright J, 2004, BRIT J HAEMATOL, V126, P878, DOI 10.1111/j.1365-2141.2004.05123.x	26	6	6	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP	2021	174	9					1207	+		10.7326/M20-7171	http://dx.doi.org/10.7326/M20-7171			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA5GQ	34224261				2023-01-03	WOS:000720675500018
J	Chou, R				Chou, Roger			In the Clinic Low Back Pain	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EPIDURAL CORTICOSTEROID INJECTIONS; PRIMARY-CARE; UNITED-STATES; GUIDELINE; PROGNOSIS; EDUCATION; EFFICACY; HISTORY		[Chou, Roger] Oregon Hlth & Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	Chou, R (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA.				American College of Physicians	American College of Physicians	American College of Physicians.	Anheyer D, 2017, ANN INTERN MED, V166, P799, DOI 10.7326/M16-1997; Burton AK, 1999, SPINE, V24, P2484, DOI 10.1097/00007632-199912010-00010; Calonge N, 2005, AM FAM PHYSICIAN, V71, P2337; Centers for Disease Control and Prevention, NAT AMB MED CAR SURV; Chappell ME, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035540; Chou R, 2015, PAIN MANAGEMENT INJE; Chou R, 2016, 16EHC004EF AG HEALTH; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459; Chou R, 2015, ANN INTERN MED, V163, P373, DOI 10.7326/M15-0934; Chou R, 2011, ANN INTERN MED, V154, P181, DOI 10.7326/0003-4819-154-3-201102010-00008; Chou R, 2010, JAMA-J AM MED ASSOC, V303, P1295, DOI 10.1001/jama.2010.344; Chou R, 2009, SPINE, V34, P1078, DOI 10.1097/BRS.0b013e3181a103b1; Chou R, 2009, LANCET, V373, P463, DOI 10.1016/S0140-6736(09)60172-0; Clark R, 2020, J GEN INTERN MED, V35, P855, DOI 10.1007/s11606-019-05476-8; Dahm KT, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007612.pub2; DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760; Deyo RA, 2014, SPINE, V39, P1128, DOI 10.1097/BRS.0000000000000434; Dieleman JL, 2020, JAMA-J AM MED ASSOC, V323, P863, DOI 10.1001/jama.2020.0734; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Downie A, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7095; Chaparro LE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004959.pub4; Fairbank J C, 1980, Physiotherapy, V66, P271; Ferraro MC, 2021, SYST REV-LONDON, V10, DOI 10.1186/s13643-021-01599-4; Furlan AD, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001929.pub3; Gagnier JJ, 2016, SPINE, V41, P116, DOI 10.1097/BRS.0000000000001310; Henschke N, 2007, EUR SPINE J, V16, P1673, DOI 10.1007/s00586-007-0412-0; Hill JC, 2011, LANCET, V378, P1560, DOI 10.1016/S0140-6736(11)60937-9; Huang RZ, 2020, BRIT J SPORT MED, V54, P766, DOI 10.1136/bjsports-2018-100035; Kamper SJ, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h444; Lemmers GPG, 2019, EUR SPINE J, V28, P937, DOI 10.1007/s00586-019-05918-1; Lin CC., BMJ-BRIT MED J, V372, pM4825; Machado GC, 2017, ANN RHEUM DIS, V76, P1269, DOI 10.1136/annrheumdis-2016-210597; Machado GC, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1225; Maher C, 2017, LANCET, V389, P736, DOI 10.1016/S0140-6736(16)30970-9; Mehling WE, 2012, SPINE, V37, P678, DOI 10.1097/BRS.0b013e318230ab20; Costa LDM, 2012, CAN MED ASSOC J, V184, pE613, DOI 10.1503/cmaj.111271; Mirza SK, 2007, SPINE, V32, P816, DOI 10.1097/01.brs.0000259225.37454.38; Mu JL, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013814; Oliveira CB, 2020, SPINE, V45, pE1405, DOI 10.1097/BRS.0000000000003651; Oliveira CB, 2018, EUR SPINE J, V27, P2791, DOI 10.1007/s00586-018-5673-2; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Paige NM, 2017, JAMA-J AM MED ASSOC, V317, P1451, DOI 10.1001/jama.2017.3086; Patel ND, 2016, J AM COLL RADIOL, V13, P1069, DOI 10.1016/j.jacr.2016.06.008; Qaseem Amir, 2017, Ann Intern Med, V166, P514, DOI 10.7326/M16-2367; Richmond H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134192; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Rubinstein SM, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l689; Shaheed CA, 2017, EUR J PAIN, V21, P228, DOI 10.1002/ejp.907; Shaheed CA, 2016, JAMA INTERN MED, V176, P958, DOI 10.1001/jamainternmed.2016.1251; Sodha R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001167; Steffens D, 2016, JAMA INTERN MED, V176, P199, DOI 10.1001/jamainternmed.2015.7431; Tegner H, 2018, CLIN J PAIN, V34, P778, DOI 10.1097/AJP.0000000000000594; Traeger AC, 2015, JAMA INTERN MED, V175, P733, DOI 10.1001/jamainternmed.2015.0217; Turner J., 2020, AHRQ COMP EFFECTIVEN; van der Gaag WH, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013581; Van Duijvenbode ICD, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001823.pub3; Verbeek JH, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005958.pub3; WADDELL G, 1980, SPINE, V5, P117, DOI 10.1097/00007632-198003000-00005; Weinstein JN, 2010, SPINE, V35, P1329, DOI 10.1097/BRS.0b013e3181e0f04d; Wu AM, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.175; Zhu FL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238544	62	0	0	4	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG	2021	174	8					ITC113	U28		10.7326/AITC202108170	http://dx.doi.org/10.7326/AITC202108170			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP3IW	34370518				2023-01-03	WOS:000695277800002
J	Palmer, KR; Tanner, M; Davies-Tuck, M; Rindt, A; Papacostas, K; Giles, ML; Brown, K; Diamandis, H; Fradkin, R; Stewart, AE; Rolnik, DL; Stripp, A; Wallace, EM; Mol, BW; Hodges, RJ				Palmer, Kirsten R.; Tanner, Michael; Davies-Tuck, Miranda; Rindt, Andrea; Papacostas, Kerrie; Giles, Michelle L.; Brown, Kate; Diamandis, Helen; Fradkin, Rebecca; Stewart, Alice E.; Rolnik, Daniel L.; Stripp, Andrew; Wallace, Euan M.; Mol, Ben W.; Hodges, Ryan J.			Widespread implementation of a low-cost telehealth service in the delivery of antenatal care during the COVID-19 pandemic: an interrupted time-series analysis	LANCET			English	Article							TELEMEDICINE; OBSTETRICS	Background Little evidence is available on the use of telehealth for antenatal care. In response to the COVID-19 pandemic, we developed and implemented a new antenatal care schedule integrating telehealth across all models of pregnancy care. To inform this clinical initiative, we aimed to assess the effectiveness and safety of telehealth in antenatal care. Methods We analysed routinely collected health data on all women giving birth at Monash Health, a large health service in Victoria (Australia), using an interrupted time-series design. We assessed the impact of telehealth integration into antenatal care from March 23, 2020, across low-risk and high-risk care models. Allowing a 1-month implementation period from March 23, 2020, we compared the first 3 months of telehealth integrated care delivered between April 20 and July 26, 2020, with conventional care delivered between Jan 1, 2018, and March 22, 2020. The primary outcomes were detection and outcomes of fetal growth restriction, pre-eclampsia, and gestational diabetes. Secondary outcomes were stillbirth, neonatal intensive care unit admission, and preterm birth (birth before 37 weeks' gestation). Findings Between Jan 1, 2018, and March 22, 2020, 20 031 women gave birth at Monash Health during the conventional care period and 2292 women gave birth during the telehealth integrated care period. Of 20 154 antenatal consultations provided in the integrated care period, 10 731 (53%) were delivered via telehealth. Overall, compared with the conventional care period, no significant differences were identified in the integrated care period with regard to the number of babies with fetal growth restriction (birthweight below the 3rd percentile; 2% in the integrated care period vs 2% in the conventional care period, p=0.72, for low-risk care models; 5% in the integrated care period vs 5% in the conventional care period, p=0.50 for high-risk care models), number of stillbirths (1% vs 1%, p=0.79; 2% vs 2%, p=0.70), or pregnancies complicated by pre-eclampsia (3% vs 3%, p=0.70; 9% vs 7%, p=0.15), or gestational diabetes (22% vs 22%, p=0.89; 30% vs 26%, p=0.06). Interrupted time-series analysis showed a significant reduction in preterm birth among women in high-risk models (-0.68% change in incidence per week [95% CI -1.37 to -0.002]; p=0.049), but no significant differences were identified in other outcome measures for low-risk or high-risk care models after telehealth integration compared with conventional care. Interpretation Telehealth integrated antenatal care enabled the reduction of in-person consultations by 50% without compromising pregnancy outcomes. This care model can help to minimise in-person interactions during the COVID-19 pandemic, but should also be considered in post-pandemic health-care models. Copyright (c) 2021 Elsevier Ltd. All rights reserved.	[Palmer, Kirsten R.; Rindt, Andrea; Papacostas, Kerrie; Giles, Michelle L.; Brown, Kate; Diamandis, Helen; Fradkin, Rebecca; Stewart, Alice E.; Rolnik, Daniel L.; Mol, Ben W.; Hodges, Ryan J.] Monash Hlth, Monash Womens & Newborn, Melbourne, Vic, Australia; [Palmer, Kirsten R.; Tanner, Michael; Giles, Michelle L.; Rolnik, Daniel L.; Wallace, Euan M.; Mol, Ben W.; Hodges, Ryan J.] Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; [Stripp, Andrew] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Davies-Tuck, Miranda] Hudson Inst Med Res, Clayton, Vic, Australia; [Stripp, Andrew] Monash Hlth, Clayton, Vic, Australia; [Wallace, Euan M.] Safer Care Victoria, Melbourne, Vic, Australia	Monash University; Monash University; Hudson Institute of Medical Research	Palmer, KR (corresponding author), Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia.	kirsten.palmer@monash.edu	Rolnik, Daniel/R-3706-2018	Rolnik, Daniel/0000-0002-2263-3592; Davies-Tuck, Miranda/0000-0003-1918-5538	National Health and Medical Research Council Investigator grant [GNT1176437]	National Health and Medical Research Council Investigator grant(National Health and Medical Research Council (NHMRC) of Australia)	BWM is supported by a National Health and Medical Research Council Investigator grant (GNT1176437). We thank all the staff involved in providing antenatal care and women receiving care who have adapted to the many changes during this year.	Alves DS, 2020, INT J MED INFORM, V134, DOI 10.1016/j.ijmedinf.2019.104004; Australian Government Department of Health, 2018, CLIN PRACTICE GUIDEL; Australian Government Department of Health, COVID 19 NAT HLTH PL; Australian Institute of Health and Welfare, AUSTR MOTH BAB DAT V; Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885; Bergman E, 2007, ACTA OBSTET GYN SCAN, V86, P671, DOI 10.1080/00016340701258867; Bhandari NR, 2020, TELEMED E-HEALTH, V26, P879, DOI 10.1089/tmj.2019.0156; Brown MA, 2018, PREGNANCY HYPERTENS, V13, P291, DOI 10.1016/j.preghy.2018.05.004; de Mooij MJM, 2018, MAYO CLIN PROC, V93, P458, DOI 10.1016/j.mayocp.2018.01.022; DeNicola N, 2020, OBSTET GYNECOL, V135, P371, DOI 10.1097/AOG.0000000000003646; Dobbins TA, 2012, MED J AUSTRALIA, V197, P291, DOI 10.5694/mja11.11331; Dowswell T, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000934.pub3; Duffy S, 2018, NEW ENGL J MED, V378, P104, DOI 10.1056/NEJMp1710735; Feroz A, 2017, BMC HEALTH SERV RES, V17, P1, DOI 10.1186/s12913-017-2664-7; Flodgren G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002098.pub2; Greiner AL, 2017, CLIN OBSTET GYNECOL, V60, P853, DOI 10.1097/GRF.0000000000000328; Gyselaers W, 2019, CURR PHARM DESIGN, V25, P615, DOI 10.2174/1381612825666190320140659; Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539; Hunt R., 2019, VICTORIAN PERINATAL; Kalafat E, 2020, PREGNANCY HYPERTENS, V19, P44, DOI 10.1016/j.preghy.2019.12.001; Khalil A, 2019, EXPERT REV MED DEVIC, V16, P653, DOI 10.1080/17434440.2019.1640116; Kruse CS, 2018, J TELEMED TELECARE, V24, P4, DOI 10.1177/1357633X16674087; Linden A, 2015, STATA J, V15, P480, DOI 10.1177/1536867X1501500208; Lurie N, 2018, JAMA INTERN MED, V178, P745, DOI 10.1001/jamainternmed.2018.1314; Magann EF, 2011, OBSTET GYNECOL SURV, V66, P170, DOI 10.1097/OGX.0b013e3182219902; Ming WK, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.6556; Ministry of Health, 1929, MAT MORT CHILDB ANT; Nankervis AMH, 2014, ADIPS CONSENSUS GUID; Papageorghiou AT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5662; Peter JR, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008136.pub3; Philip RK, 2020, REDUCTION PRETERM BI, DOI [10.1101/2020.06.03.20121442, DOI 10.1101/2020.06.03.20121442]; Selvaratnam RJ, 2020, BJOG-INT J OBSTET GY, V127, P581, DOI 10.1111/1471-0528.16038; Sovio U, 2015, LANCET, V386, P2089, DOI 10.1016/S0140-6736(15)00131-2; van den Heuvel JFM, 2019, EUR J OBSTET GYN R B, V240, P226, DOI 10.1016/j.ejogrb.2019.07.012; Who, 2016, WHO REC ANT CAR POS	35	19	19	4	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2021	398	10294					41	52						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC9PM	34217399	Green Published, Bronze			2023-01-03	WOS:000668969500028
J	Pandey, AC; Golbus, JR; Topol, EJ				Pandey, Amitabh C.; Golbus, Jessica R.; Topol, Eric J.			Digital medicine Cardiac rehabilitation in the digital era	LANCET			English	Editorial Material									[Pandey, Amitabh C.; Topol, Eric J.] Scripps Res, Scripps Res Translat Inst, La Jolla, CA 92037 USA; [Pandey, Amitabh C.; Topol, Eric J.] Scripps Clin, Div Cardiol, La Jolla, CA 92037 USA; [Golbus, Jessica R.] Univ Michigan, Dept Internal Med, Div Cardiovasc Dis, Ann Arbor, MI 48109 USA	Scripps Research Institute; Scripps Research Institute; University of Michigan System; University of Michigan	Topol, EJ (corresponding author), Scripps Res, Scripps Res Translat Inst, La Jolla, CA 92037 USA.; Topol, EJ (corresponding author), Scripps Clin, Div Cardiol, La Jolla, CA 92037 USA.	etopol@scripps.edu		Topol, Eric/0000-0002-1478-4729	NCATS NIH HHS [KL2 TR002552, UL1 TR001114] Funding Source: Medline	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))			0	2	2	5	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2021	398	10294					16	16						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC9PM	34217385				2023-01-03	WOS:000668969500013
J	Mayland, CR; Powell, RA; Clarke, GC; Ebenso, B; Allsop, MJ				Mayland, Catriona R.; Powell, Richard A.; Clarke, Gemma C.; Ebenso, Bassey; Allsop, Matthew J.			Bereavement care for ethnic minority communities: A systematic review of access to, models of, outcomes from, and satisfaction with, service provision	PLOS ONE			English	Review							OF-LIFE DISCUSSIONS; PALLIATIVE CARE; MENTAL-HEALTH; END; EXPERIENCES; SUPPORT; DEATH	Objectives To review and synthesize the existing evidence on bereavement care, within the United Kingdom (UK), for ethnic minority communities in terms of barriers and facilitators to access; models of care; outcomes from, and satisfaction with, service provision. Design A systematic review adopting a framework synthesis approach was conducted. An electronic search of the literature was undertaken in MEDLINE, Embase, PsycINFO, Social Work Abstract and CINAHL via EBSCO, Global Health, Cochrane library, the Trip database and ProQuest between 1995 and 2020. Search terms included bereavement care, ethnic minority populations and the UK setting. Results From 3,185 initial records, following screening for eligibility, and full-text review of 164 articles, seven studies were identified. There was no research literature outlining the role of family, friends and existing networks; and a real absence of evidence about outcomes and levels of satisfaction for those from an ethnic minority background who receive bereavement care. From the limited literature, the overarching theme for barriers to bereavement care was 'unfamiliarity and irregularities'. Four identified subthemes were 'lack of awareness'; 'variability in support'; 'type and format of support'; and 'culturally specific beliefs'. The overarching theme for facilitators for bereavement care was 'accessibility' with the two subthemes being 'readily available information' and 'inclusive approaches'. Three studies reported on examples of different models of care provision. Conclusions This review reveals a stark lack of evidence about bereavement care for ethnic minority populations. In particular, understanding more about the role of family, friends and existing support systems, alongside outcomes and satisfaction will begin to develop the evidence base underpinning current provision. Direct user-representation through proactive engagement and co-design approaches may begin to determine the most appropriate models and format of bereavement care for ethnic minority communities to inform service design and delivery.	[Mayland, Catriona R.] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England; [Mayland, Catriona R.] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England; [Mayland, Catriona R.] Univ Liverpool, Palliat Care Dept, Liverpool, Merseyside, England; [Powell, Richard A.] Imperial Coll London, Fac Med, Sch Publ Hlth, Dept Primary Care & Publ Hlth, London, England; [Clarke, Gemma C.; Allsop, Matthew J.] Univ Leeds, Acad Unit Palliat Care, Worsley Bldg, Leeds, W Yorkshire, England; [Ebenso, Bassey] Univ Leeds, Nuffield Ctr Int Hlth & Dev, Clarendon Way, Leeds, W Yorkshire, England	University of Sheffield; University of Sheffield; University of Liverpool; Imperial College London; University of Leeds; University of Leeds	Mayland, CR (corresponding author), Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.; Mayland, CR (corresponding author), Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England.; Mayland, CR (corresponding author), Univ Liverpool, Palliat Care Dept, Liverpool, Merseyside, England.	C.R.Mayland@sheffield.ac.uk	Ebenso, Bassey/H-5536-2017	Ebenso, Bassey/0000-0003-4147-0968; Allsop, Matthew/0000-0002-7399-0194; Mayland, Catriona/0000-0002-1440-9953	Yorkshire Cancer Research 'CONNECTS' Research Fellowship scheme [S406CM, L389MA]	Yorkshire Cancer Research 'CONNECTS' Research Fellowship scheme	We did not receive any specific funding to undertake this research study. Dr Catriona R Mayland and Dr Matthew J Allsop are currently funded by the Yorkshire Cancer Research `CONNECTS' Research Fellowship scheme (award references S406CM and L389MA respectively).	Ackroyd Rajeena, 2003, Int J Palliat Nurs, V9, P352; [Anonymous], 2020, EMERGING FINDINGS IM; [Anonymous], 2021, COVID 19 DAILY DEATH; [Anonymous], 2020, CORONAVIRUS COVID 19; [Anonymous], 2021, OXFORD 2011 LEVELS E; Aoun SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121101; Aoun SM, 2014, AUST NZ J PUBL HEAL, V38, P473, DOI 10.1111/1753-6405.12177; Balezdrova N., 2019, INVISIBLE MINORITIES; Barry V., 2013, OVERVIEW COMPASSIONA; Bignall T., 2019, RACIAL DISPARITIES M, DOI [10.12788/jhm.3240, DOI 10.12788/JHM.3240]; British Red Cross Society, 2019, BARR BEL EXPL LON PE BARR BEL EXPL LON PE; Brunton G, 2020, RES SYNTH METHODS, V11, P316, DOI 10.1002/jrsm.1399; Calanzani N., 2013, PALLIATIVE END LIFE; Dixon J., EQUITY PROVISION PAL EQUITY PROVISION PAL; ehospice, 2019, HOSPICE TEAMS HAIR S; Evans R., 2017, MORTALITY, V22, P11835, DOI [10.1080/13576275.2017.1291602, DOI 10.1080/13576275.2017.1291602]; Garrido MM, 2014, CANCER-AM CANCER SOC, V120, P918, DOI 10.1002/cncr.28495; Gunaratnam Y., 2007, IMPROVING QUALITY PA; Hong QN, 2018, EDUC INFORM, V34, P285, DOI 10.3233/EFI-180221; Koffman J, 2002, PALLIATIVE MED, V16, P540, DOI 10.1191/0269216302pm600xx; Koffman Jonathan, 2005, Palliat Support Care, V3, P183; Mayland CR, 2020, J PAIN SYMPTOM MANAG, V60, pE33, DOI 10.1016/j.jpainsymman.2020.05.012; Miranda DE, 2020, AM J COMMUN PSYCHOL, V66, P347, DOI 10.1002/ajcp.12443; Murray K., 2020, NATL MAPPING BAME ME; National Palliative and End of Life Care Partnership, 2015, NATL GEOGR; Penny A., 2017, GUIDE COMMISSIONING; Philips L., 2012, PRIM HEALTH CARE, V22, P26; Prigerson HG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000121; Rawlings Debbie, 2002, Int J Palliat Nurs, V8, P40; Robertson MJP, 2011, PEDIATR CRIT CARE ME, V12, pE111, DOI 10.1097/PCC.0b013e3181e911e3; Rogers C, 2017, BEREAVE CARE, V36, P94, DOI 10.1080/02682621.2017.1390281; Rumbold B, 2014, PROG PALLIAT CARE, V22, P131, DOI 10.1179/1743291X13Y.0000000079; Selman LE, 2020, J PAIN SYMPTOM MANAG, V60, pE81, DOI 10.1016/j.jpainsymman.2020.04.024; Singer M, 2017, LANCET, V389, P941, DOI 10.1016/S0140-6736(17)30003-X; South J., 2008, PRIM HEALTH CARE RES, V9, P310, DOI [10.1017/S146342360800087X, DOI 10.1017/S146342360800087X, DOI 10.1017/S1463.42360800087X]; Spruyt O, 1999, PALLIATIVE MED, V13, P119, DOI 10.1191/026921699667569476; Stroebe M, 2021, OMEGA-J DEATH DYING, V82, P500, DOI 10.1177/0030222820966928; UK Government, 2021, WRIT ETHN; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Yamaguchi T, 2017, J PAIN SYMPTOM MANAG, V54, P17, DOI 10.1016/j.jpainsymman.2017.03.008; Yarker S., 2020, AGEING PLACE MINORIT, DOI [10.1097/MRR.0000000000000398, DOI 10.1097/MRR.0000000000000398]; Zhang XZ, 2017, ETHNIC DIS, V27, P95, DOI 10.18865/ed.27.2.95; Zuniga-Villanueva G., J SOCIAL WORK END OF, V17, P9, DOI [10.1080/17482631.2019.1586625, DOI 10.1080/17482631.2019.1586625]	43	4	4	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2021	16	6							e0252188	10.1371/journal.pone.0252188	http://dx.doi.org/10.1371/journal.pone.0252188			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TG9EF	34191804	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000671698800013
J	VanderPluym, JH; Halker Singh, RB; Urtecho, M; Morrow, AS; Nayfeh, T; Torres Roldan, VD; Farah, MH; Hasan, B; Saadi, S; Shah, S; Abd-Rabu, R; Daraz, L; Prokop, LJ; Murad, MH; Wang, Z				VanderPluym, Juliana H.; Halker Singh, Rashmi B.; Urtecho, Meritxell; Morrow, Allison S.; Nayfeh, Tarek; Torres Roldan, Victor D.; Farah, Magdoleen H.; Hasan, Bashar; Saadi, Samer; Shah, Sahrish; Abd-Rabu, Rami; Daraz, Lubna; Prokop, Larry J.; Murad, Mohammad Hassan; Wang, Zhen			Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							EMERGENCY-DEPARTMENT TREATMENT; DIHYDROERGOTAMINE NASAL SPRAY; INTRAVENOUS MAGNESIUM-SULFATE; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; TRANSNASAL BUTORPHANOL; ABORTIVE TREATMENT; CLINICAL-TRIAL; PLACEBO; EFFICACY	Key PointsQuestionWhat are the benefits and adverse events associated with acute treatments for episodic migraine in adults? FindingsIn this systematic review and meta-analysis that included 15 systematic reviews and 115 randomized clinical trials of 28803 participants with migraine headache, multiple acute interventions, including nonsteroidal anti-inflammatory drugs, triptans, calcitonin gene-related peptide receptor antagonists, 5-HT1F receptor agonist, dihydroergotamine, acetaminophen, and remote electrical neuromodulation, were associated with improvements in short-term pain outcomes, with moderate to high strength of evidence. The evidence for these end points regarding opioids and other interventions was low or insufficient. MeaningFor the acute treatment of migraine, several established and newer therapies were associated with improvements in short-term pain outcomes, with varying strengths of evidence. ImportanceMigraine is common and can be associated with significant morbidity, and several treatment options exist for acute therapy. ObjectiveTo evaluate the benefits and harms associated with acute treatments for episodic migraine in adults. Data SourcesMultiple databases from database inception to February 24, 2021. Study SelectionRandomized clinical trials and systematic reviews that assessed effectiveness or harms of acute therapy for migraine attacks. Data Extraction and SynthesisIndependent reviewers selected studies and extracted data. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction or by using a fixed-effect model based on the Mantel-Haenszel method if the number of studies was small. Main Outcomes and MeasuresThe main outcomes included pain freedom, pain relief, sustained pain freedom, sustained pain relief, and adverse events. The strength of evidence (SOE) was graded with the Agency for Healthcare Research and Quality Methods Guide for Effectiveness and Comparative Effectiveness Reviews. FindingsEvidence on triptans and nonsteroidal anti-inflammatory drugs was summarized from 15 systematic reviews. For other interventions, 115 randomized clinical trials with 28803 patients were included. Compared with placebo, triptans and nonsteroidal anti-inflammatory drugs used individually were significantly associated with reduced pain at 2 hours and 1 day (moderate to high SOE) and increased risk of mild and transient adverse events. Compared with placebo, calcitonin gene-related peptide receptor antagonists (low to high SOE), lasmiditan (5-HT1F receptor agonist; high SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), acetaminophen (moderate SOE), antiemetics (low SOE), butorphanol (low SOE), and tramadol in combination with acetaminophen (low SOE) were significantly associated with pain reduction and increase in mild adverse events. The findings for opioids were based on low or insufficient SOE. Several nonpharmacologic treatments were significantly associated with improved pain, including remote electrical neuromodulation (moderate SOE), transcranial magnetic stimulation (low SOE), external trigeminal nerve stimulation (low SOE), and noninvasive vagus nerve stimulation (moderate SOE). No significant difference in adverse events was found between nonpharmacologic treatments and sham. Conclusions and RelevanceThere are several acute treatments for migraine, with varying strength of supporting evidence. Use of triptans, nonsteroidal anti-inflammatory drugs, acetaminophen, dihydroergotamine, calcitonin gene-related peptide antagonists, lasmiditan, and some nonpharmacologic treatments was associated with improved pain and function. The evidence for many other interventions, including opioids, was limited. This systematic review and meta-analysis assesses the benefits and harms associated with acute treatments for episodic migraine, including pharmacologic and nonpharmacologic therapies, with a focus on pain-related outcomes, function, and adverse events.			Wang, Z (corresponding author), Mayo Clin, Corresponding Author, Zhen Wang, PhD, Rochester, MN 55905 USA.	wang.zhen@mayo.edu	Nayfeh, Tarek/X-1193-2019; abd-rabu, rami/AGI-7382-2022; Daraz, Ph.D, Lubna/GRS-6972-2022; Abd Rabu, Rami/ACS-4894-2022	Nayfeh, Tarek/0000-0001-9052-5537; Daraz, Ph.D, Lubna/0000-0003-4502-835X; Abd Rabu, Rami/0000-0002-3867-8402; Urtecho, Meritxell/0000-0002-9123-0922				Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9; Alemdar M, 2007, CLIN THER, V29, P1441, DOI 10.1016/j.clinthera.2007.07.017; Amiri H, 2017, TURK J EMERG MED, V17, P61, DOI 10.1016/j.tjem.2016.12.004; Antal A, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10110888; Ashcroft DM, 2004, PHARMACOEPIDEM DR S, V13, P73, DOI 10.1002/pds.890; Ashina M, 2021, CEPHALALGIA, V41, P294, DOI 10.1177/0333102421989232; Aurora SK, 2011, HEADACHE, V51, P507, DOI 10.1111/j.1526-4610.2011.01869.x; Aurora SK, 2009, HEADACHE, V49, P826, DOI 10.1111/j.1526-4610.2009.01453.x; BELL R, 1990, ANN EMERG MED, V19, P1079, DOI 10.1016/S0196-0644(05)81507-0; Bigal ME, 2002, J EMERG MED, V23, P141, DOI 10.1016/S0736-4679(02)00502-4; Bird S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008616.pub2; Bonafede M, 2019, CEPHALALGIA, V39, P1086, DOI 10.1177/0333102419835465; Borhani-Haghighi A, 2010, INT J CLIN PRACT, V64, P451, DOI 10.1111/j.1742-1241.2009.02215.x; BOUREAU F, 1994, CEPHALALGIA, V14, P156, DOI 10.1046/j.1468-2982.1994.1402156.x; Brandes, 2020, CEPHALALGIA REP, V3, DOI 10.1177/2515816320958176; Brandes JL, 2019, CEPHALALGIA, V39, P1343, DOI 10.1177/0333102419864132; Buse DC, 2017, HEADACHE, V57, P31, DOI 10.1111/head.12962; CALLAHAM M, 1986, HEADACHE, V26, P168, DOI 10.1111/j.1526-4610.1986.hed2604168.x; CAMERON JD, 1995, ACAD EMERG MED, V2, P597, DOI 10.1111/j.1553-2712.1995.tb03596.x; Carleton SC, 1998, ANN EMERG MED, V32, P129, DOI 10.1016/S0196-0644(98)70126-X; Cete Y, 2005, CEPHALALGIA, V25, P199, DOI 10.1111/j.1468-2982.2004.00840.x; Charleston L, 2018, CEPHALALGIA, V38, P876, DOI 10.1177/0333102417716933; Chen LC, 2007, HEADACHE, V47, P1169, DOI 10.1111/j.1526-4610.2007.00884.x; Chou DE, 2019, CEPHALALGIA, V39, P3, DOI 10.1177/0333102418811573; Connelly M, 2019, PEDIAT EMERG CARE, DOI 10.1097/PEC.0000000000001851; COPPOLA M, 1995, ANN EMERG MED, V26, P541, DOI 10.1016/S0196-0644(95)70001-3; Corbo J, 2001, ANN EMERG MED, V38, P621, DOI 10.1067/mem.2001.119424; Croop R, 2019, LANCET, V394, P737, DOI 10.1016/S0140-6736(19)31606-X; Derry CJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009665; Derry CJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008615.pub2; Derry S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008783.pub3; DEXTER SL, 1985, BRIT J CLIN PRACT, V39, P388; Diener HC, 2002, EUR NEUROL, V47, P99, DOI 10.1159/000047960; Dodick DW, 2019, NEW ENGL J MED, V381, P2230, DOI 10.1056/NEJMoa1813049; Dogan NO, 2019, ACTA NEUROL SCAND, V139, P334, DOI 10.1111/ane.13063; Farahmand S, 2018, ANESTH PAIN MED, V8, DOI 10.5812/aapm.81688; Farkkila M, 2012, LANCET NEUROL, V11, P405, DOI 10.1016/S1474-4422(12)70047-9; Fernando T, 2019, ACTA NEUROL SCAND, V140, P72, DOI 10.1111/ane.13104; Ferrari MD, 2001, CEPHALALGIA, V21, P129, DOI 10.1046/j.1468-2982.2001.00169.x; Ferrari MD, 2010, CEPHALALGIA, V30, P1170, DOI 10.1177/0333102410375512; FREITAG FG, 1993, HEADACHE Q-CURR TREA, V4, P22; FRIEDMAN AP, 1989, CLIN THER, V11, P170; Friedman BW, 2008, ANN EMERG MED, V52, P399, DOI 10.1016/j.annemergmed.2007.09.027; Friedman BW, 2017, NEUROLOGY, V89, P2075, DOI 10.1212/WNL.0000000000004642; Friedman BW, 2016, ANN EMERG MED, V67, P32, DOI 10.1016/j.annemergmed.2015.07.495; Friedman BW, 2011, ANN EMERG MED, V57, P475, DOI 10.1016/j.annemergmed.2010.11.023; Fuglsang CH, 2018, CEPHALALGIA, V38, P1632, DOI 10.1177/0333102418797285; Gaffigan ME, 2015, J EMERG MED, V49, P326, DOI 10.1016/j.jemermed.2015.03.023; Gallagher RM, 1996, ARCH NEUROL-CHICAGO, V53, P1285, DOI 10.1001/archneur.1996.00550120097022; Goadsby PJ, 2019, BRAIN, V142, P1894, DOI 10.1093/brain/awz134; HAKKARAINEN H, 1982, HEADACHE, V22, P10, DOI 10.1111/j.1526-4610.1982.hed2201010.x; HOFFERT M, 1995, HEADACHE, V35, P177; HOFFERT MJ, 1995, HEADACHE, V35, P65, DOI 10.1111/j.1526-4610.1995.hed3502065.x; Hokenek NM, 2021, AM J EMERG MED, V39, P80, DOI 10.1016/j.ajem.2020.01.024; Honkaniemi J, 2006, HEADACHE, V46, P781, DOI 10.1111/j.1526-4610.2006.00438.x; JONES EB, 1994, ANN EMERG MED, V24, P237, DOI 10.1016/S0196-0644(94)70135-0; Jones J, 1996, AM J EMERG MED, V14, P262, DOI 10.1016/S0735-6757(96)90171-0; Kandil M, 2021, AM J EMERG MED, V39, P28, DOI 10.1016/j.ajem.2020.09.033; KANGASNIEMI P, 1992, J INTERN MED, V231, P551, DOI 10.1111/j.1365-2796.1992.tb00973.x; Katsarava Z, 2004, NEUROLOGY, V62, P788, DOI 10.1212/01.WNL.0000113747.18760.D2; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Kirthi V, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008041.pub3; KLAPPER JA, 1993, HEADACHE, V33, P560, DOI 10.1111/j.1526-4610.1993.hed3310560.x; Knievel K, 2020, CEPHALALGIA, V40, P19, DOI 10.1177/0333102419889350; Korucu O, 2018, ACTA NEUROL SCAND, V138, P212, DOI 10.1111/ane.12952; Kuca B, 2018, NEUROLOGY, V91, pE2222, DOI 10.1212/WNL.0000000000006641; LANE PL, 1989, ANN EMERG MED, V18, P360, DOI 10.1016/S0196-0644(89)80570-0; LANGEMARK M, 1984, PAIN, V19, P81, DOI 10.1016/0304-3959(84)90067-8; Law S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008541.pub3; Li TX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122461; Li Y, 2009, HEADACHE, V49, P805, DOI 10.1111/j.1526-4610.2009.01424.x; LIPTON RB, 2019, NEUROLOGY S, V0092; Lipton RB, 2019, JAMA-J AM MED ASSOC, V322, P1887, DOI 10.1001/jama.2019.16711; Lipton RB, 2019, NEW ENGL J MED, V381, P142, DOI 10.1056/NEJMoa1811090; Lipton RB, 2017, HEADACHE, V57, P1507, DOI 10.1111/head.13179; Lipton RB, 2010, LANCET NEUROL, V9, P373, DOI 10.1016/S1474-4422(10)70054-5; Marcus R, 2014, CEPHALALGIA, V34, P114, DOI 10.1177/0333102413500727; Marcus SV, 2008, J EMDR PRACT RES, V2, P15, DOI 10.1891/1933-3196.2.1.15; Marmura MJ, 2015, HEADACHE, V55, P3, DOI 10.1111/head.12499; MCEWEN JI, 1987, ANN EMERG MED, V16, P758, DOI 10.1016/S0196-0644(87)80569-3; Miller MA, 2009, AM J EMERG MED, V27, P160, DOI 10.1016/j.ajem.2008.01.015; Molina KC, 2018, DRUG HEALTHC PATIENT, V10, P37, DOI 10.2147/DHPS.S151073; Motamed H, 2020, ANN CLIN ANAL MED, V11, P369, DOI 10.4328/ACAM.20072; Niazi M, 2017, COMPLEMENT THER MED, V34, P35, DOI 10.1016/j.ctim.2017.07.009; Nir RR, 2015, CURR OPIN SUPPORT PA, V9, P131, DOI 10.1097/SPC.0000000000000126; Pearlman EM, 2020, HUM PSYCHOPHARM CLIN, V35, DOI 10.1002/hup.2732; Poolsup N, 2005, J CLIN PHARM THER, V30, P521, DOI 10.1111/j.1365-2710.2005.00677.x; Pringsheim T, 2016, HEADACHE, V56, P1194, DOI 10.1111/head.12870; Rabbie R, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008039.pub3; Richman PB, 2002, AM J EMERG MED, V20, P39, DOI 10.1053/ajem.2002.30007; Rover C, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0091-1; ROWAT BMT, 1991, CEPHALALGIA, V11, P207, DOI 10.1046/j.1468-2982.1991.1105207.x; RYAN R E, 1970, Headache, V9, P212, DOI 10.1111/j.1526-4610.1970.hed0904212.x; Salazar G, 2011, Recent Pat CNS Drug Discov, V6, P141; SALOMONE JA, 1994, AM J EMERG MED, V12, P134, DOI 10.1016/0735-6757(94)90231-3; Sasannejad P, 2012, EUR NEUROL, V67, P288, DOI 10.1159/000335249; SCHERL ER, 1995, HEADACHE, V35, P256, DOI 10.1111/j.1526-4610.1995.hed3505256.x; Shahrami A, 2015, J EMERG MED, V48, P69, DOI 10.1016/j.jemermed.2014.06.055; Shapiro RE, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-1044-6; Sharma S, 2002, HEADACHE, V42, P896, DOI 10.1046/j.1526-4610.2002.02210.x; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Silberstein SD, 2005, HEADACHE, V45, P1317, DOI 10.1111/j.1526-4610.2005.00264.x; Silberstein SD, 2003, NEUROLOGY, V60, P315, DOI 10.1212/01.WNL.0000042477.63516.B2; STIELL IG, 1991, ANN EMERG MED, V20, P1201, DOI 10.1016/S0196-0644(05)81471-4; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Szkutnik-Fiedler D, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121180; Taheraghdam A A, 2011, Pak J Biol Sci, V14, P682; Tanen DA, 2003, ANN EMERG MED, V41, P847, DOI 10.1067/mem.2003.195; Tassorelli C, 2018, NEUROLOGY, V91, pE364, DOI 10.1212/WNL.0000000000005857; TEK DS, 1990, ANN EMERG MED, V19, P1083, DOI 10.1016/S0196-0644(05)81508-2; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Treves TA, 1998, HEADACHE, V38, P614, DOI 10.1046/j.1526-4610.1998.3808614.x; Triner WR, 1999, AM J EMERG MED, V17, P252, DOI 10.1016/S0735-6757(99)90118-3; TULUNAY FC, 1987, CEPHALALGIA, V7, P131, DOI 10.1046/j.1468-2982.1987.0702131.x; Vinson DR, 2003, ANN EMERG MED, V41, P90, DOI 10.1067/mem.2003.24; Viswanathan M, 2018, J CLIN EPIDEMIOL, V97, P26, DOI 10.1016/j.jclinepi.2017.12.004; Voss T, 2016, CEPHALALGIA, V36, P887, DOI 10.1177/0333102416653233; Wang LP, 2012, PAIN MED, V13, P623, DOI 10.1111/j.1526-4637.2012.01376.x; Yang J, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-123; Yarnitsky D, 2019, HEADACHE, V59, P1240, DOI 10.1111/head.13551; Yarnitsky D, 2017, NEUROLOGY, V88, P1250, DOI 10.1212/WNL.0000000000003760; Zargaran A, 2018, NEUROL SCI, V39, P1345, DOI 10.1007/s10072-018-3415-1; ZIEGLER D, 1994, NEUROLOGY, V44, P447, DOI 10.1212/WNL.44.3_Part_1.447	123	14	14	10	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2021	325	23					2357	2369		10.1001/jama.2021.7939	http://dx.doi.org/10.1001/jama.2021.7939			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SU3BJ	34128998	Green Published, Bronze			2023-01-03	WOS:000663015400010
J	Wondimu, M; Balcha, F; Bacha, G; Habte, A				Wondimu, Merertu; Balcha, Fikadu; Bacha, Girma; Habte, Aklilu			The magnitude of neonatal near miss and associated factors among live births in public hospitals of Jimma Zone, Southwest Ethiopia, 2020: A facility-based cross-sectional study	PLOS ONE			English	Article								Background Neonates with severe complications at birth or during the neonatal period who nearly died but survived constitute neonatal near miss (NNM) cases. Identifying NNM cases and correcting contributing factors are of the utmost importance to get relevant controls for neonatal deaths. However, limited studies are assessing the prevalence of NNM and associated factors with NNM cases in Ethiopia. So, this study is aimed at assessing the magnitude of neonatal near miss and associated factors among live births in public hospitals of Jimma zone, southwest Ethiopia, 2020. Methods A facility-based cross-sectional study was conducted among 260 neonates from April 1-30 / 2020. Face to face interviewer-administered structured questionnaire was used to collect data from the mothers and a standard checklist was used for their neonates. The data was encoded and entered into Epi-Data version 4.2 and exported to SPSS version 23 for analysis. Independent variables with marginal associations (p-value <0.25) in the bivariable analysis were eligible for multivariable logistic regression analysis to detect an association with outcome variables. Finally, adjusted odds ratios (AOR) with 95% CI were used to estimate the strength of associations, and statistical significance was declared at a p-value < 0.05. Result The magnitude of NNM was 26.7% with [95%CI: 21.6-32.5]. Hypertension during pregnancy [AOR: 3.4; 95%CI: 1.32-8.88], mode of delivery [AOR: 3.32; 95%CI: 1.48-7.45], Obstructed labor [AOR: 2.95; 95%CI: 1.32-6.45] and non-vertex fetal presentation during delivery [AOR: 4.61; 95%CI: 2.16-9.84] were identified as significantly predictors of NNM. Conclusion and recommendation Over a quarter of the neonates were with NNM cases, which is relatively higher than the report of studies done in other countries. Hypertension during pregnancy, cesarean delivery, prolonged labor, and non-vertex fetal presentation were all found to increase the likelihood of NNM. Therefore, concerted efforts are needed from local health planners and health care providers to improve maternal health care services especially in early identification of the complications and taking appropriate management.	[Wondimu, Merertu; Balcha, Fikadu; Bacha, Girma] Jimma Univ, Inst Hlth, Sch Nursing & Midwifery, Fac Hlth Sci, Jimma, Ethiopia; [Habte, Aklilu] Wachemo Univ, Dept Publ Hlth, Coll Med & Hlth Sci, Hosanna, Ethiopia	Jimma University	Habte, A (corresponding author), Wachemo Univ, Dept Publ Hlth, Coll Med & Hlth Sci, Hosanna, Ethiopia.	akliluhabte57@gmail.com	Habte, Aklilu/ABB-7649-2020; hailegebireal, aklilu habte/ABD-1527-2020	hailegebireal, aklilu habte/0000-0002-5719-4294				Afolabi BM., 2017, J NEONATAL BIOL, V6, P1, DOI DOI 10.4172/2167-0897.1000246; [Anonymous], 2016, INT ENV AGREEMENTS P, V16, P433; [Anonymous], NEAR MISS QUALITY CA; Avenant T, 2009, BEST PRACT RES CL OB, V23, P369, DOI 10.1016/j.bpobgyn.2008.12.005; de Lima THB, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2020-x; Benzouina Soukayna, 2016, Pan Afr Med J, V23, P197, DOI 10.11604/pamj.2016.23.197.7401; Ethiopian Public Health Institute (EPHI) [Ethiopia] and ICF, 2019, ETH MIN DEM HLTH SUR; Gedefaw G, 2020, PATIENT SAF SURG, V14, DOI 10.1186/s13037-020-00236-8; Harrison MS, 2015, REPROD HEALTH, V12, DOI 10.1186/1742-4755-12-S2-S9; Jorge A, 2014, MORBIDADE NEONATAL N, P182; Kale PL, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00179115, 10.1590/0102-311x00179115]; Kongwattanakul K, 2020, J PREGNANCY, V2020, DOI 10.1155/2020/9207431; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Martinelli KG, 2019, CAD SAUDE PUBLICA, V35, DOI [10.1590/0102-311X00222218, 10.1590/0102-311x00222218]; Maskey S, 2018, J NEPAL MED ASSOC, V56, P674, DOI 10.31729/jnma.3640; Mersha A, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2684-x; Morais LR, 2019, OBSTET GYNECOL INT, V2019, DOI 10.1155/2019/8594158; Moss W., 2000, J PERINATOL, V22, P484; Moster D, 2008, NEW ENGL J MED, V359, P262, DOI 10.1056/NEJMoa0706475; da Silva AAM, 2014, CAD SAUDE PUBLICA, V30, DOI 10.1590/0102-311X00129613; Nakimuli A, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0362-3; Ninama NH., 2019, INT J COMMUNITY MED, V6, P4570, DOI DOI 10.18203/2394-6040.IJCMPH20194520; Obsa MS, 2018, J PREGNANCY CHILD HE, V04, P4, DOI DOI 10.4172/2376-127X.1000375; Pileggi C, 2010, J PEDIAT-BRAZIL, V86, P21, DOI 10.2223/JPED.1965; Pileggi-Castro C, 2014, BJOG-INT J OBSTET GY, V121, P110, DOI 10.1111/1471-0528.12637; Rodrigues D., 2019, NEONATAL MORBIDITY N; Sankar MJ, 2016, J PERINATOL, V36, pS1, DOI 10.1038/jp.2016.27; Santos JP, 2015, CLINICS, V70, P820, DOI 10.6061/clinics/2015(12)10; Say L, 2010, J PEDIAT-BRAZIL, V86, P1, DOI [10.2223/JPED.1978, 10.1590/S0021-75572010000100001]; Shroff BD, 2019, J OBSTET GYN INDIA, V69, P50, DOI 10.1007/s13224-018-1093-9; Silva Guilherme Alberto, 2017, Rev. Bras. Saude Mater. Infant., V17, P159, DOI 10.1590/1806-93042017000100009; Surve S., 2017, CURR PEDIAT RES, V21, P264; United Nations Inter-agency Group for Child Mortality Estimation (UN IGME), 2019, ESTIMATES DEV INTERA; WHO, 2014, EV NEWB ACT PLAN END	34	3	3	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2021	16	5							e0251609	10.1371/journal.pone.0251609	http://dx.doi.org/10.1371/journal.pone.0251609			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0XR	33989319	gold, Green Published			2023-01-03	WOS:000662175000051
J	Malm, F; Elfstrom, A; Ohlsson-Nevo, E; Hoglund, E				Malm, Frida; Elfstroem, Annika; Ohlsson-Nevo, Emma; Hoeglund, Erik			Time consumption for non-conveyed patients within emergency medical services (EMS): A one-year prospective descriptive and comparative study in a region of Sweden	PLOS ONE			English	Article							RETROSPECTIVE COHORT; AMBULANCE SERVICE; TRIAGE; NURSES; ASSOCIATION; GUIDELINES; TRANSPORT; SYSTEM; DELAY; CARE	Introduction Over time, ambulance assignments have increased in number both nationally and internationally, and a substantial proportion of patients encountered by emergency medical services are assessed as not being in need of services. Non-conveying patients has become a way for emergency medical services clinicians to meet this increasing workload. It has been shown that ambulances can be made available sooner if patients are non-conveyed, but there is no previous research describing the factors that influence the non-conveyance time. Study objective To describe ambulance time consumption and the factors that influence time consumption when patients are non-conveyed. Methods A prospective observational review of 2615 non-conveyed patients' ambulance and hospital medical records was conducted using a consecutive sample. Data were analysed with the Kruskal-Wallis test, Mann-Whitney U test and Spearman's rank correlation (rho) for linear correlations. Results The mean NC time for all ambulance assignments during the study period was 26 minutes, with a median of 25 minutes. The shortest NC time was 4 minutes, and the longest NC time was 73 minutes. NC times were significantly faster during the day than at night. Conclusions This study provides new knowledge about time consumption when patients are non-conveyed. Although there are time differences when patients are non-conveyed, the differences observed in this study are small and not of clinical value. Ambulances will most often become available sooner if patients are non-conveyed. Although patients might be eligible for non-conveyance, policy-makers might have to decide when it is appropriate to non-convey patients from time, resource, patient safety and patient-centred care perspectives.	[Malm, Frida; Elfstroem, Annika] Orebro Univ Hosp, Dept Emergency Care, Orebro, Region Orebro C, Sweden; [Ohlsson-Nevo, Emma; Hoeglund, Erik] Orebro Univ, Univ Hlth Care Res Ctr, Fac Med & Hlth, Orebro, Sweden	Orebro University; Orebro University	Hoglund, E (corresponding author), Orebro Univ, Univ Hlth Care Res Ctr, Fac Med & Hlth, Orebro, Sweden.	erik.hoglund@oru.se		Hoglund, Erik/0000-0001-7885-694X	Research Committee in the county council of Orebro	Research Committee in the county council of Orebro	This research received funding support from the Research Committee in the county council of Orebro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Augustine James J, 2008, EMS Mag, V37, P39; Bureau of Health Information, 2017, SPOTL MEAS MEAS REP; Christ M, 2010, DTSCH ARZTEBL INT, V107, P892, DOI 10.3238/arztebl.2010.0892; Clarey A, 2014, EMERG MED J, V31, P419, DOI 10.1136/emermed-2012-202258; Cooney DR, 2011, PREHOSP EMERG CARE, V15, P555, DOI 10.3109/10903127.2011.608871; Cushman JT, 2010, PREHOSP EMERG CARE, V14, P477, DOI 10.3109/10903127.2010.497901; Department of Health, 2007, IMPROVING AMBULANCE; Dinh MM, 2016, PREHOSP EMERG CARE, V20, P776, DOI 10.1080/10903127.2016.1182603; Evangelista A, 2008, WESTERN J NURS RES, V30, P501, DOI 10.1177/0193945907303302; Gerlacher GR, 2001, PEDIATR EMERG CARE, V17, P421, DOI 10.1097/00006565-200112000-00005; Gray JT, 2007, EMERG MED J, V24, P727, DOI 10.1136/emj.2007.048850; Hinson JS, 2018, INT J EMERG MED, V11, DOI 10.1186/s12245-017-0161-8; Hjalte L, 2007, EUR J EMERG MED, V14, P151; Hoglund E, 2019, J CLIN NURS, V28, P235, DOI 10.1111/jocn.14626; Hoikka M, 2017, ACTA ANAESTH SCAND, V61, P549, DOI 10.1111/aas.12889; Horibata K, 2015, TOHOKU J EXP MED, V235, P89, DOI 10.1620/tjem.235.89; Magnusson C, 2016, INT EMERG NURS, V26, P32, DOI 10.1016/j.ienj.2015.09.001; Norberg G, 2015, SCAND J PRIM HEALTH, V33, P311, DOI 10.3109/02813432.2015.1114347; Norden C, 2014, INT EMERG NURS, V22, P75, DOI 10.1016/j.ienj.2013.04.003; OCathain A, 2018, HEALTH SERV DELIVERY, V6, P1, DOI [10.3310/hsdr06190, DOI 10.3310/HSDR06190]; Peacock PJ, 2005, EMERG MED J, V22, P56, DOI 10.1136/emj.2004.016741; Reifman A., 2010, WINSORIZE; Shah MN, 2008, PREHOSP EMERG CARE, V12, P169, DOI 10.1080/10903120801907059; Snooks H, 2004, QUAL SAF HEALTH CARE, V13, P435, DOI 10.1136/qshc.2003.007658; Snooks HA, 2004, EMERG MED J, V21, P212, DOI 10.1136/emj.2003.005199; Swedish Council on Health Technology Assessment, 2010, TRIAGE METHODS PATIE; Tsai LH, 2017, EMERG MED J, V34, P720, DOI 10.1136/emermed-2015-205304; Vandeventer S, 2011, PREHOSP EMERG CARE, V15, P366, DOI 10.3109/10903127.2011.561412; Villani M, 2016, J DIABETES COMPLICAT, V30, P1081, DOI 10.1016/j.jdiacomp.2016.04.015; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Widgren BR, 2011, J EMERG MED, V40, P623, DOI 10.1016/j.jemermed.2008.04.003; Wireklint SC, 2018, INT EMERG NURS, V38, P21, DOI 10.1016/j.ienj.2017.12.003; Womack JP, 2018, AM FAM PHYSICIAN, V98, P240; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053	34	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2021	16	5							e0251686	10.1371/journal.pone.0251686	http://dx.doi.org/10.1371/journal.pone.0251686			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6MO	33984054	Green Published, gold			2023-01-03	WOS:000664628200115
J	Nigussie, S; Birhan, N; Amare, F; Mengistu, G; Adem, F; Abegaz, TM				Nigussie, Shambel; Birhan, Nigussie; Amare, Firehiwot; Mengistu, Getnet; Adem, Fuad; Abegaz, Tadesse Melaku			Rate of glycemic control and associated factors among type two diabetes mellitus patients in Ethiopia: A cross sectional study	PLOS ONE			English	Article							RISK-FACTORS; DETERMINANTS; MANAGEMENT; HOSPITALS; ATTITUDES; LEVEL	Objective To assess the rate of glycemic control and associated factors among type 2 diabetes mellitus patients at Dilchora Referral Hospital, Dire Dawa, Eastern Ethiopia. Methods A cross-sectional study was conducted from 13 May to 16 August 2019. Type 2 diabetic patients on follow up at Dilchora Referral Hospital who fulfilled the inclusion criteria of the study were included. Systematic random sampling was used to select study participants. Data was collected by a face-to-face interview and review of medical records. The primary outcome was the level of blood glucose during three consecutive visits. Poor glycemic control was defined as a blood sugar level of more than 154 mg/dL based on the average of measurements from three consecutive visits. Multivariate logistic regression analysis was used to identify determinants of glycemic control. Result A total of 394 participants responded to the interview and were included in the final analysis. The overall prevalence of poor glycemic control was 45.2% (95%CI: 40.6%-50.0%). Patients who were on oral anti-diabetic drug plus insulin had more than two times greater chance of poor glycemic control than patients on oral anti-diabetic drug alone: 2.177(95%CI:1.10-4.29). The odds of poor glycemic control in patients who did not understand the pharmacist's instructions was two times higher than patients with good understanding of instructions 1.86(95%CI: 1.10-3.13). Patients who had poor level of practice were found to have poor glycemic control: 1.69(95% CI: 1.13-2.55). Conclusion The overall prevalence of poor glycemic control was high among type 2 diabetes patients. Oral anti-diabetic drugs in combination with insulin, lack of understanding of pharmacist's advice, and poor practice of diabetic patients were significant factors of poor glycemic control. Pharmacists should reassure the understanding of patients before discharge during counseling. Optimization of the dose of antidiabetic medications and combination of oral hypoglycemic agents should be considered.	[Nigussie, Shambel; Amare, Firehiwot; Adem, Fuad] Haramaya Univ, Sch Pharm, Dept Clin Pharm, Coll Hlth & Med Sci, Harar, Ethiopia; [Birhan, Nigussie] Univ Gondar, Dept Nursing, Coll Med & Hlth Sci, Gondar, Ethiopia; [Mengistu, Getnet] Wollo Univ, Dept Pharm, Coll Med & Hlth Sci, Pharmacol & Toxicol Unit, Dessie, Ethiopia; [Abegaz, Tadesse Melaku] Univ Gondar, Sch Pharm, Dept Clin Pharm, Coll Med & Hlth Sci, Gondar, Ethiopia; [Abegaz, Tadesse Melaku] Univ South Australia, Clin & Hlth Sci, Adelaide, SA, Australia	Haramaya University; University of Gondar; University of Gondar; University of South Australia	Nigussie, S (corresponding author), Haramaya Univ, Sch Pharm, Dept Clin Pharm, Coll Hlth & Med Sci, Harar, Ethiopia.	shambelpharm02@gmail.com	Nigussie, Shambel/GQI-4538-2022; Amare, Firehiwot/AAG-3974-2020	Nigussie, Shambel/0000-0001-6673-9826; Amare, Firehiwot/0000-0002-9218-4008				Abebe SM, 2015, DIABET METAB SYND OB, V8, P65, DOI 10.2147/DMSO.S75467; Adeniyi OV, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010875; Al Mansari A, 2018, BMJ OPEN DIAB RES CA, V6, DOI 10.1136/bmjdrc-2018-000519; Al-Ibrahim AAH., 2012, FACTORS ASS COMPLIAN; Al-Kaabi Juma, 2008, Rev Diabet Stud, V5, P110, DOI 10.1900/RDS.2008.5.110; Al-Nuaim AR, 1998, ANN SAUDI MED, V18, P109, DOI 10.5144/0256-4947.1998.109; Al-Rasheedi AA, 2015, INT J HEALTH SCI-IJH, V9, P345; Al-Rasheedi AAS, 2014, INT J HEALTH SCI-IJH, V8, P177, DOI 10.12816/0006084; Alldredge Brian K., APPL THERAPEUTICS CL, V10th; Amer Diabet Assoc, 2021, DIABETES CARE, V44, pS111, DOI 10.2337/dc21-S009; Badedi M, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/2109542; Bayisa B., 2017, GLYCEMIC CONTROL ASS, V6; Braga MFB, 2010, CAN J CARDIOL, V26, P297, DOI 10.1016/S0828-282X(10)70393-7; Care D., 2019, DIABETES CARE, V42, pS81; Cefalu WT, 2019, DIABETES CARE, V42, pS13, DOI 10.2337/dc19-S002; Chan JCN, 2009, DIABETES CARE, V32, P227, DOI 10.2337/dc08-0435; Cho NH, 2018, DIABETES RES CLIN PR, V138, P271, DOI 10.1016/j.diabres.2018.02.023; De P., 2018, INT J RES MED SCI, V6, P545, DOI DOI 10.18203/2320-6012.IJRMS20180295.545-0; Fasil A, 2019, DIABET METAB SYND OB, V12, P75, DOI 10.2147/DMSO.S185614; Fiagbe J., 2017, DIABETES MANAGEMENT, V7, P343; Food E., 2013, CONTINUING PROFESSIO; Goudswaard AN, 2004, EUR J EPIDEMIOL, V19, P541, DOI 10.1023/B:EJEP.0000032351.42772.e7; Guo XH, 2015, INT J DIABETES DEV C, V35, P488, DOI 10.1007/s13410-015-0322-3; Hoerger TJ, 2008, DIABETES CARE, V31, P81, DOI 10.2337/dc07-1572; Kakade A.A., 2018, INTEGR OBES DIABETES, V4, DOI [10.15761/iod.1000209, DOI 10.15761/IOD.1000209]; Kamuhabwa AR, 2014, DRUG HEALTHC PATIENT, V6, P155, DOI 10.2147/DHPS.S68786; Kassahun Tefera, 2016, BMC Res Notes, V9, P78, DOI 10.1186/s13104-016-1896-7; Khan AR, 2012, J FAM COMMUNITY MED, V19, P26, DOI 10.4103/2230-8229.94008; Khattab M, 2010, J DIABETES COMPLICAT, V24, P84, DOI 10.1016/j.jdiacomp.2008.12.008; Lozovey NR, 2017, J ENDOCRINOL METAB, V7, P61, DOI 10.14740/jem390w; Lumanlan DB, 2016, DIABETES RES CLIN PR, V120, pS175; Mohammad HA., 2012, INDIAN J ENDOCRINOL, V16; Mohammadi S., 2015, SCI J PUBLIC HLTH, V3, P520, DOI DOI 10.11648/J.SJPH.20150304.20; Obied KA., 2013, INT J PHARM SCI, V4; Oluma A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247634; Organization WH., 2017, UPD FACT SHEET TOP 1; Organization WH, 2012, GLOBAL DATA VISUAL I; Pablo C., 2018, J DIABETIC COMPLICAT, V3, P2; Peyrot M, 2012, DIABETIC MED, V29, P682, DOI 10.1111/j.1464-5491.2012.03605.x; Rasheed M., 2015, J ISLAMABAD MED DENT, V4, P68; Reaven PD, 2019, NEW ENGL J MED, V380, P2215, DOI 10.1056/NEJMoa1806802; Reidpath DD, 2018, INT J PUBLIC HEALTH, V63, P193, DOI 10.1007/s00038-017-1072-4; Roglic G., 2016, INT J NONCOMMUN DIS, V1, P3, DOI [DOI 10.4103/2468-8827.184853, 10.4103/2468-8827.184853]; Samancioglu S., 2017, INT J CARING SCI, V10, P889; VENKATARAMAN RAJESH., 2018, ASIAN J PHARM CLIN R, V11, P179; Venkatesan R, 2012, Perspect Clin Res, V3, P26, DOI 10.4103/2229-3485.92304; Woldu M, 2014, ENDOCRINOL METAB SYN, V3, DOI DOI 10.4172/2161-1017.1000143	47	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2021	16	5							e0251506	10.1371/journal.pone.0251506	http://dx.doi.org/10.1371/journal.pone.0251506			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6LY	33974654	Green Accepted, gold, Green Published			2023-01-03	WOS:000664626600047
J	Kanda, M; Tateishi, K; Nakagomi, A; Iwahana, T; Okada, S; Kuwabara, H; Kobayashi, Y; Inoue, T				Kanda, Masato; Tateishi, Kazuya; Nakagomi, Atsushi; Iwahana, Togo; Okada, Sho; Kuwabara, Hiroyo; Kobayashi, Yoshio; Inoue, Takahiro			Association between early intensive care or coronary care unit admission and post-discharge performance of activities of daily living in patients with acute decompensated heart failure	PLOS ONE			English	Article							QUALITY-OF-LIFE; BARTHEL INDEX; VALIDATION; MANAGEMENT; MORTALITY; STROKE	The management of acute decompensated heart failure often requires intensive care. However, the effects of early intensive care unit/coronary care unit admission on activities of daily living (ADL) in acute decompensated heart failure patients have not been precisely evaluated. Thus, we retrospectively assessed the association between early intensive care unit admission and post-discharge ADL performance in these patients. Acute decompensated heart failure patients (New York Heart Association I-III) admitted on emergency between April 1, 2014, and December 31, 2018, were selected from the Diagnosis Procedure Combination database and divided into intensive care unit/coronary care unit (ICU) and general ward (GW) groups according to the hospitalization type on admission day 1. The propensity score was calculated to create matched cohorts where admission style (intensive care unit/coronary care unit admission) was independent of measured baseline confounding factors, including ADL at admission. The primary outcome was ADL performance level at discharge (post-ADL) defined according to the Barthel index. Secondary outcomes included length of stay and total hospitalization cost (expense). Overall, 12231 patients were eligible, and propensity score matching created 2985 pairs. After matching, post-ADL was significantly higher in the ICU group than in the GW group [mean (standard deviation), GW vs. ICU: 71.5 (35.3) vs. 78.2 (31.2) points, P<0.001; mean difference: 6.7 (95% confidence interval, 5.1-8.4) points]. After matching, length of stay was significantly shorter and expenses were significantly higher in the ICU group than in the GW group. Stratified analysis showed that the patients with low ADL at admission (Barthel index score <60) were the most benefited from early intensive care unit/coronary care unit admission. Thus, early intensive care unit/coronary care unit admission was associated with improved post-ADL in patients with emergency acute decompensated heart failure admission.	[Kanda, Masato; Tateishi, Kazuya; Iwahana, Togo; Okada, Sho; Kobayashi, Yoshio] Chiba Univ, Grad Sch Med, Dept Cardiovasc Med, Chiba, Japan; [Nakagomi, Atsushi] Harvard TH Chan Sch Publ Hlth, Takemi Program Int Hlth, Boston, MA USA; [Kuwabara, Hiroyo; Inoue, Takahiro] Chiba Univ Hosp, Res Ctr, Dept Healthcare Management, Chiba, Japan	Chiba University; Harvard University; Harvard T.H. Chan School of Public Health; Chiba University	Inoue, T (corresponding author), Chiba Univ Hosp, Res Ctr, Dept Healthcare Management, Chiba, Japan.	ifa8p8p@nifty.com		Iwahana, Togo/0000-0002-5821-0110				Al Mahrouqi MM, 2020, J FOOT ANKLE RES, V13, DOI 10.1186/s13047-020-00432-w; Asano R, 2017, INT J CARDIOL, V230, P585, DOI 10.1016/j.ijcard.2016.12.052; Ferreira JC, 2017, J BRAS PNEUMOL, V43, P162, DOI 10.1590/S1806-37562017000000170; Cattadori G, 2018, ESC HEART FAIL, V5, P222, DOI 10.1002/ehf2.12225; Cerlinskaite K, 2018, EUR J HEART FAIL, V20, P1175, DOI 10.1002/ejhf.1195; Cheshire C, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-1048; Faxen UL, 2018, INT J CARDIOL, V267, P128, DOI 10.1016/j.ijcard.2018.04.102; Garcia-Gutierrez S, 2017, INTERN EMERG MED, V12, P1197, DOI 10.1007/s11739-016-1541-4; Groenewegen A, 2020, EUR J HEART FAIL, V22, P1342, DOI 10.1002/ejhf.1858; Hsieh YW, 2007, NEUROREHAB NEURAL RE, V21, P233, DOI 10.1177/1545968306294729; Inoue T, 2013, STROKE, V44, P3142, DOI 10.1161/STROKEAHA.113.001684; Isogai T, 2016, INT J CARDIOL, V222, P163, DOI 10.1016/j.ijcard.2016.07.159; Kitamura M, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7420738; Kuwabara H, 2011, CIRC J, V75, P1107, DOI 10.1253/circj.CJ-10-0556; LaBuzetta JN, 2019, NEUROCRIT CARE, V31, P534, DOI 10.1007/s12028-019-00826-0; MAHONEY F I, 1965, Md State Med J, V14, P61; Martin-Sanchez FJ, 2016, INT J CARDIOL, V222, P62, DOI 10.1016/j.ijcard.2016.07.151; Matsushita M, 2019, INTERNAL MED, V58, P2931, DOI 10.2169/internalmedicine.2757-19; Motoki H, 2019, INT J CARDIOL, V293, P125, DOI 10.1016/j.ijcard.2019.06.071; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Raslan IR, 2017, AM HEART J, V188, P127, DOI 10.1016/j.ahj.2017.03.014; Rossello X, 2021, CIRC-HEART FAIL, V14, P312, DOI 10.1161/CIRCHEARTFAILURE.120.007347; Rossello X, 2021, EUR HEART J-ACUTE CA, V10, P142, DOI 10.1177/2048872620934318; Rossello X, 2020, EUR J HEART FAIL, V22, P834, DOI 10.1002/ejhf.1740; Rossello X, 2019, ANN EMERG MED, V73, P589, DOI 10.1016/j.annemergmed.2018.12.009; Rossello X, 2017, CARDIOLOGY, V136, P61, DOI 10.1159/000448110; Safavi KC, 2013, CIRCULATION, V127, P923, DOI 10.1161/CIRCULATIONAHA.112.001088; Sauro KM, 2020, CRIT CARE MED, V48, P946, DOI 10.1097/CCM.0000000000004327; Shigematsu K, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002736; Takabayashi K, 2019, J CARDIOL, V73, P522, DOI 10.1016/j.jjcc.2018.12.014; van Diepen S, 2017, CIRCULATION, V136, pE232, DOI 10.1161/CIR.0000000000000525; van Exel NJA, 2004, QUAL LIFE RES, V13, P427, DOI 10.1023/B:QURE.0000018496.02968.50; Yamashita M, 2020, HEART VESSELS, V35, P360, DOI 10.1007/s00380-019-01490-2; Ziaeian B, 2016, NAT REV CARDIOL, V13, P368, DOI 10.1038/nrcardio.2016.25	34	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2021	16	5							e0251505	10.1371/journal.pone.0251505	http://dx.doi.org/10.1371/journal.pone.0251505			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6LC	33970971	Green Published, gold			2023-01-03	WOS:000664624400054
J	Javadi, SS; Mathur, K; Concha-Garcia, S; Patel, H; Perry, KE; Lo, M; Taylor, J; Kaytes, A; Little, S; Gianella, S; Smith, D; Dube, K				Javadi, Sogol S.; Mathur, Kushagra; Concha-Garcia, Susanna; Patel, Hursch; Perry, Kelly E.; Lo, Megan; Taylor, Jeff; Kaytes, Andy; Little, Susan; Gianella, Sara; Smith, Davey; Dube, Karine			Attitudes and perceptions of next-of-kin/loved ones toward end-of-life HIV cure-related research: A qualitative focus group study in Southern California	PLOS ONE			English	Article							BEREAVED FAMILY-MEMBERS; ETHICAL CONSIDERATIONS; NURSING-HOME; OLDER PERSON; CARE; ISSUES; EXPERIENCES; RELATIVES; PATIENT; PEOPLE	As end-of-life (EOL) HIV cure-related research expands, understanding perspectives of participants' next-of-kin (NOK) is critical to maintaining ethical study conduct. We conducted two small focus groups and two one-on-one interviews using focus group guides with the NOK of Last Gift study participants at the University of California, San Diego (UCSD). Participating NOK included six individuals (n = 5 male and n = 1 female), including a grandmother, grandfather, partner, spouse, and two close friends. Researchers double-coded the transcripts manually for overarching themes and sub-themes using an inductive approach. We identified six key themes: 1) NOK had an accurate, positive understanding of the Last Gift clinical study; 2) NOK felt the study was conducted ethically; 3) Perceived benefits for NOK included support navigating the dying/grieving process and personal growth; 4) Perceived drawbacks included increased sadness, emotional stress, conflicted wishes between NOK and study participants, and concerns around potential invasiveness of study procedures at the EOL; 5) NOK expressed pride in loved ones' altruism; and 6) NOK provided suggestions to improve the Last Gift study, including better communication between staff and themselves. These findings provide a framework for ethical implementation of future EOL HIV cure-related research involving NOK.	[Javadi, Sogol S.; Mathur, Kushagra; Concha-Garcia, Susanna; Lo, Megan; Little, Susan; Gianella, Sara; Smith, Davey] Univ Calif San Diego, AntiViral Res Ctr, San Diego, CA 92103 USA; [Concha-Garcia, Susanna] Univ Calif San Diego, HIV Neurobehav Res Ctr, San Diego, CA 92103 USA; [Patel, Hursch; Perry, Kelly E.; Dube, Karine] UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Taylor, Jeff; Kaytes, Andy] Community Advisory Board, Antiviral Res Ctr, San Diego, CA USA; [Taylor, Jeff] HIV Aging Res Project Palm Springs HARP PS, Palm Springs, CA USA; [Little, Susan; Gianella, Sara; Smith, Davey] Univ Calif San Diego, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego	Javadi, SS (corresponding author), Univ Calif San Diego, AntiViral Res Ctr, San Diego, CA 92103 USA.	sjavadi@mednet.ucla.edu		E. Perry, Kelly/0000-0002-8637-4729; Patel, Hursch/0000-0002-0725-4922; Javadi, Sogol/0000-0002-2366-4550; Little, Susan/0000-0002-7645-9737	Department of Veterans Affairs; National Institutes of Health [AI120009, AI131385, AI100665, P30 AI036214, AI134295, HD094646]; California NeuroAIDS Tissue Network (U.S. National Institute of Mental Health, National Institutes of Health (NIMH/NIH)) [U24MH100928];  [R21MH118120]	Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California NeuroAIDS Tissue Network (U.S. National Institute of Mental Health, National Institutes of Health (NIMH/NIH)); 	This work was funded by R21MH118120 to K.D (https://projectreporter.nih.gov/project_ info_description.cfm?aid=9905559&icde=50979 632&ddparam=&ddvalue=&ddsub=&cr=2&csb= default&cs=ASC&pball=). We also acknowledge support received from the Department of Veterans Affairs and grants from the National Institutes of Health: AI120009 (R01 Smith -P3 Deep Sequencing Tech), AI131385 (P01 Smith - Revealing Reservoirs during Rebound (R3) Last Gift, Early Treatment Interruption), AI100665 (Smith - K24 Training), P30 AI036214 (Smith -UCSD CFAR), AI134295 (Gianella - Sex Hormones & Persistence), HD094646 (Gianella -Declining Sex Hormones). We also give thanks to the California NeuroAIDS Tissue Network (U.S. National Institute of Mental Health, National Institutes of Health (NIMH/NIH Award Number [U24MH100928])).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aoun SM, 2018, J PAIN SYMPTOM MANAG, V55, P368, DOI 10.1016/j.jpainsymman.2017.09.023; Appelbaum PS, 2012, CLIN TRIALS, V9, P748, DOI 10.1177/1740774512456455; Basch E, 2012, JAMA-J AM MED ASSOC, V307, P1636, DOI 10.1001/jama.2012.466; Blindheim K, 2013, J CLIN NURS, V22, P681, DOI 10.1111/j.1365-2702.2012.04349.x; Bokberg C, 2019, QUAL LIFE RES, V28, P3293, DOI 10.1007/s11136-019-02268-9; Chaillon A, 2020, J CLIN INVEST, V130, P1699, DOI 10.1172/JCI134815; Creswell JW, 2018, QUAL INQ; Creswell JW., 2014, QUALITATIVE QUANTITA, V4; Curtis JR, 2010, LANCET, V376, P1347, DOI 10.1016/S0140-6736(10)60143-2; Department of Health Education and Welfare, 2014, J Am Coll Dent, V81, P4; Donnelly S, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0365-6; Dube K, 2020, AIDS RES HUM RETROV, V36, P1033, DOI [10.1089/aid.2020.0025, 10.1089/AID.2020.0025]; Dube K, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25404; Dube K, 2018, BMC MED ETHICS, V19, DOI 10.1186/s12910-018-0321-2; Gianella S, 2017, AIDS, V31, P1, DOI 10.1097/QAD.0000000000001300; Gjerberg E, 2011, NURS ETHICS, V18, P42, DOI 10.1177/0969733010386160; Goodkin K, 2018, NURS CLIN N AM, V53, P123, DOI 10.1016/j.cnur.2017.10.010; Grossman CI, 2016, TRENDS MICROBIOL, V24, P5, DOI 10.1016/j.tim.2015.10.011; Guest G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232076; Hvalvik S, 2015, INT J QUAL STUD HEAL, V10, DOI 10.3402/qhw.v10.26554; Kentish-Barnes N, 2015, CRIT CARE MED, V43, P1839, DOI 10.1097/CCM.0000000000001092; King NMP, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt474; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; Lo B, 2013, CURR OPIN HIV AIDS, V8, P243, DOI 10.1097/COH.0b013e32835ea1c5; Mallinson RK, 2013, J ASSOC NURSE AIDS C, V24, pS61, DOI 10.1016/j.jana.2012.08.012; Morgan DL, 2013, QUAL HEALTH RES, V23, P1276, DOI 10.1177/1049732313501889; Paulsen B, 2018, NURS OPEN, V5, P431, DOI 10.1002/nop2.155; Pentz RD, 2005, NAT MED, V11, P1145, DOI 10.1038/nm1105-1145; Peter E, 2017, J EMPIR RES HUM RES, V12, P107, DOI 10.1177/1556264617696920; Prakash K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199670; Pratt MG, 2009, ACAD MANAGE J, V52, P856, DOI 10.5465/AMJ.2009.44632557; Rawlings SA, 2020, AIDS, V34, P1089, DOI 10.1097/QAD.0000000000002546; Reid J, 2009, INT J PALLIAT NURS, V15, P30, DOI 10.12968/ijpn.2009.15.1.37950; Rosen H, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1343-4; Rosenbaum L, 2020, NEW ENGL J MED, V382, P493, DOI 10.1056/NEJMp2000048; Ryan G. W., 2003, FIELD METHOD, V15, P85, DOI DOI 10.1177/1525822X02239569; Salkind N., 2010, SOCIAL DESIRABILITY, DOI [10.1097/SMJ.0b013e3181eab419, DOI 10.1097/SMJ.0B013E3181EAB419]; Smith CJ, 2014, LANCET, V384, P241, DOI 10.1016/S0140-6736(14)60604-8; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Sylla L, 2018, AIDS RES HUM RETROV, V34, P56, DOI [10.1089/aid.2017.0178, 10.1089/AID.2017.0178]; Taylor J, 2020, AIDS RES HUM RETROVI; Thoresen L, 2016, BMC MED ETHICS, V17, DOI 10.1186/s12910-016-0156-7; Tross S, 2018, AIDS BEHAV, V22, P2258, DOI 10.1007/s10461-018-2114-5; UCSD, LAST GIFT UC SAN DIE; Vasquez JJ, 2019, CLIN INFECT DIS, V69, P1068, DOI 10.1093/cid/ciz070; Verkissen MN, 2018, BRIT J CANCER, V118, P1369, DOI 10.1038/s41416-018-0070-5; Wagner D, 2017, NEW SAN DIEGO STUDY; Wiegand DL, 2016, DIMENS CRIT CARE NUR, V35, P160, DOI 10.1097/DCC.0000000000000174; Wilson S, 2008, FAM PRACT, V25, P456, DOI 10.1093/fampra/cmn076; Yamaguchi T, 2017, J PAIN SYMPTOM MANAG, V54, P17, DOI 10.1016/j.jpainsymman.2017.03.008	50	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2021	16	5							e0250882	10.1371/journal.pone.0250882	http://dx.doi.org/10.1371/journal.pone.0250882			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SX8UE	33961653	Green Published, gold			2023-01-03	WOS:000665471900025
J	Jung, YS; Kim, YE; Go, DS; Yoon, SJ				Jung, Yoon-Sun; Kim, Young-Eun; Go, Dun-Sol; Yoon, Seok-Jun			The prevalence, incidence, and admission rate of diagnosed schizophrenia spectrum disorders in Korea, 2008-2017: A nationwide population-based study using claims big data analysis	PLOS ONE			English	Article							NONAFFECTIVE PSYCHOSIS	This study estimated the prevalence and incidence rate of schizophrenia, schizotypal, and delusional disorders (SSDD) in Korea from 2008 to 2017 and analyzed the hospital admission rate, re-admission rate, and hospitalization period. It used the Korean nationwide National Health Insurance Service claims database. SSDD patients who had at least one visit to Korea's primary, secondary, or tertiary referral hospitals with a diagnosis of SSDD, according to the International Classification of Diseases, 10th Revision (ICD-10), were identified as SSDD cases if coded as F20-F29. Data were analyzed using frequency statistics. Results showed that the 12-month prevalence rate of SSDD increased steadily from 0.40% in 2008 to 0.45% in 2017. Analysis of the three-year cumulative prevalence rate of SSDD showed an increase from 0.51% in 2011 to 0.54% in 2017. In 2017, the five-year cumulative prevalence rate was 0.61%, and the 10-year cumulative prevalence rate was 0.75%. The hospital admission rate among SSDD patients decreased from 2008 (30.04%) to 2017 (28.53%). The incidence of SSDD was 0.05% and no yearly change was observed. The proportion of SSDD inpatients whose first hospital visit resulted in immediate hospitalization was 22.4% in 2017. Epidemiological indicators such as prevalence, incidence, and hospitalization rate play an important role in planning social and financial resource allocation. Therefore, efforts to produce more accurate epidemiological indicators are very important and this study's findings could have a significant social impact.	[Jung, Yoon-Sun] Korea Univ, Grad Sch, Dept Publ Hlth, Seoul, South Korea; [Kim, Young-Eun] Natl Hlth Insurance Serv, Dept Big Data Strategy, Wonju, South Korea; [Go, Dun-Sol] Korea Inst Hlth & Social Affairs, Dept Hlth Care Policy Res, Sejong, South Korea; [Yoon, Seok-Jun] Korea Univ, Dept Prevent Med, Coll Med, Seoul, South Korea	Korea University; National Health Insurance Service; Korea Institute for Health and Social Affairs; Korea University; Korea University Medicine (KU Medicine)	Yoon, SJ (corresponding author), Korea Univ, Dept Prevent Med, Coll Med, Seoul, South Korea.	yoonsj02@korea.ac.kr		Yoon, Seok-Jun/0000-0003-3297-0071	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI18C0446]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea, in the form of a grant to SJY [HI18C0446].	Asken MJ., 2013, AM PSYCH ASS DIAGN S; Chien IC, 2004, PSYCHIAT SERV, V55, P691, DOI 10.1176/appi.ps.55.6.691; Cho SJ, 2020, PSYCHIAT INVEST, V17, P61, DOI 10.30773/pi.2019.0041; Choi EK, 2020, KOREAN CIRC J, V50, P754, DOI 10.4070/kcj.2020.0171; Desai PR, 2013, J PHARM HEALTH SERV, V4, P187, DOI 10.1111/jphs.12027; Goldner EM, 2003, PSYCHIAT SERV, V54, P1017, DOI 10.1176/appi.ps.54.7.1017; Goldner EM, 2002, CAN J PSYCHIAT, V47, P833, DOI 10.1177/070674370204700904; Hong JP., 2017, SURVEY MENTAL DISORD; Jung I, 2011, CRIME ANAL; Kaplan H.I., 1998, SYNOPSIS PSYCHIAT, V8th ed.; Kendler KS, 1996, ARCH GEN PSYCHIAT, V53, P1022; Kessler RC, 2005, BIOL PSYCHIAT, V58, P668, DOI 10.1016/j.biopsych.2005.04.034; Kessler RC, 2006, EPIDEMIOL PSICHIAT S, V15, P161, DOI 10.1017/S1121189X00004395; Lee YR, 2019, J KOREAN MED SCI, V34, DOI 10.3346/jkms.2019.34.e80; O'Connor DW, 2009, PSYCHOL MED, V39, P1527, DOI 10.1017/S0033291708004728; Organisation for Economic Co-Operation and Development, 2014, MAK MENT HLTH COUNT; Organization for Economic Cooperation and Development, 2019, HEALTH DATA MANAG; Park Hyunwoo, 2019, [Korean Journal of Schizophrenia Research, 대한조현병학회지], V22, P34, DOI 10.16946/kjsr.2019.22.2.34; Park JH, 2012, PSYCHIAT INVEST, V9, P17, DOI 10.4306/pi.2012.9.1.17; Saha S, 2005, PLOS MED, V2, P413, DOI 10.1371/journal.pmed.0020141; Wu EQ, 2006, PSYCHOL MED, V36, P1535, DOI 10.1017/S0033291706008191	21	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256221	10.1371/journal.pone.0256221	http://dx.doi.org/10.1371/journal.pone.0256221			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TZ4EI	34383865	gold, Green Published			2023-01-03	WOS:000684426400002
J	Thomas, JA; Irvine, MK; Xia, Q; Harriman, GA				Thomas, Jacinthe A.; Irvine, Mary K.; Xia, Qiang; Harriman, Graham A.			Service utilization and HIV outcomes among transgender women receiving Ryan White Part A services in New York City	PLOS ONE			English	Article							HOUSING STATUS; MEDICAL-CARE; HIV/AIDS; ENGAGEMENT; RISK; SEX	Background Prior research has found evidence of gender disparities in U.S. HIV healthcare access and outcomes. In order to assess potential disparities in our client population, we compared demographics, service needs, service utilization, and HIV care continuum outcomes between transgender women, cisgender women, and cisgender men receiving New York City (NYC) Ryan White Part A (RWPA) services. Methods The analysis included HIV-positive clients with an intake assessment between January 2016 and December 2017 in an NYC RWPA services program. We examined four service need areas: food and nutrition, harm reduction, mental health, and housing. Among clients with the documented need, we ascertained whether they received RWPA services targeting that need. To compare HIV outcomes between groups, we applied five metrics: engagement in care, consistent engagement in care, antiretroviral therapy (ART) use, point-in-time viral suppression, and durable viral suppression. Results All four service needs were more prevalent among transgender women (N = 455) than among cisgender clients. Except in the area of food and nutrition services, timely (12-month) receipt of RWPA services to meet a specific assessed need was not significantly more or less common in any one of the three client groups examined. Compared to cisgender women and cisgender men, a lower proportion of transgender women were durably virally suppressed (39% versus 52% or 50%, respectively, p-value < 0.001). Conclusions Compared with cisgender women and cisgender men, transgender women more often presented with basic (food/housing) and behavioral-health service needs. In all three groups (with no consistent between-group differences), assessed needs were not typically met with the directly corresponding RWPA service category. Targeting those needs with RWPA outreach and services may support the National HIV/AIDS Strategy 2020 goal of reducing health disparities, and specifically the objective of increasing (to >= 90%) the percentage of transgender women in HIV medical care who are virally suppressed.	[Thomas, Jacinthe A.; Irvine, Mary K.; Xia, Qiang; Harriman, Graham A.] New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA	New York City Department of Health & Mental Hygiene	Thomas, JA (corresponding author), New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA.	jthomas1@health.nyc.gov		Thomas, Jacinthe/0000-0003-0173-6362	Health Resources and Services Administration [H89HA00015]	Health Resources and Services Administration(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA))	This work was supported through a grant from the Health Resources and Services Administration [H89HA00015] to the New York City Department of Health and Mental Hygiene. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aidala AA, 2016, AM J PUBLIC HEALTH, V106, pE1, DOI 10.2105/AJPH.2015.302905; [Anonymous], 2018, HRSAS RYAN WHITE HIV; [Anonymous], 2015, NATL HIV AIDS STRATE; Bradley H, 2016, CLIN INFECT DIS, V62, P90, DOI 10.1093/cid/civ708; De Santis JP, 2009, J ASSOC NURSE AIDS C, V20, P362, DOI 10.1016/j.jana.2009.06.005; Drobnik A, 2014, J PUBLIC HEALTH MAN, V20, P506, DOI 10.1097/PHH.0b013e3182a95607; HIV Epidemiology and Field Services Program, 2016, HIV SURVEILLANCE ANN; Hoffman BR, 2014, SUBST USE MISUSE, V49, P1049, DOI 10.3109/10826084.2013.855787; Irvine MK, 2017, AIDS BEHAV, V21, P1572, DOI 10.1007/s10461-016-1460-4; James S. E., 2016, REPORT US TRANSGENDE; Kalichman SC, 2017, SEX HEALTH, V14, P469, DOI 10.1071/SH17015; Kalichman SC, 2014, J COMMUN HEALTH, V39, P1133, DOI 10.1007/s10900-014-9868-0; Klein PW, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003125; Leaver CA, 2007, AIDS BEHAV, V11, pS85, DOI 10.1007/s10461-007-9246-3; Lederer DJ, 2019, ANN AM THORAC SOC, V16, P22, DOI 10.1513/AnnalsATS.201808-564PS; Maruish M., 2012, USERS MANUAL SF 12V2, V3rd ed, DOI [10.1186/1477-7525-10-154, DOI 10.1186/1477-7525-10-154]; Mizuno Y, 2015, LGBT HEALTH, V2, P228, DOI 10.1089/lgbt.2014.0099; Robertson MM, 2019, JAIDS-J ACQ IMM DEF, V80, P46, DOI 10.1097/QAI.0000000000001877; Santos GM, 2014, SEX TRANSM INFECT, V90, P430, DOI 10.1136/sextrans-2013-051342; Sevelius JM, 2014, ANN BEHAV MED, V47, P5, DOI 10.1007/s12160-013-9565-8; Sevelius JM, 2010, J ASSOC NURSE AIDS C, V21, P256, DOI 10.1016/j.jana.2010.01.005; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; Thomas J., 2019, INTEGRATED ANAL NEW; Thomas JA., 2017, NYC RYAN WHITE A; Weiser J, 2015, JAMA INTERN MED, V175, P1650, DOI 10.1001/jamainternmed.2015.4095; Wiewel EW, 2016, AM J PUBLIC HEALTH, V106, P497, DOI 10.2105/AJPH.2015.302974	26	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	7							e0253444	10.1371/journal.pone.0253444	http://dx.doi.org/10.1371/journal.pone.0253444			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TC7AG	34197479	Green Published, gold			2023-01-03	WOS:000668791400052
J	Wang, LL; Dai, L; Liu, H; Dai, HZ; Li, X; Ge, WH				Wang, Lulu; Dai, Liang; Liu, Hui; Dai, Huizhen; Li, Xin; Ge, Weihong			Availability, affordability and price components of insulin products in different-level hospital pharmacies: Evidence from two cross-sectional surveys in Nanjing, China	PLOS ONE			English	Article							ESSENTIAL MEDICINES; GLUCOSE	The essential medicine--insulin cannot be easily accessed and afforded in many countries. To help address this issue, we evaluated the availability, affordability and price of insulin products in Nanjing, eastern China. Two cross-sectional studies were conducted in 2016 and 2018. A total of 56 hospital pharmacies were sampled, using a simplified and adapted World Health Organization/Health Action International (WHO/HAI) methodology. Prices were expressed as Median Price Ratios (MPRs) to Australian Pharmaceutical Benefit Scheme (PBS) prices. In addition, we investigated the price components of seven selected insulin products as a case study before and after the Online Centralized Procurement Policy for Hospital Drugs in May, 2018. Affordability was presented as the number of daily wages of the lowest paid unskilled government worker (LPGW) required to purchase 1000IU of insulin based on the average courses of treatment, approximately 30 days' treatment. The availability of insulin products was very high in secondary hospitals and tertiary hospitals both in 2016 and 2018, but in community hospitals was very low. In 2018, the availability of prandial insulin products showed fluctuation compared to 2016. The availability of pre-mixed human insulin products was over 95% overall, and also very high (80%) in community hospitals in 2018. The prices of insulin products were much lower than PBS prices of Australian in this study, with the MPRs less than 1 (0.32 to 0.71 in 2016 vs. 0.30 to 0.68 in 2018) for all insulin types. But insulin products in Nanjing in 2016 and 2018 were considered unaffordable, because the number of daily wages of the LPGW needed to purchase for the 30 days treatment of insulin products ranged from 2.26 to 8.49 in 2016 and 1.88 to 7.09 in 2018. The manufacturers' selling price contributed the main part (74.15% to 77.70% before and 74.86% to 91.51% after the implementation of the bidding policy) of the price components of target insulin brands. The availability of insulin products was high in secondary hospitals and tertiary hospitals, but lower in community hospitals. However, the affordability in community hospitals was better than other hospitals, but the insulin products were still unaffordable for patients on low incomes. Further improvements of the availability accessibility and affordability of medicines in advancing health insurance policies and lowering drug prices should be put forward.	[Wang, Lulu; Liu, Hui; Ge, Weihong] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Pharm, Med Sch, Nanjing, Jiangsu, Peoples R China; [Dai, Liang] China Pharmaceut Univ, Lab Management Off, Nanjing, Jiangsu, Peoples R China; [Dai, Huizhen] Jiangsu Med Informat Inst, Nanjing, Jiangsu, Peoples R China; [Li, Xin] Nanjing Med Univ, Sch Pharm, Dept Clin Pharm, Nanjing, Jiangsu, Peoples R China	Nanjing University; China Pharmaceutical University; Nanjing Medical University	Wang, LL (corresponding author), Nanjing Univ, Nanjing Drum Tower Hosp, Dept Pharm, Med Sch, Nanjing, Jiangsu, Peoples R China.	hersheylulu@163.com			Jiangsu Medicine Information Institute; Nanjing Pharmaceutical Co., Ltd	Jiangsu Medicine Information Institute; Nanjing Pharmaceutical Co., Ltd	The authors are very grateful to Jiangsu Medicine Information Institute for the data and support, and Nanjing Pharmaceutical Co., Ltd for who willingly to provide their cooperation and support.	Al-Sharayri MG, 2013, SAUDI PHARM J, V21, P225, DOI 10.1016/j.jsps.2012.07.003; [Anonymous], 2011, LANCET, V378, P457, DOI 10.1016/S0140-6736(11)61232-4; Australian Department of Health, 2016, STAND PACKS PRIC REA; Babar ZUD, 2007, PLOS MED, V4, P466, DOI 10.1371/journal.pmed.0040082; Beran D, 2016, LANCET DIABETES ENDO, V4, P275, DOI 10.1016/S2213-8587(15)00521-5; Chen SL., 2001, CHIN J CONTL CHRON N, V9, P17; Currie CJ, 2010, DIABETIC MED, V27, P744, DOI 10.1111/j.1464-5491.2009.02849.x; DCCT Res Grp, 1994, J PEDIATR-US, V125, P177, DOI 10.1016/S0022-3476(94)70190-3; DEEB LC, 1994, DIABETES CARE, V17, P220, DOI 10.2337/diacare.17.3.220; Ewen M, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001410; Gelders S., 2006, PRICE AVAILABILITY A; GOPG, 2018, NOT ADJ MIN STAND JI; Hogerzeil HV, 2006, B WORLD HEALTH ORGAN, V84, P371, DOI 10.2471/BLT.06.031153; Li ZJ, 2019, TROP MED INT HEALTH, V24, P43, DOI 10.1111/tmi.13167; Liu CX, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2553-0; Madeb R, 2005, ANN INTERN MED, V143, P907, DOI 10.7326/0003-4819-143-12-200512200-00009; Management Sciences for Health, 2016, MSH INT MED PROD PRI; Mendis S, 2007, B WORLD HEALTH ORGAN, V85, P279, DOI 10.2471/BLT.06.033647; MoH, 1989, CLASS MAN STAND GEN; NDRC, 2012, STAND PRIC MAN MED S; NHC, 2018, BRIEF AN CAUS DEATH; NHFPC, 2018, NOT IMPL NEW ROUND O; NHFPC, 2018, NOT NEW ROUND ONL CE; NHFPC, 2018, NOT NEW ROUND ONL CE; NMIB, 2015, NOT PRINT DISTR OP I; NSB, 2019, NANJ 2018 NAT EC SOC; PGJP, 2015, NANJ CIT PUBL HOSP M; Randall L, 2011, DIABETES CARE, V34, P1891, DOI 10.2337/dc11-0701; Ryden A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164977; Saenz A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002966.pub3; SCIOPRC, 2015, PROGR CHIN HUM RIGHT; Seshasai SRK, 2011, NEW ENGL J MED, V364, P829, DOI 10.1056/NEJMoa1008862; SHFPC, 2016, NOT SURV FULL COV SO; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Wang YZ, 2010, CHINJHEAL POLICY, V3, P7; [翁建平 Weng Jianping], 2018, [中国科学. 生命科学, Scientia Sinica Vitae], V48, P834; WHO, 2011, WHO TECH REP SER, V965, P1; WHO, 2008, WORLD HLTH REPORT 20; World Health Organization Rotary International Centers for Disease Control and Prevention and UNICEF, 2013, GLOB ACT PLAN PREV C; Xu F., 2001, CHIN J HLTH STAT, V18, P229; Xu Y, 2013, JAMA-J AM MED ASSOC, V310, P948, DOI 10.1001/jama.2013.168118	42	0	0	6	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255742	10.1371/journal.pone.0255742	http://dx.doi.org/10.1371/journal.pone.0255742			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ4EI	34383816	Green Published, gold			2023-01-03	WOS:000684426400053
J	He, SW; Zhang, Y; Chen, L; Luo, WJ; Li, XM; Chen, Y; Huang, SY; He, QM; Yang, XJ; Li, YQ; Liu, N; Zhao, Y; Ma, J				He, Shi-Wei; Zhang, Yuan; Chen, Lei; Luo, Wei-Jie; Li, Xiao-Min; Chen, Yang; Huang, Sheng-Yan; He, Qing-Mei; Yang, Xiao-Jing; Li, Ying-Qin; Liu, Na; Zhao, Yin; Ma, Jun			Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth	FASEB JOURNAL			English	Article						cell proliferation; cisplatin; gemcitabine; nasopharyngeal carcinoma; tumor growth	INTENSITY-MODULATED RADIOTHERAPY; DRUG-COMBINATION; CANCER-CELLS; CYCLE; PHOSPHORYLATION; RESISTANCE; MECHANISM; EVOLUTION; APOPTOSIS; ABCB1	In a recently published phase III clinical trial, gemcitabine (GEM) plus cisplatin (DDP) induction chemotherapy significantly improved recurrence-free survival and overall survival and became the standard of care among patients with locoregionally advanced NPC. However, the molecular mechanisms of GEM synergized with DPP in NPC cells remain elucidated. These findings prompt us to explore the effect of the combination between GEM and DDP in NPC cell lines through proliferative phenotype, immunofluorescence, flow cytometry, and western blotting assays. In vitro studies reveal that GEM or DPP treated alone induces cell cycle arrest, promotes cell apoptosis, forces DNA damage response, and GEM synergism with DDP significantly increases the above effects in NPC cells. In vivo studies indicate that GEM or DPP treated alone significantly inhibits the tumor growth and prolongs the survival time of mice injected with SUNE1 cells compared to the control group. Moreover, the mice treated with GEM combined with DDP have smaller tumors and survive longer than those in GEM or DPP treated alone group. In addition, P-gp may be the key molecule that regulates the synergistic effect of gemcitabine and cisplatin. GEM synergizes with DPP to inhibit NPC cell proliferation and tumor growth by inducing cell cycle arrest, cell apoptosis, and DNA damage response, which reveals the mechanisms of combined GEM and DDP induction chemotherapy in improving locoregionally advanced NPC.	[He, Shi-Wei; Zhang, Yuan; Chen, Lei; Luo, Wei-Jie; Li, Xiao-Min; Chen, Yang; Huang, Sheng-Yan; He, Qing-Mei; Yang, Xiao-Jing; Li, Ying-Qin; Liu, Na; Zhao, Yin; Ma, Jun] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Zhao, Y; Ma, J (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.	zhaoyin@sysucc.org.cn; majun2@mail.sysu.edu.cn		Ma, Jun/0000-0002-1137-9349	National Natural Science Foundation of China (NSFC) [81930072]; Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) [2017A030312003]; Innovation Team Development Plan of the Ministry of Education [IRT_17R110]; Overseas Expertise Introduction Project for Discipline Innovation	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation)(National Natural Science Foundation of Guangdong Province); Innovation Team Development Plan of the Ministry of Education; Overseas Expertise Introduction Project for Discipline Innovation	National Natural Science Foundation of China (NSFC), Grant/Award Number: 81930072; Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation), Grant/Award Number: 2017A030312003; Innovation Team Development Plan of the Ministry of Education, Grant/Award Number: IRT_17R110; Overseas Expertise Introduction Project for Discipline Innovation, Grant/Award	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Al-Ejeh F, 2010, ONCOGENE, V29, P6085, DOI 10.1038/onc.2010.407; Alexa-Stratulat T, 2019, DRUG RESIST UPDATE, V46, DOI 10.1016/j.drup.2019.100643; Ashton JC, 2015, CANCER RES, V75, P2400, DOI 10.1158/0008-5472.CAN-14-3763; Besancon OG, 2012, CANCER LETT, V319, P23, DOI 10.1016/j.canlet.2011.12.016; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Binenbaum Y, 2015, DRUG RESIST UPDATE, V23, P55, DOI 10.1016/j.drup.2015.10.002; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen QY, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0330-z; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Dart Anna, 2019, Nat Rev Cancer, V19, P610, DOI 10.1038/s41568-019-0215-8; Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Gao MZ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00366; Gentilin E, 2019, TRENDS MOL MED, V25, P1123, DOI 10.1016/j.molmed.2019.08.002; Iannelli F, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01670; Indran IR, 2011, BBA-BIOENERGETICS, V1807, P735, DOI 10.1016/j.bbabio.2011.03.010; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Koh SB, 2015, CANCER RES, V75, P3583, DOI 10.1158/0008-5472.CAN-14-3347; Kurokawa M, 2009, CELL, V138, P838, DOI 10.1016/j.cell.2009.08.021; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Lee AWM, 2014, RADIOTHER ONCOL, V110, P377, DOI 10.1016/j.radonc.2014.02.003; Li WL, 2021, MOL CANCER THER, V20, P1173, DOI 10.1158/1535-7163.MCT-20-0705; Liu SZ, 2011, MOL CELL, V43, P192, DOI 10.1016/j.molcel.2011.06.019; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mao YP, 2009, INT J RADIAT ONCOL, V73, P1326, DOI 10.1016/j.ijrobp.2008.07.062; Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941; N'Guessan KF, 2020, MOL THER, V28, P1876, DOI 10.1016/j.ymthe.2020.05.013; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Pauwels B, 2003, INT J RADIAT ONCOL, V57, P1075, DOI 10.1016/S0360-3016(03)01443-3; Sinha BK, 2021, CANCERS, V13, DOI 10.3390/cancers13071680; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Sun M, 2020, BIOMATERIALS, V257, DOI 10.1016/j.biomaterials.2020.120252; Syn NL, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0010-0; Tang X, 2008, MOL CELL BIOL, V28, P2559, DOI 10.1128/MCB.01711-07; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tompkins JD, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-10; Trendowski MR, 2019, CLIN CANCER RES, V25, P1147, DOI 10.1158/1078-0432.CCR-18-2244; van Moorsel CJA, 1999, BRIT J CANCER, V80, P981, DOI 10.1038/sj.bjc.6690452; Venkatasubbarao K, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-104; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Wu CP, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052592; Zacharioudakis E, 2017, ANGEW CHEM INT EDIT, V56, P6483, DOI 10.1002/anie.201701144; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003; Zhang L, 2016, LANCET, V388, P1883, DOI 10.1016/S0140-6736(16)31388-5; Zhang Y, 2019, NEW ENGL J MED, V381, P1124, DOI 10.1056/NEJMoa1905287; Zhang Y, 2019, BIOMATERIALS, V189, P48, DOI 10.1016/j.biomaterials.2018.10.022; Zhao FG, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122643; Zisowsky J, 2007, BIOCHEM PHARMACOL, V73, P298, DOI 10.1016/j.bcp.2006.10.003	52	2	2	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2021	35	10							e21885	10.1096/fj.202100076RR	http://dx.doi.org/10.1096/fj.202100076RR			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UZ5IH	34478585				2023-01-03	WOS:000702238200015
J	Biswas, J; Banik, PC; Ahmad, N				Biswas, Jheelam; Banik, Palash Chandra; Ahmad, Nezamuddin			Physicians' knowledge about palliative care in Bangladesh: A cross-sectional study using digital social media platforms	PLOS ONE			English	Article							ATTITUDE	Introduction Palliative care is still a new concept in many developing countries like Bangladesh. Basic knowledge about palliative care is needed for all physicians to identify and provide this care. This study aims to assess the preliminary knowledge level and the misconceptions about this field among physicians. Methods This cross-sectional study was conducted among 479 physicians using a self-administered structured questionnaire adapted from Palliative Care Knowledge Scale (PaCKs) on various digital social media platforms from December 2019 to February 2020. Chi-square, Fisher's extract test, and the Monte Carlo extract test was done to compare the knowledge level with the study subjects' demographic variables. Results An almost equal number of physicians of both genders from four major specialties and their allied branches took part in the study (response rate 23.9%). The majority (71%) of the respondents had an average to an excellent level of knowledge about palliative care, with a median score of 11.0. Although most physicians had average knowledge about the primary goals and general concepts of palliative care, misconceptions are highly prevalent. The commonly present misconceptions were that palliative care discourages patients from consulting other specialties (88.9%), refrains them from taking curative treatments (83.1%), and this care is only for older adults (74.5%), cancer patients (63%), and the last six months of life (56.4%). Age, educational qualifications, and specialties had significant relationships (P<0.05) with the level of knowledge. Conclusion Despite having average or above knowledge about palliative care, the physicians' prevailing misconceptions act as a barrier to recognizing the need among the target populations. So, proper education and awareness among the physicians are necessary to cross this field's barrier and development.	[Biswas, Jheelam; Banik, Palash Chandra] Bangladesh Univ Hlth Sci BUHS, Dept Noncommunicable Dis, Dhaka, Bangladesh; [Biswas, Jheelam; Ahmad, Nezamuddin] Bangabandhu Sheikh Mujib Med Univ BSMMU, Dept Palliat Med, Dhaka, Bangladesh	Bangladesh University of Health Sciences (BUHS); Bangabandhu Sheikh Mujib Medical University (BSMMU)	Biswas, J (corresponding author), Bangladesh Univ Hlth Sci BUHS, Dept Noncommunicable Dis, Dhaka, Bangladesh.; Biswas, J (corresponding author), Bangabandhu Sheikh Mujib Med Univ BSMMU, Dept Palliat Med, Dhaka, Bangladesh.	jheelam.biswas@gmail.com	Banik, Palash Chandra/P-7613-2016	Banik, Palash Chandra/0000-0003-2395-9049; Biswas, Jheelam/0000-0003-4977-6136				Ahmad N., 2015, DAILY STAR; Akiyama M, 2016, SUPPORT CARE CANCER, V24, P347, DOI 10.1007/s00520-015-2788-4; Arain AN., 2014, PROFESSIONAL MED J, V21, P325; Badru AI, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.259.14010; Bhadra K., 2013, J MED SOC, V27, P114; Cagle JG, 2016, AM J HOSP PALLIAT ME, V33, P27, DOI 10.1177/1049909114546885; Conceição Marcos Vinícius da, 2019, Rev. Bioét., V27, P134, DOI 10.1590/1983-80422019271296; Das AG, 2015, INT J SCI RES, V4, P1790, DOI DOI 10.21275/V4I11.NOV151510; Deutskens E, 2004, MARKET LETT, V15, P21, DOI 10.1023/B:MARK.0000021968.86465.00; Fadare JO, 2014, INDIAN J PALLIAT CAR, V20, P1, DOI 10.4103/0973-1075.125547; Fernando GVMC, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4462-2; Grant L, 2011, BMC PALLIAT CARE, V10, DOI 10.1186/1472-684X-10-8; Vu HTT, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16152656; Joseph N, 2009, INDIAN J PALLIAT CAR, V15, P122, DOI 10.4103/0973-1075.58457; Kassa H, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-6; Khan F, 2014, Bangladesh Med Res Counc Bull, V40, P18; Kozlov E, 2018, AM J HOSP PALLIAT ME, V35, P647, DOI 10.1177/1049909117725725; Kozlov E, 2017, PALLIAT SUPPORT CARE, V15, P524, DOI 10.1017/S1478951516000997; Nnadi DC, 2016, INDIAN J PALLIAT CAR, V22, P343, DOI 10.4103/0973-1075.185080; Onyeka TC, 2011, INDIAN J PALLIAT CAR, V17, P131, DOI 10.4103/0973-1075.84534; Pavel O, 2017, J LIFE SCI, V3, P1110; Pohl G., 2008, PALLIAT CARE RES, V2, pPCRT.S925; Rahman A., 2011, J BANGLADESH COLL PH, V29, P1; Riley GF, 2010, HEALTH SERV RES, V45, P565, DOI 10.1111/j.1475-6773.2010.01082.x; Shah S, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00688-w; Singh Divya Pal, 2010, Indian J Palliat Care, V16, P36, DOI 10.4103/0973-1075.63133; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; World Health Organization, 2019, WHO DEF PALL CAR; World Health Organization, 2018, PALL CAR; World Health Organization, 2014, NONC DIS COUNTR PROF; Wu XM, 2020, ANN PALLIAT MED, V9, P985, DOI 10.21037/apm-20-851	31	0	0	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2021	16	9							e0256927	10.1371/journal.pone.0256927	http://dx.doi.org/10.1371/journal.pone.0256927			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG6OB	34469497	gold, Green Published			2023-01-03	WOS:000707112500065
J	Fingar, DC				Fingar, Diane C.			The yoga of Rag GTPases: Dynamic structural poses confer amino acid sensing by mTORC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							CRYSTAL-STRUCTURE; COMPLEX REVEALS; ACTIVATION; TORC1	Heterodimeric Rag GTPases play a critical role in relaying fluctuating levels of cellular amino acids to the sensor mechanistic target of rapamycin complex 1. Important mechanistic questions remain unresolved, however, regarding how guanine nucleotide binding enables Rag GTPases to transition dynamically between distinct yoga-like structural poses that control activation state. Egri and Shen identified a critical interdomain hydrogen bond within RagA and RagC that stabilizes their GDP-bound states. They demonstrate that this long-distance interaction controls Rag structure and function to confer appropriate amino acid sensing by mechanistic target of rapamycin complex 1.	[Fingar, Diane C.] Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fingar, DC (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA.	dfingar@umich.edu			National Institutes of Health [R01-GM137577]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The lab is supported by a grant to D. C. F. from the National Institutes of Health (R01-GM137577). The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.	Egri SB, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100861; Gong R, 2011, GENE DEV, V25, P1668, DOI 10.1101/gad.16968011; Gonzalez A, 2017, EMBO J, V36, P397, DOI 10.15252/embj.201696010; Jeong JH, 2012, J BIOL CHEM, V287, P29648, DOI 10.1074/jbc.C112.384420; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Shen K, 2017, MOL CELL, V68, P552, DOI 10.1016/j.molcel.2017.09.026; Yang HJ, 2017, NATURE, V552, P368, DOI 10.1038/nature25023	10	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP	2021	297	3							101103	10.1016/j.jbc.2021.101103	http://dx.doi.org/10.1016/j.jbc.2021.101103			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WF4MJ	34419448	gold, Green Published			2023-01-03	WOS:000706280200001
J	Young, EH; Pan, S; Yap, AG; Reveles, KR; Bhakta, K				Young, Eric H.; Pan, Samantha; Yap, Alex G.; Reveles, Kelly R.; Bhakta, Kajal			Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016	PLOS ONE			English	Article							DRUG-DRUG INTERACTIONS; INTERVENTIONS; RISK; PRESCRIPTIONS; CRITERIA; EVENTS; HEALTH	Background/objectives With an aging population suffering from increased prevalence of chronic conditions in the United States (U.S.), a large portion of these patients are on multiple medications. High-risk medications can increase the risk for drug-drug interactions and medication nonadherence. This study aims to describe the prevalence of polypharmacy and high-risk medication prescribing in U.S. physician offices. Methods This was a cross-sectional study of the Centers for Disease Control and Prevention's National Ambulatory Medical Care Survey from 2009 to 2016. All patients over 65 years old were included. Polypharmacy was categorized as no polypharmacy (< 2 medications), minor polypharmacy (2-3 medications), moderate polypharmacy (4-5 medications), and major polypharmacy (>5 medications). Medications were further categorized into high-risk medication categories (anticholinergics, cardiovascular agents, central nervous system (CNS) medications, pain medications, and other). Comparisons between the degrees of polypharmacy were performed utilizing chi-square or Wilcoxon rank-sum tests with JMP Pro 14(R) (SAS Institute, Cary, NC). Results Over 2 billion patient visits were included. Overall, Polypharmacy was common (65.1%): minor polypharmacy (16.2%), moderate polypharmacy (12.1%), and major polypharmacy (36.8%). Patients with major polypharmacy were older compared to those with moderate or minor polypharmacy (75 vs. 73 years, respectively) and were most frequently prescribed pain medications (477.3 per 1,000 total visits). NSAIDs were the most frequently prescribed, with 232.4 per 1,000 total visits resulting in one high-risk NSAID prescription, while 21.9 per 1,000 total visits resulted in two or more high-risk NSAIDs. Conclusion Most patients over 65 years experienced some degree of polypharmacy, with many experiencing major polypharmacy. This indicates an increased need for expanded pharmacist roles through medication therapy management and safety monitoring in this patient population.	[Young, Eric H.; Pan, Samantha; Yap, Alex G.; Reveles, Kelly R.; Bhakta, Kajal] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA; [Young, Eric H.; Pan, Samantha; Yap, Alex G.; Reveles, Kelly R.; Bhakta, Kajal] UT Hlth San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Health San Antonio	Bhakta, K (corresponding author), Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.; Bhakta, K (corresponding author), UT Hlth San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA.	bhaktak2@uthscsa.edu						Baruth JM, 2020, HOSP PRACT, V48, P56, DOI 10.1080/21548331.2019.1706995; Bergman-Evans B, 2020, GERIATR NURS, V41, P956, DOI 10.1016/j.gerinurse.2020.07.002; Chan M, 2001, INTERN MED J, V31, P199, DOI 10.1046/j.1445-5994.2001.00044.x; Chivapricha W, 2021, DRUGS-REAL WOR OUTC, V8, P39, DOI 10.1007/s40801-020-00214-7; Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149-2918(01)80109-0; Dagli Rushabh J, 2014, J Int Oral Health, V6, pi; de Gage SB, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5205; Doan J, 2013, ANN PHARMACOTHER, V47, P324, DOI 10.1345/aph.1R621; Farrell B, 2018, CAN PHARM J, V151, P395, DOI 10.1177/1715163518804276; Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Hudhra K, 2016, J EVAL CLIN PRACT, V22, P189, DOI 10.1111/jep.12452; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; Kini V, 2018, JAMA-J AM MED ASSOC, V320, P2461, DOI 10.1001/jama.2018.19271; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Oscanoa TJ, 2017, EUR J CLIN PHARMACOL, V73, P759, DOI 10.1007/s00228-017-2225-3; Pilotto A, 2003, DRUG AGING, V20, P701, DOI 10.2165/00002512-200320090-00006; Spence MM, 2013, ANN PHARMACOTHER, V47, P993, DOI 10.1345/aph.1R735; Tannenbaum C, 2014, JAMA INTERN MED, V174, P890, DOI 10.1001/jamainternmed.2014.949; Vicens C, 2014, BRIT J PSYCHIAT, V204, P471, DOI 10.1192/bjp.bp.113.134650; Waite LJ, 2004, POPUL DEV REV, V30, P3; Weddle SC, 2017, J MANAG CARE SPEC PH, V23, P520, DOI 10.18553/jmcp.2017.23.5.520; Wongrakpanich S, 2018, AGING DIS, V9, P143, DOI 10.14336/AD.2017.0306; Wright RM, 2009, J AM GERIATR SOC, V57, P243, DOI 10.1111/j.1532-5415.2008.02127.x; Zhang NQ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00326; Zhao Y, 2009, J CLIN NURS, V18, P2444, DOI 10.1111/j.1365-2702.2009.02835.x	27	10	10	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2021	16	8							e0255642	10.1371/journal.pone.0255642	http://dx.doi.org/10.1371/journal.pone.0255642			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6IR	34343225	gold, Green Published			2023-01-03	WOS:000685264200032
J	Macaulay, TR; Pa, J; Kutch, JJ; Lane, CJ; Duncan, D; Yan, LR; Schroeder, ET				Macaulay, Timothy R.; Pa, Judy; Kutch, Jason J.; Lane, Christianne J.; Duncan, Dominique; Yan, Lirong; Schroeder, E. Todd			12 weeks of strength training improves fluid cognition in older adults: A nonrandomized pilot trial	PLOS ONE			English	Article							RESISTANCE EXERCISE; CORRELATION-COEFFICIENTS; HEALTH-BENEFITS; NIH TOOLBOX; MEMORY; RELIABILITY; PERIODIZATION; INDIVIDUALS; PERFORMANCE; IMPAIRMENT	Objectives Resistance training (RT) is a promising strategy to slow or prevent fluid cognitive decline during aging. However, the effects of strength-specific RT programs have received little attention. The purpose of this single-group proof of concept clinical trial was to determine whether a 12-week strength training (ST) program could improve fluid cognition in healthy older adults 60 to 80 years of age, and to explore concomitant physiological and psychological changes. Methods Twenty participants (69.1 +/- 5.8 years, 14 women) completed this study with no drop-outs or severe adverse events. Baseline assessments were completed before an initial 12-week control period, then participants were re-tested at pre-intervention and after the 12-week ST intervention. The NIH Toolbox Cognition Battery and standard physical and psychological measures were administered at all three time points. During the 36 sessions of periodized ST (3 sessions per week), participants were supervised by an exercise specialist and challenged via autoregulatory load progression. Results Test-retest reliability over the control period was good for fluid cognition and excellent for crystallized cognition. Fluid composite scores significantly increased from pre- to post-intervention (8.2 +/- 6.1%, p < 0.01, d = 1.27), while crystallized composite scores did not (-0.5 +/- 2.8%, p = 0.46, d = -0.34). Performance on individual fluid instruments, including executive function, attention, working memory, and processing speed, also significantly improved. Surprisingly, changes in fluid composite scores had small negative correlations with changes in muscular strength and sleep quality, but a small positive correlation with changes in muscular power. Conclusions Thus, improvements in fluid cognition can be safely achieved in older adults using a 12-week high-intensity ST program, but further controlled studies are needed to confirm these findings. Furthermore, the relationship with other widespread physiological and psychological benefits remains unclear.	[Macaulay, Timothy R.; Kutch, Jason J.; Schroeder, E. Todd] Univ Southern Calif, Ostrow Sch Dent, Div Biokinesiol & Phys Therapy, Los Angeles, CA 90007 USA; [Pa, Judy; Duncan, Dominique; Yan, Lirong] Univ Southern Calif, Keck Sch Med, Mark & Mary Stevens Neuroimaging & Informat Inst, Los Angeles, CA 90007 USA; [Lane, Christianne J.] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90007 USA	University of Southern California; University of Southern California; University of Southern California	Macaulay, TR (corresponding author), Univ Southern Calif, Ostrow Sch Dent, Div Biokinesiol & Phys Therapy, Los Angeles, CA 90007 USA.	tmacaula@usc.edu		Duncan, Dominique/0000-0002-6154-9262	Southern California Clinical and Translational Science Institute (SC-CTSI) [UL1TR001855]	Southern California Clinical and Translational Science Institute (SC-CTSI)	This study was supported by the Southern California Clinical and Translational Science Institute (SC-CTSI, grant number UL1TR001855 to ETS and TRM). The SC-CTSI (https://sc-ctsi.org/) did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson-Hanley C, 2010, J CLIN EXP NEUROPSYC, V32, P996, DOI 10.1080/13803391003662702; [Anonymous], 2017, KINESIOLOGY REV; Barha CK, 2017, FRONT NEUROENDOCRIN, V46, P71, DOI 10.1016/j.yfrne.2017.04.002; Barha CK, 2017, BRIT J SPORT MED, V51, P636, DOI 10.1136/bjsports-2016-096710; Bean JF, 2007, ARCH PHYS MED REHAB, V88, P604, DOI 10.1016/j.apmr.2007.02.004; Best JR, 2015, J INT NEUROPSYCH SOC, V21, P745, DOI 10.1017/S1355617715000673; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Calamia M, 2012, CLIN NEUROPSYCHOL, V26, P543, DOI 10.1080/13854046.2012.680913; Cassilhas RC, 2012, NEUROSCIENCE, V202, P309, DOI 10.1016/j.neuroscience.2011.11.029; Cassilhas RC, 2007, MED SCI SPORT EXER, V39, P1401, DOI 10.1249/mss.0b013e318060111f; Cherup N, 2018, EXP GERONTOL, V112, P76, DOI 10.1016/j.exger.2018.09.007; Cohen J., 2016, CURR DIR PSYCHOL SCI, V1, P98, DOI [10.1111%2F1467-8721.ep10768783, 10.1111/1467-8721.ep10768783]; Cohen S., 1985, SOCIAL SUPPORT THEOR, P73, DOI 10.1007/978-94-009-5115-0_5; Conlon JA, 2016, MED SCI SPORT EXER, V48, P2426, DOI 10.1249/MSS.0000000000001053; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; de Winter JCF, 2016, PSYCHOL METHODS, V21, P273, DOI 10.1037/met0000079; Fallah N, 2013, ANN EPIDEMIOL, V23, P463, DOI 10.1016/j.annepidem.2013.05.008; Forte R, 2013, CLIN INTERV AGING, V8, P19, DOI 10.2147/CIA.S36514; Goekint M, 2010, EUR J APPL PHYSIOL, V110, P285, DOI 10.1007/s00421-010-1461-3; Gribble PA, 2012, J ATHL TRAINING, V47, P339, DOI 10.4085/1062-6050-47.3.08; Heaton RK, 2014, J INT NEUROPSYCH SOC, V20, P588, DOI 10.1017/S1355617714000241; Irandoust K., 2018, SLEEP HYPNOSIS ONLIN, V20, P160, DOI [10.1186/s12913-016-1423-5, DOI 10.1186/S12913-016-1423-5, DOI 10.5350/SLEEP.HYPN.2017.19.0148]; Iuliano E, 2017, J AGING PHYS ACTIV, V25, P612, DOI 10.1123/japa.2016-0249; Justice J, 2016, J GERONTOL A-BIOL, V71, P1415, DOI 10.1093/gerona/glw126; Kerby D.S., 2014, INNOVATIVE TEACHING, V3, DOI [10.2466/11.IT.3.1, DOI 10.2466/11.IT.3.1]; Knutzen KM, 1999, J STRENGTH COND RES, V13, P242; Komulainen P, 2010, EUR GERIATR MED, V1, P266, DOI 10.1016/j.eurger.2010.08.001; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Kovacevic A, 2018, SLEEP MED REV, V39, P52, DOI 10.1016/j.smrv.2017.07.002; Lachman ME, 2006, J AGING PHYS ACTIV, V14, P59, DOI 10.1123/japa.14.1.59; Landrigan JF, 2020, PSYCHOL RES-PSYCH FO, V84, P1167, DOI 10.1007/s00426-019-01145-x; Li SC, 2004, PSYCHOL SCI, V15, P155, DOI 10.1111/j.0956-7976.2004.01503003.x; Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494; Macaulay TR, 2020, PHYS THER, V100, P907, DOI 10.1093/ptj/pzaa013; Mann JB, 2010, J STRENGTH COND RES, V24, P1718, DOI 10.1519/JSC.0b013e3181def4a6; Mavros Y, 2017, J AM GERIATR SOC, V65, P550, DOI 10.1111/jgs.14542; McCarrey AC, 2016, PSYCHOL AGING, V31, P166, DOI 10.1037/pag0000070; Miller MA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00224; Morris SB, 2008, ORGAN RES METHODS, V11, P364, DOI 10.1177/1094428106291059; Nicol GE, 2020, J AM GERIATR SOC, V68, P922, DOI 10.1111/jgs.16443; O'Connor PJ, 2010, AM J LIFESTYLE MED, V4, P377, DOI 10.1177/1559827610368771; Pedrinolla A, 2017, CURR ALZHEIMER RES, V14, P546, DOI 10.2174/1567205014666170111145817; Perrig-Chiello P, 1998, AGE AGEING, V27, P469, DOI 10.1093/ageing/27.4.469; Peterson MD, 2011, MED SCI SPORT EXER, V43, P249, DOI 10.1249/MSS.0b013e3181eb6265; Peterson MD, 2010, AGEING RES REV, V9, P226, DOI 10.1016/j.arr.2010.03.004; Sawilowsky SS, 2009, J MOD APPL STAT METH, V8, P597, DOI 10.22237/jmasm/1257035100; Shumway-Cook A, 2000, PHYS THER, V80, P896, DOI 10.1093/ptj/80.9.896; Snyder PJ, 2011, ALZHEIMERS DEMENT, V7, P338, DOI 10.1016/j.jalz.2011.03.009; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; Villanueva MG, 2015, EUR J APPL PHYSIOL, V115, P295, DOI 10.1007/s00421-014-3014-7; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P903, DOI 10.1016/S0895-4356(98)00081-X; Weintraub S, 2014, J INT NEUROPSYCH SOC, V20, P567, DOI 10.1017/S1355617714000320; Williams MA, 2007, CIRCULATION, V116, P572, DOI 10.1161/CIRCULATIONAHA.107.185214; Williams TD, 2017, SPORTS MED, V47, P2083, DOI 10.1007/s40279-017-0734-y	54	1	1	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2021	16	7							e0255018	10.1371/journal.pone.0255018	http://dx.doi.org/10.1371/journal.pone.0255018			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2OO	34293060	Green Published, gold			2023-01-03	WOS:000678124900016
J	Noor, F; Saleem, MH; Chen, JT; Javed, MR; Al-Megrin, WA; Aslam, S				Noor, Fatima; Saleem, Muhammad Hamzah; Chen, Jen-Tsung; Javed, Muhammad Rizwan; Al-Megrin, Wafa Abdullah; Aslam, Sidra			Integrative bioinformatics approaches to map key biological markers and therapeutic drugs in Extramammary Paget's disease of the scrotum	PLOS ONE			English	Article							CELL-CYCLE; CANCER; NETWORKS	Extramammary Paget's disease (EMPD) is an intra-epidermal adenocarcinoma. Till now, the mechanisms underlying the pathogenesis of scrotal EMPD is poorly known. This present study aims to explore the knowledge of molecular mechanism of scrotal EMPD by identifying the hub genes and candidate drugs using integrated bioinformatics approaches. Firstly, the microarray datasets (GSE117285) were downloaded from the GEO database and then analyzed using GEO2R in order to obtain differentially expressed genes (DEGs). Moreover, hub genes were identified on the basis of their degree of connectivity using Cytohubba plugin of cytoscape tool. Finally, GEPIA and DGIdb were used for the survival analysis and selection of therapeutic candidates, respectively. A total of 786 DEGs were identified, of which 10 genes were considered as hub genes on the basis of the highest degree of connectivity. After the survival analysis of ten hub genes, a total of 5 genes were found to be altered in EMPD patients. Furthermore, 14 drugs of CHEK1, CCNA2, and CDK1 were found to have therapeutic potential against EMPD. This study updates the information and yields a new perspective in the context of understanding the pathogenesis of EMPD. In future, hub genes and candidate drugs might be capable of improving the personalized detection and therapies for EMPD.	[Noor, Fatima; Javed, Muhammad Rizwan; Aslam, Sidra] Govt Coll Univ, Dept Bioinformat & Biotechnol, Faisalabad, Pakistan; [Saleem, Muhammad Hamzah] Huazhong Agr Univ, Coll Plant Sci & Technol, Wuhan, Peoples R China; [Chen, Jen-Tsung] Natl Univ Kaohsiung, Dept Life Sci, Kaohsiung, Taiwan; [Al-Megrin, Wafa Abdullah] Princess Nourah Bint Abdulrahman Univ, Fac Sci, Dept Biol, Riyadh, Saudi Arabia	Government College University Faisalabad; Huazhong Agricultural University; National University Kaohsiung; Princess Nourah bint Abdulrahman University	Aslam, S (corresponding author), Govt Coll Univ, Dept Bioinformat & Biotechnol, Faisalabad, Pakistan.	sidra.aslam29@yahoo.com	Chen, Jen-Tsung/I-6733-2019; Hamzah Saleem, Muhammad/AAD-5391-2020	Chen, Jen-Tsung/0000-0002-3540-4449; Hamzah Saleem, Muhammad/0000-0002-3658-770X; Al-megrin, Wafa/0000-0001-8011-8153				Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Barth P, 2015, CASE REP ONCOL MED, V2015, DOI 10.1155/2015/895151; Bednarek K, 2016, TUMOR BIOL, V37, P11115, DOI 10.1007/s13277-016-4991-4; Berman B, 2003, CLIN EXP DERMATOL, V28, P36, DOI 10.1046/j.1365-2230.28.s1.12.x; Carbotta G, 2016, ANN MED SURG, V9, P50, DOI 10.1016/j.amsu.2016.06.012; Chandawarkar Rajiv Y, 2003, Can J Plast Surg, V11, P205; Chung PH, 2018, UROLOGY, V111, P214, DOI 10.1016/j.urology.2017.08.045; Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324; Delport ES, 2013, AUSTRALAS J DERMATOL, V54, P9, DOI 10.1111/j.1440-0960.2012.00898.x; Dinarina A, 2005, BIOCHEM J, V386, P349, DOI 10.1042/BJ20041779; Gatalica Z, 2020, CANCER MED-US, V9, P1441, DOI 10.1002/cam4.2820; Gorlov I, 2018, MELANOMA RES, V28, P380, DOI 10.1097/CMR.0000000000000473; Griffith M, 2013, NAT METHODS, V10, P1209, DOI [10.1038/nmeth.2689, 10.1038/NMETH.2689]; Guha M, 2012, NAT REV DRUG DISCOV, V11, P892, DOI 10.1038/nrd3908; Herrel LA, 2015, ANN SURG ONCOL, V22, P1625, DOI 10.1245/s10434-014-4139-y; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Hwang Bor-Jang, 2018, Oncotarget, V9, P30450, DOI 10.18632/oncotarget.25765; Izadi S, 2020, ANTI-CANCER AGENT ME, V20, P758, DOI 10.2174/1871520620666200203125712; Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795; Lam C, 2010, DERMATOL CLIN, V28, P807, DOI 10.1016/j.det.2010.08.002; Lee SJ, 2011, INT J DERMATOL, V50, P508, DOI 10.1111/j.1365-4632.2010.04661.x; Li YC, 2009, J CHIN MED ASSOC, V72, P542, DOI 10.1016/S1726-4901(09)70425-3; Ling H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061455; Liu G, 2020, BIOMED REP, V13, P22, DOI 10.3892/br.2020.1307; Liu RQ, 2017, INT J CLIN EXP MED, V10, P16750; Liu Y, 2019, CANCER RES, V79, P954, DOI 10.1158/0008-5472.CAN-18-1790; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Ng L G, 2001, Urology, V58, P105, DOI 10.1016/S0090-4295(01)00976-1; Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138; Scarbrough Chase A, 2019, J Clin Aesthet Dermatol, V12, P40; Simonds RM, 2019, INT J DERMATOL, V58, P871, DOI 10.1111/ijd.14328; Song YL, 2020, CELL RES, V30, P854, DOI 10.1038/s41422-020-0334-5; St Claire KM., 2019, DERMATOL ONLINE J, V25, P13030; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tulchinsky H, 2004, Colorectal Dis, V6, P206, DOI 10.1111/j.1463-1318.2004.00630.x; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Wagner G, 2011, J DTSCH DERMATOL GES, V9, P448, DOI 10.1111/j.1610-0387.2010.07581.x; Wang Z, 2008, BJU INT, V102, P485, DOI 10.1111/j.1464-410X.2008.07575.x; Weng SS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01114; Wright JL, 2008, UROLOGY, V72, P1139, DOI 10.1016/j.urology.2008.06.043; Wu CX, 2018, THERANOSTICS, V8, P3737, DOI 10.7150/thno.25487; Yang WJ, 2005, UROLOGY, V65, P972, DOI 10.1016/j.urology.2004.12.010; Yin S., 2021, ORPHANET J RARE DIS, V16, P1, DOI [10.1186/s13023-020-01625-z, DOI 10.1186/S13023-020-01625-Z]; Zampogna JC, 2002, J AM ACAD DERMATOL, V47, pS229, DOI 10.1067/mjd.2002.126584; Zhou SX, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3768247	45	10	10	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2021	16	7							e0254678	10.1371/journal.pone.0254678	http://dx.doi.org/10.1371/journal.pone.0254678			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2OO	34292991	Green Published, gold			2023-01-03	WOS:000678124900033
J	Oldenburg, CE; Pinsky, BA; Brogdon, J; Chen, CD; Ruder, K; Zhong, LN; Nyatigo, F; Cook, CA; Hinterwirth, A; Lebas, E; Redd, T; Porco, TC; Lietman, TM; Arnold, BF; Doan, T				Oldenburg, Catherine E.; Pinsky, Benjamin A.; Brogdon, Jessica; Chen, Cindi; Ruder, Kevin; Zhong, Lina; Nyatigo, Fanice; Cook, Catherine A.; Hinterwirth, Armin; Lebas, Elodie; Redd, Travis; Porco, Travis C.; Lietman, Thomas M.; Arnold, Benjamin F.; Thuy Doan			Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANCE	IMPORTANCE Azithromycin has been hypothesized to have activity against SARS-CoV-2. OBJECTIVE To determine whether oral azithromycin in outpatients with SARS-CoV-2 infection leads to absence of self-reported COVID-19 symptoms at day 14. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial of azithromycin vs matching placebo conducted from May 2020 through March 2021. Outpatients from the US were enrolled remotely via internet-based surveys and followed up for 21 days. Eligible participants had a positive SARS-CoV-2 diagnostic test result (nucleic acid amplification or antigen) within 7 days prior to enrollment, were aged 18 years or older, and were not hospitalized at the time of enrollment. Among 604 individuals screened, 297 were ineligible, 44 refused participation, and 263 were enrolled. Participants, investigators, and study staff were masked to treatment randomization. INTERVENTIONS Participants were randomized in a 2:1 fashion to a single oral 1.2-g dose of azithromycin (n = 171) or matching placebo (n = 92). MAIN OUTCOMES AND MEASURES The primary outcomewas absence of self-reported COVID-19 symptoms at day 14. There were 23 secondary clinical end points, including all-cause hospitalization at day 21. RESULTS Among 263 participants who were randomized (median age, 43 years; 174 [66%] women; 57% non-Hispanic White and 29% Latinx/Hispanic), 76% completed the trial. The trial was terminated by the data and safety monitoring committee for futility after the interim analysis. At day 14, there was no significant difference in proportion of participants who were symptom free (azithromycin: 50%; placebo: 50%; prevalence difference, 0%; 95% CI, -14% to 15%; P > .99). Of 23 prespecified secondary clinical end points, 18 showed no significant difference. By day 21, 5 participants in the azithromycin group had been hospitalized compared with 0 in the placebo group (prevalence difference, 4%; 95% CI, -1% to 9%; P = .16). CONCLUSIONS AND RELEVANCE Among outpatients with SARS-CoV-2 infection, treatment with a single dose of azithromycin compared with placebo did not result in greater likelihood of being symptom free at day 14. These findings do not support the routine use of azithromycin for outpatient SARS-CoV-2 infection.	[Oldenburg, Catherine E.; Brogdon, Jessica; Chen, Cindi; Ruder, Kevin; Zhong, Lina; Nyatigo, Fanice; Cook, Catherine A.; Hinterwirth, Armin; Lebas, Elodie; Redd, Travis; Porco, Travis C.; Lietman, Thomas M.; Arnold, Benjamin F.; Thuy Doan] Univ Calif San Francisco, Francis I Proctor Fdn, 490 Illinois St,Floor 2, San Francisco, CA 94143 USA; [Oldenburg, Catherine E.; Redd, Travis; Porco, Travis C.; Lietman, Thomas M.; Arnold, Benjamin F.; Thuy Doan] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA; [Oldenburg, Catherine E.; Porco, Travis C.; Lietman, Thomas M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Pinsky, Benjamin A.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA USA; [Pinsky, Benjamin A.] Stanford Hlth Care, Dept Pathol, Stanford, CA USA; [Pinsky, Benjamin A.] Stanford Sch Med, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Stanford University; Stanford University	Oldenburg, CE (corresponding author), Univ Calif San Francisco, Francis I Proctor Fdn, 490 Illinois St,Floor 2, San Francisco, CA 94143 USA.	catherine.oldenburg@ucsf.edu			Bill AMP; Melinda Gates Foundation [INV-017026]; Research to Prevent Blindness Career Development Award	Bill AMP; Melinda Gates Foundation(CGIAR); Research to Prevent Blindness Career Development Award(Research to Prevent Blindness (RPB))	This trial was supported by the Bill & Melinda Gates Foundation (grant INV-017026). Azithromycin and matching placebo were donated by Pfizer Inc. Dr Doan was supported in part by a Research to Prevent Blindness Career Development Award.	Afshinnekoo E, 2021, LANCET MICROBE, V2, pE135, DOI 10.1016/S2666-5247(21)00039-2; [Anonymous], 2020, NAT MICROBIOL, V5, P779, DOI 10.1038/s41564-020-0739-4; Astale T, 2019, AM J TROP MED HYG, V100, P696, DOI 10.4269/ajtmh.18-0781; Ayele B, 2011, AM J TROP MED HYG, V85, P291, DOI 10.4269/ajtmh.2011.11-0056; Butler CC, 2021, LANCET, V397, P1063, DOI 10.1016/S0140-6736(21)00461-X; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Gyselinck I, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05033-x; Horby PW, 2021, LANCET, V397, P605, DOI 10.1016/S0140-6736(21)00149-5; Johnston C, 2021, ECLINICALMEDICINE, V33, DOI 10.1016/j.eclinm.2021.100773; Lachin JM, 2005, STAT MED, V24, P2747, DOI 10.1002/sim.2151; Lipsitch M, 2002, EMERG INFECT DIS, V8, P347, DOI 10.3201/eid0804.010312; Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730; Nehme M, 2021, ANN INTERN MED, V174, P723, DOI 10.7326/M20-5926; O'Brien KS, 2019, LANCET INFECT DIS, V19, pE14, DOI 10.1016/S1473-3099(18)30444-4; Oldenburg CE, 2020, CLIN INFECT DIS, V70, P525, DOI 10.1093/cid/ciz455; Oliver ME, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2163; Sie A, 2021, AM J TROP MED HYG, V104, P1137, DOI 10.4269/ajtmh.20-1002; Spinato G, 2020, JAMA-J AM MED ASSOC, V323, P2089, DOI 10.1001/jama.2020.6771; Doan T, 2020, NEW ENGL J MED, V383, P1941, DOI 10.1056/NEJMoa2002606	20	41	40	2	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2021	326	6					490	498		10.1001/jama.2021.11517	http://dx.doi.org/10.1001/jama.2021.11517		JUL 2021	9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD4PP	34269813	Bronze, Green Published			2023-01-03	WOS:000673005400001
J	Amour, C; Manongi, RN; Mahande, MJ; Elewonibi, B; Farah, A; Msuya, SE; Shah, I				Amour, Caroline; Manongi, Rachel N.; Mahande, Michael J.; Elewonibi, Bilikisu; Farah, Amina; Msuya, Sia Emmanuel; Shah, Iqbal			Missed opportunity for family planning counselling along the continuum of care in Arusha region, Tanzania	PLOS ONE			English	Article							MODIFIED POISSON REGRESSION; WOMEN	Introduction Adequate sexual and reproductive health information is vital to women of reproductive age (WRA) 15 to 49 years, for making informed choices on their reproductive health including family planning (FP). However, many women who interact with the health system continue to miss out this vital service. The study aimed to identify the extent of provision of FP counselling at service delivery points and associated behavioral factors among women of reproductive age in two districts of Arusha region. It also determined the association between receipt of FP counselling and contraceptive usage. Methods Data were drawn from a cross-sectional survey of 5,208 WRA residing in two districts of Arusha region in Tanzania; conducted between January and May 2018. Multistage sampling technique was employed to select the WRA for the face-to-face interviews. FP counseling was defined as receipt of FP information by a woman during any visit at the health facility for antenatal care (ANC), or for post-natal care (PNC). Analyses on receipt of FP counseling were done on 3,116 WRA, aged 16-44 years who were in contact with health facilities in the past two years. A modified Poisson regression model was used to determine the Prevalence Ratio (PR) as a measure of association between receipt of any FP counseling and current use of modern contraception, controlling for potential confounders. Results Among the women that visited the health facility for any health-related visit in the past two years, 1,256 (40%) reported that they received FP counselling. Among the women who had had births in the last 30 months; 1,389 and 1,409 women had contact with the service delivery points for ANC and PNC visits respectively. Of these 31% and 26% had a missed FP counseling at ANC and PNC visit respectively. Women who were not formally employed were more likely to receive FP counselling during facility visit than others. WRA who received any FP counseling at PNC were significantly more likely to report current use of modern contraception than those who did not (adjusted PR [adj. PR] = 1.28; 95% Confidence Interval [CI]: 1.09, 1.49). Conclusion Overall, only 40% women reported that they received any form of FP counseling when they interfaced with the healthcare system in the past two years. Informally employed women were more likely to receive FP counselling, and women who received FP counselling during PNC visits were significantly more likely to use contraceptive in comparison to the women who did not receive FP counselling. This presents a missed opportunity for prevention of unintended pregnancies and suggests a need for further integration of FP counseling into the ANC and PNC visits.	[Amour, Caroline; Mahande, Michael J.; Msuya, Sia Emmanuel] Kilimanjaro Christian Med Univ Coll, Inst Publ Hlth, Dept Epidemiol & Biostat, Moshi, Tanzania; [Manongi, Rachel N.; Msuya, Sia Emmanuel] Kilimanjaro Christian Med Univ Coll, Inst Publ Hlth, Dept Community Hlth, Moshi, Tanzania; [Elewonibi, Bilikisu; Shah, Iqbal] Harvard Univ TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA; [Farah, Amina; Msuya, Sia Emmanuel] KCMC Hosp, Dept Community Hlth, Moshi, Tanzania	Harvard University; Harvard T.H. Chan School of Public Health	Amour, C (corresponding author), Kilimanjaro Christian Med Univ Coll, Inst Publ Hlth, Dept Epidemiol & Biostat, Moshi, Tanzania.	lyneamour@gmail.com		Farah Mohamed, Amina/0000-0002-8594-972X; Amour, Caroline/0000-0001-5328-6776				Achwoka D, 2018, CONTRACEPTION, V97, P227, DOI 10.1016/j.contraception.2017.10.001; Ali M, 2012, CAUSES CONSEQUENCES; [Anonymous], 2010, UN REP TANZ MIN HLTH UN REP TANZ MIN HLTH; Calhoun LM, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-532; Clements Steve, 2004, Afr J Reprod Health, V8, P124, DOI 10.2307/3583186; Dehingia N, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0844-0; Do M, 2012, INT PERSPECT SEX R H, V38, P23, DOI 10.1363/3802312; Dynes MM, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0593-5; Elewonibi B, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2019-002149; FP, 2013, TANZ FAM PLANN 2020 TANZ FAM PLANN 2020; Hardee K, 2014, INT PERSPECT SEX R H, V40, P206, DOI 10.1363/4020614; Jain AK, 2018, STUD FAMILY PLANN, V49, P171, DOI 10.1111/sifp.12052; Kakoko Deodatus C, 2012, Afr J Reprod Health, V16, P140; Kamhawi S, 2013, GLOB HEALTH-SCI PRAC, V1, P180, DOI 10.9745/GHSP-D-12-00051; Kanyangarara M, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0713-x; Lee JK, 2011, J GEN INTERN MED, V26, P731, DOI 10.1007/s11606-011-1647-3; Maonga AR, 2016, MATERN CHILD HLTH J, V20, P77, DOI 10.1007/s10995-015-1805-z; Ministry of Health Community Development Gender Elderly and Children (MoHCDGEC) [Tanzania Mainland] Ministry of Health (MoH) [Zanzibar] National Bureau of Statistics (NBS) Office of the Chief Government Statistician (OCGS) and ICF International, 2016, TANZ DEM HLTH SURV M; Nabirye J, 2020, BMC WOMENS HEALTH, V20, DOI 10.1186/s12905-020-00942-6; Nagai M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218187; Obare F., 2014, FAMILY PLANNING COUN, V28, P12; Puri MC, 2020, BMC WOMENS HEALTH, V20, DOI 10.1186/s12905-020-00904-y; Reddy KS, 2011, LANCET, V377, P760, DOI 10.1016/S0140-6736(10)61960-5; Schivone GB, 2017, CURR OPIN OBSTET GYN, V29, P443, DOI 10.1097/GCO.0000000000000408; Shu D, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0878-6; Stover J, 2017, STUD FAMILY PLANN, V48, P83, DOI 10.1111/sifp.12014; Tafere Tadese Ejigu, 2018, Contracept Reprod Med, V3, P28, DOI 10.1186/s40834-018-0081-x; Tafere TE., 2018, CONTRACEP REPROD MED, V3, P1, DOI [10.1186/s40834-017-0054-5, DOI 10.1186/S40834-017-0054-5]; TDHS, 2016, TANZ DEM HLTH SURV M; Tumlinson K, 2015, CONTRACEPTION, V92, P143, DOI 10.1016/j.contraception.2015.04.002; UNICEF, 2017, MATERNAL CHILD HLTH; World Health Organization United Nations Children's Fund United Nations Fund for Pop- ulation Activities World Bank Group United Nations., 2015, MENTAL HLTH WELL BEI; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	33	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2021	16	7							e0250988	10.1371/journal.pone.0250988	http://dx.doi.org/10.1371/journal.pone.0250988			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2MK	34260605	gold, Green Published			2023-01-03	WOS:000678119300018
J	Raghuraman, N; Tuuli, MG				Raghuraman, Nandini; Tuuli, Methodius G.			Preconception Care as an Opportunity to Optimize Pregnancy Outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RISK	This JAMA Insights Clinical Update discusses the issue of reducing pregnancy-related morbidity and mortality by identifying modifiable risk factors and providing targeted interventions and education prior to conception.	[Raghuraman, Nandini] Washington Univ, Dept Obstet & Gynecol, St Louis, MO 63110 USA; [Tuuli, Methodius G.] Brown Univ Providence, Sch Med, Dept Obstet & Gynecol, Providence, RI USA; [Tuuli, Methodius G.] Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA	Washington University (WUSTL); Brown University; Women & Infants Hospital Rhode Island	Tuuli, MG (corresponding author), Brown Univ, Dept Obstet & Gynecol, Warren Alpert Med Sch, Women & Infants Hosp Rhode Isl, 101 Dudley St, Providence, RI 02905 USA.	methodiustuuli@yahoo.com		Raghuraman, Nandini/0000-0003-2747-5113				Alexopoulos AS, 2019, JAMA-J AM MED ASSOC, V321, P1811, DOI 10.1001/jama.2019.4981; Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS183, DOI 10.2337/dc20-S014; [Anonymous], 2019, Obstet Gynecol, V133, pe78, DOI 10.1097/AOG.0000000000003013; De-Regil Luz Maria, 2015, Cochrane Database Syst Rev, pCD007950, DOI 10.1002/14651858.CD007950.pub3; Dean SV, 2014, REPROD HEALTH, V11, DOI [10.1186/1742-4755-11-S3-S3, 10.1186/1742-4755-11-S3-S1]; Finer LB, 2016, NEW ENGL J MED, V374, P843, DOI 10.1056/NEJMsa1506575; Frayne DJ, 2016, OBSTET GYNECOL, V127, P863, DOI 10.1097/AOG.0000000000001379; Frederiksen LE, 2018, OBSTET GYNECOL, V131, P457, DOI 10.1097/AOG.0000000000002504; Schummers L, 2015, OBSTET GYNECOL, V125, P133, DOI 10.1097/AOG.0000000000000591; US Census Bureau Population Division, 2019, TABL ANN EST POP SEL	10	6	6	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2021	326	1					79	80		10.1001/jama.2020.27244	http://dx.doi.org/10.1001/jama.2020.27244			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG4UV	34228078				2023-01-03	WOS:000671402600016
J	Kontos, N; Parsons, MW; Biffi, A; Gonzalez, RG				Kontos, Nicholas; Parsons, Michael W.; Biffi, Alessandro; Gonzalez, R. Gilberto			Case 19-2021: A 54-Year-Old Man with Irritability, Confusion, and Odd Behaviors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; BRAIN; HEAD	A Man with Irritability, Confusion, and Odd Behaviors A 54-year-old man was evaluated in the neuropsychology clinic because of irritability, confusion, and odd behaviors. Nine months earlier, he had been treated for cancer, after which chronic pain had developed. Six weeks before the current evaluation, he had been found unresponsive with medication bottles nearby. A diagnostic test was performed.	[Kontos, Nicholas; Parsons, Michael W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Biffi, Alessandro] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Gonzalez, R. Gilberto] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA; [Kontos, Nicholas; Parsons, Michael W.] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA; [Biffi, Alessandro] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA; [Gonzalez, R. Gilberto] Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kontos, N (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.; Kontos, N (corresponding author), Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA.		Parsons, Michael/AGD-0544-2022	Parsons, Michael/0000-0001-8619-9564				Budhram A, 2019, CAN MED ASSOC J, V191, pE529, DOI 10.1503/cmaj.181548; Custodio CM, 2004, ARCH PHYS MED REHAB, V85, P502, DOI 10.1016/S0003-9993(03)00471-4; Geraldo AF, 2014, J RADIOL CASE REP, V8, P1, DOI 10.3941/jrcr.v8i5.1721; Ghosh-Laskar S, 2016, J CANCER RES THER, V12, P1160, DOI 10.4103/0973-1482.184525; Jha MK., 2020, PSYCHOL MED; Kontos N., 2016, MASSACHUSETTS GEN HO, V2nd ed, P599; Kraam A, 2004, HIST PSYCHIATR, V15, P345, DOI 10.1177/0957154X04044598; Melado-Calvo N., 2009, LISHMANS ORGANIC PSY, V4th ed, P281; Mesulam M. M., 2000, PRINCIPLES BEHAV COG; Mikadze YV, 2019, ARCH CLIN NEUROPSYCH, V34, P795, DOI 10.1093/arclin/acy095; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Perini G, 2019, NEUROPSYCH DIS TREAT, V15, P1249, DOI 10.2147/NDT.S199746; Ruzevick J, 2013, J NEURO-ONCOL, V112, P449, DOI 10.1007/s11060-013-1075-9; Shprecher D, 2010, NEUROREHABILITATION, V26, P65, DOI 10.3233/NRE-2010-0536; Zamora CA, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.364	15	0	0	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2021	384	25					2438	2445		10.1056/NEJMcpc2100272	http://dx.doi.org/10.1056/NEJMcpc2100272			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UA7NI	34161710				2023-01-03	WOS:000685344400020
J	Herrmann, ML; Hahn, JM; Walter-Frank, B; Bollinger, DM; Schmauder, K; Schnauder, G; Bitzer, M; Malek, NP; Eschweiler, GW; Gopel, S				Herrmann, Matthias L.; Hahn, Johannes-Martin; Walter-Frank, Birgit; Bollinger, Desiree M.; Schmauder, Kristina; Schnauder, Gunter; Bitzer, Michael; Malek, Nisar P.; Eschweiler, Gerhard W.; Goepel, Siri			COVID-19 in persons aged 70+in an early affected German district: Risk factors, mortality and post-COVID care needs-A retrospective observational study of hospitalized and non-hospitalized patients	PLOS ONE			English	Article							FRAILTY; OLDER	Background Cohorts of hospitalized COVID-19 patients have been studied in several countries since the beginning of the pandemic. So far, there is no complete survey of older patients in a German district that includes both outpatients and inpatients. In this retrospective observational cohort study, we aimed to investigate risk factors, mortality, and functional outcomes of all patients with COVID-19 aged 70 and older living in the district of Tubingen in the southwest of Germany. Methods We retrospectively analysed all 256 patients who tested positive for SARS-CoV-2 in one of the earliest affected German districts during the first wave of the disease from February to April 2020. To ensure inclusion of all infected patients, we analysed reported data from the public health department as well as the results of a comprehensive screening intervention in all nursing homes of the district (n = 1169). Furthermore, we examined clinical data of all hospitalized patients with COVID-19 (n = 109). Results The all-cause mortality was 18%. Screening in nursing homes showed a point-prevalence of 4.6%. 39% of residents showed no COVID-specific symptoms according to the official definition at that time. The most important predictors of mortality were the need for inpatient treatment (odds ratio (OR): 3.95 [95%-confidence interval (CI): 2.00-7.86], p<0.001) and care needs before infection (non-hospitalized patients: OR: 3.79 [95%-CI: 1.01-14.27], p = 0.037, hospitalized patients: OR: 2.89 [95%-CI 1.21-6.92], p = 0.015). Newly emerged care needs were a relevant complication of COVID-19: 27% of previously self-sufficient patients who survived the disease were not able to return to their home environment after discharge from the hospital. Conclusion Our findings demonstrate the importance of a differentiated view of risk groups and long-term effects within the older population. These findings should be included in the political and social debate during the ongoing pandemic to evaluate the true effect of COVID-19 on healthcare systems and individual functional status.	[Herrmann, Matthias L.; Eschweiler, Gerhard W.] Univ Hosp Tubingen, Geriatr Ctr, Tubingen, Germany; [Herrmann, Matthias L.; Eschweiler, Gerhard W.] Univ Hosp Tubingen, Dept Psychiat & Psychotherapy, Tubingen, Germany; [Herrmann, Matthias L.] Univ Freiburg, Dept Neurol & Neurosci, Fac Med, Med Ctr, Freiburg, Germany; [Hahn, Johannes-Martin] Paul Lechler Hosp Tubingen, Tubingen, Germany; [Walter-Frank, Birgit; Bollinger, Desiree M.] Tubingen Dist Adm, Hlth Dept, Tubingen, Germany; [Schmauder, Kristina; Schnauder, Gunter; Bitzer, Michael; Malek, Nisar P.; Goepel, Siri] Univ Hosp Tubingen, Dept Internal Med 1, Tubingen, Germany; [Goepel, Siri] Comprehens Infect Dis Ctr Tubingen, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Freiburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Gopel, S (corresponding author), Univ Hosp Tubingen, Dept Internal Med 1, Tubingen, Germany.; Gopel, S (corresponding author), Comprehens Infect Dis Ctr Tubingen, Tubingen, Germany.	siri.goepel@med.uni-tuebingen.se		Bitzer, Michael/0000-0002-4463-8263	Open Access Publishing Fund of the University of Tubingen	Open Access Publishing Fund of the University of Tubingen	The authors received support from the Open Access Publishing Fund of the University of Tubingen. No additional external funding was received for this study.	[Anonymous], POP BAD WURTT 2019 D; Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X; De Smet R, 2020, J AM MED DIR ASSOC, V21, P928, DOI 10.1016/j.jamda.2020.06.008; Graham NSN, 2020, J INFECTION, V81, P411, DOI 10.1016/j.jinf.2020.05.073; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hariyanto TI, 2021, ARCH GERONTOL GERIAT, V93, DOI 10.1016/j.archger.2020.104299; Helfand BKI, 2020, JAMA INTERN MED, V180, P1546, DOI 10.1001/jamainternmed.2020.5084; Hewitt J, 2020, LANCET PUBLIC HEALTH, V5, pE444, DOI 10.1016/S2468-2667(20)30146-8; Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7; Kimball A, 2020, MMWR-MORBID MORTAL W, V69, P377, DOI 10.15585/mmwr.mm6913e1; Kojima G, 2015, J AM MED DIR ASSOC, V16, P940, DOI 10.1016/j.jamda.2015.06.025; Maltese G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072106; Organisation for Economic Co-operation and Development (OECD), **DATA OBJECT**, DOI [10.1787/data-00540-en, DOI 10.1787/DATA-00540-EN]; Posso M, 2020, ARCH BRONCONEUMOL, V56, P756, DOI [10.1016/j.arbr.2020.06.010, 10.1016/j.arbres.2020.06.012]; Robert Koch Institute, COVID 19 SUSP TEST C; Robert Koch Institute, COR DIS 2019 COVID 1; Robert Koch Institute, DASHB COR SARS COV 2; Tolksdorf K., 2020, ATEMWEGSINFEKTIONEN, V41, P3, DOI 10.25646/7111; Trevisan C, 2021, EUR J INTERN MED, V86, P41, DOI 10.1016/j.ejim.2021.01.028; Wang XH, 2020, RESEARCH-CHINA, V2020, DOI 10.34133/2020/2402961; Williamson E., 2020, MEDRXIV, P1, DOI [10.1101/2020.05.06.20092999, 10.1101/2020.05.06.20092999v1]; World Health Organisation (WHO), WHO COR DIS COVID 19; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648	23	4	4	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2021	16	6							e0253154	10.1371/journal.pone.0253154	http://dx.doi.org/10.1371/journal.pone.0253154			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BC	34143823	gold, Green Published			2023-01-03	WOS:000671690700006
J	Rome, BN; Gagne, JJ; Kesselheim, AS				Rome, Benjamin N.; Gagne, Joshua J.; Kesselheim, Aaron S.			Association of California's Prescription Drug Coupon BanWith Generic Drug Use	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Rome, Benjamin N.; Gagne, Joshua J.; Kesselheim, Aaron S.] Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA; [Gagne, Joshua J.] Exponent Inc, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Exponent	Rome, BN (corresponding author), Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	brome@bwh.harvard.edu			Anthem Public Policy Institute; Arnold Ventures	Anthem Public Policy Institute; Arnold Ventures	This work was funded by a grant from the Anthem Public Policy Institute. Dr Kesselheim is also supported by Arnold Ventures.	Dafny L, 2017, AM ECON J-ECON POLIC, V9, P91, DOI 10.1257/pol.20150588; Daubresse M, 2017, PHARMACOTHERAPY, V37, P12, DOI 10.1002/phar.1802; Karen V., 2018, PRESCRIPTION DRUG CO; Massachusetts Health Policy Commission, 2020, PRESCR DRUG COUP STU; Ross JS, 2013, NEW ENGL J MED, V369, P1188, DOI 10.1056/NEJMp1301993	5	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2021	325	23					2399	2402		10.1001/jama.2021.6568	http://dx.doi.org/10.1001/jama.2021.6568			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SU3BJ	34129007	Green Published, Bronze			2023-01-03	WOS:000663015400016
J	Menke, BM; Hass, J; Diener, C; Poschl, J				Menke, Barbara M.; Hass, Joachim; Diener, Carsten; Poeschl, Johannes			Family-centered music therapy-Empowering premature infants and their primary caregivers through music: Results of a pilot study	PLOS ONE			English	Article							NEONATAL INTENSIVE-CARE; MATERNAL DEPRESSIVE SYMPTOMS; PRETERM INFANTS; KANGAROO CARE; UNIT; PARENTS; ANXIETY; NICU; CHILDREN; MOTHER	Background In Neonatal Intensive Care Units (NICUs) premature infants are exposed to various acoustic, environmental and emotional stressors which have a negative impact on their development and the mental health of their parents. Family-centred music therapy bears the potential to positively influence these stressors. The few existing studies indicate that interactive live-improvised music therapy interventions both reduce parental stress factors and support preterm infants' development. Methods The present randomized controlled longitudinal study (RCT) with very low and extremely low birth weight infants (born <30+0 weeks of gestation) and their parents analyzed the influence of music therapy on both the physiological development of premature infants and parental stress factors. In addition, possible interrelations between infant development and parental stress were explored. 65 parent-infant-pairs were enrolled in the study. The treatment group received music therapy twice a week from the 21(st) day of life till discharge from hospital. The control group received treatment as usual. Results Compared to the control group, infants in the treatment group showed a 11.1 days shortening of caffeine therapy, 12.1 days shortening of nasogastric/ orogastric tube feed and 15.5 days shortening of hospitalization, on average. While these differences were not statistically significant, a factor-analytical compound measure of all three therapy durations was. From pre-to-post-intervention, parents showed a significant reduction in stress factors. However, there were no differences between control and treatment group. A regression analysis showed links between parental stress factors and physiological development of the infants. Conclusion This pilot study suggests that a live-improvised interactive music therapy intervention for extremely and very preterm infants and their parents may have a beneficial effect on the therapy duration needed for premature infants before discharge from hospital is possible. The study identified components of the original physiological variables of the infants as appropriate endpoints and suggested a slight change in study design to capture possible effects of music therapy on infants' development as well. Further studies should assess both short-term and long-term effects on premature infants as well as on maternal and paternal health outcomes, to determine whether a family-centered music therapy, actually experienced as an added value to developmental care, should be part of routine care at the NICU.	[Menke, Barbara M.; Poeschl, Johannes] Univ Childrens Hosp, Dept Neonatol, Heidelberg, Germany; [Menke, Barbara M.; Hass, Joachim; Diener, Carsten] SRH Univ Heidelberg, Inst Appl Res, Heidelberg, Germany; [Hass, Joachim] Heidelberg Univ, Cent Inst Mental Hlth, Med Fac Mannheim, Mannheim, Germany	Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Central Institute of Mental Health; Ruprecht Karls University Heidelberg	Menke, BM (corresponding author), Univ Childrens Hosp, Dept Neonatol, Heidelberg, Germany.; Menke, BM (corresponding author), SRH Univ Heidelberg, Inst Appl Res, Heidelberg, Germany.	Barbara.Menke@srh.de		Hass, Joachim/0000-0001-6802-7718				A von der Wense., 2013, RISIKOFAKTOR FR HGEB; Aarnoudse-Moens CSH, 2009, PEDIATRICS, V124, P717, DOI 10.1542/peds.2008-2816; Affleck G., 1991, INFANTS CRISIS PAREN; ALS H, 1986, PROGRAM GUIDE NEWBOR; Arnon S, 2014, ACTA PAEDIATR, V103, P1039, DOI 10.1111/apa.12744; Arockiasamy V, 2008, PEDIATRICS, V121, pE215, DOI 10.1542/peds.2007-1005; Bieleninik L, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0971; Brown G, 2009, NEONATAL NETW, V28, P165, DOI 10.1891/0730-0832.28.3.165; Carson C, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007942; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Ettenberger, 2014, VOICES WORLD FORUM M, V14; Ettenberger M, 2017, NORD J MUSIC THER, V26, P207, DOI 10.1080/08098131.2016.1205650; Feeley N, 2005, J DEV BEHAV PEDIATR, V26, P24; Filippa M, 2020, PEDIATR RES, V87, P249, DOI 10.1038/s41390-019-0490-9; Fischer CB., 2012, H REN BR CKE INS LEB, P19; Flacking R, 2012, ACTA PAEDIATR, V101, P1032, DOI 10.1111/j.1651-2227.2012.02787.x; Franck LS, 2005, J ADV NURS, V49, P608, DOI 10.1111/j.1365-2648.2004.03336.x; Garten L, 2013, J PERINATOL, V33, P65, DOI 10.1038/jp.2012.32; Ghetti C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025062; Gray L, 2004, CLIN PERINATOL, V31, P243, DOI 10.1016/j.clp.2004.04.013; Haslbeck F., 2017, EARLY VOCAL CONTACT, P217, DOI DOI 10.1007/978-3-319-65077-7_13; Haslbeck F, 2017, MUSIKTHER UMSCH, V38, P65; Haslbeck FB, 2020, JOVE-J VIS EXP, DOI 10.3791/60412; Haslbeck FB, 2020, NEUROIMAGE-CLIN, V25, DOI 10.1016/j.nicl.2020.102171; Haslbeck FB, 2014, NORD J MUSIC THER, V23, P36, DOI 10.1080/08098131.2013.790918; Haslbeck FB, 2014, NORD J MUSIC THER, V23, P5, DOI 10.1080/08098131.2013.780091; Heim B, 2012, SYSTEMATISCHE DARSTE; Herz E., 1996, DTSCH VERSION EDINBU; Hodel AS, 2018, DEV REV, V48, P113, DOI 10.1016/j.dr.2018.02.003; Huppertz-Kessler CJ, 2010, KLIN PADIATR, V222, pE1, DOI 10.1055/s-0030-1254096; Huppertz-Kessler CJ, 2009, KLIN PADIATR, V221, P450, DOI 10.1055/s-0029-1238277; Johnson S, 2017, ARCH DIS CHILD, V102, P97, DOI 10.1136/archdischild-2015-309581; Johnson S, 2010, J AM ACAD CHILD PSY, V49, P453, DOI 10.1016/j.jaac.2010.02.002; Kehl S, 2018, PILOTSTUDIE M GLICHE; Ki&beta;gen R., 2013, PSYCHOL NEONATOLOGIE, P60; Kuhn P, 2013, ACTA PAEDIATR, V102, P949, DOI 10.1111/apa.12330; Lai HL, 2006, INT J NURS STUD, V43, P139, DOI 10.1016/j.ijnurstu.2005.04.008; Laux L, 1981, THEORETISCHE GRUNDLA; Lefkowitz DS, 2010, J CLIN PSYCHOL MED S, V17, P230, DOI 10.1007/s10880-010-9202-7; Loewy J, 2015, ANN NY ACAD SCI, V1337, P178, DOI 10.1111/nyas.12648; Loewy J, 2013, PEDIATRICS, V131, P902, DOI 10.1542/peds.2012-1367; Lordier L, 2019, P NATL ACAD SCI USA, V116, P12103, DOI 10.1073/pnas.1817536116; Mackley Amy B, 2010, Adv Neonatal Care, V10, P200, DOI 10.1097/ANC.0b013e3181e946f0; McManus BM, 2012, INFANT BEHAV DEV, V35, P489, DOI 10.1016/j.infbeh.2012.04.005; Menke BM., 2019, MUSIC THERAPY PREMAT, P115; Moehler E, 2006, ARCH WOMEN MENT HLTH, V9, P273, DOI 10.1007/s00737-006-0149-5; Moon C.M., 2017, EARLY VOCAL CONTACT, P25, DOI DOI 10.1007/978-3-319-65077-7_2; Muller-Nix C, 2004, EARLY HUM DEV, V79, P145, DOI 10.1016/j.earlhumdev.2004.05.002; Nicol-Harper R, 2007, INFANT BEHAV DEV, V30, P161, DOI 10.1016/j.infbeh.2006.08.005; Nocker-Ribaupierre M., 2014, GUIDELINES MUSIC THE, P66; Nu┬cker-Ribaupierre, 2015, MUSIC MED, V7, P20, DOI [10.47513/mmd.v7i3.406, DOI 10.47513/MMD.V7I3.406]; Pace CC, 2016, JAMA PEDIATR, V170, P863, DOI 10.1001/jamapediatrics.2016.0810; Perlman JM, 2001, PEDIATRICS, V108, P1339, DOI 10.1542/peds.108.6.1339; Pohlman Shawn, 2005, Adv Neonatal Care, V5, P204, DOI 10.1016/j.adnc.2005.03.002; Polkki T, 2012, J SPEC PEDIATR NURS, V17, P321, DOI 10.1111/j.1744-6155.2012.00343.x; Ribeiro Mayara K A, 2018, BMC Psychol, V6, P57, DOI 10.1186/s40359-018-0271-y; Saliba S, 2018, ACTA PAEDIATR, V107, P1122, DOI 10.1111/apa.14170; schl J., 2017, FEHLGEBURTEN TOTGEBU, P291, DOI [10.1007/978-3-662-50424-6_37, DOI 10.1007/978-3-662-50424-6_37]; Schlez A, 2011, ISR MED ASSOC J, V13, P354; Schneewind KA., 1989, MATERIALBAND PSYCHOL; Smith GC, 2011, ANN NEUROL, V70, P541, DOI 10.1002/ana.22545; Teckenberg-Jansson P, 2011, NORD J MUSIC THER, V20, P22, DOI 10.1080/08098131003768123; Turner M, 2015, J REPROD INFANT PSYC, V33, P165, DOI 10.1080/02646838.2014.998184; van der Heijden MJE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161848; van Dokkum NH, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.581372; Verveur D., 2008, HEILBERUFE, V60, P10; Verveur D., 2008, HEILBERUFE, V60, P29; Vonderlin E-M., 1999, FR HGEBURT ELTERLICH; Wachman EM, 2011, ARCH DIS CHILD-FETAL, V96, pF305, DOI 10.1136/adc.2009.182014; Walworth DD, 2009, J MUSIC THER, V46, P32, DOI 10.1093/jmt/46.1.32; Wehrle FM, 2016, EARLY HUM DEV, V92, P37, DOI 10.1016/j.earlhumdev.2015.10.021; Whipple J, 2000, J MUSIC THER, V37, P250, DOI 10.1093/jmt/37.4.250; Zelkowitz P, 2011, ACTA PAEDIATR, V100, P700, DOI 10.1111/j.1651-2227.2010.02128.x; Zelkowitz P, 2009, EARLY HUM DEV, V85, P51, DOI 10.1016/j.earlhumdev.2008.06.010	74	5	5	3	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2021	16	5							e0250071	10.1371/journal.pone.0250071	http://dx.doi.org/10.1371/journal.pone.0250071			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0XR	33989286	Green Published, gold			2023-01-03	WOS:000662175000008
J	Colombo, D; Pavani, JB; Fernandez-Alvarez, J; Garcia-Palacios, A; Botella, C				Colombo, Desiree; Pavani, Jean-Baptiste; Fernandez-Alvarez, Javier; Garcia-Palacios, Azucena; Botella, Cristina			Savoring the present: The reciprocal influence between positive emotions and positive emotion regulation in everyday life	PLOS ONE			English	Article							INDIVIDUAL-DIFFERENCES; HAPPINESS; STRATEGIES; RESPONSES; BENEFITS; CIRCUMPLEX; RUMINATION; SPIRALS; EVENTS; BACK	A growing body of research has investigated the regulation of negative emotions in ecological settings, but little is known about the mechanisms underlying positive emotion regulation in everyday life. Although some evidence suggests that adopting positive strategies is beneficial for emotional well-being, the literature is inconsistent about the effects of positive emotions on subsequent regulatory processes. In the present study, we adopted a two-week ecological momentary assessment to explore the association between positive emotions and positive emotion regulation in daily life. According to our results, the less individuals felt positive emotions at one point, the more they tended to enhance their use of positive strategies from this time to the next, which in turn resulted in subsequent higher levels of positive emotions. This prototype of positive regulation can be seen as a highly adaptive mechanism that makes it possible to compensate for a lack of positive emotions by enhancing the deployment of positive strategies. The theoretical and clinical implications of these findings are discussed.	[Colombo, Desiree; Garcia-Palacios, Azucena; Botella, Cristina] Jaume 1 Univ, Dept Basic Psychol, Clin & Psychobiol, Castellon de La Plana, Spain; [Pavani, Jean-Baptiste] Aix Marseille Univ, Ctr Res Psychol Cognit Language & Emot PSYCLE, Marseille, France; [Fernandez-Alvarez, Javier] Univ Cattolica Sacro Cuore, Dept Psychol, Milan, Italy; [Garcia-Palacios, Azucena; Botella, Cristina] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBERobn, Madrid, Spain	Universitat Jaume I; UDICE-French Research Universities; Aix-Marseille Universite; Catholic University of the Sacred Heart; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III	Colombo, D (corresponding author), Jaume 1 Univ, Dept Basic Psychol, Clin & Psychobiol, Castellon de La Plana, Spain.	dcolombo@uji.es	colombo, desiree/AAG-6833-2019; Fernández Alvarez, Javier/AAH-2007-2021	colombo, desiree/0000-0003-0333-2003; Fernández Alvarez, Javier/0000-0002-2516-8809	Marie Curie EF-ST AffecTech Project [722022]	Marie Curie EF-ST AffecTech Project	This work was supported by the Marie Curie EF-ST AffecTech Project, approved at call H2020 - MSCA - ITN - 2016, under grant number 722022.	Berrios R, 2015, COGNITION EMOTION, V29, P755, DOI 10.1080/02699931.2014.939948; Brans K, 2013, EMOTION, V13, P926, DOI 10.1037/a0032400; Brockman R, 2017, COGN BEHAV THERAPY, V46, P91, DOI 10.1080/16506073.2016.1218926; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Bryant F., 2003, J MENT HEALTH, V12, P175, DOI [10.1080/0963823031000103489, DOI 10.1080/0963823031000103489]; Bryant F.B., 2017, SAVORING NEW MODEL P; Burns AB, 2008, PERS INDIV DIFFER, V44, P360, DOI 10.1016/j.paid.2007.08.015; Cacioppo JT, 1999, CURR DIR PSYCHOL SCI, V8, P133, DOI 10.1111/1467-8721.00031; Carl JR, 2013, CLIN PSYCHOL REV, V33, P343, DOI 10.1016/j.cpr.2013.01.003; Colombo D, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01333; Colombo D, 2020, COGNITIVE THER RES, V44, P906, DOI 10.1007/s10608-020-10122-3; Colombo D, 2020, EMOTION, V20, P30, DOI 10.1037/emo0000671; Davis MA, 2009, ORGAN BEHAV HUM DEC, V108, P25, DOI 10.1016/j.obhdp.2008.04.001; Diener E, 2000, AM PSYCHOL, V55, P34, DOI 10.1037/0003-066X.55.1.34; Diener E, 2002, PSYCHOL SCI, V13, P81, DOI 10.1111/1467-9280.00415; Eisele G, 2022, ASSESSMENT, V29, P136, DOI 10.1177/1073191120957102; EKMAN P, 1992, COGNITION EMOTION, V6, P169, DOI 10.1080/02699939208411068; Erisman SM, 2010, EMOTION, V10, P72, DOI 10.1037/a0017162; Feldman GC, 2008, COGNITIVE THER RES, V32, P507, DOI 10.1007/s10608-006-9083-0; Folkman S, 2004, ANNU REV PSYCHOL, V55, P745, DOI 10.1146/annurev.psych.55.090902.141456; Folkman S, 2000, AM PSYCHOL, V55, P647, DOI 10.1037//0003-066X.55.6.647; Forgas JP, 2002, PERS SOC PSYCHOL B, V28, P336, DOI 10.1177/0146167202286005; Fredrickson B. L., 1998, REV GEN PSYCHOL, V2, P300; Fredrickson BL, 2001, AM PSYCHOL, V56, P218, DOI 10.1037/0003-066X.56.3.218; Fredrickson BL, 2002, PSYCHOL SCI, V13, P172, DOI 10.1111/1467-9280.00431; Frisch M. B., 2006, QUALITY LIFE THERAPY; Gable SL, 2004, J PERS SOC PSYCHOL, V87, P228, DOI 10.1037/0022-3514.87.2.228; Gentzler AL., 2013, J EARLY ADOLESC; Giuliani NR, 2008, EMOTION, V8, P714, DOI 10.1037/a0013236; Gross J. J., 2006, EMOTION REGULATION C, P13, DOI [10.1037/11468-001, DOI 10.1037/11468-001]; Gross J.J., 1998, REV GEN PSYCHOL, V2, P271, DOI 10.1037/1089-2680.2.3.271; Gross JJ, 2015, PSYCHOL INQ, V26, P1, DOI 10.1080/1047840X.2014.940781; Gruber J, 2013, EMOTION, V13, P1, DOI 10.1037/a0030262; Heiy JE, 2014, EMOTION, V14, P878, DOI 10.1037/a0037231; Hurley DB., 2013, J HAPPINESS STUD; Jose PE, 2012, J POSIT PSYCHOL, V7, P176, DOI 10.1080/17439760.2012.671345; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kuppens P, 2010, J PERS SOC PSYCHOL, V99, P1042, DOI 10.1037/a0020962; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; LANGSTON CA, 1994, J PERS SOC PSYCHOL, V67, P1112, DOI 10.1037/0022-3514.67.6.1112; Larsen JT, 2011, J PERS SOC PSYCHOL, V100, P1095, DOI 10.1037/a0021846; Li YI, 2017, J PSYCHOPATHOL BEHAV, V39, P412, DOI 10.1007/s10862-017-9593-y; Lin WL, 2014, COGNITION EMOTION, V28, P834, DOI 10.1080/02699931.2013.854195; Livingstone KM, 2012, J RES PERS, V46, P504, DOI 10.1016/j.jrp.2012.05.009; Lyubomirsky S, 2005, PSYCHOL BULL, V131, P803, DOI 10.1037/0033-2909.131.6.803; Mori K, 2009, PERCEPT MOTOR SKILL, V109, P76, DOI 10.2466/PMS.109.1.76-78; Nelis D, 2011, PSYCHOL BELG, V51, P49, DOI 10.5334/pb-51-1-49; Neuhoff CC, 2002, PSYCHOL REP, V91, P1079, DOI 10.2466/PR0.91.7.1079-1080; Nezlek JB, 2008, J PERS, V76, P561, DOI 10.1111/j.1467-6494.2008.00496.x; Pavani JB, 2016, J HAPPINESS STUD, V17, P2077, DOI 10.1007/s10902-015-9686-9; Pettersson E, 2013, J RES PERS, V47, P57, DOI 10.1016/j.jrp.2012.10.003; Plassmann H, 2008, P NATL ACAD SCI USA, V105, P1050, DOI 10.1073/pnas.0706929105; Quoidbach J, 2019, MOTIV EMOTION, V43, P948, DOI 10.1007/s11031-019-09785-7; Quoidbach J, 2019, PSYCHOL SCI, V30, P1111, DOI 10.1177/0956797619849666; Quoidbach J, 2015, PSYCHOL BULL, V141, P655, DOI 10.1037/a0038648; Quoidbach J, 2010, PERS INDIV DIFFER, V49, P368, DOI 10.1016/j.paid.2010.03.048; RUSSELL JA, 1980, J PERS SOC PSYCHOL, V39, P1161, DOI 10.1037/h0077714; SIMON HA, 1967, PSYCHOL REV, V74, P29, DOI 10.1037/h0024127; Taquet M, 2016, P NATL ACAD SCI USA, V113, P9769, DOI 10.1073/pnas.1519998113; Trull TJ, 2020, J ABNORM PSYCHOL, V129, P56, DOI 10.1037/abn0000473; Tugade M., 2007, J HAPPINESS STUD, V8, P311, DOI [DOI 10.1007/S10902-006-9015-4, 10.1007/s10902-006-9015-4]; Tugade MM, 2004, J PERS SOC PSYCHOL, V86, P320, DOI 10.1037/0022-3514.86.2.320; Wang XX, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/390865; Wood AM, 2010, CLIN PSYCHOL REV, V30, P890, DOI 10.1016/j.cpr.2010.03.005; Wood JV, 2003, J PERS SOC PSYCHOL, V85, P566, DOI 10.1037/0022-3514.85.3.566	65	3	3	6	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2021	16	5							e0251561	10.1371/journal.pone.0251561	http://dx.doi.org/10.1371/journal.pone.0251561			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6LY	33974680	Green Published, Green Submitted, gold			2023-01-03	WOS:000664626600051
J	Hamid, MSA; Sazlina, SG				Hamid, Mohamad Shariff A.; Sazlina, Shariff Ghazali			Platelet-rich plasma for rotator cuff tendinopathy: A systematic review and meta-analysis	PLOS ONE			English	Review							MUSCULOSKELETAL DISORDERS; DIAGNOSTIC-ACCURACY; SHOULDER PAIN; PREVALENCE; ULTRASOUND; INJECTION; DISEASE; TEARS	Shoulder rotator cuff tendinopathy is a common debilitating condition that affects a person daily function and the quality of life. Despite its frequent occurrence, the best treatment is still inconclusive. This review assessed the clinical effect of platelet-rich plasma injection for rotator cuff tendinopathy. A systematic literature search was conducted using CINAHL, Medline, SCOPUS, SPORTSDiscus and Web of Science databases to retrieve articles published in peer-reviewed journals until December 2020. Randomised controlled trials (RCTs), which compared clinical effects of PRP injection to the usual care among adults diagnosed with rotator cuff conditions were reviewed. The main outcomes of interest were changes in shoulder pain symptoms and shoulder functions. All variables were analysed using random effects meta-analyses. Eight RCTs were reviewed in this study. The risk of bias for randomization was low for 6 RCTs, one study had unclear risk and the other was a high risk. Studies vary on the PRP techniques including preparation and injections. Moreover, the control intervention also differs. Four studies compared PRP with normal saline injection while in the remaining 4 RCTs the control intervention were rehabilitation program and dry needling. Meta-analysis of selected studies showed that PRP injection was safe and effective intervention for long-term pain control and shoulder function in patients with RC disorders.	[Hamid, Mohamad Shariff A.] Univ Malaya, Unit Sports Med, Fac Med, Kuala Lumpur, Malaysia; [Sazlina, Shariff Ghazali] Univ Putra Malaysia, Dept Family Med, Fac Med & Hlth Sci, Serdang, Selangor, Malaysia; [Sazlina, Shariff Ghazali] Univ Putra Malaysia, Malaysian Res Inst Ageing MyAgeing TM, Serdang, Selangor, Malaysia	Universiti Malaya; Universiti Putra Malaysia; Universiti Putra Malaysia	Sazlina, SG (corresponding author), Univ Putra Malaysia, Dept Family Med, Fac Med & Hlth Sci, Serdang, Selangor, Malaysia.; Sazlina, SG (corresponding author), Univ Putra Malaysia, Malaysian Res Inst Ageing MyAgeing TM, Serdang, Selangor, Malaysia.	sazlina@medic.upm.edu.my	HAMID, MOHAMAD SHARIFF A/B-9029-2010	HAMID, MOHAMAD SHARIFF A/0000-0001-9196-0442; Shariff-Ghazali, Sazlina/0000-0002-5737-7226				Abidin NZ., 2018, INT J ENG TECHNOL, V7, P23; Agur, 2013, CLIN ORIENTED ANATOM, P1168; Breckenridge JD, 2011, J PHYSIOTHER, V57, P197, DOI 10.1016/S1836-9553(11)70045-5; Cai Y, 2019, MED SCI SPORT EXER, V51, P227, DOI 10.1249/MSS.0000000000001781; Centeno C, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/5962354; Cook T, 2019, J ORTHOP SPORT PHYS, V49, P289, DOI 10.2519/jospt.2019.0607; de Mos M, 2008, AM J SPORT MED, V36, P1171, DOI 10.1177/0363546508314430; Germann G, 1999, Handchir Mikrochir Plast Chir, V31, P149, DOI 10.1055/s-1999-13902; Hopkins C, 2016, ASIA-PAC J SPORT MED, V4, P9, DOI 10.1016/j.asmart.2016.01.002; Hurley ET, 2019, AM J SPORT MED, V47, P753, DOI 10.1177/0363546517751397; Ilhanli I, 2015, IRAN RED CRESCENT ME, V17, DOI 10.5812/ircmj.23732; Jain NB, 2017, AM J PHYS MED REHAB, V96, P176, DOI 10.1097/PHM.0000000000000566; Julian Higgins JT, 2022, COCHRANE HDB SYSTEMA; Kesikburun S, 2013, AM J SPORT MED, V41, P2609, DOI 10.1177/0363546513496542; Khan K., 2019, CLIN SPORTS MED MED; Lewis J, 2015, J ORTHOP SPORT PHYS, V45, P923, DOI 10.2519/jospt.2015.5941; Lin MT, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10040189; Littlewood C, 2013, SHOULDER ELB, V5, P256, DOI [10.1111/sae.12028, DOI 10.1111/SAE.12028]; McClure PW., 2003, ARTHRITIS RHEUM, V49, pS50, DOI [10.1002/art.11404, DOI 10.1002/ART.11404]; Minagawa H, 2013, J ORTHOP, V10, P8, DOI 10.1016/j.jor.2013.01.008; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Nejati P, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117702366; Phadke Akshay, 2019, J Clin Orthop Trauma, V10, P244, DOI 10.1016/j.jcot.2018.10.014; Rha DW, 2013, CLIN REHABIL, V27, P113, DOI 10.1177/0269215512448388; Roquelaure Y, 2006, ARTHRIT RHEUM-ARTHR, V55, P765, DOI 10.1002/art.22222; Rughetti A, 2008, BLOOD TRANSFUS-ITALY, V6, P12, DOI 10.2450/2008.0026-07; Ryosa A, 2017, DISABIL REHABIL, V39, P1357, DOI 10.1080/09638288.2016.1198431; Say F, 2016, J ORTHOP SURG-HONG K, V24, P62, DOI 10.1177/230949901602400115; Schwitzguebel AJ, 2019, AM J SPORT MED, V47, P1885, DOI 10.1177/0363546519851097; Shams Ahmed, 2016, Eur J Orthop Surg Traumatol, V26, P837; Smith TO, 2011, CLIN RADIOL, V66, P1036, DOI 10.1016/j.crad.2011.05.007; Spargoli G, 2018, INT J SPORTS PHYS TH, V13, P1083, DOI 10.26603/ijspt20181083; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Teunis T, 2014, J SHOULDER ELB SURG, V23, P1913, DOI 10.1016/j.jse.2014.08.001; Urwin M, 1998, ANN RHEUM DIS, V57, P649, DOI 10.1136/ard.57.11.649; Wesner M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147842	37	6	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2021	16	5							e0251111	10.1371/journal.pone.0251111	http://dx.doi.org/10.1371/journal.pone.0251111			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6LC	33970936	Green Published, gold			2023-01-03	WOS:000664624400029
J	DeMerle, K; Angus, DC; Seymour, CW				DeMerle, Kimberley; Angus, Derek C.; Seymour, Christopher W.			Precision Medicine for COVID-19 Phenotype Anarchy or Promise Realized?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[DeMerle, Kimberley; Angus, Derek C.; Seymour, Christopher W.] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness CRI, Dept Crit Care Med, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Seymour, CW (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, 3550 Terrace St,Scaife Hall 639, Pittsburgh, PA 15261 USA.; Seymour, CW (corresponding author), Univ Pittsburgh, Sch Med, Dept Emergency Med, Clin Res Invest & Syst Modeling Acute Illness CRI, 3550 Terrace St,Scaife Hall 639, Pittsburgh, PA 15261 USA.	seymourcw@upmc.edu			NIH [R35GM119519]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded in part by the NIH (Dr Seymour, R35GM119519).	Challen R, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n579; Dorward DA, 2021, AM J RESP CRIT CARE, V203, P192, DOI 10.1164/rccm.202008-3265OC; Kox M, 2020, JAMA-J AM MED ASSOC, V324, P1565, DOI 10.1001/jama.2020.17052; Lauring AS, 2021, JAMA-J AM MED ASSOC, V325, P529, DOI 10.1001/jama.2020.27124; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y	7	25	25	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2021	325	20					2041	2042		10.1001/jama.2021.5248	http://dx.doi.org/10.1001/jama.2021.5248		MAY 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SJ6MR	33961002	Bronze			2023-01-03	WOS:000647843300001
J	Simonetti, M; Kuner, R				Simonetti, Manuela; Kuner, Rohini			Locus revealed: Painlessness via loss of Na(V)1.7 at central terminals of sensory neurons	NEURON			English	Editorial Material								How genetic loss of the sodium channel Na(V)1.7 results in painlessness is puzzling. MacDonald et al. (2021) demonstrate that instead of impairing peripheral excitability, Na(V)1.7 channels at central terminals of pain sensing afferents play a pivotal role in the balance between pain and analgesia.	[Simonetti, Manuela; Kuner, Rohini] Heidelberg Univ, Med Fac Heidelberg, Inst Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Kuner, R (corresponding author), Heidelberg Univ, Med Fac Heidelberg, Inst Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	rohini.kuner@pharma.uni-heidelberg.de	Kuner, Rohini/AGU-0204-2022					Gaveriaux-Ruff C, 2011, PAIN, V152, P1238, DOI 10.1016/j.pain.2010.12.031; Goodwin G, 2021, NAT REV NEUROSCI, V22, P263, DOI 10.1038/s41583-021-00444-w; Isensee J, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4874; Kuner R, 2017, NAT REV NEUROSCI, V18, P20, DOI 10.1038/nrn.2016.162; MacDonald DI, 2021, NEURON, V109, P1497, DOI 10.1016/j.neuron.2021.03.012; Machelska H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00300; Minett MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9967; Minett MS, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1795; Pereira V., 2018, WELLCOME OPEN RES, V3, P101; Waxman SG, 2019, NEURON, V101, P765, DOI 10.1016/j.neuron.2019.02.016	10	0	0	2	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	MAY 5	2021	109	9					1413	1416		10.1016/j.neuron.2021.04.011	http://dx.doi.org/10.1016/j.neuron.2021.04.011		MAY 2021	4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UO7GL	33957067				2023-01-03	WOS:000694861200002
J	Garcia-Navarro, EB; Araujo-Hernandez, M; Rigabert, A; Rojas-Ocana, MJ				Begona Garcia-Navarro, E.; Araujo-Hernandez, Miriam; Rigabert, Alina; Jesus Rojas-Ocana, Maria			Attitudes of nursing degree students towards end of life processes. A cultural approach (Spain-Senegal)	PLOS ONE			English	Article							COMMUNITY-BASED PROGRAMS; DEATH ANXIETY; CARE; ACCOUNTABILITY; COVID-19; QUALITY	Introduction The concept of death is abstract, complex and has a number of meanings. Thus, its understanding and the approach taken to it depend, to a large extent, on aspects such as age, culture, training and religion. Nursing students have regular contact with the process of death and so it is of great interest to understand the attitudes they have towards it. As we live in a plural society it is even more interesting to not only understand the attitudes of Spanish students but, also, those of students coming from other countries. In the present article, we seek to identify and compare the attitudes held by nursing degree students at Hekima-Sante University (Senegal) and the University of Huelva (Spain) about end of life processes. The study identifies elements that condition attitudes and coping with death, whilst considering curricular differences with regards to specific end of life training. Method A descriptive, cross-sectional and multi-center study was conducted. The overall sample (N = 142) was divided into groups: Hekima-Sante University (Dakar, Senegal) and the University of Huelva (Huelva, Spain). The measurement instruments used were an ad-hoc questionnaire and Bugen ' s Coping with Death Scale. Results Statistically significant differences (p = 0.005, 95%CI) were found in relation to overall Bugen Scale scores. We can confirm that specialized end of life training (University of Huelva, Spain) did not lead to better coping when compared with a population whose academic curriculum did not provide specific training and who engaged in more religious practices (Hekima-Sante University, Senegal). Conclusions In cultures where religion not only influences the spiritual dimension of the individual, but acts in the ethical and moral system and consequently in the economic, educational and family sphere, the accompaniment at the end of life transcends the formative plane. Considering the plural society in which we live, the training that integrates the Degree in Nursing with regard to the care of the final process, must be multidimensional in which spirituality and faith are integrated, working emotional and attentional skills, as well as cultural competence strategies in this process.	[Begona Garcia-Navarro, E.; Araujo-Hernandez, Miriam; Jesus Rojas-Ocana, Maria] Univ Huelva, Dept Nursing & Hlth Sci, Huelva, Spain; [Begona Garcia-Navarro, E.] Univ Huelva, Ctr Res Contemporary Thought & Innovat Dev COIDES, Social Studies & Social Intervent, Res Grp ESEIS, Huelva, Spain; [Rigabert, Alina] Andalusia Beturia Fdn Hlth Res FABIS, Methodol & Data Anal Dept, Huelva, Spain	Universidad de Huelva; Universidad de Huelva	Araujo-Hernandez, M (corresponding author), Univ Huelva, Dept Nursing & Hlth Sci, Huelva, Spain.	mirian.araujo@denf.uhu.es	Rojas Ocaña, María Jesús/AAE-1739-2020; Garcia-Navarro, E. Begoña/ABH-3242-2020; Sánchez-Junco, Alina Rigabert/O-4706-2019	Rojas Ocaña, María Jesús/0000-0003-1781-4548; Garcia-Navarro, E. Begoña/0000-0001-6913-8882; Sánchez-Junco, Alina Rigabert/0000-0003-2121-7623; Araujo Hernandez, Miriam/0000-0001-8830-6749				Ahaddour C, 2018, J RELIG HEALTH, V57, DOI 10.1007/s10943-017-0466-1; Beauvais AM, 2019, J PSYCHIATR NURS, V10, P103, DOI 10.14744/phd.2019.96636; Brunet RC, 2003, INVESTIGACION SALUD, V2; BUGEN LA, 1980, OMEGA-J DEATH DYING, V11, P175, DOI 10.2190/JQPA-QFHW-VQ7A-MCAK; Cantin B, 2009, INFOKARA, V24, P3, DOI [10.3917/inka.091.0003, DOI 10.3917/INKA.091.0003]; Magana EC, 2018, INNOEDUCA, V4, P62, DOI 10.24310/innoeduca.2018.v4i1.4129; Da Silva Catela L, 2019, REV M ESTUDOS MORTE, V2, P45; de Dios Duarte María José, 2019, Educ Med Super, V33, pe1375; De la Rica M, 2020, MED PALIAT, V27, P181, DOI [10.20986/medpal.2020.1162/2020, DOI 10.20986/MEDPAL.2020.1162/2020]; El Bouchaibi Dali I, 2013, MED PALIATIVA, V20, P46; Estevan MDG, 2017, ATEN PRIM, V49, P549, DOI 10.1016/j.aprim.2016.10.013; Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6; Henry M, 2018, J PALLIAT MED, V21, pS68, DOI 10.1089/jpm.2017.0603; Garcia-Avendano DJ, 2018, DUAZARY, V15, P281, DOI 10.21676/2389783X.2421; Kim GD, 2016, ASIAN ONCOL NURS, V16, P176, DOI 10.5388/aon.2016.16.4.176; Lince-Rivera Isabella, 2018, Univ. Med., V59, P87, DOI 10.11144/javeriana.umed59-4.isla; Lopera-Betancur M.A., 2015, Enferm. univ, V12, P73, DOI 10.1016/j.reu.2015.04.002; Nkengasong JN, 2020, LANCET, V395, P841, DOI 10.1016/S0140-6736(20)30464-5; Nunez-Alarcon M., 2011, METODOLOGIA ENCUESTA, V13, P97; Parry M, 2011, INT J PALLIAT NURS, V17, P448, DOI 10.12968/ijpn.2011.17.9.448; Perez Sales P., 2000, PSIQUIATRIA PUBLICA, V12, P259; Perez-de la Cruz S, 2020, BMC PALLIAT CARE, V19, P1, DOI [10.1186/s12904-019-0499-1, DOI 10.1186/S12904-019-0499-1]; Perez-de la Cruz S, 2018, NURS HEALTH SCI, V20, P380, DOI 10.1111/nhs.12417; Sarmiento JCA, 2019, CULT CUID, P310; Schmidt Rio Valle J, 2007, THESIS; Sharif SP, 2018, SUPPORT CARE CANCER, V26, P2571, DOI 10.1007/s00520-018-4088-2; Stroebe M, 2017, ESTUD PSICOL-MADRID, V38, P582, DOI 10.1080/02109395.2017.1340055; Teno JM, 2018, J PALLIAT MED, V21, pS81, DOI 10.1089/jpm.2017.0583; Teno JM, 2017, HEALTH AFFAIR, V36, P1227, DOI 10.1377/hlthaff.2017.0161; Thiemann P, 2015, J PAIN SYMPTOM MANAG, V50, P335, DOI 10.1016/j.jpainsymman.2015.03.014; Tomas-Sabado J., 2004, EUR J PSYCHOL ASSESS, V14, P328, DOI [10.1080/07481180590906174, DOI 10.1080/07481180590906174]; Trivate T, 2019, BMC MED EDUC, V19, DOI 10.1186/s12909-019-1871-9; Vogel L, 2011, CAN MED ASSOC J, V183, P418, DOI 10.1503/cmaj.109-3788; Welch LC, 2005, J AM GERIATR SOC, V53, P1145, DOI 10.1111/j.1532-5415.2005.53357.x; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548; Zheng RS, 2021, J ADV NURS, V77, P795, DOI 10.1111/jan.14621; 양승애, 2016, [Journal of the Korea Convergence Society, 한국융합학회논문지], V7, P141	37	0	0	7	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0254870	10.1371/journal.pone.0254870	http://dx.doi.org/10.1371/journal.pone.0254870			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UC9GQ	34415902	gold, Green Published			2023-01-03	WOS:000686828600029
J	Gonzalez-Rincon, J; Garcia-Vela, JA; Gomez, S; Fernandez-Cuevas, B; Nova-Gurumeta, S; Perez-Sanz, N; Alcoceba, M; Gonzalez, M; Anguita, E; Lopez-Jimenez, J; Gonzalez-Barca, E; Yanez, L; Perez-Persona, E; de la Serna, J; Fernaadez-Zarzoso, M; Deben, G; Penalver, FJ; Fernandez, MC; de Oteyza, JP; Andreu, MA; Ruiz-Guinaldo, MA; Paz-Arias, R; Garcia-Malo, MD; Recasens, V; Collado, R; Cordoba, R; Navarro-Matilla, B; Sanchez-Beato, M; Garcia-Marco, JA				Gonzalez-Rincon, Julia; Garcia-Vela, Jose A.; Gomez, Sagrario; Fernandez-Cuevas, Belen; Nova-Gurumeta, Sara; Perez-Sanz, Nuria; Alcoceba, Miguel; Gonzalez, Marcos; Anguita, Eduardo; Lopez-Jimenez, Javier; Gonzalez-Barca, Eva; Yanez, Lucrecia; Perez-Persona, Ernesto; de la Serna, Javier; Fernandez-Zarzoso, Miguel; Deben, Guillermo; Penalver, Francisco J.; Fernandez, Maria C.; de Oteyza, Jaime Perez; Andreu, M. angeles; Ruiz-Guinaldo, M. angeles; Paz-Arias, Raquel; Garcia-Malo, M. Dolores; Recasens, Valle; Collado, Rosa; Cordoba, Raul; Navarro-Matilla, Belen; Sanchez-Beato, Margarita; Garcia-Marco, Jose A.			Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)	PLOS ONE			English	Article							RECURRENT MUTATIONS; CLINICAL IMPACT; CODING GENOME; CLL; FLUDARABINE; NOTCH1; SURVIVAL; SF3B1; TP53; CYCLOPHOSPHAMIDE	Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in recent years by next-generation sequencing. These studies have identified recurrent somatic mutations in NOTCH1, SF3B1, ATM, TP53, BIRC3 and others genes that play roles in cell cycle, DNA repair, RNA metabolism and splicing. In this study, we have taken a deep-targeted massive sequencing approach to analyze the impact of mutations in the most frequently mutated genes in patients with CLL enrolled in the REM (rituximab en mantenimiento) clinical trial. The mutational status of our patients with CLL, except for the TP53 gene, does not seem to affect the good results obtained with maintenance therapy with rituximab after front-line FCR treatment.	[Gonzalez-Rincon, Julia; Gomez, Sagrario; Sanchez-Beato, Margarita] Inst Invest Sanitaria Puerta de Hierro Segovia de, Lymphoma Res Grp, Madrid, Spain; [Gonzalez-Rincon, Julia; Alcoceba, Miguel; Gonzalez, Marcos; Sanchez-Beato, Margarita] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Garcia-Vela, Jose A.] Hosp Univ Getafe, Hematol Dept, Madrid, Spain; [Fernandez-Cuevas, Belen; Nova-Gurumeta, Sara; Perez-Sanz, Nuria; Navarro-Matilla, Belen; Garcia-Marco, Jose A.] Hosp Univ Puerta de Hierro, Hematol Dept, Madrid, Spain; [Fernandez-Cuevas, Belen; Nova-Gurumeta, Sara; Perez-Sanz, Nuria; Navarro-Matilla, Belen; Garcia-Marco, Jose A.] Inst Invest Sanitaria Puerta de Hierro Segovia de, Madrid, Spain; [Alcoceba, Miguel; Gonzalez, Marcos] Hosp Univ Salamanca, Hematol, Salamanca, Spain; [Anguita, Eduardo] UCM, IdISSC, Hosp Clin San Carlos, Hematol, Madrid, Spain; [Lopez-Jimenez, Javier] Hosp Ramon & Cajal, Hematol, Madrid, Spain; [Gonzalez-Barca, Eva] Inst Catala Oncol, IDIBELL, Hematol, Lhospitalet De Llobregat, Spain; [Yanez, Lucrecia] Hosp Univ Marques de Valdecilla, Hematol, Santander, Spain; [Perez-Persona, Ernesto] Hosp Txagorritxu, Hematol, Vitoria, Spain; [de la Serna, Javier] Hosp Doce Octubre, Hematol, Madrid, Spain; [Fernandez-Zarzoso, Miguel] Hosp Univ Dr Peset, Hematol, Valencia, Spain; [Deben, Guillermo] CHU Juan Canalejo, Hematol, La Coruna, Spain; [Penalver, Francisco J.] Fdn Hosp Alcorcon, Hematol, Madrid, Spain; [Fernandez, Maria C.] Hosp Univ Puerta del Mar, Hematol, Cadiz, Spain; [de Oteyza, Jaime Perez] Hosp Madrid Norte Sanchinarro, Hematol, Madrid, Spain; [Andreu, M. angeles] Hosp Gen Mostoles, Hematol, Madrid, Spain; [Ruiz-Guinaldo, M. angeles] Hosp Francesc Borja, Hematol, Valencia, Spain; [Paz-Arias, Raquel] Hosp Univ La Paz, Hematol, Madrid, Spain; [Garcia-Malo, M. Dolores] Hosp Morales Meseguer, Hematol, Murcia, Spain; [Recasens, Valle] Hosp Miguel Servet, Hematol, Zaragoza, Spain; [Collado, Rosa] Consorcio Hosp Gen Univ, Citogenet & Mol Biol Lab, Valencia, Spain; [Cordoba, Raul] Hosp Fdn Jimenez Diaz, Hematol, Madrid, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Hospital Universitario de Getafe; Hospital Puerta de Hierro-Majadahonda; Complutense University of Madrid; Hospital Clinico San Carlos; Hospital Universitario Ramon y Cajal; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Universitario Marques de Valdecilla (HUMV); University Hospital of Araba; Hospital Universitario 12 de Octubre; Complejo Hospitalario Universitario A Coruna; Alcorcon Foundation University Hospital; Universidad de Cadiz; Hospital Universitario Puerta del Mar; Hospital Universitario La Paz; Miguel Servet University Hospital	Sanchez-Beato, M (corresponding author), Inst Invest Sanitaria Puerta de Hierro Segovia de, Lymphoma Res Grp, Madrid, Spain.; Sanchez-Beato, M (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.; Garcia-Marco, JA (corresponding author), Hosp Univ Puerta de Hierro, Hematol Dept, Madrid, Spain.; Garcia-Marco, JA (corresponding author), Inst Invest Sanitaria Puerta de Hierro Segovia de, Madrid, Spain.	msbeato@idiphim.org; jagarciam@aehh.org	Collado Nieto, Rosa María/GZK-9557-2022; Sanchez-Beato, Margarita/G-8753-2012; Alcoceba, Miguel/GXH-4002-2022; Alcoceba, Miguel/AAH-2784-2020; Anguita, Eduardo/AAA-2097-2019	Sanchez-Beato, Margarita/0000-0002-0058-7599; Alcoceba, Miguel/0000-0002-3819-4846; Anguita, Eduardo/0000-0003-1386-4943; Collado, Rosa/0000-0002-8205-6192; Perez Persona, Ernesto/0000-0002-2082-4213; PEREZ DE OTEYZA, JAIME/0000-0002-8338-2037	Instituto de Salud Carlos III (ISCII) of the Spanish Ministry of Economy and Competence (MINECO) ISCIII-MINECO AES-FEDER [RD12/0036/0060, PI14/00221, PIE14/0064, PI17/00272, CB16/12/00291, CB16/12/00233]; Comunidad Autonoma de Madrid [B2017/BMD3778]; Fundacion de la Asociacion Espanola Contra el Cancer; Roche Farma, S.A., Madrid, Spain; iPFIS predoctoral fellowship [IFI14/00003]; ISCIII-MINECO AES-FEDER (Plan Estatal I+D+I 2013-2016) [CPII16/00024]; Fundacion de Investigacion Biomedica Puerta de Hierro	Instituto de Salud Carlos III (ISCII) of the Spanish Ministry of Economy and Competence (MINECO) ISCIII-MINECO AES-FEDER; Comunidad Autonoma de Madrid(Comunidad de Madrid); Fundacion de la Asociacion Espanola Contra el Cancer; Roche Farma, S.A., Madrid, Spain; iPFIS predoctoral fellowship; ISCIII-MINECO AES-FEDER (Plan Estatal I+D+I 2013-2016); Fundacion de Investigacion Biomedica Puerta de Hierro	This work was supported by the Instituto de Salud Carlos III (ISCII) of the Spanish Ministry of Economy and Competence (MINECO) ISCIII-MINECO AES-FEDER (Plan Estatal de I+D+I 2008-2011 and 2013-2016 https://www.isciii.es/QueHacemos/Financiacion/Paginas/Accion-Estrategica-en-Salud.aspx) (MSB: RD12/0036/0060, PI14/00221, PIE14/0064, PI17/00272; MSB and JGR: CIBERONC CB16/12/00291, MA and MG: CB16/12/00233), Comunidad Auto ' noma de Madrid (https://www.comunidad.madrid/servicios/educacion/convocatorias-ayudas-investigacion) (MSB: B2017/BMD3778), MSB: Fundacion de la Asociacion Espanola Contra el Cancer (https://www.aecc.es/es/investigacion/fundacion-cientificaaecc) and JAGM: Roche Farma, S.A., Madrid, Spain. JGR was a recipient of an iPFIS predoctoral fellowship (IFI14/00003) and MSB held a Miguel Servet II contract (CPII16/00024), supported by ISCIII-MINECO AES-FEDER (Plan Estatal I+D+I 2013-2016) and the Fundacion de Investigacion Biomedica Puerta de Hierro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benedetti D, 2018, LEUKEMIA, V32, P654, DOI 10.1038/leu.2017.296; Blakemore SJ, 2020, LEUKEMIA, V34, P1760, DOI 10.1038/s41375-020-0723-2; Bottcher S, 2012, J CLIN ONCOL, V30, P980, DOI 10.1200/JCO.2011.36.9348; Bradburn MJ, 2003, BRIT J CANCER, V89, P605, DOI 10.1038/sj.bjc.6601120; Burns A, 2018, LEUKEMIA, V32, P573, DOI 10.1038/leu.2017.311; Damm F, 2014, CANCER DISCOV, V4, P1088, DOI 10.1158/2159-8290.CD-14-0104; Domenech E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038158; Fabbri G, 2011, J EXP MED, V208, P1389, DOI 10.1084/jem.20110921; Fischer K, 2019, NEW ENGL J MED, V380, P2225, DOI 10.1056/NEJMoa1815281; Fischer K, 2016, BLOOD, V127, P208, DOI 10.1182/blood-2015-06-651125; Garcia-Marco JA, 2019, HAEMATOLOGICA, V104, P2249, DOI 10.3324/haematol.2018.204891; Guieze R, 2015, BLOOD, V126, P2110, DOI 10.1182/blood-2015-05-647578; Guieze R, 2015, BLOOD, V126, P445, DOI 10.1182/blood-2015-02-585042; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Kater AP, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.00948; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; Ljungstrom V, 2016, BLOOD, V127, P1007, DOI 10.1182/blood-2015-10-674572; Nadeu F, 2016, BLOOD, V127, P2122, DOI 10.1182/blood-2015-07-659144; Perez C, 2015, HAEMATOLOGICA, V100, pE450, DOI 10.3324/haematol.2015.132837; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rosenquist R, 2017, LEUKEMIA, V31, P1477, DOI 10.1038/leu.2017.125; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Rossi D, 2015, BLOOD, V126, P1921, DOI 10.1182/blood-2015-05-647925; Rossi D, 2012, J EXP MED, V209, P1537, DOI 10.1084/jem.20120904; Rossi D, 2012, BLOOD, V119, P2854, DOI 10.1182/blood-2011-12-395673; Schnaiter A, 2013, BLOOD, V122, P1266, DOI 10.1182/blood-2013-03-488197; Shanafelt TD, 2019, NEW ENGL J MED, V381, P432, DOI 10.1056/NEJMoa1817073; Stilgenbauer S, 2014, BLOOD, V123, P3247, DOI 10.1182/blood-2014-01-546150; Thompson PA, 2016, BLOOD, V127, P303, DOI 10.1182/blood-2015-09-667675; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016	33	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257353	10.1371/journal.pone.0257353	http://dx.doi.org/10.1371/journal.pone.0257353			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9EM	34506616	Green Published, gold			2023-01-03	WOS:000729120700073
J	Rummun, N; Serag, A; Rondeau, P; Ramsaha, S; Bourdon, E; Bahorun, T; Farag, MA; Neergheen, VS				Rummun, Nawraj; Serag, Ahmed; Rondeau, Philippe; Ramsaha, Srishti; Bourdon, Emmanuel; Bahorun, Theeshan; Farag, Mohamed A.; Neergheen, Vidushi S.			Antiproliferative activity of Syzygium coriaceum, an endemic plant of Mauritius, with its UPLC-MS metabolite fingerprint: A mechanistic study	PLOS ONE			English	Article							APOPTOTIC INDUCTION; MASS-SPECTROMETRY; PHENOLIC CONTENTS; ANTIOXIDANT; EXTRACT; CELLS; CLASSIFICATION; MYRTACEAE; ARREST	Flowering plants from the Syzygium genus have long been used in different ethnomedicinal systems worldwide and have been under scrutiny for their biological activities. Syzygium coriaceum, an endemic plant of Mauritius has been poorly studied for its potential application against cancer. Herein, Syzygium coriaceum leaf extract has been investigated for its anticancer effect against hepatocellular carcinoma (HepG2) cells. The anticancer activity was assessed using cell proliferation assays, flow cytometry, JC-1 mitochondrial membrane potential assay, and the COMET assay. Un-targeted metabolite profiling via ultra-performance liquid chromatography coupled to high-resolution qTOF-MS (UPLC-MS) and aided by molecular networking was employed to identify the crude extract metabolites. S. coriaceum treatment induced a dose-dependent increase in lactate dehydrogenase leakage into the culture media, peaking up to 47% (p <= 0.0001), compared to untreated control. Moreover, at 40 mu g/mL, S. coriaceum led to 88.1% (p <= 0.0001) drop in mitochondrial membrane potential and 5.7% (p <= 0.001) increased in the number of the cell population in G0/G1 phase as well as increased (p < 0.05) the proportion of cells undergoing apoptotic/necrotic cell death. More so, at 10 mu g/mL, S. coriaceum induced DNA damage which was 19 folds (p < 0.001) higher than that of untreated control cells. Metabolite profiling indicated the presence of 65 metabolites, out of which 59 were identified. Tannins, flavonoids, nitrogenous compounds, and organic acids were the most predominant classes of compounds detected. Our findings showed that the presence of tannins and flavonoids in S. coriaceum leaf extract could account for the multiple mechanisms of actions underlying the antiproliferative effect against HepG2 cells.	[Rummun, Nawraj; Ramsaha, Srishti] Univ Mauritius, Fac Med & Hlth Sci, Dept Hlth Sci, Reduit, Mauritius; [Rummun, Nawraj; Ramsaha, Srishti; Bahorun, Theeshan; Neergheen, Vidushi S.] Univ Mauritius, Ctr Biomed & Biomat Res, Biopharmaceut Unit, MSIRI Bldg, Reduit, Mauritius; [Serag, Ahmed] Al Azhar Univ, Fac Pharm, Analyt Chem Dept, Cairo, Egypt; [Rondeau, Philippe; Bourdon, Emmanuel] Univ La Reunion, UMR 1188 Diabet Atherothrombose Therapies Reunion, INSERM, St Denis De La Reunion, France; [Farag, Mohamed A.] Cairo Univ, Coll Pharm, Pharmacognosy Dept, Kasr el Aini St, Cairo, Egypt; [Farag, Mohamed A.] Amer Univ Cairo, Sch Sci & Engn, Chem Dept, New Cairo, Egypt	University of Mauritius; University of Mauritius; Egyptian Knowledge Bank (EKB); Al Azhar University; Institut National de la Sante et de la Recherche Medicale (Inserm); University of La Reunion; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); American University Cairo	Neergheen, VS (corresponding author), Univ Mauritius, Ctr Biomed & Biomat Res, Biopharmaceut Unit, MSIRI Bldg, Reduit, Mauritius.; Farag, MA (corresponding author), Cairo Univ, Coll Pharm, Pharmacognosy Dept, Kasr el Aini St, Cairo, Egypt.; Farag, MA (corresponding author), Amer Univ Cairo, Sch Sci & Engn, Chem Dept, New Cairo, Egypt.	mohamed.alifarag@aucegypt.edu; v.neergheen@uom.ac.mu	Serag, Ahmed/O-1836-2019	Serag, Ahmed/0000-0003-1559-8079	Mauritius Research and Innovation Council under the National Research and Innovation Chair Program; Alexander von Humboldt Foundation, Germany	Mauritius Research and Innovation Council under the National Research and Innovation Chair Program; Alexander von Humboldt Foundation, Germany(Alexander von Humboldt Foundation)	This study was supported by the Mauritius Research and Innovation Council under the National Research and Innovation Chair Program studentship awarded to NR. MAF acknowledges the financial support received from the Alexander von Humboldt Foundation, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Dabbagh B, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2285-7; Augustine D, 2019, TOXICOL REP, V6, P347, DOI 10.1016/j.toxrep.2019.04.005; Benhusein GM, 2010, LIBYAN J MED, V5, DOI 10.3402/ljm.v5i0.4637; Byng JW, 2015, PHYTOKEYS, V46, P61, DOI 10.3897/phytokeys.46.9039; Catan A, 2019, ATHEROSCLEROSIS, V291, P87, DOI 10.1016/j.atherosclerosis.2019.10.015; Chambers MC, 2012, NAT BIOTECHNOL, V30, P918, DOI 10.1038/nbt.2377; Choi MK, 2020, J PHARM INVEST, V50, P295, DOI 10.1007/s40005-020-00475-y; Chua LK, 2019, PLANT FOOD HUM NUTR, V74, P18, DOI 10.1007/s11130-018-0704-z; Elkady AI, 2017, J BIOMATER TISS ENG, V7, P1235, DOI 10.1166/jbt.2017.1695; Farag MA, 2016, J PHARMACEUT BIOMED, V125, P292, DOI 10.1016/j.jpba.2016.03.037; Farag MA, 2015, PHYTOCHEMISTRY, V119, P41, DOI 10.1016/j.phytochem.2015.09.004; Inbathamizh L., 2017, ASIAN J PHARM CLIN R, V6, P106; Jugreet BS, 2021, CHEM BIODIVERS, V18, DOI 10.1002/cbdv.202000921; Kwan YP, 2016, PHARM BIOL, V54, P1223, DOI 10.3109/13880209.2015.1064451; Lee SY, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3537471; Li J, 2019, FOOD AGR IMMUNOL, V30, P898, DOI 10.1080/09540105.2019.1642857; Mahassni SH, 2013, SAUDI J BIOL SCI, V20, P131, DOI 10.1016/j.sjbs.2012.12.002; Mahomoodally MF, 2020, IND CROP PROD, V143, DOI 10.1016/j.indcrop.2019.111948; Menyhart O, 2016, BBA-REV CANCER, V1866, P300, DOI 10.1016/j.bbcan.2016.10.002; Mery Benoite, 2017, J Cell Death, V10, p1179670717691251, DOI 10.1177/1179670717691251; Miyaji CK, 2004, GENET MOL BIOL, V27, P108, DOI 10.1590/S1415-47572004000100018; Moreira H, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6793957; Nagano T, 2016, SCI REP-UK, V6, DOI 10.1038/srep31758; Neergheen V., 2011, U MAURITIUS RES J, V17; Neergheen VS, 2007, PHARM BIOL, V45, P9, DOI 10.1080/13880200601026242; Neergheen VS, 2006, J PLANT PHYSIOL, V163, P787, DOI 10.1016/j.jplph.2005.09.009; Ramlagan P, 2017, FOOD FUNCT, V8, P4194, DOI [10.1039/c7fo01038a, 10.1039/C7FO01038A]; Ramos AEF, 2019, NAT PROD REP, V36, P960, DOI 10.1039/c9np00006b; Ranzato E., 2014, Journal of Food Research, V3, P18; Rocchetti G, 2019, FOOD RES INT, V126, DOI 10.1016/j.foodres.2019.108715; Rummun N, 2021, S AFR J BOT, V137, P149, DOI 10.1016/j.sajb.2020.10.014; Rummun N, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13100303; Rummun N, 2018, J ETHNOPHARMACOL, V213, P111, DOI 10.1016/j.jep.2017.10.006; Rummun Nawraj, 2013, Int J Food Sci, V2013, P602312, DOI 10.1155/2013/602312; Salem MA, 2020, METABOLITES, V10, DOI 10.3390/metabo10010037; Serag A, 2020, RSC ADV, V10, P76, DOI 10.1039/c9ra07841j; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sobeh M, 2018, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2018.00566; Sobeh M, 2018, J FUNCT FOODS, V41, P223, DOI 10.1016/j.jff.2017.12.055; Sobeh M, 2018, FOOD CHEM TOXICOL, V113, P145, DOI 10.1016/j.fct.2018.01.031; Toyokuni S, 2003, FREE RADICAL RES, V37, P1215, DOI 10.1080/10715760310001598150; Wang MX, 2016, NAT BIOTECHNOL, V34, P828, DOI 10.1038/nbt.3597; Wen XY, 2009, PHYTOTHER RES, V23, P778, DOI 10.1002/ptr.2616; WHO, 2013, WORLD MALARIA REPORT 2013, P1; Willis KJ, 2017, STATE WORLDS PLANTS; Yeh RD, 2011, ANTICANCER RES, V31, P2821; Yurdakok B, 2013, PHARM BIOL, V51, P1579, DOI 10.3109/13880209.2013.803208	47	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	6							e0252276	10.1371/journal.pone.0252276	http://dx.doi.org/10.1371/journal.pone.0252276			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SL3JC	34061874	Green Published, gold			2023-01-03	WOS:000656813600052
J	Sun, YJ; Liu, Y; Liu, BY; Zhou, KH; Yue, ZH; Zhang, W; Fu, WB; Yang, J; Li, N; He, LY; Zang, ZW; Su, TS; Fang, JQ; Ding, YL; Qin, ZS; Song, HJ; Hu, H; Zhao, H; Mo, Q; Zhou, J; Wu, JN; Liu, XX; Wang, WM; Pang, R; Chen, H; Wang, XL; Liu, ZS				Sun, Yuanjie; Liu, Yan; Liu, Baoyan; Zhou, Kehua; Yue, Zenghui; Zhang, Wei; Fu, Wenbin; Yang, Jun; Li, Ning; He, Liyun; Zang, Zhiwei; Su, Tongsheng; Fang, Jianqiao; Ding, Yulong; Qin, Zongshi; Song, Hujie; Hu, Hui; Zhao, Hong; Mo, Qian; Zhou, Jing; Wu, Jiani; Liu, Xiaoxu; Wang, Weiming; Pang, Ran; Chen, Huan; Wang, Xinlu; Liu, Zhishun			Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							SYMPTOM INDEX; DOUBLE-BLIND; MEN; ELECTROACUPUNCTURE; MULTICENTER; ALFUZOSIN; DIAGNOSIS; SHAM	Background: Acupuncture has promising effects on chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), but high-quality evidence is scarce. Objective: To assess the long-term efficacy of acupuncture for CP/CPPS. Design: Multicenter, randomized, sham-controlled trial. (Clinical Trials.gov: NCT03213938) Setting: Ten tertiary hospitals in China. Participants: Men with moderate to severe CP/CPPS, regardless of prior exposure to acupuncture. Intervention: Twenty sessions of acupuncture or sham acupuncture over 8 weeks, with 24-week follow-up after treatment. Measurements: The primary outcome was the proportion of responders, defined as participants who achieved a clinically important reduction of at least 6 points from baseline on the National Institutes of Health Chronic Prostatitis Symptom Index at weeks 8 and 32. Ascertainment of sustained efficacy required the between-group difference to be statistically significant at both time points. Results: A total of 440 men (220 in each group) were recruited. At week 8, the proportions of responders were 60.6% (95% CI, 53.7% to 67.1%) in the acupuncture group and 36.8% (CI, 30.4% to 43.7%) in the sham acupuncture group (adjusted difference, 21.6 percentage points [CI, 12.8 to 30.4 percentage points]; adjusted odds ratio, 2.6 [CI, 1.8 to 4.0]; P < 0.001). At week 32, the proportions were 61.5% (CI, 54.5% to 68.1%) in the acupuncture group and 38.3% (CI, 31.7% to 45.4%) in the sham acupuncture group (adjusted difference, 21.1 percentage points [CI, 12.2 to 30.1 percentage points]; adjusted odds ratio, 2.6 [CI, 1.7 to 3.9]; P < 0.001). Twenty (9.1%) and 14 (6.4%) adverse events were reported in the acupuncture and sham acupuncture groups, respectively. No serious adverse events were reported. Limitation: Sham acupuncture might have had certain physiologic effects. Conclusion: Compared with sham therapy, 20 sessions of acupuncture over 8 weeks resulted in greater improvement in symptoms of moderate to severe CP/CPPS, with durable effects 24 weeks after treatment.	[Sun, Yuanjie; Liu, Baoyan; Qin, Zongshi; Zhou, Jing; Wu, Jiani; Liu, Xiaoxu; Wang, Weiming; Pang, Ran; Chen, Huan; Wang, Xinlu; Liu, Zhishun] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing, Peoples R China; [Liu, Yan] Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med, Minist Educ, Beijing, Peoples R China; [Zhou, Kehua] ThedaCare Reg Med Ctr Appleton, Appleton, WI USA; [Yue, Zenghui] Hunan Univ Chinese Med, Hengyang Hosp Affiliated, Hengyang, Peoples R China; [Zhang, Wei] Hunan Univ Chinese Med, Hosp 1, Changsha, Guangzhou, Peoples R China; [Fu, Wenbin] Guangdong Prov Hosp Tradit Chinese Med, Guangzhou, Peoples R China; [Yang, Jun] Anhui Univ Chinese Med, Affiliated Hosp 1, Hefei, Peoples R China; [Li, Ning] Sichuan Univ, West China Hosp, Chengdu, Peoples R China; [He, Liyun] China Acad Chinese Med Sci, Beijing, Peoples R China; [Zang, Zhiwei] Yantai Hosp Tradit Chinese Med, Yantai, Peoples R China; [Su, Tongsheng] Shaanxi Prov Hosp Tradit Chinese Med, Xian, Peoples R China; [Fang, Jianqiao] Zhejiang Chinese Med Univ, Affiliated Hosp 3, Hangzhou, Peoples R China; [Ding, Yulong] Beijing Fengtai Hosp Integrated Tradit & Western, Beijing, Peoples R China; [Song, Hujie] Xian TCM Brain Dis Hosp, Xian, Peoples R China; [Hu, Hui] Beijing Univ Chinese Med, Dongfang Hosp, Beijing, Peoples R China; [Zhao, Hong] Tradit Chinese Med, Luohu Dist Hosp, Shenzhen, Peoples R China; [Zhao, Hong] Guizhou Univ Tradit Chinese Med, Guiyang, Peoples R China	China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; Beijing University of Chinese Medicine; Hunan University of Chinese Medicine; Hunan University of Chinese Medicine; Guangzhou University of Chinese Medicine; Anhui University of Chinese Medicine; Sichuan University; China Academy of Chinese Medical Sciences; Zhejiang Chinese Medical University; Beijing University of Chinese Medicine; Guizhou University of Traditional Chinese Medicine	Liu, ZS (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Beijing, Peoples R China.; Liu, ZS (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Dept Acupuncture & Moxibust, 5 Beixiange St, Beijing 100053, Peoples R China.	zhishunjournal@163.com		Fang, Jianqiao/0000-0002-5155-8544	China Academy of Chinese Medical Sciences [ZZ10-012]; National Administration of Traditional Chinese Medicine [2019XZZX-ZJ]	China Academy of Chinese Medical Sciences(Chinese Academy of Sciences); National Administration of Traditional Chinese Medicine	By the China Academy of Chinese Medical Sciences through the First Batch of Key Research Program in the 13th Five-Year Plan (no. ZZ10-012) and the National Administration of Traditional Chinese Medicine through the Project of Building Evidence-Based Practice Capacity for TCM 2019-Project BEBPC-TCM(no. 2019XZZX-ZJ).	Alexander RB, 2004, ANN INTERN MED, V141, P581, DOI 10.7326/0003-4819-141-8-200410190-00005; Bang HJ, 2004, CONTROL CLIN TRIALS, V25, P143, DOI 10.1016/j.cct.2003.10.016; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; Birch S, 2006, J ALTERN COMPLEM MED, V12, P303, DOI 10.1089/acm.2006.12.303; Chang SC, 2017, NEUROUROL URODYNAM, V36, P474, DOI 10.1002/nau.22958; Chen Y, 2011, WORLD J UROL, V29, P381, DOI 10.1007/s00345-010-0537-3; Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65; Collins MM, 2001, J GEN INTERN MED, V16, P656; Engeler D., 2021, EAU GUIDELINES CHRON; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Franco JVA, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012552.pub2; Franco JVA, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012551.pub3; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Han JS, 2011, PAIN, V152, pS41, DOI 10.1016/j.pain.2010.10.012; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Jackson T, 2015, LANCET, V385, P10, DOI 10.1016/S0140-6736(15)60805-4; Krieger JN, 2003, WORLD J UROL, V21, P70, DOI 10.1007/s00345-003-0329-0; Krieger JN, 1999, JAMA-J AM MED ASSOC, V282, P236, DOI 10.1001/jama.282.3.236; Lee JH, 2006, AM J CHINESE MED, V34, P981, DOI 10.1142/S0192415X06004454; Lee SH, 2009, UROLOGY, V73, P1036, DOI 10.1016/j.urology.2008.10.047; Lee SWH, 2011, ACUPUNCT MED, V29, P40, DOI 10.1136/aim.2010.003137; Lee SWH, 2008, AM J MED, V121, DOI 10.1016/j.amjmed.2007.07.033; Litwin MS, 1999, J UROLOGY, V162, P369, DOI 10.1016/S0022-5347(05)68562-X; Lund Irene, 2006, Acupunct Med, V24, P13; Luo N, 2017, VALUE HEALTH, V20, P662, DOI 10.1016/j.jval.2016.11.016; MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747; Mehik A, 2003, UROLOGY, V62, P425, DOI 10.1016/S0090-4295(03)00466-7; Nickel JC, 2006, J UROLOGY, V176, P119, DOI 10.1016/S0022-5347(06)00498-8; Nickel JC, 2020, BJU INT, V125, P479, DOI 10.1111/bju.15036; Nickel JC, 2008, NEW ENGL J MED, V359, P2663, DOI 10.1056/NEJMoa0803240; Nickel JC, 2003, UROLOGY, V62, P614, DOI 10.1016/S0090-4295(03)00583-1; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202; Propert KJ, 2006, QUAL LIFE RES, V15, P299, DOI 10.1007/s11136-005-1317-1; Qin ZS, 2018, J UROLOGY, V200, P815, DOI 10.1016/j.juro.2018.05.001; Qin ZS, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2383-8; Rees J, 2015, BJU INT, V116, P509, DOI 10.1111/bju.13101; Rosen RC, 1999, INT J IMPOT RES, V11, P319, DOI 10.1038/sj.ijir.3900472; Sahin S, 2015, PROSTATE CANCER P D, V18, P249, DOI 10.1038/pcan.2015.13; Shahed AR, 2001, J UROLOGY, V166, P1738, DOI 10.1016/S0022-5347(05)65664-9; Spaliviero M, 2010, J ENDOUROL, V24, P2051, DOI 10.1089/end.2010.0296; Wang HY, 2018, AM J CHINESE MED, V46, P1387, DOI 10.1142/S0192415X18500738; Wenninger K, 1996, J UROLOGY, V155, P965, DOI 10.1016/S0022-5347(01)66359-6; Zhang JZ, 2020, AM J MENS HEALTH, V14, DOI 10.1177/1557988320903200; Zhou KH, 2011, J ALTERN COMPLEM MED, V17, P1007, DOI 10.1089/acm.2010.0652; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	45	15	17	16	41	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT	2021	174	10					1357	+		10.7326/M21-1814	http://dx.doi.org/10.7326/M21-1814			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA9CB	34399062				2023-01-03	WOS:000720935700014
J	Cabezas, C; Coma, E; Mora-Fernandez, N; Li, XT; Martinez-Marcos, M; Fina, F; Fabregas, M; Hermosilla, E; Jover, A; Contel, JC; Lejardi, Y; Enfedaque, B; Argimon, JM; Medina-Peralta, M; Prieto-Alhambra, D				Cabezas, Carmen; Coma, Ermengol; Mora-Fernandez, Nuria; Li, Xintong; Martinez-Marcos, Montse; Fina, Francesc; Fabregas, Mireia; Hermosilla, Eduardo; Jover, Angel; Contel, Juan Carlos; Lejardi, Yolanda; Enfedaque, Belen; Argimon, Josep Maria; Medina-Peralta, Manuel; Prieto-Alhambra, Daniel			Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To determine associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 among nursing home residents, nursing home staff, and healthcare workers. DESIGN Prospective cohort study. SETTING Nursing homes and linked electronic medical record, test, and mortality data in Catalonia on 27 December 2020. PARTICIPANTS 28 456 nursing home residents, 26 170 nursing home staff, and 61 791 healthcare workers. MAIN OUTCOME MEASURES Participants were followed until the earliest outcome (confirmed SARS-CoV-2 infection, hospital admission or death with covid-19) or 26 May 2021. Vaccination status was introduced as a time varying exposure, with a 14 day run-in after the first dose. Mixed effects Cox models were fitted to estimate hazard ratios with index month as a fixed effect and adjusted for confounders including sociodemographics, comorbidity, and previous medicine use. RESULTS Among the nursing home residents, SARS-CoV-2 infection was found in 2482, 411 were admitted to hospital with covid-19, and 450 died with covid-19 during the study period. In parallel, 1828 nursing home staff and 2968 healthcare workers were found to have SARS-CoV-2 infection, but fewer than five were admitted or died with covid-19. The adjusted hazard ratio for SARS-CoV-2 infection after two doses of vaccine was 0.09 (95% confidence interval 0.08 to 0.11) for nursing home residents, 0.20 (0.17 to 0.24) for nursing home staff, and 0.13 (0.11 to 0.16) for healthcare workers. Adjusted hazard ratios for hospital admission and mortality after two doses of vaccine were 0.05 (0.04 to 0.07) and 0.03 (0.02 to 0.04), respectively, for nursing home residents. Nursing home staff and healthcare workers recorded insufficient events for mortality analysis. CONCLUSIONS Vaccination was associated with 80-91% reduction in SARS-CoV-2 infection in all three cohorts and greater reductions in hospital admissions and mortality among nursing home residents for up to five months. More data are needed on longer term effects of covid-19 vaccines.	[Cabezas, Carmen; Martinez-Marcos, Montse] Generalitat Catalunya, Dept Hlth, Publ Hlth Secretariat, Barcelona, Spain; [Coma, Ermengol; Mora-Fernandez, Nuria; Fina, Francesc; Fabregas, Mireia; Jover, Angel; Enfedaque, Belen; Medina-Peralta, Manuel] Generalitat Catalunya, Inst Catala Salut ICS, Direccio Assistencial Atencio Primaria & Comunita, Barcelona, Spain; [Li, Xintong; Prieto-Alhambra, Daniel] Univ Oxford, Ctr Stat Med, NDORMS, Oxford, England; [Lejardi, Yolanda] Generalitat Catalunya, Inst Catala Salut ICS, Barcelona, Spain; [Hermosilla, Eduardo] Univ Autonoma Barcelona, Idiap Jordi Gol, Barcelona, Spain; [Contel, Juan Carlos] Generalitat Catalunya, Dept Hlth, Chron Care Program, Integrated Hlth & Social Care Plan, Barcelona, Spain; [Argimon, Josep Maria] Generalitat Catalunya, Barcelona, Spain; [Prieto-Alhambra, Daniel] Erasmus MC, Dept Med Informat, Rotterdam, Netherlands	University of Oxford; Autonomous University of Barcelona; Erasmus University Rotterdam; Erasmus MC	Cabezas, C (corresponding author), Generalitat Catalunya, Dept Hlth, Publ Hlth Secretariat, Barcelona, Spain.	carmen.cabezas@gencat.cat	Hermosilla Pérez, Eduardo/AAC-4585-2022; Redon, Ermengol Coma/AAZ-7655-2020	Hermosilla Pérez, Eduardo/0000-0002-3031-0304; Redon, Ermengol Coma/0000-0001-8000-3321; Medina Peralta, Manuel/0000-0002-2791-5847; Li, Xintong/0000-0002-6872-5804; Fina, Francesc/0000-0001-7106-5635; Cabezas, Carmen/0000-0002-4291-0454	National Institute for Health Research (NIHR) UK [SRF-2018-11-ST2-004]; Oxford NIHR Biomedical Research Centre	National Institute for Health Research (NIHR) UK(National Institute for Health Research (NIHR)); Oxford NIHR Biomedical Research Centre(National Institute for Health Research (NIHR))	DPA received partial support from the National Institute for Health Research (NIHR) UK in the form of an NIHR Senior Research Fellowship (SRF-2018-11-ST2-004) and the Oxford NIHR Biomedical Research Centre. The funders had no role in considering the study design or in the collection, analysis, or interpretation of data, writing of the report, or decision to submit the article for publication.	Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Burn E, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21100-y; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Duarte-Salles Talita, 2020, medRxiv, DOI 10.1101/2020.10.29.20222083; European Centre for Disease Prevention and Control, COVID 19 SIT UPD EU; European Medicines Agency, 2021, COVID 19 VACC AUTH; Rada AG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1554; Garcia-Gil M Del Mar, 2011, Inform Prim Care, V19, P135; Garcia-Gil M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109706; Hall VJ, 2021, EFFECTIVENESS BNT162; Baena-Diez JM, 2018, HEART, V104, P119, DOI 10.1136/heartjnl-2017-311279; Morales DR, 2021, LANCET DIGIT HEALTH, V3, pe98, DOI 10.1016/S2589-7500(20)30289-2; Morciano M, 2021, BMC MED, V19, DOI 10.1186/s12916-021-01945-2; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prieto-Alhambra D, 2020, INT J EPIDEMIOL, V49, P1930, DOI 10.1093/ije/dyaa190; Nguyen TL, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0338-0; Vasileiou E, 2021, SSRN ELECT J; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; World Health Organization, WHO COR DIS COVID 19, P2021	20	27	27	4	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 18	2021	374								n1868	10.1136/bmj.n1868	http://dx.doi.org/10.1136/bmj.n1868			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD8OW	34407952	hybrid, Green Published			2023-01-03	WOS:000687463200004
J	Bicego, A; Monseur, J; Collinet, A; Donneau, AF; Fontaine, R; Libbrecht, D; Malaise, N; Nyssen, AS; Raaf, M; Rousseaux, F; Salamun, I; Staquet, C; Teuwis, S; Tomasella, M; Faymonville, ME; Vanhaudenhuyse, A				Bicego, Aminata; Monseur, Justine; Collinet, Alain; Donneau, Anne-Francoise; Fontaine, Robert; Libbrecht, Dominique; Malaise, Nicole; Nyssen, Anne-Sophie; Raaf, Melissa; Rousseaux, Floriane; Salamun, Irene; Staquet, Cecile; Teuwis, Sandrine; Tomasella, Marco; Faymonville, Marie-Elisabeth; Vanhaudenhuyse, Audrey			Complementary treatment comparison for chronic pain management: A randomized longitudinal study	PLOS ONE			English	Article							INSOMNIA SEVERITY INDEX; PATIENT-CENTERED CARE; HEALTH SURVEY SF-36; HYPNOSIS; EMPOWERMENT; VALIDATION; THERAPY; ANXIETY; MODEL; DEFINITION	Background In chronic pain, it seems that the effect of cognitive-behavioral therapy (CBT) is boosted when it is combined with hypnosis. The aim of this study was to assess the efficacy of self-hypnosis combined with self-care (i.e., a type of CBT) compared to music/self-care, self-care and psychoeducation/CBT and to evaluate their long-term effects. Methods An open label randomized clinical trial enrolled patients with chronic pain and was carried out at the University Hospital of Liege (Belgium). Patients were randomized into four groups: self-hypnosis/self-care, music/self-care, self-care, psychoeducation/CBT (7 monthly sessions of 2 hours). Two follow-up sessions were delivered at 6- and 12-month. Levels of pain, fatigue intensity, anxiety, depression, insomnia severity, disability, health locus of control, mental and physical quality of life and attitudes (control, disability, harm, emotion, medical cure, medication, solicitude) towards pain were assessed before and after the treatments, and at follow-up. Results 203 patients were randomized: 52 in self-hypnosis/self-care, 59 in music/self-care, 47 in self-care, and 45 in psychoeducation/CBT. No group effect was found. A significant time effect was showed. Directly after the treatment, all groups decreased in pain attitudes and physical quality of life. Perceived control increased. At 6-month, all patients kept their levels of physical quality of life and perceived control, and showed decrease in pain intensity, harm, emotion and medical cure. At 12-month, scores that had change previously remained ameliorated, a decrease in insomnia severity and an increase in internal locus of control were observed. Conclusions The present findings are encouraging as they display long-term beneficial effects of complementary biopsychosocial-based treatments in chronic pain. It seems that patients continued to apply the learnt strategies as improvements were observed one year after the treatments had ended.	[Bicego, Aminata; Nyssen, Anne-Sophie; Rousseaux, Floriane; Faymonville, Marie-Elisabeth; Vanhaudenhuyse, Audrey] Univ Liege, GIGA Consciousness, Sensat & Percept Res Grp, Liege, Belgium; [Bicego, Aminata; Nyssen, Anne-Sophie; Rousseaux, Floriane] Univ Liege, Cognit Ergon & Work Intervent Dept, Liege, Belgium; [Monseur, Justine; Donneau, Anne-Francoise] Univ Liege, Dept Publ Hlth, Biostat, Liege, Belgium; [Collinet, Alain] Musicotherapie & Counselling, Boncelles, Liege, Belgium; [Fontaine, Robert; Libbrecht, Dominique; Malaise, Nicole; Raaf, Melissa; Salamun, Irene; Staquet, Cecile; Teuwis, Sandrine; Tomasella, Marco; Faymonville, Marie-Elisabeth; Vanhaudenhuyse, Audrey] Hosp Univ Liege, Interdisciplinary Algol Dept, Liege, Belgium	University of Liege; University of Liege; University of Liege; University of Liege	Bicego, A; Vanhaudenhuyse, A (corresponding author), Univ Liege, GIGA Consciousness, Sensat & Percept Res Grp, Liege, Belgium.; Bicego, A (corresponding author), Univ Liege, Cognit Ergon & Work Intervent Dept, Liege, Belgium.; Vanhaudenhuyse, A (corresponding author), Hosp Univ Liege, Interdisciplinary Algol Dept, Liege, Belgium.	abicego@uliege.be; avanhaudenhuyse@chuliege.be		Bicego, Aminata/0000-0003-2796-040X; STAQUET, Cecile/0000-0003-1754-7160	University of Liege; University Hospital of Liege; "Plan National Cancer" of Belgium [138, 139]; Cancer Foundation of Belgium [2017-064]; Benoit Foundation (Bruxelles - Belgium)	University of Liege(University of Liege); University Hospital of Liege; "Plan National Cancer" of Belgium; Cancer Foundation of Belgium; Benoit Foundation (Bruxelles - Belgium)	University of Liege and University Hospital of Liege. https://www.uliege.be/cms/c_ 8699436/fr/uliege, https://www.chuliege.be/jcms/c_15605575/fr/chu-de-liege AV: "Plan National Cancer" of Belgium (grant number 138 and 139). https://www.health.belgium.be/fr/plan-nationalcancer AV: Cancer Foundation of Belgium grant number 2017-064. https://www.cancer.be/AV: Benoit Foundation (Bruxelles - Belgium). https://fondationbenoit.be/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adachi T, 2014, INT J CLIN EXP HYP, V62, P1, DOI 10.1080/00207144.2013.841471; [Anonymous], 2009, JBI LIB SYST REV, DOI [10.11124/01938924-200907270-00001, DOI 10.11124/01938924-200907270-00001]; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Bicego A, 2021, J REHABIL MED, V53, DOI 10.2340/16501977-2824; Bocran C, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0354-0; Bulsara C, 2006, J PSYCHOSOC ONCOL, V24, P1, DOI 10.1300/J077v24n02_01; Castel A, 2012, J PAIN, V13, P255, DOI 10.1016/j.jpain.2011.11.005; CHIBNALL JT, 1994, ARCH PHYS MED REHAB, V75, P1082, DOI 10.1016/0003-9993(94)90082-5; CRISSON JE, 1988, PAIN, V35, P147, DOI 10.1016/0304-3959(88)90222-9; Dupeyron A., 2011, Annals of Physical and Rehabilitation Medicine, V54, P319, DOI 10.1016/j.rehab.2011.06.001; Epstein RM, 2000, J FAM PRACTICE, V49, P805; Feliu-Soler A, 2018, J PAIN RES, V11, P2145, DOI 10.2147/JPR.S144631; Ferguson L, 2009, J PAIN S, V10, pS73, DOI DOI 10.1016/J.JPAIN.2009.01.258; Fischer FH, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-46; Gagnon C, 2013, J AM BOARD FAM MED, V26, P701, DOI 10.3122/jabfm.2013.06.130064; Garza-Villarreal EA, 2017, PAIN PHYSICIAN, V20, P597; Gatchel RJ, 2007, PSYCHOL BULL, V133, P581, DOI 10.1037/0033-2909.133.4.581; Gauthier N, 2008, PAIN RES MANAG, V13, P327, DOI 10.1155/2008/461436; Gladman D, 2020, RMD OPEN, V6, DOI 10.1136/rmdopen-2019-000928; Goldberg DS, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-770; GRICHNIK KP, 1991, MT SINAI J MED, V58, P217; Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221; Haverfield MC, 2018, J GEN INTERN MED, V33, P1374, DOI 10.1007/s11606-018-4490-y; Howie JGR, 2004, FAM PRACT, V21, P458, DOI 10.1093/fampra/cmh419; Jensen MP, 2020, PAIN, V161, P2284, DOI 10.1097/j.pain.0000000000001943; Jensen MP, 2011, INT J CLIN EXP HYP, V59, P45, DOI 10.1080/00207144.2011.522892; Jensen MP, 2000, J PAIN, V1, P138, DOI 10.1016/S1526-5900(00)90099-3; JENSEN MP, 1993, PAIN, V55, P195, DOI 10.1016/0304-3959(93)90148-I; Jensen MP, 1999, PAIN, V81, P95, DOI 10.1016/S0304-3959(99)00005-6; Kekecs Z, 2016, PSYCHOPHYSIOLOGY, V53, P268, DOI 10.1111/psyp.12570; Kemppainen LM, 2018, SCAND J PUBLIC HEALT, V46, P448, DOI 10.1177/1403494817733869; KIRSCH I, 1995, J CONSULT CLIN PSYCH, V63, P214, DOI 10.1037/0022-006X.63.2.214; Knoerl R, 2016, WESTERN J NURS RES, V38, P596, DOI 10.1177/0193945915615869; Laroche F., 2013, REV RHUMATISME MONOG, V80, P179; Luttrell C., 2009, LONDON E UNDERSTANDI; McCormack LA, 2011, SOC SCI MED, V72, P1085, DOI 10.1016/j.socscimed.2011.01.020; McCracken LM, 1998, J OCCUP REHABIL, V8, P179, DOI 10.1023/A:1021374322673; Menon ST, 2002, NURS EDUC TODAY, V22, P28, DOI 10.1054/nedt.2001.0721; Paul-Savoie EP, 2018, PAIN RES MANAG, V2018, DOI 10.1155/2018/6375713; Pekonen A, 2020, PATIENT EDUC COUNS, V103, P777, DOI 10.1016/j.pec.2019.10.019; PERNEGER TV, 1995, J CLIN EPIDEMIOL, V48, P1051, DOI 10.1016/0895-4356(94)00227-H; Perron L, 2005, EFFET IMAGERIE MENTA; R Core Team Rf.., 2013, R LANG ENV STAT COMP; Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939; Robinson JH, 2008, J AM ACAD NURSE PRAC, V20, P600, DOI 10.1111/j.1745-7599.2008.00360.x; Rousseaux F, 2020, TRIALS, V21, DOI 10.1186/s13063-020-4222-6; Sheng JY, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/9724371; Stewart M, 2001, BRIT MED J, V322, P444, DOI 10.1136/bmj.322.7284.444; Szilagyi AK, 2014, INTERV MED APPL SCI, V6, P3, DOI 10.1556/IMAS.6.2014.1.1; THOMAS KW, 1990, ACAD MANAGE REV, V15, P666, DOI 10.2307/258687; TURK DC, 1991, PAIN, V44, P5, DOI 10.1016/0304-3959(91)90142-K; Turk DC, 2003, PAIN, V106, P337, DOI 10.1016/j.pain.2003.08.001; Turk DC, 2011, LANCET, V377, P2226, DOI 10.1016/S0140-6736(11)60402-9; Vanhaudenhuyse A, 2015, EUR J PAIN, V19, P1437, DOI 10.1002/ejp.674; Vanhaudenhuyse Audrey, 2018, J Tradit Complement Med, V8, P296, DOI 10.1016/j.jtcme.2016.09.001; Varrassi G, 2010, CURR MED RES OPIN, V26, P1231, DOI 10.1185/03007991003689175; Wallston K., 2013, ENCY BEHAV MED, P1266; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Zhuo M, 2016, TRENDS NEUROSCI, V39, P136, DOI 10.1016/j.tins.2016.01.006; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zimmerman MA, 1995, AM J COMMUN PSYCHOL, V23, P581, DOI 10.1007/BF02506983	61	5	5	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2021	16	8							e0256001	10.1371/journal.pone.0256001	http://dx.doi.org/10.1371/journal.pone.0256001			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UA6JM	34358272	Green Published, gold			2023-01-03	WOS:000685266400031
J	Bobos, P; Pouliopoulou, DV; Harriss, A; Sadi, J; Rushton, A; MacDermid, JC				Bobos, Pavlos; Pouliopoulou, Dimitra V.; Harriss, Alexandra; Sadi, Jackie; Rushton, Alison; MacDermid, Joy C.			A systematic review and meta-analysis of measurement properties of objective structured clinical examinations used in physical therapy licensure and a structured review of licensure practices in countries with well-developed regulation systems	PLOS ONE			English	Review								Background The Objective Structured Clinical Examination (OSCE) is a commonly used tool internationally to assess clinical competency. Physical therapy (PT) licensure processes vary internationally. The OSCE is the tool used in Canada to assess clinical competency for PT graduates seeking licensure. Previous studies that examined the measurement properties of OSCEs present contradictory results. Objectives The first objective was to investigate the reliability and validity of OSCEs when administered to PTs during their education or as part of a licensure process. The second objective was to conduct a structured review to report PT educational and licensing components and policies in 17 countries with well-developed PT regulation systems. Methods An electronic search was performed in four databases from inception to 31(st) March 2021 to identify relevant articles. Two reviewers performed the critical appraisal of the included studies using a validated quality assessment tool. We deployed a random effects meta-analysis on reliability and validity estimates of OSCEs and examined sources of heterogeneity with univariate meta-regressions. We searched websites of professional regulatory bodies and associations for data on educational and licencing components and policies. Educational and licensing components across countries were synthesized descriptively. Results A pooled estimate of Cronbach's alpha of 0.55, (95% CI: 0.41, 0.67) was determined for OSCEs. The pooled estimate of Intraclass Correlation Coefficient (ICC) between assessors was 0.77 (95% CI: 0.70, 0.83). The pooled estimate of Pearson Correlation between multiple OSCE stations' scores was 0.27 (95% CI: 0.15, 0.39); and between each station score and the total score was 0.71 (95% CI: 0.61, 0.79). The pooled estimates for kappa Coefficients were 0.75 (95% CI: 0.58, 0.86) and 0.84, (95% CI: 0.72, 0.91) for intra-rater and inter-rater reliability of the standardised patient respectively. From the 17 included countries, Canada (excluding Quebec) was the only country that required both a clinical and written competency exam following graduation from an accredited PT program. Two countries (USA, UAE) required a written competency exam. The remaining 14 countries did not require an additional competency examination after completion of degree requirements from an accredited program. Conclusions We found weak evidence that OSCE examinations items are internally consistent when used to assess PTs. Canada (excluding Quebec) is the only country out of 17 implementing a national clinical competency examination for their PT graduates to achieve licensure after completing professional degree requirements.	[Bobos, Pavlos; Harriss, Alexandra; Sadi, Jackie; Rushton, Alison; MacDermid, Joy C.] Western Univ, Sch Phys Therapy, Fac Hlth Sci, London, ON N6A 3K7, Canada; [Bobos, Pavlos; MacDermid, Joy C.] St Josephs Hosp, Roth McFarlane Hand & Upper Limb Ctr, London, ON, Canada; [Bobos, Pavlos] Univ Toronto, Inst Hlth Policy, Dalla Lana Sch Publ Hlth, Dept Clin Epidemiol & Hlth Care Res, Toronto, ON, Canada; [Bobos, Pavlos] St Michaels Hosp, Appl Hlth Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Pouliopoulou, Dimitra V.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Pouliopoulou, Dimitra V.] Natl & Kapodistrian Univ Athens, Dept Hyg Epidemiol & Med Stat, Athens, Greece; [MacDermid, Joy C.] McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada	Western University (University of Western Ontario); McGill University; Western University (University of Western Ontario); University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Glasgow; National & Kapodistrian University of Athens; McMaster University	Bobos, P (corresponding author), Western Univ, Sch Phys Therapy, Fac Hlth Sci, London, ON N6A 3K7, Canada.; Bobos, P (corresponding author), St Josephs Hosp, Roth McFarlane Hand & Upper Limb Ctr, London, ON, Canada.; Bobos, P (corresponding author), Univ Toronto, Inst Hlth Policy, Dalla Lana Sch Publ Hlth, Dept Clin Epidemiol & Hlth Care Res, Toronto, ON, Canada.; Bobos, P (corresponding author), St Michaels Hosp, Appl Hlth Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.	pbobos@uwo.ca	Rushton, Alison/V-1260-2017; Bobos, Pavlos/AAZ-5053-2020; MacDermid, Joy C/H-7837-2013	Rushton, Alison/0000-0001-8114-7669; Bobos, Pavlos/0000-0002-5098-4840; MacDermid, Joy C/0000-0001-9311-7379	Frederick Banting and Charles Best Canada Graduate Scholarship (CGS-D) CIHR Doctoral Award; Arthritis Society Postdoctoral Fellowship Award; Canada Research Chair in MSK Health Outcomes and Knowledge Translation; Dr. James Roth Research Chair in Musculoskeletal Measurement and Knowledge Translation	Frederick Banting and Charles Best Canada Graduate Scholarship (CGS-D) CIHR Doctoral Award(Canadian Institutes of Health Research (CIHR)); Arthritis Society Postdoctoral Fellowship Award; Canada Research Chair in MSK Health Outcomes and Knowledge Translation; Dr. James Roth Research Chair in Musculoskeletal Measurement and Knowledge Translation	Pavlos Bobos was supported by a Frederick Banting and Charles Best Canada Graduate Scholarship (CGS-D) CIHR Doctoral Award and the Arthritis Society Postdoctoral Fellowship Award. Joy C MacDermid was supported by a Canada Research Chair in MSK Health Outcomes and Knowledge Translation and Dr. James Roth Research Chair in Musculoskeletal Measurement and Knowledge Translation.	Barry M, 2013, NURSE EDUC PRACT, V13, P477, DOI 10.1016/j.nepr.2012.11.006; Bellido-Esteban A, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.622102; Evans J.D., 1996, STRAIGHTFORWARD STAT; Forbes R., 2019, J PHYS THERAPY ED, V33, P64; Gorman S., 2010, J PHYS THER ED, V24, P62, DOI [10.1097/00001416-201007000-00008, DOI 10.1097/00001416-201007000-00008]; Halman S, 2020, MED TEACH, V42, P1283, DOI 10.1080/0142159X.2020.1803251; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; John S., 2014, NATL J INTEGRATED RE, V5; Juni P, 2020, CAN MED ASSOC J, V192, pE566, DOI 10.1503/cmaj.200920; Ladyshewsky R, 2000, J PHYS THER ED, V14, P31, DOI DOI 10.1097/00001416-200001000-00008; Law M, 2014, EVIDENCE-BASED REHABILITATION: A GUIDE TO PRACTICE, THIRD EDITION, P1; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Palekar TJ., 2015, NATL J INTEGRATED RE, V6; Roy JS, 2011, J REHABIL MED, V43, P23, DOI 10.2340/16501977-0643; Silva CCBM, 2011, BRAZ J PHYS THER, V15, P481, DOI 10.1590/S1413-35552011005000033; Sola-Pola M, 2020, NURSE EDUC PRACT, V43, DOI 10.1016/j.nepr.2020.102736; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Sterne JAC, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P99; STRATFORD PW, 1990, PHYS THER, V70, P31, DOI 10.1093/ptj/70.1.31; Swift M., 2013, J PHYS THER ED, V27, P41; Swift MC, 2007, OBJECTIVE STRUCTURED; Taber KS, 2018, RES SCI EDUC, V48, P1273, DOI 10.1007/s11165-016-9602-2; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Walton DM, 2020, PHYSIOTHER CAN, V72, P26, DOI 10.3138/ptc-2018-0059; Wessel Jean, 2003, J Allied Health, V32, P266; Zhang N, 2018, PHYSIOTHER CAN, V70, P356, DOI 10.3138/ptc.2016-102.e	26	1	1	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2021	16	8							e0255696	10.1371/journal.pone.0255696	http://dx.doi.org/10.1371/journal.pone.0255696			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6IR	34343213	Green Published, gold			2023-01-03	WOS:000685264200003
J	Bluestone, JA; Buckner, JH; Herold, KC				Bluestone, Jeffrey A.; Buckner, Jane H.; Herold, Kevan C.			Immunotherapy: Building a bridge to a cure for type 1 diabetes	SCIENCE			English	Review							REGULATORY T-CELLS; BETA-CELLS; ANTITHYMOCYTE GLOBULIN; MONOCLONAL-ANTIBODY; PEPTIDE; INSULIN; THERAPY; ISLETS	Type 1 diabetes (T1D) is an autoimmune disease in which T cells attack and destroy the insulin-producing b cells in the pancreatic islets. Genetic and environmental factors increase T1D risk by compromising immune homeostasis. Although the discovery and use of insulin have transformed T1D treatment, insulin therapy does not change the underlying disease or fully prevent complications. Over the past two decades, research has identified multiple immune cell types and soluble factors that destroy insulin-producing b cells. These insights into disease pathogenesis have enabled the development of therapies to prevent and modify T1D. In this review, we highlight the key events that initiate and sustain pancreatic islet inflammation in T1D, the current state of the immunological therapies, and their advantages for the treatment of T1D.	[Bluestone, Jeffrey A.] Univ Calif San Francisco, UCSF Diabet Ctr, San Francisco, CA 94143 USA; [Buckner, Jane H.] Virginia Mason, Benaroya Res Inst, Ctr Translat Immunol, Seattle, WA 98101 USA; [Buckner, Jane H.] Univ Washington, Dept Immunol, Sch Med, Seattle, WA 98101 USA; [Herold, Kevan C.] Yale Univ, Dept Immunobiol, New Haven, CT 06520 USA; [Herold, Kevan C.] Yale Univ, Dept Internal Med, New Haven, CT 06520 USA	University of California System; University of California San Francisco; Benaroya Research Institute; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; Yale University; Yale University	Bluestone, JA (corresponding author), Univ Calif San Francisco, UCSF Diabet Ctr, San Francisco, CA 94143 USA.; Buckner, JH (corresponding author), Virginia Mason, Benaroya Res Inst, Ctr Translat Immunol, Seattle, WA 98101 USA.; Buckner, JH (corresponding author), Univ Washington, Dept Immunol, Sch Med, Seattle, WA 98101 USA.; Herold, KC (corresponding author), Yale Univ, Dept Immunobiol, New Haven, CT 06520 USA.; Herold, KC (corresponding author), Yale Univ, Dept Internal Med, New Haven, CT 06520 USA.	jeff.bluestone@ucsf.edu; jbuckner@benaroyaresearch.org; kevan.herold@yale.edu		Bluestone, Jeffrey/0000-0001-8793-7848; Herold, Kevan/0000-0003-1534-6613	NIDDK; NIAID; Hemsley Foundation; JDRF; Immune Tolerance Network	NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Hemsley Foundation; JDRF(Juvenile Diabetes Research Foundation); Immune Tolerance Network	We thank all the dedicated researchers and clinical scientists who have spent decades focused on developing immunotherapies for the treatment of T1D. Funding agencies including the NIDDK, NIAID, the Hemsley Foundation, JDRF, the Immune Tolerance Network, and TrialNet have deployed enormous resources that have made much of the research and clinical development possible. Finally, we acknowledge the families, touched by this disease, for their unwavering commitment to support efforts to find a cure for this devastating disease.	Abbas AK, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat1482; Arnush M, 1998, J CLIN INVEST, V102, P516, DOI 10.1172/JCI844; Bach JF, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.615192; Bluestone JA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad4134; Boldison J, 2020, CELL MOL IMMUNOL, V17, P843, DOI 10.1038/s41423-019-0324-z; Brusko TM, 2021, SCIENCE, V373, P516, DOI 10.1126/science.abh1657; Cabello-Kindelan C, 2020, DIABETES, V69, P215, DOI 10.2337/db19-0061; Cabrera SM, 2016, EUR J IMMUNOL, V46, P1030, DOI 10.1002/eji.201546005; Carrero JA, 2017, P NATL ACAD SCI USA, V114, pE10418, DOI 10.1073/pnas.1713543114; Chatenoud L, 2007, NAT REV IMMUNOL, V7, P622, DOI 10.1038/nri2134; Culina S, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao4013; Dayan CM, 2021, SCIENCE, V373, P506, DOI 10.1126/science.abi4742; de Brachene AC, 2020, DIABETES OBES METAB, V22, P1827, DOI 10.1111/dom.14104; DEBRAYSACHS M, 1987, EXP CLIN ENDOCRINOL, V89, P297; Edner NM, 2020, NAT IMMUNOL, V21, P1244, DOI 10.1038/s41590-020-0744-z; ElTanbouly MA, 2021, NAT REV IMMUNOL, V21, P257, DOI 10.1038/s41577-020-00454-2; Ferreira LMR, 2019, NAT REV DRUG DISCOV, V18, P749, DOI 10.1038/s41573-019-0041-4; Ferreira RC, 2014, DIABETES, V63, P2538, DOI 10.2337/db13-1777; Fraker C, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0806-7; Gitelman SE, 2016, DIABETOLOGIA, V59, P1153, DOI 10.1007/s00125-016-3917-4; Gubitosi-Klug RA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143011; Hagopian W, 2013, DIABETES, V62, P3901, DOI 10.2337/db13-0236; Haller MJ, 2018, DIABETES CARE, V41, P1917, DOI 10.2337/dc18-0494; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Herold KC, 2019, NEW ENGL J MED, V381, P603, DOI 10.1056/NEJMoa1902226; Honaker Y, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay6422; Hundhausen C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9943; Insel RA, 2015, DIABETES CARE, V38, P1964, DOI 10.2337/dc15-1419; Inshaw JRJ, 2018, NAT IMMUNOL, V19, P674, DOI 10.1038/s41590-018-0129-8; James EA, 2018, DIABETES, V67, P1035, DOI 10.2337/dbi17-0030; Keymeulen B, 2005, NEW ENGL J MED, V352, P2598, DOI 10.1056/NEJMoa043980; Leclerc M, 2016, BLOOD, V128, P1651, DOI 10.1182/blood-2016-02-700849; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; Long SA, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aai7793; Lundberg M, 2016, DIABETES, V65, P3104, DOI 10.2337/db16-0616; Marek-Trzonkowska N, 2012, DIABETES CARE, V35, P1817, DOI 10.2337/dc12-0038; Marino E, 2017, NAT IMMUNOL, V18, P552, DOI 10.1038/ni.3713; Marroqui L, 2015, DIABETES, V64, P3808, DOI 10.2337/db15-0362; Mohty M, 2007, LEUKEMIA, V21, P1387, DOI 10.1038/sj.leu.2404683; Morita S, 2017, CELL METAB, V25, P1207, DOI 10.1016/j.cmet.2017.04.026; Nikolic T, 2020, LANCET DIABETES ENDO, V8, P470, DOI [10.1016/S2213-8587(20)30104-2, 10.1016/S2213-8587(20)30149-2]; Orban T, 2014, DIABETES CARE, V37, P1069, DOI 10.2337/dc13-0604; Overwijk WW, 2021, ANNU REV MED, V72, P281, DOI 10.1146/annurev-med-073118-011031; Pang HP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.593348; Pescovitz MD, 2009, NEW ENGL J MED, V361, P2143, DOI 10.1056/NEJMoa0904452; Pugliese A, 2017, J CLIN INVEST, V127, P2881, DOI 10.1172/JCI94549; Quattrin T, 2020, NEW ENGL J MED, V383, P2007, DOI 10.1056/NEJMoa2006136; Raffin C, 2020, NAT REV IMMUNOL, V20, P158, DOI 10.1038/s41577-019-0232-6; Rigby MR, 2015, J CLIN INVEST, V125, P3285, DOI 10.1172/JCI81722; Rodriguez-Calvo T, 2021, DIABETES, V70, P752, DOI 10.2337/db20-0908; Rodriguez-Calvo T, 2014, DIABETES, V63, P3880, DOI 10.2337/db14-0549; Rondas Dieter, 2015, Diabetes, V64, P573, DOI 10.2337/db14-0621; Rosenzwajg M, 2020, DIABETOLOGIA, V63, P1808, DOI 10.1007/s00125-020-05200-w; Rouxel O, 2017, NAT IMMUNOL, V18, P1321, DOI 10.1038/ni.3854; Rui JX, 2017, CELL METAB, V25, P727, DOI 10.1016/j.cmet.2017.01.005; Schneider A, 2008, J IMMUNOL, V181, P7350, DOI 10.4049/jimmunol.181.10.7350; Simeonov DR, 2017, NATURE, V549, P111, DOI 10.1038/nature23875; Sims EK, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abc8980; Sims EK, 2019, DIABETES CARE, V42, P258, DOI 10.2337/dc17-2625; Smith EL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00392; Smith MJ, 2020, CURR OPIN ENDOCRINOL, V27, P225, DOI 10.1097/MED.0000000000000547; Snowhite I, 2021, DIABETES, V70, P638, DOI 10.2337/db20-0817; Speake C., 2020, J. Clin. Endocrinol. Metab., V105, P781; Spolski R, 2018, NAT REV IMMUNOL, V18, P648, DOI 10.1038/s41577-018-0046-y; Thompson PJ, 2019, CELL METAB, V29, P1045, DOI 10.1016/j.cmet.2019.01.021; Trivedi PM, 2017, DIABETES, V66, P1650, DOI 10.2337/db16-1250; Vomund AN, 2015, P NATL ACAD SCI USA, V112, pE5496, DOI 10.1073/pnas.1515954112; Wiedeman AE, 2020, J CLIN INVEST, V130, P480, DOI 10.1172/JCI126595	68	22	23	18	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	2021	373	6554			SI		510	515		10.1126/science.abh1654	http://dx.doi.org/10.1126/science.abh1654			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV4TF	34326232				2023-01-03	WOS:000681716000033
J	Scher, M				Scher, Marion			Inquest begins over South African mental health failings	LANCET			English	Editorial Material								An inquest has begun into the deaths of 144 patients deinstitutionalised from Life Esidimeni psychiatric care facilities. Marion Scher reports from Johannesburg.											0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	2021	398	10297					288	288						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TM9EI	34303424				2023-01-03	WOS:000675849600008
J	Kusumoto, Y; Takaki, K; Matsuda, T; Nitta, O				Kusumoto, Yasuaki; Takaki, Kenji; Matsuda, Tadamitsu; Nitta, Osamu			Relevant factors of self-care in children and adolescents with spastic cerebral palsy	PLOS ONE			English	Article							GROSS MOTOR FUNCTION; FUNCTION CLASSIFICATION-SYSTEM; UPPER-LIMB FUNCTION; MANUAL ABILITY; DISABILITY INVENTORY; PEDIATRIC EVALUATION; YOUNG-CHILDREN; HAND FUNCTION; ARM FUNCTION; ADULT NORMS	Objective Manual ability is considered one of the factors that can predict functional independence in activities of daily living. For evaluating personal tasks such as self-care, the Pediatric Evaluation of Disability Inventory (PEDI) comprises/introduces/offers a set of useful measures that assist in enhancing the capability for self-care among children and adolescents with cerebral palsy (CP). The aim of this study was to investigate the relevant factors of self-care capability and performance in children and adolescents with spastic CP. Methods This was a cross-sectional study. Seventy-six children and adolescents with spastic CP (between 5 and 18 years of age), representing levels I to IV of the Gross Motor Function Classification System-Expanded & Revised version (GMFCS), were analyzed. Multiple linear regression analysis with forward stepwise selection was conducted to examine which determinants were related to self-care capability and performance. Independent variables were age, CP type, GMFCS, Manual Ability Classification System, Box and Block Test, and grip strength in the dominant and non-dominant hands. Dependent variables were scores for the PEDI Functional Skills Scale and the PEDI Caregiver Assistance Scale. Results Results of the multiple regression analysis showed that the PEDI Functional Skills scale scores were correlated with the Box and Block Test in the dominant hand and GMFCS (Adjusted R-2 = 0.69). The PEDI Caregiver Assistance Scale scores were correlated with the Box and Block Test in the dominant hand, GMFCS, and age (adjusted R-2 = 0.71). Conclusion When considering self-care of children and adolescents with spastic CP, it is necessary to consider the evaluation of upper limb dysfunction in addition to GMFCS.	[Kusumoto, Yasuaki] Fukushima Med Univ, Dept Phys Therapy, Sch Hlth Sci, Fukushima, Fukushima, Japan; [Takaki, Kenji] Tokyo Univ Technol, Fac Hlth Sci, Dept Phys Therapy, Ohta Ku, Tokyo, Japan; [Matsuda, Tadamitsu] Juntendo Univ, Fac Hlth Sci, Dept Phys Therapy, Bunkyo Ku, Tokyo, Japan; [Nitta, Osamu] Tokyo Metropolitan Univ, Fac Hlth Sci, Dept Phys Therapy, Arakawa Ku, Tokyo, Japan	Fukushima Medical University; Tokyo University of Technology; Juntendo University	Kusumoto, Y (corresponding author), Fukushima Med Univ, Dept Phys Therapy, Sch Hlth Sci, Fukushima, Fukushima, Japan.	kusumoto@fmu.ac.jp			 [20150528-FB23]		This work was supported for YK by the FRANCE BED MEDICAL HOME CARE RESEARCH SUBSIDY PUBLIC INTEREST INCORPORATED FOUNDATIONS under Grant 20150528-FB23. URL of funder website is http://www.fbm-zaidan.or.jp/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arner M, 2008, J HAND SURG-AM, V33A, P1337, DOI 10.1016/j.jhsa.2008.02.032; Arnould C, 2007, J REHABIL MED, V39, P708, DOI 10.2340/16501977-0111; Arnould C, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00048; Chukwukere Ogoke C, 2018, CLIN THERAPEUTIC ASP, P21, DOI [10.5772/intechopen.79246, DOI 10.5772/INTECHOPEN.79246]; Dumas H, 2010, PHYS OCCUP THER PEDI, V30, P168, DOI 10.3109/01942631003640493; Dumas HM, 2012, J PEDIATR REHAB MED, V5, P29, DOI 10.3233/PRM-2011-0184; Flatters I, 2014, EXP BRAIN RES, V232, P2907, DOI 10.1007/s00221-014-3947-4; Gilmore R, 2010, DEV MED CHILD NEUROL, V52, P14, DOI 10.1111/j.1469-8749.2009.03369.x; Giray E, 2020, DISABIL REHABIL, V42, P410, DOI 10.1080/09638288.2018.1501098; Gunel MK, 2009, EUR J PEDIATR, V168, P477, DOI 10.1007/s00431-008-0775-1; Haley SM, 2010, PEDIATR PHYS THER, V22, P69, DOI 10.1097/PEP.0b013e3181cbfbf6; Hoare BJ, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004149.pub3; James S, 2014, DEV MED CHILD NEUROL, V56, P233, DOI 10.1111/dmcn.12226; Kim K, 2017, ANN REHABIL MED-ARM, V41, P266, DOI 10.5535/arm.2017.41.2.266; Klingels K, 2012, EUR J PAEDIATR NEURO, V16, P257, DOI 10.1016/j.ejpn.2011.08.001; Kondo I, 2003, AM J PHYS MED REHAB, V82, P116, DOI 10.1097/00002060-200302000-00006; Kruijsen-Terpstra AJA, 2015, PHYS OCCUP THER PEDI, V35, P265, DOI 10.3109/01942638.2014.957429; Kuijper MA, 2010, AM J OCCUP THER, V64, P614, DOI 10.5014/ajot.2010.08087; Law Karlen, 2008, J Orthop Surg Res, V3, P52, DOI 10.1186/1749-799X-3-52; Majnemer A, 2013, PHYS OCCUP THER PEDI, V33, P243, DOI 10.3109/01942638.2012.754394; MATHIOWETZ V, 1985, AM J OCCUP THER, V39, P386, DOI 10.5014/ajot.39.6.386; MATHIOWETZ V, 1985, OCCUP THER J RES, V5, P24, DOI 10.1177/153944928500500102; McCarthy ML, 2002, DEV MED CHILD NEUROL, V44, P468; Mcconnell K, 2011, DEV MED CHILD NEUROL, V53, P799, DOI 10.1111/j.1469-8749.2011.03953.x; Ministry of education culture sports science and technology, 2021, NEW PHYS FITN TEST I NEW PHYS FITN TEST I; Moon Jong-Hoon, 2017, J Phys Ther Sci, V29, P1800, DOI 10.1589/jpts.29.1800; Ohrvall AM, 2010, DEV MED CHILD NEUROL, V52, P1048, DOI 10.1111/j.1469-8749.2010.03764.x; Ostensjo S, 2004, DEV MED CHILD NEUROL, V46, P580; Ostensjo S, 2003, DEV MED CHILD NEUROL, V45, P603, DOI 10.1017/S0012162203001105; Palisano RJ, 2008, DEV MED CHILD NEUROL, V50, P744, DOI 10.1111/j.1469-8749.2008.03089.x; Park ES, 2011, RES DEV DISABIL, V32, P2389, DOI 10.1016/j.ridd.2011.07.021; Pashmdarfard M., 2017, J MODERN REHAB, V11, P93; Pashmdarfard M, 2019, IRAN J CHILD NEUROL, V13, P83; Pashmdarfard M, 2017, IRAN J CHILD NEUROL, V11, P1; Pavao SL, 2019, DISABIL REHABIL, V41, P2199, DOI 10.1080/09638288.2018.1462410; Platz T, 2005, CLIN REHABIL, V19, P404, DOI 10.1191/0269215505cr832oa; Rosenblum Sara, 2003, Physical & Occupational Therapy in Pediatrics, V23, P47; Sahinoglu D, 2017, PROSTHET ORTHOT INT, V41, P85, DOI 10.1177/0309364616637490; Saussez G, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00495; Smits DW, 2011, RES DEV DISABIL, V32, P222, DOI 10.1016/j.ridd.2010.09.025; Song CS, 2014, J PHYS THER SCI, V26, P797, DOI 10.1589/jpts.26.797; Sorsdahl AB, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-26; Toikawa H., 2004, JPN J REHABIL MED, V41, pS224; Wallen M, 2015, DISABIL REHABIL, V37, P1353, DOI 10.3109/09638288.2014.963704	47	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2021	16	7							e0254899	10.1371/journal.pone.0254899	http://dx.doi.org/10.1371/journal.pone.0254899			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2OI	34288946	Green Published, gold			2023-01-03	WOS:000678124300066
J	Rengasamy, S; Nassef, B; Bilotta, F; Pugliese, F; Nozari, A; Ortega, R				Rengasamy, Sundara; Nassef, Bishoi; Bilotta, Federico; Pugliese, Francesco; Nozari, Ala; Ortega, Rafael			Administration of Supplemental Oxygen	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							THERAPY		[Rengasamy, Sundara; Nassef, Bishoi; Nozari, Ala; Ortega, Rafael] Boston Med Ctr, Dept Anesthesiol, 750 Albany St, Boston, MA 02118 USA; [Bilotta, Federico; Pugliese, Francesco] Univ Rome, Rome, Italy	Boston Medical Center; Sapienza University Rome	Ortega, R (corresponding author), Boston Med Ctr, Dept Anesthesiol, 750 Albany St, Boston, MA 02118 USA.	rafael.ortega@bmc.org						Abdo WF, 2012, CRIT CARE, V16, DOI 10.1186/cc11475; Angus DC, 2020, NEW ENGL J MED, V382, P1054, DOI 10.1056/NEJMe2000800; GIBSON RL, 1976, ANESTHESIOLOGY, V44, P71, DOI 10.1097/00000542-197601000-00019; Hardavella G, 2019, BREATHE, V15, pE108, DOI 10.1183/20734735.0204-2019; Li J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00892-2020; Morgan T J, 1999, Crit Care Resusc, V1, P93; Nishimura M, 2019, RESP CARE, V64, P735, DOI 10.4187/respcare.06718; SEVERINGHAUS JW, 1979, J APPL PHYSIOL, V46, P599, DOI 10.1152/jappl.1979.46.3.599; SPEIR WA, 1971, J AMER MED ASSOC, V216, P879; Spoletini G, 2015, CHEST, V148, P253, DOI 10.1378/chest.14-2871; WEXLER HR, 1975, CAN ANAESTH SOC J, V22, P417, DOI 10.1007/BF03004856	11	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2021	385	3							e9	10.1056/NEJMvcm2035240	http://dx.doi.org/10.1056/NEJMvcm2035240			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM6AG	34260838	Green Published			2023-01-03	WOS:000675631800001
J	Hammes, M; Moya-Rodriguez, A; Bernstein, C; Nathan, S; Navuluri, R; Basu, A				Hammes, Mary; Moya-Rodriguez, Andres; Bernstein, Cameron; Nathan, Sandeep; Navuluri, Rakesh; Basu, Anindita			Computational modeling of the cephalic arch predicts hemodynamic profiles in patients with brachiocephalic fistula access receiving hemodialysis	PLOS ONE			English	Article							ARTERIOVENOUS-FISTULA; VEIN; ANASTOMOSIS	Background The most common configuration for arteriovenous fistula is brachiocephalic which often develop cephalic arch stenosis leading to the need for numerous procedures to maintain access patency. The hemodynamics that contributes to the development of cephalic arch stenosis is incompletely understood given the inability to accurately determine shear stress in the cephalic arch. In the current investigation our aim was to determine pressure, velocity and wall shear stress profiles in the cephalic arch in 3D using computational modeling as tools to understand stenosis. Methods Five subjects with brachiocephalic fistula access had protocol labs, Doppler, venogram and intravascular ultrasound imaging performed at 3 and 12 months. 3D reconstructions of the cephalic arch were generated by combining intravascular ultrasounds and venograms. Standard finite element analysis software was used to simulate time dependent blood flow in the cephalic arch with velocity, pressure and wall shear stress profiles generated. Results Our models generated from imaging and flow measurements at 3 and 12 months offer snapshots of the patient's cephalic arch at a precise time point, although the remodeling of the vessel downstream of an arteriovenous fistula in patients undergoing regular dialysis is a dynamic process that persists over long periods of time (similar to 5 years). The velocity and pressure increase at the cephalic bend cause abnormal hemodynamics most prominent along the inner wall of the terminal cephalic arch. The topology of the cephalic arch is highly variable between subjects and predictive of pathologic stenosis at later time points. Conclusions Low flow velocity and wall pressure along the inner wall of the bend may provide possible nidus of endothelial activation that leads to stenosis and thrombosis. In addition, 3D modelling of the arch can indicate areas of stenosis that may be missed by venograms alone. Computational modeling reconstructed from 3D radiologic imaging and Doppler flow provides important insights into the hemodynamics of blood flow in arteriovenous fistula. This technique could be used in future studies to determine optimal flow to prevent endothelial damage for patients with arteriovenous fistula access.	[Hammes, Mary] Univ Chicago, Dept Med, Sect Nephrol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Moya-Rodriguez, Andres; Basu, Anindita] Univ Chicago, Dept Med, Sect Genet Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Moya-Rodriguez, Andres] Univ Chicago, Biophys Sci Grad Program, Chicago, IL 60637 USA; [Bernstein, Cameron] Univ Chicago, Chicago, IL 60637 USA; [Nathan, Sandeep] Univ Chicago, Dept Med, Sect Cardiol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Navuluri, Rakesh] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Hammes, M (corresponding author), Univ Chicago, Dept Med, Sect Nephrol, 5841 S Maryland Ave, Chicago, IL 60637 USA.; Basu, A (corresponding author), Univ Chicago, Dept Med, Sect Genet Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	mhammes@medicine.bsd.uchicago.edu; onibasu@uchicago.edu		Navuluri, Rakesh/0000-0001-9411-8402; Hammes, Mary/0000-0002-2524-6432	National Institute of Diabetes and Digestive Diseases (NIDDK); National Institutes of Health (NIH) [RO1DK090769]; NSF GRFP fellowship; Ginny and Simon Aronson Research Award; University of Chicago Institute of Translational Medicine Pilot Award; A.B.'s research development funds	National Institute of Diabetes and Digestive Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF GRFP fellowship(National Science Foundation (NSF)NSF - Office of the Director (OD)); Ginny and Simon Aronson Research Award; University of Chicago Institute of Translational Medicine Pilot Award; A.B.'s research development funds	This publication was made possible by the National Institute of Diabetes and Digestive Diseases (NIDDK) and the National Institutes of Health (NIH) under award number RO1DK090769. A. M-R was supported by the NSF GRFP fellowship. The work was partly funded by the Ginny and Simon Aronson Research Award, University of Chicago Institute of Translational Medicine Pilot Award, and A.B.'s research development funds.	Al-Jaishi AA, 2014, AM J KIDNEY DIS, V63, P464, DOI 10.1053/j.ajkd.2013.08.023; Albayrak R, 2007, J CLIN ULTRASOUND, V35, P133, DOI 10.1002/jcu.20307; Alberts B., 2012, MOL BIOL CELL NCBI B; [Anonymous], COMS MULT; Asif A, 2006, CLIN J AM SOC NEPHRO, V1, P332, DOI 10.2215/CJN.00850805; Bennett S, 2015, J VASC ACCESS, V16, P13, DOI 10.5301/jva.5000291; Bharat A, 2012, J VASC SURG, V55, P274, DOI 10.1016/j.jvs.2011.07.090; Boghosian M. E., 2018, Journal of Medical Engineering & Technology, V42, P617, DOI 10.1080/03091902.2019.1591534; Bozzetto M, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0420-x; Carroll JE, 2020, COMPUT METH PROG BIO, V186, DOI 10.1016/j.cmpb.2019.105203; Chan CT, 2019, KIDNEY INT, V96, P37, DOI 10.1016/j.kint.2019.01.017; Cheng HS, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017238; Chhabra RP, 2011, NONNEWTONIAN FLOW AP; Corpataux JM, 2002, NEPHROL DIAL TRANSPL, V17, P1057, DOI 10.1093/ndt/17.6.1057; Crane J, 2021, J VASC ACCESS, V22, P697, DOI 10.1177/1129729820959930; El Kassem M, 2015, ADV CHRONIC KIDNEY D, V22, P453, DOI 10.1053/j.ackd.2015.02.001; Ene-Iordache B, 2017, CARDIOVASC ENG TECHN, V8, P295, DOI 10.1007/s13239-017-0318-x; Fitts Michelle K, 2014, Open Urol Nephrol J, V7, P33; Fitzgerald JT, 2004, ARCH SURG-CHICAGO, V139, P201, DOI 10.1001/archsurg.139.2.201; Fructuoso M, 2018, ANN VASC SURG, V48, DOI 10.1016/j.avsg.2017.11.034; Hammes M, 2021, J VASC ACCESS, V22, P380, DOI 10.1177/1129729820942048; Hammes M, 2019, CLIN NEPHROL, V91, P138, DOI 10.5414/CN109456; Hammes M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152873; Hammes MS, 2009, NEPHROL DIAL TRANSPL, V24, P2190, DOI 10.1093/ndt/gfp062; Hu ZZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172490; Hull JE, 2013, J VASC SURG, V58, P187, DOI 10.1016/j.jvs.2012.10.070; Karydis N, 2020, AM J KIDNEY DIS, V75, P45, DOI 10.1053/j.ajkd.2019.05.023; Kroll MH, 1996, BLOOD, V88, P1525; Lee H, 2020, VASC ENDOVASC SURG, V54, P5, DOI 10.1177/1538574419874934; Logason K, 2001, EUR J VASC ENDOVASC, V21, P311, DOI 10.1053/ejvs.2001.1331; Lu DY, 2014, J SURG RES, V188, P162, DOI 10.1016/j.jss.2014.01.042; Mallios A, 2018, J VASC SURG, V68, P1150, DOI 10.1016/j.jvs.2018.01.036; Nikam M, 2015, J VASC SURG, V61, P1020, DOI 10.1016/j.jvs.2014.11.082; Oliver MJ, 2018, J AM SOC NEPHROL, V29, P2607, DOI 10.1681/ASN.2018090922; Remuzzi A, 2017, J VASC ACCESS, V18, pS10, DOI 10.5301/jva.5000686; Ren C, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012994; Shammas NW, 2019, VASC HEALTH RISK MAN, V15, P283, DOI 10.2147/VHRM.S210928; Shinbrot T., 2019, BIOMEDICAL FLUID DYN; Shiu YT, 2019, AM J PHYSIOL-RENAL, V316, pF794, DOI 10.1152/ajprenal.00440.2018; Teodorescu V, 2012, INT J NEPHROL, V2012, DOI 10.1155/2012/508956	40	0	0	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2021	16	7							e0254016	10.1371/journal.pone.0254016	http://dx.doi.org/10.1371/journal.pone.0254016			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2MK	34260609	gold, Green Published			2023-01-03	WOS:000678119300069
J	Lee, EY; Park, JH				Lee, Eun-Young; Park, Jin-Hee			A phenomenological study on the experiences of patient transfer from the intensive care unit to general wards	PLOS ONE			English	Article								Objectives This study aimed to derive an in-depth understanding of the transfer experience of intensive care unit (ICU) patients in South Korea through a phenomenological analysis. Methods Participants were 15 adult patients who were admitted to a medical or surgical ICU at a university hospital for more than 48 hours before being transferred to a general ward. Data were collected three to five days after their transfer to the general ward from January to December 2017 through individual in-depth interviews and were analyzed using Colaizzi's phenomenological data analysis method, phenomenological reduction, intersubjective reduction, and hermeneutic circle. Data analysis yielded eight themes and four theme clusters related to the unique experiences of domestic ICU patients in the process of transfer to the general ward. Results The four main themes of the patients' transfer experiences were "hope amid despair," "gratitude for being alive," "recovery from suffering," and "seeking a return to normality." Conclusion Our findings expand the realistic and holistic understanding from the patient's perspective. This study's findings can contribute to the development of appropriate nursing interventions that can support preparation and adaptation to the transfer of ICU patients.	[Lee, Eun-Young] Ajou Univ, Shinsung Univ, Coll Nursing, Dept Nursing, Dangjin, South Korea; [Park, Jin-Hee] Ajou Univ, Res Inst Nursing Sci, Coll Nursing, Suwon, South Korea	Ajou University; Ajou University	Park, JH (corresponding author), Ajou Univ, Res Inst Nursing Sci, Coll Nursing, Suwon, South Korea.	jhee@ajou.ac.kr		Park, Jin-Hee/0000-0002-0069-7819				[Anonymous], 2008, J KOREAN CLIN NURS R; Buchner DL, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007913; Cognet S, 2014, INTENS CRIT CARE NUR, V30, P292, DOI 10.1016/j.iccn.2014.04.004; Colaizzi PF, 1978, EXISTENTIAL PHENOMEN, P6; Egerod I, 2015, INT J NURS STUD, V52, P1354, DOI 10.1016/j.ijnurstu.2015.04.017; Endacott R, 2010, RESUSCITATION, V81, P198, DOI 10.1016/j.resuscitation.2009.10.011; Enger R, 2018, J CLIN NURS, V27, pE186, DOI 10.1111/jocn.13911; Field K, 2008, CRIT CARE, V12, DOI 10.1186/cc6795; Forsberg A, 2011, INT J NURS PRACT, V17, P110, DOI 10.1111/j.1440-172X.2011.01915.x; Guest Mags, 2017, Nurs Stand, V32, P45, DOI 10.7748/ns.2017.e10670; Gustad Lise Tuset, 2008, Aust Crit Care, V21, P181, DOI 10.1016/j.aucc.2008.07.002; Kim Jinhyun, 2017, [Journal of Korean Academy of Nursing Administration, 간호행정학회지], V23, P312, DOI 10.11111/jkana.2017.23.3.312; Lee N. I., 2014, PHENOMENOLOGY QUALIT; Leith BA, 1999, HEART LUNG, V28, P210, DOI 10.1016/S0147-9563(99)70061-0; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; Ludin SM, 2013, INTENS CRIT CARE NUR, V29, P187, DOI 10.1016/j.iccn.2013.02.001; Maddox M, 2001, Intensive Crit Care Nurs, V17, P6; McKinney Aidin A, 2002, Intensive Crit Care Nurs, V18, P320, DOI 10.1016/S0964-3397(02)00069-1; Meleis AI, 2000, ADV NURS SCI, V23, P12, DOI 10.1097/00012272-200009000-00006; 이혜숙, 2014, [The Journal of the Korea Contents Association, 한국콘텐츠학회 논문지], V14, P211, DOI 10.5392/JKCA.2014.14.05.211; Needham DM, 2013, AM J RESP CRIT CARE, V188, P567, DOI 10.1164/rccm.201304-0651OC; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; Odell M, 2000, J ADV NURS, V31, P322, DOI 10.1046/j.1365-2648.2000.01294.x; Olsen KD, 2017, INTENS CRIT CARE NUR, V43, P61, DOI 10.1016/j.iccn.2017.06.008; Palinkas LA, 2015, ADM POLICY MENT HLTH, V42, P533, DOI 10.1007/s10488-013-0528-y; Park JH, 2010, J KOREAN ACAD NURS, V40, P307, DOI 10.4040/jkan.2010.40.3.307; Stelfox HT, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002653; Strahan Eunice H E, 2005, Intensive Crit Care Nurs, V21, P160; Van Manen M, 1997, RES LIVED EXPERIENCE; van Mol M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2782-2; van Sluisveld N, 2015, INTENS CARE MED, V41, P589, DOI 10.1007/s00134-015-3666-8; Wang S, 2017, J HOSP MED, V12, P831, DOI 10.12788/jhm.2827	32	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2021	16	7							e0254316	10.1371/journal.pone.0254316	http://dx.doi.org/10.1371/journal.pone.0254316			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TK6VQ	34234351	Green Published, gold			2023-01-03	WOS:000674294100037
J	Gebrekirstos, LG; Wube, TB; Gebremedhin, MH; Lake, EA				Gebrekirstos, Lielt Gebreselassie; Wube, Tsiyon Birhanu; Gebremedhin, Meron Hadis; Lake, Eyasu Alem			Magnitude and determinants of adequate antenatal care service utilization among mothers in Southern Ethiopia	PLOS ONE			English	Article							MATERNAL MORTALITY; MEDICAL-CARE; MODEL	Background Mortality from preventable pregnancy-related complications remains high in Ethiopia. Antenatal care remains a major public health intervention that prevents maternal and neonatal mortality. Thus, this study aimed to assess the magnitude and determinants of adequate antenatal care utilization in Southern Ethiopia. Methods A community-based cross-sectional study was conducted between November and December 2019. A systematic random sampling technique was used to select 670 women. Data were collected using a pre-tested structured questionnaire administered with a digital survey tool (open data kit) and directly exported to STATA version 15 for analysis. Descriptive statistics followed by a multivariable logistic regression analysis were performed. Both crude and adjusted odds ratios (ORs) with 95% confidence intervals were reported. Results The magnitude of adequate antenatal care utilization was 23.13%. Tertiary and above education (AOR,4.15;95%CI: 1.95, 8.83), having the best friend who used maternal care (AOR,2.01;95%CI: 1.18,3.41), husband support (AOR,3.84; 95%CI: 1.05, 14.08), high wealth index (AOR,3.61; 95%CI: 1.86, 6.99), follow-up in private health facilities (AOR, 2.27;95% CI:1.33, 3.88), having a history of risky pregnancy (AOR,2.59; 95%CI: 1.55, 4.35), and planned pregnancy (AOR,2.60;95% CI: 1.35, 4.99) were significant determinants of overall adequate ANC service utilization. Conclusion The utilization of adequate antenatal care services is quite low. The study findings suggest that interventions should be in place to improve husband's support, social networks, and women's education. There is also a need to counsel women to utilize family planning.	[Gebrekirstos, Lielt Gebreselassie] Wolaita Sodo Univ, Dept Matern & Reprod Hlth Nursing, Wolaita Sodo, Ethiopia; [Wube, Tsiyon Birhanu] Aksum Univ, Dept Adult Hlth Nursing, Aksum, Ethiopia; [Wube, Tsiyon Birhanu] Lazarski Univ, Dept Med, Warsaw, Poland; [Gebremedhin, Meron Hadis] Wolaita Sodo Univ, Dept Med, Wolaita Sodo, Ethiopia; [Lake, Eyasu Alem] Wolaita Sodo Univ, Dept Pediat & Child Hlth Nursing, Wolaita Sodo, Ethiopia	Uczelnia Lazarskiego w Warszawie	Gebrekirstos, LG (corresponding author), Wolaita Sodo Univ, Dept Matern & Reprod Hlth Nursing, Wolaita Sodo, Ethiopia.	lieltinamulu23@gmail.com		Birhanu, Tsiyon/0000-0001-7465-4697; gebrekirstos, lielt/0000-0003-0317-5597				Adewuyi EO, 2017, SCAND J PUBLIC HEALT, V45, P675, DOI 10.1177/1403494817705562; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2016, MAT MORT FACT SHEET; Anselm SB., 2016, ADEQUACY ANTENATAL C, DOI [10.5455/pmb.1-1439556706, DOI 10.5455/PMB.1-1439556706]; Baffour-Awuah A., 2015, INT J AFRICA NURS SC, V2, P59, DOI DOI 10.1016/J.IJANS.2015.02.001; Bahailu T., 2009, ETHIOP J HEALTH SCI, V19; Bayou YT, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0930-z; Bbaale E, 2011, AUSTRALAS MED J, V4, P516, DOI 10.4066/AMJ.2011.849; Birhane A, 2018, ETHIOP J HEALTH DEV, V32, P28; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Central Statistical Agency [Ethiopia] and Inner City Fund International (CSA and ICF International), 2012, ETH DEM HLTH SURV 20; CSA, POPULATION PROJECTIO; CSA ICF, 2016, ETH DEM HLTH SURV; Ethiopia, 2017, ETH DEM HLTH SURV 20; Frost Jennifer J, 2008, Issues Brief (Alan Guttmacher Inst), P1; Grum T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207922; Islam MM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204752; Jallow IK, 2012, INT J QUAL HEALTH C, V24, P595, DOI 10.1093/intqhc/mzs033; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Magadi MA, 2000, SOC SCI MED, V51, P551, DOI 10.1016/S0277-9536(99)00495-5; Nebeb GT., 2015, GYNECOL OBSTET SUNNY, V5, P2161; Organization WH, 2016, WHO RECOMM ANTENATAL, P152; Pallikadavath S, 2004, SOC SCI MED, V59, P1147, DOI 10.1016/j.socscimed.2003.11.045; Stanton CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060694; Story WT, 2014, HEALTH PLACE, V28, P73, DOI 10.1016/j.healthplace.2014.03.011; Tesfaye G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208729; Tran TK, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-40; UNICEF, 2015, COMMITTING CHILD SUR; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X; Vogel JP, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-19; Wang W., 2011, LEVEL TRENDS USE MAT; WHO, 2006, MAK PREGN SAF PROV E; WHO, 2002, WHO ANT CAR RAND CON; World Health Organization, WHO GLOB HLTH OBS GH; World Health Organization, 2009, WHO REC INT IMPR MAT; World Health Organization, 2015, STRATEGIES ENDING PR; World Health Organization, 2015, TRENDS MAT MORT 1990	39	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2021	16	7							e0251477	10.1371/journal.pone.0251477	http://dx.doi.org/10.1371/journal.pone.0251477			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TK6VN	34228728	gold, Green Published			2023-01-03	WOS:000674293700012
J	Skwiot, M; Sliwinski, Z; Zurawski, A; Sliwinski, G				Skwiot, Marlena; Sliwinski, Zbigniew; Zurawski, Arkadiusz; Sliwinski, Grzegorz			Effectiveness of physiotherapy interventions for injury in ballet dancers: A systematic review	PLOS ONE			English	Review							SHOCK-WAVE THERAPY; LOW-BACK-PAIN; MUSCULOSKELETAL INJURY; JOINT HYPERMOBILITY; PATELLOFEMORAL PAIN; ANKLE IMPINGEMENT; STRESS-FRACTURES; RISK-FACTORS; OS TRIGONUM; HIP PAIN	Background The unique repetitive nature of ballet dancing, which often involves transgressing endurance limits of anatomical structures, makes dancers prone to injury. The following systematic review aims to assess the effectiveness of physiotherapy interventions in the treatment of injuries in ballet dancers. Methods The review was performed in line with the PRISMA statement on preferred reporting items for systematic reviews and meta-analyses. Six electronic databases (PubMed, Ovid Embase, Cochrane, Medline, PEDro, Google Scholar) were queried. The study populations comprised active ballet dancers and/or ballet school attendees with acute and chronic injuries and those with persistent pain. There were no restrictions regarding age, sex, ethnicity or nationality. The Modified McMaster Critical Review Form for quantitative studies was used to assess the methodological quality of the studies reviewed in accordance with the relevant guidelines. Results Out of the total of 687 articles subjected to the review, 10 met the inclusion criteria. Diverse physiotherapeutic interventions were described and effectiveness was assessed using different parameters and measurements. Overall, the results indicate that physiotherapy interventions in ballet dancers exert a positive effect on a number of indices, including pain, ROM and functional status. Conclusions Due to the small amount of evidence confirming the effectiveness of physiotherapeutic interventions in ballet dancers after injuries and methodological uncertainties, it is recommended to improve the quality of prospective studies.	[Skwiot, Marlena; Sliwinski, Zbigniew; Zurawski, Arkadiusz] Jan Kochanowski Univ Humanities & Sci, Fac Hlth Sci, Kielce, Poland; [Sliwinski, Grzegorz] Tech Univ Dresden, Fac Elect & Comp Engn, Inst Biomed Engn, Dresden, Germany	Jan Kochanowski University; Technische Universitat Dresden	Skwiot, M (corresponding author), Jan Kochanowski Univ Humanities & Sci, Fac Hlth Sci, Kielce, Poland.	marlena.skwiot@gmail.com	Żurawski, Arkadiusz/A-9073-2016	Żurawski, Arkadiusz/0000-0003-2564-8607; Skwiot, Marlena/0000-0003-2523-9168	program of the Minister of Science and Higher Education called "Regional Initiative of Excellence" in the years 2019-2022 [024/RID/2018/19]	program of the Minister of Science and Higher Education called "Regional Initiative of Excellence" in the years 2019-2022	Project financed under the program of the Minister of Science and Higher Education called "Regional Initiative of Excellence" in the years 2019-2022, project no. 024/RID/2018/19 The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albisetti W, 2010, INT ORTHOP, V34, P51, DOI 10.1007/s00264-009-0784-3; Alderson Jacqueline, 2009, J Dance Med Sci, V13, P83; Allen N, 2012, J ORTHOP SPORT PHYS, V42, P781, DOI 10.2519/jospt.2012.3893; Amari R, 2009, ARCH ORTHOP TRAUM SU, V129, P397, DOI 10.1007/s00402-008-0685-8; Baigent L., 2013, J CLIN CHIROPRACTIC, V14, P1103; Ballal MS, 2016, J FOOT ANKLE SURG, V55, P927, DOI 10.1053/j.jfas.2016.04.006; Batista CG., 2010, J HLTH SCI I, V28, P47; Bronner S, 2018, PHYS THER SPORT, V31, P42, DOI 10.1016/j.ptsp.2018.01.008; Costa MSS, 2016, BRAZ J PHYS THER, V20, P166, DOI 10.1590/bjpt-rbf.2014.0142; Drezewska Marlena, 2013, Ortop Traumatol Rehabil, V15, P149, DOI 10.5604/15093492.1041451; Dunning J, 2018, CLIN J PAIN, V34, P1149, DOI 10.1097/AJP.0000000000000634; Filipa A, 2018, J ORTHOP SPORT PHYS, V48, P194, DOI 10.2519/jospt.2018.7508; Fournier-Farley C, 2016, AM J SPORT MED, V44, P2166, DOI 10.1177/0363546515617472; Gatha P., 2019, INDIAN J PUBLIC HLTH, V10, P6; Halabchi F, 2017, OPEN ACCESS J SPORTS, V8, P189, DOI 10.2147/OAJSM.S127359; Haugen T., 2016, SPORTSCIENCE, V20, P1; Hendry D, 2015, SCAND J MED SCI SPOR, V25, P888, DOI 10.1111/sms.12302; Henn ED, 2020, INT J SPORTS PHYS TH, V15, P671, DOI 10.26603/ijspt20200671; Hides J, 2008, J ORTHOP SPORT PHYS, V38, P101, DOI 10.2519/jospt.2008.2658; Houston MN, 2017, J SPORT REHABIL, V26, P365, DOI 10.1123/jsr.2016-0011; Hughes P., 2014, ASS ATHLETE BURNOUT, DOI [10.17615/ymb8-gp39, DOI 10.17615/YMB8-GP39]; Kenny SJ, 2016, BRIT J SPORT MED, V50, P997, DOI 10.1136/bjsports-2015-095121; Khoo-Summers L, 2015, MANUAL THER, V20, P623, DOI 10.1016/j.math.2015.01.015; Kline Jessica Beckmann, 2013, J Dance Med Sci, V17, P24; Koutedakis Y., 2000, J DANCE MED SCI, V4, P122; Biernacki JL, 2021, CLIN J SPORT MED, V31, pE64, DOI 10.1097/JSM.0000000000000707; Law M., 2007, CRITICAL REV FORM QU; Liederbach M, 2014, AM J SPORT MED, V42, P1089, DOI 10.1177/0363546514524525; Martinez SF, 2005, AM J SPORT MED, V33, P124, DOI 10.1177/0363546504266479; Mason JS, 2014, INT J SPORTS PHYS TH, V9, P116; McGuine TA, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114530988; Miyamoto RG, 2009, AM J SPORT MED, V37, P1150, DOI 10.1177/0363546508330973; Moen F., 2017, SPORT J, V4, P1; Moen MH, 2012, BRIT J SPORT MED, V46, P253, DOI 10.1136/bjsm.2010.081992; Nihal A, 2005, FOOT ANKLE INT, V26, P908, DOI 10.1177/107110070502601102; Nolton EC, 2018, MED PROBL PERFORM AR, V33, P286, DOI 10.21091/mppa.2018.4042; Ojofeitimi S, 2016, J ORTHOP SPORT PHYS, V46, P114, DOI 10.2519/jospt.2016.5824; Pacey V, 2010, AM J SPORT MED, V38, P1487, DOI 10.1177/0363546510364838; Porter EB, 2010, CURR SPORT MED REP, V9, P290, DOI 10.1249/JSR.0b013e3181f2731e; Prisk VR, 2008, AM J SPORT MED, V36, P2444, DOI 10.1177/0363546508326710; Quarrier NF, 1998, J ORTHOP SPORT PHYS, V28, P168, DOI 10.2519/jospt.1998.28.3.168; Roussel N, 2013, INT J SPORTS MED, V34, P138, DOI 10.1055/s-0032-1321722; Russell JA, 2010, CLIN ANAT, V23, P613, DOI 10.1002/ca.20991; Sanches SB, 2015, RHEUMATOL INT, V35, P741, DOI 10.1007/s00296-014-3127-7; Silk ZM, 2012, FOOT ANKLE INT, V33, P1128, DOI 10.3113/FAI.2012.1128; Skwiot M, 2020, PHYS MED REHAB KUROR, V30, P135, DOI 10.1055/a-1089-8125; Smith PJ, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115592621; Sohrbeck-Nohr O, 2014, BMC PEDIATR, V14, DOI 10.1186/s12887-014-0302-7; Steinberg N, 2014, INT J SPORTS MED, V35, P238, DOI 10.1055/s-0033-1349843; Stuber KJ, 2014, CLIN J SPORT MED, V24, P448, DOI 10.1097/JSM.0000000000000081; Sutlive TG, 2018, INT J SPORTS PHYS TH, V13, P462, DOI 10.26603/ijspt20180462; Twitchett Emily, 2010, J Dance Med Sci, V14, P26; Twitchett EA, 2009, J STRENGTH COND RES, V23, P2732, DOI 10.1519/JSC.0b013e3181bc1749; Vigotsky AD, 2015, PEERJ, V3, DOI 10.7717/peerj.1281; Viktoria KB, 2016, EUR J INTEGR MED, V8, P3, DOI 10.1016/j.eujim.2016.11.004; Vulpiani MC, 2007, J SPORT MED PHYS FIT, V47, P323; Weber AE, 2015, SPORTS HEALTH, V7, P346, DOI 10.1177/1941738114532431; Zaletel P, 2017, INT J OCCUP MED ENV, V30, P151, DOI 10.13075/ijomeh.1896.00818; Zarei H, 2020, ARCH PHYS MED REHAB, V101, P265, DOI 10.1016/j.apmr.2019.07.009	59	0	0	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2021	16	6							e0253437	10.1371/journal.pone.0253437	http://dx.doi.org/10.1371/journal.pone.0253437			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BX	34166414	gold, Green Published			2023-01-03	WOS:000671692800045
J	Chen, YD; Bi, FG; Sun, ZX				Chen, Yangdi; Bi, Fanggang; Sun, Zixue			A network pharmacology approach to determine the underlying mechanisms of action of Yishen Tongluo formula for the treatment of oligoasthenozoospermia	PLOS ONE			English	Article							POTENTIAL TARGETS; SPERM MOTILITY; PREDICTION; PEROXIDATION; ASSOCIATION; APOPTOSIS; CYTOKINES; EXPOSURE; ESTROGEN; GENOMES	Oligoasthenozoospermia is a complex disease caused by a variety of factors, and its incidence is increasing yearly worldwide. Yishen Tongluo formula (YSTLF), created by Professor Sun Zixue, has been used to treat oligoasthenozoospermia in clinical practice for several decades with a good therapeutic effect. However, the chemical and pharmacological profiles of YSTLF remain unclear and need to be elucidated. In this study, a network pharmacology approach was applied to explore the potential mechanisms of YSTLF in oligoasthenozoospermia treatment. All of the compounds in YSTLF were retrieved from the corresponding databases, and the bioactive ingredients were screened according to their oral bioavailability (OB) and drug-likeness (DL). The potential proteins of YSTLF were obtained from the traditional Chinese medicine systems pharmacology (TCMSP) database and the Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM) database, while the potential genes of oligoasthenozoospermia were obtained from the GeneCards database and the DisGeNET database. The STRING database was used to construct an interaction network according to the common targets identified by the online tool Venny for YSTLF and oligoasthenozoospermia. The topological characteristics of nodes were visualized and analyzed through Cytoscape. Biological functions and significant pathways were determined and analyzed using the Gene Ontology (GO) knowledgebase, the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Metascape. Finally, the disease-formula-compound-target-pathway network was constructed by Cytoscape. A total of 106 bioactive ingredients and 134 potential targets from YSTLF were associated with oligoasthenozoospermia or considered to be therapeutically relevant. Pathway analysis indicated that the PI3K/Akt, MAPK and apoptosis signaling pathways were significant pathways involved in oligoasthenozoospermia. In conclusion, the current study expounded the pharmacological actions and molecular mechanisms of YSTLF in treating oligoasthenozoospermia from a holistic viewpoint. The potential molecular mechanisms were closely related to antioxidative stress, antiapoptosis and anti-inflammation, with TNF, CCND1, ESR1, NFKBIA, NR3C1, MAPK8, and IL6 being possible targets. This network pharmacology prediction may offer a helpful tool to illustrate the molecular mechanisms of the Chinese herbal compound YSTLF in oligoasthenozoospermia treatment.	[Chen, Yangdi] Henan Univ Chinese Med, Zhengzhou, Henan, Peoples R China; [Bi, Fanggang] Zhengzhou Univ, Dept Orthoped Surg, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Sun, Zixue] Henan Univ Chinese Med, Dept Reprod Med, Henan Prov Hosp Tradit Chinese Med, Affiliated Hosp 2, Zhengzhou, Henan, Peoples R China	Henan University of Traditional Chinese Medicine; Zhengzhou University; Henan University of Traditional Chinese Medicine	Sun, ZX (corresponding author), Henan Univ Chinese Med, Dept Reprod Med, Henan Prov Hosp Tradit Chinese Med, Affiliated Hosp 2, Zhengzhou, Henan, Peoples R China.	sunhhzx@163.com			National Natural Science Foundation of China (NSFC) [81974573]; Central Plains Thousand Talents Program of Henan Province-Central Plains Famous Doctors Project [ZYMY201809]; Major Special Project of Henan Province for Chinese Medical Researches [2018ZYZD10]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Central Plains Thousand Talents Program of Henan Province-Central Plains Famous Doctors Project; Major Special Project of Henan Province for Chinese Medical Researches	This study was funded by the National Natural Science Foundation of China (NSFC) (81974573), Central Plains Thousand Talents Program of Henan Province (ZYMY201809)-Central Plains Famous Doctors Project and Major Special Project of Henan Province for Chinese Medical Researches (2018ZYZD10).	Agarwal A, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958-015-0032-1; Bai X, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80780-6; Cemeli E, 2004, ENVIRON MOL MUTAGEN, V44, P420, DOI 10.1002/em.20071; Chen Xiang, 2020, Zhonghua Nan Ke Xue, V26, P341; Cooke PS, 2017, PHYSIOL REV, V97, P995, DOI 10.1152/physrev.00018.2016; Deng C., 2020, K AKT MTOR SIGNALLIN, DOI [10.2174/1566524020666201203164910, DOI 10.2174/1566524020666201203164910]; Diao RY, 2019, AM J REPROD IMMUNOL, V82, DOI 10.1111/aji.13155; Dyer S, 2016, HUM REPROD, V31, P1588, DOI 10.1093/humrep/dew082; Fraczek M, 2008, J ANDROL, V29, P85, DOI 10.2164/jandrol.107.003319; Fraczek M, 2013, J REPROD IMMUNOL, V100, P76, DOI 10.1016/j.jri.2013.09.005; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Hu PD, 2017, CELL CYCLE, V16, P2290, DOI 10.1080/15384101.2017.1380130; Huang WY, 2019, ENVIRON POLLUT, V255, DOI 10.1016/j.envpol.2019.113317; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Kumar Naina, 2015, J Hum Reprod Sci, V8, P191, DOI 10.4103/0974-1208.170370; Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.1016/S1875-5364(13)60037-0, 10.3724/SP.J.1009.2013.00110]; Liu ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep21146; Lu HC, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1108-3; Lu J, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109777; Lu T., 2020, EFFECT NANOTITANIUM, DOI [10.1007/s12011-020-02404-4, DOI 10.1007/S12011-020-02404-4]; Luo TT, 2020, CHIN J INTEGR MED, V26, P72, DOI 10.1007/s11655-019-3064-0; Martinez P, 2007, ASIAN J ANDROL, V9, P102, DOI 10.1111/j.1745-7262.2007.00238.x; MEN Bo., 2017, CHINESE MED MODERN D, V15, P84; Min KB, 2017, ENVIRON POLLUT, V226, P118, DOI 10.1016/j.envpol.2017.03.069; Nordkap L, 2017, ANDROLOGY-US, V5, P1105, DOI 10.1111/andr.12418; Perdichizzi A, 2007, J CLIN IMMUNOL, V27, P152, DOI 10.1007/s10875-007-9071-5; Nueno VIP, 2016, CURR PHARM DESIGN, V22, P6881, DOI 10.2174/138161282246170124192058; Pinero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943; Politch JA, 2007, HUM REPROD, V22, P2928, DOI 10.1093/humrep/dem281; Potnuri AG, 2018, BIOMED PHARMACOTHER, V101, P174, DOI 10.1016/j.biopha.2018.02.068; Primmer CR, 2013, MOL ECOL, V22, P3216, DOI 10.1111/mec.12309; Rakha B., 2020, GALLUS GALLUS MURGHI, V18, P311, DOI [10.1089/bio.2020.0007, DOI 10.1089/BIO.2020.0007]; Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141; Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13; Sapozhkova Z., 2020, DIAGNOSTIKA, V65, P106, DOI [10.18821/0869-2084-2020-65-2-106-110, DOI 10.51620/0869-2084]; Saraswat S, 2020, REPROD DOMEST ANIM, V55, P1080, DOI 10.1111/rda.13746; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shen XY, 2018, INT J MOL MED, V42, P2819, DOI 10.3892/ijmm.2018.3825; Silva EJR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17944-4; Stelzer G, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2722-2; Sun W, 2014, J ASSIST REPROD GEN, V31, P541, DOI 10.1007/s10815-014-0177-4; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Tao WY, 2013, J ETHNOPHARMACOL, V145, P1, DOI 10.1016/j.jep.2012.09.051; Wang HY, 2019, BIOL RES, V52, DOI 10.1186/s40659-019-0248-1; Wang J, 2010, LUPUS, V19, P734, DOI 10.1177/0961203309359517; Wang Y, 2021, J ADV RES, V28, P231, DOI 10.1016/j.jare.2020.07.007; Xu WM, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00007; Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964; Yahyazadeh A, 2019, BIOTECH HISTOCHEM, V94, P298, DOI 10.1080/10520295.2019.1566568; Yang Z, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/7628125; Ye RJ, 2020, FITOTERAPIA, V147, DOI 10.1016/j.fitote.2020.104756; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu LS, 2019, OPEN BIOL, V9, pCP6, DOI 10.1098/rsob.180091; Zhang J, 2020, EXP CELL RES, V394, DOI 10.1016/j.yexcr.2020.112151; Zhang SN, 2017, J ETHNOPHARMACOL, V198, P131, DOI 10.1016/j.jep.2017.01.002; Zhang YH, 2015, TOXICOL REP, V2, P664, DOI 10.1016/j.toxrep.2015.04.007; Zhang ZY, 2020, J ETHNOPHARMACOL, V249, DOI 10.1016/j.jep.2019.112371; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6; Zhu Q, 2019, ARTIF CELL NANOMED B, V47, P2010, DOI 10.1080/21691401.2019.1608217	59	2	3	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2021	16	6							e0252906	10.1371/journal.pone.0252906	http://dx.doi.org/10.1371/journal.pone.0252906			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BF	34153045	Green Published, gold			2023-01-03	WOS:000671691000024
J	Sohraby, F; Aryapour, H				Sohraby, Farzin; Aryapour, Hassan			Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation	PLOS ONE			English	Article							RESPIRATORY SYNDROME-CORONAVIRUS; PROTEASE; IDENTIFICATION; VIRUS	The COVID-19 disease has infected and killed countless people all over the world since its emergence at the end of 2019. No specific therapy for COVID-19 is not currently available, and urgent treatment solutions are needed. Recent studies have found several potential molecular targets, and one of the most critical proteins of the SARS-CoV-2 virus work machine is the Papain-like protease (Plpro). Potential inhibitors are available, and their X-ray crystallographic structures in complex with this enzyme have been determined recently. However, their activities against this enzyme are insufficient and need to be characterized and improved to be of clinical values. Therefore, in this work, by utilizing the Supervised Molecular Dynamics (SuMD) simulation method, we achieved multiple unbinding events of Plpro inhibitors, GRL0617, and its derivates, and captured and understood the details of the unbinding pathway. We found that residues of the BL2 loop, such as Tyr268 and Gln269, play major roles in the unbinding pathways, but the most important contributing factor is the natural movements and behavior of the BL2 loop, which can control the entire process. We believe that the details found in this study can be used to refine and optimize potential inhibitors like GRL0617 and design more efficacious inhibitors as a treatment for the SARS-CoV-2 virus.	[Sohraby, Farzin; Aryapour, Hassan] Golestan Univ, Fac Sci, Dept Biol, Gorgan, Golestan, Iran		Aryapour, H (corresponding author), Golestan Univ, Fac Sci, Dept Biol, Gorgan, Golestan, Iran.	hassan.aryapour@gmail.com			Golestan University, Gorgan, Iran [99-213-1]	Golestan University, Gorgan, Iran	This investigation was supported by the grant number 99-213-1 from Golestan University, Gorgan, Iran.	Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001; Agrawal Umang, 2020, Med J Armed Forces India, V76, P370, DOI 10.1016/j.mjafi.2020.08.004; Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015; Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bekes M, 2015, BIOCHEM J, V468, P215, DOI 10.1042/BJ20141170; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bosken YK, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00174; Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420; Cai QX, 2020, ENGINEERING-PRC, V6, P1192, DOI 10.1016/j.eng.2020.03.007; Chakraborty I, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138882; Clementz MA, 2010, J VIROL, V84, P4619, DOI 10.1128/JVI.02406-09; Cohen MS, 2020, NEW ENGL J MED, V383, P585, DOI 10.1056/NEJMe2020388; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Deganutti G, 2020, J CHEM INF MODEL, V60, P1804, DOI 10.1021/acs.jcim.9b01094; Drozdzal S, 2020, DRUG RESIST UPDATE, V53, DOI 10.1016/j.drup.2020.100719; Duan Kai, 2020, Proc Natl Acad Sci U S A, V117, P9490, DOI 10.1073/pnas.2004168117; Gao XP, 2021, ACTA PHARM SIN B, V11, P237, DOI 10.1016/j.apsb.2020.08.014; Gohlke H, 2013, J CHEM INF MODEL, V53, P2493, DOI 10.1021/ci400370y; Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004; Heidary F, 2020, J ANTIBIOT, V73, P593, DOI 10.1038/s41429-020-0336-z; Heifetz A, 2018, METHODS MOL BIOL, V1705, P375, DOI 10.1007/978-1-4939-7465-8_19; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034; Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kaptein SJF, 2020, P NATL ACAD SCI USA, V117, P26955, DOI 10.1073/pnas.2014441117; Khan Z., 2021, Le Pharmacien Hospitalier & Clinicien, V56, P3, DOI 10.1016/j.phclin.2020.06.003; Klemm T, 2020, EMBO J, V39, DOI 10.15252/embj.2020106275; Kraus D., 2014, MED WRIT, V23, P25, DOI DOI 10.1179/2047480613Z.000000000181; Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m; Lim KP, 2000, J VIROL, V74, P1674, DOI 10.1128/JVI.74.4.1674-1685.2000; Lindner HA, 2007, ARCH BIOCHEM BIOPHYS, V466, P8, DOI 10.1016/j.abb.2007.07.006; Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272; Osipiuk J., 2020, BIORXIV, DOI [10.1101/2020.08.06.240192, DOI 10.1101/2020.08.06.240192]; PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461; Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105; Sabbadin D, 2018, METHODS MOL BIOL, V1824, P287, DOI 10.1007/978-1-4939-8630-9_17; Shin D, 2020, NATURE, V587, P657, DOI 10.1038/s41586-020-2601-5; Sohraby F, 2021, SEMIN CANCER BIOL, V68, P249, DOI 10.1016/j.semcancer.2020.04.007; Sohraby F, 2020, BIOINFORMATICS, V36, P4714, DOI 10.1093/bioinformatics/btaa565; Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI 10.1186/1756-0500-5-367; Tao YY, 2020, EXPERT OPIN EMERG DR, V25, P81, DOI 10.1080/14728214.2020.1773431; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Wu RJ, 2016, CURR TOP MED CHEM, V16, P156, DOI [10.2174/1568026615666150701114831, 10.2174/1568026615666150825142002]; Xiu SY, 2020, J MED CHEM, V63, P12256, DOI 10.1021/acs.jmedchem.0c00502; Zhai Pan, 2020, Int J Antimicrob Agents, V55, P105955, DOI 10.1016/j.ijantimicag.2020.105955	51	8	8	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2021	16	5							e0251910	10.1371/journal.pone.0251910	http://dx.doi.org/10.1371/journal.pone.0251910			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6NP	34010326	Green Published, gold			2023-01-03	WOS:000664630900078
J	Tiacci, E; De Carolis, L; Simonetti, E; Capponi, M; Ambrosetti, A; Lucia, E; Antolino, A; Pulsoni, A; Ferrari, S; Zinzani, PL; Ascani, S; Perriello, VM; Rigacci, L; Gaidano, G; Della Seta, R; Frattarelli, N; Falcucci, P; Foa, R; Visani, G; Zaja, F; Falini, B				Tiacci, Enrico; De Carolis, Luca; Simonetti, Edoardo; Capponi, Monia; Ambrosetti, Achille; Lucia, Eugenio; Antolino, Agostino; Pulsoni, Alessandro; Ferrari, Samantha; Zinzani, Pier L.; Ascani, Stefano; Perriello, Vincenzo M.; Rigacci, Luigi; Gaidano, Gianluca; Della Seta, Roberta; Frattarelli, Natalia; Falcucci, Paolo; Foa, Robin; Visani, Giuseppe; Zaja, Francesco; Falini, Brunangelo			Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINIMAL RESIDUAL DISEASE; BRAF INHIBITION; PHASE-II; CLADRIBINE; IMMUNOHISTOCHEMISTRY; ERADICATION; MANAGEMENT; MUTATIONS; DIAGNOSIS	BRAF Inhibition plus Rituximab in Hairy-Cell Leukemia The rare indolent B-cell cancer hairy-cell leukemia is often driven by activating BRAF mutations. BRAF inhibition induces responses, but relapse is common when therapy stops. The addition of rituximab (anti-CD20 antibody) to vemurafenib led to a complete response in 26 of 30 patients (87%) with relapsed or refractory disease; 78% were progression-free at 3 years. Background Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which a BRAF V600E kinase-activating mutation plays a pathogenetic role. In clinical trials involving patients with refractory or relapsed HCL, the targeting of BRAF V600E with the oral BRAF inhibitor vemurafenib led to a response in 91% of the patients; 35% of the patients had a complete response. However, the median relapse-free survival was only 9 months after treatment was stopped. Methods In a phase 2, single-center, academic trial involving patients with refractory or relapsed HCL, we assessed the safety and efficacy of vemurafenib (960 mg, administered twice daily for 8 weeks) plus concurrent and sequential rituximab (375 mg per square meter of body-surface area, administered for 8 doses over a period of 18 weeks). The primary end point was a complete response at the end of planned treatment. Results Among the 30 enrolled patients with HCL, the median number of previous therapies was 3. A complete response was observed in 26 patients (87%) in the intention-to-treat population. All the patients who had HCL that had been refractory to chemotherapy (10 patients) or rituximab (5) and all those who had previously been treated with BRAF inhibitors (7) had a complete response. Thrombocytopenia resolved after a median of 2 weeks, and neutropenia after a median of 4 weeks. Of the 26 patients with a complete response, 17 (65%) were cleared of minimal residual disease (MRD). Progression-free survival among all 30 patients was 78% at a median follow-up of 37 months; relapse-free survival among the 26 patients with a response was 85% at a median follow-up of 34 months. In post hoc analyses, MRD negativity and no previous BRAF inhibitor treatment correlated with longer relapse-free survival. Toxic effects, mostly of grade 1 or 2, were those that had previously been noted for these agents. Conclusions In this small study, a short, chemotherapy-free, nonmyelotoxic regimen of vemurafenib plus rituximab was associated with a durable complete response in most patients with refractory or relapsed HCL. (Funded by the European Research Council and others; HCL-PG03 EudraCT number, .)	[Tiacci, Enrico; De Carolis, Luca; Simonetti, Edoardo; Capponi, Monia; Ascani, Stefano; Perriello, Vincenzo M.; Falini, Brunangelo] Univ Perugia, Osped S Maria Misericordia, Inst Hematol, Perugia, Italy; [Tiacci, Enrico; De Carolis, Luca; Simonetti, Edoardo; Capponi, Monia; Ascani, Stefano; Perriello, Vincenzo M.; Falini, Brunangelo] Univ Perugia, Dept Med, Perugia, Italy; [Ambrosetti, Achille] Univ Verona, Dept Med, Sect Hematol, Verona, Italy; [Lucia, Eugenio] Osped Cosenza, Hematol Unit, Cosenza, Italy; [Antolino, Agostino] Maria Paterno Arezzo Hosp, Dept Transfus Med SIMMT, Hematol Unit, Ragusa, Italy; [Pulsoni, Alessandro; Foa, Robin] Sapienza Univ Rome, Hematol Unit, Dep Translat & Precis Med, Rome, Italy; [Rigacci, Luigi] AO San Camillo Forlanini, Hematol & Stem Cell Transplant Unit, Rome, Italy; [Ferrari, Samantha] Spedali Civili Brescia, Dept Hematol, Brescia, Italy; [Zinzani, Pier L.] Univ Bologna, Ist Emarol Seragnoli, IRCCS Azienda Osped Univ Bologna, Bologna, Italy; [Zinzani, Pier L.] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimenta, Bologna, Italy; [Gaidano, Gianluca] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy; [Della Seta, Roberta] Osped Carrara, Hematol Unit, Carrara, Italy; [Frattarelli, Natalia] Osped Frosinone, Hematol Unit, Frosinone, Italy; [Falcucci, Paolo] Osped Ronciglione, Hematol Unit, Viterbo, Italy; [Visani, Giuseppe] Osped Pesaro, Hematol Unit, Pesaro, Italy; [Zaja, Francesco] Azienda Sanitaria Univ Integrara Osped Maggiore, Hematol Unit, Trieste, Italy	Hospital Santa Maria della Misericordia; University of Perugia; University of Perugia; University of Verona; Civile M.P. Arezzo Hospital; Sapienza University Rome; Azienda Ospedaliera San Camillo-Forlanini; Hospital Spedali Civili Brescia; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; University of Bologna; University of Eastern Piedmont Amedeo Avogadro	Tiacci, E; Falini, B (corresponding author), Osped S Maria Misericordia, Ctr Ric Ematooncol, Blocco R,Piano 2,Piazzale Menghini 8, I-06132 Perugia, Italy.	enrico.tiacci@unipg.it; brunangelo.falini@unipg.it	Gaidano, Gianluca/AAW-2773-2021	Gaidano, Gianluca/0000-0002-4681-0151	Associazione Italiana per la Ricerca sul Cancro [grant Metastasis/5-per-mille no. 21198 to BF and R, IG-14447 to ET] Funding Source: Medline; Fondation ARC pour la Recherche sur le Cancer [Leopold Griffuel Prize 2015 to BF] Funding Source: Medline; Leukemia and Lymphoma Society [Scholarship in Clinical Research 2030-14 to ET] Funding Source: Medline; Ministero della Salute [RF-2016-02362264 to ET] Funding Source: Medline; Hairy Cell Leukemia Foundation [grant 2016 to ET and BF] Funding Source: Medline	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Ministero della Salute(Ministry of Health, Italy); Hairy Cell Leukemia Foundation		Benz R, 2020, BLOOD ADV, V4, P3699, DOI 10.1182/bloodadvances.2020002160; Bohn JP, 2019, AM J HEMATOL, V94, pE180, DOI 10.1002/ajh.25474; Brown NA, 2015, AM J CLIN PATHOL, V143, P89, DOI 10.1309/AJCPDN4Q1JTFGCFC; Chakraborty R, 2020, COLD SPRING HARB PER; Chihara D, 2020, J CLIN ONCOL, V38, P1527, DOI 10.1200/JCO.19.02250; Chihara D, 2016, BRIT J HAEMATOL, V174, P760, DOI 10.1111/bjh.14129; Dietrich S, 2016, BLOOD, V127, P2847, DOI 10.1182/blood-2015-11-680074; Dietrich S, 2012, NEW ENGL J MED, V366, P2038, DOI 10.1056/NEJMc1202124; Else M, 2015, BEST PRACT RES CL HA, V28, P217, DOI 10.1016/j.beha.2015.09.004; Falini B, 2019, HEMATOL ONCOL, V37, P30, DOI 10.1002/hon.2594; Falini B, 2016, BLOOD, V128, P1918, DOI 10.1182/blood-2016-07-418434; Foucar K, 2017, WHO CLASSIFICATION T, P226; Glenthoj A, 2021, EUR J HAEMATOL, V106, P72, DOI 10.1111/ejh.13519; Grever MR, 2017, BLOOD, V129, P553, DOI 10.1182/blood-2016-01-689422; Grever MR, 2010, BLOOD, V115, P21, DOI 10.1182/blood-2009-06-195370; Grever MR, LEUKEMIA; Gupta GK, 2020, AM J CLIN PATHOL, V153, P322, DOI 10.1093/ajcp/aqz171; Kreitman RJ, 2018, LEUKEMIA, V32, P1768, DOI 10.1038/s41375-018-0210-1; Kreitman RJ, 2018, BLOOD, V131, P2331, DOI 10.1182/blood-2017-09-803072; Lee LYW, 2020, LANCET ONCOL, V21, P1309, DOI 10.1016/S1470-2045(20)30442-3; Maitre E, 2019, AM J HEMATOL, V94, P1413, DOI 10.1002/ajh.25653; Nieva J, 2003, BLOOD, V102, P810, DOI 10.1182/blood-2003-01-0014; Ortiz-Maldonado V, 2018, BRIT J HAEMATOL, V183, P127, DOI 10.1111/bjh.14900; Paillassa J, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0328-z; Pettirossi V, 2015, BLOOD, V125, P1207, DOI 10.1182/blood-2014-10-603100; Raspadori D, 1999, LEUKEMIA, V13, P1254, DOI 10.1038/sj.leu.2401476; Rosenberg JD, 2014, BLOOD, V123, P177, DOI 10.1182/blood-2013-06-508754; Sarid N, 2015, BRIT J HAEMATOL, V171, P784, DOI 10.1111/bjh.13767; Shenoi DP, 2019, BLOOD ADV, V3, P116, DOI 10.1182/bloodadvances.2018027466; Sigal DS, 2010, BLOOD, V115, P1893, DOI 10.1182/blood-2009-10-251645; Tiacci E, 2015, NEW ENGL J MED, V373, P1733, DOI 10.1056/NEJMoa1506583; Tiacci E, 2006, NAT REV CANCER, V6, P437, DOI 10.1038/nrc1888; Tiacci E, 2021, LEUKEMIA, V35, P3314, DOI 10.1038/s41375-021-01210-8; Tiacci E, 2017, J CLIN ONCOL, V35, P1002, DOI 10.1200/JCO.2016.71.1556; Tiacci E, 2013, HAEMATOLOGICA, V98, P635, DOI 10.3324/haematol.2012.078071; Tiacci E, 2012, BLOOD, V119, P192, DOI 10.1182/blood-2011-08-371179; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; Vergote V, 2014, ANN HEMATOL, V93, P2087, DOI 10.1007/s00277-014-2104-2	38	34	35	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2021	384	19					1810	1823		10.1056/NEJMoa2031298	http://dx.doi.org/10.1056/NEJMoa2031298			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SD6UF	33979489	Bronze, Green Published			2023-01-03	WOS:000651509400009
J	Fernandez-Rodriguez, R; Alvarez-Bueno, C; Reina-Gutierrez, S; Torres-Costoso, A; Nunez de Arenas-Arroyo, S; Martinez-Vizcaino, V				Fernandez-Rodriguez, Ruben; Alvarez-Bueno, Celia; Reina-Gutierrez, Sara; Torres-Costoso, Ana; Nunez de Arenas-Arroyo, Sergio; Martinez-Vizcaino, Vicente			Effectiveness of Pilates and Yoga to improve bone density in adult women: A systematic review and meta-analysis	PLOS ONE			English	Review							MINERAL DENSITY; EXERCISE; BALANCE; PERFORMANCE; QUALITY	Background The ageing population brings about the appearance of age-related health disorders, such as osteoporosis or osteopenia. These disorders are associated with fragility fractures. The impact is greater among postmenopausal women due to an acceleration of bone mineral density (BMD) loss. Objective To estimate the effectiveness of Pilates or Yoga on BMD in adult women. Methods Five electronics databases were searched up to April 2021. Randomized controlled trials (RCTs), non-RCTs and pre-post studies were included. The main outcome was BMD. Risk of bias was evaluated using the Cochrane risk of bias tool. A random effects model was used to pool data from primary studies. Subgroup analyses based on the type of exercise were conducted. Results Eleven studies including 591 participants aged between 45 and 78 years were included. The mean length of the interventions ranged from 12 to 32 weeks, and two studies were performed for a period of at least one year. The pooled effect size for the effect of the intervention (Pilates/Yoga) vs the control group was 0.07 (95% Confidence interval [CI]: -0.05 to 0.19; I-2 = 0.0%), and 0.10 (95% CI: 0.01 to 0.18; I-2 = 18.4%) for the secondary analysis of the pre-post intervention. Conclusions Despite of the non-significant results, the BMD maintenance in the postmenopausal population, when BMD detrimental is expected, could be understood as a positive result added to the beneficial impact of Pilates-Yoga in multiple fracture risk factors, including but not limited to, strength and balance.	[Fernandez-Rodriguez, Ruben; Alvarez-Bueno, Celia] Univ Castilla La Mancha, Movi Fitness SL, Cuenca, Spain; [Fernandez-Rodriguez, Ruben; Alvarez-Bueno, Celia; Reina-Gutierrez, Sara; Nunez de Arenas-Arroyo, Sergio; Martinez-Vizcaino, Vicente] Univ Castilla La Mancha, Hlth & Social Res Ctr, Cuenca, Spain; [Alvarez-Bueno, Celia] Univ Politecn & Artist Paraguay, Asuncion, Paraguay; [Torres-Costoso, Ana] Univ Castilla La Mancha, Escuela Fisioterapia & Enfermeria, Toledo, Spain; [Martinez-Vizcaino, Vicente] Univ Autonoma Chile, Fac Ciencias Salud, Talca, Chile	Universidad de Castilla-La Mancha; Universidad de Castilla-La Mancha; Universidad de Castilla-La Mancha; Universidad Autonoma de Chile	Alvarez-Bueno, C (corresponding author), Univ Castilla La Mancha, Hlth & Social Res Ctr, Cuenca, Spain.; Alvarez-Bueno, C (corresponding author), Univ Politecn & Artist Paraguay, Asuncion, Paraguay.	celia.alvarezbueno@uclm.es	VIZCAINO, VICENTE MARTINEZ/AAZ-9034-2021; Reina, Sara/AAY-8751-2021; Núñez de Arenas-Arroyo, Sergio/AAY-8958-2021; VIZCAINO, VICENTE MARTINEZ/R-4336-2017	VIZCAINO, VICENTE MARTINEZ/0000-0001-6121-7893; VIZCAINO, VICENTE MARTINEZ/0000-0001-6121-7893; Torres-Costoso, Ana/0000-0001-8961-3169; Nunez de Arenas-Arroyo, Sergio/0000-0001-7774-8437; Alvarez-Bueno, Celia/0000-0002-6176-1618; Reina Gutierrez, Sara/0000-0003-4310-3715	European Regional Development Fund	European Regional Development Fund(European Commission)	This study was funded by European Regional Development Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguado-Henche S, 2017, REV INT MED CIENC AC, V17, P493, DOI 10.15366/rimcafd2017.67.007; Angin E, 2015, J BACK MUSCULOSKELET, V28, P849, DOI 10.3233/BMR-150604; Armijo-Olivo S, 2012, J EVAL CLIN PRACT, V18, P12, DOI 10.1111/j.1365-2753.2010.01516.x; Armstrong MEG, 2020, J BONE MINER RES, V35, P277, DOI 10.1002/jbmr.3896; Babatunde OO, 2020, ARCH PHYS MED REHAB, V101, P487, DOI 10.1016/j.apmr.2019.07.007; Benedetti MG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4840531; Bezerra L., 2010, J EXERC PHYSL ONLINE; de Souza ROB, 2018, AM J PHYS MED REHAB, V97, P414, DOI 10.1097/PHM.0000000000000883; Cauley JA, 2020, LANCET DIABETES ENDO, V8, P150, DOI 10.1016/S2213-8587(19)30351-1; CHILIBECK PD, 1995, SPORTS MED, V19, P103, DOI 10.2165/00007256-199519020-00003; Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198-014-2794-2; Daly RM, 2019, BRAZ J PHYS THER, V23, P170, DOI 10.1016/j.bjpt.2018.11.011; de Oliveira LC, 2019, J GERIATR PHYS THER, V42, pE23, DOI 10.1519/JPT.0000000000000184; Deng HW, 2002, J BONE MINER METAB, V20, P358, DOI 10.1007/s007740200052; Moreira LDF, 2014, ARQ BRAS ENDOCRINOL, V58, P514, DOI 10.1590/0004-2730000003374; Fong SSM, 2018, INTEGR CANCER THER, V17, P124, DOI 10.1177/1534735416686687; Gandolfi NRS, 2020, QUAL LIFE RES, V29, P381, DOI 10.1007/s11136-019-02293-8; Giannakou I, 2021, MUSCULOSKELET CARE, V19, P67, DOI 10.1002/msc.1511; Gonzalo-Encabo P, 2019, SCAND J MED SCI SPOR, V29, P1121, DOI 10.1111/sms.13443; Grande GHD, 2018, BRIT J SPORT MED, V52, P199, DOI 10.1136/bjsports-2016-097073; Grindler NM, 2015, MENOPAUSE, V22, P1351, DOI 10.1097/GME.0000000000000536; Hernandez CJ, 2003, OSTEOPOROSIS INT, V14, P843, DOI 10.1007/s00198-003-1454-8; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins P., 2019, ROB 2 O DEV GR; Howe TE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000333, 10.1002/14651858.CD000333.pub2]; Irez GB, 2009, MEDICINE; Ruiz-Montero PJ, 2014, CLIN INTERV AGING, V9, P742; Kang C., 2014, KOREAN J OPTHALMOLOG, V23, P50, DOI [10.7570/KJO.2014.23.1.50, DOI 10.7570/KJO.2014.23.1.50]; Kemmler W, 2016, BONE, V89, P1, DOI 10.1016/j.bone.2016.04.019; Kim S, 2015, J SPORT SCI MED, V14, P756; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; Kohrt WM, 2004, MED SCI SPORT EXER, V36, P1985, DOI 10.1249/01.MSS.0000142662.21767.58; LaMonte MJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.14084; Lein D., 2018, J YOGA PHYSIOTHER, V4, P7, DOI [10.19080/JYP.2018.04.555649, DOI 10.19080/JYP.2018.04.555649]; Lewiecki EM, 2008, BONE, V43, P1115, DOI 10.1016/j.bone.2008.08.106; Liu FH, 2017, J CHIN MED ASSOC, V80, P790, DOI 10.1016/j.jcma.2016.06.010; Lu YH, 2016, TOP GERIATR REHABIL, V32, P81, DOI 10.1097/TGR.0000000000000085; Mikalacki M, 2015, INT J MORPHOL, V33, P1220, DOI 10.4067/S0717-95022015000400004; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Motorwala Zainab S, 2016, Int J Yoga, V9, P44, DOI 10.4103/0973-6131.171717; Serbescu C.I., 2017, GEOSPORT SOC, V6, P14; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Stone TM, 2016, MED SCI SPORT EXER, V48, P186, DOI 10.1249/01.mss.0000485560.75692.b8; Sutton AJAK, 2000, METHODS METAANALYSIS; Thalheimer W., 2002, WORK LEARNING RES, V1, P1, DOI DOI 10.1113/JPHYSIOL.2004.078915; Tong XY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8171897; Turner CH, 2002, OSTEOPOROSIS INT, V13, P97, DOI 10.1007/s001980200000; Wade SW, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657-014-0182-3; Youkhana S, 2016, AGE AGEING, V45, P21, DOI 10.1093/ageing/afv175	51	4	4	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2021	16	5							e0251391	10.1371/journal.pone.0251391	http://dx.doi.org/10.1371/journal.pone.0251391			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SX8UE	33961670	gold, Green Published			2023-01-03	WOS:000665471900058
J	Byiringiro, S; Wong, R; Logan, J; Kaneza, D; Gitera, J; Umutesi, S; Kirk, CM				Byiringiro, Samuel; Wong, Rex; Logan, Jenae; Kaneza, Deogratias; Gitera, Joseph; Umutesi, Sharon; Kirk, Catherine M.			A qualitative study to explore the experience of parents of newborns admitted to neonatal care unit in rural Rwanda	PLOS ONE			English	Article							FAMILY-CENTERED CARE; POSTPARTUM DEPRESSION; PRETERM; INFANTS; MOTHERS	Background Neonatal Care Units (NCUs) provide special care to sick and small newborns and help reduce neonatal mortality. For parents, having a hospitalized newborn can be a traumatic experience. In sub-Saharan Africa, there is limited literature about the parents' experience in NCUs. Objective Our study aimed to explore the experience of parents in the NCU of a rural district hospital in Rwanda. Methods A qualitative study was conducted with parents whose newborns were hospitalized in the Ruli District Hospital NCU from September 2018 to January 2019. Interviews were conducted using a semi-structured guide in the participants' homes by trained data collectors. Data were transcribed, translated, and then coded using a structured code book. All data were organized using Dedoose software for analysis. Results Twenty-one interviews were conducted primarily with mothers (90.5%, n = 19) among newborns who were most often discharged home alive (90.5%, n = 19). Four themes emerged from the interviews. These were the parental adaptation to having a sick neonate in NCU, adaptation to the NCU environment, interaction with people (healthcare providers and fellow parents) in the NCU, and financial stressors. Conclusion The admission of a newborn to the NCU is a source of stress for parents and caregivers in rural Rwanda, however, there were several positive aspects which helped mothers adapt to the NCU. The experience in the NCU can be improved when healthcare providers communicate and explain the newborn's status to the parents and actively involve them in the care of their newborn. Expanding the NCU access for families, encouraging peer support, and ensuring financial accessibility for neonatal care services could contribute to improved experiences for parents and families in general.	[Byiringiro, Samuel; Kirk, Catherine M.] Partners Hlth Inshuti Mu Buzima, Maternal & Child Hlth Dept, Rwinkwavu, Rwanda; [Byiringiro, Samuel; Wong, Rex; Logan, Jenae; Kirk, Catherine M.] Univ Global Hlth Equ, Bill & Joyce Cummings Inst Global Hlth, Butaro, Rwanda; [Wong, Rex] Yale Univ, Sch Publ Hlth, New Haven, CT USA; [Kaneza, Deogratias] Minist Hlth, Ruli Dist Hosp, Gakenke, Rwanda; [Gitera, Joseph] Minist Hlth, Clin & Publ Hlth Serv Div, Kigali, Rwanda; [Umutesi, Sharon] Rwanda Biomed Ctr, Maternal Child & Community Hlth Div, Kigali, Rwanda; [Byiringiro, Samuel] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA; [Logan, Jenae] Partners In Hlth, Boston, MA USA	Yale University; Rwanda Biomedical Center; Johns Hopkins University	Byiringiro, S (corresponding author), Partners Hlth Inshuti Mu Buzima, Maternal & Child Hlth Dept, Rwinkwavu, Rwanda.; Byiringiro, S (corresponding author), Univ Global Hlth Equ, Bill & Joyce Cummings Inst Global Hlth, Butaro, Rwanda.; Byiringiro, S (corresponding author), Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA.	sam6as@yahoo.com		Logan, Jenae/0000-0002-3002-0809; Kirk, Catherine/0000-0001-9103-2611; Byiringiro, Samuel/0000-0001-9165-0348	Grand Challenges Canada Saving Lives at Birth	Grand Challenges Canada Saving Lives at Birth	CMK: Received funding from Grand Challenges Canada Saving Lives at Birth as part of the evaluation of the All Babies Count initiative. SB: University of Global Health Equity covered the cost of Dedoose software utilized in the analysis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adama EA., 2017, J NEONATAL NURS, V23, P275, DOI [10.1016/j.jnn.2017.05.003, DOI 10.1016/J.JNN.2017.05.003]; Agaba F., 2019, CHILD SURVIV PROGR; Altimier L, 2009, NEWBORN INFANT NURS, V9, pE12, DOI 10.1053/j.nainr.2009.06.001; [Anonymous], 2004, Paediatr Child Health, V9, P575; [Anonymous], 2016, RWAND 2014 15 STUD F, V47, P395, DOI [10.1111/sifp.12002, DOI 10.1111/SIFP.12002]; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Black MM, 2017, LANCET, V389, P77, DOI 10.1016/S0140-6736(16)31389-7; Charpak N, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2063; Darcy Mahoney Ashley, 2020, J Perinatol, V40, P36, DOI 10.1038/s41372-020-0753-7; Dunn MS, 2006, PEDIATRICS, V118, pS95, DOI 10.1542/peds.2006-0913F; EFCNI, 2016, WELC FAM NEON INT CA; Eichner JM, 2012, PEDIATRICS, V129, P394, DOI 10.1542/peds.2011-3084; Fisher D., 2018, J NEONATAL NURS, V24, P306, DOI [10.1016, DOI 10.1016/J.JNN.2018.08.007]; Griffin T, 2013, J PERINAT NEONAT NUR, V27, P160, DOI 10.1097/JPN.0b013e3182907f26; Guimaraes H, 2015, J PEDIATR NEONATAL I, V4, DOI 10.7363/040244; Hagen IH, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-018-3854-7; Hansen A., 2015, PUBLIC HEAL ACTION, V5, P2220; Hawell E., 2011, PICK I EUR, P1; Heidari Haydeh, 2013, Iran J Nurs Midwifery Res, V18, P208; Karlsson V, 2012, J PEDIATR-US, V161, P422, DOI 10.1016/j.jpeds.2012.02.034; Lakshmanan A., 2015, ARCH DIS CHILD, V100, pA47; Lefkowitz DS, 2010, J CLIN PSYCHOL MED S, V17, P230, DOI 10.1007/s10880-010-9202-7; Martinez AM, 2012, J PAEDIATR CHILD H, V48, P852, DOI 10.1111/j.1440-1754.2012.02544.x; Murray PD, 2020, J PERINATOL, V40, P1576, DOI 10.1038/s41372-020-00781-1; Musabirema P., 2015, CURATIONIS DENOSA, DOI [10.4102/curationis.v38i2.1499, DOI 10.4102/CURATIONIS.V38I2.1499]; Ncube RK., 2016, CURATIONIS, V39, P9; Nyishime M, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1334-1; O'Brien K, 2018, LANCET CHILD ADOLESC, V2, P245, DOI 10.1016/S2352-4642(18)30039-7; Obeidat HM, 2009, J PERINAT EDUC, V18, P23, DOI 10.1624/105812409X461199; Ostergaard LR, 2015, GLOB PUBLIC HEALTH, V10, P1046, DOI 10.1080/17441692.2015.1019538; Ottosson C, 2017, J NEONATAL NURS, V23, P112, DOI [10.1016/j.jnn.2016.11.001, DOI 10.1016/J.JNN.2016.11.001]; Poehlmann J, 2009, J FAM PSYCHOL, V23, P690, DOI 10.1037/a0016117; Rogers CE, 2013, J PERINATOL, V33, P171, DOI 10.1038/jp.2012.75; Ruzibiza Y, 2021, GLOB PUBLIC HEALTH, V16, P763, DOI 10.1080/17441692.2020.1751230; Rwanda Ministry of Health, 2017, RWAND HLTH MAN INF S; Rwanda Ministry of Health, 2012, NEON CLIN TREATM GUI; Rwanda MOH., 2017, HLTH SERV PACK HLTH; Rwanda Social Security Board, 2019, COMMUNITY BASED HLTH; Steyn Erika, 2017, Curationis, V40, P1, DOI 10.4102/curationis.v40i1.1698; Tandberg BS., 2013, J NEONATAL NURS, V19, P317; Tuncalp O, 2015, BJOG-INT J OBSTET GY, V122, P1045, DOI 10.1111/1471-0528.13451; Verma A, 2017, INDIAN PEDIATR, V54, P455, DOI 10.1007/s13312-017-1047-9; WHO, 2018, WORLD HEAL ORGAN, P2017; Williams KG, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010060; World Energy Council, 2019, WMO GREENH GAS B STA, P1	45	0	0	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0252776	10.1371/journal.pone.0252776	http://dx.doi.org/10.1371/journal.pone.0252776			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TZ8RN	34388168	Green Submitted, gold, Green Published			2023-01-03	WOS:000684737400037
J	Secunda, KE; Krolikowski, KA; Savage, MF; Kruser, JM				Secunda, Katharine E.; Krolikowski, Kristyn A.; Savage, Madeline F.; Kruser, Jacqueline M.			Evaluation of automated specialty palliative care in the intensive care unit: A retrospective cohort study	PLOS ONE			English	Article							OF-LIFE CARE; CRITICALLY-ILL; PROACTIVE APPROACH; SOFA SCORE; CONSULTATION; ICU; STATEMENT; CONSENSUS; MULTICENTER; VARIABILITY	Introduction Automated specialty palliative care consultation (SPC) has been proposed as an intervention to improve patient-centered care in the intensive care unit (ICU). Existing automated SPC trigger criteria are designed to identify patients at highest risk of in-hospital death. We sought to evaluate common mortality-based SPC triggers and determine whether these triggers reflect actual use of SPC consultation. We additionally aimed to characterize the population of patients who receive SPC without meeting mortality-based triggers. Methods We conducted a retrospective cohort study of all adult ICU admissions from 2012-2017 at an academic medical center with five subspecialty ICUs to determine the sensitivity and specificity of the five most common SPC triggers for predicting receipt of SPC. Among ICU admissions receiving SPC, we assessed differences in patients who met any SPC trigger compared to those who met none. Results Of 48,744 eligible admissions, 1,965 (4.03%) received SPC; 979 (49.82%) of consultations met at least 1 trigger. The sensitivity and specificity for any trigger predicting SPC was 49.82% and 79.61%, respectively. Patients who met no triggers but received SPC were younger (62.71 years vs 66.58 years, mean difference (MD) 3.87 years (95% confidence interval (CI) 2.44-5.30) p<0.001), had longer ICU length of stay (11.43 days vs 8.42 days, MD -3.01 days (95% CI -4.30 --1.72) p<0.001), and had a lower rate of in-hospital death (48.68% vs 58.12%, p<0.001). Conclusion Mortality-based triggers for specialty palliative care poorly reflect actual use of SPC in the ICU. Reliance on such triggers may unintentionally overlook an important population of patients with clinician-identified palliative care needs.	[Secunda, Katharine E.] Univ Penn, Perelman Sch Med, Dept Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA; [Krolikowski, Kristyn A.; Savage, Madeline F.] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA; [Kruser, Jacqueline M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Allergy Pulm & Crit Care, Madison, WI USA	University of Pennsylvania; Pennsylvania Medicine; Northwestern University; Feinberg School of Medicine; University of Wisconsin System; University of Wisconsin Madison	Secunda, KE (corresponding author), Univ Penn, Perelman Sch Med, Dept Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA.	Katharine.Secunda@pennmedicine.upenn.edu		Kruser, Jacqueline/0000-0003-3258-1869	Northwestern University Center for Bioethics and Medical Humanities Exploratory Grant; NIH/NHLBI [K23HL146890]	Northwestern University Center for Bioethics and Medical Humanities Exploratory Grant; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	K.E.S was supported through Northwestern University Center for Bioethics and Medical Humanities Exploratory Grant. J.M.K was supported, in part, through NIH/NHLBI K23HL146890. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Baldwin Matthew R, 2013, Ann Am Thorac Soc, V10, P458, DOI 10.1513/AnnalsATS.201303-039OC; Bekelman DB, 2009, J GEN INTERN MED, V24, P592, DOI 10.1007/s11606-009-0931-y; Bischoff K, 2018, JAMA INTERN MED, V178, P48, DOI 10.1001/jamainternmed.2017.6313; Bradley CT, 2009, CRIT CARE MED, V37, P946, DOI 10.1097/CCM.0b013e3181968f68; Campbell ML, 2003, CHEST, V123, P266, DOI 10.1378/chest.123.1.266; Campbell ML, 2004, CRIT CARE MED, V32, P1839, DOI 10.1097/01.CCM.0000138560.56577.88; Carlet J, 2004, INTENS CARE MED, V30, P770, DOI 10.1007/s00134-004-2241-5; Courtright KR, 2019, J GEN INTERN MED, V34, P1841, DOI 10.1007/s11606-019-05169-2; Cox CE, 2018, ANN AM THORAC SOC, V15, P59, DOI 10.1513/AnnalsATS.201706-500OC; Ersek M, 2013, J PALLIAT MED, V16, P1180, DOI 10.1089/jpm.2013.9474; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Ferrell BR, 2017, J CLIN ONCOL, V35, P96, DOI 10.1200/JCO.2016.70.1474; Goldsmith B, 2008, J PALLIAT MED, V11, P1094, DOI 10.1089/jpm.2008.0053; Alshehri HH, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00616-y; Hua MS, 2018, J CRIT CARE, V46, P79, DOI 10.1016/j.jcrc.2018.04.014; Hua MS, 2014, AM J RESP CRIT CARE, V189, P428, DOI 10.1164/rccm.201307-1229OC; Humphreys J, 2014, J COMMUNITY SUPPORT, V12, P129, DOI 10.12788/jcso.0034; Kruser JM, 2019, CRIT CARE MED, V47, P784, DOI 10.1097/CCM.0000000000003711; Lanken PN, 2008, AM J RESP CRIT CARE, V177, P912, DOI 10.1164/rccm.200605-587ST; Liu AY, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0020; Lupu D, 2010, J PAIN SYMPTOM MANAG, V40, P899, DOI 10.1016/j.jpainsymman.2010.07.004; Morris DA, 2017, AM J HOSP PALLIAT ME, V34, P466, DOI 10.1177/1049909116641606; Mularski RA, 2006, CRIT CARE MED, V34, pS404, DOI 10.1097/01.CCM.0000242910.00801.53; Mun E, 2018, AM J HOSP PALLIAT ME, V35, P60, DOI 10.1177/1049909116684821; Nelson JE, 2013, CRIT CARE MED, V41, P2318, DOI 10.1097/CCM.0b013e31828cf12c; Norton SA, 2007, CRIT CARE MED, V35, P1530, DOI 10.1097/01.CCM.0000266533.06543.0C; O'Mahony S, 2010, PALLIATIVE MED, V24, P154, DOI 10.1177/0269216309346540; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Schoenherr LA, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.17043; Secunda K, 2020, J GEN INTERN MED, V35, P1559, DOI 10.1007/s11606-019-05446-0; Sihra L, 2011, J PAIN SYMPTOM MANAG, V42, P672, DOI 10.1016/j.jpainsymman.2011.08.002; Slavin SD, 2020, REV ESP CARDIOL, V73, P78, DOI [10.1016/j.recesp.2019.07.028, 10.1016/j.rec.2019.07.013]; Stix B, 2016, INTENS CARE MED, V42, P2104, DOI 10.1007/s00134-016-4489-y; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wang D, 2019, J PAIN SYMPTOM MANAG, V57, P73, DOI 10.1016/j.jpainsymman.2018.10.270; Wysham NG, 2017, CRIT CARE MED, V45, pE372, DOI 10.1097/CCM.0000000000002099; Zalenski RJ, 2017, J PAIN SYMPTOM MANAG, V53, P5, DOI 10.1016/j.jpainsymman.2016.08.003; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0	41	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255989	10.1371/journal.pone.0255989	http://dx.doi.org/10.1371/journal.pone.0255989			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY8KW	34379687	gold, Green Published			2023-01-03	WOS:000684029800075
J	Li, Q; Liu, JX; Liu, C; Piao, JF; Yang, W; An, NY; Zhu, JY				Li, Qian; Liu, Junxiu; Liu, Cheng; Piao, Junfeng; Yang, Wei; An, Ningyu; Zhu, Jinyan			Effects of intense pulsed light treatment on tear cytokines and clinical outcomes in meibomian gland dysfunction	PLOS ONE			English	Article							DRY EYE DISEASE; INTERNATIONAL WORKSHOP; INTERFERON-GAMMA; EXPRESSION; MATRIX-METALLOPROTEINASE-9; PATHOPHYSIOLOGY; MODERATE; KC	Meibomian gland dysfunction (MGD) has become a prevalent ocular surface disorder. Its pathogenesis is regarded as a self-perpetuating inflammatory vicious circle. Intense Pulsed Light (IPL) treatment was recently applied to improve the meibomian gland function and reduce symptoms of MGD. However, studies investigating the change of specific inflammatory cytokines during IPL treatment remained sparse. To further figure out how IPL treatment modulates the inflammatory cytokines in tears of MGD, we therefore performed a cross-sectional study and enrolled 32 patients from March 2019 to December 2020. The patients received 3 sessions of IPL treatment (10 to 16 J/cm(2)) at 4-week interval. The signs and symptoms of MGD were evaluated by ocular surface disease index (OSDI), tear film breakup time (TBUT), and meibomian gland yield secretion score (MGYSS). The clinical evaluators and tear samples were analyzed at baseline and at each IPL treatment session. Concentrations of (chemokine ligand) CXCL1, (C-C motif chemokine) CCL11, (tumor necrosis factor) TNF-alpha, (interferon) IFN-gamma, (interleukin) IL-2, IL-6 and (tissue inhibitor of metalloproteinase) TIMP-1were measured by Quantibody Human Dry Eye Disease Array1. OSDI significantly decreased after IPL treatment compared with baseline. TBUT and MGYSS increased consecutively during treatment. CXCL1, CCL11, TNF-alpha, IFN-gamma, IL-2, IL-6 presented significantly decrease and TIMP-1 showed significantly increase from the pretreatment baseline. The changed concentrations of TNF-alpha, IFN-gamma, IL-2, TIMP-1 correlated with TBUT, the changed values of CXCL1, TNF-alpha, IFN-gamma, CCL11, IL-2, IL-6, TIMP-1 correlated with MGYSS, and the changed concentrations of CXCL1, IFN-gamma, CCL11, IL-2, IL-6 correlated with TIMP-1. The data supported IPL treatment could significantly relieve both signs and symptoms of MGD. The therapeutic effect of IPL treatment may originate from regulation of inflammatory cytokines including CXCL1, TNF-alpha, IFN-gamma, CCL11, IL-2, IL-6, and TIMP-1.	[Li, Qian; Liu, Junxiu; Piao, Junfeng; Yang, Wei; An, Ningyu; Zhu, Jinyan] Northwest Univ Nationalities, Dept Ophthalmol, Peoples Hosp Ningxia Hui Autonomous Reg,Ningxia E, Ningxia Clin Res Ctr Dis Blindness Eye,Affiliated, Yinchuan, Ningxia, Peoples R China; [Liu, Cheng] Ningxia Med Univ, Med Sci Tech Res Ctr, Yinchuan, Ningxia, Peoples R China	Northwest Minzu University; Ningxia Medical University	Li, Q (corresponding author), Northwest Univ Nationalities, Dept Ophthalmol, Peoples Hosp Ningxia Hui Autonomous Reg,Ningxia E, Ningxia Clin Res Ctr Dis Blindness Eye,Affiliated, Yinchuan, Ningxia, Peoples R China.	1801887056@qq.com			National Natural Science Foundation of China [81960184]; Ningxia Key Research and Development Program (General Subject) [2018YBZD1445]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ningxia Key Research and Development Program (General Subject)	This work was supported by the National Natural Science Foundation of China (81960184), and Ningxia Key Research and Development Program (General Subject) (2018YBZD1445). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albietz JM, 2018, CLIN EXP OPTOM, V101, P23, DOI 10.1111/cxo.12541; Argueso P, 2002, INVEST OPHTH VIS SCI, V43, P1004; Arita R, 2019, OCUL SURF, V17, P104, DOI 10.1016/j.jtos.2018.11.004; Arita R, 2009, OPHTHALMOLOGY, V116, P2058, DOI 10.1016/j.ophtha.2009.04.037; Arpino V, 2015, MATRIX BIOL, V44-46, P247, DOI 10.1016/j.matbio.2015.03.005; Asatsuma M, 2004, CLIN CHIM ACTA, V345, P99, DOI 10.1016/j.cccn.2004.03.006; Baudouin C, 2018, ACTA OPHTHALMOL, V96, P111, DOI 10.1111/aos.13436; Baudouin C, 2016, BRIT J OPHTHALMOL, V100, P300, DOI 10.1136/bjophthalmol-2015-307415; Benitez-Del-Castillo Sanchez J, 2017, Arch Soc Esp Oftalmol, V92, P210, DOI 10.1016/j.oftal.2016.12.009; Borchman D, 2019, OCUL SURF, V17, P360, DOI 10.1016/j.jtos.2019.02.005; Borchman D, 2011, INVEST OPHTH VIS SCI, V52, P3805, DOI 10.1167/iovs.10-6514; BRON A J, 1991, Eye (London), V5, P395; Choi M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44000-0; Cuerda-Galindo E, 2015, ANN ANAT, V198, P66, DOI 10.1016/j.aanat.2014.11.005; Cunha TM, 2005, P NATL ACAD SCI USA, V102, P1755, DOI 10.1073/pnas.0409225102; De Filippo K, 2008, J IMMUNOL, V180, P4308, DOI 10.4049/jimmunol.180.6.4308; Dell SJ, 2017, CLIN OPHTHALMOL, V11, DOI 10.2147/OPTH.S139894; Farrell HP, 2010, J APPL MICROBIOL, V108, P1494, DOI 10.1111/j.1365-2672.2009.04545.x; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Jackson DC, 2016, INVEST OPHTH VIS SCI, V57, P4824, DOI 10.1167/iovs.16-19757; Jamerson EC, 2020, EYE CONTACT LENS, V46, pS57, DOI 10.1097/ICL.0000000000000668; Jung JW, 2016, CLIN EXP OPHTHALMOL, V44, P555, DOI 10.1111/ceo.12744; Kimura K, 2013, INVEST OPHTH VIS SCI, V54, P2752, DOI 10.1167/iovs.12-11294; de Godoy CHL, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-229; Lee H, 2014, AM J OPHTHALMOL, V158, P1172, DOI 10.1016/j.ajo.2014.08.015; Lee SY, 2013, AM J OPHTHALMOL, V156, P247, DOI 10.1016/j.ajo.2013.04.003; Lee SY, 2015, J AGR FOOD CHEM, V63, P7024, DOI 10.1021/acs.jafc.5b02183; Lienert JP, 2016, OPHTHALMOLOGY, V123, P425, DOI 10.1016/j.ophtha.2015.10.011; Liu RX, 2017, AM J OPHTHALMOL, V183, P81, DOI 10.1016/j.ajo.2017.08.021; Manjavachi MN, 2014, NEUROPHARMACOLOGY, V79, P17, DOI 10.1016/j.neuropharm.2013.10.026; Massingale ML, 2009, CORNEA, V28, P1023, DOI 10.1097/ICO.0b013e3181a16578; Nelson JD, 2017, OCUL SURF, V15, P269, DOI 10.1016/j.jtos.2017.05.005; Nichols KK, 2011, INVEST OPHTH VIS SCI, V52, P1922, DOI 10.1167/iovs.10-6997a; Nocturne G, 2015, ARTHRITIS RHEUMATOL, V67, P3226, DOI 10.1002/art.39315; Pflugfelder SC, 2017, OPHTHALMOLOGY, V124, pS4, DOI 10.1016/j.ophtha.2017.07.010; Pflugfelder SC, 2015, INVEST OPHTH VIS SCI, V56, P7545, DOI 10.1167/iovs.15-17627; Piccolo D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/618206; Ribelles A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/467039; Rong B, 2018, PHOTOMED LASER SURG, V36, P562, DOI 10.1089/pho.2018.4499; Schaumberg DA, 2011, INVEST OPHTH VIS SCI, V52, P1994, DOI 10.1167/iovs.10-6997e; Silva RL, 2017, NEUROBIOL DIS, V105, P109, DOI 10.1016/j.nbd.2017.06.001; Szodoray P, 2005, CLIN IMMUNOL, V117, P168, DOI 10.1016/j.clim.2005.06.016; Thode AR, 2015, DRUGS, V75, P1177, DOI 10.1007/s40265-015-0432-8; Tomlinson A, 2011, INVEST OPHTH VIS SCI, V52, P2006, DOI 10.1167/iovs.10-6997f; Uchino M, 2014, AM J OPHTHALMOL, V157, P294, DOI 10.1016/j.ajo.2013.10.014; Vegunta S, 2016, CORNEA, V35, P318, DOI 10.1097/ICO.0000000000000735; Yin Y, 2018, CURR EYE RES, V43, P308, DOI 10.1080/02713683.2017.1406525	48	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2021	16	8							e0256533	10.1371/journal.pone.0256533	http://dx.doi.org/10.1371/journal.pone.0256533			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	US1HA	34437596	Green Published, gold			2023-01-03	WOS:000697186000059
J	Sun, JM; Shen, L; Shah, MA; Enzinger, P; Adenis, A; Doi, T; Kojima, T; Metges, JP; Li, ZG; Kim, SB; Cho, BC; Mansoor, W; Li, SH; Sunpaweravong, P; Maqueda, MA; Goekkurt, E; Hara, H; Antunes, L; Fountzilas, C; Tsuji, A; Oliden, VC; Liu, Q; Shah, S; Bhagia, P; Kato, K				Sun, Jong-Mu; Shen, Lin; Shah, Manish A.; Enzinger, Peter; Adenis, Antoine; Doi, Toshihiko; Kojima, Takashi; Metges, Jean-Philippe; Li, Zhigang; Kim, Sung-Bae; Cho, Byoung Chul; Mansoor, Wasat; Li, Shau-Hsuan; Sunpaweravong, Patrapim; Maqueda, Maria Alsina; Goekkurt, Eray; Hara, Hiroki; Antunes, Luis; Fountzilas, Christos; Tsuji, Akihito; Oliden, Victor Castro; Liu, Qi; Shah, Sukrut; Bhagia, Pooja; Kato, Ken		KEYNOTE-590 Investigators	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study	LANCET			English	Article							SQUAMOUS-CELL CARCINOMA; GASTROESOPHAGEAL JUNCTION; OPEN-LABEL; NIVOLUMAB; ADENOCARCINOMA; THERAPY; CHOICE; TRIAL	Background First-line therapy for advanced oesophageal cancer is currently limited to fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the antitumour activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced oesophageal cancer and Siewert type 1 gastro-oesophageal junction cancer. Methods We did a randomised, placebo-controlled, double-blind, phase 3 study across 168 medical centres in 26 countries. Patients aged 18 years or older with previously untreated, histologically or cytologically confirmed, locally advanced, unresectable or metastatic oesophageal cancer or Siewert type 1 gastro-oesophageal junction cancer (regardless of PD-L1 status), measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1, and Eastern Cooperative Oncology Group performance status of 0-1, were randomly assigned (1:1) to intravenous pembrolizumab 200 mg or placebo, plus 5-fluorouracil and cisplatin (chemotherapy), once every 3 weeks for up to 35 cycles. Randomisation was stratified by geographical region, histology, and performance status. Patients, investigators, and site staff were masked to group assignment and PD-L1 biomarker status. Primary endpoints were overall survival in patients with oesophageal squamous cell carcinoma and PD-L1 combined positive score (CPS) of 10 or more, and overall survival and progression-free survival in patients with oesophageal squamous cell carcinoma, PD-L1 CPS of 10 or more, and in all randomised patients. This trial is registered with ClinicalTrials.gov, NCT03189719, and is closed to recruitment. Findings Between July 25, 2017, and June 3, 2019, 1020 patients were screened and 749 were enrolled and randomly assigned to pembrolizumab plus chemotherapy (n=373 [50%]) or placebo plus chemotherapy (n=376 [50%]). At the first interim analysis (median follow-up of 22.6 months), pembrolizumab plus chemotherapy was superior to placebo plus chemotherapy for overall survival in patients with oesophageal squamous cell carcinoma and PD-L1 CPS of 10 or more (median 13.9 months vs 8.8 months; hazard ratio 0.57 [95% CI 0.43-0.75]; p<0.0001), oesophageal squamous cell carcinoma (12.6 months vs 9.8 months; 0.72 [0.60-0.88]; p=0.0006), PD-L1 CPS of 10 or more (13.5 months vs 9.4 months; 0.62 [0.49-0.78]; p<0.0001), and in all randomised patients (12.4 months vs 9.8 months; 0.73 [0.62-0.86]; p<0.0001). Pembrolizumab plus chemotherapy was superior to placebo plus chemotherapy for progression-free survival in patients with oesophageal squamous cell carcinoma (6.3 months vs 5.8 months; 0.65 [0.54-0.78]; p<0.0001), PD-L1 CPS of 10 or more (7.5 months vs 5.5 months; 0.51 [0.41-0.65]; p<0.0001), and in all randomised patients (6.3 months vs 5.8 months; 0.65 [0.55-0.76]; p<0.0001). Treatment-related adverse events of grade 3 or higher occurred in 266 (72%) patients in the pembrolizumab plus chemotherapy group versus 250 (68%) in the placebo plus chemotherapy group. Interpretation Compared with placebo plus chemotherapy, pembrolizumab plus chemotherapy improved overall survival in patients with previously untreated, advanced oesophageal squamous cell carcinoma and PD-L1 CPS of 10 or more, and overall survival and progression-free survival in patients with oesophageal squamous cell carcinoma, PD-L1 CPS of 10 or more, and in all randomised patients regardless of histology, and had a manageable safety profile in the total as-treated population.	[Sun, Jong-Mu] Sungkyunkwan Univ, Samsung Med Ctr, Seoul 06351, South Korea; [Shen, Lin] Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Shah, Manish A.] Weill Cornell Med Coll, New York, NY USA; [Enzinger, Peter] Dana Farber Canc Inst, Boston, MA 02115 USA; [Adenis, Antoine] Univ Montpellier, ICM, INSERM, Inst Rech Cancerol Montpellier IRCM, Montpellier, France; [Doi, Toshihiko; Kojima, Takashi] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan; [Metges, Jean-Philippe] CHU Brest, Inst Cancerol & Hematol, ARPEGO Network, Brest, France; [Li, Zhigang] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sect Oesophageal Surg, Shanghai, Peoples R China; [Kim, Sung-Bae] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea; [Cho, Byoung Chul] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea; [Mansoor, Wasat] Christie Hosp NHS Trust, Manchester, Lancs, England; [Li, Shau-Hsuan] Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan; [Li, Shau-Hsuan] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Sunpaweravong, Patrapim] Prince Songkla Univ Hosp, Songkhla, Thailand; [Maqueda, Maria Alsina] Vall dHebron Inst Oncol VHIO, Barcelona, Spain; [Goekkurt, Eray] Hematol Oncol Practice Eppendorf, Hamburg, Germany; [Goekkurt, Eray] Univ Canc Ctr Hamburg, Hamburg, Germany; [Hara, Hiroki] Saitama Canc Ctr, Saitama, Japan; [Antunes, Luis] Univ Fed Santa Maria, Univ Hosp Santa Maria, Santa Maria, RS, Brazil; [Antunes, Luis] Viver Res Ctr, Santa Maria, RS, Brazil; [Fountzilas, Christos] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA; [Tsuji, Akihito] Kagawa Univ Hosp, Miki, Kagawa, Japan; [Oliden, Victor Castro] Inst Nacl Enfermedades Neoplas, Lima, Peru; [Liu, Qi; Shah, Sukrut; Bhagia, Pooja] Merck, Kenilworth, NJ USA; [Kato, Ken] Natl Canc Ctr, Tokyo, Japan	Sungkyunkwan University (SKKU); Samsung Medical Center; Peking University; Cornell University; Harvard University; Dana-Farber Cancer Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); National Cancer Center - Japan; CHU Brest; Shanghai Jiao Tong University; University of Ulsan; Asan Medical Center; Yonsei University; Yonsei University Health System; Christie NHS Foundation Trust; Christie Hospital; Chang Gung Memorial Hospital; Chang Gung University; Prince of Songkla University; Vall d'Hebron Institut d'Oncologia (VHIO); University of Hamburg; University Medical Center Hamburg-Eppendorf; Universidade Federal de Santa Maria (UFSM); Kagawa University; Instituto Nacional de Enfermedades Neoplasicas; Merck & Company; National Cancer Center - Japan	Sun, JM (corresponding author), Sungkyunkwan Univ, Samsung Med Ctr, Seoul 06351, South Korea.	jongmu.sun@skku.edu	ADENIS, ANTOINE/AAH-2034-2022; Shah, Manish A/AHI-4322-2022; ADENIS, ANTOINE/AFL-9835-2022; Castro Oliden, Victor Castro/AAX-6998-2021	Castro Oliden, Victor Castro/0000-0003-2828-7325; Fountzilas, Christos/0000-0003-3837-5644; Cho, Byoung Chul/0000-0002-5562-270X	Merck Sharp Dohme	Merck Sharp Dohme(Merck & Company)	Merck Sharp & Dohme.	Adenis A, 2019, EUR J CANCER, V111, P12, DOI 10.1016/j.ejca.2019.01.016; Al-Batran SE, 2008, J CLIN ONCOL, V26, P1435, DOI 10.1200/JCO.2007.13.9378; Arnold M, 2015, GUT, V64, P381, DOI 10.1136/gutjnl-2014-308124; Bang YJ, 2019, GASTRIC CANCER, V22, P828, DOI 10.1007/s10120-018-00909-5; Belkhiri A, 2015, ONCOTARGET, V6, P1348, DOI 10.18632/oncotarget.2752; Boku N, 2020, ANN ONCOL, V31, pS1192, DOI 10.1016/j.annonc.2020.08.2297; Fuchs CS, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0013; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Huang J, 2020, LANCET ONCOL, V21, P832, DOI 10.1016/S1470-2045(20)30110-8; Janjigian YY, 2021, LANCET, V398, P27, DOI 10.1016/S0140-6736(21)00797-2; Kang YK, 2017, LANCET, V390, P2461, DOI 10.1016/S0140-6736(17)31827-5; Kato K, 2020, ANN ONCOL, V31, pS1192, DOI 10.1016/j.annonc.2020.08.2298; Kato K, 2019, LANCET ONCOL, V20, P1506, DOI 10.1016/S1470-2045(19)30626-6; Kojima T, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01888; Lim SH, 2016, EUR J CANCER, V52, P1, DOI 10.1016/j.ejca.2015.09.019; Lorenzen S, 2009, ANN ONCOL, V20, P1667, DOI 10.1093/annonc/mdp069; Mansoor W, 2021, P AM SOC CLIN ONCOL, V39, P168; Merck, 2021, US PRESCR INF; Moehler M, 2020, ANN ONCOL, V31, P228, DOI 10.1016/j.annonc.2019.10.018; Muro K, 2019, ANN ONCOL, V30, P34, DOI 10.1093/annonc/mdy498; National Comprehensive Cancer Network, 2021, NCCN GUID ESOPH ES J; Ng MCH, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-4699; Pacheco JM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00195; Paz-Ares L, 2019, LANCET, V394, P1929, DOI 10.1016/S0140-6736(19)32222-6; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Shah MA, 2019, JAMA ONCOL, V5, P546, DOI 10.1001/jamaoncol.2018.5441; Shitara K, 2020, JAMA ONCOL, V6, P1571, DOI 10.1001/jamaoncol.2020.3370	30	213	214	12	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2021	398	10302					759	771		10.1016/S0140-6736(21)01234-4	http://dx.doi.org/10.1016/S0140-6736(21)01234-4		AUG 2021	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH1QA	34454674				2023-01-03	WOS:000689712800025
J	Kazandjian, D; Landgren, O				Kazandjian, Dickran; Landgren, Ola			A new era of novel immunotherapies for multiple myeloma	LANCET			English	Editorial Material									[Kazandjian, Dickran; Landgren, Ola] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Serv, Miami, FL 33136 USA	University of Miami	Kazandjian, D (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Serv, Miami, FL 33136 USA.	dkazandjian@miami.edu						Anon, CANCER DISCOV, V2021; Frerichs KA, 2020, CLIN CANCER RES, V26, P2203, DOI 10.1158/1078-0432.CCR-19-2299; GLOBOCAN, 2020, CANC TOD; Im A, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0453-8; Kazandjian D, 2016, SEMIN ONCOL, V43, P682, DOI 10.1053/j.seminoncol.2016.10.008; Lancman G, 2020, HEMATOL-AM SOC HEMAT, P264, DOI 10.1182/hematology.2020000110; Munshi NC, 2021, NEW ENGL J MED, V384, P705, DOI 10.1056/NEJMoa2024850; National Cancer Institute, SURV EP RES PROGR MY; Shah UA, 2020, BEST PRACT RES CL HA, V33, DOI 10.1016/j.beha.2020.101141; US Food and Drug Administration, DRUG APPR DAT; Usmani SZ, 2021, LANCET, V398, P665, DOI 10.1016/S0140-6736(21)01338-6; van de Donk NWCJ, 2021, LANCET HAEMATOL, V8, pE446, DOI 10.1016/S2352-3026(21)00057-0	12	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2021	398	10301					642	643		10.1016/S0140-6736(21)01602-0	http://dx.doi.org/10.1016/S0140-6736(21)01602-0		AUG 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UD5XX	34388394				2023-01-03	WOS:000687280700003
J	Wu, Y; Peng, T; Chen, Y; Huang, L; He, BS; Wei, SB				Wu, Yang; Peng, Tao; Chen, Yu; Huang, Li; He, Bisong; Wei, Shaobin			Acupuncture for glucose and lipid metabolic disorders of polycystic ovarian syndrome: A systematic review protocol	PLOS ONE			English	Review							INSULIN-RESISTANCE; ADIPOSE-TISSUE; MECHANISMS; METFORMIN; CONSENSUS; OBESITY	Background Polycystic ovary syndrome (PCOS) is a common gynecological disease that is often accompanied by some metabolic abnormality such as insulin resistance and dyslipidemia. As a non-pharmacological therapy, acupuncture is widely used for the treatment of PCOS, but the effectiveness for insulin resistance and lipid metabolic disorder remains controversial. Objectives To assess the effectiveness and safety of acupuncture for insulin resistance and lipid metabolic disorder of women with PCOS. Search methods Eight databases will be searched from inception to June 2021, three clinical trial registration platforms will be searched for relevant trials. Selection criteria Randomized controlled trials (RCTs) of acupuncture therapy for insulin resistance and lipid metabolic of PCOS will be included. Data collection and analysis Study screening, data collection, and analysis will be performed by two or more reviewers independently. We will calculate mean difference (MD), standard mean difference (SMD) with 95% confidence intervals (CIs). Data synthesis will be performed with RevMan V.5.3 software and with Stata V.15.0 software when necessary.	[Wu, Yang; Peng, Tao; He, Bisong] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China; [Chen, Yu] Chengdu Second Peoples Hosp, Dept Tradit Chinese Med, Chengdu, Sichuan, Peoples R China; [Huang, Li; Wei, Shaobin] Hosp Chengdu Univ Tradit Chinese Med, Dept Gynecol, Chengdu, Sichuan, Peoples R China	Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine	Wei, SB (corresponding author), Hosp Chengdu Univ Tradit Chinese Med, Dept Gynecol, Chengdu, Sichuan, Peoples R China.	weishaobin5620@163.com			Science and Technology Development Fund of Hospital of Chengdu University of Traditional Chinese Medicine [18ZL11]	Science and Technology Development Fund of Hospital of Chengdu University of Traditional Chinese Medicine	SW received sponsorship from Dr. Hong Ding with the Science and Technology Development Fund of Hospital of Chengdu University of Traditional Chinese Medicine, grant number 18ZL11. The sponsor and funder had and will not have a role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Capurso C, 2012, VASC PHARMACOL, V57, P91, DOI 10.1016/j.vph.2012.05.003; Chen H, 2019, CURR OPIN OBSTET GYN, V31, P428, DOI 10.1097/GCO.0000000000000582; Cibula D, 2004, HUM REPROD, V19, P757, DOI 10.1093/humrep/deh137; Diamanti-Kandarakis E, 2012, ENDOCR REV, V33, P981, DOI 10.1210/er.2011-1034; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098; Gonzalez F, 2020, HUM REPROD, V35, P1168, DOI 10.1093/humrep/deaa056; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Jabbour R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232299; Jo J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007066; Johansson J, 2013, AM J PHYSIOL-ENDOC M, V304, pE934, DOI 10.1152/ajpendo.00039.2013; Kang HS, 2011, MATURITAS, V68, P346, DOI 10.1016/j.maturitas.2011.02.001; Klop B, 2013, NUTRIENTS, V5, P1218, DOI 10.3390/nu5041218; Li J, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1854-2; Li R, 2014, BMC ENDOCR DISORD, V14, DOI 10.1186/1472-6823-14-76; Li Zhi-Xing, 2019, Zhen Ci Yan Jiu, V44, P231, DOI 10.13702/j.1000-0607.180057; Liao Yan-Jun, 2012, Zhen Ci Yan Jiu, V37, P72; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lim SS, 2013, OBES REV, V14, P95, DOI 10.1111/j.1467-789X.2012.01053.x; [刘海宁 Liu Haining], 2017, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V17, P117; Liu Xia, 2016, Zhongguo Zhen Jiu, V36, P957, DOI 10.13703/j.0255-2930.2016.09.019; Manneras L, 2008, ENDOCRINOLOGY, V149, P3559, DOI 10.1210/en.2008-0053; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McCreight LJ, 2016, DIABETOLOGIA, V59, P426, DOI 10.1007/s00125-015-3844-9; Ng NYH, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002953; Ren Li-Na, 2014, Zhen Ci Yan Jiu, V39, P238; Rosenberg DE, 2005, DIABETES OBES METAB, V7, P642, DOI 10.1111/j.1463-1326.2004.00446.x; Rosenfield RL, 2016, ENDOCR REV, V37, P467, DOI 10.1210/er.2015-1104; Shen Kejian, 2018, Zhongguo Zhen Jiu, V38, P1273, DOI 10.13703/j.0255-2930.2018.12.006; Stener-Victorin E, 2008, J NEUROENDOCRINOL, V20, P290, DOI 10.1111/j.1365-2826.2007.01634.x; Stener-Victorin E, 2016, OBES SCI PRACT, V2, P426, DOI 10.1002/osp4.78; Stener-Victorin E, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024733; Sun LH, 2019, THERANOSTICS, V9, P77, DOI 10.7150/thno.30080; Tully PJ, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-127; [王丹 WANG Dan], 2009, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V9, P1115; Wang Jing-Zhi, 2014, Zhen Ci Yan Jiu, V39, P46; Wu LQ, 2019, COMPLEMENT THER CLIN, V37, P11, DOI 10.1016/j.ctcp.2019.08.002; Zhao JG, 2017, JAMA-J AM MED ASSOC, V318, P2466, DOI 10.1001/jama.2017.19344; Zheng RQ, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/5555028	40	0	0	4	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2021	16	8							e0255732	10.1371/journal.pone.0255732	http://dx.doi.org/10.1371/journal.pone.0255732			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6JF	34352018	gold, Green Published			2023-01-03	WOS:000685265700088
J	Mai, HQ; Chen, QY; Chen, DP; Hu, CS; Yang, KY; Wen, JY; Li, JG; Shi, YR; Jin, F; Xu, RL; Pan, JJ; Qu, SH; Li, P; Hu, CH; Liu, YC; Jiang, Y; He, X; Wang, HM; Lim, WT; Liao, WJ; He, XH; Chen, XZ; Liu, ZG; Yuan, XL; Li, Q; Lin, XY; Jing, SH; Chen, YJ; Lu, Y; Hsieh, CY; Yang, MH; Yen, CJ; Samol, J; Feng, H; Yao, S; Keegan, P; Xu, RH				Mai, Hai-Qiang; Chen, Qiu-Yan; Chen, Dongping; Hu, Chaosu; Yang, Kunyu; Wen, Jiyu; Li, Jingao; Shi, Ying-Rui; Jin, Feng; Xu, Ruilian; Pan, Jianji; Qu, Shenhong; Li, Ping; Hu, Chunhong; Liu, Yi-Chun; Jiang, Yi; He, Xia; Wang, Hung-Ming; Lim, Wan-Teck; Liao, Wangjun; He, Xiaohui; Chen, Xiaozhong; Liu, Zhigang; Yuan, Xianglin; Li, Qi; Lin, Xiaoyan; Jing, Shanghua; Chen, Yanju; Lu, Yin; Hsieh, Ching-Yun; Yang, Muh-Hwa; Yen, Chia-Jui; Samol, Jens; Feng, Hui; Yao, Sheng; Keegan, Patricia; Xu, Rui-Hua			Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial	NATURE MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; ANTITUMOR-ACTIVITY; NIVOLUMAB; SAFETY; RECURRENT; SURVIVAL; PEMBROLIZUMAB; RADIOTHERAPY; EFFICACY	Gemcitabine-cisplatin (GP) chemotherapy is the standard first-line systemic treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double-blind, phase 3 trial (ClinicalTrials.gov identifier: NCT03581786), 289 patients with RM-NPC and no previous chemotherapy for recurrent or metastatic disease were randomized (1/1) to receive either toripalimab, a monoclonal antibody against human programmed death-1 (PD-1), or placebo in combination with GP every 3 weeks for up to six cycles, followed by monotherapy with toripalimab or placebo. The primary endpoint was progression-free survival (PFS) as assessed by a blinded independent review committee according to RECIST v.1.1. At the prespecified interim PFS analysis, a significant improvement in PFS was detected in the toripalimab arm compared to the placebo arm: median PFS of 11.7 versus 8.0 months, hazard ratio (HR) = 0.52 (95% confidence interval (CI): 0.36-0.74), P = 0.0003. An improvement in PFS was observed across key subgroups, including PD-L1 expression. As of 18 February 2021, a 40% reduction in risk of death was observed in the toripalimab arm compared to the placebo arm (HR = 0.603 (95% CI: 0.364-0.997)). The incidence of grade >= 3 adverse events (AEs) (89.0 versus 89.5%), AEs leading to discontinuation of toripalimab/placebo (7.5 versus 4.9%) and fatal AEs (2.7 versus 2.8%) was similar between the two arms; however, immune-related AEs (39.7 versus 18.9%) and grade >= 3 infusion reactions (7.5 versus 0.7%) were more frequent in the toripalimab arm. In conclusion, the addition of toripalimab to GP chemotherapy as a first-line treatment for patients with RM-NPC provided superior PFS compared to GP alone, and with a manageable safety profile. Interim analysis from the randomized phase 3 JUPITER-02 trial shows that the addition of anti-PD-1 toripalimab to standard gemcitabine/cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma has manageable toxicity and improves progression-free survival, suggesting a potential new treatment standard in this setting.	[Mai, Hai-Qiang; Chen, Qiu-Yan] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Nasopharyngeal Carcinoma, Guangzhou, Peoples R China; [Chen, Dongping] Inst Guangzhou Med Univ, Affiliated Canc Hosp, Guangzhou, Peoples R China; [Hu, Chaosu] Fudan Univ, Ctr Canc, Shanghai, Peoples R China; [Yang, Kunyu] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China; [Wen, Jiyu] Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China; [Li, Jingao] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China; [Shi, Ying-Rui] Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China; [Jin, Feng] Guizhou Med Univ, Guizhou Canc Hosp, Guiyang, Peoples R China; [Xu, Ruilian] Shenzhen Peoples Hosp, Shenzhen, Peoples R China; [Pan, Jianji] Fujian Prov Canc Hosp, Fuzhou, Peoples R China; [Qu, Shenhong] Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China; [Li, Ping] Sichuan Univ, West China Hosp, Chengdu, Peoples R China; [Hu, Chunhong] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China; [Liu, Yi-Chun] Taichung Vet Gen Hosp, Taichung, Taiwan; [Jiang, Yi] Shantou Univ, Coll Med, Canc Hosp, Shantou, Peoples R China; [He, Xia] Jiangsu Canc Hosp, Nanjing, Peoples R China; [Wang, Hung-Ming] Chang Gung Mem Hosp, Taoyuan, Taiwan; [Lim, Wan-Teck] Natl Canc Ctr, Singapore, Singapore; [Liao, Wangjun] Nanfang Hosp, Guangzhou, Peoples R China; [He, Xiaohui] Chinese Acad Med Sci, Peking Union Med Coll, Canc Hosp, Beijing, Peoples R China; [Chen, Xiaozhong] Zhejiang Canc Hosp, Hangzhou, Peoples R China; [Liu, Zhigang] Sun Yat Sen Univ, Affiliated Hosp 1, Zhuhai, Peoples R China; [Yuan, Xianglin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China; [Li, Qi] Shanghai Gen Hosp, Shanghai, Peoples R China; [Lin, Xiaoyan] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China; [Jing, Shanghua] Hebei Med Univ, Hebei Canc Hosp, Hosp 4, Shijiazhuang, Hebei, Peoples R China; [Chen, Yanju] Hainan Gen Hosp, Haikou, Hainan, Peoples R China; [Lu, Yin] Liuzhou Workers Hosp, Liuzhou, Peoples R China; [Hsieh, Ching-Yun] China Med Univ Hosp, Taichung, Taiwan; [Yang, Muh-Hwa] Taipei Vet Gen Hosp, Taipei, Taiwan; [Yen, Chia-Jui] Natl Cheng Kung Univ, Tainan, Taiwan; [Samol, Jens] Tan Tock Seng Hosp, Singapore, Singapore; [Samol, Jens] Johns Hopkins Univ, Baltimore, MD USA; [Feng, Hui; Yao, Sheng; Keegan, Patricia] Shanghai Junshi Biosci, Shanghai, Peoples R China; [Feng, Hui; Yao, Sheng; Keegan, Patricia] Top Alliance Biosci, Rockville, MD USA; [Xu, Rui-Hua] Sun Yat Sen Univ, Dept Med Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Fudan University; Huazhong University of Science & Technology; Guangdong Medical University; Guizhou Medical University; Jinan University; Sichuan University; Central South University; Taichung Veterans General Hospital; Shantou University; Nanjing Medical University; Chang Gung Memorial Hospital; National Cancer Centre Singapore (NCCS); Southern Medical University - China; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Zhejiang Cancer Hospital; Sun Yat Sen University; Huazhong University of Science & Technology; Fujian Medical University; Hebei Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; Taipei Veterans General Hospital; National Cheng Kung University; Tan Tock Seng Hospital; Johns Hopkins University; State Key Lab Oncology South China; Sun Yat Sen University	Xu, RH (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China.	xurh@sysucc.org.cn	Xu, Rui-Hua/AAW-4766-2021; liu, yi/GXE-9662-2022; xu, rui/GRX-5734-2022; Lim, Darren Wan Teck/L-2007-2016	Xu, Rui-Hua/0000-0001-9771-8534; Lim, Darren Wan Teck/0000-0002-4655-0206	National Major Science & Technology Major Projects [2017ZX09302009]; Shanghai Science and Technology Committee Technology Grant [17431900700]; Shanghai Junshi Biosciences	National Major Science & Technology Major Projects; Shanghai Science and Technology Committee Technology Grant; Shanghai Junshi Biosciences	This study is sponsored by Shanghai Junshi Biosciences. The authors thank the patients who participated in this study and their families. This work was supported by National Major Science & Technology Major Projects (no. 2017ZX09302009) awarded to H.F., and a Shanghai Science and Technology Committee Technology Grant awarded to H.F. (no. 17431900700).	Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Chen YP, 2021, J CLIN ONCOL, V39, P840, DOI 10.1200/JCO.20.03237; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Chen YP, 2015, RADIOTHER ONCOL, V116, P157, DOI 10.1016/j.radonc.2015.07.030; Chin YM, 2015, INT J CANCER, V136, P678, DOI 10.1002/ijc.29035; Corry J, 2006, INT J RADIAT ONCOL, V64, P63, DOI 10.1016/j.ijrobp.2005.06.041; Fang WF, 2018, LANCET ONCOL, V19, P1338, DOI 10.1016/S1470-2045(18)30495-9; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Hsu C, 2017, J CLIN ONCOL, V35, P4050, DOI 10.1200/JCO.2017.73.3675; Huang ZL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0863-5; Hui EP, 2018, CLIN CANCER RES, V24, P1030, DOI 10.1158/1078-0432.CCR-17-1667; Ma BBY, 2018, J CLIN ONCOL, V36, P1412, DOI 10.1200/JCO.2017.77.0388; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Ngan HL, 2018, CANCERS, V10, DOI 10.3390/cancers10070210; Ou SHI, 2007, ANN ONCOL, V18, P29, DOI 10.1093/annonc/mdl320; Ren C, 2020, J CLIN ONCOL, V38; Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9; Sun LM, 2007, AM J EPIDEMIOL, V165, P271, DOI [10.1093/aje/kwm271, 10.1093/aje/kwk008]; Tang BX, 2020, CLIN CANCER RES, V26, P4250, DOI 10.1158/1078-0432.CCR-19-3922; Tang LQ, 2013, J CLIN ONCOL, V31, P2861, DOI 10.1200/JCO.2012.46.0816; Tian W, 2015, TISSUE ANTIGENS, V86, P15, DOI 10.1111/tan.12576; Wang FH, 2021, J CLIN ONCOL, V39, P704, DOI 10.1200/JCO.20.02712; Wang ZJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13770; Wei XL, 2020, CANCER COMMUN, V40, P345, DOI 10.1002/cac2.12068; Zhang L, 2016, LANCET, V388, P1883, DOI 10.1016/S0140-6736(16)31388-5; Zhao C, 2019, ANN ONCOL, V30, P637, DOI 10.1093/annonc/mdz020	26	58	58	7	63	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2021	27	9					1536	+		10.1038/s41591-021-01444-0	http://dx.doi.org/10.1038/s41591-021-01444-0		AUG 2021	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	UQ3MG	34341578				2023-01-03	WOS:000680370900001
J	Chen, YP; Liu, X; Zhou, Q; Yang, KY; Jin, F; Zhu, XD; Shi, M; Hu, GQ; Hu, WH; Sun, Y; Wu, HF; Wu, H; Lin, Q; Wang, H; Tian, Y; Zhang, N; Wang, XC; Shen, LF; Liu, ZZ; Huang, J; Luo, XL; Li, L; Zang, J; Mei, Q; Zheng, BM; Yue, D; Xu, J; Wu, SG; Shi, YX; Mao, YP; Chen, L; Li, WF; Zhou, GQ; Sun, R; Guo, R; Zhang, Y; Xu, C; Lv, JW; Guo, Y; Feng, HX; Tang, LL; Xie, FY; Sun, Y; Ma, J				Chen, Yu-Pei; Liu, Xu; Zhou, Qin; Yang, Kun-Yu; Jin, Feng; Zhu, Xiao-Dong; Shi, Mei; Hu, Guo-Qing; Hu, Wei-Han; Sun, Yan; Wu, Hong-Fen; Wu, Hui; Lin, Qin; Wang, Hui; Tian, Ye; Zhang, Ning; Wang, Xi-Cheng; Shen, Liang-Fang; Liu, Zheng-Zheng; Huang, Jing; Luo, Xiu-Ling; Li, Ling; Zang, Jian; Mei, Qi; Zheng, Bao-Min; Yue, Dan; Xu, Jing; Wu, San-Gang; Shi, Yan-Xia; Mao, Yan-Ping; Chen, Lei; Li, Wen-Fei; Zhou, Guan-Qun; Sun, Rui; Guo, Rui; Zhang, Yuan; Xu, Cheng; Lv, Jia-Wei; Guo, Ying; Feng, Hui-Xia; Tang, Ling-Long; Xie, Fang-Yun; Sun, Ying; Ma, Jun			Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial	LANCET			English	Article; Proceedings Paper	Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)	JUN 04-08, 2021	ELECTR NETWORK	Amer Soc Clin Oncol			INTENSITY-MODULATED RADIOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; STAGING SYSTEM; 8TH EDITION; CHEMOTHERAPY; RECURRENT; CANCER; TIME	Background Patients with locoregionally advanced nasopharyngeal carcinoma have a high risk of disease relapse, despite a high proportion of patients attaining complete clinical remission after receiving standard-of-care treatment (ie, definitive concurrent chemoradiotherapy with or without induction chemotherapy). Additional adjuvant therapies are needed to further reduce the risk of recurrence and death. However, the benefit of adjuvant chemotherapy for nasopharyngeal carcinoma remains controversial, highlighting the need for more effective adjuvant treatment options. Methods This multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial was done at 14 hospitals in China. Patients (aged 18-65 years) with histologically confirmed, high-risk locoregionally advanced nasopharyngeal carcinoma (stage III-IVA, excluding T3-4N0 and T3N1 disease), no locoregional disease or distant metastasis after definitive chemoradiotherapy, an Eastern Cooperative Oncology Group performance status of 0 or 1, sufficient haematological, renal, and hepatic function, and who had received their final radiotherapy dose 12-16 weeks before randomisation, were randomly assigned (1:1) to receive either oral metronomic capecitabine (650 mg/m(2) body surface area twice daily for 1 year; metronomic capecitabine group) or observation (standard therapy group). Randomisation was done with a computer-generated sequence (block size of four), stratified by trial centre and receipt of induction chemotherapy (yes or no). The primary endpoint was failure-free survival, defined as the time from randomisation to disease recurrence (distant metastasis or locoregional recurrence) or death due to any cause, in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of capecitabine or who had commenced observation. This trial is registered with ClinicalTrials.gov, NCT02958111. Findings Between Jan 25, 2017, and Oct 25, 2018, 675 patients were screened, of whom 406 were enrolled and randomly assigned to the metronomic capecitabine group (n=204) or to the standard therapy group (n=202). After a median follow-up of 38 months (IQR 33-42), there were 29 (14%) events of recurrence or death in the metronomic capecitabine group and 53 (26%) events of recurrence or death in the standard therapy group. Failure-free survival at 3 years was significantly higher in the metronomic capecitabine group (85.3% [95% CI 80.4-90.6]) than in the standard therapy group (75.7% [69.9-81.9]), with a stratified hazard ratio of 0.50 (95% CI 0.32- 0.79; p=0.0023). Grade 3 adverse events were reported in 35 (17%) of 201 patients in the metronomic capecitabine group and in 11 (6%) of 200 patients in the standard therapy group; hand-foot syndrome was the most common adverse event related to capecitabine (18 [9%] patients had grade 3 hand-foot syndrome). One (<1%) patient in the metronomic capecitabine group had grade 4 neutropenia. No treatment-related deaths were reported in either group. Interpretation The addition of metronomic adjuvant capecitabine to chemoradiotherapy significantly improved failure-free survival in patients with high-risk locoregionally advanced nasopharyngeal carcinoma, with a manageable safety profile. These results support a potential role for metronomic chemotherapy as an adjuvant therapy in the treatment of nasopharyngeal carcinoma. (C) 2021 Elsevier Ltd. All rights reserved.	[Chen, Yu-Pei; Liu, Xu; Hu, Wei-Han; Sun, Yan; Mao, Yan-Ping; Chen, Lei; Li, Wen-Fei; Zhou, Guan-Qun; Sun, Rui; Guo, Rui; Zhang, Yuan; Xu, Cheng; Lv, Jia-Wei; Feng, Hui-Xia; Tang, Ling-Long; Xie, Fang-Yun; Ma, Jun] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China,Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med,Guangdong Key Lab, Guangzhou 510060, Peoples R China; [Shi, Yan-Xia] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China,Dept Med Oncol, Collaborat Innovat Ctr Canc Med,Guangdong Key Lab, Guangzhou, Guangdong, Peoples R China; [Zhou, Qin; Shen, Liang-Fang; Liu, Zheng-Zheng] Cent South Univ, Dept Oncol, Xiangya Hosp, Changsha, Peoples R China; [Wang, Hui] Cent South Univ, Hunan Canc Hosp, Dept Radiat Oncol, Changsha, Peoples R China; [Wang, Hui] Cent South Univ, Affiliated Canc Hosp Xiangya, Sch Med, Changsha, Peoples R China; [Yang, Kun-Yu; Huang, Jing] Huazhong Univ Sci & Technol, Dept Oncol, Canc Ctr, Union Hosp,Tongji Med Coll, Wuhan, Peoples R China; [Hu, Guo-Qing; Mei, Qi] Huazhong Univ Sci & Technol, Canc Ctr, Dept Oncol, Tongji Hosp,Tongji Med Coll, Wuhan, Peoples R China; [Jin, Feng; Luo, Xiu-Ling] Guizhou Med Univ, Affiliated Canc Hosp, Affiliated Hosp, Dept Oncol, Guiyang, Peoples R China; [Zhu, Xiao-Dong; Li, Ling] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Radiat Oncol, Nanning, Peoples R China; [Zhu, Xiao-Dong] Guangxi Med Univ, Affiliated Wuming Hosp, Dept Oncol, Nanning, Peoples R China; [Shi, Mei; Zang, Jian] Air Force Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Xian, Peoples R China; [Zheng, Bao-Min; Sun, Ying] Peking Univ Canc Hosp, Dept Radiat Oncol, Beijing, Peoples R China; [Wu, Hong-Fen; Yue, Dan] Jilin Canc Hosp, Dept Radiat Oncol, Changchun, Peoples R China; [Wu, Hui; Xu, Jing] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Radiat Oncol, Zhengzhou, Peoples R China; [Lin, Qin; Wu, San-Gang] Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Ctr, Dept Radiat Oncol, Xiamen, Peoples R China; [Tian, Ye] Soochow Univ, Affiliated Hosp 2, Dept Radiat Oncol, Suzhou, Peoples R China; [Zhang, Ning] First Peoples Hosp Foshan, Dept Radiat Oncol, Foshan, Peoples R China; [Wang, Xi-Cheng] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Radiat Oncol, Guangzhou, Peoples R China; [Guo, Ying] Sun Yat Sen Univ, Clin Trials Ctr, Canc Ctr, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Central South University; Central South University; Central South University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Guizhou Medical University; Guangxi Medical University; Guangxi Medical University; Air Force Military Medical University; Peking University; Zhengzhou University; Xiamen University; Soochow University - China; Guangdong Pharmaceutical University; Sun Yat Sen University	Ma, J (corresponding author), Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China,Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med,Guangdong Key Lab, Guangzhou 510060, Peoples R China.	majun2@mail.sysu.edu.cn	Wu, San-Gang/AAA-8959-2022	Chen, Yupei/0000-0002-0010-3494; Ma, Jun/0000-0002-1137-9349; Liu, Xu (Steve)/0000-0003-4827-5524; Hu, Guoqing/0000-0001-6856-7220	National Natural Science Foundation of China [81930072]; Key-Area Research and Development Program of Guangdong Province [2019B020230002]; Natural Science Foundation of Guangdong Province [2021B1515020010, 2017A030312003]; Innovation Team Development Plan of the Ministry of Education [IRT_17R110]; Overseas Expertise Introduction Project for Discipline Innovation (111 Project) [B14035]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key-Area Research and Development Program of Guangdong Province; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Innovation Team Development Plan of the Ministry of Education; Overseas Expertise Introduction Project for Discipline Innovation (111 Project)	This trial was investigator-initiated. This study was supported by the grants from the National Natural Science Foundation of China (81930072), the Key-Area Research and Development Program of Guangdong Province (2019B020230002), the Natural Science Foundation of Guangdong Province (2021B1515020010 and 2017A030312003), the Innovation Team Development Plan of the Ministry of Education (IRT_17R110), and the Overseas Expertise Introduction Project for Discipline Innovation (111 Project, B14035). Chia Tai Tianqing Pharmaceutical provided capecitabine free of charge for this study. Sun Yat-sen University was involved in trial management and auditing. We thank the patients who participated in this study and their families; the medical, nursing, and research staff at the study centres; Rui-Yao Ou, Ying Wang, Juan Liu, Qiu-Hui Zheng, and Xiao-Dan Jiang (Department of Radiation Oncology, Sun Yat-sen University Cancer Center) for their assistance with data management and logistic support; and the staff of the National Clinical Study Center for Anticancer Drugs, Sun Yat-sen University Cancer Center, for trial monitoring, data management, and statistical analysis. This study will be presented at the annual meeting of the American Society of Clinical Oncology (Chicago, IL, USA) as an oral presentation on June 7, 2021.	Amin MB, 2017, AJCC CANC STAGING MA, V8th; Andre N, 2013, LANCET ONCOL, V14, pE239, DOI 10.1016/S1470-2045(13)70056-1; Bisogno G, 2019, LANCET ONCOL, V20, P1566, DOI 10.1016/S1470-2045(19)30617-5; Bocci G, 2016, NAT REV CLIN ONCOL, V13, P659, DOI 10.1038/nrclinonc.2016.64; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Browder T, 2000, CANCER RES, V60, P1878; Chan ATC, 2018, J CLIN ONCOL, V36, P3091, DOI 10.1200/JCO.2018.77.7847; Chen JH, 2019, HEAD NECK-J SCI SPEC, V41, P3775, DOI 10.1002/hed.25904; Chen L, 2017, EUR J CANCER, V75, P150, DOI 10.1016/j.ejca.2017.01.002; Chen L, 2012, LANCET ONCOL, V13, P163, DOI 10.1016/S1470-2045(11)70320-5; Chen YL, 2017, CANCER LETT, V400, P282, DOI 10.1016/j.canlet.2017.01.040; Chen YP, 2021, J CLIN ONCOL, V39, P840, DOI 10.1200/JCO.20.03237; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Chen YP, 2018, CLIN CANCER RES, V24, P1824, DOI 10.1158/1078-0432.CCR-17-2656; Chow S. C., 2003, SAMPLE SIZE CALCULAT; Chua D, 2008, JPN J CLIN ONCOL, V38, P244, DOI 10.1093/jjco/hyn022; Chua DTT, 2003, ORAL ONCOL, V39, P361, DOI 10.1016/S1368-8375(02)00120-3; Ciuleanu E, 2008, J BUON, V13, P37; Fayers P, 2001, EORTC QLQ C30 SCORIN, V3th; Fisher DJ, 2011, J CLIN EPIDEMIOL, V64, P949, DOI 10.1016/j.jclinepi.2010.11.016; Ghonim MA, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-001643; He XR, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000807; Hui EP, 2009, J CLIN ONCOL, V27, P242, DOI 10.1200/JCO.2008.18.1545; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Lee AWM, 2015, CANCER-AM CANCER SOC, V121, P1328, DOI 10.1002/cncr.29208; Lee AWM, 2011, EUR J CANCER, V47, P656, DOI 10.1016/j.ejca.2010.10.026; Li WF, 2019, INT J CANCER, V145, P295, DOI 10.1002/ijc.32099; Liu YC, 2017, ORAL ONCOL, V64, P15, DOI 10.1016/j.oraloncology.2016.11.008; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Pan JJ, 2016, CANCER-AM CANCER SOC, V122, P546, DOI 10.1002/cncr.29795; Pasquier E, 2010, NAT REV CLIN ONCOL, V7, P455, DOI 10.1038/nrclinonc.2010.82; Patil VM, 2019, J CLIN ONCOL, V37, P3032, DOI 10.1200/JCO.19.01076; Peereboom DM, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130748; Pocock SJ, 2002, LANCET, V359, P1686, DOI 10.1016/S0140-6736(02)08594-X; Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3; Sun Y, 2016, LANCET ONCOL, V17, P1509, DOI 10.1016/S1470-2045(16)30410-7; Tang LL, 2017, J NATL COMPR CANC NE, V15, P913, DOI 10.6004/jnccn.2017.0121; Twu CW, 2014, INT J RADIAT ONCOL, V89, P21, DOI 10.1016/j.ijrobp.2014.01.052; Wang X, JAMA-J AM MED ASSOC, V325, P50; Wileyto EP, 2013, BIOSTATISTICS, V14, P340, DOI 10.1093/biostatistics/kxs043; Xiao WW, 2011, CANCER-AM CANCER SOC, V117, P1874, DOI 10.1002/cncr.25754; Zhang Y, 2019, NEW ENGL J MED, V381, P1124, DOI 10.1056/NEJMoa1905287; Zhou GQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17672-w; Zsiros E, 2021, JAMA ONCOL, V7, P78, DOI 10.1001/jamaoncol.2020.5945	45	43	43	13	67	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	2021	398	10297					303	313		10.1016/S0140-6736(21)01123-5	http://dx.doi.org/10.1016/S0140-6736(21)01123-5		JUL 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TM9EI	34111416				2023-01-03	WOS:000675849600022
J	Jung, HO; Han, SW				Jung, Hyun-Ok; Han, Seung-Woo			Implementing psychological first aid ontology	PLOS ONE			English	Article								Background This study develops an ontology of Psychological First Aid (PFA) by extracting relevant knowledge from a review of PFA literature. Materials and methods This study was conducted using the PFA ontology development 101 method. This review processes previously-developed PFA studies by consulting Google Scholar, CINHL, PUBMED, and MEDLINE. Protege 5.0 program was used to integrate with ontology development. The developed PFA ontology consisted of eight super classes: Action agenda, Assessment, Concrete method, Disaster type, Disaster disposition, Purpose, Qualification and Skill, Reaction. In total, 166 terms were collected. Results The eight super classes were divided into 72 classes and 64 subclasses. The composition yielded in a total of 166 axioms (85 logical axioms; 81 declaration axioms). Conclusions This study provides basic data to guide development and composition of PFA arbitration programs.	[Jung, Hyun-Ok] Kyungpook Natl Univ, Coll Nursing, Daegu, South Korea; [Han, Seung-Woo] Kyungil Univ, Dept Emergency Med Technol, Gyongsan, South Korea	Kyungpook National University; Kyungil University	Han, SW (corresponding author), Kyungil Univ, Dept Emergency Med Technol, Gyongsan, South Korea.	swhan@kiu.ac.kr						[Anonymous], 2015, PHILIPPINE J PSYCHOL; Brymer M., 2006, PSYCHOL 1 AID FIELD, V2nd; Kang SH., 2016, DISASTER MENNTAL HLT, V2th ed; Kim HS., 2015, DAEGU DISASTER PSYCH, V1th ed; Kwon JH., 2014, PSYCHOL 1 AID DISAST, V2th ed; McCabe OL., 2008, INT J EMERG MENT HLT, V9, P181; McGuinness Deborah L, 2001, ONTOLOGY DEV; O Bodenreider A., 2005, MED INFORM; Park HA, 2018, KOR J I COMMUNICATIO, V35, P85; Ruzek J.I., 2007, J MENTAL HLTH COUNS, V29, P17, DOI [DOI 10.17744/MEHC.29.1.5RACQXJUEAFABGWP, https://doi.org/10.17744/mehc.29.1.5racqxjueafabgwp]; Sakuma A, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0440-y; SMITH Barry., 2012, FURNITURE WORLD; Strawbridge WJ, 1997, AM J PUBLIC HEALTH, V87, P957, DOI 10.2105/AJPH.87.6.957; Veenema TG., 2016, READYRN E BOOK HDB D; WHO CBM World Vision UNICEF, 2014, FAC MAN PSYCH 1 AID; WHO Team Mental Health and Substance Use, 2011, PSYCHOL 1 AID GUIDE	16	0	0	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2021	16	6							e0252891	10.1371/journal.pone.0252891	http://dx.doi.org/10.1371/journal.pone.0252891			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RW	34106955	Green Published			2023-01-03	WOS:000664642200062
J	Rossa-Roccor, V; Richardson, CG; Murphy, RA; Gadermann, AM				Rossa-Roccor, Verena; Richardson, Chris G.; Murphy, Rachel A.; Gadermann, Anne M.			The association between diet and mental health and wellbeing in young adults within a biopsychosocial framework	PLOS ONE			English	Article							QUALITY-OF-LIFE; VEGETARIAN DIETS; ANXIETY DISORDERS; PHYSICAL-ACTIVITY; PRIMARY-CARE; DEPRESSION; STRESS; PREVALENCE; PATTERNS; PHQ-9	Objective Predominantly plant-based diets can co-benefit human physical health and the planet. Young adults appear to be on the forefront of the shift to plant-based diets. However, little is known about the relationship between plant-based diets and mental health in this population even though mental health disorders contribute substantially to the global burden of disease, particularly among this age group. Design In this cross-sectional study we utilize a biopsychosocial framework to assess the association between dietary intake and mental health and wellbeing. Mental health was assessed using self-reported measures of anxiety (GAD-7), depression (PHQ-9) and quality of life (single-item). Dietary intake in the prior month was assessed using a dietary screener (DSQ) and participants were asked to self-identify a diet preference (e.g., vegan). Setting and participants 339 university undergraduate students. Results A principal component analysis of dietary intake found three dominant dietary patterns (plant-based, animal-based, and 'junk foods'); 28.1% (n = 95) of participants self-identified as pescatarian, vegetarian, vegan, other. The association between dietary patterns, diet preference and mental health was assessed through regression analysis. After controlling for covariables, we found a significant positive association between the junk food component and depression (z-score beta = .21, p <= .001; adj. R-2 = .39) and anxiety (z-score beta = .14; p <= .001; adj. R-2 = .32) while no association was found between plant-based, animal-based or self-identified diet preference and the mental health measures. Conclusions We did not find a negative association between predominantly plant-based diet patterns and mental health and wellbeing. It is important to consider dietary composition and to conceptualize diet as a health behaviour that is embedded in a biopsychosocial framework.	[Rossa-Roccor, Verena; Richardson, Chris G.; Murphy, Rachel A.; Gadermann, Anne M.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Rossa-Roccor, Verena] Univ British Columbia, Inst Resources Environm & Sustainabil, Vancouver, BC, Canada; [Richardson, Chris G.; Gadermann, Anne M.] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Providence Hlth Care Res Inst, Vancouver, BC, Canada; [Murphy, Rachel A.] BC Canc, Canc Control Res, Vancouver, BC, Canada; [Gadermann, Anne M.] Univ British Columbia, Sch Populat & Publ Hlth, Human Early Learning Partnership, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; St. Paul's Hospital; University of Saskatchewan; University of British Columbia	Rossa-Roccor, V (corresponding author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.; Rossa-Roccor, V (corresponding author), Univ British Columbia, Inst Resources Environm & Sustainabil, Vancouver, BC, Canada.	verena.rossa-roccor@ubc.ca						AARO LE, 1995, HEALTH EDUC RES, V10, P83, DOI 10.1093/her/10.1.83; Alonso J, 2004, ACTA PSYCHIAT SCAND, V109, P38; Arroll B, 2010, ANN FAM MED, V8, P348, DOI 10.1370/afm.1139; Bailey M.J., 2011, 17633 NAT BUR EC RES; Bailey RL, 2007, J NUTR, V137, P421, DOI 10.1093/jn/137.2.421; Baines S, 2007, PUBLIC HEALTH NUTR, V10, P436, DOI 10.1017/S1368980007217938; Beard C, 2016, J AFFECT DISORDERS, V193, P267, DOI 10.1016/j.jad.2015.12.075; Beezhold B, 2015, NUTR NEUROSCI, V18, P289, DOI 10.1179/1476830514Y.0000000164; Beezhold BL, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-26; Beiter R, 2015, J AFFECT DISORDERS, V173, P90, DOI 10.1016/j.jad.2014.10.054; Beydoun MA, 2010, J AFFECT DISORDERS, V123, P52, DOI 10.1016/j.jad.2009.09.021; Blanco C, 2008, ARCH GEN PSYCHIAT, V65, P1429, DOI 10.1001/archpsyc.65.12.1429; Bowling A, 2005, J EPIDEMIOL COMMUN H, V59, P342, DOI 10.1136/jech.2004.021204; Breslau J, 2008, J PSYCHIATR RES, V42, P708, DOI 10.1016/j.jpsychires.2008.01.016; Burcusa SL, 2007, CLIN PSYCHOL REV, V27, P959, DOI 10.1016/j.cpr.2007.02.005; Burkert NT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088278; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Conklin AI, 2014, SOC SCI MED, V100, P167, DOI 10.1016/j.socscimed.2013.08.018; De Silva MJ, 2005, J EPIDEMIOL COMMUN H, V59, P619, DOI 10.1136/jech.2004.029678; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; Derbyshire EJ, 2017, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00055; Diener E, 2002, PSYCHOL SCI, V13, P81, DOI 10.1111/1467-9280.00415; Dobersek U, 2021, CRIT REV FOOD SCI, V61, P622, DOI 10.1080/10408398.2020.1741505; Enders C. K., 2010, APPL MISSING DATA AN; Evans TM, 2018, NAT BIOTECHNOL, V36, P282, DOI 10.1038/nbt.4089; Fahy T, 1999, BRIT J PSYCHIAT, V175, P426, DOI 10.1192/bjp.175.5.426; Field A., 2013, DISCOVERING STAT USI; Flanagan, 2018, CTV NEWS; Gibb SJ, 2010, BRIT J PSYCHIAT, V197, P122, DOI 10.1192/bjp.bp.109.076570; Gibson EL, 2006, PHYSIOL BEHAV, V89, P53, DOI 10.1016/j.physbeh.2006.01.024; Hibbeln JR, 2018, J AFFECT DISORDERS, V225, P13, DOI 10.1016/j.jad.2017.07.051; Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002; Jacka FN, 2011, PSYCHOSOM MED, V73, P483, DOI 10.1097/PSY.0b013e318222831a; Jacka FN, 2010, AM J PSYCHIAT, V167, P305, DOI 10.1176/appi.ajp.2009.09060881; Jantaratnotai N, 2017, OBES RES CLIN PRACT, V11, P1, DOI 10.1016/j.orcp.2016.07.003; Kaplan BJ, 2015, CLIN PSYCHOL SCI, V3, P964, DOI 10.1177/2167702614555413; Karatsoreos IN, 2011, TRENDS COGN SCI, V15, P576, DOI 10.1016/j.tics.2011.10.005; Kessler RC, 2007, CURR OPIN PSYCHIATR, V20, P359, DOI 10.1097/YCO.0b013e32816ebc8c; Keurn BT, 2018, PSYCHOL ASSESSMENT, V30, P1096, DOI 10.1037/pas0000550; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004; Kuehner C, 2005, J AFFECT DISORDERS, V86, P205, DOI 10.1016/j.jad.2005.01.014; Lai JS, 2014, AM J CLIN NUTR, V99, P181, DOI 10.3945/ajcn.113.069880; Lassale C, 2019, MOL PSYCHIATR, V24, P965, DOI 10.1038/s41380-018-0237-8; Le Port A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051593; Leitzmann C, 2014, AM J CLIN NUTR, V100, p496S, DOI 10.3945/ajcn.113.071365; Li Y, 2017, PSYCHIAT RES, V253, P373, DOI 10.1016/j.psychres.2017.04.020; Logan AC, 2014, J PHYSIOL ANTHROPOL, V33, DOI 10.1186/1880-6805-33-22; Martin W., 2017, HDB STRESS HLTH, P459, DOI [10.1002/9781118993811.ch28, DOI 10.1002/9781118993811.CH28]; McGorry PD, 2018, EVID-BASED MENT HEAL, V21, P182, DOI 10.1136/ebmental-2018-300060; Michalak J, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-67; Moubarac JC, 2014, CAN J DIET PRACT RES, V75, P15, DOI 10.3148/75.1.2014.15; Neely E, 2014, APPETITE, V82, P50, DOI 10.1016/j.appet.2014.07.005; Nettleton JA, 2006, AM J CLIN NUTR, V83, P1369, DOI 10.1093/ajcn/83.6.1369; Neumark-Sztainer D, 2006, J ADOLESCENT HEALTH, V39, P244, DOI 10.1016/j.jadohealth.2005.12.001; O'Malley PM, 2002, J STUD ALCOHOL, P23, DOI 10.15288/jsas.2002.s14.23; Paluska SA, 2000, SPORTS MED, V29, P167, DOI 10.2165/00007256-200029030-00003; Patton GC, 2007, LANCET, V369, P1130, DOI 10.1016/S0140-6736(07)60366-3; Prince JP, 2015, MENT HLTH PREV, V3, P5, DOI DOI 10.1016/J.MHP.2015.03.001; Sabate J, 2003, AM J CLIN NUTR, V78, p502S, DOI 10.1093/ajcn/78.3.502S; Satija A, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002039; Sawyer SM, 2012, LANCET, V379, P1630, DOI 10.1016/S0140-6736(12)60072-5; Somers JM, 2006, CAN J PSYCHIAT, V51, P100, DOI 10.1177/070674370605100206; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Statistics Canada, 2018, MENTAL HLTH WELL BEI; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Subar AF, 2015, J NUTR, V145, P2639, DOI 10.3945/jn.115.219634; The Nielsen Company, 2017, NIELSEN; Thompson FE, 2017, J NUTR, V147, P1226, DOI 10.3945/jn.116.246058; Thomson A., 2018, CTV NEWS; Tiggemann Marika, 2005, Body Image, V2, P129, DOI 10.1016/j.bodyim.2005.03.006; Trautmann S, 2016, EMBO REP, V17, P1245, DOI 10.15252/embr.201642951; VanKim NA, 2013, AM J HEALTH PROMOT, V28, P7, DOI 10.4278/ajhp.111101-QUAN-395; Weersink A, 2019, CONVERSATION; Weidner G, 1996, ANXIETY STRESS COPIN, V9, P123, DOI 10.1080/10615809608249396; Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Willett W, 2019, LANCET, V393, P447, DOI 10.1016/S0140-6736(18)31788-4	77	2	2	7	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2021	16	6							e0252358	10.1371/journal.pone.0252358	http://dx.doi.org/10.1371/journal.pone.0252358			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SW6QS	34081708	Green Published, gold			2023-01-03	WOS:000664639200016
J	Roquilly, A; Moyer, JD; Huet, O; Lasocki, S; Cohen, B; Dahyot-Fizelier, C; Chalard, K; Seguin, P; Jeantrelle, C; Vermeersch, V; Gaillard, T; Cinotti, R; Latte, DDD; Mahe, PJ; Vourc'h, M; Martin, FP; Chopin, A; Lerebourg, C; Flet, L; Chiffoleau, A; Feuillet, F; Asehnoune, K				Roquilly, Antoine; Moyer, Jean Denis; Huet, Olivier; Lasocki, Sigismond; Cohen, Benjamin; Dahyot-Fizelier, Claire; Chalard, Kevin; Seguin, Philippe; Jeantrelle, Caroline; Vermeersch, Veronique; Gaillard, Thomas; Cinotti, Raphael; Latte, Dominique Demeure Dit; Mahe, Pierre Joachim; Vourc'h, Mickael; Martin, Florian Pierre; Chopin, Alice; Lerebourg, Celine; Flet, Laurent; Chiffoleau, Anne; Feuillet, Fanny; Asehnoune, Karim		Atlanrea Study Grp; Soc Francaise Anesthesie Reanima	Effect of Continuous Infusion of Hypertonic Saline vs Standard Care on 6-Month Neurological Outcomes in Patients With Traumatic Brain Injury: The COBI Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPY; ASSOCIATION; MODERATE; HYPERNATREMIA; EPIDEMIOLOGY; MULTICENTER; RELIABILITY; GUIDELINES; MANAGEMENT; MORTALITY	Key PointsQuestionWhat is the effect of continuous infusion of hypertonic saline solution in patients with traumatic brain injury? FindingsIn this randomized clinical trial that included 370 adults with moderate to severe traumatic brain injury, treatment with continuous infusion of 20% hypertonic saline vs standard care resulted in an odds ratio for better neurological outcomes (based on the Extended Glasgow Outcome Scale) of 1.02 after 6 months; this was not statistically significant. MeaningAmong patients with moderate to severe traumatic brain injury, treatment with continuous infusion of 20% hypertonic saline compared with standard care did not result in a significantly better neurological status at 6 months. ImportanceFluid therapy is an important component of care for patients with traumatic brain injury, but whether it modulates clinical outcomes remains unclear. ObjectiveTo determine whether continuous infusion of hypertonic saline solution improves neurological outcome at 6 months in patients with traumatic brain injury. Design, Setting, and ParticipantsMulticenter randomized clinical trial conducted in 9 intensive care units in France, including 370 patients with moderate to severe traumatic brain injury who were recruited from October 2017 to August 2019. Follow-up was completed in February 2020. InterventionsAdult patients with moderate to severe traumatic brain injury were randomly assigned to receive continuous infusion of 20% hypertonic saline solution plus standard care (n=185) or standard care alone (controls; n=185). The 20% hypertonic saline solution was administered for 48 hours or longer if patients remained at risk of intracranial hypertension. Main Outcomes and MeasuresThe primary outcome was Extended Glasgow Outcome Scale (GOS-E) score (range, 1-8, with lower scores indicating worse functional outcome) at 6 months, obtained centrally by blinded assessors and analyzed with ordinal logistic regression adjusted for prespecified prognostic factors (with a common odds ratio [OR] >1.0 favoring intervention). There were 12 secondary outcomes measured at multiple time points, including development of intracranial hypertension and 6-month mortality. ResultsAmong 370 patients who were randomized (median age, 44 [interquartile range, 27-59] years; 77 [20.2%] women), 359 (97%) completed the trial. The adjusted common OR for the GOS-E score at 6 months was 1.02 (95% CI, 0.71-1.47; P=.92). Of the 12 secondary outcomes, 10 were not significantly different. Intracranial hypertension developed in 62 (33.7%) patients in the intervention group and 66 (36.3%) patients in the control group (absolute difference, -2.6% [95% CI, -12.3% to 7.2%]; OR, 0.80 [95% CI, 0.51-1.26]). There was no significant difference in 6-month mortality (29 [15.9%] in the intervention group vs 37 [20.8%] in the control group; absolute difference, -4.9% [95% CI, -12.8% to 3.1%]; hazard ratio, 0.79 [95% CI, 0.48-1.28]). Conclusions and RelevanceAmong patients with moderate to severe traumatic brain injury, treatment with continuous infusion of 20% hypertonic saline compared with standard care did not result in a significantly better neurological status at 6 months. However, confidence intervals for the findings were wide, and the study may have had limited power to detect a clinically important difference. Trial RegistrationClinicalTrials.gov Identifier: NCT03143751 This clinical trial conducted in France explores whether continuous infusion of hypertonic saline solution improves neurological outcome at 6 months in patients with traumatic brain injury.	[Roquilly, Antoine; Cinotti, Raphael; Latte, Dominique Demeure Dit; Mahe, Pierre Joachim; Vourc'h, Mickael; Martin, Florian Pierre; Chopin, Alice; Lerebourg, Celine; Asehnoune, Karim] Univ Nantes, Serv Anesthesie Reanimat Chirurg, CHU Nantes, Pole Anesthesie Reanimat,Hotel Dieu, Nantes, France; [Moyer, Jean Denis; Jeantrelle, Caroline] Beaujon Hosp, AP HP Nord, Dept Anesthesiol & Crit Care, DMU Parabol, Paris, France; [Huet, Olivier; Vermeersch, Veronique] CHU Brest, Anesthesia & Intens Care Unit, Brest, France; [Lasocki, Sigismond; Gaillard, Thomas] CHU Angers, Anesthesia & Intens Care Unit, Angers, France; [Cohen, Benjamin] CHU Tours, Anesthesia & Intens Care Unit, Tours, France; [Dahyot-Fizelier, Claire] CHU Potiers, Anesthesia & Intens Care Unit, Poitiers, France; [Chalard, Kevin] CHU Montpellier, Anesthesia & Intens Care Unit, Montpellier, France; [Seguin, Philippe] CHU Rennes, Anesthesia & Intens Care Unit, Rennes, France; [Flet, Laurent] CHU Nantes, Hotel Dieu, Serv Pharm, Nantes, France; [Chiffoleau, Anne] CHU Nantes, Dept Promot, DRCI, Cellule Vigilances, Nantes, France; [Feuillet, Fanny] CHU Nantes, DRCI, Plateforme Methodol & Biostat, Nantes, France; [Feuillet, Fanny] Univ Nantes, Univ Tours, INSERM, SPHERE U1246, Nantes, France	Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Brest; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Tours; Universite de Montpellier; CHU de Montpellier; CHU Rennes; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite de Tours	Roquilly, A (corresponding author), CHU Nantes, Hotel Dieu HME, Serv Anesthesie Reanimat Chirurg, 5 Allee Lile Gloriette, F-4400 Nantes, France.	antoine.roquilly@chu-nantes.fr	FLET, Laurent/X-1192-2019; Seguin, Philippe/P-9487-2019	FLET, Laurent/0000-0001-8305-7085; Seguin, Philippe/0000-0002-7774-4257; MARTIN, Florian/0000-0002-5968-5484				Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Asehnoune K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1918-4; Bouzat P, 2016, ANESTHESIOLOGY, V125, P346, DOI 10.1097/ALN.0000000000001165; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Cooper DJ, 2018, JAMA-J AM MED ASSOC, V320, P2211, DOI 10.1001/jama.2018.17075; Darmon M, 2010, NEPHROL DIAL TRANSPL, V25, P2510, DOI 10.1093/ndt/gfq067; Dewan MC, 2019, J NEUROSURG, V130, P1065, DOI 10.3171/2017.10.JNS17439; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Geeraerts T, 2018, ANAESTH CRIT CARE PA, V37, P171, DOI 10.1016/j.accpm.2017.12.001; Hauer EM, 2011, CRIT CARE MED, V39, P1766, DOI 10.1097/CCM.0b013e318218a390; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Ichai C, 2013, INTENS CARE MED, V39, P1413, DOI 10.1007/s00134-013-2978-9; James SL, 2019, LANCET NEUROL, V18, P56, DOI 10.1016/S1474-4422(18)30415-0; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maggiore U, 2009, CRIT CARE, V13, DOI 10.1186/cc7953; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Oddo M, 2018, INTENS CARE MED, V44, P449, DOI 10.1007/s00134-018-5086-z; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Roquilly A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018035; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; Rowland MJ, 2020, LANCET NEUROL, V19, P208, DOI 10.1016/S1474-4422(20)30003-X; Semler MW, 2018, NEW ENGL J MED, V378, P829, DOI 10.1056/NEJMoa1711584; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tan SKR, 2016, CAN J ANESTH, V63, P664, DOI 10.1007/s12630-016-0633-y; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; Udy AA, 2013, CRIT CARE, V17, DOI 10.1186/cc12544; Wagner I, 2011, STROKE, V42, P1540, DOI 10.1161/STROKEAHA.110.609479; Watanitanon A, 2018, CRIT CARE MED, V46, P781, DOI 10.1097/CCM.0000000000002991; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Zuercher P, 2016, J NEUROTRAUM, V33, P1768, DOI 10.1089/neu.2015.4266	40	27	29	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2021	325	20					2056	2066		10.1001/jama.2021.5561	http://dx.doi.org/10.1001/jama.2021.5561			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SJ6MR	34032829	Bronze, Green Published			2023-01-03	WOS:000655647300020
J	Kitzman, DW; Whellan, DJ; Duncan, P; Pastva, AM; Mentz, RJ; Reeves, GR; Nelson, MB; Chen, HY; Upadhya, B; Reed, SD; Espeland, MA; Hewston, L; O'Connor, CM				Kitzman, Dalane W.; Whellan, David J.; Duncan, Pamela; Pastva, Amy M.; Mentz, Robert J.; Reeves, Gordon R.; Nelson, M. Benjamin; Chen, Haiying; Upadhya, Bharathi; Reed, Shelby D.; Espeland, Mark A.; Hewston, LeighAnn; O'Connor, Christopher M.			Physical Rehabilitation for Older Patients Hospitalized for Heart Failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC REHABILITATION; PERFORMANCE-MEASURES; OUTCOMES; ASSOCIATION; THERAPY; RESPONSIVENESS; INTERVENTION; MANAGEMENT; STATEMENT; EFFICACY	BACKGROUND Older patients who are hospitalized for acute decompensated heart failure have high rates of physical frailty, poor quality of life, delayed recovery, and frequent rehospitalizations. Interventions to address physical frailty in this population are not well established. METHODS We conducted a multicenter, randomized, controlled trial to evaluate a transitional, tailored, progressive rehabilitation intervention that included four physical-function domains (strength, balance, mobility, and endurance). The intervention was initiated during, or early after, hospitalization for heart failure and was continued after discharge for 36 outpatient sessions. The primary outcome was the score on the Short Physical Performance Battery (total scores range from 0 to 12, with lower scores indicating more severe physical dysfunction) at 3 months. The secondary outcome was the 6-month rate of rehospitalization for any cause. RESULTS A total of 349 patients underwent randomization; 175 were assigned to the rehabilitation intervention and 174 to usual care (control). At baseline, patients in each group had markedly impaired physical function, and 97% were frail or prefrail; the mean number of coexisting conditions was five in each group. Patient retention in the intervention group was 82%, and adherence to the intervention sessions was 67%. After adjustment for baseline Short Physical Performance Battery score and other baseline characteristics, the least-squares mean (+/- SE) score on the Short Physical Performance Battery at 3 months was 8.3 +/- 0.2 in the intervention group and 6.9 +/- 0.2 in the control group (mean between-group difference, 1.5; 95% confidence interval [CI], 0.9 to 2.0; P<0.001). At 6 months, the rates of rehospitalization for any cause were 1.18 in the intervention group and 1.28 in the control group (rate ratio, 0.93; 95% CI, 0.66 to 1.19). There were 21 deaths (15 from cardiovascular causes) in the intervention group and 16 deaths (8 from cardiovascular causes) in the control group. The rates of death from any cause were 0.13 and 0.10, respectively (rate ratio, 1.17; 95% CI, 0.61 to 2.27). CONCLUSIONS In a diverse population of older patients who were hospitalized for acute decompensated heart failure, an early, transitional, tailored, progressive rehabilitation intervention that included multiple physical-function domains resulted in greater improvement in physical function than usual care.	[Kitzman, Dalane W.; Nelson, M. Benjamin; Upadhya, Bharathi] Wake Forest Sch Med, Dept Internal Med, Sect Cardiovasc Med, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA; [Kitzman, Dalane W.; Espeland, Mark A.] Wake Forest Sch Med, Sect Gerontol & Geriatr Med, Dept Internal Med, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA; [Duncan, Pamela] Wake Forest Sch Med, Dept Neurol, Winston Salem, NC 27101 USA; [Chen, Haiying; Espeland, Mark A.] Wake Forest Sch Med, Dept Biostat & Data Sci, Winston Salem, NC 27101 USA; [Pastva, Amy M.] Duke Univ, Sch Med, Dept Orthoped Surg, Doctor Phys Therapy Div, Durham, NC USA; [Mentz, Robert J.] Duke Univ, Sch Med, Dept Med, Div Cardiol, Durham, NC 27706 USA; [Reed, Shelby D.] Duke Univ, Sch Med, Dept Populat Hlth Sci, Durham, NC USA; [Reeves, Gordon R.] Novant Hlth Heart & Vasc Inst, Charlotte, NC USA; [Whellan, David J.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Med, Philadelphia, PA 19107 USA; [Hewston, LeighAnn] Thomas Jefferson Univ, Jefferson Coll Rehabil Sci, Dept Phys Therapy, Philadelphia, PA 19107 USA; [O'Connor, Christopher M.] Inova Heart & Vasc Inst, Fairfax, VA USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; Duke University; Duke University; Duke University; Jefferson University; Jefferson University; Inova Fairfax Hospital	Kitzman, DW (corresponding author), Wake Forest Sch Med, Dept Internal Med, Sect Cardiovasc Med, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.; Kitzman, DW (corresponding author), Wake Forest Sch Med, Sect Gerontol & Geriatr Med, Dept Internal Med, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.	dkitzman@wakehealth.edu	Mentz, Robert/AAV-4758-2021; Pastva, Amy/AFK-5944-2022; Pastva, Amy/AAG-4332-2022	Pastva, Amy/0000-0002-0891-745X; Pastva, Amy/0000-0002-0891-745X; Mentz, Robert/0000-0002-3222-1719	National Institutes of Health [R01AG045551, R01AG18915, P30AG021332, P30AG028716, U24AG059624]; Oristano Family Fund at Wake Forest School of Medicine	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Oristano Family Fund at Wake Forest School of Medicine	Supported by research grants from the National Institutes of Health (R01AG045551, R01AG18915, P30AG021332, P30AG028716, and U24AG059624), the Kermit Glenn Phillips II Chair in Cardiovascular Medicine, and the Oristano Family Fund at Wake Forest School of Medicine.	Acanfora D, 2016, INT J CARDIOL, V225, P313, DOI 10.1016/j.ijcard.2016.10.026; Alahdab MT, 2009, J CARD FAIL, V15, P130, DOI 10.1016/j.cardfail.2008.10.006; [Anonymous], 2018, BIG DATA RES, V11, piii, DOI 10.1016/S2214-5796(18)30058-3; [Anonymous], 2017, CIRC-HEART FAIL, V10, ps1; Babu Abraham Samuel, 2011, Heart Views, V12, P99, DOI 10.4103/1995-705X.95064; Cheng RK, 2014, AM HEART J, V168, P721, DOI 10.1016/j.ahj.2014.07.008; Chiarantini D, 2010, J CARD FAIL, V16, P390, DOI 10.1016/j.cardfail.2010.01.004; Contrepois K, 2020, CELL, V181, P1112, DOI 10.1016/j.cell.2020.04.043; Davies EJ, 2010, EUR J HEART FAIL, V12, P706, DOI 10.1093/eurjhf/hfq056; Faber MJ, 2006, ARCH PHYS MED REHAB, V87, P885, DOI 10.1016/j.apmr.2006.04.005; Fleg JL, 2018, JACC-HEART FAIL, V6, P153, DOI 10.1016/j.jchf.2017.12.012; Fleg JL, 2015, CIRC-HEART FAIL, V8, P209, DOI 10.1161/CIRCHEARTFAILURE.113.001420; Flynn KE, 2009, JAMA-J AM MED ASSOC, V301, P1451, DOI 10.1001/jama.2009.457; Forman DE, 2017, CIRCULATION, V135, pE894, DOI 10.1161/CIR.0000000000000483; Forman DE, 2012, J AM COLL CARDIOL, V60, P2653, DOI 10.1016/j.jacc.2012.08.1010; Giallauria F, 2010, J GERONTOL A-BIOL, V65, P1353, DOI 10.1093/gerona/glq138; Gill TM, 2010, JAMA-J AM MED ASSOC, V304, P1919, DOI 10.1001/jama.2010.1568; Heidenreich PA, 2013, CIRC-HEART FAIL, V6, P606, DOI 10.1161/HHF.0b013e318291329a; Huusko J, 2020, ESC HEART FAIL, V7, P2406, DOI 10.1002/ehf2.12792; Johnson TJ, 2012, J CARD FAIL, V18, P246, DOI 10.1016/j.cardfail.2011.12.005; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; Lorenzo M, 2020, EUR J INTERN MED, V81, P78, DOI 10.1016/j.ejim.2020.05.017; Mudge AM, 2018, JACC-HEART FAIL, V6, P143, DOI 10.1016/j.jchf.2017.11.016; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Pandey A, 2019, JACC-HEART FAIL, V7, P1079, DOI 10.1016/j.jchf.2019.10.003; Pastva AM, 2018, CONTEMP CLIN TRIALS, V64, P118, DOI 10.1016/j.cct.2017.10.014; Pavasini R, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0763-7; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Reeves GR, 2017, JACC-HEART FAIL, V5, P359, DOI 10.1016/j.jchf.2016.12.019; Reeves GR, 2017, AM HEART J, V185, P130, DOI 10.1016/j.ahj.2016.12.012; Reeves GR, 2016, AM J CARDIOL, V117, P1953, DOI 10.1016/j.amjcard.2016.03.046; Sarbjit G, 2018, WILEY INTERDISCIPL R, V7, pe286, DOI 10.1002/WENE.286; Scrutinio D, 2012, J CARDIOPULM REHABIL, V32, P71, DOI 10.1097/HCR.0b013e31823be124; Soubra R, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1354362; Spertus JA, 2008, QUAL LIFE RES, V17, P291, DOI 10.1007/s11136-007-9302-5; Volpato S, 2011, J GERONTOL A-BIOL, V66, P89, DOI 10.1093/gerona/glq167; Wang W, 2017, COMPUT METH PROG BIO, V138, P23, DOI 10.1016/j.cmpb.2016.10.003; Witham MD, 2012, CIRC-HEART FAIL, V5, P209, DOI 10.1161/CIRCHEARTFAILURE.111.963132; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; 2019, BRAIN STIMUL MAR, V12, pe0080	40	112	114	11	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2021	385	3					203	216		10.1056/NEJMoa2026141	http://dx.doi.org/10.1056/NEJMoa2026141		MAY 2021	14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM6AG	33999544	Green Accepted, Bronze			2023-01-03	WOS:000652592000001
J	Schneider, J; Jaenigen, B; Wagner, D; Rieg, S; Hornuss, D; Biever, PM; Kern, WV; Walz, G				Schneider, Johanna; Jaenigen, Bernd; Wagner, Dirk; Rieg, Siegbert; Hornuss, Daniel; Biever, Paul M.; Kern, Winfried V.; Walz, Gerd			Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; COMBINATION; MANAGEMENT; INHIBITOR; ABT-378; DISEASE; MODEL	Background Acute kidney injury (AKI) is an independent risk factor for mortality, which affects about 5% of hospitalized coronavirus disease-2019 (COVID-19) patients and up to 25-29% of severely ill COVID-19 patients. Lopinavir/ritonavir and hydroxychloroquine show in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and have been used for the treatment of COVID-19. Both, lopinavir and hydroxychloroquine are metabolized by cytochrome P450 (CYP) 3A4. The impact of a triple therapy with lopinavir/ritonavir and hydroxychloroquine (triple therapy) on kidney function in COVID-19 is currently not known. Methods We retrospectively analyzed both non-ICU and ICU patients with COVID-19 receiving triple therapy for the incidence of AKI. Patients receiving standard therapy served as a control group. All patients were hospitalized at the University Hospital of Freiburg, Germany, between March and April 2020. A matched-pair analysis for the National Early Warning Score (NEWS) 2 was performed to control for the severity of illness among non-intensive care unit (ICU) patients. Results In non-ICU patients, the incidence of AKI was markedly increased following triple therapy (78.6% vs. 21.4% in controls, p = 0.002), while a high incidence of AKI was observed in both groups of ICU patients (triple therapy: 80.0%, control group: 90.5%). ICU patients treated with triple therapy showed a trend towards more oliguric or anuric kidney injury. We also observed a linear correlation between the duration of the triple therapy and the maximum serum creatinine level (p = 0.004, R-2 = 0.276, R = 0.597). Conclusion Triple therapy is associated with an increase in the incidence of AKI in non-ICU COVID-19 patients. The underlying mechanisms may comprise a CYP3A4 enzyme interaction, and may be relevant for any future therapy combining hydroxychloroquine with antiviral agents.	[Schneider, Johanna; Walz, Gerd] Univ Freiburg, Med Ctr, Fac Med, Dept Med 4, Freiburg, Germany; [Jaenigen, Bernd] Univ Freiburg, Med Ctr, Fac Med, Dept Gen & Digest Surg, Freiburg, Germany; [Wagner, Dirk; Rieg, Siegbert; Hornuss, Daniel; Biever, Paul M.; Kern, Winfried V.] Univ Freiburg, Med Ctr, Fac Med, Div Infect Dis,Dept Med 2, Freiburg, Germany; [Biever, Paul M.] Univ Freiburg, Med Ctr, Fac Med, Dept Med Interdisciplinary Med Intens Care 3, Freiburg, Germany; [Biever, Paul M.] Univ Freiburg, Heart Ctr Freiburg Univ, Fac Med, Med Ctr,Dept Cardiol & Angiol 1, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Universitats Herzzentrum Freiburg; University of Freiburg	Schneider, J (corresponding author), Univ Freiburg, Med Ctr, Fac Med, Dept Med 4, Freiburg, Germany.	johanna.schneider@uniklinik-freiburg.de		Hornuss, Daniel/0000-0002-2621-3341; Schneider, Johanna/0000-0003-0661-6984				Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Baeza MT, 2007, AIDS, V21, P119, DOI 10.1097/QAD.0b013e3280117f6f; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005; Collins KP, 2018, J PHARMACOL EXP THER, V365, P447, DOI 10.1124/jpet.117.245639; Costa RM, 2013, CLIN KIDNEY J, V6, P533, DOI 10.1093/ckj/sft089; Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004; Dussol B, 2008, AM J KIDNEY DIS, V52, P699, DOI 10.1053/j.ajkd.2008.04.013; Groneberg DA, 2005, LANCET INFECT DIS, V5, P147, DOI 10.1016/S1473-3099(05)70022-0; Hamzah L, 2015, AIDS, V29, P1831, DOI 10.1097/QAD.0000000000000736; Hoste EAJ, 2003, J AM SOC NEPHROL, V14, P1022, DOI 10.1097/01.ASN.0000059863.48590.E9; Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789; Kostakis I, 2021, RESUSCITATION, V159, P150, DOI 10.1016/j.resuscitation.2020.10.039; Kumar GN, 2004, PHARM RES-DORDR, V21, P1622, DOI 10.1023/B:PHAM.0000041457.64638.8d; Landray PWHaM, 2020, EFFECT HYDROXYCHLORO; Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; Niu WJ, 2019, BASIC CLIN PHARMACOL, V124, P456, DOI 10.1111/bcpt.13154; Oldfield V, 2006, DRUGS, V66, P1275, DOI 10.2165/00003495-200666090-00012; Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7; Ryom L, 2013, J INFECT DIS, V207, P1359, DOI 10.1093/infdis/jit043; Santoriello D, 2020, J AM SOC NEPHROL, V31, P2158, DOI 10.1681/ASN.2020050744; Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072; Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218, DOI 10.1128/AAC.42.12.3218; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003; Sun J, 2020, CLIN PHARMACOL THER, V108, P791, DOI 10.1002/cpt.1866; Wu SZ, 2019, WORLD J CLIN CASES, V7, P4377, DOI 10.12998/wjcc.v7.i24.4377; Xie JY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15383-w; Yang X, 2020, LANCET RESP MED, V8, P475; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237	33	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2021	16	5							e0249760	10.1371/journal.pone.0249760	http://dx.doi.org/10.1371/journal.pone.0249760			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6LY	33974624	Green Published, gold			2023-01-03	WOS:000664626600007
J	Shapira, S; Finkelshtein, E; Kazanov, D; Naftali, E; Stepansky, I; Loyter, A; Elbirt, D; Hay-Levy, M; Brazowski, E; Bedny, F; Dekel, R; Hershkovitz, D; Blachar, A; Wolf, I; Arber, N				Shapira, Shiran; Finkelshtein, Eynat; Kazanov, Dina; Naftali, Esmira; Stepansky, Irena; Loyter, Abraham; Elbirt, Daniel; Hay-Levy, Mori; Brazowski, Eli; Bedny, Faina; Dekel, Roy; Hershkovitz, Dov; Blachar, Arye; Wolf, Ido; Arber, Nadir			Integrase-derived peptides together with CD24-targeted lentiviral particles inhibit the growth of CD24 expressing cancer cells	ONCOGENE			English	Article							HIV-1 INTEGRASE; REV; GENE; CARCINOGENESIS; REPLICATION; MARKER	The integration of viral DNA into the host genome is mediated by viral integrase, resulting in the accumulation of double-strand breaks. Integrase-derived peptides (INS and INR) increase the number of integration events, leading to escalated genomic instability that induces apoptosis. CD24 is a surface protein expressed mostly in cancer cells and is very rarely found in normal cells. Here, we propose a novel targeted cancer therapeutic platform based on the lentiviral integrase, stimulated by integrase-derived peptides, that are specifically delivered to cancerous cells via CD24 antigen-antibody targeting. INS and INR were synthesized and humanized and anti-CD24 antibodies were fused to the lentivirus envelope. The activity, permeability, stability, solubility, and toxicity of these components were analyzed. Cell death was measured by fluorescent microscopy and enzymatic assays and potency were tested in vitro and in vivo. Lentivirus particles, containing non-functional DNA led to massive cell death (40-70%). Raltegravir, an antiretroviral drug, inhibited the induction of apoptosis. In vivo, single and repeated administrations of INS/INR were well tolerated without any adverse effects. Tumor development in nude mice was significantly inhibited (by 50%) as compared to the vehicle arm. In summary, a novel and generic therapeutic platform for selective cancer cell eradication with excellent efficacy and safety are presented.	[Shapira, Shiran; Kazanov, Dina; Hay-Levy, Mori; Dekel, Roy; Arber, Nadir] Sourasky Med Ctr, Hlth Promot Ctr, Tel Aviv, Israel; [Shapira, Shiran; Kazanov, Dina; Hay-Levy, Mori; Dekel, Roy; Arber, Nadir] Sourasky Med Ctr, Integrated Canc Prevent Ctr, Tel Aviv, Israel; [Shapira, Shiran; Arber, Nadir] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Finkelshtein, Eynat; Naftali, Esmira] Zion Med BV, De Bilt, Netherlands; [Stepansky, Irena; Wolf, Ido] Tel Aviv Med Ctr & Sch Med, Oncol Div, Tel Aviv, Israel; [Loyter, Abraham] Hebrew Univ Jerusalem, Alexander Inst Life Sci, Dept Biol Chem, Jerusalem, Israel; [Elbirt, Daniel] Hadassah Hebrew Univ, Clin Immunol Allergy & AIDS Ctr Kaplan Med Ctr, Med Sch Jerusalem, Rehovot, Israel; [Brazowski, Eli; Bedny, Faina; Hershkovitz, Dov] Tel Aviv Sourasky Med Ctr, Pathol Inst, Tel Aviv, Israel; [Blachar, Arye] Tel Aviv Sourasky Med Ctr, Dept Radiol, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Arber, N (corresponding author), Sourasky Med Ctr, Hlth Promot Ctr, Tel Aviv, Israel.; Arber, N (corresponding author), Sourasky Med Ctr, Integrated Canc Prevent Ctr, Tel Aviv, Israel.; Arber, N (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	nadir@tlvmc.gov.il						Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Cooper A, 2013, NATURE, V498, P376, DOI 10.1038/nature12274; Craigie R, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006890; Fogel M, 1999, CANCER LETT, V143, P87, DOI 10.1016/S0304-3835(99)00195-0; Gelderblom HC, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-60; Grewe B, 2010, J GEN VIROL, V91, P1893, DOI 10.1099/vir.0.022509-0; Gromova I, 1999, ELECTROPHORESIS, V20, P241, DOI 10.1002/(SICI)1522-2683(19990201)20:2<241::AID-ELPS241>3.3.CO;2-1; HUANG LR, 1995, CANCER RES, V55, P4717; Kammerer R, 2004, J PATHOL, V204, P258, DOI 10.1002/path.1657; Lesbats P, 2016, CHEM REV, V116, P12730, DOI 10.1021/acs.chemrev.6b00125; Levin A, 2010, NUCLEUS-PHILA, V1, P190, DOI 10.4161/nucl.1.2.11300; Levin A, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-31; Levin A, 2010, BIOPOLYMERS, V93, P740, DOI 10.1002/bip.21469; Levin A, 2009, PROTEIN ENG DES SEL, V22, P753, DOI 10.1093/protein/gzp060; Levin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004155; Redston M, 2001, MODERN PATHOL, V14, P236, DOI 10.1038/modpathol.3880292; Rosenbluh J, 2007, J BIOL CHEM, V282, P15743, DOI 10.1074/jbc.M609864200; Rutsaert S, 2019, J ANTIMICROB CHEMOTH, V74, P3030, DOI 10.1093/jac/dkz269; Rutsaert S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35403-6; Rutsaert S, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0399-0; Sagiv E, 2006, BIOMED PHARMACOTHER, V60, P280, DOI 10.1016/j.biopha.2006.06.006; Sagiv E, 2008, CANCER RES, V68, P2803, DOI 10.1158/0008-5472.CAN-07-6463; Sagiv E, 2006, GASTROENTEROLOGY, V131, P630, DOI 10.1053/j.gastro.2006.04.028; Senner V, 1999, J NEUROPATH EXP NEUR, V58, P795, DOI 10.1097/00005072-199908000-00002; Shapira S, 2011, GASTROENTEROLOGY, V140, P935, DOI 10.1053/j.gastro.2010.12.004; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yoder KE, 2000, J VIROL, V74, P11191, DOI 10.1128/JVI.74.23.11191-11200.2000	27	0	0	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3815	3825		10.1038/s41388-021-01779-5	http://dx.doi.org/10.1038/s41388-021-01779-5		MAY 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33958722	Green Published, hybrid			2023-01-03	WOS:000648041500002
J	Dimai, S; Semmler, L; Prabhu, A; Stachelscheid, H; Huettemeister, J; Klaucke, SC; Lacour, P; Blaschke, F; Kruse, J; Parwani, A; Boldt, LH; Bullinger, L; Pieske, BM; Heinzel, FR; Hohendanner, F				Dimai, Sanzio; Semmler, Lukas; Prabhu, Ashok; Stachelscheid, Harald; Huettemeister, Judith; Klaucke, Sandra C.; Lacour, Philipp; Blaschke, Florian; Kruse, Jan; Parwani, Abdul; Boldt, Leif-Hendrik; Bullinger, Lars; Pieske, Burkert M.; Heinzel, Frank R.; Hohendanner, Felix			COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab	PLOS ONE			English	Article							NECROSIS-FACTOR-ALPHA; CYTOKINE STORM; INTERLEUKIN-1; IL-1-BETA; COVID-19	Background Cardiac injury associated with cytokine release frequently occurs in SARS-CoV-2 mediated coronavirus disease (COVID19) and mortality is particularly high in these patients. The mechanistic role of the COVID19 associated cytokine-storm for the concomitant cardiac dysfunction and associated arrhythmias is unclear. Moreover, the role of anti-inflammatory therapy to mitigate cardiac dysfunction remains elusive. Aims and methods We investigated the effects of COVID19-associated inflammatory response on cardiac cellular function as well as its cardiac arrhythmogenic potential in rat and induced pluripotent stem cell derived cardiomyocytes (iPS-CM). In addition, we evaluated the therapeutic potential of the IL-1 beta antagonist Canakinumab using state of the art in-vitro confocal and ratiometric high-throughput microscopy. Results Isolated rat ventricular cardiomyocytes were exposed to control or COVID19 serum from intensive care unit (ICU) patients with severe ARDS and impaired cardiac function (LVEF 41 +/- 5%; 1/3 of patients on veno-venous extracorporeal membrane oxygenation; CK 154 +/- 43 U/l). Rat cardiomyocytes showed an early increase of myofilament sensitivity, a decrease of Ca2+ transient amplitudes and altered baseline [Ca2+] upon exposure to patient serum. In addition, we used iPS-CM to explore the long-term effect of patient serum on cardiac electrical and mechanical function. In iPS-CM, spontaneous Ca2+ release events were more likely to occur upon incubation with COVID19 serum and nuclear as well as cytosolic Ca2+ release were altered. Co-incubation with Canakinumab had no effect on pro-arrhythmogenic Ca2+ release or Ca2+ signaling during excitation-contraction coupling, nor significantly influenced cellular automaticity. Conclusion Serum derived from COVID19 patients exerts acute cardio-depressant and chronic pro-arrhythmogenic effects in rat and iPS-derived cardiomyocytes. Canakinumab had no beneficial effect on cellular Ca2+ signaling during excitation-contraction coupling. The presented method utilizing iPS-CM and in-vitro Ca2+ imaging might serve as a novel tool for precision medicine. It allows to investigate cytokine related cardiac dysfunction and pharmacological approaches useful therein.	[Dimai, Sanzio; Semmler, Lukas; Prabhu, Ashok; Huettemeister, Judith; Lacour, Philipp; Blaschke, Florian; Parwani, Abdul; Boldt, Leif-Hendrik; Pieske, Burkert M.; Heinzel, Frank R.; Hohendanner, Felix] Charite, Dept Internal Med & Cardiol, Berlin, Germany; [Dimai, Sanzio] Paracelsus Med Privatuniv, Inst Physiol & Pathophysiol, Nurnberg, Germany; [Semmler, Lukas; Prabhu, Ashok; Lacour, Philipp; Blaschke, Florian; Parwani, Abdul; Boldt, Leif-Hendrik; Pieske, Burkert M.; Heinzel, Frank R.; Hohendanner, Felix] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany; [Stachelscheid, Harald; Pieske, Burkert M.; Hohendanner, Felix] Charite Univ Med Berlin, Berlin Inst Hlth BIH, Berlin, Germany; [Klaucke, Sandra C.] Imperial Coll London, Hammersmith Hosp, London, England; [Kruse, Jan] Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany; [Bullinger, Lars] Charite, Dept Hematol Oncol & Tumorimmunol, Berlin, Germany; [Pieske, Burkert M.] German Heart Ctr Berlin, Dept Internal Med & Cardiol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Centre for Cardiovascular Research; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Imperial College London; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Heart Center Berlin	Hohendanner, F (corresponding author), Charite, Dept Internal Med & Cardiol, Berlin, Germany.; Hohendanner, F (corresponding author), German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany.; Hohendanner, F (corresponding author), Charite Univ Med Berlin, Berlin Inst Hlth BIH, Berlin, Germany.	felix.hohendanner@charite.de	; Pieske, Burkert/M-8089-2016	Boldt, Leif-Hendrik/0000-0002-3320-0880; Bullinger, Lars/0000-0002-5890-5510; Pieske, Burkert/0000-0002-6466-5306; Stachelscheid, Harald/0000-0002-9283-4605; Heinzel, Frank R./0000-0002-4529-5282	DZHK (German Centre for Cardiovascular Research); BMBF (German Ministry of Education and Research); Else-Kroner-Fresenius Foundation; Berlin Institute of Health	DZHK (German Centre for Cardiovascular Research); BMBF (German Ministry of Education and Research)(Federal Ministry of Education & Research (BMBF)); Else-Kroner-Fresenius Foundation; Berlin Institute of Health	This study was supported by the DZHK (German Centre for Cardiovascular Research) and by the BMBF (German Ministry of Education and Research) as well as by the Else-Kroner-Fresenius Foundation and the Berlin Institute of Health (FH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbate A, 2020, CIRC RES, V126, P1260, DOI 10.1161/CIRCRESAHA.120.315937; Bonow RO, 2020, JAMA CARDIOL, V5, P751, DOI 10.1001/jamacardio.2020.1105; Cain BS, 1999, CRIT CARE MED, V27, P1309, DOI 10.1097/00003246-199907000-00018; Cirulis MM, 2019, INTENS CARE MED EXP, V7, DOI 10.1186/s40635-019-0271-0; Costela-Ruiz VJ, 2020, CYTOKINE GROWTH F R, V54, P62, DOI 10.1016/j.cytogfr.2020.06.001; Curl CL, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007451; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; Di Iorio A, 2003, CYTOKINE, V22, P198, DOI 10.1016/S1043-4666(03)00152-2; Duncan DJ, 2010, CELL CALCIUM, V47, P378, DOI 10.1016/j.ceca.2010.02.002; Fontes JA, 2015, CYTOKINE, V74, P62, DOI 10.1016/j.cyto.2014.12.024; Garcia-Zamora S, 2021, PACE, V44, P1062, DOI 10.1111/pace.14247; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hobai IA, 2015, SHOCK, V43, P3, DOI 10.1097/SHK.0000000000000261; Hohendanner F, 2018, J MOL CELL CARDIOL, V115, P10, DOI 10.1016/j.yjmcc.2017.12.012; Hossini AM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154770; Huke S, 2010, J MOL CELL CARDIOL, V48, P824, DOI 10.1016/j.yjmcc.2010.01.011; Jeong HS, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010263; Katia F, 2021, IMMUN INFLAMM DIS, V9, P399, DOI 10.1002/iid3.400; Kim JJ, 2015, J MOL CELL CARDIOL, V81, P81, DOI 10.1016/j.yjmcc.2015.01.013; Lian XJ, 2012, P NATL ACAD SCI USA, V109, pE1848, DOI 10.1073/pnas.1200250109; Liu SJ, 1999, AM J PHYSIOL-HEART C, V276, pH141, DOI 10.1152/ajpheart.1999.276.1.H141; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Mitrokhin VM, 2015, INT IMMUNOPHARMACOL, V28, P780, DOI 10.1016/j.intimp.2015.08.006; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Rowaiye AB, 2021, J INFLAMM RES, V14, P1487, DOI 10.2147/JIR.S301784; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402; Sheng CC, 2020, CLIN CARDIOL, V43, P1055, DOI 10.1002/clc.23451; Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950; Todd J, 2013, CYTOKINE, V64, P660, DOI 10.1016/j.cyto.2013.09.018; Tschope C, 2019, CIRC RES, V124, P1568, DOI 10.1161/CIRCRESAHA.118.313578; van de Veerdonk FL, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03166-0; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu XS, 2005, CRIT CARE MED, V33, P598, DOI 10.1097/01.ccm.0000152223.27176.A6	34	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255976	10.1371/journal.pone.0255976	http://dx.doi.org/10.1371/journal.pone.0255976			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC2PD	34411149	Green Accepted, Green Published, gold			2023-01-03	WOS:000686373300056
J	Rounis, K; Makrakis, D; Papadaki, C; Monastirioti, A; Vamvakas, L; Kalbakis, K; Gourlia, K; Xanthopoulos, I; Tsamardinos, I; Mavroudis, D; Agelaki, S				Rounis, Konstantinos; Makrakis, Dimitrios; Papadaki, Chara; Monastirioti, Alexia; Vamvakas, Lambros; Kalbakis, Konstantinos; Gourlia, Krystallia; Xanthopoulos, Iordanis; Tsamardinos, Ioannis; Mavroudis, Dimitrios; Agelaki, Sofia			Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study	PLOS ONE			English	Article							COST-EFFECTIVENESS; DOCETAXEL; IMMUNOTHERAPY; NIVOLUMAB	Objective We prospectively recorded clinical and laboratory parameters from patients with metastatic non-small cell lung cancer (NSCLC) treated with 2nd line PD-1/PD-L1 inhibitors in order to address their effect on treatment outcomes. Materials and methods Clinicopathological information (age, performance status, smoking, body mass index, histology, organs with metastases), use and duration of proton pump inhibitors, steroids and antibiotics (ATB) and laboratory values [neutrophil/lymphocyte ratio, LDH, albumin] were prospectively collected. Steroid administration was defined as the use of > 10 mg prednisone equivalent for >= 10 days. Prolonged ATB administration was defined as ATB >= 14 days 30 days before or within the first 3 months of treatment. JADBio, a machine learning pipeline was applied for further multivariate analysis. Results Data from 66 pts with non-oncogenic driven metastatic NSCLC were analyzed; 15.2% experienced partial response (PR), 34.8% stable disease (SD) and 50% progressive disease (PD). Median overall survival (OS) was 6.77 months. ATB administration did not affect patient OS [HR = 1.35 (CI: 0.761-2.406, p = 0.304)], however, prolonged ATBs [HR = 2.95 (CI: 1.62-5.36, p = 0.0001)] and the presence of bone metastases [HR = 1.89 (CI: 1.02-3.51, p = 0.049)] independently predicted for shorter survival. Prolonged ATB administration, bone metastases, liver metastases and BMI < 25 kg/m(2) were selected by JADbio as the important features that were associated with increased probability of developing disease progression as response to treatment. The resulting algorithm that was created was able to predict the probability of disease stabilization (PR or SD) in a single individual with an AUC = 0.806 [95% CI:0.714-0.889]. Conclusions Our results demonstrate an adverse effect of prolonged ATBs on response and survival and underscore their importance along with the presence of bone metastases, liver metastases and low BMI in the individual prediction of outcomes in patients treated with immunotherapy.	[Rounis, Konstantinos; Makrakis, Dimitrios; Vamvakas, Lambros; Kalbakis, Konstantinos; Mavroudis, Dimitrios; Agelaki, Sofia] Univ Gen Hosp, Dept Med Oncol, Iraklion, Greece; [Makrakis, Dimitrios] Univ Washington, Div Oncol, Med Sch, Washington, DC USA; [Papadaki, Chara; Monastirioti, Alexia; Mavroudis, Dimitrios; Agelaki, Sofia] Univ Crete, Sch Med, Lab Translat Oncol, Iraklion, Greece; [Gourlia, Krystallia; Xanthopoulos, Iordanis; Tsamardinos, Ioannis] Univ Crete, Dept Comp Sci, Iraklion, Greece	University Hospital of Heraklion; University of Washington; University of Crete; University of Crete	Rounis, K (corresponding author), Univ Gen Hosp, Dept Med Oncol, Iraklion, Greece.	kostas@rounis.gr		Rounis, Konstantinos/0000-0002-6643-9855; Agelaki, Sofia/0000-0002-7850-0457; PAPADAKI, CHARA/0000-0002-4591-3757	Anticancer Research Support Association (ARSA); ARSA [2440338]	Anticancer Research Support Association (ARSA); ARSA	This work was partly supported by Anticancer Research Support Association (ARSA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. One of the coauthors, Dimitrios Makrakis, at the time of data collection, was receiving a scholarship for cancer research from ARSA (ID: 2440338).	Arbour KC, 2018, J CLIN ONCOL, V36, P2872, DOI 10.1200/JCO.2018.79.0006; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Borboudakis G, 2017, MACH LEARN, V107; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Boser B. E., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P144, DOI 10.1145/130385.130401; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Brusselle Guy, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS322, DOI 10.1513/AnnalsATS.201403-118AW; Cawley GC, 2010, J MACH LEARN RES, V11, P2079; Derosa L, 2018, ANN ONCOL, V29, P1437, DOI 10.1093/annonc/mdy103; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Georgieva M, 2018, LUNG CANCER, V124, P248, DOI 10.1016/j.lungcan.2018.08.018; HOERL AE, 1970, TECHNOMETRICS, V12, P55, DOI 10.1080/00401706.1970.10488634; Hopkins AM, 2020, CLIN CANCER RES, V26, P5487, DOI 10.1158/1078-0432.CCR-20-1876; Hopkins AM, 2017, BRIT J CANCER, V117, P913, DOI 10.1038/bjc.2017.274; Imhann F, 2016, GUT, V65, P740, DOI 10.1136/gutjnl-2015-310376; Kazandjian D, 2019, JAMA ONCOL, V5, P1481, DOI 10.1001/jamaoncol.2019.1747; Kichenadasse G, 2019, JAMA ONCOL; Laird BJ, 2013, CLIN CANCER RES, V19, P5456, DOI 10.1158/1078-0432.CCR-13-1066; Landi L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0793-8; Martin L, 2015, J CLIN ONCOL, V33, P90, DOI 10.1200/JCO.2014.56.1894; Orfanoudaki G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03557-4; Palleja A, 2018, NAT MICROBIOL, V3, P1255, DOI 10.1038/s41564-018-0257-9; Panagopoulou M, 2019, ONCOGENE, V38, P3387, DOI 10.1038/s41388-018-0660-y; Park W, 2020, BRIT J CANCER, V122, P340, DOI 10.1038/s41416-019-0643-y; Pinato DJ, 2019, JAMA ONCOL, V5, P1774, DOI 10.1001/jamaoncol.2019.2785; PRAAGMAN J, 1985, EUR J OPER RES, V19, P144, DOI 10.1016/0377-2217(85)90321-2; Prelaj A, 2019, CANCERS, V11, DOI 10.3390/cancers11121954; Ren FP, 2019, ONCOTARGETS THER, V12, P4235, DOI 10.2147/OTT.S199176; Ricciuti B, 2019, J CLIN ONCOL, V37, P1927, DOI 10.1200/JCO.19.00189; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Sun HF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144663; Tinsley N, 2020, ONCOLOGIST, V25, P55, DOI 10.1634/theoncologist.2019-0160; Trebeschi S, 2019, ANN ONCOL, V30, P998, DOI 10.1093/annonc/mdz108; Verma V, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0442-7; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Weide B, 2016, CLIN CANCER RES, V22, P5487, DOI 10.1158/1078-0432.CCR-16-0127	40	9	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	6							e0252537	10.1371/journal.pone.0252537	http://dx.doi.org/10.1371/journal.pone.0252537			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SL3JC	34061904	Green Published, gold			2023-01-03	WOS:000656813600005
J	Xu, Z; Hueckel, T; Irvine, WTM; Sacanna, S				Xu, Zhe; Hueckel, Theodore; Irvine, William T. M.; Sacanna, Stefano			Transmembrane transport in inorganic colloidal cell-mimics	NATURE			English	Article							PARTICLES; BEHAVIOR	Hollow colloidal capsules, each with a single micropore, act as artificial cell-like structures that can capture and release payloads such as solid particles or bacteria from the external environment. A key aspect of living cells is their ability to harvest energy from the environment and use it to pump specific atomic and molecular species in and out of their system-typically against an unfavourable concentration gradient(1). Active transport allows cells to store metabolic energy, extract waste and supply organelles with basic building blocks at the submicrometre scale. Unlike living cells, abiotic systems do not have the delicate biochemical machinery that can be specifically activated to precisely control biological matter(2-5). Here we report the creation of microcapsules that can be brought out of equilibrium by simple global variables (illumination and pH), to capture, concentrate, store and deliver generic microscopic payloads. Borrowing no materials from biology, our design uses hollow colloids serving as spherical cell-membrane mimics, with a well-defined single micropore. Precisely tunable monodisperse capsules are the result of a synthetic self-inflation mechanism and can be produced in bulk quantities. Inside the hollow unit, a photoswitchable catalyst(6) produces a chemical gradient that propagates to the exterior through the membrane's micropore and pumps target objects into the cell, acting as a phoretic tractor beam(7). An entropic energy barrier(8,9) brought about by the micropore's geometry retains the cargo even when the catalyst is switched off. Delivery is accomplished on demand by reversing the sign of the phoretic interaction. Our findings provide a blueprint for developing the next generation of smart materials, autonomous micromachinery and artificial cell-mimics.	[Xu, Zhe; Hueckel, Theodore; Sacanna, Stefano] NYU, Dept Chem, Mol Design Inst, New York, NY 10013 USA; [Irvine, William T. M.] Univ Chicago, Enrico Fermi Inst, Dept Phys, James Franck Inst, Chicago, IL 60637 USA	New York University; University of Chicago	Sacanna, S (corresponding author), NYU, Dept Chem, Mol Design Inst, New York, NY 10013 USA.; Irvine, WTM (corresponding author), Univ Chicago, Enrico Fermi Inst, Dept Phys, James Franck Inst, Chicago, IL 60637 USA.	wtmirvine@uchicago.edu; s.sacanna@nyu.edu	Sacanna, Stefano/ABE-9434-2021	Sacanna, Stefano/0000-0002-8399-3524; Xu, Zhe/0000-0002-8599-079X; irvine, william/0000-0002-4925-2060				Cheng KL, 2008, J CHEM PHYS, V129, DOI 10.1063/1.3009621; Datta SS, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.134302; Dinsmore AD, 2002, SCIENCE, V298, P1006, DOI 10.1126/science.1074868; Fujii S, 2013, P NATL ACAD SCI USA, V110, P16796, DOI 10.1073/pnas.1314585110; Grigoriev IV, 2002, J CHEM PHYS, V116, P9574, DOI 10.1063/1.1475756; Im SH, 2005, NAT MATER, V4, P671, DOI 10.1038/nmat1448; Kar A, 2015, ACS NANO, V9, P746, DOI 10.1021/nn506216b; Kim SH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4068; Kim SH, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/7/075014; Kuijk A, 2011, J AM CHEM SOC, V133, P2346, DOI 10.1021/ja109524h; Li GZ, 2001, J INORG ORGANOMET P, V11, P123, DOI 10.1023/A:1015287910502; Okubo M, 2017, LANGMUIR, V33, P3468, DOI 10.1021/acs.langmuir.7b00232; Opdam J, 2020, SOFT MATTER, V16, P7438, DOI 10.1039/d0sm00942c; Palacci J, 2014, PHILOS T R SOC A, V372, DOI 10.1098/rsta.2013.0372; Qiao Y, 2017, NAT CHEM, V9, P110, DOI [10.1038/NCHEM.2617, 10.1038/nchem.2617]; Qiu JC, 2019, ANGEW CHEM INT EDIT, V58, P10606, DOI 10.1002/anie.201904549; Rideau E, 2018, CHEM SOC REV, V47, DOI 10.1039/c8cs00162f; Rodriguez-Arco L, 2017, NAT MATER, V16, P857, DOI [10.1038/NMAT4916, 10.1038/nmat4916]; Sacanna S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2694; Shang LR, 2021, MATTER-US, V4, P95, DOI 10.1016/j.matt.2020.10.003; Shi H, 2019, LANGMUIR, V35, P12150, DOI 10.1021/acs.langmuir.9b01952; Silletta EV, 2018, J PHYS CHEM B, V122, P4931, DOI 10.1021/acs.jpcb.8b01638; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SUGIMOTO T, 1993, COLLOID SURFACE A, V70, P167, DOI 10.1016/0927-7757(93)80285-M; Taylor JW, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00177-4; Tweedy L, 2020, SCIENCE, V369, P1075, DOI 10.1126/science.aay9792; van der Wel C, 2017, LANGMUIR, V33, P8174, DOI 10.1021/acs.langmuir.7b01398; Wadhams GH, 2004, NAT REV MOL CELL BIO, V5, P1024, DOI 10.1038/nrm1524; Yang ZJ, 2018, NATURE, V553, P313, DOI 10.1038/nature25137; Yewdall NA, 2018, INTERFACE FOCUS, V8, DOI 10.1098/rsfs.2018.0023; Yin YD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10658; Zhu TF, 2012, P NATL ACAD SCI USA, V109, P9828, DOI 10.1073/pnas.1203212109; Zhu TF, 2009, J AM CHEM SOC, V131, P5705, DOI 10.1021/ja900919c	33	11	12	22	148	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 9	2021	597	7875					220	+		10.1038/s41586-021-03774-y	http://dx.doi.org/10.1038/s41586-021-03774-y			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ1FZ	34497391				2023-01-03	WOS:000695818300011
J	Koch, M; Graetz, C				Koch, Martin; Graetz, Christian			Spray mist reduction by means of a high-volume evacuation system-Results of an experimental study	PLOS ONE			English	Article							FLOW	Objectives High-speed tooth preparation requires effective cooling to avoid thermal damage, which generates spray mist, which is a mixture of an aerosol, droplets and particles of different sizes. The aim of this experimental study was to analyze the efficacy of spray mist reduction with an intraoral high-volume evacuation system (HVE) during simulated high-speed tooth preparation for suboptimal versus optimal suction positions of 16 mm sized cannulas and different flow rates of the HVE. Material and methods In a manikin head, the upper first premolar was prepared with a dental turbine, and generated particles of 5-50 microns were analyzed fifty millimeters above the mouth opening with the shadow imaging technique (frame: 6.6x5.3x1.1 mm). This setup was chosen to generate a reproducible spray mist in a vertical direction towards an imaginary operator head (worst case scenario). The flow rate (FR) of the HVE was categorized into five levels (<= 120 l/min up to 330 l/min). The number of particles per second (NP; p/s) was counted, and the mass volume flow of particles per second (MVF; mu g/s*cm(3)) was calculated for 10 sec. Statistical tests were nonparametric and two-sided (p <= 0.05). Results With increasing flow rate, the NP/MVF values decreased significantly (eta: 0.671/0.678; p <= 0.001). Using a suboptimally positioned cannula with an FR <= 160 l/min, significantly higher NP values (meanSD) of 731.67 +/- 54.24 p/s (p <= 0.019) and an MVF of 3.72 +/- 0.42 mu g/s*cm(3) (p <= 0.010) were measured compared to those of the optimal cannula position and FR >= 300 l/min (NP/MVF: 0/0). No significant difference in NP and MVF was measurable between FR >= 250 l/min and FR>300 l/min (p = 0.652, p = 0.664). Conclusion Within the limitations of the current experimental study, intraoral high-flow rate suction with >= 300 l/min with an HVE effectively reduced 5-50 mu m sized particles of the spray mist induced by high-speed tooth preparation with a dental turbine.	[Koch, Martin] Tech Acad DURR Dent SE, Bietigheim Bissingen, Germany; [Graetz, Christian] Univ Kiel, Clin Conservat Dent & Periodontol, Kiel, Germany	University of Kiel	Graetz, C (corresponding author), Univ Kiel, Clin Conservat Dent & Periodontol, Kiel, Germany.	graetz@konspar.uni-kiel.de			DURR DENTAL SE	DURR DENTAL SE	DURR DENTAL SE provided financial support in the form of M. Kochs' salaries. DURR DENTAL SE did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allison JR, 2021, J ORAL REHABIL, V48, P61, DOI 10.1111/joor.13098; [Anonymous], 1996, J AM DENT ASSOC, V127, P672; BENTLEY CD, 1994, J AM DENT ASSOC, V125, P579, DOI 10.14219/jada.archive.1994.0093; Benzian H, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00520; Bizzoca ME, 2020, BMC ORAL HEALTH, V20, DOI 10.1186/s12903-020-01301-5; Comisi JC, 2021, J ESTHET RESTOR DENT, V33, P466, DOI 10.1111/jerd.12717; DAVIES MH, 1971, BRIT DENT J, V130, P483, DOI 10.1038/sj.bdj.4802680; Graetz C, 2014, MED-SURG J, V118, P1122; Gross K B, 1992, J Dent Hyg, V66, P314; Harrel SK, 1999, QUINTESSENCE INT, V30, P623; Harrel Stephen K, 2004, J Calif Dent Assoc, V32, P901; Jacks Mary E, 2002, J Dent Hyg, V76, P202; Kaufmann M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244020; Kun-Szabo F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246543; Kwon Su-Jung, 2013, Restor Dent Endod, V38, P105, DOI 10.5395/rde.2013.38.3.105; Leung NHL, 2020, NAT MED, V26, P676, DOI 10.1038/s41591-020-0843-2; Mamoun JS., 2011, DENT ASSIST, V80; Mu''ller L.K., 2020, DTSCH ZAHN RZTL INT, V2, P164; Nagraj SK, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013686.pub2; Polednik B, 2021, BUILD ENVIRON, V187, DOI 10.1016/j.buildenv.2020.107388; Reitemeier B., 2010, ZMK, V26, P662; Samaranayake LP, 2021, ACTA ODONTOL SCAND, V79, P69, DOI 10.1080/00016357.2020.1839673; Shiu EYC, 2019, CURR OPIN INFECT DIS, V32, P372, DOI 10.1097/QCO.0000000000000563; Szymanska J, 2007, ANN AGR ENV MED, V14, P203; Veena HR, 2015, J INFECT PUBLIC HEAL, V8, P260, DOI 10.1016/j.jiph.2014.11.004; von Fraunhofer JA, 2000, OPER DENT, V25, P544; WALMSLEY AD, 1988, ULTRASOUND MED BIOL, V14, P15, DOI 10.1016/0301-5629(88)90159-7	27	4	4	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2021	16	9							e0257137	10.1371/journal.pone.0257137	http://dx.doi.org/10.1371/journal.pone.0257137			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5RG	34478480	Green Published, gold			2023-01-03	WOS:000707051200033
J	Xia, JY; Yang, C; Xu, DF; Xia, H; Yang, LG; Sun, GJ				Xia, Jia-yue; Yang, Chao; Xu, Deng-feng; Xia, Hui; Yang, Li-gang; Sun, Gui-ju			Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: A systematic review and meta-analysis with trial sequential analysis	PLOS ONE			English	Review							DOUBLE-BLIND; JUICE; PREVENTION; BACTERIURIA; EPIDEMIOLOGY; PRODUCTS; CHILDREN; REDUCE	The efficacy of cranberry (Vaccinium spp.) as adjuvant therapy in preventing urinary tract infections (UTIs) remains controversial. This study aims to update and determine cranberry effects as adjuvant therapy on the recurrence rate of UTIs in susceptible groups. According to PRISMA guidelines, we conducted a literature search in Web of Science, PubMed, Embase, Scopus, and the Cochrane Library from their inception dates to June 2021. We included articles with data on the incidence of UTIs in susceptible populations using cranberry-containing products. We then conducted a trial sequential analysis to control the risk of type I and type II errors. This meta-analysis included 23 trials with 3979 participants. We found that cranberry-based products intake can significantly reduce the incidence of UTIs in susceptible populations (risk ratio (RR) = 0.70; 95% confidence interval(CI): 0.59 ~ 0.83; P<0.01). We identified a relative risk reduction of 32%, 45% and 51% in women with recurrent UTIs (RR = 0.68; 95% CI: 0.56 ~ 0.81), children (RR = 0.55; 95% CI: 0.31 ~ 0.97) and patients using indwelling catheters (RR = 0.49; 95% CI: 0.33 ~ 0.73). Meanwhile, a relative risk reduction of 35% in people who use cranberry juice compared with those who use cranberry capsule or tablet was observed in the subgroup analysis (RR = 0.65; 95% CI: 0.54 ~ 0.77). The TSA result for the effects of cranberry intake and the decreased risk of UTIs in susceptible groups indicated that the effects were conclusive. In conclusion, our meta-analysis demonstrates that cranberry supplementation significantly reduced the risk of developing UTIs in susceptible populations. Cranberry can be considered as adjuvant therapy for preventing UTIs in susceptible populations. However, given the limitations of the included studies in this meta-analysis, the conclusion should be interpreted with caution.	[Xia, Jia-yue; Yang, Chao; Xu, Deng-feng; Xia, Hui; Yang, Li-gang; Sun, Gui-ju] Southeast Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Med & Engn, Nanjing, Peoples R China; [Xia, Jia-yue; Yang, Chao; Xu, Deng-feng; Xia, Hui; Yang, Li-gang; Sun, Gui-ju] Southeast Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Nanjing, Peoples R China	Southeast University - China; Southeast University - China	Sun, GJ (corresponding author), Southeast Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Med & Engn, Nanjing, Peoples R China.; Sun, GJ (corresponding author), Southeast Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Nanjing, Peoples R China.	gjsun@seu.edu.cn						Barbosa-Cesnik C, 2011, CLIN INFECT DIS, V52, P23, DOI 10.1093/cid/ciq073; Blumberg JB, 2013, ADV NUTR, V4, P618, DOI 10.3945/an.113.004473; Caljouw MAA, 2014, J AM GERIATR SOC, V62, P103, DOI 10.1111/jgs.12593; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Ermel G, 2012, J MED FOOD, V15, P126, DOI 10.1089/jmf.2010.0312; Ferrara P, 2009, SCAND J UROL NEPHROL, V43, P369, DOI 10.3109/00365590902936698; Flores-Mireles AL, 2015, NAT REV MICROBIOL, V13, P269, DOI 10.1038/nrmicro3432; Foxman B, 2003, INFECT DIS CLIN N AM, V17, P227, DOI 10.1016/S0891-5520(03)00005-9; Foxman B, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.04.003; George BJ, 2016, J NUCL CARDIOL, V23, P690, DOI 10.1007/s12350-015-0249-6; Guay DRP, 2009, DRUGS, V69, P775, DOI 10.2165/00003495-200969070-00002; Hess MJ, 2008, SPINAL CORD, V46, P622, DOI 10.1038/sc.2008.25; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Jepson RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001321.pub5; JOHNSON CC, 1991, MED CLIN N AM, V75, P241, DOI 10.1016/S0025-7125(16)30451-5; Kontiokari T, 2001, BMJ-BRIT MED J, V322, P1571, DOI 10.1136/bmj.322.7302.1571; Kumar MS, 2017, ADV COLLOID INTERFAC, V249, P53, DOI 10.1016/j.cis.2017.06.010; Luis A, 2017, J UROLOGY, V198, P614, DOI 10.1016/j.juro.2017.03.078; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Maki KC, 2016, AM J CLIN NUTR, V103, P1434, DOI 10.3945/ajcn.116.130542; McGuinness SD, 2002, J NEUROSCI NURS, V34, P4; McMurdo MET, 2005, AGE AGEING, V34, P256, DOI 10.1093/ageing/afi101; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Mooren ES, 2020, NEUROUROL URODYNAM, V39, P1543, DOI 10.1002/nau.24391; Pappas E, 2009, CRIT REV FOOD SCI, V49, P741, DOI 10.1080/10408390802145377; Salo J, 2012, CLIN INFECT DIS, V54, P340, DOI 10.1093/cid/cir801; Schlager TA, 1999, J PEDIATR-US, V135, P698, DOI 10.1016/S0022-3476(99)70087-9; Sengupta K, 2011, CURR BIOACT COMPD, V7, P39; Stothers Lynn, 2002, Can J Urol, V9, P1558; Sun J, 2015, J FUNCT FOODS, V17, P235, DOI 10.1016/j.jff.2015.05.016; Takahashi S, 2013, J INFECT CHEMOTHER, V19, P112, DOI 10.1007/s10156-012-0467-7; Temiz Z, 2018, COMPLEMENT THER CLIN, V31, P111, DOI 10.1016/j.ctcp.2018.01.017; Vostalova J, 2015, PHYTOTHER RES, V29, P1559, DOI 10.1002/ptr.5427; Waites KB, 2004, J SPINAL CORD MED, V27, P35, DOI 10.1080/10790268.2004.11753728; Wan KS, 2016, ALTERN THER HEALTH M, V22, P20; Wang CH, 2012, ARCH INTERN MED, V172, P988, DOI 10.1001/archinternmed.2012.3004; Wetterslev J, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0315-7; Wing DA, 2008, J UROLOGY, V180, P1367, DOI 10.1016/j.juro.2008.06.016	38	3	3	3	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2021	16	9							e0256992	10.1371/journal.pone.0256992	http://dx.doi.org/10.1371/journal.pone.0256992			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5QV	34473789	gold, Green Published			2023-01-03	WOS:000707050100084
J	Neal, B; Wu, Y; Feng, X; Zhang, R; Zhang, Y; Shi, J; Zhang, J; Tian, M; Huang, L; Li, Z; Yu, Y; Zhao, Y; Zhou, B; Sun, J; Liu, Y; Yin, X; Hao, Z; Yu, J; Li, KC; Zhang, X; Duan, P; Wang, F; Ma, B; Shi, W; Di Tanna, GL; Stepien, S; Shan, S; Pearson, SA; Li, N; Yan, LL; Labarthe, D; Elliott, P				Neal, B.; Wu, Y.; Feng, X.; Zhang, R.; Zhang, Y.; Shi, J.; Zhang, J.; Tian, M.; Huang, L.; Li, Z.; Yu, Y.; Zhao, Y.; Zhou, B.; Sun, J.; Liu, Y.; Yin, X.; Hao, Z.; Yu, J.; Li, K. -C.; Zhang, X.; Duan, P.; Wang, F.; Ma, B.; Shi, W.; Di Tanna, G. L.; Stepien, S.; Shan, S.; Pearson, S. -A.; Li, N.; Yan, L. L.; Labarthe, D.; Elliott, P.			Effect of Salt Substitution on Cardiovascular Events and Death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-PRESSURE; DISEASE; SODIUM; POTASSIUM; STROKE	BACKGROUND Salt substitutes with reduced sodium levels and increased potassium levels have been shown to lower blood pressure, but their effects on cardiovascular and safety outcomes are uncertain. METHODS We conducted an open-label, cluster-randomized trial involving persons from 600 villages in rural China. The participants had a history of stroke or were 60 years of age or older and had high blood pressure. The villages were randomly assigned in a 1:1 ratio to the intervention group, in which the participants used a salt substitute (75% sodium chloride and 25% potassium chloride by mass), or to the control group, in which the participants continued to use regular salt (100% sodium chloride). The primary outcome was stroke, the secondary outcomes were major adverse cardiovascular events and death from any cause, and the safety outcome was clinical hyperkalemia. RESULTS A total of 20,995 persons were enrolled in the trial. The mean age of the participants was 65.4 years, and 49.5% were female, 72.6% had a history of stroke, and 88.4% a history of hypertension. The mean duration of follow-up was 4.74 years. The rate of stroke was lower with the salt substitute than with regular salt (29.14 events vs. 33.65 events per 1000 person-years; rate ratio, 0.86; 95% confidence interval [CI], 0.77 to 0.96; P=0.006), as were the rates of major cardiovascular events (49.09 events vs. 56.29 events per 1000 person-years; rate ratio, 0.87; 95% CI, 0.80 to 0.94; P<0.001) and death (39.28 events vs. 44.61 events per 1000 person-years; rate ratio, 0.88; 95% CI, 0.82 to 0.95; P<0.001). The rate of serious adverse events attributed to hyperkalemia was not significantly higher with the salt substitute than with regular salt (3.35 events vs. 3.30 events per 1000 person-years; rate ratio, 1.04; 95% CI, 0.80 to 1.37; P=0.76). CONCLUSIONS Among persons who had a history of stroke or were 60 years of age or older and had high blood pressure, the rates of stroke, major cardiovascular events, and death from any cause were lower with the salt substitute than with regular salt.	[Neal, B.; Tian, M.; Huang, L.; Liu, Y.; Yin, X.; Yu, J.; Li, K. -C.; Di Tanna, G. L.; Stepien, S.; Shan, S.] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia; [Pearson, S. -A.] Univ New South Wales, Ctr Big Data Res Hlth, Sydney, NSW, Australia; [Li, N.] George Clin, Sydney, NSW, Australia; [Neal, B.; Li, K. -C.; Elliott, P.] Sch Publ Hlth, London, England; [Elliott, P.] UK Dementia Res Inst, London, England; [Elliott, P.] British Heart Fdn Ctr Res Excellence, London, England; [Elliott, P.] NIHR Imperial Biomed Res Ctr, London, England; [Elliott, P.] Imperial Coll London, Hlth Data Res, London, England; [Elliott, P.] NIHR Hlth Protect Res Unit Chem & Radiat Threats, London, England; [Elliott, P.] Med Res Council Ctr Environm & Hlth, London, England; [Wu, Y.] Peking Univ, Peking Univ Clin Res Ctr, 38 Xueyuan Rd, Beijing, Peoples R China; [Wu, Y.; Tian, M.; Hao, Z.; Zhang, X.; Yan, L. L.] Peking Univ, Hlth Sci Ctr, George Inst Global Hlth, Rm 052A,Unit 1,Tayuan Diplomatic Off Bldg, 14 Lia, Beijing, Peoples R China; [Yu, J.] Peking Univ Third Hosp, Dept Cardiol, Beijing, Peoples R China; [Feng, X.; Li, Z.; Duan, P.] Changzhi Med Coll, Sch Publ Hlth, Changzhi, Peoples R China; [Zhang, R.; Yu, Y.] Xi An Jiao Tong Univ, Sch Publ Hlth, Xian, Peoples R China; [Zhang, Y.; Zhao, Y.; Wang, F.] Ningxia Med Univ, Sch Publ Hlth & Management, Yinchuan, Ningxia, Peoples R China; [Shi, J.; Zhou, B.; Ma, B.] First Hosp China Med Univ, Dept Evidence Based Med, Shenyang, Peoples R China; [Zhang, J.; Sun, J.; Shi, W.] Ctr Dis Control Hebei Prov, Dept Noncommunicable Dis Prevent & Control, Shijiazhuang, Hebei, Peoples R China; [Tian, M.] Harbin Med Univ, Sch Publ Hlth, Harbin, Peoples R China; [Yan, L. L.] Duke Kunshan Univ, Global Hlth Res Ctr, Kunshan, Peoples R China; [Yan, L. L.] Wuhan Univ, Sch Hlth Sci, Wuhan, Peoples R China; [Labarthe, D.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	George Institute for Global Health; University of New South Wales Sydney; University of Sydney; University of New South Wales Sydney; Imperial College London; Peking University; Peking University; Peking University; Changzhi Medical College; Xi'an Jiaotong University; Ningxia Medical University; Harbin Medical University; Duke Kunshan University; Wuhan University; Northwestern University; Feinberg School of Medicine	Wu, Y (corresponding author), Peking Univ, Peking Univ Clin Res Ctr, 38 Xueyuan Rd, Beijing, Peoples R China.; Tian, M (corresponding author), Peking Univ, Hlth Sci Ctr, George Inst Global Hlth, Rm 052A,Unit 1,Tayuan Diplomatic Off Bldg, 14 Lia, Beijing, Peoples R China.	wuyf@bjmu.edu.cn; mtian@georgeinstitute.org.cn		Huang, Liping/0000-0002-0945-8988; Shan, Sana/0000-0001-5416-6055; Zhang, Yuhong/0000-0002-7110-8401; Yu, Jie/0000-0002-7401-7580; Zhao, Yi/0000-0002-0958-0350; Tian, Maoyi/0000-0002-5660-8571; Yin, Xuejun/0000-0001-8446-9591; Neal, Bruce/0000-0002-0490-7465; Di Tanna, Gian Luca/0000-0002-5470-3567	National Health and Medical Research Council of Australia [APP1164206, APP1049417, APP1197709]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by research grants (APP1164206 and APP1049417) and an investigator grant (APP1197709, to Dr. Neal) from the National Health and Medical Research Council of Australia; the salt substitute used in the trial was purchased by the investigators from local manufacturers in each province for years 1, 2, and 5 but was donated by Jiangsu Sinokone Technology for years 3 to 4.	Aburto Nancy J, 2013, BMJ, V346, pf1378, DOI 10.1136/bmj.f1378; Aburto NJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1326; Adrogue HJ, 2007, NEW ENGL J MED, V356, P1966, DOI 10.1056/NEJMra064486; Bhat S, 2020, ADV NUTR, V11, P677, DOI 10.1093/advances/nmz134; Brown IJ, 2009, INT J EPIDEMIOL, V38, P791, DOI 10.1093/ije/dyp139; Cobb LK, 2014, CIRCULATION, V129, P1173, DOI 10.1161/CIR.0000000000000015; Cogswell ME, 2016, NEW ENGL J MED, V375, P580, DOI 10.1056/NEJMsb1607161; DYER AR, 1994, AM J EPIDEMIOL, V139, P940, DOI 10.1093/oxfordjournals.aje.a117100; Filippini T, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015719; Greer RC, 2020, HYPERTENSION, V75, P266, DOI 10.1161/HYPERTENSIONAHA.119.13241; He FJ, 2018, INT J EPIDEMIOL, V47, P1784, DOI 10.1093/ije/dyy114; Huang LP, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m315; Huang LP, 2020, AM HEART J, V221, P136, DOI 10.1016/j.ahj.2019.12.020; Jafarnejad S, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872-020-01347-x; Marklund M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m824; Meng QY, 2014, B WORLD HEALTH ORGAN, V92, P447, DOI 10.2471/BLT.13.131532; Murray CJL, 2020, LANCET, V396, P1223, DOI 10.1016/S0140-6736(20)30752-2; Neal, 2020, J EPIDEMIOL COMMUN H; Neal B, 2017, AM HEART J, V188, P109, DOI 10.1016/j.ahj.2017.02.033; Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca; Yin XJ, 2021, JMIR PUBLIC HLTH SUR, V7, DOI 10.2196/27423	21	124	127	24	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2021	385	12					1067	1077		10.1056/NEJMoa2105675	http://dx.doi.org/10.1056/NEJMoa2105675		AUG 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ4IT	34459569	Green Published, Bronze			2023-01-03	WOS:000691611200001
J	Fuller, JM; Barenfeld, E; Ekman, I				Fuller, Joanne M.; Barenfeld, Emmelie; Ekman, Inger			Why do patients struggle with their medicines?-A phenomenological hermeneutical study of how patients experience medicines in their everyday lives	PLOS ONE			English	Article							MEDICATION ADHERENCE INTERVENTIONS; HEART-FAILURE; CARE; UNDERSTAND; DIAGNOSIS	Why do so many people struggle with their medicines despite decades of research on medicines taking? Research into how people experience medicines in their everyday life remains scarce with the majority of research in this area of focusing on whether or not people take their medicines as prescribed. Hence, this study used a phenomenological hermeneutical qualitative design to gain a deeper understanding of individuals' perspectives on the lived experience of medicine-taking. Findings from this study highlight five main themes where participants experience medicines as: 1) life-saving and indispensable, 2) normal and a daily routine, 3) confusing and concerning, 4) unsuitable without adjustment, and 5) intrusive and unwelcome. These results can be the basis for mutually agreed prescribing through a co-creative approach that aims at enhancing open and honest dialogues between patients and healthcare professionals in partnership about medicines.	[Fuller, Joanne M.; Barenfeld, Emmelie; Ekman, Inger] Univ Gothenburg, Sahlgrenska Acad, Inst Hlth & Care Sci, Gothenburg, Sweden; [Fuller, Joanne M.; Barenfeld, Emmelie; Ekman, Inger] Univ Gothenburg, Sahlgrenska Acad, Gothenburg Ctr Person Centred Care GPCC, Gothenburg, Sweden; [Barenfeld, Emmelie] Sahlgrens Univ Hosp, Dept Occupat Therapy & Physiotherapy, Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; Sahlgrenska University Hospital	Fuller, JM (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Hlth & Care Sci, Gothenburg, Sweden.; Fuller, JM (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Gothenburg Ctr Person Centred Care GPCC, Gothenburg, Sweden.	Joanne.fuller@gu.se		Fuller, Joanne M/0000-0003-3139-3532	Swedish Heart-Lung Foundation [20180183]; Swedish Research Council [2017-01230]; Centre for Person-Centred Care at the University of Gothenburg (GPCC), Sweden; Hjalmar Svensson Foundation, Sweden [HJSV2020090]	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Centre for Person-Centred Care at the University of Gothenburg (GPCC), Sweden; Hjalmar Svensson Foundation, Sweden	This work was supported by the Swedish Heart-Lung Foundation (DNr. 20180183, Principal Investigator (PI) Inger Ekman (IE), https://www.hjart-lungfonden.se/om-oss/in-english/; The Swedish Research Council (DNr. 2017-01230), PI IE, https://www.vr.se/english.html; The Centre for Person-Centred Care at the University of Gothenburg (GPCC), Sweden, PI IE, https://www.gu.se/en/gpcc; and The Hjalmar Svensson Foundation, Sweden (HJSV2020090), Mainapplicant JF. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham J, 2010, SOCIOLOGY, V44, P603, DOI 10.1177/0038038510369368; Ahmed R, 2014, INT J CLIN PHARM-NET, V36, P4, DOI 10.1007/s11096-013-9856-y; Ali L, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-036356; Ali L, 2018, J CLIN NURS, V27, pE1089, DOI 10.1111/jocn.14170; Allemann SS, 2017, J CLIN EPIDEMIOL, V91, P70, DOI 10.1016/j.jclinepi.2017.07.011; Bachelard Gaston, 1994, POETICS SPACE; Baxter R, 2020, GERONTOLOGIST, V60, P859, DOI 10.1093/geront/gnz142; Brannstrom M, 2007, SCAND J CARING SCI, V21, P338, DOI 10.1111/j.1471-6712.2007.00485.x; Britten N, 2003, BMJ-BRIT MED J, V327, P840, DOI 10.1136/bmj.327.7419.840; Britten N, 2017, HEALTH EXPECT, V20, P407, DOI 10.1111/hex.12468; Britten N, 2016, HEALTH-LONDON, V20, P77, DOI 10.1177/1363459315619021; Brown MT, 2011, MAYO CLIN PROC, V86, P304, DOI 10.4065/mcp.2010.0575; Brundisini F, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1174-8; Buus N, 2014, SOC SCI MED, V123, P105, DOI 10.1016/j.socscimed.2014.11.010; Chandler D., 2020, HERMENEUTIC CIRCLE, V3 ed; Conn VS, 2016, RES SOC ADMIN PHARM, V12, P218, DOI 10.1016/j.sapharm.2015.06.001; Critical Appraisal Skills Programme, 2019, CASP CAS CONTR CHECK; Denford S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004172; Dobler CC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4065; Dohnhammar U, 2016, HEALTH EXPECT, V19, P179, DOI 10.1111/hex.12345; Ewuneid HA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250919; Fors A, 2015, INT J CARDIOL, V187, P693, DOI 10.1016/j.ijcard.2015.03.336; Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC; Granger BB, 2013, EUR J CARDIOVASC NUR, V12, P276, DOI 10.1177/1474515112447734; Hains IM, 2009, CANCER-AM CANCER SOC, V115, P5579, DOI 10.1002/cncr.24600; Hansen DL, 2009, QUAL HEALTH RES, V19, P829, DOI 10.1177/1049732309335447; Hawking MKD, 2020, QUAL HEALTH RES, V30, P2316, DOI 10.1177/1049732320951772; Heaton J, 2017, PRIM HEALTH CARE RES, V18, P24, DOI 10.1017/S1463423616000207; Hennink M.M., 2011, QUALITATIVE RES METH; Holman D, 2016, MED HUMANIT, V42, P143, DOI 10.1136/medhum-2015-010688; Jubraj B, 2016, INT J PHARM PRACT, V24, P367, DOI 10.1111/ijpp.12268; Lindseth A, 2004, SCAND J CARING SCI, V18, P145, DOI 10.1111/j.1471-6712.2004.00258.x; Moerman DE, 2002, ANN INTERN MED, V136, P471, DOI 10.7326/0003-4819-136-6-200203190-00011; Mohammed MA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010035; Morin L, 2018, CLIN EPIDEMIOL, V10, P289, DOI 10.2147/CLEP.S153458; Morrissey Eimear C, 2017, Psychol Health, V32, P1195, DOI 10.1080/08870446.2016.1273356; Moser A, 2017, EUR J GEN PRACT, V24, DOI [10.1080/13814788.2017.1375091, 10.1080/13814788.2017.1375092]; Naci H, 2015, ANNU REV PHARMACOL, V55, P169, DOI 10.1146/annurev-pharmtox-010814-124614; NICE Medicines and Prescribing Centre (UK), 2015, MED OPT SAF EFF US M; Nieuwlaat R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub4; Oosterom-Calo R, 2013, HEART FAIL REV, V18, P409, DOI 10.1007/s10741-012-9321-3; Politi MC, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7066; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Rathbone AP, 2017, RES SOC ADMIN PHARM, V13, P403, DOI 10.1016/j.sapharm.2016.06.004; Rathbone AP, 2021, J CLIN PHARM THER, V46, P352, DOI 10.1111/jcpt.13288; Rathbone AP, 2016, SOCIOL RES ONLINE, V21, DOI 10.5153/sro.3888; Reimers M, 2018, DRUG AGING, V35, P243, DOI 10.1007/s40266-017-0509-z; Ricoeur P., 1976, INTERPRETATION THEOR; Rosengren L, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18063308; Sabat E, 2003, ADHERENCE LONG TERM; Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP; Wilhelmsen NC, 2019, EUR J HOSP PHARM, V26, P187, DOI 10.1136/ejhpharm-2018-001725; Wolf A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016491	53	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2021	16	8							e0255478	10.1371/journal.pone.0255478	http://dx.doi.org/10.1371/journal.pone.0255478			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UA6JM	34358258	gold, Green Published			2023-01-03	WOS:000685266400039
J	Guimaraes, PO; Quirk, D; Furtado, RH; Maia, LN; Saraiva, JF; Antunes, MO; Kalil, R; Junior, VM; Soeiro, AM; Tognon, AP; Veiga, VC; Martins, PA; Moia, DDF; Sampaio, BS; Assis, SRL; Soares, RVP; Piano, LPA; Castilho, K; Momesso, RGRAP; Monfardini, F; Guimaraes, HP; de Leon, DP; Dulcine, M; Pinheiro, MRT; Gunay, LM; Deuring, JJ; Rizzo, LV; Koncz, T; Berwanger, O				Guimaraes, Patricia O.; Quirk, Daniel; Furtado, Remo H.; Maia, Lilia N.; Saraiva, Jose F.; Antunes, Murillo O.; Kalil Filho, Roberto; Junior, Vagner M.; Soeiro, Alexandre M.; Tognon, Alexandre P.; Veiga, Viviane C.; Martins, Priscilla A.; Moia, Diogo D. F.; Sampaio, Bruna S.; Assis, Silvia R. L.; Soares, Ronaldo V. P.; Piano, Luciana P. A.; Castilho, Kleber; Momesso, Roberta G. R. A. P.; Monfardini, Frederico; Guimaraes, Helio P.; Ponce de Leon, Dario; Dulcine, Majori; Pinheiro, Marcia R. T.; Gunay, Levent M.; Deuring, J. Jasper; Rizzo, Luiz V.; Koncz, Tamas; Berwanger, Otavio		STOP-COVID Trial Investigators	Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPY	BACKGROUND The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. METHODS We randomly assigned, in a 1:1 ratio, hospitalized adults with Covid-19 pneumonia to receive either tofacitinib at a dose of 10 mg or placebo twice daily for up to 14 days or until hospital discharge. The primary outcome was the occurrence of death or respiratory failure through day 28 as assessed with the use of an eight-level ordinal scale (with scores ranging from 1 to 8 and higher scores indicating a worse condition). All-cause mortality and safety were also assessed. RESULTS A total of 289 patients underwent randomization at 15 sites in Brazil. Overall, 89.3% of the patients received glucocorticoids during hospitalization. The cumulative incidence of death or respiratory failure through day 28 was 18.1% in the tofacitinib group and 29.0% in the placebo group (risk ratio, 0.63; 95% confidence interval [CI], 0.41 to 0.97; P = 0.04). Death from any cause through day 28 occurred in 2.8% of the patients in the tofacitinib group and in 5.5% of those in the placebo group (hazard ratio, 0.49; 95% CI, 0.15 to 1.63). The proportional odds of having a worse score on the eight-level ordinal scale with tofacitinib, as compared with placebo, was 0.60 (95% CI, 0.36 to 1.00) at day 14 and 0.54 (95% CI, 0.27 to 1.06) at day 28. Serious adverse events occurred in 20 patients (14.1%) in the tofacitinib group and in 17 (12.0%) in the placebo group. CONCLUSIONS Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo.	[Guimaraes, Patricia O.; Furtado, Remo H.; Moia, Diogo D. F.; Sampaio, Bruna S.; Assis, Silvia R. L.; Soares, Ronaldo V. P.; Piano, Luciana P. A.; Castilho, Kleber; Momesso, Roberta G. R. A. P.; Monfardini, Frederico; Guimaraes, Helio P.; Rizzo, Luiz V.; Berwanger, Otavio] Hosp Israelita Albert Einstein, Av Albert Einstein 627, BR-05620900 Sao Paulo, Brazil; [Furtado, Remo H.; Kalil Filho, Roberto; Junior, Vagner M.] Univ Sao Paulo, Med Sch, Heart Inst, InCor, Sao Paulo, Brazil; [Soeiro, Alexandre M.] BP Mirante A Beneficencia Portuguesa Sao Paulo, Sao Paulo, Brazil; [Veiga, Viviane C.] BP A Beneficencia Portuguesa Sao Paulo, Sao Paulo, Brazil; [Dulcine, Majori; Pinheiro, Marcia R. T.] Pfizer, Sao Paulo, Brazil; [Maia, Lilia N.] Sao Jose Rio Preto Med Sch, Hosp Base, Ctr Integrado Pesquisa, Sao Jose Do Rio Preto, Brazil; [Saraiva, Jose F.] Pontificia Univ Catolica Campinas, Campinas, Brazil; [Antunes, Murillo O.] Hosp Univ Sao Francisco Assis Prov Deus & Irmanda, Braganca Paulista, SP, Brazil; [Tognon, Alexandre P.] Hosp Sao Vicente Paulo, Passo Fundo, RS, Brazil; [Martins, Priscilla A.] Hosp Estadual Jayme Santos Neves, Vila Velha, Brazil; [Quirk, Daniel] Pfizer, Collegeville, PA USA; [Ponce de Leon, Dario] Pfizer, Lima, Peru; [Gunay, Levent M.] Pfizer, Istanbul, Turkey; [Deuring, J. Jasper] Pfizer, Rotterdam, Netherlands; [Koncz, Tamas] Pfizer, New York, NY USA	Hospital Israelita Albert Einstein; Universidade de Sao Paulo; Pfizer; Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Pontificia Universidade Catolica de Campinas; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer	Berwanger, O (corresponding author), Hosp Israelita Albert Einstein, Av Albert Einstein 627, BR-05620900 Sao Paulo, Brazil.	otavioberwanger@gmail.com	Maia, Lilia Nigro/AAV-6938-2021; Veiga, Viviane/AAQ-9783-2021	Veiga, Viviane/0000-0002-0287-3601	Pfizer	Pfizer(Pfizer)	Supported by Pfizer.	Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Boor PPC, 2017, TRANSL RES, V188, P67, DOI 10.1016/j.trsl.2016.11.006; Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017; Dowty ME, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.537; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Fleischmann R, 2017, LANCET, V390, P457, DOI 10.1016/S0140-6736(17)31618-5; Gadina M, 2018, J LEUKOCYTE BIOL, V104, P499, DOI 10.1002/JLB.5RI0218-084R; Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249; Goletti D, 2021, NEW ENGL J MED, V384, P867, DOI 10.1056/NEJMe2034982; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Kalil AC, 2021, NEW ENGL J MED, V384, P795, DOI 10.1056/NEJMoa2031994; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Lescure FX, 2021, LANCET RESP MED, V9, P522, DOI 10.1016/S2213-2600(21)00099-0; Rodriguez-Garcia JL, 2021, RHEUMATOLOGY, V60, P399, DOI 10.1093/rheumatology/keaa587; Maeshima K, 2012, ARTHRITIS RHEUM-US, V64, P1790, DOI 10.1002/art.34329; Mariette X, 2021, LANCET RESP MED, V9, P295, DOI 10.1016/S2213-2600(20)30556-7; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Petrone L, 2021, J INFECTION, V82, P58, DOI 10.1016/j.jinf.2021.02.023; Pulkstenis E, 2004, STAT MED, V23, P999, DOI 10.1002/sim.1659; Rizk JG, 2020, DRUGS, V80, P1267, DOI 10.1007/s40265-020-01367-z; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Rubin D, 2020, NEW ENGL J MED, V383, P2598, DOI 10.1056/NEJMp2032369; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Sandborn WJ, 2017, NEW ENGL J MED, V376, P1723, DOI 10.1056/NEJMoa1606910; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Titanji BK, 2021, CLIN INFECT DIS, V72, P1247, DOI 10.1093/cid/ciaa879	29	175	176	3	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2021	385	5					406	415		10.1056/NEJMoa2101643	http://dx.doi.org/10.1056/NEJMoa2101643		JUN 2021	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ5FF	34133856	Bronze, Green Published			2023-01-03	WOS:000663460500001
J	Conen, K; Guthrie, DM; Stevens, T; Winemaker, S; Seow, H				Conen, Katrin; Guthrie, Dawn M.; Stevens, Tara; Winemaker, Samantha; Seow, Hsien			Symptom trajectories of non-cancer patients in the last six months of life: Identifying needs in a population-based home care cohort	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; EARLY PALLIATIVE CARE; COGNITIVE IMPAIRMENT; PAIN MANAGEMENT; ADVANCED CANCER; SCALE; END; BREATHLESSNESS; DIAGNOSIS; ILLNESS	Introduction The end-of-life symptom prevalence of non-cancer patients have been described mostly in hospital and institutional settings. This study aims to describe the average symptom trajectories among non-cancer patients who are community-dwelling and used home care services at the end of life. Materials and methods This is a retrospective, population-based cohort study of non-cancer patients who used home care services in the last 6 months of life in Ontario, Canada, between 2007 and 2014. We linked the Resident Assessment Instrument for Home Care (RAI-HC) (standardized home care assessment tool) and the Discharge Abstract Databases (for hospital deaths). Patients were grouped into four non-cancer disease groups: cardiovascular, neurological, respiratory, and renal (not mutually exclusive). Our outcomes were the average prevalence of these outcomes, each week, across the last 6 months of life: uncontrolled moderate-severe pain as per the Pain Scale, presence of shortness of breath, mild-severe cognitive impairment as per the Cognitive Performance Scale, and presence of caregiver distress. We conducted a multivariate logistic regression to identify factors associated with having each outcome respectively, in the last 6 months. Results A total of 20,773 non-cancer patient were included in our study, which were analyzed by disease groups: cardiovascular (n = 12,923); neurological (n = 6,935); respiratory (n = 6,357); and renal (n = 3,062). Roughly 80% of patients were > 75 years and half were female. In the last 6 months of life, moderate to severe pain was frequent in the cardiovascular (57.2%), neurological (42.7%), renal (61.0%) and respiratory (58.3%) patients. Patients with renal disease had significantly higher odds for reporting uncontrolled moderate to severe pain (odds ratio [OR] = 1.21; 95% CI: 1.08 to 1.34) than those who did not. Patients with respiratory disease reported significantly higher odds for shortness of breath (5.37; 95% CI, 5.00 to 5.80) versus those who did not. Patients with neurological disease compared to those without were 9.65 times more likely to experience impaired cognitive performance and had 56% higher odds of caregiver distress (OR = 1.56; 95% CI: 1.43 to 1.71). Discussion In our cohort of non-cancer patients dying in the community, pain, shortness of breath, impaired cognitive function and caregiver distress are important symptoms to manage near the end of life even in non-institutional settings.	[Conen, Katrin] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Conen, Katrin; Winemaker, Samantha; Seow, Hsien] McMaster Univ, Div Palliat Care, Dept Family Med, Hamilton, ON, Canada; [Guthrie, Dawn M.; Stevens, Tara] Wilfrid Laurier Univ, Dept Kinesiol & Phys Educ, Waterloo, ON, Canada; [Guthrie, Dawn M.] Wilfrid Laurier Univ, Dept Hlth Sci, Waterloo, ON, Canada; [Seow, Hsien] McMaster Univ, Dept Oncol, Hamilton, ON, Canada	McMaster University; McMaster University; Wilfrid Laurier University; Wilfrid Laurier University; McMaster University	Conen, K (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.; Conen, K (corresponding author), McMaster Univ, Div Palliat Care, Dept Family Med, Hamilton, ON, Canada.	conenk@mcmaster.ca	Seow, Hsien/AAQ-1438-2021	Seow, Hsien/0000-0001-6701-1714; Conen, Katrin/0000-0002-6438-7414	Canadian Centre for Applied Research in Cancer Control (ARCC); Canadian Cancer Society Research Institute [2015-703549]; Canada Research Chairs program	Canadian Centre for Applied Research in Cancer Control (ARCC); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Canada Research Chairs program(Canada Research Chairs)	This work is funded by the Canadian Centre for Applied Research in Cancer Control (ARCC). ARCC receives core funding from the Canadian Cancer Society Research Institute (grant #2015-703549). The senior author is also supported by the Canada Research Chairs program. Authors otherwise did not receive funding for this work.	Amblas-Novellas J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012340; Bausewein C, 2007, RESP MED, V101, P399, DOI 10.1016/j.rmed.2006.07.003; Bausewein C, 2010, J PALLIAT MED, V13, P1109, DOI 10.1089/jpm.2010.0068; Bostwick D, 2017, J PAIN SYMPTOM MANAG, V53, P1079, DOI 10.1016/j.jpainsymman.2017.02.014; Brumley Richard D, 2003, J Palliat Med, V6, P715, DOI 10.1089/109662103322515220; Cantin B, 2009, J PALLIAT CARE, V25, P92, DOI 10.1177/082585970902500203; Cook RJ, 2013, ARCH PHYS MED REHAB, V94, P1038, DOI 10.1016/j.apmr.2012.12.024; Dalkin SM, 2016, PALLIATIVE MED, V30, P690, DOI 10.1177/0269216315626352; Dirikkan F, 2018, TURK KARDIYOL DERN A, V46, P692, DOI [10.5543/tkda.2018.10.5543/tkda.2018.69057, 10.5543/tkda.2018.69057]; Ellershaw J, 2001, J PAIN SYMPTOM MANAG, V21, P12, DOI 10.1016/S0885-3924(00)00240-2; Fassbender K, 2015, ANN PALLIAT MED, V4, P135, DOI 10.3978/j.issn.2224-5820.2015.06.01; Fries BE, 2001, GERONTOLOGIST, V41, P173, DOI 10.1093/geront/41.2.173; Gomes B, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007760.pub2, 10.1590/1516-3180.20161341T2]; Hawes C, 2007, GERONTOLOGIST, V47, P378, DOI 10.1093/geront/47.3.378; Hirdes JP, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-277; Horton R, 2013, J PALLIAT MED, V16, P67, DOI 10.1089/jpm.2012.0285; Hui D, 2013, CANCER-AM CANCER SOC, V119, P1098, DOI 10.1002/cncr.27854; Jansen WJJ, 2015, J PALLIAT MED, V18, P67, DOI 10.1089/jpm.2013.0645; Kim H, 2015, GERIATR GERONTOL INT, V15, P220, DOI 10.1111/ggi.12330; Kite S, 1999, PALLIATIVE MED, V13, P477, DOI 10.1191/026921699670359259; Koncicki HM, 2017, AM J KIDNEY DIS, V69, P451, DOI 10.1053/j.ajkd.2016.08.039; Lorenz Karl, 2006, Evid Rep Technol Assess (Full Rep), P1; Lorenz KA, 2006, J CLIN ONCOL, V24, P4933, DOI 10.1200/JCO.2006.06.8650; Luddington L, 2001, Int J Palliat Nurs, V7, P221; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Martin L, 2008, AGE AGEING, V37, P51, DOI 10.1093/ageing/afm162; Mavounza C, 2020, AGING MENT HEALTH, V24, P423, DOI 10.1080/13607863.2018.1544208; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Morris JN, 1999, RAI HOME CARE RAI HC; Morris JN, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-128; Murray SA, 2005, BRIT MED J, V330, P611, DOI 10.1136/bmj.330.7492.611; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Murray SA, 2005, BRIT MED J, V330, P671, DOI 10.1136/bmj.330.7492.671-a; Ponikowski Piotr, 2016, Rev Esp Cardiol (Engl Ed), V69, P1167, DOI 10.1016/j.rec.2016.11.005; Quinn KL, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0677; Quinn KL, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2257; Romem A, 2015, PALLIATIVE MED, V29, P464, DOI 10.1177/0269216315570411; Seow H, 2021, PSYCHO-ONCOLOGY, V30, P103, DOI 10.1002/pon.5559; Seow H, 2020, J PALLIAT MED, V23, P1644, DOI 10.1089/jpm.2019.0416; Seow H, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021147; Seow H, 2011, J CLIN ONCOL, V29, P1151, DOI 10.1200/JCO.2010.30.7173; Sevilla-Cazes J, 2018, J GEN INTERN MED, V33, P1700, DOI 10.1007/s11606-018-4542-3; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; Soto-Rubio A, 2017, ARCH GERONTOL GERIAT, V73, P113, DOI 10.1016/j.archger.2017.07.024; Steinhauser KE, 2011, J PAIN SYMPTOM MANAG, V42, P331, DOI 10.1016/j.jpainsymman.2010.11.006; Szeto JYY, 2016, J PARKINSON DIS, V6, P589, DOI 10.3233/JPD-160823; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	49	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2021	16	6							e0252814	10.1371/journal.pone.0252814	http://dx.doi.org/10.1371/journal.pone.0252814			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SX8VJ	34129643	Green Published, gold			2023-01-03	WOS:000665475100012
J	Martens, T; Beck, RW; Bailey, R; Ruedy, KJ; Calhoun, P; Peters, AL; Pop-Busui, R; Philis-Tsimikas, A; Bao, SC; Umpierrez, G; Davis, G; Kruger, D; Bhargava, A; Young, L; McGill, JB; Aleppo, G; Nguyen, QT; Orozco, I; Biggs, W; Lucas, KJ; Polonsky, WH; Buse, JB; Price, D; Bergenstal, RM; Group, MS				Martens, Thomas; Beck, Roy W.; Bailey, Ryan; Ruedy, Katrina J.; Calhoun, Peter; Peters, Anne L.; Pop-Busui, Rodica; Philis-Tsimikas, Athena; Bao, Shichun; Umpierrez, Guillermo; Davis, Georgia; Kruger, Davida; Bhargava, Anuj; Young, Laura; McGill, Janet B.; Aleppo, Grazia; Nguyen, Quang T.; Orozco, Ian; Biggs, William; Lucas, K. Jean; Polonsky, William H.; Buse, John B.; Price, David; Bergenstal, Richard M.; Group, Mobile Study			Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPOGLYCEMIA; INJECTIONS	IMPORTANCE Continuous glucose monitoring (CGM) has been shown to be beneficial for adults with type 2 diabetes using intensive insulin therapy, but its use in type 2 diabetes treated with basal insulin without prandial insulin has not been well studied. OBJECTIVE To determine the effectiveness of CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin in primary care practices. DESIGN, SETTING, AND PARTICIPANTS This randomized clinical trialwas conducted at 15 centers in the US (enrollment from July 30, 2018, to October 30, 2019; follow-up completed July 7, 2020) and included adults with type 2 diabetes receiving their diabetes care from a primary care clinician and treated with 1 or 2 daily injections of long- or intermediate-acting basal insulin without prandial insulin, with or without noninsulin glucose-lowering medications. INTERVENTIONS Random assignment 2:1 to CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59). MAIN OUTCOMES AND MEASURES The primary outcome was hemoglobin A1c (HbA1c) level at 8 months. Key secondary outcomes were CGM-measured time in target glucose range of 70 to 180mg/dL, time with glucose level at greater than 250mg/dL, and mean glucose level at 8 months. RESULTS Among 175 randomized participants (mean [SD] age, 57 [9] years; 88 women [50%]; 92 racial/ethnic minority individuals [53%]; mean [SD] baseline HbA1c level, 9.1% [0.9%]), 165 (94%) completed the trial. Mean HbA1c level decreased from 9.1% at baseline to 8.0% at 8 months in the CGM group and from 9.0% to 8.4% in the BGM group (adjusted difference, -0.4%[95% CI, -0.8% to -0.1%]; P =.02). In the CGM group, compared with the BGM group, the mean percentage of CGM-measured time in the target glucose range of 70 to 180mg/dL was 59% vs 43%(adjusted difference, 15%[95% CI, 8% to 23%]; P <.001), the mean percentage of time at greater than 250mg/dL was 11% vs 27%(adjusted difference, -16%[95% CI, -21% to -11%]; P <.001), and the means of the mean glucose values were 179mg/dL vs 206mg/dL (adjusted difference, -26mg/dL [95% CI, -41 to -12]; P <.001). Severe hypoglycemic events occurred in 1 participant (1%) in the CGM group and in 1 (2%) in the BGM group. CONCLUSIONS AND RELEVANCE Among adults with poorly controlled type 2 diabetes treated with basal insulin without prandial insulin, continuous glucose monitoring, as compared with blood glucose meter monitoring, resulted in significantly lower HbA1c levels at 8 months.	[Martens, Thomas] Pk Nicollet Internal Med, Int Diabet Ctr, Minneapolis, MN USA; [Beck, Roy W.; Bailey, Ryan; Ruedy, Katrina J.; Calhoun, Peter] Jaeb Ctr Hlth Res, Tampa, FL USA; [Peters, Anne L.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA; [Pop-Busui, Rodica] Univ Michigan, Ann Arbor, MI 48109 USA; [Philis-Tsimikas, Athena] Scripps Whittier Diabet Inst, San Diego, CA USA; [Bao, Shichun] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Umpierrez, Guillermo; Davis, Georgia] Emory Univ, Sch Med, Atlanta, GA USA; [Kruger, Davida] Henry Ford Hlth Syst, Detroit, MI USA; [Bhargava, Anuj] Iowa Diabet Res, W Des Moines, IA USA; [Young, Laura; Buse, John B.] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA; [McGill, Janet B.] Washington Univ, Sch Med, St Louis, MO USA; [Aleppo, Grazia] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Nguyen, Quang T.] Las Vegas Endocrinol, Henderson, NV USA; [Orozco, Ian] Carteret Med Grp, Morehead City, NC USA; [Biggs, William] Amarillo Med Specialists, Amarillo, TX USA; [Lucas, K. Jean] Diabet & Endocrinol Consultants Pc, Morehead City, NC USA; [Polonsky, William H.] Behav Diabet Inst, San Diego, CA USA; [Price, David] Dexcom Inc, San Diego, CA USA; [Bergenstal, Richard M.] HealthPartners Inst, Int Diabet Ctr, Minneapolis, MN USA	International Diabetes Center; JAEB Center For Health Research; University of Southern California; University of Michigan System; University of Michigan; Vanderbilt University; Emory University; Henry Ford Health System; Henry Ford Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Washington University (WUSTL); Northwestern University; Feinberg School of Medicine; International Diabetes Center	Beck, RW (corresponding author), Jaeb Ctr Hlth Res Fdn Inc, 15310 Amberly Dr,Ste 350, Tampa, FL 33647 USA.	rbeck@jaeb.org		Martens, Thomas/0000-0002-9858-2138	Dexcom Inc.	Dexcom Inc.	Study funding and study devices were provided by Dexcom Inc.	[Anonymous], 1995, DIABETES, V44, P968; Battelino T, 2019, DIABETES CARE, V42, P1593, DOI 10.2337/dci19-0028; Beck RW, 2017, ANN INTERN MED, V167, P365, DOI 10.7326/M16-2855; Beck RW, 2017, JAMA-J AM MED ASSOC, V317, P371, DOI 10.1001/jama.2016.19975; Beck RW., 2021, DIABETES TECHNOL THE, V23, P1; Bolinder J, 2016, LANCET, V388, P2254, DOI 10.1016/S0140-6736(16)31535-5; Danne T, 2017, DIABETES CARE, V40, P1631, DOI 10.2337/dc17-1600; Falk J, 2017, CAN J DIABETES, V41, P385, DOI 10.1016/j.jcjd.2016.12.007; Hermanns Norbert, 2014, J Diabetes Sci Technol, V8, P516, DOI 10.1177/1932296814524105; Kazemian P, 2019, JAMA INTERN MED, V179, P1376, DOI 10.1001/jamainternmed.2019.2396; Kleinman LC, 2009, HEALTH SERV RES, V44, P288, DOI 10.1111/j.1475-6773.2008.00900.x; Lind M, 2017, JAMA-J AM MED ASSOC, V317, P379, DOI 10.1001/jama.2016.19976; Murata GH, 2003, DIABETES CARE, V26, P1759, DOI 10.2337/diacare.26.6.1759; Peters A, 2021, DIABETES OBES METAB, V23, P631, DOI 10.1111/dom.14238; Rossi MC, 2018, ACTA DIABETOL, V55, P1059, DOI 10.1007/s00592-018-1186-z; Schnell Oliver, 2014, J Diabetes Sci Technol, V8, P609, DOI 10.1177/1932296814528134; Selvin E, 2016, DIABETES CARE, V39, pE33, DOI 10.2337/dc15-2229; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; van Beers CAJ, 2016, LANCET DIABETES ENDO, V4, P893, DOI 10.1016/S2213-8587(16)30193-0; Wong JC, 2014, DIABETES CARE, V37, P2702, DOI 10.2337/dc14-0303	20	58	60	7	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2021	325	22					2262	2272		10.1001/jama.2021.7444	http://dx.doi.org/10.1001/jama.2021.7444		JUN 2021	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SS1CN	34077499	Bronze, Green Published			2023-01-03	WOS:000657799900001
J	Eke, PC; Ossai, EN; Eze, II; Ogbonnaya, LU				Eke, Pearl Chizobam; Ossai, Edmund Ndudi; Eze, Irene Ifeyinwa; Ogbonnaya, Lawrence Ulu			Exploring providers' perceived barriers to utilization of antenatal and delivery services in urban and rural communities of Ebonyi state, Nigeria: A qualitative study	PLOS ONE			English	Article							SKILLED PREGNANCY CARE; MATERNAL HEALTH-CARE; FACILITY DELIVERY; WOMEN; DETERMINANTS; MORTALITY; ACCESS; COUNTY; ZAMBIA; KENYA	Objective To determine providers' perceived barriers to utilization of antenatal and delivery services in urban and rural communities of Ebonyi state, Nigeria. Methods A descriptive exploratory study design was used. Qualitative data was collected through the use of a pre-tested interview guide. Twelve providers participated in the study in urban and rural communities of Ebonyi State, Nigeria. They included nine officers in charge of primary health centers, two Chief Nursing Officers of a tertiary health institution and mission hospital and one Medical Officer-in-charge of a General hospital. QDA Miner Lite v2.0.6 was used in the analysis of the data. Results Most providers in urban and rural communities attributed good utilization of maternal health services to delivery of quality care. Most providers in urban linked poor utilization to poor health seeking behavior of women. In rural, poor utilization was credited to poor attitude of health workers. Few of participants (urban and rural) pointed out the neglect of primary health centers resulting in poor utilization. Most participants (urban and rural) considered ignorance as the main barrier to using health facilities for antenatal and delivery services. Another constraint identified was cost of services. Most participants attested that good provider attitude and public enlightenment will improve utilization of health facilities for antenatal and delivery care. All participants agreed on the need to involve men in matters related to maternal healthcare. Conclusions Participants were aware of values of good provider attitude and this is commendable. This combined with the finding of poor attitude of health workers necessitates that health workers should be trained on quality of care. There is need for public enlightenment on need to utilize health facilities for antenatal and delivery services. Community ownership of primary health centers especially in rural communities will enhance utilization of such facilities for maternal healthcare services and should be encouraged. Involvement of men in matters related to maternal healthcare may have a positive influence in improving maternal health in Nigeria.	[Eke, Pearl Chizobam] Alex Ekwueme Fed Univ Teaching Hosp Abakaliki, Dept Nursing Serv, Abakaliki, Nigeria; [Ossai, Edmund Ndudi; Eze, Irene Ifeyinwa; Ogbonnaya, Lawrence Ulu] Ebonyi State Univ Abakaliki, Coll Hlth Sci, Dept Community Med, Abakaliki, Nigeria; [Ossai, Edmund Ndudi; Eze, Irene Ifeyinwa; Ogbonnaya, Lawrence Ulu] Alex Ekwueme Fed Univ, Teaching Hosp Abakaliki, Dept Community Med, Abakaliki, Nigeria		Ossai, EN (corresponding author), Ebonyi State Univ Abakaliki, Coll Hlth Sci, Dept Community Med, Abakaliki, Nigeria.; Ossai, EN (corresponding author), Alex Ekwueme Fed Univ, Teaching Hosp Abakaliki, Dept Community Med, Abakaliki, Nigeria.	ossai_2@yahoo.co.uk						Abdulhamid Z, 2017, J COMPLEMENTARY ALTE, V2, P1; Abimbola JM, 2016, AFR HEALTH SCI, V16, P962, DOI 10.4314/ahs.v16i4.12; Adam V. Y., 2014, Journal of Medicine and Biomedical Research, V13, P117; Adewemimo AW, 2014, MIDWIFERY, V30, pE7, DOI 10.1016/j.midw.2013.09.005; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; [Anonymous], 2019, TRENDS MATERNAL MORT; Bello OO, 2020, PAN AFR MED J, V36, DOI 10.11604/pamj.2020.36.22.22204; Byford-Richardson L, 2013, J OBSTET GYNAECOL CA, V35, P125, DOI 10.1016/S1701-2163(15)31016-1; Chama-Chiliba CM, 2015, HEALTH POLICY PLANN, V30, P78, DOI 10.1093/heapol/czt099; Choe SA, 2016, HEALTH POLICY PLANN, V31, P277, DOI 10.1093/heapol/czv054; Christiandolus EO, 2012, OPEN ACCESS SCI REPO, V1, P530; Crissman Halley P, 2013, Afr J Reprod Health, V17, P15; Dahab R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124292; Fagbamigbe AF, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0527-y; Ganle JK, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0083-y; Gitonga E, 2016, PAN AFR MED J, V25, DOI 10.11604/pamj.supp.2016.25.2.10273; Hernandez B, 2017, HEALTH POLICY PLANN, V32, P769, DOI 10.1093/heapol/czx010; Idris Suleman Hadejia, 2013, Niger Med J, V54, P27, DOI 10.4103/0300-1652.108890; Kea AZ, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1721-5; Khatri RB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177602; Kuhnt J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017122; Machira K, 2017, STUD ETHNO-MED, V11; Mafuyai MJ., 2020, INT J NURSING MIDWIF, V12, P79, DOI [https%3A//doi.org/10.5897/IJNM2020.0417, DOI 10.5897/IJNM2020.0417]; Mason L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0453-z; Mukaddas H, 2018, J MED SCI CLIN RES, V6, P216; National Population Commission ICF International, 2019, NIGERIA DEMOGRAPHIC; Ochieng CA, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2485-2; Ogunyomi MT., 2016, J COMMUNITY MED PRIM, V28, P40; Okonofua F, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1730-4; Okonofua F, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0305-6; Onasoga AO., 2014, BAYELSA STATE INT J, V6, P10; Ongolly Fernandos K., 2019, Afr. j. prim. health care fam. med. (Online), V11, P1, DOI 10.4102/phcfm.v11i1.1911; Onta S, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.24580; Ossai EN, 2015, NIGERIA IJTDH, V8, P13; Ossai EN., 2020, AJPCB, V3, P41; Ossai EN, 2015, BJMMR, V10, P1; Rurangirwa AA, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1328-2; Sarfraz Mariyam, 2015, J Ayub Med Coll Abbottabad, V27, P843; Sarker BK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146161; Shehu C. E., 2016, Journal of Public Health and Epidemiology, V8, P91, DOI 10.5897/JPHE2016.0817; Sheth E, 2015, WORKING PAPER SERIES; Shiferaw S, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-5; Sialubanje C, 2014, HEALTH EDUC RES, V29, P521, DOI 10.1093/her/cyu011; Sipsma H, 2013, GLOB PUBLIC HEALTH, V8, P1014, DOI 10.1080/17441692.2013.835434; Storeng KT, 2017, CRIT PUBLIC HEALTH, V27, P163, DOI 10.1080/09581596.2016.1259459; Sumankuuro J, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021223; Tey NP, 2013, SCI WORLD J, DOI 10.1155/2013/423403; Titaley CR, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-43; Tukur I, 2016, IRAN J PUBLIC HEALTH, V45, P586; Utuk NM., 2017, J NURSING HLTH SCI, V6, P10; World Health Organization, 2014, CONSENSUS STATEMENT; Yaya S, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0752-3; Yaya S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196896; Yaya S, 2018, INT HEALTH, V10, P310, DOI 10.1093/inthealth/ihx073	54	2	2	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2021	16	5							e0252024	10.1371/journal.pone.0252024	http://dx.doi.org/10.1371/journal.pone.0252024			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6NW	34015000	Green Published, gold			2023-01-03	WOS:000664631600102
J	Song, X; Liu, M; Waitman, LR; Patel, A; Simpson, SQ				Song, Xing; Liu, Mei; Waitman, Lemuel R.; Patel, Anurag; Simpson, Steven Q.			Clinical factors associated with rapid treatment of sepsis	PLOS ONE			English	Article							ORGAN FAILURE; DEFINITIONS	Purpose To understand what clinical presenting features of sepsis patients are historically associated with rapid treatment involving antibiotics and fluids, as appropriate. Design This was a retrospective, observational cohort study using a machine-learning model with an embedded feature selection mechanism (gradient boosting machine). Methods For adult patients (age >= 18 years) who were admitted through Emergency Department (ED) meeting clinical criteria of severe sepsis from 11/2007 to 05/2018 at an urban tertiary academic medical center, we developed gradient boosting models (GBMs) using a total of 760 original and derived variables, including demographic variables, laboratory values, vital signs, infection diagnosis present on admission, and historical comorbidities. We identified the most impactful factors having strong association with rapid treatment, and further applied the Shapley Additive exPlanation (SHAP) values to examine the marginal effects for each factor. Results For the subgroups with or without fluid bolus treatment component, the models achieved high accuracy of area-under-receiver-operating-curve of 0.91 [95% CI, 0.86-0.95] and 0.84 [95% CI, 0.81-0.86], and sensitivity of 0.81[95% CI, 0.72-0.87] and 0.91 [95% CI, 0.81-0.97], respectively. We identified the 20 most impactful factors associated with rapid treatment for each subgroup. In the non-hypotensive subgroup, initial physiological values were the most impactful to the model, while in the fluid bolus subgroup, value minima and maxima tended to be the most impactful. Conclusion These machine learning methods identified factors associated with rapid treatment of severe sepsis patients from a large volume of high-dimensional clinical data. The results provide insight into differences in the rapid provision of treatment among patients with sepsis.	[Song, Xing; Waitman, Lemuel R.] Univ Missouri, Sch Med, Hlth Management & Informat, Columbia, MO 65211 USA; [Liu, Mei] Univ Kansas, Med Ctr, Dept Internal Med, Div Med Informat, Kansas City, KS 66103 USA; [Patel, Anurag] Anurag4Health, Kansas City, KS USA; [Simpson, Steven Q.] Univ Kansas, Med Ctr, Dept Internal Med, Pulm & Crit Care Div, Kansas City, KS 66103 USA	University of Missouri System; University of Missouri Columbia; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Song, X (corresponding author), Univ Missouri, Sch Med, Hlth Management & Informat, Columbia, MO 65211 USA.; Simpson, SQ (corresponding author), Univ Kansas, Med Ctr, Dept Internal Med, Pulm & Crit Care Div, Kansas City, KS 66103 USA.	xsm7f@health.missouri.edu; ssimpson3@kumc.edu	Simpson, Steven/GVT-5914-2022	Song, Xing/0000-0002-3712-2904	Blue KC Outcome Research Grants [0925-0001]; CTSA from NCRR/NIH [UL1TR002366]	Blue KC Outcome Research Grants; CTSA from NCRR/NIH	SQS and AP received Blue KC Outcome Research Grants (No.0925-0001) and the authors played role in study design, decision to publish and preparation of the manuscript. LRW received CTSA grant UL1TR002366 from NCRR/NIH and the author played role in data collection and preparation of the manuscript. XS played role in study design, developed the training and testing setup, extracted the study cohort, cleaned up the data and performed all experiments ML played role in study design and manuscript revision. The funders provided support in the form of salaries for authors XS, ML, LRW, AP, SQS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section as well as above.	BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brandt BN, 2015, AM J MED QUAL, V30, P559, DOI 10.1177/1062860614541291; Chen T., 2016, KDD16 P 22 ACM, P785, DOI DOI 10.1145/2939672.2939785; Cherifa M, 2020, ANESTH ANALG, V130, P1157, DOI 10.1213/ANE.0000000000004539; Churpek MM, 2017, AM J RESP CRIT CARE, V195, P906, DOI 10.1164/rccm.201604-0854OC; Croft CA, 2014, J TRAUMA ACUTE CARE, V76, P311, DOI 10.1097/TA.0000000000000121; Deis AS, 2018, CHEST, V153, P39, DOI 10.1016/j.chest.2017.09.031; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Filbin MR, 2018, CRIT CARE MED, V46, P1592, DOI 10.1097/CCM.0000000000003260; Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451; He K, 2016, BIOINFORMATICS, V32, P50, DOI 10.1093/bioinformatics/btv517; Itzhak N, 2020, LECT NOTES ARTIF INT, P392, DOI 10.1007/978-3-030-59137-3_35; Komorowski M., 2019, ARXIV PREPRINT ARXIV; Lauritsen SM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17431-x; Levy MM, 2015, CRIT CARE MED, V43, P3, DOI [10.1097/CCM.0000000000000723, 10.1007/s00134-014-3496-0]; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Liu Vincent, 2013, Ann Am Thorac Soc, V10, P466, DOI 10.1513/AnnalsATS.201304-099OC; Liu VX, 2016, AM J RESP CRIT CARE, V193, P1264, DOI 10.1164/rccm.201507-1489OC; Lundberg SM, 2017, ADV NEUR IN, V30; Mao QQ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017833; Murphy SN, 2010, J AM MED INFORM ASSN, V17, P124, DOI 10.1136/jamia.2009.000893; Pruinelli L, 2018, CRIT CARE MED, V46, P500, DOI [10.1097/CCM.0000000000002949, 10.1097/ccm.0000000000002949]; Reyna MA, 2020, CRIT CARE MED, V48, P210, DOI 10.1097/CCM.0000000000004145; Rhee C, 2017, JAMA-J AM MED ASSOC, V318, P1241, DOI 10.1001/jama.2017.13836; Saeys Y, 2007, BIOINFORMATICS, V23, P2507, DOI 10.1093/bioinformatics/btm344; Torio C.M., 2006, HCUP STAT BRIEFS; Uffen JW, 2021, CLIN MICROBIOL INFEC, V27, P192, DOI 10.1016/j.cmi.2020.02.022; Waitman Lemuel R, 2011, AMIA Annu Symp Proc, V2011, P1454; Weber I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188210; Whiles BB, 2017, CRIT CARE MED, V45, P623, DOI 10.1097/CCM.0000000000002262; Yang MC, 2020, CRIT CARE MED, V48, pE1091, DOI 10.1097/CCM.0000000000004550	32	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2021	16	5							e0250923	10.1371/journal.pone.0250923	http://dx.doi.org/10.1371/journal.pone.0250923			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6GE	33956846	Green Published, gold			2023-01-03	WOS:000664611400048
J	Russo, G; Solimini, A; Zuccala, P; Zingaropoli, MA; Carraro, A; Pasculli, P; Perri, V; Marocco, R; Kertusha, B; Del Borgo, C; Del Giudice, E; Fondaco, L; Tieghi, T; D'Agostino, C; Oliva, A; Vullo, V; Ciardi, MR; Mastroianni, CM; Lichtner, M				Russo, Gianluca; Solimini, Angelo; Zuccala, Paola; Zingaropoli, Maria Antonella; Carraro, Anna; Pasculli, Patrizia; Perri, Valentina; Marocco, Raffaella; Kertusha, Blerta; Del Borgo, Cosmo; Del Giudice, Emanuela; Fondaco, Laura; Tieghi, Tiziana; D'Agostino, Claudia; Oliva, Alessandra; Vullo, Vincenzo; Ciardi, Maria Rosa; Mastroianni, Claudio Maria; Lichtner, Miriam			Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study	PLOS ONE			English	Article							OFF-LABEL USE; MULTICENTER; MORTALITY	Objective To evaluate the effectiveness of Tocilizumab (with or without corticosteroids) in a real-life context among moderate-to-severe COVID-19 patients hospitalized at the Infectious Diseases ward of two hospitals in Lazio region, Italy, during the first wave of SARS-CoV-2 pandemic. Method We conducted a retrospective cohort study among moderate-to-severe COVID-19 pneumonia to assess the influence of tocilizumab (with or without corticosteroids) on: 1) primary composite outcome: risk for death/invasive mechanical ventilation/ICU-transfer at 14 days from hospital admission; 2) secondary outcome: COVID-related death only. Both outcomes were also assessed at 28 days and restricted to baseline more severe cases. We also evaluated the safety of tocilizumab. Results Overall, 412 patients were recruited, being affected by mild (6.8%), moderate (66.3%) or severe (26.9%) COVID-19 at baseline. The median participant' age was 63 years, 56.5% were men, the sum of comorbidities was 1.34 (+/- 1.44), and the median time from symptom onset to hospital admission was 7 [3-10] days. Patients were subdivided in 4 treatment groups: standard of care (SoC) only (n = 172), SoC plus corticosteroid (n = 65), SoC plus tocilizumab (n = 50), SoC plus tocilizumab and corticosteroid (n = 125). Twenty-six (6.3%) patients underwent intubation, and 37 (9%) COVID-related deaths were recorded. After adjusting for several factors, multivariate analysis showed that tocilizumab (with or without corticosteroids) was associated to improved primary and secondary outcomes at 14 days, and at 28-days only when tocilizumab administered without corticosteroid. Among more severe cases the protective effect of tocilizumab (+/- corticosteroids) was observed at both time-points. No safety concerns were recorded. Conclusion Although contrasting results from randomized clinical trials to date, in our experience tocilizumab was a safe and efficacious therapeutic option for patients with moderate-to-severe COVID-19 pneumonia. Its efficacy was improved by the concomitant administration of corticosteroids in patients affected by severe-COVID-19 pneumonia at baseline.	[Russo, Gianluca; Solimini, Angelo; Zingaropoli, Maria Antonella; Pasculli, Patrizia; Perri, Valentina; D'Agostino, Claudia; Oliva, Alessandra; Vullo, Vincenzo; Ciardi, Maria Rosa; Mastroianni, Claudio Maria; Lichtner, Miriam] Sapienza Univ Rome, Policlin Umberto Hosp 1, Dept Publ Hlth & Infect Dis, Rome, Italy; [Zuccala, Paola; Carraro, Anna; Marocco, Raffaella; Kertusha, Blerta; Del Borgo, Cosmo; Del Giudice, Emanuela; Fondaco, Laura; Tieghi, Tiziana; Lichtner, Miriam] Sapienza Univ Rome, S Maria Goretti Hosp, Infect Dis Unit, Latina, Italy	Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome	Russo, G (corresponding author), Sapienza Univ Rome, Policlin Umberto Hosp 1, Dept Publ Hlth & Infect Dis, Rome, Italy.	gianluca.russo@uniroma1.it	Russo, Gianluca/H-5128-2017; Del Giudice, Emanuela/GNW-6695-2022; Russo, Gianluca/N-4362-2019	Del Giudice, Emanuela/0000-0002-3334-4884; pasculli, patrizia/0000-0002-6678-6865; Solimini, Angelo/0000-0002-5281-7624; Russo, Gianluca/0000-0002-8764-7389				Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Biran N, 2020, LANCET RHEUMATOL, V2, pE603, DOI 10.1016/S2665-9913(20)30277-0; Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021; Cantini F, 2020, DRUGS, V80, P1929, DOI 10.1007/s40265-020-01421-w; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; De Rossi N, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100459; Di Minno A, 2020, SEMIN THROMB HEMOST, V46, P763, DOI 10.1055/s-0040-1715456; Eimer J, 2021, J INTERN MED, V289, P434, DOI 10.1111/joim.13162; Fernandez-Ruiz M, 2021, J MED VIROL, V93, P831, DOI 10.1002/jmv.26308; Fisher MJ, 2021, INT J INFECT DIS, V103, P536, DOI 10.1016/j.ijid.2020.12.021; Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI [10.1056/NEJMoa2100433, 10.1056/NEJMc2108482]; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Gupta S, 2021, JAMA INTERN MED, V181, P41, DOI 10.1001/jamainternmed.2020.6252; Hazbun Munir E, 2020, Crit Care Explor, V2, pe0145, DOI 10.1097/CCE.0000000000000145; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Hill JA, 2021, J MED VIROL, V93, P2270, DOI 10.1002/jmv.26674; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Iba T, 2020, CRIT CARE MED, V48, P1358, DOI 10.1097/CCM.0000000000004458; Ip A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237693; ISS Istituto Superiore di Sanita 2021, TASK FORC COVID 19 D; Klopfenstein T, 2020, INT J INFECT DIS, V99, P491, DOI 10.1016/j.ijid.2020.08.024; Knorr JP, 2020, J MED VIROL, V92, P2813, DOI 10.1002/jmv.26191; Leisman DE, 2020, LANCET RESP MED, V8, P1233, DOI 10.1016/S2213-2600(20)30404-5; Leppkes M, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102925; Martinez-Sanz J, 2021, CLIN MICROBIOL INFEC, V27, P238, DOI 10.1016/j.cmi.2020.09.021; McCreary EK, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n244; Mikulska M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237831; Morena V, 2020, EUR J INTERN MED, V76, P36, DOI 10.1016/j.ejim.2020.05.011; Moreno-Perez O, 2020, J AUTOIMMUN, V114, DOI 10.1016/j.jaut.2020.102523; Morrison AR, 2020, J AUTOIMMUN, V114, DOI 10.1016/j.jaut.2020.102512; Narain S, 2021, CHEST, V159, P933, DOI 10.1016/j.chest.2020.09.275; Nicolai L, 2020, CIRCULATION, V142, P1176, DOI 10.1161/CIRCULATIONAHA.120.048488; Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y; Potere N, 2021, ANN RHEUM DIS, V80, P271, DOI 10.1136/annrheumdis-2020-218243; Prescott HC, 2020, JAMA-J AM MED ASSOC, V324, P1292, DOI 10.1001/jama.2020.16747; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Rossi B, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13100317; Rossotti R, 2020, J INFECTION, V81, pE11, DOI 10.1016/j.jinf.2020.07.008; Rubio-Rivas M, 2020, INT J INFECT DIS, V101, P290, DOI 10.1016/j.ijid.2020.09.1486; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Herrero FS, 2021, J INTERN MED, V289, P259, DOI 10.1111/joim.13145; Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529; Somers EC, 2021, CLIN INFECT DIS, V73, pE445, DOI [10.1093/cid/ciaa954, 10.1101/2020.05.29.20117358]; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Thachil J, 2020, SEMIN THROMB HEMOST, V46, P777, DOI 10.1055/s-0040-1712155; Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568; Tsai A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76187-y; Veiga VC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n84; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zingaropoli MA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.627548	58	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257376	10.1371/journal.pone.0257376	http://dx.doi.org/10.1371/journal.pone.0257376			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9EM	34506608	Green Published, gold			2023-01-03	WOS:000729120700048
J	Feng, ZL; Glinskaya, E; Chen, HT; Gong, S; Qiu, Y; Xu, JM; Yip, WN				Feng, Zhanlian; Glinskaya, Elena; Chen, Hongtu; Gong, Sen; Qiu, Yue; Xu, Jianming; Yip, Winnie			Long-term care system for older adults in China: policy landscape, challenges, and future prospects	LANCET			English	Review							ELDER CARE; ALZHEIMERS-DISEASE; GLOBAL BURDEN; INSURANCE; LESSONS; DEMENTIA; SUPPORT; MARKET; HOMES	In China, the population is rapidly ageing and the capacity of the system that cares for older people is increasingly a concern. In this Review, we provide a profile of the long-term care system and policy landscape in China. The long-term care system is characterised by rapid growth of the residential care sector, slow development of home and community-based services, and increasing involvement of the private sector. The long-term care workforce shortage and weak quality assurance are concerning. Public long-term care financing is minimal and largely limited to supporting welfare recipients and subsidising the construction of residential care beds and operating costs. China is piloting social insurance long-term care financing models and, concurrently, programmes for integrating health care and long-term care services in selected settings across the country; the effectiveness and sustainability of these pilots remain to be seen. Informed by international long-term care experiences, we offer policy recommendations to strengthen the evolving care system for older people in China.	[Feng, Zhanlian] RTI Int, Waltham, MA USA; [Glinskaya, Elena] World Bank, 1818 H St NW, Washington, DC 20433 USA; [Yip, Winnie] Harvard Univ, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Chen, Hongtu] Harvard Univ, Dept Global Hlth & Social Med, Boston, MA 02115 USA; [Chen, Hongtu] Harvard Univ, Dept Psychiat, Boston, MA 02115 USA; [Gong, Sen] Ctr Int Knowledge Dev, Beijing, Peoples R China; [Qiu, Yue] China Dev Res Fdn, Dev Res Ctr State Council, Beijing, Peoples R China; [Xu, Jianming] Fudan Univ, Sch Nursing, Shanghai, Peoples R China	Research Triangle Institute; The World Bank; Harvard University; Harvard University; Harvard University; Fudan University	Yip, WN (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.	wyip@hsph.harvard.edu	Feng, Zhanlian/AAA-8985-2021	Feng, Zhanlian/0000-0002-5231-6870				Bennett L., 2018, NEW MODELS HOME CARE; Chan KY, 2013, LANCET, V381, P2016, DOI 10.1016/S0140-6736(13)60221-4; Chang S, 2020, SOC SCI MED, V244, DOI 10.1016/j.socscimed.2019.112667; China National Health and Family Planning Commission WHO, 2018, INT MED SERV ELD CAR; China National Health and Family Planning Commission WHO, 2018, GEN REP STAT INT ELD; Colombo F., 2011, RES PAPER SERIES; Dang J., 2014, SURVEY 10000 SENIORS; de la Maisonneuve C, 2015, OECD J EC STUDIES, V2014, P61, DOI 10.1787/eco_studies-2014-5jz0v44s66nw; Doty P, 2015, MILBANK Q, V93, P359, DOI 10.1111/1468-0009.12125; Feng P., 2015, GREEN BOOK HLTH REFO; Feng Z., 2012, POPULATION DEV, V18, P16, DOI DOI 10.3969/J.ISSN.1674-1668.2012.06.002; Feng ZL, 2020, INT J HEALTH POLICY, V9, P356, DOI 10.15171/ijhpm.2019.121; Feng ZL, 2014, HLTH ECON POL MANAGE, P409; Feng ZL, 2012, HEALTH AFFAIR, V31, P2764, DOI 10.1377/hlthaff.2012.0535; Feng ZL, 2011, J AM GERIATR SOC, V59, P738, DOI 10.1111/j.1532-5415.2011.03330.x; Feng Zhanlian, 2018, OPTIONS AGED CARE CH, P129; Feng ZX, 2017, 2017 INTERNATIONAL CONFERENCE ON ROBOTS & INTELLIGENT SYSTEM (ICRIS), P266, DOI 10.1109/ICRIS.2017.74; Flaherty JH, 2009, J AM MED DIR ASSOC, V10, P453, DOI 10.1016/j.jamda.2009.06.006; Giles J, 2006, ELDER PARENT HLTH MI; Giles J, 2010, J POPUL AGEING, V3, P183, DOI 10.1007/s12062-011-9036-6; Glinskaya E., 2018, OPTIONS AGED CARE CH; Graham WCK, 2017, MILBANK Q, V95, P358, DOI 10.1111/1468-0009.12264; Guo M, 2009, AGEING SOC, V29, P1085, DOI 10.1017/S0144686X0900871X; Ikegami N, 2019, INT J HEALTH POLICY, V8, P462, DOI 10.15171/ijhpm.2019.35; Kohlbacher Florian, 2015, International Journal of Technology, Policy and Management, V15, P21; Leichsenring Kai, 2004, Int J Integr Care, V4, pe10; Li B., 2018, ADV EC BUSINESS MANA, V60, P139; Li FY, 2018, INT J HEALTH PLAN M, V33, P479, DOI 10.1002/hpm.2488; Li Y, 2018, OPTIONS AGED CARE CH, P155; Ling W, 2019, J AM GERIATR SOC, V67, P858, DOI 10.1111/jgs.15793; Liu C., 2018, OPTIONS AGED CARE CH, P263, DOI DOI 10.1596/978-1-4648-1075-6_CH8; Liu C, 2014, J AM GERIATR SOC, V62, P371, DOI 10.1111/jgs.12647; Liu S, 2017, J CLIN NURS, V26, P1291, DOI 10.1111/jocn.13601; Lu B, 2017, HEALTH SYST REFORM, V3, P182, DOI 10.1080/23288604.2017.1346549; Lu JM, 2018, INT CONF ADV CLOUD B, P281, DOI 10.1109/CBD.2018.00057; Ma C., 2019, CHINA IND EC, V12, P42; Ministry of Civil Affairs, 2019, **NON-TRADITIONAL**; Ministry of Civil Affairs, 2013, MEAS LIC SEN CAR FAC; Ministry of Civil Affairs China, 2018, CHIN CIV AFF STAT YB; Ministry of Civil Affairs of the People's Republic of China, 2019, PRESS BRIEF PROM NAT; Ministry of Human Resources and Social Security, 2016, GUID OP IN LONG TERM; Mor V, 2014, HLTH ECON POL MANAGE, P1, DOI 10.1017/CBO9781107323711; Mosca I, 2017, INT J HEALTH POLICY, V6, P195, DOI 10.15171/ijhpm.2016.109; Nadash P, 2018, GERONTOLOGIST, V58, P588, DOI 10.1093/geront/gnx018; Nadash P, 2017, HEALTH POLICY, V121, P588, DOI 10.1016/j.healthpol.2017.03.006; National Bureau of Statistics of China, 2015, STAT COMM CHIN 2014; National Bureau of Statistics of China, 2016, 2015 NAT EC SOC DEV; National Health Commission of the People's Republic of China, 2016, INT MED SERV ELD CAR; National Healthcare Security Administration, 2020, GUID EXP LONG TERM C; Population Reference Bureau, 2015, CHIN AB ON CHILD POL; Rhee JC, 2015, HEALTH POLICY, V119, P1319, DOI 10.1016/j.healthpol.2015.06.001; Scheil-Adlung X., 2015, LONG TERM CARE PROTE; Shum MHY, 2015, J AM MED DIR ASSOC, V16, P784, DOI 10.1016/j.jamda.2015.04.010; Smith DB, 2010, HEALTH AFFAIR, V29, P29, DOI 10.1377/hlthaff.2009.0507; Song YT, 2014, INT J NURS SCI, V1, P423, DOI 10.1016/j.ijnss.2014.10.003; Spasova S., 2018, CHALLENGES LONG TERM; State Council, 2015, GUID OP ADV INT MED; State Council, 2013, OP ADV DEV HLTH SERV; State Council China, 2020, OP ACC DEV AG CAR SE; State Council China, 2020, OP PROM DEV AG CAR S; The European Institute of Innovation and Technology, 2017, RIS NEED ELD CAR EUR; Wang D., 2018, OPTIONS AGED CARE CH, P101; Wang Q, 2018, WEISHENG JINGJI YANJ, V374, P41; Wang Q, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010006; Wiener JM, 2018, OPTIONS AGED CARE CH, P191; World Bank WHO, 2019, HLTH CHIN DEEP HLTH; World Health Organization, 2015, CHIN COUNTR ASS REP; World Health Organization, 2015, WORLD REP AG HLTH 20; Wu Bei, 2005, J Aging Soc Policy, V17, P37, DOI 10.1300/J031v17n04_03; Xu JF, 2017, B WORLD HEALTH ORGAN, V95, P18, DOI [10.2471/BLT.15.167726, 10.2471/blt.15.167726]; Yang GH, 2013, LANCET, V381, P1987, DOI 10.1016/S0140-6736(13)61097-1; Yang H, 2013, FAM MED COMMUNITY HE, V1, P32, DOI 10.15212/FMCH.2013.0206; Yang J., 2014, POPUL RES, V38, P36; [杨菊华 Yang Juhua], 2018, [中国卫生政策研究, Chinese Journal of Health Policy], V11, P1; Yang W, 2016, HEALTH POLICY PLANN, V31, P1391, DOI 10.1093/heapol/czw081; Yip WN, 2019, LANCET, V394, P1192, DOI 10.1016/S0140-6736(19)32136-1; Yip WCM, 2012, LANCET, V379, P833, DOI 10.1016/S0140-6736(11)61880-1; Zeng Y, 2016, LANCET, V388, P1930, DOI 10.1016/S0140-6736(16)31405-2; Zhan Heying J, 2006, J Aging Soc Policy, V18, P85, DOI 10.1300/J031v18n02_06; Zhan HYJ, 2002, INT J AGING HUM DEV, V54, P267, DOI 10.2190/GYRF-84VC-JKCK-W0MU; Zhang R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024268; Zhang YZ, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16203826; Zheng NT, 2018, OPTIONS AGED CARE CH, P243; Zhou MG, 2019, LANCET, V394, P1145, DOI 10.1016/S0140-6736(19)30427-1; Zhou MG, 2016, LANCET, V387, P251, DOI 10.1016/S0140-6736(15)00551-6; Zhu YM, 2019, INT J HEALTH PLAN M, V34, pE1661, DOI 10.1002/hpm.2879	86	73	74	38	126	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	2020	396	10259					1362	1372						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OF2SS	34338215				2023-01-03	WOS:000581064900032
J	Fried, TR; Paiva, AL; Redding, CA; Iannone, L; O'Leary, JR; Zenoni, M; Risi, MM; Mejnartowicz, S; Rossi, JS				Fried, Terri R.; Paiva, Andrea L.; Redding, Colleen A.; Iannone, Lynne; O'Leary, John R.; Zenoni, Maria; Risi, Megan M.; Mejnartowicz, Slawomir; Rossi, Joseph S.			Effect of the STAMP (Sharing and Talking About My Preferences) Intervention on Completing Multiple Advance Care Planning Activities in Ambulatory Care A Cluster Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							OLDER-ADULTS; HEALTH; DOCUMENTATION; MORTALITY; ILLNESS; INDEX	Background: Interventions with the potential for broad reach in ambulatory settings are necessary to achieve a life course approach to advance care planning. Objective: To examine the effect of a computer-tailored, behavioral health model-based intervention on the engagement of adults in advance care planning recruited from ambulatory care settings. Design: Cluster randomized controlled trial with participant-level analysis. (ClinicalTrials.gov: NCT03137459) Setting: 10 pairs of primary and selected specialty care practices matched on patient sociodemographic information. Participants: English-speaking adults aged 55 years or older; 454 adults at practices randomly assigned to usual care and 455 at practices randomly assigned to intervention. Intervention: Brief telephone or web-based assessment generating a mailed, individually tailored feedback report with a stage-matched brochure at baseline, 2 months, and 4 months. Measurements: The primary outcome was completion of the following 4 advance care planning activities at 6 months: identifying and communicating with a trusted person about views on quality versus quantity of life, assignment of a health care agent, completion of a living will, and ensuring that the documents are in the medical record-assessed by a blinded interviewer. Secondary outcomes were completion of individual advance care planning activities. Results: Participants were 64% women and 76% White. The mean age was 68.3 years (SD, 8.3). The predicted probability of completing all advance care planning activities in usual care sites was 8.2% (95% CI, 4.9% to 11.4%) versus 14.1% (CI, 11.0% to 17.2%) in intervention sites (adjusted risk difference, 5.2 percentage points [CI, 1.6 to 8.8 percentage points]). Prespecified subgroup analysis found no statistically significant interactions between the intervention and age, education, or race. Limitations: The study was done in a single region and excluded non-English speaking participants. No information was collected about nonparticipants. Conclusion: A brief, easily delivered, tailored print intervention increased participation in advance care planning in ambulatory care settings.	[Fried, Terri R.] Yale Sch Med New Haven, West Haven, CT USA; [Fried, Terri R.] VA Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA; [Paiva, Andrea L.; Redding, Colleen A.; Rossi, Joseph S.] Univ Rhode Isl, Coll Hlth Sci, Canc Prevent Res Ctr, Kingston, RI 02881 USA; [Iannone, Lynne; O'Leary, John R.; Zenoni, Maria] VA Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA; [O'Leary, John R.; Zenoni, Maria] Yale Sch Med, New Haven, CT USA; [Risi, Megan M.] Univ Rhode Isl, Coll Hlth Sci, Kingston, RI 02881 USA; [Mejnartowicz, Slawomir] Yale Sch Med, New Haven, CT USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Rhode Island; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; University of Rhode Island; Yale University	Fried, TR (corresponding author), VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA.	terri.fried@yale.edu		Rossi, Joseph/0000-0002-1831-1195; Fried, Terri/0000-0001-8083-8265	National Institute of Nursing Research [R01 NR016007]; National Institute of Aging [P30 AG21342]	National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By grants from the National Institute of Nursing Research (R01 NR016007) and National Institute of Aging (P30 AG21342).	Bazargan M, 2021, AM J HOSP PALLIAT ME, V38, P688, DOI 10.1177/1049909120966585; Block BL, 2020, JAMA INTERN MED, V180, P786, DOI 10.1001/jamainternmed.2019.7535; Bravo G, 2008, SOC SCI MED, V67, P1122, DOI 10.1016/j.socscimed.2008.06.006; Detering K., 2012, BMJ SUPPORT PALLIAT, V2, P182, DOI [10.1136/bmjspcare-2012-000250.45, DOI 10.1136/BMJSPCARE-2012-000250.45]; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Edmonds KP, 2019, J PALLIAT MED, V22, P1546, DOI 10.1089/jpm.2019.0059; Fried TR, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-025340; Fried TR, 2016, J AM GERIATR SOC, V64, P359, DOI 10.1111/jgs.13934; Fried TR, 2012, PATIENT EDUC COUNS, V86, P25, DOI 10.1016/j.pec.2011.04.035; Fried TR, 2010, J AM GERIATR SOC, V58, P2329, DOI 10.1111/j.1532-5415.2010.03184.x; Fried TR, 2010, JAMA-J AM MED ASSOC, V303, P269, DOI 10.1001/jama.2009.1956; Fried TR, 2009, J AM GERIATR SOC, V57, P1547, DOI 10.1111/j.1532-5415.2009.02396.x; Fried TR, 2003, J AM GERIATR SOC, V51, P1398, DOI 10.1046/j.1532-5415.2003.51457.x; Garner KK, 2017, J PAIN SYMPTOM MANAG, V53, P1, DOI 10.1016/j.jpainsymman.2016.10.356; GRAHAM JW, 1984, EVALUATION REV, V8, P247, DOI 10.1177/0193841X8400800206; Green MJ, 2009, HEALTH EXPECT, V12, P60, DOI 10.1111/j.1369-7625.2008.00517.x; Harrison KL, 2016, JAMA INTERN MED, V176, P1872, DOI 10.1001/jamainternmed.2016.6751; Houben CHM, 2014, J AM MED DIR ASSOC, V15, P477, DOI 10.1016/j.jamda.2014.01.008; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; Institute of Medicine, 2015, DYING AM IMPR HON IN; Jimenez G, 2018, J PAIN SYMPTOM MANAG, V56, P436, DOI 10.1016/j.jpainsymman.2018.05.016; Kaldjian LC, 2020, J GEN INTERN MED, V35, P913, DOI 10.1007/s11606-019-05522-5; Koenig HG, 2010, RELIGIONS, V1, P78, DOI 10.3390/rel1010078; Lamas D, 2018, J PALLIAT MED, V21, P522, DOI 10.1089/jpm.2017.0451; Lee SJ, 2006, JAMA-J AM MED ASSOC, V295, P801, DOI 10.1001/jama.295.7.801; MacKenzie MA, 2018, AM J HOSP PALLIAT ME, V35, P897, DOI 10.1177/1049909117745789; McMahan RD, 2021, J AM GERIATR SOC, V69, P234, DOI 10.1111/jgs.16801; Paiva A, 2019, J AM GERIATR SOC, V67, P1917, DOI 10.1111/jgs.16035; PEARLIN LI, 1981, J HEALTH SOC BEHAV, V22, P337, DOI 10.2307/2136676; Prochaska J.O., 2008, HLTH BEHAV HLTH ED T, P97; Rossi J. S., 2013, HDB PSYCHOL, V2, P71; Sudore RL, 2018, JAMA INTERN MED, V178, P1616, DOI 10.1001/jamainternmed.2018.4657; Sudore RL, 2018, J PAIN SYMPTOM MANAG, V55, P245, DOI 10.1016/j.jpainsymman.2017.08.025; Sudore RL, 2017, JAMA INTERN MED, V177, P1102, DOI 10.1001/jamainternmed.2017.1607; Sudore RL, 2017, J PAIN SYMPTOM MANAG, V53, P821, DOI 10.1016/j.jpainsymman.2016.12.331; Sudore RL, 2014, J PAIN SYMPTOM MANAG, V47, P674, DOI 10.1016/j.jpainsymman.2013.05.023; VELICER WF, 1993, ADDICT BEHAV, V18, P269, DOI 10.1016/0306-4603(93)90029-9; Volandes AE, 2016, J GEN INTERN MED, V31, P1035, DOI 10.1007/s11606-016-3730-2; Walker DM, 2020, TELEMED E-HEALTH, V26, P603, DOI 10.1089/tmj.2019.0065; Wiley JA, 2015, HEALTH AFFAIR, V34, P78, DOI 10.1377/hlthaff.2014.0404; Wilson KS, 2014, J AM GERIATR SOC, V62, P2420, DOI 10.1111/jgs.13136; Wright DR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10907; Yadav KN, 2017, HEALTH AFFAIR, V36, P1244, DOI 10.1377/hlthaff.2017.0175	43	5	5	2	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV	2021	174	11					1519	+		10.7326/M21-1007	http://dx.doi.org/10.7326/M21-1007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YI2OV	34461035	Green Accepted			2023-01-03	WOS:000743694300017
J	Davis, DR; Morean, ME; Bold, KW; Camenga, D; Kong, G; Jackson, A; Simon, P; Krishnan-Sarin, S				Davis, Danielle R.; Morean, Meghan E.; Bold, Krysten W.; Camenga, Deepa; Kong, Grace; Jackson, Asti; Simon, Patricia; Krishnan-Sarin, Suchitra			Cooling e-cigarette flavors and the association with e-cigarette use among a sample of high school students	PLOS ONE			English	Article							MENTHOL; NICOTINE; APPEAL; TRPM8	Introduction E-liquid flavor is typically presented by flavor category (e.g. menthol, mint, fruit, dessert). Cooling sensations produced by flavor additives such as menthol enhance appeal of e-cigarettes among youth, but not all e-liquids that produce cooling sensations are labeled as menthol. Sensory experiences produced by flavors may allow for a new way to capture e-cigarette flavor use. This study aims to examine use of flavors that produce cooling sensations among youth and its association with e-cigarette use behaviors. Methods A 2019 survey of high school students (n = 4875) examined use of e-cigarette flavors that produced cooling sensations (cooling flavors) among past 30-day e-cigarette users. E-cigarette use behaviors (flavor use, nicotine use, frequency of use) were examined between those who did and did not use cooling flavors. A binary logistic regression was used to examine associations between vaping frequency, nicotine (vs. non-nicotine) use, and vaping cooling flavors while controlling for demographics, number of flavors vaped in the past month, and vaping age of onset. Results 51.6% (n = 473/916) of the analytic sample endorsed vaping cooling flavors. There were no demographic differences by vaping cooling flavors. Vaping cooling flavors was associated with vaping more frequently (AOR:1.04,95% CI:1.03,1.05) and vaping nicotine (AOR:2.37,95% CI:1.53,3.67). Conclusion Vaping cooling flavors was associated with greater nicotine vaping and frequency of e-cigarette use. Assessing sensory experience, such as cooling, in addition to flavor category may more fully capture e-cigarette flavor use and its impacts on youth e-cigarette use behaviors.	[Davis, Danielle R.; Morean, Meghan E.; Bold, Krysten W.; Camenga, Deepa; Kong, Grace; Jackson, Asti; Simon, Patricia; Krishnan-Sarin, Suchitra] Yale Sch Med, Dept Psychiat, New Haven, CT 06510 USA; [Camenga, Deepa] Yale Sch Med, Dept Emergency Med, New Haven, CT USA	Yale University; Yale University	Davis, DR (corresponding author), Yale Sch Med, Dept Psychiat, New Haven, CT 06510 USA.	danielle.davis@yale.edu		Davis, Danielle/0000-0002-9436-9575	National Institute on Drug Abuse (NIDA) [K12DA000167, T32DA007238, R25DA0352163, 1K01DA051882-01]; Food & Drug Administration's Center for Tobacco Products (CTP) [P50DA036151, U54DA036151]	National Institute on Drug Abuse (NIDA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Food & Drug Administration's Center for Tobacco Products (CTP)	This work was supported by the National Institute on Drug Abuse (NIDA) (K12DA000167 [KB], T32DA007238 [DD], R25DA0352163, 1K01DA051882-01 [AJ]) and the Food & Drug Administration's Center for Tobacco Products (CTP) (P50DA036151, U54DA036151). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Food and Drug Administration.	Bold KW, 2017, DRUG ALCOHOL DEPEN, V181, P146, DOI 10.1016/j.drugalcdep.2017.09.025; DeVito EE, 2020, NICOTINE TOB RES, V22, P771, DOI 10.1093/ntr/ntz057; Erythropel HC, 2021, TOB CONTROL, V30, P453, DOI 10.1136/tobaccocontrol-2019-055500; Goldenson NI, 2019, CURR ADDICT REP, V6, P98, DOI 10.1007/s40429-019-00244-4; Goldenson NI, 2016, DRUG ALCOHOL DEPEN, V168, P176, DOI 10.1016/j.drugalcdep.2016.09.014; Green BG, 2012, CHEM SENSES, V37, P201, DOI 10.1093/chemse/bjr119; Han SL, 2016, NICOTINE TOB RES, V18, P708, DOI 10.1093/ntr/ntv189; Jackson A, 2020, ADDICT BEHAV, V110, DOI 10.1016/j.addbeh.2020.106516; Kreslake JM, 2008, AM J PUBLIC HEALTH, V98, P1685, DOI 10.2105/AJPH.2007.125542; Krishnan-Sarin S, 2019, DRUG ALCOHOL DEPEN, V194, P395, DOI 10.1016/j.drugalcdep.2018.10.022; Krishnan-Sarin S, 2017, DRUG ALCOHOL DEPEN, V180, P193, DOI 10.1016/j.drugalcdep.2017.07.044; Krusemann EJZ, 2019, NICOTINE TOB RES, V21, P1310, DOI 10.1093/ntr/nty101; Liu BY, 2013, PAIN, V154, P2169, DOI 10.1016/j.pain.2013.06.043; Paschke M, 2017, TOXICOL LETT, V271, P50, DOI 10.1016/j.toxlet.2017.02.020; Rosbrook K, 2016, NICOTINE TOB RES, V18, P1588, DOI 10.1093/ntr/ntw019; Wang TW, 2020, MMWR-MORBID MORTAL W, V69, P1310, DOI 10.15585/mmwr.mm6937e1; Wang TW, 2019, MMWR SURVEILL SUMM, V68, P1, DOI 10.15585/mmwr.ss6812a1	17	10	10	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2021	16	9							e0256844	10.1371/journal.pone.0256844	http://dx.doi.org/10.1371/journal.pone.0256844			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG6OB	34469460	gold, Green Published			2023-01-03	WOS:000707112500053
J	Sacks, CA				Sacks, Chana A.			Neutrophilic Eccrine Hidradenitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	2021	385	6					E19	E19		10.1056/NEJMicm2101571	http://dx.doi.org/10.1056/NEJMicm2101571			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ7DN	34347955				2023-01-03	WOS:000684629900002
J	Abebe, H; Beyene, GA; Mulat, BS				Abebe, Haimanot; Beyene, Girma Alemayehu; Mulat, Berhanu Semra			Harmful cultural practices during perinatal period and associated factors among women of childbearing age in Southern Ethiopia: Community based cross-sectional study	PLOS ONE			English	Article							BELIEFS; MOTHERS	Introduction Although the maternal mortality ratio has decreased by 38% in the last decade, 810 women die from preventable causes related to pregnancy and childbirth every day, and two-thirds of maternal deaths occur in Sub-Saharan Africa alone. The lives of women and newborns before, during, and after childbirth can be saved by skilled care. The main factors that prevent women from receiving care during pregnancy and childbirth are harmful cultural practices. The aim of this study was to assess the level of harmful cultural practices during pregnancy, childbirth, and postnatal period, and associated factors among women of childbearing age in Southern Ethiopia. Methods A community-based cross-sectional study design was conducted in the Gurage zone, among representative sample of 422 women of reproductive age who had at least one history of childbirth. A simple random sampling technique was used to recruit participants. Data were collected by six experienced and trained data collectors using a pretested structured questionnaire with face to face interviews. Harmful cultural practices are assessed using 11 questions and those who participate in any one of them are considered as harmful cultural practices. Descriptive statistics were performed and the findings were presented in text and tables. Binary logistic regression was used to assess the association between each independent variable and outcome variable. Results Harmful cultural practices were found to be 71.4% [95%CI, 66.6-76.0]. The mean age of study participants was 27.6 (SD +/- 5.4 years). Women with no formal education [AOR 3.79; 95%CI, 1.97-7.28], being a rural resident [AOR 4.41, 95%CI, 2.63-7.39], having had no antenatal care in the last pregnancy [AOR 2.62, 95%CI, 1.54-4.48], and pregnancy being attended by untrained attendants [AOR 2.67, 95%CI, 1.58-4.51] were significantly associated with harmful cultural practice during the perinatal period. Conclusion In this study we found that low maternal education, rural residence, lack of antenatal care and lack of trained birth attendant were independent risk factors associated with women employing harmful cultural practices during the perinatal period. Thus, strong multi-sectoral collaboration targeted at improving women's educational status and primary health care workers should take up the active role of women's health education on the importance of ANC visits to tackle harmful cultural practices.	[Abebe, Haimanot; Beyene, Girma Alemayehu; Mulat, Berhanu Semra] Wolkite Univ, Coll Hlth Sci & Med, Dept Publ Hlth, Wolkite, Ethiopia		Abebe, H (corresponding author), Wolkite Univ, Coll Hlth Sci & Med, Dept Publ Hlth, Wolkite, Ethiopia.	haimanotabebe78@gmail.com						Adatara P, 2019, INT J WOMENS HEALTH, V11, P353, DOI 10.2147/IJWH.S190402; [Anonymous], 2018, INT J COMMUNITY MED; [Anonymous], 2015, SCI J PUBLIC HEAL, DOI DOI 10.11648/J.SJPH.20150305.32; Asefa F., 2014, SCI J PUBLIC HLTH, V2, P182, DOI [DOI 10.11648/J.SJPH.20140203.17, 10.11648/j.sjph.20140203.17]; Bawadi HA, 2017, INT NURS REV, V64, P187, DOI 10.1111/inr.12322; Chakona G, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112668; Choudhury N, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-791; Ethiopia Central Statistical Agency (CSA) ICF, 2016, ETH DEM HLTH SURV 20; FDRE M.o.W, 2013, NAT STRAT ACT PLAN H NAT STRAT ACT PLAN H; Federal Democratic Republic of Ethiopia Central Statistical Agency, 2013, POPULATION PROJECTIO; Foad HS, 2015, EUROPEAN J POLITICAL, V54, P1; Gebrekirstos K, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-46; Gedamu H., 2018, INT J REPROD MED; Hadush Znabu, 2017, BMC Nutr, V3, P40, DOI 10.1186/s40795-017-0159-x; Hossain K, 2020, AM J BIOMEDICAL SCI, V9; Huang Y-C., 2010, DIVERSITY HLTH CARE, V7, P239; Kassahun G, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4631-3; Legesse M, 2015, J TROP PEDIATRICS, V61, P357, DOI 10.1093/tropej/fmv039; Mesele HA., 2018, ANAT PHYSL, V08, P1, DOI [10.4172/2161-0940.1000298, DOI 10.4172/2161-0940.1000298]; Nana A, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1822-1; Oni O, 2012, NUTR TABOOS PREGNANT; Otoo P, 2015, ADV REPROD SCI, V3, P41, DOI [10.4236/arsci.2015.33005, DOI 10.4236/ARSCI.2015.33005]; Raman S, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0991-z; Saxena V, 2020, J FAM MED PRIM CARE, V9, P156, DOI 10.4103/jfmpc.jfmpc_697_19; Sena Belina Kitila WondwosenMolla., 2018, GYNECOL OBSTET, V8, P3; Sharma S, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0938-4; Sumankuuro J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185537; Turner C, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1305-9; World Health Organization, 2019, MAT MORT FACT SHEET; Zenebe K, 2016, GYNECOLOGY OBSTET, V6; Zepro N.B, 2015, ETHIOPIA SCI J PUBLI, V3, P410, DOI [10.11648/j.sjph.20150303.27, DOI 10.11648/J.SJPH.20150303.27]	31	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2021	16	7							e0254095	10.1371/journal.pone.0254095	http://dx.doi.org/10.1371/journal.pone.0254095			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9LR	34214133	Green Published, gold			2023-01-03	WOS:000671718200056
J	Zeleke, S; Kassaw, A; Eshetie, Y				Zeleke, Shegaw; Kassaw, Amare; Eshetie, Yeshambaw			Non-pharmacological pain management practice and barriers among nurses working in Debre Tabor Comprehensive Specialized Hospital, Ethiopia	PLOS ONE			English	Article							KNOWLEDGE; ATTITUDE; CARE	Background Pain is an unpleasant sensory and emotional experience associated with or resembling that actual or potential tissue damage. Different study findings show that about 55% to 78.6% of inpatients experience moderate-to-severe pain. Nurses are one of the health professional who may hear of pain suffered by the patients and who can manage patient suffering by themselves. Therefore, their correct skill is very important in non- pharmacology and pharmacology pain management methods. Objective To assess non-pharmacological pain management practice and barriers among nurses working in Debre Tabor Comprehensive Specialized Hospital, Ethiopia. Methods Data were collected using structured observational check list with interviewer administered questionnaires that measure nurses' practice on non-pharmacological pain management. Data were entered using Epi Data version 3.1 and analyzed using SPSS (Stastical Package for Social Sciences) version 23. Bivariable and multivariable analysis were conducted to examine the association between independent and outcome variables. Results A total of 169 nurses participated in the study, with a response rate of 100%. Among the study participants 94 (55.6%) were females, and the mean age of nurses were 34.9(SD = 5.7) years. Only 44(26%) of nurses had good practice on non- pharmacology pain management methods. About 130(77.55%), 125(74.0%), and 123(72.8%) of nurses reported that inadequate cooperation of physicians, multiple responsibilities of nurses and insufficient number of nurses per patient ratio as barriers for practice of non -pharmacology pain management respectively. Conclusion Majority of nurses didn't apply non-pharmacological pain management practices for their patients in pain and the overall practice level of nurses was very poor. The major identified obstacle factors for the poor practice of non-pharmacological pain management methods were nurses' fatigue, inadequate cooperation of physicians, heavy workload, multiple responsibilities of nurses, and insufficient number of nurses per patient ratio and unfavorable attitude of nurse on non-pharmacology pain management. Even if nurses experiences different challenges, they shall use non-pharmacological pain management methods complementary to pharmacological treatment of pain as they are low cost and safe. And also boosting nurse's attitude towards the effect of non-pharmacological pain management methods is crucial.	[Zeleke, Shegaw; Eshetie, Yeshambaw] Debre Tabor Univ, Coll Hlth Sci, Dept Adult Hlth Nursing, Debre Tabor, Ethiopia; [Kassaw, Amare] Debre Tabor Univ, Coll Hlth Sci, Dept Pediat, Debre Tabor, Ethiopia; [Kassaw, Amare] Debre Tabor Univ, Coll Hlth Sci, Dept Child Hlth Nursing, Debre Tabor, Ethiopia		Zeleke, S (corresponding author), Debre Tabor Univ, Coll Hlth Sci, Dept Adult Hlth Nursing, Debre Tabor, Ethiopia.	shegawzn@gmail.com	Zeleke, Shegaw/AHA-7554-2022	Zeleke, Shegaw/0000-0002-3555-0147				Ali H.S., 2013, LIFE SCI J, V2; Ali NS, 2015, EGYPTIAN J NURSING, V10; Alzghoul Bashar I, 2015, Glob J Health Sci, V8, P154, DOI 10.5539/gjhs.v8n6p154; Benimana O., 2017, KNOWLEDGE ATTITUDES, DOI [10.4155/fmc-2017-0001, DOI 10.4155/FMC-2017-0001]; Bicek E, 2004, NURSES ATTITUDES KNO; Callister LC, 2003, HOME HLTH CARE MANAG, V15, P207, DOI [DOI 10.1177/1084822302250687, 10.1177/1084822302250687]; Craig KD, 2009, CAN PSYCHOL, V50, P22, DOI 10.1037/a0014772; Dukes IM., 2018, INCREASING PATIENT S; El Geziry A., 2018, PAIN MANAGEMENT SPEC, P1, DOI [10.5772/intechopen.79689, DOI 10.5772/INTECHOPEN.79689]; Fosnocht D., 2005, ANN EMERG MED, V3, P49; Fosnocht DE, 2004, AM J EMERG MED, V22, P286, DOI 10.1016/j.ajem.2004.04.011; Hossain MS., 2010, NURSES KNOWLEDGE ATT; Jira L, 2020, J PAIN RES, V13, P2917, DOI 10.2147/JPR.S265544; Khallil NS, 2018, APPL NURS RES, V44, P33, DOI 10.1016/j.apnr.2018.09.001; Kia Z, 2021, COMPLEMENT THER MED, V58, DOI 10.1016/j.ctim.2021.102705; Kumar S, 2013, CURR OPIN SUPPORT PA, V7, P216, DOI 10.1097/SPC.0b013e3283610255; Kwekkeboom K L, 2001, Crit Care Nurs Clin North Am, V13, P181; Lakha SF, 2016, MED PRIN PRACT, V25, P29, DOI 10.1159/000442526; Linton SJ, 2011, PHYS THER, V91, P700, DOI 10.2522/ptj.20100330; Liyew B, 2020, PAIN RES MANAG, V2020, DOI 10.1155/2020/6036575; Lui LYY, 2008, J CLIN NURS, V17, P2014, DOI 10.1111/j.1365-2702.2007.02183.x; Manwere A., 2015, HLTH SCI J, V9, P1; Moceri JT, 2014, J EMERG NURS, V40, P6, DOI 10.1016/j.jen.2012.04.014; Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939; Rawlinson F., 2014, ECANCERMEDICALSCIENC, P8; Snell K., PALLIATIVE CARE CURR; Snyder JS., 2019, PHARM NURSING PROCES; Woldehaimanot TE, 2014, EUR J THER, V20, P254, DOI 10.5455/GMJ-30-157196	28	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2021	16	6							e0253086	10.1371/journal.pone.0253086	http://dx.doi.org/10.1371/journal.pone.0253086			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SX8VJ	34129616	gold, Green Published			2023-01-03	WOS:000665475100023
J	Ali, B; Khan, A; Alyami, HS; Ullah, M; Wahab, A; Badshah, M; Naz, A				Ali, Beenish; Khan, Amjad; Alyami, Hamad S.; Ullah, Majeed; Wahab, Abdul; Badshah, Munair; Naz, Attiqa			Evaluation of the effect of carrier material on modification of release characteristics of poor water soluble drug from liquisolid compacts	PLOS ONE			English	Article							DISSOLUTION RATE ENHANCEMENT; IN-VITRO; SOLID DISPERSION; CLOPIDOGREL; PHARMACOKINETICS; PHARMACODYNAMICS; BIOEQUIVALENCE; FORMULATIONS; SOLUBILITY; PRASUGREL	Liquisolid compact is a novel dosage form in which a liquid medication (liquid drug, drug solution/dispersion in non-volatile solvent/solvent system) is converted to a dry, free flowing powder and compressed. Objective of the study was to elucidate the effect of carrier material on release characteristics of clopidogrel from liquisolid compacts. Different formulations of liquisolid compacts were developed using microcrystalline cellulose, starch maize, polyvinyl pyrollidone and hydroxypropyl methylcellulose as carrier material in three concentrations (40, 30 and 20%, w/w). Liquid vehicle was selected on the basis of solubility of clopidogrel. Colloidal silicondioxide was used as coating material and ratio of carrier to coating material was kept 10. A control formulation comprised of microcrystalline cellulose (diluents), tabletose-80 (diluents), primojel (disintegrant) and magnesium stearate (lubricant) was prepared by direct compression technique and was used for comparison. All the formulations were evaluated at pre and post compression level. Acid solubility profile showed higher solubility in HCl buffer pH2 (296.89 +/- 3.49 mu g/mL). Mixture of propylene glycol and water (2:1, v/v) was selected as liquid vehicle. Drug content was in the range of 99-101% of the claimed quantity. All the formulations showed better mechanical strength and their friability was within the official limits (<1%). Microcrystalline cellulose and starch maize resulted in faster drug release while polyvinyl pyrollidone and HPMC resulted in sustaining drug release by gel formation. It is concluded from results that both fast release and sustained release of clopidogrel can be achieved by proper selection of carrier material.	[Ali, Beenish; Naz, Attiqa] Abasyn Univ, Dept Pharm, Peshawar, Pakistan; [Khan, Amjad; Ullah, Majeed; Wahab, Abdul] Kohat Univ Sci & Technol, Dept Pharm, Kohat, Pakistan; [Alyami, Hamad S.] Najran Univ, Dept Pharmaceut, Najran, Saudi Arabia; [Badshah, Munair] Islam Coll Pharm, Sialkot, Pakistan	Kohat University of Science & Technology; Najran University	Khan, A (corresponding author), Kohat Univ Sci & Technol, Dept Pharm, Kohat, Pakistan.	dr.amjad@kust.edu.pk	Naz, Attiqa/AAW-9422-2021; Ullah, Majeed/GRS-5563-2022	Naz, Attiqa/0000-0002-6125-5643; Khan, Dr. Amjad/0000-0002-4121-2400	Ferozsons Laboratories Ltd.	Ferozsons Laboratories Ltd.	Funder Name: Ferozsons Laboratories Ltd.; Grant Number: None; Grant Recipient: None This study received material support from the following sources: Ferozsons Laboratories Ltd. Nowshera, Pakistan provided API and facilities to carry out this study. The model drug clopidogrel (Mithri Laboratories Ltd. India; purity 99.81% with reference to USP standard) was obtained from Ferozsons Laboratories Ltd. Nowshera, Pakistan. Excipients used in the study, included tablettose-80 (Molkerei Meggle, Germany), microcrystalline cellulose (F.M.C International, Ireland), primojel {sodium starch glycolate} (F.M.C International, Ire Land), Colloidal silicon dioxide {Aerosil-200} (F.M.C International, Ireland), hydroxylpropyl methylcellulose (Merck KGA, Germany), polyvinyl pyrollidone (I.S.P. Technology, Texas), starch maize (I.C.I, Pakistan) and magnesium stearate (Coin Powder International Company Ltd, Taiwan) were purchased from local market of Peshawar, Pakistan. All the excipients were of pharmaceutical grade and were used as received.	Akinlade Babatunde, 2010, Sci Pharm, V78, P325, DOI 10.3797/scipharm.0912-23; Aparna TN., 2017, WORLD J PHARM PHARM, P1219, DOI [10.20959/wjpps20177-9529, DOI 10.20959/WJPPS20177-9529]; Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1; Di Girolamo G, 2010, CLIN THER, V32, P161, DOI 10.1016/j.clinthera.2010.01.010; Fahmy RH, 2008, EUR J PHARM BIOPHARM, V69, P993, DOI 10.1016/j.ejpb.2008.02.017; Farid NA, 2007, CLIN PHARMACOL THER, V81, P735, DOI 10.1038/sj.clpt.6100139; Gavhane YN, 2012, SAUDI PHARM J, V20, P331, DOI 10.1016/j.jsps.2012.03.005; Gonjari ID, 2009, DIG J NANOMATER BIOS, V4, P651; Hart M.L., 2013, J DEV DRUGS, V2, P1, DOI [10.4172/2329-6631.1000115, DOI 10.4172/2329-6631.1000115]; Hentzschel CM, 2012, EUR J PHARM BIOPHARM, V80, P130, DOI 10.1016/j.ejpb.2011.08.001; Javadzadeh Y., 2005, Farmaco (Lausanne), V60, P361, DOI 10.1016/j.farmac.2004.09.005; Javadzadeh Y, 2007, INT J PHARM, V341, P26, DOI 10.1016/j.ijpharm.2007.03.034; Javadzadeh Y, 2008, INT J PHARMACEUT, V362, P102, DOI 10.1016/j.ijpharm.2008.06.022; Karazniewicz-Lada M, 2014, CLIN PHARMACOKINET, V53, P155, DOI 10.1007/s40262-013-0105-2; Khan A, 2015, SAUDI PHARM J, V23, P650, DOI 10.1016/j.jsps.2015.01.025; Kim YI, 2011, INT J PHARMACEUT, V415, P129, DOI 10.1016/j.ijpharm.2011.05.059; Lima AAN, 2008, LAT AM J PHARM, V27, P789; Loh ZH, 2015, ASIAN J PHARM SCI, V10, P255, DOI 10.1016/j.ajps.2014.12.006; Lu M, 2017, ASIAN J PHARM SCI, V12, P115, DOI 10.1016/j.ajps.2016.09.007; Mamani PL, 2012, AAPS PHARMSCITECH, V13, P1073, DOI 10.1208/s12249-012-9829-9; Mega JL, 2016, J THROMB THROMBOLYS, V41, P374, DOI 10.1007/s11239-015-1264-9; Nokhodchi A, 2007, J PHARM PHARMACOL, V59, pA19; Patole T, 2014, INT J PHARM SCI RES, V5, P3566, DOI 10.13040/IJPSR.0975-8232.5(9).3566-76; Rashmi VT., 2011, PHARMACIA LETTRE, V3, P8; Raymond C. Rowe, 2009, HDB PHARM EXCIPIENTS; Sangkuhl K, 2011, PHARMACOGENET GENOM, V21, P516, DOI 10.1097/FPC.0b013e3283406323; Sangkuhl K, 2010, PHARMACOGENET GENOM, V20, P463, DOI 10.1097/FPC.0b013e3283385420; Singh SK, 2012, DRUG DEV IND PHARM, V38, P961, DOI 10.3109/03639045.2011.634810; Skillman KL, 2010, AM J HEALTH-SYST PH, V67, P559, DOI 10.2146/ajhp090163; Spireas S, 1998, J PHARM SCI, V87, P867, DOI 10.1021/js970346g; Spireas S, 1998, INT J PHARM, V166, P177, DOI 10.1016/S0378-5173(98)00046-5; Tayel SA, 2008, EUR J PHARM BIOPHARM, V69, P342, DOI 10.1016/j.ejpb.2007.09.003; The United States Pharmacopeia, 2015, USP38NF33 USP38NF33; Tiong N, 2009, EUR J PHARM BIOPHARM, V73, P373, DOI 10.1016/j.ejpb.2009.08.002; Ullah F, 2020, LAT AM J PHARM, V39, P73; Yadav V. B., 2009, J PHARM SCI RES, V1, P44	36	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0249075	10.1371/journal.pone.0249075	http://dx.doi.org/10.1371/journal.pone.0249075			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TT3IC	34339440	gold, Green Published			2023-01-03	WOS:000680243400048
J	Morisson, L; Laferriere-Langlois, P; Carrier, FM; Page, G; Godbout, C; Fortier, LP; Ogez, D; Letourneau, G; Jarry, S; Denault, A; Fortier, A; Guertin, MC; Verdonck, O; Richebe, P				Morisson, Louis; Laferriere-Langlois, Pascal; Carrier, Francois Martin; Page, Gabrielle; Godbout, Cedric; Fortier, Louis-Philippe; Ogez, David; Letourneau, Genevieve; Jarry, Stephanie; Denault, Andre; Fortier, Annik; Guertin, Marie-Claude; Verdonck, Olivier; Richebe, Philippe			Effect of electroencephalography-guided anesthesia on neurocognitive disorders in elderly patients undergoing major non-cardiac surgery: A trial protocol The POEGEA trial (POncd Elderly GEneral Anesthesia)	PLOS ONE			English	Article							POSTOPERATIVE DELIRIUM; VERBAL FLUENCY; NORMATIVE DATA; NOL INDEX; VALIDATION; FRAILTY; REMIFENTANIL; SUPPRESSION; NOCICEPTION; DECREASES	Introduction The number of elderly patients undergoing major surgery is rapidly increasing. They are particularly at risk of developing postoperative neurocognitive disorders (NCD). Earlier studies suggested that processed electroencephalographic (EEG) monitors may reduce the incidence of postoperative NCD. However, none of these studies controlled for intraoperative nociception levels or personalized blood pressure targets. Their results remain unclear if the reduction in the incidence of postoperative NCD relates to avoidance of any electroencephalographic pattern suggesting excessive anesthesia depth. Objective The objective of this trial is to investigate-in patients >= 70 years old undergoing major non-cardiac surgery-the effect of EEG-guided anesthesia on postoperative NCD while controlling for intraoperative nociception, personalized blood pressure targets, and using detailed information provided by the EEG monitor (including burst suppression ratio, density spectral array, and raw EEG waveform). Material and methods This prospective, randomized, controlled trial will be conducted in a single Canadian university hospital. Patients >= 70 years old undergoing elective major non-cardiac surgery will be included in the trial. The administration of sevoflurane will be adjusted to maintain a BIS index value between 40 and 60, to keep a Suppression Ratio (SR) at 0%, to keep a direct EEG display without any suppression time and a spectrogram with most of the EEG wave frequency within the alpha, theta, and delta frequencies in the EEG-guided group. In the control group, sevoflurane will be administered to achieve an age-adjusted minimum alveolar concentration of [0.8-1.2]. In both groups, a nociception monitor will guide intraoperative opioid administration, individual blood pressure targets will be used, and cerebral oximetry used to tailor intraoperative hemodynamic management. The primary endpoint will be the incidence of NCD at postoperative day 1, as evaluated by the Montreal Cognitive Assessment (MoCA). Secondary endpoints will include the incidence of postoperative NCD at different time points and the evaluation of cognitive trajectories up to 90 days after surgery among EEG-guided and control groups.	[Morisson, Louis; Laferriere-Langlois, Pascal; Godbout, Cedric; Fortier, Louis-Philippe; Ogez, David; Verdonck, Olivier; Richebe, Philippe] Univ Montreal, Maisonneuve Rosemt Hosp, CIUSSS Est Ile Montreal, Dept Anesthesiol & Pain Med, Montreal, PQ, Canada; [Laferriere-Langlois, Pascal; Carrier, Francois Martin; Page, Gabrielle; Godbout, Cedric; Fortier, Louis-Philippe; Ogez, David; Denault, Andre; Verdonck, Olivier; Richebe, Philippe] Univ Montreal, Dept Anesthesiol & Pain Med, Montreal, PQ, Canada; [Carrier, Francois Martin] Univ Montreal, Ctr Hosp Univ Montreal CHUM, Dept Anesthesiol, Montreal, PQ, Canada; [Carrier, Francois Martin] Univ Montreal, Ctr Hosp Univ Montreal CHUM, Dept Med, Crit Care Div, Montreal, PQ, Canada; [Carrier, Francois Martin; Page, Gabrielle] Univ Montreal, CHUM Ctr Hosp Univ Montreal, Res Ctr, Montreal, PQ, Canada; [Page, Gabrielle] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Godbout, Cedric; Fortier, Louis-Philippe; Ogez, David; Letourneau, Genevieve; Verdonck, Olivier; Richebe, Philippe] Univ Montreal, CIUSSS Est Ile Montreal, Res Ctr, Montreal, PQ, Canada; [Jarry, Stephanie; Denault, Andre] Montreal Heart Inst, Dept Anesthesiol, Montreal, PQ, Canada; [Fortier, Annik; Guertin, Marie-Claude] Montreal Hlth Innovat Coordinating Ctr MHICC, Dept Stat, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Richebe, P (corresponding author), Univ Montreal, Maisonneuve Rosemt Hosp, CIUSSS Est Ile Montreal, Dept Anesthesiol & Pain Med, Montreal, PQ, Canada.; Richebe, P (corresponding author), Univ Montreal, Dept Anesthesiol & Pain Med, Montreal, PQ, Canada.; Richebe, P (corresponding author), Univ Montreal, CIUSSS Est Ile Montreal, Res Ctr, Montreal, PQ, Canada.	philippe.richebe@umontreal.ca	Carrier, François Martin/AAE-4623-2021; Page, Gabrielle/AGV-0325-2022; Pagé, M. Gabrielle/ABB-9660-2020	Carrier, François Martin/0000-0003-0310-0616; Page, Gabrielle/0000-0002-7742-2717; Pagé, M. Gabrielle/0000-0002-7742-2717	Department of Anesthesiology and Pain Medicine of the Maisonneuve-Rosemont Hospital/CEMTL, University of Montreal	Department of Anesthesiology and Pain Medicine of the Maisonneuve-Rosemont Hospital/CEMTL, University of Montreal	This study will be supported by the Department of Anesthesiology and Pain Medicine of the Maisonneuve-Rosemont Hospital/CEMTL, University of Montreal and Dr Richebe's research funds. An application for external funding was sent and is pending. Dr Gabrielle Page ' and Dr Francois Martin Carrier are a Junior 1 research scholars from the "Fonds de Recherche du Quebec en Sante''.	Abraham P, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1315-8; Amer Soc Anesthesiologists, 2015, ANESTHESIOLOGY, V122, P241, DOI 10.1097/ALN.0000000000000463; Amzica F, 2009, EPILEPSIA, V50, P38, DOI 10.1111/j.1528-1167.2009.02345.x; [Anonymous], 2011, IND SANT 2011 IND SANT 2011; Aube DS., 2016, K VIEILLISSEMENT QUE; Austin CA, 2019, JAMA SURG, V154, P328, DOI 10.1001/jamasurg.2018.5093; Ballard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037410; Bunker L, 2017, INT J GERIATR PSYCH, V32, P991, DOI 10.1002/gps.4558; Chan MTV, 2020, ANESTH ANALG, V130, P1278, DOI 10.1213/ANE.0000000000004502; Chan MTV, 2013, J NEUROSURG ANESTH, V25, P33, DOI 10.1097/ANA.0b013e3182712fba; Evered L, 2018, ANESTHESIOLOGY, V129, P872, DOI 10.1097/ALN.0000000000002334; Evered L, 2018, BRIT J ANAESTH, V121, P1005, DOI 10.1016/j.bja.2017.11.087; Fritz BA, 2016, ANESTH ANALG, V122, P234, DOI 10.1213/ANE.0000000000000989; Hou RX, 2018, BRAIN BEHAV, V8, DOI 10.1002/brb3.910; Inouye SK, 2014, ANN INTERN MED, V160, P526, DOI 10.7326/M13-1927; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Manea L, 2015, GEN HOSP PSYCHIAT, V37, P67, DOI 10.1016/j.genhosppsych.2014.09.009; Marceaux JC, 2019, INT J GERIATR PSYCH, V34, P578, DOI 10.1002/gps.5054; McIsaac DI, 2020, ANESTH ANALG, V130, P1450, DOI 10.1213/ANE.0000000000004602; Nagin DS, 2010, J QUANT CRIMINOL, V26, P445, DOI 10.1007/s10940-010-9113-7; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Punjasawadwong Y, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003843.pub3; Purdon PL, 2015, BRIT J ANAESTH, V115, P46, DOI 10.1093/bja/aev213; Radtke FM, 2013, BRIT J ANAESTH, V110, P98, DOI 10.1093/bja/aet055; Renaud-Roy E, 2019, CAN J ANESTH, V66, P1049, DOI 10.1007/s12630-019-01372-1; Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051; Rockwood K, 2020, CAN GERIATR J, V23, P254, DOI 10.5770/cgj.23.463; Sessler DI, 2012, ANESTHESIOLOGY, V116, P1195, DOI 10.1097/ALN.0b013e31825683dc; St-Hilaire A, 2016, CLIN NEUROPSYCHOL, V30, P1126, DOI 10.1080/13854046.2016.1195014; Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; Stockle PA, 2018, MINERVA ANESTESIOL, V84, P1160, DOI 10.23736/S0375-9393.18.12720-9; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Vacas S, 2013, BRIT MED BULL, V106, P161, DOI 10.1093/bmb/ldt006; Wan YJ, 2010, CRIT CARE MED, V38, P2190, DOI 10.1097/CCM.0b013e3181f17bcb; Wildes TS, 2019, JAMA-J AM MED ASSOC, V321, P473, DOI 10.1001/jama.2018.22005; Willingham M, 2014, BRIT J ANAESTH, V113, P1001, DOI 10.1093/bja/aeu105	39	0	0	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255852	10.1371/journal.pone.0255852	http://dx.doi.org/10.1371/journal.pone.0255852			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY1UP	34375362	gold, Green Published			2023-01-03	WOS:000683572000017
J	Valois-Santos, NT; de Almeida, RBF; Jacques, IDAA; Santos, DD; Silva, KSDE; Nappo, SA; de Brito, AM				Valois-Santos, Naide Teodosio; Fernandes de Almeida, Renata Barreto; Almeida Alves Jacques, Iracema de Jesus; Santos, Daianny de Paula; de Brito E Silva, Keila Silene; Nappo, Solange Aparecida; de Brito, Ana Maria			Association between alcohol and crack: Prevalence, effects, associated factors and experiences of combined use	PLOS ONE			English	Article							DRUG-USE; COCAINE; CONSUMPTION	Objective To estimate the prevalence and factors associated with the effect of alcohol on crack cocaine use and to analyze experiences related to combined use. Materials and methods: sequential mixed methods (qualitative and quantitative) research, carried out between August 2014 and August 2015 with people who use crack. In the quantitative approach, a cross-sectional study was conducted with 1,062 participants. Factors associated with "alcohol use with the effect of increasing the effect of crack/crack craving" were estimated by multiple regression. In the qualitative approach, 39 interviews were conducted using Bardin's content analysis technique. Results 871 (82.0%) participants reported consuming alcohol, among them, 668 (76.7%) used alcohol combined with crack: 219 (32.8%) reported feeling an effect of reduction in paranoia and/or crack craving and 384 (57.5%) reported feeling an increase in the effect of crack and in the craving to consume the drug. This relationship was also observed in the narratives of the people who use crack, with the possibility of a cyclic effect of consumption of the two substances. Those who related alcohol use to the effect of increasing crack craving (384) were more likely to use alcohol before crack (OR: 1.81; 95%CI: 1.13-2.89); to consume more than 20 stones daily (OR: 1.48; 95%CI: 1.01-2.16); to remain in abstinence from crack for less than one month (OR: 3.20; 95%CI: 1.91-5.35); to use dependence treatment services (OR: 1.85; 95%CI: 1.26-2.71); and to commit physical violence (OR:1.67; 95%CI:1.08-2.56). Conclusion The findings of this study indicate that the modulation of the effect of alcohol use on crack cocaine depends on the moment when the drugs are consumed, and the use of alcohol before crack consumption is associated with characteristics that suggest a greater vulnerability to patterns of harmful crack use. Even though combined use is referred to as a way of reducing the negative effects of crack, the damage of this association may be greater than its possible benefits.	[Valois-Santos, Naide Teodosio; de Brito, Ana Maria] Fundacao Oswaldo Cruz, Dept Saude Colet, Inst Aggeu Magalhaes, Recife, PE, Brazil; [Fernandes de Almeida, Renata Barreto] Ctr Univ UniFBV, Curso Psicol, Recife, PE, Brazil; [Almeida Alves Jacques, Iracema de Jesus; Santos, Daianny de Paula] Fundacao Oswaldo Cruz, Inst Aggeu Magalhaes, Programa Posgrad Saude Publ, Recife, PE, Brazil; [de Brito E Silva, Keila Silene] Univ Fed Pernambuco, Ctr Acad Vitoria, Nucleo Saude Colet, Vitoria, PE, Brazil; [Nappo, Solange Aparecida] Univ Fed Sao Paulo, Ctr Brasileiro Informacoes Drogas Psicotrop CEBRI, Dept Med Prevent, Sao Paulo, SP, Brazil; [Nappo, Solange Aparecida] Univ Fed Sao Paulo, Dept Ciencias Farmaceut, Sao Paulo, SP, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade Federal de Pernambuco; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	Valois-Santos, NT (corresponding author), Fundacao Oswaldo Cruz, Dept Saude Colet, Inst Aggeu Magalhaes, Recife, PE, Brazil.	naide.valois@fiocruz.br		BRITO E SILVA, KEILA SILENE/0000-0002-0291-0708				Acioli Neto M., 2014, OS CONTEXTOS USO CRA, V1a ed; Almeida RBF., 2020, SALUD COLECT, V16, P2528; Almeida RBF., 2017, THESIS U FEDERAL SAO; Barbosa KKS., 2015, REV ENFERMAGEM UFSM, V5, P286; Bardin L, 2004, ANALISE CONTEUDO; Bastos F.I.P.M., 2017, 3 LEVANTAMENTO NACL; Bastos FI, 2013, PERFIL USUARIOS CRAC; Jorge MSB, 2013, CIENC SAUDE COLETIVA, V18, P2909, DOI 10.1590/S1413-81232013001000015; Castro-Neto AG., 2019, NEUROSCIENCE ALCOHOL, P573; Chaves Tharcila V, 2011, Rev. Saúde Pública, V45, P1168, DOI 10.1590/S0034-89102011005000066; Crane HM, 2017, AIDS BEHAV, V21, P1914, DOI 10.1007/s10461-017-1740-7; Creswell JW, 2017, DESIGNING CONDUCTING; da Costa JSD, 2004, REV SAUDE PUBL, V38, P284, DOI 10.1590/S0034-89102004000200019; Daniulaityte R, 2007, SUBST USE MISUSE, V42, P129, DOI 10.1080/10826080601174678; Dias AC, 2011, REV SAUDE PUBL, V45, P938, DOI 10.1590/S0034-89102011005000049; dos Santos H.N, 2013, INFLUENCIA MEIOS COM; Duailibi Lígia Bonacim, 2008, Cad. Saúde Pública, V24, ps545, DOI 10.1590/S0102-311X2008001600007; Eastwood B, 2019, DRUG ALCOHOL DEPEN, V194, P438, DOI 10.1016/j.drugalcdep.2018.11.008; Evans S., 2017, LICOES BRASILEIRAS S; Goncalves JR, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2063-0; Gossop M, 2006, ADDICTION, V101, P1292, DOI 10.1111/j.1360-0443.2006.01497.x; Higgins ST, 2003, ARCH GEN PSYCHIAT, V60, P1043, DOI 10.1001/archpsyc.60.9.1043; Leite S. C., 2015, SMAD. Revista Eletronica Saude Mental Alcool e Drogas, V11, P97; Magura S, 2000, ADDICT BEHAV, V25, P117, DOI 10.1016/S0306-4603(98)00128-2; Malchy L, 2008, INT J DRUG POLICY, V19, P339, DOI 10.1016/j.drugpo.2007.06.005; Minayo MCS., 2005, AVALIACAO TRIANGULAC, P71; Nappo SA, 2012, AM J ADDICTION, V21, P574, DOI 10.1111/j.1521-0391.2012.00272.x; Parker RB, 2010, DRUG METAB DISPOS, V38, P317, DOI 10.1124/dmd.109.030056; Patton M. Q., 2014, QUALITATIVE RES EVAL; Ratton JL., 2016, POLITICAS DROGAS RED; Ribeiro LA, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-671; Ribeiro Luciana Abeid, 2010, J. bras. psiquiatr., V59, P210, DOI 10.1590/S0047-20852010000300007; Rigoni R., 2018, SPEED LIMITS HARM RE; Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x; Rocha WS., 2015, SAUDE MENTAL ALCOOL, V11, P129; Rohsenow DJ, 1999, ALCOHOL RES HEALTH, V23, P225; Santos NTV., 2016, VULNERABILIDADE USU; Sayago CB., 2013, ALETHEIA CANOAS, V42, P164; Singulane RBA., 2016, REV PSICO USF, V21, P395, DOI [10.1590/1413-82712016210215, DOI 10.1590/1413-82712016210215]; Teixeira Mirna Barros, 2017, Saúde debate, V41, P311, DOI 10.1590/0103-1104201711225; Thoft DS, 2021, DEMENTIA-LONDON, V20, P1005, DOI 10.1177/1471301220919887; Trape S, 2014, J ADDICT MED, V8, P33, DOI 10.1097/ADM.0000000000000003; World Health Organization, 2018, GLOBAL STATUS REPORT, P450	44	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2021	16	9							e0256414	10.1371/journal.pone.0256414	http://dx.doi.org/10.1371/journal.pone.0256414			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5QV	34473735	gold, Green Published			2023-01-03	WOS:000707050100035
J	Kerkhoff, AD; Kagujje, M; Nyangu, S; Mateyo, K; Sanjase, N; Chilukutu, L; Eshun-Wilson, I; Geng, EH; Havlir, DV; Muyoyeta, M				Kerkhoff, Andrew D.; Kagujje, Mary; Nyangu, Sarah; Mateyo, Kondwelani; Sanjase, Nsala; Chilukutu, Lophina; Eshun-Wilson, Ingrid; Geng, Elvin H.; Havlir, Diane V.; Muyoyeta, Monde			Pathways to care and preferences for improving tuberculosis services among tuberculosis patients in Zambia: A discrete choice experiment	PLOS ONE			English	Article							THERAPY FAILURE; PREVALENCE; ACCURACY; GUIDANCE	Background Delays in the diagnosis of tuberculosis (TB) contribute to a substantial proportion of TB-related mortality, especially among people living with HIV (PLHIV). We sought to characterize the diagnostic journey for HIV-positive and HIV-negative patients with a new TB diagnosis in Zambia, to understand drivers of delay, and characterize their preferences for service characteristics to inform improvements in TB services. Methods We assessed consecutive adults with newly microbiologically-confirmed TB at two public health treatment facilities in Lusaka, Zambia. We administered a survey to document critical intervals in the TB care pathway (time to initial care-seeking, diagnosis and treatment initiation), identify bottlenecks and their reasons. We quantified patient preferences for a range of characteristics of health services using a discrete choice experiment (DCE) that assessed 7 attributes (distance, wait times, hours of operation, confidentiality, sex of provider, testing incentive, TB test speed and notification method). Results Among 401 patients enrolled (median age of 34 years, 68.7% male, 46.6% HIV-positive), 60.9% and 39.1% were from a first-level and tertiary hospital, respectively. The median time from symptom onset to receipt of TB treatment was 5.0 weeks (IQR: 3.6-8.0) and was longer among HIV-positive patients seeking care at a tertiary hospital than HIV-negative patients (6.4 vs. 4.9 weeks, p = 0.002). The time from symptom onset to initial presentation for evaluation accounted for the majority of time until treatment initiation (median 3.0 weeks, IQR: 1.0-5.0)-an important minority of 11.0% of patients delayed care-seeking >= 8 weeks. The DCE found that patients strongly preferred same-day TB test results (relative importance, 37.2%), facilities close to home (18.0%), and facilities with short wait times (16.9%). Patients were willing to travel to a facility up to 7.6 kilometers further away in order to access same-day TB test results. Preferences for improving current TB services did not differ according to HIV status. Conclusions Prolonged intervals from TB symptom onset to treatment initiation were common, especially among PLHIV, and were driven by delayed health-seeking. Addressing known barriers to timely diagnosis and incorporating patients' preferences into TB services, including same-day TB test results, may facilitate earlier TB care engagement in high burden settings.	[Kerkhoff, Andrew D.; Havlir, Diane V.] Univ Calif San Francisco, Div HIV Infect Dis & Global Med, Zuckerberg San Francisco Gen Hosp & Trauma Ctr, San Francisco, CA 94143 USA; [Kagujje, Mary; Nyangu, Sarah; Sanjase, Nsala; Chilukutu, Lophina; Muyoyeta, Monde] Ctr Infect Dis Res Zambia, Lusaka, Zambia; [Mateyo, Kondwelani] Univ Teaching Hosp, Dept Internal Med, Lusaka, Zambia; [Eshun-Wilson, Ingrid; Geng, Elvin H.] Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA	University of California System; University of California San Francisco; University of Zambia; Washington University (WUSTL)	Kerkhoff, AD (corresponding author), Univ Calif San Francisco, Div HIV Infect Dis & Global Med, Zuckerberg San Francisco Gen Hosp & Trauma Ctr, San Francisco, CA 94143 USA.	andrew.kerkhoff@ucsf.edu						Auld AF, 2016, T ROY SOC TROP MED H, V110, P432, DOI 10.1093/trstmh/trw056; Boulanger RF, 2013, LANCET INFECT DIS, V13, P540, DOI 10.1016/S1473-3099(13)70042-2; Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013; Bulterys MA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010111; Centers for Disease Control, 2017, CDC ZAMB; Chin DP, 2017, J INFECT DIS, V216, pS675, DOI 10.1093/infdis/jix368; Cremers AL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119861; Daftary A, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000515; de Vries SG, 2017, LANCET INFECT DIS, V17, pE128, DOI 10.1016/S1473-3099(16)30531-X; Di Gennaro F, 2017, TUBERCULOSIS, V103, P44, DOI 10.1016/j.tube.2017.01.002; Dowdy DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070485; Drain PK, 2019, J INFECT DIS, V220, pS108, DOI 10.1093/infdis/jiz356; Gupta RK, 2015, AIDS, V29, P1987, DOI 10.1097/QAD.0000000000000802; Hanrahan CF, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002796; Harries AD, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17396; Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223; Kagujje M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237931; Kapata N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146392; Kerkhoff AD, 2020, AIDS 2020 JUL 5 10 2; Kerkhoff AD, 2020, NEW ENGL J MED, V382, P1185, DOI 10.1056/NEJMc1916666; Krishnan Lakshmi, 2014, Tuberc Res Treat, V2014, P215059, DOI 10.1155/2014/215059; Mangham LJ, 2009, HEALTH POLICY PLANN, V24, P151, DOI 10.1093/heapol/czn047; McCreesh N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23797-2; McKay MM, 2020, PSYCHIAT RES, V283, DOI 10.1016/j.psychres.2019.112585; Nathavitharana RR, 2019, J INFECT DIS, V220, pS116, DOI 10.1093/infdis/jiz243; Needham DM, 2001, TROP MED INT HEALTH, V6, P256, DOI 10.1046/j.1365-3156.2001.00709.x; Orme B, 2010, GETTING STARTED CONJ; Orme B.K., 2017, BECOMING EXPERT CONJ; Partnership ST, 2018, FIND MISS PEOPL TB C; Pizzol Damiano, 2018, BMC Res Notes, V11, P99, DOI 10.1186/s13104-018-3209-9; Reid MJA, 2019, LANCET, V393, P1331, DOI 10.1016/S0140-6736(19)30024-8; STOP TB Partnership, 2018, INT TB CAS FIND FAC; Vesga JF, 2019, LANCET GLOB HEALTH, V7, pE585, DOI 10.1016/S2214-109X(19)30037-3; Wells WA, 2017, INT J TUBERC LUNG D, V21, P1101, DOI 10.5588/ijtld.17.0271; WHO, 2019, 10 THREATS GLOB HLTH; World Health Organization, 2017, WHO M REPORT TECHNIC; World Health Organization, 2011, SAM DAY DIAGN TUB MI; World Health Organization, 2013, SYST SCREEN ACT TUB; World Health Organization, 2012, WHO POLICY COLLABORA; World Health Organization, 2018, ETH GUID IMPL END TB; World Health Organization, 2020, RAPID COMMUNICATION	41	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2021	16	8							e0252095	10.1371/journal.pone.0252095	http://dx.doi.org/10.1371/journal.pone.0252095			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZI5YE	34464392	Green Published, gold			2023-01-03	WOS:000761695800005
J	Sawadogo, NH; Sanou, H; Greene, JA; Duclos, V				Sawadogo, N. Helene; Sanou, Hamidou; Greene, Jeremy A.; Duclos, Vincent			Promises and perils of mobile health in Burkina Faso	LANCET			English	Editorial Material									[Sawadogo, N. Helene] Univ Catholique Afrique Ouest, Dept Sociol, Bobo Dioulasso, Burkina Faso; [Sanou, Hamidou] Univ Joseph Ki Zerbo, Grp Rech Initiat Locales, Ouagadougou, Burkina Faso; [Greene, Jeremy A.] Johns Hopkins Univ, Sch Med, Dept Hist Med, Baltimore, MD USA; [Duclos, Vincent] Univ Quebec Montreal, Dept Commun Sociale & Publ, Montreal, PQ H2L 2C4, Canada	Johns Hopkins University; University of Quebec; University of Quebec Montreal	Duclos, V (corresponding author), Univ Quebec Montreal, Dept Commun Sociale & Publ, Montreal, PQ H2L 2C4, Canada.	duclos-belanger.vincent@uqam.ca							0	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2021	398	10302					738	739		10.1016/S0140-6736(21)01001-1	http://dx.doi.org/10.1016/S0140-6736(21)01001-1		AUG 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UH1QA	34058136				2023-01-03	WOS:000689712800010
J	Chaaithanya, IK; Abnave, D; Bawaskar, H; Pachalkar, U; Tarukar, S; Salvi, N; Bhoye, P; Yadav, A; Mahale, SD; Gajbhiye, RK				Chaaithanya, Itta Krishna; Abnave, Dipak; Bawaskar, Himmatrao; Pachalkar, Ujwal; Tarukar, Sandip; Salvi, Neha; Bhoye, Prabhakar; Yadav, Arun; Mahale, Smita D.; Gajbhiye, Rahul K.			Perceptions, awareness on snakebite envenoming among the tribal community and health care providers of Dahanu block, Palghar District in Maharashtra, India	PLOS ONE			English	Article							MANAGEMENT; PROFILE; BITES	Introduction India has remarkably the highest number of snakebite cases contributing to nearly 50% of the global snakebite deaths. Despite this fact, there is limited knowledge and awareness regarding the management practices for snakebite in the Indian population. The study aimed to explore the knowledge, awareness, and perception of snakes and snakebites, first aid, and treatment amongst the community and the frontline health workers in a tribal block of Dahanu, Maharashtra, India. Methods A cross-sectional study was carried out from June 2016 to October 2018 in the Dahanu Block, Maharashtra. Perceptions, knowledge, awareness, and first-aid practices on the snakebites among the community were studied through focus group discussions (FGDs). Semi-structured questionnaires were used to assess the knowledge, awareness, and experience of the traditional faith healers, snake rescuers, frontline health workers on the snakebites and their management. A facility check survey was conducted using pre-tested questionnaires for different levels of the government health care facilities. Results Most of the tribal community was aware of the commonly found snakes and their hiding places. However, there was inadequate knowledge on the identification and classification of venomous snakes. Belief in a snake god, the perception that snakes will not come out during thunderstorms, change in taste sensation, the ability of tamarind seeds or magnet to reduce the venom effect were some of the superstitions reported by the tribal community. The application of a harmful method (Tourniquet) as the first aid for snakebite was practiced by the tribal community. They preferred herbal medicines and visiting the traditional faith healers before shifting the patient to the government health facility. The knowledge on the ability to identify venomous snakebites and anti-venom was significantly higher amongst nurses and accredited social health activists (ASHAs) than auxiliary nurse midwives (ANMs) and multi-purpose workers (MPWs) (p < 0.05). None of the traditional faith healers; but nearly 60% of snake rescuers were aware of anti-venom. Fifty percent of the medical officers in Dahanu block did not have correct knowledge about the Krait bite symptoms, and renal complications due to the Russell viper bite. Conclusions Inappropriate perception, inadequate awareness, and knowledge about snakes and snakebites may predispose the tribal community to increased risks of venomous snakebites. Unproven and harmful methods for snakebite treatment practiced by the community and traditional faith healers could be dangerous leading to high mortality. Therefore, a multi-sectoral approach of community awareness, mapping of vulnerable populations, capacity building of health care facility, empowerment of health care workers (HCWs) could be useful for reducing the mortality and morbidity due to snakebite envenoming in India.	[Chaaithanya, Itta Krishna; Abnave, Dipak; Pachalkar, Ujwal; Tarukar, Sandip; Salvi, Neha; Mahale, Smita D.; Gajbhiye, Rahul K.] Govt India, Dept Hlth Res, Model Rural Hlth Res Unit, Dahanu, Maharashtra, India; [Chaaithanya, Itta Krishna; Mahale, Smita D.; Gajbhiye, Rahul K.] ICMR Natl Inst Res Reprod Hlth, Mumbai, Maharashtra, India; [Bawaskar, Himmatrao] Bawaskar Hosp & Clin Res Ctr, Raigad, Maharashtra, India; [Bhoye, Prabhakar; Yadav, Arun] Sub Dist Hosp, Dahanu, Maharashtra, India; [Abnave, Dipak] Tata Inst Social Sci, Tuljapur, Maharashtra, India; [Yadav, Arun] St George Hosp Campus, Directorate Hlth Serv, Arogya Bhavan, Mumbai, Maharashtra, India	Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Reproductive Health (NIRRH); Tata Institute of Social Sciences	Gajbhiye, RK (corresponding author), Govt India, Dept Hlth Res, Model Rural Hlth Res Unit, Dahanu, Maharashtra, India.; Gajbhiye, RK (corresponding author), ICMR Natl Inst Res Reprod Hlth, Mumbai, Maharashtra, India.	gajbhiyer@nirrh.res.in	Gajbhiye, Rahul/AAE-6889-2022	Gajbhiye, Rahul/0000-0003-3864-1818	Indian Council of Medical Research [Tribal/113/2016-ECD-II]	Indian Council of Medical Research(Indian Council of Medical Research (ICMR))	This study received support from Indian Council of Medical Research (www.icmr.nic.in) in the form of a grant (Tribal/113/2016-ECD-II) awarded to RKG. No additional external funding was received for this study.	[Anonymous], 2019, LANCET, V393, P2175, DOI 10.1016/S0140-6736(19)31232-2; [Anonymous], 2016, STANDARD TREATMENT G; Armstrong LJ, 2019, TROP DOCT, V49, P285, DOI 10.1177/0049475519865036; Bawaskar HS, 2010, LANCET, V375, P805, DOI 10.1016/S0140-6736(10)60345-5; Bawaskar H S, 2008, J Assoc Physicians India, V56, P88; Bawaskar HS, 2004, WILD ENVIRON MED, V15, P257; Bawaskar HS, 2002, T ROY SOC TROP MED H, V96, P79, DOI 10.1016/S0035-9203(02)90250-6; Bhaumik S, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f628; Bolon I, 2019, PREV VET MED, V170, DOI 10.1016/j.prevetmed.2019.104729; Bush SP, 1999, WILD ENVIRON MED, V10, P247, DOI 10.1580/1080-6032(1999)010[0247:NAWSSP]2.3.CO;2; Chaaithanya Itta Krishna, 2020, J Assoc Physicians India, V68, P87; Chippaux Jean-Philippe, 2007, Sante, V17, P127, DOI 10.1684/san.2007.0076; Chippaux JP, 1998, B WORLD HEALTH ORGAN, V76, P515; Dey A, 2012, AFR J TRADIT COMPLEM, V9, P153, DOI 10.4314/ajtcam.v9i1.20; Dhole PrasenjitBhagwan., 2019, INT J ADV RES INNOVA, V5, P603; Gajbhiye R, 2019, INDIAN J MED RES, V150, P412, DOI 10.4103/ijmr.IJMR_1148_18; HURWITZ B J, 1971, South African Medical Journal, V45, P969; Jain A, 2011, INDIAN J TRADIT KNOW, V10, P258; Jayawardana S, 2018, J MULTIDISCIP HEALTH, V11, P279, DOI 10.2147/JMDH.S126648; Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218; Mohan MM, 2020, J FAM MED PRIM CARE, V9, P508, DOI 10.4103/jfmpc.jfmpc_992_19; Longbottom J, 2018, LANCET, V392, P673, DOI 10.1016/S0140-6736(18)31224-8; Majumder Dayalbandhu, 2014, Indian J Public Health, V58, P17, DOI 10.4103/0019-557X.128158; Mallik S, 2017, INT J PREVENTIVE MED, V8, DOI 10.4103/2008-7802.197686; Michael GC, 2011, T ROY SOC TROP MED H, V105, P95, DOI 10.1016/j.trstmh.2010.09.005; Pandey DP, 2016, J ETHNOBIOL ETHNOMED, V12, DOI 10.1186/s13002-016-0092-0; Pandey DP, 2013, J TOXICOL ENV HLTH S, V5, P43, DOI [10.5897/JTEHS12.059, DOI 10.5897/JTEHS12.059]; Pearn J, 2000, TOXICON, V38, P1715, DOI 10.1016/S0041-0101(00)00102-1; Ranawaka UK, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002302; Ren MH, 2019, LANCET GLOB HEALTH, V7, pE837, DOI 10.1016/S2214-109X(19)30225-6; Robinson T.P., 2011, GLOBAL LIVESTOCK PRO; Rodrigo C, 2017, J OCCUP MED TOXICOL, V12, DOI 10.1186/s12995-017-0156-7; Schioldann E, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006299; Sharma SK, 2004, AM J TROP MED HYG, V71, P234, DOI 10.4269/ajtmh.2004.71.234; Simpson ID, 2008, T ROY SOC TROP MED H, V102, P1108, DOI 10.1016/j.trstmh.2008.04.013; Subedi N, 2018, J OCCUP MED TOXICOL, V13, DOI 10.1186/s12995-018-0210-0; Suraweera W, 2020, ELIFE, V9, DOI 10.7554/eLife.54076; Vaiyapuri S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080090; Vongphoumy I, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003887; WHO, WHO SNAK ENV STRAT; World Health Organization, GUIDELINES MANAGEMEN	41	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2021	16	8							e0255657	10.1371/journal.pone.0255657	http://dx.doi.org/10.1371/journal.pone.0255657			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6JF	34351997	gold, Green Published			2023-01-03	WOS:000685265700008
J	Coldea, A; Morand, S; Veniero, D; Harvey, M; Thut, G				Coldea, Andra; Morand, Stephanie; Veniero, Domenica; Harvey, Monika; Thut, Gregor			Parietal alpha tACS shows inconsistent effects on visuospatial attention	PLOS ONE			English	Article							ALTERNATING-CURRENT STIMULATION; VISUAL-SPATIAL ATTENTION; NEURAL OSCILLATIONS; REPRODUCIBILITY; INHIBITION; CONFIDENCE; NEGLECT; TARGET; BIAS	Transcranial alternating current stimulation (tACS) is a popular technique that has been used for manipulating brain oscillations and inferring causality regarding the brain-behaviour relationship. Although it is a promising tool, the variability of tACS results has raised questions regarding the robustness and reproducibility of its effects. Building on recent research using tACS to modulate visuospatial attention, we here attempted to replicate findings of lateralized parietal tACS at alpha frequency to induce a change in attention bias away from the contra- towards the ipsilateral visual hemifield. 40 healthy participants underwent tACS in two separate sessions where either 10 Hz tACS or sham was applied via a high-density montage over the left parietal cortex at 1.5 mA for 20 min, while performance was assessed in an endogenous attention task. Task and tACS parameters were chosen to match those of previous studies reporting positive effects. Unlike these studies, we did not observe lateralized parietal alpha tACS to affect attention deployment or visual processing across the hemifields as compared to sham. Likewise, additional resting electroencephalography immediately offline to tACS did not reveal any notable effects on individual alpha power or frequency. Our study emphasizes the need for more replication studies and systematic investigations of the factors that drive tACS effects.	[Coldea, Andra; Harvey, Monika; Thut, Gregor] Univ Glasgow, Inst Neurosci & Psychol, Ctr Cognit Neuroimaging, Glasgow, Lanark, Scotland; [Morand, Stephanie] Univ Glasgow, Sch Life Sci, MVLS Coll, Glasgow, Lanark, Scotland; [Veniero, Domenica] Univ Nottingham, Sch Psychol, Nottingham, England	University of Glasgow; University of Glasgow; University of Nottingham	Coldea, A; Thut, G (corresponding author), Univ Glasgow, Inst Neurosci & Psychol, Ctr Cognit Neuroimaging, Glasgow, Lanark, Scotland.	a.coldea.1@research.gla.ac.uk; gregor.thut@glasgow.ac.uk			ESRC [ES/P000681/1]	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	This work was supported by the ESRC (grant number ES/P000681/1 to A.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarts A.A., 2015, SCIENCE, V349, P1, DOI [DOI 10.1126/SCIENCE.AAC4716, DOI 10.1126/science.aac4716]; Ahn S, 2019, NEUROIMAGE, V186, P126, DOI 10.1016/j.neuroimage.2018.10.056; Alexander ML, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0439-0; Ali MM, 2013, J NEUROSCI, V33, P11262, DOI 10.1523/JNEUROSCI.5867-12.2013; Antal A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00317; Asamoah B, 2019, BRAIN STIMUL, V12, P1001, DOI 10.1016/j.brs.2019.03.011; Asamoah B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08183-w; Baker M, 2016, NATURE, V533, P452, DOI 10.1038/533452a; Battaglini L, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01765; Battaglini L, 2020, NEUROIMAGE, V208, DOI 10.1016/j.neuroimage.2019.116451; Benwell CSY, 2022, EUR J NEUROSCI, V55, P3125, DOI 10.1111/ejn.15166; Benwell CSY, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0182-17.2017; Benwell CSY, 2018, EUR J NEUROSCI, V48, P2566, DOI 10.1111/ejn.13688; Benwell CSY, 2015, CORTEX, V69, P152, DOI 10.1016/j.cortex.2015.05.007; Bikson M, 2018, BRAIN STIMUL, V11, P465, DOI 10.1016/j.brs.2017.12.008; Bland NS, 2019, EXP BRAIN RES, V237, P3071, DOI 10.1007/s00221-019-05666-0; Bland NS, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00304; Boncompte G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160347; Brauer H, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/3156796; Brignani D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056589; Bruers S, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00279; Cecere R, 2015, CURR BIOL, V25, P231, DOI 10.1016/j.cub.2014.11.034; Clayton MS, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00067; Corbetta M, 2011, ANNU REV NEUROSCI, V34, P569, DOI 10.1146/annurev-neuro-061010-113731; Cousineau D, 2005, TUTOR QUANT METHODS, V1, P42, DOI 10.20982/tqmp.01.1.p042; Datta A, 2008, J NEURAL ENG, V5, P163, DOI 10.1088/1741-2560/5/2/007; Deng YQ, 2019, ELIFE, V8, DOI 10.7554/eLife.51184; Duecker F, 2017, J COGNITIVE NEUROSCI, V29, P1267, DOI 10.1162/jocn_a_01119; Elyamany O, 2021, EUR ARCH PSY CLIN N, V271, P135, DOI 10.1007/s00406-020-01209-9; Fekete T, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00428; Feurra M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49166-1; Feurra M, 2013, J NEUROSCI, V33, P17483, DOI 10.1523/JNEUROSCI.1414-13.2013; Foster JJ, 2019, CURR OPIN PSYCHOL, V29, P34, DOI 10.1016/j.copsyc.2018.11.001; Foxe JJ, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00154; Frohlich F, 2015, PROG BRAIN RES, V222, P41, DOI 10.1016/bs.pbr.2015.07.025; Ghiani A, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.643677; Giglia G, 2011, BRAIN STIMUL, V4, P294, DOI 10.1016/j.brs.2011.01.003; Gould IC, 2011, J NEUROPHYSIOL, V105, P1318, DOI 10.1152/jn.00653.2010; Handel BF, 2011, J COGNITIVE NEUROSCI, V23, P2494, DOI 10.1162/jocn.2010.21557; Heroux ME, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175635; Herrmann CS, 2016, J NEUROSCI, V36, P5328, DOI 10.1523/JNEUROSCI.0236-16.2016; Hopfinger JB, 2017, COGN NEUROSCI-UK, V8, P102, DOI 10.1080/17588928.2016.1194261; Huang Y, 2017, ELIFE, V6, DOI 10.7554/eLife.18834; Iemi L, 2017, J NEUROSCI, V37, P807, DOI 10.1523/JNEUROSCI.1432-16.2016; Jones KT, 2019, BRAIN RES, V1720, DOI 10.1016/j.brainres.2019.146324; Kasten FH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68992-2; Kemmerer SK, 2020, FREQUENCY SPECIFIC T, DOI [10.1101/2020.08.04.236109, DOI 10.1101/2020.08.04.236109]; Krause B, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00025; Lafon B, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01045-x; Learmonth G, 2021, NEUROPSYCHOL REHABIL, V31, P1163, DOI 10.1080/09602011.2020.1767161; Li LM, 2015, EUR J NEUROSCI, V42, P2904, DOI 10.1111/ejn.13086; Limbach K, 2016, PSYCHOPHYSIOLOGY, V53, P1154, DOI 10.1111/psyp.12666; Mellin JM, 2018, EUR PSYCHIAT, V51, P25, DOI 10.1016/j.eurpsy.2018.01.004; Minami S, 2017, CURR BIOL, V27, P2344, DOI 10.1016/j.cub.2017.06.033; Neuling T, 2017, NEUROIMAGE, V147, P960, DOI 10.1016/j.neuroimage.2016.11.022; Neuling T, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00161; Noury N, 2016, NEUROIMAGE, V140, P99, DOI 10.1016/j.neuroimage.2016.03.065; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Polania R, 2018, NAT NEUROSCI, V21, P174, DOI 10.1038/s41593-017-0054-4; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; R Core Team, 2020, R LANGUAGE ENV STAT; Riddle J, 2022, BIOL PSYCHIAT-COGN N, V7, P302, DOI 10.1016/j.bpsc.2021.07.001; Rihs TA, 2007, EUR J NEUROSCI, V25, P603, DOI 10.1111/j.1460-9568.2007.05278.x; Ronconi L, 2022, EUR J NEUROSCI, V55, P3438, DOI 10.1111/ejn.15017; Samaha J, 2017, CONSCIOUS COGN, V54, P47, DOI 10.1016/j.concog.2017.02.005; Sauseng P, 2005, EUR J NEUROSCI, V22, P2917, DOI 10.1111/j.1460-9568.2005.04482.x; Schneider BA, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00474; Schuhmann T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217729; Tavakoli AV, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00214; Thut G, 2006, J NEUROSCI, V26, P9494, DOI 10.1523/JNEUROSCI.0875-06.2006; Thut G, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00170; Van Diepen RM, 2019, CURR OPIN PSYCHOL, V29, P229, DOI 10.1016/j.copsyc.2019.03.015; Van Dijk H, 2008, J NEUROSCI, V28, P1816, DOI 10.1523/JNEUROSCI.1853-07.2008; van Schouwenburg MR, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00433; Veniero D, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00952; Voroslakos M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02928-3; Vossen A, 2015, BRAIN STIMUL, V8, P499, DOI 10.1016/j.brs.2014.12.004; Vosskuhl J, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00211; Whelan R, 2008, PSYCHOL REC, V58, P475, DOI 10.1007/BF03395630; Wittenberg MA, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00311; Wostmann M, 2018, BRAIN STIMUL, V11, P752, DOI 10.1016/j.brs.2018.04.006; Worden MS, 2000, J NEUROSCI, V20; Wright JM, 2014, J VISION, V14, DOI 10.1167/14.9.5; Yavari F, 2018, NEUROSCI BIOBEHAV R, V85, P81, DOI 10.1016/j.neubiorev.2017.06.015	84	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2021	16	8							e0255424	10.1371/journal.pone.0255424	http://dx.doi.org/10.1371/journal.pone.0255424			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UA6JF	34351972	Green Accepted, Green Published, gold			2023-01-03	WOS:000685265700128
J	Sheetz, KH; Gerhardinger, L; Ryan, AM; Waits, SA				Sheetz, Kyle H.; Gerhardinger, Laura; Ryan, Andrew M.; Waits, Seth A.			Changes in Dialysis Center Quality Associated With the End-Stage Renal Disease Quality Incentive Program An Observational Study With a Regression Discontinuity Design	ANNALS OF INTERNAL MEDICINE			English	Article							RISK-FACTORS; FACILITY; IMPROVEMENT; ADEQUACY	Background: In 2012, the Centers for Medicare & Medicaid Services started levying performance-based financial penalties against outpatient dialysis centers under the mandatory End-Stage Renal Disease Quality Incentive Program. Objective: To determine whether penalization was associated with improvement in dialysis center quality. Design: Leveraging the threshold for penalization (total performance score < 60), a regression discontinuity design was used to examine the effect of penalization on quality over 2 years. Publicly available Medicare data from 2015-2018 were used. The effect of penalization at dialysis centers with different characteristics (for example, size or chain affiliation) was also examined. Setting: United States. Participants: Outpatient dialysis centers (n=5830). Measurements: Dialysis center total performance scores (a composite metric ranging from 0 to 100 based on clinical quality and adherence to reporting requirements) and individual measures that contribute to the total performance score. Results: There were 1109 (19.0%) outpatient dialysis centers that received penalties in 2017 on the basis of performance in 2015. Penalized centers were located in ZIP codes with a higher average proportion of non-White residents (36.4% vs. 31.2%; P < 0.001) and residents with lower median income ($49 290 vs. $51 686; P < 0.001). Penalization was not associated with improvement in total performance scores in 2017 (0.4 point [95% CI, -2.5 to 3.2 points]) or 2018 (0.3 point [CI, -2.8 to 3.4 points]). This was consistent across dialysis centers with different characteristics. There was also no association between penalization and improvement in specific measures. Limitation: The study could not account for how centers respond to penalization. Conclusion: Penalization under the End-Stage Renal Disease Quality Incentive Program was not associated with improvement in the quality of outpatient dialysis centers.	[Sheetz, Kyle H.] Univ Michigan, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA; [Sheetz, Kyle H.] Univ Michigan, Ctr Evaluating Hlth Reform, Ann Arbor, MI 48109 USA; [Gerhardinger, Laura; Waits, Seth A.] Ctr Healthcare Outcomes & Policy, 2800 Plymouth Rd,NCRC 8016,Room 100N-11, Ann Arbor, MI 48109 USA; [Ryan, Andrew M.] Ctr Evaluating Hlth Reform, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI USA; [Ryan, Andrew M.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; [Waits, Seth A.] Univ Michigan, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Sheetz, KH (corresponding author), Ctr Healthcare Outcomes & Policy, 2800 Plymouth Rd,NCRC 8016,Room 100N-11, Ann Arbor, MI 48109 USA.	ksheetz@med.umich.edu						Ajmal F, 2020, AM J KIDNEY DIS, V75, P177, DOI 10.1053/j.ajkd.2019.07.023; Ajmal F, 2019, AM J NEPHROL, V49, P64, DOI 10.1159/000495262; Brady BM, 2018, JAMA INTERN MED, V178, P1358, DOI 10.1001/jamainternmed.2018.3756; Calonico S, 2017, STATA J, V17, P372, DOI 10.1177/1536867X1701700208; Calonico S, 2014, STATA J, V14, P909, DOI 10.1177/1536867X1401400413; Centers for Medicare and Medicaid Services, 2020, ESRD QUAL INC PROGR; Centers for Medicare & Medicaid Services, DIAL FAC COMP TOOL; Centers for Medicare & Medicaid Services, 2016, END STAG REN DIS ESR, P1; Centers for Medicare & Medicaid Services (CMS) HHS, 2011, Fed Regist, V76, P627; Desai S, 2018, NEW ENGL J MED, V378, P539, DOI 10.1056/NEJMsa1706475; Diamond LH, 2016, ADV CHRONIC KIDNEY D, V23, P377, DOI 10.1053/j.ackd.2016.11.007; Fink JC, 2002, J AM SOC NEPHROL, V13, P2338, DOI 10.1097/01.ASN.0000027978.98194.1F; Hirth RA, 2001, AM J KIDNEY DIS, V38, P824, DOI 10.1053/ajkd.2001.27702; Johnston KJ, 2019, HEALTH AFFAIR, V38, P569, DOI 10.1377/hlthaff.2018.05032; Kliger AS, 2009, AM J KIDNEY DIS, V54, P993, DOI 10.1053/j.ajkd.2009.09.005; Maddox KEJ, 2019, HEALTH SERV RES, V54, P327, DOI 10.1111/1475-6773.13133; McClellan WM, 1998, J AM SOC NEPHROL, V9, P1940; Medicare Payment Advisory Commission, 2019, C MED PAYM POL; Paul S, 2018, CLIN J AM SOC NEPHRO, V13, P282, DOI 10.2215/CJN.04690417; Qi AC, 2019, HEALTH AFFAIR, V38, P1101, DOI 10.1377/hlthaff.2018.05406; Rodriguez RA, 2007, ANN INTERN MED, V146, P493, DOI 10.7326/0003-4819-146-7-200704030-00005; Sankaran R, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4109; Saunders MR, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2764-4; Saunders MR, 2013, MED CARE, V51, P413, DOI 10.1097/MLR.0b013e318287d720; U.S. Census Bureau, AM FACTFINDER COMM F; Venkataramani AS, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1216; Weiner D, 2017, J AM SOC NEPHROL, V28, P1697, DOI 10.1681/ASN.2016101079	27	4	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG	2021	174	8					1058	+		10.7326/M20-6662	http://dx.doi.org/10.7326/M20-6662			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP3IW	34058101				2023-01-03	WOS:000695277800015
J	Tsai, YP; Vogt, TM; Zhou, FJ				Tsai, Yuping; Vogt, Tara M.; Zhou, Fangjun			Patient Characteristics and Costs Associated With COVID-19-Related Medical Care Among Medicare Fee-for-Service Beneficiaries	ANNALS OF INTERNAL MEDICINE			English	Article							AGE	Background: New cases of COVID-19 continue to occur daily in the United States, and the need for medical treatments continues to grow. Knowledge of the direct medical costs of COVID-19 treatments is limited. Objective: To examine the characteristics of older adults with COVID-19 and their costs for COVID-19-related medical care. Design: Retrospective observational study. Setting: Medical claims for Medicare fee-for-service (FFS) beneficiaries. Patients: Medicare FFS beneficiaries aged 65 years or older who had a COVID-19-related medical encounter during April through December 2020. Measurements: Patient characteristics and direct medical costs of COVID-19-related hospitalizations and outpatient visits. Results: Among 28.1 million Medicare FFS beneficiaries, 1 181 127 (4.2%) sought COVID-19-related medical care. Among these patients, 23.0% had an inpatient stay and 4.2% died during hospitalization. The majority of the patients were female (57.0%), non-Hispanic White (79.6%), and residents of an urban county (77.2%). Medicare FFS costs for COVID-19 related medical care were $6.3 billion; 92.6% of costs were for hospitalizations. The mean hospitalization cost was $21 752, and the mean length of stay was 9.2 days; hospitalization cost and length of stay were higher if the patient needed a ventilator ($49 441 and 17.1 days) or died ($32 015 and 11.3 days). The mean cost per outpatient visit was $164. Patients aged 75 years or older were more likely to be hospitalized, but their hospitalizations were associated with lower costs than for younger patients. Male sex and non-White race/ethnicity were associated with higher probability of being hospitalized and higher medical costs. Limitation: Results are based on Medicare FFS patients. Conclusion: The COVID-19 pandemic has resulted in substantial disease and economic burden among older Americans, particularly those of non-White race/ethnicity.	[Tsai, Yuping; Vogt, Tara M.; Zhou, Fangjun] Ctr Dis Control & Prevent, Ctr Immunizat & Resp Dis, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Tsai, YP (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS H24-4, Atlanta, GA 30329 USA.	ytsai@cdc.gov						Bartsch SM, 2020, HEALTH AFFAIR, V39, P927, DOI 10.1377/hlthaff.2020.00426; Berenson RA, 2015, HEALTH AFFAIR, V34, P1289, DOI 10.1377/hlthaff.2014.1427; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6915e4; Centers for Disease Control and Prevention, 2021, OLD AD GREAT RISK RE; Centers for Disease Control and Prevention, COVID DAT TRACK; Centers for Disease Control and Prevention, RISK COVID 19 INF HO; Centers for Disease Control and Prevention, RAT COVID 19 ASS HOS; Centers for Medicare & Medicaid Services, 2017, CHRON COND DAT WAR C; Centers for Medicare & Medicaid Services, MED SEC PAYER; Centers for Medicare & Medicaid Services, 2021, MED ENR SECT; Centers for Medicare & Medicaid Services, 2020, FAQS FAM 1 COR RESP; Centers for Medicare Medicaid Services, 2022, COVID 19 NURS HOM DA; Chen JL, 2018, AM J MANAG CARE, V24, P341, DOI 10.1016/j.addma.2018.10.007; Hamel L., 2020, KFF COVID 19 VACC MO; Hamel MB, 2000, J AM GERIATR SOC, V48, pS176, DOI 10.1111/j.1532-5415.2000.tb03129.x; Hansen CH, 2021, LANCET, V397, P1204, DOI 10.1016/S0140-6736(21)00575-4; Ioannou GN, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.22310; Katz MH, 2021, JAMA INTERN MED, V181, P381, DOI 10.1001/jamainternmed.2020.5415; Levinsky NG, 1999, J AM GERIATR SOC, V47, P553, DOI 10.1111/j.1532-5415.1999.tb02569.x; Levinsky NG, 2001, JAMA-J AM MED ASSOC, V286, P1349, DOI 10.1001/jama.286.11.1349; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Mallapaty S, 2020, NATURE, V585, P16, DOI 10.1038/d41586-020-02483-2; Marshall M, 2020, NATURE, V585, P339, DOI 10.1038/d41586-020-02598-6; National Center for Health Statistics, CTR DIS CONTROL PREV; Nicholson CJ, 2021, ECLINICALMEDICINE, V33, DOI 10.1016/j.eclinm.2021.100765; Sun HY, 2020, J AM GERIATR SOC, V68, pE19, DOI 10.1111/jgs.16533; The Centers for Medicare Medicaid Services (CMS), 2021, COVID 19 FREQ ASK QU; U.S. Food and Drug Administration, EM US AUTH; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yanez ND, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09826-8; Zane A, 2018, CRIT CARE MED, V46, P215, DOI 10.1097/01.ccm.0000528481.75970.e7; Zhurova L.I., 2022, PROJ EC IMP COVID 19, V2, P217	33	20	21	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG	2021	174	8					1101	+		10.7326/M21-1102	http://dx.doi.org/10.7326/M21-1102			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP3IW	34058109	Green Published			2023-01-03	WOS:000695277800020
J	Chang, M; Ando, H; Maeda, T; Naruse, Y				Chang, Ming; Ando, Hideyuki; Maeda, Taro; Naruse, Yasushi			Behavioral effect of mismatch negativity neurofeedback on foreign language learning	PLOS ONE			English	Article							TRAINING JAPANESE LISTENERS; PHONEME REPRESENTATIONS; EEG-NEUROFEEDBACK; DISCRIMINATION; PERCEPTION; INTELLIGENCE; PLASTICITY; FREQUENCY; ATTENTION; RECALL	Listening is critical for foreign language learning. Listening difficulties can occur because of an inability to perceive or recognize sounds while listening to speech, whereas successful listening can boost understanding and improve speaking when learning a foreign language. Previous studies in our laboratory revealed that EEG-neurofeedback (NF) using mismatch negativity event-related brain potential successfully induced unconscious learning in terms of auditory discrimination of speech sounds. Here, we conducted a feasibility study with a small participant group (NF group and control group; six participants each) to examine the practical effects of mismatch negativity NF for improving the perception of speech sounds in a foreign language. Native Japanese speakers completed a task in which they learned to perceive and recognize spoken English words containing the consonants "l" or "r". Participants received neurofeedback training while not explicitly attending to auditory stimuli. The results revealed that NF training significantly improved the proportion of correct in discrimination and recognition trials, even though the training time for each word pair was reduced to 20% of the training time reported in our previous study. The learning effect was not affected by training with three pairs of words with different vowels. The current results indicate that NF resulted in long-term learning that persisted for at least 2 months.	[Chang, Ming; Ando, Hideyuki; Maeda, Taro; Naruse, Yasushi] Natl Inst Informat & Commun Technol, Ctr Informat & Neural Networks CiNet, Nishi Ku, Iwaoka Cho, Kobe, Hyogo, Japan; [Chang, Ming; Ando, Hideyuki; Maeda, Taro; Naruse, Yasushi] Osaka Univ, Nishi Ku, Iwaoka Cho, Kobe, Hyogo, Japan; [Chang, Ming; Ando, Hideyuki; Maeda, Taro] Osaka Univ, Grad Sch Informat Sci & Technol, Suita, Osaka, Japan	National Institute of Information & Communications Technology (NICT) - Japan; Osaka University; Osaka University	Naruse, Y (corresponding author), Natl Inst Informat & Commun Technol, Ctr Informat & Neural Networks CiNet, Nishi Ku, Iwaoka Cho, Kobe, Hyogo, Japan.; Naruse, Y (corresponding author), Osaka Univ, Nishi Ku, Iwaoka Cho, Kobe, Hyogo, Japan.	y_naruse@nict.go.jp			Center of Innovation Program from Japan Science and Technology Agency, JST	Center of Innovation Program from Japan Science and Technology Agency, JST	This research was partially supported by the Center of Innovation Program from Japan Science and Technology Agency, JST. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	ALHO K, 1994, PSYCHOPHYSIOLOGY, V31, P469, DOI 10.1111/j.1469-8986.1994.tb01050.x; Anderson S.C, 1985, J W AFRICAN LANGUAGE, V15, P61; Andre E., 1974, THESIS OHIO STATE U; Angelakis E, 2007, CLIN NEUROPSYCHOL, V21, P110, DOI 10.1080/13854040600744839; Anzaldua G., 1983, THIS BRIDGE CALLED M, P165; BADDELEY AD, 1978, ERGONOMICS, V21, P627, DOI 10.1080/00140137808931764; Becerra J, 2012, J ALZHEIMERS DIS, V28, P357, DOI 10.3233/JAD-2011-111055; Bell MC, 2014, MEMORY, V22, P276, DOI 10.1080/09658211.2013.778294; Best C.T., 1995, SPEECH PERCEPTION LI, P171; Best CT, 2001, J ACOUST SOC AM, V109, P775, DOI 10.1121/1.1332378; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Caria A, 2007, NEUROIMAGE, V35, P1238, DOI 10.1016/j.neuroimage.2007.01.018; Chang M, 2014, PSYCHOL SCHOOLS, V51, P32, DOI 10.1002/pits.21734; Chang M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178694; Chang M, 2014, SCI REP-UK, V4, DOI 10.1038/srep06729; Cheour M, 1998, NAT NEUROSCI, V1, P351, DOI 10.1038/1561; Coben R, 2010, APPL PSYCHOPHYS BIOF, V35, P13, DOI 10.1007/s10484-009-9102-5; Donovan JJ, 1999, J APPL PSYCHOL, V84, P795, DOI 10.1037/0021-9010.84.5.795; Escolano C, 2011, IEEE ENG MED BIO, P2327, DOI 10.1109/IEMBS.2011.6090651; Flege J.E., 1995, SPEECH PERCEPTION LI, P233, DOI DOI 10.1075/LLLT.17.08STR; Garrido MI, 2009, CLIN NEUROPHYSIOL, V120, P453, DOI 10.1016/j.clinph.2008.11.029; Gilakjani A.P., 2011, J LANGUAGE TEACHING, V2, P977, DOI DOI 10.4304/JLTR.2.5.977-988; Gruzelier JH, 2014, NEUROSCI BIOBEHAV R, V44, P124, DOI 10.1016/j.neubiorev.2013.09.015; Guion SG, 2000, J ACOUST SOC AM, V107, P2711, DOI 10.1121/1.428657; Hammond DC, 2007, J NEUROTHER, V10, P25, DOI DOI 10.1300/J184V10N04; Horvath J, 2001, COGNITIVE BRAIN RES, V12, P131, DOI 10.1016/S0926-6410(01)00038-6; Johnston SJ, 2010, NEUROIMAGE, V49, P1066, DOI 10.1016/j.neuroimage.2009.07.056; Keizer AW, 2010, INT J PSYCHOPHYSIOL, V75, P25, DOI 10.1016/j.ijpsycho.2009.10.011; KRAUS N, 1995, J COGNITIVE NEUROSCI, V7, P25, DOI 10.1162/jocn.1995.7.1.25; Kuhl P.K., 1995, SPEECH PERCEPTION LI, P121; KUHL PK, 1993, J PHONETICS, V21, P125; Kuhl PK, 2004, NAT REV NEUROSCI, V5, P831, DOI 10.1038/nrn1533; LIVELY SE, 1994, J ACOUST SOC AM, V96, P2076, DOI 10.1121/1.410149; LOGAN JS, 1991, J ACOUST SOC AM, V89, P874, DOI 10.1121/1.1894649; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; Moore DR, 2005, BRAIN LANG, V94, P72, DOI 10.1016/j.bandl.2004.11.009; MURRAY DJ, 1965, CAN J PSYCHOLOGY, V19, P333, DOI 10.1037/h0082913; Naatanen R, 2007, CLIN NEUROPHYSIOL, V118, P2544, DOI 10.1016/j.clinph.2007.04.026; Naatanen R, 2001, TRENDS NEUROSCI, V24, P283, DOI 10.1016/S0166-2236(00)01790-2; Naatanen R, 1997, NATURE, V385, P432, DOI 10.1038/385432a0; Naatanen R, 1999, PSYCHOL BULL, V125, P826, DOI 10.1037/0033-2909.125.6.826; Okuno T, 2016, LANG LEARN TECHNOL, V20, P61; Peltola MS, 2003, NEUROSCI LETT, V352, P25, DOI 10.1016/j.neulet.2003.08.013; Phillips C., 1995, MIT WORKING PAPERS L, V26, P125; PIMSLEUR P, 1962, J EDUC PSYCHOL, V53, P15, DOI 10.1037/h0044336; Postovsky ValerianA., 1974, MOD LANG J, V58, P229, DOI 10.1111/j.1540-4781.1974.tb05104.x; Renukadevi D., 2014, INT J ED INFORM STUD, V4, P59; Ros T, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-87; Saito K, 2018, INT J APPL LINGUIST, V28, P3, DOI 10.1111/ijal.12175; Shibata K, 2011, SCIENCE, V334, P1413, DOI 10.1126/science.1212003; Shiga Y., 2013, J NATL I INFORM COMM, V59; Sussman E, 2006, BRAIN RES, V1075, P165, DOI 10.1016/j.brainres.2005.12.074; Szymanski MD, 1999, J ACOUST SOC AM, V106, P3492, DOI 10.1121/1.428202; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81; TIITINEN H, 1994, NATURE, V372, P90, DOI 10.1038/372090a0; Tremblay K, 1998, NEUROREPORT, V9, P3557, DOI 10.1097/00001756-199811160-00003; UNDERWOOD BJ, 1970, J VERB LEARN VERB BE, V9, P573, DOI 10.1016/S0022-5371(70)80104-9; Winkler I, 1999, PSYCHOPHYSIOLOGY, V36, P638, DOI 10.1111/1469-8986.3650638; YAMADA RA, 1992, PERCEPT PSYCHOPHYS, V52, P376, DOI 10.3758/BF03206698; Yildirim S., 2016, IMPORTANCE LISTENING	60	0	0	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2021	16	7							e0254771	10.1371/journal.pone.0254771	http://dx.doi.org/10.1371/journal.pone.0254771			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2NX	34283873	gold, Green Published			2023-01-03	WOS:000678123200040
J	Sweeney, C; Bracarda, S; Sternberg, CN; Chi, KN; Olmos, D; Sandhu, S; Massard, C; Matsubara, N; Alekseev, B; Parnis, F; Atduev, V; Buchschacher, GL; Gafanov, R; Corrales, L; Borre, M; Stroyakovskiy, D; Alves, GV; Bournakis, E; Puente, J; Harle-Yge, ML; Gallo, J; Chen, G; Hanover, J; Wongchenko, MJ; Garcia, J; de Bono, JS				Sweeney, Christopher; Bracarda, Sergio; Sternberg, Cora N.; Chi, Kim N.; Olmos, David; Sandhu, Shahneen; Massard, Christophe; Matsubara, Nobuaki; Alekseev, Boris; Parnis, Francis; Atduev, Vagif; Buchschacher, Gary L., Jr.; Gafanov, Rustem; Corrales, Luis; Borre, Michael; Stroyakovskiy, Daniil; Alves, Gustavo Vasconcelos; Bournakis, Evangelos; Puente, Javier; Harle-Yge, Marie-Laurence; Gallo, Jorge; Chen, Geng; Hanover, Justin; Wongchenko, Matthew J.; Garcia, Josep; de Bono, Johann S.			Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial	LANCET			English	Article							AKT INHIBITOR; SURVIVAL ANALYSIS; PTEN; ENZALUTAMIDE; GDC-0068; CRITERIA; ACETATE; MEN	Background The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss status have hyperactivated AKT signalling. Dual pathway inhibition with AKT inhibitor ipatasertib plus abiraterone might have greater benefit than abiraterone alone. We aimed to compare ipatasertib plus abiraterone with placebo plus abiraterone in patients with previously untreated mCRPC with or without tumour PTEN loss. Methods We did a randomised, double-blind, phase 3 trial at 200 sites across 26 countries or regions. Patients aged 18 years or older with previously untreated asymptomatic or mildly symptomatic mCRPC who had progressive disease and Eastern Collaborative Oncology Group performance status of 0 or 1 were randomly assigned (1:1; permuted block method) to receive ipatasertib (400 mg once daily orally) plus abiraterone (1000 mg once daily orally) and prednisolone (5 mg twice a day orally) or placebo plus abiraterone and prednisolone (with the same dosing schedule). Patients received study treatment until disease progression, intolerable toxicity, withdrawal from the study, or study completion. Stratification factors were previous taxane-based therapy for hormone-sensitive prostate cancer, type of progression, presence of visceral metastasis, and tumour PTEN-loss status by immunohistochemistry. Patients, investigators, and the study sponsor were masked to the treatment allocation. The coprimary endpoints were investigator-assessed radiographical progression-free survival in the PTEN-loss-by-immunohistochemistry population and in the intention-to-treat population. This study is ongoing and is registered with ClinicalTrials.gov, NCT03072238. Findings Between June 30, 2017, and Jan 17, 2019, 1611 patients were screened for eligibility and 1101 (68%) were enrolled; 554 (50%) were assigned to the placebo-abiraterone group and 547 (50%) to the ipatasertib-abiraterone group. At data cutoff (March 16, 2020), median follow-up duration was 19 months (range 0-33). In the 521 (47%) patients who had tumours with PTEN loss by immunohistochemistry (261 in the placebo-abiraterone group and 260 in the ipatasertib-abiraterone group), median radiographical progression-free survival was 16.5 months (95% CI 13.9-17.0) in the placebo-abiraterone group and 18.5 months (16.3-22.1) in the ipatasertib-abiraterone group (hazard ratio [HR] 0.77 [95% CI 0.61-0.98]; p=0.034; significant at a=0.04). In the intention-to-treat population, median progression-free survival was 16.6 months (95% CI 15.6-19.1) in the placebo-abiraterone group and 19.2 months (16.5-22.3) in the ipatasertib-abiraterone group (HR 0.84 [95% CI 0.71-0.99]; p=0.043; not significant at a=0.01). Grade 3 or higher adverse events occurred in 213 (39%) of 546 patients in the placebo-abiraterone group and in 386 (70%) of 551 patients in the ipatasertib-abiraterone group; adverse events leading to discontinuation of placebo or ipatasertib occurred in 28 (5%) in the placebo-abiraterone group and 116 (21%) in the ipatasertib-abiraterone group. Deaths due to adverse events deemed related to treatment occurred in two patients (<1%; acute myocardial infarction [n=1] and lower respiratory tract infection [n=1]) in the placebo-abiraterone group and in two patients (<1%; hyperglycaemia [n=1] and chemical pneumonitis [n=1]) in the ipastasertb-abiraterone group. Interpretation Ipatasertib plus abiraterone significantly improved radiographical progression-free survival compared with placebo plus abiraterone among patients with mCRPC with PTEN-loss tumours, but there was no significant difference between the groups in the intention-to-treat population. Adverse events were consistent with the known safety profiles of each agent. These data suggest that combined AKT and androgen-receptor signalling pathway inhibition with ipatasertib and abiraterone is a potential treatment for men with PTEN-loss mCRPC, a population with a poor prognosis. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Sweeney, Christopher] Dana Farber Canc Inst, Boston, MA 02115 USA; [Bracarda, Sergio] Azienda Osped Santa Maria, Terni, Italy; [Sternberg, Cora N.] New York Presbyterian, Englander Inst Precis Med, Weill Cornell Med, New York, NY USA; [Chi, Kim N.] BC Canc, Vancouver, BC, Canada; [Olmos, David] Spanish Natl Canc Res Ctr CNIO, Malaga, Spain; [Olmos, David] Inst Invest Biomed Malaga IBIMA, Malaga, Spain; [Sandhu, Shahneen] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Sandhu, Shahneen] Univ Melbourne, Melbourne, Vic, Australia; [Massard, Christophe] Inst Gustave Roussy, Villejuif, France; [Matsubara, Nobuaki] Natl Canc Ctr Hosp East, Chiba, Japan; [Alekseev, Boris] PA Herzen Moscow Oncol Res Inst, Moscow, Russia; [Parnis, Francis] Ashford Canc Ctr Res, Kurralta Pk, SA, Australia; [Atduev, Vagif] Volga Dist Med Ctr Fed Med & Biol Agcy Russia, Nizhnii Novgorod, Russia; [Buchschacher, Gary L., Jr.] Kaiser Permanente Southern Calif, Los Angeles Med Ctr, Los Angeles, CA USA; [Gafanov, Rustem] Russian Sci Ctr Roentgenol & Radiol, Moscow, Russia; [Corrales, Luis] Ctr Invest & Manejo Canc CIMCA, Med Oncol, San Jose, Costa Rica; [Borre, Michael] Aarhus Univ Hosp, Aarhus, Denmark; [Stroyakovskiy, Daniil] Moscow City Oncol Hosp 62, Moscow Healthcare Dept, Moscow, Moscow Oblast, Russia; [Alves, Gustavo Vasconcelos] Hosp Nossa Senhora Conceicao, Ctr Integrad Pesquisa Oncol, Porto Alegre, RS, Brazil; [Bournakis, Evangelos] Metropolitan Gen Hosp, Oncol Clin Trials & Res Clin, Athens, Greece; [Puente, Javier] Hosp Clin San Carlos, Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Med Oncol Dept, CIBERONC, Madrid, Spain; [Harle-Yge, Marie-Laurence; Gallo, Jorge; Garcia, Josep] F Hoffmann La Roche, Basel, Switzerland; [Chen, Geng; Hanover, Justin; Wongchenko, Matthew J.] Genentech Inc, San Francisco, CA 94080 USA; [de Bono, Johann S.] Inst Canc Res, Div Clin Studies, London SM2 5PT, England; [de Bono, Johann S.] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England	Harvard University; Dana-Farber Cancer Institute; Cornell University; NewYork-Presbyterian Hospital; Centro Nacional de Investigaciones Oncologicas (CNIO); Universidad de Malaga; Peter Maccallum Cancer Center; University of Melbourne; UNICANCER; Gustave Roussy; National Cancer Center - Japan; Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Aarhus University; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Hospital Clinico San Carlos; Roche Holding; Roche Holding; Genentech; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	de Bono, JS (corresponding author), Inst Canc Res, Div Clin Studies, London SM2 5PT, England.	johann.de-bono@icr.ac.uk	Gafanov, Rustem Ayratovich/P-3454-2017; Alekseev, Boris/O-1008-2017	Olmos Hidalgo, David/0000-0002-7003-4826; Stroyakovskiy, Daniil/0000-0003-1973-1092; Bracarda, Sergio/0000-0002-0703-2959; Alekseev, Boris/0000-0002-3398-4128; PUENTE, JAVIER/0000-0002-6910-1331	F Hoffmann-La Roche; Genentech	F Hoffmann-La Roche(Hoffmann-La Roche); Genentech(Roche HoldingGenentech)	The study was funded by F Hoffmann-La Roche and Genentech, a member of the Roche group. We thank the patients who participated in the trial and the clinical site investigators. Medical writing assistance for this manuscript was provided by Scott Battle PhD (Health Interactions, Chicago, IL, USA), funded by F Hoffmann-La Roche.	Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Beer TM, 2017, EUR UROL, V71, P151, DOI 10.1016/j.eururo.2016.07.032; Blake JF, 2012, J MED CHEM, V55, P8110, DOI 10.1021/jm301024w; Buttigliero C, 2015, CANCER TREAT REV, V41, P884, DOI 10.1016/j.ctrv.2015.08.002; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; de Bono JS, 2019, CLIN CANCER RES, V25, P928, DOI 10.1158/1078-0432.CCR-18-0981; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Doi T, 2019, CANCER CHEMOTH PHARM, V84, P393, DOI 10.1007/s00280-019-03882-7; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Isakoff SJ, 2020, ANN ONCOL, V31, P626, DOI 10.1016/j.annonc.2020.02.007; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Kim SB, 2017, LANCET ONCOL, V18, P1360, DOI 10.1016/S1470-2045(17)30450-3; Lin J, 2013, CLIN CANCER RES, V19, P1760, DOI 10.1158/1078-0432.CCR-12-3072; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nuhn P, 2019, EUR UROL, V75, P88, DOI 10.1016/j.eururo.2018.03.028; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Oliveira M, 2019, ANN ONCOL, V30, P1289, DOI 10.1093/annonc/mdz177; Rescigno P, 2018, EUR UROL ONCOL, V1, P71, DOI 10.1016/j.euo.2018.02.006; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7; Sangale Z, 2011, APPL IMMUNOHISTO M M, V19, P173, DOI 10.1097/PAI.0b013e3181f1da13; Sarker D, 2009, CLIN CANCER RES, V15, P4799, DOI 10.1158/1078-0432.CCR-08-0125; Sartor O, 2018, NEW ENGL J MED, V378, P645, DOI 10.1056/NEJMra1701695; Saura C, 2017, CANCER DISCOV, V7, P102, DOI 10.1158/2159-8290.CD-16-0512; Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702; Schmid P, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.00368; Shi Z, 2020, J CLIN ONCOL, V38; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026	32	59	58	2	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2021	398	10295					131	142						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG0BQ	34246347				2023-01-03	WOS:000671078800024
J	Hekne, L; Montgomery, C; Johansen, K				Hekne, Linnea; Montgomery, Cecilia; Johansen, Kine			Early access to physiotherapy for infants with cerebral palsy: A retrospective chart review	PLOS ONE			English	Review							EARLY INTERVENTION; DEVELOPMENTAL SURVEILLANCE; MOTOR-PERFORMANCE; DIAGNOSIS; CHILDREN; AGE; EXPERIENCES	Aim This study aimed to investigate whether children with cerebral palsy (CP) had equal access to timely physiotherapy. Additionally, to learn more about clinical characteristics of infants with CP, we explored differences in neonatal clinical history and CP profile between children referred by a neonatologist or enrolled in neonatal follow-up and those referred by other healthcare professionals as well as those referred before and after 5 months corrected age. Methods We conducted a retrospective chart review study including children born in Uppsala County, Sweden, from 2010 to 2016, who had received a CP diagnosis by July 2019. Entries by doctors and physiotherapists working at Uppsala University Children's Hospital were reviewed. Results Thirty-eight children were included (21 girls, 55.3%) in the study. Twenty-two (57.9%) were born at term. Twenty-five children (66%) had their first visit to a physiotherapist before 5 months corrected age, and this included all children (n = 22, 57.9%) referred by a neonatologist or enrolled in neonatal follow-up. The latter group had significantly earlier access to physiotherapy compared to children referred by other healthcare professionals, with a median of 1.9 (min-max: -1-4) and 7.6 (min-max: 1-24) months, respectively (p < 0.0001). Referral source explained unique variance in predicting time of referral to physiotherapist (R-2 0.550, B 4.213, p < 0.0001) when controlling for both number of risk factors and severity of motor impairment. However, number of risk factor was vital for early access to physiotherapy for children referred by other health care professionals. Children referred by a neonatologist or enrolled in neonatal follow-up or referred before 5 months corrected age differed on all measured variables concerning neonatal clinical history and CP profile, compared to children referred by other healthcare professionals or after 5 months corrected age. The latter groups had milder forms of CP. In total, twenty-eight children (73.7%) were ambulatory at 2 years of age. Bilateral spastic CP was most common among those referred by a neonatologist or enrolled in neonatal follow-up or referred before 5 months corrected age, while unilateral spastic CP was most common among those referred by other healthcare professionals or after 5 months corrected age. Conclusion Infants with CP have unequal access to timely physiotherapy, and children considered at low risk for CP receive therapy later. Neonatal follow-up of infants considered at high risk for CP that involves an assessment of motor performance using an evidence-based method during the first months of life corrected age seems to be effective in identifying CP early. Conversely, measuring milestone attainment seems to be a less reliable method for early identification. To provide safe and equal care, all professionals performing developmental surveillance should receive proper training and use evidence-based assessment methods. Physiotherapy should be available prior to formal medical diagnosis.	[Hekne, Linnea] Vastmanland Hosp Vasteras, Pediat Dept, Vasteras, Sweden; [Montgomery, Cecilia; Johansen, Kine] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden	Vasteras Central Hospital; Uppsala University	Johansen, K (corresponding author), Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden.	kine.johansen@kbh.uu.se	Johansen, Kine/AAN-8208-2020	Johansen, Kine/0000-0002-9212-8452; Montgomery, Cecilia/0000-0002-5290-4090				Alriksson-Schmidt AI, 2017, DISABIL REHABIL, V39, P830, DOI 10.3109/09638288.2016.1161843; Boychuck Z, 2020, J PEDIATR-US, V216, P173, DOI 10.1016/j.jpeds.2019.09.035; Boychuck Z, 2019, DEV MED CHILD NEUROL, V61, P908, DOI 10.1111/dmcn.14034; Eliasson AC, 2018, RES DEV DISABIL, V72, P191, DOI 10.1016/j.ridd.2017.11.006; Garfinkle J, 2020, PEDIATR NEUROL, V102, P56, DOI 10.1016/j.pediatrneurol.2019.07.006; Granild-Jensen JB, 2015, DEV MED CHILD NEUROL, V57, P931, DOI 10.1111/dmcn.12760; Hadders-Algra M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040861; Hix-Small H, 2007, PEDIATRICS, V120, P381, DOI 10.1542/peds.2006-3583; Hubermann L, 2016, J CHILD NEUROL, V31, P364, DOI 10.1177/0883073815596610; Johansen K., 2017, THESIS UPPSALA U; Johansen K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181398; Johansen K, 2016, J EVAL CLIN PRACT, V22, P227, DOI 10.1111/jep.12459; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; King TM, 2003, CURR OPIN PEDIATR, V15, P624, DOI 10.1097/00008480-200312000-00014; KOHN LT, 2000, ERR IS HUMAN BUILDIN, P155; Lindstrom K, 1997, ACTA PAEDIATR, V86, P736, DOI 10.1111/j.1651-2227.1997.tb08577.x; Lobo MA, 2013, PHYS THER, V93, P94, DOI 10.2522/ptj.20120158; Magnusson M, 2001, CHILD CARE HLTH DEV, V27, P117, DOI 10.1046/j.1365-2214.2001.00180.x; McIntyre S, 2011, DEV DISABIL RES REV, V17, P114, DOI 10.1002/ddrr.1106; Montgomery C, 2017, EARLY HUM DEV, V113, P31, DOI 10.1016/j.earlhumdev.2017.07.009; Morgan C, 2021, JAMA PEDIATR, V175, P846, DOI 10.1001/jamapediatrics.2021.0878; Morgan C, 2018, J PAEDIATR CHILD H, V54, P1159, DOI 10.1111/jpc.14177; Novak I, 2020, CURR NEUROL NEUROSCI, V20, DOI 10.1007/s11910-020-1022-z; Novak I, 2017, JAMA PEDIATR, V171, P897, DOI 10.1001/jamapediatrics.2017.1689; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Reuter A., 2017, RIKSHANDBOKEN BARNH; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x; Sakzewski L, 2019, DEV MED CHILD NEUROL, V61, P563, DOI 10.1111/dmcn.14091; Svenska Neonatalforeningen [The Swedish Neonatal Association, NAT RIKTL UPPF NEON; te Velde A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101599; Tell J., 2019, SWEDISH CHILD HLTH S; The National Board of Health and Welfare, 2016, STAT PREGN DEL NEWB; Wallby T, 2011, ACTA PAEDIATR, V100, P1495, DOI 10.1111/j.1651-2227.2011.02344.x	33	3	3	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2021	16	6							e0253846	10.1371/journal.pone.0253846	http://dx.doi.org/10.1371/journal.pone.0253846			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9CN	34170965	Green Published, gold			2023-01-03	WOS:000671694400035
J	Truong, K; Park, S; Tsiros, MD; Milne, N				Truong, Kim; Park, Sandra; Tsiros, Margarita D.; Milne, Nikki			Physiotherapy and related management for childhood obesity: A systematic scoping review	PLOS ONE			English	Review							PHYSICAL-ACTIVITY INTERVENTION; SCHOOL-BASED INTERVENTION; BODY-MASS INDEX; CARDIOVASCULAR RISK-FACTORS; FUNDAMENTAL MOVEMENT SKILLS; PROMOTE SIMILAR BENEFITS; LIFE-STYLE INTERVENTION; CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; ACTIVITY PROGRAM	Introduction Despite targeted efforts globally to address childhood overweight/obesity, it remains poorly understood and challenging to manage. Physiotherapists have the potential to manage children with obesity as they are experts in movement and physical activity. However, their role remains unclear due to a lack of physiotherapy-specific guidelines. This scoping review aims to explore existing literature, critically appraising and synthesising findings to guide physiotherapists in the evidence-based management of childhood overweight/obesity. Method A scoping review was conducted, including literature up to May 2020. A review protocol exists on Open Science Framework at https://osf.io/fap8g/. Four databases were accessed including PubMed, Embase, CINAHL, Medline via OVID, with grey literature searched through google via "file:pdf". A descriptive synthesis was undertaken to explore the impact of existing interventions and their efficacy. Results From the initial capture of 1871 articles, 263 intervention-based articles were included. Interventions included qualitative focused physical activity, quantitative focused physical activity and multicomponent interventions. Various outcome measures were utilised including health-, performance- and behaviour-related outcomes. The general trend for physiotherapy involvement with children who are obese appears to favour: 1) multicomponent interventions, implementing more than one component with environmental modification and parental involvement and 2) quantitative physical activity interventions, focusing on the quantity of bodily movement. These approaches most consistently demonstrated desirable changes across behavioural and health-related outcome measures for multicomponent and quantitative physical activity interventions respectively. Conclusion When managing children with obesity, physiotherapists should consider multicomponent approaches and increasing the quantity of physical activity, given consistent improvements in various obesity-related outcomes. Such approaches are well suited to the scope of physiotherapists and their expertise in physical activity prescription for the management of childhood obesity. Future research should examine the effect of motor skill interventions and consider the role of environmental modification/parental involvement as factors contributing to intervention success.	[Truong, Kim; Park, Sandra; Milne, Nikki] Bond Univ, Bond Inst Hlth & Sport, Fac Hlth Sci & Med, Gold Coast, Qld, Australia; [Tsiros, Margarita D.] Univ South Australia, UniSA Allied Hlth & Human Performance, Alliance Res Exercise Nutr & Act, Adelaide, SA, Australia	Bond University; University of South Australia	Milne, N (corresponding author), Bond Univ, Bond Inst Hlth & Sport, Fac Hlth Sci & Med, Gold Coast, Qld, Australia.	nmilne@bond.edu.au	Tsiros, Margarita/F-4205-2013	Tsiros, Margarita/0000-0001-5359-3776; Milne, Nikki/0000-0002-5121-9825				Abbott A, 1998, SOCIOL METHOD RES, V27, P148, DOI 10.1177/0049124198027002002; Aires L, 2016, ANN HUM BIOL, V43, P183, DOI 10.3109/03014460.2015.1059889; Al-Khudairy L, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012691; Alexander AG, 2014, OBESITY, V22, P249, DOI 10.1002/oby.20557; Alonso-Fernandez D, 2019, SCI SPORT; Alves ASR, 2019, AN ACAD BRAS CIENC, V91, DOI 10.1590/0001-3765201920181264; Bianchini JAA, 2013, EUR J PEDIATR, V172, P215, DOI 10.1007/s00431-012-1865-7; An JH, 2019, DISABIL HEALTH J, V12, P727, DOI 10.1016/j.dhjo.2019.03.012; Andrade A, 2019, CYBERPSYCH BEH SOC N, V22, P724, DOI 10.1089/cyber.2019.0341; Angelopoulos PD, 2009, EUR J PUBLIC HEALTH, V19, P319, DOI 10.1093/eurpub/ckp004; [Anonymous], 2017, INT J ENV RES PUBLIC; APA, 2013, HLTH WELLBEING CHILD; APA, SCOPE PRACTICE POSIT; APPT, FACT SHEET ROLE SCOP; APTA, CLIN RECOMMENDATIONS; Ariza C, 2019, J NUTR, V149, P258, DOI 10.1093/jn/nxy259; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Ashem HN, 2019, ANN CLIN ANAL MED, V10, P496, DOI 10.4328/ACAM.6027; Atlantis E, 2006, INT J OBESITY, V30, P1027, DOI 10.1038/sj.ijo.0803286; Augustijn MJCM, 2019, HUM BRAIN MAPP, V40, P137, DOI 10.1002/hbm.24360; Augustijn MJCM, 2018, J DEV BEHAV PEDIATR, V39, P642, DOI [10.1097/dbp.0000000000000589, 10.1097/DBP.0000000000000589]; Azad Ahmad, 2011, Tanaffos, V10, P24; Bagby Karen, 2007, J Sch Nurs, V23, P137, DOI 10.1177/10598405070230030301; Bai Y, 2017, AM J PREV MED, V52, P311, DOI 10.1016/j.amepre.2016.10.009; Baker JL, 2007, NEW ENGL J MED, V357, P2329, DOI 10.1056/NEJMoa072515; Garcia NB, 2019, QUAL LIFE RES, V28, P1803, DOI 10.1007/s11136-019-02141-9; Baranowski T, 2010, NEW ENGL J MED, V363, P443, DOI 10.1056/NEJMoa1001933; Barbeau P, 1999, AM J CLIN NUTR, V69, P705; Bedard C, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00094; Benjamins MR, 2010, J SCHOOL HEALTH, V80, P378, DOI 10.1111/j.1746-1561.2010.00517.x; Bharath LP, 2018, EUR J APPL PHYSIOL, V118, P1653, DOI 10.1007/s00421-018-3898-8; Bhave S, 2016, ARCH DIS CHILD, V101, P33, DOI 10.1136/archdischild-2015-308673; Bilinska I, 2017, ANTHROPOL ANZ, V74, P89, DOI 10.1127/anthranz/2017/0719; Brand C, 2020, J SPORT SCI, V38, P682, DOI 10.1080/02640414.2020.1725384; Braun HA, 2017, PUBLIC HEALTH REP, V132, p24S, DOI 10.1177/0033354917719701; Brown EC, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4902714; BROWNELL KD, 1983, PEDIATRICS, V71, P515; BROWNELL KD, 1982, AM J CLIN NUTR, V35, P277, DOI 10.1093/ajcn/35.2.277; Bryan Charity, 2013, NASN Sch Nurse, V28, P20; Burgi F, 2012, PREV MED, V54, P335, DOI 10.1016/j.ypmed.2012.02.007; Burguera B, 2011, OBESITY FACTS, V4, P400, DOI 10.1159/000333436; Cadzow RB, 2015, J COMMUN HEALTH, V40, P709, DOI 10.1007/s10900-015-9989-0; Camhi SM, 2011, J SCHOOL HEALTH, V81, P409, DOI 10.1111/j.1746-1561.2011.00609.x; Canavera M, 2009, INT Q COMMUNITY HEAL, V29, P57, DOI 10.2190/IQ.29.1.e; Carnier J, 2012, PHYSIOL BEHAV, V105, P175, DOI 10.1016/j.physbeh.2011.08.014; Carrel AL, 2005, ARCH PEDIAT ADOL MED, V159, P963, DOI 10.1001/archpedi.159.10.963; Carvalho HM, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/618595; CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126; Chehab LG, 2007, J ADOLESCENT HEALTH, V40, P474, DOI 10.1016/j.jadohealth.2006.12.009; Chen XL, 2008, CIRCULATION, V117, P3171, DOI 10.1161/CIRCULATIONAHA.107.730366; Chilton JM., 2012, EFFECT TOTAL GIRL WE; Chomitz VR, 2010, OBESITY, V18, pS45, DOI 10.1038/oby.2009.431; Cislak A, 2012, CHILD CARE HLTH DEV, V38, P321, DOI 10.1111/j.1365-2214.2011.01285.x; Clark ML, 2008, AM J NURSE PRACTITIO, V12, P62; Cluss P, 2016, AM J HEALTH EDUC, V47, P343, DOI 10.1080/19325037.2016.1219287; COHEN CJ, 1991, J SPORT MED PHYS FIT, V31, P183; Cohen TR, 2018, APPETITE, V125, P81, DOI 10.1016/j.appet.2018.01.017; Cohen TR, 2017, CALCIFIED TISSUE INT, V101, P612, DOI 10.1007/s00223-017-0318-8; Coknaz D, 2019, EUR J PEDIATR, V178, P1567, DOI 10.1007/s00431-019-03457-x; Colquitt JL, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012105; Corbin C. B., 2000, PRESIDENTS COUNCIL P; Cordova A, 2012, REV ESP CARDIOL, V65, P620, DOI [10.1016/j.rec.2012.01.028, 10.1016/j.recesp.2012.01.026]; CPA, 2006, PHYS ACTIVITY YOUTH; Craike M, 2018, INT J BEHAV NUTR PHY, V15, DOI 10.1186/s12966-018-0676-2; Crouter SE, 2017, J SPORT SCI, V35, P1034, DOI 10.1080/02640414.2016.1209305; Crova C, 2014, J SPORT SCI, V32, P201, DOI 10.1080/02640414.2013.828849; CSP, 2015, PHYSIOTHERAPY WORKS; CSP, 2015, PHYSIOTHERAPY WORKS; Cvetkovic N, 2018, SCAND J MED SCI SPOR, V28, P18, DOI 10.1111/sms.13241; da Silva DF, 2015, APPETITE, V87, P229, DOI 10.1016/j.appet.2014.12.221; Campos RMD, 2017, J SPORT MED PHYS FIT, V57, P831, DOI 10.23736/S0022-4707.16.06235-6; Dauenhauer B, 2016, J PRIM PREV, V37, P313, DOI 10.1007/s10935-016-0430-y; Davis CL, 2007, RES Q EXERCISE SPORT, V78, P510, DOI 10.5641/193250307X13082512817660; De Bourdeaudhuij I, 2011, OBES REV, V12, P205, DOI 10.1111/j.1467-789X.2009.00711.x; Miguel-Etayo P, 2015, NUTR HOSP, V32, P2525, DOI 10.3305/nh.2015.32.6.9663; de Vries AGM, 2015, ACTA PAEDIATR, V104, P414, DOI 10.1111/apa.12880; Deitz Jean C, 2007, Phys Occup Ther Pediatr, V27, P87, DOI 10.1300/J006v27n04_06; Deldin A, 2019, CHILD OBES, V15, P216, DOI 10.1089/chi.2018.0329; Delgado-Floody P, 2019, J EXERC SCI FIT, V17, P35, DOI 10.1016/j.jesf.2018.11.003; Delgado-Floody P, 2018, EUR J PEDIATR, V177, P1019, DOI 10.1007/s00431-018-3149-3; Derenne C, 2008, J CANCER EDUC, V23, P230, DOI 10.1080/08858190802188602; Dhar P, 2016, APPL ECON LETT, V23, P584, DOI 10.1080/13504851.2015.1090541; Di Pietro Mario, 2004, Acta Biomed, V75, P118; Dias KA, 2015, PEDIATRICS, V136, pE648, DOI 10.1542/peds.2015-0616; DIMDI, 2005, INT CLASS FUNCT DIS; Doak CM, 2006, OBES REV, V7, P111, DOI 10.1111/j.1467-789X.2006.00234.x; Domaradzki J, 2020, INT J ENV RES PUBLIC, V17; Donnelly JE, 1996, OBES RES, V4, P229, DOI 10.1002/j.1550-8528.1996.tb00541.x; Ebbeling CB, 2002, LANCET, V360, P473, DOI 10.1016/S0140-6736(02)09678-2; ECOG, 2015, PHYS ACTIVITY PLAY C; ECOG, PHYS ACTIVITY PLAY C; Edmunds LD, 2005, FAM PRACT, V22, P287, DOI 10.1093/fampra/cmh729; Eichner JE, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/pcd13.150495; Elder JP, 2011, ADV NUTR, V2, p171S, DOI 10.3945/an.111.000380; Engel AC, 2018, SPORTS MED, V48, P1845, DOI 10.1007/s40279-018-0923-3; EPSTEIN LH, 1983, AM J DIS CHILD, V137, P654, DOI 10.1001/archpedi.1983.02140330038010; Erfle SE, 2015, J SCHOOL HEALTH, V85, P27, DOI 10.1111/josh.12217; Errisuriz VL, 2018, J PRIM PREV, V39, P303, DOI 10.1007/s10935-018-0507-x; Faigenbaum AD, 2013, STRENGTH COND J, V35, P34, DOI 10.1519/SSC.0b013e318285618c; Farah BQ, 2014, PEDIATR OBES, V9, P111, DOI 10.1111/j.2047-6310.2012.00145.x; Farias ED, 2015, J PEDIAT-BRAZIL, V91, P122, DOI 10.1016/j.jped.2014.06.004; Feng L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184704; Flatt JP, 2011, OBESITY, V19, P676, DOI 10.1038/oby.2011.7; Fogel VA, 2010, J APPL BEHAV ANAL, V43, P591, DOI 10.1901/jaba.2010.43-591; Freedman DS, 2008, INT J OBESITY, V32, P749, DOI 10.1038/sj.ijo.0803798; Freedman DS, 1999, PEDIATRICS, V103, P1175, DOI 10.1542/peds.103.6.1175; Freedman DS, 2001, PEDIATRICS, V108, P712, DOI 10.1542/peds.108.3.712; Friedemann C, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4759; Gallotta MC, 2016, PEERJ, V4, DOI 10.7717/peerj.1880; Gao Z., 2019, J CLIN MED, V8; Gao Z, 2017, J SPORT HEALTH SCI, V6, P11, DOI 10.1016/j.jshs.2016.11.008; Garcia-Hermoso A, 2016, OBES REV, V17, P531, DOI 10.1111/obr.12395; Garcia-Hermoso A, 2019, J SCI MED SPORT, V22, P76, DOI 10.1016/j.jsams.2018.07.006; Garcia-Hermoso A, 2018, BEHAV SCI, V8, DOI 10.3390/bs8010009; Garcia-Hermoso A, 2016, PEDIATR RES, V79, P522, DOI 10.1038/pr.2015.274; Gentier I, 2015, ACTA PAEDIATR, V104, pE263, DOI 10.1111/apa.12899; Gesell SB, 2010, CLIN PEDIATR, V49, P323, DOI 10.1177/0009922809339386; Going S, 2003, PREV MED, V37, pS62, DOI 10.1016/j.ypmed.2003.08.005; Golan M, 2006, INT J PEDIATR OBES, V1, P66, DOI 10.1080/17477160600644272; Silva HJG, 2015, J PHYS ACT HEALTH, V12, P553, DOI 10.1123/jpah.2013-0199; Gortmaker SL, 1999, ARCH PEDIAT ADOL MED, V153, P409, DOI 10.1001/archpedi.153.4.409; Graf C, 2006, CARDIOL YOUNG, V16, P474, DOI 10.1017/S1047951106000667; Grimmer K, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-63; Guerendiain M, 2018, CLIN NUTR, V37, P149, DOI 10.1016/j.clnu.2016.11.006; Guerra PH, 2016, J PEDIAT-BRAZIL, V92, P15, DOI 10.1016/j.jped.2015.06.005; Gutin B, 2008, INT J PEDIATR OBES, V3, P3, DOI 10.1080/17477160801896457; HALFON ST, 1988, ADOLESCENCE, V23, P405; Halliday JA, 2014, INT J OBESITY, V38, P480, DOI 10.1038/ijo.2013.213; Han A, 2018, J SCI MED SPORT, V21, P89, DOI 10.1016/j.jsams.2017.07.001; Harrell JS, 1998, PEDIATRICS, V102, P371, DOI 10.1542/peds.102.2.371; Harris KC, 2009, CAN MED ASSOC J, V180, P719, DOI 10.1503/cmaj.080966; Harrison M, 2006, J SCI MED SPORT, V9, P388, DOI 10.1016/j.jsams.2006.06.012; Hawthorne A, 2011, J SCH NURS, V27, P43, DOI 10.1177/1059840510391669; HAYASHI T, 1987, INT J OBESITY, V11, P465; HILLS AP, 1988, CHILD CARE HLTH DEV, V14, P409, DOI 10.1111/j.1365-2214.1988.tb00592.x; Hintze LJ, 2012, ACTA SCI-HEALTH SCI, V34, P137, DOI 10.4025/actascihealthsci.v34i2.8934; Hollis JL, 2016, INT J OBESITY, V40, P1486, DOI 10.1038/ijo.2016.107; Hong QN, 2018, EDUC INFORM, V34, P285, DOI 10.3233/EFI-180221; Horsak B, 2019, GAIT POSTURE, V70, P122, DOI 10.1016/j.gaitpost.2019.02.032; Hystad HT, 2013, BRIT J NUTR, V110, P1143, DOI 10.1017/S0007114513000056; Inoue DS, 2015, J DIABETES COMPLICAT, V29, P258, DOI 10.1016/j.jdiacomp.2014.11.002; Irwin CC, 2010, J SCHOOL HEALTH, V80, P333, DOI 10.1111/j.1746-1561.2010.00510.x; Jakubowski TL, 2018, MCN-AM J MATERN-CHIL, V43, P278, DOI 10.1097/NMC.0000000000000463; Jansen W, 2011, INT J PEDIATR OBES, V6, pE70, DOI 10.3109/17477166.2011.575151; Jiang J, 2007, CHILD CARE HLTH DEV, V33, P641, DOI 10.1111/j.1365-2214.2007.00738.x; Jones M, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.2995; Jones M, 2020, J SPORT HEALTH SCI, V9, P3, DOI 10.1016/j.jshs.2019.06.009; Jones RA, 2015, PEDIATR EXERC SCI, V27, P535, DOI 10.1123/pes.2015-0116; Juhola J, 2011, J PEDIATR-US, V159, P584, DOI 10.1016/j.jpeds.2011.03.021; Julian V, 2019, SCAND J MED SCI SPOR, V29, P4, DOI 10.1111/sms.13301; Jurg ME, 2006, HEALTH PROMOT INT, V21, P320, DOI 10.1093/heapro/dal032; Kain J, 2004, INT J OBESITY, V28, P483, DOI 10.1038/sj.ijo.0802611; Kain J, 2014, J OBES, V2014, DOI 10.1155/2014/618293; Karacabey K, 2009, J INT MED RES, V37, P1472, DOI 10.1177/147323000903700523; Kaufman C, 2007, PEDIATR EXERC SCI, V19, P82, DOI 10.1123/pes.19.1.82; Khammassi M, 2019, PHYSIOL BEHAV, V210, DOI 10.1016/j.physbeh.2019.05.010; King AK, 2019, CHILDREN-BASEL, V6, DOI 10.3390/children6090099; Kirschenbaum DS, 2005, OBES RES, V13, P1527, DOI 10.1038/oby.2005.187; Klakk H, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-170; Kriemler S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c785; Krombholz H, 2012, PERCEPT MOTOR SKILL, V115, P919, DOI 10.2466/06.10.25.PMS.115.6.919-932; Kuhr P, 2020, ACTA PAEDIATR, V109, P595, DOI 10.1111/apa.15005; Labayen I, 2020, DIABETES CARE, V43, P306, DOI 10.2337/dc19-0351; Lakshman R, 2012, CIRCULATION, V126, P1770, DOI 10.1161/CIRCULATIONAHA.111.047738; Lambrick D, 2016, J SPORT SCI, V34, P190, DOI 10.1080/02640414.2015.1048521; Larsen KT, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0627-5; Lau PWC, 2015, EUR J SPORT SCI, V15, P182, DOI 10.1080/17461391.2014.933880; Lee S, 2019, J PEDIATR-US, V206, P91, DOI 10.1016/j.jpeds.2018.10.059; Lee SS, 2015, J PHYS THER SCI, V27, P1903, DOI 10.1589/jpts.27.1903; Leite N, 2009, BRAZ J PHYS THER, V13, P73, DOI 10.1590/S1413-35552009005000009; Leite N, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-7; Li XH, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1282; Liang J, 2014, INT J OBESITY, V38, P494, DOI 10.1038/ijo.2013.142; Lobelo F, 2013, J SCHOOL HEALTH, V83, P668, DOI 10.1111/josh.12080; LoMauro A, 2016, APPL PHYSIOL NUTR ME, V41, P649, DOI 10.1139/apnm-2015-0269; Lopera CA, 2016, PHYSIOL BEHAV, V165, P365, DOI 10.1016/j.physbeh.2016.08.019; Lopes WA, 2016, J SPORT SCI, V34, P1902, DOI 10.1080/02640414.2016.1142107; Lowry KW, 2007, J PEDIATR PSYCHOL, V32, P1179, DOI 10.1093/jpepsy/jsm048; Lubans DR, 2010, SPORTS MED, V40, P1019, DOI 10.2165/11536850-000000000-00000; Magnani Branco BH., 2018, J STRENGTH COND RES; Branco BHM, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01013; Manley D, 2014, J PEDIATR NURS, V29, P228, DOI 10.1016/j.pedn.2013.10.011; Mardones F, 2017, J NUTR SCI, V6, DOI 10.1017/jns.2017.14; Marild S, 2013, PEDIATR OBES, V8, P207, DOI 10.1111/j.2047-6310.2012.00105.x; Martinez-Lopez EJ, 2012, J SPORT SCI MED, V11, P312; Matvienko O, 2010, AM J HEALTH PROMOT, V24, P299, DOI 10.4278/ajhp.08050146; Mead E, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012651; Meyer U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087929; Militao AG, 2013, DIABETES METAB SYNDR, V6, P445, DOI 10.2147/DMSO.S52166; Miller TA, 2013, GAMES HEALTH J, V2, P96, DOI 10.1089/g4h.2012.0058; Milne N, 2016, AUST J PRIM HEALTH, V22, P140, DOI 10.1071/PY14101; Mistry K, 2019, BMC MED EDUC, V19, DOI 10.1186/s12909-019-1540-z; Molina-Garcia P, 2019, MED SCI SPORT EXER; Monsalves-Alvarez M, 2015, NUTR HOSP, V32, P1576, DOI 10.3305/nh.2015.32.4.9514; Monteiro PA, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0152-9; Morano M, 2014, J SPORT SCI, V32, P345, DOI 10.1080/02640414.2013.824602; Morgan EH, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012547.pub2; Morrison JA, 2009, METABOLISM, V58, P1277, DOI 10.1016/j.metabol.2009.04.009; Muller I, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16020232; Naul R, 2012, FAM PRACT, V29, pi110, DOI 10.1093/fampra/cmr097; Nayak BS, 2016, J CLIN DIAGN RES, V10, pSC24, DOI 10.7860/JCDR/2016/23766.9116; Nemet D, 2006, INT J SPORTS MED, V27, P666, DOI 10.1055/s-2005-872920; Neumark-Sztainer DR, 2010, AM J PREV MED, V39, P421, DOI 10.1016/j.amepre.2010.07.017; Ng M, 2014, LANCET, V384, P746; NHMRC, 2013, CLIN PRACT GUID MAN; NHMRC, 2013, SUMMARY GUIDE MANAGE; NHMRC, 2013, SUMM GUID MAN OV OB; NHMRC, 2013, CLIN PRACTIVE GUIDEL; NICE, 2015, OBESITY CHILDREN YOU; NICE, 2006, GUIDANCE PREVENTION; NICE, 2006, GUIDANCE PREVENTION; NICE, 2015, OBESITY CHILDREN YOU; NICHOLS JF, 1989, INT J OBESITY, V13, P683; Niemeier BS, 2012, PREV MED, V55, P3, DOI 10.1016/j.ypmed.2012.04.021; Nobre GG, 2017, J STRENGTH COND RES, V31, P2091, DOI 10.1519/JSC.0000000000001684; Nogueira RC, 2014, BONE, V68, P92, DOI 10.1016/j.bone.2014.08.006; Nunez-Gaunaurd A, 2011, HPA RESOURCE, V11, pJ2; Nystrom CD, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5569-4; Nystrom CD, 2017, AM J CLIN NUTR, V105, P1327, DOI 10.3945/ajcn.116.150995; Oliveira CB, 2020, SCAND J MED SCI SPOR, V30, P4, DOI 10.1111/sms.13539; Olvera N, 2010, OBESITY, V18, pS102, DOI 10.1038/oby.2009.439; Oude Luttikhuis H, 2009, EVID BASED CHILD HLT, V4, P1571, DOI DOI 10.1002/EBCH.462; Paravidino VB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147141; Park Kyung-Shin, 2015, J Exerc Nutrition Biochem, V19, P81, DOI 10.5717/jenb.2015.15052005; Park TG, 2007, ANN NUTR METAB, V51, P197, DOI 10.1159/000104137; Paulis WD, 2014, OBES REV, V15, P52, DOI 10.1111/obr.12067; Peralta LR, 2009, PREV MED, V48, P537, DOI 10.1016/j.ypmed.2009.04.007; Peters MDJ, 2015, INT J EVID-BASED HEA, V13, P141, DOI 10.1097/XEB.0000000000000050; Porta M.S., 2014, DICT EPIDEMIOLOGY, V6th; Prosper M, 2009, CALIFORNIAN J HLTH P, V7, P1; Puder JJ, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6195; Quinn M, 2013, J PEDIATR HEALTH CAR, V27, P3, DOI 10.1016/j.pedhc.2011.03.011; Racil G, 2017, J ENDOCRINOL INVEST, V40, P1227, DOI 10.1007/s40618-017-0689-8; Racil G, 2016, APPL PHYSIOL NUTR ME, V41, P103, DOI 10.1139/apnm-2015-0384; Rajjo T, 2017, J CLIN ENDOCR METAB, V102, P763, DOI 10.1210/jc.2016-2574; Rauber Suliane Beatriz, 2018, Nutrition and Health (Bicester), V24, P145, DOI 10.1177/0260106018771519; Reed JA, 2013, J PHYS ACT HEALTH, V10, P185, DOI 10.1123/jpah.10.2.185; Regaieg Sofien, 2013, Indian J Endocrinol Metab, V17, P1040, DOI 10.4103/2230-8210.122619; Reilly JJ, 2003, ARCH DIS CHILD, V88, P748, DOI 10.1136/adc.88.9.748; Reznik M, 2015, CHILD OBES, V11, P314, DOI 10.1089/chi.2014.0090; Robinson E, 2017, PSYCHOL SCI, V28, P320, DOI 10.1177/0956797616682027; Rofey DL, 2009, J PEDIATR PSYCHOL, V34, P156, DOI 10.1093/jpepsy/jsn057; Rosenkranz RR, 2008, NUTR REV, V66, P123, DOI 10.1111/j.1753-4887.2008.00017.x; Rosner B, 2009, HYPERTENSION, V54, P502, DOI 10.1161/HYPERTENSIONAHA.109.134049; ROWLAND TW, 1991, J ADOLESCENT HEALTH, V12, P30, DOI 10.1016/0197-0070(91)90037-M; Ruebel Meghan L, 2011, Int J Exerc Sci, V4, P217; Sacchetti R, 2013, J SCHOOL HEALTH, V83, P639, DOI 10.1111/josh.12076; Sadeghi B, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6897-8; Saenz KH., 2003, USE HEART RATE MONIT; Safdie M, 2013, SALUD PUBLICA MEXICO, V55, pS374; Sahoo Krushnapriya, 2015, J Family Med Prim Care, V4, P187, DOI 10.4103/2249-4863.154628; Aguilar FS, 2010, J PEDIATR-US, V157, P36, DOI 10.1016/j.jpeds.2009.12.046; SALLIS JF, 1993, ANN NY ACAD SCI, V699, P127, DOI 10.1111/j.1749-6632.1993.tb18844.x; Salmon J, 2007, EPIDEMIOL REV, V29, P144, DOI 10.1093/epirev/mxm010; Scheffler C, 2007, ANTHROPOL ANZ, V65, P193, DOI 10.1127/anthranz/65/2007/193; Schwanke NL, 2016, MANUAL THER, V22, P138, DOI 10.1016/j.math.2015.11.004; Seabra A, 2016, J SPORT SCI, V34, P1822, DOI 10.1080/02640414.2016.1140219; SELTZER CC, 1970, AM J PUBLIC HEALTH N, V60, P679, DOI 10.2105/AJPH.60.4.679; Sepulveda AR, 2020, EUR EAT DISORD REV, V28, P184, DOI 10.1002/erv.2702; Serra-Paya N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144502; Sharma M, 2006, OBES REV, V7, P261, DOI 10.1111/j.1467-789X.2006.00227.x; Shofan Y, 2011, EUR J CLIN NUTR, V65, P768, DOI 10.1038/ejcn.2011.25; Siegrist M, 2013, SCAND J MED SCI SPOR, V23, P323, DOI 10.1111/j.1600-0838.2011.01387.x; Sigmund E, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-570; Silveira DS, 2018, J SPORT SCI, V36, P2317, DOI 10.1080/02640414.2018.1452142; Singh AS, 2009, ARCH PEDIAT ADOL MED, V163, P309, DOI 10.1001/archpediatrics.2009.2; Singh AS, 2007, ARCH PEDIAT ADOL MED, V161, P565, DOI 10.1001/archpedi.161.6.565; Slawta J, 2008, HEALTH PROMOT PRACT, V9, P305, DOI 10.1177/1524839906289221; Sleddens EFC, 2011, INT J PEDIATR OBES, V6, pE12, DOI 10.3109/17477166.2011.566339; Smith JJ, 2018, MENT HEALTH PHYS ACT, V15, P88, DOI 10.1016/j.mhpa.2018.08.002; Smith JJ, 2016, J SPORT SCI, V34, P772, DOI 10.1080/02640414.2015.1069383; Sollerhed AC, 2008, SCAND J MED SCI SPOR, V18, P102, DOI 10.1111/j.1600-0838.2007.00636.x; Son WM, 2017, CLIN EXP HYPERTENS, V39, P546, DOI 10.1080/10641963.2017.1288742; Song JK, 2012, J SPORT MED PHYS FIT, V52, P522; SOUTHAM MA, 1984, ADOLESCENCE, V19, P855; SPEAKER JG, 1983, INT J OBESITY, V7, P73; SPRINGER NS, 1973, MENT RETARD, V11, P20; Steinberg N, 2017, PEDIATR PHYS THER, V29, P330, DOI 10.1097/PEP.0000000000000440; Steinberg N, 2013, EUR J PEDIATR, V172, P1619, DOI 10.1007/s00431-013-2090-8; Stodden DF, 2008, QUEST, V60, P290, DOI 10.1080/00336297.2008.10483582; Stuart Wilma Powell, 2005, J Sch Nurs, V21, P77, DOI 10.1177/10598405050210020401; Sun C, 2013, OBES REV, V14, P818, DOI 10.1111/obr.12047; Sung KD, 2019, EUR J APPL PHYSIOL, V119, P577, DOI 10.1007/s00421-018-4051-4; Tan SJ, 2010, PEDIATR EXERC SCI, V22, P477, DOI 10.1123/pes.22.3.477; Taylor Mary Jean, 2005, Pediatr Phys Ther, V17, P180, DOI 10.1097/01.PEP.0000176576.94482.9a; Telford RD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076124; Ten Hoor GA, 2018, INT J BEHAV NUTR PHY, V15, DOI 10.1186/s12966-018-0727-8; Thivel D, 2011, EUR J PEDIATR, V170, P1435, DOI 10.1007/s00431-011-1466-x; Togashi K, 2010, RES SPORTS MED, V18, P62, DOI 10.1080/15438620903423924; Tomiyama AJ, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1116-5; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Tsiros MD, 2011, OBES REV, V12, P26, DOI 10.1111/j.1467-789X.2009.00706.x; Tsiros MD, 2019, PHYS THER, V99, P490, DOI 10.1093/ptj/pzz016; Tucker JM, 2014, J OBES, V2014, DOI 10.1155/2014/370403; Twig G, 2016, NEW ENGL J MED, V374, P2430, DOI 10.1056/NEJMoa1503840; Tzou IL, 2012, PARENTAL INFLUENCE C; Vajda I, 2007, ACTA PHYSIOL HUNG, V94, P191, DOI 10.1556/APhysiol.94.2007.3.4; van Middelkoop M, 2017, FAM PRACT, V34, P702, DOI 10.1093/fampra/cmx056; van Sluijs EMF, 2007, BMJ-BRIT MED J, V335, P703, DOI 10.1136/bmj.39320.843947.BE; Vasconcellos F, 2016, J SPORT SCI, V34, P564, DOI 10.1080/02640414.2015.1064150; Vasconcellos F, 2014, SPORTS MED, V44, P1139, DOI 10.1007/s40279-014-0193-7; Vignolo M, 2008, EUR J CLIN NUTR, V62, P1047, DOI 10.1038/sj.ejcn.1602819; Villa-Gonzalez E, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3934-8; Vissers D, 2008, EUR E J CLIN NUTR ME, V3, pe196; Vizcaino VM, 2008, INT J OBESITY, V32, P12, DOI 10.1038/sj.ijo.0803738; Volger S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209787; Nga VT, 2019, DIABETES METAB SYND, V13, P2495, DOI 10.1016/j.dsx.2019.07.014; Wadley, 2006, AUSTR OCCUPATIONAL T, V53, P27, DOI DOI 10.1111/J.1440-1630.2006.00537.X; Walther C, 2009, CIRCULATION, V120, P2251, DOI 10.1161/CIRCULATIONAHA.109.865808; Wang JJ, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2535-2; Wanless E, 2014, SCI WORLD J, DOI 10.1155/2014/370759; WCPT, 2018, PROMOTING PHYS ACTIV; Webber LS, 1996, PREV MED, V25, P432, DOI 10.1006/pmed.1996.0075; Whipp B J, 1971, J Sports Med Phys Fitness, V11, P146; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Willi SM, 2012, PEDIATR OBES, V7, P230, DOI 10.1111/j.2047-6310.2011.00042.x; Wong PCH, 2008, ANN ACAD MED SINGAP, V37, P286; World Health Organization, TAKING ACTION CHILDH; World Health Organization, 2021, INJ VIOL; World Health Organization, 2004, GLOB STRAT DIET PHYS; WPTD, RESOURCES WHY PHYS T; Wright K, 2013, INT J NURS STUD, V50, P727, DOI 10.1016/j.ijnurstu.2012.09.004; Yetgin MK, 2018, J PAK MED ASSOC, V68, P929; Yin ZN, 2012, CHILD OBES, V8, P60, DOI 10.1089/chi.2011.0085; Yuksel HS, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010347; Zenzen W, 2009, J PEDIATR HEALTH CAR, V23, P242, DOI 10.1016/j.pedhc.2008.04.008; Zguira MS, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16050751; Zhang H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18086-3; Zhou ZX, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-118; Ziviani J, 2008, AUST OCCUP THER J, V55, P2, DOI 10.1111/j.1440-1630.2006.00646.x; Zorba E, 2011, J SPORT MED PHYS FIT, V51, P664	331	0	0	4	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2021	16	6							e0252572	10.1371/journal.pone.0252572	http://dx.doi.org/10.1371/journal.pone.0252572			37	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6SI	34125850	Green Accepted, Green Published, gold			2023-01-03	WOS:000664643500008
J	Gyasi, RM; Frimpong, S; Amoako, GK; Adam, AM				Gyasi, Razak M.; Frimpong, Siaw; Amoako, Gilbert Kwabena; Adam, Anokye M.			Financial inclusion and physical health functioning among aging adults in the sub-Saharan African context: Exploring social networks and gender roles	PLOS ONE			English	Article							SELF-RATED HEALTH; IMPACT; EMPOWERMENT; IMPAIRMENT; BENEFITS; SERVICES	Background It remains poorly understood how financial inclusion influences physical health functioning in later life in sub-Saharan African context and whether the association differs by gender and social relationships. We aim 1) to examine the associations of financial inclusion with functional impairment during older age in Ghana; and 2) to evaluate whether gender and social networks modify this association. Methods The cross-sectional analyses are based on a sample (N = 1,201) of study participants aged 50 years and over (M = 66.5 years, SD = 11.9, 63.3% female) deriving from the 2016-2017 AgeHeaPsyWel-HeaSeeB Study. Ordinary least squares (OLS) regression analyses with interactions were performed to estimate the link between financial inclusion and functional health and how the association is modified by gender and older age social networks. Results The mean financial inclusion score was 1.66 (SD = 1.74) in women and 2.33 (SD = 1.82) in men whilst mean activities of daily living (ADL) score was 13.03 (SD = 4.99) and 14.85 (SD = 5.06) in women and men respectively. We found that financial inclusion was associated with decreases in ADL (total sample: beta = -.548, p < .001; women: <beta> = -.582, p < .001; men: <beta> = -1.082 p < .001) and instrumental ADL (IADL) (total sample: <beta> = -.359, p = .034; women: beta = -.445, p = .026 but not in men). Social networks significantly moderated the association of financial inclusion with ADL such that the financially included who were embedded in a stronger constellation of social networks were 6% less likely to report ADL impairment compared to those with weaker social networks (beta = -.062, p = .025). Conclusions The study provides empirical evidence for a better understanding of the association between financial inclusion and physical health functioning in the context of later life social networks. Interventions for functional health through financial inclusion in sub-Saharan Africa should include improving interpersonal and social networks for older adult and also through gender lenses.	[Gyasi, Razak M.] African Populat & Hlth Res Ctr APHRC, Nairobi, Kenya; [Frimpong, Siaw; Adam, Anokye M.] Univ Cape Coast, Sch Business, Dept Finance, Cape Coast, Ghana; [Amoako, Gilbert Kwabena] Kumasi Tech Univ, Dept Accountancy & Accounting Informat Syst, Kumasi, Ghana	African Population & Health Research Centre; University of Cape Coast	Gyasi, RM (corresponding author), African Populat & Hlth Res Ctr APHRC, Nairobi, Kenya.	RGyasi@aphrc.org	Frimpong, Siaw/AEO-6397-2022; Gyasi, Razak M/V-2309-2018; Adam, Anokye Mohammed/L-5818-2019	Gyasi, Razak M/0000-0002-6733-1539; Adam, Anokye Mohammed/0000-0003-3830-1186; Amoako, Dr Gilbert Kwabena/0000-0002-8428-5212	Lingnan University, Hong Kong [RPG 1129310]	Lingnan University, Hong Kong	This work was supported by Lingnan University, Hong Kong [RPG 1129310] to RMG (https://www.ln.edu.hk/about-lu/introducinglingnan).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott S, 2006, HEALTH SOC CARE COMM, V14, P1, DOI 10.1111/j.1365-2524.2005.00582.x; Agrigoroaei S, 2017, RES AGING, V39, P1075, DOI 10.1177/0164027516658502; Aguila E, 2016, ECON LETT, V144, P41, DOI 10.1016/j.econlet.2016.04.013; Aguila E, 2015, P NATL ACAD SCI USA, V112, P70, DOI 10.1073/pnas.1414453112; Allmark P, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1589-5; Allmark P, 2013, HEALTH SOC CARE COMM, V21, P59, DOI 10.1111/j.1365-2524.2012.01087.x; [Anonymous], 2015, Wkly Epidemiol Rec, V90, P33; Atkinson A., 2008, EVIDENCE IMPACT OVER; Babych Y, 2018, 849 ADBI; Bank World., 2016, GHAN ACC FIN NOT; Das PJ, 2022, EDUC PRIM CARE, DOI 10.1080/14739879.2022.2137856; Demirguc-Kunt A., 2018, GLOBAL FINDEX DATABA; Duvendack M, 2019, CAMPBELL SYST REV, V15, DOI 10.4073/csr.2019.2; Finkelstein A, 2012, Q J ECON, V127, P1057, DOI 10.1093/qje/qjs020; GEIGER M., 2019, ARXIV190608034; Grohmann A, 2018, WORLD DEV, V111, P84, DOI 10.1016/j.worlddev.2018.06.020; Gyasi R. M, 2018, THESIS LINGNAN U; Gyasi RM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229840; Gyasi RM, 2021, J APPL GERONTOL, V40, P189, DOI 10.1177/0733464820907441; Gyasi RM, 2020, GERONTOLOGIST, V60, P416, DOI 10.1093/geront/gnz052; Gyasi RM, 2019, RES AGING, V41, P794, DOI 10.1177/0164027519846604; Gyasi RM, 2019, WOMEN HEALTH, V59, P1089, DOI 10.1080/03630242.2019.1587666; Gyasi RM, 2018, ARCH GERONTOL GERIAT, V77, P174, DOI 10.1016/j.archger.2018.05.010; Hageman SA, 2019, SOC WORK PUBLIC HLTH, V34, P176, DOI 10.1080/19371918.2019.1575310; Hajek A, 2017, AGE AGEING, V46, P813, DOI 10.1093/ageing/afx012; Hamad R, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0194-7; Han SH, 2021, J GERONTOL B-PSYCHOL, V76, P360, DOI 10.1093/geronb/gbz161; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Kim YD, 2017, INT J STROKE, V12, P869, DOI 10.1177/1747493017694389; Krause N, 2011, J GERONTOL B-PSYCHOL, V66, P207, DOI 10.1093/geronb/gbq086; Lwanga S.K., 1991, SIZE ESTIMATION HLTH; McCracken K, 2017, GLOBALIZATION HEALTH, V2nd; Morrow-Howell N, 2014, FINANCIAL CAPABILITY; Nussbaum M.C., 2011, CREATING CAPABILITIE; Orton L, 2016, B WORLD HEALTH ORGAN, V94, P694, DOI 10.2471/BLT.15.168252; Paterson DH, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-38; Pearlin LI, 1996, GERONTOLOGIST, V36, P239, DOI 10.1093/geront/36.2.239; Raj A, 2018, SOC SCI MED, V196, P197, DOI 10.1016/j.socscimed.2017.11.042; Sarma M, 2011, J INT DEV, V23, P613, DOI 10.1002/jid.1698; Schneekloth U, 1993, POTENTIALS LIMITATIO; Shankar A, 2013, PSYCHOSOM MED, V75, P161, DOI 10.1097/PSY.0b013e31827f09cd; Stoeckel KJ, 2016, INT PSYCHOGERIATR, V28, P39, DOI 10.1017/S1041610215000538; Taylor M., 2009, OCCASIONAL PAPERS SE; Tevfik Bedirhan., 2010, MEASURING HLTH DISAB; Tomas MT, 2018, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00244; United Nations, 2015, TRANSF OUR WORLD 203; UNSGSA, 2019, UNSGSA ANN REP 2019; World Bank, 2018, FINANCIAL INCLUSION	48	1	1	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2021	16	6							e0252007	10.1371/journal.pone.0252007	http://dx.doi.org/10.1371/journal.pone.0252007			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SW6SA	34111127	Green Published, gold			2023-01-03	WOS:000664642700016
J	Chou, MSH; Ting, NCH; El-Turk, N; Harrington, Z; Dobler, CC				Chou, Michael S. H.; Ting, Natasha C. H.; El-Turk, Nicole; Harrington, Zinta; Dobler, Claudia C.			Treatment burden experienced by patients with obstructive sleep apnoea using continuous positive airway pressure therapy	PLOS ONE			English	Article							CPAP ADHERENCE; BARRIERS; EXERCISE; ACCEPTANCE	Background Little is known about the treatment burden experienced by patients with obstructive sleep apnoea (OSA) who use continuous positive airway pressure (CPAP) therapy. Participants 18 patients (33.3% males, mean age 59.711.8 years) with OSA who use CPAP therapy were interviewed. Methods Patients treated with CPAP for OSA at a tertiary hospital outpatient clinic in Sydney, Australia, were invited to participate in an interview in person or via phone. Semi-structured interviews were used to explore the treatment burden associated with using CPAP. The interviews were recorded, transcribed, and analysed using NVivo 12 qualitative analysis software. Results Four categories of OSA-specific treatment burden were identified: healthcare tasks, consequences of healthcare tasks, exacerbating and alleviating factors of treatment burden. Participants reported a significant burden associated with using CPAP, independently of how frequently they used their device. Common sources of their treatment burden included attending healthcare appointments, the financial cost of treatment, lifestyle changes, treatment-related side effects and general discomfort. Conclusions This study demonstrated that there is a significant treatment burden associated with the use of CPAP, and that treatment non-adherence is not the only consequence of treatment burden. Other consequences include relationship burden, stigma and financial burden. It is important for physicians to identify other negative impacts of treatment burden in order to optimise the patient experience.	[Chou, Michael S. H.; Ting, Natasha C. H.; El-Turk, Nicole; Harrington, Zinta; Dobler, Claudia C.] Liverpool Hosp, Dept Resp & Sleep Med, Sydney, NSW, Australia; [Chou, Michael S. H.; Ting, Natasha C. H.; El-Turk, Nicole; Harrington, Zinta; Dobler, Claudia C.] Univ New South Wales UNSW, South Western Sydney Clin Sch, Sydney, NSW, Australia; [Dobler, Claudia C.] Bond Univ, Inst Evidence Based Healthcare, Gold Coast, Qld, Australia; [Dobler, Claudia C.] Gold Coast Univ Hosp, Gold Coast, Qld, Australia	Liverpool Hospital; University of New South Wales Sydney; Bond University; Gold Coast University Hospital	Chou, MSH (corresponding author), Liverpool Hosp, Dept Resp & Sleep Med, Sydney, NSW, Australia.; Chou, MSH (corresponding author), Univ New South Wales UNSW, South Western Sydney Clin Sch, Sydney, NSW, Australia.	michaelcsh1718@gmail.com		El-Turk, Nicole/0000-0003-1112-9670; Chou, Michael/0000-0002-1537-4289; Dobler, Claudia/0000-0002-5460-0189	South Western Sydney Local Health District (SWSLHD)	South Western Sydney Local Health District (SWSLHD)	Claudia C. Dobler was supported by an award from the South Western Sydney Local Health District (SWSLHD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida FR, 2013, SLEEP BREATH, V17, P659, DOI 10.1007/s11325-012-0739-6; Baron KG, 2012, J CLIN SLEEP MED, V8, P147, DOI 10.5664/jcsm.1766; Brostrom A, 2010, SLEEP MED, V11, P126, DOI 10.1016/j.sleep.2009.04.010; Butner Katrina L, 2013, N Am J Med Sci, V5, P362, DOI 10.4103/1947-2714.114168; Dempsey JA, 2010, PHYSIOL REV, V90, P47, DOI 10.1152/physrev.00043.2008; Dobler CC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4065; EnableNSW, HOM RESP PROGR; Eton DT, 2015, PATIENT-RELAT OUTCOM, V6, P117, DOI 10.2147/PROM.S78955; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Galetke W, 2011, RESPIRATION, V82, P155, DOI 10.1159/000322838; Gallacher K, 2011, ANN FAM MED, V9, P235, DOI 10.1370/afm.1249; Harb N., 2015, INT J CHRONIC OBSTR, P1641, DOI [10.2147/COPD.S83596, DOI 10.2147/COPD.S83596]; Irvine A, 2013, QUAL RES, V13, P87, DOI 10.1177/1468794112439086; Justine M, 2013, SINGAP MED J, V54, P581, DOI 10.11622/smedj.2013203; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; Lee CHK, 2017, SLEEP SCI, V10, P57, DOI 10.5935/1984-0063.20170010; Li YY, 2016, INT J PSYCHIAT MED, V51, P554, DOI 10.1177/0091217417696737; Luyster FS, 2016, BEHAV SLEEP MED, V14, P67, DOI 10.1080/15402002.2014.946597; Mair FS, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6680; McEvoy RD, 2016, NEW ENGL J MED, V375, P919, DOI 10.1056/NEJMoa1606599; Parthasarathy S, 2013, J CLIN SLEEP MED, V9, P543, DOI 10.5664/jcsm.2744; Pepin JL, 2012, THORAX, V67, P1025, DOI 10.1136/thoraxjnl-2012-202807; Pires FS, 2013, SLEEP BREATH, V17, P993, DOI 10.1007/s11325-012-0789-9; Quadri F, 2017, RESP PHYSIOL NEUROBI, V236, P51, DOI 10.1016/j.resp.2016.11.004; Rezaie L, 2018, PATIENT PREFER ADHER, V12, P1299, DOI 10.2147/PPA.S165905; Rotenberg BW, 2016, J OTOLARYNGOL-HEAD N, V45, DOI 10.1186/s40463-016-0156-0; Rueda AD., 2009, SLEEP SCI, V2, P8; Sav A, 2013, HEALTH SOC CARE COMM, V21, P665, DOI 10.1111/hsc.12052; Sawyer AM, 2010, QUAL HEALTH RES, V20, P873, DOI 10.1177/1049732310365502; Schutzer KA, 2004, PREV MED, V39, P1056, DOI 10.1016/j.ypmed.2004.04.003; Senaratna CV, 2017, SLEEP MED REV, V34, P70, DOI 10.1016/j.smrv.2016.07.002; Sjors C, 2014, INTERACT J MED RES, V3, P2, DOI 10.2196/ijmr.3191; Tan B, 2018, AM J OTOLARYNG, V39, P501, DOI 10.1016/j.amjoto.2018.05.012; Tietjens JR, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.010440; Tran VT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0356-x; Troxel WM, 2007, SLEEP MED REV, V11, P389, DOI 10.1016/j.smrv.2007.05.002; Weaver TE, 2012, AM J RESP CRIT CARE, V186, P677, DOI 10.1164/rccm.201202-0200OC; Ye LC, 2017, SLEEP HEALTH, V3, P362, DOI 10.1016/j.sleh.2017.07.003; Zhao YY, 2017, SLEEP, V40, DOI 10.1093/sleep/zsx040	39	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2021	16	6							e0252915	10.1371/journal.pone.0252915	http://dx.doi.org/10.1371/journal.pone.0252915			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RH	34097721	gold, Green Published			2023-01-03	WOS:000664640700022
J	Fernando, SM; Rochwerg, B				Fernando, Shannon M.; Rochwerg, Bram			In COVID-19, tocilizumab reduces all-cause mortality at 28 d	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Fernando, Shannon M.] Univ Ottawa, Ottawa, ON, Canada; [Rochwerg, Bram] McMaster Univ, Hamilton, ON, Canada	University of Ottawa; McMaster University	Fernando, SM (corresponding author), Univ Ottawa, Ottawa, ON, Canada.							Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023	5	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN	2021	174	6					JC63	JC63		10.7326/ACPJ202106150-063	http://dx.doi.org/10.7326/ACPJ202106150-063			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SS5IR	34058104				2023-01-03	WOS:000661788700004
J	Faust, JS; Du, CA; Mayes, KD; Li, SX; Lin, ZQ; Barnett, ML; Krumholz, HM				Faust, Jeremy S.; Du, Chengan; Mayes, Katherine Dickerson; Li, Shu-Xia; Lin, Zhenqiu; Barnett, Michael L.; Krumholz, Harlan M.			Mortality From Drug Overdoses, Homicides, Unintentional Injuries, Motor Vehicle Crashes, and Suicides During the Pandemic, March-August 2020	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Faust, Jeremy S.] Brigham & Womens Hosp, Dept Emergency Med, 10 Vining St, Boston, MA 02115 USA; [Du, Chengan; Krumholz, Harlan M.] Yale Univ, Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT USA; [Mayes, Katherine Dickerson] Harvard Affiliated Emergency Med Residency, Boston, MA USA; [Li, Shu-Xia; Lin, Zhenqiu] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Yale University; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Faust, JS (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 10 Vining St, Boston, MA 02115 USA.	jsfaust@gmail.com	Barnett, Michael/AAF-4017-2019	Barnett, Michael/0000-0002-4884-6609	NCATS NIH HHS [UL1 TR001863] Funding Source: Medline	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		FBI, 2020, OV PREL UN CRIM REP; Holland KM, 2021, JAMA PSYCHIAT, V78, P372, DOI 10.1001/jamapsychiatry.2020.4402; Huskamp HA, 2020, JAMA-J AM MED ASSOC, V324, P2440, DOI 10.1001/jama.2020.21512; National Center for Health Statistics, MONTHL COUNTS DEATHS; National Highway Traffic Safety Administration, 2016, BEHAV RES	5	34	34	4	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2021	326	1					84	87		10.1001/jama.2021.8012	http://dx.doi.org/10.1001/jama.2021.8012		MAY 2021	5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG4UV	34019096	Bronze, Green Published			2023-01-03	WOS:000652627800001
J	Brewster, DJ; Nickson, CP; McGloughlin, S; Pilcher, D; Sarode, VV; Gatward, JJ				Brewster, David J.; Nickson, Christopher P.; McGloughlin, Steve; Pilcher, David; Sarode, Vineet V.; Gatward, Jonathan J.			Preparation for airway management in Australia and New Zealand ICUs during the COVID-19 pandemic	PLOS ONE			English	Article								Background This paper aimed to describe the airway practices of intensive care units (ICUs) in Australia and New Zealand specific to patients presenting with COVID-19 and to inform whether consistent clinical practice was achieved. Specific clinical airway guidelines were endorsed in March 2020 by the Australian and New Zealand Intensive Care Society (ANZICS) and College of Intensive Care Medicine (CICM). Methods and findings Prospective, structured questionnaire for all ICU directors in Australia and New Zealand was completed by 69 ICU directors after email invitation from ANZICS. The online questionnaire was accessible for three weeks during September 2020 and analysed by cloud-based software. Basic ICU demographics (private or public, metropolitan or rural) and location, purchasing, airway management practices, guideline uptake, checklist and cognitive aid use and staff training relevant to airway management during the COVID-19 pandemic were the main outcome measures. The 69 ICU directors reported significant simulation-based inter-professional airway training of staff (97%), and use of video laryngoscopy (94%), intubation checklists (94%), cognitive aids (83%) and PPE "spotters" (89%) during the airway management of patients with COVID-19. Tracheal intubation was almost always performed by a Specialist (97% of ICUs), who was more likely to be an intensivist than an anaesthetist (61% vs 36%). There was a more frequent adoption of specific airway guidelines for the management of COVID-19 patients in public ICUs (94% vs 71%) and reliance on specialist intensivists to perform intubations in private ICUs (92% vs 53%). Conclusion There was a high uptake of a standardised approach to airway management in COVID-19 patients in ICUs in Australia and New Zealand, likely due to endorsement of national guidelines.	[Brewster, David J.; Sarode, Vineet V.] Cabrini Hosp, Intens Care Unit, Malvern, Vic, Australia; [Brewster, David J.; Sarode, Vineet V.] Monash Univ, Fac Med, Cent Clin Sch, Melbourne, Vic, Australia; [Nickson, Christopher P.; McGloughlin, Steve] Alfred Hlth, Intens Care Unit, Melbourne, Vic, Australia; [Nickson, Christopher P.; Pilcher, David] Alfred Hlth, Ctr Hlth Innovat, Melbourne, Vic, Australia; [Nickson, Christopher P.; Pilcher, David] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [McGloughlin, Steve] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Gatward, Jonathan J.] Royal North Shore, Intens Care Unit, Sydney, NSW, Australia; [Gatward, Jonathan J.] Univ Sydney, Northern Clin Sch, Sydney, NSW, Australia	Cabrini Health; Monash University; Monash University; Monash University; Royal North Shore Hospital; University of Sydney	Brewster, DJ (corresponding author), Cabrini Hosp, Intens Care Unit, Malvern, Vic, Australia.; Brewster, DJ (corresponding author), Monash Univ, Fac Med, Cent Clin Sch, Melbourne, Vic, Australia.	dbrewster@cabrini.com.au	Nickson, Christopher/AAD-9853-2022; Sarode, Vineet/GXV-1434-2022	Nickson, Christopher/0000-0002-6968-3087; Brewster, David/0000-0002-0710-1889				Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Brazil Victoria, 2020, Adv Simul (Lond), V5, P9, DOI 10.1186/s41077-020-00127-z; Brenner MJ, 2020, BRIT J ANAESTH, V125, pE104, DOI 10.1016/j.bja.2020.04.054; Brewster DJ, 2018, ANAESTH INTENS CARE, V46, P190, DOI 10.1177/0310057X1804600208; Brewster DJ, 2020, MED J AUSTRALIA, V212, P472, DOI 10.5694/mja2.50598; Brydges Ryan, 2020, Adv Simul (Lond), V5, P8, DOI 10.1186/s41077-020-00128-y; Burrell AJC, 2021, MED J AUSTRALIA, V214, P23, DOI 10.5694/mja2.50883; Chan AKM, 2021, BMJ SIMUL TECHNOL EN, V7, P199, DOI 10.1136/bmjstel-2020-000635; Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054; El-Boghdadly K, 2020, ANAESTHESIA, V75, P1437, DOI 10.1111/anae.15170; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Leotsakos A, 2014, INT J QUAL HEALTH C, V26, P109, DOI 10.1093/intqhc/mzu010; Litton E, 2020, MED J AUSTRALIA, V212, P463, DOI 10.5694/mja2.50596; Low XM, 2018, J CRIT CARE, V48, P283, DOI 10.1016/j.jcrc.2018.09.015; Marshall S, 2013, ANESTH ANALG, V117, P1162, DOI 10.1213/ANE.0b013e31829c397b; Quah P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03006-1; Sarode, 2020, PREPARING ICUS COVID; Sorbello M, 2020, ANAESTHESIA, V75, P724, DOI 10.1111/anae.15049; Sorbello M, 2020, ANESTH ANALG, V131, pE128, DOI 10.1213/ANE.0000000000004970; Toolis M, 2019, CRIT CARE RESUSC, V21, P139; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5	21	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2021	16	5							e0251523	10.1371/journal.pone.0251523	http://dx.doi.org/10.1371/journal.pone.0251523			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SX8UE	33961677	Green Published, gold			2023-01-03	WOS:000665471900063
J	Mohammadi, M; Zaki, L; KarimiPourSaryazdi, A; Tavakoli, P; Tavajjohi, A; Poursalehi, R; Delavari, H; Ghaffarifar, F				Mohammadi, Mohsen; Zaki, Leila; KarimiPourSaryazdi, Amir; Tavakoli, Pooya; Tavajjohi, Atiyeh; Poursalehi, Reza; Delavari, Hamid; Ghaffarifar, Fatemeh			Efficacy of green synthesized silver nanoparticles via ginger rhizome extract against Leishmania major in vitro	PLOS ONE			English	Article							CUTANEOUS LEISHMANIASIS; PROMASTIGOTES; CYTOTOXICITY; APOPTOSIS; DOTS	Introduction Leishmaniasis is a major public health problem that causes by parasite of the genus Leishmania. The pentavalent antimonial compounds that used for treatment are not safe or effective enough. The aim of the present study was preparation and evaluation of the efficacy of green synthesized silver nanoparticles against Leishmania major (L. major) in vitro. Methods To synthesis silver (Ag) nanoparticles (NPs), ginger extract was added to the 0.2mM AgNO3 aqueous solution (1:20). Effects of different concentrations of Ag-NPs on the number of L. major promastigotes were investigated using counting assay. The MTT test was applied to determine the toxicity of Ag-NPs on promastigotes of L. major, as well as, macrophage cells. Then, to evaluate the anti-amastigotes effects of Ag-NPs, parasites within the macrophages were counted by light microscope. Furthermore, to determine the induced apoptosis and necrotic effects of Ag-NPs on promastigotes, flow cytometry method was employed using annexin staining. Results The effect of Ag-NPs on promastigotes and amastigotes of L. major was effective and has a reverse relationship with its concentration. According to the results of anti-amastigote assay, the IC50 value of this nanoparticle was estimated 2.35 ppm after 72h. Also, Ag-NPs caused Programmed Cell Death (PCD) in promastigotes of L. major and showed 60.18% of apoptosis. Discussion Based on the mentioned results, it can be concluded that Ag NPs has a beneficial effect on promastigote and amastigote forms of L. major in vitro. Hence, these nanoparticles could be applied as promising antileishmanial agents for treatment of Leishmania infections.	[Mohammadi, Mohsen; Tavajjohi, Atiyeh; Poursalehi, Reza; Delavari, Hamid] Tarbiat Modares Univ, Dept Mat Engn, Nanomat Grp, Tehran, Iran; [Zaki, Leila; KarimiPourSaryazdi, Amir; Tavakoli, Pooya; Ghaffarifar, Fatemeh] Tarbiat Modares Univ, Fac Med Sci, Dept Parasitol, Tehran, Iran	Tarbiat Modares University; Tarbiat Modares University	Ghaffarifar, F (corresponding author), Tarbiat Modares Univ, Fac Med Sci, Dept Parasitol, Tehran, Iran.	ghafarif@modares.ac.ir		KarimiPourSaryazdi, Amir/0000-0002-6028-8638				Abazari R, 2018, ULTRASON SONOCHEM, V43, P248, DOI 10.1016/j.ultsonch.2018.01.022; Abdoli A, 2017, COMP IMMUNOL MICROB, V51, P15, DOI 10.1016/j.cimid.2017.02.001; Akhoundi M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004349; Allahverdiyev AM, 2011, INT J NANOMED, V6, P2705, DOI 10.2147/IJN.S23883; Almalki MA, 2020, J PHOTOCH PHOTOBIO B, V204, DOI 10.1016/j.jphotobiol.2020.111786; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Baiocco P, 2011, ACS MED CHEM LETT, V2, P230, DOI 10.1021/ml1002629; Bajpai VK, 2020, THERANOSTICS, V10, P7841, DOI 10.7150/thno.42291; Bajpai VK, 2020, J BIOMED NANOTECHNOL, V16, P283, DOI 10.1166/jbn.2020.2899; de Menezes JPB, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/815023; Croft SL, 2006, INDIAN J MED RES, V123, P399; Dalimi A, 2018, TROP BIOMED, V35, P50; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; Dolat E, 2015, BIOELECTROMAGNETICS, V36, P586, DOI 10.1002/bem.21945; El-khadragy M, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15051037; Ghaffarifar F, 2015, IRAN J PARASITOL, V10, P258; Husain S, 2021, MAT SCI ENG C-MATER, V122, DOI 10.1016/j.msec.2021.111888; Jebali A, 2013, TOXICOL IN VITRO, V27, P1896, DOI 10.1016/j.tiv.2013.06.002; KarimiPourSaryazdi A, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112910; Karimkhani C, 2016, LANCET INFECT DIS, V16, P584, DOI 10.1016/S1473-3099(16)00003-7; Lia SJ, 2019, INT J NANOMED, V14, P1469, DOI 10.2147/IJN.S191340; Liu MH, 2019, MACROMOL RAPID COMM, V40, DOI 10.1002/marc.201800216; Maspi N, 2017, APMIS, V125, P249, DOI 10.1111/apm.12651; Mohammadi M, 2019, IET NANOBIOTECHNOL, V13, P114, DOI 10.1049/iet-nbt.2018.5146; Mohammadi M, 2019, MICRO NANO LETT, V14, P239, DOI 10.1049/mnl.2018.5145; Mohan A, 2020, MATER TODAY CHEM, V17, DOI 10.1016/j.mtchem.2020.100299; Mohebali M, 2009, DARU, V17, P285; Siddiqi KS, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0334-5; Singh N, 2012, ASIAN PAC J TROP MED, V5, P485, DOI 10.1016/S1995-7645(12)60084-4; Soosaraei M, 2017, ANN MED SURG, V21, P63, DOI 10.1016/j.amsu.2017.07.057; Sosa N, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007253; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Tavakoli P, 2019, J TRACE ELEM MED BIO, V56, P162, DOI 10.1016/j.jtemb.2019.08.003; Tiuman TS, 2011, INT J INFECT DIS, V15, pE525, DOI 10.1016/j.ijid.2011.03.021; Tripathi KM, 2020, ACS BIOMATER SCI ENG, V6, P5527, DOI 10.1021/acsbiomaterials.0c00831; Verma SK, 2018, MAT SCI ENG C-MATER, V92, P807, DOI 10.1016/j.msec.2018.07.037; Verma SK, 2018, TOXICOL SCI, V161, P125, DOI 10.1093/toxsci/kfx204; Zahir AA, 2015, ANTIMICROB AGENTS CH, V59, P4782, DOI 10.1128/AAC.00098-15	38	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255571	10.1371/journal.pone.0255571	http://dx.doi.org/10.1371/journal.pone.0255571			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB7PL	34407085	gold, Green Published			2023-01-03	WOS:000686033500011
J	Schmidt, CN; Butrick, E; Musange, S; Mulindahabi, N; Walker, D				Schmidt, Christina N.; Butrick, Elizabeth; Musange, Sabine; Mulindahabi, Nathalie; Walker, Dilys			Towards stronger antenatal care: Understanding predictors of late presentation to antenatal services and implications for obstetric risk management in Rwanda	PLOS ONE			English	Article							MATERNAL MORTALITY; NEONATAL-MORTALITY; PERFORMANCE; MORBIDITY; IMPACT	Background Early antenatal care (ANC) reduces maternal and neonatal morbidity and mortality through identification of pregnancy-related complications, yet 44% of Rwandan women present to ANC after 16 weeks gestational age (GA). The objective of this study was to identify factors associated with delayed initiation of ANC and describe differences in the obstetric risks identified at the first ANC visit (ANC-1) between women presenting early and late to care. Methods This secondary data analysis included 10,231 women presenting for ANC-1 across 18 health centers in Rwanda (May 2017-December 2018). Multivariable logistic regression models were constructed using backwards elimination to identify predictors of presentation to ANC at >= 16 and >= 24 weeks GA. Logistic regression was used to examine differences in obstetric risk factors identified at ANC-1 between women presenting before and after 16- and 24-weeks GA. Results Sixty-one percent of women presented to ANC at >= 16 weeks and 24.7% at >= 24 weeks GA, with a mean (SD) GA at presentation of 18.9 (6.9) weeks. Younger age (16 weeks: OR = 1.36, 95% CI: 1.06, 1.75; 24 weeks: OR = 1.33, 95% CI: 0.95, 1.85), higher parity (16 weeks: 1-4 births, OR = 1.55, 95% CI: 1.39, 1.72; five or more births, OR = 2.57, 95% CI: 2.17, 3.04; 24 weeks: 1-4 births, OR = 1.93, 95% CI: 1.78, 2.09; five or more births, OR = 3.20, 95% CI: 2.66, 3.85), lower educational attainment (16 weeks: primary, OR = 0.75, 95% CI: 0.65, 0.86; secondary, OR = 0.60, 95% CI: 0.47,0.76; university, OR = 0.48, 95% CI: 0.33, 0.70; 24 weeks: primary, OR = 0.64, 95% CI: 0.53, 0.77; secondary, OR = 0.43, 95% CI: 0.29, 0.63; university, OR = 0.12, 95% CI: 0.04, 0.32) and contributing to household income (16 weeks: OR = 1.78, 95% CI: 1.40, 2.25; 24 weeks: OR = 1.91, 95% CI: 1.42, 2.55) were associated with delayed ANC-1 (>= 16 and >= 24 weeks GA). History of a spontaneous abortion (16 weeks: OR = 0.74, 95% CI: 0.66, 0.84; 24 weeks: OR = 0.70, 95% CI: 0.58, 0.84), pregnancy testing (16 weeks: OR = 0.48, 95% CI: 0.33, 0.71; 24 weeks: OR = 0.41, 95% CI: 0.27, 0.61; 24 weeks) and residing in the same district (16 weeks: OR = 1.55, 95% CI: 1.08, 2.22; 24 weeks: OR = 1.73, 95% CI: 1.04, 2.87) or catchment area (16 weeks: OR = 1.53, 95% CI: 1.05, 2.23; 24 weeks: OR = 1.84, 95% CI: 1.28, 2.66; 24 weeks) as the health facility were protective against delayed ANC-1. Women with a prior preterm (OR, 0.71, 95% CI, 0.53, 0.95) or low birthweight delivery (OR, 0.72, 95% CI, 0.55, 0.95) were less likely to initiate ANC after 16 weeks. Women with no obstetric history were more likely to present after 16 weeks GA (OR, 1.18, 95% CI, 1.06, 1.32). Conclusion This study identified multiple predictors of delayed ANC-1. Focusing existing Community Health Worker outreach efforts on the populations at greatest risk of delaying care and expanding access to home pregnancy testing may improve early care attendance. While women presenting late to care were less likely to present without an identified obstetric risk factor, lower than expected rates were identified in the study population overall. Health centers may benefit from provider training and standardized screening protocols to improve identification of obstetric risk factors at ANC-1.	[Schmidt, Christina N.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; [Butrick, Elizabeth; Walker, Dilys] Univ Calif San Francisco, Inst Global Hlth Sci, San Francisco, CA 94143 USA; [Musange, Sabine; Mulindahabi, Nathalie] Natl Univ Rwanda, Sch Publ Hlth, Kigali, Rwanda; [Walker, Dilys] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Rwanda; University of California System; University of California San Francisco	Schmidt, CN (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.	Christina.Schmidt@ucsf.edu			Bill & Melinda Gates Foundation	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	This work is part of the East Africa Preterm Birth Initiative which is funded by the Bill & Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamu Y M, 2002, J Obstet Gynaecol, V22, P600, DOI 10.1080/0144361021000020349; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Andersen K, 2013, GLOB HEALTH-SCI PRAC, V1, P372, DOI 10.9745/GHSP-D-12-00026; [Anonymous], 2016, WHO RECOMMENDATIONS; Arunda M, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1328796; Assefa N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039957; Baqui AH, 2018, LANCET GLOB HEALTH, V6, pE1297, DOI 10.1016/S2214-109X(18)30385-1; Basinga P, 2011, LANCET, V377, P1421, DOI 10.1016/S0140-6736(11)60177-3; BENOVA L, 2018, BMJ GLOB HEALTH, V3, DOI DOI 10.1136/BMJGH-2018-000779; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P93, DOI 10.4314/ejhs.v24i0.9S; Berhe AK, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1667-7; Beta J, 2011, PRENATAL DIAG, V31, P75, DOI 10.1002/pd.2662; Birmeta K, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-256; Birungi F., 2018, DHS FURTHER ANAL REP, V108; Bucagu M., 2016, J COMMUNITY MED HLTH, V6, P434; Carroli G, 2001, PAEDIATR PERINAT EP, V15, P1; Carroli G, 2001, LANCET, V357, P1565, DOI 10.1016/S0140-6736(00)04723-1; Carvajal-Aguirre L, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020501; Chemouni B, 2018, WORLD DEV, V106, P87, DOI 10.1016/j.worlddev.2018.01.023; Christian P, 2008, PUBLIC HEALTH, V122, P161, DOI 10.1016/j.puhe.2007.06.003; Comfort AB, 2019, HEALTH POLICY PLANN, V34, P566, DOI 10.1093/heapol/czz080; Doku DT, 2017, INT J EPIDEMIOL, V46, P1668, DOI 10.1093/ije/dyx125; Ebonwu J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191903; Gebremeskel F, 2015, J ENVIRON PUBLIC HEA, V2015, DOI 10.1155/2015/971506; Gross K, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-16; Gudayu TW, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-287; Hager ER, 2010, PEDIATRICS, V126, pE26, DOI 10.1542/peds.2009-3146; Hodgins S, 2014, GLOB HEALTH-SCI PRAC, V2, P173, DOI 10.9745/GHSP-D-13-00176; Iams JD, 1998, AM J OBSTET GYNECOL, V178, P1035, DOI 10.1016/S0002-9378(98)70544-7; Kalisa R, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1119-1; Kalk A, 2010, TROP MED INT HEALTH, V15, P182, DOI 10.1111/j.1365-3156.2009.02430.x; Kisuule I, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-121; Makaka A, 2012, LANCET S2, V380, pS7, DOI DOI 10.1016/S0140-6736(13)60293-7; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Manzi A, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2939-7; Manzi A, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-290; MCCAWBINNS A, 1995, SOC SCI MED, V40, P1003, DOI 10.1016/0277-9536(94)00175-S; McCurdy RJ, 2011, ACTA OBSTET GYN SCAN, V90, P779, DOI 10.1111/j.1600-0412.2011.01133.x; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Morroni C., 2006, BMC Pregnancy and Childbirth, V6; Musange Sabine Furere, 2019, Gates Open Res, V3, P1548, DOI 10.12688/gatesopenres.13053.1; Myer L, 2003, J MIDWIFERY WOM HEAL, V48, P268, DOI 10.1016/S1526-9523(02)00421-X; National Institute of Statistics of Rwanda (NISR) Ministry of Health (MOH) & ICF International, 2015, RWAND DEM HLTH SURV; Nsanzimana S, 2017, LANCET HIV, V4, pE457, DOI 10.1016/S2352-3018(17)30124-8; Pafs J, 2015, MIDWIFERY, V31, P1149, DOI 10.1016/j.midw.2015.09.010; Payne B., 2016, FIGO TXB PREGNANCY H; Pell C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053747; Pervin J, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-036699; Raatikainen K, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-268; Republic of Rwanda Ministy of Health, 2015, HLTH SECT POL; Roost M, 2010, ACTA OBSTET GYN SCAN, V89, P335, DOI 10.3109/00016340903511050; Rurangirwa AA, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3694-5; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Semasaka JPS, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1138-y; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Turyasiima M, 2014, East Afr Med J, V91, P317; UN Inter-agency Group for Child Mortality Estimation, 2015, LEVELS TRENDS CHILD, P36; UNICEF WHO World Bank UN-DESA Population Division, 2019, LEVELS TRENDS CHILD; Uwizeye D, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05037; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X	60	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256415	10.1371/journal.pone.0256415	http://dx.doi.org/10.1371/journal.pone.0256415			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9YC	34432829	gold, Green Published			2023-01-03	WOS:000729171700027
J	Mulcahy, AW; Schwam, D; Rao, PT; Rennane, S; Shetty, K				Mulcahy, Andrew W.; Schwam, Daniel; Rao, Preethi; Rennane, Stephanie; Shetty, Kanaka			Estimated Savings From International Reference Pricing for Prescription Drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Mulcahy, Andrew W.; Schwam, Daniel; Rao, Preethi; Rennane, Stephanie] RAND Corp, Arlington, VA USA; [Shetty, Kanaka] RAND Corp, Santa Monica, CA USA	RAND Corporation; RAND Corporation	Mulcahy, AW (corresponding author), 1200 S Hayes St, Arlington, VA 22202 USA.	amulcahy@rand.org		Schwam, Daniel/0000-0003-1831-1483; Rennane, Stephanie/0000-0002-6995-2339	Arnold Ventures	Arnold Ventures	This study was funded by Arnold Ventures.	Brodie M., 2019, KFF TRACKING POLL FE; Keehan SP, 2020, HEALTH AFFAIR, V39, P704, DOI 10.1377/hlthaff.2020.00094; Mulcahy AW, 2021, INT PRESCRIPTION DRU; Yang EJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.28510	4	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2021	326	17					1744	1745		10.1001/jama.2021.13338	http://dx.doi.org/10.1001/jama.2021.13338		SEP 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WW8DB	34505870	Green Published, Bronze			2023-01-03	WOS:000695637300001
J	Baker, RG; Koroshetz, WJ; Volkow, ND				Baker, Rebecca G.; Koroshetz, Walter J.; Volkow, Nora D.			The Helping to End Addiction Long-term (HEAL) Initiative of the National Institutes of Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Baker, Rebecca G.] NIH, One Ctr Dr,Ste 218, Bethesda, MD 20892 USA; [Koroshetz, Walter J.] NINDS, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Volkow, Nora D.] NIDA, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Baker, RG (corresponding author), NIH, One Ctr Dr,Ste 218, Bethesda, MD 20892 USA.	rebecca.baker@nih.gov						Ahmad F., 2021, NATL HLTH STAT REPOR; Chandler RK, 2020, DRUG ALCOHOL DEPEN, V217, DOI 10.1016/j.drugalcdep.2020.108329; Volkow ND, 2017, NEW ENGL J MED, V377, P1798; Young LW, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-008839	4	4	4	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	2021	326	11					1005	1006		10.1001/jama.2021.13300	http://dx.doi.org/10.1001/jama.2021.13300		AUG 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ4IM	34436519	Bronze			2023-01-03	WOS:000689743800001
J	Fausther-Bovendo, H; Kobinger, G				Fausther-Bovendo, Hugues; Kobinger, Gary			Plant-made vaccines and therapeutics	SCIENCE			English	Editorial Material							I CLINICAL-TRIAL; EFFICACY; PROTEIN; SAFETY; ALPHA		[Fausther-Bovendo, Hugues] Univ Laval, Fac Med, Quebec City, PQ, Canada; [Kobinger, Gary] Galveston Natl Lab, Galveston, TX 77550 USA	Laval University	Kobinger, G (corresponding author), Galveston Natl Lab, Galveston, TX 77550 USA.	gary.pignac-kobinger.1@ulaval.ca						Almon E, 2017, J IMMUNOL METHODS, V446, P21, DOI 10.1016/j.jim.2017.03.023; Chan HT, 2016, PLANT BIOTECHNOL J, V14, P2190, DOI 10.1111/pbi.12575; Davey RT, 2016, NEW ENGL J MED, V375, P1448, DOI 10.1056/NEJMoa1604330; Ma JKC, 2015, PLANT BIOTECHNOL J, V13, P1106, DOI 10.1111/pbi.12416; Merlin M, 2017, BRIT J CLIN PHARMACO, V83, P71, DOI 10.1111/bcp.12949; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Rosales-Mendoza S, 2018, TRENDS BIOTECHNOL, V36, P1054, DOI 10.1016/j.tibtech.2018.05.010; Sahin U, 2018, SCIENCE, V359, P1355, DOI 10.1126/science.aar7112; Sainsbury F, 2020, CURR OPIN BIOTECH, V61, P110, DOI 10.1016/j.copbio.2019.11.002; Sander VA, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00020; Schillberg S, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00720; Shanmugaraj B, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9070842; Takeyama Natsumi, 2015, Ther Adv Vaccines, V3, P139, DOI 10.1177/2051013615613272; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Zimran A, 2016, AM J HEMATOL, V91, P656, DOI 10.1002/ajh.24369	15	11	11	23	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	2021	373	6556					740	741		10.1126/science.abf5375	http://dx.doi.org/10.1126/science.abf5375			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TZ6HP	34385382				2023-01-03	WOS:000684572100025
J	Eastment, MC; Kinuthia, J; Wang, L; Wanje, G; Wilson, K; Kaggiah, A; Simoni, JM; Mandaliya, K; Poole, DN; Richardson, BA; Jaoko, W; John-Stewart, G; McClelland, RS				Eastment, McKenna C.; Kinuthia, John; Wang, Lei; Wanje, George; Wilson, Katherine; Kaggiah, Anne; Simoni, Jane M.; Mandaliya, Kishorchandra; Poole, Danielle N.; Richardson, Barbra A.; Jaoko, Walter; John-Stewart, Grace; McClelland, R. Scott			Late antiretroviral refills and condomless sex in a cohort of HIV-seropositive pregnant and postpartum Kenyan women	PLOS ONE			English	Article							INTIMATE PARTNER VIOLENCE; HUMAN-IMMUNODEFICIENCY-VIRUS; UNPROTECTED SEX; INFECTED WOMEN; ALCOHOL-USE; LOW-INCOME; ADHERENCE; THERAPY; PREVENTION; HEALTH	Introduction The postpartum period can be challenging for women living with HIV. Understanding how the postpartum period impacts ART adherence and condomless sex could inform the development of comprehensive sexual and reproductive health and HIV services tailored to the needs of women living with HIV during this critical interval. Methods In a longitudinal cohort study of HIV-seropositive Kenyan women, late ART refills and self-reported condomless sex were compared between the woman's pregnancy and the postpartum period. Analyses were conducted using generalized estimating equations and adjusted for alcohol use, depressive symptoms, intimate partner violence (IPV), and having a recent regular partner. Effect modification was explored for selected variables. Results and discussion 151 women contributed visits. Late ART refills occurred at 7% (32/439) of pregnancy visits compared to 18% (178/1016) during the postpartum period (adjusted relative risk [aRR] 2.44, 95% confidence interval [CI] 1.62-3.67). This association differed by women's education level. Women with >= 8 years of education had late ART refills more during the postpartum period than pregnancy (aRR 3.00, 95%CI 1.95-4.62). In contrast, in women with <8 years of education, late ART refills occurred similarly during pregnancy and the postpartum period (aRR 0.88, 95%CI 0.18-4.35). Women reported condomless sex at 10% (60/600) of pregnancy visits compared to 7% (72/1081) of postpartum visits (aRR 0.76, 95%CI 0.45-1.27). This association differed by whether women had experienced recent IPV. Women without recent IPV had a significant decline in condomless sex from pregnancy to postpartum (aRR 0.53, 95%CI 0.30-0.95) while women with recent IPV had no significant change in condomless sex from pregnancy to postpartum (aRR 1.76, 95%CI 0.87-3.55). Conclusion Improved support for ART adherence during the postpartum period and addressing IPV to limit condomless sex could improve HIV treatment and prevention outcomes for HIV-seropositive women as well as their infants and sexual partners.	[Eastment, McKenna C.; John-Stewart, Grace; McClelland, R. Scott] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Kinuthia, John; Wang, Lei; Wilson, Katherine; Simoni, Jane M.; Mandaliya, Kishorchandra; Richardson, Barbra A.; John-Stewart, Grace; McClelland, R. Scott] Univ Washington, Global Hlth, Seattle, WA 98195 USA; [Kinuthia, John; Kaggiah, Anne] Kenyatta Natl Hosp, Nairobi, Kenya; [Wanje, George; Jaoko, Walter; McClelland, R. Scott] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; [Simoni, Jane M.] Univ Washington, Psychol, Seattle, WA 98195 USA; [Poole, Danielle N.] Dartmouth Coll, Dept Geog, Hanover, NH 03755 USA; [Richardson, Barbra A.] Univ Washington, Biostat, Seattle, WA 98195 USA; [John-Stewart, Grace; McClelland, R. Scott] Univ Washington, Epidemiol, Seattle, WA 98195 USA; [John-Stewart, Grace] Univ Washington, Pediat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Kenyatta National Hospital; University of Nairobi; University of Washington; University of Washington Seattle; Dartmouth College; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Eastment, MC (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.	mceast@uw.edu	Eastment, McKenna/AGT-5397-2022	Eastment, McKenna/0000-0002-9185-0902	National Institutes of Health [R01 HD072617]; University of Washington Center for AIDS Research [P30-AI27757]; STD and AIDS Research and Training Program [T32 AI07140, K08CA228761];  [K24HD88229]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Washington Center for AIDS Research; STD and AIDS Research and Training Program; 	This work was supported by a grant from the National Institutes of Health (R01 HD072617). RSM receives support for mentoring through K24HD88229. Infrastructure and logistical support for the Mombasa site were provided through the University of Washington Center for AIDS Research (P30-AI27757). MCE received support from the STD and AIDS Research and Training Program (T32 AI07140) and K08CA228761. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal A, 2014, MATERN CHILD HLTH J, V18, P1985, DOI 10.1007/s10995-014-1444-9; [Anonymous], 2020, HIGH POSS COST COVID; Baeten JM, 2016, NEW ENGL J MED, V375, P2121, DOI 10.1056/NEJMoa1506110; Barry A, 2018, TROP MED INT HEALTH, V23, P270, DOI 10.1111/tmi.13026; Bloom DE, 2011, SCIENCE, V333, P562, DOI 10.1126/science.1209290; Buchberg MK, 2015, AIDS PATIENT CARE ST, V29, P126, DOI 10.1089/apc.2014.0227; Chuma J, 2013, FREE MATERNAL CARE R; Cohen MS, 2013, LANCET, V382, P1515, DOI 10.1016/S0140-6736(13)61998-4; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; Deeks SG, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.35; Desgrees-du-Lou A, 2002, INT J STD AIDS, V13, P462, DOI 10.1258/09564620260079617; Devries KM, 2013, SCIENCE, V340, P1527, DOI 10.1126/science.1240937; Dillabaugh LL, 2012, AIDS RES TREAT, V2012, DOI 10.1155/2012/602120; Drake A, 2012, CONTRACEPTION, V86, P307, DOI 10.1016/j.contraception.2012.05.082; El-Khatib Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017518; El-Khatib Z, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-88; Ellsberg M, 2008, LANCET, V371, P1165, DOI 10.1016/S0140-6736(08)60522-X; Eyassu MA, 2016, AFR J PRIM HEALTH CA, V8, DOI 10.4102/phcfm.v8i2.924; Garcia-Moreno C, 2006, LANCET, V368, P1260, DOI 10.1016/S0140-6736(06)69523-8; Silva JAG, 2015, CAD SAUDE PUBLICA, V31, P1188, DOI 10.1590/0102-311X00106914; Golin CE, 2002, J GEN INTERN MED, V17, P756, DOI 10.1046/j.1525-1497.2002.11214.x; Hatcher AM, 2015, AIDS, V29, P2183, DOI 10.1097/QAD.0000000000000842; Health KMo, 2016, GUIDELINES USE ANTIR; Henegar CE, 2015, JAIDS-J ACQ IMM DEF, V68, P477, DOI 10.1097/QAI.0000000000000501; Herlihy JM, 2015, JAIDS-J ACQ IMM DEF, V70, pE123, DOI 10.1097/QAI.0000000000000760; Hochmeister MN, 1999, J FORENSIC SCI, V44, P1057; Homsy J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212119; Irungu E, 2012, AIDS, V26, P997, DOI 10.1097/QAD.0b013e3283524ca1; Kacanek D, 2013, JAIDS-J ACQ IMM DEF, V64, P400, DOI 10.1097/QAI.0b013e3182a6b0be; Kassutto S, 2006, CLIN INFECT DIS, V42, P1024, DOI 10.1086/500410; Keating MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039109; Kenya National Bureau of Statistics, 2015, REP KEN KEN DEM HLTH; Kinuthia J, 2017, JAIDS-J ACQ IMM DEF, V74, P142, DOI 10.1097/QAI.0000000000001225; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Monahan PO, 2009, J GEN INTERN MED, V24, P189, DOI 10.1007/s11606-008-0846-z; Myer L, 2017, JAIDS-J ACQ IMM DEF, V75, pS115, DOI [10.1097/QAI.0000000000001343, 10.1097/qai.0000000000001343]; Nachega JB, 2012, AIDS, V26, P2039, DOI 10.1097/QAD.0b013e328359590f; Nanni MG, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-014-0530-4; Omoro SAO, 2006, INT J PSYCHIAT MED, V36, P367, DOI 10.2190/8W7Y-0TPM-JVGV-QW6M; Peltzer K, 2014, AIDS CARE, V26, P186, DOI 10.1080/09540121.2013.803016; Peltzer K, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-57; Phillips T, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19242; Phillips TK, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25114; R Core Team Rf.., 2013, R LANG ENV STAT COMP; Reyes HLM, 2019, AIDS CARE, V31, P707, DOI 10.1080/09540121.2018.1556380; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schnippel K, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0778-2; Shamu S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017591; Shannon K, 2018, LANCET, V392, P698, DOI 10.1016/S0140-6736(18)31439-9; Sturt AS, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008440; Taibbi Matt., 2021, US; Technau KG, 2014, JAIDS-J ACQ IMM DEF, V65, pE170, DOI 10.1097/QAI.0000000000000068; Turan JM, 2015, JAIDS-J ACQ IMM DEF, V69, pe172, DOI 10.1097/QAI.0000000000000678; UNAIDS, 2020, UNAIDS 2020 GLOB REP; Vazquez L, 2019, AIDS PATIENT CARE ST, V33, P214, DOI 10.1089/apc.2018.0242; Vrazo AC, 2018, TROP MED INT HEALTH, V23, P136, DOI 10.1111/tmi.13014; Wagner GJ, 2002, AIDS CARE, V14, P105, DOI 10.1080/09540120220097973; Washington S, 2015, JAIDS-J ACQ IMM DEF, V69, pe164, DOI 10.1097/QAI.0000000000000656; Weigel R, 2012, TROP MED INT HEALTH, V17, P751, DOI 10.1111/j.1365-3156.2012.02980.x; White AB, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011323; White D, 2016, SEX TRANSM DIS, V43, P642, DOI 10.1097/OLQ.0000000000000502; WHO WHO, CONSOLIDATED GUIDELI; Wilson KS, 2016, AIDS BEHAV, V20, P2065, DOI 10.1007/s10461-016-1420-z; Wilson KS, 2016, AIDS BEHAV, V20, P2054, DOI 10.1007/s10461-016-1399-5; Wilson TE, 2003, JAIDS-J ACQ IMM DEF, V33, P608, DOI 10.1097/00126334-200308150-00010; World Health Organization: HIV/AIDS Programme, 2012, PROGR UPD US ANT DRU	66	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2021	16	7							e0254767	10.1371/journal.pone.0254767	http://dx.doi.org/10.1371/journal.pone.0254767			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2NL	34280229	gold, Green Published			2023-01-03	WOS:000678122000016
J	Nam, NH; Tien, PTM; Truong, LV; El-Ramly, TA; Anh, PG; Hien, NT; Mahmoud, E; Eltaras, MM; Khader, SA; Desokey, MS; Gayed, RM; Alhady, STM; Le, BTD; Nguyen, DPN; Tiwari, R; Eldoadoa, M; Howard, B; Trung, TT; Huy, NT				Nguyen Hai Nam; Phan Thi My Tien; Le Van Truong; El-Ramly, Toka Aziz; Pham Gia Anh; Nguyen Thi Hien; Mahmoud, El Marabea; Eltaras, Mennatullah Mohamed; Khader, Sarah Abd Elaziz; Desokey, Mohammed Salah; Gayed, Ramy Magdy; Alhady, Shamael Thabit Mohammed; Bao-Tran Do Le; Do Phuc Nhu Nguyen; Tiwari, Ranjit; Eldoadoa, Mohammed; Howard, Britney; Tran Thanh Trung; Nguyen Tien Huy			Early centralized isolation strategy for all confirmed cases of COVID-19 remains a core intervention to disrupt the pandemic spreading significantly	PLOS ONE			English	Article							TIME	Background In response to the spread of the coronavirus disease 2019 (COVID-19), plenty of control measures were proposed. To assess the impact of current control measures on the number of new case indices 14 countries with the highest confirmed cases, highest mortality rate, and having a close relationship with the outbreak's origin; were selected and analyzed. Methods In the study, we analyzed the impact of five control measures, including centralized isolation of all confirmed cases, closure of schools, closure of public areas, closure of cities, and closure of borders of the 14 targeted countries according to their timing; by comparing its absolute effect average, its absolute effect cumulative, and its relative effect average. Results Our analysis determined that early centralized isolation of all confirmed cases was represented as a core intervention in significantly disrupting the pandemic's spread. This strategy helped in successfully controlling the early stage of the outbreak when the total number of cases were under 100, without the requirement of the closure of cities and public areas, which would impose a negative impact on the society and its economy. However, when the number of cases increased with the apparition of new clusters, coordination between centralized isolation and non-pharmaceutical interventions facilitated control of the crisis efficiently. Conclusion Early centralized isolation of all confirmed cases should be implemented at the time of the first detected infectious case.	[Nguyen Hai Nam] Kyoto Univ, Grad Sch Med, Kyoto, Japan; [Nguyen Hai Nam] Harvard Med Sch, Global Clin Scholars Res Training Program, Boston, MA 02115 USA; [Nguyen Hai Nam; Phan Thi My Tien; Le Van Truong; El-Ramly, Toka Aziz; Pham Gia Anh; Nguyen Thi Hien; Mahmoud, El Marabea; Eltaras, Mennatullah Mohamed; Khader, Sarah Abd Elaziz; Desokey, Mohammed Salah; Gayed, Ramy Magdy; Alhady, Shamael Thabit Mohammed; Bao-Tran Do Le; Do Phuc Nhu Nguyen; Tiwari, Ranjit; Eldoadoa, Mohammed; Howard, Britney; Tran Thanh Trung] Online Res Club, Nagasaki, Japan; [Phan Thi My Tien; Pham Gia Anh] Univ Med & Pharm Ho Chi Minh City, Ho Chi Minh City, Vietnam; [Le Van Truong] Minist Publ Secur, Tradit Med Hosp, Hanoi, Vietnam; [El-Ramly, Toka Aziz] Univ Alexandria, Fac Med, Alexandria, Egypt; [Nguyen Thi Hien] Hue City Hosp, Emergency Dept, Hue City, Vietnam; [Mahmoud, El Marabea] Tanta Univ, Fac Med, Tanta, Egypt; [Eltaras, Mennatullah Mohamed] Al Azhar Univ, Fac Med Girls, Cairo, Egypt; [Khader, Sarah Abd Elaziz] Ain Shams Univ, Fac Med, Cairo, Egypt; [Desokey, Mohammed Salah] Aswan Univ, Fac Med, Aswan, Egypt; [Gayed, Ramy Magdy] Cairo Univ, Fac Med, Cairo, Egypt; [Alhady, Shamael Thabit Mohammed] Univ Gezira, Fac Med, Wad Madani, Sudan; [Bao-Tran Do Le] Univ Calif Los Angeles, Los Angeles, CA USA; [Do Phuc Nhu Nguyen] Inst Publ Hlth Ho Chi Minh City, Epidemiol Dept, Ho Chi Minh City, Vietnam; [Tiwari, Ranjit] Tribhuvan Univ, Fac Med, Inst Med, Kathmandu, Nepal; [Eldoadoa, Mohammed] Milton Keynes Univ Hosp, Milton Keynes, Bucks, England; [Howard, Britney] Amer Univ, Caribbean Sch Med, Cupecoy, Sint Maarten; [Nguyen Tien Huy] Nagasaki Univ, Sch Trop Med & Global Hlth, Nagasaki, Japan	Kyoto University; Harvard University; Harvard Medical School; Hochiminh City University of Medicine & Pharmacy; Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge Bank (EKB); Tanta University; Egyptian Knowledge Bank (EKB); Al Azhar University; Egyptian Knowledge Bank (EKB); Ain Shams University; Egyptian Knowledge Bank (EKB); Aswan University; Egyptian Knowledge Bank (EKB); Cairo University; University of California System; University of California Los Angeles; Tribhuvan University; Institute of Medicine (IoM) - Nepal; Nagasaki University	Huy, NT (corresponding author), Nagasaki Univ, Sch Trop Med & Global Hlth, Nagasaki, Japan.	tienhuy@nagasaki-u.ac.jp	Huy, Nguyen Tien/B-2573-2010; khader, sara/GLN-6434-2022; Van Truong, Le/ABA-6093-2021	Huy, Nguyen Tien/0000-0002-9543-9440; Van Truong, Le/0000-0002-7474-0453; Nam, Nguyen Hai/0000-0001-5184-6936; A. Khader, Sara/0000-0002-4397-3852; El ramly, Toka/0000-0003-2188-9796; Magdy Gayed, Ramy/0000-0003-3972-6194; Desokey, Mohammed Salah/0000-0002-5255-959X				Adams-Prassl Teodora B, 2020, IMPACT CORONAVIRUS L; [Anonymous], 2002, Bull World Health Organ, V80, P983; Borro M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155573; Bruhn CAW, 2017, P NATL ACAD SCI USA, V114, P1524, DOI 10.1073/pnas.1612833114; Chaudhry R, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100464; Comunian S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124487; Dietz K, 1993, Stat Methods Med Res, V2, P23, DOI 10.1177/096228029300200103; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Kavaliunas A, 2020, HEALTH POLICY TECHN, V9, P598, DOI 10.1016/j.hlpt.2020.08.009; Li Q., 2020, NEW ENGL J MED, V382, P1199, DOI [10.1056/NEJMoa2001316, DOI 10.1056/NEJMOA2001316]; Liu JY, 2020, EMERG INFECT DIS, V26, P1320, DOI 10.3201/eid2606.200239; Miles DK, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13674; PAINTER PR, 1967, J GEN MICROBIOL, V48, P155, DOI 10.1099/00221287-48-1-155; Ren SY, 2020, WORLD J CLIN CASES, V8, P1391, DOI 10.12998/wjcc.v8.i8.1391; Toraih EA, 2021, ANN SURG, V273, P28, DOI 10.1097/SLA.0000000000004590; Varian HR, 2016, P NATL ACAD SCI USA, V113, P7310, DOI 10.1073/pnas.1510479113; WHO, SARS SEV AC RESP SYN; WHO, 2020, WHO TIM COVID 19; who, MIDDLE E RESP SYNDRO; World Health Organization, PNEUM UNKN CAUS CHIN; Zhu Y, 2020, BRAIN BEHAV IMMUN, V87, P142, DOI 10.1016/j.bbi.2020.05.009; Zoran MA, 2020, SCI TOTAL ENVIRON, V738, DOI 10.1016/j.scitotenv.2020.139825	22	2	2	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2021	16	7							e0254012	10.1371/journal.pone.0254012	http://dx.doi.org/10.1371/journal.pone.0254012			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2MX	34264966	gold, Green Published			2023-01-03	WOS:000678120600061
J	Rujumba, J; Homsy, J; Mbazzi, FB; Namukwaya, Z; Amone, A; Rukundo, G; Katabira, E; Byamugisha, J; Fowler, MG; King, RL				Rujumba, Joseph; Homsy, Jaco; Mbazzi, Femke Bannink; Namukwaya, Zikulah; Amone, Alexander; Rukundo, Gordon; Katabira, Elly; Byamugisha, Josaphat; Fowler, Mary Glenn; King, Rachel L.			Pregnant women, their male partners and health care providers' perceptions of HIV self-testing in Kampala, Uganda: Implications for integration in prevention of mother-to-child transmission programs and scale-up	PLOS ONE			English	Article							RISK	Background HIV status awareness is critical for HIV prevention and care but HIV testing rates remain low in Uganda, especially among men. One suggested approach to increase access and utilisation of HIV testing services is HIV self-testing. We explored perceptions of pregnant and lactating women and their male partners who attended antenatal care, and health care providers in a government hospital in Kampala, Uganda, about HIV self-testing for initial or repeat testing for women and their partners during pregnancy and postpartum We draw implications for scaling-up this new testing approach in Uganda. Methods This was a qualitative study conducted at Mulago National Referral Hospital, Kampala, Uganda, between April and December 2017. We conducted in-depth interviews with five pregnant or lactating women and their five male partners; five focus group discussions (two with women, two with health workers and one with male partners of women attending antenatal care) and five key informant interviews with health workers providing prevention of mother-to-child HIV transmission (PMTCT) services. Data were analysed using content thematic approach. Results There was limited awareness about HIV self-testing especially among pregnant or lactating women and their male partners. Study participants mentioned that HIV self-testing would enable people to know their HIV status faster, they thought the approach would be cost- and time-saving compared to health facility-based HIV testing, improve confidentiality and reduce stigma for those who test HIV positive. They expressed however, a general fear that HIV self-testing would lead to harm to self and others in case one tested HIV positive, including suicide, violence among couples, intentional transmission of HIV, and limited linkage to care due to lack of counselling. The likely misinterpretation of HIV test results especially among those with no or limited education, and possible coercion exerted by male partners on their wives were other potential concerns raised about the use of HIV self-testing. Conclusions There was limited knowledge about HIV self-testing among pregnant and lactating women, their partners and health workers. While the self-testing modality was perceived to be critical for helping people, especially those in casual and distant relationships, to know their HIV status and that of their partners, most study participants believed that HIV self-testing could potentially result in a multitude of negative outcomes in the absence of pre- and post-test counselling. Successful scale-up and integration of self-testing in HIV programs requires community education, provision of information materials and making self-test kits accessible and affordable, especially in rural areas.	[Rujumba, Joseph] Makerere Univ, Coll Hlth Sci, Dept Pediat & Child Hlth, Kampala, Uganda; [Homsy, Jaco; King, Rachel L.] Univ Calif San Francisco, Inst Global Hlth Sci, San Francisco, CA 94143 USA; [Mbazzi, Femke Bannink] Univ Ghent, Fac Psychol & Educ Sci, Ghent, Belgium; [Mbazzi, Femke Bannink] MRC UVRI, Entebbe, Uganda; [Mbazzi, Femke Bannink] LSHTM Uganda Res Unit, Entebbe, Uganda; [Namukwaya, Zikulah] Makerere Univ Kampala, Infect Dis Inst, Kampala, Uganda; [Amone, Alexander; Rukundo, Gordon; Katabira, Elly; Fowler, Mary Glenn] Makerere Univ Johns Hopkins Univ MU JHU Res Colla, Kampala, Uganda; [Katabira, Elly] Makerere Univ, Dept Med, Sch Med, Kampala, Uganda; [Katabira, Elly] Makerere Univ, Coll Hlth Sci, Sch Med, Kampala, Uganda; [Byamugisha, Josaphat] Makerere Univ, Dept Obstet & Gynecol, Sch Med, Kampala, Uganda; [Fowler, Mary Glenn] Johns Hopkins Univ, Dept Med, Baltimore, MD USA	Makerere University; University of California System; University of California San Francisco; Ghent University; Makerere University; Makerere University; Makerere University; Makerere University; Makerere University; Johns Hopkins University	Rujumba, J (corresponding author), Makerere Univ, Coll Hlth Sci, Dept Pediat & Child Hlth, Kampala, Uganda.	jrujumba@yahoo.com		Bannink Mbazzi, Femke/0000-0001-6436-3431; Rujumba, Joseph/0000-0002-9485-8790	NIH-NICHD [R01HD070767-01]	NIH-NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	JH received funding from NIH-NICHD, Grant No: R01HD070767-01 through MUJHU as a sub-grantee in Uganda. The funder had no role in the design, data collection, analysis and decision to publish, or preparation of the manuscript.	Asiimwe S, 2014, AIDS BEHAV, V18, P2477, DOI 10.1007/s10461-014-0765-4; Bulterys MA, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050318; Burke VM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183280; Chamie G, 2021, LANCET HIV, V8, pe225, DOI 10.1016/S2352-3018(21)00023-0; Choko AT, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001873; Choko AT, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001102; Drake AL, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001608; Figueroa C, 2015, AIDS BEHAV, V19, P1949, DOI 10.1007/s10461-015-1097-8; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Gray RH, 2005, LANCET, V366, P1182, DOI 10.1016/S0140-6736(05)67481-8; Harichund C, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-018-6366-9; Hershow RB, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25293; Hlongwa M, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8184-0; Homsy J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212119; Indravudh PP, 2018, CURR OPIN INFECT DIS, V31, P14, DOI 10.1097/QCO.0000000000000426; Kalibala S, 2014, AIDS BEHAV, V18, pS405, DOI 10.1007/s10461-014-0830-z; Kebede B, 2013, PAN AFR MED J, V15, DOI 10.11604/pamj.2013.15.50.2328; Kelvin EA, 2018, AIDS BEHAV, V22, P580, DOI 10.1007/s10461-017-1783-9; Korte JE, 2020, JAIDS-J ACQ IMM DEF, V84, P271, DOI 10.1097/QAI.0000000000002341; Kumwenda M, 2014, AIDS BEHAV, V18, pS396, DOI 10.1007/s10461-014-0817-9; Lockman S, 2009, J INFECT DIS, V200, P667, DOI 10.1086/605124; Mangenah Collin, UNITAID PSI HIV SELF; Matovu JKB, 2018, GLOBAL HEALTH ACTION, V11, DOI 10.1080/16549716.2018.1503784; Matovu JKB, 2017, INT J STD AIDS, V28, P1341, DOI 10.1177/0956462417705800; Mbazzi FB, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08738-x; Mhango M, 2020, AIDS BEHAV, V24, P3014, DOI 10.1007/s10461-020-02939-6; Ministry of Health, 2017, IMPLIMENTATION GUIDE; Ministry of Health, 2018, CONSOLIDATED GUIDELI; Moodley D, 2009, AIDS, V23, P1255, DOI 10.1097/QAD.0b013e32832a5934; Njau B, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7685-1; Oyaro P, 2020, JAIDS-J ACQ IMM DEF, V84, P365, DOI 10.1097/QAI.0000000000002347; Peck RB, 2014, AIDS BEHAV, V18, pS422, DOI 10.1007/s10461-014-0818-8; Pierre G, 2020, PAN AFR MED J, V37, DOI 10.11604/pamj.2020.37.138.24353; Ponticiello M, 2020, AIDS BEHAV, V24, P3006, DOI 10.1007/s10461-020-02935-w; Rujumba J, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-189; Rujumba J, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17429; Thirumurthy H, 2016, LANCET HIV, V3, pE266, DOI 10.1016/S2352-3018(16)00041-2; Uganda Bureau of Statistics, 2016, UG NAT HOUS SURV 201; Uganda Bureau of Statistics, 2019, UG STAT ABSTR; UNAIDS, UNAIDS REP GLOB AIDS; van Rooyen H, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19445; WHO UNAIDS, 2013, REP 1 INT S SELF TES; World Health Organization, 2016, POL BRIEF WHO REC HI; World Health organization UNAIDS., 2014, SHORT TECHN UPD SELF	44	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2021	16	6							e0253616	10.1371/journal.pone.0253616	http://dx.doi.org/10.1371/journal.pone.0253616			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9DM	34185799	gold, Green Published, Green Accepted			2023-01-03	WOS:000671696900022
J	Jaam, M; Naseralallah, LM; Hussain, TA; Pawluk, SA				Jaam, Myriam; Naseralallah, Lina Mohammad; Hussain, Tarteel Ali; Pawluk, Shane Ashley			Pharmacist-led educational interventions provided to healthcare providers to reduce medication errors: A systematic review and meta-analysis	PLOS ONE			English	Review							PRESCRIBING ERRORS; INTENSIVE-CARE; ADMINISTRATION ERRORS; CLINICAL PHARMACISTS; IMPACT; HOSPITALS; PROGRAM	Introduction Medication errors are avoidable events that can occur at any stage of the medication use process. They are widespread in healthcare systems and are linked to an increased risk of morbidity and mortality. Several strategies have been studied to reduce their occurrence including different types of pharmacy-based interventions. One of the main pharmacist-led interventions is educational programs, which seem to have promising benefits. Objective To describe and compare various pharmacist-led educational interventions delivered to healthcare providers and to evaluate their impact qualitatively and quantitatively on medication error rates. Methods A systematic review and meta-analysis was conducted through searching Cochrane Library, EBSCO, EMBASE, Medline and Google Scholar from inception to June 2020. Only interventional studies that reported medication error rate change after the intervention were included. Two independent authors worked through the data extraction and quality assessment using Crowe Critical Appraisal Tool (CCAT). Summary odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model for rates of medication errors. Research protocol is available in The International Prospective Register of Systematic Reviews (PROSPERO) under the registration number CRD42019116465. Results Twelve studies involving 115058 participants were included. The two main recipients of the educational interventions were nurses and resident physicians. Educational programs involved lectures, posters, practical teaching sessions, audit and feedback method and flash cards of high-risk abbreviations. All studies included educational sessions as part of their program, either alone or in combination with other approaches, and most studies used errors encountered before implementing the intervention to inform the content of these sessions. Educational programs led by a pharmacist were associated with significant reductions in the overall rate of medication errors occurrence (OR, 0.38; 95% CI, 0.22 to 0.65). Conclusion Pharmacist-led educational interventions directed to healthcare providers are effective at reducing medication error rates. This review supports the implementation of pharmacist-led educational intervention aimed at reducing medication errors.	[Jaam, Myriam; Naseralallah, Lina Mohammad; Hussain, Tarteel Ali] Qatar Univ, QU Hlth, Coll Pharm, Clin Pharm & Practice Dept, Doha, Qatar; [Pawluk, Shane Ashley] Childrens & Womens Hlth Ctr British Columbia, Dept Pharm, Vancouver, BC, Canada; [Pawluk, Shane Ashley] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada	Qatar University; BC Women's Hospital & Health Centre; University of British Columbia	Jaam, M (corresponding author), Qatar Univ, QU Hlth, Coll Pharm, Clin Pharm & Practice Dept, Doha, Qatar.	myriamj@live.co.uk		Naseralallah, Lina/0000-0003-3035-1357; Jaam, Myriam/0000-0002-3199-1172				Abu Farha R, 2018, SAUDI PHARM J, V26, P611, DOI 10.1016/j.jsps.2018.03.002; Ahmed T, 2016, VALUE HEALTH, V19, pA630, DOI 10.1016/j.jval.2016.09.1632; Alagha HZ, 2011, ACTA PAEDIATR, V100, pE169, DOI 10.1111/j.1651-2227.2011.02270.x; Alex S, 2016, QUAL MANAG HEALTH CA, V25, P32, DOI 10.1097/QMH.0000000000000080; [Anonymous], 2016, PHARMACISTS IMPACT P PHARMACISTS IMPACT P; Assiri GA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019101; Bester N, 2016, ADV THER, V33, P167, DOI 10.1007/s12325-016-0284-y; Bjorksten KS, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1695-9; Boyko EJ, 2013, J DIABETES COMPLICAT, V27, P642, DOI 10.1016/j.jdiacomp.2013.07.007; Brabeck M., 2010, PRACTICE KNOWLEDGE A, DOI [10.1016/j.bbrc.2010.02.015, DOI 10.1016/J.BBRC.2010.02.015]; Bruner RF., 2001, SSRN; Campino A, 2009, ACTA PAEDIATR, V98, P782, DOI 10.1111/j.1651-2227.2009.01234.x; Chedoe I, 2012, ARCH DIS CHILD-FETAL, V97, pF449, DOI 10.1136/fetalneonatal-2011-300989; Chung HO, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0653-x; Cohen V, 2009, AM J HEALTH-SYST PH, V66, P1353, DOI 10.2146/ajhp080304; Costello JL, 2007, AM J HEALTH-SYST PH, V64, P1422, DOI 10.2146/ajhp060296; Crowe M, 2013, CROWE CRITICAL APPRA; de Araujo BC, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00439; De Oliveira GS, 2021, J PATIENT SAF, V17, P375, DOI 10.1097/PTS.0000000000000283; Elden Nesreen Mohamed Kamal, 2016, Glob J Health Sci, V8, P54510, DOI 10.5539/gjhs.v8n8p243; Elfil M, 2017, EMERGENCY, V5; Enhancing the QUAlity and Transparency Of Health Research Network, EQUATOR NETW; Fawaz MG., 2017, INT J PHARM SCI REV, V42, P100; George D, 2019, PHARM PRACT-GRANADA, V17, DOI [10.18549/PharmPract.2019.3.1501, 10.18549/pharmpract.2019.3.1501]; Gursanscky Jared, 2018, Journal of Pharmacy Practice and Research, V48, P26, DOI 10.1002/jppr.1330; Haseeb A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011401; Nguyen HT, 2014, BMJ QUAL SAF, V23, P319, DOI 10.1136/bmjqs-2013-002357; Institute of Medicine, 2000, ERR IS HUMAN BUILDIN, DOI [10.17226/9728, DOI 10.17226/9728]; Jaam M., 2019, PHARMACIST LED ED IN; Keers RN, 2014, DRUG SAFETY, V37, P317, DOI 10.1007/s40264-014-0152-0; Keers RN, 2013, DRUG SAFETY, V36, P1045, DOI 10.1007/s40264-013-0090-2; Khalil H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003942.pub3; Lewis PJ, 2009, DRUG SAFETY, V32, P379, DOI 10.2165/00002018-200932050-00002; Likic R, 2009, BRIT J CLIN PHARMACO, V67, P656, DOI 10.1111/j.1365-2125.2009.03423.x; Maidment ID, 2006, QUAL SAF HEALTH CARE, V15, P409, DOI 10.1136/qshc.2006.018267; Manias E, 2020, THER ADV DRUG SAF, V11, DOI 10.1177/2042098620968309; Manias E, 2012, BRIT J CLIN PHARMACO, V74, P411, DOI 10.1111/j.1365-2125.2012.04220.x; Mansur JM, 2016, DRUG AGING, V33, P213, DOI 10.1007/s40266-016-0358-1; Mekonnen AB, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010003; Mostafa LS, 2020, J PUBLIC HEALTH-UK, V42, P169, DOI 10.1093/pubmed/fdy216; Naseralallah LM, 2020, INT J CLIN PHARM-NET, V42, P979, DOI 10.1007/s11096-020-01034-z; National Coordinating Council on Medication Error Reporting and Prevention, MED ERRORS; Noormandi A, 2019, DARU, V27, P361, DOI 10.1007/s40199-019-00245-8; Page M., 2020, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, DOI 10.1136/BMJ.N71]; Pawluk S, 2017, INT J CLIN PHARM-NET, V39, P88, DOI 10.1007/s11096-016-0399-x; Peek N, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003286; Peeters MJ, 2009, J HOSP MED, V4, P97, DOI 10.1002/jhm.387; Pfister B, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360-017-0157-2; Riordan DO, 2016, SAGE OPEN MED, V4, DOI 10.1177/2050312116652568; Roughead EE, 2016, INT J EVID-BASED HEA, V14, P113, DOI 10.1097/XEB.0000000000000075; Sabzi Zahra, 2019, Open Access Maced J Med Sci, V7, P3579, DOI 10.3889/oamjms.2019.722; Sjolander M, 2019, RES SOC ADMIN PHARM, V15, P287, DOI 10.1016/j.sapharm.2018.05.006; Tariq RA., 2021, STATPEARLS; Taylor Simone E., 2007, Journal of Pharmacy Practice and Research, V37, P214; Tran T, 2019, ANN PHARMACOTHER, V53, P252, DOI 10.1177/1060028018802472; Walsh EK, 2017, PHARMACOEPIDEM DR S, V26, P481, DOI 10.1002/pds.4188; Wang TS, 2015, J CRIT CARE, V30, P1101, DOI 10.1016/j.jcrc.2015.06.018; Winder MB, 2015, J AM PHARM ASSOC, V55, P238, DOI 10.1331/JAPhA.2015.14130; Wittich CM, 2014, MAYO CLIN PROC, V89, P1116, DOI 10.1016/j.mayocp.2014.05.007; World Health Organization, 2017, MED HARM GLOB PAT CH MED HARM GLOB PAT CH	60	8	8	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2021	16	6							e0253588	10.1371/journal.pone.0253588	http://dx.doi.org/10.1371/journal.pone.0253588			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BO	34161388	gold, Green Published			2023-01-03	WOS:000671691900029
J	Barakat, M; Al-Qudah, R; Akour, A; Abu-Asal, M; Thiab, S; Dallal Bashi, YH				Barakat, Muna; Al-Qudah, Raja'a; Akour, Amal; Abu-Asal, Mona; Thiab, Samar; Dallal Bashi, Yahya H.			Knowledge and beliefs about the use/abuse of oral contraceptive pills among males: A mixed-method explanatory sequential study in community pharmacy settings	PLOS ONE			English	Article							ABUSE; PRESCRIPTION; BENEFITS	Background Oral contraceptive pills (OCPs) are considered one of the most important birth control methods globally. However, these pills were designed for female administration rather than males. This study was designed to investigate patterns of OCPs use and abuse among Jordanian males, according to the community pharmacists' observations. Method A mixed-method explanatory sequential study was conducted using an online self-administered survey, followed by semi-structured in-depth interviews for registered pharmacists, assistant pharmacists and pharmacy interns. The interviews were utilized using a conceptual framework. Inductive thematic analysis and descriptive/regression analyses were completed using Nvivo and SPSS, respectively. Results A total of 158 questionnaire responses and 22 interviews were included in our analysis. Around half (48.4%) of the questionnaire responses confirmed that males could use OCPs for hair growth enhancement, muscle gain and acne treatment 12.7%, 31.7% and 4.4%, respectively. Through the interviews, the participating pharmacists highlighted that males use OCPs mostly for bodybuilding purposes, according to recommendations by their coaches at the gym. The most abused OCPs containing estrogen (Ethinyl estradiol) and progestins (Drospirenone or Levonorgestrel). Conclusion This study provided insight into unexpected uses of OCPs by males in Jordan. Community pharmacists have a crucial role in the management of OCPs use and abuse. However, restricted regulations and monitoring must be released and implemented on the community to limit such practices.	[Barakat, Muna; Al-Qudah, Raja'a; Abu-Asal, Mona; Thiab, Samar] Appl Sci Private Univ, Fac Pharm, Amman, Jordan; [Akour, Amal] Al Zaytoonah Univ Jordan, Fac Pharm, Dept Pharm, Amman, Jordan; [Akour, Amal] Univ Jordan, Sch Pharm, Dept Biopharmaceut & Clin Pharm, Amman, Jordan; [Dallal Bashi, Yahya H.] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland	Al-Zaytoonah University of Jordan; University of Jordan; Queens University Belfast	Barakat, M (corresponding author), Appl Sci Private Univ, Fac Pharm, Amman, Jordan.	m_barakat@asu.edu.jo	Thiab, Samar/AAF-8629-2020; Barakat, Muna/AAN-8778-2020	Thiab, Samar/0000-0002-9625-4915; Barakat, Muna/0000-0002-7966-1172; Dallal Bashi, Yahya H/0000-0002-8480-9776				Albsoul-Younes A, 2010, SUBST USE MISUSE, V45, P1319, DOI 10.3109/10826080802490683; Alharthi TF, 2018, AUSTRALAS MED J, V11, P289, DOI 10.21767/AMJ.2018.3305; Althobiti SD., PREVALENCE ATTITUDE, P1512; Bahr SJ, 2016, WILEY HANDB CRIMINOL, P197; Barakat M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244373; Bardaweel SK, 2019, BMC WOMENS HEALTH, V19, DOI 10.1186/s12905-019-0770-x; Bardaweel SK, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0275-1; Boynton PM, 2004, BRIT MED J, V328, P1312, DOI 10.1136/bmj.328.7451.1312; Brennan BP, 2011, AM J ADDICTION, V20, P9, DOI 10.1111/j.1521-0391.2010.00093.x; Ciccarone D, 2011, PRIMARY CARE, V38, P41, DOI 10.1016/j.pop.2010.11.004; Connelly Lynne M, 2016, Medsurg Nurs, V25, P435; Cooper D. B., 2020, ORAL CONTRACEPTIVE P; Cooper D.B., 2019, ORAL CONTRACEPTIVE P; Dalgaard LB, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00824; Daniels K., 2014, CURRENT CONTRACEPTIV; Fay J.J., 2018, CONT SECURITY MANAGE, VFourth Edition, P391; Finkelstein JS, 2013, NEW ENGL J MED, V369, P1011, DOI 10.1056/NEJMoa1206168; Fu S, 2016, ADV CLIN CHEM, V76, P123, DOI 10.1016/bs.acc.2016.05.003; Hajhashemi V, 2007, PHYSIOL PHARMACOL, V11, P68; Handelsman DJ., 2017, ENDOCRINOLOGY TESTIS, P1251; Hansen M, 2012, J GERONTOL A-BIOL, V67, P1005, DOI 10.1093/gerona/gls007; Herzog BJ., 2020, ANDROGENS CLIN RES T, V1, P62, DOI [10.1089/andro.2020.0005, DOI 10.1089/ANDRO.2020.0005]; Huang QL, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016440; Ilardo ML, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17020536; Irwin AN, 2019, RES SOC ADMIN PHARM, V15, P650, DOI 10.1016/j.sapharm.2018.08.003; Jordan Food and Drug Administration (JFDA), LIST NONPR MED 2018; Kanayama G, 2012, CURR OPIN ENDOCRINOL, V19, P211, DOI 10.1097/MED.0b013e3283524008; Kennedy CE, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001402; Kirkpatrick K., 2015, WHAT MAN TAKES BIRTH; Kridli SA, 2005, INT NURS REV, V52, P109, DOI 10.1111/j.1466-7657.2005.00260.x; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Mahmoud MA., 2018, COMMUNITY PHARM; McIntosh J, 2011, PHARMACOTHERAPY, V31, P424, DOI 10.1592/phco.31.4.424; Rafie S, 2019, PHARMACY-BASEL, V7, DOI 10.3390/pharmacy7030096; Roerig JL, 2010, DRUGS, V70, P1487, DOI 10.2165/11898640-000000000-00000; Russell N, 2019, EUR J ENDOCRINOL, V181, pR23, DOI 10.1530/EJE-18-1000; Sagoe D, 2018, CURR OPIN ENDOCRINOL, V25, P185, DOI 10.1097/MED.0000000000000403; Schindler AE, 2013, INT J ENDOCRINOL MET, V11, P41, DOI 10.5812/ijem.4158; Soares AH, 2018, INT J OBESITY, V42, P953, DOI 10.1038/s41366-018-0105-2; Spooner C., 2005, SOCIAL DETERMINANTS; Tabachnick B. G., 2007, USING MULTIVARIATE S, V5, P481; Tahtamouni LH, 2008, EUR J PUBLIC HEALTH, V18, P661, DOI 10.1093/eurpub/ckn062; Tan RS., USE CLOMIPHENE CITRA; The United States Agency for International Development (USAID), JORD PROGR PROF 2015; Thirumalai A, 2019, J CLIN ENDOCR METAB, V104, P423, DOI 10.1210/jc.2018-01452; WHO, 2016, AB DRUG ALC CHEM SUB	46	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2021	16	5							e0251302	10.1371/journal.pone.0251302	http://dx.doi.org/10.1371/journal.pone.0251302			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SX8UE	33961665	gold, Green Published			2023-01-03	WOS:000665471900049
J	Yoo, KH; Kim, HJ; Min, YH; Hong, DS; Lee, WS; Kim, HJ; Shin, HJ; Park, Y; Lee, JH; Kim, H				Yoo, Kwai Han; Kim, Hyeoung-Joon; Min, Yoo Hong; Hong, Dae-Sik; Lee, Won Sik; Kim, Hee-Je; Shin, Ho-Jin; Park, Yong; Lee, Je-Hwan; Kim, Hawk			Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry	PLOS ONE			English	Article							COLONY-STIMULATING FACTOR; ACUTE MYELOCYTIC-LEUKEMIA; CYTOGENETIC ABNORMALITIES; ELDERLY PATIENTS; ADULT PATIENTS; OLDER-ADULTS; CHEMOTHERAPY; DAUNORUBICIN; CANCER; IDARUBICIN	Objective The clinical characteristics and therapeutic strategy in acute myeloid leukemia (AML) are influenced by patients' age. We evaluated the impact of age on remission induction therapy for AML. Methods We retrospectively analyzed 3,011 adult AML patients identified from a nationwide database between January 2007 and December 2011. Results Three hundred twenty-nine (10.9%) acute promyelocytic leukemia (APL) and 2,682 (89.1%) non-APL patients were analyzed. The median age was 51 years and 55% of patients were male. Six hundred twenty-three patients (21%) were at favorable risk, 1522 (51%) were at intermediate risk, and 743 (25%) were at poor risk. As the age increased, the proportion of those at favorable risk and who received induction chemotherapy decreased. After induction therapy, complete response (CR) was achieved in 81.5% (243/298) of APL and 62.4% (1,409/2,258) of non-APL patients; these rates decreased as the age increased, with an obvious decrement in those older than 60 years. The median overall survival of non-APL patients was 18.7 months, while that of APL patients was not reached, with a 75% five-year survival rate. Conclusions Age impacts both the biology and clinical outcomes of AML patients. Further studies should confirm the role of induction remission chemotherapy by age group.	[Yoo, Kwai Han; Kim, Hawk] Gachon Univ, Coll Med, Gil Med Ctr, Incheon, South Korea; [Kim, Hyeoung-Joon] Chonnam Natl Univ, Coll Med, Hwasun Hosp, Gwangju, South Korea; [Min, Yoo Hong] Yonsei Univ, Coll Med, Severance Hosp, Seoul, South Korea; [Hong, Dae-Sik] Soonchunhyang Univ, Coll Med, Soonchunhyang Univ Hosp, Bucheon, South Korea; [Lee, Won Sik] Inje Univ, Coll Med, Busan Paik Hosp, Busan, South Korea; [Kim, Hee-Je] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Catholic Hematol Hosp, Seoul, South Korea; [Shin, Ho-Jin] Pusan Univ, Coll Med, Pusan Natl Univ Hosp, Busan, South Korea; [Park, Yong] Korea Univ, Coll Med, Anam Hosp, Seoul, South Korea; [Lee, Je-Hwan] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea	Gachon University; Chonnam National University; Yonsei University; Yonsei University Health System; Soonchunhyang University; Soonchunhyang University Hospital; Inje University; Catholic University of Korea; Seoul St. Mary's Hospital; Pusan National University; Pusan National University Hospital; Korea University; Korea University Medicine (KU Medicine); University of Ulsan	Kim, H (corresponding author), Gachon Univ, Coll Med, Gil Med Ctr, Incheon, South Korea.	kimhawkmd@gmail.com		Yoo, Kwai Han/0000-0002-3049-9055; min, yoo hong/0000-0001-8542-9583	Gachon University [GCU-2017-5257]; Korean Society of Hematology AML/MDS Working Party [AMLMDSWP-15-R-0]	Gachon University; Korean Society of Hematology AML/MDS Working Party	HK was supported by the Gachon University research fund of 2017 (GCU-2017-5257). This study was also supported by The Korean Society of Hematology AML/MDS Working Party (AMLMDSWP-15-R-02). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Gachon University (https://www.gachon.ac.kr) Korean Society of Hematology AML/MDS Working Party (https://www.hematology.or.kr/research_member/main.html?comm_code= com_01).	Alcalai R, 2003, AM J HEMATOL, V72, P127, DOI 10.1002/ajh.10270; Appelbaum FR, 2006, BLOOD, V107, P3481, DOI 10.1182/blood-2005-09-3724; Bullinger L, 2017, J CLIN ONCOL, V35, P934, DOI 10.1200/JCO.2016.71.2208; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Byun JM, 2016, ANN HEMATOL, V95, P1223, DOI 10.1007/s00277-016-2691-1; DOMBRET H, 1995, NEW ENGL J MED, V332, P1678, DOI 10.1056/NEJM199506223322504; Fernandez HF, 2009, NEW ENGL J MED, V361, P1249, DOI 10.1056/NEJMoa0904544; Juliusson G, 2009, BLOOD, V113, P4179, DOI 10.1182/blood-2008-07-172007; Klepin HD, 2014, J CLIN ONCOL, V32, P2541, DOI 10.1200/JCO.2014.55.1564; Koh Y, 2014, BLOOD, V124, P2387, DOI [10.1182/blood.V124.21.2387.2387, DOI 10.1182/BLOOD.V124.21.2387.2387]; Lee JH, 2017, J CLIN ONCOL, V35, P2754, DOI 10.1200/JCO.2017.72.8618; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Medeiros BC, 2015, ANN HEMATOL, V94, P1127, DOI 10.1007/s00277-015-2351-x; Medinger M, 2017, BRIT J HAEMATOL, V179, P530, DOI 10.1111/bjh.14823; Metzeler KH, 2016, BLOOD, V128, P686, DOI 10.1182/blood-2016-01-693879; Nazha A, 2014, LEUKEMIA LYMPHOMA, V55, P979, DOI 10.3109/10428194.2013.828348; O'Donnell MR, 2017, J NATL COMPR CANC NE, V15, P926, DOI 10.6004/jnccn.2017.0116; Ossenkoppele G, 2015, BLOOD, V125, P767, DOI 10.1182/blood-2014-08-551499; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Patel MI, 2015, CANCER EPIDEM BIOMAR, V24, P344, DOI 10.1158/1055-9965.EPI-14-0963; Pollyea DA, 2011, BRIT J HAEMATOL, V152, P524, DOI 10.1111/j.1365-2141.2010.08470.x; Prassek VV, 2018, HAEMATOLOGICA, V103, P1853, DOI 10.3324/haematol.2018.191536; PREISLER H, 1987, BLOOD, V69, P1441; RAI KR, 1981, BLOOD, V58, P1203; Rowe JM, 2004, BLOOD, V103, P479, DOI 10.1182/blood-2003-05-1686; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; So CC, 2011, CANCER GENET-NY, V204, P430, DOI 10.1016/j.cancergen.2011.06.003; Stone RM, 2018, HAEMATOLOGICA, V103, P1758, DOI 10.3324/haematol.2018.201848; STONE RM, 1995, NEW ENGL J MED, V332, P1671, DOI 10.1056/NEJM199506223322503; van der Holt B, 2007, BRIT J HAEMATOL, V136, P96, DOI 10.1111/j.1365-2141.2006.06403.x; Walter RB, 2015, LEUKEMIA, V29, P770, DOI 10.1038/leu.2014.216; Wei H, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0566-8; WIERNIK PH, 1992, BLOOD, V79, P313; Williams WJ, 2016, WILLIAMS HEMATOLOGY; Witz F, 1998, BLOOD, V91, P2722; YATES J, 1982, BLOOD, V60, P454	36	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2021	16	5							e0251011	10.1371/journal.pone.0251011	http://dx.doi.org/10.1371/journal.pone.0251011			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SX8UE	33961640	Green Published, gold			2023-01-03	WOS:000665471900028
J	Du, XQ; Shi, LP; Cao, WF; Zuo, BA; Zhou, AM				Du, Xuqin; Shi, Lipeng; Cao, Wenfu; Zuo, Biao; Zhou, Aimin			Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: A systematic review and meta-analysis	PLOS ONE			English	Review							PNEUMONIA; CELLS	Introduction Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic since its outbreak in Wuhan, China. It is an urgent task to prevent and treat COVID-19 effectively early. In China's experience combating the COVID-19 pandemic, Chinese herbal medicine (CHM) has played an indispensable role. A large number of epidemiological investigations have shown that mild to moderate COVID-19 accounts for the largest proportion of cases. It is of great importance to treat such COVID-19 cases, which can help control epidemic progression. Many trials have shown that CHM combined with conventional therapy in the treatment of mild to moderate COVID-19 was superior to conventional therapy alone. This review was designed to evaluate the add-on effect of CHM in the treatment of mild to moderate COVID-19. Methods Eight electronic databases including PubMed, EMBASE, Cochrane Central Register of Controlled Trials, the Clinical Trials.gov website, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Wanfang Database and China Biology Medicine (CBM) were searched from December 2019 to March 2021 without language restrictions. Two reviewers searched and selected studies, and extracted data according to inclusion and exclusion criteria independently. Cochrane Risk of Bias (ROB) tool was used to assess the methodological quality of the included RCTs. Review Manager 5.3.0 software was used for statistical analysis. Results Twelve eligible RCTs including 1393 participants were included in this meta-analysis. Our meta-analyses found that lung CT parameters [RR = 1.26, 95% CI (1.15, 1.38), P<0.00001] and the clinical cure rate [RR = 1.26, 95%CI (1.16, 1.38), P<0.00001] of CHM combined with conventional therapy in the treatment of mild to moderate COVID-19 were better than those of conventional therapy. The rate of conversion to severe cases [RR = 0.48, 95%CI (0.32, 0.73), P = 0.0005], TCM symptom score of fever [MD = -0.62, 95%CI (-0.79, -0.45), P<0.00001], cough cases [RR = 1.43, 95%CI (1.16, 1.75), P = 0.0006], TCM symptom score of cough[MD = -1.07, 95%CI (-1.29, -0.85), P<0.00001], TCM symptom score of fatigue[MD = -0.66, 95%CI (-1.05, -0.28), P = 0.0007], and CRP[MD = -5.46, 95%CI (-8.19, -2.72), P<0.0001] of combination therapy was significantly lower than that of conventional therapy. The WBC count was significantly higher than that of conventional therapy[MD = 0.38, 95%CI (0.31, 0.44), PConclusion Chinese herbal medicine combined with conventional therapy may be effective and safe in the treatment of mild to moderate COVID-19. More high-quality RCTs are needed in the future.	[Du, Xuqin; Shi, Lipeng; Cao, Wenfu; Zuo, Biao] Chongqing Med Univ, Coll Tradit Chinese Med, Chongqing, Peoples R China; [Du, Xuqin; Shi, Lipeng; Cao, Wenfu; Zuo, Biao] Chongqing Key Lab Tradit Chinese Med Prevent & Cu, Chongqing, Peoples R China; [Cao, Wenfu] Chongqing Med Univ, Dept Chinese Tradit Med, Affiliated Hosp 1, Chongqing, Peoples R China; [Zhou, Aimin] Tradit Chinese Med Hosp Dianjiang Chongqing, Dept Cardiovasc Unit, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University	Shi, LP; Cao, WF (corresponding author), Chongqing Med Univ, Coll Tradit Chinese Med, Chongqing, Peoples R China.; Shi, LP; Cao, WF (corresponding author), Chongqing Key Lab Tradit Chinese Med Prevent & Cu, Chongqing, Peoples R China.; Cao, WF (corresponding author), Chongqing Med Univ, Dept Chinese Tradit Med, Affiliated Hosp 1, Chongqing, Peoples R China.	shilipeng0206@163.com; caowenfu9316@163.com		Shi, Lipeng/0000-0002-4478-0622; shi, lipeng/0000-0002-3258-3891	National Natural Science Foundation of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China	Ang L, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051583; Bai XY, 2020, J FUNCT FOODS, V65, DOI 10.1016/j.jff.2019.103758; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chen YQ., 2018, CHIN J HOSP PHARM, V38, P810, DOI DOI 10.13286/j.cnki.chinhosppharmacyj.2018.08.02; [段璨 Duan Can], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P1473; Fara A, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200160; Fu X.X., 2020, TRADITIONAL CHINESE, V31, P600; [傅晓霞 Fu Xiaoxia], 2020, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V26, P44; Ganji A, 2020, BLOOD CELL MOL DIS, V83, DOI 10.1016/j.bcmd.2020.102437; Gao D, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00746; Gao MX, 2019, DRUG DES DEV THER, V13, P3579, DOI 10.2147/DDDT.S220030; Gao XM., 2000, TRADITIONAL CHINESE; Green S., COCHRANE REV HDB 5 3; He WG, 2018, AM J TRANSL RES, V10, P670; Hu F., J TRADIT CHIN MED 1; Hu K, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2020.153242; Jiang Q, 2020, INT IMMUNOPHARMACOL, V79, DOI 10.1016/j.intimp.2019.106083; Lee K, 2009, GLOB INST, P1; Liu M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104896; Ministry of Health of the People's Republic of China, 2002, GUID PRINC CLIN RES, V186; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; National Health Commission & National Administration of Traditional Chinese Medicine, 2020, CHIN J VIRAL DIS, V10, P321, DOI DOI 10.16505/J.2095-0136.2020.0071; Ni LQ, 2020, ACTA PHARM SIN B, V10, P1149, DOI 10.1016/j.apsb.2020.06.009; Panahi Y, 2015, CLIN NUTR, V34, P1101, DOI 10.1016/j.clnu.2014.12.019; Professional Committee of infection and inflammation radiology of Chinese Research Hospital Association, 2020, CHIN J MED IMAGING T, V36, P1; Qiu M., 2020, J EMERG TRADIT CHIN, V29, P1129, DOI 10.3969/j.issn.1004-745X.2020.07.001; Qu XY, 2016, ARCH PHARM RES, V39, P998, DOI 10.1007/s12272-016-0775-z; Ragab D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01446; Sattler A, 2020, J CLIN INVEST, V130, DOI 10.1172/JCI140965; Sun CY, 2020, AM J EMERG MED, V38, P2153, DOI 10.1016/j.ajem.2020.06.069; Sun H, 2020, CHRONOBIOL INT, V37, P327, DOI 10.1080/07420528.2020.1730881; Tian JX, 2020, PHARMACOL RES, V161, DOI 10.1016/j.phrs.2020.105127; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Wei WY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00961; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xia QD, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12949; Xin SY, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110500; Xiong XJ, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.105056; Yan W, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05847-9; Yang J., 2006, WARM DIS; [杨明博 Yang Mingbo], 2020, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V26, P7; Ye MB, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2020.153401; You C, 2020, INT J HYG ENVIR HEAL, V228, DOI 10.1016/j.ijheh.2020.113555; [余平 Yu Ping], 2020, [中国药学杂志, Chinese Pharmaceutical Journal], V55, P1042; Zeng MJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238828; [张传涛 Zhang Chuantao], 2020, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V36, P43; Zhang XY, PHYTOTHER RES, P7141; Zhang Y.L., 2020, CHINA PHARM IND, V29, P23; Zhou WaiMin, 2020, Chinese Journal of Virology, V36, P160, DOI 10.13242/j.cnki.bingduxuebao.003679; Zhou XY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205415	51	12	13	9	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256429	10.1371/journal.pone.0256429	http://dx.doi.org/10.1371/journal.pone.0256429			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC9GQ	34415962	gold, Green Published			2023-01-03	WOS:000686828600019
J	Scholer, D; Castoldi, M; Jordens, MS; Schulze-Hagen, M; Kuhl, C; Keitel, V; Luedde, T; Roderburg, C; Loosen, SH				Schoeler, David; Castoldi, Mirco; Joerdens, Markus S.; Schulze-Hagen, Max; Kuhl, Christiane; Keitel, Verena; Luedde, Tom; Roderburg, Christoph; Loosen, Sven H.			Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series	PLOS ONE			English	Article							BIOMARKERS	Background Transarterial chemoembolization (TACE) has evolved as a standard treatment option in patients with intermediate stage, unresectable HCC [Barcelona Clinic Liver Cancer (BCLC) stage B] as well as in patients with liver metastases, when surgery or systemic therapy is considered not appropriate. Concentration and sizes of extracellular vesicles (EVs) recently emerged as novel diagnostic and prognostic biomarkers in patients with liver cancer, but no data on its prognostic relevance in the context of TACE exists. Here, we evaluate pre-interventional EVs as a potential biomarker in patients undergoing TACE for primary and secondary hepatic malignancies. Methods Vesicle size distribution and concentration were measured by nanoparticle tracking analysis (NTA) in patient sera before and after TACE in 38 patients. Results Extracellular vesicle size distribution measured before TACE is of prognostic significance with respect to overall survival in patients after TACE. Overall survival is significantly reduced when initial vesicle size (X50) is in the upper quartile (>145.65nm). Median overall survival in patients in the upper quartile was only 314 days, compared to 799 days in patients with vesicle size in the first to third quartile (<145.65nm; p = 0.007). Vesicle size was also shown to be a significant prognostic marker for overall survival in Cox regression analysis [HR 1.089, 95% CI: 1.021-1.162, p = 0.010]. In addition, a significant correlation was observed between initial EVs concentration/BMI (r(S) = 0.358, p = 0.029), X50/IL-8-concentration (r(S) = 0.409, p = 0.011) and X50/CRP-concentration (r(S) = 0.404, p = 0.016). In contrast, with regard to immediate tumor response after TACE, EVs concentration and size did not differ. Sizes (but not concentrations) of EVs represent a novel prognostic marker in patients receiving TACE for primary and secondary hepatic malignancies since patients with enlarged EVs display a significantly impaired prognosis after TACE.	[Schoeler, David; Castoldi, Mirco; Joerdens, Markus S.; Keitel, Verena; Luedde, Tom; Roderburg, Christoph; Loosen, Sven H.] Heinrich Heine Univ Dusseldorf, Univ Hosp Dusseldorf, Med Fac, Clin Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany; [Schulze-Hagen, Max; Kuhl, Christiane] Univ Hosp RWTH Aachen, Dept Diagnost & Intervent Radiol, Aachen, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Roderburg, C (corresponding author), Heinrich Heine Univ Dusseldorf, Univ Hosp Dusseldorf, Med Fac, Clin Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany.	christoph.roderburg@med.uni-duesseldorf.de	Luedde, Tom/AAE-9135-2022; Roderburg, Christoph/AHC-8101-2022; Kuhl, Christiane K/H-3301-2013; Loosen, Sven/AHC-5236-2022	Luedde, Tom/0000-0002-6288-8821; Roderburg, Christoph/0000-0002-1409-7697; Kuhl, Christiane K/0000-0001-8696-2363; Loosen, Sven/0000-0002-2799-2287; Scholer, David/0000-0002-2736-9778; Keitel, Verena/0000-0003-1383-7662	GermanResearch-Foundation grant (DFG) [CA830-1/3]	GermanResearch-Foundation grant (DFG)(German Research Foundation (DFG))	This study was funded by a GermanResearch-Foundation grant (DFG, CA830-1/3) to M.C. and T.L. (https://www.dfg.de).The funder provided support in the form of salaries for Mirco Castoldi [M.C.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Abd El Gwad A, 2018, J CELL BIOCHEM, V119, P8600, DOI 10.1002/jcb.27109; Abhange K, 2021, BIOACT MATER, V6, P3705, DOI 10.1016/j.bioactmat.2021.03.015; Baran J, 2010, CANCER IMMUNOL IMMUN, V59, P841, DOI 10.1007/s00262-009-0808-2; Bester L, 2014, J MED IMAG RADIAT ON, V58, P341, DOI 10.1111/1754-9485.12163; Brodsky SV, 2008, J GASTROINTEST LIVER, V17, P261; Bruix J, 2015, J HEPATOL, V62, pS144, DOI 10.1016/j.jhep.2015.02.007; Chen WJ, 2021, CLIN CHIM ACTA, V517, P15, DOI 10.1016/j.cca.2021.02.003; Dorr NM, 2020, ANTICANCER RES, V40, P1, DOI 10.21873/anticanres.13921; Dutta R, 2017, PHARMACOL THERAPEUT, V173, P106, DOI 10.1016/j.pharmthera.2017.02.010; European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019; Karanicolas P, 2021, CLIN COLORECTAL CANC, V20, P20, DOI 10.1016/j.clcc.2020.09.008; Kwok ZH, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10050965; Liu WF, 2017, ONCOTARGETS THER, V10, P3843, DOI 10.2147/OTT.S140062; Loosen SH, 2017, J HEPATOL, V67, P749, DOI 10.1016/j.jhep.2017.06.020; Lu MR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.566299; Matsuura Y, 2019, DIGEST DIS SCI, V64, P792, DOI 10.1007/s10620-018-5380-1; Mehdiani A, 2015, JOVE-J VIS EXP, DOI 10.3791/50974; Raoul JL, 2019, CANCER TREAT REV, V72, P28, DOI 10.1016/j.ctrv.2018.11.002; Roderburg C, 2019, DEUT MED WOCHENSCHR, V144, P1650, DOI 10.1055/a-0733-6122; Sangro B, 2011, EXPERT OPIN PHARMACO, V12, P1057, DOI 10.1517/14656566.2011.545346; Srinivas AN, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.627424; Szajnik Marta, 2013, Gynecol Obstet (Sunnyvale), VSuppl 4, P3; Thietart S, 2020, J HEPATOL, V73, P1507, DOI 10.1016/j.jhep.2020.07.014; Urban SK, 2019, SEMIN LIVER DIS, V39, P70, DOI 10.1055/s-0038-1676122; URIEN S, 1988, J CLIN PHARMACOL, V28, P458, DOI 10.1002/j.1552-4604.1988.tb05760.x; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Wang WJ, 2013, CANCER BIOMARK, V13, P351, DOI 10.3233/CBM-130370; Xia XH, 2021, IMMUNOLOGY, V163, P416, DOI 10.1111/imm.13329; Yamamoto S, 2015, SCI REP-UK, V5, DOI 10.1038/srep08505; Zhao Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14450-6	30	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255983	10.1371/journal.pone.0255983	http://dx.doi.org/10.1371/journal.pone.0255983			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB7PL	34407090	gold, Green Published			2023-01-03	WOS:000686033500075
J	Tsuruya, K; Arima, H; Iseki, K; Hirakata, H				Tsuruya, Kazuhiko; Arima, Hisatomi; Iseki, Kunitoshi; Hirakata, Hideki		Kyushu Dialysis-Related Amyloidosi	Association of dialysis-related amyloidosis with lower quality of life in patients undergoing hemodialysis for more than 10 years: The Kyushu Dialysis-Related Amyloidosis Study	PLOS ONE			English	Article							JAPANESE SOCIETY; GUIDELINE; ADSORPTION; PROTEIN; COLUMN; DEATH; RISK	Background Dialysis-related amyloidosis (DRA) commonly develops in patients undergoing long-term dialysis and can lead to a decline in activities of daily living and quality of life (QOL), mainly owing to orthopedic complications. Methods First, we determined utility scores of the EuroQol 5-Dimensions 3-Levels (EQ-5D-3L) questionnaire in 1,323 patients with DRA who had undergone dialysis for more than 10 years and compared the score between those with and without DRA. Second, a 2-year follow-up was also performed, in which patients were divided into three groups: those complicated by DRA from the beginning, those with newly developed DRA within the 2-year period, and those not complicated by DRA throughout the survey period; changes in the EQ-5D-3L utility score were compared. In the group already complicated by DRA at the survey baseline, changes in the EQ-5D-3L utility score were compared according to the dialysis treatment method. Results A total of 1,314 and 931 patients were included in the first and second studies, respectively. EQ-5D-3L utility scores among patients diagnosed with DRA were significantly lower than scores in those not diagnosed with DRA. The reduction in the EQ-5D-3L utility score over the 2-year follow-up was significantly greater in patients newly complicated by DRA during the follow-up period after enrollment but not in those complicated by DRA from the beginning, as compared with patients not complicated by DRA throughout the survey period. The reduction in utility score tended to be lower in patients routinely treated with a beta 2-microglobulin adsorption column than in untreated patients with DRA. Conclusion Complication by DRA in patients undergoing long-term hemodialysis was significantly associated with a decline in QOL.	[Tsuruya, Kazuhiko] Nara Med Univ, Dept Nephrol, Kashihara, Nara, Japan; [Tsuruya, Kazuhiko] Kyushu Univ, Grad Sch Med Sci, Dept Integrated Therapy Chron Kidney Dis, Fukuoka, Japan; [Arima, Hisatomi] Fukuoka Univ, Dept Prevent Med & Publ Hlth, Fukuoka, Japan; [Iseki, Kunitoshi] Nakamura Clin, Clin Res Support Ctr, Urasoe, Japan; [Hirakata, Hideki] Fukuoka Renal Clin, Fukuoka, Japan	Nara Medical University; Kyushu University; Fukuoka University	Tsuruya, K (corresponding author), Nara Med Univ, Dept Nephrol, Kashihara, Nara, Japan.; Tsuruya, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Integrated Therapy Chron Kidney Dis, Fukuoka, Japan.	tsuruya@naramed-u.ac.jp		Arima, Hisatomi/0000-0002-2064-2014	Kaneka Corporation	Kaneka Corporation	This study was funded by a grant from Kaneka Corporation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2018, KDIGO CKD MBD SUMMIT; Blayney MJ., 2009, NDT PLUS S2, V2, pII650; Chertow GM, 1996, J AM SOC NEPHROL, V7, P1235; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; Fukuhara S, 2006, KIDNEY INT, V70, P1866, DOI 10.1038/sj.ki.5001832; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Gejyo F, 2013, THER APHER DIAL, V17, P40, DOI 10.1111/j.1744-9987.2012.01130.x; Hoshino J, 2017, CLIN EXP NEPHROL, V21, P300, DOI 10.1007/s10157-016-1287-3; Hoshino J, 2016, NEPHROL DIAL TRANSPL, V31, P595, DOI 10.1093/ndt/gfv276; Hoshino J, 2014, AM J NEPHROL, V39, P449, DOI 10.1159/000362567; Isoyama N, 2014, CLIN J AM SOC NEPHRO, V9, P1720, DOI 10.2215/CJN.10261013; Ketteler M, 2017, KIDNEY INT, V92, P26, DOI 10.1016/j.kint.2017.04.006; Kittiskulnam P, 2017, KIDNEY INT, V92, P238, DOI 10.1016/j.kint.2017.01.024; Kuragano T, 2011, BLOOD PURIFICAT, V32, P317, DOI 10.1159/000330332; Nishi S, 2019, RENAL REPLACE THER, V5, DOI 10.1186/s41100-019-0205-z; Nishi S, 2018, NEPHROLOGY, V23, P640, DOI 10.1111/nep.13077; Panichi V, 2000, BLOOD PURIFICAT, V18, P30, DOI 10.1159/000014405; Schiffl H, 2014, HEMODIAL INT, V18, P136, DOI 10.1111/hdi.12057; Tajima R, 2010, CLIN EXP NEPHROL, V14, P340, DOI 10.1007/s10157-010-0304-1; Tentori F, 2014, KIDNEY INT, V85, P166, DOI 10.1038/ki.2013.279; The Committee for Clinical Practice Guideline for Chronic Pain, 2018, CLIN PRACTICE GUIDEL, DOI [10.1097/j.pain.0000000000001067, DOI 10.1097/J.PAIN.0000000000001067]; Tsuchiya A, 2002, HEALTH ECON, V11, P341, DOI 10.1002/hec.673; Wakasugi M, 2013, J BONE MINER METAB, V31, P315, DOI 10.1007/s00774-012-0411-z; WARREN DJ, 1975, POSTGRAD MED J, V51, P450, DOI 10.1136/pgmj.51.597.450; Watanabe Y, 2015, THER APHER DIAL, V19, P67, DOI 10.1111/1744-9987.12294; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wyld M, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001307; Yamamoto S, 2009, BONE, V45, pS39, DOI 10.1016/j.bone.2009.03.655	28	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256421	10.1371/journal.pone.0256421	http://dx.doi.org/10.1371/journal.pone.0256421			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE5RC	34428227	gold, Green Published			2023-01-03	WOS:000687944100004
J	Herrmann, Y; Starck, T; Brindl, N; Kitchen, PJ; Radeker, L; Sebastian, J; Koppel, L; Tobian, F; Souares, A; Mihaljevic, AL; Merle, U; Hippchen, T; Herth, F; Knorr, B; Welker, A; Denkinger, CM				Herrmann, Yannis; Starck, Tim; Brindl, Niall; Kitchen, Philip J.; Raedeker, Lukas; Sebastian, Jakob; Koeppel, Lisa; Tobian, Frank; Souares, Aurelia; Mihaljevic, Andre L.; Merle, Uta; Hippchen, Theresa; Herth, Felix; Knorr, Britta; Welker, Andreas; Denkinger, Claudia M.			Description and analysis of representative COVID-19 cases-A retrospective cohort study	PLOS ONE			English	Article								Background Most data on COVID-19 was collected in hospitalized cases. Much less is known about the spectrum of disease in entire populations. In this study, we examine a representative cohort of primarily symptomatic cases in an administrative district in Southern Germany. Methods We contacted all confirmed SARS-CoV-2 cases in the administrative district. Consenting participants answered a retrospective survey either via a telephone, electronically or via mail. Clinical and sociodemographic features were compared between hospitalized and non-hospitalized patients. Additionally, we assessed potential risk factors for hospitalization and time to hospitalization in a series of regression models. Results We included 897 participants in our study, 69% out of 1,305 total cases in the district with a mean age of 47 years (range 2-97), 51% of which were female and 47% had a pre-existing illness. The percentage of asymptomatic, mild, moderate (leading to hospital admission) and critical illness (requiring mechanical ventilation) was 54 patients (6%), 713 (79%), 97 (11%) and 16 (2%), respectively. Seventeen patients (2%) died. The most prevalent symptoms were fatigue (65%), cough (62%) and dysgeusia (60%). The risk factors for hospitalization included older age (OR 1.05 per year increase; 95% CI 1.04-1.07) preexisting lung conditions (OR 3.09; 95% CI 1.62-5.88). Female sex was a protective factor (OR 0.51; 95% CI 0.33-0.77). Conclusion This representative analysis of primarily symptomatic COVID-19 cases confirms age, male sex and preexisting lung conditions but not cardiovascular disease as risk factors for severe illness. Almost 80% of infection take a mild course, whereas 13% of patients suffer moderate to severe illness.	[Herrmann, Yannis; Brindl, Niall; Kitchen, Philip J.; Raedeker, Lukas; Sebastian, Jakob] Ruprecht Karl Univ Heidelberg, Fac Med, Heidelberg, Germany; [Starck, Tim; Souares, Aurelia; Denkinger, Claudia M.] Heidelberg Univ Hosp, Heidelberg Inst Global Hlth, Heidelberg, Germany; [Koeppel, Lisa; Tobian, Frank] Heidelberg Univ Hosp, Div Trop Med, Ctr Infect Dis, Heidelberg, Germany; [Mihaljevic, Andre L.] Heidelberg Univ Hosp, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany; [Merle, Uta; Hippchen, Theresa] Heidelberg Univ Hosp, Dept Gastroenterol, Heidelberg, Germany; [Herth, Felix] Heidelberg Univ Hosp, Chest Hosp, Dept Pneumol & Crit Care Med, Heidelberg, Germany; [Knorr, Britta; Welker, Andreas] Landratsamt Rhein Neckar, Dept Publ Hlth, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Herrmann, Y (corresponding author), Ruprecht Karl Univ Heidelberg, Fac Med, Heidelberg, Germany.; Denkinger, CM (corresponding author), Heidelberg Univ Hosp, Heidelberg Inst Global Hlth, Heidelberg, Germany.	Claudia.denkinger@uni-heidelberg.de; y.herrmann@stud.uni-heidelberg.de		Koppel, Lisa/0000-0003-4445-7881; Brindl, Niall/0000-0002-2834-664X; Herrmann, Yannis/0000-0003-3524-0381; Kitchen, Philip James/0000-0002-1681-7838	Heidelberg University Hospital	Heidelberg University Hospital	This work was supported by internal COVID funds of the Heidelberg University Hospital.	Baggett TP., 2020, 20059618 MEDRXIV, P2020; Baggett TP, 2020, JAMA-J AM MED ASSOC, V323, P2191, DOI 10.1001/jama.2020.6887; BBC, 2020, BBC NEWS; Bohk-Ewald C, 2020, INT J EPIDEMIOL, V49, P1963, DOI 10.1093/ije/dyaa198; Cen Y, 2020, CLIN MICROBIOL INFEC, V26, P1242, DOI 10.1016/j.cmi.2020.05.041; Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; Dijkman R, 2012, J GEN VIROL, V93, P1924, DOI 10.1099/vir.0.043919-0; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020; Emami A, 2020, ARCH ACAD EMERG MED, V8, DOI 10.22037/aaem.v8i1.600; Gao M, 2021, LANCET DIABETES ENDO, V9, P350, DOI 10.1016/S2213-8587(21)00089-9; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Intensivregister-Team am RKI, 2020, COR DIS 2019 COVID 1; Krieger N, 2020, LANCET, V395, P1829, DOI 10.1016/S0140-6736(20)31234-4; Landratsamt Rhein-Neckar, 2020, FAKT COR COVID 19 LA; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Liang WH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00562-2020; Moriarty LF, 2020, MMWR-MORBID MORTAL W, V69, P347, DOI 10.15585/mmwr.mm6912e3; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Statistisches Landesamt B-W, 2020, BEV LANDKR RHEIN NEC; Statistisches Landesamt B-W, 2018, ECKD BEV STADT; Tabata S, 2020, LANCET INFECT DIS, V20, P1043, DOI 10.1016/S1473-3099(20)30482-5; Tang DL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008536; The Economist Group, 2020, TRACK COVID 19 EXC D; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wood R, 2021, ARCH DIS CHILD, V106, P1212, DOI 10.1136/archdischild-2021-321604; World Health Organization, 2020, OFF LAB US MED COVID; World Health Organizations, WHO COR DIS COVID 19; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	37	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2021	16	7							e0255513	10.1371/journal.pone.0255513	http://dx.doi.org/10.1371/journal.pone.0255513			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6CU	34329364	Green Published, gold			2023-01-03	WOS:000685248600045
J	de Queiros, VS; dos Santos, IK; Almeida-Neto, PF; Dantas, M; de Franca, IM; Vieira, WHD; Neto, GR; Dantas, PMS; Cabral, BGDTC				de Queiros, Victor Sabino; dos Santos, Isis Kelly; Almeida-Neto, Paulo Francisco; Dantas, Matheus; de Franca, Ingrid Martins; Vieira, Wouber Herickson de Brito; Neto, Gabriel Rodrigues; Dantas, Paulo Moreira Silva; Cabral, Breno Guilherme de Araujo Tinoco			Effect of resistance training with blood flow restriction on muscle damage markers in adults: A systematic review	PLOS ONE			English	Review							ECCENTRIC EXERCISE; TIME-COURSE; INTENSITY; CONTRACTIONS; STRENGTH; SORENESS; RHABDOMYOLYSIS; PERFORMANCE; RECOVERY; INCREASE	Background The purpose of this review was to systematically analyze the evidence regarding the occurrence of muscle damage (changes in muscle damage markers) after resistance training with blood flow restriction sessions. Materials and methods This systematic review was conducted in accordance with the PRISMA recommendations. Two researchers independently and blindly searched the following electronic databases: PubMed, Scopus, Web of Science, CINAHL, LILACS and SPORTdicus. Randomized and non-randomized clinical trials which analyzed the effect of resistance training with blood flow restriction on muscle damage markers in humans were included. The risk of bias assessment was performed by two blinded and independent researchers using the RoB2 tool. Results A total of 21 studies involving 352 healthy participants (men, n = 301; women, n = 51) were eligible for this review. The samples in 66.6% of the studies (n = 14) were composed of untrained individuals. All included studies analyzed muscle damage using indirect markers. Most studies had more than one muscle damage marker and Delayed Onset Muscle Soreness was the measure most frequently used. The results for the occurrence of significant changes in muscle damage markers after low-load resistance training with blood flow restriction sessions were contrasting, and the use of a pre-defined repetition scheme versus muscle failure seems to be the determining point for this divergence, mainly in untrained individuals. Conclusions In summary, the use of sets until failure is seen to be determinant for the occurrence of significant changes in muscle damage markers after low-load resistance training with blood flow restriction sessions, especially in individuals not used to resistance exercise.	[de Queiros, Victor Sabino; Almeida-Neto, Paulo Francisco; Dantas, Matheus; Dantas, Paulo Moreira Silva; Cabral, Breno Guilherme de Araujo Tinoco] Fed Univ Rio Grande Norte UFRN, Grad Program Phys Educ, Natal, RN, Brazil; [dos Santos, Isis Kelly; Dantas, Paulo Moreira Silva] Fed Univ Rio Grande Norte UFRN, Grad Program Hlth Sci, Natal, RN, Brazil; [de Franca, Ingrid Martins; Vieira, Wouber Herickson de Brito] Fed Univ Rio Grande Norte UFRN, Grad Program Physiotherapy, Natal, RN, Brazil; [Neto, Gabriel Rodrigues] Fac Nursing & Med Nova Esperanc FACENE FAMENE, Grad Program Family Hlth, Joao Pessoa, Paraiba, Brazil	Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte	de Queiros, VS (corresponding author), Fed Univ Rio Grande Norte UFRN, Grad Program Phys Educ, Natal, RN, Brazil.	victorsabino97@ufrn.edu.br	Kelly, Isis/AAY-1786-2020	Kelly, Isis/0000-0001-7615-416X; Sabino de Queiros, Victor/0000-0003-4117-0295; VIEIRA, WOUBER/0000-0003-3588-5577; Dantas, Matheus Peixoto Dantas/0000-0002-1815-2251				Alvarez IF, 2020, EUR J SPORT SCI, V20, P125, DOI 10.1080/17461391.2019.1614680; Barauna VG., 2020, FRONT PHYSIOL, P11, DOI [10.3389/fphys.2020.00011, DOI 10.3389/FPHYS.2020.00011]; Baumert P, 2016, EUR J APPL PHYSIOL, V116, P1595, DOI 10.1007/s00421-016-3411-1; Behringer M, 2018, J PHYSIOL SCI, V68, P589, DOI 10.1007/s12576-017-0568-2; Brandner CR, 2017, J STRENGTH COND RES, V31, P3101, DOI 10.1519/JSC.0000000000001779; Centner C, 2019, SPORTS MED, V49, P95, DOI 10.1007/s40279-018-0994-1; Chapman D, 2006, INT J SPORTS MED, V27, P591, DOI 10.1055/s-2005-865920; Chen TC, 2007, J APPL PHYSIOL, V102, P992, DOI 10.1152/japplphysiol.00425.2006; Chen TVC, 2020, EUR J APPL PHYSIOL, V120, P267, DOI 10.1007/s00421-019-04272-w; Chen TC, 2011, EUR J APPL PHYSIOL, V111, P211, DOI 10.1007/s00421-010-1648-7; Cheung K, 2003, SPORTS MED, V33, P145, DOI 10.2165/00007256-200333020-00005; Clark BC, 2017, CLIN J SPORT MED, V27, pE1, DOI 10.1097/JSM.0000000000000309; Clarke M., 2020, BMJ-BRIT MED J, P368; Clarkson PM, 2002, AM J PHYS MED REHAB, V81, pS52, DOI [10.1097/00002060-200211001-00007, 10.1097/01.PHM.0000029772.45258.43]; Coutinho Evandro Silva Freire, 2005, Rev. Bras. Psiquiatr., V27, P146, DOI 10.1590/S1516-44462005000200015; CRENSHAW AG, 1988, ACTA ORTHOP SCAND, V59, P447, DOI 10.3109/17453678809149401; Curty VM, 2018, CLIN PHYSIOL FUNCT I, V38, P468, DOI 10.1111/cpf.12439; Damas F, 2016, INT J SPORTS MED, V37, P633, DOI 10.1055/s-0042-100281; Dorneles GP, 2016, CLIN PHYSIOL FUNCT I, V36, P311, DOI 10.1111/cpf.12231; Ertel KA, 2020, J SPORT MED PHYS FIT, V60, P449, DOI 10.23736/S0022-4707.19.10151-X; Freitas EDS, 2017, INT J SPORTS MED, V38, P1009, DOI 10.1055/s-0043-118342; Hill EC, 2019, EUR J APPL PHYSIOL, V119, P2363, DOI 10.1007/s00421-019-04220-8; Hughes L, 2017, BRIT J SPORT MED, V51, P1003, DOI 10.1136/bjsports-2016-097071; Husmann F, 2018, MED SCI SPORT EXER, V50, P436, DOI 10.1249/MSS.0000000000001475; Hyldahl RD, 2017, EXERC SPORT SCI REV, V45, P24, DOI 10.1249/JES.0000000000000095; Iversen E, 2010, CLIN J SPORT MED, V20, P218, DOI 10.1097/JSM.0b013e3181df8d10; Kadam Prashant, 2010, Int J Ayurveda Res, V1, P55, DOI 10.4103/0974-7788.59946; Karabulut M, 2013, CLIN PHYSIOL FUNCT I, V33, P393, DOI 10.1111/cpf.12044; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Ladlow P, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01269; Loenneke JP, 2014, SCAND J MED SCI SPOR, V24, pE415, DOI 10.1111/sms.12210; Loenneke JP, 2013, EUR J APPL PHYSIOL, V113, P923, DOI 10.1007/s00421-012-2502-x; Loenneke JP, 2012, EUR J APPL PHYSIOL, V112, P2903, DOI 10.1007/s00421-011-2266-8; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Moran-Navarro R, 2017, EUR J APPL PHYSIOL, V117, P2387, DOI 10.1007/s00421-017-3725-7; Neto GR, 2018, J SPORT SCI, V36, P104, DOI 10.1080/02640414.2017.1283430; NEWHAM DJ, 1983, J NEUROL SCI, V61, P109, DOI 10.1016/0022-510X(83)90058-8; Nielsen JL, 2017, J PHYSIOL-LONDON, V595, P4857, DOI 10.1113/JP273907; Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4; Pareja-Blanco F, 2020, J STRENGTH COND RES, V34, P2867, DOI 10.1519/JSC.0000000000002756; Pareja-Blanco F, 2017, CLIN PHYSIOL FUNCT I, V37, P630, DOI 10.1111/cpf.12348; Patterson SD, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00533; Patterson SD, 2018, J SPORT SCI, V36, P123, DOI 10.1080/02640414.2017.1284341; Pedersen BK, 2007, TRENDS PHARMACOL SCI, V28, P152, DOI 10.1016/j.tips.2007.02.002; Sato Y., 2005, INT J KAATSU TRAIN R, V1, P1, DOI [DOI 10.3806/IJKTR.1.1, 10.3806/ijktr.1.1]; Shiromaru FF, 2019, SCAND J MED SCI SPOR, V29, P1713, DOI 10.1111/sms.13516; Sieljacks P, 2016, EUR J APPL PHYSIOL, V116, P513, DOI 10.1007/s00421-015-3304-8; Slysz J, 2016, J SCI MED SPORT, V19, P669, DOI 10.1016/j.jsams.2015.09.005; Sudo M, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12449; Sugaya M, 2011, CLIN PHYSIOL FUNCT I, V31, P411, DOI 10.1111/j.1475-097X.2011.01033.x; Tabata S, 2016, J STRENGTH COND RES, V30, P2064, DOI 10.1519/JSC.0000000000001295; Takarada Y, 2000, J APPL PHYSIOL, V88, P61, DOI 10.1152/jappl.2000.88.1.61; Tetzlaff JM, 2012, SYST REV-LONDON, V1, DOI 10.1186/2046-4053-1-43; Thiebaud RS, 2014, ACTA PHYSIOL HUNG, V101, P150, DOI 10.1556/APhysiol.101.2014.2.3; Thiebaud RS, 2013, INTERV MED APPL SCI, V5, P53, DOI 10.1556/IMAS.5.2013.2.1; Torres PA, 2015, OCHSNER J, V15, P58; Umbel JD, 2009, EUR J APPL PHYSIOL, V107, P687, DOI 10.1007/s00421-009-1175-6; Vechin Felipe C, 2015, J Strength Cond Res, V29, P1071, DOI 10.1519/JSC.0000000000000703; Vincent HK, 1997, INT J SPORTS MED, V18, P431; Volek JS, 2002, AM J PHYSIOL-ENDOC M, V282, pE474, DOI 10.1152/ajpendo.00277.2001; Wernbom M, 2012, EUR J APPL PHYSIOL, V112, P2051, DOI 10.1007/s00421-011-2172-0; Wilson JM, 2013, J STRENGTH COND RES, V27, P3068, DOI 10.1519/JSC.0b013e31828a1ffa; Yasuda T, 2015, EUR J APPL PHYSIOL, V115, P919, DOI 10.1007/s00421-014-3073-9	63	2	2	4	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2021	16	6							e0253521	10.1371/journal.pone.0253521	http://dx.doi.org/10.1371/journal.pone.0253521			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BC	34143837	Green Published, gold			2023-01-03	WOS:000671690700071
J	Adisasmita, A; Izati, Y; Choirunisa, S; Pratomo, H; Adriyanti, L				Adisasmita, Asri; Izati, Yulia; Choirunisa, Septyana; Pratomo, Hadi; Adriyanti, Luzy			Kangaroo mother care knowledge, attitude, and practice among nursing staff in a hospital in Jakarta, Indonesia	PLOS ONE			English	Article							IMPLEMENTATION; BIRTH; INFANTS; SKIN	Background Kangaroo mother care (KMC) has been proven to decrease rates of morbidity and mortality among premature and low-birth-weight infants. Thus, this study aimed to obtain baseline data regarding KMC knowledge, attitudes, and practices (KAP) among nursing staff caring for mothers and newborns in a hospital in Indonesia. Methods This cross-sectional study included 65 participants from three hospital wards at Koja District Hospital, North Jakarta. Participants included 29 perinatal ward nurses, 21 postnatal ward nurses and midwives, and 15 labor ward midwives. Data on KAP of KMC were collected using a self-administered questionnaire with closed-ended questions. Each questionnaire can be completed in approximately 1 hour. Results Among the included nursing staff, 12.3% (8/65) were determined to have received specific training on KMC, whereas 21.5% (14/65) had received more general training that included KMC content. About 46.2% of the nursing staff had good knowledge concerning KMC, 98.5% had good knowledge of KMC benefits, and 100% had a positive attitude toward KMC. All perinatal ward nurses had some experience assisting and implementing KMC. Some KAP that were observed among the nursing staff included lack of knowledge about the eligible infant weight for KMC and weight gain of infants receiving KMC, lack of education/training about KMC, and concerns regarding necessary equipment in KMC wards. Conclusions This study identified several issues that need to be addressed, including knowledge of feeding and weight gain, workload, incubator use, and the need for well-equipped KMC wards. We recommend that hospitals improve their nursing staff's knowledge of KMC and establish well-equipped KMC wards.	[Adisasmita, Asri] Univ Indonesia, Dept Epidemiol, Fac Publ Hlth, Depok, Indonesia; [Adisasmita, Asri; Izati, Yulia; Choirunisa, Septyana; Pratomo, Hadi] Univ Indonesia, Kangaroo Mother Care Res Project, Fac Publ Hlth, Depok, Indonesia; [Pratomo, Hadi] Univ Indonesia, Dept Hlth Educ & Behav Sci, Fac Publ Hlth, Depok, Indonesia; [Adriyanti, Luzy] Koja Dist Gen Hosp, North Jakarta, Jakarta Provinc, Indonesia	University of Indonesia; University of Indonesia; University of Indonesia	Adisasmita, A (corresponding author), Univ Indonesia, Dept Epidemiol, Fac Publ Hlth, Depok, Indonesia.; Adisasmita, A (corresponding author), Univ Indonesia, Kangaroo Mother Care Res Project, Fac Publ Hlth, Depok, Indonesia.	aadsmt237@gmail.com		Choirunisa, Septyana/0000-0001-5756-8957	PEER (Partnerships for Enhanced Engagement in Research) Program; USAID; Universitas Indonesia [2019: PENG-1/UN2. R3.1/PPM.00/2019];  [AID-OAA-A-11-00012]	PEER (Partnerships for Enhanced Engagement in Research) Program; USAID(United States Agency for International Development (USAID)); Universitas Indonesia(Ministry of Research and Technology of the Republic of Indonesia (RISTEK)); 	This study was made possible by the generous support of the American people through the PEER (Partnerships for Enhanced Engagement in Research) Program. The program is supported by USAID and implemented by the U.S. National Academies of Sciences. HP (as the principal investigator of this study) received funding under Sponsor Grant Award Number: AID-OAA-A-11-00012. NAS URL: http://www.nasonline.org/USAID PEER Program https://www.usaid.gov/what-we-do/GlobalDevLab/international-researchscience-programs/peer The contents of this study are the sole responsibility of the authors and do not necessarily reflect the views of the USAID or the United States Government. The publication of this study was made possible by support of Universitas Indonesia (UI research grant 2019: PENG-1/UN2. R3.1/PPM.00/2019) including funding for publication. The funders had no role in the study design; data collection and analysis, decision to publish, or preparation of the manuscript.	ACCESS and USAID, 2009, KANG MOTH CAR FAC GU; Bergh AM, 2003, ACTA PAEDIATR, V92, P709, DOI 10.1080/08035250310002399; Bergh AM., 2007, RETROSPECTIVE EVALUA; Bergh AM, 2012, S AFR J CHILD HEALTH, V6, P38; Cattaneo A, 1998, ACTA PAEDIATR, V87, P976, DOI 10.1080/080352598750031653; Chan G, 2017, HEALTH POLICY PLANN, V32, P1466, DOI 10.1093/heapol/czx098; Chan GJ, 2016, B WORLD HEALTH ORGAN, V94, P130, DOI 10.2471/BLT.15.157818; Charpak N, 1997, PEDIATRICS, V100, P682, DOI 10.1542/peds.100.4.682; Charpak N, 2006, ACTA PAEDIATR, V95, P529, DOI 10.1080/08035250600599735; Chawanpaiboon S, 2019, LANCET GLOB HEALTH, V7, pE37, DOI 10.1016/S2214-109X(18)30451-0; Chia P, 2006, AUST J ADV NURS, V23, P20; Conde-Agudelo A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002771.pub2; Conde-Agudelo A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002771.pub4; Desai RP., 2013, NHL J MED SCI, V2, P2319; DiMenna L, 2006, NEONATAL NETW, V25, P405, DOI 10.1891/0730-0832.25.6.405; El-Nagar S., 2013, Journal of Natural Sciences Research, V3, P175; Engler Arthur J, 2002, MCN Am J Matern Child Nurs, V27, P146, DOI 10.1097/00005721-200205000-00004; Hendricks-Munoz KD, 2010, AM J PERINAT, V27, P193, DOI 10.1055/s-0029-1234039; Johnson AN, 2007, MCN-AM J MATERN-CHIL, V32, P25; JSI Research & Training Institute, 2010, HLTH SERV PROGR HSP; KMC (Kangaroo Mother Care) research team PEER (Partnership of Engaging and Enhancement Research) USAID, 2016, KANG MOTH CAR BAS RE; Kristoffersen L, 2016, JOGNN-J OBST GYN NEO, V45, P339, DOI 10.1016/j.jogn.2016.02.007; Lawn JE, 2010, INT J EPIDEMIOL, V39, P144, DOI 10.1093/ije/dyq031; Lee HC, 2012, BREASTFEED MED, V7, P79, DOI 10.1089/bfm.2011.0004; Lipato T, 2012, EVALUATION KANGAROO; Mallet I, 2007, ARCH PEDIATRIE, V14, P881, DOI 10.1016/j.arcped.2007.01.017; McMaster P, 2000, TROP DOCT, V30, P136, DOI 10.1177/004947550003000307; Moore ER, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub3; Nyqvist KH, 2011, THESIS UPPSALA U UPP; Pratomo Hadi, 2020, Clin Exp Pediatr, V63, P433, DOI 10.3345/cep.2018.06506; Seidman G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125643; Solomons N, 2012, S AFR J CLIN NUTR, V25, P33; Vidya G. S., 2015, International Journal of Health and Allied Sciences, V4, P230; WHO, 2016, EARL IN BREASTF; WHO Immediate KMC Study Group, 2020, BMC TRIALS, V21, P280, DOI [10.1186/s13063-020-4101-1, DOI 10.1186/S13063-020-4101-1]; Zhang Y, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021740	36	1	1	4	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2021	16	6							e0252704	10.1371/journal.pone.0252704	http://dx.doi.org/10.1371/journal.pone.0252704			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RB	34086791	Green Published, gold			2023-01-03	WOS:000664640100110
J	Dulay, RM; Valdez, BC; Li, Y; Chakrabarti, S; Dhillon, B; Kalaw, SP; Reyes, RG; Cabrera, EC				Dulay, Rich Milton; Valdez, Benigno C.; Li, Yang; Chakrabarti, Seemanti; Dhillon, Braham; Kalaw, Sofronio P.; Reyes, Renato G.; Cabrera, Esperanza C.			Cytotoxicity of Gymnopilus purpureosquamulosus extracts on hematologic malignant cells through activation of the SAPK/JNK signaling pathway	PLOS ONE			English	Article							METABOLIC OXIDATIVE STRESS; KINASE; APOPTOSIS; MUSHROOM; DEATH; LINES; ASK1; JNK	Treatment of hematologic malignancies is a formidable challenge for hematologists and there is an urgent need to identify safe and efficacious agents either via synthesis in the laboratory or isolation from natural products. Here, we report the cytotoxicity of extracts from mushroom Gymnopilus purpureosquamulosus HOil (G. pps) and describe its molecular mechanisms. Using leukemia, lymphoma and multiple myeloma cell lines, 28-35 ppm G. pps extract inhibited cell proliferation by similar to 46-79%, which correlates with activation of apoptosis as indicated by increase in annexin V-positive cells (similar to 5-8-fold), production of reactive oxygen species (similar to 2-3-fold), cells in sub G0/G1 phase (similar to 3-13-fold), caspase 3 enzymatic activity (similar to 1.6-2.9-fold), DNA fragmentation, PARP1 cleavage and down-regulation of prosurvival proteins. Mitochondrial membrane potential decreased and leakage of pro-apoptotic factors to cytoplasm was observed, consistent with the activation of intrinsic apoptosis. Western blot analysis showed activation of the ASK1-MEK-SAPK/JNK and ASK1-P38 MAPK pathways possibly due to changes in the cellular redox status as suggested by decreased protein levels of peroxiredoxin, thioredoxin and thioredoxin reductase. Moreover, antioxidant N-acetylcysteine alleviated the cytotoxicity of G. pps. Pharmacological inhibition of SAPK/JNK and P38 alleviated the G. pps-mediated cytotoxicity. The extract activated apoptosis in leukemia and lymphoma patient cell samples but not in mononuclear cells from healthy donors further supporting the therapeutic values of G. pps for hematologic malignancies.	[Dulay, Rich Milton; Kalaw, Sofronio P.; Reyes, Renato G.] Cent Luzon State Univ, Coll Sci, Ctr Trop Mushroom Res & Dev, Dept Biol Sci, Sci City Of Munoz, Nueva Ecija, Philippines; [Dulay, Rich Milton; Cabrera, Esperanza C.] De La Salle Univ, Coll Sci, Dept Biol, Manila, Philippines; [Valdez, Benigno C.; Li, Yang] UT MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [Chakrabarti, Seemanti; Dhillon, Braham] Univ Florida, Ft Lauderdale Res & Educ Ctr, Dept Plant Pathol, Davie, FL USA	Central Luzon State University; De La Salle University; University of Texas System; UTMD Anderson Cancer Center; State University System of Florida; University of Florida	Valdez, BC (corresponding author), UT MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.	bvaldez@mdanderson.org		Dulay, Rich Milton/0000-0002-5438-878X	Philippine Department of Science and Technology-Science Education Institute scholarship grant; National Institutes of Health through M.D. Anderson's Cancer Center Support Grant [CA016672]	Philippine Department of Science and Technology-Science Education Institute scholarship grant; National Institutes of Health through M.D. Anderson's Cancer Center Support Grant	RMD was supported by the Philippine Department of Science and Technology-Science Education Institute scholarship grant. Part of this research was performed in the Flow Cytometry & Cellular Imaging Facility, which is supported in part by the National Institutes of Health through M.D. Anderson's Cancer Center Support Grant CA016672.	Al-Kandari N, 2019, MOLECULES, V24, DOI 10.3390/molecules24183333; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; American Cancer Society, 2020, CANC FACTS FIG 2020; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Arnante MES, 2017, P DLSU RES C 2017 SA; Badalyan SM, 2014, P 8 INT C MUSHR BIOL; Bharali DJ, 2009, INT J NANOMED, V4, P1; Boukes GJ, 2017, S AFR J BOT, V113, P62, DOI 10.1016/j.sajb.2017.07.010; Buniel PAS, 2018, INT J PHARM SCI RES, V9, P4201, DOI 10.13040/IJPSR.0975-8232.9(10).4201-09; Chaitanya MVNL, 2019, ASIAN PAC J TROP MED, V12, P531, DOI 10.4103/1995-7645.272482; Culala JM., 2018, INT J BIOL PHARM ALL, V7, P1890, DOI DOI 10.31032/IJBPAS/2018/7.10.4565; De Leon A., 2016, CURR RES ENVIRON APP, V6, P61; Dhanasekaran Danny N, 2017, Genes Cancer, V8, P682, DOI 10.18632/genesandcancer.155; Dulay RMR, 2020, BIOCATAL AGR BIOTECH, V27, DOI 10.1016/j.bcab.2020.101666; Dulay RMR., 2017, INT J BIOL PHARM ALL, V6, P1459; Durgo K, 2013, INT J MED MUSHROOMS, V15, P435, DOI 10.1615/IntJMedMushr.v15.i5.20; Fang EF, 2016, NAT REV MOL CELL BIO, V17, P308, DOI 10.1038/nrm.2016.14; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351; Hseu YC, 2019, FOOD CHEM TOXICOL, V124, P30, DOI 10.1016/j.fct.2018.11.043; Joseph TP, 2018, INTEGR CANCER THER, V17, P200, DOI 10.1177/1534735417736861; Kim HS, 2005, MOL CELL BIOL, V25, P6821, DOI 10.1128/MCB.25.15.6821-6833.2005; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Liwanag JMG., 2017, INT J BIOL PHARM ALL, V6, P1060; Manikanta K, 2020, HAEMATOLOGICA, V105, pE419, DOI 10.3324/haematol.2019.233908; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Matsuzawa A, 2008, BBA-GEN SUBJECTS, V1780, P1325, DOI 10.1016/j.bbagen.2007.12.011; MEG DE CASTRO, 2015, J CHEM BIOL PHYS SCI, V5, P1646; Nadeau PJ, 2007, MOL BIOL CELL, V18, P3903, DOI 10.1091/mbc.E07-05-0491; Papadakis ES, 2006, FEBS LETT, V580, P1320, DOI 10.1016/j.febslet.2006.01.053; Patel S, 2012, 3 BIOTECH, V2, P1, DOI 10.1007/s13205-011-0036-2; Psenakova K, 2020, FEBS J, V287, P1626, DOI 10.1111/febs.15101; Ragasa C.Y., 2020, ASIAN J CHEM, V32, P1197, DOI [10.14233/ajchem.2020.22591, DOI 10.14233/AJCHEM.2020.22591]; Sadi G, 2015, PHARMACOGN MAG, V11, pS6, DOI 10.4103/0973-1296.157665; Saha P, 2020, MOL CELL NEUROSCI, V108, DOI 10.1016/j.mcn.2020.103551; Sak Katrin, 2012, Chemother Res Pract, V2012, P282570, DOI 10.1155/2012/282570; Soethoudt M, 2014, FREE RADICAL BIO MED, V77, P331, DOI 10.1016/j.freeradbiomed.2014.09.025; Song JJ, 2005, J CELL BIOL, V170, P61, DOI 10.1083/jcb.200502070; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Valdez BC, 2008, LEUKEMIA RES, V32, P1684, DOI 10.1016/j.leukres.2008.01.016; Wasser SP, 2010, INT J MED MUSHROOMS, V12, P1, DOI 10.1615/IntJMedMushr.v12.i1.10; White J., 1990, PCR PROTOCOL GUIDE M, P315; World Health Organization, WHO REP CANC SETT PR; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xu R, 2015, J BIOMED INFORM, V55, P64, DOI 10.1016/j.jbi.2015.03.009; Zhang JF, 2016, ONCOL LETT, V12, P413, DOI 10.3892/ol.2016.4659; Zhang M, 2019, PROG MOL BIOL TRANSL, V163, P297, DOI 10.1016/bs.pmbts.2019.02.013; Zheng L, 2018, MOL MED REP, V18, P938, DOI 10.3892/mmr.2018.9035	48	2	2	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2021	16	5							e0252541	10.1371/journal.pone.0252541	http://dx.doi.org/10.1371/journal.pone.0252541			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6PN	34048499	Green Published, gold			2023-01-03	WOS:000664636100065
J	Gutierrez, JJ; Leturiondo, M; de Gauna, SR; Ruiz, JM; Azcarate, I; Gonzalez-Otero, DM; Urtusagasti, JF; Russell, JK; Daya, MR				Julio Gutierrez, Jose; Leturiondo, Mikel; Ruiz de Gauna, Sofia; Maria Ruiz, Jesus; Azcarate, Izaskun; Maria Gonzalez-Otero, Digna; Francisco Urtusagasti, Juan; Russell, James Knox; Daya, Mohamud Ramzan			Assessment of the evolution of end-tidal carbon dioxide within chest compression pauses to detect restoration of spontaneous circulation	PLOS ONE			English	Article							CARDIAC-ARREST PATIENTS; CARDIOPULMONARY-RESUSCITATION; EXTERNAL DEFIBRILLATORS; PARTIAL-PRESSURE; CO2; CPR; GUIDELINES; RECOVERY; MONITOR; RETURN	Background Measurement of end-tidal CO2 (ETCO2) can help to monitor circulation during cardiopulmonary resuscitation (CPR). However, early detection of restoration of spontaneous circulation (ROSC) during CPR using waveform capnography remains a challenge. The aim of the study was to investigate if the assessment of ETCO2 variation during chest compression pauses could allow for ROSC detection. We hypothesized that a decay in ETCO2 during a compression pause indicates no ROSC while a constant or increasing ETCO2 indicates ROSC. Methods We conducted a retrospective analysis of adult out-of-hospital cardiac arrest (OHCA) episodes treated by the advanced life support (ALS). Continuous chest compressions and ventilations were provided manually. Segments of capnography signal during pauses in chest compressions were selected, including at least three ventilations and with durations less than 20 s. Segments were classified as ROSC or non-ROSC according to case chart annotation and examination of the ECG and transthoracic impedance signals. The percentage variation of ETCO2 between consecutive ventilations was computed and its average value, Delta ETavg, was used as a single feature to discriminate between ROSC and non-ROSC segments. Results A total of 384 segments (130 ROSC, 254 non-ROSC) from 205 OHCA patients (30.7% female, median age 66) were analyzed. Median (IQR) duration was 16.3 (12.9,18.1) s. Delta ETavg was 0.0 (-0.7, 0.9)% for ROSC segments and -11.0 (-14.1, -8.0)% for non-ROSC segments (p < 0.0001). Best performance for ROSC detection yielded a sensitivity of 95.4% (95% CI: 90.1%, 98.1%) and a specificity of 94.9% (91.4%, 97.1%) for all ventilations in the segment. For the first 2 ventilations, duration was 7.7 (6.0, 10.2) s, and sensitivity and specificity were 90.0% (83.5%, 94.2%) and 89.4 (84.9%, 92.6%), respectively. Our method allowed for ROSC detection during the first compression pause in 95.4% of the patients. Conclusion Average percent variation of ETCO2 during pauses in chest compressions allowed for ROSC discrimination. This metric could help confirm ROSC during compression pauses in ALS settings.	[Julio Gutierrez, Jose; Leturiondo, Mikel; Ruiz de Gauna, Sofia; Maria Ruiz, Jesus; Azcarate, Izaskun; Maria Gonzalez-Otero, Digna] Univ Basque Country, UPV EHU, Dept Commun Engn, Bilbao, Spain; [Maria Gonzalez-Otero, Digna] Bexen Cardio, Ermua, Spain; [Francisco Urtusagasti, Juan] Basque Country Hlth Syst, Emergentziak Osakidetza, Basque Country, Spain; [Russell, James Knox; Daya, Mohamud Ramzan] Oregon Hlth & Sci Univ OHSU, Portland, OR USA	University of Basque Country; Oregon Health & Science University	de Gauna, SR (corresponding author), Univ Basque Country, UPV EHU, Dept Commun Engn, Bilbao, Spain.	sofia.ruizdegauna@ehu.eus	Russell, James/AAW-8820-2021; Gutierrez, J. Julio/G-7867-2014	Russell, James/0000-0002-5133-9720; Gonzalez-Otero, Digna Maria/0000-0002-6594-5748; Gutierrez, J. Julio/0000-0003-3539-0320; Ruiz de Gauna, Sofia/0000-0002-0414-0946	Basque Government [IT1087-16, PRE-2019-2-0251]; Spanish Ministry of Science, Innovation and Universities [RTI2018-094396-B-I00]; program Torres Quevedo [PTQ-16-08201]	Basque Government(Basque Government); Spanish Ministry of Science, Innovation and Universities; program Torres Quevedo	Authors JJG, JMR, IA, and SRG received research support from the Basque Government through the grant IT1087-16 (for research groups), and author ML through the predoctoral grant PRE-2019-2-0251. https://www.euskadi.eus Authors JJG, JMR, ML, and SRG received research support from the Spanish Ministry of Science, Innovation and Universities through the grant RTI2018-094396-B-I00 and author DMGO from the program Torres Quevedo PTQ-16-08201. http://www.ciencia.gob.es/None of the above organizations had any additional role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Bexen Cardio (http://www.bexencardio.com) provided support in the form of salaries for author DMGO, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Authors JFU, JKR and MRD received no funding for this work. The specific role of each author is articulated in the Author Contributions section.	Alonso E, 2016, RESUSCITATION, V99, P56, DOI 10.1016/j.resuscitation.2015.11.014; Brinkrolf P, 2018, RESUSCITATION, V122, P19, DOI 10.1016/j.resuscitation.2017.11.040; Cromie NA, 2008, CRIT CARE MED, V36, P1578, DOI 10.1097/CCM.0b013e318170a03b; Cromie NA, 2010, CRIT CARE MED, V38, P510, DOI 10.1097/CCM.0b013e3181c02ca1; Davis DP, 2013, RESUSCITATION, V84, P25, DOI 10.1016/j.resuscitation.2012.07.040; Edelson DP, 2006, RESUSCITATION, V71, P137, DOI 10.1016/j.resuscitation.2006.04.008; Elola A, 2019, RESUSCITATION, V142, P153, DOI 10.1016/j.resuscitation.2019.03.048; Gazmuri RJ, 2012, RESUSCITATION, V83, P259, DOI 10.1016/j.resuscitation.2011.07.034; GUDIPATI CV, 1988, CIRCULATION, V77, P234, DOI 10.1161/01.CIR.77.1.234; Hamrick JL, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000450; Gutierrez JJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228395; Kolar M, 2008, CRIT CARE, V12, DOI 10.1186/cc7009; Levine RL, 1997, NEW ENGL J MED, V337, P301, DOI 10.1056/NEJM199707313370503; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; Losert H, 2007, RESUSCITATION, V73, P221, DOI 10.1016/j.resuscitation.2006.10.001; Murphy RA, 2016, PREHOSP EMERG CARE, V20, P369, DOI 10.3109/10903127.2015.1115929; Paiva EF, 2018, RESUSCITATION, V123, P1, DOI 10.1016/j.resuscitation.2017.12.003; Pantazopoulos C, 2015, HEART LUNG CIRC, V24, P1053, DOI 10.1016/j.hlc.2015.05.013; Pellis T, 2002, CRIT CARE MED, V30, pS176, DOI 10.1097/00003246-200204001-00012; Pokorna M, 2010, J EMERG MED, V38, P614, DOI 10.1016/j.jemermed.2009.04.064; Poon KM, 2016, RESUSCITATION, V102, P80, DOI 10.1016/j.resuscitation.2016.02.021; Risdal M, 2008, IEEE T BIO-MED ENG, V55, P60, DOI 10.1109/TBME.2007.910644; Rognas L, 2014, RESUSCITATION, V85, P332, DOI 10.1016/j.resuscitation.2013.12.009; Ruiz JM, 2018, RESUSCITATION, V128, P158, DOI 10.1016/j.resuscitation.2018.04.036; SANDERS AB, 1985, AM J EMERG MED, V3, P147, DOI 10.1016/0735-6757(85)90039-7; Sandroni C, 2018, RESUSCITATION, V132, P73, DOI 10.1016/j.resuscitation.2018.08.018; Sandroni C, 2016, RESUSCITATION, V104, pA5, DOI 10.1016/j.resuscitation.2016.05.018; Savastano S, 2017, RESUSCITATION, V121, P71, DOI 10.1016/j.resuscitation.2017.09.010; Sehra R, 2003, PACE, V26, P515, DOI 10.1046/j.1460-9592.2003.00085.x; Sheak KR, 2015, RESUSCITATION, V89, P149, DOI 10.1016/j.resuscitation.2015.01.026; Soar J, 2015, RESUSCITATION, V95, P100, DOI 10.1016/j.resuscitation.2015.07.016; STOCK MC, 1995, CRIT CARE CLIN, V11, P219, DOI 10.1016/S0749-0704(18)30093-9; Tat LC, 2016, RESUSCITATION, V104, P53, DOI 10.1016/j.resuscitation.2016.04.018; Vaillancourt C, 2011, RESUSCITATION, V82, P1501, DOI 10.1016/j.resuscitation.2011.07.011; Wang AY, 2016, AM J EMERG MED, V34, P2367, DOI 10.1016/j.ajem.2016.08.052; WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011	36	2	2	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2021	16	5							e0251511	10.1371/journal.pone.0251511	http://dx.doi.org/10.1371/journal.pone.0251511			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6NI	34003839	Green Published, gold			2023-01-03	WOS:000664630200023
J	Roh, JA; Kim, KI; Jung, HJ				Roh, Ji-Ae; Kim, Kwan-Il; Jung, Hee-Jae			The efficacy of manual therapy for chronic obstructive pulmonary disease: A systematic review	PLOS ONE			English	Review							QUALITY-OF-LIFE; OSTEOPATHIC MANIPULATIVE TREATMENT; PHYSICAL-ACTIVITY; EXERCISE CAPACITY; BACK-PAIN; COPD; STATEMENT; CARE; MANAGEMENT; PEOPLE	Background Manual therapy (MT) can be beneficial in the management of chronic obstructive pulmonary disease (COPD). However, evidence of the efficacy of MT for COPD is not clear. Therefore, we aimed to review the effects of MT, including Chuna, in people diagnosed with COPD. Methods MEDLINE via PubMed, EMBASE, The Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Database (CNKI), KoreaMed, Korean Medical Database (KMbase), and Oriental Medicine Advanced Searching Integrated System (OASIS) were searched. Randomized controlled trials (RCTs) and crossover RCTs were included. The main inclusion criteria were COPD diagnosis (forced expiratory volume in the first second [FEV1]/forced vital capacity [FVC] < 0.70). The primary outcomes were lung function and exercise capacity. The secondary outcomes were symptoms, quality of life (QoL), and adverse event (AE)s. Studies reporting one or both of the primary outcomes were included. The Cochrane RoB 2.0 tool was used to assess the risk of bias. Data synthesis and analysis were conducted according to the trial design. Results Of the 2564 searched articles, 13 studies were included. For the primary outcomes, the effect of MT on pulmonary function and exercise capacity in COPD was partly significant but could not be confirmed due to the limited number of studies included in the subgroups. For the secondary outcomes, no definitive evidence regarding the improvement of symptoms and QoL was found, and some minor adverse effects were reported. Conclusions There is insufficient evidence to support the role of MT in the management of COPD. High-quality studies are needed to thoroughly evaluate the effect of MT on COPD.	[Roh, Ji-Ae; Kim, Kwan-Il; Jung, Hee-Jae] Kyung Hee Univ, Grad Sch, Dept Clin Korean Med, Seoul, South Korea; [Roh, Ji-Ae; Kim, Kwan-Il; Jung, Hee-Jae] Kyung Hee Univ, Coll Korean Med, Dept Internal Med Immune & Resp Syst, Div Allergy, Seoul, South Korea	Kyung Hee University; Kyung Hee University	Kim, KI; Jung, HJ (corresponding author), Kyung Hee Univ, Grad Sch, Dept Clin Korean Med, Seoul, South Korea.; Kim, KI; Jung, HJ (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Internal Med Immune & Resp Syst, Div Allergy, Seoul, South Korea.	myhappy78@naver.com; hanfish@khmc.or.kr	Kim, Kwan-Il/GXM-4190-2022	Kim, Kwan-Il/0000-0002-8071-3881	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HF20C0030]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) and funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HF20C0030).	Alter P, 2020, ERJ OPEN RES, V6, DOI 10.1183/23120541.00092-2020; Andenaes R, 2014, J MULTIDISCIP HEALTH, V7, P239, DOI 10.2147/JMDH.S62476; [Anonymous], 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001009; [Anonymous], 2014, BIOL MANUAL THERAPIE; Arne M, 2009, SCAND J PRIM HEALTH, V27, P141, DOI 10.1080/02813430902808643; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Bougie JDMA., 2001, AGING BODY CONSERVAT, V1st ed ed; Boutron I, 2017, ANN INTERN MED, V167, P40, DOI 10.7326/M17-0046; Brien SB, 2016, NPJ PRIM CARE RESP M, V26, DOI 10.1038/npjpcrm.2016.51; Buscemi Andrea, 2019, J Complement Integr Med, V17, DOI 10.1515/jcim-2018-0128; Carnes D, 2010, MANUAL THER, V15, P2, DOI 10.1016/j.math.2009.02.003; Chen Q ZL., 2006, CHIN J CLIN REHABIL, V10, P10; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Santos CMD, 2007, REV LAT-AM ENFERM, V15, P508, DOI 10.1590/S0104-11692007000300023; Decramer M, 2012, LANCET, V379, P1341, DOI 10.1016/S0140-6736(11)60968-9; Deeks J., 2021, COCHRANE HDB SYSTEMA; Durr S, 2014, COPD, V11, P689, DOI 10.3109/15412555.2014.898050; Engel RM, 2016, J MAN MANIP THER, V24, DOI 10.1179/2042618614Y.0000000074; Galletti J, 2018, J ALTERN COMPLEM MED, V24, P677, DOI 10.1089/acm.2017.0390; Global Initiative for chronic obstructive lung disease (GOLD), 2021, GLOBAL STRATEGY DIAG, DOI [10.1164/rccm.202009-3533SO, DOI 10.1164/RCCM.202009-3533SO]; Heneghan NR, 2012, MANUAL THER, V17, P507, DOI 10.1016/j.math.2012.05.004; Higgins JP, 2021, COCHRANE HDB SYSTEMA; Higgins JPT., 2021, COCHRANE; Holland AE, 2014, EUR RESPIR J, V44, P1428, DOI 10.1183/09031936.00150314; Hsieh PC, 2019, COMPLEMENT THER CLIN, V35, P208, DOI 10.1016/j.ctcp.2019.02.016; In Heo, 2015, [The Journal of Korea CHUNA Manual Medicine for Spine & Nerves, 척추신경추나의학회지], V10, P1; 이남우, 2017, [The Journal of Korea CHUNA Manual Medicine for Spine & Nerves, 척추신경추나의학회지], V12, P1; Kim Mikyung, 2019, [The Journal of Korea CHUNA Manual Medicine for Spine & Nerves, 척추신경추나의학회지], V14, P15, DOI 10.30581/jkcmm.2019.14.2.15; Kruis AL, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009437.pub2; Kurzaj M, 2013, ADV CLIN EXP MED, V22, P721; Lee H, 2017, INT J CHRONIC OBSTR, V12, P3301, DOI 10.2147/COPD.S145910; Lee Ji-Eun, 2019, [The Journal of Korea CHUNA Manual Medicine for Spine & Nerves, 척추신경추나의학회지], V14, P119, DOI 10.30581/jkcmm.2019.14.1.119; Lee NW, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/8218139; Lim KT, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3302-y; Maltais F, 2014, AM J RESP CRIT CARE, V189, P1121, DOI 10.1164/rccrn.201402-0373ST; Maskey-Warzechowska M, 2019, ADV EXP MED BIOL, V1222, P17, DOI 10.1007/5584_2019_418; Miller WD., 1975, RES STATUS SPINAL MA, P295; Moon TW, 2013, CHIN J INTEGR MED, V19, P228, DOI 10.1007/s11655-012-1238-0; Noll Donald R, 2009, Osteopath Med Prim Care, V3, P9, DOI 10.1186/1750-4732-3-9; Noll DR, 2008, J AM OSTEOPATH ASSOC, V108, P251; Paanalahti K, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-77; Park SY, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010144; Park TY, 2014, INTEGR MED RES, V3, P49, DOI 10.1016/j.imr.2013.08.001; Pinto-Plata VM, 2004, EUR RESPIR J, V23, P28, DOI 10.1183/09031936.03.00034603; Pitta F, 2005, AM J RESP CRIT CARE, V171, P972, DOI 10.1164/rccm.200407-855OC; Polastri M, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55050151; Putt MT, 2008, ARCH PHYS MED REHAB, V89, P1103, DOI 10.1016/j.apmr.2007.11.033; Rabe KF, 2017, LANCET, V389, P1931, DOI 10.1016/S0140-6736(17)31222-9; Rehman H, 2017, RESP CARE, V62, P1043, DOI 10.4187/respcare.04984; Reychler G, 2018, CLIN RESPIR J, V12, P1247, DOI 10.1111/crj.12658; Rocha T, 2015, J PHYSIOTHER, V61, P182, DOI 10.1016/j.jphys.2015.08.009; Rochester CL, 2015, AM J RESP CRIT CARE, V192, P1373, DOI 10.1164/rccm.201510-1966ST; Roh JA, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018832; Shakil-ur-Rehman S., 2013, RAWAL MED J, V38, P36; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647; Simonelli C, 2019, PULMONOLOGY, V25, P236, DOI 10.1016/j.pulmoe.2018.12.008; Spruit MA, 2013, AM J RESP CRIT CARE, V188, pE13, DOI 10.1164/rccm.201309-1634ST; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Swait G, 2017, CHIROPR MAN THER, V25, DOI 10.1186/s12998-017-0168-5; The Lancet, 2017, LANCET, V389, pP574, DOI [10.1016/S0140-6736%2817%2930327-6, DOI 10.1016/S0140-6736%2817%2930327-6]; Vanfleteren LEGW, 2016, LANCET RESP MED, V4, P911, DOI 10.1016/S2213-2600(16)00097-7; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; Wada JT, 2016, INT J CHRONIC OBSTR, V11, P2691, DOI 10.2147/COPD.S114548; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wearing J, 2016, J ALTERN COMPLEM MED, V22, P108, DOI 10.1089/acm.2015.0199; Weldam SWM, 2013, INT J NURS STUD, V50, P688, DOI 10.1016/j.ijnurstu.2012.07.017; Yelvar GDY, 2016, INT J CHRONIC OBSTR, V11, P1353, DOI 10.2147/COPD.S107408; yong Kim ju, 2016, [The Journal of Korea CHUNA Manual Medicine for Spine & Nerves, 척추신경추나의학회지], V11, P1; Zanotti E, 2012, COMPLEMENT THER MED, V20, P16, DOI 10.1016/j.ctim.2011.10.008	69	2	2	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2021	16	5							e0251291	10.1371/journal.pone.0251291	http://dx.doi.org/10.1371/journal.pone.0251291			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6NI	34003822	Green Published, gold			2023-01-03	WOS:000664630200013
J	Calderon-Parra, J; Muino-Miguez, A; Bendala-Estrada, AD; Ramos-Martinez, A; Munez-Rubio, E; Carracedo, EF; Montes, JT; Rubio-Rivas, M; Arnalich-Fernandez, F; Beato Perez, JL; Brunen, JMG; Beamonte, ED; Fontan, PMP; Carmona, MD; Martinez, RFM; Garcia, AG; Mosteiro, CS; de Almeida, CT; Moraleja, JG; Deodati, F; Escalante, MDM; Tomas, MLA; Huelgas, RG; Rojo, JMC; Nunez-Cortes, JM				Calderon-Parra, Jorge; Muino-Miguez, Antonio; Bendala-Estrada, Alejandro D.; Ramos-Martinez, Antonio; Munez-Rubio, Elena; Fernandez Carracedo, Eduardo; Tejada Montes, Javier; Rubio-Rivas, Manuel; Arnalich-Fernandez, Francisco; Beato Perez, Jose Luis; Garcia Brunen, Jose Miguel; del Corral Beamonte, Esther; Pesqueira Fontan, Paula Maria; Carmona, Maria del Mar; Fernandez-Madera Martinez, Rosa; Gonzalez Garcia, Andres; Salazar Mosteiro, Cristina; Tunon de Almeida, Carlota; Gonzalez Moraleja, Julio; Deodati, Francesco; Martin Escalante, Maria Dolores; Asensio Tomas, Maria Luisa; Gomez Huelgas, Ricardo; Casas Rojo, Jose Manuel; Millan Nunez-Cortes, Jesus		SEMI-COVID-19 Network	Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID	PLOS ONE			English	Article							RESISTANCE	Background Most patients with COVID-19 receive antibiotics despite the fact that bacterial co-infections are rare. This can lead to increased complications, including antibacterial resistance. We aim to analyze risk factors for inappropriate antibiotic prescription in these patients and describe possible complications arising from their use. Methods The SEMI-COVID-19 Registry is a multicenter, retrospective patient cohort. Patients with antibiotic were divided into two groups according to appropriate or inappropriate prescription, depending on whether the patient fulfill any criteria for its use. Comparison was made by means of multilevel logistic regression analysis. Possible complications of antibiotic use were also identified. Results Out of 13,932 patients, 3047 (21.6%) were prescribed no antibiotics, 6116 (43.9%) were appropriately prescribed antibiotics, and 4769 (34.2%) were inappropriately prescribed antibiotics. The following were independent factors of inappropriate prescription: February-March 2020 admission (OR 1.54, 95%CI 1.18-2.00), age (OR 0.98, 95%CI 0.97-0.99), absence of comorbidity (OR 1.43, 95%CI 1.05-1.94), dry cough (OR 2.51, 95%CI 1.94-3.26), fever (OR 1.33, 95%CI 1.13-1.56), dyspnea (OR 1.31, 95%CI 1.04-1.69), flu-like symptoms (OR 2.70, 95%CI 1.75-4.17), and elevated C-reactive protein levels (OR 1.01 for each mg/L increase, 95% CI 1.00-1.01). Adverse drug reactions were more frequent in patients who received ANTIBIOTIC (4.9% vs 2.7%, p < .001). Conclusion The inappropriate use of antibiotics was very frequent in COVID-19 patients and entailed an increased risk of adverse reactions. It is crucial to define criteria for their use in these patients. Knowledge of the factors associated with inappropriate prescribing can be helpful.	[Calderon-Parra, Jorge; Ramos-Martinez, Antonio; Munez-Rubio, Elena] Puerta Hierro Univ Hosp, Dept Internal Med, Infect Dis Unit, Madrid, Spain; [Muino-Miguez, Antonio; Bendala-Estrada, Alejandro D.; Fernandez Carracedo, Eduardo; Millan Nunez-Cortes, Jesus] Gregorio Maranon Univ Hosp, Dept Internal Med, Madrid, Spain; [Tejada Montes, Javier] Octubre Univ Hosp, Dept Internal Med, Madrid, Spain; [Rubio-Rivas, Manuel] Bellvitge Univ Hosp, Hosp Llobregat, Dept Internal Med, Barcelona, Spain; [Arnalich-Fernandez, Francisco] Paz Univ Hosp, Dept Internal Med, Madrid, Spain; [Beato Perez, Jose Luis] Albacete Univ Hosp Complex, Dept Internal Med, Albacete, Spain; [Garcia Brunen, Jose Miguel] Miguel Servet Hosp, Dept Internal Med, Zaragoza, Spain; [del Corral Beamonte, Esther] Royo Villanova Hosp, Dept Internal Med, Zaragoza, Spain; [Pesqueira Fontan, Paula Maria] Santiago Clin Hosp, Dept Internal Med, Santiago, Spain; [Carmona, Maria del Mar] Dr Peset Univ Hosp, Dept Internal Med, Valencia, Spain; [Fernandez-Madera Martinez, Rosa] Cabuenes Hosp, Dept Internal Med, Gijon, Spain; [Gonzalez Garcia, Andres] Ramon & Cajal Univ Hosp, Dept Internal Med, System Autoimmune Dis & Rare Dis Unit, IRYCIS, Madrid, Spain; [Salazar Mosteiro, Cristina] Nuestra Senora Prado Hosp, Dept Internal Med, Toledo, Spain; [Tunon de Almeida, Carlota] Zamora Hosp Complex, Dept Internal Med, Zamora, Spain; [Gonzalez Moraleja, Julio] Virgen Salud Hosp, Dept Internal Med, Toledo, Spain; [Deodati, Francesco; Casas Rojo, Jose Manuel] Infanta Cristina Univ Hosp, Dept Internal Med, Madrid, Spain; [Martin Escalante, Maria Dolores] Costa Sol Hosp, Dept Internal Med, Malaga, Spain; [Asensio Tomas, Maria Luisa] San Juan Alicante Univ Hosp, Gen Internal Med Dept, Alicante, Spain; [Gomez Huelgas, Ricardo] Univ Malaga, Reg Univ Hosp Malaga, Biomed Res Inst Malaga, Dept Internal Med, Malaga, Spain	Hospital Puerta de Hierro-Majadahonda; General University Gregorio Maranon Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Miguel Servet University Hospital; Hospital de Cabuenes; Hospital Universitario Ramon y Cajal; Universidad de Malaga	Calderon-Parra, J (corresponding author), Puerta Hierro Univ Hosp, Dept Internal Med, Infect Dis Unit, Madrid, Spain.	jorge050390@gmail.com	Arnalich, Francisco/AAF-5924-2021; Arnalich, Francisco/K-7723-2014; Calderon-Parra, Jorge/AGJ-4075-2022; Gomez-Huelgas, Ricardo/ABF-5100-2021; Ramos-Martinez, Antonio/G-5535-2016	Arnalich, Francisco/0000-0003-2943-0373; Calderon-Parra, Jorge/0000-0002-0369-9369; Gomez-Huelgas, Ricardo/0000-0002-9909-3555; Casas Rojo, Jose Manuel/0000-0002-6649-4301; Martin Escalante, Maria Dolores/0000-0003-1932-8682; Munez Rubio, Elena/0000-0002-5256-097X; Bendala Estrada, Alejandro/0000-0002-7705-2656; Fernandez Carracedo, Eduardo/0000-0001-6105-6647; Ramos-Martinez, Antonio/0000-0002-4840-9425				Antinori Spinello, 2020, Infez Med, V28, P29; Belliato M., 2020, J ANTIMICROB CHEMOTH, P1, DOI DOI 10.1093/JAC/DKZ325; BS, 2020, ANN INTERN MED; Canton R, 2020, CURR OPIN CRIT CARE, V26, P433, DOI 10.1097/MCC.0000000000000755; Cheng KP, 2020, RISK MANAG HEALTHC P, V13, P2593, DOI 10.2147/RMHP.S277963; Clancy CJ, 2020, CLIN INFECT DIS, V71, P2736, DOI 10.1093/cid/ciaa524; Di Gennaro F, 2020, J GLOB ANTIMICROB RE, V23, P167, DOI 10.1016/j.jgar.2020.08.022; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Dudoignon E, 2021, CLIN INFECT DIS, V72, P905, DOI 10.1093/cid/ciaa762; Echeverria-Esnal D, 2021, EXPERT REV ANTI-INFE, V19, P147, DOI 10.1080/14787210.2020.1813024; Garcia-Vidal C, 2021, CLIN MICROBIOL INFEC, V27, P83, DOI 10.1016/j.cmi.2020.07.041; Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663; Neto AGM, 2021, J MED VIROL, V93, P1489, DOI 10.1002/jmv.26441; Huttner BD, 2020, CLIN MICROBIOL INFEC, V26, P808, DOI 10.1016/j.cmi.2020.04.024; Khan DA, 2019, J ALLER CL IMM-PRACT, V7, P2105, DOI 10.1016/j.jaip.2019.06.001; Langford BJ, 2021, CLIN MICROBIOL INFEC, V27, P520, DOI 10.1016/j.cmi.2020.12.018; Langford BJ, 2020, CLIN MICROBIOL INFEC, V26, P1622, DOI 10.1016/j.cmi.2020.07.016; Lendrum, 2020, CLIN MED; Metlay JP, 2020, ANN INTERN MED, V173, P304, DOI 10.7326/M20-2189; Priore EL, 2020, J INFECT; Rawson TM, 2020, NAT REV MICROBIOL, V18, P409, DOI 10.1038/s41579-020-0395-y; Rawson TM, 2020, J ANTIMICROB CHEMOTH, V75, P1681, DOI 10.1093/jac/dkaa194; Rawson TM, 2020, CLIN INFECT DIS, V71, P2459, DOI 10.1093/cid/ciaa530; Ressaire A, 2020, CLIN INFECT DIS, P1; Rogado J, 2020, LUNG CANCER, V146, P19, DOI 10.1016/j.lungcan.2020.05.034; Roy-Vallejo, 2020, REV CLIN ESP, P19; Ruiz J, 2021, J HOSP INFECT, V107, P114, DOI 10.1016/j.jhin.2020.11.010; Sandhu A, 2020, EMERG INFECT DIS, V26, P2272, DOI 10.3201/eid2609.202126; Sieswerda E, 2021, CLIN MICROBIOL INFEC, V27, P61, DOI 10.1016/j.cmi.2020.09.041; Spernovasilis NA, 2021, INFECT CONT HOSP EP, V42, P378, DOI 10.1017/ice.2020.246; Spigaglia P, 2020, ANAEROBE, V64, DOI 10.1016/j.anaerobe.2020.102233; Stevens MP, 2020, INFECT CONT HOSP EP, V41, P744, DOI 10.1017/ice.2020.69; Sturdy A, 2020, J HOSP INFECT, V105, P593, DOI 10.1016/j.jhin.2020.06.027; Tang ML, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.929783; Usman M, 2020, SCI TOTAL ENVIRON, V745, DOI 10.1016/j.scitotenv.2020.141053; Vaughn VM, 2021, CLIN INFECT DIS, V72, pE533, DOI 10.1093/cid/ciaa1239; Wei W., 2020, LTD ROLE ANTIBIOTICS, DOI 10.1101/2020.06.16.20133181	37	35	35	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2021	16	5							e0251340	10.1371/journal.pone.0251340	http://dx.doi.org/10.1371/journal.pone.0251340			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6LY	33974637	Green Published, gold			2023-01-03	WOS:000664626600031
J	Han, S; Park, HJ; Nah, S; Lee, EH; Lee, HJ; Park, JO; Lee, CA				Han, Sangsoo; Park, Hye Ji; Nah, Sangun; Lee, Eun Hae; Lee, Hyun Ji; Park, Ju Ok; Lee, Choung Ah			Instructor-led distance learning for training students in cardiopulmonary resuscitation: A randomized controlled study	PLOS ONE			English	Article							BASIC LIFE-SUPPORT; CPR	Study hypothesis Cardiopulmonary resuscitation (CPR) training can increase the likelihood of patient survival and better neurological outcomes. However, conventional learning (CL) has cost, time, and space constraints. This study aimed to evaluate whether laypersons who completed instructor-led distance learning (DL) acquired a level of CPR skill comparable to that achieved via CL training. Methods This randomized controlled study recruited students from 28 Korean high schools who were randomized to complete instructor-led DL or CL training. The CL training involved classroom-based face-to-face training, whereas the instructor-led DL training was provided online using a videoconferencing system. Results The study enrolled 62 students who were randomized to the CL group (31 participants) or the DL group (31 participants). Relative to the CL group, the DL group achieved remarkably similar results in terms of most CPR variables. In addition, the DL group had a significant improvement in the mean compression depth (before: 46 mm [interquartile range: 37-52 mm] vs. after: 49 mm [interquartile range: 46-54 mm], p<0.001). Conclusions Instructor-led DL can be a suitable alternative to CL for providing CPR training to laypersons. In settings like the current COVID-19 pandemic, where face-to-face CL is not practical, DL may be a useful tool for delivering CPR training.	[Han, Sangsoo; Nah, Sangun] Soonchunhyang Univ Bucheon Hosp, Dept Emergency Med, Bucheon, South Korea; [Park, Hye Ji; Lee, Hyun Ji; Park, Ju Ok; Lee, Choung Ah] Hallym Univ, Dongtan Sacred Heart Hosp, Dept Emergency Med, Hwaseong Si, Gyeonggi Do, South Korea; [Lee, Eun Hae] Korea Dis Control & Prevent Agcy, Div Injury Prevent & Control, Cheongju, Chungcheongbuk, South Korea	Soonchunhyang University; Hallym University	Lee, CA (corresponding author), Hallym Univ, Dongtan Sacred Heart Hosp, Dept Emergency Med, Hwaseong Si, Gyeonggi Do, South Korea.	cuccum@hanmail.net	Han, Sangsoo/AAK-5908-2020; Park, Ju Ok/AGY-1372-2022; Park, Ju Ok/GWQ-9476-2022	Han, Sangsoo/0000-0002-9709-3332; Park, Ju Ok/0000-0002-1024-3626; LEE, Choung Ah/0000-0003-2487-8988; Nah, Sangun/0000-0003-2667-2211; Lee, EunHae/0000-0003-3169-751X	Korean Association of Cardiopulmonary Resuscitation; Soonchunhyang University Research Fund	Korean Association of Cardiopulmonary Resuscitation; Soonchunhyang University Research Fund	This research was supported by the Korean Association of Cardiopulmonary Resuscitation. This work was supported by the Soonchunhyang University Research Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Balas M, 2020, BMC MED EDUC, V20, DOI 10.1186/s12909-020-02257-4; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Baldi E, 2017, CAN J EMERG MED, V19, P480, DOI 10.1017/cem.2016.410; Bhanji F, 2015, CIRCULATION, V132, pS561, DOI 10.1161/CIR.0000000000000268; Birkun A, 2020, RESUSCITATION, V152, P105, DOI 10.1016/j.resuscitation.2020.05.023; Bray JE, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005972; Einspruch EL, 2007, RESUSCITATION, V74, P476, DOI 10.1016/j.resuscitation.2007.01.030; Farahmand Shervin, 2016, Acta Med Iran, V54, P600; Jones I, 2007, RESUSCITATION, V75, P350, DOI 10.1016/j.resuscitation.2007.04.030; Kragholm K, 2017, NEW ENGL J MED, V376, P1737, DOI 10.1056/NEJMoa1601891; Lynch B, 2005, RESUSCITATION, V67, P31, DOI 10.1016/j.resuscitation.2005.04.017; Moore JL, 2011, INTERNET HIGH EDUC, V14, P129, DOI 10.1016/j.iheduc.2010.10.001; Nolan JP, 2020, RESUSCITATION, V153, P45, DOI 10.1016/j.resuscitation.2020.06.001; Oermann MH, 2011, RESUSCITATION, V82, P447, DOI 10.1016/j.resuscitation.2010.11.022; Perkins GD, 2015, RESUSCITATION, V95, pE43, DOI 10.1016/j.resuscitation.2015.07.041; Tobase L, 2017, REV ESC ENFERM USP, V51, DOI [10.1590/S1980-220X2016043303288, 10.1590/s1980-220x2016043303288]; Tobase L, 2017, INT J MED EDUC, V8, P309, DOI 10.5116/ijme.5985.cbce; Wang AI, 2020, COMPUT EDUC, V149, DOI 10.1016/j.compedu.2020.103818; Yeung J, 2009, RESUSCITATION, V80, P743, DOI 10.1016/j.resuscitation.2009.04.012	19	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2021	16	5							e0251277	10.1371/journal.pone.0251277	http://dx.doi.org/10.1371/journal.pone.0251277			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6GE	33956873	gold, Green Published			2023-01-03	WOS:000664611400088
J	Choi, A; Kim, H; Cho, A; Noh, J; Park, I; Chung, HS				Choi, Arom; Kim, Ha Yan; Cho, Ara; Noh, Jiyoung; Park, Incheol; Chung, Hyun Soo			Efficacy of a four-tier infection response system in the emergency department during the coronavirus disease-2019 outbreak	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; COLLATERAL DAMAGE; COVID-19; IMPACT; CARE	Introduction The coronavirus disease (COVID-19) pandemic has delayed the management of other serious medical conditions. This study presents an efficient method to prevent the degradation of the quality of diagnosis and treatment of other critical diseases during the pandemic. Methods We performed a retrospective observational study. The primary outcome was ED length of stay (ED LOS). The secondary outcomes were the door-to-balloon time in patients with suspected ST-segment elevation myocardial infarction and door-to-brain computed tomography time for patients with suspected stroke. The outcome measures were compared between patients who were treated in the red and orange zones designated as the changeable isolation unit and those who were treated in the non-isolation care unit. To control confounding factors, we performed propensity score matching, following which, outcomes were analyzed for non-inferiority. Results The mean ED LOS for hospitalized patients in the isolation and non-isolation care units were 406.5 min (standard deviation [SD], 237.9) and 360.2 min (SD, 226.4), respectively. The mean difference between the groups indicated non-inferiority of the isolation care unit (p = 0.037) but not in the patients discharged from the ED (p>0.999). The mean difference in the ED LOS for patients admitted to the ICU between the isolation and non-isolation care units was -22.0 min (p = 0.009). The mean difference in the door-to-brain computed tomography time between patients with suspected stroke in the isolation and non-isolation care units was 7.4 min for those with confirmed stroke (p = 0.013), and -20.1 min for those who were discharged (p = 0.012). The mean difference in the door-to-balloon time between patients who underwent coronary angiography in the isolation and non-isolation care units was -2.1 min (p<0.001). Conclusions Appropriate and efficient handling of a properly planned ED plays a key role in improving the quality of medical care for other critical diseases during the COVID-19 outbreak.	[Choi, Arom; Cho, Ara; Park, Incheol; Chung, Hyun Soo] Yonsei Univ, Dept Emergency Med, Coll Med, Seoul, South Korea; [Kim, Ha Yan] Yonsei Univ, Dept Biomed Syst Informat, Biostat Collaborat Unit, Coll Med, Seoul, South Korea; [Noh, Jiyoung; Chung, Hyun Soo] Yonsei Univ, Severance Hosp, Ctr Disaster Relief Training & Res, Coll Med, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Chung, HS (corresponding author), Yonsei Univ, Dept Emergency Med, Coll Med, Seoul, South Korea.; Chung, HS (corresponding author), Yonsei Univ, Severance Hosp, Ctr Disaster Relief Training & Res, Coll Med, Seoul, South Korea.	hsc104@yuhs.ac		Choi, Arom/0000-0002-0262-3370; Park, Incheol/0000-0001-7033-766X; Chung, Hyun Soo/0000-0001-6110-1495				Arefian H, 2016, AM J INFECT CONTROL, V44, P160, DOI 10.1016/j.ajic.2015.09.005; Ball J, 2020, RESUSCITATION, V156, P157, DOI 10.1016/j.resuscitation.2020.09.017; Barrett K, 2020, CAN MED ASSOC J, V192, pE640, DOI 10.1503/cmaj.200715; Bersano A, 2020, EUR J NEUROL, V27, P1794, DOI 10.1111/ene.14375; Bjornsen Lars Petter, 2020, Tidsskr Nor Laegeforen, V140, DOI 10.4045/tidsskr.20.0277; Bojti PP, 2020, ORVOSI HETILAP, V161, P1395, DOI 10.1556/650.2020.31936; Centers for Disease Control and Prevention, 2020, MMWR-MORBID MORTAL W, V69, P795, DOI [10.15585/mmwr.mm6925e2, DOI 10.15585/MMWR.MM6925E2]; Chong CF, 2020, ARCH ACAD EMERG MED, V8; Chudasama YV, 2020, DIABETES METAB SYND, V14, P965, DOI 10.1016/j.dsx.2020.06.042; Chung HS, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e189; Connell L, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001711; De Luca G, 2020, J AM COLL CARDIOL, V76, P2321, DOI 10.1016/j.jacc.2020.09.546; Diegoli H, 2020, STROKE, V51, P2315, DOI 10.1161/STROKEAHA.120.030481; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Griffin KM, 2020, AM J RESP CRIT CARE, V201, P1337, DOI 10.1164/rccm.202004-1037CP; Katsanos AH, 2021, CAN J NEUROL SCI, V48, P59, DOI 10.1017/cjn.2020.170; Kerleroux B, 2020, STROKE, V51, P2012, DOI 10.1161/STROKEAHA.120.030373; Lange SJ, 2020, AM J TRANSPLANT, V20, P2612, DOI 10.1111/ajt.16239; Mafham MM, 2020, LANCET, V396, P381, DOI 10.1016/S0140-6736(20)31356-8; Maria FM, 2021, EUR J TRAUMA EMERG S, V47, P693, DOI 10.1007/s00068-020-01558-z; Masroor S, 2020, J CARDIAC SURG, V35, P1345, DOI 10.1111/jocs.14638; McGuinness MJ, 2021, ANZ J SURG, V91, P633, DOI 10.1111/ans.16711; Ministry of Employment and Labor Republic of Korea, SURV EMPL COND; Murphy AC, 2020, INTERN MED J, V50, P1020, DOI 10.1111/imj.14939; National Statistical Office Republic of Korea, SURV EC ACT POP; Quah LJ, 2020, INT J EMERG MED, V13, DOI 10.1186/s12245-020-00294-w; Rainisch G, 2020, INT J INFECT DIS, V96, P376, DOI 10.1016/j.ijid.2020.05.043; Range G, 2020, JACEP OPEN, V1, P1168, DOI 10.1002/emp2.12325; Rattka M, 2021, HEART, V107, P482, DOI 10.1136/heartjnl-2020-318360; Rosales JS, 2020, MEDICINA-BUENOS AIRE, V80, P65; Siegler JE, 2021, STROKE, V52, P40, DOI 10.1161/STROKEAHA.120.032789; Singer AJ, 2020, ANN EMERG MED, V76, P394, DOI 10.1016/j.annemergmed.2020.05.011; Sung CW, 2020, RESUSCITATION, V153, P185, DOI 10.1016/j.resuscitation.2020.06.021; Sykes DL, 2021, ERJ OPEN RES, V7, DOI 10.1183/23120541.00822-2020; Udwadia ZF, 2021, LUNG INDIA, V38, pS1, DOI 10.4103/lungindia.lungindia_60_21; Wang JS, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039177; Wee LE, 2020, ACAD EMERG MED, V27, P379, DOI 10.1111/acem.13984; Xiang DC, 2020, J AM COLL CARDIOL, V76, P1318, DOI 10.1016/j.jacc.2020.06.039	38	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256116	10.1371/journal.pone.0256116	http://dx.doi.org/10.1371/journal.pone.0256116			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ4EI	34383840	Green Published, gold			2023-01-03	WOS:000684426400105
J	Degu, S; Abebe, A; Gemeda, N; Bitew, A				Degu, Sileshi; Abebe, Abiy; Gemeda, Negero; Bitew, Adane			Evaluation of antibacterial and acute oral toxicity of Impatiens tinctoria A. Rich root extracts	PLOS ONE			English	Article								The high prevalence of morbidity and mortality from bacterial infections, together with the growing threat of antibacterial resistance, necessitated the development of alternative new drugs from traditional medicine. In Ethiopia, Impatiens tinctoria A. Rich has been traditionally used for the treatment of fungal infections such as ringworms that cause tinea pedis and it have also different medical values. Scientific information on its biological activity against a broad range of bacteria and safety data is scant, compared to its folklore data. In this study, we evaluated antibacterial activities and acute oral toxicity of aqueous, ethanol and ethyl acetate root extracts of Impatiens tinctoria A. Rich. Aqueous, ethanol and ethyl acetate extracts of the plant were evaluated using agar hole diffusion and agar dilution methods. Biological activities of the plant extracts were expressed as a zone of inhibition diameter, minimum inhibitory concentration (mg/ml), and minimum bactericidal concentration (mg/ml). The safety studies were performed by oral acute toxicity study according to the organization of economic cooperation and development test Guidelines 420.Gram-positive bacteria were more susceptible to the extracts compared to gram-negative bacteria, especially against S. aureus and S. epidermidis, which are commonly found in the skin. Ethyl acetate extract was more potent than ethanol and aqueous extracts. The 50% lethal dose (LD50) of tested mice was above 9600 mg/kg. This study provides a scientific basis for the antibacterial activity of the root extracts of I. tinctoria A. Rich, where, the ethyl acetate extract showed the most promising activity. Therefore, the antibacterial potential and practical non-toxicity of the study plant extracts suggested the possibility of using it for the development of antimicrobial drugs by further studying the plant in different directions.	[Degu, Sileshi; Abebe, Abiy; Gemeda, Negero] Ethiopian Publ Hlth Inst, Tradit & Modern Med Res Directorate, Addis Ababa, Ethiopia; [Bitew, Adane] Addis Ababa Univ, Coll Hlth Sci, Sch Med Lab Sci, Addis Ababa, Ethiopia	Addis Ababa University	Degu, S (corresponding author), Ethiopian Publ Hlth Inst, Tradit & Modern Med Res Directorate, Addis Ababa, Ethiopia.	degusilesh@gmail.com						Ahameethunisa AR, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-6; Appelbaum PC, 2007, CLIN INFECT DIS, V45, pS165, DOI 10.1086/519474; Asgedom SW, 2018, J PATHOG, V2018, DOI 10.1155/2018/7104921; Asmare TW., 2018, J TRADIT MED CLIN NA, V7, P27; Berhane T, 2015, INT J PHARM SCI RES, V6, P2451, DOI 10.13040/IJPSR.0975-8232.6(6).2451-61; CLSI, 2018, CLSI STANDARD M02, V4th; Delgado-Rodriguez FV, 2017, ANC SCI LIFE, V37, P16, DOI 10.4103/asl.ASL_162_17; Dye C, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2014.0055; Dye C, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0426; EL Farran CA, 2013, INDIAN J MED MICROBI, V31, P19, DOI 10.4103/0255-0857.108712; El Hilaly J, 2004, J ETHNOPHARMACOL, V91, P43, DOI 10.1016/j.jep.2003.11.009; Fern Ken, TROPICAL PLANTS DATA; Gopal N.M., 2014, INT J INNOV PHARM SC, V2, P2498; Hodge A., TOXICITY CLASSES; Islam K., 2014, INT J SCI ENV TECH, V3, P867, DOI DOI 10.13005/BPJ/1424; Karou D, 2006, AFR J BIOTECHNOL, V5, P195; Klancnik A, 2010, J MICROBIOL METH, V81, P121, DOI 10.1016/j.mimet.2010.02.004; Misganaw A, 2017, POPUL HEALTH METR, V15, DOI 10.1186/s12963-017-0145-1; Mostafa AA, 2018, SAUDI J BIOL SCI, V25, P361, DOI 10.1016/j.sjbs.2017.02.004; Mulu A, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-82; Obeidat M., 2012, Research Journal of Microbiology, V7, P59, DOI 10.3923/jm.2012.59.67; Organisation for Economic Co-operation and Development, 2001, 420 ORG EC COOP DEV; Otto Michael, 2010, Expert Rev Dermatol, V5, P183, DOI 10.1586/edm.10.6; Parasuraman S, 2011, J PHARMACOL PHARMACO, V2, P74, DOI 10.4103/0976-500X.81895; Parekh J., 2007, AFR J BIOMED RES, V10, P175; Parekh Jigna, 2005, Turkish Journal of Biology, V29, P203; Robinson JP., 2009, ADV BIO RES, V3, P185; Seboka N., 2017, BIOPROSPECTING POTEN; Seebaluck-Sandoram R, 2017, MEDICINAL SPICES AND VEGETABLES FROM AFRICA: THERAPEUTIC POTENTIAL AGAINST METABOLIC, INFLAMMATORY, INFECTIOUS AND SYSTEMIC DISEASES, P133, DOI 10.1016/B978-0-12-809286-6.00005-4; Shakya AK., 2016, INT J HERB MED, V4, P59; Shrestha P., 2015, TOXICOLOGY FOOD TECH, P11; Singh P., 2016, INT J LIFE SCI SCI R, V2, P671; Stapleton Paul D., 2002, Science Progress, V85, P57, DOI 10.3184/003685002783238870; Tiwari P, 2011, INT PHARMACEUTICA SC, V1, P98, DOI DOI 10.3923/IJBC.2017.17.22; Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14; Tuem KB, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4536905; WHO, BRIEF GUID EM INF DI; Woldeamanuel Y, 2017, ETHIOP J HEALTH DEV, V31, P124; World Health Organization, ANT RES GLOB REP SUR	40	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255932	10.1371/journal.pone.0255932	http://dx.doi.org/10.1371/journal.pone.0255932			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY8KW	34379681	Green Published, gold			2023-01-03	WOS:000684029800011
J	Grotta, JC; Yamal, J; Parker, SA; Rajan, SS; Gonzales, NR; Jones, WJ; Alexandrov, AW; Navi, BB; Nour, M; Spokoyny, I; Mackey, J; Persse, D; Jacob, AP; Wang, M; Singh, N; Alexandrov, AV; Fink, ME; Saver, JL; English, J; Barazangi, N; Bratina, PL; Gonzalez, M; Schimpf, BD; Ackerson, K; Sherman, C; Lerario, M; Mir, S; Im, J; Willey, JZ; Chiu, D; Eisshofer, M; Miller, J; Ornelas, D; Rhudy, JP; Brown, KM; Villareal, BM; Gausche-Hill, M; Bosson, N; Gilbert, G; Collins, SQ; Silnes, K; Volpi, J; Misra, V; McCarthy, J; Flanagan, T; Rao, CPV; Kass, JS; Griffin, L; Rangel-Gutierrez, N; Lechuga, E; Stephenson, J; Phan, K; Sanders, Y; Noser, EA; Bowry, R				Grotta, J. C.; Yamal, J.; Parker, S. A.; Rajan, S. S.; Gonzales, N. R.; Jones, W. J.; Alexandrov, A. W.; Navi, B. B.; Nour, M.; Spokoyny, I; Mackey, J.; Persse, D.; Jacob, A. P.; Wang, M.; Singh, N.; Alexandrov, A., V; Fink, M. E.; Saver, J. L.; English, J.; Barazangi, N.; Bratina, P. L.; Gonzalez, M.; Schimpf, B. D.; Ackerson, K.; Sherman, C.; Lerario, M.; Mir, S.; Im, J.; Willey, J. Z.; Chiu, D.; Eisshofer, M.; Miller, J.; Ornelas, D.; Rhudy, J. P.; Brown, K. M.; Villareal, B. M.; Gausche-Hill, M.; Bosson, N.; Gilbert, G.; Collins, S. Q.; Silnes, K.; Volpi, J.; Misra, V; McCarthy, J.; Flanagan, T.; Rao, C. P., V; Kass, J. S.; Griffin, L.; Rangel-Gutierrez, N.; Lechuga, E.; Stephenson, J.; Phan, K.; Sanders, Y.; Noser, E. A.; Bowry, R.			Prospective, Multicenter, Controlled Trial of Mobile Stroke Units	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE ISCHEMIC-STROKE; HEALTH-CARE PROFESSIONALS; PROPENSITY SCORE METHODS; ENDOVASCULAR TREATMENT; FUNCTIONAL OUTCOMES; EARLY MANAGEMENT; THROMBOLYSIS; ALTEPLASE; TIME; OPTIMIZATION	Background Mobile stroke units (MSUs) are ambulances with staff and a computed tomographic scanner that may enable faster treatment with tissue plasminogen activator (t-PA) than standard management by emergency medical services (EMS). Whether and how much MSUs alter outcomes has not been extensively studied. Methods In an observational, prospective, multicenter, alternating-week trial, we assessed outcomes from MSU or EMS management within 4.5 hours after onset of acute stroke symptoms. The primary outcome was the score on the utility-weighted modified Rankin scale (range, 0 to 1, with higher scores indicating better outcomes according to a patient value system, derived from scores on the modified Rankin scale of 0 to 6, with higher scores indicating more disability). The main analysis involved dichotomized scores on the utility-weighted modified Rankin scale (>= 0.91 or <0.91, approximating scores on the modified Rankin scale of <= 1 or >1) at 90 days in patients eligible for t-PA. Analyses were also performed in all enrolled patients. Results We enrolled 1515 patients, of whom 1047 were eligible to receive t-PA; 617 received care by MSU and 430 by EMS. The median time from onset of stroke to administration of t-PA was 72 minutes in the MSU group and 108 minutes in the EMS group. Of patients eligible for t-PA, 97.1% in the MSU group received t-PA, as compared with 79.5% in the EMS group. The mean score on the utility-weighted modified Rankin scale at 90 days in patients eligible for t-PA was 0.72 in the MSU group and 0.66 in the EMS group (adjusted odds ratio for a score of >= 0.91, 2.43; 95% confidence interval [CI], 1.75 to 3.36; P<0.001). Among the patients eligible for t-PA, 55.0% in the MSU group and 44.4% in the EMS group had a score of 0 or 1 on the modified Rankin scale at 90 days. Among all enrolled patients, the mean score on the utility-weighted modified Rankin scale at discharge was 0.57 in the MSU group and 0.51 in the EMS group (adjusted odds ratio for a score of >= 0.91, 1.82; 95% CI, 1.39 to 2.37; P<0.001). Secondary clinical outcomes generally favored MSUs. Mortality at 90 days was 8.9% in the MSU group and 11.9% in the EMS group. Conclusions In patients with acute stroke who were eligible for t-PA, utility-weighted disability outcomes at 90 days were better with MSUs than with EMS. (Funded by the Patient-Centered Outcomes Research Institute; BEST-MSU ClinicalTrials.gov number, .) Trial of Mobile Stroke Units Mobile stroke units have CT scanners and personnel trained to administer tissue plasminogen activator. In a multicity trial, functional outcomes at 90 days after acute stroke were better with mobile stroke units than with standard care by emergency medical services and transfer to an emergency department.	[Grotta, J. C.; McCarthy, J.; Flanagan, T.] Texas Med Ctr, Mobile Stroke Unit, Mem Hermann Hosp, 6410 Fannin St,Suite 1423, Houston, TX 77030 USA; [Yamal, J.; Jacob, A. P.; Wang, M.; Singh, N.; Gonzalez, M.] Univ Texas Houston, Sch Publ Hlth, Dept Biostat, Houston, TX USA; [Yamal, J.; Jacob, A. P.; Wang, M.; Singh, N.; Gonzalez, M.] Univ Texas Houston, Sch Publ Hlth, Dept Data Sci, Houston, TX USA; [Rajan, S. S.] Univ Texas Houston, Sch Publ Hlth, Dept Management, Houston, TX USA; [Rajan, S. S.] Univ Texas Houston, Sch Publ Hlth, Dept Policy, Houston, TX USA; [Rajan, S. S.] Univ Texas Houston, Sch Publ Hlth, Dept Commun Heath, Houston, TX USA; [Parker, S. A.; Gonzales, N. R.; Bratina, P. L.; Rangel-Gutierrez, N.; Lechuga, E.; Stephenson, J.; Phan, K.; Sanders, Y.; Noser, E. A.; Bowry, R.] Univ Texas Houston, McGovern Med Sch, Dept Neurol, Houston, TX USA; [Persse, D.] Univ Texas Houston, McGovern Med Sch, Dept Emergency Med, Houston, TX USA; [Persse, D.] Baylor Coll Med, Dept Emergency Med, Houston, TX USA; [Rao, C. P., V] Baylor Coll Med, Dept Neurol, Houston, TX USA; [Chiu, D.; Volpi, J.; Misra, V] Houston Methodist Hosp, Dept Neurol, Houston, TX USA; [Kass, J. S.] Harris Hlth Ben Taub Gen Hosp, Dept Neurol, Houston, TX USA; [Griffin, L.] HCA Houston HealthCare, Houston, TX USA; [Jones, W. J.; Schimpf, B. D.; Ackerson, K.; Eisshofer, M.; Ornelas, D.] Univ Colorado, Dept Neurol, UCHlth Anschutz Med Campus, Aurora, CO USA; [Miller, J.] UCE Lealth Mem Hosp, Dept Neurol, Colorado Springs, CO USA; [Alexandrov, A. W.; Alexandrov, A., V; Rhudy, J. P.] Univ Tennessee, Hlth Sci Ctr, Dept Neurol, Memphis, TN USA; [Navi, B. B.; Fink, M. E.; Sherman, C.; Lerario, M.; Mir, S.] Weill Cornell Med, Dept Neurol, New York, NY USA; [Willey, J. Z.] Columbia Univ, Dept Neurol, Irving Med Ctr, New York, NY USA; [Nour, M.; Saver, J. L.; Brown, K. M.; Villareal, B. M.] Ronald Reagan Ucla Med Ctr, Dept Neurol, Los Angeles, CA USA; [Spokoyny, I; English, J.; Barazangi, N.; Im, J.] Mills Peninsula Med Ctr, Dept Neurol, Burlingame, CA USA; [Gausche-Hill, M.; Bosson, N.] Los Angeles Cty Emergency Med Serv, Santa Fe Springs, CA USA; [Gilbert, G.] San Mateo Cty Emergency Med Serv, San Francisco, CA USA; [Mackey, J.; Collins, S. Q.; Silnes, K.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Tennessee System; University of Tennessee Health Science Center; Cornell University; Columbia University; NewYork-Presbyterian Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Ronald Reagan UCLA Medical Center; Indiana University System; Indiana University Bloomington	Grotta, JC (corresponding author), Texas Med Ctr, Mobile Stroke Unit, Mem Hermann Hosp, 6410 Fannin St,Suite 1423, Houston, TX 77030 USA.	james.c.grotta@uth.tmc.edu	Lerario, Mackenzie P/ABB-4338-2021; Lerario, Mackenzie/ABC-3517-2021	Lerario, Mackenzie/0000-0003-0806-9670; Gilbert, Gregory/0000-0002-4697-2281; Yamal, Jose-Miguel/0000-0003-2505-0090; Singh, Noopur/0000-0002-8091-6072; grotta, james/0000-0002-3667-4248				Agarwal S, 2020, STROKE, V51, P1226, DOI 10.1161/STROKEAHA.119.027476; Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Bowry R, 2018, STROKE, V49, P1528, DOI 10.1161/STROKEAHA.117.020585; Bowry R, 2015, STROKE, V46, P3370, DOI 10.1161/STROKEAHA.115.011093; Braitman LE, 2002, ANN INTERN MED, V137, P693, DOI 10.7326/0003-4819-137-8-200210150-00015; Broderick JP, 2017, STROKE, V48, P2007, DOI 10.1161/STROKEAHA.117.017866; Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792; Cepeda MS, 2003, AM J EPIDEMIOL, V158, P280, DOI 10.1093/aje/kwg115; Chaisinanunkul N, 2015, STROKE, V46, P2238, DOI 10.1161/STROKEAHA.114.008547; Cranston JS, 2017, STROKE, V48, P2946, DOI 10.1161/STROKEAHA.117.017496; Czap AL, 2020, STROKE, V51, P1613, DOI 10.1161/STROKEAHA.119.028626; Demaerschalk BM, 2016, STROKE, V47, P581, DOI 10.1161/STR.0000000000000086; Ebinger M, 2021, JAMA-J AM MED ASSOC, V325, P454, DOI 10.1001/jama.2020.26345; Ebinger M, 2015, JAMA NEUROL, V72, P25, DOI 10.1001/jamaneurol.2014.3188; Ebinger M, 2014, JAMA-J AM MED ASSOC, V311, P1622, DOI 10.1001/jama.2014.2850; Feeny D, 2000, MED CARE, V38, P151; Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Jolugbo P, 2021, STROKE, V52, P1131, DOI 10.1161/STROKEAHA.120.032810; Kim JT, 2017, CIRCULATION, V135, P128, DOI 10.1161/CIRCULATIONAHA.116.023336; Kim J, 2021, INT J STROKE, V16, P466, DOI 10.1177/1747493020929944; Kim YD, 2015, STROKE, V46, P1877, DOI 10.1161/STROKEAHA.114.008247; Kunz A, 2016, LANCET NEUROL, V15, P1035, DOI 10.1016/S1474-4422(16)30129-6; Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442; Parker SA, 2015, STROKE, V46, P1384, DOI 10.1161/STROKEAHA.114.007993; Pickard AS, 2019, VALUE HEALTH, V22, P931, DOI 10.1016/j.jval.2019.02.009; Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Sarraj A, 2020, STROKE, V51, P1207, DOI 10.1161/STROKEAHA.120.028850; Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061; Saver JL, 2010, STROKE, V41, P992, DOI 10.1161/STROKEAHA.109.571364; Sessler DI, 2020, ANESTHESIOLOGY, V132, P69, DOI 10.1097/ALN.0000000000002989; Shah BR, 2005, J CLIN EPIDEMIOL, V58, P550, DOI 10.1016/j.jclinepi.2004.10.016; Sheth SA, 2015, ANN NEUROL, V78, P584, DOI 10.1002/ana.24474; Smith SNC, 2016, NEUROLOGY, V87, P19, DOI 10.1212/WNL.0000000000002799; Sturmer T, 2006, J CLIN EPIDEMIOL, V59, P437, DOI 10.1016/j.jclinepi.2005.07.004; Walter S, 2012, LANCET NEUROL, V11, P397, DOI 10.1016/S1474-4422(12)70057-1; Wang MX, 2020, CLIN TRIALS, V17, P637, DOI 10.1177/1740774520942466; Wu TC, 2017, STROKE, V48, P493, DOI 10.1161/STROKEAHA.116.015363; Yamal JM, 2018, INT J STROKE, V13, P321, DOI 10.1177/1747493017711950	41	53	54	3	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2021	385	11					971	981		10.1056/NEJMoa2103879	http://dx.doi.org/10.1056/NEJMoa2103879			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN0RH	34496173				2023-01-03	WOS:000693730200009
J	Bentham, R; Litchfield, K; Watkins, TBK; Lim, EL; Rosenthal, R; Martinez-Ruiz, C; Hiley, CT; Al Bakir, M; Salgado, R; Moore, DA; Jamal-Hanjani, M; Swanton, C; McGranahan, N				Bentham, Robert; Litchfield, Kevin; Watkins, Thomas B. K.; Lim, Emilia L.; Rosenthal, Rachel; Martinez-Ruiz, Carlos; Hiley, Crispin T.; Al Bakir, Maise; Salgado, Roberto; Moore, David A.; Jamal-Hanjani, Mariam; Swanton, Charles; McGranahan, Nicholas		TRACERx Consortium	Using DNA sequencing data to quantify T cell fraction and therapy response	NATURE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; COPY NUMBER; GENOMIC CHARACTERIZATION; MUTATIONAL LANDSCAPE; BRANCHED EVOLUTION; CTLA-4 BLOCKADE; PD-1 BLOCKADE; HETEROGENEITY; ARCHITECTURE; IPILIMUMAB	The immune microenvironment influences tumour evolution and can be both prognostic and predict response to immunotherapy(1,2). However, measurements of tumour infiltrating lymphocytes (TI Ls) are limited by a shortage of appropriate data. Whole-exome sequencing (WES) of DNA is frequently performed to calculate tumour mutational burden and identify actionable mutations. Here we develop T cell exome TREC tool (T cell ExTRECT), a method for estimation ofT cell fraction from WES samples using a signal from T cell receptor excision circle (TREC) loss during V(D)J recombination of the T cell receptor-alpha gene (TCRA (also known as TRA)). TCRA T cell fraction correlates with orthogonal TIL estimates and is agnosticto sample type. Blood TCRA T cell fraction is higher in females than in males and correlates with both tumour immune infiltrate and presence of bacterial sequencing reads. Tumour TCRA T cell fraction is prognostic in lung adenocarcinoma. Using a meta-analysis of tumour streated with immunotherapy, we show that tumour TCRA T cell fraction predicts immunotherapy response, providing value beyond measuring tumour mutational burden. Applying T cell ExTRECT to a multi-sample pan-cancer cohort reveals a high diversity of the degree of immune infiltration within tumours. Subclonal loss of 12q24.31-32, encompassing SPPL3, is associated with reduced TCRA T cell fraction. T cell ExTRECT provides a cost-effective technique to characterize immune infiltrate alongside somatic changes.	[Bentham, Robert; Martinez-Ruiz, Carlos; McGranahan, Nicholas] UCL, Canc Res UK Lung Canc Ctr Excellence, Canc Genome Evolut Res Grp, Canc Inst, London, England; [Bentham, Robert; Litchfield, Kevin; Lim, Emilia L.; Martinez-Ruiz, Carlos; Hiley, Crispin T.; Moore, David A.; Jamal-Hanjani, Mariam; Swanton, Charles; McGranahan, Nicholas] UCL, Canc Res UK Lung Canc Ctr Excellence, Canc Inst, London, England; [Litchfield, Kevin] UCL, Canc Res UK Lung Canc Ctr Excellence, Tumour Immunogen & Immunosurveillance Lab, Canc Inst, London, England; [Watkins, Thomas B. K.; Lim, Emilia L.; Rosenthal, Rachel; Hiley, Crispin T.; Al Bakir, Maise; Swanton, Charles] Francis Crick Inst, Canc Evolut & Genome Instabil Lab, London, England; [Salgado, Roberto] GZA ZNA, Dept Pathol, Antwerp, Belgium; [Salgado, Roberto] Univ Melbourne, Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic, Australia; [Moore, David A.] Univ Coll London Hosp, Dept Cellular Pathol, London, England; [Moore, David A.; Jamal-Hanjani, Mariam; Swanton, Charles] Univ Coll London Hosp, Dept Med Oncol, London, England; [Jamal-Hanjani, Mariam] UCL, Canc Metastasis Lab, Canc Inst, London, England	Cancer Research UK; University of London; University College London; Cancer Research UK; University of London; University College London; Cancer Research UK; University of London; University College London; Francis Crick Institute; Peter Maccallum Cancer Center; University of Melbourne; University College London Hospitals NHS Foundation Trust; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London	McGranahan, N (corresponding author), UCL, Canc Res UK Lung Canc Ctr Excellence, Canc Genome Evolut Res Grp, Canc Inst, London, England.; McGranahan, N (corresponding author), UCL, Canc Res UK Lung Canc Ctr Excellence, Canc Inst, London, England.	nicholas.mcgranahan.10@ucl.ac.uk	Aerts, Hugo/ABF-2821-2020; Demeulemeester, Jonas/J-6130-2014; Tanic, Miljana/A-5458-2014; McGranahan, Nicholas/ABD-6561-2021; Wilson, Claire/Q-8626-2017; Black, James/I-2283-2017; Ottensmeier, Christian/E-8131-2012	Aerts, Hugo/0000-0002-2122-2003; Demeulemeester, Jonas/0000-0002-2660-2478; Tanic, Miljana/0000-0003-3102-776X; McGranahan, Nicholas/0000-0001-9537-4045; Gimeno Valiente, Francisco/0000-0003-0544-9459; Lowe, Helen/0000-0001-8630-378X; Navani, Neal/0000-0002-6412-7516; Swanton, Charles/0000-0002-4299-3018; READING, JAMES/0000-0001-5381-978X; Edwards, John/0000-0002-7935-5327; Pearce, David/0000-0001-8443-2924; Wilson, Claire/0000-0002-6401-2014; Black, James/0000-0001-5598-7752; Marrone, Domenic/0000-0003-2058-1693; Hynds, Robert/0000-0002-2170-8791; Ottensmeier, Christian/0000-0003-3619-1657; Litchfield, Kevin/0000-0002-3725-0914; Escudero, Mickael/0000-0002-1336-815X; Middleton, Gary/0000-0001-5695-3474; Johnson, Diana/0000-0003-0479-1228; Herrero, Javier/0000-0001-7313-717X	NIHR BRC at University College London Hospitals - UK Medical Research Council [MR/P014712/1, MR/V033077/1]; Rosetrees Trust and Cotswold Trust [A2437]; Cancer Research UK [C11496/A17786]; Francis Crick Institute; UK Medical Research Council [FC001169]; Wellcome Trust; Marie Curie ITN Project PLOIDYNET [607722]; Breast Cancer Research Foundation (BCRF); Royal Society Research Professorships Enhancement Award [RP/EA/180007]; Foulkes Foundation; NovoNordisk Foundation [ID16584]; Rosetrees; NIHR BRC at University College London Hospitals; National Institute for Health Research; Rosetrees Trust; NIHR University College London Hospitals Biomedical Research Centre - Wellcome Trust; Royal Society [211179/Z/18/Z]; CRUK University College London Experimental Cancer Medicine Centre; Royal Society Napier Research Professor; Wellcome Trust - Cancer Research UK; (CRUK Cancer Immunotherapy Catalyst Network); Cancer Research UK Lung Cancer Centre of Excellence; Stoneygate Trusts; CRUK-UCL Centre, Experimental Cancer Medicine Centre; Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant [SU2C-AACR-DT23-17]; Stand Up To Cancer is a program of the Entertainment Industry Foundation; Scientific Partner of SU2C; European Research Council (ERC) under the European Union [FP7-THESEUS-617844]; European Commission ITN [607722]; ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union [835297]; European Union [665233, NCT01888601]; University College London [UCL/12/0279, 13/LO/1546]; UCL Cancer Trials Centre; National Human Genome Research Institute; Medical Research Council [MR/L016311/1]; High-Performance Computing at the Francis Crick Institute; UCL Department of Computer Science Cluster; CRUK City of London Centre Award [C7893/A26233]; Bristol-Myers Squibb - Merck and Co.	NIHR BRC at University College London Hospitals - UK Medical Research Council; Rosetrees Trust and Cotswold Trust; Cancer Research UK(Cancer Research UK); Francis Crick Institute; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Marie Curie ITN Project PLOIDYNET; Breast Cancer Research Foundation (BCRF); Royal Society Research Professorships Enhancement Award; Foulkes Foundation; NovoNordisk Foundation(Novo Nordisk FoundationNovocure Limited); Rosetrees(Rosetrees Trust); NIHR BRC at University College London Hospitals; National Institute for Health Research(National Institute for Health Research (NIHR)); Rosetrees Trust(Rosetrees Trust); NIHR University College London Hospitals Biomedical Research Centre - Wellcome Trust; Royal Society(Royal Society of London); CRUK University College London Experimental Cancer Medicine Centre; Royal Society Napier Research Professor; Wellcome Trust - Cancer Research UK(Wellcome TrustCancer Research UK); (CRUK Cancer Immunotherapy Catalyst Network); Cancer Research UK Lung Cancer Centre of Excellence; Stoneygate Trusts; CRUK-UCL Centre, Experimental Cancer Medicine Centre; Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant; Stand Up To Cancer is a program of the Entertainment Industry Foundation; Scientific Partner of SU2C; European Research Council (ERC) under the European Union(European Research Council (ERC)); European Commission ITN; ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union; European Union(European Commission); University College London(General Electric); UCL Cancer Trials Centre; National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); High-Performance Computing at the Francis Crick Institute; UCL Department of Computer Science Cluster; CRUK City of London Centre Award; Bristol-Myers Squibb - Merck and Co.	R.B. is supported by the NIHR BRC at University College London Hospitals. K.L. is funded by the UK Medical Research Council (MR/P014712/1 and MR/V033077/1), Rosetrees Trust and Cotswold Trust (A2437) and Cancer Research UK (C69256/A30194). T.B.K.W. is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001169), the UK Medical Research Council (FC001169) and the Wellcome Trust (FC001169) as well as the Marie Curie ITN Project PLOIDYNET (FP7-PEOPLE-2013, 607722), Breast Cancer Research Foundation (BCRF), Royal Society Research Professorships Enhancement Award (RP/EA/180007) and the Foulkes Foundation. E.L.L. receives funding from NovoNordisk Foundation (ID 16584). R.R. is supported by Royal Society Research Professorships Enhancement Award (RP/EA/180007). C.M.-R. is supported by Rosetrees. C.T.H. is supported by the NIHR BRC at University College London Hospitals. M.J.-H. has received funding from Cancer Research UK, National Institute for Health Research, Rosetrees Trust, UKI NETs and NIHR University College London Hospitals Biomedical Research Centre. N.M. is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (Grant Number 211179/Z/18/Z) and also receives funding from Cancer Research UK, Rosetrees and the NIHR BRC at University College London Hospitals and the CRUK University College London Experimental Cancer Medicine Centre. C.S. is a Royal Society Napier Research Professor. His work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001169), the UK Medical Research Council (FC001169) and the Wellcome Trust (FC001169). C.S. is funded by Cancer Research UK (TRACERx, PEACE and CRUK Cancer Immunotherapy Catalyst Network), Cancer Research UK Lung Cancer Centre of Excellence, the Rosetrees Trust, Butterfield and Stoneygate Trusts, NovoNordisk Foundation (ID16584), Royal Society Research Professorships Enhancement Award (RP/EA/180007), the NIHR BRC at University College London Hospitals, the CRUK-UCL Centre, Experimental Cancer Medicine Centre and the Breast Cancer Research Foundation (BCRF). This research is supported by a Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant (SU2C-AACR-DT23-17). Stand Up To Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. C.S. also receives funding from the European Research Council (ERC) under the European Union's Seventh Framework Programme (FP7/2007-2013) Consolidator Grant (FP7-THESEUS-617844), European Commission ITN (FP7-PloidyNet 607722), an ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020 research and innovation programme (835297) and Chromavision from the European Union's Horizon 2020 research and innovation programme (665233). The TRACERx study (Clinicaltrials.gov no: NCT01888601) is sponsored by University College London (UCL/12/0279) and has been approved by an independent Research Ethics Committee (13/LO/1546). TRACERx is funded by Cancer Research UK (C11496/A17786) and coordinated through the Cancer Research UK and UCL Cancer Trials Centre. The results published here are based in part on data generated by The Cancer Genome Atlas pilot project established by the NCI and the National Human Genome Research Institute.; The data were retrieved through the database of Genotypes and Phenotypes (dbGaP) authorization (accession number phs000178.v9.p8). Information about TCGA and the constituent investigators and institutions of the TCGA research network can be found at http://cancergenome.nih.gov/.This project was enabled through access to the MRC eMedLab Medical Bioinformatics infrastructure, supported by the Medical Research Council (MR/L016311/1). In particular, we acknowledge the support of the High-Performance Computing at the Francis Crick Institute as well as the UCL Department of Computer Science Cluster and the support team. In addition, this work was supported by the CRUK City of London Centre Award (C7893/A26233). We thank all investigators, funders and industry partners that supported the generation of the data within this study, as well as patients for their participation. Specifically, we thank Merck & Co, Genentech and Bristol-Myers Squibb for generating the industry datasets used in this study, and E. Van Allen, L. Diaz, T. A. Chan, L. A. Garraway, R. S. Lo, D. F. Bajorin, D. Schadendorf, T. Powles, S.-H. Lee, A. Ribas and S. Ogawa for academic datasets. This work has been funded by Merck and Co. We gratefully acknowledge the patients and their families, the investigators and site personnel who participated in the KEYNOTE-001, -006, -012 and -028 studies.	AbdulJabbar K, 2020, NAT MED, V26, P1054, DOI 10.1038/s41591-020-0900-x; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Brastianos PK, 2015, CANCER DISCOV, V5, P1164, DOI 10.1158/2159-8290.CD-15-0369; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Capone I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00552; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Conforti F, 2021, CLIN CANCER RES, V27, P4311, DOI 10.1158/1078-0432.CCR-21-0136; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Danaher P, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0367-1; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; Denkert C, 2016, MODERN PATHOL, V29, P1155, DOI 10.1038/modpathol.2016.109; Favero F, 2015, ANN ONCOL, V26, P64, DOI 10.1093/annonc/mdu479; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Goodman AM, 2017, MOL CANCER THER, V16, P2598, DOI 10.1158/1535-7163.MCT-17-0386; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Harbst K, 2016, CANCER RES, V76, P4765, DOI 10.1158/0008-5472.CAN-15-3476; Hendry S, 2017, ADV ANAT PATHOL, V24, P235, DOI 10.1097/PAP.0000000000000162; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jongsma MLM, 2021, IMMUNITY, V54, P132, DOI 10.1016/j.immuni.2020.11.003; Kuchenbecker L, 2015, BIOINFORMATICS, V31, P2963, DOI 10.1093/bioinformatics/btv309; Lamy P, 2016, CANCER RES, V76, P5894, DOI 10.1158/0008-5472.CAN-16-0436; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Levy E, 2016, SCI REP-UK, V6, DOI 10.1038/srep30064; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Litchfield K, 2021, CELL, V184, P596, DOI 10.1016/j.cell.2021.01.002; Lopez S, 2020, NAT GENET, V52, P283, DOI 10.1038/s41588-020-0584-7; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; McDermott DF, 2018, NAT MED, V24, P749, DOI 10.1038/s41591-018-0053-3; Messaoudene M, 2019, ANN ONCOL, V30, P934, DOI 10.1093/annonc/mdz112; Middleton G, 2020, NATURE, V583, P807, DOI 10.1038/s41586-020-2481-8; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Poore GD, 2020, NATURE, V579, P567, DOI 10.1038/s41586-020-2095-1; Racle J, 2017, ELIFE, V6, DOI 10.7554/eLife.26476; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rosenthal R, 2019, NATURE, V567, P479, DOI 10.1038/s41586-019-1032-7; Savas P, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002204; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schwartz LH, 2016, EUR J CANCER, V62, P132, DOI 10.1016/j.ejca.2016.03.081; Seshan V., 2015, DEP EPIDEMIOLOGY BIO, V50; Shim JH, 2020, ANN ONCOL, V31, P902, DOI 10.1016/j.annonc.2020.04.004; Snyder A, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002309; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Turajlic S, 2018, CELL, V173, P595, DOI 10.1016/j.cell.2018.03.043; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; van der Spek J, 2015, J CLIN IMMUNOL, V35, P416, DOI 10.1007/s10875-015-0152-6; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907; Watkins TBK, 2020, NATURE, V587, P126, DOI 10.1038/s41586-020-2698-6; Wood DE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r46; Yokoyama A, 2019, NATURE, V565, P312, DOI 10.1038/s41586-018-0811-x	56	8	8	5	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2021	597	7877					555	+		10.1038/s41586-021-03894-5	http://dx.doi.org/10.1038/s41586-021-03894-5		SEP 2021	25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW6NQ	34497419	Green Submitted			2023-01-03	WOS:000693875600002
J	Shankar-Hari, M; Vale, CL; Godolphin, PJ; Fisher, D; Higgins, JPT; Spiga, F; Savovic, J; Tierney, J; Baron, G; Benbenishty, JS; Berry, LR; Broman, N; Cavalcanti, AB; Colman, R; De Buyser, SL; Derde, LPG; Domingo, P; Omar, SF; Fernandez-Cruz, A; Feuth, T; Garcia, F; Garcia-Vicuna, R; Gonzalez-Alvaro, I; Gordon, AC; Haynes, R; Hermine, O; Horby, PW; Horick, NK; Kumar, K; Lambrecht, BN; Landray, MJ; Leal, L; Lederer, DJ; Lorenzi, E; Mariette, X; Merchante, N; Misnan, NA; Mohan, SV; Nivens, MC; Oksi, J; Perez-Molina, JA; Pizov, R; Porcher, R; Postma, S; Rajasuriar, R; Ramanan, AV; Ravaud, P; Reid, PD; Rutgers, A; Sancho-Lopez, A; Seto, TB; Sivapalasingam, S; Soin, AS; Staplin, N; Stone, JH; Strohbehn, GW; Sunden-Cullberg, J; Torre-Cisneros, J; Tsai, LW; van Hoogstraten, H; van Meerten, T; Veiga, VC; Westerweel, PE; Murthy, S; Diaz, JV; Marshall, JC; Sterne, JAC				Shankar-Hari, Manu; Vale, Claire L.; Godolphin, Peter J.; Fisher, David; Higgins, Julian P. T.; Spiga, Francesca; Savovic, Jelena; Tierney, Jayne; Baron, Gabriel; Benbenishty, Julie S.; Berry, Lindsay R.; Broman, Niklas; Cavalcanti, Alexandre Biasi; Colman, Roos; De Buyser, Stefanie L.; Derde, Lennie P. G.; Domingo, Pere; Omar, Sharifah Faridah; Fernandez-Cruz, Ana; Feuth, Thijs; Garcia, Felipe; Garcia-Vicuna, Rosario; Gonzalez-Alvaro, Isidoro; Gordon, Anthony C.; Haynes, Richard; Hermine, Olivier; Horby, Peter W.; Horick, Nora K.; Kumar, Kuldeep; Lambrecht, Bart N.; Landray, Martin J.; Leal, Lorna; Lederer, David J.; Lorenzi, Elizabeth; Mariette, Xavier; Merchante, Nicolas; Misnan, Nor Arisah; Mohan, Shalini, V; Nivens, Michael C.; Oksi, Jarmo; Perez-Molina, Jose A.; Pizov, Reuven; Porcher, Raphael; Postma, Simone; Rajasuriar, Reena; Ramanan, Athimalaipet, V; Ravaud, Philippe; Reid, Pankti D.; Rutgers, Abraham; Sancho-Lopez, Aranzazu; Seto, Todd B.; Sivapalasingam, Sumathi; Soin, Arvinder Singh; Staplin, Natalie; Stone, John H.; Strohbehn, Garth W.; Sunden-Cullberg, Jonas; Torre-Cisneros, Julian; Tsai, Larry W.; van Hoogstraten, Hubert; van Meerten, Tom; Veiga, Viviane Cordeiro; Westerweel, Peter E.; Murthy, Srinivas; Diaz, Janet, V; Marshall, John C.; Sterne, Jonathan A. C.		WHO Rapid Evidence Appraisal COVID	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METAANALYSIS	IMPORTANCE Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. OBJECTIVE To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes. DATA SOURCES Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial status or language. Additional trials were identified through contact with experts. STUDY SELECTION Eligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom IL-6 antagonists were administered and to a group in whom neither IL-6 antagonists nor any other immunomodulators except corticosteroids were administered. Among 72 potentially eligible trials, 27 (37.5%) met study selection criteria. DATA EXTRACTION AND SYNTHESIS In this prospectivemeta-analysis, risk of biaswas assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I-2 statistic. The primary analysis was an inverse variance-weighted fixed-effects meta-analysis of odds ratios (ORs) for 28-day all-cause mortality. MAIN OUTCOMES AND MEASURES The primary outcome measurewas all-cause mortality at 28 days after randomization. There were 9 secondary outcomes including progression to invasive mechanical ventilation or death and risk of secondary infection by 28 days. RESULTS A total of 10 930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included. By 28 days, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo (summary OR, 0.86 [95% CI, 0.79-0.95]; P =.003 based on a fixed-effects meta-analysis). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The corresponding summary ORs were 0.83 (95% CI, 0.74-0.92; P <.001) for tocilizumab and 1.08 (95% CI, 0.86-1.36; P =.52) for sarilumab. The summary ORs for the association with mortality compared with usual care or placebo in those receiving corticosteroids were 0.77 (95% CI, 0.68-0.87) for tocilizumab and 0.92 (95% CI, 0.61-1.38) for sarilumab. The ORs for the association with progression to invasive mechanical ventilation or death, compared with usual care or placebo, were 0.77 (95% CI, 0.70-0.85) for all IL-6 antagonists, 0.74 (95% CI, 0.66-0.82) for tocilizumab, and 1.00 (95% CI, 0.74-1.34) for sarilumab. Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16). CONCLUSIONS AND RELEVANCE In this prospectivemeta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.	[Shankar-Hari, Manu] Guys & St Thomas NHS Fdn Trust, St Thomas Hosp, ICU Support Off, London, England; [Shankar-Hari, Manu] Kings Coll London, Sch Immunol & Microbial Sci, London, England; [Vale, Claire L.; Godolphin, Peter J.; Fisher, David; Tierney, Jayne] UCL, MRC Clin Trials Unit, UCL, London, England; [Higgins, Julian P. T.; Savovic, Jelena; Sterne, Jonathan A. C.] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England; [Higgins, Julian P. T.; Sterne, Jonathan A. C.] NIHR Bristol Biomed Res Ctr, Bristol, Avon, England; [Higgins, Julian P. T.; Savovic, Jelena] Univ Hosp Bristol, Natl Inst Hlth Res Appl Res Collaborat West, Bristol, Avon, England; [Higgins, Julian P. T.; Savovic, Jelena] Weston NHS Fdn Trust, Bristol, Avon, England; [Spiga, Francesca] Univ Bristol, Bristol, Avon, England; [Baron, Gabriel; Porcher, Raphael; Ravaud, Philippe] Hop Hotel Dieu, Assistance Publ Hop Paris, Ctr Clin Epidemiol, Paris, France; [Baron, Gabriel; Porcher, Raphael; Ravaud, Philippe] Univ Paris, METHODS Team, Ctr Rech Epidemiol & Stat, INSERM UMRS 1153, Paris, France; [Benbenishty, Julie S.] Hadassah Hebrew Univ Med Ctr, Dept Nursing, Jerusalem, Israel; [Berry, Lindsay R.; Lorenzi, Elizabeth] Berry Consultants, Austin, TX USA; [Broman, Niklas; Oksi, Jarmo] Turku Univ Hosp, Dept Infect Dis, Turku, Finland; [Cavalcanti, Alexandre Biasi; Veiga, Viviane Cordeiro] BP Beneficencia Portuguesa Sao Paulo, Rua Maestro Cardim, Sao Paulo, Brazil; [Colman, Roos; De Buyser, Stefanie L.] Univ Ghent, Dept Publ Hlth & Primary Care, Ghent, Belgium; [Derde, Lennie P. G.] Univ Med Ctr Utrecht, Dept Intens Care Med, Utrecht, Netherlands; [Domingo, Pere] Hosp Santa Creu & Sant Pau, Dept Infect Dis, Barcelona, Spain; [Omar, Sharifah Faridah; Rajasuriar, Reena] Univ Malaya, Dept Med, Kuala Lumpur, Malaysia; [Fernandez-Cruz, Ana] Hosp Univ Puerta de Hierro Majadahonda, Internal Med Dept, Infect Dis Unit, Madrid, Spain; [Feuth, Thijs] Turku Univ Hosp, Dept Pulm Dis, Turku, Finland; [Garcia, Felipe; Leal, Lorna] Hosp Clin Barcelona, Infect Dis Dept, IDIBAPS, Barcelona, Spain; [Garcia-Vicuna, Rosario; Gonzalez-Alvaro, Isidoro] Hosp Univ La Princesa IIS IP, Rheumatol, Madrid, Spain; [Gordon, Anthony C.] Imperial Coll London, Div Anaesthet Pain Med & Intens Care, London, England; [Haynes, Richard; Landray, Martin J.; Staplin, Natalie] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England; [Haynes, Richard; Landray, Martin J.; Staplin, Natalie] Univ Oxford, MRC Populat Hlth Res Unit, Oxford, England; [Hermine, Olivier] Hop Necker Enfants Malad, Dept Hematol, Paris, France; [Hermine, Olivier] Univ Paris, Imagine Inst, INSERM U1153, Paris, France; [Horby, Peter W.] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England; [Horby, Peter W.] Univ Oxford, Int Severe Acute Resp & Emerging Infect Consortiu, Oxford, England; [Horby, Peter W.] Univ Oxford, Pandem Sci Ctr, Oxford, England; [Horick, Nora K.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Kumar, Kuldeep; Soin, Arvinder Singh] Medanta, Inst Liver Transplantat & Regenerat Med, Gurugram, India; [Kumar, Kuldeep] Medanta Inst Educ & Res, Res Dept, Gurugram, India; [Lambrecht, Bart N.] Univ Ghent, VIB Ctr Inflammat Res, Ghent, Belgium; [Lambrecht, Bart N.] Univ Ghent, Dept Internal Med & Pediat, Ghent, Belgium; [Lederer, David J.; Nivens, Michael C.; Sivapalasingam, Sumathi] Regeneron Pharmaceut Inc, Tarrytown, NY USA; [Mariette, Xavier] Univ Paris Saclay, Ctr Immunol Viral Infect & Autoimmune Dis, INSERM UMR1184, Paris, France; [Mariette, Xavier] Assistance Publ Hop Paris, Dept Rheumatol, Paris, France; [Merchante, Nicolas] Valme Univ Hosp, Inst Biomed Sevilla, Unit Infect Dis & Microbiol, Seville, Spain; [Misnan, Nor Arisah] Minist Hlth, Hosp Sungai Buloh, Buloh, Malaysia; [Mohan, Shalini, V; Tsai, Larry W.] Genentech Inc, San Francisco, CA 94080 USA; [Perez-Molina, Jose A.] Hosp Univ Ramon y Cajal IRYCIS, Infect Dis Dept, Madrid, Spain; [Pizov, Reuven] Hadassah Hebrew Univ Hosp, Dept Anesthesil Crit Care & Pain Med, Jerusalem, Israel; [Porcher, Raphael; Ravaud, Philippe] Univ Paris, INRA, INSERM, CRESS UMR1153, Paris, France; [Postma, Simone; Rutgers, Abraham] Univ Hosp Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, Groningen, Netherlands; [Rajasuriar, Reena] Univ Melbourne, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia; [Ramanan, Athimalaipet, V] Univ Hosp Bristol NHS Fdn Trust, Dept Paediat Rheumatol, Bristol, Avon, England; [Reid, Pankti D.] Univ Chicago, Med Ctr, Dept Med Rheumatol, Chicago, IL 60637 USA; [Sancho-Lopez, Aranzazu] Hosp Univ Puerta de Hierro Majadahonda, Dept Clin Pharmacol, Madrid, Spain; [Seto, Todd B.] Queens Med Ctr, Ctr Outcomes Res & Evaluat, Honolulu, HI USA; [Stone, John H.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Stone, John H.] Massachusetts Gen Hosp, Dept Med Rheumatol, Boston, MA USA; [Strohbehn, Garth W.] VA Ann Arbor, Ctr Clin Management & Res, Ann Arbor, MI USA; [Sunden-Cullberg, Jonas] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Infect Dis, Stockholm, Sweden; [Torre-Cisneros, Julian] Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Inst Biomed Res Cordoba, Cordoba, Spain; [van Hoogstraten, Hubert] Sanofi Genzyme, Global Med Affairs, Bridgewater, NJ USA; [van Meerten, Tom] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands; [Westerweel, Peter E.] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands; [Murthy, Srinivas] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada; [Diaz, Janet, V] World Hlth Org, Clin Unit, Hlth Emergencies Programme, Geneva, Switzerland; [Marshall, John C.] Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada; [Sterne, Jonathan A. C.] Hlth Data Res UK South West, Bristol, Avon, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Medical Research Council Clinical Trials Unit; University of London; University College London; University of Bristol; University of Bristol; University of Bristol; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Hebrew University of Jerusalem; University of Turku; Ghent University; Ghent University Hospital; Utrecht University; Utrecht University Medical Center; Hospital of Santa Creu i Sant Pau; Universiti Malaya; Hospital Puerta de Hierro-Majadahonda; University of Turku; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Imperial College London; University of Oxford; University of Oxford; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Oxford; University of Oxford; University of Oxford; Harvard University; Massachusetts General Hospital; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Regeneron; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Hospital Valme; Kementerian Kesihatan Malaysia; Roche Holding; Genentech; Hospital Universitario Ramon y Cajal; Hebrew University of Jerusalem; Hadassah University Medical Center; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Groningen; University of Melbourne; University of Bristol; University of Chicago; University of Chicago Medical Center; Hospital Puerta de Hierro-Majadahonda; The Queen's Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Karolinska Institutet; Karolinska University Hospital; Universidad de Cordoba; Sanofi-Aventis; Genzyme Corporation; University of Groningen; Albert Schweitzer Ziekenhuis; University of British Columbia; World Health Organization; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Shankar-Hari, M (corresponding author), Guys & St Thomas NHS Fdn Trust London, St Thomas Hosp, East Wing, London SE1 7EH, England.	manu.shankar-hari@kcl.ac.uk	Higgins, Julian PT/H-4008-2011; Almuedo Riera, Alex/AAD-4957-2022; Rajasuriar, Reena/B-9569-2010; Godolphin, Peter/AAO-5845-2020; Reid, Pankti/AHA-0817-2022; Derde, Lennie/AAF-2725-2021; Gordon, Anthony/A-3472-2012; Lambrecht, Bart N/K-2484-2014; OMAR, SHARIFAH FARIDAH SFSO SYED/B-9752-2010; Tong, Steven/N-2353-2013; Cruz, Ana Fernández/L-2429-2019; Leal, Lorna/L-2773-2015; Benbenishty, Julie Sarah/AFK-9001-2022; Asgeirsson, Hilmir/AAY-5583-2021; de VicuÃa, Rosario Garcia/ABD-7892-2020; , Felipe/F-4242-2014; Feuth, Thijs/F-6264-2013; Benito, Natividad/D-1855-2010; Hermine, Olivier/Q-7072-2018; Tharaux, Pierre-Louis/A-9155-2009; Campos, Jose/H-1531-2012; Shankar-Hari, Manu/I-6948-2012; Faust, Saul/J-9779-2014	Higgins, Julian PT/0000-0002-8323-2514; Almuedo Riera, Alex/0000-0003-4643-4456; Rajasuriar, Reena/0000-0003-3756-0629; Godolphin, Peter/0000-0003-0648-0992; Reid, Pankti/0000-0002-7645-0919; Derde, Lennie/0000-0002-3577-5629; Gordon, Anthony/0000-0002-0419-547X; Lambrecht, Bart N/0000-0003-4376-6834; Tong, Steven/0000-0002-1368-8356; Cruz, Ana Fernández/0000-0003-1189-1120; Asgeirsson, Hilmir/0000-0003-3869-8021; de VicuÃa, Rosario Garcia/0000-0001-9096-3780; , Felipe/0000-0001-7658-5832; Feuth, Thijs/0000-0001-6691-556X; Benito, Natividad/0000-0001-6410-013X; Tharaux, Pierre-Louis/0000-0002-6062-5905; Campos, Jose/0000-0003-1744-0910; Shankar-Hari, Manu/0000-0002-5338-2538; Prats, Joao/0000-0002-8084-0602; De Leeuw, Elisabeth/0000-0002-7826-8141; Avendano Sola, Cristina/0000-0001-5437-7215; Fisher, David/0000-0002-2512-2296; ALONSO PEREZ, TAMARA/0000-0002-6312-4575; Mouncey, Paul/0000-0002-8510-8517; Estcourt, Lise/0000-0003-4309-9162; Haynes, Richard/0000-0002-1179-0023; Sterne, Jonathan/0000-0001-8496-6053; Tierney, Jayne/0000-0002-4734-3014; Savovic, Jelena/0000-0002-2861-0578; Faust, Saul/0000-0003-3410-7642; Spiga, Francesca/0000-0002-6904-2247; Murthy, Srinivas/0000-0002-9476-839X; Syed Omar, Sharifah Faridah/0000-0002-4947-4878; Perez-Molina, Jose Antonio/0000-0001-8735-4124; Haniffa, Rashan/0000-0002-8288-449X; Munez Rubio, Elena/0000-0002-5256-097X; Castro Rebollo, Pedro/0000-0002-6118-8970				Areri H, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05618-y; Fisher DJ, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j573; Fisher DJ, 2015, STATA J, V15, P369, DOI 10.1177/1536867X1501500203; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Langan D, 2019, RES SYNTH METHODS, V10, P83, DOI 10.1002/jrsm.1316; Leisman DE, 2020, LANCET RESP MED, V8, P1233, DOI 10.1016/S2213-2600(20)30404-5; Lescure FX, 2021, LANCET RESP MED, V9, P522, DOI 10.1016/S2213-2600(21)00099-0; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; McElvaney OJ, 2021, LANCET RESP MED, V9, P643, DOI 10.1016/S2213-2600(21)00103-X; Nikolakopoulou A, 2014, EVID-BASED MENT HEAL, V17, P53, DOI 10.1136/eb-2014-101795; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Rucker G, 2017, RES SYNTH METHODS, V8, P392, DOI 10.1002/jrsm.1259; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Serghiou S, 2019, JAMA-J AM MED ASSOC, V321, P301, DOI 10.1001/jama.2018.19684; Soin AS, 2021, LANCET RESP MED, V9, P511, DOI 10.1016/S2213-2600(21)00081-3; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Tierney JF, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003629; Veiga VC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n84; White IR, 2015, STATA J, V15, P951, DOI 10.1177/1536867X1501500403; Xu C, 2021, J CLIN PHARMACOL, V61, P714, DOI 10.1002/jcph.1795	26	264	266	18	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2021	326	6					499	518		10.1001/jama.2021.11330	http://dx.doi.org/10.1001/jama.2021.11330			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD4PP	34228774	Green Published, Bronze			2023-01-03	WOS:000687190200016
J	Rutkowski, NA; Sabri, E; Yang, C				Rutkowski, Nicole Anna; Sabri, Elham; Yang, Christine			Post-stroke fatigue: A factor associated with inability to return to work in patients <60 years-A 1-year follow-up	PLOS ONE			English	Article							MONTREAL COGNITIVE ASSESSMENT; STROKE PATIENTS EXPERIENCES; PRACTICE GUIDELINES; CANADIAN-STROKE; REHABILITATION; OUTCOMES; LONG; SYMPTOMS; SCALE; STATE	This study investigated the association between post-stroke fatigue and inability to return to work/drive in young patients aged <60 years with first stroke who were employed prior to infarct while controlling for stroke severity, age, extent of disability, cognitive function, and depression. The Fatigue Severity Scale (FSS) was used to evaluate post-stroke fatigue in this 1-year prospective cohort study. Follow-ups were completed at 3, 6, and 12 months post rehabilitation discharge. A total of 112 patients were recruited, 7 were excluded, due to loss to follow-up (n = 6) and being palliative (n = 1), resulting in 105 participants (71% male, average age 49 +/- 10.63 years). Stroke patients receiving both inpatient and outpatient rehabilitation were consecutively recruited. Persistent fatigue remained associated with inability to return to work when controlling for other factors at 3 months (adjusted OR = 18, 95% CI: 2.9, 110.3, p = 0.002), 6 months (adjusted OR = 29.81, 95% CI: 1.7, 532.8, p = 0.021), and 12 months (adjusted OR = 31.6, 95% CI: 1.8, 545.0, p = 0.018). No association was found between persistent fatigue and return to driving. Fatigue at admission was associated with inability to return to work at 3 months but not return to drive. Persistent fatigue was found to be associated with inability to resume work but not driving. It may be beneficial to routinely screen post-stroke fatigue in rehabilitation and educate stroke survivors and employers on the impacts of post-stroke fatigue on return to work.	[Rutkowski, Nicole Anna] Univ Ottawa, Sch Psychol, Fac Social Sci, Ottawa, ON, Canada; [Sabri, Elham] Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Yang, Christine] Elisabeth Bruyere Hosp, Dept Phys Med & Rehabil, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Yang, C (corresponding author), Elisabeth Bruyere Hosp, Dept Phys Med & Rehabil, Ottawa, ON, Canada.	cyang@bruyere.org	Sabri, Elham/GXG-8198-2022	Yang, Christine/0000-0002-9059-5452	Bruyere Academic Medical Organization Incentive fund	Bruyere Academic Medical Organization Incentive fund	This study was funded by the Bruyere Academic Medical Organization Incentive fund. The funds were awarded to CY. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alaszewski A, 2007, DISABIL REHABIL, V29, P1858, DOI 10.1080/09638280601143356; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5; Andersen G, 2012, ACTA NEUROL SCAND, V125, P248, DOI 10.1111/j.1600-0404.2011.01557.x; Balasooriya-Smeekens C, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009974; Banks JL, 2007, STROKE, V38, P1091, DOI 10.1161/01.STR.0000258355.23810.c6; Bejot Y, 2016, PRESSE MED, V45, pE391, DOI 10.1016/j.lpm.2016.10.003; Carlsson GE, 2003, CEREBROVASC DIS, V16, P383, DOI 10.1159/000072561; Choi-Kwon S, 2005, CEREBROVASC DIS, V19, P84, DOI 10.1159/000082784; Christensen D, 2008, CEREBROVASC DIS, V26, P134, DOI 10.1159/000139660; Corr S., 2003, BRIT J OCCUPATIONAL, V66, P186, DOI DOI 10.1177/030802260306600502; Dozois DJA, 1998, PSYCHOL ASSESSMENT, V10, P83, DOI 10.1037/1040-3590.10.2.83; Edwards JD, 2018, INT J STROKE, V13, P243, DOI 10.1177/1747493017743059; Eskes GA, 2015, INT J STROKE, V10, P1130, DOI 10.1111/ijs.12557; Flinn NA, 2010, OCCUP THER INT, V17, P81, DOI 10.1002/oti.286; Ghoshchi SG, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17145233; Gilworth G, 2009, WORK, V34, P95, DOI 10.3233/WOR-2009-0906; Glader EL, 2002, STROKE, V33, P1327, DOI 10.1161/01.STR.0000014248.28711.D6; Hackett ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041795; Harris C, 2014, STROKE, V45, pE174, DOI 10.1161/STROKEAHA.114.006205; Hartke RJ, 2015, TOP STROKE REHABIL, V22, P326, DOI 10.1179/1074935714Z.0000000044; Hebert D, 2016, INT J STROKE, V11, P459, DOI 10.1177/1747493016643553; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Johansson B, 2012, BRAIN INJURY, V26, P1621, DOI 10.3109/02699052.2012.700082; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lanctot KL, 2020, INT J STROKE, V15, P668, DOI 10.1177/1747493019847334; LEEGAARD OF, 1983, ACTA NEUROL SCAND, V67, P348; Lerdal A, 2009, J PAIN SYMPTOM MANAG, V38, P928, DOI 10.1016/j.jpainsymman.2009.04.028; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Medin J, 2006, DISABIL REHABIL, V28, P1051, DOI 10.1080/09638280500494819; Mittmann N, 2012, CAN J NEUROL SCI, V39, P793, DOI 10.1017/S0317167100015638; Moradi V, 2021, IRAN J PUBLIC HEALTH, V50, P209, DOI 10.18502/ijph.v50i1.5092; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; National Institute For Health And Care Excellence [NICE], 2013, STROKE REHABILITATIO; Ntsiea MV, 2015, CLIN REHABIL, V29, P663, DOI 10.1177/0269215514554241; Passier PECA, 2011, J STROKE CEREBROVASC, V20, P324, DOI 10.1016/j.jstrokecerebrovasdis.2010.02.001; Perrier MJ, 2010, ARCH PHYS MED REHAB, V91, P868, DOI 10.1016/j.apmr.2010.03.009; Pihlaja R, 2014, J PSYCHOSOM RES, V77, P380, DOI 10.1016/j.jpsychores.2014.08.011; Roding J, 2003, DISABIL REHABIL, V25, P867, DOI 10.1080/0963828031000122276; Rost NS, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002433; Schepers VP, 2006, ARCH PHYS MED REHAB, V87, P184, DOI 10.1016/j.apmr.2005.10.005; Snaphaan L, 2011, EUR J NEUROL, V18, P611, DOI 10.1111/j.1468-1331.2010.03217.x; Staub F, 2001, CEREBROVASC DIS, V12, P75, DOI 10.1159/000047685; Toglia J, 2011, ARCH PHYS MED REHAB, V92, P792, DOI 10.1016/j.apmr.2010.12.034; van de Port IGL, 2007, CEREBROVASC DIS, V23, P40, DOI 10.1159/000095757; van der Werf SP, 2001, EUR NEUROL, V45, P28, DOI 10.1159/000052085; Walsh ME, 2015, DISABIL REHABIL, V37, P1834, DOI 10.3109/09638288.2014.981302; Wang YC, 2014, WORK, V47, P553, DOI 10.3233/WOR-131627; Wei XJ, 2016, BRIT J OCCUP THER, V79, P299, DOI 10.1177/0308022615624710; Westerlind E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169759; Wu SM, 2015, STROKE, V46, P893, DOI 10.1161/STROKEAHA.114.006647; Yu S, 2016, INT J STROKE, V11, P799, DOI 10.1177/1747493016641952; Zedlitz AMEE, 2012, STROKE, V43, P1046, DOI 10.1161/STROKEAHA.111.632117	52	3	3	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2021	16	8							e0255538	10.1371/journal.pone.0255538	http://dx.doi.org/10.1371/journal.pone.0255538			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UA6IY	34347804	gold, Green Published			2023-01-03	WOS:000685264900011
J	Kim, HS; Lee, CE; Yang, YS				Kim, Hyang Sook; Lee, Chung Eun; Yang, Yong Sook			Factors associated with caring behaviors of family caregivers for patients receiving home mechanical ventilation with tracheostomy: A cross-sectional study	PLOS ONE			English	Article							ASSISTED INDIVIDUALS; PERSPECTIVES; CARE; LIFE	Background The number of patients on home mechanical ventilation (HMV) worldwide has been steadily rising as medical technological advanced. To ensure the safety and quality care of the patients receiving HMV with tracheostomy, caring behavior of family caregivers is critical. However, studies on caring behavior of family caregivers and its associated factors were remained unexplored. This study aimed to describe the caring behaviors of family caregivers for patients receiving home mechanical ventilation with tracheostomy and to identify factors associated with their caring behaviors. Methods This was a cross-sectional study for 95 family caregivers for patients with invasive home mechanical ventilation in South Korea. Caring behaviors were assessed by the Caring Behavior Scale with 74 items with 5-point Likert scale. Data were analyzed using multiple regression analysis. Results Caring behaviors score of caregivers was 304.68 +/- 31.05 out of 370. They were significantly associated with knowledge on emergency care (beta = 0.22, p = .011), number of required instruments for care (beta = 0.21, p = .010), frequency of home visit care (beta = 0.19, p = .017), experience of emergency situation for the last six months (beta = 0.19, p = .009) and activities of daily living of patient (beta = 0.27, p = .002). Conclusion Development of standardized multidisciplinary discharge education for improving the caring capacity of caregivers is required for successful and healthy application of home mechanical ventilation.	[Kim, Hyang Sook; Lee, Chung Eun; Yang, Yong Sook] Yonsei Univ, Coll Nursing Brain Korea 21 FOUR Project, Seoul, South Korea; [Kim, Hyang Sook; Lee, Chung Eun] Severance Hosp, Seoul, South Korea	Yonsei University; Yonsei University; Yonsei University Health System	Yang, YS (corresponding author), Yonsei Univ, Coll Nursing Brain Korea 21 FOUR Project, Seoul, South Korea.	ysyang100061@gmail.com		LEE, CHUNG EUN/0000-0001-8567-1062				Ahn JJ, 2000, TUBERC RESPIR DIS SE, V49, P624, DOI [10.4046/trd.2000.49.5.624, DOI 10.4046/TRD.2000.49.5.624]; Ambrosino N, 2018, MULTIDISCIP RESP MED, V13, DOI 10.1186/s40248-018-0118-7; Bodenham A, 2014, STANDARDS CARE ADULT; Brooks D, 2008, PATIENT EDUC COUNS, V71, P244, DOI 10.1016/j.pec.2008.01.018; Evans R, 2012, CAN RESPIR J, V19, P373, DOI 10.1155/2012/452898; Hwang MS., 2016, J KOREAN ACAD SOC HO, V23, P25; Hwang MS., 2012, J KOREAN ACAD SOC HO, V20, P5; Karaca T, 2019, WOUND MANAG PREV, V65, P22, DOI 10.25270/wmp.2019.3.2229; Kim DH, 2010, ANN REHABIL MED-ARM, V34, P347; 김미화, 2012, Child Health Nursing Research, V18, P9; Kim HI, 2019, RESP CARE, V64, P528, DOI 10.4187/respcare.06310; Kun SS, 2010, PEDIATR PULM, V45, P270, DOI 10.1002/ppul.21169; Lopez-Campos JL, 2008, RESP MED, V102, P605, DOI 10.1016/j.rmed.2007.11.005; Mallory LA, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2015-4626; Marchese S, 2008, RESP MED, V102, P430, DOI 10.1016/j.rmed.2007.10.006; McCormick ME, 2015, OTOLARYNG HEAD NECK, V153, P914, DOI 10.1177/0194599815599525; Ministry of Health and Welfare, 2016, PART AM INS BEN STAN PART AM INS BEN STAN; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; Mun SW, 2016, ALLERGY ASTHMA RESPI, V4, P195, DOI 10.4168/aard.2016.4.3.195; Ock Kim Soon, 2018, [Journal of Korean Public Health Nursing, 한국보건간호학회지], V32, P288; Oh J, 2015, J KOREAN ACAD NURS, V45, P202, DOI 10.4040/jkan.2015.45.2.202; Povitz M, 2018, RESP CARE, V63, P380, DOI 10.4187/respcare.05689; Rose L, 2019, CAN J RESP CRIT CARE, V3, P100, DOI 10.1080/24745332.2018.1514674; Rose L, 2015, RESP CARE, V60, P695, DOI 10.4187/respcare.03609; Simonds AK, 2016, ANN AM THORAC SOC, V13, P2035, DOI 10.1513/AnnalsATS.201606-454FR; Wijkstra P J, 2000, Monaldi Arch Chest Dis, V55, P130; 황문숙, 2017, [Korean Journal of Adult Nursing, 성인간호학회지], V29, P406, DOI 10.7475/kjan.2017.29.4.406; 이미경, 2017, [Journal of Korean Academic Society of Home Health Care Nursing, 가정간호학회지], V24, P210, DOI 10.22705/jkashcn.2017.24.2.210; 황문숙, 2014, [Korean Journal of Adult Nursing, 성인간호학회지], V26, P191, DOI 10.7475/kjan.2014.26.2.191	29	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2021	16	7							e0254987	10.1371/journal.pone.0254987	http://dx.doi.org/10.1371/journal.pone.0254987			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2OI	34288975	Green Published, gold			2023-01-03	WOS:000678124300052
J	Nguyen, HT; Vu, TY; Dakal, TC; Dhabhai, B; Nguyen, XHQ; Tatipamula, VB				Ha Thi Nguyen; Thien-Y Vu; Dakal, Tikam Chand; Dhabhai, Bhanupriya; Xuan Hong Quan Nguyen; Tatipamula, Vinay Bharadwaj			Cleroda-4(18),13-dien-15,16-olide as novel xanthine oxidase inhibitors: An integrated in silico and in vitro study	PLOS ONE			English	Article							PROTEIN; ACID; ALLOPURINOL; FLAVONOIDS; MECHANISM; BINDING; OXIDOREDUCTASE; DERIVATIVES; DOCKING; MODEL	In the present study, in silico predictions and molecular docking were performed on five clerodane diterpenes (1-5) from Polyalthia longifolia seeds to evaluate their potential as xanthine oxidase (XO) inhibitors. The initial screening was conducted by target prediction using TargetNet web server application and only compounds 3 and 4 showed a potential interaction with XO. Compounds 3 and 4 were subsequently subjected to in silico analyses on XO protein structure (PDB: 1N5X) using Schrodinger Release 2020-3 followed by structural modeling & molecular simulation studies to confirm the initial prediction result and identify the binding mode of these compounds to the XO. Molecular docking results revealed that compounds 3 (-37.3 kcal/mol) and 4 (-32.0 kcal/mol) binds more stably to XO than the reference drug allopurinol (-27.0 kcal/mol). Interestingly, two residues Glu 802 and Thr 1010 were observed as the two main H-bond binding sites for both tested compounds and the allopurinol. The center scaffold of allopurinol was positioned by some pi-pi stacking with Phe 914 and Phe 1009, while that of compounds 3 and 4 were supported by many hydrophobic interactions mainly with Leu 648, Phe 649, Phe 1013, and Leu 1014. Additionally, the docking simulation predicted that the inhibitory effect of compounds 3 and 4 was mediated by creating H-bond with particularly Glu 802, which is a key amino acid for XO enzyme inhibition. Altogether, in vitro studies showed that compounds 3 and 4 had better inhibitory capacity against XO enzyme with IC50 values significantly (p < 0.001) lower than that of allopurinol. In short, the present study identified cleroda-4(18),13-dien-15,16-olide as novel potential XO inhibitors, which can be potentially used for the treatment of gout.	[Ha Thi Nguyen; Tatipamula, Vinay Bharadwaj] Duy Tan Univ, Inst Res & Dev, Da Nang, Vietnam; [Ha Thi Nguyen; Tatipamula, Vinay Bharadwaj] Duy Tan Univ, Fac Med, Da Nang, Vietnam; [Thien-Y Vu] Ton Duc Thang Univ, Fac Pharm, Ho Chi Minh City, Vietnam; [Dakal, Tikam Chand; Dhabhai, Bhanupriya] Mohanlal Sukhadia Univ, Dept Biotechnol, Genome & Computat Biol Lab, Udaipur, Rajasthan, India; [Xuan Hong Quan Nguyen] Nguyen Thai Binh Sch, Ho Chi Minh City, Vietnam	Duy Tan University; Duy Tan University; Ton Duc Thang University; Mohanlal Sukhadia University	Tatipamula, VB (corresponding author), Duy Tan Univ, Inst Res & Dev, Da Nang, Vietnam.; Tatipamula, VB (corresponding author), Duy Tan Univ, Fac Med, Da Nang, Vietnam.; Vu, TY (corresponding author), Ton Duc Thang Univ, Fac Pharm, Ho Chi Minh City, Vietnam.	vuthieny@tdtu.edu.vn; vinaybharadwajtatipamula@duytan.edu.vn	Nguyen, Ha Thi/Y-3064-2019; TATIPAMULA, VINAY BHARADWAJ/L-8352-2018	Nguyen, Ha Thi/0000-0001-9222-632X; TATIPAMULA, VINAY BHARADWAJ/0000-0002-9376-1911	National Foundation for Science and Technology Development (NAFOSTED) [106-YS.01-2015.12]	National Foundation for Science and Technology Development (NAFOSTED)(National Foundation for Science & Technology Development (NAFOSTED))	The study was supported by the National Foundation for Science and Technology Development (NAFOSTED; Grant no. 106-YS.01-2015.12). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali MM., 2019, AM J NURS RES, V7, P128, DOI [10.12691/ajnr-7-2-4, DOI 10.12691/AJNR-7-2-4]; Bai XS, 2021, TECHNOL HEALTH CARE, V29, P121, DOI 10.3233/THC-191951; Bowers K.J., 2006, SCALABLE ALGORITHMS, P43, DOI DOI 10.1109/SC.2006.54; Cos P, 1998, J NAT PROD, V61, P71, DOI 10.1021/np970237h; COSTANTINO L, 1992, PLANTA MED, V58, P342, DOI 10.1055/s-2006-961481; Day RO, 2007, CLIN PHARMACOKINET, V46, P623, DOI 10.2165/00003088-200746080-00001; Fields M, 1996, FREE RADICAL BIO MED, V20, P595, DOI 10.1016/0891-5849(95)02056-X; Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o; Greenidge PA, 2013, J CHEM INF MODEL, V53, P201, DOI [10.1021/ci300425v, 10.1021/cI300025v]; Harris MD, 1999, AM FAM PHYSICIAN, V59, P925; Jayaraj P., 2014, BIOMED PREV NUTR, V4, P1, DOI 10.1016/j.bionut.2014.04.002; Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284; Ketha A, 2020, FUTUR J PHARM SCI, V6, DOI 10.1186/s43094-020-00028-y; Kushiyama A, 2014, WORLD J DIABETES, V5, P787, DOI 10.4239/wjd.v5.i6.787; Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106; Lin HC, 2008, BIOCHEM PHARMACOL, V75, P1416, DOI 10.1016/j.bcp.2007.11.023; Liu HX, 2015, PHYTOCHEM LETT, V12, P133, DOI 10.1016/j.phytol.2015.03.005; Murata K, 2009, J NAT MED-TOKYO, V63, P355, DOI 10.1007/s11418-009-0331-y; Nguyen HT, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72840-8; Nishino T, 2008, FEBS J, V275, P3278, DOI 10.1111/j.1742-4658.2008.06489.x; Okamoto K, 2003, J BIOL CHEM, V278, P1848, DOI 10.1074/jbc.M208307200; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; Pauff JM, 2009, J BIOL CHEM, V284, P8751, DOI 10.1074/jbc.M804517200; Rasoulzadeh F, 2009, SPECTROCHIM ACTA A, V72, P190, DOI 10.1016/j.saa.2008.09.021; Riegersperger M, 2011, INT UROL NEPHROL, V43, P441, DOI 10.1007/s11255-011-9929-6; Roddy E, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3199; Roman Youssef M, 2019, Hawaii J Med Public Health, V78, P71; Santi MD, 2018, EUR J MED CHEM, V143, P577, DOI 10.1016/j.ejmech.2017.11.071; Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8; Sharma S, 2014, BIOORG MED CHEM LETT, V24, P495, DOI 10.1016/j.bmcl.2013.12.031; Shen L, 2009, BIOORG MED CHEM LETT, V19, P5990, DOI 10.1016/j.bmcl.2009.09.076; Shi DH, 2014, EUR J MED CHEM, V75, P289, DOI 10.1016/j.ejmech.2014.01.058; Shi SY, 2012, FOOD CHEM, V135, P1083, DOI 10.1016/j.foodchem.2012.05.049; Unno T, 2004, J ETHNOPHARMACOL, V93, P391, DOI 10.1016/j.jep.2004.04.012; Wang WJ, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/680853; Xie ZD, 2017, BIOORG MED CHEM LETT, V27, P3602, DOI 10.1016/j.bmcl.2017.01.053; Yamaguchi Y, 2007, J BIOCHEM, V141, P513, DOI 10.1093/jb/mvm053; Yan JK, 2013, FOOD CHEM, V141, P3766, DOI 10.1016/j.foodchem.2013.06.092; Yao ZJ, 2016, J COMPUT AID MOL DES, V30, P413, DOI 10.1007/s10822-016-9915-2; Yasuda T, 2008, MOL CANCER RES, V6, P1852, DOI 10.1158/1541-7786.MCR-08-0012	40	3	3	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2021	16	6							e0253572	10.1371/journal.pone.0253572	http://dx.doi.org/10.1371/journal.pone.0253572			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9EF	34191831	gold, Green Published			2023-01-03	WOS:000671698800035
J	Chow, R; Im, J; Chiu, N; Chiu, L; Aggarwal, R; Lee, J; Choi, YG; Prsic, EH; Shin, HJ				Chow, Ronald; Im, James; Chiu, Nicholas; Chiu, Leonard; Aggarwal, Rahul; Lee, Jihui; Choi, Young-Geun; Prsic, Elizabeth Horn; Shin, Hyun Joon			The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis	PLOS ONE			English	Review								Introduction Statins may reduce a cytokine storm, which has been hypothesized as a possible mechanism of severe COVID-19 pneumonia. The aim of this study was to conduct a systematic review and meta-analysis to report on adverse outcomes among COVID-19 patients by statin usage. Methods Literatures were searched from January 2019 to December 2020 to identify studies that reported the association between statin usage and adverse outcomes, including mortality, ICU admissions, and mechanical ventilation. Studies were meta-analyzed for mortality by the subgroups of ICU status and statin usage before and after COVID-19 hospitalization. Studies reporting an odds ratio (OR) and hazard ratio (HR) were analyzed separately. Results Thirteen cohorts, reporting on 110,078 patients, were included in this meta-analysis. Individuals who used statins before their COVID-19 hospitalization showed a similar risk of mortality, compared to those who did not use statins (HR 0.80, 95% CI: 0.50, 1.28; OR 0.62, 95% CI: 0.38, 1.03). Patients who were administered statins after their COVID-19 diagnosis were at a lower risk of mortality (HR 0.53, 95% CI: 0.46, 0.61; OR 0.57, 95% CI: 0.43, 0.75). The use of statins did not reduce the mortality of COVID-19 patients admitted to the ICU (OR 0.65; 95% CI: 0.26, 1.64). Among non-ICU patients, statin users were at a lower risk of mortality relative to non-statin users (HR 0.53, 95% CI: 0.46, 0.62; OR 0.64, 95% CI: 0.46, 0.88). Conclusion Patients administered statins after COVID-19 diagnosis or non-ICU admitted patients were at lower risk of mortality relative to non-statin users.	[Chow, Ronald] Yale Univ, Yale Sch Publ Hlth, New Haven, CT 06520 USA; [Chow, Ronald; Prsic, Elizabeth Horn] Yale Univ, Yale Sch Med, Yale New Haven Hlth, New Haven, CT 06520 USA; [Chow, Ronald; Shin, Hyun Joon] Hanyang Impact Sci Res Ctr, Seoul, South Korea; [Im, James] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Chiu, Nicholas; Aggarwal, Rahul] Harvard Univ, Beth Israel Deaconess Med Ctr, Harvard Med Sch, Boston, MA 02215 USA; [Chiu, Leonard] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA; [Lee, Jihui] Weill Cornell Med, New York, NY USA; [Choi, Young-Geun] Sookmyung Womens Univ, Seoul, South Korea; [Shin, Hyun Joon] Lemuel Shattuck Hosp, Jamaica Plain, MA 02130 USA; [Shin, Hyun Joon] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Yale University; Yale University; University of Toronto; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Columbia University; Cornell University; Sookmyung Women's University; Harvard University; Brigham & Women's Hospital	Chow, R (corresponding author), Yale Univ, Yale Sch Publ Hlth, New Haven, CT 06520 USA.; Chow, R (corresponding author), Yale Univ, Yale Sch Med, Yale New Haven Hlth, New Haven, CT 06520 USA.; Chow, R; Shin, HJ (corresponding author), Hanyang Impact Sci Res Ctr, Seoul, South Korea.; Shin, HJ (corresponding author), Lemuel Shattuck Hosp, Jamaica Plain, MA 02130 USA.; Shin, HJ (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	ronald.chow@yale.edu; hyun.shin@mass.gov	Chiu, Nicholas/AAH-3639-2021; Chow, Ronald/V-3117-2019; C, R/HJA-9099-2022	Chiu, Nicholas/0000-0002-8535-8428; Chow, Ronald/0000-0001-6195-8624; Chiu, Leonard/0000-0002-7803-7052				Bloom AB., 2021, UPTODATE LIT REV CUR; Cariou B, 2021, DIABETES METAB, V47, DOI 10.1016/j.diabet.2020.10.001; Chow R, 2020, ANN PALLIAT MED, V9, P3716, DOI 10.21037/apm-20-1538; Daniels LB, 2020, AM J CARDIOL, V136, P149, DOI 10.1016/j.amjcard.2020.09.012; De Spiegeleer A, 2020, J AM MED DIR ASSOC, V21, P909, DOI 10.1016/j.jamda.2020.06.018; Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20; Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539; Gupta Aakriti, 2020, Res Sq, DOI 10.21203/rs.3.rs-56210/v1; Hariyanto TI, 2020, DIABETES METAB SYND, V14, P1613, DOI 10.1016/j.dsx.2020.08.023; Israel A., 2020, LARGE POPULATION STU, DOI [10.1101/2020.10.13.20211953, DOI 10.1101/2020.10.13.20211953]; Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2; Kow CS, 2020, AM J CARDIOL, V134, P153, DOI 10.1016/j.amjcard.2020.08.004; Lock, 2020, ROBUST ARE RESULTS O; Mallow Peter J, 2020, J Health Econ Outcomes Res, V7, P165, DOI 10.36469/jheor.2020.17331; Masana L, 2022, EUR HEART J-CARD PHA, V8, P157, DOI 10.1093/ehjcvp/pvaa128; Nguyen AB, 2020, OUTCOMES CARDIOVASCU, DOI [10.1101/2020.06.28.20141929, DOI 10.1101/2020.06.28.20141929]; Rodriguez-Nava G, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03154-4; Saeed O, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.018475; Scicali R, 2020, NUTR METAB CARDIOVAS, V30, P1068, DOI 10.1016/j.numecd.2020.05.003; Song SL, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090759; Soto-Acosta R, 2013, VIROLOGY, V442, P132, DOI 10.1016/j.virol.2013.04.003; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Yan HD, 2020, CLIN PHARMACOL THER, V108, P1185, DOI 10.1002/cpt.2047; Zhang XJ, 2020, CELL METAB, V32, P176, DOI 10.1016/j.cmet.2020.06.015	24	18	18	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2021	16	6							e0253576	10.1371/journal.pone.0253576	http://dx.doi.org/10.1371/journal.pone.0253576			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BX	34166458	Green Submitted, gold, Green Published			2023-01-03	WOS:000671692800023
J	Kumbeni, MT; Apanga, PA; Yeboah, EO; Lettor, IBK				Kumbeni, Maxwell Tii; Apanga, Paschal Awingura; Yeboah, Eugene Osei; Lettor, Isaac Bador Kamal			Knowledge and preventive practices towards COVID-19 among pregnant women seeking antenatal services in Northern Ghana	PLOS ONE			English	Article							EDUCATION	Background COVID-19 is a novel respiratory disease associated with severe morbidity and high mortality in the elderly population and people with comorbidities. Studies have suggested that pregnant women are more susceptible to COVID-19 compared to non-pregnant women. However, it's unclear whether pregnant women in Ghana are knowledgeable about COVID-19 and practice preventive measures against it. This study sought to assess the knowledge and preventive practices towards COVID-19 among pregnant women seeking antenatal services in Northern Ghana. Methods A cross-sectional study was conducted using a structured questionnaire in the Nabdam district in Ghana. A total of 527 pregnant women were randomly sampled from health facilities offering antenatal care services in the district. Multivariable logistic regression analysis was used to assess the association between the predictors and outcome variables. Results The prevalence of adequate knowledge and good COVID-19 preventive practices were 85.6%, (95% CI: 82.57, 88.59) and 46.6%, (95% CI: 42.41, 50.95) respectively. Having at least a primary education, residing in an urban area, and receiving COVID-19 education at a health facility were positively associated with adequate knowledge on COVID-19. Factors positively associated with good COVID-19 preventive practices were older age, having at least a primary education, pregnant women with a chronic disease, and living in an urban area. Multiparity was negatively associated with good COVID-19 preventive practices. Conclusion Although majority of women had adequate knowledge of COVID-19, less than half of them were engaged in good COVID-19 preventive practices. Education of pregnant women on COVID-19 preventive practices should be intensified at health facilities while improving upon the water, sanitation and hygiene need particularly in rural communities.	[Kumbeni, Maxwell Tii] Nabdam Dist Hlth Directorate, Ghana Hlth Serv, Nangodi, Ghana; [Apanga, Paschal Awingura] Univ Nevada, Sch Community Hlth Sci, Reno, NV 89557 USA; [Yeboah, Eugene Osei] Bolgatanga East Dist Hlth Directorate, Ghana Hlth Serv, Zuarungu, Ghana; [Lettor, Isaac Bador Kamal] Bawku Tech Inst, Bawku, Upper East Regi, Ghana	Nevada System of Higher Education (NSHE); University of Nevada Reno	Kumbeni, MT (corresponding author), Nabdam Dist Hlth Directorate, Ghana Hlth Serv, Nangodi, Ghana.	tiimax2@gmail.com		yeboah, eugene/0000-0002-7777-5838; Kumbeni, maxwell/0000-0001-5525-4022				Addo LK, 2020, SOC SCI RES NETW, P1; Afulani PA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117996; Akalu Y, 2020, INFECT DRUG RESIST, V13, P1949, DOI 10.2147/IDR.S258736; Al-Hanawi MK, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00217; [Anonymous], 2002, Bull World Health Organ, V80, P983; Baloch S, 2020, TOHOKU J EXP MED, V250, P271, DOI 10.1620/tjem.250.271; Bloom Benjamin, 1956, HDB 1 COGNITIVE DOMA; Brady KD, 1999, BIOORGAN MED CHEM, V7, P621, DOI 10.1016/S0968-0896(99)00009-7; Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Feinstein BL., 2006, WHAT ARE EFFECTS ED, P171; Ghana Statistical Service, 2020, GHAN STAT SERV; Greenaway ES, 2012, J BIOSOC SCI, V44, P733, DOI 10.1017/S0021932012000041; Guan WJ, 2020, NEW ENGL J MED, V382, P1861, DOI 10.1056/NEJMc2005203; Hantoushzadeh S, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.04.030; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jia Q, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176161; Karimi-Zarchi M, 2020, FETAL PEDIATR PATHOL, V39, P246, DOI 10.1080/15513815.2020.1747120; Mallapaty Smriti, 2021, Nature, DOI 10.1038/d41586-021-00450-z; Masters PS, 2019, VIROLOGY, V537, P198, DOI 10.1016/j.virol.2019.08.031; Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633; Nwafor JI, 2020, INT J GYNECOL OBSTET, V150, P121, DOI 10.1002/ijgo.13186; Olum R, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00181; Qiao J, 2020, LANCET, V395, P760, DOI 10.1016/S0140-6736(20)30365-2; Rasmussen SA, 2020, JAMA-J AM MED ASSOC, V324, P190, DOI 10.1001/jama.2020.8883; Rasmussen SA, 2020, AM J OBSTET GYNECOL, V222, P415, DOI 10.1016/j.ajog.2020.02.017; Sarfo A.K., 2020, T INDIAN NATL ACAD E, V5, P193, DOI [10.1007/s41403-020-00145-3, DOI 10.1007/S41403-020-00145-3]; Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194; Serwaa D, 2020, PAN AFR MED J, V35, DOI [10.11604/pamj.2020.35.2.22630, 10.11604/pamj.supp.2020.35.2.22630]; Sokey P. P., 2017, SOC SCI QUART, V6, DOI [10.3390/socsci6020066, DOI 10.3390/SOCSCI6020066]; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Yadav A, 2018, SAUDI J ANAESTH, V12, P287, DOI 10.4103/sja.SJA_474_17; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017; Zeng LK, 2020, JAMA PEDIATR, V174, P722, DOI 10.1001/jamapediatrics.2020.0878; Zhao XY, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05010-w; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	36	8	8	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2021	16	6							e0253446	10.1371/journal.pone.0253446	http://dx.doi.org/10.1371/journal.pone.0253446			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9AX	34138946	Green Published, gold			2023-01-03	WOS:000671690200044
J	Malhani, AA; Enani, MA; Sharif-Askari, FS; Alghareeb, MR; Bin-Brikan, RT; AlShahrani, SA; Halwani, R; Tleyjeh, IM				Malhani, Areej A.; Enani, Mushira A.; Sharif-Askari, Fatemeh Saheb; Alghareeb, Mona R.; Bin-Brikan, Roaa T.; AlShahrani, Safar A.; Halwani, Rabih; Tleyjeh, Imad M.			Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study	PLOS ONE			English	Article							VALVE SURGERY; ASSOCIATION; MORTALITY; SELECTION; DISEASE; MODEL	Objectives Our study aims at comparing the efficacy and safety of IFN-based therapy (lopinavir/ritonavir, ribavirin, and interferon beta -1b) vs. favipiravir (FPV) in a cohort of hospitalized patients with non-critical COVID-19. Methods Single center observational study comparing IFN-based therapy (interferon beta -1b, ribavirin, and lopinavir/ritonavir) vs. FPV in non-critical hospitalized COVID-19 patients. Allocation to either treatment group was non-random but based on changes to national treatment protocols rather than physicians' selection (quasi-experimental). We examined the association between IFN-based therapy and 28-day mortality using Cox regression model with treatment as a time-dependent covariate. Results The study cohort included 222 patients, of whom 68 (28%) received IFN-based therapy. Antiviral therapy was started at a median of 5 days (3-6 days) from symptoms onset in the IFN group vs. 6 days (4-7 days) for the FPV group, P <0.0001. IFN-based therapy was associated with a lower 28-day mortality as compared to FPV (6 (9%) vs. 18 (12%)), adjusted hazard ratio [aHR] (95% Cl) = 0.27 (0.08-0.88)). No difference in hospitalization duration between the 2 groups, 9 (7-14) days vs. 9 (7-13) days, P = 0.732 was found. IFN treated group required less use of systemic corticosteroids (57%) as compared to FPV (77%), P = 0.005 after adjusting for disease severity and other confounders. Patients in the IFN treated group were more likely to have nausea and diarrhea as compared to FPV group (13%) vs. (3%), P = 0.013 and (18%) vs. (3%), P<0.0001, respectively. Conclusion Early IFN-based triple therapy was associated with lower 28-days mortality as compared to FPV.	[Malhani, Areej A.] King Fahad Med City, Pharm Serv Adm, Clin Pharm Dept, Riyadh, Saudi Arabia; [Enani, Mushira A.; Tleyjeh, Imad M.] King Fahad Med City, Dept Med Specialties, Infect Dis Sect, Riyadh, Saudi Arabia; [Sharif-Askari, Fatemeh Saheb; Halwani, Rabih] Univ Sharjah, Coll Med, Sharjah Med Inst Res, Sharjah, U Arab Emirates; [Alghareeb, Mona R.; Bin-Brikan, Roaa T.] King Fahad Med City, Collage Med, Riyadh, Saudi Arabia; [AlShahrani, Safar A.] King Fahad Med City, Pharm Serv Adm, Outpatient Pharm Dept, Riyadh, Saudi Arabia; [Halwani, Rabih] Univ Sharjah, Coll Med, Dept Clin Sci, Sharjah, U Arab Emirates; [Halwani, Rabih] King Saud Univ, Fac Med, Dept Pediat, Riyadh, Saudi Arabia; [Tleyjeh, Imad M.] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia; [Tleyjeh, Imad M.] Mayo Clin, Coll Med & Sci, Div Infect Dis, Rochester, MN 55905 USA; [Tleyjeh, Imad M.] Mayo Clin, Coll Med & Sci, Div Epidemiol, Rochester, MN 55905 USA	King Fahad Medical City; King Fahad Medical City; University of Sharjah; King Fahad Medical City; King Fahad Medical City; University of Sharjah; King Saud University; Alfaisal University; Mayo Clinic; Mayo Clinic	Tleyjeh, IM (corresponding author), King Fahad Med City, Dept Med Specialties, Infect Dis Sect, Riyadh, Saudi Arabia.; Tleyjeh, IM (corresponding author), Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia.; Tleyjeh, IM (corresponding author), Mayo Clin, Coll Med & Sci, Div Infect Dis, Rochester, MN 55905 USA.; Tleyjeh, IM (corresponding author), Mayo Clin, Coll Med & Sci, Div Epidemiol, Rochester, MN 55905 USA.	Tleyjeh.Imad@mayo.edu	Alshahrani, Safar/CAI-9932-2022	Tleyjeh, Imad/0000-0002-5551-0353				Agrawal Umang, 2020, Med J Armed Forces India, V76, P370, DOI 10.1016/j.mjafi.2020.08.004; [Anonymous], CLIN INFECT DIS; Cai QX, 2020, ENGINEERING-PRC, V6, P1192, DOI 10.1016/j.eng.2020.03.007; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cevik M, 2021, LANCET MICROBE, V2, pE13, DOI 10.1016/S2666-5247(20)30172-5; Cinatl J, 2004, EXPERT OPIN BIOL TH, V4, P827, DOI 10.1517/14712598.4.6.827; Clementi N, 2020, J INFECT DIS, V222, P722, DOI 10.1093/infdis/jiaa350; Davoudi-Monfared E, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01061-20; Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012; EUnetHTA Rolling Collaborative Review (RCR11) Authoring Team, 2020, FAV TREATM COVID 19; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Izcovich A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241955; Joshi S, 2021, INT J INFECT DIS, V102, P501, DOI 10.1016/j.ijid.2020.10.069; Kashour Z, 2021, CTS-CLIN TRANSL SCI, V14, P1101, DOI 10.1111/cts.13001; Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06; McCoy K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040700; Meffre E, 2020, NATURE, V587, P374, DOI 10.1038/d41586-020-03070-1; Monk PD, 2021, LANCET RESP MED, V9, P196, DOI 10.1016/S2213-2600(20)30511-7; Myrstad M, 2020, SCAND J TRAUMA RESUS, V28, DOI 10.1186/s13049-020-00764-3; Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y; Pencina MJ, 2004, STAT MED, V23, P2109, DOI 10.1002/sim.1802; Perveen R A, 2020, Med J Malaysia, V75, P710; Procter B, EARLY AMBULATORY MUL, V2021; Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791; Schoggins JW, 2011, CURR OPIN VIROL, V1, P519, DOI 10.1016/j.coviro.2011.10.008; Sharif-Askari FS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095991; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.3.CO;2-S; Steyerberg EW., 2009, CLIN PREDICTION MODE, DOI [10.1007/978-0-387-77244-8, DOI 10.1007/978-0-387-77244-8]; Sy RW, 2009, CIRC-CARDIOVASC QUAL, V2, P469, DOI 10.1161/CIRCOUTCOMES.109.857938; Tangri N, 2011, JAMA-J AM MED ASSOC, V305, P1553, DOI 10.1001/jama.2011.451; Taylor M. W., 2014, VIRUSES MAN HIST INT; Tleyjeh IM, 2007, CIRCULATION, V115, P1721, DOI 10.1161/CIRCULATIONAHA.106.658831; Tleyjeh IM, 2010, J CLIN EPIDEMIOL, V63, P130, DOI 10.1016/j.jclinepi.2008.06.022; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wolkewitz M, 2017, J CLIN EPIDEMIOL, V84, P121, DOI 10.1016/j.jclinepi.2017.01.008; Wu JF, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa627; Yuan SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060628; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570	40	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2021	16	6							e0252984	10.1371/journal.pone.0252984	http://dx.doi.org/10.1371/journal.pone.0252984			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6SA	34111191	Green Published, gold			2023-01-03	WOS:000664642700080
J	Heilbroner, SP; Xanthopoulos, EP; Buono, D; Carrier, D; Durkee, BY; Corradetti, M; Wang, TJC; Neugut, AI; Hershman, DL; Cheng, SK				Heilbroner, Samuel P.; Xanthopoulos, Eric P.; Buono, Donna; Carrier, Daniel; Durkee, Ben Y.; Corradetti, Michael; Wang, Tony J. C.; Neugut, Alfred I.; Hershman, Dawn L.; Cheng, Simon K.			Efficacy and cost of high-frequency IGRT in elderly stage III non-small-cell lung cancer patients	PLOS ONE			English	Article							BEAM COMPUTED-TOMOGRAPHY; RADIATION-THERAPY; IMAGE-GUIDANCE; PROSTATE-CANCER; RADIOTHERAPY; OUTCOMES; IMPACT; ASSOCIATION; BREAST; MOTION	Background High-frequency image-guided radiotherapy (hfIGRT) is ubiquitous but its benefits are unproven. We examined the cost effectiveness of hfIGRT in stage III non-small-cell lung cancer (NSCLC). Methods We selected stage III NSCLC patients >= 66 years old who received definitive radiation therapy from the Surveillance, Epidemiology, and End-Results-Medicare database. Patients were stratified by use of hfIGRT using Medicare claims. Predictors for hfIGRT were calculated using a logistic model. The impact of hfIGRT on lung toxicity free survival (LTFS), esophageal toxicity free survival (ETFS), cancer-specific survival (CSS), overall survival (OS), and cost of treatment was calculated using Cox regressions, propensity score matching, and bootstrap methods. Results Of the 4,430 patients in our cohort, 963 (22%) received hfIGRT and 3,468 (78%) did not. By 2011, 49% of patients were receiving hfIGRT. Predictors of hfIGRT use included treatment with intensity-modulated radiotherapy (IMRT) (OR = 7.5, p < 0.01), recent diagnosis (OR = 51 in 2011 versus 2006, p < 0.01), and residence in regions where the Medicare intermediary allowed IMRT (OR = 1.50, p < 0.01). hfIGRT had no impact on LTFS (HR 0.97; 95% CI 0.86-1.09), ETFS (HR 1.05; 95% CI 0.93-1.18), CSS (HR 0.94; 95% CI 0.84-1.04), or OS (HR 0.95; 95% CI 0.87-1.04). Mean radiotherapy and total medical costs six months after diagnosis were $17,330 versus $15,024 (p < 0.01) and $71,569 versus $69,693 (p = 0.49), respectively. Conclusion hfIGRT did not affect clinical outcomes in elderly patients with stage III NSCLC but did increase radiation cost. hfIGRT deserves further scrutiny through a randomized controlled trial.	[Heilbroner, Samuel P.; Carrier, Daniel; Wang, Tony J. C.; Cheng, Simon K.] New York Presbyterian Hosp, Dept Radiat Oncol, New York, NY 10032 USA; [Xanthopoulos, Eric P.] Univ Wisconsin, Beloit Hlth Canc Ctr, Beloit, WI USA; [Buono, Donna; Neugut, Alfred I.; Hershman, Dawn L.] Herbert Irving Comprehens Canc Ctr, New York, NY USA; [Durkee, Ben Y.] Univ Wisconsin, Dept Radiat Oncol, Madison, WI USA; [Corradetti, Michael] Duke Canc Ctr, Raleigh, NC USA	NewYork-Presbyterian Hospital; University of Wisconsin System; University of Wisconsin System; University of Wisconsin Madison	Cheng, SK (corresponding author), New York Presbyterian Hosp, Dept Radiat Oncol, New York, NY 10032 USA.	sc2335@cumc.columbia.edu		Heilbroner, Samuel/0000-0003-0036-5440				Bissonnette JP, 2009, INT J RADIAT ONCOL, V73, P927, DOI 10.1016/j.ijrobp.2008.08.059; Boero IJ, 2016, J CLIN ONCOL, V34, P684, DOI 10.1200/JCO.2015.63.9898; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; Chen AB, 2014, SEMIN RADIAT ONCOL, V24, P25, DOI 10.1016/j.semradonc.2013.08.003; Chetty IJ, 2003, MED PHYS, V30, P1776, DOI 10.1118/1.1581412; Chung PWM, 2004, INT J RADIAT ONCOL, V60, P329, DOI 10.1016/j.ijrobp.2004.03.038; Cms, CHRON COND DAT WAR C; Craig T, 2003, INT J RADIAT ONCOL, V57, P833, DOI 10.1016/S0360-3016(03)00638-2; de Crevoisier R, 2018, INT J RADIAT ONCOL, V102, P1420, DOI 10.1016/j.ijrobp.2018.07.2006; Deek MP, 2016, J THORAC DIS, V8, P2602, DOI 10.21037/jtd.2016.08.95; Du XL, 2007, CANCER, V110, P660, DOI 10.1002/cncr.22826; Guckenberger M, 2007, RADIOTHER ONCOL, V83, P57, DOI 10.1016/j.radonc.2007.01.012; Hawkins MA, 2006, INT J RADIAT ONCOL, V66, P610, DOI 10.1016/j.ijrobp.2006.03.026; Kilburn JM, 2016, PRACT RADIAT ONCOL, V6, pE73, DOI 10.1016/j.prro.2015.10.004; Klabunde CN, 2007, ANN EPIDEMIOL, V17, P584, DOI 10.1016/j.annepidem.2007.03.011; Klabunde CN, 2000, J CLIN EPIDEMIOL, V53, P1258, DOI 10.1016/S0895-4356(00)00256-0; Kong F.-M.S, 2018, WHAT HAPPENS PROTON; Kupelian PA, 2008, INT J RADIAT ONCOL, V70, P1151, DOI 10.1016/j.ijrobp.2007.07.2371; Li W, 2010, MED DOSIM, V35, P287, DOI 10.1016/j.meddos.2009.09.003; Meyer J, 2007, INT J RADIAT ONCOL, V67, P1220, DOI 10.1016/j.ijrobp.2006.11.010; Nabavizadeh N, 2016, INT J RADIAT ONCOL, V94, P850, DOI 10.1016/j.ijrobp.2015.09.035; Sethi RA, 2007, INT J RADIAT ONCOL, V69, pS341, DOI 10.1016/j.ijrobp.2007.07.1420; Shirvani SM, 2013, LUNG CANCER, V82, P252, DOI 10.1016/j.lungcan.2013.08.015; Smith BD, 2011, JNCI-J NATL CANCER I, V103, P798, DOI 10.1093/jnci/djr100; Song WY, 2006, INT J RADIAT ONCOL, V64, P289, DOI 10.1016/j.ijrobp.2005.08.037; Sonke JJ, 2009, INT J RADIAT ONCOL, V74, P567, DOI 10.1016/j.ijrobp.2008.08.004; Tondel H, 2018, RADIOTHER ONCOL, V126, P229, DOI 10.1016/j.radonc.2017.10.029; van Haaren PMA, 2009, RADIOTHER ONCOL, V90, P291, DOI 10.1016/j.radonc.2008.12.021; Velec M, 2011, INT J RADIAT ONCOL, V80, P265, DOI 10.1016/j.ijrobp.2010.05.023; Warren JL, 2002, MED CARE, V40, P55; Zeidan OA, 2007, INT J RADIAT ONCOL, V67, P670, DOI 10.1016/j.ijrobp.2006.09.040	31	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2021	16	5							e0252053	10.1371/journal.pone.0252053	http://dx.doi.org/10.1371/journal.pone.0252053			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6PJ	34043677	Green Submitted, gold, Green Published			2023-01-03	WOS:000664635700049
J	Goh, SL; Jaafar, Z; Gan, YN; Choong, A; Kaur, J; Kundakci, B; Abdul Karim, S; Jaffar, MR; Hamid, MSA				Goh, Siew-Li; Jaafar, Zulkarnain; Gan, Yan-Nee; Choong, Alston; Kaur, Jaspreet; Kundakci, Burak; Abdul Karim, Samihah; Jaffar, Muhammad Rahmani; Hamid, Mohamad Shariff A.			Efficacy of prolotherapy in comparison to other therapies for chronic soft tissue injuries: A systematic review and network meta-analysis	PLOS ONE			English	Review							HYALURONIC-ACID	Introduction Prolotherapy and other injections, primarily acting on pathways associated with maladaptive tissue repair, are recommended for recalcitrant chronic soft tissue injuries (CSTI). However, selection of injection is challenging due to mixed results. This network meta-analysis (NMA) aimed to compare prolotherapy with other therapies, particularly injections, for CSTI and establish robustness of the results. Methodology Pubmed, Medline, SPORTDiscus and Google scholar were searched from inception to 4(th) January 2021 for randomised controlled trials (RCTs) involving injection therapies (e.g. blood derivatives, corticosteroid, hyaluronic acid, botulinum toxin) for CSTI. The primary and secondary outcomes were pain and function, respectively, at (or nearest to) 6 months. Effect size (ES) was presented as standardised mean difference with 95% confidence interval (CI). Frequentist random effect NMA was used to generate the overall estimates, subgroup estimates (by region and measurement time point) and sensitivity analyses. Results A total of 91 articles (87 RCTs; 5859 participants) involving upper limb (74%), lower limb (23%) and truncal/hip (3%) injuries were included. At all time points, prolotherapy had no statistically significant pain benefits over other therapies. This observation remained unchanged when tested under various assumptions and with exclusion of studies with high risk of bias. Although prolotherapy did not offer statistically significant functional improvement compared to most therapies, its ES was consistently better than non-injections and corticosteroid injection for both outcomes. At selected time points and for selected injuries, prolotherapy demonstrated potentially better pain improvement over placebo (<4 months: shoulder [ES 0.65; 95% CI 0.00 to 1.30]; 4-8 months: elbow [ES 0.91; 95% CI 0.12 to 1.70]; >8 months: shoulder [ES 2.08; 95% CI 1.49, to 2.68]). Injections generally produced greater ES when combined with non-injection therapy. Conclusion While clinical outcomes were generally comparable across types of injection therapy, prolotherapy may be used preferentially for selected conditions at selected times.	[Goh, Siew-Li; Jaafar, Zulkarnain; Choong, Alston; Abdul Karim, Samihah; Jaffar, Muhammad Rahmani; Hamid, Mohamad Shariff A.] Univ Malaya, Sports & Exercise Med Res & Educ Grp, Kuala Lumpur, Malaysia; [Gan, Yan-Nee] Minist Hlth, Malaysian Hlth Technol Assessment Sect MaHTAS, Kuala Lumpur, Malaysia; [Kaur, Jaspreet; Kundakci, Burak] Univ Nottingham, Arthrit Res UK Pain Ctr, Nottingham, England	Universiti Malaya; Kementerian Kesihatan Malaysia; University of Nottingham	Goh, SL (corresponding author), Univ Malaya, Sports & Exercise Med Res & Educ Grp, Kuala Lumpur, Malaysia.	gsiewli@um.edu.my	HAMID, MOHAMAD SHARIFF A/B-9029-2010; JAAFAR, ZULKARNAIN/C-1155-2010; Goh, Siew Li/L-1533-2014; Choong, Alston/AAX-5637-2021; Karim, samihah/GMW-4563-2022; Gan, Yan Nee/N-8869-2018	HAMID, MOHAMAD SHARIFF A/0000-0001-9196-0442; JAAFAR, ZULKARNAIN/0000-0002-4331-788X; Goh, Siew Li/0000-0001-5898-1196; Choong, Alston/0000-0001-8048-9616; Karim, samihah/0000-0002-0175-9372; Gan, Yan Nee/0000-0001-5558-243X	University of Malaya (UM), University of Malaya Medical Centre (UMMC), Faculty of Medicine [GPF007C-2019]; Malaysian Health Technology Assessment Section (MaHTAS); UM [GPF007C-2019]; University of Nottingham; UM; MaHTAS; UMMC	University of Malaya (UM), University of Malaya Medical Centre (UMMC), Faculty of Medicine; Malaysian Health Technology Assessment Section (MaHTAS); UM; University of Nottingham; UM; MaHTAS; UMMC	This work received funding from University of Malaya (UM), University of Malaya Medical Centre (UMMC), Faculty of Medicine (Grant No. GPF007C-2019) and Malaysian Health Technology Assessment Section (MaHTAS). UM provided support in the form of salaries for authors [SLG, ZJ, AC, SAK, MSAH]. MaHTAS provided support in the form of salaries for YNG. UMMC provided support in the form of salaries for MRJ. Materials for this work are funded by UM, Grant No GPF007C-2019 and University of Nottingham. All funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funder also did not alter our adherence to PLOS ONE policies on sharing data and materials. The specific roles of these authors are articulated in the `author contributions' section.	Aicale R, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-1017-5; Aicale R, 2020, EXPERT OPIN PHARMACO, V21, P1467, DOI 10.1080/14656566.2020.1763306; Altman RD, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0775-z; Bannuru RR, 2015, ANN INTERN MED, V162, P46, DOI 10.7326/M14-1231; Bhabra G, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967116670635; Brukner P, 1997, BRIT J SPORT MED, V31, P2, DOI 10.1136/bjsm.31.1.2; Cook JL, 2016, BRIT J SPORT MED, V50, P1187, DOI 10.1136/bjsports-2015-095422; Corrigan P, 2020, ORTHOP J SPORTS MED, V8, DOI 10.1177/2325967120917271; Di Matteo B, 2015, Musculoskelet Surg, V99, P1, DOI 10.1007/s12306-014-0340-1; DiFiori JP, 2014, BRIT J SPORT MED, V48, DOI 10.1136/bjsports-2013-093299; Docking SI, 2019, J SCI MED SPORT, V22, P145, DOI 10.1016/j.jsams.2018.07.016; Doiron-Cadrin P, 2020, ARCH PHYS MED REHAB, V101, P1233, DOI 10.1016/j.apmr.2019.12.017; Figueroa David, 2016, J Am Acad Orthop Surg, V24, pe184; Fogli M, 2017, MLTJ-MUSCLE LIGAMENT, V7, P388, DOI 10.11138/mltj/2017.7.2.388; Goswami Amitabh, 2012, J Pain Palliat Care Pharmacother, V26, P376, DOI 10.3109/15360288.2012.734900; Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026; Hauser RA, 2016, CLIN MED INSIGHTS-AR, V9, P139, DOI 10.4137/CMAMD.S39160; Kaux JF, 2015, MLTJ-MUSCLE LIGAMENT, V5, P264, DOI [10.11138/mltj/2015.5.3.264, 10.11138/mltj/2015.5.4.264]; Lee JC, 2019, EUR J RADIOL, V110, P193, DOI 10.1016/j.ejrad.2018.12.001; Lian J, 2019, AM J SPORT MED, V47, P3019, DOI 10.1177/0363546518801914; Lin MT, 2019, ARCH PHYS MED REHAB, V100, P336, DOI 10.1016/j.apmr.2018.06.028; Sadosky A, 2016, J PAIN RES, V9, P405, DOI 10.2147/JPR.S97770; Steiner JL, 2017, J APPL BIOBEHAV RES, V22, DOI 10.1111/jabr.12079; Steinmann S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030844; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Sudol-Szopinska I, 2015, J ULTRASON, V15, P72, DOI 10.15557/JoU.2015.0006; Tang SQ, 2020, PM&R, V12, P397, DOI 10.1002/pmrj.12287; Tsikopoulos K, 2016, BRIT J SPORT MED, V50, P1367, DOI 10.1136/bjsports-2015-095437; Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135	29	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2021	16	5							e0252204	10.1371/journal.pone.0252204	http://dx.doi.org/10.1371/journal.pone.0252204			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6OP	34038486	Green Published, gold			2023-01-03	WOS:000664633500067
J	Sue, KL; Fiellin, DA				Sue, Kimberly L.; Fiellin, David A.			Bringing Harm Reduction into Health Policy - Combating the Overdose Crisis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Bringing Harm Reduction into Health Policy In the face of increasing drug-related morbidity and mortality, the Biden administration could signal a change in federal strategy by fully endorsing harm reduction as a valid, evidence-based policy to improve the health of people who use drugs.	[Sue, Kimberly L.; Fiellin, David A.] Yale Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Sue, Kimberly L.; Fiellin, David A.] Yale Sch Med, Program Addict Med, New Haven, CT 06510 USA; [Fiellin, David A.] Yale Sch Med, Dept Emergency Med, New Haven, CT USA; [Fiellin, David A.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA; [Sue, Kimberly L.] Natl Harm Reduct Coalit, New York, NY 10016 USA	Yale University; Yale University; Yale University; Yale University	Sue, KL (corresponding author), Yale Sch Med, Dept Internal Med, New Haven, CT 06510 USA.; Sue, KL (corresponding author), Yale Sch Med, Program Addict Med, New Haven, CT 06510 USA.; Sue, KL (corresponding author), Natl Harm Reduct Coalit, New York, NY 10016 USA.			Sue, Kimberly/0000-0002-5594-9198				[Anonymous], 2017, NAL OV PREV LAWS PRE; Bensinger P, 2016, HEROIN EPIDEMIC NOW; Dasgupta S, 2019, AIDS BEHAV, V23, P3257, DOI 10.1007/s10461-019-02600-x; National Harm Reduction Coalition, PRINC HARM RED	4	2	2	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2021	384	19					1781	1783		10.1056/NEJMp2103274	http://dx.doi.org/10.1056/NEJMp2103274		MAY 2021	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	SD6UF	33983692				2023-01-03	WOS:000649041100001
J	Osuafor, NG; Ukwe, CV; Okonta, M				Osuafor, Nkeiruka Grace; Ukwe, Chinwe Victoria; Okonta, Mathew			Evaluation of availability, price, and affordability of cardiovascular, diabetes, and global medicines in Abuja, Nigeria	PLOS ONE			English	Article							DISEASES	Objective To assess the availability, price, and affordability of cardiovascular, diabetes, and global medicines in Abuja, Nigeria. Methods A cross-sectional survey involving 27 private pharmacies, 13 public pharmacies, and 25 private hospital pharmacies in Abuja was conducted using the standardized World Health Organization/Health Action International methodology. The availability percentage for each pharmacy sector and each medicine was analyzed. The median price ratio (MPR) (ratio of the median price to the international reference prices) of the medicines were evaluated accordingly. Affordability was assessed by calculating the number of days' wages the lowest-paid unskilled government worker required to purchase a month worth of the standard treatment for a chronic condition. Results The availability of cardiovascular (CV) medicines ranged from 28.4% (in private hospital pharmacies) to 59.9% (in private pharmacies). There was mixed variability in the mean availability of Originator Brands (OBs) and Lowest Priced Generics (LPGs) anti-diabetic drugs with the highest availability being OBs 36% and LPGs 40.2%, in private pharmacies and public pharmacies, respectively. The availability of global drugs ranged from 49.7% in private hospitals to 68.8% in private pharmacies. Two cardiovascular and four global medicines had greater than 80% availability across the pharmaceutical sectors. The median price ratio for OBs and LPGs was 9.60 and 1.72 for procurement, it was 8.08 and 2.60 in private pharmacies, 13.56 and 2.66 in public hospitals, and 16.38 and 7.89 in private hospitals. The percentage markup on LPG was 49.4% in public hospitals, 51.4% in private pharmacies, and 323% in private hospitals. Only nine medicines in both public hospitals and private pharmacies and two in the private hospital pharmacies required less than the daily wage of the lowest-paid government worker. Conclusion The availability of cardiovascular, diabetes, and global medicines was below 80% across the different pharmaceutical sectors in Abuja and the medicines were unaffordable. Although the prices were generally exorbitant, private pharmacies offered the best options in terms of availability, pricing, and affordability of medicines. Therefore, the results of this study emphasize the pertinence of enforcing policies that facilitate the availability, pricing, and affordability of cardiovascular, diabetes, and global medicines.	[Osuafor, Nkeiruka Grace; Ukwe, Chinwe Victoria] Univ Nigeria, Fac Pharmaceut Sci, Dept Clin Pharm & Pharm Management, Nsukka, Nigeria	University of Nigeria	Osuafor, NG (corresponding author), Univ Nigeria, Fac Pharmaceut Sci, Dept Clin Pharm & Pharm Management, Nsukka, Nigeria.	nkeiruka.osuafor.pg76799@unn.edu.ng		Osuafor, Nkeiruka/0000-0001-7559-8199				Alwan A, 2011, GLOBAL STATUS REPORT ON NONCOMMUNICABLE DISEASES 2010, P1; [Anonymous], 2004, WHO MED STRAT COUNTR; Beran D, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-17; Beran D., 2012, INT INSUL FOUND INT; Bertoldi AD, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-6; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Chuku I., 2016, J HEAL MED NURS, V27, P45; Dabare P. R. L., 2014, BMC Public Health, V14; Ewen M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171284; F. M. of H. Nigeria and World Health Organization, 2016, NIG STAND TREATM GUI; Federal Ministry of Health Nigeria, 2016, NIG ESS MED LIST, V6th; Foster S.D., 1990, IMPROVING SUPPLY USE; Gelders S., 2006, PRICE AVAILABILITY A; Global Health Policy Forum, 2014, EUROPEAN COMMISSION; Hogerzeil HV, 2013, LANCET, V381, P680, DOI 10.1016/S0140-6736(12)62128-X; International Diabetes Federation World Heart Federation and Framework Convention Alliance, 2011, NONC DIEAS PRIOR WOM; Jiang MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070836; Jingi AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111812; Kaiser AH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226169; Kassim S. A., 2015, Journal of Public Health and Epidemiology, V7, P274; Kheder SI, 2014, SUDAN MED MONIT, V9, P19; Khuluza F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212125; Kotwani A, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-285; Lu Y, 2011, WORLD MED SITUATION; Management Sciences for Health, 2015, INT MED PROD PRIC GU; Mendis S, 2007, B WORLD HEALTH ORGAN, V85, P279, DOI 10.2471/BLT.06.033647; National Academics of Sciences Engineering and Medicine, 2017, MAK MED AFF NATL IMP; Nigeria Federal Ministry of Health W. H. Organization and Health Action International, 2006, MED PRIC NIG; Office of the the High Commissioner, 2000, 14 OFF HIGH COMM CES; Osuafor N.G., 2019, INT J PHARM PHARM SC, V11, P21; Sharma Abhishek, 2016, J Pharm Policy Pract, V9, P12, DOI 10.1186/s40545-016-0059-5; United Nations General Assembly, 2011, POL DECL HIGH LEV M; Ushie BA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165707; V Chobanian A., 2004, US DEP HEAL HUM SERV, P49; van Mourik MSM, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-25; WHO, 2017, TACKLING NCDS BEST B; World Health Organisation, 2018, GLOB HLTH ES 2016 DE; World Health Organization, 2011, MED TERM STRAT PLAN; World Health Organization, 2016, ATL AFR HLTH STAT HL; World Health Organization, 2018, NONCOMMUNICABLE DIS; World Health Organization and Health Action International, 2016, WHO HAI WORKB 1; World Health Organization  Health Action International, 2008, MEAS MED PRIC AV AFF, V2nd edition; World Health Organization Rotary International Centers for Disease Control and Prevention and UNICEF, 2013, GLOB ACT PLAN PREV C; Yusuf A., 2019, ASIAN J CARDIOL RES, V2, P1	44	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255567	10.1371/journal.pone.0255567	http://dx.doi.org/10.1371/journal.pone.0255567			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ4EI	34383799	gold, Green Published			2023-01-03	WOS:000684426400074
J	Xu, X; Xia, J; Zhao, SY; Wang, Q; Ge, GB; Xu, F; Liu, X; Zhang, WD; Yang, YL				Xu, Xin; Xia, Jun; Zhao, Shiyi; Wang, Qun; Ge, Guangbo; Xu, Feng; Liu, Xia; Zhang, Weidong; Yang, Yili			Qing-Fei-Pai-Du decoction and wogonoside exert anti-inflammatory action through down-regulating USP14 to promote the degradation of activating transcription factor 2	FASEB JOURNAL			English	Article						ATF2; KLHL5; QFPDD; ubiquitination; USP14; wogonoside	DISEASE 2019 COVID-19; CONVERTING ENZYME 2; UBIQUITIN; PROGRESSION; PROGNOSIS; PROTEIN; ATF2	COVID-19 is often characterized by dysregulated inflammatory and immune responses. It has been shown that the Traditional Chinese Medicine formulation Qing-Fei-Pai-Du decoction (QFPDD) is effective in the treatment of the disease, especially for patients in the early stage. Our network pharmacology analyses indicated that many inflammation and immune-related molecules were the targets of the active components of QFPDD, which propelled us to examine the effects of the decoction on inflammation. We found in the present study that QFPDD effectively alleviated dextran sulfate sodium-induced intestinal inflammation in mice. It inhibited the production of pro-inflammatory cytokines IL-6 and TNF alpha, and promoted the expression of anti-inflammatory cytokine IL-10 by macrophagic cells. Further investigations found that QFPDD and one of its active components wogonoside markedly reduced LPS-stimulated phosphorylation of transcription factor ATF2, an important regulator of multiple cytokines expression. Our data revealed that both QFPDD and wogonoside decreased the half-life of ATF2 and promoted its proteasomal degradation. Of note, QFPDD and wogonoside down-regulated deubiquitinating enzyme USP14 along with inducing ATF2 degradation. Inhibition of USP14 with the small molecular inhibitor IU1 also led to the decrease of ATF2 in the cells, indicating that QFPDD and wogonoside may act through regulating USP14 to promote ATF2 degradation. To further assess the importance of ubiquitination in regulating ATF2, we generated mice that were intestinal-specific KLHL5 deficiency, a CUL3-interacting protein participating in substrate recognition of E3s. In these mice, QFPDD mitigated inflammatory reaction in the spleen, but not intestinal inflammation, suggesting CUL3-KLHL5 may function as an E3 for ATF2 degradation.	[Xu, Xin; Zhao, Shiyi; Wang, Qun; Yang, Yili] Chinese Acad Med Sci & Peking Union Med Coll, Suzhou Inst Syst Med, Suzhou, Jiangsu, Peoples R China; [Xia, Jun; Xu, Feng] Soochow Univ, Dept Emergency Med, Affiliated Hosp 1, Suzhou, Peoples R China; [Ge, Guangbo; Zhang, Weidong] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China; [Liu, Xia] Second Mil Med Univ, Sch Pharm, Dept Clin Pharm, Shanghai 200433, Peoples R China; [Yang, Yili] China Reg Res Ctr, Int Ctr Genet Engn & Biotechnol, Taizhou, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Soochow University - China; Shanghai University of Traditional Chinese Medicine; Naval Medical University	Yang, YL (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Suzhou Inst Syst Med, Suzhou, Jiangsu, Peoples R China.; Liu, X (corresponding author), Second Mil Med Univ, Sch Pharm, Dept Clin Pharm, Shanghai 200433, Peoples R China.	lxflying@aliyun.com; yangyl@ism.pumc.edu.cn		Yang, Yili/0000-0002-4152-1801	National Key Research and Development Program of China [2020YFC0845400]; NSFC \ National Natural Science Foundation of China [81973358]	National Key Research and Development Program of China; NSFC \ National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	National Key Research and Development Program of China, Grant/Award Number: 2020YFC0845400; NSFC vertical bar National Natural Science Foundation of China, Grant/Award Number: 81973358	[Anonymous], 2020, Drug Ther Bull, V58, P133, DOI 10.1136/dtb.2020.000045; Bajema KL, 2021, JAMA INTERN MED, V181, P450, DOI 10.1001/jamainternmed.2020.7976; Cao P, 2020, CARBOHYD POLYM, V240, DOI 10.1016/j.carbpol.2020.116346; Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3; Chen JNS, 2021, J VIROL, V95, DOI 10.1128/JVI.00014-21; Cheng H, 2020, J MED VIROL, V92, P726, DOI 10.1002/jmv.25785; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; Ding WP, 2015, MOL MED REP, V11, P968, DOI 10.3892/mmr.2014.2838; Fan E, 2020, LANCET RESP MED, V8, P816, DOI 10.1016/S2213-2600(20)30304-0; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Gendrot M, 2020, INT J INFECT DIS, V99, P437, DOI 10.1016/j.ijid.2020.08.032; Geng L, 2020, BIOCHEM BIOPH RES CO, V524, P16, DOI 10.1016/j.bbrc.2019.12.128; Goh KJ, 2020, ANN ACAD MED SINGAP, V49, P108; Harrison AG, 2020, TRENDS IMMUNOL, V41, P1100, DOI 10.1016/j.it.2020.10.004; Hong KH, 2020, ANN LAB MED, V40, P351, DOI 10.3343/alm.2020.40.5.351; Hu SS, 2020, J MED VIROL, V92, P1425, DOI 10.1002/jmv.25937; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huebner K, 2019, MUTAGENESIS, V34, P375, DOI 10.1093/mutage/gez041; Kihara N, 2003, GUT, V52, P713, DOI 10.1136/gut.52.5.713; Kohli A, 2021, STATPEARLS INTERNET; Luo ED, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00317-x; Ma J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0809-0; Mann ER, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6197; Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621; Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4; Powell JA, 2019, BIOCHEM J, V476, P3211, DOI 10.1042/BCJ20190245; Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743; Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2; Sacchi A, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03125-1; Sanchez-Cerrillo I, 2020, J CLIN INVEST, V130, P6290, DOI 10.1172/JCI140335; Schneekloth JS, 2011, CURR DRUG TARGETS, V12, P1581; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Shi NN, 2020, PHARMACOL RES, V161, DOI 10.1016/j.phrs.2020.105290; Stebbing Justin, 2020, Lancet Infect Dis, V20, P400, DOI 10.1016/S1473-3099(20)30132-8; Wang S, 2001, BIOCHEM GENET, V39, P227, DOI 10.1023/A:1010203114697; Watson G, 2017, PHARMACOL RES, V119, P347, DOI 10.1016/j.phrs.2017.02.004; Wong AYS, 2021, ANN RHEUM DIS, V80, P943, DOI 10.1136/annrheumdis-2020-219517; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Zhao J, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2020.153315; Zhuang M, 2009, MOL CELL, V36, P39, DOI 10.1016/j.molcel.2009.09.022	41	3	4	3	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2021	35	9							e21870	10.1096/fj.202100370RR	http://dx.doi.org/10.1096/fj.202100370RR			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ2LG	34436790				2023-01-03	WOS:000691122900063
J	Muller, SA; Diallo, AOK; Rocha, C; Wood, R; Landsmann, L; Camara, BS; Schlindwein, L; Tounkara, O; Arvand, M; Diallo, M; Borchert, M				Mueller, Sophie Alice; Diallo, Alpha Oumar Karim; Rocha, Carlos; Wood, Rebekah; Landsmann, Lena; Camara, Bienvenu Salim; Schlindwein, Laszlo; Tounkara, Ousmane; Arvand, Mardjan; Diallo, Mamadou; Borchert, Matthias			Mixed methods study evaluating the implementation of the WHO hand hygiene strategy focusing on alcohol based handrub and training among health care workers in Faranah, Guinea	PLOS ONE			English	Article								Introduction The most frequent adverse health events in healthcare worldwide are healthcare-associated infection. Despite ongoing implementation of the WHO multimodal Hand Hygiene (HH) Improvement Strategy, healthcare-associated infection rate continues to be twofold higher in low- than in high-income countries. This study focused on continued evaluation of HH compliance and knowledge. The mixed method approach, with inclusion of patients and care-givers, provided insight into challenges and facilitators of the WHO HH Improvement Strategy, and highlighted improvement points. Methods An uncontrolled, before-and-after intervention, mixed methods study in Faranah Regional Hospital was conducted from December 2017 to August 2019. The intervention implemented the WHO HH Strategy including HH training for healthcare workers (HCWs), and the relaunch of the local production of alcohol-based handrub (ABHR). A baseline assessment of HH knowledge, perception and compliance of HCWs was done prior to the intervention and compared to two follow-up assessments. The second follow-up assessment was complemented by a qualitative component. Results Overall compliance six months post-intervention was 45.1% and significantly higher than baseline but significantly lower than in first follow-up. Knowledge showed similar patterns of improvement and waning. The perception survey demonstrated high appreciation of the intervention, such as local production of ABHR. HCW's were concerned about overconsuming of ABHR, however simultaneous quantitative measurements showed that consumption in fact was 36% of the estimated amount needed for sufficient HH compliance. Potential fields for improvement identified by HCWs to enhance sustainability were permanent ABHR availability, having a dedicated person with ownership over continuous simulation HH trainings including simulations to improve technique. Conclusion The study shows that the WHO multimodal HH strategy has a positive effect on HCW compliance and knowledge. Improvement points identified by local staff like sensitization on appropriate ABHR amount per HH action should be considered for sustainable HH improvement.	[Mueller, Sophie Alice; Rocha, Carlos; Wood, Rebekah; Borchert, Matthias] Robert Koch Inst, Ctr Int Hlth Protect, Berlin, Germany; [Diallo, Alpha Oumar Karim; Tounkara, Ousmane; Diallo, Mamadou] Faranah Reg Hosp, Faranah, Guinea; [Landsmann, Lena; Arvand, Mardjan] Robert Koch Inst, Unit Hosp Hyg Infect Prevent & Control, Berlin, Germany; [Camara, Bienvenu Salim] Ctr Natl Format & Rech Sante Rurale Maferinyah, Mafeinya, Guinea; [Schlindwein, Laszlo] Robert Koch Inst, Global Hlth & Biosecur, Berlin, Germany	Robert Koch Institute; Robert Koch Institute; Robert Koch Institute	Muller, SA (corresponding author), Robert Koch Inst, Ctr Int Hlth Protect, Berlin, Germany.	muellers@rki.de	Camara, Bienvenu/HGA-3369-2022	Rocha, Carlos Alberto/0000-0002-3881-4494; Muller, Sophie/0000-0001-7723-3943; wood, rebekah/0000-0002-6667-082X	BMZ (Bundesministerium fur Zusammenarbeit) as part of the GIZ (Gesellschaft fur Internationale Zusammenarbeit) University; Hospital Partnerships in Africa (ESTHER) Program (Ensemble pour une Solidarite Therapeutique Hospitaliere en Reseau) [81213469]	BMZ (Bundesministerium fur Zusammenarbeit) as part of the GIZ (Gesellschaft fur Internationale Zusammenarbeit) University; Hospital Partnerships in Africa (ESTHER) Program (Ensemble pour une Solidarite Therapeutique Hospitaliere en Reseau)	This study was funded by the BMZ (Bundesministerium fur Zusammenarbeit) as part of the GIZ (Gesellschaft fur Internationale Zusammenarbeit) University and Hospital Partnerships in Africa (ESTHER) Program (Ensemble pour une Solidarite Therapeutique Hospitaliere en Reseau) (Award Number 81213469). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Aho J, 2010, AIDS BEHAV, V14, P1287, DOI 10.1007/s10461-009-9602-6; Allegranzi B, 2010, INFECT CONT HOSP EP, V31, P133, DOI 10.1086/649796; Chen LF, 2015, INFECT CONT HOSP EP, V36, P1444, DOI 10.1017/ice.2015.216; Guinea Ministry of Health, 2017, FASC MON AM HOP; Han CY, 2021, INFECTION, V49, P977, DOI 10.1007/s15010-021-01626-5; Holmen IC, 2016, INFECT CONT HOSP EP, V37, P834, DOI 10.1017/ice.2016.71; Jeanes A, 2019, AM J INFECT CONTROL, V47, P313, DOI 10.1016/j.ajic.2018.08.004; Jones Mark, 2015, J Infect Prev, V16, P200, DOI 10.1177/1757177415584452; Levy P LS., 1991, SAMPLING POPULATIONS, V2nd; Loftus MJ, 2019, INT J INFECT DIS, V86, P25, DOI 10.1016/j.ijid.2019.06.002; Muller SA, 2020, ANTIMICROB RESIST IN, V9, DOI 10.1186/s13756-020-00723-8; Pfafflin F, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-016-0165-9; Pittet D, 2006, INT J INFECT DIS, V10, P419, DOI 10.1016/j.ijid.2006.06.001; Resnic FS, 2012, JACC-CARDIOVASC INTE, V5, P82, DOI 10.1016/j.jcin.2011.09.017; Rothe C, 2013, J HOSP INFECT, V85, P257, DOI 10.1016/j.jhin.2013.09.008; Salmon S, 2015, J HOSP INFECT, V91, P95, DOI 10.1016/j.jhin.2015.04.011; Tartari E, 2019, ANTIMICROB RESIST IN, V8, DOI 10.1186/s13756-019-0511-9; Whitby M, 2006, INFECT CONT HOSP EP, V27, P484, DOI 10.1086/503335; WHO, GUIDELINE HAND HYGIE; WHO, WHO 10 FACTS PAT SAF; WHO, GUID HAND HYG HLTH C; WHO, PAT SAF 2018; World Health Organization, GUIDE IMPLEMENTATION; World Health Organization, REP BURD END HLTH CA; World Health Organization, 2006, WHO GUID HAND HYG HL	25	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2021	16	8							e0256760	10.1371/journal.pone.0256760	http://dx.doi.org/10.1371/journal.pone.0256760			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	US1HA	34437634	gold, Green Published			2023-01-03	WOS:000697186000094
J	Fujimoto, K; Kawasaki, M; Endo, Y; Yokoyama, T; Yamane, I; Yamazaki, H; Kure, K; Haga, T; Sugiura, K				Fujimoto, Kyoko; Kawasaki, Mai; Endo, Yuko; Yokoyama, Takashi; Yamane, Itsuro; Yamazaki, Hisanori; Kure, Katsumasa; Haga, Takeshi; Sugiura, Katsuaki			Antimicrobial use on 74 Japanese pig farms in 2019: A comparison of Japanese and European defined daily doses in the field	PLOS ONE			English	Article							FOOD ANIMALS	Defined daily doses (DDD) have been established in human medicine to standardize the measurement of treatment in a population. In veterinary medicine, the European Medicine Agency published defined daily dose (DDDvet) values for antimicrobial agents used in food-producing animals in 2016. National defined doses (DDDjp) for antimicrobials used for pigs in Japan have recently been determined. The aim of this study was to compare the results of calculated antimicrobial use in the field using the DDDjp and DDDvet values. Data from 74 pig farms in Japan relative to antimicrobial use in 2019 was collected. The numbers of DDDs (the weight of biomass treated in kg-days) using DDDjp and DDDvet values for each farm and for different antimicrobial classes were compared. Associations between calculated numbers of DDDjp and DDDvet on farm level were investigated. In addition, differences in antimicrobial use were investigated between different production types of farms (farrowing, finishing and farrow-to-finish farms). Using DDDjp and DDDvet values, the aggregated number of DDDs for 74 farms were 4,099,188 and 2,217,085 respectively, with the former being larger by 1.85 times than the latter. The most frequently used antimicrobial class was penicillin regardless of whether DDDjp or DDDvet was used. The absence of DDDvet values for certain antimicrobial agents used in Japan and the differences in the number of DDDjps/PCU and DDDvets/PCU indicated the need for Japanese DDDs. The number of DDDs per kg population correction unit (PCU) per farm tended to be higher in farrowing farms than in farrow-to-finish farms and finishing farms, with no significant difference (P = 0.19).	[Fujimoto, Kyoko; Kawasaki, Mai; Endo, Yuko; Sugiura, Katsuaki] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Environm Sci Sustainable Dev, Bunkyo Ku, Tokyo, Japan; [Yamane, Itsuro; Yamazaki, Hisanori] Natl Agr & Food Res Org, Div Bacterial & Parasit Dis, Natl Inst Anim Hlth, Tsukuba, Ibaraki, Japan; [Kure, Katsumasa] Value Farm Consulting, Tsukuba, Ibaraki, Japan; [Haga, Takeshi] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Med Sci, Bunkyo Ku, Tokyo, Japan; [Sugiura, Katsuaki] Nippon Inst Biol Sci, Tokyo, Japan	University of Tokyo; National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan; University of Tokyo	Sugiura, K (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Environm Sci Sustainable Dev, Bunkyo Ku, Tokyo, Japan.; Sugiura, K (corresponding author), Nippon Inst Biol Sci, Tokyo, Japan.	aksugiur@g.ecc.u-tokyo.ac.jp		Sugiura, Katsuaki/0000-0002-8807-7584	Ministry of Agriculture, Forestry and Fisheries of Japan [KS JPJ008617.17935699]	Ministry of Agriculture, Forestry and Fisheries of Japan(Ministry of Agriculture Forestry & Fisheries - Japan)	KS JPJ008617.17935699 Ministry of Agriculture, Forestry and Fisheries of Japan https://www.maff.go.jp/The funder provided support in the form of salaries for authors [KF, HY], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Abe R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241644; Callens B, 2012, PREV VET MED, V106, P53, DOI 10.1016/j.prevetmed.2012.03.001; Collineau L, 2017, ZOONOSES PUBLIC HLTH, V64, P165, DOI 10.1111/zph.12298; Echtermann T, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00240; EMA, PRINC ASS DEF DAIL D; European Medicine Agency (EMA), SAL VET ANT AG 30 EU; European Medicines Agency (EMA), DEF DAIL DOS AN DDD; European Medicines Agency (EMA), REV ESVAC REFL PAP C; Fujimoto K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245105; Holmes AH, 2016, LANCET, V387, P176, DOI 10.1016/S0140-6736(15)00473-0; Hosoi Y, 2014, REV SCI TECH OIE, V33, P1007, DOI 10.20506/rst.33.3.2337; Hybschmann GK, 2011, PREV VET MED, V98, P190, DOI 10.1016/j.prevetmed.2010.10.005; Japan Pig Producers Association (JPPA), REP ACT SIT PIG PROD; Jensen VF, 2014, PREV VET MED, V117, P554, DOI 10.1016/j.prevetmed.2014.08.006; Jensen VF, 2004, PREV VET MED, V64, P201, DOI 10.1016/j.prevetmed.2004.04.001; Kako K, BASIC STUDY PIG MEAT; Lei ZH, 2019, PREV VET MED, V173, DOI 10.1016/j.prevetmed.2019.104802; Marshall BM, 2011, CLIN MICROBIOL REV, V24, P718, DOI 10.1128/CMR.00002-11; Matsuda M., 2018, J VET MED ASS, V71, P15; Matsuda M, 2017, J ANIMAL HYG, V42, P191; Merle R, 2012, PREV VET MED, V104, P34, DOI 10.1016/j.prevetmed.2011.10.013; Ministry of Agriculture Forestry and Fisheries (MAFF), NATL ACTION PLAN ANT; Ministry of Agriculture Forestry and Fisheries (MAFF)., BIOS STAND PIG WILD; Ministry of Agriculture Forestry and Fisheries (MAFF), LIV STAT 1 FEB 2019; Ministry of Agriculture Forestry and Fisheries (MAFF), 2020, NAT TARG GEN IMPR LI; Netherlands Veterinary Institute (SDa), US ANT AGR LIB NETH; O'Neill J., 2016, Tackling drug-resistant infections globally: final report and recommendations; O'Neill L, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.558793; Sarrazin S, 2019, J ANTIMICROB CHEMOTH, V74, P807, DOI 10.1093/jac/dky503; Sjolund M, 2016, PREV VET MED, V130, P41, DOI 10.1016/j.prevetmed.2016.06.003; Staten Serum Institute, DANMAP 2017 US ANT A; Takagi H., 2017, JAPANESE J ANIMAL HY, V45, P155; Tarakdjian J, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10030417; The AACTING-network, OV FARM LEV AMU MON; Trauffler M, 2014, VET REC, V175, P402, DOI 10.1136/vr.102520; Van Boeckel TP, 2015, P NATL ACAD SCI USA, V112, P5649, DOI 10.1073/pnas.1503141112; van Rennings L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119114; Vieira AR, 2011, FOODBORNE PATHOG DIS, V8, P1295, DOI 10.1089/fpd.2011.0950; WHO, ANTIMICROBIAL RESIST; World Organisation for Animal Health (OIE), 4 OIE ANN REP ANT AG; Yamane I, 2018, PIGINFO BIOANTIMICRO, P25	41	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2021	16	8							e0255632	10.1371/journal.pone.0255632	http://dx.doi.org/10.1371/journal.pone.0255632			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6JM	34358280	Green Published, gold			2023-01-03	WOS:000685266400040
J	Fotheringham, J; Barnes, T; Dunn, L; Lee, S; Ariss, S; Young, T; Walters, SJ; Laboi, P; Henwood, A; Gair, R; Wilkie, M				Fotheringham, James; Barnes, Tania; Dunn, Louese; Lee, Sonia; Ariss, Steven; Young, Tracey; Walters, Stephen J.; Laboi, Paul; Henwood, Andy; Gair, Rachel; Wilkie, Martin			A breakthrough series collaborative to increase patient participation with hemodialysis tasks: A stepped wedge cluster randomised controlled trial	PLOS ONE			English	Article							HOSPITALIZATION; INTERVENTION; ADHERENCE; RISK	Background Compared to in-centre, home hemodialysis is associated with superior outcomes. The impact on patient experience and clinical outcomes of consistently providing the choice and training to undertake hemodialysis-related treatment tasks in the in-centre setting is unknown. Methods A stepped-wedge cluster randomised trial in 12 UK renal centres recruited prevalent in-centre hemodialysis patients with sites randomised into early and late participation in a 12-month breakthrough series collaborative that included data collection, learning events, Plan-Study-Do-Act cycles, and teleconferences repeated every 6 weeks, underpinned by a faculty, co-production, materials and a nursing course. The primary outcome was the proportion of patients undertaking five or more hemodialysis-related tasks or home hemodialysis. Secondary outcomes included independent hemodialysis, quality of life, symptoms, patient activation and hospitalisation. ISRCTN Registration Number 93999549. Results 586 hemodialysis patients were recruited. The proportion performing 5 or more tasks or home hemodialysis increased from 45.6% to 52.3% (205 to 244/449, difference 6.2%, 95% CI 1.4 to 11%), however after analysis by step the adjusted odds ratio for the intervention was 1.63 (95% CI 0.94 to 2.81, P = 0.08). 28.3% of patients doing less than 5 tasks at baseline performed 5 or more at the end of the study (69/244, 95% CI 22.2-34.3%, adjusted odds ratio 3.71, 95% CI 1.66-8.31). Independent or home hemodialysis increased from 7.5% to 11.6% (32 to 49/423, difference 4.0%, 95% CI 1.0-7.0), but the remaining secondary endpoints were unaffected. Conclusions Our intervention did not increase dialysis related tasks being performed by a prevalent population of centre based patients, but there was an increase in home hemodialysis as well as an increase in tasks among patients who were doing fewer than 5 at baseline. Further studies are required that examine interventions to engage people who dialyse at centres in their own care.	[Fotheringham, James; Barnes, Tania; Dunn, Louese; Lee, Sonia; Wilkie, Martin] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield Kidney Inst, Sheffield, S Yorkshire, England; [Ariss, Steven; Young, Tracey; Walters, Stephen J.] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Laboi, Paul; Henwood, Andy] York Teaching Hosp NHS Fdn Trust, Renal Dept, York, N Yorkshire, England; [Gair, Rachel] UK Renal Registry, Think Kidneys, Bristol, Avon, England	University of Sheffield; University of Sheffield	Wilkie, M (corresponding author), Sheffield Teaching Hosp NHS Fdn Trust, Sheffield Kidney Inst, Sheffield, S Yorkshire, England.	martin.wilkie@nhs.net	Ariss, Steven/HHS-5791-2022	Fotheringham, James/0000-0002-8980-2223; Walters, Stephen/0000-0001-9000-8126; Ariss, Steven/0000-0002-5557-4613	Health Foundation Scaling Up Award	Health Foundation Scaling Up Award	The Health Foundation Scaling Up Award.	Barnes T, 2013, J REN CARE, V39, P10, DOI 10.1111/j.1755-6686.2013.12028.x; Bowman BT, 2019, CLIN J AM SOC NEPHRO, V14, P765, DOI 10.2215/CJN.12301018; Cabada J., 2015, POSTER BRIT RENAL SO; Campbell MJ, 2014, STAT PRACT, P1, DOI 10.1002/9781118763452; Chew LD, 2008, J GEN INTERN MED, V23, P561, DOI 10.1007/s11606-008-0520-5; Flythe JE, 2014, CLIN J AM SOC NEPHRO, V9, P1418, DOI 10.2215/CJN.03280314; Fotheringham J, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0748-6; Fotheringham J, 2014, NEPHROL DIAL TRANSPL, V29, P422, DOI 10.1093/ndt/gft363; Gair R, VALUING INDIVIDUALS; Glidewell L, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-118; Griva K, 2018, AM J KIDNEY DIS, V71, P371, DOI 10.1053/j.ajkd.2017.09.014; Hemming K, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k1614; Hemming K, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1833-7; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hibbard JH, 2004, HEALTH SERV RES, V39, P1005, DOI 10.1111/j.1475-6773.2004.00269.x; Howren MB, 2016, ANN BEHAV MED, V50, P167, DOI 10.1007/s12160-015-9741-0; Huang BY, 2018, NEPHROLOGY, V23, P755, DOI 10.1111/nep.13098; Institute for Healthcare improvement, 2003, IHI INNOVATION SERIE; Knight R, 2019, CLIN J AM SOC NEPHRO, V14, P1795, DOI 10.2215/CJN.10560919; Moattari M, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-115; Morton RL, 2019, CLIN J AM SOC NEPHRO, V14, P623, DOI 10.2215/CJN.10380818; Murphy EL, 2009, NEPHRON CLIN PRACT, V111, pC74, DOI 10.1159/000183177; Nair D, 2020, J AM SOC NEPHROL, V31, P1435, DOI 10.1681/ASN.2019121331; Parry GJ, 2013, ACAD PEDIATR, V13, pS23, DOI 10.1016/j.acap.2013.04.007; Saran R, 2017, AM J KIDNEY DIS, V69, DOI 10.1053/j.ajkd.2016.12.004; Sethna CB, 2016, CLIN J AM SOC NEPHRO, V11, P1590, DOI 10.2215/CJN.02540316; Suri RS, 2015, KIDNEY INT, V88, P360, DOI 10.1038/ki.2015.68; The Health Foundation, 2015, EN SELF MAN SHAR HAE; The Shared Haemodialysis Care programme, 2019, SHAR HAEM CAR 2019; Wells S, 2018, BMJ QUAL SAF, V27, P226, DOI 10.1136/bmjqs-2017-006926; Wileman V, 2014, ANN BEHAV MED, V48, P275, DOI 10.1007/s12160-014-9597-8	31	1	1	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2021	16	7							e0253966	10.1371/journal.pone.0253966	http://dx.doi.org/10.1371/journal.pone.0253966			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2NX	34283851	Green Published, Green Accepted, gold			2023-01-03	WOS:000678123200045
J	Donecker, J; Fabiani, M; Gaschen, L; Aulakh, KS				Donecker, John; Fabiani, Michelle; Gaschen, Lorrie; Aulakh, Karanvir Singh			Treatment response in dogs with naturally occurring grade 3 elbow osteoarthritis following intra-articular injection of Sn-117m (tin) colloid	PLOS ONE			English	Article							BRIEF PAIN INVENTORY; RADIATION SYNOVECTOMY; SYNOVITIS; CARTILAGE; KNEE; RADIOSYNOVIORTHESIS; JOINTS; MRI	The radionuclide Sn-117m (tin-117m) embedded in a homogeneous colloid is a novel radiosynoviorthesis (RSO) device for intra-articular (IA) administration to treat synovial inflammation and mitigate osteoarthritis (OA) in dogs. A study to evaluate tin-117m colloid treatment response in dogs with OA was conducted at two centers, the School of Veterinary Medicine at Louisiana State University, and at a referral practice in Houston, Texas. The tin-117m colloid was administered per-protocol to 14 client-owned dogs with radiographically confirmed, grade 3 OA in one or both elbow joints. Dog owners and attending clinicians assessed the level of pain at baseline (BL) and the post-treatment pain response at 90-day intervals for one year. Owners assessed treatment response according to a pain severity score (PSS) and a pain interference score (PIS) as defined by the Canine Brief Pain Inventory. Clinicians reported a lameness score using a 0-5 scale, from no lameness to continuous non-weight bearing lameness, when observing dogs at a walk and a trot. The rate of treatment success as determined by improved mean PSS and PIS scores reported by dog owners was >70% at all time points. Clinicians reported an improved mean pain score from BL at post-treatment Days 90 (p<0.05), 180, and 270. The dog owner and clinician assessments of treatment success were significantly correlated (p>0.05) at Day 90 and Day 180 time points. Results indicated that a single IA dose of tin-117m colloid provided a significant reduction in pain and lameness and improved functionality for up to a full year, with no adverse treatment related effects, in a high percentage of dogs with advanced, clinical OA of the elbow joint.	[Donecker, John] Exubrion Therapeut, Buford, GA 30518 USA; [Fabiani, Michelle] Gulf Coast Vet Specialists, Houston, TX USA; [Gaschen, Lorrie; Aulakh, Karanvir Singh] Louisiana State Univ, Sch Vet Med, Baton Rouge, LA USA	Louisiana State University School of Veterinary Medicine; Louisiana State University System; Louisiana State University	Donecker, J (corresponding author), Exubrion Therapeut, Buford, GA 30518 USA.	jdonecker@exubrion.com			Exubrion Therapeutics; LSU [44181]; Veterinary Specialists of Texas, PC Clinical Site Agreement	Exubrion Therapeutics; LSU; Veterinary Specialists of Texas, PC Clinical Site Agreement	Exubrion Therapeutics was the sole funding source for this study. Dr. John Donecker, Chief Veterinary Officer for Exubrion Therapeutics in association with Georgetown Clinical Consulting, Atlanta, GA designed the study at the request of Exubrion Therapeutics. Investigators at both centers adhered to the animal welfare standards as approved by the Louisiana State University Institutional Animal Care and Use Committee. This study was funded by amendment 2 of LSU protocol number 44181(KA) and the Veterinary Specialists of Texas, PC Clinical Site Agreement dated 6/15/2017 (MF). Owners of enrolled dogs signed consent forms indicating agreement for experimental RSO treatment and periodic reevaluations during the 1-year duration of the study. Exubrion Therapeutics was not involved with data collection or analysis however statistical review was conducted by Dr. Sheila Gross and funded by Exubrion Therapeutics. The decision to publish and prepare this manuscript was funded by Exubrion Therapeutics.	Anderson A, 2011, J SMALL ANIM PRACT, V52, P182, DOI 10.1111/j.1748-5827.2011.01049.x; [Anonymous], Osteoarthritis in Dogs; Aulakh KS, 2021, VET MED-RES REP, V12, P117, DOI 10.2147/VMRR.S295309; Baers G, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00422; Benito MJ, 2005, ANN RHEUM DIS, V64, P1263, DOI 10.1136/ard.2004.025270; Boge GS, 2019, ACTA VET SCAND, V61, DOI 10.1186/s13028-019-0454-4; Brandt KD, 2006, RHEUMATOLOGY, V45, P1389, DOI 10.1093/rheumatology/kel100; Brown DC, 2013, J VET INTERN MED, V27, P22, DOI 10.1111/jvim.12004; Brown DC, 2008, JAVMA-J AM VET MED A, V233, P1278, DOI 10.2460/javma.233.8.1278; Brown DC, 2007, AM J VET RES, V68, P631, DOI 10.2460/ajvr.68.6.631; Brown DC, 2009, PAIN MED, V10, P133, DOI 10.1111/j.1526-4637.2008.00513.x; DELBARR F, 1968, Presse Medicale, V76, P1045; Deng CF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22454-z; Doerr C., 2015, J NUCL MED, Vsuppl 3, P1243; Gineyts E, 2004, ANN RHEUM DIS, V63, P857, DOI 10.1136/ard.2003.007302; James HK, 2020, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00490; Johnston SA, 1997, VET CLIN N AM-SMALL, V27, P699, DOI 10.1016/S0195-5616(97)50076-3; Jones A, 1996, ANN RHEUM DIS, V55, P829, DOI 10.1136/ard.55.11.829; Kampen WU, 2007, RHEUMATOLOGY, V46, P16, DOI 10.1093/rheumatology/kel352; Karavida N, 2010, HIPPOKRATIA, V14, P22; Kisielinski K, 2010, JOINT BONE SPINE, V77, P252, DOI 10.1016/j.jbspin.2010.02.010; Klett R, 2007, RHEUMATOLOGY, V46, P1531, DOI 10.1093/rheumatology/kem155; Lattimer JC, 2019, VET RADIOL ULTRASOUN, V60, P567, DOI 10.1111/vru.12757; Modder G., 1995, RADIOSYNOVIORTHESIS, P13; Pirich C, 1999, J NUCL MED, V40, P1277; Roemer FW, 2011, ANN RHEUM DIS, V70, P1804, DOI 10.1136/ard.2011.150243; Rossi F, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00074; Sanderson RO, 2009, VET REC, V164, P418, DOI 10.1136/vr.164.14.418; Scanzello CR, 2009, OSTEOARTHR CARTILAGE, V17, P1040, DOI 10.1016/j.joca.2009.02.011; Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159; Stevenson NR, 2015, J RADIOANAL NUCL CH, V305, P99, DOI 10.1007/s10967-015-4031-7; Stevenson NR, 2015, WORLD J NUCL MED, V14, pS15; Wenham CYJ, 2010, THER ADV MUSCULOSKEL, V2, P349, DOI 10.1177/1759720X10378373	33	3	3	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2021	16	7							e0254613	10.1371/journal.pone.0254613	http://dx.doi.org/10.1371/journal.pone.0254613			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2NL	34280212	gold, Green Published			2023-01-03	WOS:000678122000038
J	Rafi, S; Rasheed, H; Usman, M; Nawaz, HA; Anjum, SM; Chaudhry, M; Babar, ZUD				Rafi, Sunaina; Rasheed, Huma; Usman, Muhammad; Nawaz, Hafiz Awais; Anjum, Syed Muneeb; Chaudhry, Mamoona; Babar, Zaheer-Ud-Din			Availability of essential medicines in Pakistan-A comprehensive document analysis	PLOS ONE			English	Article							ACTIVATED-CHARCOAL; AFFORDABILITY; ACCESS	Introduction Access to essential medicines (EMs) is a basic human right. Non-availability and shortages of EMs are reported for Pakistan but there is insufficient data to define the nature and magnitude of this problem. The current study is designed to systematically analyze the medicines included in the National Essential Medicines List (NEML) for their availability through comprehensive document analysis. Methods An expanded list of medicinal items was developed using the NEML of Pakistan (2018) to enlist individual medicines with their specifications. Registration status of the medicines was searched using three publicly accessible information sources; Pharmaguide 25(th) Edition, 2018-19, the on-line Drug Information System, and the Mobile Application Pharmapedia followed by a later 3-step validation of the data. The unregistered EMs were then further categorized into three subgroups in accordance with their possible remedial strategies. Findings The 19 studied categories comprised 690 EMs and it was found that 179 (26%) of these EMs don not have a registration status. However, it was also identified that the availability of 47 (26.2%) out of 179 unregistered EMs can be enssured by strengthening compounding services, and prioritizing registration of age-appropriate formulations. Availability of another 39 (21.7%) such medicines can be ensured by revising the NEML or the product registrations for the slight differences in their different specifications. The categories showing high proportion of unregistered medicines included anti-Parkinson's medicines (100%), antidotes and other substances used in poisoning (60%), diuretics (47%), anticonvulsants/antiepileptics (42%), hormones and other endocrine medicines and contraceptives (38%), medicines for mental and behavioral disorders (30%), anti-infectives (27%), medicines for pain and palliative care (26%), medicines for neonatal care (25%), medicines for diseases of joint (25%), gastrointestinal medicines (24%) and cardiovascular medicines (15%). Conclusion The study shows the absence of registration status of a significant number of EMs in Pakistan. This could be major barrier in their access. Strategies are needed to strengthen the processes of their registration on priority basis.	[Rafi, Sunaina; Rasheed, Huma; Usman, Muhammad; Nawaz, Hafiz Awais; Anjum, Syed Muneeb] Univ Vet & Anim Sci, Inst Pharmaceut Sci, Lahore, Pakistan; [Chaudhry, Mamoona] Univ Vet & Anim Sci, Dept Epidemiol & Publ Hlth, Lahore, Pakistan; [Babar, Zaheer-Ud-Din] Univ Huddersfield, Ctr Pharmaceut Policy & Practice Res, Huddersfield, W Yorkshire, England	University of Veterinary & Animal Science - Pakistan; University of Veterinary & Animal Science - Pakistan; University of Huddersfield	Rasheed, H (corresponding author), Univ Vet & Anim Sci, Inst Pharmaceut Sci, Lahore, Pakistan.	humarasheed@uvas.edu.pk	Chaudhry, M/AEV-6074-2022	Rasheed, Huma/0000-0002-5541-8856				Abassi Y, 2021, EXPRESS TRIBUNE 0619 EXPRESS TRIBUNE 0619; Algren DA., 2008, 2 M SUBC EXP COMM SE 2 M SUBC EXP COMM SE; Am Acad Clin Toxicol, 2005, CLIN TOXICOL, V43, P61, DOI 10.1081/CLT-200051867; [Anonymous], 2011, MEDIA REPORTS MED QU; Aslam N, 2012, ARCH PHARM PRACT, V3, P297, DOI 10.4103/2045-080X.106259; Atif M, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027028; Atif M, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1932-2; Babar ZUD, 2013, PHARMACOECONOMICS, V31, P1063, DOI 10.1007/s40273-013-0095-9; BASKIN SI, 1992, J CLIN PHARMACOL, V32, P368, DOI 10.1002/j.1552-4604.1992.tb03849.x; Bowen GA, 2009, QUAL RES J, V9, P27, DOI 10.3316/QRJ0902027; Bushra bibi MSH., 2019, THE SAMAA NEWS 0321 THE SAMAA NEWS 0321; Canadian Paediatric Society, 2019, ANT AG COMM OUTP PAE ANT AG COMM OUTP PAE; Chauhdary A, PRICE ISSUE PERSISTS; CORDS, 2016, LEISHM GAP AN REP AC LEISHM GAP AN REP AC; Drug Regularity Authority of Pakistan, NAT ESS MED LIST 201 NAT ESS MED LIST 201; Drug Regularity Authority Pakistan, 2018, NAT ESS MED LIST PAK NAT ESS MED LIST PAK; Drug Regulatory Authority of Pakistan, NEML DRAP 2018 MOB A NEML DRAP 2018 MOB A; Ershad M, 2020, STATPEARLS; Faber P, 2005, ANAESTHESIA, V60, P575, DOI 10.1111/j.1365-2044.2005.04185.x; Flament MP, 2000, DRUG DEV IND PHARM, V26, P731, DOI 10.1081/DDC-100101291; Forum WE, HALF WORLDS POPULATI; Guan XD, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0870-5; Health Action International (HAI), WHO HLTH ACT INT PRO WHO HLTH ACT INT PRO; Husain MJ, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015302; Ilyas F, SHORTAGE FOLIC ACID; Jabri P, 2019, STRICT ACTION BE TAK; Kneale M, 2016, J ANTIMICROB CHEMOTH, V71, P3599, DOI 10.1093/jac/dkw325; Lapus RM, 2007, CURR OPIN PEDIATR, V19, P216, DOI 10.1097/MOP.0b013e32801da2a9; Melbourne RCH, RECT DIAZ RECT DIAZ; Michele TM, 2002, J ASTHMA, V39, P391, DOI 10.1081/JAS-120004032; Narsai K, 2021, J PHARM POLICY PRACT, V14, DOI 10.1186/s40545-021-00314-x; Nationwide Childrens Hospital, 2010, SOP ITR OR SOL 40MG SOP ITR OR SOL 40MG; Organization WH, 2016, GLOB APPR ADDR SHORT GLOB APPR ADDR SHORT; Pakistan DRAo, PROV LIST REG MED 20 PROV LIST REG MED 20; Perumal-Pillay VA, 2021, S AFR FAM PRACT, V63, DOI 10.4102/safp.v63i1.5145; Pfab R, 2017, TOXICOL REP, V4, P49, DOI 10.1016/j.toxrep.2016.12.007; PharmaGuide, 2018, PHARMAGUIDE, V25th ed; Pharmapedia, 2018, PHARM PAK PHARM DEV PHARM PAK PHARM DEV; Phuong JM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215837; Rasheed H, 2005, 13 INT PHARM C EXH L 13 INT PHARM C EXH L; Rasheed H, 2019, J PHARM POLICY PRACT, V12, DOI 10.1186/s40545-019-0184-z; Raza SI., 2020, GOVT ALLOWS RISE PRI; Royal Pharmaceutical Society, 2020, BRIT NATL FORMULARY; Saeed A, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.595008; Saeed A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216122; sahoutara N, 2019, DAWN NEWS; Siddiqui F., 2015, PAKISTAN J NEUROL SC, V10, P47; Sunyoto T, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000709; The Network for Consumer Protection in Pakistan, MISS ESS DRUGS NETW MISS ESS DRUGS NETW, p200L; Tong Henry H Y, 2010, Int J Pharm Compd, V14, P342; van Mourik MSM, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-25; WHO, 2017, WHO GLOB SURV MON SY; WHO, WHO MOD LIST ESS MED; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; World Health Organization, 2004, EQ ACC ESS MED FRAM; World Health Organization, 2017, ESSE MED LIST; World Health Organization, 2013, GLOB ACT PLAN PREV C; World Health Organization and Health Organizaion, PRIC AV AFF INT COMP PRIC AV AFF INT COMP; World Health Organization (WHO), 2017, 1 10 MED PROD DEV CO; Yousafzai A, 2021, SMUGGLED MED SAVE LI; Yousafzai Ashfaq., 2018, PESHAWAR DELAY CUSTO; Zaidi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063515; Zikria Saleem, 2021, Cost Effectiveness and Resource Allocation, V19, DOI 10.1186/s12962-021-00263-x	63	0	0	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2021	16	7							e0253880	10.1371/journal.pone.0253880	http://dx.doi.org/10.1371/journal.pone.0253880			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK6YI	34242249	Green Published, gold			2023-01-03	WOS:000674301400150
J	Karasawa, Y; Kamae, I; Nozawa, K; Zeniya, S; Murata, T; Soen, S; Sakamoto, C				Karasawa, Yusuke; Kamae, Isao; Nozawa, Kazutaka; Zeniya, Shigeki; Murata, Tatsunori; Soen, Satoshi; Sakamoto, Choitsu			Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan	PLOS ONE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS	Objectives The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pharmacotherapy for gastrointestinal bleeding. Methods This cost-effectiveness analysis was performed as a long-term simulation using the Markov model from the Japanese public healthcare payer's perspective. The analysis was conducted using loxoprofen with real-world weighted price by branded/generic distribution (hereinafter, loxoprofen with weighted price) as a comparator. In the model, we simulated the prognosis of patients with chronic pain by OA, RA, and LBP treated with loxoprofen or celecoxib, over a lifetime period. Results A cost-increase of 129,688 JPY (1,245.00 USD) for branded celecoxib and a cost-reduction of 6,268 JPY (60.17 USD) for AG celecoxib were recognized per patient in lifetime horizon, compared to loxoprofen with weighted price. No case was recognized to reverse the results of cost-saving by AG celecoxib in one-way sensitivity analysis. The incremental cost-effectiveness ratio of branded celecoxib attained 5,403,667 JPY/QALY (51,875.20 USD/QALY), compared to loxoprofen with the weighted price. Conclusion The current cost-effectiveness analysis for AG celecoxib revealed its good value for costs, considering the patients' future risk of gastrointestinal injury; also, the impact on costs due to AG celecoxib against loxoprofen will be small. It implies that the disadvantage of AG celecoxib being slightly more expensive than generic loxoprofen could be offset by the good cost-effectiveness during the prognosis.	[Karasawa, Yusuke; Nozawa, Kazutaka] Viatris Pharmaceut Japan Inc, Med Affairs, Tokyo, Japan; [Kamae, Isao] Univ Tokyo, Grad Sch Publ Policy, Dept Hlth Policy & Technol Assessment, Tokyo, Japan; [Zeniya, Shigeki; Murata, Tatsunori] CRECON Med Assessment Inc, Tokyo, Japan; [Soen, Satoshi] Soen Orthopaed Osteoporosis & Rheumatol Clin, Kobe, Hyogo, Japan; [Sakamoto, Choitsu] Nippon Med Sch, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan	University of Tokyo; Nippon Medical School	Karasawa, Y (corresponding author), Viatris Pharmaceut Japan Inc, Med Affairs, Tokyo, Japan.	yusuke.karasawa@viatris.com		Nozawa, Kazutaka/0000-0003-4245-2657; Karasawa, Yusuke/0000-0002-8086-1366	Viatris Pharmaceuticals Japan Inc.	Viatris Pharmaceuticals Japan Inc.	This study was sponsored by Viatris Pharmaceuticals Japan Inc. The funder provided support in the form of salaries for authors (YK and KN), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section. Yusuke Karasawa and Kazutaka Nozawa drafted the concept of this research. Shigeki Zeniya created the simulation model and performed all analyses using the model. Shigeki Zeniya and Tatsunori Murata drafted the manuscript. All Cover Letter authors participated in the interpretation of study results and in the drafting, critical revision, and approval of the final version of the manuscript.	Abe Y., 2006, PROGR MED, V26, P2820; [Anonymous], 2019, GUIDELINE PREPARING; Fukuda T., 2019, HOKEN IRYO KAGAKU, V8, P27; Hernandez-Diaz S, 2000, ARCH INTERN MED, V160, P2093, DOI 10.1001/archinte.160.14.2093; Higa Koji, 2011, Nihon Shokakibyo Gakkai Zasshi, V108, P418; Hiraishi H, 2010, J THERAPY, V92, P435; Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010; Iidaka T, 2016, OSTEOARTHR CARTILAGE, V24, P117, DOI 10.1016/j.joca.2015.07.017; Kawaguchi I, 2014, VALUE HEALTH, V17, pA533, DOI 10.1016/j.jval.2014.08.1697; Kikuchi S., 2009, PROGR MED, V29, P2853; Latimer N, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2538; Maetzel A, 2002, 23 CAN COORD OFF HLT 23 CAN COORD OFF HLT; Ministry of Health Labour and Welfare, 2019, COMPREHENSIVE SURVEY; National Institute for Health and Care Excellence, 2014, CG177 NAT I HLTH CAR; Pairet M, 1996, FUND CLIN PHARMACOL, V10, P1, DOI 10.1111/j.1472-8206.1996.tb00144.x; Sakamoto C, 2011, DIGESTION, V83, P108, DOI 10.1159/000318746; Sugano K, 2012, J GASTROENTEROL, V47, P540, DOI 10.1007/s00535-012-0541-z; Sugawara S., 2006, PROGR MED, V26, P2911; Tsumura H, 2007, INTERNAL MED, V46, P927, DOI 10.2169/internalmedicine.46.0003; World Health Organization (WHO), 2021, GLOB HLTH OBS 2021 GLOB HLTH OBS 2021; Yajima H, 2007, J ORTHOP SCI, V12, P341, DOI 10.1007/s00776-007-1139-9; Yamanaka H, 2014, MOD RHEUMATOL, V24, P33, DOI 10.3109/14397595.2013.854059; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104; Yoshimura N, 2009, J BONE MINER METAB, V27, P620, DOI 10.1007/s00774-009-0080-8	24	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2021	16	7							e0253547	10.1371/journal.pone.0253547	http://dx.doi.org/10.1371/journal.pone.0253547			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK6VN	34228745	gold, Green Published			2023-01-03	WOS:000674293700029
J	Taniguchi, C; Seto, N; Shimizu, Y				Taniguchi, Chinatsu; Seto, Natsuko; Shimizu, Yasuko			Outpatient nursing support for self-monitoring in patients with chronic heart failure	PLOS ONE			English	Article							CARE; MANAGEMENT; SYMPTOMS; OUTCOMES	Background Early symptoms of worsening heart failure are difficult for patients to detect and manage, contributing to the high readmission rate for worsening heart failure. Thus, it is important to promote self-monitoring and to support patients in recognizing and interpreting their symptoms. This study aimed to explore the ways in which specialized nurses in the outpatient setting provide support for self-monitoring in patients with chronic heart failure in Japan. Methods This exploratory study adopted a qualitative study design. The participants were a convenience sample of five nurses certified in chronic heart failure nursing and one advanced practice nurse certified in chronic care nursing, all with experience in outpatient nursing in Japan. Data were collected from June 2017 to October 2017 through semi-structured one-on-one interviews and were analyzed using an established qualitative inductive method. Results The analysis identified seven themes describing the nursing support provided by the study participants. Among these were three themes describing different forms of direct support for self-monitoring: "Encourage patients to reflect on their own," "Support touching the body and developing body awareness," and "Support sharing the task." Two themes described practice perspectives: "Support self-monitoring that is not overly sensitive" and "Support connection with the patient's life." Two final themes described contextual factors in the outpatient care setting: "Struggling with constraints and powerlessness" and "Building a support system in the outpatient setting." Conclusions The findings provide a practice for nurses promoting self-monitoring in patients with chronic heart failure in the outpatient setting. The study findings inform and provide goals for the support of self-monitoring in patients with heart failure and also, suggest the need to establish a strong support system for outpatient care in Japan.	[Taniguchi, Chinatsu; Shimizu, Yasuko] Osaka Univ, Grad Sch Med, Div Hlth Sci, Suita, Osaka, Japan; [Seto, Natsuko] Kansai Med Univ, Fac Nursing, Grad Sch Nursing, Hirakata, Osaka, Japan	Osaka University; Kansai Medical University	Taniguchi, C (corresponding author), Osaka Univ, Grad Sch Med, Div Hlth Sci, Suita, Osaka, Japan.	uetachnt@gmail.com			JSPS KAKENHI [15H06778]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI Grant Number 15H06778. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Dickson VV, 2008, EUR J CARDIOVASC NUR, V7, P171, DOI 10.1016/j.ejcnurse.2007.11.005; Dickson VV, 2014, PATIENT EDUC COUNS, V96, P188, DOI 10.1016/j.pec.2014.04.018; Dorsch MP, 2015, TELEMED E-HEALTH, V21, P267, DOI 10.1089/tmj.2014.0095; Emerman CL., 2003, REV CARDIOVASC MED, V4, P13; Fukuda R, 2015, INT J QUAL STUD HEAL, V10, DOI 10.3402/qhw.v10.25828; Gheorghiade M, 2005, AM J CARDIOL, V96, p11G, DOI 10.1016/j.amjcard.2005.07.016; Hattori Y., 2010, J JAPAN ACAD NURS SC, V30, P74; Health Annual, LABOUR WELFARE REPOR; Jurgens CY, 2013, HEART LUNG, V42, P273, DOI 10.1016/j.hrtlng.2013.03.005; Kawakita J., 1967, HASSOHO; Kawakita J, 1970, ZOKU HASSOHO ZOKU HASSOHO; Lee S, 2018, J CARDIOVASC NURS, V33, P204, DOI 10.1097/JCN.0000000000000445; Lucas C, 2000, AM HEART J, V140, P840, DOI 10.1067/mhj.2000.110933; Moser DK, 2008, J CARDIOVASC NURS, V23, P205, DOI 10.1097/01.JCN.0000305097.09710.a5; Riegel B, 2002, PATIENT EDUC COUNS, V46, P287, DOI 10.1016/S0738-3991(01)00165-3; Riegel B, 2018, HEART LUNG, V47, P107, DOI 10.1016/j.hrtlng.2017.11.002; Saltzberg MT., 2004, REV CARDIOVASC MED, V5, P17; Santos GC, 2021, INT J NURS STUD, V116, DOI 10.1016/j.ijnurstu.2020.103524; Savarese Gianluigi, 2017, Card Fail Rev, V3, P7, DOI 10.15420/cfr.2016:25:2; Sethares KA, 2017, HEART LUNG, V46, P192, DOI 10.1016/j.hrtlng.2017.03.002; Tsuchihashi-Makaya M, 2009, CIRC J, V73, P1893, DOI 10.1253/circj.CJ-09-0254; Tsuchihashi-Makaya M, 2009, CIRC J, V73, P280, DOI 10.1253/circj.CJ-08-0625; Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757; Wakefield B, 2016, J CARDIOVASC NURS, V31, P42, DOI 10.1097/JCN.0000000000000213; Wilde MH, 2007, J ADV NURS, V57, P339, DOI 10.1111/j.1365-2648.2006.04089.x; Yamaura H, 2008, KANGO KENKYU, V41, P11; Yoneda A., 2003, J JAPAN ACAD DIABETE, V7, P96	27	0	0	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2021	16	7							e0254019	10.1371/journal.pone.0254019	http://dx.doi.org/10.1371/journal.pone.0254019			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9LR	34214121	Green Published, gold			2023-01-03	WOS:000671718200059
J	Caplan, M; Duburcq, T; Moreau, AS; Poissy, J; Nseir, S; Parmentier-Decrucq, E				Caplan, Morgan; Duburcq, Thibault; Moreau, Anne-Sophie; Poissy, Julien; Nseir, Saad; Parmentier-Decrucq, Erika			Hyperbaric hyperoxemia as a risk factor for ventilator-acquired pneumonia?	PLOS ONE			English	Article							OXYGEN-THERAPY; ARTERIAL HYPEROXIA; LIPID-PEROXIDATION; BRAIN; ASSOCIATION; INJURY	Objectives Ventilator-acquired pneumonia (VAP) is the leading cause of serious associated infections in Intensive Care Units (ICU) and is associated with significant morbidity. The use of hyperbaric oxygen therapy (HBOT) in patients on mechanical ventilation may increase exposure to certain risk factors such as hyperoxemia and the need for multiple transfers. The aim of our study was to assess the relationship between HBOT and VAP. Method This retrospective observational study was performed from March 2017 to March 2018 in a 10-bed ICU using HBOT. All patients receiving mechanical ventilation (MV) for more than 48 hours were eligible. VAP was defined using clinical and radiological criteria. Data collection was carried out via digital medical records. Risk factors for VAP were determined by univariate and multivariate analysis. Results Forty-two (23%) of the 182 patients enrolled developed at least one episode of VAP. One hundred and twenty-four (68%) patients received HBOT. The incidence rate of VAP was 34 per 1000 ventilator days. The occurrence of VAP was significantly associated with immunosuppression (p.029), MV duration (5 [3-7] vs 8 [5-11.5] days, p.0001), length of stay (8 [5-13] vs 19.5 [13-32] days, p.0001), reintubation (p.0001), intra-hospital transport (p = 0.001), use of paralytic agents (p = 0.013), tracheotomy (p = 0.003) and prone position (p = 0.003). The use of HBOT was not associated with the occurrence of VAP. Multivariate analysis identified reintubation (OR: 8.3 [2.6-26.6]; p.0001), intra-hospital transport (OR: 3.5 [1.3-9.2]; p = 0.011) and the use of paralytic agents (OR: 3.3 [1.3-8.4]; p = 0.014) as independent risk factors for VAP. Conclusion Known risk factors for VAP are to be found within our ICU population. HBOT, however, is not an extra risk factor for VAP within this group. Further experimental and clinical investigations are needed to understand the impact of HBOT on the occurrence of VAP and on physiological microbiome.	[Caplan, Morgan; Duburcq, Thibault; Moreau, Anne-Sophie; Poissy, Julien; Nseir, Saad; Parmentier-Decrucq, Erika] Lille Univ Hosp, Intens Care Unit, Lille, France; [Caplan, Morgan; Duburcq, Thibault; Moreau, Anne-Sophie; Poissy, Julien; Nseir, Saad; Parmentier-Decrucq, Erika] Lille Univ Hosp, Hyperbar Ctr, Lille, France	Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille	Parmentier-Decrucq, E (corresponding author), Lille Univ Hosp, Intens Care Unit, Lille, France.	erika.parmentier@chru-lille.fr		Parmentier-Decrucq, Erika/0000-0002-5836-5956; caplan, Morgan/0000-0002-6016-0749				ALLEN MC, 1993, UNDERSEA HYPERBAR M, V20, P39; Ayzac L, 2016, INTENS CARE MED, V42, P871, DOI 10.1007/s00134-015-4167-5; Barrot L, 2020, NEW ENGL J MED, V382, P999, DOI 10.1056/NEJMoa1916431; Bessereau J, 2017, INT MARIT HEALTH, V68, P46, DOI 10.5603/IMH.2017.0008; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; Corcoran T, 2017, PROSTAG LEUKOTR ESS, V127, P16, DOI 10.1016/j.plefa.2017.10.003; Dananche C, 2018, CRIT CARE MED, V46, P869, DOI 10.1097/CCM.0000000000003019; DANTZKER DR, 1974, J PHYSIOL-LONDON, V242, pP72; Fosen KM, 2014, ANTIOXID REDOX SIGN, V21, P1634, DOI 10.1089/ars.2014.5940; Hadanny A, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0893-8; Hafner S, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0084-6; Helmerhorst HJF, 2015, CRIT CARE MED, V43, P1508, DOI 10.1097/CCM.0000000000000998; Hiner C, 2010, AM J CRIT CARE, V19, P164, DOI 10.4037/ajcc2010917; Infectiologie, INFECTIOLOGIE; Jain, 2017, TXB HYPERBARIC MED; Kalns J, 2002, IMMUNOL LETT, V83, P125, DOI 10.1016/S0165-2478(02)00068-8; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Koulenti D, 2017, EUR J CLIN MICROBIOL, V36, P1999, DOI 10.1007/s10096-016-2703-z; Martin-Loeches I, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9070380; Mathieu D, 2006, HDB HYPERBARIC MED, P401, DOI [10.1007/1-4020-4448-8_20, DOI 10.1007/1-4020-4448-8_20]; Mathieu D, 2017, DIVING HYPERB MED, V47, P24, DOI 10.28920/dhm47.1.24-32; MILLER JD, 1970, J NEUROL NEUROSUR PS, V33, P745, DOI 10.1136/jnnp.33.6.745; Organisation-Securite-Ethique, ORG SEC ETH; Palmer E, 2019, AM J RESP CRIT CARE, V200, P1373, DOI 10.1164/rccm.201904-0849OC; Panwar R, 2016, AM J RESP CRIT CARE, V193, P43, DOI 10.1164/rccm.201505-1019OC; Patel VS, 2013, AM J RESP CELL MOL, V48, P280, DOI 10.1165/rcmb.2012-0279OC; SACKNER MA, 1976, CHEST, V69, P164, DOI 10.1378/chest.69.2.164; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Six S, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1368-4; THOM SR, 1992, J APPL PHYSIOL, V73, P1584, DOI 10.1152/jappl.1992.73.4.1584; THOM SR, 1993, TOXICOL APPL PHARM, V123, P248, DOI 10.1006/taap.1993.1243; Thom SR, 2006, AM J PHYSIOL-HEART C, V290, pH1378, DOI 10.1152/ajpheart.00888.2005; THOM SR, 1990, TOXICOL APPL PHARM, V105, P340, DOI 10.1016/0041-008X(90)90195-Z; Thorsen E, 1998, EUR RESPIR J, V12, P1442, DOI 10.1183/09031936.98.12061442; Tsuneyoshi I, 2001, J Anesth, V15, P29, DOI 10.1007/s005400170048; Weaver LK, 2015, DIVING HYPERB MED, V45, P1; Yokoyama S, 2019, SHOCK, V51, P593, DOI 10.1097/SHK.0000000000001221	38	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2021	16	6							e0253198	10.1371/journal.pone.0253198	http://dx.doi.org/10.1371/journal.pone.0253198			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BO	34161365	Green Published, gold			2023-01-03	WOS:000671691900004
J	Taylor, JS; Madhavan, S; Han, RW; Chandler, JM; Tenakoon, L; Chao, S				Taylor, Jordan S.; Madhavan, Sriraman; Han, Ryan W.; Chandler, Julia M.; Tenakoon, Lakshika; Chao, Stephanie			Financial burden of pediatric firearm-related injury admissions in the United States	PLOS ONE			English	Article							COSTS; INCOME	Pediatric firearm-related injuries pose a significant public health problem in the United States, yet the associated financial burden has not been well described. This is the first study examining national data on the cost of initial hospitalization for pediatric firearm-related injuries. In this retrospective review, the Healthcare Cost and Utilization Project Kids' Inpatient Database from the years 2003, 2006, 2009, and 2012 was used to identify all patients 18 years of age and under who were admitted with firearm-related injuries. We compared demographic and discharge-level data including injury severity score, hospital length of stay, income quartile, injury intent, and inflation-adjusted hospital costs across age groups (0-5, 6-9, 10-15, 16-18 years). There were approximately 4,753 pediatric firearm-related admissions each year, with a median hospitalization cost of $12,984 per patient. Annual initial hospitalization costs for pediatric firearm injuries were approximately $109 million during the study period. Pediatric firearm-related injuries predominately occured among older teenagers (74%, 16-18 years), males (89%), black individuals (55%), and those from the lowest income quartile (53%). We found significant cost variation based on patient race, income quartile, injury severity score, intent, hospital length of stay, disposition, and hospital region. Inflation-adjusted hospitalization costs have increased significantly over the study period (p < 0.001). Pediatric firearm-related injuries are a large financial burden to the United States healthcare system. There are significant variations in cost based on predictable factors like hospital length of stay and injury severity score; however, there are also substantial discrepancies based on hospital region, patient race, and income quartile that require further investigation.	[Taylor, Jordan S.; Chandler, Julia M.; Chao, Stephanie] Stanford Univ, Dept Surg, Div Pediat Surg, Stanford, CA 94305 USA; [Madhavan, Sriraman] Stanford Univ, Dept Stat, Stanford, CA 94305 USA; [Han, Ryan W.] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Tenakoon, Lakshika] Stanford Univ, Dept Surg, Div Gen Surg, Stanford, CA USA	Stanford University; Stanford University; Stanford University; Stanford University	Chao, S (corresponding author), Stanford Univ, Dept Surg, Div Pediat Surg, Stanford, CA 94305 USA.	sdchao1@stanford.edu		Chao, Stephanie/0000-0003-0139-8551; Han, Ryan/0000-0001-5345-4186				Centers for Disease Control and Prevention National Center for Injury Prevention and Control, WEB BAS INJ STAT QUE; DiScala C, 2004, PEDIATRICS, V113, P1306, DOI 10.1542/peds.113.5.1306; Fisher ES, 2009, NEW ENGL J MED, V360, P849, DOI 10.1056/NEJMp0809794; Fowler KA, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-3486; Grinshteyn E, 2016, AM J MED, V129, P266, DOI 10.1016/j.amjmed.2015.10.025; Kids' Inpatient Database (KID), HEALTHC COST UT PROJ; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; Martin TM, REGIONAL PRICE PARIT; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; Miller T, 2012, COST FIREARM VIOLENC; Parikh Kavita, 2017, Hosp Pediatr, V7, P303, DOI 10.1542/hpeds.2016-0146; Peek-Asa Corinne, 2017, Inj Epidemiol, V4, P20, DOI 10.1186/s40621-017-0120-0; Shenassa ED, 2003, J EPIDEMIOL COMMUN H, V57, P120, DOI 10.1136/jech.57.2.120; Spitzer SA, 2017, AM J PUBLIC HEALTH, V107, P770, DOI 10.2105/AJPH.2017.303684; Webster DW, 2004, JAMA-J AM MED ASSOC, V292, P594, DOI 10.1001/jama.292.5.594	15	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2021	16	6							e0252821	10.1371/journal.pone.0252821	http://dx.doi.org/10.1371/journal.pone.0252821			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TG9BO	34161341	Green Published, gold			2023-01-03	WOS:000671691900010
J	Alnaqbi, A; Shousha, T; AlKetbi, H; Hegazy, FA				Alnaqbi, Arwa; Shousha, Tamer; AlKetbi, Hamda; Hegazy, Fatma A.			Physiotherapists' perspectives on barriers to implementation of direct access of physiotherapy services in the United Arab Emirates: A cross-sectional study	PLOS ONE			English	Article							EPISODES; CARE	Background There are two primary ways of accessing physiotherapy for service users around the world. The direct access, as opposed to the indirect access which requires a referral from a general physician, has several merits including better quality, timeliness, cost effectiveness of treatment and better probability of preventing acute conditions from turning into chronic ailments. Despite these benefits, several countries including the UAE, do not allow direct access to physiotherapists. This study aims to understand the level of awareness among practicing physiotherapists in the United Arab Emirates (UAE) about direct access and to determine whether any of their demographic variables influence the way they perceive the concept. Further, the study sought to explore the perceived barriers and benefits of direct access according to the participating physiotherapists. Subjects and methods An observational cross-sectional study was employed. The questionnaire survey developed by Bury and Stokes in 2013 was adapted and employed in this study. The instrument had six sections with close-ended items using a Likert five-point scale to rate them. Two hundred and sixty-four physiotherapists answered the questionnaire shared with them through a web link. Finally, MANOVA was employed to explore any influence of demographic variables on the opinions of the respondents. Results The findings showed that 70% of participants were aware about direct access while nearly 30% were completely unaware. Younger physiotherapists were more willing to endorse the practice whereas older ones were more apprehensive of the barriers. The main barriers reported were the limited support from the physicians and policy makers, professional autonomy, and the limited scope of practice for the physiotherapists, as well as evidence-based practice. The impact of demographic variables on direct access indicated that physiotherapists under the age of 23 endorsed direct access more strongly than other age groups. Conclusion More efforts are needed to implement direct access in the UAE, considering the benefits of improved professional status, cost savings, patient satisfaction, and higher efficiency. This study recommends leadership support, professional autonomy, and mentorship as possible ways to achieve this goal.	[Alnaqbi, Arwa] Kuwait Hosp, MOHAP, Physiotherapy Deparment, Dubai, U Arab Emirates; [Shousha, Tamer; Hegazy, Fatma A.] Univ Sharjah, Coll Hlth Sci, Dept Physiotherapy, Sharjah, U Arab Emirates; [Shousha, Tamer] Cairo Univ, Fac Phys Therapy, Dept Phys Therapy Musculoskeletal Disordered & It, Giza, Egypt; [AlKetbi, Hamda] Rashid Hosp, DHA, Phys Med & Rehabil Dept, Dubai, U Arab Emirates; [Hegazy, Fatma A.] Cairo Univ, Fac Phys Therapy, Dept Phys Therapy Growth & Dev Disorders Children, Giza, Egypt	University of Sharjah; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Cairo University	Hegazy, FA (corresponding author), Univ Sharjah, Coll Hlth Sci, Dept Physiotherapy, Sharjah, U Arab Emirates.; Hegazy, FA (corresponding author), Cairo Univ, Fac Phys Therapy, Dept Phys Therapy Growth & Dev Disorders Children, Giza, Egypt.	fhegazy@sharjah.ac.ae	Shousha, Tamer/AAR-1384-2021	Shousha, Tamer/0000-0002-0712-4490; Hegazy, Fatma/0000-0001-7457-083X				Aiken AB, 2008, J INTERPROF CARE, V22, P253, DOI 10.1080/13561820801984134; Al Ghamdi AH, 2019, PHYS MED REHAB KUROR, V29, P26, DOI 10.1055/s-0043-124973; Bishop A, 2021, PHYSIOTHERAPY, V111, P48, DOI 10.1016/j.physio.2020.04.006; Bury TJ, 2013, PHYS THER, V93, P449, DOI 10.2522/ptj.20120060; Demont A, 2021, DISABIL REHABIL, V43, P1637, DOI 10.1080/09638288.2019.1674388; Evans A, APTA REPORT DIRECT A; Garrity BM, 2020, PHYS THER, V100, P107, DOI 10.1093/ptj/pzz152; Goodwin R, 2020, PHYSIOTHERAPY, V108, P29, DOI 10.1016/j.physio.2020.02.003; Holdsworth LK, 2008, PHYSIOTHERAPY, V94, P236, DOI 10.1016/j.physio.2008.01.006; Holdsworth LK., 2004, PHYSIOTHERAPY, V90, DOI [10.1016/j.physio.2004.01.005, DOI 10.1016/J.PHYSIO.2004.01.005]; Igwesi-Chidobe CN., 2020, PHYSIOTHERAPY, DOI [10.1016/j.physio.2020.07.002 33316866, DOI 10.1016/J.PHYSIO.2020.07.00233316866]; Kruger J, 2010, J PHYSIOTHER, V56, P217, DOI 10.1016/S1836-9553(10)70001-1; Laliberte Maude, 2017, Narrat Inq Bioeth, V7, P157, DOI 10.1353/nib.2017.0046; Leemrijse CJ, 2008, PHYS THER, V88, P936, DOI 10.2522/ptj.20070308; Lim A., 2020, EUR J PHYSIOTHER, V21, P1; Mbada CE., 2015, NIGER J MED REHAB, DOI [10.34058/njmr.v18i1.105, DOI 10.34058/NJMR.V18I1.105]; Mitchell JM, 1997, PHYS THER, V77, P10, DOI 10.1093/ptj/77.1.10; Moore JH, 2005, J ORTHOP SPORT PHYS, V35, P67, DOI 10.2519/jospt.2005.35.2.67; Ojha HA, 2014, PHYS THER, V94, P14, DOI 10.2522/ptj.20130096; Papageorgiou G, 2018, INTERACT CARDIOV TH, V27, P153, DOI 10.1093/icvts/ivy102; Piano Leonardo, 2017, J Phys Ther Sci, V29, P1463, DOI 10.1589/jpts.29.1463; Piscitelli D, 2018, CLIN TER, V169, pE249, DOI 10.7417/CT.2018.2087; Schreier M., 2018, SAGE HDB QUALITATIVE, P84, DOI DOI 10.4135/9781526416070.N6; Schrepp M, 2020, J USABILITY STUD, V15, P247; Swinkels IC., 2007, NED TIJDSCHR FYSIOTH, V117, P158; World Physiotherapy. Emirates Physiotherapy Society, WORLD PHYS	26	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2021	16	6							e0253155	10.1371/journal.pone.0253155	http://dx.doi.org/10.1371/journal.pone.0253155			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6SD	34115810	gold, Green Published			2023-01-03	WOS:000664643000050
J	Ao, ZJ; Chan, M; Ouyang, MJ; Olukitibi, TA; Mahmoudi, M; Kobasa, D; Yao, XJ				Ao, Zhujun; Chan, Mable; Ouyang, Maggie Jing; Olukitibi, Titus Abiola; Mahmoudi, Mona; Kobasa, Darwyn; Yao, Xiaojian			Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry	PLOS ONE			English	Article							SPIKE PROTEIN; CYTOPLASMIC TAIL; HIV-1; SURAMIN; PATHOGENESIS; SARS-COV-2; MECHANISM; AIDS	Until now, antiviral therapeutic agents are still urgently required for treatment or prevention of SARS-coronavirus 2 (SCoV-2) virus infection. In this study, we established a sensitive SCoV-2 Spike glycoprotein (SP), including an SP mutant D614G, pseudotyped HIV-1-based vector system and tested their ability to infect ACE2-expressing cells. Based on this system, we have demonstrated that an aqueous extract from the Natural herb Prunella vulgaris (NhPV) displayed potent inhibitory effects on SCoV-2 SP (including SPG614 mutant) pseudotyped virus (SCoV-2-SP-PVs) mediated infections. Moreover, we have compared NhPV with another compound, Suramin, for their anti-SARS-CoV-2 activities and the mode of their actions, and found that both NhPV and Suramin are able to directly interrupt SCoV-2-SP binding to its receptor ACE2 and block the viral entry step. Importantly, the inhibitory effects of NhPV and Suramin were confirmed by the wild type SARS-CoV-2 (hCoV-19/Canada/ON-VIDO-01/2020) virus infection in Vero cells. Furthermore, our results also demonstrated that the combination of NhPV/Suramin with an anti-SARS-CoV-2 neutralizing antibody mediated a more potent blocking effect against SCoV2-SP-PVs. Overall, by using SARS-CoV-2 SP-pseudotyped HIV-1-based entry system, we provide strong evidence that NhPV and Suramin have anti-SARS-CoV-2 activity and may be developed as a novel antiviral approach against SARS-CoV-2 infection.	[Ao, Zhujun; Ouyang, Maggie Jing; Olukitibi, Titus Abiola; Mahmoudi, Mona; Yao, Xiaojian] Univ Manitoba, Dept Med Microbiol & Infect Dis, Lab Mol Human Retrovirol, Rady Fac Hlth Sci,Coll Med, Winnipeg, MB, Canada; [Chan, Mable; Kobasa, Darwyn] Publ Hlth Agcy Canada, Special Pathogens Program, Natl Microbiol Lab, Winnipeg, MB, Canada	University of Manitoba; Public Health Agency of Canada	Yao, XJ (corresponding author), Univ Manitoba, Dept Med Microbiol & Infect Dis, Lab Mol Human Retrovirol, Rady Fac Hlth Sci,Coll Med, Winnipeg, MB, Canada.	xiao-jian.yao@umanitoba.ca		OLUKITIBI, TITUS/0000-0002-6831-4239; Yao, Xiaojian/0000-0002-5022-1309; Ouyang, Jing/0000-0002-4592-2688	Canadian Institute of Health Research (CIHR) [OV5-170710]; Research Manitoba; Manitoba Research Chair Award from the Research Manitoba; Research Manitoba/Manitoba Institute of Child Health	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Research Manitoba; Manitoba Research Chair Award from the Research Manitoba; Research Manitoba/Manitoba Institute of Child Health	This work was supported by Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding (OV5-170710) by Canadian Institute of Health Research (CIHR) and Research Manitoba. Dr. X-j Y holds a Manitoba Research Chair Award from the Research Manitoba. O.T.A is the recipient of PhD scholarship from the Research Manitoba/Manitoba Institute of Child Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdollahi E, 2020, CAN MED ASSOC J, V192, pE666, DOI 10.1503/cmaj.200711; Ahmed MU, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00518; Ao ZJ, 2007, J BIOL CHEM, V282, P13456, DOI 10.1074/jbc.M610546200; Ao ZJ, 2016, J VIROL METHODS, V228, P95, DOI 10.1016/j.jviromet.2015.11.019; Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Chen LY, 2013, ANTIMICROB AGENTS CH, V57, P3547, DOI 10.1128/AAC.00100-13; CHESON BD, 1987, JAMA-J AM MED ASSOC, V258, P1347, DOI 10.1001/jama.258.10.1347; Clarisse Salgado Benvindo da Silva MT., 2020, ANTIMICROB AGENTS CH, DOI [10.1101/2020.1105.1106.081968, DOI 10.1101/2020.1105.1106.081968]; DECLERCQ E, 1987, ANTIVIR RES, V7, P1, DOI 10.1016/0166-3542(87)90034-9; Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016; Huang D, 2021, J MED VIROL, V93, P481, DOI 10.1002/jmv.26256; Hussain S, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00353-7; Jaimes JA, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101212; Jarek Juraszek LR., 2020, BIORXIV, DOI [10.1101/2020.07.10.197814, DOI 10.1101/2020.07.10.197814]; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Jie Hu C-LH., 2020, BIORXIVSSSSSSSSSSSSS, DOI [10.1101/2020.06.20.161323, DOI 10.1101/2020.06.20.161323]; Kim GU, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.04.040; Korber B., 2020, BIORXIV, DOI 10.1101/2020.04.29.069054; Kuo SC, 2016, ANTIVIR RES, V134, P89, DOI 10.1016/j.antiviral.2016.07.025; Li Q., 2020, NEW ENGL J MED, V382, P1199, DOI [10.1056/NEJMoa2001316, DOI 10.1056/NEJMOA2001316]; Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013; Liu SW, 2002, LIFE SCI, V71, P1779, DOI 10.1016/S0024-3205(02)01939-2; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; McBride CE, 2007, J VIROL, V81, P2418, DOI 10.1128/JVI.02146-06; Millet JK, 2019, JOVE-J VIS EXP, DOI 10.3791/59010; Organization WH, 2020, EST MORT COVID 19 SC; Park SJ, 2020, MBIO, V11, DOI 10.1128/mBio.01114-20; Petit CM, 2005, VIROLOGY, V341, P215, DOI 10.1016/j.virol.2005.06.046; Qiu XG, 2011, CLIN IMMUNOL, V141, P218, DOI 10.1016/j.clim.2011.08.008; Raj VS, 2014, CURR OPIN VIROL, V5, P58, DOI 10.1016/j.coviro.2014.01.010; Sadasivan J, 2017, J BIOSCIENCES, V42, P231, DOI 10.1007/s12038-017-9676-7; Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003; Wang M., 2020, CELL RES, V30, P269, DOI [10.1038/s41422-020-0282-02020, DOI 10.1038/s41422-020-0282-0]; Wolfel R, 2020, NATURE, V581, P465, DOI 10.1038/s41586-020-2196-x; Xu HX, 1999, ANTIVIR RES, V44, P43, DOI 10.1016/S0166-3542(99)00053-4; YAO XJ, 1991, AIDS, V5, P1389, DOI 10.1097/00002030-199111000-00021; YAO XJ, 1992, VIROLOGY, V187, P56, DOI 10.1016/0042-6822(92)90294-Y; Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405; Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726; Zhang X, 2016, ANTIVIR RES, V127, P20, DOI 10.1016/j.antiviral.2016.01.001; Zhang Y-Z., 2020, SEVERE ACUTE RESP SY; Zheng M, 1990, Zhong Xi Yi Jie He Za Zhi, V10, P39; Zhou ZQ, 2020, J NEUROL, V267, P2179, DOI 10.1007/s00415-020-09929-7	44	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2021	16	6							e0251649	10.1371/journal.pone.0251649	http://dx.doi.org/10.1371/journal.pone.0251649			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RW	34106944	Green Published, gold			2023-01-03	WOS:000664642200016
J	Elsayed, HH; Hassaballa, AS; Ahmed, TA; Gumaa, M; Sharkawy, HY; Moharram, AA				Elsayed, Hany Hasan; Hassaballa, Aly Sherif; Ahmed, Taha Aly; Gumaa, Mohammed; Sharkawy, Hazem Youssef; Moharram, Assem Adel			Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: A systematic review and meta-analysis	PLOS ONE			English	Review							CRITICALLY-ILL PATIENTS; NEW-YORK-CITY; CLINICAL-COURSE; MULTICENTER	Background COVID 19 is the most recent cause of Adult respiratory distress syndrome ARDS. Invasive mechanical ventilation IMV can support gas exchange in patients failing non-invasive ventilation, but its reported outcome is highly variable between countries. We conducted a systematic review and meta-analysis on IMV for COVID-associated ARDS to study its outcome among different countries. Methods CENTRAL, MEDLINE/PubMed, Cochrane Library, and Scopus were systematically searched up to August 8, 2020. Studies reporting five or more patients with end point outcome for severe COVID 19 infection treated with IMV were included. The main outcome assessed was mortality. Baseline, procedural, outcome, and validity data were systematically appraised and pooled with random-effect methods. Subgroup analysis for different countries was performed. Meta-regression for the effect of study timing and patient age and were tested. Publication bias was examined. This trial was registered with PROSPERO under registration number CRD42020190365. Findings Our electronic search retrieved 4770 citations, 103 of which were selected for full-text review. Twenty-one studies with a combined population of 37359 patients with COVID-19 fulfilled the inclusion criteria. From this population, 5800 patients were treated by invasive mechanical ventilation. Out of those, 3301 patients reached an endpoint of ICU discharge or death after invasive mechanical ventilation while the rest were still in the ICU. Mortality from IMV was highly variable among the included studies ranging between 21% and 100%. Random-effect pooled estimates suggested an overall in-hospital mortality risk ratio of 0.70 (95% confidence interval 0.608 to 0.797; I2 = 98%). Subgroup analysis according to country of origin showed homogeneity in the 8 Chinese studies with high pooled mortality risk ratio of 0.97 (I2 = 24%, p = 0.23) (95% CI = 0.94-1.00), similar to Italy with a low pooled mortality risk ratio of 0.26 (95% CI 0.08-0.43) with homogeneity (p = 0.86) while the later larger studies coming from the USA showed pooled estimate mortality risk ratio of 0.60 (95% CI 0.43-0.76) with persistent heterogeneity (I2 = 98%, p<0.001). Meta-regression showed that outcome from IMV improved with time (p<0.001). Age had no statistically significant effect on mortality (p = 0.102). Publication bias was excluded by visualizing the funnel plot of standard error, Egger's test with p = 0.714 and Begg&Mazumdar test with p = 0.334. Interpretation The study included the largest number of patients with outcome findings of IMV in this current pandemic. Our findings showed that the use of IMV for selected COVID 19 patients with severe ARDS carries a high mortality, but outcome has improved over the last few months and in more recent studies. The results should encourage physicians to use this facility when indicated for severely ill COVID-19 patients.	[Elsayed, Hany Hasan] Ain Shams Univ, Thorac Surg Dept ARDS Taskforce, Cairo, Egypt; [Hassaballa, Aly Sherif; Ahmed, Taha Aly; Sharkawy, Hazem Youssef] Ain Shams Univ, Dept Cardiothorac Surg, Cairo, Egypt; [Gumaa, Mohammed] TRUST Res Ctr, Cairo, Egypt; [Moharram, Assem Adel] Ain Shams Univ, Anaethesia Pain & Intens Care Dept, Cairo, Egypt	Egyptian Knowledge Bank (EKB); Ain Shams University; Egyptian Knowledge Bank (EKB); Ain Shams University; Egyptian Knowledge Bank (EKB); Ain Shams University	Elsayed, HH (corresponding author), Ain Shams Univ, Thorac Surg Dept ARDS Taskforce, Cairo, Egypt.	hanyhassan77@hotmail.com	Gumaa, Mohammed/L-8829-2019; Hassaballa, Aly S./A-4840-2019	Gumaa, Mohammed/0000-0003-1658-0129; Hassaballa, Aly S./0000-0002-4996-2476				[Anonymous], 2018, CAS MIX PROGR SUMM S, P2019; Arabi YM, 2019, INT J INFECT DIS, V81, P184, DOI 10.1016/j.ijid.2019.01.041; Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC; Arabi YM, 2017, CRIT CARE MED, V45, P1683, DOI 10.1097/CCM.0000000000002621; Argenziano MG, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1996; Auld SC, 2020, CRIT CARE MED, V48, pE799, DOI 10.1097/CCM.0000000000004457; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dhital R, 2018, J COMMUNITY HOSP INT, V8, P49, DOI 10.1080/20009666.2018.1450592; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003; Gadre SK, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010487; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hur K, 2020, OTOLARYNG HEAD NECK, V163, P170, DOI 10.1177/0194599820929640; Intensive Care National Audit and Research Centre, 2020, ICNARC REPORT COVID; Kato H, 2020, J INFECT CHEMOTHER, V26, P865, DOI 10.1016/j.jiac.2020.05.005; Lim ZJ, 2021, AM J RESP CRIT CARE, V203, P54, DOI 10.1164/rccm.202006-2405OC; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Mitra AR, 2020, CAN MED ASSOC J, V192, pE694, DOI 10.1503/cmaj.200794; Pedersen HP, 2020, DAN MED J, V67; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Soran A, 2000, J SURG RES, V91, P89, DOI 10.1006/jsre.2000.5925; Tobin MJ, 2020, AM J RESP CRIT CARE, V201, P1319, DOI 10.1164/rccm.202004-1076ED; Wang Jiafang, 2020, Nan Fang Yi Ke Da Xue Xue Bao, V40, P337, DOI 10.12122/j.issn.1673-4254.2020.03.07; WHO, 2020, 107 WHO, V2019, P2633; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Xu PP, 2020, THERANOSTICS, V10, P6372, DOI 10.7150/thno.46833; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Yu Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02939-x; Zangrillo A, 2020, CRIT CARE RESUSC, V22, P200; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	36	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2021	16	6							e0252760	10.1371/journal.pone.0252760	http://dx.doi.org/10.1371/journal.pone.0252760			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RB	34086779	Green Published, gold, Green Submitted			2023-01-03	WOS:000664640100128
J	Doidge, C; Lima, E; Lovatt, F; Hudson, C; Kaler, J				Doidge, Charlotte; Lima, Eliana; Lovatt, Fiona; Hudson, Chris; Kaler, Jasmeet			From the other perspective: Behavioural factors associated with UK sheep farmers' attitudes towards antibiotic use and antibiotic resistance	PLOS ONE			English	Article							COGNITIVE-DISSONANCE; ANTIMICROBIAL USE; DAIRY FARMERS; USAGE; LAMENESS; ABORTION; TRAVEL; HABIT; RISK	Research suggests that many sheep farmers continue to carry out traditional antibiotic use practices despite new 'good practice' recommendations. The aim of this study was to group farmers depending on their attitudes around antibiotic use and antibiotic resistance, and determine the behaviours that are associated with the farmers in these groups. In 2017, a flock health survey was sent to British sheep farmers. K-means cluster analysis was used to identify groups of farmers with similar attitudes towards antibiotic use and resistance. A multivariable logistic regression model was built to determine the associations between farmers' past behaviours and their antibiotic attitude group. There were 461 responses. Two groups of farmers were identified based on their antibiotic attitudes. Cluster 1 were defined as the "discordant" group who had positive views of using antibiotics prophylactically and negative views of reducing antibiotic use. Cluster 2 were defined as the "concordant" group who were positive about reducing antibiotic use and had negative views about using antibiotics prophylactically. Using antibiotics in all lambs (OR = 2.689, CI = 1.571, 4.603), using antibiotics in all ewes (OR = 3.388, CI = 1.318, 8.706), always trimming diseased feet over the past three years (OR = 2.487, CI = 1.459, 4.238), not using a computer to record information over the past three years (OR = 1.996, CI = 1.179, 3.381), not changing worming practices over the past three years (OR = 1.879, CI = 1.144, 3.087), and farmers' perceptions that their sheep flock did not make a financial loss in the past three years (OR = 2.088, CI = 1.079, 4.040) were significantly associated with belonging to the discordant group. Talking to their veterinarian about antibiotic use or the frequency of veterinary visits were not associated with antibiotic attitude group. These results suggest that farmers who had attitudes relating to antibiotic use that did not align with current recommendations carried out more traditional practices, which were strengthened by their positive perceptions of profitability.	[Doidge, Charlotte; Lima, Eliana; Lovatt, Fiona; Hudson, Chris; Kaler, Jasmeet] Univ Nottingham, Sch Vet Med & Sci, Sutton, Surrey, England	University of Nottingham	Kaler, J (corresponding author), Univ Nottingham, Sch Vet Med & Sci, Sutton, Surrey, England.	jasmeet.kaler@nottingham.ac.uk	; Hudson, Chris/G-5561-2011	Doidge, Charlotte/0000-0003-1344-7808; Hudson, Chris/0000-0003-4777-062X	Agriculture and Horticulture Development Board [61110063]	Agriculture and Horticulture Development Board	CD was funded by the Agriculture and Horticulture Development Board (61110063) (website: https://ahdb.org.uk/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AHDB, 2018, UK YB 2018 SHEEP; AHDB, RED LAMB LOSS BETT R; AHDB, MED HUB SHEEP CATTLE; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Bem D.J., 1972, ADV EXP SOC PSYCHOL, V6, P1, DOI DOI 10.1016/S0065-2601(08)60024-6; Best CM, 2020, PREV VET MED, V181, DOI 10.1016/j.prevetmed.2020.105064; Bourdieu P., 1997, ED CULTURE EC SOC, P46; Burton RJF, 2008, SOCIOL RURALIS, V48, P16, DOI 10.1111/j.1467-9523.2008.00452.x; Butler D, 2016, SOCIOL RURALIS, V56, P513, DOI 10.1111/soru.12103; Clements RH, 2014, VET REC, V175, P225, DOI 10.1136/vr.102161; Clifton R, 2020, J RURAL STUD, V74, P67, DOI 10.1016/j.jrurstud.2019.11.014; de Leeuw RNH, 2008, ADDICTION, V103, P1713, DOI 10.1111/j.1360-0443.2008.02293.x; De Vaus D, 2013, SURVEYS SOCIAL RES, V5th; De Vos J, 2020, TRANSPORT RES A-POL, V138, P525, DOI 10.1016/j.tra.2020.06.014; DEFRA, FARM STAT FIN LAND U; DEFRA, FARM BUS INC TYP FAR; DEFRA, 2014, SHEEP GOATS TYP COMB; Doidge C, 2021, PREV VET MED, V186, DOI 10.1016/j.prevetmed.2020.105226; Doidge C, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00524; Doidge C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213855; Dunn H, 2018, WESTERN J NURS RES, V40, P1658, DOI 10.1177/0193945917707705; Essig A, 2015, CURR CLIN MICROBIOL, V2, P22, DOI 10.1007/s40588-015-0014-2; Etienne J., 2017, EFSA Supporting Publications, V14, pEN, DOI 10.2903/sp.efsa.2017.en-1183; Festinger L., 1957, THEORY COGNITIVE DIS, Vxi; Gama H, 2009, PHARMACOEPIDEM DR S, V18, P175, DOI 10.1002/pds.1703; Gardner B., 2019, OXFORD RES ENCY PSYC, DOI [10.1093/acrefore/9780190236557.013.129, DOI 10.1093/ACREFORE/9780190236557.013.129, https://doi.org/10.1093/acrefore/9780190236557.013.129]; Gardner B, 2019, BRIT J HEALTH PSYCH, V24, P241, DOI 10.1111/bjhp.12369; Goff DA, 2017, LANCET INFECT DIS, V17, pE56, DOI 10.1016/S1473-3099(16)30386-3; Gonzalez SM, 2010, PREV VET MED, V95, P50, DOI 10.1016/j.prevetmed.2010.03.004; Gorton M, 2008, J RURAL STUD, V24, P322, DOI 10.1016/j.jrurstud.2007.10.001; Green L, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00161; Guillem EE, 2012, J ENVIRON MANAGE, V110, P226, DOI 10.1016/j.jenvman.2012.06.020; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Harmon-Jones E, 2002, PERS SOC PSYCHOL B, V28, P711, DOI 10.1177/0146167202289001; Hidano A, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00137; Jager W., 2003, HUMAN DECISION MAKIN; Jermias J, 2001, ACCOUNT ORG SOC, V26, P141, DOI 10.1016/S0361-3682(00)00008-8; Jones Christopher R, 2019, Front Psychol, V10, P2701, DOI 10.3389/fpsyg.2019.02701; Jones PJ, 2015, PREV VET MED, V121, P30, DOI 10.1016/j.prevetmed.2015.05.010; Kaler J, 2010, J VET INTERN MED, V24, P420, DOI 10.1111/j.1939-1676.2009.0450.x; Kaler J, 2009, PREV VET MED, V92, P52, DOI 10.1016/j.prevetmed.2009.08.001; Kaler J, 2019, PREV VET MED, V170, DOI 10.1016/j.prevetmed.2019.104715; Kramer T, 2017, PREV VET MED, V147, P142, DOI 10.1016/j.prevetmed.2017.08.023; Kroesen M, 2017, TRANSPORT RES A-POL, V101, P190, DOI 10.1016/j.tra.2017.05.013; Kurz T, 2015, WIRES CLIM CHANGE, V6, P113, DOI 10.1002/wcc.327; Lally P, 2010, EUR J SOC PSYCHOL, V40, P998, DOI 10.1002/ejsp.674; Learmount J, 2016, VET PARASITOL, V226, P116, DOI 10.1016/j.vetpar.2016.06.037; Lima E, 2019, ANIMAL, V13, P2630, DOI 10.1017/S1751731119001058; Lima E, 2020, PREV VET MED, V174, DOI 10.1016/j.prevetmed.2019.104851; Lokhorst AM, 2011, APPL PSYCHOL-INT REV, V60, P337, DOI 10.1111/j.1464-0597.2011.00438.x; Longbottom D, 2013, VET J, V195, P257, DOI 10.1016/j.tvjl.2012.06.018; McDougall S, 2017, NEW ZEAL VET J, V65, P84, DOI 10.1080/00480169.2016.1246214; O'Neill J., 2016, REV ANTIMICROBIAL RE; Olson M.A., 2008, ATTITUDES ATTITUDE C; Oyserman D, 2010, COUNS PSYCHOL, V38, P1001, DOI 10.1177/0011000010374775; Prosser NS, 2019, PREV VET MED, V173, DOI 10.1016/j.prevetmed.2019.104801; RCVS, COD PROF COND VET SU; Red Tractor Assurance, BEEF LAMB STAND 2020; Red Tractor Assurance, 2018, COD REC WELF LIV; Ritter C, 2017, J DAIRY SCI, V100, P3329, DOI 10.3168/jds.2016-11977; RUMA, TARG TASK FORC REP 2; *RUMA, 2019, COL IS GOLD; Scherpenzeel CGM, 2016, J DAIRY SCI, V99, P8259, DOI 10.3168/jds.2016-11349; Shortall O, 2018, SOCIOL RURALIS, V58, P583, DOI 10.1111/soru.12205; Stubbings L., 2012, TECHNICAL MANUAL VET; Swinkels JM, 2015, J DAIRY SCI, V98, P2369, DOI 10.3168/jds.2014-8488; van der Zwaluw CS, 2013, ADDICT BEHAV, V38, P2110, DOI 10.1016/j.addbeh.2013.01.012; van Dijk WFA, 2016, LAND USE POLICY, V59, P207, DOI 10.1016/j.landusepol.2016.09.003; van Rijn M, 2019, PUBLIC UNDERST SCI, V28, P486, DOI 10.1177/0963662518823701; Velde FV, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00255; VMD, UK VET ANT RES SAL S; VMD, UK VARSS 2019 SUPPL; Whitmarsh L., 2012, ENGAGING PUBLIC CLIM, DOI 10.4324/9781849775243; Winter JR, 2015, PREV VET MED, V122, P121, DOI 10.1016/j.prevetmed.2015.09.014	74	1	1	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2021	16	5							e0251439	10.1371/journal.pone.0251439	http://dx.doi.org/10.1371/journal.pone.0251439			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SW6PJ	34043635	Green Published, gold			2023-01-03	WOS:000664635700021
J	Unoki, T; Sakuramoto, H; Uemura, S; Tsujimoto, T; Yamaguchi, T; Shiba, Y; Hino, M; Kuribara, T; Fukuda, Y; Nagao, T; Kitayama, M; Shirasaka, M; Haruna, J; Satoi, Y; Masuda, Y				Unoki, Takeshi; Sakuramoto, Hideaki; Uemura, Sakura; Tsujimoto, Takahiro; Yamaguchi, Takako; Shiba, Yuko; Hino, Mayumi; Kuribara, Tomoki; Fukuda, Yuko; Nagao, Takumi; Kitayama, Mio; Shirasaka, Masako; Haruna, Junpei; Satoi, Yosuke; Masuda, Yoshiki		SMAP-HoPe Study Project	Prevalence of and risk factors for post-intensive care syndrome: Multicenter study of patients living at home after treatment in 12 Japanese intensive care units, SMAP-HoPe study	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; CRITICAL ILLNESS; HOSPITAL ANXIETY; DEPRESSION; SURVIVORS; SYMPTOMS; SCALE; RELIABILITY; VALIDITY	Few studies have examined the epidemiology of post-intensive care syndrome in Japan. This study investigated the mental health and quality of life of patients living at home in Japan after intensive care unit (ICU) discharge. Additionally, we examined whether unplanned admission to the ICU was associated with more severe post-traumatic stress disorder (PTSD), anxiety, and depressive symptoms. An ambidirectional cohort study was conducted at 12 ICUs in Japan. Patients who stayed in the ICU for > 3 nights and were living at home for 1 year afterward were included. One year after ICU discharge, we retrospectively screened patients and performed a mail survey on a monthly basis, including the Impact of Event Scale-Revised (IER-S), the Hospital Anxiety Depression Scale (HADS), and the EuroQOL-5 Dimension (EQ-5D-L) questionnaires. Patients' characteristics, delirium and coma status, drugs used, and ICU and hospital length of stay were assessed from medical records. Descriptive statistics and multilevel linear regression modeling were used to examine our hypothesis. Among 7,030 discharged patients, 854 patients were surveyed by mail. Of these, 778 patients responded (response rate = 91.1%). The data from 754 patients were analyzed. The median IES-R score was 3 (interquartile range [IQR] = 19), and the prevalence of suspected PTSD was 6.0%. The median HADS anxiety score was 4.00 (IQR = 1.176.00), and the prevalence of anxiety was 16.6%. The median HADS depression score was 5 (IQR = 28), and the prevalence of depression was 28.1%. EQ-5D-L scores were lower in our participants than in the sex- and age-matched Japanese population. Unplanned admission was an independent risk factor for more severe PTSD, anxiety, and depressive symptoms. Approximately one-third of patients in the general ICU population experienced mental health issues one year after ICU discharge. Unplanned admission was an independent predictor for more severe PTSD symptoms.	[Unoki, Takeshi] Sapporo City Univ, Sch Nursing, Dept Acute & Crit Care Nursing, Sapporo, Hokkaido, Japan; [Sakuramoto, Hideaki] Ibaraki Christian Univ, Coll Nursing, Dept Adult Hlth Nursing, Hitachi, Ibaraki, Japan; [Uemura, Sakura] Osaka City Gen Hosp, Emergency & Crit Care Med Ctr, Osaka, Japan; [Tsujimoto, Takahiro] Nara Med Univ Hosp, Nursing Practice & Career Support Ctr, Kashihara, Nara, Japan; [Yamaguchi, Takako] Nippon Med Sch, Musashikosugi Hosp, Intens Care Unit, Kawasaki, Kanagawa, Japan; [Shiba, Yuko] Univ Tsukuba Hosp, Intens Care Unit, Tsukuba, Ibaraki, Japan; [Hino, Mayumi] Tohoku Med & Pharmaceut Univ Hosp, Intens Care Unit, Sendai, Miyagi, Japan; [Kuribara, Tomoki] Japanese Red Cross Maebashi Hosp, Adv Emergency Med Serv Ctr, Intens Care Unit, Maebashi, Gumma, Japan; [Fukuda, Yuko] Jichi Med Univ Hosp, Intens Care Unit, Yakushiji Shimotsuke, Tochigi, Japan; [Nagao, Takumi] Sakakibara Heart Inst, Intens Care Unit, Fuchu, Tokyo, Japan; [Kitayama, Mio] Kanazawa Med Univ Hosp, Heart Ctr, Nursing Dept, Uchinada, Ishikawa, Japan; [Shirasaka, Masako] Japanese Red Cross Fukuoka Hosp, Intens Care Unit, Fukuoka, Japan; [Shirasaka, Masako] Japanese Red Cross Fukuoka Hosp, Cardiac Care Unit, Fukuoka, Japan; [Haruna, Junpei] Sapporo Med Univ Hosp, Intens Care Unit, Sapporo, Hokkaido, Japan; [Satoi, Yosuke] Naha City Hosp, Intens Care Unit, Naha, Okinawa, Japan; [Masuda, Yoshiki] Sapporo Med Univ Hosp, Dept Intens Care Med, Sapporo, Hokkaido, Japan	Osaka City General Hospital; Nara Medical University; Nippon Medical School; University of Tsukuba; Tohoku Medical & Pharmaceutical University; Maebashi Red Cross Hospital; Kanazawa Medical University; Sapporo Medical University; Sapporo Medical University	Unoki, T (corresponding author), Sapporo City Univ, Sch Nursing, Dept Acute & Crit Care Nursing, Sapporo, Hokkaido, Japan.	t.unoki@scu.ac.jp		Unoki, Takeshi/0000-0002-7778-4355	JSPS KAKENHI [19K10929]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	TU received JSPS KAKENHI Grant Number 19K10929. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal TM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242849; Alexandersen I, 2019, J CLIN NURS, V28, P3991, DOI 10.1111/jocn.14980; Hosseini SMA, 2021, NURS CRIT CARE, V26, P102, DOI 10.1111/nicc.12532; Asnaani A, 2017, CURR OPIN PSYCHOL, V14, P96, DOI 10.1016/j.copsyc.2016.12.005; Asukai N, 2002, J NERV MENT DIS, V190, P175, DOI 10.1097/00005053-200203000-00006; Australian and New Zealand Intensive Care Society, 2019, CTR OUTC RES EV 2019; Barreto BB, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2678-0; Bell Melanie L, 2016, BMC Res Notes, V9, P479; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Brown SM, 2019, ANN AM THORAC SOC, V16, P947, DOI 10.1513/AnnalsATS.201812-913FR; Cummings P, 2013, JAMA PEDIATR, V167, P656, DOI 10.1001/jamapediatrics.2013.1329; Deja M, 2006, CRIT CARE, V10, DOI 10.1186/cc5070; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Gerth AMJ, 2019, ANAESTHESIA, V74, P100, DOI 10.1111/anae.14444; Hatch R, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2223-6; Hatch R, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0319-3; Hatta H., 1998, JAPANESE J PSYCHOSOM, V38, P309; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hosey MM, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2759-0; Hosey MM, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2553-z; Iljazi A, 2020, NEUROL SCI, V41, P2737, DOI 10.1007/s10072-020-04458-7; Inoue S, 2019, ACUTE MED SURG, V6, P233, DOI 10.1002/ams2.415; Intensive Care National Audit and Research Centre, KEY STAT CAS MIX PRO; Irie H, 2020, J CRIT CARE, V55, P86, DOI 10.1016/j.jcrc.2019.09.004; Jackson JC, 2014, LANCET RESP MED, V2, P369, DOI 10.1016/S2213-2600(14)70051-7; Jensen JF, 2016, INTENS CARE MED, V42, P1733, DOI 10.1007/s00134-016-4522-1; Jutte JE, 2015, J CRIT CARE, V30, P793, DOI 10.1016/j.jcrc.2015.04.006; Kalfon P, 2019, INTENS CARE MED, V45, P223, DOI 10.1007/s00134-018-05511-y; Kawakami D, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03501-z; Kerckhoffs MC, 2019, INTENS CARE MED, V45, P806, DOI 10.1007/s00134-019-05583-4; Koenen KC, 2017, PSYCHOL MED, V47, P2260, DOI 10.1017/S0033291717000708; Kok L, 2018, CRIT CARE MED, V46, P1673, DOI 10.1097/CCM.0000000000003300; Latif A, 2017, J PAK MED ASSOC, V67, P884; Lee M, 2020, AUST CRIT CARE, V33, P287, DOI 10.1016/j.aucc.2019.10.004; McCartney E, 2020, CRIT CARE NURS CLIN, V32, P313, DOI 10.1016/j.cnc.2020.02.011; McGiffin JN, 2016, REHABIL PSYCHOL, V61, P120, DOI 10.1037/rep0000073; Myhren H, 2010, CRIT CARE, V14, DOI 10.1186/cc8870; Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75; Nikayin S, 2016, GEN HOSP PSYCHIAT, V43, P23, DOI 10.1016/j.genhosppsych.2016.08.005; Patel MB, 2016, AM J RESP CRIT CARE, V193, P1373, DOI 10.1164/rccm.201506-1158OC; Rabiee A, 2016, CRIT CARE MED, V44, P1744, DOI 10.1097/CCM.0000000000001811; Righy C, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2489-3; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shima N, 2020, ACUTE MED SURG, V7, DOI 10.1002/ams2.557; Shiroiwa T, 2016, VALUE HEALTH, V19, P648, DOI 10.1016/j.jval.2016.03.1834; Shiroiwa T, 2016, QUAL LIFE RES, V25, P707, DOI 10.1007/s11136-015-1108-2; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Teixeira C., 2021, CHEST, DOI [10.1016/j.chest.2021.02.034, DOI 10.1016/J.CHEST.2021.02.034]; Tripathy S, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-02632-x; United Nations, 2017, 2017 WORLD POP AG; Visser-Meily JMA, 2013, CEREBROVASC DIS, V36, P126, DOI 10.1159/000353642; Wade DM, 2019, JAMA-J AM MED ASSOC, V321, P665, DOI 10.1001/jama.2019.0073; Wang S, 2017, J HOSP MED, V12, P831, DOI 10.12788/jhm.2827; Weiss Daniel S., 1997, P399; Wu K K, 2018, East Asian Arch Psychiatry, V28, P39; Yoshino Y, 2021, NURS OPEN, V8, P1436, DOI 10.1002/nop2.760; Zampieri FG., 2017, REV BRAS TER INTENSI, V29; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	58	4	4	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2021	16	5							e0252167	10.1371/journal.pone.0252167	http://dx.doi.org/10.1371/journal.pone.0252167			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6PJ	34043682	gold, Green Published			2023-01-03	WOS:000664635700063
J	Zhang, J; Wang, XJ; Wu, LJ; Yang, L; Yang, YT; Zhang, D; Hong, J; Li, XY; Dong, XQ; Guo, XC; Han, R; Ma, XP				Zhang, Ji; Wang, Xue-jun; Wu, Li-jie; Yang, Ling; Yang, Yan-ting; Zhang, Dan; Hong, Jue; Li, Xi-ying; Dong, Xiao-qing; Guo, Xiao-cong; Han, Rong; Ma, Xiaopeng			Herb-partitioned moxibustion alleviates colonic inflammation in Crohn's disease rats by inhibiting hyperactivation of the NLRP3 inflammasome via regulation of the P2X7R-Pannexin-1 signaling pathway	PLOS ONE			English	Article							NF-KAPPA-B; P2X7 RECEPTOR; PANNEXIN-1 CHANNELS; ULCERATIVE-COLITIS; A20 EXPRESSION; MOUSE MODEL; CELLS; ACTIVATION; BLOCKADE	Crohn's disease is a chronic inflammatory bowel disease and the NLRP3 inflammasome plays an important role in Crohn's disease. Previous studies have shown that Herb-partitioned moxibustion treating (at Qihai (CV 6) and Tianshu (ST 25)) prevented the excessive activation of the NLRP3 inflammasome and repaired damaged colonic mucosa in Crohn's disease. However, the mechanism by which Herb-partitioned moxibustion (at CV 6 and ST 25) regulates NLRP3 remains unclear. In this study, we treated Crohn's disease rats with herb-partitioned moxibustion (at CV 6 and ST 25) to investigate the mechanism by which Herb-partitioned moxibustion regulates the colonic NLRP3 inflammasome by observing colon length, the colon macroscopic damage indexes, and the expression of ATP, P2X7R, Pannexin-1, NF-kappa Bp65, NLRP3, ASC, caspase-1, IL-1 beta and IL-18 in the colon in Crohn's disease. Here, this study shows that herb-partitioned moxibustion (at CV 6 and ST 25) can reduce colon macroscopic damage indexes and colon histopathological scores, alleviate colon shortening and block the abnormal activation of the NLRP3 inflammasome by inhibiting the ATP content and the expression of P2X7R, Pannexin-1 and NF-kappa Bp65, thereby reducing the release of the downstream inflammatory cytokine IL-1 beta and ultimately suppressing colonic inflammation in Crohn's disease rats. This study for the first time identifies the mechanism by which herb-partitioned moxibustion (at CV 6 and ST 25) may inhibit the abnormal activation of the NLRP3 inflammasome by inhibiting the P2X7R-Pannexin-1 signaling pathway in Crohn's disease rats.	[Zhang, Ji; Wang, Xue-jun; Wu, Li-jie; Li, Xi-ying; Dong, Xiao-qing; Guo, Xiao-cong; Han, Rong; Ma, Xiaopeng] Shanghai Univ Tradit Chinese Med, Yueyang Clin Med Sch, Shanghai, Peoples R China; [Wu, Li-jie] Zhejiang Prov Hosp Tradit Chinese Med, Acupuncture & Moxibust Dept, Hangzhou, Zhejiang, Peoples R China; [Yang, Ling; Yang, Yan-ting; Zhang, Dan; Hong, Jue; Ma, Xiaopeng] Shanghai Univ Tradit Chinese Med, Key Lab Acupuncture Moxibust & Immunol, Shanghai Res Inst Acupuncture & Meridian, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine; Zhejiang Chinese Medical University; Shanghai University of Traditional Chinese Medicine	Ma, XP (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Clin Med Sch, Shanghai, Peoples R China.; Ma, XP (corresponding author), Shanghai Univ Tradit Chinese Med, Key Lab Acupuncture Moxibust & Immunol, Shanghai Res Inst Acupuncture & Meridian, Shanghai, Peoples R China.	pengpengma@163.com		ma, xiaopeng/0000-0002-9532-4870	National Natural Science Foundation of China [81674073, 81273843]; Natural Science Foundation of Shanghai [20ZR1453000]; Training Project for Outstanding Discipline Leaders of Shanghai Municipal Commission of Health and Family Planning [2017BR047]; National Key Basic Research Program of China (973 Program) [2015CB554501]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Training Project for Outstanding Discipline Leaders of Shanghai Municipal Commission of Health and Family Planning; National Key Basic Research Program of China (973 Program)(National Basic Research Program of China)	This research was supported by the National Natural Science Foundation of China, No. 81674073 and 81273843, Natural Science Foundation of Shanghai, No. 20ZR1453000, Training Project for Outstanding Discipline Leaders of Shanghai Municipal Commission of Health and Family Planning, No. 2017BR047 and National Key Basic Research Program of China (973 Program), No. 2015CB554501.	Adinolfi E, 2018, BIOCHEM PHARMACOL, V151, P234, DOI 10.1016/j.bcp.2017.12.021; Arbore G, 2016, SCIENCE, V352, DOI 10.1126/science.aad1210; Argollo M, 2019, CURR DRUG TARGETS, V20, P1327, DOI 10.2174/1389450120666190320110809; Bartlett R, 2014, PHARMACOL REV, V66, P638, DOI 10.1124/pr.113.008003; Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9; Cheifetz AS, 2013, JAMA-J AM MED ASSOC, V309, P2150, DOI 10.1001/jama.2013.4466; Ciccocioppo R, 2019, JGH OPEN, V3, P249, DOI 10.1002/jgh3.12141; Dassopoulos T, 2012, GASTROENTEROL CLIN N, V41, P393, DOI 10.1016/j.gtc.2012.01.004; Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020; Diezmos EF, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00865; Diezmos EF, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00311; Dotlacil V, 2020, EUR J PEDIATR SURG, V30, P27, DOI 10.1055/s-0039-1697909; Elia PP, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/936193; Ferrero Maria E, 2009, Recent Pat Antiinfect Drug Discov, V4, P108; Gajendran M, 2018, DM-DIS MON, V64, P20, DOI 10.1016/j.disamonth.2017.07.001; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gombault A, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00414; Han CL, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1139-z; Inami A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082371; Kihara N, 2003, GUT, V52, P713, DOI 10.1136/gut.52.5.713; Kirchgesner J, 2018, GASTROENTEROLOGY, V155, P337, DOI 10.1053/j.gastro.2018.04.012; Kirk RGW, 2018, SCI TECHNOL HUM VAL, V43, P622, DOI 10.1177/0162243917726579; Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108; Kurashima Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2023; Lazaridis LD, 2017, DIGEST DIS SCI, V62, P2348, DOI 10.1007/s10620-017-4609-8; Li Shuang, 2019, Zhongguo Zhong Yao Za Zhi, V44, P2433, DOI 10.19540/j.cnki.cjcmm.20190221.004; Li YQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15836-2; Lightner Amy L, 2019, Curr Gastroenterol Rep, V21, P16, DOI 10.1007/s11894-019-0672-y; Lim KH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03035-2; Liu YH, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00084; Mao LM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02566; Mao LM, 2018, J CLIN INVEST, V128, P1793, DOI 10.1172/JCI98642; Marques CC, 2014, BBA-MOL BASIS DIS, V1842, P65, DOI 10.1016/j.bbadis.2013.10.012; Mehta N, 2014, BIOORGAN MED CHEM, V22, P54, DOI 10.1016/j.bmc.2013.10.054; Mehto S, 2019, MOL CELL, V73, P429, DOI 10.1016/j.molcel.2018.11.018; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; Mousseau M, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aas9846; Nakao S, 2017, J ANUS RECTUM COLON, V1, P56, DOI 10.23922/jarc.2016-006; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Ozen M, 2020, PEDIATR RES, V87, P463, DOI 10.1038/s41390-019-0557-7; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Qiao Y, 2012, FEBS LETT, V586, P1022, DOI 10.1016/j.febslet.2012.02.045; Silva PARE, 2021, CLIN SCI, V135, P687, DOI 10.1042/CS20201419; Shen XY, 2006, COMPLEMENT THER MED, V14, P213, DOI 10.1016/j.ctim.2005.09.003; Shi Y., 2003, JIANGXI J TCM, V34, P16; Shi Y., 2011, SHANGHAI J TCM, V45, P45; Shi Y, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109149; Shteingart S, 2009, GUT, V58, P790, DOI 10.1136/gut.2008.153981; Sun Yi, 2019, Zhen Ci Yan Jiu, V44, P1, DOI 10.13702/j.1000-0607.180512; Torres J, 2017, LANCET, V389, P1741, DOI 10.1016/S0140-6736(16)31711-1; Tourkochristou E, 2019, WORLD J GASTROENTERO, V25, P4796, DOI 10.3748/wjg.v25.i33.4796; Vavricka SR, 2015, INFLAMM BOWEL DIS, V21, P1982, DOI 10.1097/MIB.0000000000000392; WALLACE JL, 1992, GASTROENTEROLOGY, V102, P18, DOI 10.1016/0016-5085(92)91779-4; Wang Hong-Yun, 2014, Zhong Yao Cai, V37, P1391; Wang XM, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/949065; Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242; Wu LY, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00175; Xu J, 2018, J CELL PHYSIOL, V233, P2075, DOI 10.1002/jcp.25906; Yao YK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15402; Yu Y, 2019, CYTOKINE, V119, P175, DOI 10.1016/j.cyto.2019.03.019; Zhang Chuan-Ying, 2018, Zhen Ci Yan Jiu, V43, P687, DOI 10.13702/j.1000-0607.180229; Zhang D, 2018, WORLD J GASTROENTERO, V24, P3384, DOI 10.3748/wjg.v24.i30.3384; Zhang J, 2019, SHANGHAI ZHEN JIU ZA, V38, P119, DOI DOI 10.3969/j.issn.1004-5589.2019.01.011; Zhao JM, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/3405146; Zhou J, 2019, WORLD J GASTROENTERO, V25, P2071, DOI 10.3748/wjg.v25.i17.2071; Zhou JT, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7956274	66	2	2	8	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2021	16	5							e0252334	10.1371/journal.pone.0252334	http://dx.doi.org/10.1371/journal.pone.0252334			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6PJ	34043726	gold, Green Published			2023-01-03	WOS:000664635700089
J	Chevance, G; Baretta, D; Heino, M; Perski, O; Olthof, M; Klasnja, P; Hekler, E; Godino, J				Chevance, Guillaume; Baretta, Dario; Heino, Matti; Perski, Olga; Olthof, Merlijn; Klasnja, Predrag; Hekler, Eric; Godino, Job			Characterizing and predicting person-specific, day-to-day, fluctuations in walking behavior	PLOS ONE			English	Article							TIME ADAPTIVE INTERVENTIONS; DAILY PHYSICAL-ACTIVITY; PATTERNS; DISEASE; MODELS; SERIES	Despite the positive health effect of physical activity, one third of the world's population is estimated to be insufficiently active. Prior research has mainly investigated physical activity on an aggregate level over short periods of time, e.g., during 3 to 7 days at baseline and a few months later, post-intervention. To develop effective interventions, we need a better understanding of the temporal dynamics of physical activity. We proposed here an approach to studying walking behavior at "high-resolution" and by capturing the idiographic and day-to-day changes in walking behavior. We analyzed daily step count among 151 young adults with overweight or obesity who had worn an accelerometer for an average of 226 days (similar to 25,000 observations). We then used a recursive partitioning algorithm to characterize patterns of change, here sudden behavioral gains and losses, over the course of the study. These behavioral gains or losses were defined as a 30% increase or reduction in steps relative to each participants' median level of steps lasting at least 7 days. After the identification of gains and losses, fluctuation intensity in steps from each participant's individual time series was computed with a dynamic complexity algorithm to identify potential early warning signals of sudden gains or losses. Results revealed that walking behavior change exhibits discontinuous changes that can be described as sudden gains and losses. On average, participants experienced six sudden gains or losses over the study. We also observed a significant and positive association between critical fluctuations in walking behavior, a form of early warning signals, and the subsequent occurrence of sudden behavioral losses in the next days. Altogether, this study suggests that walking behavior could be well understood under a dynamic paradigm. Results also provide support for the development of "just-in-time adaptive" behavioral interventions based on the detection of early warning signals for sudden behavioral losses.	[Chevance, Guillaume] Barcelona Inst Global Hlth, ISGlobal, Barcelona, Spain; [Chevance, Guillaume; Hekler, Eric; Godino, Job] Univ Calif San Diego, Ctr Wireless & Populat Hlth Syst, Qualcomm Inst, San Diego, CA 92103 USA; [Chevance, Guillaume; Hekler, Eric; Godino, Job] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA; [Chevance, Guillaume; Hekler, Eric; Godino, Job] Univ Calif San Diego, Exercise & Phys Act Resource Ctr, San Diego, CA 92103 USA; [Heino, Matti] Univ Helsinki, Fac Social Sci, Helsinki, Finland; [Perski, Olga] UCL, Dept Behav Sci & Hlth, London, England; [Olthof, Merlijn] Radboud Univ Nijmegen, Inst Behav Sci, Nijmegen, Netherlands; [Klasnja, Predrag] Univ Michigan, Sch Informat, Ann Arbor, MI 48109 USA	ISGlobal; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Helsinki; University of London; University College London; Radboud University Nijmegen; University of Michigan System; University of Michigan	Chevance, G (corresponding author), Barcelona Inst Global Hlth, ISGlobal, Barcelona, Spain.; Chevance, G (corresponding author), Univ Calif San Diego, Ctr Wireless & Populat Hlth Syst, Qualcomm Inst, San Diego, CA 92103 USA.; Chevance, G (corresponding author), Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA.; Chevance, G (corresponding author), Univ Calif San Diego, Exercise & Phys Act Resource Ctr, San Diego, CA 92103 USA.	guillaume.chevance@isglobal.org		Perski, Olga/0000-0003-3285-3174; Heino, Matti/0000-0003-0094-2455; Hekler, Eric B/0000-0002-7434-0775; Baretta, Dario/0000-0002-2866-3290	National Heart, Lung, and Blood Institute (NHLBI) [R01HL136769]; Spanish Ministry of Science and Innovation and State Research Agency through the "Centro de Excelencia Severo Ochoa 2019-2023" Program [CEX2018-000806S]; Generalitat de Catalunya through the CERCA Program	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Spanish Ministry of Science and Innovation and State Research Agency through the "Centro de Excelencia Severo Ochoa 2019-2023" Program(Ministry of Science and Innovation, Spain (MICINN)); Generalitat de Catalunya through the CERCA Program	The present research was funded by a grant from the National Heart, Lung, and Blood Institute (NHLBI); R01HL136769 awarded to the last author (JG). The first author (GC) acknowledges support from the Spanish Ministry of Science and Innovation and State Research Agency through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018-000806S), and support from the Generalitat de Catalunya through the CERCA Program.	Ashwin P, 2012, PHILOS T R SOC A, V370, P1166, DOI 10.1098/rsta.2011.0306; Bai J, 2003, J APPL ECONOMET, V18, P1, DOI 10.1002/jae.659; Bardi U., 2020, COLLAPSE GUIDE OTHER; Barr DJ, 2013, J MEM LANG, V68, P255, DOI 10.1016/j.jml.2012.11.001; Bates D., 2015, J STAT SOFTW, V67, DOI [10.18637/jss.v067.i01, DOI 10.18637/JSS.V067.I01, DOI 10.18637/jss.v067.i01]; Bernard P, 2021, SPORTS MED, V51, P1041, DOI 10.1007/s40279-021-01439-4; Cavill N, 2020, J PUBLIC HEALTH RES, V9, P278, DOI 10.4081/jphr.2020.1759; Chevance G, 2021, HEALTH PSYCHOL, V40, P30, DOI 10.1037/hea0001044; Chevance G, 2021, TRANSL BEHAV MED, V11, P676, DOI 10.1093/tbm/ibaa026; Conroy DE, 2015, HEALTH PSYCHOL, V34, P653, DOI 10.1037/hea0000157; de Mooij SMM, 2020, COMPUT METH PROG BIO, V193, DOI 10.1016/j.cmpb.2020.105448; Dunton GF, 2018, JAMA-J AM MED ASSOC, V320, P639, DOI 10.1001/jama.2018.6621; Ekkekakis P., 2016, SPORT EXERCISE PSYCH; Feehan LM, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/10527; Gal R, 2018, SPORTS MED-OPEN, V4, DOI 10.1186/s40798-018-0157-9; GOMEZ V, 1994, J AM STAT ASSOC, V89, P611, DOI 10.2307/2290864; Guastello SJ., 1999, NONLINEAR DYN PSYCHO, V3, P259; Guthold R, 2018, LANCET GLOB HEALTH, V6, pE1077, DOI [10.1016/S2214-109X(18)30357-7, 10.1016/s2214-109x(18)30357-7]; Haas E, 2002, J CLIN PSYCHOL, V58, P1157, DOI 10.1002/jclp.10044; Haken H., 1978, SPRINGER SERIES SYNE, V2nd; Hardeman W, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/s12966-019-0792-7; Hayes AM, 2007, CLIN PSYCHOL REV, V27, P715, DOI 10.1016/j.cpr.2007.01.008; Heino M. T. J., STUDYING BEHAV CHANG; Hekler EB, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8622; Hekler EB, 2016, AM J PREV MED, V51, P825, DOI 10.1016/j.amepre.2016.06.013; Helmich MA, 2020, J CONSULT CLIN PSYCH, V88, P119, DOI 10.1037/ccp0000469; Hooker SA, 2020, J PHYS ACT HEALTH, V17, P45, DOI 10.1123/jpah.2019-0207; Kelly MP, 2016, PUBLIC HEALTH, V136, P109, DOI 10.1016/j.puhe.2016.03.030; Klasnja P, 2019, ANN BEHAV MED, V53, P573, DOI 10.1093/abm/kay067; Korinek EV, 2018, J BEHAV MED, V41, P74, DOI 10.1007/s10865-017-9878-3; Kwasnicka D, 2016, HEALTH PSYCHOL REV, V10, P277, DOI 10.1080/17437199.2016.1151372; Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9; Maher JP, 2016, J SPORT EXERCISE PSY, V38, P423, DOI 10.1123/jsep.2016-0058; Matthews CE, 2002, MED SCI SPORT EXER, V34, P1376, DOI 10.1097/00005768-200208000-00021; Molenaar P. C. M., 2004, MEASUREMENT, V2, P201, DOI [DOI 10.1207/S15366359MEA0204_1, 10.1207/s15366359mea0204_1]; Molenaar PCM, 2009, CURR DIR PSYCHOL SCI, V18, P112, DOI 10.1111/j.1467-8721.2009.01619.x; Morabia A, 2010, PREV MED, V51, P449, DOI 10.1016/j.ypmed.2010.11.004; Moritz S, 2015, ARXIV151003924; Murray JM, 2017, SOC SCI MED, V192, P125, DOI 10.1016/j.socscimed.2017.09.021; Nahum-Shani I, 2018, ANN BEHAV MED, V52, P446, DOI 10.1007/s12160-016-9830-8; Nahum-Shani I, 2015, HEALTH PSYCHOL, V34, P1209, DOI 10.1037/hea0000306; O'Driscoll R, 2020, BRIT J SPORT MED, V54, P332, DOI 10.1136/bjsports-2018-099643; Olthof M, 2020, CLIN PSYCHOL SCI, V8, P25, DOI 10.1177/2167702619865969; Pedersen ESL, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3890-3; Post P., 2013, J CLIMATOLOGY HINDAW, V2013; R Core Team Rf.., 2013, R LANG ENV STAT COMP; Ram N., 2014, ROUTLEDGE HDB ONLINE; Resnicow K, 2006, INT J BEHAV NUTR PHY, V3, DOI 10.1186/1479-5868-3-25; Resnicow K, 2008, AM J PUBLIC HEALTH, V98, P1382, DOI 10.2105/AJPH.2007.129460; Scheffer M, 2012, SCIENCE, V338, P344, DOI 10.1126/science.1225244; Scheffer M, 2009, NATURE, V461, P53, DOI 10.1038/nature08227; Schiepek G, 2010, BIOL CYBERN, V102, P197, DOI 10.1007/s00422-009-0362-1; Scholz U, 2019, APPL PSYCHOL-HLTH WE, V11, P173, DOI 10.1111/aphw.12156; Steffen W, 2018, P NATL ACAD SCI USA, V115, P8252, DOI 10.1073/pnas.1810141115; ten Broeke P, 2020, P NATL ACAD SCI USA, V117, P14883, DOI 10.1073/pnas.2001284117; Therneau T, 2019, **DATA OBJECT**; Vallacher RR, 2002, PERS SOC PSYCHOL REV, V6, P264, DOI 10.1207/S15327957PSPR0604_01; Venegas JG, 2005, NATURE, V434, P777, DOI 10.1038/nature03490; Warren K, 2003, ADDICT BEHAV, V28, P369, DOI 10.1016/S0306-4603(01)00234-9	59	4	4	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2021	16	5							e0251659	10.1371/journal.pone.0251659	http://dx.doi.org/10.1371/journal.pone.0251659			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ST0XR	33989338	Green Published, Green Submitted, gold			2023-01-03	WOS:000662175000057
J	Zaaijer, S; Capes-Davis, A				Zaaijer, Sophie; Capes-Davis, Amanda			Ancestry matters: Building inclusivity into preclinical study design Comment	CELL			English	Editorial Material								Human cell lines (CLs) are key assets for biomedicine but lack ancestral diversity. Here, we explore why genetic diversity among cell-based models is essential for making preclinical research more equitable and widely translatable. We lay out practical actions that can be taken to improve inclusivity in study design.	[Zaaijer, Sophie] Cornell Tech, New York, NY 10044 USA; [Zaaijer, Sophie] FIND Genom, New York, NY 10029 USA; [Capes-Davis, Amanda] Univ Sydney, Childrens Med Res Inst, CellBank Australia, Westmead, NSW, Australia	Children's Medical Research Institute - Australia; University of Sydney	Zaaijer, S (corresponding author), Cornell Tech, New York, NY 10044 USA.; Zaaijer, S (corresponding author), FIND Genom, New York, NY 10029 USA.	sophie@cornell.edu		Capes-Davis, Amanda/0000-0003-4184-6339	FIND Genomics Inc.; Jacobs Technion-Cornell Institute; Elisha M. Friedman Postdoctoral Fellowship; Cell Bank Australia; Children's Medical Research Institute (CMRI); International Cell Line Authentication Committee (ICLAC)	FIND Genomics Inc.; Jacobs Technion-Cornell Institute; Elisha M. Friedman Postdoctoral Fellowship; Cell Bank Australia; Children's Medical Research Institute (CMRI); International Cell Line Authentication Committee (ICLAC)	We thank Simon (Niels) Groen, PhD and Tyler Joseph for helpful discussions and help with editing the manuscript. S.Z. is supported by FIND Genomics Inc., the Jacobs Technion-Cornell Institute, and the Elisha M. Friedman Postdoctoral Fellowship. A.C.D. has received support for writing and data analysis from FIND Genomics Inc. and acknowledges additional funding and support from CellBank Australia, Children's Medical Research Institute (CMRI), and the International Cell Line Authentication Committee (ICLAC). The authors acknowledge many excellent studies on warfarin, CLs, GWAS, and genetic diversity that could not be cited in this commentary due to space limitations.	Beaton A, 2017, GENET MED, V19, P345, DOI 10.1038/gim.2016.111; Choudhury A, 2020, NATURE, V586, P741, DOI 10.1038/s41586-020-2859-7; Dutil J, 2019, CANCER RES, V79, P1263, DOI 10.1158/0008-5472.CAN-18-2747; Harlemon M, 2020, CANCER RES, V80, P2956, DOI 10.1158/0008-5472.CAN-19-2165; Kessler MD, 2019, CANCER-AM CANCER SOC, V125, P2076, DOI 10.1002/cncr.32020; Li J, 2014, BMC GENET, V15, DOI 10.1186/1471-2156-15-52; Mulshine JL, 2020, J CELL BIOCHEM, V121, P3986, DOI 10.1002/jcb.29564; Perera MA, 2013, LANCET, V382, P790, DOI 10.1016/S0140-6736(13)60681-9; Research America, 2017, CLIN TRIALS SURV DAT; Sirugo G, 2019, CELL, V177, P26, DOI 10.1016/j.cell.2019.02.048; Sodeke SO, 2019, J HEALTH CARE POOR U, V30, P1, DOI 10.1353/hpu.2019.0109; Valdez P., 2020, RIGOR REPRODUCIBILIT; van der Meer D, 2019, NUCLEIC ACIDS RES, V47, pD923, DOI 10.1093/nar/gky872; Weinstein JN, 2012, NATURE, V483, P544, DOI 10.1038/483544a; Zhong YZ, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008662	15	5	5	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 13	2021	184	10					2525	2531		10.1016/j.cell.2021.03.041	http://dx.doi.org/10.1016/j.cell.2021.03.041		MAY 2021	7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	SF5YM	33989545	Bronze			2023-01-03	WOS:000652830800001
J	Nixon, AC; Bampouras, TM; Gooch, HJ; Young, HML; Finlayson, KW; Pendleton, N; Mitra, S; Brady, ME; Dhaygude, AP				Nixon, Andrew C.; Bampouras, Theodoros M.; Gooch, Helen J.; Young, Hannah M. L.; Finlayson, Kenneth W.; Pendleton, Neil; Mitra, Sandip; Brady, Mark E.; Dhaygude, Ajay P.			Home-based exercise for people living with frailty and chronic kidney disease: A mixed-methods pilot randomised controlled trial	PLOS ONE			English	Article							PHYSICAL PERFORMANCE; PATIENT ACTIVATION; SYMPTOM-BURDEN; OLDER-ADULTS; SAMPLE-SIZE; SHORT-FORM; MORTALITY; OUTCOMES; HEMODIALYSIS; INDIVIDUALS	Background Frailty is associated with adverse health outcomes in people with chronic kidney disease (CKD). Evidence supporting targeted interventions is needed. This pilot randomised controlled trial (RCT) aimed to inform the design of a definitive RCT evaluating the effectiveness of a home-based exercise intervention for pre-frail and frail older adults with CKD. Methods Participants were recruited from nephrology outpatient clinics to this two-arm parallel group mixed-methods pilot RCT. Inclusion criteria were: >= 65 years old; CKD G3b-5; and Clinical Frailty Scale score >= 4. Participants categorised as pre-frail or frail using the Frailty Phenotype were randomised to a 12-week progressive multi-component home-based exercise programme or usual care. Primary outcome measures included eligibility, recruitment, adherence, outcome measure completion and participant attrition rate. Semi-structured interviews were conducted with participants to explore trial and intervention acceptability. Results Six hundred and sixty-five patients had an eligibility assessment with 217 (33%; 95% CI 29, 36) eligible. Thirty-five (16%; 95% CI 12, 22) participants were recruited. Six were categorised as robust and withdrawn prior to randomisation. Fifteen participants were randomised to exercise and 14 to usual care. Eleven (73%; 95% CI 45, 91) participants completed >= 2 exercise sessions/week. Retained participants completed all outcome measures (n = 21; 100%; 95% CI 81, 100). Eight (28%; 95% CI 13, 47) participants were withdrawn. Fifteen participated in interviews. Decision to participate/withdraw was influenced by perceived risk of exercise worsening symptoms. Participant perceived benefits included improved fitness, balance, strength, well-being, energy levels and confidence. Conclusions This pilot RCT demonstrates that progression to definitive RCT is possible provided recruitment and retention challenges are addressed. It has also provided preliminary evidence that home-based exercise may be beneficial for people living with frailty and CKD.	[Nixon, Andrew C.; Brady, Mark E.; Dhaygude, Ajay P.] Lancashire Teaching Hosp NHS Fdn Trust, Dept Renal Med, Preston, Lancs, England; [Nixon, Andrew C.] Univ Manchester, Div Cardiovasc Sci, Manchester, Lancs, England; [Nixon, Andrew C.; Gooch, Helen J.] Lancashire Teaching Hosp NHS Fdn Trust, Natl Inst Hlth Res, Lancashire Clin Res Facil, Ctr Hlth Res & Innovat, Preston, Lancs, England; [Bampouras, Theodoros M.] Univ Lancaster, Lancaster Med Sch, Lancaster, England; [Bampouras, Theodoros M.] Univ Lancaster, Ctr Ageing Res, Lancaster, England; [Gooch, Helen J.] Lancashire Teaching Hosp NHS Fdn Trust, Core Therapies Dept, Preston, Lancs, England; [Young, Hannah M. L.] Univ Leicester, Dept Resp Sci, Leicester, Leics, England; [Young, Hannah M. L.] Univ Hosp Leicester NHS Trust, Dept Res & Innovat, Leicester, Leics, England; [Finlayson, Kenneth W.] Univ Cent Lancashire, Res Childbirth & Hlth Unit, Preston, Lancs, England; [Pendleton, Neil] Univ Manchester, Div Neurosci & Expt Psychol, Manchester, Lancs, England; [Mitra, Sandip] Univ Manchester, Manchester Acad, Hlth Sci Ctr, Manchester, Lancs, England; [Mitra, Sandip] Natl Inst Hlth Res MedTech & Invitro Diagnost Coo, Devices Dign, Newcastle Upon Tyne, Tyne & Wear, England; [Mitra, Sandip] Manchester Univ NHS Fdn Trust, Dept Renal Med, Manchester, Lancs, England	University of Manchester; Lancaster University; Lancaster University; University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; University of Central Lancashire; University of Manchester; University of Manchester	Bampouras, TM (corresponding author), Univ Lancaster, Lancaster Med Sch, Lancaster, England.; Bampouras, TM (corresponding author), Univ Lancaster, Ctr Ageing Res, Lancaster, England.	t.bampouras@lancaster.ac.uk	Nixon, Andrew/GPC-7475-2022; Bampouras, Theodoros M./I-5865-2019	Nixon, Andrew/0000-0002-4093-6204; Bampouras, Theodoros M./0000-0002-8991-4655; young, hannah/0000-0002-4249-9060; Gooch, Helen/0000-0002-0675-4722	Kidney Research UK [IN_013_20180306]; Department of Renal Medicine at LTHTR; NIHR [DRF-2016-09-015]; NIHR Devices for Dignity Med tech Co-operative (D4D)	Kidney Research UK(Kidney Research UK (KRUK)); Department of Renal Medicine at LTHTR; NIHR(National Institute for Health Research (NIHR)); NIHR Devices for Dignity Med tech Co-operative (D4D)	The EX-FRAIL CKD Trial is supported by a grant from Kidney Research UK (IN_013_20180306), which has funded equipment costs and HJG's study-related activity. The Department of Renal Medicine at LTHTR provided funding for participant travel costs. ACN and HJG receive non-financial support from the National Institute for Health Research (NIHR) Lancashire Clinical Research Facility. HMLY is supported by a grant from the NIHR (DRF-2016-09-015). SM's research is supported by the NIHR Devices for Dignity Med tech Co-operative (D4D). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no role in the study design; collection, analysis, and interpretation of the data; writing the report; and the decision to submit the report for publication.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Akishita M, 2013, J AM MED DIR ASSOC, V14, P479, DOI 10.1016/j.jamda.2013.01.009; Archibald M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035339; Avery KNL, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013537; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Clarke AL, 2015, NEPHROL DIAL TRANSPL, V30, P1885, DOI 10.1093/ndt/gfv208; Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9; D'Agostino RB, 2009, NEW ENGL J MED, V361, P1304, DOI 10.1056/NEJMsm0904209; Delbaere K, 2010, AGE AGEING, V39, P210, DOI 10.1093/ageing/afp225; Dent E, 2019, LANCET, V394, P1376, DOI 10.1016/S0140-6736(19)31785-4; Farmer T, 2006, QUAL HEALTH RES, V16, P377, DOI 10.1177/1049732305285708; Farrington K, 2016, NEPHROL DIAL TRANSPL, V31, P1, DOI 10.1093/ndt/gfw356; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Ferrucci L, 2004, J AM GERIATR SOC, V52, P625, DOI 10.1111/j.1532-5415.2004.52174.x; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Greenwood SA, 2019, NEPHROL DIAL TRANSPL, V34, P618, DOI 10.1093/ndt/gfy351; Greenwood SA, 2012, NEPHROL DIAL TRANSPL, V27, P126, DOI 10.1093/ndt/gfs272; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hibbard JH, 2005, HEALTH SERV RES, V40, P1918, DOI 10.1111/j.1475-6773.2005.00438.x; Hibbard JH, 2017, PATIENT EDUC COUNS, V100, P5, DOI 10.1016/j.pec.2016.07.006; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Hoogendijk EO, 2019, LANCET, V394, P1365, DOI 10.1016/S0140-6736(19)31786-6; Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185; Kendrick J, 2019, KIDNEY MED, V1, P131, DOI 10.1016/j.xkme.2019.03.004; MacKinnon HJ, 2018, THER ADV CHRONIC DIS, V9, P209, DOI 10.1177/2040622318785575; MAHONEY F I, 1965, Md State Med J, V14, P61; McAdams-DeMarco MA, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-224; McAdams-DeMarco MA, 2013, J AM GERIATR SOC, V61, P896, DOI 10.1111/jgs.12266; Mody L, 2008, J AM GERIATR SOC, V56, P2340, DOI 10.1111/j.1532-5415.2008.02015.x; Murphy EL, 2009, NEPHRON CLIN PRACT, V111, pC74, DOI 10.1159/000183177; Nakamura K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75405-x; Nixon AC, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-02063-6; Nixon AC, 2020, CLIN KIDNEY J, V13, P85, DOI 10.1093/ckj/sfz038; Nixon AC, 2019, NEPHRON, V141, P147, DOI 10.1159/000494223; Nixon AC, 2018, CLIN KIDNEY J, V11, P236, DOI 10.1093/ckj/sfx134; Nixon Andrew Christopher, 2020, BMJ Open, V10, pe035344, DOI 10.1136/bmjopen-2019-035344; Overbeek A, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-017-0696-9; Ramer SJ, 2018, J AM SOC NEPHROL, V29, P2870, DOI 10.1681/ASN.2018060657; Reese PP, 2013, AM J NEPHROL, V38, P307, DOI 10.1159/000355568; Richards DA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-032081; Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Stookey AD, 2020, CURR GERIATR REP, V9, P163, DOI 10.1007/s13670-020-00326-6; Urquhart-Secord R, 2016, AM J KIDNEY DIS, V68, P444, DOI 10.1053/j.ajkd.2016.02.037; Van Bulck L, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-0917-2; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Watson EL, 2018, AM J PHYSIOL-RENAL, V314, pF1188, DOI 10.1152/ajprenal.00012.2018; Whitehead AL, 2016, STAT METHODS MED RES, V25, P1057, DOI 10.1177/0962280215588241; Wilkinson TJ, 2020, CURR OPIN NEPHROL HY, V29, P471, DOI 10.1097/MNH.0000000000000627; Wilkinson TJ, 2021, NEPHROL DIAL TRANSPL, V36, P641, DOI 10.1093/ndt/gfz235; Wilkinson TJ, 2019, CLIN KIDNEY J, V12, P113, DOI 10.1093/ckj/sfy071; Zhang QC, 2020, INT UROL NEPHROL, V52, P363, DOI 10.1007/s11255-019-02369-x; Zhang XX, 2020, J AM GERIATR SOC, V68, P1484, DOI 10.1111/jgs.16391; Zhao YX, 2020, INT UROL NEPHROL, V52, P115, DOI 10.1007/s11255-019-02310-2	55	3	3	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	7							e0251652	10.1371/journal.pone.0251652	http://dx.doi.org/10.1371/journal.pone.0251652			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TC7AG	34197486	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000668791400062
J	Draper-Joyce, CJ; Bhola, R; Wang, JN; Bhattarai, A; Nguyen, ATN; Cowie-Kent, I; O'Sullivan, K; Chia, LY; Venugopal, H; Valant, C; Thal, DM; Wootten, D; Panel, N; Carlsson, J; Christie, MJ; White, PJ; Scammells, P; May, LT; Sexton, PM; Danev, R; Miao, YL; Glukhova, A; Imlach, WL; Christopoulos, A				Draper-Joyce, Christopher J.; Bhola, Rebecca; Wang, Jinan; Bhattarai, Apurba; Nguyen, Anh T. N.; Cowie-Kent, India; O'Sullivan, Kelly; Chia, Ling Yeong; Venugopal, Hariprasad; Valant, Celine; Thal, David M.; Wootten, Denise; Panel, Nicolas; Carlsson, Jens; Christie, Macdonald J.; White, Paul J.; Scammells, Peter; May, Lauren T.; Sexton, Patrick M.; Danev, Radostin; Miao, Yinglong; Glukhova, Alisa; Imlach, Wendy L.; Christopoulos, Arthur			Positive allosteric mechanisms of adenosine A(1) receptor-mediated analgesia	NATURE			English	Article							G-PROTEIN; MOLECULAR-DYNAMICS; FORCE-FIELD; EXTRACELLULAR LOOP; STRUCTURAL BASIS; MODULATOR; BINDING; PAIN; VALIDATION; ACTIVATION	The adenosine A(1) receptor (A,R) is a promising therapeutic target for non-opioid analgesic agents to treat neuropathic pain(1,2). However, development of analgesic orthosteric A(1)R agonists has failed because of a lack of sufficient on-target selectivity as well as off-tissue adverse effects(3). Here we show that [2-amino-4-(3,5-bis(trifluoromethyl) phenyl)thiophen-3-yl)(4-chlorophenyl)methanone] (MIPS521), a positive allosteric modulator of the A(1)R, exhibits analgesic efficacy in rats in vivo through modulation of the increased levels of endogenous adenosine that occur in the spinal cord of rats with neuropathic pain. We also report the structure of the co-bound to adenosine, MIPS521 and a G(12) heterotrimer, revealing an extrahelicallipid-detergent-facing allosteric binding pocket that involves transmembrane helixes 1, 6 and 7. Molecular dynamics simulations and ligand kinetic binding experiments support a mechanism whereby MIPS521 stabilizes the adenosine-receptor-G protein complex. This study provides proof of concept for structure-based allosteric drug design of non-opioid analgesic agents that are specific to disease contexts.	[Draper-Joyce, Christopher J.; Nguyen, Anh T. N.; Chia, Ling Yeong; Valant, Celine; Thal, David M.; Wootten, Denise; White, Paul J.; May, Lauren T.; Sexton, Patrick M.; Glukhova, Alisa; Christopoulos, Arthur] Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol, Parkville, Vic, Australia; [Draper-Joyce, Christopher J.; Nguyen, Anh T. N.; Chia, Ling Yeong; Valant, Celine; Thal, David M.; Wootten, Denise; White, Paul J.; May, Lauren T.; Sexton, Patrick M.; Glukhova, Alisa; Christopoulos, Arthur] Monash Univ, Monash Inst Pharmaceut Sci, Dept Pharmacol, Parkville, Vic, Australia; [Bhola, Rebecca; Cowie-Kent, India; O'Sullivan, Kelly; Imlach, Wendy L.] Monash Univ, Monash Biomed Discovery Inst, Dept Physiol, Clayton, Vic, Australia; [Wang, Jinan; Bhattarai, Apurba; Miao, Yinglong] Univ Kansas, Ctr Computat Biol, Lawrence, KS 66045 USA; [Wang, Jinan; Bhattarai, Apurba; Miao, Yinglong] Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; [Venugopal, Hariprasad] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Wootten, Denise; Sexton, Patrick M.; Christopoulos, Arthur] Monash Univ, ARC Ctr Cryoelectron Microscopy Membrane Prot, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia; [Panel, Nicolas; Carlsson, Jens] Uppsala Univ, Dept Cell & Mol Biol, Sci Life Lab, Uppsala, Sweden; [Christie, Macdonald J.] Univ Sydney, Fac Med & Hlth, Discipline Pharmacol, Camperdown, NSW, Australia; [Scammells, Peter] Monash Univ, Monash Inst Pharmaceut Sci, Med Chem, Parkville, Vic, Australia; [Danev, Radostin] Univ Tokyo, Grad Sch Med, Tokyo, Japan; [Draper-Joyce, Christopher J.] Univ Melbourne, Frorey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Glukhova, Alisa] Walter & Eliza Hall Inst Med Res, Struct Biol Div, Parkville, Vic, Australia; [Glukhova, Alisa] Univ Melbourne, Dept Biochem & Pharmacol, Parkville, Vic, Australia	Monash University; Monash University; Monash University; University of Kansas; University of Kansas; Monash University; Monash University; Uppsala University; University of Sydney; Monash University; University of Tokyo; University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne	Glukhova, A; Christopoulos, A (corresponding author), Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol, Parkville, Vic, Australia.; Glukhova, A; Christopoulos, A (corresponding author), Monash Univ, Monash Inst Pharmaceut Sci, Dept Pharmacol, Parkville, Vic, Australia.; Imlach, WL (corresponding author), Monash Univ, Monash Biomed Discovery Inst, Dept Physiol, Clayton, Vic, Australia.; Christopoulos, A (corresponding author), Monash Univ, ARC Ctr Cryoelectron Microscopy Membrane Prot, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia.; Glukhova, A (corresponding author), Walter & Eliza Hall Inst Med Res, Struct Biol Div, Parkville, Vic, Australia.; Glukhova, A (corresponding author), Univ Melbourne, Dept Biochem & Pharmacol, Parkville, Vic, Australia.	glukhova.a@wehi.edu.au; wendy.imlach@monash.edu; arthur.christopoulos@monash.edu	Nguyen, Anh/GPK-4377-2022; Wootten, Denise/ABD-5703-2021; Thal, David/GXH-4911-2022; Nguyen, Anh/GQQ-3393-2022; Imlach, Wendy/G-7609-2011	Nguyen, Anh/0000-0002-6385-0585; Wootten, Denise/0000-0003-4563-1642; Glukhova, Alisa/0000-0003-4146-965X; Draper-Joyce, Christopher/0000-0003-2055-7706; Valant, Celine/0000-0002-2509-7465; Imlach, Wendy/0000-0002-7521-9969; May, Lauren/0000-0002-4412-1707	National Health and Medical Research Council of Australia (NHMRC) [1145420, 1147291, 1050083]; American Heart Association [17SDG33370094]; National Institutes of Health [R01GM132572]; Australian Research Council; Swedish Research Council [2017-04676, VCP171, MIPS521]; MASSIVE HPC facility; Extreme Science and Engineering Discovery Environment supercomputing [TG-MCB180049]	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); American Heart Association(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Australian Research Council(Australian Research Council); Swedish Research Council(Swedish Research CouncilEuropean Commission); MASSIVE HPC facility; Extreme Science and Engineering Discovery Environment supercomputing	This work was supported by the National Health and Medical Research Council of Australia (NHMRC) project grants 1145420 and 1147291, NHMRC program grant 1050083, American Heart Association grant 17SDG33370094 and the National Institutes of Health grant R01GM132572. P.M.S., W.L.I. and D.W. are NHMRC Senior Principal Research, Career Development and Senior Research Fellows, respectively. C.J.D.-J., A.G. and D.M.T. are Australian Research Council Discovery Early Career Research Fellows. L.T.M. is an Australian Heart Foundation Future Leaders Fellow. J.C. acknowledges support from the Swedish Research Council (2017-04676). We are grateful to S. Charman and K. White for performing the VCP171 and MIPS521 plasma and liver microsome stability studies. We acknowledge use of facilities within the Monash Ramaciotti Cryo-EM platform. This work was supported by the MASSIVE HPC facility (https://www.massive.org.au) and the Extreme Science and Engineering Discovery Environment supercomputing award TG-MCB180049.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Aurelio L, 2009, J MED CHEM, V52, P4543, DOI 10.1021/jm9002582; Baltos JA, 2016, BIOCHEM PHARMACOL, V99, P101, DOI 10.1016/j.bcp.2015.11.013; Bernstein N, 2012, PHYS CHEM CHEM PHYS, V14, P646, DOI 10.1039/c1cp22600b; Bonin RP, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-26; BRUNS RF, 1990, MOL PHARMACOL, V38, P939; Busse JW, 2018, JAMA-J AM MED ASSOC, V320, P2448, DOI 10.1001/jama.2018.18472; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Cheng RKY, 2017, NATURE, V545, P112, DOI 10.1038/nature22309; Childers SR, 2005, J NEUROCHEM, V93, P715, DOI 10.1111/j.1471-4159.2005.03044.x; CHOCA JI, 1987, J PHARMACOL EXP THER, V242, P905; CHOCA JI, 1988, J PHARMACOL EXP THER, V247, P757; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; DeVree BT, 2016, NATURE, V535, P182, DOI 10.1038/nature18324; Draper-Joyce CJ, 2018, NATURE, V558, P559, DOI 10.1038/s41586-018-0236-6; Dror RO, 2011, P NATL ACAD SCI USA, V108, P18684, DOI 10.1073/pnas.1110499108; Dror RO, 2015, SCIENCE, V348, P1361, DOI 10.1126/science.aaa5264; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; GEIGER JD, 1984, J NEUROSCI, V4, P2303; Glukhova A, 2017, CELL, V168, P867, DOI 10.1016/j.cell.2017.01.042; Gramec D, 2014, CHEM RES TOXICOL, V27, P1344, DOI 10.1021/tx500134g; Huang J, 2017, NAT METHODS, V14, P71, DOI [10.1038/NMETH.4067, 10.1038/nmeth.4067]; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Imlach WL, 2016, SCI REP-UK, V6, DOI 10.1038/srep37104; Imlach WL, 2015, MOL PHARMACOL, V88, P460, DOI 10.1124/mol.115.099499; Johansson B, 2001, P NATL ACAD SCI USA, V98, P9407, DOI 10.1073/pnas.161292398; King A, 2019, NATURE, V573, pS4, DOI 10.1038/d41586-019-02683-5; King T, 2009, NAT NEUROSCI, V12, P1364, DOI 10.1038/nn.2407; Klauda JB, 2010, J PHYS CHEM B, V114, P7830, DOI 10.1021/jp101759q; Leach K, 2010, NEUROPSYCHOPHARMACOL, V35, P855, DOI 10.1038/npp.2009.194; Li XH, 2002, PAIN, V97, P117, DOI 10.1016/S0304-3959(02)00011-8; Liang YL, 2018, ACS PHARMACOL TRANSL, V1, P12, DOI 10.1021/acsptsci.8b00017; Liu XY, 2019, SCIENCE, V364, P1283, DOI 10.1126/science.aaw8981; Lu J, 2017, NAT STRUCT MOL BIOL, V24, P570, DOI 10.1038/nsmb.3417; Maeda S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06002-w; May LT, 2007, ANNU REV PHARMACOL, V47, P1, DOI 10.1146/annurev.pharmtox.47.120505.105159; Miao YL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35266-x; Miao YL, 2018, P NATL ACAD SCI USA, V115, P3036, DOI 10.1073/pnas.1800756115; Miao YL, 2016, P NATL ACAD SCI USA, V113, P12162, DOI 10.1073/pnas.1614538113; Miao YL, 2015, J CHEM THEORY COMPUT, V11, P3584, DOI 10.1021/acs.jctc.5b00436; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Nakamura I, 1997, ANESTHESIOLOGY, V87, P577, DOI 10.1097/00000542-199709000-00018; Nguyen ATN, 2016, MOL PHARMACOL, V90, P703, DOI 10.1124/mol.116.105007; Nguyen ATN, 2016, MOL PHARMACOL, V90, P715, DOI 10.1124/mol.116.105015; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Poon A, 1998, PAIN, V74, P235, DOI 10.1016/S0304-3959(97)00186-3; Ribeiro JA, 2002, PROG NEUROBIOL, V68, P377, DOI 10.1016/S0301-0082(02)00155-7; Robertson N, 2018, NATURE, V553, P111, DOI 10.1038/nature25025; Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schorb M, 2019, NAT METHODS, V16, P471, DOI 10.1038/s41592-019-0396-9; Schulte G, 2003, NEUROSCIENCE, V121, P907, DOI 10.1016/S0306-4522(03)00480-9; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; Shao ZH, 2019, NAT CHEM BIOL, V15, P1199, DOI 10.1038/s41589-019-0387-2; Storkson RV, 1996, J NEUROSCI METH, V65, P167, DOI 10.1016/0165-0270(95)00164-6; Thal DM, 2018, NATURE, V559, P45, DOI 10.1038/s41586-018-0259-z; Usoskin D, 2015, NAT NEUROSCI, V18, P145, DOI 10.1038/nn.3881; Valant C, 2014, P NATL ACAD SCI USA, V111, P4614, DOI 10.1073/pnas.1320962111; Vanommeslaeghe K, 2015, BBA-GEN SUBJECTS, V1850, P861, DOI 10.1016/j.bbagen.2014.08.004; Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3155, DOI 10.1021/ci3003649; Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3144, DOI 10.1021/ci300363c; Vincenzi F, 2014, NEUROPHARMACOLOGY, V81, P6, DOI 10.1016/j.neuropharm.2014.01.028; Wang JN, 2019, J PHYS CHEM B, V123, P6462, DOI 10.1021/acs.jpcb.9b04867; Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104; Wu ZY, 2017, FRONT NEURAL CIRCUIT, V11, DOI 10.3389/fncir.2017.00055; Yang ZQ, 2002, AM J PHYSIOL-HEART C, V282, pH949, DOI 10.1152/ajpheart.00741.2001; Zhang DD, 2015, NATURE, V520, P317, DOI 10.1038/nature14287; Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003; Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193; Zhuang YW, 2021, CELL RES, V31, P593, DOI 10.1038/s41422-021-00482-0; Zylka MJ, 2011, TRENDS MOL MED, V17, P188, DOI 10.1016/j.molmed.2010.12.006	73	25	24	7	34	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	2021	597	7877					571	+		10.1038/s41586-021-03897-2	http://dx.doi.org/10.1038/s41586-021-03897-2		SEP 2021	25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW6NQ	34497422	Green Accepted			2023-01-03	WOS:000693875600006
J	Hoek, JM; Field, SM; de Vries, YA; Linde, M; Pittelkow, MM; Muradchanian, J; van Ravenzwaaij, D				Hoek, Joyce M.; Field, Sarahanne M.; de Vries, Ymkje Anna; Linde, Maximilian; Pittelkow, Merle-Marie; Muradchanian, Jasmine; van Ravenzwaaij, Don			Rethinking remdesivir for COVID-19: A Bayesian reanalysis of trial findings	PLOS ONE			English	Article								Background Following testing in clinical trials, the use of remdesivir for treatment of COVID-19 has been authorized for use in parts of the world, including the USA and Europe. Early authorizations were largely based on results from two clinical trials. A third study published by Wang et al. was underpowered and deemed inconclusive. Although regulators have shown an interest in interpreting the Wang et al. study, under a frequentist framework it is difficult to determine if the non-significant finding was caused by a lack of power or by the absence of an effect. Bayesian hypothesis testing does allow for quantification of evidence in favor of the absence of an effect. Findings Results of our Bayesian reanalysis of the three trials show ambiguous evidence for the primary outcome of clinical improvement and moderate evidence against the secondary outcome of decreased mortality rate. Additional analyses of three studies published after initial marketing approval support these findings. Conclusions We recommend that regulatory bodies take all available evidence into account for endorsement decisions. A Bayesian approach can be beneficial, in particular in case of statistically non-significant results. This is especially pressing when limited clinical efficacy data is available.	[Hoek, Joyce M.; Field, Sarahanne M.; de Vries, Ymkje Anna; Linde, Maximilian; Pittelkow, Merle-Marie; Muradchanian, Jasmine; van Ravenzwaaij, Don] Univ Groningen, Behav & Social Sci, Groningen, Netherlands	University of Groningen	Hoek, JM (corresponding author), Univ Groningen, Behav & Social Sci, Groningen, Netherlands.	j.m.hoek@rug.nl	; Field, Sarahanne/H-9004-2017	Linde, Maximilian/0000-0001-8421-090X; Field, Sarahanne/0000-0001-7874-1261; Muradchanian, Jasmine/0000-0002-2914-9197; Hoek, Joyce/0000-0003-3003-3199	Dutch scientific organization VIDI fellowship [016. Vidi.188.001]	Dutch scientific organization VIDI fellowship	This research was supported by a Dutch scientific organization VIDI fellowship grant (016. Vidi.188.001, http://www.nwo.nl) to DvR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; CSSE Johns Hopkins University, 2021, COVID 19 DASHB CTR S; EMA, 2020, 1 COVID 19 TREATM RE; EMA, 2020, EMA STARTS ROLL REV; EMA, 2020, VEKL EPAR PUBL ASS R; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; GUNEL E, 1974, BIOMETRIKA, V61, P545; Ibrahim JG., 2014, BAYESIAN SURVIVAL AN; Jeffreys H., 1961, THEORY PROBABILITY, V3rd; Lee M. D., 2014, BAYESIAN COGNITIVE M; Linde M., 2019, **DATA OBJECT**; Morey R. D., 2018, PACKAGE BAYESFACTOR; PMDA, 2020, SPEC APPR EM REMD CO; Rouder JN, 2009, PSYCHON B REV, V16, P225, DOI 10.3758/PBR.16.2.225; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; U.S. Food and Drug Administration, 2020, FACT SHEET HLTH CAR; van Ravenzwaaij D, 2021, ADV METH PRACT PSYCH, V4, DOI 10.1177/2515245920972624; van Ravenzwaaij D, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0699-7; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184	21	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2021	16	7							e0255093	10.1371/journal.pone.0255093	http://dx.doi.org/10.1371/journal.pone.0255093			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2PW	34297766	Green Published, gold, Green Submitted			2023-01-03	WOS:000678128300002
J	Maguire, R; McCann, L; Kotronoulas, G; Kearney, N; Ream, E; Armes, J; Patiraki, E; Furlong, E; Fox, P; Gaiger, A; McCrone, P; Berg, G; Miaskowkski, C; Cardone, A; Orr, D; Flowerday, A; Katsaragakis, S; Darley, A; Lubowitzki, S; Harris, J; Skene, S; Miller, M; Moore, M; Lewis, L; DeSouza, N; Donnan, PT				Maguire, Roma; McCann, Lisa; Kotronoulas, Grigorios; Kearney, Nora; Ream, Emma; Armes, Jo; Patiraki, Elisabeth; Furlong, Eileen; Fox, Patricia; Gaiger, Alexander; McCrone, Paul; Berg, Geir; Miaskowkski, Christine; Cardone, Antonella; Orr, Dawn; Flowerday, Adrian; Katsaragakis, Stylianos; Darley, Andrew; Lubowitzki, Simone; Harris, Jenny; Skene, Simon; Miller, Morven; Moore, Margaret; Lewis, Liane; DeSouza, Nicosha; Donnan, Peter T.			Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT-SYSTEM ASYMS(C); BREAST-CANCER; EHEALTH INTERVENTION; COLORECTAL-CANCER; WORK LIMITATIONS; PATIENT; CARE; SCALE; VALIDATION; HEALTH	To evaluate effects of remote monitoring of adjuvant chemotherapy related side effects via the Advanced Symptom Management System (ASyMS) on symptom burden, quality of life, supportive care needs, anxiety, self-efficacy, and work limitations. DESIGN Multicentre, repeated measures, parallel group, evaluator masked, stratified randomised controlled trial. SETTING Twelve cancer centres in Austria, Greece, Norway, Republic of Ireland, and UK. PARTICIPANTS 829 patients with non-metastatic breast cancer, colorectal cancer, Hodgkin's disease, or nonHodgkin's lymphoma receiving first line adjuvant chemotherapy or chemotherapy for the first time in five years. INTERVENTION Patients were randomised to ASyMS (intervention; n=415) or standard care (control; n=414) over six cycles of chemotherapy. MAIN OUTCOME MEASURES The primary outcome was symptom burden (Memorial Symptom Assessment Scale; MSAS). Secondary outcomes were health related quality of life (Functional Assessment of Cancer Therapy-General; FACT-G), Supportive Care Needs Survey Short-Form (SCNS-SF34), State-Trait Anxiety Inventory-Revised (STAI-R), Communication and Attitudinal Self-Efficacy scale for cancer (CASE-Cancer), and work limitations questionnaire (WLQ). RESULTS For the intervention group, symptom burden remained at pre-chemotherapy treatment levels, whereas controls reported an increase from cycle 1 onwards (least squares absolute mean difference -0.15, 95% confidence interval -0.19 to -0.12; P(0.001; Cohen's D effect size=0.5). Analysis of MSAS sub-domains indicated significant reductions in favour of ASyMS for global distress index (-0.21, -0.27 to -0.16; P(0.001), psychological symptoms (-0.16, -0.23 to - 0.10; P(0.001), and physical symptoms (-0.21, -0.26 to -0.17; P(0.001). FACT-G scores were higher in the intervention group across all cycles (mean difference 4.06, 95% confidence interval 2.65 to 5.46; P(0.001), whereas mean scores for STAI-R trait (-1.15, -1.90 to - 0.41; P=0.003) and STAI-R state anxiety (-1.13, -2.06 to -0.20; P=0.02) were lower. CASE-Cancer scores were higher in the intervention group (mean difference 0.81, 0.19 to 1.43; P=0.01), and most SCNS-SF34 domains were lower, including sexuality needs (-1.56, -3.11 to - 0.01; P(0.05), patient care and support needs (-1.74, - 3.31 to -0.16; P=0.03), and physical and daily living needs (-2.8, -5.0 to -0.6; P=0.01). Other SCNS-SF34 domains and WLQ were not significantly different. Safety of ASyMS was satisfactory. Neutropenic events were higher in the intervention group. CONCLUSIONS Significant reduction in symptom burden supports the use of ASyMS for remote symptom monitoring in cancer care. A "medium" Cohen's effect size of 0.5 showed a sizable, positive clinical effect of ASyMS on patients' symptom experiences. Remote monitoring systems will be vital for future services, particularly with blended models of care delivery arising from the covid-19 pandemic. TRIAL REGISTRATION Clinicaltrials.gov NCT02356081.	[Maguire, Roma; McCann, Lisa; Miller, Morven; Moore, Margaret] Univ Strathclyde, Comp & Informat Sci, Glasgow, Lanark, Scotland; [Kotronoulas, Grigorios] Univ Glasgow, Sch Med Dent & Nursing, Glasgow, Lanark, Scotland; [Ream, Emma; Armes, Jo; Harris, Jenny] Univ Surrey, Sch Hlth Sci, Guildford, Surrey, England; [Patiraki, Elisabeth; Katsaragakis, Stylianos] Natl & Kapodistrian Univ Athens, Sch Hlth Sci, Athens, Greece; [Furlong, Eileen; Fox, Patricia] Univ Coll Dublin, Sch Nursing Midwifery & Hlth Syst, Dublin, Ireland; [Gaiger, Alexander; Lubowitzki, Simone] Med Univ Vienna, Div & Lematol & Hemostaseol, Dept Internal Med 1, Vienna, Austria; [McCrone, Paul] Kings Coll London, Dept Hlth Serv & Populat Res, Inst Psychiat Psychol & Neurosci, London, England; [Berg, Geir] NTNU, Dept Hlth Sci, Gjovik, Norway; [Miaskowkski, Christine] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Cardone, Antonella] European Canc Patient Coalit, Brussels, Belgium; [Orr, Dawn] NHS 24, Glasgow, Lanark, Scotland; [Flowerday, Adrian] Docobo Ltd, Leatherhead, Surrey, England; [Darley, Andrew] Univ Coll Dublin, Sch Med, Dublin, Ireland; [Skene, Simon] Univ Surrey, Surrey Clin Trials Unit, Guildford, Surrey, England; [Lewis, Liane] Johnson & Johnson Med, Norderstedt, Germany; [DeSouza, Nicosha; Donnan, Peter T.] Univ Dundee, Med Sch, Populat Hlth & Genom, Dundee, Scotland	University of Strathclyde; University of Glasgow; University of Surrey; National & Kapodistrian University of Athens; University College Dublin; Medical University of Vienna; University of London; King's College London; Norwegian University of Science & Technology (NTNU); University of California System; University of California San Francisco; University College Dublin; University of Surrey; Johnson & Johnson; University of Dundee	Maguire, R (corresponding author), Univ Strathclyde, Comp & Informat Sci, Glasgow, Lanark, Scotland.	Roma.maguire@strath.ac.uk	Gaiger, Alexander/GVS-1038-2022; Skene, Simon S/L-6239-2015	Gaiger, Alexander/0000-0001-6340-3446; Skene, Simon S/0000-0002-7828-3122; Armes, Jo/0000-0002-7994-0796; Fox, Patricia/0000-0002-4216-9176; Darley, Andrew/0000-0002-4256-0044; Maguire, Roma/0000-0001-7935-3447; Donnan, Peter/0000-0001-7828-0610; Kotronoulas, Grigorios/0000-0002-9508-9989; McCrone, Paul/0000-0001-7001-4502	European Commission [FP7-HEALTH-2013-INNOVATION-1, 602289]; University of Strathclyde	European Commission(European CommissionEuropean Commission Joint Research Centre); University of Strathclyde	This trial was funded by the European Commission via the FP7-HEALTH-2013-INNOVATION-1 grant award scheme, grant award number 602289. The trial was sponsored by the University of Strathclyde. The views expressed in this article are those of the authors and not necessarily those of the European Commission or the University of Strathclyde. The funders and the sponsors of the trial had no role in the design, undertaking, and reporting of the study. The funders received status reports.	Absolom K, 2021, J CLIN ONCOL, V39, P734, DOI 10.1200/JCO.20.02015; Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213; Basch E, 2016, J CLIN ONCOL, V34, P557, DOI 10.1200/JCO.2015.63.0830; Ben Charif A, 2016, J SEX MED, V13, P1686, DOI 10.1016/j.jsxm.2016.09.005; Boyes A, 2009, J EVAL CLIN PRACT, V15, P602, DOI 10.1111/j.1365-2753.2008.01057.x; Brant JM, 2011, EUR J ONCOL NURS, V15, P470, DOI 10.1016/j.ejon.2010.12.002; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Chang VT, 2004, J CLIN ONCOL, V22, p795S; Cohen J., 2013, STAT POWER ANAL BEHA; Coolbrandt A, 2011, EUR J ONCOL NURS, V15, P130, DOI 10.1016/j.ejon.2010.06.010; Curcio KR, 2016, CLIN J ONCOL NURS, V20, P144, DOI 10.1188/16.CJON.20-01AP; de Naurois J, 2010, ANN ONCOL, V21, pv252, DOI 10.1093/annonc/mdq196; Denis F, 2019, JAMA-J AM MED ASSOC, V321, P306, DOI 10.1001/jama.2018.18085; Devlin EJ, 2017, J PAIN SYMPTOM MANAG, V54, P245, DOI 10.1016/j.jpainsymman.2017.03.017; Dumas A, 2020, J CLIN ONCOL, V38, P734, DOI 10.1200/JCO.19.01726; European Commission, CONS TRANSF HLTH CAR; European Commission DG Enterprise and Industry, GUID MED DEV VIG SYS; Fjell M, 2020, BREAST, V51, P85, DOI 10.1016/j.breast.2020.03.004; Fox P, 2017, EUR J ONCOL NURS, V26, P63, DOI 10.1016/j.ejon.2016.12.008; Fromme EK, 2016, SUPPORT CARE CANCER, V24, P1897, DOI 10.1007/s00520-015-2983-3; Furlong E, 2019, JMIR CANCER, V5, DOI 10.2196/10813; Dapueto JJ, 2014, J PAIN SYMPTOM MANAG, V47, P936, DOI 10.1016/j.jpainsymman.2013.06.020; Kearney N, 2009, SUPPORT CARE CANCER, V17, P437, DOI 10.1007/s00520-008-0515-0; Kotronoulas G, 2014, J CLIN ONCOL, V32, P1480, DOI 10.1200/JCO.2013.53.5948; Larson JL, 2018, TELEMED E-HEALTH, V24, P397, DOI 10.1089/tmj.2017.0112; Lehoux P, 2019, INT J HEALTH POLICY, V8, P63, DOI 10.15171/ijhpm.2018.110; Lennon MR, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.6900; Lerner D, 2002, J CLIN EPIDEMIOL, V55, P197, DOI 10.1016/S0895-4356(01)00424-3; Lizee T, 2019, J THORAC ONCOL, V14, P1012, DOI 10.1016/j.jtho.2019.02.005; Loiselle CG, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.8309; Maguire R, 2008, EUR J ONCOL NURS, V12, P380, DOI 10.1016/j.ejon.2008.04.007; Maguire R, 2020, J MED INTERNET RES, V22, DOI 10.2196/19180; Maguire R, 2018, EUR J CANCER CARE, V27, DOI 10.1111/ecc.12890; Maguire Roma, 2017, BMJ Open, V7, pe015016, DOI 10.1136/bmjopen-2016-015016; Maguire R, 2015, CANCER NURS, V38, pE37, DOI 10.1097/NCC.0000000000000150; McCann L, 2009, EUR J CANCER CARE, V18, P156, DOI 10.1111/j.1365-2354.2008.00938.x; Mooney KH, 2017, CANCER MED-US, V6, P537, DOI 10.1002/cam4.1002; Moradian S, 2018, SUPPORT CARE CANCER, V26, P361, DOI 10.1007/s00520-017-3900-8; O'Cathain A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029954; O'Connor SR, 2019, PATIENT EDUC COUNS, V102, P850, DOI 10.1016/j.pec.2018.12.015; Oakley CM, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e21560; Osborn J, 2020, SUPPORT CARE CANCER, V28, P1469, DOI 10.1007/s00520-019-04945-4; Paterson CL, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e21711; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; Ruland CM, 2013, CANCER NURS, V36, P6, DOI 10.1097/NCC.0b013e31824d90d4; Shahsavari H, 2020, J EDUC HEALTH PROMOT, V9, DOI 10.4103/jehp.jehp_649_19; Sheng JY, 2019, BREAST, V48, pS103, DOI 10.1016/S0960-9776(19)31135-X; Spielberger C., 1983, MANUAL STATE TRAIT A; Tai E, 2017, J ONCOL PRACT, V13, P386, DOI 10.1200/JOP.2016.019588; Tevaarwerk A, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.5_suppl.18; van Muijen P, 2017, OCCUP MED-OXFORD, V67, P703, DOI 10.1093/occmed/kqx165; Velikova G, 2020, J CLIN ONCOL, V38; Wang YH, 2020, MOL PSYCHIATR, V25, P1487, DOI 10.1038/s41380-019-0595-x; Whitelaw S, 2020, LANCET DIGIT HEALTH, V2, pE435, DOI 10.1016/S2589-7500(20)30142-4; Wolf MS, 2005, PATIENT EDUC COUNS, V57, P333, DOI 10.1016/j.pec.2004.09.005	55	23	24	2	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 22	2021	374								n1647	10.1136/bmj.n1647	http://dx.doi.org/10.1136/bmj.n1647			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TQ1WF	34289996	Green Accepted, Green Submitted, Green Published, hybrid			2023-01-03	WOS:000678076900002
J	Kato, M; Mori, Y; Watanabe, D; Onoda, H; Fujiyama, K; Toda, M; Kito, K				Kato, Michitaka; Mori, Yuji; Watanabe, Daisuke; Onoda, Hiroshige; Fujiyama, Keita; Toda, Masahiro; Kito, Kazuya			Relationship between average daily rehabilitation time and decline in instrumental activity of daily living among older patients with heart failure: A preliminary analysis of a multicenter cohort study, SURUGA-CARE	PLOS ONE			English	Article							HOSPITALIZATION-ASSOCIATED DISABILITY; FUNCTIONAL DECLINE; ASSOCIATION; GUIDELINES; PROGRAM	Background Limitation of instrumental activity of daily living (IADL) is independently associated with an adverse prognosis in older heart failure (HF) patients. Aims This multicenter study aims to examine the relationship between average daily rehabilitation time (ADRT) and risk of IADL decline during acute hospitalization in older patients with HF. Methods Four hundred eleven older patients who were hospitalized due to acute HF and underwent rehabilitation were divided into three groups based on the tertile of the ADRT: short, intermediate, and long groups. IADL was assessed by the National Center for Geriatrics and Gerontology Activities of Daily Living (NCGG-ADL) scale. Change in NCGG-ADL (Delta NCGG-ADL) was calculated by subtracting the pre-hospitalization score from the at-discharge score and IADL decline was defined as Delta NCGG-ADL < = -1 point. Logistic regression analysis was carried out examining the association between ADRT and occurrence of IADL decline. Results The ADRT was 23.9, 32.0, and 38.6 minutes in short, intermediate, and long group, respectively. The proportion of patients with IADL decline during hospitalization was 21% among all subjects and short group had the highest proportion of IADL decline (33%) and long group had the lowest proportion (14%). The long group had significantly lower odds of IADL decline compared with the short group (OR:0.475, 95% CI:0.231-0.975, P = 0.042). Among the items of NCGG-ADL scale, significant decreases in the "go out by oneself", "travel using a bus or train", "shop for necessities", "vacuum", and "manage medication" were observed at discharge compared to pre-hospitalization in the short group (p<0.01, p<0.01, p<0.01, p<0.05, and p<0.05). Conclusions The present study demonstrated that short of ADRT may be associated with the risk of IADL decline during hospitalization in older patients with HF.	[Kato, Michitaka] Tokoha Univ, Dept Shizuoka Phys Therapy, Fac Hlth Sci, Shizuoka, Japan; [Mori, Yuji; Kito, Kazuya] Shizuoka Med Ctr, Dept Rehabil, Shizuoka, Japan; [Watanabe, Daisuke] Juntendo Univ Shizuoka Hosp, Dept Rehabil, Shizuoka, Japan; [Onoda, Hiroshige] Shizuoka City Hosp, Dept Rehabil, Shizuoka, Japan; [Fujiyama, Keita] Fujinomiya City Gen Hosp, Dept Rehabil, Shizuoka, Japan; [Toda, Masahiro] Hamamatsu Univ Hosp, Dept Rehabil, Shizuoka, Japan	Juntendo University; Hamamatsu University School of Medicine	Kato, M (corresponding author), Tokoha Univ, Dept Shizuoka Phys Therapy, Fac Hlth Sci, Shizuoka, Japan.	katomanzooo@sz.tokoha-u.ac.jp			JSPS KAKENHI [21K17501]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this research was supported by JSPS KAKENHI (grant number 21K17501).	Agmon M, 2017, JAMA INTERN MED, V177, P272, DOI 10.1001/jamainternmed.2016.7266; Cabinet Office Government of Japan, ANN REP AG SOC; Covinsky KE, 2011, JAMA-J AM MED ASSOC, V306, P1782, DOI 10.1001/jama.2011.1556; D'Onofrio A, 2018, INT J OLDER PEOPLE N, V13, DOI 10.1111/opn.12164; Dunlay SM, 2015, CIRC-HEART FAIL, V8, P261, DOI 10.1161/CIRCHEARTFAILURE.114.001542; Gomez-Gomez ME, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112842; Falvey JR, 2015, PHYS THER, V95, P1307, DOI 10.2522/ptj.20140511; Guo HJ, 2020, STATPEARLS; Iwai N, 2011, J PHYS THER SCI, V23, P333, DOI 10.1589/jpts.23.333; Izawa H, 2019, CIRC J, V83, P2394, DOI 10.1253/circj.CJ-19-0670; Jonckers M, 2018, ACTA CARDIOL, V73, P566, DOI 10.1080/00015385.2017.1421300; Kato Michitaka, 2019, Phys Ther Res, V22, P1, DOI 10.1298/ptr.E9957; Kato M, 2017, J CARDIOPULM REHABIL, V37, P130, DOI 10.1097/HCR.0000000000000229; Ko H, 2020, ANN REHABIL MED-ARM, V44, P101, DOI 10.5535/arm.2020.44.2.101; KOYANO W, 1991, ARCH GERONTOL GERIAT, V13, P103, DOI 10.1016/0167-4943(91)90053-S; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Loyd C, 2020, J AM MED DIR ASSOC, V21, P455, DOI 10.1016/j.jamda.2019.09.015; Makino K, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072291; Mikkelsen N, 2020, EUR J PREV CARDIOL, V27, P811, DOI 10.1177/2047487319887835; Nohara R, 2014, CIRC J, V78, P2022, DOI 10.1253/circj.CJ-66-0094; Okura Y, 2008, CIRC J, V72, P489, DOI 10.1253/circj.72.489; Ortiz-Alonso J, 2020, J AM MED DIR ASSOC, V21, P531, DOI 10.1016/j.jamda.2019.11.027; Pavon JM, 2020, J AM GERIATR SOC, V68, P261, DOI 10.1111/jgs.16231; Portela D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17207387; Saitoh M, 2020, CIRC J, V84, P1083, DOI 10.1253/circj.CJ-19-1037; Shimada H., 2013, SURVEY INSTRUMENTAL; Singh NA, 2012, J AM MED DIR ASSOC, V13, P24, DOI 10.1016/j.jamda.2011.08.005; Van Grootven B, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01510-1; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; Yamashita M, 2020, HEART VESSELS, V35, P360, DOI 10.1007/s00380-019-01490-2; Yasuda S, 2016, CIRC J, V80, P2327, DOI 10.1253/circj.CJ-16-0196; Yosef-Brauner O, 2015, CLIN RESPIR J, V9, P1, DOI 10.1111/crj.12091; Zisberg A, 2015, J AM GERIATR SOC, V63, P55, DOI 10.1111/jgs.13193; Zores F, 2019, ARCH CARDIOVASC DIS, V112, P723, DOI 10.1016/j.acvd.2019.07.003	34	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2021	16	7							e0254128	10.1371/journal.pone.0254128	http://dx.doi.org/10.1371/journal.pone.0254128			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TG9LR	34214129	gold, Green Published			2023-01-03	WOS:000671718200012
J	Janjigian, YY; Shitara, K; Moehler, M; Garrido, M; Salman, P; Shen, L; Wyrwicz, L; Yamaguchi, K; Skoczylas, T; Bragagnoli, AC; Liu, TS; Schenker, M; Yanez, P; Tehfe, M; Kowalyszyn, R; Karamouzis, MV; Bruges, R; Zander, T; Pazo-Cid, R; Hitre, E; Feeney, K; Cleary, JM; Poulart, V; Cullen, D; Lei, M; Xiao, H; Kondo, K; Li, MS; Ajani, JA				Janjigian, Yelena Y.; Shitara, Kohei; Moehler, Markus; Garrido, Marcelo; Salman, Pamela; Shen, Lin; Wyrwicz, Lucjan; Yamaguchi, Kensei; Skoczylas, Tomasz; Bragagnoli, Arinilda Campos; Liu, Tianshu; Schenker, Michael; Yanez, Patricio; Tehfe, Mustapha; Kowalyszyn, Ruben; Karamouzis, Michalis V.; Bruges, Ricardo; Zander, Thomas; Pazo-Cid, Roberto; Hitre, Erika; Feeney, Kynan; Cleary, James M.; Poulart, Valerie; Cullen, Dana; Lei, Ming; Xiao, Hong; Kondo, Kaoru; Li, Mingshun; Ajani, Jaffer A.			First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial	LANCET			English	Article							DOUBLE-BLIND; HER2 STATUS; CANCER; OXALIPLATIN; CISPLATIN; CAPECITABINE; PROGNOSIS; IMPACT	Background First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year. We aimed to evaluate first-line programmed cell death (PD)-1 inhibitor-based therapies in gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma. We report the first results for nivolumab plus chemotherapy versus chemotherapy alone. Methods In this multicentre, randomised, open-label, phase 3 trial (CheckMate 649), we enrolled adults (>= 18 years) with previously untreated, unresectable, non-HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, regardless of PD-ligand 1 (PD-L1) expression from 175 hospitals and cancer centres in 29 countries. Patients were randomly assigned (1:1:1 while all three groups were open) via interactive web response technology (block sizes of six) to nivolumab (360 mg every 3 weeks or 240 mg every 2 weeks) plus chemotherapy (capecitabine and oxaliplatin every 3 weeks or leucovorin, fluorouracil, and oxaliplatin every 2 weeks), nivolumab plus ipilimumab, or chemotherapy alone. Primary endpoints for nivolumab plus chemotherapy versus chemotherapy alone were OS or progression-free survival (PFS) by blinded independent central review, in patients whose tumours had a PD-L1 combined positive score (CPS) of five or more. Safety was assessed in all patients who received at least one dose of the assigned treatment. This study is registered with ClinicalTrials.gov, NCT02872116. Findings From March 27, 2017, to April 24, 2019, of 2687 patients assessed for eligibility, we concurrently randomly assigned 1581 patients to treatment (nivolumab plus chemotherapy [n=789, 50%] or chemotherapy alone [n=792, 50%]). The median follow-up for OS was 13.1 months (IQR 6.7-19.1) for nivolumab plus chemotherapy and 11.1 months (5.8-16.1) for chemotherapy alone. Nivolumab plus chemotherapy resulted in significant improvements in OS (hazard ratio [HR] 0.71 [98.4% CI 0.59-0.86]; p<0.0001) and PFS (HR 0.68 [98 % CI 0.56-0.81]; p<0.0001) versus chemotherapy alone in patients with a PD-L1 CPS of five or more (minimum follow-up 12.1 months). Additional results showed significant improvement in OS, along with PFS benefit, in patients with a PD-L1 CPS of one or more and all randomly assigned patients. Among all treated patients, 462 (59%) of 782 patients in the nivolumab plus chemotherapy group and 341 (44%) of 767 patients in the chemotherapy alone group had grade 3-4 treatment-related adverse events. The most common any-grade treatment-related adverse events (>= 25%) were nausea, diarrhoea, and peripheral neuropathy across both groups. 16 (2%) deaths in the nivolumab plus chemotherapy group and four (1%) deaths in the chemotherapy alone group were considered to be treatment-related. No new safety signals were identified. Interpretation Nivolumab is the first PD-1 inhibitor to show superior OS, along with PFS benefit and an acceptable safety profile, in combination with chemotherapy versus chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma. Nivolumab plus chemotherapy represents a new standard first-line treatment for these patients. Funding Bristol Myers Squibb, in collaboration with Ono Pharmaceutical. Copyright (c) 2021 Elsevier Ltd. All rights reserved.	[Janjigian, Yelena Y.] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, 1275 York Ave, New York, NY 10021 USA; [Janjigian, Yelena Y.] Weill Cornell Med Coll, Dept Med, New York, NY USA; [Shitara, Kohei] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba 2778577, Japan; [Moehler, Markus] Johannes Gutenberg Univ Clin, Dept Med, Mainz, Germany; [Garrido, Marcelo] Pontificia Univ Catolica, Dept Hematooncol, Clin San Carlos de Apoquindo, Santiago, Chile; [Salman, Pamela] Fdn Arturo Lopez Perez, Oncovida Canc Ctr, Dept Med Oncol, Providencia, Chile; [Shen, Lin] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ Beijing, Beijing, Peoples R China; [Wyrwicz, Lucjan] Narodowy Inst Onkol, Klin Onkol & Radioterapii, Warsaw, Poland; [Yamaguchi, Kensei] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Chemotherapy, Tokyo, Japan; [Skoczylas, Tomasz] Med Univ Lublin, Klin Chirurg Ogolnej Gastroenterologicznej & Nowo, Lublin, Poland; [Bragagnoli, Arinilda Campos] Fundacao Pio Xii Hosp Canc Barretos, Dept Med Oncol, Barretos, Brazil; [Liu, Tianshu] Fudan Univ, Dept Med Oncol, Zhongshan Hosp, Shanghai, Peoples R China; [Schenker, Michael] Sfantul Nectarie Oncol Ctr, Dept Med Oncol, Dolj, Romania; [Yanez, Patricio] Univ La Frontera, Dept Internal Med, Oncol Unit, Temuco, Chile; [Tehfe, Mustapha] Ctr Hosp Univ Montreal, Oncol Ctr, Hematol Oncol, Montreal, PQ, Canada; [Kowalyszyn, Ruben] Clin Viedma SA, Inst Multidisciplinario Oncol, Viedma, Argentina; [Karamouzis, Michalis V.] Natl & Kapodistrian Univ Athens, Dept Biol Chem, Athens, Greece; [Karamouzis, Michalis V.] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp Med Sch, Athens, Greece; [Bruges, Ricardo] Inst Nacl Cancerol Empresa Social Estado, Clin Oncol, Internal Med, Bogota, Colombia; [Zander, Thomas] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Dept Internal Med, Cologne, Germany; [Pazo-Cid, Roberto] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain; [Hitre, Erika] Natl Inst Oncol, Dept Chemotherapy, Budapest, Hungary; [Feeney, Kynan] St John God Murdoch Hosp, Dept Oncol Haematol & Palliat Care, Murdoch, WA, Australia; [Cleary, James M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Poulart, Valerie; Cullen, Dana; Lei, Ming; Xiao, Hong; Kondo, Kaoru; Li, Mingshun] Bristol Myers Squibb, Princeton, NJ USA; [Ajani, Jaffer A.] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	Memorial Sloan Kettering Cancer Center; Cornell University; National Cancer Center - Japan; Johannes Gutenberg University of Mainz; Pontificia Universidad Catolica de Chile; Japanese Foundation for Cancer Research; Medical University of Lublin; Hospital de Cancer de Barretos; Fudan University; Universidad de La Frontera; Universite de Montreal; National & Kapodistrian University of Athens; Laiko General Hospital; National & Kapodistrian University of Athens; University of Cologne; Miguel Servet University Hospital; National Institute of Oncology Hungary; St John of God Health Care; Harvard University; Dana-Farber Cancer Institute; Bristol-Myers Squibb; University of Texas System; UTMD Anderson Cancer Center	Shitara, K (corresponding author), Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba 2778577, Japan.	kshitara@east.ncc.go.jp	Shitara, Kohei/AAA-3877-2021; Schenker, Michael/AAD-6920-2022; Wyrwicz, Lucjan/ABD-6558-2021	Schenker, Michael/0000-0003-2645-6391; Wyrwicz, Lucjan/0000-0003-0808-6892; liu, tianshu/0000-0002-2318-2869; Jaramillo Garcia, Luis Fernando/0000-0003-2909-9318; Pazo-Cid, Roberto A./0000-0002-8026-7391; Skoczylas, Tomasz/0000-0002-1276-3828	Bristol Myers Squibb; Ono Pharmaceutical Co.	Bristol Myers Squibb(Bristol-Myers Squibb); Ono Pharmaceutical Co.	This study was supported by Bristol Myers Squibb and Ono Pharmaceutical Co. We thank the patients and their families for making the study possible and the investigators and the clinical study teams at Bristol Myers Squibb (Princeton, NJ, USA) and Ono Pharmaceutical Co (Osaka, Japan). From Bristol Myers Squibb we thank protocol managers Maria Kistkina and Charlotte Corbisier. Analysis of patient-reported outcomes was supported by Steven Blum (Bristol Myers Squibb), and Lawrence Rasouliyan and David McSorley (RTI Health Solutions, Research Triangle Park, NC, USA). Dako (Santa Clara, CA, USA) participated in collaborative development of the PD-L1 immunohistochemistry 28-8 pharmDx assay. Professional medical writing assistance was provided by Tanmayi Mankame of Parexel International, funded by Bristol Myers Squibb.	Ajani JA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.36; Al-Batran SE, 2008, J CLIN ONCOL, V26, P1435, DOI 10.1200/JCO.2007.13.9378; Arnold M, 2020, GUT, V69, P1564, DOI 10.1136/gutjnl-2020-321600; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1; Chau I, 2009, ANN ONCOL, V20, P885, DOI 10.1093/annonc/mdn716; Chua TC, 2012, INT J CANCER, V130, P2845, DOI 10.1002/ijc.26292; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Fassan M, 2020, VIRCHOWS ARCH, V477, P151, DOI 10.1007/s00428-019-02693-8; Fuchs CS, 2019, LANCET ONCOL, V20, P420, DOI 10.1016/S1470-2045(18)30791-5; Hagi T, 2020, BRIT J CANCER, V123, P965, DOI 10.1038/s41416-020-0975-7; Hsu JT, 2011, ONCOLOGIST, V16, P1706, DOI 10.1634/theoncologist.2011-0199; Janjigian YY, 2012, ANN ONCOL, V23, P2656, DOI 10.1093/annonc/mds104; Japanese Gastric Canc Assoc, 2017, GASTRIC CANCER, V20, P1, DOI [10.1007/s10120-016-0622-4, 10.1007/s10120-020-01042-y]; Kang YK, 2017, LANCET, V390, P2461, DOI 10.1016/S0140-6736(17)31827-5; Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805; Kulangara K, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.4065; Lei M, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-2673; Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5; National Comprehensive Cancer Network, NCCN CLIN PRACTICE G; Oh D-Y, 2020, NIVOLUMAB PLUS CHEMO; Pape M, 2020, J CLIN ONCOL, V38; Park SJ, 2019, ORAL ONCOL, V95, P127, DOI 10.1016/j.oraloncology.2019.06.016; Salem ME, 2018, ONCOLOGIST, V23, P1319, DOI 10.1634/theoncologist.2018-0143; Shah MA, 2017, JAMA ONCOL, V3, P620, DOI 10.1001/jamaoncol.2016.5580; Sheng WQ, 2013, ANN ONCOL, V24, P2360, DOI 10.1093/annonc/mdt232; Shitara K, 2020, JAMA ONCOL, V6, P1571, DOI 10.1001/jamaoncol.2020.3370; Shitara K, 2018, LANCET, V392, P123, DOI 10.1016/S0140-6736(18)31257-1; Smyth EC, 2016, ANN ONCOL, V27, pv38, DOI 10.1093/annonc/mdw350; Suda K, 2020, J THORAC DIS, V12, P1770, DOI 10.21037/jtd-20-1661; Van Cutsem E, 2015, GASTRIC CANCER, V18, P476, DOI 10.1007/s10120-014-0402-y; Wang CY, 2014, CANCER IMMUNOL RES, V2, P846, DOI 10.1158/2326-6066.CIR-14-0040; Wang FH, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0349-9; Wang WW, 2017, BIOCHEM BIOPH RES CO, V487, P1, DOI 10.1016/j.bbrc.2016.12.180; Ye M, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01273-0	35	447	459	37	111	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2021	398	10294					27	40		10.1016/S0140-6736(21)00797-2	http://dx.doi.org/10.1016/S0140-6736(21)00797-2		JUL 2021	14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC9PM	34102137	Green Accepted			2023-01-03	WOS:000668969500027
J	Oh, JS; Park, J; Kim, K; Jeong, HH; Oh, YM; Choi, S; Choi, KH				Oh, Joo Suk; Park, Jungtaek; Kim, Kiwook; Jeong, Hyun Ho; Oh, Young Min; Choi, Semin; Choi, Kyoung Ho			HSP70-mediated neuroprotection by combined treatment of valproic acid with hypothermia in a rat asphyxial cardiac arrest model	PLOS ONE			English	Article							HISTONE DEACETYLASE INHIBITION; CEREBRAL-ISCHEMIA; MILD-HYPOTHERMIA; DOWN-REGULATION; MESSENGER-RNA; HSP70; HEAT-SHOCK-PROTEIN-70; EXPRESSION; BRAIN; INDUCTION	It has been reported that valproic acid (VPA) combined with therapeutic hypothermia can improve survival and neurologic outcomes in a rat asphyxial cardiac arrest model. However, neuroprotective mechanisms of such combined treatment of valproic acid with hypothermia remains unclear. We hypothesized that epigenetic regulation of HSP70 by histone acetylation could increase HSP70-mediated neuroprotection suppressed under hypothermia. Male Sprague-Dawley rats that achieved return of spontaneous circulation (ROSC) from asphyxial cardiac arrest were randomized to four groups: normothermia (37 degrees C +/- 1 degrees C), hypothermia (33 degrees C +/- 1 degrees C), normothermia + VPA (300 mg/kg IV initiated 5 minutes post-ROSC and infused over 20 min), and hypothermia + VPA. Three hours after ROSC, acetyl-histone H3 was highly expressed in VPA-administered groups (normothermia + VPA, hypothermia + VPA). Four hours after ROSC, HSP70 mRNA expression levels were significantly higher in normothermic groups (normothermia, normothermia + VPA) than in hypothermic groups (hypothermia, hypothermia + VPA). The hypothermia + VPA group showed significantly higher HSP70 mRNA expression than the hypothermia group. Similarly, at five hours after ROSC, HSP70 protein levels were significantly higher in normothermic groups than in hypothermic groups. HSP70 levels were significantly higher in the hypothermia + VPA group than in the hypothermia group. Only the hypothermia + VPA group showed significantly attenuated cleaved caspase-9 levels than the normothermia group. Hypothermia can attenuate the expression of HSP70 at transcriptional level. However, VPA administration can induce hyperacetylation of histone H3, leading to epigenetic transcriptional activation of HSP70 even in a hypothermic status. Combining VPA treatment with hypothermia may compensate for reduced activation of HSP70-mediated anti-apoptotic pathway.	[Oh, Joo Suk; Park, Jungtaek; Kim, Kiwook; Jeong, Hyun Ho; Oh, Young Min; Choi, Semin; Choi, Kyoung Ho] Catholic Univ Korea, Coll Med, Uijeongbu St Marys Hosp, Dept Emergency Med, Uijeongbu Si, South Korea	Catholic University of Korea	Oh, JS (corresponding author), Catholic Univ Korea, Coll Med, Uijeongbu St Marys Hosp, Dept Emergency Med, Uijeongbu Si, South Korea.	erkeeper@catholic.ac.kr		Kim, Kiwook/0000-0001-7630-2046; Oh, Joo Suk/0000-0003-0519-9824	National Research Foundation of Korea (NRF) - Korea government (Ministry of Science and ICT) [2017R1C1B1004140]; Catholic University of Korea, Uijeongbu St. Mary's Hospital Clinical Research Laboratory Foundation [UJBCRL201727, UJBCRL201825]	National Research Foundation of Korea (NRF) - Korea government (Ministry of Science and ICT); Catholic University of Korea, Uijeongbu St. Mary's Hospital Clinical Research Laboratory Foundation	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and ICT) (2017R1C1B1004140), and the Catholic University of Korea, Uijeongbu St. Mary's Hospital Clinical Research Laboratory Foundation program in the year of 2017 (UJBCRL201727), 2018 (UJBCRL201825).	Airaksinen S, 2003, COMP BIOCHEM PHYS B, V136, P275, DOI 10.1016/S1096-4959(03)00205-7; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bright R, 2004, J NEUROSCI, V24, P6880, DOI 10.1523/JNEUROSCI.4474-03.2004; Brucken A, 2017, RESUSCITATION, V117, P32, DOI 10.1016/j.resuscitation.2017.05.029; Cao GD, 2002, J CEREBR BLOOD F MET, V22, P534, DOI 10.1097/00004647-200205000-00005; CHOPP M, 1992, STROKE, V23, P104, DOI 10.1161/01.STR.23.1.104; Colbourne F, 2003, P NATL ACAD SCI USA, V100, P2906, DOI 10.1073/pnas.2628027100; Colbourne F, 1996, J NEUROSCI METH, V67, P185, DOI 10.1016/0165-0270(96)00047-7; Cullen KE, 1997, J BIOL CHEM, V272, P1742, DOI 10.1074/jbc.272.3.1742; Duenas-Gonzalez A, 2008, CANCER TREAT REV, V34, P206, DOI 10.1016/j.ctrv.2007.11.003; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Hsu CH, 2020, RESUSC PLUS, V1-2, DOI 10.1016/j.resplu.2020.100007; Jin G, 2014, SURGERY, V156, P221, DOI 10.1016/j.surg.2014.03.038; KATZ L, 1995, J CEREBR BLOOD F MET, V15, P1032, DOI 10.1038/jcbfm.1995.129; Kawamura Y, 2000, J NEUROTRAUM, V17, P243, DOI 10.1089/neu.2000.17.243; Kim Nuri, 2012, Inflammopharmacology, V20, P177, DOI 10.1007/s10787-011-0115-3; Krech J, 2017, MITOCHONDRION, V35, P1, DOI 10.1016/j.mito.2017.04.001; Krueger AMR, 1999, MOL BRAIN RES, V71, P265, DOI 10.1016/S0169-328X(99)00198-9; Kumar K, 1995, METAB BRAIN DIS, V10, P283, DOI 10.1007/BF02109359; Lee BS, 2017, CELL STRESS CHAPERON, V22, P409, DOI 10.1007/s12192-017-0782-0; Lee JH, 2015, AM J EMERG MED, V33, P1773, DOI 10.1016/j.ajem.2015.08.036; Lee JH, 2013, RESUSCITATION, V84, P1443, DOI 10.1016/j.resuscitation.2013.04.027; Lee SM, 2009, J CEREBR BLOOD F MET, V29, P1589, DOI 10.1038/jcbfm.2009.81; LIU AYC, 1994, J BIOL CHEM, V269, P14768; Liu L, 2008, J NEUROCHEM, V106, P541, DOI 10.1111/j.1471-4159.2008.05411.x; Mancuso A, 2000, BRAIN RES, V887, P34, DOI 10.1016/S0006-8993(00)02963-2; Marinova Z, 2009, J NEUROCHEM, V111, P976, DOI 10.1111/j.1471-4159.2009.06385.x; MATZ JM, 1995, AM J PHYSIOL-REG I, V269, pR38, DOI 10.1152/ajpregu.1995.269.1.R38; Monti Barbara, 2009, Curr Mol Pharmacol, V2, P95; Oh JS, 2017, CRIT CARE MED, V45, pE1149, DOI 10.1097/CCM.0000000000002690; Olsson T, 2004, EXP BRAIN RES, V154, P442, DOI 10.1007/s00221-003-1683-2; Pan TH, 2005, FEBS LETT, V579, P6716, DOI 10.1016/j.febslet.2005.10.067; Perrone S, 2010, PEDIATR NEUROL, V43, P236, DOI 10.1016/j.pediatrneurol.2010.05.009; Qian YR, 2010, KOREAN J PHYSIOL PHA, V14, P435, DOI 10.4196/kjpp.2010.14.6.435; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Sabirzhanov B, 2012, J NEUROCHEM, V123, P542, DOI 10.1111/j.1471-4159.2012.07927.x; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Terao Y, 2009, NEUROREPORT, V20, P745, DOI 10.1097/WNR.0b013e32832a2f32; TURNBULL DM, 1986, J NEUROL NEUROSUR PS, V49, P405, DOI 10.1136/jnnp.49.4.405; Vishwakarma SK, 2017, TISSUE CELL, V49, P638, DOI 10.1016/j.tice.2017.09.004; Williams JA, 2006, ANN THORAC SURG, V81, P2235, DOI 10.1016/j.athoracsur.2005.12.060; Yenari M, 2008, STROKE, V39, P2910, DOI 10.1161/STROKEAHA.108.514471; Yenari MA, 2006, NEUROCHEM INT, V49, P164, DOI 10.1016/j.neuint.2006.03.016; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhao H, 2007, J NEUROSURG, V107, P636, DOI 10.3171/JNS-07/09/0636	48	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2021	16	6							e0253328	10.1371/journal.pone.0253328	http://dx.doi.org/10.1371/journal.pone.0253328			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9AX	34138955	gold, Green Published			2023-01-03	WOS:000671690200043
J	Son, MBF; Murray, N; Friedman, K; Young, CC; Newhams, MM; Feldstein, LR; Loftis, LL; Tarquinio, KM; Singh, AR; Heidemann, SM; Soma, VL; Riggs, BJ; Fitzgerald, JC; Kong, M; Doymaz, S; Giuliano, JS; Keenaghan, MA; Hume, JR; Hobbs, CV; Schuster, JE; Clouser, KN; Hall, MW; Smith, LS; Horwitz, SM; Schwartz, SP; Irby, K; Bradford, TT; Maddux, AB; Babbitt, CJ; Rowan, CM; McLaughlin, GE; Yager, PH; Maamari, M; Mack, EH; Carroll, CL; Montgomery, VL; Halasa, NB; Cvijanovich, NZ; Coates, BM; Rose, CE; Newburger, JW; Patel, MM; Randolph, AG				Son, Mary Beth F.; Murray, Nancy; Friedman, Kevin; Young, Cameron C.; Newhams, Margaret M.; Feldstein, Leora R.; Loftis, Laura L.; Tarquinio, Keiko M.; Singh, Aalok R.; Heidemann, Sabrina M.; Soma, Vijaya L.; Riggs, Becky J.; Fitzgerald, Julie C.; Kong, Michele; Doymaz, Sule; Giuliano, John S., Jr.; Keenaghan, Michael A.; Hume, Janet R.; Hobbs, Charlotte V.; Schuster, Jennifer E.; Clouser, Katharine N.; Hall, Mark W.; Smith, Lincoln S.; Horwitz, Steven M.; Schwartz, Stephanie P.; Irby, Katherine; Bradford, Tamara T.; Maddux, Aline B.; Babbitt, Christopher J.; Rowan, Courtney M.; McLaughlin, Gwenn E.; Yager, Phoebe H.; Maamari, Mia; Mack, Elizabeth H.; Carroll, Christopher L.; Montgomery, Vicki L.; Halasa, Natasha B.; Cvijanovich, Natalie Z.; Coates, Bria M.; Rose, Charles E.; Newburger, Jane W.; Patel, Manish M.; Randolph, Adrienne G.		Overcoming COVID-19 Investigators	Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE; SHOCK	MIS-C - Initial Therapy and Outcomes An analysis of surveillance data on inpatients younger than 21 years of age who had multisystem inflammatory syndrome in children and were hospitalized between March 15 and October 31, 2020, showed that initial treatment with IVIG plus glucocorticoids was associated with a lower risk of cardiovascular dysfunction and a lower incidence of adjunctive therapy use than IVIG alone. Background The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy. Methods We analyzed surveillance data on inpatients younger than 21 years of age who had MIS-C and were admitted to 1 of 58 U.S. hospitals between March 15 and October 31, 2020. The effectiveness of initial immunomodulatory therapy (day 0, indicating the first day any such therapy for MIS-C was given) with intravenous immune globulin (IVIG) plus glucocorticoids, as compared with IVIG alone, was evaluated with propensity-score matching and inverse probability weighting, with adjustment for baseline MIS-C severity and demographic characteristics. The primary outcome was cardiovascular dysfunction (a composite of left ventricular dysfunction or shock resulting in the use of vasopressors) on or after day 2. Secondary outcomes included the components of the primary outcome, the receipt of adjunctive treatment (glucocorticoids in patients not already receiving glucocorticoids on day 0, a biologic, or a second dose of IVIG) on or after day 1, and persistent or recurrent fever on or after day 2. Results A total of 518 patients with MIS-C (median age, 8.7 years) received at least one immunomodulatory therapy; 75% had been previously healthy, and 9 died. In the propensity-score-matched analysis, initial treatment with IVIG plus glucocorticoids (103 patients) was associated with a lower risk of cardiovascular dysfunction on or after day 2 than IVIG alone (103 patients) (17% vs. 31%; risk ratio, 0.56; 95% confidence interval [CI], 0.34 to 0.94). The risks of the components of the composite outcome were also lower among those who received IVIG plus glucocorticoids: left ventricular dysfunction occurred in 8% and 17% of the patients, respectively (risk ratio, 0.46; 95% CI, 0.19 to 1.15), and shock resulting in vasopressor use in 13% and 24% (risk ratio, 0.54; 95% CI, 0.29 to 1.00). The use of adjunctive therapy was lower among patients who received IVIG plus glucocorticoids than among those who received IVIG alone (34% vs. 70%; risk ratio, 0.49; 95% CI, 0.36 to 0.65), but the risk of fever was unaffected (31% and 40%, respectively; risk ratio, 0.78; 95% CI, 0.53 to 1.13). The inverse-probability-weighted analysis confirmed the results of the propensity-score-matched analysis. Conclusions Among children and adolescents with MIS-C, initial treatment with IVIG plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. (Funded by the Centers for Disease Control and Prevention.)	[Son, Mary Beth F.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Friedman, Kevin; Newburger, Jane W.] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA; [Young, Cameron C.; Newhams, Margaret M.; Randolph, Adrienne G.] Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA USA; [Yager, Phoebe H.] MassGen Hosp Children, Div Pediat Crit Care Med, Boston, MA USA; [Randolph, Adrienne G.] Harvard Med Sch, Dept Anesthesia, Boston, MA 02115 USA; [Son, Mary Beth F.; Friedman, Kevin; Yager, Phoebe H.; Newburger, Jane W.; Randolph, Adrienne G.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Murray, Nancy; Feldstein, Leora R.; Rose, Charles E.; Patel, Manish M.] Ctr Dis Control & Prevent, COVID 19 Response Team, Atlanta, GA USA; [Tarquinio, Keiko M.] Emory Univ, Sch Med, Dept Pediat, Div Crit Care Med,Childrens Healthcare Atlanta, Atlanta, GA 30303 USA; [Feldstein, Leora R.; Patel, Manish M.] US PHS, Commissioned Corps, Rockville, MD USA; [Riggs, Becky J.] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Div Pediat Anesthesiol & Crit Care Med, Baltimore, MD USA; [Loftis, Laura L.] Baylor Coll Med, Dept Pediat, Sect Crit Care Med, Houston, TX 77030 USA; [Maamari, Mia] Univ Texas Southwestern, Dept Pediat, Div Crit Care Med, Childrens Med Ctr Dallas, Dallas, TX USA; [Singh, Aalok R.] Maria Fareri Childrens Hosp, Westchester Med Ctr, Pediat Crit Care Div, Valhalla, NY USA; [Singh, Aalok R.] New York Med Coll, Valhalla, NY 10595 USA; [Soma, Vijaya L.] NYU, Dept Pediat, Grossman Sch Med, Div Pediat Infect Dis, New York, NY 10016 USA; [Doymaz, Sule] SUNY Downstate Hlth Sci Univ, Dept Pediat, Div Pediat Crit Care, Brooklyn, NY USA; [Keenaghan, Michael A.] Kings Cty Hosp, New York City Hlth & Hosp, Pediat Crit Care, Brooklyn, NY USA; [Heidemann, Sabrina M.] Cent Michigan Univ, Dept Pediat, Div Pediat Crit Care Med, Detroit, MI USA; [Fitzgerald, Julie C.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Div Crit Care, Philadelphia, PA 19104 USA; [Kong, Michele] Univ Alabama Birmingham, Dept Pediat, Div Pediat Crit Care Med, Birmingham, AL USA; [Giuliano, John S., Jr.] Yale Univ, Sch Med, Dept Pediat, Div Crit Care, New Haven, CT 06510 USA; [Carroll, Christopher L.] Connecticut Childrens, Div Crit Care, Hartford, CT USA; [Hume, Janet R.] M Hlth Fairview Univ Minnesota, Masonic Childrens Hosp, Div Pediat Crit Care, Minneapolis, MN USA; [Hobbs, Charlotte V.] Univ Mississippi, Med Ctr, Dept Microbiol, Dept Pediat,Div Infect Dis, Jackson, MS 39216 USA; [Schuster, Jennifer E.] Childrens Mercy Kansas City, Dept Pediat, Div Pediat Infect Dis, Kansas City, MO USA; [Clouser, Katharine N.] Hackensack Univ, Med Ctr, Joseph M Sanzari Childrens Hosp, Dept Pediat, Hackensack, NJ USA; [Horwitz, Steven M.] Rutgers State Univ, Robert Wood Johnson Med Sch, Bristol Myers Squibb Childrens Hosp, Dept Pediat,Div Pediat Crit Care, New Brunswick, NJ USA; [Hall, Mark W.] Nationwide Childrens Hosp, Dept Pediat, Div Crit Care Med, Columbus, OH USA; [Smith, Lincoln S.] Univ Washington, Dept Pediat, Div Pediat Crit Care Med, Seattle, WA 98195 USA; [Schwartz, Stephanie P.] Univ N Carolina, Childrens Hosp, Dept Pediat, Chapel Hill, NC 27515 USA; [Irby, Katherine] Arkansas Childrens Hosp, Dept Pediat, Sect Pediat Crit Care, Little Rock, AR 72202 USA; [Bradford, Tamara T.] Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, Div Cardiol, New Orleans, LA USA; [Bradford, Tamara T.] Childrens Hosp New Orleans, New Orleans, LA USA; [Maddux, Aline B.] Univ Colorado, Sch Med, Dept Pediat, Sect Crit Care Med, Aurora, CO USA; [Maddux, Aline B.] Childrens Hosp Colorado, Aurora, CO USA; [Babbitt, Christopher J.] Miller Childrens & Womens Hosp Long Beach, Div Pediat Crit Care, Long Beach, CA USA; [Cvijanovich, Natalie Z.] Univ Calif San Francisco, Div Crit Care Med, Benioff Childrens Hosp Oakland, Oakland, CA USA; [Rowan, Courtney M.] Indiana Univ Sch Med, Dept Pediat, Div Pediat Crit Care Med, Riley Hosp Children, Indianapolis, IN 46202 USA; [McLaughlin, Gwenn E.] Univ Miami, Miller Sch Med, Dept Pediat, Div Pediat Crit Care Med, Miami, FL 33136 USA; [Mack, Elizabeth H.] Med Univ South Carolina, Div Pediat Crit Care Med, Charleston, SC 29425 USA; [Montgomery, Vicki L.] Univ Louisville, Dept Pediat, Louisville, KY 40292 USA; [Montgomery, Vicki L.] Norton Childrens Hosp, Louisville, KY 40292 USA; [Halasa, Natasha B.] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Infect Dis, Nashville, TN 37232 USA; [Coates, Bria M.] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Feinberg Sch Med,Div Crit Care Med, Chicago, IL 60611 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Centers for Disease Control & Prevention - USA; Children's Healthcare of Atlanta (CHOA); Emory University; United States Public Health Service; Johns Hopkins University; Johns Hopkins Medicine; Baylor College of Medicine; University of Texas System; University of Texas Southwestern Medical Center Dallas; Westchester Medical Center; New York Medical College; New York University; Central Michigan University; University of Pennsylvania; Pennsylvania Medicine; University of Alabama System; University of Alabama Birmingham; Yale University; University of Mississippi; University of Mississippi Medical Center; Children's Mercy Hospital; Hackensack University Medical Center; Bristol-Myers Squibb; Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill; Arkansas Children's Hospital; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Children's Hospital of New Orleans; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children; University of Miami; Medical University of South Carolina; University of Louisville; Vanderbilt University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Randolph, AG (corresponding author), Boston Childrens Hosp, 300 Longwood Ave,Bader 634, Boston, MA 02115 USA.	adrienne.randolph@childrens.harvard.edu	Fernandes, Neil Dominic/AAF-5852-2019; Hymes, Saul Robert/V-5312-2019	Fernandes, Neil Dominic/0000-0002-3024-1994; Hymes, Saul Robert/0000-0002-2276-7160; Dapul, Heda/0000-0002-7209-1285; Young, Cameron/0000-0001-7323-4834; Randolph, Adrienne/0000-0002-3084-3071; Maddux, Aline/0000-0002-0949-4284; Wellnitz, Kari/0000-0001-9451-8879; Son, Mary Beth/0000-0002-7394-2862; Schwartz, Stephanie/0000-0003-4314-6117; Hume, Janet/0000-0002-8891-6800; Hobbs, Charlotte/0000-0003-4829-0791	Centers for Disease Control and Prevention; Boston Children's Hospital	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Boston Children's Hospital	Supported by the Centers for Disease Control and Prevention under a contract with Boston Children's Hospital.	Belhadjer Z, 2020, CIRCULATION, V142, P2282, DOI 10.1161/CIRCULATIONAHA.120.050147; Belhadjer Z, 2020, CIRCULATION, V142, P429, DOI 10.1161/CIRCULATIONAHA.120.048360; Carter MJ, 2020, NAT MED, V26, P1701, DOI 10.1038/s41591-020-1054-6; Centers for Disease Control and Prevention, 2020, IMMUNOLOGIYA; Diorio C, 2020, J CLIN INVEST, V130, P5967, DOI 10.1172/JCI140970; Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756; Feldstein LR, 2021, JAMA-J AM MED ASSOC, V325, P1074, DOI 10.1001/jama.2021.2091; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Felsenstein S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103293; Godfred-Cato S, 2020, MMWR-MORBID MORTAL W, V69, P1074, DOI 10.15585/mmwr.mm6932e2; Harwood R, 2021, LANCET CHILD ADOLESC, V5, P133, DOI 10.1016/S2352-4642(20)30304-7; Henderson LA, 2021, ARTHRITIS RHEUMATOL, V73, pE13, DOI 10.1002/art.41616; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Jonat B, 2021, PEDIATR CRIT CARE ME, V22, pe178, DOI 10.1097/PCC.0000000000002598; Kanegaye JT, 2009, PEDIATRICS, V123, pE783, DOI 10.1542/peds.2008-1871; Kobayashi T, 2012, LANCET, V379, P1613, DOI 10.1016/S0140-6736(11)61930-2; Lee PY, 2020, J CLIN INVEST, V130, P5942, DOI 10.1172/JCI141113; Lin MS, 2019, BMC CARDIOVASC DISOR, V19, DOI 10.1186/s12872-018-0981-3; McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484; Ouldali N, 2021, JAMA-J AM MED ASSOC, V325, P855, DOI 10.1001/jama.2021.0694; Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]; Robinson J, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004370.pub4; Swann OV, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3249; Thomas L, 2020, JAMA-J AM MED ASSOC, V323, P466, DOI 10.1001/jama.2019.21558; Valverde I, 2021, CIRCULATION, V143, P21, DOI 10.1161/CIRCULATIONAHA.120.050065; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X; Walensky RP, 2021, JAMA-J AM MED ASSOC, V325, P1037, DOI 10.1001/jama.2021.2294	28	134	139	2	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2021	385	1					23	34		10.1056/NEJMoa2102605	http://dx.doi.org/10.1056/NEJMoa2102605		JUN 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU5EV	34133855	Green Published, Bronze			2023-01-03	WOS:000663459700001
J	Karbowiak, M; Holme, T; Khan, K; Mohan, A				Karbowiak, Marta; Holme, Thomas; Khan, Kamran; Mohan, Arvind			Dupuytren's disease	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							COLLAGENASE CLOSTRIDIUM-HISTOLYTICUM; PERCUTANEOUS NEEDLE FASCIOTOMY; LIMITED FASCIECTOMY; CONTRACTURE; DERMOFASCIECTOMY; MANAGEMENT; ALCOHOL; RISK		[Karbowiak, Marta] Royal Surrey Cty Hosp, Egerton Rd, Guildford GU2 7XX, Surrey, England; [Holme, Thomas] Epsom Hosp, Epsom KT18 7EG, Surrey, England; [Khan, Kamran] Stovell House Surg, Croydon CR0 6AH, England; [Mohan, Arvind] Croydon Hlth Serv NHS Trust, Croydon CR7 7YE, England	Royal Surrey County Hospital	Karbowiak, M (corresponding author), Royal Surrey Cty Hosp, Egerton Rd, Guildford GU2 7XX, Surrey, England.	mkarbowiak@doctors.org.uk		Karbowiak, Marta/0000-0003-3884-632X				Armstrong JR, 2000, J BONE JOINT SURG BR, V82B, P90, DOI 10.1302/0301-620X.82B1.9808; Bainbridge Christopher, 2012, Eur Orthop Traumatol, V3, P31; Ball C, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1200-y; Bristol North Somerset and South Gloucestershire Clinical Commissioning Group, 2019, COMM POL DUPUYTRENS; British Dupuytren's Society, 2019, DUP DIS TREATM; Burke FD, 2007, J HAND SURG-BRIT EUR, V32E, P400, DOI 10.1016/j.jhse.2005.02.002; Camper SB., 2019, J HAND SURG GLOB ONL, V1, P57; Christie WS, 2012, MANUAL THER, V17, P479, DOI 10.1016/j.math.2011.11.001; Cocci A, 2020, EUR UROL, V77, P660, DOI 10.1016/j.eururo.2019.11.019; Desai SS, 2011, J HAND SURG-AM, V36A, P936, DOI 10.1016/j.jhsa.2011.03.002; Fagernaes C, 2018, DAN MED J, V65; Geoghegan JM, 2004, J HAND SURG-BRIT EUR, V29B, P423, DOI 10.1016/j.jhsb.2004.06.006; Gerber RA, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-73; Gilpin D, 2010, J HAND SURG-AM, V35A, P2027, DOI 10.1016/j.jhsa.2010.08.007; Godtfredsen NS, 2004, J CLIN EPIDEMIOL, V57, P858, DOI 10.1016/j.jclinepi.2003.11.015; Gudmundsson KG, 2000, J CLIN EPIDEMIOL, V53, P291, DOI 10.1016/S0895-4356(99)00145-6; Gudmundsson KG, 2001, SCAND J RHEUMATOL, V30, P31; Harrogate and Rural District CCG, 2019, EVIDENCE BASED INTER; Hindocha Sandip, 2009, Hand (N Y), V4, P256, DOI 10.1007/s11552-008-9160-9; Hurst LC, 2009, NEW ENGL J MED, V361, P968, DOI 10.1056/NEJMoa0810866; Iacobucci G, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k2903; Ipswich and East Suffolk Clinical Commissioning Group, 2016, LOW PRIOR PROC POL T; Jerosch-Herold C, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-136; Kan HJ, 2016, PLAST RECONSTR SURG, V137, P1800, DOI 10.1097/PRS.0000000000002224; Kemler MA, 2012, J HAND SURG-EUR VOL, V37E, P733, DOI 10.1177/1753193412437631; Ketchum LD, 2000, J HAND SURG-AM, V25A, P1157; Larsen S, 2015, J HAND SURG-EUR VOL, V40, P171, DOI 10.1177/1753193414535720; Lipman Marc D, 2017, Hand (N Y), V12, P13, DOI 10.1177/1558944716647101; Markham D E, 1980, Physiotherapy, V66, P55; National Institute for Health and Care Excellence, 2016, WINT WARMTH PIL PUBL; National Institute for Health and Care Excellence, 2016, RAD THERAP EARL DUP; Nunn AC, 2014, J HAND SURG-ASIAN-PA, V19, P481, DOI 10.1142/S0218810414300058; Peimer CA, 2013, J HAND SURG-AM, V38A, P12, DOI 10.1016/j.jhsa.2012.09.028; Rayan GM, 1999, HAND CLIN, V15, P87; Rodrigues JN, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010143.pub2; Scherman P, 2018, J HAND SURG-EUR VOL, V43, P836, DOI 10.1177/1753193418786947; Skov ST, 2017, J HAND SURG-AM, V42, P321, DOI 10.1016/j.jhsa.2017.03.003; TONKIN MA, 1984, J HAND SURG-BRIT EUR, V9B, P156, DOI 10.1016/S0266-7681(84)80018-2; Trojian TH, 2007, AM FAM PHYSICIAN, V76, P86; Van Rijssen AL, 2006, J HAND SURG-BRIT EUR, V31B, P498, DOI 10.1016/j.jhsb.2006.03.174; van Rijssen AL, 2012, PLAST RECONSTR SURG, V129, P469, DOI 10.1097/PRS.0b013e31823aea95	41	1	1	2	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	2021	373								n1308	10.1136/bmj.n1308	http://dx.doi.org/10.1136/bmj.n1308			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ST8AE	34088710				2023-01-03	WOS:000662659600016
J	Khalil, DM; Elmorsy, E; Arafa, A; Nafady, HA; Saleh, L				Khalil, Doaa Mahmoud; Elmorsy, Elmorsy; Arafa, Ahmed; Nafady, Hesham Ahmed; Saleh, Lamiaa			Factors affecting prehospital time delay of the injured patients arriving at the Emergency Department of Beni-Suef University Hospital in Egypt: A cross-sectional study	PLOS ONE			English	Article							LEVEL; CARE; SERVICES	Purpose This study aimed to assess the factors affecting the prehospital time delay of the injured patients arriving at the Emergency Department of Beni-Suef University Hospital in Upper Egypt. Materials and methods In this cross-sectional study, the following data were retrieved from the hospital records of 632 injured patients between 1/1/2018 and 31/3/2018: age, sex, residence, means of transportation to the hospital, prehospital time delay, consciousness level on admission, source of injury, and type of worst injury. Results The prehospital time delay (>one hour) of the injured patients was positively associated with age >60 years and rural residence but inversely associated with consciousness level with odds ratios (95% confidence intervals) of 5.14 (2.26-11.68), 3.49 (2.22-5.48), and 0.56 (0.32-0.96), respectively. Conclusion The prehospital time delay of the injured patients arriving at the Emergency Department of Beni-Suef University Hospital in Egypt was associated with old age, rural residence, and consciousness level.	[Khalil, Doaa Mahmoud; Elmorsy, Elmorsy; Arafa, Ahmed; Saleh, Lamiaa] Beni Suef Univ, Dept Publ Hlth & Community Med, Fac Med, Bani Suwayf, Egypt; [Arafa, Ahmed] Osaka Univ, Dept Social Med, Publ Hlth, Grad Sch Med, Osaka, Japan; [Nafady, Hesham Ahmed] Beni Suef Univ, Dept Gen Surg, Fac Med, Bani Suwayf, Egypt	Egyptian Knowledge Bank (EKB); Beni Suef University; Osaka University; Egyptian Knowledge Bank (EKB); Beni Suef University	Khalil, DM (corresponding author), Beni Suef Univ, Dept Publ Hlth & Community Med, Fac Med, Bani Suwayf, Egypt.	doaamahmoud@med.bsu.edu.eg	Arafa, Ahmed/GNH-2073-2022; , Ahmed/AAJ-3610-2020	, Ahmed/0000-0002-3335-2243; Mahmoud, Doaa/0000-0002-9003-0136				Arafa A, 2019, INT J INJ CONTROL SA, V26, P372, DOI 10.1080/17457300.2019.1638419; Boutayeb A, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-23; CAPMAS. Central Agency for Public Mobilization and Statistics, 2018, EG STAT FIN RES 2017; Chang KC, 2004, STROKE, V35, P700, DOI 10.1161/01.STR.0000117236.90827.17; Chiang CF, 2013, NAGOYA J MED SCI, V75, P225; Elgazzar H, 2009, HEALTH ECON POLICY L, V4, P445, DOI 10.1017/S1744133109004939; Harrington DT, 2005, ANN SURG, V241, P961, DOI 10.1097/01.sla.0000164178.62726.f1; James SL, 2020, INJURY PREV; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; McCoy CE, 2013, ANN EMERG MED, V61, P167, DOI 10.1016/j.annemergmed.2012.08.026; McNarry AF, 2004, ANAESTHESIA, V59, P34, DOI 10.1111/j.1365-2044.2004.03526.x; Mohan B, 2018, INDIAN HEART J, V70, pS194, DOI 10.1016/j.ihj.2018.10.395; Newgard CD, 2015, ANN EMERG MED, V66, P30, DOI 10.1016/j.annemergmed.2014.12.004; Nguyen HL, 2010, CIRC-CARDIOVASC QUAL, V3, P82, DOI 10.1161/CIRCOUTCOMES.109.884361; Raj R, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-67; Rouleau DM, 2009, CAN FAM PHYSICIAN, V55, P1006; Sakran JV, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-64; Saleh HM, 2018, EUR J TRAUMA EMERG S, V44, P225, DOI 10.1007/s00068-017-0762-1; WHO, 2018, GLOB HLTH EST 2019 D; WHO, 2014, VIOL INJ PREV; Yu WY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176907	21	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2021	16	6							e0252044	10.1371/journal.pone.0252044	http://dx.doi.org/10.1371/journal.pone.0252044			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6QL	34077438	Green Published, gold			2023-01-03	WOS:000664638500024
J	O'Connor, S				O'Connor, Simon			In patients hospitalized with COVID-19, adding azithromycin to usual care did not reduce 28-d mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[O'Connor, Simon] Tamworth Rural Referral Hosp, Tamworth, NSW, Australia		O'Connor, S (corresponding author), Tamworth Rural Referral Hosp, Tamworth, NSW, Australia.							Zimmermann P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00302	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN	2021	174	6					JC64	JC64		10.7326/ACPJ202106150-064	http://dx.doi.org/10.7326/ACPJ202106150-064			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SS5IR	34058103				2023-01-03	WOS:000661788700005
J	Ferrari, R; Domingues, LB; Carpes, LD; Frank, PD; Schneider, VM; Fuchs, SC				Ferrari, Rodrigo; Domingues, Lucas Betti; Carpes, Leandro de Oliveira; Frank, Paula de Azevedo; Schneider, Vinicius Mallmann; Fuchs, Sandra C.		GET Study Grp	Effects of combined training performed two or four times per week on 24-h blood pressure, glycosylated hemoglobin and other health-related outcomes in aging individuals with hypertension: Rationale and study protocol of a randomized clinical trial	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; POSTEXERCISE HYPOTENSION; GLYCEMIC CONTROL; EXERCISE; RESISTANCE; STRENGTH; ADULTS; ASSOCIATION; MECHANISMS	Background Acute blood pressure lowering after exercise seems to predict the extent of blood pressure reduction after chronic exercise training interventions. Based on that, the same weekly amount of exercise performed more frequently could be more beneficial for controlling blood pressure. Purpose To compare the effects of a combined training program (resistance plus aerobic exercise) performed four or two times per week on 24-h ambulatory blood pressure and other health-related outcomes in middle-aged and older individuals with hypertension. Methods This study will be a randomized, parallel group, two-arm, superiority trial. Ninety-eight participants aged 50-80 years with a previous physician diagnosis of hypertension will be randomized to perform two or four sessions per week of combined training using the same total weekly overload. Primary outcomes will be 24-h ambulatory blood pressure and glycosylated hemoglobin; secondary outcomes will be endothelial function, physical fitness and quality of life. The outcomes will be assessed at baseline and at the end of 12 weeks period. Results Our conceptual hypothesis is that a combined exercise program performed four or two times per week with equalized weekly volume/overload will improve all outcomes in comparison to the baseline values, and that reductions in 24-h blood pressure and glycosylated hemoglobin will be more pronounced in the group that trained four times a week than twice. The results of this trial are expected to provide evidences to support that higher weekly frequency of combined training should be emphasized in aging adults with hypertension.	[Ferrari, Rodrigo; Domingues, Lucas Betti; Carpes, Leandro de Oliveira; Frank, Paula de Azevedo; Fuchs, Sandra C.] Univ Fed Rio Grande do Sul, Postgrad Program Cardiol, Porto Alegre, RS, Brazil; [Ferrari, Rodrigo] Univ Fed Rio Grande do Sul, Phys Educ Sch, Porto Alegre, RS, Brazil; [Ferrari, Rodrigo; Domingues, Lucas Betti; Carpes, Leandro de Oliveira; Frank, Paula de Azevedo; Schneider, Vinicius Mallmann; Fuchs, Sandra C.; GET Study Grp] Hosp Clin Porto Alegre, Sports & Exercise Training Study Grp, Porto Alegre, RS, Brazil	Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul	Ferrari, R (corresponding author), Univ Fed Rio Grande do Sul, Postgrad Program Cardiol, Porto Alegre, RS, Brazil.; Ferrari, R (corresponding author), Univ Fed Rio Grande do Sul, Phys Educ Sch, Porto Alegre, RS, Brazil.; Ferrari, R (corresponding author), Hosp Clin Porto Alegre, Sports & Exercise Training Study Grp, Porto Alegre, RS, Brazil.	rodrigo.ferrari@ufrgs.br	Domingues, Lucas Betti/GXH-8665-2022; Carpes, Leandro de Oliveira/HII-7241-2022	Domingues, Lucas Betti/0000-0002-7387-3190; Carpes, Leandro de Oliveira/0000-0003-1886-2517	Research and Education Funds from the Hospital de Clinicas de Porto Alegre (FIPE/HCPA) [3.641.905]; Coordination for the Improvement of Higher Education Personnel (CAPES), through PROEX, Brazil [001]; National Council for Scientific and Technological Development (CNPq) [151775/2019-2]; CNPq [309023/2015-7]	Research and Education Funds from the Hospital de Clinicas de Porto Alegre (FIPE/HCPA); Coordination for the Improvement of Higher Education Personnel (CAPES), through PROEX, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This study is partially funded by the Research and Education Funds from the Hospital de Clinicas de Porto Alegre (FIPE/HCPA no 3.641.905) and the Coordination for the Improvement of Higher Education Personnel (CAPES), through PROEX, Brazil (Finance Code 001). Rodrigo Ferrari received a fellowship from the National Council for Scientific and Technological Development (CNPq -no. 151775/2019-2) and Sandra C Fuchs had a fellowship from CNPq (no. 309023/2015-7). The funders will not have a role in the study design, data collection, analysis, interpretation of results or the manuscript.	Abramson Joseph H, 2011, Epidemiol Perspect Innov, V8, P1, DOI 10.1186/1742-5573-8-1; Ben-Sira D, 2007, EUR REV AGING PHYS A, V4, P85, DOI 10.1007/s11556-007-0023-0; Borg G. A., 1998, BORGS PERCEIVED EXER; Cadore EL, 2014, AGING DIS, V5, P183, DOI 10.14336/AD.2014.0500183; Cadore EL, 2012, EXP GERONTOL, V47, P164, DOI 10.1016/j.exger.2011.11.013; Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586; Coccina F, 2019, BLOOD PRESS MONIT, V24, P179, DOI 10.1097/MBP.0000000000000381; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; DeVan AE, 2011, ATHEROSCLEROSIS, V219, P191, DOI 10.1016/j.atherosclerosis.2011.07.099; Farrag HMA, 2019, BLOOD PRESS MONIT, V24, P221, DOI 10.1097/MBP.0000000000000383; Ferrari R, 2013, EXP GERONTOL, V48, P1236, DOI 10.1016/j.exger.2013.07.016; Fleck MP, 2006, REV SAUDE PUBL, V40, P785, DOI 10.1590/S0034-89102006000600007; Fleg JL, 2005, CIRCULATION, V112, P674, DOI 10.1161/CIRCULATIONAHA.105.545459; Foldvari M, 2000, J GERONTOL A-BIOL, V55, pM192, DOI 10.1093/gerona/55.4.M192; Halliwill JR, 2013, EXP PHYSIOL, V98, P7, DOI 10.1113/expphysiol.2011.058065; Hamer M, 2006, SPORTS MED, V36, P109, DOI 10.2165/00007256-200636020-00002; HOWLEY ET, 1995, MED SCI SPORT EXER, V27, P1292; Ishiguro H, 2016, SPORTS MED, V46, P67, DOI 10.1007/s40279-015-0379-7; Izquierdo M, 2004, MED SCI SPORT EXER, V36, P435, DOI 10.1249/01.MSS.0000117897.55226.9A; Jones CJ, 1999, RES Q EXERCISE SPORT, V70, P113, DOI 10.1080/02701367.1999.10608028; KENNEY MJ, 1993, HYPERTENSION, V22, P653, DOI 10.1161/01.HYP.22.5.653; Kirkman MS, 2012, DIABETES CARE, V35, P2650, DOI 10.2337/dc12-1801; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Liu S, 2012, MED SCI SPORT EXER, V44, P1644, DOI 10.1249/MSS.0b013e31825408fb; Long AN, 2011, J CLIN HYPERTENS, V13, P244, DOI 10.1111/j.1751-7176.2011.00434.x; Nualnim N, 2012, AM J CARDIOL, V109, P1005, DOI 10.1016/j.amjcard.2011.11.029; O'Brien E, 2013, J HYPERTENS, V31, P1731, DOI 10.1097/HJH.0b013e328363e964; Pahor M, 2014, JAMA-J AM MED ASSOC, V311, P2387, DOI 10.1001/jama.2014.5616; Pescatello LS, 2015, MAYO CLIN PROC, V90, P801, DOI 10.1016/j.mayocp.2015.04.008; Petrie JR, 2018, CAN J CARDIOL, V34, P575, DOI 10.1016/j.cjca.2017.12.005; Picon RV, 2013, AM J HYPERTENS, V26, P541, DOI 10.1093/ajh/hps076; Piercy KL, 2018, JAMA-J AM MED ASSOC, V320, P2020, DOI 10.1001/jama.2018.14854; Barroso WKS, 2021, ARQ BRAS CARDIOL, V116, P516, DOI 10.36660/abc.20201238; Thijssen DHJ, 2019, EUR HEART J, V40, P2534, DOI 10.1093/eurheartj/ehz350; Tibana RA, 2015, INT J SPORTS MED, V36, P82, DOI 10.1055/s-0034-1382017; Umpierre D, 2013, DIABETOLOGIA, V56, P242, DOI 10.1007/s00125-012-2774-z; Umpierre D, 2011, JAMA-J AM MED ASSOC, V305, P1790, DOI 10.1001/jama.2011.576; Whelton PK, 2018, HYPERTENSION, V71, pE13, DOI [10.1161/HYP.0000000000000066, 10.1161/HYP.0000000000000065]	39	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2021	16	5							e0251654	10.1371/journal.pone.0251654	http://dx.doi.org/10.1371/journal.pone.0251654			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6OP	34038410	Green Published, gold			2023-01-03	WOS:000664633500027
J	McGeorge, E; James, J; Abraham, N				McGeorge, Elizabeth; James, Jo; Abraham, Nicola			The art of medicine The intergenerational project: creating space for play in health care	LANCET			English	Editorial Material									[McGeorge, Elizabeth; James, Jo] Imperial Coll Healthcare NHS Trust, London W2 1NY, England; [Abraham, Nicola] Royal Cent Sch Speech & Drama, London, England	Imperial College London	McGeorge, E (corresponding author), Imperial Coll Healthcare NHS Trust, London W2 1NY, England.	e.mcgeorge@nhs.net							0	0	0	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	2021	397	10288					1876	1877						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SF1XN	34022977	Green Accepted			2023-01-03	WOS:000652556000011
J	Buresh, M; Stern, R; Rastegar, D				Buresh, Megan; Stern, Robert; Rastegar, Darius			Treatment of opioid use disorder in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HEPATITIS-C VIRUS; BUPRENORPHINE MAINTENANCE TREATMENT; EXTENDED-RELEASE NALTREXONE; RANDOMIZED CONTROLLED-TRIAL; INVOLVED OVERDOSE DEATHS; HIV TREATMENT OUTCOMES; INJECTING DRUG-USERS; QUALITY-OF-LIFE; METHADONE-MAINTENANCE; DEPENDENT PATIENTS	Opioid use disorder (OUD) is a common, treatable chronic disease that can be effectively managed in primary care settings. Untreated OUD is associated with considerable morbidity and mortality-notably, overdose, infectious complications of injecting drug use, and profoundly diminished quality of life. Withdrawal management and medication tapers are ineffective and are associated with increased rates of relapse and death. Pharmacotherapy is the evidence based mainstay of OUD treatment, and many studies support its integration into primary care settings. Evidence is strongest for the opioid agonists buprenorphine and methadone, which randomized controlled trials have shown to decrease illicit opioid use and mortality. Discontinuation of opioid agonist therapy is associated with increased rates of relapse and mortality. Less evidence is available for the opioid antagonist extended release naltrexone, with a meta-analysis of randomized controlled trials showing decreased illicit opioid use but no effect on mortality. Treating OUD in primary care settings is cost effective, improves outcomes for both OUD and other medical comorbidities, and is highly acceptable to patients. Evidence on whether behavioral interventions improve outcomes for patients receiving pharmacotherapy is mixed, with guidelines promoting voluntary engagement in psychosocial supports, including counseling. Further work is needed to promote the integration of OUD treatment into primary care and to overcome regulatory barriers to integrating methadone into primary care treatment in the US.	[Buresh, Megan; Stern, Robert; Rastegar, Darius] Johns Hopkins Univ, Sch Med, Dept Addict Med, Baltimore, MD 21218 USA; [Buresh, Megan] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Buresh, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Addict Med, Baltimore, MD 21218 USA.; Buresh, M (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA.	mburesh2@jhmi.edu						Accurso AJ, 2016, J SUBST ABUSE TREAT, V61, P74, DOI 10.1016/j.jsat.2015.09.004; Akiyama MJ, 2019, ANN INTERN MED, V170, P594, DOI 10.7326/M18-1715; Alderks C. E., 2013, TRENDS USE METHADONE; Alford DP, 2011, ARCH INTERN MED, V171, P425, DOI 10.1001/archinternmed.2010.541; Altice FL, 2011, JAIDS-J ACQ IMM DEF, V56, pS22, DOI 10.1097/QAI.0b013e318209751e; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2020, J ADDICT MED, V14, P1, DOI 10.1097/ADM.0000000000000633; Antoine D, 2021, AM J ADDICTION, V30, P83, DOI 10.1111/ajad.13069; Artenie AA, 2019, CAN MED ASSOC J, V191, pE462, DOI 10.1503/cmaj.181506; Astals M, 2008, SUBST USE MISUSE, V43, P612, DOI 10.1080/10826080701204813; Bailey GL, 2013, J SUBST ABUSE TREAT, V45, P302, DOI 10.1016/j.jsat.2013.04.002; Barry DT, 2007, J GEN INTERN MED, V22, P242, DOI 10.1007/s11606-006-0050-y; Basu S, 2006, CLIN INFECT DIS, V42, P716, DOI 10.1086/500200; Behar E, 2018, PREV MED, V114, P79, DOI 10.1016/j.ypmed.2018.06.005; Behar E, 2015, DRUG ALCOHOL DEPEN, V148, P209, DOI 10.1016/j.drugalcdep.2014.12.009; Bernstein J, 2005, DRUG ALCOHOL DEPEN, V77, P49, DOI 10.1016/j.drugalcdep.2004.07.006; Bertholet N, 2020, DRUG ALCOHOL DEPEN, V213, DOI 10.1016/j.drugalcdep.2020.108001; Bickel WK, 2008, EXP CLIN PSYCHOPHARM, V16, P132, DOI 10.1037/1064-1297.16.2.132; Bizzarri J, 2005, SUBST USE MISUSE, V40, P1765, DOI 10.1080/10826080500260800; Bloom-Foster J, 2020, J ALTERN COMPLEM MED, V26, P34, DOI 10.1089/acm.2019.0242; Brands B, 2003, J ADDICT DIS, V22, P19, DOI 10.1300/J069v22n03_03; Brown JL, 2017, J SUBST ABUSE TREAT, V76, P77, DOI 10.1016/j.jsat.2017.01.017; Butler SF, 2007, PAIN, V130, P144, DOI 10.1016/j.pain.2007.01.014; Canadian Research Initiative in Substance Misuse, 2018, NAT GUID CLIN MAN OP; CAPLEHORN JRM, 1994, INT J ADDICT, V29, P1361, DOI 10.3109/10826089409048714; Carrieri PM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112328; Carroll KM, 2017, AM J PSYCHIAT, V174, P738, DOI 10.1176/appi.ajp.2016.16070792; Center for Substance Abuse Treatment. Substance Abuse Treatment: Group Therapy, 2005, SUBSTANCE ABUSE TREA, V41; Centers for Disease Control National Center for Health Statistics., 2020, NAT VIT STAT RAP REL; Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7; Chou R, 2019, ANN INTERN MED, V171, P427, DOI 10.7326/M19-1488; Christensen DR, 2014, J CONSULT CLIN PSYCH, V82, P964, DOI 10.1037/a0037496; Clark RE, 2014, HEALTH SERV RES, V49, P1964, DOI 10.1111/1475-6773.12201; Coe MA, 2019, J ADDICT MED, V13, P93, DOI 10.1097/ADM.0000000000000457; Cornish R, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5475; Correia CJ, 2006, PSYCHOPHARMACOLOGY, V189, P297, DOI 10.1007/s00213-006-0571-4; Cousins G, 2017, DRUG ALCOHOL DEPEN, V173, P126, DOI 10.1016/j.drugalcdep.2016.12.009; Cousins G, 2016, ADDICTION, V111, P73, DOI 10.1111/add.13087; Coviello DM, 2011, J SUBST ABUSE TREAT, V40, P165, DOI 10.1016/j.jsat.2010.09.007; Cunningham EB, 2020, CLIN INFECT DIS, V71, pE115, DOI 10.1093/cid/ciz1089; D'Onofrio G, 2017, J GEN INTERN MED, V32, P660, DOI 10.1007/s11606-017-3993-2; Davison JW, 2006, J ADDICT DIS, V25, P27, DOI 10.1300/J069v25n04_03; Degenhardt L, 2018, LANCET PSYCHIAT, V5, P987, DOI 10.1016/S2215-0366(18)30337-7; Degenhardt L, 2017, LANCET GLOB HEALTH, V5, pE1192, DOI 10.1016/S2214-109X(17)30375-3; Degenhardt L, 2012, LANCET, V379, P55, DOI 10.1016/S0140-6736(11)61138-0; Dey P, 2002, J PUBLIC HEALTH MED, V24, P38, DOI 10.1093/pubmed/24.1.38; DOLE VP, 1967, ARCH INTERN MED, V120, P19, DOI 10.1001/archinte.120.1.19; Dowell D, 2017, JAMA-J AM MED ASSOC, V318, P1065, DOI 10.1001/jama.2017.9308; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Drucker E, 2007, ADDICT DISORD TREAT, V6, P121, DOI 10.1097/ADT.0b013e31802b4ea1; Dunlap LJ, 2018, J SUBST ABUSE TREAT, V94, P81, DOI 10.1016/j.jsat.2018.07.014; Dupouy J, 2017, ANN FAM MED, V15, P355, DOI 10.1370/afm.2098; Edelman EJ, 2014, DRUG ALCOHOL DEPEN, V139, P79, DOI 10.1016/j.drugalcdep.2014.03.006; Faggiano F., 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002208, DOI 10.1002/14651858.CD002208]; Fanucchi L, 2019, CURR HIV-AIDS REP, V16, P1, DOI [10.1007/s11904-019-00436-7, 10.1007/s1190]; Fareed A, 2012, J ADDICT DIS, V31, P8, DOI 10.1080/10550887.2011.642758; Fatseas M, 2007, Curr Psychiatry Rep, V9, P358, DOI 10.1007/s11920-007-0046-2; Fiellin DA, 2001, JAMA-J AM MED ASSOC, V286, P1724, DOI 10.1001/jama.286.14.1724; Fiellin DA, 2008, AM J ADDICTION, V17, P116, DOI 10.1080/10550490701860971; Fiellin DA, 2006, NEW ENGL J MED, V355, P365, DOI 10.1056/NEJMoa055255; Fiellin DA, 2014, JAMA INTERN MED, V174, P1947, DOI 10.1001/jamainternmed.2014.5302; Fiellin DA, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2012.07.005; Fiellin DA, 2011, JAIDS-J ACQ IMM DEF, V56, pS33, DOI 10.1097/QAI.0b013e3182097537; Fox AD, 2016, SUBST ABUS, V37, P70, DOI 10.1080/08897077.2015.1088496; Fox AD, 2012, SUBST ABUS, V33, P361, DOI 10.1080/08897077.2011.638734; Gibson AE, 2003, MED J AUSTRALIA, V179, P38, DOI 10.5694/j.1326-5377.2003.tb05417.x; Goldman JE, 2019, HARM REDUCT J, V16, DOI 10.1186/s12954-018-0276-0; Gossop M, 1999, BRIT J GEN PRACT, V49, P31; Gossop M, 2003, J SUBST ABUSE TREAT, V24, P313, DOI 10.1016/S0740-5472(03)00040-0; Grebely J, 2018, LANCET GASTROENTEROL, V3, P153, DOI 10.1016/S2468-1253(17)30404-1; Gunderson EW, 2010, ADDICT BEHAV, V35, P537, DOI 10.1016/j.addbeh.2010.01.001; Haddad MS, 2015, J URBAN HEALTH, V92, P193, DOI 10.1007/s11524-014-9924-1; Haight BR, 2019, LANCET, V393, P778, DOI 10.1016/S0140-6736(18)32259-1; Hammig R, 2016, SUBST ABUSE REHABIL, V7, P99, DOI 10.2147/SAR.S109919; Herget Greg, 2005, HIV AIDS Policy Law Rev, V10, P23; Hickman M, 2018, ADDICTION, V113, P1461, DOI 10.1111/add.14188; Hser YI, 2014, ADDICTION, V109, P79, DOI 10.1111/add.12333; Hsu YJ, 2019, POPUL HEALTH MANAG, V22, P292, DOI 10.1089/pop.2018.0163; Hurley SF, 1997, LANCET, V349, P1797, DOI 10.1016/S0140-6736(96)11380-5; Jansson LM, 2009, BREASTFEED MED, V4, P225, DOI 10.1089/bfm.2009.9987; Jarlais DCD, 1996, LANCET, V348, P987, DOI 10.1016/S0140-6736(96)02536-6; Jarvis BP, 2018, ADDICTION, V113, P1188, DOI 10.1111/add.14180; Jarvis M, 2017, J ADDICT MED, V11, P163, DOI 10.1097/ADM.0000000000000323; Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664; Jones HE, 2010, NEW ENGL J MED, V363, P2320, DOI 10.1056/NEJMoa1005359; Kampman K, 2015, J ADDICT MED, V9, P358, DOI 10.1097/ADM.0000000000000166; Kaner EFS, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004148.pub4; Knisely JS, 2008, J SUBST ABUSE TREAT, V35, P380, DOI 10.1016/j.jsat.2008.02.001; Komaromy M, 2016, SUBST ABUS, V37, P20, DOI 10.1080/08897077.2015.1129388; Korthuis PT, 2017, ANN INTERN MED, V166, P268, DOI 10.7326/M16-2149; Korthuis PT, 2012, JAIDS-J ACQ IMM DEF, V61, P171, DOI 10.1097/QAI.0b013e31826741aa; Krans EE, 2018, ADDICT BEHAV, V86, P124, DOI 10.1016/j.addbeh.2018.05.016; Krans EE, 2015, CLIN OBSTET GYNECOL, V58, P370, DOI 10.1097/GRF.0000000000000098; Krawczyk N, 2020, ADDICTION, V115, P1683, DOI 10.1111/add.14991; Krist AH, 2020, JAMA-J AM MED ASSOC, V323, P2301, DOI 10.1001/jama.2020.8020; Krupitsky E, 2011, LANCET, V377, P1506, DOI 10.1016/S0140-6736(11)60358-9; LaBelle CT, 2016, J SUBST ABUSE TREAT, V60, P6, DOI 10.1016/j.jsat.2015.06.010; Lagisetty PA, 2019, JAMA PSYCHIAT, V76, P979, DOI 10.1001/jamapsychiatry.2019.0876; Lanier D., 2008, SCREENING PRIMARY CA; Lee JD, 2018, LANCET, V391, P309, DOI 10.1016/S0140-6736(17)32812-X; Liebschutz JM, 2014, JAMA INTERN MED, V174, P1369, DOI 10.1001/jamainternmed.2014.2556; Ling W, 2020, J SUBST ABUSE TREAT, V110, P1, DOI 10.1016/j.jsat.2019.11.004; Ling W, 2013, ADDICTION, V108, P1788, DOI 10.1111/add.12266; Lofwall MR, 2018, JAMA INTERN MED, V178, P764, DOI 10.1001/jamainternmed.2018.1052; Low AJ, 2016, CLIN INFECT DIS, V63, P1094, DOI 10.1093/cid/ciw416; Mark TL, 2019, J SUBST ABUSE TREAT, V103, P58, DOI 10.1016/j.jsat.2019.05.001; Mascola MA, 2017, OBSTET GYNECOL, V130, pE81, DOI 10.1097/AOG.0000000000002235; Mattick RP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub4; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; MCAULIFFE WE, 1990, J PSYCHOACTIVE DRUGS, V22, P197, DOI 10.1080/02791072.1990.10472544; McKnight S, 2016, AM J PERINAT, V33, P495, DOI 10.1055/s-0035-1566295; McNeely J, 2000, J URBAN HEALTH, V77, P96, DOI 10.1007/BF02350965; Mintzer IL, 2007, ANN FAM MED, V5, P146, DOI 10.1370/afm.665; Miotto K, 2012, J ADDICT MED, V6, P68, DOI 10.1097/ADM.0b013e318233d621; Morgan JR, 2019, DRUG ALCOHOL DEPEN, V200, P34, DOI 10.1016/j.drugalcdep.2019.02.031; Mullen L, 2012, AM J DRUG ALCOHOL AB, V38, P551, DOI 10.3109/00952990.2012.694516; Nelson PK, 2011, LANCET, V378, P571, DOI 10.1016/S0140-6736(11)61097-0; OCONNOR PG, 1995, J GEN INTERN MED, V10, P255, DOI 10.1007/BF02599882; OCONNOR PG, 1992, J GEN INTERN MED, V7, P532, DOI 10.1007/BF02599459; OConnor PG, 1996, AM J DRUG ALCOHOL AB, V22, P523, DOI 10.3109/00952999609001678; Olfson M, 2019, JAMA-J AM MED ASSOC, V322, P2340, DOI 10.1001/jama.2019.16566; Palepua A, 2006, DRUG ALCOHOL DEPEN, V84, P188, DOI 10.1016/j.drugalcdep.2006.02.003; Patnode CD, 2020, JAMA-J AM MED ASSOC, V323, P2310, DOI 10.1001/jama.2019.21381; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Primary Care Collaborative, 2019, VERM HUB SPOK HLTH H; Reif S, 2014, PSYCHIAT SERV, V65, P301, DOI 10.1176/appi.ps.201300242; Rich KM, 2018, CURR HIV-AIDS REP, V15, P266, DOI 10.1007/s11904-018-0396-x; Roncero C, 2016, PSYCHIAT RES, V243, P174, DOI 10.1016/j.psychres.2016.06.024; Rosenthal ES, 2020, CLIN INFECT DIS, V71, P1715, DOI 10.1093/cid/ciaa105; Roux P, 2016, ADDICTION, V111, P94, DOI 10.1111/add.13089; Roux P, 2013, PAIN, V154, P1442, DOI 10.1016/j.pain.2013.05.004; Roy-Byrne P, 2014, JAMA-J AM MED ASSOC, V312, P492, DOI 10.1001/jama.2014.7860; Saitz R, 2014, JAMA-J AM MED ASSOC, V312, P502, DOI 10.1001/jama.2014.7862; Schiff DM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.5734; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Schottenfeld RS, 2005, AM J PSYCHIAT, V162, P340, DOI 10.1176/appi.ajp.162.2.340; Sibai M, 2020, AM J DRUG ALCOHOL AB, V46, P289, DOI 10.1080/00952990.2019.1700265; Smith DK, 2013, MMWR-MORBID MORTAL W, V62, P463; Soeffing JM, 2009, J SUBST ABUSE TREAT, V37, P426, DOI 10.1016/j.jsat.2009.05.003; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Stein MD, 2007, J ADDICT DIS, V26, P1, DOI 10.1300/J069v26n02_01; Stein MD, 2015, J SUBST ABUSE TREAT, V59, P99, DOI 10.1016/j.jsat.2015.07.002; Streck JM, 2018, EXP CLIN PSYCHOPHARM, V26, P403, DOI 10.1037/pha0000199; Substance Abuse and Mental Health Services Administration, 2018, TREATMENT IMPROVEMEN, V63; Substance Abuse and Mental Health Services Administration, 2019, KEY SUBSTANCE USE ME; Substances Abuse and Mental Health Services Administration, 2020, METH; Sullivan M, 2017, AM J PSYCHIAT, V174, P459, DOI 10.1176/appi.ajp.2016.16050548; Sullivan MA, 2019, AM J PSYCHIAT, V176, P129, DOI 10.1176/appi.ajp.2018.17070732; Suzuki Joji, 2014, J Opioid Manag, V10, P159, DOI 10.5055/jom.2014.0204; Terplan M, 2018, OBSTET GYNECOL, V131, P803, DOI 10.1097/AOG.0000000000002562; Tiet QQ, 2015, JAMA INTERN MED, V175, P1371, DOI 10.1001/jamainternmed.2015.2438; Timko C, 2006, ADDICTION, V101, P678, DOI 10.1111/j.1360-0443.2006.01391.x; Tuchman E, 2006, ADDICT DISORD TREAT, V5, P43, DOI 10.1097/01.adt.0000210713.80198.d1; Turner KME, 2011, ADDICTION, V106, P1978, DOI 10.1111/j.1360-0443.2011.03515.x; US Department of Health and Human Services, 2019, HHS GUID CLIN APPR D; US Preventive Serv Task Force, 2020, JAMA-J AM MED ASSOC, V323, P970, DOI 10.1001/jama.2020.1123; Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1; Weinstein ZM, 2017, J SUBST ABUSE TREAT, V74, P65, DOI 10.1016/j.jsat.2016.12.010; Weisner C, 2001, JAMA-J AM MED ASSOC, V286, P1715, DOI 10.1001/jama.286.14.1715; Weiss L, 2008, 17 INT AIDS C 3 8 AU; Weiss L, 2011, JAIDS-J ACQ IMM DEF, V56, pS68, DOI 10.1097/QAI.0b013e31820a8226; Weiss RD, 2011, ARCH GEN PSYCHIAT, V68, P1238, DOI 10.1001/archgenpsychiatry.2011.121; Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Wilson N, 2020, MMWR-MORBID MORTAL W, V69, P290, DOI 10.15585/mmwr.mm6911a4; Wright NMJ, 2007, BMC FAM PRACT, V8, DOI 10.1186/1471-2296-8-3; Zaller Nickolas D, 2010, J Opioid Manag, V6, P365; Zanis DA, 1998, DRUG ALCOHOL DEPEN, V52, P257, DOI 10.1016/S0376-8716(98)00097-0	167	5	5	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 19	2021	373								n784	10.1136/bmj.n784	http://dx.doi.org/10.1136/bmj.n784			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	SJ5SO	34011512				2023-01-03	WOS:000655594700011
J	Motta, PD; Motta, LJ; da Mota, ACC; Goncalves, MLL; Silva, T; Momolli, M; de Andrade, DC; Fernandes, KPS; Mesquita-Ferrari, RA; Deana, AM; Wainwright, M; Prates, RA; Horliana, ACRT; Bussadori, SK				Motta, Pamella de Barros; Motta, Lara Jansiski; Costa da Mota, Ana Carolina; Leal Goncalves, Marcela Leticia; Silva, Tamiris; Momolli, Marcos; de Andrade, David Casimiro; Santos Fernandes, Kristianne Porta; Mesquita-Ferrari, Raquel Agnelli; Deana, Alessandro Melo; Wainwright, Mark; Prates, Renato Araujo; Ratto Tempestini Horliana, Anna Carolina; Bussadori, Sandra Kalil			Comparative study between photodynamic therapy with urucum plus Led and probiotics in halitosis reduction-protocol for a controlled clinical trial	PLOS ONE			English	Article							ORAL MALODOR; ADOLESCENTS; LASER	Background Halitosis is a term that defines any foul odor emanating from the oral cavity. The origin may be local or systemic. The aim of the proposed protocol is to determine whether treatment with antimicrobial photodynamic therapy (aPDT) and treatment with probiotics are effective at eliminating halitosis. Materials and methods Eighty-eight patients, from 18 to 25 years old with a diagnosis of halitosis (H2S >= 112 ppb, determined by gas chromatography) will be randomly allocated to four groups (n = 22) that will receive different treatments: Group 1 -treatment with teeth brushing, dental floss and tongue scraper; Group 2 -brushing, dental floss and aPDT; Group 3 -brushing, dental floss and probiotics; Group 4 -brushing, flossing, aPDT and probiotics. The results of the halimetry will be compared before, immediately after, seven days and thirty days after treatment. The microbiological analysis of the coated tongue will be performed at these same times. The normality of the data will be determined using the Shapiro-Wilk test. Data with normal distribution will be analyzed using analysis of variance (ANOVA). Non-parametric data will be analyzed using the Kruskal-Wallis test. The Wilcoxon test will be used to analyze the results of each treatment at the different evaluation periods. Clinical trail registration NCT03996044.	[Motta, Pamella de Barros; Motta, Lara Jansiski; Costa da Mota, Ana Carolina; Leal Goncalves, Marcela Leticia; Silva, Tamiris; Momolli, Marcos; Santos Fernandes, Kristianne Porta; Mesquita-Ferrari, Raquel Agnelli; Deana, Alessandro Melo; Prates, Renato Araujo; Ratto Tempestini Horliana, Anna Carolina; Bussadori, Sandra Kalil] Univ Nove Julho, Post Grad Program Biophoton Appl Hlth Sci, Sao Paulo, SP, Brazil; [Leal Goncalves, Marcela Leticia; Bussadori, Sandra Kalil] Univ Metropolitana Santos UNIMES, Dent Coll, Santos, SP, Brazil; [de Andrade, David Casimiro] Univ Porto, Sch Dent, Porto, Portugal; [Wainwright, Mark] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Liverpool, Merseyside, England	Universidade Nove de Julho; Universidade do Porto; Liverpool John Moores University	Motta, PD (corresponding author), Univ Nove Julho, Post Grad Program Biophoton Appl Hlth Sci, Sao Paulo, SP, Brazil.	pamellabmotta@gmail.com	Ferrari, Raquel/I-4419-2016; de Andrade, David José Casimiro/A-9968-2013; Horliana, Anna/ABH-9640-2020; Horliana, Anna Carolina Ratto Tempestini/J-3257-2015; Motta, Lara/M-1966-2014; Gonçalves, Marcela Leticia Leal/GMW-6413-2022; Fernandes, Kristianne Porta Santos/I-4417-2016	Ferrari, Raquel/0000-0001-5142-9526; de Andrade, David José Casimiro/0000-0002-2454-2467; Horliana, Anna Carolina Ratto Tempestini/0000-0003-3476-9064; Motta, Lara/0000-0002-7774-4345; Fernandes, Kristianne Porta Santos/0000-0001-7156-9286; Motta, Pamella/0000-0001-9086-4301; Silva, Tamiris/0000-0003-2023-4798	FAPESP [2019/14229-6]; CNPq [306324/2017-2]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES) [001]	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This research was supported by FAPESP grant number 2019/14229-6 and CNPq 306324/2017-2. And it was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Ni ' vel Superior -Brasil (CAPES) -Finance code 001.	Armstrong Brenda L, 2010, J Dent Hyg, V84, P65; Benic GZ, 2019, J BREATH RES, V13, DOI 10.1088/1752-7163/ab1c81; Bicak DA, 2018, OPEN DENT J, V12, P322, DOI 10.2174/1874210601812010322; Bustamante M, 2020, PROBIOTICS ANTIMICRO, V12, P325, DOI 10.1007/s12602-019-9521-4; Calil CM, 2006, LIFE SCI, V79, P660, DOI 10.1016/j.lfs.2006.02.010; Chiarelli M., 1998, AVALIACAO EFICACIA T; da Mota ACC, 2016, J BIOPHOTONICS, V9, P1337, DOI 10.1002/jbio.201600067; Ciarcia ACCDM, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000013939; Du MQ, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903-019-0734-4; Elias MS, 2006, REV LAT-AM ENFERM, V14, P821, DOI [10.1590/s0104-11692006000500026, DOI 10.1590/S0104-11692006000500026]; Hope CK, 2006, J ANTIMICROB CHEMOTH, V57, P1227, DOI 10.1093/jac/dkl096; Kara C, 2006, INT J PAEDIATR DENT, V16, P399, DOI 10.1111/j.1365-263X.2006.00769.x; Kara C, 2008, INT DENT J, V58, P151, DOI 10.1922/IDJ_1863Kara08; Kellesarian SV, 2017, QUINTESSENCE INT, V48, P575, DOI 10.3290/j.qi.a38264; Goncalves MLL, 2020, PHOTODIAGN PHOTODYN, V30, DOI 10.1016/j.pdpdt.2020.101751; Goncalves MLL, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2913-z; Goncalves MLL, 2017, J BREATH RES, V11, DOI 10.1088/1752-7163/aa8209; Lopes RG, 2016, LASER MED SCI, V31, P41, DOI 10.1007/s10103-015-1822-6; Lopes RG, 2014, J LASERS MED SCI, V5, P146; Motta LJ, 2011, CLINICS, V66, P939, DOI 10.1590/S1807-59322011000600003; Porter SR, 2006, BMJ-BRIT MED J, V333, P632, DOI 10.1136/bmj.38954.631968.AE; Salminen S, 1998, INT J FOOD MICROBIOL, V44, P93, DOI 10.1016/S0168-1605(98)00128-7; Scully C, 2012, ORAL DIS, V18, P333, DOI 10.1111/j.1601-0825.2011.01890.x; Shimizu T, 2007, J ORAL REHABIL, V34, P442, DOI 10.1111/j.1365-2842.2007.01733.x; Springfield J, 2001, J DENT RES, V80, P1441, DOI 10.1177/00220345010800051101; Suzuki N, 2019, MOL ORAL MICROBIOL, V34, P85, DOI 10.1111/omi.12259; Tangerman A, 2008, J BREATH RES, V2, DOI 10.1088/1752-7155/2/1/017010; Tolentino ED, 2011, J APPL ORAL SCI, V19, P90; Van der Weijden FA, 2015, J CLIN PERIODONTOL, V42, pS77, DOI 10.1111/jcpe.12359; Ye W, 2020, J BREATH RES, V14, DOI 10.1088/1752-7163/ab47b4; Yoo JI, 2019, PROBIOTICS ANTIMICRO, V11, P150, DOI 10.1007/s12602-017-9351-1	32	0	0	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2021	16	5							e0247096	10.1371/journal.pone.0247096	http://dx.doi.org/10.1371/journal.pone.0247096			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ST0XR	33989296	Green Published, Green Accepted, gold			2023-01-03	WOS:000662175000002
J	Jin, YM; Assanangkornchai, S; Du, YR; Liu, J; Bai, JS; Yang, YR				Jin, Yongmei; Assanangkornchai, Sawitri; Du, Yingrong; Liu, Jun; Bai, Jingsong; Yang, Yongrui			Measuring and explaining inequality of continuous care for people living with HIV receiving antiretroviral therapy in Kunming, China	PLOS ONE			English	Article							MENTAL-HEALTH; SERVICES; OUTCOMES; EQUITY; COHORT; ADULTS	Background In the context of scaling up free antiretroviral therapy (ART), healthcare equality is essential for people living with HIV. We aimed to assess socioeconomic-related inequalities in uptake of continuous care for people living with HIV receiving ART, including retention in care in the last six months, routine toxicity monitoring, adequate immunological and virological monitoring, and uptake of mental health assessment in the last 12 months. We also determined the contributions of socioeconomic factors to the degree of inequalities. Methods A hospital-based cross-sectional survey was conducted among consecutive clients visiting an HIV treatment center in Kunming, China in 2019. Participants were 702 people living with HIV aged >= 18 years (median age: 41.0 years, 69.4% male) who had been on ART for 1-5 years. Socioeconomic-related inequality and its contributing factors were assessed by a normalized concentration index (CIn) with a decomposition approach. Results The uptake of mental health assessment was low (15%) but significantly higher among the rich (CIn 0.1337, 95% CI: 0.0140, 0.2534). Retention in care, toxicity, and immunological monitoring were over 80% but non-significant in favor of the rich (CIn: 0.0117, 0.0315, 0.0736, respectively). The uptake of adequate virological monitoring was 15% and higher among the poor (CIn = -0.0308). Socioeconomic status positively contributed to inequalities of all care indicators, with the highest contribution for mental health assessment (124.9%) and lowest for virological monitoring (2.7%). Conclusions These findings suggest virological monitoring and mental health assessment be given more attention in long-term HIV care. Policies allocating need-oriented resources geared toward improving equality of continuous care should be developed.	[Jin, Yongmei; Assanangkornchai, Sawitri; Du, Yingrong; Liu, Jun; Bai, Jingsong; Yang, Yongrui] Third Peoples Hosp Kunming City, Dept Infect Dis, Kunming, Yunnan, Peoples R China; [Jin, Yongmei; Assanangkornchai, Sawitri] Prince Songkla Univ, Epidemiol Unit, Fac Med, Hat Yai, Songkhla, Thailand	Prince of Songkla University	Assanangkornchai, S (corresponding author), Prince Songkla Univ, Epidemiol Unit, Fac Med, Hat Yai, Songkhla, Thailand.	savitree.a@psu.ac.th		Assanangkornchai, Sawitri/0000-0003-2174-3287	Higher Education Research Promotion and Thailand's Education Hub for Southern Region of ASEAN Countries Project Office of the Higher Education Commission; Scientific Research Fund of Yunnan Provincial Department of Education, Yunnan province, China [2020J0610]	Higher Education Research Promotion and Thailand's Education Hub for Southern Region of ASEAN Countries Project Office of the Higher Education Commission; Scientific Research Fund of Yunnan Provincial Department of Education, Yunnan province, China	This work was supported by the Higher Education Research Promotion and Thailand's Education Hub for Southern Region of ASEAN Countries Project Office of the Higher Education Commission and the Scientific Research Fund of Yunnan Provincial Department of Education, Yunnan province, China (Grant No. 2020J0610).	AIDS and Hepatitis C Professional Group Society of Infectious Diseases Chinese Medical Association, 2018, Zhonghua Nei Ke Za Zhi, V57, P867, DOI 10.3760/cma.j.issn.0578-1426.2018.12.002; Tran BX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168687; Beltran VM, 2011, PUBLIC HEALTH REP, V126, P41, DOI 10.1177/00333549111260S309; Bing EG, 2001, ARCH GEN PSYCHIAT, V58, P721, DOI 10.1001/archpsyc.58.8.721; Blas E, 2008, LANCET, V372, P1684, DOI 10.1016/S0140-6736(08)61693-1; Burnam MA, 2001, ARCH GEN PSYCHIAT, V58, P729, DOI 10.1001/archpsyc.58.8.729; Cai JL, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0624-9; Chen ML, 2017, JAIDS-J ACQ IMM DEF, V76, P281, DOI 10.1097/QAI.0000000000001500; Citro C. F., 1995, MEASURING POVERTY NE; Dieleman JL, 2018, LANCET, V391, P1799, DOI 10.1016/S0140-6736(18)30698-6; Chu DT, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16183240; Ehrenkranz PD, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002820; European AIDS Clinical Society(ECAS), 2020, GUID VERS 10; Fu XZ, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0861-6; Kakwani N, 1997, J ECONOMETRICS, V77, P87, DOI 10.1016/S0304-4076(96)01807-6; Kohn R, 2004, B WORLD HEALTH ORGAN, V82, P858; Koirala S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176914; Kranzer K, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17383; Liang D, 2018, HEALTH POLICY PLANN, V33, P107, DOI 10.1093/heapol/czx137; Liao B, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4658-z; Ma Y, 2018, CLIN INFECT DIS, V66, P833, DOI 10.1093/cid/cix911; Murphy RA, 2010, AIDS, V24, P1007, DOI 10.1097/QAD.0b013e3283333639; National Center for AIDS/STD Control and Prevention, 2019, 2018 CHIN NAT HIV ST; National Center for AIDS/STD Prevention and Control Chinese Center for Disease Control and Prevention, 2016, CHIN FREE ANT TREATM; Ngamjarus C., 2016, Siriraj Medical Journal, V68, P160; Niu L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153489; Nuesch R, 2006, J ANTIMICROB CHEMOTH, V58, P637, DOI 10.1093/jac/dkl313; O'Donnell O., 2008, Analyzing health equity using household survey data: a guide to techniques and their implementation; O'Donnell O, 2016, STATA J, V16, P112, DOI 10.1177/1536867X1601600112; Panel of Antiretroviral Guidelines for Adults and Adolescents, GUIDELINES USE ANTIR; Pham MD, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0131-5; Roberts T, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17324; Schwartz SR, 2017, J INT AIDS SOC, V20, P43, DOI 10.1002/jia2.25003; Si L, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0516-z; Silva-Santisteban A, 2013, GLOBALIZATION HEALTH, V9, DOI 10.1186/1744-8603-9-22; Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5; Teeraananchai S, 2017, HIV MED, V18, P256, DOI 10.1111/hiv.12421; Topp SM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193641; TRICKEY A, 2017, LANCET HIV, V4, DOI DOI 10.1016/S2352-3018%2817%2930066-8; Villa G, 2020, ECLINICALMEDICINE, V18, DOI 10.1016/j.eclinm.2019.12.001; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; Wagstaff A, 2005, HEALTH ECON, V14, P429, DOI 10.1002/hec.953; Wagstaff A, 2004, HEALTH ECON, V13, P297, DOI 10.1002/hec.822; Wagstaff A, 2003, J ECONOMETRICS, V112, P207, DOI 10.1016/S0304-4076(02)00161-6; WHO, 2016, CONGUID UANT DRU; Wong NS, 2018, AIDS BEHAV, V22, P701, DOI 10.1007/s10461-017-1893-4; Wood S, 2018, AIDS, V32, P895, DOI [10.1097/QAD.0000000000001772, 10.1097/qad.0000000000001772]; World Health Organization, 2020, WHOUCNHHS2001; WU Z, 2010, INT J EPIDEMIOL S2, V39, P1, DOI DOI 10.1093/IJE/DYQ220; Wu ZY, 2019, CURR HIV-AIDS REP, V16, P458, DOI 10.1007/s11904-019-00471-4; Yehia BR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129376; Zhang N, 2018, CLIN INFECT DIS, V67, P808, DOI 10.1093/cid/ciy162; Zhou ZL, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-34; Zinkernagel C, 2001, J ACQ IMMUN DEF SYND, V28, P240, DOI 10.1097/00042560-200111010-00006	54	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2021	16	5							e0251252	10.1371/journal.pone.0251252	http://dx.doi.org/10.1371/journal.pone.0251252			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SW6LY	33974670	gold, Green Published			2023-01-03	WOS:000664626600025
J	Lundgren, JR; Janus, C; Jensen, SBK; Juhl, CR; Olsen, LM; Christensen, RM; Svane, MS; Bandholm, T; Bojsen-Moller, KN; Blond, MB; Jensen, JEB; Stallknecht, BM; Holst, JJ; Madsbad, S; Torekov, SS				Lundgren, Julie R.; Janus, Charlotte; Jensen, Simon B. K.; Juhl, Christian R.; Olsen, Lisa M.; Christensen, Rasmus M.; Svane, Maria S.; Bandholm, Thomas; Bojsen-Moller, Kirstine N.; Blond, Martin B.; Jensen, Jens-Erik B.; Stallknecht, Bente M.; Holst, Jens J.; Madsbad, Sten; Torekov, Signe S.			Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Weight Loss Maintenance with Exercise and Liraglutide In this trial, adults with obesity without diabetes were randomly assigned, after an 8-week low-calorie diet, to 1 year of placebo, an exercise program, liraglutide, or exercise plus liraglutide. Combined treatment with exercise and liraglutide improved healthy weight loss maintenance more than either treatment alone. Background Weight regain after weight loss is a major problem in the treatment of persons with obesity. Methods In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. Results After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, -4.1 kg (95% confidence interval [CI], -7.8 to -0.4; P=0.03); in the liraglutide group, -6.8 kg (95% CI, -10.4 to -3.1; P<0.001); and in the combination group, -9.5 kg (95% CI, -13.1 to -5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, -5.4 kg; 95% CI, -9.0 to -1.7; P=0.004) but not liraglutide (-2.7 kg; 95% CI, -6.3 to 0.8; P=0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (-1.7 percentage points; 95% CI, -3.2 to -0.2; P=0.02) and the liraglutide group (-1.9 percentage points; 95% CI, -3.3 to -0.5; P=0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. Conclusions A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone. (Funded by the Novo Nordisk Foundation and others; EudraCT number, ; ClinicalTrials.gov number, .)	[Lundgren, Julie R.; Janus, Charlotte; Jensen, Simon B. K.; Juhl, Christian R.; Olsen, Lisa M.; Christensen, Rasmus M.; Blond, Martin B.; Stallknecht, Bente M.; Holst, Jens J.; Torekov, Signe S.] Univ Copenhagen, Dept Biomed Sci, Panum Rm 12-4-06,Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark; [Lundgren, Julie R.; Janus, Charlotte; Jensen, Simon B. K.; Juhl, Christian R.; Olsen, Lisa M.; Christensen, Rasmus M.; Holst, Jens J.; Torekov, Signe S.] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark; [Bandholm, Thomas; Jensen, Jens-Erik B.] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark; [Svane, Maria S.; Bojsen-Moller, Kirstine N.; Jensen, Jens-Erik B.; Madsbad, Sten] Copenhagen Univ Hosp Amager & Hvidovre, Dept Endocrinol, Copenhagen, Denmark; [Bandholm, Thomas] Copenhagen Univ Hosp Amager & Hvidovre, Dept Clin Res, Copenhagen, Denmark; [Blond, Martin B.] Steno Diabet Ctr Copenhagen, Gentofte, Denmark	University of Copenhagen; Novo Nordisk Foundation; University of Copenhagen; University of Copenhagen; Steno Diabetes Center	Torekov, SS (corresponding author), Univ Copenhagen, Dept Biomed Sci, Panum Rm 12-4-06,Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark.	torekov@sund.ku.dk	Holst, Jens/AAA-8022-2022; Sandsdal, Rasmus Michael/HHS-1465-2022; Janus, Charlotte/P-3593-2018	Sandsdal, Rasmus Michael/0000-0003-0590-6285; Holst, Jens Juul/0000-0001-6853-3805; Juhl, Christian Rimer/0000-0003-3024-4017; Stallknecht, Bente Merete/0000-0003-3117-0451; Jensen, Jens-Erik Beck/0000-0003-4290-0480; Bandholm, Thomas/0000-0001-6884-1971; Janus, Charlotte/0000-0001-5111-7047; Jensen, Simon Birk Kjaer/0000-0002-1437-2150; Torekov, Signe/0000-0001-6779-0252; Blond, Martin Baek/0000-0002-2032-1560				Astbury NM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3760; Astrup A, 2009, LANCET, V374, P1606, DOI 10.1016/S0140-6736(09)61375-1; Bohm M, 2015, AM J MED, V128, P219, DOI 10.1016/j.amjmed.2014.09.016; Borg P, 2002, INT J OBESITY, V26, P676, DOI 10.1038/sj.ijo.0801962; Bull FC, 2020, BRIT J SPORT MED, V54, P1451, DOI 10.1136/bjsports-2020-102955; Church TS, 2007, JAMA-J AM MED ASSOC, V297, P2081, DOI 10.1001/jama.297.19.2081; Fogelholm M, 2000, ARCH INTERN MED, V160, P2177, DOI 10.1001/archinte.160.14.2177; Foright RM, 2018, PHYSIOL BEHAV, V188, P86, DOI 10.1016/j.physbeh.2018.01.025; Iepsen EW, 2015, INT J OBESITY, V39, P834, DOI 10.1038/ijo.2014.177; Iepsen EW, 2018, CELL METAB, V28, P23, DOI 10.1016/j.cmet.2018.05.008; Iepsen EW, 2016, EUR J ENDOCRINOL, V174, P775, DOI 10.1530/EJE-15-1116; Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee; Jensen SBK, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031431; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Knowler WC, 2015, DIABETES CARE, V38, P51, DOI 10.2337/dc14-0886; Lean MEJ, 2019, LANCET DIABETES ENDO, V7, P344, DOI 10.1016/S2213-8587(19)30068-3; Lean MEJ, 2018, LANCET, V391, P541, DOI 10.1016/S0140-6736(17)33102-1; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Logue J, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c154; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; Pi-Sunyer X, 2015, NEW ENGL J MED, V373, P11, DOI 10.1056/NEJMoa1411892; Pietilainen KH, 2008, OBESITY, V16, P409, DOI 10.1038/oby.2007.72; Purcell K, 2014, LANCET DIABETES ENDO, V2, P954, DOI 10.1016/S2213-8587(14)70200-1; Ross R, 2000, ANN INTERN MED, V133, P92, DOI 10.7326/0003-4819-133-2-200007180-00008; Ross R, 2016, CIRCULATION, V134, pE653, DOI 10.1161/CIR.0000000000000461; Stringhini S, 2017, LANCET, V389, P1229, DOI 10.1016/S0140-6736(16)32380-7; Sumithran P, 2011, NEW ENGL J MED, V365, P1597, DOI 10.1056/NEJMoa1105816; Taheri S, 2020, LANCET DIABETES ENDO, V8, P477, DOI 10.1016/S2213-8587(20)30117-0; van Baak MA, 2019, NAT REV ENDOCRINOL, V15, P274, DOI 10.1038/s41574-018-0148-4; van Can J, 2014, INT J OBESITY, V38, P784, DOI 10.1038/ijo.2013.162; Wadden TA, 2013, INT J OBESITY, V37, P1443, DOI 10.1038/ijo.2013.120; Ward ZJ, 2019, NEW ENGL J MED, V381, P2440, DOI 10.1056/NEJMsa1909301; Wilding JPH, 2021, NEW ENGL J MED, V384, P989, DOI 10.1056/NEJMoa2032183; Willis LH, 2012, J APPL PHYSIOL, V113, P1831, DOI 10.1152/japplphysiol.01370.2011; Wing RR., 2013, NEW ENGL J MED, V369, P145, DOI [10.1056/NEJMoa1212914, DOI 10.1056/NEJMOA1212914]	35	62	61	10	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2021	384	18					1719	1730		10.1056/NEJMoa2028198	http://dx.doi.org/10.1056/NEJMoa2028198			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY1SU	33951361				2023-01-03	WOS:000647698500010
J	Li, JP; Zhao, M; She, HC; Chandra, A				Li, Jipeng; Zhao, Meng; She, Haicheng; Chandra, Aman			The impact of the COVID-19 pandemic lockdown on rhegmatogenous retinal detachment services-Experiences from the Tongren eye center in Beijing	PLOS ONE			English	Article							PROLIFERATIVE VITREORETINOPATHY; CHOROIDAL DETACHMENT; RISK-FACTORS; MANAGEMENT	Purpose To investigate the impact on services for rhegmatogenous retinal detachment (RRD) patients during the COVID-19 (2019coronal virus disease) pandemic in one tertiary center in Beijing. Methods A retrospective cohort study. Two reviewed consecutive RRD patients cohorts of the same length were treated during two different periods: the COVID-19 pandemic and the pre-COVID-19 group. The characteristics of patients, surgery, anesthesia methods, length of hospital stay, and the latest follow-up were recorded and analyzed. Results There were 79 patients in the COVID-19 pandemic group with a 55.9% reduction (179). Compared to patients in the pre-COVID-19, patients in the COVID-19 pandemic had a longer presurgical waiting times (28days, 3days, p<0.001), a higher percentage of patients with presurgical poor (less than 0.02) visual acuity (55.7%, 32.4%, p = 0.009), and a higher percentage of patients with presurgical choroidal detachment (34.2%, 19.6%, p = 0.01). There was no significant difference in the severity of presurgical proliferative vitreoretinopathy between the two groups (p = 0.64). Surgeries on pathological myopia patients with macular hole retinal detachment were postponed in the COVID-19 pandemic. There was a lower percentage of scleral buckling (27.8%, 41.3%, p = 0.02) and a lower rate of subretinal fluid drainage (45.4%, 75.7%, p = 0.01) in the COVID-19 pandemic. There was no significant difference in either postoperative visual acuity (p = 0.73) or the rate of single-surgery retinal attachment (p = 1) between the two groups. Patients in the COVID-19 pandemic had a shorter length of hospital stay (3hours, 35 hours, p<0.001), and a lower percentage of patients received general anesthesia (48.1%, 83.2%, p<0.001). None was infected with COVID-19 disease during the pandemic. Conclusion The COVID-19 pandemic lockdown caused prolonged presurgical waiting times, shorter hospital stays, less general anesthesia, and a significant reduction of RRD surgeries. The RD were more complicated, the surgeons were more conservative on procedures and patients selection, while the surgery outcomes were comparable.	[Li, Jipeng; Zhao, Meng; She, Haicheng] Capital Med Univ, Beijing Tongren Hosp, Beijing Key Lab Ophthalmol & Visual Sci, Beijing Tongren Eye Ctr,Dept Ophthalmol, Beijing, Peoples R China; [Chandra, Aman] Anglia Ruskin Univ, Southend Univ Hosp, Dept Ophthalmol, Mid & South Essex NHS Fdn Trust, Cambridge, England	Capital Medical University; Anglia Ruskin University	Zhao, M (corresponding author), Capital Med Univ, Beijing Tongren Hosp, Beijing Key Lab Ophthalmol & Visual Sci, Beijing Tongren Eye Ctr,Dept Ophthalmol, Beijing, Peoples R China.	zhaomeng_jasmine@sina.com						Adelman RA, 2014, OPHTHALMOLOGY, V121, P1715, DOI 10.1016/j.ophtha.2014.03.012; ASRS) ASoRS, 2020, AM SOC RET SPEC ASRS; Awad M, 2021, EYE, V35, P1282, DOI 10.1038/s41433-020-1056-0; Callizo J, 2017, GRAEF ARCH CLIN EXP, V255, P1559, DOI 10.1007/s00417-017-3696-8; Haugstad M, 2017, ACTA OPHTHALMOL, V95, P247, DOI 10.1111/aos.13295; Ikuno Y, 2017, RETINA-J RET VIT DIS, V37, P2347, DOI 10.1097/IAE.0000000000001489; Ivanisevic M, 1997, OPHTHALMOLOGICA, V211, P90, DOI 10.1159/000310766; Kreissig I, 2020, EYE, V34, P285, DOI 10.1038/s41433-019-0683-9; Laviers H, 2018, EYE, V32, P1743, DOI 10.1038/s41433-018-0166-4; Li ZH, 2012, RETINA-J RET VIT DIS, V32, P2020, DOI 10.1097/IAE.0b013e3182561f7c; Malagola R, 2015, G CHIR, V36, P106, DOI 10.11138/gchir/2015.36.3.106; Ohno-Matsui K, 2017, RETINA-J RET VIT DIS, V37, P1043, DOI 10.1097/IAE.0000000000001348; Ophthalmology AAo, 2020, RECOMM URG NON PAT C; Ortisi E, 2012, RETINA-J RET VIT DIS, V32, P1704, DOI 10.1097/IAE.0b013e31826b671c; Park SW, 2018, CLIN OPHTHALMOL, V12, P1605, DOI 10.2147/OPTH.S153717; Pastor JC, 1998, SURV OPHTHALMOL, V43, P3, DOI 10.1016/S0039-6257(98)00023-X; Patel LG, 2021, OPHTHALMOLOGY, V128, P686, DOI 10.1016/j.ophtha.2020.10.009; Patriti A, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00314-3; Potic J, 2018, GRAEF ARCH CLIN EXP, V256, P489, DOI 10.1007/s00417-017-3880-x; SEELENFREUND MH, 1974, ARCH OPHTHALMOL-CHIC, V91, P254; Steward JE, 2020, J ENDOUROL, V34, P541, DOI 10.1089/end.2020.0342; Surgeons ACo, 2020, COVID 19 GUID TRIAG; Tseng W, 2004, AM J OPHTHALMOL, V137, P1105, DOI 10.1016/j.ajo.2004.02.008; Vail D, 2020, OSLI RETINA, V51, P328, DOI 10.3928/23258160-20200603-03; Velez-Montoya Raul, 2016, Med Hypothesis Discov Innov Ophthalmol, V5, P18; Wickham L, 2011, BRIT J OPHTHALMOL, V95, P1234, DOI 10.1136/bjo.2010.190306; Williamson TH, 2014, RETINA-J RET VIT DIS, V34, P1421, DOI 10.1097/IAE.0000000000000094; Yoshida I, 2018, CLIN OPHTHALMOL, V12, P2213, DOI 10.2147/OPTH.S177594; Yu YJ, 2019, CURR EYE RES, V44, P329, DOI 10.1080/02713683.2018.1540705; Yu YJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0319-9; Znaor L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009562.pub2	31	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0254751	10.1371/journal.pone.0254751	http://dx.doi.org/10.1371/journal.pone.0254751			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC2PD	34411135	gold, Green Accepted, Green Published			2023-01-03	WOS:000686373300072
J	Tamene, A				Tamene, Aiggan			What it takes to save lives: An assessment of water, sanitation, and hygiene facilities in temporary COVID-19 isolation and treatment centers of Southern Ethiopia: A mixed-methods evaluation	PLOS ONE			English	Article							HEALTH-CARE FACILITIES; SERVICES; WASH	Background Quality water, sanitation, and hygiene facilities act as barricades to the transmission of COVID-19 in health care facilities. These facilities ought to also be available, accessible, and functional in temporary treatment centers. Despite numerous studies on health care facilities, however, there is limited information on the status of WASH facilities in such centers. Methods The assessment of health care facilities for the COVID-19 response checklist and key informant interviews, were used for data collection. 35 treatment centers in Southern Ethiopia were surveyed. Eightkey informants were interviewed to gain an understanding of the WASH conditions in the treatment centers. The Quantitative data was entered using EPI-INFO 7 and exported to SPSS 20 for analysis. Results are presented using descriptive statistics. Open Code 4.02 was used for the thematic analysis of the qualitative data. Results Daily water supply interruptions occurred at 27 (77.1%) of the surveyed sites. Only 30 (85.72%) had bathrooms that were segregated for personnel and patients, and only 3 (3.57%) had toilets that were handicapped accessible. 20(57.2%) of the treatment centers did not have a hand hygiene protocol that satisfied WHO guidelines. In terms of infection prevention and control, 16 (45.71%) of the facilities lacked adequate personal protective equipment stocks. Between urban and rural areas, there was also a significant difference in latrine maintenance, hand hygiene protocol design and implementation, and incineration capacity. Conclusion The results reveal crucial deficiencies in the provision of WASH in the temporary COVID-19 treatment centers. Efforts to improve WASH should offer priority to hygiene service interventions to minimize the risk of healthcare-acquired infections. The sustainable provision of hygiene services, such as hand washing soap, should also be given priority.	[Tamene, Aiggan] Wachemo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Environm Hlth Unit, Hossaena, Ethiopia	University of Gondar	Tamene, A (corresponding author), Wachemo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Environm Hlth Unit, Hossaena, Ethiopia.	apublic22@gmail.com	Tamene, Aiggan/ABB-7893-2021	Tamene, Aiggan/0000-0001-5504-0905				Abdella NM, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-96; Albright J, 2018, AM J INFECT CONTROL, V46, P1104, DOI 10.1016/j.ajic.2018.04.205; Alemayehu TA, 2020, ENVIRON MONIT ASSESS, V192, DOI 10.1007/s10661-020-08297-z; Allegranzi B, 2011, LANCET, V377, P228, DOI 10.1016/S0140-6736(10)61458-4; Alzyood M, 2020, J CLIN NURS, V29, P2760, DOI 10.1111/jocn.15313; Angaw KW, 2021, CLINICOECONOMIC OUTC, V13, P279, DOI 10.2147/CEOR.S300695; BARRIE D, 1994, J HOSP INFECT, V27, P219, DOI 10.1016/0195-6701(94)90130-9; Bartram J., 2008, ESSENTIAL ENV HLTH S; Baye K., 2020, INT FOOD POLICY RES; Begashaw G., 2020, RISK TRANSMISSION KN; Boelee E, 2019, ACTA TROP, V193, P217, DOI 10.1016/j.actatropica.2019.03.011; Carling PC, 2008, INFECT CONT HOSP EP, V29, P1035, DOI 10.1086/591940; Central statistical agency/CSA/EthiopiaICF, 2016, ETH DEM HLTH SURV 20; Chang MC, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8030195; Cohen J, 2020, PREV MED, V141, DOI 10.1016/j.ypmed.2020.106263; Dancer SJ, 2009, J HOSP INFECT, V73, P378, DOI 10.1016/j.jhin.2009.03.030; Debebe S., 2020, Agriculture and Food Security, V9, DOI 10.1186/s40066-020-00269-3; Denisov E. I., 2013, Meditsina Truda i Promyshlennaya Ekologiya, P18; Ferioli M, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0068-2020; Guo A, 2017, AM J TROP MED HYG, V97, P1033, DOI 10.4269/ajtmh.17-0208; Hon Kam Lun, 2020, Drugs Context, V9, DOI 10.7573/dic.2020-4-15; Hossain MR, 2020, INTRO WATER SANITATI; Hsia RY, 2012, HEALTH POLICY PLANN, V27, P234, DOI 10.1093/heapol/czr023; Johnson RC, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2154-y; Kalpana P, 2020, INDAN J COMMUNITY HE, V32, P244; Lotfi M, 2020, CLIN CHIM ACTA, V508, P254, DOI 10.1016/j.cca.2020.05.044; Mathai E, 2010, INDIAN J MED MICROBI, V28, P100, DOI 10.4103/0255-0857.62483; Mbongwe B, 2008, WASTE MANAGE, V28, P226, DOI 10.1016/j.wasman.2006.12.019; Nzediegwu C, 2020, RESOUR CONSERV RECY, V161, DOI 10.1016/j.resconrec.2020.104947; Odagiri M., 2018, AM J MED HYGIENE, P99; Ohwo O., 2018, EUROPEAN SCI J ESJ, P14; Oli AN., 2016, ASIAN PAC J TROP BIO, P6; Patel K, 2019, REV ENVIRON HEALTH, V34, P435, DOI 10.1515/reveh-2019-0001; PEELE ER, 1981, APPL ENVIRON MICROB, V41, P873, DOI 10.1128/AEM.41.4.873-879.1981; Rajbhandari A., 2018, J PATAN ACAD HLTH SC, V5, P90; Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005; Shigute Z, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010369; Shrivastava SR, 2015, J RES MED SCI, V20, P1016, DOI 10.4103/1735-1995.172799; Singh N, 2020, RESOUR CONSERV RECY, V163, DOI 10.1016/j.resconrec.2020.105071; Sprague Joseph G, 2003, World Hosp Health Serv, V39, P35; Syed TR, 2020, INT J SCI RES, V9, P1; Unhale S.S., 2020, WJPLS, V2020, P109; Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748; Weber N, 2019, J WATER SANIT HYG DE, V9, P380, DOI 10.2166/washdev.2019.090; Wondimagegn D, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.020369; Wondimu W, 2020, J MULTIDISCIP HEALTH, V13, P917, DOI 10.2147/JMDH.S269359; World Health O United Nations Children's Fund, 2020, WATER SANITATION HYG	47	2	2	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256086	10.1371/journal.pone.0256086	http://dx.doi.org/10.1371/journal.pone.0256086			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ8RN	34388184	Green Published, gold			2023-01-03	WOS:000684737400056
J	Raschke, RA; Stoffer, B; Assar, S; Fountain, S; Olsen, K; Heise, CW; Gallo, T; Padilla-Jones, A; Gerkin, R; Parthasarathy, S; Curry, SC				Raschke, Robert A.; Stoffer, Brenda; Assar, Seth; Fountain, Stephanie; Olsen, Kurt; Heise, C. William; Gallo, Tyler; Padilla-Jones, Angela; Gerkin, Richard; Parthasarathy, Sairam; Curry, Steven C.			The relationship of tidal volume and driving pressure with mortality in hypoxic patients receiving mechanical ventilation	PLOS ONE			English	Article							ACUTE RESPIRATORY-DISTRESS; ACUTE LUNG INJURY; PROTECTIVE-VENTILATION; HOSPITAL MORTALITY; ADULT PATIENTS; CARE; ARDS; METAANALYSIS; ASSOCIATION; OUTCOMES	Purpose To determine whether tidal volume/predicted body weight (TV/PBW) or driving pressure (DP) are associated with mortality in a heterogeneous population of hypoxic mechanically ventilated patients. Methods A retrospective cohort study involving 18 intensive care units included consecutive patients >= 18 years old, receiving mechanical ventilation for >= 3 days, with a PaO2/FiO(2) ratio <= 300 mmHg, whether or not they met full criteria for ARDS. The main outcome was hospital mortality. Multiple logistic regression (MLR) incorporated TV/PBW, DP, and potential confounders including age, APACHE IVa(R) predicted hospital mortality, respiratory system compliance (C-RS), and PaO2/FiO(2). Predetermined strata of TV/PBW were compared using MLR. Results Our cohort comprised 5,167 patients with mean age 61.9 years, APACHE IVa(R) score 79.3, PaO2/FiO(2) 166 mmHg and C-RS 40.5 ml/cm H2O. Regression analysis revealed that patients receiving DP one standard deviation above the mean or higher (>= 19 cmH(2)0) had an adjusted odds ratio for mortality (ORmort) = 1.10 (95% CI: 1.06-1.13, p = 0.009). Regression analysis showed a U-shaped relationship between strata of TV/PBW and adjusted mortality. Using TV/PBW 4-6 ml/kg as the referent group, patients receiving >10 ml/kg had similar adjusted ORmort, but those receiving 6-7, 7-8 and 8-10 ml/kg had lower adjusted ORmort (95%CI) of 0.81 (0.65-1.00), 0.78 (0.63-0.97) and 0.80 0.67-1.01) respectively. The adjusted ORmort in patients receiving 4-6 ml/kg was 1.26 (95%CI: 1.04-1.52) compared to patients receiving 6-10 ml/kg. Conclusions Driving pressures >= 19 cmH(2)O were associated with increased adjusted mortality. TV/PBW 4-6ml/kg were used in less than 15% of patients and associated with increased adjusted mortality compared to TV/PBW 6-10 ml/kg used in 82% of patients. Prospective clinical trials are needed to prove whether limiting DP or the use of TV/PBW 6-10 ml/kg versus 4-6 ml/kg benefits mortality.	[Raschke, Robert A.; Heise, C. William; Gallo, Tyler; Padilla-Jones, Angela; Gerkin, Richard; Curry, Steven C.] Univ Arizona, Coll Med Phoenix, Dept Med, Div Clin Data Analyt & Decis Support, Phoenix, AZ 85004 USA; [Stoffer, Brenda] Banner Hlth, Informat Technol, Phoenix, AZ USA; [Assar, Seth; Fountain, Stephanie; Olsen, Kurt] Univ Arizona, Coll Med Phoenix, Pulm Crit Care Med Fellowship, Phoenix, AZ USA; [Padilla-Jones, Angela; Curry, Steven C.] Banner Univ, Med Ctr Phoenix, Dept Med Toxicol, Phoenix, AZ USA; [Gerkin, Richard] Banner Univ, Med Ctr Phoenix, Dept Med, Phoenix, AZ USA; [Parthasarathy, Sairam] Univ Arizona, Coll Med, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Tucson, AZ USA	University of Arizona; Banner Research; Banner Health; University of Arizona; University of Arizona	Raschke, RA (corresponding author), Univ Arizona, Coll Med Phoenix, Dept Med, Div Clin Data Analyt & Decis Support, Phoenix, AZ 85004 USA.	Raschkebob@gmail.com	Gerkin, Richard/AAM-5406-2020	Gerkin, Richard/0000-0002-6389-8888; Gallo, Tyler/0000-0002-0378-3958; Heise, Craig/0000-0002-4795-1060; Raschke, Robert/0000-0003-3495-7065	Flinn Foundation [2196]; NIH [HL126140, HL151254, AG059202, AI135108, HL140144, HL128954]; PCORI [DI-2018C213161, EADI-16493, CER-2018C2-13262]	Flinn Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PCORI(Patient-Centered Outcomes Research Institute - PCORI)	This study was funded in part by grant 2196 from the Flinn Foundation. SP was funded by NIH(HL126140, HL151254, AG059202, AI135108, HL140144, HL128954) and PCORI (DI-2018C213161, EADI-16493, CER-2018C2-13262. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Aoyama H, 2018, CRIT CARE MED, V46, P300, DOI 10.1097/CCM.0000000000002838; ASHBAUGH DG, 1967, LANCET, V2, P319; Assar S, 2018, AM J RESP CRIT CARE, V197; Beitler JR, 2016, CLIN CHEST MED, V37, P633, DOI 10.1016/j.ccm.2016.07.004; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Carmichael LC, 1996, J CRIT CARE, V11, P9, DOI 10.1016/S0883-9441(96)90015-5; Deans KJ, 2005, CRIT CARE MED, V33, P1141, DOI 10.1097/01.CCM.0000162384.71993.A3; Determann RM, 2010, CRIT CARE, V14, DOI 10.1186/cc8230; Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1510, DOI 10.1164/rccm.200208-956OC; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST; FEIHL F, 1994, AM J RESP CRIT CARE, V150, P1722, DOI 10.1164/ajrccm.150.6.7952641; Fountain S, 2018, AM J RESP CRIT CARE, V197; Fuller BM, 2018, SHOCK, V49, P311, DOI 10.1097/SHK.0000000000000977; Gattinoni L, 2011, CHEST, V140, P11, DOI 10.1378/chest.11-0827; Gilstrap D, 2013, AM J RESP CRIT CARE, V188, P1058, DOI 10.1164/rccm.201212-2214CI; Hubmayr RD, 2011, CHEST, V140, P9, DOI 10.1378/chest.11-0825; Kallet RH, 2006, CRIT CARE MED, V34, P8, DOI 10.1097/01.CCM.0000194538.32158.AF; Lanspa MJ, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2698-9; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; Loring SH, 2015, NEW ENGL J MED, V372, P776, DOI 10.1056/NEJMe1414218; Needham DM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2124; Neto AS, 2012, JAMA-J AM MED ASSOC, V308, P1651, DOI 10.1001/jama.2012.13730; Olson K Shamsid-Deen N, 2019, CRIT CARE MED, V47, P549; Orme J, 2003, AM J RESP CRIT CARE, V167, P690, DOI 10.1164/rccm.200206-542OC; Parhar KKS, 2019, ANN AM THORAC SOC, V16, P1263, DOI 10.1513/AnnalsATS.201812-910OC; PARKER JC, 1993, CRIT CARE MED, V21, P131, DOI 10.1097/00003246-199301000-00024; Parshuram C, 2003, AM J RESP CRIT CARE, V167, P798, DOI 10.1164/ajrccm.167.5.950; Parthasarathy S, 1998, AM J RESP CRIT CARE, V158, P1471, DOI 10.1164/ajrccm.158.5.9802014; Peng JM, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1606-4; Pham T, 2017, MAYO CLIN PROC, V92, P1382, DOI 10.1016/j.mayocp.2017.05.004; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Raschke RA, 2018, SW J PULM CRIT CARE, V17, P153; Sahetya SK, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2635-y; Schmidt MFS, 2018, CHEST, V153, P46, DOI 10.1016/j.chest.2017.10.004; Shah CV, 2010, CHEST, V138, P1054, DOI 10.1378/chest.09-2697; Simonis FD, 2018, JAMA-J AM MED ASSOC, V320, P1872, DOI 10.1001/jama.2018.14280; Sjoding MW, 2018, CHEST, V153, P361, DOI 10.1016/j.chest.2017.11.037; Sjoding MW, 2016, ANN AM THORAC SOC, V13, P1123, DOI 10.1513/AnnalsATS.201601-072OC; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; Thille AW, 2006, INTENS CARE MED, V32, P1515, DOI 10.1007/s00134-006-0301-8; Thompson BT, 2001, CHEST, V120, P1622, DOI 10.1378/chest.120.5.1622; Tremblay LN, 2005, AM J PHYSIOL-LUNG C, V288, pL596, DOI 10.1152/ajplung.00438.2004; Barbas CSV, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.06.26; Villar J, 2017, CRIT CARE MED, V45, P843, DOI 10.1097/CCM.0000000000002330; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Weiss CH, 2017, ANN AM THORAC SOC, V14, P1682, DOI 10.1513/AnnalsATS.201612-973OC; Weiss CH, 2016, CRIT CARE MED, V44, P1515, DOI 10.1097/CCM.0000000000001710; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0	53	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2021	16	8							e0255812	10.1371/journal.pone.0255812	http://dx.doi.org/10.1371/journal.pone.0255812			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6JQ	34370773	gold, Green Published			2023-01-03	WOS:000685266800009
J	Tekalign, T; Lemma, T; Silesh, M; Lake, EA; Teshome, M; Yitna, T; Awoke, N				Tekalign, Tiwabwork; Lemma, Tesfanesh; Silesh, Mulualem; Lake, Eyasu Alem; Teshome, Mistire; Yitna, Tesfaye; Awoke, Nefsu			Mothers' utilization and associated factors of preconception care in Africa, a systematic review and meta-analysis	PLOS ONE			English	Review							PREGNANT-WOMEN; FOLIC-ACID; RECOMMENDATIONS; KNOWLEDGE; OUTCOMES; TRIAL	Background As the studies show, in every minute in the world, 380 women become pregnant and 190 face unplanned or unwanted pregnancies; 110 experience pregnancy-related complications, and one woman dies from a pregnancy-related cause. Preconception care is one of the proven strategies for the reduction in mortality and decreases the risk of adverse health effects for the woman, fetus, and neonate by optimizing maternal health services and improves woman's health. Therefore, this study aimed to estimate the pooled prevalence of utilization of preconception of care and associated factors in Africa. Methods Systematic search of published studies done on PubMed, EMBASE, MEDLINE, Cochrane, Scopus, Web of Science CINAHL, and manually on Google Scholar. This meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The quality of studies was assessed by the modified Newcastle-Ottawa Scale (NOS). Meta-analysis was carried out using a random-effects method using the STATA((TM)) Version 14 software. Result From 249,301 obtained studies, 28 studies from 3 African regions involving 13067 women included in this Meta-analysis. The overall pooled prevalence of utilization of preconception care among pregnant women in Africa was found to be 18.72% (95% CI: 14.44, 23.00). Knowledge of preconception care (P = <0.001), preexisting medical condition (P = 0.045), and pregnancy intention (P = 0.016) were significantly associated with the utilization of preconception care. Conclusion The results of this meta-analysis indicated, as one of best approaches to improve birth outcomes, the utilization of preconception care is significantly low among mothers in Africa. Therefore, health care organizations should work on strategies to improve preconception care utilization.	[Tekalign, Tiwabwork; Lake, Eyasu Alem; Teshome, Mistire; Yitna, Tesfaye; Awoke, Nefsu] Wolaita Sodo Univ, Coll Hlth Sci & Med, Sch Nursing, Wolaita Sodo, Ethiopia; [Lemma, Tesfanesh; Silesh, Mulualem] Debre Berhan Univ, Coll Hlth Sci & Med, Dept Midwifery, Debre Berhan, Ethiopia		Tekalign, T (corresponding author), Wolaita Sodo Univ, Coll Hlth Sci & Med, Sch Nursing, Wolaita Sodo, Ethiopia.	tiwabworkt@gmail.com	Tekalign, Tiwabwork/AAO-8840-2020; Awoke, Nefsu/AFV-2432-2022	Tekalign, Tiwabwork/0000-0002-4200-4216; Awoke, Nefsu/0000-0002-1037-5004; Silesh, Mulualem/0000-0002-1943-041X; Guta, Mistire Teshome/0000-0002-7195-4827; Lemma, Tesfanesh/0000-0003-3038-5821				Adebo OO, 2017, BR J MIDWIFERY, V25, P358, DOI [10.12968/bjom.2017.25.6.358, DOI 10.12968/BJOM.2017.25.6.358]; Adeyemo AA, 2021, AFRICAN J MED HLTH S, V20, P18; Ahmed K., 2015, INT J PUBLIC HEALTH, V3, P223; Akinajo OR, 2019, J CLIN SCI, V16, P87, DOI 10.4103/jcls.jcls_41_18; Al-Darzi W, 2014, E MEDITERR HEALTH J, V20, P561, DOI 10.26719/2014.20.9.561; Alkema Leontine, 2016, Lancet, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Alsammani MA, 2017, E MEDITERR HEALTH J, V23, P662, DOI 10.26719/2017.23.10.662; [Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; [Anonymous], 2013, Pract Midwife, V16, P7; Smith Nicole M., 2006, Morbidity and Mortality Weekly Report, V55, P1; [Anonymous], 2017, MENTAL HLTH PRACTICE, V20, P7; [Anonymous], 2019, PREV TREAT CARDIO CE, V19, P1, DOI [DOI 10.5230/jgc.2019.19.e8, DOI 10.1186/s12877-019-1185-0]; [Anonymous], 2006, BRIDGES WEEKLY, V10, P3; [Anonymous], 2014, PEERJ, V2, pe447; Anzaku A.S., 2013, J BASIC CLIN REPROD, V2, P13, DOI [10.4103/2278-960X.112574, DOI 10.4103/2278-960X.112574]; Ayele AD, 2021, REPROD HEALTH, V18, DOI 10.1186/s12978-021-01132-9; Batra P, 2016, MATERN CHILD HLTH J, V20, P1170, DOI 10.1007/s10995-015-1904-x; Boakye-Yiadom AKWASI., 2020, AM J HLTH MED NURSIN, V5, P66, DOI [DOI 10.47672/AJHMN.516, 10.47672/ajhmn.516]; Braspenningx S, 2013, FACTS VIEWS VIS OBGY, V5, P13; CSA ICF-International., 2016, ETH DEM HLTH SURV 20; CZEIZEL AE, 1994, ARCH GYNECOL OBSTET, V255, P131; Dean S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001508; Demisse TL, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0758-x; Dessie MA, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1506-2; Dunlop AL, 2008, AM J OBSTET GYNECOL, V199, pS310, DOI 10.1016/j.ajog.2008.08.031; Ebadi T., 2019, J RES DEV NURS MIDWI, V16, P30; Ekem NN, 2018, J OBSTET GYNAECOL, V38, P739, DOI 10.1080/01443615.2017.1405922; ENUKU C A., 2019, INT J NURSING MED SC, V8, P10; Ezegwui HU, 2008, J OBSTET GYNAECOL, V28, P765, DOI 10.1080/01443610802462647; Fekene DB, 2020, BMC WOMENS HEALTH, V20, DOI 10.1186/s12905-020-00900-2; Frey KA, 2006, MATERN CHILD HLTH J, V10, pS73, DOI 10.1007/s10995-006-0110-2; Gezahegn A., 2016, THESIS; Goshu YA., 2018, J WOMENS HLTH CARE, V7, DOI [DOI 10.4172/2167-0420.1000445, 10.4172/2167-0420.1000445]; Habte A, 2021, REPROD HEALTH, V18, DOI 10.1186/s12978-021-01154-3; Herzog R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-154; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jack BW, 2008, AM J OBSTET GYNECOL, V199, pS266, DOI 10.1016/j.ajog.2008.07.067; Junior MAS, 2008, REV MED MINAS GER S1, V18, pS161; KIRKE PN, 1992, ARCH DIS CHILD, V67, P1442, DOI 10.1136/adc.67.12.1442; Lassi ZS, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030606; Lassi ZS, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-S3-S5; Lawal TA, 2014, PAN AFR MED J, V19, DOI 10.11604/pamj.2014.19.113.4448; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lu MC, 2007, AM FAM PHYSICIAN, V76, P397; METASEBIA G., 2020, THESIS; Modesti PA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147601; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nepali G., 2017, INT J PERCEPTIONS PU, V1, P224; Ofifinni OO, 2021, AFR J REPROD HEALTH, V25, P28, DOI 10.29063/ajrh2021/v25i2.3; Okemo J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17207430; Okon UA, 2020, PAN AFR MED J, V37, DOI 10.11604/pamj.2020.37.60.22848; Olowokere AE, 2015, J COMMUNITY HLTH PRI, V27, P83; Sardasht FG, 2017, J MIDWIFERY REPROD H, V5, P942; Senoga I, KNOWLEDGE ATTITUDES; Setegn M ., 2021, PRIMARY HLTH CARE OP, V11, P1; Shamliyan T, 2010, J CLIN EPIDEMIOL, V63, P1061, DOI 10.1016/j.jclinepi.2010.04.014; Steel A, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0165-6; Taddese F., THESIS; Teshome F, 2021, J WOMENS HLTH CARE, V10, P519; WHO, 2012, M DEV GLOB CONS PREC; World Health Organization [WHO], PREC CAR MAX GAINS M	62	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2021	16	7							e0254935	10.1371/journal.pone.0254935	http://dx.doi.org/10.1371/journal.pone.0254935			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2PW	34297760	gold, Green Published			2023-01-03	WOS:000678128300031
J	Koyanagi, Y; Fukushi, I; Nakamura, M; Suzuki, K; Oda, N; Aita, T; Seki, H				Koyanagi, Yasuki; Fukushi, Isato; Nakamura, Masatoshi; Suzuki, Kouji; Oda, Nobuhito; Aita, Takashi; Seki, Hareaki			The effect of body weight-supported overground gait training for patients with Parkinson's disease: A retrospective case-control observational study	PLOS ONE			English	Article							PHYSICAL-THERAPY; REHABILITATION TREATMENT; TREADMILL WALKING; PEOPLE; BALANCE; STRATEGIES; PARAMETERS; MOBILITY; PROGRAM; TESTS	Objective To evaluate the effects of body weight-supported overground gait training (BWSOGT) on motor abilities, such as gait and balance, in patients with Parkinson's disease (PD). Design Retrospective case-controlled observational study with a 4-week follow-up. Setting Inpatient rehabilitation. Participants We selected 37 of 68 patients with PD. Inclusion criteria were (1) Hoehn & Yahr stage II-IV, (2) no medication adjustment during the study period, (3) at least 1 week since last medication adjustment, and (4) ability to walk more than 10 meters on their own. Exclusion criteria were (1) cerebrovascular disease or other complications affecting movement, (2) difficulty in measurement, (3) early discharge, (4) medication change during the study, and (5) development of complications. Interventions Patients were divided into two groups. Patients in Group I underwent 20 minutes of BWSOGT with a mobile hoist in addition to the standard exercises; Group II performed 20 minutes of gait training in place of BWSOGT. In both groups, training was performed for a total of 15 times/4 weeks. Main outcome measure(s) Participants were evaluated using the Unified Parkinson's Disease Rating Scale total, part II, and part III; 10-m walk test; velocity; stride length; 6-minute walk test; timed up and go test; Berg Balance Scale; and freezing of gait before and after the intervention. Results There were significant decreases in the Unified Parkinson's Disease Rating Scale total, part II, and part III in both groups; however, 6-minute walk test, timed up and go test, and freezing of gait results only improved in Group I. Conclusions BWSOGT for patients with PD improves gait ability and dynamic balance more than standard gait training.	[Koyanagi, Yasuki] Natl Hosp Org Sendai Med Ctr, Dept Rehabil, Sendai, Miyagi, Japan; [Koyanagi, Yasuki; Suzuki, Kouji; Oda, Nobuhito; Aita, Takashi; Seki, Hareaki] Natl Hosp Org Iwaki Hosp, Dept Neurol & Rehabil, Iwaki, Fukushima, Japan; [Fukushi, Isato] Uekusa Gakuen Univ, Fac Hlth Sci, Chiba, Japan; [Fukushi, Isato] Murayama Med Ctr, Clin Res Ctr, Musashimurayama, Japan; [Nakamura, Masatoshi] Niigata Univ Hlth & Welf, Inst Human Movement & Med Sci, Niigata, Japan	Niigata University	Koyanagi, Y (corresponding author), Natl Hosp Org Sendai Med Ctr, Dept Rehabil, Sendai, Miyagi, Japan.; Koyanagi, Y (corresponding author), Natl Hosp Org Iwaki Hosp, Dept Neurol & Rehabil, Iwaki, Fukushima, Japan.	yasuki.koyanagi@outlook.jp		Fukushi, Isato/0000-0001-5007-3978				Azulay JP, 2006, J NEUROL SCI, V248, P192, DOI 10.1016/j.jns.2006.05.008; Behrman AL, 1998, J NEUROL NEUROSUR PS, V65, P580, DOI 10.1136/jnnp.65.4.580; Bello O, 2013, GAIT POSTURE, V38, P590, DOI 10.1016/j.gaitpost.2013.02.005; BERG K, 1989, Physiotherapy Canada, V41, P304; BLIN O, 1991, J NEUROL SCI, V103, P51, DOI 10.1016/0022-510X(91)90283-D; Bloem BR, 1996, MOVEMENT DISORD, V11, P509, DOI 10.1002/mds.870110506; Cohen J., 2013, STAT POWER ANAL BEHA; Combs SA, 2014, GAIT POSTURE, V39, P784, DOI 10.1016/j.gaitpost.2013.10.019; COMELLA CL, 1994, NEUROLOGY, V44, P376, DOI 10.1212/WNL.44.3_Part_1.376; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; de Dreu M J, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS114, DOI 10.1016/S1353-8020(11)70036-0; de Goede CJT, 2001, ARCH PHYS MED REHAB, V82, P509, DOI 10.1053/apmr.2001.22352; Dietz V, 2002, BRAIN, V125, P2626, DOI 10.1093/brain/awf273; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; Erro R, 2014, MOV DISORD CLIN PRAC, V1, P62, DOI [10.1002/mdc3.12005, 10.1002/mdc3.12007]; Ferrarin M, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P1224; Fok P, 2011, CLIN REHABIL, V25, P396, DOI 10.1177/0269215510387648; Frazzitta G, 2015, NEUROREHAB NEURAL RE, V29, P123, DOI 10.1177/1545968314542981; Frazzitta G, 2013, J NEUROL, V260, P71, DOI 10.1007/s00415-012-6585-4; Frazzitta G, 2009, MOVEMENT DISORD, V24, P1139, DOI 10.1002/mds.22491; Frenkel-Toledo S, 2005, MOVEMENT DISORD, V20, P1109, DOI 10.1002/mds.20507; Gama GL, 2017, ARCH PHYS MED REHAB, V98, P738, DOI 10.1016/j.apmr.2016.11.022; Ganesan M, 2015, ARCH PHYS MED REHAB, V96, P1557, DOI 10.1016/j.apmr.2015.05.007; Ganesan M, 2014, PM&R, V6, P22, DOI 10.1016/j.pmrj.2013.08.604; Goodwin VA, 2008, MOVEMENT DISORD, V23, P631, DOI 10.1002/mds.21922; GRILLNER S, 1978, BRAIN RES, V146, P269, DOI 10.1016/0006-8993(78)90973-3; Herman T, 2009, J NEURAL TRANSM, V116, P307, DOI 10.1007/s00702-008-0139-z; HUGHES AJ, 1993, ARCH NEUROL-CHICAGO, V50, P140, DOI 10.1001/archneur.1993.00540020018011; Zanardi APJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80768-2; Keus SHJ, 2009, MOVEMENT DISORD, V24, P1, DOI 10.1002/mds.22141; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Lamontagne A, 2004, STROKE, V35, P2543, DOI 10.1161/01.STR.0000144685.88760.d7; Lehman David A, 2005, J Neurol Phys Ther, V29, P2; MacKay-Lyons M, 2013, NEUROREHAB NEURAL RE, V27, P644, DOI 10.1177/1545968313484809; Mehrholz J., 2015, COCHRANE DB SYST REV, V8, P1; Miyai I, 2002, ARCH PHYS MED REHAB, V83, P1370, DOI 10.1053/apmr.2002.34603; Miyai I, 2000, ARCH PHYS MED REHAB, V81, P849, DOI 10.1053/apmr.2000.4439; Miyai I., 2004, GERIATR GERONTOL INT, V4, pS205, DOI [10.1111/j.1447-0594.2004.00201.x, DOI 10.1111/J.1447-0594.2004.00201.X]; Monteiro EP, 2017, SCAND J MED SCI SPOR, V27, P351, DOI 10.1111/sms.12652; Morris ME, 1996, BRAIN, V119, P551, DOI 10.1093/brain/119.2.551; Morris ME, 1996, HUM MOVEMENT SCI, V15, P649, DOI 10.1016/0167-9457(96)00020-6; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI [10.1249/mss.0b013e3180616aa2, 10.1161/CIRCULATIONAHA.107.185650]; Nieuwboer A, 2001, J REHABIL MED, V33, P266; Nutt JG, 2011, LANCET NEUROL, V10, P734, DOI 10.1016/S1474-4422(11)70143-0; Plotnik M, 2005, ANN NEUROL, V57, P656, DOI 10.1002/ana.20452; Plotnik M, 2008, EUR J NEUROSCI, V27, P1999, DOI 10.1111/j.1460-9568.2008.06167.x; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Poewe W, 2009, PARKINSONISM RELAT D, V15, pS28; Rose MH, 2013, ARCH PHYS MED REHAB, V94, P687, DOI 10.1016/j.apmr.2012.11.025; Schaafsma JD, 2003, EUR J NEUROL, V10, P391, DOI 10.1046/j.1468-1331.2003.00611.x; Solway S, 2001, CHEST, V119, P256, DOI 10.1378/chest.119.1.256; Toole T, 2005, NEUROREHABILITATION, V20, P307; van Eijkeren FJM, 2008, MOVEMENT DISORD, V23, P2239, DOI 10.1002/mds.22293	53	2	3	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2021	16	7							e0254415	10.1371/journal.pone.0254415	http://dx.doi.org/10.1371/journal.pone.0254415			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2NX	34283843	Green Published, gold			2023-01-03	WOS:000678123200049
J	Schilling, TM; Bossert, M; Konig, M; Wirtz, G; Weisbrod, M; Aschenbrenner, S				Schilling, Thomas M.; Bossert, Magdalena; Koenig, Miriam; Wirtz, Gustav; Weisbrod, Matthias; Aschenbrenner, Steffen			Acute effects of a single dose of 2 mA of anodal transcranial direct current stimulation over the left dorsolateral prefrontal cortex on executive functions in patients with schizophrenia-A randomized controlled trial	PLOS ONE			English	Article							WORKING-MEMORY; MOTOR CORTEX; NEUROANATOMY; METAANALYSIS; DIVERSITY; THOUGHT; UNITY; DLPFC; TASKS	Objective Cognitive impairments are a frequent and difficult to treat symptom in patients with schizophrenia and the strongest predictor for a successful reintegration in occupational and everyday life. Recent research suggests transcranial direct current stimulation (tDCS) to enhance cognition in this patient group. However, the question regarding its acute effectiveness on executive functions remains largely unanswered. Here, we examined in a randomized, double blind, sham-controlled repeated-measures design the impact of tDCS on performance in several executive functions in patients with schizophrenia, schizoaffective disorder or acute transient psychotic disorder. Methods Patients (N = 48) were tested twice using standardized, well-constructed and clinically validated neuropsychological tests assessing verbal working memory, response inhibition, mental flexibility and problem solving. In session 1 they solely underwent the neuropsychological assessment, whereas in session 2 they additionally received 2 mA of anodal tDCS stimulation over the left dorsolateral prefrontal cortex (DLPFC), cathode right supraorbital ridge, or sham stimulation for 20 minutes. Results Patients of both groups were not able to correctly discriminate the type of stimulation received confirming the success of the blinding procedure. However, analyzing the whole sample the change in performance from session 1 to session 2 was the same in the verum as in the sham condition (all p >.5). Moreover, a subsequent exploratory analysis showed that performance in the response inhibition task was worse for patients that engaged in the task within 20 minutes after the end of the verum stimulation. Conclusion Hence, 2 mA of anodal tDCS applied over the left DLPFC did not acutely enhance executive functions in patients with schizophrenia or related disorders but impaired performance in the response inhibition task shortly after. Future studies should continue to seek for effective stimulation configurations for this patient group.	[Schilling, Thomas M.; Bossert, Magdalena; Koenig, Miriam; Aschenbrenner, Steffen] SRH Clin Karlsbad Langensteinbach, Sect Clin Psychol & Neuropsychol, Karlsbad, Germany; [Wirtz, Gustav] SRH Psychiat Rehabil Ctr, Karlsbad, Germany; [Weisbrod, Matthias] SRH Clin Karlsbad Langensteinbach, Dept Psychiat & Psychotherapy, Karlsbad, Germany; [Weisbrod, Matthias] Heidelberg Univ, Ctr Psychosocial Med, Dept Gen Psychiat, Heidelberg, Germany	Ruprecht Karls University Heidelberg	Schilling, TM (corresponding author), SRH Clin Karlsbad Langensteinbach, Sect Clin Psychol & Neuropsychol, Karlsbad, Germany.	Thomas.Schilling@srh.de			SRH-Forderstiftung, SRH-Holding, Heidelberg, Germany [2018-910012]	SRH-Forderstiftung, SRH-Holding, Heidelberg, Germany	This work and its publication were supported the SRH-Forderstiftung, SRH-Holding, Heidelberg, Germany, (grant number 2018-910012 to S.A.), URL: https://www.srh.de/de/die-srh/srhholding/foerderstiftung/.The SRH-Forderstiftung had no further role in study design, collection, analysis or interpretation of data, in the writing of the report or the decision to submit the article for publication.	Aron AR, 2014, TRENDS COGN SCI, V18, P177, DOI 10.1016/j.tics.2013.12.003; Aschenbrenner S., 2012, WIENER TESTSYSTEM TE; Barbey AK, 2013, CORTEX, V49, P1195, DOI 10.1016/j.cortex.2012.05.022; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Cohen J., 2013, STAT POWER ANAL BEHA; Coutlee CG, 2012, BRAIN RES, V1428, P3, DOI 10.1016/j.brainres.2011.05.053; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Dickinson D, 2007, ARCH GEN PSYCHIAT, V64, P532, DOI 10.1001/archpsyc.64.5.532; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Forbes NF, 2009, PSYCHOL MED, V39, P889, DOI 10.1017/S0033291708004558; Friedman NP, 2017, CORTEX, V86, P186, DOI 10.1016/j.cortex.2016.04.023; Glahn DC, 2008, BIOL PSYCHIAT, V64, P774, DOI 10.1016/j.biopsych.2008.03.031; Gmehlin D., 2012, TASK SWITCHING SWITC; Goegler N, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00259; Hautzinger M., 2006, DTSCH BEARBEITUNG HD; Hoy KE, 2014, SCHIZOPHR RES, V155, P96, DOI 10.1016/j.schres.2014.03.006; Jamil A, 2017, J PHYSIOL-LONDON, V595, P1273, DOI 10.1113/JP272738; Johnson-Selfridge M, 2001, SCHIZOPHRENIA BULL, V27, P305, DOI 10.1093/oxfordjournals.schbul.a006876; Kaller CP., 2015, TOWER LONDON FREIBUR; Kern RS, 2011, SCHIZOPHR RES, V126, P124, DOI 10.1016/j.schres.2010.11.008; Kerns JG, 2008, BIOL PSYCHIAT, V64, P26, DOI 10.1016/j.biopsych.2008.04.027; Lefaucheur JP, 2019, NEUROPHYSIOL CLIN, V49, P269, DOI 10.1016/j.neucli.2019.07.013; Lefaucheur JP, 2017, CLIN NEUROPHYSIOL, V128, P56, DOI 10.1016/j.clinph.2016.10.087; Lehrl S., 2005, MANUAL ZUM MWT B MEH; McCleery A, 2019, DIALOGUES CLIN NEURO, V21, P239, DOI 10.31887/DCNS.2019.21.3/amccleery; Mesholam-Gately RI, 2009, NEUROPSYCHOLOGY, V23, P315, DOI 10.1037/a0014708; Michalopoulou PG, 2013, EUR NEUROPSYCHOPHARM, V23, P790, DOI 10.1016/j.euroneuro.2013.03.012; Minzenberg MJ, 2009, ARCH GEN PSYCHIAT, V66, P811, DOI 10.1001/archgenpsychiatry.2009.91; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Nejati V, 2018, NEUROSCIENCE, V369, P109, DOI 10.1016/j.neuroscience.2017.10.042; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nuechterlein KH, 2011, SCHIZOPHRENIA BULL, V37, pS33, DOI 10.1093/schbul/sbr084; Orlov ND, 2017, BRAIN, V140, P2490, DOI 10.1093/brain/awx170; Owen MJ, 2016, LANCET, V388, P86, DOI 10.1016/S0140-6736(15)01121-6; Papazova I, 2018, SCHIZOPHR RES, V202, P203, DOI 10.1016/j.schres.2018.06.032; Potkin SG, 2009, SCHIZOPHRENIA BULL, V35, P19, DOI 10.1093/schbul/sbn162; Rassovsky Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197023; Rosenbloom MH, 2012, J NEUROPSYCH CLIN N, V24, P266, DOI 10.1176/appi.neuropsych.11060139; Salehinejad Mohammad Ali, 2021, Brain Neurosci Adv, V5, p23982128211007769, DOI 10.1177/23982128211007769; Schellig D., 2009, N BACK VERBAL; Stanislaw H, 1999, BEHAV RES METH INS C, V31, P137, DOI 10.3758/BF03207704; Tsuchida A, 2013, CORTEX, V49, P1790, DOI 10.1016/j.cortex.2012.10.014; Weisbrod M., 2013, HIBIT R RESPONSE INH	44	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2021	16	7							e0254695	10.1371/journal.pone.0254695	http://dx.doi.org/10.1371/journal.pone.0254695			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2NF	34270620	Green Published, gold			2023-01-03	WOS:000678121400054
J	Verma, S; Dutta, SK; Firnberg, E; Phillips, L; Vinayek, R; Nair, PP				Verma, Sandeep; Dutta, Sudhir K.; Firnberg, Elad; Phillips, Laila; Vinayek, Rakesh; Nair, Padmanabhan P.			Identification and engraftment of new bacterial strains by shotgun metagenomic sequence analysis in patients with recurrent Clostridioides difficile infection before and after fecal microbiota transplantation and in healthy human subjects	PLOS ONE			English	Article							GUT MICROBIOME; EPIDEMIOLOGY; CLINDAMYCIN; ACETATE	Background Recurrent Clostridioides difficile infection (RCDI) is associated with major bacterial dysbiosis and colitis. Fecal microbiota transplantation (FMT) is a highly effective therapeutic modality for RCDI. While several studies have identified bacterial species associated with resolution of symptoms in patients, characterization of the fecal microbiome at the bacterial strain level in RCDI patients before and after FMT and healthy donors, has been lacking. The aim of this study was to examine the ability of bacterial strains from healthy donors to engraft in the gastrointestinal tract of patients with RCDI following FMT. Methods Fecal samples were collected from 22 patients with RCDI before and after FMT and their corresponding healthy donors. Total DNA was extracted from each sample and analyzed by shotgun metagenomic sequencing. The Cosmos-ID analysis platform was used for taxonomic assignment of sequences and calculation of the relative abundance (RA) of bacterial species and strains. From these data, the total number of bacterial strains (BSI), Shannon diversity index, dysbiosis index (DI), and bacterial engraftment factor, were calculated for each strain. Findings A marked reduction (p<0 center dot 0001) in the RA of total and specific bacterial strains, especially from phylum Firmicutes, was observed in RCDI patients prior to FMT. This change was associated with an increase in the DI (p<0 center dot 0001) and in pathobiont bacterial strains from phylum Proteobacteria, such as Escherichia coli O157:H7 and Klebsiella pneumoniae UCI 34. BSI was significantly lower in this group of patients as compared to healthy donors and correlated with the Shannon Index. (p<0 center dot 0001). Identification and engraftment of bacterial strains from healthy donors revealed a greater diversity and higher relative abundance of short-chain fatty acid (SCFA)-producing bacterial strains, including Lachnospiraceae bacterium 5_1_63FAA_u_t, Dorea formicigenerans ATCC 27755, Anaerostipes hadrusand others, in RCDI patients after FMT. Interpretation These observations identify a group of SCFA-producing bacterial strains from healthy donors that engraft well in patients with RCDI following FMT and are associated with complete resolution of clinical symptoms and bacterial dysbiosis.	[Verma, Sandeep; Dutta, Sudhir K.; Firnberg, Elad; Phillips, Laila; Vinayek, Rakesh] Sinai Hosp, Div Gastroenterol, Baltimore, MD 21215 USA; [Dutta, Sudhir K.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Nair, Padmanabhan P.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Nair, Padmanabhan P.] Noninvas Technol, Elkridge, MD USA	Sinai Hospital of Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Verma, S (corresponding author), Sinai Hosp, Div Gastroenterol, Baltimore, MD 21215 USA.	docsandeepverma@gmail.com		Phillips, Laila/0000-0002-9565-0246; Verma, Sandeep/0000-0001-8072-6693	Harry and Jeanette Weinberg Foundation; James and Carolyn Frenkil Foundation; Eric Cowan Fund; Friedman Friedman, LLP; NonInvasive Technologies LLC	Harry and Jeanette Weinberg Foundation; James and Carolyn Frenkil Foundation; Eric Cowan Fund; Friedman Friedman, LLP; NonInvasive Technologies LLC	SKD received support from The Harry and Jeanette Weinberg Foundation, the James and Carolyn Frenkil Foundation, the Eric Cowan Fund, and Friedman & Friedman, LLP for research activities. NonInvasive Technologies LLC provided support in the form of salary for author PPN. The specific roles of this author is articulated in the `author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Abt MC, 2016, NAT REV MICROBIOL, V14, P609, DOI 10.1038/nrmicro.2016.108; Atarashi K, 2017, SCIENCE, V358, P359, DOI 10.1126/science.aan4526; Balsells E, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010407; Buffie CG, 2012, INFECT IMMUN, V80, P62, DOI 10.1128/IAI.05496-11; Cai H, 2007, MICROBIOL-SGM, V153, P2655, DOI 10.1099/mic.0.2007/006452-0; Canfora EE, 2015, NAT REV ENDOCRINOL, V11, P577, DOI 10.1038/nrendo.2015.128; D'Argenio V, 2015, CLIN CHIM ACTA, V451, P97, DOI 10.1016/j.cca.2015.01.003; Dickson I, 2018, NAT REV GASTRO HEPAT, V15, DOI 10.1038/nrgastro.2018.19; Duncan SH, 2002, APPL ENVIRON MICROB, V68, P5186, DOI 10.1128/AEM.68.10.5186-5190.2002; Dutta SK, 2014, CLIN GASTROENTEROL H, V12, P1572, DOI 10.1016/j.cgh.2013.12.032; Fraser-Liggett CM, 2005, GENOME RES, V15, P1603, DOI 10.1101/gr.3724205; Garg S, 2013, DIGEST DIS SCI, V58, P3407, DOI 10.1007/s10620-013-2848-x; Gerding DN, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01700; Girotra M, 2016, DIGEST DIS SCI, V61, P3007, DOI 10.1007/s10620-016-4229-8; Hasan NA, 2015, P NATL ACAD SCI USA, V112, pE2813, DOI 10.1073/pnas.1503928112; Isaac S, 2017, J ANTIMICROB CHEMOTH, V72, P128, DOI 10.1093/jac/dkw383; Kamada N, 2013, NAT IMMUNOL, V14, P685, DOI 10.1038/ni.2608; King CH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0206484; Lax S, 2014, SCIENCE, V345, P1048, DOI 10.1126/science.1254529; Leonard MM, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-00906-w; Levy M, 2017, NAT REV IMMUNOL, V17, P219, DOI 10.1038/nri.2017.7; Meehan CJ, 2014, GENOME BIOL EVOL, V6, P703, DOI 10.1093/gbe/evu050; Miller TL, 1996, APPL ENVIRON MICROB, V62, P1589, DOI 10.1128/AEM.62.5.1589-1592.1996; Ng KM, 2013, NATURE, V502, P96, DOI 10.1038/nature12503; Ottesen A, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0894-1; Venegas DP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00277; Ponnusamy D, 2016, P NATL ACAD SCI USA, V113, P722, DOI 10.1073/pnas.1523817113; Riviere A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00979; Rothschild D, 2018, NATURE, V555, P210, DOI 10.1038/nature25973; Rupnik M, 2009, NAT REV MICROBIOL, V7, P526, DOI 10.1038/nrmicro2164; Shin H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075729, 10.1371/journal.pone.0081330]; Smillie CS, 2018, CELL HOST MICROBE, V23, P229, DOI 10.1016/j.chom.2018.01.003; STACKEBRANDT E, 1994, INT J SYST BACTERIOL, V44, P846, DOI 10.1099/00207713-44-4-846; Tettelin H, 2005, P NATL ACAD SCI USA, V102, P13950, DOI 10.1073/pnas.0506758102; Walter J, 2011, ANNU REV MICROBIOL, V65, P411, DOI 10.1146/annurev-micro-090110-102830; WAYNE LG, 1988, ZBL BAKT-INT J MED M, V268, P433; Whittemore JC, 2019, GUT MICROBES, V10, P521, DOI 10.1080/19490976.2018.1560754; Yan Q, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.01182-18; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zhang SS, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1786-6	41	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 12	2021	16	7							e0251590	10.1371/journal.pone.0251590	http://dx.doi.org/10.1371/journal.pone.0251590			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK6YQ	34252073	Green Published, gold			2023-01-03	WOS:000674302200039
J	von Schwartzenberg, RJ; Bisanz, JE; Lyalina, S; Spanogiannopoulos, P; Ang, QY; Cai, JW; Dickmann, S; Friedrich, M; Liu, SY; Collins, SL; Ingebrigtsen, D; Miller, S; Turnbaugh, JA; Patterson, AD; Pollard, KS; Mai, K; Spranger, J; Turnbaugh, PJ				von Schwartzenberg, Reiner Jumpertz; Bisanz, Jordan E.; Lyalina, Svetlana; Spanogiannopoulos, Peter; Ang, Qi Yan; Cai, Jingwei; Dickmann, Sophia; Friedrich, Marie; Liu, Su-Yang; Collins, Stephanie L.; Ingebrigtsen, Danielle; Miller, Steve; Turnbaugh, Jessie A.; Patterson, Andrew D.; Pollard, Katherine S.; Mai, Knut; Spranger, Joachim; Turnbaugh, Peter J.			Caloric restriction disrupts the microbiota and colonization resistance	NATURE			English	Article							CHAIN FATTY-ACIDS; CLOSTRIDIUM-DIFFICILE; GUT MICROBIOTA; TOXIN-B; ALIGNMENT; DATABASE; GENES; TESTS; DIET	Diet is a major factor that shapes the gut microbiome(1), but the consequences of diet-induced changes in the microbiome for host pathophysiology remain poorly understood. We conducted a randomized human intervention study using a very-low-calorie diet (NCT01105143). Although metabolic health was improved, severe calorie restriction led to a decrease in bacterial abundance and restructuring of the gut microbiome. Transplantation of post-diet microbiota to mice decreased their body weight and adiposity relative to mice that received pre-diet microbiota. Weight loss was associated with impaired nutrient absorption and enrichment in Clostridioides difficile, which was consistent with a decrease in bile acids and was sufficient to replicate metabolic phenotypes in mice in a toxin-dependent manner. These results emphasize the importance of diet-microbiome interactions in modulating host energy balance and the need to understand the role of diet in the interplay between pathogenic and beneficial symbionts.	[von Schwartzenberg, Reiner Jumpertz; Dickmann, Sophia; Friedrich, Marie; Mai, Knut; Spranger, Joachim] Charite Univ Med Berlin, Dept Endocrinol & Metab Dis, Berlin, Germany; [von Schwartzenberg, Reiner Jumpertz; Mai, Knut; Spranger, Joachim] Berlin Inst Hlth BIH, Berlin, Germany; [von Schwartzenberg, Reiner Jumpertz; Spranger, Joachim] DZHK German Ctr Cardiovasc Res, Ctr Cardiovasc Res CCR, Partner Site Berlin, Berlin, Germany; [Bisanz, Jordan E.; Spanogiannopoulos, Peter; Ang, Qi Yan; Turnbaugh, Jessie A.; Turnbaugh, Peter J.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Lyalina, Svetlana; Pollard, Katherine S.] Gladstone Inst, San Francisco, CA USA; [Cai, Jingwei; Collins, Stephanie L.; Patterson, Andrew D.] Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & BiomedicarSci, University Pk, PA 16802 USA; [Liu, Su-Yang] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Ingebrigtsen, Danielle; Miller, Steve] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA USA; [Pollard, Katherine S.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA; [Pollard, Katherine S.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA USA; [Pollard, Katherine S.] Univ Calif San Francisco, Inst Computat Hlth Sci, San Francisco, CA 94143 USA; [Pollard, Katherine S.] Chan Zuckerberg Biohub, San Francisco, CA USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; German Centre for Cardiovascular Research; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Spranger, J (corresponding author), Charite Univ Med Berlin, Dept Endocrinol & Metab Dis, Berlin, Germany.; Spranger, J (corresponding author), Berlin Inst Hlth BIH, Berlin, Germany.; Spranger, J (corresponding author), DZHK German Ctr Cardiovasc Res, Ctr Cardiovasc Res CCR, Partner Site Berlin, Berlin, Germany.; Turnbaugh, PJ (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.	joachim.spranger@charite.de; peter.turnbaugh@ucsf.edu		Mai, Knut/0000-0003-0126-3155; Jumpertz von Schwartzenberg, Reiner/0000-0002-5544-099X; Cai, Jingwei/0000-0002-3626-3350; Ang, Qi Yan/0000-0002-9788-1283; Turnbaugh, Peter/0000-0002-0888-2875; Grenkowitz, Sophia/0000-0002-3237-6710; Bisanz, Jordan/0000-0002-8649-1706	National Institutes of Health [R01HL122593, R21CA227232, P30DK098722, 1R01AR074500, 1R01DK114034]; Damon Runyon Cancer Research Foundation [DRR-42-16]; UCSF Program for Breakthrough Biomedical Research - Sandler Foundation; Searle Scholars Program; Natural Sciences and Engineering Research Council of Canada Postdoctoral Fellowship; National Institute of Allergy and Infectious Diseases [K99AI147165]; Canadian Institutes of Health Research Fellowship program; A*STAR (Agency for Science, Technology and Research), Singapore; Berlin Institute of Health; German Research Foundation (DFG) [CRG192, CRG218, CRC/TR 296 Locotact]; DZHK (German Centre for Cardiovascular Research) partner site Berlin; BMBF (German Ministry of Education and Research); Einstein Foundation Berlin via the Einstein Center for Regenerative Therapies; Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Germany; NSF [DMS-1850638]; Sugar, Stress, Environment, and Weight (SSEW) Center; Charite-Universitatsmedizin Berlin; Gladstone Institutes	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation; UCSF Program for Breakthrough Biomedical Research - Sandler Foundation; Searle Scholars Program; Natural Sciences and Engineering Research Council of Canada Postdoctoral Fellowship(Natural Sciences and Engineering Research Council of Canada (NSERC)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Canadian Institutes of Health Research Fellowship program(Canadian Institutes of Health Research (CIHR)); A*STAR (Agency for Science, Technology and Research), Singapore(Agency for Science Technology & Research (A*STAR)); Berlin Institute of Health; German Research Foundation (DFG)(German Research Foundation (DFG)); DZHK (German Centre for Cardiovascular Research) partner site Berlin; BMBF (German Ministry of Education and Research)(Federal Ministry of Education & Research (BMBF)); Einstein Foundation Berlin via the Einstein Center for Regenerative Therapies; Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Germany; NSF(National Science Foundation (NSF)); Sugar, Stress, Environment, and Weight (SSEW) Center; Charite-Universitatsmedizin Berlin; Gladstone Institutes(University of California System)	We thank the UCSF Gnotobiotic Core Facility, and the Lynch lab (UCSF) for technical support; S. Brachs from the Spranger Lab for technical and scientific support with the animal experiments; and P. B. Smith in the Metabolomics Facility of Penn State. The Turnbaugh lab was supported by the National Institutes of Health (R01HL122593; R21CA227232; P30DK098722; 1R01AR074500; 1R01DK114034) and the Sugar, Stress, Environment, and Weight (SSEW) Center. P.J.T. was a Chan Zuckerberg Biohub investigator and a Nadia<BOLD>'</BOLD>s Gift Foundation Innovator supported, in part, by the Damon Runyon Cancer Research Foundation (DRR-42-16), the UCSF Program for Breakthrough Biomedical Research (partially funded by the Sandler Foundation), and the Searle Scholars Program. J.E.B. was the recipient of a Natural Sciences and Engineering Research Council of Canada Postdoctoral Fellowship and received support from the National Institute of Allergy and Infectious Diseases (K99AI147165). P.S. was supported by the Canadian Institutes of Health Research Fellowship program. Q.Y.A. was the recipient of a graduate fellowship from A*STAR (Agency for Science, Technology and Research), Singapore. Funding was also provided by the Berlin Institute of Health (J.S., R.J.v.S., K.M.) and the German Research Foundation (DFG) to J.S. (CRC/TR 296 Locotact, CRG192 and CRG218) as well as the DZHK (German Centre for Cardiovascular Research) partner site Berlin (R.J.v.S., J.S.), DZD (German Centre for Diabetes Research) partner site Berlin (J.S.), and the BMBF (German Ministry of Education and Research) (K.M., J.S.). R.J.v.S. was a participant in the BIH Charite Clinician Scientist Program funded by the Charite-Universitatsmedizin Berlin and the Berlin Institute of Health. Further funding was provided by the Einstein Foundation Berlin via the Einstein Center for Regenerative Therapies (R.J.v.S.) and the Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, Germany (R.J.v.S.). Funding support was also provided via the Gladstone Institutes and NSF grant DMS-1850638 (K.S.P.).	Alneberg J, 2014, NAT METHODS, V11, P1144, DOI [10.1038/NMETH.3103, 10.1038/nmeth.3103]; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021; Bauer MP, 2011, LANCET, V377, P63, DOI 10.1016/S0140-6736(10)61266-4; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brouns F, 2005, NUTR RES REV, V18, P145, DOI 10.1079/NRR2005100; Buchfink B, 2015, NAT METHODS, V12, P59, DOI 10.1038/nmeth.3176; Buffie CG, 2015, NATURE, V517, P205, DOI 10.1038/nature13828; Cai JW, 2017, ANAL CHEM, V89, P7900, DOI 10.1021/acs.analchem.7b00848; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Cani PD, 2019, NAT METAB, V1, P34, DOI 10.1038/s42255-018-0017-4; Cao Y, 2014, BIOINFORMATICS, V30, P1674, DOI 10.1093/bioinformatics/btu104; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Carmody RN, 2019, NAT MICROBIOL, V4, P2052, DOI 10.1038/s41564-019-0569-4; Chaumeil PA, 2020, BIOINFORMATICS, V36, P1925, DOI 10.1093/bioinformatics/btz848; Chen EZ, 2016, BIOINFORMATICS, V32, P2611, DOI 10.1093/bioinformatics/btw308; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/nar/17.19.7843; Erben U, 2014, INT J CLIN EXP PATHO, V7, P4557; Fang FC, 2017, J CLIN MICROBIOL, V55, P670, DOI 10.1128/JCM.02463-16; Fernandes AD, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-15; Fernandes AD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067019; Festi D, 1998, INT J OBESITY, V22, P592, DOI 10.1038/sj.ijo.0800634; Fouladi F, 2020, ISME J, V14, P1809, DOI 10.1038/s41396-020-0645-z; Furuya-Kanamori L, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1258-4; Harris JK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110396; Heinsen FA, 2016, OBESITY FACTS, V9, P379, DOI 10.1159/000449506; Hunt JJ, 2013, MICROBIOL MOL BIOL R, V77, P567, DOI 10.1128/MMBR.00017-13; Johansson K, 2014, AM J CLIN NUTR, V99, P14, DOI 10.3945/ajcn.113.070052; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Kohl KD, 2014, FEMS MICROBIOL ECOL, V90, P883, DOI 10.1111/1574-6941.12442; Kubota H, 2016, APPL ENVIRON MICROB, V82, P5806, DOI 10.1128/AEM.01540-16; Kuehne SA, 2010, NATURE, V467, P711, DOI 10.1038/nature09397; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lombard V, 2014, NUCLEIC ACIDS RES, V42, pD490, DOI 10.1093/nar/gkt1178; Louis S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149564; Menzel P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11257; Morrison DJ, 2016, GUT MICROBES, V7, P189, DOI 10.1080/19490976.2015.1134082; Nayfach S, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0611-7; Parks DH, 2015, GENOME RES, V25, P1043, DOI 10.1101/gr.186072.114; Persson S, 2008, CLIN MICROBIOL INFEC, V14, P1057, DOI 10.1111/j.1469-0691.2008.02092.x; Pritchard L, 2016, ANAL METHODS-UK, V8, P12, DOI [10.1039/c5ay02550h, 10.1039/C5AY02550H]; Sarafian MH, 2015, ANAL CHEM, V87, P9662, DOI 10.1021/acs.analchem.5b01556; Segata N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3304; Sorg JA, 2008, J BACTERIOL, V190, P2505, DOI 10.1128/JB.01765-07; Spranger L., 2021, THRIFTY ENERGY PHENO, DOI [10.1101/2021.03.25.21254300v1, DOI 10.1101/2021.03.25.21254300V1]; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; Uchiyama T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126967; Uritskiy GV, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0541-1; van Passel MWJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016876; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wattam AR, 2017, NUCLEIC ACIDS RES, V45, pD535, DOI 10.1093/nar/gkw1017; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wood DE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1891-0; Wu D, 2010, BIOINFORMATICS, V26, P2176, DOI 10.1093/bioinformatics/btq401; WUST J, 1982, J CLIN MICROBIOL, V16, P1096; Zacharioudakis IM, 2015, AM J GASTROENTEROL, V110, P381, DOI 10.1038/ajg.2015.22; Zarrinpar A, 2014, CELL METAB, V20, P1006, DOI 10.1016/j.cmet.2014.11.008; Zhao YA, 2012, BIOINFORMATICS, V28, P125, DOI 10.1093/bioinformatics/btr595; Zheng XJ, 2013, METABOLOMICS, V9, P818, DOI 10.1007/s11306-013-0500-6	63	49	49	19	85	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 8	2021	595	7866					272	+		10.1038/s41586-021-03663-4	http://dx.doi.org/10.1038/s41586-021-03663-4		JUN 2021	21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE9OU	34163067	Green Published, Green Accepted			2023-01-03	WOS:000664816200003
J	McArdle, AJ; Vito, O; Patel, H; Seaby, EG; Shah, PY; Wilson, C; Broderick, C; Nijman, R; Tremoulet, AH; Munblit, D; Ulloa-Gutierrez, R; Carter, MJ; De, TS; Hoggart, C; Whittaker, E; Herberg, JA; Kaforou, M; Cunnington, AJ; Levin, M				McArdle, Andrew J.; Vito, Ortensia; Patel, Harsita; Seaby, Eleanor G.; Shah, Priyen; Wilson, Clare; Broderick, Claire; Nijman, Ruud; Tremoulet, Adriana H.; Munblit, Daniel; Ulloa-Gutierrez, Rolando; Carter, Michael J.; De, Tisham; Hoggart, Clive; Whittaker, Elizabeth; Herberg, Jethro A.; Kaforou, Myrsini; Cunnington, Aubrey J.; Levin, Michael		BATS Consortium	Treatment of Multisystem Inflammatory Syndrome in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE RESPIRATORY SYNDROME; KAWASAKI-LIKE DISEASE; TOXIC-SHOCK-SYNDROME; MANAGEMENT; OUTCOMES	BACKGROUND Evidence is urgently needed to support treatment decisions for children with multisystem inflammatory syndrome (MIS-C) associated with severe acute respiratory syndrome coronavirus 2. METHODS We performed an international observational cohort study of clinical and outcome data regarding suspected MIS-C that had been uploaded by physicians onto a Web-based database. We used inverse-probability weighting and generalized linear models to evaluate intravenous immune globulin (IVIG) as a reference, as compared with IVIG plus glucocorticoids and glucocorticoids alone. There were two primary outcomes: the first was a composite of inotropic support or mechanical ventilation by day 2 or later or death; the second was a reduction in disease severity on an ordinal scale by day 2. Secondary outcomes included treatment escalation and the time until a reduction in organ failure and inflammation. RESULTS Data were available regarding the course of treatment for 614 children from 32 countries from June 2020 through February 2021; 490 met the World Health Organization criteria for MIS-C. Of the 614 children with suspected MIS-C, 246 received primary treatment with IVIG alone, 208 with IVIG plus glucocorticoids, and 99 with glucocorticoids alone; 22 children received other treatment combinations, including biologic agents, and 39 received no immunomodulatory therapy. Receipt of inotropic or ventilatory support or death occurred in 56 patients who received IVIG plus glucocorticoids (adjusted odds ratio for the comparison with IVIG alone, 0.77; 95% confidence interval [CI], 0.33 to 1.82) and in 17 patients who received glucocorticoids alone (adjusted odds ratio, 0.54; 95% CI, 0.22 to 1.33). The adjusted odds ratios for a reduction in disease severity were similar in the two groups, as compared with IVIG alone (0.90 for IVIG plus glucocorticoids and 0.93 for glucocorticoids alone). The time until a reduction in disease severity was similar in the three groups. CONCLUSIONS We found no evidence that recovery from MIS-C differed after primary treatment with IVIG alone, IVIG plus glucocorticoids, or glucocorticoids alone, although significant differences may emerge as more data accrue.	[McArdle, Andrew J.; Vito, Ortensia; Patel, Harsita; Seaby, Eleanor G.; Shah, Priyen; Wilson, Clare; Broderick, Claire; Nijman, Ruud; De, Tisham; Whittaker, Elizabeth; Kaforou, Myrsini; Cunnington, Aubrey J.; Levin, Michael] Imperial Coll London, Dept Infect Dis, Sect Pediat Infect Dis, London, England; [Munblit, Daniel] Imperial Coll London, Natl Heart & Lung Inst, Fac Med, Inflammat Repair & Dev Sect, London, England; [Nijman, Ruud; Whittaker, Elizabeth; Herberg, Jethro A.; Cunnington, Aubrey J.; Levin, Michael] Imperial Coll Healthcare NHS Trust, Dept Pediat, London, England; [Carter, Michael J.] Kings Coll London, St Thomas Hosp, Sch Life Course Sci, Dept Women & Childrens Hlth, London, England; [Seaby, Eleanor G.] Univ Southampton, Genom Informat Grp, Southampton, Hants, England; [Seaby, Eleanor G.] Broad Inst MIT & Harvard, Translat Genom Grp, Cambridge, MA 02142 USA; [Tremoulet, Adriana H.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Tremoulet, Adriana H.] Rady Childrens Hosp, San Diego, CA USA; [Munblit, Daniel] Sechenov Univ, Dept Pediat & Pediat Infect Dis, Moscow, Russia; [Ulloa-Gutierrez, Rolando] Hosp Nacl Ninos Dr Carlos Saenz Herrera, Ctr Ciencias Med, Serv Infectol, Caja Costarricense Seguro Social, San Jose, Costa Rica; [Hoggart, Clive] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA	Imperial College London; Imperial College London; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Southampton; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; Sechenov First Moscow State Medical University; Icahn School of Medicine at Mount Sinai	Levin, M (corresponding author), Imperial Coll London, Med Sch, St Marys Campus,Norfolk Pl, London W2 1PG, England.	m.levin@imperial.ac.uk	Bianco, Francesco/Z-1839-2019; SIMONINI, Gabriele/K-2647-2018; Ulloa-Gutierrez, Rolando/U-3513-2019; Bucciarelli, Valentina/AAK-3629-2021; Farmaki, Evangelia/AAA-6768-2022; Arandes, Antonio Soriano/Q-3348-2016; Medina, Rafael A./AAW-4418-2020; Belot, Alexandre/C-7378-2013; Haerynck, Filomeen/AAD-6761-2020; Munblit, Daniel/H-7336-2019; Anastasiia, Glazyrina/ABE-2483-2021; Hoste, Levi/AAF-2764-2019; Rodriguez-Gonzalez, Moises/J-9699-2019; Rivière, Jacques G./ABH-8867-2020; Seddon, James/HHC-2093-2022; Martinon-Torres, Federico/E-4982-2016; Lau, Yu Lung/C-4322-2009; Brodin, Petter/C-3317-2011; Hoste, Levi/ABB-7628-2020	SIMONINI, Gabriele/0000-0002-5919-4861; Ulloa-Gutierrez, Rolando/0000-0002-9157-9227; Medina, Rafael A./0000-0002-5013-6884; Belot, Alexandre/0000-0003-4902-5332; Munblit, Daniel/0000-0001-9652-6856; Rodriguez-Gonzalez, Moises/0000-0002-5587-435X; Rivière, Jacques G./0000-0003-1055-2063; VALENZUELA GALAZ, GONZALO/0000-0002-5538-8749; Castano Guerra, Elizabeth/0000-0001-9119-8697; Grandjean, Louis/0000-0002-1457-8327; VALENTINI, Piero/0000-0001-6095-9510; Sanchez-Manubens, Judith/0000-0002-7615-4765; Biggs, Catherine/0000-0002-4363-2660; Nijman, Ruud Gerard/0000-0001-9671-8161; Rivero Calle, Irene/0000-0002-3678-9264; Bianco, Francesco/0000-0001-9785-3402; Shah, Priyen/0000-0001-9164-8862; Levin, Michael/0000-0003-2767-6919; Yock-Corrales, Adriana/0000-0002-8251-2434; Carrol, Enitan/0000-0001-8357-7726; Rodrigues, Charlene/0000-0003-0942-3707; Zapata Yarleque, Elmer Hans/0000-0002-4371-0964; Kovygina, Karina/0000-0001-8143-4668; Ramnarayan, Padmanabhan/0000-0003-0784-8154; Kwan, Mike Yat Wah/0000-0002-1476-9625; Brotschi, Barbara/0000-0002-4472-5199; Basu Roy, Robindra/0000-0001-5648-3628; Peralta-Ponce, Carlos Antonio/0000-0002-1078-7682; Yeung, Shunmay/0000-0002-0997-0850; Seddon, James/0000-0002-2296-2302; Hacohen, Yael/0000-0001-8490-9657; Vermont, Clementien/0000-0002-2219-856X; Broderick, Claire/0000-0003-2582-4527; Haerynck, Filomeen/0000-0001-9161-7361; Whittaker, Elizabeth/0000-0002-7944-8793; Martinon-Torres, Federico/0000-0002-9023-581X; Bustos Betanzo, Raul/0000-0003-0005-4829; Soriano-Arandes, Antoni/0000-0001-9613-7228; Lau, Yu Lung/0000-0002-4780-0289; Bobkova, Polina/0000-0002-6604-7173; Brodin, Petter/0000-0002-8103-0046; Seaby, Eleanor/0000-0002-6814-8648; Vito, Ortensia/0000-0001-5509-6351; Grasa, Carlos/0000-0002-9323-2024; Iakovleva (Spiridonova), Ekaterina/0000-0002-3107-5414; Mazza, Angelo/0000-0002-3976-5495; CARTER, Michael/0000-0003-3403-4746; Hoste, Levi/0000-0001-9733-1049	European Union's Horizon 2020 Program [848196, 668303]; Imperial Biomedical Research Centre (BRC) of the National Institute for Health Research (NIHR); Lee Family Foundation; Wellcome Trust [203928/Z/16/Z, RDA02, 206508/Z/17/Z, MRF-1600008-ELP-KAFO-C0801]; BRC; Medical Research Foundation [206508/Z/17/Z, MRF-1600008-ELP-KAFO-C0801]; NIHR [ACL-2018-021-007]; National Institutes of Health [GA5R01AI128765]	European Union's Horizon 2020 Program; Imperial Biomedical Research Centre (BRC) of the National Institute for Health Research (NIHR); Lee Family Foundation; Wellcome Trust(Wellcome Trust); BRC; Medical Research Foundation(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR(National Institute for Health Research (NIHR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by the European Union's Horizon 2020 Program under grants (848196 DIAMONDS and 668303 PERFORM, to Dr. Levin), by the Imperial Biomedical Research Centre (BRC) of the National Institute for Health Research (NIHR) for the enrollment of patients in London, by a grant (to Dr. McArdle) from the Lee Family Foundation, a grant (203928/Z/16/Z, to Dr. Wilson) from the Wellcome Trust, a grant (RDA02, to Dr. Broderick) from the Wellcome Trust and the BRC, grants (206508/Z/17/Z and MRF-1600008-ELP-KAFO-C0801, to Dr. Kaforou) from the Wellcome Trust and the Medical Research Foundation, a grant (ACL-2018-021-007, to Dr. Nijman) from the NIHR, and a grant (GA5R01AI128765, to Dr. Levin) from the National Institutes of Health.	Belhadjer Z, 2020, CIRCULATION, V142, P2282, DOI 10.1161/CIRCULATIONAHA.120.050147; Bowles L, 2020, NEW ENGL J MED, V383, P288, DOI 10.1056/NEJMc2013656; Capone CA, 2020, J PEDIATR-US, V224, P141, DOI [10.1018/j.jpeds.2020.08.044, 10.1016/j.jpeds.2020.06.044]; Centers for Disease Control and Prevention, INF HEALTHC PROV MUL; Crayne C, 2020, EUR J RHEUMATOL, V7, pS13, DOI 10.5152/eurjrheum.2019.19150; Davies P, 2021, PEDIATR CRIT CARE ME, V22, pE282, DOI 10.1097/PCC.0000000000002728; Davies P, 2020, LANCET CHILD ADOLESC, V4, P669, DOI 10.1016/S2352-4642(20)30215-7; Feldstein LR, 2021, JAMA-J AM MED ASSOC, V325, P1074, DOI 10.1001/jama.2021.2091; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Floh A, 2017, CIRCULATION, V136; Godfred-Cato S, 2020, MMWR-MORBID MORTAL W, V69, P1074, DOI 10.15585/mmwr.mm6932e2; Gottlieb M, 2018, J EMERG MED, V54, P807, DOI 10.1016/j.jemermed.2017.12.048; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Harwood R, 2021, LANCET CHILD ADOLESC, V5, P133, DOI 10.1016/S2352-4642(20)30304-7; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285; Irfan O, 2021, ARCH DIS CHILD, V106, P440, DOI 10.1136/archdischild-2020-321385; Levin M, 2020, NEW ENGL J MED, V383, P393, DOI 10.1056/NEJMe2023158; Lopez L, 2017, CIRC-CARDIOVASC IMAG, V10, DOI 10.1161/CIRCIMAGING.117.006979; Ouldali N, 2021, JAMA-J AM MED ASSOC, V325, P855, DOI 10.1001/jama.2021.0694; Pouletty M, 2020, ANN RHEUM DIS, V79, P999, DOI 10.1136/annrheumdis-2020-217960; Riphagen Shelley, 2020, Lancet, V395, P1607, DOI 10.1016/S0140-6736(20)31094-1; Royal College of Paediatrics and Child Health, 2020, GUID PAED MULT INFL; Sood Mangla, 2021, SN Compr Clin Med, V3, P38, DOI 10.1007/s42399-020-00690-6; Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191; Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094; Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X; Viner RM, 2020, LANCET, V395, P1741, DOI 10.1016/S0140-6736(20)31129-6; Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369; Wilkins AL, 2017, J INFECTION, V74, pS147, DOI 10.1016/S0163-4453(17)30206-2; World Health Organization, 2020, TRANSMISSION SARS CO	30	127	132	5	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2021	385	1					11	22		10.1056/NEJMoa2102968	http://dx.doi.org/10.1056/NEJMoa2102968		JUN 2021	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WU5EV	34133854	Green Published, Bronze			2023-01-03	WOS:000663460100001
J	Jaffe, S				Jaffe, Susan			US drug importation plan hits snag	LANCET			English	Editorial Material																			0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2021	397	10291					2240	2240						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	SQ0SX	34119053				2023-01-03	WOS:000660072500011
J	Pinzon, MA; Ortiz, S; Holguin, H; Betancur, JF; Arango, DC; Laniado, H; Arias, CA; Munoz, B; Quiceno, J; Jaramillo, D; Ramirez, Z				Pinzon, Miguel Alejandro; Ortiz, Santiago; Holguin, Hector; Betancur, Juan Felipe; Arango, Doris Cardona; Laniado, Henry; Arias, Carolina Arias; Munoz, Bernardo; Quiceno, Julian; Jaramillo, Daniel; Ramirez, Zoraida			Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia	PLOS ONE			English	Article								Background There is no effective therapy for the severe acute respiratory syndrome by coronavirus 2 (SARS-CoV2) responsible for the Coronavirus disease 2019 (Covid-19). To date, dexamethasone has shown a decrease in mortality in patients who require oxygen, especially those with invasive mechanical ventilation. However, it is unknown if another corticosteroid can be used, the optimal dose and its duration, to achieve a better clinical outcome. The objective of the study was to compare the differences in clinical outcome and laboratory results in hospitalized patients with severe SARS-CoV2 Pneumonia treated with dexamethasone at 6 mg doses versus patients treated with high-dose methylprednisolone. Materials and methods Ambispective cohort study with survival analysis of 216 patients diagnosed with severe Covid-19 pneumonia confirmed by polymerase chain reaction for SARS-CoV2 by Berlin protocol, who were hospitalized in a high-complexity clinic in Medellin, Colombia. The patients should also have supplementary oxygen and radiological confirmation of Pneumonia by chest tomography. Sample size was not calculated since the total population that met the inclusion criteria was evaluated. 111 patients were treated with the institutional protocol with intravenous dexamethasone 6 mg QD for seven to 10 days if they required oxygen. Since September 15, 2020, the hospitalization protocol of the clinic was modified by the Infectious Diseases and Pulmonology service, recommending a high dose of methylprednisolone of 250 to 500 mg every day for three days with a subsequent change to oral prednisone 50 mg every day for 14 days. The protocol was not applied in the intensive care unit, where dexamethasone continued to be administered. The clinical outcome and differences in laboratory results of the patients who received dexamethasone vs. the prospective cohort that received methylprednisolone from September 15 to October 31, 2020, were evaluated. Follow-up was carried out by outpatient consultation one month after discharge or by telephone, inquiring about readmission or living-dead status. Results 216 patients had Covid-19 pneumonia documented by ground-glass imaging and alveolar pressure / inspired oxygen fraction (PaFi) less than 300. 111 patients received dexamethasone (DXM) and 105 received methylprednisolone (MTP). Patients in the DXM group evolved to severe ARDS in a higher proportion (26.1% vs 17.1% than the MTP group). Upon completion 4 days of treatment with parenteral corticosteroid, laboratory markers of severity decreased significantly in the group that received MTP, CRP 2.85 (2.3-3.8) vs 7.2 (5.4-9.8), (p-value < 0.0001), D-dimer 691 (612-847) vs 1083 (740-1565) (p-value = 0.04) and DHL 273 (244-289) vs 355 (270.6-422) (p-value = 0.01). After starting the corticosteroid, transfer to the intensive care unit (4.8% vs. 14.4%) and mortality (9,5% vs. 17.1%) was lower in the group that received MTP. Recovery time was shorter in patients treated with MTP, three days (3-4) vs. DXM 6 days (5-8) (p-value < 0.0001). At 30-day follow-up, 88 (92.6%) were alive in MTP vs 58 (63.1%) of those who received dexamethasone. Conclusions In this study, the treatment of severe Covid-19 Pneumonia with high-dose methylprednisolone for three days followed by oral prednisone for 14 days, compared with 6 mg dexamethasone for 7 to 10 days, statistically significantly decreased the recovery time, the need for transfer to intensive care and the severity markers C-reactive protein (CRP), D-dimer and LDH. Randomized controlled studies with methylprednisolone are required to corroborate its effect, and studies in a population hospitalized in intensive care wards.	[Pinzon, Miguel Alejandro] Clin Medellin, Grp Quironsalud, Dept Infect Dis, Medellin, Antioquia, Colombia; [Ortiz, Santiago; Laniado, Henry] Univ EAFIT, Dept Math Sci, Medellin, Antioquia, Colombia; [Holguin, Hector] Clin Medellin, Grp Quironsalud, Pharmaceut Serv, Medellin, Antioquia, Colombia; [Betancur, Juan Felipe; Quiceno, Julian; Ramirez, Zoraida] Clin Medellin, Grp Quironsalud, Dept Internal Med, Medellin, Antioquia, Colombia; [Arango, Doris Cardona] CES Univ, Dept Publ Hlth, Medellin, Antioquia, Colombia; [Arias, Carolina Arias] CES Univ, Dept Epidemiol, Medellin, Antioquia, Colombia; [Munoz, Bernardo] Clin Medellin, Grp Quironsalud, Dept Pulmonol, Medellin, Antioquia, Colombia; [Jaramillo, Daniel] CES Univ, Clin Leon XIII, Dept Rheumatol & Autoimmune Dis, Medellin, Antioquia, Colombia	Universidad EAFIT	Pinzon, MA (corresponding author), Clin Medellin, Grp Quironsalud, Dept Infect Dis, Medellin, Antioquia, Colombia.	alejandropinzon01@yahoo.es	Ortiz, Santiago/ABD-3604-2021	Ortiz, Santiago/0000-0002-9121-3807	Universidad EAFIT	Universidad EAFIT	This study was partially supported by Universidad EAFIT. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2020, CORONAVIRUS UPDATE L; Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099; Bednarski T., 2006, COXROBUST ROBUST EST; Caly Leon, 2020, Antiviral Res, V178, P104787, DOI 10.1016/j.antiviral.2020.104787; COX DR, 1972, J R STAT SOC B, V34, P187; Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136; Edalatifard M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02808-2020; Fan E, 2020, LANCET RESP MED, V8, P816, DOI 10.1016/S2213-2600(20)30304-0; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Kory P, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000724; Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m641; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Minder CE, 1996, STAT MED, V15, P1033, DOI 10.1002/(SICI)1097-0258(19960530)15:10<1033::AID-SIM215>3.0.CO;2-Y; R Core Team, 2021, R LANG ENV STAT COMP; Ragab D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01446; Ruiz-Irastorza G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239401; Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2; Scarsi M, 2020, ANN RHEUM DIS, V79, P1286, DOI 10.1136/annrheumdis-2020-217712; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Therneau TM, 2020, PACKAGE SURVIVAL ANA; Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Yang RR, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13412; Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237; Zhao Z, 2003, J MED MICROBIOL, V52, P715, DOI 10.1099/jmm.0.05320-0; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	29	58	59	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2021	16	5							e0252057	10.1371/journal.pone.0252057	http://dx.doi.org/10.1371/journal.pone.0252057			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6OL	34033648	gold, Green Published			2023-01-03	WOS:000664633100026
J	Veldhuizen, JD; van den Bulck, AOE; Elissen, AMJ; Mikkers, MC; Schuurmans, MJ; Bleijenberg, N				Veldhuizen, Jessica D.; van den Bulck, Anne O. E.; Elissen, Arianne M. J.; Mikkers, Misja C.; Schuurmans, Marieke J.; Bleijenberg, Nienke			Nurse-sensitive outcomes in district nursing care: A Delphi study	PLOS ONE			English	Article								Objectives To determine nurse-sensitive outcomes in district nursing care for community-living older people. Nurse-sensitive outcomes are defined as patient outcomes that are relevant based on nurses' scope and domain of practice and that are influenced by nursing inputs and interventions. Design A Delphi study following the RAND/UCLA Appropriateness Method with two rounds of data collection. Setting District nursing care in the community care setting in the Netherlands. Participants Experts with current or recent clinical experience as district nurses as well as expertise in research, teaching, practice, or policy in the area of district nursing. Main outcome measures Experts assessed potential nurse-sensitive outcomes for their sensitivity to nursing care by scoring the relevance of each outcome and the ability of the outcome to be influenced by nursing care (influenceability). The relevance and influenceability of each outcome were scored on a nine-point Likert scale. A group median of 7 to 9 indicated that the outcome was assessed as relevant and/or influenceable. To measure agreement among experts, the disagreement index was used, with a score of <1 indicating agreement. Results In Delphi round two, 11 experts assessed 46 outcomes. In total, 26 outcomes (56.5%) were assessed as nurse-sensitive. The nurse-sensitive outcomes with the highest median scores for both relevance and influenceability were the patient's autonomy, the patient's ability to make decisions regarding the provision of care, the patient's satisfaction with delivered district nursing care, the quality of dying and death, and the compliance of the patient with needed care. Conclusions This study determined 26 nurse-sensitive outcomes for district nursing care for community-living older people based on the collective opinion of experts in district nursing care. This insight could guide the development of quality indicators for district nursing care. Further research is needed to operationalise the outcomes and to determine which outcomes are relevant for specific subgroups.	[Veldhuizen, Jessica D.; Bleijenberg, Nienke] Univ Appl Sci Utrecht, Fac Hlth Care, Res Ctr Hlth & Sustainable Living, Utrecht, Netherlands; [van den Bulck, Anne O. E.; Elissen, Arianne M. J.] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Fac Hlth Med & Life Sci, Dept Hlth Serv Res, Maastricht, Netherlands; [Mikkers, Misja C.] Dutch Healthcare Author NZa, Utrecht, Netherlands; [Mikkers, Misja C.] Tilburg Sch Econ & Management, Dept Econ, Tilburg, Netherlands; [Schuurmans, Marieke J.] Univ Med Ctr Utrecht, UMC Utrecht Acad, Educ Ctr, Utrecht, Netherlands	Maastricht University; Tilburg University; Utrecht University; Utrecht University Medical Center	Veldhuizen, JD (corresponding author), Univ Appl Sci Utrecht, Fac Hlth Care, Res Ctr Hlth & Sustainable Living, Utrecht, Netherlands.	Jessica.veldhuizen@HU.nl		Veldhuizen, Jessica/0000-0002-7761-5690	University of Applied Sciences Utrecht	University of Applied Sciences Utrecht	This study was funded by the University of Applied Sciences Utrecht. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akpan A, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-017-0701-3; [Anonymous], 2006, QUAL CAR PROC MAK ST; Carrera F, 2013, REFORMS LONG TERM CA, P23; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Doran D., 2010, NURSING OUTCOMES; European Statistical System, 2011, POPULATION HOUSING C; Hoegee I., 2018, TOETSINGSKADER WAT V; Jarrin OF, 2019, NURS EDUC TODAY, V73, P83, DOI 10.1016/j.nedt.2018.11.020; Joling KJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190298; Junger S, 2017, PALLIATIVE MED, V31, P684, DOI 10.1177/0269216317690685; Keleher H, 2009, INT J NURS PRACT, V15, P16, DOI 10.1111/j.1440-172X.2008.01726.x; MacLean L, 2014, ANNU REV PUBL HEALTH, V35, P443, DOI 10.1146/annurev-publhealth-032013-182508; Mant J, 2001, INT J QUAL HEALTH C, V13, P475, DOI 10.1093/intqhc/13.6.475; Maurits EEM, 2019, THESIS UTRECHT U; Maybin J., 2016, UNDERSTANDING QUALIT; McDonnell J., 2001, RANDUCLA APPROPRIATE; Moorhead S., 2018, MEASUREMENT HLTH OUT, V6th ed.; Morris JN, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-128; Oliver D., 2014, MAKING OUR HLTH CARE; Qualtrics, 2005, QUALTR; Stall N, 2014, J AM GERIATR SOC, V62, P2243, DOI 10.1111/jgs.13088; Tarricone R, 2008, HOME CARE EUROPE SOL; Tegelaar R., 2015, WAT WILLEN MENSEN ZE; United Nations, 2019, WORLD POPULATION PRO; Van Eenoo L, 2016, EUR J PUBLIC HEALTH, V26, P213, DOI 10.1093/eurpub/ckv152; Vektis, 2020, FACTSH WIJKV; World Health Organization (WHO), 2012, HOME CARE EUROPE CUR	27	2	2	4	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2021	16	5							e0251546	10.1371/journal.pone.0251546	http://dx.doi.org/10.1371/journal.pone.0251546			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SW6MO	33984030	Green Published, gold			2023-01-03	WOS:000664628200094
J	de Oliveira, AR; Gozalo-Marcilla, M; Ringer, SK; Schauvliege, S; Fonseca, MW; Trindade, PHE; Puoli, JNP; Luna, SPL				de Oliveira, Alice Rodrigues; Gozalo-Marcilla, Miguel; Ringer, Simone Katja; Schauvliege, Stijn; Fonseca, Mariana Werneck; Esteves Trindade, Pedro Henrique; Prospero Puoli Filho, Jose Nicolau; Loureiro Luna, Stelio Pacca			Development and validation of the facial scale (FaceSed) to evaluate sedation in horses	PLOS ONE			English	Article							CONSTANT RATE INFUSION; ASSESSING POSTOPERATIVE PAIN; STANDING SEDATION; COEFFICIENT ALPHA; DETOMIDINE; ROMIFIDINE; BUTORPHANOL; DEXMEDETOMIDINE; ANALGESIA; XYLAZINE	Although facial characteristics are used to estimate horse sedation, there are no studies measuring their reliability and validity. This randomised controlled, prospective, horizontal study aimed to validate a facial sedation scale for horses (FaceSed). Seven horses received detomidine infusion i.v. in low or high doses/rates alone (DL 2.5 mu g/kg+6.25 mu g/kg/h; DH 5 mu g/kg+12.5 mu g/kg/h) or combined with methadone (DLM and DHM, 0.2 mg/kg+0.05 mg/kg/h) for 120 min, or acepromazine boli i.v. in low (ACPL 0.02 mg/kg) or high doses (ACPH 0.09 mg/kg). Horses' faces were photographed at i) baseline, ii) peak, iii) intermediate, and iv) end of sedation. After randomisation of moments and treatments, photos were sent to four evaluators to assess the FaceSed items (ear position, orbital opening, relaxation of the lower and upper lip) twice, within a one-month interval. The intraclass correlation coefficient of intra- and interobserver reliability of FaceSed scores were good to very good (0.74-0.94) and moderate to very good (0.57-0.87), respectively. Criterion validity based on Spearman correlation between the FaceSed versus the numerical rating scale and head height above the ground were 0.92 and -0.75, respectively. All items and the FaceSed total score showed responsiveness (construct validity). According to the principal component analysis all FaceSed items had load factors >0.50 at the first dimension. The high internal consistency (Cronbach ' s alpha = 0.83) indicated good intercorrelation among items. Item-total Spearman correlation was adequate (rho 0.3-0.73), indicating homogeneity of the scale. All items showed sensitivity (0.82-0.97) to detect sedation, however only orbital opening (0.79) and upper lip relaxation (0.82) were specific to detect absence of sedation. The limitations were that the facial expression was performed using photos, which do not represent the facial movement and the horses were docile, which may have reduced specificity. The FaceSed is a valid and reliable tool to assess tranquilisation and sedation in horses.	[de Oliveira, Alice Rodrigues; Fonseca, Mariana Werneck; Esteves Trindade, Pedro Henrique; Prospero Puoli Filho, Jose Nicolau; Loureiro Luna, Stelio Pacca] Sao Paulo State Univ UNESP, Sch Vet Med & Anim Sci, Dept Vet Surg & Anim Reprod, Botucatu, SP, Brazil; [Gozalo-Marcilla, Miguel] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland; [Gozalo-Marcilla, Miguel] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland; [Ringer, Simone Katja] Univ Zurich, Vetsuisse Fac, Dept Clin Diagnost & Serv, Sect Anaesthesiol, Zurich, Switzerland; [Schauvliege, Stijn] Univ Ghent, Fac Vet Med, Dept Surg & Anaesthesia Domest Anim, Merelbeke, Belgium	Universidade Estadual Paulista; University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Zurich; Ghent University	Luna, SPL (corresponding author), Sao Paulo State Univ UNESP, Sch Vet Med & Anim Sci, Dept Vet Surg & Anim Reprod, Botucatu, SP, Brazil.	stelio.pacca@unesp.br	Luna, Stelio/C-4527-2013; Esteves Trindade, Pedro Henrique/K-1178-2017	Luna, Stelio/0000-0001-5312-9076; Esteves Trindade, Pedro Henrique/0000-0002-8522-5553	Sao Paulo Research Foundation (FAPESP) [2017/16208-0, 2017/12815-0, 2017/01425-6]	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	Sao Paulo Research Foundation (FAPESP) for the doctoral scholarship granted (ARO), protocol 2017/16208-0, thematic project (SPLL) 2017/12815-0 and post-doctoral grant (M. G.M) 2017/01425-6. Funder website: https://fapesp.br/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, STATS; Ashkenazy Shelly, 2011, Heart Lung, V40, pe44, DOI 10.1016/j.hrtlng.2009.12.011; Benredouane K, 2011, VET REC, V169, p364A, DOI 10.1136/vr.d5333; Brondani JT, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-143; Brondani JT, 2011, AM J VET RES, V72, P174, DOI 10.2460/ajvr.72.2.174; Bryant C. E, 1991, Journal of Veterinary Anaesthesia, P55, DOI 10.1111/j.1467-2995.1991.tb00511.x; Bussieres G, 2008, RES VET SCI, V85, P294, DOI 10.1016/j.rvsc.2007.10.011; Carenzo L, 2020, ANAESTHESIA, V75, P928, DOI 10.1111/anae.15072; Clarke K. W., 1991, Journal of Veterinary Anaesthesia, V18, P25, DOI 10.1111/j.1467-2995.1991.tb00008.x; CLARKE KW, 1986, EQUINE VET J, V18, P366, DOI 10.1111/j.2042-3306.1986.tb03655.x; Clutton RE, 2010, VET CLIN N AM-EQUINE, V26, P493, DOI 10.1016/j.cveq.2010.07.002; Correia-Caeiro C, 2020, ANIM COGN, V23, P465, DOI 10.1007/s10071-020-01348-5; Costa GL, 2015, VET ANAESTH ANALG, V42, P220, DOI 10.1111/vaa.12210; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Dalla Costa E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092281; Darwin C., 1872, P374; de Lemos J, 2000, J CLIN EPIDEMIOL, V53, P908, DOI 10.1016/S0895-4356(00)00208-0; de Oliveira FA, 2014, J EQUINE VET SCI, V34, P380, DOI 10.1016/j.jevs.2013.07.012; de Oliveira FA, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0200-0; De Vet H.C., 2011, MEASUREMENT MED PRAC; DeVellis RF, 2016, SCALE DEV THEORY APP, V4, P256; ENGLAND GCW, 1992, J VET PHARMACOL THER, V15, P194, DOI 10.1111/j.1365-2885.1992.tb01007.x; Evangelista MC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55693-8; Figueiredo J. P., 2005, International Journal of Applied Research in Veterinary Medicine, V3, P249; Finka LR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46330-5; Freeman SL, 2000, VET REC, V147, P507, DOI 10.1136/vr.147.18.507; Gleerup KB, 2015, VET ANAESTH ANALG, V42, P103, DOI 10.1111/vaa.12212; Gozalo-Marcilla M, 2019, EQUINE VET J, V51, P530, DOI 10.1111/evj.13054; Gozalo-Marcilla M, 2019, EQUINE VET J, V51, P517, DOI 10.1111/evj.13031; Gozalo-Marcilla M, 2019, J VET PHARMACOL THER, V42, P738, DOI 10.1111/jvp.12815; Gozalo-Marcilla M, 2019, VET ANAESTH ANALG, V46, P325, DOI 10.1016/j.vaa.2019.01.005; Gozalo-Marcilla M, 2017, VET ANAESTH ANALG, V44, P1116, DOI 10.1016/j.vaa.2017.03.009; Grimsrud KN, 2012, VET ANAESTH ANALG, V39, P38, DOI 10.1111/j.1467-2995.2011.00669.x; Hageri C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175839; Hair J.F., 1998, MULTIVARIATE DATA AN, V5th; Hall C, 1991, PRACTICAL STAT MED R, P404; HAMM D, 1991, J EQUINE VET SCI, V11, P86, DOI 10.1016/S0737-0806(07)80136-5; Hays R D, 1992, Qual Life Res, V1, P73, DOI 10.1007/BF00435438; Holton LL, 1998, J AM VET MED ASSOC, V212, P61; JOHNSTON GM, 1995, VET SURG, V24, P518; Johnston GM, 2002, VET ANAESTH ANALG, V29, P159, DOI 10.1046/j.1467-2995.2002.00106.x; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; Kano F, 2010, ANIM BEHAV, V79, P227, DOI 10.1016/j.anbehav.2009.11.003; l'Ami JJ, 2013, VET J, V196, P253, DOI 10.1016/j.tvjl.2012.08.016; Luna SPL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233552; Love EJ, 2011, VET ANAESTH ANALG, V38, P3, DOI 10.1111/j.1467-2995.2010.00580.x; Mallat J, 2015, BRIT J ANAESTH, V115, P449, DOI 10.1093/bja/aev222; Mama KR, 2009, EQUINE VET J, V41, P772, DOI 10.2746/042516409X421624; Marly C, 2014, VET ANAESTH ANALG, V41, P491, DOI 10.1111/vaa.12174; Martin P., 2007, MEASURING BEHAV INTR, Vthird, DOI DOI 10.1017/CBO9780511810893; Mathis MW, 2020, CURR OPIN NEUROBIOL, V60, P1, DOI 10.1016/j.conb.2019.10.008; McDowell I, 2006, SOCIOLOGY HLTH ILLNE, V3rd ed, DOI [10.1111/1467-9566.ep10838657, DOI 10.1111/1467-9566.EP10838657]; Medeiros LQ, 2017, VET REC, V181, DOI 10.1136/vr.104359; Mellor DJ, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10040572; Mich PM, 2010, J VET MED EDUC, V37, P358, DOI 10.3138/jvme.37.4.358; Miot Hélio Amante, 2016, J. vasc. bras., V15, P89, DOI 10.1590/1677-5449.004216; Mullard J, 2017, J VET BEHAV, V18, P7, DOI 10.1016/j.jveb.2016.11.005; de Oliveira AR, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.611729; Plichta SB., 2011, MUNROS STAT METHODS, V6th ed; Potter JJ, 2016, VET ANAESTH ANALG, V43, P189, DOI 10.1111/vaa.12316; Ranheim B, 2015, J VET PHARMACOL THER, V38, P93, DOI 10.1111/jvp.12157; Ringer SK, 2013, VET ANAESTH ANALG, V40, P157, DOI 10.1111/j.1467-2995.2012.00784.x; Ringer SK, 2012, VET ANAESTH ANALG, V39, P12, DOI 10.1111/j.1467-2995.2011.00681.x; Ringer SK, 2012, VET ANAESTH ANALG, V39, P1, DOI 10.1111/j.1467-2995.2011.00653.x; Roughan JV, 2006, APPL ANIM BEHAV SCI, V96, P327, DOI 10.1016/j.applanim.2005.06.012; Sacks M, 2017, VET ANAESTH ANALG, V44, P1128, DOI 10.1016/j.vaa.2016.12.061; Schanz L, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00154; Schauvliege S, 2019, VET ANAESTH ANALG, V46, P4, DOI 10.1016/j.vaa.2018.08.005; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Silva NEOF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239622; Solano AM, 2009, EQUINE VET J, V41, P153, DOI 10.2746/042516408X342984; Streiner D. L., 2015, HLTH MEASUREMENT SCA, V5<feminine, DOI [10.1093/med/9780199685219.001.0001, DOI 10.1093/MED/9780199685219.001.0001, 10.1093/MED/9780199685219.001.0001]; Streiner DL, 2007, CAN J PSYCHIAT, V52, P121, DOI 10.1177/070674370705200210; Streiner DL, 2003, J PERS ASSESS, V80, P99, DOI 10.1207/S15327752JPA8001_18; Taffarel MO, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0395-8; van Loon JPAM, 2015, VET J, V206, P356, DOI 10.1016/j.tvjl.2015.08.023; VanDierendonck MC, 2016, VET J, V216, P175, DOI 10.1016/j.tvjl.2016.08.004; Waltz CF., 2010, MEASUREMENT NURSING; Wathan J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131738; Zhang EQ, 2019, J AM ASSOC LAB ANIM, V58, P178, DOI [10.30802/AALAS-JAALAS-18-000044, 10.30802/aalas-jaalas-18-000044]	80	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	6							e0251909	10.1371/journal.pone.0251909	http://dx.doi.org/10.1371/journal.pone.0251909			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SL3JC	34061878	Green Published, gold			2023-01-03	WOS:000656813600029
J	Long, JC; Pomare, C; Ellis, LA; Churruca, K; Braithwaite, J				Long, Janet C.; Pomare, Chiara; Ellis, Louise A.; Churruca, Kate; Braithwaite, Jeffrey			The pace of hospital life: A mixed methods study	PLOS ONE			English	Article							BURNOUT; VALIDITY; IMPACT	The pace-of-life hypothesis is a socio-psychological theory postulating that citizens of different cities transact the business of life at varying paces, and this pace is associated with a number of population level variables. Here we apply the pace-of-life hypothesis to a hospital context to empirically test the association between pace and patient and staff outcomes. As pressure on hospitals grow and pace increases to keep up with demand, is there empirical evidence of a trade-off between a rapid pace and poorer outcomes? We collected data from four large Australian hospitals, inviting all staff (clinical and non-clinical) to complete a survey, and conducted a series of observations of hospital staff's walking pace and transactional pace. From these data we constructed three measures of pace: staff perception of pace, transactional pace, and walking pace. Outcome measures included: hospital culture, perceived patient safety, and staff well-being outcomes of job satisfaction and burnout. Overall, participants reported experiencing a "fast-paced" "hurried" and "rapid" pace-of-life working in the Australian hospital sector. We found a significant difference in perceived pace across four hospital sites, similar to trends observed for transactional pace. This provides support that the pace-of-life hypothesis may apply to the hospital context. We tested associations between faster perceived pace, hospital culture, staff well-being and patient safety. Results revealed perceived faster pace significantly predicted negative perceptions of organizational culture, greater burnout and lower job satisfaction. However, perceived pace did not predict perceptions of patient safety. Different perceptions of hospital pace-of-life were found between different clinical settings and the type of care delivered; staff working in emergency departments reported significantly "faster-paced" work environments than staff working in palliative, aged care, or rehabilitation wards.	[Long, Janet C.; Pomare, Chiara; Ellis, Louise A.; Churruca, Kate; Braithwaite, Jeffrey] Macquarie Univ, Australian Inst Hlth Innovat, Sydney, NSW, Australia	Macquarie University	Long, JC (corresponding author), Macquarie Univ, Australian Inst Hlth Innovat, Sydney, NSW, Australia.	janet.long@mq.edu.au	Churruca, Kate/H-8623-2019; Braithwaite, Jeffrey/AAN-1467-2020	Churruca, Kate/0000-0002-9923-3116; Braithwaite, Jeffrey/0000-0003-0296-4957; Pomare, Chiara/0000-0002-9118-7207; Long, Janet/0000-0002-0553-682X	NHMRC [APP1176620, 9100002]	NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This work is supported in part by NHMRC Investigator Grant APP1176620 and NHMRC Partnership Grant (9100002), chief investigator JB.	Agency for Healthcare Research and Quality, 2010, HOSP SURVEY PATIENT; Alarcon GM, 2011, J VOCAT BEHAV, V79, P549, DOI 10.1016/j.jvb.2011.03.007; AMATO PR, 1983, J CROSS CULT PSYCHOL, V14, P353, DOI 10.1177/0022002183014003008; Australian Bureau of Statistics, 2016, IRSD INTERACTIVE MAP; Ballard DI, 2004, COMMUN RES, V31, P135, DOI 10.1177/0093650203261504; BORNSTEIN MH, 1976, NATURE, V259, P557, DOI 10.1038/259557a0; Bowling NA, 2008, J VOCAT BEHAV, V73, P63, DOI 10.1016/j.jvb.2008.01.004; Braithwaite J, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3350-0; Braithwaite J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017708; Connolly M, 2009, J CLIN NURS, V18, P549, DOI 10.1111/j.1365-2702.2008.02551.x; Creswell J., 2017, CONCISE INTRO MIXED; Hall LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159015; Hunt KJ, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-3; IBM Corp, 2016, IBM SPSS STAT WINDOW; Kc DS, 2009, MANAGE SCI, V55, P1486, DOI 10.1287/mnsc.1090.1037; Kilroy A, 2016, HUM RESOUR MANAGE, P1, DOI [10.1002/hrm.21803, DOI 10.1002/HRM.21803, DOI 10.1002/HRM]; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Laschinger HKS, 2006, J NURS ADMIN, V36, P259; Lauer Robert, 1981, TEMPORAL MAN MEANING; Lehnbom EC., 2016, DIGITAL HLTH INNOVAT; Levine RV, 1999, J CROSS CULT PSYCHOL, V30, P178, DOI 10.1177/0022022199030002003; Levine RV., 1988, SOCIAL PSYCHOL TIME, V39, P92; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; MASLACH C, 1981, J OCCUP BEHAV, V2, P99, DOI 10.1002/job.4030020205; Moore WE., 1965, MAN TIME AND SOC; Nugus P, 2010, SOC SCI MED, V70, P511, DOI 10.1016/j.socscimed.2009.11.001; Patton MQ, 1999, HEALTH SERV RES, V34, P1189; Qualtrics, QUALTRICS 2014; Reader TW, 2008, INTENS CARE MED, V34, P4, DOI 10.1007/s00134-007-0908-4; Schaufeli W., 2006, HDB HUMAN FACTORS ER, P217; Schaufeli WB, 2001, PSYCHOL HEALTH, V16, P565, DOI 10.1080/08870440108405527; SCHAUFELI WB, 1993, S AP PSYC S, P199; Sexton JB, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-44; Westbrook JI, 2010, QUAL SAF HEALTH CARE, V19, P284, DOI 10.1136/qshc.2009.039255; Westbrook Johanna I, 2009, Int J Med Inform, V78 Suppl 1, pS25, DOI 10.1016/j.ijmedinf.2008.09.003	35	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0255775	10.1371/journal.pone.0255775	http://dx.doi.org/10.1371/journal.pone.0255775			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UB7PL	34407092	gold, Green Published			2023-01-03	WOS:000686033500016
J	Thompson, MG; Stenehjem, E; Grannis, S; Ball, SW; Naleway, AL; Ong, TC; DeSilva, MB; Natarajan, K; Bozio, CH; Lewis, N; Dascomb, K; Dixon, BE; Birch, RJ; Irving, SA; Rao, S; Kharbanda, E; Han, J; Reynolds, S; Goddard, K; Grisel, N; Fadel, WF; Levy, ME; Ferdinands, J; Fireman, B; Arndorfer, J; Valvi, NR; Rowley, EA; Patel, P; Zerbo, O; Griggs, EP; Porter, RM; Demarco, M; Blanton, L; Steffens, A; Zhuang, Y; Olson, N; Barron, M; Shifflett, P; Schrag, SJ; Verani, JR; Fry, A; Gaglani, M; Azziz-Baumgartner, E; Klein, NP				Thompson, M. G.; Stenehjem, E.; Grannis, S.; Ball, S. W.; Naleway, A. L.; Ong, T. C.; DeSilva, M. B.; Natarajan, K.; Bozio, C. H.; Lewis, N.; Dascomb, K.; Dixon, B. E.; Birch, R. J.; Irving, S. A.; Rao, S.; Kharbanda, E.; Han, J.; Reynolds, S.; Goddard, K.; Grisel, N.; Fadel, W. F.; Levy, M. E.; Ferdinands, J.; Fireman, B.; Arndorfer, J.; Valvi, N. R.; Rowley, E. A.; Patel, P.; Zerbo, O.; Griggs, E. P.; Porter, R. M.; Demarco, M.; Blanton, L.; Steffens, A.; Zhuang, Y.; Olson, N.; Barron, M.; Shifflett, P.; Schrag, S. J.; Verani, J. R.; Fry, A.; Gaglani, M.; Azziz-Baumgartner, E.; Klein, N. P.			Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARS-COV-2 INFECTION; UNITED-STATES; INFLUENZA; BNT162B2; WORKERS; ADULTS	Background There are limited data on the effectiveness of the vaccines against symptomatic coronavirus disease 2019 (Covid-19) currently authorized in the United States with respect to hospitalization, admission to an intensive care unit (ICU), or ambulatory care in an emergency department or urgent care clinic. Methods We conducted a study involving adults (>= 50 years of age) with Covid-19-like illness who underwent molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed 41,552 admissions to 187 hospitals and 21,522 visits to 221 emergency departments or urgent care clinics during the period from January 1 through June 22, 2021, in multiple states. The patients' vaccination status was documented in electronic health records and immunization registries. We used a test-negative design to estimate vaccine effectiveness by comparing the odds of a positive test for SARS-CoV-2 infection among vaccinated patients with those among unvaccinated patients. Vaccine effectiveness was adjusted with weights based on propensity-for-vaccination scores and according to age, geographic region, calendar time (days from January 1, 2021, to the index date for each medical visit), and local virus circulation. Results The effectiveness of full messenger RNA (mRNA) vaccination (>= 14 days after the second dose) was 89% (95% confidence interval [CI], 87 to 91) against laboratory-confirmed SARS-CoV-2 infection leading to hospitalization, 90% (95% CI, 85 to 93) against infection leading to an ICU admission, and 91% (95% CI, 89 to 93) against infection leading to an emergency department or urgent care clinic visit. The effectiveness of full vaccination with respect to a Covid-19-associated hospitalization or emergency department or urgent care clinic visit was similar with the BNT162b2 and mRNA-1273 vaccines and ranged from 81% to 95% among adults 85 years of age or older, persons with chronic medical conditions, and Black or Hispanic adults. The effectiveness of the Ad26.COV2.S vaccine was 68% (95% CI, 50 to 79) against laboratory-confirmed SARS-CoV-2 infection leading to hospitalization and 73% (95% CI, 59 to 82) against infection leading to an emergency department or urgent care clinic visit. Conclusions Covid-19 vaccines in the United States were highly effective against SARS-CoV-2 infection requiring hospitalization, ICU admission, or an emergency department or urgent care clinic visit. This vaccine effectiveness extended to populations that are disproportionately affected by SARS-CoV-2 infection. (Funded by the Centers for Disease Control and Prevention.) Covid-19 Vaccine Effectiveness in Medical Settings A study with a test-negative design analyzed 41,552 admissions to 187 hospitals and 21,522 visits to 221 EDs or urgent care clinics. The mRNA-based vaccines (>= 14 days after the second dose) were highly effective against SARS-CoV-2 infection leading to hospitalization (89%), ICU admission (90%), or an urgent care visit (91%).	[Thompson, M. G.; Bozio, C. H.; Reynolds, S.; Ferdinands, J.; Patel, P.; Griggs, E. P.; Porter, R. M.; Blanton, L.; Steffens, A.; Olson, N.; Schrag, S. J.; Verani, J. R.; Fry, A.; Azziz-Baumgartner, E.] Ctr Dis Control & Prevent, COVID 19 Response Team, Atlanta, GA 30333 USA; [Stenehjem, E.; Dascomb, K.; Grisel, N.; Arndorfer, J.] Intermt Healthcare, Div Infect Dis & Clin Epidemiol, Salt Lake City, UT USA; [Grannis, S.; Dixon, B. E.; Fadel, W. F.; Valvi, N. R.] Regenstrief Inst Hlth Care, Ctr Biomed Informat, Indianapolis, IN USA; [Grannis, S.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Dixon, B. E.; Fadel, W. F.; Valvi, N. R.] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA; [Ball, S. W.; Birch, R. J.; Levy, M. E.; Rowley, E. A.; Demarco, M.; Zhuang, Y.; Shifflett, P.] Westat Corp, Rockville, MD USA; [Naleway, A. L.; Irving, S. A.] Kaiser Permanente Northwest Ctr Hlth Res, Portland, OR USA; [Ong, T. C.; Rao, S.; Barron, M.] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA; [DeSilva, M. B.; Kharbanda, E.] HealthPartners Inst, Minneapolis, MN USA; [Natarajan, K.; Han, J.] Columbia Univ, Dept Biomed Informat, Irving Med Ctr, New York, NY USA; [Natarajan, K.] New York Presbyterian Hosp, New York, NY USA; [Lewis, N.; Goddard, K.; Fireman, B.; Zerbo, O.; Klein, N. P.] Kaiser Permanente Northern Calif, Div Res, Vaccine Study Ctr, Oakland, CA USA; [Gaglani, M.] Texas A&M Univ, Coll Med, Baylor Scott & White Hlth, Temple, TX 76508 USA	Centers for Disease Control & Prevention - USA; Intermountain Healthcare; Intermountain Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Westat; Kaiser Permanente; University of Colorado System; University of Colorado Anschutz Medical Campus; Columbia University; NewYork-Presbyterian Hospital; NewYork-Presbyterian Hospital; Kaiser Permanente; Baylor Health Care System; Texas A&M University System	Thompson, MG (corresponding author), Ctr Dis Control & Prevent, Influenza Div, Mailstop A32,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	isq8@cdc.gov	Dixon, Brian E/A-9494-2013; Gaglani, Manjusha/AFQ-6802-2022	Dixon, Brian E/0000-0002-1121-0607; Gaglani, Manjusha/0000-0002-3952-9230; Bozio, Catherine/0000-0001-6566-7138; Porter, Rachael/0000-0002-6632-4038; Olson, Natalie/0000-0003-2175-4138; Irving, Stephanie/0000-0001-7437-6797	Centers for Disease Control and Prevention [75D30120C07986, 75D30120C07765]	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Supported by the Centers for Disease Control and Prevention (contracts 75D30120C07986 to Westat and 75D30120C07765 to Kaiser Foundation Hospitals).	Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; Andrew MK, 2021, CLIN INTERV AGING, V16, P731, DOI 10.2147/CIA.S295522; Andrew MK, 2020, LANCET, V396, P1942, DOI 10.1016/S0140-6736(20)32481-8; Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Azar KMJ, 2020, HEALTH AFFAIR, V39, P1253, DOI 10.1377/hlthaff.2020.00598; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Cassidy EL, 2001, AM J GERIAT PSYCHIAT, V9, P136, DOI 10.1176/appi.ajgp.9.2.136; Cates J, 2020, MMWR-MORBID MORTAL W, V69, P1528, DOI 10.15585/mmwr.mm6942e3; Chua HY, 2020, EPIDEMIOLOGY, V31, P43, DOI 10.1097/EDE.0000000000001116; Chung H, 2021, EFFECTIVENESS BNT162; Cohen J., 2013, STAT POWER ANAL BEHA; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; De Serres G, 2013, Euro Surveill, V18; Ferdinands JM, 2019, J INFECT DIS, V220, P1265, DOI 10.1093/infdis/jiy723; Ferdinands JM, 2012, CLIN INFECT DIS, V54, P25, DOI 10.1093/cid/cir750; Ferdinands JM, 2011, VACCINE, V29, P1935, DOI 10.1016/j.vaccine.2010.12.098; Foppa IM, 2016, INT J EPIDEMIOL, V45, P2052, DOI 10.1093/ije/dyw022; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; George S, 2014, AM J PUBLIC HEALTH, V104, pE16, DOI 10.2105/AJPH.2013.301706; Gu T, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25197; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053; Killerby ME, 2020, MMWR-MORBID MORTAL W, V69, P790, DOI 10.15585/mmwr.mm6925e1; Kim L, 2021, CLIN INFECT DIS, V72, P206, DOI DOI 10.1093/cid/ciaa1012; Kwong JC, 2013, CLIN INFECT DIS, V57, P820, DOI 10.1093/cid/cit404; Mansson R, 2007, AM J EPIDEMIOL, V166, P332, DOI 10.1093/aje/kwm069; McCaffrey DF, 2004, PSYCHOL METHODS, V9, P403, DOI 10.1037/1082-989X.9.4.403; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P674, DOI 10.15585/mmwr.mm7018e1; Thompson MG, 2021, NEW ENGL J MED, V385, P320, DOI 10.1056/NEJMoa2107058; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Thompson MG, 2019, CLIN INFECT DIS, V68, P1444, DOI 10.1093/cid/ciy737; Nguyen TL, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0338-0; Wingert A., 2021, BMJ OPEN, V11; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	40	154	154	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	2021	385	15					1355	1371		10.1056/NEJMoa2110362	http://dx.doi.org/10.1056/NEJMoa2110362		SEP 2021	17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XP7AB	34496194	Green Published, Bronze			2023-01-03	WOS:000693740200001
J	Frings, VG; Schoffski, O; Goebeler, M; Presser, D				Frings, Verena Gerlinde; Schoeffski, Oliver; Goebeler, Matthias; Presser, Dagmar			Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital	PLOS ONE			English	Article							DEPRESSION; PREVALENCE; BURDEN; CARE; LIFE	Background and objectives Hidradenitis suppurativa (HS) significantly affects the patient`s quality of life and leads to multiple medical consultations. Aim of this study was to assess the utilization of medical care of HS patients. Patients and methods All patients presenting in 2017 for an outpatient, day patient and / or inpatient treatment with leading claim type HS at the Department of Dermatology, University Hospital Wurzburg, were included. Primary outcome was the economic burden of HS patients, measured by resource utilization in euro. Results The largest share of the direct medical costs for HS were the inpatient costs with a leading surgical diagnosis-related group (DRG). Antiseptics were the predominant topical prescription. While doxycycline was the most frequently prescribed systemic therapy, adalimumab was the main cost driver. The difference between in-patient (euro 110.25) and outpatient (euro 26.34) direct non-medical costs was statistically significant (p < 0.001). With regards to indirect medical costs, a statistically significantly higher loss of gross value added (inpatient mean euro 1,827.00; outpatient mean euro 203.00) and loss of production (inpatient mean euro 1,026.00; outpatient mean euro 228.00) could be noted (p < 0.001), respectively. Conclusions The present study on disease-specific costs of HS confirms that the hospital care of patients with this disease is cost-intensive. However, the primary goal of physicians is not and should not be to save costs regarding their patients`treatment, but rather the premise to utilize the existing resources as efficient as possible. Reducing the use of costly therapeutics and inpatient stays therefore requires more effective therapy options with an improved cost-benefit profile.	[Frings, Verena Gerlinde; Goebeler, Matthias; Presser, Dagmar] Univ Hosp Wurzburg, Dept Dermatol Venereol & Allergol, Wurzburg, Bavaria, Germany; [Schoeffski, Oliver] Friedrich Alexander Univ Erlangen Nurnberg, Chair Hlth Management, Sch Business Econ & Soc, Nurnberg, Bavaria, Germany	University of Wurzburg; University of Erlangen Nuremberg	Frings, VG (corresponding author), Univ Hosp Wurzburg, Dept Dermatol Venereol & Allergol, Wurzburg, Bavaria, Germany.	frings_v@ukw.de			Interdisziplinares Zentrum fur Klinische Forschung (IZKF), University Hospital Wurzburg, Germany [ZZ/25]	Interdisziplinares Zentrum fur Klinische Forschung (IZKF), University Hospital Wurzburg, Germany	This work was supported in part by the Interdisziplinares Zentrum fur Klinische Forschung (IZKF), University Hospital Wurzburg, Germany (ZZ/25). There was no additional internal or external funding received for this study.	Andersen RK, 2020, JAMA DERMATOL, V156, P780, DOI 10.1001/jamadermatol.2020.1281; [Anonymous], 2017, BUND ARB ARB BUND ARB ARB; Bouazzi D, 2020, DERMATOL SURG, V46, P914, DOI 10.1097/DSS.0000000000002323; Cosmatos I, 2013, J AM ACAD DERMATOL, V68, P412, DOI 10.1016/j.jaad.2012.07.027; Desai N, 2017, BRIT J DERMATOL, V176, P1048, DOI 10.1111/bjd.14976; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Frings VG, 2019, EUR J DERMATOL, V29, P294, DOI 10.1684/ejd.2019.3552; Gao M, 2006, J INVEST DERMATOL, V126, P1302, DOI 10.1038/sj.jid.5700272; Henke KD., 1986, FINANZIERUNG GESUNDH; Hurley H., 1989, DERMATOLOGIC SURG PR, V729, P39; Jemec GBE, 1996, J AM ACAD DERMATOL, V35, P191, DOI 10.1016/S0190-9622(96)90321-7; Khalsa A, 2015, J AM ACAD DERMATOL, V73, P609, DOI 10.1016/j.jaad.2015.06.053; Kirby JS, 2017, JAMA DERMATOL, V153, P1263, DOI 10.1001/jamadermatol.2017.3596; Kirby JS, 2014, JAMA DERMATOL, V150, P937, DOI 10.1001/jamadermatol.2014.691; Kohorst JJ, 2016, DERMATOL SURG, V42, P1030, DOI 10.1097/DSS.0000000000000806; Lee EY, 2017, CAN FAM PHYSICIAN, V63, P114; Matusiak L, 2010, ACTA DERM-VENEREOL, V90, P264, DOI 10.2340/00015555-0866; Onderdijk AJ, 2013, J EUR ACAD DERMATOL, V27, P473, DOI 10.1111/j.1468-3083.2012.04468.x; Ramos-Rodriguez AJ, 2018, INT J DERMATOL, V57, P547, DOI 10.1111/ijd.13932; Rychlik R., 1997, GESUNDHEITSOKONOMIE GESUNDHEITSOKONOMIE; Rychlik R, 1996, INTERNISTISCHE PRAXI, P463; Schwartz F., 2003, PUBLIC HLTH BUCH EFF; Thorlacius L, 2018, J INVEST DERMATOL, V138, P52, DOI 10.1016/j.jid.2017.09.008; Tzellos T, 2019, BRIT J DERMATOL, V181, P147, DOI 10.1111/bjd.17101; Zouboulis CC, 2019, J EUR ACAD DERMATOL, V33, P19, DOI 10.1111/jdv.15233; Zouboulis CC, 2015, J EUR ACAD DERMATOL, V29, P619, DOI 10.1111/jdv.12966	26	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2021	16	8							e0255560	10.1371/journal.pone.0255560	http://dx.doi.org/10.1371/journal.pone.0255560			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6IY	34347845	Green Published, gold			2023-01-03	WOS:000685264900027
J	Siu, PM; Yu, AP; Chin, EC; Yu, DS; Hui, SS; Woo, J; Fong, DY; Wei, GX; Irwin, MR				Siu, Parco M.; Yu, Angus P.; Chin, Edwin C.; Yu, Doris S.; Hui, Stanley S.; Woo, Jean; Fong, Daniel Y.; Wei, Gao X.; Irwin, Michael R.			Effects of Tai Chi or Conventional Exercise on Central Obesity in Middle-Aged and Older Adults A Three-Group Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-MASS INDEX; ABDOMINAL OBESITY; PRESSURE; WEIGHT	Background: Central obesity is a major manifestation of metabolic syndrome, which is a common health problem in middle-aged and older adults. Objective: To examine the therapeutic efficacy of tai chi for management of central obesity. Design: Randomized, controlled, assessor-blinded trial. (ClinicalTrials.gov: NCT03107741) Setting: A single research site in Hong Kong between 27 February 2016 and 28 February 2019. Participants: Adults aged 50 years or older with central obesity. Intervention: 543 participants were randomly assigned in a 1:1:1 ratio to a control group with no exercise intervention (n = 181), conventional exercise consisting of aerobic exercise and strength training (EX group) (n = 181), and a tai chi group (TC group) (n = 181). Interventions lasted 12 weeks. Measurements: Outcomes were assessed at baseline, week 12, and week 38. The primary outcome was waist circumference (WC). Secondary outcomes were body weight; body mass index; high-density lipoprotein cholesterol (HDL-C), triglyceride, and fasting plasma glucose levels; blood pressure; and incidence of remission of central obesity. Results: The adjusted mean difference in WC from baseline to week 12 in the control group was 0.8 cm (95% CI, -4.1 to 5.7 cm). Both intervention groups showed reductions in WC relative to control (adjusted mean differences: TC group vs. control, -1.8 cm [CI, -2.3 to -1.4 cm]; P<0.001; EX group vs. control: -1.3 cm [CI, -1.8 to -0.9 cm]; P<0.001); both intervention groups also showed reductions in body weight (P<0.05) and attenuation of the decrease in HDL-C level relative to the control group. The favorable changes in WC and body weight were maintained in both the TC and EX groups, whereas the beneficial effect on HDL-C was only maintained in the TC group at week 38. Limitations: High attrition and no dietary intervention. Conclusion: Tai chi is an effective approach to reduce WC in adults with central obesity aged 50 years or older.	[Siu, Parco M.; Yu, Angus P.; Chin, Edwin C.; Yu, Doris S.; Fong, Daniel Y.] Univ Hong Kong, Pokfulam, Hong Kong, Peoples R China; [Hui, Stanley S.; Woo, Jean] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China; [Wei, Gao X.] Chinese Acad Sci, Beijing, Peoples R China; [Irwin, Michael R.] Univ Calif Los Angeles, Los Angeles, CA USA; [Siu, Parco M.; Yu, Angus P.; Chin, Edwin C.] Univ Hong Kong, Sch Publ Hlth, Pokfulam, Room 3-01C,3-F HKJC Bldg Interdisciplinary Res, Hong Kong, Peoples R China; [Yu, Doris S.; Fong, Daniel Y.] Univ Hong Kong, Sch Nursing, Pokfulam, 4-F William MW Mong Block,21 Sassoon Rd, Hong Kong, Peoples R China; [Hui, Stanley S.] Chinese Univ Hong Kong, Dept Sports Sci & Phys Educ, Shatin, Kwok Sports Bldg, Hong Kong, Peoples R China; [Woo, Jean] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, 9-F Lui Che Woo Clin Sci Bldg, Hong Kong, Peoples R China; [Wei, Gao X.] Chinese Acad Sci, Inst Psychol, 16 Lincui Rd, Beijing 100101, Peoples R China; [Irwin, Michael R.] Univ Calif Los Angeles, Cousins Ctr Psychoneuroimmunol, 300 UCLA Med Plaza 3109, Los Angeles, CA 90095 USA; [Irwin, Michael R.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza 3109, Los Angeles, CA 90095 USA	University of Hong Kong; Chinese University of Hong Kong; Chinese Academy of Sciences; University of California System; University of California Los Angeles; University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese Academy of Sciences; Institute of Psychology, CAS; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Siu, PM (corresponding author), Univ Hong Kong, Sch Publ Hlth, Pokfulam, Room 3-01C,3-F HKJC Bldg Interdisciplinary Res, Hong Kong, Peoples R China.		Irwin, Michael/H-4870-2013; Woo, Jean/K-2625-2014; Fong, Daniel/C-4269-2009	Irwin, Michael/0000-0002-1502-8431; Siu, Parco/0000-0002-3548-5058; HUI, Stanley Sai-chuen/0000-0002-2462-4622; Chin, Edwin/0000-0002-5762-4549; yu, doris/0000-0002-9359-1748; Woo, Jean/0000-0001-7593-3081; Fong, Daniel/0000-0001-7365-9146; Wei, Gao-Xia/0000-0002-6350-9096	Health and Medical Research Fund [12131841]; Food and Health Bureau, Hong Kong SAR	Health and Medical Research Fund; Food and Health Bureau, Hong Kong SAR	By the Health and Medical Research Fund (12131841) of the Food and Health Bureau, Hong Kong SAR.	Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8; Alenazi AM, 2018, J ALTERN COMPLEM MED, V24, P220, DOI 10.1089/acm.2017.0104; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Beebe N, 2013, J ALTERN COMPLEM MED, V19, P759, DOI 10.1089/acm.2012.0531; Cerhan JR, 2014, MAYO CLIN PROC, V89, P335, DOI 10.1016/j.mayocp.2013.11.011; Crump C, 2016, JAMA INTERN MED, V176, P210, DOI 10.1001/jamainternmed.2015.7444; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; Fitzmaurice G.M., 2011, APPL LONGITUDINAL AN; Freemantle N, 2008, INT J CLIN PRACT, V62, P1391, DOI 10.1111/j.1742-1241.2008.01805.x; Hui DSC, 2009, HONG KONG MED J, V15, P4; HUI SSC, 2015, EVID-BASED COMPL ALT, V2015, P76123, DOI DOI 10.1155/2015/976123; Khan SS, 2018, JAMA CARDIOL, V3, P280, DOI 10.1001/jamacardio.2018.0022; Lauche R, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000008517, 10.1097/md.0000000000008517]; Lee MS, 2010, J EVAL CLIN PRACT, V16, P818, DOI 10.1111/j.1365-2753.2009.01210.x; Lee SH, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.25; Liu X, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/879712; Nahin, 2008, NATL HLTH STAT REPOR, P1, DOI DOI 10.1155/2017/6751856; Paley CA, 2018, BMC SPORTS SCI MED R, V10, DOI 10.1186/s13102-018-0097-1; Piercy KL, 2018, JAMA-J AM MED ASSOC, V320, P2020, DOI 10.1001/jama.2018.14854; Ross R, 2020, NAT REV ENDOCRINOL, V16, P177, DOI 10.1038/s41574-019-0310-7; Salazar A, 2016, STAT MED, V35, P3424, DOI 10.1002/sim.6947; Smith U, 2015, J CLIN INVEST, V125, P1790, DOI 10.1172/JCI81507; Sun L, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017509; Tchernof A, 2013, PHYSIOL REV, V93, P359, DOI 10.1152/physrev.00033.2011; Tian JY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10176-6; Verheggen RJHM, 2016, OBES REV, V17, P664, DOI 10.1111/obr.12406; Wang C, 2015, DIABETES RES CLIN PR, V107, P424, DOI 10.1016/j.diabres.2014.09.059; World Health Organization, 2020, GUIDELINES PHYS ACTI; World Health Organization Western Pacific Region, 2000, ASIA PACIFIC PERSPEC; Xu SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078270; Yang GY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120655	31	10	10	13	78	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG	2021	174	8					1050	+		10.7326/M20-7014	http://dx.doi.org/10.7326/M20-7014			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP3IW	34058100				2023-01-03	WOS:000695277800014
J	Augustin, HG; Kipnis, J				Augustin, Hellmut G.; Kipnis, Jonathan			AGING Vascular rejuvenation is geroprotective	SCIENCE			English	Editorial Material							VEGF; MOUSE		[Augustin, Hellmut G.] Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci ECAS, Heidelberg, Germany; [Augustin, Hellmut G.] German Canc Res Ctr Heidelberg DKFZ ZMBH Alliance, Div Vasc Oncol & Metastasis, Heidelberg, Germany; [Kipnis, Jonathan] Washington Univ, Dept Pathol & Immunol, Ctr Brain Immunol & Glia BIG, St Louis, MO 63110 USA	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Washington University (WUSTL)	Augustin, HG (corresponding author), Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci ECAS, Heidelberg, Germany.; Augustin, HG (corresponding author), German Canc Res Ctr Heidelberg DKFZ ZMBH Alliance, Div Vasc Oncol & Metastasis, Heidelberg, Germany.	augustin@angioscience.de	Kipnis, Jonathan/AGG-9735-2022	Kipnis, Jonathan/0000-0002-3714-517X				Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249; Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021; Baker DJ, 2018, J CLIN INVEST, V128, P1208, DOI 10.1172/JCI95145; Di Francesco A, 2018, SCIENCE, V362, P770, DOI 10.1126/science.aau2095; Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2; Grunewald M, 2021, SCIENCE, V373, P533, DOI 10.1126/science.abc8479; Hughes BG, 2016, GENETICS, V204, P905, DOI 10.1534/genetics.116.192369; Lehallier B, 2019, NAT MED, V25, P1843, DOI 10.1038/s41591-019-0673-2; Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031; Mattison JA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14063; Rafii S, 2016, NATURE, V529, P316, DOI 10.1038/nature17040; Tanaka H, 2019, HYPERTENSION, V74, P237, DOI 10.1161/HYPERTENSIONAHA.119.13179; Yanga YL, 2013, P NATL ACAD SCI USA, V110, P12018, DOI 10.1073/pnas.1301331110; Yousefzadeh MJ, 2021, NATURE, V594, P100, DOI 10.1038/s41586-021-03547-7	14	1	1	3	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	2021	373	6554			SI		490	491		10.1126/science.abj8674	http://dx.doi.org/10.1126/science.abj8674			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TV4TF	34326223				2023-01-03	WOS:000681716000021
J	Rocha, JA; Cardoso, JC; Freitas, A; Allison, TG; Azevedo, LF				Rocha, J. Afonso; Cardoso, Jose Carlos; Freitas, Alberto; Allison, Thomas G.; Azevedo, Luis F.			Time-trends and predictors of interhospital transfers and 30-day rehospitalizations after acute coronary syndrome from 2000-2015	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; IMMEDIATE THROMBOLYSIS; HOSPITAL READMISSION; EUROPEAN-SOCIETY; TRANSPORT; MORTALITY; OUTCOMES; MODELS	Aims Assess trends and factors associated with interhospital transfers (IHT) and 30-day acute coronary syndrome (ACS) rehospitalizations in a national administrative database of patients admitted with an ACS between 2000-2015. Methods and results Cohort study of patients hospitalized with ACS from 2000 to 2015, using a validated linkage algorithm to identify and link patient-level sequential hospitalizations occurring within 30 days from first admission (considering all hospitalizations within the 30-day timeframe as belonging to the same ACS episode of care-ACS-EC). From 212,481 ACS-EC, 42,670 (20.1%) had more than one hospitalization. ACS-EC hospitalization rates decreased throughout the study period (2000: 207.7/100.000 person-years to 2015: 185,8/100,000 person-years, p for trend <0.05). Proportion of IHT increased from 10.5% in 2000 to 20.1% in 2015 compared to a reduction in both planned and unplanned 30-day ACS rehospitalization from 9.0% in 2000 to 2.7% in 2015. After adjusting for patient and first admission hospital's characteristics, compared to 2000-2003, in 2012-2015 the odds of IHT increased by 3.81 (95%CI: 3.65-3.98); the odds of unplanned and planned 30-day ACS rehospitalization decreased by 0.36 (95%CI: 0.33; 0.39) and 0.47 (95%CI: 0.43; 0.53), respectively. Female sex, older age and the presence and severity of comorbidities were associated with lower likelihood of being transferred or having a planned 30-day ACS rehospitalization. Unplanned 30-day ACS rehospitalization was more likely in patients with higher comorbidity burden. Conclusion IHT and 30-day ACS rehospitalization reflect coronary referral network efficiency and access to specialized treatment. Identifying factors associated with higher likelihood of IHT and 30-day ACS rehospitalization may allow heightened surveillance and interventions to reduce rehospitalizations and inequities in access to specialized treatment.	[Rocha, J. Afonso] Ctr Hosp Univ Sao Joao, Dept Phys Med & Rehabil, Cardiovasc Rehabil Unit, Porto, Portugal; [Rocha, J. Afonso; Freitas, Alberto; Azevedo, Luis F.] Univ Porto, Fac Med, Ctr Hlth Technol & Serv Res CINTESIS, Porto, Portugal; [Cardoso, Jose Carlos] Ctr Hosp Univ Sao Joao, Dept Cardiol, Porto, Portugal; [Cardoso, Jose Carlos] Univ Porto, Fac Med, Porto, Portugal; [Freitas, Alberto; Azevedo, Luis F.] Univ Porto, Fac Med, Dept Community Med Informat & Hlth Decis Sci MEDC, Porto, Portugal; [Allison, Thomas G.] Mayo Sch Med & Sci, Rochester, MN USA; [Rocha, J. Afonso] Ctr Hosp Univ Sao Joao, Dept Phys Med & Rehabil, Porto, Portugal	Universidade do Porto; Universidade do Porto; Universidade do Porto	Rocha, JA (corresponding author), Ctr Hosp Univ Sao Joao, Dept Phys Med & Rehabil, Cardiovasc Rehabil Unit, Porto, Portugal.; Rocha, JA (corresponding author), Univ Porto, Fac Med, Ctr Hlth Technol & Serv Res CINTESIS, Porto, Portugal.; Rocha, JA (corresponding author), Ctr Hosp Univ Sao Joao, Dept Phys Med & Rehabil, Porto, Portugal.	afonso.rocha@chsj.min-saude.pt	Azevedo, Luís/J-7819-2012; Freitas, Alberto/C-1972-2012; Freitas, Alberto/AAH-3193-2019	Azevedo, Luís/0000-0002-8421-2937; Freitas, Alberto/0000-0003-2113-9653; Freitas, Alberto/0000-0003-2113-9653; ROCHA, J AFONSO/0000-0003-0824-4598	FCT - Fundacao para a Ciencia e a Tecnologia, I.P., within CINTESIS, RD Unit [UIDB/4255/2020]	FCT - Fundacao para a Ciencia e a Tecnologia, I.P., within CINTESIS, RD Unit(Portuguese Foundation for Science and Technology)	This article was supported by National Funds through FCT - Fundacao para a Ciencia e a Tecnologia, I.P., within CINTESIS, R&D Unit (reference UIDB/4255/2020).	ACSS ACdSdS, 2019, COND PROC PAG PREST; Alonso V, 2020, HEALTH INF MANAG J, V49, P28, DOI 10.1177/1833358319826351; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Axon RN, 2011, JAMA-J AM MED ASSOC, V305, P504, DOI 10.1001/jama.2011.72; Bednar Frantisek, 2003, J Interv Cardiol, V16, P201, DOI 10.1034/j.1600-0854.2003.8047.x; Chen HY, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002291; Clegg LX, 2009, STAT MED, V28, P3670, DOI 10.1002/sim.3733; CNDCV, 2010, HEM CARD INT CIR CAR; Desai MM, 2009, CIRC-CARDIOVASC QUAL, V2, P500, DOI 10.1161/CIRCOUTCOMES.108.832949; DGS, 2015, RED REF CARD; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; DM, 1991, CANC REGISTRATION PR; Dunlay SM, 2012, ANN INTERN MED, V157, P11, DOI 10.7326/0003-4819-157-1-201207030-00004; Gale CP, 2015, HEART, V101, P998, DOI 10.1136/heartjnl-2015-307508; Galie N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317; Gurwitz JH, 2002, AM J MED, V112, P528, DOI 10.1016/S0002-9343(02)01072-0; Hornbrook M C, 1982, Med Care Rev, V39, P73, DOI 10.1177/107755878203900201; Hosmer DW, 2013, WILEY SER PROBAB ST, P269; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kociol RD, 2012, JAMA-J AM MED ASSOC, V307, P66, DOI 10.1001/jama.2011.1926; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Li J, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.119.005628; Lopez D, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-019226; Matthews PAGJNS, 2001, STAT METHODS MED RES; Neumann JT, 2020, CLIN RES CARDIOL, V109, P1186, DOI 10.1007/s00392-020-01612-1; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Ranasinghe I, 2015, HEART, V101, P1032, DOI 10.1136/heartjnl-2014-306966; Reichlin T, 2009, NEW ENGL J MED, V361, P858, DOI 10.1056/NEJMoa0900428; Rocha A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-033486; Rosamond WD, 2012, CIRCULATION, V125, P1848, DOI 10.1161/CIRCULATIONAHA.111.047480; Rymer JA, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012059; Souza J, 2019, BURNS, V45, P1571, DOI 10.1016/j.burns.2018.09.013; Thygesen K, 2019, EUR HEART J, V40, P237, DOI [10.1093/eurheartj/ehy462, 10.1016/j.jacc.2018.08.1038, 10.1016/j.rec.2018.11.011]; Townsend, 2017, EUROPEAN CARDIOVASCU; Wang HJ, 2019, CLIN CARDIOL, V42, P889, DOI 10.1002/clc.23238; Wei-Randall HK, 2013, HEALTH REP, V24, P3; Westfall JM, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-22; Widimsky P, 2000, EUR HEART J, V21, P823, DOI 10.1053/euhj.1999.1993; Widimsky P, 2007, EUR HEART J, V28, P679, DOI 10.1093/eurheartj/ehl535; Yeh RW, 2010, NEW ENGL J MED, V362, P2155, DOI 10.1056/NEJMoa0908610	41	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2021	16	7							e0255134	10.1371/journal.pone.0255134	http://dx.doi.org/10.1371/journal.pone.0255134			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2OO	34293045	gold, Green Published			2023-01-03	WOS:000678124900008
J	Gamma, A; Metzinger, T				Gamma, Alex; Metzinger, Thomas			The Minimal Phenomenal Experience questionnaire (MPE-92M): Towards a phenomenological profile of "pure awareness" experiences in meditators	PLOS ONE			English	Article							PHILOSOPHY; MIND	Objective To develop a fine-grained phenomenological analysis of "pure awareness" experiences in meditators. Methods An online survey in five language versions (German, English, French, Spanish, Italian) collected data from January to March 2020. A total of 92 questionnaire items on a visual analogue scale were submitted to exploratory and confirmatory factor analysis. Results Out of 3627 submitted responses, 1403 were usable. Participants had a median age of 52 years (range: 17-88) and were evenly split between men and women (48.5% vs 50.0%). The majority of meditators practiced regularly (77.3%), were free of diagnosed mental disorders (92.4%) and did not regularly use any psychoactive substances (84.0%). Vipassana (43.9%) followed by Zen (34.9%) were the most frequently practiced meditation techniques. German (63.4%) and English (31.4%) were by far the most frequent questionnaire languages. A solution with 12 factors explaining 44% of the total variance was deemed optimal under joint conceptual and statistical considerations. The factors were named "Time, Effort and Desire," "Peace, Bliss and Silence," "Self-Knowledge, Autonomous Cognizance and Insight," "Wakeful Presence," "Pure Awareness in Dream and Sleep," "Luminosity," "Thoughts and Feelings," "Emptiness and Non-egoic Self-awareness," "Sensory Perception in Body and Space," "Touching World and Self," "Mental Agency," and "Witness Consciousness." This factor structure fit the data moderately well. Conclusions We have previously posited a phenomenological prototype for the experience of "pure awareness" as it occurs in the context of meditation practice. Here we offer a tentative 12-factor model to describe its phenomenal character in a fine-grained way. The current findings are in line with an earlier study extracting semantic constraints for a working definition of minimal phenomenal experience.	[Gamma, Alex] Univ Hosp Psychiat, Res Dept, Zurich, Switzerland; [Metzinger, Thomas] Johannes Gutenberg Univ Mainz, Philosoph Seminar, Arbeitsbereich Theoret Philosophie, Mainz, Germany	Johannes Gutenberg University of Mainz	Gamma, A (corresponding author), Univ Hosp Psychiat, Res Dept, Zurich, Switzerland.; Metzinger, T (corresponding author), Johannes Gutenberg Univ Mainz, Philosoph Seminar, Arbeitsbereich Theoret Philosophie, Mainz, Germany.	alex.gamma@uzh.ch; metzinger@uni-mainz.de			Gutenberg Research College, Johannes Gutenberg-Universitat Mainz	Gutenberg Research College, Johannes Gutenberg-Universitat Mainz	This work was funded by a 5-year Fellowship awarded to TM by the Gutenberg Research College, Johannes Gutenberg-Universitat Mainz (https://www.grc.uni-mainz.de/).The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, OPEN MIND, DOI DOI 10.15502/9783958571174; Ataria Y, 2015, PHILOS PSYCHOL, V28, P1128, DOI 10.1080/09515089.2014.969801; Ataria Y, 2015, CONSCIOUS COGN, V37, P133, DOI 10.1016/j.concog.2015.09.002; Bachmann JK., 2014, ACCOUNTING PURE CONS, DOI [10.7939/R32V2CJ7Z, DOI 10.7939/R32V2CJ7Z]; Batterman RW, 2014, PHILOS SCI, V81, P349, DOI 10.1086/676677; Batterman RW, 2002, BRIT J PHILOS SCI, V53, P21, DOI 10.1093/bjps/53.1.21; Bayne T, 2016, TRENDS COGN SCI, V20, P405, DOI 10.1016/j.tics.2016.03.009; Blanke O, 2009, TRENDS COGN SCI, V13, P7, DOI 10.1016/j.tics.2008.10.003; Brown T. A, 2015, CONFIRMATORY FACTOR, V2nd; Fink SB., 2020, PHILOS MIND SCI, V1, P3, DOI [DOI 10.33735/PHIMISCI.2020.I.40, 10.33735/phimisci.2020.I.40]; FORT AO, 1984, J INDIAN PHILOS, V12, P277; Gupta B., 1998, DISINTERESTED WITNES; Hanley AW, 2018, PSYCHOL ASSESSMENT, V30, P1625, DOI 10.1037/pas0000615; Hasenkamp W., 2018, OXFORD HDB SPONTANEO, P539; Hasenkamp W, 2012, NEUROIMAGE, V59, P750, DOI 10.1016/j.neuroimage.2011.07.008; Higgins D, 2012, RELIG COMPASS, V6, P441, DOI 10.1111/rec3.12004; Higgins David, 2013, PHILOS FDN CLASSICAL; Hyman IE, 1998, CLIN PSYCHOL REV, V18, P933, DOI 10.1016/S0272-7358(98)00041-5; Killingsworth MA, 2010, SCIENCE, V330, P932, DOI 10.1126/science.1192439; Lindahl J. R., 2019, OXFORD HDB MEDITATIO; Lockwood M., 1993, OBJECTIONS PHYS OBJECTIONS PHYS; Louchakova-Schwartz O, 2013, NEUROPHENOMENOLOGY AND ITS APPLICATIONS TO PSYCHOLOGY, P61, DOI 10.1007/978-1-4614-7239-1_3; MacLean KA, 2012, J SCI STUD RELIG, V51, P721, DOI 10.1111/j.1468-5906.2012.01685.x; Manjurmitra Lipman K., 1987, PRIMORDIAL EXPERIENC; Marsh HW, 2005, PSYCHOL ASSESSMENT, V17, P81, DOI 10.1037/1040-3590.17.1.81; Metzinger T, 2003, BRADFORD BOOKS, P1; Metzinger T., 2020, PHILOS MIND SCI, V1, P1, DOI [DOI 10.33735/PHIMISCI.2020.I.46, 10.33735/phimisci.2020.I.46]; Metzinger T., 2018, MINDRXIV, DOI DOI 10.31231/OSF.IO/5WYG7; Metzinger T, 1995, CONSCIOUS EXPERIENCE, P425; Metzinger T, 2017, PHILOS PREDICTIVE PR, P1; Metzinger T., 2018, OXFORD HDB SONTANEOU, P97; Metzinger T, 2020, COGN NEUROPSYCHOL, V37, P197, DOI 10.1080/02643294.2020.1729110; Metzinger T, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00931; Milliere R., 2020, PHIMISCI, V1, P1, DOI [10.33735/phimisci.2020.I.48, DOI 10.33735/PHIMISCI.2020.I.48]; NAGEL T, 1974, PHILOS REV, V83, P435, DOI 10.2307/2183914; Petitmengin C, 2019, CURR OPIN PSYCHOL, V28, P54, DOI 10.1016/j.copsyc.2018.10.009; Przyrembel M, 2018, CONSCIOUS COGN, V62, P82, DOI 10.1016/j.concog.2018.04.004; Satorra A., 1994, LATENT VARIABLES ANA, P399; Schooler JW, 2011, TRENDS COGN SCI, V15, P319, DOI 10.1016/j.tics.2011.05.006; SELLARS W, 1956, MINN STUD PHILOS SCI, V1, P253; Shear J., 2007, BLACKWELL COMPANION, P697, DOI DOI 10.1002/9780470751466.CH55; Silverstein AB, 1990, PSYCHOL ASSESS, V2, P3, DOI [10.1037/1040-3590.2.1.3, DOI 10.1037/1040-3590.2.1.3]; Smith GT, 2000, PSYCHOL ASSESSMENT, V12, P102, DOI 10.1037/1040-3590.12.1.102; Thomas JW, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00074; Thompson E., 2015, OPEN MIND, DOI [10.15502/9783958570351, DOI 10.15502/9783958570351]; Thrangu O'Hearn P., 2011, POINTING OUT DHARMAK; Travis F, 2000, INT J NEUROSCI, V100, P77, DOI 10.3109/00207450008999678; Vieten C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205740; Wiese W, 2020, NEUROSCI CONSCIOUS, V6, DOI 10.1093/nc/niaa013; Woods TJ, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01259	50	11	11	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2021	16	7							e0253694	10.1371/journal.pone.0253694	http://dx.doi.org/10.1371/journal.pone.0253694			39	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2MK	34260614	Green Published, gold			2023-01-03	WOS:000678119300041
J	Dickson, KS; Adde, KS; Ameyaw, EK				Dickson, Kwamena Sekyi; Adde, Kenneth Setorwu; Ameyaw, Edward Kwabena			Women empowerment and skilled birth attendance in sub-Saharan Africa: A multi-country analysis	PLOS ONE			English	Article							MATERNAL HEALTH-CARE; INTIMATE PARTNER VIOLENCE; SERVICES	Introduction In 2017, the highest global maternal deaths occurred in sub-Saharan Africa (SSA). The WHO advocates that maternal deaths can be mitigated with the assistance of skilled birth attendants (SBAs) at childbirth. Women empowerment is also acknowledged as an enabling factor to women's functionality and healthcare utilisation including use of SBAs' services. Consequently, this study investigated the association between women empowerment and skilled birth attendance in SSA. Materials and methods This study involved the analysis of secondary data from the Demographic and Health Surveys of 29 countries conducted between January 1, 2010, and December 3, 2018. For this study, only women who had given birth in the five years prior to the surveys were included, which is 166,022. At 95% confidence interval, Binary Logistic Regression analyses were conducted and findings were presented as adjusted odds ratios (aORs). Results The overall prevalence of skilled birth attendance was 63.0%, with the lowest prevalence in Tanzania (13.8%) and highest in Rwanda (91.2%). Women who were empowered with high level of knowledge (aOR = 1.60, 95% CI = 1.51, 1.71), high decision-making power (aOR = 1.19, 95% CI = 1.15, 1.23), and low acceptance of wife beating had higher likelihood of skill birth attendance after adjusting for socio-demographic characteristics. Women from rural areas had lesser likelihood (OR = 0.53, 95% CI = 0.51-0.55) of skilled birth attendance compared to women from urban areas. Working women had a lesser likelihood of skilled birth attendance (OR = 0.91, 95% CI = 0.88-0.94) as compared to those not working. Women with secondary (OR = 2.13, 95% CI = 2.03-2.22), or higher education (OR = 4.40, 95% CI = 3.81-5.07), and women in the richest wealth status (OR = 3.50, 95% CI = 3.29-3.73) had higher likelihood of skilled birth attendance. Conclusion These findings accentuate that going forward, successful skilled birth attendant interventions are the ones that can prioritise the empowerment of women.	[Dickson, Kwamena Sekyi; Adde, Kenneth Setorwu] Univ Cape Coast, Coll Humanities & Legal Studies, Dept Populat & Hlth, Cape Coast, Ghana; [Ameyaw, Edward Kwabena] Univ Technol Sydney, Fac Hlth, Sch Publ Hlth, Sydney, NSW, Australia	University of Cape Coast; University of Technology Sydney	Adde, KS (corresponding author), Univ Cape Coast, Coll Humanities & Legal Studies, Dept Populat & Hlth, Cape Coast, Ghana.	kenneth.adde@stu.ucc.edu.gh	Adde, Kenneth/ABD-6317-2021; Dickson, Kwamena Sekyi/AAE-9964-2022; Dickson, Kwamena Sekyi/AFF-8066-2022; Dickson, Kwamena Sekyi/AEP-5571-2022	Adde, Kenneth/0000-0003-2475-7326; Dickson, Kwamena Sekyi/0000-0002-3152-2317; Dickson, Kwamena Sekyi/0000-0002-3152-2317; Dickson, Kwamena Sekyi/0000-0002-3152-2317; Ameyaw, Edward Kwabena/0000-0002-6617-237X				Abdulai T., 2017, J HEALTH COMMUN, V2, P2472; Acharya DR, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-15; Adewemimo AW, 2014, MIDWIFERY, V30, pE7, DOI 10.1016/j.midw.2013.09.005; Ahuru RR, 2019, INT J HEALTHCARE MAN, V12, P1; Alam N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120922; Alemayehu M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/436938; Ameyaw EK, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8258-z; Ameyaw Edward Kwabena, 2016, Int J Reprod Med, V2016, P6569514, DOI 10.1155/2016/6569514; Ameyaw EK., 2017, ADV SEXUAL MED; Asaolu IO, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00994; Atuoye KN, 2017, GLOB PUBLIC HEALTH, V12, P728, DOI 10.1080/17441692.2017.1315441; Ayele GS, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7818-6; Bhowmik J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231489; Castro LV, 2014, PHILIPPINE STAT AUTH; Gelis U, 2015, CHALLENGING PATRIARC; Gitimu A, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0442-2; Goli S, 2018, J BIOSOC SCI, V50, P749, DOI 10.1017/S0021932017000530; Haque M., 2011, BANGLADESH E J SOCIO, V8, P17; Hasin F., 2018, J FUNDAMENTAL APPL S; Islam N, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-86; Kabir R, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6939684; Kantachote K., 2013, WORKSHOP INT PUBLIC WORKSHOP INT PUBLIC; Kawarazuka N, 2019, GENDER PLACE CULT, V26, P384, DOI 10.1080/0966369X.2018.1552559; Kazanga I, 2019, INT J HEALTH POLICY, V8, P700, DOI 10.15171/ijhpm.2019.67; Khan MN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198833; Khatiwada J, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03309-9; Koramah D., 2019, ADV PUBLIC HLTH; Kwagala B, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0167-3; Lemiere C, 2013, DIR DEV, P147; Mishra N.K., 2011, ECON POLIT WEEKLY, V46, P58; Moyer Cheryl A, 2013, Afr J Reprod Health, V17, P30; Musoke D, 2014, AFR HEALTH SCI, V14, DOI 10.4314/ahs.v14i4.36; Naeem Akram, 2019, Pakistan Economic and Social Review, V57, P93; Sado L, 2014, SOC SCI MED, V114, P169, DOI 10.1016/j.socscimed.2014.05.047; Sai F T, 1987, IPPF Med Bull, V21, P1; Schuler SR, 2013, STUD FAMILY PLANN, V44, P243, DOI 10.1111/j.1728-4465.2013.00356.x; Sebayang SK, 2019, WOMEN HEALTH, V59, P1155, DOI 10.1080/03630242.2019.1593282; Sharma GD, 2017, RES J BUSINESS MANAG, V11, P15; Shimamoto K, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0591-3; Teklesilasie W, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1954-3; WHO, 2019, MAT MORT; Woldegiorgis MA, 2019, HEALTH SERV RES, V54, P1110, DOI 10.1111/1475-6773.13163; Woldemicael G, 2010, HEALTH CARE WOMEN IN, V31, P599, DOI 10.1080/07399331003599555; Yaya S, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0658-5; Yount KM, 2013, DEMOGRAPHY, V50, P333, DOI 10.1007/s13524-012-0143-7; Zelalem Ayele Desalew, 2014, Int Sch Res Notices, V2014, P917058, DOI 10.1155/2014/917058	46	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2021	16	7							e0254281	10.1371/journal.pone.0254281	http://dx.doi.org/10.1371/journal.pone.0254281			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TK6VQ	34234362	Green Published, gold			2023-01-03	WOS:000674294100009
J	Koo, K; Ward, R; Smith, RL; Ruben, J; Carne, PWG; Elsaleh, H				Koo, Kendrick; Ward, Rachel; Smith, Ryan L.; Ruben, Jeremy; Carne, Peter W. G.; Elsaleh, Hany			Temporal determinants of tumour response to neoadjuvant rectal radiotherapy	PLOS ONE			English	Article							PATHOLOGICAL COMPLETE RESPONSE; PREOPERATIVE RADIATION-THERAPY; LATE AFTERNOON RADIOTHERAPY; OPTIMAL TIME-INTERVAL; DELAYED SURGERY; CHEMORADIATION THERAPY; CANCER ANALYSIS; CHEMORADIOTHERAPY; IMPACT; RESECTION	Introduction In locally advanced rectal cancer, longer delay to surgery after neoadjuvant radiotherapy increases the likelihood of histopathological tumour response. Chronomodulated radiotherapy in rectal cancer has recently been reported as a factor increasing tumour response to neoadjuvant treatment in patients having earlier surgery, with patients receiving a larger proportion of afternoon treatments showing improved response. This paper aims to replicate this work by exploring the impact of these two temporal factors, independently and in combination, on histopathological tumour response in rectal cancer patients. Methods A retrospective review of all patients with rectal adenocarcinoma who received long course (>= 24 fractions) neoadjuvant radiotherapy with or without chemotherapy at a tertiary referral centre was conducted. Delay to surgery and radiotherapy treatment time were correlated to clinicopathologic characteristics with a particular focus on tumour regression grade. A review of the literature and meta-analysis were also conducted to ascertain the impact of time to surgery from preoperative radiotherapy on tumour regression. Results From a cohort of 367 patients, 197 patients met the inclusion criteria. Complete pathologic response (AJCC regression grade 0) was seen in 46 (23%) patients with a further 44 patients (22%) having at most small groups of residual cells (AJCC regression grade 1). Median time to surgery was 63 days, and no statistically significant difference was seen in tumour regression between patients having early or late surgery. There was a non-significant trend towards a larger proportion of morning treatments in patients with grade 0 or 1 regression (p = 0.077). There was no difference in tumour regression when composite groups of the two temporal variables were analysed. Visualisation of data from 39 reviewed papers (describing 27379 patients) demonstrated a plateau of response to neoadjuvant radiotherapy after approximately 60 days, and a meta-analysis found improved complete pathologic response in patients having later surgery. Conclusions There was no observed benefit of chronomodulated radiotherapy in our cohort of rectal cancer patients. Review of the literature and meta-analysis confirms the benefit of delayed surgery, with a plateau in complete response rates at approximately 60-days between completion of radiotherapy and surgery. In our cohort, time to surgery for the majority of our patients lay along this plateau and this may be a more dominant factor in determining response to neoadjuvant therapy, obscuring any effects of chronomodulation on tumour response. We would recommend surgery be performed between 8 and 11 weeks after completion of neoadjuvant radiotherapy in patients with locally advanced rectal cancer.	[Koo, Kendrick; Ward, Rachel; Smith, Ryan L.; Ruben, Jeremy; Elsaleh, Hany] Alfred Hlth, Radiat Oncol, Melbourne, Vic, Australia; [Carne, Peter W. G.] Alfred Hlth, Colorectal Surg Unit, Melbourne, Vic, Australia; [Carne, Peter W. G.] Cabrini Monash Univ, Dept Surg, Melbourne, Vic, Australia	Monash University	Elsaleh, H (corresponding author), Alfred Hlth, Radiat Oncol, Melbourne, Vic, Australia.	H.Elsaleh@alfred.org.au		Koo, Kendrick/0000-0001-7941-7199				Akbar Ali, 2016, Asian Pac J Cancer Prev, V17, P89; Akgun E, 2018, BRIT J SURG, V105, P1417, DOI 10.1002/bjs.10984; Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117; Bin Fang C, 2013, ABCD-ARQ BRAS CIR DI, V26, P31, DOI 10.1590/S0102-67202013000100007; Bjarnason GA, 2009, INT J RADIAT ONCOL, V73, P166, DOI 10.1016/j.ijrobp.2008.07.009; Calvo FA, 2014, J CANCER RES CLIN, V140, P1651, DOI 10.1007/s00432-014-1718-z; Chang L, 2016, INT J CLIN PHARM TH, V54, P856, DOI 10.5414/CP202654; Coucke PA, 2006, ACTA ONCOL, V45, P1086, DOI 10.1080/02841860600891317; Crane CH, 2010, INT J RADIAT ONCOL, V76, P824, DOI 10.1016/j.ijrobp.2009.02.037; de Campos-Lobato LF, 2011, J GASTROINTEST SURG, V15, P444, DOI 10.1007/s11605-010-1197-8; Dolinsky CM, 2007, J SURG ONCOL, V96, P207, DOI 10.1002/jso.20815; Elsaleh H, 1999, Australas Radiol, V43, P215, DOI 10.1046/j.1440-1673.1999.00653.x; Evans J, 2011, DIS COLON RECTUM, V54, P1251, DOI 10.1097/DCR.0b013e3182281f4b; Foster JD, 2016, TECH COLOPROCTOL, V20, P683, DOI 10.1007/s10151-016-1514-7; Francois Y, 1999, J CLIN ONCOL, V17, P2396, DOI 10.1200/JCO.1999.17.8.2396; Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072; Garcia-Aguilar J, 2011, ANN SURG, V254, P97, DOI 10.1097/SLA.0b013e3182196e1f; Garrer Waheed Yousry, 2016, Asian Pac J Cancer Prev, V17, P4381; Gasinska A, 2011, J GASTROINTEST SURG, V15, P1568, DOI 10.1007/s11605-011-1589-4; George TJ, 2015, CURR COLORECT CANC R, V11, P275, DOI 10.1007/s11888-015-0285-2; Gerard JP, 2006, J CLIN ONCOL, V24, P4620, DOI 10.1200/JCO.2006.06.7629; Gerard JP, 2010, J CLIN ONCOL, V28, P1638, DOI 10.1200/JCO.2009.25.8376; Goyal M, 2009, INT J RADIAT BIOL, V85, P504, DOI 10.1080/09553000902883802; Habr-Gama A, 2008, INT J RADIAT ONCOL, V71, P1181, DOI 10.1016/j.ijrobp.2007.11.035; Huang YW, 2017, ASIA-PAC J CLIN ONCO, V13, pE171, DOI 10.1111/ajco.12456; Jeong DH, 2013, J KOREAN SURG SOC, V84, P338, DOI 10.4174/jkss.2013.84.6.338; Johnson K, 2019, CLIN ONCOL-UK, V31, P9, DOI 10.1016/j.clon.2018.10.001; Kalady MF, 2009, ANN SURG, V250, P582, DOI 10.1097/SLA.0b013e3181b91e63; Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580; Kerr SF, 2008, BRIT J SURG, V95, P1534, DOI 10.1002/bjs.6377; Kiessling S, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0349-7; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Kim MJ, 2018, ANN COLOPROCTOL, V34, P241, DOI 10.3393/ac.2018.01.01; Lefevre JH, 2016, J CLIN ONCOL, V34, P3773, DOI 10.1200/JCO.2016.67.6049; LEVI FA, 1994, JNCI-J NATL CANCER I, V86, P1608, DOI 10.1093/jnci/86.21.1608; Lim SB, 2008, ANN SURG, V248, P243, DOI 10.1097/SLA.0b013e31817fc2a0; Maas M, 2010, LANCET ONCOL, V11, P835, DOI 10.1016/S1470-2045(10)70172-8; Macchia G, 2017, CLIN TRANSL RAD ONCO, V4, P8, DOI 10.1016/j.ctro.2017.04.004; Maliske S, 2019, J GASTROINTEST ONCOL, V10, P597, DOI 10.21037/jgo.2019.02.02; Mihmanli M, 2016, WORLD J GASTRO ONCOL, V8, P695, DOI 10.4251/wjgo.v8.i9.695; Moore HG, 2004, DIS COLON RECTUM, V47, P279, DOI 10.1007/s10350-003-0062-1; Noh JM, 2014, J RADIAT RES, V55, P553, DOI 10.1093/jrr/rrt141; Pach R, 2012, LANGENBECK ARCH SURG, V397, P801, DOI 10.1007/s00423-011-0890-8; Probst CP, 2015, J AM COLL SURGEONS, V221, P430, DOI 10.1016/j.jamcollsurg.2015.04.010; Rickles AS, 2015, ANN SURG, V262, P891, DOI 10.1097/SLA.0000000000001391; Roxburgh CSD, 2019, ANN SURG ONCOL, V26, P2019, DOI 10.1245/s10434-019-07340-9; Saglam S, 2014, J GASTROINTEST ONCOL, V5, P9, DOI 10.3978/j.issn.2078-6891.2013.025; Savvidis C, 2012, MOL MED, V18, P1249, DOI 10.2119/molmed.2012.00077; Shukla P, 2010, CANCER-AM CANCER SOC, V116, P2031, DOI 10.1002/cncr.24867; Sirohi B, 2014, INDIAN J MED PAEDIAT, V35, P263, DOI 10.4103/0971-5851.144986; Sloothaak DAM, 2013, BRIT J SURG, V100, P933, DOI 10.1002/bjs.9112; Squire T, 2017, CHRONOBIOL INT, V34, P492, DOI 10.1080/07420528.2017.1301462; Stein DE, 2003, DIS COLON RECTUM, V46, P448, DOI 10.1007/s10350-004-6579-0; Sun ZF, 2016, J AM COLL SURGEONS, V222, P367, DOI 10.1016/j.jamcollsurg.2015.12.017; Supiot S, 2006, COLORECTAL DIS, V8, P430, DOI 10.1111/j.1463-1318.2006.00990.x; Terzi C, 2020, COLORECTAL DIS, V22, P279, DOI 10.1111/codi.14867; TIMUDOM K, 2016, GASTROENT RES PRACT, V2016, P70815, DOI DOI 10.1155/2016/7870815; Trakarnsanga A, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju248; Tran CL, 2006, AM J SURG, V192, P873, DOI 10.1016/j.amjsurg.2006.08.061; Tulchinsky H, 2008, ANN SURG ONCOL, V15, P2661, DOI 10.1245/s10434-008-9892-3; Veenhof AAFA, 2007, INT J COLORECTAL DIS, V22, P507, DOI 10.1007/s00384-006-0195-5; Wo JY, 2021, PRACT RADIAT ONCOL, V11, P13, DOI 10.1016/j.prro.2020.08.004; Wolthuis AM, 2012, ANN SURG ONCOL, V19, P2833, DOI 10.1245/s10434-012-2327-1; You KY, 2015, J CANCER RES CLIN, V141, P719, DOI 10.1007/s00432-014-1843-8; Zeng WG, 2014, J SURG ONCOL, V110, P463, DOI 10.1002/jso.23665	65	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2021	16	6							e0254018	10.1371/journal.pone.0254018	http://dx.doi.org/10.1371/journal.pone.0254018			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9EF	34191861	gold, Green Published			2023-01-03	WOS:000671698800057
J	Derici, GE; Ozdas, S; Canatar, I; Koc, M				Derici, Gizem Ece; Ozdas, Sibel; Canatar, Ipek; Koc, Murat			Antidiabetic activities of Bolanthus spergulifolius (Caryophyllaceae) extracts on insulin-resistant 3T3-L1 adipocytes	PLOS ONE			English	Article							APOPTOSIS; ADIPOGENESIS; INHIBITION; INDUCTION; ANTIOXIDANT; EXPRESSION; OBESITY; GROWTH	Diabetes mellitus (DM) is a metabolic disorder with chronic hyperglycemia featured by metabolic outcomes owing to insufficient insulin secretion and/or insulin effect defect. It is critical to investigate new therapeutic approaches for T2DM and alternative, natural agents that target molecules in potential signal pathways. Medicinal plants are significant resources in the research of alternative new drug active ingredients. Bolanthus spergulifolius (B. spergulifolius) is one of the genera of the family Caryophyllaceae. In this study, it was explored the potential anti-diabetic effects in vitro of B. spergulifolius extracts on 3T3-L1 adipocytes. The total phenolic contents (TPC) of methanolic (MeOH), ethyl acettate (EA) and aqueous extracts of B. spergulifolius were evaluated via Folin-Ciocateau. B. spergulifolius extracts showing highly TPC (Aqueous< MeOH< EA) and their different concentrations were carried out on preadipocytes differentiated in to mature 3T3-L1 adipocytes to investigate their half-maximal (50%) inhibitory concentration (IC50) value by using Thiazolyl blue tetrazolium bromide (MTT) assay. The IC50 of MeOH, EA and Aqueous extracts were observed as 305.7 +/- 5.583 mu g/mL, 567.4 +/- 3.008 mu g/mL, and 418.3 +/- 4.390 mu g/mL and used for further experiments. A live/dead assay further confirmed the cytotoxic effects of MeOH, EA and Aqueous extracts (respectively, 69.75 +/- 1.70%, 61.75 +/- 1.70%, 70 +/- 4.24%, and for all p< 0.05). Also, effects of extracts on lipid accumulation in mature 3T3-L1 adipocytes were evaluated by Oil-Red O staining assay. The extracts effectively decreased lipid-accumulation compared to untreated adipocytes (for all p< 0.05). Moreover, effect of extracts on apoptosis regulated by the Bax and Bcl-2 was investigated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The extracts significantly induced apoptosis by up-regulating pro-apoptotic Bax expression but down-regulated anti-apoptotic Bcl-2 gene expression compared to untreated adipocytes (for all p< 0.05). The Glut-4 expression linked with insulin resistance was determined by qRT-PCR, Western-blot analysis, and immunofluorescence staining. In parallel, the expression of Glut-4 in adipocytes treated with extracts was significantly higher compared to untreated adipocytes (for all p< 0.05). Extracts significantly suppressed cell migration after 30 h of wounding in a scratch-assay (for all p< 0.05). Cell morphology and diameter were further evaluated by phase-contrast microscopy, scanning electron microscopy, Immunofluorescence with F-Actin and Giemsa staining. The adipocytes treated with extracts partially lost spherical morphology and showed smaller cell-diameter compared to untreated adipocytes (for all p< 0.05). In conclusion, these results suggest that extracts of B. spergulifolius cause to an induce apoptosis, decrease lipid-accumulation, wound healing, up-regulating Glut-4 level and might contribute to reducing of insulin-resistance in DM.	[Derici, Gizem Ece; Ozdas, Sibel; Canatar, Ipek] Adana Alpaslan Turke Sci & Technol Univ, Fac Engn Sci, Dept Bioengn, Adana, Turkey; [Koc, Murat] Ankara Yildirim Beyazit Univ, Grad Sch Publ Hlth, Dept Tradit Complementary & Integrat Med, Ankara, Turkey	Ankara Yildirim Beyazit University	Ozdas, S (corresponding author), Adana Alpaslan Turke Sci & Technol Univ, Fac Engn Sci, Dept Bioengn, Adana, Turkey.	sozdas@atu.edu.tr		OZDAS, Sibel/0000-0003-4610-2785	Adana Science and Technology University Scientific Research Projects Coordination Unit [19332006, 20103005]	Adana Science and Technology University Scientific Research Projects Coordination Unit	The author(s) received funding for this work by Adana Science and Technology University Scientific Research Projects Coordination Unit (Award Number: Project No: 19332006 and Project No: 20103005 | Recipient: SibelOzdas, PhD). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akinrinde A, 2018, ACTA PHARMACEUT, V68, P389, DOI 10.2478/acph-2018-0023; Berenguer M, 2011, BIOCHIMIE, V93, P697, DOI 10.1016/j.biochi.2010.12.013; Boissier PE., 1867, FLORA ORIENTALIS, V1, P25; Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x; Chaiittianan R, 2017, J ETHNOPHARMACOL, V201, P9, DOI 10.1016/j.jep.2017.02.044; Chan S. W., 2009, INT FOOD RES J, V2, P203; Chandra S, 2015, INTEGR MED RES, V4, P123, DOI 10.1016/j.imr.2015.06.004; Cho NH, 2018, DIABETES RES CLIN PR, V138, P271, DOI 10.1016/j.diabres.2018.02.023; Choi KC, 2003, ENDOCRINOLOGY, V144, P754, DOI 10.1210/en.2002-220783; De Melo N, 2019, BIOMIMETICS-BASEL, V4, DOI 10.3390/biomimetics4030048; Dey Lucy, 2002, Altern Med Rev, V7, P45; Forouhi Nita Gandhi, 2014, Medicine (Abingdon), V42, P698; FROST SC, 1985, J BIOL CHEM, V260, P2646; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Hamzaoglu E, 2017, NORD J BOT, V35, P563, DOI 10.1111/njb.01521; Handala L, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020165; Hauner H, 1998, INT J OBESITY, V22, P448, DOI 10.1038/sj.ijo.0800606; Hebi Morad, 2019, Cardiovascular & Hematological Agents in Medicinal Chemistry, V17, P47, DOI 10.2174/1871525717666190227231834; Hernandez-Ledesma P, 2015, WILLDENOWIA, V45, P281, DOI 10.3372/wi.45.45301; Hsiao CY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/508972; Hsu CL, 2007, J AGR FOOD CHEM, V55, P1730, DOI 10.1021/jf062912b; Hu J, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-267; Hu XF, 2018, FITOTERAPIA, V127, P129, DOI 10.1016/j.fitote.2018.02.015; Huber-Morath A., 1967, FLORA TURKEY E AEGEA, V2, P171; Hulkower Keren I, 2011, Pharmaceutics, V3, P107, DOI 10.3390/pharmaceutics3010107; Hyun TK, 2016, SAUDI J BIOL SCI, V23, P181, DOI 10.1016/j.sjbs.2015.02.008; Kim GS, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-31; Koc M, 2019, FOLIA GEOBOT, V54, P279, DOI 10.1007/s12224-019-09348-1; Koc M, 2015, PHYTOKEYS, V52, P81, DOI 10.3897/phytokeys.52.4479; Langlois NEI, 2000, J ROY COLL SURG EDIN, V45, P211; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsuda M, 2013, OBES RES CLIN PRACT, V7, pE330, DOI 10.1016/j.orcp.2013.05.004; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Patel D. K., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P411, DOI 10.1016/S2221-1691(12)60067-7; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Pratima N.A., 2018, ARC ORG INORG CHEM S, V1, P26, DOI [10.32474/AOICS.2018.01.000103, DOI 10.32474/AOICS.2018.01.000103]; PRINS JB, 1994, BIOCHEM BIOPH RES CO, V201, P500, DOI 10.1006/bbrc.1994.1730; Rasouli H, 2017, FOOD FUNCT, V8, P1942, DOI [10.1039/C7FO00220C, 10.1039/c7fo00220c]; Raveendran Arkiath V, 2018, Eur Endocrinol, V14, P31, DOI 10.17925/EE.2018.14.2.31; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Saeedi P, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107843; Schindelin J, 2015, MOL REPROD DEV, V82, P518, DOI 10.1002/mrd.22489; Shanik MH, 2008, DIABETES CARE, V31, pS262, DOI 10.2337/dc08-s264; Shi J, 2005, FOOD REV INT, V21, P139, DOI 10.1081/FRI-200040606; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Somaida A, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13110357; Stalikas CD, 2007, J SEP SCI, V30, P3268, DOI 10.1002/jssc.200700261; Taylor SC, 2013, MOL BIOTECHNOL, V55, P217, DOI 10.1007/s12033-013-9672-6; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; Vaid B, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4045365; VanEppsFung M, 1997, ENDOCRINOLOGY, V138, P4338, DOI 10.1210/en.138.10.4338; Xu F, 2017, IND CROP PROD, V103, P251, DOI 10.1016/j.indcrop.2017.04.006; Yang JY, 2008, LIFE SCI, V82, P1032, DOI 10.1016/j.lfs.2008.03.003; Zengin G, 2018, FOOD BIOSCI, V23, P75, DOI 10.1016/j.fbio.2018.03.010; Zheleva-Dimitrova D, 2018, J PHARMACEUT BIOMED, V155, P56, DOI 10.1016/j.jpba.2018.03.040; Zielinski H, 2000, J AGR FOOD CHEM, V48, P2008, DOI 10.1021/jf990619o	58	0	0	5	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2021	16	6							e0252707	10.1371/journal.pone.0252707	http://dx.doi.org/10.1371/journal.pone.0252707			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG8YE	34133443	Green Published, gold			2023-01-03	WOS:000671682700037
J	McHugh, MD; Aiken, LH; Sloane, DM; Windsor, C; Douglas, C; Yates, P				McHugh, Matthew D.; Aiken, Linda H.; Sloane, Douglas M.; Windsor, Carol; Douglas, Clint; Yates, Patsy			Effects of nurse-to-patient ratio legislation on nurse staffing and patient mortality, readmissions, and length of stay: a prospective study in a panel of hospitals	LANCET			English	Article							CHARLSON COMORBIDITY INDEX; WORK ENVIRONMENTS; CALIFORNIA; EDUCATION; COUNTRIES; OUTCOMES; MANDATE	Background Substantial evidence indicates that patient outcomes are more favourable in hospitals with better nurse staffing. One policy designed to achieve better staffing is minimum nurse-to-patient ratio mandates, but such policies have rarely been implemented or evaluated. In 2016, Queensland (Australia) implemented minimum nurse-to-patient ratios in selected hospitals. We aimed to assess the effects of this policy on staffing levels and patient outcomes and whether both were associated. Methods For this prospective panel study, we compared Queensland hospitals subject to the ratio policy (27 intervention hospitals) and those that discharged similar patients but were not subject to ratios (28 comparison hospitals) at two timepoints: before implementation of ratios (baseline) and 2 years after implementation (post-implementation). We used standardised Queensland Hospital Admitted Patient Data, linked with death records, to obtain data on patient characteristics and outcomes (30-day mortality, 7-day readmissions, and length of stay [LOS]) for medical-surgical patients and survey data from 17 010 medical-surgical nurses in the study hospitals before and after policy implementation. Survey data from nurses were used to measure nurse staffing and, after linking with standardised patient data, to estimate the differential change in outcomes between patients in intervention and comparison hospitals, and determine whether nurse staffing changes were related to it. Findings We included 231 902 patients (142 986 in intervention hospitals and 88 916 in comparison hospitals) assessed at baseline (2016) and 257 253 patients (160 167 in intervention hospitals and 97 086 in comparison hospitals) assessed in the post-implementation period (2018). After implementation, mortality rates were not significantly higher than at baseline in comparison hospitals (adjusted odds ratio [OR] 1.07, 95% CI 0.97-1.17, p=0.18), but were significantly lower than at baseline in intervention hospitals (0.89, 0.84-0.95, p=0.0003). From baseline to post-implementation, readmissions increased in comparison hospitals (1.06, 1.01-1.12, p=0.015), but not in intervention hospitals (1.00, 0.95-1.04, p=0.92). Although LOS decreased in both groups post-implementation, the reduction was more pronounced in intervention hospitals than in comparison hospitals (adjusted incident rate ratio [IRR] 0.95, 95% CI 0.92-0.99, p=0.010). Staffing changed in hospitals from baseline to post-implementation: of the 36 hospitals with reliable staffing measures, 30 (83%) had more than 4.5 patients per nurse at baseline, with the number decreasing to 21 (58%) post-implementation. The majority of change was at intervention hospitals, and staffing improvements by one patient per nurse produced reductions in mortality (OR 0.93, 95% CI 0.86-0.99, p=0.045), readmissions (0.93, 0.89-0.97, p<0.0001), and LOS (IRR 0.97, 0.94-0.99, p=0.035). In addition to producing better outcomes, the costs avoided due to fewer readmissions and shorter LOS were more than twice the cost of the additional nurse staffing. Interpretation Minimum nurse-to-patient ratio policies are a feasible approach to improve nurse staffing and patient outcomes with good return on investment. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[McHugh, Matthew D.; Aiken, Linda H.; Sloane, Douglas M.] Univ Penn, Sch Nursing, Ctr Hlth Outcomes & Policy Res, Philadelphia, PA 19104 USA; [Windsor, Carol; Douglas, Clint; Yates, Patsy] Queensland Univ Technol, Sch Nursing, Kelvin Grove, Qld, Australia; [Windsor, Carol; Douglas, Clint; Yates, Patsy] Queensland Univ Technol, Fac Hlth, Ctr Healthcare Transformat, Brisbane, Qld, Australia; [Douglas, Clint] Royal Brisbane & Womens Hosp, Metro North Hosp & Hlth Serv, Herston, Qld, Australia	University of Pennsylvania; Queensland University of Technology (QUT); Queensland University of Technology (QUT); Royal Brisbane & Women's Hospital	McHugh, MD (corresponding author), Univ Penn, Sch Nursing, Ctr Hlth Outcomes & Policy Res, Philadelphia, PA 19104 USA.	mchughm@nursing.upenn.edu		Yates, Patsy/0000-0001-8946-8504; Douglas, Clint/0000-0003-4131-5044	Queensland Health, National Institutes of Health, National Institute of Nursing Research	Queensland Health, National Institutes of Health, National Institute of Nursing Research	Queensland Health, National Institutes of Health, National Institute of Nursing Research.	Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; Aiken LH, 2014, LANCET, V383, P1824, DOI 10.1016/S0140-6736(13)62631-8; Aiken LH, 2011, MED CARE, V49, P1047, DOI 10.1097/MLR.0b013e3182330b6e; Aiken LH, 2010, HEALTH SERV RES, V45, P904, DOI 10.1111/j.1475-6773.2010.01114.x; AIKEN M, 1968, AM SOCIOL REV, V33, P912, DOI 10.2307/2092683; Ball JE, 2018, INT J NURS STUD, V78, P10, DOI 10.1016/j.ijnurstu.2017.08.004; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Chen Michelle, 2018, NATION; Cho E, 2015, INT J NURS STUD, V52, P535, DOI 10.1016/j.ijnurstu.2014.08.006; Dillman D. A., 2014, TAILORED DESIGN METH; Duffield C, 2011, APPL NURS RES, V24, P244, DOI 10.1016/j.apnr.2009.12.004; Fairbrother M, 2014, POLIT SCI RES METH, V2, P119, DOI 10.1017/psrm.2013.24; Gerdtz M F, 2007, J Nurs Manag, V15, P64, DOI 10.1111/j.1365-2934.2006.00657.x; International Council of Nurses, 2018, EV BAS SAF NURS STAF; KAHN KL, 1988, JAMA-J AM MED ASSOC, V260, P3625, DOI 10.1001/jama.260.24.3625; Lasater KB, 2021, BMJ QUAL SAF, V30, P639, DOI 10.1136/bmjqs-2020-011512; Lasater KB, 2021, MED CARE, V59, P444, DOI 10.1097/MLR.0000000000001519; Lasater KB, 2021, AM J INFECT CONTROL, V49, P868, DOI 10.1016/j.ajic.2020.12.002; Lasater KB, 2019, MED CARE, V57, P742, DOI 10.1097/MLR.0000000000001167; Lasater KB, 2016, INT J QUAL HEALTH C, V28, P253, DOI 10.1093/intqhc/mzw007; Li B, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-12; Massey DS, 2013, ANN AM ACAD POLIT SS, P645; McHugh MD, 2011, HEALTH AFFAIR, V30, P1299, DOI 10.1377/hlthaff.2010.1118; Nantsupawat A, 2011, J NURS SCHOLARSHIP, V43, P426, DOI 10.1111/j.1547-5069.2011.01419.x; National Research Council, 2013, NONRESPONSE SOCIAL S; Needleman J, 2011, NEW ENGL J MED, V364, P1037, DOI 10.1056/NEJMsa1001025; Pensions DfWa, 2021, ANN REP FISC YEAR 20; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Queensland Health, 2020, WAG RAT NURS STREAM; Rafferty AM, 2007, INT J NURS STUD, V44, P175, DOI 10.1016/j.ijnurstu.2006.08.003; Silber JH, 2016, JAMA SURG, V151, P527, DOI 10.1001/jamasurg.2015.4908; Sloane DM, 2018, MED CARE, V56, P1001, DOI 10.1097/MLR.0000000000001002; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Twigg D, 2011, INT J NURS STUD, V48, P540, DOI 10.1016/j.ijnurstu.2010.07.013; Van den Heede K, 2020, HEALTH POLICY, V124, P1064, DOI 10.1016/j.healthpol.2020.08.003; WHO, 2021, 20 YEAR NURS MIDW	36	47	47	4	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	2021	397	10288					1905	1913		10.1016/S0140-6736(21)00768-6	http://dx.doi.org/10.1016/S0140-6736(21)00768-6		MAY 2021	9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	SF1XN	33989553	Green Published			2023-01-03	WOS:000652556000026
J	Lam, CS; Koon, HK; Chung, VCH; Cheung, YT				Lam, Chun Sing; Koon, Ho Kee; Chung, Vincent Chi-Ho; Cheung, Yin Ting			A public survey of traditional, complementary and integrative medicine use during the COVID-19 outbreak in Hong Kong	PLOS ONE			English	Article							ALTERNATIVE MEDICINE	Background During COVID-19, the public actively sought non-pharmacological and self-management approaches to prevent infection. Little is known on the use of traditional, complementary and integrative medicine (TCIM) by the public as preventive measures. This study investigated the prevalence and patterns of TCIM use during the pandemic, and identified factors associated with its use among the general population in Hong Kong. Methods An online cross-sectional survey was conducted from November to December 2020. The survey solicited information on the respondents' sociodemographic characteristics, risk perception of the pandemic, and use of TCIM before and during the pandemic. Logistic regression analysis was conducted to determine predictors of TCIM use. Results In total, 632 responses (completion rate = 88.1%) were analyzed. TCIM was used by 44.0% of respondents during the pandemic. The most popular forms of TCIM were vitamins or other dietary supplements (n = 160, 25.3%) and Chinese herbal medicine (n = 122, 19.3%) during the pandemic. The most frequently reported indication was strengthening the immune system, especially for vitamins or other dietary supplements (n = 142/160, 88.8%). Respondents who reported using TCIM were more likely to be female (adjusted odds ratio [aOR] = 1.82, 95% confidence interval [CI] = 1.29-2.59), had higher education attainment (aOR = 2.21, 95% CI = 1.39-3.59), and older-aged (age >55 years: aOR = 1.77, 95% CI = 1.04-3.02). Respondents who resided in districts with moderate to high number of confirmed COVID-19 cases (aOR = 1.60, 95% CI = 1.07-2.42) and had a higher level of risk perception (aOR = 1.04, 95% CI = 1.01-1.07) were also more likely to use TCIM. Conclusion TCIM was used commonly in Hong Kong during the COVID-19 pandemic. While vaccination and social distancing remain the mainstay of controlling the pandemic, professional bodies should proactively consider public preferences and provide information regarding the effectiveness and safety of TCIM for COVID-19 prevention and treatment.	[Lam, Chun Sing; Cheung, Yin Ting] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Hong Kong, Peoples R China; [Koon, Ho Kee; Chung, Vincent Chi-Ho] Chinese Univ Hong Kong, Fac Med, Sch Chinese Med, Hong Kong, Peoples R China; [Chung, Vincent Chi-Ho] Chinese Univ Hong Kong, Fac Med, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Cheung, YT (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Pharm, Hong Kong, Peoples R China.	yinting.cheung@cuhk.edu.hk	Cheung, Yin Ting/AAT-4384-2021; Chung, Vincent CH/K-2447-2013	Cheung, Yin Ting/0000-0001-9874-8938; Chung, Vincent CH/0000-0002-5947-4492; Koon, Ho-Kee/0000-0003-4272-6494				Alyami HS, 2020, SAUDI PHARM J, V28, P1326, DOI 10.1016/j.jsps.2020.08.023; Arora R, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/586506; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Barnes J, 2003, BRIT J CLIN PHARMACO, V55, P331, DOI 10.1046/j.1365-2125.2003.01811.x; Cenat JM, 2021, PSYCHIAT RES, V295, DOI 10.1016/j.psychres.2020.113599; Charan J., 2020, INDIAN J CLIN BIOCHE, V36, P1; Ching S, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1017-0; Chung VCH, 2020, ADV INTEGR MED, V7, P51, DOI 10.1016/j.aimed.2020.04.001; Chung VCH, 2014, HEALTH EXPECT, V17, P622, DOI 10.1111/j.1369-7625.2012.00794.x; Conboy L, 2005, J ALTERN COMPLEM MED, V11, P977, DOI 10.1089/acm.2005.11.977; Constant A, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.579460; Department of Health HK, 2021, GUIDELINES PREVENTIO; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Fan AY, 2020, J INTEGR MED-JIM, V18, P385, DOI 10.1016/j.joim.2020.07.008; Friis K, 2016, J HEALTH COMMUN, V21, P54, DOI 10.1080/10810730.2016.1201175; Ho LTF, 2020, EUR J INTEGR MED, V36, DOI 10.1016/j.eujim.2020.101116; Hwang JH, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-02945-0; James PB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223068; Jovic TH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092550; Kwok KO, 2020, EMERG INFECT DIS, V26, P1575, DOI 10.3201/eid2607.200500; Littlewood RA, 2008, AIDS CARE, V20, P1002, DOI 10.1080/09540120701767216; Liu M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104896; Liu XM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004882.pub3; Midi H, 2010, J INTERDISCIP MATH, V13, P253, DOI 10.1080/09720502.2010.10700699; Miller MJ, 2021, AM J MANAG CARE, V27, pE54, DOI 10.37765/ajmc.2021.88535; National Center for Complementary and Integrative Health, 2015, COMPLEMENTARY ALTERN; Ng JY, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-03151-8; Pao J, 2020, ASIA TIMES; Park HL, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429103; Perrin A., 2015, PEW RES CTR, V125, P52; Seifert G, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.587749; Shahid Z, 2020, J AM GERIATR SOC, V68, P926, DOI 10.1111/jgs.16472; Shakoor H, 2021, MATURITAS, V143, P1, DOI 10.1016/j.maturitas.2020.08.003; Sharma M, 2020, J MED SYST, V44, DOI 10.1007/s10916-020-01588-5; The Government of the HKSAR, 2021, LAT SIT COR DIS COVI; WHO, TRADITIONAL COMPLEME; WHO, 2020, WHO DIR GEN STAT EM; WHO, 2020, PNEUM UNKN CAUS CHIN; World Health Organization, 2021, COVID 19 VACC PROGR; World Health Organization, 2021, ADV PUBL COR DIS COV; Xiong XJ, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.105056; Yildirim M, 2021, PSYCHOL HEALTH MED, V26, P35, DOI 10.1080/13548506.2020.1776891; Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/710750; Zuo T, 2020, GASTROENTEROLOGY, V159, P944, DOI 10.1053/j.gastro.2020.05.048	44	13	14	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	7							e0253890	10.1371/journal.pone.0253890	http://dx.doi.org/10.1371/journal.pone.0253890			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TC7AG	34197523	Green Published, gold			2023-01-03	WOS:000668791400080
J	Weiner, F; Schille, JT; Hein, JI; Wu, XF; Beller, M; Junghanss, C; Escobar, HM; Nolte, I				Weiner, Franziska; Schille, Jan Torben; Hein, Jens Ingo; Wu, Xiao-Feng; Beller, Matthias; Junghanss, Christian; Murua Escobar, Hugo; Nolte, Ingo			Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines	PLOS ONE			English	Article							DNA METHYLTRANSFERASE INHIBITOR; GENE-EXPRESSION; CANCER-CELLS; 5-AZACYTIDINE; ESTABLISHMENT; CYTOTOXICITY; PACLITAXEL; RESISTANCE; PATTERNS; TUMORS	The isoquinolinamine FX-9 is a novel potential chemotherapeutic agent showing antiproliferative effects against hematologic and prostate cancer cell lines such as B- and T-acute lymphoblastic leukemia and prostate cancer (PC) of different species. Interestingly, FX-9 shows no hemolytic activity and low toxicity in benign adherent cells. The detailed FX-9 molecular mode of action is currently not fully understood. But application on neoplastic cells induces pro-apoptotic and antimitotic effects. Canine prostate cancer (cPC) represents a unique spontaneous occurring animal model for human androgen-independent PC. Human androgen-independent PC as well as cPC are currently not satisfactorily treatable with chemotherapeutic protocols. Accordingly, the evaluation of novel agent combinations bears significant potential for identifying novel treatment strategies. In this study, we combined FX-9 with the currently approved therapeutic agents doxorubicin, carboplatin, the demethylating substance azacitidine as well as further potentially antitumorigenic agents such as dichloroacetic acid (DCA) in order to evaluate the respective synergistic potential. The combinations with 1-5 mu M FX-9 were evaluated regarding the effect after 72 hours on cell viability, cell count and apoptotic/necrotic cells in two human prostate cancer cell lines (LNCaP, PC-3) and a canine prostate cancer cell line (Adcarc1258) representing androgen-dependent and -independent PC/cPC forms. FX-9 in combination with azacitidine decreases cell viability and increases cell death with positive Bliss values. Furthermore, this decreases the cell count with neutral Bliss values on PC-3. Carboplatin in combination with FX-9 reduces cell viability with a neutral Bliss value and increases cell death on LNCaP with calculated positive Bliss values. DCA or doxorubicin in combination with FX-9 do not show synergistic or additive effects on the cell viability. Based on these results, azacitidine or carboplatin in combination with FX-9 offers synergistic/additive efficacy against prostate adenocarcinoma cell lines in vitro. The beneficial effects of both combinations are worth further investigation.	[Weiner, Franziska; Schille, Jan Torben; Hein, Jens Ingo; Nolte, Ingo] Univ Vet Med Hannover, Small Anim Clin, Hannover, Germany; [Schille, Jan Torben; Junghanss, Christian; Murua Escobar, Hugo] Univ Rostock, Dept Med, Clin 3, Hematol,Oncol,Palliat Med, Rostock, Germany; [Wu, Xiao-Feng; Beller, Matthias] Leibniz Inst Catalysis, Rostock, Germany	University of Veterinary Medicine Hannover, Foundation; University of Rostock; Leibniz Institut fur Katalyse e.V. an der Universitat Rostock (LIKAT)	Escobar, HM (corresponding author), Univ Rostock, Dept Med, Clin 3, Hematol,Oncol,Palliat Med, Rostock, Germany.	hugo.murua.escobar@med.uni-rostock.de	Wu, Xiao-Feng/I-5235-2012	Wu, Xiao-Feng/0000-0001-6622-3328; Schille, Jan Torben/0000-0001-9736-7105	Deutsche Forschungsgemeinschaft; Universitat Rostock/Universitatsmedizin Rostock	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Universitat Rostock/Universitatsmedizin Rostock	This publication was supported by Deutsche Forschungsgemeinschaft and Universitat Rostock/Universitatsmedizin Rostock within the funding program Open Access Publishing.	Abdulhaq H, 2007, EXPERT OPIN INV DRUG, V16, P1967, DOI 10.1517/13543784.16.12.1967; American Veterinary Medical Association, WITHDR PACC VET; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Brabec V, 2005, DRUG RESIST UPDATE, V8, P131, DOI 10.1016/j.drup.2005.04.006; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chan GKY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063583; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Choy H, 2000, CANCER-AM CANCER SOC, V88, P1336, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1336::AID-CNCR9>3.0.CO;2-M; Chung KS, 2013, CARCINOGENESIS, V34, P1852, DOI 10.1093/carcin/bgt133; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; de Sousa GF, 2014, BRAZ J PHARM SCI, V50, P693, DOI 10.1590/S1984-82502014000400004; Dozmorov MG, 2009, PROSTATE, V69, P1077, DOI 10.1002/pros.20960; Drugs@FDA, 2004, DRUGS FDA; Drugs@FDA. Center for Drug Evaluation and Research, 1989, CARBOPLATIN LABEL; European Medicines Agency, 2012, WITHDR PACC VET; Feng JB, 2016, ADV SYNTH CATAL, V358, P2179, DOI 10.1002/adsc.201600169; Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; del Alba AG, 2021, CLIN TRANSL ONCOL, V23, P969, DOI 10.1007/s12094-021-02561-5; Gossnitzer E, 2003, EUR J PHARM SCI, V19, P151, DOI 10.1016/S0928-0987(03)00086-1; Gutteridge CE, 2011, BIOORG MED CHEM LETT, V21, P786, DOI 10.1016/j.bmcl.2010.11.099; Hah SS, 2006, CHEM RES TOXICOL, V19, P622, DOI 10.1021/tx060058c; Hahn NM, 2012, J UROLOGY, V187, P302, DOI 10.1016/j.juro.2011.09.010; Harman RM, 2016, J MAMMARY GLAND BIOL, V21, P51, DOI 10.1007/s10911-016-9350-y; Harting T, 2016, INT J ONCOL, V49, P2341, DOI 10.3892/ijo.2016.3720; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; KAIGHN ME, 1979, INVEST UROL, V17, P16; Khadka DB, 2015, EUR J MED CHEM, V92, P583, DOI 10.1016/j.ejmech.2015.01.016; Khanna C, 2015, J VET INTERN MED, V29, P1006, DOI 10.1111/jvim.12596; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Kiziltepe T, 2007, MOL CANCER THER, V6, P1718, DOI 10.1158/1535-7163.MCT-07-0010; Kwitniewski M, 2011, PHOTOCH PHOTOBIO SCI, V10, P25, DOI 10.1039/c0pp00193g; LeRoy BE, 2009, VET J, V180, P149, DOI 10.1016/j.tvjl.2008.07.012; Li YF, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.08.030; Litwin MS, 2017, JAMA-J AM MED ASSOC, V317, P2532, DOI 10.1001/jama.2017.7248; Meredith AM, 2016, J PHARM PHARMACOL, V68, P729, DOI 10.1111/jphp.12539; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723; Packeiser EM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230272; Roolf C, 2019, BIOMOL THER, V27, P492, DOI 10.4062/biomolther.2018.199; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Schille JT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225567; Schoch R, 2007, AZACITIDINE AZA TREA; Sekeres MA, 2012, BLOOD, V120, P4945, DOI 10.1182/blood-2012-06-434639; Tataranni T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8201079; TILLEY WD, 1990, CANCER RES, V50, P5382; von Euler H, 2013, VET COMP ONCOL, V11, P243, DOI 10.1111/j.1476-5829.2011.00314.x; Weaver BA, 2014, MOL BIOL CELL, V25, P2677, DOI 10.1091/mbc.E14-04-0916; Winkler S, 2005, J HERED, V96, P782, DOI 10.1093/jhered/esi085; Withrow SJ., 2013, WITHROW MACEWENS SMA, V5, P167; Yang F, 2014, BBA-REV CANCER, V1845, P84, DOI 10.1016/j.bbcan.2013.12.002; Yang SH, 2010, EUR J MED CHEM, V45, P5493, DOI 10.1016/j.ejmech.2010.08.042	53	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256468	10.1371/journal.pone.0256468	http://dx.doi.org/10.1371/journal.pone.0256468			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9YC	34432846	Green Published, gold			2023-01-03	WOS:000729171700010
J	Yunihastuti, E; Hariyanto, R; Sulaiman, AS; Harimurti, K				Yunihastuti, Evy; Hariyanto, Rahmat; Sulaiman, Andri Sanityoso; Harimurti, Kuntjoro			Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia	PLOS ONE			English	Article							DIRECT-ACTING ANTIVIRALS; COINFECTED PATIENTS; LIVER-DISEASE; GENOTYPE 3; HIV; DACLATASVIR; ELIMINATION; SOFOSBUVIR; INFECTION; SAFETY	Introduction Direct-acting antiviral drugs (DAAs) have changed the paradigm of hepatitis C therapy for both HCV/HIV co-infected and HCV mono-infected patients. We aimed to describe the HCV continuum of care of HIV-infected patients treated in an HIV clinic after a free DAA program in Indonesia and identify factors correlated with sofosbuvir-daclatasvir (SOF-DCV) treatment failure. Methods We did a retrospective cohort study of adult HIV/HCV co-infected patients under routine HIV-care from November 2019 to April 2020 in the HIV integrated clinic of Cipto Mangunkusumo Hospital, Jakarta, Indonesia. We evaluated some factors correlated with sofosbuvir-daclatasvir treatment failure: gender, diabetes mellitus, previous IFN failure, cirrhosis, concomitant ribavirin use, high baseline HCV-RNA, and low CD4 cell count. Results and discussion Overall, 640 anti-HCV positive patients were included in the study. Most of them were male (88.3%) and former intravenous drug users (76.6%) with a mean age of 40.95 (SD 4.60) years old. Numbers and percentages for the stages of the HCV continuum of care were as follows: HCV-RNA tested (411; 64.2%), pre-therapeutic evaluation done (271; 42.3%), HCV treatment initiated (210; 32.8%), HCV treatment completed (207; 32.2%), but only 178 of these patients had follow-up HCV-RNA tests to allow SVR assessment; and finally SVR12 achieved (178; 27.8%). For the 184 who completed SOF-DCV treatment, SVR12 was achieved by 95.7%. In multivariate analysis, diabetes mellitus remained a significant factor correlated with SOF-DCV treatment failure (adjusted RR 17.0, 95%CI: 3.28-88.23, p = 0.001). Conclusions This study found that in the HCV continuum of care for HIV/HCV co-infected patients, gaps still exist at all stages. As the most commonly used DAA combination, sofosbuvir daclatasvir treatment proved to be effective and well-tolerated in HIV/HCV co-infected patients. Diabetes mellitus was significant factor correlated with not achieving SVR12 in this population.	[Yunihastuti, Evy; Hariyanto, Rahmat; Sulaiman, Andri Sanityoso; Harimurti, Kuntjoro] Univ Indonesia, Cipto Mangunkusumo Hosp, Fac Med, Dept Internal Med, Jakarta, Indonesia; [Yunihastuti, Evy] Cipto Mangunkusumo Hosp, HIV Integrated Clin, Jakarta, Indonesia	University of Indonesia; University of Indonesia	Yunihastuti, E (corresponding author), Univ Indonesia, Cipto Mangunkusumo Hosp, Fac Med, Dept Internal Med, Jakarta, Indonesia.; Yunihastuti, E (corresponding author), Cipto Mangunkusumo Hosp, HIV Integrated Clin, Jakarta, Indonesia.	evy.yunihastuti@gmail.com	Yunihastuti, Evy/AGD-5382-2022	Yunihastuti, Evy/0000-0001-6650-0559; Harimurti, Kuntjoro/0000-0002-9771-803X				Abdel-Moneim A, 2018, HEPATOL INT, V12, P348, DOI 10.1007/s12072-018-9868-8; Adekunle RO., 2020, OPEN FORUM INFECT DI, V7, P1; Amele S, 2019, HIV MED, V20, P264, DOI 10.1111/hiv.12711; Bartlett JG, 2004, INFECT DIS CLIN PRAC, V12, P368; Berenguer J, 2017, HEPATOLOGY, V66, P344, DOI 10.1002/hep.29071; Bhattacharya D, 2017, CLIN INFECT DIS, V64, P1711, DOI 10.1093/cid/cix111; Boeke CE, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003767; Boerekamps A, 2018, CLIN INFECT DIS, V66, P1352, DOI 10.1093/cid/cix1004; Chung RT, 2018, CLIN INFECT DIS, V67, P1477, DOI 10.1093/cid/ciy585; Clement ME, 2018, INFECT DIS CLIN N AM, V32, P407, DOI 10.1016/j.idc.2018.02.005; Durier N, 2017, J VIRAL HEPATITIS, V24, P187, DOI 10.1111/jvh.12630; Hasan I, 2017, KONSENSUS NASIONAL P; Leroy V, 2016, HEPATOLOGY, V63, P1430, DOI 10.1002/hep.28473; Martin NK, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25062; Martinello M, 2016, AIDS REV, V18, P69; Milazzo L, 2017, HIV MED, V18, P284, DOI 10.1111/hiv.12429; Miranda AC, 2020, J VIRAL HEPATITIS, V27, P715, DOI 10.1111/jvh.13281; Nelson DR, 2015, HEPATOLOGY, V61, P1127, DOI 10.1002/hep.27726; Patel SV, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228847; Rizk C, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz361; Romero-Gomez M, 2008, J HEPATOL, V48, P721, DOI 10.1016/j.jhep.2007.11.022; Rossotti R, 2020, DIGEST LIVER DIS, V52, P447, DOI 10.1016/j.dld.2019.12.007; Sacks-Davis R, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25051; Saris J, 2017, AIDS, V31, P1779, DOI 10.1097/QAD.0000000000001566; Sikavi C, 2018, DIGEST DIS SCI, V63, P2829, DOI 10.1007/s10620-018-5215-0; Smith CJ, 2014, LANCET, V384, P241, DOI 10.1016/S0140-6736(14)60604-8; Thomas DL, 2019, NEW ENGL J MED, V380, P2041, DOI 10.1056/NEJMra1810477; Trickey A, 2020, LIVER INT, V40, P286, DOI 10.1111/liv.14232; Tsui Judith I, 2016, Hepatol Med Policy, V1, DOI 10.1186/s41124-016-0020-x; WHO, 2018, PROGR REP ACC HEP C; World Health Organization, 2018, GUID CAR TREATM PERS; Yunihastuti E, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05069-5; Zheng YX, 2020, J GASTROEN HEPATOL, V35, P1477, DOI 10.1111/jgh.15051; Zuckerman A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199174	34	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256164	10.1371/journal.pone.0256164	http://dx.doi.org/10.1371/journal.pone.0256164			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ4EI	34383853	Green Published, gold			2023-01-03	WOS:000684426400033
J	Fujikura, Y; Sugihara, H; Hatakeyama, M; Oishi, K; Yamanouchi, K				Fujikura, Yuri; Sugihara, Hidetoshi; Hatakeyama, Masaki; Oishi, Katsutaka; Yamanouchi, Keitaro			Ketogenic diet with medium-chain triglycerides restores skeletal muscle function and pathology in a rat model of Duchenne muscular dystrophy	FASEB JOURNAL			English	Article						Duchenne muscular dystrophy; ketogenic diet; ketone bodies; nutrition therapy; skeletal muscle	FAT; PROLIFERATION; MECHANISMS; RESISTANCE; THERAPY	Duchenne muscular dystrophy (DMD) is an intractable genetic disease associated with progressive skeletal muscle weakness and degeneration. Recently, it was reported that intraperitoneal injections of ketone bodies partially ameliorated muscular dystrophy by increasing satellite cell (SC) proliferation. Here, we evaluated whether a ketogenic diet (KD) with medium-chain triglycerides (MCT-KD) could alter genetically mutated DMD in model rats. We found that the MCT-KD significantly increased muscle strength and fiber diameter in these rats. The MCT-KD significantly suppressed the key features of DMD, namely, muscle necrosis, inflammation, and subsequent fibrosis. Immunocytochemical analysis revealed that the MCT-KD promoted the proliferation of muscle SCs, suggesting enhanced muscle regeneration. The muscle strength of DMD model rats fed with MCT-KD was significantly improved even at the age of 9 months. Our findings suggested that the MCT-KD ameliorates muscular dystrophy by inhibiting myonecrosis and promoting the proliferation of muscle SCs. As far as we can ascertain, this is the first study to apply a functional diet as therapy for DMD in experimental animals. Further studies are needed to elucidate the underlying mechanisms of the MCT-KD-induced improvement of DMD.	[Fujikura, Yuri; Oishi, Katsutaka] Natl Inst Adv Ind Sci & Technol, Cellular & Mol Biotechnol Res Inst, Hlth Food Sci Res Grp, Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan; [Sugihara, Hidetoshi; Yamanouchi, Keitaro] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, Tokyo, Japan; [Hatakeyama, Masaki] Miyagi Hlth Innovat, Sendai, Miyagi, Japan; [Oishi, Katsutaka] Tokyo Univ Sci, Grad Sch Sci & Technol, Dept Appl Biol Sci, Noda, Chiba, Japan; [Oishi, Katsutaka] Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol & Med Sci, Kashiwa, Chiba, Japan; [Oishi, Katsutaka] Univ Tsukuba, Sch Integrat & Global Majors SIGMA, Tsukuba, Ibaraki, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo; Tokyo University of Science; University of Tokyo; University of Tsukuba	Oishi, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Cellular & Mol Biotechnol Res Inst, Hlth Food Sci Res Grp, Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.; Yamanouchi, K (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Physiol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	k-ooishi@aist.go.jp; akeita@g.ecc.u-tokyo.ac.jp	Oishi, Katsutaka/L-6906-2018; Fujikura, Yuri/H-1612-2019	Oishi, Katsutaka/0000-0002-4870-0837; Fujikura, Yuri/0000-0002-3257-5146	Biosignal Research Center, Kobe University [202004]; Japan Health Foundation	Biosignal Research Center, Kobe University; Japan Health Foundation(Japan Health Foundation)	Biosignal Research Center, Kobe University, Grant/Award Number: 202004; Japan Health Foundation	Augustin K, 2018, LANCET NEUROL, V17, P84, DOI 10.1016/S1474-4422(17)30408-8; Bencze M., 2019, J VIS EXP, V5, P154; Campbell WW, 2002, J PHYSIOL-LONDON, V542, P631, DOI 10.1113/jphysiol.2002.020685; Deemer SE, 2020, NUTR RES, V77, P1, DOI 10.1016/j.nutres.2020.02.010; Fairclough RJ, 2013, NAT REV GENET, V14, P373, DOI 10.1038/nrg3460; Fujiwara D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218329; Geng SS, 2016, EUR J NUTR, V55, P931, DOI 10.1007/s00394-015-0907-0; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grounds MD, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.043638; Harvey CJDC, 2018, J NUTR METAB, V2018, DOI 10.1155/2018/2630565; HUTTENLOCHER PR, 1971, NEUROLOGY, V21, P1097, DOI 10.1212/WNL.21.11.1097; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.3.CO;2-S; Klement RJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155050; Kuang S, 2008, CELL STEM CELL, V2, P22, DOI 10.1016/j.stem.2007.12.012; Kuswanto W, 2016, IMMUNITY, V44, P355, DOI 10.1016/j.immuni.2016.01.009; Lapidos KA, 2004, CIRC RES, V94, P1023, DOI 10.1161/01.RES.0000126574.61061.25; Mercuri E, 2013, LANCET, V381, P845, DOI 10.1016/S0140-6736(12)61897-2; Motohashi N, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091066; Nakamura K, 2014, SCI REP-UK, V4, DOI 10.1038/srep05635; NAKANO K, 1972, J NUTR, V102, P283, DOI 10.1093/jn/102.2.283; Nakao R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56166-8; Ni FF, 2016, SEIZURE-EUR J EPILEP, V38, P17, DOI 10.1016/j.seizure.2016.03.006; Noakes M, 2006, NUTR METAB, V3, DOI 10.1186/1743-7075-3-7; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Okeke EB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00680; Ribeiro AF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48156-7; Riuzzi F, 2012, J CELL SCI, V125, P1440, DOI 10.1242/jcs.092163; ROBINSON AM, 1980, PHYSIOL REV, V60, P143, DOI 10.1152/physrev.1980.60.1.143; Sugihara H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73315-6; Tinsley GM, 2016, INT J SPORT NUTR EXE, V26, P78, DOI 10.1123/ijsnem.2015-0070; Usas A, 2011, MEDICINA-LITHUANIA, V47, P469, DOI 10.3390/medicina47090068; Verhaart IEC, 2019, NAT REV NEUROL, V15, P373, DOI 10.1038/s41582-019-0203-3; Villalta SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009925; Wang YX, 2012, NAT REV MOL CELL BIO, V13, P127, DOI 10.1038/nrm3265; Xin LJ, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00062; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844; Zeng L, 2010, J BIOL CHEM, V285, P36060, DOI 10.1074/jbc.M110.160879; Zhang HB, 2016, SCIENCE, V352, P1436, DOI 10.1126/science.aaf2693; Zou XT, 2016, J BIOL CHEM, V291, P2181, DOI 10.1074/jbc.M115.676510	39	5	5	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2021	35	9							e21861	10.1096/fj.202100629R	http://dx.doi.org/10.1096/fj.202100629R			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ2LG	34416029				2023-01-03	WOS:000691122900046
J	Van Hollebeke, M; Poddighe, D; Gojevic, T; Clerckx, B; Muller, J; Hermans, G; Gosselink, R; Langer, D				Van Hollebeke, Marine; Poddighe, Diego; Gojevic, Tin; Clerckx, Beatrix; Muller, Jan; Hermans, Greet; Gosselink, Rik; Langer, Daniel			Measurement validity of an electronic training device to assess breathing characteristics during inspiratory muscle training in patients with weaning difficulties	PLOS ONE			English	Article							SPIROMETRY	Inspiratory muscle training (IMT) improves respiratory muscle function and might enhance weaning outcomes in patients with weaning difficulties. An electronic inspiratory loading device provides valid, automatically processed information on breathing characteristics during IMT sessions. Adherence to and quality of IMT, as reflected by work of breathing and power generated by inspiratory muscles, are related to improvements in inspiratory muscle function in patients with chronic obstructive pulmonary disease. The aim of this study was to investigate the validity of an electronic training device to assess and provide real-time feedback on breathing characteristics during inspiratory muscle training (IMT) in patient with weaning difficulties. Patients with weaning difficulties performed daily IMT sessions against a tapered flow-resistive load of approximately 30 to 50% of the patient's maximal inspiratory pressure. Airflow and airway pressure measurements were simultaneously collected with the training device (POWERbreatheKH2, POWERbreathe International Ltd, UK) and a portable spirometer (reference device, Pocket-Spiro USB/BT100, M.E.C, Belgium). Breath by breath analysis of 1002 breaths of 27 training sessions (n = 13) against a mean load of 46 +/- 16% of the patient's maximal inspiratory pressure were performed. Good to excellent agreement (Intraclass correlation coefficients: 0.73-0.97) was observed for all breathing characteristics. When individual differences were plotted against mean values of breaths recorded by both devices, small average biases were observed for all breathing characteristics. To conclude, the training device provides valid assessments of breathing characteristics to quantify inspiratory muscle effort (e.g. work of breathing and peak power) during IMT in patients with weaning difficulties. Availability of valid real-time data of breathing responses provided to both the physical therapist and the patient, can be clinically usefull to optimize the training stimulus. By adapting the external load based on the visual feedback of the training device, respiratory muscle work and power generation during IMT can be maximized during the training.	[Van Hollebeke, Marine; Poddighe, Diego; Gojevic, Tin; Gosselink, Rik; Langer, Daniel] Katholieke Univ Leuven, Res Grp Rehabil Internal Disorders, Dept Rehabil Sci, Fac Movement & Rehabil Sci, Leuven, Belgium; [Van Hollebeke, Marine; Poddighe, Diego; Clerckx, Beatrix; Muller, Jan; Hermans, Greet; Gosselink, Rik; Langer, Daniel] Univ Hosp Leuven, Dept Intens Care Med, Leuven, Belgium; [Muller, Jan; Hermans, Greet] Katholieke Univ Leuven, Lab Intens Care Med, Div Cellular & Mol Med, Leuven, Belgium	KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven	Langer, D (corresponding author), Katholieke Univ Leuven, Res Grp Rehabil Internal Disorders, Dept Rehabil Sci, Fac Movement & Rehabil Sci, Leuven, Belgium.; Langer, D (corresponding author), Univ Hosp Leuven, Dept Intens Care Med, Leuven, Belgium.	Daniel.langer@kuleuven.be	Langer, Daniel/B-7307-2014; Poddighe, Diego/GVU-6145-2022; Gosselink, Rik/AAK-4655-2020	Langer, Daniel/0000-0001-8738-9482; Poddighe, Diego/0000-0003-0428-3338; Gosselink, Rik/0000-0003-0444-8606; Van Hollebeke, Marine/0000-0002-9749-569X	Research Foundation Flanders (FWO) [G053721N]	Research Foundation Flanders (FWO)(FWO)	This research project was supported by Research Foundation Flanders (FWO, https://www.fwo.be/en/): grant number G053721N. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Argus CK, 2011, J STRENGTH COND RES, V25, P3282, DOI 10.1519/JSC.0b013e3182133b8c; Charususin N, 2018, THORAX, V73, P942, DOI 10.1136/thoraxjnl-2017-211417; Enright PL, 2004, AM J RESP CRIT CARE, V169, P235, DOI 10.1164/rccm.200204-347OC; Graham BL, 2019, AM J RESP CRIT CARE, V200, pE70, DOI 10.1164/rccm.201908-1590ST; Guimaraes BD, 2021, CRIT CARE MED, V49, P589, DOI 10.1097/CCM.0000000000004787; Hoffman M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021091; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Langer D, 2013, RESP MED, V107, P633, DOI 10.1016/j.rmed.2013.01.020; Tonella Rodrigo Marques, 2017, J Clin Med Res, V9, P929, DOI 10.14740/jocmr3169w; Vorona S, 2018, ANN AM THORAC SOC, V15, P735, DOI 10.1513/AnnalsATS.201712-961OC; Weakley JJS, 2019, J STRENGTH COND RES, V33, P2420, DOI 10.1519/JSC.0000000000002133	11	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2021	16	8							e0255431	10.1371/journal.pone.0255431	http://dx.doi.org/10.1371/journal.pone.0255431			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	US1HA	34437582	gold, Green Published			2023-01-03	WOS:000697186000019
J	Papineni, P				Papineni, Padmasayee			A Pink Salwar	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								A Pink Salwar Throughout the course of the past year, patients with Covid-19 - people of all ages - have continued to fill the hospital beds. The city outside may be eerily quiet, the seasons changing as smoothly and beautifully as ever, but the virus is wicked and keeps taking.	[Papineni, Padmasayee] London North West Univ Healthcare NHS Trust, Dept Infect Dis, Ealing Hosp, London, England		Papineni, P (corresponding author), London North West Univ Healthcare NHS Trust, Dept Infect Dis, Ealing Hosp, London, England.			Papineni, Padmasayee/0000-0001-6923-1542					0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2021	385	9					774	775		10.1056/NEJMp2104037	http://dx.doi.org/10.1056/NEJMp2104037		AUG 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UJ5BP	34415688	Bronze			2023-01-03	WOS:000687762500001
J	Garrett, NFMD; da Costa, ACC; Ferreira, EB; Damiani, G; dos Reis, PED; Vasques, CI				Mineiro dos Santos Garrett, Nathali Felicia; Carvalho da Costa, Ana Cristina; Barros Ferreira, Elaine; Damiani, Giovanni; Diniz dos Reis, Paula Elaine; Inocencio Vasques, Christiane			Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis	PLOS ONE			English	Review							IMMUNE CHECKPOINT BLOCKADE; NIVOLUMAB PLUS IPILIMUMAB; ADVERSE EVENTS; METASTATIC MELANOMA; JAPANESE PATIENTS; OPEN-LABEL; CHOICE CHEMOTHERAPY; CLINICAL BENEFIT; PHASE I/II; STAGE-III	Background Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated. Objective To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune checkpoint inhibitors as monotherapy and/or in combination with chemotherapy and/or radiotherapy. Materials and methods We performed a systematic review and meta-analysis, which encompassed both clinical trials and observational studies describing the dermatological toxicities in patients treated with immune checkpoint inhibitors. The protocol was registered in the International Prospective Register of Systematic Review under the number CRD42018091915. The searches were performed using the CINAHL, Cochrane CENTRAL, LILACS, LIVIVO, PubMed, Scopus, and Web of Science databases. The methodological quality of the studies was evaluated with the JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data Results A total of 9,802 articles were identified in the databases. The final sample comprised 39 studies. The evaluated drugs were ipilimumab, tremelimumab, pembrolizumab, and nivolumab. The results suggest that the most prevalent side effect was grade 1 and 2 pruritus (24%), followed by grade 1 and 2 rash (21%) and grade 1 and 2 vitiligo (10%). Conclusion The most prevalent side effects in patients treated with checkpoint inhibitors are pruritus, rash, and vitiligo, and they are rated mostly as grades 1 and 2 adverse events. Remarkably, vitiligo is most commonly found in patients treated with PD-1 inhibitors.	[Mineiro dos Santos Garrett, Nathali Felicia; Barros Ferreira, Elaine; Diniz dos Reis, Paula Elaine; Inocencio Vasques, Christiane] Univ Brasilia, Sch Hlth Sci, Brasilia, DF, Brazil; [Carvalho da Costa, Ana Cristina] Dept Hlth Fed Dist, Brasilia, DF, Brazil; [Damiani, Giovanni] IRCCS Ist Ortoped Galeazzi, Clin Dermatol, Milan, Italy; [Damiani, Giovanni] Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy; [Damiani, Giovanni] Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA; [Damiani, Giovanni] Univ Padua, Dept Drug Sci, Padua, Italy	Universidade de Brasilia; IRCCS Istituto Ortopedico Galeazzi; University of Milan; Case Western Reserve University; University of Padua	Vasques, CI (corresponding author), Univ Brasilia, Sch Hlth Sci, Brasilia, DF, Brazil.	chvasques@unb.br	vasques, christiane/X-1670-2019	vasques, christiane/0000-0001-9586-9486; Diniz dos Reis, Paula Elaine/0000-0002-9782-3366; Mineiro dos Santos Garrett, Nathali Felicia/0000-0003-4799-6880	National Council for Scientific and Technological Development (CNPq), Brazil [437802/2018-3]	National Council for Scientific and Technological Development (CNPq), Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was funded by a grant from the National Council for Scientific and Technological Development (CNPq), Brazil to CIV (Grant no. 437802/2018-3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Rahman O, 2015, FUTURE ONCOL, V11, P2471, DOI 10.2217/fon.15.118; Abdel-Wahab N, 2017, ADV EXP MED BIOL, V995, P155, DOI 10.1007/978-3-319-53156-4_8; Altomonte M, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-82; Ascierto PA, 2017, LANCET ONCOL, V18, P611, DOI 10.1016/S1470-2045(17)30231-0; Bourke JM, 2016, MED J AUSTRALIA, V205, P418, DOI 10.5694/mja16.00586; Byrne EH, 2017, CANCER-AM CANCER SOC, V123, P2143, DOI 10.1002/cncr.30444; Camacho LH, 2009, J CLIN ONCOL, V27, P1075, DOI 10.1200/JCO.2008.19.2435; Chen TW, 2015, ANN ONCOL, V26, P1824, DOI 10.1093/annonc/mdv182; Collins LK, 2017, CURR PROB CANCER, V41, P125, DOI 10.1016/j.currproblcancer.2016.12.001; Cooper AJ, 2015, MELANOMA MANAG, V2, P267, DOI [10.2217/MMT.15.17, 10.2217/mmt.15.17]; Curry JL, 2017, J CUTAN PATHOL, V44, P158, DOI 10.1111/cup.12858; De Tursi M, 2017, ONCOTARGETS THER, V10, P3007, DOI 10.2147/OTT.S127795; Dika E, 2017, EUR J DERMATOL, V27, P266, DOI 10.1684/ejd.2017.3023; Doi, 2018, INT J EVID-BASED HEA, V16, P000; Eggermont AMM, 2016, NEW ENGL J MED, V375, P1845, DOI 10.1056/NEJMoa1611299; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Endnote&TRADE; basic, THOMSON REUTERS; Ferreira, PREVALENCE DERMATOLO; Freeman-Keller M, 2016, CLIN CANCER RES, V22, P886, DOI 10.1158/1078-0432.CCR-15-1136; Ghate SR, 2018, AM HEALTH DRUG BENEF, V11, P334; Gordon R, 2017, CLIN J ONCOL NURS, V21, P45, DOI 10.1188/17.CJON.S2.45-52; Gravalos C, 2019, CLIN TRANSL ONCOL, V21, P556, DOI 10.1007/s12094-018-1953-x; Hamad Bin Khalifa University, QAT COMP RES I RAYYA; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hodi FS, 2016, LANCET ONCOL, V17, P1558, DOI 10.1016/S1470-2045(16)30366-7; Hua C, 2016, JAMA DERMATOL, V152, P45, DOI 10.1001/jamadermatol.2015.2707; Hwang Shelley Ji Eun, 2018, Curr Probl Dermatol, V53, P82, DOI 10.1159/000478081; Jamovi, 2021, JAM PROJ VERS 1 6 CO; Joanna Briggs Institute, 2017, CHECKL AN CROSS SECT; Jung M, 2017, CANCER RES TREAT, V49, P44, DOI 10.4143/crt.2016.024; Khoja L, 2017, ANN ONCOL, V28, P2377, DOI 10.1093/annonc/mdx286; Ku GY, 2010, CANCER-AM CANCER SOC, V116, P1767, DOI 10.1002/cncr.24951; Lacouture ME, 2015, J NATL COMPR CANC NE, V13, P686, DOI 10.6004/jnccn.2015.0204; Larkin J, 2018, J CLIN ONCOL, V36, P383, DOI 10.1200/JCO.2016.71.8023; Long GV, 2017, JAMA ONCOL, V3, P1511, DOI 10.1001/jamaoncol.2017.1588; Long GV, 2017, LANCET ONCOL, V18, P1202, DOI 10.1016/S1470-2045(17)30428-X; Mantia CM, 2019, HEMATOL ONCOL CLIN N, V33, P275, DOI 10.1016/j.hoc.2018.12.008; Ruiz-Morales JM, 2014, GAC MEX ONCOL, V13, P157; Margolin K, 2012, LANCET ONCOL, V13, P459, DOI 10.1016/S1470-2045(12)70090-6; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Naidoo J, 2016, ANN ONCOL, V27, P1362, DOI 10.1093/annonc/mdw141; Nakamura Y, 2017, J DERMATOL, V44, P117, DOI 10.1111/1346-8138.13520; Namikawa K, 2018, EUR J CANCER, V105, P114, DOI 10.1016/j.ejca.2018.09.025; Nelson, 2017, DERMATOL ONLINE J, V23; Ott PA, 2013, CLIN CANCER RES, V19, P5300, DOI 10.1158/1078-0432.CCR-13-0143; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pavlick Anna C, 2019, Am Soc Clin Oncol Educ Book, V39, P564, DOI 10.1200/EDBK_243071; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMc1801663, 10.1056/NEJMra1703481]; Postow Michael A, 2015, Am Soc Clin Oncol Educ Book, P76, DOI 10.14694/EdBook_AM.2015.35.76; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Postow MA, 2013, ONCOLOGIST, V18, P726, DOI 10.1634/theoncologist.2012-0464; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Ribas A, 2013, J CLIN ONCOL, V31, P616, DOI 10.1200/JCO.2012.44.6112; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rudzki JD, 2018, MEMO-MAG EUR MED ONC, V11, P132, DOI 10.1007/s12254-018-0416-y; Russo I, 2018, SCIENTIFICA, V2018, DOI 10.1155/2018/5036213; Sadreddini S, 2019, J CELL PHYSIOL, V234, P8541, DOI 10.1002/jcp.27816; Shoushtari AN, 2018, JAMA ONCOL, V4, P98, DOI 10.1001/jamaoncol.2017.2391; Sibaud V, 2018, ANN DERMATOL VENER, V145, P313, DOI 10.1016/j.annder.2018.01.047; Sibaud V, 2018, AM J CLIN DERMATOL, V19, P345, DOI 10.1007/s40257-017-0336-3; Sibaud V, 2016, CURR OPIN ONCOL, V28, P254, DOI 10.1097/CCO.0000000000000290; Soldatos TG, 2018, DIAGNOSTICS, V8, DOI 10.3390/diagnostics8040076; Spain L, 2016, EXPERT OPIN BIOL TH, V16, P389, DOI 10.1517/14712598.2016.1141195; Utsunomiya A, 2018, CASE REP DERMATOL, V10, P1, DOI 10.1159/000485910; Voskens CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053745; Wang PF, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00730; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Weber Jeffrey, 2013, Cancer Immun, V13, P7; Weber JS, 2016, ONCOLOGIST, V21, P1230, DOI 10.1634/theoncologist.2016-0055; Weber JS, 2008, J CLIN ONCOL, V26, P5950, DOI 10.1200/JCO.2008.16.1927; Wen XZ, 2017, CANCER IMMUNOL IMMUN, V66, P1153, DOI 10.1007/s00262-017-1989-8; Willemsen M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.579022; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Xu C, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4226; Yamazaki N, 2015, CANCER CHEMOTH PHARM, V76, P997, DOI 10.1007/s00280-015-2873-x; Yamazaki N, 2017, CANCER SCI, V108, P1223, DOI 10.1111/cas.13241; Yamazaki N, 2017, CANCER SCI, V108, P1022, DOI 10.1111/cas.13226; Yamazaki N, 2017, CANCER CHEMOTH PHARM, V79, P651, DOI 10.1007/s00280-016-3237-x; Yousefi H, 2017, EXPERT REV CLIN IMMU, V13, P1001, DOI 10.1080/1744666X.2017.1366315; Zimmer L, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0716-5; Zimmer L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118564	84	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2021	16	8							e0255716	10.1371/journal.pone.0255716	http://dx.doi.org/10.1371/journal.pone.0255716			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6JM	34358260	Green Published, gold			2023-01-03	WOS:000685266400011
J	Dawodu, OG; Akanbi, RB				Dawodu, O. G.; Akanbi, R. B.			Isolation and identification of microorganisms associated with automated teller machines on Federal Polytechnic Ede campus	PLOS ONE			English	Article							STAPHYLOCOCCUS-AUREUS MRSA; COMPUTER KEYBOARDS; BACTERIAL-CONTAMINATION; SURVIVAL; PATHOGENS; GROWTH	Automated Teller Machines (ATM) are visited everyday by millions of people. This machine is accessible to the general public irrespective of class, age or race. The contact point of all ATM machines is the hand which on their own are 'vaults' of microorganisms. An elaborate survey was taken for complete assessment of possible microbial contamination in the Federal Polytechnic Ede campus. Selected ATM machines on campus were used as case study to characterize, identify and determine the degree of bacterial contamination of microorganisms and their potential as reservoir of microbes. Swabs were collected from each ATM screen, buttons, floor, user's hand, and exposure of plates. After collection of the samples, they were plated in nutrient agar. The results showed the presence of increased bacterial count subsequently, most pathogens on characterization revealed the genus of the particular organisms E. coli, Pseudomonas, Staphylococcus aureus, Klebsiella, Micrococcus, Salmonella and Serratia. The study showed the potential hazard inherent in ATM machine usage and draws attention to our level of hand hygiene compliance.	[Dawodu, O. G.; Akanbi, R. B.] Fed Polytech Ede, Dept Sci Lab Technol, Ede, Osun State, Nigeria		Dawodu, OG (corresponding author), Fed Polytech Ede, Dept Sci Lab Technol, Ede, Osun State, Nigeria.	dawgrace@yahoo.com		Dawodu, Olufunke/0000-0003-0367-5153				Abban S., 2011, NAT SCI, V9, P63; Alemu A., 2014, BIOMEDICINE BIOTECHN, V2, P46; Allen M., 2015, PRIMARY SCI, P35; Anderson G, 2009, AM J INFECT CONTROL, V37, P507, DOI 10.1016/j.ajic.2008.10.032; Aquino S., 2021, WORLD J BIOL PHARM H, V5, P027; Awe S., 2013, AM J RECOMMUNICATI, V1, P398; Balkwill DL, 1997, INT J SYST BACTERIOL, V47, P191, DOI 10.1099/00207713-47-1-191; Barbosa JIB, 2020, INT J ENVIRON STUD, V77, P208, DOI [10.1080/00207233.2019.1674584, DOI 10.1080/00207233.2019.1674584]; Barkalar N, 2016, NEW YORK TIMES; Bello CSS., 2002, LAB MANUAL STUDENTS, P80; BENNION RS, 1990, ANN SURG, V211, P165, DOI 10.1097/00000658-199002000-00008; Benson HJ., 1990, MICROBIOLOGICAL APPL, V5th, P459; Bures S, 2000, AM J INFECT CONTROL, V28, P465, DOI 10.1067/mic.2000.107267; Cheesebrough M, 2006, DISTRICT LAB PRACTIC, V38, P62; Chen YH, 2001, J FOOD PROTECT, V64, P72, DOI 10.4315/0362-028X-64.1.72; Christner BC., 2008, PSYCHROPHILES BIODIV; Ducel G., 2002, SURVEILLANCE RESPONS, P27; El-Dars FMSE, 2005, INT J ENVIRON HEAL R, V15, P235, DOI 10.1080/09603120500105976; Eltablawy SY., 2009, WORLD APPL SCI J, V6, P162; Famurewa O., 2009, WORLD RURAL OBSERVAT, V1, P69; Filho PPG., 1987, J CLIN MICROBIOL, V23, P552; Fraser MA, 2009, VET REC, V165, P26, DOI 10.1136/vetrec.165.1.26; French GL, 2004, J HOSP INFECT, V57, P31, DOI 10.1016/j.jhin.2004.03.006; Gholamreza S., 2009, IRAN AM J APPL SCI, V6, P806; Girma G, 2015, J FOOD NUTR SCI, V2, P1; Hardy KJ, 2006, INFECT CONT HOSP EP, V27, P127, DOI 10.1086/500622; Hood SK, 1997, INT J FOOD MICROBIOL, V37, P145, DOI 10.1016/S0168-1605(97)00071-8; HUMPHREY TJ, 1994, EPIDEMIOL INFECT, V113, P403, DOI 10.1017/S0950268800068412; Itah Alfred Young, 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P202; Kissiedu KO, 2002, THESIS U GHANA LEGON; Kramer A, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-130; Kuffner M, 2010, J APPL MICROBIOL, V108, P1471, DOI 10.1111/j.1365-2672.2010.04670.x; Lalonde M, 2007, INT COMMUN GAZ; Lamichhane J., 2009, NEPAL J SCI TECHNOL, V10, P161; Lindberg E, 2004, J CLIN MICROBIOL, V42, P530, DOI 10.1128/JCM.42.2.530-534.2004; Mabel JC., 2014, INDIA INT J PUB HLTH, V3, P51; McFaddin JF., 2000, BIOCH TEST IDENTIFIC; Michaels B., 2002, Food Service Technology, V2, P1, DOI 10.1046/j.1471-5740.2002.00030.x; Micheals B., 2003, FOOD SERVING TECHNOL, V3, P71; Nagajothi J, 2015, INT J EARTH ENV HLTH, V1, P27, DOI [10.4103/2423-7752.159924, DOI 10.4103/2423-7752.159924]; Neely AN, 2000, J CLIN MICROBIOL, V38, P724, DOI 10.1128/JCM.38.2.724-726.2000; Neely AN, 2002, J AM MED INFORM ASSN, V9, P500, DOI 10.1197/jamia.M1082; Nworie O, 2012, AM J INFECT DIS, V8, P168, DOI 10.3844/ajidsp.2012.168.174; Ogilvie LA., 2012, MICROBIAL ECOLOGY TH; Oluduro A. O., 2011, Revista de Ciencias Farmaceuticas Basica e Aplicada, V32, P323; Onibere EA, 2001, INTERACT COMPUT, V13, P497, DOI 10.1016/S0953-5438(00)00052-7; Onuoha S. C., 2014, AM J PUBLIC HLTH RES, V2, P46; Ozkan VK, 2016, J PHARM CHEM BIOL SC, V3, P528; Pope CTW, 2002, SOUTH MED J, V95, P1408, DOI 10.1097/00007611-200295120-00011; Prescott LM., 2002, MICROBIOLOGY, V5th, P1026; Reynolds KA, 2005, INT J ENVIRON HEAL R, V15, P225, DOI 10.1080/09603120500115298; Rusin P, 2002, J APPL MICROBIOL, V93, P585, DOI 10.1046/j.1365-2672.2002.01734.x; Rutala WA, 2004, CLIN INFECT DIS, V39, P702, DOI 10.1086/423182; Saroja V., 2013, J MODERN BIOTECHNOLO, V2, P14; Schultz M, 2003, INFECT CONT HOSP EP, V24, P302, DOI 10.1086/502200; Sharma S., 2014, INT J RECENT SCI RES, V5, P1533; Taylor MW, 2013, ISME J, V7, P438, DOI 10.1038/ismej.2012.111; Ulger F, 2009, ANN CLIN MICROB ANTI, V8, DOI 10.1186/1476-0711-8-7; Umeh E. U., 2007, Research Journal of Environmental Sciences, V1, P336; Wagenvoort JHT, 1997, J HOSP INFECT, V35, P322, DOI 10.1016/S0195-6701(97)90229-2; Webster C, 2000, INFECT CONT HOSP EP, V21, P246, DOI 10.1086/503214; Xu JR, 2005, J ENVIRON HEALTH, V67, P51; Yigit N, 2008, J INT MED RES, V36, P1378, DOI 10.1177/147323000803600627	63	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2021	16	8							e0254658	10.1371/journal.pone.0254658	http://dx.doi.org/10.1371/journal.pone.0254658			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6JF	34351934	Green Published			2023-01-03	WOS:000685265700066
J	Blackwood, B; Tume, LN; Morris, KP; Clarke, M; McDowell, C; Hemming, K; Peters, MJ; McIlmurray, L; Jordan, J; Agus, A; Murray, M; Parslow, R; Walsh, TS; Macrae, D; Easter, C; Feltbower, RG; McAuley, DF				Blackwood, Bronagh; Tume, Lyvonne N.; Morris, Kevin P.; Clarke, Mike; McDowell, Cliona; Hemming, Karla; Peters, Mark J.; McIlmurray, Lisa; Jordan, Joanne; Agus, Ashley; Murray, Margaret; Parslow, Roger; Walsh, Timothy S.; Macrae, Duncan; Easter, Christina; Feltbower, Richard G.; McAuley, Daniel F.		SANDWICH Collaborators	Effect of a Sedation and Ventilator Liberation Protocol vs Usual Care on Duration of Invasive Mechanical Ventilation in Pediatric Intensive Care Units A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN	IMPORTANCE There is limited evidence on the optimal strategy for liberating infants and children from invasive mechanical ventilation in the pediatric intensive care unit. OBJECTIVE To determine if a sedation and ventilator liberation protocol intervention reduces the duration of invasive mechanical ventilation in infants and children anticipated to require prolonged mechanical ventilation. DESIGN, SETTING, AND PARTICIPANTS A pragmatic multicenter, stepped-wedge, cluster randomized clinical trial was conducted that included 17 hospital sites (18 pediatric intensive care units) in the UK sequentially randomized from usual care to the protocol intervention. From February 2018 to October 2019, 8843 critically ill infants and children anticipated to require prolonged mechanical ventilation were recruited. The last date of follow-up was November 11, 2019. INTERVENTIONS Pediatric intensive care units provided usual care (n = 4155 infants and children) or a sedation and ventilator liberation protocol intervention (n = 4688 infants and children) that consisted of assessment of sedation level, daily screening for readiness to undertake a spontaneous breathing trial, a spontaneous breathing trial to test ventilator liberation potential, and daily rounds to review sedation and readiness screening and set patient-relevant targets. MAIN OUTCOMES AND MEASURES The primary outcome was the duration of invasive mechanical ventilation from initiation of ventilation until the first successful extubation. The primary estimate of the treatment effect was a hazard ratio (with a 95% CI) adjusted for calendar time and cluster (hospital site) for infants and children anticipated to require prolonged mechanical ventilation. RESULTS There were a total of 8843 infants and children (median age, 8 months [interquartile range, 1 to 46 months]; 42% were female) who completed the trial. There was a significantly shorter median time to successful extubation for the protocol intervention compared with usual care (64.8 hours vs 66.2 hours, respectively; adjusted median difference, -6.1 hours [interquartile range, -8.2 to -5.3 hours]; adjusted hazard ratio, 1.11 [95% CI, 1.02 to 1.20], P =.02). The serious adverse event of hypoxia occurred in 9 (0.2%) infants and children for the protocol intervention vs 11 (0.3%) for usual care; nonvascular device dislodgement occurred in 2 (0.04%) vs 7 (0.1%), respectively. CONCLUSIONS AND RELEVANCE Among infants and children anticipated to require prolonged mechanical ventilation, a sedation and ventilator liberation protocol intervention compared with usual care resulted in a statistically significant reduction in time to first successful extubation. However, the clinical importance of the effect size is uncertain.	[Blackwood, Bronagh; McIlmurray, Lisa; Jordan, Joanne; McAuley, Daniel F.] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland; [Tume, Lyvonne N.] Univ Salford, Sch Hlth & Soc, Manchester, Lancs, England; [Tume, Lyvonne N.] Alder Hey Childrens NHS Trust, Liverpool, Merseyside, England; [Morris, Kevin P.] Birmingham Womens & Childrens NHS Fdn Trust, Birmingham, W Midlands, England; [Morris, Kevin P.] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Clarke, Mike] Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland; [McDowell, Cliona; Agus, Ashley; Murray, Margaret] Royal Hosp, Northern Ireland Clin Trials Unit, Belfast, Antrim, North Ireland; [Hemming, Karla; Easter, Christina] Univ Birmingham, Birmingham, W Midlands, England; [Peters, Mark J.] Great Ormond St Hosp Sick Children, London, England; [Peters, Mark J.] UCL, Great Ormond St Inst Child Hlth, NIHR Biomed Res Ctr, London, England; [Parslow, Roger; Feltbower, Richard G.] Univ Leeds, Leeds Inst Data Analyt, Sch Med, Leeds, W Yorkshire, England; [Walsh, Timothy S.] Univ Edinburgh, Usher Inst Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Macrae, Duncan] Royal Brompton Hosp, London, England	Queens University Belfast; University of Salford; Alder Hey Children's NHS Foundation Trust; University of Birmingham; Queens University Belfast; University of Birmingham; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of Leeds; University of Edinburgh; Royal Brompton Hospital	Blackwood, B (corresponding author), Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	b.blackwood@qub.ac.uk	Blackwood, Bronagh/GPS-9197-2022	hemming, karla/0000-0002-2226-6550; McAuley, Daniel/0000-0002-3283-1947; Pappachan, John/0000-0002-3559-0595; Garcia Cusco, Mireia/0000-0003-0185-4705; Agus, Ashley/0000-0001-9839-6282; Inwald, David/0000-0001-9518-7821; Peters, Mark/0000-0003-3653-4808; Tume, Lyvonne N/0000-0002-2547-8209; Pathan, Nazima/0000-0001-7656-9453; Meghari, Hamza/0000-0002-3571-1940	National Institute for Health Research [HTA 15/104/01]; Paediatric Critical Care Society Study Group	National Institute for Health Research(National Institute for Health Research (NIHR)); Paediatric Critical Care Society Study Group	This trial (HTA 15/104/01) was commissioned and funded by the National Institute for Health Research and supported by the Paediatric Critical Care Society Study Group. The Queen's University Belfast took legal responsibility for all aspects of the research but did not provide specific funding.	Baisch Steven D, 2005, Pediatr Crit Care Med, V6, P312, DOI 10.1097/01.PCC.0000161119.05076.91; Balcells Ramirez J, 2004, An Pediatr (Barc), V61, P533; BLACKWOOD B, 2015, TRIALS; Blackwood B, PRAGMATIC EXPLANATOR; Blackwood B, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031630; Blackwood B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009082.pub2; Blackwood B, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006904.pub2; Burns KEA, 2018, ANN AM THORAC SOC, V15, P494, DOI 10.1513/AnnalsATS.201705-410OC; Curley MAQ, 2015, JAMA-J AM MED ASSOC, V313, P379, DOI 10.1001/jama.2014.18399; Ely EW, 1999, INTENS CARE MED, V25, P581, DOI 10.1007/s001340050906; Farias JA, 2012, PEDIATR CRIT CARE ME, V13, P158, DOI 10.1097/PCC.0b013e3182257b82; Ferreira FV, 2019, PEDIATR CRIT CARE ME, V20, P940, DOI 10.1097/PCC.0000000000002006; Foronda FK, 2011, CRIT CARE MED, V39, P2526, DOI 10.1097/CCM.0b013e3182257520; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Gupta DM, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0555-2; Hemming K, 2020, INT J EPIDEMIOL, V49, P979, DOI 10.1093/ije/dyz237; Hemming K, 2020, INT J EPIDEMIOL, V49, P1043, DOI 10.1093/ije/dyaa077; Ivers NM, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-120; Jouvet PA, 2013, INTENS CARE MED, V39, P919, DOI 10.1007/s00134-013-2837-8; Kurachek, 2004, CRIT CARE MED, V32, P1632; Leyrat C, 2018, INT J EPIDEMIOL, V47, P1012, DOI 10.1093/ije/dyy057; McIlmurray L, SANDWICH SEDATION WE; Moore GF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1258; Paediatric Intensive Care Audit Network, 2019 ANN REP; Randolph AG, 2002, JAMA-J AM MED ASSOC, V288, P2561, DOI 10.1001/jama.288.20.2561; Schultz T R, 2001, Respir Care, V46, P772; Thompson JA, 2021, STAT METHODS MED RES, V30, P425, DOI 10.1177/0962280220958735; Wolfler A, 2011, PEDIATR CRIT CARE ME, V12, P141, DOI 10.1097/PCC.0b013e3181dbaeb3	28	18	16	2	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2021	326	5					401	410		10.1001/jama.2021.10296	http://dx.doi.org/10.1001/jama.2021.10296			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA6VH	34342620	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000685297500015
J	Pokorny, D; Truebestein, L; Fleming, KD; Burke, JE; Leonard, TA				Pokorny, Daniel; Truebestein, Linda; Fleming, Kaelin D.; Burke, John E.; Leonard, Thomas A.			In vitro reconstitution of Sgk3 activation by phosphatidylinositol 3-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOX HOMOLOGY DOMAIN; PROTEIN-KINASE-C; PHOSPHOINOSITIDE 3-KINASE; STRUCTURAL BASIS; AKT; SERUM; PI3K; PHOSPHORYLATION; INHIBITOR; PATHWAY	Serum-and glucocorticoid-regulated kinase 3 (Sgk3) is a serine/threonine protein kinase activated by the phospholipid phosphatidylinositol 3-phosphate (PI3P) downstream of growth factor signaling via class I phosphatidylinositol 3-kinase (PI3K) signaling and by class III PI3K/Vps34-mediated PI3P production on endosomes. Upregulation of Sgk3 activity has recently been linked to a number of human cancers; however, the precise mechanism of activation of Sgk3 is unknown. Here, we use a wide range of cell biological, biochemical, and biophysical techniques, including hydrogen-deuterium exchange mass spectrometry, to investigate the mechanism of activation of Sgk3 by PI3P. We show that Sgk3 is regulated by a combination of phosphorylation and allosteric activation. We demonstrate that binding of Sgk3 to PI3P via its regulatory phox homology (PX) domain induces large conformational changes in Sgk3 associated with its activation and that the PI3P-binding pocket of the PX domain of Sgk3 is sequestered in its inactive conformation. Finally, we reconstitute Sgk3 activation via Vps34-mediated PI3P synthesis on phosphatidylinositol liposomes in vitro. In addition to identifying the mechanism of Sgk3 activation by PI3P, our findings open up potential therapeutic avenues in allosteric inhibitor development to target Sgk3 in cancer.	[Pokorny, Daniel; Truebestein, Linda; Leonard, Thomas A.] Max Perutz Labs, Dept Struct & Computat Biol, Vienna, Austria; [Pokorny, Daniel; Truebestein, Linda; Leonard, Thomas A.] Med Univ Vienna, Dept Med Biochem, Vienna, Austria; [Fleming, Kaelin D.; Burke, John E.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada; [Burke, John E.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna; University of Victoria; University of British Columbia	Leonard, TA (corresponding author), Max Perutz Labs, Dept Struct & Computat Biol, Vienna, Austria.; Leonard, TA (corresponding author), Med Univ Vienna, Dept Med Biochem, Vienna, Austria.	thomas.leonard@meduniwien.ac.at	Burke, John/H-3922-2019; Leonard, Thomas/A-5143-2013	Burke, John/0000-0001-7904-9859; Leonard, Thomas/0000-0001-6853-666X; Pokorny, Daniel/0000-0002-0343-0466; Fleming, Kaelin/0000-0003-3063-7865	Austrian Science Fund (FWF) [P28135, P30584, P33066, W1261]; Hertha Firnberg Postdoctoral Fellowship from the Austrian Science Fund [FWF T915]; Michael Smith Foundation for Health Research (MSFHR) Scholar award [17686]; Cancer Research Society [CRS-24368]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Hertha Firnberg Postdoctoral Fellowship from the Austrian Science Fund; Michael Smith Foundation for Health Research (MSFHR) Scholar award(Michael Smith Foundation for Health Research); Cancer Research Society	This work was supported by the Austrian Science Fund (FWF) grants P28135, P30584, P33066, and W1261 to T. A. L. L. T. was supported by a Hertha Firnberg Postdoctoral Fellowship from the Austrian Science Fund (FWF T915). J. E. B. was supported by a Michael Smith Foundation for Health Research (MSFHR) Scholar award (17686) and an operating grant from the Cancer Research Society (CRS-24368).	Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799; Backer JM, 2008, BIOCHEM J, V410, P1, DOI 10.1042/BJ20071427; Backer JM, 2016, BIOCHEM J, V473, P2251, DOI 10.1042/BCJ20160170; Bago R, 2016, EMBO J, V35, P1902, DOI 10.15252/embj.201693929; Bago R, 2014, BIOCHEM J, V463, P413, DOI 10.1042/BJ20140889; Bieniossek Christoph, 2008, Curr Protoc Protein Sci, VChapter 5, DOI 10.1002/0471140864.ps0520s51; Chan TO, 2011, P NATL ACAD SCI USA, V108, pE1120, DOI 10.1073/pnas.1109879108; Chandra M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09355-y; Chen W, 2009, J BIOL CHEM, V284, P3453, DOI 10.1074/jbc.M807502200; Dai FY, 2002, BIOCHEM BIOPH RES CO, V293, P1191, DOI 10.1016/S0006-291X(02)00349-2; Ebner M, 2017, MOL CELL, V65, P416, DOI 10.1016/j.molcel.2016.12.028; Elsner DJ, 2019, J BIOL CHEM, V294, P14422, DOI 10.1074/jbc.RA119.008713; Endicott JA, 2012, ANNU REV BIOCHEM, V81, P587, DOI 10.1146/annurev-biochem-052410-090317; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gasser JA, 2014, MOL CELL, V56, P595, DOI 10.1016/j.molcel.2014.09.023; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Goulden BD, 2019, J CELL BIOL, V218, P1066, DOI 10.1083/jcb.201809026; Hastie CJ, 2006, NAT PROTOC, V1, P968, DOI 10.1038/nprot.2006.149; Hauge C, 2007, EMBO J, V26, P2251, DOI 10.1038/sj.emboj.7601682; Hurley JH, 2017, ANNU REV BIOCHEM, V86, P225, DOI 10.1146/annurev-biochem-061516-044820; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Ivetac I, 2005, MOL BIOL CELL, V16, P2218, DOI 10.1091/mbc.e04-09-0799; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Landel I, 2020, ACS MED CHEM LETT, V11, P225, DOI 10.1021/acsmedchemlett.9b00548; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Lapierre JM, 2016, J MED CHEM, V59, P6455, DOI 10.1021/acs.jmedchem.6b00619; Leonard TA, 2011, CURR OPIN STRUC BIOL, V21, P785, DOI 10.1016/j.sbi.2011.07.006; Leonard TA, 2011, CELL, V144, P55, DOI 10.1016/j.cell.2010.12.013; Lin K, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002618; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Liu SL, 2018, MOL CELL, V71, P1092, DOI 10.1016/j.molcel.2018.07.035; Lucic I, 2018, P NATL ACAD SCI USA, V115, pE3940, DOI 10.1073/pnas.1716109115; Lucic I, 2016, J MOL BIOL, V428, P121, DOI 10.1016/j.jmb.2015.11.001; Malik N, 2018, BIOCHEM J, V475, P117, DOI 10.1042/BCJ20170650; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Masson GR, 2019, NAT METHODS, V16, P595, DOI 10.1038/s41592-019-0459-y; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271; Pao AC, 2007, AM J PHYSIOL-RENAL, V292, pF1741, DOI 10.1152/ajprenal.00027.2007; Sawa-Makarska J, 2020, SCIENCE, V369, P1206, DOI 10.1126/science.aaz7714; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tessier M, 2006, J BIOL CHEM, V281, P23978, DOI 10.1074/jbc.M604333200; Theile CS, 2013, NAT PROTOC, V8, P1800, DOI 10.1038/nprot.2013.102; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Wang YZ, 2017, P NATL ACAD SCI USA, V114, pE1500, DOI 10.1073/pnas.1612991114; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Weisner J, 2019, CANCER RES, V79, P2367, DOI 10.1158/0008-5472.CAN-18-2861; Xing Y, 2004, J BIOL CHEM, V279, P30662, DOI 10.1074/jbc.M404107200; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111	55	3	3	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG	2021	297	2							100919	10.1016/j.jbc.2021.100919	http://dx.doi.org/10.1016/j.jbc.2021.100919			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UI8WG	34181950	Green Submitted, gold, Green Published			2023-01-03	WOS:000690879300002
J	Pratoomchart, C; Klunklin, P; Wanwilairat, S; Nobnop, W; Kittidachanan, K; Chitapanarux, I				Pratoomchart, Chalardchay; Klunklin, Pitchayaponne; Wanwilairat, Somsak; Nobnop, Wannapha; Kittidachanan, Kittikun; Chitapanarux, Imjai			The advantages of abdominal compression with shallow breathing during left-sided postmastectomy radiotherapy by Helical TomoTherapy	PLOS ONE			English	Article							RADIATION-THERAPY; EARLY-STAGE; BREAST; HEART; HOLD; GUIDELINE; WOMEN; LUNG	Background Left-sided post-mastectomy radiotherapy (PMRT) certainly precedes some radiation dose to the cardiopulmonary organs causing many side effects. To reduce the cardiopulmonary dose, we created a new option of the breathing adapted technique by using abdominal compression applied with a patient in deep inspiration phase utilizing shallow breathing. This study aimed to compare the use of abdominal compression with shallow breathing (ACSB) with the free breathing (FB) technique in the left-sided PMRT. Materials and methods Twenty left-sided breast cancer patients scheduled for PMRT were enrolled. CT simulation was performed with ACSB and FB technique in each patient. All treatment plans were created on a TomoTherapy planning station. The target volume and dose, cardiopulmonary organ volume and dose were analyzed. A linear correlation between cardiopulmonary organ volumes and doses were also tested. Results Regarding the target volumes and dose coverage, there were no significant differences between ACSB and FB technique. For organs at risk, using ACSB resulted in a significant decrease in mean (9.17 vs 9.81 Gy, p<0.0001) and maximum heart dose (43.79 vs 45.45 Gy, p = 0.0144) along with significant reductions in most of the evaluated volumetric parameters. LAD doses were also significantly reduced by ACSB with mean dose 19.24 vs 21.85 Gy (p = 0.0036) and the dose to 2% of the volume (D2%) 34.46 vs 37.33 Gy (p = 0.0174) for ACSB and FB technique, respectively. On the contrary, the lung dose metrics did not show any differences except the mean V5 of ipsilateral lung. The positive correlations were found between increasing the whole lung volume and mean heart dose (p = 0.05) as well as mean LAD dose (p = 0.041) reduction. Conclusions The ACSB technique significantly reduced the cardiac dose compared with the FB technique in left-sided PMRT treated by Helical TomoTherapy. Our technique is uncomplicated, well-tolerated, and can be applied in limited resource center.	[Pratoomchart, Chalardchay; Klunklin, Pitchayaponne; Wanwilairat, Somsak; Nobnop, Wannapha; Kittidachanan, Kittikun; Chitapanarux, Imjai] Chiang Mai Univ, Fac Med, Div Radiat Oncol, Chiangmai, Thailand; [Klunklin, Pitchayaponne; Nobnop, Wannapha; Chitapanarux, Imjai] Chiang Mai Univ, Fac Med, Northern Thai Res Grp Radiat Oncol NTRG RO, Chiang Mai, Thailand	Chiang Mai University; Chiang Mai University	Klunklin, P (corresponding author), Chiang Mai Univ, Fac Med, Div Radiat Oncol, Chiangmai, Thailand.; Klunklin, P (corresponding author), Chiang Mai Univ, Fac Med, Northern Thai Res Grp Radiat Oncol NTRG RO, Chiang Mai, Thailand.	pitchayaponne.kl@cmu.ac.th	Klunklin, Pitchayaponne/N-7073-2018	Klunklin, Pitchayaponne/0000-0003-4791-6940				Bouilhol G, 2013, PHYS MEDICA, V29, P333, DOI 10.1016/j.ejmp.2012.04.006; Cardoso F, 2019, ANN ONCOL, V30, P1194, DOI 10.1093/annonc/mdz173; Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825; Duma MN, 2019, STRAHLENTHER ONKOL, V195, P861, DOI 10.1007/s00066-019-01495-w; Eldredge-Hindy H, 2015, PRACT RADIAT ONCOL, V5, P4, DOI 10.1016/j.prro.2014.06.004; Gagliardi G, 2010, INT J RADIAT ONCOL, V76, pS77, DOI 10.1016/j.ijrobp.2009.04.093; Giraud P, 2013, ISRN PULMONOL, V2013, DOI 10.1155/2013/519602; Giraud P, 2012, CANCER INVEST, V30, P323, DOI 10.3109/07357907.2012.657818; Goddu SM, 2009, INT J RADIAT ONCOL, V73, P1243, DOI 10.1016/j.ijrobp.2008.11.004; ICRU Report 83, 2010, 83 ICRU INT COMM RAD 83 ICRU INT COMM RAD; Magder S, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.06.19; McGale P, 2014, LANCET, V383, P2127, DOI 10.1016/S0140-6736(14)60488-8; National Comprehensive Cancer Network,, 2021, PLYM M PLYM M; Nissen HD, 2013, RADIOTHER ONCOL, V106, P28, DOI 10.1016/j.radonc.2012.10.016; NRG Oncology, BREAST CANC ATL TEMP BREAST CANC ATL TEMP, pC2019; Offersen BV, 2015, RADIOTHER ONCOL, V114, P3, DOI 10.1016/j.radonc.2014.11.030; Pham TT, 2016, J MED IMAG RADIAT ON, V60, P545, DOI 10.1111/1754-9485.12459; Recht A, 2016, PRACT RADIAT ONCOL, V6, pE219, DOI 10.1016/j.prro.2016.08.009; Rosner B., 1995, FUNDAMENTALS BIOSTAT, P221; Schonecker S, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0716-5; Schubert LK, 2011, RADIOTHER ONCOL, V100, P241, DOI 10.1016/j.radonc.2011.01.004; Senkus-Konefka E, 2007, CANCER TREAT REV, V33, P578, DOI 10.1016/j.ctrv.2007.07.011; Snider JW, 2015, ABDOMINAL COMPRESSIO, pS116, DOI [10.1016/j.ijrobp.2015.07.278, DOI 10.1016/J.IJROBP.2015.07.278]; Swanson T, 2013, AM J CLIN ONCOL-CANC, V36, P24, DOI 10.1097/COC.0b013e31823fe481; Taylor CW, 2015, INT J RADIAT ONCOL, V93, P845, DOI 10.1016/j.ijrobp.2015.07.2292; Testolin A, 2019, BRIT J RADIOL, V92, DOI 10.1259/bjr.20190150; Walston S, 2017, TECHNOL CANCER RES T, V16, P22, DOI 10.1177/1533034615624311	29	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2021	16	7							e0254934	10.1371/journal.pone.0254934	http://dx.doi.org/10.1371/journal.pone.0254934			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2NF	34270624	Green Published, gold, Green Submitted			2023-01-03	WOS:000678121400066
J	Mohseni, M; Kucharski, C; Bahadur, KCR; Nasrullah, M; Jiang, XY; Uludag, H; Brandwein, J				Mohseni, Mahsa; Kucharski, Cezary; Bahadur, Remant K. C.; Nasrullah, Mohammad; Jiang, Xiaoyan; Uludag, Hasan; Brandwein, Joseph			Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL)	PLOS ONE			English	Article							PATHWAY; BIOLOGY; TARGET; CANCER; RNAI	Overexpression and persistent activation of STAT5 play an important role in the development and progression of acute lymphoblastic leukemia (ALL), the most common pediatric cancer. Small interfering RNA (siRNA)-mediated downregulation of STAT5 represents a promising therapeutic approach for ALL to overcome the limitations of current treatment modalities such as high relapse rates and poor prognosis. However, to effectively transport siRNA molecules to target cells, development of potent carriers is of utmost importance to surpass hurdles of delivery. In this study, we investigated the use of lipopolymers as non-viral delivery systems derived from low molecular weight polyethylenimines (PEI) substituted with lauric acid (Lau), linoleic acid (LA) and stearic acid (StA) to deliver siRNA molecules to ALL cell lines and primary samples. Among the lipid-substituted polymers explored, Lau- and LA-substituted PEI displayed excellent siRNA delivery to SUP-B15 and RS4;11 cells. STAT5A gene expression was downregulated (36-92%) in SUP-B15 and (32%) in RS4;11 cells using the polymeric delivery systems, which consequently reduced cell growth and inhibited the formation of colonies in ALL cells. With regard to ALL primary cells, siRNA-mediated STAT5A gene silencing was observed in four of eight patient cells using our leading polymeric delivery system, 1.2PEI-Lau8, accompanied by the significant reduction in colony formation in three of eight patients. In both BCR-ABL positive and negative groups, three of five patients demonstrated marked cell growth inhibition in both MTT and trypan blue exclusion assays using 1.2PEI-Lau8/siRNA complexes in comparison with their control siRNA groups. Three patient samples did not show any positive results with our delivery systems. Differential therapeutic responses to siRNA therapy observed in different patients could result from variable genetic profiles and patient-to-patient variability in delivery. This study supports the potential of siRNA therapy and the designed lipopolymers as a delivery system in ALL therapy.	[Mohseni, Mahsa; Brandwein, Joseph] Univ Alberta, Fac Med & Dent, Dept Med, Edmonton, AB, Canada; [Kucharski, Cezary; Bahadur, Remant K. C.; Nasrullah, Mohammad; Uludag, Hasan] Univ Alberta, Fac Engn, Dept Chem & Mat Engn, Edmonton, AB, Canada; [Jiang, Xiaoyan] Univ British Columbia, Fac Med, Dept Med Genet, Vancouver, BC, Canada; [Uludag, Hasan] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB, Canada; [Uludag, Hasan] Univ Alberta, Fac Med & Dent, Dept Biomed Engn, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of British Columbia; University of Alberta; University of Alberta	Brandwein, J (corresponding author), Univ Alberta, Fac Med & Dent, Dept Med, Edmonton, AB, Canada.; Uludag, H (corresponding author), Univ Alberta, Fac Engn, Dept Chem & Mat Engn, Edmonton, AB, Canada.; Uludag, H (corresponding author), Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB, Canada.; Uludag, H (corresponding author), Univ Alberta, Fac Med & Dent, Dept Biomed Engn, Edmonton, AB, Canada.	huludag@ualberta.ca; jbrandwe@ualberta.ca		Uludag, Hasan/0000-0002-1118-4170; Nasrullah, Mohammad/0000-0003-1346-355X	Women and Children's Health Research Institute; Canadian Institutes of Health Research [MOP 142202]; Hair Massacure Foundation; Alex's Lemonade Stand Foundation [RES0048095]	Women and Children's Health Research Institute; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Hair Massacure Foundation; Alex's Lemonade Stand Foundation	This project was financially supported by operating grants from Women and Children's Health Research Institute (HU), Canadian Institutes of Health Research (HU; MOP 142202), Hair Massacure Foundation (JB), and Alex's Lemonade Stand Foundation (HU, XJ, JB; RES0048095). Equipment support by provided by Edmonton Civic Employees Charitable Assistance Fund (HU).	Abbasi M, 2013, MED RES REV, V33, P33, DOI 10.1002/med.20244; Aliabadi HM, 2015, PHARM RES-DORDR, V32, P3813, DOI 10.1007/s11095-015-1741-z; Aliabadi HM, 2011, MACROMOL BIOSCI, V11, P662, DOI 10.1002/mabi.201000402; Anchang B, 2018, P NATL ACAD SCI USA, V115, pE4294, DOI 10.1073/pnas.1711365115; Aslanturk OS., 2018, GENOTOXICITY PREDICT; Bahadur K.C.R., 2016, POLYM NANOMATERIALS, P29, DOI 10.1016/B978-0-08-100520-0.00002-3; Brenner DR, 2020, CAN MED ASSOC J, V192, pE199, DOI 10.1503/cmaj.191292; Bueno C, 2013, BLOOD, V121, P3867, DOI 10.1182/blood-2012-11-470146; Dai XZ, 2007, J IMMUNOL, V179, P1068, DOI 10.4049/jimmunol.179.2.1068; Edwards DK., RNAI SCREENING TYROS; Ferrajoli A, 2006, CURR CANCER DRUG TAR, V6, P671, DOI 10.2174/156800906779010227; Forsell J., EVALUATION FACTORS A; Goetz CA, 2004, J IMMUNOL, V172, P4770, DOI 10.4049/jimmunol.172.8.4770; Golan T, 2015, ONCOTARGET, V6, P24560, DOI 10.18632/oncotarget.4183; Gul-Uludag H, 2014, LEUKEMIA RES, V38, P1299, DOI 10.1016/j.leukres.2014.08.008; He W, 2014, MOL THER, V22, P359, DOI 10.1038/mt.2013.210; Heltemes-Harris LM, 2011, J EXP MED, V208, P1135, DOI 10.1084/jem.20101947; Hoelbl A, 2010, EMBO MOL MED, V2, P98, DOI 10.1002/emmm.201000062; Hong SW, 2014, NUCLEIC ACID THER, V24, P192, DOI 10.1089/nat.2013.0466; Hsu CYM, 2012, NAT PROTOC, V7, P935, DOI 10.1038/nprot.2012.038; Jain S, 2020, ARCH PATHOL LAB MED, V144, P150, DOI 10.5858/arpa.2019-0194-RA; Kamga Paul Takam, 2018, Oncotarget, V9, P18341, DOI 10.18632/oncotarget.24836; Kolosenko I, 2017, J CONTROL RELEASE, V261, P199, DOI 10.1016/j.jconrel.2017.07.002; Landry B, 2016, J CONTROL RELEASE, V224, P8, DOI 10.1016/j.jconrel.2015.12.052; Landry B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044197; Li H., 2016, ARXIV160808710, Vabs/1608.08710; Malin S, 2010, CURR OPIN IMMUNOL, V22, P168, DOI 10.1016/j.coi.2010.02.004; Man LM, 2017, CURR HEMATOL MALIG R, V12, P197, DOI 10.1007/s11899-017-0380-3; Maude SL, 2015, BLOOD, V125, P1759, DOI 10.1182/blood-2014-06-580480; Minieri V., 2018, CANCER RES; Mohseni M, 2018, AM J BLOOD RES, V8, P29; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; Parmar MB, 2016, J BIOMED MATER RES A, V104, P3031, DOI 10.1002/jbm.a.35846; Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966; Plianwong S, 2020, PHARM RES-DORDR, V37, DOI 10.1007/s11095-020-2770-9; Remant Bahadur KC., 2011, ACTA BIOMATER; Remant KC, 2019, STEM CELLS DEV, V28, P734, DOI 10.1089/scd.2018.0196; Roberts KG, 2018, BEST PRACT RES CL HA, V31, P351, DOI 10.1016/j.beha.2018.09.003; Roberts KG, 2017, BEST PRACT RES CL HA, V30, P212, DOI 10.1016/j.beha.2017.07.003; Roberts KG, 2012, CANCER CELL, V22, P153, DOI 10.1016/j.ccr.2012.06.005; Sahin B, 2014, BIOMATERIALS, V35, P9382, DOI 10.1016/j.biomaterials.2014.07.029; Santiago R, 2017, EXPERT OPIN PHARMACO, V18, P1081, DOI 10.1080/14656566.2017.1340938; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sundaram DNM, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201600430; Sundaram P, 2013, EUR J PHARM SCI, V48, P259, DOI 10.1016/j.ejps.2012.10.014; Tasian SK, 2012, BLOOD, V120, P833, DOI 10.1182/blood-2011-12-389932; Uckun FM., 2018, CANC DRUG RESIST, DOI [10.20517/cdr.2017.03, DOI 10.20517/CDR.2017.03]; Uludag H, 2016, DRUG DISCOV TODAY, V21, P1412, DOI 10.1016/j.drudis.2016.04.018; Valencia-Serna J., 2014, POTENTIAL SIRNA THER; Valencia-Serna J, 2019, J CONTROL RELEASE, V310, P141, DOI 10.1016/j.jconrel.2019.08.018; Valencia-Serna J, 2013, J CONTROL RELEASE, V172, P495, DOI 10.1016/j.jconrel.2013.05.014; Vermeulen J, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr065; Warsch W, 2011, BLOOD, V117, P3409, DOI 10.1182/blood-2009-10-248211; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Wingelhofer B, 2018, LEUKEMIA, V32, P1135, DOI 10.1038/s41375-017-0005-9; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Yadav BD., DENOTES EQUAL SENIOR, V7; Yamaguchi H, 2009, EXP HEMATOL, V37, P701, DOI 10.1016/j.exphem.2009.02.007; Yao Q, 2005, LEUKEMIA, V19, P1605, DOI 10.1038/sj.leu.2403881; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	60	1	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2021	16	6							e0251719	10.1371/journal.pone.0251719	http://dx.doi.org/10.1371/journal.pone.0251719			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BH	34157051	Green Published, gold			2023-01-03	WOS:000671691200022
J	Purwati; Miatmoko, A; Nasronudin; Hendrianto, E; Karsari, D; Dinaryanti, A; Ertanti, N; Ihsan, IS; Purnama, DS; Asmarawati, TP; Marfiani, E; Yulistiani; Rosyid, AN; Wulaningrum, PA; Setiawan, HW; Siswanto, I; Puspaningsih, NNT				Purwati; Miatmoko, Andang; Nasronudin; Hendrianto, Eryk; Karsari, Deya; Dinaryanti, Aristika; Ertanti, Nora; Ihsan, Igo Syaiful; Purnama, Disca Sandyakala; Asmarawati, Tri Pudy; Marfiani, Erika; Yulistiani; Rosyid, Alfian Nur; Wulaningrum, Prastuti Asta; Setiawan, Herley Windo; Siswanto, Imam; Puspaningsih, Ni Nyoman Tri			An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia	PLOS ONE			English	Article							PHARMACOKINETICS; LOPINAVIR/RITONAVIR; DOXYCYCLINE; PREVENTION; DOCKING; HISTORY	A potent therapy for the infectious coronavirus disease COVID-19 is urgently required with, at the time of writing, research in this area still ongoing. This study aims to evaluate the in vitro anti-viral activities of combinations of certain commercially available drugs that have recently formed part of COVID-19 therapy. Dual combinatory drugs, namely; Lopinavir-Ritonavir (LOPIRITO)-Clarithromycin (CLA), LOPIRITO-Azithromycin (AZI), LOPIRITO-Doxycycline (DOXY), Hydroxychloroquine (HCQ)-AZI, HCQ-DOXY, Favipiravir (FAVI)-AZI, HCQ-FAVI, and HCQ-LOPIRITO, were prepared. These drugs were mixed at specific ratios and evaluated for their safe use based on the cytotoxicity concentration (CC50) values of human umbilical cord mesenchymal stem cells. The anti-viral efficacy of these combinations in relation to Vero cells infected with SARS-CoV-2 virus isolated from a patient in Universitas Airlangga hospital, Surabaya, Indonesia and evaluated for IC50 24, 48, and 72 hours after viral inoculation was subsequently determined. Observation of the viral load in qRT-PCR was undertaken, the results of which indicated the absence of high levels of cytotoxicity in any samples and that dual combinatory drugs produced lower cytotoxicity than single drugs. In addition, these combinations demonstrated considerable effectiveness in reducing the copy number of the virus at 48 and 72 hours, while even at 24 hours, post-drug incubation resulted in low IC50 values. Most combination drugs reduced pro-inflammatory markers, i.e. IL-6 and TNF-alpha, while increasing the anti-inflammatory response of IL-10. According to these results, the descending order of effective dual combinatory drugs is one of LOPIRITO-AZI>LOPIRITO-DOXY>HCQ-AZI>HCQ-FAVI>LOPIRITO-CLA>HCQ-DOX. It can be suggested that dual combinatory drugs, e.g. LOPIRITO-AZI, can potentially be used in the treatment of COVID-19 infectious diseases.	[Purwati; Miatmoko, Andang; Hendrianto, Eryk; Karsari, Deya; Dinaryanti, Aristika; Ertanti, Nora; Ihsan, Igo Syaiful; Purnama, Disca Sandyakala] Univ Airlangga, Stem Cell Res & Dev Ctr, Inst Trop Dis, Surabaya, Indonesia; [Purwati] Univ Airlangga, Fac Vocat, Surabaya, Indonesia; [Purwati] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Miatmoko, Andang; Yulistiani] Univ Airlangga, Fac Pharm, Surabaya, Indonesia; [Nasronudin; Asmarawati, Tri Pudy; Marfiani, Erika; Yulistiani; Rosyid, Alfian Nur; Wulaningrum, Prastuti Asta; Setiawan, Herley Windo] Univ Airlangga, Rumah Sakit Umum & Rumah Sakit Khusus Infeksi, Surabaya, Indonesia; [Siswanto, Imam] Univ Airlangga, Bioinformat Lab, UCoE Res Ctr Biomol Engn, Surabaya, Indonesia; [Puspaningsih, Ni Nyoman Tri] Univ Airlangga, Fac Sci & Technol, Dept Chem, Surabaya, Indonesia	Airlangga University; Airlangga University; Asia University Taiwan; Airlangga University; Airlangga University; Airlangga University; Airlangga University	Purwati (corresponding author), Univ Airlangga, Stem Cell Res & Dev Ctr, Inst Trop Dis, Surabaya, Indonesia.; Purwati (corresponding author), Univ Airlangga, Fac Vocat, Surabaya, Indonesia.; Purwati (corresponding author), Asia Univ, Dept Biotechnol, Taichung, Taiwan.	purwati@fk.unair.ac.id	Yulistiani, Yulistiani/GRN-9628-2022; Setiawan, Herley Windo/GQP-5179-2022; Miatmoko, Andang/AGN-5633-2022; Asmarawati, Tri Pudy/ABE-4015-2020; Purwati, Purwati/HCH-5018-2022	Miatmoko, Andang/0000-0003-1658-0778; Asmarawati, Tri Pudy/0000-0001-9869-5098; , Purwati/0000-0002-6144-2481; Siswanto, Imam/0000-0001-9811-0977; Ihsan, Igo Syaiful/0000-0003-0111-0781; nasronudin, nasronudin/0000-0001-7882-9992; effendi, wiwin is/0000-0003-3716-2452	State Intelligence Agency (BIN) of Republic of Indonesia	State Intelligence Agency (BIN) of Republic of Indonesia	This study was funded by State Intelligence Agency (BIN) of Republic of Indonesia. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AbbVie Deutschland GmbH Co, 2020, W764 EUR MED AG; Agrawal Umang, 2020, Med J Armed Forces India, V76, P370, DOI 10.1016/j.mjafi.2020.08.004; Allen WJ, 2015, J COMPUT CHEM, V36, P1132, DOI 10.1002/jcc.23905; Arabi YM, 2019, INT J INFECT DIS, V81, P184, DOI 10.1016/j.ijid.2019.01.041; Bacharier LB, 2015, JAMA-J AM MED ASSOC, V314, P2034, DOI 10.1001/jama.2015.13896; Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392; Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658; Covas DT, 2003, BRAZ J MED BIOL RES, V36, P1179, DOI 10.1590/S0100-879X2003000900006; Damle B, 2020, CLIN PHARMACOL THER, V108, P201, DOI 10.1002/cpt.1857; Dayer M. R., 2020, ARXIV200304524; Dayer MR., 2017, ARCH CLIN INFECT DIS, V12, P13823; Devaux Christian A, 2020, Int J Antimicrob Agents, V55, P105938, DOI 10.1016/j.ijantimicag.2020.105938; Dinos GP, 2017, BRIT J PHARMACOL, V174, P2967, DOI 10.1111/bph.13936; Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012; Du X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020144; Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844; FRASCHINI F, 1993, CLIN PHARMACOKINET, V25, P189, DOI 10.2165/00003088-199325030-00003; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08; Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001; Lu LL, 2006, HAEMATOLOGICA, V91, P1017; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Manusubroto W, 2020, WORLD NEUROSURG, V140, pE360, DOI 10.1016/j.wneu.2020.05.124; Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146; Mennan C, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/916136; Meyerowitz EA, 2020, FASEB J, V34, P6027, DOI 10.1096/fj.202000919; Nelson ML, 2011, ANN NY ACAD SCI, V1241, P17, DOI 10.1111/j.1749-6632.2011.06354.x; Newton PN, 2005, ANTIMICROB AGENTS CH, V49, P1622, DOI 10.1128/AAC.49.4.1622-1625.2005; Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Rothan HA, 2014, ARCH VIROL, V159, P711, DOI 10.1007/s00705-013-1880-7; Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945; Sargiacomo C, 2020, AGING-US, V12, P6511, DOI 10.18632/aging.103001; Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5; SINGLAS E, 1995, PATHOL BIOL, V43, P505; Taisho Toyama Pharmaceutical, 2017, L AV FAV TABL PRESCR; Wang Z, 2016, PHYS CHEM CHEM PHYS, V18, P12964, DOI 10.1039/c6cp01555g; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	41	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2021	16	6							e0252302	10.1371/journal.pone.0252302	http://dx.doi.org/10.1371/journal.pone.0252302			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BC	34143818	Green Accepted, gold, Green Published			2023-01-03	WOS:000671690700015
J	Eckl, DB; Eben, SS; Schottenhaml, L; Eichner, A; Vasold, R; Spath, A; Baumler, W; Huber, H				Eckl, Daniel Bernhard; Eben, Stefanie Susanne; Schottenhaml, Laura; Eichner, Anja; Vasold, Rudolf; Spaeth, Andreas; Baeumler, Wolfgang; Huber, Harald			Interplay of phosphate and carbonate ions with flavin photosensitizers in photodynamic inactivation of bacteria	PLOS ONE			English	Article							SINGLET OXYGEN; METHYLENE-BLUE; WASTE-WATER; FATTY-ACIDS; RIBOFLAVIN; PATHOGENS; THERAPY; PHOTOINACTIVATION; OXIDATION; CURCUMIN	Photodynamic inactivation (PDI) of pathogenic bacteria is a promising technology in different applications. Thereby, a photosensitizer (PS) absorbs visible light and transfers the energy to oxygen yielding reactive oxygen species (ROS). The produced ROS are then capable of killing microorganisms via oxidative damage of cellular constituents. Among other PS, some flavins are capable of producing ROS and cationic flavins are already successfully applied in PDI. When PDI is used for example on tap water, PS like flavins will encounter various ions and other small organic molecules which might hamper the efficacy of PDI. Thus, the impact of carbonate and phosphate ions on PDI using two different cationic flavins (FLASH-02a, FLASH-06a) was investigated using Staphylococcus aureus and Pseudomonas aeruginosa as model organisms. Both were inactivated in vitro at a low light exposure of 0.72 J cm(-)(2). Upon irradiation, FLASH-02a reacts to single substances in the presence of carbonate or phosphate, whereas the photochemical reaction for FLASH-06a was more unspecific. DPBF-assays indicated that carbonate and phosphate ions decreased the generation of singlet oxygen of both flavins. Both microorganisms could be easily inactivated by at least one PS with up to 6 log(10) steps of cell counts in low ion concentrations. Using the constant radiation exposure of 0.72 J cm(-2), the inactivation efficacy decreased somewhat at medium ion concentrations but reached almost zero for high ion concentrations. Depending on the application of PDI, the presence of carbonate and phosphate ions is unavoidable. Only upon light irradiation such ions may attack the PS molecule and reduce the efficacy of PDI. Our results indicate concentrations for carbonate and phosphate, in which PDI can still lead to efficient reduction of bacterial cells when using flavin based PS.	[Eckl, Daniel Bernhard; Eben, Stefanie Susanne; Schottenhaml, Laura; Huber, Harald] Univ Regensburg, Dept Microbiol, Regensburg, Germany; [Eichner, Anja; Baeumler, Wolfgang] Univ Hosp Regensburg, Clin & Polyclin Dermatol, Regensburg, Germany; [Vasold, Rudolf] Univ Regensburg, Dept Organ Chem, Regensburg, Germany; [Spaeth, Andreas] TriOptoTec GmbH, Regensburg, Germany	University of Regensburg; University of Regensburg; University of Regensburg	Eckl, DB (corresponding author), Univ Regensburg, Dept Microbiol, Regensburg, Germany.	Daniel.eckl@ur.de		Schottenhaml, Laura/0000-0002-7983-1186	German Research Foundation (Deutsche Forschungsgemeinschaft DFG) [415812443]	German Research Foundation (Deutsche Forschungsgemeinschaft DFG)(German Research Foundation (DFG))	HH and WB received a grand (415812443) from the German Research Foundation (Deutsche Forschungsgemeinschaft DFG; www.dfg.de).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. TriOptoTec GmbH provided support in the form of salaries for the author Andreas Spath, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the "author contributions" section.	Ahmad I, 2004, J PHOTOCH PHOTOBIO B, V75, P13, DOI 10.1016/j.jphotobiol.2004.04.001; Ahmad I., 2006, FLAVINS PHOTOCHEMIST, P13, DOI DOI 10.1039/9781847555397-00013; Almeida J, 2014, PHOTOCH PHOTOBIO SCI, V13, P626, DOI 10.1039/c3pp50195g; Baumler W, 2012, PHOTOCH PHOTOBIO SCI, V11, P107, DOI 10.1039/c1pp05142c; Baier J, 2006, BIOPHYS J, V91, P1452, DOI 10.1529/biophysj.106.082388; Bashford CL., 1987, SPECTROPHOTOMETRY SP; Bechert T, 2000, NAT MED, V6, P1053, DOI 10.1038/79568; Berlett BS, 2000, ANAL BIOCHEM, V287, P329, DOI 10.1006/abio.2000.4876; Bhavya ML, 2019, INT J FOOD MICROBIOL, V290, P296, DOI 10.1016/j.ijfoodmicro.2018.10.021; Blyth AW., 1879, J CHEM SOC, V530, P530, DOI [10.1039/CT8793500530, DOI 10.1039/CT8793500530]; Bundesministerium fuar Gesundheit, 1998, VER ZUL ZUS LEB TECH; Carvalho CMB, 2007, J PHOTOCH PHOTOBIO B, V88, P112, DOI 10.1016/j.jphotobiol.2007.04.015; Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4; CHACON JN, 1988, PHOTOCHEM PHOTOBIOL, V47, P647, DOI 10.1111/j.1751-1097.1988.tb02760.x; Cieplik F, 2013, FREE RADICAL BIO MED, V65, P477, DOI 10.1016/j.freeradbiomed.2013.07.031; Eckl DB, 2020, PHOTOCHEM PHOTOBIOL, V96, P883, DOI 10.1111/php.13229; Eckl DB, 2018, PHOTOCHEM PHOTOBIOL, V94, P165, DOI 10.1111/php.12846; Eichler M, 2005, LASER SURG MED, V37, P314, DOI 10.1002/lsm.20239; Eichner, 2018, BRIT J DERMATOL, V179, pE242, DOI [10.1111/bjd.17287, DOI 10.1111/BJD.17287]; Eichner A, 2020, J HOSP INFECT, V104, P85, DOI 10.1016/j.jhin.2019.07.016; Eichner A, 2015, PHOTOCH PHOTOBIO SCI, V14, P387, DOI 10.1039/c4pp00285g; ENGEBRECHT J, 1983, CELL, V32, P773, DOI 10.1016/0092-8674(83)90063-6; Engelhardt V, 2010, PHOTOCH PHOTOBIO SCI, V9, P365, DOI 10.1039/b9pp00144a; Fabritius M, 2020, MATERIALS, V13, DOI 10.3390/ma13061415; GALLOT S, 1993, FRESEN J ANAL CHEM, V346, P976, DOI 10.1007/BF00322762; GALSTON AW, 1949, P NATL ACAD SCI USA, V35, P10, DOI 10.1073/pnas.35.1.10; Galstyan A, 2019, J PHOTOCH PHOTOBIO B, V197, DOI 10.1016/j.jphotobiol.2019.111554; Glueck M, 2019, PHOTOCH PHOTOBIO SCI, V18, P1700, DOI 10.1039/c9pp00128j; Glueck M, 2017, PHOTOCH PHOTOBIO SCI, V16, P1784, DOI 10.1039/c7pp00165g; Gsponer NS, 2015, PHOTODIAGN PHOTODYN, V12, P67, DOI 10.1016/j.pdpdt.2014.12.004; Hamblin MR, 2002, J ANTIMICROB CHEMOTH, V49, P941, DOI 10.1093/jac/dkf053; Huang LY, 2017, ACS INFECT DIS, V3, P320, DOI 10.1021/acsinfecdis.7b00004; Huang LY, 2012, FREE RADICAL BIO MED, V53, P2062, DOI 10.1016/j.freeradbiomed.2012.09.006; Jemli M, 2002, J ENVIRON MONITOR, V4, P511, DOI 10.1039/b204637g; Jori G, 2011, J ENVIRON PATHOL TOX, V30, P261, DOI 10.1615/JEnvironPatholToxicolOncol.v30.i3.90; Kainz QM, 2012, CHEMISTRYOPEN, V1, P125, DOI 10.1002/open.201200008; Kashiwabuchi RT, 2012, ARQ BRAS OFTALMOL, V75, P423, DOI 10.1590/S0004-27492012000600011; Ke MR, 2020, EMERG MICROBES INFEC, P1, DOI [10.1080/22221751.2019.1699450, DOI 10.1080/22221751.2019.1699450]; Kottke T, 2003, BIOPHYS J, V84, P1192, DOI 10.1016/S0006-3495(03)74933-9; Kuznetsova NA, 2007, J HAZARD MATER, V146, P487, DOI 10.1016/j.jhazmat.2007.04.064; Lambrechts SAG, 2005, ANTIMICROB AGENTS CH, V49, P2026, DOI 10.1128/AAC.49.5.2026-2034.2005; Maisch T, 2007, P NATL ACAD SCI USA, V104, P7223, DOI 10.1073/pnas.0611328104; Maisch T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111792; Mansoorabadi SO, 2007, J ORG CHEM, V72, P6329, DOI 10.1021/jo0703092; Massey V, 2000, BIOCHEM SOC T, V28, P283, DOI 10.1042/0300-5127:0280283; Morrison PWJ, 2013, MOL PHARMACEUT, V10, P756, DOI 10.1021/mp3005963; Mueller JH, 1941, P SOC EXP BIOL MED, V48, P330, DOI 10.3181/00379727-48-13311; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Patterson MJ, 2000, EXP PHYSIOL, V85, P869, DOI 10.1017/S0958067000020583; Penzkofer A, 2012, INT J MOL SCI, V13, P9157, DOI 10.3390/ijms13079157; POSTHUMA J, 1960, BIOCHIM BIOPHYS ACTA, V41, P538, DOI 10.1016/0006-3002(60)90058-5; Regensburger J, 2012, EXP DERMATOL, V21, P135, DOI 10.1111/j.1600-0625.2011.01414.x; Remucal CK, 2011, ENVIRON SCI TECHNOL, V45, P5230, DOI 10.1021/es200411a; Roberts, 2013, ENCY BIOPHYSICS, P771; SATO K, 1989, J AM ACAD DERMATOL, V20, P537, DOI 10.1016/S0190-9622(89)70063-3; Schoenen J, 1998, NEUROLOGY, V50, P466, DOI 10.1212/WNL.50.2.466; Song SH, 2007, J PHOTOCH PHOTOBIO B, V87, P37, DOI 10.1016/j.jphotobiol.2006.12.007; Spath A, 2014, J MED CHEM, V57, P5157, DOI 10.1021/jm4019492; Sputh A., 2012, Patent No. [2012/175729 A1, 2012175729]; Sun Y, 2020, INT WOUND J, V17, P285, DOI 10.1111/iwj.13269; TAGLIAFERRI E, 1992, Mitteilungen aus dem Gebiete der Lebensmitteluntersuchung und Hygiene, V83, P435; Tavares A, 2010, MAR DRUGS, V8, P91, DOI 10.3390/md8010091; Thakuri P S, 2011, Nepal Med Coll J, V13, P281; Thomas O, 2007, TECH INSTRUMENT, V27, P21, DOI 10.1016/S0167-9244(07)80004-7; Tim M, 2015, J PHOTOCH PHOTOBIO B, V150, P2, DOI 10.1016/j.jphotobiol.2015.05.010; Vaid FHM, 2019, J PHOTOCH PHOTOBIO A, V371, P59, DOI 10.1016/j.jphotochem.2018.10.048; Yang MY, 2018, J PHOTOCH PHOTOBIO B, V189, P21, DOI 10.1016/j.jphotobiol.2018.09.021; Yuan LT, 2020, J PHOTOCH PHOTOBIO B, V203, DOI 10.1016/j.jphotobiol.2019.111730	68	2	2	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2021	16	6							e0253212	10.1371/journal.pone.0253212	http://dx.doi.org/10.1371/journal.pone.0253212			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6SD	34115813	Green Published, gold			2023-01-03	WOS:000664643000059
J	Cohen, SP; Vase, L; Hooten, WM				Cohen, Steven P.; Vase, Lene; Hooten, William M.			Chronic pain: an update on burden, best practices, and new advances	LANCET			English	Review							LOW-BACK-PAIN; THERMAL RADIOFREQUENCY NEUROTOMY; CHRONIC POSTSURGICAL PAIN; QUALITY-OF-LIFE; EPIDURAL INJECTIONS; NEUROPATHIC PAIN; NECK PAIN; AMERICAN-COLLEGE; DISC HERNIATION; OPIOID THERAPY	Chronic pain exerts an enormous personal and economic burden, affecting more than 30% of people worldwide according to some studies. Unlike acute pain, which carries survival value, chronic pain might be best considered to be a disease, with treatment (eg, to be active despite the pain) and psychological (eg, pain acceptance and optimism as goals) implications. Pain can be categorised as nociceptive (from tissue injury), neuropathic (from nerve injury), or nociplastic (from a sensitised nervous system), all of which affect work-up and treatment decisions at every level; however, in practice there is considerable overlap in the different types of pain mechanisms within and between patients, so many experts consider pain classification as a continuum. The biopsychosocial model of pain presents physical symptoms as the denouement of a dynamic interaction between biological, psychological, and social factors. Although it is widely known that pain can cause psychological distress and sleep problems, many medical practitioners do not realise that these associations are bidirectional. While predisposing factors and consequences of chronic pain are well known, the flipside is that factors promoting resilience, such as emotional support systems and good health, can promote healing and reduce pain chronification. Quality of life indicators and neuroplastic changes might also be reversible with adequate pain management. Clinical trials and guidelines typically recommend a personalised multimodal, interdisciplinary treatment approach, which might include pharmacotherapy, psychotherapy, integrative treatments, and invasive procedures.	[Cohen, Steven P.] Johns Hopkins Sch Med, Baltimore, MD 21205 USA; [Cohen, Steven P.] Uniformed Serv Univ Hlth Sci, Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA; [Vase, Lene] Aarhus Univ Hosp, Dept Psychol & Behav Sci, Neurosci Div, Aarhus, Denmark; [Hooten, William M.] Mayo Sch Med, Rochester, MN USA	Johns Hopkins University; Johns Hopkins Medicine; Uniformed Services University of the Health Sciences - USA; Walter Reed National Military Medical Center; Aarhus University; Mayo Clinic	Cohen, SP (corresponding author), Johns Hopkins Sch Med, Baltimore, MD 21205 USA.	scohen40@jhmi.edu		Vase, Lene/0000-0002-0379-2256				Ahmed SU, 2015, ANESTHESIOLOGY, V123, P191, DOI 10.1097/ALN.0000000000000693; American Cancer Society, 2019, CANC FACTS FIG; Baldini Angee, 2012, Prim Care Companion CNS Disord, V14, DOI 10.4088/PCC.11m01326; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Bicket MC, 2013, ANESTHESIOLOGY, V119, P907, DOI 10.1097/ALN.0b013e31829c2ddd; Brindle M, 2020, BJS OPEN, V4, P157, DOI 10.1002/bjs5.50238; British Orthopaedic Association and Royal College of Surgeons, 2017, COMM GUID PAINF OST; Brummett CM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.0504; Brutcher RE, 2019, ANN INTERN MED, V170, P309, DOI 10.7326/M18-2736; Buford TW, 2013, SPORTS MED, V43, P157, DOI 10.1007/s40279-013-0018-0; Busse JW, 2018, JAMA-J AM MED ASSOC, V320, P2448, DOI 10.1001/jama.2018.18472; Bydon M, 2014, J SPINAL DISORD TECH, V27, P297, DOI 10.1097/BSD.0000000000000072; Cauda F, 2014, NEUROIMAGE-CLIN, V4, P676, DOI 10.1016/j.nicl.2014.04.007; Chapman C Richard, 2017, J Pain, V18, DOI 10.1016/j.jpain.2016.11.004; Chen BL, 2018, CLIN REHABIL, V32, P146, DOI 10.1177/0269215517719952; Chou Roger, 2014, Evid Rep Technol Assess (Full Rep), P1, DOI 10.23970/AHRQEPCERTA218; Chou R, 2017, ANN INTERN MED, V166, P480, DOI 10.7326/M16-2458; Chou R, 2011, ANN INTERN MED, V154, P181, DOI 10.7326/0003-4819-154-3-201102010-00008; Chou R, 2009, SPINE, V34, P1066, DOI 10.1097/BRS.0b013e3181a1390d; Clauw DJ, 2019, POSTGRAD MED, V131, P185, DOI 10.1080/00325481.2019.1574403; Cohen SP, 2020, REGION ANESTH PAIN M, V45, P424, DOI 10.1136/rapm-2019-101243; Cohen SP, 2019, MAYO CLIN PROC, V94, P2385, DOI 10.1016/j.mayocp.2019.10.006; Cohen SP, 2019, PAIN REP, V4, DOI 10.1097/PR9.0000000000000687; Cohen SP, 2014, ANESTHESIOLOGY, V121, P1045, DOI 10.1097/ALN.0000000000000409; Cohen SP, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f7656; Cohen SP, 2013, REGION ANESTH PAIN M, V38, P175, DOI 10.1097/AAP.0b013e31828ea086; Coulter ID, 2019, PAIN PHYSICIAN, V22, pE55; Coulter ID, 2018, SPINE J, V18, P866, DOI 10.1016/j.spinee.2018.01.013; Crofford LJ, 2015, BEST PRACT RES CL RH, V29, P147, DOI 10.1016/j.berh.2015.04.027; Dahlhamer J, 2018, MMWR-MORBID MORTAL W, V67, P1001, DOI 10.15585/mmwr.mm6736a2; Vieira EBD, 2012, CAD SAUDE PUBLICA, V28, P1459, DOI 10.1590/S0102-311X2012000800005; Deer TR, 2017, NEUROMODULATION, V20, P96, DOI 10.1111/ner.12538; Deloitte Access Economics, 2019, COST PAIN AUSTR; Department of Health. Government of Western Australia, 2016, PAINHEALTH NNT NNH P; Derry S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007393.pub4; Derry S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010958.pub2; Descalzi G, 2015, TRENDS NEUROSCI, V38, P237, DOI 10.1016/j.tins.2015.02.001; DiBonaventura MD, 2017, J PAIN RES, V10, P2525, DOI 10.2147/JPR.S127014; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Duarte RV, 2020, PAIN, V161, P24, DOI 10.1097/j.pain.0000000000001689; Edwards RR, 2016, J PAIN, V17, pT70, DOI 10.1016/j.jpain.2016.01.001; Elliott AM, 2002, PAIN, V99, P299, DOI 10.1016/S0304-3959(02)00138-0; Engel A, 2016, PAIN MED, V17, P658, DOI 10.1111/pme.12928; Fayaz A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010364; Finnerup NB, 2016, PAIN, V157, P1599, DOI 10.1097/j.pain.0000000000000492; Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Fisher Rebecca, 2013, F1000Res, V2, P164, DOI 10.12688/f1000research.2-164.v1; Fitzcharles MA, 2021, LANCET, V397, P2098, DOI 10.1016/S0140-6736(21)00392-5; Fletcher D, 2015, EUR J ANAESTH, V32, P725, DOI 10.1097/EJA.0000000000000319; Foell J, 2014, EUR J PAIN, V18, P729, DOI 10.1002/j.1532-2149.2013.00433.x; Freynhagen R, 2019, CURR MED RES OPIN, V35, P1011, DOI 10.1080/03007995.2018.1552042; Furlan AD, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001929.pub3; Gallagher Rollin M, 2016, Anesthesiol Clin, V34, P357, DOI 10.1016/j.anclin.2016.01.003; Garza-Villarreal EA, 2017, PAIN PHYSICIAN, V20, P597; Gatchel RJ, 2014, AM PSYCHOL, V69, P119, DOI 10.1037/a0035514; Genc H, 2012, PAIN MED, V13, P270, DOI 10.1111/j.1526-4637.2011.01300.x; Geneen LJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011279.pub3; Gibson W, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011890.pub3; Goldenberg DL, 2016, MAYO CLIN PROC, V91, P640, DOI 10.1016/j.mayocp.2016.02.002; Hall A, 2017, PHYS THER, V97, P227, DOI 10.2522/ptj.20160246; Heir GM, 2018, ORAL MAXIL SURG CLIN, V30, P279, DOI 10.1016/j.coms.2018.05.001; Hilton L, 2017, ANN BEHAV MED, V51, P199, DOI 10.1007/s12160-016-9844-2; Hughes LS, 2017, CLIN J PAIN, V33, P552, DOI 10.1097/AJP.0000000000000425; Huntoon M., 2021, LANCET, V397, P2111; Ibor PJ, 2017, CLIN J PAIN, V33, P1100, DOI 10.1097/AJP.0000000000000491; Juch JNS, 2017, JAMA-J AM MED ASSOC, V318, P68, DOI 10.1001/jama.2017.7918; Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55; Klimas J, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.3365; Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI [10.1002/art.41142, 10.1002/acr.24131]; Kwon M, 2014, PAIN PRACT, V14, P656, DOI 10.1111/papr.12145; Lamer TJ, 2019, MAYO CLIN PROC, V94, P1475, DOI 10.1016/j.mayocp.2018.12.037; Landefeld JC, 2017, J PAIN, V18, P1036, DOI 10.1016/j.jpain.2017.03.011; Lee IS, 2020, NEUROIMAGE, V204, DOI 10.1016/j.neuroimage.2019.116254; Lee JH, 2018, PAIN PHYSICIAN, V21, P433; Levy MH, 2008, CANCER J, V14, P401, DOI 10.1097/PPO.0b013e31818f5aa7; Liu R, 2017, REGION ANESTH PAIN M, V42, P52, DOI 10.1097/AAP.0000000000000505; Liu XQ, 2018, BRIT J SPORT MED, V52, P167, DOI 10.1136/bjsports-2016-097333; Macfarlane GJ, 2017, ANN RHEUM DIS, V76, P318, DOI 10.1136/annrheumdis-2016-209724; Machado GC, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1225; Manchikanti L, 2015, PAIN PHYSICIAN, V18, P39; Manchikanti L, 2016, PAIN PHYSICIAN, V19, pE365; Martucci KT, 2018, ANESTHESIOLOGY, V128, P1241, DOI 10.1097/ALN.0000000000002137; McAlindon TE, 2017, JAMA-J AM MED ASSOC, V317, P1967, DOI 10.1001/jama.2017.5283; Meints SM, 2018, PROG NEURO-PSYCHOPH, V87, P168, DOI 10.1016/j.pnpbp.2018.01.017; MELZACK R, 1968, P423; Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071; Mills SEE, 2019, BRIT J ANAESTH, V123, pE273, DOI 10.1016/j.bja.2019.03.023; Morasco BJ, 2011, PAIN, V152, P488, DOI 10.1016/j.pain.2010.10.009; Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805; National Institutes of Health, 2017, FED PAIN RES STRAT O; Neumann S, 1996, NATURE, V384, P360, DOI 10.1038/384360a0; NICE,, 2021, CHRON PAIN PRIM SEC; Oliveira CB, 2020, COCHRANE DATABASE SY, V4; Page GG, 2003, ADV EXP MED BIOL, V521, P117; Paley CA, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56010006; Peppin JF, 2016, J PAIN RES, V9, P23, DOI 10.2147/JPR.S99629; Pogatzki-Zahn EM, 2017, PAIN REP, V2, DOI 10.1097/PR9.0000000000000588; Pollard EM, 2019, J PAIN RES, V12, P1311, DOI 10.2147/JPR.S186662; Quinten C, 2009, LANCET ONCOL, V10, P865, DOI 10.1016/S1470-2045(09)70200-1; Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939; Ray WA, 2015, JAMA INTERN MED, V175, P420, DOI 10.1001/jamainternmed.2014.6294; Rhee J, 2017, GLOB SPINE J, V7, p35S, DOI 10.1177/2192568217703083; Richebe P, 2018, ANESTHESIOLOGY, V129, P590, DOI 10.1097/ALN.0000000000002238; Riddle DL, 2019, J BONE JOINT SURG AM, V101, P218, DOI 10.2106/JBJS.18.00621; Rodriguez-Raecke R, 2009, J NEUROSCI, V29, P13746, DOI 10.1523/JNEUROSCI.3687-09.2009; Rosenberg JM, 2018, PAIN MED, V19, P928, DOI 10.1093/pm/pnx203; Saavedra-Hernandez M, 2012, AM J PHYS MED REHAB, V91, P1070, DOI 10.1097/PHM.0b013e31827449a5; Samoborec S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198352; Sanapati J, 2018, PAIN PHYSICIAN, V21, P515; Schmulson MJ, 2017, J NEUROGASTROENTEROL, V23, P151, DOI 10.5056/jnm16214; Schneider BJ, 2020, PAIN MED, V21, P1122, DOI 10.1093/pm/pnz349; Seminowicz DA, 2011, J NEUROSCI, V31, P7540, DOI 10.1523/JNEUROSCI.5280-10.2011; Sielski R, 2017, INT J BEHAV MED, V24, P25, DOI 10.1007/s12529-016-9572-9; Smith D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099048; Spahr N, 2017, MUSCULOSKEL SCI PRAC, V27, P40, DOI 10.1016/j.msksp.2016.12.006; St Sauver JL, 2013, MAYO CLIN PROC, V88, P56, DOI 10.1016/j.mayocp.2012.08.020; Steglitz J, 2012, TRANSL BEHAV MED, V2, P6, DOI 10.1007/s13142-012-0110-2; Tang NKY, 2006, PSYCHOL MED, V36, P575, DOI 10.1017/S0033291705006859; Thapa P, 2018, KOREAN J PAIN, V31, P155, DOI 10.3344/kjp.2018.31.3.155; Thornton JD, 2017, QUAL LIFE RES, V26, P1955, DOI 10.1007/s11136-017-1538-0; Toljan K., 2018, MED SCI BASEL, P6; Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160; US Department of Health and Human Services, 2019, PAIN MAN BEST PRACT; van Middelkoop M, 2013, EUR SPINE J, V22, P87, DOI 10.1007/s00586-012-2553-z; Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005; Vleggeert-Lankamp CLA, 2019, SPINE J, V19, P965, DOI 10.1016/j.spinee.2018.12.013; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Voon P, 2017, SUBST ABUSE TREAT PR, V12, DOI 10.1186/s13011-017-0120-7; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1; Wieland LS, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010671.pub2; Williams ACD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007407.pub3; Woolf CJ, 1998, PAIN, V77, P227, DOI 10.1016/S0304-3959(98)00099-2; Wylde V, 2011, PAIN, V152, P566, DOI 10.1016/j.pain.2010.11.023; Yabuki Shoji, 2019, Asian J Anesthesiol, V57, P37, DOI 10.6859/aja.201906_57(2).0003; Yarborough BJH, 2019, PAIN MED, V20, P1148, DOI 10.1093/pm/pny179; Zaina F, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010264.pub2; Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/710750	138	136	143	43	79	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2021	397	10289					2082	2097						16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	SK5LX	34062143				2023-01-03	WOS:000656257800027
J	Horner, D; Goodacre, S; Davis, S; Burton, N; Hunt, BJ				Horner, Daniel; Goodacre, Steve; Davis, Sarah; Burton, Neil; Hunt, Beverley J.			Which is the best model to assess risk for venous thromboembolism in hospitalised patients?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DEEP-VEIN THROMBOSIS; MEDICAL PATIENTS; ANTICOAGULANT PROPHYLAXIS; PULMONARY-EMBOLISM; ELECTRONIC ALERTS; AMERICAN SOCIETY; VTE; METAANALYSIS; PREVENTION; IDENTIFICATION		[Horner, Daniel] Salford Royal NHS Fdn Trust, Salford, Lancs, England; [Horner, Daniel] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Horner, Daniel; Goodacre, Steve; Davis, Sarah] Univ Sheffield, Ctr Urgent & Emergency Care Res CURE, Sheffield, S Yorkshire, England; [Burton, Neil] Thrombosis UK, Llanwrda, England; [Hunt, Beverley J.] Guys & St Thomas NHS Fdn Trust, Kings Healthcare Partners & Thrombosis & Haemophi, London, England	Salford Royal NHS Foundation Trust; University of Manchester; University of Sheffield; Guy's & St Thomas' NHS Foundation Trust	Horner, D (corresponding author), Salford Royal NHS Fdn Trust, Salford, Lancs, England.; Horner, D (corresponding author), Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England.; Horner, D (corresponding author), Univ Sheffield, Ctr Urgent & Emergency Care Res CURE, Sheffield, S Yorkshire, England.	danielhorner@nhs.net		Hunt, Beverley Jane/0000-0002-4709-0774; Goodacre, Steve/0000-0003-0803-8444; Davis, Sarah/0000-0002-6609-4287; Horner, Daniel Edward/0000-0002-0400-2017	NIHR [127454]	NIHR(National Institute for Health Research (NIHR))	We would like to acknowledge the wider project management group directly conducting the VTEAM project (NIHR 127454) , including project manager Helen Shulver, data analyst Saleema Rex, literature expert Abdullah Pandor, clerical assistant Heather Dakin, and topic experts Mark Holland, Xavier Griffen, and Kerstin de Wit. We would also like to acknowledge the valuable input from the patient and public representatives Robin PierceWilliams, Chris Tweedy, Ben Langsdale, Deb Smith (Thrombosis UK) , Shan Bennett, and Enid Hirst (Sheffield Emergency Care Forum) .	Alikhan R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003747.pub4; Anderson DR, 2019, BLOOD ADV, V3, P3898, DOI 10.1182/bloodadvances.2019000975; Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x; Baroletti S, 2008, J THROMB THROMBOLYS, V25, P146, DOI 10.1007/s11239-007-0081-1; Baumgartner C, 2020, RISK STRATIFICATION; Beckman MG, 2010, AM J PREV MED, V38, pS495, DOI 10.1016/j.amepre.2009.12.017; Darzi AJ, 2020, BLOOD ADV, V4, P2557, DOI 10.1182/bloodadvances.2020001937; Darzi AJ, 2020, BLOOD, V135, P1788, DOI 10.1182/blood.2019003603; Dentali F, 2020, EFFICACY USE RISK SC; Dentali F, 2007, ANN INTERN MED, V146, P278, DOI 10.7326/0003-4819-146-4-200702200-00007; Falck-Ytter Y, 2012, CHEST, V141, pE278S, DOI 10.1378/chest.11-2404; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Goodacre SG, 2020, NIH RES; Healthcare ACoSaQi Healthcare ACoSaQi, 2020, VEN THROMB PREV CLIN; Heit JA, 2002, ARCH INTERN MED, V162, P1245, DOI 10.1001/archinte.162.11.1245; Huang W, 2013, J THROMB THROMBOLYS, V35, P67, DOI 10.1007/s11239-012-0780-0; Hunt BJ, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l4239; Komaroff A.L, 2021, COVID 19 RAP GUID MA; Kucher N, 2005, NEW ENGL J MED, V352, P969, DOI 10.1056/NEJMoa041533; Lloyd NS, 2008, J THROMB HAEMOST, V6, P405, DOI 10.1111/j.1538-7836.2007.02847.x; Mismetti P, 2000, THROMB HAEMOSTASIS, V83, P14; Moumneh T, 2020, J THROMB HAEMOST, V18, P1398, DOI 10.1111/jth.14796; Muntz J, 2004, INT J TECHNOL ASSESS, V20, P405, DOI 10.1017/S026646230400128X; National Institute for Health and Care Excellence, 2019, VEN THROMB 16S RED R; Nendaz M, 2014, THROMB HAEMOSTASIS, V111, P531, DOI 10.1160/TH13-05-0427; Raskob GE, 2014, SEMIN THROMB HEMOST, V40, P724, DOI 10.1055/s-0034-1390325; Roberts LN, 2017, BRIT J HAEMATOL, V178, P162, DOI 10.1111/bjh.14769; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Schulman S, 2010, J THROMB HAEMOST, V8, P202, DOI 10.1111/j.1538-7836.2009.03678.x; Schunemann HJ, 2018, BLOOD ADV, V2, P3198, DOI 10.1182/bloodadvances.2018022954; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929; Spyropoulos Alex C, 2020, TH Open, V4, pe59, DOI 10.1055/s-0040-1705137; Stuck AK, 2017, THROMB HAEMOSTASIS, V117, P801, DOI 10.1160/TH16-08-0631; Tagalakis V, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2013.02.024	35	1	1	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 27	2021	373								n1106	10.1136/bmj.n1106	http://dx.doi.org/10.1136/bmj.n1106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SM1OF	34045235	Green Accepted			2023-01-03	WOS:000657380500002
J	Belete, ZW; Berihun, G; Keleb, A; Ademas, A; Berhanu, L; Abebe, M; Gizeyatu, A; Hassen, S; Teshome, D; Lingerew, M; Feleke, A; Natnael, T; Adane, M				Belete, Zebader Walle; Berihun, Gete; Keleb, Awoke; Ademas, Ayechew; Berhanu, Leykun; Abebe, Masresha; Gizeyatu, Adinew; Hassen, Seada; Teshome, Daniel; Lingerew, Mistir; Feleke, Alelgne; Natnael, Tarikuwa; Adane, Metadel			Knowledge, attitude, and preventive practices towards COVID-19 and associated factors among adult hospital visitors in South Gondar Zone Hospitals, Northwest Ethiopia	PLOS ONE			English	Article							UNIVERSITY	Background Coronavirus disease 2019 (COVID-19) is currently the critical health problem of the globe, including Ethiopia. Visitors of healthcare facilities are the high-risk groups due to the presence of suspected and confirmed cases of COVID-19 in the healthcare setting. Increasing the knowledge, attitude, and practices towards COVID-19 prevention among hospital visitors are very important to prevent transmissions of the pandemic despite the lack of evidence remains a challenge in Ethiopia. Therefore, this study was designed to investigate the status of knowledge, attitude, and preventive practice towards COVID-19 and associated factors among hospital visitors in South Gondar Zone Hospitals, Northwest Ethiopia. Methods A facility-based cross-sectional study design was employed during August 1 to 30, 2020 from randomly selected 404 adult hospital visitors in South Gondar Zone Hospitals, Northwest Ethiopia. The data was collected using interviewer-administered questionnaire. The outcome of this study was good or poor knowledge, positive or negative attitude and good or poor preventive practice towards COVID-19. Three different binary logistic regression models with 95% CI (Confidence interval) was used for data analysis. For each mode, bivariable analysis (crude odds ratio [COR]) and multivariable analysis (adjusted odds ratio [AOR]) was used during data analysis. From the bivariable analysis, variables with a p-value <0.25 were retained into the multivariable logistic regression analysis. From the multivariable logistic regression analysis, variables with a significance level of p-value <0.05 were taken as factors independently associated with knowledge, attitude and preventive practices towards COVID-19. Main findings About 69.3% of the respondents had good knowledge, 62.6% had a positive attitude, and 49.3% had good preventive practice towards the prevention of COVID-19. We found that factors significantly associated with good knowledge about COVID-19 were educational status who can read and write (AOR = 2.78; 95%CI: 1.18-6.56) and college and above (AOR = 6.15; 95%CI: 2.18-17.40), and use of social media (AOR = 2.96; 95%CI: 1.46-6.01). Furthermore, factors significantly associated with a positive attitude towards COVID-19 includes the presence of chronic illnesses (AOR = 5.00; 95%CI; 1.71-14.67), training on COVID-19 (AOR = 3.91; 95%CI: 1.96-7.70), and peer/family as a source of information (AOR = 2.45; 95%CI: 1.06-5.63). Being a student (AOR = 7.70; 95%CI: 1.15-15.86) and participants who had a good knowledge on COVID-19 (AOR = 4.49; 95%CI: 2.41-8.39) were factors significantly associated with good practice towards COVID-19. Conclusion We found that knowledge, attitude, and preventive practices towards prevention of COVID-19 among adult hospital visitors were low. Therefore, we recommended that different intervention strategies for knowledge, attitude and preventive practices are urgently needed to control the transmission of COVID-19 among adult hospital visitors. Health education of those who could not read and write about COVID-19 knowledge issues and advocating use of social media that transmit messages about COVID-19 are highly encouraged to increase the good knowledge status of adult hospital visitors. Furthermore, providing training about COVID-19 prevention methods and using various sources of information about COVID-19 will help for improving positive attitude towards COVID-19 prevention, whereas for increasing the status of good preventive practices towards COVID-19, improving the good knowledge about COVID-19 of adult hospital visitors are essential.	[Belete, Zebader Walle; Berihun, Gete] Debre Tabor Univ, Coll Hlth Sci, Dept Publ Hlth, Debre Tabor, Ethiopia; [Berihun, Gete; Keleb, Awoke; Ademas, Ayechew; Berhanu, Leykun; Abebe, Masresha; Gizeyatu, Adinew; Hassen, Seada; Lingerew, Mistir; Feleke, Alelgne; Natnael, Tarikuwa; Adane, Metadel] Wollo Univ, Coll Med & Hlth Sci, Dept Environm Hlth, Dessie, Ethiopia; [Teshome, Daniel] Wollo Univ, Coll Med & Hlth Sci, Dept Anat, Dessie, Ethiopia	University of Gondar; University of Gondar	Berihun, G (corresponding author), Wollo Univ, Coll Med & Hlth Sci, Dept Environm Hlth, Dessie, Ethiopia.	geteberihun@gmail.com	Ademas, Ayechew/AAG-5984-2021; Hassen, Seada/GOH-0623-2022; Teshome, Daniel/AAD-1584-2022; Berhanu, Leykun/AAC-6695-2022; Walle, Zebader/AAE-5149-2022; Keleb, Awoke/AGX-2940-2022; Adane, Metadel/AFQ-9478-2022	Ademas, Ayechew/0000-0003-2602-162X; Teshome, Daniel/0000-0002-9124-3045; Berhanu, Leykun/0000-0002-2998-0917; Walle, Zebader/0000-0001-5361-5226; Keleb, Awoke/0000-0002-7510-3448; Adane, Metadel/0000-0002-7039-4768				Ababa A, 2013, FEDERAL DEMOCRATIC R; Abate BA., 2017, BASIC EMERGENCY MATE, V9, P11; Abate H, 2020, INFECT DRUG RESIST, V13, P4355, DOI 10.2147/IDR.S282792; Abdelhafiz AS, 2020, J COMMUN HEALTH, V45, P881, DOI 10.1007/s10900-020-00827-7; Admissions R., 2020, COVID 19 INFECT PREV, P1; Ahmad NA, 2020, COMMUNITY PERCEPTION; Al-Hanawi MK, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00217; Asemahagn MA, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-020-00254-3; Awasthi AA., 2020, RES ARTICLE KNOWLEDG, V11, P38990; Baye K, 2020, CURRENT REALITIES PR; Brief TA, 2020, EPIDEMIOLOGY, V7, P1; Cases T, 2020, CORONAVIRUS CASES; Cases TC., 2004, PATHOLOGY, P26; Defar A., 2020, KNOWLEDGE PRACTICE A, V19; DP S., 2020, KNOWLEDGE ATTITUDE A, V8, P3504; Elhadi M, 2020, AM J TROP MED HYG, V103, P828, DOI 10.4269/ajtmh.20-0330; Gebretsadik D, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246154; Hussain I, 2021, J COMMUN HEALTH, V46, P441, DOI 10.1007/s10900-020-00879-9; Giao H, 2020, ASIAN PAC J TROP MED, V13, P260, DOI 10.4103/1995-7645.280396; Iannone P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234025; Jemal B, 2020, KNOWLEDGE ATTITUDE P; Kebede Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233744; Lone SA, COVID 19 PANDEMIC AF, P10; Nallani VRR, 2020, INT J COMMUNITY MED, V7, P3450, DOI 10.18203/ 2394-6040.ijcmph20203906; Okorhi JO, 2020, ASSESSMENT MANAGEMEN, P1, DOI [10.5772/intechopen.88075, DOI 10.5772/INTECHOPEN.88075]; Olum R, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00181; Paget J, 2009, EPIDEMIOL BIOSTAT PU, V6, P257; Person B, 2004, EMERG INFECT DIS, V10, P358, DOI 10.3201/eid1002.030750; Priyadarsini SL, 2020, INT J HEALTHCARE MAN, V13, P89, DOI 10.1080/20479700.2020.1755804; Reuben RC, 2021, J COMMUN HEALTH, V46, P457, DOI 10.1007/s10900-020-00881-1; Saqlain M, 2020, J HOSP INFECT, V105, P419, DOI 10.1016/j.jhin.2020.05.007; Singh JP., 2020, ASSESSING KNOWLEDGE; Ssebuufu R., 2020, AWARENESS KNOWLEDGE, P1; Tolu LB., 2020, PREPARED IS AFRICA C; WHO Regional Office for Africa, 2020, 15 WHO REG OFF AFR; World Health Organization, 2020, COVID 19 STRAT PREP; World Health Organization, 2020, CORONAVIRUS DIS 2019, P2; World Health Organization, 2020, SURV TOOL GUID RAP S; Zegarra-Valdivia J. A., KNOWLEDGE PERCEPTION; Zhang M, 2020, J HOSP INFECT, V105, P183, DOI 10.1016/j.jhin.2020.04.012; Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221	41	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2021	16	5							e0250145	10.1371/journal.pone.0250145	http://dx.doi.org/10.1371/journal.pone.0250145			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6NC	33999925	Green Published, gold			2023-01-03	WOS:000664629600006
J	Ibuka, Y; Ohtsu, Y				Ibuka, Yoko; Ohtsu, Yui			Socioeconomic status and the likelihood of informal care provision in Japan: An analysis considering survival probability of care recipients	PLOS ONE			English	Article							FORMAL CARE; CO-RESIDENT; HEALTH-CARE; INEQUALITIES; DETERMINANTS; OUTCOMES; PEOPLE; GENDER; CAREGIVERS; INSURANCE	Studies show that the burden of caregiving tends to fall on individuals of low socioeconomic status (SES); however, the association between SES and the likelihood of caregiving has not yet been established. We studied the relationship between SES and the likelihood of adults providing long-term care for their parents in Japan, where compulsory public long-term insurance has been implemented. We used the following six comprehensive measures of SES for the analysis: income, financial assets, expenditure, living conditions, housing conditions, and education. We found that for some SES measures the probability of care provision for parents was greater in higher SES categories than in the lowest category, although the results were not systematically related to the order of SES categories or consistent across SES measures. The results did not change even after the difference in the probability of parents' survival according to SES was considered. Overall, we did not find evidence that individuals with lower SES were more likely to provide care to parents than higher-SES individuals. Although a negative association between SES and care burden has been repeatedly reported in terms of care intensity, the caregiving decision could be different in relation to SES. Further research is necessary to generalize the results.	[Ibuka, Yoko] Keio Univ, Fac Econ, Tokyo, Japan; [Ohtsu, Yui] Saitama Univ, Grad Sch Humanities & Social Sci, Saitama, Japan	Keio University; Saitama University	Ibuka, Y (corresponding author), Keio Univ, Fac Econ, Tokyo, Japan.	ibuka@econ.keio.ac.jp		Ibuka, Yoko/0000-0001-5505-8988	Open Research Areas for Social Sciences (ORA program) of the Japan Society for the Promotion of Science [JPJSJRP20181403]	Open Research Areas for Social Sciences (ORA program) of the Japan Society for the Promotion of Science	This research is financially supported by the Open Research Areas for Social Sciences (ORA program) of the Japan Society for the Promotion of Science (JPJSJRP20181403). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abajo M, 2017, J ADV NURS, V73, P700, DOI 10.1111/jan.13172; Adelman RD, 2014, JAMA-J AM MED ASSOC, V311, P1052, DOI 10.1001/jama.2014.304; [Anonymous], 2007, JAP STUD AG RET, V2009, P2011; Beckett M, 2000, J HEALTH SOC BEHAV, V41, P106, DOI 10.2307/2676363; Benzeval M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-947; Bertogg A, 2020, AGEING SOC, V40, P735, DOI 10.1017/S0144686X18001320; Bolin K, 2008, HEALTH ECON, V17, P393, DOI 10.1002/hec.1275; Bonsang E, 2009, J HEALTH ECON, V28, P143, DOI 10.1016/j.jhealeco.2008.09.002; Bremer P, 2017, HEALTH POLICY, V121, P613, DOI 10.1016/j.healthpol.2017.03.013; Carmichael F, 2010, J HEALTH ECON, V29, P182, DOI 10.1016/j.jhealeco.2009.11.003; Carrieri V, 2017, FISC STUD, V38, P445, DOI 10.1111/j.1475-5890.2017.12138; Dahlberg L, 2007, HEALTH SOC CARE COMM, V15, P439, DOI 10.1111/j.1365-2524.2007.00702.x; De Koker B, 2009, EUR J AGEING, V6, P3, DOI 10.1007/s10433-008-0103-7; Fu R, 2017, J HEALTH ECON, V56, P103, DOI 10.1016/j.jhealeco.2017.09.011; Nguyen HT, 2017, ECON REC, V93, P395, DOI 10.1111/1475-4932.12333; HEADEN AE, 1992, INQUIRY-J HEALTH CAR, V29, P440; Hiedemann B, 2018, J HUM RESOUR, V53, P663, DOI 10.3368/jhr.53.3.0213-5454R1; Huisman M, 2004, J EPIDEMIOL COMMUN H, V58, P468, DOI 10.1136/jech.2003.010496; Ichimura H, 2020, RIETI DISCUSSION PAP; Jimenez-Martin S, 2012, EUR J HEALTH ECON, V13, P461, DOI 10.1007/s10198-011-0317-z; Johnson PA, 2002, APPL ECON LETT, V9, P159, DOI 10.1080/13504850110052988; Jones AM, 2006, J R STAT SOC A STAT, V169, P543, DOI 10.1111/j.1467-985X.2006.00399.x; Karagiannaki E, 2017, J ECON INEQUAL, V15, P217, DOI 10.1007/s10888-017-9350-1; Kondo A, 2017, ASIAN ECON POLICY R, V12, P95, DOI 10.1111/aepr.12163; Pena-Longobardo LM, 2015, EUR J HEALTH ECON, V16, P507, DOI 10.1007/s10198-014-0604-6; Mentzakis E, 2009, REV ECON HOUSEHOLD, V7, P283, DOI 10.1007/s11150-008-9047-0; Ministry of Health Labour and Welfare, 2020, HEIS 28 NEN KOK NO G; Oliva-Moreno J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217016; Oshio T, 2018, J JPN INT ECON, V49, P1, DOI 10.1016/j.jjie.2018.01.001; Paraponaris A, 2012, EUR J HEALTH ECON, V13, P327, DOI 10.1007/s10198-011-0305-3; ROBINS JM, 1995, J AM STAT ASSOC, V90, P106, DOI 10.2307/2291134; Saito T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194919; Sanzenbacher GT, 2021, N AM ACTUAR J, V25, pS566, DOI 10.1080/10920277.2019.1676788; Stringhini S, 2010, JAMA-J AM MED ASSOC, V303, P1159, DOI 10.1001/jama.2010.297; Swinkels J, 2019, J GERONTOL B-PSYCHOL, V74, P309, DOI 10.1093/geronb/gbx036; Tamiya N, 2011, LANCET, V378, P1183, DOI 10.1016/S0140-6736(11)61176-8; Tokunaga M, 2017, SOC SCI MED, V173, P48, DOI 10.1016/j.socscimed.2016.11.037; Tokunaga M, 2015, HEALTH POLICY, V119, P840, DOI 10.1016/j.healthpol.2014.10.015; van Groenou MIB, 2016, EUR J AGEING, V13, P271, DOI 10.1007/s10433-016-0370-7; Van Houtven CH, 2004, J HEALTH ECON, V23, P1159, DOI 10.1016/j.jhealeco.2004.04.008; Yamada H, 2015, J ECON AGEING, V6, P79, DOI 10.1016/j.jeoa.2015.02.003	41	0	0	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256107	10.1371/journal.pone.0256107	http://dx.doi.org/10.1371/journal.pone.0256107			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TZ8RN	34388176	Green Published, gold			2023-01-03	WOS:000684737400022
J	Goc, J; Lv, M; Bessman, NJ; Flamar, AL; Sahota, S; Suzuki, H; Teng, F; Putzel, GG; Eberl, G; Withers, DR; Arthur, JC; Shah, MA; Sonnenberg, GF				Goc, Jeremy; Lv, Mengze; Bessman, Nicholas J.; Flamar, Anne-Laure; Sahota, Sheena; Suzuki, Hiroaki; Teng, Fei; Putzel, Gregory G.; Eberl, Gerard; Withers, David R.; Arthur, Janelle C.; Shah, Manish A.; Sonnenberg, Gregory F.		JRI Live Cell Bank	Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer	CELL			English	Article							INNATE LYMPHOID-CELLS; GUT MICROBIOTA; INFLAMMATION; TUMOR; DISEASE; BACTERIA; IMMUNITY; RECEPTOR; TUMORIGENESIS; INFECTIONS	Group 3 innate lymphoid cells (ILC3s) regulate immunity and inflammation, yet their role in cancer remains elusive. Here, we identify that colorectal cancer (CRC) manifests with altered ILC3s that are characterized by reduced frequencies, increased plasticity, and an imbalance with T cells. We evaluated the consequences of these changes in mice and determined that a dialog between ILC3s and T cells via major histocompatibility complex class II (MHCII) is necessary to support colonization with microbiota that subsequently induce type1 immunity in the intestine and tumor microenvironment. As a result, mice lacking ILC3-specific MHCII develop invasive CRC and resistance to anti-PD-1 immunotherapy. Finally, humans with dysregulated intestinal ILC3s harbor microbiota that fail to induce type-1 immunity and immunotherapy responsiveness when transferred to mice. Collectively, these data define a protective role for ILC3s in cancer and indicate that their inherent disruption in CRC drives dysfunctional adaptive immunity, tumor progression, and immunotherapy resistance.	[Goc, Jeremy; Lv, Mengze; Bessman, Nicholas J.; Flamar, Anne-Laure; Sahota, Sheena; Suzuki, Hiroaki; Teng, Fei; Putzel, Gregory G.; Sonnenberg, Gregory F.; JRI Live Cell Bank] Cornell Univ, Weill Cornell Med, Jill Roberts Inst Res Inflammatory Bowel Dis, New York, NY 10021 USA; [Goc, Jeremy; Lv, Mengze; Bessman, Nicholas J.; Flamar, Anne-Laure; Sahota, Sheena; Suzuki, Hiroaki; Teng, Fei; Sonnenberg, Gregory F.] Cornell Univ, Weill Cornell Med, Div Gastroenterol & Hepatol, Joan & Sanford I Weill Dept Med, New York, NY 10021 USA; [Goc, Jeremy; Lv, Mengze; Bessman, Nicholas J.; Flamar, Anne-Laure; Sahota, Sheena; Suzuki, Hiroaki; Teng, Fei; Sonnenberg, Gregory F.] Cornell Univ, Weill Cornell Med, Dept Microbiol & Immunol, New York, NY 10021 USA; [Eberl, Gerard] Inst Pasteur, Microenvironm & Immun Unit, Paris, France; [Withers, David R.] Univ Birmingham, Inst Immunol & Immunotherapy, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Arthur, Janelle C.] Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27515 USA; [Arthur, Janelle C.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Arthur, Janelle C.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA; [Shah, Manish A.] Cornell Univ, Weill Cornell Med, Dept Med, Div Hematol & Med Oncol, New York, NY 10021 USA; [Shah, Manish A.] Cornell Univ, Weill Cornell Med, New York Presbyterian Hosp,Gastrointestinal Oncol, Sandra & Edward Meyer Canc Ctr,Ctr Adv Digest Car, New York, NY 10021 USA; [Bessman, Nicholas J.] Univ Med & Dent New Jersey, Ctr Immun & Inflammat, Dept Med, Newark, NJ USA; [Flamar, Anne-Laure] Mem Sloan Kettering Canc Ctr, Parker Inst Canc Immunotherapy, Immunol Program, Swim Amer & Ludwig Collaborat Lab, 1275 York Ave, New York, NY 10021 USA; [Suzuki, Hiroaki] EA Pharma Co Ltd, Kawasaki, Kanagawa, Japan	Cornell University; Cornell University; Cornell University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Birmingham; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Cornell University; Cornell University; NewYork-Presbyterian Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Memorial Sloan Kettering Cancer Center; Eisai Co Ltd	Sonnenberg, GF (corresponding author), Cornell Univ, Weill Cornell Med, Jill Roberts Inst Res Inflammatory Bowel Dis, New York, NY 10021 USA.; Sonnenberg, GF (corresponding author), Cornell Univ, Weill Cornell Med, Div Gastroenterol & Hepatol, Joan & Sanford I Weill Dept Med, New York, NY 10021 USA.; Sonnenberg, GF (corresponding author), Cornell Univ, Weill Cornell Med, Dept Microbiol & Immunol, New York, NY 10021 USA.	gfsonnenberg@med.cornell.edu	Goc, Jeremy/O-7254-2018; Lyu, Mengze/GXV-3779-2022; Shah, Manish A/AHI-4322-2022; Withers, David/C-7055-2015	Goc, Jeremy/0000-0002-4214-8877; Lyu, Mengze/0000-0002-8509-7969; Withers, David/0000-0003-3757-7594	JRI; Rosanne H. Silbermann Foundation; Sanders Family; Weill Cornell Medicine Division of Pediatric Gastroenterology and Nutrition; NIH [R01AI143842, R01AI123368, R01AI145989, U01AI095608, R21CA249274, R01AI162936, F32AI124517, K01DK103952, R01DK124617]; Burroughs Wellcome Fund; Wade F.B. Thompson/Cancer Research Institute (CRI) CLIP Investigator grant; Meyer Cancer Center Collaborative Research Initiative; Dalton Family Foundation; Crohn's and Colitis Foundation [519428]; Philippe Foundation; Jill Roberts Center for IBD; Cure for IBD	JRI; Rosanne H. Silbermann Foundation; Sanders Family; Weill Cornell Medicine Division of Pediatric Gastroenterology and Nutrition; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Wade F.B. Thompson/Cancer Research Institute (CRI) CLIP Investigator grant; Meyer Cancer Center Collaborative Research Initiative; Dalton Family Foundation; Crohn's and Colitis Foundation; Philippe Foundation; Jill Roberts Center for IBD; Cure for IBD	We thank the Epigenomics and the Microbiome Cores of Weill Cornell Medicine and all contributing members of the JRI IBD Live Cell Bank, which is supported by the JRI, Jill Roberts Center for IBD, Cure for IBD, the Rosanne H. Silbermann Foundation, the Sanders Family, and Weill Cornell Medicine Division of Pediatric Gastroenterology and Nutrition. We thank members of the Sonnenberg Laboratory for discussions and critical reading of the manuscript. Research in the Sonnenberg Laboratory is supported by the NIH (R01AI143842, R01AI123368, R01AI145989, U01AI095608, R21CA249274, and R01AI162936), an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund, a Wade F.B. Thompson/Cancer Research Institute (CRI) CLIP Investigator grant, the Meyer Cancer Center Collaborative Research Initiative, The Dalton Family Foundation, and Linda and Glenn Greenberg. J.G. is supported by fellowships from the Crohn's and Colitis Foundation (519428) and the Philippe Foundation. N.J.B. is supported by a fellowship from the NIH (F32AI124517). G.F.S. is a CRI Lloyd J. Old STAR. J.C.A. is supported by NIH (K01DK103952 and R01DK124617).	Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Atarashi K, 2017, SCIENCE, V358, P359, DOI 10.1126/science.aan4526; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Beaugerie L, 2015, NEW ENGL J MED, V372, P1441, DOI 10.1056/NEJMra1403718; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bergmann H, 2017, EUR J IMMUNOL, V47, P1342, DOI 10.1002/eji.201646765; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Bialkowska AB, 2016, JOVE-J VIS EXP, DOI 10.3791/54161; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Blander JM, 2017, NAT IMMUNOL, V18, P851, DOI 10.1038/ni.3780; Brennan CA, 2016, ANNU REV MICROBIOL, V70, P395, DOI 10.1146/annurev-micro-102215-095513; Bressenot A, 2014, WORLD J GASTROENTERO, V20, P3164, DOI 10.3748/wjg.v20.i12.3164; Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; Carrega P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9280; Cella M, 2019, NAT IMMUNOL, V20, P980, DOI 10.1038/s41590-019-0425-y; Chan IH, 2014, MUCOSAL IMMUNOL, V7, P842, DOI 10.1038/mi.2013.101; Cole JR, 2014, NUCLEIC ACIDS RES, V42, pD633, DOI 10.1093/nar/gkt1244; Colonna M, 2018, IMMUNITY, V48, P1104, DOI 10.1016/j.immuni.2018.05.013; CORBETT TH, 1975, CANCER RES, V35, P2434; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; de Martel C, 2020, LANCET GLOB HEALTH, V8, pE180, DOI 10.1016/S2214-109X(19)30488-7; de Martel C, 2009, CRIT REV ONCOL HEMAT, V70, P183, DOI 10.1016/j.critrevonc.2008.07.021; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dodt Matthias, 2012, Biology (Basel), V1, P895, DOI 10.3390/biology1030895; Dzutsev A, 2017, ANNU REV IMMUNOL, V35, P199, DOI 10.1146/annurev-immunol-051116-052133; Edgar R.C., 2016, BIORXIV, DOI [10.1101/074161, DOI 10.1101/074161]; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Eisenring M, 2010, NAT IMMUNOL, V11, P1030, DOI 10.1038/ni.1947; Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972; Goc J, 2016, INT IMMUNOL, V28, P43, DOI 10.1093/intimm/dxv056; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gronke K, 2019, NATURE, V566, P249, DOI 10.1038/s41586-019-0899-7; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7; Hepworth MR, 2015, SCIENCE, V348, P1031, DOI 10.1126/science.aaa4812; Hepworth MR, 2013, NATURE, V498, P113, DOI 10.1038/nature12240; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Honda K, 2012, ANNU REV IMMUNOL, V30, P759, DOI 10.1146/annurev-immunol-020711-074937; Huerta-Cepas J, 2016, MOL BIOL EVOL, V33, P1635, DOI 10.1093/molbev/msw046; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Irshad S, 2017, CANCER RES, V77, P1083, DOI 10.1158/0008-5472.CAN-16-0598; Kirchberger S, 2013, J EXP MED, V210, P917, DOI 10.1084/jem.20122308; Koh J, 2019, CLIN CANCER RES, V25, P4026, DOI 10.1158/1078-0432.CCR-18-3458; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Li J, 2017, CLIN EXP IMMUNOL, V190, P143, DOI 10.1111/cei.12996; Liao Y, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz114; Litchfield K, 2021, CELL, V184, P596, DOI 10.1016/j.cell.2021.01.002; Liu YH, 2019, EBIOMEDICINE, V41, P333, DOI 10.1016/j.ebiom.2019.02.050; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mackley EC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6862; Mager LF, 2020, SCIENCE, V369, P1481, DOI 10.1126/science.abc3421; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martin JC, 2019, CELL, V178, P1493, DOI 10.1016/j.cell.2019.08.008; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Mattar Mark C, 2011, Gastrointest Cancer Res, V4, P53; Mazzurana L, 2019, EUR J IMMUNOL, V49, P1344, DOI 10.1002/eji.201848075; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Melo-Gonzalez F, 2019, J EXP MED, V216, P728, DOI 10.1084/jem.20180871; Nalbantoglu I, 2016, METHODS MOL BIOL, V1422, P309, DOI 10.1007/978-1-4939-3603-8_27; Nussbaum K, 2017, J EXP MED, V214, P2331, DOI 10.1084/jem.20162031; Parada AE, 2016, ENVIRON MICROBIOL, V18, P1403, DOI 10.1111/1462-2920.13023; Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109; Plichta DR, 2019, CELL, V178, P1041, DOI 10.1016/j.cell.2019.07.045; Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490; Routy B, 2018, NAT REV CLIN ONCOL, V15, P382, DOI 10.1038/s41571-018-0006-2; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Rozeman EA, 2021, NAT MED, V27, P256, DOI 10.1038/s41591-020-01211-7; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Sonnenberg GE, 2019, NAT REV IMMUNOL, V19, P599, DOI 10.1038/s41577-019-0194-8; Sonnenberg GF, 2015, NAT MED, V21, P698, DOI 10.1038/nm.3892; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Stevens M.H.H., 2016, VEGAN COMMUNITY ECOL; Tanoue T, 2019, NATURE, V565, P600, DOI 10.1038/s41586-019-0878-z; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Thaker AI, 2012, JOVE-J VIS EXP, DOI 10.3791/4100; Thompson LR, 2017, NATURE, V551, P457, DOI 10.1038/nature24621; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Trinchieri G, 2012, ANNU REV IMMUNOL, V30, P677, DOI 10.1146/annurev-immunol-020711-075008; Tsushima H, 1996, GASTROENTEROLOGY, V110, P375, DOI 10.1053/gast.1996.v110.pm8566583; Uhlig HH, 2018, ANNU REV IMMUNOL, V36, P755, DOI 10.1146/annurev-immunol-042617-053055; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; von Burg N, 2014, P NATL ACAD SCI USA, V111, P12835, DOI 10.1073/pnas.1406908111; Vonarbourg C, 2010, IMMUNITY, V33, P736, DOI 10.1016/j.immuni.2010.10.017; Wang KP, 2014, IMMUNITY, V41, P1052, DOI 10.1016/j.immuni.2014.11.009; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Wirtz S, 2017, NAT PROTOC, V12, P1295, DOI 10.1038/nprot.2017.044; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Xuan X, 2020, CLIN TRANSL ONCOL, V22, P563, DOI 10.1007/s12094-019-02160-5; Zhou L, 2019, NATURE, V568, P405, DOI 10.1038/s41586-019-1082-x	107	40	42	7	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 16	2021	184	19					5015	+		10.1016/j.cell.2021.07.029	http://dx.doi.org/10.1016/j.cell.2021.07.029		SEP 2021	32	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC7PA	34407392	Green Accepted, Bronze			2023-01-03	WOS:000704445100015
J	Shionoya, Y; Taniguchi, T; Kasai, H; Sakuma, N; Imai, S; Shikano, K; Takayanagi, S; Yahaba, M; Nakada, TA; Igari, H; Sakao, S; Suzuki, T				Shionoya, Yu; Taniguchi, Toshibumi; Kasai, Hajime; Sakuma, Noriko; Imai, Shun; Shikano, Kohei; Takayanagi, Shin; Yahaba, Misuzu; Nakada, Taka-aki; Igari, Hidetoshi; Sakao, Seiichiro; Suzuki, Takuji			Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study	PLOS ONE			English	Article							RNA	Introduction Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2. Although most patients with COVID-19 develop asymptomatic or mild disease, some patients develop severe disease. The effectiveness of various therapeutic agents, including antiviral drugs, steroids, and anti-inflammatories for COVID-19, have been being confirmed. The effect of administering steroids in early disease is unclear. This study therefore aimed to evaluate the effectiveness and risk of exacerbation of steroids administered preceding antiviral drugs in patients with COVID-19 pneumonia. Methods This retrospective, single-center, observational study included consecutive patients with COVID-19 between March 2020 and March 2021. Patients were divided into a steroids-first group and antiviral-drugs-first group. Mortality, duration of hospitalization, incidence rate and duration of intensive care unit (ICU) admission, intubation, and extracorporeal membrane oxygenation (ECMO) induction of the two groups were compared. Results A total of 258 patients were admitted during the study period. After excluding patients who received symptomatic treatment only, who were taking immunosuppressive drugs, or who were administered antiviral drugs only, 68 patients were included in the analysis, 16 in the steroids-first group and 52 in the antiviral-drugs-first group. The rate of intubation, ICU admission and ECMO induction were significantly higher in the steroids-first group than in the antiviral-drugs-first group (81.3% vs. 33.3, p<0.001, 75.0% vs. 29.4%, p = 0.001, and 31.3% vs. 7.8%, p = 0.017, respectively). Furthermore, patients who received steroids within ten days after starting antiviral drugs had significantly lower rates of ICU admission, intubation, and ECMO induction. (81.3% vs. 42.9% p = 0.011, 75.0% vs. 37.1% p = 0.012, and 31.3% vs. 8.6% p = 0.039, respectively). Conclusions Administering steroids prior to antiviral drugs soon after symptom onset can aggravate disease severity. When administration of steroids is considered soon after symptom onset, it may be safer to initiate antiviral drugs first.	[Shionoya, Yu; Kasai, Hajime; Sakuma, Noriko; Imai, Shun; Shikano, Kohei; Sakao, Seiichiro; Suzuki, Takuji] Chiba Univ, Grad Sch Med, Dept Respirol, Chiba, Japan; [Taniguchi, Toshibumi; Yahaba, Misuzu; Igari, Hidetoshi] Chiba Univ Hosp, Dept Infect Dis, Chiba, Japan; [Kasai, Hajime] Chiba Univ Hosp, Hlth Profess Dev Ctr, Chiba, Japan; [Takayanagi, Shin] Matsudo City Gen Hosp, Dept Infect Dis, Matsudo, Chiba, Japan; [Nakada, Taka-aki] Chiba Univ, Dept Emergency & Crit Care Med, Grad Sch Med, Chiba, Japan	Chiba University; Chiba University; Chiba University; Chiba University	Kasai, H (corresponding author), Chiba Univ, Grad Sch Med, Dept Respirol, Chiba, Japan.; Kasai, H (corresponding author), Chiba Univ Hosp, Hlth Profess Dev Ctr, Chiba, Japan.	daikasai6075@yahoo.co.jp		Shikano, Kohei/0000-0001-8781-2367; Kasai, Hajime/0000-0002-6759-2026				Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cantini F, 2020, DRUGS, V80, P1929, DOI 10.1007/s40265-020-01421-w; Chen WL, 2020, EMERG MICROBES INFEC, V9, P469, DOI 10.1080/22221751.2020.1732837; Chen YF, 2021, CLIN INFECT DIS, V72, P1298, DOI 10.1093/cid/ciaa832; Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00028-20; Ding C, 2020, INFECT DIS THER, V9, P943, DOI 10.1007/s40121-020-00337-y; Frediansyah A, 2021, CLIN EPIDEMIOL GLOB, V9, P90, DOI 10.1016/j.cegh.2020.07.006; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Lee K, 2009, GLOB INST, P1; Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006; Leentjens J, 2021, LANCET HAEMATOL, V8, DOI 10.1016/S2352-3026(21)00105-8; Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9; Li SJ, 2021, CLIN INFECT DIS, V72, P1297, DOI 10.1093/cid/ciaa829; Liu FF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70387-2; Liu J, 2020, J CLIN INVEST, V130, P6417, DOI 10.1172/JCI140617; Mishra GP, 2021, LANCET RESP MED, V9, pE8, DOI 10.1016/S2213-2600(20)30530-0; National Institutes of Health, THER MAN HOSP AD COV; Ohl ME, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.14741; Pasin L, 2021, J CARDIOTHOR VASC AN, V35, P578, DOI 10.1053/j.jvca.2020.11.057; Pinzon MA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252057; Prevention CfDCa, PEOPL CERT MED COND; Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012; Spagnuolo V, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78039-1; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Wang YQ, 2020, J CLIN INVEST, V130, P5235, DOI [10.1172/JCI138759, 10.1172/JCI138759.]; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648	29	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2021	16	9							e0256977	10.1371/journal.pone.0256977	http://dx.doi.org/10.1371/journal.pone.0256977			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5QV	34473766	Green Published, gold			2023-01-03	WOS:000707050100079
J	[Anonymous]				[Anonymous]			Update to living WHO guideline on drugs for covid-19	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 6	2021	374								n1703	10.1136/bmj.n1703	http://dx.doi.org/10.1136/bmj.n1703			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ1WO	34230027				2023-01-03	WOS:000744327900001
J	Sirica, AE				Sirica, Alphonse E.			The 2021 FASEB Virtual Catalyst Conference on Cholangiocarcinoma: Molecular Drivers, Microenvironment, and Precision Medicine, April 7, 2021	FASEB JOURNAL			English	Editorial Material									[Sirica, Alphonse E.] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23284 USA	Virginia Commonwealth University	Sirica, AE (corresponding author), Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23284 USA.	alphonse.sirica@vcuhealth.org							0	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2021	35	7							e21670	10.1096/fj.202100745	http://dx.doi.org/10.1096/fj.202100745			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TB2YH	34169576	Bronze			2023-01-03	WOS:000667814100027
J	Okamura, A; de Moraes, VY; Neto, JR; Tamaoki, MJ; Faloppa, F; Belloti, JC				Okamura, Aldo; de Moraes, Vinicius Ynoe; Neto, Jorge Raduan; Tamaoki, Marcel Jun; Faloppa, Flavio; Belloti, Joao Carlos			No benefit for elbow blocking on conservative treatment of distal radius fractures: A 6-month randomized controlled trial	PLOS ONE			English	Article							RATED WRIST EVALUATION; COLLES FRACTURE; CULTURAL-ADAPTATION; EVALUATION PRWE; SHORT FORM-36; BELOW-ELBOW; LONG-ARM; HAND; QUESTIONNAIRE; SHOULDER	Purpose For displaced distal radius fracture, this trial aimed to compare an above-elbow (AE) and below-elbow (BE) cast at the end of a 24-week follow-up using the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire as a primary outcome. Methods This is a clinical trial with parallel groups (1:1) and a blinded evaluator. There are two non-surgical interventions: AE and BE. A total of 128 adult patients with acute (up to 7 days) displaced distal radius fracture of type A2-3, C1-3 by the AO classification were included. The follow-up was 24 weeks. The primary outcome was the DASH questionnaire at 24 weeks. Secondary outcomes were the maintenance of reduction by the evaluation of radiographic parameters, pain measured by VAS, PRWE, objective functional evaluation and rate of adverse effects. Results The difference between the two groups in the DASH score at 24 weeks was not significant, with the mean (95% CI) DASH score being AE: 9.44 (2.70 to 16.17) vs. BE: 9.88 (3.19 to 16.57) (p = 0.895). The above-elbow group had a significantly greater worsening of the mean DASH score from baseline to 2 weeks (p < 0.001). No statistically significant differences were found between the 2 groups in any of the other follow-up assessments. Objective functional evaluation, PRWE, radiographical measures and rates of reduction loss were similar between groups. Above-elbow casting resulted in more adverse effects (mostly shoulder pain; 19 events vs. 9 events); RR = 0.39 (0.19-0.94); p = 0.033 at the end of six-month follow-up. Conclusions This study did not demonstrate a difference between above-elbow and below-elbow cast in terms of DASH outcome at 6 months in non-surgical treatment of deviated distal radius fractures. However, below-elbow casting is less debilitating during the treatment period, has comparable performance in maintaining the reduction, and is related to fewer minor adverse effects than above-elbow casting.	[Okamura, Aldo; de Moraes, Vinicius Ynoe; Neto, Jorge Raduan; Tamaoki, Marcel Jun; Faloppa, Flavio; Belloti, Joao Carlos] Univ Fed Sao Paulo Unifesp EPM, Dept Orthopaed & Traumatol, Unit Hand Surg, Sao Paulo, Brazil; [Okamura, Aldo] Hosp Campo Limpo, Div Orthopaed & Traumatol, Hosp Municipal Dr Fernando Mauro Pires Rocha, Sao Paulo, Brazil; [Okamura, Aldo; de Moraes, Vinicius Ynoe; Neto, Jorge Raduan; Belloti, Joao Carlos] Hosp Alvorada Moema, Hand Surg Div, United Hlth Grp, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP)	Okamura, A (corresponding author), Univ Fed Sao Paulo Unifesp EPM, Dept Orthopaed & Traumatol, Unit Hand Surg, Sao Paulo, Brazil.; Okamura, A (corresponding author), Hosp Campo Limpo, Div Orthopaed & Traumatol, Hosp Municipal Dr Fernando Mauro Pires Rocha, Sao Paulo, Brazil.; Okamura, A (corresponding author), Hosp Alvorada Moema, Hand Surg Div, United Hlth Grp, Sao Paulo, Brazil.	a.okamura@unifesp.br	PPGCT, Ortop/ABC-3666-2021; Belloti, João Carlos/F-7164-2012	Belloti, joao/0000-0002-1439-6064	FAPESP - Fundacao de Amparao a Pesquisa do Estado de Sao Paulo [2019/04546-4]	FAPESP - Fundacao de Amparao a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	JCB (senior author) received the grant. This research was funded by public funding FAPESP - Fundacao de Amparao a Pesquisa do Estado de Sao Paulo, under the number:2019/04546-4 (no COI from industry). http://www.fapesp.br	Arora R, 2011, J BONE JOINT SURG AM, V93A, P2146, DOI 10.2106/JBJS.J.01597; Ayhan C, 2015, CLIN BIOMECH, V30, P296, DOI 10.1016/j.clinbiomech.2014.12.015; Bailey PL, 1994, INTRAVENOUS OPIOID A, V4th, P291; Batra S, 2002, INJURY, V33, P499, DOI 10.1016/S0020-1383(01)00174-7; Belloti JC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0206895; Bong MR, 2006, J HAND SURG-AM, V31A, P766, DOI 10.1016/j.jhsa.2006.01.016; BUNGER C, 1984, ARCH ORTHOP TRAUM SU, V103, P251, DOI 10.1007/BF00387330; Caruso G, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018-019-1530-1; Charnley J., 1999, TREATMENT CLOSED FRA, V4th, P146; Chung KC, 2001, J HAND SURG-AM, V26A, P908, DOI 10.1053/jhsu.2001.26322; Chung KC, 2009, J HAND THER, V22, P302, DOI 10.1016/j.jht.2009.04.007; Cui Z, 2011, INT ORTHOP, V35, P1333, DOI 10.1007/s00264-011-1300-0; Rodrigues EKD, 2015, J HAND THER, V28, P69, DOI 10.1016/j.jht.2014.09.008; de Moraes VY, 2014, ACTA ORTOP BRAS, V22, DOI 10.1590/1413-78522014220601009; Diaz-Garcia RJ, 2011, J HAND SURG-AM, V36A, P824, DOI 10.1016/j.jhsa.2011.02.005; Donald B. Rubin, 1987, MULTIPLE IMPUTATION; Gamba C, 2017, INT ORTHOP, V41, P1723, DOI 10.1007/s00264-017-3518-y; Goldhahn J, 2014, ARCH ORTHOP TRAUM SU, V134, P197, DOI 10.1007/s00402-013-1767-9; Grafstein E, 2010, CAN J EMERG MED, V12, P192; Grewal R, 2007, J HAND SURG-AM, V32A, P962, DOI 10.1016/j.jhsa.2007.05.009; Gummesson C, 2003, BMC MUSCULOSKELET DI, V4, DOI 10.1186/1471-2474-4-11; Gutierrez-Espinoza H, 2019, CLIN REHABIL, V33, P1931, DOI 10.1177/0269215519866240; Gwilym S, 2020, BONE JOINT J, V102B, P48, DOI 10.1302/0301-620X.102B1.BJJ-2019-0243.R2; Handoll HH, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000314; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Hooper RC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232684; JENKINS NH, 1988, J HAND SURG-BRIT EUR, V13B, P291, DOI 10.1016/0266-7681(88)90090-3; Johnson N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210462; Kleinlugtenbelt YV, 2018, BONE JOINT RES, V7, P36, DOI 10.1302/2046-3758.71.BJR-2017-0081.R1; KNIRK JL, 1986, J BONE JOINT SURG AM, V68A, P647, DOI 10.2106/00004623-198668050-00003; Lichtman DM, 2010, J AM ACAD ORTHOP SUR, V18, P180, DOI 10.5435/00124635-201003000-00007; Luokkala T, 2020, EFORT OPEN REV, V5, P361, DOI 10.1302/2058-5241.5.190060; MacDermid JC, 2000, J HAND SURG-AM, V25A, P330, DOI 10.1053/jhsu.2000.jhsu25a0330; Maluta T, 2019, INT ORTHOP, V43, P2391, DOI 10.1007/s00264-018-4197-z; MANN FA, 1992, RADIOLOGY, V184, P15, DOI 10.1148/radiology.184.1.1609073; Mazer N., 1994, REV BRAS ORTOP, V29, P759; MCQUEEN M, 1988, J BONE JOINT SURG BR, V70, P649, DOI 10.1302/0301-620X.70B4.3403617; Navarro CM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214362; Ng CY, 2011, J BONE JOINT SURG BR, V93B, P145, DOI 10.1302/0301-620X.93B2.25631; Ochen Y, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3497; Okamura A, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2007-9; Orfale AG, 2005, BRAZ J MED BIOL RES, V38, P293, DOI 10.1590/S0100-879X2005000200018; Pang EQ, 2018, BONE JOINT J, V100B, P205, DOI 10.1302/0301-620X.100B2.BJJ-2017-0358.R1; Park MJ, 2017, J HAND SURG-EUR VOL, V42, P487, DOI 10.1177/1753193417690464; Pool C, 1973, J Bone Joint Surg Br, V55, P540; Raittio L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232153; REVILL SI, 1976, ANAESTHESIA, V31, P1191, DOI 10.1111/j.1365-2044.1976.tb11971.x; Ritting AW, 2012, HAND CLIN, V28, P165, DOI 10.1016/j.hcl.2012.03.003; SARMIENTO A, 1975, J BONE JOINT SURG AM, VA 57, P311, DOI 10.2106/00004623-197557030-00004; Shafer SL., 1993, SEMIN ANESTH PERIO M, V12, P222; STEWART HD, 1984, J BONE JOINT SURG BR, V66, P749, DOI 10.1302/0301-620X.66B5.6389558; Tumia N, 2003, J BONE JOINT SURG BR, V85B, P78, DOI 10.1302/0301-620X.85B1.12468; Voineskos SH, 2014, HAND CLIN, V30, P285, DOI 10.1016/j.hcl.2014.04.008; WAHLSTROM O, 1982, ACTA ORTHOP SCAND, V53, P225, DOI 10.3109/17453678208992206; Webb GR, 2006, J BONE JOINT SURG AM, V88A, P9, DOI 10.2106/JBJS.E.00131; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Wik TS, 2009, INJURY, V40, P400, DOI 10.1016/j.injury.2008.08.044; Wilcke MKT, 2007, J HAND THER, V20, P290, DOI 10.1197/j.jht.2007.06.001	58	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2021	16	6							e0252667	10.1371/journal.pone.0252667	http://dx.doi.org/10.1371/journal.pone.0252667			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6SA	34111160	Green Published, gold			2023-01-03	WOS:000664642700036
J	Walsh, CS; Kamrava, M; Rogatko, A; Kim, S; Li, A; Cass, I; Karlan, B; Rimel, BJ				Walsh, Christine S.; Kamrava, Mitchell; Rogatko, Andre; Kim, Sungjin; Li, Andrew; Cass, Ilana; Karlan, Beth; Rimel, Bobbie J.			Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer	PLOS ONE			English	Article							CHECKPOINT INHIBITORS; ANTITUMOR-ACTIVITY; SAFETY	Objective To evaluate the combination of pembrolizumab, cisplatin and gemcitabine in recurrent platinum-resistant ovarian cancer. Methods Patients received six cycles of chemotherapy with gemcitabine and cisplatin on day 1 and day 8 of a 21-day treatment cycle. Pembrolizumab was administered on day 1 of cycles 3-6 and as maintenance monotherapy in cycles 7-34. Palliative radiation to a non-target symptomatic lesion was allowed. The primary objective was overall response rate by RECIST 1.1 criteria. Secondary objectives included safety, progression-free survival, time to progression, duration of response and overall survival. Results An interim analysis for futility was performed at 18 evaluable patients. Overall response rate was 60%, duration of response was 4.9 months and time to progression was 5.2 months. Progression-free survival at 6 and 12 months was 43% and 5%. Median progression-free survival was 6.2 months and median overall survival was 11.3 months. In all patients, CA125 levels reflected response and progression. There were no pseudoprogression events. After receiving palliative radiation during pembrolizumab maintenance, a patient with recurrent ovarian clear cell carcinoma had an exceptional and durable response that is ongoing for greater than 2 years. After consultation with the sponsor, based on the modest duration of response observed at the interim analysis for futility, the decision was made to close the trial to further accrual. Conclusions The addition of pembrolizumab to cisplatin and gemcitabine did not appear to provide benefit beyond chemotherapy alone in patients with recurrent platinum-resistant ovarian cancer.	[Walsh, Christine S.; Li, Andrew; Cass, Ilana; Karlan, Beth; Rimel, Bobbie J.] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Los Angeles, CA 90048 USA; [Walsh, Christine S.; Kamrava, Mitchell; Rogatko, Andre; Kim, Sungjin; Li, Andrew; Cass, Ilana; Karlan, Beth; Rimel, Bobbie J.] Cedars Sinai Med Ctr, Cedars Sinai Canc, Los Angeles, CA 90048 USA; [Kamrava, Mitchell] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA; [Rogatko, Andre; Kim, Sungjin] Cedars Sinai Med Ctr, Biostat & Bioinformat Res Ctr, Los Angeles, CA 90048 USA; [Walsh, Christine S.] Univ Colorado, Dept Obstet & Gynecol, Aurora, CO USA; [Cass, Ilana] Dartmouth Hitchcock Med Ctr, Dept Obstet & Gynecol, Lebanon, NH 03766 USA; [Karlan, Beth] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; Dartmouth College; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Walsh, CS (corresponding author), Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Los Angeles, CA 90048 USA.; Walsh, CS (corresponding author), Cedars Sinai Med Ctr, Cedars Sinai Canc, Los Angeles, CA 90048 USA.; Walsh, CS (corresponding author), Univ Colorado, Dept Obstet & Gynecol, Aurora, CO USA.	christine.walsh@cshs.org		Rogatko, Andre/0000-0001-8935-8890; Walsh, Christine/0000-0002-0903-3971	Merck Investigator Studies Program (MISP) [52261]	Merck Investigator Studies Program (MISP)	Funded by Merck Investigator Studies Program (MISP) grant #52261 to C.W. http://engagezone.msd.com/ds_documentation.php. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brewer CA, 2006, GYNECOL ONCOL, V103, P446, DOI 10.1016/j.ygyno.2006.03.018; Disis ML, 2019, JAMA ONCOL, V5, P393, DOI 10.1001/jamaoncol.2018.6258; Dolled-Filhart M, 2016, ARCH PATHOL LAB MED, V140, P1259, DOI 10.5858/arpa.2015-0544-OA; Doo DW, 2019, GYNECOL ONCOL REP, V29, P48, DOI 10.1016/j.gore.2019.06.003; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Gonzalez-Martin A, 2019, CANCER-AM CANCER SOC, V125, P4616, DOI 10.1002/cncr.32520; Hamanishi J, 2015, J CLIN ONCOL, V33, P4015, DOI 10.1200/JCO.2015.62.3397; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; Lynch TJ, 2012, J CLIN ONCOL, V30, P2046, DOI 10.1200/JCO.2011.38.4032; Matulonis UA, 2019, ANN ONCOL, V30, P1080, DOI 10.1093/annonc/mdz135; Nagourney RA, 2003, GYNECOL ONCOL, V88, P35, DOI 10.1006/gyno.2002.6855; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; PETERS GJ, 1995, SEMIN ONCOL, V22, P72; Rose PG, 2003, GYNECOL ONCOL, V88, P17, DOI 10.1006/gyno.2002.6850; Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9; Varga A, 2019, GYNECOL ONCOL, V152, P243, DOI 10.1016/j.ygyno.2018.11.017	17	7	10	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2021	16	6							e0252665	10.1371/journal.pone.0252665	http://dx.doi.org/10.1371/journal.pone.0252665			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6QS	34081738	Green Published, gold			2023-01-03	WOS:000664639200041
J	Ross, J; Ingabire, C; Umwiza, F; Gasana, J; Munyaneza, A; Murenzi, G; Nsanzimana, S; Remera, E; Akiyama, MJ; Anastos, KM; Adedimeji, A				Ross, Jonathan; Ingabire, Charles; Umwiza, Francine; Gasana, Josephine; Munyaneza, Athanase; Murenzi, Gad; Nsanzimana, Sabin; Remera, Eric; Akiyama, Matthew J.; Anastos, Kathryn M.; Adedimeji, Adebola			How early is too early? Challenges in ART initiation and engaging in HIV care under Treat All in Rwanda-A qualitative study	PLOS ONE			English	Article							TRAUMA; PERSPECTIVES; DIAGNOSIS; PROGRAM; MALAWI; WOMEN	Introduction HIV treatment guidelines recommend that all people living with HIV (PLWH) initiate antiretroviral therapy (ART) as soon as possible after diagnosis (Treat All). As Treat All is more widely implemented, an increasing proportion of PLWH are likely to initiate ART when they are asymptomatic, and they may view the relative benefits and risks of ART differently than those initiating at more advanced disease stages. To date, patient perspectives of initiating care under Treat All in sub-Saharan Africa have not been well described. Methods From September 2018 to March 2019, we conducted individual, semi-structured, qualitative interviews with 37 patients receiving HIV care in two health centers in Kigali, Rwanda. Data were analyzed using a mixed deductive and inductive thematic analysis approach to describe perceived barriers to, facilitators of and acceptability of initiating and adhering to ART rapidly under Treat All. Results Of 37 participants, 27 were women and the median age was 31 years. Participants described feeling traumatized and overwhelmed by their HIV diagnosis, resulting in difficulty accepting their HIV status. Most were prescribed ART soon after diagnosis, yet fear of lifelong medication and severe side effects in the immediate period after initiating ART led to challenges adhering to therapy. Moreover, because many PLWH initiated ART while healthy, taking medications and attending appointments were visible signals of HIV status and highly stigmatizing. Nonetheless, many participants expressed enthusiasm for Treat All as a program that improved health as well as health equity. Conclusion For newly-diagnosed PLWH in Rwanda, initiating ART rapidly under Treat All presents logistical and emotional challenges despite the perceived benefits. Our findings suggest that optimizing early engagement in HIV care under Treat All requires early and ongoing intervention to reduce trauma and stigma, and promote both individual and community benefits of ART.	[Ross, Jonathan; Akiyama, Matthew J.; Anastos, Kathryn M.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA; [Ingabire, Charles; Umwiza, Francine; Gasana, Josephine; Munyaneza, Athanase; Murenzi, Gad] Rwanda Mil Hosp, Clin Educ & Res Div, Kigali, Rwanda; [Nsanzimana, Sabin; Remera, Eric] Rwanda Biomed Ctr, Inst HIV Dis Prevent & Control, Kigali, Rwanda; [Adedimeji, Adebola] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Rwanda Biomedical Center; Yeshiva University; Albert Einstein College of Medicine	Ross, J (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA.	joross@montefiore.org	Ross, Jonathan/AAV-2402-2020	Ross, Jonathan/0000-0001-6126-3048; INGABIRE, CHARLES/0000-0002-6700-6410; Murenzi, Gad/0000-0002-5513-5522; Akiyama, Matthew/0000-0003-4290-3083; Munyaneza, Athanase/0000-0001-6332-3040	U.S. National Institute of Mental Health [K23 MH114752]; U.S. National Institutes of Health's NIAID; NIMH; NIDA [U01 AI096299]; Einstein-Rockefeller-CUNY Center for AIDS Research [P30 AI124414]; NICHD; NIA; NCI; NHBL; NIDA; FIC; OAR; NIAID	U.S. National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); U.S. National Institutes of Health's NIAID; NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Einstein-Rockefeller-CUNY Center for AIDS Research; NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHBL; NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); FIC; OAR; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the U.S. National Institute of Mental Health (K23 MH114752); by the U.S. National Institutes of Health's NIAID, NICHD, NCI, NIMH, and NIDA, as part of Central Africa IeDEA (U01 AI096299); and by the Einstein-Rockefeller-CUNY Center for AIDS Research (P30 AI124414), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHBL, NIDA, NIMH, NIA, FIC, and OAR.	Ahmed S, 2018, SOC SCI MED, V213, P72, DOI 10.1016/j.socscimed.2018.05.048; [Anonymous], DEDOOSE VERSION 7023; Ayieko J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202990; Black S, 2014, AIDS CARE, V26, P736, DOI 10.1080/09540121.2013.855300; Cordova MJ, 2017, LANCET PSYCHIAT, V4, P330, DOI 10.1016/S2215-0366(17)30014-7; Craw JA, 2008, JAIDS-J ACQ IMM DEF, V47, P597, DOI 10.1097/QAI.0b013e3181684c51; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; Davey DJ, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25529; Derksen L, NATURAL FIELD EXPT 0; Dovel K, 2020, GLOBAL HEALTH ACTION, V13, DOI 10.1080/16549716.2020.1728830; Earnshaw VA, 2018, AIDS BEHAV, V22, P2543, DOI 10.1007/s10461-018-2101-x; Ford N, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25078; Ford N, 2018, AIDS, V32, P17, DOI [10.1097/QAD.0000000000001671, 10.1097/qad.0000000000001671]; Gieseler F, 2018, ONCOLOGIST, V23, P752, DOI 10.1634/theoncologist.2017-0478; Ingabire C, 2018, AIDS 2018 C; Katirayi L, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3767-5; Katirayi L, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20919; Katz IT, 2015, AIDS BEHAV, V19, P704, DOI 10.1007/s10461-014-0920-y; Katz IT, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.3.18640; Kerschberger B, 2021, AM J EPIDEMIOL, DOI [10.1093/aje/kwab032, DOI 10.1093/AJE/KWAB032]; Koenig SP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002357; Kumwenda M, 2021, GLOB PUBLIC HEALTH, V16, P227, DOI 10.1080/17441692.2020.1851386; Layer EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104961; Lilian RR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227572; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; MCLEROY KR, 1988, HEALTH EDUC QUART, V15, P351, DOI 10.1177/109019818801500401; Mgbako O, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09342-9; Ministry of Health Rwanda Centers for Disease Control and Prevention (CDC) University of California San Francisco and ICAP at Columbia University, 2019, RWAND POP BAS HIV IM; Mody A, 2018, CLIN INFECT DIS, V66, P237, DOI 10.1093/cid/cix756; Rodger AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097340; Rosen S, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002106, DOI 10.1371/journal.pmed.1002106]; Ross J, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25279; Sales JM, 2016, CURR HIV-AIDS REP, V13, P374, DOI 10.1007/s11904-016-0337-5; Shubber Z, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002183; Songo J, 2021, GLOB PUBLIC HEALTH, V16, P256, DOI 10.1080/17441692.2020.1771395; Swindells S, 2020, NEW ENGL J MED, V382, P1112, DOI 10.1056/NEJMoa1904398; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Tymejczyk O, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002822; Venables E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164634; Williams SM, 2021, GLOB PUBLIC HEALTH, V16, P167, DOI 10.1080/17441692.2020.1851385; World Health Organization, 2017, GUIDELINES MANAGING; World Health Organization Department of HIV/AIDS, GUID START ANT THER; NATL GUIDELINES PREV	43	3	3	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2021	16	5							e0251645	10.1371/journal.pone.0251645	http://dx.doi.org/10.1371/journal.pone.0251645			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SW6MO	33984044	gold, Green Published			2023-01-03	WOS:000664628200111
J	Loch, AP; Rocha, SQ; Fonsi, M; Caraciolo, JMD; Kalichman, AO; Souza, RD; Gianna, MC; Goncalves, A; Short, D; Pimenta, SL; Bagnola, L; Menuzzo, CW; Meireles, ZD; Diz, EN; Zajdenverg, R; Prudente, I; Nemes, MIB				Loch, Ana Paula; Rocha, Simone Queiroz; Fonsi, Mylva; de Magalhaes Caraciolo, Joselita Maria; Kalichman, Artur Olhovetchi; Souza, Rosa de Alencar; Gianna, Maria Clara; Goncalves, Alexandre; Short, Duncan; Pimenta, Shenia Liane; Bagnola, Lea; Menuzzo, Carolina Wonhnrath; Meireles, Zulmira da Rocha; Diz, Eunice Natividade; Zajdenverg, Roberto; Prudente, Isidoro; Battistella Nemes, Maria Ines			Improving the continuum of care monitoring in Brazilian HIV healthcare services: An implementation science approach	PLOS ONE			English	Article							NORMALIZATION PROCESS THEORY; ANTIRETROVIRAL THERAPY; NOMAD INSTRUMENT; ADHERENCE; FRAMEWORK	Objective To evaluate the impact of an intervention improving the continuum of care monitoring (CCM) within HIV public healthcare services in SAo Paulo, Brazil, and implementing a clinical monitoring system. This system identified three patient groups prioritized for additional care engagement: (1) individuals diagnosed with HIV, but not receiving treatment (the treatment gap group); (2) individuals receiving treatment for >6 months with a detectable viral load (the virologic failure group); and (3) patients lost to follow-up (LTFU). Methods The implementation strategies included three training sessions, covering system logistics, case discussions, and development of maintenance goals. These strategies were conducted within 30 HIV public healthcare services (May 2019 to April 2020). After each training session, professionals shared their experiences with CCM at regional meetings. Before and after the intervention, providers were invited to answer 23 items from the normalization process theory questionnaire (online) to understand contextual factors. The mean item scores were compared using the Mann-Whitney U test. The RE-AIM implementation science framework (evaluating reach, effectiveness, adoption, implementation, and maintenance) was used to evaluate the integration of the CCM. Results In the study, 47 (19.3%) of 243 patients with a treatment gap initiated treatment, 456 (49.1%) of 928 patients with virologic failure achieved suppression, and 700 of 1552 (45.1%) LTFU patients restarted treatment. Strategies for the search and reengagement of patients were developed and shared. Providers recognized the positive effects of CCM on their work and how it modified existing activities (3.7 vs. 4.4, p<0.0001, and 3.9 vs. 4.1, p<0.05); 27 (90%) centers developed plans to sustain routine CCM. Conclusion Implementing CCM helped identify patients requiring more intensive attention. This intervention led to changes in providers' perceptions of CCM and care and management processes, which increased the number of patients engaged across the care continuum and improved outcomes.	[Loch, Ana Paula; Rocha, Simone Queiroz; Fonsi, Mylva; de Magalhaes Caraciolo, Joselita Maria; Kalichman, Artur Olhovetchi; Souza, Rosa de Alencar; Gianna, Maria Clara; Goncalves, Alexandre] Ctr Referencia & Treinamento DST AIDS Estado Sao, Sao Paulo, Brazil; [Short, Duncan] ViiV Healthcare Innovat & Implementat Sci, London, England; [Pimenta, Shenia Liane] Secretaria Estadual Saude Sao Paulo, Grp Vigilancia Epidemiol Campinas GVE 17, Campinas, SP, Brazil; [Bagnola, Lea] Programa Municipal IST Aids Votuporanga, Votuporanga, SP, Brazil; [Menuzzo, Carolina Wonhnrath] Prefeitura Municipal Sumare, Sumare, SP, Brazil; [Meireles, Zulmira da Rocha] Grp Vigilancia Epidemiol Sao Jose do Rio Preto, Sao Paulo, Brazil; [Diz, Eunice Natividade] Grp Vigilancia Epidemiol Osasco, Osasco, SP, Brazil; [Zajdenverg, Roberto] ViiV Healthcare Sci Affairs & Publ Hlth, Rio De Janeiro, Brazil; [Prudente, Isidoro] ViiV Healthcare, Med Affairs, Montevideo, Uruguay; [Battistella Nemes, Maria Ines] Univ Sao Paulo, Fac Med, Dept Med Prevent, Sao Paulo, SP, Brazil	Universidade de Sao Paulo	Loch, AP (corresponding author), Ctr Referencia & Treinamento DST AIDS Estado Sao, Sao Paulo, Brazil.	anapaulaloch@gmail.com	NEMES, MARIA INES B/C-5597-2012	Loch, Ana Paula/0000-0002-1725-4213; Nemes, Maria Ines B/0000-0001-9862-1603; Duncan, Short/0000-0003-1000-7532	ViiV Healthcare [210027]	ViiV Healthcare	The study was supported by the ViiV Healthcare under Grant 210027 (https://viivhealthcare.com/en-gb/).DS, RZ and IP received salary from ViiV Health Care and GlaxoSmithKline. The funder provided support in the form of salaries for authors [DS, RZ and IP], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Al-Dakkak I, 2013, AIDS CARE, V25, P400, DOI 10.1080/09540121.2012.712667; Nemes MIB, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-51; Brazilian Ministry of Health, SIST MON CLIN PESS V; Brazilian Ministry of Health, CLIN HIV MON REP; Campos Gastão Wagner de Sousa, 2007, Ciênc. saúde coletiva, V12, P849, DOI 10.1590/S1413-81232007000400007; Curran GM, 2012, MED CARE, V50, P217, DOI 10.1097/MLR.0b013e3182408812; Feldstein AC, 2008, JT COMM J QUAL PATIE, V34, P228, DOI 10.1016/S1553-7250(08)34030-6; Finch TL, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0591-x; Funcia FR, 2019, CIENC SAUDE COLETIVA, V24, P4405, DOI 10.1590/1413-812320182412.25892019; Glasgow RE, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00064; Grierson J, 2011, HIV MED, V12, P562, DOI 10.1111/j.1468-1293.2011.00928.x; Gurses AP, 2010, CRIT CARE MED, V38, pS282, DOI 10.1097/CCM.0b013e3181e69e02; International Advisory Panel on HIV Care Continuum Optimization, 2015, J Int Assoc Provid AIDS Care, V14 Suppl 1, pS3, DOI 10.1177/2325957415613442; Loch AP, 2020, REV ASSOC MED BRAS, V66, P1383, DOI 10.1590/1806-9282.66.10.1383; Loch AP, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311x00136219, 10.1590/0102-311X00136219]; Loch AP, 2018, CAD SAUDE PUBLICA, V34, DOI 10.1590/0102-311X00047217; Melchior R, 2006, REV SAUDE PUBL, V40, P143, DOI 10.1590/S0034-89102006000100022; Murray E, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-63; Nachega JB, 2014, CLIN INFECT DIS, V58, P1297, DOI 10.1093/cid/ciu046; Nemes Maria Ines Battistella, 2019, Rev. bras. epidemiol., V22, pe190010, DOI 10.1590/1980-549720190010.supl.1; Nemes MIB, 2004, AIDS, V18, pS15, DOI 10.1097/00002030-200406003-00004; Powell BJ, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0209-1; Rapley T, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0590-y; Rodrigues Marilza, 2017, Saúde debate, V41, P526, DOI 10.1590/0103-1104201711314; Shiau S, 2020, AIDS BEHAV, V24, P2244, DOI 10.1007/s10461-020-02871-9; University of Sao Paulo Medical School, QUAL SIST AV QUAL OR; Wilkinson L, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25503	27	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2021	16	5							e0250060	10.1371/journal.pone.0250060	http://dx.doi.org/10.1371/journal.pone.0250060			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6LC	33970914	Green Published, gold			2023-01-03	WOS:000664624400011
J	Karmarkar, EN; O'Donnell, K; Prestel, C; Forsberg, K; Gade, L; Jain, S; Schan, D; Chow, N; McDermott, D; Rossow, J; Toda, M; Ruiz, R; Hun, S; Dale, JL; Gross, A; Maruca, T; Glowicz, J; Brooks, R; Bagheri, H; Nelson, T; Gualandi, N; Khwaja, Z; Horwich-Scholefield, S; Jacobs, J; Cheung, M; Walters, M; Jacobs-Slifka, K; Stone, ND; Mikhail, L; Chaturvedi, S; Klein, L; Vagnone, PS; Schneider, E; Berkow, EL; Jackson, BR; Vallabhaneni, S; Zahn, M; Epson, E				Karmarkar, Ellora N.; O'Donnell, Kathleen; Prestel, Christopher; Forsberg, Kaitlin; Gade, Lalitha; Jain, Seema; Schan, Douglas; Chow, Nancy; McDermott, Darby; Rossow, John; Toda, Mitsuru; Ruiz, Ryan; Hun, Sopheay; Dale, Jennifer L.; Gross, Annastasia; Maruca, Tyler; Glowicz, Janet; Brooks, Richard; Bagheri, Hosniyeh; Nelson, Teresa; Gualandi, Nicole; Khwaja, Zenith; Horwich-Scholefield, Sam; Jacobs, Josh; Cheung, Michele; Walters, Maroya; Jacobs-Slifka, Kara; Stone, Nimalie D.; Mikhail, Lydia; Chaturvedi, Sudha; Klein, Liore; Vagnone, Paula Snippes; Schneider, Emily; Berkow, Elizabeth L.; Jackson, Brendan R.; Vallabhaneni, Snigdha; Zahn, Matthew; Epson, Erin			Rapid Assessment and Containment of Candida auris Transmission in Postacute Care Settings-Orange County, California, 2019	ANNALS OF INTERNAL MEDICINE			English	Article							NEW-YORK; RESISTANT; FACILITIES; OUTBREAK	Background: Candida auris, a multidrug-resistant yeast, can spread rapidly in ventilator-capable skilled-nursing facilities (vSNFs) and long-term acute care hospitals (LTACHs). In 2018, a laboratory serving LTACHs in southern California began identifying species of Candida that were detected in urine specimens to enhance surveillance of C auris, and C auris was identified in February 2019 in a patient in an Orange County (OC), California, LTACH. Further investigation identified C auris at 3 associated facilities. Objective: To assess the prevalence of C auris and infection prevention and control (IPC) practices in LTACHs and vSNFs in OC. Design: Point prevalence surveys (PPSs), postdischarge testing for C auris detection, and assessments of IPC were done from March to October 2019. Setting: All LTACHs (n = 3) and vSNFs (n = 14) serving adult patients in OC. Participants: Current or recent patients in LTACHs and vSNFs in OC. Intervention: In facilities where C auris was detected, PPSs were repeated every 2 weeks. Ongoing IPC support was provided. Measurements: Antifungal susceptibility testing and whole-genome sequencing to assess isolate relatedness. Results: Initial PPSs at 17 facilities identified 44 additional patients with C auris in 3 (100%) LTACHs and 6 (43%) vSNFs, with the first bloodstream infection reported in May 2019. By October 2019, a total of 182 patients with C auris were identified by serial PPSs and discharge testing. Of 81 isolates that were sequenced, all were clade III and highly related. Assessments of IPC identified gaps in hand hygiene, transmission-based precautions, and environmental cleaning. The outbreak was contained to 2 facilities by October 2019. Limitation: Acute care hospitals were not assessed, and IPC improvements over time could not be rigorously evaluated. Conclusion: Enhanced laboratory surveillance and prompt investigation with IPC support enabled swift identification and containment of C auris.	[Karmarkar, Ellora N.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA USA; [Karmarkar, Ellora N.] Dept Publ Hlth, Atlanta, GA USA; [O'Donnell, Kathleen; Schan, Douglas; Jacobs, Josh; Cheung, Michele; Mikhail, Lydia; Zahn, Matthew] Orange Cty Hlth Care Agcy, Santa Ana, CA USA; [Prestel, Christopher; Rossow, John; Toda, Mitsuru] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA USA; [Forsberg, Kaitlin] Ctr Dis Control & Prevent & IHRC, Atlanta, GA USA; [Gade, Lalitha; Chow, Nancy; McDermott, Darby; Glowicz, Janet; Gualandi, Nicole; Walters, Maroya; Jacobs-Slifka, Kara; Stone, Nimalie D.; Berkow, Elizabeth L.; Jackson, Brendan R.; Vallabhaneni, Snigdha] Ctr Dis Control & Prevent, Atlanta, GA USA; [Jain, Seema; Bagheri, Hosniyeh; Nelson, Teresa; Khwaja, Zenith; Horwich-Scholefield, Sam; Epson, Erin] Calif Dept Publ Hlth, Richmond, CA USA; [Ruiz, Ryan; Hun, Sopheay; Epson, Erin] Washington State Publ Hlth Labs, Shoreline, WA USA; [Dale, Jennifer L.; Gross, Annastasia; Vagnone, Paula Snippes] Minnesota Dept Hlth Publ Hlth Lab, St Paul, MN USA; [Maruca, Tyler; Klein, Liore] Maryland Dept Hlth, Labs Adm, Baltimore, MD USA; [Brooks, Richard] Ctr Dis Control & Prevent, Atlanta, GA USA; [Brooks, Richard] Maryland Dept Hlth, Infect Dis Epidemiol & Outbreak Response Bur, Baltimore, MD USA; [Chaturvedi, Sudha] New York State Dept Hlth, Albany, NY 11101 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; California Department of Public Health; Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA; State University of New York (SUNY) System	Karmarkar, EN (corresponding author), Calif Dept Publ Hlth, Ctr Dis Control & Prevent, 850 Marina Bay Pkwy, Richmond, CA 94804 USA.	Ellora.Karmarkar@cdph.ca.gov		Rossow, John/0000-0001-9471-7536; Prestel, Christopher/0000-0001-6835-8023; Forsberg, Kaitlin/0000-0002-5779-2446	Centers for Disease Control and Prevention	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Centers for Disease Control and Prevention.	Adams EH, 2018, OPEN FORUM INFECT DI, V5, pS149; Adams E, 2018, EMERG INFECT DIS, V24, P1816, DOI 10.3201/eid2410.180649; Argimon S, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000093; CDC, 2019, ANTIBIOTIC RESISTANC, DOI 10.15620/cdc:82532; Centers for Disease Control and Prevention, ANT SUSC TEST INT; Centers for Disease Control and Prevention, TRACK CAND AUR; Centers for Disease Control and Prevention, GUID DET COL CAND AU; Chow NA, 2020, MBIO, V11, DOI 10.1128/mBio.03364-19; Chow NA, 2018, LANCET INFECT DIS, V18, P1377, DOI 10.1016/S1473-3099(18)30597-8; Clinical and Laboratory Standards Institute, 2008, M27A3 CLIN LAB STAND; Eyre DW, 2018, NEW ENGL J MED, V379, P1322, DOI 10.1056/NEJMoa1714373; Forsberg K, 2019, MED MYCOL, V57, P1, DOI 10.1093/mmy/myy054; Greenko J., 2018, OPEN FORUM INFECT DI, V5, pS594, DOI 10.1093/o fid /ofy210.1695; Herzig CTA, 2016, J AM MED DIR ASSOC, V17, P85, DOI 10.1016/j.jamda.2015.10.017; Jeffery-Smith A, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00029-17; Katz MJ, 2019, INFECT CONT HOSP EP, V40, P95, DOI 10.1017/ice.2018.308; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]; Kurtz S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r12; Leach L, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01223-17; Lee MH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229911; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lockhart SR, 2017, CLIN INFECT DIS, V64, P134, DOI 10.1093/cid/ciw691; Lyman M, 2021, MMWR-MORBID MORTAL W, V70, P1022, DOI 10.15585/mmwr.mm7029a2; McMichael TM, 2020, MMWR-MORBID MORTAL W, V69, P339, DOI 10.15585/mmwr.mm6912e1; Munoz JF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07779-6; Munoz-Price LS, 2009, CLIN INFECT DIS, V49, P438, DOI 10.1086/600391; Ostrowsky B, 2020, MMWR-MORBID MORTAL W, V69, P6, DOI 10.15585/mmwr.mm6901a2; Pacilli M, 2020, CLIN INFECT DIS, V71, pE718, DOI 10.1093/cid/ciaa435; Prestel C, 2021, MMWR-MORBID MORTAL W, V70, P56, DOI 10.15585/mmwr.mm7002e3; Price TK, EMERGENCE CLADE 3 CA, DOI 10/1101/2020.10.26.20214908; Rossow J, 2021, CLIN INFECT DIS, V72, pE753, DOI 10.1093/cid/ciaa1462; Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026; State of California-Health and Human Services Agency California Department of Public Health, 2020, HLTH ADV RES CAND AU; Uppuluri P, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00972-19; Vallabhaneni S, 2016, MMWR-MORBID MORTAL W, V65, P1234, DOI 10.15585/mmwr.mm6544e1	36	3	3	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV	2021	174	11					1554	+		10.7326/M21-2013	http://dx.doi.org/10.7326/M21-2013			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YI2OV	34487450				2023-01-03	WOS:000743694300020
J	Garg, S; Patel, K; Pham, H; Whitaker, M; O'Halloran, A; Milucky, J; Anglin, O; Kirley, PD; Reingold, A; Kawasaki, B; Herlihy, R; Yousey-Hindes, K; Maslar, A; Anderson, EJ; Openo, KP; Weigel, A; Teno, K; Ryan, PA; Monroe, ML; Reeg, L; Kim, S; Como-Sabetti, K; Bye, E; Davis, SS; Eisenberg, N; Muse, A; Barney, G; Bennett, NM; Felsen, CB; Billing, L; Shiltz, J; Sutton, M; Abdullah, N; Talbot, HK; Schaffner, W; Hill, M; Chatelain, R; Wortham, J; Taylor, C; Hall, A; Fry, AM; Kim, L; Havers, FP				Garg, Shikha; Patel, Kadam; Pham, Huong; Whitaker, Michael; O'Halloran, Alissa; Milucky, Jennifer; Anglin, Onika; Kirley, Pam D.; Reingold, Arthur; Kawasaki, Breanna; Herlihy, Rachel; Yousey-Hindes, Kimberly; Maslar, Amber; Anderson, Evan J.; Openo, Kyle P.; Weigel, Andrew; Teno, Kenzie; Ryan, Patricia A.; Monroe, Maya L.; Reeg, Libby; Kim, Sue; Como-Sabetti, Kathryn; Bye, Erica; Davis, Sarah Shrum; Eisenberg, Nancy; Muse, Alison; Barney, Grant; Bennett, Nancy M.; Felsen, Christina B.; Billing, Laurie; Shiltz, Jess; Sutton, Melissa; Abdullah, Nasreen; Talbot, H. Keipp; Schaffner, William; Hill, Mary; Chatelain, Ryan; Wortham, Jonathan; Taylor, Christopher; Hall, Aron; Fry, Alicia M.; Kim, Lindsay; Havers, Fiona P.			Clinical Trends Among US Adults Hospitalized With COVID-19, March to December 2020 A Cross-Sectional Study	ANNALS OF INTERNAL MEDICINE			English	Article							NEW-YORK-CITY; UNITED-STATES; OUTCOMES; RATES	Background: The COVID-19 pandemic has caused substantial morbidity and mortality. Objective: To describe monthly clinical trends among adults hospitalized with COVID-19. Design: Pooled cross-sectional study. Setting: 99 counties in 14 states participating in the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET). Patients: U.S. adults (aged >= 18 years) hospitalized with laboratory-confirmed COVID-19 during 1 March to 31 December 2020. Measurements: Monthly hospitalizations, intensive care unit (ICU) admissions, and in-hospital death rates per 100 000 persons in the population; monthly trends in weighted percentages of interventions, including ICU admission, mechanical ventilation, and vasopressor use, among an age- and site-stratified random sample of hospitalized case patients. Results: Among 116 743 hospitalized adults with COVID-19, the median age was 62 years, 50.7% were male, and 40.8% were non-Hispanic White. Monthly rates of hospitalization (105.3 per 100 000 persons), ICU admission (20.2 per 100 000 persons), and death (11.7 per 100 000 persons) peaked during December 2020. Rates of all 3 outcomes were highest among adults aged 65 years or older, males, and Hispanic or non-Hispanic Black persons. Among 18 508 sampled hospitalized adults, use of remdesivir and systemic corticosteroids increased from 1.7% and 18.9%, respectively, in March to 53.8% and 74.2%, respectively, in December. Frequency of ICU admission, mechanical ventilation, and vasopressor use decreased from March (37.8%, 27.8%, and 22.7%, respectively) to December (20.5%, 12.3%, and 12.8%, respectively); use of noninvasive respiratory support increased from March to December. Limitation: COVID-NET covers approximately 10% of the U.S. population; findings may not be generalizable to the entire country. Conclusion: Rates of COVID-19-associated hospitalization, ICU admission, and death were highest in December 2020, corresponding with the third peak of the U.S. pandemic. The frequency of intensive interventions for management of hospitalized patients decreased over time. These data provide a longitudinal assessment of clinical trends among adults hospitalized with COVID-19 before widespread implementation of COVID-19 vaccines.	[Garg, Shikha; Pham, Huong; Whitaker, Michael; O'Halloran, Alissa; Milucky, Jennifer; Wortham, Jonathan; Taylor, Christopher; Hall, Aron; Fry, Alicia M.; Kim, Lindsay; Havers, Fiona P.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS H24-7, Atlanta, GA 30329 USA; [Garg, Shikha; Wortham, Jonathan; Fry, Alicia M.; Kim, Lindsay; Havers, Fiona P.] US PHS, Rockville, MD USA; [Patel, Kadam; Anglin, Onika] Ctr Dis Control & Prevent & Gen Dynam Informa, Atlanta, GA USA; [Kirley, Pam D.; Reingold, Arthur] Calif Emerging Infect Program, Oakland, CA USA; [Kawasaki, Breanna; Herlihy, Rachel] Colorado Dept Publ Hlth & Environm, Denver, CO USA; [Yousey-Hindes, Kimberly; Maslar, Amber] Yale Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA; [Anderson, Evan J.] Emory Univ, Sch Med & Georgia Emerging Infect Program, Georgia Dept Hlth, Atlanta, GA USA; [Openo, Kyle P.] Georgia Dept Hlth, Georgia Emerging Infect Program, Atlanta, GA USA; [Ryan, Patricia A.; Monroe, Maya L.] Iowa Dept Publ Hlth, Des Moines, IA USA; [Reeg, Libby; Kim, Sue] Michigan Dept Hlth & Human Serv, Lansing, MI USA; [Davis, Sarah Shrum; Eisenberg, Nancy] New Mexico Dept Hlth, Santa Fe, NM USA; [Muse, Alison; Barney, Grant] New York State Dept Hlth, Albany, NY USA; [Bennett, Nancy M.; Felsen, Christina B.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Billing, Laurie; Shiltz, Jess] Ohio Dept Hlth, Columbus, OH USA; [Sutton, Melissa; Abdullah, Nasreen] Oregon Hlth Author, Portland, OR USA; [Talbot, H. Keipp; Schaffner, William] Vanderbilt Univ, Sch Med, Nashville, TN USA; [Hill, Mary; Chatelain, Ryan] Salt Lake Cty Hlth Dept, Salt Lake City, UT USA	Centers for Disease Control & Prevention - USA; United States Public Health Service; California Emerging Infections Program; Colorado Department of Public Health & Environment; Yale University; Emory University; MDHHS - Michigan Department of Health & Human Services; New Mexico Department of Health; State University of New York (SUNY) System; University of Rochester; Vanderbilt University	Garg, S (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS H24-7, Atlanta, GA 30329 USA.	izj7@cdc.gov	Sutton, Melissa/ABH-9659-2020	Sutton, Melissa/0000-0001-8817-8724; , Andy/0000-0002-8775-0466	CDC [CK17-1701]; CDC through Council of State and Territorial Epidemiologists cooperative agreement [NU38OT000297-02-00]	CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); CDC through Council of State and Territorial Epidemiologists cooperative agreement(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	By the CDC through an Emerging Infections Program cooperative agreement (grant CK17-1701) and through a Council of State and Territorial Epidemiologists cooperative agreement (grant NU38OT000297-02-00).	Anesi GL, 2021, ANN INTERN MED, V174, P613, DOI 10.7326/M20-5327; Armstrong RA, 2020, ANAESTHESIA, V75, P1340, DOI 10.1111/anae.15201; Asch DA, 2021, JAMA INTERN MED, V181, P471, DOI 10.1001/jamainternmed.2020.8193; Auld SC, 2020, CRIT CARE MED, V48, pE1382, DOI 10.1097/CCM.0000000000004687; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Boehmer TK, 2020, MMWR-MORBID MORTAL W, V69, P1404, DOI 10.15585/mmwr.mm6939e1; Bravata DM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.34266; Centers for Disease Control and Prevention, INTR COVID 19 RAC ET; Centers for Disease Control and Prevention, 2019, US CENS POP BRIDG RA; Centers for Disease Control and Prevention, 2020, EST DIS BURD COVID 1; Coppadoro A, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03502-y; Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2; Dai CZL, 2021, CLIN INFECT DIS, V73, P2193, DOI [10.1093/cid/ciab154, 10.1101/2020.10.14.20212803]; Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00028-20; Escobar GJ, 2021, ANN INTERN MED, V174, P786, DOI 10.7326/M20-6979; Finelli L, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.6556; Gandhi M, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2026913; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Gold JAW, 2020, MMWR-MORBID MORTAL W, V69, P545, DOI 10.15585/mmwr.mm6918e1; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horwitz LI, 2021, J HOSP MED, V16, P90, DOI 10.12788/jhm.3552; Joo H, 2021, MMWR-MORBID MORTAL W, V70, P212, DOI 10.15585/mmwr.mm7006e2externalicon; Kalil AC, 2021, NEW ENGL J MED, V384, P795, DOI 10.1056/NEJMoa2031994; Karaca-Mandic P, 2021, JAMA INTERN MED, V181, P131, DOI 10.1001/jamainternmed.2020.3857; Kim L, 2021, CLIN INFECT DIS, V72, pE206, DOI 10.1093/cid/ciaa1012; Ko JY, 2021, CLIN INFECT DIS, V72, pE695, DOI 10.1093/cid/ciaa1419; Mackey K, 2021, ANN INTERN MED, V174, P362, DOI 10.7326/M20-6306; Mathews KS, 2021, CRIT CARE MED, V49, P1026, DOI 10.1097/CCM.0000000000004938; Mellado-Artigas R, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03469-w; Munoz-Price LS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.21892; National Institutes of Health, 2020, COVID 19 TREATM GUID; Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001; Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Podewils LJ, 2020, MMWR-MORBID MORTAL W, V69, P1812, DOI [10.15585/mmwr.mm6948a3, 10.15585/mmwr.mm6948a3externalicon]; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Reddy YNV, 2020, AM J KIDNEY DIS, V76, P696, DOI 10.1053/j.ajkd.2020.07.005; Reese H, 2021, CLIN INFECT DIS, V72, pE1010, DOI 10.1093/cid/ciaa1780; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Vahidy FS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245556; Wu H, 2022, INFECT CONT HOSP EP, V43, P1473, DOI 10.1017/ice.2021.280	44	24	24	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT	2021	174	10					1409	+		10.7326/M21-1991	http://dx.doi.org/10.7326/M21-1991			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA9CB	34370517	Green Published, Green Submitted			2023-01-03	WOS:000720935700020
J	Ruple, BA; Godwin, JS; Mesquita, PHC; Osburn, SC; Vann, CG; Lamb, DA; Sexton, CL; Candow, DG; Forbes, SC; Fruge, AD; Kavazis, AN; Young, KC; Seaborne, RA; Sharples, AP; Roberts, MD				Ruple, Bradley A.; Godwin, Joshua S.; Mesquita, Paulo H. C.; Osburn, Shelby C.; Vann, Christopher G.; Lamb, Donald A.; Sexton, Casey L.; Candow, Darren G.; Forbes, Scott C.; Fruge, Andrew D.; Kavazis, Andreas N.; Young, Kaelin C.; Seaborne, Robert A.; Sharples, Adam P.; Roberts, Michael D.			Resistance training rejuvenates the mitochondrial methylome in aged human skeletal muscle	FASEB JOURNAL			English	Article						aging; methylation; mitochondrial DNA; resistance training	DNA METHYLATION; EXERCISE; PROTEIN; TRANSCRIPTION; TRANSLATION; EPIGENETICS; ADAPTATIONS; EXPRESSION; DISEASE; GENOME	Resistance training (RT) dynamically alters the skeletal muscle nuclear DNA methylome. However, no study has examined if RT affects the mitochondrial DNA (mtDNA) methylome. Herein, ten older, Caucasian untrained males (65 +/- 7 y.o.) performed six weeks of full-body RT (twice weekly). Body composition and knee extensor torque were assessed prior to and 72 h following the last RT session. Vastus lateralis (VL) biopsies were also obtained. VL DNA was subjected to reduced representation bisulfite sequencing providing excellent coverage across the similar to 16-kilobase mtDNA methylome (254 CpG sites). Biochemical assays were also performed, and older male data were compared to younger trained males (22 +/- 2 y.o., n = 7, n = 6 Caucasian & n = 1 African American). RT increased whole-body lean tissue mass (p = .017), VL thickness (p = .012), and knee extensor torque (p = .029) in older males. RT also affected the mtDNA methylome, as 63% (159/254) of the CpG sites demonstrated reduced methylation (p < .05). Several mtDNA sites presented a more "youthful" signature in older males after RT in comparison to younger males. The 1.12 kilobase mtDNA D-loop/control region, which regulates replication and transcription, possessed enriched hypomethylation in older males following RT. Enhanced expression of mitochondrial H- and L-strand genes and complex III/IV protein levels were also observed (p < .05). While limited to a shorter-term intervention, this is the first evidence showing that RT alters the mtDNA methylome in skeletal muscle. Observed methylome alterations may enhance mitochondrial transcription, and RT evokes mitochondrial methylome profiles to mimic younger men. The significance of these findings relative to broader RT-induced epigenetic changes needs to be elucidated.	[Ruple, Bradley A.; Godwin, Joshua S.; Mesquita, Paulo H. C.; Osburn, Shelby C.; Vann, Christopher G.; Sexton, Casey L.; Kavazis, Andreas N.; Young, Kaelin C.; Roberts, Michael D.] Auburn Univ, Sch Kinesiol, Auburn, AL 36849 USA; [Lamb, Donald A.; Fruge, Andrew D.] Auburn Univ, Dept Nutr Dietet & Hospitality Management, Auburn, AL 36849 USA; [Candow, Darren G.] Univ Regina, Fac Kinesiol & Hlth Studies, Regina, SK, Canada; [Forbes, Scott C.] Brandon Univ, Fac Educ, Dept Phys Educ Studies, Brandon, MB, Canada; [Young, Kaelin C.; Roberts, Michael D.] Edward Via Coll Osteopath Med, Auburn, AL USA; [Seaborne, Robert A.] Queen Mary Univ London, Ctr Genom & Child Hlth, Barts & London Sch Med & Dent, Blizard Inst, London, England; [Sharples, Adam P.] Norwegian Sch Sport Sci, Inst Phys Performance, Oslo, Norway	Auburn University System; Auburn University; Auburn University System; Auburn University; University of Regina; Brandon University; University of London; Queen Mary University London; Norwegian School of Sport Sciences	Roberts, MD (corresponding author), Auburn Univ, Sch Kinesiol, Mol & Appl Sci Lab, 301 Wire Rd,Off 286, Auburn, AL 36849 USA.; Seaborne, RA (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, Genom & Child Hlth, 4 Newark St, London E1 2AT, England.	robseaborne@googlemail.com; mdr0024@auburn.edu	Mesquita, Paulo H. C./G-4912-2017; Seaborne, Robert/K-7916-2019; Candow, Darren/AFF-7575-2022; Candow, Darren/AAE-9931-2022	Mesquita, Paulo H. C./0000-0003-1112-5493; Seaborne, Robert/0000-0003-2491-3747; Sharples, Adam/0000-0003-1526-9400	Peanut Institute; Research Council of Norway [314157]	Peanut Institute; Research Council of Norway(Research Council of Norway)	The Peanut Institute; The Research Council of Norway, Grant/Award Number: 314157	Bagley JR, 2020, J STRENGTH COND RES, V34, P1574, DOI 10.1519/JSC.0000000000003185; Barres R, 2012, CELL METAB, V15, P405, DOI 10.1016/j.cmet.2012.01.001; Blocquiaux S., 2020, RECURRENT TRAINING R; Brown WM, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2014-094073; D'Aquila P, 2015, EPIGENOMICS-UK, V7, P707, DOI 10.2217/epi.15.30; Day K, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r102; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Goldsmith C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87457-8; Groennebaek T, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00713; Haun CT, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215267; Holloway GP, 2018, CELL REP, V22, P2837, DOI 10.1016/j.celrep.2018.02.069; Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195; Kephart WC, 2016, AMINO ACIDS, V48, P779, DOI 10.1007/s00726-015-2125-8; Kephart WC, 2015, EXP PHYSIOL, V100, P852, DOI 10.1113/EP085160; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Lamb DA, 2020, J INT SOC SPORT NUTR, V17, DOI 10.1186/s12970-020-00397-y; Lamb DA, 2020, AGING-US, V12, P9447, DOI 10.18632/aging.103218; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Ling C, 2007, J CLIN INVEST, V117, P3427, DOI 10.1172/JCI30938; Maasar MF, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.619447; Manev Hari, 2012, Biomol Concepts, V3, P107; Mawlood SK, 2016, AGING-US, V8, P636, DOI 10.18632/aging.100892; Mechta M, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00166; Mesquita PHC, 2020, PHYSIOL REP, V8, DOI 10.14814/phy2.14526; NASS MMK, 1973, J MOL BIOL, V80, P155, DOI 10.1016/0022-2836(73)90239-8; Nitert MD, 2012, DIABETES, V61, P3322, DOI 10.2337/db11-1653; Parise G, 2005, EXP GERONTOL, V40, P173, DOI 10.1016/j.exger.2004.09.002; Parry HA, 2020, INT J SPORTS MED, V41, P349, DOI 10.1055/a-1121-7851; Patil V, 2019, NUCLEIC ACIDS RES, V47, P10072, DOI 10.1093/nar/gkz762; Pillon NJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13869-w; Roberts MD, 2018, PEERJ, V6, DOI 10.7717/peerj.5338; Robinson MM, 2017, CELL METAB, V25, P581, DOI 10.1016/j.cmet.2017.02.009; Ronn T, 2008, DIABETOLOGIA, V51, P1159, DOI 10.1007/s00125-008-1018-8; Sawka MN, 2007, MED SCI SPORT EXER, V39, P377, DOI 10.1249/mss.0b013e31802ca597; Seaborne RA, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.213; Seaborne RA, 2020, EXERC SPORT SCI REV, V48, P188, DOI 10.1249/JES.0000000000000227; Seaborne RA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20287-3; Sharples AP, 2016, AGING CELL, V15, P603, DOI 10.1111/acel.12486; Shokolenko IN, 2017, FRONT BIOSCI-LANDMRK, V22, P835, DOI 10.2741/4520; Sun X, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0590-0; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Turner DC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72730-z; Voisin S., 2020, 315838 BIORXIV; Voisin S, 2020, J CACHEXIA SARCOPENI, V11, P887, DOI 10.1002/jcsm.12556; Wang HQ, 2011, BIOINFORMATICS, V27, P225, DOI 10.1093/bioinformatics/btq650; Wong M, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00279; Wu XJ, 2017, NAT REV GENET, V18, P517, DOI 10.1038/nrg.2017.33; Zykovich A, 2014, AGING CELL, V13, P360, DOI 10.1111/acel.12180	49	11	11	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2021	35	9							e21864	10.1096/fj.202100873RR	http://dx.doi.org/10.1096/fj.202100873RR			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ2LG	34423880	Green Submitted			2023-01-03	WOS:000691122900039
J	Montalli, VAM; de Freitas, PR; Torres, MD; Torres, OD; De Vilhena, DHM; Junqueira, JLC; Napimoga, MH				Martins Montalli, Victor Angelo; de Freitas, Patricia Rejane; Torres, Milenna de Figueiredo; Torres Junior, Oscar de Figueiredo; Moutinho De Vilhena, Dienne Hellen; Cintra Junqueira, Jose Luiz; Napimoga, Marcelo Henrique			Biosafety devices to control the spread of potentially contaminated dispersion particles. New associated strategies for health environments	PLOS ONE			English	Article								Dental procedures produce a large amount of spatter and aerosols that create concern for the transmission of airborne diseases, such as Covid-19. This study established a methodology with the objective of evaluating new associated strategies to reduce the risk of cross-transmission in a health environment by simulating spread of potentially contaminated dispersion particles (PCDP) in the environment. This crossover study, was conducted in a school clinic environment (4 clinics containing 12 dental chairs each). As a positive control group (without barriers), 12 professionals activated at the same time the turbine of dental drill, for one minute, with a bacterial solution (Lactobacillus casei Shirota, 1.5x10(8) CFU/mL), which had been added in the cooling reservoir of the dental equipment. In the experimental groups, the professionals made use of; a) an individual biosafety barrier in dentistry (IBBD) which consists of a metal support covered by a disposable PVC film barrier; b) a Mobile Unit of Disinfection by Ultraviolet-C, consisting of 8 UV lamps-C of 95W, of 304 mu W/cm(2) of irradiance each, connected for 15 minutes (UV-C) and; c) the association between the two methods (IBBD + UV-C). In each clinic, 56 Petri dishes containing MRS agar were positioned on the lamps, benches and on the floor. In addition, plates were placed prior to each test (negative control group) and plates were also placed in the corridor that connects the four clinics. In the groups without barrier and IBBD + UV-C the passive air microorganisms in Petri dishes was also evaluated at times of 30, 60, 90 and 120 minutes after the end of the dental's drill activation. The mean (standard deviation) of CFU of L. casei Shirota for the positive control group was 3905 (1521), while in the experimental groups the mean using the IBBD was 940 (466) CFU, establishing a reduction on average, of 75% (p<0.0001). For the UV-C group, the mean was 260 (309) CFU and the association of the use of IBBD + UV-C promoted an overall average count of 152 (257) CFU, establishing a reduction on average of 93% and 96%, respectively (p<0.0001). Considering these results and the study model used, the individual biosafety barrier associated with UV-C technology showed to be efficient strategies to reduce the dispersion of bioaerosols generated in an environment with high rate of PCDP generation and may be an alternative for the improvement of biosafety in different healthy environment.	[Martins Montalli, Victor Angelo; de Freitas, Patricia Rejane; Torres, Milenna de Figueiredo; Moutinho De Vilhena, Dienne Hellen; Cintra Junqueira, Jose Luiz; Napimoga, Marcelo Henrique] Inst Sao Leopoldo Mandic, Fac Sao Leopoldo Mandic, Campinas, SP, Brazil; [Torres Junior, Oscar de Figueiredo] UVCtec Co, Sao Paulo, SP, Brazil	Faculdade Sao Leopoldo Mandic	Montalli, VAM (corresponding author), Inst Sao Leopoldo Mandic, Fac Sao Leopoldo Mandic, Campinas, SP, Brazil.	victor.montalli@slmandic.edu.br	Napimoga, Marcelo/S-2434-2019; Montalli, Victor/E-7246-2013	Napimoga, Marcelo/0000-0003-4472-365X; Montalli, Victor/0000-0002-1927-7718	CAPES [001]	CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	CAPES #001.	Allison JR, 2021, J ORAL REHABIL, V48, P61, DOI 10.1111/joor.13098; Bogdan A, 2014, J OCCUP ENVIRON HYG, V11, P415, DOI 10.1080/15459624.2013.875183; Boyce JM, 2016, INFECT CONT HOSP EP, V37, P667, DOI 10.1017/ice.2016.35; Buchan AG, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76597-y; Cadnum JL, 2016, INFECT CONT HOSP EP, V37, P555, DOI 10.1017/ice.2015.349; Carling PC, 2008, INFECT CONT HOSP EP, V29, P1035, DOI 10.1086/591940; Chin AWH, 2020, LANCET MICROBE, V1, pE10, DOI [10.1016/S2666-5247(20)30003-3, 10.1016/S2666-5247(20)30095-1]; Choi H, 2022, INFECT CONT HOSP EP, V43, P72, DOI 10.1017/ice.2021.51; Clementini M, 2022, ORAL DIS, V28, P852, DOI 10.1111/odi.13649; Ehtezazi T, 2021, BRIT DENT J, DOI 10.1038/s41415-020-2504-8; Epstein JB, 2021, LANCET INFECT DIS, V21, pE73, DOI 10.1016/S1473-3099(20)30636-8; Han PP, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app11041914; Huang N, 2021, NAT MED, V27, P892, DOI 10.1038/s41591-021-01296-8; Innes N, 2021, J DENT, V105, DOI 10.1016/j.jdent.2020.103556; Ionescu AC, 2020, J AM DENT ASSOC, V151, P660, DOI 10.1016/j.adaj.2020.06.002; Jayaweera M, 2020, ENVIRON RES, V188, DOI 10.1016/j.envres.2020.109819; Knobling B, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.618263; Kowalski W, 2009, ULTRAVIOLET GERMICIDAL IRRADIATION HANDBOOK, P1, DOI 10.1007/978-3-642-01999-9; Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3; Montalli VAM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247029; McDevitt JJ, 2012, APPL ENVIRON MICROB, V78, P1666, DOI 10.1128/AEM.06960-11; MICIK RE, 1969, J DENT RES, V48, P49, DOI 10.1177/00220345690480012401; Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205; MONTALLI Victor Angelo Martins, 2020, RGO, Rev. Gaúch. Odontol., V68, pe20200088, DOI 10.1590/1981-863720200001820200088; Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730; Nicholson WL, 2003, APPL ENVIRON MICROB, V69, P1327, DOI 10.1128/AEM.69.2.1327-1330.2003; Proano A, 2017, CLIN INFECT DIS, V64, P1174, DOI 10.1093/cid/cix039; Shoults DC, 2019, INT J HYG ENVIR HEAL, V222, P111, DOI 10.1016/j.ijheh.2018.08.007; Spagnuolo G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062094; Storm N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79600-8; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1101/2020.03.09.20033217, 10.1056/NEJMc2004973]; Viani Isabella, 2020, Acta Biomed, V91, P92, DOI 10.23750/abm.v91i3-S.9434; Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786; World Health Organization, 2019, PATIENT SAFETY; Zaffina S, 2012, PHOTOCHEM PHOTOBIOL, V88, P1001, DOI 10.1111/j.1751-1097.2012.01151.x	35	2	2	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2021	16	8							e0255533	10.1371/journal.pone.0255533	http://dx.doi.org/10.1371/journal.pone.0255533			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	US1HA	34437589	Green Published, gold			2023-01-03	WOS:000697186000023
J	Xu, HL; Zou, LL; Chen, MB; Wang, H; Shen, WM; Zheng, QH; Cui, WY				Xu, Hua-Lan; Zou, Li-Li; Chen, Mao-bing; Wang, Hua; Shen, Wen-Ming; Zheng, Qi-Han; Cui, Wei-Yan			Efficacy of probiotic adjuvant therapy for irritable bowel syndrome in children: A systematic review and meta-analysis	PLOS ONE			English	Review							DOUBLE-BLIND; ABDOMINAL-PAIN; GUT MICROBIOTA; INTRAEPITHELIAL LYMPHOCYTES; LACTOBACILLUS-GG; GERM-FREE; PATHOGENESIS; MULTICENTER; DISORDERS; IMPROVES	Objective Irritable bowel syndrome (IBS) affects children's quality of life and learning. The purpose of this research was to systematically evaluate the efficacy of probiotic adjuvant therapy for IBS in children. Methods The Web of Science, PubMed, Cochrane Library, EMBASE and Clinical Trials databases were electronically searched for randomized controlled trials (RCTs) published prior to January 2021 exploring the use of probiotic adjuvant therapy for IBS in children. Strict screening and quality evaluations of the eligible articles were performed independently by 2 researchers. Outcome indexes were extracted, and a meta-analysis of the data was performed using RevMan 5.4.1 and STATA 16 software. Finally, the risk of bias in the included studies was assessed with the RCT bias risk assessment tool recommended in the Cochrane Handbook for Systematic Reviews of Interventions (5.1.0). Results A total of nine RCTs were included. In children, probiotics significantly reduced the abdominal pain score (I-2 = 95%, SMD = -1.15, 95% (-2.05, -0.24), P = 0.01) and Subject's Global Assessment of Relief (SGARC) score (I-2 = 95%, MD = -3.84, 95% (-6.49, -1.20), P = 0.004), increased the rate of abdominal pain treatment success (I-2 = 0%, RR = 3.44, 95% (1.73, 6.87), P = 0.0005) and abdominal pain relief (I-2 = 40%, RR = 1.48, 95% (0.96, 2.28), P = 0.08), and reduced the frequency of abdominal pain (I-2 = 2%, MD = -0.82, 95% (-1.57, -0.07), P = 0.03). However, we found that it might not be possible to relieve abdominal pain by increasing the daily intake of probiotics. Conclusions Probiotics are effective at treating abdominal pain caused by IBS in children, however, there was no significant correlation between abdominal pain and the amount of probiotics ingested. More attention should be given to IBS in children, and a standardized evaluation should be adopted.	[Xu, Hua-Lan; Wang, Hua; Cui, Wei-Yan] Jiangsu Univ, Dept ICU, Wujin People Hosp, Changzhou, Jiangsu, Peoples R China; [Xu, Hua-Lan; Zou, Li-Li; Chen, Mao-bing; Wang, Hua; Shen, Wen-Ming; Zheng, Qi-Han; Cui, Wei-Yan] Xuzhou Med Univ, Wujin Clin Coll, Changzhou, Jiangsu, Peoples R China; [Zou, Li-Li] Jiangsu Univ, Dept Nursing, Wujin People Hosp, Changzhou, Jiangsu, Peoples R China; [Chen, Mao-bing; Shen, Wen-Ming; Zheng, Qi-Han] Jiangsu Univ, Dept Emergency, Wujin People Hosp, Changzhou, Jiangsu, Peoples R China	Jiangsu University; Xuzhou Medical University; Jiangsu University; Jiangsu University	Wang, H (corresponding author), Jiangsu Univ, Dept ICU, Wujin People Hosp, Changzhou, Jiangsu, Peoples R China.; Wang, H (corresponding author), Xuzhou Med Univ, Wujin Clin Coll, Changzhou, Jiangsu, Peoples R China.	wanghua2249@163.com			Changzhou Applied Basic Research Project, Changzhou City, Jiangsu Province, China [CJ20200005]	Changzhou Applied Basic Research Project, Changzhou City, Jiangsu Province, China	This work was funded by the Changzhou Applied Basic Research Project (no. CJ20200005 to WMS), Changzhou City, Jiangsu Province, China.	Agerholm-Larsen L, 2000, EUR J CLIN NUTR, V54, P856, DOI 10.1038/sj.ejcn.1601104; Algieri F, 2021, EUR J NUTR, V60, P2537, DOI 10.1007/s00394-020-02441-8; Allegretti JR, 2019, LANCET, V394, P420, DOI 10.1016/S0140-6736(19)31266-8; Augusteijn HEM, 2019, PSYCHOL METHODS, V24, P116, DOI 10.1037/met0000197; Basturk A, 2016, TURK J GASTROENTEROL, V27, P439, DOI 10.5152/tjg.2016.16301; Bausserman M, 2005, J PEDIATR-US, V147, P197, DOI 10.1016/j.jpeds.2005.05.015; Chey WD, 2015, JAMA-J AM MED ASSOC, V313, P949, DOI 10.1001/jama.2015.0954; Chiou E, 2010, EXPERT REV GASTROENT, V4, P293, DOI [10.1586/egh.10.28, 10.1586/EGH.10.28]; Cukrowska B, 2001, IMMUNOBIOLOGY, V204, P425, DOI 10.1078/0171-2985-00052; Cukrowska B, 2017, WORLD J GASTROENTERO, V23, P7505, DOI 10.3748/wjg.v23.i42.7505; Ding L, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016068; Ding X, 2019, DRUG SAFETY, V42, P869, DOI 10.1007/s40264-019-00809-2; Drossman Douglas A, 2016, Gastroenterology, DOI 10.1053/j.gastro.2016.02.032; Egan CE, 2011, MUCOSAL IMMUNOL, V4, P658, DOI 10.1038/mi.2011.31; Ford AC, 2017, NEW ENGL J MED, V376, P2566, DOI 10.1056/NEJMra1607547; Ford AC, 2014, AM J GASTROENTEROL, V109, P1350, DOI 10.1038/ajg.2014.148; Francavilla R, 2010, PEDIATRICS, V126, pE1445, DOI 10.1542/peds.2010-0467; Gareau MG, 2010, NAT REV GASTRO HEPAT, V7, P503, DOI 10.1038/nrgastro.2010.117; Gawronska A, 2007, ALIMENT PHARM THER, V25, P177, DOI 10.1111/j.1365-2036.2006.03175.x; Geuking MB, 2013, CELL RES, V23, P1339, DOI 10.1038/cr.2013.125; Giannetti E, 2017, J CLIN GASTROENTEROL, V51, pE5, DOI 10.1097/MCG.0000000000000528; Guandalini S, 2010, J PEDIATR GASTR NUTR, V51, P24, DOI 10.1097/MPG.0b013e3181ca4d95; Herrador BRG, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1701-x; Hill C, 2014, NAT REV GASTRO HEPAT, V11, P506, DOI 10.1038/nrgastro.2014.66; Khanna R, 2014, J CLIN GASTROENTEROL, V48, P505, DOI 10.1097/MCG.0b013e3182a88357; Kianifar Hamidreza, 2015, Electron Physician, V7, P1255, DOI 10.14661/1255; Kozakova H, 2016, CELL MOL IMMUNOL, V13, P251, DOI 10.1038/cmi.2015.09; Lacy BE, 2016, GASTROENTEROLOGY, V150, P1393, DOI 10.1053/j.gastro.2016.02.031; Laino J, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/7983217; Li B, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00332; Martin R, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-71; Pabst O, 2012, NAT REV IMMUNOL, V12, P821, DOI 10.1038/nri3322; Rahmani Parisa, 2020, Clin Exp Pediatr, V63, P485, DOI 10.3345/cep.2019.01613; Rijkers GT, 2011, BRIT J NUTR, V106, P1291, DOI 10.1017/S000711451100287X; Shogbesan O, 2018, CAN J GASTROENTEROL, V2018, DOI 10.1155/2018/1394379; Sideri S, 2018, J CLIN EPIDEMIOL, V100, P103, DOI 10.1016/j.jclinepi.2018.01.003; Slashinski MJ, 2012, BMC MED ETHICS, V13, DOI 10.1186/1472-6939-13-28; Sudha MR, 2018, BENEF MICROBES, V9, P563, DOI [10.3920/BM2017.0129, 10.3920/bm2017.0129]; Tlaskalova-Hogenova H, 2011, CELL MOL IMMUNOL, V8, P110, DOI 10.1038/cmi.2010.67; Tokuhara D, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.700058; Vilela SFG, 2015, VIRULENCE, V6, P29, DOI 10.4161/21505594.2014.981486; Vinderola G, 2021, ARCH ARGENT PEDIATR, V119, P56, DOI 10.5546/aap.2021.eng.56; Vivinus-Nebot M, 2014, GUT, V63, P744, DOI 10.1136/gutjnl-2012-304066; Wang JM, 2021, CHIN MED-UK, V16, DOI 10.1186/s13020-020-00417-8; Weidler Erica M, 2017, Clin Gastroenterol Hepatol, V15, P140, DOI 10.1016/j.cgh.2016.08.021; Weil AA, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv005; Xu HY, 2021, EUR J NUTR, V60, P2553, DOI 10.1007/s00394-020-02437-4	47	5	5	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2021	16	8							e0255160	10.1371/journal.pone.0255160	http://dx.doi.org/10.1371/journal.pone.0255160			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6JM	34358238	gold, Green Published			2023-01-03	WOS:000685266400013
J	Winitchaikul, T; Sawong, S; Surangkul, D; Srikummool, M; Somran, J; Pekthong, D; Kamonlakorn, K; Nangngam, P; Parhira, S; Srisawang, P				Winitchaikul, Thanwarat; Sawong, Suphunwadee; Surangkul, Damratsamon; Srikummool, Metawee; Somran, Julintorn; Pekthong, Dumrongsak; Kamonlakorn, Kittiya; Nangngam, Pranee; Parhira, Supawadee; Srisawang, Piyarat			Calotropis gigantea stem bark extract induced apoptosis related to ROS and ATP production in colon cancer cells	PLOS ONE			English	Article							EHRLICHS ASCITES-CARCINOMA; FLAVONOID CONTENT; ROOT BARK; 5-FLUOROURACIL; CARDENOLIDES; L.; IDENTIFICATION; MITOCHONDRIA; MECHANISMS; GLYCOSIDES	Conventional chemotherapeutic agents for colorectal cancer (CRC) cause systemic side effects and eventually become less efficacious owing to the development of drug resistance in cancer cells. Therefore, new therapeutic regimens have focused on the use of natural products. The anticancer activity of several parts of Calotropis gigantea has been reported; however, the effects of its stem bark extract on inhibition of cancer cell proliferation have not yet been examined. In this study, the anticancer activity of C. gigantea stem bark extract, both alone and in combination with 5-fluorouracil (5-FU), was evaluated. A crude ethanolic extract was prepared from dry, powdered C. gigantea barks using 95% ethanol. This was then partitioned to obtain dichloromethane (CGDCM), ethyl acetate, and water fractions. Quantitative analysis of the constituent secondary metabolites and calotropin was performed. These fractions exhibited cytotoxicity in HCT116 and HT-29 cells, with CGDCM showing the highest potency in both the cell lines. A combination of CGDCM and 5-FU significantly enhanced the cytotoxic effect. Moreover, the resistance of normal fibroblast, HFF-1, cells to this combination demonstrated its safety in normal cells. The combination significantly enhanced apoptosis through the mitochondria-dependent pathway. Additionally, the combination reduced adenosine triphosphate production and increased the production of reactive oxygen species, demonstrating the mechanisms involved in the induction of apoptosis. Our results suggest that CGDCM is a promising anti-cancer agent and may enhance apoptosis induction by 5-FU in the treatment of CRC, while minimizing toxicity toward healthy cells.	[Winitchaikul, Thanwarat; Sawong, Suphunwadee; Srisawang, Piyarat] Naresuan Univ, Dept Physiol, Fac Med Sci, Phitsanulok, Thailand; [Surangkul, Damratsamon; Srikummool, Metawee] Naresuan Univ, Dept Biochem, Fac Med Sci, Phitsanulok, Thailand; [Somran, Julintorn] Naresuan Univ, Dept Pathol, Fac Med, Phitsanulok, Thailand; [Pekthong, Dumrongsak] Naresuan Univ, Fac Pharmaceut Sci, Dept Pharm Practice, Phitsanulok, Thailand; [Kamonlakorn, Kittiya] Naresuan Univ, Fac Pharmaceut Sci, Dept Pharmaceut Chem & Pharmacognosy, Phitsanulok, Thailand; [Nangngam, Pranee] Naresuan Univ, Dept Biol, Fac Sci, Phitsanulok, Thailand; [Parhira, Supawadee] Naresuan Univ, Fac Pharmaceut Sci, Dept Pharmaceut Technol, Phitsanulok, Thailand	Naresuan University; Naresuan University; Naresuan University; Naresuan University; Naresuan University; Naresuan University; Naresuan University	Srisawang, P (corresponding author), Naresuan Univ, Dept Physiol, Fac Med Sci, Phitsanulok, Thailand.; Parhira, S (corresponding author), Naresuan Univ, Fac Pharmaceut Sci, Dept Pharmaceut Technol, Phitsanulok, Thailand.	supawadeep@nu.ac.th; piyarats@nu.ac.th		Parhira, Supawadee/0000-0002-2077-5888	Thailand Science Research and Innovation [R2564B007]; Department of Physiology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand [61063417]	Thailand Science Research and Innovation; Department of Physiology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand	SP and PS received grant supported from Thailand Science Research and Innovation, [Grant NO. R2564B007]. TW received the graduate thesis funding from the Department of Physiology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand [Grant NO. 61063417]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Attia YM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35083-2; Baba SA, 2015, J TAIBAH UNIV SCI, V9, P449, DOI 10.1016/j.jtusci.2014.11.001; Bianchi G, 2018, CARCINOGENESIS, V39, P1141, DOI 10.1093/carcin/bgy076; Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532; Cai-Xia Y., 2017, AM J ORG CHEM, V7, P13; Chang CL, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/984295; Chen SJ, 2020, NUTR CANCER, V72, P209, DOI 10.1080/01635581.2019.1622739; Cheng ZY, 2020, ENVIRON TOXICOL, V35, P911, DOI 10.1002/tox.22927; Davoodi H, 2013, IRAN J PHARM RES, V12, P453; Erkisa M, 2020, BIOCHIMIE, V175, P159, DOI 10.1016/j.biochi.2020.05.010; Focaccetti C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115686; Giampazolias E, 2016, FEBS J, V283, P803, DOI 10.1111/febs.13603; Grada A, 2017, J INVEST DERMATOL, V137, pE11, DOI 10.1016/j.jid.2016.11.020; Habib MR, 2011, ASIAN PAC J TROP MED, V4, P786, DOI 10.1016/S1995-7645(11)60194-6; Habib MR, 2013, PHARMACOL REP, V65, P761, DOI 10.1016/S1734-1140(13)71057-0; Habib MR, 2010, J APPL BIOMED, V8, P47, DOI 10.2478/v10136-009-0007-7; Huang YH, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12451; Khan M, 2015, INT J BIOL SCI, V11, P1100, DOI 10.7150/ijbs.11595; Kharat KR, 2019, IRAN J MED SCI, V44, P483, DOI 10.30476/ijms.2019.44966; Kumar N. S., 2015, Research Journal of Phytochemistry, V9, P137, DOI 10.3923/rjphyto.2015.137.143; Lee J., 2018, CALOTROPIS GIGANTEA; Lee JH, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-018-1008-7; da Silva LAL, 2015, PHARMACOGN MAG, V11, P96, DOI 10.4103/0973-1296.149721; Li B, 2014, ONCOTARGET, V5, P11576, DOI 10.18632/oncotarget.2596; Li HL, 2018, FOOD CHEM TOXICOL, V119, P169, DOI 10.1016/j.fct.2018.04.054; Li XX, 2020, BIOMED PHARMACOTHER, V124, DOI 10.1016/j.biopha.2020.109852; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Luo M, 2018, BIOMED PHARMACOTHER, V106, P593, DOI 10.1016/j.biopha.2018.06.077; Mhaidat NM, 2014, ONCOL LETT, V8, P699, DOI 10.3892/ol.2014.2211; Miura Koh, 2010, Cancers (Basel), V2, P1717, DOI 10.3390/cancers2031717; Mutiah R., 2016, ALCHEMY, V5, P1, DOI DOI 10.18860/AL.V5I1.3690; Mutiah R, 2016, INT J PHARM CHEM RES, V8, P167; Mutiah R, 2017, INT J PHARM PHARM SC, V9, P83; Mutiah Roihatul, 2018, Asian Pac J Cancer Prev, V19, P1457, DOI 10.22034/APJCP.2018.19.6.1457; Ng PL, 2014, J ZHEJIANG UNIV-SC B, V15, P692, DOI 10.1631/jzus.B1300303; Oh SH, 2018, FOOD CHEM TOXICOL, V121, P326, DOI 10.1016/j.fct.2018.09.008; Organization WH, 2020, WHO REP CANC SETT PR; Oven Ustaalioglu BB., 2018, CAPECITABINE CISPLAT, DOI [10.4103/0973-1482.183548, DOI 10.4103/0973-1482.183548]; Parhira S, 2016, J ETHNOPHARMACOL, V194, P930, DOI 10.1016/j.jep.2016.10.070; Parhira S, 2014, SCI REP-UK, V4, DOI 10.1038/srep04748; Park C, 2019, CANCERS, V11, DOI 10.3390/cancers11101494; Park HY, 2014, CHEMBIOCHEM, V15, P872, DOI 10.1002/cbic.201300786; Patel RK, 2015, INT J PHARM PHARM SC, V7; Pederson PJ, 2020, J NAT PROD, V83, P2269, DOI 10.1021/acs.jnatprod.0c00423; Khang PV, 2014, NAT PROD RES, V28, P1191, DOI 10.1080/14786419.2014.909419; Lopez EPF, 2019, ARCH ORAL BIOL, V101, P8, DOI 10.1016/j.archoralbio.2019.02.018; Rascon-Valenzuela LA, 2016, J ETHNOPHARMACOL, V193, P303, DOI 10.1016/j.jep.2016.08.022; Regasini LO, 2009, J CHIL CHEM SOC, V54, P218, DOI 10.4067/S0717-97072009000300004; Satari A, 2019, ADV PHARM BULL, V9, P462, DOI 10.15171/apb.2019.055; Seema Singh, 2013, International Research Journal of Pharmaceutical and Applied Sciences, V3, P1; Shi Y, 2020, J CELL MOL MED, V24, P760, DOI 10.1111/jcmm.14785; Soebagjo HD., 2019, RES J PHARM TECHNOLO, V12, P1307; Song W, 2017, BIOMED PHARMACOTHER, V89, P845, DOI 10.1016/j.biopha.2017.01.062; Sun M, 2017, ONCOTARGET, V8, P32807, DOI 10.18632/oncotarget.16454; Sur S, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0447-y; Tao T, 2019, J CELL PHYSIOL, V234, P3088, DOI 10.1002/jcp.27129; Tatsumi T, 2003, CARDIOVASC RES, V59, P428, DOI 10.1016/S0008-6363(03)00391-2; Tecza Karolina, 2018, Oncotarget, V9, P9114, DOI 10.18632/oncotarget.24148; THAKUR S, 1984, PHYTOCHEMISTRY, V23, P2085, DOI 10.1016/S0031-9422(00)84985-7; Tofighi Z, 2016, RES J PHARMACOGN, V3, P25; Van der Jeught K, 2018, WORLD J GASTROENTERO, V24, P3834, DOI 10.3748/wjg.v24.i34.3834; Van Quaquebeke E, 2005, J MED CHEM, V48, P849, DOI 10.1021/jm049405a; Wang H., 2021, RHEUMATOLOGY, DOI [10.1093/rheumatology/keab018, DOI 10.1093/rheumatology/keab018]; Wang ZN, 2008, MOLECULES, V13, P3033, DOI 10.3390/molecules13123033; You HY, 2013, STEROIDS, V78, P1029, DOI 10.1016/j.steroids.2013.06.002; Zhang M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127386; Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551; Zhang P., 2017, CLIN CANCER RES, V36, P1; Zhou LM, 2019, ONCOTARGETS THER, V12, P4047, DOI 10.2147/OTT.S200873	69	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2021	16	8							e0254392	10.1371/journal.pone.0254392	http://dx.doi.org/10.1371/journal.pone.0254392			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6IR	34343190	gold, Green Published			2023-01-03	WOS:000685264200021
J	Depelsenaire, ACI; Witham, K; Veitch, M; Wells, JW; Anderson, CD; Lickliter, JD; Rockman, S; Bodle, J; Treasure, P; Hickling, J; Fernando, GJP; Forster, AH				Depelsenaire, Alexandra C. I.; Witham, Katey; Veitch, Margaret; Wells, James W.; Anderson, Christopher D.; Lickliter, Jason D.; Rockman, Steve; Bodle, Jesse; Treasure, Peter; Hickling, Julian; Fernando, Germain J. P.; Forster, Angus H.			Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial	PLOS ONE			English	Article							ACCEPTABILITY; CELLS	Microarray patches (MAPs) have the potential to be a safer, more acceptable, easier to use and more cost-effective method for administration of vaccines when compared to the needle and syringe. Since MAPs deliver vaccine to the dermis and epidermis, a degree of local immune response at the site of application is expected. In a phase 1 clinical trial (ACTRN 12618000112268), the Vaxxas high-density MAP (HD-MAP) was used to deliver a monovalent, split inactivated influenza virus vaccine into the skin. HD-MAP immunisation led to significantly enhanced humoral responses on day 8, 22 and 61 compared with IM injection of a quadrivalent commercial seasonal influenza vaccine (Afluria Quadrivalent (R)). Here, the aim was to analyse cellular responses to HD-MAPs in the skin of trial subjects, using flow cytometry and immunohistochemistry. HD-MAPs were coated with a split inactivated influenza virus vaccine (A/Singapore/GP1908/2015 [H1N1]), to deliver 5 mu g haemagglutinin (HA) per HD-MAP. Three HD-MAPs were applied to the volar forearm (FA) of five healthy volunteers (to achieve the required 15 mu g HA dose), whilst five control subjects received three uncoated HD-MAPs (placebo). Local skin response was recorded for over 61 days and haemagglutination inhibition antibody titres (HAI) were assessed on days 1, 4, 8, 22, and 61. Skin biopsies were taken before (day 1), and three days after HD-MAP application (day 4) and analysed by flow-cytometry and immunohistochemistry to compare local immune subset infiltration. HD-MAP vaccination with 15 mu g HA resulted in significant HAI antibody titres compared to the placebo group. Application of uncoated placebo HD-MAPs resulted in mild erythema and oedema in most subjects, that resolved by day 4 in 80% of subjects. Active, HA-coated HD-MAP application resulted in stronger erythema responses on day 4, which resolved between days 22-61. Overall, these erythema responses were accompanied by an influx of immune cells in all subjects. Increased cell infiltration of CD3(+), CD4(+), CD8(+) T cells as well as myeloid CD11b(+) CD11c(+) and non-myeloid CD11b(-) dendritic cells were observed in all subjects, but more pronounced in active HD-MAP groups. In contrast, CD19(+)/CD20(+) B cell counts remained unchanged. Key limitations include the use of an influenza vaccine, to which the subjects may have had previous exposure. Different results might have been obtained with HD-MAPs inducing a primary immune response. In conclusion, influenza vaccine administered to the forearm (FA) using the HD-MAP was well-tolerated and induced a mild to moderate skin response with lymphocytic infiltrate at the site of application.	[Depelsenaire, Alexandra C. I.; Witham, Katey; Fernando, Germain J. P.; Forster, Angus H.] Vaxxas Pty Ltd, Brisbane, Qld, Australia; [Veitch, Margaret; Wells, James W.] Univ Queensland, Diamantina Inst, Woolloongabba, Qld, Australia; [Anderson, Christopher D.] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden; [Lickliter, Jason D.] Nucleus Network Pty Ltd, Melbourne, Vic, Australia; [Rockman, Steve; Bodle, Jesse] Seqirus Pty Ltd, Parkville, Vic, Australia; [Rockman, Steve] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Treasure, Peter] Peter Treasure Stat Serv Ltd, Kings Lynn, England; [Hickling, Julian] Tandem Ltd, Cambridge, England; [Fernando, Germain J. P.] Univ Queensland, Fac Sci, Sch Chem & Mol Biosci, Brisbane, Qld, Australia	University of Queensland; Linkoping University; University of Melbourne; University of Queensland	Forster, AH (corresponding author), Vaxxas Pty Ltd, Brisbane, Qld, Australia.	aforster@vaxxas.com	Wells, James W./C-7480-2011; Fernando, Germain/C-3733-2009	Wells, James W./0000-0002-9618-6940; Depelsenaire, Alexandra/0000-0001-6743-0097; Fernando, Germain/0000-0003-3260-0548	Vaxxas Pty Ltd, Brisbane QLD Australia; Vaxxas Pty Ltd	Vaxxas Pty Ltd, Brisbane QLD Australia; Vaxxas Pty Ltd	The study was entirely funded by Vaxxas Pty Ltd, Brisbane QLD 4102 Australia, www.vaxxas.com.Vaxxas, through its employees, was therefore directly involved in the study design, data collection, analysis as well as preparation of his manuscript for publication -AHF is an employee of Vaxxas Pty Ltd and is the corresponding author of the manuscript. AHF was directly involved in the study design, data collection, as well as preparation of his manuscript for publication and decision to publish. -ACID and KW are the joint-lead authors of this manuscript and employees of Vaxxas Pty Ltd, and were directly involved in the study design, sample processing, data collection, analysis as well as preparation of his manuscript for publication. ACID is an inventor on patents licensed to Vaxxas Pty Ltd. -JWW, CDA, PT, JH and GJPF received consulting fees from Vaxxas Pty Ltd to support their contribution to this research. They were directly involved in the study design, data collection, data interpretation as well as preparation of the manuscript for publication. PT was involved in data analysis, data interpretation as well as editing of the manuscript for publication. -JWW and MV are employees of the University of Queensland. They carried out assay development on a contract basis paid for by Vaxxas Pty Ltd, and were directly involved in the experimental design, sample processing, data analysis as well as preparation of the manuscript for publication. -JDL is an employee of Nucleus Network, which carried out the clinical trial (trial site) on a contract basis paid for by Vaxxas Pty Ltd. JDL was directly involved in sample processing, data interpretation as well as preparation of the manuscript for publication. -SR and JB are employed by Seqirus, which provided Vaxxas with vaccine for the clinical trial. They were involved in preparation of his manuscript for publication but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bachy V, 2013, P NATL ACAD SCI USA, V110, P3041, DOI 10.1073/pnas.1214449110; Becker PD, 2015, VACCINE, V33, P4691, DOI 10.1016/j.vaccine.2015.04.046; BRYAN JP, 1992, CLIN INFECT DIS, V14, P697, DOI 10.1093/clinids/14.3.697; Carey JB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022442; Chen XY, 2014, J CONTROL RELEASE, V192, P310, DOI 10.1016/j.jconrel.2014.08.006; Chua BY, 2015, MBIO, V6, DOI 10.1128/mBio.01024-15; Crichton ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep27217; Depelsenaire ACI, 2014, J INVEST DERMATOL, V134, P2361, DOI 10.1038/jid.2014.174; Fernando GJP, 2018, VACCINE, V36, P3779, DOI 10.1016/j.vaccine.2018.05.053; Fernando GJP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010266; Forster AH, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003024; Griffin P, 2017, VACCINE, V35, P6676, DOI 10.1016/j.vaccine.2017.10.021; Hirobe S, 2015, BIOMATERIALS, V57, P50, DOI 10.1016/j.biomaterials.2015.04.007; Hyer R, 2018, VACCINE, V36, P2604, DOI 10.1016/j.vaccine.2018.03.067; Jones S, 2009, VACCINE, V27, P2506, DOI 10.1016/j.vaccine.2009.02.061; Kabashima K, 2019, NAT REV IMMUNOL, V19, P19, DOI 10.1038/s41577-018-0084-5; Kessels J, 2019, VACCINE, V37, pA107, DOI 10.1016/j.vaccine.2019.01.041; Liu Y, 2018, CRIT REV IMMUNOL, V38, P79, DOI 10.1615/CritRevImmunol.2018025653; Mahnke YD, 2013, EUR J IMMUNOL, V43, P2797, DOI 10.1002/eji.201343751; Marra F, 2013, INFLUENZA OTHER RESP, V7, P584, DOI 10.1111/irv.12000; Marshall S, 2016, HUM VACC IMMUNOTHER, V12, P2975, DOI 10.1080/21645515.2016.1171440; Martin MD, 2012, MBIO, V3, DOI 10.1128/mBio.00012-12; Ng HI, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0134-4; Ng HI, 2012, J CONTROL RELEASE, V162, P477, DOI 10.1016/j.jconrel.2012.07.024; Norman JJ, 2014, VACCINE, V32, P1856, DOI 10.1016/j.vaccine.2014.01.076; Okayasu H, 2017, J INFECT DIS, V216, pS161, DOI 10.1093/infdis/jix038; Pearson FE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067888; Rattanapak T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089503; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P3203, DOI 10.1001/jama.254.22.3203; Rock KL, 2008, ANNU REV PATHOL-MECH, V3, P99, DOI 10.1146/annurev.pathmechdis.3.121806.151456; Roukens AH, 2010, VACCINE, V28, P4288, DOI 10.1016/j.vaccine.2010.04.029; Rouphael NG, 2017, LANCET, V390, P649, DOI 10.1016/S0140-6736(17)30575-5; Salimi M, 2016, CLIN EXP DERMATOL, V41, P552, DOI 10.1111/ced.12802; Tozuka M, 2016, J DERMATOL SCI, V82, P38, DOI 10.1016/j.jdermsci.2015.11.008; WARRELL MJ, 1983, LANCET, V2, P301	35	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2021	16	7							e0255282	10.1371/journal.pone.0255282	http://dx.doi.org/10.1371/journal.pone.0255282			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6CU	34329337	Green Published, gold			2023-01-03	WOS:000685248600029
J	Habibi, M; Taheri, G				Habibi, Mahnaz; Taheri, Golnaz			Topological network based drug repurposing for coronavirus 2019	PLOS ONE			English	Article							COVID-19	The COVID-19 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become the current health concern and threat to the entire world. Thus, the world needs the fast recognition of appropriate drugs to restrict the spread of this disease. The global effort started to identify the best drug compounds to treat COVID-19, but going through a series of clinical trials and our lack of information about the details of the virus's performance has slowed down the time to reach this goal. In this work, we try to select the subset of human proteins as candidate sets that can bind to approved drugs. Our method is based on the information on human-virus protein interaction and their effect on the biological processes of the host cells. We also define some informative topological and statistical features for proteins in the protein-protein interaction network. We evaluate our selected sets with two groups of drugs. The first group contains the experimental unapproved treatments for COVID-19, and we show that from 17 drugs in this group, 15 drugs are approved by our selected sets. The second group contains the external clinical trials for COVID-19, and we show that 85% of drugs in this group, target at least one protein of our selected sets. We also study COVID-19 associated protein sets and identify proteins that are essential to disease pathology. For this analysis, we use DAVID tools to show and compare disease-associated genes that are contributed between the COVID-19 comorbidities. Our results for shared genes show significant enrichment for cardiovascular-related, hypertension, diabetes type 2, kidney-related and lung-related diseases. In the last part of this work, we recommend 56 potential effective drugs for further research and investigation for COVID-19 treatment. Materials and implementations are available at: .https://github.com/ MahnazHabibi/Drug-repurposing.	[Habibi, Mahnaz] Islamic Azad Univ, Dept Math, Qazvin Branch, Qazvin, Iran; [Taheri, Golnaz] KTH Royal Inst Technol, Dept Elect Engn & Comp Sci, Stockholm, Sweden; [Taheri, Golnaz] Sci Life Lab, Stockholm, Sweden	Islamic Azad University; Royal Institute of Technology	Habibi, M (corresponding author), Islamic Azad Univ, Dept Math, Qazvin Branch, Qazvin, Iran.	mhabibi@ipm.ir		Habibi, Mahnaz/0000-0002-8969-2706				Alanis-Lobato G, 2017, NUCLEIC ACIDS RES, V45, pD408, DOI 10.1093/nar/gkw985; Alonso-Lopez D, 2019, DATABASE-OXFORD, DOI 10.1093/database/baz005; Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049; Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055; Chatr-aryamontri A, 2017, NUCLEIC ACIDS RES, V45, pD369, DOI 10.1093/nar/gkw1102; Cheng FX, 2019, METHODS MOL BIOL, V1878, P243, DOI 10.1007/978-1-4939-8868-6_15; Cheng FX, 2016, TRENDS MOL MED, V22, P919, DOI 10.1016/j.molmed.2016.09.006; Cheng FX, 2017, BRIEF BIOINFORM, V18, P682, DOI 10.1093/bib/bbw051; Durez P, 2022, ACTA CLIN BELG, V77, P233, DOI 10.1080/17843286.2020.1812830; Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1; Galvez Romero JL., 2020, JOU INT MED, V286, P906; Ghandili S, 2020, BLOOD ADV, V4, P5936, DOI 10.1182/bloodadvances.2020002543; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9; Gysi DM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2025581118; Habibi M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88427-w; Hashimoto H, 2021, J DERMATOL, V48, pE122, DOI 10.1111/1346-8138.15696; Hazeldine J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.680134; Luck K, 2020, NATURE, V580, P402, DOI 10.1038/s41586-020-2188-x; Marchetti M, 2020, ANN HEMATOL, V99, P1701, DOI 10.1007/s00277-020-04138-8; Morales-Ortega A, 2021, J INFECTION, V82, P213, DOI 10.1016/j.jinf.2021.02.002; Patil Ashwini, 2005, Biophysics (Nagoya-shi), V1, P21, DOI 10.2142/biophysics.1.21; Perisic O, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10091346; Quaglino P., 2020, ANTI BRAF ANTIMEK TA, V17, P759; Reznik SE, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.105055; Salgado-Benvindo C, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00900-20; Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230; Serebrovska ZO, 2020, ACTA PHARMACOL SIN, V41, P1539, DOI 10.1038/s41401-020-00554-8; Shah K, 2020, DIABETES METAB SYND, V14, P1143, DOI 10.1016/j.dsx.2020.07.003; Sharma S, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108183; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Smith T., 2020, COVID 19 DRUG THERAP; Taheri G, 2013, J BIOINF COMPUT BIOL, V11, DOI 10.1142/S0219720013410084; Tong S, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106114; Villani A, 2020, J AM ACAD DERMATOL, V82, pE205, DOI 10.1016/j.jaad.2020.03.057; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037; Wuchty S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011796; Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37	38	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2021	16	7							e0255270	10.1371/journal.pone.0255270	http://dx.doi.org/10.1371/journal.pone.0255270			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6CQ	34324563	Green Published, gold			2023-01-03	WOS:000685248200073
J	Hamel, C; Garritty, C; Hersi, M; Butler, C; Esmaeilisaraji, L; Rice, D; Straus, S; Skidmore, B; Hutton, B				Hamel, Candyce; Garritty, Chantelle; Hersi, Mona; Butler, Claire; Esmaeilisaraji, Leila; Rice, Danielle; Straus, Sharon; Skidmore, Becky; Hutton, Brian			Models of provider care in long-term care: A rapid scoping review	PLOS ONE			English	Review							NURSING-HOME RESIDENTS; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; HEALTH-CARE; PALLIATIVE CARE; ORAL-HEALTH; REDUCE HOSPITALIZATIONS; OUTREACH SERVICE; FOOT MASSAGE; DEMENTIA	Introduction One of the current challenges in long-term care homes (LTCH) is to identify the optimal model of care, which may include specialty physicians, nursing staff, person support workers, among others. There is currently no consensus on the complement or scope of care delivered by these providers, nor is there a repository of studies that evaluate the various models of care. We conducted a rapid scoping review to identify and map what care provider models and interventions in LTCH have been evaluated to improve quality of life, quality of care, and health outcomes of residents. Methods We conducted this review over 10-weeks of English language, peer-reviewed studies published from 2010 onward. Search strategies for databases (e.g., MEDLINE) were run on July 9, 2020. Studies that evaluated models of provider care (e.g., direct patient care), or interventions delivered to facility, staff, and residents of LTCH were included. Study selection was performed independently, in duplicate. Mapping was performed by two reviewers, and data were extracted by one reviewer, with partial verification by a second reviewer. Results A total of 7,574 citations were screened based on the title/abstract, 836 were reviewed at full text, and 366 studies were included. Studies were classified according to two main categories: healthcare service delivery (n = 92) and implementation strategies (n = 274). The condition/ focus of the intervention was used to further classify the interventions into subcategories. The complex nature of the interventions may have led to a study being classified in more than one category/subcategory. Conclusion Many healthcare service interventions have been evaluated in the literature in the last decade. Well represented interventions (e.g., dementia care, exercise/mobility, optimal/appropriate medication) may present opportunities for future systematic reviews. Areas with less research (e.g., hearing care, vision care, foot care) have the potential to have an impact on balance, falls, subsequent acute care hospitalization.	[Hamel, Candyce; Garritty, Chantelle; Hersi, Mona; Butler, Claire; Esmaeilisaraji, Leila; Rice, Danielle; Skidmore, Becky; Hutton, Brian] Ottawa Hosp Res Inst, Knowledge Synth Grp, Ottawa, ON, Canada; [Straus, Sharon] Univ Toronto, Dept Med, Toronto, ON, Canada; [Straus, Sharon] St Michaels Hosp, Toronto, ON, Canada; [Hutton, Brian] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Ottawa	Hamel, C (corresponding author), Ottawa Hosp Res Inst, Knowledge Synth Grp, Ottawa, ON, Canada.	cahamel@ohri.ca	Garritty, Chantelle Marie/AAC-4136-2022	Skidmore, Becky/0000-0001-8293-9238; Hamel, Candyce/0000-0002-5871-2137	Royal Society of Canada (RSC) through the SPOR Evidence Alliance	Royal Society of Canada (RSC) through the SPOR Evidence Alliance	Funding was provided by The Royal Society of Canada (RSC) through the SPOR Evidence Alliance. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of RSC.	[Anonymous], WORLD POPULATION PRO; [Anonymous], 2011, GLOB HLTH AG; [Anonymous], 2020, WHAT IS PHYS ASSISTA; [Anonymous], 2021, POP AG 65 POP; [Anonymous], 2020, ALB MOV REG HLTH CAR; [Anonymous], 2020, CBC; Arendts G, 2018, ARCH GERONTOL GERIAT, V77, P129, DOI 10.1016/j.archger.2018.05.001; Armstrong P, 2020, POLICY BRIEFING WORK; Azermai M, 2017, ACTA CLIN BELG, V72, P163, DOI 10.1080/17843286.2017.1287230; Balsom C, 2020, INT J CLIN PHARM-NET, V42, P1153, DOI 10.1007/s11096-020-01073-6; Barbe AG, 2020, INT J DENT HYG, V18, P238, DOI 10.1111/idh.12439; Barbe AG, 2019, INT J DENT HYG, V17, P327, DOI 10.1111/idh.12389; Barker RO, 2018, J AM MED DIR ASSOC, V19, P1069, DOI 10.1016/j.jamda.2018.07.006; Barreto PD, 2016, BRIT J CLIN PHARMACO, V81, P759, DOI 10.1111/bcp.12847; Beaupre LA, 2020, J GERONTOL A-BIOL, V75, pE159, DOI 10.1093/gerona/glaa074; Beck AM, 2016, NUTRITION, V32, P199, DOI 10.1016/j.nut.2015.08.009; Bell D., 2020, COVID 19 MORTALITY L; Boorsma M, 2011, CAN MED ASSOC J, V183, pE724, DOI 10.1503/cmaj.101498; Borbasi S, 2011, PERSPECT PUBLIC HEAL, V131, P124, DOI 10.1177/1757913911400143; Boyd M, 2014, J AM GERIATR SOC, V62, P1962, DOI 10.1111/jgs.13022; Brett L, 2021, PHYSIOTHER THEOR PR, V37, P38, DOI 10.1080/09593985.2019.1594470; Wilson CB, 2019, GERONTOLOGIST, V59, pE731, DOI 10.1093/geront/gnz020; Canadian Institute for Health Information, 2020, PAND EXP LONG TERM C; Canadian Institute of Health Information (CIHI), 2014, HLTH SPEND NURS HOM; Chapman M, 2018, BMJ SUPPORT PALLIAT, V8, P102, DOI 10.1136/bmjspcare-2015-001071; Cochrane EDective Practice Organisation of Care (EPOC)., 2017, EPOC TAX HLTH SYST I; Connolly MJ, 2018, MATURITAS, V117, P45, DOI 10.1016/j.maturitas.2018.08.014; Connolly MJ, 2016, AGE AGEING, V45, P415, DOI 10.1093/ageing/afw037; Connolly MJ, 2015, J AM MED DIR ASSOC, V16, P49, DOI 10.1016/j.jamda.2014.07.008; Conway J, 2015, INT EMERG NURS, V23, P190, DOI 10.1016/j.ienj.2014.11.005; Cool C, 2018, BRIT J CLIN PHARMACO, V84, P1598, DOI 10.1111/bcp.13598; Corazzini KN, 2019, J AM MED DIR ASSOC, V20, P598, DOI 10.1016/j.jamda.2019.01.123; Cordato NJ, 2018, J AM MED DIR ASSOC, V19, DOI 10.1016/j.jamda.2017.12.008; Craswell A, 2020, COLLEGIAN, V27, P281, DOI 10.1016/j.colegn.2019.08.009; Crotty M, 2019, AGE AGEING, V48, P373, DOI 10.1093/ageing/afz005; D'Arcy LP, 2013, J AM GERIATR SOC, V61, P4, DOI 10.1111/jgs.12039; De Luca R, 2016, AGING CLIN EXP RES, V28, P753, DOI 10.1007/s40520-015-0463-8; de Mazieres CL, 2019, EUR GERIATR MED, V10, P285, DOI 10.1007/s41999-018-00155-z; Doernberg SB, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0095-y; Dorfman R, 2020, J AM MED DIR ASSOC, V21, P823, DOI 10.1016/j.jamda.2020.04.009; Edvardsson D, 2019, GERONTOL GERIATR MED, V5, P1, DOI 10.1177/2333721419842672; El Haddad K, 2020, EUR GERIATR MED, V11, P863, DOI 10.1007/s41999-019-00279-w; Employment and Social Development, GOV CAN ACT SEN REP; Forbat L, 2020, PALLIATIVE MED, V34, P571, DOI 10.1177/0269216319891077; Ganann R, 2010, IMPLEMENT SCI, V5, P10, DOI 10.1186/1748-5908-5-56; Gloth FM, 2011, J AM MED DIR ASSOC, V12, P384, DOI 10.1016/j.jamda.2010.11.010; Goncalves JR, 2021, EUR GERIATR MED, V12, P673, DOI 10.1007/s41999-021-00469-5; Grabowski DC, 2014, HEALTH AFFAIR, V33, P244, DOI 10.1377/hlthaff.2013.0922; Guion V, 2018, J AM MED DIR ASSOC, V19, P1118, DOI 10.1016/j.jamda.2018.09.031; Haines TP, 2020, MED J AUSTRALIA, V212, P409, DOI 10.5694/mja2.50565; Hamel C, 2021, J CLIN EPIDEMIOL, V129, P74, DOI 10.1016/j.jclinepi.2020.09.041; Harris-Kojetin L., 2019, LONG TERM CARE PROVI, DOI [10.3928/19404921-20181212-03, DOI 10.3928/19404921-20181212-03]; Harvey P, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-48; Hashimoto R, 2020, GERIATR GERONTOL INT, V20, P229, DOI 10.1111/ggi.13850; Hauen J, 2020, DEATH RATES FOR PROF; Health Canada, LONG TERM FAC BAS CA; Henskens M, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0642-x; Hewitt J, 2019, CLIN REHABIL, V33, P524, DOI 10.1177/0269215518808051; Hopper T, 2016, J SPEECH LANG HEAR R, V59, P1533, DOI 10.1044/2016_JSLHR-H-15-0135; Hsu AT, 2016, CAN J AGING, V35, P175, DOI 10.1017/S0714980816000192; Hullick C, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0279-1; Hutchinson AF, 2015, AGE AGEING, V44, P365, DOI 10.1093/ageing/afu196; Justine M, 2010, TOP GERIATR REHABIL, V26, P70, DOI 10.1097/TGR.0b013e3181cd6949; Kaasalainen S, 2016, INT J NURS STUD, V62, P156, DOI 10.1016/j.ijnurstu.2016.07.022; Kane RL, 2017, JAMA INTERN MED, V177, P1257, DOI 10.1001/jamainternmed.2017.2657; Killington M, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-019-1321-x; Kobewka DM, 2020, J AM MED DIR ASSOC, V21, P469, DOI 10.1016/j.jamda.2019.06.004; Kulakci H, 2013, RES GERONTOL NURS, V6, P242, DOI 10.3928/19404921-20130729-01; Lacny S, 2016, J ADV NURS, V72, P2138, DOI 10.1111/jan.12989; Lin WY, 2010, ARCH GERONTOL GERIAT, V50, pS22, DOI 10.1016/S0167-4943(10)70007-8; Lindelof N, 2013, ARCH GERONTOL GERIAT, V57, P369, DOI 10.1016/j.archger.2013.05.003; Liu WM, 2020, J AM GERIATR SOC, V68, P305, DOI 10.1111/jgs.16192; Man REK, 2020, BRIT J OPHTHALMOL, V104, P1585, DOI 10.1136/bjophthalmol-2019-315620; Marchini L, 2018, SPEC CARE DENT, V38, P345, DOI 10.1111/scd.12327; McCarthy A, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4821-7; McDerby Nicole, 2020, Medicines (Basel), V7, DOI 10.3390/medicines7040020; McDerby N, 2019, J CLIN PHARM THER, V44, P595, DOI 10.1111/jcpt.12822; McGregor Margaret J, 2010, Health Rep, V21, P27; McSweeney K, 2012, INT J GERIATR PSYCH, V27, P1163, DOI 10.1002/gps.3762; Mileski M, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8020114; Miller SC, 2017, J PAIN SYMPTOM MANAG, V54, P9, DOI 10.1016/j.jpainsymman.2017.03.005; Miller SC, 2016, J AM GERIATR SOC, V64, P2280, DOI 10.1111/jgs.14469; Morciano M, 2020, HEALTH POLICY, V124, P826, DOI 10.1016/j.healthpol.2020.06.004; Morino T, 2014, INT J DENT HYG, V12, P291, DOI 10.1111/idh.12068; Moyle W, 2016, INT PSYCHOGERIATR, V28, P1091, DOI 10.1017/S1041610216000296; Moyle W, 2014, INT J NURS STUD, V51, P856, DOI 10.1016/j.ijnurstu.2013.10.019; Moyle W, 2014, J ALTERN COMPLEM MED, V20, P305, DOI 10.1089/acm.2013.0177; Nishiyama Y, 2010, ARCH GERONTOL GERIAT, V51, pE139, DOI 10.1016/j.archger.2010.04.009; Nurse Practitioners, COLL NURS ONT 2020; Patterson SM, 2010, J AM GERIATR SOC, V58, P44, DOI 10.1111/j.1532-5415.2009.02617.x; Pedersen LH, 2017, EUR GERIATR MED, V8, P330, DOI 10.1016/j.eurger.2017.05.006; Pedersen LH, 2018, EUR GERIATR MED, V9, P329, DOI 10.1007/s41999-018-0045-3; Peters MDJ., 2020, JBI MANUAL EVIDENCE, DOI [10.46658/JBIMES-20-12, DOI 10.46658/JBIMES-20-12]; Rantz MJ, 2018, J AM MED DIR ASSOC, V19, P541, DOI 10.1016/j.jamda.2017.10.014; Rapp MA, 2013, J AM MED DIR ASSOC, V14, P690, DOI 10.1016/j.jamda.2013.05.017; Rodriguez-Mansilla J, 2013, J TRADIT CHIN MED, V33, P461, DOI 10.1016/S0254-6272(13)60149-1; Rolland Y, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0049; Rolland Y, 2016, J AM GERIATR SOC, V64, P193, DOI 10.1111/jgs.13874; Sackley CM, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20150; Seblega BK, 2010, MED CARE RES REV, V67, P232, DOI 10.1177/1077558709342253; Seleskog B, 2018, INT J DENT HYG, V16, P476, DOI 10.1111/idh.12343; Sluggett JK, 2020, J AM MED DIR ASSOC, V21, P1114, DOI 10.1016/j.jamda.2020.02.003; Snider KT, 2012, J AM OSTEOPATH ASSOC, V112, P489; Staykov E, 2020, J AM MED DIR ASSOC, V21, P1951, DOI 10.1016/j.jamda.2020.04.016; Sumi Y, 2010, ARCH GERONTOL GERIAT, V51, P125, DOI 10.1016/j.archger.2009.09.038; Telenius EW, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0151-8; Telenius EW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126102; Temkin-Greener H, 2018, MED CARE, V56, P11, DOI 10.1097/MLR.0000000000000835; Temkin-Greener H, 2017, CONTEMP CLIN TRIALS, V56, P1, DOI 10.1016/j.cct.2017.01.011; Torma J, 2015, J NUTR HEALTH AGING, V19, P70, DOI 10.1007/s12603-014-0522-4; Travers C, 2017, DEMENTIA-LONDON, V16, P204, DOI 10.1177/1471301215586069; Tricco A.C., 2017, RAPID REV STRENGTHEN; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Tricco AC, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0116-4; Tynan A, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3321-5; United Nations Department of Economic and Social Affairs, 2020, REV 1; Verkaik R, 2011, INT J GERIATR PSYCH, V26, P723, DOI 10.1002/gps.2586; Verrue C, 2012, ACTA CLIN BELG, V67, P423, DOI 10.2143/ACB.67.6.2062707; Weatherall CD, 2019, HEALTH SERV RES, V54, P547, DOI 10.1111/1475-6773.13112; Wenborn J, 2013, INT J GERIATR PSYCH, V28, P1296, DOI 10.1002/gps.3960; Wikstrom M, 2017, GERODONTOLOGY, V34, P240, DOI 10.1111/ger.12256; Wu MP, 2010, ARCH GERONTOL GERIAT, V50, P315, DOI 10.1016/j.archger.2009.05.004; Wylie G, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0541-1; Yorozuya K, 2019, DEMENT GERIATR COGN, V48, P1, DOI 10.1159/000503445; Zenthofer A, 2016, CLIN INTERV AGING, V11, P1755, DOI 10.2147/CIA.S118330; Zenthofer A, 2013, COMMUNITY DENT ORAL, V41, P261, DOI 10.1111/cdoe.12007	126	2	2	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2021	16	7							e0254527	10.1371/journal.pone.0254527	http://dx.doi.org/10.1371/journal.pone.0254527			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TQ2NF	34270578	gold, Green Published			2023-01-03	WOS:000678121400008
J	Benckiser, E				Benckiser, Eva			A touch more unconventional	SCIENCE			English	Editorial Material									[Benckiser, Eva] Max Planck Inst Solid State Res, Heisenbergstr 1, D-70569 Stuttgart, Germany	Max Planck Society	Benckiser, E (corresponding author), Max Planck Inst Solid State Res, Heisenbergstr 1, D-70569 Stuttgart, Germany.	e.benckiser@fkf.mpg.de		Benckiser, Eva/0000-0002-7638-2282				Bernardini F, 2020, J PHYS-MATER, V3, DOI 10.1088/2515-7639/ab9d0f; Geisler B, 2020, PHYS REV B, V102, DOI 10.1103/PhysRevB.102.020502; Jiang M, 2020, PHYS REV LETT, V124, DOI 10.1103/PhysRevLett.124.207004; Katukuri VM, 2020, PHYS REV B, V102, DOI 10.1103/PhysRevB.102.241112; Li DF, 2019, NATURE, V572, P624, DOI 10.1038/s41586-019-1496-5; Lin JQ, 2021, PHYS REV LETT, V126, DOI 10.1103/PhysRevLett.126.087001; Liu Z, 2020, NPJ QUANTUM MATER, V5, DOI 10.1038/s41535-020-0229-1; Lu H, 2021, SCIENCE, V373, P213, DOI 10.1126/science.abd7726; Wang BX, 2020, PHYS REV MATER, V4, DOI 10.1103/PhysRevMaterials.4.084409	9	0	0	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2021	373	6551					157	157		10.1126/science.abi6855	http://dx.doi.org/10.1126/science.abi6855			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TP8PA	34244396				2023-01-03	WOS:000677855400013
J	Chandra, RA; Keane, FK; Voncken, FEM; Thomas, CR				Chandra, Ravi A.; Keane, Florence K.; Voncken, Francine E. M.; Thomas, Charles R., Jr.			Contemporary radiotherapy: present and future	LANCET			English	Review							SQUAMOUS-CELL CARCINOMA; LONG-TERM OUTCOMES; STEREOTACTIC ABLATIVE RADIOTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; INVASIVE BLADDER-CANCER; NO AXILLARY DISSECTION; EARLY BREAST-CANCER; 20-YEAR FOLLOW-UP; LUNG-CANCER; RADIATION-THERAPY	Oncology care is increasingly a multidisciplinary endeavour, and radiation therapy continues to have a key role across the disease spectrum in nearly every cancer. However, the field of radiation oncology is still one of the most poorly understood of the cancer disciplines. In this Review, we attempt to summarise and contextualise developments within the field of radiation oncology for the non-radiation oncologist. We discuss advancements in treatment technologies and imaging, followed by an overview of the interplay with advancements in systemic therapy and surgical techniques. Finally, we review new frontiers in radiation oncology, including advances within the metastatic disease continuum, reirradiation, and emerging types of radiation therapy.	[Chandra, Ravi A.; Thomas, Charles R., Jr.] Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR 97239 USA; [Keane, Florence K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [Voncken, Francine E. M.] Netherlands Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands	Oregon Health & Science University; Harvard University; Massachusetts General Hospital; Netherlands Cancer Institute	Chandra, RA (corresponding author), Oregon Hlth & Sci Univ, Dept Radiat Med, Portland, OR 97239 USA.	chandrav@ohsu.edu						Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Ang KK, 2001, INT J RADIAT ONCOL, V50, P1013, DOI 10.1016/S0360-3016(01)01599-1; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Atun R, 2015, LANCET ONCOL, V16, P1153, DOI 10.1016/S1470-2045(15)00222-3; Ball D, 2019, LANCET ONCOL, V20, P494, DOI 10.1016/S1470-2045(18)30896-9; Barton MB, 2014, RADIOTHER ONCOL, V112, P140, DOI 10.1016/j.radonc.2014.03.024; Batumalai V, 2020, RADIOTHER ONCOL, V152, P70, DOI 10.1016/j.radonc.2020.07.038; Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118; Bentzen SM, 2008, LANCET, V371, P1098, DOI 10.1016/S0140-6736(08)60348-7; Bentzen SM, 2008, LANCET ONCOL, V9, P331, DOI [10.1016/S1470-2045(08)60348-7, 10.1016/S1470-2045(08)70077-9]; Bourhis J, 2019, RADIOTHER ONCOL, V139, P18, DOI 10.1016/j.radonc.2019.06.019; Bristow RG, 2018, LANCET ONCOL, V19, pE240, DOI 10.1016/S1470-2045(18)30096-2; Brown PD, 2020, J CLIN ONCOL, V38, P1019, DOI 10.1200/JCO.19.02767; Brunt AM, 2020, LANCET, V395, P1613, DOI 10.1016/S0140-6736(20)30932-6; Chakraborty M, 2003, J IMMUNOL, V170, P6338, DOI 10.4049/jimmunol.170.12.6338; Chandra RA., 2020, HEMATOL ONCOL CLIN, V34, DOI [10.1016/S0889-8588(19)30142-X, DOI 10.1016/S0889-8588(19)30142-X]; Chang JY, 2015, LANCET ONCOL, V16, P630, DOI 10.1016/S1470-2045(15)70168-3; Chao HH, 2017, J THORAC ONCOL, V12, P281, DOI 10.1016/j.jtho.2016.10.018; Chaudhuri AA, 2017, CANCER DISCOV, V7, P1394, DOI 10.1158/2159-8290.CD-17-0716; Chow R, 2019, RADIOTHER ONCOL, V141, P56, DOI 10.1016/j.radonc.2019.06.037; Chun SG, 2017, J CLIN ONCOL, V35, P56, DOI 10.1200/JCO.2016.69.1378; Cuculich PS, 2017, NEW ENGL J MED, V377, P2325, DOI 10.1056/NEJMoa1613773; Demaria S, 2005, CLIN CANCER RES, V11, P728; Dinkelborg PH, 2019, BREAST CANCER RES TR, V174, P605, DOI 10.1007/s10549-018-05079-7; Donker M, 2014, LANCET ONCOL, V15, P1303, DOI 10.1016/S1470-2045(14)70460-7; Efstathiou JA, 2012, EUR UROL, V61, P705, DOI 10.1016/j.eururo.2011.11.010; EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109, DOI 10.1016/0360-3016(91)90171-Y; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Formenti SC, 2018, NAT MED, V24, P1845, DOI 10.1038/s41591-018-0232-2; Galimberti V, 2013, LANCET ONCOL, V14, P297, DOI 10.1016/S1470-2045(13)70035-4; Gerber SA, 2013, AM J PATHOL, V182, P2345, DOI 10.1016/j.ajpath.2013.02.041; Ghosh S, 2018, RADIOTHER ONCOL, V127, P114, DOI 10.1016/j.radonc.2018.01.017; Gillison ML, 2019, LANCET, V393, P40, DOI 10.1016/S0140-6736(18)32779-X; Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90; Gleber-Netto FO, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124762; Golden EB, 2012, FRONT ONCOL, V2, P1, DOI [10.3389/fonc.2012.00088, 10.3389/fonc.2012.00153]; Gomez DR, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.19.00201; Gomez DR, 2016, LANCET ONCOL, V17, P1672, DOI 10.1016/S1470-2045(16)30532-0; Guren MG, 2014, RADIOTHER ONCOL, V113, P151, DOI 10.1016/j.radonc.2014.11.021; Hashmi A, 2016, J NEUROSURG-SPINE, V25, P646, DOI 10.3171/2016.4.SPINE151523; HELLMAN S, 1995, J CLIN ONCOL, V13, P8, DOI 10.1200/JCO.1995.13.1.8; Hoebers F, 2011, INT J RADIAT ONCOL, V81, pE111, DOI 10.1016/j.ijrobp.2011.01.004; Hong TS, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx031; Hu ZQ, 2021, NUTR CANCER, V73, P1459, DOI 10.1080/01635581.2020.1801777; Huang SH, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0484-y; Iyengar P, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.3501; James RD, 2013, LANCET ONCOL, V14, P516, DOI 10.1016/S1470-2045(13)70086-X; Jeong Y, 2017, CANCER DISCOV, V7, P86, DOI 10.1158/2159-8290.CD-16-0127; Jimenez YA, 2018, J MED RADIAT SCI, V65, P158, DOI 10.1002/jmrs.282; Kamran SC, 2019, CLIN CANCER RES, V25, P5561, DOI 10.1158/1078-0432.CCR-19-0908; Kawamoto T, 2019, RADIOTHER ONCOL, V131, P240, DOI 10.1016/j.radonc.2018.09.020; Keane FK, 2015, CANCER-AM CANCER SOC, V121, P2594, DOI 10.1002/cncr.29402; Klopp AH, 2007, CANCER RES, V67, P11687, DOI 10.1158/0008-5472.CAN-07-1406; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Landoni F, 1997, LANCET, V350, P535, DOI 10.1016/S0140-6736(97)02250-2; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Leeman JE, 2017, LANCET ONCOL, V18, pE254, DOI 10.1016/S1470-2045(17)30179-1; Liao ZX, 2018, J CLIN ONCOL, V36, P1813, DOI 10.1200/JCO.2017.74.0720; Lievens Y, 2020, RADIOTHER ONCOL, V148, P157, DOI 10.1016/j.radonc.2020.04.003; Lin SH, 2012, INT J RADIAT ONCOL, V84, P1078, DOI 10.1016/j.ijrobp.2012.02.015; Lordick F, 2007, LANCET ONCOL, V8, P797, DOI 10.1016/S1470-2045(07)70244-9; Lundkvist J, 2005, ACTA ONCOL, V44, P850, DOI 10.1080/02841860500341157; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mehanna H, 2019, LANCET, V393, P51, DOI 10.1016/S0140-6736(18)32752-1; Michalski JM, 2013, INT J RADIAT ONCOL, V87, P932, DOI 10.1016/j.ijrobp.2013.07.041; Mitin T, 2014, J CLIN ONCOL, V32, P2855, DOI 10.1200/JCO.2014.55.1945; Monninkhof EM, 2018, RADIOTHER ONCOL, V127, P74, DOI 10.1016/j.radonc.2017.12.022; Nichols AC, 2019, LANCET ONCOL, V20, P1349, DOI 10.1016/S1470-2045(19)30410-3; Nieder C, 2006, INT J RADIAT ONCOL, V66, P1446, DOI 10.1016/j.ijrobp.2006.07.1383; Nieder C, 2018, STRAHLENTHER ONKOL, V194, P365, DOI 10.1007/s00066-018-1266-6; Nieder C, 2017, STRAHLENTHER ONKOL, V193, P515, DOI 10.1007/s00066-017-1130-0; NIGRO ND, 1983, CANCER, V51, P1826, DOI 10.1002/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L; Noordman BJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4034-1; Ost P, 2018, J CLIN ONCOL, V36, P446, DOI 10.1200/JCO.2017.75.4853; Paganetti H, 2012, PHYS MED BIOL, V57, pR99, DOI 10.1088/0031-9155/57/11/R99; Paix A, 2018, RADIOTHER ONCOL, V128, P534, DOI 10.1016/j.radonc.2018.04.013; Palma DA, 2019, LANCET, V393, P2051, DOI 10.1016/S0140-6736(18)32487-5; Parikh A, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.391; Parikh AR, 2019, NAT MED, V25, P1415, DOI 10.1038/s41591-019-0561-9; Parikh AR, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3514; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Pastorino U, 1997, J THORAC CARDIOV SUR, V113, P37, DOI 10.1016/S0022-5223(97)70397-0; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Pham TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45450-2; Phillips R, 2020, JAMA ONCOL, V6, P650, DOI 10.1001/jamaoncol.2020.0147; Pitroda SP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04278-6; Pompos A, 2016, JAMA ONCOL, V2, P1539, DOI 10.1001/jamaoncol.2016.2646; Porceddu SV, 2020, INT J RADIAT ONCOL, V107, P641, DOI 10.1016/j.ijrobp.2020.03.024; Nguyen QN, 2019, JAMA ONCOL, V5, P872, DOI 10.1001/jamaoncol.2019.0192; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rockne RC, 2019, JCO CLIN CANCER INFO, V3, DOI 10.1200/CCI.19.00010; Sahgal A, 2012, INT J RADIAT ONCOL, V82, P107, DOI 10.1016/j.ijrobp.2010.08.021; Sanford NN, 2019, INT J RADIAT ONCOL, V105, P64, DOI 10.1016/j.ijrobp.2019.01.076; Scott JG, 2021, J THORAC ONCOL, V16, P428, DOI 10.1016/j.jtho.2020.11.008; Scott JG, MATH ONCOLOGY; Shah C, 2019, INT J RADIAT ONCOL, V103, P397, DOI 10.1016/j.ijrobp.2018.09.021; Sharabi AB, 2015, LANCET ONCOL, V16, pE498, DOI 10.1016/S1470-2045(15)00007-8; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; SHIPLEY WU, 1987, JAMA-J AM MED ASSOC, V258, P931, DOI 10.1001/jama.258.7.931; Singh R, 2016, CUREUS, V8, DOI 10.7759/cureus.554; Sitthideatphaiboon P, 2021, CLIN CANCER RES, V27, P1720, DOI 10.1158/1078-0432.CCR-20-2859; Smith BD, 2018, PRACT RADIAT ONCOL, V8, P145, DOI 10.1016/j.prro.2018.01.012; Smith JJ, 2019, JAMA ONCOL, V5, DOI 10.1001/jamaoncol.2018.5896; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Stahl M, 2005, J CLIN ONCOL, V23, P2310, DOI 10.1200/JCO.2005.00.034; Stieb S, 2020, HEMATOL ONCOL CLIN N, V34, P293, DOI 10.1016/j.hoc.2019.09.010; Tanvetyanon T, 2008, J CLIN ONCOL, V26, P1142, DOI 10.1200/JCO.2007.14.2091; Tao YA, 2020, RADIOTHER ONCOL, V150, P18, DOI 10.1016/j.radonc.2020.05.021; Theelen WSME, 2019, JAMA ONCOL, V5, P1276, DOI 10.1001/jamaoncol.2019.1478; Tie J, 2019, GUT, V68, P663, DOI 10.1136/gutjnl-2017-315852; Timmerman R, 2010, JAMA-J AM MED ASSOC, V303, P1070, DOI 10.1001/jama.2010.261; Tomlinson JS, 2007, J CLIN ONCOL, V25, P4575, DOI 10.1200/JCO.2007.11.0833; Trip AK, 2014, RADIOTHER ONCOL, V112, P284, DOI 10.1016/j.radonc.2014.05.003; van de Lindt TN, 2019, RADIOTHER ONCOL, V138, P132, DOI 10.1016/j.radonc.2019.06.007; van der Valk MJM, 2018, LANCET, V391, P2537, DOI 10.1016/S0140-6736(18)31078-X; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618; Vanpouille-Box C, 2015, VACCINE, V33, P7415, DOI 10.1016/j.vaccine.2015.05.105; Vega RBM, 2013, CANCER-AM CANCER SOC, V119, P4299, DOI 10.1002/cncr.28322; Verheij M, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.4000; Verma V, 2016, CANCER-AM CANCER SOC, V122, P1483, DOI 10.1002/cncr.29882; Veronesi U, 2002, NEW ENGL J MED, V347, P1227, DOI 10.1056/NEJMoa020989; Versteijne E, 2020, J CLIN ONCOL, V38, P1763, DOI 10.1200/JCO.19.02274; Ward MC, 2018, INT J RADIAT ONCOL, V100, P586, DOI 10.1016/j.ijrobp.2017.06.012; Whelan TJ, 2010, NEW ENGL J MED, V362, P513, DOI 10.1056/NEJMoa0906260; Wichmann G, 2015, INT J CANCER, V137, P2846, DOI 10.1002/ijc.29649; Willers H, 2015, SEMIN RADIAT ONCOL, V25, P237, DOI 10.1016/j.semradonc.2015.05.007; Willers H, 2013, CANCER J, V19, P200, DOI 10.1097/PPO.0b013e318292e4e3; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402; Yap Mei Ling, 2016, J Glob Oncol, V2, P207, DOI 10.1200/JGO.2015.001545; Yock TI, 2016, LANCET ONCOL, V17, P287, DOI 10.1016/S1470-2045(15)00167-9	132	25	26	12	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2021	398	10295					171	184		10.1016/S0140-6736(21)00233-6	http://dx.doi.org/10.1016/S0140-6736(21)00233-6		JUL 2021	14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG0BQ	34166607				2023-01-03	WOS:000671078800028
J	Mweteni, W; Kabirigi, J; Matovelo, D; Laisser, R; Yohani, V; Shabani, G; Shayo, P; Brenner, J; Chaput, K				Mweteni, Wemaeli; Kabirigi, Julieth; Matovelo, Dismas; Laisser, Rose; Yohani, Victoria; Shabani, Girles; Shayo, Prosper; Brenner, Jennifer; Chaput, Katie			Implications of power imbalance in antenatal care seeking among pregnant adolescents in rural Tanzania: A qualitative study	PLOS ONE			English	Article								Background Adolescent girls (10-19 years) are at increased risk of morbidity and mortality from pregnancy and childbirth complications, compared with older mothers. Low and middle-income countries, including Tanzania, bear the largest proportion of adolescent perinatal deaths. Few adolescent girls in Tanzania access antenatal care at health facilities, the reasons for which are poorly understood. Methods We conducted a qualitative thematic analysis study of the experiences of pregnant adolescents with accessing antenatal care in Misungwi district, Tanzania. We recruited 22 pregnant or parenting adolescent girls using purposive sampling, and conducted in-depth interviews (IDIs) about antenatal care experiences. IDI data were triangulated with data from eight focus group discussions (FGDs) involving young fathers and elder men/women, and nine key informant interviews (KIIs) conducted with local health care providers. FGDs, KIIs and IDIs were transcribed verbatim in Swahili. Transcripts were then translated to English and analysed using emergent thematic analysis. Results Four main themes emerged: 1) Lack of maternal personal autonomy, 2) Stigma and judgment, 3) Vulnerability to violence and abuse, and 4) Knowledge about antenatal care, and highlighted the complex power imbalance that underlies barriers and facilitators to care access at the individual, family/interpersonal, community, and health-systems levels, faced by pregnant adolescents in rural Tanzania. Conclusion Adolescent antenatal care-seeking is compromised by a complex power imbalance that involves financial dependence, lack of choice, lack of personal autonomy in decision making, experiences of social stigma, judgement, violence and abuse. Multi-level interventions are needed to empower adolescent girls, and to address policies and social constructs that may act as barriers, thereby, potentially reducing maternal morbidity and mortality in Tanzania.	[Mweteni, Wemaeli] Bugando Med Ctr BMC, Dept Community Hlth Res & Consultancies, Mwanza, Tanzania; [Kabirigi, Julieth] Catholic Univ Hlth & Allied Sci CUHAS, Dept Pediat, Mwanza, Tanzania; [Matovelo, Dismas; Yohani, Victoria; Shabani, Girles; Shayo, Prosper] Catholic Univ Hlth & Allied Sci CUHAS, Dept Gynecol & Obstet, Mwanza, Tanzania; [Laisser, Rose] Catholic Univ Hlth & Allied Sci CUHAS, Sch Nursing, Mwanza, Tanzania; [Brenner, Jennifer] Univ Calgary, Cumming Sch Med, Dept Pediat, Calgary, AB, Canada; [Brenner, Jennifer] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada; [Chaput, Katie] Univ Calgary, Dept Obstet & Gynecol, Calgary, AB, Canada; [Chaput, Katie] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary	Chaput, K (corresponding author), Univ Calgary, Dept Obstet & Gynecol, Calgary, AB, Canada.; Chaput, K (corresponding author), Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada.	khchaput@ucalgary.ca		Chaput, Kathleen/0000-0001-7596-6019	Innovating for Maternal and Child Health in Africa initiative; Global Affairs Canada (GAC); Canadian Institutes of Health Research (CIHR); Canada's International Development Research Centre (IDRC) [108547-001]	Innovating for Maternal and Child Health in Africa initiative; Global Affairs Canada (GAC)(CGIAR); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canada's International Development Research Centre (IDRC)	This work was carried out with the aid of a grant from the Innovating for Maternal and Child Health in Africa initiative, a partnership of Global Affairs Canada (GAC), the Canadian Institutes of Health Research (CIHR) and Canada's International Development Research Centre (IDRC) (Project #108547-001, Principal Investigator JB). The views expressed herein do not necessarily represent those of IDRC or its Board of Governors.	[Anonymous], 2015, ALL ENDADOLESCENTAID; ASTM, 2016, STANDARD TEST METHOD; Bailey LD, 2012, ADV NEONAT CARE, V12, P102, DOI 10.1097/ANC.0b013e31824c81d6; Brenner J. l, 2020, MAMA MTOTO; BRONFENBRENNER U, 1977, AM PSYCHOL, V32, P513, DOI 10.1037/0003-066x.32.7.513; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; ELANSARY AI, 1972, J MARKETING RES, V9, P47, DOI 10.2307/3149605; EMERSON RM, 1962, AM SOCIOL REV, V27, P31, DOI 10.2307/2089716; Essabbar D., 2016, INT J SUPPLY OPER MA, V2, P1021, DOI [10.22034/2015.4.04, DOI 10.22034/2015.4.04]; Hammerly C, 2022, LINGUIST INQ, V53, P823, DOI 10.1162/ling_a_00422; Heise L L, 1998, Violence Against Women, V4, P262, DOI 10.1177/1077801298004003002; Hokororo A, 2015, ACTA PAEDIATR, V104, P1291, DOI 10.1111/apa.12886; Kaphagawani NC, 2017, GLOB PUBLIC HEALTH, V12, P694, DOI 10.1080/17441692.2016.1229354; Kassa GM, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0640-2; Kruk ME, 2008, TROP MED INT HEALTH, V13, P1442, DOI 10.1111/j.1365-3156.2008.02173.x; Kumar M, 2018, GLOB SOC WELFARE, V5, P11, DOI 10.1007/s40609-017-0102-8; Kuzma EK, 2016, J AM ASSOC NURSE PRA, V28, P353, DOI 10.1002/2327-6924.12331; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; Miura PO, 2018, CIENC SAUDE COLETIVA, V23, P1601, DOI 10.1590/1413-81232018235.14152016; Mubyazi G.M., 2004, E AFR J PUBLIC HLTH; Olausson PO, 1999, BRIT J OBSTET GYNAEC, V106, P116, DOI 10.1111/j.1471-0528.1999.tb08210.x; Sallis J.F., 2008, ECOLOGICAL MODELS HL; Shahabuddin A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169109; Van eerdewijk A., 2017, WHITE PAPER CONCEPTU; W.H. Organization, 2014, ADOLESCENT PREGNANCY; Weber M., 1947, THEORY SOCIAL EC ORG; WHO, 2011, EUR CTR ENV HLTH BUR; Worku Eshetu Bekele, 2016, Int J MCH AIDS, V5, P134	28	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2021	16	6							e0250646	10.1371/journal.pone.0250646	http://dx.doi.org/10.1371/journal.pone.0250646			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TG9EF	34191800	Green Published, gold, Green Submitted			2023-01-03	WOS:000671698800047
J	Jaen, I; Diaz-Garcia, A; Pastor, MC; Garcia-Palacios, A				Jaen, Irene; Diaz-Garcia, Amanda; Pastor, M. Carmen; Garcia-Palacios, Azucena			Emotion regulation and peripheral psychophysiological correlates in the management of induced pain: A systematic review	PLOS ONE			English	Review							COGNITIVE REAPPRAISAL; INDIVIDUAL-DIFFERENCES; REGULATION STRATEGIES; COMMITMENT THERAPY; PROCESS MODEL; ACCEPTANCE; ANXIETY; MINDFULNESS; DISTRACTION; SUPPRESSION	Cognitive reappraisal and acceptance strategies have been shown to be effective in reducing pain experience and increasing pain tolerance. However, no systematic reviews have focused on the relationship between the use of these two strategies and peripheral physiological correlates when pain is experimentally induced. This systematic review aims to summarize the existing literature that explores the relationship between emotion regulation strategies (i.e., cognitive reappraisal and acceptance) and peripheral correlates of the autonomic nervous system and facial electromyography, such as affect-modulated responses and corrugator activity, on laboratory tasks where pain is induced. The systematic review identifies nine experimental studies that meet our inclusion criteria, none of which compare these strategies. Although cognitive reappraisal and acceptance strategies appear to be associated with decreased psychological responses, mixed results were found for the effects of the use of both strategies on all the physiological correlates. These inconsistencies between the studies might be explained by the high methodological heterogeneity in the task designs, as well as a lack of consistency between the instructions used in the different studies for cognitive reappraisal, acceptance, and the control conditions.	[Jaen, Irene; Pastor, M. Carmen; Garcia-Palacios, Azucena] Univ Jaume 1, Clin Psychol & Psychobiol, Basic Psychol, Castellon de La Plana, Spain; [Diaz-Garcia, Amanda] Univ Zaragoza, Psychol & Sociol, Zaragoza, Spain; [Jaen, Irene] Univ Jaume 1, Fac Ciencias Salud, Dept Psicol Basica Clin & Psicobiol, Castellon de La Plana, Spain	Universitat Jaume I; University of Zaragoza; Universitat Jaume I	Jaen, I (corresponding author), Univ Jaume 1, Clin Psychol & Psychobiol, Basic Psychol, Castellon de La Plana, Spain.; Jaen, I (corresponding author), Univ Jaume 1, Fac Ciencias Salud, Dept Psicol Basica Clin & Psicobiol, Castellon de La Plana, Spain.	ijaen@uji.es	Pastor, M. Carmen/N-1692-2019; Jaén, Irene/T-9208-2019; Pastor, M. Carmen/H-7183-2015; Diaz-Garcia, Amanda/E-4001-2019	Pastor, M. Carmen/0000-0001-9909-3646; Jaén, Irene/0000-0002-8001-911X; Pastor, M. Carmen/0000-0001-9909-3646; Diaz-Garcia, Amanda/0000-0003-4398-4014	Universitat Jaume I [UJIB2029-33, UJI-B2016-39, UJI-B2019-34, PREDOC/2017/26]	Universitat Jaume I	This work was supported by the Universitat Jaume I, by two Research Projects to AG-P (UJIB2029-33 and UJI-B2016-39), a Research Project to MP (UJI-B2019-34), and a Predoctoral Grant to IJ (PREDOC/2017/26).	Aldao A, 2010, CLIN PSYCHOL REV, V30, P217, DOI 10.1016/j.cpr.2009.11.004; Arsenault M, 2013, NEUROSCIENCE, V231, P102, DOI 10.1016/j.neuroscience.2012.11.011; Barnes SM., 2010, IMAG COGN PERS, V30, P77, DOI [10.2190/IC.30.1.e, DOI 10.2190/IC.30.1.E]; Beck A. T., 1979, COGNITIVE THERAPY DE; Bernat EM, 2011, DEV NEUROPSYCHOL, V36, P493, DOI 10.1080/87565641.2010.549881; Blacker KJ, 2012, BEHAV MODIF, V36, P37, DOI 10.1177/0145445511420281; Braams BR, 2012, J BEHAV THER EXP PSY, V43, P1014, DOI 10.1016/j.jbtep.2012.04.001; Bradley MM, 2008, PSYCHOPHYSIOLOGY, V45, P602, DOI 10.1111/j.1469-8986.2008.00654.x; Bradley MM, 2001, EMOTION, V1, P276, DOI 10.1037//1528-3542.1.3.276; Bushnell MC, 2013, NAT REV NEUROSCI, V14, P502, DOI 10.1038/nrn3516; CACIOPPO JT, 1986, J PERS SOC PSYCHOL, V50, P260, DOI 10.1037/0022-3514.50.2.260; Conzelmann A, 2015, PSYCHOPHYSIOLOGY, V52, P1257, DOI 10.1111/psyp.12450; Denson TF, 2014, PSYCHONEUROENDOCRINO, V49, P69, DOI 10.1016/j.psyneuen.2014.07.003; Denson TF, 2011, MOTIV EMOTION, V35, P14, DOI 10.1007/s11031-011-9201-5; Desrosiers A, 2014, J AFFECT DISORDERS, V165, P31, DOI 10.1016/j.jad.2014.04.024; Diers K, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00347; Dillon DG, 2005, BEHAV NEUROSCI, V119, P1118, DOI 10.1037/0735-7044.119.4.1118; Driscoll D, 2009, INT J PSYCHOPHYSIOL, V72, P61, DOI 10.1016/j.ijpsycho.2008.03.012; Eippert F, 2007, HUM BRAIN MAPP, V28, P409, DOI 10.1002/hbm.20291; Evans DR, 2014, J APPL SOC PSYCHOL, V44, P23, DOI 10.1111/jasp.12196; Fuentes-Sanchez N, 2019, PSYCHOPHYSIOLOGY, V56, DOI 10.1111/psyp.13372; Goldin PR, 2019, COGN AFFECT BEHAV NE, V19, P927, DOI 10.3758/s13415-019-00690-7; Gross J.J., 1998, REV GEN PSYCHOL, V2, P271, DOI 10.1037/1089-2680.2.3.271; Gross J. J., 2014, HDB EMOTION REGULATI, V2nd, P3; Gross JJ, 1998, J PERS SOC PSYCHOL, V74, P224, DOI 10.1037/0022-3514.74.1.224; GROSS JJ, 1993, J PERS SOC PSYCHOL, V64, P970, DOI 10.1037/0022-3514.64.6.970; Gross JJ, 2002, PSYCHOPHYSIOLOGY, V39, P281, DOI 10.1017/S0048577201393198; Gross JJ, 1997, J ABNORM PSYCHOL, V106, P95, DOI 10.1037/0021-843X.106.1.95; Gutierrez O, 2004, BEHAV THER, V35, P767, DOI 10.1016/S0005-7894(04)80019-4; Hampton AJD, 2015, PAIN, V156, P868, DOI 10.1097/j.pain.0000000000000126; HANDWERKER HO, 1993, PHYSIOL REV, V73, P639, DOI 10.1152/physrev.1993.73.3.639; Haspert V, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01514; Hayes SC, 2004, BEHAV THER, V35, P639, DOI 10.1016/S0005-7894(04)80013-3; HAYES SC, 1994, BEHAV ANALYST, V17, P289, DOI 10.1007/BF03392677; Hofmann SG, 2009, BEHAV RES THER, V47, P389, DOI 10.1016/j.brat.2009.02.010; HOLMES DS, 1974, J PERS SOC PSYCHOL, V29, P212, DOI 10.1037/h0035912; Hovasapian A, 2016, COGNITION EMOTION, V30, P1222, DOI 10.1080/02699931.2015.1049937; Jokic-Begic N., 2009, ACUTE PAIN, V11, P113; Kabat-Zinn J., 2013, FULL CATASTROPHE LIV; Kalisch R, 2005, J COGNITIVE NEUROSCI, V17, P874, DOI 10.1162/0898929054021184; Keefe FJ, 2001, J CLIN PSYCHOL, V57, P587, DOI 10.1002/jclp.1030; Kober H, 2019, SOC COGN AFFECT NEUR, V14, P1147, DOI 10.1093/scan/nsz104; Koechlin H, 2018, J PSYCHOSOM RES, V107, P38, DOI 10.1016/j.jpsychores.2018.02.002; Kohl A, 2014, J BEHAV THER EXP PSY, V45, P467, DOI 10.1016/j.jbtep.2014.06.006; Kohl A, 2013, J PAIN, V14, P305, DOI 10.1016/j.jpain.2012.12.005; Kohl A, 2012, J BEHAV THER EXP PSY, V43, P988, DOI 10.1016/j.jbtep.2012.03.004; LANG PJ, 1995, AM PSYCHOL, V50, P372, DOI 10.1037/0003-066X.50.5.372; Lapate RC, 2012, J COGNITIVE NEUROSCI, V24, P148, DOI 10.1162/jocn_a_00125; Linehan M., 1994, ACCEPTANCE CHANGE CO, P73; Lissek S, 2007, BIOL PSYCHOL, V76, P124, DOI 10.1016/j.biopsycho.2007.07.002; Lohani M, 2014, COGNITION EMOTION, V28, P678, DOI 10.1080/02699931.2013.853648; Matthewson GM, 2019, PAIN, V160, P2338, DOI 10.1097/j.pain.0000000000001621; Mauersberger H, 2018, PSYCHOPHYSIOLOGY, V55, DOI 10.1111/psyp.13086; Mauss IB, 2005, EMOTION, V5, P175, DOI 10.1037/1528-3542.5.2.175; Mauss IB, 2007, INT J PSYCHOPHYSIOL, V66, P116, DOI 10.1016/j.ijpsycho.2007.03.017; McCracken LM, 2004, PAIN, V107, P159, DOI 10.1016/j.pain.2003.10.012; McRae K., 2017, EMOTION REGULATION P, P43; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Melzack R, 1996, PAIN FORUM, V5, P128; Peters ML, 2015, MOD TR PHARMACOPSYCH, V30, P138, DOI 10.1159/000435938; Prins B, 2014, EUR J PAIN, V18, P1307, DOI 10.1002/j.1532-2149.2014.491.x; Rainville P, 2005, PAIN, V118, P306, DOI 10.1016/j.pain.2005.08.022; Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939; Ray RD, 2010, EMOTION, V10, P587, DOI 10.1037/a0019015; Roemer L, 2002, CLIN PSYCHOL-SCI PR, V9, P54, DOI 10.1093/clipsy/9.1.54; Sheppes G, 2007, PERS SOC PSYCHOL B, V33, P1518, DOI 10.1177/0146167207305537; Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x; Tang NKY, 2008, PAIN, V138, P392, DOI 10.1016/j.pain.2008.01.018; Teper R, 2014, EMOTION, V14, P105, DOI 10.1037/a0034296; Treede R-D, 2018, PAIN REP, V3, P3; van Laarhoven AIM, 2012, BRIT J DERMATOL, V167, P262, DOI 10.1111/j.1365-2133.2012.10933.x; Webb TL, 2012, PSYCHOL BULL, V138, P775, DOI 10.1037/a0027600; Wilson K. G, 1999, ACCEPTANCE COMMITMEN; Wolgast M, 2011, BEHAV RES THER, V49, P858, DOI 10.1016/j.brat.2011.09.011; Woo CW, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002036; Zaehringer J, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00470	76	1	1	6	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2021	16	6							e0253509	10.1371/journal.pone.0253509	http://dx.doi.org/10.1371/journal.pone.0253509			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TG9DM	34185792	gold, Green Published			2023-01-03	WOS:000671696900001
J	Lueyot, A; Rungsardthong, V; Vatanyoopaisarn, S; Hutangura, P; Wonganu, B; Wongsa-Ngasri, P; Charoenlappanit, S; Roytrakul, S; Thumthanaruk, B				Lueyot, Artima; Rungsardthong, Vilai; Vatanyoopaisarn, Savitri; Hutangura, Pokkwan; Wonganu, Benjamaporn; Wongsa-Ngasri, Pisit; Charoenlappanit, Sawanya; Roytrakul, Sittiruk; Thumthanaruk, Benjawan			Influence of collagen and some proteins on gel properties of jellyfish gelatin	PLOS ONE			English	Article							ACID-SOLUBLE COLLAGEN; BIGEYE SNAPPER; FUNCTIONAL-PROPERTIES; SKIN GELATIN; EXTRACTION; OPTIMIZATION	Marine gelatin is one of the food proteins used in food and non-food products, offering desirable functionalities such as gelling, thickening, and binding. Jellyfish has been chosen for this gelatin research, in view of the benefits of its main collagen protein and lower fat content, which may reduce the amounts of chemicals used in the preparative steps of gelatin production. To date, the lack of identified proteins in gelatin has limited the understanding of differentiating intrinsic factors quantitatively and qualitatively affecting gel properties. No comparison has been made between marine gelatin of fish and that of jellyfish, regarding protein type and distribution differences. Therefore, the study aimed at characterizing jellyfish gelatin extracted from by-products, that are i.e., pieces that have broken off during the grading and cleaning step of salted jellyfish processing. Different pretreatment by hydrochloric acid (HCl) concentrations (0.1 and 0.2 M) and hot water extraction time (12 and 24 h) were studied as factors in jellyfish gelatin extraction. The resultant jellyfish gelatin with the highest gel strength (JFG1), as well as two commercial gelatins of fish gelatin (FG) and bovine gelatin (BG), were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The results show that the jellyfish gelatin (JFG1) extracted with 0.1 M HCl at 60 degrees C for 12 h delivered a maximum gel strength of 323.74 g, which is lower than for FG and BG, exhibiting 640.65 and 540.06 g, respectively. The gelling and melting temperatures of JFG1 were 7.1 degrees C and 20.5 degrees C, displaying a cold set gel and unstable gel at room temperature, whereas the gelling and melting temperatures of FG and BG were 17.4 degrees C, 21.3 degrees C, and 27.5 degrees C, 32.7 degrees C, respectively. Proteomic analysis shows that 29 proteins, of which 10 are types of collagen proteins and 19 are non-collagen proteins, are common to all BG, FG, and JFG1, and that JFG1 is missing 3 other collagen proteins (collagen alpha-2 (XI chain), collagen alpha-2 (I chain), and collagen alpha-2 (IV chain), that are important to gel networks. Thus, the lack of these 3 collagen types influences the inferior gel properties of jellyfish gelatin.	[Lueyot, Artima; Rungsardthong, Vilai; Vatanyoopaisarn, Savitri; Hutangura, Pokkwan; Thumthanaruk, Benjawan] King Mongkuts Univ Technol North Bangkok, Fac Appl Sci, Dept AgroInd Food & Environm Technol, Bangkok, Thailand; [Wonganu, Benjamaporn] King Mongkuts Univ Technol North Bangkok, Fac Appl Sci, Dept Biotechnol, Bangkok, Thailand; [Wongsa-Ngasri, Pisit] Minist Agr & Cooperat, Fishery Technol Dev Div, Dept Fisheries, Bangkok, Thailand; [Charoenlappanit, Sawanya; Roytrakul, Sittiruk] Natl Sci & Technol Dev Agcy, Natl Ctr Genet Engn & Biotechnol, Funct Ingredients & Food Innovat Res Grp, Klongluang, Pathumthani, Thailand	King Mongkuts University of Technology North Bangkok; King Mongkuts University of Technology North Bangkok; Ministry of Agriculture & Cooperatives - Thailand; National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC)	Thumthanaruk, B (corresponding author), King Mongkuts Univ Technol North Bangkok, Fac Appl Sci, Dept AgroInd Food & Environm Technol, Bangkok, Thailand.	benjawan.t@sci.kmutnb.ac.th		Charoenlappanit, Sawanya/0000-0003-0852-7029; Thumthanaruk, Benjawan/0000-0002-8511-5215	Thailand Science Research and Innovation (TSRI) [PHD59I0041]; National Research Council of Thailand through the NRCT Senior Research Scholar Program [814-2020]	Thailand Science Research and Innovation (TSRI); National Research Council of Thailand through the NRCT Senior Research Scholar Program	Artima was awarded by Thailand Science Research and Innovation (TSRI) (No. PHD59I0041). Benjawan and Vilai was awarded by National Research Council of Thailand through the NRCT Senior Research Scholar Program (Contract no. 814-2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad M, 2010, FOOD HYDROCOLLOID, V24, P588, DOI 10.1016/j.foodhyd.2010.03.001; AOAC, 2012, OF METH AN; Arnesen JA, 2007, BIORESOURCE TECHNOL, V98, P53, DOI 10.1016/j.biortech.2005.11.021; Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-293; Benjakul S., 2012, FISH GELATIN, P388; Brotz L, 2017, REV FISH BIOL FISHER, V27, P1, DOI 10.1007/s11160-016-9445-y; Chancharern P, 2016, INT FOOD RES J, V23, P419; Cheow CS, 2007, FOOD CHEM, V101, P386, DOI 10.1016/j.foodchem.2006.01.046; Cho SM, 2005, FOOD HYDROCOLLOID, V19, P221, DOI 10.1016/j.foodhyd.2004.05.005; Cho Suengmok, 2014, Fisheries and Aquatic Sciences, V17, P299, DOI 10.5657/FAS.2014.0299; GMIA, 1986, STANDARD METHODS SAM; Gomez-Guillen MC, 2011, FOOD HYDROCOLLOID, V25, P1813, DOI 10.1016/j.foodhyd.2011.02.007; Howe EA, 2011, BIOINFORMATICS, V27, P3209, DOI 10.1093/bioinformatics/btr490; Intarasirisawat R, 2007, FOOD HYDROCOLLOID, V21, P537, DOI 10.1016/j.foodhyd.2006.05.012; Johnston FA., 1990, FOOD GELS; Jongjareonrak A, 2006, EUR FOOD RES TECHNOL, V222, P229, DOI 10.1007/s00217-005-0004-3; Jongjareonrak A, 2010, LWT-FOOD SCI TECHNOL, V43, P161, DOI 10.1016/j.lwt.2009.06.012; Kaewruang P, 2013, FOOD CHEM, V138, P1431, DOI 10.1016/j.foodchem.2012.09.114; Karim AA, 2009, FOOD HYDROCOLLOID, V23, P563, DOI 10.1016/j.foodhyd.2008.07.002; Khong NMH, 2016, FOOD CHEM, V196, P953, DOI 10.1016/j.foodchem.2015.09.094; Kittiphattanabawon P, 2005, FOOD CHEM, V89, P363, DOI 10.1016/j.foodchem.2004.02.042; Kittiphattanabawon P, 2016, LWT-FOOD SCI TECHNOL, V66, P186, DOI 10.1016/j.lwt.2015.10.029; Kittiphattanabawon P, 2010, FOOD HYDROCOLLOID, V24, P164, DOI 10.1016/j.foodhyd.2009.09.001; Klaiwong T., 2014, Journal of Agricultural Science and Technology B, V4, P555; Lin L, 2017, TRENDS FOOD SCI TECH, V68, P102, DOI 10.1016/j.tifs.2017.08.012; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mariod AA, 2013, ACTA SCI POLON-TECHN, V12, P135; Mirzapour-Kouhdasht A, 2019, J TEXTURE STUD, V50, P416, DOI 10.1111/jtxs.12408; Mohtar NF, 2010, FOOD CHEM, V122, P307, DOI 10.1016/j.foodchem.2010.02.027; Muyonga JH, 2004, FOOD CHEM, V86, P325, DOI 10.1016/j.foodchem.2003.09.038; Nalinanon S, 2008, FOOD HYDROCOLLOID, V22, P615, DOI 10.1016/j.foodhyd.2007.01.012; Norziah MH, 2014, FOOD BIOSCI, V5, P9, DOI 10.1016/j.fbio.2013.10.001; Omori M, 2001, HYDROBIOLOGIA, V451, P19, DOI 10.1023/A:1011879821323; Rodsuwan U, 2016, INT FOOD RES J, V23, P507; Sae-Leaw T, 2016, LWT-FOOD SCI TECHNOL, V65, P661, DOI 10.1016/j.lwt.2015.08.060; Sanaei A. V., 2013, International Food Research Journal, V20, P423; Thumthanaruk B., 2014, J APPL SCI, V2, P33; Thumthanaruk B, 2017, J FOOD PROCESS PRES, V41, DOI 10.1111/jfpp.12808; Tumerkan ETA, 2019, FOOD CHEM, V287, P273, DOI 10.1016/j.foodchem.2019.02.088; Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136; van Boekel MAJS, 1998, FOOD CHEM, V62, P403, DOI 10.1016/S0308-8146(98)00075-2; Yilmaz MT, 2013, FOOD CHEM, V141, P2450, DOI 10.1016/j.foodchem.2013.05.096	42	2	2	7	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2021	16	6							e0253254	10.1371/journal.pone.0253254	http://dx.doi.org/10.1371/journal.pone.0253254			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9BC	34143821	gold, Green Published			2023-01-03	WOS:000671690700047
J	Saib, A; Amara, W; Wang, P; Cattan, S; Dellal, A; Regaieg, K; Nahon, S; Nallet, O; Nguyen, LS				Saib, Anis; Amara, Walid; Wang, Pascal; Cattan, Simon; Dellal, Azeddine; Regaieg, Kais; Nahon, Stephane; Nallet, Olivier; Nguyen, Lee S.			Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study	PLOS ONE			English	Article								Background Hydroxychloroquine combined with azithromycin (HCQ/AZI) has initially been used against coronavirus disease-2019 (COVID-19). In this retrospective study, we assessed the clinical effects of HCQ/AZI, with a 28-days follow-up. Methods In a registry-study which included patients hospitalized for COVID-19 between March 15 and April 2, 2020, we compared patients who received HCQ/AZI to those who did not, regarding a composite outcome of mortality and mechanical ventilation with a 28-days follow-up. QT was monitored for patients treated with HCQ/AZI. Were excluded patients in intensive care units, palliative care and ventilated within 24 hours of admission. Three analyses were performed to adjust for selection bias: propensity score matching, multivariable survival, and inverse probability score weighting (IPSW) analyses. Results Overall, 203 patients were included: 60 patients treated by HCQ/AZI and 143 control patients. During the 28-days follow-up, 32 (16.3%) patients presented the primary outcome and 23 (12.3%) patients died. Propensity-score matching identified 52 unique pairs of patients with similar characteristics. In the matched cohort (n = 104), HCQ/AZI was not associated with the primary composite outcome (log-rank p-value = 0.16). In the overall cohort (n = 203), survival and IPSW analyses also found no benefit from HCQ/AZI. In the HCQ/AZI group, 11 (18.3%) patients prolonged QT interval duration, requiring treatment cessation. Conclusions HCQ/AZI combination therapy was not associated with lower in-hospital mortality and mechanical ventilation rate, with a 28-days follow-up. In the HCQ/AZI group, 18.3% of patients presented a prolonged QT interval requiring treatment cessation, however, control group was not monitored for this adverse event, making comparison impossible.	[Saib, Anis; Amara, Walid; Cattan, Simon; Nallet, Olivier] Grp Hosp Intercommunal Le Raincy Montfermeil, Cardiol Dept, Montfermeil, France; [Wang, Pascal] Grp Hosp Intercommunal Le Raincy Montfermeil, Pneumol Dept, Montfermeil, France; [Dellal, Azeddine] Grp Hosp Intercommunal Le Raincy Montfermeil, Rheumatol Dept, Montfermeil, France; [Regaieg, Kais] Grp Hosp Intercommunal Le Raincy Montfermeil, Intens Care Med Dept, Montfermeil, France; [Nahon, Stephane] Grp Hosp Intercommunal Le Raincy Montfermeil, Gastroenterol Dept, Montfermeil, France; [Nguyen, Lee S.] CMC Ambroise Pare, Res & Innovat Dept RICAP, Neuilly Sur Seine, France		Nguyen, LS (corresponding author), CMC Ambroise Pare, Res & Innovat Dept RICAP, Neuilly Sur Seine, France.	nguyen.lee@icloud.com		WANG, Pascal/0000-0002-4057-3765; NGUYEN, Lee S./0000-0002-6014-6269				[Anonymous], DECRET N 2020 314 25; Aromolaran AS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208321; Austin PC, 2017, STAT METHODS MED RES, V26, P1654, DOI 10.1177/0962280215584401; Capel RA, 2015, HEART RHYTHM, V12, P2186, DOI 10.1016/j.hrthm.2015.05.027; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Choi Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1574806; Cortegiani A, 2020, J CRIT CARE, V59, P176, DOI 10.1016/j.jcrc.2020.06.019; Costedoat-Chalumeau N, 2007, RHEUMATOLOGY, V46, P808, DOI 10.1093/rheumatology/kel402; Danial P, 2018, INTENS CARE MED, V44, P2153, DOI 10.1007/s00134-018-5442-z; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663; Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Lunceford JK, 2004, STAT MED, V23, P2937, DOI 10.1002/SIM.1903; Mahevas M., 2020, NO EVIDENCE CLIN EFF, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]; Nguyen LS, 2020, CIRCULATION, V142, P303, DOI 10.1161/CIRCULATIONAHA.120.048238; Nguyen LS, 2020, AM J TRANSPLANT, V20, P2791, DOI 10.1111/ajt.15849; Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMc1207269; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Rossi B, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13100317; Salem, 2020, LANCET LONDON ENGLAN, V396, P2, DOI DOI 10.1016/S0140-6736%2820%2931528-2; Trinkley KE, 2013, CURR MED RES OPIN, V29, P1719, DOI 10.1185/03007995.2013.840568; Vandenberk B, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003264; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wang M., 2020, CELL RES, V30, P269, DOI [10.1038/s41422-020-0282-02020, DOI 10.1038/s41422-020-0282-0]; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; YANG X, 2020, LANCET RESP MED, DOI [DOI 10.1016/S2213-2600(20)30079-5, 10.1016/S2213-2600(20)30079-5, 10.1016/S2213-2600(20)30079]; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237; Yazdany J, 2020, ANN INTERN MED, V172, P754, DOI 10.7326/M20-1334; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	31	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2021	16	6							e0252388	10.1371/journal.pone.0252388	http://dx.doi.org/10.1371/journal.pone.0252388			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RW	34106964	Green Published, gold			2023-01-03	WOS:000664642200047
J	Yu, GC; Yu, WF; Xu, XD; Ye, B; Yao, LW				Yu, Guocan; Yu, Wenfeng; Xu, Xudong; Ye, Bo; Yao, Liwei			Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis	PLOS ONE			English	Article							SURVIVAL	Background Esophageal cancer is a highly malignant cancer with a very poor prognosis. For resectable esophageal cancer, neoadjuvant treatment could improve the prognosis of esophageal cancer. However, current clinical neoadjuvant treatment options for esophageal cancer are still limited. The application of immunotherapy is a potentially beneficial new neoadjuvant treatment option for esophageal cancer. The objective of this meta-analysis is to evaluate the efficacy and safety of immunotherapy for the neoadjuvant treatment of esophageal cancer. Methods We will search Wanfang Database, SinoMed, China National Knowledge Infrastructure, Embase, Web of Science, Pubmed, and Cochrane Library for relevant articles published before July, 2021. We will also search the unpublished clinical trials of neoadjuvant immunotherapy in esophageal cancer in preprint website (such as bioRXiv and medRxiv) up to July, 2021. We will perform a meta-analysis to evaluate the efficacy and safety of neoadjuvant immunotherapy for resectable esophageal cancer. Randomized controlled trials (RCTs) will be included in this study. The risk of bias will be evaluated for each included study using the Cochrane Handbook for Systematic Reviews of Interventions. We will use RevMan 5.3 software for statistical analysis of the data. Results The results of this study will provide evidence of immunotherapy using as neoadjuvant treatment for esophageal cancer. This meta-analysis will be submitted to a peer-reviewed journal seeking for publication. Conclusion The results of this study will provide a reliable basis for clinicians and patients to formulate the best pre-surgical treatment plan for resectable esophageal cancer. Systematic review registration INPLASY202120026.	[Yu, Guocan; Yu, Wenfeng; Xu, Xudong; Ye, Bo] Zhejiang Univ, Sch Med, Affiliated Hangzhou Chest Hosp, Dept Thorac Surg, Hangzhou, Zhejiang, Peoples R China; [Yao, Liwei] Zhejiang Univ, Sch Med, Affiliated Hangzhou Chest Hosp, Dept Nursing, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Ye, B (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hangzhou Chest Hosp, Dept Thorac Surg, Hangzhou, Zhejiang, Peoples R China.; Yao, LW (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hangzhou Chest Hosp, Dept Nursing, Hangzhou, Zhejiang, Peoples R China.	yeboboye@126.com; ylwmed@163.com			Hangzhou Science and Technology Bureau [20201203B179]	Hangzhou Science and Technology Bureau	Guocan Yu, 20201203B179, Hangzhou Science and Technology Bureau, http://kj.hangzhou.gov.cn.The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alsop BR, 2016, GASTROENTEROL CLIN N, V45, P399, DOI 10.1016/j.gtc.2016.04.001; Babic B, 2020, CHIRURG, V91, P379, DOI 10.1007/s00104-020-01150-6; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buderi SI, 2017, INTERACT CARDIOV TH, V24, P115, DOI 10.1093/icvts/ivw281; Faggion CM, 2015, J EVID-BASED DENT PR, V15, P164, DOI 10.1016/j.jebdp.2015.09.002; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Ilson DH, 2018, GASTROENTEROLOGY, V154, P437, DOI 10.1053/j.gastro.2017.09.048; Jia XH, 2020, LUNG CANCER, V147, P143, DOI 10.1016/j.lungcan.2020.07.001; Jing SW, 2019, FUTURE ONCOL, V15, P2413, DOI 10.2217/fon-2019-0024; Kakeji Y, 2021, ESOPHAGUS-TOKYO, V18, P25, DOI 10.1007/s10388-020-00782-1; Kojima T, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0590-9; Kono K, 2018, ESOPHAGUS-TOKYO, V15, P1, DOI 10.1007/s10388-017-0596-2; Malthaner R, 2010, CLIN ONCOL-UK, V22, P250, DOI 10.1016/j.clon.2010.02.005; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Rouvelas I, 2005, LANCET ONCOL, V6, P864, DOI 10.1016/S1470-2045(05)70347-8; Shen YQ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243765; Watanabe M, 2020, SURG TODAY, V50, P12, DOI 10.1007/s00595-019-01878-7; Yang H, 2018, J CLIN ONCOL, V36, P2796, DOI 10.1200/JCO.2018.79.1483; Yu G., 2021, NEOADJUVANT IMMUNOTH, DOI [10.37766/inplasy2021.2.0026, DOI 10.37766/INPLASY2021.2.0026]; Yu GC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243161; Yu GC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242982; Zhao Q, 2019, CANCER MED-US, V8, P4519, DOI 10.1002/cam4.2336	25	1	1	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2021	16	6							e0252829	10.1371/journal.pone.0252829	http://dx.doi.org/10.1371/journal.pone.0252829			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RB	34086821	Green Published, gold			2023-01-03	WOS:000664640100143
J	Venkatesh, AK; Janke, A; Rothenberg, C; Chan, E; Becher, RD				Venkatesh, Arjun K.; Janke, Alexander; Rothenberg, Craig; Chan, Edwin; Becher, Robert D.			National trends in emergency department closures, mergers, and utilization, 2005-2015	PLOS ONE			English	Article							HEALTH-CARE; ASSOCIATION; INTEGRATION; POPULATION; CENTERS; ACCESS	Study objectives To describe nationwide hospital-based emergency department (ED) closures and mergers, as well as the utilization of emergency departments and inpatient beds, over time and across varying geographic areas in the United States. Methods Observational analysis of the American Hospital Association (AHA) Annual Survey from 2005 to 2015. Primary outcomes were hospital-based ED closure and merger. Secondary outcomes were yearly ED visits per hospital-based ED and yearly hospital admissions per hospital bed. Results The total number of hospital-based EDs decreased from 4,500 in 2005 to 4,460 in 2015, with 200 closures, 138 mergers, and 160 new hospital-based EDs. While yearly ED visits per hospital-based ED exhibited a 28.6% relative increase (from 25,083 to 32,248), yearly hospital admissions per hospital bed had a 3.3% relative increase (from 45.4 to 43.9) from 2005 to 2015. The number of hospital admissions and hospital beds did not change significantly in urban areas and declined in rural areas. ED visits grew more uniformly across urban and rural areas. Conclusions The number of hospital-based ED closures is small when accounting for mergers, but occurs as many more patients are presenting to a stable number of EDs in larger health systems, though rural areas may differentially affected. EDs were managing accelerating patient volumes alongside stagnant inpatient bed capacity.	[Venkatesh, Arjun K.; Janke, Alexander; Rothenberg, Craig; Chan, Edwin] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT 06510 USA; [Venkatesh, Arjun K.] Yale Univ, Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT 06510 USA; [Becher, Robert D.] Yale Univ, Sch Med, Sect Gen Surg Trauma & Surg Crit Care, New Haven, CT USA	Yale University; Yale University; Yale University	Venkatesh, AK (corresponding author), Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT 06510 USA.; Venkatesh, AK (corresponding author), Yale Univ, Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT 06510 USA.	arjun.venkatesh@yale.edu			Emergency Medicine Foundation Health Policy Scholar Award; Yale Center for Clinical Investigation from the National Center for Advancing Translational Science [KL2TR000140]; National Institutes of Health (NIH); National Academy of Medicine - American Board of Emergency Medicine Anniversary Fellowship	Emergency Medicine Foundation Health Policy Scholar Award; Yale Center for Clinical Investigation from the National Center for Advancing Translational Science; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Academy of Medicine - American Board of Emergency Medicine Anniversary Fellowship	Dr. Venkatesh reports support from the Emergency Medicine Foundation Health Policy Scholar Award (https://www.emfoundation.org/) and the Yale Center for Clinical Investigation KL2TR000140 from the National Center for Advancing Translational Science (https://ncats.nih.gov/), a component of the National Institutes of Health (NIH), as well as support by the National Academy of Medicine -American Board of Emergency Medicine Anniversary Fellowship (https://nam.edu/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agency for Healthcare Research and Quality, 2018, CHARTB ACC HLTH CAR; American Hospital Association, ANN HOSP SURV; [Anonymous], SUPPLEMENTAL RES DAT; Baicker K, 2013, NEW ENGL J MED, V369, P789, DOI 10.1056/NEJMp1306268; Baker LC, 2014, HEALTH AFFAIR, V33, P756, DOI 10.1377/hlthaff.2013.1279; Barnett ML, 2018, JAMA-J AM MED ASSOC, V320, P2147, DOI 10.1001/jama.2018.12354; Bellolio MF, 2017, WEST J EMERG MED, V18, P835, DOI 10.5811/westjem.2017.5.34152; Bernstein SL, 2009, ACAD EMERG MED, V16, P1, DOI 10.1111/j.1553-2712.2008.00295.x; Burwell SM, 2015, NEW ENGL J MED, V372, P897, DOI 10.1056/NEJMp1500445; Carr BG, 2017, INJURY, V48, P332, DOI 10.1016/j.injury.2017.01.008; ERMANN D, 1985, MED CARE, V23, P401, DOI 10.1097/00005650-198505000-00006; Hoot NR, 2008, ANN EMERG MED, V52, P126, DOI 10.1016/j.annemergmed.2008.03.014; Hsia RY, 2011, JAMA-J AM MED ASSOC, V305, P1978, DOI 10.1001/jama.2011.620; Hsia RYJ, 2011, HEALTH AFFAIR, V30, P1912, DOI 10.1377/hlthaff.2011.0510; Keeney T., FREE STANDING ERS NE; Koeze E., 2020, NEW YORK TIMES; Lin MP, 2018, JAMA INTERN MED, V178, P1708, DOI 10.1001/jamainternmed.2018.4725; Lindrooth RC, 2018, HEALTH AFFAIR, V37, P111, DOI 10.1377/hlthaff.2017.0976; Liu C, 2014, HEALTH AFFAIR, V33, P1323, DOI 10.1377/hlthaff.2013.1203; Morley C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203316; Moskop JC., 2018, ANN EMERG MED; National Center for Health Statistics, 2017, EMERGENCY DEP VISITS, V8, P2020; Neprash HT, 2015, JAMA INTERN MED, V175, P1932, DOI 10.1001/jamainternmed.2015.4610; Oberlander J, 2017, NEW ENGL J MED, V376, P1, DOI 10.1056/NEJMp1614438; RAND Corp, HOSP EM DEP US IMP R; Rural Health Research Center, RUC DAT ZIP COD RUC; Schuur JD, 2017, ANN EMERG MED, V69, P383, DOI 10.1016/j.annemergmed.2016.05.019; Shen YC, 2016, CIRCULATION, V134, P1595, DOI 10.1161/CIRCULATIONAHA.116.025057; Sun R, 2018, HEALTHCARE COST UTIL; U.S. Census Bureau, AM COMMUNITY SURVEY; U.S Department of Agriculture Economic Research Service Documentation, 2010, RUR URB COMM AR RUCA; Venkatesh AK, 2020, ACAD EMERG MED, V27, P570, DOI 10.1111/acem.13971; Venkatesh AK, 2019, JAMA INTERN MED, V179, P686, DOI 10.1001/jamainternmed.2019.0037; Walker DM, 2018, MED CARE, V56, P831, DOI 10.1097/MLR.0000000000000980; Yee T, 2013, 26 CTR STUD HLTH SYS; Young GJ, 2017, MILBANK MEMORIAL FUN	36	8	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2021	16	5							e0251729	10.1371/journal.pone.0251729	http://dx.doi.org/10.1371/journal.pone.0251729			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6NW	34015007	Green Published, gold			2023-01-03	WOS:000664631600057
J	Michie, S; West, R				Michie, Susan; West, Robert			Sustained behavior change is key to preventing and tackling future pandemics	NATURE MEDICINE			English	Editorial Material								Investment in research and programs to discover and apply the principles that underpin sustained behavior change is needed to address the continuing threat from COVID-19 and future pandemics and will require collaboration among behavioral, social, biomedical, public-health and clinical scientists.	[Michie, Susan] UCL, Ctr Behav Change, London, England; [West, Robert] UCL, Inst Epidemiol & Healthcare, Dept Behav Sci & Hlth, London, England	University of London; University College London; University of London; University College London	Michie, S (corresponding author), UCL, Ctr Behav Change, London, England.; West, R (corresponding author), UCL, Inst Epidemiol & Healthcare, Dept Behav Sci & Hlth, London, England.	s.michie@ucl.ac.uk; robertwest100@gmail.com	Michie, Susan/A-1745-2010; West, Robert/B-5414-2009	Michie, Susan/0000-0003-0063-6378; West, Robert/0000-0001-6398-0921				Atchison C, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-043577; Brewer M. B., 2008, RATIONALITY SOCIAL R, DOI [DOI 10.4324/9780203889695, 10.4324/9780203889695]; Fancourt D, 2020, PREPRINT MEDRXIV, DOI [10.1101/2020.10.19.20215376, DOI 10.1101/2020.10.19.20215376]; Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7; Head MG, 2020, LANCET GLOB HEALTH, V8, pE1295, DOI 10.1016/S2214-109X(20)30357-0; Houghton C, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013582; Kerrouche E., 2020, PREPRINT, DOI [10.2139/ssrn.3652543, DOI 10.2139/SSRN.3652543]; Lorencatto F, 2020, PUBLIC HLTH ENGLAND; Michie S., 2014, GUIDE DESIGNING INTE; Michie S, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2982; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Pichler S, 2020, HEALTH AFFAIR, V39, P2197, DOI 10.1377/hlthaff.2020.00863; Rajan S., 2020, Eurohealth, V26, P34; Smith LE, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n608; Tyler TR, 2003, PERS SOC PSYCHOL REV, V7, P349, DOI 10.1207/S15327957PSPR0704_07; West R., 2020, QEIOS, DOI [10.32388/WW04E6, DOI 10.32388/WW04E6, 10.32388/WW04E6.2, DOI 10.32388/WW04E6.2]; West R, 2020, NAT HUM BEHAV, V4, P451, DOI 10.1038/s41562-020-0887-9; Wood P., 2020, CITYAM; World Health Organization, 2020, REG OFF EUR	19	20	20	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2021	27	5					749	752		10.1038/s41591-021-01345-2	http://dx.doi.org/10.1038/s41591-021-01345-2		MAY 2021	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	SC5GH	33972794	Bronze, Green Submitted			2023-01-03	WOS:000648805100004
J	Quek, A; Zaini, HM; Kassim, NK; Sulaiman, F; Rukayadi, Y; Ismail, A; Abidin, ZZ; Awang, K				Quek, Alexandra; Zaini, Hafizah Mohd; Kassim, Nur Kartinee; Sulaiman, Fadzil; Rukayadi, Yaya; Ismail, Amin; Abidin, Zamirah Zainal; Awang, Khalijah			Oxygen radical antioxidant capacity (ORAC) and antibacterial properties of Melicope glabra bark extracts and isolated compounds	PLOS ONE			English	Article							ANTIMICROBIAL ACTIVITY; COUMARINS	Melicope glabra (Blume) T. G. Hartley from the Rutaceae family is one of the richest sources of plant secondary metabolites, including coumarins and flavanoids. This study investigates the free radical scavenging and antibacterial activities of M. glabra and its isolated compounds. M. glabra ethyl acetate and methanol extracts were prepared using the cold maceration technique. The isolation of compounds was performed with column chromatography. The free radical scavenging activity of the extracts and isolated compounds were evaluated based on their oxygen radical absorbance capacity (ORAC) activities. The extracts and compounds were also subjected to antibacterial evaluation using bio-autographic and minimal inhibitory concentration (MIC) techniques against two oral pathogens, Enterococcus faecalis and Streptococcus mutans. Isolation of phytoconstituents from ethyl acetate extract successfully yielded quercetin 3, 5, 3'-trimethyl ether (1) and kumatakenin (2), while the isolation of the methanol extract resulted in scoparone (3), 6, 7, 8-trimethoxycoumarin (4), marmesin (5), glabranin (6), umbelliferone (7), scopoletin (8), and sesamin (9). The study is the first to isolate compound (1) from Rutaceae plants, and also the first to report the isolation of compounds (2-5) from M. glabra. The ORAC evaluation showed that the methanol extract is stronger than the ethyl acetate extract, while umbelliferone (7) exhibited the highest ORAC value of 24 965 mu molTE/g followed by glabranin (6), sesamin (9) and scopoletin (8). Ethyl acetate extract showed stronger antibacterial activity towards E. faecalis and S. mutans than the methanol extract with MIC values of 4166.7 +/- 1443.4 mu g/ml and 8303.3 +/- 360.8 mu g/ml respectively. Ethyl acetate extract inhibited E. faecalis growth, as shown by the lowest optical density value of 0.046 at a concentration of 5.0 mg/mL with a percentage inhibition of 95%. Among the isolated compounds tested, umbelliferone (7) and sesamin (9) exhibited promising antibacterial activity against S. mutans with both exhibiting MIC values of 208.3 +/- 90.6 mu g/ml. Findings from this study suggests M. glabra as a natural source of potent antioxidant and antibacterial agents.	[Quek, Alexandra; Zaini, Hafizah Mohd; Kassim, Nur Kartinee; Sulaiman, Fadzil] Univ Putra Malaysia, Fac Sci, Dept Chem, Serdang, Selangor, Malaysia; [Kassim, Nur Kartinee] Univ Putra Malaysia, Fac Sci, Integrated Chem BioPhys Res, Serdang, Selangor, Malaysia; [Rukayadi, Yaya] Univ Putra Malaysia, Inst Biosci, Lab Nat Prod, Serdang, Selangor, Malaysia; [Ismail, Amin] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Dietet, Serdang, Selangor, Malaysia; [Abidin, Zamirah Zainal] Univ Kebangsaan Malaysia Kuala Lumpur, Fac Dent, Dept Oral Clin Biol, Kuala Lumpur, Malaysia; [Awang, Khalijah] Univ Malaya, Fac Sci, Dept Chem, Kuala Lumpur, Malaysia	Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Kebangsaan Malaysia; Universiti Malaya	Kassim, NK (corresponding author), Univ Putra Malaysia, Fac Sci, Dept Chem, Serdang, Selangor, Malaysia.; Kassim, NK (corresponding author), Univ Putra Malaysia, Fac Sci, Integrated Chem BioPhys Res, Serdang, Selangor, Malaysia.	kartinee@upm.edu.my	Quek, Alexandra/AAZ-8786-2021; AWANG, KHALIJAH/B-8781-2010	AWANG, KHALIJAH/0000-0001-5971-6570; Zainal-Abidin, Zamirah/0000-0001-8426-8044	FRGS [FRGS/1/2016/WAB11/UPM/02/1]; Grant Putra IPM [9445700]	FRGS; Grant Putra IPM	This work was supported by the FRGS Grant (FRGS/1/2016/WAB11/UPM/02/1) and Grant Putra IPM (Grant Vot No: 9445700).	Alviano WS, 2008, ARCH ORAL BIOL, V53, P545, DOI 10.1016/j.archoralbio.2007.12.001; Asgarpanah J, 2011, AFR J BIOTECHNOL, V10, P11287; Bonifait L, 2012, FITOTERAPIA, V83, P996, DOI 10.1016/j.fitote.2012.06.003; Chanda S, 2009, AFR J MICROBIOL RES, V3, P981; Mota KSD, 2012, MOLECULES, V17, P14418, DOI 10.3390/molecules171214418; HAMBURGER MO, 1987, J NAT PROD, V50, P19, DOI 10.1021/np50049a003; Huong DT, 2005, PHARMAZIE, V60, P627; IIDA T, 1982, PHYTOCHEMISTRY, V21, P673, DOI 10.1016/0031-9422(82)83163-4; Kandhare AD, 2013, BIOMED AGING PATHOL, V3, P23; Kassim NK, 2013, FOOD CHEM, V139, P87, DOI 10.1016/j.foodchem.2013.01.108; KUMAR V, 1990, PHYTOCHEMISTRY, V29, P243, DOI 10.1016/0031-9422(90)89042-8; LEE RE, 1981, ARZNEIMITTEL-FORSCH, V31-1, P640; Ma CH, 2006, CHROMATOGRAPHIA, V64, P83, DOI 10.1365/s10337-006-0789-7; MANANDHAR MD, 1985, PHYTOCHEMISTRY, V24, P199, DOI 10.1016/S0031-9422(00)80844-4; Masoko P, 2017, J EVID-BASED INTEGR, V22, P936, DOI 10.1177/2515690X17746774; Naqvi S.A.R., 2019, ANTIOXIDANTS-BASEL, DOI [10.5772/INTECHOPEN.84864, DOI 10.5772/INTECHOPEN.84864]; Nur Kartinee Kassim, 2012, International Proceedings of Chemical, Biological and Environmental Engineering (IPCBEE), V38, P31; Ohara A, 2008, FOOD SCI TECHNOL RES, V14, P190, DOI 10.3136/fstr.14.190; Park KM, 2003, J ETHNOPHARMACOL, V84, P181, DOI 10.1016/S0378-8741(02)00318-5; PAYA M, 1992, BIOCHEM PHARMACOL, V44, P205, DOI 10.1016/0006-2952(92)90002-Z; Salehi B, 2019, MOLECULES, V24, DOI 10.3390/molecules24132454; Salih EYA, 2017, S AFR J BOT, V108, P370, DOI 10.1016/j.sajb.2016.08.020; Saputri Ratih Dewi, 2018, Natural Product Sciences, V24, P155, DOI 10.20307/nps.2018.24.3.155; Semple SJ, 1999, J ETHNOPHARMACOL, V68, P283, DOI 10.1016/S0378-8741(99)00050-1; Sharifi-Rad M, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00694; Silva WPK, 2002, MYCOPATHOLOGIA, V153, P199, DOI 10.1023/A:1014910132595; Singh R, 2010, FOOD CHEM, V120, P825, DOI 10.1016/j.foodchem.2009.11.022; Siqueira JF, 2001, J ENDODONT, V27, P563, DOI 10.1097/00004770-200109000-00002; Tanase C, 2019, MOLECULES, V24, DOI 10.3390/molecules24061182; Tanase C, 2018, BIORESOURCES, V13, P2247, DOI 10.15376/biores.13.2.2247-2267; Tanzer J M, 2001, J Dent Educ, V65, P1028; Trumble JT, 1996, J AGR FOOD CHEM, V44, P2859, DOI 10.1021/jf960156b; van Vuuren SF, 2008, J ETHNOPHARMACOL, V119, P462, DOI 10.1016/j.jep.2008.05.038; Villaflores OB, 2010, PHARMACOGN MAG, V6, P339, DOI 10.4103/0973-1296.71785	34	4	4	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2021	16	5							e0251534	10.1371/journal.pone.0251534	http://dx.doi.org/10.1371/journal.pone.0251534			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6LC	33970960	gold, Green Published			2023-01-03	WOS:000664624400057
J	Makhlouf, AM; Ibrahim, MIM; Awaisu, A; Vyas, SK; Yusuff, KB				Makhlouf, Ahmed Mohamed; Ibrahim, Mohamed Izham Mohamed; Awaisu, Ahmed; Vyas, Saseendran Kattezhathu; Yusuff, Kazeem Babatunde			Management of common minor ailments in Qatar: Community pharmacists' self-perceived competency and its predictors	PLOS ONE			English	Article							MEDICATION; PROVISION; MEDICINES; EFFICACY; ADVICE; CARE	Studies focused on comprehensive assessment of self-perceived competency of community pharmacists to manage minor ailments are scanty despite that self-perceived competency is a valid determinant of task performance. The objectives of the study were to assess community pharmacists' self-perceived competency to manage fourteen common minor ailments in Qatar, and identify its significant predictors. A cross-sectional assessment of 307 community pharmacists was conducted with a pre-tested 20-item questionnaire. Self-perceived competency was assessed with nine elements on a scale of 1-10 (Maximum obtainable score: Each minor ailment = 90; each element = 140). Mann-Whitney U and bivariate logistic regression were used for data analyses. The response rate was 91.9% (282/307). The majority of the respondents were males (68.1%; 192/282), within the age range of 31-40 years (55.3%; 156/282). The minor ailments with the highest median competency score were constipation (76), and cold/catarrh (75) while travel sickness (69), and ringworm (69) had the lowest. The two condition-specific competency elements with the highest median score were recommendation of over-the-counter (OTC) medicines (115), and provision of instructions to guide its use (115). Ability to differentiate minor ailments from other medical conditions had the lowest median competency score (109). The significant predictors self-perceived competency were female gender (OR = 2.39, 95%CI: 1.34-4.25, p = 0.003), and working for chain pharmacies (OR = 2.54, 95%CI: 1.30-4.96, p = 0.006). Overall, Community pharmacists' self-perceived competency was adequate for majority of the common minor ailments, and it was highest for constipation and cold/catarrh, and specifically for the recommendation of OTC medicines and provision of instructions to guide its use. However, diagnostic ability to differentiate minor ailments from other medical conditions with similar features had the lowest median competency score. Female gender and working in chain pharmacies were the significant predictors of self-perceived competency to manage minor ailments.	[Makhlouf, Ahmed Mohamed; Ibrahim, Mohamed Izham Mohamed; Awaisu, Ahmed; Yusuff, Kazeem Babatunde] Qatar Univ, Coll Pharm, Dept Clin Pharm & Practice, QU Hlth, Doha, Qatar; [Vyas, Saseendran Kattezhathu] Wellcare Grp, Doha, Qatar	Qatar University	Yusuff, KB (corresponding author), Qatar Univ, Coll Pharm, Dept Clin Pharm & Practice, QU Hlth, Doha, Qatar.	kyusuff@qu.edu.qa	; Yusuff, Kazeem/M-4500-2016	Awaisu, Ahmed/0000-0002-9029-8925; Yusuff, Kazeem/0000-0001-6512-7879; Makhlouf, Ahmed/0000-0003-4447-8834	Qatar National Research Foundation [UREP24-147-3043]	Qatar National Research Foundation(National Research Foundation of Korea)	The study was funded by the Qatar National Research Foundation's Undergraduate Research Experience Program [UREP24-147-3043]. The funder provided support in the form of honorarium for authors MII, AMM, SKV, KBY, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Al-Sulaiti F, 2021, INT Q COMMUNITY HEAL, V41, P285, DOI 10.1177/0272684X20918048; Aly M, 2018, RES SOC ADMIN PHARM, V14, P989, DOI 10.1016/j.sapharm.2017.12.004; [Anonymous], QAT NAT HLTH STRAT 2; Ayele AA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190583; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bednall R, 2003, FAM PRACT, V20, P54, DOI 10.1093/fampra/20.1.54; Brata C, 2015, RES SOC ADMIN PHARM, V11, P136, DOI 10.1016/j.sapharm.2014.07.003; Brata C, 2013, RES SOC ADMIN PHARM, V9, P370, DOI 10.1016/j.sapharm.2012.08.001; Cleland, 2014, COMMUNITY PHARM MANA; Coelho Raquel B, 2014, Pharm Pract (Granada), V12, P451; Hammad EA, 2018, INT J CLIN PHARM-NET, V40, P982, DOI 10.1007/s11096-018-0679-8; Ibrahim Mohamed I., 2016, Pharmacy Pract (Granada), V14, P800, DOI [10.18549/pharmpract.2016.04.800, 10.18549/PharmPract.2016.04.800]; Jacob J, 2013, INT J BUS MANAGE, V8; John O.P., 1998, HDB PERSONALITY THEO, P154; Kheir N, 2008, AM J PHARM EDUC, V72, DOI 10.5688/aj7206133; Lunenburg F., 2011, INT J MANAGE BUS ADM, V14; Manasseh NI., 2015, PSYCHOL BEHAV SCI, V4, P170, DOI [10.11648/j.pbs.20150404.15, DOI 10.11648/J.PBS.20150404.15, DOI 10.11648/j.pbs.20150404.15]; Mansell K, 2015, INT J PHARM PRACT, V23, P95, DOI 10.1111/ijpp.12128; MedSask University of Saskatchewan, GUID PRESCR MIN AL P; Mesquita AR, 2013, INT J CLIN PHARM-NET, V35, P647, DOI 10.1007/s11096-013-9787-7; NHS Highland Area Drug and Therapeutics Committee, 2016, COMMUNITY PHARM MINO; Paudyal V, 2013, BRIT J GEN PRACT, V63, pE472, DOI 10.3399/bjgp13X669194; Paudyal V, 2011, HEALTH POLICY, V101, P253, DOI 10.1016/j.healthpol.2011.05.010; Pelicano-Romano J, 2015, HEALTH EXPECT, V18, P1721, DOI 10.1111/hex.12165; Pharmaceutical Society of Australia, 2014, BETT HLTH OUTC IMPR; Porteous T, 2006, BRIT J GEN PRACT, V56, P911; Qatar National Vision 2030, GEN SECR DEV PLANN; Royal Pharmaceutical Society of Great Britain, 2014, SCOTT MIN AL SERV; Selvaraj A, 2020, INT J CLIN PHARM-NET, V42, P777, DOI 10.1007/s11096-020-00973-x; Stajkovic AD, 1998, PSYCHOL BULL, V124, P240, DOI 10.1037/0033-2909.124.2.240; Stewart D, 2007, BRIT J CLIN PHARMACO, V64, P90, DOI 10.1111/j.1365-2125.2007.02865.x; Taylor JG, 2016, INT J GEN MED, V9, P291, DOI 10.2147/IJGM.S99540; Tsai YF, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-98; United Nations (UN), 2020, WORLD POPULATION REV; Watson MC, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006261; Wheeler James S, 2018, Am J Pharm Educ, V82, P6461, DOI 10.5688/ajpe6461; World Health Organization (WHO), 1988, ROL PHARM HLTH CAR S; You Joyce H, 2011, BMC Clin Pharmacol, V11, P19, DOI 10.1186/1472-6904-11-19	38	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256156	10.1371/journal.pone.0256156	http://dx.doi.org/10.1371/journal.pone.0256156			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UC2NW	34398894	gold, Green Published			2023-01-03	WOS:000686370000032
J	Nkosi-Gondwe, T; Robberstad, B; Mukaka, M; Idro, R; Opoka, RO; Banda, S; Kuhl, MJ; Ter Kuile, FO; Blomberg, B; Phiri, KS				Nkosi-Gondwe, Thandile; Robberstad, Bjarne; Mukaka, Mavuto; Idro, Richard; Opoka, Robert O.; Banda, Saidon; Kuhl, Melf-Jakob; O. Ter Kuile, Feiko; Blomberg, Bjorn; Phiri, Kamija S.			Adherence to community versus facility-based delivery of monthly malaria chemoprevention with dihydroartemisinin-piperaquine for the post-discharge management of severe anemia in Malawian children: A cluster randomized trial	PLOS ONE			English	Article							INTERMITTENT PREVENTIVE TREATMENT; SULFADOXINE-PYRIMETHAMINE; HEALTH-WORKERS; PREGNANCY; REMINDERS; MORTALITY	Background The provision of post-discharge malaria chemoprevention (PMC) in children recently admitted with severe anemia reduces the risk of death and re-admissions in malaria endemic countries. The main objective of this trial was to identify the most effective method of delivering dihydroartemesinin-piperaquine to children recovering from severe anemia. Methods This was a 5-arm, cluster-randomized trial among under-5 children hospitalized with severe anemia at Zomba Central Hospital in Southern Malawi. Children were randomized to receive three day treatment doses of dihydroartemesinin-piperaquine monthly either; 1) in the community without a short text reminder; 2) in the community with a short message reminder; 3) in the community with a community health worker reminder; 4) at the facility without a short text reminder; or 5) at the facility with a short message reminder. The primary outcome measure was adherence to all treatment doses of dihydroartemesinin-piperaquine and this was assessed by pill-counts done by field workers during home visits. Poisson regression was utilized for analysis. Results Between March 2016 and October 2018, 1460 clusters were randomized. A total of 667 children were screened and 375 from 329 clusters were eligible and enrolled from the hospital. Adherence was higher in all three community-based compared to the two facility-based delivery (156/221 [70.6%] vs. 78/150 [52.0%], IRR = 1.24,95%CI 1.06-1.44, p = 0.006). This was observed in both the SMS group (IRR = 1.41,1.21-1.64, p<0.001) and in the non-SMS group (IRR = 1.37,1.18-1.61, p<0.001). Although adherence was higher among SMS recipients (98/148 66.2%] vs. non-SMS 82/144 (56.9%), there was no statistical evidence that SMS reminders resulted in greater adherence ([IRR = 1.03,0.88-1.21, p = 0.68). When compared to the facility-based non-SMS arm (control arm), community-based delivery utilizing CHWs resulted in higher adherence [39/76 (51.3%) vs. 54/79 (68.4%), IRR = 1.32, 1.14-1.54, p<0.001]. Interpretation Community-based delivery of dihydroartemesinin-piperaquine for post-discharge malaria chemoprevention in children recovering from severe anemia resulted in higher adherence compared to facility-based methods.	[Nkosi-Gondwe, Thandile; Robberstad, Bjarne; Kuhl, Melf-Jakob; Blomberg, Bjorn] Univ Malawi, Sch Publ Hlth & Family Med, Coll Med, Blantyre, Malawi; [Nkosi-Gondwe, Thandile; Robberstad, Bjarne; Kuhl, Melf-Jakob; Blomberg, Bjorn] Univ Bergen, Dept Global Publ Hlth & Primary Care, Ctr Int Hlth, Bergen, Norway; [Mukaka, Mavuto] Mahidol Univ, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand; [Mukaka, Mavuto] Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Oxford, England; [Idro, Richard; Opoka, Robert O.] Makerere Univ, Dept Pediat & Child Hlth, Coll Hlth Sci, Kampala, Uganda; [O. Ter Kuile, Feiko] Kenya Med Res Inst KEMRI, Ctr Global Hlth Res, Kisumu, Kenya; [O. Ter Kuile, Feiko] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool, Merseyside, England; [Blomberg, Bjorn] Univ Bergen, Dept Clin Sci, Bergen, Norway; [Blomberg, Bjorn] Haukeland Hosp, Norwegian Natl Advisory Unit Trop Infect Dis, Bergen, Norway	University of Malawi; University of Bergen; Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; University of Oxford; Makerere University; Kenya Medical Research Institute; Liverpool School of Tropical Medicine; University of Bergen; University of Bergen; Haukeland University Hospital	Nkosi-Gondwe, T (corresponding author), Univ Malawi, Sch Publ Hlth & Family Med, Coll Med, Blantyre, Malawi.; Nkosi-Gondwe, T (corresponding author), Univ Bergen, Dept Global Publ Hlth & Primary Care, Ctr Int Hlth, Bergen, Norway.	thandile_nkosi@yahoo.com	Blomberg, Bjorn/B-9605-2015	Blomberg, Bjorn/0000-0001-5647-4297; ter Kuile, Feiko/0000-0003-3663-5617; Mukaka, Mavuto/0000-0002-5036-6583	Research Council of Norway through the Global Health and Vaccination Programme (GLOBVAC) [234487]; European Union	Research Council of Norway through the Global Health and Vaccination Programme (GLOBVAC); European Union(European Commission)	The study was funded by the Research Council of Norway through the Global Health and Vaccination Programme (GLOBVAC), project number 234487. GLOBVAC is part of the EDCTP2 programme supported by the European Union. The funders had no role in the design of the study, in the collection, analysis and interpretation of the data, or in writing, preparation and submission of the manuscript. https://www.forskningsradet.no/en/.	Ahorlu CK., 2012, MALARIA J, V11, pP108; Akech SO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-256; Antwi GD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166951; Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7; Banek K, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2370-x; Bhutta Z.A., 2010, GLOB HLTH WORKFORCE, V1, P61; Bojang KA, 1997, ANN TROP PAEDIATR, V17, P355, DOI 10.1080/02724936.1997.11747910; Bojang KA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000409; Calis JCJ, 2008, NEW ENGL J MED, V358, P888, DOI 10.1056/NEJMoa072727; Dhabangi A, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1398-6; Diawara F, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1974-x; Gondwe T, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1199-3; Health Organization, 2012, UPD WHO POL REC INT; Kwambai TK, 2020, NEW ENGL J MED, V383, P2242, DOI 10.1056/NEJMoa2002820; Kwambai TK, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2972-1; Kweku M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007256; Lackritz EM, 1997, AIDS, V11, P1487, DOI 10.1097/00002030-199712000-00013; Mbonye AK, 2008, B WORLD HEALTH ORGAN, V86, P93, DOI 10.2471/BLT.07.041822; Moraleda C, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0816-x; Msyamboza KP, 2009, TROP MED INT HEALTH, V14, P183, DOI 10.1111/j.1365-3156.2008.02197.x; Mwapasa V, 2017, JAIDS-J ACQ IMM DEF, V75, pS123, DOI [10.1097/QAI.0000000000001340, 10.1097/qai.0000000000001340]; Ngasala BE, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-64; Nkosi-Gondwe T, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3791-5; Otieno G, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-44; Pallas SW, 2013, AM J PUBLIC HEALTH, V103, pE74, DOI 10.2105/AJPH.2012.301102; Patouillard E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024871; Phiri K, 2012, LANCET INFECT DIS, V12, P191, DOI 10.1016/S1473-3099(11)70320-6; Phiri KS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002903; Pop-Eleches C, 2011, AIDS, V25, P825, DOI 10.1097/QAD.0b013e32834380c1; Salam RA, 2014, INFECT DIS POVERTY, V3, DOI 10.1186/2049-9957-3-25; Steinhardt LC, 2019, AM J TROP MED HYG, V100, P460, DOI 10.4269/ajtmh.18-0529; Svege S, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3327-z; Verhoef H, 2002, LANCET, V360, P908, DOI 10.1016/S0140-6736(02)11027-0; White A, 2016, CIN-COMPUT INFORM NU, V34, P206, DOI [10.1097/CIN.0000000000000231, 10.1097/01.NCN.0000484013.73650.48]; White NJ, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2509-9; WHO, 2011, WHO TECH REP SER, V959, P1; World Health Organisation, 2011, INT PREV TREATM INF; World Health Organization, 2011, GLOBAL PREVALENCE AN, Vfourth, P1; Zurovac D, 2013, GLOBALIZATION HEALTH, V9, DOI 10.1186/1744-8603-9-20; Zurovac D, 2011, LANCET, V378, P795, DOI 10.1016/S0140-6736(11)60783-6	40	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0255769	10.1371/journal.pone.0255769	http://dx.doi.org/10.1371/journal.pone.0255769			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9EM	34506503	Green Published, gold, Green Accepted			2023-01-03	WOS:000729120700030
J	Price, J; Rushton, A; Tyros, V; Heneghan, NR				Price, Jonathan; Rushton, Alison; Tyros, Vasileios; Heneghan, Nicola R.			Expert consensus on the important chronic non-specific neck pain motor control and segmental exercise and dosage variables: An international e-Delphi study	PLOS ONE			English	Article							RESISTANCE TRAINING FREQUENCY; DOSE-RESPONSE RELATIONSHIP; PHYSICAL-THERAPY; MUSCLE HYPERTROPHY; STRENGTH; INTERVENTIONS; PRESCRIPTION; DURATION; CRITERIA	Background Chronic non-specific neck pain is highly prevalent, resulting in significant disability. Despite exercise being a mainstay treatment, guidance on optimal exercise and dosage variables is lacking. Combining submaximal effort deep cervical muscles exercise (motor control) and superficial cervical muscles exercise (segmental) reduces chronic non-specific neck pain, but evaluation of optimal exercise and dosage variables is prevented by clinical heterogeneity. Objective To gain consensus on important motor control and segmental exercise and dosage variables for chronic non-specific neck pain. Methods An international 3-round e-Delphi study, was conducted with experts in neck pain management (academic and clinical). In round 1, exercise and dosage variables were obtained from expert opinion and clinical trial data, then analysed thematically (two independent researchers) to develop themes and statements. In rounds 2 and 3, participants rated their agreement with statements (1-5 Likert scale). Statement consensus was evaluated using progressively increased a priori criteria using descriptive statistics. Results Thirty-seven experts participated (10 countries). Twenty-nine responded to round 1 (79%), 26 round 2 (70%) and 24 round 3 (65%). Round 1 generated 79 statements outlining the interacting components of exercise prescription. Following rounds 2 and 3, consensus was achieved for 46 important components of exercise and dosage prescription across 5 themes (clinical reasoning, dosage variables, exercise variables, evaluation criteria and progression) and 2 subthemes (progression criteria and progression variables). Excellent agreement and qualitative data supports exercise prescription complexity and the need for individualised, acceptable, and feasible exercise. Only 37% of important exercise components were generated from clinical trial data. Agreement was highest (88%-96%) for 3 dosage variables: intensity of effort, frequency, and repetitions. Conclusion Multiple exercise and dosage variables are important, resulting in complex and individualised exercise prescription not found in clinical trials. Future research should use these important variables to prescribe an evidence-informed approach to exercise.	[Price, Jonathan] Birmingham Community Healthcare NHS Fdn Trust, Musculoskeletal Physiotherapy Serv, Birmingham, W Midlands, England; [Price, Jonathan; Rushton, Alison; Heneghan, Nicola R.] Univ Birmingham, Coll Life & Environm Sci, Ctr Precis Rehabil Spinal Pain CPR Spine, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England; [Rushton, Alison] Western Univ, Sch Phys Therapy, London, ON, Canada; [Tyros, Vasileios] Edgbaston Physiotherapy Clin, Birmingham, W Midlands, England	University of Birmingham; Western University (University of Western Ontario)	Price, J (corresponding author), Birmingham Community Healthcare NHS Fdn Trust, Musculoskeletal Physiotherapy Serv, Birmingham, W Midlands, England.; Price, J (corresponding author), Univ Birmingham, Coll Life & Environm Sci, Ctr Precis Rehabil Spinal Pain CPR Spine, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England.	Jonathan.price2@nhs.net	Rushton, Alison/V-1260-2017; R Heneghan, Nicola/B-2647-2016	Rushton, Alison/0000-0001-8114-7669; R Heneghan, Nicola/0000-0001-7599-3674; Price, Jonathan/0000-0002-5505-1564	Health Education England; National Institute for Health Research (HEE/NIHR ICA Programme Pre-doctoral Clinical Academic Fellowship) [ICAPCAF-2018-01-117]	Health Education England; National Institute for Health Research (HEE/NIHR ICA Programme Pre-doctoral Clinical Academic Fellowship)	This work was completed as part of a Clinical Health Research MRes at the University of Birmingham, UK funded by Health Education England and National Institute for Health Research (HEE/NIHR ICA Programme Pre-doctoral Clinical Academic Fellowship, Mr Jonathan Price, ICAPCAF-2018-01-117). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.	Alreni ASE., 2018, ORTHOPAEDIC P S2, V100-B, P14, DOI [10.1302/1358-992X.2018.2.014, DOI 10.1302/1358-992X.2018.2.014]; Andersen CH, 2013, J STRENGTH COND RES, V27, P3322, DOI 10.1519/JSC.0b013e31828f12c6; Andersen CH, 2012, BRIT J SPORT MED, V46, P1004, DOI 10.1136/bjsports-2011-090813; [Anonymous], 2010, DELPHI TECHNIQUE NUR; Aouni J, 2020, J BIOPHARM STAT, V30, P662, DOI 10.1080/10543406.2020.1730874; Babatunde OO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178621; Bird SP, 2005, SPORTS MED, V35, P841, DOI 10.2165/00007256-200535100-00002; Blomgren J, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2324-z; Braun V., 2013, SUCCESSFUL QUALITATI; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Cagnie B, 2011, CLIN J PAIN, V27, P392, DOI 10.1097/AJP.0b013e31820e11a2; Cantrill JA, 2011, INT J PHARM PRACT, V4, P67, DOI DOI 10.1111/J.2042-7174.1996.TB00844.X; Conchin S, 2018, CLIN NUTR, V37, P1992, DOI 10.1016/j.clnu.2017.09.005; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; de Loe RC, 2016, TECHNOL FORECAST SOC, V104, P78, DOI 10.1016/j.techfore.2015.12.009; Ford J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091334; Geneen LJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011279.pub3; Gizzi L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137844; GOODMAN CM, 1987, J ADV NURS, V12, P729, DOI 10.1111/j.1365-2648.1987.tb01376.x; Grgic J, 2019, J SCI MED SPORT, V22, P361, DOI 10.1016/j.jsams.2018.09.223; Grgic J, 2018, SPORTS MED, V48, P1207, DOI 10.1007/s40279-018-0872-x; Gross A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004250.pub5; Haddad M, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00612; Hariohm K, 2017, BRAZ J PHYS THER, V21, P281, DOI 10.1016/j.bjpt.2017.05.006; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Holden S, 2018, BRIT J SPORT MED, V52, P386, DOI 10.1136/bjsports-2017-097547; IBM, IBM SPSS STAT, P25; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Jin ZY, 2020, ANN RHEUM DIS, V79, P1014, DOI [10.1136/annrheumdis-2020-217050, 10.1136/annrheumdis-2020-219536]; Junger S, 2017, PALLIATIVE MED, V31, P684, DOI 10.1177/0269216317690685; Kim MJ, 2017, KOREAN J FAM MED, V38, P284, DOI 10.4082/kjfm.2017.38.5.284; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Maissan F, 2018, MUSCULOSKEL SCI PRAC, V35, P8, DOI 10.1016/j.msksp.2018.01.011; Major DH, 2019, BMJ OPEN SPORT EXERC, V5, DOI 10.1136/bmjsem-2019-000656; Morishita S, 2018, STRENGTH COND J, V40, P94, DOI 10.1519/SSC.0000000000000373; NIHR, 2019, WHAT IS PAT PUBL INV; Nikander R, 2006, MED SCI SPORT EXER, V38, P2068, DOI 10.1249/01.mss.0000229105.16274.4b; North B, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5801-3; Nunes JP, 2021, EUR J SPORT SCI, V21, P149, DOI 10.1080/17461391.2020.1733672; O'Leary S, 2012, ARCH PHYS MED REHAB, V93, P1225, DOI 10.1016/j.apmr.2012.02.018; O'Neil J, 2018, CLIN REHABIL, V32, P980, DOI 10.1177/0269215518763714; Pedersen MT, 2013, J STRENGTH COND RES, V27, P229, DOI 10.1519/JSC.0b013e3182541ceb; Polaski AM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210418; Price J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234511; Price J, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037656; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Robinson KR, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-65; Schmidt RC, 1997, DECISION SCI, V28, P763, DOI 10.1111/j.1540-5915.1997.tb01330.x; Schoenfeld BJ, 2017, J STRENGTH COND RES, V31, P3508, DOI 10.1519/JSC.0000000000002200; Schoenfeld BJ, 2017, J SPORT SCI, V35, P1073, DOI 10.1080/02640414.2016.1210197; Schoenfeld BJ, 2016, SPORTS MED, V46, P1689, DOI 10.1007/s40279-016-0543-8; Schoenfeld BJ, 2015, SPORTS MED, V45, P577, DOI 10.1007/s40279-015-0304-0; Schoenfeld BJ, 2019, J SPORT SCI, V37, P1286, DOI 10.1080/02640414.2018.1555906; Silva PV, 2019, J ORTHOP SPORT PHYS, V49, P666, DOI 10.2519/jospt.2019.8704; Slade SC, 2016, BRIT J SPORT MED, V50, P1428, DOI 10.1136/bjsports-2016-096651; Slade SC, 2012, BRIT J SPORT MED, V46, P1110, DOI 10.1136/bjsports-2011-090290; Spencer S, 2016, J ATHL TRAINING, V51, P613, DOI 10.4085/1062-6050-51.10.03; Staniszewska S, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3453; Stenner R, 2016, PHYSIOTHERAPY, V102, P339, DOI 10.1016/j.physio.2015.08.005; Stephens G, 2019, MUSCULOSKEL SCI PRAC, V40, P10, DOI 10.1016/j.msksp.2019.01.004; Svedmark A, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1263-9; van der Lee L, 2019, J EVAL CLIN PRACT, V25, P230, DOI 10.1111/jep.13077; von der Gracht HA, 2012, TECHNOL FORECAST SOC, V79, P1525, DOI 10.1016/j.techfore.2012.04.013; Wheatley A, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1066-6; Wiangkham T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011764; Yamato T, 2016, PHYS THER, V96, P930, DOI 10.2522/ptj.2016.96.7.930; Yamato TP, 2016, PHYSIOTHERAPY, V102, P121, DOI 10.1016/j.physio.2016.03.001; Yeung E, 2015, J MAN MANIP THER, V23, P27, DOI 10.1179/2042618613Y.0000000051; Yildiz TI, 2018, J SPORT REHABIL, V27, P403, DOI 10.1123/jsr.2017-0024; Zambaldi M, 2017, BRIT J SPORT MED, V51, P1221, DOI 10.1136/bjsports-2016-097131	73	3	3	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	7							e0253523	10.1371/journal.pone.0253523	http://dx.doi.org/10.1371/journal.pone.0253523			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TC7AG	34197481	Green Published, gold			2023-01-03	WOS:000668791400102
J	Shaheen, MJ; Bekdash, AM; Itani, HA; Borjac, JM				Shaheen, Mariam J.; Bekdash, Amira M.; Itani, Hana A.; Borjac, Jamilah M.			Saffron extract attenuates neuroinflammation in rmTBI mouse model by suppressing NLRP3 inflammasome activation via SIRT1	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; HUMAN SERUM-ALBUMIN; CROCUS-SATIVUS L.; CROCETIN; EXPRESSION; PATHWAY; SYSTEM; CAROTENOIDS; INVOLVEMENT	Traumatic brain injury (TBI) remains a major cause of morbidity and disability worldwide and a healthcare burden. TBI is an important risk factor for neurodegenerative diseases hallmarked by exacerbated neuroinflammation. Neuroinflammation in the cerebral cortex plays a critical role in secondary injury progression following TBI. The NOD-like receptors (NLR) family pyrin domain containing 3 (NLRP3) inflammasome is a key player in initiating the inflammatory response in various central nervous system disorders entailing TBI. This current study aims to investigate the role of NLRP3 in repetitive mild traumatic brain injury (rmTBI) and identify the potential neuroprotective effect of saffron extract in regulating the NLRP3 inflammasome. 24 hours following the final injury, rmTBI causes an upregulation in mRNA levels of NLRP3, caspase-1, the apoptosis-associated speck-like protein containing a CARD (ASC), nuclear factor kappa B (NF-kappa B), interleukin-1Beta (IL-1 beta), interleukin 18 (IL-18), nuclear factor erythroid 2-related factor 2 (NRF2) and heme oxygenase 1 (HMOX1). Protein levels of NLRP3, sirtuin 1 (SIRT1), glial fibrillary acidic protein (GFAP), ionized calcium-binding adaptor molecule 1 (Iba1), and neuronal nuclei (Neu N) also increased after rmTBI. Administration of saffron alleviated the degree of TBI, as evidenced by reducing the neuronal damage, astrocyte, and microglial activation. Pretreatment with saffron inhibited the activation of NLRP3, caspase-1, and ASC concurrent to reduced production of the inflammatory cytokines IL-1 beta and IL-18. Additionally, saffron extract enhanced SIRT1 expression, NRF2, and HMOX1 upregulation. These results suggest that NLRP3 inflammasome activation and the subsequent inflammatory response in the mice cortex are involved in the process of rmTBI. Saffron blocked the inflammatory response and relieved TBI by activating detoxifying genes and inhibiting NLRP3 activation. The effect of saffron on the NLRP3 inflammasome may be SIRT1 and NF-kappa B dependent in the rmTBI model. Thus, brain injury biomarkers will help in identifying a potential therapeutic target in treating TBI-induced neurodegenerative diseases.	[Shaheen, Mariam J.; Borjac, Jamilah M.] Beirut Arab Univ, Dept Biol Sci, Debbieh, Lebanon; [Bekdash, Amira M.; Itani, Hana A.] Amer Univ Beirut, Fac Med, Dept Pharmacol & Toxicol, Beirut, Lebanon; [Itani, Hana A.] Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN 37235 USA	Beirut Arab University; American University of Beirut; Vanderbilt University	Borjac, JM (corresponding author), Beirut Arab Univ, Dept Biol Sci, Debbieh, Lebanon.; Itani, HA (corresponding author), Amer Univ Beirut, Fac Med, Dept Pharmacol & Toxicol, Beirut, Lebanon.; Itani, HA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN 37235 USA.	hi40@aub.edu.lb; j.borjac@bau.edu.lb		Bekdash, Amira/0000-0002-5065-5131	HAI through the AUB Medical Practice Plan fund; Carl W. Gottschalk Research Scholar Award [M0048845]; American University of Beirut Faculty of Medicine Medical Practice Plan [MPP 320174]	HAI through the AUB Medical Practice Plan fund; Carl W. Gottschalk Research Scholar Award; American University of Beirut Faculty of Medicine Medical Practice Plan	This study has been supported by MS, the first author of this paper, who purchased the kits needed to measure the cytokines levels, the primers, and the kits needed to measure the gene expression, and by HAI through the AUB Medical Practice Plan fund who covered for the reagents used in western blot experiment along with 3 antibodies (NLRP3, SIRT1, and Beta tubulin). The lab assistant AB received a salary from the American Society of Nephrology (ASN), Carl W. Gottschalk Research Scholar Award (M0048845), and the American University of Beirut Faculty of Medicine Medical Practice Plan (MPP 320174). The funders had role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abedimanesh N, 2020, PHYTOTHER RES, V34, P1114, DOI 10.1002/ptr.6580; Alavizadeh SH, 2014, FOOD CHEM TOXICOL, V64, P65, DOI 10.1016/j.fct.2013.11.016; Amin B, 2015, EXCLI J, V14, P411, DOI 10.17179/excli2014-510; Asai A, 2005, J AGR FOOD CHEM, V53, P7302, DOI 10.1021/jf0509355; Baldwin KT, 2017, CURR OPIN NEUROBIOL, V45, P113, DOI 10.1016/j.conb.2017.05.006; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Bian YQ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.579052; Bostan HB, 2017, IRAN J BASIC MED SCI, V20, P110, DOI 10.22038/ijbms.2017.8230; Brickler T, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6373506; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Cabezas R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00211; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; CCAC-Canadian Council of Animal Care, 1993, GUID HANDL US EXP AN; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chalatsa I, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00249; Christodoulou E, 2015, J PHARM PHARMACOL, V67, P1634, DOI 10.1111/jphp.12456; Das N, 2016, CELL REP, V17, P1128, DOI 10.1016/j.celrep.2016.09.076; Dempsey C, 2017, BRAIN BEHAV IMMUN, V61, P306, DOI 10.1016/j.bbi.2016.12.014; Dewan MC, 2019, J NEUROSURG, V130, P1080, DOI 10.3171/2017.10.JNS17352; Diao M, 2017, EXP THER MED, V13, P117, DOI 10.3892/etm.2016.3912; Donmez G, 2013, EMBO MOL MED, V5, P344, DOI 10.1002/emmm.201302451; Donmez G, 2012, TRENDS PHARMACOL SCI, V33, P494, DOI 10.1016/j.tips.2012.05.007; Ettehadi H., 2013, J BEHAV BRAIN SCI, V3, P315, DOI [10.4236/jbbs.2013.33031, DOI 10.4236/JBBS.2013.33031]; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Farokhnia M, 2014, HUM PSYCHOPHARM CLIN, V29, P351, DOI 10.1002/hup.2412; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fernandez-Albarral JA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174110; Ge XT, 2018, BRAIN RES, V1697, P10, DOI 10.1016/j.brainres.2018.06.008; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Gout B, 2010, NUTR RES, V30, P305, DOI 10.1016/j.nutres.2010.04.008; Gudarzi S, 2022, NUTR NEUROSCI, V25, P1137, DOI 10.1080/1028415X.2020.1840118; Gusel'nikova VV, 2015, ACTA NATURAE, V7, P42, DOI 10.32607/20758251-2015-7-2-42-47; Hatziagapiou K, 2019, CURR NEUROPHARMACOL, V17, P377, DOI 10.2174/1570159X16666180321095705; Hol EM, 2015, CURR OPIN CELL BIOL, V32, P121, DOI 10.1016/j.ceb.2015.02.004; Hosseinzadeh H, 2008, DNA CELL BIOL, V27, P657, DOI 10.1089/dna.2008.0767; Huang KP, 2015, MOL CELL ENDOCRINOL, V399, P178, DOI 10.1016/j.mce.2014.08.014; Huang KP, 2013, FREE RADICAL BIO MED, V65, P528, DOI 10.1016/j.freeradbiomed.2013.07.029; Hwang JW, 2013, FREE RADICAL BIO MED, V61, P95, DOI 10.1016/j.freeradbiomed.2013.03.015; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Jafarisani M, 2018, J BIOMOL STRUCT DYN, V36, P1681, DOI 10.1080/07391102.2017.1331865; Jaliani HZ, 2013, IRAN J BASIC MED SCI, V16, P101; Jiao FZ, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6782872; Bagur MJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23010030; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kanakis CD, 2007, J AGR FOOD CHEM, V55, P970, DOI 10.1021/jf062638l; Kigerl KA, 2018, BRAIN BEHAV IMMUN, V72, P22, DOI 10.1016/j.bbi.2017.11.018; Kim JH, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/728709; Kopitar-Jerata N, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00073; Kuwar R, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1471-y; Langer L, 2020, J HEAD TRAUMA REHAB, V35, pE60, DOI 10.1097/HTR.0000000000000503; Lautenschlager M, 2015, PHYTOMEDICINE, V22, P36, DOI 10.1016/j.phymed.2014.10.009; Lazaridis C, 2019, NEUROPHARMACOLOGY, V145, P145, DOI 10.1016/j.neuropharm.2018.06.005; Li D, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0841-6; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo H, 2017, ASIAN PAC J TROP MED, V10, P1185, DOI 10.1016/j.apjtm.2017.10.027; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Mashmoul M, 2014, J FUNCT FOODS, V8, P180, DOI 10.1016/j.jff.2014.03.017; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Miyamoto A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00070; Morganti-Kossmann MC, 2019, ACTA NEUROPATHOL, V137, P731, DOI 10.1007/s00401-018-1944-6; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; Naghshineh A, 2015, CHEM-BIOL INTERACT, V238, P151, DOI 10.1016/j.cbi.2015.06.023; Ohsawa K, 2004, J NEUROCHEM, V88, P844, DOI 10.1046/j.1471-4159.2003.02213.x; Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054; Pathophysiology KwonB., 2004, SPINE J, V4, DOI [10.1016/j.spinee.2003.07.007, DOI 10.1016/J.SPINEE.2003.07.007]; Ramli FN, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/1247946; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Salman M, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.045021; Salminen A, 2008, BIOESSAYS, V30, P939, DOI 10.1002/bies.20799; Saresella M, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0088-1; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Toy Dana, 2013, Exp Neurobiol, V22, P68, DOI 10.5607/en.2013.22.2.68; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Wang H, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01863-9; Wang K, 2015, NEUROSCI LETT, V591, P53, DOI 10.1016/j.neulet.2015.02.016; WHO, 2003, GUID GOOD AGR COLL P; Xiong YY, 2015, IMMUNOPHARM IMMUNOT, V37, P236, DOI 10.3109/08923973.2015.1021356; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; Yang HC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046364; Yang Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1413-8; Yoshino F, 2011, J CLIN BIOCHEM NUTR, V49, P182, DOI 10.3164/jcbn.11-01; Zhang XJ, 2018, CELL PHYSIOL BIOCHEM, V48, P1088, DOI 10.1159/000491975; Zhang YQ, 2020, EUR J PHARMACOL, V867, DOI 10.1016/j.ejphar.2019.172847; Ziaee T, 2014, JUNDISHAPUR J NAT PH, V9, P3; Zou P, 2018, MOL MED REP, V17, P3212, DOI 10.3892/mmr.2017.8241	92	8	8	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257211	10.1371/journal.pone.0257211	http://dx.doi.org/10.1371/journal.pone.0257211			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9EM	34506597	Green Published, gold			2023-01-03	WOS:000729120700107
J	Monari, S; Ferri, M; Montecchi, B; Salinitro, M; Tassoni, A				Monari, Stefania; Ferri, Maura; Montecchi, Beatrice; Salinitro, Mirko; Tassoni, Annalisa			Phytochemical characterization of raw and cooked traditionally consumed alimurgic plants	PLOS ONE			English	Article							NUTRITIONAL COMPOSITION; ANTIOXIDANT ACTIVITY; PHENOLIC-COMPOUNDS; BIOGENIC-AMINE; FOOD PLANTS; WILD; POLYAMINES; PROFILES; COOKING	In the past, wild edible alimurgic plants became an important alternative food source when poverty, wars or drought made it difficult to access crops. These plants were considered rich in highly nutritional compounds and also frequently used as food-medicine given their health-promoting properties. With the aim of improving our knowledge on the content of beneficial or detrimental compounds in relation with past local dietary and curative traditions, 12 wild food plant species were collected from two study areas selected for their very different degree of industrialization, urbanization, and conservation of local past traditions among the population: the Bologna province (Northern Italy) and the Middle Agri Valley (Southern Italy). Protein, polyphenol flavonoid and biogenic amine (both free and conjugated) contents and antioxidant activity of raw and boiled wild food plant extracts, and of cooking water were analyzed by means of spectrophotometric and high-performance liquid chromatography methods. The results demonstrated that most of the phenolic compounds were released in the cooking water which also showed the highest antioxidant activity. Seventeen different phenolic compounds were identified, of which the health-related luteolin, luteolin-7-glucoside and rutin were the most abundant (e.g., S. pratensis L. and C. intybus L.). On the other hand, biogenic amines were absent or present at very low levels in cooking water of those very same species (e.g., S. pratensis L., T. officinalis Weber, C. vesicaria subsp. taraxacifolia and C. intybus L.) of which traditionally a decoction is used for therapeutic purposes. Free and conjugated spermidine and spermine were generally the most abundant biogenic amines, while none of the known detrimental monoamines (e.g., histamine) was detected. In conclusion, the present results seem to support past local popular traditions which indicated beneficial medical properties of some wild edible plant, as well as of their cooking water.	[Monari, Stefania; Ferri, Maura; Montecchi, Beatrice; Salinitro, Mirko; Tassoni, Annalisa] Univ Bologna, Dept Biol Geol & Environm Sci, Bologna, Italy; [Ferri, Maura] Univ Bologna, Dept Civil Chem Environm & Mat Engn, Bologna, Italy	University of Bologna; University of Bologna	Ferri, M; Tassoni, A (corresponding author), Univ Bologna, Dept Biol Geol & Environm Sci, Bologna, Italy.; Ferri, M (corresponding author), Univ Bologna, Dept Civil Chem Environm & Mat Engn, Bologna, Italy.	maura.ferri@unibo.it; annalisa.tassoni2@unibo.it	TASSONI, ANNALISA/G-3981-2012	TASSONI, ANNALISA/0000-0002-3541-4030				Arias-Rico J, 2020, FOODS, V9, DOI 10.3390/foods9050599; Bagni N, 2001, AMINO ACIDS, V20, P301, DOI 10.1007/s007260170046; Beneduce L, 2010, ANN MICROBIOL, V60, P573, DOI 10.1007/s13213-010-0094-4; Catena S, 2020, ULTRASON SONOCHEM, V68, DOI 10.1016/j.ultsonch.2020.105231; Collins JD, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2393; Dias MI, 2014, FOOD RES INT, V56, P266, DOI 10.1016/j.foodres.2014.01.003; Dominguez R, 2020, FOOD CHEM, V330, DOI 10.1016/j.foodchem.2020.127266; El Gueder D, 2018, ENVIRON SCI POLLUT R, V25, P36545, DOI 10.1007/s11356-018-3477-x; Ferri M, 2009, PROTEOMICS, V9, P610, DOI 10.1002/pmic.200800386; Ferri M, 2020, J ADV RES, V24, P1, DOI 10.1016/j.jare.2020.02.015; Ferri M, 2020, NEW BIOTECHNOL, V56, P38, DOI 10.1016/j.nbt.2019.10.010; Ferri M, 2017, NEW BIOTECHNOL, V39, P51, DOI 10.1016/j.nbt.2017.07.002; Ferri M, 2013, J FOOD COMPOS ANAL, V30, P94, DOI 10.1016/j.jfca.2013.02.004; Garcia-Herrera P, 2020, FOODS, V9, DOI 10.3390/foods9121761; Guarrera PM, 2016, J ETHNOPHARMACOL, V185, P202, DOI 10.1016/j.jep.2016.02.050; Guil-Guerrero JL, 1998, J SCI FOOD AGR, V76, P628, DOI [10.1002/(SICI)1097-0010(199804)76:4<628::AID-JSFA997>3.3.CO;2-L, 10.1002/(SICI)1097-0010(199804)76:4&lt;628::AID-JSFA997&gt;3.0.CO;2-U]; Gunathilake KDPP, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7090117; Hadjichambis AC, 2008, INT J FOOD SCI NUTR, V59, P383, DOI 10.1080/09637480701566495; Hithamani G, 2017, J BIOSCIENCES, V42, P603, DOI 10.1007/s12038-017-9705-6; Kusano T, 2008, PLANTA, V228, P367, DOI 10.1007/s00425-008-0772-7; Leonti M, 2006, ECON BOT, V60, P130, DOI 10.1663/0013-0001(2006)60[130:WGFPIT]2.0.CO;2; Lo Scalzo R, 2016, FOOD CHEM, V194, P835, DOI 10.1016/j.foodchem.2015.08.063; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luczaj L, 2012, ACTA SOC BOT POL, V81, P359, DOI 10.5586/asbp.2012.031; Guil-Guerrero JL, 2014, J FOOD COMPOS ANAL, V35, P18, DOI 10.1016/j.jfca.2014.05.002; MANEZ S, 1994, BIOCHEM SYST ECOL, V22, P297, DOI 10.1016/0305-1978(94)90104-X; Maritim AC, 2003, J BIOCHEM MOL TOXIC, V17, P24, DOI 10.1002/jbt.10058; Marrelli M, 2018, PLANT BIOSYST, V152, P759, DOI 10.1080/11263504.2017.1330778; Melgarejo E, 2010, AMINO ACIDS, V38, P519, DOI 10.1007/s00726-009-0411-z; Neagu E, 2014, ROM BIOTECH LETT, V19, P9203; Nitta Y, 2007, J AGR FOOD CHEM, V55, P299, DOI 10.1021/jf062392k; Otles S, 2012, SCI WORLD J, P1, DOI 10.1100/2012/564367; Palermo M, 2014, J SCI FOOD AGR, V94, P1057, DOI 10.1002/jsfa.6478; Lima GPP, 2008, INT J FOOD SCI TECH, V43, P1838, DOI 10.1111/j.1365-2621.2008.01725.x; Pieroni A, 2002, PHYTOTHER RES, V16, P467, DOI 10.1002/ptr.1243; Pieroni A, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-16; Pinela J, 2017, FOOD CHEM TOXICOL, V110, P165, DOI 10.1016/j.fct.2017.10.020; Preti R, 2017, J FOOD QUALITY, DOI 10.1155/2017/5329070; Sanchez-Mata MC, 2012, GENET RESOUR CROP EV, V59, P431, DOI 10.1007/s10722-011-9693-6; Sansanelli S, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0177-4; Sansanelli S, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-69; Sarker U, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57687-3; Sarker U, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50977-5; Sawicki T, 2018, FOOD CHEM, V259, P292, DOI 10.1016/j.foodchem.2018.03.143; Tassoni A, 2000, PLANT PHYSIOL BIOCH, V38, P383, DOI 10.1016/S0981-9428(00)00757-9; Tassoni A, 2013, FOOD CHEM, V139, P405, DOI 10.1016/j.foodchem.2013.01.041; Trichopoulou A, 2000, FOOD CHEM, V70, P319, DOI 10.1016/S0308-8146(00)00091-1; Viapiana A, 2017, PLANT FOOD HUM NUTR, V72, P82, DOI 10.1007/s11130-016-0594-x	48	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2021	16	8							e0256703	10.1371/journal.pone.0256703	http://dx.doi.org/10.1371/journal.pone.0256703			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	US1HA	34437649	Green Published, gold			2023-01-03	WOS:000697186000085
J	Kardos, P; Beeh, KM; Sent, U; Bissmann, G				Kardos, Peter; Beeh, Kai-Michael; Sent, Ulrike; Bissmann, Guido			Impact of guideline awareness on the counseling of patients with acute cough among general practitioners and pharmacy personnel	PLOS ONE			English	Article							DOUBLE-BLIND; ACUTE BRONCHITIS; CLINICAL-TRIAL; THYME HERB; IVY LEAVES; EFFICACY; TOLERABILITY; PLACEBO; ADULTS; MULTICENTER	Objective To explore the awareness and knowledge of applicable guidelines on acute cough among general practitioners, pharmacists and pharmacy technicians and to compare their recommendation behavior and clinical decision making to the evidence-based recommendation in the applicable guidelines. Methods An anonymous online survey was performed among 303 members of an existing panel of healthcare professionals (HCPs). They were presented with a hypothetical case vignette representative of their daily practice and asked for their treatment recommendations. After being shown an excerpt from the applicable guidelines, these questions were repeated. Results Forty-six % of participants reported to seek information on cough and respiratory conditions very often or often. Among 12 non-prescription treatments-commonly used over-the-counter-products for acute cough, HCPs most often recommended various plant extract-based products (phytotherapeutic remedies) for the acute cough case, whereas chemically defined options such as ambroxol or N-acetyl-cysteine were recommended less often. Following presentation of the guidelines excerpt, recommendations of the phytotherapeutic remedies decreased moderately whereas that of the guideline-recommended ambroxol more than doubled. Among stated reasons for the recommendation guideline conformity increased from 5% to 35% among the top-3 reasons. Conclusions The recommendations for the treatment of acute cough by professionals involved in primary healthcare deviated considerably from the applicable guideline recommendation but changed after presentation of a guidelines excerpt and knowledge thereof. We conclude that dissemination of applicable guideline knowledge is relevant to improve evidence-based healthcare and clinical decision making.	[Kardos, Peter] Red Cross Maingau Hosp, Ctr Allergy Resp & Sleep Med, Grp Practice, Frankfurt, Germany; [Beeh, Kai-Michael] Resp Res Inst, INSAF, Wiesbaden, Germany; [Sent, Ulrike; Bissmann, Guido] Sanofi Aventis Deutschland GmbH, Med Affairs Consumer Healthcare, Frankfurt, Germany	Sanofi-Aventis	Sent, U (corresponding author), Sanofi Aventis Deutschland GmbH, Med Affairs Consumer Healthcare, Frankfurt, Germany.	ulrike.sent@sanofi.com		Kardos, Peter/0000-0002-4725-4820	Sanofi-Aventis Germany GmbH	Sanofi-Aventis Germany GmbH(Sanofi-Aventis)	The study and medical writing services were funded by Sanofi-Aventis Germany GmbH. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript, but the involvement of authors US and GB in the study and manuscript occurred as part of their employment by the funder.	[Anonymous], 2019, TROCKEN ODER VERSCHL; [Anonymous], ABDA BAK LEITLINIE H; Barnes J, 2018, POSTGRAD MED, V130, P428, DOI 10.1080/00325481.2018.1464364; Eberlin M, 2020, BMC GASTROENTEROL, V20, DOI 10.1186/s12876-020-01338-4; Fischer Juergen, 2013, Cough, V9, P25, DOI 10.1186/1745-9974-9-25; Gillissen A, 2013, Drug Res (Stuttg), V63, P19, DOI 10.1055/s-0032-1331182; Heintze C, 2014, DEGAM LEITLINIE NR 1; Irwin RS, 2006, CHEST, V129, p25S, DOI 10.1378/chest.129.1_suppl.25S; Irwin RS, 2006, CHEST, V129, P1, DOI 10.1378/chest.129.1.1; Kardos P, 2019, PNEUMOLOGIE, V73, P143, DOI 10.1055/a-0808-7409; Kemmerich B, 2007, ARZNEIMITTELFORSCH, V57, P607; Kemmerich B, 2006, ARZNEIMITTELFORSCH, V56, P652; Kraus EM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174584; Malesker MA, 2017, CHEST, V152, P1021, DOI 10.1016/j.chest.2017.08.009; Matthys H, 2000, ARZNEIMITTELFORSCH, V50, P700; McKenzie KE, 2020, AM J INFECT CONTROL, V48, P940, DOI 10.1016/j.ajic.2020.02.006; Michel MC, 2020, MOL PHARMACOL, V97, P49, DOI 10.1124/mol.119.118927; Morice AH, 2006, THORAX, V61, pI1, DOI 10.1136/thx.2006.065144; Morice A, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2016-000137; Morice AH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01136-2019; Moritz K, 2019, J CLIN PHARM THER, V44, P895, DOI 10.1111/jcpt.13013; Scarpato E, 2017, J PEDIATR GASTR NUTR, V64, pE142, DOI 10.1097/MPG.0000000000001550; Schaefer A, 2016, PHARMAZIE, V71, P504, DOI 10.1691/ph.2016.6712; Tiedje D, 2017, UROLOGE, V56, P910, DOI 10.1007/s00120-017-0352-1; Timmer A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006323.pub3; Yang CH, 2015, J PEDIATR GASTR NUTR, V60, P308, DOI 10.1097/MPG.0000000000000591	26	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2021	16	8							e0254086	10.1371/journal.pone.0254086	http://dx.doi.org/10.1371/journal.pone.0254086			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6JF	34351926	gold, Green Published			2023-01-03	WOS:000685265700080
J	Agnoli, A; Xing, GB; Tancredi, DJ; Magnan, E; Jerant, A; Fenton, JJ				Agnoli, Alicia; Xing, Guibo; Tancredi, Daniel J.; Magnan, Elizabeth; Jerant, Anthony; Fenton, Joshua J.			Association of Dose Tapering With Overdose or Mental Health Crisis Among Patients Prescribed Long-term Opioids	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; CHRONIC PAIN; THERAPY; DISCONTINUATION; DEATHS; DRUG	IMPORTANCE Opioid-related mortality and national prescribing guidelines have led to tapering of doses among patients prescribed long-term opioid therapy for chronic pain. There is limited information about risks related to tapering, including overdose and mental health crisis. OBJECTIVE To assess whether there are associations between opioid dose tapering and rates of overdose and mental health crisis among patients prescribed stable, long-term, higher-dose opioids. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study using deidentified medical and pharmacy claims and enrollment data from the OptumLabs Data Warehouse from 2008 to 2019. Adults in the US prescribed stable higher doses (mean >= 50 morphine milligram equivalents/d) of opioids for a 12-month baseline period with at least 2 months of follow-up were eligible for inclusion. EXPOSURES Opioid tapering, defined as at least 15% relative reduction in mean daily dose during any of 6 overlapping 60-day windows within a 7-month follow-up period. Maximum monthly dose reduction velocity was computed during the same period. MAIN OUTCOMES AND MEASURES Emergency or hospital encounters for (1) drug overdose or withdrawal and (2) mental health crisis (depression, anxiety, suicide attempt) during up to 12 months of follow-up. Discrete time negative binomial regression models estimated adjusted incidence rate ratios (aIRRs) of outcomes as a function of tapering (vs no tapering) and dose reduction velocity. RESULTS The final cohort included 113 618 patients after 203 920 stable baseline periods. Among the patients who underwent dose tapering, 54.3% were women (vs 53.2% among those who did not undergo dose tapering), the mean age was 57.7 years (vs 58.3 years), and 38.8% were commercially insured (vs 41.9%). Posttapering patient periods were associated with an adjusted incidence rate of 9.3 overdose events per 100 person-years compared with 5.5 events per 100 person-years in nontapered periods (adjusted incidence rate difference, 3.8 per 100 person-years [95% CI, 3.0-4.6]; aIRR, 1.68 [95% CI, 1.53-1.85]). Tapering was associated with an adjusted incidence rate of 7.6 mental health crisis events per 100 person-years compared with 3.3 events per 100 person-years among nontapered periods (adjusted incidence rate difference, 4.3 per 100 person-years [95% CI, 3.2-5.3]; aIRR, 2.28 [95% CI, 1.96-2.65]). Increasing maximum monthly dose reduction velocity by 10% was associated with an aIRR of 1.09 for overdose (95% CI, 1.07-1.11) and of 1.18 for mental health crisis (95% CI, 1.14-1.21). CONCLUSIONS AND RELEVANCE Among patients prescribed stable, long-term, higher-dose opioid therapy, tapering events were significantly associated with increased risk of overdose and mental health crisis. Although these findings raise questions about potential harms of tapering, interpretation is limited by the observational study design.	[Agnoli, Alicia; Magnan, Elizabeth; Jerant, Anthony; Fenton, Joshua J.] Univ Calif Davis, Dept Family & Community Med, 4860 Y St,Ste 2300, Sacramento, CA 95817 USA; [Agnoli, Alicia; Xing, Guibo; Tancredi, Daniel J.; Magnan, Elizabeth; Jerant, Anthony; Fenton, Joshua J.] Univ Calif Davis, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA; [Tancredi, Daniel J.] Univ Calif Davis, Dept Pediat, Sacramento, CA 95817 USA; [Fenton, Joshua J.] OptumLabs, Eden Prairie, MN USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Optum	Agnoli, A (corresponding author), Univ Calif Davis, Dept Family & Community Med, 4860 Y St,Ste 2300, Sacramento, CA 95817 USA.	aagnoli@ucdavis.edu	Tancredi, Daniel J/O-3381-2013	Tancredi, Daniel J/0000-0002-3884-7907	University of California-OptumLabs Research Credit; Department of Family and Community Medicine, University of California, Davis; University of California, Davis School of Medicine Dean's Office	University of California-OptumLabs Research Credit; Department of Family and Community Medicine, University of California, Davis; University of California, Davis School of Medicine Dean's Office(University of California System)	This study was supported by a University of California-OptumLabs Research Credit and the Department of Family and Community Medicine, University of California, Davis. Dr Agnoli was supported by the University of California, Davis School of Medicine Dean's Office (Dean's Scholarship inWomen's Health Research).	[Anonymous], 2019, CHR COND DAT WAR CON; [Anonymous], 2019, HHS GUID CLIN APPR D; [Anonymous], 2019, FDA IDENT HARM REP S; Binswanger IA, 2020, DRUG ALCOHOL DEPEN, V217, DOI 10.1016/j.drugalcdep.2020.108248; Bohnert ASB, 2018, ANN INTERN MED, V169, P367, DOI 10.7326/M18-1243; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Demidenko MI, 2017, GEN HOSP PSYCHIAT, V47, P29, DOI 10.1016/j.genhosppsych.2017.04.011; Dowell D, 2019, NEW ENGL J MED, V380, P2285, DOI 10.1056/NEJMp1904190; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Fenton JJ, 2021, PAIN MED, V22, P1660, DOI 10.1093/pm/pnaa470; Fenton JJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.16271; Fiest KM, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0289-5; Frank JW, 2017, ANN INTERN MED, V167, P181, DOI 10.7326/M17-0598; Frank JW, 2016, PAIN MED, V17, P1838, DOI 10.1093/pm/pnw078; Green CA, 2017, PHARMACOEPIDEM DR S, V26, P509, DOI 10.1002/pds.4157; Henry SG, 2019, J PAIN, V20, P181, DOI 10.1016/j.jpain.2018.09.001; James JR, 2019, J GEN INTERN MED, V34, P2749, DOI 10.1007/s11606-019-05301-2; Jeffery MM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k2833; Kertesz Stefan G, 2018, Spinal Cord Ser Cases, V4, P64, DOI 10.1038/s41394-018-0092-5; Lovejoy TI, 2017, PAIN, V158, P526, DOI 10.1097/j.pain.0000000000000796; Manhapra A, 2018, SUBST ABUS, V39, P152, DOI 10.1080/08897077.2017.1381663; Mark TL, 2019, J SUBST ABUSE TREAT, V103, P58, DOI 10.1016/j.jsat.2019.05.001; Moore BJ, 2017, MED CARE, V55, P698, DOI 10.1097/MLR.0000000000000735; Morgan MM, 2011, BRIT J PHARMACOL, V164, P1322, DOI 10.1111/j.1476-5381.2011.01335.x; Oliva EM, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m283; Pitt AL, 2018, AM J PUBLIC HEALTH, V108, P1394, DOI 10.2105/AJPH.2018.304590; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Slavova S, 2020, PUBLIC HEALTH REP, V135, P262, DOI 10.1177/0033354920904087; Sullivan MD, 2017, J PAIN, V18, P308, DOI 10.1016/j.jpain.2016.11.003; Swain RS, 2019, INT J EPIDEMIOL, V48, P1636, DOI 10.1093/ije/dyz038; United States Department of Agriculture, DOC 2010 RUR URB COM; Vivolo-Kantor A, 2021, INJURY PREV, V27, pi56, DOI 10.1136/injuryprev-2019-043521; Wilson N, 2020, MMWR-MORBID MORTAL W, V69, P290, DOI 10.15585/mmwr.mm6911a4	33	59	58	3	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2021	326	5					411	419		10.1001/jama.2021.11013	http://dx.doi.org/10.1001/jama.2021.11013			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UA6VH	34342618	Green Published, Bronze			2023-01-03	WOS:000685297500016
J	Chorazka, M; Flury, D; Herzog, K; Albrich, WC; Vuichard-Gysin, D				Chorazka, Magdalena; Flury, Domenica; Herzog, Kathrin; Albrich, Werner C.; Vuichard-Gysin, Danielle			Clinical outcomes of adults hospitalized for laboratory confirmed respiratory syncytial virus or influenza virus infection	PLOS ONE			English	Article							RISK; MORTALITY	Objectives Respiratory syncytial virus (RSV) can cause severe disease in adults, but far less is known than for influenza. The aim of our study was to compare the disease course of RSV infections with influenza infections among hospitalized adults. Methods We retrieved clinical data from an ongoing surveillance of adults hospitalized with RSV or influenza virus infection in two acute care hospitals in North-Eastern Switzerland during the winter seasons 2017/2018 and 2018/2019. Our main analysis compared the odds between RSV and influenza patients for admission to an intensive care unit (ICU) or in-hospital death within 7 days after admission. Results There were 548 patients, of whom 79 (14.4%) had an RSV and 469 (85.6%) an influenza virus infection. Both groups were similar with respect to age, sex, smoking status, nutritional state, and comorbidities. More RSV patients had an infiltrate on chest radiograph on admission (46.4% vs 29.9%, p = .007). The proportion of patients with RSV who died or were admitted to ICU within seven days after admission was 19.0% compared to 10.2% in influenza patients (p = .024). In multivariable analysis, a higher leukocyte count (adjusted OR 1.07, 95% CI 1.02-1.13, p = .013) and the presence of a pneumonic infiltrate (aOR 3.41, 95% CI 1.93-6.02) significantly increased the risk for experiencing the adverse primary outcome while the effect of the underlying viral pathogen became attenuated (aOR 1.18, 95% CI 0.58-2.41, p = .0.655). Conclusions Our results suggest that RSV is responsible for clinical courses at least as severe as influenza in adults. This supports the need for better guidance on diagnostic strategies as well as on preventive and therapeutic measures for hospitalized adults with RSV infection.	[Chorazka, Magdalena; Vuichard-Gysin, Danielle] Thurgau Hosp Grp, Cantonal Hosp Muensterlingen, Dept Internal Med, Muensterlingen, Switzerland; [Flury, Domenica; Albrich, Werner C.] Cantonal Hosp St Gallen, Dept Infect Dis & Hosp Epidemiol, St Gallen, Switzerland; [Herzog, Kathrin] Thurgau Hosp Grp, Dept Clin Microbiol, Muensterlingen, Switzerland; [Vuichard-Gysin, Danielle] Thurgau Hosp Grp, Cantonal Hosp Muensterlingen, Dept Infect Dis & Hosp Epidemiol, Muensterlingen, Switzerland	Kantonsspital St. Gallen	Vuichard-Gysin, D (corresponding author), Thurgau Hosp Grp, Cantonal Hosp Muensterlingen, Dept Internal Med, Muensterlingen, Switzerland.; Vuichard-Gysin, D (corresponding author), Thurgau Hosp Grp, Cantonal Hosp Muensterlingen, Dept Infect Dis & Hosp Epidemiol, Muensterlingen, Switzerland.	danielle.vuichard-gysin@stgag.ch						Ackerson B, 2019, CLIN INFECT DIS, V69, P197, DOI 10.1093/cid/ciy991; Amaury T, 2021, SWISS MED WKLY, V151, DOI 10.4414/smw.2021.20475; Belongia EA, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy316; Call SA, 2005, JAMA-J AM MED ASSOC, V293, P987, DOI 10.1001/jama.293.8.987; Christ-Crain M, 2006, CRIT CARE, V10, DOI 10.1186/cc4955; Cohen DM, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01237-17; Colosia AD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182321; Cui DW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165437; Ellis SE, 2003, J AM GERIATR SOC, V51, P761, DOI 10.1046/j.1365-2389.2003.51254.x; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Falsey AR, 2000, CLIN MICROBIOL REV, V13, P371, DOI 10.1128/CMR.13.3.371-384.2000; French CE, 2016, INFLUENZA OTHER RESP, V10, P268, DOI 10.1111/irv.12379; Frohlich GM., 2020, COVID 19 MORE A LITT, DOI [10.1101/2020.11.17.20233080v1, DOI 10.1101/2020.11.17.20233080V1]; IBM, 2013, IBM SPSS STAT WINDOW; Ivey KS, 2018, J AM COLL CARDIOL, V71, P1574, DOI 10.1016/j.jacc.2018.02.013; Ling LF, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01691-17; Loubet P, 2017, CLIN MICROBIOL INFEC, V23, P253, DOI 10.1016/j.cmi.2016.11.014; Matias G, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4177-z; Purcell K, 2007, PEDIATR INFECT DIS J, V26, P311, DOI 10.1097/01.inf.0000258627.23337.00; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Uyeki TM, 2018, JAMA-J AM MED ASSOC, V320, P755, DOI 10.1001/jama.2018.8113; Vuichard-Gysin D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212050; Walsh EE, 2007, J INFECT DIS, V195, P1046, DOI 10.1086/511986; Zhang YL, 2020, INFLUENZA OTHER RESP, V14, P483, DOI 10.1111/irv.12754; Zhou H, 2012, CLIN INFECT DIS, V54, P1427, DOI 10.1093/cid/cis211; Ziegler T, 2018, INFLUENZA OTHER RESP, V12, P558, DOI 10.1111/irv.12570; Zou XH, 2019, INT J INFECT DIS, V80, P92, DOI 10.1016/j.ijid.2018.12.014	27	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2021	16	7							e0253161	10.1371/journal.pone.0253161	http://dx.doi.org/10.1371/journal.pone.0253161			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2OO	34292983	Green Published, gold			2023-01-03	WOS:000678124900062
J	Caricchio, R; Abbate, A; Gordeev, I; Meng, J; Hsue, PY; Neogi, T; Arduino, R; Fomina, D; Bogdanov, R; Stepanenko, T; Ruiz-Seco, P; Gonzalez-Garcia, A; Chen, Y; Li, YH; Whelan, S; Noviello, S				Caricchio, Roberto; Abbate, Antonio; Gordeev, Ivan; Meng, Jamie; Hsue, Priscilla Y.; Neogi, Tuhina; Arduino, Roberto; Fomina, Daria; Bogdanov, Roman; Stepanenko, Tatiana; Ruiz-Seco, Pilar; Gonzalez-Garcia, Andres; Chen, Yu; Li, Yuhan; Whelan, Sarah; Noviello, Stephanie		CAN-COVID Investigators	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19 A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANAKINRA	This clinical trial compares the efficacy of canakinumab vs placebo on survival without invasive mechanical ventilation (IMV) in patients hospitalized with severe COVID-19. Importance Effective treatments for patients with severe COVID-19 are needed. Objective To evaluate the efficacy of canakinumab, an anti-interleukin-1 beta antibody, in patients hospitalized with severe COVID-19. Design, Setting, and Participants This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States. A total of 454 hospitalized patients with COVID-19 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), and systemic hyperinflammation defined by increased blood concentrations of C-reactive protein or ferritin were enrolled between April 30 and August 17, 2020, with the last assessment of the primary end point on September 22, 2020. Intervention Patients were randomly assigned 1:1 to receive a single intravenous infusion of canakinumab (450 mg for body weight of 40-<60 kg, 600 mg for 60-80 kg, and 750 mg for >80 kg; n = 227) or placebo (n = 227). Main Outcomes and Measures The primary outcome was survival without IMV from day 3 to day 29. Secondary outcomes were COVID-19-related mortality, measurements of biomarkers of systemic hyperinflammation, and safety evaluations. Results Among 454 patients who were randomized (median age, 59 years; 187 women [41.2%]), 417 (91.9%) completed day 29 of the trial. Between days 3 and 29, 198 of 223 patients (88.8%) survived without requiring IMV in the canakinumab group and 191 of 223 (85.7%) in the placebo group, with a rate difference of 3.1% (95% CI, -3.1% to 9.3%) and an odds ratio of 1.39 (95% CI, 0.76 to 2.54; P = .29). COVID-19-related mortality occurred in 11 of 223 patients (4.9%) in the canakinumab group vs 16 of 222 (7.2%) in the placebo group, with a rate difference of -2.3% (95% CI, -6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.30 to 1.50). Serious adverse events were observed in 36 of 225 patients (16%) treated with canakinumab vs 46 of 223 (20.6%) who received placebo. Conclusions and Relevance Among patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood of survival without IMV at day 29. Question Is the anti-interleukin-1 beta antibody canakinumab effective to treat patients hospitalized with COVID-19 and hyperinflammation? Finding This randomized clinical trial included 454 patients hospitalized with severe COVID-19 not requiring invasive mechanical ventilation (IMV) and with elevated C-reactive protein or ferritin levels. Treatment with intravenous canakinumab vs placebo resulted in survival without IMV at 29 days of 88.8% vs 85.7%, a difference that was not statistically significant. Meaning Among patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood of survival without IMV.	[Caricchio, Roberto] Temple Univ, Dept Med, Div Rheumatol, Lewis Katz Sch Med, 3322 N Broad St, Philadelphia, PA 19140 USA; [Abbate, Antonio] Virginia Commonwealth Univ, Wright Ctr Clin & Translat Res, Richmond, VA USA; [Gordeev, Ivan] City Clin Hosp 15, Moscow, Russia; [Meng, Jamie] Maimonides Hosp, Brooklyn, NY 11219 USA; [Hsue, Priscilla Y.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, San Francisco, CA 94143 USA; [Neogi, Tuhina] Boston Med Ctr, Boston, MA USA; [Neogi, Tuhina] Boston Univ, Sch Med, Boston, MA 02118 USA; [Arduino, Roberto] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA; [Fomina, Daria] Clin City Hosp 52, Ctr Allergy & Immunol, Moscow, Russia; [Fomina, Daria] Minist Hlth Russian Federat, Dept Allergy & Clin Immunol, IM Sechenov First Moscow State Med Univ, Moscow, Russia; [Bogdanov, Roman] Aleksandrovskaya Hosp, Therapeut Dept, St Petersburg, Russia; [Stepanenko, Tatiana] City Multispecialty Hosp 2, St Petersburg, Russia; [Ruiz-Seco, Pilar] Hosp Univ Infanta Sofia, Unidad Med Interna, Madrid, Spain; [Gonzalez-Garcia, Andres] Hosp Ramon & Cajal, Serv Med Interna, Unidad Enfermedades Sistem Autoinmunes & Minorita, Madrid, Spain; [Chen, Yu; Li, Yuhan; Noviello, Stephanie] Novartis Pharmaceut, E Hanover, NJ USA; [Whelan, Sarah] Novartis Ireland Ltd, Dublin, Ireland	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Virginia Commonwealth University; Maimonides Medical Center; University of California System; University of California San Francisco; Boston Medical Center; Boston University; University of Texas System; University of Texas Health Science Center Houston; Ministry of Health of the Russian Federation; Sechenov First Moscow State Medical University; Hospital Universitario Infanta Sofia; Hospital Universitario Ramon y Cajal; Novartis; Novartis	Caricchio, R (corresponding author), Temple Univ, Dept Med, Div Rheumatol, Lewis Katz Sch Med, 3322 N Broad St, Philadelphia, PA 19140 USA.	lupus@temple.edu	li, Yu/HCI-9086-2022; Li, YuHan/GZM-2095-2022; Fomina, Daria/AAJ-8545-2020; li, yu/HGL-9518-2022	Fomina, Daria/0000-0002-5083-6637; Priday, Anna/0000-0002-3360-5685; Wohlford, George/0000-0002-5670-7916; Savic, Sinisa/0000-0001-7910-0554; Solanich, Xavier/0000-0002-2572-2187				Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575; Caricchio R, 2021, ANN RHEUM DIS, V80, P88, DOI 10.1136/annrheumdis-2020-218323; Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6915e4; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; Dimopoulos G, 2020, CELL HOST MICROBE, V28, P117, DOI 10.1016/j.chom.2020.05.007; Dinarello CA, 2019, NAT REV RHEUMATOL, V15, P612, DOI 10.1038/s41584-019-0277-8; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Ge MM, 2011, DRUG INF J, V45, P481, DOI 10.1177/009286151104500409; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8; Iglesias-Julian E, 2020, J AUTOIMMUN, V115, DOI 10.1016/j.jaut.2020.102537; Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7; Langer-Gould A, 2020, INT J INFECT DIS, V99, P291, DOI 10.1016/j.ijid.2020.07.081; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Mariette X, 2021, LANCET RESP MED, V9, P295, DOI 10.1016/S2213-2600(20)30556-7; Navarro-Millan I, 2020, ARTHRITIS RHEUMATOL, V72, P1990, DOI 10.1002/art.41422; Pontali E, 2020, J ALLERGY CLIN IMMUN, V146, P213, DOI 10.1016/j.jaci.2020.05.002; Rodrigues TS, 2021, J EXP MED, V218, DOI 10.1084/jem.20201707; Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Toldo S, 2021, INFLAMM RES, V70, P7, DOI 10.1007/s00011-020-01413-2; WHO, 2020, COVID 19 THER TRIAL; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	27	81	82	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	2021	326	3					230	239		10.1001/jama.2021.9508	http://dx.doi.org/10.1001/jama.2021.9508			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP4YG	34283183	Green Published, Bronze			2023-01-03	WOS:000677602400016
J	Blum, MR; Sallevelt, BTGM; Spinewine, A; O'Mahony, D; Moutzouri, E; Feller, M; Baumgartner, C; Roumet, M; Jungo, KT; Schwab, N; Bretagne, L; Beglinger, S; Aubert, CE; Wilting, I; Thevelin, S; Murphy, K; Huibers, CJA; Drenth-van Maanen, AC; Boland, B; Crowley, E; Eichenberger, A; Meulendijk, M; Jennings, E; Adam, L; Roos, MJ; Gleeson, L; Shen, ZR; Marien, S; Meinders, AJ; Baretella, O; Netzer, S; de Montmollin, M; Fournier, A; Mouzon, A; O'Mahony, C; Aujesky, D; Mavridis, D; Byrne, S; Jansen, PAF; Schwenkglenks, M; Spruit, M; Dalleur, O; Knol, W; Trelle, S; Rodondi, N				Blum, Manuel R.; Sallevelt, Bastiaan T. G. M.; Spinewine, Anne; O'Mahony, Denis; Moutzouri, Elisavet; Feller, Martin; Baumgartner, Christine; Roumet, Marie; Jungo, Katharina Tabea; Schwab, Nathalie; Bretagne, Lisa; Beglinger, Shanthi; Aubert, Carole E.; Wilting, Ingeborg; Thevelin, Stefanie; Murphy, Kevin; Huibers, Corlina J. A.; Drenth-van Maanen, A. Clara; Boland, Benoit; Crowley, Erin; Eichenberger, Anne; Meulendijk, Michiel; Jennings, Emma; Adam, Luise; Roos, Marvin J.; Gleeson, Laura; Shen, Zhengru; Marien, Sophie; Meinders, Arend-Jan; Baretella, Oliver; Netzer, Seraina; de Montmollin, Maria; Fournier, Anne; Mouzon, Ariane; O'Mahony, Cian; Aujesky, Drahomir; Mavridis, Dimitris; Byrne, Stephen; Jansen, Paul A. F.; Schwenkglenks, Matthias; Spruit, Marco; Dalleur, Olivia; Knol, Wilma; Trelle, Sven; Rodondi, Nicolas			Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMPUTERIZED DECISION-SUPPORT; ADVERSE DRUG-REACTIONS; PHARMACIST INTERVENTION; PRIMARY-CARE; POLYPHARMACY; PEOPLE; RISK; PREVALENCE; MORBIDITY; MORTALITY	OBJECTIVE To examine the effect of optimising drug treatment on drug related hospital admissions in older adults with multimorbidity and polypharmacy admitted to hospital. DESIGN Cluster randomised controlled trial. SETTING 110 clusters of inpatient wards within university based hospitals in four European countries (Switzerland, Netherlands, Belgium, and Republic of Ireland) defined by attending hospital doctors. PARTICIPANTS 2008 older adults (>= 70 years) with multimorbidity (>= 3chronic conditions) and polypharmacy (>= 5 drugs used long term). INTERVENTION Clinical staff clusters were randomised to usual care or a structured pharmacotherapy optimisation intervention performed at the individual level jointly by a doctor and a pharmacist, with the support of a clinical decision software system deploying the screening tool of older person's prescriptions and screening tool to alert to the right treatment (STOPP/START) criteria to identify potentially inappropriate prescribing. MAIN OUTCOME MEASURE Primary outcome was first drug related hospital admission within 12 months. RESULTS 2008 older adults (median nine drugs) were randomised and enrolled in 54 intervention clusters (963 participants) and 56 control clusters (1045 participants) receiving usual care. In the intervention arm, 86.1% of participants (n=789) had inappropriate prescribing, with a mean of 2.75 (SD 2.24) STOPP/START recommendations for each participant. 62.2% (n=491) had >= 1 recommendation successfully implemented at two months, predominantly discontinuation of potentially inappropriate drugs. In the intervention group, 211 participants (21.9%) experienced a first drug related hospital admission compared with 234 (22.4%) in the control group. In the intention-to-treat analysis censored for death as competing event (n=375, 18.7%), the hazard ratio for first drug related hospital admission was 0.95 (95% confidence interval 0.77 to 1.17). In the per protocol analysis, the hazard ratio for a drug related hospital admission was 0.91 (0.69 to 1.19). The hazard ratio for first fall was 0.96 (0.79 to 1.15; 237 v263 first falls) and for death was 0.90 (0.71 to 1.13; 172 v 203 deaths). CONCLUSIONS Inappropriate prescribing was common in older adults with multimorbidity and polypharmacy admitted to hospital and was reduced through an intervention to optimise pharmacotherapy, but without effect on drug related hospital admissions. Additional efforts are needed to identify pharmacotherapy optimisation interventions that reduce inappropriate prescribing and improve patient outcomes.	[Blum, Manuel R.; Moutzouri, Elisavet; Feller, Martin; Baumgartner, Christine; Schwab, Nathalie; Bretagne, Lisa; Beglinger, Shanthi; Aubert, Carole E.; Adam, Luise; Baretella, Oliver; Netzer, Seraina; de Montmollin, Maria; Aujesky, Drahomir; Rodondi, Nicolas] Univ Bern, Dept Gen Internal Med, Bern Univ Hosp, Inselspital, Bern, Switzerland; [Blum, Manuel R.; Moutzouri, Elisavet; Feller, Martin; Jungo, Katharina Tabea; Schwab, Nathalie; Beglinger, Shanthi; Aubert, Carole E.; Baretella, Oliver; Netzer, Seraina; de Montmollin, Maria; Rodondi, Nicolas] Univ Bern, Inst Primary Hlth Care BIHAM, Bern, Switzerland; [Sallevelt, Bastiaan T. G. M.; Wilting, Ingeborg; Jansen, Paul A. F.] Univ Utrecht, Univ Med Ctr Utrecht, Clin Pharm, Utrecht, Netherlands; [Spinewine, Anne; Thevelin, Stefanie; Fournier, Anne; Dalleur, Olivia] Catholic Univ Louvain, Louvain Drug Res Inst, Clin Pharm Res Grp, Louvain, Belgium; [Spinewine, Anne; Mouzon, Ariane] CHU UCL Namur, Dept Pharm, Yvoir, Belgium; [O'Mahony, Denis; Jennings, Emma] Univ Coll Cork, Sch Med, Cork, Ireland; [Roumet, Marie; Trelle, Sven] Univ Bern, CTU Bern, Bern, Switzerland; [Aubert, Carole E.] Vet Affairs Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA; [Aubert, Carole E.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI USA; [Murphy, Kevin; Crowley, Erin; Gleeson, Laura; O'Mahony, Cian; Byrne, Stephen] Univ Coll Cork, Sch Pharm, Pharmaceut Care Res Grp, Cork, Ireland; [Huibers, Corlina J. A.; Drenth-van Maanen, A. Clara; Roos, Marvin J.; Knol, Wilma] Univ Utrecht, Univ Med Ctr Utrecht, Dept Geriatr Med, Utrecht, Netherlands; [Huibers, Corlina J. A.; Drenth-van Maanen, A. Clara; Roos, Marvin J.; Knol, Wilma] Univ Utrecht, Univ Med Ctr Utrecht, Expertise Ctr Pharmacotherapy Old Persons, Utrecht, Netherlands; [Boland, Benoit; Marien, Sophie] Clin Univ St Luc, Geriatr Med Div, Brussels, Belgium; [Boland, Benoit; Marien, Sophie] Catholic Univ Louvain, Inst Hlth & Soc, Louvain, Belgium; [Eichenberger, Anne] Univ Bern, Bern Univ Hosp, Inst Hosp Pharm, Bern, Switzerland; [Meulendijk, Michiel; Shen, Zhengru; Spruit, Marco] Univ Utrecht, Dept Informat & Comp Sci, Utrecht, Netherlands; [Adam, Luise] Univ Bern, Bern Univ Hosp, Swiss Cardiovasc Ctr, Div Angiol,Inselspital, Bern, Switzerland; [Meinders, Arend-Jan] St Antonius Hosp, Dept Internal Med & Intens Care Unit, Nieuwegein, Netherlands; [Meinders, Arend-Jan] St Antonius Hosp, Dept Internal Med & Intens Care Unit, Utrecht, Netherlands; [Mavridis, Dimitris] Univ Ioannina, Dept Primary Sch Educ, Ioannina, Greece; [Schwenkglenks, Matthias] Univ Basel, Inst Pharmaceut Med, Basel, Switzerland; [Spruit, Marco] Leiden Univ, Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands; [Dalleur, Olivia] Clin Univ St Luc, Pharm, Brussels, Belgium	University of Bern; University Hospital of Bern; University of Bern; Utrecht University; Utrecht University Medical Center; Universite Catholique Louvain; University College Cork; University of Bern; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University College Cork; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; University of Bern; University Hospital of Bern; Utrecht University; University of Bern; University Hospital of Bern; St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht; University of Ioannina; University of Basel; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Rodondi, N (corresponding author), Univ Bern, Dept Gen Internal Med, Bern Univ Hosp, Inselspital, Bern, Switzerland.; Rodondi, N (corresponding author), Univ Bern, Inst Primary Hlth Care BIHAM, Bern, Switzerland.	nicolassodondi@insel.ch	Trelle, Sven/D-3760-2009	Trelle, Sven/0000-0002-8162-8910; Beglinger, Shanthi/0000-0002-7965-4466; Baumgartner, Christine/0000-0003-2296-9632; Crowley, Erin/0000-0002-0687-2665; Murphy, Kevin/0000-0001-5630-4060; Schwenkglenks, Matthias/0000-0001-7217-1173; Aubert, Carole Elodie/0000-0001-8325-8784; O'Mahony, Cian/0000-0003-3581-5077; Jungo, Katharina/0000-0002-1782-1345; Rodondi, Nicolas/0000-0001-9083-6896	European Union [634238]; Swiss State Secretariat for Education, Research, and Innovation (SERI) [15.0137]; Swiss National Scientific Foundation [SNSF 320030_188549]	European Union(European Commission); Swiss State Secretariat for Education, Research, and Innovation (SERI); Swiss National Scientific Foundation(Swiss National Science Foundation (SNSF))	This work is part of the project OPERAM: OPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No 634238, and by the Swiss State Secretariat for Education, Research, and Innovation (SERI) under contract number 15.0137. The opinions expressed herein are those of the authors and do not necessarily reflect the official views of the European Commission and the Swiss government. This project was also partially funded by the Swiss National Scientific Foundation (SNSF 320030_188549). The funder of the study had no role in the study design; data collection, analysis, and interpretation; or writing of the report. MR and ST had full access to all the data in the study, and all authors had final responsibility for the decision to submit for publication.	Adam L, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026769; Anderson K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006544; Anrys P, J AM MED DIR ASSOC, V2021; Arnold BF, 2016, JAMA-J AM MED ASSOC, V316, P2597, DOI 10.1001/jama.2016.17700; Aubert CE, 2016, EUR J INTERN MED, V35, P35, DOI 10.1016/j.ejim.2016.05.022; Beuscart JB, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1007-9; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Cassell A, 2018, BRIT J GEN PRACT, V68, pE245, DOI 10.3399/bjgp18X695465; Chan M, 2001, INTERN MED J, V31, P199, DOI 10.1046/j.1445-5994.2001.00044.x; Chiu PKC, 2018, HONG KONG MED J, V24, P98, DOI 10.12809/hkmj176871; Counter D, 2018, BRIT J CLIN PHARMACO, V84, P1757, DOI 10.1111/bcp.13607; Crotty Maria, 2004, Am J Geriatr Pharmacother, V2, P257, DOI 10.1016/j.amjopharm.2005.01.001; Crowley EK, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-5056-3; Dalleur O, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0149-2; Dalton K, 2019, DRUG AGING, V36, P279, DOI 10.1007/s40266-018-0627-2; Dalton K, 2018, AGE AGEING, V47, P670, DOI 10.1093/ageing/afy086; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Drenth-van Maanen AC, 2018, J EVAL CLIN PRACT, V24, P317, DOI 10.1111/jep.12787; Drenth-van Maanen AC, 2011, J AM GERIATR SOC, V59, P1976, DOI 10.1111/j.1532-5415.2011.03610_11.x; Fortin M, 2012, ANN FAM MED, V10, P142, DOI 10.1370/afm.1337; Fortin M, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-111; Gallagher PF, 2011, CLIN PHARMACOL THER, V89, P845, DOI 10.1038/clpt.2011.44; Gillespie U, 2009, ARCH INTERN MED, V169, P894, DOI 10.1001/archinternmed.2009.71; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hemming K, 2013, STATA J, V13, P114, DOI 10.1177/1536867X1301300109; Hernan MA, 2017, NEW ENGL J MED, V377, P1391, DOI 10.1056/NEJMsm1605385; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Jadad AR, 2011, JAMA-J AM MED ASSOC, V306, P2670, DOI 10.1001/jama.2011.1886; Jin H, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-127; Krousel-Wood M, 2009, AM J MANAG CARE, V15, P59; Kuijpers MAJ, 2008, BRIT J CLIN PHARMACO, V65, P130, DOI 10.1111/j.1365-2125.2007.02961.x; Leendertse AJ, 2008, ARCH INTERN MED, V168, P1890, DOI 10.1001/archinternmed.2008.3; MAHONEY F I, 1965, Md State Med J, V14, P61; Menotti A, 2001, J CLIN EPIDEMIOL, V54, P680, DOI 10.1016/S0895-4356(00)00368-1; Meulendijk MC, 2015, DRUG AGING, V32, P495, DOI 10.1007/s40266-015-0270-0; Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x; Morisky DE, 2011, J CLIN EPIDEMIOL, V64, P255, DOI 10.1016/j.jclinepi.2010.09.002; O'Mahony D, 2020, AGE AGEING, V49, P605, DOI 10.1093/ageing/afaa072; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; O'Sullivan D, 2014, DRUG AGING, V31, P471, DOI 10.1007/s40266-014-0172-6; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; R Core Team, 2021, R LANG ENV STAT COMP; Rankin A, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008165.pub4; Ravn-Nielsen LV, 2018, JAMA INTERN MED, V178, P375, DOI 10.1001/jamainternmed.2017.8274; Reeve E, 2013, DRUG AGING, V30, P793, DOI 10.1007/s40266-013-0106-8; Rieckert A, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1822; Ryan C, 2009, BRIT J CLIN PHARMACO, V68, P936, DOI 10.1111/j.1365-2125.2009.03531.x; Senn Stephen, 2014, GUEST POST ERROR STA; Shah BM, 2012, CLIN GERIATR MED, V28, P173, DOI 10.1016/j.cger.2012.01.002; Shen Z, 2016, 24 EUR C INF SYST EC; Smeeth L, 2002, CONTROL CLIN TRIALS, V23, P409, DOI 10.1016/S0197-2456(02)00208-8; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Tal S, 2011, QJM-INT J MED, V104, P933, DOI 10.1093/qjmed/hcr093; Taylor CT, 2003, AM J HEALTH-SYST PH, V60, P1123, DOI 10.1093/ajhp/60.11.1123; Terrell KM, 2009, J AM GERIATR SOC, V57, P1388, DOI 10.1111/j.1532-5415.2009.02352.x; Therneau TM, 2020, PACKAGE SURVIVAL ANA; Thevelin S, 2018, BRIT J CLIN PHARMACO, V84, P2600, DOI 10.1111/bcp.13716; Torgerson DJ, 2001, BMJ-BRIT MED J, V322, P355, DOI 10.1136/bmj.322.7282.355; Yang SY, 2020, CONTEMP CLIN TRIALS, V88, DOI 10.1016/j.cct.2019.04.016	60	33	33	2	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2021	374								n1585	10.1136/bmj.n1585	http://dx.doi.org/10.1136/bmj.n1585			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM9EH	34257088	Green Published, hybrid			2023-01-03	WOS:000675849500004
J	Hamo, CE; Abdelmoneim, SS; Han, SY; Chandy, E; Muntean, C; Khan, SA; Sunkesula, P; Meykler, M; Ramachandran, V; Rosenberg, E; Klem, I; Sacchi, TJ; Heitner, JF				Hamo, Carine E.; Abdelmoneim, Sahar S.; Han, Seol Young; Chandy, Elizabeth; Muntean, Cornelia; Khan, Saadat A.; Sunkesula, Prasanthi; Meykler, Marcella; Ramachandran, Vidhya; Rosenberg, Emelie; Klem, Igor; Sacchi, Terrence J.; Heitner, John F.			OUTpatient intravenous LASix Trial in reducing hospitalization for acute decompensated heart failure (OUTLAST)	PLOS ONE			English	Article							DIURETIC THERAPY; MULTIDISCIPLINARY; MANAGEMENT; INTERVENTION; UPDATE; READMISSION; SOCIETY; CARE	Background Hospitalization for acute decompensated heart failure (ADHF) remains a major source of morbidity and mortality. The current study aimed to investigate the feasibility, safety, and efficacy of outpatient furosemide intravenous (IV) infusion following hospitalization for ADHF. Methods In a single center, prospective, randomized, double-blind study, 100 patients were randomized to receive standard of care (Group 1), IV placebo infusion (Group 2), or IV furosemide infusion (Group 3) over 3h, biweekly for a one-month period following ADHF hospitalization. Patients in Groups 2/3 also received a comprehensive HF-care protocol including bi-weekly clinic visits for dose-adjusted IV-diuretics, medication adjustment and education. Echocardiography, quality of life and depression questionnaires were performed at baseline and 30-day follow-up. The primary outcome was 30-day re-hospitalization for ADHF. Results Overall, a total of 94 patients were included in the study (mean age 64 years, 56% males, 69% African American). There were a total of 14 (15%) hospitalizations for ADHF at 30 days, 6 (17.1%) in Group 1, 7 (22.6%) in Group 2, and 1 (3.7%) in Group 3 (overall p = 0.11; p = 0.037 comparing Groups 2 and 3). Patients receiving IV furosemide infusion experienced significantly greater urine output and weight loss compared to those receiving placebo without any significant increase creatinine and no significant between group differences in echocardiography parameters, KCCQ or depression scores. Conclusion The use of a standardized protocol of outpatient IV furosemide infusion for a one-month period following hospitalization for ADHF was found to be safe and efficacious in reducing 30-day re-hospitalization.	[Hamo, Carine E.] Johns Hopkins Univ, Div Cardiol, Baltimore, MD USA; [Abdelmoneim, Sahar S.; Han, Seol Young; Chandy, Elizabeth; Muntean, Cornelia; Khan, Saadat A.; Sunkesula, Prasanthi; Meykler, Marcella; Ramachandran, Vidhya; Rosenberg, Emelie; Sacchi, Terrence J.; Heitner, John F.] Brooklyn New York Presbyterian Hosp, Div Cardiol, Brooklyn, NY 11215 USA; [Klem, Igor] Duke Clin Res Inst, Durham, NC USA	Johns Hopkins University; Duke University	Heitner, JF (corresponding author), Brooklyn New York Presbyterian Hosp, Div Cardiol, Brooklyn, NY 11215 USA.	jfh9003@nyp.org	Ramachandran, Vidhya/HGA-8671-2022	Hamo, Carine/0000-0002-7063-1727; Ramachandran, Vidhya/0000-0002-6011-0899	National Heart, Lung, and Blood Institute, National Institutes of Health [T32 HL007024]	National Heart, Lung, and Blood Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Carine Hamo reports support from the National Heart, Lung, and Blood Institute, National Institutes of Health (Grant Number T32 HL007024). All other authors have no relationships to disclose.	Banerjee P, 2012, CLIN MED, V12, P133, DOI 10.7861/clinmedicine.12-2-133; Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Blue L, 2001, BRIT MED J, V323, P715, DOI 10.1136/bmj.323.7315.715; Buckley LF, 2016, JACC-HEART FAIL, V4, P1, DOI 10.1016/j.jchf.2015.06.017; Cline CMJ, 1998, HEART, V80, P442, DOI 10.1136/hrt.80.5.442; Felker GM, 2011, NEW ENGL J MED, V364, P797, DOI 10.1056/NEJMoa1005419; Green CP, 2000, J AM COLL CARDIOL, V35, P1245, DOI 10.1016/S0735-1097(00)00531-3; Hamo CE, 2018, J CARD FAIL, V24, P783, DOI 10.1016/j.cardfail.2018.08.007; Hauptman PJ, 2008, J CARD FAIL, V14, P801, DOI 10.1016/j.cardfail.2008.10.005; Hebert Kathy, 2011, Congest Heart Fail, V17, P309, DOI 10.1111/j.1751-7133.2011.00224.x; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003; Makadia S, 2015, AM J MED, V128, P527, DOI 10.1016/j.amjmed.2014.11.028; McDonald K, 2002, J CARD FAIL, V8, P142, DOI 10.1054/jcaf.2002.124340; Nyjo S, 2017, EUR HEART J, V38, P299; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Roberts JDGA, 2018, J CARD FAIL, V24; Ross JS, 2010, CIRC-HEART FAIL, V3, P97, DOI 10.1161/CIRCHEARTFAILURE.109.885210; Ryder M, 2008, EUR J HEART FAIL, V10, P267, DOI 10.1016/j.ejheart.2008.01.003; Schipper JE DG., 2012, J CARD FAIL, P18; Stewart S, 1999, LANCET, V354, P1077, DOI 10.1016/S0140-6736(99)03428-5; van Jaarsveld CHM, 2006, EUR J HEART FAIL, V8, P23, DOI 10.1016/j.ejheart.2005.04.012; Yancy CW, 2017, J AM COLL CARDIOL, V70, P776, DOI [10.1016/j.jacc.2017.04.025, 10.1161/CIR.0000000000000509]	23	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2021	16	6							e0253014	10.1371/journal.pone.0253014	http://dx.doi.org/10.1371/journal.pone.0253014			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9CN	34170908	gold, Green Published			2023-01-03	WOS:000671694400051
J	Demeke, G; Mengistu, G; Abebaw, A; Toru, M; Yigzaw, M; Shiferaw, A; Mengist, HM; Dilnessa, T				Demeke, Gebreselassie; Mengistu, Getachew; Abebaw, Abtie; Toru, Milkiyas; Yigzaw, Molla; Shiferaw, Aster; Mengist, Hylemariam Mihiretie; Dilnessa, Tebelay			Effects of intestinal parasite infection on hematological profiles of pregnant women attending antenatal care at Debre Markos Referral Hospital, Northwest Ethiopia: Institution based prospective cohort study	PLOS ONE			English	Article							ANEMIA; PREVALENCE	Background Intestinal parasitosis is a common disease that causes misery and disability in poor populations. The number of individuals affected is staggering. From two billion peoples who harbor parasites worldwide, 300 million suffer severe morbidity and more than 25% of pregnant women are infected with hookworm, which causes intestinal bleeding and blood loss, and has been most commonly associated with anemia. Intestinal parasite infection during pregnancy has been associated with iron deficiency, maternal anemia, and impaired nutritional status, as well as decreased infant birth weight. Objective This study aimed to assess the effects of intestinal parasite infection on hematological profiles of pregnant women attending antenatal care in Debre Markos Referral Hospital from December 2017 to February 2019. Method A prospective cohort study design was conducted among 94 intestinal parasite-infected pregnant women as an exposed group and 187 pregnant women free from intestinal parasite were used as a control group. The effect of intestinal parasites on hematological profiles of pregnant women was assessed at Debre Markos Referral Hospital antenatal care ward. Socio-demographic data and nutrition status were assessed by using structured questionnaires and mid-upper arm circumference (MUAC), respectively. Two ml of venous blood and 2 gm of stool samples were collected to analyze the hematological profiles and detect intestinal parasites, respectively. Wet mount and formol-ether concentration (FEC) techniques were used to detect intestinal parasites. Hematological profile was analyzed using Mind ray BC-3000 plus instrument. Data were double entered into EpiData version 3.1 software and exported to SPSS version 24 software for analysis. Results were presented using tables and graphs. Associations of hemoglobin levels with intestinal parasitic infections were determined using binary logistic regression models. P <= 0.05 was considered statistically significant. The mean hematological profile difference between parasite-infected and parasite-free pregnant women was computed using independent t-test. Results In the present study, the predominant parasites identified were Entamoeba histolytica, hookworm, Giardia lamblia, Schistosoma mansoni, and Ascaris lumbricoides. About 8.2% of intestinal parasite-infected pregnant women had mild anemia while 4% had moderate anemia. Only 1.2% of intestinal parasite-free pregnant women developed moderate anemia. The mean HGB, HCT, MCV, MCH, and MCHC values of intestinal parasite-infected pregnant women were 12.8g/dl, 38.2%, 94.7fl, 33.1pg and 34.7g/dl, respectively. But the mean HGB, HCT, MCV, MCH and MCHC values of pregnant women who were free from intestinal parasites were 14.4 g/dl, 39.8%, 94.9fl, 33.9pg and 35.5g/dl, respectively. Anemia was strongly associated with hookworm (AOR = 21.29, 95%CI: 8.28-54.75, P<0.001), S.mansoni (AOR = 63.73, 95% CI: 19.15-212, P<0.001) and A.lumbricoide (AOR = 14.12, 95% CI 3.28-60.65, P<0.001). Conclusion Intestinal parasitic infection in pregnant women caused adverse impact on hematological profiles and was an independent predictor of anemia. Intestinal parasitic infection significantly decreased pregnant the level of HGB, HCT, MCV, MCH, and MCHC values. To minimize maternal anemia deworming could be good before pregnancy.	[Demeke, Gebreselassie; Mengistu, Getachew; Abebaw, Abtie; Toru, Milkiyas; Yigzaw, Molla; Mengist, Hylemariam Mihiretie; Dilnessa, Tebelay] Debre Markos Univ, Dept Med Lab Sci, Coll Hlth Sci, Debre Markos, Ethiopia; [Shiferaw, Aster] Debre Markos Univ, Dept Midwifery, Coll Hlth Sci, Debre Markos, Ethiopia		Demeke, G (corresponding author), Debre Markos Univ, Dept Med Lab Sci, Coll Hlth Sci, Debre Markos, Ethiopia.	gebredemeke@yahoo.com	Demeke, Gebreselassie/ABH-1198-2021; Mengistu, Getachew/GRF-0245-2022; Mengist, Hylemariam Mihiretie/AAA-6133-2022; Dilnessa, Tebelay/AAV-9340-2021; Tantu, Milkiyas Toru/AAZ-9628-2021; Shiferaw, Abtie Ababaw/I-5040-2019	Mengistu, Getachew/0000-0002-3556-3650; Dilnessa, Tebelay/0000-0002-3713-6783; Tantu, Milkiyas Toru/0000-0001-8278-0343; Shiferaw, Abtie Ababaw/0000-0002-8132-4001; Birhanu, Molla Yigzaw/0000-0001-6286-446X; Demeke, Gebreselassie/0000-0002-2758-2915	Gebreselassie Demeke Funder:-Debre Debre Markos University	Gebreselassie Demeke Funder:-Debre Debre Markos University	Fund received author: Gebreselassie Demeke Funder:-Debre Debre Markos University The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abebe S, 2018, COMPUT WATER ENERGY, V07, P81, DOI DOI 10.4236/CWEEE.2018.73005; Alemayehu A, 2016, ANEMIA, V2016, DOI 10.1155/2016/9817358; Allen LH, 2000, AM J CLIN NUTR, V71, p1280S, DOI 10.1093/ajcn/71.5.1280s; Arinola GO, 2015, ANN GLOB HEALTH, V81, P705, DOI 10.1016/j.aogh.2015.10.001; Bolka A, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4135-8; Brooker S, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000291; Debebe D, 2011, THESIS ADDIS ABABA U; Derso A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1859-6; Hailu T, 2019, TROP DIS TRAVEL MED, V5, DOI 10.1186/s40794-019-0088-6; Kedir H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078601; Kefiyalew Filagot, 2014, BMC Res Notes, V7, P771, DOI 10.1186/1756-0500-7-771; Kelsey J.L., 1996, METHODS OBSERVATIONA; Kenea A, 2018, ANEMIA, V2018, DOI 10.1155/2018/9201383; Mengist Hylemariam Mihiretie, 2017, BMC Res Notes, V10, P440, DOI 10.1186/s13104-017-2770-y; Mireku MO, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003463; Ndibazza J, 2010, CLIN INFECT DIS, V50, P531, DOI 10.1086/649924; Nurdia D, 2001, IMPACT INTESTINAL HE; Obiezue NR, 2013, IRAN J PUBLIC HEALTH, V42, P497; Okia CC, 2019, J BLOOD MED, V10, P351, DOI 10.2147/JBM.S216613; Okube O.T., 2016, OPEN J OBSTET GYNECO, V6, P16; Rodriguez-Morales A.J., 2006, INFECT DIS OBSTET GY, V2006, DOI [10.1155/IDOG/2006/23125, DOI 10.1155/IDOG/2006/23125]; Shitie Dessalegn, 2018, BMC Res Notes, V11, P704, DOI 10.1186/s13104-018-3805-8; Sousa-Figueiredo JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033189; Ververs M.-t., 2013, PLOS CURR-TREE LIFE, V5, DOI 10.1371/currents.dis.54a8b618c1bc031ea140e3f2934599c8; WHO, 2002, WHO TRADITIONAL MED	25	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2021	16	5							e0250990	10.1371/journal.pone.0250990	http://dx.doi.org/10.1371/journal.pone.0250990			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6LC	33970934	Green Published, gold			2023-01-03	WOS:000664624400026
J	Ebrahiminaseri, A; Sadeghizadeh, M; Moshaii, A; Asgaritarghi, G; Safari, Z				Ebrahiminaseri, Afsaneh; Sadeghizadeh, Majid; Moshaii, Ahmad; Asgaritarghi, Golareh; Safari, Zohreh			Combination treatment of dendrosomal nanocurcumin and low-level laser therapy develops proliferation and migration of mouse embryonic fibroblasts and alter TGF-beta, VEGF, TNF-alpha and IL-6 expressions involved in wound healing process	PLOS ONE			English	Article							GROWTH-FACTOR; GENE-EXPRESSION; BLUE-LIGHT; IN-VITRO; PRESSURE ULCERS; CURCUMIN; CELLS; PHOTOBIOMODULATION; INTERLEUKIN-6; MECHANISMS	Introduction Pressure ulcer (PU) is known as the third most costly disorder usually caused by prolonged pressure and stagnation in various parts of the body. Although several therapeutic approaches are employing, obstacles in appropriate healing for skin lesions still exist which necessitates new practical alternative or adjunctive treatments. Low level laser therapy (LLLT) as one of the mentioned new strategies have gained attention. Besides, curcumin is an herbal medicine extracted from turmeric with anti-inflammatory and antioxidative properties with promising beneficial therapeutic effects in wound healing. Employing dendrosomal nanoparticles, we overcome the hydrophobicity of curcumin in the present study. We hypothesized that combination treatment of DNC+LLLT (450 nm) simultaneously may promote the wound healing process. Material and methods MTT assay, PI staining followed by flowcytometry, scratch assay and intracellular ROS measurement were used to investigate the effects caused by DNC and LLLT (450 nm) alone and in combination, on proliferation, cell cycle, migration and oxidative stress mouse embryonic fibroblast cells, respectively. The levels of growth factors and pro-inflammatory cytokines were evaluated by qRT-PCR and ELISA. Results Our results indicated that combination exposure with DNC and LLLT leads to increased proliferation and migration of MEFs as well as being more efficient in significantly upregulating growth factors (TGF-beta, VEGF) and decline in inflammatory cytokines (TNF-alpha, IL-6). Moreover, findings of this research provide persuasive support for the notion that DNC could reduce the LLLT-induced enhancement in intracellular ROS in mouse embryonic fibroblasts. Conclusion Concurrent exposure to anti-oxidant concentrations of DNC and LLLT enriched S phase entry and therefor increased proliferation as well as migration on MEFs through regulating the expression levels growth factors and shortening the inflammatory phase by modulating of cytokines. It should be noted that DNC were able to reduce the laser-induced oxidative stress, during wound healing, representing an informative accompaniment with LLLT.	[Ebrahiminaseri, Afsaneh; Sadeghizadeh, Majid; Asgaritarghi, Golareh; Safari, Zohreh] Tarbiat Modares Univ, Fac Biol Sci, Dept Genet, Tehran, Iran; [Moshaii, Ahmad] Tarbiat Modares Univ, Dept Phys, Tehran, Iran	Tarbiat Modares University; Tarbiat Modares University	Sadeghizadeh, M (corresponding author), Tarbiat Modares Univ, Fac Biol Sci, Dept Genet, Tehran, Iran.	sadeghma@modares.ac.ir			Iran National Science Foundation (INSF)	Iran National Science Foundation (INSF)(Iran National Science Foundation (INSF))	We would like to acknowledge the Iran National Science Foundation (INSF) for its financial support of the project.	Akbik D, 2014, LIFE SCI, V116, P1, DOI 10.1016/j.lfs.2014.08.016; Altavilla D, 2011, SURGERY, V149, P253, DOI 10.1016/j.surg.2010.04.024; Anthony D, 2019, J WOUND CARE, V28, P702, DOI 10.12968/jowc.2019.28.11.702; Baghi N, 2018, GENE, V670, P55, DOI 10.1016/j.gene.2018.05.025; Bamps M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00343; Barchitta M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051119; Bhattacharya S, 2015, INDIAN J PLAST SURG, V48, P4, DOI 10.4103/0970-0358.155260; Boyko TV, 2018, ADV WOUND CARE, V7, P57, DOI 10.1089/wound.2016.0697; Canedo-Dorantes L, 2019, INT J INFLAMM, V2019, DOI 10.1155/2019/3706315; Sanchez MC, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7080098; Carroll JD, 2014, DENT MATER, V30, P465, DOI 10.1016/j.dental.2014.02.006; Castellano-Pellicena I, 2019, LASER SURG MED, V51, P370, DOI 10.1002/lsm.23015; Chen HL, 2016, AIP ADV, V6, DOI 10.1063/1.4948442; Cheng KP, 2016, SCI REP-UK, V6, DOI 10.1038/srep21172; Chittoria RK., 2018, LOW LEVEL LASER THER; Coelho V., 2017, J NURS CARE, V6; Costanza B, 2017, J CLIN MED, V6, DOI 10.3390/jcm6010007; Dai TH, 2012, DRUG RESIST UPDATE, V15, P223, DOI 10.1016/j.drup.2012.07.001; Dai XY, 2017, NPG ASIA MATER, V9, DOI 10.1038/am.2017.31; Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337; Esmaeelinejad M, 2013, J COSMET LASER THER, V15, P310, DOI 10.3109/14764172.2013.803366; Farsani SSM, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117840; Szezerbaty SKF, 2018, LASER MED SCI, V33, P315, DOI 10.1007/s10103-017-2375-7; Finnson KW, 2013, ADV WOUND CARE, V2, P225, DOI 10.1089/wound.2012.0419; Fushimi T, 2012, WOUND REPAIR REGEN, V20, P226, DOI 10.1111/j.1524-475X.2012.00771.x; Garza ZCF, 2018, CURR MED CHEM, V25, P5564, DOI 10.2174/0929867324666170727112206; Guo DQ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00428; Hayta SB, 2018, CUTAN OCUL TOXICOL, V37, P24, DOI 10.1080/15569527.2017.1326497; Huang C, 2014, APOPTOSIS, V19, P922, DOI 10.1007/s10495-014-0983-2; Kant V, 2017, J SURG RES, V212, P130, DOI 10.1016/j.jss.2017.01.011; Karimian M., 2016, Journal of Mazandaran University of Medical Sciences, V26, pPe203; Keskiner I, 2016, PHOTOMED LASER SURG, V34, P263, DOI 10.1089/pho.2016.4094; Kim SE, 2018, J IND ENG CHEM, V58, P123, DOI 10.1016/j.jiec.2017.09.016; Kumari N, 2016, TUMOR BIOL, V37, P11553, DOI 10.1007/s13277-016-5098-7; Larouche J, 2018, ADV WOUND CARE, V7, P209, DOI 10.1089/wound.2017.0761; Li YY, 2017, ADV WOUND CARE, V6, P297, DOI 10.1089/wound.2017.0728; Li ZY, 2020, INT J NURS STUD, V105, DOI 10.1016/j.ijnurstu.2020.103546; Ma H., 2018, J WOUND MANAG RES, V14, P1, DOI [DOI 10.22467/JWMR.2018.00283, 10.22467/jwmr.2018.00283]; Martignago CCS, 2015, LASER MED SCI, V30, P203, DOI 10.1007/s10103-014-1644-y; Martin P, 2015, BRIT J DERMATOL, V173, P370, DOI 10.1111/bjd.13954; Masson-Meyers DS, 2016, J PHOTOCH PHOTOBIO B, V160, P53, DOI 10.1016/j.jphotobiol.2016.04.007; McInnes E, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001735.pub5; Migliario M, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201800025; Mignon C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02802-0; Mussttaf RA, 2019, INT J RADIAT BIOL, V95, P120, DOI 10.1080/09553002.2019.1524944; Niu TH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138754; Nuru N, 2015, BMC NURS, V14, DOI 10.1186/s12912-015-0076-8; Padula WV, 2019, INT WOUND J, V16, P634, DOI 10.1111/iwj.13071; Prasad R., 2017, INT J CURR MICROBIOL, V6, P2263, DOI DOI 10.20546/IJCMAS.2017.607.266; Radomska-Lesniewska DM, 2019, CENT EUR J IMMUNOL, V44, P181, DOI 10.5114/ceji.2019.87070; Repi G., 2014, ACTA MED MEDIANAE, V53, P75; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rodrigues M, 2019, PHYSIOL REV, V99, P665, DOI 10.1152/physrev.00067.2017; Ruh AC, 2018, LASER MED SCI, V33, P165, DOI 10.1007/s10103-017-2384-6; Safari Z, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47413-z; Sahori Y., 2020, SCI REPORTS NATURE P, V10; Samaneh R., 2015, BIOSCI BIOTECH RES A, V12, P217, DOI [10.13005/bbra/1626, DOI 10.13005/BBRA/1626, DOI 10.13005/bbra/162610]; Shah A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051068; Shariati Molood, 2018, Iran Biomed J, V22, P171; TAHMASEBI B.M., 2015, DENDROSOMAL NANOCURC; Tatmatsu-Rocha JC, 2016, J PHOTOCH PHOTOBIO B, V164, P96, DOI 10.1016/j.jphotobiol.2016.09.017; Tejada S, 2016, CURR PHARM BIOTECHNO, V17, DOI 10.2174/1389201017666160721123109; Velasquez JT, 2016, NEUROSCIENCE, V324, P140, DOI 10.1016/j.neuroscience.2016.02.073; Wang J, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060969; Wang TY, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/1390795; Yussof SJM, 2012, INDIAN J PLAST SURG, V45, P220, DOI 10.4103/0970-0358.101282; Zhao RL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122085	67	3	3	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2021	16	5							e0247098	10.1371/journal.pone.0247098	http://dx.doi.org/10.1371/journal.pone.0247098			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6GE	33956815	Green Published, gold			2023-01-03	WOS:000664611400006
J	Milic, J; Banchelli, F; Meschiari, M; Franceschini, E; Ciusa, G; Gozzi, L; Volpi, S; Faltoni, M; Franceschi, G; Iadisernia, V; Yaacoub, D; Dolci, G; Bacca, E; Rogati, C; Tutone, M; Burastero, G; Raimondi, A; Menozzi, M; Cuomo, G; Corradi, L; Orlando, G; Santoro, A; Digaetano, M; Puzzolante, C; Carli, F; Bedini, A; Busani, S; Girardis, M; Cossarizza, A; Miglio, R; Mussini, C; Guaraldi, G; D'Amico, R				Milic, Jovana; Banchelli, Federico; Meschiari, Marianna; Franceschini, Erica; Ciusa, Giacomo; Gozzi, Licia; Volpi, Sara; Faltoni, Matteo; Franceschi, Giacomo; Iadisernia, Vittorio; Yaacoub, Dina; Dolci, Giovanni; Bacca, Erica; Rogati, Carlotta; Tutone, Marco; Burastero, Giulia; Raimondi, Alessandro; Menozzi, Marianna; Cuomo, Gianluca; Corradi, Luca; Orlando, Gabriella; Santoro, Antonella; Digaetano, Margherita; Puzzolante, Cinzia; Carli, Federica; Bedini, Andrea; Busani, Stefano; Girardis, Massimo; Cossarizza, Andrea; Miglio, Rossella; Mussini, Cristina; Guaraldi, Giovanni; D'Amico, Roberto			The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study	PLOS ONE			English	Article								Background The benefit of tocilizumab on mortality and time to recovery in people with severe COVID pneumonia may depend on appropriate timing. The objective was to estimate the impact of tocilizumab administration on switching respiratory support states, mortality and time to recovery. Methods In an observational study, a continuous-time Markov multi-state model was used to describe the sequence of respiratory support states including: no respiratory support (NRS), oxygen therapy (OT), non-invasive ventilation (NIV) or invasive mechanical ventilation (IMV), OT in recovery, NRS in recovery. Results Two hundred seventy-one consecutive adult patients were included in the analyses contributing to 695 transitions across states. The prevalence of patients in each respiratory support state was estimated with stack probability plots, comparing people treated with and without tocilizumab since the beginning of the OT state. A positive effect of tocilizumab on the probability of moving from the invasive and non-invasive mechanical NIV/IMV state to the OT in recovery state (HR = 2.6, 95% CI = 1.2-5.2) was observed. Furthermore, a reduced risk of death was observed in patients in NIV/IMV (HR = 0.3, 95% CI = 0.1-0.7) or in OT (HR = 0.1, 95% CI = 0.0-0.8) treated with tocilizumab. Conclusion To conclude, we were able to show the positive impact of tocilizumab used in different disease stages depicted by respiratory support states. The use of the multi-state Markov model allowed to harmonize the heterogeneous mortality and recovery endpoints and summarize results with stack probability plots. This approach could inform randomized clinical trials regarding tocilizumab, support disease management and hospital decision making.	[Milic, Jovana; Mussini, Cristina; Guaraldi, Giovanni] Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, Modena, Italy; [Banchelli, Federico; Miglio, Rossella; D'Amico, Roberto] Azienda Osped Univ, Unit Stat & Methodol Support Clin Res, Modena, Italy; [Banchelli, Federico; Cossarizza, Andrea; Miglio, Rossella; D'Amico, Roberto] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy; [Meschiari, Marianna; Franceschini, Erica; Ciusa, Giacomo; Gozzi, Licia; Volpi, Sara; Faltoni, Matteo; Franceschi, Giacomo; Iadisernia, Vittorio; Yaacoub, Dina; Dolci, Giovanni; Bacca, Erica; Rogati, Carlotta; Tutone, Marco; Burastero, Giulia; Raimondi, Alessandro; Menozzi, Marianna; Cuomo, Gianluca; Corradi, Luca; Orlando, Gabriella; Santoro, Antonella; Digaetano, Margherita; Puzzolante, Cinzia; Carli, Federica; Bedini, Andrea; Busani, Stefano; Mussini, Cristina; Guaraldi, Giovanni] Azienda Osped Univ Modena, Infect Dis Clin, Modena, Italy; [Girardis, Massimo] Univ Modena & Reggio Emilia, Dept Anesthesia & Intens Care, Modena, Italy	Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; Universita di Modena e Reggio Emilia	Milic, J; Guaraldi, G (corresponding author), Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, Modena, Italy.; Guaraldi, G (corresponding author), Azienda Osped Univ Modena, Infect Dis Clin, Modena, Italy.	jovana.milic@gmail.com; giovanni.guaraldi@unimore.it	Mussini, Cristina/K-8672-2016; franceschini, erica/AAC-4025-2022; FRANCESCHI, GIACOMO/AAC-3903-2022; Puzzolante, Cinzia/GXH-9653-2022; Miglio, Rossella/AAE-6036-2022; Meschiari, Marianna/AAC-1916-2022; GIRARDIS, Massimo/K-8974-2016	Mussini, Cristina/0000-0002-6615-4198; FRANCESCHI, GIACOMO/0000-0003-0047-6634; Puzzolante, Cinzia/0000-0002-1179-1341; Meschiari, Marianna/0000-0002-1254-9995; Dolci, Giovanni/0000-0001-9948-652X; Franceschini, Erica/0000-0001-6922-5759; Santoro, Antonella/0000-0002-2345-9135; GIRARDIS, Massimo/0000-0002-2453-0829				[Anonymous], 2020, JAMA INTERNAL MED, DOI DOI 10.1001/JAMAINTERNMED.2020.3596; Beigel JH, 2020, N ENGL J MED; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cube Mvon., 2020, HARMONIZING HETEROGE; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Harris MS., 2020, NEW ENGL J MED, P2; Hazard D, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-01082-z; Hennigan Stephanie, 2008, Ther Clin Risk Manag, V4, P767; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Horby PW, 2021, MEDRXIV, DOI [10.1101/2021.02.11.21249258, DOI 10.1101/2021.02.11.21249258]; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028; Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x; McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1; Meng YF, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008520; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Parrish JM, 2020, J NEUROSURG-SPINE, V33, P446, DOI 10.3171/2020.3.SPINE20134; Pinheiro I, 2011, BIOESSAYS, V33, P791, DOI 10.1002/bies.201100047; Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Somers EC, 2021, CLIN INFECT DIS, V73, pE445, DOI [10.1093/cid/ciaa954, 10.1101/2020.05.29.20117358]; Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8; Valdiglesias V, 2018, EXP GERONTOL, V112, P119, DOI 10.1016/j.exger.2018.09.010; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9	27	4	3	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0251378	10.1371/journal.pone.0251378	http://dx.doi.org/10.1371/journal.pone.0251378			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ4EI	34383784	gold, Green Published			2023-01-03	WOS:000684426400060
J	Mehta, HB; An, HJ; Andersen, KM; Mansour, O; Madhira, V; Rashidi, ES; Bates, B; Setoguchi, S; Joseph, C; Kocis, PT; Moffitt, R; Bennett, TD; Chute, CG; Garibaldi, BT; Alexander, GC				Mehta, Hemalkumar B.; An, Huijun; Andersen, Kathleen M.; Mansour, Omar; Madhira, Vithal; Rashidi, Emaan S.; Bates, Benjamin; Setoguchi, Soko; Joseph, Corey; Kocis, Paul T.; Moffitt, Richard; Bennett, Tellen D.; Chute, Christopher G.; Garibaldi, Brian T.; Alexander, G. Caleb		Natl COVID Cohort Collaborati	Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States A Retrospective Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							GEOGRAPHIC-VARIATION; CARE	Background: Relatively little is known about the use patterns of potential pharmacologic treatments of COVID-19 in the United States. Objective: To use the National COVID Cohort Collaborative (N3C), a large, multicenter, longitudinal cohort, to characterize the use of hydroxychloroquine, remdesivir, and dexamethasone, overall as well as across individuals, health systems, and time. Design: Retrospective cohort study. Setting: 43 health systems in the United States. Participants: 137 870 adults hospitalized with COVID-19 between 1 February 2020 and 28 February 2021. Measurements: Inpatient use of hydroxychloroquine, remdesivir, or dexamethasone. Results: Among 137 870 persons hospitalized with confirmed or suspected COVID-19, 8754 (6.3%) received hydroxychloroquine, 29 272 (21.2%) remdesivir, and 53 909 (39.1%) dexamethasone during the study period. Since the release of results from the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial in mid-June, approximately 78% to 84% of people who have had invasive mechanical ventilation have received dexamethasone or other glucocorticoids. The use of hydroxychloroquine increased during March 2020, peaking at 42%, and started declining by April 2020. By contrast, remdesivir and dexamethasone use gradually increased over the study period. Dexamethasone and remdesivir use varied substantially across health centers (intraclass correlation coefficient, 14.2% for dexamethasone and 84.6% for remdesivir). Limitation: Because most N3C data contributors are academic medical centers, findings may not reflect the experience of community hospitals. Conclusion: Dexamethasone, an evidence-based treatment of COVID-19, may be underused among persons who are mechanically ventilated. The use of remdesivir and dexamethasone varied across health systems, suggesting variation in patient case mix, drug access, treatment protocols, and quality of care.	[Mehta, Hemalkumar B.; An, Huijun; Andersen, Kathleen M.; Rashidi, Emaan S.; Joseph, Corey; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Madhira, Vithal] Palila Software, Reno, NV USA; [Bates, Benjamin; Setoguchi, Soko] Rutgers Ctr Pharmacoepidemiol & Treatment Sci, New Brunswick, NJ USA; [Kocis, Paul T.] Penn State Hlth Milton S Hershey Med Ctr, Hershey, PA USA; [Moffitt, Richard] SUNY Stony Brook, Stony Brook, NY USA; [Bennett, Tellen D.] Univ Colorado, Sch Med, Aurora, CO USA; [Chute, Christopher G.] Johns Hopkins Univ, Schools Med Publ Hlth & Nursing, Baltimore, MD USA; [Garibaldi, Brian T.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Alexander, G. Caleb] Johns Hopkins Sch Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Colorado System; University of Colorado Anschutz Medical Campus; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Alexander, GC (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 North Wolfe St, Baltimore, MD 21205 USA.	hbmehta@jhu.edu; han13@jhmi.edu; galexan9@jhmi.edu	Mehta, Hemalkumar/GXV-4110-2022		National Institute on Aging [1K01AG070329-01]; National Heart, Lung, and Blood Institute Pharmacoepidemiology T32 Training Program [T32HL139426-03]; Johns Hopkins Institute for Clinical and Translational Research [UL1TR001079]	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Heart, Lung, and Blood Institute Pharmacoepidemiology T32 Training Program; Johns Hopkins Institute for Clinical and Translational Research	Dr. Mehta receives support from the National Institute on Aging (grant 1K01AG070329-01). Ms. Andersen and Mr. Joseph receive doctoral training support from the National Heart, Lung, and Blood Institute Pharmacoepidemiology T32 Training Program (grant T32HL139426-03). The authors also acknowledge assistance for clinical data coordination and retrieval from the Core for Clinical Research Data Acquisition, supported in part by the Johns Hopkins Institute for Clinical and Translational Research (grant UL1TR001079).	Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; [Anonymous], 2020, REUTERS 0506; Asch DA, 2021, JAMA INTERN MED, V181, P471, DOI 10.1001/jamainternmed.2020.8193; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bennett TD, 2021, JAMA NETW OPEN, V4, DOI [10.1001/jamanetworkopen.2021.16915, 10.1001/jamanetworkopen.2021.16901]; Boodman E, 2020, STAT-US; Bull-Otterson L, 2020, MMWR-MORBID MORTAL W, V69, P1210, DOI 10.15585/mmwr.mm6935a4; Carlet J, 2020, LANCET, V396, pE61, DOI 10.1016/S0140-6736(20)32132-2; Center for Systems Science and Engineering at Johns Hop-kins University, COVID 19 DASHB 2021; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014; Eysenbach G, 2020, J MED INTERNET RES, V22, DOI 10.2196/21820; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Haendel MA, 2021, J AM MED INFORM ASSN, V28, P427, DOI 10.1093/jamia/ocaa196; Hasnain-Wynia R, 2006, HEALTH SERV RES, V41, P1501, DOI 10.1111/j.1475-6773.2006.00552.x; Hinton D, 2020, LETT REVOKING EUA CH; Hinton D. M., 2020, VEKLURY REMDESIVIR E; Hinton Denise M, 2020, RE REQUEST EMERGENCY; Horby P, 2020, NEW ENGL J MED, V383, P2030, DOI 10.1056/NEJMoa2022926; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085; Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586-020-01824-5; Lin KJ, 2020, DRUGS, V80, P1961, DOI 10.1007/s40265-020-01424-7; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; Mercuro Nicholas J, 2020, JAMA Cardiol, V5, P1036, DOI 10.1001/jamacardio.2020.1834; Morgan SG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015883; National Center for Advancing Translational Sciences,, DAT TRANSF AGR SIGN; National Institutes of Health, COR DIS 2019 COVID 1; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Saag MS, 2020, JAMA-J AM MED ASSOC, V324, P2161, DOI 10.1001/jama.2020.22389; Shehab N, 2020, JAMA INTERN MED, V180, P1384, DOI 10.1001/jamainternmed.2020.2594; Silverman E, 2020, HOSP SEE SHORTAGES C; Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849; U.S. Food and Drug Administration,, FDA CAUT US HYDR CHL; Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835; Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; Zarocostas J, 2020, LANCET, V395, P676, DOI 10.1016/S0140-6736(20)30461-X; Zhang YT, 2012, ARCH INTERN MED, V172, P1465, DOI 10.1001/archinternmed.2012.3717; Zhang YT, 2010, NEW ENGL J MED, V363, P1985, DOI 10.1056/NEJMp1010220	41	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT	2021	174	10					1395	+		10.7326/M21-0857	http://dx.doi.org/10.7326/M21-0857			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA9CB	34399060	Green Published			2023-01-03	WOS:000720935700018
J	Balachandran, K				Balachandran, Kirthana			Who will comfort me when I transition to adult services?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												kirthana9@hotmail.co.uk							0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2021	374								n1792	10.1136/bmj.n1792	http://dx.doi.org/10.1136/bmj.n1792			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK8TM	34475018	Bronze			2023-01-03	WOS:000692238200012
J	Lawler, PR; Golighe, EC; Berge, JS; Neal, MD; McVerry, BJ; Nicolau, JC; Gong, MN; Carrier, M; Rosenson, RS; Reynolds, HR; Turgeon, AF; Escobedo, J; Huang, DT; Bradbury, CA; Houston, BL; Kornblith, LZ; Kumar, A; Kah, NSR; Cushman, M; McQuilten, Z; Slutsky, AS; Kim, KS; Gordon, AC; Kirwan, BA; Brooks, MM; Higgins, AM; Lewis, RJ; Lorenzi, E; Berry, SM; Berry, LR; Angus, DC; McArthur, CJ; Webb, SA; Farkouh, ME; Hochman, JS; Zarychanski, R; Aday, AW; Al-Beidh, F; Annane, D; Arabi, YM; Aryal, D; Kreuziger, LB; Beane, A; Bhimani, Z; Bihari, S; Billett, HH; Bond, L; Bonten, M; Brunkhorst, F; Buxton, M; Buzgau, A; Castellucci, LA; Chekuri, S; Chen, JT; Cheng, AC; Chkhikvadzw, T; Coiffard, B; Costantini, TW; de Brouwer, S; Derde, LPG; Detry, MA; Duggal, A; Dzavik, V; Effron, MB; Estcourt, LJ; Everett, BM; Fergusson, DA; Fitzgerald, M; Fowler, RA; Galanaud, JP; Galen, BT; Gandotra, S; Garcia-Madrona, S; Girard, TD; Godoy, LC; Goodman, AL; Goossens, H; Green, C; Greenstein, YY; Gross, PL; Hamburg, NM; Haniffa, R; Hanna, G; Hanna, N; Hegde, SM; Hendrickson, CM; Hite, RD; Hindenburg, AA; Hope, AA; Horowitz, JM; Horvat, CM; Hudock, K; Hunt, BJ; Husain, M; Hyzy, RC; Iyer, VN; Jacobson, JR; Jayakumar, D; Keller, NM; Khan, A; Kim, Y; Kindzelski, AL; Kin, AJ; Knudson, MM; Kornblith, AE; Krishnan, V; Kutcher, ME; Laffan, MA; Lamontagne, F; Le Gal, G; Leeper, CM; Leifer, ES; Lim, G; Lima, FG; Linstrum, K; Litton, E; Lopez-Sendon, J; Moreno, JLLS; Lother, SA; Malhotra, S; Marcos, M; Marinez, AS; Marshall, JC; Marten, N; Matthay, MA; McAuley, DF; McDonald, EG; McGlothlin, A; McGuinness, SP; Middeldorp, S; Montgomery, SK; Moore, SC; Guerreor, RM; Mouncey, PR; Murthy, S; Nair, GB; Nair, R; Nichol, AD; Nunez-Garcia, B; Pandey, A; Park, PK; Parke, RL; Parker, JC; Parnia, S; Paul, JD; Gonzalez, YSP; Pompilio, M; Prekker, ME; Quigley, JG; Rost, NS; Rowan, K; Santos, FO; Santos, M; Santos, MO; Satterwhite, L; Saunders, CT; Schutgens, REG; Seymour, CW; Siegal, DM; Silva, DG; Shankar-Hari, M; Sheehan, JP; Singhal, AB; Solvaso, D; Stanworth, SJ; Tritschler, T; Turner, AM; Van Bentum-Puijk, W; van de Veerdonk, FL; van Diepen, S; Vazquez-Grande, G; Wahid, L; Wareham, V; Wells, BJ; Widmer, RJ; Wilson, JG; Yuriditsky, E; Zampieri, FG				Lawler, Patrick R.; Golighe, Ewan C.; Berge, Jeffrey S.; Neal, Matthew D.; McVerry, Bryan J.; Nicolau, Jose C.; Gong, Michelle N.; Carrier, Marc; Rosenson, Robert S.; Reynolds, Harmony R.; Turgeon, Alexis F.; Escobedo, Jorge; Huang, David T.; Bradbury, Charlotte A.; Houston, Brett L.; Kornblith, Lucy Z.; Kumar, Anand; Kah, Susan R. n; Cushman, Mary; McQuilten, Zoe; Slutsky, Arthur S.; Kim, Keri S.; Gordon, Anthony C.; Kirwan, Bridget-Anne; Brooks, Maria M.; Higgins, Alisa M.; Lewis, Roger J.; Lorenzi, Elizabeth; Berry, Scott M.; Berry, Lindsay R.; Angus, Derek C.; McArthur, Colin J.; Webb, Steven A.; Farkouh, Michael E.; Hochman, Judith S.; Zarychanski, Ryan; Aday, Aaron W.; Al-Beidh, Farah; Annane, Djillali; Arabi, Yaseen M.; Aryal, Diptesh; Kreuziger, Lisa Baumann; Beane, Abi; Bhimani, Zahra; Bihari, Shailesh; Billett, Henny H.; Bond, Lindsay; Bonten, Marc; Brunkhorst, Frank; Buxton, Meredith; Buzgau, Adrian; Castellucci, Lana A.; Chekuri, Sweta; Chen, Jen-Ting; Cheng, Allen C.; Chkhikvadzw, Tamta; Coiffard, Benjamin; Costantini, Todd W.; de Brouwer, Sophie; Derde, Lennie P. G.; Detry, Michelle A.; Duggal, Abhijit; Dzavik, Vladimir; Effron, Mark B.; Estcourt, Lise J.; Everett, Brendan M.; Fergusson, Dean A.; Fitzgerald, Mark; Fowler, Robert A.; Galanaud, Jean P.; Galen, Benjamin T.; Gandotra, Sheetal; Garcia-Madrona, Sebastian; Girard, Timothy D.; Godoy, Lucas C.; Goodman, Andrew L.; Goossens, Herman; Green, Cameron; Greenstein, Yonatan Y.; Gross, Peter L.; Hamburg, Naomi M.; Haniffa, Rashan; Hanna, George; Hanna, Nicholas; Hegde, Sheila M.; Hendrickson, Carolyn M.; Hite, R. Duncan; Hindenburg, Alexander A.; Hope, Aluko A.; Horowitz, James M.; Horvat, Christopher M.; Hudock, Kristin; Hunt, Beverley J.; Husain, Mansoor; Hyzy, Robert C.; Iyer, Vivek N.; Jacobson, Jeffrey R.; Jayakumar, Devachandran; Keller, Norma M.; Khan, Akram; Kim, Yuri; Kindzelski, Andrei L.; Kin, Andrew J.; Knudson, M. Margaret; Kornblith, Aaron E.; Krishnan, Vidya; Kutcher, Matthew E.; Laffan, Michael A.; Lamontagne, Francois; Le Gal, Gregoire; Leeper, Christine M.; Leifer, Eric S.; Lim, George; Lima, Felipe Gallego; Linstrum, Kelsey; Litton, Edward; Lopez-Sendon, Jose; Moreno, Jose L. Lopez-Sendon; Lother, Sylvain A.; Malhotra, Saurabh; Marcos, Miguel; Marinez, Andrea Saud; Marshall, John C.; Marten, Nicole; Matthay, Michael A.; McAuley, Daniel F.; McDonald, Emily G.; McGlothlin, Anna; McGuinness, Shay P.; Middeldorp, Saskia; Montgomery, Stephanie K.; Moore, Steven C.; Guerreor, Raquel Morillo; Mouncey, Paul R.; Murthy, Srinivas; Nair, Girish B.; Nair, Rahul; Nichol, Alistair D.; Nunez-Garcia, Brenda; Pandey, Ambarish; Park, Pauline K.; Parke, Rachael L.; Parker, Jane C.; Parnia, Sam; Paul, Jonathan D.; Gonzalez, Yessica S. Perez; Pompilio, Mauricio; Prekker, Matthew E.; Quigley, John G.; Rost, Natalia S.; Rowan, Kathryn; Santos, Fernanda O.; Santos, Marlene; Santos, Mayler Olombrada; Satterwhite, Lewis; Saunders, Christina T.; Schutgens, Roger E. G.; Seymour, Christopher W.; Siegal, Deborah M.; Silva, Delcio G., Jr.; Shankar-Hari, Manu; Sheehan, John P.; Singhal, Aneesh B.; Solvaso, Dayna; Stanworth, Simon J.; Tritschler, Tobias; Turner, Anne M.; Van Bentum-Puijk, Wilma; van de Veerdonk, Frank L.; van Diepen, Sean; Vazquez-Grande, Gloria; Wahid, Lana; Wareham, Vanessa; Wells, Bryan J.; Widmer, R. Jay; Wilson, Jennifer G.; Yuriditsky, Eugene; Zampieri, Fernando G.		ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19. METHODS In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline D-dimer level. RESULTS The trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high D-dimer cohort, 92.9% in the low D-dimer cohort, and 97.3% in the unknown D-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis. CONCLUSIONS In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis.	[Lawler, Patrick R.; Farkouh, Michael E.; Dzavik, Vladimir; Galanaud, Jean P.; Godoy, Lucas C.; Hanna, George] Univ Hlth Network, Peter Munk Cardiac Ctr, Toronto, ON, Canada; [Lawler, Patrick R.; Golighe, Ewan C.; Slutsky, Arthur S.; Farkouh, Michael E.; Dzavik, Vladimir; Fowler, Robert A.; Godoy, Lucas C.; Hanna, George; Husain, Mansoor] Univ Toronto, Toronto, ON, Canada; [Golighe, Ewan C.; Husain, Mansoor] Univ Hlth Network, Toronto, ON, Canada; [Slutsky, Arthur S.; Bhimani, Zahra; Marshall, John C.; Santos, Marlene] St Michaels Hosp Unity Hlth, Toronto, ON, Canada; [Bond, Lindsay; Derde, Lennie P. G.; Wareham, Vanessa] Ozmosis Res, Toronto, ON, Canada; [Galanaud, Jean P.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Carrier, Marc; Castellucci, Lana A.; Fergusson, Dean A.; Le Gal, Gregoire; Siegal, Deborah M.] Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Carrier, Marc; Le Gal, Gregoire] Inst Savoir Montfort, Ottawa, ON, Canada; [Castellucci, Lana A.; Fergusson, Dean A.; Siegal, Deborah M.] Univ Ottawa, Ottawa, ON, Canada; [Turgeon, Alexis F.] Univ Laval, Quebec City, PQ, Canada; [Turgeon, Alexis F.] CHU Quebec Univ Laval Res Ctr, Quebec City, PQ, Canada; [Houston, Brett L.; Kumar, Anand; Zarychanski, Ryan; Lother, Sylvain A.; Solvaso, Dayna; Vazquez-Grande, Gloria] Univ Manitoba, Winnipeg, MB, Canada; [Houston, Brett L.; Zarychanski, Ryan] CancerCare Manitoba, Winnipeg, MB, Canada; [Marten, Nicole] St Boniface Gen Hosp, Winnipeg, MB, Canada; [Kah, Susan R. n; McDonald, Emily G.] McGill Univ, Montreal, PQ, Canada; [Gross, Peter L.] McMaster Univ, Hamilton, ON, Canada; [Gross, Peter L.] Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada; [Lamontagne, Francois] Univ Sherbrooke, Sherbrooke, PQ, Canada; [Murthy, Srinivas; Rowan, Kathryn] Univ British Columbia, Vancouver, BC, Canada; [van Diepen, Sean] Univ Alberta, Edmonton, AB, Canada; [Berge, Jeffrey S.; Reynolds, Harmony R.; Hochman, Judith S.; Chkhikvadzw, Tamta; Keller, Norma M.; Parnia, Sam] NYU Langone Hlth, NYU Grossman Sch Med, New York, NY USA; [Rosenson, Robert S.] NYU Langone Hlth, Icahn Sch Med Mt Sinai, New York, NY USA; [Rosenson, Robert S.] NYU Langone Hlth, Mt Sinai Heart, New York, NY USA; [Chkhikvadzw, Tamta; Horowitz, James M.; Yuriditsky, Eugene] NYU Langone Hosp, New York, NY USA; [Keller, Norma M.] Bellevue Hosp, New York, NY USA; [Gong, Michelle N.; Billett, Henny H.; Chekuri, Sweta; Chen, Jen-Ting; Nair, Rahul] Montefiore Med Ctr, Bronx, NY USA; [Gong, Michelle N.; Billett, Henny H.; Galen, Benjamin T.; Hope, Aluko A.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Hite, R. Duncan; Hindenburg, Alexander A.] NYU Langone Long Isl, Mineola, NY USA; [Neal, Matthew D.; McVerry, Bryan J.; Huang, David T.; Brooks, Maria M.; Angus, Derek C.; Kin, Andrew J.; Leeper, Christine M.; Linstrum, Kelsey; Montgomery, Stephanie K.; Seymour, Christopher W.] Univ Pittsburgh, Pittsburgh, PA USA; [Neal, Matthew D.; McVerry, Bryan J.; Angus, Derek C.; Linstrum, Kelsey; Montgomery, Stephanie K.] UPMC, Pittsburgh, PA USA; [Girard, Timothy D.] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA USA; [Horvat, Christopher M.] UPMC Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Moore, Steven C.] Penn State Hershey Med Ctr, Emergency Med, Hershey, PA USA; [Nicolau, Jose C.; Godoy, Lucas C.; Lima, Felipe Gallego] Univ Sao Paulo, Hosp Clin, Fac Med, Inst Coracao, Sao Paulo, SP, Brazil; [Marinez, Andrea Saud] Avanti Pesquisa Clin, Sao Paulo, Brazil; [Santos, Fernanda O.] Hosp Julho, Sao Paulo, Brazil; [Zampieri, Fernando G.] Hosp Coracao, Sao Paulo, Brazil; [Pompilio, Mauricio] Hosp Cora Mato Grosso do Sul, Campo Grande, MS, Brazil; [Pompilio, Mauricio] Univ Fed Mato Grosso do Sul, Campo Grande, MS, Brazil; [Silva, Delcio G., Jr.] Hosp Univ Maria Aparecida Pedrossia, Campo Grande, MS, Brazil; [Silva, Delcio G., Jr.] Hosp Unimed Campo Grande, Campo Grande, MS, Brazil; [Santos, Mayler Olombrada] Clin Res Ctr, INGOH, Goiania, Go, Brazil; [Escobedo, Jorge; Gonzalez, Yessica S. Perez] Inst Mexicano Seguro Social, Mexico City, DF, Mexico; [Bradbury, Charlotte A.] Univ Bristol, Bristol, Avon, England; [Bradbury, Charlotte A.] Univ Hosp Bristol & Weston NHS Fdn Trust, Bristol, Avon, England; [Gordon, Anthony C.; Al-Beidh, Farah; Laffan, Michael A.] Imperial Coll London, London, England; [Gordon, Anthony C.] Imperial Coll Healthcare NHS Trust, St Marys Hosp, London, England; [Kirwan, Bridget-Anne] London Sch Hyg & Trop Med, London, England; [Haniffa, Rashan] Univ Coll London Hosp, London, England; [Hunt, Beverley J.] Kings Healthcare Partners, London, England; [Mouncey, Paul R.] Intens Care Natl Audit & Res Ctr, London, England; [Shankar-Hari, Manu] Guys & St Thomas NHS Fdn Trust, London, England; [Shankar-Hari, Manu] Kings Coll London, London, England; [Neal, Matthew D.; Stanworth, Simon J.] Univ Oxford, Oxford, England; [Estcourt, Lise J.; Stanworth, Simon J.] NHS Blood & Transplant, Oxford, England; [McAuley, Daniel F.] Queens Univ Belfast, Belfast, Antrim, North Ireland; [McAuley, Daniel F.] Royal Victoria Hosp, Belfast, Antrim, North Ireland; [Kornblith, Lucy Z.; Farkouh, Michael E.; Hendrickson, Carolyn M.; Knudson, M. Margaret; Kornblith, Aaron E.; Matthay, Michael A.; Nunez-Garcia, Brenda] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, San Francisco, CA 94143 USA; [Lewis, Roger J.; Saunders, Christina T.] Harbor UCLA Med Ctr, Los Angeles, CA USA; [Buxton, Meredith] Global Coalit Adapt Res, Los Angeles, CA USA; [Lim, George] Univ Calif Los Angeles, Los Angeles, CA USA; [Costantini, Todd W.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; [Wilson, Jennifer G.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Cushman, Mary] Univ Vermont, Larner Coll Med, Burlington, VT USA; [McVerry, Bryan J.; McQuilten, Zoe; Higgins, Alisa M.; McArthur, Colin J.; Webb, Steven A.; Cheng, Allen C.; Green, Cameron; McGuinness, Shay P.; Nichol, Alistair D.; Parker, Jane C.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Cheng, Allen C.; Nichol, Alistair D.] Alfred Hlth, Melbourne, Vic, Australia; [Webb, Steven A.; Litton, Edward] St John God Subiaco Hosp, Perth, WA, Australia; [Litton, Edward] Fiona Stanley Hosp, Perth, WA, Australia; [Bihari, Shailesh] Flinders Univ S Australia, Bedford Pk, SA, Australia; [Kim, Keri S.; Jacobson, Jeffrey R.; Quigley, John G.] Univ Illinois, Chicago, IL USA; [Malhotra, Saurabh] Cook Cty Hlth, Chicago, IL USA; [Malhotra, Saurabh] Rush Med Coll, Chicago, IL 60612 USA; [Paul, Jonathan D.] Univ Chicago, Chicago, IL 60637 USA; [Kirwan, Bridget-Anne] SOCAR Res SA, Nyon, Switzerland; [Tritschler, Tobias] Univ Bern, Bern Univ Hosp, Inselspital, Bern, Switzerland; [Lewis, Roger J.; Lorenzi, Elizabeth; Berry, Scott M.; Berry, Lindsay R.; Detry, Michelle A.; Fitzgerald, Mark; McGlothlin, Anna; Satterwhite, Lewis] Berry Consultants, Austin, TX USA; [Pandey, Ambarish] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Widmer, R. Jay] Baylor Scott & White Hlth, Temple, TX USA; [McArthur, Colin J.; McGuinness, Shay P.; Parke, Rachael L.] Auckland City Hosp, Auckland, New Zealand; [Parke, Rachael L.] Univ Auckland, Auckland, New Zealand; [McArthur, Colin J.; Turner, Anne M.] Med Res Inst New Zealand, Wellington, New Zealand; [Aday, Aaron W.] Vanderbilt Univ Sch Med, Nashville, TN USA; [Goodman, Andrew L.] TriStar Centennial Med Ctr, Nashville, TN USA; [Annane, Djillali] Univ Versailles St Quentin En Yvelines, Raymond Poincare Hosp, Federat Hosp Univ, Garches, France; [Coiffard, Benjamin] Aix Marseille Univ, Marseille, France; [Arabi, Yaseen M.] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia; [Arabi, Yaseen M.] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [Aryal, Diptesh] Nepal Mediciti Hosp, Lalitpur, Nepal; [Aryal, Diptesh] Nepal Intens Care Res Fdn, Kathmandu, Nepal; [Kreuziger, Lisa Baumann; Estcourt, Lise J.] Versiti Blood Res Inst, Milwaukee, WI USA; [Sheehan, John P.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Beane, Abi] Natl Intens Care Surveillance Mahidol Oxford Trop, Colombo, Sri Lanka; [Bonten, Marc; Schutgens, Roger E. G.; Van Bentum-Puijk, Wilma] Univ Utrecht, Univ Med Ctr Utrecht, Utrecht, Netherlands; [Middeldorp, Saskia; van de Veerdonk, Frank L.] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands; [Brunkhorst, Frank] Jena Univ Hosp, Jena, Germany; [Duggal, Abhijit] Cleveland Clin, Cleveland, OH 44106 USA; [Krishnan, Vidya] Case Western Reserve Univ, Metro Hlth Med Ctr, Cleveland, OH 44106 USA; [Effron, Mark B.] Univ Queensland, Ochsner Med Ctr, Ochsner Clin Sch, New Orleans, LA USA; [Everett, Brendan M.; Kim, Yuri; Rost, Natalia S.; Singhal, Aneesh B.] Harvard Med Sch, Boston, MA 02115 USA; [Everett, Brendan M.; Hegde, Sheila M.; Kim, Yuri] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Hamburg, Naomi M.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Hamburg, Naomi M.] Boston Med Ctr, Boston, MA USA; [Rost, Natalia S.; Singhal, Aneesh B.] Massachusetts Gen Hosp, Boston, MA USA; [Gandotra, Sheetal] Univ Alabama Birmingham, Birmingham, AL USA; [Garcia-Madrona, Sebastian; Moreno, Jose L. Lopez-Sendon; Guerreor, Raquel Morillo] Hosp Ramon & Cajal, Madrid, Spain; [Lopez-Sendon, Jose] Univ Autonoma, IdiPaz Res Inst, Madrid, Spain; [Marcos, Miguel] Univ Salamanca IBSAL, Univ Hosp Salamanca, Salamanca, Spain; [Goossens, Herman] Univ Antwerp, Antwerp, Belgium; [Greenstein, Yonatan Y.] Rutgers New Jersey Med Sch, Newark, NJ USA; [Haniffa, Rashan] Univ Oxford, Bangkok, Thailand; [Hanna, Nicholas] Ascens St John Heart & Vasc Ctr, Tulsa, OK USA; [Hanna, Nicholas] Univ Oklahoma, Coll Med, Oklahoma City, OK 73190 USA; [Hudock, Kristin] Univ Cincinnati, Cincinnati, OH USA; [Hyzy, Robert C.; Park, Pauline K.] Univ Michigan, Ann Arbor, MI USA; [Nair, Girish B.] Beaumont Hlth, Royal Oak, MI USA; [Nair, Girish B.] OUWB Sch Med, Auburn Hills, MI USA; [Iyer, Vivek N.] Mayo Clin, Rochester, MN USA; [Prekker, Matthew E.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; [Jayakumar, Devachandran] Apollo Special Hosp OMR, Chennai, Tamil Nadu, India; [Khan, Akram; Leifer, Eric S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Kindzelski, Andrei L.] NHLBI, Bldg 10, Bethesda, MD 20892 USA; [Kutcher, Matthew E.] Univ Mississippi, Med Ctr, Jackson, TN USA; [Nichol, Alistair D.] Univ Coll Dublin, Dublin, Ireland; [Satterwhite, Lewis] Univ Kansas, Sch Med, Kansas City, KS USA; [Wahid, Lana] Duke Univ Hosp, Durham, NC USA; [Wells, Bryan J.] Emory Univ, Atlanta, GA 30322 USA	University of Toronto; Peter Munk Cardiac Centre; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Laval University; University of Manitoba; CancerCare Manitoba Foundation; University of Manitoba; Children's Hospital Research Institute of Manitoba; McGill University; McMaster University; McMaster University; University of Sherbrooke; University of British Columbia; University of Alberta; NYU Langone Medical Center; Icahn School of Medicine at Mount Sinai; NYU Langone Medical Center; NYU Langone Medical Center; Bellevue Hospital Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Universidade de Sao Paulo; Hospital do Coracao - HCor; Universidade Federal de Mato Grosso do Sul; Instituto Mexicano del Seguro Social; University of Bristol; Imperial College London; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; University College London Hospitals NHS Foundation Trust; University of London; University College London; Intensive Care National Audit & Research Centre; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford; Queens University Belfast; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California System; University of California San Diego; Stanford University; University of Vermont; Monash University; St John of God Health Care; Flinders University South Australia; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; University of Chicago; University of Bern; University Hospital of Bern; University of Texas System; University of Texas Southwestern Medical Center Dallas; Baylor Health Care System; Auckland City Hospital; University of Auckland; Medical Research Institute Of New Zealand; Vanderbilt University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Aix-Marseille Universite; King Saud Bin Abdulaziz University for Health Sciences; King Saud Bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center (KAIMRC); University of Wisconsin System; University of Wisconsin Madison; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; Friedrich Schiller University of Jena; Cleveland Clinic Foundation; Case Western Reserve University; MetroHealth System; Ochsner Health System; University of Queensland; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Boston University; Boston Medical Center; Harvard University; Massachusetts General Hospital; University of Alabama System; University of Alabama Birmingham; Hospital Universitario Ramon y Cajal; Autonomous University of Madrid; University of Salamanca; University of Antwerp; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Oxford; University of Oklahoma System; University of Oklahoma Health Sciences Center; University System of Ohio; University of Cincinnati; University of Michigan System; University of Michigan; Beaumont Health; Mayo Clinic; Hennepin County Medical Center; Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Mississippi Medical Center; University College Dublin; University of Kansas; University of Kansas Medical Center; Duke University; Emory University	Zarychanski, R (corresponding author), Univ Manitoba, Sect Hematol Oncol, Winnipeg, MB R3E 0V9, Canada.; Zarychanski, R (corresponding author), Univ Manitoba, Sect Crit Care, Winnipeg, MB R3E 0V9, Canada.; Hochman, JS (corresponding author), NYU, New York Univ Langone Hlth, Grossman Sch Med, 530 First Ave,Skirball 9R, New York, NY 10016 USA.	judith.hochman@nyumc.org; rzarychanski@cancercare.mb.ca	Khan, Akram/AAB-6446-2022; Shankar-Hari, Manu/I-6948-2012; Middeldorp, Saskia/ABI-8197-2020; Derde, Lennie/AAF-2725-2021; van de Veerdonk, Frank L/C-7256-2008; Effron, Mark B./P-9300-2015; Marcos, Miguel/B-3550-2008; Gómez, Oswaldo Sinoe Medina/L-2224-2019; Thiruchelvam, Nirosshan/ABD-2646-2020; Russell, Derek W./X-7040-2019; Bégin, Philippe/AAU-9126-2021; Veenith, Tonny/AAI-3067-2020; Neal, Matthew/GMW-5601-2022; Parke, Rachael/AAX-4004-2021; Lim, George/HJG-7477-2022; Tong, Steven/N-2353-2013; King, Andrew Joseph/AAW-5399-2021; Veenith, Tonny/A-9948-2010; Zarychanski, Ryan/AAB-6369-2022; Tritschler, Tobias/ABH-1772-2021; Vazquez-Grande, Gloria/GZK-8271-2022; Leaf, David/AAO-8977-2021; Gordon, Anthony/A-3472-2012; Dushianthan, Ahilanandan/T-8390-2019; Summers, Charlotte/A-6973-2012; Fysh, Edward/E-2855-2018; Presneill, Jeffrey/B-4894-2012; Puskarich, Michael/N-7849-2014	Khan, Akram/0000-0003-3091-632X; Shankar-Hari, Manu/0000-0002-5338-2538; Middeldorp, Saskia/0000-0002-1006-6420; Derde, Lennie/0000-0002-3577-5629; van de Veerdonk, Frank L/0000-0002-1121-4894; Effron, Mark B./0000-0003-4050-5030; Marcos, Miguel/0000-0003-1269-4487; Gómez, Oswaldo Sinoe Medina/0000-0003-1286-7317; Thiruchelvam, Nirosshan/0000-0001-5974-3317; Russell, Derek W./0000-0002-2716-1344; Veenith, Tonny/0000-0002-4125-8804; Neal, Matthew/0000-0001-8931-6236; Parke, Rachael/0000-0003-4209-0334; Tong, Steven/0000-0002-1368-8356; King, Andrew Joseph/0000-0002-9809-0563; Veenith, Tonny/0000-0002-4125-8804; Tritschler, Tobias/0000-0002-8775-0511; Vazquez-Grande, Gloria/0000-0001-5866-1045; Leaf, David/0000-0001-7875-090X; Gordon, Anthony/0000-0002-0419-547X; Dushianthan, Ahilanandan/0000-0002-0165-3359; Baillie, John Kenneth/0000-0001-5258-793X; Beane, Abigail/0000-0001-7046-1580; Summers, Charlotte/0000-0002-7269-2873; McGlothlin, Anna/0000-0002-9079-6166; Puxty, Kathryn/0000-0002-5742-6171; Young, Paul/0000-0002-3428-3083; Haniffa, Rashan/0000-0002-8288-449X; Aday, Aaron/0000-0001-6243-3432; Fysh, Edward/0000-0003-1126-3773; Hays, Leanne/0000-0002-6936-1459; Houston, Brett/0000-0002-8776-4083; Kim, Keri S./0000-0002-8480-4801; Rogers, Angela/0000-0001-6969-6200; Tolppa, Timo/0000-0002-4119-7335; Jhanji, Shaman/0000-0002-1116-628X; Turner, Anne/0000-0002-4092-1424; Ashktorab, Kimia/0000-0001-6262-7560; Presneill, Jeffrey/0000-0001-7177-7667; Kiiski, Heikki/0000-0002-5235-1772; Shekar, Kiran/0000-0002-1239-7514; Dark, Paul/0000-0003-3309-0164; Chkhikvadze, Tamta/0000-0002-1476-2415; Hormis, Anil/0000-0001-5510-7639; Malley, Brian/0000-0002-1731-1046; Lurie, Fedor/0000-0003-0644-0560; Duffy, Eamon/0000-0002-4515-5116; Escobedo, Jorge/0000-0003-1942-7402; Jia, Shijing/0000-0002-3467-8149; Nichol, Alistair/0000-0002-4689-1238; Estcourt, Lise/0000-0003-4309-9162; Husain, Mansoor/0000-0002-3740-6739; Welters, Ingeborg/0000-0002-3408-8798; Bannard-Smith, Jonathan/0000-0001-7120-480X; Coiffard, Benjamin/0000-0002-8896-5346; Mouncey, Paul/0000-0002-8510-8517; Rowan, Kathryn/0000-0001-8217-5602; Laffan, Michael/0000-0002-8268-3268; Gandotra, Sheetal/0000-0002-5475-9704; Wahid, Lana/0000-0002-2160-3287; Harvey, Daniel/0000-0002-5165-3277; parnia, sam/0000-0002-6158-4404; Marin-Corral, Judith/0000-0003-1320-4427; Douglas, Ivor/0000-0002-4541-1431; Vodovar, Dominique/0000-0002-8196-5511; Jayakumar, Devachandran/0000-0001-7134-3746; Binnie, Alexandra/0000-0003-2969-8177; Berry, Scott/0000-0002-3541-0443; Murthy, Srinivas/0000-0002-9476-839X; Hunt, Beverley Jane/0000-0002-4709-0774; Lamontagne, Francois/0000-0002-0360-3427; McGuinness, Shay/0000-0003-0620-4787; Waite, Alicia/0000-0001-8734-994X; Yee, Kimberly/0000-0002-3703-1367; Puskarich, Michael/0000-0001-6358-4670	LifeArc Foundation, Thistledown Foundation, Research Manitoba; Ontario Ministry of Health, Peter Munk Cardiac Centre; CancerCare Manitoba Foundation; Victoria General Hospital Foundation; National Heart, Lung, and Blood Institute, National Institutes of Health (NIH) [OTA-20-011, 1OT2HL156812-01, UL1TR001445]; New York University Clinical and Translational Science Award program; National Center for Advancing Translational Sciences of the NIH; European Union through FP7HEALTH-2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium [602525]; Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium [101003589]; Australian National Health and Medical Research Council [APP1101719, APP1116530]; Health Research Council of New Zealand [16/631]; Canadian Institutes of Health Research (Strategy for Patient-Oriented Research Innovative Clinical Trials Program) [158584, 447335]; U.K. National Institute for Health Research (NIHR); NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland [CTN 2014-012]; Breast Cancer Research Foundation; French Ministry of Health [PHRC-20-0147]; Minderoo Foundation; Amgen; Global Coalition for Adaptive Research; Wellcome Trust [215522]; Canadian Institutes of Health Research [AR7-162822]; NIHR Research Professorship [RP-2015-06-18]; NIHR Clinician Scientist Fellowship [CS-2016-16-011]; Lyonel G. Israels Research Chair in Hematology (University of Manitoba)	LifeArc Foundation, Thistledown Foundation, Research Manitoba; Ontario Ministry of Health, Peter Munk Cardiac Centre; CancerCare Manitoba Foundation; Victoria General Hospital Foundation; National Heart, Lung, and Blood Institute, National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); New York University Clinical and Translational Science Award program; National Center for Advancing Translational Sciences of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); European Union through FP7HEALTH-2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium; Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Health Research Council of New Zealand(Health Research Council of New Zealand); Canadian Institutes of Health Research (Strategy for Patient-Oriented Research Innovative Clinical Trials Program)(Canadian Institutes of Health Research (CIHR)); U.K. National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland; Breast Cancer Research Foundation; French Ministry of Health; Minderoo Foundation; Amgen(Amgen); Global Coalition for Adaptive Research; Wellcome Trust(Wellcome Trust); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIHR Research Professorship; NIHR Clinician Scientist Fellowship; Lyonel G. Israels Research Chair in Hematology (University of Manitoba)	The ATTACC platform was supported by grants from the Ca-nadian Institutes of Health Research, LifeArc Foundation, Thistledown Foundation, Research Manitoba, Ontario Ministry of Health, Peter Munk Cardiac Centre, CancerCare Manitoba Foundation, and Victoria General Hospital Foundation. The ACTIV-4a platform was sponsored by the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH) (grant numbers, OTA-20-011 and 1OT2HL156812-01). The pilot program (PROTECT) was funded in part by a grant (UL1TR001445) from the New York University Clinical and Translational Science Award program, supported by the National Center for Advancing Translational Sciences of the NIH. The REMAP-CAP platform was supported by the European Union through FP7HEALTH-2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium (602525) and the Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium (101003589); by the Australian National Health and Medical Research Council (APP1101719 and APP1116530), the Health Research Council of New Zealand (16/631), the Canadian Institutes of Health Research (Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant [158584] and Covid-19 Rapid Research Operating Grant [447335]), the U.K. National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the Learning While Doing Program at the University of Pittsburgh Medical Center, the Breast Cancer Research Foundation, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation, Amgen, Eisai, the Global Coalition for Adaptive Research, and the Wellcome Trust Innovations Project (215522). Dr. Goligher is the recipient of an Early Career Investigator award from the Canadian Institutes of Health Research (grant AR7-162822). Dr. Gordon is supported by an NIHR Research Professorship (RP-2015-06-18), Dr. Shankar-Hari by an NIHR Clinician Scientist Fellowship (CS-2016-16-011), and Dr. Turgeon by a Canada Research Chair (Tier 2). Dr. Zarychanski is the recipient of the Lyonel G. Israels Research Chair in Hematology (University of Manitoba).	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Angus DC, 2020, ANN AM THORAC SOC, V17, P879, DOI 10.1513/AnnalsATS.202003-192SD; Bilaloglu S, 2020, JAMA-J AM MED ASSOC, V324, P799, DOI 10.1001/jama.2020.13372; Buijsers B, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102969; Chowdhury JF, 2020, NEW ENGL J MED, V383, P1675, DOI 10.1056/NEJMclde2028217; Clausen TM, 2020, CELL, V183, P1043, DOI [10.1016/j.cell.2020.09.033, 10.1101/2020.07.14.201616]; Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000; Fisher J, 2017, J INTERN MED, V281, P562, DOI 10.1111/joim.12604; Flaczyk A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03273-y; Frohlich GM, 2021, CLIN RES CARDIOL, V110, P1041, DOI 10.1007/s00392-020-01783-x; Garibaldi BT, 2021, ANN INTERN MED, V174, P33, DOI 10.7326/M20-3905; Godoy LC, 2020, CAN MED ASSOC J, V192, pE1156, DOI 10.1503/cmaj.201240; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Hanley B, 2020, LANCET MICROBE, V1, pE245, DOI 10.1016/S2666-5247(20)30115-4; Houston BL, 2020, CLIN TRIALS, V17, P491, DOI 10.1177/1740774520943846; Ionescu F, 2021, EUR J HAEMATOL, V106, P165, DOI 10.1111/ejh.13533; Jimenez D, 2021, CHEST, V159, P1182, DOI 10.1016/j.chest.2020.11.005; Lewnard JA, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1923; Liu J, 2020, RES PRACT THROMB HAE, V4, P518, DOI 10.1002/rth2.12353; McGlothlin AE, 2018, JAMA-J AM MED ASSOC, V320, P2365, DOI 10.1001/jama.2018.17977; Mody A, 2021, AM J EPIDEMIOL, V190, P539, DOI 10.1093/aje/kwaa286; Mycroft-West CJ, 2020, THROMB HAEMOSTASIS, V120, P1700, DOI 10.1055/s-0040-1721319; Nadkarni GN, 2020, J AM COLL CARDIOL, V76, P1815, DOI 10.1016/j.jacc.2020.08.041; Rapkiewicz AV, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100434; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rosovsky RP, 2020, RES PRACT THROMB HAE, V4, P969, DOI 10.1002/rth2.12414; Sadeghipour P, 2021, JAMA-J AM MED ASSOC, V325, P1620, DOI 10.1001/jama.2021.4152; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Short SAP, 2021, CRIT CARE MED, V49, pE500, DOI 10.1097/CCM.0000000000004917; White D, 2020, J THROMB THROMBOLYS, V50, P287, DOI 10.1007/s11239-020-02145-0; Xue MS, 2021, ERJ OPEN RES, V7, DOI 10.1183/23120541.00741-2020; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	32	304	307	4	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2021	385	9					790	802		10.1056/NEJMoa2105911	http://dx.doi.org/10.1056/NEJMoa2105911		AUG 2021	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ5BP	34351721	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000683386400001
J	Li, Y; Dong, JL; Xiao, HW; Wang, B; Chen, ZY; Zhang, SQ; Jin, YX; Li, YL; Fan, SJ; Cui, M				Li, Yuan; Dong, Jiali; Xiao, Huiwen; Wang, Bin; Chen, Zhiyuan; Zhang, Shuqin; Jin, Yuxiao; Li, Yiliang; Fan, Saijun; Cui, Ming			Caloric restriction alleviates radiation injuries in a sex-dependent fashion	FASEB JOURNAL			English	Article						caloric restriction; intestinal microbiota; radiation injury; sex-specific	DIETARY RESTRICTION; DIMORPHISM; CANCER; MECHANISMS; PROTECTS; LIVER	Safe and effective regimens are still needed given the risk of radiation toxicity from iatrogenic irradiation. The gut microbiota plays an important role in radiation damage. Diet has emerged as a key determinant of the intestinal microbiome signature and function. In this report, we investigated whether a 30% caloric restriction (CR) diet may ameliorate radiation enteritis and hematopoietic toxicity. Experimental mice were either fed ad libitum (AL) or subjected to CR preconditioning for 10 days and then exposed to total body irradiation (TBI) or total abdominal irradiation (TAI). Gross examinations showed that short-term CR pretreatment restored hematogenic organs and improved the intestinal architecture in both male and female mice. Intriguingly, CR preconditioning mitigated radiation-induced systemic and enteric inflammation in female mice, while gut barrier function improved in irradiated males. 16S rRNA high-throughput sequencing showed that the frequency of pro-inflammatory microbes, including Helicobacter and Desulfovibrionaceae, was reduced in female mice after 10 days of CR preconditioning, while an enrichment of short-chain fatty acid (SCFA)-producing bacteria, such as Faecalibaculum, Clostridiales, and Lactobacillus, was observed in males. Using fecal microbiota transplantation (FMT) or antibiotic administration to alter the gut microbiota counteracted the short-term CR-elicited radiation tolerance of both male and female mice, further indicating that the radioprotection of a 30% CR diet depends on altering the gut microbiota. Together, our findings provide new insights into CR in clinical applications and indicate that a short-term CR diet prior to radiation modulates sex-specific gut microbiota configurations, protecting male and female mice against the side effects caused by radiation challenge.	[Li, Yuan; Dong, Jiali; Wang, Bin; Chen, Zhiyuan; Zhang, Shuqin; Li, Yiliang; Fan, Saijun; Cui, Ming] Chinese Acad Med Sci & Peking Union Med Coll, Inst Radiat Med, Tianjin Key Lab Radiat Med & Mol Nucl Med, 238 Baidi Rd, Tianjin 300192, Peoples R China; [Xiao, Huiwen] Nankai Univ, Dept Microbiol, Coll Life Sci, Tianjin, Peoples R China; [Jin, Yuxiao] Soochow Univ, Dept Gen Surg, Affiliated Hosp 2, Suzhou, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Radiation Medicine - CAMS; Peking Union Medical College; Nankai University; Soochow University - China	Fan, SJ; Cui, M (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Radiat Med, Tianjin Key Lab Radiat Med & Mol Nucl Med, 238 Baidi Rd, Tianjin 300192, Peoples R China.	fansaijun@irm-cams.ac.cn; cuiming0403@bjmu.edu.cn			Science Foundation for Distinguished Young Scholars of Tianjin [20JCJQJC00100]; Natural Science Foundation of China [82003399, 81872555, 81730086]	Science Foundation for Distinguished Young Scholars of Tianjin; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Science Foundation for Distinguished Young Scholars of Tianjin, Grant/Award Number: 20JCJQJC00100; Natural Science Foundation of China, Grant/Award Number: 82003399, 81872555 and 81730086	Bae MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32225; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Bonilla MD, 2019, INT J RADIAT ONCOL, V105, P537, DOI 10.1016/j.ijrobp.2019.06.2533; Brandhorst S, 2017, AGEING RES REV, V39, P68, DOI 10.1016/j.arr.2017.02.001; Caffa I, 2020, NATURE, V583, P620, DOI 10.1038/s41586-020-2502-7; Cai YP, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61851-0; Chassaing B, 2015, NATURE, V519, P92, DOI 10.1038/nature14232; Cho YE, 2021, HEPATOLOGY, V73, P2180, DOI 10.1002/hep.30652; Collins N, 2019, CELL, V178, P1088, DOI 10.1016/j.cell.2019.07.049; Conforti F, 2019, JNCI-J NATL CANCER I, V111, P772, DOI 10.1093/jnci/djz094; Conforti F, 2018, LANCET ONCOL, V19, P737, DOI 10.1016/S1470-2045(18)30261-4; Cook MB, 2011, CANCER EPIDEM BIOMAR, V20, P1629, DOI 10.1158/1055-9965.EPI-11-0246; Cui M, 2019, ADV SCI, V6, DOI 10.1002/advs.201901048; Cui M, 2017, EMBO MOL MED, V9, P448, DOI 10.15252/emmm.201606932; D'Abbondanza M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092748; Diaz-Ruiz A, 2019, J GERONTOL A-BIOL, V74, P155, DOI 10.1093/gerona/gly112; Downer S, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2482; Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3; Gerdts E, 2019, NAT MED, V25, P1657, DOI 10.1038/s41591-019-0643-8; Gibbs VK, 2018, J GERONTOL A-BIOL, V73, P157, DOI 10.1093/gerona/glx127; Greenhill Claire, 2016, Nat Rev Endocrinol, V12, P496, DOI 10.1038/nrendo.2016.112; Guo H, 2020, SCIENCE, V370, P549, DOI 10.1126/science.aay9097; Guo TZ, 2019, PAIN, V160, P2013, DOI 10.1097/j.pain.0000000000001592; Hauer-Jensen M, 2014, NAT REV GASTRO HEPAT, V11, P470, DOI 10.1038/nrgastro.2014.46; Hines M, 2020, J NEUROSCI, V40, P37, DOI 10.1523/JNEUROSCI.0750-19.2019; Honjoh S, 2017, CELL REP, V21, P3646, DOI 10.1016/j.celrep.2017.11.108; Jairam V, 2019, JAMA ONCOL, V5, P1028, DOI 10.1001/jamaoncol.2019.0086; Jia FP, 2020, LIVER CANCER, V9, P529, DOI 10.1159/000508308; Jordan S, 2019, CELL, V178, P1102, DOI 10.1016/j.cell.2019.07.050; Kamran MZ, 2016, MED RES REV, V36, P461, DOI 10.1002/med.21386; Kelly CJ, 2013, MUCOSAL IMMUNOL, V6, P1110, DOI 10.1038/mi.2013.6; Kitzman DW, 2016, JAMA-J AM MED ASSOC, V315, P36, DOI 10.1001/jama.2015.17346; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Kopeina GS, 2017, BBA-REV CANCER, V1867, P29, DOI 10.1016/j.bbcan.2016.11.002; Kraus WE, 2019, LANCET DIABETES ENDO, V7, P673, DOI 10.1016/S2213-8587(19)30151-2; Kumagai T, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101405; Lee C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003293; Liu T, 2019, MBIO, V10, DOI 10.1128/mBio.02903-18; Lu LN, 2020, JPEN-PARENTER ENTER, V44, P1308, DOI 10.1002/jpen.1744; Maggi A, 2018, MOL METAB, V15, P3, DOI 10.1016/j.molmet.2018.02.012; Mutoh E, 2011, OBES RES CLIN PRACT, V5, pE119, DOI 10.1016/j.orcp.2010.12.006; Naghshi S, 2020, BMJ-BRIT MED J, V370, DOI [10.1136/bmj.m2412, 10.1136bmj.m2412]; Perry RJ, 2018, CELL METAB, V27, P210, DOI 10.1016/j.cmet.2017.10.004; Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016; Ploeger JM, 2017, CANCER PREV RES, V10, P660, DOI 10.1158/1940-6207.CAPR-17-0174; Schoenberg MH, 2016, VISC MED, V32, P199, DOI 10.1159/000446492; Tonneau M, 2021, CANCER RADIOTHER, V25, P283, DOI 10.1016/j.canrad.2020.08.047; Tonneau M, 2021, RADIOTHER ONCOL, V156, P1, DOI 10.1016/j.radonc.2020.10.033; Tye H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06125-0; Viennois E, 2019, CELL MOL GASTROENTER, V8, P61, DOI 10.1016/j.jcmgh.2019.02.008; Wang P, 2020, INT J OBESITY, V44, P213, DOI 10.1038/s41366-019-0332-1; Wells JCK, 2007, BEST PRACT RES CL EN, V21, P415, DOI 10.1016/j.beem.2007.04.007; Winkler EA, 2015, NAT NEUROSCI, V18, P521, DOI 10.1038/nn.3966; Wu MN, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092809; Zhao RZ, 2020, NATURE, V577, P416, DOI 10.1038/s41586-019-1873-0; Zheng XJ, 2018, FRONT MED-PRC, V12, P634, DOI 10.1007/s11684-018-0670-8; Zhu YZ, 2019, CANCER LETT, V466, P35, DOI 10.1016/j.canlet.2019.08.017	57	1	1	2	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2021	35	8							e21787	10.1096/fj.202100351RR	http://dx.doi.org/10.1096/fj.202100351RR			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR4ZX	34320242				2023-01-03	WOS:000678975300017
J	Lee, T; Rosario, H; Cifuentes, E; Cui, JW; Lin, EC; Miller, VA; Lin, HC				Lee, Tyler; Rosario, Hinette; Cifuentes, Elizabeth; Cui, Jiawei; Lin, Emery C.; Miller, Victoria A.; Lin, Henry C.			Review of interruptions in a pediatric subspecialty outpatient clinic	PLOS ONE			English	Review							INTERPERSONAL SKILLS; MEDICAL ENCOUNTER; COMMUNICATION; PHYSICIAN; DOCTOR; CARE; COMPETENCE; POWER	Introduction The objective of this study was to describe interruptions in the pediatric ambulatory setting and to assess their impact on perceived physician communication, patient satisfaction and recall of provided physician instructions. Methods An observational study was performed at the Children's Hospital of Philadelphia, Pediatric Gastroenterology clinic. Participation consisted of video recording the clinic visit and the caregiver completed post-visit surveys on communication and satisfaction. Video recordings were coded for interruptions, which were divided into 3 main categories: Visit Associated, Pediatric Associated, and Unanticipated. An interruption rate was calculated and correlated with the following outcome variables to assess the impact of interruptions: caregiver satisfaction, caregiver perception on the quality of physician communication, and caregiver instruction recall. Results There were 675 interruptions noted in the 81 clinic visits, with an average of 7.96 (sigma = 7.68) interruptions per visit. Six visits had no interruptions. The Patient was the most frequent interrupter. Significantly higher interruption rates occurred in clinic visits with younger patients (<7 years old) with most of the interruptions being Pediatric Associated interruptions. There was minimal correlation between the clinic visit interruption rate and caregiver satisfaction with the communication, caregiver perception of quality of communication, or caregiver instruction recall rate. Conclusion The effect of interruptions on the pediatric visit remains unclear. Interruptions may be part of the communication process to ensure alignment of the patient's agenda. Additional studies are needed to help determine the impact of interruptions and guide medical education on patient communication.	[Lee, Tyler] Philadelphia Coll Osteopath Med, Philadelphia, PA USA; [Lee, Tyler; Rosario, Hinette; Cifuentes, Elizabeth; Cui, Jiawei] Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA; [Lin, Emery C.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; [Miller, Victoria A.] Childrens Hosp Philadelphia, Div Adolescent Med, Philadelphia, PA 19104 USA; [Miller, Victoria A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lin, Henry C.] Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Gastroenterol, Doernbecher Childrens Hosp, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Oregon Health & Science University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Oregon Health & Science University	Lin, HC (corresponding author), Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Gastroenterol, Doernbecher Childrens Hosp, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA.	linhe@ohsu.edu						[Anonymous], 2017, MEDSCAPE PHYS COMPEN; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; Benson BJ, 2014, ACAD PEDIATR, V14, pS55, DOI 10.1016/j.acap.2013.11.016; Blocker RC, 2017, J EMERG MED, V53, P798, DOI 10.1016/j.jemermed.2017.08.067; Brunett PH, 2001, ACAD MED, V76, P390, DOI 10.1097/00001888-200104000-00021; Byrne P.S., 1976, DOCTORS TALKING PATI; Calhoun AW, 2009, SIMUL HEALTHC, V4, P22, DOI 10.1097/SIH.0b013e318184377a; Chin J. J., 2002, SMJ Singapore Medical Journal, V43, P152; DeWane M, 2018, Int J Womens Dermatol, V4, P238, DOI 10.1016/j.ijwd.2017.12.002; Duffy FD, 2004, ACAD MED, V79, P495, DOI 10.1097/00001888-200406000-00002; FRANKEL RM, 1984, DISCOURSE PROCESS, V7, P135, DOI 10.1080/01638538409544587; GOLDBERG JA, 1990, J PRAGMATICS, V14, P883, DOI 10.1016/0378-2166(90)90045-F; Grundgeiger T, 2016, BMJ QUAL SAF, V25, P392, DOI 10.1136/bmjqs-2015-004083; Hall JA, 2002, PATIENT EDUC COUNS, V48, P69, DOI 10.1016/S0738-3991(02)00071-X; Hall LM, 2010, J PEDIATR NURS, V25, P167, DOI 10.1016/j.pedn.2008.09.005; IRISH JT, 1995, SOC SCI MED, V41, P873, DOI 10.1016/0277-9536(94)00399-E; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Koong AYL, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0330-x; LARSSON US, 1987, SOC SCI MED, V25, P1129, DOI 10.1016/0277-9536(87)90354-6; Li Han Z, 2004, Commun Med, V1, P145, DOI 10.1515/come.2004.1.2.145; Marshall GN., 1994, PATIENT SATISFACTION; Marvel MK, 1999, JAMA-J AM MED ASSOC, V281, P283, DOI 10.1001/jama.281.3.283; Mauksch LB, 2008, ARCH INTERN MED, V168, P1387, DOI 10.1001/archinte.168.13.1387; Mauksch LB, 2017, JAMA-J AM MED ASSOC, V317, P1021, DOI 10.1001/jama.2016.16068; Mischler Elliott, 1984, DISCOURSE MED DIALEC; MISHRA S, 1987, WESTERN J MED, V147, P328; Oda Y, 2014, J CLIN BIOCHEM NUTR, V55, P72, DOI 10.3164/jcbn.14-29; Ospina NS, 2019, J GEN INTERN MED, V34, P36, DOI 10.1007/s11606-018-4540-5; Realini T, 1995, Arch Fam Med, V4, P1028, DOI 10.1001/archfami.4.12.1028; Rhoades DR, 2001, FAM MED, V33, P528; Rivera-Rodriguez AJ, 2010, QUAL SAF HEALTH CARE, V19, P304, DOI 10.1136/qshc.2009.033282; SCHEGLOFF EA, 1977, LANGUAGE, V53, P361, DOI 10.2307/413107; Schneider A, 2019, BMJ QUAL SAF, V28, P296, DOI 10.1136/bmjqs-2018-007811; STREET RL, 1988, HUM COMMUN RES, V15, P60, DOI 10.1111/j.1468-2958.1988.tb00171.x; STREET RL, 1991, MED CARE, V29, P1146, DOI 10.1097/00005650-199111000-00006; Teutsch C, 2003, MED CLIN N AM, V87, P1115, DOI 10.1016/S0025-7125(03)00066-X; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WEST C, 1984, SYMB INTERACT, V7, P87, DOI 10.1525/si.1984.7.1.87	38	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2021	16	7							e0254528	10.1371/journal.pone.0254528	http://dx.doi.org/10.1371/journal.pone.0254528			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UA6CQ	34324552	Green Published, gold			2023-01-03	WOS:000685248200040
J	Ghonimi, TAL; Alkad, MM; Abuhelaiqa, EA; Othman, MM; Elgaali, MA; Ibrahim, RAM; Joseph, SM; Al-Malki, HA; Hamad, AI				Ghonimi, Tarek Abdel Latif; Alkad, Mohamad Mahmood; Abuhelaiqa, Essa Abdulla; Othman, Muftah M.; Elgaali, Musab Ahmed; Ibrahim, Rania Abdelaziz M.; Joseph, Shajahan M.; Al-Malki, Hassan Ali; Hamad, Abdullah Ibrahim			Mortality and associated risk factors of COVID-19 infection in dialysis patients in Qatar: A nationwide cohort study	PLOS ONE			English	Article							HEMODIALYSIS-PATIENTS; OUTCOMES	Context Patients on maintenance dialysis are more susceptible to COVID-19 and its severe form. We studied the mortality and associated risks of COVID-19 infection in dialysis patients in the state of Qatar. Methods This was an observational, analytical, retrospective, nationwide study. We included all adult patients on maintenance dialysis therapy who tested positive for COVID-19 (PCR assay of the nasopharyngeal swab) during the period from February 1, 2020, to July 19, 2020. Our primary outcome was to study the mortality of COVID-19 in dialysis patients in Qatar and risk factors associated with it. Our secondary objectives were to study incidence and severity of COVID-19 in dialysis patients and comparing outcomes between hemodialysis and peritoneal dialysis patients. Patient demographics and clinical features were collected from a national electronic medical record. Univariate Cox regression analysis was performed to evaluate potential risk factors for mortality in our cohort. Results 76 out of 1064 dialysis patients were diagnosed with COVID-19 (age 56 +/- 13.6, 56 hemodialysis and 20 peritoneal dialysis, 56 males). During the study period, 7.1% of all dialysis patients contracted COVID-19. Male dialysis patients had double the incidence of COVID-19 than females (9% versus 4.5% respectively; p<0.01). The most common symptoms on presentation were fever (57.9%), cough (56.6%), and shortness of breath (25%). Pneumonia was diagnosed in 72% of dialysis patients with COVID-19. High severity manifested as 25% of patients requiring admission to the intensive care unit, 18.4% had ARDS, 17.1% required mechanical ventilation, and 14.5% required inotropes. The mean length of hospital stay was 19.2 +/- -12 days. Mortality due to COVID-19 among our dialysis cohort was 15%. Univariate Cox regression analysis for risk factors associated with COVID-19-related death in dialysis patients showed significant increases in risks with age (OR 1.077, CI 95%(1.018-1.139), p = 0.01), CHF and COPD (both same OR 8.974, CI 95% (1.039-77.5), p = 0.046), history of DVT (OR 5.762, CI 95% (1.227-27.057), p = 0.026), Atrial fibrillation (OR 7.285, CI 95%(2.029-26.150), p = 0.002), hypoxia (OR: 16.6; CI 95%(3.574-77.715), p = <0.001), ICU admission (HR30.8, CI 95% (3.9-241.2), p = 0.001), Mechanical ventilation (HR 50.07 CI 95% (6.4-391.2)), p<0.001) and using inotropes(HR 19.17, CI 95% (11.57-718.5), p<0.001). In a multivariate analysis, only ICU admission was found to be significantly associated with death [OR = 32.8 (3.5-305.4), p = 0.002)]. Conclusion This is the first study to be conducted at a national level in Qatar exploring COVID-19 in a dialysis population. Dialysis patients had a high incidence of COVID-19 infection and related mortality compared to previous reports of the general population in the state of Qatar (7.1% versus 4% and 15% versus 0.15% respectively). We also observed a strong association between death related to COVID-19 infection in dialysis patients and admission to ICU.	[Ghonimi, Tarek Abdel Latif; Alkad, Mohamad Mahmood; Abuhelaiqa, Essa Abdulla; Othman, Muftah M.; Elgaali, Musab Ahmed; Ibrahim, Rania Abdelaziz M.; Joseph, Shajahan M.; Al-Malki, Hassan Ali; Hamad, Abdullah Ibrahim] Hamad Med Corp, Doha, Qatar	Hamad Medical Corporation	Hamad, AI (corresponding author), Hamad Med Corp, Doha, Qatar.	ahamad9@hamad.qa	Alkadi, Mohamad/AAA-7016-2022	Ibrahim, Rania/0000-0003-4241-3746; Alkadi, Mohamad/0000-0003-0009-5823; hamad, abdullah/0000-0003-4677-7686				AlSahow A, 2016, SAUDI J KIDNEY DIS T, V27, P12, DOI 10.4103/1319-2442.194885; Bwire George M, 2020, SN Compr Clin Med, V2, P874, DOI 10.1007/s42399-020-00341-w; Fontana F, 2020, CLIN KIDNEY J, V13, P334, DOI 10.1093/ckj/sfaa084; Goicoechea M, 2020, KIDNEY INT, V98, P27, DOI 10.1016/j.kint.2020.04.031; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Hawkins RB, 2020, PUBLIC HEALTH, V189, P129, DOI 10.1016/j.puhe.2020.09.016; Henry BM, 2020, INT UROL NEPHROL, V52, P1193, DOI 10.1007/s11255-020-02451-9; Hsu WT, 2020, HYPERTENSION, V75, P483, DOI 10.1161/HYPERTENSIONAHA.119.13197; Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152; Koh W, 2020, 20108746 MEDRXIV, V15, DOI [DOI 10.1101/2020.05.21.20108746, 10.1101/2020.05.21.20108746]; Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286; Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001; Oh TK, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10207-y; Omrani AS, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05511-8; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Sachdeva M, 2020, AM J NEPHROL, V51, P669, DOI 10.1159/000510259; Shaheen FAM, 2016, SAUDI J KIDNEY DIS T, V27, P24, DOI 10.4103/1319-2442.194886; Sipahi S, 2021, TURK J MED SCI, V51, P421, DOI 10.3906/sag-2006-54; Vancheri SG, 2020, EUR RADIOL, V30, P6161, DOI 10.1007/s00330-020-06967-7; Vaziri ND, 2012, J RENAL NUTR, V22, P149, DOI 10.1053/j.jrn.2011.10.020; Wang R, 2020, AM J KIDNEY DIS, V76, P141, DOI 10.1053/j.ajkd.2020.03.009; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134	23	10	10	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2021	16	7							e0254246	10.1371/journal.pone.0254246	http://dx.doi.org/10.1371/journal.pone.0254246			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2OO	34293004	Green Published, gold			2023-01-03	WOS:000678124900089
J	Navar, AM; Purinton, SN; Hou, QJ; Taylor, RJ; Peterson, ED				Navar, Ann M.; Purinton, Stacey N.; Hou, Qingjiang; Taylor, Robert J.; Peterson, Eric D.			The impact of race and ethnicity on outcomes in 19,584 adults hospitalized with COVID-19	PLOS ONE			English	Article								Introduction At the population level, Black and Hispanic adults in the United States have increased risk of dying from COVID-19, yet whether race and ethnicity impact on risk of mortality among those hospitalized for COVID-19 is unclear. Methods Retrospective cohort study using data on adults hospitalized with COVID-19 from the electronic health record from 52 health systems across the United States contributing data to Cerner Real World Data(TM). In-hospital mortality was evaluated by race first in unadjusted analysis then sequentially adjusting for demographics and clinical characteristics using logistic regression. Results Through August 2020, 19,584 patients with median age 52 years were hospitalized with COVID-19, including n = 4,215 (21.5%) Black and n = 5,761 (29.4%) Hispanic patients. Relative to white patients, crude mortality was slightly higher in Black adults [22.7% vs 20.8%, unadjusted OR 1.12 (95% CI 1.02-1.22)]. Mortality remained higher among Black adults after adjusting for demographic factors including age, sex, date, region, and insurance status (OR 1.13, 95% CI 1.01-1.27), but not after including comorbidities and body mass index (OR 1.07, 95% CI 0.93-1.23). Compared with non-Hispanic patients, Hispanic patients had lower mortality both in unadjusted and adjusted models [mortality 12.7 vs 25.0%, unadjusted OR 0.44(95% CI 0.40-0.48), fully adjusted OR 0.71 (95% CI 0.59-0.86)]. Discussion In this large, multicenter, EHR-based analysis, Black adults hospitalized with COVID-19 had higher observed mortality than white patients due to a higher burden of comorbidities in Black adults. In contrast, Hispanic ethnicity was associated with lower mortality, even in fully adjusted models.	[Navar, Ann M.; Peterson, Eric D.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Purinton, Stacey N.; Hou, Qingjiang; Taylor, Robert J.] Cerner Corp, Kansas City, MO USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Navar, AM (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.	Ann.navar@utsouthwestern.edu	Peterson, Eric David/ABF-5033-2021	Navar, Ann/0000-0002-6197-9860	Cerner Corporation; Amazon Web Services	Cerner Corporation; Amazon Web Services	This study was supported by Cerner Corporation who provided access to the dataset and employee time to participate on the research study. The dataset for this study was created by Cerner for use by academic researchers with support from Amazon Web Services, and is available for access to external researchers upon request. Cerner Corporation-employed co-authors (QH, RT, SP) received salary from Cerner corporation during the time they participated on this research project. Cerner Corp. provided in-kind support for the study through their effort and through providing access to data. Cerner Corp. coauthors were a part of the study team and had roles in creating the dataset and data acquisition (RT, SP), data analysis (QH), the concept and design of the study, data interpretation, and critical revision of the manuscript (QH, RT, SP). EP and AMN receive fees for research consulting to Cerner Corporation outside of the present work. EP and AMN were not compensated for their work on this manuscript.	Ahmad FB, 2021, MMWR-MORBID MORTAL W, V70, P519, DOI [10.15585/mmwr.mm7014e1, 10.15585/mmwr.mm7014e1externalicon]; Asch DA, 2021, JAMA INTERN MED, V181, P471, DOI 10.1001/jamainternmed.2020.8193; Centers for Disease Control, HOSP DEATH RAC ETHN HOSP DEATH RAC ETHN; Changa A., 2021, NEWSONE; Cowger TL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.16933; Daw J, 2017, AM J PREV MED, V52, pS95, DOI 10.1016/j.amepre.2016.07.036; Gross CP, 2020, J GEN INTERN MED, V35, P3097, DOI 10.1007/s11606-020-06081-w; Gu T, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25197; Hamel L, 2020, KFF COVID 19 VACCINE; Kabarriti R, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.19795; King JT, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241825; McCarty TR, 2020, CLIN INFECT DIS PUBL; Ndugga N., 2021, KAISER FAMILY FDN; Ogedegbe G, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.26881; Rodriguez F, 2021, CIRCULATION, V143, P2332, DOI 10.1161/CIRCULATIONAHA.120.052278; US Census Bureau, 2019, FOOD CONTROL; Wang ZC, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-040441	17	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2021	16	7							e0254809	10.1371/journal.pone.0254809	http://dx.doi.org/10.1371/journal.pone.0254809			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2OI	34288941	Green Published, gold			2023-01-03	WOS:000678124300057
J	Aiba, H; Kimura, H; Yamada, S; Okamoto, H; Hayashi, K; Miwa, S; Kawaguchi, Y; Saito, S; Sakai, T; Tatematsu, T; Nakanishi, R; Murakami, H				Aiba, Hisaki; Kimura, Hiroaki; Yamada, Satoshi; Okamoto, Hideki; Hayashi, Katsuhiro; Miwa, Shinji; Kawaguchi, Yohei; Saito, Shiro; Sakai, Takao; Tatematsu, Tsutomu; Nakanishi, Ryoichi; Murakami, Hideki			Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis	PLOS ONE			English	Article							SARCOMA; MANAGEMENT; CAVITATION; THERAPY	To investigate pneumothorax patterns in pazopanib treatment by focusing on the positional relationship between the visceral pleura and metastatic lung tumor, we examined 20 patients with advanced soft tissue tumors who developed lung metastases and underwent pazopanib treatment between 2012 and 2019. Pneumothorax was classified into two types based on the location of the metastatic lesion around the visceral pleural area before pazopanib treatment: subpleural type, within 5 mm from the pleura; and central type, >5 mm from the pleura. We investigated the rates of pneumothorax and the associated risk factors. Five patients experienced pneumothorax (three subpleural and two central types). Cavitation preceded pneumothorax in 83% of patients and led to connection of the cavitated cyst of the metastatic lesion to the chest cavity in the shorter term in patients with the subpleural type. Conversely, a more gradual increase in the cavity size and sudden cyst rupture were observed in the central type. The risk factors for pneumothorax were cavitation after initiating pazopanib and intervention before pazopanib, either ablation or surgery. The location of the metastatic lesions was not a risk factor for the occurrence of pneumothorax. In conclusion, pneumothorax is an adverse event associated with pazopanib treatment. Therefore, attention must be paid to predisposing factors such as the formation of cavitation after pazopanib initiation and previous interventions to the lungs. Moreover, because subpleural pneumothorax tends to occur earlier than the central type, a different time course can be anticipated based on the positional relationships of the metastatic lesions to the visceral pleura.	[Aiba, Hisaki; Kimura, Hiroaki; Yamada, Satoshi; Okamoto, Hideki; Hayashi, Katsuhiro; Miwa, Shinji; Kawaguchi, Yohei; Saito, Shiro; Sakai, Takao; Murakami, Hideki] Nagoya City Univ, Dept Orthopaed Surg, Nagoya, Aichi, Japan; [Hayashi, Katsuhiro; Miwa, Shinji; Saito, Shiro] Kanazawa Univ, Dept Orthopaed Surg, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan; [Tatematsu, Tsutomu; Nakanishi, Ryoichi] Nagoya City Univ, Dept Oncol Immunol & Surg, Nagoya, Aichi, Japan	Nagoya City University; Kanazawa University; Nagoya City University	Aiba, H (corresponding author), Nagoya City Univ, Dept Orthopaed Surg, Nagoya, Aichi, Japan.	hisakiaiba@yahoo.co.jp	Hayashi, K/C-4685-2015	Hayashi, K/0000-0001-8665-2154; Aiba, Hisaki/0000-0002-3438-9814				Al-Saleh S, 2008, CAN RESPIR J, V15, P129, DOI 10.1155/2008/136708; BOISSET GF, 1972, J PEDIATR-US, V81, P259, DOI 10.1016/S0022-3476(72)80292-0; Celik B, 2018, TURK THORAC J, V19, P49, DOI 10.5152/TurkThoracJ.2018.030118; Crabb SJ, 2009, J CLIN ONCOL, V27, P404, DOI 10.1200/JCO.2008.16.2545; Deng YL, 2013, XENOBIOTICA, V43, P443, DOI 10.3109/00498254.2012.734642; Evaluation and Licensing Division, PHARM FOOD SAF BUR M PHARM FOOD SAF BUR M; Hasegawa S, 1999, CHEST, V116, P263, DOI 10.1378/chest.116.1.263; Interiano RB, 2015, J PEDIATR SURG, V50, P1484, DOI 10.1016/j.jpedsurg.2015.01.005; MacDuff A, 2010, THORAX, V65, P18, DOI 10.1136/thx.2010.136986; Marom EM, 2008, J THORAC ONCOL, V3, P351, DOI 10.1097/JTO.0b013e318168c7e9; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989; Nakahara Y, 2017, CASE REP ONCOL, V10, P333, DOI 10.1159/000463380; Nakamura T, 2016, CANCER-AM CANCER SOC, V122, P1408, DOI 10.1002/cncr.29961; Nakano K, 2014, CLIN ONCOL-UK, V26, P357, DOI 10.1016/j.clon.2014.02.010; QUIGLEY MJ, 1988, AM J ROENTGENOL, V150, P1275, DOI 10.2214/ajr.150.6.1275; Sangro P, 2017, ONCOTARGET, V9, P6652, DOI [10.18632/oncotarget.23599, DOI 10.18632/ONCOTARGET.23599]; Soulsby T, 1998, J ACCID EMERG MED, V15, P317; van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5; Verschoor AJ, 2014, CLIN SARCOMA RES, V4, DOI 10.1186/2045-3329-4-14	19	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2021	16	7							e0254866	10.1371/journal.pone.0254866	http://dx.doi.org/10.1371/journal.pone.0254866			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TQ2NF	34270626	gold, Green Published			2023-01-03	WOS:000678121400042
J	Otake, H; Sato, Y; Nakatani, E; Hawke, P; Takei, S; Ogino, A; Asai, H; Abe, A; Fukuta, K; Adachi, M				Otake, Hiroki; Sato, Yoko; Nakatani, Eiji; Hawke, Philip; Takei, Shingo; Ogino, Akihiko; Asai, Hideaki; Abe, Atsushi; Fukuta, Kohta; Adachi, Moriyasu			Oxytetracycline-hydrocortisone ointment reduces the occurrence of both dry socket and post-extraction pain after third molar extraction: An observational study	PLOS ONE			English	Article							POSTOPERATIVE LOCALIZED OSTEITIS; PLATELET-RICH FIBRIN; ALVEOLAR OSTEITIS; SURGERY; GEL	Objectives Dry socket and post-extraction pain are typical discomforts experienced by patients after tooth extraction. In this study, we inserted gauze coated with oxytetracycline-hydrocortisone ointment into the extraction socket immediately after lower third molar extraction and then evaluated the occurrence of dry socket and post-extraction pain compared with gauze non-insertion. Methods This retrospective study was carried out on patients undergoing lower third molar extraction in the Department of Oral Surgery at Shizuoka Prefectural General Hospital in Shizuoka, Japan from November 2018 to October 2019. A comparison was carried out between a gauze-insertion group and a non-insertion group. The occurrence versus non-occurrence of dry socket was determined, and degree of pain was assessed based on a visual analogue scale (VAS) and on patients reporting the number of loxoprofen sodium oral analgesic tablets (60mg/tablet) that they had taken. Dry socket was defined as patient-reported spontaneous pain that did not subside 1 to 3 days postoperatively. Spontaneous post-extraction pain was recorded four times: on the operative day, on the first postoperative day (POD1), on POD3, and during suture removal (POD7). Results The occurrence of dry socket was lower in the gauze-insertion group than in the non-insertion group (0.9%, 2/215 vs. 19.6%, 9/46, p<0.001). The results also showed that both VAS-defined pain level and the number of analgesic tablets taken were lower in the gauze-insertion group than in the non-insertion group on POD3 and POD7.	[Otake, Hiroki; Takei, Shingo; Ogino, Akihiko; Fukuta, Kohta; Adachi, Moriyasu] Shizuoka Prefectural Gen Hosp, Dept Oral & Maxillofacial Surg, Shizuoka, Japan; [Sato, Yoko; Nakatani, Eiji] Shizuoka Prefectural Gen Hosp, Res Support Ctr, Shizuoka, Japan; [Hawke, Philip] Univ Shizuoka, Sch Pharmaceut Sci, Shizuoka, Japan; [Asai, Hideaki] Holy Spirit Hosp, Dept Oral & Maxillofacial Surg, Nagoya, Aichi, Japan; [Abe, Atsushi] Nagoya Ekisaikai Hosp, Dept Oral & Maxillofacial Surg, Nagoya, Aichi, Japan	Shizuoka General Hospital; Shizuoka General Hospital; University of Shizuoka	Adachi, M (corresponding author), Shizuoka Prefectural Gen Hosp, Dept Oral & Maxillofacial Surg, Shizuoka, Japan.	moriyasu-adachi@i.shizuoka-pho.jp	Nakatani, Eiji/O-2782-2013	Nakatani, Eiji/0000-0002-4876-446X; Abe, Atsushi/0000-0001-8215-2769	Shizuoka Prefectural General Hospital	Shizuoka Prefectural General Hospital	The study was funded by Shizuoka Prefectural General Hospital.	Akota I, 1998, ACTA ODONTOL SCAND, V56, P25, DOI 10.1080/000163598423027; Alexander RE, 2000, ORAL SURG ORAL MED O, V90, P406, DOI 10.1067/moe.2000.109778; Blum IR, 2002, INT J ORAL MAX SURG, V31, P309, DOI 10.1054/ijom.2002.0263; Bowe Denise C, 2011, J Ir Dent Assoc, V57, P305; Bun S., 2020, JCO ONCOL PRACT; Burgoyne CC, 2010, J ORAL MAXIL SURG, V68, P144, DOI 10.1016/j.joms.2009.06.033; CATELLANI JE, 1979, J ORAL SURG, V37, P42; Coello-Gomez A, 2018, MED ORAL PATOL ORAL, V23, pE716, DOI 10.4317/medoral.22622; COHEN ME, 1995, ORAL SURG ORAL MED O, V79, P416, DOI 10.1016/S1079-2104(05)80120-9; Eshghpour M, 2014, J ORAL MAXIL SURG, V72, P1463, DOI 10.1016/j.joms.2014.03.029; Gulsen U, 2017, BMC ORAL HEALTH, V17, DOI 10.1186/s12903-017-0371-8; Hita-Iglesias P, 2008, J ORAL MAXIL SURG, V66, P441, DOI 10.1016/j.joms.2007.06.641; Ito A., 2001, DENT OUTLOOK, V97, P995; Kolokythas A, 2010, INT J DENT, V2010, DOI 10.1155/2010/249073; Nakamura N., 2010, ORAL MAXILLOFAC SURG, P505; NITZAN D, 1978, ARCH ORAL BIOL, V23, P465, DOI 10.1016/0003-9969(78)90078-X; Nusair Y M, 2007, J Contemp Dent Pract, V8, P53; Nusair Yanal M, 2006, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, V101, pe89, DOI 10.1016/j.tripleo.2005.11.021; Oginni FO, 2003, J ORAL MAXIL SURG, V61, P871, DOI 10.1016/S0278-2391(03)00248-9; PARRY EW, 1991, J COMP PATHOL, V104, P121, DOI 10.1016/S0021-9975(08)80095-3; Penarrocha M, 2001, ORAL SURG ORAL MED O, V92, P260, DOI 10.1067/moe.2001.115722; RUD J, 1970, British Journal of Oral Surgery, V7, P153; SCHOW SR, 1974, ORAL SURG ORAL MED O, V38, P352, DOI 10.1016/0030-4220(74)90360-0; Susarla SM, 2004, J ORAL MAXIL SURG, V62, P1363, DOI 10.1016/j.joms.2004.05.214; SWEET JB, 1977, AM J OBSTET GYNECOL, V127, P518, DOI 10.1016/0002-9378(77)90446-X; Torres-Lagares Daniel, 2005, Med Oral Patol Oral Cir Bucal, V10, P81	26	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2021	16	7							e0254221	10.1371/journal.pone.0254221	http://dx.doi.org/10.1371/journal.pone.0254221			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9LR	34214141	gold, Green Published			2023-01-03	WOS:000671718200034
J	DaLomba, E; Gramstad, A; Johnson, SG; Carstensen, T; Stigen, L; Mork, G; Magne, TA; Bonsaksen, T				DaLomba, Elaina; Gramstad, Astrid; Johnson, Susanne G.; Carstensen, Tove; Stigen, Linda; Mork, Gry; Magne, Trine A.; Bonsaksen, Tore			Predictors of students' participation in a learning environment survey with annual follow-ups	PLOS ONE			English	Article							TEACHING QUALITY; HIGHER-EDUCATION; PERCEPTIONS; PERFORMANCE; EXPERIENCE	Background Longitudinal research is one effective way to gauge changes in a student cohort over time, however attrition in these studies is typically high, which can result in study bias. This study explored learning environment factors, approaches to studying, and academic performance as predictors of occupational therapy students' consistent participation in data collection conducted over three years of their professional program. Method A longitudinal study of Norwegian occupational therapy students (analyzed n = 240) was conducted. Logistic regression analysis was used to explore occupational therapy students' perceptions of the learning environment, their approaches to studying, and exam grades as they related to the likelihood of consistent participation at three annual surveys. Results Annual response rates varied between 55.1%, and 65.6%, and consistent participation was observed among 49.2%. The fully adjusted regression models showed that higher strategic approach scores increased the odds of consistent participation (adjusted OR: 1.04, p < 0.01), whereas higher surface approach scores decreased the odds of consistent participation (adjusted OR: 0.95, p < 0.05). Neither sociodemographic factors, learning environment factors nor academic performance predicted participation over time. Conclusions Researchers can anticipate relatively high levels of attrition in longitudinal studies of occupational therapy students, but attrition seems to be largely proportional between groups. However, completers in longitudinal studies may be somewhat more well-organized and academically oriented than drop-outs.	[DaLomba, Elaina] Samuel Merritt Univ, Occupat Therapy Dept, Oakland, CA USA; [Gramstad, Astrid] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Hlth & Care Sci, Tromso, Norway; [Gramstad, Astrid] Ctr Care Res, Bangor, Gwynedd, Wales; [Johnson, Susanne G.] Western Norway Univ Appl Sci, Dept Hlth & Social Functioning, Bergen, Norway; [Carstensen, Tove; Magne, Trine A.] Norwegian Univ Sci & Technol NTNU, Dept Neurosci & Movement Sci, Trondheim, Norway; [Stigen, Linda] Norwegian Univ Sci & Technol NTNU, Dept Hlth Sci, Gjovik, Norway; [Mork, Gry; Bonsaksen, Tore] VID Specialized Univ, Fac Hlth Studies, Sandnes, Norway; [Bonsaksen, Tore] Inland Norway Univ Appl Sci, Fac Social & Hlth Sci, Dept Hlth & Nursing Sci, Elverum, Norway	Samuel Merritt University; UiT The Arctic University of Tromso; Western Norway University of Applied Sciences; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); VID Specialised University; Inland Norway University of Applied Sciences	Bonsaksen, T (corresponding author), VID Specialized Univ, Fac Hlth Studies, Sandnes, Norway.; Bonsaksen, T (corresponding author), Inland Norway Univ Appl Sci, Fac Social & Hlth Sci, Dept Hlth & Nursing Sci, Elverum, Norway.	tore.bonsaksen@inn.no	Bonsaksen, Tore/U-5148-2018	Bonsaksen, Tore/0000-0001-6315-1111; Johnson, Susanne G./0000-0002-2500-8952; Magne, Trine Alise/0000-0003-2063-6009; Mork, Gry/0000-0001-6887-7333; Gramstad, Astrid/0000-0002-2301-5067				Berger LK, 2009, INT J SOC RES METHOD, V12, P79, DOI 10.1080/13645570701606077; Biering K, 2015, CLIN EPIDEMIOL, V7, P91, DOI 10.2147/CLEP.S72247; Bonsaksen T, 2019, AUST OCCUP THER J, V66, P33, DOI 10.1111/1440-1630.12504; Bonsaksen T, 2017, OCCUP THER MENT HEAL, V33, P326, DOI 10.1080/0164212X.2017.1295006; Bonsaksen T, 2016, BRIT J OCCUP THER, V79, P361, DOI 10.1177/0308022615627174; Carson R, 2019, AM J OCCUP THER, V73, DOI 10.5014/ajot.2019.032623; DaLomba EJ., 2020, J OCCUP THER ED, V4, P4; DaLomba E, 2021, BMC MED EDUC, V21, DOI 10.1186/s12909-021-02550-w; Diseth A., 2001, SCAND J EDUC RES, V45, P381, DOI [https://doi.org/10.1080/00313830120096789, DOI 10.1080/00313830120096789]; Entwistle N, 2004, EDUC PSYCHOL REV, V16, P325, DOI 10.1007/s10648-004-0003-0; Entwistle N.J., 2013, REPORT DEV USE INVEN; Entwistle N, 2018, STUDENT LEARNING AND ACADEMIC UNDERSTANDING: A RESEARCH PERSPECTIVE WITH IMPLICATIONS FOR TEACHING, P237, DOI 10.1016/B978-0-12-805359-1.00012-7; Flood B, 2003, ASSESS EVAL HIGH EDU, V28, P135, DOI [10.1080/02602930301668, DOI 10.1080/02602930301668]; Fredricks JA, 2011, THEOR PRACT, V50, P327, DOI 10.1080/00405841.2011.607401; Galea S, 2007, ANN EPIDEMIOL, V17, P643, DOI 10.1016/j.annepidem.2007.03.013; Ginns P, 2007, STUD HIGH EDUC, V32, P603, DOI 10.1080/03075070701573773; Gramstad A., 2020, OPEN J OCCUP THER, V8; Gribble N, 2019, BMC MED EDUC, V19, DOI 10.1186/s12909-019-1520-3; Gustavson K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-918; Liew SC, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0327-0; Lizzio A, 2002, STUD HIGH EDUC, V27, P27, DOI 10.1080/03075070120099359; Long K, 2011, INTERNET J ALLIED HE, V9; MARTON F, 1976, BRIT J EDUC PSYCHOL, V46, P4, DOI 10.1111/j.2044-8279.1976.tb02980.x; Mork G, 2020, BMC MED EDUC, V20, DOI 10.1186/s12909-020-02033-4; Pettersen RC., 2007, STUDENTS EXPERIENCE; Portney LG., 2020, FDN CLIN RES APPL EV, V4, P491; RAMSDEN P, 1991, STUD HIGH EDUC, V16, P129, DOI 10.1080/03075079112331382944; Teague S, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0586-7; The Norwegian Association of Higher Education Institutions, 2004, GRAD SYST GEN QUAL D; Thordardottir B, 2022, SCAND J OCCUP THER, V29, P25, DOI 10.1080/11038128.2020.1831058; Thorrisen MM, 2022, SCAND J OCCUP THER, V29, P13, DOI 10.1080/11038128.2020.1831056; Thygesen H., 2020, IR J OCCUP THER, V48, P91, DOI [https://doi.org/10.1108/IJOT-10-2019-0015, DOI 10.1108/IJOT-10-2019-0015]; Trigwell K, 2012, STUD HIGH EDUC, V37, P811, DOI 10.1080/03075079.2010.549220; Tuononen T, 2016, HIGH EDUC, V72, P41, DOI 10.1007/s10734-015-9937-z; Wong RL, 2016, J INTERPROF CARE, V30, P191, DOI 10.3109/13561820.2015.1121215; Woodall T, 2014, STUD HIGH EDUC, V39, P48, DOI 10.1080/03075079.2011.648373	36	0	0	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2021	16	6							e0253773	10.1371/journal.pone.0253773	http://dx.doi.org/10.1371/journal.pone.0253773			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9CN	34170940	Green Published, gold			2023-01-03	WOS:000671694400049
J	Maston, G; Franklin, J; Hocking, S; Swinbourne, J; Gibson, A; Manson, E; Sainsbury, A; Markovic, T				Maston, Gabrielle; Franklin, Janet; Hocking, Samantha; Swinbourne, Jessica; Gibson, Alice; Manson, Elisa; Sainsbury, Amanda; Markovic, Tania			Dietary adherence and program attrition during a severely energy-restricted diet among people with complex class III obesity: A qualitative exploration	PLOS ONE			English	Article							WEIGHT-LOSS INTERVENTIONS; SELF-DETERMINATION THEORY; SOCIOECONOMIC DISADVANTAGE; RISK-FACTOR; HEALTH; METAANALYSIS; OVERWEIGHT; INCREASES; EFFICACY; DISEASE	Meal replacement Severely Energy-Restricted Diets (SERDs) produce >= 10% loss of body mass when followed for 6 weeks or longer in people with class III obesity (BMI >= 40 kg/m(2)). The efficacy of SERDs continues to be questioned by healthcare professionals, with concerns about poor dietary adherence. This study explored facilitators and barriers to dietary adherence and program attrition among people with class III obesity who had attempted or completed a SERD in a specialised weight loss clinic. Participants who commenced a SERD between January 2016 to May 2018 were invited to participate. Semi-structured in-depth interviews were conducted from September to October 2018 with 20 participants (12 women and 8 men). Weight change and recounted events were validated using the participants' medical records. Data were analysed by thematic analysis using line-by-line inductive coding. The mean age +/- SD of participants was 51.2 +/- 11.3 years, with mean +/- SD BMI at baseline 63.7 +/- 12.6 kg/m(2). Five themes emerged from participants' recounts that were perceived to facilitate dietary adherence: (1.1) SERD program group counselling and psychoeducation sessions, (1.2) emotionally supportive clinical staff and social networks that accommodated and championed change in dietary behaviours, (1.3) awareness of eating behaviours and the relationship between these and progression of disease, (1.4) a resilient mindset, and (1.5) dietary simplicity, planning and self-monitoring. There were five themes on factors perceived to be barriers to adherence, namely: (2.1) product unpalatability, (2.2) unrealistic weight loss expectations, (2.3) poor program accessibility, (2.4) unforeseeable circumstances and (2.5) externalised weight-related stigma. This study highlights opportunities where SERD programs can be optimised to facilitate dietary adherence and reduce barriers, thus potentially improving weight loss outcomes with such programs. Prior to the commencement of a SERD program, healthcare professionals facilitating such programs could benefit from reviewing participants to identify common barriers. This includes identifying the presence of product palatability issues, unrealistic weight loss expectations, socio-economic disadvantage, and behaviour impacting experiences of externalised weight-related stigma.	[Maston, Gabrielle; Hocking, Samantha; Markovic, Tania] Univ Sydney, Charles Perkins Ctr, Boden Collaborat Obes Nutr Exercise & Eating Diso, Camperdown, NSW, Australia; [Maston, Gabrielle; Franklin, Janet; Hocking, Samantha; Swinbourne, Jessica; Manson, Elisa; Markovic, Tania] Royal Prince Alfred Hosp, Metab & Obes Serv, Camperdown, NSW, Australia; [Hocking, Samantha; Markovic, Tania] Univ Sydney, Fac Med & Hlth, Sydney Sch Med, Cent Clin Sch, Camperdown, NSW, Australia; [Gibson, Alice] Univ Sydney, Fac Med & Hlth, Menzies Ctr Hlth Policy, Sch Publ Hlth, Camperdown, NSW, Australia; [Sainsbury, Amanda] Univ Western Australia, Fac Sci, Sch Human Sci, Crawley, WA, Australia	University of Sydney; University of Sydney; University of Sydney; University of Sydney; University of Western Australia	Maston, G (corresponding author), Univ Sydney, Charles Perkins Ctr, Boden Collaborat Obes Nutr Exercise & Eating Diso, Camperdown, NSW, Australia.; Maston, G (corresponding author), Royal Prince Alfred Hosp, Metab & Obes Serv, Camperdown, NSW, Australia.	gmas2269@uni.sydney.edu.au	Franklin, Janet/ACG-7579-2022; Salis, Amanda/A-3187-2011	Salis, Amanda/0000-0001-9176-1574; Hocking, Samantha/0000-0002-2514-9392; Maston, Gabrielle/0000-0002-3847-1508	National Health and Medical Research Council (NHMRC) of Australia [APP1135897]	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia)	AS was supported by a Senior Research Fellowship (APP1135897) from the National Health and Medical Research Council (NHMRC) of Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdullah A, 2010, DIABETES RES CLIN PR, V89, P309, DOI 10.1016/j.diabres.2010.04.012; Ahnis A, 2012, PATIENT PREFER ADHER, V6, P165, DOI 10.2147/PPA.S28022; Almeida OP, 2012, J AFFECT DISORDERS, V138, P322, DOI 10.1016/j.jad.2012.01.021; Appel LJ, 2011, NEW ENGL J MED, V365, P1959, DOI 10.1056/NEJMoa1108660; Astbury NM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238645; Astbury NM, 2019, OBES REV, V20, P569, DOI 10.1111/obr.12816; Australian Breau of Statistics, 2008, INFORM PAPER INTRO S; Australian Breau of Statistics, 2016, CENS POP HOUS SOC IN; Australian Institute of Health and Welfare, 2017, PICTURE OVERWEIGHT O; Beleigoli AM, 2019, J MED INTERNET RES, V21, DOI 10.2196/jmir.9609; Bradley EH, 2007, HEALTH SERV RES, V42, P1758, DOI 10.1111/j.1475-6773.2006.00684.x; Brennan L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003818.pub3; Brown A, 2019, NUTR BULL, V44, P7, DOI 10.1111/nbu.12372; Christensen BJ, 2017, OBESITY FACTS, V10, P633, DOI 10.1159/000481138; Codex Alimentarius Commission, 1995, REP 19 SESSS COD COM; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; Cooper S, 2007, EMERG MED J, V24, P816, DOI 10.1136/emj.2007.050641; Dalle Grave R, 2005, OBES RES, V13, P1961, DOI 10.1038/oby.2005.241; David LA, 2016, EAT BEHAV, V22, P87, DOI 10.1016/j.eatbeh.2016.03.030; de Gelder R, 2017, EUR J PUBLIC HEALTH, V27, P93, DOI 10.1093/eurpub/ckv141; Dixon JB, 2013, DIABETES RES CLIN PR, V101, P131, DOI 10.1016/j.diabres.2013.05.017; FISHER RJ, 1993, J CONSUM RES, V20, P303, DOI 10.1086/209351; Gami AS, 2007, J AM COLL CARDIOL, V49, P565, DOI 10.1016/j.jacc.2006.08.060; Ghosh A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010405; Gibson AA, 2016, OBES SCI PRACT, V2, P162, DOI 10.1002/osp4.48; Gibson AA, 2016, HEALTHCARE-BASEL, V4, DOI 10.3390/healthcare4030071; Greenway FL, 2009, J CLIN ENDOCR METAB, V94, P4898, DOI 10.1210/jc.2009-1350; Grock S, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0948-2; Gustafsson PE, 2012, EUR J PUBLIC HEALTH, V22, P322, DOI 10.1093/eurpub/ckr061; Hamdy O, 2017, BMJ OPEN DIAB RES CA, V5, DOI 10.1136/bmjdrc-2016-000259; Harper C, 2018, OBES REV, V19, P1412, DOI 10.1111/obr.12715; Hayes A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026525; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Kim TJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019862; King T, 2006, INT J OBESITY, V30, P281, DOI 10.1038/sj.ijo.0803176; Kizirian NA-S., 2016, AUSTR OBESITY MANAGE; Kovesdy CP, 2017, KIDNEY INT, V91, P260, DOI 10.1016/j.kint.2016.10.019; Laberge MA, 2012, SKELETAL RADIOL, V41, P633, DOI 10.1007/s00256-011-1259-3; Leung AY, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14080922; Locock L., 2020, UNDERSTANDING FRONT, V8, P13; Martin JH, 2012, BRIT J CLIN PHARMACO, V73, P685, DOI 10.1111/j.1365-2125.2011.04159.x; Maston G, 2020, BEHAV SCI-BASEL, V10, DOI 10.3390/bs10090136; Maston G, 2019, BEHAV SCI-BASEL, V9, DOI 10.3390/bs9120144; Munsch S, 2012, BEHAV RES THER, V50, P775, DOI 10.1016/j.brat.2012.08.009; National Health and Medical Research Council, 2006, NUTR REF VAL AUSTR N; National Health and Medical Research Council, 2001, CLIN PRACT GUID MAN; Oliver I, 2012, IEEE IC COMP COM NET; Patel ML, 2019, PREV MED, V126, DOI 10.1016/j.ypmed.2019.05.026; Pearl RL, 2018, OBES REV, V19, P1141, DOI 10.1111/obr.12701; Perri MG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.6764; Pi-Sunyer FX, 1998, AM J CLIN NUTR, V68, P899; Poobalan A, 2004, Obes Rev, V5, P43, DOI 10.1111/j.1467-789X.2004.00127.x; Raves DM, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01497; Rehackova L, 2017, DIABETIC MED, V34, P1554, DOI 10.1111/dme.13426; Remmert JE, 2019, OBES SCI PRACT, V5, P555, DOI 10.1002/osp4.379; Rutledge T, 2017, OBES RES CLIN PRACT, V11, P344, DOI 10.1016/j.orcp.2016.11.005; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Schippers M, 2017, OBES REV, V18, P450, DOI 10.1111/obr.12492; Seers K, 2015, BRIT J PAIN, V9, P36, DOI 10.1177/2049463714549777; Sharma AM, 2009, INT J OBESITY, V33, P289, DOI 10.1038/ijo.2009.2; Sheldon K., 2003, SELF DETERMINATION T; Sturm R, 2004, HEALTH AFFAIR, V23, P199, DOI 10.1377/hlthaff.23.2.199; Tongco M. D. C., 2007, Ethnobotany Research and Applications, V5, P147; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; Wight RG, 2008, SOC SCI MED, V66, P862, DOI 10.1016/j.socscimed.2007.11.002; Williams GC, 2009, DIABETES EDUCATOR, V35, P484, DOI 10.1177/0145721709333856; World Health Organization, 2000, WHO TECHN REP SER, V894; Yumuk V, 2015, OBESITY FACTS, V8, P402, DOI 10.1159/000442721	68	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2021	16	6							e0253127	10.1371/journal.pone.0253127	http://dx.doi.org/10.1371/journal.pone.0253127			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TG9AX	34138917	gold, Green Published			2023-01-03	WOS:000671690200116
J	Kragstrup, TW; Singh, HS; Grundberg, I; Nielsen, ALL; Rivellese, F; Mehta, A; Goldberg, MB; Filbin, MR; Qvist, P; Bibby, BM				Kragstrup, Tue W.; Singh, Helene Sogaard; Grundberg, Ida; Nielsen, Ane Langkilde-Lauesen; Rivellese, Felice; Mehta, Arnav; Goldberg, Marcia B.; Filbin, Michael R.; Qvist, Per; Bibby, Bo Martin			Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients	PLOS ONE			English	Article							ANGIOTENSIN-CONVERTING ENZYME-2; FUNCTIONAL RECEPTOR; SARS CORONAVIRUS; INFECTION; INHIBITION; EXPRESSION; SARS-COV-2; DISEASES; PROTEIN; KIDNEY	Aims Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin converting enzyme 2 (ACE2) enabling entrance of the virus into cells and causing the infection termed coronavirus disease of 2019 (COVID-19). Here, we investigate associations between plasma ACE2 and outcome of COVID-19. Methods and results This analysis used data from a large longitudinal study of 306 COVID-19 positive patients and 78 COVID-19 negative patients (MGH Emergency Department COVID-19 Cohort). Comprehensive clinical data were collected on this cohort, including 28-day outcomes. The samples were run on the Olink (R) Explore 1536 platform which includes measurement of the ACE2 protein. High admission plasma ACE2 in COVID-19 patients was associated with increased maximal illness severity within 28 days with OR = 1.8, 95%-CI: 1.4-2.3 (P < 0.0001). Plasma ACE2 was significantly higher in COVID-19 patients with hypertension compared with patients without hypertension (P = 0.0045). Circulating ACE2 was also significantly higher in COVID-19 patients with pre-existing heart conditions and kidney disease compared with patients without these pre-existing conditions (P = 0.0363 and P = 0.0303, respectively). Conclusion This study suggests that measuring plasma ACE2 is potentially valuable in predicting COVID-19 outcomes. Further, ACE2 could be a link between COVID-19 illness severity and its established risk factors hypertension, pre-existing heart disease and pre-existing kidney disease.	[Kragstrup, Tue W.; Singh, Helene Sogaard; Nielsen, Ane Langkilde-Lauesen; Qvist, Per] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Kragstrup, Tue W.] Aarhus Univ Hosp, Dept Rheumatol, Aarhus, Denmark; [Grundberg, Ida] Olink Prote, Uppsala, Sweden; [Nielsen, Ane Langkilde-Lauesen] Randers Reg Hosp, Randers, Denmark; [Rivellese, Felice] Queen Mary Univ London, Ctr Expt Med & Rheumatol, William Harvey Res Inst, Barts & London Sch Med & Dent, London, England; [Mehta, Arnav] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA; [Mehta, Arnav] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Goldberg, Marcia B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Goldberg, Marcia B.] Harvard Med Sch, Dept Microbiol, Boston, MA 02115 USA; [Filbin, Michael R.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Qvist, Per] IPSYCH, Lundbeck Fdn Initiat Integrat Psychiat Res, Aarhus, Denmark; [Qvist, Per] Aarhus Univ, Ctr Genom & Personalized Med, Aarhus, Denmark; [Bibby, Bo Martin] Aarhus Univ, Dept Biostat, Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; University of London; Queen Mary University London; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH); Aarhus University; Aarhus University	Kragstrup, TW (corresponding author), Aarhus Univ, Dept Biomed, Aarhus, Denmark.; Kragstrup, TW (corresponding author), Aarhus Univ Hosp, Dept Rheumatol, Aarhus, Denmark.	kragstrup@biomed.au.dk	Qvist, Per/H-4238-2019	Qvist, Per/0000-0002-0750-0089; Mehta, Arnav/0000-0002-0313-2848; Kragstrup, Tue Wenzel/0000-0002-6439-397X; RIVELLESE, Felice/0000-0002-6759-7521	American Lung Association COVID-19 Action Initiative award; Independent Research Fund Denmark clinician scientist award [9039-00015B]; Olink Proteomics	American Lung Association COVID-19 Action Initiative award; Independent Research Fund Denmark clinician scientist award; Olink Proteomics	American Lung Association COVID-19 Action Initiative award (MBG). Independent Research Fund Denmark clinician scientist award 9039-00015B, TWK). Olink Proteomics financed and performed the proteomics assays presented in this work as part of the collaboration with Massachusetts General Hospital (MGH and the Broad Institute on the MGH Emergency Department COVID-19 Cohort. Olink Proteomics provided support in the form of salaries for IG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors are articulated in the 'author contributions' section.	Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Atlas SA, 2007, J MANAGE CARE PHARM, V13, pS9, DOI 10.18553/jmcp.2007.13.s8-b.9; Banerjee A, 2020, LANCET, V395, P1715, DOI 10.1016/S0140-6736(20)30854-0; Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163; Boulpaep WBE., 2017, MED PHYSL, V3; Chan KK, 2020, SCIENCE, V369, P1261, DOI 10.1126/science.abc0870; Cummings Matthew J, 2020, medRxiv, DOI [10.1016/S0140-6736(20)31189-2, 10.1101/2020.04.15.20067157]; Emilsson Valur, 2020, medRxiv, DOI 10.1101/2020.06.04.20122044; Epelman S, 2009, J CARD FAIL, V15, P565, DOI 10.1016/j.cardfail.2009.01.014; Fagyas M, 2021, GEROSCIENCE, V43, P19, DOI 10.1007/s11357-020-00300-2; Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8; Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461; Filbin Michael R, 2020, bioRxiv, DOI 10.1101/2020.11.02.365536; Forrester SJ, 2018, PHYSIOL REV, V98, P1627, DOI 10.1152/physrev.00038.2017; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x; Kintscher U, 2020, HYPERTENSION, V76, pE34, DOI 10.1161/HYPERTENSIONAHA.120.15841; Kreutz R, 2020, CARDIOVASC RES, V116, P1688, DOI 10.1093/cvr/cvaa097; Lee IT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19145-6; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Lores E, 2020, CLIN SCI, V134, P2791, DOI 10.1042/CS20200484; Lundstrom A, 2021, J MED VIROL, V93, P5908, DOI 10.1002/jmv.27144; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004; Munker D, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.02724-2020; Nagy B, 2021, INT J INFECT DIS, V103, P412, DOI 10.1016/j.ijid.2020.11.184; Narula S, 2020, LANCET, V396, P968, DOI 10.1016/S0140-6736(20)31964-4; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Patel SK, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.03730-2020; Pavel AB, 2021, ALLERGY, V76, P875, DOI 10.1111/all.14522; Ocaranza MP, 2020, NAT REV CARDIOL, V17, P116, DOI 10.1038/s41569-019-0244-8; Perrotta F, 2020, RESP MED, V168, DOI 10.1016/j.rmed.2020.105996; Putman M, 2021, ARTHRITIS RHEUMATOL, V73, P36, DOI 10.1002/art.41469; Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975; Rieder M, 2021, AM J HYPERTENS, V34, P278, DOI 10.1093/ajh/hpaa169; Rivellese F, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102536; Sama IE, 2020, EUR HEART J, V41, P1810, DOI 10.1093/eurheartj/ehaa373; Serfozo P, 2020, HYPERTENSION, V75, P173, DOI 10.1161/HYPERTENSIONAHA.119.14071; Tikellis C, 2008, DIABETES, V57, P1018, DOI 10.2337/db07-1212; van Lier D, 2021, ERJ OPEN RES, V7, DOI 10.1183/23120541.00848-2020; Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20; Wysocki J, 2021, J AM SOC NEPHROL, V32, P795, DOI 10.1681/ASN.2020101537; Wysocki J, 2020, J AM SOC NEPHROL, V31, P1941, DOI 10.1681/ASN.2020050667; Yamaleyeva LM, 2012, AM J PHYSIOL-RENAL, V302, pF1374, DOI 10.1152/ajprenal.00656.2011; Yang CW, 2017, RENAL FAILURE, V39, P719, DOI 10.1080/0886022X.2017.1398665; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0	51	52	52	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2021	16	6							e0252799	10.1371/journal.pone.0252799	http://dx.doi.org/10.1371/journal.pone.0252799			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6RB	34086837	Green Published, gold			2023-01-03	WOS:000664640100135
J	[Anonymous]				[Anonymous]			Rethinking chronic pain	LANCET			English	Editorial Material																			0	9	9	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	2021	397	10289					2023	2023						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	SK5LX	34062132	Bronze			2023-01-03	WOS:000656257800001
J	Thompson, AF; Moraes, L; Rocha, NN; Fernandes, MVS; Antunes, MA; Abreu, SC; Santos, CL; Capelozzi, VL; Samary, CS; de Abreu, MG; Saddy, F; Pelosi, P; Silva, PL; Rocco, PRM				Thompson, Alessandra F.; Moraes, Lillian; Rocha, Nazareth N.; Fernandes, Marcos V. S.; Antunes, Mariana A.; Abreu, Soraia C.; Santos, Cintia L.; Capelozzi, Vera L.; Samary, Cynthia S.; de Abreu, Marcelo G.; Saddy, Felipe; Pelosi, Paolo; Silva, Pedro L.; Rocco, Patricia R. M.			Impact of different frequencies of controlled breath and pressure-support levels during biphasic positive airway pressure ventilation on the lung and diaphragm in experimental mild acute respiratory distress syndrome	PLOS ONE			English	Article							MECHANICAL VENTILATION; RELEASE VENTILATION; INJURY; ESOPHAGEAL; MORTALITY; PULMONARY; PERFUSION; ATROPHY	Background We hypothesized that a decrease in frequency of controlled breaths during biphasic positive airway pressure (BIVENT), associated with an increase in spontaneous breaths, whether pressure support (PSV)-assisted or not, would mitigate lung and diaphragm damage in mild experimental acute respiratory distress syndrome (ARDS). Materials and methods Wistar rats received Escherichia coli lipopolysaccharide intratracheally. After 24 hours, animals were randomly assigned to: 1) BIVENT-100+PSV0%: airway pressure (P-high) adjusted to V-T = 6 mL/kg and frequency of controlled breaths (f) = 100 bpm; 2) BIVENT-50+PSV0%: P-high adjusted to V-T = 6 mL/kg and f = 50 bpm; 3) BIVENT-50+PSV50% (PSV set to half the P-high reference value, i.e., PSV50%); or 4) BIVENT-50+PSV100% (PSV equal to P-high reference value, i.e., PSV100%). Positive end-expiratory pressure (P-low) was equal to 5 cmH(2)O. Nonventilated animals were used for lung and diaphragm histology and molecular biology analysis. Results BIVENT-50+PSV0%, compared to BIVENT-100+PSV0%, reduced the diffuse alveolar damage (DAD) score, the expression of amphiregulin (marker of alveolar stretch) and muscle atrophy F-box (marker of diaphragm atrophy). In BIVENT-50 groups, the increase in PSV (BIVENT-50+PSV50% versus BIVENT-50+PSV100%) yielded better lung mechanics and less alveolar collapse, interstitial edema, cumulative DAD score, as well as gene expressions associated with lung inflammation, epithelial and endothelial cell damage in lung tissue, and muscle ring finger protein 1 (marker of muscle proteolysis) in diaphragm. Transpulmonary peak pressure (Ppeak,L) and pressure-time product per minute (PTPmin) at P-high were associated with lung damage, while increased spontaneous breathing at P-low did not promote lung injury. Conclusion In the ARDS model used herein, during BIVENT, the level of PSV and the phase of the respiratory cycle in which the inspiratory effort occurs affected lung and diaphragm damage. Partitioning of inspiratory effort and transpulmonary pressure in spontaneous breaths at P-low and P-high is required to minimize VILI.	[Thompson, Alessandra F.; Moraes, Lillian; Rocha, Nazareth N.; Fernandes, Marcos V. S.; Antunes, Mariana A.; Abreu, Soraia C.; Santos, Cintia L.; Samary, Cynthia S.; Saddy, Felipe; Silva, Pedro L.; Rocco, Patricia R. M.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, Rio De Janeiro, RJ, Brazil; [Thompson, Alessandra F.; Saddy, Felipe] Copa DOr Hosp, Rio De Janeiro, Brazil; [Rocha, Nazareth N.] Fluminense Fed Univ, Biomed Inst, Dept Physiol & Pharmacol, Niteroi, RJ, Brazil; [Capelozzi, Vera L.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil; [Samary, Cynthia S.] Univ Fed Rio de Janeiro, Dept Phys Therapy, Rio De Janeiro, RJ, Brazil; [de Abreu, Marcelo G.] Tech Univ Dresden, Univ Hosp Dresden, Dept Anesthesiol & Intens Care Therapy, Pulm Engn Grp, Dresden, Germany; [de Abreu, Marcelo G.] Outcomes Res Consortium, Cleveland, OH USA; [Saddy, Felipe] Pro Cardiaco Hosp, Rio De Janeiro, Brazil; [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, Genoa, Italy; [Pelosi, Paolo] IRCCS Oncol & Neurosci, San Martino Policlin Hosp, Genoa, Italy	Universidade Federal do Rio de Janeiro; Universidade Federal Fluminense; Universidade de Sao Paulo; Universidade Federal do Rio de Janeiro; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Genoa	Rocco, PRM (corresponding author), Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, Rio De Janeiro, RJ, Brazil.	prmrocco@biof.ufrj.br	Silva, Pedro Leme/AAD-8236-2019; , Capelozzi/N-1737-2019; Antunes, Mariana/F-8994-2012	Silva, Pedro Leme/0000-0001-5838-4949; , Capelozzi/0000-0001-9732-5853; Rieken Macedo Rocco, Patricia/0000-0003-1412-7136; Antunes, Mariana/0000-0002-2004-3628; samary, cynthia/0000-0002-1860-4166	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [421067/2016-0, 443894/2018-3]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro [E-26/210.910/2016, E-26/010.001488/2019]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ))	This study was supported by Conselho Nacional de Desenvolvimento Cienti ' fico e Tecnolo ' gico in the form of grants awarded to PRMR (421067/2016-0) and PLS (443894/20183), and Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro in the form of grants awarded to PRMR (E-26/210.910/2016, E-26/010.001488/2019).	Araujo MN, 2017, ANESTH ANALG, V125, P491, DOI 10.1213/ANE.0000000000001927; Archer DP, 2007, ANESTH ANALG, V105, P993, DOI 10.1213/01.ane.0000282023.42639.b2; Heil LBB, 2016, ANESTH ANALG, V122, P1015, DOI 10.1213/ANE.0000000000001114; BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788; Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP; Carvalho AR, 2011, J APPL PHYSIOL, V110, P1083, DOI 10.1152/japplphysiol.00804.2010; da Cruz DG, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246891; de Abreu MG, 2010, CRIT CARE, V14, DOI 10.1186/cc8912; Demoule A, 2013, AM J RESP CRIT CARE, V188, P213, DOI 10.1164/rccm.201209-1668OC; Dolinay T, 2006, PHYSIOL GENOMICS, V26, P68, DOI 10.1152/physiolgenomics.00110.2005; du Sert NP, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000411; Engelberts D, 2012, INTENS CARE MED, V38, P879, DOI 10.1007/s00134-012-2512-5; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC; Felix NS, 2019, ANESTHESIOLOGY, V130, P767, DOI 10.1097/ALN.0000000000002630; Goligher EC, 2018, AM J RESP CRIT CARE, V197, P204, DOI 10.1164/rccm.201703-0536OC; Henzler D, 2019, INTENS CARE MED EXP, V7, DOI 10.1186/s40635-019-0272-z; Hudson MB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137693; Kaplan LJ, 2001, CRIT CARE, V5, P221, DOI 10.1186/cc1027; Kiss T, 2016, BRIT J ANAESTH, V116, P708, DOI 10.1093/bja/aew093; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; McMullen SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040190; Menezes SLS, 2005, J APPL PHYSIOL, V98, P1777, DOI 10.1152/japplphysiol.01182.2004; Mireles-Cabodevila E, 2016, RESP CARE, V61, P761, DOI 10.4187/respcare.04653; Moraes L, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0474-4; MORTOLA JP, 1983, J APPL PHYSIOL, V55, P250, DOI 10.1152/jappl.1983.55.1.250; Pinto EF, 2020, ANESTHESIOLOGY, V132, P307, DOI 10.1097/ALN.0000000000003060; Putensen C, 2004, CRIT CARE, V8, P492, DOI 10.1186/cc2919; Putensen C, 2001, AM J RESP CRIT CARE, V164, P43, DOI 10.1164/ajrccm.164.1.2001078; Putensen C, 1999, AM J RESP CRIT CARE, V159, P1241, DOI 10.1164/ajrccm.159.4.9806077; Rocco PRM, 2020, INTENS CARE MED, V46, P2377, DOI 10.1007/s00134-020-06143-x; Saddy F, 2013, CRIT CARE, V17, DOI 10.1186/cc13051; Saddy F, 2010, INTENS CARE MED, V36, P1417, DOI 10.1007/s00134-010-1808-6; Samary CS, 2016, CRIT CARE MED, V44, pE553, DOI 10.1097/CCM.0000000000001611; Samary CS, 2015, ANESTHESIOLOGY, V123, P423, DOI 10.1097/ALN.0000000000000716; Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; Spieth PM, 2009, AM J RESP CRIT CARE, V179, P684, DOI 10.1164/rccm.200806-975OC; SUKI B, 1994, NATURE, V368, P615, DOI 10.1038/368615a0; Thille AW, 2006, INTENS CARE MED, V32, P1515, DOI 10.1007/s00134-006-0301-8; Uhlig C, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-56; van Haren F, 2019, CRIT CARE MED, V47, P229, DOI 10.1097/CCM.0000000000003519; Watson AC, 2001, CRIT CARE MED, V29, P1325, DOI 10.1097/00003246-200107000-00005; Yoshida T, 2020, CURR OPIN CRIT CARE, V26, P59, DOI 10.1097/MCC.0000000000000691; Zhang ZH, 2019, CRIT CARE MED, V47, P315, DOI 10.1097/CCM.0000000000003499	46	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0256021	10.1371/journal.pone.0256021	http://dx.doi.org/10.1371/journal.pone.0256021			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC9GQ	34415935	Green Published, gold			2023-01-03	WOS:000686828600015
J	Perkins, GD; Callaway, CW; Haywood, K; Neumar, RW; Lilja, G; Rowland, MJ; Sawyer, KN; Skrifvars, MB; Nolan, JP				Perkins, Gavin D.; Callaway, Clifton W.; Haywood, Kirstie; Neumar, Robert W.; Lilja, Gisela; Rowland, Matthew J.; Sawyer, Kelly N.; Skrifvars, Markus B.; Nolan, Jerry P.			Brain injury after cardiac arrest	LANCET			English	Review							TARGETED TEMPERATURE MANAGEMENT; 2020 INTERNATIONAL CONSENSUS; CARDIOVASCULAR CARE SCIENCE; QUALITY-OF-LIFE; THERAPEUTIC HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; SURVIVORS; REHABILITATION; WITHDRAWAL; OUTCOMES	As more people are surviving cardiac arrest, focus needs to shift towards improving neurological outcomes and quality of life in survivors. Brain injury after resuscitation, a common sequela following cardiac arrest, ranges in severity from mild impairment to devastating brain injury and brainstem death. Effective strategies to minimise brain injury after resuscitation include early intervention with cardiopulmonary resuscitation and defibrillation, restoration of normal physiology, and targeted temperature management. It is important to identify people who might have a poor outcome, to enable informed choices about continuation or withdrawal of life-sustaining treatments. Multimodal prediction guidelines seek to avoid premature withdrawal in those who might survive with a good neurological outcome, or prolonging treatment that might result in survival with severe disability. Approximately one in three admitted to intensive care will survive, many of whom will need intensive, tailored rehabilitation after discharge to have the best outcomes.	[Perkins, Gavin D.; Haywood, Kirstie; Nolan, Jerry P.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England; [Perkins, Gavin D.] Univ Hosp Birmingham, Crit Care Unit, Birmingham, W Midlands, England; [Callaway, Clifton W.; Sawyer, Kelly N.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Neumar, Robert W.] Univ Michigan, Dept Emergency Med, Michigan Ctr Integrat Res Crit Care, Ann Arbor, MI 48109 USA; [Lilja, Gisela] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Neurol, Lund, Sweden; [Rowland, Matthew J.] Univ Oxford, Nuffield Dept Clin Neurosci, Kadoorie Ctr Crit Care Res, Oxford, England; [Skrifvars, Markus B.] Univ Helsinki, Dept Emergency Care & Serv, Helsinki, Finland; [Skrifvars, Markus B.] Helsinki Univ Hosp, Helsinki, Finland; [Nolan, Jerry P.] Royal United Hosp, Anaesthesia & Intens Care Med, Bath, Avon, England	University of Warwick; University of Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; Lund University; Skane University Hospital; University of Oxford; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Perkins, GD (corresponding author), Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.	g.d.perkins@warwick.ac.uk		Perkins, Gavin/0000-0003-3027-7548; Lilja, Gisela/0000-0003-1860-1456				Adiguzel E, 2018, INT J REHABIL RES, V41, P47, DOI 10.1097/MRR.0000000000000261; Ameloot K, 2015, RESUSCITATION, V90, P121, DOI 10.1016/j.resuscitation.2015.03.001; Ameloot K, 2019, EUR HEART J, V40, P1804, DOI 10.1093/eurheartj/ehz120; Andersen LW, 2020, RESUSCITATION, V147, P1, DOI 10.1016/j.resuscitation.2019.12.003; [Anonymous], 2021, EUR J PREV CARDIOL, DOI [DOI 10.1177/2047487320913379, 10.1177/2047487320913379]; Arrich J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010570.pub2; Bayley MT, 2018, J HEAD TRAUMA REHAB, V33, P296, DOI 10.1097/HTR.0000000000000428; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bernard SA, 2016, CIRCULATION, V134, P797, DOI 10.1161/CIRCULATIONAHA.116.021989; Bohm M, 2019, RESUSCITATION, V135, P197, DOI 10.1016/j.resuscitation.2018.10.028; Boncyk CS, 2019, CURR OPIN CRIT CARE, V25, P218, DOI 10.1097/MCC.0000000000000615; Bro-Jeppesen J, 2017, RESUSCITATION, V121, P179, DOI 10.1016/j.resuscitation.2017.09.019; Cardiac Arrest Registry to Enhance Survival, 2020, CARES SUMM REP 2019; Caro-Codon J, 2018, RESUSCITATION, V133, P33, DOI 10.1016/j.resuscitation.2018.09.015; Cronberg T, 2020, LANCET NEUROL, V19, P611, DOI 10.1016/S1474-4422(20)30117-4; Dankiewicz J, 2021, NEW ENGL J MED, V384, P2283, DOI 10.1056/NEJMoa2100591; Dragancea I, 2015, RESUSCITATION, V93, P164, DOI 10.1016/j.resuscitation.2015.04.013; Elmer J, 2016, ANN NEUROL, V80, P175, DOI 10.1002/ana.24697; Elmer J, 2016, RESUSCITATION, V102, P127, DOI 10.1016/j.resuscitation.2016.01.016; Esdaille CJ, 2020, RESUSCITATION, V153, P111, DOI 10.1016/j.resuscitation.2020.05.049; Geense WW, 2019, CRIT CARE MED, V47, P1607, DOI 10.1097/CCM.0000000000003974; Hayman EG, 2018, NEUROCRIT CARE, V28, P276, DOI 10.1007/s12028-017-0474-8; Haywood K, 2018, RESUSCITATION, V127, P147, DOI 10.1016/j.resuscitation.2018.03.022; Haywood KL, 2021, RESUSCITATION, V160, P84, DOI 10.1016/j.resuscitation.2021.01.019; Helmy MM, 2011, ANN NEUROL, V69, P493, DOI 10.1002/ana.22223; Hofland JV, 2018, RESUSCITATION, V128, P198, DOI 10.1016/j.resuscitation.2018.03.016; Holmberg MJ, 2020, RESUSCITATION, V152, P107, DOI 10.1016/j.resuscitation.2020.04.031; Holzer M, 2002, NEW ENGL J MED, V346, P549; Int Liaison Comm Resuscitation, 2005, RESUSCITATION, V67, P181, DOI 10.1016/j.resuscitation.2005.09.010; Israelsson J, 2017, RESUSCITATION, V114, P27, DOI 10.1016/j.resuscitation.2017.02.006; Jakkula P, 2018, INTENS CARE MED, V44, P2091, DOI 10.1007/s00134-018-5446-8; Kiguchi T, 2020, RESUSCITATION, V152, P39, DOI 10.1016/j.resuscitation.2020.02.044; Kim YJ, 2017, RESUSCITATION, V118, P70, DOI 10.1016/j.resuscitation.2017.07.005; Kim YJ, 2016, RESUSCITATION, V105, P109, DOI 10.1016/j.resuscitation.2016.05.020; Kirkegaard H, 2017, JAMA-J AM MED ASSOC, V318, P341, DOI 10.1001/jama.2017.8978; Lascarrou JB, 2019, NEW ENGL J MED, V381, P2327, DOI 10.1056/NEJMoa1906661; Lilja G, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.117.003566; Lybeck A, 2018, RESUSCITATION, V126, P166, DOI 10.1016/j.resuscitation.2018.01.027; Mackle D, 2020, NEW ENGL J MED, V382, P989, DOI 10.1056/NEJMoa1903297; Mark NM, 2015, INTENS CARE MED, V41, P1572, DOI 10.1007/s00134-015-3810-5; Moseby-Knappe M, 2020, RESUSCITATION, V156, P273, DOI 10.1016/j.resuscitation.2020.09.004; Moseby-Knappe M, 2020, INTENS CARE MED, V46, P1852, DOI 10.1007/s00134-020-06080-9; Moulaert VRM, 2017, NEUROREHAB NEURAL RE, V31, P530, DOI 10.1177/1545968317697032; Moulaert VRM, 2015, INT J CARDIOL, V193, P8, DOI 10.1016/j.ijcard.2015.04.229; Nelskyla A, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-35; Nichol G, 2015, RESUSCITATION, V93, P74, DOI 10.1016/j.resuscitation.2015.05.011; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nolan JP, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1390-6; Nolan JP, 2021, INTENS CARE MED, V47, P369, DOI 10.1007/s00134-021-06368-4; Nordberg P, 2019, JAMA-J AM MED ASSOC, V321, P1677, DOI 10.1001/jama.2019.4149; Nordstrom EB, 2017, RESUSCITATION, V118, P8, DOI 10.1016/j.resuscitation.2017.06.012; Oddo M, 2018, INTENS CARE MED, V44, P2102, DOI 10.1007/s00134-018-5448-6; Oh SH, 2020, RESUSCITATION, V150, P154, DOI 10.1016/j.resuscitation.2020.02.029; Olai H, 2020, INTENS CARE MED EXP, V8, DOI 10.1186/s40635-019-0291-9; Olasveengen TM, 2020, RESUSCITATION, V156, pA35, DOI 10.1016/j.resuscitation.2020.09.010; Peberdy MA, 2016, RESUSCITATION, V103, P117, DOI 10.1016/j.resuscitation.2016.01.006; Perkins GD, 2018, NEW ENGL J MED, V379, P711, DOI 10.1056/NEJMoa1806842; Rapun IA, 2017, RESUSCITATION, V115, P169, DOI 10.1016/j.resuscitation.2017.03.020; Rohaut B, 2018, BRIT J ANAESTH, V120, P5, DOI 10.1016/j.bja.2017.11.007; Sandroni C, 2020, INTENS CARE MED, V46, P1803, DOI 10.1007/s00134-020-06198-w; Sandroni C, 2016, INTENS CARE MED, V42, P1661, DOI 10.1007/s00134-016-4549-3; Sawyer KN, 2020, CIRCULATION, V141, pE654, DOI 10.1161/CIR.0000000000000747; Scarpino M, 2019, RESUSCITATION, V143, P115, DOI 10.1016/j.resuscitation.2019.07.032; Scarpino M, 2018, RESUSCITATION, V129, P114, DOI 10.1016/j.resuscitation.2018.04.016; Schjorring OL, 2021, NEW ENGL J MED, V384, P1301, DOI 10.1056/NEJMoa2032510; Sekhon MS, 2019, CRIT CARE MED, V47, P960, DOI 10.1097/CCM.0000000000003745; Sekhon MS, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1670-9; Smith K, 2015, CIRCULATION, V131, P174, DOI 10.1161/CIRCULATIONAHA.114.011200; Soar J, 2020, RESUSCITATION, V156, pA80, DOI 10.1016/j.resuscitation.2020.09.012; Sondergaard KB, 2020, RESUSCITATION, V148, P251, DOI 10.1016/j.resuscitation.2019.12.006; Soto CL, 2020, NEUROCRIT CARE, V32, P206, DOI 10.1007/s12028-019-00842-0; Steinbusch CVM, 2017, RESUSCITATION, V120, P132, DOI 10.1016/j.resuscitation.2017.08.007; Uray T, 2018, CRIT CARE MED, V46, pE508, DOI 10.1097/CCM.0000000000003070; Vaahersalo J, 2013, INTENS CARE MED, V39, P826, DOI 10.1007/s00134-013-2868-1; Westhall E, 2016, NEUROLOGY, V86, P1482, DOI 10.1212/WNL.0000000000002462; Witten L, 2019, RESUSCITATION, V136, P93, DOI 10.1016/j.resuscitation.2019.01.031; Yan SJ, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2773-2; Yannopoulos D, 2020, LANCET, V396, P1807, DOI 10.1016/S0140-6736(20)32338-2; Young P, 2020, INTENS CARE MED, V46, P17, DOI 10.1007/s00134-019-05857-x	79	20	22	5	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	2021	398	10307					1269	1278		10.1016/S0140-6736(21)00953-3	http://dx.doi.org/10.1016/S0140-6736(21)00953-3		SEP 2021	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC6VF	34454687	Green Accepted			2023-01-03	WOS:000704393000025
J	Wang, L; Hong, PJ; May, C; Rehman, Y; Oparin, Y; Hong, CJ; Hong, BY; AminiLari, M; Gallo, L; Kaushal, A; Craigie, S; Couban, RJ; Kum, E; Shanthanna, H; Price, I; Upadhye, S; Ware, MA; Campbell, F; Agoritsas, T; Buchbinder, R; Busse, JW				Wang, Li; Hong, Patrick J.; May, Curtis; Rehman, Yasir; Oparin, Yvgeniy; Hong, Chris J.; Hong, Brian Y.; AminiLari, Mahmood; Gallo, Lucas; Kaushal, Alka; Craigie, Samantha; Couban, Rachel J.; Kum, Elena; Shanthanna, Harsha; Price, Ira; Upadhye, Suneel; Ware, Mark A.; Campbell, Fiona; Agoritsas, Thomas; Buchbinder, Rachelle; Busse, Jason W.			Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CHRONIC NEUROPATHIC PAIN; MULTIPLE-SCLEROSIS CAMS; DOUBLE-BLIND; OROMUCOSAL SPRAY; SOCIOECONOMIC BURDEN; ADJUNCTIVE THERAPY; MEDICINAL EXTRACTS; OUTCOME DOMAINS; PARALLEL-GROUP; EFFICACY	OBJECTIVE To determine the benefits and harms of medical cannabis and cannabinoids for chronic pain. DESIGN Systematic review and meta-analysis. DATA SOURCES MEDLINE, EMBASE, AMED, PsycInfo, CENTRAL, CINAHL, PubMed, Web of Science, Cannabis-Med, Epistemonikos, and trial registries up to January 2021. STUDY SELECTION Randomised clinical trials of medical cannabis or cannabinoids versus any non-cannabis control for chronic pain at >= 1 month follow-up. DATA EXTRACTION AND SYNTHESIS Paired reviewers independently assessed risk of bias and extracted data. We performed random-effects models meta-analyses and used GRADE to assess the certainty of evidence. RESULTS A total of 32 trials with 5174 adult patients were included, 29 of which compared medical cannabis or cannabinoids with placebo. Medical cannabis was administered orally (n=30) or topically (n=2). Clinical populations included chronic non-cancer pain (n=28) and cancer related pain (n=4). Length of follow-up ranged from 1 to 5.5 months. Compared with placebo, non-inhaled medical cannabis probably results in a small increase in the proportion of patients experiencing at least the minimally important difference (MID) of 1 cm (on a 10 cm visual analogue scale (VAS)) in pain relief (modelled risk difference (RD) of 10% (95% confidence interval 5% to 15%), based on a weighted mean difference (WMD) of -0.50 cm (95% CI -0.75 to -0.25 cm, moderate certainty)). Medical cannabis taken orally results in a very small improvement in physical functioning (4% modelled RD (0.1% to 8%) for achieving at least the MID of 10 points on the 100-point SF-36 physical functioning scale, WMD of 1.67 points (0.03 to 3.31, high certainty)), and a small improvement in sleep quality (6% modelled RD (2% to 9%) for achieving at least the MID of 1 cm on a 10 cm VAS, WMD of -0.35 cm (-0.55 to -0.14 cm, high certainty)). Medical cannabis taken orally does not improve emotional, role, or social functioning (high certainty). Moderate certainty evidence shows that medical cannabis taken orally probably results in a small increased risk of transient cognitive impairment (RD 2% (0.1% to 6%)), vomiting (RD 3% (0.4% to 6%)), drowsiness (RD 5% (2% to 8%)), impaired attention (RD 3% (1% to 8%)), and nausea (RD 5% (2% to 8%)), but not diarrhoea; while high certainty evidence shows greater increased risk of dizziness (RD 9% (5% to 14%)) for trials with <3 months follow-up versus RD 28% (18% to 43%) for trials with >= 3 months followup; interaction test P=0.003; moderate credibility of subgroup effect). CONCLUSIONS Moderate to high certainty evidence shows that non-inhaled medical cannabis or cannabinoids results in a small to very small improvement in pain relief, physical functioning, and sleep quality among patients with chronic pain, along with several transient adverse side effects, compared with placebo. The accompanying BMJ Rapid Recommendation provides contextualised guidance based on this body of evidence.	[Wang, Li; Oparin, Yvgeniy; Shanthanna, Harsha; Busse, Jason W.] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada; [Wang, Li; Rehman, Yasir; AminiLari, Mahmood; Craigie, Samantha; Couban, Rachel J.] McMaster Univ, Michael G DeGroote Inst Pain Res & Care, Hamilton, ON, Canada; [Wang, Li; Rehman, Yasir; AminiLari, Mahmood; Kum, Elena; Upadhye, Suneel] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Hong, Patrick J.] Univ Toronto, Dept Anesthesiol & Pain Med, Toronto, ON, Canada; [May, Curtis] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Hong, Chris J.] Univ Toronto, Dept Otolaryngol Head Neck Surg, Toronto, ON, Canada; [Hong, Brian Y.] Univ Toronto, Div Plast Surg, Dept Surg, Toronto, ON, Canada; [Gallo, Lucas] McMaster Univ, Div Plast Surg, Hamilton, ON, Canada; [Kaushal, Alka] Univ Manitoba, Dept Family Med, Winnipeg, MB, Canada; [Price, Ira] McMaster Univ, Dept Med, Div Emergency Med, Hamilton, ON, Canada; [Upadhye, Suneel] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Ware, Mark A.] McGill Univ, Hlth Ctr, Alan Edwards Pain Management Unit, Montreal, PQ, Canada; [Ware, Mark A.] McGill Univ, Dept Family Med & Anesthesia, Montreal, PQ, Canada; [Campbell, Fiona] Univ Toronto, Hosp Sick Children, Dept Anesthesia & Pain Med, Toronto, ON, Canada; [Buchbinder, Rachelle] Monash Univ, Sch Publ Hlth & Preventat Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Buchbinder, Rachelle] Cabrini Inst, Monash Dept Clin Epidemiol, Melbourne, Vic, Australia; [Buchbinder, Rachelle] Univ Hosp Geneva, Dept Med, Div Gen Internal Med, Geneva, Switzerland; [Busse, Jason W.] McMaster Univ, Michael G DeGroote Ctr Med Cannabis Res, Hamilton, ON, Canada; [Busse, Jason W.] Chron Pain Ctr Excellence Canadian Vet, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University; University of Toronto; University of British Columbia; University of Toronto; University of Toronto; McMaster University; University of Manitoba; McMaster University; McMaster University; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Monash University; Cabrini Health; Monash University; University of Geneva; McMaster University	Wang, L (corresponding author), McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada.; Wang, L (corresponding author), McMaster Univ, Michael G DeGroote Inst Pain Res & Care, Hamilton, ON, Canada.; Wang, L (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.	wangli1@mcmaster.ca	Busse, Jason/CAH-3696-2022; Rehman, Yasir/D-5335-2018; Couban, Rachel/AAV-1568-2021; Wang, Li/T-1407-2017	Busse, Jason/0000-0002-0178-8712; Rehman, Yasir/0000-0002-2817-3638; Couban, Rachel/0000-0001-8672-2845; Wang, Li/0000-0003-1585-8846; Kum, Elena/0000-0002-6548-2632	Canadian Institutes of Health Research (CIHR) [FRN 147994]; Australian National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Australian National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by a grant from the Canadian Institutes of Health Research (CIHR) (FRN 147994, Co-PIs: JW Busse, MA Ware) . RB is supported by an Australian National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship. The funding organisations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Akl EA, 2012, J CLIN EPIDEMIOL, V65, P262, DOI 10.1016/j.jclinepi.2011.04.015; Allan GM, 2018, CAN FAM PHYSICIAN, V64, pE78; Allan GM, 2018, CAN FAM PHYSICIAN, V64, P111; Amato L, 2017, EPIDEMIOL PREV, V41, P279, DOI 10.19191/EP17.5-6.AD01.069; Andresen SR, 2016, PAIN, V157, P2097, DOI 10.1097/j.pain.0000000000000623; [Anonymous], 2011, EUCTR201100092631CZ; [Anonymous], 2008, EUCTR200600591011DE; [Anonymous], 2005, EUCTR200400250963GB; [Anonymous], 2007, EUCTR200700213813GB; Australian Government Department of Health Therapeutic Goods Administration, 2017, GUID US MED CANN TRE; Australian Institute of Health and Welfare, 2020, CHRON PAIN AUSTR; Baker WL, 2009, INT J CLIN PRACT, V63, P1426, DOI 10.1111/j.1742-1241.2009.02168.x; Blake DR, 2006, RHEUMATOLOGY, V45, P50, DOI 10.1093/rheumatology/kei183; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Breivik H, 2012, EUR J PAIN, V16, P167, DOI 10.1002/j.1532-2149.2011.00025.x; Busse JW, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2040; Busse JW, 2018, JAMA-J AM MED ASSOC, V320, P2448, DOI 10.1001/jama.2018.18472; Busse JW, 2015, J RHEUMATOL, V42, P1962, DOI 10.3899/jrheum.141440; Chang-Douglass S, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1108; ClinicalTrials.gov, 2012, NCT01599234 STUD EV; ClinicalTrials.gov, 2008, NCT00711646 STUD SAT; ClinicalTrials.gov, 2006, NCT00384410 US CANN; ClinicalTrials.gov, 2006, NCT00710424 STUD SAT; Cobellis L, 2011, EUR J OBSTET GYN R B, V158, P82, DOI 10.1016/j.ejogrb.2011.04.011; Corey-Bloom J, 2012, CAN MED ASSOC J, V184, P1143, DOI 10.1503/cmaj.110837; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Dahlhamer J, 2018, MMWR-MORBID MORTAL W, V67, P1001, DOI 10.15585/mmwr.mm6736a2; de Vries M, 2017, CLIN GASTROENTEROL H, V15, P1079, DOI 10.1016/j.cgh.2016.09.147; de Vries M, 2016, BRIT J CLIN PHARMACO, V81, P525, DOI 10.1111/bcp.12811; Debray TPA, 2018, RES SYNTH METHODS, V9, P41, DOI 10.1002/jrsm.1266; Duenas M, 2016, J PAIN RES, V9, P457, DOI 10.2147/JPR.S105892; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eibach L, 2021, CLIN PHARMACOL THER, V109, P1055, DOI 10.1002/cpt.2016; Faig-Marti J, 2020, J ORTHOP TRAUMATOL, V21, DOI 10.1186/s10195-019-0540-4; Fairhurst C, 2020, DEV MED CHILD NEUROL, V62, P1031, DOI 10.1111/dmcn.14548; Fallon MT, 2017, BRIT J PAIN, V11, P119, DOI 10.1177/2049463717710042; Frank B, 2008, BRIT MED J, V336, P199, DOI 10.1136/bmj.39429.619653.80; Germini F, 2017, DRUG AGING, V34, P941, DOI 10.1007/s40266-017-0506-2; Giammusso B, 2017, ARCH ITAL UROL ANDRO, V89, P17, DOI 10.4081/aiua.2017.1.17; Gustavsson A, 2012, EUR J PAIN, V16, P289, DOI 10.1016/j.ejpain.2011.07.006; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Hackshaw A, 2008, EUR RESPIR J, V32, P1141, DOI 10.1183/09031936.00136408; Hauser W, 2018, EUR J PAIN, V22, P455, DOI 10.1002/ejp.1118; Hauser W, 2019, SCHMERZ, V33, P424, DOI 10.1007/s00482-019-0373-3; Hauser W, 2018, EUR J PAIN, V22, P1547, DOI 10.1002/ejp.1297; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; Haupts M, 2016, EUR NEUROL, V75, P236, DOI 10.1159/000445943; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hunter D, 2018, OSTEOARTHR CARTILAGE, V26, pS26, DOI 10.1016/j.joca.2018.02.067; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Johnson JR, 2010, J PAIN SYMPTOM MANAG, V39, P167, DOI 10.1016/j.jpainsymman.2009.06.008; Karst M, 2003, JAMA-J AM MED ASSOC, V290, P1757, DOI 10.1001/jama.290.13.1757; Killestein J, 2002, NEUROLOGY, V58, P1404, DOI 10.1212/WNL.58.9.1404; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langford RM, 2013, J NEUROL, V260, P984, DOI 10.1007/s00415-012-6739-4; Lichtman AH, 2018, J PAIN SYMPTOM MANAG, V55, P179, DOI 10.1016/j.jpainsymman.2017.09.001; Lynch ME, 2014, J PAIN SYMPTOM MANAG, V47, P166, DOI 10.1016/j.jpainsymman.2013.02.018; Malik Z, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12455; Markova J, 2019, INT J NEUROSCI, V129, P119, DOI 10.1080/00207454.2018.1481066; Mills SEE, 2019, BRIT J ANAESTH, V123, pE273, DOI 10.1016/j.bja.2019.03.023; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moulin DE, 2014, PAIN RES MANAG, V19, P328; Murad MH., 2015, USERSGUIDE MEDICAL L; Murina F, 2013, J LOW GENIT TRACT DI, V17, P111, DOI 10.1097/LGT.0b013e3182652316; National Institute for Health and Care Excellence, 2019, CANN BAS MED PROD NI; Nitecka-Buchta A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111886; Notcutt W, 2004, ANAESTHESIA, V59, P440, DOI 10.1111/j.1365-2044.2004.03674.x; Novotna A, 2011, EUR J NEUROL, V18, P1122, DOI 10.1111/j.1468-1331.2010.03328.x; Nurmikko TJ, 2007, PAIN, V133, P210, DOI 10.1016/j.pain.2007.08.028; Park JY, 2017, DRUG ALCOHOL DEPEN, V177, P1, DOI 10.1016/j.drugalcdep.2017.03.009; Phillips Ceri J, 2009, Rev Pain, V3, P2, DOI 10.1177/204946370900300102; Phillips Ceri J, 2006, Expert Rev Pharmacoecon Outcomes Res, V6, P591, DOI 10.1586/14737167.6.5.591; Pini LA, 2012, J HEADACHE PAIN, V13, P677, DOI 10.1007/s10194-012-0490-1; Pinsger M, 2006, WIEN KLIN WOCHENSCHR, V118, P327, DOI 10.1007/s00508-006-0611-4; Portenoy RK, 2012, J PAIN, V13, P438, DOI 10.1016/j.jpain.2012.01.003; Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939; Riva N, 2019, LANCET NEUROL, V18, P155, DOI 10.1016/S1474-4422(18)30406-X; Rog DJ, 2005, NEUROLOGY, V65, P812, DOI 10.1212/01.wnl.0000176753.45410.8b; Sa KN, 2019, PAIN REP, V4, DOI 10.1097/PR9.0000000000000779; Santesso N, 2020, J CLIN EPIDEMIOL, V119, P126, DOI 10.1016/j.jclinepi.2019.10.014; Schandelmaier S, 2020, CAN MED ASSOC J, V192, pE901, DOI 10.1503/cmaj.200077; Schimrigk S, 2017, EUR NEUROL, V78, P320, DOI 10.1159/000481089; Schopflocher D, 2011, PAIN RES MANAG, V16, P445, DOI 10.1155/2011/876306; Schunemann HJ, 2005, HEALTH SERV RES, V40, P593, DOI 10.1111/j.1475-6773.2005.0k375.x; Selvarajah D, 2010, DIABETES CARE, V33, P128, DOI 10.2337/dc09-1029; Serpell M, 2014, EUR J PAIN, V18, P999, DOI 10.1002/j.1532-2149.2013.00445.x; Skrabek RQ, 2008, J PAIN, V9, P164, DOI 10.1016/j.jpain.2007.09.002; Svendsen KB, 2004, BMJ-BRIT MED J, V329, P253, DOI 10.1136/bmj.38149.566979.AE; Thorlund K, 2011, RES SYNTH METHODS, V2, P188, DOI 10.1002/jrsm.46; Toth C, 2012, PAIN, V153, P2073, DOI 10.1016/j.pain.2012.06.024; Treede RD, 2019, PAIN, V160, P19, DOI 10.1097/j.pain.0000000000001384; Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160; Turk DC, 2003, PAIN, V106, P337, DOI 10.1016/j.pain.2003.08.001; Turk DC, 2008, PAIN, V137, P276, DOI 10.1016/j.pain.2007.09.002; van Amerongen G, 2018, CLIN THER, V40, P1467, DOI 10.1016/j.clinthera.2017.01.016; van de Donk T, 2019, PAIN, V160, P860, DOI 10.1097/j.pain.0000000000001464; van Hecke O, 2013, BRIT J ANAESTH, V111, P13, DOI 10.1093/bja/aet123; Wade DT, 2004, MULT SCLER, V10, P434, DOI 10.1191/1352458504ms1082oa; Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135; Ward MM, 2014, ARTHRIT CARE RES, V66, P1783, DOI 10.1002/acr.22392; Weber M, 2010, J NEUROL NEUROSUR PS, V81, P1135, DOI 10.1136/jnnp.2009.200642; Wissel J, 2006, J NEUROL, V253, P1337, DOI 10.1007/s00415-006-0218-8; Xu DXH, 2020, CURR PHARM BIOTECHNO, V21, P390, DOI 10.2174/1389201020666191202111534; Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1; Zajicek JP, 2012, J NEUROL NEUROSUR PS, V83, P1125, DOI 10.1136/jnnp-2012-302468; Zajicek JP, 2005, J NEUROL NEUROSUR PS, V76, P1664, DOI 10.1136/jnnp.2005.070136; Zisapel N, 2003, J SLEEP RES, V12, P291, DOI 10.1046/j.0962-1105.2003.00365.x	109	36	37	4	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2021	374								n1034	10.1136/bmj.n1034	http://dx.doi.org/10.1136/bmj.n1034			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ3VV	34497047	Bronze			2023-01-03	WOS:000702137100015
J	Gentry, SB; Nowak, SJ; Ni, XL; Hill, SA; Wade, LR; Clark, WR; Keelaghan, AP; Morris, DP; McMurry, JL				Gentry, Schuyler B.; Nowak, Scott J.; Ni, Xuelei; Hill, Stephanie A.; Wade, Lydia R.; Clark, William R.; Keelaghan, Aidan P.; Morris, Daniel P.; McMurry, Jonathan L.			A real-time assay for cell-penetrating peptide-mediated delivery of molecular cargos	PLOS ONE			English	Article							INTERNALIZATION MECHANISMS; ENDOSOMAL ESCAPE	Cell-penetrating peptides (CPPs) are capable of transporting molecules to which they are tethered across cellular membranes. Unsurprisingly, CPPs have attracted attention for their potential drug delivery applications, but several technical hurdles remain to be overcome. Chief among them is the so-called 'endosomal escape problem,' i.e. the propensity of CPP-cargo molecules to be endocytosed but remain entrapped in endosomes rather than reaching the cytosol. Previously, a CPP fused to calmodulin that bound calmodulin binding site-containing cargos was shown to efficiently deliver cargos to the cytoplasm, effectively overcoming the endosomal escape problem. The CPP-adaptor, "TAT-CaM," evinces delivery at nM concentrations and more rapidly than we had previously been able to measure. To better understand the kinetics and mechanism of CPP-adaptor-mediated cargo delivery, a real-time cell penetrating assay was developed in which a flow chamber containing cultured cells was installed on the stage of a confocal microscope to allow for observation ab initio. Also examined in this study was an improved CPP-adaptor that utilizes naked mole rat (Heterocephalus glaber) calmodulin in place of human and results in superior internalization, likely due to its lesser net negative charge. Adaptor-cargo complexes were delivered into the flow chamber and fluorescence intensity in the midpoint of baby hamster kidney cells was measured as a function of time. Delivery of 400 nM cargo was observed within seven minutes and fluorescence continued to increase linearly as a function of time. Cargo-only control experiments showed that the minimal uptake which occurred independently of the CPP-adaptor resulted in punctate localization consistent with endosomal entrapment. A distance analysis was performed for cell-penetration experiments in which CPP-adaptor-delivered cargo showing wider dispersions throughout cells as compared to an analogous covalently-bound CPP-cargo. Small molecule endocytosis inhibitors did not have significant effects upon delivery. The real-time assay is an improvement upon static endpoint assays and should be informative in a broad array of applications.	[Gentry, Schuyler B.; Nowak, Scott J.; Hill, Stephanie A.; Wade, Lydia R.; Clark, William R.; Keelaghan, Aidan P.; Morris, Daniel P.; McMurry, Jonathan L.] Kennesaw State Univ, Dept Mol & Cellular Biol, Kennesaw, GA 30144 USA; [Ni, Xuelei] Kennesaw State Univ, Sch Data Sci & Analyt, Kennesaw, GA USA; [Gentry, Schuyler B.] Q2 Solut, Atlanta, GA USA; [Keelaghan, Aidan P.] Emory Univ, Sch Med, Atlanta, GA USA	University System of Georgia; Kennesaw State University; University System of Georgia; Kennesaw State University; Emory University	McMurry, JL (corresponding author), Kennesaw State Univ, Dept Mol & Cellular Biol, Kennesaw, GA 30144 USA.	jmcmurr1@kennesaw.edu		Ni, Xuelei/0000-0003-0634-0025	National Institute on Biomedical Imaging and Engineering [EB028609]; AHA grant [18AIREA33960109]; KSU Graduate College	National Institute on Biomedical Imaging and Engineering; AHA grant; KSU Graduate College	This work was supported by National Institute on Biomedical Imaging and Engineering (https://www.nibib.nih.gov/) grant EB028609 (to JLM). SJN is supported by AHA grant 18AIREA33960109 (www.heart.org).SBG was supported by a graduate research assistantship from the KSU Graduate College. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bolhassani A, 2017, PEPTIDES, V87, P50, DOI 10.1016/j.peptides.2016.11.011; Brock DJ, 2018, TRAFFIC, V19, P421, DOI 10.1111/tra.12566; Christensen MV, 2019, J BIOMOL NMR, V73, P167, DOI 10.1007/s10858-019-00239-3; Derakhshankhah H, 2018, BIOMED PHARMACOTHER, V108, P1090, DOI 10.1016/j.biopha.2018.09.097; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; FELLER W, 1948, ANN MATH STAT, V19, P177, DOI 10.1214/aoms/1177730243; Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001; Francia V, 2019, NANOMEDICINE-UK, V14, P1533, DOI 10.2217/nnm-2018-0446; Glogau R, 2012, J DRUGS DERMATOL, V11, P38; Goodrich JA., 2007, BINDING KINETICS MOL, P69; Habault J, 2019, MOLECULES, V24, DOI 10.3390/molecules24050927; Johnson RM, 2011, METHODS MOL BIOL, V683, P535, DOI 10.1007/978-1-60761-919-2_38; Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279; Kim HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11719; Kim H, 2011, NAT METHODS, V8, P941, DOI [10.1038/NMETH.1733, 10.1038/nmeth.1733]; LeCher Julia C., 2017, BioMolecular Concepts, V8, P131, DOI 10.1515/bmc-2017-0023; Lonn P, 2015, EXPERT OPIN DRUG DEL, V12, P1627, DOI 10.1517/17425247.2015.1046431; Mager I, 2010, BBA-BIOMEMBRANES, V1798, P338, DOI 10.1016/j.bbamem.2009.11.001; Magidson V, 2013, METHOD CELL BIOL, V114, P545, DOI 10.1016/B978-0-12-407761-4.00023-3; McMurry JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134884; McMurry JL, 2011, FEBS J, V278, P4943, DOI 10.1111/j.1742-4658.2011.08395.x; Ngwa VM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178648; Ngwa VM, 2016, THESIS KENNESAW STAT; Pooga M, 1998, FASEB J, V12, P67, DOI 10.1096/fasebj.12.1.67; Rezgui R, 2016, BBA-BIOMEMBRANES, V1858, P1499, DOI 10.1016/j.bbamem.2016.03.023; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Salerno JC, 2016, J CELL SCI, V129, P893, DOI 10.1242/jcs.182113; Sung MH, 2011, WIRES SYST BIOL MED, V3, P167, DOI 10.1002/wsbm.108; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Xie J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00697	30	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2021	16	9							e0254468	10.1371/journal.pone.0254468	http://dx.doi.org/10.1371/journal.pone.0254468			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG5QV	34473728	Green Submitted, gold, Green Published			2023-01-03	WOS:000707050100013
J	Gornowicz, A; Szymanowski, W; Czarnomysy, R; Bielawski, K; Bielawska, A				Gornowicz, Agnieszka; Szymanowski, Wojciech; Czarnomysy, Robert; Bielawski, Krzysztof; Bielawska, Anna			Anti-HER2 monoclonal antibodies intensify the susceptibility of human gastric cancer cells to etoposide by promoting apoptosis, but not autophagy	PLOS ONE			English	Article							METASTATIC BREAST-CANCER; MULTICENTER PHASE-II; ANTITUMOR-ACTIVITY; PLATINUM(II) COMPLEX; OPEN-LABEL; TRASTUZUMAB; THERAPY; COMBINATION; PERTUZUMAB; EFFICACY	Background Gastric cancer (GC) is a multifactorial disease with high mortality. Anti-HER2 therapy is a promising strategy in GC treatment and trastuzumab was approved by FDA (Food and Drug Administration) as the first and the second line of treatment of the disease. Purpose The aim of the study was to examine the effectiveness of a combination of etoposide with trastuzumab or pertuzumab in AGS gastric cancer cells and breast cancer cells such as MCF-7, MDA-MB-231 and HCC1954. Methods and findings The cytotoxic effects of the tested compounds against gastric and breast cancer cells were checked by MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) assay. The anti-proliferative potential was analyzed by the incorporation of [H-3]-thymidine into DNA. Fluorescent microscopy and flow cytometry was used to demonstrate the effect of the compounds on apoptosis. The mitochondrial membrane potential, and the activity of caspase-8 and caspase-9 were assessed. Autophagosomes and autolysosomes formation was checked by flow cytometry. The concentrations of Beclin-1, LC3A and LC3B were performed using ELISA. The expression of LC3A/B was also determined. The results from our study proved that the combination of etoposide with anti-HER2 antibodies was not cytotoxic against breast cancer cells, whereas the combination of etoposide with anti-HER2 antibodies decreased viability and DNA biosynthesis in gastric cancer cells. The interaction of etoposide with pertuzumab or trastuzumab induced programmed cell death via extrinsic and intrinsic apoptotic pathways in AGS gastric cancer cells, but did not affect autophagy, where a decrease of Beclin-1, LC3A and LC3B was observed in comparison with the untreated control. Conclusions The study demonstrated that etoposide (12.5 mu M) with pertuzumab represent a promising strategy in gastric cancer treatment, but further in vivo examinations are also required.	[Gornowicz, Agnieszka; Szymanowski, Wojciech; Bielawska, Anna] Med Univ Bialystok, Dept Biotechnol, Bialystok, Poland; [Czarnomysy, Robert; Bielawski, Krzysztof] Med Univ Bialystok, Dept Synth & Technol Drugs, Bialystok, Poland	Medical University of Bialystok; Medical University of Bialystok	Gornowicz, A (corresponding author), Med Univ Bialystok, Dept Biotechnol, Bialystok, Poland.	agnieszka.gornowicz@umb.edu.pl		Szymanowski, Wojciech/0000-0002-4760-4253; Gornowicz, Agnieszka/0000-0002-0945-7870	Medical University of Bialystok, Poland [SUB/2/DN/21/001/2229]	Medical University of Bialystok, Poland	This study was funded by the Research Grants: SUB/2/DN/21/001/2229 from Medical University of Bialystok, Poland.	Adams CW, 2006, CANCER IMMUNOL IMMUN, V55, P717, DOI 10.1007/s00262-005-0058-x; AlMazmomy AM, 2019, CUREUS, V11, DOI 10.7759/cureus.6295; BAJETTA E, 1994, EUR J CANCER, V30A, P596, DOI 10.1016/0959-8049(94)90527-4; Bang YJ, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.4014; Bang YJ, 2013, J CLIN ONCOL, V31; Bang YJ, 2010, LANCET, V376, P687, DOI 10.1016/S0140-6736(10)61121-X; Boone JJM, 2009, MOL CANCER THER, V8, P3015, DOI 10.1158/1535-7163.MCT-09-0219; Burstein HJ, 2003, J CLIN ONCOL, V21, P2889, DOI 10.1200/JCO.2003.02.018; Czajkowska A, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9153403; El-Sahwi K, 2010, BRIT J CANCER, V102, P134, DOI 10.1038/sj.bjc.6605448; Fernald K, 2013, TRENDS CELL BIOL, V23, P620, DOI 10.1016/j.tcb.2013.07.006; Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029; Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5; Fujimoto-Ouchi K, 2007, CANCER CHEMOTH PHARM, V59, P795, DOI 10.1007/s00280-006-0337-z; Gerratana L, 2017, EXPERT OPIN BIOL TH, V17, P365, DOI 10.1080/14712598.2017.1282944; Gornowicz A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155221; Gornowicz A, 2015, MOL CELL BIOCHEM, V408, P103, DOI 10.1007/s11010-015-2486-z; Gornowicz A, 2014, MOL CELL BIOCHEM, V392, P161, DOI 10.1007/s11010-014-2018-2; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Harada S, 2015, MOL CLIN ONCOL, V3, P987, DOI 10.3892/mco.2015.609; He GW, 2017, J EXP MED, V214, P1655, DOI 10.1084/jem.20160442; Hoff P, 2013, ANN ONCOL         S4, V24, piv67, DOI DOI 10.1093/ANNONC/MDT203.109; Ishii K, 2019, CORE EVID, V14, P51, DOI 10.2147/CE.S217848; Jaeger PA, 2010, ARCH NEUROL-CHICAGO, V67, P1181, DOI 10.1001/archneurol.2010.258; Jamil S, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0231-z; Jung HJ, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12596; Kristjansdottir K, 2010, EXPERT OPIN BIOL TH, V10, P243, DOI 10.1517/14712590903514090; Lazar DC, 2016, WORLD J GASTROENTERO, V22, P6776, DOI 10.3748/wjg.v22.i30.6776; McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109; Naruse I, 2002, JPN J CANCER RES, V93, P574, DOI 10.1111/j.1349-7006.2002.tb01293.x; Oral O, 2012, APOPTOSIS, V17, P810, DOI 10.1007/s10495-012-0735-0; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P759, DOI 10.1093/jnci/djh133; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P739, DOI 10.1093/jnci/djh131; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Perez EA, 2004, ONCOLOGIST, V9, P518, DOI 10.1634/theoncologist.9-5-518; Pfeffer CM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020448; Robert N, 2006, J CLIN ONCOL, V24, P2786, DOI 10.1200/JCO.2005.04.1764; Satoh T, 2015, GASTRIC CANCER, V18, P824, DOI 10.1007/s10120-014-0420-9; Schulze-Bergkamen H, 2002, MED ONCOL, V19, P43; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sun J, 2019, INT J ONCOL, V54, P1601, DOI 10.3892/ijo.2019.4757; Tabernero J, 2018, LANCET ONCOL, V19, P1372, DOI 10.1016/S1470-2045(18)30481-9; Thuss-Patience PC, 2017, LANCET ONCOL, V18, P640, DOI 10.1016/S1470-2045(17)30111-0; Tompkins KD, 2019, YALE J BIOL MED, V92, P707; Van Cutsem E, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.4_suppl.lba3; Yun CW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010179; Zhang DX, 2010, GUT, V59, P292, DOI 10.1136/gut.2008.155226; Zhao FF, 2021, ANTI-CANCER DRUG, V32, P386, DOI 10.1097/CAD.0000000000001032; Zhu F, 2019, J ZHEJIANG UNIV-SC B, V20, P399, DOI 10.1631/jzus.B1900160	51	1	1	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2021	16	8							e0255585	10.1371/journal.pone.0255585	http://dx.doi.org/10.1371/journal.pone.0255585			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	US1HA	34437575	gold, Green Published			2023-01-03	WOS:000697186000024
J	Alqahtani, JS; Oyelade, T; Aldhahir, AM; Mendes, RG; Alghamdi, SM; Miravitlles, M; Mandal, S; Hurst, JR				Alqahtani, Jaber S.; Oyelade, Tope; Aldhahir, Abdulelah M.; Mendes, Renata Goncalves; Alghamdi, Saeed M.; Miravitlles, Marc; Mandal, Swapna; Hurst, John R.			Reduction in hospitalised COPD exacerbations during COVID-19: A systematic review and meta-analysis	PLOS ONE			English	Review							OBSTRUCTIVE PULMONARY-DISEASE	Background Reports have suggested a reduction in exacerbations of chronic obstructive pulmonary disease (COPD) during the coronavirus disease 2019 (COVID-19) pandemic, particularly hospital admissions for severe exacerbations. However, the magnitude of this reduction varies between studies. Method Electronic databases were searched from January 2020 to May 2021. Two independent reviewers screened titles and abstracts and, when necessary, full text to determine if studies met inclusion criteria. A modified version of the Newcastle-Ottawa Scale was used to assess study quality. A narrative summary of eligible studies was synthesised, and meta-analysis was conducted using a random effect model to pool the rate ratio and 95% confidence intervals (95% CI) for hospital admissions. Exacerbation reduction was compared against the COVID-19 Containment and Health Index. Results A total of 13 of 745 studies met the inclusion criteria and were included in this review, with data from nine countries. Nine studies could be included in the meta-analysis. The pooled rate ratio of hospital admissions for COPD exacerbations during the pandemic period was 0.50 (95% CI 0.44-0.57). Findings on the rate of community-treated exacerbations were inconclusive. Three studies reported a significant decrease in the incidence of respiratory viral infections compared with the pre-pandemic period. There was not a significant relationship between exacerbation reduction and the COVID-19 Containment and Health Index (rho = 0.20, p = 0.53). Conclusion There was a 50% reduction in admissions for COPD exacerbations during the COVID-19 pandemic period compared to pre-pandemic times, likely associated with a reduction in respiratory viral infections that trigger exacerbations. Future guidelines should consider including recommendations on respiratory virus infection control measures to reduce the burden of COPD exacerbations beyond the pandemic period.	[Alqahtani, Jaber S.; Mandal, Swapna; Hurst, John R.] UCL, UCL Resp, London, England; [Alqahtani, Jaber S.] Prince Sultan Mil Coll Hlth Sci, Dept Resp Care, Dammam, Saudi Arabia; [Oyelade, Tope] UCL Div Med, London, England; [Aldhahir, Abdulelah M.] Jazan Univ, Fac Appl Med Sci, Resp Care Dept, Jazan, Saudi Arabia; [Mendes, Renata Goncalves] Univ Fed Sao Carlos, Dept Phys Therapy, Cardiopulm Physiotherapy Lab, Sao Paulo, Brazil; [Alghamdi, Saeed M.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Alghamdi, Saeed M.] Umm Al Qura Univ, Fac Appl Med Sci, Mecca, Saudi Arabia; [Miravitlles, Marc] Hosp Univ Vall Hebron, Dept Pneumol, Vall Hebron Inst Recerca VHIR, Vall Hebron Hosp Campus,CIBER Enfermedades Resp C, Barcelona, Spain; [Mandal, Swapna; Hurst, John R.] Royal Free London NHS Fdn Trust, London, England	University of London; University College London; Prince Sultan Military College of Health Sciences; University of London; University College London; Jazan University; Universidade Federal de Sao Carlos; Imperial College London; Umm Al Qura University; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of London; University College London; Royal Free London NHS Foundation Trust	Alqahtani, JS (corresponding author), UCL, UCL Resp, London, England.; Alqahtani, JS (corresponding author), Prince Sultan Mil Coll Hlth Sci, Dept Resp Care, Dammam, Saudi Arabia.	Alqahtani-Jaber@hotmail.com	Alqahtani, Jaber/K-4767-2019; Alghamdi, Saeed/AAT-1965-2021; Mendes, Renata Gonçalves/E-9284-2013	Alqahtani, Jaber/0000-0003-1795-5092; Alghamdi, Saeed/0000-0002-6677-1110; Mendes, Renata Gonçalves/0000-0003-4683-2657; Mandal, Swapna/0000-0002-2232-5880; Hurst, John/0000-0002-7246-6040; Miravitlles, Marc/0000-0002-9850-9520				Action on Smoking and Health, MILL PEOPL HAV STOPP; Alqahtani JS, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0166-2019; Alqahtani JS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233147; Alqahtani JS., LANCET RESP MED, DOI [10.1016/S2213-2600%2821%2900227-7, DOI 10.1016/S2213-2600%2821%2900227-7]; Anderson JO, 2012, J MED TOXICOL, V8, P166, DOI 10.1007/s13181-011-0203-1; Baeza-Martinez C, 2020, OPEN RESP ARCH, V2, p201 202, DOI [10.1016/j.opresp.2020.06.003, DOI 10.1016/J.OPRESP.2020.06.003]; Berghaus TM., 2020, IN PRESS, P106120, DOI [10.1016/j.rmed.2020.106120, DOI 10.1016/J.RMED.2020.106120]; Chan KPF, 2020, RESP MED, V171, DOI 10.1016/j.rmed.2020.106085; Davies GA, 2021, THORAX, V76, P867, DOI 10.1136/thoraxjnl-2020-216380; Faria N, 2021, COPD, V18, P226, DOI 10.1080/15412555.2021.1904387; Gerayeli FV, 2021, ECLINICALMEDICINE, V33, DOI 10.1016/j.eclinm.2021.100789; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2021, GLOBAL STRATEGY DIAG; Gonzalez J, 2021, CHEST, V160, P135, DOI 10.1016/j.chest.2020.12.057; Hale T, 2021, NAT HUM BEHAV, V5, P529, DOI 10.1038/s41562-021-01079-8; Helgeland J, 2021, SCAND J PUBLIC HEALT, V49, P681, DOI 10.1177/14034948211000813; Hewitt R, 2016, THER ADV RESPIR DIS, V10, P158, DOI 10.1177/1753465815618113; Hu WH, 2020, INT J CHRONIC OBSTR, V15, P2237, DOI 10.2147/COPD.S265004; Huh K, 2021, THORAX, V76, P939, DOI 10.1136/thoraxjnl-2020-216526; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Hurst JR., 2021, LONG TERM ACC HYGIEN, DOI [10.1101/2021.04.09.21255189, DOI 10.1101/2021.04.09.21255189]; Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4; Kyriakopoulos C., 2021, RESPIRATION, P1, DOI [10.1159/000515323, DOI 10.1159/000515323]; McAuley H, 2021, ERJ OPEN RES, V7, DOI 10.1183/23120541.00718-2020; Njoku CM, 2020, RESP MED, V173, DOI 10.1016/j.rmed.2020.105988; Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7647; Stohr E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242653; Sykes DL, 2021, ERJ OPEN RES, V7, DOI 10.1183/23120541.00822-2020; Tan JY, 2021, THORAX, V76, P512, DOI 10.1136/thoraxjnl-2020-216083; Textor J, 2016, INT J EPIDEMIOL, V45, P1887, DOI 10.1093/ije/dyw341; The Air Quality Expert Group to the Department for Environment Food and Rural Affairs, 2020, EST CHANG POLL EMISS; Wedzicha JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00791-2016; Wells BS GA, NEWCASTLE OTTAWA SCA; World Health Organization, HOM CAR PAT SUSP CON; World Health Organization (WHO), CHRONIC OBSTRUCTIVE; Wu F, 2021, BMJ OPEN RESPIR RES, V8, DOI 10.1136/bmjresp-2020-000817; Zhang Y, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00222-2018	37	30	30	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2021	16	8							e0255659	10.1371/journal.pone.0255659	http://dx.doi.org/10.1371/journal.pone.0255659			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UA6IR	34343205	gold, Green Published, Green Submitted			2023-01-03	WOS:000685264200007
J	Drekonja, DM; Trautner, B; Amundson, C; Kuskowski, M; Johnson, JR				Drekonja, Dimitri M.; Trautner, Barbara; Amundson, Carla; Kuskowski, Michael; Johnson, James R.			Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE UNCOMPLICATED CYSTITIS; CIPROFLOXACIN; GUIDELINES; PNEUMONIA; DURATION; DISEASES; AMERICA; SOCIETY	IMPORTANCE Determination of optimal treatment durations for common infectious diseases is an important strategy to preserve antibiotic effectiveness. OBJECTIVE To determine whether 7 days of treatment is noninferior to 14 days when using ciprofloxacin or trimethoprim/sulfamethoxazole to treat urinary tract infection (UTI) in afebrile men. DESIGN, SETTING, AND PARTICIPANTS Randomized, double-blind, placebo-controlled noninferiority trial of afebrile men with presumed symptomatic UTI treated with ciprofloxacin or trimethoprim/sulfamethoxazole at 2 US Veterans Affairs medical centers (enrollment, April 2014 through December 2019; final follow-up, January 28, 2020). Of 1058 eligible men, 272 were randomized. INTERVENTIONS Participants continued the antibiotic prescribed by their treating clinician for 7 days of treatment and were randomized to receive continued antibiotic therapy (n = 136) or placebo (n = 136) for days 8 to 14 of treatment. MAIN OUTCOMES AND MEASURES The prespecified primary outcomewas resolution of UTI symptoms by 14 days after completion of active antibiotic treatment. A noninferiority margin of 10% was selected. The as-treated population (participants who took >= 26 of 28 doses and missed no more than 2 consecutive doses) was used for the primary analysis, and a secondary analysis included all patients as randomized, regardless of treatment adherence. Secondary outcomes included recurrence of UTI symptoms and/or adverse events within 28 days of stopping study medication. RESULTS Among 272 patients (median [interquartile range] age, 69 [62-73] years) who were randomized, 100% completed the trial and 254 (93.4%) were included in the primary as-treated analysis. Symptom resolution occurred in 122/131 (93.1%) participants in the 7-day group vs 111/123 (90.2%) in the 14-day group (difference, 2.9% [1-sided 97.5% CI, -5.2% to infinity]), meeting the noninferiority criterion. In the secondary as-randomized analysis, symptom resolution occurred in 125/136 (91.9%) participants in the 7-day group vs 123/136 (90.4%) in the 14-day group (difference, 1.5% [1-sided 97.5% CI, -5.8% to infinity]) Recurrence of UTI symptoms occurred in 13/131 (9.9%) participants in the 7-day group vs 15/123 (12.9%) in the 14-day group (difference, -3.0% [95% CI, -10.8% to 6.2%]; P = .70). Adverse events occurred in 28/136 (20.6%) participants in the 7-day group vs 33/136 (24.3%) in the 14-day group. CONCLUSIONS AND RELEVANCE Among afebrile men with suspected UTI, treatment with ciprofloxacin or trimethoprim/sulfamethoxazole for 7 days was noninferior to 14 days of treatment with regard to resolution of UTI symptoms by 14 days after antibiotic therapy. The findings support the use of a 7-day course of ciprofloxacin or trimethoprim/sulfamethoxazole as an alternative to a 14-day course for treatment of afebrile men with UTI.	[Drekonja, Dimitri M.; Amundson, Carla; Johnson, James R.] Minneapolis Vet Affairs Hlth Care Syst, 1 Vet Dr,Mail Code 111F, Minneapolis, MN 55417 USA; [Drekonja, Dimitri M.; Kuskowski, Michael; Johnson, James R.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Trautner, Barbara] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Trautner, Barbara] Baylor Coll Med, Houston, TX 77030 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Baylor College of Medicine	Drekonja, DM (corresponding author), Minneapolis Vet Affairs Hlth Care Syst, 1 Vet Dr,Mail Code 111F, Minneapolis, MN 55417 USA.	drek0002@umn.edu			VA Merit Review Program [I01BX007080]; Houston VA Health Services Research AMP; Development Center for Innovations in Quality [CIN 13-413]	VA Merit Review Program(US Department of Veterans Affairs); Houston VA Health Services Research AMP; Development Center for Innovations in Quality	The study was funded by the VA Merit Review Program, grant number I01BX007080. Dr Trautner's work is supported in part by a grant from the Houston VA Health Services Research & Development Center for Innovations in Quality, Effectiveness, and Safety (CIN 13-413).	Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chastre J, 2003, JAMA-J AM MED ASSOC, V290, P2588, DOI 10.1001/jama.290.19.2588; Dow G, 2004, CLIN INFECT DIS, V39, P658, DOI 10.1086/423000; Drekonja DM, 2013, JAMA INTERN MED, V173, P62, DOI 10.1001/2013.jamainternmed.829; Gariani K, 2021, CLIN INFECT DIS, V73, pE1539, DOI 10.1093/cid/ciaa1758; Germanos GJ, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz216; Gupta K, 2007, ARCH INTERN MED, V167, P2207, DOI 10.1001/archinte.167.20.2207; Gupta K, 2017, ANN INTERN MED, V167, pITC49, DOI 10.7326/AITC201710030; Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]; Hepburn MJ, 2004, ARCH INTERN MED, V164, P1669, DOI 10.1001/archinte.164.15.1669; Kronenberg A, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4784; Sawyer RG, 2015, NEW ENGL J MED, V372, P1996, DOI 10.1056/NEJMoa1411162; Shan GG, 2013, R J, V5, P63; TALAN DA, 2000, JAMA-J AM MED ASSOC, V283; Tamma PD, 2011, CLIN INFECT DIS, V52, P1324, DOI 10.1093/cid/cir203; Ulleryd P, 2003, SCAND J INFECT DIS, V35, P34, DOI 10.1080/0036554021000026988; Uranga A, 2016, JAMA INTERN MED, V176, P1257, DOI 10.1001/jamainternmed.2016.3633; van Nieuwkoop C, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0835-3; Veve MP, 2016, INT J ANTIMICROB AG, V48, P56, DOI 10.1016/j.ijantimicag.2016.04.014	20	24	24	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	2021	326	4					324	331		10.1001/jama.2021.9899	http://dx.doi.org/10.1001/jama.2021.9899			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TY5HC	34313686	Bronze, Green Published			2023-01-03	WOS:000683814400018
J	Rideout, A; Murray, C; Isles, C				Rideout, Andrew; Murray, Calum; Isles, Chris			Regional variation in COVID-19 positive hospitalisation across Scotland during the first wave of the pandemic and its relation to population density: A cross-sectional observation study	PLOS ONE			English	Article								Background There have been large regional differences in COVID-19 virus activity across the UK with many commentators suggesting that these are related to age, ethnicity and social class. There has also been a focus on cases, hospitalisations and deaths rather than on hospitalisation rates expressed per 100,000 population. The purpose of our study was to examine regional variation in COVID-19 positive hospitalisation rates in Scotland during the first wave of the pandemic and the possibility that these might be related to population density. Methods and findings This was a repeated point prevalence study. The number of COVID-19 positive patients hospitalised in the eleven Scottish mainland health boards peaked at 1517 on 19th April, then fell to a low of 243 on 16th August before rising slightly to 262 on 15th September. In July, August and September only four boards had more than 5 hospitalised patients. There was a statistically significant relationship between hospitalisation rates and population density on 97.7% of individual days during the first wave of the pandemic (Pearson's r 0.62-0.93, with 123 of a possible 174 days having p values <0.001). Multiple linear regression analyses performed on data from the 11 mainland boards across six time points suggest that population density accounted for 70.2% of the variation in hospitalisation rate in April, 72.3% in May, 81.2% in June, 91.0% in July, 91.0% in August, and 88.1% in September. Neither population median age nor median social deprivation score at health board level were statistically significant in the final model for hospitalisation. Conclusion There were large differences in crude COVID-19 hospitalisation rates across the 11 mainland Scottish health boards, that were significantly related to population density. Given that lockdown was originally introduced to prevent the NHS from being overwhelmed, we believe our results support a regional rather than a national approach to lifting or reimposing more restrictive measures, and that hospitalisation rates should be part of the decision making process.	[Rideout, Andrew] Dumfries & Galloway Royal Infirm, Dept Publ Hlth, Dumfries, Scotland; [Murray, Calum] Dumfries & Galloway Royal Infirm, Educ Ctr, Dumfries, Scotland; [Isles, Chris] Dumfries & Galloway Royal Infirm, Med Unit, Dumfries, Scotland		Isles, C (corresponding author), Dumfries & Galloway Royal Infirm, Med Unit, Dumfries, Scotland.	christopher.isles@nhs.scot		Isles, Chris/0000-0001-7830-7561				[Anonymous], 2019, EPI INFO V 7 2 3 1 C EPI INFO V 7 2 3 1 C; Block P, 2020, NAT HUM BEHAV, V4, P588, DOI 10.1038/s41562-020-0898-6; Branden M, 2020, LANCET HEALTH LONGEV, V1, pE80, DOI 10.1016/S2666-7568(20)30016-7; Chandra S, 2013, INT J HEALTH GEOGR, V12, DOI 10.1186/1476-072X-12-9; Clark D., UK UK POPULATION DEN; Grantz KH, 2016, P NATL ACAD SCI USA, V113, P13839, DOI 10.1073/pnas.1612838113; Hamidi S, 2020, J AM PLANN ASSOC, V86, P495, DOI 10.1080/01944363.2020.1777891; Han E, 2020, LANCET, V396, P1525, DOI 10.1016/S0140-6736(20)32007-9; Hsu J., 2020, SCI AM 0916; JASP Team, 2019, JASP VERS 0 10 2 COM; Miller L., 2007, J RURAL SOC SCI, V22; National Records of Scotland, MID 2019 POP EST SCO; Roesch E, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1712; The Scottish Government, COR COVID 19 MOD EP COR COVID 19 MOD EP; Verhagen MD, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01646-2; Webb L., 2020, J PSYCH MENTAL HLTH, DOI [10.1111/jim.12644, DOI 10.1111/JIM.12644]; Yip WF, 2021, LANCET REG HEALTH-W, V7, DOI 10.1016/j.lanwpc.2020.100091	18	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2021	16	7							e0253636	10.1371/journal.pone.0253636	http://dx.doi.org/10.1371/journal.pone.0253636			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK6YI	34242268	gold, Green Published			2023-01-03	WOS:000674301400012
J	Linden, K				Linden, Karolina			Expanding the concept of safety in antenatal care provision	LANCET			English	Editorial Material							OUTCOMES		[Linden, Karolina] Univ Gothenburg, Sahlgrenska Acad, Inst Hlth & Care Sci, SE-40530 Gothenburg, Sweden	University of Gothenburg	Linden, K (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Hlth & Care Sci, SE-40530 Gothenburg, Sweden.	karolina.linden@gu.se	Linden, Karolina/AAV-5349-2021	Linden, Karolina/0000-0002-2792-3142				Aziz A, 2020, AM J PERINAT, V37, P800, DOI 10.1055/s-0040-1712121; DeNicola N, 2020, OBSTET GYNECOL, V135, P371, DOI 10.1097/AOG.0000000000003646; Downe S, 2016, BJOG-INT J OBSTET GY, V123, P529, DOI 10.1111/1471-0528.13819; Evans ML, 2020, N ENGL J MED; Kruk ME, 2018, LANCET GLOB HEALTH, V6, pE1196, DOI 10.1016/S2214-109X(18)30386-3; Lurie N, 2018, JAMA INTERN MED, V178, P745, DOI 10.1001/jamainternmed.2018.1314; Naurin E, 2020, EUR J PUBLIC HEALTH, V31, P7; Palmer KR, 2021, LANCET, V398, P41, DOI 10.1016/S0140-6736(21)00668-1; Tuncalp O, 2015, BJOG-INT J OBSTET GY, V122, P1045, DOI 10.1111/1471-0528.13451; UN Population Fund WHO UNICEF World Bank Group UN Population Division, 2019, TRENDS MAT MORT 2000; Who, 2016, WHO REC ANT CAR POS	11	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2021	398	10294					4	5						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC9PM	34217398	Green Published			2023-01-03	WOS:000668969500005
J	Ibrahim, H; Athar, S; Harhara, T; Elhag, SA; MElnour, S; Sukkar, HH; Kamour, AM				Ibrahim, Halah; Athar, Syed; Harhara, Thana; Elhag, Shahad Abasaeed; MElnour, Salma; Sukkar, Hoor H.; Kamour, Ashraf M.			Post-infectious and post-acute sequelae of critically ill adults with COVID-19	PLOS ONE			English	Article							SEPSIS; SARS	Background Data on the post-acute and post-infectious complications of patients who have recovered from severe coronavirus disease 2019 (COVID-19) are limited. While studies report that approximately 5-15% of COVID-19 hospitalized patients require intensive care and mechanical ventilation, a substantially higher number need non-invasive ventilation and are subject to prolonged hospitalizations, with long periods of immobility and isolation. The purpose of this study is to describe the post-infectious sequelae of severe viral illness and the post-acute complications of intensive care treatments in critically ill patients who have recovered from severe COVID-19 infection. Methods We performed a retrospective chart review of adult patients initially hospitalized with confirmed COVID-19 infection, who recovered and were transferred to a general medical ward or discharged home between March 15, 2020 and May 15, 2020, dates inclusive, after an intensive care unit (ICU) or high dependency unit (HDU) admission in a designated COVID-19 hospital in the United Arab Emirates. Demographic data, underlying comorbidities, treatment, complications, and outcomes were collected. Descriptive statistical analyses were performed. Results Of 71 patients transferred out of ICU (n = 38, 54%) and HDU (n = 33, 46%), mean age was 48 years (SD, 9.95); 96% men; 54% under age 50. Mean ICU stay was 12.4 days (SD, 5.29), HDU stay was 13.4 days (SD, 4.53). Pre-existing conditions were not significantly associated with developing post-acute complications (Odds Ratio [OR] 1.1, 95% confidence interval [CI] 0.41, 2.93, p = 1.00). Fifty nine percent of patients had complications; myopathy, swallowing impairments, and pressure ulcers were most common. Delirium and confusion were diagnosed in 18% (n = 13); all were admitted to the ICU and required mechanical ventilation. Of note, of all patients studied, 59.2% (n = 42/71) had at least 1 complication, 32.4% (n = 23) had at least 2 complications, and 19.7% (n = 14) suffered 3 or more sequelae. Complications were significantly more common in ICU patients (n = 33/38, 87%), compared to HDU patients (n = 9/33, 27%) (OR 17.6, 95% CI 5.23, 59.21, p <0.05). Conclusion In a subset of critically ill patients who recovered from severe COVID-19 infection, there was considerable short-term post-infectious and post-acute disability. Long-term follow-up of COVID-19 survivors is warranted.	[Ibrahim, Halah; Athar, Syed; Harhara, Thana; Kamour, Ashraf M.] Sheikh Khalifa Med City, Dept Med, Abu Dhabi, U Arab Emirates; [Elhag, Shahad Abasaeed; MElnour, Salma; Sukkar, Hoor H.] Sheikh Khalifa Med City, Educ Inst, Abu Dhabi, U Arab Emirates		Ibrahim, H (corresponding author), Sheikh Khalifa Med City, Dept Med, Abu Dhabi, U Arab Emirates.	halahibrahim@gmail.com	Ibrahim, Halah/AAX-5576-2021	Harhara, Thana/0000-0003-0145-5798				Abhyankar S, 2012, CRIT CARE, V16, DOI 10.1186/cc11903; Alhazzani W, 2021, CRIT CARE MED, V49, pE219, DOI 10.1097/CCM.0000000000004899; Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022; Bauer M, 2013, CURR OPIN CRIT CARE, V19, P123, DOI 10.1097/MCC.0b013e32835eba6d; Bhaskaran K, 2018, LANCET DIABETES ENDO, V6, P944, DOI [10.1016/S2213-8587(18)30288-2, 10.1016/s2213-8587(18)30288-2]; Cheng SKW, 2004, BRIT J PSYCHIAT, V184, P359, DOI 10.1192/bjp.184.4.359; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Goldberg TE, 2020, JAMA NEUROL, V77, P1373, DOI 10.1001/jamaneurol.2020.2273; Grabowski DC, 2020, JAMA-J AM MED ASSOC, V323, P2007, DOI 10.1001/jama.2020.4686; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hermans G, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0993-7; Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018; Jothimani D, 2020, J HEPATOL, V73, P1231, DOI 10.1016/j.jhep.2020.06.006; Lindenauer PK, 2020, JAMA-J AM MED ASSOC, V323, P1813, DOI 10.1001/jama.2020.4437; Mak WWS, 2009, PSYCHOL HEALTH, V24, P161, DOI 10.1080/08870440701447649; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Marra A, 2017, CRIT CARE CLIN, V33, P225, DOI 10.1016/j.ccc.2016.12.005; Mattison MLP, 2020, ANN INTERN MED, V173, pITC49, DOI 10.7326/AITC202010060; Navas-Blanco JR, 2020, BMC ANESTHESIOL, V20, DOI 10.1186/s12871-020-01095-7; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Silver SA, 2021, KIDNEY MED, V3, P83, DOI 10.1016/j.xkme.2020.11.008; Spronk PE, 2009, INTENS CARE MED, V35, P1276, DOI 10.1007/s00134-009-1466-8; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; World Health Organization (WHO), CRIT REL COVID 19 PA; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648	28	3	3	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2021	16	6							e0252763	10.1371/journal.pone.0252763	http://dx.doi.org/10.1371/journal.pone.0252763			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TG9AX	34138871	gold, Green Published			2023-01-03	WOS:000671690200029
J	O'Connell, J; Murray, JA; Kaukinen, K				O'Connell, James; Murray, Joseph A.; Kaukinen, Katri			Uncertain Diagnosis of Celiac Disease and Implications for Management	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MILD ENTEROPATHY	Uncertain Diagnosis of Celiac Disease This interactive feature about a patient presenting with heartburn and a family history of celiac disease offers a case vignette accompanied by two essays with differing viewpoints on whether to recommend a gluten-free diet.	[O'Connell, James] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland; Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland	Tampere University; Tampere University Hospital; Tampere University	O'Connell, J (corresponding author), Tampere Univ Hosp, Dept Internal Med, Tampere, Finland.			O'Connell, James/0000-0003-1553-4489				Fass R, 2020, GASTROENTEROLOGY, V158, P2286, DOI 10.1053/j.gastro.2020.01.034; Husby S, 2019, GASTROENTEROLOGY, V156, P885, DOI 10.1053/j.gastro.2018.12.010; Kurppa K, 2014, GASTROENTEROLOGY, V147, P610, DOI 10.1053/j.gastro.2014.05.003; Kurppa K, 2009, GASTROENTEROLOGY, V136, P816, DOI 10.1053/j.gastro.2008.11.040; Lebwohl B, 2011, GASTROINTEST ENDOSC, V74, P103, DOI 10.1016/j.gie.2011.03.1236; Mooney PD, 2016, GASTROENTEROLOGY, V150, P1125, DOI 10.1053/j.gastro.2016.01.029; Popp A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020320; Setty M, 2015, GASTROENTEROLOGY, V149, P681, DOI 10.1053/j.gastro.2015.05.013; Trovato Chiara Maria, 2019, Gastroenterol Res Pract, V2019, P8974751, DOI 10.1155/2019/8974751; Walker MM, 2010, GASTROENTEROLOGY, V139, P112, DOI 10.1053/j.gastro.2010.04.007; Zanini B, 2013, CLIN GASTROENTEROL H, V11, P253, DOI 10.1016/j.cgh.2012.09.027	11	1	1	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2021	384	24					2346	2348		10.1056/NEJMclde2102480	http://dx.doi.org/10.1056/NEJMclde2102480			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SV2KH	34133866				2023-01-03	WOS:000663653100020
J	Tan, SMY; Zhang, Y; Chen, Y; See, KC; Feng, ML				Tan, Sandra M. Y.; Zhang, Yuan; Chen, Ying; See, Kay Choong; Feng, Mengling			Association of fluid balance with mortality in sepsis is modified by admission hemoglobin levels: A large database study	PLOS ONE			English	Article							PULSE CO-OXIMETRY; SEPTIC SHOCK; CRITICALLY-ILL; RESUSCITATION; OUTCOMES; VOLUME; EPIDEMIOLOGY; TRANSFUSION; GUIDELINES; PHYSIOLOGY	Purpose Sepsis involves a dysregulated inflammatory response to infection that leads to organ dysfunction. Early fluid resuscitation has been advocated by the Surviving Sepsis Campaign guidelines. However, recent studies have shown that a positive fluid balance is associated with increased mortality in septic patients. We investigated if haemoglobin levels on admission to the intensive care unit (ICU) could modify the association of fluid balance with mortality in patients with sepsis. We hypothesized that with increasing fluid balance, patients with moderate anemia (hemoglobin 7-10g/dL) would have poorer outcomes compared to those without moderate anemia (hemoglobin >10g/dL). Materials and methods This retrospective study utilized the Medical Information Mart for Intensive Care-III (MIMIC-III) database. Patients with sepsis, as identified by the International Classification of Diseases, 9th, Clinical Modification codes, were studied. Patients were stratified into those with and without moderate anemia at ICU admission. We investigated the influence of fluid balance measured within 24 hours of ICU admission on 28-day mortality for both patient groups using multivariable logistic regression models. Subgroup and sensitivity analyses were conducted. Results 8,132 patients (median age 68.6 years, interquartile range 55.1-79.8 years; 52.8% female) were included. Increasing fluid balance (in L) was associated with a significantly decreased risk of 28-day mortality in patients without moderate anemia (OR 0.91, 95%CI 0.84-0.97, p = 0.005, at 6-hour). Conversely, increasing fluid balance was associated with a significantly increased risk of 28-day mortality in patients with moderate anemia (OR 1.05, 95% CI 1.01-1.1, p = 0.022, at 24-hour). Interaction analyses showed that mortality was highest when haemoglobin decreased in patients with moderate anemia who had the most positive fluid balance. Multiple subgroups and sensitivity analyses yielded consistent results. Conclusions In septic patients admitted to ICU, admission hemoglobin levels modified the association between fluid balance and mortality and are an important consideration for future fluid therapy trials.	[Tan, Sandra M. Y.] Natl Univ Singapore Hosp, Div Adv Internal Med, Dept Med, Singapore, Singapore; [Zhang, Yuan] Ping An Healthcare Technol, Beijing, Peoples R China; [Chen, Ying] Genome Inst Singapore, Computat & Syst Biol, Singapore, Singapore; [See, Kay Choong] Natl Univ Singapore Hosp, Div Resp & Crit Care Med, Dept Med, Singapore, Singapore; [Feng, Mengling] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Feng, Mengling] Natl Univ Hlth Syst, Singapore, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; National University of Singapore; National University of Singapore	Tan, SMY (corresponding author), Natl Univ Singapore Hosp, Div Adv Internal Med, Dept Med, Singapore, Singapore.; See, KC (corresponding author), Natl Univ Singapore Hosp, Div Resp & Crit Care Med, Dept Med, Singapore, Singapore.	sandra_tan@nuhs.edu.sg; kay_choong_see@nuhs.edu.sg	Ying, Chen/GRX-5695-2022	Feng, Mengling/0000-0002-5338-6248; Chen, Ying/0000-0001-7876-4877	National Research Foundation Singapore under its AI Singapore Programme [AISG-100E-2020-055]	National Research Foundation Singapore under its AI Singapore Programme(National Research Foundation, Singapore)	This study is partially supported by the National Research Foundation Singapore under its AI Singapore Programme (Award Number: AISG-100E-2020-055). The National Research Foundation Singapore did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. And the funder, Ping An Healthcare Technology, Beijing, China, provided support in the form of salaries for author Yuan Zhang, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the author are articulated in the 'author contributions' section.	Andrews B, 2017, JAMA-J AM MED ASSOC, V318, P1233, DOI 10.1001/jama.2017.10913; Angus Derek C., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P207; Ba VN, 2003, CRIT CARE MED, V31, P406, DOI 10.1097/01.CCM.0000048623.00778.3F; Barie PS, 2004, CRIT CARE, V8, pS34, DOI 10.1186/cc2454; Bubenek-Turconi SI., 2019, ANESTH ANALG; Chang DW, 2014, J CRIT CARE, V29, P1011, DOI 10.1016/j.jcrc.2014.06.005; Cros J, 2020, J CLIN MONIT COMPUT, V34, P683, DOI 10.1007/s10877-019-00367-z; Effenberger-Neidnicht K, 2018, INFLAMMATION, V41, P1569, DOI 10.1007/s10753-018-0810-y; FAQUIN WC, 1992, BLOOD, V79, P1987; Guarracino F, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2414-9; HADFIELD RJ, 1995, AM J RESP CRIT CARE, V152, P1545, DOI 10.1164/ajrccm.152.5.7582291; Hayden SJ, 2012, AM J RESP CRIT CARE, V185, P1049, DOI 10.1164/rccm.201110-1915CI; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Jaffee W, 2018, J INTENSIVE CARE MED, V33, P502, DOI 10.1177/0885066617742832; Jansma G, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0035-7; JARDIN F, 1990, CRIT CARE MED, V18, P1055, DOI 10.1097/00003246-199010000-00001; Johnson AEW, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.35; Johnson AEW, 2013, CRIT CARE MED, V41, P1711, DOI 10.1097/CCM.0b013e31828a24fe; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Lumb AB, 2015, ANESTHESIOLOGY, V122, P932, DOI 10.1097/ALN.0000000000000569; Macknet MR, 2010, ANESTH ANALG, V111, P1424, DOI 10.1213/ANE.0b013e3181fc74b9; Maiden MJ, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2029-6; Maitland K, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-68; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Malbrain MLNG, 2014, ANAESTH INTENSIVE TH, V46, P361, DOI 10.5603/AIT.2014.0060; Marik P, 2016, BRIT J ANAESTH, V116, P339, DOI 10.1093/bja/aev349; Marik PE, 2017, INTENS CARE MED, V43, P625, DOI 10.1007/s00134-016-4675-y; Merx MW, 2007, CIRCULATION, V116, P793, DOI 10.1161/CIRCULATIONAHA.106.678359; Monnet X, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0400-z; Murphy SM, 2018, ANESTH ANALG, V126, P1519, DOI 10.1213/ANE.0000000000002721; Payen D, 2008, CRIT CARE, V12, DOI 10.1186/cc6916; Perel A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1872-1; Qi DS, 2021, SHOCK, V55, P215, DOI 10.1097/SHK.0000000000001612; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Sadaka F, 2014, J INTENSIVE CARE MED, V29, P213, DOI 10.1177/0885066613478899; Sakr Y, 2005, CHEST, V128, P3098, DOI 10.1378/chest.128.5.3098; Shen YF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28781-4; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602	42	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2021	16	6							e0252629	10.1371/journal.pone.0252629	http://dx.doi.org/10.1371/journal.pone.0252629			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	SW6SI	34125858	Green Published, gold			2023-01-03	WOS:000664643500010
J	Thodberg, K; Videbech, PB; Hansen, TGB; Pedersen, AB; Christensen, JW				Thodberg, Karen; Videbech, Poul B.; Hansen, Tia G. B.; Pedersen, Anne Bak; Christensen, Janne W.			Dog visits in nursing homes - increase complexity or keep it simple? A randomised controlled study	PLOS ONE			English	Article							ANIMAL-ASSISTED INTERVENTIONS; TERM-CARE RESIDENTS; ENGAGEMENT; DEMENTIA; THERAPY; PARTICIPATION; PEOPLE; IMPACT; STATE; PET	Objective To compare the immediate response of nursing home residents to dog visits with or without an activity, and the impact of cognitive ability. Methods In a randomly controlled trial, 174 nursing home residents were allocated to 12 bi-weekly 10-minute visits: either ordinary dog visits (D, n = 57, 49 analysed), dog visits with an activity (DA, n = 56, 48 analysed), or visits with activity but no dog (A, n = 61, 54 analysed). We recorded frequency and duration of residents' verbal and physical interactions with the dog and persons. Data were analysed in three periods of four visits (period 1-3) as binomial variables (generalised linear models) or durations (non-parametric statistics). Results Both visit type and impairment level affected the likelihood of interacting with the dog (D and DA). In some periods increased cognitive impairment lowered odds of touching the dog in DA visits (period 1: F-1,F-85 = 5.17, P < 0.05) and talking to it directly (period 1: F-1,F-90 = 4.60, P < 0.05; period 3: F-1,F-87 = 5.34, P < 0.05). Throughout, residents talked less to persons during DA visits compared to D and A (P = 0.01-0.05), and level of cognitive impairment correlated negatively with talk duration (P < 0.001). Generally, high cognitive impairment level lowered odds of interacting with (period 1: F-1,F-89 = 7.89, P < 0.01; period 2: F-1,F-97 = 6.76, P = 0.01; period 3: F-1,F-92 = 13.57, P < 0.001) and talking about the activities (period 1: F-1,F-89 = 13.78, P <0.001; period 2: F-1,F-88 = 3.27, P = 0.07; period 3: F-1,F-86 = 3.88, P = 0.05). Conclusion Visits without specific activities stimulated residents to interact with the dog, whereas increasing the complexity of dog visits by adding activities resulted in less interaction with the dog for severely impaired residents. The optimal dog visit for the less cognitively impaired residents could include activities and thereby a possibility to interact with the dog in different ways, whereas for severely impaired residents, just being with the dog seems more appropriate.	[Thodberg, Karen; Pedersen, Anne Bak; Christensen, Janne W.] Aarhus Univ, Dept Anim Sci, Aarhus, Denmark; [Videbech, Poul B.] Psychiat Ctr Glostrup, Glostrup, Denmark; [Hansen, Tia G. B.] Aalborg Univ, Ctr Dev & Appl Psychol Sci, Aalborg, Denmark	Aarhus University; Aalborg University	Thodberg, K (corresponding author), Aarhus Univ, Dept Anim Sci, Aarhus, Denmark.	karen.thodberg@anis.au.dk		Christensen, Janne Winther/0000-0003-0227-0648; Hansen, Tia Gitte Bondesen/0000-0002-8823-5183; Thodberg, Karen/0000-0001-8369-9491	TrygFonden [106330]	TrygFonden	The study was supported by a grant from TrygFonden to KT (106330; TrygFonden.dk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarskog NK, 2019, PHYS OCCUP THER GERI, V37, P77, DOI 10.1080/02703181.2019.1613466; Ambrosi C, 2019, PSYCHOGERIATRICS, V19, P55, DOI 10.1111/psyg.12367; Bernstein PL, 2000, ANTHROZOOS, V13, P213, DOI 10.2752/089279300786999743; Bjork S, 2017, J ADV NURS, V73, P1884, DOI 10.1111/jan.13275; Brane G, 2001, DEMENT GERIATR COGN, V12, P1, DOI 10.1159/000051230; Chung JCC, 2004, OTJR-OCCUP PART HEAL, V24, P22, DOI 10.1177/153944920402400104; Cohen-Mansfield J, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0357-z; Cohen-Mansfield J, 2017, PSYCHIAT RES, V257, P375, DOI 10.1016/j.psychres.2017.07.045; Cohen-Mansfield J, 2010, PSYCHIAT RES, V177, P216, DOI 10.1016/j.psychres.2009.02.010; Cohen-Mansfield J, 2009, INT J GERIATR PSYCH, V24, P755, DOI 10.1002/gps.2192; De Santis M, 2018, VET ITAL, V54, P323, DOI 10.12834/VetIt.1226.6831.1; Dobbs D, 2005, GERONTOLOGIST, V45, P81, DOI 10.1093/geront/45.suppl_1.81; FICK KM, 1993, AM J OCCUP THER, V47, P529, DOI 10.5014/ajot.47.6.529; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedmann E, 2019, ANTHROZOOS, V32, P221, DOI 10.1080/08927936.2019.1569905; Gee NR, 2019, ANTHROZOOS, V32, P183, DOI 10.1080/08927936.2019.1569903; Zafra-Tanaka JH, 2019, BMC PSYCHIATRY, V19, DOI 10.1186/s12888-018-2009-z; Handlin L, 2018, ANTHROZOOS, V31, P567, DOI 10.1080/08927936.2018.1505268; Hediger K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42280-0; HENDY HM, 1987, INT J AGING HUM DEV, V25, P279, DOI 10.2190/D3DD-VB2N-UQJ8-8AGN; Hughes MJ, 2020, CLIN GERONTOLOGIST, V43, P365, DOI 10.1080/07317115.2019.1650863; IAHAIO, IAHAIO WHIT PAP DEF; Jadhav A, 2019, APPL ARTIF INTELL, V33, P913, DOI 10.1080/08839514.2019.1637138; Jain B, 2020, INT J OLDER PEOPLE N, V15, DOI 10.1111/opn.12320; Kaps M., 2017, BIOSTATISTICS ANIMAL, V3rd; Klimova B, 2016, J APPL BIOMED, V14, P97, DOI 10.1016/j.jab.2016.02.002; Kramer SC, 2009, ANTHROZOOS, V22, P43, DOI 10.2752/175303708X390464; Lai NM, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013243.pub2; Lundqvist M, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1844-7; Martin P., 2007, MEASURING BEHAV; Ministry of Health, NAT UND FORTH PA PLE; Olsen C, 2019, DEMENTIA-LONDON, V18, P245, DOI 10.1177/1471301216667320; Peluso S, 2018, J GERIATR PSYCH NEUR, V31, P149, DOI 10.1177/0891988718774634; Petersson M, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01796; Schuurmans L, 2016, J AM MED DIR ASSOC, V17, P647, DOI 10.1016/j.jamda.2016.03.015; Sengupta M, 2019, J HOUS ELDER, V33, P120, DOI 10.1080/02763893.2018.1534178; Smit D, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0564-7; Tak SH, 2015, EDUC GERONTOL, V41, P182, DOI 10.1080/03601277.2014.937217; Thodberg K., 2014, Animal Frontiers, V4, P43, DOI 10.2527/af.2014-0021; Thodberg K, 2016, ANTHROZOOS, V29, P107, DOI 10.1080/08927936.2015.1089011; Tierney L, 2020, INT J OLDER PEOPLE N, V15, DOI 10.1111/opn.12306; Wells DL, 2019, ANTHROZOOS, V32, P169, DOI 10.1080/08927936.2019.1569902; Wesenberg S, 2019, PSYCHOGERIATRICS, V19, P219, DOI 10.1111/psyg.12385; Yakimicki ML, 2019, CLIN NURS RES, V28, P9, DOI 10.1177/1054773818756987	44	0	0	4	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2021	16	5							e0251571	10.1371/journal.pone.0251571	http://dx.doi.org/10.1371/journal.pone.0251571			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	SW6OP	34038451	gold, Green Published			2023-01-03	WOS:000664633500024
J	Assele, DD; Lendado, TA; Awato, MA; Workie, SB; Faltamo, WF				Assele, Desalegn Dawit; Lendado, Tigabu Addisu; Awato, Merid Assefa; Workie, Shimelash Bitew; Faltamo, Wolde Facha			Incidence and predictors of mortality among patients with head injury admitted to Hawassa University Comprehensive Specialized Hospital, Southern Ethiopia: A retrospective follow-up study	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CLINICAL CHARACTERISTICS; EPIDEMIOLOGY; MANAGEMENT; OUTCOMES; HYPERTHERMIA; PATTERNS; IMPACT	Introduction Head injury is the leading cause of morbidity and mortality throughout the world, especially in resource-limited countries including Ethiopia. However, little is known about the mortality rate and its predictors among these patients in Ethiopia. Thus, the study aims to assess the incidence rate of mortality and its predictors among patients with head injury admitted at Hawassa University Comprehensive Specialized Hospital. Methods Institutional based retrospective follow-up study was conducted among 1220 randomly selected head injury patients admitted from July 2017 to July 2019. Bivariable and multivariable Cox regression models were fitted to identify the predictors of mortality. Proportionality assumption was tested by a global test based on the Schoenfeld residuals test. Results The incidence of the mortality rate was 2.26 (95%CI: 1.9-2.6) per 100-person day observation. The independent predictors of time to death were age above 65 years (AHR:3.49, 95%CI:1.63, 7.48), severe TBI (AHR: 8.8, 95%CI:5.13, 15.0), moderate TBI (AHR:3, 95%CI:1.73,5.31), hypotension (AHR:1.72, 95%CI: 1.11,2.66), hypoxia (AHR:1.92, 95%CI: 1.33,2.76), hyperthermia (AHR:1.8, 95%CI: 1.23,2.63) and hypoglycemic (AHR:1.94, 95%CI: 1.34, 2.81) positively associated with mortality, while underwent neurosurgery was negatively associated with mortality (AHR: 0.25, 95% CI: 0.11,0.53). Conclusion The incidence of mortality rate among head injury patients was high. Older age, moderate and severe TBI, hypotension and hypoxia at admission, neurosurgical procedure, and the episode of hyperthermia and hypoglycemia during hospitalization were the independent predictors of mortality among head injury patients. Therefore, intervention to reduce earlier deaths should focus on the prevention of secondary brain insults.	[Assele, Desalegn Dawit] Hawassa Univ Comprehens Specialized Hosp, Dept Nursing, Hawassa, Ethiopia; [Lendado, Tigabu Addisu; Awato, Merid Assefa] Wolaita Zone Hlth Dept, Wolaita Sodo, Ethiopia; [Workie, Shimelash Bitew; Faltamo, Wolde Facha] Wolaita Sodo Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Coll Hlth Sci & Med, Wolaita Sodo, Ethiopia		Assele, DD (corresponding author), Hawassa Univ Comprehens Specialized Hosp, Dept Nursing, Hawassa, Ethiopia.	desalegndawit96@gmail.com	Lendado, Tigabu Addisu/AFJ-7981-2022	Addisu, Tigabu/0000-0001-5918-3575; Dawit Assele, Desalegn/0000-0003-2006-6368; Bitew, Shimelash/0000-0002-6159-6309				Abdelgadir J, 2017, WORLD NEUROSURG, V102, P526, DOI 10.1016/j.wneu.2017.03.019; Aenderl I, 2014, ETHIOP J HEALTH SCI, V24, P27, DOI 10.4314/ejhs.v24i1.4; Banker A, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0633-7; Boniface Respicious, 2017, Pan Afr Med J, V26, P140, DOI 10.11604/pamj.2017.26.140.10345; Bonow RH, 2018, WORLD NEUROSURG, V111, pE82, DOI 10.1016/j.wneu.2017.11.171; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Dash HH, 2018, KOREAN J ANESTHESIOL, V71, P12, DOI 10.4097/kjae.2018.71.1.12; de Ramirez SS, 2012, ANNU REV PUBL HEALTH, V33, P175, DOI 10.1146/annurev-publhealth-031811-124558; Dewan MC, 2019, J NEUROSURG, V130, P1080, DOI 10.3171/2017.10.JNS17352; Duko B, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4192-5; Eaton J, 2017, WORLD NEUROSURG, V105, P257, DOI 10.1016/j.wneu.2017.05.153; Ekeke ON, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.6.10690; Elahi C, 2019, NEUROSURG FOCUS, V47, DOI 10.3171/2019.7.FOCUS19316; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Greenberg MS., 2020, HEAD TRUMA HDB NEURO, V9, P858; Henry S, 2018, ADV TRAUMA LIFE SUPP, V10; Hosmer D. W., 2008, APPL SURVIVAL ANAL R; Hunchak Cheryl, 2015, BMC Res Notes, V8, P605, DOI 10.1186/s13104-015-1592-z; Jerome E, 2017, SAMJ S AFR MED J, V107, P621, DOI [10.7196/SAMJ.2017.v107i7.10562, 10.7196/samj.2017.v107i7.10562]; Kamal VK, 2016, J NEUROSCI RURAL PRA, V7, P515, DOI 10.4103/0976-3147.188637; Kim YJ, 2011, J EMERG NURS, V37, P328, DOI 10.1016/j.jen.2010.04.017; Krebs E, 2017, WORLD NEUROSURG, V102, P571, DOI 10.1016/j.wneu.2017.03.001; Krishnamoorthy V, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0113-4; Kuo BJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182285; Landes M, 2017, AFR J EMERG MED, V7, P130, DOI 10.1016/j.afjem.2017.04.001; Leo P., 2016, TRANSLATIONAL RES TR; Li J, 2012, J NEUROTRAUM, V29, P96, DOI 10.1089/neu.2011.1753; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; McCafferty RR, 2018, MIL MED, V183, P67, DOI 10.1093/milmed/usy071; Nyholm L, 2017, UPSALA J MED SCI, V122, P177, DOI 10.1080/03009734.2017.1319440; Onwuchekwa R. C., 2018, Journal of Medicine in the Tropics, V20, P24, DOI 10.4103/jomt.jomt_28_17; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; Saadat S, 2012, ULUS TRAVMA ACIL CER, V18, P219, DOI [10.5505/tjtes.2012.03453, 10.5505/tjtes.2012. 03453]; Smart LR, 2017, WORLD NEUROSURG, V105, P238, DOI 10.1016/j.wneu.2017.05.101; Staton CA, 2017, INT J INJ CONTROL SA, V24, P69, DOI 10.1080/17457300.2015.1061562; Tohme S, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-1; Tran TM, 2015, WORLD NEUROSURG, V83, P269, DOI 10.1016/j.wneu.2014.12.028; Williams SN., 2018, MCCASKIE TRAUMATIC B, V27	39	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	8							e0254245	10.1371/journal.pone.0254245	http://dx.doi.org/10.1371/journal.pone.0254245			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC2PD	34411116	Green Published, gold			2023-01-03	WOS:000686373300060
J	Park, J; Park, J; Oh, S; Yea, JW; Lee, JE; Park, JW				Park, Jongmoo; Park, Jaehyeon; Oh, Sean; Yea, Ji Woon; Lee, Jeong Eun; Park, Jae Won			Multi-criteria optimization for planning volumetric-modulated arc therapy for prostate cancer	PLOS ONE			English	Article							CONFORMAL RADIATION-THERAPY; TOXICITY; RADIOTHERAPY; GENITOURINARY; IMPACT; LIFE	We aimed to compare the volumetric-modulated arc therapy (VMAT) plans with or without multi-criteria optimization (MCO) on commercial treatment-planning systems (Eclipse, Varian Medical System, Palo Alto, CA, USA) for patients with prostate cancer. We selected 25 plans of patients with prostate cancer who were previously treated on the basis of a VMAT plan. All plans were imported into the Eclipse Treatment Planning System version 15.6, and re-calculation and re-optimization were performed. The MCO plan was then generated. The dosimetric quality of the plans was evaluated using dosimetric parameters and dose indices that account for target coverage and sparing of the organs at risk (OARs). We defined the rectum, bladder, and bilateral femoral heads. The VMAT-MCO plan offers an improvement of gross treatment volume coverage with increased minimal dose and reduced maximal dose. In the planning treatment volume, the D-mean and better gradient, homogeneity, and conformity indexes improved despite the increasing hot and cold spots. When implemented through the MCO plan, a steeper fall off the adjacent OARs in the overlap area was achieved to obtain lower dose parameters. MCO generated better sparing of the rectum and bladder through a tradeoff of the increasing dose to the bilateral femoral heads within the tolerable dose constraints. Compared with re-optimization and re-calculation, respectively, significant dose reductions were observed in the bladder (241 cGy and 254 cGy; p<0.001) and rectum (474 cGy and 604 cGy, p<0.001) with the MCO. Planning evaluation and dosimetric measurements showed that the VMAT-MCO plan using visualized navigation can provide sparing of OAR doses without compromising the target coverage in the same OAR dose constraints.	[Park, Jongmoo] Kyungpook Natl Univ, Chilgok Hosp, Dept Radiat Oncol, Daegu, South Korea; [Park, Jaehyeon; Oh, Sean; Yea, Ji Woon; Park, Jae Won] Yeungnam Univ, Coll Med, Dept Radiat Oncol, Daegu, South Korea; [Lee, Jeong Eun] Kyungpook Natl Univ, Sch Med, Dept Radiat Oncol, Daegu, South Korea	Kyungpook National University; Yeungnam University; Kyungpook National University	Park, JW (corresponding author), Yeungnam Univ, Coll Med, Dept Radiat Oncol, Daegu, South Korea.; Lee, JE (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Radiat Oncol, Daegu, South Korea.	jelee@knu.ac.kr; kapicap@naver.com		Park, Jaewon/0000-0003-1100-5301; Oh, SeAn/0000-0002-8835-2814	2019 Yeungnam University Research Grant - Korean government (MSIT); National Research Foundation of Korea [NRF-2019M3E5D1A02068143]	2019 Yeungnam University Research Grant - Korean government (MSIT); National Research Foundation of Korea(National Research Foundation of Korea)	This work was partially supported by the 2019 Yeungnam University Research Grant, funded by the the Korean government (MSIT). supported by the the National Research Foundation of Korea [NRF-2019M3E5D1A02068143] The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bekelman JE, 2018, J CLIN ONCOL, V36, P3251, DOI 10.1200/JCO.18.00606; Bokrantz R, 2012, MED PHYS, V39, P6712, DOI 10.1118/1.4754652; Carvalho IT, 2018, ACTA ONCOL, V57, P1003, DOI 10.1080/0284186X.2018.1478126; Chen HX, 2014, MED DOSIM, V39, P64, DOI 10.1016/j.meddos.2013.10.001; Cotrutz C, 2001, PHYS MED BIOL, V46, P2161, DOI 10.1088/0031-9155/46/8/309; Craft D, 2005, PHYS MED BIOL, V50, P5857, DOI 10.1088/0031-9155/50/24/007; Craft D, 2012, MED PHYS, V39, P686, DOI 10.1118/1.3675601; Craft David L, 2012, Int J Radiat Oncol Biol Phys, V82, pe83, DOI 10.1016/j.ijrobp.2010.12.007; de Crevoisier R, 2018, INT J RADIAT ONCOL, V102, P1420, DOI 10.1016/j.ijrobp.2018.07.2006; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Ghadjar P, 2014, INT J RADIAT ONCOL, V88, P339, DOI 10.1016/j.ijrobp.2013.10.042; Ghandour S, 2015, J APPL CLIN MED PHYS, V16, P258, DOI 10.1120/jacmp.v16i3.5410; Guerrero M, 2020, MED DOSIM, V45, P7, DOI 10.1016/j.meddos.2019.04.003; Hamdy FC, 2016, NEW ENGL J MED, V375, P1415, DOI 10.1056/NEJMoa1606220; Kierkels RGJ, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0385-9; Kopp RW, 2011, MED DOSIM, V36, P365, DOI 10.1016/j.meddos.2010.09.004; Mattes MD, 2014, RADIAT ONCOL J, V32, P23, DOI 10.3857/roj.2014.32.1.23; McGarry CK, 2014, MED DOSIM, V39, P205, DOI 10.1016/j.meddos.2014.02.002; Michalski JM, 2013, INT J RADIAT ONCOL, V87, P932, DOI 10.1016/j.ijrobp.2013.07.041; Muller BS, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0903-z; Network N.C.C, 2020, PROSTATE CANC VERSIO; Olsson CE, 2018, INT J RADIAT ONCOL, V102, P1514, DOI 10.1016/j.ijrobp.2018.08.015; Palma D, 2008, INT J RADIAT ONCOL, V72, P996, DOI 10.1016/j.ijrobp.2008.02.047; Roach M, 2015, INT J RADIAT ONCOL, V93, P1064, DOI 10.1016/j.ijrobp.2015.08.005; Sanda MG, 2018, J UROLOGY, V199, P990, DOI 10.1016/j.juro.2018.01.002; Schaake W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197757; Schaake W, 2016, RADIOTHER ONCOL, V119, P381, DOI 10.1016/j.radonc.2016.04.005; Schaake W, 2014, RADIOTHER ONCOL, V110, P284, DOI 10.1016/j.radonc.2013.11.011; Sutani S, 2015, RADIOTHER ONCOL, V117, P270, DOI 10.1016/j.radonc.2015.08.019; Wolff D, 2009, RADIOTHER ONCOL, V93, P226, DOI 10.1016/j.radonc.2009.08.011; Wortel RC, 2015, INT J RADIAT ONCOL, V91, P737, DOI 10.1016/j.ijrobp.2014.12.017; Zelefsky MJ, 2011, EUR UROL, V60, P1133, DOI 10.1016/j.eururo.2011.08.029	32	0	0	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	9							e0257216	10.1371/journal.pone.0257216	http://dx.doi.org/10.1371/journal.pone.0257216			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM9EM	34506581	gold, Green Published			2023-01-03	WOS:000729120700101
J	Seessle, J; Hippchen, T; Schnitzler, P; Gsenger, J; Giese, T; Merle, U				Seessle, Jessica; Hippchen, Theresa; Schnitzler, Paul; Gsenger, Julia; Giese, Thomas; Merle, Uta			High rate of HSV-1 reactivation in invasively ventilated COVID-19 patients: Immunological findings	PLOS ONE			English	Article							HERPES-SIMPLEX-VIRUS; BRONCHOALVEOLAR LAVAGE FLUID; INTERFERON-STIMULATED GENES; RESPIRATORY-TRACT; INDUCTION	SARS-CoV-2 infection can lead to severe acute respiratory distress syndrome with the need of invasive ventilation. Pulmonary herpes simplex-1 (HSV-1) reactivation in invasively ventilated patients is a known phenomenon. To date very little is known about the frequency and the predisposing factors of HSV-1 reactivation in COVID-19. Therefore, we evaluated our cohort of invasively ventilated COVID-19 patients with severe pneumonia for HSV-1 in respiratory specimens and combined these results with functional immunomonitoring of the peripheral blood. Tracheal secretions and bronchial lavages were screened by PCR for HSV-1 positivity. Comprehensive immunophenotyping and quantitative gene expression analysis of Interferon-stimulated genes (IFI44L, MX1, RSAD2, ISIG15 and IFIT1) and IL-1 beta were performed in whole blood. Time course of infection beginning at symptom onset was grouped into three phases ("early" phase 1: day 1-10, "middle" phase 2: day 11-30 and "late" phase 3: day 31-40). Pulmonary HSV-1 reactivation was exclusively observed in the later phases 2 and 3 in 15 of 18 analyzed patients. By FACS analysis a significant increase in activated CD8 T cells (CD38(+)HLADR(+)) in phase 2 was found when compared with phase 1 (p<0.05). Expression of Interferon-stimulated genes (IFI44L, RSAD2 ISIG15, MX1, IFIT1) was significantly lower after HSV-1 detection than before. Taken together, reactivation of HSV-1 in the later phase of SARS-CoV-2- infection occurs in parallel with a drop of antiviral innate responsiveness as shown by decreased expression of Interferon-stimulated genes and a concurrent increase of highly activated CD38(+)HLADR(+) CD8 T cells.	[Seessle, Jessica; Hippchen, Theresa; Merle, Uta] Univ Hosp Heidelberg, Dept Gastroenterol, Heidelberg, Germany; [Schnitzler, Paul; Gsenger, Julia] Univ Hosp Heidelberg, Inst Virol, Heidelberg, Germany; [Giese, Thomas] Univ Hosp Heidelberg, Inst Immunol, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Merle, U (corresponding author), Univ Hosp Heidelberg, Dept Gastroenterol, Heidelberg, Germany.	uta.merle@med.uni-heidelberg.de						Acharya D, 2020, NAT REV IMMUNOL, V20, P397, DOI 10.1038/s41577-020-0346-x; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Bruynseels P, 2003, LANCET, V362, P1536, DOI 10.1016/S0140-6736(03)14740-X; Coisel Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051340; Eidson KM, 2002, J VIROL, V76, P2180, DOI 10.1128/JVI.76.5.2180-2191.2002; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Lin RT, 2004, J VIROL, V78, P1675, DOI 10.1128/JVI.78.4.1675-1684.2004; Linssen CFM, 2008, INTENS CARE MED, V34, P2202, DOI 10.1007/s00134-008-1231-4; Luyt CE, 2007, AM J RESP CRIT CARE, V175, P935, DOI 10.1164/rccm.200609-1322OC; Luyt CE, 2014, CURR OPIN INFECT DIS, V27, P194, DOI 10.1097/QCO.0000000000000049; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Ong GM, 2004, J MED VIROL, V72, P121, DOI 10.1002/jmv.10524; Oras A, 2020, CLIN EXP IMMUNOL, V202, P363, DOI 10.1111/cei.13491; Ormond-Parker L, 2012, ARCH SCI-NETHERLANDS, V12, P191, DOI 10.1007/s10502-011-9154-1; Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Saugel B, 2016, J CRIT CARE, V32, P138, DOI 10.1016/j.jcrc.2015.11.019; Scheithauer S, 2010, INFECTION, V38, P401, DOI 10.1007/s15010-010-0036-x; Schoggins JW, 2014, CURR OPIN VIROL, V6, P40, DOI 10.1016/j.coviro.2014.03.006; Tognarelli EI, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00127; Traen S, 2014, J CLIN VIROL, V60, P215, DOI 10.1016/j.jcv.2014.04.010; TUXEN DV, 1982, AM REV RESPIR DIS, V126, P416; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Whitley RJ, 2001, LANCET, V357, P1513, DOI 10.1016/S0140-6736(00)04638-9; Zhao QW, 2020, INT J INFECT DIS, V96, P131, DOI 10.1016/j.ijid.2020.04.086; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	29	13	13	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2021	16	7							e0254129	10.1371/journal.pone.0254129	http://dx.doi.org/10.1371/journal.pone.0254129			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TC7AG	34197543	gold, Green Published			2023-01-03	WOS:000668791400060
